<SEC-DOCUMENT>0001564590-21-016723.txt : 20210330
<SEC-HEADER>0001564590-21-016723.hdr.sgml : 20210330
<ACCEPTANCE-DATETIME>20210330171631
ACCESSION NUMBER:		0001564590-21-016723
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		188
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210330
DATE AS OF CHANGE:		20210330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioNTech SE
		CENTRAL INDEX KEY:			0001776985
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			2M
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39081
		FILM NUMBER:		21787957

	BUSINESS ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
		BUSINESS PHONE:		0049613190847081

	MAIL ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>bntx-20f_20201231.htm
<DESCRIPTION>BNTX-20-F-2020
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-20f_20201231.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="line-height:5pt;border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:36.23%;margin-right:36.23%;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 20-F</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:36.23%;margin-right:36.23%;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark One)</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.93%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:9pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:9pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr></table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OR</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.93%;white-space:nowrap">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:bold;font-size:9pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:9pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</font></p></td>
<td valign="top">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr></table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended December 31, 2020</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OR</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.93%;white-space:nowrap">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:bold;font-size:9pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:9pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr></table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OR</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.93%;white-space:nowrap">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:bold;font-size:9pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:9pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr></table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission file number: 001-39081</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BioNTech SE</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its charter)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Federal Republic of Germany</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Jurisdiction of incorporation or organization)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">An der Goldgrube 12</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">D-55131 Mainz</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Germany</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Prof. Ugur Sahin, M.D.,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">c/o BioNTech SE</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">An der Goldgrube 12<font style="font-size:10pt;font-weight:normal;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">D-55131 Mainz</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Germany</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> +49 6131-9084-0 (Tel), +49 6131 9084-390 (Fax), info@biontech.de (E-mail)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:36.23%;margin-right:36.23%;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered or to be registered, pursuant to Section&#160;12(b) of the Act</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">American Depositary Shares, each Representing one ordinary share</p></td>
<td valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BNTX</p></td>
<td valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Nasdaq Stock Market LLC</p></td>
</tr>
<tr style="height:7.65pt;">
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ordinary shares, no par value, with a notional amount attributable to each ordinary share of &#8364;1*</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Nasdaq Stock Market LLC*</p></td>
</tr>
</table></div>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered or to be registered pursuant to Section&#160;12(g) of the Act: <font style="font-weight:bold;">None</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities for which there is a reporting obligation pursuant to Section&#160;15(d) of the Act: <font style="font-weight:bold;">None</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate the number of outstanding shares of each of the issuer&#8217;s classes of capital stock or common stock as of the close of business covered by the annual report.</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.93%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ordinary shares, no par value, with a notional amount attributable to each share of &#8364;1 outstanding as of March 30,&#160;2021, no par value: 241,521,065</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934.&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font>&#160;&#160;&#160;No&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:16.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large accelerated filer</p></td>
<td valign="top"  style="width:8.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:13.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated filer</p></td>
<td valign="top"  style="width:12.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:16.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="top"  style="width:8.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:20.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top"  style="width:3.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8201;&#8224; provided pursuant to Section 13(a) of the Exchange Act. &#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;</font><font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:20%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.&#160;GAAP&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">International Financial Reporting Standards as issued</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by the International Accounting Standards Board&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p></td>
</tr>
</table></div>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If &#8220;Other&#8221; has been checked in response to the previous question indicate by check mark which financial statement item the registrant has elected to follow.&#160;&#160;&#160;&#160;Item&#160;17&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font>&#160;&#160;&#160;&#160;Item&#160;18&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* Listed not for trading or quotation purposes, but only in connection with the registration of American Depositary Shares representing such ordinary shares pursuant to the requirements of the Securities and Exchange Commission. The American Depositary Shares are registered under the Securities Act of 1933, as amended, pursuant to a separate registration statement on Form F-6 (File No. 333-233898).</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:10.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#GENERAL_INFORMATION"><font style="text-decoration:underline;">GENERAL INFORMATION</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CAUTIONARY_STATEMENT_REGARDING_FORWARDLO"><font style="text-decoration:underline;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 1.</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_IDENTITY_DIRECTORS_SENIOR_MANAGEM"><font style="text-decoration:underline;">IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 2.</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_FER_STATISTICS_EXPECTED_TIMETABLE"><font style="text-decoration:underline;">OFFER STATISTICS AND EXPECTED TIMETABLE</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 3.</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_KEY_INFORMATION"><font style="text-decoration:underline;">KEY INFORMATION</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_A"><font style="text-decoration:underline;">A. Selected Consolidated Financial Data</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_B"><font style="text-decoration:underline;">B. Capitalization and Indebtedness</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_C"><font style="text-decoration:underline;">C. Reasons for the Offer and Use of Proceeds</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_D"><font style="text-decoration:underline;">D. Risk Factors</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 4.</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4"><font style="text-decoration:underline;">INFORMATION ON THE COMPANY</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_4_A"><font style="text-decoration:underline;">A. History and Development of the Company</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_B"><font style="text-decoration:underline;">B. Business Overview</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_C"><font style="text-decoration:underline;">C. Organizational Structure</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_D"><font style="text-decoration:underline;">D. Property, Plant and Equipment</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 4A.</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4A_UNRESOLVED_STAFF_COMMENTS"><font style="text-decoration:underline;">UNRESOLVED STAFF COMMENTS</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 5.</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_OPERATING_FINANCIAL_REVIEW_PROSPE"><font style="text-decoration:underline;">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_A"><font style="text-decoration:underline;">A. Operating Results</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_B"><font style="text-decoration:underline;">B. Research and Development, Patents and Licenses, etc</font></a><font style="text-decoration:underline;">.</font></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_C"><font style="text-decoration:underline;">C. Trend Information </font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_D"><font style="text-decoration:underline;">D. Liquidity and Capital Resources</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_E"><font style="text-decoration:underline;">E. Off-Balance Sheet Arrangements</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_F"><font style="text-decoration:underline;">F. Tabular Disclosure of Contractual Obligations</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_G"><font style="text-decoration:underline;">G. Safe Harbor</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 6.</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_DIRECTORS_SENIOR_MANAGEMENT_AND_E"><font style="text-decoration:underline;">DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_A"><font style="text-decoration:underline;">A. Directors and Senior Management</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_B"><font style="text-decoration:underline;">B. Compensation</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">191</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_C"><font style="text-decoration:underline;">C. Board Practices</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_D"><font style="text-decoration:underline;">D. Employees</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_E"><font style="text-decoration:underline;">E. Share Ownership</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 7.</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MAJOR_SHAREHOLDERS_RELATED_PARTY_"><font style="text-decoration:underline;">MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_A"><font style="text-decoration:underline;">A. Major Shareholders</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_B"><font style="text-decoration:underline;">B. Related Party Transactions</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_C"><font style="text-decoration:underline;">C. Interests of Experts and Counsel</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;8.</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_INFORMATION"><font style="text-decoration:underline;">FINANCIAL INFORMATION</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_A"><font style="text-decoration:underline;">A. Consolidated Statements and Other Financial Information</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_B"><font style="text-decoration:underline;">B. Significant Changes</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;9.</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_FER_LISTING"><font style="text-decoration:underline;">THE OFFER AND LISTING</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_A"><font style="text-decoration:underline;">A. Offer and Listing Details</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_B"><font style="text-decoration:underline;">B. Plan Of Distribution</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_C"><font style="text-decoration:underline;">C. Markets</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_D"><font style="text-decoration:underline;">D. Selling Shareholders</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_E"><font style="text-decoration:underline;">E. Dilution</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_F"><font style="text-decoration:underline;">F. Expenses of the Issue</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 10.</font></p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_ADDITIONAL_INFORMATION"><font style="text-decoration:underline;">ADDITIONAL INFORMATION</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_A"><font style="text-decoration:underline;">A. Share capital</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_B"><font style="text-decoration:underline;">B. Memorandum and Articles of Association</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_C"><font style="text-decoration:underline;">C. Material Contracts</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">210</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_D"><font style="text-decoration:underline;">D. Exchange Controls</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">210</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_E"><font style="text-decoration:underline;">E. Taxation</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">210</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_F"><font style="text-decoration:underline;">F. Dividends and Paying Agents</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_G"><font style="text-decoration:underline;">G. Statement by Experts</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_H"><font style="text-decoration:underline;">H. Documents on Display</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_I"><font style="text-decoration:underline;">I. Subsidiary Information</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 11.</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_QUANTITATIVE_QUALITATIVE_DISCLOS"><font style="text-decoration:underline;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 12.</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_DESCRIPTION_SECURITIES_OR_THAN_E"><font style="text-decoration:underline;">DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">221</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_A"><font style="text-decoration:underline;">A. Debt Securities</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">221</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_B"><font style="text-decoration:underline;">B. Warrants and Rights</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">221</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_C"><font style="text-decoration:underline;">C. Other Securities</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">221</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_D"><font style="text-decoration:underline;">D. American Depositary Shares</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">221</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART II</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 13.</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_DEFAULTS_DIVIDEND_ARREARAGES_DEL"><font style="text-decoration:underline;">DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 14.</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_MATERIAL_MODIFICATIONS_TO_RIGHTS"><font style="text-decoration:underline;">MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 15.</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_CONTROLS_PROCEDURES"><font style="text-decoration:underline;">CONTROLS AND PROCEDURES</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 16</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16A_AUDIT_COMMITTEE_FINANCIAL_EXPER"><font style="text-decoration:underline;">A. Audit Committee Financial Expert</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16B_CODE_ETHICS"><font style="text-decoration:underline;">B. Code of Ethics</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16C_PRINCIPAL_ACCOUNTANT_FEES_SERVI"><font style="text-decoration:underline;">C. Principal Accountant Fees and Services</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16D_EXEMPTIONS_FROM_LISTING_STARDS_"><font style="text-decoration:underline;">D. Exemptions from the Listing Standards for Audit Committees</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">225</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16E_PURCHASES_EQUITY_SECURITIES_BY_"><font style="text-decoration:underline;">E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">225</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16F_CHANGE_IN_REGISTRANTS_CERTIFY"><font style="text-decoration:underline;">F. Changes in Registrant&#8217;s Certifying Accountant</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">225</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16G_CORPORATE_GOVERNANCE"><font style="text-decoration:underline;">G. Corporate Governance</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">225</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16H_MINE_SAFETY_DISCLOSURE"><font style="text-decoration:underline;">H. Mine Safety Disclosure</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">234</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART III</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;17.</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_17_FINANCIAL_STATEMENTS"><font style="text-decoration:underline;">FINANCIAL STATEMENTS</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">235</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;18.</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_18_FINANCIAL_STATEMENTS"><font style="text-decoration:underline;">FINANCIAL STATEMENTS</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">235</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;19.</p></td>
<td valign="top"  style="width:74.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_19_EXHIBITS"><font style="text-decoration:underline;">EXHIBITS</font></a></p></td>
<td valign="top"  style="width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">235</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="GENERAL_INFORMATION"></a><a name="GENERAL_INFORMATION"></a>GENERAL INFORMATION</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In this annual report on Form 20-F (&#8220;Annual Report&#8221;), &#8220;BioNTech,&#8221; the &#8220;Group,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to BioNTech SE and its consolidated subsidiaries, except where the context otherwise requires.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In response to the fact that our consolidated financial statements are published in Euro, the selected consolidated financial data is presented in Euro as well. Amounts in U.S. dollar are translated into Euro using the exchange rates as per period end or average exchange rates for the periods indicated as published by the <font style="color:#000000;">German Central Bank (</font><font style="font-style:italic;color:#000000;">Deutsche Bundesbank</font><font style="color:#000000;">)</font>. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All references in this <font style="color:#000000;">Annual Report</font> to &#8220;$&#8221; mean U.S. dollars and all references to &#8220;&#8364;&#8221; mean Euros.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CAUTIONARY_STATEMENT_REGARDING_FORWARDLO"></a>CAUTIONARY<a name="CAUTIONARY_STATEMENT_REGARDING_FORWARDLO"></a> STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report contains forward-looking statements concerning our business, operations and financial performance and condition as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements that are not of historical facts may be deemed to be forward-looking statements. Many of the forward-looking statements contained in this Annual Report can be identified by the use of forward-looking words such as &#8220;believes&#8221;, &#8220;estimates&#8221;, &#8220;anticipates&#8221;, &#8220;expects&#8221;, &#8220;plans&#8221;, &#8220;intends&#8221;, &#8220;may&#8221;, &#8220;could&#8221;, &#8220;might&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;aims&#8221; or other similar expressions that convey uncertainty of future events or outcomes.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that could <font style="color:#000000;">cause</font> our actual results of operations, financial condition, liquidity, performance, prospects, opportunities, achievements or industry results, as well as those of the markets we serve or intend to serve, to differ materially from those expressed in, or suggested by, these forward-looking statements. These forward-looking statements are based on assumptions regarding our present and future business strategies and the environment in which we expect to operate in the future. Important factors that could cause those differences include, but are not limited to:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:1.61%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our expected revenues and net profit related to sales of our COVID-19 vaccine, referred to as COMIRNATY<font style="color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></font> in the European Union as authorized for use under conditional marketing approval, in territories controlled by our collaboration partners, particularly for those figures that are derived from preliminary estimates provided by our partners;</p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our pricing and coverage negotiations with governmental authorities, private health insurers and other third-party payors after our initial sales to national governments;</p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the extent to which a COVID-19 vaccine continues to be necessary in the future;</p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>competition from other COVID-19 vaccines or related to our other product candidates, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, efficacy, cost, convenience of storage and distribution, breadth of approved use, side-effect profile and durability of immune response; </p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our ability and that of our collaborators to commercialize our COVID-19 vaccine and our product candidates, if approved;</p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the pricing and reimbursement of our COVID-19 vaccine and our investigational medicines, if approved;</p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the rate and degree of market acceptance of our COVID-19 vaccine and our investigational medicines, if approved;</p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;</p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the timing of and our ability to obtain and maintain regulatory approval for our product candidates;</p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our ability to identify research opportunities and discover and develop investigational medicines;</p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the ability and willingness of our third-party collaborators to continue research and development activities relating to our development candidates and investigational medicines;</p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our expectations regarding the size of the patient populations for our product candidates, if approved for commercial use;</p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the impact of the COVID-19 pandemic on our development programs, supply chain, collaborators and financial performance;</p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>unforeseen safety issues and claims for personal injury or death arising from the use of our COVID-19 vaccine and other products and product candidates developed or manufactured by us;</p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our estimates of our expenses, ongoing losses, future revenue and capital requirements and our needs for or ability to obtain additional financing;</p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our ability to identify, recruit and retain key personnel;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our and our collaborators&#8217; ability to protect and enforce our intellectual property protection for our proprietary and collaborative product candidates, and the scope of such protection;</p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the development of and projections relating to our competitors or our industry;</p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our ability and that of our collaborators to commercialize and market our product candidates, if approved, including our COVID-19 vaccine;</p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the pricing and reimbursement of our investigational medicines, if approved, including our COVID-19 vaccine;</p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the rate and degree of market acceptance of our investigational medicines, if approved, including our COVID-19 vaccine;</p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the amount of and our ability to use net operating losses and research and development credits to offset future taxable income;</p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our ability to manage our development and expansion;</p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>regulatory developments in the United States and foreign countries;</p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our ability to effectively scale our production capabilities and manufacture our products, including our COVID-19 vaccine, and our product candidates;</p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our ability to implement, maintain and improve effective internal controls; and</p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>other factors not known to us at this time.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. The forward-looking statements contained in this Annual Report speak only as of the date of this report, and unless otherwise required by law, we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_I"></a><a name="PART_I"></a>PART I</p>
<p style="margin-top:6pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1_IDENTITY_DIRECTORS_SENIOR_MANAGEM"></a><a name="ITEM_1_IDENTITY_DIRECTORS_SENIOR_MANAGEM"></a>Item 1. Identity of Directors, Senior Management and Advisers</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not <font style="color:#231F20;">applicable</font>. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_2_FER_STATISTICS_EXPECTED_TIMETABLE"></a><a name="ITEM_2_FER_STATISTICS_EXPECTED_TIMETABLE"></a>Item 2. Offer Statistics and Expected Timetable</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_3_KEY_INFORMATION"></a><a name="ITEM_3_KEY_INFORMATION"></a>Item 3. Key Information</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">A.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_3_A"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_3_A"></a>Selected Consolidated Financial Data</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">B.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_3_B"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_3_B"></a>Capitalization and Indebtedness</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">C.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_3_C"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Reasons for the Offer and Use of Proceeds</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">D.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_3_D"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Risk Factors</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_Risk_Factors"></a><a name="RISK_FACTORS"></a>Our business is subject to various risks, including those described below. You should consider carefully the risks and uncertainties described below and in our future filings. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. Additionally, risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, results of operations and/or prospects.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risk Factors Summary</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investing in the ADSs involves various risks. You should carefully read and consider the matters discussed in this Annual Report under the heading &#8220;Risk Factors,&#8221; which include the following risks:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Our revenue depends heavily on sales of our COVID-19 vaccine, and our future revenues from our COVID-19 vaccine are uncertain. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Our commercial revenue is based on preliminary estimates of COVID-19 vaccine sales and costs from Pfizer Inc., or Pfizer, that are likely to change in future periods, which will impact our reported financial results.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>We may not be able to demonstrate sufficient efficacy or safety of our COVID-19 vaccine to obtain permanent regulatory approval in the United States, the United Kingdom, the European Union, or other countries where it has been authorized for emergency use or granted conditional marketing approval.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>We face significant competition with other makers of COVID-19 vaccines and may be unable to maintain a competitive market share for our COVID-19 vaccine.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>We have only recently built our marketing and sales organization. If we are unable to continue to increase our marketing and sales capabilities on our own or through third parties, we may not be able to market and sell our product candidates effectively in the United States and other jurisdictions, if approved, or generate product sales revenue.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Even if we obtain regulatory approval for our product candidates, the products may not gain the market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community necessary for commercial success.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Our operating results may fluctuate significantly, which makes our future operating results difficult to predict. If our operating results fall below expectations, the price of the ADSs representing our shares could decline.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may require substantial additional financing to achieve our goals, and a failure to obtain this capital on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>We have in the past identified a material weakness in our internal control over financial reporting and may identify additional material weaknesses in the future that may cause us to fail to meet our reporting obligations or result in material misstatements in our financial statements. If we fail to remediate our material weakness, we may not be able to report our financial results accurately or to prevent fraud.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>As a &#8220;foreign private issuer,&#8221; we are exempt from a number of rules under the U.S. securities laws, as well as Nasdaq rules, and we are permitted to file less information with the SEC than U.S. companies. This may limit the information available to holders of the ADSs and may make our ordinary shares and the ADSs less attractive to investors.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>We face risks related to health epidemics and pandemics, such as COVID-19, that could adversely affect our operations.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>mRNA drug development has substantial clinical development and regulatory risks due to limited regulatory experience with mRNA immunotherapies.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Clinical development involves a lengthy and expensive process with an uncertain outcome, and delays can occur for a variety of reasons outside of our control. Clinical trials of our product candidates may be delayed, and certain programs may never advance in the clinic or may be more costly to conduct than we anticipate, any of which can affect our ability to fund our company and would have a material adverse impact on our business.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Results of earlier studies and trials of our product candidates may not be predictive of future trial results.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Our mRNA product candidates are based on novel technologies and any product candidates we develop may be complex and difficult to manufacture. We may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management or shipping. If we or any of the third-party manufacturers we work with encounter such difficulties, our ability to supply materials for clinical trials or any approved product could be delayed or stopped.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>If our efforts to obtain, maintain, protect, defend and/or enforce the intellectual property related to our COVID-19 vaccine or our product candidates and technologies are not adequate, we may not be able to compete effectively in our market.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>We have experienced and may continue to experience significant volatility in the market price of the ADSs representing our ordinary shares.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Our principal shareholders and management own a significant percentage of our ordinary shares and will be able to exert significant control over matters subject to shareholder approval. </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risk Factors </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Our business is subject to various risks, including those described below. You should consider carefully the risks and uncertainties described below and in our future filings. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. Additionally, risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, results of operations and/or prospects.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to our COVID-19 vaccine and the Commercialization of our Pipeline</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our revenue depends heavily on sales of our COVID-19 vaccine, and our future revenues from our COVID-19 vaccine are uncertain. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our COVID-19 vaccine <font style="color:#000000;">was granted emergency use authorization in the United States and the United Kingdom, and conditional marketing approval in the European Union, in December 2020, followed by emergency or limited use authorization in a number of other countries and approval for use in certain other countries. Prior to this, we had not sold or marketed any products in our pipeline. As a result, we expect that a majority of our total revenues, and all of our product revenues, in 2021 will be attributable to sales of </font>our COVID-19 vaccine<font style="color:#000000;">. There is intense competition in the field of COVID-19 vaccines, including with other vaccines that have been authorized for emergency use and those in late-stage clinical development. Our future revenues from sales of </font>our COVID-19 vaccine <font style="color:#000000;">depend on numerous factors, including:</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">competition from other COVID-19 vaccines, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, efficacy, cost, convenience of storage and distribution, breadth of approved use, side-effect profile and durability of immune response;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the extent of the spread of COVID-19 infection;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the extent to which a COVID-19 vaccine continues to be necessary beyond the current pandemic;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the durability of immune response generated by <font style="color:#000000;">our COVID-19 vaccine</font>, which has not yet been demonstrated in clinical trials;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our ability to receive full regulatory approvals;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our pricing and coverage negotiations with governmental authorities, private health insurers and other third-party payors after our initial sales to national governments;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the extent to which SARS-CoV-2 mutates and the efficacy of <font style="color:#000000;">our COVID-19 vaccine </font>in preventing COVID-19 infection from mutated strains;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the ability of countries and jurisdictions to store and distribute doses of <font style="color:#000000;">our COVID-19 vaccine </font>to end users at cold temperatures;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the safety profile of <font style="color:#000000;">our COVID-19 vaccine</font>, including if previously unknown side effects or increased incidence or severity of known side effects as compared to those seen during clinical trials are identified with <font style="color:#000000;">our COVID-19 vaccine </font>with widespread global use after approval; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our manufacturing and distribution capabilities for <font style="color:#000000;">our COVID-19 vaccine</font>.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While <font style="color:#000000;">our COVID-19 vaccine </font>has established a competitive commercial profile, we cannot ensure it will maintain its competitive position as competing vaccines become approved, and we cannot accurately predict the revenues our COVID-19 vaccine will generate in future periods or for how long <font style="color:#000000;">our COVID-19 vaccine </font>will continue to generate material revenues. If our revenues, market share and/or other indicators of market acceptance of <font style="color:#000000;">our COVID-19 vaccine </font>do not meet the expectations of investors or securities analysts, the market price of the ADSs representing our ordinary shares may decline. In addition, if one or more of the factors above negatively affects <font style="color:#000000;">our COVID-19 vaccine </font>sales, our business and financial condition could be materially harmed.&nbsp;&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our commercial revenue is based on preliminary estimates of COVID-19 vaccine sales and costs from Pfizer Inc., or Pfizer, that are likely to change in future periods, which may impact our reported financial results.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our reported commercial revenue is based on preliminary estimates from Pfizer, and other assumptions and judgments that we have made, which may be subject to significant uncertainties. Although our revenue recognition policy is based on facts and circumstances known to us and various other assumptions that we believe to be reasonable under the circumstances, our actual results may deviate from such reported revenue.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We depend on Pfizer to determine and provide estimates of the costs and profits to be shared with us in the countries where it is commercializing our COVID-19 vaccine under our collaboration agreement with Pfizer for our COVID-19 vaccine, which we refer to as the Pfizer Agreement. Because the information supplied by Pfizer is preliminary and is subject to change, the commercial revenue we report based on such information is also subject to finalization. This is particularly true for vaccine sales outside of the United States, where Pfizer has a different reporting cycle than ours. As a result, we may not have the complete sales results outside of the United States for any given period, but we are nonetheless required to report estimated figures.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, for the year ended December 31, 2020, Pfizer provided us profit figures for our COVID-19 vaccine sales in the United States using standard U.S. transfer prices and manufacturing and shipping cost variances (as far as those have been identified) that could be subject to adjustment (e.g., due to changes in manufacturing costs or the price of our COVID-19 vaccine). Pfizer also provided estimated profits for COVID-19 vaccine sales outside of the United States that were preliminary in nature, as Pfizer's subsidiaries outside of the United States do not have a fiscal year end of December 31. These estimated figures are likely to change as we receive final data from Pfizer for the year ended December 31, 2020 in accordance with the reporting cycle of its ex-U.S. subsidiaries and as actual costs become known. Further, to the extent that Pfizer does not provide such preliminary information in the future, our provisional sales figures for territories outside of the United States will be subject to an even greater level of estimates and judgments. Any changes to the preliminary data we report herein may have an impact on our reported revenues and expenses, profitability or financial position.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">O</font><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ur COVID-19</font><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> vaccine</font><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> is sensitive to temperature, shipping and storage conditions and could be subject to risk of loss or damage.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our COVID-19 is, and other product candidates we develop could be, sensitive to temperature, storage and handling conditions. In particular, our COVID-19 vaccine must be shipped and stored at very cold temperatures. Loss in supply of our COVID-19 vaccine and our product candidates could occur if the product or product intermediates are not stored or handled properly. Shelf life for our product candidates may vary by product, and it is possible that supply of our COVID-19 vaccine or our product candidates could be lost due to expiration prior to use. This has in the past led and could in the future lead to additional manufacturing costs and delays in our ability to supply required quantities for clinical trials or for commercial purposes. Such distribution challenges may make our COVID-19 vaccine a less attractive product than other COVID-19 vaccines that do not require extremely cold storage, and <font style="color:#000000;">our COVID-19 vaccine</font> may become increasingly less competitive as additional other vaccines become authorized for emergency use. If we, our partners and customers are unable to adequately manage these issues, the market opportunity for our COVID-19 vaccine may be reduced which could adversely affect our business prospects and our financial condition could be materially harmed.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to demonstrate sufficient efficacy or safety of our COVID-19 vaccine to obtain permanent regulatory approval in the United States, the United Kingdom, the European Union, or other countries where it has been authorized for emergency use or granted conditional marketing approval.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our COVID-19 vaccine was granted emergency use authorization in the United States and the United Kingdom, and conditional marketing approval in the European Union, in December 2020, followed by emergency or limited use authorization in a number of other countries and approval for use in certain other countries. Our COVID-19 vaccine has not yet been approved by the U.S Food and Drug Administration, or FDA, the European Medical Agency, or EMA, or other regulatory authorities in a number of countries. We and Pfizer Inc. or Pfizer, intend to continue to observe our COVID-19 vaccine and other variants of a COVID-19 vaccine candidate in global clinical trials. It is possible that subsequent data from these clinical trials may not be as favorable as data we submitted to the FDA, the EMA or other regulatory authorities to support our applications for emergency use authorization or conditional marketing approval or that concerns with the safety of our COVID-19 vaccine will arise from the widespread use of our COVID-19 vaccine outside of clinical trials. Our COVID-19 vaccine may not receive approval outside of the emergency use setting in the countries where it is not currently approved, which could adversely affect our business prospects.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we discover safety issues with our products, including our COVID-19 vaccine, that were not known at the time of approval or if we fail to comply with continuing regulatory requirements, commercialization efforts for our products could be negatively affected, approved products could lose their approval or sales could be suspended, and our business and reputation could be materially harmed. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our COVID-19 vaccine <font style="color:#000000;">and any other product candidates for which we receive approval or emergency use authorization are subject to continuing regulatory oversight, including the review of additional safety information. O</font>ur COVID-19 vaccine <font style="color:#000000;">will be more widely used by patients as an authorized product than it was used in clinical trials and therefore side effects and other problems may be observed after emergency use authorization that were not seen or anticipated, or were not as prevalent or severe, during clinical trials. We cannot provide assurance that newly discovered or developed safety issues will not arise. With the use of any vaccine by a wide patient population, serious adverse events may occur from time to time that did not arise in the clinical trials of the product or that initially appeared to be unrelated to the vaccine itself and only with the collection of subsequent information were found to be causally related to the product. Any such safety issues could cause us to suspend or cease marketing of our approved products, possibly subject us to substantial liabilities, and adversely affect our ability to generate revenue and our financial condition. The subsequent discovery of previously unknown problems with a product could negatively affect commercial sales of the product, result in restrictions on the product or lead to the withdrawal of the product from the market. The reporting of adverse safety events involving our products or public speculation about such events could cause the price of the ADSs representing our ordinary shares to decline or experience periods of volatility. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unexpected safety issues, including any that we have not yet observed in our clinical trials for <font style="color:#000000;">our COVID-19 vaccine</font>, could lead to significant reputational damage for us and our product development platforms going forward and other issues, including delays in our other programs, the need for re-design of our clinical trials and the need for significant additional financial resources. We also may be restricted or prohibited from marketing or manufacturing <font style="color:#000000;">our COVID-19 vaccine</font>, even after obtaining product approval, if previously unknown problems with the product or its manufacture are subsequently discovered. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or our collaborators fail to comply with applicable continuing regulatory requirements, we or our collaborators may be subject to fines, suspension or withdrawal of regulatory approvals for specific drugs, product recalls and seizures, operating restrictions and/or criminal prosecutions. In addition, the manufacturers we engage to make our products and the manufacturing facilities in which our products are made are subject to periodic review and inspection by the FDA and foreign regulatory authorities. If problems are identified during the review or inspection of these manufacturers or manufacturing facilities, it could result in our inability to use the facility to make our product or a determination that inventories are not safe for commercial sale.</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these factors </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adversely affect our business prospects and our financial </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">position</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> could be materially harmed.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities, private health insurers and other third-party payors provide coverage and adequate reimbursement levels and implement pricing policies favorable for our product candidates. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford certain treatments, including <font style="color:#000000;">our COVID-19 vaccine </font>and other product candidates we may develop and sell. In addition, because our mRNA product candidates represent an entirely new therapeutic modality, we cannot accurately estimate how future products we may develop and sell would be priced, whether reimbursement could be obtained, or any potential revenue. Sales of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit, and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize an adequate return on our investment in any of our products.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products in particular in the United States, including genetic medicines. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS, as CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payors tend to follow CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for novel products such as ours. Reimbursement agencies in Europe may be more conservative than CMS. For example, a number of cancer drugs have been approved for reimbursement in the United States but have not been approved for reimbursement in certain European countries.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside the United States, certain countries, including a number of member states of the European Union, set prices and reimbursement for pharmaceutical products, with limited participation from the marketing authorization holders. We cannot be sure that such prices and reimbursement will be acceptable to us or our collaborators. If the regulatory authorities in these jurisdictions set prices or reimbursement levels that are not commercially attractive for us or our collaborators, our revenues from sales by us or our collaborators, and the potential profitability of our drug products, in those countries would be negatively affected. An increasing number of countries are taking initiatives to attempt to reduce large budget deficits by focusing cost-cutting efforts on pharmaceuticals for their state-run health care systems. These international price control efforts have impacted all regions of the world but have been most drastic in the European Union. Additionally, some countries require approval of the sale price of a product before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then may experience delays in the reimbursement approval of our product or be subject to price regulations that would delay our commercial launch of the product, possibly for lengthy time periods, which could negatively impact the revenues we are able to generate from the sale of the product in that particular country.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, increasing efforts by governmental and third-party payors, in the United States and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. For example, the U.S. government recently released a &#8220;blueprint,&#8221; which is a plan to reduce the cost of drugs. The blueprint contains certain measures that the HHS is already working to implement. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to experience pricing pressures in connection with the sale of any of our product candidates, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products in the marketplace.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The imposition of export controls on our COVID-19 vaccine in the European Union or in other jurisdictions could severely and adversely impact our manufacturing activities, commercial activities and financial results.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Governments of the jurisdictions in which we or our partners produce our COVID-19 vaccine may prohibit us from delivering orders of our COVID-19 vaccine to customers in other jurisdictions. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The European Union and other regions have imposed, or threatened to impose, export controls that would limit or block the delivery of COVID-19 vaccines manufactured in their territories in instances where manufacturers have been delayed or have not fully satisfied their delivery obligations to such governments. If the European Union enforces an export authorization scheme on COVID-19 vaccines, we may be prohibited from exporting commercial supply of the vaccine from our manufacturing site in Germany to non-EU countries (and Pfizer may likewise be prohibited from exporting out of its manufacturing site in Belgium). Such restrictions may have a material impact on our manufacturing or distribution activities, and the commercialization of our COVID-19 vaccine.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our ability to generate income from sales of our COVID-19 vaccine is uncertain, due to government interest and public perception regarding a vaccine.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the emergency pandemic situations in many countries, there is a heightened risk that a COVID-19 vaccine may be subject to adverse governmental actions in certain countries, including intellectual property expropriation, compulsory licenses, strict price controls or other actions. Additionally, we may need to, or we may be required by governmental or non-governmental authorities to, set aside specific quantities of doses of <font style="color:#000000;">our COVID-19 vaccine </font>for designated purposes or geographic areas. We face challenges related to the allocation of supply of <font style="color:#000000;">our COVID-19 vaccine</font>, particularly with respect to geographic distribution.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, public sentiment regarding commercialization of a COVID-19 vaccine may limit or negate our ability to generate income from sales of <font style="color:#000000;">our COVID-19 vaccine</font>. Given that COVID-19 has been designated as a pandemic and represents an urgent public health crisis, we have faced significant public attention and scrutiny over any current and any future business models and pricing decisions with respect to <font style="color:#000000;">our COVID-19 vaccine</font>. If we are unable to successfully manage these risks, we could face significant reputational harm, which could negatively affect the price of the ADSs representing our ordinary shares.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face significant competition with other makers of COVID-19 vaccines and may be unable to maintain a competitive market share for our COVID-19 vaccine.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A large number of vaccine manufacturers, academic institutions and other organizations currently have programs to develop COVID-19 vaccine candidates and certain other vaccines have been authorized for emergency use or approved in various countries. For example, Moderna, Inc.&#8217;s vaccine candidate, mRNA-1273, has been approved for emergency use in the United States, United Kingdom, European Union and other countries. While we are not aware of all of our competitors&#8217; efforts, other vaccine candidates developed by the Gamaleya Research Institute of Epidemiology and Microbiology, the University of Oxford/AstraZeneca plc, CanSino Biologics Inc., Johnson &amp; Johnson, the Vector Institute, Novavax, Inc., China National Pharmaceutical Group (Sinopharm)/Beijing Institute of Biological Products and Wuhan Institute of Biological Products, Sinovac Biotech Ltd., Bharat Biotech International Limited and other companies are in late stages of clinical development or have been authorized for emergency use or approved in certain countries. Our competitors pursuing vaccine candidates may have greater financial, product candidate development, manufacturing and marketing resources than we do. Larger pharmaceutical and biotechnology companies have extensive experience in clinical testing and obtaining regulatory approval for their products, and may have the resources to invest heavily to accelerate discovery and development of their vaccine candidates.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our efforts to successfully commercialize our<font style="color:#000000;"> COVID-19 vaccine </font>may fail if competitors develop and commercialize COVID-19 vaccines that are safer, more effective, produce longer immunity against COVID-19, require fewer administrations, have fewer or less severe side effects, have broader market acceptance, are more convenient to administer or distribute or are less expensive than any vaccine candidate that we have developed or we may develop.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We </font><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">are developing other product candidates</font><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </font><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">in an environment of rapid technological and scientific change, and our failure to effectively compete would prevent us from achieving significant market penetration. Most of our competitors have significantly greater resources than we do and we may not be able to compete successfully.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The pharmaceutical market is intensely competitive and rapidly changing. Many large pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and other public and private research organizations are pursuing the development of novel drugs for the same diseases that we are targeting or expect to target. Many of our competitors have:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>greater financial, technical and human resources than we have at every stage of the discovery, development, manufacture and commercialization of products&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>more extensive experience in preclinical testing, conducting clinical trials, obtaining regulatory approvals, and in manufacturing, marketing and selling drug products&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>product candidates that are based on previously tested or accepted technologies&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>products that have been approved or are in late stages of development&#894; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>collaborative arrangements in our target markets with leading companies and research institutions.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will face intense competition from drugs that have already been approved and accepted by the medical community for the treatment of the conditions for which we may develop drugs in the future. We also expect to face competition from new drugs that enter the market. There are a number of drugs currently under development, which may become commercially available in the future, for the treatment of conditions for which we are trying, or may in the future try, to develop drugs. These drugs may be more effective, safer, less expensive, or marketed and sold more effectively, than any products we develop.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate competing with the largest pharmaceutical companies in the world, many of which are all currently conducting research in the fields of infectious diseases, immuno-oncology, rare genetic diseases and cancer immunotherapies. Some of these companies have greater financial and human resources than we currently have. In addition to these large pharmaceutical companies, we may directly compete with fully-integrated biopharmaceutical companies and other immunotherapy-focused oncology companies, as well as a number of companies focused on immunotherapies or shared tumor antigen and neoantigen therapeutics, some of which have entered into collaboration and funding agreements with larger pharmaceutical or biotechnology companies.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we successfully develop other product candidates, and obtain approval for them, we will face competition based on many different factors, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the safety and effectiveness of our products relative to alternative therapies, if any&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the timing and scope of regulatory approvals for these products&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the availability and cost of manufacturing, marketing and sales capabilities&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the price of any approved immunotherapy&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>reimbursement coverage&#894; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>intellectual property position.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our competitors may develop or commercialize products with significant advantages over any products we develop based on any of the factors listed above or on other factors. In addition, our competitors may develop collaborations with or receive funding from larger pharmaceutical or biotechnology companies, providing them with an advantage over us. Our competitors therefore may be more successful in commercializing their products than we are, which could adversely affect our competitive position and business. Competitive products may make any products we develop obsolete or noncompetitive before we can recover the expenses of developing and commercializing our products, if approved.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The market opportunities for certain of our product candidates may be small due to the rarity of the disease, or limited to those patients who are ineligible for or have failed prior treatments. As the target patient populations for some </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of our programs are small, </font><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">we may never achieve or maintain profitability without obtaining regulatory approval for additional indication</font><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA often approves new cancer therapies initially only for use by patients with relapsed or refractory advanced cancer. We expect to seek approval initially of certain of our product candidates in this context. Subsequently, for those products that prove to be sufficiently beneficial, we would expect to seek approval in earlier lines of treatment and potentially as a first-line therapy but there is no guarantee that our product candidates, even if approved, would be approved for earlier lines of therapy, and, prior to any such approvals, we may have to conduct additional clinical trials. We are also developing product candidates for the treatment of rare diseases.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our projections of the number of people who have or will have the diseases we may be targeting may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of trial participants may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. Even if we obtain significant market share for our products, if approved, because the potential target populations may be small, we may never achieve or maintain profitability without obtaining regulatory approval for additional indications.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have only recently built our marketing and sales organization. If we are unable to continue to increase our marketing and sales capabilities on our own or through third parties, we may not be able to market and sell our product candidates effectively in the United States and other jurisdictions, if approved, or generate product sales revenue.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have only recently developed our sales, distribution or marketing capabilities, and, other than for our COVID-19 vaccine, we have not historically designed our preclinical studies and clinical trials with specific commercialization or marketing considerations in mind. To successfully commercialize <font style="color:#000000;">our COVID-19 vaccine </font>and any other products that may result from our development programs, we will need to continue developing sales and marketing capabilities in the United States, Europe and other regions, either on our own or with others. We may enter into collaborations with other entities to utilize their mature marketing and distribution capabilities, but we may be unable to enter into marketing agreements on favorable terms, if at all. If our current and future collaborators do not commit sufficient resources to commercialize our COVID-19 vaccine and our future products, if any, and we are unable to develop the necessary marketing capabilities on our own, we may be unable to generate sufficient product sales revenue to sustain our business. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without a significant internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our ability to achieve or maintain profitability depends in part on our and our collaborators&#8217; ability to penetrate global markets, where we would be subject to additional regulatory burdens and other risks and uncertainties associated with international operations that could materially adversely affect our business.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to achieve or maintain profitability will depend in part on our ability and the ability of our collaborators to commercialize any products that we or our collaborators may develop in markets throughout the world. Commercialization of products in various markets could subject us to risks and uncertainties, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>obtaining, on a country-by-country basis, the applicable marketing authorization from the competent regulatory authority&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the burden of complying with complex and changing regulatory, tax, accounting, labor and other legal requirements in each jurisdiction that we or our collaborators pursue&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>reduced protection for intellectual property rights&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>differing medical practices and customs affecting acceptance in the marketplace&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>import or export licensing requirements&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>governmental controls, trade restrictions or changes in tariffs&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>economic weakness, including inflation, or political instability in particular non-U.S. economies and markets&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>longer accounts receivable collection times&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>longer lead times for shipping&#894;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>language barriers&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>foreign currency exchange rate fluctuations&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the impact of public health epidemics and pandemics, such as the COVID-19 pandemic, on employees and the global economy&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>reimbursement, pricing and insurance regimes&#894; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the interpretation of contractual provisions governed by local laws in the event of a contract dispute.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have prior experience in all of these areas, and the experience we do have in some of these areas is limited. Our collaborators may have limited experience in these areas as well. Failure to successfully navigate these risks and uncertainties may limit or prevent market penetration for any products that we or our collaborators may develop, which would limit their commercial potential and our revenues.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we obtain regulatory approval for our product candidates, the products may not gain the market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community necessary for commercial success.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even with the requisite approvals, the commercial success of our products will depend in part on the medical community, patients, and third- party or governmental payors accepting immunotherapies in general, and our products in particular, as medically useful, cost-effective and safe.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product that we bring to the market may not gain market acceptance by physicians, trial participants, third-party payors, and others in the medical community. Additionally, ethical, social and legal concerns about genetic research could result in additional regulations restricting or prohibiting the products and processes we may use. If these products do not achieve an adequate level of acceptance, we may not generate significant product sales revenue and may not be able to achieve or maintain profitability. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the potential efficacy and potential advantages over alternative treatments&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the ability to offer our products, if approved, at competitive prices&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the prevalence and severity of any side effects, including any limitations or warnings contained in a product&#8217;s approved labeling&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the prevalence and severity of any side effects resulting from checkpoint inhibitors or other drugs or therapies with which our products are administered&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>relative convenience and ease of transportation, storage and administration&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>any restrictions on the use of our products, if approved, together with other medications&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the willingness of the target patient population to try new therapies, such as mRNA vaccines and therapies, and of physicians to prescribe these therapies&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the strength of marketing and distribution support and timing of market introduction of competitive products&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>publicity concerning our products or competing products and treatments&#894; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>sufficient third-party insurance coverage or reimbursement, and patients&#8217; willingness to pay out-of-pocket in the absence of third- party coverage or adequate reimbursement.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if a potential product displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of the product will not be known until after it is launched. Our efforts to educate the medical community and third-party payors on the benefits of the products may require significant resources and may never be successful. Our efforts to educate the marketplace may require more resources than are required by the conventional technologies marketed by our competitors due to the complexity and uniqueness of our programs.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if any of our products are approved for marketing, we or a collaborator will be subject to significant regulatory obligations regarding the submission of safety and other post-marketing information and reports for such product, and will need to continue to comply (or ensure that our third-party providers comply) with current good manufacturing practices, or GMP, and current good clinical practices, or GCP, for any clinical trials that we or a </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">collaborator conduct post-approval. In addition, there is always the risk that we or a collaborator or regulatory authority might identify previously unknown problems with a product post-approval, such as adverse events of unanticipated severity or frequency. Compliance with these requirements is costly, and any such failure to comply or other issues with our product candidates identified post-approval could have a material adverse impact on our business, financial condition and results of operations.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if approved, profitably.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Successful sales of our product candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors including governmental healthcare programs, such as Medicare and Medicaid, managed care organizations and commercial payors, among others. Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In addition, because our product candidates represent new approaches to the treatment of cancer, we cannot accurately estimate the potential revenue from our product candidates.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Obtaining coverage and adequate reimbursement from third-party payors is critical to new product acceptance.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party payors decide which drugs and treatments they will cover and the amount of reimbursement. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&#8217;s determination that use of a product is:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>a covered benefit under its health plan&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>safe, effective and medically necessary&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>appropriate for the specific patient&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>cost-effective&#894; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>neither experimental nor investigational.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining coverage and reimbursement of a product from a government or other third-party payor is a time- consuming and costly process that could require us to provide to the payor supporting scientific, clinical and cost-effectiveness data for the use of our products. Third-party payors could require us to conduct additional studies, including post-marketing studies related to the cost effectiveness of a product, to qualify for reimbursement, which could be costly and divert our resources. Even if we obtain coverage for a given product, if the resulting reimbursement rates are insufficient, hospitals may not approve our product for use in their facility or third-party payors may require co-payments that patients find unacceptably high. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used. Further, from time to time, CMS revises the reimbursement systems used to reimburse health care providers, including the Medicare Physician Fee Schedule and Outpatient Prospective Payment System, which may result in reduced Medicare payments. In some cases, private third-party payors rely on all or portions of Medicare payment systems to determine payment rates. Changes to government healthcare programs that reduce payments under these programs may negatively impact payments from private third-party payors, and reduce the willingness of physicians to use our product candidates.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to seek approval to market our product candidates in the United States, the European Union and other selected jurisdictions. If we obtain approval for our product candidates in any particular jurisdiction, we will be subject to rules and regulations in that jurisdiction. In some countries, particularly those in Europe, the pricing of biologics is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">after obtaining marketing approval of a product candidate. Some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products into the marketplace. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The advancement of healthcare reform legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize any product candidates we or our collaborators develop and may adversely affect the prices for such product candidates.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or the ACA, was passed, which substantially changes the way health care is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs, and promoted a new Medicare Part D coverage gap discount program. Considerable uncertainty remains regarding the implementation and impact of the ACA.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of the provisions of the ACA have yet to be fully implemented, while certain provisions have been subject to judicial and Congressional challenges. The Tax Cuts and Jobs Act of 2017, or the TCJA, includes a provision repealing the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; CMS has recently proposed regulations that would give states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. Further, on October 13, 2017, an executive order was signed terminating the cost-sharing reduction, or CSR, subsidies that reimburse insurers under the ACA. The loss of the CSR payments is expected to increase premiums on certain policies issued by qualified health plans under the ACA. Several state Attorneys General filed suit to stop the administration from terminating the subsidies, but their request for a restraining order was denied by a federal judge in California on October 25, 2017. Another executive order was signed directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. With the current presidential administration and Congress, there may be additional administrative or legislative changes, including modification, repeal or replacement of all, or certain provisions of, the ACA. However, it remains to be seen whether new legislation modifying the ACA will be enacted and, if so, precisely what the new legislation will provide, when it will be enacted and what impact it will have on the availability of healthcare and containing or lowering the cost of healthcare. The implications of a potential repeal or replacement of the ACA, for our and our collaborators&#8217; business and financial condition, if any, are not yet clear.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. The Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year. These reductions will remain in effect through 2025 unless additional congressional action is taken.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">constraints in most </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EU</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing European Union and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post- approval activities, and affect our ability to commercialize any products for which we obtain marketing approval.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that additional healthcare reform measures or proposals will be adopted in the future, any of which could limit the amounts that governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. In the event that the pricing structures for healthcare products, such as the product candidates we are developing, change materially and limit payments for such product candidates, our business will be adversely impacted as our products may no longer be commercially viable based on their expected net present value&#894; we may have invested significant resources in products that cannot be commercially developed&#894; or we may determine that assets that have reached an early phase of development cannot or will not be taken into further development, notwithstanding their clinical viability. In addition, development assets or clinical programs that are part of our collaborations may no longer be deemed commercially viable to pursue based on our collaborators&#8217; assessments of the impact of any proposed, announced, or legislated pricing reforms.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot predict what healthcare reform initiatives may be adopted in the future. Further legislative and regulatory developments are likely, and we expect ongoing initiatives to increase pressure on drug pricing. Such reforms could have an adverse effect on anticipated revenues from product candidates that we may successfully develop and for which we may obtain regulatory approval, and may affect our overall financial condition and ability to develop product candidates.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">European Union drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the member states of the European Union.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to seek approval to market our product candidates in both the United States and in other selected jurisdictions. If we obtain approval for our product candidates in a particular jurisdiction, we will be subject to rules and regulations in that jurisdiction. In some countries, particularly those in the European Union, the pricing of biologics is subject to governmental control and other market regulations that could put pressure on the pricing and usage of our product candidates. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In addition, market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for our product candidates and may be affected by existing and future healthcare reform measures.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in most countries outside the United States, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. In some countries, we may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of any of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and, generally, prices tend to be significantly lower in the European Union. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales by us or our collaborators and the potential profitability of any of our product candidates in those countries would be negatively affected.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to our Financial Condition and Capital Requirements</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU52"></a>We have incurred significant losses since our inception and we may continue to incur significant losses in the foreseeable future, which makes it difficult to assess our future viability.<font style="font-weight:normal;font-style:normal;color:#000000;"> </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the past, we have incurred significant losses leading to accumulated losses of &#8364;409.6&#160;million as of December 31, 2020. We have devoted most of our financial resources to research and development, including our clinical and preclinical </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development activities and the development of our platforms. </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to December 2020</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, we financed our operations primarily through the sale of equity securities and proceeds from collaborations and, to a lesser extent, through revenue from manufacturing operations and grants from governmental and private organizations. </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">More recently, we have financed our operations from revenues from sales of </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our COVID-19 vaccine</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Even for those products for which we have obtained regulatory approval or emergency use authorization our future revenues will depend upon the</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">size of any markets in which our product candidates have received approval</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or authorization to market, </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our ability to achieve sufficient market acceptance, reimbursement from third-party payors, and adequate market share in those markets. </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If achieved, p</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rofitability is difficult to maintain over time and </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">highly dependent on various factors</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Our future financial results will depend, in part, on the rate of our future expenditures, the extent to which we experience long-term success of our commercial products and our ability to obtain funding through equity or debt financings, sales of assets, collaborations or grants</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to continue to incur significant and increasing operating expenses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we and our collaborators:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>continue or expand our research or development of our programs in preclinical development&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>continue or expand the scope of our clinical trials for our product candidates&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>initiate additional preclinical, clinical, or other trials for our product candidates, including under our collaboration agreements&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>continue to invest in our immunotherapy platforms to conduct research to identify novel technologies&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>change or increase our manufacturing capacity or capability&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>change or add additional suppliers&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>add additional infrastructure to our quality control, quality assurance, legal, compliance and other groups to support our operations as a public company and our product development and commercialization efforts, including expansion of sites in Germany and new sites in the United States, and potentially others globally&#894; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>attract and retain skilled personnel&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>seek marketing approvals and reimbursement for our product candidates&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>develop our sales, marketing, and distribution infrastructure for our COVID-19 vaccine and any other products for which we may obtain marketing approval or emergency use authorization&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>seek to identify and validate additional product candidates&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>acquire or in-license other product candidates and technologies&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>make milestone or other payments under any in-license agreements&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>maintain, protect, defend, enforce and expand our intellectual property portfolio&#894; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>experience any delays or encounter issues with any of the above.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict. If our operating results fall below expectations, the price of the ADSs representing our shares could decline.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU53"></a>Our financial condition and operating results have varied in the past and will continue to fluctuate from one financial period to the next due to a variety of factors, many of which are beyond our control. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Factors relating to our business that may contribute to these fluctuations include the following, as well as other factors described elsewhere in this report:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the size and timing of orders for our COVID-19 vaccine;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>delays or failures in advancement of existing or future product candidates into the clinic or in clinical trials&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our ability to develop and manufacture our product candidates and commercialize and manufacture our COVID-19 vaccine at commercial scale&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our ability to manage our growth&#894;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the outcomes of research programs, clinical trials, or other product development or approval processes conducted by us and our collaborators&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the ability of our collaborators to develop and successfully commercialize products developed from our suite of therapeutic classes&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our relationships, and any associated exclusivity terms, with collaborators&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our contractual or other obligations to provide resources to fund our product candidates, and to provide resources to our collaborators or to the collaborations themselves&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>risks associated with the international aspects of our business outside Germany, including the conduct of clinical trials in multiple locations and potential commercialization in such locations&#894; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our ability to minimize and manage product recalls or inventory losses caused by unforeseen events, cold chain interruption or testing difficulties;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our ability to report our financial results accurately and in a timely manner&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our dependence on, and the need to attract and retain, key management and other personnel&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our ability to obtain, protect, maintain, defend and enforce our intellectual property rights&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our ability to prevent the theft or infringement, misappropriation or other violation of our intellectual property, trade secrets, know- how or technologies&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our and our collaborators&#8217; ability to defend against claims of infringement of the intellectual property rights of third parties;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>potential advantages that our competitors and potential competitors may have in securing funding, obtaining the rights to critical intellectual property or developing competing technologies or products&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our ability to obtain additional capital that may be necessary to expand our business&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our collaborators&#8217; ability to obtain and devote additional capital that may be necessary to develop and commercialize products under our collaboration agreements, including our COVID-19 vaccine&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our ability to minimize and manage product liability claims arising from the use of our COVID-19 vaccine and our product candidates and other future products, if approved;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>business interruptions such as power outages, strikes, acts of terrorism or natural disasters&#894; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our ability to use our net operating loss carryforwards to offset future taxable income.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of the factors listed above may be affected by the COVID-19 pandemic&#8217;s or its impact on the global community and the global economy.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to the various factors mentioned above, and others, the results of any of our periods should not be relied upon as indications of our future operating performance. Our operating results may fluctuate significantly from one reporting period to the next, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU54"></a>In any particular period, our operating results could be below the expectations of securities analysts or investors, which could cause the price of the ADSs to decline. While as a general matter we intend to periodically report on the status of our product candidate pipeline, including articulating anticipated next steps in the form of development plans or potential data readouts, we may not always be able to provide forward-looking guidance on the timing of those next steps. In addition, we do not control the timing of disclosures of any milestones related to any of our programs that are managed by our collaborators. Any disclosure by a collaborator of data that are perceived as negative, whether or not such data are related to other data that we or others release, may have a material adverse impact on the price of the ADSs or overall valuation. The price of the ADSs may decline as a result of unexpected clinical trial results in one or more of our programs, including adverse safety events reported for any of our programs.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Profitability is difficult to maintain over time and highly dependent on various factors</font><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to generate revenue and achieve and maintain profitability depends on our ability, alone or with collaborators, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, our product candidates. Although we generate revenue from sales of our COVID-19 vaccine and additional limited revenue from sales of products by our subsidiaries making other sales transactions, the amount of long-term revenue from such sales, including the sales of our COVID-19 vaccine, is uncertain at this time. Our ability to generate future revenues from other pharmaceutical product sales depends heavily on our success in:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>completing research and preclinical and clinical development of our product candidates&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>seeking and obtaining U.S. and non-U.S. marketing approvals for product candidates for which we complete clinical trials&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>furthering the development of our own manufacturing capabilities and manufacturing relationships with third parties in order to provide adequate (in amount and quality) products and services to support clinical development and the market demand for our product candidates, if approved&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>obtaining market acceptance of our product candidates as a treatment option&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>launching and commercializing product candidates for which we obtain marketing approval and reimbursement, either through collaborations or, if launched independently, by establishing a sales force, marketing and distribution infrastructure&#894; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>addressing any competing technological and market developments&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>implementing additional internal systems and infrastructure&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>maintaining, defending, protecting, enforcing and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how&#894; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>attracting, hiring and retaining qualified personnel.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we have incurred significant costs associated with the commercialization of our COVID-19 vaccine. Our expenses could increase beyond our expectations if we are required by the FDA, the EMA, or other regulatory agencies to perform clinical and other trials or make changes to our manufacturing or quality systems in addition to those that we currently anticipate. Accordingly, such costs could adversely affect our future profitability. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The amount of and our ability to use, net operating losses and research and development credits to offset future taxable income may be subject to certain limitations and uncertainty. In addition, pending and future tax audits within our group, disputes with tax authorities and changes in tax law or fiscal regulations could lead to additional tax liabilities. We are subject to routine tax audits by the respective local tax authorities. Any additional tax liability could have an adverse effect on our business, financial conditions, results of operations or prospects.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU55"></a>In Germany,<font style="letter-spacing:0.05pt;"> </font>we have unused tax<font style="letter-spacing:0.05pt;"> </font>loss<font style="letter-spacing:0.05pt;"> </font>carryforwards<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>corporate<font style="letter-spacing:0.1pt;"> </font>taxes,<font style="letter-spacing:0.05pt;"> </font>though we have not recognized deferred<font style="letter-spacing:0.1pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>assets<font style="letter-spacing:0.05pt;"> </font><font style="color:#000000;">related</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#000000;">to</font> such loss<font style="letter-spacing:0.05pt;"> </font><font style="color:#000000;">carryforwards</font><font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>International<font style="letter-spacing:0.15pt;"> </font>Financial<font style="letter-spacing:0.1pt;"> </font>Reporting<font style="letter-spacing:0.05pt;"> </font>Standards,<font style="letter-spacing:0.05pt;"> </font>or IFRS, reporting<font style="letter-spacing:0.1pt;"> </font>purposes in previous years.<font style="letter-spacing:0.05pt;"> </font>In general,<font style="letter-spacing:0.05pt;"> </font>net<font style="letter-spacing:0.05pt;"> </font>operating<font style="letter-spacing:0.1pt;"> </font>loss,<font style="letter-spacing:0.05pt;"> </font>or NOL,<font style="letter-spacing:-0.05pt;"> </font>carryforwards<font style="letter-spacing:0.1pt;"> </font>in Germany<font style="letter-spacing:0.05pt;"> </font>do not expire.<font style="letter-spacing:0.05pt;"> Even though we recognized deferred tax assets on a majority of German tax loss carry forwards in 2020, t</font><font style="color:#000000;">hey</font> are,<font style="color:#000000;"> </font>however, subject<font style="letter-spacing:0.05pt;"> </font>to review<font style="letter-spacing:0.05pt;"> </font>and possible<font style="letter-spacing:0.05pt;"> </font>adjustment<font style="letter-spacing:0.1pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>authorities.<font style="letter-spacing:0.15pt;"> Deferred tax assets are recognized for unused tax losses only to the extent that it is probable that taxable profit will be available against which the losses can be utilized. </font>Furthermore,<font style="letter-spacing:0.1pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>current German<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>laws, certain<font style="letter-spacing:0.1pt;"> </font>substantial<font style="letter-spacing:0.1pt;"> </font>changes<font style="letter-spacing:0.05pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>Company&#8217;s<font style="letter-spacing:0.05pt;"> </font>ownership<font style="letter-spacing:0.05pt;"> </font>and business<font style="letter-spacing:0.05pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>further<font style="letter-spacing:0.1pt;"> </font>limit<font style="letter-spacing:0.1pt;"> </font>the amount<font style="letter-spacing:0.05pt;"> </font>of NOL<font style="letter-spacing:-0.05pt;"> </font>carryforwards<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>can be used annually<font style="letter-spacing:0.05pt;"> </font>to offset<font style="letter-spacing:0.1pt;"> </font>future<font style="letter-spacing:0.05pt;"> </font>taxable<font style="letter-spacing:0.05pt;"> </font>income.<font style="letter-spacing:0.05pt;"> </font>In addition,<font style="letter-spacing:0.05pt;"> we </font>have U.S.<font style="letter-spacing:-0.05pt;"> </font>federal<font style="letter-spacing:0.1pt;"> </font>and state<font style="letter-spacing:0.05pt;"> </font>NOL<font style="letter-spacing:-0.05pt;"> </font>carryforwards<font style="letter-spacing:0.1pt;"> </font>due to our subsidiaries in the<font style="letter-spacing:0.05pt;"> </font>United<font style="letter-spacing:0.05pt;"> </font>States, which may be subject to limitations on use after an ownership change. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to utilize a material portion of our NOLs or credits in either Germany or the United States.<font style="letter-spacing:0.05pt;"> </font>In addition,<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>rules<font style="letter-spacing:0.05pt;"> </font>regarding<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>timing<font style="letter-spacing:0.1pt;"> </font>of revenue<font style="letter-spacing:0.05pt;"> </font>and expense<font style="letter-spacing:0.05pt;"> </font>recognition<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>purposes<font style="letter-spacing:0.05pt;"> </font>in connection<font style="letter-spacing:0.05pt;"> </font>with various<font style="letter-spacing:0.05pt;"> </font>transactions<font style="letter-spacing:0.15pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>complex<font style="letter-spacing:0.05pt;"> </font>and uncertain<font style="letter-spacing:0.1pt;"> </font>in many<font style="letter-spacing:0.05pt;"> </font>respects,<font style="letter-spacing:0.1pt;"> </font>and, if challenged, our recognition<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>be subject<font style="letter-spacing:0.05pt;"> </font>to a revised assessment. In the<font style="letter-spacing:0.05pt;"> </font>event<font style="letter-spacing:0.05pt;"> </font>any such challenge<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>sustained,<font style="letter-spacing:0.1pt;"> </font>our NOLs<font style="letter-spacing:-0.05pt;"> </font>could<font style="letter-spacing:0.05pt;"> </font>be materially<font style="letter-spacing:0.15pt;"> </font>reduced<font style="letter-spacing:0.05pt;"> </font>or we could<font style="letter-spacing:0.05pt;"> </font>be determined<font style="letter-spacing:0.1pt;"> </font>to be a material<font style="letter-spacing:0.15pt;"> </font>cash<font style="letter-spacing:0.05pt;"> </font>taxpayer<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>one or more<font style="letter-spacing:0.05pt;"> </font>years which could have an adverse effect on our business, financial conditions, results of operations or prospects.<font style="letter-spacing:0.05pt;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, our ability</font><font style="letter-spacing:0.1pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to use our NOLs</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or credits</font><font style="letter-spacing:0.1pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</font><font style="letter-spacing:0.05pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conditioned</font><font style="letter-spacing:0.1pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">upon our attaining</font><font style="letter-spacing:0.1pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">profitability</font><font style="letter-spacing:0.15pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and generating</font><font style="letter-spacing:0.1pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">taxable income.</font><font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:0.05pt;">Taxable income exceeding NOLs will be subject to taxation resulting tax liabilities. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As described</font><font style="letter-spacing:0.1pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">above, we have incurred</font><font style="letter-spacing:0.1pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">significant</font><font style="letter-spacing:0.15pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">net</font><font style="letter-spacing:0.05pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">losses</font><font style="letter-spacing:0.05pt;"> in every year </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">since</font><font style="letter-spacing:0.05pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our inception</font><font style="letter-spacing:0.1pt;"> other tha</font><font style="letter-spacing:0.1pt;">n</font><font style="letter-spacing:0.1pt;"> 2018 </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and anticipate</font><font style="letter-spacing:0.1pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that in the future</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> we may incur</font><font style="letter-spacing:0.05pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">significant</font><font style="letter-spacing:0.15pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">losses</font><font style="letter-spacing:0.05pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</font><font style="letter-spacing:0.05pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">some of the group entities.</font><font style="letter-spacing:0.05pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;">to utilize</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">our NOL</font><font style="color:#231F20;letter-spacing:-0.05pt;"> </font><font style="color:#231F20;">or credit</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">carryforwards in the </font><font style="color:#231F20;">United States</font><font style="color:#231F20;"> </font><font style="color:#231F20;">and for some German group entities is uncertain.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Under German tax laws, we are obligated to withhold a percentage of royalty payments we make to third party licensors of intellectual property rights and remit those withholdings to German tax authorities. Late withholding tax payments may subject us to penalties and fees.<font style="font-weight:normal;font-style:normal;color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under German tax laws, we are obligated to withhold a percentage of royalty payments we make to third parties in consideration of the grant of rights under their intellectual property, and remit those withholdings to German tax authorities. As a result of an internal review, we discovered that in the 11-year period before April 2019 we and certain of our subsidiaries did not withhold, report and remit certain withholding taxes in connection with the in-licensing of intellectual property as required to be withheld under German tax laws, and have not made the requisite recordings in our and their financial books and records in relation to such withholding taxes. We notified the tax authorities of the late payments and made the respective payments in 2019. No administrative offence or criminal proceeding were opened or are expected in the future. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is possible to seek the refund of these withholding taxes from the German Federal Central Tax office after filing exemption and refund applications. We have filed such refund and exemption applications and the majority of the taxes paid have already been refunded. We expect further refunds to be paid out in the future. However, there is a possibility that the relevant claims against the licensors and/or the tax authorities, may in some instances, not be enforceable as a result of a licensor no longer existing, the lapse of time or any other facts preventing the enforcement of such claims.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may require substantial additional financing to achieve our goals, and a failure to obtain this capital on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.<font style="font-weight:normal;font-style:normal;color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU56"></a>As of December 31, 2020, we had cash and cash equivalents of &#8364;1,320.2 million. Our operating plans may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings, government or other third-party funding, sales of assets, marketing and distribution arrangements, other collaborations and licensing arrangements, or a combination of these approaches. We will require additional capital to obtain regulatory approval for, and to commercialize, future product candidates. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations. Our spending will vary based on new and ongoing development and corporate activities. Due to the high uncertainty of the length of time and activities associated with discovery and development of our product candidates, we are unable to estimate the actual funds we will require for development, marketing and commercialization activities.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk55421272"></a>Our future funding requirements, both near and long term, will depend on many factors, including, but not limited to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the initiation, progress, timing, costs, and results of preclinical or nonclinical studies and clinical trials for our product candidates&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the amount and timing of revenues and associated costs from sales of our COVID-19 vaccine;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the results of research and our other platform activities&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the clinical development plans we establish for our product candidates&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the terms of any agreements with our current or future collaborators, and the achievement of any milestone payments under such agreements to be paid to us or our collaborators&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the number and characteristics of product candidates that we develop or may in-license&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the outcome, timing and cost of meeting regulatory requirements established by the FDA, the EMA and other comparable regulatory authorities&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the cost of filing, prosecuting, obtaining, maintaining, protecting, defending and enforcing our patent claims and other intellectual property rights, including actions for patent and other intellectual property infringement, </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">misappropriation and other violations brought by third parties against us regarding our product candidates or actions by us challenging the patent or intellectual property rights of others&#894;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the effect of competing technological and market developments, including other products that may compete with one or more of our product candidates&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the cost and timing of completion and further expansion of clinical and commercial scale manufacturing activities sufficient to support all of our current and future programs&#894; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the cost of establishing sales, marketing, and distribution capabilities for any product candidates for which we may receive marketing approval and reimbursement in regions where we choose to commercialize our products on our own.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have financed our operations primarily through the sale of equity securities, revenue from collaborations, and revenue from sales of our COVID-19 vaccine, and we cannot be certain that additional funding will be available on favorable terms, or at all. Until we can generate sufficient product sales or royalty revenue to finance our operations, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, licensing arrangements, and other marketing or distribution arrangements. Any fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts, at the right time, on favorable terms, or at all, including as a result of the impact that the COVID-19 pandemic may have on the capital markets.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Negative clinical trial data or setbacks, or perceived setbacks, in our programs or with respect to our technology could impair our ability to raise additional financing on favorable terms, or at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our shareholders, and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. If we raise additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that may adversely affect our shareholders&#8217; rights.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU57"></a>Further, to the extent that we raise additional capital through the sale of ADSs, ordinary shares or securities convertible or exchangeable into ordinary shares, share ownership interests will be diluted. We have entered into five credit facilities with an aggregate drawing capacity of &#8364;173.0million. As of December&#160;31, 2020, three secured credit facilities with an aggregate drawing capacity of &#8364;23.0&#160;million were drawn down, and the first scheduled repayments have occurred on three of the four credit facilities. <font style="color:#000000;">In </font>addition, during December 2020, <font style="color:#000000;">we drew down &#8364;50.0&#160;million (Credit A) from our European Investment Bank, or EIB, financing and </font>may enter into additional credit facilities from time to time, which may be secured, to fund certain of our operations. If we raise additional capital through debt financing, we would be subject to fixed payment obligations and may be subject to security interests in our assets and covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional capital through marketing and distribution arrangements, sales of assets, collaborations, or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs. We also could be required to seek collaborators for one or more of our current or future product candidates at an earlier stage than otherwise would be desirable or relinquish our rights to product candidates or intellectual property that we otherwise would seek to develop or commercialize ourselves. If we are unable to raise additional capital in sufficient amounts, at the right time, on favorable terms, or at all, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our products or product candidates, or one or more of our other research and development initiatives. Any of the above events could significantly harm our business, prospects, financial condition and results of operations, cause the price of the ADSs to decline, and negatively impact our ability to fund operations.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will need to continue to develop and expand our company, and we may encounter difficulties in managing this development and expansion, which could disrupt our operations.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To manage our anticipated development and expansion, we must continue to implement and improve our managerial, operational, legal, compliance and financial systems, expand our facilities, and continue to recruit and train additional qualified personnel. In addition, our management may need to divert a disproportionate amount of its attention away from its day-to-day activities and devote a substantial amount of time to managing these development activities.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a growing biotechnology company, we are actively pursuing drug classes, platforms and product candidates in many therapeutic areas and across a wide range of diseases. Successfully developing products for, and fully understanding </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the regulatory and manufacturing pathways to</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> all of these therapeutic areas and disease states requires a significant depth of talent, resources and corporate processes in order to allow simultaneous execution across multiple areas. Due to our limited resources, we may not be able to effectively manage this simultaneous execution and the expansion of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, give rise to operational mistakes, legal or regulatory compliance failures, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The physical expansion of our operations may lead to significant costs and may divert financial resources from other projects, such as the development of our product candidates. If our management is unable to effectively manage our expected development and expansion, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and we may not be able to</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> effectively</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> implement our business strategy. Our future financial performance and our ability to compete effectively and commercialize our</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> COVID-19 vaccine and our</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> product candidates, if approved, will depend in part on our ability to effectively manage the </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">current and </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">future development and expansion of our company.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have incurred increased costs as a result of operating as a public company, and our management has been required to devote substantial time to new compliance initiatives. We are subject to financial reporting and other requirements for which our accounting and other management systems and resources may not be adequately prepared. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, which could result in sanctions or other penalties that would harm the business.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU58"></a>As a public company, we incur significant legal, accounting and other expenses. The federal securities laws, including the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, and rules subsequently implemented by the SEC and the Nasdaq Stock Market LLC, or Nasdaq, have imposed various requirements on public companies, including requirements to file annual and event-driven reports with respect to our business and financial condition, and to establish and maintain effective disclosure and financial controls and corporate governance practices. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased our legal and financial compliance costs and have made some activities more time-consuming and costly. We may not be able to produce reliable financial statements or file these financial statements as part of a periodic report in a timely manner with the SEC or comply with Nasdaq listing requirements. In addition, we could make errors in our financial statements that could require us to restate our financial statements.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 404 of the Sarbanes-Oxley Act, or Section 404, concurrent with this Annual Report on Form 20-F we are required to furnish a report by our management on our internal control over financial reporting, including the attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we have initiated the process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we have needed to continue to dedicate internal resources, have engaged outside consultants, and have adopted a detailed work plan to assess and document the adequacy of internal control over financial reporting. We will continue to implement steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that in the future neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act contains significant corporate governance and executive compensation related provisions that require the SEC to adopt additional rules and regulations in these areas such as &#8220;say on pay&#8221; and proxy access. Shareholder activism, the current political environment, and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">In the past we have identified a material weakness in our internal control over financial reporting and may identify additional material weaknesses in the future that may cause us to fail to meet our reporting obligations or result in material misstatements in our financial statements. If we identify material weaknesses in the future and fail to remediate such material weaknesses, we may not be able to report our financial results accurately or to prevent fraud.<font style="font-weight:normal;font-style:normal;color:#000000;"> </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU59"></a>Our management is responsible for establishing and maintaining internal control over financial reporting, disclosure controls, and compliance with the other requirements of the Sarbanes-Oxley Act and the rules promulgated by the SEC </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">thereunder. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with international financial reporting standards. A material weakness is defined as a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company&#8217;s annual or interim financial statements will not be prevented or detected by the company&#8217;s internal controls on a timely basis.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to our initial public offering, we operated as a private company that was not required to comply with the obligations of a public company with respect to internal control over financial reporting. We have historically operated with limited accounting personnel and other resources with which to address our internal control over financial reporting.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and our auditors identified a material weakness in 2019 primarily related to (i) a lack of sufficient accounting and supervisory personnel who have the appropriate level of technical accounting experience and training, (ii) a lack of supervision over external consultants providing technical accounting services and (iii) a lack of consistent application of accounting processes and procedures by our accounting personnel. These deficiencies constitute a material weakness in our internal control over financial reporting in both design and operation. As a result of the material weakness, management failed to identify adjustments in various areas, including but not limited to revenue, capitalization of tangible and intangible assets, and share-based compensation. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we identify material weaknesses in the future and are unable to successfully remediate such material weaknesses or successfully supervise and rely on outside advisors with expertise in these matters to assist us in the preparation of our financial statements, our financial statements could contain material misstatements that, when discovered in the future, could cause us to fail to meet our future reporting obligations and cause the price of the ADSs to decline.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU60"></a>As a &#8220;foreign private issuer,&#8221; we are exempt from a number of rules under the U.S. securities laws, as well as Nasdaq rules, and we are permitted to file less information with the SEC than U.S. companies. This may limit the information available to holders of the ADSs and may make our ordinary shares and the ADSs less attractive to investors.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a &#8220;foreign private issuer,&#8221; as defined in the rules and regulations of the SEC, and, consequently, we are not subject to all of the disclosure requirements applicable to companies organized within the United States. For example, we are exempt from certain rules under the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act, that regulate disclosure obligations and procedural requirements related to the solicitation of proxies, consents or authorizations applicable to a security registered under the Exchange Act. In addition, our officers and directors are exempt from the reporting and &#8220;short-swing&#8221; profit recovery provisions of Section 16 of the Exchange Act and related rules with respect to their purchases and sales of our securities. Moreover, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. public companies. Accordingly, there may be less publicly available information concerning our company than there is for U.S. public companies.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU61"></a>As a foreign private issuer, we file an Annual Report on Form 20-F within four months of the close of each fiscal year ending December 31 and reports on Form 6-K relating to certain material events promptly after we publicly announce these events. Additionally, we rely on a provision in Nasdaq&#8217;s Listed Company Manual that allows us to follow German company law and European law applicable to European stock corporations in general, the German Stock Corporation Act (<font style="font-style:italic;">Aktiengesetz</font>), the Council Regulation (EC) No 2157/2001 of October 8, 2001 on the Statute for a European company (SE), or the SE Regulation, and the German Act on the Implementation of Council Regulation (EC) No 2157/2001 of October 8, 2001 on the Statute for a European company (SE) (<font style="font-style:italic;">Gesetz zur Ausf&#252;hrung der Verordnung (EG) NR. 2157/2001 des Rates vom 8. Oktober 2001 &#252;ber das Statut der Europ&#228;ischen Gesellschaft (SE)</font>) (<font style="font-style:italic;">SE-Ausf&#252;hrungsgesetz-SEAG</font>), in particular with regard to certain aspects of corporate governance. This allows us to follow certain corporate governance practices that differ in significant respects from the corporate governance requirements applicable to U.S. companies listed on Nasdaq.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, we are exempt from regulations of Nasdaq that require a listed U.S. company to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>have a majority of the board of directors consist of independent directors;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>require non-management directors to meet on a regular basis without management present;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>adopt a code of conduct and promptly disclose any waivers of the code for directors or executive officers that should address certain specified items;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>have an independent compensation committee;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>have an independent nominating committee;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>solicit proxies and provide proxy statements for all shareholder meetings;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>review related party transactions; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>seek shareholder approval for the implementation of certain equity compensation plans and issuances of ordinary shares.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a foreign private issuer, we are permitted to follow home country practice in lieu of the above requirements. We therefore continue to follow German corporate governance practices in lieu of the corporate governance requirements of Nasdaq in certain respects. In particular, we follow German corporate governance practices in connection with the distribution of annual and interim reports to shareholders, the application of our code of conduct to our Supervisory Board, proxy solicitation in connection with shareholders&#8217; meetings, and obtaining shareholder approval in connection with the establishment of, or material amendment to, certain equity- based compensation plans.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with our Nasdaq listing, our audit committee is required to comply with the provisions of Section 301 of the Sarbanes-Oxley Act, and Rule 10A-3 of the Exchange Act, both of which are also applicable to U.S. companies listed on Nasdaq. As we are a foreign private issuer, however, our audit committee is not subject to additional requirements of Nasdaq applicable to listed U.S. companies, including an affirmative determination that all members of the audit committee are &#8220;independent,&#8221; using more stringent criteria than those applicable to us as a foreign private issuer.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to the above exemptions for foreign private issuers, our shareholders will not be afforded the same protections or information generally available to investors holding shares in public companies organized in the United States, some investors may find the ADSs less attractive as a result, and there may be a less active trading market for the ADSs.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face risks related to health epidemics and pandemics, such as COVID-19, that could adversely affect our operations.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business could be adversely impacted by the effects of COVID-19 or other epidemics or pandemics. The COVID-19 pandemic may negatively impact our operations in the future and could also affect our ability to enroll patients in clinical studies and complete clinical trials on the timelines we currently anticipate. Certain of our programs have experienced delays in the clinical development process as a result of the COVID-19 pandemic. In addition, we have modified our business practices, in response to the spread of COVID-19, including restricting employee travel, developing social distancing plans for employees and cancelling physical participation in meetings, events and conferences. This partial disruption, even temporary, may severely impact our operations and overall business by delaying the progress of our clinical trials and preclinical studies. Our operations, including research and manufacturing, could also be disrupted due to the potential impact of staff absences as a result of self-isolation procedures or extended illness.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU62"></a>Our suppliers, licensors or collaborators could also be disrupted by conditions related to COVID-19, or other epidemics, possibly resulting in disruption to our supply chain, clinical trials, partnerships or operations. If our suppliers, licensors, contract research organizations, or CROs, or collaborators are unable or fail to fulfill their obligations to us for any reason, our business could be adversely affected. Our customers could also be disrupted by conditions related to COVID-19 or other epidemics, possibly through deferring purchasing decisions or delaying research programs. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we have generated revenues from sales of our COVID-19 vaccine, there remains uncertainty regarding other potential effects of COVID-19 on our business. For example, if a new variant of COVID-19 emerges for which existing vaccines, including our COVID-19 vaccine, are ineffective, infections may become even more widespread or result in an economic downturn that could affect demand for our products and services or our ability to raise capital, which could have a material adverse effect on our business, operating results and financial condition.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not carry insurance for all categories of risk that our business may encounter and insurance coverage is becoming increasingly expensive. We do not know if we will be able to maintain existing insurance with adequate levels of coverage, and any liability insurance coverage we acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. We currently maintain insurance coverage for losses relating to an interruption of our development, manufacturing or commercialization efforts caused by contamination in an amount of &#8364;50,000,000 per claim up to an aggregate cap of &#8364;160,000,000 in any two-year period.&#160;With the grant of the first marketing approvals for our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 vaccine</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we have acquired additional insurance coverage for losses relating to transportation of </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our COVID-19 vaccine</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and product liability claims arising from its use,</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and the coverage or coverage limits of our insurance policies may not be adequate. If our losses exceed our insurance coverage, our financial condition would be adversely affected. In the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources. Clinical trials or regulatory approvals for any of our product candidates could be suspended, which could adversely affect our results of operations and business, including by preventing or limiting the development and commercialization of any product candidates that we or our collaborators may develop.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, operating as a public company has made it more expensive for us to obtain director and officer liability insurance. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our Supervisory Board, our Management Board, or our board committees.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to our Business</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our business is dependent on the successful development, regulatory approval and commercialization of product candidates based on our technology platforms. If we and our collaborators are unable to obtain approval for and effectively commercialize our product candidates for the treatment of patients in their intended indications, our business would be significantly harmed.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU63"></a>Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain, and we may not be able to obtain approvals for the commercialization of product candidates we may develop. Any immunotherapy we may develop and the activities associated with its development and commercialization, including design, testing, manufacture, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and by comparable global health authorities. To obtain the requisite regulatory approvals to commercialize any of our product candidates, we and our collaborators must demonstrate through extensive preclinical studies and clinical trials that our products are safe and effective, including in the target populations. Successful completion of clinical trials is a prerequisite to submitting a biologics license application, or BLA, or a new drug application, or NDA, to the FDA, a Marketing Authorization Application, or MAA, to the EMA, and similar marketing applications to comparable global regulatory authorities, for each product candidate and, consequently, the ultimate approval and commercial marketing of any product candidates.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate in a given jurisdiction. Although our COVID-19 vaccine has received emergency use authorization or approval in certain countries, it is possible that it will not receive widespread regulatory approval and that none of our other product candidates, or any product candidates we may seek to develop in the future, will ever obtain regulatory approval. We have limited experience in filing and supporting the applications necessary to gain marketing approvals and may need to rely on third-party CROs, regulatory consultants or collaborators to assist us in this process. Although we expect to submit BLAs for our mRNA-based product candidates in the United States, and in the European Union, mRNA therapies have been classified as gene therapy medicinal products, and other jurisdictions may consider our mRNA-based product candidates to be new drugs, not biologics or gene therapy medicinal products, and require different marketing applications. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Any product candidates we develop may not be effective, may be only moderately effective, or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process of obtaining marketing approvals in the United States, the European Union and elsewhere, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application. The FDA, EMA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that the data are insufficient for approval and require additional preclinical, clinical or other trials. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. Additional delays or non-approval may result if an FDA panel of experts, referred to as an Advisory Committee, or other regulatory authority recommends non-approval or restrictions on approval. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical trials, and the review process.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory agencies also may approve an immunotherapy for fewer or more limited indications than requested or may grant approval subject to the performance of post-marketing studies. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA, EMA and other regulatory agencies review the Quality or Chemistry, Manufacturing and Controls, or CMC, section of regulatory filings. Any aspects found unsatisfactory by regulatory agencies may result in delays in clinical trials and commercialization. In addition, the regulatory agencies typically conduct pre-approval inspections at the time of a BLA, MAA or comparable filing. Any findings by regulatory agencies and failure to comply with requirements may lead to delay in approval and failure to commercialize the potential mRNA product candidate.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU64"></a>If we experience delays in obtaining, or if we fail to obtain, approval of any product candidates we may develop, the commercial prospects for those product candidates will be harmed, and our ability to generate revenues will be materially impaired. Additionally, even if we are successful in obtaining marketing approval for product candidates, because our preclinical studies and clinical trials have not been designed with specific commercialization considerations, the commercial prospects for those product candidates could be harmed, and our ability to generate revenues could be materially impaired.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">mRNA drug development has substantial clinical development and regulatory risks due to limited regulatory experience with mRNA immunotherapies.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To our knowledge, other than our COVID-19 vaccine and MRNA-1273, no mRNA immunotherapies have been approved or received emergency use authorization or conditional marketing authorization to date by the FDA, the EMA or other comparable regulatory authority. Successful discovery and development of mRNA-based (and other) immunotherapies by either us or our collaborators is highly uncertain and depends on numerous factors, many of which are beyond our or their control. Our product candidates that appear promising in the early phases of development may fail to advance, experience delays in the clinic or clinical holds, or fail to reach the market for many reasons, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>discovery efforts aimed at identifying potential immunotherapies may not be successful&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>nonclinical or preclinical study results may show product candidates to be less effective than desired or have harmful or problematic side effects&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>clinical trial results may show the product candidates to be less effective than expected, including a failure to meet one or more endpoints or have unacceptable side effects or toxicities&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>manufacturing or distribution failures or insufficient supply of GMP materials for clinical trials, or higher than expected cost could delay or set back clinical trials, or make our product candidates commercially unattractive&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our improvements in the manufacturing processes may not be sufficient to satisfy the clinical or commercial demand of our product candidates or regulatory requirements for clinical trials&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>changes that we make to optimize our manufacturing, testing or formulating of GMP materials could impact the safety, tolerability and efficacy of our product candidates&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>pricing or reimbursement issues or other factors could delay clinical trials or make any immunotherapy uneconomical or noncompetitive with other therapies&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the failure to timely advance our programs or receive the necessary regulatory approvals, or a delay in receiving such approvals, due to, among other reasons, slow or failure to complete enrollment in clinical trials, withdrawal by trial participants from trials, failure to achieve trial endpoints, additional time requirements for data analysis, data integrity issues, BLA, MAA or the equivalent application, discussions with the FDA or the EMA, a regulatory request for additional nonclinical or clinical data, or safety formulation or manufacturing issues may lead to our inability to obtain sufficient funding&#894; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the proprietary rights, products and technologies of our competitors may prevent our immunotherapies from being commercialized.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU65"></a><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently, mRNA is considered a gene therapy product by the FDA. Unlike certain gene therapies that irreversibly alter cell DNA and may cause certain side effects, mRNA-based medicines are designed not to irreversibly change cell DNA. Side effects observed in other gene therapies, however, could negatively impact the perception of immunotherapies despite the differences in mechanism. In addition, the regulatory pathway in the United States and may other jurisdictions for approval is uncertain. The pathway for an individualized therapy, such as our iNeST mRNA-based immunotherapy where each patient receives a different combination of mRNAs, remains particularly unsettled. The number and design of the clinical and preclinical studies required for the approval of these types of medicines have not been established, may be different from those required for gene therapy products or therapies that are not individualized or may require safety testing like gene therapy products. Moreover, the length of time necessary to complete clinical trials and submit an application for marketing approval by a regulatory authority varies significantly from one pharmaceutical product to the next and may be difficult to predict.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU66"></a><a name="_AEIOULastRenderedPageBreakAEIOU67"></a><a name="_AEIOULastRenderedPageBreakAEIOU68"></a>Our product candidates may not work as intended, may cause undesirable side effects or may have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As with most biological products, use of our product candidates could be associated with side effects or adverse events which can vary in severity from minor reactions to death and in frequency from infrequent to prevalent. The potential for adverse events is especially acute in the oncology setting, where patients may have advanced disease, have compromised immune and other systems and be receiving numerous other therapies. Undesirable side effects or unacceptable toxicities caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, the EMA or comparable regulatory authorities. Results of our trials could reveal a high and unacceptable severity and prevalence of side effects.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU69"></a>If unacceptable side effects arise in the development of our product candidates, we, the FDA, competent authorities of EU member states, ethics committees, the institutional review boards, or IRBs, at the institutions in which our studies are conducted, or the Data Safety Monitoring Board, or DSMB, could suspend or terminate our clinical trials. The FDA or comparable regulatory authorities could also order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete any of our clinical trials or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Monitoring the safety of patients receiving our product candidates is challenging, which could adversely affect our ability to obtain regulatory approval and commercialize our product candidates.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In our ongoing and planned clinical trials, we have contracted, and are expected to continue to contract, with academic medical centers and hospitals experienced in the assessment and management of toxicities arising during clinical trials. Nonetheless, these centers and hospitals may have difficulty observing patients and treating toxicities, which may be more challenging due to personnel changes, inexperience, shift changes, house staff coverage or related issues. This could lead to more severe or prolonged toxicities or even patient deaths, which could result in us or the FDA, the EMA or other comparable regulatory authority delaying, suspending or terminating one or more of our clinical trials, and which could jeopardize regulatory approval. We also expect the centers using our product candidates, if approved on a commercial basis, could have similar difficulty in managing adverse events. Medicines used at centers to help manage adverse side effects of our product candidates may not adequately control the side effects and may have a detrimental impact on the efficacy of the treatment. Use of these medicines may increase with new physicians and centers administering our product candidates.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, even if we successfully advance one of our product candidates into and through clinical trials, such trials will likely only include a limited number of patients and limited duration of exposure to our product candidates. As a result, we cannot be assured that adverse effects of our product candidates will not be uncovered when a significantly larger number of patients are exposed to the product candidate. Further, any clinical trials may not be sufficient to determine the effects and safety consequences of taking our product candidates over a multi-year period.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our product candidates receives marketing approval and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>regulatory authorities may withdraw their approval of the product&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we may be required to recall a product or change the way such product is administered to patients&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a Medication Guide outlining the risks of such side effects for distribution to patients&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we could be sued and held liable for harm caused to patients&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the product may become less competitive&#894; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our reputation may suffer.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of the foregoing events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and result in the loss of significant revenues to us, which would materially and adversely affect our results of operations and business. In addition, if one or more of our product candidates or our immunotherapy approach generally prove to be unsafe, our technology platforms and pipeline could be affected, which would have a material and adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU70"></a>Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all and would have an adverse effect on our business.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Much of our pipeline is in preclinical development and these programs could be delayed or not advance into the clinic. Before we can initiate clinical trials for product candidates, we must complete extensive preclinical studies, including IND-enabling Good Laboratory Practice toxicology testing, that support our planned Investigational New Drug applications, or INDs, in the United States or similar applications in other jurisdictions. We must also complete extensive work on CMC activities (including collecting yield, purity and stability data) to be included in the IND filing. CMC activities for a new category of medicines such as mRNA therapies require extensive manufacturing processes and analytical development, which are uncertain and lengthy. For instance, batch failures have occurred as we scale up our manufacturing and may occur in the future. In addition, we have had in the past, and may in the future have, difficulty identifying appropriate buffers and storage conditions to enable sufficient shelf life of batches of our preclinical or clinical product candidates. If we are required to produce new batches of our product candidates due to insufficient shelf life, it may delay the commencement or completion of preclinical or clinical trials of such product candidates. For example, we cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the FDA or other regulatory authorities will accept the results of our preclinical testing or our proposed clinical programs or if the outcome of our preclinical testing, studies and CMC activities will ultimately support the further development of our programs. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical development involves a lengthy and expensive process with an uncertain outcome, and delays can occur for a variety of reasons outside of our control. Clinical trials of our product candidates may be delayed, and certain programs may never advance in the clinic or may be more costly to conduct than we anticipate, any of which can affect our ability to fund our company and would have a material adverse impact on our business.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical testing is expensive and complex and can take many years to complete. Its outcome is inherently uncertain. We may not be able to initiate, may experience delays in, or may have to discontinue clinical trials for our product candidates. We and our collaborators also may experience numerous unforeseen events during, or as a result of, any clinical trials that we or our collaborators conduct that could delay or prevent us or our collaborators from successfully developing our product candidates, including:</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the FDA, other regulators, IRBs or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site for any number of reasons, including concerns regarding safety and aspects of the clinical trial design&#894;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we may experience delays in reaching, or fail to reach, agreement on favorable terms with prospective trial sites and prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we have optimized in the past and may in the future optimize our manufacturing processes, including through changes to the scale and site of manufacturing, which may lead to additional studies (including bridging and bioequivalence studies) or potentially significant changes in our clinical trial designs, requiring additional cost and time, and, as a consequence, lead to a delay in plans for progressing one or more product candidates&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the outcome of our preclinical studies and our early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU71"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>in an effort to optimize product features, we have made in the past and may continue to make changes to our product candidates after we commence clinical trials of a medicine which may require us to repeat earlier stages of clinical testing or delay later-stage testing of the medicine&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>clinical trials of any product candidates may fail to show safety or efficacy, or may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional nonclinical studies or clinical trials, or we may decide to abandon product development programs&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>differences in trial design between early-stage clinical trials and later-stage clinical trials may make it difficult to extrapolate the results of earlier clinical trials to later clinical trials&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>preclinical and clinical data are often susceptible to varying interpretations and analyses, and many product candidates believed to have performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our product candidates may have undesirable side effects or other unexpected characteristics. One or more of such effects or events could cause regulators to impose a clinical hold on the applicable trial, or cause us or our investigators, IRBs or ethics committees to suspend or terminate the trial of that product candidate or any other of our product candidates for which a clinical trial may be ongoing&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the number of trial participants required for clinical trials of any product candidates may be larger than we anticipate, identification of trial participants for such trials may be limited, enrollment in these clinical trials may be slower than we anticipate due to perceived adverse effects, limited patient populations, competitive trials or other reasons, or participants may withdraw from clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or withdraw from the trial, which may require that we add new clinical trial sites&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>regulators may elect to impose a clinical hold, or we, our investigators, IRBs or ethics committees may elect to suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to an unacceptable benefit-risk ratio&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>with respect to infectious disease vaccine trials in particular, we have to wait for particular level of infection in the placebo arm in order to assess protection provided by vaccine, and we cannot control the rate of exposure or infection which can make timing uncertain;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the cost of preclinical or nonclinical testing and studies and clinical trials of any product candidates may be greater than we anticipate&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the supply or quality of our product candidates or other materials necessary to conduct clinical trials may be insufficient or inadequate&#894;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">safety or efficacy concerns regarding our product candidates may result from any concerns arising from nonclinical or clinical testing of other therapies targeting a similar disease state or other therapies, such as gene therapy, that are perceived as similar to ours&#894; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the FDA or other regulatory authorities may require us to submit additional data, such as long-term toxicology studies, or impose other requirements before permitting us to initiate a clinical trial.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU72"></a>We could also encounter delays if a clinical trial is suspended or terminated by us, the FDA or other regulatory authorities, ethics committees, or the IRBs of the institutions in which such trials are being conducted, or if such trial is recommended for suspension or termination by the DSMB. We may in the future be delayed in gaining clearance from the FDA or other regulators to initiate clinical trials through, among other things, the imposition of a clinical hold in order to address comments from such regulators on our clinical trial design or other elements of our clinical trials. A suspension or termination may be imposed due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols&#894; inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold&#894; unforeseen safety issues or adverse side effects&#894; failure to demonstrate a benefit, or adequate benefit-risk ratio, from using a product candidate&#894; failure to establish or achieve clinically meaningful trial endpoints&#894; changes in governmental regulations or administrative actions&#894; or lack of adequate funding to continue the clinical trial. Many of the factors that cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. We could also experience delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. We must also complete extensive work on CMC activities that require extensive manufacturing processes and analytical development, which are uncertain and lengthy.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. For example, the FDA and regulatory authorities in other jurisdictions have limited experience with commercial development of several of our technologies. The FDA may require an Advisory Committee to deliberate on the adequacy of the safety and efficacy data to support licensure. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain licensure of the product candidates based on the completed clinical trials, as the FDA often adheres to the Advisory Committee&#8217;s recommendations. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be certain.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, the FDA and other regulatory authorities have indicated that, prior to commencing later stage clinical trials for our mRNA-based product candidates, we will need to scale up and further refine assays to measure and predict the potency of a given dose of these product candidates. Any delay in the scaling and refining of assays that are acceptable to the FDA or other regulatory authorities could delay the start of future clinical trials. Further, the FDA or other regulatory authorities may disagree with our clinical trial design and our interpretation of data for our clinical trials or may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant preclinical or nonclinical testing and studies or clinical trial delays for our product candidates also could allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of operations. Any delays in the development of our product candidates may harm our business, financial condition and prospects significantly. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we or our collaborators encounter difficulties enrolling participants in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU73"></a>We depend on enrollment of participants in our clinical trials for our product candidates. In the past, our collaborators have found, and we or our collaborators may in the future find, it difficult to enroll trial participants in our clinical studies, which could delay or prevent clinical studies of our product candidates. The COVID-19 pandemic has introduced additional challenges in enrolling patients into many of our clinical trials. Identifying and qualifying trial participants to participate in clinical studies of our product candidates is critical to our success. The timing of our clinical studies depends on the speed at which we can recruit trial participants to participate in testing our product candidates. Delays in enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates. If trial participants are unwilling to participate in our studies because of negative publicity from adverse events in our trials or other trials of similar products, or those related to specific a therapeutic area, or for other reasons, including competitive clinical studies for similar patient populations, the timeline for recruiting trial participants, conducting studies, and obtaining regulatory </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval of potential products may be delayed. These delays could result in increased costs, delays in advancing our product development, delays in testing the effectiveness of our product, or termination of the clinical studies altogether.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to identify, recruit and enroll a sufficient number of trial participants, or those with required or desired characteristics to achieve diversity in a study, to complete our clinical trials in a timely manner. Patient and subject enrollment is affected by factors including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>severity of the disease under investigation&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>complexity and design of the study protocol&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>size of the patient population&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>eligibility criteria for the study in question&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>proximity and availability of clinical study sites for prospective trial participants&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>availability of competing therapies and clinical trials, including between our own clinical trials&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>efforts to facilitate timely enrollment in clinical trials&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>patient referral practices of physicians&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>ability to monitor trial participants adequately during and after treatment&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>ability to recruit clinical trial investigators with the appropriate competencies and experience&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>clinicians&#8217; and trial participants&#8217; perceptions of the potential advantages and side effects of the product candidate being studied in relation to other available therapies, including any new drugs or treatments that may be approved for the indications we are investigating&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our ability to obtain and maintain participant informed consent&#894; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>impacts of the COVID-19 global pandemic; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the risk that trial participants enrolled in clinical trials will not complete a clinical trial.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of trial participants available to us because some trial participants who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by a third party. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of trial participants who are available for our clinical trials at such clinical trial sites. Moreover, because in some cases our product candidates represent a departure from more traditional methods for disease treatment and prevention, potential trial participants and their doctors may be inclined to use conventional therapies or other new therapies rather than enroll trial participants in any future clinical trial involving individualized product candidates. Additionally, if new product candidates, such as gene editing therapies, show encouraging results, potential trial participants and their doctors may be inclined to enroll trial participants in clinical trials using those product candidates. If such new product candidates show discouraging results or other adverse safety indications, potential trial participants and their doctors may be less inclined to enroll trial participants in our clinical trials. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In particular, certain conditions for which we plan to evaluate our current product candidates are rare diseases with limited patient pools from which to draw for clinical trials. The eligibility criteria of our clinical trials will further limit the pool of available trial participants. Additionally, the process of finding and diagnosing patients may prove costly. As discussed above, each of the foregoing risks is exacerbated by the COVID-19 pandemic currently affecting the global community and the global economy.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU74"></a>A variety of risks associated with conducting research and clinical trials abroad and marketing our product candidates internationally could materially adversely affect our business.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials of our product candidates are currently being conducted in several countries, and we plan to commercialize our product candidates, if approved, globally. Accordingly, we are subject to additional risks related to operating in multiple countries, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>differing regulatory requirements in such countries&#894;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>increased difficulties in managing the logistics and transportation of storing and shipping product candidates produced in Germany and shipping the product candidate to the patient abroad&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>import and export requirements and restrictions&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>economic weakness, including inflation, or political instability in particular economies and markets&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>compliance with tax, employment, immigration and labor laws for employees living or traveling abroad&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>taxes, including withholding of payroll taxes&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>difficulties staffing and managing operations outside of Germany&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>workforce uncertainty in countries where labor unrest is more common&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>differing payor reimbursement regimes, governmental payors or patient self-pay systems, and price controls&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>potential liability under the U.S. Foreign Corrupt Practices Act of 1977 or comparable regulations in other jurisdictions&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>challenges enforcing our contractual and intellectual property rights, especially in those countries that do not respect and protect intellectual property rights to the same extent as Germany and the United States&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad&#894; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>business interruptions resulting from geopolitical actions, including war and terrorism, or public health epidemics or pandemics.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The extent to which the COVID-19 pandemic continues to impact our operations, including our clinical trial operations, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. In the future, similar events could affect our ability to manufacture and commercialize our product candidates.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These and other risks associated with our international operations and our collaborations with our collaborators may materially adversely affect our ability to attain or maintain profitable operations.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interim top-line and preliminary data from studies or trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU75"></a>From time to time, we may publish interim top-line or preliminary data from preclinical studies or clinical trials. Interim data are subject to the risk that one or more of the outcomes may materially change as more data become available. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully evaluate all data. As a result, the top-line results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Preliminary or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Additionally, interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to disclose publicly regarding a particular study or clinical trial is based on what is typically extensive information, and our securityholders may not agree with what we determine is the material or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed significant by our securityholders or others with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the top-line data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, product candidates may be harmed, which could significantly harm our business prospects.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Results of earlier studies and trials of our product candidates may not be predictive of future trial results.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Success in preclinical studies and early clinical trials does not ensure that later clinical trials will be successful. A number of companies in the biotechnology and pharmaceutical industries have suffered significant setbacks in clinical trials, even after positive results in earlier preclinical studies or clinical trials. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unreported adverse events. Notwithstanding any potential promising results in earlier studies and trials, we cannot be certain that we will not face similar setbacks. Even if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval for our product candidates. In addition, the results of our preclinical studies may not be predictive of the results of outcomes in human clinical trials. For example, our tumor-specific cancer immunotherapy candidates and any future product candidates may demonstrate different chemical, biological and pharmacological properties in patients than they do in laboratory studies or may interact with human biological systems in unforeseen or harmful ways. Product candidates in later stages of clinical trials may fail to show the desired pharmacological properties or safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. Even if we are able to initiate and complete clinical trials, the results may not be sufficient to obtain regulatory approval for our product candidates.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU76"></a>Our planned clinical trials or those of our collaborators may reveal significant adverse events not seen in our preclinical or nonclinical studies and may result in a safety profile that could delay or terminate clinical trials, or delay or prevent regulatory approval or market acceptance of any of our product candidates.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is typically an extremely high rate of attrition for product candidates across categories of medicines proceeding through clinical trials.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These product candidates may fail to show the desired safety and efficacy profile in later stages of clinical trials despite having progressed through nonclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in later-stage clinical trials due to lack of efficacy or unacceptable safety profiles, notwithstanding promising results in earlier trials. Most product candidates that commence clinical trials are never approved as products and there can be no assurance that any of our current or future clinical trials will ultimately be successful or support further clinical development of any of our product candidates.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of our product candidates are being developed or are intended to be co-administered with other developmental therapies or approved medicines. For example, autogene cevumeran (BNT122) is being developed to be co-administered with checkpoint inhibitors. Such combinations may have additional side effects, which may be difficult to predict in future clinical trials.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting trial participants to any of our clinical trials, trial participants may withdraw from trials, or we may be required to abandon the trials or our development efforts of one or more product candidates altogether. We, the FDA or other regulatory authorities, ethics committees or an IRB may impose a clinical hold on, or suspend or terminate, clinical trials of a product candidate at any time for various reasons, including a belief that participants in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the drug from obtaining or maintaining marketing approval, an unfavorable benefit-risk ratio may inhibit market acceptance of the approved product due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition and prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are not successful in discovering, developing and commercializing additional product candidates beyond our current portfolio, our ability to expand our business and achieve our strategic objectives would be impaired.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although a substantial amount of our efforts will focus on the clinical trials and potential approval of our existing product candidates, a key element of our strategy is to discover, develop and potentially commercialize additional products beyond our current portfolio to treat various conditions and in a variety of therapeutic areas. We intend to do so by investing in our own drug and target discovery efforts, exploring potential collaborations for the development of new products, and in-licensing technologies. Identifying new product candidates requires substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Even if we identify product candidates that initially show promise, we may fail to develop and commercialize such products successfully for many reasons, including the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the research methodology used may not be successful in identifying potential product candidates&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>competitors may develop alternatives that render our product candidates obsolete&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>product candidates we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>a product candidate may, on further study, be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU85"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all&#894; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>an approved product may not be accepted as safe and effective by trial participants, the medical community or third-party payors.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unsuccessful in identifying and developing additional products, our potential for growth may be impaired.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified senior management and scientific personnel.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent upon members of our management and scientific teams. We may not be able to retain these persons due to the competitive environment in the biotechnology industry. The loss of any of these persons&#8217; services may adversely impact the achievement of our research, development, financing and commercialization objectives. We currently do not have &#8220;key person&#8221; insurance on any of our employees.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we rely on consultants, contractors and advisors, including scientific and clinical advisors, to assist us in formulating our research and development, regulatory approval and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. The loss of the services of one or more of our current employees or advisors might impede the achievement of our research, development, regulatory approval and commercialization objectives. In addition, we have flexibly grown our workforce through the use of contractors and part-time workers. We may not be able to retain the services of such personnel, which might result in delays in the operation of our business.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recruiting and retaining other qualified employees, consultants and advisors for our business, including scientific and technical personnel, will be critical to our success as well. Competition for skilled personnel, including in mRNA research, clinical operations, regulatory affairs, therapeutic area management and manufacturing, is intense and the turnover rate can be high. We may not be able to attract and retain personnel on favorable terms given the competition among numerous pharmaceutical and biotechnology companies and academic institutions for individuals with similar skill sets. In addition, adverse publicity, failure to succeed in preclinical studies or clinical trials or applications for marketing approval may make it more challenging to recruit and retain qualified personnel. The inability to recruit, or loss of services of certain executives, key employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives and have a material adverse impact on our business, financial condition, results of operations and prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our employees, principal investigators and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading, which could have an adverse effect on </font><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">the</font><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </font><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">results of </font><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our </font><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">operations.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators and consultants. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the European Union and other jurisdictions, provide accurate information to the FDA, the EMA and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations and prospects, including the imposition of significant fines or other sanctions.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Employee litigation and unfavorable publicity could negatively affect our future business.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time our employees may bring lawsuits against us regarding injury, creating a hostile work place, discrimination, wage and hour disputes, sexual harassment or other employment issues. In recent years, there has been an increase in the number of discrimination and harassment claims generally. Coupled with the expansion of social media platforms and similar devices that allow individuals access to a broad audience, these claims have had a significant negative impact on some businesses. Certain companies that have faced employment- or harassment- related lawsuits have had to terminate management or other key personnel, and have suffered reputational harm that has negatively impacted their business. If we were to face any employment-related claims, our business could be negatively affected.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We and our collaborators or other contractors or consultants depend on information technology systems, and any failure of these systems could harm our business. Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations and financial condition.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our internal computer systems and those of our current and any future collaborators, vendors, and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, cybersecurity threats, war, and telecommunication and electrical failures. If any such material system failure, accident or security breach were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from one or more ongoing or completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, because of our approach to running multiple clinical trials in parallel, any breach of our computer systems may result in a loss of data or compromised data integrity across many of our programs in many stages of development. Any such breach, loss or compromise of clinical trial participant personal data may also subject us to civil fines and penalties, including under the EU General Data Protection Regulation, or the GDPR, relevant law of an EU member state, HIPAA, and other relevant state and federal privacy laws in the United States. To the extent that any disruption or security breach were to result in a loss of, or damage to, data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we have not experienced any material system failures, accidents or security breaches to date, we and a vendor have separately in the past been subject to a security breach resulting in us unknowingly making payments to third parties that were able to gain unauthorized access to our and the vendor&#8217;s email systems. <font style="color:#000000;">Additionally, in December 2020, </font><font style="Background-color:#FFFFFF;">we were informed by the EMA that the agency was subject to a cyber attack and that some documents relating to our regulatory submission for our COVID-19 vaccine candidate, which was stored on an EMA server, had been unlawfully accessed. None of our systems were breached in connection with this incident and we are unaware that any study participants were identified through the data being accessed.</font><font style="color:#000000;"> </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have put systems and procedures in place to minimize the likelihood of such incidents reoccurring&#894; however<font style="color:#000000;">, we cannot guarantee that third parties will not be able to gain unauthorized access to or otherwise breach our systems in the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">future. Any such unauthorized access or breach could adversely affect our business, results of operations and financial condition.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize the need for, and are in the early stages of, developing disaster recovery, business continuity and document retention plans that would allow us to be operational despite casualties or unforeseen events impacting our corporate headquarters or distribution center.<font style="color:#000000;"> </font>Without disaster recovery, business continuity and document retention plans, if we encounter difficulties or disasters with our manufacturing facilities or at our corporate headquarters, our critical systems, operations and information may not be restored in a timely manner, or at all, and this could have an adverse effect on our business.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of our current or future product candidates.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face an inherent risk of product liability exposure related to the testing of any of our current or future product candidates in clinical trials, and an even greater risk related to any commercialized products, such as our COVID-19 vaccine. If we cannot successfully defend ourselves against claims that our product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>decreased demand for any product candidate that we may develop&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>loss of revenue&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>substantial monetary awards to patients, healthy volunteers or their children&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>significant time and costs to defend the related litigation&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>withdrawal of clinical trial participants&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the inability to commercialize any product candidates that we may develop&#894; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>injury to our reputation and significant negative media attention.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We carry clinical trial insurance, including product liability insurance, which we believe to be sufficient in light of our current commercial operations and clinical programs&#894; however, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. We have expanded our insurance coverage to include product liability claims arising from the use of BNT162b2&#894; however, the amount of coverage we have obtained may not be adequate, and we may be unable to maintain product liability insurance for our COVID019 vaccine on commercially reasonable terms in the future. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause the price of the ADS to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our products become subject to a product recall it could harm our reputation, business and financial results.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and similar governmental authorities in other jurisdictions have the authority to require the recall of certain commercialized products. In the case of the FDA, the authority to require a recall of a biologic product must be based on an FDA finding that a batch, lot of other quantity of the biologic product presents an imminent or substantial hazard to the public health. In addition, some governmental bodies outside the United States have the authority to require the recall of any product candidate in the event of material deficiencies or defects in design or manufacture. Manufacturers may, under their own initiative, recall a product if any material deficiency in a product is found. A government-mandated or voluntary recall by us could occur as a result of manufacturing errors, design or labeling defects or other deficiencies and issues.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recalls of any of our product candidates would divert managerial and financial resources and have an adverse effect on our financial condition and results of operations. A recall announcement could harm our reputation with customers and negatively affect our sales, if any.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Manufacturing of our COVID-19 vaccine, our Product Candidates and Future Pipeline</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our mRNA product candidates are based on novel technologies and any product candidates we develop may be complex and difficult to manufacture. We may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management or shipping. If we or any of the third-party manufacturers we work with </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">encounter such difficulties, our ability to supply materials for clinical trials or any approved product could be delayed or stopped.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The manufacturing processes for our COVID-19 vaccine and our product candidates are novel and complex. Due to the novel nature of this technology and limited experience at larger scale production, we may encounter difficulties in manufacturing, product release, shelf life, testing, storage and supply chain management, or shipping. These difficulties could be due to any number of reasons including, but not limited to, complexities of producing batches at larger scale, equipment failure, choice and quality of raw materials and excipients, analytical testing technology, and product instability. In an effort to optimize product features, we have in the past and may in the future make changes to our product candidates in their manufacturing and stability formulation and conditions. This has resulted in the past, and may in the future result, in our having to resupply batches for preclinical, clinical, or commercial activities when there is insufficient product stability during storage and insufficient supply. Insufficient stability or shelf life of our product candidates could materially delay our or our collaborators&#8217; ability to continue the clinical trial for that product candidate or require us to begin a new clinical trial with a newly formulated drug product, due to the need to manufacture additional preclinical, clinical or commercial supply.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, in March 2021 we received product quality complaints related to our COVID-19 vaccine in Hong Kong.&nbsp;&nbsp;A thorough investigation into these complaints concluded that the reported product quality complaints were due to the combination of a deficient container closure process, or crimping, at one specific contract manufacturing organization when such containers were later shipped at ultra-cold conditions created by shipping on dry ice. The investigation did not identify any safety issues related to the product quality complaints. We and our COVID-19 vaccine in Hong Kong are in the process of supplying Hong Kong with replacement COVID-19 vaccine vials. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our rate of innovation is high, which has resulted in, and will continue to cause a high degree of, technology change that can negatively impact product comparability during and after clinical development. Furthermore, technology changes may drive the need for changes in, modification to, or the sourcing of, new manufacturing infrastructure or may adversely affect third-party relationships.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process to generate mRNA medicines is complex and, if not developed and manufactured under well-controlled conditions, can adversely impact pharmacological activity. We may encounter difficulties in scaling up our manufacturing process, thereby potentially impacting clinical and commercial supply. Additionally, for individualized therapies, we may encounter issues with our ability to timely and efficiently manufacture product given the on-demand requirements of such therapies, thereby potentially impacting clinical and commercial supply.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we continue developing new manufacturing processes for our drug substance and drug product, the changes we implement to the manufacturing process may impact, in turn, specification and stability of the drug product. Changes in our manufacturing processes may lead to failure of lots and this could lead to a substantial delay in our clinical trials <font style="color:#000000;">or an inability to supply sufficient commercial quantities of drug product</font>. Our mRNA product, if approved, and product candidates may prove to have a stability profile that leads to an unfavorable shelf life. This poses risk in supply requirements, wasted stock and higher cost of goods.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU86"></a>We are dependent on a number of equipment providers who are also implementing novel technology. Further, we have developed our own custom manufacturing equipment for certain of our product candidates. If such equipment malfunctions or we encounter unexpected performance issues, we could encounter delays or interruptions to clinical and commercial supply.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to the number of different programs, we may have cross contamination of products inside of our factories, CROs, suppliers or in the clinic that affect the integrity of our products. Additionally, for some programs the manufacturing scale is extremely small compared to the standard volumes of supply, such that we run the risk of contaminating the process each time we reopen a container to use remaining supplies.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we scale the manufacturing output for particular programs, we plan to continuously improve yield, purity and the pharmaceutical properties of our product candidates from IND-enabling studies through commercial launch, including shelf life stability and solubility properties of drug product and drug substance. Due to continuous improvement in manufacturing processes, we may switch processes for a particular program during development. However, after the change in process, more time is required for pharmaceutical property testing, such as six- or 12- month stability testing. That may require resupplying clinical material, or making additional GMP batches to keep up with clinical trial demand before such pharmaceutical property testing is completed.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are utilizing a number of raw materials and excipients that are either new to the pharmaceutical industry or are being employed in a novel manner. Some of these raw materials and excipients have not been scaled to a level to support commercial supply and could experience unexpected manufacturing or testing failures, or supply shortages. Such issues with raw materials and excipients could cause delays or interruptions to clinical and commercial supply of our </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 vaccine and our </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product candidates. Further, now and in the future</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> one or more of our programs may have a single source of supply for raw materials and excipients.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have established a number of analytical assays, and may have to establish several more, to assess the quality of our mRNA product candidates. We may identify gaps in our analytical testing strategy that might prevent release of product or could require product withdrawal or recall. For example, we may discover new impurities that have an impact on product safety, efficacy or stability. This may lead to an inability to release mRNA product candidates until the manufacturing or testing process is rectified.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product and product intermediates are extremely temperature sensitive, and we may learn that any or all of our products are less stable than desired. We may also find that transportation conditions negatively impact product quality. This may require changes to the formulation or manufacturing process for one or more of our product candidates and result in delays or interruptions to clinical or commercial supply. In addition, the cost associated with such transportation services and the limited pool of vendors may also add additional risks of supply disruptions.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Certain of our product candidates are uniquely manufactured for each patient and we may encounter difficulties in production, particularly with respect to scaling our manufacturing capabilities. If we or any of the third-party manufacturers with whom we contract encounter these types of difficulties, our ability to provide our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We custom design and manufacture certain product candidates that are unique and tailored specifically for each patient. Manufacturing unique lots of these product candidates is susceptible to product loss or failure due to issues with:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>logistics associated with the collection of a patient&#8217;s tumor, blood or other tissue sample&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>shipping such samples to a facility for genetic sequencing&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>next-generation sequencing of the tumor mRNA&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>biopsy of a sufficient quantity of cancerous tissue to allow for proper sequencing and identification of tumor-specific mutations&#894; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>identification of appropriate tumor-specific mutations&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU87"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the use of a software program, including proprietary and open source components, which is hosted in the cloud and a part of our product candidate, to assist with the design of the patient-specific mRNA, which software must be maintained and secured&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>effective design of the patient-specific mRNA that encodes for the required neoantigens&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>batch-specific manufacturing failures or issues that arise due to the uniqueness of each patient-specific batch that may not have been foreseen&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>quality control testing failures&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>unexpected failures of batches placed on stability&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>shortages or quality control issues with single-use assemblies, consumables or critical parts sourced from third-party vendors that must be changed out for each patient-specific batch&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>significant costs associated with individualized manufacturing that may adversely affect our ability to continue development&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>successful and timely manufacture and release of the patient-specific batch&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>shipment issues encountered during transport of the batch to the site of patient care&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the ability to define a consistent safety profile at a given dose when each participant receives a unique treatment&#894; and</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our reliance on single source suppliers.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also continue to evolve our own custom manufacturing equipment. This equipment may not function as designed, which may lead to deviations in the drug product being produced. This can lead to increased batch failure and the inability to supply patients enrolled in the clinical trial. If our clinical development plans are expanded, due to the custom nature of the equipment and single-use assemblies, we may not be able to supply this expanded need reliably without significant investments. In addition, there will be considerable time to scale up our facilities or build new facilities before we can begin to meet any commercial demand if one or more of our product candidates are approved. This expansion or addition of new facilities could also lead to product comparability issues, which can further delay introduction of new capacity.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As certain of our product candidates are manufactured for each individual patient, we will be required to maintain a chain of identity with respect to each patient&#8217;s tissue sample, sequence data derived from such tissue sample, analyze results of such patient&#8217;s genomic analysis and the custom manufactured product for each patient. Maintaining such a chain of identity is difficult and complex, and failure to do so could result in product mix-up, adverse patient outcomes, loss of product, or regulatory action, including withdrawal of any approved products from the market. Further, as our product candidates are developed through early-stage clinical studies to later-stage clinical trials towards approval and commercialization, we expect that multiple aspects of the complicated collection, analysis, manufacture and delivery processes will be modified in an effort to optimize processes and results. These changes may not achieve the intended objectives, and any of these changes could cause our product candidates to perform differently than we expect, potentially affecting the results of clinical trials.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our inability to manufacture sufficient quantities of our COVID-19 vaccine or any of our product candidates, or our failure to comply with applicable regulatory requirements, would materially and adversely affect our business.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing is a vital component of our individualized immunotherapy approach, and we have invested significantly in our manufacturing facilities, including the acquisition of a manufacturing site in Marburg, Germany. All internal manufacturing is performed under GMP guidelines. We also rely on a network of external contract manufacturing organizations, or CMOs, for the manufacture of our COVID-19 vaccine. We do not rely on any external CMOS for the manufacture of our product candidates and at this time, and we have limited redundancy among our facilities. Due to the individualized nature of our product candidates, we do not maintain product reserves. If any of our or our external CMOs&#8217; manufacturing facilities experience difficulties, including related to manufacturing, product release, shelf life, testing, storage and supply chain management or shipping, our clinical development programs may be delayed or suspended until we or our external CMOs can resume operations. We may also be required to incur significant expenditures to resolve such difficulties.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our facilities are subject to various regulatory requirements and may be subject to the inspection of the FDA or other regulatory authorities.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU88"></a>If we or our external CMOs cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, the EMA or comparable regulatory authorities in other jurisdictions, we may not be able to rely on our or our external CMOs&#8217; manufacturing facilities for the manufacture of our product candidates. If the FDA, the EMA or another comparable regulatory authority finds our facilities inadequate for the manufacture of our COVID-19 vaccine or our product candidates or if such facilities are subject to enforcement action in the future or are otherwise inadequate, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our COVID-19 vaccine or our product candidates.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments. If we were to encounter any of these difficulties, our ability to provide our COVID-19 vaccine or our product candidates to patients in clinical trials, or to provide products for the treatment of patients, once approved, would be jeopardized.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are subject to regulatory and operational risks associated with the physical and digital infrastructure at both our internal manufacturing facilities and at those of our external service providers.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The designs of our facilities are based on current standards for biotechnology facilities. They have been reviewed and approved by local German authorities and have also received GMP manufacturing licenses. We have designed our facilities to incorporate a significant level of automation of equipment with integration of several digital systems to improve efficiency of operations. We have attempted to achieve a high level of digitization for clinical manufacturing facilities relative to industry standards. While this is meant to improve operational efficiency, this may pose additional risk of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">process equipment malfunction and even overall manufacturing system failure or shutdown due to internal or external factors including, but not limited to, design issues, system compatibility or potential cybersecurity breaches. This may lead to delay in supply or shutdown of our facilities. Any disruption in our manufacturing capabilities could cause delays in our production capacity for our drug substances or drug products, impose additional costs, or may require us to identify, qualify and establish an alternative manufacturing site, the occurrence of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we expand our development and commercial capacity, we may establish additional manufacturing capabilities and expand to other locations or geographies, which may lead to regulatory delays or prove costly. If we fail to select the correct location, complete the construction in an efficient manner, recruit the required personnel, and generally manage our growth effectively, the development and production of our product candidates could be delayed or curtailed. Additional investments may be needed if changes in our manufacturing process lead to required changes in our infrastructure.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our COVID-19 vaccine and certain of our product candidates rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates require many specialty raw materials, some of which are manufactured by small companies with limited resources and experience to support a commercial product, and the suppliers may not be able to deliver raw materials to our specifications. In addition, some such suppliers normally support blood-based hospital businesses and generally do not have the capacity to support commercial products manufactured under GMP by biopharmaceutical firms. These suppliers may be ill-equipped to support our needs, especially in non-routine circumstances like an FDA inspection or medical crisis, such as widespread contamination. We also do not have contracts with many of these suppliers, and we may not be able to contract with them on acceptable terms or at all. Accordingly, we have experienced and we may in the future experience delays in receiving key raw materials to support clinical or commercial manufacturing.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU89"></a>In addition, some raw materials are currently available from a single supplier, or a small number of suppliers. We cannot be sure that these suppliers will remain in business or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new supplier. The time and effort to qualify a new supplier could result in additional costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results. Further, we may be unable to enter into agreements with a new supplier on commercially reasonable terms, which could have a material adverse impact on our business.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are subject to significant regulatory oversight with respect to manufacturing our product candidates. Our manufacturing facilities or the manufacturing facilities of our third-party manufacturers or suppliers may not meet regulatory requirements. Failure to meet GMP requirements set forth in regulations promulgated by the FDA, the EMA and other comparable regulatory authorities could result in significant delays in and costs of our products.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The manufacturing of immunotherapies for clinical trials or commercial sale is subject to extensive regulation. GMP requirements govern manufacturing processes and procedures, including record-keeping, and the implementation and operation of quality systems to control and assure the quality of products and materials used in our products and product candidates. Poor control of the GMP production processes can lead to product quality failures that can impact our ability to supply product, resulting in loss of potential product sales revenue, cost overruns and delays to clinical timelines for our clinical programs, which could be extensive. Such production process issues include but are not limited to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>critical deviations in the manufacturing process&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>facility and equipment failures&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>contamination of the product due to an ineffective quality control strategy&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>facility contamination as assessed by the facility and utility environmental monitoring program&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>ineffective process, equipment or analytical change management, resulting in failed lot release criteria&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>raw material failures due to ineffective supplier qualification or regulatory compliance issues at critical suppliers&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>ineffective product stability&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>failed lot release or facility and utility quality control testing&#894;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>ineffective corrective actions or preventative actions taken to correct or avoid critical deviations due to our developing understanding of the manufacturing process as we scale&#894; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>failed or defective components or consumables.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We must supply all necessary documentation in support of a BLA or other marketing authorization application on a timely basis and must adhere to the FDA&#8217;s, the EMA&#8217;s and other countries&#8217; GMP requirements, which are enforced, in the case of the FDA, in part through its facilities inspection program.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU90"></a>Regulatory authorities typically require representative manufacturing site inspections to assess adequate compliance with GMPs and manufacturing controls as described in the filing. If either we or one of our third-party manufacturing sites fails to provide sufficient quality assurance or control, approval to commercialize our product candidates may not be granted. Inspections by regulatory authorities may occur at any time during the development or commercialization phase of products. The inspections may be product-specific or facility-specific for broader GMP inspections or as a follow up to market or development issues that the regulatory agency may identify. Deficient inspection outcomes may influence the ability of our third-party manufacturers or suppliers to fulfill their supply obligations, impacting or delaying supply or delaying programs.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The manufacturing process for any products that we may develop is subject to the FDA&#8217;s, the EMA&#8217;s and other regulatory authorities&#8217; approval processes, and we may need to contract with manufacturers who we believe can meet applicable regulatory authority requirements on an ongoing basis. If we or our third-party manufacturers are unable to reliably produce product candidates to specifications acceptable to the FDA, the EMA or other regulatory authorities, we or our collaborators may not obtain or maintain the approvals we or they need to commercialize such products. Even if we or our collaborators obtain regulatory approval for any of our immunotherapies, there is no assurance that either we or our CMOs will be able to manufacture our product candidates to specifications acceptable to the FDA, the EMA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates, impair commercialization efforts or increase our cost of goods. The occurrence of any of the foregoing could have an adverse effect on our business, financial condition, results of operations and growth prospects.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may not have direct control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. Furthermore, all of our CMOs are engaged with other companies to supply or manufacture materials or products for such companies, which exposes our CMOs to regulatory risks for the production of such materials and products. As a result, failure to meet the regulatory requirements for the production of those materials and products may generally affect the regulatory status of our CMOs&#8217; facilities. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our products and product candidates (including those of our collaborators) and our overall business operations. Our potential future dependence upon others for the manufacture of our products, product candidates and raw materials may adversely affect our future profit margins and our ability to commercialize any products that receive regulatory approval on a timely and competitive basis.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA, the EMA and other regulatory authorities may require us to submit product samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA or other regulatory authorities may require that we do not distribute a lot or lots until the relevant agency authorizes such release. Deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Our CMOs have, in the past, experienced lot failures and some may have experienced product recalls. Lot failures or product recalls with respect to product produced by either our own facilities or those of our third-party manufacturers could cause us and our collaborators to delay clinical trials or product launches, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also may encounter problems hiring and retaining the experienced scientific, quality-control and manufacturing personnel needed to operate our manufacturing processes and operations, which could result in delays in production or difficulties in maintaining compliance with applicable regulatory requirements. While we train and qualify all personnel </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">around the appropriate handling of our products and materials, we may not be able to control for or ultimately detect intentional sabotage or negligence by any employee or contractor.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU91"></a><a name="_AEIOULastRenderedPageBreakAEIOU92"></a><a name="_AEIOULastRenderedPageBreakAEIOU94"></a><a name="_AEIOULastRenderedPageBreakAEIOU96"></a><a name="_AEIOULastRenderedPageBreakAEIOU97"></a><a name="_AEIOULastRenderedPageBreakAEIOU98"></a><a name="_AEIOULastRenderedPageBreakAEIOU99"></a>Risks Related to our Reliance on Third Parties</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have entered into several arrangements with a related party for the performance of nonclinical research programs, and these arrangements present potential conflicts of interest.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have had a longstanding relationship with Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz (<font style="font-style:italic;">Translationale Onkologie an der Universit&#228;tsmedizin der Johannes Gutenberg Universit&#228;t Mainz gemeinn&#252;tzige GmbH</font>), or TRON, a non-profit limited liability company engaged in biopharmaceutical research, for the performance of nonclinical research. For more information about our relationship with TRON, see Item 7.B. Major Shareholders and Related Party Transactions in this Annual Report on Form 20-F, below. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The existence or appearance of a conflict of interest could depress the price of the ADSs or attract scrutiny from shareholders, regulators or other stakeholders. Additionally, any conflicts of interest would create the risk that our officers may favor their personal interests over those of our shareholders.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on third parties in the conduct of significant aspects of our preclinical studies and clinical trials and intend to rely on third parties in the conduct of future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or fail to meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently rely, and expect to continue to rely, on third parties, such as CROs, clinical data management organizations, collaborators, medical institutions and clinical investigators, to conduct various and significant elements of our clinical trials. We currently rely, and expect to continue to rely, on third parties to conduct certain research and preclinical testing activities. In some cases, these third parties may terminate their engagements with us. If we need to enter into alternative arrangements, it would delay our discovery or product development activities.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our regulatory or contractual responsibilities. We are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards. For example, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU100"></a>Moreover, the FDA requires us to comply with GCP for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity, and civil and criminal sanctions. For any violations of laws and regulations during the conduct of our preclinical studies and clinical trials, we could be subject to warning letters or enforcement action that may include civil penalties up to and including criminal prosecution.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and our CROs are required to comply with regulations, including GCP, for conducting, monitoring, recording and reporting the results of preclinical studies and clinical trials to ensure that the data and results are scientifically credible and accurate and that the trial participants are adequately informed, among other things, of the potential risks of participating in clinical trials. We also are responsible for ensuring that the rights of our clinical trial participants are protected. These regulations are enforced by the FDA, the regulatory authorities of the EU member states, and comparable regulatory authorities of other jurisdictions for any product candidates in clinical development. The FDA enforces GCP regulations through periodic inspections of clinical trial sponsors, principal investigators and trial sites. If we or our CROs fail to comply with applicable GCP, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable regulatory authorities of other jurisdictions may require us to perform additional clinical trials before approving our marketing applications. We cannot be sure that, upon inspection, the FDA will determine that any of our future clinical trials will comply with GCP. In addition, our clinical trials must be conducted with product candidates produced in accordance with the requirements of GMP regulations. Our failure or the failure of our CROs to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process and could also subject us to enforcement action.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we have designed</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and in the future intend to </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">desig</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the clinical trials for certain of our product candidates, our collaborators will design the clinical trials that they are managing (in some cases, with our input) and in the case of clinical trials controlled by us, we expect that CROs will conduct all of the clinical trials. As a result, many important aspects of our development programs, including their conduct and timing, are outside of our direct control. Our reliance on third parties to conduct future preclinical studies and clinical trials results in less direct control over the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also potentially lead to mistakes as well as difficulties in coordinating activities. Outside parties may:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>have staffing difficulties&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>fail to comply with contractual obligations&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>experience regulatory compliance issues&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>undergo changes in priorities or become financially distressed&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>form relationships with other entities, some of which may be our competitors&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>have human errors&#894; or</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>be subject to cyberattacks.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These factors may materially adversely affect the willingness or ability of third parties to conduct our preclinical studies and clinical trials and may subject us to unexpected cost increases that are beyond our control. If the CROs do not perform preclinical studies and clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with regulatory requirements, the development, regulatory approval and commercialization of our product candidates may be delayed, we may not be able to obtain regulatory approval and commercialize our product candidates, or our development programs may be materially and irreversibly harmed. If we are unable to rely on preclinical and clinical data collected by our CROs, we could be required to repeat, extend the duration of, or increase the size of any clinical trials we conduct and this could significantly delay commercialization and require significantly greater expenditures.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU101"></a>We also rely on other third parties to transport, store and distribute the required materials for our clinical trials. In the past, certain of our third-party vendors have mishandled our materials, resulting in loss of full or partial lots of material. Any further performance failure on the part of these third parties could result in damaged products and could delay clinical development or marketing approval of any product candidates we may develop or commercialization of our medicines, if approved, producing additional losses and depriving us of potential product sales revenue, causing us to default on our contractual commitments, result in losses that are not covered by insurance, and damage our reputation and overall perception of our products in the marketplace. Each of the risks set forth above may be exacerbated by the COVID-19 pandemic currently affecting the global community and the global economy.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our existing collaborations, or any future collaboration arrangements that we may enter into, may not be successful, which could significantly limit the likelihood of receiving the potential economic benefits of the collaboration and adversely affect our ability to develop and commercialize our product candidates.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into collaborations under which our collaborators have provided, and may in the future provide, funding and other resources for developing and commercializing our product candidates. We expect to enter into additional collaborations to access additional funding, capabilities and expertise in the future. Our existing collaborations, and any future collaborations we enter into, may pose a number of risks, including the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>collaborators may not perform or prioritize their obligations as expected&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the clinical trials conducted as part of such collaborations may not be successful&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization of programs based on clinical trial results, changes in the collaborators&#8217; focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>collaborators may delay clinical trials, provide insufficient funding for clinical trials, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing&#894;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours&#894;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>product candidates developed in collaborations with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the development or commercialization of our product candidates&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of any such product&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development of any product candidates, may cause delays or termination of the research, development or commercialization of such product candidates, may lead to additional responsibilities for us with respect to such product candidates, or may result in litigation or arbitration, any of which would be time-consuming and expensive&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>collaborators may not properly maintain, protect, defend or enforce our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>disputes may arise with respect to the ownership of intellectual property developed pursuant to our collaborations&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>collaborators may infringe, misappropriate or otherwise violate the intellectual property rights of third parties, which may expose us to litigation and potential liability&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>collaborations may be terminated for the convenience of the collaborator and, if terminated, the development of our product candidates may be delayed, and we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU102"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>future relationships may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing shareholders, or disrupt our management and business&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we could face significant competition in seeking appropriate collaborators, and the negotiation process is time-consuming and complex&#894; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our international operations through any future collaborations, acquisitions or joint ventures may expose us to certain operating, legal and other risks not encountered in the United States.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our collaborations do not result in the successful development and commercialization of programs, or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone, earn-out, royalty or other contingent payments under the collaborations. If we do not receive the funding we expect under these agreements, our development of product candidates could be delayed and we may need additional resources to develop our product candidates. In addition, in general our collaborators have the right to terminate their agreements with us for convenience. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and the perception of us in the business and financial communities could be adversely affected. All of the risks relating to product development, regulatory approval and commercialization described in this report apply to the activities of our collaborators.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are not able to establish collaborations on commercially reasonable terms, we may have to alter our research, development and commercialization plans.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and product development programs and the potential commercialization of any product candidates we develop alone or with collaborators will require substantial additional cash to fund expenses, and we expect that we will continue to seek collaborative arrangements with others in connection with the development and potential commercialization of current and future product candidates or the development of ancillary technologies. We face significant competition in establishing relationships with appropriate collaborators. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Whether or not we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include, among other things and as applicable for the type of potential product or technology, an assessment of the opportunities and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">risks of our technology, the design or results of studies or trials, the likelihood of approval, if necessary, of the FDA or </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">comparable </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products and technologies and industry and market conditions generally.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current or future collaborators may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us. Additionally, we may be restricted under existing collaboration agreements from entering into future agreements on certain terms or for certain development activities with potential collaborators. For example, we have granted exclusive rights or options to Pfizer for certain targets, and under the terms of our respective collaboration agreements with them, we will be restricted from granting rights to other parties to use our mRNA technology to pursue potential products that address those targets. Similarly, our collaboration agreements have in the past and may in the future contain non-competition provisions that could limit our ability to enter into collaborations with future collaborators.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU103"></a>Collaborations are complex and time-consuming to negotiate and document. We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we do enter into additional collaboration agreements, the negotiated terms may force us to relinquish rights that diminish our potential profitability from development and commercialization of the subject product candidates or others. If we are unable to enter into additional collaboration agreements, we may have to curtail the research and development of the product candidate or technology for which we are seeking to collaborate, reduce or delay research and development programs, delay potential commercialization timelines, reduce the scope of any sales or marketing activities or undertake research, development or commercialization activities at our own expense. If we elect to increase our expenditures to fund research, development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have entered into in-licensing arrangements and may form or seek to enter into additional licensing arrangements in the future, and we may not realize the benefits of such licensing arrangements.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a party to licenses that give us rights to third-party intellectual property, including patents and patent applications, that are necessary or useful for our business. In particular, we have obtained licenses from CellScript LLC and its affiliate, mRNA RiboTherapeutics, Inc., to patent rights claiming certain uses of modified RNA, as well as licenses from certain other parties for intellectual property useful in pharmaceutical formulations. We may enter into additional licenses to third-party intellectual property in the future.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The success of products developed based on in-licensed technology will depend in part on the ability of our current and future licensors to prosecute, obtain, maintain, protect, enforce and defend patent protection for our in-licensed intellectual property. Our current and future licensors may not successfully prosecute the patent applications we license. Even if patents were issued in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue such litigation less aggressively than we would. Without protection for the intellectual property we license, other companies might be able to offer substantially identical products for sale, which could adversely affect our competitive business position and harm our business prospects. In addition, we sublicense our rights under various third-party licenses to our collaborators. Any impairment of these sublicensed rights could result in reduced revenues under our collaboration agreements or result in termination of an agreement by one or more of our collaborators.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the scope of rights granted under the license agreement and other interpretation-related issues&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>whether and the extent to which our technology and processes infringe, misappropriate or otherwise violate the intellectual property of the licensor that is not subject to the licensing agreement&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our right to sublicense patent and other intellectual property rights to third parties under collaborative relationships&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our diligence obligations with respect to the use of the licensed intellectual property and technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations&#894;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the ownership of inventions, trade secrets, know-how and other intellectual property resulting from the joint creation or use of intellectual property by our licensors and us and our collaborators&#894; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the priority of invention of patented technology.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If disputes over intellectual property that we have in-licensed or other related contractual rights prevent or impair our ability to maintain our current licensing arrangements on favorable terms, we may be unable to successfully develop and commercialize the affected product candidates.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU104"></a>We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which are described below. If we, our co-owners or our licensors fail to adequately protect, defend, maintain or enforce this intellectual property, our ability to commercialize products could suffer.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we commit certain material breaches and fail to cure them (if such breach is curable), we are required to repurchase shares held by the Bill &amp; Melinda Gates Foundation.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we commit a specified material breach under the letter agreement with the Bill &amp; Melinda Gates Foundation, or BMGF, and such breach remains uncured after a specified period of time (if curable), we are required to either (i) repurchase the shares held by BMGF or locate a third party to purchase the shares from BMGF, in either case at a price that is the greater of the original purchase price or the fair market value of the shares at the time of repurchase, or (ii) if we cannot meet the requirements under (i) (e.g., because we do not have sufficient cash reserves), then we must use our best efforts to effect BMGF&#8217;s withdrawal right as soon as practicable, which may mean acquiring the shares in tranches over time. If we are required to repurchase BMGF&#8217;s shares, our financial position could be materially and adversely affected.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on third parties to manufacture certain of our clinical product supplies, and we may have to rely on third parties to produce and process our product candidates, if approved.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we expect to continue using our own clinical manufacturing facilities, we also rely on outside vendors to manufacture supplies and process our product candidates. We have only recently begun to manufacture our COVID-19 vaccine on a commercial scale and may not be able to achieve commercial- scale manufacturing and processing for our product candidates, if approved, and may be unable to create an inventory of mass-produced, off-the-shelf product to satisfy demands for our product candidates, if approved.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing and processing of our product candidates, and the actual cost to manufacture and process our product candidates could materially and adversely affect the commercial viability of our product candidates. As a result, we may not be able to develop commercially viable products other than <font style="color:#000000;">our COVID-19 vaccine</font>.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our reliance on a limited number of CMOs exposes us to the following risks:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA or other regulatory authorities may have questions regarding any replacement contractor. This may require new testing and regulatory interactions. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our products after receipt of regulatory authority questions, if any&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our CMOs might be unable to timely formulate and manufacture our product or produce the quantity and quality required to meet our clinical and commercial needs, if any&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>CMOs may not be able to execute our manufacturing procedures appropriately&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our future CMOs may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our products&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the U.S. Drug Enforcement Administration and corresponding state agencies and by regulatory authorities in other jurisdictions to ensure strict compliance with GMP and other government regulations and corresponding standards in other jurisdictions. We do not have control over CMOs&#8217; compliance with these regulations and standards&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we may not own, or may have to share, the intellectual property rights to any improvements made in the manufacturing process for our products&#894;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CMOs</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> could breach or terminate their agreement with us&#894; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our CMOs would also be subject to the same risks we face in developing our own manufacturing capabilities, as described above.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of these risks could delay our clinical trials, the approval, if any, of our COVID-19 vaccine or product candidates by the FDA or regulatory authorities in other jurisdictions or the commercialization of our COVID-19 vaccine or product candidates, or result in higher costs or deprive us of potential product sales revenue. In addition, we will rely on third parties to perform release tests on our COVID-19 or our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are dependent on single source suppliers for some of the components and materials used in, and the processes required to develop, our COVID-19 vaccine and our product candidates.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently depend on single source suppliers for some of the components and materials used in, and manufacturing processes required to develop, our COVID-19 and our product candidates. We cannot ensure that these suppliers or service providers will remain in business, or have sufficient capacity or supply to meet our needs, or that they will not be purchased by one of our competitors or another company that is not interested in continuing to work with us. Our use of single source suppliers of raw materials, components, key processes and finished goods exposes us to several risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components, materials and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single source supplier or service provider could lead to supply delays or interruptions which would damage our business, financial condition, results of operations and prospects.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we have to switch to a replacement supplier, the manufacture and delivery of our product candidates could be interrupted for an extended period, which could adversely affect our business. Establishing additional or replacement suppliers for any of the components or processes used in our COVID-19 vaccine and our product candidates, if required, may not be accomplished quickly. If we are able to find a replacement supplier, the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the single source components and materials used in our COVID-19 vaccine and our product candidates, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand for our COVID-19 vaccine and product candidates.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as part of the FDA&#8217;s approval of our product candidates, we will also require FDA review of the individual components of our process, which include the manufacturing processes and facilities of our single source suppliers.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our reliance on these suppliers, service providers and manufacturers subjects us to a number of risks that could harm our reputation, business and financial condition, including, among other things:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">delays to the development timelines for our product candidates&#894;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">interruption of supply resulting from modifications to or discontinuation of a supplier&#8217;s operations&#894;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">delays in product shipments resulting from uncorrected defects, reliability issues, or a supplier&#8217;s variation in a component&#894;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a lack of long-term supply arrangements for key components with our suppliers&#894;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">inability to obtain adequate supply in a timely manner, or to obtain adequate supply on commercially reasonable terms&#894;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">difficulty and cost associated with locating and qualifying alternative suppliers for our components in a timely manner&#894;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">production delays related to the evaluation and testing of components from alternative suppliers, and corresponding regulatory qualifications&#894;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">delay in delivery due to our suppliers&#8217; prioritizing other customer orders over ours&#894;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">damage to our reputation caused by defective components produced by our suppliers&#894; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU106"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">fluctuation in delivery by our suppliers due to changes in demand from us or their other customers.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of these risks materialize, costs could significantly increase and our ability to meet demand for our products could be impacted</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to our Intellectual Property </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our efforts to obtain, maintain, protect, defend and/or enforce the intellectual property related to our COVID-19 vaccine or our product candidates and technologies are not adequate, we may not be able to compete effectively in our market.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on our ability to obtain, maintain, protect, defend and enforce patent and other intellectual property, including trade secret and know-how, protection for our COVID-19 vaccine and for our product candidates, proprietary technologies and their uses, as well as our ability to operate, develop, manufacture and commercialize our COVID-19 vaccine or one or more of our product candidates without infringing, misappropriating or otherwise violating the intellectual property or other proprietary rights of our competitors or any other third parties, including any non-practicing entities or patent assertion entities. We generally seek to protect our intellectual property position by filing and/or licensing patent applications in the United States and abroad related to our product candidates, proprietary technologies (including methods of manufacture) and their uses that are important to our business. Our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent that the issued claims cover third parties&#8217; activities in the countries in which they are performed. We cannot be certain that the claims in any of our patent applications will be considered patentable by the United States Patent and Trademark Office, or the USPTO, courts in the United States or the patent offices and courts in other jurisdictions, including Europe, nor can we be certain that the claims in our issued patents will not be found invalid or unenforceable if challenged. Accordingly, there can be no assurance that our patent applications or those of our licensors will result in additional patents being issued or that issued patents will adequately cover our COVID-19 vaccine or our product candidates, or otherwise afford sufficient protection against competitors with similar technology, nor can there be any assurance that issued patents will not be infringed, designed around, invalidated or held unenforceable. Furthermore, we may not be able to apply for patents on certain aspects of our current or future products or product candidates, proprietary technologies and their uses in a timely fashion, at a reasonable cost, in all jurisdictions, or at all, and any potential patent protection we obtain may not be sufficient to prevent substantial competition.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even issued patents may later be found invalid or unenforceable, or may be modified or revoked in proceedings before various patent offices or in courts in the United States, Europe or other jurisdictions. The degree of future protection for our intellectual property and other proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. If we do not adequately obtain, maintain, protect, defend and enforce our intellectual property and proprietary technology, competitors may be able to use our product candidates and proprietary technologies and erode or negate any competitive advantage we may have, which could have a material adverse effect on our financial condition and results of operations.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our current or future licensors or collaborators will be successful in prosecuting, obtaining, protecting, maintaining, enforcing or defending patents and patent applications necessary or useful to protect our products or product candidates, proprietary technologies (including methods of manufacture) and their uses. These risks and uncertainties include, from time to time, the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the USPTO and various other governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patenting process, the noncompliance with which can result in abandonment or lapse of a patent or patent application or a finding that a patent is unenforceable, and partial or complete loss of patent rights in the relevant jurisdiction&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU107"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>patent applications may not result in any patents being issued&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>issued patents that we own (solely or jointly) or have in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>other parties may have designed around our patent claims or developed technologies that may be related or competitive to our COVID-19 vaccine or to our product candidates or other technologies, may have filed or may file patent applications and may have received or may receive patents that overlap or conflict with our patent </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">filings, either by claiming the same or overlapping methods, products, reagents or devices or by claiming subject matter that could dominate one or more of our patent claims&#894;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>any successful opposition to any patents owned by or in-licensed to us could deprive us of rights necessary for the development and exploitation of our COVID-19 vaccine or our product candidates and other technologies, or the successful commercialization of any product candidates and other technologies that we may develop&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>because patent applications in the United States and most other jurisdictions are confidential for a period of time after filing, we cannot be certain that we, our co-owners or our licensors were the first to file any patent application related to our product candidates, proprietary technologies and their uses&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>a court or patent office proceeding, such as a derivative action or interference, can be provoked or instituted by a third party or a patent office, and might determine that one or more of the inventions described in our patent filings, or in those we licensed, was first invented by someone else, so that we may lose rights to such invention(s)&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>a court or other patent proceeding, such as an inter partes review, post grant review or opposition, can be instituted by a third party to challenge the inventorship, scope, validity and/or enforceability of our patent claims and might result in invalidation or revision of one or more of our patent claims, or in a determination that such claims are unenforceable&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; existing legislation (for example, in the United States, the Public Readiness and Emergency Preparedness Act, etc.) may be interpreted, and new legislation may be passed, to permit third-party use of patented technologies relating to a public health concern (for example, the COVID-19 pandemic), with little or no compensation to the patent holder(s)&#894; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing competitors a better opportunity to create, develop and market competing product candidates.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. The standards that the USPTO and its counterparts use to grant patents are not always applied predictably or uniformly and can change. Similarly, the ultimate degree of protection that will be afforded to biotechnology inventions, including ours, in the United States and other countries, remains uncertain and is dependent upon the scope of the protection decided upon by patent offices, courts and lawmakers. Moreover, there are periodic changes in patent law, as well as discussions in the U.S. Congress and in international jurisdictions about modifying various aspects of patent law. There is no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. In certain countries, for example, methods for the medical treatment of humans are not patentable. More generally, the laws of some countries do not protect intellectual property rights to the same extent as U.S. laws, and those countries may lack adequate rules and procedures for granting, maintaining, protecting, defending and enforcing our intellectual property rights.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU108"></a>Furthermore, the patent prosecution process is expensive and time-consuming, and we may not be able to file, prosecute, maintain, protect, defend, enforce or license all necessary or desirable patents or patent applications, as applicable, at a reasonable cost or in a timely manner. It is possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. We also rely to a certain extent on trade secrets, know-how, and technology, which are not protected by patents, to maintain our competitive position. If any trade secret, know-how or other technology not protected by a patent were to be disclosed to or independently developed by a competitor, our business and financial condition could be materially adversely affected.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The issuance of a patent is not conclusive as to its inventorship, priority date, scope, term, validity or enforceability so that any patents that may issue or that we may license may be challenged in the courts or patent offices in the United States, Europe and other jurisdictions. Once granted, patents may remain open to a variety of challenges, including opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">before patent offices or similar proceedings, and furthermore, may be challenged as a defense in any enforcement action that we might bring; for example, various third parties have filed opposition papers challenging our issued EP patent number 2714071, which relates to our iNeST product candidates, and whose claims recite steps relating to neoantigen selection. Such challenges may result in loss of exclusivity or in patent claims being narrowed, terminated, disclaimed, invalidated, assigned to others or held unenforceable, any or all of which could limit our ability to stop others from using or commercializing similar or identical products, or limit the scope and/or term of patent protection of our products and product candidates and/ or eliminate it altogether, thus hindering or removing our ability to limit third parties from making, using or selling products or technologies that are similar or identical to ours, and/or reduce or eliminate royalty payments to us from our licensees. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Furthermore, our pending and future patent applications may not result in patents being issued which protect our technology or our product(s) or product candidates, or which effectively prevent others from commercializing competitive technologies and products. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to enforce our owned and in-licensed patent and other intellectual property rights depends on our ability to detect infringement, misappropriation and other violation of such patents and other intellectual property. It may be difficult to detect infringers, misappropriators and other violators who do not advertise the components or methods that are used in connection with their products and services. Moreover, it may be difficult or impossible to obtain evidence of infringement, misappropriation or other violation in a competitor&#8217;s or potential competitor&#8217;s product or service, and in some cases we may not be able to introduce obtained evidence into a proceeding or otherwise utilize it to successfully demonstrate infringement. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded if we were to prevail may not be commercially meaningful. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, patents or other intellectual property rights that we may be able to secure for our COVID-19 vaccine or our other COVID-19 vaccine candidates could be restricted or preempted if governments determine that they will not enforce, or will require compulsory licensing of, technologies useful to address the COVID-19 pandemic.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU109"></a>In addition, proceedings to enforce or defend our owned or in-licensed patents could put our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Such proceedings could also provoke third parties to assert claims against us, including that some or all of the claims in one or more of our patents are invalid or otherwise unenforceable. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. If any of our owned or in-licensed patents covering our product candidates or other technologies are narrowed, invalidated or found unenforceable, or if a court found that valid, enforceable patents held by third parties covered one or more of our product candidates or other technologies, our competitive position could be harmed or we could be required to incur significant expenses to protect, enforce or defend our rights. If we initiate lawsuits to protect, defend or enforce our patents, or litigate against third-party claims, such proceedings would be expensive and would divert the attention of our management and technical personnel, even if the eventual outcome is favorable to us.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection for our intellectual property and other proprietary rights is uncertain, and we cannot ensure that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our product(s), our product candidates and other technologies&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>any of our pending patent applications or those of our licensors may issue as patents&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>others will not or may not be able to make, use, offer to sell or sell products that are the same as or similar to our own but that are not covered by the claims of the patents that we own or license&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we will be able to successfully commercialize our products on a substantial scale, if approved, before the relevant patents that we own or license expire&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we were the first to make the inventions covered by each of the patents and pending patent applications that we own or license&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we, our co-owners or our licensors were the first to file patent applications for these inventions&#894;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>others will not develop similar or alternative products or technologies that do not infringe the patents we own or license&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>any of the patents we own or license will be found to ultimately be valid and enforceable&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable product candidates and other technologies or will provide us with any competitive advantages&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>a third party may not challenge the patents we own or license and, if challenged, a court would hold that such patents are valid, enforceable and infringed&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we may develop or in-license additional proprietary technologies that are patentable&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the patents of others will not have an adverse effect on our ability to issue patents, or otherwise on our business&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our competitors do not conduct research and development activities in countries where we do not have enforceable patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we will develop additional proprietary technologies, product(s) or product candidates that are separately patentable&#894; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our development and commercialization activities, including our manufacturing processes, or products will not infringe patents of our competitors or any other third parties, including any non-practicing entities or patent assertion entities.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other companies or organizations may challenge our intellectual property rights or may assert intellectual property rights that prevent us from developing and commercializing our COVID-19 vaccine or our product candidates and other technologies.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU110"></a>We practice in new and evolving scientific fields, the continued development and potential use of which has resulted in many different patents and patent applications from organizations and individuals seeking to obtain intellectual property protection in the fields. We own and in-license patent applications and issued patents that describe and/or claim certain technologies, including products, reagents, formulations and methods including uses and manufacturing methods, or features or aspects of any of these. These issued patents and pending patent applications claim certain compositions of matter and methods relating to the discovery, development, manufacture and commercialization of therapeutic modalities and our delivery technologies, including lipid nanoparticles, or LNPs. If we, our co-owners or our licensors are unable to obtain, maintain, protect, defend or enforce patent protection with respect to our product candidates and other technology and any products or product candidates and technology we develop, our business, financial condition, results of operations and prospects could be materially harmed.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As the scientific fields mature, our known competitors and other third parties have filed, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents, and will continue to file, patent applications claiming inventions in the field in the United States and abroad. This may limit, interfere with or eliminate our ability to make, use, sell, import or otherwise exploit our COVID-19 vaccine or our product candidates or other technologies. There is uncertainty about which patents will issue, and, if they do, as to when, to whom and with what claims. With respect to both in-licensed and owned intellectual property, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We, our co-owners or our licensors may in the future become a party to patent proceedings or priority disputes in the United States, Europe or other jurisdictions. The Leahy-Smith America Invents Act, or the America Invents Act, includes a number of significant changes that affect the way patent applications are prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent through USPTO-administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. We expect that our competitors and other third parties will institute litigation and other proceedings, such as interference, reexamination and opposition proceedings, as well as inter partes and post-grant review proceedings against us and the patents and patent applications that we own and in-license. For example, various third parties have filed opposition papers challenging our issued EP patent 2714071 which relates to our iNeST product candidates, and whose claims recite steps relating to neoantigen selection.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that we will be subject to similar proceedings or priority disputes, including oppositions, in Europe or other foreign jurisdictions relating to patents and patent applications in our portfolio.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we, our co-owners or our licensors are unsuccessful in any interference proceedings or other priority or validity disputes, including any derivations, post-grant review, inter partes review or oppositions, to which we or they are subject, we may lose valuable intellectual property rights through the narrowing or loss of one or more patents owned or in-licensed, or our owned or in-licensed patent claims may be narrowed, invalidated or held unenforceable. In many cases, the possibility of appeal exists for either us or our opponents, and it may be years before final, unappealable rulings are made with respect to these patents in certain jurisdictions. The timing and outcome of these and other proceedings is uncertain and may adversely affect our business if we are not successful in defending the patentability and scope of our pending and issued patent claims. Even if our rights are not directly challenged, disputes could lead to the weakening of our intellectual property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could be costly to us, could require significant time and attention of our management and could have a material adverse impact on our business and our ability to successfully compete against our current and future competitors.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU111"></a>There are many issued and pending patent filings that claim aspects of technologies that we may need for our mRNA products or product candidates, or other product candidates, including patent filings that relate to relevant delivery technologies. There are also many issued patents that claim targeting genes or portions of genes that may be relevant for immunotherapies we wish to develop. In addition, there may be issued and pending patent applications that may be asserted against us in a court proceeding or otherwise based upon the asserting party&#8217;s belief that we may need such patents for the development, manufacturing and commercialization of our COVID-19 vaccine or of our product candidates. Thus, it is possible that one or more organizations, ranging from our competitors to non-practicing entities or patent assertion entities, has or will hold patent rights to which we may need a license, or hold patent rights which could be asserted against us. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If those organizations refuse to grant us a license to such patent rights on reasonable terms, if we fail to invalidate relevant patents, or if a court or other governing body determines that we need such patent rights that have been asserted against us and we are not able to obtain a license on reasonable terms or at all, we may be unable to perform research and development or other activities or market products covered by such patents, and we may need to cease the development, manufacture and commercialization of one or more of the product candidates we may develop. Any of the foregoing could result in a material adverse effect on our business, financial condition, results of operations or prospects.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be successful in obtaining, maintaining, protecting or defending the necessary intellectual property rights to allow us to identify and develop product candidates, product components and manufacturing processes for our development pipeline.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have rights to certain intellectual property through our owned and in-licensed patents and other intellectual property rights, relating to identification and development of our product candidates or other technologies. As our pipeline may involve additional product candidates that could require the use of intellectual property and other proprietary rights held by third parties, the growth of our business could depend in part on our ability to acquire, in-license or use such intellectual property and proprietary rights. In addition, our product candidates may require specific formulations to work effectively and efficiently and these intellectual property and other proprietary rights may be held by others. We may be unable to secure such licenses or otherwise acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary, on reasonable terms, or at all, for product candidates and other technologies that we may develop. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, we sometimes collaborate with academic institutions in certain aspects of our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. However, these institutions may not honor our option and right of first negotiation for intellectual property rights or we may otherwise be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program or otherwise continue to develop certain product candidates or other technologies.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, some of our owned patents and patent applications are, and may in the future be, co-owned with third parties. If we are unable to obtain, or continue to maintain, exclusive rights to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technologies. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, third parties that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain, protect, defend or enforce the existing intellectual property rights we have, we may have to abandon the development and commercialization of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU112"></a>The lifespans of our patents may not be sufficient to effectively protect our products or product candidates, technologies and business.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after its first effective non- provisional filing date, assuming maintenance fees are timely paid after the patent has issued. Most foreign jurisdictions also provide a 20-year nominal patent term, though many require payment of regular, often annual, annuities to maintain pendency of an application or viability of an issued patent. In some jurisdictions, one or more options for extension of a patent term may be available, but even with such extensions, the lifespan of a patent, and the protection it affords, is limited. Even if patents covering our product candidates, proprietary technologies and their uses are obtained, once the patent term has expired, we may be subject to competition from third parties that can then use the inventions included in such patents to create competing products and technologies. In addition, although upon issuance in the United States a patent&#8217;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such candidates are commercialized. If any patents that we own or in-license expire, we would not be able to stop others from using or commercializing similar or identical technology and products, and our competitors could market competing products and technology. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and prospects could be materially harmed.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are heavily reliant upon licenses to certain intellectual property and other proprietary rights from third parties that are important or necessary to the development and commercialization of our technology and product(s) or product candidates, and we expect to enter into similar license agreements in the future. Licensing of intellectual property is important to our business and involves complex legal, business and scientific issues and is complicated by the rapid pace of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">scientific discovery in our industry. Our licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in territories included in any or all of our licenses.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU113"></a>Where we obtain licenses from, or collaborate with, third parties, in some circumstances we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications covering the technology that we license from third parties, or such activities, if controlled by us, may require the input of such third parties. In some cases, patent prosecution of our in-licensed intellectual property is controlled solely by the licensor. We may also require the cooperation of our licensors and collaborators to enforce or defend any in-licensed patent rights, and such cooperation may not be provided. Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, protected, enforced or defended in a manner consistent with the best interests of our business. Any patents or patent applications that we in-license may be challenged, narrowed, circumvented, invalidated or held unenforceable, or our licensors may not properly maintain such patents or patent applications and they may expire. If our licensors fail to obtain, maintain, defend, protect or enforce the intellectual property we license from them, we could lose our rights to the intellectual property and our competitors could market competing products using the inventions in such intellectual property. In certain cases, we control the prosecution of patents included from in-licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our collaborators. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, any failure to satisfy obligations or any material breach under any of our licenses to third-party intellectual property could give the licensor the right to terminate the license. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone and royalty payment, exclusivity and other obligations on us. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, the licensor may have the right to terminate the license agreement, in which event we would not be able to develop, market and commercialize product(s) or product candidates covered by the license agreement. In spite of our best efforts and even if we disagree, our licensors might still conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize the product(s) or product candidates covered by these license agreements. In the event that any of our license agreements were to be terminated by the licensor, we may need to negotiate new or reinstated agreements, which may not be available to us on equally favorable terms, or at all. If these license agreements are terminated, or if the underlying patents or other intellectual property fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market and commercialize, products similar or identical to ours. In addition, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing license agreements in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable third parties (potentially including our competitors) to receive licenses to a portion of the intellectual property that is subject to our existing licenses.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which are described in this section. If we, our co-owners or our licensors fail to adequately protect this intellectual property, our ability to develop, market and commercialize our product(s) or product candidates could suffer. Moreover, if disputes over intellectual property that we have in-licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop, market and commercialize the affected product(s) or product candidates, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Some of our in-licensed intellectual property has been discovered through government-funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights and certain reporting requirements, and compliance with such regulations may limit our exclusive rights and our ability to contract with manufacturers.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU114"></a>Certain intellectual property rights that have been in-licensed, including patent applications and patents that we in-license from the University of Pennsylvania, the Louisiana State University, the Broad Institute, the National Institute of Health (NIH), Genevant, and Cellscript, have been generated through the use of U.S. government funding and are therefore subject to certain federal regulations. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole Act of 1980, or the Bayh-Dole Act. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">licensor to grant exclusive, partially exclusive or non-exclusive licenses to any of these inventions to a third party if it determines that (i) adequate steps have not been taken to commercialize the invention, (ii) government action is necessary to meet public health or safety needs or (iii) government action is necessary to meet requirements for public use under federal regulations (also collectively referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if the licensor fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Any exercise by the government of such rights could harm our competitive position, business, financial condition, results of operations and prospects. Intellectual property generated under a government-funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture the products substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. We may not be able to obtain a waiver of this preference for U.S. industry, and this preference may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our owned or in-licensed future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply. If we are unable to comply with these manufacturing requirements, we may experience a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our current proprietary position for certain products and product candidates depends upon our owned or in-licensed patent filings covering components, manufacturing-related methods, formulations and/or methods of use, which may not adequately prevent a competitor or other third party from using the same product candidate for the same or a different use.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU115"></a>Composition of matter patent protection is generally considered to be desirable because it provides protection without regard to any particular method of use or manufacture or formulation. While we have obtained patent protection covering components of certain product candidates, manufacturing-related methods, formulations and/or methods of use, we have not obtained patent protection components for all product candidates, manufacturing-related methods, formulations and/or methods of use. For instance, we do not currently have any claims in our owned or in-licensed issued U.S. patents that cover the overall construct used in our COVID-19 vaccine, or that used in our iNeST product candidates. &#160;We also cannot be certain that claims in any future patents issuing from our pending owned or in-licensed patent applications or our future owned or in-licensed patent applications will cover the composition of matter, manufacturing-related methods, formulations and/or methods of use of our current or future product candidates. Method of use patents protect the use of a product for the specified method and formulation patents cover formulations to deliver therapeutics. These types of patents do not prevent a competitor or other third party from developing, marketing or commercializing a similar or identical product for an indication that is outside the scope of the patented method or from developing a different formulation that is outside the scope of the patented formulation. Moreover, with respect to method of use patents, even if competitors or other third parties do not actively promote their product for our targeted indications or uses for which we may obtain patents, physicians may recommend that patients use these products off-label, or patients may do so themselves. Although off-label use may infringe or contribute to the infringement of method of use patents, the practice is common and this type of infringement is difficult to prevent or enforce. Consequently, we may not be able to prevent third parties from practicing our inventions in the United States or abroad<a name="_AEIOULastRenderedPageBreakAEIOU115"></a>. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property rights of third parties could adversely affect our ability to commercialize our product(s) and product candidates, and we might be required to litigate or obtain licenses from third parties in order to develop or market our product(s) and product candidates.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because our products and product candidates are still in early stages of development or commercialization, and one or more features of the products or product candidates, or related technologies such as their manufacture, formulation or use, may still change, we cannot be confident that we are aware of all third-party intellectual property that might be relevant to products that we eventually hope to commercialize.&nbsp;&nbsp;Furthermore, even if all aspects of our product(s) or product candidate(s), or of other technology, were known, it is possible that third-party intellectual property, which may or may not currently be public, could develop in a manner (for example, through issuance of additional patents) that could impede our ability to make or use relevant products or product candidates, or other technology. Various third-party competitors practice in relevant spaces, and may have issued patents, or patent applications that will issue as patents in the future, that will </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">impede or preclude our ability to commercialize products. Furthermore, while U.S. patent laws provide a &#8220;safe harbor&#8221; to our clinical product candidates under 35 U.S.C. &#167; 271(e)(1), which exempts from patent infringement activities related to pursuing FDA approval for a drug product, that exemption expires when an NDA is submitted. Accordingly, </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our COVID-19 vaccine</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was granted emergency use authorization in December 2020, at which the 271(e)(1) safe harbor may no longer provide the same level of protection from third party patent infringement claims for that product. We may become exposed to one or more lawsuits from third parties who consider </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our COVID-19 vaccine</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to infringe their patents. Given the uncertainty of clinical trials, we cannot be certain of the timing of their completion and it is possible that we might want to submit an NDA at a time when one or more relevant third-party patents is in force. Thus, it is possible that at the time that we commercialize our product candidates, one or more third parties may have issued patent claims that cover our products or critical features of their production or use. We may not be able to commercialize our products if patents issued to third parties or other third-party intellectual property rights cover, or may be alleged to cover, our products or elements thereof, or their methods of manufacture or use at the time that we seek to commercialize them. In such cases, we may not be in a position to develop or commercialize product candidates unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned, successfully design around their claims, or enter into a license agreement with the intellectual property right holder(s). Such litigation or licenses could be costly or not available on commercially reasonable terms or at all, and design-around could be prohibitively expensive or impossible. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, with respect to our COVID-19 vaccine and our other COVID-19 product candidates and related technologies, it is unclear whether the U.S. government, or other governments around the world, will protect vaccine manufacturers for liability from infringement of third party intellectual property, at least during the period of the pandemic.&nbsp;&nbsp;Thus, it is possible that third parties may assert intellectual property rights against us relating to our COVID-19 vaccine, and that we will not be successful in arguing that commercialization of <font style="color:#000000;">our COVID-19 vaccine </font>is exempted from infringement (for example, under 35 U.S.C. &#167; 271(e)(1), discussed above, or under the Public Readiness and Emergency Preparedness Act, or the PREP Act, etc.).&nbsp;&nbsp;Furthermore, even if such commercialization is deemed protected from infringement during the period of pandemic crisis, once that period has passed, or as otherwise might be established, any such exemption may be terminated so that continuing commercialization could expose us to liability, and might even be precluded if third party(ies) who hold relevant intellectual property rights are able to secure injunction(s) or are unwilling to license to us on commercially feasible terms.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is also possible that we have failed to identify relevant third-party patents that cover, or applications that will mature into patents that cover, one or more aspects of our platform or product(s) and product candidates. Given that, in most jurisdictions, a patent application is confidential when initially filed, and typically remains so until it is published about 18 months after the initial filing, it may not be possible for us to identify certain relevant filings in time to avoid using the technology that they claim. Additionally, the claims of pending patent applications can, subject to certain limitations, be amended over time, so that even patent applications whose claims did not cover our products or activities when published could be amended to cover one or more aspects of our platform or product candidates over time, and we might not be aware that such amendment had been made.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be involved in lawsuits to protect or enforce our intellectual property or the intellectual property of our licensors, or to defend against third-party claims that we infringe, misappropriate or otherwise violate such third party&#8217;s intellectual property, each of which could be expensive, time consuming and unsuccessful.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, ex parte reexaminations, post-grant review, and inter partes review proceedings before the USPTO and corresponding European and other non-U.S. patent offices.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU116"></a>Competitors and other third parties may infringe, misappropriate or otherwise violate our intellectual property rights or those of our licensors. To prevent infringement, misappropriation or other unauthorized use, we may be required to file claims, which can be expensive and time-consuming. In certain instances, we have instituted and may in the future institute inter partes review proceedings against issued U.S. patents and opposition proceedings against European patents owned by third parties in the field of immunotherapy. We have a number of these opposition proceedings ongoing at the European Patent Office against third-party patents related to mRNA technologies; also, multiple oppositions have been filed against our EP patent number 2714071, which relates to our iNeST product candidates, and whose claims recite steps relating to neoantigen selection. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in a patent infringement proceeding, our owned or in-licensed patents may be challenged and a court may decide that a patent we own or in-license is not valid, is unenforceable and/or is not infringed. If we or any of our potential future collaborators were to initiate legal proceedings against a third party to enforce a patent directed at one of our product(s) and/or product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before the USPTO, even outside the context of litigation. Similar mechanisms for challenging the validity and enforceability of a patent exist in ex-U.S. patent offices and may result in the revocation, cancellation or amendment of any ex-U.S. patents we hold in the future. The outcome following legal assertions of invalidity and unenforceability is unpredictable, and prior art could render our patents or those of our licensors invalid. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product and/or product candidate. Such a loss of patent protection would have a material adverse impact on our competitive position, business, financial conditions, results of operations and prospects.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties, ranging from our competitors to non-practicing entities or patent assertion entities, may assert that we are employing their intellectual property and other proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use, development, manufacture or commercialization of our COVID-19 vaccine or product candidates. As patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product(s) and/or product candidates may infringe. In addition, third parties may obtain patents in the future and claim that our technologies infringe upon these patents. If any third- party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product(s) and/or product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may obtain injunctive or other equitable relief, which could effectively block our ability to develop and commercialize such product and/or product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product and/or product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms, or at all, or may be non- exclusive.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU117"></a>Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same intellectual property and technology. Our defense of litigation, interference, derivation or similar proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, and our research programs, license necessary technology from third parties or enter into development or manufacturing collaborations that would help us bring our product(s) and/or product candidates to market.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of a successful claim of infringement, misappropriation or other violation against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products, or obtain one or more licenses from third parties, which may not be made available on commercially favorable terms, if at all, or may require substantial time and expense.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Such licenses are likely to be non-exclusive and, therefore, our competitors may have access to the same intellectual property and technology licensed to us. If we fail to obtain a required license and are unable to design around a patent, we may be unable to effectively market some of our technology and product(s) and/or product candidates, which could limit our ability to generate revenues or achieve</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or maintain</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> profitability and possibly prevent us from generating revenue sufficient to sustain our operations. Moreover, certain of our collaborations provide, and we expect additional collaborations to provide, that royalties payable to us for licenses to our intellectual property may be offset by amounts paid by our collaborators to third parties for licenses to such third parties&#8217; intellectual property in the relevant fields, which could result in significant reductions in our revenues from products developed through collaborations.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in connection with certain license and collaboration agreements, we have agreed to indemnify certain third parties for certain costs incurred in connection with litigation relating to intellectual property rights or the subject matter of the agreements. The cost to us of any litigation or other proceeding relating to intellectual property rights, even if resolved in our favor, could be substantial.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments in any litigation or other intellectual property proceedings. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of the ADSs.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non- compliance with these requirements.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU118"></a>Periodic maintenance fees, renewal fees, annuity fees, and various other governmental fees on patents and applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents or applications. We have systems in place to remind us to pay these fees and we employ an outside firm and rely on our outside counsel to pay these fees due to non-U.S. patent agencies&#894; however, we cannot guarantee that we will successfully pay these fees. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. We are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our in-licensed intellectual property, and we cannot guarantee that they will do so. In such an event, our competitors might be able to enter the market with similar or identical products or technology, and this would have a material adverse impact on our business, financial condition, results of operations and prospects.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in patent law in the United States or in other countries could diminish the value of patents in general, thereby impairing our ability to protect our products.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is the case with other biotechnology companies, our success is heavily dependent on our intellectual property rights, particularly patents that we own and in-license. Obtaining and enforcing patents in the biotechnology industry involve both technological and legal complexity, and therefore obtaining and enforcing biotechnology patents is costly, time-consuming and inherently uncertain. Moreover, there are periodic changes in patent law. For example, after March 2013, under the America Invents Act, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. The America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, and their equivalents in other jurisdictions, the laws and regulations governing patents could change in unpredictable ways that could </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have a material adverse effect on our existing patent portfolio and our ability to obtain, maintain, protect, defend or enforce our intellectual property in the future.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to seeking patent protection for some of our technology, product(s) and product candidates, we also seek to rely on trade secret protection and confidentiality agreements to maintain our competitive position and protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets and know-how may be difficult to protect.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU119"></a>We seek to protect these trade secrets, know-how and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants and require all of our employees and key consultants who have access to our trade secrets, proprietary know-how, information or technology to enter into confidentiality agreements. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Despite our best efforts, any of these parties may breach the agreements and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. We may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret or know-how is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets and know-how. If any of our trade secrets or know-how were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results, financial condition and prospects.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims that we have wrongfully hired an employee from a competitor, or that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have received confidential and proprietary information from third parties in the course of our research and other collaborations with others in the industry, academic institutions and other third parties. In addition, many of our employees, consultants and advisors are currently or were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, independent contractors and advisors do not use the confidential or proprietary information, trade secrets or know-how of others in their work for us, we may be subject to claims that we have inadvertently or otherwise used or disclosed confidential or proprietary information, trade secrets or know-how of these third parties, or that our employees, consultants, independent contractors or advisors have inadvertently or otherwise used or disclosed confidential information, trade secrets or know-how of such individual&#8217;s current or former employer. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees. Claims that we, our employees, consultants or advisors have misappropriated the confidential or proprietary information, trade secrets or know-how of third parties could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the future, we may be subject to claims that current or former employees, consultants, independent contractors, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. While it is our policy to require our employees, consultants, independent contractors, collaborators and other third parties who may be involved in the conception, development or reduction to practice of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives, develops or reduces to practice such intellectual property that we regard as our own. In addition, certain such agreements, even if successfully executed may distribute ownership or control of intellectual property rights between </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or among parties, for example based on subject matter, relationship to other intellectual property, and/or one or more aspects of development of the intellectual property; after the agreements are in place disputes may arise over such distribution principles or over proper treatment of particular developed intellectual property in accordance with them. Disagreements may be difficult or impossible to resolve, may be expensive to address, and may result in our failing to </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">secure</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or maintain ownership in or control of intellectual </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">property</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> necessary or important to our business.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU120"></a>The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached. For example, we may have inventorship or ownership disputes arise from conflicting obligations of employees, consultants, independent contractors, collaborators or other third parties who are involved in developing and commercializing our product(s) and/or product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business, operating results and financial condition. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, the laws of some other countries do not protect intellectual property and other proprietary rights or establish ownership of inventions to the same extent or in the same manner as the U.S. laws. A majority of our employees work in Germany and are subject to German employment law. Ideas, developments, discoveries and inventions made by such employees and consultants are subject to the provisions of the German Act on Employees&#8217; Inventions, which regulates the ownership of, and compensation for, inventions made by employees. We face the risk that disputes can occur between us and our employees or former employees pertaining to alleged non-adherence to the provisions of this act that may be costly to defend and take up our management&#8217;s time and efforts whether we prevail or fail in any such dispute. There is a risk that the compensation we provided to employees who assign patents to us may be deemed to be insufficient and we may be required under German law to increase the compensation due to such employees for the use of the patents. In those cases, where employees&#8217; rights have not been assigned to us, we may need to pay compensation for the use of those patents. If we are required to pay additional compensation or face other disputes under the German Act on Employees&#8217; Inventions, our business, results of operations and financial condition could be adversely affected.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will not seek to protect our intellectual property rights in all jurisdictions throughout the world, and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting and defending patents on product(s) and/or product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some countries do not protect intellectual property rights to the same extent as laws in Germany and the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and to the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own product candidates and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product(s) and/or product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have encountered significant problems in protecting and defending intellectual property rights in certain jurisdictions, particularly outside of the United States. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement, misappropriation or other violation of our patents and other intellectual property or development, marketing and commercialization of competing products in violation of our intellectual property and other proprietary rights generally. Proceedings to enforce our intellectual property rights in such jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or in-license.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU121"></a>Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and trade names by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks, and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, know-how, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and prospects.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>others may be able to make COVID-19 vaccines or therapies, and/or personalized cancer immunotherapies that are similar to our COVID-19 vaccine and/or any product candidates we may develop and commercialize or utilize similar technologies that are not covered by the claims of the patents that we now or may in the future own or have exclusively in-licensed&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we, our co-owners or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or have exclusively in-licensed&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we, our co-owners or our licensors or future collaborators might not have been the first to file patent applications covering certain of our or their inventions&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or in-licensed intellectual property rights&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>it is possible that our pending patent applications or those that we may own or in-license in the future will not lead to issued patents&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>issued patents that we own or have exclusively in-licensed may be held invalid or unenforceable, including as a result of legal challenges by our competitors&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we may not develop additional proprietary technologies that are patentable&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU122"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the patents of others may have an adverse effect on our business&#894; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Government Regulation</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to develop or obtain approval for companion diagnostics required for commercialization of some of our product candidates.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Administration of some of our product candidates may require the use of immuno-assays and bioinformatic tools in which patients are screened for optimal target antigens of our product candidates. If safe and effective use of a biologic product depends on an <font style="font-style:italic;">in vitro</font> diagnostic, then the FDA generally requires approval or clearance of the diagnostic, known as a companion diagnostic, concurrently with approval of the therapeutic product. To date, the FDA has generally required <font style="font-style:italic;">in vitro</font> companion diagnostics intended to select the patients who will respond to cancer treatment to obtain a pre-market approval, or PMA, for that diagnostic, which can take up to several years, simultaneously with approval of the biologic product. Similarly, in the European Union, an <font style="font-style:italic;">in vitro</font> companion diagnostic may be placed on the market only if it conforms to certain &#8220;essential requirements&#8221; and bears the Conformit&#233; Europ&#233;ene Mark, or CE Mark, and the conformity assessment process to obtain the CE Mark can be lengthy.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For our individualized immunotherapy candidates, the FDA and comparable regulatory authorities outside of the United States may require the development and regulatory approval of a companion diagnostic assay as a condition to approval. The FDA may require PMA supplemental approvals for use of that same companion diagnostic as a condition of approval of additional individualized therapeutic candidates. We do not have experience or capabilities in developing or commercializing companion diagnostics and plan to rely in large part on third parties to perform these functions. Companion diagnostic assays are subject to regulation by the FDA and other comparable regulatory authorities in other jurisdictions as medical devices and require separate regulatory approval prior to the use of such diagnostic assays with our individualized therapeutic candidates. If we, or any third parties that we engage to assist us, are unable to successfully develop companion diagnostic assays for use with our individualized therapeutic candidates, or are unable to obtain regulatory approval or experience delays in either development or obtaining regulatory approval, we may be unable to identify patients with the specific profile targeted by our product candidates for enrollment in our clinical trials. Accordingly, further investment may be required to further develop or obtain the required regulatory approval for the relevant companion diagnostic assay, which would delay or substantially impact our ability to conduct additional clinical trials or obtain regulatory approval.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because we are developing some of our product candidates for the treatment of diseases in which there is little clinical experience and, in some cases, using new endpoints or methodologies, the FDA, the EMA or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There may not be pharmacologic therapies approved to treat the underlying causes of many diseases that we may address in the future. For instance, we and our collaborators are applying our technology to develop therapeutics in indications such as certain rare diseases, including some for which no or few clinical trials have been attempted. As a result, any future design and conduct of clinical trials of product candidates for the treatment of certain rare diseases may take longer, be more costly, or be less effective as part of the novelty of development in these diseases. Even if we decide to conduct clinical trials and the FDA does find our success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoint to a degree of statistical significance in any pivotal or other clinical trials we or our collaborators may conduct for our programs. Further, even if we do achieve the pre-specified criteria, our trials may produce results that are unpredictable or inconsistent with the results of the more traditional efficacy endpoints in the trial. The FDA also could give overriding weight to other efficacy endpoints over a primary endpoint, even if we achieve statistically significant results on that endpoint, if we do not do so on our secondary efficacy endpoints. The FDA also weighs the benefits of a product against its risks and the FDA may view the efficacy results in the context of safety as not being supportive of licensure. Other regulatory authorities in Europe and other countries may make similar findings with respect to these endpoints.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The FDA, the EMA or other comparable regulatory authorities may disagree with our regulatory plan and we may fail to obtain regulatory approval of our product candidates.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the results of our clinical trials are sufficiently compelling, we or our collaborators intend to discuss with the FDA submission of a BLA for our product candidates. However, we do not have any agreement or guidance from the FDA that our regulatory development plans will be sufficient for submission of a BLA for any of our product candidates. The FDA, the EMA or other regulatory agencies may grant accelerated approval for our product candidates and, as a condition for accelerated approval, the FDA, the EMA or other regulatory agencies may require a sponsor of a drug or biologic receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug or biologic may be subject to withdrawal procedures by the FDA, the EMA or other regulatory agencies that are more accelerated than those available for regular approvals. In addition, the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">standard of care may change with the approval of new products in the same indications that we are studying. This may result in the FDA, </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EMA or other regulatory agencies requesting additional studies to show that our product candidate is superior to the new products.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our clinical trial results may also not support approval. In addition, our product candidates could fail to receive regulatory approval for many reasons, including the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the FDA, the EMA or comparable regulatory authorities may disagree with the design or implementation of our clinical trials&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we may be unable to demonstrate to the satisfaction of the FDA, the EMA or comparable regulatory authorities that our product candidates are safe and effective for any of their proposed indications&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the results of clinical trials may not meet the level of statistical significance required by the FDA, the EMA or comparable regulatory authorities for approval, including due to the heterogeneity of patient populations&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we may be unable to demonstrate that our product candidates&#8217; clinical and other benefits outweigh their safety risks&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the FDA, the EMA or comparable regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA, the EMA or comparable regulatory authorities to support the submission of a BLA or other comparable submissions or to obtain regulatory approval in the United States or elsewhere&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the FDA, the EMA or comparable regulatory authorities will inspect our manufacturing facilities and may not approve our facilities&#894; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the approval policies or regulations of the FDA, the EMA or comparable regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to file INDs with the FDA, clinical trial applications with the competent authorities of the member states of the European Union or similar applications with other comparable regulatory authorities to commence additional clinical trials on the timelines we expect, and even if we are able to, one or more of these regulatory authorities may not permit us to proceed.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The timing of filing on our product candidates is dependent on further preclinical, clinical and manufacturing success. We cannot be sure that submission of an IND or IND amendment with the FDA, a clinical trial application with the regulatory authorities of the EU member states or similar application with other comparable regulatory authorities will result in the FDA, the regulatory authorities of the EU member states or any comparable regulatory authority allowing testing and clinical trials to begin, or that, once begun, issues will not arise that result in the suspension or termination of such clinical trials. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND, clinical trial application or similar applications, we cannot guarantee that such regulatory authorities will not change their requirements in the future.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may seek orphan drug designation for some or all of our product candidates across various indications, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our strategy includes filing for orphan drug designation where available for our product candidates. Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug or biologic intended to treat a rare disease or condition, which is defined as one occurring in a patient population of fewer than 200,000 in the United States, or a patient population of 200,000 or greater in the United States where there is no reasonable expectation that the cost of developing the drug or biologic will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives, such as opportunities for grant funding toward clinical trial costs, tax advantages, and user-fee waivers. In addition, if a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a full new drug application or a BLA, to market the same drug or biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the original manufacturer is unable to assure sufficient product quantity. Similar rules apply in the European Union with respect to drugs or biologics designated as orphan medicinal products.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not protect the product</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> effectively</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> from competition because different drugs with different active moieties may receive and be approved for the same condition, and only the first applicant to receive approval will receive the benefits of marketing exclusivity. Even after an orphan-designated product is approved, the FDA can subsequently approve a later drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior if it is shown to be safer, more effective, or makes a major contribution to patient care. Similar considerations apply in the European Union with respect to drugs or biologics designated as orphan medicinal products. Orphan drug designation neither shortens the development time or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval process. In addition, while we may seek orphan drug designation for our product candidates, we may never receive such designations.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may seek breakthrough therapy or fast-track designation for one or more of our product candidates, but we may not receive such designations. Even if we do, it may not lead to a faster development or regulatory review or approval process, and it may not increase the likelihood that such product candidates will receive marketing approval.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek a breakthrough therapy designation in the United States for one or more of our product candidates. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the submission of the BLA.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Designation as a breakthrough therapy is at the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a drug may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidate no longer meets the conditions for qualification or it may decide that the time period for FDA review or approval will not be shortened.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also seek Fast Track Designation in the United States for some of our product candidates. If a therapy is intended for the treatment of a serious or life-threatening condition and the therapy demonstrates the potential to address significant unmet medical needs for this condition, the drug sponsor may apply for Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, and even if we believe a particular product candidate is eligible for this designation, we cannot be sure that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track Designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We expect some of the product candidates we develop will be regulated as biologics in the United States and therefore they may be subject to competition from biosimilars approved through an abbreviated regulatory pathway.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ACA includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-approved reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of the other company&#8217;s product. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation and meaning are subject to uncertainty.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that any of our product candidates approved as a biological product under a BLA should qualify for a 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Some of our product candidates are classified as gene therapies by the FDA and the EMA, and the FDA has indicated that our product candidates will be reviewed within its Center for Biologics Evaluation and Research, or CBER. Even though our mRNA product candidates are designed to have a different mechanism of action from gene therapies, the association of our product candidates with gene therapies could result in increased regulatory burdens, impair the reputation of our product candidates, or negatively impact our platform or our business.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been few approvals of gene therapy products in the United States and other jurisdictions, and there have been well-reported significant adverse events associated with their testing and use. Gene therapy products have the effect of introducing new DNA and potentially irreversibly changing the DNA in a cell. In contrast, mRNA is highly unlikely to localize to the nucleus, integrate into cell DNA, or otherwise make any permanent changes to cell DNA. Consequently, we expect that our product candidates will have a different potential side effect profile from gene therapies because they lack risks associated with altering cell DNA irreversibly. Further, we may avail ourselves of ways of mitigating side effects in developing our product candidates to address safety concerns that are not available to all gene therapies, such as lowering the dose of our product candidates during repeat dosing or stopping treatment to potentially ameliorate undesirable side effects.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory requirements governing gene and cell therapy products have evolved and may continue to change in the future, and the implications for mRNA-based therapies is unknown. For example, the FDA has established the Office of Tissues and Advanced Therapies within CBER to consolidate the review of gene therapy and related products, and convenes the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. In the European Union, mRNA has been characterized as a Gene Therapy Medicinal Product. In certain countries, mRNA therapies have not yet been classified or any such classification is not known to us. Specifically, in Japan, the Pharmaceuticals and Medical Devices Agency has not taken a position on the regulatory classification. Notwithstanding the differences between our mRNA product candidates and gene therapies, the classification of some of our mRNA product candidates as gene therapies in the United States, the European Union and potentially other counties could adversely impact our ability to develop our product candidates, and could negatively impact our platform and our business. For instance, a clinical hold on gene therapy products across the field due to risks associated with altering cell DNA irreversibly may apply to our mRNA product candidates irrespective of the mechanistic differences between gene therapies and mRNA.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adverse events reported with respect to gene therapies or genome editing therapies could adversely impact one or more of our programs. Although our mRNA product candidates are designed not to make any permanent changes to cell DNA, regulatory agencies or others could believe that adverse effects of gene therapy products caused by introducing new DNA and irreversibly changing the DNA in a cell could also be a risk for our mRNA investigational therapies, and as a result may delay one or more of our trials or impose additional testing for long-term side effects. Any new requirements and guidelines promulgated by regulatory review agencies may have a negative effect on our business by lengthening the regulatory review process, requiring us to perform additional or larger studies, or increasing our development costs, any of which could lead to changes in regulatory positions and interpretations, delay or prevent advancement or approval and commercialization of our product candidates or lead to significant post-approval studies, limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory agencies and advisory committees and comply with applicable requirements and guidelines. If we fail to do so, we may be required to delay or discontinue development of some or all of our product candidates.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The regulatory landscape that will govern our product candidates is uncertain. Regulations relating to more established gene therapy and cell therapy products are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our product candidates or unexpected costs in obtaining regulatory approval.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulatory requirements to which our product candidates will be subject are not entirely clear. Even with respect to more established products that fit into the categories of gene therapies or cell therapies, the regulatory landscape is still developing. For example, regulatory requirements governing gene therapy products and cell therapy products have changed frequently and may continue to change in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of existing gene therapy products and cell therapy products. Although the FDA decides whether individual gene therapy protocols may proceed, the review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical study, even if the FDA has reviewed the study and approved its initiation. Conversely, the FDA can place an IND application on clinical hold even if such other entities have provided a favorable review. Furthermore, gene therapy clinical trials are also subject to review and oversight by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees basic and clinical research conducted at the institution participating in the clinical trial. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other regulatory bodies to change the requirements for approval of any of our product candidates.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Complex regulatory environments exist in other jurisdictions in which we might consider seeking regulatory approvals for our product candidates, further complicating the regulatory landscape. For example, in the European Union, a special committee called the Committee for Advanced Therapies, or CAT, was established within the EMA in accordance with Regulation (EC) No 1394/2007 on advanced-therapy medicinal products, or ATMPs, to assess the quality, safety and efficacy of ATMPs, and to follow scientific developments in the field. ATMPs include gene therapy products as well as somatic cell therapy products and tissue engineered products.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These various regulatory review committees and advisory groups and new or revised guidelines that they promulgate from time to time may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As the regulatory landscape for our CAR-T cell immunotherapy product candidates is new, we may face even more cumbersome and complex regulations than those emerging for gene therapy products and cell therapy products. Furthermore, even if our product candidates obtain required regulatory approvals, such approvals may later be withdrawn as a result of changes in regulations or the interpretation of regulations by applicable regulatory agencies.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product sales revenue to maintain our business.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be unable to obtain regulatory approval for our product candidates under applicable international regulatory requirements.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The denial or delay of such approval would delay commercialization of our product candidates and adversely impact our potential to generate revenue, our business and our results of operations.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approval by the FDA in the United States, if obtained, does not ensure approval by regulatory authorities in other countries or jurisdictions. In order to market our product candidates in any other jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a jurisdiction-by-jurisdiction basis regarding safety and efficacy. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Seeking regulatory approval in other jurisdictions could result in difficulties and costs for us and require additional preclinical studies or clinical trials which could be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. The European Union and other jurisdictions&#8217; regulatory approval processes involve all of the risks associated with the FDA approval. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of our products will be unrealized.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">A third-party investigational drug used in combination with our product candidates may be unable to obtain regulatory approval, which may delay commercialization of our product candidates.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing several of our product candidates to be used in combination with our and third-party drugs. Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA, the EMA or comparable regulatory authorities in other jurisdictions could revoke approval of the therapy used in combination with our product or that safety, efficacy, manufacturing or supply issues could arise with any of those existing therapies. If the therapies we use in combination with our product candidates are replaced as the standard of care for the indications we choose for any of our product candidates, the FDA, the EMA or comparable regulatory authorities in other jurisdictions may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our own products, if approved, being removed from the market or being less successful commercially. We also plan to evaluate current and future product candidates in combination with one or more therapies that have not yet been approved for marketing by the FDA, the EMA or comparable regulatory authorities in other jurisdictions. We will not be able to market any product candidate we develop in combination with an unapproved therapy if that unapproved therapy does not ultimately obtain marketing approval. In addition, unapproved therapies face the same risks described with respect to our product candidates currently in development and clinical trials, including the potential for serious adverse effects, delay in their clinical trials and lack of FDA, EMA or comparable regulatory authority approval.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA, the EMA or comparable regulatory authorities in other jurisdictions do not approve these other drugs or revoke their approval of, or if safety, efficacy, manufacturing or supply issues arise with, the drugs we choose to evaluate in combination with any product candidate we develop, we may be unable to obtain approval of or market any product candidate we develop.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our COVID-19 vaccine and any other product candidates for which we receive approval or emergency use authorization are subject to continuing regulatory oversight, and we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. We may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our COVID-19 vaccine<font style="color:#000000;"> and any other product candidates for which we receive approval or emergency use authorization are subject to continuing regulatory oversight, including the review of additional safety information, and the applicable regulatory authority may still impose significant restrictions on the indicated uses or marketing of our product or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. For example, the holder of an approved BLA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. The holder of an approved BLA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to comply with applicable regulatory requirements following approval of any of our product candidates, a regulatory agency may:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>issue a warning letter asserting that we are in violation of the law&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>seek an injunction or impose civil or criminal penalties or monetary fines&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>suspend or withdraw regulatory approval or revoke a license&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>suspend any ongoing clinical studies&#894; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>refuse to approve a pending BLA or supplements to a BLA submitted by us&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>seize product&#894; or</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>refuse to allow us to enter into supply contracts, including government contracts.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize any approved products and generate revenues.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our product candidates cause undesirable side effects, it could delay or prevent their regulatory approval, limit the commercial potential, or result in significant negative consequences following any potential marketing approval. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product candidates we may develop may be associated with an adverse immune response or other serious adverse events, undesirable side effects or unexpected characteristics. In addition to serious adverse events or side effects caused by any of our product candidates, the administration process or related procedures also can cause undesirable side effects. If any such events occur, the clinical trials of any of our product candidates could be suspended or terminated.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If in the future we are unable to demonstrate that such adverse events were caused by factors other than our product candidate, the FDA, the EMA or other regulatory authorities could order us to cease further development of, or deny approval of, any of our product candidates for any or all targeted indications. Even if we are able to demonstrate that all future serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled trial participants to complete the trial. Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of any of our product candidates, the commercial prospects of such product candidates may be harmed and our ability to generate product sale revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our ability to identify and develop product candidates, and may harm our business, financial condition, result of operations and prospects significantly.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, following regulatory approval of a product candidate, the FDA or other regulatory authority could require us to adopt a REMS or a risk management plan, or RMP, to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a medication guide outlining the risks of the product for distribution to patients, a communication plan to health care practitioners, extensive patient monitoring, or distribution systems and processes that are highly controlled, restrictive, and more costly than what is typical for the industry.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, if we or others later identify undesirable side effects caused by any product that we develop, several potentially significant negative consequences could result, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>regulatory authorities may suspend or withdraw approvals or revoke licenses of such product&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>regulatory authorities may require additional warnings on the label&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we may be required to change the way a product is administered or conduct additional clinical trials&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we could be sued and held liable for harm caused to patients and their children&#894; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our reputation may suffer.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could prevent us from achieving or maintaining market acceptance of any products we may identify and develop and could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are successful in gaining approval for any of our product candidates, we will continue to face significant regulatory oversight of the manufacturing and distribution of our products. Product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with GMP and adherence to commitments made in the BLA. If we or a regulatory agency discovers previously unknown problems with a product such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and other healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be subject to additional healthcare regulation and enforcement by the U.S. federal government and by authorities in the United States, the European Union and other jurisdictions in which we conduct our business.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations will be directly, or indirectly through our prescribers, customers and purchasers, subject to various federal and state fraud and abuse laws and regulations, including, without limitation, the federal Health Care Program Anti-Kickback Statute, the federal civil and criminal False Claims Act, and the Physician Payments Sunshine Act and regulations. Many states and other jurisdictions have similar laws and regulations, some of which may be broader in scope. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These laws will impact, among other things, our proposed sales, marketing and educational programs. In addition, we may be subject to patient privacy laws enacted by both the federal government and the states in which we conduct our business. The laws that will affect our operations include, but are not limited to the following:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>The federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, in return for the purchase, recommendation, leasing or furnishing of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers, and formulary managers on the other. The ACA amends the intent requirement of the federal Anti-Kickback Statute to provide that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>The federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment or approval from Medicare, Medicaid or other government payors. The ACA provides, and recent government cases against pharmaceutical and medical device manufacturers support, the view that federal Anti-Kickback Statute violations and certain marketing practices, including off-label promotion, may implicate the False Claims Act.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit a person from knowingly and willfully executing a scheme or making false or fraudulent statements to defraud any healthcare benefit program, regardless of the payor (<font style="font-style:italic;">e.g.</font>, public or private).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization by entities subject to the rule, such as health plans, health care clearinghouses and health care providers.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU123"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>The U.S. Federal Food, Drug, and Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>The U.S. Public Health Service Act, which prohibits, among other things, the introduction into interstate commerce of a biological product unless a biologics license is in effect for that product.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Federal transparency laws, including the federal Physician Payment Sunshine Act, which require disclosure of payments and other transfers of value provided to physicians and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>State law equivalents of each of the above federal laws, state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, and state laws governing the privacy and security of health information in certain circumstances which are also applicable to us, and many of them differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts in certain circumstances.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>The U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents, as well as non-U.S. companies that are registered with the SEC, from authorizing, promising, offering or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof&#894; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Similar healthcare laws and regulations in the European Union and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the European Union. The provision of benefits or advantages to physicians is also governed by the national anti- bribery laws of European Union member states, such as the U.K. Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments made to physicians in certain EU member states must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization or the regulatory authorities of the individual EU member states. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the EU member states. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are subject to certain anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU124"></a>Among other matters, anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, which are collectively referred to as &#8220;trade laws,&#8221; prohibit companies and their employees, agents, CROs, legal counsel, accountants, consultants, contractors and other collaborators from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of trade laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, intellectual property (including patents) and other regulatory approvals, and we can be held liable for the corrupt or other illegal activities of our personnel, agents or collaborators, even if we do not explicitly authorize or have prior knowledge of such activities.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are subject to stringent privacy laws, information security policies and contractual obligations governing the use, processing, and cross-border transfer of personal information and our data privacy and security practices.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We receive, generate and store significant and increasing volumes of sensitive information, such as employee, personal and patient data.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to a variety of local, state, national and international laws, directives and regulations that apply to the collection, use, storage, retention, protection, disclosure, transfer and other processing of personal data, collectively referred to as &#8220;data processing&#8221;, in the different jurisdictions in which we operate, including comprehensive regulatory systems in the United States and Europe. Legal requirements relating to data processing continue to evolve and may result in ever-increasing public scrutiny and escalating levels of enforcement, sanctions and increased costs of compliance.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compliance with U.S. and international data protection laws and regulations could cause us to incur substantial costs or require us to change our business practices and compliance procedures in a manner adverse to our business. Moreover, complying with these various laws could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend, could result in adverse publicity and could have a material adverse effect on our business, financial condition and results of operations.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The collection and use of personal health data in the European Union had previously been governed by the provisions of the GDPR. While the Data Protection Directive did not apply to organizations based outside the European Union, the GDPR has expanded its reach to include any business, regardless of its location, that provides goods or services to residents in the European Union. The GDPR imposes strict requirements on controllers and processors of personal data, including special protections for &#8220;sensitive information&#8221; which includes health and genetic information of patients residing in the European Union. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States and other countries. In addition, the GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU125"></a><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since we are located in the European Union, we are subject to the GDPR. Additionally, as the GDPR applies extraterritorially, we are also subject to the GDPR even where our data processing activities occur outside of the European Union if such activities involve the personal data of individuals located in the European Union. GDPR regulations have imposed additional responsibility and liability in relation to the personal data that we process and we may be required to put in place additional mechanisms to ensure compliance with the new data protection rules. This may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition, results of operations and prospects.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other jurisdictions outside the European Union are similarly introducing or enhancing privacy and data security laws, rules and regulations, which could increase our compliance costs and the risks associated with non-compliance. We cannot guarantee that we are, or will be, in compliance with all applicable international regulations as they are enforced now or as they evolve. For example, our privacy policies may be insufficient to protect any personal information we collect, or may not comply with applicable laws, in which case we may be subject to regulatory enforcement actions, lawsuits or reputational damage, all of which may adversely affect our business. There is significant uncertainty related to the manner in which data protection authorities will seek to enforce compliance with the GDPR, especially with regard to clinical trial conduct. For example, it is not clear if the authorities will conduct random audits of companies doing business in the European Union, or if the authorities will wait for complaints to be filed by individuals who claim their rights have been violated. Enforcement uncertainty and the costs associated with ensuring GDPR compliance may be onerous and adversely affect our business, financial condition, results of operations and prospects. If we fail to comply with the GDPR and the applicable national data protection laws of the EU member states, or if regulators assert we have failed to comply with these laws, it may lead to regulatory enforcement actions, which can result in monetary penalties of up to &#8364;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. If any of these events were to occur, our business and financial results could be significantly disrupted and adversely affected.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we take measures to protect sensitive data from unauthorized access, use or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or breached due to employee error, malfeasance or other malicious or inadvertent disruptions. Any such breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, manipulated, publicly disclosed, lost or stolen. Any such access, breach or other loss of information could result in legal claims or proceedings, and liability under federal or state laws that protect the privacy of personal information, as well as regulatory penalties. In the United States, notice of breaches must be made to affected individuals and the U.S. Secretary of HHS, and for extensive breaches, notice may need to be made to the media or U.S. state Attorneys General. Such a notice could harm our reputation and our ability to compete. HHS has the discretion to impose penalties without attempting to resolve violations through informal means. In addition, U.S. state Attorneys General are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. Although we have implemented security measures to prevent unauthorized access to patient data, such data is currently accessible through multiple channels, and there is no guarantee we can protect our data from breach. Unauthorized access, loss or dissemination could also damage our reputation or disrupt our operations, including our ability to conduct our analyses, deliver test results, process claims and appeals, provide customer assistance, conduct research and development activities, collect, process and prepare company financial information, provide information about our tests and other patient and physician education and outreach efforts through our website, and manage the administrative aspects of our business.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we or our third-party suppliers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU126"></a>We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also may produce hazardous waste products. We generally anticipate contracting with third parties for the disposal of these materials and wastes. We will not be able to eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from any use by us of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly and time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Ownership of the ADSs</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have experienced and may continue to experience significant volatility in the market price of the ADSs representing our ordinary shares.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU127"></a>Biopharmaceutical companies that are developing potential therapeutics and vaccines to combat COVID-19, including BioNTech SE, have experienced significant volatility in the price of their securities upon publication of preclinical and clinical data as well as news about their development programs. For example, during 2020 the closing sales price of the ADSs representing our ordinary shares on the Nasdaq Global Select Market ranged from $29.21 to $129.54, with significant volatility occurring shortly after announcements related to the development, approval, and commercialization of our COVID-19 vaccine. Given the attention being paid to the COVID-19 pandemic and the public scrutiny of COVID-19 development and commercialization announcements, and given that our COVID-19 vaccine is among the first vaccines to receive emergency use authorization, we expect that the public announcements we and Pfizer intend to make in the coming months regarding additional supply agreements and any news regarding manufacturing and distribution of our COVID-19 vaccine or unanticipated side effects of our COVID-19 vaccine will attract significant attention and scrutiny and that, as a result, the price of the ADSs representing our ordinary shares likely will continue to be volatile.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU128"></a><a name="_AEIOULastRenderedPageBreakAEIOU129"></a><a name="_AEIOULastRenderedPageBreakAEIOU130"></a>If we engage in future acquisitions, joint ventures or collaborations, this may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. We may not realize the benefits of these acquisitions, joint ventures or collaborations.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may evaluate various acquisitions and collaborations, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition, joint venture or collaboration may entail numerous risks, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>increased operating expenses and cash requirements&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the assumption of additional indebtedness or contingent liabilities&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel&#894;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition&#894;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals&#894; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our inability to generate revenue from acquired technology or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if we undertake acquisitions, we may utilize our cash, issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, we may not be able to locate suitable acquisition or collaboration opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our Articles of Association designate specific courts in the United States as the exclusive forum for certain U.S. litigation that may be initiated by our shareholders, which could limit our shareholders&#8217; ability to obtain a favorable judicial forum for disputes with us.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Articles of Association provide that the United States District Court for the Southern District of New York shall be the competent court of jurisdiction for the resolution of any litigation on the grounds of or in connection with U.S. federal or state capital market laws. In the absence of these provisions, under the Securities Act of 1933, as amended, or the Securities Act, U.S. federal and state courts have been found to have concurrent jurisdiction over suits brought to enforce duties or liabilities created by the Securities Act. This choice of forum provision will not apply to suits brought to enforce duties or liabilities created by the Securities Exchange Act of 1934, as amended, which already provides that such federal district courts have exclusive jurisdictions over such suits. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU131"></a>The choice of forum provision contained in our Articles of Association may limit a shareholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our executive officers, directors, or other employees, or impose additional litigation costs on shareholders in pursuing any such claims, particularly if the shareholders do not reside in or near the state of New York, which may discourage such lawsuits. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other U.S. or German courts will enforce our choice of forum provision. The enforceability of similar choice of forum provisions in other companies&#8217; governing documents has been challenged in recent legal proceedings, and it is possible that a court in the relevant jurisdictions with respect to us could find the choice of forum provision contained our Articles of Association to be inapplicable or unenforceable. If the relevant court were to find the choice of forum provision contained in our articles of association to be inapplicable or unenforceable, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business, financial condition and operating results. The choice of forum provision may also impose additional litigation costs on shareholders who assert that the provision is not enforceable or invalid. The United States District Court for the Southern District of New York may also reach different judgments or results than would other courts, including courts where a shareholder considering a U.S.-based action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our shareholders.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Holders of the ADSs may not be able to participate in any future preemptive subscription rights issues or elect to receive dividends in shares, which may cause additional dilution to their holdings.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under German law, the existing shareholders of a company generally have a preemptive right in proportion to the amount of shares they hold in connection with any issuance of ordinary shares, convertible bonds, bonds with warrants, profit participation rights and participating bonds. However, our shareholders in a shareholders&#8217; meeting may vote, by a majority representing at least three-quarters of the share capital represented at the meeting, to waive this preemptive right provided that, from the company&#8217;s perspective, there exists good and objective cause for such waiver.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The deposit agreement provides that the depositary need not make rights available to you unless the distribution to ADS holders of both the rights and any related securities are either registered under the Securities Act or exempted from </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">registration under the Securities Act. We are under no obligation to file a registration statement with respect to any such rights or securities or to endeavor to cause such a registration statement to be declared effective. Moreover, we may not be able to establish an exemption from registration under the Securities Act. Accordingly, ADS holders may be unable to participate in our future rights offerings and may experience dilution in their holdings. For example, ADS holders were unable to participate in our summer 2020 rights offering. In addition, if the depositary is unable to sell rights that are not exercised or not distributed or if the sale is not lawful or reasonably practicable, it will allow the rights to lapse, in which case you will receive no value for these rights.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our principal shareholders and management own a significant percentage of our ordinary shares and will be able to exert significant control over matters subject to shareholder approval. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our executive officers, directors, five percent shareholders, and their affiliates beneficially own a majority of our ordinary shares (including ordinary shares represented by ADSs) as of December 31, 2020, and will have the ability to influence us through their ownership positions. For example, these shareholders, acting together, may be able to exert significant influence over matters such as elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our ordinary shares that shareholders may believe are in their best interest. Such insiders may also act in concert to waive rights to participate in rights offerings, as was done in our summer 2020 rights offering, which would have the effect of permitting the ADSs or shares underlying such waived rights to be offered to the public in an underwritten offering without contravening German law pricing requirements.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The large number of shares eligible for sale or subject to rights requiring us to register them for sale could cause the market price of the ADSs to drop significantly, even if our business is performing well.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have filed a registration statement on Form S-8 under the Securities Act, to register all ordinary shares issued or issuable under our equity plans. Such Form S-8 registration statements and any other registration statements on Form S-8 we file in the future become effective upon filing, upon which shares registered under such registration statements become available for sale in the open market.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU132"></a>Additionally, certain sales of ADSs or our ordinary shares that we have made included holding period restrictions or registration rights. Sales of ADSs or our ordinary shares as restrictions end or pursuant to registration rights may make it more difficult for us to finance our operations through the sale of equity securities in the future at a time and at a price that we deem appropriate. These sales also could cause the trading price of the ADSs to fall and make it more difficult to sell the ADSs on favorable terms.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_4"></a>Item 4. Information on the Company</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">A.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="Item_4_A"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">History and Development of the Company</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were founded and incorporated on June 2, 2008 as Petersberg 91, V AG, a German stock corporation (<font style="font-style:italic;">Aktiengesellschaft</font>). We <font style="color:#000000;">changed</font> our name to BioNTech AG on December 11, 2008. On March 8, 2019, we converted to a European stock corporation (<font style="font-style:italic;">Societas Europaea</font>, or SE) under the laws of Germany and the European Union called BioNTech SE. We completed our initial public offering in October 2019. ADSs representing our ordinary shares are currently listed on the Nasdaq Global Select Market under the symbol &#8220;BNTX.&#8221;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our <font style="color:#000000;">principal</font> executive offices are located at An der Goldgrube 12, D-55131 Mainz, Germany. Our telephone number is +49 6131-9084-0. Our website address is http://www.biontech.de. The information contained on, or that can be accessed through, our website is not part of this document. Our agent for service of process in the United States is c/o BioNTech US Inc., 40 Erie Street, Suite 110, Cambridge, Massachusetts 02139, +1 (617) 337-4701.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">B.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_4_B"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Business Overview</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:bold;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">I.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Overview</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech was founded in 2008 on the understanding that every cancer patient&#8217;s tumor is unique and that in order to effectively address this challenge, we must create individualized treatments for each patient. To realize this vision, we combine decades of groundbreaking research in immunology, cutting-edge therapeutic platforms and a suite of patient profiling and bioinformatic tools to develop immunotherapies for cancer and other diseases. We leverage powerful new therapeutic mechanisms and exploit a diverse array of biological targets to harness the power of each patient&#8217;s immune system to address the unique molecular signature of each patient&#8217;s underlying disease. The breadth of our immunotherapy </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">technologies and expertise enable</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> us to develop </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">potential </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">therapies to address a range of rare and infectious diseases, and we rapidly mobilized these to address the COVID-19 pandemic </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with our COVID-19 vaccine, </font><font style="color:#231F20;">referred to as COMIRNATY</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#174;</font><font style="color:#231F20;"> in the E</font><font style="color:#231F20;">uropean </font><font style="color:#231F20;">U</font><font style="color:#231F20;">nion</font><font style="color:#231F20;"> and other locations where we have received marketing approval.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe <font style="color:#000000;">our</font> successful development of a first-in-class COVID-19 mRNA vaccine in less than one year validates our execution capabilities and the power of our technologies to change lives.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to invest the revenues we generate from sales of our COVID-19 vaccine to accelerate the maturation of our oncology and infectious disease pipeline and the expansion into additional therapeutic areas, such as autoimmunity, allergy, regenerative medicine and inflammatory diseases. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe <font style="color:#000000;">we</font> are well positioned to develop and commercialize the next generation of immunotherapies with the potential to transform treatment paradigms for many severe diseases and significantly improve clinical outcomes for patients. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdc15tqwxkbk000001.jpg" title="" alt="" style="width:561px;height:294px;"></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our immunotherapy product candidates span the following four distinct drug classes: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">mRNA Therapeutics.</font><font style="color:#000000;"> We are utilizing messenger ribonucleic acid, or mRNA, to deliver genetic information to cells, where it is used to express proteins for therapeutic effect. We are developing a portfolio of immunotherapies that utilize four different mRNA formats and three different formulations to derive five distinct platforms for the treatment of cancer. Four of these platforms are currently in human testing: (i) our off-the-shelf shared antigen immunotherapy, or FixVac; (ii) our individualized neoantigen specific immunotherapy, or iNeST, in collaboration with Genentech, Inc.; (iii) our intratumoral immunotherapy, in collaboration with Sanofi, S.A.; and (iv) our mRNA encoding for specific cytokines, or RiboCytokines. In addition, we are developing another platform in which we use mRNA to express directly in the patient particular antibodies, or RiboMabs. We are also leveraging our mRNA technology to address COVID-19, influenza and other infectious diseases and rare diseases. In December 2020, our COVID-19 vaccine became the first mRNA vaccine to be authorized or approved for emergency or temporary use or granted conditional marketing authorization in over 65 countries worldwide.&nbsp;&nbsp;&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Cell Therapies.</font> We are developing a range of cell therapies, including chimeric antigen receptorT cells, or CAR-T, neoantigen-based T cell therapies and T cell receptor, or TCR, therapies, in which the patient&#8217;s T cells are modified or primed to target cancer-specific antigens We are also combining our mRNA FixVac platform with our first CAR-T product candidates to enhance the persistence of CAR-T cells<font style="font-style:italic;"> in vivo</font>. Our first CARVac product candidate entered into clinical testing in solid tumors in February 2021.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Antibodies.</font> We are developing, in collaboration with Genmab A/S, next-generation bispecific antibodies that are designed to target immune checkpoints that modulate the patient&#8217;s immune response to cancer. We are also </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exploring additional targeted cancer antibody approaches utilizing our in-house capabilities. Our first </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">two </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> candidates</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> under this collaboration </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in clinical testing. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Small Molecule Immunomodulators.</font> We use small molecules to augment the activity of other drug classes by inducing specific and discrete patterns of immunomodulation. We have a small molecule toll-like receptor 7, or TLR7, immunomodulator for the treatment of solid tumors in clinical testing. </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have leveraged these four drug classes to build a robust pipeline of over 20 product candidates in oncology and additional product candidates in infectious disease. We believe our technology and expertise is broadly applicable across a number of therapeutic areas, such as oncology, infectious diseases and rare diseases. Longer-term, we see applications for the technology in the fields of auto-immune diseases, allergy, inflammatory disease, and even regenerative medicine. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our first commercial stage program is our BNT162 vaccine program to prevent COVID-19, which includes our COVID-19 vaccine development program, BNT162. We are co-developing BNT162 with Pfizer, Inc., or Pfizer, worldwide (ex-China) and with Shanghai Fosun Pharmaceutical (Group) Co., Ltd., or Fosun Pharma in China. We initiated the BNT162 program in late January 2020 and as of March 2021, our COVID-19 vaccine has been authorized or approved for emergency use or temporary use or granted conditional marketing authorization in over 65 countries around the world, including the United States, the United Kingdom, and Canada and has received conditional marketing authorization following rolling submissions with the EMA. Our COVID-19 vaccine has not been approved or licensed by the U.S. FDA, but has been authorized for emergency use by the FDA under an Emergency Use Authorization, or EUA, to prevent COVID-19 for use in individuals 16 years of age and older, as well as for emergency use in several other countries around the world. As of March 23, 2021, we and Pfizer have supplied 200 million doses of our COVID-19 vaccine globally. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In our oncology therapeutic programs, we have to-date treated over 800 patients across more than 20 solid tumor types. We also are developing more than four additional preclinical programs and expect to initiate clinical testing with several of them in 2021. In our Phase 1 trial for BNT111, our lead FixVac off-the-shelf product candidate, we have observed antigen-specific immune responses in over 90% of advanced melanoma patients treated with BNT111 as a single agent. In addition, we have observed single-agent antigen-specific immune responses in patients treated with the precursor to autogene cevumeran (RO7198457, BNT122), our iNeST product candidate. In both trials, we have observed durable objective responses (reduction in tumor volume) in both the monotherapy and checkpoint-combination settings. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our Team</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our team combines proven biotechnology entrepreneurs, world-renowned immunologists and sophisticated biopharma investors. We were founded in 2008 by our scientific founders, Prof. Ugur Sahin, M.D., Prof. Christoph Huber, M.D. and &#214;zlem T&#252;reci, M.D., with a seed investment of &#8364;150 million from the Str&#252;ngmann family, through its investment vehicle, AT Impf, and MIG Fonds, or MIG. Andreas and Thomas Str&#252;ngmann are serial entrepreneurs, having co-founded Hexal AG, a German pharmaceutical firm, which they built and sold to Novartis, along with their majority stake in Eon Labs, Inc., a U.S. public pharmaceutical firm, for a combined &#8364;5.6 billion (at the time, $8.3 billion). Helmut Jeggle and Michael Motschmann, on behalf of the Str&#252;ngmann family and MIG, respectively, along with Dr. Huber, were founding members of our Supervisory Board. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech has been supported since its inception by Prof. Rolf Zinkernagel, M.D., Ph.D. and Prof. Hans Hengartner, Ph.D., who serve on our Scientific Advisory Board. Dr. Zinkernagel is a Professor Emeritus at the University of Zurich, University Hospital, and former head of the Institute of Experimental Immunology in Zurich. Prof. Zinkernagel was awarded the Nobel Prize in 1996 for the discovery of how the immune system recognizes virus-infected cells. Prof. Hengartner is a world-renowned immunologist and Professor Emeritus at the Federal Institute of Technology ETH Zurich and the University of Zurich. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our initial group of scientific founders have been joined by experienced pharmaceutical executives, immunologists and biotechnology specialty investors. Sean Marett, our Chief Business Officer and Chief Commercial Officer, led the business development teams at Evotec, and previously was an executive at GlaxoSmithKline in the United States. Dr. Sierk Poetting, our Chief Financial Officer and Chief Operating Officer, joined us from Sandoz, where he served as the Chief Financial Officer in North America. Ryan Richardson, our Chief Strategy Officer, joined us from J.P. Morgan Securities LLC, where he served as Executive Director, Healthcare Investment Banking. We have also attracted talented scientists such as Katalin Karik&#243;, our Senior Vice President &amp; Head of RNA Protein Replacement, who has more than 30 years of experience working with RNA, has published more than 70 peer-reviewed papers and is co-inventor on mRNA-related patents, including a foundational patent relating to modified mRNA. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;font-weight:bold;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">II.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;"></font><font style="color:#000000;"></font><font style="color:#000000;">Our</font><font style="color:#000000;"> </font><font style="color:#000000;">Products</font><font style="color:#000000;"> and Pipeline of Product Candidates </font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are advancing a deep and broad portfolio of product candidates derived from our four drug classes focused on the treatment of cancer, infectious and rare diseases to complement our commercial product, our COVID-19 vaccine: </p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdc15tqwxkbk000002.jpg" title="" alt="" style="width:593px;height:631px;"></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">A.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Commercial Product: COVID-19 Vaccine </font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our mRNA-based COVID-19 vaccine product has been authorized or approved for emergency or temporary use <font style="color:#000000;">or</font> granted conditional marketing authorization in over 65 countries worldwide.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In response to the COVID-19 pandemic, we initiated our COVID-19 vaccine development program, BNT162, in late January 2020, leveraging our proprietary mRNA platform, and assembled a global consortium of partners including Pfizer (worldwide collaboration outside of China) and Fosun Pharma (China). In April 2020, we initiated a first-in-human clinical trial of BNT162b2 following preclinical studies. In July 2020, we initiated, along with our partner Pfizer, a phase 3 clinical trial of BNT162b2 and published the clinical results in November 2020. Subsequently, our COVID-19 vaccine has been authorized or approved for emergency use or temporary use or granted conditional marketing authorization in over 65 countries around the world, including the United States, the United Kingdom, and Canada and has received CMA following rolling submissions with the EMA.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We seek to drive long-term sustainable revenues from our COVID-19 vaccine program by increasing patient access through enhancing manufacturing and supply capabilities, broadening distribution geographies, expanding the label, and optimizing the formulation.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Clinical Research and Development</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and Pfizer have jointly conducted clinical trials for COVID-19 vaccine candidates across approximately 150 clinical trial sites globally. In late April 2020, we and Pfizer announced that the German regulatory authority, the Paul-Ehrlich-Institut, approved the Phase 1/2 clinical trial and the first patients in the first cohort of the Phase 1/2 clinical trial were dosed shortly thereafter. In early May 2020, we and Pfizer initiated a clinical trial for BNT162 in the U.S. and the first participants were dosed shortly thereafter. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on preclinical and clinical data observed, we and Pfizer progressed our BNT162 program into a Phase 2b/3 trial which commenced in late July 2020. For the initial Phase 2b/3 trial, we selected our nucleoside-modified mRNA (modRNA) vaccine candidate variant targeting the 2P-mutated full spike protein, BNT162b2. Both BNT162b2 and our BNT162b1 vaccine candidate, which uses modRNA and encodes the receptor binding domain antigen, received Fast Track status from the FDA. On the basis of data collected and analyzed for BNT162b1 and BNT162b2, including the overall observed safety, tolerability and immunogenicity profiles for each vaccine candidate at different dose levels, along with input from the FDA, we selected BNT162b2 as our lead candidate to take into a Phase 2b/3 trial.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Phase 3 clinical trial of BNT162b2 began in July 2020 and enrolled more than 44,000 participants from approximately 150 clinical trials sites in the United States, Germany, Turkey, South Africa, Brazil and Argentina. The Phase 3 trial is designed as a 1:1 vaccine candidate to placebo, randomized, observer-blinded study to obtain safety, immune response, and efficacy data needed for regulatory review. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, we and Fosun initiated a Phase 1 study to evaluate safety and immunogenicity in Chinese participants. In November 2020, we initiated a Phase 2 clinical trial of vaccine candidate BNT162b2 in Jiangsu Province, China to assess the safety and immunogenicity of the vaccine candidate and to support future Biologic License Application (BLA) in China.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 6, 2020, we announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2. The EMA&#8217;s decision to start a rolling review follows the encouraging preliminary results from pre-clinical and early clinical studies in adults, which suggest that BNT162b2 triggers the production of neutralizing antibodies and TH-1 dominant CD4+ and CD8+ T cells that target SARS-CoV-2. A combination of an antibody and T cell response is believed to be important in eliciting protection against viral infection and disease. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 21, 2020 we and Pfizer announced initiation of a Phase 1/2 clinical trial in Japan to evaluate safety, tolerability and immunogenicity of two doses separated by 21 days and a single dose of BNT162b2. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 18, 2020, we and Pfizer announced that, after conducting the final efficacy analysis in our ongoing Phase 3 study, BNT162b2 met all of the study&#8217;s primary efficacy endpoints. <font style="color:#000000;">In this pivotal Phase 3 trial of BNT162b2, there were over 44,000 participants who were 16 years and older, 21,720 of whom received the two-dose regimen of 30 &#956;g BNT162b2, which was given 21 days apart, and 21,728 of whom received the placebo.</font> Among 36,523 participants who had no evidence of existing or prior SARS-CoV-2 infection at the time of the immunizations, there were 170 cases of COVID-19 observed at least seven days after the second dose. <font style="color:#000000;">Of these 170 cases of COVID-19, 162 cases occurred among placebo </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">recipients</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and eight</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> cases occurred in vaccine recipients, corresponding to 95.0% vaccine efficacy</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Among participants with and without evidence of prior SARS CoV-2</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">infection, there were </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nine</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> cases of COVID-19 among vaccine recipients and 169 among placebo recipients, corresponding to </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94.6% vaccine efficacy</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cumulative incidence of COVID-19 cases over time among placebo and vaccine recipients began to diverge by 12 days after the first dose, and 52.4% vaccine efficacy was observed between </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the first and second </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dose</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, indicating the early onset of a partially protective effect of immunization. Two doses of vaccine provide the maximum protection observed. Ten cases of severe COVID-19 were observed with onset after the first dose. Nine cases occurred among placebo recipients and one among BNT162b2 recipients. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BNT162b2 exhibited a favorable tolerability and safety profile. Based on a data cut-off date of October 9, 2020, 37,706, participants had a median of at least two months of safety data available after the second dose and contributed to the main safety dataset. Among these participants, 49% were female; 83% were White; 9% were Black or African American; 28% were Hispanic/Latinx; 35% were obese (BMI &#8805;30.0 kg/m2); and 21% had at least one underlying comorbidity. The median age was 52 years, and 42% were older than 55 years. The most common adverse events of BNT162b2 were transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days. These reactions were less common and milder in older adults than younger adults. Severe reactions (Grade 3) were reported in fewer than 2% of vaccine recipients after either dose except for fatigue (3.8%) and headache (2.0%). Fever (&#8805;38 &#176;C) was reported in similar proportions of younger (16%) and older (11%) vaccine recipients. Rates of serious adverse events were similar between vaccine and placebo groups (0.6% and 0.5%). There were no COVID-19-related deaths. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All trial participants will continue to be monitored to assess long-term protection and safety for an additional two years after their second dose. Data from this study, including longer term safety, comprehensive information on duration of protection, efficacy against asymptomatic SARS-CoV-2 infection, and safety and immunogenicity in adolescents 12 to 15 years of age will be gathered. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="color:#000000;">On December 10, 2020, results from the Phase 3 trial of BNT162b2 were published in The New England Journal of Medicine. We have also published several scientific papers on the new rapidly spreading variants of SARS-CoV-2 and how they might affect the efficacy of BNT162b2. In December 2020, we published data on a panel of 18 SARS-CoV-2 RBD variants identified through publicly available information. Sera collected seven days after the booster dose of BNT162b2 showed high neutralising titers to each of the SARS-CoV-2 S variants, demonstrating the breadth of the neutralising response against circulating strains.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2021, we released three other publications on the vaccine efficacy against new SARS-CoV-2 strains. One publication showed that sera from vaccinated individuals neutralized SARS-CoV-2 with an introduced N501Y mutation, a key target of virus neutralizing antibodies, as efficiently as SARS-CoV-2 without the mutation. Another publication showed that pseudovirus bearing the U.K. strain SARS-CoV-2 spike with the full set of mutations was inhibited by BNT162b2-immune sera with a neutralization range that is biologically equivalent to the unmutated SARS-CoV-2 Spike.&nbsp;&nbsp;A third set of data was published by Xie et al. demonstrating that three recombinant SARS-CoV-2 variants containing key spike mutations from the newly emerged U.K. and South African variants (N501Y from the United Kingdom and South Africa; 69/70-deletion+N501Y+D614G from the United Kingdom; and E484K+N501Y+D614G from South Africa) were neutralized by sera from vaccinated individuals with a GMT neutralization rate against the wild-type strain of 1.46, 1.41, and 0.81, respectively. In March, we and Pfizer published data in the New England Journal of Medicine from an in vitro study of the neutralizing activity of BNT162b2-elicited serum against the variants first detected in the United Kingdom (B.1.1.2 lineage), Brazil (P.1 lineage), and South Africa (B.1.351 lineage). Sera neutralized all the viruses tested and showed no significant reduction in activity against both B.1.1.7-spike and P.1-spike viruses. While neutralization of the B.1.351-spike virus was lower, it was still robust. Thus, the neutralization data provide support that BNT162b2 will continue to protect against the variants first detected in the United Kingdom and Brazil.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While these findings do not indicate an immediate need for a new vaccine to address the emerging variants, we will continue to monitor emerging SARS-CoV-2 strains and continue to conduct studies to monitor the vaccine&#8217;s real-world effectiveness. We intend to respond quickly if a variant of SARS-CoV-2 shows clinical evidence of escaping immunity from our vaccine and will proactively prepare new vaccine constructs if needed. We believe that the flexibility of our proprietary mRNA vaccine platform is well suited to develop new vaccine variants if required (requiring potentially as short as six weeks to design a new product candidate). </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021, we and Pfizer announced that the first participants had been dosed in a global Phase 2/3 study to further evaluate the safety, tolerability, and immunogenicity of BNT162b2 in preventing COVID-19 in healthy pregnant </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">women 18 years of age and older. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and Pfizer are also planning studies to further evaluate the vaccine in people with compromised immune systems.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> announced that</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">safety and efficacy data from the global Phase 3 study with subjects 12 to 15 years of age are expected to be submitted to the regulatory authorities in the second quarter of 2021</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 25, 2021, we and Pfizer announced the initiation of a trial to evaluate the safety and immunogenicity of a third dose of our COVID-19 vaccine on prolonging immunity against COVID-19 and to address potential newly emerging SARS-CoV-2 variants.<font style="margin-left:14pt;">In March 2021, the</font> U.S. FDA approved an additional amendment to the study protocol of the global Phase 1/2/3 trial for an additional dose of BNT162b2 or its modified version carrying the spike protein sequence of the so-called South African variant (BNT162b2<sub style="font-size:85%; vertical-align:bottom">SA</sub>) in order to further describe duration of protection, and protection against the emerging variants of concern. An additional dose of either BNT162b2 or BNT162b2<sub style="font-size:85%; vertical-align:bottom">SA</sub> will be given to approximately 600 Phase 3 participants approximately five to seven months after their second dose of BNT162b2. A further dose of BNT162b2<sub style="font-size:85%; vertical-align:bottom">SA</sub> will be given to approximately 30 of those participants who receive BNT162b2<sub style="font-size:85%; vertical-align:bottom">SA</sub>. Approximately 300 BNT162b2-na&#239;ve participants will be enrolled and receive 2 doses of BNT162b2<sub style="font-size:85%; vertical-align:bottom">SA</sub> to describe protection against the emerging variants of concern and reference strains. The part of the trial with BNT162b2<sub style="font-size:85%; vertical-align:bottom">SA</sub> is expected to start in the second quarter of 2021.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, we also announced real-world evidence demonstrating dramatically lower incidence rates of COVID-19 disease in individuals fully vaccinated with our COVID-19 vaccine in Israel, underscoring the observed substantial public health impact of Israel&#8217;s nationwide immunization program. These new data, collected by the Israel Ministry of Health, demonstrate the vaccine&#8217;s effectiveness in preventing symptomatic SARS-CoV-2 infections, COVID-19 cases, hospitalizations, severe and critical hospitalizations, and deaths. Additionally, the analysis from the Israel Ministry of Health showed that that two weeks after the second vaccine dose protection vaccine effectiveness was at least 97% in preventing symptomatic disease, severe/critical disease and death. The analysis also showed a vaccine effectiveness of 94% against asymptomatic SARS-CoV-2 infections. Since this observational analysis was conducted when the variant B.1.1.7 was the dominant strain in Israel, it also provides real-world evidence of the effectiveness of BNT162b2 for prevention of COVID-19 infections, hospitalizations, and deaths due to variant B.1.1.7.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, the first participants were dosed in a Phase 1/2/3 study in healthy children 6 months to under 12 years of age. The Phase 1 dose finding portion is evaluating the safety, tolerability and immunogenicity of two doses of BNT162b2 separated by 21 days in up to three age groups (&#8805;5 to &lt;12 years, &#8805;2 to &lt;5 years, and &#8805;6 months to &lt;2 years of age). Once the preferred dose level of BNT162b2 is identified for each age group, a Phase 2/3 trial to evaluate the safety, tolerability and immunogenicity in each age group will start. Efficacy against confirmed COVID-19 and asymptomatic infection will also be assessed.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, in March 2021, we announced that we will start a Phase 3 trial to evaluate the safety, tolerability and immunogenicity of lyophilized BNT162b2 presented in single-dose vials and of frozen liquid BNT162b2 in multidose vials. This trial will also assess the noninferiority of the lyophilized formulation. The trial will be conducted in healthy adults 18 through 55 years of age and will start in the United States in April.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Regulatory</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 2021, our COVID-19 vaccine has been authorized or approved for emergency use or temporary use in over 65 countries around the world, including the United States, the United Kingdom, the European Union and Canada. Our COVID-19 vaccine has not been approved or licensed by the U.S. FDA, but has been authorized for emergency use by the FDA under an EUA, to prevent COVID-19 for use in individuals 16 years of age and older.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under our collaboration with Pfizer, we are the designated regulatory authorization worldwide. Pfizer has marketing and distribution rights worldwide with the exception of China, Germany, and Turkey. Fosun Pharma has marketing and distribution rights in China.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 28, 2021, the EMA published a safety update from its Pharmacovigilance Risk Assessment Committee, or PRAC. The safety data reviewed for our COVID-19 vaccine are in line with the vaccine&#8217;s known benefit-risk profile. The review covered all new safety data emerging since December 21, 2020, including the first Summary Monthly Safety Report from the marketing authorization holder. PRAC noted that a recent analysis in the United States estimated the frequency of anaphylaxis as approximately 11 cases per million doses of our COVID-19 vaccine administered. With respect to reports of suspected side effects with fatal outcome, specifically in frail elderly individuals, PRAC stated that in many cases concerning individuals above 65 years of age, progression of (multiple) pre-existing diseases seemed to be a plausible explanation for death. In some individuals, palliative care had already been initiated before vaccination. PRAC concluded </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that based on the current data there was no need to amend the product information regarding how </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our COVID-19 vaccine</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">should be used, including in frail elderly individuals. PRAC requested </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">continued thorough</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> review</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">all reports of suspected side effects with fatal outcome.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 25, 2021, the U.S. FDA, and on March 26, 2021, the EMA, approved that undiluted frozen vials of BNT162b2 may be transported and stored at conventional temperatures commonly found in pharmaceutical freezers (-25&#176;C to -15&#176;C or -13&#176;F to 5&#176;F) for a period of up to two weeks. Further formulation optimization activities are ongoing.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.03%;text-indent:2.9%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing and Delivery Capabilities</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and Pfizer continue to work in collaboration with governments and health ministries around the world that will distribute the vaccine, subject to country authorization or approval and terms of supply agreements, to help ensure it can reach those most in need as quickly as possible. We and Pfizer are leveraging Pfizer&#8217;s leading vaccine manufacturing and distribution capabilities to quickly scale, manufacture and distribute large quantities of the vaccine at high quality, complementing BioNTech&#8217;s mRNA manufacturing expertise gained over almost a decade. Based on projections as of March 2021, Pfizer&#8217;s and BioNTech&#8217;s combined manufacturing network has the potential to supply globally up to 2.5&#160;billion doses by the end of 2021 (subject to regulatory approval or authorization). Additionally, as of March 23, 2021 we and Pfizer have supplied 200 million doses of our COVID-19 vaccine globally.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Through our existing mRNA production sites in Germany, we were able to begin producing our COVID-19 vaccine for commercial supply before receiving regulatory authorization or approval. We have increased and will continue to increase our manufacturing capacity, including through our acquisition of a manufacturing site in Marburg, Germany. Our Marburg site is one of the key factors in the expansion of our manufacturing network and will become one of the largest mRNA manufacturing sites in Europe with an annual production capacity of up to one billion doses of our COVID-19 vaccine, once fully operational. We and Pfizer also leverage Pfizer&#8217;s manufacturing site in Puurs, Belgium, one of Pfizer&#8217;s largest sterile injectable sites, for European supply and as back up supply to the primary manufacturing site for the U.S. market, which is in Kalamazoo, Michigan. Our European manufacturing network has continually expanded from three partners in December 2020 when we received our first authorizations to 13 sites (including the Marburg facility) as of March 2021, and we are continuing to strengthen this network.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer has vast experience and expertise in cold-chain shipping and has an established infrastructure to supply the vaccine worldwide, including distribution hubs where vaccine can be stored until its expiration. Pfizer&#8217;s distribution is built on a flexible just-in-time system that can ship the frozen vials quickly to designated points of vaccination at the time of need, minimizing the need for long term storage. Vaccination in a pandemic situation is expected to be rapid, and we do not expect that the product will need to be stored at any location for more than 30 days. To assure product quality, we and Pfizer have developed specially designed, temperature-controlled shippers for the vaccine, which can maintain recommended shipping conditions (-80&#186;C to -60&#186;C (-112&#186;F to -76&#186;F)) for extended periods of time with dry ice. The shipper can maintain temperature for 10 days unopened which allows for transportation to markets globally. Once open, a vaccination center may store the vaccine in an ultra-low temperature freezer at (-75&#176;C &#177;15&#176;C) for up to six months, or use the specially designed shippers as a temporary storage solution to maintain the required temperatures for up to 30 days with re-icing every five days in accordance with the handling instructions. Alternatively, pursuant to the U.S. FDA&#8217;s and the EMA&#8217;s approvals in February and March 2021, respectively, the vials may be stored at -25&#176;C to -15&#176;C (-13&#176;F to 5&#176;F), temperatures more commonly found in pharmaceutical freezers and refrigerators. Once thawed, the vaccine vial can be stored safely for up to five days at refrigerated (2-8&#176;C) conditions. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commercial update</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 2021, we have signed orders for more than 1.4&#160;billion doses in 2021, and discussions for additional dose commitments are ongoing. This includes agreements with the governments in the United States, United Kingdom, Japan, Canada and the European Union. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, we and Pfizer announced a second agreement with the U.S. government to supply an additional 100 million doses of our COVID-19 vaccine. In February 2021, we and Pfizer announced that the U.S. government exercised its option for an additional 100 million doses of our COVID-19 vaccine. This agreement brings the total number of doses to be delivered to the United States to 300 million. Consistent with the original agreement announced in July 2020, the U.S. government will pay $1.95 billion for the additional 200 million doses.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in December 2020, we and Pfizer announced we and Pfizer will supply an additional 100 million doses of our COVID-19 vaccine to the EU member states in 2021, as a result on an option exercised under an advanced purchase </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agreement with the European Commission, or the EC. In February 2021 we and Pfizer announced a new agreement with the EC to supply an additional 200 million doses of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our COVID-19 vaccine</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, with the option to request a supply of an additional 100 million doses. This agreement brings the total number of doses to be delivered to the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uropean</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Union</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to 500 million</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, with the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">potential</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to increase to 600 million based on the option granted in the new agreement</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">B. Our Clinical Stage Product Candidates in Oncology</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing a broad and deep pipeline of over 20 product candidates across our four drug classes. 13 oncology product candidates are currently being investigated in 14 clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-top:6pt;text-align:justify;margin-bottom:0pt;margin-left:8.55%;text-indent:-3.62%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Our mRNA Product Class in Oncology</p>
<p style="margin-top:6pt;text-align:justify;margin-bottom:0pt;margin-left:8.55%;text-indent:-3.62%;;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">a) FixVac</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FixVac is our wholly owned, systemic, off-the-shelf mRNA-based cancer immunotherapy platform, from which we are developing several first-in-human and potential first-in-class product candidates. Our FixVac product candidates contain selected combinations of pharmacologically optimized uridine mRNA encoding known cancer-specific shared antigens. FixVac product candidates feature our proprietary immunogenic mRNA backbone and proprietary RNA-LPX delivery formulation, which are designed to enhance stability and translation as well as trigger both innate and adaptive immune responses. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">i. BNT111: Our FixVac Cancer Immunotherapy for the Treatment of Advanced Melanoma</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing our mRNA-based FixVac product candidate BNT111 for the treatment of advanced melanoma in patients with metastatic tumors and as an adjuvant treatment after tumor resection. We are currently studying BNT111 in an ongoing Phase 1 clinical trial and expect to start a randomized Phase 2 clinical trial in first half of 2021.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our BNT111 Targets</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BNT111 is designed to elicit an immune response to the following four antigens that have each been found to be associated with melanoma: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>New York esophageal squamous cell carcinoma 1, or NY-ESO-1, a well-known cancer-testis antigen that is also expressed in numerous cancers, including melanoma; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>melanoma-associated antigen A3, or MAGE-A3, which is not expressed in normal tissues, except the testis; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>tyrosinase, an enzyme that is required for melanin production and that is expressed at high levels in melanoma; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>trans-membrane phosphatase with tensin homology, or TPTE, a novel cancer/testis antigen that we discovered internally. </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequencing data from 337 melanoma tumors showed that at least one of these four antigens is detected in over 90% of such melanoma tumors. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.93%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdc15tqwxkbk000003.jpg" title="" alt="" style="width:597px;height:100px;"></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BNT111 antigens detected in over 90% of melanoma tumors.<font style="font-weight:normal;"> The graphic above shows expression of BNT111 target antigens on a patient by patient basis. Each row at the bottom of the graphic represents an antigen, and each vertical line represents a patient, depicting whether or not that patient&#8217;s tumor expressed each antigen. Red/yellow = antigen is expressed in patient&#8217;s tumor; white = no expression. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our BNT111 Clinical Trials </font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Ongoing Phase 1 Trial in Advanced Melanoma Patients (LIPOMERIT trial) </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are conducting a multi-center, open-label, first-in-human, Phase 1 dose escalation study evaluating the safety and tolerability of multiple intravenous administrations of BNT111 in patients with advanced melanoma. This is the first clinical trial worldwide in which an mRNA-based cancer immunotherapy is administered intravenously for systemic treatment. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trial employed a conventional 3+3 design in which patients were dosed in groups of three at incrementally greater dosages until the maximum tolerated dose was identified, during the dose escalation phase, which was then followed by expanded dose cohorts. Patients were treated with doses from 7.2&#181;g up to the highest administered dose of 400&#181;g of total RNA. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">July 2020 Data from BNT111 Lipo-MERIT Trial published in Nature</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020 we published interim Phase 1 data in the journal&#160;<font style="font-style:italic;">Nature</font>. The publication titled &#8220;An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma&#8221; summarizes the findings of the exploratory interim analysis (data extraction date July 29, 2019). </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Overall, the preliminary Phase 1 results from the Lipo-MERIT trial with data from 89 patients highlight a favorable tolerability profile of BNT111 in advanced melanoma patients. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">No dose-limiting toxicities to BNT111 have been reported. The overall adverse event profile was dominated by mild-to-moderate, transient and manageable flu-like symptoms. These symptoms were managed by pre-medication with non-steroidal antipyretics, such as ibuprofen and acetaminophen. Eight patients dosed with BNT111 experienced related treatment-emergent serious adverse events, or TESAEs. There were confounding factors, such as treatment with other therapies or underlying medical conditions, for the patients with related TESAEs. We could not establish a clear causal relationship between BNT111 and the cases of anaphylactic reaction, retinopathy, encephalopathy syndrome, seizure and suspected pancreatitis. There have been no deaths in this trial that were assessed by the investigators as related to BNT111.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The efficacy analysis in a subset of 42 checkpoint-inhibitor (CPI)-experienced metastatic melanoma patients showed that BNT111 mediates durable responses both as a single agent and in combination with anti-PD-1 antibodies. Durable objective responses by BNT111 were associated with activation and strong expansion of tumor-antigen-specific CD4+ and CD8+ T cells.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical activity<font style="font-style:italic;"> </font>was assessed in 25 patients that received BNT111 as a monotherapy, and 17 patients that received BNT111 in combination with an anti-PD-1 checkpoint inhibitor, or CPI (either pembrolizumab or nivolumab). In the BNT111 monotherapy cohort, we observed clinical activity for all 25 patients. All of these patients had received at least one line of prior treatment with a checkpoint inhibitor (CPI), and 24 of the 25 patients had failed prior sequential or combination treatment with anti-PD-1 and anti-CTLA4 antibodies. Three of 25 patients (12%) showed a partial response, or PR, one patient had a metabolic complete response and seven patients (28%) demonstrated stable disease. The clinical benefit rate, or CBR, is 44%. In the cohort treated with BNT111 in combination with a PD-1 CPI, 16 of the 17 patients had prior treatment with CPI. Six patients (35%) showed a partial response, and two patients (12%) demonstrated stable disease. The CBR is 47%. Objective responses were observed across all dose levels explored in expansion cohorts (14&#181;g, 50&#181;g and 100&#181;g).</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This interim data suggests that BNT111 alone and in combination with PD-1 checkpoint blockade, while being well tolerated, may mediate durable objective responses in melanoma patients that had progressed on or after prior checkpoint blockade. Vaccine-induced antigen-specific memory T&#160;cells persisted for more than one year under continuous monthly vaccination.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.07%;text-indent:2.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Phase 2 Trial with anti-PD-1 Therapy</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, we announced a strategic collaboration with Regeneron to jointly conduct a randomized Phase 2 trial for the treatment of patients with advanced melanoma progressing during or after prior therapy with a PD-1 inhibitor, utilizing a combination of BNT111 and Regeneron and Sanofi&#8217;s Libtayo (cemiplimab). Our IND for this trial in the United States is active. We received CTA approval in Spain and clinical trial applications are under review in Australia and five European countries (France, Germany, Italy, Poland, and the United Kingdom). We are targeting commencement of the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trial in the U</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nited States</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and in the European Union</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> first half of 2021.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ii. BNT112: Our FixVac Cancer Immunotherapy for the Treatment of Prostate Cancer </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing BNT112 for the treatment of prostate cancer. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our BNT112 Targets </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BNT112 is designed to elicit an immune response to five prostate cancer-specific antigens, including prostate-specific antigen, or PSA, a transmembrane protein that is expressed by virtually all prostate cancers, prostatic acid phosphatase, or PAP, and three additional tumor-associated antigens. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdc15tqwxkbk000004.jpg" title="" alt="" style="width:492px;height:333px;"></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our BNT112 Clinical Trials </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Ongoing Phase 1/2 Clinical Trial (PRO-MERIT) </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRO-MERIT is a first-in-human, dose titration and expansion trial to evaluate safety, immunogenicity and preliminary efficacy of BNT112 monotherapy and in combination with cemiplimab in patients with prostate cancer. The study is a Phase 1/2a, open-label, multicenter trial for metastatic castration resistant prostate cancer patients (mCRPC) and patients with high-risk, localized prostate cancer (LPC) eligible for treatment with androgen deprivation therapy (ADT) followed by radical prostatectomy. The Phase 1/2a trial consists of two parts: dose titration (Part 1) and dose expansion (Part 2).&nbsp;&nbsp;The trial started end of 2019. In January 2021 we enrolled the first patient in the expansion part of the trial. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary objectives of this study are to establish the safety and tolerability profile of BNT112 monotherapy or in combination with cemiplimab (Parts 1 and 2), and to evaluate preliminary anti-tumor activity of BNT112 monotherapy and in combination with cemiplimab in patients with mCRPC based on ORR (Part 2). The secondary objectives of the trial are to examine the immunogenicity of BNT112 alone or in combination with cemiplimab, to evaluate anti-tumor activity based on levels of PSA, and to evaluate preliminary anti-tumor activity of BNT112 monotherapy and in combination with cemiplimab in patients with mCRPC based on ORR (Part 1).</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Part 1 is a first-in-human, single arm design for mCRPC patients. It starts with an intra-patient dose titration in Cycle 1 for the initial safety assessment and recommended expansion dose range assessment. Part 2 consists of four arms (1A, 1B, 2 and 3), with similar intra-patient dose titration in Cycle 1, for both mCRPC and LPC indications, and targeting to enroll approximately 106 patients. Arms 1A and 1B are designed to treat mCRPC patients with a combination treatment (BNT112 and cemiplimab) and monotherapy (BNT112), respectively. Arms 2 and 3 are designed to treat LPC patients with a combination treatment (BNT112 and cemiplimab) and monotherapy (BNT112), respectively, plus a background medication of an androgen-deprivation therapy (<font style="font-style:italic;">e.g.</font> goserelin acetate).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">iii. BNT113: Our FixVac Cancer Immunotherapy for the Treatment of HPV16+ Head and Neck Cancer</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing BNT113 for the treatment of HPV+ head and neck cancer.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our BNT113 Targets </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BNT113 is designed to elicit an immune response against the well-characterized HPV16-derived oncoproteins E6 and E7, which are strongly immunogenic, viral neoantigens that are found in HPV16+ solid cancers such as head and neck squamous cell carcinoma. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our BNT113 Clinical Trials </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:2.07%;text-indent:2.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Ongoing Phase 1/2 Basket Trial (Investigator-Sponsored) </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BNT113 is being studied by the University of Southampton in an investigator sponsored open-label, Phase 1/2 dose escalation basket study with two different arms in approximately 44 patients with HPV16+ head and neck and other cancers. The first arm will perform dose escalation in patients with previously treated HPV16+ head and neck cancer using two dose cohorts to establish a safe, tolerable and recommended dose of BNT113. The second arm will perform dose escalation in patients with advanced HPV16+ cancers, including head and neck, anogenital, penile and cervical cancers, using a single cohort to establish a safe, tolerable and recommended dose. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Planned BNT113 Phase 2 Trial</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to start an open-label, controlled, multi-site, interventional, 2-arm, Phase 2 trial evaluating BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first-line treatment in patients with unresectable recurrent or metastatic HPV16+ head and neck squamous cell carcinoma (HNSCC) expressing PD-L1 in the first half of 2021 in US and EU</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The BNT113 IND was activated in the United States in October 2020 and since then we have received CTA approval from Health Canada (December 2020) and Hungary (January 2021).</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA placed a partial clinical hold on the second arm, part B, of the Phase 2 trial in October 2020. BNT113 has not been combined with anti-PD1 before and the Phase 2 trial will start with a run in portion designed to demonstrate the safety of the combination of BNT113 and pembrolizumab. These data is required to address the partial clinical hold on the subsequent randomized part of the Phase 2 trial.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">iv. BNT114: Our FixVac Cancer Immunotherapy for the Treatment of Triple Negative Breast Cancer</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are studying eight antigens selected for BNT114 in a three-arm clinical trial as both a monotherapy and in combination with our individualized neoantigen specific vaccine in patients with triple negative breast cancers (TNBC).&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.07%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our BNT114 Targets </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients are treated with individualized combinations of BNT114 antigens. BNT114 is designed to provide patients with an optimal combination of antigens and to elicit an immune response to selected antigens that are expressed in the patients&#8217; tumor. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.07%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our BNT114 Clinical Trial </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Ongoing Phase 1 Clinical Trial (BNT114 monotherapy and in combination with our neoantigen vaccine) </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are conducting an international, multi-center, open-label, three-arm Phase 1 study of BNT114 as a monotherapy and in combination with our individualized neoantigen specific immunotherapy in TNBC patients who had previously received the standard of care therapy (<font style="font-style:italic;">i.e.</font>, surgery, chemotherapy and/or radiotherapy). The primary endpoints of the study are to assess safety, feasibility and tolerability. These endpoints will be analyzed by occurrence of treatment emergent adverse events or TEAEs within a patient and by regular assessment of clinical and laboratory parameters. The secondary endpoint of the study is to determine vaccine-induced T-cell responses resulting from multiple vaccination cycles. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients in the first arm receive BNT114, patients in the second arm receive a combination of optional BNT114 followed by individualized neoantigen specific immunotherapy and patients in the third arm receive BNT114 in combination with RNA-LPX encoding tetanus-toxoid&#8209;derived helper epitopes. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recruitment and treatment were completed in 2020 in all three arms. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 18, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a data update was presented at the ESMO Virtual Congress 2020 for the second treatment arm investigating the individualized neoantigen vaccine encoding up to 20 cancer neoantigens determined by next generation sequencing. The preliminary analysis showed that the neoantigen vaccine is highly efficient in inducing strong poly-epitopic T-cell responses in the post- (neo) adjuvant setting. In all 14 patients vaccine-induced T-cell responses against up to 10 neoantigens could be detected of which the majority was de novo. In 12 out of 14 patients T-cell responses were of such high magnitude that they could be detected directly </font><font style="font-style:italic;">ex vivo</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">v. BNT115: Our FixVac Cancer Immunotherapy for the Treatment of Ovarian Cancer </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing BNT115 for the treatment of ovarian cancer. BNT115 is currently being studied in an ongoing investigator-initiated and -sponsored Phase 1 trial. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our BNT115 Targets </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BNT115 is designed to elicit an immune response to selected antigens that are found in ovarian cancers. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our BNT115 Clinical Trial </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Ongoing Phase 1 Trial (Investigator-Initiated and Sponsored) </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BNT115 is being studied in an investigator-initiated and -sponsored, first-in-human, open label, Phase&#160;1 dose escalation trial in 10 evaluable ovarian cancer patients eligible for standard-of-care treatment with (neo-) adjuvant chemotherapy. Eight doses of BNT115 will be administered prior to and in combination with the (neo-) adjuvant chemotherapy to induce an anti-tumor immune response. Systemic immune responses will be determined using peripheral blood mononuclear cells collected before, during and after vaccinations. Intratumoral accumulation of T-cells recognizing vaccine-encoded tumor-associated antigens will be determined before vaccination in a tumor biopsy and in tumor tissue derived from interval surgery after 3 cycles of chemotherapy and 5 vaccinations. The trial is currently recruiting.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">vi. Other FixVac Indications</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also exploring FixVac development candidates in other cancer indications, including non-small cell lung cancer (BNT116). </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">b) Individualized Neoantigen Specific Immunotherapy (iNeST)</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iNeST is an individualized cancer immunotherapy that targets specific neoantigens that are present on a patient&#8217;s tumor. Our iNeST immunotherapies contain pharmacologically optimized uridine mRNA encoding up to 20 patient-specific neoantigens, as well as our proprietary RNA-LPX formulation. We are developing our iNeST cancer immunotherapy in collaboration with Genentech. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">i. Autogene cevumeran (BNT122): Our iNeST Cancer Immunotherapy for Multiple Potential Indications</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and our collaborator Genentech are developing autogene cevumeran (BNT122) for the treatment of metastatic melanoma and other solid tumors. We are currently conducting a randomized Phase 2 trial of autogene cevumeran in collaboration with Genentech in first-line melanoma in combination with pembrolizumab. In collaboration with Genentech, we are also studying autogene cevumeran as a monotherapy and in combination with atezolizumab in a Phase 1a/1b study of patients with locally advanced or metastatic solid tumors (including melanoma, non-small cell lung cancer, bladder cancer as well as other solid tumors). The Phase 1a/1b trial is a non-registrational, signal-seeking study recruiting mostly patients with late-stage advanced cancers including patients who failed multiple lines of prior treatment. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our autogene cevumeran (BNT122) Targets </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Autogene cevumeran (BNT122) is an individualized neoantigen-specific immunotherapy. Each autogene cevumeran dose includes up to 20 different neoantigens selected on a patient-by-patient basis. We believe that neoantigenspecific T cells induced by autogene cevumeran may be able to enhance the therapeutic efficacy of immune checkpoint blockade. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our autogene cevumeran (BNT122) Clinical Trials </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Ongoing Phase 2 Clinical Trial (First-line melanoma with pembrolizumab) </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and Genentech are investigating the safety and efficacy of autogene cevumeran (BNT122) in 126 patients with previously untreated metastatic melanoma in a Phase 2, open-label, multi-center, randomized clinical trial. Patients in the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">experimental arm will receive pembrolizumab by intravenous infusion every three weeks, plus a selected dose of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">autogene cevumeran </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at defined intervals. Patients in the active comparator arm will receive 200mg of pembrolizumab by intravenous infusion every three weeks. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients in the comparator arm experiencing confirmed disease progression will be permitted to cross over to combination therapy with autogene cevumeran.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary endpoint is: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>progression-free survival, or PFS, of patients treated with <font style="color:#000000;">autogene cevumeran </font>compared with patients receiving pembrolizumab alone, according to RECIST v1.1. </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Secondary endpoints include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>objective response rate, or ORR, in patients treated with <font style="color:#000000;">autogene cevumeran </font>compared with patients receiving pembrolizumab alone, defined as the proportion of participants with complete response, or CR, or partial response, or PR; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>overall survival, or OS, of patients treated with <font style="color:#000000;">autogene cevumeran </font>compared with patients receiving pembrolizumab only; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>duration of response according to RECIST v1.1 of patients treated with <font style="color:#000000;">autogene cevumeran </font>compared with patients receiving pembrolizumab only; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>mean change in health-related quality of life, scores of patients treated with <font style="color:#000000;">autogene cevumeran </font>compared with patients receiving pembrolizumab only; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>percentage of patients with CR or PR following cross-over from pembrolizumab monotherapy to combination therapy following cross-over, according to RECIST v1.1; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>incidence and severity of adverse events. </p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Ongoing Phase 1 Clinical Trial </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Phase 1a (monotherapy)/1b (in combination with atezolizumab) trial is a non-registrational, signal seeking study recruiting patients with locally advanced or metastatic solid tumors, including patients with melanoma, non-small cell lung cancer, bladder cancer, colorectal cancer, TNBC, renal cancer, head and neck cancer and sarcomas as well as other solid tumors. The study is designed to enroll both patients with and without prior checkpoint inhibitor regimens. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary objective of the study was to assess safety (including dose-limiting toxicities), and additional objectives included evaluation of immunogenicity and preliminary assessment of anti-tumor activity. The trial included a Phase 1a (monotherapy) dose escalation, a Phase 1b (combination) dose escalation, and multiple Phase 1b expansion cohorts. Patients received nine doses of the vaccine administered I.V. in weekly and bi-weekly intervals during the 12-week induction stage and every 24 weeks during the maintenance stage. In the Phase 1b portion of the trial, atezolizumab was administered on day one of each 21-day cycle. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Autogene cevumeran was manufactured on a per-patient basis including in-house determination of cancer mutation profiles, computational prediction of neoantigens, design, and manufacturing of autogene cevumeran based on liposomally formulated RNA (RNA-LPX). Each drug product contained up to 20 patient-specific neoantigens.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">June 2020 Monotherapy Data Update Phase 1a/basket trial</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the 2020 AACR conference, we presented data from monotherapy dose-finding cohorts of our autogene cevumeran phase 1 trial in multiple solid tumors in which autogene cevumeran was observed to have a manageable safety profile and induced strong neoantigen-specific immune responses in patients with low and intermediate mutational load tumor types. This data related to 31 patients enrolled in cohorts with doses ranging from 25-100&#181;g. Most patients enrolled had a low level of PD-L1 expression in the tumor as determined by immunohistochemistry. The majority of adverse events were Grade 1 or Grade 2 and those occurring in more than 20% of patients included infusion related reaction (IRR), fatigue, cytokine release syndrome (CRS), nausea, and diarrhea. IRR and CRS were transient and reversible and presented primarily as Grade 1 or Grade 2 chills and fever. A single dose-limiting toxicity of Grade 3 CRS occurred at the 100&#181;g dose level. None of the patients discontinued autogene cevumeran due to AEs. <font style="font-style:italic;">Ex vivo</font> T cell responses were detected in approximately 86% of patients treated with autogene cevumeran as a monotherapy. Autogene cevumeran induced T cells against multiple neoantigens were detected in post-treatment tumor biopsies. Of 26 patients that underwent at least one tumor assessment, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one patient with gastric cancer and metastatic liver lesions had a durable best response of confirmed complete response and remain</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> on study after 1.5 years (3.8%) and 12 patients had stable disease (46.2%). </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">June 2020 Combination Therapy Data Update Phase 1b/basket trial</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At AACR conference 2020, we presented data from 142 patients enrolled in cohorts with doses ranging from 15&#181;g to 50&#181;g of autogene cevumeran in combination with 1200mg atezolizumab. The most common tumor types enrolled were NSCLC, TNBC, melanoma and colorectal cancer with a median of three lines of prior therapies (range 1-11). The patient population included both CPI experienced and inexperienced patients. Most patients enrolled had low level of PD-L1 expression in the tumor as determined by immunohistochemistry (93% patients with &lt;5% PD-L1 expression on tumor cells (TC0/1) and 79% patients with &lt;5% PD-L1 expression on immune cells (IC0/1)). The majority of adverse events were Grade 1 or Grade 2 and those occurring in more than 15% of patients included infusion related reaction (IRR), fatigue, nausea, cytokine release syndrome (CRS) and diarrhea. IRR and CRS were transient and reversible and presented primarily as Grade 1 or Grade 2 chills and fever. There were no dose limiting toxicities. Eight patients (5.6%) discontinued due to AEs related to study drugs. Autogene cevumeran induced a self-limiting increase of pro-inflammatory cytokines with each dose, consistent with the TLR agonist activity of RNA. <font style="font-style:italic;">Ex vivo</font> T cell responses were observed in peripheral blood in 46 out of 63 (73%) patients. Induction of up to 5.7% MHC multimer-stained CD8+ T-cells with effector memory phenotype was observed in the peripheral blood. Autogene cevumeran induced T cells against multiple neoantigens were detected in post-treatment tumor biopsies. Of 108 patients that underwent at least one tumor assessment, 1 patient had a complete response as their best response (0.9%), 8 patients had partial responses (7.4%), and 53 patients had stable disease (49.1%). </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on data from our study of BNT121 (a prior iNeST precursor to autogene cevumeran) as an adjunct to surgery in patients with metastatic melanoma, we believe that autogene cevumeran is potentially well suited to control metastatic relapses in patients with a lower tumor burden. Additionally, autogene cevumeran as a monotherapy and in combination with atezolizumab has been observed to have a manageable safety profile to date and to induce significant levels of neoantigen-specific immune responses, even in late-stage, heavily pre-treated patients. Accordingly, we and our collaborator, Genentech, believe that autogene cevumeran is best suited for adjuvant and minimal residual disease settings. Therefore, we are evaluating options for treating early disease cancer patients with autogene cevumeran.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Planned Phase 2 Trial in adjuvant colorectal cancer </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to start a randomized, multi-site, open-label Phase 2 trial to compare the efficacy and safety of autogene cevumeran versus watchful waiting in resected, Stage II (High Risk) and Stage III colorectal cancer patients who are ctDNA positive following resection. The IND was approved in the United States in July 2020. First dosing is expected in the first half of 2021.&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Planned Phase 2 Trial in adjuvant NSCLC discontinued</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given challenging accrual timelines in the context of the SARS-CoV2 pandemic and the evolving landscape of treatment options in NSCLC, we and Genentech have jointly decided not to go forward with the IMcode002 study in ctDNA+ early stage NSCLC and are evaluating other options for treating early disease cancer patients with autogene cevumeran.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.86%;text-indent:2.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Completed Phase 1 Clinical Trial (First Generation iNeST) </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2017, we published the results of a 13-patient, first-in-human trial of our first-generation intranodal iNeST product candidate in patients with late-stage malignant melanoma. The objective of this clinical trial was to study the feasibility, safety, tolerability, immunogenicity and potential anti-tumoral activity of iNeST. All patients had stable disease at enrollment with a high risk for relapse. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All 13 patients developed T cell immune responses against multiple immunotherapy neoantigens at up to high single-digit percentages. As shown below, 60% of the selected neoantigens elicited a T cell response. The detected immune response comprised both CD4+ and CD8+ T cells and the majority of the response was induced <font style="font-style:italic;">de novo</font>, which we believe to be an important requirement for an effective immune response and an added benefit beyond checkpoint inhibition alone. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No severe adverse drug reactions were reported in the study. Common adverse events included flu-like symptoms. </font></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdc15tqwxkbk000005.jpg" title="" alt="" style="width:307px;height:345px;"></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Immune responses documented in our prior BNT121 study<font style="font-weight:normal;">. Patients showed immune responses, including both CD4+ and CD8+ responses, against multiple neoantigens.</font> <font style="font-weight:normal;">Source: Nature 547, 222-226 (13 July 2017)</font>. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, metastases resected from two patients following treatment with BNT121 demonstrated evidence of BNT121-induced infiltration with neoantigenspecific T cells and neoantigenspecific killing of tumor cells. The cumulative rate of metastatic events was significantly reduced after the start of treatment, resulting in a sustained progression-free survival. Of the 13 patients entering the trial, eight patients that had no radiologically detectable lesions at start of neoantigen treatment were relapse free and remained recurrence-free for the whole follow-up period (12 to 23 months). Five patients experienced melanoma relapses shortly after inclusion in the trial and despite initiation of standard treatment had progressing metastases at start of their BNT121 treatment. Of these, two patients developed BNT121-treatment-related objective clinical responses. One of these patients exhibited a complete response and remained relapse-free for 26 months. The second patient had an immunotherapy-related partial response. This patient had a late relapse owing to outgrowth of &#223;2-microglobulin-deficient melanoma cells as an acquired resistance mechanism. A third patient developed a complete response to treatment in combination with PD-1 blockade therapy. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of October 2019, nine out of 13 patients had remained recurrence free through follow-up of up to 60 months post-vaccination.</font></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdc15tqwxkbk000006.jpg" title="" alt="" style="width:567px;height:226px;"></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Metastatic relapses before and after treatment with BNT121.<font style="font-weight:normal;"> The chart above shows the 27 metastatic relapses of patients before and 3 after treatment with BNT121. Each horizontal line represents the time course of a single patient. The vertical line indicates the treatment start of BNT121. Source: Nature 547, 222-226 (October 2019).</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">c) Intratumoral Immunotherapy</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We, in collaboration with Sanofi, are developing intratumoral immunotherapies utilizing our proprietary mRNA technology. These immunotherapies are designed to be administered directly into the tumor in order to alter the tumor microenvironment and enhance the immune system&#8217;s ability to recognize and fight cancer within the tumor (proximal) as well as in other untreated locations (distal). </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">i. SAR441000 (BNT131): Our Initial Intratumoral Immunotherapy for the Treatment of Solid Tumors</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In a collaboration with Sanofi, we are developing SAR441000 (BNT131) as a novel intratumoral immunotherapy for the treatment of solid tumors. SAR441000 (BNT131) consists of modified mRNA encoding immunomodulatory cytokines for direct intratumoral injection. Once delivered into the tumor, the cytokine mRNAs are expected to be taken up by tumor and other resident cells and translated into functional cytokine proteins which are thought to modulate the tumor microenvironment. SAR441000 (BNT131) is being studied in a Sanofi-sponsored Phase 1 clinical trial as monotherapy and in combination with an anti-PD-1/PD-L1 checkpoint inhibitor in patients with advanced solid tumors. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our SAR441000 (BNT131) Targets </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SAR441000 (BNT131) comprises mRNA encoding the cytokines IL-12sc, IL-15sushi, IFN-&#945; and GM-CSF, that we have identified as mediators of tumor regression across different murine tumor models. By expressing these cytokines in the tumor microenvironment, the immune system may more easily recognize and fight cancer. Combining the mRNAs with checkpoint inhibitors enhanced antitumor responses in both injected and non-injected tumors, improving survival and tumor regression in mice. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our SAR441000 (BNT131) Clinical Trials </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Ongoing Phase 1 Clinical Trial </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sanofi, in collaboration with us, commenced a first-in-human, multi-center, open-label, Phase 1, dose escalation and expansion trial to evaluate the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of SAR441000 (BNT131) administered intratumorally as monotherapy and in combination with cemiplimab, with an estimated enrollment of up to 231 patients with certain advanced solid tumors. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In this trial, eligible patients are treated with weekly intratumoral administration of SAR441000 (BNT131) in the monotherapy arm or in combination with a fixed dose of 350 mg cemiplimab q3wks in the combination arm. Plasma samples and tumor biopsies are collected to characterize the pharmacokinetic/pharmacodynamic profile of SAR441000 (BNT131), immune cell tumor infiltration and the presence of tumor proinflammatory signatures.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interim data were presented at SITC 2020: As of July 2020, 17 patients across various solid tumor types had received SAR441000 (BNT131) as a monotherapy at varying dose levels. Six patients received SAR441000 (BNT131) in combination therapy. No dose limited toxicities were observed, and no grade three, four, or five adverse events related to study treatment were reported. Adverse events related to study treatment in two or more </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patients</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in both treatment groups combined were nonserious grade one or two fatigue, vomiting, nausea, local injection site reaction, chills, diarrhea, and rash. In some patients, increases in plasma IP10 and IFN gamma and CD8+ T cell infiltration in tumor biopsies were observed.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">d) RiboMabs</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our RiboMab product candidates, BNT141 and BNT142, are designed to encode secreted antibodies for expression <font style="font-style:italic;">in vivo</font> by the patient&#8217;s cells. RiboMab product candidates consist of our proprietary nucleoside-modified mRNA that is designed to minimize the immunomodulatory activity of the mRNA, and these candidates are formulated using liver-targeting LNPs for intravenous delivery. RiboMabs potentially address the limitations of recombinant antibodies, including costly manufacturing processes and unfavorable pharmacokinetics, such as short plasma half-life. We are conducting preclinical studies for two development candidates, and have published compelling preclinical data. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">i. BNT141: Our Initial RiboMab for the Treatment of Solid Tumors</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BNT141 is our RiboMab product candidate for the treatment of solid tumors. BNT141 encodes an IgG antibody which upon injection is secreted into the bloodstream.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our BNT141 Targets </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BNT141 is designed to encode an antibody targeting multiple epithelial solid tumors, including gastric and pancreatic cancers.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Planned BNT141 Clinical Trials<font style="font-weight:normal;font-style:normal;"> </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate starting an open-label, multi-site, Phase I/IIa dose escalation, safety, and pharmacokinetic trial of&#160;BNT141&#160;followed by expansion cohorts in patients with CLDN18.2-positive tumors. First dosing is expected in the second half of 2021.&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trial design consists of three parts. The first part will perform dose escalation as monotherapy in patients with unresectable or metastatic Claudin 18.2-positive gastric cancer, gastroesophageal junction (GEJ) and esophageal cancer of the adenocarcinoma subtype, colorectal cancer, pancreatic cancer, biliary tract cancers, and mucinous ovarian cancer, for which there is no available standard therapy likely to confer clinical benefit. Part 1B is a dose escalation in combination with standard of care (SOC) nab-paclitaxel and gemcitabine in patients with advanced unresectable or metastatic CLDN18.2-positive pancreatic adenocarcinoma or cholangiocarcinoma who are eligible for treatment with SOC nab-paclitaxel and gemcitabine. Part 1B intends to define the MTD and/or RP2D of the combination. Part 2 (expansion) consists of the following pre-defined expansion cohorts: (1) CLDN18.2-positive unresectable locally advanced or metastatic pancreatic adenocarcinoma eligible for treatment with SOC nab-paclitaxel and gemcitabine; and (2) CLDN18.2-positive unresectable locally advanced or metastatic cholangiocarcinoma eligible for treatment with SOC nab-paclitaxel and gemcitabine. Part 2 will be further defined via an amendment after careful evaluation of all available safety, PK and PD, and efficacy data generated in Parts 1A and 1B by the Safety Review Committee (SRC).</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ii. BNT142: Our Second RiboMab for the Treatment of Solid Tumors </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BNT142 is our RiboMab product candidate for the treatment of solid tumors. BNT142 is designed to encode a secreted bispecific antibody that targets CD3 and CLDN6. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.03%;text-indent:2.9%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our BNT142 Targets </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BNT142 is designed to encode bispecific antibodies that target CD3, a T cell receptor that plays a key role in the activation of CD8+ and CD4+ T cells, and CLDN6, a highly specific oncofetal cell surface antigen that is found in solid tumors, but not in normal cells. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Planned BNT142 Clinical Trials</font><font style="font-weight:normal;font-style:normal;"> </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to start a Phase 1 clinical trial for BNT142 in the second half of 2021.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.55%;text-indent:-3.62%;;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e) RiboCytokines </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our RiboCytokine product candidates, BNT151, BNT152 and BNT153, utilize mRNA that encodes the desired cytokines for expression <font style="font-style:italic;">in vivo</font> by the patient&#8217;s cells. RiboCytokine product candidates consist of modified mRNA designed to encode secreted cytokines that are formulated to use liver-targeting LNP for intravenous delivery. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our RiboCytokine product candidates are designed to address the limitations of recombinantly expressed cytokines, including limited serum half-life and production costs. We are developing RiboCytokines to be used primarily in combination with other drugs, including our other pipeline candidates. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">i. BNT151: Our Initial RiboCytokine for the Treatment of Solid Tumors </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing BNT151, our RiboCytokine designed to encode a modified version of the human interleukin-2, or optimized IL-2, cytokine for the treatment of solid tumors. BNT151 is designed to stimulate T cells without triggering immunosuppression in the tumor microenvironment. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our BNT151 Target </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BNT151 comprises our nucleoside-modified mRNA that encodes mRNA for a function-modified IL-2. IL-2 is a key cytokine in T cell immunity, supporting the differentiation, proliferation, survival and effector functions of T cells. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recombinant IL-2, aldesleukin, was the first approved cancer immunotherapy, and has been marketed globally for the treatment of late stage melanoma and renal cell cancer for decades. Most patients with complete responses after IL-2 treatment remain regression free for more than 25 years after initial treatment, but overall response rates are low due in part to the limitations of recombinant cytokines. Recombinant IL-2 has a very short half-life, requiring high and frequent dosing and a partially unfavorable activity profile, which leads to increased side effects, thus limiting its utility as a cancer treatment.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.91%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our BNT151 Clinical Trials</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.91%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Ongoing Phase I/IIa trial</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We dosed the first patient in February 2021 in an open-label, multicenter Phase I/IIa trial. The trial evaluates dose escalation, safety, pharmacokinetics and pharmacodynamics of BNT151 with expansion cohorts in various solid tumor indications. The trial consists of three parts with adaptive design elements. The monotherapy dose escalation (Part 1) of this clinical trial will enroll patients with various solid tumors that are metastatic (Stage IV) or unresectable for whom there is no available standard therapy likely to confer clinical benefit, or patients who are not candidates for such available therapy. During combination dose escalation (Part 2A), patients of different specific solid tumors (one cohort per indication) will be enrolled and treated with a combination of BNT151 and the respective standard of care treatment. Part 2B is the expansion phase where a predefined number of patients in each indication cohort will be treated with the confirmed recommended phase II dose of BNT151 in combination with respective standard of care treatment. We estimate to enroll up to 54 study participants.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ii. BNT152: Our Second RiboCytokine for the Treatment of Solid Tumors </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing BNT152, our RiboCytokine designed to encode IL-7 for the treatment of solid tumors.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">iii. BNT153: Our Third RiboCytokine for the Treatment of Solid Tumors </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing BNT153, our RiboCytokine designed to secrete IL-2 for the treatment of solid tumors. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our BNT152+153 Clinical Trials</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Planned Phase 1<font style="font-weight:bold;color:#000000;font-size:13.5pt;font-style:normal;"> </font><font style="font-weight:bold;">Dose Escalation Trial of BNT152+153</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to start in the first half of 2021 an open-label, multisite Phase I dose escalation trial, which will evaluate the safety, pharmacokinetics and pharmacodynamics, and preliminary anti-tumor activity of BNT152+153. The clinical trial will enroll patients with various solid tumors that are metastatic or unresectable for whom there is no available standard therapy likely to confer clinical benefit, or patients who are not candidates for such available therapy.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trial consists of 2 parts with adaptive design elements. Part 1 consists of Groups A and B.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Group A is a BNT153 monotherapy dose escalation in patients with advanced solid malignancies until the maximal tolerated dose (MTD) is defined. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Group B is a BNT152 monotherapy dose escalation in patients with advanced solid malignancies until the MTD or optimal biological dose (OBD) is defined, whichever occurs earlier.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Part 2 will start once Part 1 is completed, <font style="font-style:italic;">i.e.</font>, when dose escalations for both BNT152 and BNT153 monotherapy are completed, and will evaluate the combination treatment of BNT152 and BNT153.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. Our Oncology Cell Therapy Product Candidates </p>
<p style="margin-top:6pt;text-align:justify;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">a) CAR-T </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are advancing multiple CAR-T product candidates, the most advanced of which, BNT211, is targeting the novel and highly specific target CLDN6+ in solid tumors. We plan to use our initial CAR-T cell product candidates in combination with a FixVac immunotherapy that encodes the same target as the CAR-T. The FixVac selectively targets dendritic cells, which leads to uptake, antigen expression and maturation of the dendritic cells. The co-stimulation provided by dendritic cell maturation has been shown in preclinical studies to amplify and expand CAR-T cells<font style="font-style:italic;"> in vivo</font>, leading to increased persistence of the CAR-T.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">i. BNT211: Our CAR-T Cell Therapy for the Treatment of CLDN6+ Solid Tumors </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BNT211 is our CAR-T cell therapy for the treatment of CLDN6+ solid tumors. BNT211 targets CLDN6 and will initially be evaluated in combination with a CARVac that encodes CLDN6. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our BNT211 Target</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BNT211 targets Claudin 6, or CLDN6, a highly specific oncofetal cell surface antigen that is found in multiple cancers, including ovarian, testicular and lung cancers, but not in normal cells. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Ongoing Phase 1/2a Clinical Trial </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We started a Phase 1/2a open-label, multi-center dose escalation and dose expansion basket trial of BNT211 with or without a CLDN6 CARVac immunotherapy with first patient dosed with BNT211 in February 2021. We are enrolling patients with CLDN6-positive relapsed or refractory advanced solid tumors, including ovarian and testicular cancers. The trial assesses CLDN6 CAR-T cell immunotherapy in combination with a CLDN6 RNA vaccine for improved expansion and persistence of CAR-T cells (CARVac). The primary outcome measure of the trial will be safety, with secondary efficacy outcome measures to include objective response rate, disease control rate and duration of response. Part 1 is the dose escalation with CLDN6 CAR-T cell therapy after lymphodepletion, followed by part 2 dose escalation that combines CLDN6 CAR-T cell therapy plus CLDN6 RNA-LPX vaccination.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect a data update in the second half of 2021.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">b) Neoantigen-Targeting T Cells. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our neoantigen-targeting T cell stimulation platform can be utilized to develop product candidates across several neoantigen-targeting non-engineered and engineered T cell therapies. Our lead product candidate under this platform is our individualized neoantigen-targeting T cell therapy, BNT221. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also developing NEO-STC-01 (BNT222), targeting shared RAS neoantigens prevalent across many solid tumor types. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">i. BNT221 (NEO-PTC-01): Our Individualized Neoantigen-targeting T Cell Therapy for the Treatment of Cancer </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BNT221 (NEO-PTC-01) is our individualized neoantigen-targeting T cell therapy for the treatment of cancer. BNT221 (NEO-PTC-01) targets selected sets of individualized neoantigens.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our BNT221 (NEO-PTC-01) Target </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BNT221 (NEO-PTC-01) is a personal neoantigen-targeted T cell therapy candidate derived from patients` peripheral </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">blood cells. The product consists of multiple CD8+ and CD4+ T cell populations targeting multiple selected neoantigens from each patient`s tumor.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The proprietary stimulation process allows for the induction of T cells from the na&#239;ve, as well as expansion of T cells from the memory compartment. Other product characteristics are i. cells with high specificity profile towards the mutant epitope; ii. cells exhibiting multiple effector functions; iii. a product that contains both central and effector memory T cells; iv. cells that have cytotoxic response towards endogenously processed and presented antigens as well as recognition of autologous tumor.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The neoantigens are selected using our proprietary RECON bioinformatics engine. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Planned Phase 1 Clinical Trial </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are focusing the initial clinical development of BNT221 (NEO-PTC-01) in solid tumors, where we believe we can generate<font style="font-style:italic;"> de novo</font> neoantigen T cell populations<font style="font-style:italic;"> ex vivo</font>. A CTA was filed with the Dutch Health Authority in December 2019 to evaluate BNT221 (NEO-PTC-01) in a first-in-human clinical trial in patients with advanced or metastatic melanoma refractory to checkpoint inhibitor therapy. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dosing of the first patient in the first-in-human trial is expected in the first half of 2021. Major objectives of this study include evaluation of the safety and feasibility of administering BNT221 (NEO-PTC-01), as well as evaluations of immunogenicity and clinical efficacy. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on data from the first in human trial, we will decide how to best proceed with further clinical development of BNT221 (NEO-PTC-01), including expanding to other tumor types and potential development in the United States. </p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. Our Antibody Product Candidates in Oncology </p>
<p style="margin-top:6pt;text-align:justify;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">a) Next-Generation Checkpoint Immunomodulators </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In our 50:50 collaboration program with Genmab, we are currently studying two bispecific antibody checkpoint immunomodulators. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-style:italic;font-weight:bold;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.24%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">i.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-style:italic;font-weight:bold;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">GEN1046 (BNT311): Our Jointly Owned DuoBody&#174; PD-L1x4-1BB Bispecific Antibody for the Treatment of Solid Tumors</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GEN1046 (BNT311), our jointly owned PD-L1x4-1BB product candidate, is a potential first-in-class bispecific antibody combining PD-L1 checkpoint inhibition with 4-1BB checkpoint activation. The first patient in a Phase 1/2a trial of GEN1046 (BNT311) for the treatment of malignant solid tumors was dosed in 2019. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our GEN1046 (BNT311) Targets</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GEN1046 (BNT311) is a PD-L1x4-1BB bispecific antibody that induces activation of T cells through conditional 4-1BB stimulation which is dependent on simultaneous binding to PD-L1. In addition, the PD-L1-specific arm of DuoBody-PD-L1x4-1BB functions as a classical immune checkpoint inhibitor by blocking the PD-1/PD-L1 axis, even in the absence of 4-1BB binding. PD-L1 is a validated target that is expressed on tumor cells. 4-1BB is a trans-membrane receptor belonging to the TNF super-family and is expressed predominantly on activated T cells. DuoBody<font style="font-size:8.5pt;">&#174;</font> is a registered trademark of Genmab. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GEN1046 (BNT311) Trials</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Ongoing Phase 1/2a Clinical Trial</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ongoing Phase 1/2a, open-label, single-arm GEN1046 (BNT311) trial with multiple expansion cohorts, conducted in collaboration with Genmab, is expected to enroll approximately 192 patients with malignant solid tumors. The trial consists of a dose escalation part and an expansion part. The dose escalation part will determine the safety profile of GEN1046 (BNT311) in patients with certain relapsed or refractory, advanced and/or metastatic malignant solid tumors who are no longer candidates for standard therapy. The expansion part will be initiated once the recommended Phase 2 dose has been established in Phase 1. In the expansion part, GEN1046 (BNT311) will be administered intravenously once every 21 days. The primary endpoints of the trial are dose-limiting toxicities, adverse events and safety laboratory parameters, including hematology, biochemistry, coagulation and endocrinology. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dose escalation has been finalized and seven dose expansion cohorts are currently recruiting. The expansion phase 2 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dose is 100 mg</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Q3W</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interim data from the Phase 1/2a trial of GEN1046 (BNT311) (DuoBody-PD-L1x4-1BB) in 61 heavily pretreated patients with advanced solid tumors was presented at SITC 2020. In the dose escalation phase, GEN1046 (BNT311) demonstrated a manageable safety profile and encouraging early single-agent clinical activity. Most adverse events were mild to moderate and treatment-related Grade 3 transaminase elevations resolved with corticosteroids. No treatment-related bilirubin increases or Grade 4 transaminase elevations were observed. Clinical benefit was observed across tumor types and dose levels, including in patients resistant to prior immunotherapy and with tumor types less sensitive to immune checkpoint inhibitors. Disease control was achieved in 65.6% of patients in the dose escalation portion, including partial responses in one TNBC patient, one ovarian cancer patient and two immune checkpoint inhibitor pre-treated NSCLC patients. In the expansion cohort, which includes patients with PD-L1 relapsed/refractory NSCLC, two of 12 patients that could be objectively assessed achieved confirmed single-agent partial responses. One patient had an unconfirmed partial response and four patients demonstrated stable disease.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect a data update in the second half of 2021.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-style:italic;font-weight:bold;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ii.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-style:italic;font-weight:bold;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">GEN1042 (BNT312): Our Jointly Owned DuoBody&#174; CD40x4-1BB Bispecific Antibody for the Treatment of Solid Tumors </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GEN1042 (BNT312), our jointly owned CD40x4-1BB antibody product candidate, is a potential first-in-class bispecific antibody designed to induce conditional immune activation by crosslinking CD40 and 4-1BB positive cells. We and Genmab began recruitment and screening for a Phase 1/2a trial of GEN1042 (BNT312) for the treatment of malignant solid tumors in 2019. We expect the first data disclosure in the second half of 2021.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GEN1042 (BNT312) Targets </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GEN1042 (BNT312) is a bispecific antibody designed to enhance an anti-tumor immune response by crosslinking CD-40 on antigen presenting cells with 4-1BB+ T cells to induce conditional stimulation and co-stimulatory activity in both types of cells. It has demonstrated increased tumor infiltrating lymphocyte expansion in human tumor tissue cultures <font style="font-style:italic;">ex vivo</font>, and induces activation of B cells in the presence of 4-1BB+ cells. Both 4-1BB and CD40 are members of the tumor necrosis factor receptor superfamily. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">b) Targeted Cancer Antibodies </p>
<p style="margin-top:6pt;text-align:justify;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">i. BNT321 (MVT-5873): Our Targeted Cancer Antibody for the Treatment of Pancreatic Cancer</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2019, we acquired certain antibody assets from MabVax Therapeutics Holding, Inc., including MVT-5873 (BNT321), a clinical-stage targeted cancer antibody.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our MVT-5873 (BNT321) Target </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BNT321 (MVT-5873) is a fully human IgG1 monoclonal antibody targeting sialyl Lewis A (sLea), an epitope on CA19-9 that is expressed in pancreatic and other gastrointestinal cancers that plays a role in tumor adhesion and metastasis formation, and is a marker of an aggressive cancer phenotype. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Ongoing BNT321 (MVT-5873) Trial</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BNT321 (MVT-5873) is being investigated in an open-label, multi-center, non-randomized dose escalation/expansion trial evaluating the safety and recommended Phase 2 dose of BNT321 (MVT-5873) for a Q2 and Q4 week schedule in approximately 108 patients with pancreatic and other CA19-9+ malignancies. Secondary objectives include evaluating tumor response rate by RECIST 1.1, duration of response, and determining pharmacokinetics. This study utilizes a conventional 3+3 design to identify the recommended Phase 2 dose. </p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. Our Oncology Small Molecule Immunomodulator Product Candidates </p>
<p style="margin-top:6pt;text-align:justify;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">i. BNT411: Our Small Molecule TLR7 Agonist for the Treatment of Solid Tumors, Including Small Cell Lung Cancer </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BNT411 is our novel small molecule TLR7 agonist product candidate. BNT411 is designed to activate both the adaptive and innate immune system through the TLR7 pathway. We are developing BNT411 to be used both as a monotherapy and in combination with chemotherapy and checkpoint inhibitors. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.03%;text-indent:2.9%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our BNT411 Target </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BNT411 is a TLR7 agonist that is designed to activate both the adaptive and innate immune system through the TLR7 pathway. This activity and the release of cytokines and chemokines are designed to result in the potent stimulation of antigen-specific CD8+ T cells, B cells and innate immune cells such as NK cells and macrophages.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Ongoing Phase 1/2a Trial</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initiated phase 1/2a, first-in-human, open-label, dose-escalation trial with expansion cohorts evaluates safety, PK, PD, and preliminary efficacy of BNT411 as a monotherapy in patients with solid tumors and in combination with atezolizumab, carboplatin and etoposide in patients with chemotherapy-na&#239;ve ES-SCLC. We dosed the first patient in July 2020 and expect a first data update in the second half of 2021.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. Our Infectious Disease mRNA Product Candidates </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We view our infectious disease program as representing a long-term growth pillar. There is substantial unmet medical need in an increasing number of highly unaddressed indications. The successful development of a COVID-19 vaccine in less than one year validates our ability to develop technologies and execute on our long-term strategies.  </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Infectious Disease mRNA Product Candidates </p>
<p style="margin-top:6pt;text-align:justify;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">a) Prophylactic Vaccine for the Prevention of COVID-19 </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We hold conditional marketing approvals, emergency use authorizations or equivalent in multiple countries worldwide for our COVID-19 vaccine. We are collaborating with Pfizer and Fosun Pharma to obtain additional marketing approvals of our COVID-19 vaccine. We and Pfizer are continuing to jointly conduct clinical trials for the COVID-19 vaccine development program and life cycle management worldwide excluding China. Furthermore, we are jointly evaluating strategies to optimize the current product with regards to transport, stability and, against newly emerging SARS-CoV-2 strains. We and Fosun are continuing to conduct clinical trials for the COVID-19 vaccine development program in China.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">i. Our BNT162 Targets and mRNA Formats </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The overall development program initially included multiple vaccine candidate variants, some of which target the entire 2P-mutated full spike protein antigen and others which target the more specific receptor binding domain subunit of the antigen protein. The Phase 1 clinical studies are conducted with several different candidates, however to-date we have only advanced further development on BNT162b2. Clinical development programs for other BNT162 candidates are ongoing. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:84%;">
<tr>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BNT 162 Candidate or Product</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.5pt;width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Target</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.5pt;width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">mRNA Format</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162a1</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RBD subunit</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uRNA (prime/boost)]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162b1</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RBD subunit</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">modRNA (prime/boost)</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162b2</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2P-mutated full Spike protein</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">modRNA (prime/boost)</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162b3</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Membrane-anchored RBD subunit</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">modRNA (prime/boost)</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162c2</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2P-mutated full Spike protein</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">saRNA (single injection)</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">b) Prophylactic Vaccine for the Prevention of Influenza </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are collaborating with Pfizer to develop an influenza vaccine based on our mRNA drug classes. The product candidate, BNT161, will be designed to encode influenza virus antigens selected by the WHO in advance of a given flu season.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">c) Other Infectious Diseases </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have a research collaboration with Penn, under which we have the exclusive option to develop and commercialize prophylactic mRNA immunotherapies for the treatment of up to 10 infectious disease indications. On September 20, 2019, Penn announced positive preclinical results of a vaccine product candidate using its mRNA technology. Penn reported that the immunization led to &#8220;mostly sterilizing immunity&#8221; from the virus. In addition to our collaboration with Penn, our infectious diseases portfolio also includes HIV, Tuberculosis vaccines (in collaboration with the Bill &amp; Melinda Gates foundation) and additional 6 undisclosed programs. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6. Our Rare Disease Protein Replacement mRNA Product Candidates </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are collaborating with Genevant, in order to combine our mRNA technology with Genevant&#8217;s LNP delivery technology, to create up to five mRNA protein replacement therapies for the treatment of rare diseases with high unmet medical needs. The first product candidate under the Genevant collaboration, BNT171, is being developed for Ornithine Transcarbamylase (OTC) Deficiency. Our mRNA replacement product candidate is associated with a favorable tolerability profile and good protein expression (in mice) and demonstrated phenotype rescue in a mouse disease model. Currently, we have put the programs under review in order to focus on other disease areas.&nbsp;&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">III. Challenges and Opportunities of Cancer Therapies </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancer results from an accumulation of abnormalities, known as somatic mutations, in the genome of cells over time leading to malignant transformation, combined with a failure by the immune system to detect and eradicate such transformed cells. Due to their random nature, the vast majority of these aberrations are unique to the individual patient. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a consequence, heterogeneity is an intrinsic hallmark of cancer, posing a key challenge for cancer therapy: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Interindividual tumor heterogeneity.</font> Tumors, even within the same cancer type, differ at the molecular level. For example, two patients with the same type of cancer usually share less than five percent of their mutations. As a result, patients often respond very differently to the same drug. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Intratumor heterogeneity.</font> Within the same patient, cancer also evolves over time so that different tumor cell clones co-exist, in a manner known as clonal evolution. As a result, a patient&#8217;s cancer may be intra-tumorally as well as inter-tumorally heterogeneous. Therapies might target only a subfraction of tumor cell clones. This can lead to immune escape and therapy failure. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Cancer evolution and immune escapes</font>. Cancer cells can adapt to therapeutic pressure, which results in treatment resistance. During immunotherapy, tumor cell clones may evolve that no longer express T cell recognized antigens or have defects in their antigen presentation machinery. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Tumor microenvironment</font>. Tumors induce various forms of immunosuppressive microenvironments that prevent T cells from proliferating and executing their anti-tumor effector function. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Host, environment and immune system</font>. The functional state of each patient&#8217;s immune system is dependent on the patient&#8217;s age, genetic makeup and environmental exposures. For example, the HLA haplotype, or the genetic makeup that encodes the major histocompatibility complex, is highly individual and decisive for which epitopes of an antigen are presented to T cells. Whereas a given tumor antigen might be a good target in one patient, a second patient might not be able to respond to it at all. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:12pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The graphic below depicts the interaction between three key factors influencing the patient unique tumor profile: </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdc15tqwxkbk000007.jpg" title="" alt="" style="width:606px;height:452px;"></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interindividual heterogeneity of patients. <font style="font-weight:normal;">The interaction between cancer and immune system is shaped by various host, tumor and environmental factors. The complex interplay of these sources of interpatient heterogeneity affects both the course of disease and the efficacy of immunotherapy. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Together, these factors make cancer an extremely complex and heterogeneous disease. As a consequence, in the majority of cancer types, many treated individuals do not benefit from highly potent approved therapies, and responses are often not durable. While these hallmarks of cancer are a challenge for cancer therapy, they also present opportunities for immunotherapy. These interconnected layers of complexity and variability require a deep understanding of an individual cancer and call for a patient-centric approach in order to find an optimal treatment. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">IV. The BioNTech Approach </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In oncology, we are focused on bringing cancer immunotherapy into the next generation. We believe that we can accomplish this by applying the following principles: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Exploiting the full potential of the immune system. </font>Our broad pipeline includes mRNA-based immune activators, antigen-targeting T cells and antibodies, and defined immunomodulators of various immune cell mechanisms. This portfolio is designed to mirror the evolution of the immune system to rely on multiple complementary pathways. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Broadening the universe of patients benefiting from cancer immunotherapy. </font>We discover and exploit novel targets and target combinations. Our aim is to extend the utility of immunotherapy to patient populations that are not currently amenable or do not benefit from the targets of current immunotherapies. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Improving the success rate. </font>We engineer and develop highly potent drug candidates designed to achieve precision for the specific target. We further augment activity and counteract resistance mechanisms by combining compounds with non-overlapping, synergistic mechanisms of action, such as combining our FixVac immunotherapy (CARVac) with our novel CAR-T therapies. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Focusing on curative approaches. </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The root cause of recurrence or for lack of tumor eradication is interindividual variability and cancer heterogeneity. Addressing this biological reality is one of the mandatory design aspects of the product candidates we develop. For example, each of our cancer immunotherapies incorporates multiple targets in order to account for this variability. </font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have applied these four guiding principles to a broad suite of therapeutic platforms optimized for a distinct mode of action, high precision targeting, high potency and efficacy. We expect each platform to yield a pipeline of drug candidates for further development. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe this technology-agnostic range of platforms and product candidates positions us to remain at the forefront of the shift toward an individually tailored, patient-centric therapeutic approach in oncology. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similarly, in infectious disease, we are deploying our full suite of technologies and immunotherapeutic understanding to develop mRNA vaccines against emerging infectious diseases, such as COVID-19, in a manner that is designed to be faster and more easily scalable, and with more flexible constructs, than traditional vaccine development. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patient-Centric Approach </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our patient-centric approach starts with profiling and diagnostics by utilizing a target identification engine. This engine combines next generation sequencing, genomics, bioinformatics, machine learning and artificial intelligence to (a) identify gene targets of interest, (b) characterize the functional relevance of these targets (<font style="font-style:italic;">i.e.</font> the ability to raise an immune response to or through a target) and (c) demonstrate their drugability. From our very beginning onwards, we have been developing the novel technologies needed to match the identified targets to the optimal individualized treatment approach. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdc15tqwxkbk000008.jpg" title="" alt="" style="width:605px;height:493px;"></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our patient-centric approach.<font style="font-weight:normal;"> Utilizing patient profiling, diagnostics and bioinformatics, we select from our suite of drug classes to provide optimal individualized treatment. Our treatments include off-the-shelf drugs as well as highly tailored immunotherapies that are produced on-demand for the individual patient. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:2.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utilizing this approach: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We develop and leverage our competencies in target discovery, biomarker science and computational medicine to thoroughly profile a patient&#8217;s tumor sample and immune cells for the selection of suitable targets and treatments, and use this data to develop next-generation product candidates. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Each of our therapeutic platforms bundles innovations designed to deliver a distinct mode of action with high-precision targeting, high potency and efficacy. Each platform is being developed to provide a pipeline of drug candidates with complementary and potentially synergistic modes of action. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Our drug platforms are highly versatile and support the fast development of scalable manufacturing processes. We develop and establish highly digitalized and automated manufacturing technologies and quality controlled processes enabling fast delivery of customized therapies comprising off-the-shelf drugs, on-demand immunotherapies, and combinations thereof. </p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Broad and Potentially Synergistic Suite of Platforms </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe the depth and breadth of our understanding of immune system and cancer biology allows us to create an extensive pipeline of specific and potentially efficacious product candidates. We are exploiting a comprehensive repertoire of known and proprietary therapeutically relevant immuno-oncology targets and are developing a diverse spectrum of immunotherapeutic approaches, as shown in the chart below. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdc15tqwxkbk000009.jpg" title="" alt="" style="width:604px;height:221px;"></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that harnessing complementary, potentially synergistic modes of action increases the likelihood of therapeutic success, reduces the risk of emergence of secondary resistance mechanisms, and also unlocks a larger potential market. Critically, this approach allows us to pursue a technology agnostic approach, providing the most appropriate therapeutic platform or a combination thereof for the intended patient and purpose. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, we believe our neoantigen immunotherapies are particularly well-suited to treat high mutation load cancers in the adjuvant setting to prevent the tumor from spreading or recurring following initial treatment, such as surgery. In this setting, tumor volumes tend to be low and there remains the potential for strong T cell responses since the patient&#8217;s immune system has not been weakened by prior lines of treatment, and checkpoint inhibition alone often offers a poor risk-benefit profile or low response rate. Similarly, we believe our FixVac, CAR-T, neoantigen-targeted T cell and next-generation checkpoint immunomodulator platforms may have especially strong potential in lower mutation burden tumors such as ovarian or prostate cancers, which comprise a significant proportion of tumors and often also have a poor response to checkpoint inhibition. Likewise, we believe that monoclonal targeted cancer antibodies and CAR-T cell therapies are particularly well-suited for tumors that have defects in their antigen-presentation machinery. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:12pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our breadth of our technology positions us to combine modes of action in a coordinated way to treat cancer in a more efficacious manner than current existing therapies. We further believe that our patient-centric approach and our broad, potentially synergistic portfolio of drug platforms place us at the forefront of the paradigm shift toward individualized immunotherapies. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdc15tqwxkbk000010.jpg" title="" alt="" style="width:607px;height:305px;"></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Diversity of cancer patient populations, challenges and our therapeutic strategies.<font style="font-weight:normal;"> We believe our diversified portfolio allows us to potentially address a large share of cancer patients. Abbreviations: B2M, beta-2 microglobulin, a component of MHC. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">V. Selection of Therapeutic Targets and Therapies </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Immunotherapy targets can be categorized as <font style="font-style:italic;">antigens</font> for targeted immunotherapy with antibody- or T cell-based effector mechanisms and <font style="font-style:italic;">immunomodulatory targets</font> to be exploited to improve the anti-tumoral function of immune cells. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">A. Targeting Cancer Antigens </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to address the broadest possible number of patients, our therapeutically targeted cancer antigen library comprises tumor associated antigens, viral neoantigens and mutant neoantigens: </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Tumor Associated Antigens </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tumor associated antigens, or TAAs, are cancer selective targets that typically have a highly restricted expression pattern in normal tissues but are frequently expressed in a wide range of human cancers. Over the last 15 years, we have built up a database of approximately 200 cancer-selective antigens, including proprietary disease targets that could be used as targets for immunotherapy-based approaches. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Cancer-Germline and Cancer-Embryo-Fetal Antigens, which are normally expressed during embryonal development and silenced after birth or restricted to germline cells. These antigens are aberrantly expressed in a variety of human malignancies and are generally not expressed in healthy tissue, making them particularly suitable for our FixVac-, antibody- and CAR-T cell-based therapeutic approaches. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Differentiation antigens, which are normally expressed in a highly tissue-specific manner in normal tissues (<font style="font-style:italic;">e.g.</font>, on melanocytes or on prostate cells) but are also present in a high proportion of tumors derived from these tissues, are well-suited for therapeutic targeting with FixVac and antibody approaches. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Tumor-associated carbohydrate antigens are carbohydrate-based cell surface tumor antigens generated by cancer cell-specific aberrant glycosylation that enable the development of antibody and CAR-T cell therapies. </p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2. Viral Neoantigens </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Viral oncoproteins, or viral neoantigens, are virus-derived proteins that drive the oncogenic transformation of infected cells by viruses that can cause cancer. Examples are the E6 and E7 oncoproteins from human papilloma virus, or HPV. Viral oncoproteins are commonly acknowledged as safe and promising targets for immunotherapy as they are (i) </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">absent from any non-infected tissue, (ii) highly immunogenic since they are not prone to central tolerance mechanisms and (iii) not subject to immune escape by gene silencing as they are crucial to maintaining the transformed state of the tumor cells. We leverage viral neoantigens as targets for our BNT113 FixVac program in HPV16+ head and neck cancer. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">3. Mutant Neoantigens </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Somatic mutations, or mutations of non-germline cells, are a hallmark of cancer. Driver mutations promote the oncogenic process, whereas passenger mutations are considered as functionally irrelevant. Both types of mutations, however, can alter the sequence of proteins and create new epitopes which are processed and presented on specialized major histocompatibility complex, or MHC, molecules. Mutated epitopes that are recognized by T cells are called neoepitopes and the sequence-altered proteins they are derived from are neoantigens. They are promising targets for cancer immunotherapy as (i) activation of the immune system against such antigens is highly specific (they are only expressed on cancer cells) and (ii) mutant neoantigens are exempt from central tolerance and thus T cell affinity for neoantigens may be significantly superior. We utilize individualized mutant neoantigens as targets for our iNeST product candidates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">B. Immunomodulatory Targets </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The activity of immune cells can be controlled or manipulated by the targeting of receptors that control key biological processes in these cells, known as immunomodulation. Immunomodulatory targeting strategies include: </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1. Checkpoint Inhibition </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Checkpoint inhibition is a therapeutic approach by which T cell function is stimulated with mAbs that block their inhibitory receptors, which can be exploited by cancer cells to shut down T cell activity. Examples of checkpoint targets are PD-1, PD-L1, CTLA-4, TIGIT, LAG3 and many others. The concept is known as &#8220;releasing the brakes&#8221; and has been shown to be therapeutically effective in tumors with strong pre-existing immune cell infiltration. Our GEN1046 (BNT311) product candidate is a next-generation bispecific checkpoint immunomodulator, with one arm targeting PD-L1.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2. Immunostimulation </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Immunostimulatory approaches are directed against receptors known to directly activate immune cells. Examples of these targets include co-stimulatory molecules such as CD40 and 4-1BB or cytokine receptors such as IL-2R, IL-7R and IL-12R. Immunostimulatory approaches provide a powerful opportunity to enhance immune activation, even in types of cancer that are not responsive to checkpoint inhibition due to lack of immune cell infiltration. However, this approach is often limited by a narrow therapeutic window associated with dose-limiting toxicity. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that both concepts can be combined in a potentially synergistic and safe fashion by developing precisely engineered molecules, such as our BNT151 RiboCytokine program or GEN1042 (BNT312), our next-generation bispecific checkpoint immunomodulator targeting both CD40 and 4-1BB.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C. Our Computational Approach to Individualized Immunotherapy </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bioinformatics are critical in the production of individualized therapies. We have accumulated a high level of experience in bioinformatic approaches to mutation detection, cancer genomics and immunotherapy through our ongoing research and preclinical studies and clinical trials. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:12pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our validated patient-centric bioinformatic process, as illustrated below, allows the application of complex algorithms to the patient&#8217;s data in the context of drug manufacturing. Our bioinformatics processes are robust and scalable, incorporating our experience handling genomic data in a high-throughput environment, as we target making on-demand production of individualized immunotherapies commercially viable. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdc15tqwxkbk000011.jpg" title="" alt="" style="width:608px;height:158px;"></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">From Patient to Analysis.<font style="font-weight:normal;"> Our bioinformatic process for the selection of neoepitopes. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1. Sequencing </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We sequence the patient&#8217;s tumor and healthy tissue samples using NGS technology. Comparison of the patient&#8217;s sequenced tumor and healthy samples provides us with the data from which we can identify targets for the design of individualized cancer immunotherapies. This is a multi-step process in which mutation detection and neoantigen prediction are particularly important. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2. Mutation Detection </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mutation detection, which defines which tumor-specific mutations are present in any cancer, is the starting point for defining targets for individualized immunotherapy. Determining mutations from NGS data with high precision and sensitivity is challenging because numerous factors can lead to false positives, which can mask mutations. Despite advances in the field, commonly used mutation detection algorithms still exhibit high false positive mutation detections. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">3. Neoepitope Selection </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Only a portion of mutated peptides (neoepitopes) are suitable for raising an immune response <font style="font-style:italic;">in vivo</font>. Our approach focuses on evoking responses involving both CD8+ T cells and CD4+ T cells. We do this by discerning the likelihood of presentation of the neoepitope to the T cell receptor as an MHC peptide complex using data from mRNA expression levels and MHC binding affinity predictions, among other factors. For example, in our first individualized neoepitope immunotherapy clinical study, all 13 stage III and IV melanoma patients selected for treatment developed a CD4+ and/or CD8+ T cell response, achieving an overall 60% immune response rate to predicted neoepitopes. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Presentation of a neoepitope on an MHC molecule does not, however, guarantee recognition by T cells, and an integrated view combining several properties impacting immunogenicity is necessary. Our algorithms are continuously being improved and extended with data collections from various sources such as our past and current clinical studies as well as HLA data. By using machine learning approaches applied to these large datasets we aim to further improve prediction of overall presentation of neoepitopes tailored to patients&#8217; specific HLA types. With our acquisition of Neon Therapeutics, Inc., or Neon, we further bolstered our neoepitope selection capabilities with the addition of Neon&#8217;s RECON bioinformatics engine. RECON uses a number of inputs from each patient, including DNA sequences from samples of tumor and normal tissue, RNA sequences from tumor samples, and the patient&#8217;s specific MHC allele profile. RECON processes data from these inputs using a proprietary combination of algorithms in order to produce a prioritized list of neoantigen-targeting peptides that can be manufactured for use in our product candidates. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">VI. Our mRNA Drug Class </p>
<p style="text-align:justify;Background-color:#BFBFBF;margin-top:6pt;margin-bottom:0pt;margin-left:2.03%;text-indent:2.9%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">At a glance: mRNA as a Therapeutic Drug Class </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Natural molecule found universally within cells, with well-characterized properties. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Suitable to encode for antibodies, antigens, cytokines and any other type of protein. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Transient, with adaptable activity and half-life. Avoids genomic integration problems sometimes seen in gene therapy, potentially resulting in a better safety profile. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Can be designed and optimized pharmacologically and immunologically, making it suitable for a broad range of applications. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Fast manufacturability, making it a cost-effective and flexible therapeutic to produce. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Our mRNA portfolio includes BNT162b2, our mRNA-based COVID-19 vaccine</font>, which has received emergency or temporary use authorization or approval or been granted conditional marketing approval in over 65 countries</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the last decade mRNA has progressed into a promising new class of medicine, with the potential to treat a wide variety of diseases with high unmet medical needs. mRNA is a long, polymeric molecule, composed of four different building blocks called nucleotides. In mRNA, hundreds or thousands of these nucleotides are linked in a unique order to convey genetic information to cells, where it is used to express proteins with biological effects. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Considering that all mRNA is generated with four different building blocks, but with unique sequence order, all therapeutic mRNAs have highly similar compositions, while having the capacity to encode a variety of different proteins. These characteristics allow for rapid development of mRNA therapeutics that are broadly applicable for treatment of many diseases, including cancer, infectious diseases and rare diseases. Our mRNA pipeline addresses all of these therapeutic areas. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">A. General Principles of mRNA Pharmacology </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a drug, manufactured mRNA provides instructions to a target cell to produce a desired therapeutic protein. An mRNA drug will temporarily change the status of the target cell where these instructions are translated into proteins. Based on the information encoded by the mRNA, the proteins will be either secreted or remain intracellular. The mRNA drug will eventually be degraded and eliminated from the body. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our mRNA drugs are synthesized from a DNA template. With the exception of the 5&#8217; cap, the template determines all structural elements of the mRNA. The mRNA molecule comprises: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>an open reading frame, or ORF, which encodes for the protein of interest; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>untranslated regions, or UTRs, which flank the ORF; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the cap and the poly(A) tail, which are the two terminal structures of the linear mRNA, and are responsible for increased stability and translational efficiency of mRNA. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:12pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The mRNA drug needs to be appropriately formulated in order to protect it from breakdown by extracellular RNAses. The formulation is selected based on the intended application and route of delivery. After uptake into the target cell, the mRNA molecules are loaded into ribosomes, where translation into protein takes place. Subsequently, the mRNA is degraded by cellular mechanisms. In case of an immunotherapy application, the protein is degraded into immunogenic epitopes. These are loaded onto specialized molecules, namely MHC I or MHC II. These molecules present the epitopes to immune cells to provoke the desired immune response. In the case of other mRNA applications, the mRNA encodes proteins that are secreted from the cells, such as antibodies, and function extracellularly. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdc15tqwxkbk000012.jpg" title="" alt="" style="width:608px;height:393px;"></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:2.86%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">General principles of mRNA pharmacology. <font style="font-weight:normal;">Step 1: mRNA is either delivered in a buffered solution as naked molecules or formulated as nano-particles to protect degradation by extracellular enzymes and is taken up by cells. Step 2: Subsequently, mRNA is released from endosomes into the cytoplasm. Step 3: mRNA is translated by the protein synthesis machinery of host cells. Step 4: Termination of translation </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by degradation of mRNA. Step 5: The translated protein product acts in the cell in which it has been generated. Step 6: Alternatively, the protein product is secreted and may act via autocrine, paracrine or systemic, body-wide mechanisms. Steps 7 and 8: For vaccine activity, mRNA encoded antigens are degraded into shorter fragments and loaded onto MHC class I and class II molecules. Step 9: Protein-derived epitopes can then be presented on the cell surface by both MHC class I and MHC class II molecules, enabling stimulation of CD8+ and CD4+ T cells. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The structural elements of the mRNA have an impact on its performance. This includes potential immunogenicity, efficacy of translation and stability of the molecule. We leverage our extensive experience to design, synthesize, manufacture and formulate our therapeutic mRNA, and adapt its composition to suit the desired application.  </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">B. Our mRNA Backbone Concepts and Technologies </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our mRNAs all contain basic structural elements, including the 5&#8217; cap, the untranslated regions and the poly(A) tail, in addition to a coding sequence, that are all encoded by our DNA template. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdc15tqwxkbk000013.jpg" title="" alt="" style="width:605px;height:321px;"></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>The cap is added to the 5&#8217; end of the mRNA during its synthesis. Our studies have demonstrated that incorporation of a unique cap analogue into the mRNA helps to achieve superior translational performance by stabilizing the mRNA molecule and directing the immune response. This unique cap analogue is extremely useful for our immunotherapy approaches. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>The composition and structure of the 5&#8217; and 3&#8217; untranslated regions of the mRNA molecule are important determinants of the intracellular stability of mRNA. As a result of rigorous screening of different mRNA sequences, we identified specific UTRs that promote increased protein translation for long duration. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>We have performed extensive research on the structure of the poly(A) tail and the translational performance of mRNA and customized our template design accordingly. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The translational performance of mRNA can be increased by removing contaminating double-stranded RNA from the mRNA. We have extensive expertise in different mRNA purification procedures. We have also invented a novel mRNA purification method that greatly impacts translatability of our mRNA. Depending on the protein characteristics needed for treatment of a disease, we optimize the DNA template through a proprietary codon optimization process, changing the nucleotide sequence of the template without altering the amino acid composition of the encoded protein. We make further adjustments during mRNA production. We believe these fine tunings of the respective molecules are essential for the purpose-adapted performance of our mRNA. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdc15tqwxkbk000014.jpg" title="" alt="" style="width:576px;height:472px;"></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our mRNA formats. <font style="font-weight:normal;">As shown above, we have developed four mRNA formats, each optimized for different therapeutic applications. Abbreviations: y, 1-methylpseudouridine; UTR, untranslated region. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our mRNA formats include: </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1. Optimized Uridine mRNA (uRNA) </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The nucleotide sequence of mRNA determines the amino acid sequence of the protein. In addition, the nature of nucleosides used for production of mRNA drugs can also influence recognition of the molecule by the immune system. Presence of naturally occurring uridine (U) in our optimized uridine mRNA makes it immunogenic by activating immune sensors. We have further optimized our uridine mRNA for immunogenicity (augmented antigen presentation on MHC I and MHC II) and pharmacological activity (enhanced stability and translational efficiency). Immunogenicity of the mRNA is an added benefit when mRNA is used for immunotherapy applications, by acting as an immunotherapy adjuvant. This makes our therapeutics for iNeST and FixVac even more potent. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2. Nucleoside-modified mRNA (modRNA) </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Immunogenic reaction against mRNA drugs needs to be avoided in applications where therapeutic proteins are produced, such as in our RiboMab and RiboCytokine platforms. We have profound expertise in incorporating naturally-occurring modified nucleosides into our therapeutic mRNAs. We have demonstrated that the presence of a variety of modified nucleosides in the manufactured mRNA suppresses its intrinsic immune activation, while leading to superior </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">protein production for long duration. Deimmunizing mRNA by incorporating modified nucleosides helps to avoid production of anti-drug antibodies and broaden the therapeutic application of these types of mRNA drugs. We believe this customization has resulted in therapeutic mRNA that is both potent and well tolerated. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">3. Self-amplifying mRNA (saRNA) </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our self-amplifying mRNA, or saRNA, drugs use the concept of viral replication, while not being an infectious, disease-causing agent itself. saRNA resembles conventional mRNA encoding the protein of interest, but also encoding a polymerase, called replicase, that multiplies part of the mRNA within the target cell. During self-amplification inside the cell, a double-stranded RNA intermediate is generated, which is recognized by intracellular immune sensors. This makes saRNA a very potent activator of the immune system and therefore an excellent category of immunotherapy. As we have demonstrated, our saRNA ensures high levels of sustained antigen production with a small amount of initial mRNA input. Our scientific team has designed this mRNA technology to act as a potent tool for prophylactic vaccination, with the potential application in infectious diseases with high medical needs. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">4. Trans-amplifying mRNA (taRNA) </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have also expanded on our self-amplifying mRNA capabilities, developing a novel mRNA amplification technology by separating the target mRNA to be amplified and the replicase encoding mRNA. This advancement broadens the spectrum of applications by making the development of therapeutic mRNAs even more flexible, as the replicase can amplify mRNA encoding of not only one protein, but several different ones. In the case of vaccines, this allows us to produce the replicase in advance for use with different vaccines. Our trans-amplifying mRNA is a proprietary mRNA format that is particularly well-suited for prophylactic vaccines to prevent infectious diseases. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C. Our mRNA Delivery Formulation Technologies </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have deep and broad expertise in the targeted delivery of mRNA therapeutics. We are convinced that our development of suitable delivery formulations in conjunction with our own therapeutic mRNAs is a key competitive advantage.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We employ multiple mRNA delivery formulations, each designed for different functions and optimized for therapeutic product needs: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Lipoplex:</font> Our lipoplex formulation, or LPX, embeds the mRNA between a lipid bilayer, which is used for our FixVac and iNeST platforms. We use a proprietary size- and charge-based non-viral mRNA lipoplex that was developed to deliver mRNA to dendritic cells in lymphoid compartments such as the spleen for optimal antigen presentation and immune response activation. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">LNPs: </font>For other applications, we encapsulate our mRNA in lipid nanoparticles, or LNPs. These formulations are suitable for our RiboMab, RiboCytokine and rare disease protein replacement platforms. Our LNP formulations can be adjusted according to our needs for delivery to particular target tissues, such as the liver in the case of our rare disease protein replacement platform. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Polyplexes: </font>Our portfolio also comprises polyplexes, which are being utilized in certain of our discovery programs, in which the mRNA is bound to a polymer and then forms nanoparticles. </p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.86%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RNA-LPX Technology </p>
<p style="text-align:justify;Background-color:#BFBFBF;margin-top:6pt;margin-bottom:0pt;margin-left:2.03%;text-indent:2.9%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">At a glance: RNA-LPX Cancer Immunotherapy Technology </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Potential first-in-class clinical intravenous nano-particulate mRNA immunotherapy, allowing systemic delivery. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Strong potency by systemic targeting to dendritic cells in lymphoid tissues. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Universally applicable for all cancer antigens. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Opportunity to deliver multiple antigens in parallel, enabling the induction of poly-specific T cell responses. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Synchronized adjuvant effect mediated by toll-like receptor 7 (TLR7)-triggering and type-I interferon-driven innate and adaptive immune stimulation. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Preclinical anti-tumoral activity demonstrated against multiple tumors. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.09%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.04%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Unprecedented clinical immune responses against shared TAAs. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Beneficial clinical activity demonstrated in advanced melanoma patients. </font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:12pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To advance from local to systemic dendritic cell, or DC, targeting, we developed an innovative liposome-based RNA-lipoplex formulation, RNA-LPX, that allows for intravenous administration of our mRNA cancer immunotherapies. We have demonstrated in the clinic that systemic DC targeting by mRNA cancer immunotherapies can result in potent activity at very low doses. Consequently, less material is required for treating high patient numbers, making manufacturing more cost-effective. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdc15tqwxkbk000015.jpg" title="" alt="" style="width:606px;height:395px;"></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our RNA-LPX technology.<font style="font-weight:normal;"> Our proprietary RNA-LPX formulation is designed to deliver vaccine mRNA precisely into DCs and macrophages in the spleen and other lymphoid compartments. The RNA-LPX has an inherent adjuvant function stimulating the release of cytokines such as IFN-a thereby promoting the activation of DCs and the induction of strong T cell responses. Abbreviations: BM, bone marrow; LN, lymph node; DC, dendritic cell; pDC, plasmacytoid dendritic cell; M&#248;, macrophage; IFN-a, interferon alpha. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RNA-LPX protects mRNA from degradation outside of the cell and mediates its efficient uptake and expression of encoded antigens in various dendritic cell populations. Our RNA-LPX technology is designed to target a wide variety of antigens and address cancer patients with all possible HLA haplotypes. Utilizing RNA-LPX, we can target fixed groups of known shared antigens with our FixVac platform and a whole new class of patient-specific neoantigen targets with our iNeST platform.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">D. Our mRNA Platforms </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing multiple mRNA-based therapeutic platforms. These include FixVac, iNeST, mRNA-based intratumoral immunotherapy, RiboMabs and RiboCytokines in the oncology space. In addition, we have implemented mRNA platforms for the development of infectious disease vaccines and protein replacement therapies for rare diseases. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:12pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Importantly, each of these platforms enables the development of multiple pharmaceutical product candidates or programs. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdc15tqwxkbk000016.jpg" title="" alt="" style="width:597px;height:312px;"></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our mRNA Platforms. <font style="font-weight:normal;">We have multiple mRNA-based platforms utilizing different mRNA formats and delivery formulations, directed at a range of biological targets in oncology and infectious and rare diseases. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Cancer Immunotherapies </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our goal is to develop safe, potent, efficacious and cost-effective cancer immunotherapies which stimulate and potently expand tumor cell specific CD4+ and CD8+ T cells in cancer patients. Our cancer immunotherapy development integrates our competencies in mRNA backbone optimization, formulation development and immunological research. </p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">a) FixVac</p>
<p style="text-align:justify;Background-color:#BFBFBF;margin-top:6pt;margin-bottom:0pt;margin-left:2.03%;text-indent:2.9%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">At a glance: Our FixVac Platform </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Concept:</font> Cancer immunotherapies targeting shared antigens that we have identified to be frequently expressed across patients with a specific cancer type. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">mRNA Format:</font> Optimized uridine mRNA providing superior immunogenicity. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">mRNA Delivery Formulation:</font> Proprietary size- and charge-based RNA-LPX targeting <font style="color:#000000;">dendritic cells (DCs)</font>. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Development Approach:</font> Worldwide rights; wholly owned. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Lead Candidate:</font> BNT111 for metastatic melanoma. </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our FixVac approach involves off-the-shelf mRNA immunotherapies targeting cancer cell-specific shared tumor associated antigens, or TAAs, for selected patient populations. Our FixVac product candidates target TAAs which are commonly expressed by a significant portion of patients in a given cancer type. We have developed a sophisticated target selection process which enables us to produce poly-specific FixVac immunotherapies that cover up to 95% of patients with a given cancer type. The use of off-the-shelf FixVac immunotherapies allows for large-batch manufacturing and prompt supply to patients with ready-to-use medication, ensuring a straight-forward cost- and time-efficient manufacturing process with favorable logistics. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Besides targeting commonly expressed TAAs, our target selection strategy facilitates the identification of suitable viral oncoproteins for the treatment of virus-induced cancers like HPV+ head and neck cancer. Patient stratification, if needed, can easily be performed at the clinical site or a central lab using standard biotechnological methods, thereby reducing treatment costs. As the viral genome is comparatively small, encoding only for a few proteins, we believe our FixVac approach is ideally suited for the treatment of virus-induced cancers. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">b) Individualized Neoantigen Specific Immunotherapy (iNeST) </font></p>
<p style="text-align:justify;Background-color:#BFBFBF;margin-top:6pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">At a glance: Our iNeST Platform </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Concept:</font> Individualized cancer immunotherapy targeting neoantigens identified on a patient by patient basis and selected for immunogenicity. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">mRNA Format:</font> Optimized uridine mRNA providing superior immunogenicity. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">mRNA Delivery Formulation:</font> Proprietary size- and charge-based RNA-LPX targeting DCs. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Development Approach:</font> 50:50 cost share with Genentech. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Lead Candidate: </font>autogene cevumeran (BNT122) as a first-line melanoma therapy in combination with pembrolizumab. </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:12pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a pioneer and global leader in developing fully individualized cancer immunotherapies. We have developed a first of its kind, on-demand manufacturing process to treat each individual patient based on the mutation profile of the patient&#8217;s tumor. We are investigating this treatment approach in the clinic in collaboration with Genentech. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdc15tqwxkbk000017.jpg" title="" alt="" style="width:559px;height:155px;"></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our iNeST process.<font style="font-weight:normal;"> The figure above depicts our iNeST process for the on-demand production of individualized mRNA cancer immunotherapies. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our iNeST process is summarized below: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>A blood sample and tumor biopsy is taken from the patient to obtain healthy cells and tumor tissue. We extract healthy cells from the patient&#8217;s blood sample and tumor cells from the tumor sample. We use NGS to analyze genetic material (DNA and RNA) of these cells to identify which mutations are present in the cancer cells compared to healthy cells. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">We apply proprietary bioinformatic algorithms to identify tumor-specific mutations. The mutations within a cancer cell differ widely from patient to patient and form a unique signature for each tumor. This genomic information can be further utilized to analyze tumor heterogeneity and microenvironment as well as individual aspects of the immune system like the HLA type. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Based on these bioinformatic algorithms, we then select mutations that are the most promising therapeutic targets. The specific traits of the patient&#8217;s immune system, including HLA type, are key to the selection of the most appropriate targets. Picking multiple mutations increases the chance to induce potent T cell responses and reduces the risk that the tumor evades T cell attack over time. We account for heterogeneity of each tumor by preferentially selecting mutations that are expressed on all tumor cells. Importantly, the selected mutations are intended to ensure both CD4+ and CD8+ T cell induction. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Following mutation selection, we design the structure for the iNeST product. The chosen mutations have to be arranged in a certain order and the DNA sequence of the mutations has to be optimized. This is important to ensure a robust production of the starting material, or DNA matrix, for the GMP manufacturing of the iNeST product. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Next we produce the patient-specific iNeST product under GMP conditions and the iNeST product undergoes numerous different quality control tests. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>The iNeST product is transferred to the hospital and injected into the same patient by the physician. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>This process has been designed for the on-demand delivery of our iNeST products, and currently takes approximately six weeks. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently developing iNeST therapeutics for the treatment of metastatic melanoma and multiple solid tumors.</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">c) Intratumoral mRNA Immunotherapy </p>
<p style="text-align:justify;Background-color:#BFBFBF;margin-top:6pt;margin-bottom:0pt;margin-left:2.03%;text-indent:2.9%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">At a glance: Our Intratumoral mRNA Platform </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Concept:</font> Immunomodulator-encoding mRNA injected directly into the tumor in order to avoid off-target toxicities. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">mRNA Format:</font> Nucleoside-modified mRNA engineered for minimal immunogenicity in order to avoid immune detection and allow translation of the encoded cytokines to occur within the cells. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">mRNA Delivery Formulation:</font> Various formulations, delivered by intratumoral injection. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Development Approach:</font> Co-development and co-commercialization, at our option, in collaboration with Sanofi. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Lead Candidate: </font>SAR441000 (BNT131) for advanced solid tumors as a monotherapy and in combination with cemiplimab. </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In collaboration with Sanofi, we are leveraging our mRNA technology to develop intratumoral immunotherapies for the treatment of solid tumors. Intratumoral immunotherapy is designed to promote innate and adaptive immune responses against tumors, without toxicities related to systemic administration. Our intratumoral immunotherapy involves injection of cytokine-encoding mRNA directly into a tumor in order to alter the tumor microenvironment and promote greater T cell activity. This approach has been found in preclinical studies to boost cancer-specific immune responses locally, while also producing tumor responses in remote parts of the body due to the circulation of properly activated anti-tumor immune cells, known as an abscopal effect. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The first intratumoral immunotherapy product candidate arising from our collaboration, SAR441000 (BNT131), includes modified mRNA that encodes for the IL-15sushi, IL-12sc, GM-CSF and IFN-&#945; cytokines. We and Sanofi published data from our Phase 1 trial of SAR441000 (BNT131) as a monotherapy and in combination with cemiplimab in advanced solid tumors in July 2020, in which no patient experienced a dose limiting toxicity and no grade 3, 4, or 5 adverse events related to study treatment were reported. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. Infectious Disease Vaccines </p>
<p style="text-align:justify;Background-color:#BFBFBF;margin-top:6pt;margin-bottom:0pt;margin-left:2.03%;text-indent:2.9%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">At a glance: Our Infectious Disease Vaccine Platform </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Concept:</font> mRNA-based vaccines targeting infectious disease pathogens. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">mRNA Format:</font> Multiple. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">mRNA Delivery Formulation:</font> LNPs. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Development Approach:</font> Collaborations with Pfizer and Fosun Pharma and exclusive option arrangement with Penn. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Commercial Product: </font>COVID-19 vaccine (COMIRNATY in the European Union and other locations where we have received marketing approval). </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Lead Candidates: </font>Influenza vaccine candidate BNT161 and other vaccine candidate variants in our BNT162 development program. </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expanding beyond our research in oncology, we are leveraging our mRNA technologies to direct the immune system more effectively against infectious diseases. Our infectious disease vaccine candidates contain self-replicating or trans-replicating, modified mRNA-encoding antigens specific to a target pathogen, delivered in various LNP formulations in order to activate and direct T cells and B cells to fight the pathogen. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">BNT162b2 COVID-19 vaccine and Other COVID-19 Vaccine Candidates</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our COVID-19 vaccine, referred to as COMIRNATY in the European Union and other locations where we have received marketing approval, has received emergency or temporary use authorization or approval in over 65 countries.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and Pfizer are also investigating other COVID-19 vaccine candidate variants in clinical trials as part of our BNT162 program.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Influenza Vaccine </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are collaborating with Pfizer to develop an influenza vaccine using our mRNA-based immunotherapy technology. Current influenza vaccines consist of antigens from inactivated influenza viruses, recombinant influenza haemagglutinin, or HA, proteins or live attenuated influenza viruses and are available as trivalent (containing two influenza A strains and one influenza B strain) or quadrivalent (containing two influenza A strains and two influenza B strains) vaccines. Currently available influenza vaccines are produced in chicken eggs or cell culture and take about five to six months to produce. This requires the composition of the coming season&#8217;s vaccine to be selected by the World Health Organization, or WHO, far in advance for the vaccine to be available on time, which reduces the reliability of that prediction. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that our mRNA-based vaccines can be manufactured within three months from the time the recommendation is published, including cloning and production and therefore the WHO&#8217;s review of the vaccine components can occur closer to the influenza season to obtain a more reliable prediction. In addition, the mRNA manufacturing process is designed to produce an HA vaccine antigen that matches the HA of circulating influenza strains, in contrast to egg- or cell-based processes which can introduce mutations in the HA amino acid sequence. The flexibility of the mRNA vaccine platform could allow for generation of vaccines against genetically drifted seasonal viruses or pandemic strains.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. mRNA-based Protein Replacement Platform for Rare Diseases </p>
<p style="text-align:justify;Background-color:#BFBFBF;margin-top:6pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">At a glance: Our Protein Replacement Platform for Rare Diseases </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Concept:</font> Therapeutic proteins encoded by mRNA and produced in the patient as an alternative to recombinant protein replacement. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">mRNA Format:</font> Nucleoside-modified mRNA, deimmunized to avoid immune activation in order to allow for translation of the therapeutic protein in the cells. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">mRNA Delivery Formulation:</font> Liver-targeting LNPs. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Development Approach:</font> 50:50 cost and profit share with Genevant. </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By incorporating modified nucleosides into our mRNA, we are able to reduce the immunogenicity of our product candidates, thereby allowing their use for therapeutic protein production. In addition, we utilize advanced mRNA delivery methods to protect the mRNA cargo <font style="font-style:italic;">en route</font> to its target and promote its uptake into liver cells. Current protein-based replacement therapies were developed to treat rare diseases by administering recombinant proteins. Such therapies are limited to diseases where the missing protein function is extracellular. However, mRNA-based protein replacement therapy also has the potential to treat illnesses with intracellular protein defects, as long as the mRNA can be delivered into the affected cells. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our mRNA-based protein replacement therapy features: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Nucleoside-modified mRNA.</font> Replacing uridines in mRNA with modified analogues is important to avoid immune activation that can provoke anti-drug antibody production and would limit efficacy of the treatment. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Liver targeted expression.</font> mRNA encoding therapeutic proteins are formulated into LNPs using in-licensed clinically-validated LNP delivery technology owned by Genevant. The mRNA-loaded LNPs are less than 100nm in size. When injected intravenously, these particles are selectively taken up by hepatocytes, the major cell component of the liver. </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our protein replacement technology is designed for the treatment of: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Genetic disorders that manifest due to a missing or defective protein, where mRNA would need to be administered regularly for a lifetime. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Acute diseases caused by transient depletion of a protein, such as a hormone, where treatment of such diseases with a single or a few doses of the encoding mRNA could be curative. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therapeutic proteins encoded by the mRNA can either act intracellularly or be secreted and act extracellularly, in order to produce the desired therapeutic effect. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mRNA-based protein replacement technology has several advantages over recombinant proteins: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">No need to develop a procedure for protein purification.</font> The development of recombinant proteins is a laborious and expensive procedure due to the requirement for a unique purification protocol for each protein. During mRNA-based protein replacement the protein is produced by the patient, which we believe avoids the need for purification and also accelerates drug development. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">The protein has proper post-translational modification. </font>To function properly, most recombinant proteins need to be modified after synthesis. Proteins produced in patients from mRNA are more likely to obtain the correct modifications than recombinant proteins produced in cultured bacterial or mammalian cells. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Continuous </font><font style="font-weight:bold;font-style:italic;">in vivo</font><font style="font-weight:bold;"> supply of encoded protein. </font>Recombinant proteins, especially those with short half-lives, can be cleared from the body very quickly, thereby limiting therapeutic effect. During mRNA-based therapy, the encoded therapeutic protein is produced for a longer duration (<font style="font-style:italic;">e.g</font>., 10-14 days). </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Production of intracellular proteins. </font>Recombinant proteins have limited intracellular therapeutic effects. In contrast, proteins encoded by mRNA can reach any cellular compartment and potentially help to cure diseases where the therapeutic protein needs to function in different subcellular locations, including the mitochondria, nucleus or cell membrane. </p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. RiboMabs </p>
<p style="text-align:justify;Background-color:#BFBFBF;margin-top:6pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">At a glance: Our RiboMab Platform </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Concept:</font> Antibodies encoded by mRNA and produced in the patient as an alternative to recombinant antibodies. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">mRNA Format:</font> Nucleoside-modified mRNA engineered for minimal immunogenicity in order to avoid immune detection and allow translation of the encoded antibodies to occur within the cells. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">mRNA Delivery Formulation:</font> Various liver-targeting LNP formulations, delivered intravenously, to ensure systemic availability and prolonged production of the antibody <font style="font-style:italic;">in vivo</font>. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Development Approach:</font> Worldwide rights; wholly owned. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Lead Candidate: </font>BNT141 in multiple solid tumors. </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our RiboMab product candidates are designed to encode secreted antibodies for expression <font style="font-style:italic;">in vivo</font> by the patient&#8217;s cells. We believe our RiboMab technology represents the next generation of antibody-based drugs. Antibody drugs are a leading class of biologics for the treatment of various diseases, but have a number of limitations. The development of antibodies is currently challenged by demanding and costly procedures of production, purification and formulation of a recombinant protein, which we believe hampers the rapid development and clinical testing of new drugs in this class. Recombinant protein antibodies require development of a cell line, establishment and adaptation of processes for production, purification and analytical testing. The whole process typically takes 18 to 30 months to optimize, scale-up and produce first clinical batches. Some of these antibodies are produced in low yields making them unsuitable for therapeutic application. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:12pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By contrast, mRNA not only involves a simpler and less expensive manufacturing process, but also is effective in much lower volumes than are required to produce similar effects using recombinant proteins. RiboMabs provide an antibody&#8217;s mRNA sequence, and the body does the production work itself. This simplicity is designed to allow for both shorter development times and a greater diversity of druggable targets. For efficient RiboMab production, the encoding mRNA is encapsulated in LNPs that deliver the mRNA to the liver cells. For cancer treatment, we focus on tumor-associated antigens to keep adverse effects for the patients as low as possible. We believe we can integrate any antibody sequence in our RiboMab-encoding mRNA. We have demonstrated the feasibility of our RiboMab technology for a variety of antibody formats, such as full immunoglobulins (Ig), primarily IgG, or different bispecific antibody variants, all of which engage the patient&#8217;s own immune cells to eradicate antigen-positive tumor cells. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdc15tqwxkbk000018.jpg" title="" alt="" style="width:613px;height:437px;"></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our RiboMab technology. <font style="font-weight:normal;">The figure above depicts the structure of </font><font style="font-style:italic;font-weight:normal;">in vitro</font><font style="font-weight:normal;"> transcribed (IVT) IgG and bi-(scFv)2 RiboMabs. IVT-mRNA encoding the therapeutic antibody is encapsulated in LNPs and injected intravenously into patients. The mRNA is delivered to the liver where it is translated into antibodies and secreted into the blood stream. Abbreviations: A100, poly adenosine tail; bi-(scFv)2, bispecific single chain variable fragment; C, C-terminus; CH, constant heavy domain; CL, constant light domain; IgG, immunoglobulin G; IVT, </font><font style="font-style:italic;font-weight:normal;">in vitro</font><font style="font-weight:normal;"> transcribed; L, linker; LNP, lipid nanoparticles; m1y, 1-methylpseudouridine; N, N-terminus; TAA, tumor-associated antigen; VH, variable heavy domain; VL, variable light domain; UTR, untranslated region. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our broad portfolio of antibody formats will enable us to produce mRNAs encoding the appropriate antibody format for the individual patient&#8217;s medical need and the desired treatment regimen (<font style="font-style:italic;">e.g.,</font> monotherapy or combination therapy). </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. RiboCytokines </p>
<p style="text-align:justify;Background-color:#BFBFBF;margin-top:6pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">At a glance: Our RiboCytokine Platform </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Concept:</font> Cytokines encoded by mRNA and produced in the patient as an alternative to recombinant cytokines. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">mRNA Format:</font> Nucleoside-modified mRNA engineered for minimal immunogenicity in order to avoid immune detection and allow translation of the encoded cytokines to occur within the cells. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">mRNA Delivery Formulation:</font> Various liver-targeting LNP formulations, delivered intravenously, to ensure systemic availability and prolonged production of the cytokine <font style="font-style:italic;">in vivo</font>. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Development Approach:</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Worldwide rights; wholly owned. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Lead Candidate:</font> BNT151 in multiple advanced malignancies. </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our RiboCytokine product candidates utilize mRNA that encodes the desired cytokines for expression <font style="font-style:italic;">in vivo</font> by the patient&#8217;s cells. Cytokines represent a large group of relatively small proteins (&lt;30 kDa) that regulate a variety of biological functions as they elicit signaling for immune and non-immune cells. In particular, cytokines play a pivotal role in orchestrating the initiation, execution and extinction of innate and adaptive immunity against pathogens as well as malignant cells. Due to their natural role as immunomodulators, recombinant cytokines are currently used for the treatment of a number of infectious, inflammatory, autoimmune and malignant diseases. One of the major challenges associated with the therapeutic use of cytokines relates to their short serum half-life and low bioavailability. This impedes therapeutic efficacy as it necessitates high and frequent dosing, which often results in dose-limiting toxicities. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:12pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have developed a wholly owned, novel mRNA-based platform technology called RiboCytokines, designed to address the limitations of recombinantly expressed cytokines. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdc15tqwxkbk000019.jpg" title="" alt="" style="width:609px;height:403px;"></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concept of our RiboCytokine technology.<font style="font-weight:normal;"> The graphic above depicts our RiboCytokine technology, including mRNA formulated in LNPs and administered by injection, having a beneficial pharmacokinetic profile. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our RiboCytokine platform allows for sustained delivery of the encoded cytokines with prolonged half-life, including through: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Usage of N1-methylpseudouridine modified mRNA.</font> N1-methylpseudouridine as a nucleoside analogue prevents the recognition of mRNA by TLRs, avoiding immune attack against the RiboCytokines. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Liver targeted expression.</font> RiboCytokines are formulated using clinically validated LNP delivery technology owned by Genevant. LNPs selectively target the liver resulting in high-level expression. </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that apart from a beneficial pharmacokinetic profile, our mRNA-based RiboCytokine technology has a number of additional advantages over other types of cytokine therapies: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Less immunogenic than recombinant cytokines.</font> Expression of self and foreign antigens in the liver is associated with immune tolerance due to a unique anti-inflammatory microenvironment. We expect </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RiboCytokines to be less likely to trigger an immune response when compared to their recombinant counterparts. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Shorter development times and greater diversity.</font> The development of recombinant cytokines is a challenge due to demanding and costly CMC procedures of production, purification and formulation. The simplicity of our mRNA manufacturing allows for both shorter development times and a greater diversity of druggable targets. </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our RiboCytokine technology is particularly well-suited to identify candidates for combination treatment with our proprietary CAR-T cell and cancer immunotherapies platforms. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">VII. Our Cell Therapies Drug Class </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The tailored reprogramming of autologous T cells from cancer patients to recognize and attack their tumors has become a disruptive medical innovation. Retargeting of T cells can be achieved via introduction of tumor-specific receptors into patient-derived T cells. For that purpose, T cells are mostly engineered by retroviral gene transfer to express either T cell receptors, or TCRs, or chimeric antigen receptors, or CARs. Recently, CAR expressing T cells, or CAR-T cells, became the first engineered T cell therapy to obtain FDA approval for some B cell derived hematological malignancies. Additionally, with our Neon acquisition we recently acquired an adoptive T cell platform targeting patient-specific and shared neoantigens. This platform utilizes a proprietary <font style="font-style:italic;">ex vivo</font> co-culture process, NEO-STIM, to prime, activate and expand autologous neoantigen-specific T cells specific either for a personal set of neoantigens for each patient or for a set of selected shared neoantigens. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">A. CAR-T Cells </p>
<p style="text-align:justify;Background-color:#BFBFBF;margin-top:6pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">At a glance: Our CAR-T Platform </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Concept:</font> Second-generation CAR-T therapy designed to overcome the shortcomings of CAR-T therapy in solid tumors. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Mechanism:</font> T cells with CARs engineered to target cancer-specific antigens, including novel antigens selected from our proprietary antigen library and administered with an mRNA-based immune booster, which we refer to as CARVac, to enhance CAR-T cell expansion and persistence. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Development Approach:</font> Worldwide rights; wholly owned. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Lead Candidate:</font> BNT211 for multiple solid tumors. </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CARs are artificial receptors that consist of an antigen recognition domain derived from a tumor-specific antibody linked to intracellular T cell signaling domains. CARs redirect T cells to eradicate tumors through specific recognition of native surface proteins expressed on tumor cells in a non-MHC-restricted manner. Therefore, CAR-T cells can be used for the treatment of all individuals whose tumor expresses the respective target, independent of the individual&#8217;s HLA genotype. CARs can be used for redirection of both CD4+ and CD8+ T cells. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdc15tqwxkbk000020.jpg" title="" alt="" style="width:436px;height:366px;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Second-generation CAR.<font style="font-weight:normal;"> The figure above illustrates the basic structure of a second-generation CAR, such as those included in our BNT211 and BNT212 product candidates. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While CAR-T therapy has shown potent anti-tumor responses in patients with B cell malignancies, clinical efficacy in solid tumors so far is limited. The main hurdles for application of CAR-T therapies in solid tumors are: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Lack of highly tumor-selective targets, which are needed for safe and effective tumor targeting; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Low anti-tumoral activity due to insufficient expansion of engineered T cells. </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing the next generation of engineered T cell therapies that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>target novel and known tumor-specific antigens, including mutant neoantigens, and a broad spectrum of tumor-associated antigens expressed in a wide range of cancers; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>leverage our proprietary CARVac technology for controlled <font style="font-style:italic;">in vivo</font> stimulation, activation and expansion of engineered T cells. </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The powerful characteristics of CAR-T cells, including their potential to eradicate targeted tumor cells in combination with their potentially life-long persistence in the host, require careful target selection. We believe the essential features of an ideal antigen for T cell-based immunotherapy are: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Absence of expression from any toxicity-relevant non-malignant tissue, to prevent off-tumor/on-target toxicity; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Expression on the cell surface of tumor cells at sufficient levels to allow for recognition and lysis by CAR-T cells. </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing CAR-T programs targeting two different members of the Claudin family, namely CLDN6 and CLDN18.2. Claudins, or CLDNs, are central components of tight junctions that regulate epithelial-cell barrier function and polarity. Most of the CLDNs are broadly expressed, while CLDN6 and CLDN18.2 are exclusively expressed in different high medical need cancers. Disturbance and dysregulation of tight junction molecules is a frequent hallmark of cancer cells and often associated with malignant transformation and metastasis and, hence, disease progression.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.03%;text-indent:2.9%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">In-vivo</font><font style="font-style:italic;"> expansion of engineered T cells using liposomally formulated mRNA </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Besides targeting an ideal tumor-specific antigen, the frequency and the persistence of CAR-T cells in the respective patient is a critical factor determining antitumor efficacy. A positive correlation between clinical outcome and CAR-T cell engraftment and persistence has been shown in several CD19-targeting CAR-T trials. Both tend to be much more limited in the solid tumor setting, likely due to the lack of circulating antigen-presenting cells, or APCs, such as dendritic cells expressing the target CAR antigen. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:12pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To address this critical factor, we developed an approach for <font style="font-style:italic;">in vivo</font> stimulation of CAR-T cells that relies on our proprietary FixVac technology for systemic mRNA delivery in combination with our CAR-T product candidates. Intravenous administration of a FixVac encoding for the tumor antigen induces expression of the desired target on antigen-presenting cells in secondary lymphoid tissues. FixVac treatment facilitates <font style="font-style:italic;">in vivo</font> expansion of CAR-T cells in a dose-dependent manner. Moreover, repetitive administration of FixVac results in an improved CAR-T cell persistence as well as increased anti-tumor activity. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdc15tqwxkbk000021.jpg" title="" alt="" style="width:606px;height:427px;"></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our CAR-T cell immunotherapies combined with CARVac-mediated <font style="font-style:italic;">in vivo</font> expansion. <font style="font-weight:normal;">(A) Autologous T cells engineered to express a CAR are adoptively transferred into the patient. (B) Full-length CAR target-encoding mRNA is complexed with liposomes to form RNA-LPX lipoplexes (CARVac). (C) Intravenously administered CARVac selectively targets APCs in secondary lymphoid organs facilitating uptake, antigen expression and maturation of APCs. Exposure of CAR-T cells to their target results in CAR-T cell </font><font style="font-style:italic;font-weight:normal;">in vivo </font><font style="font-weight:normal;">expansion. (D) CARVac can be administered repetitively to achieve controlled expansion and persistence of CAR-T cells within the therapeutic window. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">B. Neoantigen-targeting T Cells </p>
<p style="text-align:justify;Background-color:#BFBFBF;margin-top:6pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">At a glance: Our Neoantigen-targeting T Cell Platform </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Concept:</font> Adoptive T cell therapies targeting personal or shared sets of cancer neoantigens. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Mechanism:</font> Autologous, neoantigen-specific T cells primed, activated and expanded utilizing a proprietary antigen-specific T cell induction protocol, NEO-STIM, to target either a personal set of neoantigens for each patient or a set of selected shared neoantigens. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Development Approach:</font> Worldwide rights. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Lead Candidate:</font> BNT221 for metastatic melanoma and other potential cancer indications. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Through our acquisition of Neon in 2020, we obtained a neoantigen-targeting T cell platform. This platform can be utilized to develop product candidates across several neoantigen-targeting non-engineered and engineered T cell therapies using two distinct approaches: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>An individualized approach enabling neoantigen-targeted therapies that are tailored for the individual profile of each patient&#8217;s tumor.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>A shared neoantigen approach enabling neoantigen therapies that target prevalent neoantigens that are shared across subsets of patients or tumor types. </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our RECON bioinformatics engine is designed to predict the most therapeutically-relevant neoantigen targets associated with each patient&#8217;s tumor. Effective prediction is critical because, although many mutations within a patient&#8217;s tumor will lead to the production of a mutated protein, not all mutated proteins lead to suitable therapeutic neoantigen targets. RECON uses a number of inputs from each patient, including DNA sequences from samples of tumor and normal tissue, RNA sequences from tumor samples, and the patient&#8217;s specific MHC allele profile. RECON processes data from these inputs using a proprietary combination of algorithms in order to produce a prioritized list of neoantigen-targeting peptides that can be manufactured for use in product candidates. After selection of the target neoantigens, our proprietary method for<font style="font-style:italic;"> ex vivo</font> T cell stimulation, which we call NEO-STIM, allows us to directly prime, activate and expand antigen-specific T cells. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C. TCRs </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The T cell receptor, or TCR, is part of a complex signaling machinery, which includes the TCR a and &#223; chains that are responsible for antigen recognition, the co-receptor CD4+ or CD8+ and the CD3 signal transduction complex. TCRs recognize antigens presented on the cell surface as small peptides loaded on the patients&#8217; HLA molecules. Those peptides are derived from proteins after intracellular degradation. In contrast to CARs that recognize solely native membrane proteins, the repertoire of suitable TCR target antigens include TAAs and mutant neoantigens.  </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our TCR Discovery and Validation Platform </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have developed an integrated technology platform for the systematic identification of functional, fully human TCRs from single antigen-reactive T cells. This technology consists of a proprietary high-throughput approach for the fast retrieval, cloning and rapid validation of novel paired T cell receptor sequences. Our approach facilitates the isolation of tumor cell specific TCRs against multiple antigens and various HLA class I and II alleles. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our TCR discovery technology has the potential to unlock an array of patient- and tumor-specific TCRs suitable for clinical use. We believe this technology has potential utility for: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>therapeutic TCR products encompassing single TCRs to target a specific antigen; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>a therapeutic TCR warehouse encompassing multiple TCRs to target one or more tumor antigens; or </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>individualized T cell therapy involving on-demand identification and timely manufacturing of customized, engineered T cells with autologous TCRs against neoepitopes for adoptive transfer. </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">VIII. Our Antibodies Drug Class </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the past decades, monoclonal antibodies, or mAbs, have transformed from scientific tools to powerful human therapeutics. As one of the fastest growing classes of drugs, to date, dozens of mAbs have been approved to treat a variety of diseases including cancer, inflammation, autoimmune diseases and others. In addition, identified antigen-binding domains are also fundamental elements for the construction of novel therapeutic formats and formulations, such as CAR-T cells, bispecific therapeutics and targeted nanoparticles. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have developed and integrated multiple complementary antibody and antibody-mimetic protein technologies into our overall portfolio of treatment approaches. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">A. Our Next-generation Checkpoint Immunomodulators </font></p>
<p style="text-align:justify;Background-color:#BFBFBF;margin-top:6pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">At a glance: Our Next-generation Checkpoint Immunomodulators </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Concept:</font> Bispecific antibodies for dual immunomodulation, initially targeting 4-1BB, an immune checkpoint that is expressed on T cells and NK cells and can enhance immune cell proliferation and activation, in combination with simultaneous checkpoint inhibition. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Mechanism:</font> Conditional activation of 4-1BB checkpoint only upon simultaneous binding of PD-L1 or CD40 (in the case of our initial candidates), potentially avoiding toxicities seen in prior attempts at 4-1BB agonism by localizing 4-1BB activation to the tumor environment. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Development Approach:</font> 50:50 cost and profit share with Genmab, combining our and Genmab&#8217;s immunostimulatory antibodies and extensive immunology expertise with Genmab&#8217;s DuoBody<font style="font-size:8.5pt;">&#174;</font> bispecific antibody platform. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Lead Candidate:</font> GEN1046 (BNT311), our PD-L1x4-1BB product candidate for multiple solid tumors. </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following the success of immune checkpoint-blocking antibodies targeting CTLA-4, PD-1 or PD-L1 in cancer treatment, bispecific antibody approaches represent the next generation of emerging immunotherapies with the potential to further improve clinical efficacy. In addition to bispecific T cell engager formats, which redirect T-cell cytotoxicity to malignant cells, bispecific antibodies can be formatted as tumor-targeted immunomodulators and dual immunomodulators. Tumor-targeted immunomodulators direct potent immune costimulation to the tumor-infiltrating immune cells, whereas dual immunomodulators simultaneously address two immunomodulating targets, resulting in blockade of inhibitory targets, depletion of suppressive cells or activation of immune effector cells. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing, in collaboration with Genmab, bispecific antibodies that function as tumor-targeted and dual immunomodulators, applying Genmab&#8217;s proprietary DuoBody<font style="font-size:8.5pt;">&#174;</font> technology in combination with our joint target identification and product concept expertise. These next-generation checkpoint immunomodulators are thought to induce beneficial co-stimulation, promoting specific T cell activation, survival, proliferation and T cell effector functions. Our collaboration encompasses three potential classes of immunotherapeutic bispecific antibodies: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Tumor-targeted DuoBody<font style="font-size:8.5pt;">&#174;</font> molecules are bispecific antibodies targeting a tumor-specific antigen expressed by the malignant cell, and an immunomodulatory receptor expressed by tumor-infiltrating immune cells. This is expected to induce powerful activation of tumor-specific effector immune cells with reduced risk of immune-related adverse events. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Cis-activating DuoBody<font style="font-size:8.5pt;">&#174;</font> molecules are bispecific antibodies that bind two distinct immunomodulating targets presented on the same cell. These targets are specifically expressed on activated immune cells with the rationale to boost existing immune responses by additive or synergistic effects of dual immunomodulation. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Trans-activating DuoBody<font style="font-size:8.5pt;">&#174;</font> molecules are bispecific antibodies that bind two distinct immunomodulating targets expressed on two separate cell subsets. By simultaneously targeting, for example, effector immune cells and antigen-presenting cells, these compounds are thought to amplify the immune cell priming process and augment subsequent effector responses. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdc15tqwxkbk000022.jpg" title="" alt="" style="width:271px;height:289px;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Next-generation checkpoint immunomodulators.<font style="font-weight:normal;"> Our collaboration with Genmab potentially includes bispecific antibodies from three different classes: trans-activating, cis-activating and tumor-targeting antibodies. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">IX. Our Small Molecule Immunomodulator Drug Class </p>
<p style="text-align:justify;Background-color:#BFBFBF;margin-top:6pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">At a glance: Our Small Molecule Immunomodulators </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Concept:</font> Small molecule therapies, with a specific focus on TLRs, that can be used synergistically with other cancer therapeutics, including other product candidates in our portfolio. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Development Approach:</font> Worldwide rights; wholly owned. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;">Lead Candidate:</font> BNT411, our TLR7 agonist product candidate intended as a monotherapy or in combination with chemotherapy and/or checkpoint inhibitors. </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Small molecule cancer therapeutics can be used to regulate cancer growth, halt blood vessel formation in tumors, deliver toxins to cancer cells and mark cancer cells for destruction by the immune system. Unlike larger antibody-based cancer therapies, small molecule compounds are often developed for targets located within cells since they can enter the cells more easily as a result of their physical properties and low molecular weight. Small molecules also often have other intrinsic benefits including relative ease and cost of production compared to larger compounds, as well as more frequently having the potential for oral administration to patients. They can also often be used synergistically in combination with other therapeutics such as mRNA, checkpoint inhibitors, radiation therapy and chemotherapy. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our immunomodulatory small molecule product class focuses on a range of endosomal and intracellular targets that are known to stimulate the activity of a wide range of immune cells. We have a particular emphasis on TLRs, a family of pattern recognition receptors that function as primary sensors of the innate immune system to recognize pathogens. We believe TLRs represent a promising target class for cancer immunotherapy, particularly for inflammatory re-programming of the tumor microenvironment. In many cancers, tumors are protected by an anti-inflammatory environment, which reduces the ability of the immune system to attack the cancer cells. TLR7 agonists are able to initiate a direct cellular immune response, for example, by activating immature dendritic cells, cytotoxic T cells and NK cells, as well as stimulating the release of signal molecules such as cytokines and chemokines including IFN-a and IP-10, which can be directed against tumor cells. The activation of the innate and adaptive immune system and the release of cytokines and chemokines, for instance by our small molecule TLR7 agonist, results in the potent stimulation of antigen-specific T cells, B cells and innate immune cells such as NK cells and macrophages. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our initial focus is on small molecule product candidates that activate the innate and adaptive immune system via TLR7 and are designed to be used in combination with chemotherapeutics as well as checkpoint inhibitors. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">X. Sales, Marketing and Distribution</font></p>
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;text-indent:4.91%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our commercial organization focuses on supporting sales of our COVID-19 vaccine in Germany and certain markets where approved or authorized. Our sales and marketing organizations are responsible for promoting our products to health care providers and providing information to stakeholders, including governmental organizations, in the countries where we have authorization to sell the vaccine. Our commercial organization is also responsible for preparing and obtaining reimbursement from third-party payors, including governmental organizations, for our COVID-19 vaccine and will have the same responsibilities for our clinical-stage oncology product candidates, if approved. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our German commercial team is comprised of a small number of individuals to support commercialization of our COVID-19 vaccine. We focus our marketing and sales efforts in Germany on all physicians and health care professionals involved in the vaccination efforts against COVID-19. If and when we receive full marketing authorization for our COVID-19 vaccine, we will market our products through personal interactions with physicians and allied health care professionals. Our government and public affairs group advocates for policies that promote life sciences innovation and increase awareness of the diseases on which we are focusing, with state and federal legislatures, government agencies, public health officials and other policy-makers. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The commercialization models in the countries where we have the rights to commercialize are adjusted based on the respective commercialization agreements with our collaborators as well as the nature of the supply agreements with the governments for our COVID-19 vaccine.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">XI. Manufacturing </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are building a fully integrated biotechnology company, with operations spanning from research through clinical development, and manufacturing through sales and marketing. We operate four GMP-certified manufacturing facilities in Germany, where we manufacture mRNA therapeutics and engineered cell therapies for our own pipeline and for external customers, including a state-of-the art, multi-platform, GMP-certified manufacturing facility located in a life science industrial park in Marburg, Germany, which we acquired in October 2020 from Novartis AG to increase manufacturing capacity of our COVID-19 vaccine for commercial supply commencing in 2021. We also operate a fifth facility in Germany where we manufacture custom peptides to support our extensive immunomonitoring activities within our development programs. Our subsidiary BioNTech Innovative Manufacturing Services GmbH, or BioNTech IMFS, has been manufacturing GMP-certified cellular products since 1999. It was granted its first GMP license for manufacturing mRNA in 2011 and has been manufacturing individualized mRNA products since 2014. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have expanded our capability to produce and supply drug products to support clinical development of our, and our collaborators&#8217;, product candidates. To date, we have manufactured about 1000 drug substance batches in our manufacturing facilities. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our approach has been to proactively build capacity in anticipation of demand from internal research and development, as well as from our collaborators. We have done so by continuing to make significant investments in manufacturing infrastructure and increasingly expanding our capacity to manufacture mRNA, viral vectors, cellular products and peptides. We believe the development and optimization of our manufacturing processes in parallel to drug development is crucial to our success. We have also collaborated with Siemens to develop a process for a fully-automated, on-demand production of mRNA therapies. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our Manufacturing Operations </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">COVID-19 Vaccine.<font style="font-style:normal;"> Our recently acquired manufacturing site in Marburg was approved by the EMA for manufacturing of the COVID-19 drug product in March 2021. This approval makes it one of the largest mRNA manufacturing sites worldwide alongside two of our existing GMP facilities, which currently produce the COVID-19 vaccine candidates for clinical trials, and it will have an annual production capacity of up to one billion doses of our COVID-19 vaccine, once fully operational. We also expect that the first vaccines manufactured at the Marburg site to be delivered in the second half of April 2021. We will rely on a network of sub-contractors to provide drug substance, drug conjugate, drug product, and fill and finish services to enable production. While we have already signed orders for 1.4 billion doses of the vaccine for 2021 based on existing supply agreements with governments worldwide, and discussions for additional dose commitments are ongoing, our manufacturing capacity target is 2.5 billion doses in total by the end of 2021. Additionally, as of March 23, 2021 we have shipped 200 million doses of our COVID-19 vaccine globally. This estimate is based on the six BioNTech and Pfizer manufacturing sites producing the vaccine, the updated label permitting six doses per </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:normal;">vial </font><font style="font-style:normal;">and </font><font style="font-style:normal;">continuous process improvements and expansion at our current facilities. It is further contingent upon us contracting with more suppliers and external contract manufacturers to expand LNP and fill and finish capacity.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Marburg site contains approximately 100,000 square feet of laboratory and office space, including 50,000 square feet of GMP facilities and currently employs approximately 400 people. We plan to manufacture additional therapeutic and vaccine drug candidates at the plant, such as other mRNA vaccine, antibody, and cell and gene therapy product candidates to support the development of our product pipeline. The site is also fully equipped to hold cell culture labs and produce viral vectors, with further potential for long-term growth and expansion. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">mRNA<font style="font-style:normal;">. We believe scaling up manufacturing for mRNA can best be executed as part of a proprietary manufacturing approach, not as part of an outsourcing strategy. We believe this approach allows us to maintain control of our proprietary processes and gives us the flexibility we need for scheduling batch production for our drug substances to match our development plans as they evolve. Our mRNA manufacturing is currently conducted at our in-house BioNTech IMFS facility and our BioNTech East Wing facility, and will also be conducted at our Marburg facility. The East Wing facility is dedicated to iNeST and bulk mRNA manufacturing. Our mRNA manufacturing process involves standardized production of all mRNA constructs and minimal restrictions in construct length. We have the capacity to undertake sterile filtration and final filling in up to 1,200 vials of various sizes. Batch sizes range from a few milligrams for individualized applications (</font>i.e.<font style="font-style:normal;">, iNeST) to 10g for standard mRNA applications (</font>i.e.<font style="font-style:normal;">, FixVac, intratumoral immunotherapies and infectious diseases, </font>e.g.<font style="font-style:normal;">, COVID-19), with batch sizes of up to 10g currently possible. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have produced more than 500 batches of mRNA drug substance to support our studies. We currently have infrastructure capable of producing more than 100 batches of mRNA drug substance and formulated drug product per month with a turnaround time of about 30 to 40 days from sequence identification to released product. We believe we currently have the capacity to supply needs of our product candidates in clinical trials up to registration. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In recent years, we have successfully decreased the time required to deliver individualized immunotherapy to patients. In 2014, it took us over three months to manually manufacture and deliver individualized immunotherapies to patients. Since December 2017, with the implementation of semiautomatic GMP manufacturing in collaboration with Siemens, we have been consistently manufacturing and delivering individualized immunotherapies in under six weeks. This advancement represents significant progress toward our target commercial manufacturing turnaround time of less than 28 days. We believe this is achievable, and we plan to continue to develop additional process improvements, which we expect will further reduce our turnaround times as we progress through clinical development. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cell Therapy Products<font style="font-style:normal;">. We have end-to-end capabilities and over 20 years of experience in cell therapy manufacturing. Our manufacturing process for cellular products involves the isolation of primary human cells and subpopulations, including CD34+ and CD3+ cells. We engage in the culturing, expansion and genetic modification of primary human cells as well as mammalian cell lines. Our processes include vector production for transfection of cells with CARs, cell banking and cryopreservation. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have set up a broad range of quality control assays for the characterization of cell therapy products that allow us to certify the manufactured drug products in a short time. We are a leader in the production of gamma retroviral vectors. To date, we have produced more than 50 different cell therapy products. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Peptides.<font style="font-style:normal;"> Our custom peptide synthesis business has developed unique technologies to produce several million peptides during the past three years to support our growing clinical pipeline. These include fast small-scale manufacturing of peptides for target and epitope discovery as well as for neoepitope characterization and production of high content arrays. It is important to synthesize highly purified peptides in order to avoid false positives in immunomonitoring in our mRNA immunotherapy trials. We also use these peptides as starting material in our engineered cell therapies. We have developed know-how to produce highly complex and purified peptide pools that consist of overlapping peptides spanning entire antigens or neoepitopes. We plan to establish a new production facility, which will roughly double our current capacity. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our Manufacturing Facilities </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the recently acquired Marburg site, we operate four other manufacturing and packaging facilities in Germany. In these facilities, we manufacture and package individualized mRNA, bulk mRNA, retroviral vectors, cellular products and peptides. In Mainz, we are currently constructing another facility for iNeST manufacturing at a commercial scale, which is planned to start manufacturing in 2022 and will supply markets mainly in Europe and the United States. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">BioNTech IMFS</font><font style="font-style:normal;">. Our manufacturing operations for retroviral vectors, cell therapy products and mRNA are housed in our wholly owned subsidiary, BioNTech IMFS. Founded in 1997, BioNTech IMFS specializes in services for innovative therapeutic approaches. In 2009, BioNTech IMFS became our wholly owned subsidiary, giving us access to synergistic platforms and complementary expertise for development, testing and manufacturing services. BioNTech IMFS and its predecessors have had GMP-certified cell and gene therapy manufacturing capabilities since 1999, and obtained GMP manufacturing authorization for mRNA production in 2011. In 2017, BioNTech IMFS began automated manufacturing of the iNeST product candidate and entered into its first commercial supply contract for retroviral vectors. Located near Mainz, the BioNTech IMFS facility occupies over 30,000 square feet. Two hundred and twenty staff members are employed at this facility, with collective expertise in molecular biology, cell biology and virology. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">BioNTech iNeST Clinical Manufacturing (East Wing)<font style="font-style:normal;">. We dedicate our GMP-certified manufacturing facility at our headquarters in Mainz, Germany to the production of iNeST immunotherapies. In 2015, our wholly owned subsidiary, BioNTech RNA Pharmaceuticals GmbH, or BioNTech RNA, and Siemens announced a collaboration for developing an automated, paperless and digitalized production site for individualized mRNA. We obtained our GMP manufacturing authorization for iNeST production at our East Wing facility in June 2018 and released our first drug product there the following month.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This facility contains approximately 17,000 square feet of laboratory and office space, including 4,300 square feet of GMP facilities. About 200 staff members are employed at this facility and operate it seven days per week. In its first year of operation the facility manufactured and released more than 250 batches of mRNA and has, since inception, manufactured and released more than 450 batches of mRNA. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">BioNTech Clinical Manufacturing.<font style="font-style:normal;"> Our GMP-certified manufacturing facility in Kupferbergterrasse, Mainz, Germany is authorized to conduct secondary packing, labeling, storage and batch release of primary packed investigational medicinal products. This facility contains approximately 11,500 square feet of laboratory and office space, including 1,250 square feet of GMP facilities. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">JPT.<font style="font-style:normal;"> JPT, our peptide manufacturing facility, was established in 2004 and became a wholly owned subsidiary of BioNTech in 2008. JPT is located in Berlin, Germany and occupies over 16,000 square feet of clean rooms, laboratory and office space. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Certifications </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Diagnostics has a quality management system that is certified according to ISO 13485:2016 and JPT maintains a ISO 9001:2015 certified Quality Management System to allow production of European CE marked companion diagnostics. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Quality Assurance </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have implemented and maintain several Quality Assurance systems. BioNTech IMFS, BioNTech Clinical Manufacturing and BioNTech iNeST Clinical Manufacturing have implemented GMP-certified quality assurance systems. BioNTech Diagnostics has a quality management system that is certified according to ISO 13485:2016 and JPT maintains a ISO 9001:2015 certified Quality Management System. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">XII. Third-Party Collaborations </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have forged productive collaborations with pharmaceutical companies and academic research institutions with area expertise and resources in an effort to advance and accelerate our discovery and development programs in oncology, and also to leverage our drug classes into additional disease indications while minimizing our incremental costs. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our collaborations include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Pfizer for our COVID-19 and influenza vaccine programs, which leverage technology from our infectious disease mRNA-based platform;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Fosun Pharma for our COVID-19 vaccine program;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Genentech for our iNeST platform in our mRNA drug class; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Sanofi for our intratumoral therapy platform in our mRNA drug class; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Genmab for our next-generation checkpoint immunomodulator platform in our antibodies drug class; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Genevant for our rare disease protein replacement therapy platform in our mRNA drug class. </p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We either wholly own or retain significant rights to all of our clinical stage programs, either in the form of a global share of profit and co-commercialization rights with our collaborators in certain markets or significant royalties and milestones. We plan to continue to identify potential collaborators who can contribute meaningful resources and insights to our programs and allow us to more rapidly expand our impact to broader patient populations. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pfizer-COVID-19 Collaboration </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 9, 2020, effective as of March 17, 2020, we entered into a Collaboration Agreement with Pfizer for the research and development of immunogenic compositions comprising RNA encoding a SARS-CoV-2 polypeptide or fragment thereof for prophylaxis against SARS-CoV-2 in humans, which we refer to as the Pfizer Corona Field. On January 29, 2021, effective as of March 17, 2020, we entered into an amended and restated Collaboration Agreement with Pfizer for the research, development and commercialization of immunogenic compositions comprising RNA in the Pfizer Corona Field. which we refer to as the Pfizer Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and Pfizer agreed to collaborate on research and development in the Pfizer Corona Field worldwide (excluding the Fosun Territory) which we refer to as the Pfizer Territory. The details of such activities are set forth in a research and development plan that is governed by a joint steering committee. Each party bears its own personnel and capital expenditures costs, but the parties will share the costs of all other agreed development activities (including the costs of manufacturing material for use in clinical trials) evenly. Each party will, in good faith, seek funding from government funds, non-governmental organizations and other third-party organizations to support their research and development activities. Under the Pfizer Agreement, Pfizer will lead clinical development of and seek regulatory approval for any candidates or products in the United States and we will lead clinical development of and seek regulatory approval for any candidates or products in the European Union, and we will agree on a strategy for all other countries. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech can solely commercialize the vaccine in Germany and Turkey, as well as specified developing countries (collectively referred to as the BioNTech Territory) for so long as we or a third-party funding organization is conducting vaccine commercialization in such countries, and subject to any future agreement with the third-party funding organization. We have the option to opt-out of commercializing the vaccine in Germany and/or Turkey, whereupon such countries will become part of the Pfizer Territory. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer has the right to commercialize any approved vaccine (such as our COVID-19 vaccine) in the rest of the Pfizer Territory. On a country-by-country basis in relation to the United Arab Emirates and certain countries of southeast Asia, if we obtain funding from a third-party government, non-governmental organization or other organization that obligates us to commercialize an approved vaccine in such country, we are obligated to request from Pfizer in writing a decision as to whether Pfizer wishes to commercialize such vaccine in such country in accordance with the requirements agreed with the third-party funder. If Pfizer elects not to commercialize the vaccine in such country, then such country shall become a part of the BioNTech Territory. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our Collaboration Agreement with Fosun expires or is otherwise terminated for any reason, as between us and any international pharmaceutical group headquartered outside of China, we granted Pfizer a right of first negotiation to expand the Pfizer Territory to include the Fosun Territory. See &#8220;Fosun-COVID-19 Collaboration&#8221; below for more information on the Fosun Agreement. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and Pfizer will share responsibilities for manufacturing and supplying the approved vaccine. If there is insufficient supply to satisfy the entire demand for a vaccine in the Pfizer Territory, we and Pfizer have agreed to determine by mutual consent the allocation of supplies on a fair and equitable basis, subject also to any applicable law, export controls, any government supply obligations, or supply obligations included in any agreement reached with a third-party funding organization. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Pfizer Agreement, we granted Pfizer an exclusive, sublicensable license in the Pfizer Territory under certain of our intellectual property, including our patents and know-how, relating to uridine RNA, modified RNA and replicons in the Pfizer Corona Field as well as certain intellectual property in-licensed by us from third parties, to use, research, develop, manufacture, commercialize and otherwise exploit candidates and products selected under the Pfizer Agreement. We undertake to maintain in full effect all intellectual property licenses held by us at the time we entered into the Pfizer Agreement and not to modify or amend any such license in a manner that would adversely affect any of the rights </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">granted to Pfizer under the Pfizer Agreement. We are obligated to notify Pfizer of any breach of our current licenses and may be obligated to take steps to maintain Pfizer&#8217;s access to any intellectual property licensed under such licenses. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the term of the Pfizer Agreement and a certain period thereafter, we and Pfizer have committed not to research, develop, manufacture, commercialize or otherwise exploit immunogenic compositions comprising RNA in the Pfizer Corona Field, or exploit vaccine candidates or products developed under the agreement for any use, other than pursuant to the Pfizer Agreement, provided, however, that Pfizer shall have the right to work as a contract manufacturer for a third party and Pfizer shall not be precluded from acquiring a third party, or being acquired by a third party, that at the time of acquisition is active in the development or commercialization of an immunogenic composition comprising mRNA in the Pfizer Corona Field. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 9, 2020, Pfizer also subscribed for $113 million of our ordinary shares under a separate investment agreement. In addition, under the Pfizer Agreement, Pfizer made an upfront payment of $72 million and agreed to make potential payments of up to $563 million upon the achievement of specified regulatory and commercial milestones. We and Pfizer agreed to share development costs equally. We and Pfizer will share the cost of and profits from commercializing a vaccine evenly. The Pfizer Agreement continues for so long as either at least a vaccine is being developed for use in the Pfizer Territory or a vaccine is being commercialized anywhere in the Pfizer Territory. In addition to termination rights granted to each party in the case of the other party&#8217;s uncured material breach, Pfizer may terminate the agreement (i) upon our insolvency or (ii) on a country-by-country basis or in its entirety for convenience upon one (1) year&#8217;s prior written notice provided that any such termination shall not become effective less than two (2) years from the first commercial sale of an approved vaccine. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fosun-COVID-19 Collaboration </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 13, 2020, we entered into a Development and License Agreement with Shanghai Fosun Pharmaceutical Industrial Development, Co., Ltd, or Fosun Pharma, for the development and commercialization in mainland China, Hong Kong SAR, Macau Special Administrative Regions and in Taiwan, or the Fosun Territory, of immunogenic compositions generated by BioNTech and comprising uridine RNA, modified RNA and/or replicon technology for prophylaxis against SARS-CoV-2 in humans. We refer to this agreement as the Fosun Agreement. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The details of the development activities to be undertaken by Fosun Pharma are to be set forth in a development plan that is overseen by a joint steering committee. Fosun Pharma&#8217;s development activities are to be undertaken at its own cost and expense. Fosun Pharma has the sole responsibility to prepare, obtain and maintain regulatory approvals for the vaccine candidates in the Fosun Territory. We agreed to give Fosun Pharma reasonable assistance with the regulatory aspects of these activities. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fosun Pharma has the sole responsibility, authority and control of the commercialization of a vaccine candidate in the Fosun Territory, but must use commercially reasonable efforts to do so in accordance with an agreed commercialization plan, including by launching a vaccine product in the Fosun Territory within three months after receiving marketing approval for it, provided sufficient quantities of the vaccine have been delivered. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We retain the sole right to manufacture (or have manufactured) and supply any vaccine candidates and products for development purposes and commercial sale in the Fosun Territory. We agreed to manufacture and supply all quantities of vaccine from a GMP-certified RNA manufacturing facility. As compensation for supply of the vaccine Fosun Pharma will reimburse us our manufacturing costs plus an administrative fee that is between 10 and 19 percent. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Fosun Agreement, we granted Fosun Pharma an exclusive license under certain of our owned or in-licensed intellectual property, including our patents relating to replicons, uridine RNA and modified RNA and other mRNA technology or a vaccine to use, develop, commercialize and otherwise exploit the vaccine candidates in the Fosun Territory. In the event of any failure of the development of a vaccine, we agreed to grant Fosun Pharma a right of first negotiation on a separate competent vaccine for the prophylaxis of COVID-19 in the Fosun Territory. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration of the rights granted to Fosun Pharma under the Fosun Agreement, Fosun Pharma subscribed for $50 million of our ordinary shares under a separate investment agreement. In addition, under the Fosun Agreement, Fosun Pharma made an upfront payment of $1 million and agreed to potential payments of up to $14 million upon the achievement of specified development and regulatory milestones and up to $70 million upon the achievement of specified sales milestones. Fosun Pharma further agreed to pay us a royalty rate that is between 30 and 39 percent of its profits on net sales of a vaccine product, if approved, for a period of 15 years from launch of that vaccine in the Fosun Territory. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Fosun Agreement ends upon expiration of the royalty term. Fosun Pharma may elect to continue to pay royalties and extend the agreement and its rights thereunder. In addition to termination rights granted to each party in the case of the other party&#8217;s uncured material breach or insolvency, Fosun Pharma may terminate the agreement, in whole, for convenience and with or without reason at any time upon 180 days&#8217; prior written notice. If the agreement is terminated by Fosun Pharma for cause, the licenses to Fosun Pharma survive, we will manufacture and deliver the vaccine candidate or product for one year and we will grant a non-exclusive license to a reasonably acceptable contract manufacturing organization for manufacturing of the vaccine candidate or product thereafter for development and commercialization by Fosun Pharma in the Fosun Territory. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the term of the Fosun Agreement, we have committed not to, and not to license the licensed intellectual property to any third party to, develop or commercialize the same vaccine candidate or vaccine in the Fosun Territory. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Genentech-iNeST Collaboration </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:2.07%;text-indent:2.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Collaboration Agreement </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 20, 2016, we and BioNTech RNA entered into a Collaboration Agreement with Genentech and F. Hoffman-La Roche Ltd, which, as amended on June 1, 2018 and December 6, 2019, we refer to as the Genentech Collaboration Agreement, to jointly research, develop, manufacture and commercialize certain pharmaceutical products that comprise neoepitope RNAs, or the Genentech Collaboration Products, which include our iNeST development candidates, for any use worldwide. Under the Genentech Collaboration Agreement, we and Genentech agreed to perform joint research under a research plan to further improve our technology platform for the manufacturing of Genentech Collaboration Products. Under the terms of the Genentech Collaboration Agreement, Genentech paid us $310 million in upfront and near-term milestone payments. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and Genentech must use commercially reasonable efforts to jointly develop one or more Genentech Collaboration Products in accordance with an agreed global development plan, with the costs of such development to be shared equally. We will continue certain clinical studies that were initiated prior to the execution of the Genentech Collaboration Agreement at our sole expense, and any future material changes in the operation of such clinical studies require Genentech&#8217;s approval. Genentech may access and use any data generated in these ongoing clinical studies. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the clinical studies included in the global development plan, we may propose certain additional clinical studies for indications not included in the global development plan, and if the joint development committee formed by the parties does not elect to include the proposed studies in the global development plan, then we may conduct the study at our sole expense under certain conditions, and subject to certain restrictions. Genentech has the option to select any candidate in such studies for potential further joint development and/or commercialization by Genentech as a Genentech Collaboration Product. In the case that Genentech wishes to pursue the clinical development of a Genentech Collaboration Product in an indication that we are not interested in pursuing, then under certain conditions, we may opt out of the co-funding of such development and Genentech may continue do so at its own costs, except that we are obligated to repay Genentech&#8217;s development costs in the event that such product subsequently receives regulatory approval. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Genentech has the sole right to commercialize the Genentech Collaboration Products on a worldwide basis, with all profits and losses from such commercialization to be split equally with us. If we exercise our right to opt out of sharing equally in future development costs for any Genentech Collaboration Products, then we will no longer split all such profits and losses for such Genentech Collaboration Products equally with Genentech and will instead receive a royalty on annual worldwide net sales of such Genentech Collaboration Products that are covered by a valid claim included in certain of our patents and certain joint patents that arise out of the collaboration. Furthermore, for certain Genentech Collaboration Products for which we share co-promotion rights with Genentech, we have the option to assume a percentage to be determined of the total sales force in the United States and certain other countries, including Germany and other major European markets. In addition, under certain regulatory and other circumstances, we have the right to independently commercialize Genentech Collaboration Products in indications that the joint development committee declines to pursue and that Genentech does not subsequently elect to commercialize, provided that we market such Genentech Collaboration Products under a separate brand and trademark that is approved by the joint commercialization committee established by the parties as not confusingly similar to the Genentech Collaboration Products being commercialized by Genentech. Our ability to research, develop, co-promote and/or independently commercialize Genentech Collaboration Products may be terminated or limited in the event we undergo a change of control. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We granted to Genentech an exclusive license under certain of our intellectual property, and our interest in any jointly-owned intellectual property developed under this agreement, to research, develop, make, sell and import any </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pharmaceutical products that comprise neoepitope RNA. Genentech granted to us an exclusive, non-transferable, sublicensable licenses under certain Genentech intellectual property, our intellectual property exclusively licensed to Genentech, and their interest in any jointly-owned intellectual property developed under this agreement for the performance of our ongoing clinical studies and the exercise of our rights and obligations under the Genentech Collaboration Agreement. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until the first marketing approval for a Genentech Collaboration Product, we have granted Genentech the first right to negotiate an exclusive license to develop, manufacture and commercialize combination therapies involving pharmaceutical products based on neoepitope RNA and pharmaceutical products based on non-neoepitope RNA for the treatment of cancer in humans. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Genentech Collaboration Agreement will remain in effect so as long as Genentech Collaboration Products are in development or commercialization, or until the date of the expiration of the last royalty term if BioNTech has exercised its option to opt-out of joint development of Genentech Collaboration Products. If the agreement expires, the licenses granted to Genentech become fully-paid up, royalty-free and irrevocable. Genentech may terminate the Collaboration Agreement if we fail to achieve certain milestone targets or at any time for convenience with or without reason upon 60 days&#8217; prior written notice. In the event of any such termination, all rights to the development and commercialization of Genentech Collaboration Products developed under the collaboration would revert to us and Genentech would grant us licenses under its intellectual property to further develop and commercialize Genentech Collaboration Products. We would be required to pay certain royalties to Genentech for such license(s). In addition, either party may terminate the agreement upon the other party&#8217;s uncured material breach or insolvency. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Manufacturing Development and Supply Agreement </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with the Genentech Collaboration Agreement, we and BioNTech RNA entered into a Manufacturing Development and Supply Agreement with Genentech and F. Hoffman-La Roche Ltd, or the Genentech Manufacturing Agreement, which governs the manufacturing, related manufacturing development activities and supply of Genentech Collaboration Products. Pursuant to the Genentech Manufacturing Agreement, we are responsible for clinical manufacturing and supply, for developing and implementing manufacturing processes (including pursuant to specified target turnaround times), and for constructing, commissioning, qualifying and obtaining permits for the clinical facilities. We are permitted to subcontract certain steps in the clinical manufacturing process to our affiliate, BioNTech IMFS. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we are responsible for developing the commercial manufacturing process, which requires more stringent turnaround times than the clinical manufacturing process. Genentech will generally be responsible for conducting commercial manufacturing. We are obligated to use commercially reasonable efforts to achieve certain predetermined clinical manufacturing capacity commitments. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Genentech Manufacturing Agreement, we and Genentech will jointly develop a manufacturing network plan detailing the location, capacity, scale-out, associated timing and other appropriate details of the commercial manufacturing facilities. We may participate in commercial manufacturing through our right to include as part of the commercial manufacturing network one of our own facilities in the European Union or the United States and one of our own facilities in another region to be agreed upon with Genentech (provided that in each region our facility is not the first facility to be included in the commercial manufacturing network). </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sanofi-Intratumoral Therapy Collaboration </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 2, 2015, BioNTech RNA entered into a Collaboration and License Agreement with Sanofi, which we refer to as the Sanofi Agreement. Pursuant to the Sanofi Agreement, we and Sanofi will collaborate on intratumorally administered mRNA-based therapeutics for the treatment of solid tumors in humans. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Sanofi Agreement contemplates: (i) research, (ii) development and commercialization and (iii) possible co-development and co-commercialization activities with us. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the research phase, the parties seek to identify, characterize and validate up to five &#8220;mixtures&#8221; of two or more mRNAs encoding different proteins administered together in the same solution. Sanofi at its sole discretion may select up to five mixtures created under the research plan for further development and commercialization, which we refer to as Sanofi Collaboration Products. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After selection of a Sanofi Collaboration Product, Sanofi would be responsible for all development and commercialization activities involving that product. We have the option, by payment of an exercise fee, to co-develop and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">co-commercialize up to two Sanofi Collaboration Products primarily in the United States and in some European countries, including the United Kingdom, France, Germany, Italy and Spain. If we exercise such an option, the costs for co-development and co-commercialization of the chosen Sanofi Collaboration Products would be allocated between the parties. In turn, Sanofi has an option to co-develop and co-commercialize certain mixtures developed by us or with third parties that contain a certain amount of the mRNAs of a Sanofi Collaboration Product. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2018, Sanofi selected the first Sanofi Collaboration Product for further development and commercialization and we exercised our option for co-development and co-commercialization of the Sanofi Collaboration Product. Effective as of March 2018, the parties entered into a separate development agreement for the co-development of this Sanofi Collaboration Product. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Sanofi Agreement, Sanofi has paid upfront and near-term milestone payments of approximately &#8364;60 million. We are entitled to receive up to approximately &#8364;260 million per product upon achievement of certain development, regulatory and commercial milestones. If commercialized successfully, we would also be eligible for mid-single digit to very low double-digit tiered royalties on net sales on a country-by-country and product-by-product basis until the later of (i) expiration of the last relevant patent covering such product in such country, (ii) 10 years following first commercial sale of such product in such country, (iii) expiration of regulatory data exclusivity for such product in such country and (iv) the market entry of a generic biological product with a certain market share in relation to such product in such country. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Sanofi Agreement will remain effective until the last-to-expire royalty term (or, when a co-development option has been exercised, the completion of all co-development and co-commercialization activities). The parties may terminate the Sanofi Agreement in its entirety or terminate certain co-development activities for convenience, with or without cause. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Sanofi Agreement provides that we may not engage in certain research and development activities relating to the intratumoral injection of mRNAs. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.07%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Genmab-Next-generation Immunomodulator Collaboration </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 19, 2015, we entered into a License and Collaboration Agreement with Genmab (together with all amendments and side letters thereto, collectively referred to as the Genmab Agreement) to jointly research, develop and commercialize polypeptide-based bispecific antibodies against certain target combinations for the treatment of cancer in humans worldwide, or the Genmab Agreement Field, using certain Genmab technology. In connection with our entry into the Genmab Agreement, Genmab paid us an upfront fee of $10 million. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Genmab Agreement, we and Genmab must use commercially reasonable efforts to research and develop clinical candidates, including our next-generation checkpoint immunomodulators, with costs split equally during the research and evaluation phase. Our joint activities in this phase are governed by a research plan, which is subject to annual review and updates, and which specifies the clinical candidates to be developed. This research and evaluation phase is currently set to expire on May 19, 2022, but has in the past been extended. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the research and evaluation phase, we and Genmab may propose clinical candidates for consideration by a joint research committee for further preclinical and clinical development. If a party, through the joint research committee, indicates that it is not interested in further development and commercialization of any clinical candidate, the other party may continue development and commercialization of such products on a unilateral basis, at its sole expense. The party that continues such development and commercialization is obligated to pay the other party certain development, regulatory and sales milestone payments and royalties on net sales of the applicable Unilateral Products. During either party&#8217;s development and commercialization of a Unilateral Product, the other party must not develop or commercialize any bispecific antibody targeting the same target combination of such Genmab Unilateral Product if such bispecific antibody was generated as part of the collaboration under this agreement. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and Genmab must use commercially reasonable efforts to develop candidates selected by the joint research committee, or the Genmab Collaboration Products, through preclinical and clinical development. In addition, the joint research committee may select an additional candidate, or the Genmab Back-up Candidate, as a back-up for each Genmab Collaboration Product and may decide at any time to replace the Genmab Collaboration Product with its Genmab Back-up Candidate. The preclinical and clinical development of the Genmab Collaboration Products would be performed pursuant to a development plan to be agreed upon by us and Genmab, with costs to be split equally. The joint steering committee may designate a third party as a manufacturer of a Genmab Collaboration Product or of any of its components. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and Genmab must use commercially reasonable efforts to jointly commercialize all Genmab Collaboration Products and share equally all expenses and profits arising from such commercialization. We and Genmab, on a product-by-product basis and at least 12 months prior to the anticipated start of a pivotal clinical trial for a Genmab Collaboration Product, will jointly designate between the two of us a lead party responsible for establishing the distribution and marketing operations in each geographical region. Each party would be entitled to equally co-promote the products pursuant to a separately negotiated global commercialization agreement that the parties agree to negotiate. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless otherwise agreed by the joint steering committee established under the agreement, Genmab is responsible for all regulatory actions and shall own all regulatory approvals obtained for the Genmab Collaboration Products. Genmab is obligated to provides regular updates to us on regulatory activities. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each party grants to the other party a worldwide, co-exclusive, sublicensable, royalty-free license under certain of such first party&#8217;s intellectual property, including certain patents and know-how, to perform the research under this agreement and to research, develop, make, import, use and sell Genmab Collaboration Products in the Genmab Agreement Field pursuant to the terms of the Genmab Agreement. These licenses shall continue on a country-by-country and product-by-product basis for as long as development or commercialization activities are contemplated under the Genmab Agreement. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the research and evaluation phase prior to the selection of a Genmab Collaboration Product, neither we nor Genmab may engage in any research and development activity in the Genmab Agreement Field relating to the development of any bispecific antibody which targets any combination that is the subject of our joint research plan. During the preclinical and clinical development phase for any Genmab Collaboration Product, engagement in research and development activities in the Genmab Agreement Field unilaterally by a party relating to a Genmab Collaboration Product or its Genmab Back-up Candidate or any bispecific antibody which targets the same target combination for which such Genmab Collaboration Product or Genmab Back-up Candidate has been developed would require the other party&#8217;s prior written consent. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each party has the right to discontinue its participation in the further development and commercialization of a Genmab Collaboration Product at two points: (i) when an IND submission package has been agreed upon by the parties and (ii) when the draft clinical trial report from the first Phase 1/2 clinical trial becomes available. The party that wishes to opt out of such further development and commercialization may choose to permit the other party to continue the development and commercialization of the Genmab Collaboration Product or divest its interest in such Genmab Collaboration Product. If the opt-out party permits continued development and commercialization, the other party may elect to pursue development and commercialization of such Genmab Collaboration Product alone as a Unilateral Product, at its sole cost and subject to pre-defined milestone and royalty payments and certain additional pre-defined terms. If the other party wishes to not pursue such continued development and commercialization on such pre-defined payment and additional terms, then the parties will jointly divest their interest in such Genmab Collaboration Product to a third party, and if such divestiture fails, the parties will cease all development and commercialization of such Genmab Collaboration Product. Alternatively, if the opt-out party seeks to unilaterally divest its interest in the applicable Genmab Collaboration Product, the other party has the right of first exclusive negotiation to obtain exclusive, worldwide rights to develop and commercialize such Genmab Collaboration Product. If such unilateral divestiture fails after the other party&#8217;s exercise of its right of first exclusive negotiation, the opt-out party may either continue development and commercialization of such Genmab Collaboration Product or offer the other party to continue such development and commercialization on such pre-defined payment and additional terms as set forth above. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Genmab Agreement will remain in effect until the later of (i) the expiration of the last-to-expire royalty term for any Unilateral Product and (ii) the time when no Genmab Collaboration Products are being developed or commercialized under this agreement. Either party may terminate the agreement in its entirety or on a product-by-product basis with immediate effect upon the other party&#8217;s uncured material breach or insolvency. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pfizer-Influenza Collaboration </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 20, 2018, we and BioNTech RNA entered into a Research Collaboration and License Agreement with Pfizer, or the Pfizer Influenza Agreement, for the research, development and Pfizer&#8217;s commercialization of immunogenic compositions comprising modified RNA and/or replicon technology for prophylaxis against influenza in humans, which we refer to as the Pfizer Influenza Agreement Field. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and Pfizer agreed to collaborate on the research in the Pfizer Influenza Agreement Field for an initial period of three years. The details of such research were set forth in a research plan that is governed by a joint steering committee, with Pfizer holding the final decision-making right. Each party will bear its own costs under the research plan. The research term will be extended automatically by a reasonable amount of time if the activities or deliverables under the research plan are delayed due to our material breach of our research obligations under the research plan. In addition, Pfizer may unilaterally extend the research term by up to a year by making an additional payment to us. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the research term expires, Pfizer has the sole responsibility, authority and control of the development, manufacturing and commercialization of all candidates and products. Pfizer undertakes to use commercially reasonable efforts to seek regulatory approval for one product in the United States and in two countries out of France, Germany, Italy, Spain, the United Kingdom and Japan, and to commercialize such product in such countries where such product has received regulatory approval. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Pfizer Influenza Agreement, we grant to Pfizer an exclusive, worldwide, sublicensable license under certain of our intellectual property, including our patents and know-how, relating to replicons and modified RNA in the Pfizer Influenza Agreement Field as well as certain intellectual property in-licensed by us from third parties, to use, research, develop, manufacture, commercialize and otherwise exploit candidates and products selected under the Pfizer Influenza Agreement. We also grant to Pfizer a non-exclusive, royalty-free, sublicensable license under all intellectual property controlled by us or our affiliates to use, develop, manufacture, commercialize and otherwise exploit candidates and products selected under the Pfizer Influenza Agreement in the Pfizer Influenza Agreement Field. We undertake to maintain in full effect all intellectual property licenses held by us at the time we entered into the agreement and to not modify or amend any such license in a manner that would adversely affect any of the rights granted to Pfizer under the Pfizer Influenza Agreement. We are obligated to notify Pfizer of any breach of our current licenses and may be obligated to take steps to maintain Pfizer&#8217;s access to any intellectual property licensed under such licenses. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also granted Pfizer a right of first negotiation to acquire an exclusive worldwide license under certain intellectual property controlled by us for Pfizer to develop, manufacture and commercialize immunogenic products comprising RNA for prophylaxis against respiratory syncytial virus or human cytomegalovirus. The right of first negotiation may be exercised until the end of the research term. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration of the rights granted to Pfizer under the agreement, Pfizer subscribed to shares in BioNTech AG under a separate investment agreement. In addition, under the Pfizer Influenza Agreement, Pfizer made an upfront payment of $50 million and agreed to potential payments of up to $325 million upon the achievement of specified development, regulatory and commercial milestones. Pfizer further agreed to a mid-single digit to very low double-digit tiered royalty on net sales if a product is commercialized. Royalties are subject to stacking provisions. The obligation of Pfizer to pay royalties ends, on a country-by-country and a product-by-product, basis upon the later of (i) the expiration of the last valid licensed patent right covering such product category in such country, (ii) 10 years after the first commercial sale of a product of such product category in such country and (iii) the lapse of regulatory data exclusivity for the first product in such product category in such country. There are only two product categories: one for modified RNA and a second for replicon products. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the term of the Pfizer Influenza Agreement, we have committed not to research, develop, manufacture, commercialize or otherwise exploit immunogenic compositions compromising RNA in the Pfizer Influenza Agreement Field other than pursuant to the Pfizer Influenza Agreement. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Pfizer Influenza Agreement ends on a country-by-country basis upon expiration of the last royalty term for any product in that country. Thereafter, the licenses granted to Pfizer with respect to such product in such country will convert into a perpetual, exclusive, fully paid-up and royalty-free license. In addition to termination rights granted to each party in the case of the other party&#8217;s uncured material breach, Pfizer may terminate the agreement, in whole or in part, for convenience and with or without reason at any time upon 60 days&#8217; prior written notice. In addition, Pfizer is entitled to terminate the agreement and initiate a technology transfer of certain intellectual property if one of its key competitors acquires control over us. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Genevant-Rare Disease Protein Replacement Therapy Strategic Collaboration </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2018, our wholly owned subsidiary BioNTech RNA Pharmaceuticals GmbH, or BioNTech RNA, entered into a license and co-development agreement with Genevant Sciences GmbH, or Genevant for the joint development of certain </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pharmaceutical products and the licensing of specified rights to Genevant&#8217;s lipid nanoparticle delivery technology to BioNTech RNA. We refer to this agreement as the Genevant Agreement. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Genevant Agreement, BioNTech RNA and Genevant have agreed to collaborate to develop pharmaceutical products that contain any of five mRNA payloads created by BioNTech RNA encapsulated within a Genevant (or, if the parties agree, a third party) LNP, or the Co-Development Products, for the treatment, prevention and diagnosis of liver diseases, excluding any oncology diseases, or the Co-Development Field. Each party granted to the other party a worldwide, co-exclusive license or sublicense, with limited sublicensing rights, under certain of its patents and know-how to research, develop, make, have made, use, distribute, sell, offer for sale, have sold, import, export and otherwise commercialize the Co-Development Products in the Co-Development Field as provided in development and commercialization plans approved by a joint steering committee and subject to certain restrictions under the Genevant Agreement. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, BioNTech RNA obtained an exclusive, worldwide, royalty-bearing license or sublicense under Genevant&#8217;s LNP delivery technology to research, develop, make, have made, use, distribute, sell, offer for sale, have sold, import, export and otherwise commercialize pharmaceutical products containing BioNTech mRNA payloads encapsulated within an LNP, or the BioNTech Products, for the treatment, prevention and diagnosis of illnesses in the field of oncology, or the BioNTech Field. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each party retained certain rights to practice its intellectual property for all purposes outside of the Co-Development Field or in the Co-Development Field with any product that is not a Co-Development Product, subject to the next sentence as to BioNTech. During the term of the Genevant Agreement for each Co-Development Product or BioNTech Product, BioNTech RNA has agreed not to conduct or enable any clinical development, promotion or commercialization of any product involving the use of LNP with the BioNTech mRNA payload contained in the Co-Development Product or BioNTech Product other than in collaboration with Genevant pursuant to the Genevant Agreement. Genevant has also retained rights to practice its intellectual property for all purposes outside the BioNTech Field, or in the BioNTech Field with any product that is not a BioNTech Product. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The parties are jointly responsible for the development of, and must use commercially reasonable efforts to develop, the Co-Development Products in accordance with a development plan approved by a joint steering committee. Genevant is responsible for the preclinical, clinical and commercial manufacture of the Co-Development Products, and BioNTech RNA is obligated to supply the mRNA payloads for use in manufactured Co-Development Products. The parties share equally all costs for the development of Co-Development Products as well as any profits and losses. For each Co-Development Product, one or the other party will take the lead responsibility for commercialization of the Co-Development Product in the Co-Development Field. Each party must use commercially reasonable efforts to perform the commercialization activities allocated to it in a commercialization plan approved by a joint steering committee. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each party may opt-out of the co-development of any Co-Development Product with 90 days&#8217; prior notice at any time after the filing of an IND or equivalent for the Co-Development Product. In such event, the other party may continue the development of the Co-Development Product on its own, at its sole cost and expense apart from specified obligations to support manufacturing and any ongoing clinical studies, but has to pay to the party that opted out pre-defined regulatory and sales milestones for the Co-Development Product of up to a low nine figure U.S. dollar amount in the aggregate and tiered low to mid-single digit percentage royalties on aggregate net sales of the Co-Development Product. In the event that a party opts out of the co-development of any Co-Development Product, the license granted by the party opting out to the other party shall become exclusive licenses, even as to the opting out party. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech RNA is solely responsible for the development and commercialization of the BioNTech Products, including the performance of preclinical and clinical trials, all regulatory activities, and marketing and sales, and bears all related costs. BioNTech RNA must use commercially reasonable efforts to develop and obtain regulatory approval for BioNTech Products in the BioNTech Field in the United States, Germany, United Kingdom, France, Spain and Italy. Genevant is responsible for the manufacturing of the BioNTech Products, and the details of such manufacturing are to be agreed in a separate manufacturing and supply agreement. BioNTech RNA is obligated to pay regulatory and sales milestone payments on each BioNTech Product, and royalties based on aggregate net sales of all BioNTech Products, to Genevant. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Genevant Agreement continues until later of (i) the expiration of the last-to-expire royalty term for any BioNTech Product worldwide and (ii) the date on which all Co-Development Products cease being developed or commercialized. BioNTech RNA may terminate the agreement for convenience with respect to one or more BioNTech </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Products at any time with 90 or 180 days&#8217; prior notice, depending on whether regulatory approval has been granted. The Genevant Agreement grants each party termination rights: if the other party challenges the validity, enforceability or scope of any patents licensed to it under the Genevant Agreement; for uncured material breaches of the other party; for the other party&#8217;s insolvency; or if the other party undergoes a change of control through which it is controlled by a competitor, if specified by the parties at the time of the Genevant Agreement, before the earlier of July 4, 2021 or when the other party undergoes an initial public offering. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under certain scenarios, if BioNTech RNA terminates the Genevant Agreement with respect to a particular BioNTech Product, before granting a license to a third party for the BioNTech mRNA payload included in the BioNTech Product, Genevant has the right of negotiation with BioNTech. Under certain scenarios, if Genevant terminates the Genevant Agreement, Genevant keeps all licenses and have certain rights, but not the obligation, to continue the development and commercialization of Co-Development Products, and BioNTech RNA has certain obligations to provide assistance, documentation, and certain know-how and inventions to enable Genevant&#8217;s continued development and commercialization of Co-Development Products. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:4.91%;text-indent:3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">XIII.<font style="margin-left:14pt;">Government Regulation </font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government authorities in the United States, at the federal, state and local levels, and in the European Union and other countries and jurisdictions, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, record-keeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting and import and export of pharmaceutical products, including biological products. In addition, some jurisdictions regulate the pricing of pharmaceutical products. The processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other requirements of regulatory authorities, require the expenditure of substantial time and financial resources. <font style="font-size:1pt;">&#160;</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Regulation and Procedures Governing Approval of Drug and Biological Products in the United States </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or the FDCA, and its implementing regulations and biologics under the FDCA, the Public Health Service Act, or the PHSA, and their implementing regulations. Both drugs and biologics are subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state and local statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or following approval may subject a sponsor to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, license revocation, clinical hold, untitled or warning letters, voluntary or mandatory product recalls, market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A sponsor seeking approval to market and distribute a new drug or biological product in the United States generally must satisfactorily complete each of the following steps: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">preclinical laboratory tests, animal studies and formulation studies all performed in accordance with applicable regulations, including the FDA&#8217;s good laboratory practices, or GLP, regulations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">submission to the FDA of an IND application for human clinical testing, which must become effective before human clinical trials may begin; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">approval by the IRB representing each clinical site before each clinical trial may be initiated; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">performance of adequate and well-controlled human clinical trials to establish the safety, potency and purity of the product candidate for each proposed indication, in accordance applicable regulations, including with GCP, regulations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">preparation and submission to the FDA of a NDA for a drug product, or a BLA for a biological product requesting marketing approval for one or more proposed indications, including submission of detailed information on the manufacture and composition of the product in clinical development, evidence of safety, purity and potency from preclinical testing and clinical trials, and proposed labeling; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">review of the product by an FDA advisory committee, if applicable; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities, including those of third parties, at which the product, or components thereof, are produced to assess compliance with current GMP requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">satisfactory completion of any FDA audits of the clinical study sites to assure compliance with GCPs, and the integrity of clinical data in support of the NDA or BLA; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">payment of user fees and securing FDA approval of the NDA or BLA; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">compliance with any post-approval requirements, including the potential requirement to implement a REMS and to conduct any post-approval studies required by the FDA. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our investigational medicines and any future investigational medicines will be granted on a timely basis, or at all. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical Studies and Investigational New Drug Application </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before testing any drug or biological product candidate in humans, the product candidate must undergo preclinical testing. Preclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as animal studies to evaluate the potential for activity and toxicity. The conduct of the preclinical tests and formulation of the compounds for testing must comply with federal regulations and requirements. The results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, are submitted to the FDA as part of an IND application. The IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions about the product or conduct of the proposed clinical trial, including concerns that patients will be exposed to unreasonable health risks, and places the trial on a clinical hold. In that case, the IND sponsor and the FDA must resolve any outstanding FDA concerns before the clinical trial can begin. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, submission of the IND may result in the FDA not allowing the trial to commence or not be conducted on the terms originally specified by the sponsor in the IND. If the FDA raises concerns or questions either during this initial 30-day period, or at any time during the IND process, it may choose to impose a partial or complete clinical hold. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA. A clinical hold issued by the FDA may therefore delay either a proposed clinical study or cause suspension of an ongoing study, until all outstanding concerns have been adequately addressed and the FDA has notified the company that investigation may proceed. This could cause significant difficulties in completing planned clinical trials in a timely manner. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may impose clinical holds on a biological product candidate at any time before or during clinical trials due to safety concerns or non-compliance. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Human Clinical Trials in Support of an NDA or a BLA </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of the investigational product candidate to healthy volunteers or patients with the disease to be treated under the supervision of qualified principal investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCP requirements, which include the requirement that all patients provide their informed consent for their participation. Clinical trials are conducted under study protocols detailing, among other things, the objectives of the study, inclusion and exclusion criteria, the parameters to be used in monitoring safety, dosing procedures and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A sponsor who wishes to conduct a clinical trial outside the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of the NDA or BLA so long as the clinical trial is well-designed and well-conducted in accordance with GCP, including review and approval by an independent ethics committee, and the FDA is able to validate the study data through an onsite inspection, if necessary. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, each clinical trial must be reviewed and approved by an IRB either centrally or individually at each institution at which the clinical trial will be conducted. The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors and the safety of patients. An IRB must operate in compliance with FDA </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulations. The FDA, IRB, or the clinical trial sponsor may suspend or discontinue a clinical trial at any time for various reasons, including a finding that the clinical trial is not being conducted in accordance with FDA requirements or that the patients are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive GCP rules and the requirements for informed consent. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee, or DSMB. This group may recommend continuation of the study as planned, changes in study conduct, or cessation of the study at designated check points based on access to certain data from the study. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may be required after approval. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Phase 1 clinical trials (or Phase 1) are initially conducted in a limited population to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion and pharmacodynamics in healthy humans or, on occasion, in patients, such as in the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Phase 2 clinical trials (or Phase 2) are generally conducted in a limited patient population to identify possible adverse effects and safety risks, preliminarily evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger Phase 3 clinical trials. When a drug is intended to treat life-threatening or severely debilitating illnesses, the FDA may accept well-controlled Phase 2 clinical trials as adequate to provide sufficient data on the drug&#8217;s safety and effectiveness to support a decision on its approvability for marketing, in which case Phase 3 clinical trials would not be required. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Phase 3 clinical trials (or Phase 3) proceed if the Phase 2 clinical trials demonstrate that a certain dose or dose range of the product candidate is potentially effective and has an acceptable safety profile. Phase 3 clinical trials are undertaken within an expanded patient population, often at geographically dispersed clinical trial sites, to gather additional information about safety and effectiveness necessary to evaluate the overall benefit-risk relationship of the product and to provide an adequate basis for product labeling. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some cases, the FDA may approve an NDA or a BLA for a product candidate but require the sponsor to conduct additional clinical trials to further assess the product candidate&#8217;s safety and effectiveness after approval. Such post-approval trials are typically referred to as Phase 4 clinical trials (or Phase 4). These studies may be used to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of biologics approved under accelerated approval regulations. If the FDA approves a product while a company has ongoing clinical trials that were not necessary for approval, a company may be able to use the data from these clinical trials to meet all or part of any Phase 4 clinical trial requirement or to request a change in the product labeling. Failure to exhibit due diligence with regard to conducting required Phase 4 clinical trials could result in withdrawal of approval for products. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators for serious and unexpected adverse events, any findings from other trials, tests in laboratory animals or <font style="font-style:italic;">in vitro</font> testing that suggest a significant risk for patients, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information. The FDA or the sponsor or its DSMB may suspend a clinical trial at any time on various grounds, including a finding that the patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the new drug candidate or biological product candidate has been associated with unexpected serious harm to patients. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Sponsors of clinical trials of FDA-regulated products, including biologics, are required to register and disclose certain clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product, patient population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Compliance with GMP Requirements </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving an NDA or a BLA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in full compliance with GMP requirements and adequate to assure consistent production of the product within required specifications. Among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final drug or biological product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug or biological product does not undergo unacceptable deterioration over its shelf life. In particular, the PHSA emphasizes the importance of manufacturing control for products like biologics whose attributes cannot be precisely defined. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturers and others involved in the manufacture and distribution of drugs and biological products must also register their establishments with the FDA and certain state agencies. Both domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing process. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The manufacturing facilities may be subject to periodic unannounced inspections by government authorities to ensure compliance with GMPs and other laws. Manufacturers may have to provide, on request, electronic or physical records regarding their establishments. Delaying, denying, limiting or refusing inspection by the FDA may lead to a product being deemed to be adulterated. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Review and Approval of an NDA or a BLA </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results of product candidate development, preclinical testing and clinical trials, including negative or ambiguous results as well as positive findings, are submitted to the FDA as part of an NDA or a BLA requesting a license to market the product. These applications must contain extensive manufacturing information and detailed information on the composition of the product and proposed labeling. The FDA adjusts the Prescription Drug User Fee Act, or PDUFA, user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs or BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has 60 days after submission of the application to conduct an initial review to determine whether the NDA or BLA is sufficient to accept for filing based on the agency&#8217;s threshold determination that it is substantially complete so as to permit substantive review. Once the submission has been accepted for filing, the FDA begins an in-depth review of the application. Under the goals and policies agreed to by the FDA under PDUFA, the FDA aims to complete its initial review of a standard application and respond to the sponsor within ten months of the 60-day filing date, and for a priority review application within six months. The FDA does not always meet its PDUFA goal dates for standard and priority NDA or BLA applications, and its review goals are subject to change from time to time. The review process may often be significantly extended by FDA requests for additional information or clarification. The review process and the PDUFA goal date may also be extended by three months if the FDA requests or if the sponsor otherwise provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA reviews NDA and BLA applications to determine, among other things, whether the proposed product is safe and potent, and/or effective, for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with GMP requirements to assure and preserve the product&#8217;s identity, safety, strength, quality, potency and purity. On the basis of the FDA&#8217;s evaluation of the application and accompanying information, including the results of the inspection of the manufacturing facilities and any FDA audits of clinical trial sites to assure compliance with GCPs, the FDA may issue an approval letter, denial letter or complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. Under the FDCA, the FDA may approve an NDA if it determines that the product is safe and effective for its intended use, the benefits of the drug outweigh any risks, and the methods used in manufacturing the drug and the controls used to maintain the drug&#8217;s quality are adequate to preserve the drug&#8217;s identity, strength, quality and purity. Under the PHSA, the FDA may approve a BLA if it determines that the product is safe, pure and potent and the facility where the product will be manufactured meets </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">standards designed to ensure that it continues to be safe, pure and potent. If the application is not approved, the FDA may issue a complete response letter, which will contain the conditions that must be met in order to secure final approval of the application, and when possible will outline recommended actions the sponsor might take to obtain approval of the application. If a complete response letter is issued, the sponsor may either resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sponsors that receive a complete response letter who elect to address the deficiencies may submit to the FDA information that represents a complete response to the issues identified by the FDA in the response letter. Such resubmissions are classified under PDUFA as either Class&#160;1 or Class&#160;2, based on the information submitted by a sponsor in response to an action letter. Under the goals and policies agreed to by the FDA under PDUFA, the FDA aims to review and act on a Class&#160;1 resubmission with two months of receipt and, with respect to a Class&#160;2 resubmission, within six months of receipt. The FDA will not approve an application until issues identified in the complete response letter have been addressed. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may also refer the application to an Advisory Committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions. In particular, the FDA may refer applications for novel drug or biological products or drug or biological products that present difficult questions of safety or efficacy to an advisory committee. Typically, an Advisory Committee is a panel of independent experts, including clinicians and other scientific experts. The FDA is not bound by the recommendations of an Advisory Committee, but it considers such recommendations carefully when making decisions. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA approves a new product, it may limit the approved indications for use of the product, or limit the approval to specific dosages. It may also require that certain contraindications, warnings or precautions be included in the product labeling. In addition, the FDA may call for post-approval studies, including Phase 4 clinical trials, to further assess the product&#8217;s safety after approval. The agency may also require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including risk evaluation and mitigation strategies, or REMS, to help ensure that the benefits of the product outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patent registries. If the FDA concludes a REMS is needed, the sponsor of the NDA or BLA must submit a proposed REMS; the FDA will not approve the NDA or BLA without a REMS, if required. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Fast Track, Breakthrough Therapy and Priority Review Designations </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may designate certain products for expedited review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs include fast track designation, breakthrough therapy designation and priority review designation. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may designate a product for fast track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new drug or biologic may request that the FDA designate the drug or biologic as a fast track product at any time during the clinical development of the product. For fast track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a fast track product&#8217;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. However, the FDA&#8217;s time period goal for reviewing a fast track application does not begin until the last section of the application is submitted. Fast track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2012, Congress enacted the Food and Drug Administration Safety and Innovation Act, or the FDASIA. This law established a new regulatory scheme allowing for expedited review of products designated as &#8220;breakthrough therapies.&#8221; A product may be designated as a breakthrough therapy if it is intended, either alone or in combination with one or more other </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to facilitate the design of clinical trials in an efficient manner. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines, on a case-by-case basis, whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s goal for taking action on a marketing application to six months (compared to 10 months under standard review). </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fast track designation, priority review and breakthrough therapy designation may expedite the development or approval process, but do not change the standards for approval. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Accelerated Approval Pathway </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may grant accelerated approval to a product for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over existing treatments based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. Products granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a product, such as an effect on IMM. The FDA has stated that although it has limited experience with accelerated approvals based on intermediate clinical endpoints, such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a product. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a product. Thus, accelerated approval has been used extensively in the development and approval of products for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large trials to demonstrate a clinical or survival benefit. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accelerated approval pathway is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product&#8217;s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or to confirm a clinical benefit during post-marketing studies, may lead the FDA to withdraw the product from the market. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated approval pathways are available for regenerative medicine therapies that meet certain conditions. Regenerative medicine therapies include cell therapies (both allogenic and autologous), therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products, except those </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulated under section 361 of the PHSA. Human gene therapies, including genetically modified cells, that lead to a sustained effect on cells or tissues, may also meet the definition of a regenerative medicine therapy, as may xenogeneic cell products. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regenerative medicine therapies designed to treat, modify, reverse or cure serious conditions are eligible for FDA&#8217;s expedited programs, including fast track designation, breakthrough therapy designation, priority review and accelerated approval, if they meet the criteria for such programs. They may also be eligible for Regenerative Medicine Advanced Therapy Designation, or RMAT designation. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An investigational drug is eligible for RMAT designation if it meets the definition of regenerative medicine therapy, it is intended to treat, modify, reverse or cure a serious condition, and preliminary clinical evidence indicates that the regenerative medicine therapy has the potential to address unmet medical needs for such condition. An unmet medical need is a condition whose treatment or diagnosis is not addressed adequately by available therapy. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RMAT designation confers all the benefits of the fast track and breakthrough therapy designation programs, including early interactions with the FDA. The FDA reviews each application on a case-by-case basis to determine whether the clinical evidence is sufficient to support RMAT designation, considering factors such as the rigor of data collection, the consistency and persuasiveness of the outcomes, the number of patients, and the severity, rarity or prevalence of the condition, among other factors. The FDA may decline to grant RMAT designation if it finds the clinical evidence insufficient. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RMAT designation may expedite the development or approval process, but it does not change the standards for approval. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Emergency Use Authorizations</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Secretary of Health and Human Services has the authority to authorize unapproved medical products, including vaccines, to be marketed in the context of an actual or potential emergency that has been designated by government officials. The COVID-19 pandemic has been designated such a national emergency. After an emergency has been announced, the Secretary of Health and Human Services may authorize the issuance of, and the FDA Commissioner may issue, Emergency Use Authorizations, or EUAs, for the use of specific products based on criteria established by statute, including that the product at issue may be effective in diagnosing, treating, or preventing serious or life-threatening diseases when there are no adequate, approved, and available alternatives. An EUA is subject to additional conditions and restrictions and is product-specific. An EUA terminates when the emergency determination underlying the EUA terminates. An EUA is not a long-term alternative to obtaining FDA approval, licensure, or clearance for a product. FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, so it is not possible to predict how long an EUA may remain in place.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Post-Approval Regulation </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If regulatory approval for marketing of a product or for a new indication for an existing product is obtained, the sponsor will be required to comply with rigorous and extensive post-approval regulatory requirements as well as any post-approval requirements that the FDA has imposed on the particular product as part of the approval process. The sponsor will be required, among other things, to report certain adverse reactions and production problems to the FDA, provide updated safety and efficacy information and comply with requirements concerning advertising and promotional labeling. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including GMP regulations, which impose certain procedural and documentation requirements upon manufacturers. Accordingly, the BLA holder and its third-party manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with GMP regulations and other regulatory requirements. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented, and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market study requirements or clinical trial requirements to assess new safety risks; or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">fines, untitled letters or warning letters or holds on post-approval clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">adverse publicity; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">product seizure or detention, or refusal to permit the import or export of products; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">injunctions, fines, debarment, disgorgement of profits or the imposition of civil or criminal penalties. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Pharmaceutical products may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Orphan Drug Designation </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orphan drug designation in the United States is designed to encourage sponsors to develop products intended for rare diseases or conditions. In the United States, a rare disease or condition is statutorily defined as a disease or condition that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States but for which there is no reasonable expectation that the cost of developing and making available the product for the disease or condition will be recovered from sales of the product in the United States. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orphan drug designation qualifies a company for certain financial incentives, including tax advantages and, if the product receives the first FDA approval for the indication for which it has orphan designation, market exclusivity for seven years following the date of the product&#8217;s marketing approval. An application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. Once a product receives orphan drug designation from the Office of Orphan Products Development at the FDA, the product must then go through the review and approval process like any other product. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, a sponsor of a product that is otherwise the same product as an already approved orphan drug may seek and obtain orphan drug designation for the subsequent product for the same rare disease or condition if it can present a plausible hypothesis that its product may be clinically superior to the first product. More than one sponsor may receive orphan drug designation for the same product for the same rare disease or condition, but each sponsor seeking orphan drug designation must file a complete request for designation. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The period of exclusivity begins on the date that the marketing application is approved by the FDA and applies only to the indication for which the product has been designated. The FDA may approve a second application for the same product for a different use or a second application for a clinically superior version of the product for the same use. The FDA cannot, however, approve the same product made by another manufacturer for the same indication during the market exclusivity period unless it has the consent of the sponsor, the manufacturer makes a showing of clinical superiority over the product with orphan exclusivity, or the sponsor is unable to provide sufficient quantities. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Pediatric Studies and Exclusivity </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Pediatric Research Equity Act of 2003, an NDA or a BLA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Sponsors who are planning to submit a marketing application for a drug or biological product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration must also submit pediatric study plans prior to the assessment data, and no later than 60 calendar days following an end-of-Phase 2 meeting </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with the FDA or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 study. Pediatric study plans must contain an outline of the proposed pediatric study or studies the sponsor plans to conduct, including study objectives and design, any deferral or waiver requests and other information required by regulation. The sponsor, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other and agree upon a final plan. The FDA or the sponsor may request an amendment to the plan at any time. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may, on its own initiative or at the request of the sponsor, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Additional requirements and procedures relating to deferral requests and requests for extension of deferrals are contained in FDASIA. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent and orphan exclusivity. This six-month exclusivity may be granted if an NDA or a BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Biosimilars and Reference Product Exclusivity </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-approved reference biological product. To date, a number of biosimilars have been licensed under the BPCIA, and numerous biosimilars have been approved in Europe. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, recent government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate implementation and impact of the BPCIA is subject to significant uncertainty. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Regulation of Combination Products in the United States </font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain products may be comprised of components that would normally be regulated under different types of regulatory authorities and frequently by different centers at the FDA. These products are known as combination products. Specifically, under regulations issued by the FDA, a combination product may be: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">A product comprised of two or more regulated components that are physically, chemically or otherwise combined or mixed and produced as a single entity; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Two or more separate products packaged together in a single package or as a unit and comprised of drug and device products, device and biological products, or biological and drug products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">A drug, or device or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, device or biological product where both are required to achieve the intended use, indication or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, </font><font style="font-style:italic;color:#000000;">e.g</font><font style="color:#000000;">., to reflect a change in intended use, dosage form, strength, route of administration or significant change in dose; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Any investigational drug, device or biological product packaged separately that according to its proposed labeling is for use only with another individually specified investigational drug, device or biological product where both are required to achieve the intended use, indication or effect. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the FDCA, the FDA is charged with assigning a center with primary jurisdiction, or a lead center, for review of a combination product. That determination is based on the &#8220;primary mode of action&#8221; of the combination product. Thus, if the primary mode of action of a device-biologic combination product is attributable to the biological product, the FDA center responsible for premarket review of the biological product would have primary jurisdiction for the combination product. The FDA has also established an Office of Combination Products to address issues surrounding combination products and provide more certainty to the regulatory review process. That office serves as a focal point for combination product issues for agency reviewers and industry. It is also responsible for developing guidance and regulations to clarify the regulation of combination products, and for assignment of the FDA center that has primary jurisdiction for review of combination products where the jurisdiction is unclear or in dispute. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, an applicant will need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can initiate clinical trials or market and sell the product in those countries or jurisdictions. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Regulation and Procedures Governing Approval of Medicinal Products in the European Union </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process governing approval of medicinal products, including biological medicinal products and advanced therapy medicinal products, or ATMPs, which comprise gene therapy products, somatic cell therapy products and tissue-engineered products, in the European Union generally follows the same lines as in the United States. It entails satisfactory completion of pharmaceutical development, nonclinical and clinical studies to establish the safety and efficacy of the medicinal product for each proposed indication. Moreover, an applicant must also demonstrate the ability to manufacture the product to a suitable quality. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Clinical Trial Approval </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the currently applicable Clinical Trials Directive 2001/20/EC and the Directive 2005/28/EC on GCP, a system for the approval of clinical trials in the European Union has been implemented through national legislation of the member states. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials must be conducted in accordance with European Union and national regulations and the International Conference on Harmonization, or ICH, guidelines on GCP. Additional GCP guidelines from the European Commission, focusing in particular on traceability, apply to clinical trials of advanced therapy medicinal products. If the sponsor of the clinical trial is not established within the European Union, it must appoint an entity within the European Union to act as its legal representative. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under this system, a sponsor must obtain approval from the competent national authority of a European Union member state in which the clinical trial is to be conducted or in multiple member states if the clinical trial is to be conducted </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in a number of member states. Furthermore, the sponsor may only start a clinical trial at a specific study site after the independent ethics committee has issued a favorable opinion. The clinical trial application must be accompanied by a copy of the trial protocol and an investigational medicinal product dossier with supporting information prescribed by Directive 2001/20/EC and Directive 2005/28/EC and corresponding national laws of the member states and further detailed in applicable guidance documents. Moreover, the sponsor must take out a clinical trial insurance policy, and in most European Union countries the sponsor is liable to provide &#8216;no fault&#8217; compensation to any study subject injured in the clinical trial. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2014, the European Union adopted a new Clinical Trials Regulation (EU) No 536/2014, which is set to replace the current Clinical Trials Directive 2001/20/EC. It is expected that the new Clinical Trials Regulation will apply at earliest at the end of 2021. It will overhaul the current system of approvals for clinical trials in the European Union. Specifically, the new regulation, which will be directly applicable in all member states, aims to simplify and streamline the approval of clinical trials in the European Union. For instance, the new Clinical Trials Regulation provides for a streamlined application procedure using a single entry point and strictly defined deadlines for the assessment of clinical trial applications. This means that one national authority takes the lead in reviewing the application and the other national authorities have only a limited involvement. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be notified to or approved by the relevant competent authorities and ethics committees. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The sponsor of a clinical trial must register the clinical trial in advance, and information related to the product, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial will be made public as part of the registration. The results of the clinical trial must be submitted to the competent authorities and, with the exception of non-pediatric Phase 1 trials, will be made public at the latest within 12 months after the end of the trial. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the development of a medicinal product, the European Medicines Agency, or EMA, and national medicines regulators within the European Union provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Scientific Advice Working Party of the Committee for Medicinal Products for Human Use, or CHMP. A fee is incurred with each scientific advice procedure. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk-management programs. Advice is not legally binding with regard to any future marketing authorization application of the product concerned. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Marketing Authorization </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To obtain a marketing authorization for a product under the European Union regulatory system, a sponsor must submit a marketing authorization application, or MAA, either under a centralized procedure administered by the EMA or one of the procedures administered by competent authorities in European Union member states (decentralized procedure, national procedure or mutual recognition procedure). </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All application procedures require an application in the common technical document, or CTD, format, which includes the submission of detailed information about the manufacturing and quality of the product, and nonclinical and clinical trial information. There is an increasing trend in the European Union toward greater transparency and, while the manufacturing or quality information is currently generally protected as confidential information, the EMA and national regulatory authorities are now liable to disclose much of the nonclinical and clinical information in marketing authorization dossiers, including the full clinical study reports, in response to freedom of information requests after the marketing authorization has been granted. In October 2014, the EMA adopted a policy under which clinical study reports would be posted on the agency&#8217;s website following the grant, denial or withdrawal of a MAA, subject to procedures for limited redactions and protection against unfair commercial use. A similar requirement is contained in the new Clinical Trials Regulation that is currently expected to take effect at earliest at the end of 2021.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A marketing authorization may be granted only to a sponsor established in the European Union. Regulation (EC) No.&#160;1901/2006 on medicinal products for pediatric use provides that prior to obtaining a marketing authorization in the European Union in the centralized procedure, a sponsor must demonstrate compliance with all measures included in an EMA-approved Pediatric Investigation Plan covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, class waiver or deferral for one or more of the measures included in the Pediatric Investigation Plan. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all European Union member states. Pursuant to Regulation (EC) No.&#160;726/2004, the centralized procedure is compulsory for specific products, including for medicines (including vaccines) produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products and products with a new active substance indicated for the treatment of certain diseases, including products for the treatment of cancer. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure may be optional. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the centralized procedure, the CHMP established at the EMA is responsible for conducting the assessment of a product to define its risk/benefit profile. Under the centralized procedure, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions from the CHMP. Accelerated evaluation may be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health determined by three cumulative criteria: (i)&#160;the seriousness of the disease (<font style="font-style:italic;">e.g</font>., heavy disabling or life-threatening diseases) to be treated, (ii)&#160;the absence or insufficiency of an appropriate alternative therapeutic approach, and (iii)&#160;anticipation of high therapeutic benefit. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the CHMP accepts such a request, the time limit of 210 days will be reduced to 150 days, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that it is no longer appropriate to conduct an accelerated assessment. The Committee for Advanced Therapies, or CAT, is responsible in conjunction with the CHMP for the evaluation of ATMPs. The CAT is primarily responsible for the scientific evaluation of ATMPs and prepares a draft opinion on the quality, safety and efficacy of each ATMP for which a MAA is submitted. The CAT&#8217;s opinion is then taken into account by the CHMP when giving its final recommendation regarding the authorization of a product in view of the balance of benefits and risks identified. Although the CAT&#8217;s draft opinion is submitted to the CHMP for final approval, the CHMP may depart from the draft opinion if it provides detailed scientific justification. The CHMP and CAT are also responsible for providing guidelines on ATMPs and have published numerous guidelines, including specific guidelines on gene therapies and cell therapies. These guidelines, which are not legally binding, provide additional guidance on the factors that the EMA will consider in relation to the development and evaluation of ATMPs and include, inter alia, the preclinical studies required to characterize ATMPs, the manufacturing and control information that should be submitted in a MAA; and post-approval measures required to monitor patients and evaluate the long term efficacy and potential adverse reactions of ATMPs. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The European Commission may grant a so-called &#8220;marketing authorization under exceptional circumstances.&#8221; Such authorization is intended for products for which the applicant can demonstrate that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use, because the indications for which the product in question is intended are encountered so rarely that the applicant cannot reasonably be expected to provide comprehensive evidence, or in the present state of scientific knowledge, comprehensive information cannot be provided, or it would be contrary to generally accepted principles of medical ethics to collect such information. Consequently, marketing authorization under exceptional circumstances may be granted subject to certain specific obligations, which may include the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the applicant must complete an identified program of studies within a time period specified by the competent authority, the results of which form the basis of a reassessment of the benefit/risk profile; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the medicinal product in question may be supplied on medical prescription only and may in certain cases be administered only under strict medical supervision, possibly in a hospital, and in the case of a radio-pharmaceutical, by an authorized person; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the package leaflet and any medical information must draw the attention of the medical practitioner to the fact that the particulars available concerning the medicinal product in question are as yet inadequate in certain specified respects. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A marketing authorization under exceptional circumstances is subject to annual review to reassess the risk-benefit balance in an annual re-assessment procedure. Continuation of the authorization is linked to the annual reassessment and a negative assessment could potentially result in the marketing authorization being suspended or revoked. The renewal of the marketing authorization of a medicinal product under exceptional circumstances follows the same rules as a &#8220;normal&#8221; marketing authorization. After five years, the marketing authorization will then be renewed under exceptional circumstances for an unlimited period, unless the EMA decides, on justified grounds, to proceed with one additional five-year renewal. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The European Commission may also grant a so-called &#8220;conditional marketing authorization&#8221; prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional marketing authorizations may be granted for product candidates (including medicines designated as orphan medicinal products and vaccines) if the CHMP finds that all the following requirements are met: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the benefit-risk balance of the product is positive; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">it is likely that the applicant will be able to provide comprehensive data; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">unmet medical needs will be fulfilled; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the benefit to public health of the medicinal product&#8217;s immediate availability on the market outweighs the risks due to need for further data. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new studies, and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions and/or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization. Once comprehensive data on the medicinal product have been obtained, the marketing authorization may be converted into a standard marketing authorization which is no longer subject to specific obligations. Initially, this is valid for five years, but can be renewed for unlimited validity. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For COVID-19 vaccines to date, the EMA has followed a so-called &#8216;rolling review&#8217; process, an <font style="font-style:italic;">ad hoc</font> procedure by which data is assessed as it becomes available with the aim of granting a conditional marketing authorization.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The European Union medicines rules expressly permit the member states to adopt national legislation prohibiting or restricting the sale, supply or use of any medicinal products containing, consisting of or derived from a specific type of human or animal cell, such as embryonic stem cells. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Periods of Authorization and Renewals </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A marketing authorization is valid for five years, in principle, and it may be renewed after five years on the basis of a reevaluation of the risk benefit balance by the EMA or by the competent authority of the authorizing Member State. To that end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal period. Any authorization that is not followed by the placement of the product on the European Union market (in the case of the centralized procedure) or on the market of the authorizing Member State within three years after authorization ceases to be valid. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Emergency Use Authorizations </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The European Union medicines rules, as implemented into the national laws of the EU member states, permit national authorities to authorize temporarily the distribution of an unapproved medicinal product in certain emergency situations, including suspected or confirmed spread of pathogenic agents.&nbsp;&nbsp;Such an Emergency Use Authorization (EUA) would apply for the duration of the emergency only and would be limited to the member state in which it has been issued.&nbsp;&nbsp;When considering whether to grant an EUA, the relevant member state decides, which data it requires for the grant of the EUA.&nbsp;&nbsp;For COVID-19 vaccines to date, the EU member states have not relied on EUAs.&nbsp;&nbsp;Rather products have followed the centralized procedure combined with a rolling review of data with a view to granting conditional marketing authorizations.&nbsp;&nbsp;Member states have relied on EUAs to permit the distribution and use of certain unapproved medicines for in unapproved indications to assist in the treatment of COVID-19 patients.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Regulatory Requirements after Marketing Authorization </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following approval, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of the medicinal product. These include compliance with the European Union&#8217;s stringent pharmacovigilance or safety reporting rules, pursuant to which post-authorization studies and additional monitoring obligations can be imposed. The holder of a marketing authorization must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance who is responsible for </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports, or PSURs. All new MAAs must include a risk management plan, or RMP, describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the marketing authorization. Such risk-minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies. RMPs and PSURs are routinely available to third parties requesting access, subject to limited redactions. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the manufacturing of authorized products, for which a separate manufacturer&#8217;s license is mandatory, must also be conducted in strict compliance with the EMA&#8217;s GMP requirements and comparable requirements of other regulatory bodies in the European Union, which mandate the methods, facilities and controls used in the manufacturing, processing and packing of products to assure their safety and identity. Specifically, medicinal products may only be manufactured in the European Union, or imported into the European Union from another country, by the holder of a manufacturing/import authorization from the competent national authority. The manufacturer or importer must have a qualified person who is responsible for certifying that each batch of product has been manufactured in accordance with European Union standards of good manufacturing practice, or GMP, before releasing the product for commercial distribution in the European Union or for use in a clinical trial. Manufacturing facilities are subject to periodic inspections by the competent authorities for compliance with GMP. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finally, the marketing and promotion of authorized products, including industry-sponsored continuing medical education and advertising directed toward the prescribers of products and/or the general public, are strictly regulated in the European Union. In principle, all advertising and promotional activities for the product must be consistent with the approved summary of product characteristics, and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription medicines (including vaccines) is also prohibited in the European Union. Although general requirements for advertising and promotion of medicinal products are established under Directive 2001/83/EC, as amended, the details are governed by regulations in each member state and can differ from one country to another. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Human Cells and Tissues </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human cells and tissues that are intended for human applications but that do not fall within the scope of rules governing medicinal products or medical devices are not subject to premarket review and approval, nor do they require extensive preclinical and clinical testing. However, there are European Union rules governing the donation, procurement, testing and storage of human cells and tissues intended for human application, whether or not they are ATMPs. These rules also cover the processing, preservation and distribution of human cell and tissues that are not ATMPs. Establishments that conduct such activities must be licensed and are subject to inspection by regulatory authorities. Such establishments must implement appropriate quality systems and maintain appropriate records to ensure that cells and tissues can be traced from the donor to the recipient and vice versa. There are also requirements to report serious adverse events and reactions linked to the quality and safety of cells and tissues. More detailed rules may exist at the national level. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Named Patient Supplies </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The European Union medicines rules allow individual member states to permit the supply of a medicinal product without a marketing authorization to fulfill special needs, where the product is supplied in response to a bona fide unsolicited order, formulated in accordance with the specifications of a healthcare professional and for use by an individual patient under his direct personal responsibility. This may in certain countries also apply to products manufactured in a country outside the European Union and imported to treat specific patients or small groups of patients. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Orphan Drug Designation and Exclusivity </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulation (EC) No.&#160;141/2000 and Regulation (EC) No.&#160;847/2000 provide that a product can be designated as an orphan drug by the European Commission if its sponsor can establish: that the product is intended for the diagnosis, prevention or treatment of (i)&#160;a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union when the application is made, or (ii)&#160;a life-threatening, seriously debilitating or serious and chronic condition in the European Union and that without incentives it is unlikely that the marketing of the product in the European Union would generate sufficient return to justify the necessary investment. For either of these conditions, the sponsor must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the European Union or, if such method exists, the product has to be of significant benefit compared to products available for the condition. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">148</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An orphan drug designation provides a number of benefits, including fee reductions, regulatory assistance and the possibility to apply for a centralized European Union marketing authorization. Marketing authorization for an orphan drug leads to a 10-year period of market exclusivity. During this market exclusivity period, neither the EMA nor the European Commission or the member states can accept an application or grant a marketing authorization for a &#8220;similar medicinal product.&#8221; A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic indication. The market exclusivity period for the authorized therapeutic indication may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation because, for example, the product is sufficiently profitable not to justify market exclusivity. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">European Data Collection and Data Protection Laws </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are required to comply with strict data protection and privacy legislation in the jurisdictions in which we operate, including the General Data Protection Regulation (EU) 2016/679, or GDPR. The GDPR governs our collection and use of personal data in the European Union relating to individuals (<font style="font-style:italic;">e.g</font>., patients). The GDPR imposes several requirements on organizations that process such data, including: to observe core data processing principles; to comply with various accountability measures; to provide more detailed information to individuals about data processing activities; to establish a legal basis to process personal data (including enhanced consent requirements); to maintain the integrity, security and confidentiality of personal data; and to report personal data breaches. The GDPR also restricts the transfer of personal data outside of the European Economic Area (<font style="font-style:italic;">e.g</font>., to the United States and other countries that are not deemed to provide adequate protection under their domestic laws). The GDPR may impose additional responsibility and liability in relation to personal data that we process, and require us to put in place additional mechanisms ensuring compliance with the new data protection rules. This may be onerous and adversely affect our business, financial condition, results of operations and prospects. Failure to comply with the requirements of the GDPR and related national data protection laws of European Union member states may result in a variety of enforcement measures, including significant fines and other administrative measures. The GDPR has introduced substantial fines for breaches of the data protection rules, increased powers for regulators, enhanced rights for individuals, and new rules on judicial remedies and collective redress. We may be subject to claims by third parties, such as patients or regulatory bodies, that we or our employees or independent contractors inadvertently or otherwise breached GDPR and related data protection rules. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we do not prevail, we could be required to pay substantial fines and/or damages and could suffer significant reputational harm. Even if we are successful, litigation could result in substantial cost and be a distraction to management and other employees. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Coverage, Pricing and Reimbursement </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we may obtain regulatory approval. Even if our product candidates are approved for marketing, sales of such product candidates will depend, in part, on the extent to which third-party payors, including government health programs in the United States (such as Medicare and Medicaid), commercial health insurers and managed care organizations, provide coverage and establish adequate reimbursement levels for such product candidates. In the United States, the member states of the European Union and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Reimbursement rules and levels are not harmonized in the European Union and therefore differ from member state to member state. Patients are unlikely to use any product candidates we may develop unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of such product candidates. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services and imposing controls to manage costs. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, and the cost of these studies would be in addition to the costs required to obtain FDA or other comparable marketing approvals. Even after pharmacoeconomic studies are conducted, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover any product candidates we may develop could reduce physician utilization of such product candidates once approved and have a material adverse effect on our sales, results of operations and financial condition. Additionally, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. For example, the payor may require co-payments that patients find unacceptably high. Further, one payor&#8217;s determination to provide coverage for a product does not assure that </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such coverage will continue or that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. Third-party reimbursement and coverage may not be adequate to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. The insurance coverage and reimbursement status of newly approved products for orphan diseases is particularly uncertain, and failure to obtain or maintain adequate coverage and reimbursement for any such product candidates could limit a company&#8217;s ability to generate revenue. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The containment of healthcare costs also has become a priority of federal, state and foreign governments as well as other third-party payors such as statutory health insurance funds, and the prices of pharmaceuticals have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue from the sale of any approved products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented or coverage may be ended in the future. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside the United States, we will face challenges in ensuring and obtaining adequate coverage and payment for any product candidates we may develop. Pricing of prescription pharmaceuticals is subject to governmental control in many countries, including in particular the member states of the European Union. Pricing negotiations with governmental authorities or other third-party payors such as statutory health insurance funds can extend well beyond the receipt of regulatory marketing approval for a product and may require us to conduct a clinical trial that compares the cost effectiveness of any product candidates we may develop to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in our commercialization efforts. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost effectiveness of a particular product candidate to currently available therapies (so called health technology assessments) in order to obtain reimbursement or pricing approval. Moreover, European Union member states may restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Member states may approve a specific price for a product or may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on health care costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products in the marketplace. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel trade (arbitrage between low-priced and high-priced member states) can further reduce prices. Special pricing and reimbursement rules may apply to orphan drugs. Inclusion of orphan drugs in reimbursement systems tend to focus on the medical usefulness, need, quality and economic benefits to patients and the healthcare system as for any product. Acceptance of any medicinal product for reimbursement may come with cost, use and often volume restrictions, which again can vary by country. In addition, results based rules of reimbursement may apply. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products, if approved in those countries. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For COVID-19 vaccine candidates in the European Union, no pricing and reimbursement or health technology assessments discussions have taken place with the respective health insurances and competent bodies at a national member state level.&nbsp;&nbsp;Currently, COVID-19 vaccine candidates are supplied in the European Union based on vaccine supply agreements with the European Commission that is acting on behalf and in the name of the member states of the European Union. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Brexit and the Regulatory Framework in the United Kingdom</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 23, 2016, in a national referendum, a majority of the electorate voted in favour of the United Kingdom leaving the European Union (commonly referred to as &#8220;Brexit&#8221;).&nbsp;&nbsp;On March 29, 2017, the United Kingdom Government </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">formally notified the European Union of its intention to withdraw from the Union pursuant to Article 50 of the Treaty on the European Union.&nbsp;&nbsp;The United Kingdom formally left the European Union on January 31, 2020.&nbsp;&nbsp;Pursuant to the terms of the Withdrawal Agreement between the European Union and the United Kingdom, a transitional period ran between February 1, 2020 and December 31, 2020, during which all applicable EU law, including the regulation of medicinal products, applied to and in the United Kingdom.&nbsp;&nbsp;This transitional period has now come to an end.&nbsp;&nbsp;On December 24, 2020, the United Kingdom and the European Union announced that they have reached agreement on the terms of their future relationship as set out in the Trade and Cooperation Agreement (&#8220;TCA&#8221;).&nbsp;&nbsp;The European Union and the United Kingdom have agreed to provisionally apply the terms of the TCA, while the formal execution is still ongoing.&nbsp;&nbsp;While the TCA governs tariff and quota free trade between the United Kingdom and the European Union markets, it does not provide for regulatory alignment.&nbsp;&nbsp;The regulatory framework for medicinal products in the United Kingdom is predominantly derived from European Union law.&nbsp;&nbsp;Currently, domestic United Kingdom law provides that all existing European Union law is transposed into national law, subject to certain revisions that have become necessary as a result of Brexit.&nbsp;&nbsp;Thus, at least initially, the United Kingdom and the European Union laws are aligned.&nbsp;&nbsp;However, Brexit could have a material impact on the regulatory regime in the United Kingdom, as the country is free to deviate from the European Union regime.&nbsp;&nbsp;One example of such deviation is the approval of COVID-19 vaccines.&nbsp;&nbsp;While in the European Union vaccines have been granted conditional marketing authorizations, in the United Kingdom, vaccine candidates were granted emergency use authorizations.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Rest of the World Regulation</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The requirements governing the conduct of clinical trials, product (including vaccine) licensing, pricing, and reimbursement vary from country to country in markets outside the EU and the United States. In many markets, clinical trials must be conducted in accordance with Good Clinical Practice and applicable regulatory requirements. Ethical standards typically follow the Declaration of Helsinki principles. In response to the COVID-19 pandemic, some markets have granted or are considering the grant of emergency use authorizations for vaccine candidates instead of the otherwise available regulatory approval pathways. Supply of the COVID-19 vaccine to a number of countries outside of the US and the EU is similarly governed by vaccine supply agreements with local governments. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to adhere to regulatory requirements may lead to, among others, fines, suspension or withdrawal of regulatory authorizations or approvals, product recalls, seizure of products, restrictions or suspensions of operations, or criminal prosecution. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Greater China</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-style:normal;color:#000000;"></font><font style="color:#000000;">Mainland China</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar to the United States and the European Union, Mainland China has rules governing the approval for development and commercialization of drugs, including specialized rules for vaccines. China&#8217;s drug law and regulations require that the National Medical Products Administration&#8217;s, or NMPA&#8217;s, Center for Drug Evaluation, or CDE, approve a clinical trial application prior to initiating a study to support the safety and effectiveness of a drug. This clinical trial application and the testing procedure that may precede it can be expedited if there is a pressing declared health emergency, as was the case with COVID-19. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once approved, vaccine clinical trials must be conducted at sites that are qualified disease prevention and control, or CDC, institutions and grade III hospitals, and the implementation of the trial must be in accordance with China&#8217;s vaccine good clinical practice regulations and related guidelines. Furthermore, prior to the commencement of the clinical trial in China the site&#8217;s ethics committees must approve the trial, and the Office of Human Genetic Resources Administration must approve the use of samples and related data. The human genetic resources, or HGR, approval requires a joint approval or record-filing application with the Chinese and foreign parties, setting forth the parties that will handle data and samples, the type and amount of samples that will be utilized during the study, the tests/analysis run, and the plans for storage or destruction, and the intellectual property sharing arrangement among the parties, among other items.&nbsp;&nbsp;Once approved, the HGR approval/filing may require updates and amendments and additional procedures to transfer data to certain foreign parties. Once a clinical trial in China is complete and/or foreign data is assembled, a company may submit an application for a marketing authorization, or MA, of the vaccine. This procedure will include submission of clinical data, manufacturing information and test results, among other items, and may include an onsite pre-market verification by the NMPA. This application may be expedited under various expedited programs, including &#8220;special approval&#8221; procedures for drugs needed to control a public health emergency. Therapeutic biologics and small molecule drugs follow similar steps to approval for development and marketing.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At both the clinical trial and MA stages, drug applicants located outside of China must list a regula</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tory agent on the application. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agent must be an entity in China, and it assists the sponsor and marketing authorization holder</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or MAH, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with fulfilling its drug re</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gulatory obligations in China. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agent of the MAH is jointly liable with the MAH for these drug regulatory obligations.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once approved, vaccines may be procured by the CDC through platforms organized by the provincial governments.&nbsp;&nbsp;Vaccines in China must be sold and directly distributed by domestic manufacturers or general distributors appointed to represent overseas makers to municipal level CDCs, which handle allocation and distribution to points of vaccination in China. Distributors of all drugs must possess a MA for the drug they are distributing or a drug distribution license. As is the case with all drugs, once on the market, MAHs will also have post-market obligations, including safety reporting and compensation for injuries caused adverse events following inoculation, or AEFIs. MAHs of vaccines that are not part of the National Inoculation Program, or NIP, must bear the cost of injuries determined by experts to be AEFI injuries. The government bears the cost of NIP vaccines and related AEFIs. Vaccine MAHs are also subject to other post-market obligations for drug marketing authorization holders, including recalls, annual reporting, and inspections. Vaccine MAs must typically be renewed every five years.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Hong Kong and Macao</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mainland China&#8217;s drug regulatory system does not apply in Hong Kong or Macao. These administrative regions are governed by separate laws on the development and approval of drugs, including vaccines. They also have separate laws on the importation and distribution of those vaccines.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Turkey</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other countries such as Turkey and those in the Middle East have regulatory review processes and data requirements for medicinal products, including vaccines, similar to those described for the European Union. The regulatory licensing process in these countries may include local marketing authorization requirements, manufacturing/testing facility inspections, testing of drug product upon importation and other domestic requirements.&nbsp;&nbsp;Some countries, such as Turkey, have introduced specific emergency authorization regimes for COVID-19 vaccines.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Healthcare Law and Regulation </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Healthcare providers and third-party payors play a primary role in the recommendation and prescription of pharmaceutical products that are granted marketing approval. Our current and future arrangements with providers, researchers, consultants, third-party payors and customers are subject to broadly applicable federal and state fraud and abuse, anti-kickback, false claims, transparency and patient privacy laws and regulations and other healthcare laws and regulations that may constrain our business and/or financial arrangements. Restrictions under applicable federal and state healthcare laws and regulations include, without limitation, the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in-cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or a specific intent to violate it in order to have committed a violation. Moreover, the government may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false, fictitious, or fraudulent or knowingly making, using, or causing to be made or used a false record or statement to avoid, decrease, or conceal an obligation to pay money to the federal government; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">HIPAA, which created additional federal criminal laws that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or a specific intent to violate it in order to have committed a violation; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their respective implementing regulations, including the Final Omnibus Rule published in January 2013, which impose obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without the appropriate authorization by entities subject to the law, such as healthcare providers, health plans and healthcare clearinghouses and their respective business associates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the federal transparency requirements known as the federal Physician Payments Sunshine Act, under the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, within the U.S. Department of Health and Human Services, information related to payments and other transfers of value made by that entity to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">federal government price reporting laws, which require us to calculate and report complex pricing metrics to government programs and which may be used in the calculation of reimbursement and/or discounts on marketed products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the Foreign Corrupt Practices Act, a U.S. law which regulates certain financial relationships with foreign government officials (which could include, for example, certain medical professionals); </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the national anti-bribery laws and laws governing interactions with healthcare professionals of European Union member states; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the U.K. Bribery Act 2010; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to healthcare items or services that are reimbursed by non-governmental third-party payors, including private insurers. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring pharmaceutical manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures and pricing information. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Violations of these laws can subject us to criminal, civil and administrative sanctions including monetary penalties, damages, fines, disgorgement, individual imprisonment and exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, reputational harm, and we may be required to curtail or restructure our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to similar actions, penalties, and sanctions. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#8217;s attention from the business. Moreover, we expect that there will continue to be federal and state laws and regulations, proposed and implemented, that could impact our future operations and business. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-weight:bold;font-style:italic;font-size:10pt;">Current and Future Healthcare Reform Legislation </font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our investigational medicines, restrict or regulate post-approval activities, and affect our ability to profitably sell any investigational medicines </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for which we obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any collaborators, may receive for any approved products. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ACA, for example, contains provisions that subject biological products to potential competition by lower-cost biosimilars and may reduce the profitability of drug products through increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid-managed care plans, mandatory discounts for certain Medicare Part D beneficiaries, and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. With the current presidential administration and Congress, there may be additional administrative or legislative changes, including modification, repeal or replacement of all, or certain provisions of, the ACA, which may impact reimbursement for drugs and biologics. On January&#160;20, 2017, an Executive Order was signed directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. On October&#160;13, 2017, an executive order was signed terminating the cost-sharing subsidies that reimburse insurers under the ACA. Several state Attorneys General filed suit to stop the administration from terminating the subsidies, but their request for a restraining order was denied by a federal judge in California on October&#160;25, 2017. In addition, CMS has recently proposed regulations that would give states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. Further, each chamber of Congress has put forth multiple bills this year designed to repeal or repeal and replace portions of the ACA. While Congress has not passed repeal legislation, the TCJA includes a provision repealing the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; Congress may consider other legislation to repeal and replace elements of the ACA. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, other federal health reform measures have been proposed and adopted in the United States since the ACA was enacted: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2025 unless additional Congressional action is taken. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The Middle Class&#160;Tax Relief and Job Creation Act of 2012 required that CMS reduce the Medicare clinical laboratory fee schedule by 2% in 2013, which served as a base for 2014 and subsequent years. In addition, effective January&#160;1, 2014, CMS also began bundling the Medicare payments for certain laboratory tests ordered while a patient received services in a hospital outpatient setting. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which have resulted in several recent Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. In addition, the federal government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs, including price-controls, restrictions on reimbursement, and requirements for substitution of generic products for branded prescription drugs to limit the growth of government-paid health care costs. For example, the federal government has passed legislation requiring pharmaceutical manufacturers to provide rebates and discounts to certain entities and governmental payors to participate in federal healthcare programs. Individual states in the United States have also become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation, from other countries and bulk purchasing. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">154</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Packaging and Distribution in the United States </font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The failure to comply with any of these laws or regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, exclusion from federal healthcare programs, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, or refusal to allow a firm to enter into supply contracts, including government contracts. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in regulations, statutes, or the interpretation of existing regulations could impact our business in the future by requiring, for example, (i)&#160;changes to our manufacturing arrangements, (ii)&#160;additions or modifications to product labeling, (iii)&#160;the recall or discontinuation of our products or (iv)&#160;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other U.S. Environmental, Health and Safety Laws and Regulations </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain workers&#8217; compensation employers&#8217; liability insurance to cover us for costs and expenses we may incur due to injuries to our employees, but this insurance may not provide adequate coverage against potential liabilities. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">XIV. Intellectual Property </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">A. Introduction </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We pursue a layered intellectual property strategy to protect our various technology platforms and their application to the treatment of cancer and other serious diseases. One focus of our intellectual property strategy is to provide protection for our platforms and products as they are developed. We also pursue intellectual property protection for assets that may be used in future development programs and/or that may be of interest to our collaborators, or otherwise may prove valuable in the field. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Various aspects of our technology platforms and our product candidates are claimed by patent filings. We also pursue other modalities of protection, including trademark and trade secret protection, as appropriate. Many of our intellectual property assets were developed and are owned solely by us, some have been developed via collaboration and are jointly owned, and some have been acquired by acquisition and/or licensed from third parties. We expect that we will continue to make additional patent application filings, and will continue to pursue opportunities to acquire and license additional intellectual property assets, technologies, platforms or product candidates, as developments arise or are identified. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regardless, we cannot be certain that any of the patent filings or other intellectual property rights that we have pursued or obtained will provide protection for any products as commercialized. Our product candidates are currently in clinical testing, with no certainty that they will be successful, or that significant modification or adjustment may not be required for successful commercialization; even our </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 vaccine </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> has been granted only </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">emergency use, temporary use or </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conditional marketing approval; its composition, manufacture, and use may yet be adjusted or modified and our filings may not protect it.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future commercial success depends, in part, on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business; defend and enforce our patents and other intellectual property; preserve the confidentiality of our trade secrets; and operate without infringing, misappropriating or violating the valid and enforceable patents and other intellectual property rights of third parties. Our ability to stop third parties from making, using, selling, offering to sell or importing our products may depend on the extent to which we have rights under valid and enforceable patents, trade secrets or other intellectual property rights that cover these activities. With respect to both our owned and licensed intellectual property, we cannot be sure that patents will issue with respect to any of the owned or licensed pending patent applications or with respect to any patent applications that we, our co-owners or our licensors may file in the future, nor can we be sure that any of our owned or licensed patents or any patents that may be issued in the future to us or our licensors will be commercially useful in protecting any products that we ultimately attempt to commercialize or any method of making or using such products. Moreover, we may be unable to obtain patent protection for certain of our product candidates generally as well as with respect to certain indications. See &#8220;Risk Factors&#8212;Risks Related to our Intellectual Property&#8221; in this Annual Report on Form 20-F. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 15, 2020, our overall owned and in-licensed patent portfolio included more than 200 patent families, each of which includes at least one filing in the United States or Europe, and several of which are pending or granted in multiple jurisdictions. The patent families include at least 100 patent families that are solely or jointly owned by BioNTech, including certain families acquired through our acquisitions of antibody assets and infrastructure from MabVax Therapeutics Holdings, Inc. as well as intellectual property assets acquired through our acquisitions of Lipocalyx GmbH and Neon, and others that we have licensed from a third party. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An issued patent provides its owner (or possibly its licensee) with a right to exclude others from making, using or selling that which is claimed in the patent, for a specified period of time (the &#8220;term&#8221; of the patent), in the jurisdiction in which the patent is issued. In the United States, and in many other countries, patents have a presumptive term of 20 years from their effective filing date (which is the earliest non-provisional filing date to which the patent claims priority). However, many jurisdictions, including the United States, require the payment of periodic maintenance fees in order for patents to remain in force for the full 20-year term. The United States also has provisions that require a patent term to be shortened if its claims are too similar to another patent owned by the same party that has a shorter term. The United States and certain other jurisdictions also have provisions that permit extension of patent term for patents that claim a drug or drug product, or its approved use, if the patent was issued before clinical trials were completed and certain other requirements were satisfied. In the United States, such extension is called a Patent Term Extension, or PTE, and it is limited to a period of not more than five years, or the total patent term including the PTE cannot exceed 14 years after the date of regulatory approval; only one patent can be extended per product approval. The United States also offers a different form of patent term extension, known as Patent Term Adjustment, or PTA, whereby a particular patent&#8217;s term is automatically extended beyond the 20-year date if the United States Patent and Trademark Office, or the USPTO, caused delay during its examination; however, potentially available PTA is reduced by any amount of any delay caused by the patent applicant. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Below, we provide a summary of the contours of our current patent portfolio as it relates to different aspects of relevant technology, including noting ownership and 20-year terms for filings included in the portfolio that are directed to such aspects. Particularly given our pre-commercial state of development, we cannot be certain that any of the patent filings in our portfolio will provide meaningful protection for any product we ultimately attempt to commercialize. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">B. Patent Portfolio </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent portfolios for our most advanced programs are summarized below. Patent prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the USPTO and its foreign equivalents can be significantly narrowed by the time they issue, if they issue at all. We expect this could be the case with respect to some of our pending patent applications referred to below. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. mRNA </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">156</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent portfolio for our mRNA therapeutic platforms and product candidates includes patent filings directed to features of therapeutic mRNA structures, some of which are included in current development candidates. Our patent portfolio also includes patent filings directed to mRNA formulations, including the lipoplex formulations currently utilized with our FixVac and iNeST platforms, and the lipid nanoparticles currently utilized with our RiboMab and RiboCytokine platforms, as well as patent filings directed to mRNA manufacturing, and to uses of mRNA therapeutics. We provide more detail below regarding the patent filings directed to these features. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">mRNA Structure </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our patent portfolio includes patent filings directed to various features of mRNA structure, which may, for example, contribute to increased immunogenicity (<font style="font-style:italic;">e.g</font>., antigen presentation), translation efficiency, and/or stability of mRNA constructs that include them. Such features include, for example, antigen-MHC fusions, 5&#8217; cap structures, 3&#8217; UTR structures, polyA tails, reduced-uracil content mRNAs, and modified nucleoside RNAs. Filings directed to each of these features, or collectively, the mRNA Structure Filings, have been made in the United States and various foreign jurisdictions. Some such mRNA Structure Filings are owned solely by BioNTech SE or BioNTech RNA which are referred to collectively in this section as BioNTech, some jointly by BioNTech and one or more third parties, and some by BioNTech licensors, such as Louisiana State University, or LSU, and the terms of the applicable agreement with LSU, are further summarized below in &#8220;&#8212;C. In-Licensing.&#8221; We have non-exclusive rights to use certain US and European patent filings owned by University of Pennsylvania and relating to RNA containing modified nucleosides through our sublicense agreements with mRNA RiboTherapeutics, Inc. (MRT) and CellScript, LLC, collectively the MRT-CellScript Sublicenses and summarized below in &#8220;--C. In-Licensing&#8221;. Issued existing mRNA Structure Filings have, and pending existing mRNA Structure Filings, if issued, would have, 20-year terms that extend into the mid-2020s to the mid-2030s.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">mRNA Formulations </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our patent portfolio includes patent filings directed to various formulations for mRNA delivery, some of which are utilized with current development candidates. For example, our portfolio includes patent filings directed to lipoplex formulations, with 20-year terms that extend into 2038, if issued, or collectively, the mRNA Lipoplex Filings, although none of these filings is currently an issued patent. Such mRNA Lipoplex Filings are solely owned by BioNTech RNA. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our portfolio includes U.S. and foreign patent filings directed to lipid nanoparticles and polyplex technologies, which are jointly owned by BioNTech RNA and TRON, or collectively, the mRNA Lipid Nanoparticle/Polyplex Filings. Issued mRNA Lipid Nanoparticle/Polyplex Filings have, and pending mRNA Lipid Nanoparticle/Polyplex Filings, if issued, would have, 20 year terms that extend into the mid- to late-2030s. Some such mRNA Lipid Nanoparticle/Polyplex Filings were granted in certain foreign jurisdictions, but do not currently include any U.S. issued patents. The terms of the co-ownership of such patent filings with TRON are summarized below in &#8220;&#8212;C. In-Licensing.&#8221;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">mRNA Manufacturing </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As discussed below, we utilize trade secret protection for many aspects of our mRNA manufacturing technologies, including as currently utilized for production of certain of our development candidates. In addition, our patent portfolio includes certain patent filings relevant to mRNA manufacturing, or collectively, the mRNA Manufacturing Filings, which we believe may provide commercial value to protect product candidates and/or support collaborations or other licensing arrangements. For example, our mRNA Manufacturing Filings include U.S. and foreign patent filings relating to certain aspects of mRNA purification and production. These mRNA Manufacturing Filings are either solely owned by BioNTech SE or BioNTech RNA, or jointly owned by BioNTech RNA and TRON and, if issued, would have 20-year terms that would extend into mid 2030 to early 2040s, although none is currently an issued patent. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">mRNA Commercial Products and Product Candidates </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Our COVID-19 vaccine<font style="font-style:normal;">. Our COVID-19 vaccine (BNT162b2) is our most advanced mRNA product, and has received conditional marketing approval in various jurisdictions.&nbsp;&nbsp;Additional COVID-19 vaccine candidates, and certain mRNA oncology product candidates are in clinical development and involve various platforms. Our pipeline also includes mRNA product candidates for treatment of certain infectious diseases beyond COVID-19, and mRNA product candidates for protein replacement therapy in certain rare diseases. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">BNT162b2 and Other COVID-19 Vaccine mRNA Product Candidates</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our COVID-19 vaccine (</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BNT162b2</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> is a nucleoside-modified mRNA formulated in lipid nanoparticles and encodes an optimized SARS-COV-2 full-length spike protein antigen. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our platform patent filings relevant to Our COVID-19 vaccine (BNT162b2), collectively, the &#8220;BNT162b2 Platform Filings&#8221;, include certain mRNA Structure Filings relating to features for increasing translation efficiency and/or stability of mRNA constructs <font style="font-style:italic;">(e.g</font>., certain 3&#8217; UTR structures containing a specific sequence element, and interrupted polyA tails), including filings which are jointly owned by BioNTech RNA and TRON; also relevant are certain mRNA Manufacturing Filings. Issued BNT162b2 Platform Filings have, and pending BNT162b2 Platform Filings, if issued, would have 20-year terms extending into the late-2020s to the early-2040s.&nbsp;&nbsp;We also have undertaken various patent filings specifically related to BNT162b2 structure, composition, formulation, packaging, use and/or manufacture, or the BNT162b2 Platform Filings, including filings that have arisen through collaboration with third parties such as Pfizer. Such filings relevant to our COVID-19 vaccine, if issued, would have 20-year terms that would extend into early 2040s; there are presently no issued patents within the BNT162b2 Platform Filings.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As noted above, our MRT-CellScript Sublicenses grant us rights to use certain U.S. and European patents and applications relating to RNAs containing modified nucleosides, including as used in BNT162b2. We also have a non-exclusive license from the National Institutes of Health granting us right to use certain US and European patent filings relating to SARS-COV-2 spike (S) protein variants that lock the S protein in an antigenically preferred prefusion conformation; such a variant is utilized in BNT162b2. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we have obtained third-party licenses to technologies relating to certain lipids and/or lipid nanoparticles and formulations used in BNT162b2, including a non-exclusive license from Acuitas Therapeutics, grants use rights relevant to proprietary lipid nanoparticles and formulations used in BNT162b2.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other COVID-19 Vaccine mRNA product candidates are being developed and tested in clinical trials, which share with BNT162b2certain structural elements, and/or features of composition, formulation, packaging, use and manufacture.&nbsp;&nbsp;Thus, some or all of the BNT162b2 Platform Filings and/or BNT162b2 Filings, as well as the in-licensed rights discussed above with respect to BNT162b2, may be relevant to certain of these candidates.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Oncology mRNA Product Candidates </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All our current clinical programs outside of COVID-19 are in oncology. Our most advanced clinical oncology programs involve our iNeST immunotherapy product candidates being developed with our collaborator, Genentech. We also have FixVac product candidates in Phase 1 clinical trials and have initiated Phase 1 clinical trials of our mRNA-based intratumoral immunotherapy developed through our collaboration with Sanofi. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">FixVac</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our FixVac product candidates share many of the structural elements involved in our iNeST product candidates. Thus, some or all of the mRNA Structure Filings relevant to our iNeST product candidates and discussed below are also relevant to our FixVac product candidates. These patent filings, or the FixVac Platform Filings, include mRNA Structure Filings relating to antigen-MHC fusions, certain 5&#8217; cap structures, 3&#8217; UTR structures containing a specific sequence element, and interrupted polyA tails, which are solely or jointly owned by BioNTech or BioNTech&#8217;s licensors. Issued FixVAC Platform Filings have, and pending FixVac Platform Filings, if issued, would have, 20-year terms extending into the mid-2020s to the mid-2030s. While we have pursued or obtained patent protection covering components of FixVac product candidates, manufacturing-related methods and/or formulations, we do not currently have any claims in our owned or in-licensed issued patents that cover the overall construct used in our FixVac product candidates. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our patent portfolio further includes U.S. and foreign patent filings relating to combined uses of our FixVac and iNeST product candidates. Such issued patent filings have, and such pending patent filings, if issued, would have, 20-year terms that extend into 2033, and are jointly owned by BioNTech RNA and TRON. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current Phase 1 clinical trials for FixVac product candidates are studying such product candidates in treatment of advanced melanoma, head and neck cancer, breast cancer (particularly triple negative breast cancer), prostate cancer, and ovarian cancer. While we do not currently have any claims in our owned or in-licensed issued patents that are directed to use of our FixVac product candidates in the indications of these clinical trials, certain FixVac Platform Filings include specific reference to treatment of each of these indications. Additionally, our patent portfolio relevant to FixVac product candidates further includes U.S. and foreign patent filings relating to use of particular tumor antigens for treatment of triple negative breast cancer included in Phase 1 clinical trials, or the Triple Negative Breast Cancer FixVAC Filings. Issued </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Triple Negative Breast Cancer FixVac Filings have, and pending Triple Negative Breast Cancer FixVac Filings, if issued, would have, 20-year terms extending into the early- to mid-2030s, and are jointly owned by BioNTech SE and TRON. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.03%;text-indent:2.9%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">iNeST</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our patent filings relevant to our iNeST product candidates include mRNA Structure Filings relating to features for increasing antigen presentation (<font style="font-style:italic;">e.g</font>., antigen-MHC fusions) and features for increasing translation efficiency and/or stability of mRNA constructs (<font style="font-style:italic;">e.g.</font>, certain 5&#8217; cap structures, 3&#8217; UTR structures containing a specific sequence element, and polyA tails of a particular length or interrupted polyA tails); mRNA Lipoplex Filings relating to negatively charged lipoplexes (<font style="font-style:italic;">e.g</font>., for spleen targeting); and mRNA Manufacturing Filings, or collectively, the iNeST mRNA Platform Filings. While we have pursued or obtained patent protection covering components of iNeST product candidates, manufacturing-related methods and/or formulations, we do not currently have any claims in our owned or in-licensed issued patents that cover the overall construct used in our iNeST product candidates. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our patent portfolio further includes U.S. and foreign filings directed to the process of identifying neoantigens in patient samples and/or predicting those that will be immunoreactive in an iNeST immunotherapy product, or collectively, the Neoantigen Filings. Certain issued Neoantigen Filings have, and certain pending Neoantigen Filings, if issued, would have 20-year terms that extend into the 2030s, although none is a U.S. issued patent. Many of the Neoantigen Filings are solely owned by BioNTech RNA, or jointly owned by BioNTech RNA and TRON; our acquisition of Neon added various Neoantigen Filings, including both BioNTech US-owned and in-licensed filings. BioNTech RNA and TRON jointly own issued EP patent number 2714071, whose claims recite steps relating to neoantigen selection, that has recently been opposed by multiple third parties; claims in the related U.S. case have recently been allowed. If we are unsuccessful in these oppositions, the patent claims for our iNeST product candidates may be narrowed, or a patent may not issue at all. See &#8220;Risk Factors&#8212;Risks Related to our Intellectual Property&#8221; in this Annual Report on Form 20-F. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently studying our iNeST product candidates for the treatment of metastatic melanoma in Phase 2 clinical trials and those for the treatment of various solid tumors in Phase 1 clinical trials. Certain iNeST mRNA Platform Filings and Neoantigen Filings cover treatment of each of these indications. However, we do not currently have any claims in our owned or in-licensed issued patents that are directed to use of iNeST product candidates in the indications of these clinical trials. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Intratumoral Immunotherapies</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of the mRNA Structure Filings (including some that are relevant to iNeST and/or FixVac product candidates, as discussed above) are also directed to one or more features of our intratumoral immunotherapies, including our most advanced intratumoral immunotherapy, which we are developing through our collaboration with Sanofi, and which has recently entered Phase 1 clinical trials. For example, mRNA Structure Filings relating to 3&#8217; UTR structures containing a specific sequence element, interrupted polyA tail structures, and reduced-uracil content mRNAs, which, as noted above are solely or jointly owned by BioNTech and, if issued, would have 20-year terms extending into the mid-2030s, provide protection to our current intratumoral immunotherapy development candidate. However, these filings do not currently include any issued patents. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain patent filings that are relevant to intratumoral immunotherapies include certain patent filings under the MRT-CellScript Sublicenses, which include patent filings directed to nucleotide-modified mRNAs.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, certain patent filings have arisen from our collaboration relating to compositions including mRNAs encoding particular cytokines for treatment of solid tumors, or the mRNA Cytokine Filings. Such mRNA Cytokine Filings, if issued, would have 20-year terms that would extend into 2038. However, these filings do not currently include any issued patents. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">RiboMabs and RiboCytokines </font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own or license a number of patent filings directed to our RiboMab and RiboCytokine programs. Many are owned solely by us, some are jointly owned, and some have been acquired or licensed. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patent filings relevant to our RiboMab and RiboCytokine programs include certain mRNA Structure Filings relevant to our iNeST and/or FixVac product candidates, specifically relating to 3&#8217; UTR structures containing a specific sequence element, interrupted polyA tail structures, and reduced-uracil content mRNAs; mRNA Lipid Nanoparticle/Polyplex Filings; and patent filings under the MRT-CellScript Sublicenses relating to nucleoside-modified mRNAs. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have also recently acquired patent assets from MabVax Therapeutics Holding, Inc., or the MabVax Filings, that relate to various antibodies, including certain antibodies targeting sialyl Lewis A and ganglioside GD2, as well as nucleic acid encoding them. Issued MabVax Filings have, and the pending MabVax Filings, if issued, would have, 20-year terms that extend into the mid-2030s.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.03%;text-indent:2.9%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Infectious Diseases beyond COVID-19 </font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is discussed elsewhere, we have collaborated with third parties, including Pfizer and Penn to develop infectious disease mRNA vaccines. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain patent filings that might be useful to our infectious disease mRNA vaccines include certain of the mRNA Structure Filings and the mRNA Lipid Nanoparticle/Polyplex Filings as well as certain patent filings under the MRT-CellScript Sublicenses, which include patent filings directed to nucleotide-modified mRNAs. Self-Amplifying RNA Filings as discussed above may also be relevant. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have also licensed technologies relating to certain lipids and/or lipid nanoparticles and formulations that may be useful for certain infectious disease mRNA vaccines. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.07%;text-indent:2.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Rare Diseases </font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing mRNA-based protein replacement therapy for several rare disease indications through our collaboration with Genevant. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of the mRNA Structure Filings (including some that are relevant to iNeST and/or FixVac product candidates, as discussed above) and patent filings under the MRT-CellScript Sublicenses include patent filings directed to nucleoside-modified mRNAs also provide protection for one or more features of mRNA-based protein replacement product candidates. For example, mRNA Structure Filings include patent filings directed to 3&#8217; UTR structures containing a specific sequence element, interrupted poly A tail structures and reduced-uracil content mRNAs, which, as noted above are solely or jointly owned by BioNTech, and, if issued, would have 20-year terms that would extend into the mid-2030s. However, these filings do not currently include any issued patents. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our patent portfolio relating to our rare disease programs also include certain patent filings that we have licensed from Genevant, or the Genevant Filings. Specifically, the Genevant Filings are owned by Arbutus Biopharma Corporation and relate primarily to lipid or non-liposomal formulations that might be useful in these programs, and have been filed primarily in the United States and Europe, with 20-year terms that extend into mid-2020s to mid-2030s for the issued Genevant Filings and the pending Genevant Filings, if issued. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. Cell Therapy</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Engineered Cell Therapy </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our engineered cell therapy product class features use of chimeric antigen receptor, or CAR-, T cell or individualized T cell receptors for oncology therapy. Our patent filings relevant to these platforms and product candidates, or the CAR-T/TCR Filings, are generally co-owned by BioNTech Cell &amp; Gene Therapies GmbH, or BioNTech C&amp;GT, and TRON. For example, the CAR-T/TCR Filings include patent filings directed to various CAR-T formats and methods of enhancing CAR-T cells by nucleic acid vaccination, as well as patent filings directed to processes of identifying and/or making individualized T cell receptors. The CAR-T/TCR Patent Filings, if issued, would have 20-year terms that would extend into the mid- to late-2030s. However, these filings do not currently include any issued patents. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain CAR-T programs involve CAR-T cell product candidates that target different members of the claudin family. Our patent portfolio includes certain patent filings specifically relevant to our claudin-specific CAR-T cell product candidates and are jointly owned by BioNTech C&amp;GT, TRON and Ganymed, or the Claudin-Specific CAR-T Cell Filings. The issued Claudin-Specific CAR-T Cell Filings have, and the pending Claudin-Specific CAR-T Cell Filings, if issued, would have, 20-year terms extending into the mid-2030s. However, these filings do not currently include any U.S. issued patents. The terms of our co-ownership of such patent filings with TRON and Ganymed are summarized below in &#8220;&#8212;C. In-Licensing.&#8221;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Activated T Cells </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our acquisition of Neon included technologies for using peripheral blood mononuclear cells, or PBMCs, (</font><font style="font-style:italic;">e.g</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">., collected from apheresis material of patients) as a starting material to induce and/or expand </font><font style="font-style:italic;">ex vivo</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> functional T cells specific for therapeutically-relevant neoantigens. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our BNT221 program, formerly Neon&#8217;s NEO-PTC-01 program, is a personalized adoptive T cell therapy, which uses multiple T cell populations expanded from an individual patient&#8217;s PBMCs that together target a set of neoantigens expressed by that patient&#8217;s tumor. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patent filings relevant to BNT221, referred to herein as the T Cell Induction/Expansion Filings, are generally solely owned by BioNTech US, or co-owned by BioNTech US and the Netherlands Cancer Institute (NKI). For example, the T Cell Induction/Expansion Filings include patent filings directed to therapeutic T cell compositions and methods of <font style="font-style:italic;">ex vivo</font> induction and/or expansion of antigen-specific T cells, for example, using T cells of specific phenotypes for induction/expansion. The T Cell Induction/Expansion Filings, if issued, would have 20-year terms that would extend into the late-2030s to early-2040s. These filings do not currently include any issued patents. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of the Neoantigens Filings may also be relevant to BNT221. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. Antibodies </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our antibodies product class features bispecific checkpoint immunomodulators for oncology therapy, which are developed through collaboration with Genmab. Our development candidates include bispecific antibodies that are designed to activate 4-1BB upon simultaneous binding to PD-L1 or CD-40. Our patent portfolio includes certain patent filings relevant to such bispecific antibodies, or the Bispecific Checkpoint Modulator Filings, co-owned by us and Genmab. Such Bispecific Checkpoint Modulator Filings, if issued, would have 20-year terms that would extend into the late-2030s and do not currently include any issued patents. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. Small Molecule Immunomodulators </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our small molecule therapeutics product class features oncology treatment using small molecule product candidates that activate the immune system via TLR7 agonism. Our patent portfolio includes patent filings relevant to these TLR7 agonists, or the TLR7 Agonist Filings. Certain TLR7 Agonist Filings are directed to substituted imidazoquinolines, and, if issued, would have 20-year terms that would extend into the late 2030s. However, these filings do not currently include any issued patents. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C. In-Licensing </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of our intellectual property assets have been acquired by acquisition and/or in-licensing.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have pursued a strategy of identifying and in-licensing third-party patents that we believe are complementary to or otherwise interact synergistically with our own intellectual property portfolio. We have entered into material intellectual property licensing or option arrangements with TRON, Louisiana State University and MRT-CellScript.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The key terms of these arrangements are summarized below. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">TRON Agreements </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2015, we and our subsidiaries BioNTech RNA, BioNTech Diagnostics GmbH, BioNTech Protein Therapeutics GmbH, BioNTech Cell &amp; Gene Therapies GmbH, Eufets GmbH and JPT Peptide Technologies GmbH entered into a Master Agreement for Research Services with TRON. Concurrently with this Master Agreement for Research Services, or the TRON Research Agreement, we entered into a License Agreement with Ganymed, TRON, Johannes Gutenberg-Universit&#228;t Mainz and Universit&#228;tsmedizin der Johannes Gutenberg-Universit&#228;t Mainz, or the TRON License Agreement. The TRON Research Agreement and TRON License Agreement together replaced and superseded our 2008 Cooperation, Purchase and Licensing Agreement with the University Mainz, or the 2008 Cooperation Agreement. In 2019, we and our subsidiaries BioNTech RNA Pharmaceuticals GmbH, BioNTech Diagnostics GmbH, BioNTech Protein Therapeutics GmbH, BioNTech Cell &amp; Gene Therapies GmbH, BioNTech Innovative Manufacturing Services GmbH and JPT Peptide Technologies GmbH, entered into a Framework Collaboration Agreement with TRON, or the TRON Collaboration Agreement. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">TRON Research Agreement </font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the TRON Research Agreement, TRON from time to time performs certain services for us under work orders, which may comprise innovative applied research projects, pre-defined research and development or clinical research services. We and TRON meet at regular intervals, but no less than annually, to prepare an overall non-binding project plan, which sets the scope, period and costs for the relevant projects contemplated for that period. Individual work orders set the specific binding terms of each project or service. TRON is obligated to render services in accordance with the scientific standards, all applicable laboratory and legal provisions and with the care customary in the industry. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are entitled to the exclusive rights to all inventions, methods, specifications, materials, documents, data, know-how and other results (together, the Results) developed or discovered by TRON or by us and TRON jointly under the TRON Research Agreement, except to the extent they constitute improvements of the technologies applied by TRON in the relevant projects. Under the TRON Research Agreement, TRON granted us a non-exclusive, royalty-free license to use TRON Improvements if such TRON Improvements are necessary for the continued development and exploitation of the Results or the manufacture or marketing of products which contain any of the Results and are covered by a patent claiming any of the Results. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the TRON Research Agreement, TRON&#8217;s services rendered in the field of applied research are invoiced at cost. For other services, fixed prices are to be set forth in the individual work orders. TRON invoices us monthly and our payments are due no later than 10 days thereafter. Additionally, we are obligated to pay to TRON low single-digit tiered royalties on net sales of any product developed under the TRON Research Agreement that is covered by a patent claiming any of the Results. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The TRON Research Agreement limits each party&#8217;s liability to the other to intentional and grossly negligent actions and, in the case of gross negligence, liability for indirect and consequential damages and lost profits is excluded. We are obligated to indemnify TRON for all product liability claims in connection with the products and for third-party claims asserting that the Results violate third-party intellectual property rights. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The TRON Research Agreement has an indefinite term, but may be terminated by either party on six months&#8217; notice. If one of our subsidiaries terminates its role in the TRON Research Agreement, the agreement will survive and continue without that subsidiary. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2017, we and TRON entered into an agreement to include certain research and development activities regarding neoepitope RNA immunotherapies as work included in the TRON Research Agreement. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">TRON License Agreement </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The TRON License Agreement governs the ownership of and licenses under certain patents, inventions, know-how, technologies and other knowledge (together, the Development Results) filed and created before January 1, 2015 in the course of our collaboration with TRON, Johannes Gutenberg-Universit&#228;t Mainz and Universit&#228;tsmedizin der Johannes Gutenberg-Universit&#228;t Mainz (collectively, the University Parties) and Ganymed pursuant to the 2008 Cooperation Agreement. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The TRON License Agreement sets forth the parties&#8217; rights with respect to the Development Results, mainly depending on which parties have contributed to such Development Results. Ownership of the Development Results and any patents and other intellectual property in certain shares to TRON, on the one hand, and BioNTech and/or Ganymed, on the other hand included therein is allocated. Each party may assign its share in the co-owned Development Results to its affiliates provided that such party provide notice of the transfer and the identity of the new co-owner to the other co-owners. However, in case of an assignment of such share to a third party (except in case of a material asset sale), the assigning party must obligate the assignee to comply with the terms of the TRON License Agreement and the assigning party will remain bound by the obligations of the TRON License Agreement unless the other co-owners have consented to discharge the assigning party from such obligations. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The parties to the TRON License Agreement grant licenses to each other under their shares in the Development Results substantially as follows. Ganymed is exclusively entitled to use the Development Results for certain antibodies and antibody fragments that bind to certain defined targets, or the Ganymed Field of Use. We are exclusively entitled to use the Development Results in any other field of use (including immunological therapeutics, small molecule compounds, siRNA-based therapeutics, micro-proteins, antibody based <font style="font-style:italic;">in vitro</font> (except for those in the Ganymed Field of Use), diagnostics and therapeutics based on long-chain RNA as well as other cell therapy applications, immune cells transgenized with </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">recombinant directed against certain defined targets or chimeric antigene receptors and RNA-based pharmaceuticals). The University Parties may use the Development Results for internal research purposes only. We have an obligation to use reasonable efforts to develop and commercialize products in our field of use worldwide. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the TRON License Agreement, we and Ganymed must agree on which party will have the primary role in filing, prosecuting, maintaining and defending jointly owned patents. We and Ganymed each have the exclusive right to enforce the Development Results in our respective fields of use, subject to certain step-in rights of the other parties. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are obligated to pay to the University Parties low single-digit tiered royalties on net sales on any product that is covered by certain of the patents including in the Development Results. If licenses are granted to third parties, we are obligated to pay to the University Parties a mid-single-digit share of all upfront payments, milestone payments and other remuneration we receive from such third parties in consideration for the license. Regarding upfront payments only, the University Parties&#8217; share will be offset against subsequent license fees on net sales. In addition, we are obligated to pay certain development and regulatory milestones up to a low seven-figure amount to Johannes Gutenberg-Universit&#228;t Mainz. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The TRON License Agreement contains a limitation on liability as between the parties, wherein the parties will only be liable to each other for intentional and grossly negligent actions, and, in the case of gross negligence, liability for indirect and consequential damages and lost profits is excluded. We are obligated to indemnify the University Parties and Ganymed for third-party claims of product liability or violation of applicable law based on our distribution of our products or if we breach the TRON License Agreement or if we or one of our agents acts culpably. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The TRON License Agreement will remain in effect as long as there are any obligations on us or Ganymed to pay license fees. After expiry of the TRON License Agreement, each party will have a perpetual, non-exclusive, royalty-free license to use the Developments Results. The TRON License Agreement may be terminated by any party on six months&#8217; notice. The licenses granted between the parties will survive such termination. The TRON License Agreement also grants all parties termination rights for uncured material breaches. If only one party terminates its role in the Agreement, the Agreement will survive and continue between the other parties. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">TRON Collaboration Agreement </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the TRON Collaboration Agreement, TRON from time to time undertakes certain projects in collaboration with us under separate project specific agreements, comprising innovative non-clinical research and development projects. We and TRON meet regularly to review and update project plans, and no less than annually to agree the budget for the on-going projects for the coming calendar year. Individual project agreements set the specific binding terms of each project. TRON is obligated to perform its obligations in accordance with the scientific standards, all applicable technical laboratory and legal provisions and with the care customary in the non-clinical biotechnology research industry. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except for the results of a particular research project which has been funded exclusively by TRON, or the RNT Project, all of the inventions, methods, specifications, materials, documents, data, know-how and other results (together, the Results) developed or discovered by TRON or by us and TRON jointly under the TRON Collaboration Agreement are jointly owned. The Results of the RNT Project are owned exclusively by TRON. Under the TRON Collaboration Agreement, TRON grants us an exclusive, worldwide, sublicensable license under its interest in the Results to research and have researched, develop and have developed, make and have made, use, and otherwise commercialize or have commercialized, and otherwise commercially exploit, products in a field that is specified in the corresponding project agreement. The field of use is either (a) the prophylaxis, diagnosis and treatment of all indications in humans and animals; (b) the prophylaxis, diagnosis and treatment of oncological diseases, infectious diseases and rare genetic diseases; or (c) in the case of the Results from the RNT Project only, the prophylaxis, diagnosis and treatment of rectal neuroendocrine tumors in humans. We are required to use our reasonable efforts to develop and commercialize products that exploit the Results. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the TRON Collaboration Agreement, TRON&#8217;s activities are invoiced at cost. TRON invoices us monthly and our payments are due no later than 10 days thereafter. Additionally, we are obligated to pay to TRON low single-digit tiered royalties on net sales of any product developed under the TRON Collaboration Agreement that is covered by a patent claiming any of the Results or, in certain circumstances, by a patentable invention forming part of the Results which we elect to maintain as a trade secret. If licenses under Results are granted to third parties, we are obligated to pay to TRON a mid-single-digit share of all upfront payments, milestone payments and other remuneration we receive from such third parties in consideration for the license. In addition, we are obligated to pay a one-time only milestone of a low seven-figure </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">amount to TRON the first time annual sales of a product developed under the TRON Collaboration Agreement reach a low nine-figure number. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The TRON Collaboration Agreement limits each party&#8217;s liability to the other to cases of willful misconduct and gross negligence and, in the case of gross negligence, liability for indirect and consequential damages and lost profits is excluded. We are obligated to indemnify TRON for all product liability claims in connection with the products and for third-party claims asserting that the Results violate third-party intellectual property rights. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The TRON Collaboration Agreement came into force with retroactive effect from January 2015 and has an indefinite term, but may be terminated by either party on nine months&#8217; notice. If one of our subsidiaries terminates its role in the TRON Collaboration Agreement, the agreement will survive and continue without that subsidiary. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LSU License Agreement </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2015, we entered into a Patent License Agreement with the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, or LSU, and the University of Warsaw, or UW. The agreement (which we refer to as the LSU Agreement) replaces and supersedes the earlier license agreement between the parties. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the LSU Agreement, UW and LSU granted to us an exclusive royalty-bearing license under certain patent rights relating to mRNA cap analogs and the synthesis and use of anti-reverse phosphorothioate analogs of the mRNA cap in the United States, certain jurisdictions in the European Union and other countries. As consideration for the license granted, we are obligated to pay running royalties in the low single digits on all net sales of products utilizing the licensed patents and to pay annual maintenance fees to LSU. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are obligated to use commercially reasonable efforts to develop one or more marketable products utilizing the licensed patents, upon which we would owe additional milestone payments to LSU. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The LSU Agreement remains in effect until expiration of the licensed patents. We have the right to terminate the LSU Agreement for convenience with 60 days&#8217; prior notice, and LSU and UW may terminate for our uncured material breach. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:2.05%;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CellScript and mRNA Ribotherapeutics License Agreement </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech RNA entered into the two MRT-CellScript Sublicenses discussed above. Together, the MRT-CellScript Sublicenses grant BioNTech RNA worldwide, non-exclusive sublicenses under the Penn Modified mRNA Patent Rights (as defined in the MRT-CellScript Sublicenses) to research, develop, make, import, use and commercialize products for <font style="font-style:italic;">in vivo</font> uses in humans and non-human animals, including therapeutic and prophylactic applications, and for certain uses in the diagnostic and prognostic field of use and certain laboratory research or screening uses. Under these sublicenses, BioNTech RNA has the right to grant sublicenses to affiliates and third parties. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech RNA must use reasonable efforts to develop and commercialize products under the sublicenses. Furthermore, BioNTech RNA is obliged to pay MRT and CellScript development milestone payments of up to approximately $26 million as well as royalties in the low to mid-single digits on net sales of licensed products, depending on the field of use. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agreements continue until the expiration or abandonment of the last licensed patent to expire or be abandoned. BioNTech RNA may terminate the agreement for convenience with respect to all or certain patent rights with 60 days&#8217; prior written notice. MRT or CellScript may terminate the respective sublicense agreement for payment default, uncured material breach or the bankruptcy of BioNTech RNA. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">D. Trademark Portfolio </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain features of our business and our product candidates are protected by trademarks. Our trademark portfolio includes, but is not limited to, registrations for each of COMIRNATY&#174;, FixVac&#174;, IVAC&#174;, RiboCytokine&#174;, RiboMab&#174;, RECON&#174;, NEO-STIM&#174;, Precision NEO-STIM&#174; and MAPTAC&#174;, as well as certain other trademarks, including design versions of some of these trademarks. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">E. Trade Secret Protection </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of our technologies, including in particular certain proprietary manufacturing processes or technologies and/or neoantigen prediction technologies, are protected as trade secrets. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to patent protection, we rely upon unpatented trade secrets and confidential know-how and continuing technological innovation to develop and maintain our competitive position. We protect certain of our technologies, including, in particular, certain proprietary manufacturing processes and technologies and/or neoantigen prediction technologies, as trade secrets. However, trade secrets and confidential know-how are difficult to protect. We seek to protect our proprietary information, in part, by using confidentiality agreements with any future collaborators, scientific advisors, employees and consultants, and invention assignment agreements with our employees. We also have agreements requiring assignment of inventions with selected consultants, scientific advisors and collaborators. These agreements may not provide meaningful protection. These agreements may also be breached, and we may not have an adequate remedy for any such breach. In addition, our trade secrets and/or confidential know-how may become known or be independently developed by a third party, or misused by any collaborator to whom we disclose such information. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our products or to obtain or use information that we regard as proprietary. Although we take steps to protect our proprietary information, third parties may independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our trade secrets and proprietary information.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">XV. Competition </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We compete in an industry characterized by rapidly advancing technologies, intense competition and a complex intellectual property landscape. We face substantial competition from many different sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions and governmental agencies and public and private research institutions.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our competitors and potential competitors, either alone or with their collaborators, have greater scientific, research and product development capabilities as well as greater financial, marketing, sales and human resources and experience than we do. In addition, smaller or early-stage companies, including immunotherapy-focused therapeutics companies, may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Some of our collaborators, such as Genmab, Pfizer and Sanofi, may also be competitors within the same market or other markets. Accordingly, our competitors may be more successful than us in developing and potentially commercializing technologies and achieving widespread market acceptance. In addition, our competitors may design technologies that are more efficacious, safer or more effectively marketed than ours or have fewer side effects, or may obtain regulatory approvals more quickly than we are able, which could eliminate or reduce our commercial potential. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that the key competitive factors affecting our technologies will be efficacy, safety, cost and convenience, ease of distribution, storage and administration, as well as our ability to build a fully-integrated biotechnology company. The availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our products. The timing of market introduction of our products and competitive products will also affect competition among products. We expect the relative speed with which we can develop our products, complete the clinical trials and approval processes, and supply commercial quantities of the products to the market to be important competitive factors. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specifically, BNT162b2 competes with, and any other COVID-19 vaccines we and Pfizer develop would compete with, other COVID-19 vaccines that have been approved or authorized for temporary or emergency use and a large number of vaccine manufacturers, academic institutions and other organizations currently have programs to develop COVID-19 vaccine candidates.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">XVI. Legal Proceedings </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may be involved in legal proceedings in the ordinary course of business. We are currently not a party to any material legal or administrative proceedings. In addition, we are not aware of any material legal or administrative proceedings contemplated to be brought against us. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">C.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_4_C"></a><font style="text-decoration:none;Background-color:#auto;"></font><font style="color:#000000;"></font><font style="color:#000000;">Organizational</font><font style="color:#000000;"> </font><font style="color:#000000;">S</font><font style="color:#000000;">tructure</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="toc838504_10"></a>See<font style="color:#231F20;"> Item 18. </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">D.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_4_D"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Property, Plant and Equipment </font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our headquarters are located in Mainz, Germany, where we occupy: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Approximately 9,416 square meters (equivalent to approximately 101,353 square feet) of laboratory, GMP manufacturing, storage and office space under a lease for the entire building located at An der Goldgrube 12, 55131 Mainz under a lease that has an initial term that expires on October 31, 2027, but which we have the option to extend until October, 2042. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Approximately 1,069 square meters (equivalent to approximately 11,507 square feet) of office and GMP manufacturing space under a lease for part of the building located at Kupferbergterrasse 15, 17019, 44116 Mainz under a lease that expires in March 31, 2022.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Approximately 4,882 square meters (equivalent to approximately 52,549 square feet) of flexible use space intended for laboratory and office use located at Adam-Opel-Stra&#223;e 10, 55129 Mainz, which is owned by us.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Approximately 210,639 square meters (equivalent to approximately 22,673 square feet) of office and storage space under a lease for part of the building located at Robert-Koch- Stra&#223;e 50, 55129 Mainz under a lease that expires in November 15, 2025.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Approximately 82,881 square meters (equivalent to approximately 892,124 square feet) of office space and a further area of land associated with this office space of approximately 12,600 square meters (equivalent to approximately 135,625 square feet), which is owned by BioNTech.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Approximately 360 square meters (equivalent to approximately 3,875 square feet) of office space under a lease for part of the building located at Heiligkreuzweg 90, 55130 Mainz under a lease that expires in December 31, 2022.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We also own a plot of land of approximately 8,753 square meters (equivalent to 94,216 square feet) at Hechtsheimer Stra&#223;e, 55131 Mainz, where construction for a GMP manufacturing facility has commenced early this year. </font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our BioNTech IMFS facility in Idar-Oberstein, Germany, occupies approximately 2,800 square meters (equivalent to approximately 30,140 square feet). This includes 650 square meters (approximately 7,000 square feet) of clean room area, and 700 square meters (approximately 7,500 square feet) of development and quality control laboratories. We occupy approximately 575 square meters (equivalent to approximately 6,200 square feet) of this space, which is used primarily for storage, under a lease that has an initial expiry date of October 1, 2021, but which we have the right to extend by an additional five years. We occupy approximately 100 square meters (equivalent to approximately 1,075 square feet) of this space, which is used primarily for storage, under a lease that can be terminated by either party on six months&#8217; written notice (but not earlier than May 1, 2020). We occupy approximately 80 square meters (equivalent to approximately 860 square feet) of this space, which is used as office space, under a lease that can be terminated by either party on three months&#8217; written notice. The rest of this facility, including the GMP-certified manufacturing suites, is owned by BioNTech. We also recently purchased a building of approximately 802 square meters (equivalent to 8,632 square feet) near our IMFS facility in Idar-Oberstein, which will be used as office space. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have completed construction of two new buildings at our BioNTech IMFS facility in Idar-Oberstein, Germany, occupy an additional 780 square meters (equivalent to approximately 8,395 square feet) of clean room space and 550 square meters (<font style="color:#000000;">equivalent</font> to approximately 5,900 square feet) of laboratory space, expanding our capacity for GMP cell therapy manufacturing and 650 square meters (equivalent to approximately 7,000 square feet) of office space.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At our manufacturing facility in Marburg, Germany, we occupy approximately 10,240 square meters (equivalent to approximately 110,220 square feet), including 4,589 square meters (equivalent to approximately 49,400 square feet) of GMP space, 2,422 <font style="color:#000000;">square</font> meters (equivalent to approximately 26,070 square feet) of technical and storage facilities, 540 square meters (equivalent to approximately 5,810 square feet) of laboratory space and 2,690 square meters (equivalent to approximately 28,960 square feet) of offices. That lease will expire December 31, 2034.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At our JPT facility in Berlin, Germany, we occupy approximately 1,794 square meters (equivalent to approximately 19,299 square feet) of office, laboratory and other space. Approximately 250 square meters of that space (equivalent to approximately 2,690 square feet) is occupied under a lease</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> which has an expiry date of June 20, 2020 and will continue for further six-month periods, unless terminated by either party on three months&#8217; prior written notice. Approximately 1,523 square meters (equivalent to approximately 16,199 square feet) are occupied under a lease for an indeterminate period but which may be terminated by either party on 12 months&#8217; prior written notice. The remaining approximately 20 square meters (equivalent to approximately 215 square feet) of storage space is occupied under a lease on a monthly basis and can be terminated by either party giving two weeks&#8217; written notice. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Martinsried, Germany, outside Munich, Germany, we occupy approximately 1,681 square meters (equivalent to approximately 18,100 square feet) under a lease that had an initial term which expired on December 31, 2020, but which we exercised the option to extend until December 31, 2024. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Neuried, Germany, outside Munich, Germany, we occupy approximately 725 square meters (equivalent to approximately 7,800 square feet) of laboratory and office space under a lease that expires on December 31, 2021, but which we have the option to extend until December 31, 2026. If the lease is not terminated before December 31, 2021 (where the option is not exercised) or December 31, 2026 (where the option is exercised) the lease will renew automatically for an additional one-year period until terminated by either party on 12 months&#8217; prior written notice. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Halle (Saale), Germany, we have since the beginning of 2020 occupied approximately 415 square meters (equivalent to approximately 4,467 square feet) of office and other space under a lease that expires on February 28, 2022. We further occupy 90 square meters (equivalent to approximately 968 square feet) of laboratory space under a lease that also expires on February 28, 2022. Each lease will renew automatically for an additional one-year period until terminated by either party on six months&#8217; prior written notice to expire at the end of the lease period (or any extension thereof). </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Cambridge, Massachusetts we occupy approximately 2,490 square meters (equivalent to approximately 26,802 square feet) of laboratory and office space under a lease that has an initial term that expires on September 30, 2024, but which we have the option to extend until December 31, 2024. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to expand our capacity as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">In the second quarter of 2021, we will commence construction of a four-story building at our BioNTech Campus at An der Goldgrube 12 in Mainz, Germany, which we will own. We have planned laboratory space for research and development, offices, storage facilities, a conference center and cafeteria. As a result, we will occupy an additional 24,000 square meters (equivalent to approximately 258,300 square feet) of laboratory space and office space.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We anticipate purchasing property and the construction of a new office building adjacent to the planned iNeST GMP manufacturing facility. Upon completion of the construction project, we will occupy up to approximately 6100 additional square meters (equivalent to approximately 65,650 square feet) of useable floor space for offices, storage, meeting areas and cafeteria.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We anticipate completing the construction of a new building complex for our JPT business in Berlin, Germany, possibly as early as 2023. Upon completion of the construction project, we will occupy up to approximately 5,000 additional square meters (equivalent to approximately 53,820 square feet) of useable floor space split between laboratories, offices and storage.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are committed to the continued development of world-class laboratory and manufacturing operations to support our research and development and clinical manufacturing needs, to prepare for commercial scale manufacturing of our product candidates, and to realize external commercial opportunities. Our planned laboratory and manufacturing investments include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">two new buildings at our BioNTech IMFS facility, including three floors each of clean rooms and additional development and quality control laboratories;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our planned commercial scale facility in Mainz, which will occupy more than 100,000 square feet and will house cleanrooms, laboratories and offices; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">an expansion of our JPT facility, which is designed to more than double our capacity; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">an expansion of our laboratory space for research and development on our Mainz campus. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_4A_UNRESOLVED_STAFF_COMMENTS"></a><a name="ITEM_4A_UNRESOLVED_STAFF_COMMENTS"></a>Item 4A. Unresolved Staff Comments </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are no written <font style="color:#000000;">comments</font> from the staff of the U.S. Securities and Exchange Commission which remain unresolved before the end of the fiscal year to which the Annual Report relates.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_5_OPERATING_FINANCIAL_REVIEW_PROSPE"></a><a name="ITEM_5_OPERATING_FINANCIAL_REVIEW_PROSPE"></a>Item 5. Operating and Financial Review and Prospects</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The following &#8220;Operating and Financial Review and Prospects&#8221; should be read together with the information in our financial statements and related notes included elsewhere in this Annual Report. The following discussion is based on our financial information prepared in accordance with the International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB, which may differ in material respects from generally accepted accounting principles in other jurisdictions, including U.S. GAAP. The following discussion includes forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including but not limited to those described in &#8220;Risk Factors&#8221; and elsewhere in this Annual Report. Please also see &#8220;Cautionary Statement Regarding Forward-Looking Statements.&#8221;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">A.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_5_A"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_5_A"></a>Operating Results</font></p></td></tr></table></div>
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Operations Overview</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table shows our consolidated statements of operations for each period presented:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.64%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.64%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research &amp; development revenues</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;178,849</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;84,428</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;101,837</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial revenues</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">303,476</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,161</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,738</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">482,325</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">108,589</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">127,575</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of sales</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59,333)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,361)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,690)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(645,029)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(226,466)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(143,040)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,512)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,718)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,041)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(94,049)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,547)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,334)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,358)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(739)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(720)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.64%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other operating income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250,539</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,724</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,396</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(82,417)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(181,518)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(53,854)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.64%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance income*</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,564</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,122</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,046</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance expenses*</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(62,946)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(326)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(48)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expenses related to lease liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,003)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,718)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,721)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.64%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share of loss of equity method investees</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(84)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss before tax</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(145,802)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(179,440)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(47,662)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.64%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.64%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161,000</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">268</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(600)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Profit / (Loss) for the period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15,198</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(179,172)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(48,262)</p></td>
</tr>
<tr>
<td colspan="6" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* Foreign exchange differences on a cumulative basis are either shown as finance income or expenses.</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Important Financial and Operating Terms and Concepts</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Revenues</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Historically, our revenue has primarily been derived from our collaborations and license agreements in the research and development phase. Research and development revenues were derived from upfront payments, development milestone payments and reimbursement of development expenses. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 2020, our COVID-19 vaccine has been authorized or approved for emergency or temporary use</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">granted</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> conditional marketing authorization in over </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">countries worldwide</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> which </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">resulted in</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> recognition of revenues from </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sale of pharmaceutical products for the first time</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Consequently, we have progressed from earning revenues primarily for research and development to earning</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> our </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">first </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">revenues from commercial </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sales</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial revenues are primarily collaboration revenues from earnings based on our partners&#8217; gross profit, which is shared under the respective collaboration agreements and sales milestone payments in addition to revenue from other sales transactions, which consists of sales of diagnostic products, peptides, retroviral vectors for clinical supply, and development and manufacturing services sold to third-party customers. We recognize revenues from selling COVID-19 vaccine manufactured by us to collaboration partners for further processing and to external customers in markets within our territory. Revenues for our share of the collaboration partners&#8217; profit is recognized as sales occur which is when the performance obligation has been satisfied. As described further in &#8220;Critical Accounting Policies and Use of Estimates&#8221; and Note 3 to our consolidated financial statements included elsewhere in this Annual Report, we use certain information from our collaboration partners, some of which is based on preliminary data shared between the partners and might vary once final data is available. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to generate revenue from sales of pharmaceutical products and sustain profitability depends upon our and our collaborators&#8217; ability to further successfully commercialize our product candidates and products. Our ability to generate COVID-19 vaccine revenues depends, in part, upon our production capacity. The timing of product manufacturing and delivery will determine the period in which revenue may be recognized. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that existing or potential future collaborations generate revenue, our revenue may vary due to many uncertainties in the development of further product candidates and other factors.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For further information on our revenue recognition policies, see &#8220;&#8212;Critical Accounting Policies and Use of Estimates&#8212;Revenue Recognition.&#8221; </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cost of sales</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our cost of sales includes royalty expenses, purchased services, personnel-related expenses and laboratory supplies, which are generally expensed in the period in which the associated revenue occurs. Cost of sales also includes amounts paid to collaboration partners for their share of profits earned in collaboration arrangements where we are the principal in the transaction. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our cost of sales may increase subject to us progressing our commercial activities with respect to our COVID-19 vaccine. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The nature of our business and primary focus of our activities, including development of our platforms and manufacturing technologies, generate a significant amount of research and development expenses, which in this respect, still account for the largest component of our total operating expenses. Research and development expenses include our share of expenses under the terms of collaboration agreements and 100% of the expenses for wholly-owned product candidates. Research and development expenses shared under our collaboration agreements, which are initially incurred by the collaboration partners and subsequently charged to us, are recorded as purchased services classified within research and development. Cost reimbursements from partners for research and development expenses initially incurred by us and due to us under the agreements, are recorded as a reduction to purchased services classified within research and development expenses. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into agreements under which third parties grant licenses to us. Consideration paid under those agreements include upfront payments, development milestone payments and development expense reimbursements as well as sales-based milestone and royalty payments. Milestone payments are recorded when the specific milestone has been achieved. If those licenses grant access to technologies, both parties jointly perform research or development activities and both are exposed to significant risks and rewards of the activities. Costs incurred with the agreements are not treated differently from costs related to own product candidates. If the agreements grant us rights to use certain patents and technologies that meet the definition of an identifiable assets, they are treated as acquired intangible assets. This assessment is made based on the facts and circumstances of each contractual agreement. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">169</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The value of goods and services received from contract research organizations</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or CROs,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and contract manufacturing organizations</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or CMOs,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in the reporting period are estimated based on the level of services performed and progress made in the respective period. Amounts are recorded as accrued expenses </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> we have not received an invoice from the service provider. Advance payments for goods or services that will be used or rendered for future research and development activities are recognized as other current assets or other current financial assets respectively. The amounts are currently expensed as the related goods are delivered or the services performed. Management&#8217;s estimates are based on the best information available at </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> time. However, additional information may become available in the future and management may adjust the estimate in such future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We consider resulting increases or decreases in cost as changes in estimates and reflects such changes in research and development expenses in the period identified.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research costs are expensed as incurred. Development expenditures on an individual project are recognized as an intangible asset if, and only if, the capitalization criteria are met. Due to the inherent risk of failure in pharmaceutical development and the uncertainty of approval, management has determined that these criteria are not met in the biotech sector. The related expenditure is reflected in the consolidated statements of operations in the period in which the expenditure is incurred. Sales-based milestone or royalty payments incurred under license agreements relating to self-developed intangibles after the approval date of the respective pharmaceutical product are considered as contingent considerations. These contingent considerations are recognized as expenses as incurred. Costs relating to production of pre-launch products are expensed as research and development expenses in the period incurred. If pre-launch products are sold, the respective product gross margin may be higher compared to the expected recurring margin as the underlying costs will not be included in cost of sales.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses represent costs incurred for the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">costs to develop our platforms;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">discovery efforts leading to product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">clinical development expenses for our programs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">costs related to pre-launch products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">costs to develop our manufacturing technology and infrastructure; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">digital infrastructure costs.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:4.91%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The costs above comprise the following categories:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>personnel-related expenses, including salaries, benefits, share-based compensation expense and social security expense;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>shared development expenses incurred under collaboration agreements with our partners;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>expenses incurred under agreements with third parties, such as consultants, investigative sites, CROs that conduct our preclinical studies and clinical trials, and in-licensing arrangements;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>costs of acquiring, developing and manufacturing materials for preclinical studies and clinical trials, including both internal manufacturing and CMO;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>expenses incurred for the procurement of materials, laboratory supplies and non-capital equipment used in the research and development process; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>facilities, depreciation and amortization, and other direct and allocated expenses incurred as a result of research and development activities.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot reasonably estimate the nature, timing and amount of research and development expenses required to complete the development of the product candidates we are currently developing or may develop in the future. A change in expectations or outcomes of any of the known or unknown risks and uncertainties may materially impact our expected research and development expenditures. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Continued research and development is central to the ongoing activities of our business. Product candidates in later stages of clinical development generally have higher development expenses than those in earlier stages of clinical </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development, primarily due to the increased size and duration of later-stage clinical trials. We expect these costs to continue to increase in the future as our product candidates progress through the development phases and as we identify and develop additional programs. However, we do not believe that it is possible at this time to accurately project total program-specific expenses through commercialization. There are numerous factors associated with the successful commercialization of any of our product candidates</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or products</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. Additionally, future commercial and regulatory factors beyond our control will impact our clinical development programs and plans.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Sales and Marketing Expenses</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our sales and marketing expenses mainly consist of purchased services and personnel-related costs. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our sales and marketing expenses may increase subject to us progressing our commercial activities with respect to our COVID-19 vaccine. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of personnel-related costs including salaries, benefits, share-based compensation expense and social security expense for finance, legal, human resources, business development and other administrative and operational functions, professional fees, accounting and legal services, information technology and facility-related costs. These costs relate to the operation of the business, unrelated to the research and development function or any individual program.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate general and administrative expenses will increase as research, development and commercial activities expand. This increase will likely relate to additional personnel and increased purchased service costs related in part to finance, legal and intellectual property-related matters along with increased expenses related to administrating our commercial activities with respect to our COVID-19 vaccine. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other<font style="color:#000000;"> Operating Income / Expenses</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our other operating income and expenses consists primarily of income from government grants.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Finance<font style="color:#000000;"> Income / Expenses</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our finance income and expenses consist of interest income and interest expenses on cash, fair value changes on certain financial liabilities as well as foreign exchange gains and losses. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes mainly include deferred tax benefits derived from recording deferred tax assets on differences between financial reporting and tax bases of assets and liabilities tax loss carry forwards. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The realization of deferred tax assets is dependent upon the generation of future taxable income, the amount and timing of which are subject to uncertainties. We may become subject to income tax audits and adjustments by local tax authorities. The assessments as to the recoverability of deferred tax assets and the nature of uncertain tax positions is subject to significant judgment by management and subject to change, which may be substantial.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For further information on our income tax policies, see &#8220;&#8212;Critical Accounting Policies and Use of Estimates&#8212;Income Tax.&#8221; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Comparison of the </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">year ended December&#160;31, 2020</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> and </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">year ended December&#160;31, 2019</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Revenues</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of revenues recognized for the periods indicated:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.84%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.84%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.84%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.84%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research &amp; development revenues from collaborations</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;178,849</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;84,428</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;94,421</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">112</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.84%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Pfizer Inc.</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">121,597</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">14,348</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">107,249</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">747</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.84%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Genentech Inc.</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">49,195</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">64,026</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(14,831)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(23)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.84%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Shanghai Fosun Pharmaceutical (Group) Co., Ltd</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">5,074</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">5,074</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.84%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2,983</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">6,054</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(3,071)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(51)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.84%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commercial revenues</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">303,476</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">24,161</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">279,315</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1,156</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.84%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 vaccine revenues</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">270,490</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">270,490</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.84%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Sales to collaboration partner*</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">61,460</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">61,460</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.84%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Direct product sales to BioNTech customers</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">20,553</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">20,553</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.84%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Share of collaboration partner's gross profit</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">188,477</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">188,477</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.84%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other sales</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,986</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,161</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,825</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.84%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;482,325</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;108,589</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;373,736</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">344</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Represents sales to our collaboration partner of products manufactured by us. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From the year ended December&#160;31, 2019 to year ended December&#160;31, 2020 total revenues from contracts with customers increased by &#8364;373.7&#160;million or 344% from &#8364;108.6&#160;million to &#8364;482.3&#160;million, which is mainly due to revenues recognized for the first time under our two new collaboration agreements which we entered into during the year ended December&#160;31, 2020 in order to develop a COVID-19 vaccine and ultimately led to the recognition of COVID-19 vaccine commercial revenues. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research &amp; Development Revenues from Collaborations</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of our BNT162 program we collaborate with Pfizer and Fosun Pharma. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue from Pfizer was mainly derived from the collaboration and license agreement to develop a COVID-19 vaccine and, in addition, includes an amount of &#8364;3.5&#160;million revenue derived from our existing Influenza collaboration. During the year ended December&#160;31, 2020 a non-refundable upfront cash payment of &#8364;66.3&#160;million was received. A regulatory milestone payment of &#8364;51.8&#160;million became due, but has not yet been received. Both were fully recognized as revenue during the year ended December&#160;31, 2020. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fosun Pharma is the collaboration partner with whom we work together on the development of a COVID-19 vaccine in China. Through the collaboration agreement, we are conducting clinical trials in China, using BioNTech&#8217;s proprietary mRNA technology and leveraging Fosun Pharma&#8217;s extensive clinical development, regulatory, and commercial capabilities in the country. Fosun Pharma has paid a non-refundable upfront cash payment of &#8364;0.9&#160;million and development milestones of &#8364;4.2&#160;million that were recognized as revenue during year ended December&#160;31, 2020. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For certain collaboration programs, the commencement of trials has been delayed, partially due to slowed patient enrollment or other delays as a result of the COVID-19 pandemic. Accordingly, during the year ended December&#160;31, 2020, revenues from our collaboration programs with Genentech, Sanofi and from the Influenza collaboration with Pfizer have generally decreased compared to the prior year periods. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Commercial Revenues</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our COVID-19 vaccine has evolved from the BNT162 program and has been authorized or approved for emergency or temporary use or has been granted conditional marketing authorization in over 65 countries worldwide, which resulted in recognition of revenues from the sale of pharmaceutical products for the first time. We are the marketing authorization holder in the European Union, and holder of emergency use authorizations or equivalent in the United States, United </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kingdom, Canada and other countries in advance of a planned application for full marketing authorizations in these countries.</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have marketing and distribution rights in Germany and Turkey.</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer has marketing and distribution rights worldwide with the exception of China, Germany and Turkey. Fosun Pharma has marketing and distribution rights in China. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 vaccine manufacturing process leverages Pfizer&#8217;s and our manufacturing facilities, consequently responsibilities are shared between Pfizer and us. Whenever responsibilities in the manufacturing and supply process of the COVID-19 vaccine shift and the COVID-19 vaccine is transferred, it is sold from one partner to the other. During <font style="color:#000000;">the year ended December&#160;31, 2020, we recognized &#8364;61.5&#160;million of revenues from selling </font>d<font style="Background-color:#FFFFFF;">rug product batches manufactured by us to Pfizer&#8217;s manufacturing site for fill and finish</font>. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon receiving a conditional marketing authorization, emergency or temporary use authorization<font style="color:#000000;">, we and Pfizer</font> started selling the product. The allocation of marketing and distribution rights defines territories in which the collaboration partners act as a principal respectively. For supplying our territory, Germany, we acquired the COVID-19 vaccine from Pfizer and recognized &#8364;20.6&#160;million of revenues from direct COVID-19 vaccine sales during the year ended December&#160;31, 2020. The share of gross profit that our collaboration partner has earned based on these sales, is recognized as cost of sales. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on Pfizer&#8217;s COVID-19 vaccine sales in the collaboration partner&#8217;s territory, we are eligible to receive a share of the respective gross profit which represents a net figure and is recognized as collaboration revenues during the commercial phase. During the year ended December&#160;31, 2020, we recognized a gross profit share of &#8364;188.5&#160;million. In order to determine our share of collaboration partner&#8217;s gross profits, we used certain information from our collaboration partner, including revenue from the sale of products, some of which is based on preliminary data shared between the partners and might vary once final data is available. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues resulting from other sales transaction increased by &#8364;8.8&#160;million, or 36%, to &#8364;24.2&#160;million in the year ended December&#160;31, 2019 to &#8364;33.0&#160;million in the year ended December&#160;31, 2020. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cost of Sales</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our cost of sales for the periods indicated:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cost of sales</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of sales related to COVID-19 vaccine revenues</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;35,616</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;35,616</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost related to other sales</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,717</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,361</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,356</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total cost of sales</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;59,333</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;17,361</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;41,972</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">242</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From the year ended December&#160;31, 2019 to the year ended December&#160;31, 2020, cost of sales increased by &#8364;41.9&#160;million or 241% from &#8364;17.4&#160;million to &#8364;59.3&#160;million. Cost of sales were recognized for the first time with respect to our COVID-19 vaccine sales and included Pfizer&#8217;s share of gross profit earned by us in transactions, where we are the principal. Costs of sales do not include costs relating to production of pre-launch products since those are expensed as research and development expenses in the period incurred. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our research and development expenses for the periods indicated:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchased services</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;359,880</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;65,552</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;294,328</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">449</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wages, benefits and social security expense</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,298</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,213</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,085</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory supplies</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,792</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,218</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,574</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">190</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,192</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,533</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,659</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IT costs</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,118</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,800</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,318</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease and lease related cost</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,725</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,527</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,198</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transport costs</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,135</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,081</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,054</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,889</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,542</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,347</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;645,029</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;226,466</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;418,563</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">185</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses increased by &#8364;418.5&#160;million or 185% from &#8364;226.5&#160;million during the year ended December&#160;31, 2019 to &#8364;645.0&#160;million during the year ended December&#160;31, 2020. The increase was mainly due to an increase in research and development expenses from our BNT162 program. Research and development expenses include our share of expenses under the terms of the Pfizer collaboration agreement. Development costs, which are shared, are divided equally between Pfizer and us. The amount of shared development expenses, which were initially incurred by Pfizer and subsequently charged to us were recorded as purchased services classified within research and development and the reimbursement from Pfizer for research and development expenses initially incurred by us were recorded as a reduction to research and development expenses. The increase was further driven by an increase in expenses for purchased laboratory supplies as well as an increase in headcount leading to higher wages, benefits and social security expenses. In addition, from May 6, 2020, the date of acquisition, our new U.S.-based subsidiary, BioNTech US Inc., contributed &#8364;21.0&#160;million to the research and development expenses of the Group. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Sales and Marketing Expenses</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our sales and marketing expenses for the periods indicated:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchased services</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;10,929</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;247</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;10,682</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,325</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wages, benefits and social security expense</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,636</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,938</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(302)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,947</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">533</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,414</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">265</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total sales and marketing expenses</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;14,512</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,718</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;11,794</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">434</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses increased by &#8364;11.8&#160;million or 437% from &#8364;2.7&#160;million during the year ended December&#160;31, 2019 to &#8364;14.5&#160;million during the year ended December&#160;31, 2020 which is mainly due to an increase in purchased service which we incurred in connection with progressing our commercial activities with respect to our COVID-19 vaccine. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">General </font><font style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">and</font><font style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> Administrative Expenses</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our general and administrative expenses for the periods indicated:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wages, benefits and social security expense</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;33,007</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;19,122</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;13,885</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchased services</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,022</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,419</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,603</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">305</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IT and office equipment</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,404</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,573</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,831</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,104</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,855</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance premiums</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,840</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,061</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,779</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">356</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Job advertisement expenses</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,897</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">548</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,349</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">429</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease and lease related cost</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,390</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,715</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">675</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research services</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,033</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,801</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">776</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory supplies</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,191</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">785</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">406</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract staffing</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,108</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">686</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">422</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,053</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,551</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,502</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total general and administrative expenses</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;94,049</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;45,547</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.16%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;48,502</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses increased by &#8364;48.5&#160;million or 107% from &#8364;45.5&#160;million during the year ended December&#160;31, 2019 to &#8364;94.0&#160;million during the year ended December&#160;31, 2020.<font style="color:#000000;"> The increase was mainly influenced by higher expenses for purchased management consulting and legal services, an increase in headcount leading to higher wages, benefits and social security expenses and higher insurance premiums. </font>In addition, from May 6, 2020, the date of acquisition, our new U.S.-based subsidiary, BioNTech US Inc., contributed &#8364;7.4&#160;million to the general and administrative expenses of the Group, respectively.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other Operating Income / Expenses</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our other result, including other operating income and expenses, for the periods indicated:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other result</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government grants</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;239,017</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,547</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;237,470</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,350</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bargain purchase</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,002</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,002</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other operating income</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,520</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,177</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,343</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">284</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other operating income</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">250,539</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2,724</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">247,815</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9,097</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other operating expenses</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,358)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(739)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,619)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">219</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other operating expenses</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2,358)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(739)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1,619)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">219</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total other result</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;248,181</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,985</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;246,196</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12,403</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our other result increased by &#8364;246.2&#160;million from &#8364;2.0&#160;million during the year ended December&#160;31, 2019 to &#8364;248.2&#160;million during the year ended December&#160;31, 2020. The increase mainly results from government grants for which we became eligible as part of an initiative by the German Federal Ministry of Education (<font style="font-style:italic;">Bundesministerium f&#252;r Bildung und Forschung</font>, or the BMBF) to support our COVID-19 vaccine program, BNT162 (as described below in &#8220;&#8212;Liquidity and Capital Resources&#8221;). The proportion of the grant that related to expenses incurred by us is recognized as other operating income with an amount of &#8364;238.9 million; the proportion which was received and will compensate us for future expenses, has been deferred and is presented as government grant in the consolidated statements of financial position with an amount of &#8364;88.0 million.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">175</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Finance Income </font><font style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">/ </font><font style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expenses</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our finance result for the periods indicated:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Finance result</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,564</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,781</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(217)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange gains, net</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,341</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,341)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(100)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Finance income</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1,564</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4,122</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2,558)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(62)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of financial instruments</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,048)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(326)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,722)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">835</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value adjustments of financial instruments measured at fair value</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,289)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,289)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange loss, net</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42,609)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42,609)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Finance expenses</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(62,946)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(326)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(62,620)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">19,209</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Interest expenses related to lease liabilities</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2,003)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1,718)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(285)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total finance result</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(63,385)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,078</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(65,463)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(3,150)</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our financial result decreased by &#8364;65.5&#160;million from &#8364;2.1&#160;million finance income, net during the year ended December&#160;31, 2019 to &#8364;63.4&#160;million finance expenses, net during the year ended December&#160;31, 2020. The latter included &#8364;17.3&#160;million in expenses arising from fair value measurement adjustments of the derivative embedded within the convertible note. Furthermore, there were &#8364;42.6&#160;million in foreign exchange losses that occurred during the year ended December&#160;31, 2020 compared to &#8364;2.3&#160;million foreign exchange gains that had been recorded during the year ended December&#160;31, 2019. Foreign exchange differences on a cumulative basis, are either shown as finance income or expenses. The increase in foreign exchange losses is mainly due to higher balances in U.S. dollar bank accounts and the weakening of the U.S. dollar when compared to the Euro. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we had accumulated tax losses with respect to corporate tax and trade tax. Our accumulated tax losses amounted to &#8364;596.4&#160;million with respect to corporate income tax and &#8364;513.6&#160;million with respect to trade tax comprising tax losses of our German tax group, German entities not within the tax group and our U.S. tax group. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accumulated tax losses related to the German tax group include &#8364;457.9&#160;million corporate income tax losses and &#8364;450.9&#160;million trade tax losses. Under German law, tax losses do not expire. Deferred tax assets on tax losses had not been capitalized in previous years, as there was not sufficient probability in terms of IAS 12 that there would have been future taxable profits available against which the unused tax losses could have been utilized. Following the authorization and approval of our COVID-19 vaccine for emergency or temporary use or having been granted conditional marketing authorization in over 65 countries worldwide, we re-evaluated previously unrecognized tax losses. Based on our product-based business plan, including commercial supply commitments agreed with various governments and health ministries under which we either directly supply the COVID-19 vaccine or, if they relate to territories which have been allocated to Pfizer, we will receive the profit share to which we are eligible, it is now considered highly probable that taxable profits for the German tax group will be available against which the tax losses can be utilized. On this basis, we have recognized deferred tax assets and liabilities with a net amount of &#8364;161.0&#160;million for the cumulative tax losses and temporary differences determined for the German tax group as of December 31, 2020. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accumulated tax losses related to German entities not within the tax group include &#8364;1.7&#160;million corporate income tax losses and &#8364;1.8&#160;million trade tax losses. With respect to those tax losses, no deferred tax assets have been capitalized, as there is not sufficient probability in terms of IAS 12 that there will be future taxable profits available against which the unused tax losses can be utilized. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accumulated tax losses related to U.S. tax group include &#8364;136.8&#160;million federal tax losses and &#8364;60.9&#160;million state tax losses. The tax losses related to the U.S. tax group include &#8364;20.9&#160;million federal losses that are expected to expire in 2033 and &#8364;115.9&#160;million federal losses which have no expiration date and can be carried forward indefinitely. In addition, the U.S. tax group has state tax losses of &#8364;60.9&#160;million, which may be available to offset future income tax liabilities that expire at various dates beginning in 2033. Our forecast for the U.S. tax group does not provide sufficient probability for the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">use of existing tax loss carryforwards in the near future. Therefore, the requirements set out by IAS 12 are not fulfilled for the U.S. tax group. As of December 31, 2020, deferred tax assets are only recognized to the extent of deferred tax liabilities.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to accumulated tax losses, we had accumulated federal tax credits of &#8364;0.8&#160;million and state tax credits of &#8364;0.3&#160;million in the United States as of December 31, 2020. The tax credits in the United States will expire at various dates beginning in 2035 if they are not used. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The realization of deferred tax assets is dependent upon the generation of future taxable income, the amount and timing of which are subject to uncertainties. We may become subject to income tax audits and adjustments by local tax authorities. The assessments as to the recoverability of deferred tax assets and the nature of uncertain tax positions is subject to significant judgment by management and subject to change, which may be substantial.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Comparison of the year ended December&#160;31, 2019 and year ended December&#160;31, 2018</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of revenues recognized for the periods indicated:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.24%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.24%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.24%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.24%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.24%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research &amp; development revenues from collaborations</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;84,428</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;101,837</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(17,409)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(17)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.24%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Pfizer Inc.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">14,348</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">7,173</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">7,175</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">100</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.24%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Genentech Inc.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">64,026</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">49,536</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">14,490</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.24%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">6,054</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">45,128</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(39,074)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(87)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.24%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commercial revenues</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">24,161</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">25,738</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1,577)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(6)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.24%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;108,589</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;127,575</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(18,986)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(15)</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From the year ended December&#160;31, 2018 to the year ended December&#160;31, 2019 total revenues decreased by &#8364;19.0&#160;million or 15% from &#8364;127.6&#160;million to &#8364;108.6 million. The revenue recognized in the year ended December&#160;31, 2018 included an amount of &#8364;33.2&#160;million collaboration revenues from our Sanofi collaboration for a reimbursement of 50% of CellScript sublicense costs pursuant to a separate sub-sublicense agreement dated December 22, 2018. This transaction only occurred in the year ended December&#160;31, 2018. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cost of Sales</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following<font style="color:#000000;"> table summarizes our cost of sales for the periods indicated:</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cost of sales</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product sales</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;17,361</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.42%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;13,690</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;3,671</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total cost of sales</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;17,361</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;13,690</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;3,671</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">177</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our research and development expenses for the periods indicated:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchased services</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;65,552</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;42,079</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;23,473</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wages, benefits and social security expense</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,213</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,668</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,545</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory supplies</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,218</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,921</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,297</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,533</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,312</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,221</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IT costs</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,800</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,572</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,228</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease and lease related cost</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,527</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,404</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transport costs</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,081</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">668</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">413</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,542</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,416</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,874)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;226,466</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;143,040</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;83,426</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses increased by &#8364;83.5&#160;million or 58% from &#8364;143.0&#160;million during the year ended December&#160;31, 2018 to &#8364;226.5&#160;million during the year ended December&#160;31, 2019 mainly due to an increase in wages, benefits and social security expenses due to an increase in headcount and the full-year reflection of the ESOP program expenses during the year ended December&#160;31, 2019 as well as higher development expenses spent on purchased services and laboratory supplies. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Sales and Marketing Expenses</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses amounted to &#8364;2.7&#160;million during the year ended December&#160;31, 2019, &#8364;0.2&#160;million of which constituted expenses for purchased services. Sales and marketing expenses amounted to &#8364;3.0&#160;million during the year ended December&#160;31, 2018, &#8364;0.8&#160;million of which constituted expenses for purchased services. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our general and administrative expenses for the periods indicated:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wages, benefits and social security expense</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;19,122</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;8,582</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;10,540</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchased services</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,419</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,177</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,242</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IT and office equipment</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,573</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,774</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">799</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,855</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,284</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,571</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance premiums</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,061</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">916</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">632</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Job advertisement expenses</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">548</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">861</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(313)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease and lease related cost</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,715</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,012</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">703</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research services</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">792</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory supplies</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">785</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">456</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">329</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract staffing</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">686</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">781</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,551</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,236</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,315</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total general and administrative expenses</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;45,547</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;26,334</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-left:solid 0.75pt #70AD47; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;19,213</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses increased by &#8364;19.2&#160;million or 73% from &#8364;26.3&#160;million during the year ended December&#160;31, 2018 to &#8364;45.5&#160;million during the year ended December&#160;31, 2019. This increase was mainly influenced by an increase in headcount and the full-year reflection of the ESOP program expenses during the year ended December&#160;31, 2019 as well as a charge of &#8364;2.6&#160;million in connection with certain withholding tax payments for intellectual property licenses </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">related to prior years that was recorded during the </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">year ended December&#160;31, 2019</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> but not during the </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">year ended December&#160;31, 2018</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other Operating Income / Expenses</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2019, our other operating income amounted to &#8364;2.7&#160;million, &#8364;1.5&#160;million of which constituted government grants. In the year ended December&#160;31, 2018, our other operating income amounted to &#8364;5.4&#160;million, &#8364;4.2&#160;million of which constituted government grants.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Finance Income / Expenses</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2019, our finance income amounted to &#8364;4.1&#160;million, &#8364;2.3&#160;million of which was attributable to unrealized foreign exchange gains. During the year ended December&#160;31, 2018, our finance income amounted to &#8364;8.0&#160;million, &#8364;6.1&#160;million of which was attributable to unrealized foreign exchange gains.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2019, our finance expense amounted to &#8364;0.3&#160;million. During the year ended December&#160;31, 2018, our finance expense amounted to &#8364;48&#160;thousand. In both years, no foreign exchange losses were reported under finance expense.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2019 and December 31, 2018, interest expenses related to lease liabilities amounted to &#8364;1.7&#160;million, for each year.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Tax Losses</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019, we had accumulated tax losses of &#8364;356.0&#160;million with respect to corporate tax and &#8364;352.3&#160;million with respect to trade tax as of December 31, 2019. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets on tax losses had not been capitalized in previous years, as there was not sufficient probability in terms of IAS 12 that there would have been future taxable profits available against which the unused tax losses could have been utilized. The accumulated tax losses as at December 31, 2019 relate to Germany and the United States (as at December 31, 2018: Germany). There is no expiration date for any of the accumulated tax losses under German tax law. The tax losses generated in the United States prior to December 31, 2017 begin to expire in 2033. Any tax losses generated after that date have no expiration date and can be carried forward indefinitely. The tax credits incurred in the United States are expected to expire at various dates beginning in 2035. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Information about our operating segments</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Historically we reported four segments: Clinical, Technology Platform, Manufacturing and Product Sales &amp; External Services. In the course of the year ended December&#160;31, 2020, we leveraged the breadth of our immunotherapy technologies and used our expertise to mobilize these rapidly to address the COVID-19 pandemic. In December 2020, our COVID-19 vaccine was authorized or approved for emergency or temporary use or granted conditional marketing authorization in over 65 countries worldwide. Beginning in the fourth quarter, given the financial and operational significance of the activities to develop and then market, produce and transport the COVID-19 vaccine, our Management Board, as the chief operating decision maker (CODM), reviewed financial information presented on a consolidated basis. Decisions with respect to business operations and resource allocations are made by the CODM based on BioNTech as a whole. Accordingly, we operate and make decisions as a single operating segment, which is also our reporting segment. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Related<font style="color:#231F20;"> Party Transactions</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related party transactions that occurred during the years ended December 31, 2020 and December&#160;31, 2019 are explained in Item 7 of this Annual Report as well as in Note 21 o<font style="color:#000000;">f our consolidated financial statements included elsewhere in this Annual Report</font>. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Merger Agreement with BioNTech US Inc. (formerly Neon Therapeutics, Inc.)</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 6, 2020, we acquired Neon Therapeutics, Inc. (formerly Nasdaq: NTGN), or Neon, a biotechnology company <font style="color:#000000;">developing</font> novel neoantigen-based T-cell therapies, through a stock transaction and including de minimis cash consideration, or the Merger. The Merger was announced on January 16, 2020. Neon, now BioNTech US Inc., or BioNTech US, is operated as a wholly-owned subsidiary of BioNTech SE. The new subsidiary is based in Cambridge, Massachusetts and serves as our U.S. headquarters. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction combines two organizations with a common culture of pioneering translational science and a shared vision for the future of cancer immunotherapy. Through the acquisition, we leverage Neon&#8217;s deep expertise in the development of neoantigen therapies, with both vaccine and T-cell capabilities. Our most advanced program acquired in the Merger is BNT221 (NEO-PTC-01), a personalized neoantigen-targeted T-cell therapy candidate consisting of multiple T-cell populations targeting the most therapeutically relevant neoantigens from each patient&#8217;s tumor. We also acquired a precision T-cell therapy program targeting shared neoantigens in genetically defined patient populations. The lead program from this approach, BNT222 (NEO-STC-01), is a T-cell therapy candidate targeting shared RAS neoantigens. In addition, Neon had assembled libraries of high-quality TCRs against various shared neoantigens across common HLAs. This pipeline is underpinned by Neon&#8217;s platform technologies including RECON&#174;, its machine-learning bioinformatics platform, and NEO-STIM&#8482;, its proprietary process to directly prime, activate and expand neoantigen-targeting T-cells ex vivo.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further details are explained in Note 5 o<font style="color:#000000;">f our consolidated financial statements included elsewhere in this Annual Report</font>. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Impact of COVID-19</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we advance <font style="color:#000000;">our</font> clinical programs, we are in close contact with our principal investigators and clinical sites, which are located in jurisdictions affected by the COVID-19 pandemic, and are assessing the impact of the COVID-19 pandemic on our clinical trials, expected timelines and costs on an ongoing basis. We have modified our business practices in response to the spread of COVID-19, including restricting employee travel, developing social distancing plans for employees and cancelling physical participation in meetings, events and conferences. In addition, for certain programs, including BNT111, BNT113, BNT122, BNT141 and BNT142 (RiboMabs), BNT151 and BNT152/153 (RiboCytokines), BNT221, BNT161 (Influenza) and BNT171 (Rare Disease), the commencement of trials has been delayed, partially due to slowed patient enrollment or other delays as a result of the COVID-19 pandemic. After several months of delay to focus efforts on our COVID-19 vaccine, we started Phase 1 clinical trials for BNT211 (CARVac), BNT151 (RiboCytokines) and BNT 411 (TLR-agonist). This partial disruption, even temporary, may severely impact our operations and overall business by delaying the progress of our clinical trials and preclinical studies. Our operations, including research and manufacturing, could also be disrupted due to the potential impact of staff absences as a result of self-isolation procedures or extended illness. Such factors were evaluated and considered carefully when preparing this annual report for the year ended December&#160;31, 2020. We will continue to evaluate potential effects of the COVID-19 pandemic.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 Collaborations</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In response to the COVID-19 pandemic, we initiated our COVID-19 vaccine development program, BNT162, in late January 2020, leveraging our proprietary mRNA platform, and assembled a global consortium of partners including Pfizer (worldwide collaboration outside of China) and Fosun Pharma (China). In April 2020, we initiated a first-in-human clinical trial of BNT162b2 following preclinical studies. In July 2020, we initiated, along with our partner Pfizer, a phase 3 clinical trial of BNT162b2 and published the clinical results in November 2020. Subsequently, BNT162 vaccine has been authorized or approved for emergency use or temporary use or granted conditional marketing authorization in over 65 countries around the world, including the United States, the U.K., and Canada and has received CMA following rolling submissions with the EMA.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Details about our COVID-19 collaborations are described further in Items 4 and 5 as well as the notes to our consolidated financial statements <font style="color:#231F20;">included</font> elsewhere in this Annual Report.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Use of Estimates</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our consolidated financial statements for the years ended December&#160;31, 2020 and December&#160;31, 2019 have been prepared in accordance with IFRS, as issued by the IASB. Our accounting policies employed are described in Note 3 to our consolidated financial statements included elsewhere in this Annual Report. We have reviewed these critical accounting policies and estimates with the Audit Committee of our Supervisory Board.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In applying these policies, we make estimates and assumptions that affect the reported amounts of assets and liabilities, contingent assets and liabilities as well as revenues and expenses arising during the fiscal year. When evaluating which judgments to make, or which estimates and assumptions to apply, we consider the sensitivity of each as a range of various outcomes is possible. We ultimately base our assumptions and estimates on the most appropriate parameters available when the consolidated financial statements were prepared. Existing circumstances and assumptions about future </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">developments, however, may change due to market changes or circumstances arising that are beyond our control. Hence, the actual </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">outcome may differ from those estimates</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of these policies require a high level of judgment because the areas are especially subjective or complex. The most critical accounting policies and significant areas of judgment and estimation are in the areas discussed in further detail below. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting policies applied and the estimates and assumptions used when preparing the consolidated financial statements have not changed compared to prior year. However, upon receiving regulatory authorization and approval for emergency or temporary use or being granted conditional marketing authorization for our COVID-19 vaccine and with recognizing revenues from the sale of pharmaceutical products for the first time, certain new judgments and estimates needed to be made, most notably with respect to revenue recognition and income taxes. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to revenue recognition and research and development expenses, our judgments and estimates made in evaluating cut-off may impact the financial results between periods. Fair values in business combinations, share-based payment arrangements and financial instruments are determined using valuation models which could differ in outcome depending on input parameters used. We have estimated fair values based on reasonable assumptions as described below.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize revenue through collaboration and license agreements, rendering of services and sales of products based on the facts and circumstances of each contractual agreement.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Identification and Determination of Performance Obligations</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our collaboration and license agreements, described in more detail in &#8220;Business&#8212;XIV. Third-Party Collaborations&#8221;, typically contain multiple elements, and have been determined as qualifying as contracts with customers. At inception of each agreement, we apply judgment when determining which promises represent distinct performance obligations. When licenses are granted, we determined that the grant of the license is the predominant promise within the combined performance obligations and the promise to grant a license is accounted for as a performance obligation satisfied over time as our customer simultaneously receives and consumes the benefits from our performance.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Measurement of the Transaction Price</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestone payments<font style="color:#000000;"> are contingent upon the occurrence of a future event and represent variable consideration. As there are usually only two possible outcomes (</font><font style="font-style:italic;color:#000000;">i.e.</font><font style="color:#000000;">, milestone is reached or not), we have assessed that the method of the most likely amount is the best method to predict the amount of consideration to which we will be entitled. At contract inception, the most likely amount for milestone payments is estimated to be zero. At each reporting date, we use judgment to determine when to include variable consideration in the transaction price, such that it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with respect to the variable consideration is subsequently resolved. We have concluded that future milestone payments are fully constrained at the end of the current fiscal year.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Allocation of the Transaction Price to Performance Obligations and Revenue Recognition as Performance Obligations are satisfied</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We allocate the transaction price to performance obligations based on their relative standalone selling prices, which are generally based on our best estimates and interpretations of <font style="color:#000000;">facts and circumstances of each contractual agreement and </font>may require significant judgment to determine appropriate allocation.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront payments and reimbursement for expenses are initially deferred on our <font style="color:#000000;">consolidated </font>statements of financial position. <font style="color:#000000;">We assessed that no significant financing component exists within our collaboration agreements since the overall business purpose of advanced payments is to support the payment structure other than to provide a significant benefit of financing. For performance obligations in which the costs vary based on progress, an input-based measure considering cost incurred depicts most reliably the progress of the related research activities. In other cases, revenue recognition on a straight-line basis may most reliably depict our performance toward complete satisfaction. If the contractual activities progress, the achievement of development milestones will be used to measure the progress toward complete satisfaction. </font>We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net loss in the period of adjustment.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon successfully commercializing a pharmaceutical product, the collaboration and license agreements also provide for </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">additional profit-sharing or tiered royalties earned when customers recognize net sales of licensed products as well as sales milestone payments. Revenue is recognized based on the sales-based or usage-based royalty </font><font style="color:#000000;">exemption </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">when, or as, the underlying sales occur, which is when the performance obligation has been satisfied. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Principal-Agent Considerations</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration agreements that involve two or more partners who contribute to the provision of a specific good or service to a customer are assessed in terms of principal-agent considerations. Under our current collaboration agreements, the allocation of marketing and distribution rights defines territories in which the collaboration partner acts as a principal respectively. We recognize revenue net based on the collaboration partners&#8217; gross profit in territories where the partner is responsible for supply and on a gross basis when directly supplying our customers in our territories<font style="color:#000000;"> </font>when control has been transferred. Amounts paid to collaboration partners for their share of our profits earned where we are the principal in the transaction are recorded as cost of sales. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Pfizer Agreement Characteristics</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to our collaboration with Pfizer, commercial revenue is recognized based on our collaboration partners&#8217; gross profit from COVID-19 vaccine sales, which is shared under the respective collaboration agreement. In determining commercial revenue pursuant to this collaboration agreement, we are reliant on our collaboration partner for detail regarding its gross profit for the period at hand. We have been informed by our collaboration partner that certain of the information it intends to provide us with regard to the gross profit will be, by necessity, preliminary and subject to change. This is mainly due to the fact that our partner&#8217;s financial reporting cycle differs from ours. Pfizer&#8217;s subsidiaries outside the United States have a fiscal year-end of November 30; that is, the details on sales in these territories are required by us in advance of closing the respective reporting periods. As a result, our determination of our share of such gross profit for the purposes of recognizing revenues will be subject to risks that amounts reported might vary from actual amounts reported once our collaboration partner&#8217;s final financial results are available. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the period covered in the financial statements presented in this Annual Report, Pfizer has calculated gross profit for COVID-19 vaccine sales in the U.S. territory as well as shared preliminary gross profit for COVID-19 vaccine sales in territories outside the United States, both of which will be reconciled and finalized. The respective gross profit shares are calculated based on sales and include consideration of transfer prices. The latter includes manufacturing and shipping costs, which represent standard prices and include mark-ups on manufacturing costs as specified by the terms of the agreement. Manufacturing and shipping cost variances were considered as far as those have been identified. Nevertheless, those input parameters maybe adjusted once actual costs are determined. The sales for the U.S. territory, as reported by Pfizer, as well as sales preliminary reported for territories outside the United States have been used to estimate license obligations in terms of royalties and sales milestones. Sales milestones and royalties are recognized as they are earned by the partners. Sales milestones are shared equally, while royalty payments are shared on the basis of revenue in the territories for which the partners are responsible. The estimated royalty fees applied to net sales reflect the license obligations to the extent currently identified from third party contractual arrangements. Changes in estimates are accounted for prospectively, when determined. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These estimated figures are likely to change prospectively in future periods as we receive final data from Pfizer. Those changes in our share of the collaboration partner&#8217;s gross profit will be recognized prospectively as changes to our commercial revenues. To the extent that Pfizer does not provide such preliminary information in the future, our provisional sales figures for territories outside of the United States will be subject to a greater level of estimation and judgment.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:1.09%;width:99.88%;">
<tr>
<td style="width:37.14%;"></td>
<td style="width:13.59%;"></td>
<td style="width:15.4%;"></td>
<td style="width:18.5%;"></td>
<td style="width:15.26%;"></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="bottom"  BGCOLOR="#FFFFFF">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2020</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-bottom:solid 1pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-bottom:solid 1pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">German territory</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-bottom:solid 1pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">U.S. territory</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-bottom:solid 1pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Territories outside the U.S.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-bottom:solid 1pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style=" border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#C6E0B4" style=" border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct product sales to BioNTech customers</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 20,553</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style=" border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 20,553</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#C6E0B4" style=" border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share of collaboration partner's gross profit</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 46,997</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style=" border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 141,480</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 188,477</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Input parameters used within gross profit share calculation</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:10pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Sales</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">reported</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">preliminary <br />reported </p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Transfer price (manufacturing, shipping costs and respective variances)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">standard <br />prices</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">standard <br />prices</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">182</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:1.09%;width:99.88%;">
<tr>
<td style="width:37.14%;"></td>
<td style="width:13.59%;"></td>
<td style="width:15.4%;"></td>
<td style="width:18.5%;"></td>
<td style="width:15.26%;"></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">License payments</font></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">identified<br />royalty rate</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">identified <br />royalty rate</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer&#8217;s determination of manufacturing and shipping costs also affects the transfer prices that have been charged to <font style="color:#000000;">COVID</font>-19 vaccine supplies that it manufactures and supplies to us and may be subject to adjustment whenever manufacturing and shipping cost variances are identified<font style="color:#000000;">. Likewise, our own cost of sales and the respective gross profit share owed to our partner may be adjusted prospectively, when changes are determined. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For further information regarding our revenue recognition policy, please refer to Note 2.3.4 to our consolidated financial statements included elsewhere in this Annual Report.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Business Combinations</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The allocation of the purchase price for business acquisitions to the identifiable assets acquired and liabilities assumed based on their respective fair values, requires use of accounting estimates and judgment. Acquired intangible assets are valued using valuation models such as the Multi Period Excess Earnings Method under which fair values are derived from future net cash flows, which are discounted to the acquisition date using an appropriate discount factor. We have estimated fair values of assets acquired, liabilities assumed and contingent considerations based on reasonable assumptions. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to collect information and reevaluate these provisional estimates and assumptions in accordance with IFRS 3. We record any adjustments to these provisional estimates and assumptions against goodwill provided they arise within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statements of operations. For further information regarding our business combination policy, please refer to Note 2.3.1 to our consolidated financial statements included elsewhere in this Annual Report.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Share-Based Awards</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We used valuation models like a binomial or Monte-Carlo simulation model, for the measurement of the cash- and equity-settled transactions&#8217; fair value at the grant date considering certain assumption relating to,<font style="font-style:italic;"> e.g., </font>the volatility of stock price, the determination of an appropriate risk-free interest rate, expected dividends and the probability of reaching a minimum hurdle to exercise the relevant options. For awards which were granted prior to the initial public offering, at a time where no quoted market prices existed, the valuation model assumptions included the option&#8217;s underlying share price. For awards which were granted post the initial public offering, the grant date&#8217;s share prices on the Nasdaq Global Select Market were included in the valuation. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For further information regarding our share-based payments accounting policy and disclosures, see Note 2.3.17 and Note 17 <font style="color:#000000;">to our consolidated financial statements included elsewhere in this Annual Report</font>.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Embedded Derivatives</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We used the Cox-Rubinstein binomial tree model when determining the fair value of the conversion right, the embedded derivative which was bifurcated from the convertible note, as host contract. The primary inputs used in the model include stock price volatility, credit spreads, risk-free interest rate and foreign exchange forward rates. Stock price volatility is based on our implied volatility, credit risk is model implied and adjusted for movement in credit spreads for B-rated corporates at each valuation date, the risk-free interest rate is based on currency specific time congruent IBOR and swap rates whereas the foreign exchange forward rates are based on observable market data. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For further information regarding our financial instrument policy and disclosures relating to financial instruments, see Note 2.3.11 and Note 12 <font style="color:#000000;">to our consolidated financial statements included elsewhere in this Annual Report</font>.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income <font style="color:#000000;">Taxes</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When determining whether sufficient future taxable profit will be available against which the deductible temporary differences, tax loss carry forwards and tax credits can be utilized, significant management <font style="color:#000000;">judgment </font>is required. This includes management&#8217;s assessment on the character and amounts of taxable future profits, the periods in which those profits are expected to occur, and the availability of tax planning opportunities. As a matter of policy, convincing evidence </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">supporting the recognition of deferred tax assets is required if an entity has suffered a loss in either the current or the preceding </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">periods</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, based on our <font style="color:#000000;">product-based business plan, including commercial supply commitments agreed with various governments and health ministries under which we either directly supply the COVID-19 vaccine or, if they relate to territories which have been allocated to Pfizer, we will receive the profit share to which we are eligible, it is now considered highly probable that taxable profits for the German tax group will be available against which the tax losses can be utilized.</font> On this basis, we have determined that we can recognize a deferred tax asset with respect to the German tax group&#8217;s tax losses carried forward. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the other hand, management has determined that deferred tax assets on tax losses carried forward that relate to subsidiaries which have a loss making history cannot be recognized. This includes the assessment that those subsidiaries neither have any taxable temporary difference nor any tax planning opportunities available that could support the recognition of deferred tax assets. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For further disclosures relating to deferred taxes, see Note 8 to<font style="color:#000000;"> our consolidated financial statements included elsewhere in this Annual Report</font>.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">B.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_5_B"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_5_B"></a>Research and Development, Patents and Licenses, etc.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Full details of our research and development activities and expenditures are given in Item 4 and under the description of the &#8220;Operating Results&#8221; in this Item 5 within this Annual Report.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">C.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_5_C"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_5_C"></a>Trend Information</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See the description of &#8220;Operating Results&#8221; in this Item 5 within this Annual Report.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">D.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_5_D"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_5_D"></a>Liquidity and Capital Resources</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have historically funded our operations primarily from private placements of our ordinary shares, from issuing ordinary shares in connection with public financing transactions, which includes our initial public offering in 2019 and the global offering in 2020, from generating proceeds under our collaboration agreements and receiving proceeds from secured bank loans. Recently we issued a convertible note as part of a private investment. As of December&#160;31, 2020, we had cash and cash equivalents of &#8364;1.2&#160;billion. Cash and cash equivalents are invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation, and consist primarily of cash in banks and on hand and short-term deposits with an original maturity of three months or less, which are stated at fair value. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain two secured loans with Deutsche Bank AG, or Deutsche Bank, to finance the buildouts of our JPT Peptide Technologies GmbH facility and BioNTech Innovative Manufacturing Services GmbH facility. Our &#8364;10.0 million secured credit facility, entered into with Deutsche Bank by our subsidiary BioNTech Innovative Manufacturing Services GmbH, bears interest at a rate of 2.15% and matures on December 30, 2027. The loan is repayable in equal quarterly installments of &#8364;0.3&#160;million commencing on June 30, 2020. As of December&#160;31, 2020, the full amount under this facility is drawn down and the first three scheduled repayments have occurred. Our &#8364;9.45 million secured credit facility, entered into with Deutsche Bank by our subsidiary JPT Peptide Technologies GmbH, bears interest at a rate of 2.08% and matures on September 30, 2028. The loan is repayable by quarterly installments of &#8364;0.3&#160;million commencing on September 30, 2020. As of December&#160;31, 2020, the full amount under this facility is drawn down and the first two scheduled repayments have occurred. Each of these facilities is secured by liens over our property. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December&#160;31, 2019, we signed a financing arrangement with the European Investment Bank, or the EIB, to partially support the implementation of certain technical aspects of our investment in the development of patient-tailored therapeutic vaccines for cancer in Germany, or the Investment. Under this arrangement, the EIB has agreed to provide us with a credit in an amount of up to &#8364;50 million to partially finance the Investment, provided that the amount of credit does not exceed 50% of the cost of the Investment. The credit consists of (i) a term loan in the amount of &#8364;25 million that may be drawn in a single tranche upon the achievement of certain milestone events, not all of which have been achieved (Credit A), and (ii) a term loan in the amount of &#8364;25 million that may be drawn in a maximum of four tranches each of which must be for a minimum of &#8364;5 million or the balance of the remaining facility (Credit B). Tranches under Credit B may only be drawn after Credit A has been drawn down and upon the achievement of certain milestone events. Each tranche under Credit A and Credit B must be repaid within six years from the date on which the tranche is disbursed to us. The financing </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arrangement is to be secured by way of liens over certain of our property. As of </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, there has been no draw down. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2020, we entered into an agreement with the EIB for a &#8364;100 million credit facility to partially support the development of BNT162 and fund expansion of our manufacturing capacity to provide worldwide supply of BNT162 in response to the COVID-19 pandemic. The credit consists of (i) a term loan in the amount of &#8364;50 million that may be drawn in a single tranche upon the achievement of certain milestone events (Credit A), and (ii) a term loan in the amount of &#8364;50&#160;million that may be drawn in a single tranche (Credit B). Credit B may only be drawn down after Credit A has been drawn down and upon the achievement of certain milestone events. The financing arrangement is to be secured by way of liens over certain of our property. On December 21, 2020, &#8364;50&#160;million from Credit A was drawn down. Interest is payable on the outstanding balance of Credit A at the cash interest fixed rate of 1% per annum quarterly in arrears, plus deferred interest at fixed rate of 2.5% per annum. The nominal amount must be repaid on December 21, 2026. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 27, 2020, 5,500,000 ADS each representing one of our ordinary shares were offered on the Nasdaq Global Select Market at a public offering price of $93.00 per ADS (&#8220;Underwritten Offering&#8221;). On August 27, 2020, following the Underwritten Offering, 16,124 ADS each representing one of our ordinary shares were issued additionally at a public offering price of $93.00 per ADS (&#8220;Rights Offering&#8221;). The Underwritten Offering and the Rights Offering are part of a single, global offering, which we refer to as the Global Offering. The gross proceeds of the Global Offering were &#8364;436.3&#160;million ($513.0&#160;million). </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A fund associated with Temasek Capital Management Pte. Ltd., or Temasek, and another accredited investor, contributed a private investment, which closed as of August 28, 2020 following the satisfaction of customary closing conditions. The private placement includes an investment in ordinary shares and a &#8364;100.0 million four-year mandatory convertible note with a coupon of 4.5% per annum and a conversion premium of 20% above the reference price. The investment of &#8364;123.9 million for 2,595,996 of our ordinary shares was registered with the commercial register (<font style="font-style:italic;">Handelsregister</font>) on September 8, 2020. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2020, we became eligible to receive up to &#8364;375.0 million in funding from an initiative by the German Federal Ministry of Education (<font style="font-style:italic;">Bundesministerium f&#252;r Bildung und Forschung</font>, or the BMBF) to support our COVID-19 vaccine program, BNT162. The BMBF funding was granted to accelerate our vaccine development and to upscale manufacturing capabilities in Germany.<font style="color:#000000;"> </font>The funding will also compensate further costs that incur since the COVID-19 vaccine continues to be tested in clinical trials, for example to test it against new variants or to approve it for additional groups (pregnant women, <font style="color:#000000;">individuals less 16 years</font>), and because study participants will continue to be followed for two years to continue evaluating safety and efficacy. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, we entered into a sales agreement (the "Sales Agreement") with Jefferies LLC and SVB Leerink LLC, as sales agents, to establish an at-the-market offering program, pursuant to which the Company may sell, from time to time, ADSs representing ordinary shares for aggregate gross proceeds of up to $500 million. During the year ended December&#160;31, 2020, we sold 735,490 ADSs, each representing one of our ordinary shares and previously held in treasury, under the Sales Agreement for aggregate gross proceeds of &#8364;76.5&#160;million ($92.9&#160;million). The remaining capacity under the Sales Agreement is $407.1&#160;million.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash Flow</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the primary sources and uses of cash for each period presented:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.34%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net cash flows from (used in):</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(13,474)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(198,537)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(58,877)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(144,848)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(77,115)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,452)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">894,725</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">383,290</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">365,177</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total cash inflow</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;736,403</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;107,638</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;239,848</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">185</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Operating Activities</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We derive cash flows from operations primarily from collaborations, the sale of products and services rendered. Our cash flows from operating activities are significantly influenced by our use of cash for operating expenses and working capital to support the business. We have historically experienced negative cash flows from operating activities as we have invested in the development of our technologies and manufacturing capabilities, as well as for clinical and preclinical development of our product candidates.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities for the year ended December&#160;31, 2020 was &#8364;13.5&#160;million, comprising a loss before tax of &#8364;145.8&#160;million, non-cash&#160;adjustments of &#8364;227.2&#160;million, and a net negative change in assets and liabilities of &#8364;93.1&#160;million. Non-cash&#160;items primarily included movements in government grant, depreciation and amortization as well as<font style="color:#FF0000;"> </font>share-based compensation expenses and non-cash effective finance expenses. The net negative change in assets and liabilities was primarily due to an increase in trade receivables and a decrease in payables and liabilities as well as inventories.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities for the year ended December&#160;31, 2019 was &#8364;198.5&#160;million, comprising a loss before tax of &#8364;179.4&#160;million, non-cash&#160;adjustments of &#8364;65.0&#160;million, and a net negative change in assets and liabilities of &#8364;83.4&#160;million. Non-cash items primarily included depreciation and amortization as well as share-based compensation expenses. The net negative change in assets and liabilities was primarily due to a decrease in contract liabilities and trade payables.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities for the year ended December&#160;31, 2018 was &#8364;58.9&#160;million, comprising a loss before tax of &#8364;47.7&#160;million, non-cash&#160;adjustments of &#8364;29.9&#160;million, and a net negative change in assets and liabilities of &#8364;41.1&#160;million. Non-cash&#160;items primarily included depreciation and amortization as well as<font style="color:#FF0000;"> </font>share-based compensation expenses. The net negative change in assets and liabilities was primarily due to a<font style="color:#000000;"> </font>decrease in payables and liabilities.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The decrease in net cash used in operating activities from the year ended December&#160;31, 2019 to the year ended December&#160;31, 2020 was primarily due to the fact that higher spending has been overcompensated by upfront and grant funding received as well as increased deferred payments. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The increase in net cash used in operating activities from the year ended December&#160;31, 2018 to the year ended December&#160;31, 2019 was primarily due to an increase in amounts spent for wages, benefits and social security expenses as headcount increases and higher research and development expenditures.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investing Activities</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities for the year ended December&#160;31, 2020 was &#8364;144.8&#160;million, of which &#8364;66.0&#160;million was attributable to the purchase of property, plant and equipment, partially offset by proceeds from the sale of property, plant and equipment amounting to &#8364;1.2 million and &#8364;60.6&#160;million were mainly attributable to the acquisition of our new manufacturing facility in Marburg, Germany. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities for the year ended December&#160;31, 2019 was &#8364;77.1&#160;million, of which &#8364;32.5&#160;million was attributable to the purchase of intangible assets, including the final installment payment for the license agreement for the CellScript patent, and &#8364;38.6&#160;million was attributable to the purchase of property, plant and equipment. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities for the year ended December&#160;31, 2018 was &#8364;66.5&#160;million, of which &#8364;37.3&#160;million was attributable to the purchase of intangible assets, including the payment for the license agreement for the CellScript patent, and &#8364;29.9&#160;million was attributable to the purchase of property, plant and equipment. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Financing Activities</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our primary financing activities consist of issuances of share capital, proceeds from bank loans and payments of lease liabilities.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, we generated cash from financing activities of &#8364;894.7&#160;million, primarily from proceeds from the issuance of shares in the amount of &#8364;753.0&#160;million and proceeds from loans and borrowings in the amount of &#8364;156.0&#160;million, partially offset by the payment of lease liabilities in the amount of &#8364;12.7&#160;million.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">year ended December&#160;31, 2019</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, we generated cash from financing activities of</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;383.3</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;million, primarily from proceeds from the issuance of shares in the amount of</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;375.4</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;million and proceeds from loans and borrowings in the amount of</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;11.0</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;million, partially offset by the payment of lease liabilities in the amount of</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;3.1</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;million.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2018, we generated cash from financing activities of &#8364;365.2&#160;million, primarily from proceeds from the issuance of shares in the amount of &#8364;361.7&#160;million and proceeds from loans and borrowings in the amount of &#8364;5.6&#160;million, partially offset by the payment of lease liabilities in the amount of &#8364;2.1million. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operation and Funding Requirements</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have incurred significant losses and negative cash flows from operations due to our significant research and development expenses and our investment in our manufacturing capabilities. We have accumulated losses of &#8364;409.6&#160;million as of December&#160;31, 2020 and &#8364;424.8&#160;million as of December&#160;31, 2019. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to continue to incur significant and increasing operating expenses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we and our collaborators:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>continue or expand our research or development of our programs in preclinical development&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>continue or expand the scope of our clinical trials for our product candidates&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>initiate additional preclinical, clinical, or other trials for our product candidates, including under our collaboration agreements&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>continue to invest in our immunotherapy platforms to conduct research to identify novel technologies&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>change or increase our manufacturing capacity or capability&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>change or add additional suppliers&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>add additional infrastructure to our quality control, quality assurance, legal, compliance and other groups to support our operations as a public company and our product development and commercialization efforts, including expansion of sites in Germany and new sites in the United States, and potentially others globally&#894; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>attract and retain skilled personnel&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>seek marketing approvals and reimbursement for our product candidates&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>develop our sales, marketing, and distribution infrastructure for our COVID-19 vaccine and any other products for which we may obtain marketing approval or emergency use authorization&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>seek to identify and validate additional product candidates&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>acquire or in-license other product candidates and technologies&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>make milestone or other payments under any in-license agreements&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>maintain, protect, defend, enforce and expand our intellectual property portfolio&#894; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>experience any delays or encounter issues with any of the above.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a party to license and research and development agreements with universities and other third parties, as well as patent assignment agreements, under which we have obtained rights to patents, patent applications and know-how. We enter into contracts in the normal course of business with CROs for clinical trials, clinical and commercial supply manufacturing, with vendors for preclinical research studies and for other services and products for operating purposes. We work together with CMOs, who manufacture our product candidates and products and enter into lease agreements to lease laboratory, GMP manufacturing, storage and office spaces. Purchase obligations under our agreements to the extent that they are quantifiable and not cancelable have been considered when defining our guidance for future cash commitments. Most of the committed cash outflow within the next twelve months in 2021 is related to CMO purchase obligations amounting to &#8364;144.5&#160;million and lease payments amounting to &#8364;8.5&#160;million. Further, we have purchase obligations with an amount of &#8364;97.8&#160;million for the year 2022 and lease payment obligations of &#8364;99.1&#160;million for the years 2022 and beyond. The Group has various lease contracts that have not yet commenced as of December&#160;31, 2020. The future lease payments for these non-cancellable lease contracts are &#8364;2.8&#160;million for the year 2021 and &#8364;10.2&#160;million for the years 2022 and beyond.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">187</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to all of the risks related to the development and commercialization of pharmaceutical products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business.</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;">We intend to invest the </font><font style="color:#000000;">revenues</font><font style="color:#000000;"> we generate from sales of our COVID-19 vaccine to accelerate the maturation of our oncology and infectious disease pipeline and </font><font style="color:#000000;">the </font><font style="color:#000000;">expansion into additional therapeutic areas. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future funding requirements, both near and long term, will depend on many factors, including, but not limited to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the initiation, progress, timing, costs, and results of preclinical or nonclinical studies and clinical trials for our product candidates&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the amount and timing of revenues and associated costs from sales of our COVID-19 vaccine;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the results of research and our other platform activities&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the clinical development plans we establish for our product candidates&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the terms of any agreements with our current or future collaborators, and the achievement of any milestone payments under such agreements to be paid to us or our collaborators&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the number and characteristics of product candidates that we develop or may in-license&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the outcome, timing and cost of meeting regulatory requirements established by the FDA, the EMA and other comparable regulatory authorities&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the cost of filing, prosecuting, obtaining, maintaining, protecting, defending and enforcing our patent claims and other intellectual property rights, including actions for patent and other intellectual property infringement, misappropriation and other violations brought by third parties against us regarding our product candidates or actions by us challenging the patent or intellectual property rights of others&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the effect of competing technological and market developments, including other products that may compete with one or more of our product candidates&#894;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the cost and timing of completion and further expansion of clinical and commercial scale manufacturing activities sufficient to support all of our current and future programs&#894; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">the cost of establishing sales, marketing, and distribution capabilities for any product candidates for which we may receive marketing approval and reimbursement in regions where we choose to commercialize our products on our own.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">E.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_5_E"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Off-B<a name="ITEM_5_E"></a>alance Sheet Arrangements</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any off-balance sheet arrangements. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">F.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_5_F"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_5_F"></a>Tabular Disclosure of Contractual Obligations</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2020, the Securities and Exchange Commission (SEC) voted to adopt amendments to certain financial disclosure requirements in Regulation S-K (also referred to as &#8220;November 19, 2020 amendments to Regulation S-K&#8221;). Compliance is mandatory on August 9, 2021 and rules can be applied early on or after February 10, 2020. We have elected to early adopt the November 19, 2020 amendments to Regulation S-K in this Annual Report and have omitted the presentation of contractual obligations in a tabular form. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">G.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_5_G"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_5_G"></a>Safe Harbor</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See the beginning of this Item and &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; included elsewhere in this Annual Report.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_6_DIRECTORS_SENIOR_MANAGEMENT_AND_E"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_6_DIRECTORS_SENIOR_MANAGEMENT_AND_E"></a>Item 6. Di</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">rectors, Senior Management and Employees</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">A.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_6_A"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_6_A"></a>Directors and Senior Management</font></p></td></tr></table></div>
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Management Board (<font style="font-style:italic;">Vorstand</font>)</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following<font style="letter-spacing:0.05pt;"> </font>table<font style="letter-spacing:0.05pt;"> </font>sets<font style="letter-spacing:0.05pt;"> </font>forth<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>names<font style="letter-spacing:0.05pt;"> </font>and functions<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>current<font style="letter-spacing:0.1pt;"> </font>members<font style="letter-spacing:0.1pt;"> </font>of our Management<font style="letter-spacing:0.1pt;"> </font>Board, their<font style="letter-spacing:0.05pt;"> </font><font style="color:#000000;">ages</font><font style="letter-spacing:0.05pt;"> </font>as of December&#160;31, 2020 and their<font style="letter-spacing:0.05pt;"> </font>terms:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.3%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.58%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Age</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Term Expires</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.06%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Position</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.3%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prof. Ugur Sahin, M.D.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.58%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.06%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sean Marett</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-left:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Business Officer and Chief Commercial Officer</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Sierk Poetting</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-left:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer and Chief Operating Officer</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. &#214;zlem T&#252;reci, M.D.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-left:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Medical Officer</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ryan Richardson</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-left:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Strategy Officer</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="color:#231F20;"> </font>business<font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">address</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">members</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">of our Management</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">Board is</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">same</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">as our business</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">address:</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">An der Goldgrube</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">12, D-55131 Mainz,</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Germany.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <font style="color:#000000;">following</font><font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>a brief<font style="letter-spacing:0.05pt;"> </font>summary<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>business<font style="letter-spacing:0.05pt;"> </font>experience<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>members<font style="letter-spacing:0.1pt;"> </font>of our Management<font style="letter-spacing:0.1pt;"> </font>Board:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;color:#231F20;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Prof. Ugur Sahin, M.D. <font style="font-weight:normal;">co-founded</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">BioNTech in 2008 and has served</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">as our Chief</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Executive</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Officer</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">since that</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">time.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Prof.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Sahin also</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">served</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">as the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">head of the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Scientific</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Advisory</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Board of Ganymed Pharmaceuticals</font><font style="letter-spacing:0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">AG from</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">2008 until</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">company</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">was acquired</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">by </font><font style="color:#000000;font-weight:normal;">Astellas</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Pharma</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Inc.,</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">or Astellas,</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">in 2016. In 2010, Prof.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Sahin co-founded</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">TRON,</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">and served</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">as a Managing</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Director</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">from</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">2010 until</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">2019 and he currently supports the research and development at TRON as a close scientific advisor and supervisor for PhD students. Prof.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Sahin has also</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">been a professor</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">(W3)</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">at</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Mainz</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="color:#000000;font-weight:normal;">University</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Medical</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Center</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">since</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">2014. Prof.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Sahin co-founded</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Ci3, the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">German Cluster</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Initiative</font><font style="letter-spacing:0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">of Individualized</font><font style="letter-spacing:0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">ImmunIntervention</font><font style="letter-spacing:0.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">(Ci3),</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">a non-profit</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">organization.</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Prof.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Sahin earned</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">an M.D. in 1990 from</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">University</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">of Cologne. Prof.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Sahin is</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">married</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">to Dr. &#214;zlem</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">T&#252;reci.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;color:#231F20;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sean Marett<font style="letter-spacing:0.05pt;"> </font><font style="font-weight:normal;">joined</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">BioNTech in 2012. Prior</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">to joining</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">BioNTech, he worked in global</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">strategic</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">and regional</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">marketing</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">and sales</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">roles</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">at</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">GlaxoSmithKline</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">in the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">United</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">States</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">and Pfizer</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">in Europe before</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">taking business</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="color:#000000;font-weight:normal;">development</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">executive</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">roles</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">at</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Evotec</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">and Lorantis,</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">latter</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">of which he helped</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">to successfully</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">sell</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">to Celldex</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="color:#000000;font-weight:normal;">Therapeutics</font><font style="font-weight:normal;">,</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Inc.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">He has successfully</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">executed</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">complex</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">licensing</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">transactions</font><font style="letter-spacing:0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">with large pharmaceutical</font><font style="letter-spacing:0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">companies,</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">negotiated</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">M&amp;A transactions</font><font style="letter-spacing:0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">and raised</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">finance</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">from</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">investors.</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Mr.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Marett</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">built</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">and ran</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">a contract</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">clinical</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">manufacturing</font><font style="letter-spacing:0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">organization</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">with operations</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">across</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Europe and the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">United</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">States</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">for</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">over half</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">a decade</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">for</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">contract</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">manufacturer,</font><font style="letter-spacing:0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">NextPharma.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Mr.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Marett</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">has been Chairman</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">of PHMR</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Ltd, a company</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">specializing</font><font style="letter-spacing:0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">in market</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">access</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">and pharmaceutical</font><font style="letter-spacing:0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">reimbursement,</font><font style="letter-spacing:0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">since</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">2017. He became a member of the supervisory board of AiCuris AG in February 2021. He previously</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">held non-executive</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">directorship</font><font style="letter-spacing:0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">of KWS BioTest</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Ltd (successfully</font><font style="letter-spacing:0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">sold</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">to Charles</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">River)</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">from</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">2011 until</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">2018 and was a member</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">of the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">investment</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">committee</font><font style="letter-spacing:0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">of Mann BioInvest</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Ltd, a fund dedicated</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">to biotechnology</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">and pharmaceutical</font><font style="letter-spacing:0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">company</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">investments</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">from</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">2013 until</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">2016. He holds</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">a BSc (Hons)</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">in Biochemistry</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">from</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Kings College</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">London and an MBA</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">from</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Manchester</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Business</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">School.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;color:#231F20;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dr. Sierk Poetting<font style="letter-spacing:0.05pt;"> </font><font style="font-weight:normal;">is</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">our Chief</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Financial</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Officer</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">and Chief</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Operating</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Officer.</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Dr. Poetting</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">joined BioNTech in September</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">2014 from</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Novartis,</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">where he served</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">from</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">May 2012 to August 2014 as Vice President and Chief</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Financial</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="color:#000000;font-weight:normal;">Officer</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">for</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Sandoz Division</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">in </font><font style="color:#000000;font-weight:normal;">North</font><font style="font-weight:normal;"> America.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Dr. Poetting</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">started</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">his</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">career</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">as a consultant</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">with McKinsey</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">&amp; Company. A German</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">citizen,</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Dr. Poetting</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">holds</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">a Master</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">of Science</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">in Optical Sciences</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">from</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">University</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">of Arizona</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">and a Ph.D.</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">in Physics</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">from</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Ludwig-Maximilians</font><font style="letter-spacing:0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">University</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">in Munich.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;color:#231F20;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dr. &#214;zlem<font style="letter-spacing:0.1pt;"> </font>T&#252;reci <font style="font-weight:normal;">is</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">our Chief</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Medical</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Officer.</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Dr. T&#252;reci</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">joined</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">BioNTech in 2008 as a clinical</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">and scientific</font><font style="letter-spacing:0.15pt;font-weight:normal;"> </font><font style="color:#000000;font-weight:normal;">advisory</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">board</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">member,</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">before</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">becoming</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">our Chief</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Medical</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Officer</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">in 2018. Dr. T&#252;reci</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">co-founded Ganymed Pharmaceuticals AG,</font><font style="letter-spacing:0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">now a subsidiary</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">of Astellas,</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">in 2001 as Chief</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Scientific</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Officer</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">and became</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">its</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Chief Executive</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Officer</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">in 2008. Dr. T&#252;reci</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">is</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">chairman</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">and co-initiator</font><font style="letter-spacing:0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">of Ci3. Dr. T&#252;reci</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">is</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">also</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">President</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">of the Association</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">for</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="color:#000000;font-weight:normal;">Cancer</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Immunotherapy</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">(CIMT).</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Dr. T&#252;reci</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">earned</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">her</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">M.D. from</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Saarland</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">University</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Faculty</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">of Medicine,</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Homburg. Dr. T&#252;reci</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">is</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">married</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">to Prof.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Ugur Sahin, M.D.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;color:#231F20;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#231F20;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ryan</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-weight:bold;color:#231F20;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Richardson </font><font style="font-weight:normal;">is</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">our Chief</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Strategy</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Officer.</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Mr.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Richardson</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">joined</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">BioNTech in September</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">2018 from J.P. Morgan</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Securities</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">LLC, where he served</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">from</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">June 2010 to September</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">2018 in various</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">roles,</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">including</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">as Executive</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Director,</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Healthcare</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Investment</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Banking. </font><font style="color:#000000;font-weight:normal;">Prior</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">to his</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">time</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">at</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">J.P. Morgan</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Securities</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">LLC, Mr.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Richardson</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">served</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">in various</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">roles</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">in the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">healthcare</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">economics</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">and consulting</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">field,</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">including</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">as co-founder of Quantitative</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Insights.</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Mr.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Richardson</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">earned</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">an MBA</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">from</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">University</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">of Chicago Booth School of Business,</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">a MSc from</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">London School of Economics</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">and Political</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Science</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">and a B.S.</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">in Biology from</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the University</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">of Kansas.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supervisory Board (<font style="font-style:italic;">Aufsichtsrat</font>)</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following<font style="letter-spacing:0.05pt;"> </font>table<font style="letter-spacing:0.05pt;"> </font>sets<font style="letter-spacing:0.05pt;"> </font>forth<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>names<font style="letter-spacing:0.05pt;"> </font>and functions<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>current<font style="letter-spacing:0.1pt;"> </font>members<font style="letter-spacing:0.1pt;"> </font>of our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board, their<font style="letter-spacing:0.05pt;"> </font>ages<font style="letter-spacing:0.05pt;"> </font>as of December&#160;31, 2020, their<font style="letter-spacing:0.05pt;"> </font>terms<font style="letter-spacing:0.1pt;"> </font>(which<font style="letter-spacing:0.05pt;"> </font>expire<font style="letter-spacing:0.05pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>date<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>relevant<font style="letter-spacing:0.1pt;"> </font>year&#8217;s<font style="letter-spacing:0.05pt;"> </font>general<font style="letter-spacing:0.05pt;"> </font>shareholders&#8217; meeting)<font style="letter-spacing:0.1pt;"> </font>and their<font style="letter-spacing:0.05pt;"> </font>principal<font style="letter-spacing:0.1pt;"> </font>occupations<font style="letter-spacing:0.1pt;"> </font>outside<font style="letter-spacing:0.05pt;"> </font>of our Company:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.3%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.58%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Age</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Term Expires</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.06%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Principal Occupation</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.3%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Helmut Jeggle</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.58%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.06%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General Partner ATHOS KG</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Motschmann</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-left:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Member of the Board of Management and Head of Equity Investments of MIG Verwaltungs AG</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prof. Christoph Huber, M.D.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-left:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chairman Emeritus at the Johannes-Gutenberg University Mainz</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Ulrich Wandschneider</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-left:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Independent consultant to companies in the pharma, biotech, medtech sciences and health care industry</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Th<font style="color:#000000;">e business address of the members of our Supervisory Board is the same as our business address: An der Goldgrube 12, D-55131 Mainz, Germany.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a brief summary of the prior business experience of the members of our Supervisory Board:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;color:#231F20;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Helmut<font style="letter-spacing:0.1pt;"> </font>Jeggle<font style="letter-spacing:0.05pt;"> </font><font style="font-weight:normal;">has served</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">as the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Chairman</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">of our </font><font style="color:#000000;font-weight:normal;">Supervisory</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Board since</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">2008. Mr. Jeggle has served as General Partner at ATHOS KG, the family office of the Str&#252;ngmann brothers, since 2015. From</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">2007 until 2015, Mr.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Jeggle</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">served</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">as the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Head of Direct</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Investments</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">of ATHOS</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Service</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">GmbH. From</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">2002 until</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">2007, Mr.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Jeggle</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">held</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">various</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">positions</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">with Hexal AG,</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="color:#000000;font-weight:normal;">including</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Head of Business</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Planning</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">&amp; Analyses.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Mr.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Jeggle is</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">currently</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Chief</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="color:#000000;font-weight:normal;">Executive</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Officer</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">of each</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">of Salvia</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">GmbH (since</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">2014), Neula Holding GmbH (since 2010) and AT-Gruppe (since</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">2008) and a manager</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">of Santo Group (since</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">2011). Mr. Jeggle is a member of the supervisory board of 4SC AG and AiCuris AG. Mr. Jeggle</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">has a degree</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">in business</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">administration</font><font style="letter-spacing:0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">from</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the University</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">of Applied</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Sciences</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Neu-Ulm</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="color:#000000;font-weight:normal;">and</font><font style="font-weight:normal;"> earned</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">his</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Master</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">of Business</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Administration</font><font style="letter-spacing:0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">from</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Stuttgart Institute</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">of Management</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">and Technology.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;color:#231F20;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Michael<font style="letter-spacing:0.05pt;"> </font>Motschmann<font style="letter-spacing:0.05pt;"> </font><font style="font-weight:normal;">has served</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">as a </font><font style="color:#000000;font-weight:normal;">member</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">of our Supervisory</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Board since</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">2008. Mr.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Motschmann co-founded</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">MIG </font><font style="color:#000000;font-weight:normal;">Verwaltungs</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">AG,</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">or </font><font style="color:#000000;font-weight:normal;">MIG</font><font style="font-weight:normal;">, in 2004, where he serves</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">on the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Management</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Board and as Head of Equity</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Investments.</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">In his</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">role</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">with MIG, Mr.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Motschmann</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">currently</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">serves</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">on the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">supervisory</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">boards</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">of several private</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">portfolio</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">companies.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;color:#231F20;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Prof. Christoph Huber, M.D. <font style="font-weight:normal;">is</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">a co-founder</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">of BioNTech and has served</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">as a member</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">of our Supervisory Board since</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">2008. Prof.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Huber has more</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">than</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">50 years</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">of professional</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">experience</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">in hematology,</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">oncology</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">and translational</font><font style="letter-spacing:0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">immunology.</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Prof.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Huber served</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">as Chairman</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">of the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Department</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">of Hematology</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">and Oncology at</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Johannes-Gutenberg</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">University</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Mainz from 1990 to 2009 and, since 2009, has served as Chairman Emeritus of the Department of Hematology and Oncology.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Prof.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Huber was a co-founder</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">of Ganymed Pharmaceuticals AG, now a subsidiary</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">of Astellas.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">He is</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">an </font><font style="color:#000000;font-weight:normal;">executive</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">board</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">member</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">of CIMT and a board member</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">of Ci3. From</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">2018 to April</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">2019, Prof.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Huber served</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">as a member</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">of the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">supervisory</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">board</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">of TRON. Prof.</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Huber earned</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">his</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">M.D. at</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">University</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">of Innsbruck.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dr. Ulrich Wandschneider, Ph.D<font style="font-weight:normal;">. has served as a member of our Supervisory Board since 2018. Dr. Wandschneider has more than 20 years of experience in the healthcare sector as a manager in the operative business and as a member of boards and committees. He was a Partner at Arthur Andersen until 2002 and at Deloitte from 2002 to 2004 in the healthcare and life science sector for many years. From 2004 to 2016 Dr. Wandschneider served as Chief Executive Officer first of Mediclin AG later of Asklepios Kliniken GmbH &amp; Co. KGaA. Dr. Wandschneider currently serves on various supervisory and advisory boards.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">190</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">B.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_6_B"></a><font style="text-decoration:none;Background-color:#auto;"></font><font style="color:#000000;"></font><font style="color:#000000;"><a name="ITEM_6_B"></a>Compen</font><font style="color:#000000;">sation</font></p></td></tr></table></div>
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Remuneration of Supervisory Board Members</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Articles of Association provide for a fixed annual remuneration for each member of the Supervisory Board of &#8364;50,000 per year. However, the chairman is entitled to receive &#8364;150,000 per year and the vice chairman &#8364;75,000 per year. In addition, the chairman of the audit committee is entitled to be paid an additional &#8364;20,000 per year. All members of the Supervisory Board are reimbursed for their expenses. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.58%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.02%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Helmut Jeggle</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Michael Motschmann</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Prof. Dr. Christoph Huber, M.D.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dr. Ulrich Wandschneider</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.58%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.02%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;150</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;50</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;50</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;95</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;150</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;50</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;50</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;95</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A member of the Supervisory Board who serves for only a portion of a given fiscal year or who holds the position of chairman or vice chairman of the Supervisory Board or of chairman of the Audit Committee for only a portion of a given fiscal year shall only be remunerated pro-rata. The same is true if the clause of the Articles of Association regarding the remuneration of the members of the Supervisory Board becomes ineffective (e.g., because it is repealed) during the course of a year.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In case any remuneration or reimbursement of expenses is subject to value added tax, such amount shall be paid additionally by the Company.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are no arrangements or understandings between us and any member of our Supervisory Board providing for benefits upon termination of their service as director.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Remuneration of the Members of Our Management Board</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered<font style="letter-spacing:0.05pt;"> </font>into<font style="letter-spacing:0.05pt;"> </font>agreements<font style="letter-spacing:0.1pt;"> </font>with all<font style="letter-spacing:0.05pt;"> </font>current<font style="letter-spacing:0.1pt;"> </font>members<font style="letter-spacing:0.1pt;"> </font>of our Management<font style="letter-spacing:0.1pt;"> </font>Board.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that the agreements between us and the members of our Management Board provide for payments and benefits (including upon termination of employment) that are in line with customary market practice.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following sets forth the end dates of the current service agreements of our Management Board: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.09%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Prof. Ugur Sahin: December 31, 2022</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.09%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Sean Marett: September 30, 2022</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.09%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Dr. Sierk Poetting: September 30, 2022</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.09%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Dr. &#214;zlem T&#252;reci: May 31, 2022</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.09%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Ryan Richardson: December 31, 2022</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From January 1, 2019 until August 31, 2019, the annual base salaries for our Management Board members, Prof. Ugur Sahin, Sean Marett, Dr. Sierk Poetting and Dr. &#214;zlem T&#252;reci, were &#8364;210,000, &#8364;360,000, &#8364;300,000 and &#8364;300,000, respectively. Effective September 1, 2019 the annual base salaries for Prof. Ugur Sahin, Sean Marett, Dr. Sierk Poetting and Dr. &#214;zlem T&#252;reci are &#8364;360,000, &#8364;400,000, &#8364;360,000 and &#8364;360,000, respectively. Effective January 1, 2020 the annual base salary for Ryan Richardson is &#8364;320,000. In December 2019, the Management Board members, Prof. Ugur Sahin, Sean Marett, Dr. Sierk Poetting and Dr. &#214;zlem T&#252;reci, were each awarded a cash bonus of &#8364;50,000, which was paid in 2020.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current service agreements with our Management Board provide for short-term incentive compensation of up to a maximum of 50% of the annual base salary. The amount of such short-term incentive compensation will depend on the achievement of certain company goals in a particular fiscal year, which goals will be set uniformly for all members of the Management Board. Half of the incentive compensation will be paid promptly upon achievement of the applicable company goals, with the remaining amount payable one year later, subject to adjustment relative to our share price performance during that year. The provisions in relation to the short-term incentive compensation took effect from January&#160;1, 2020, being the beginning of the first year after the year in which BioNTech Shares or ADSs of the Company were listed on a stock exchange or other multilateral trading system.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">191</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The service agreements of our Management Board provide for long-term incentive compensation in terms of a yearly grant of options to purchase </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech S</font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hares. The options granted each year will be subject to the terms, conditions, definitions and provisions of our ESOP and the applicable option agreement thereunder. The number of options to be granted each year to Prof. Ugur Sahin, Sean Marett, Dr. Sierk Poetting, Dr. &#214;zlem T&#252;reci and Ryan Richardson is to be calculated based on a value of &#8364;750,000, &#8364;300,000, &#8364;300,000, &#8364;300,000 and &#8364;260,000, respectively, in each case divided by the amount by which a certain target share price exceeds the exercise price (which in the case of each grant is equal to the stock price as of the time of that grant). </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The value used to calculate the number of options for Ryan Richardson increases to &#8364;280,000 for the year 2022. </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These provisions in relation to the long-term incentive compensation took effect from January 1, 2020.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are no arrangements or understandings between us and any member of our Management Board providing for benefits upon termination of their service as director.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the years ended December&#160;31, 2020 and December&#160;31, 2019, the members of our Management Board received<font style="letter-spacing:0.1pt;"> </font>aggregate<font style="letter-spacing:0.1pt;"> </font>remuneration<font style="letter-spacing:0.15pt;"> </font>of &#8364;23.7&#160;million<font style="letter-spacing:0.1pt;"> </font>and &#8364;19.6&#160;millio<font style="letter-spacing:0.1pt;">n</font>, respectively.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.8%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Prof. Ugur Sahin, M.D.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sean Marett</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dr. Sierk Poetting</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dr. &#214;zlem T&#252;reci</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ryan Richardson <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.8%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fixed compensation and short-term incentive incurred</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;450</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;500</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;450</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;450</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;400</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;311</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;423</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;370</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;370</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fringe Benefits <sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Short-term incentive accrued <sup style="font-size:85%;line-height:120%;vertical-align:top">(3)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">148</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">148</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">148</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share-based payments <sup style="font-size:85%;line-height:120%;vertical-align:top">(4)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,913</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,613</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,613</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">433</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,128</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,748</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,180</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,180</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,043</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;16,517</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,287</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,222</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,031</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,665</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7,064</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,615</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,561</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;9,413</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Ryan Richardson was appointed to the Management Board as Chief Strategy Officer (CSO) and Managing Director on January 12, 2020. Expenses from a bonus arrangement agreed with Ryan Richardson in advance of his appointment to the Management Board are included in the share-based payments amount. During the year ended December 31, 2020, the arrangement was modified from an all-equity share-based payment arrangement into a partly cash and partly equity settled share-based payment arrangement including 4,534 ordinary shares which have not yet been issued. </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:3.04%;text-indent:-3.04%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Includes social security, health and additional insurance, company bike and travel expenses.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:3.04%;text-indent:-3.04%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(3)</sup></font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">The fair value of the second installment of the short-term incentive compensation which has been classified as cash-settled share-based payment arrangement was determined pursuant to the regulations of IFRS 2 &#8220;Share-based Payments.&#8221; This table shows the pro-rata share of personnel expenses for the respective financial year that are recognized over the award&#8217;s vesting period beginning as of the service commencement date (January 1, 2020) until each separate determination date and are remeasured until settlement date. </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:3.04%;text-indent:-3.04%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(4)</sup></font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">The fair value was determined pursuant to the regulations of IFRS 2 &#8220;Share-based Payments.&#8221; This table shows the pro-rata share of personnel expenses resulting from stock-based compensation for the respective financial year. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below provides an overview of the share options granted to our Management Board in the years ended </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2018</font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.04%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant Date <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number of Ordinary Shares Underlying Share Options <sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Option Exercise Price (&#8364;)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Option Expiration Date</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.04%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prof. Ugur Sahin, M.D.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/15/2018</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,830,348</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/17/2026</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/10/2019 <sup style="font-size:85%;line-height:120%;vertical-align:top">(3)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,374,963</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.60</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/11/2029</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/13/2020 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">4</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,420</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.32</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/13/2030</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021 <sup style="font-size:85%;line-height:120%;vertical-align:top">(5)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,826 <sup style="font-size:85%;line-height:120%;vertical-align:top">(5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.26 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2031 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,817 <sup style="font-size:85%;line-height:120%;vertical-align:top">(5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.27 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2032 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sean Marett</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/15/2018</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">610,110</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/17/2026</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/13/2020 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">4</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,968</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.32</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/13/2030</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021 <sup style="font-size:85%;line-height:120%;vertical-align:top">(5)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,930 <sup style="font-size:85%;line-height:120%;vertical-align:top">(5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.26 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2031 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,927 <sup style="font-size:85%;line-height:120%;vertical-align:top">(5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.27 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2032 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Sierk Poetting</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/15/2018</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">610,110</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/17/2026</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/13/2020 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">4</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,968</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.32</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/13/2030</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021 <sup style="font-size:85%;line-height:120%;vertical-align:top">(5)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,930 <sup style="font-size:85%;line-height:120%;vertical-align:top">(5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.26 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2031 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,927 <sup style="font-size:85%;line-height:120%;vertical-align:top">(5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.27 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2032 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. &#214;zlem T&#252;reci</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/15/2018 <sup style="font-size:85%;line-height:120%;vertical-align:top">(6)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,952,334</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/17/2026</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/13/2020 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">4</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,968</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.32</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/13/2030</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021 <sup style="font-size:85%;line-height:120%;vertical-align:top">(5)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,930 <sup style="font-size:85%;line-height:120%;vertical-align:top">(5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.26 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2031 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,927 <sup style="font-size:85%;line-height:120%;vertical-align:top">(5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.27 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2032 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ryan Richardson <sup style="font-size:85%;line-height:120%;vertical-align:top">(7)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:13pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/15/2018 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">8</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149,508</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/17/2026</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/13/2020 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">4</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,772</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.32</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/13/2030</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021 <sup style="font-size:85%;line-height:120%;vertical-align:top">(5)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,806 <sup style="font-size:85%;line-height:120%;vertical-align:top">(5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.26 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2031 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,865 <sup style="font-size:85%;line-height:120%;vertical-align:top">(5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.27 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2032 <sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:2.72%;text-indent:-3.12%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.12%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup>Except as otherwise indicated, all options fully vest on September 16, 2022.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:2.72%;text-indent:-3.12%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.12%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">18-for-1 stock split of our ordinary shares which became effective on September 18, 2019, upon registration with the commercial register (<font style="font-style:italic;">Handelsregister</font>) is reflected in share amounts granted in advance.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:2.72%;text-indent:-3.12%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.12%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(3)</sup></font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Options vest in four equal installments on October 10 of 2020, 2021, 2022 and 2023.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:2.72%;text-indent:-3.12%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.12%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(4)</sup></font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Options vest in four equal installments on February 13 of 2021, 2022, 2023 and 2024.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:2.72%;text-indent:-3.12%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.12%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(5)</sup></font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">As of December 31, 2020, the assessment about options expected to be granted in 2021 and 2022 was based on estimated allocation dates in the middle of the years 2021 and 2022, respectively. For the awards with estimated allocation dates the exercise prices and the numbers of options expected to be allocated have been derived from the Monte-Carlo simulation model. Those parameters will be adjusted until the actual allocation has occurred and the number of options granted and the exercise price has ultimately been determined. The options will vest annually in equal installments over four years commencing on the first anniversary of the allocation date and will be exercisable four years after the allocation date. </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:2.72%;text-indent:-3.12%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.12%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(6)</sup></font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Options fully vested on March 16, 2019, however these options will not become exercisable until September&#160;16,&#160;2022.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:2.72%;text-indent:-3.12%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.12%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(7)</sup></font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Ryan Richardson was appointed to the Management Board as Chief Strategy Officer (CSO) and Managing Director on January 12, 2020. The share options granted on November 15, 2018 under the Employee<font style="letter-spacing:0.05pt;"> </font>Stock Ownership Plan were granted before his appointment to the Management Board. </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:2.72%;text-indent:-3.12%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.12%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(8)</sup></font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Options fully vested on October 10, 2019, however these options will not become exercisable until September&#160;16,&#160;2022.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:2.72%;text-indent:-3.12%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">193</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Employee<font style="letter-spacing:0.05pt;"> </font>Stock Ownership Plan</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on a pertinent<font style="letter-spacing:0.1pt;"> </font>authorization<font style="letter-spacing:0.15pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>general<font style="letter-spacing:0.05pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>on August 18, 2017, we established<font style="letter-spacing:0.1pt;"> </font>a share option<font style="letter-spacing:0.05pt;"> </font>program<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>which we granted<font style="letter-spacing:0.05pt;"> </font>selected<font style="letter-spacing:0.1pt;"> </font>employees<font style="letter-spacing:0.1pt;"> </font>options<font style="letter-spacing:0.05pt;"> </font>to receive<font style="letter-spacing:0.1pt;"> </font>our shares.<font style="letter-spacing:0.05pt;"> </font>The program<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>designed<font style="color:#000000;"> </font>as an Employee<font style="letter-spacing:0.05pt;"> </font>Stock Ownership Plan, or ESOP.<font style="letter-spacing:-0.05pt;"> </font>We have offered<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>participants<font style="letter-spacing:0.15pt;"> </font>a certain<font style="letter-spacing:0.1pt;"> </font>number<font style="letter-spacing:0.05pt;"> </font>of rights<font style="letter-spacing:0.05pt;"> </font>by explicit<font style="letter-spacing:0.1pt;"> </font>acceptance<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>participants.<font style="letter-spacing:0.15pt;"> </font>The exercise<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>option<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>in accordance<font style="letter-spacing:0.1pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>agreement<font style="letter-spacing:0.1pt;"> </font>gives the<font style="letter-spacing:0.05pt;"> </font>participants<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>right<font style="letter-spacing:0.05pt;"> </font>to obtain<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>payment<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>exercise<font style="letter-spacing:0.1pt;"> </font>price.<font style="letter-spacing:0.05pt;"> </font>The option<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>(other<font style="letter-spacing:0.05pt;"> </font>than Dr. &#214;zlem T&#252;reci&#8217;s<font style="letter-spacing:0.1pt;"> and Ryan Richardson&#8217;s </font>options<font style="letter-spacing:0.05pt;"> </font>referred<font style="letter-spacing:0.1pt;"> </font>to above) generally<font style="letter-spacing:0.1pt;"> </font>fully<font style="letter-spacing:0.05pt;"> </font>vest<font style="letter-spacing:0.05pt;"> </font>after<font style="letter-spacing:0.1pt;"> </font>four<font style="letter-spacing:0.05pt;"> </font>years<font style="letter-spacing:0.05pt;"> </font>and can only be exercised<font style="letter-spacing:0.1pt;"> </font>if:<font style="letter-spacing:0.05pt;"> </font>(i)<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>waiting<font style="letter-spacing:0.05pt;"> </font>period<font style="letter-spacing:0.05pt;"> </font>of four<font style="letter-spacing:0.05pt;"> </font>years<font style="letter-spacing:0.05pt;"> </font>has elapsed;<font style="letter-spacing:0.1pt;"> </font>and (ii)<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>of exercise,<font style="letter-spacing:0.1pt;"> </font>the average<font style="letter-spacing:0.05pt;"> </font>closing<font style="letter-spacing:0.05pt;"> </font>price<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Company or the<font style="letter-spacing:0.05pt;"> </font>average<font style="letter-spacing:0.05pt;"> </font>closing<font style="letter-spacing:0.05pt;"> </font>price<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>right<font style="letter-spacing:0.05pt;"> </font>or certificate<font style="letter-spacing:0.15pt;"> </font>to be converted<font style="letter-spacing:0.05pt;"> </font>into<font style="letter-spacing:0.05pt;"> </font>an amount<font style="letter-spacing:0.05pt;"> </font>per<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>previous<font style="letter-spacing:0.05pt;"> </font>ten<font style="letter-spacing:0.05pt;"> </font>trading<font style="letter-spacing:0.05pt;"> </font>days preceding<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>exercise<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>option<font style="letter-spacing:0.05pt;"> </font>right exceeds<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>strike<font style="letter-spacing:0.1pt;"> </font>price<font style="letter-spacing:0.05pt;"> </font>by a minimum<font style="letter-spacing:0.1pt;"> </font>of 32%, with this<font style="letter-spacing:0.05pt;"> </font>percentage<font style="letter-spacing:0.1pt;"> </font>increasing<font style="letter-spacing:0.1pt;"> </font>by eight<font style="letter-spacing:0.05pt;"> </font>percentage<font style="letter-spacing:0.1pt;"> </font>points<font style="letter-spacing:0.05pt;"> </font>as of the<font style="letter-spacing:0.05pt;"> </font>fifth<font style="letter-spacing:0.1pt;"> </font>anniversary<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>respective<font style="letter-spacing:0.1pt;"> </font>issue<font style="letter-spacing:0.05pt;"> </font>date<font style="letter-spacing:0.05pt;"> </font>and as of each<font style="letter-spacing:0.05pt;"> </font>subsequent<font style="letter-spacing:0.05pt;"> </font>anniversary<font style="letter-spacing:0.1pt;"> </font>date.<font style="letter-spacing:0.05pt;"> </font>The option<font style="letter-spacing:0.05pt;"> </font>rights can be exercised<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>latest<font style="letter-spacing:0.1pt;"> </font>eight<font style="letter-spacing:0.05pt;"> </font>years<font style="letter-spacing:0.05pt;"> </font>after<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>allocation<font style="letter-spacing:0.1pt;"> </font>date.<font style="letter-spacing:0.05pt;"> </font>If<font style="letter-spacing:0.05pt;"> </font>they<font style="letter-spacing:0.05pt;"> </font>have not been exercised<font style="letter-spacing:0.1pt;"> </font>by that<font style="letter-spacing:0.05pt;"> </font>date, they<font style="letter-spacing:0.05pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>forfeit<font style="letter-spacing:0.1pt;"> </font>without<font style="letter-spacing:0.05pt;"> </font>compensation. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By way of shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>resolution<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>general<font style="letter-spacing:0.05pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>on August 19, 2019, the<font style="letter-spacing:0.05pt;"> </font>authorization<font style="letter-spacing:0.15pt;"> </font>to issue such option<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>was amended<font style="letter-spacing:0.05pt;"> </font>such, that,<font style="letter-spacing:0.05pt;"> </font>in order<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>options<font style="letter-spacing:0.05pt;"> </font>to be exercisable,<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>average<font style="letter-spacing:0.05pt;"> </font>closing<font style="letter-spacing:0.05pt;"> </font>price<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Company&#8217;s<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>or the<font style="letter-spacing:0.05pt;"> </font>average<font style="letter-spacing:0.05pt;"> </font>closing<font style="letter-spacing:0.05pt;"> </font>price<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>right<font style="letter-spacing:0.05pt;"> </font>or certificate<font style="letter-spacing:0.15pt;"> </font>to be converted<font style="letter-spacing:0.05pt;"> </font>into<font style="letter-spacing:0.05pt;"> </font>an amount<font style="letter-spacing:0.05pt;"> </font>per share<font style="letter-spacing:0.05pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>ten<font style="letter-spacing:0.05pt;"> </font>trading<font style="letter-spacing:0.05pt;"> </font>days immediately<font style="letter-spacing:0.15pt;"> </font>preceding<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>exercise<font style="letter-spacing:0.1pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>exceed<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>strike<font style="letter-spacing:0.1pt;"> </font>price<font style="letter-spacing:0.05pt;"> </font>by a minimum<font style="letter-spacing:0.1pt;"> </font>of 28%, with this<font style="letter-spacing:0.05pt;"> </font>percentage<font style="letter-spacing:0.1pt;"> </font>increasing<font style="letter-spacing:0.1pt;"> </font>by seven<font style="letter-spacing:0.05pt;"> </font>percentage<font style="letter-spacing:0.1pt;"> </font>points<font style="letter-spacing:0.05pt;"> </font>as of the<font style="letter-spacing:0.05pt;"> </font>fifth<font style="letter-spacing:0.1pt;"> </font>anniversary<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>issue<font style="letter-spacing:0.05pt;"> </font>date<font style="letter-spacing:0.05pt;"> </font>and as of each<font style="letter-spacing:0.05pt;"> </font>subsequent<font style="letter-spacing:0.05pt;"> </font>anniversary<font style="letter-spacing:0.1pt;"> </font>date.<font style="letter-spacing:0.05pt;"> </font>Also, in addition<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>aforementioned<font style="letter-spacing:0.15pt;"> </font>requirements,<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>exercise<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>only possible<font style="letter-spacing:0.05pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>price<font style="letter-spacing:0.05pt;"> </font>(calculated<font style="letter-spacing:0.15pt;"> </font>by reference<font style="letter-spacing:0.1pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>price<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>ordinary<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>underlying<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>ADS)<font style="letter-spacing:-0.05pt;"> </font>has performed<font style="letter-spacing:0.1pt;"> </font>similar<font style="letter-spacing:0.1pt;"> </font>to or better<font style="letter-spacing:0.1pt;"> </font>than<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Nasdaq Biotechnology<font style="letter-spacing:0.05pt;"> </font>Index.<font style="letter-spacing:0.05pt;"> </font>The changes<font style="letter-spacing:0.05pt;"> </font>made<font style="letter-spacing:0.05pt;"> </font>do not affect<font style="letter-spacing:0.1pt;"> </font>option rights<font style="letter-spacing:0.05pt;"> </font>already<font style="letter-spacing:0.05pt;"> </font>issued.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Chief Executive Officer Grant</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2019, we granted Prof. Ugur Sahin, M.D., our co-founder and Chief Executive Officer, an option to purchase 4,374,963 of our ordinary shares, subject to Prof. Sahin&#8217;s continuous employment with us. The option is subject to the terms, conditions, definitions and provisions of our ESOP and the applicable option agreement thereunder. The options&#8217; exercise price per share is the Euro translation of the public offering price from our initial public offering, &#8364;13.60 ($15.00). The option will vest annually in equal installments after four years commencing on the first anniversary of our initial public offering and will be exercisable four years after our initial public offering. The option rights can be exercised up to ten years after the allocation date. If they have not been exercised by that date, they will lapse without compensation.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Management Board Grant</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From the beginning of 2020, the first year following the completion of our IPO, until the end of the term of the Management Board member&#8217;s employment agreement, the service agreements with our Management Board provide for a long-term incentive compensation in terms of a yearly grant of options to purchase ordinary shares. The options allocated each year will be subject to the terms, conditions, definitions and provisions of the ESOP and the applicable option agreement thereunder. The allocation of the number of issued options in 2020 occurred as of February 13, 2020. As of December 31, 2020, the assessment about options expected to be granted in 2021 and 2022 was based on estimated allocation dates in the middle of the years 2021 and 2022, respectively. The per share exercise price of the options is the Euro equivalent of the arithmetic mean of the closing prices of the ten last trading days prior to the allocation date. For the award allocated as of February 13, 2020 the exercise price has been determined to be $30.78 (&#8364;28.32). For the awards with estimated allocation dates the exercise prices and the numbers of options <font style="color:#000000;">expected to be allocated</font> have been derived from the Monte-Carlo simulation model. Those parameters will be adjusted until the actual allocation has occurred and the number of options granted and the exercise price has ultimately been determined. The options will vest annually in equal installments over four years commencing on the first anniversary of the allocation date and will be exercisable four years after the allocation date. The options expire ten years after the allocation date. If they have not been exercised by that date, they will lapse without compensation.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">C.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_6_C"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_6_C"></a>Board Practices</font></p></td></tr></table></div>
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Two-Tiered Board Structure</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are<font style="letter-spacing:0.05pt;"> </font>a European<font style="letter-spacing:0.05pt;"> </font>public<font style="letter-spacing:0.05pt;"> </font>company<font style="letter-spacing:0.05pt;"> </font>with limited<font style="letter-spacing:0.1pt;"> </font>liability<font style="letter-spacing:0.15pt;"> </font>(<font style="font-style:italic;">Societas</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">Europaea </font>or SE) (also<font style="letter-spacing:0.05pt;"> </font>referred<font style="letter-spacing:0.1pt;"> </font>to as <font style="color:#000000;">European</font><font style="letter-spacing:0.05pt;"> </font>stock<font style="letter-spacing:0.05pt;"> </font><font style="color:#000000;">corporation</font>,<font style="letter-spacing:0.1pt;"> </font>and in the<font style="letter-spacing:0.05pt;"> </font>official<font style="letter-spacing:0.1pt;"> </font>terminology<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>European<font style="letter-spacing:0.05pt;"> </font>legislation<font style="letter-spacing:0.15pt;"> </font>referred<font style="letter-spacing:0.1pt;"> </font>to as European public<font style="letter-spacing:0.05pt;"> </font>limited-liability<font style="letter-spacing:0.25pt;"> </font>company),<font style="letter-spacing:0.05pt;"> </font>having<font style="letter-spacing:0.05pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>seat<font style="letter-spacing:0.05pt;"> </font>in Germany.<font style="letter-spacing:0.05pt;"> </font>We have chosen<font style="letter-spacing:0.05pt;"> </font>to have a two-tiered<font style="letter-spacing:0.1pt;"> </font>structure. Hence, our corporate<font style="letter-spacing:0.1pt;"> </font>bodies<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board (<font style="font-style:italic;">Vorstan</font><font style="font-style:italic;letter-spacing:0.05pt;">d</font>), the<font style="letter-spacing:0.05pt;"> </font>Supervisory<font style="letter-spacing:0.05pt;"> </font>Board (<font style="font-style:italic;">Aufsichtsra</font><font style="font-style:italic;letter-spacing:0.1pt;">t</font>) and the <font style="color:#000000;">shareholders&#8217;</font><font style="letter-spacing:0.15pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-style:italic;">Hauptversammlung</font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">). Our Management</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Supervisory</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boards are</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">entirely</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">separate, and, as a rule,</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no individual</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">simultaneously</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be a member</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of both boards. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Management<font style="letter-spacing:0.1pt;"> </font><font style="color:#000000;">Board</font> is<font style="letter-spacing:0.05pt;"> </font>responsible<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>day-to-day<font style="letter-spacing:0.1pt;"> </font>management<font style="letter-spacing:0.1pt;"> </font>of our business<font style="letter-spacing:0.05pt;"> </font>in accordance<font style="letter-spacing:0.1pt;"> </font>with applicable<font style="letter-spacing:0.1pt;"> </font>laws, our Articles<font style="letter-spacing:0.1pt;"> </font>of Association<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Satzun</font><font style="font-style:italic;letter-spacing:0.05pt;">g</font>) and the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board&#8217;s<font style="letter-spacing:0.05pt;"> </font>internal<font style="letter-spacing:0.1pt;"> </font>rules<font style="letter-spacing:0.05pt;"> </font>of procedure (<font style="font-style:italic;">Gesch&#228;ftsordnun</font><font style="font-style:italic;letter-spacing:0.05pt;">g</font>). Our Management<font style="letter-spacing:0.1pt;"> </font>Board represents<font style="letter-spacing:0.1pt;"> </font>us in our dealings<font style="letter-spacing:0.05pt;"> </font>with third<font style="letter-spacing:0.05pt;"> </font>parties.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <font style="color:#000000;">principal</font><font style="letter-spacing:0.1pt;"> </font>function<font style="letter-spacing:0.05pt;"> </font>of our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board is<font style="letter-spacing:0.05pt;"> </font>to supervise<font style="letter-spacing:0.1pt;"> </font>our Management<font style="letter-spacing:0.1pt;"> </font>Board. The Supervisory Board is<font style="letter-spacing:0.05pt;"> </font>also<font style="letter-spacing:0.05pt;"> </font>responsible<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>appointing<font style="letter-spacing:0.05pt;"> </font>and removing<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>members<font style="letter-spacing:0.1pt;"> </font>of our Management<font style="letter-spacing:0.1pt;"> </font>Board, representing<font style="letter-spacing:0.1pt;"> </font>us in connection<font style="letter-spacing:0.05pt;"> </font>with transactions<font style="letter-spacing:0.15pt;"> </font>between<font style="letter-spacing:0.05pt;"> </font>a current<font style="letter-spacing:0.1pt;"> </font>or former<font style="letter-spacing:0.1pt;"> </font>member<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font><font style="color:#000000;">Board</font> and us, and granting<font style="letter-spacing:0.05pt;"> </font>approvals<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>certain<font style="letter-spacing:0.1pt;"> </font>significant<font style="letter-spacing:0.15pt;"> </font>matters.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Management<font style="letter-spacing:0.1pt;"> </font>Board and our <font style="color:#000000;">Supervisory</font><font style="letter-spacing:0.05pt;"> </font>Board are<font style="letter-spacing:0.05pt;"> </font>solely<font style="letter-spacing:0.05pt;"> </font>responsible<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>and manage<font style="letter-spacing:0.05pt;"> </font>their<font style="letter-spacing:0.05pt;"> </font>own areas of competency<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Kompetenztrennun</font><font style="font-style:italic;letter-spacing:0.05pt;">g</font>);<font style="letter-spacing:0.05pt;"> </font>therefore,<font style="letter-spacing:0.1pt;"> </font>neither<font style="letter-spacing:0.1pt;"> </font>board<font style="letter-spacing:0.05pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>make<font style="letter-spacing:0.05pt;"> </font>decisions<font style="letter-spacing:0.1pt;"> </font>that,<font style="letter-spacing:0.05pt;"> </font>pursuant<font style="letter-spacing:0.05pt;"> </font>to applicable law, our Articles<font style="letter-spacing:0.1pt;"> </font>of Association<font style="letter-spacing:0.1pt;"> </font>or the<font style="letter-spacing:0.05pt;"> </font>internal<font style="letter-spacing:0.1pt;"> </font>rules<font style="letter-spacing:0.05pt;"> </font>of procedure<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>responsibility<font style="letter-spacing:0.15pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>board. Members<font style="letter-spacing:0.1pt;"> </font>of both boards<font style="letter-spacing:0.05pt;"> </font>owe a duty of loyalty<font style="letter-spacing:0.05pt;"> </font>and care<font style="letter-spacing:0.05pt;"> </font>to us. In carrying<font style="letter-spacing:0.1pt;"> </font>out their<font style="letter-spacing:0.05pt;"> </font>duties,<font style="letter-spacing:0.05pt;"> </font>they<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>required<font style="letter-spacing:0.1pt;"> </font>to exercise<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>standard<font style="letter-spacing:0.05pt;"> </font>of care<font style="letter-spacing:0.05pt;"> </font>of a prudent<font style="letter-spacing:0.05pt;"> </font>and diligent<font style="letter-spacing:0.1pt;"> </font><font style="color:#000000;">businessperson</font>.<font style="letter-spacing:0.1pt;"> </font>If<font style="letter-spacing:0.05pt;"> </font>they<font style="letter-spacing:0.05pt;"> </font>fail<font style="letter-spacing:0.05pt;"> </font>to observe<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>appropriate standard<font style="letter-spacing:0.05pt;"> </font>of care,<font style="letter-spacing:0.05pt;"> </font><font style="color:#000000;">they</font><font style="letter-spacing:0.05pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>become<font style="letter-spacing:0.05pt;"> </font>liable<font style="letter-spacing:0.1pt;"> </font>to us.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In carrying<font style="letter-spacing:0.1pt;"> </font>out their<font style="letter-spacing:0.05pt;"> </font>duties,<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>members<font style="letter-spacing:0.1pt;"> </font>of both boards<font style="letter-spacing:0.05pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>take<font style="letter-spacing:0.05pt;"> </font>into<font style="letter-spacing:0.05pt;"> </font>account<font style="letter-spacing:0.05pt;"> </font>a broad<font style="letter-spacing:0.05pt;"> </font>range<font style="letter-spacing:0.05pt;"> </font>of considerations<font style="letter-spacing:0.15pt;"> </font>when making<font style="letter-spacing:0.05pt;"> </font>decisions,<font style="letter-spacing:0.1pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>our interests<font style="letter-spacing:0.1pt;"> </font>and the<font style="letter-spacing:0.05pt;"> </font>interests<font style="letter-spacing:0.1pt;"> </font>of our shareholders,<font style="letter-spacing:0.1pt;"> </font>employees, creditors<font style="letter-spacing:0.1pt;"> </font>and, to a limited<font style="letter-spacing:0.1pt;"> </font>extent,<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>general<font style="letter-spacing:0.05pt;"> </font>public,<font style="letter-spacing:0.05pt;"> </font>while<font style="letter-spacing:0.05pt;"> </font>respecting<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>of our shareholders<font style="letter-spacing:0.1pt;"> </font>to be treated on equal<font style="letter-spacing:0.05pt;"> </font>terms.<font style="letter-spacing:0.1pt;"> </font>Additionally,<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board is<font style="letter-spacing:0.05pt;"> </font>responsible<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>implementing<font style="letter-spacing:0.15pt;"> </font>an internal<font style="letter-spacing:0.1pt;"> </font>monitoring system<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>risk<font style="letter-spacing:0.05pt;"> </font>management<font style="letter-spacing:0.1pt;"> </font>purposes.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board has comprehensive<font style="letter-spacing:0.1pt;"> </font>monitoring<font style="letter-spacing:0.1pt;"> </font>responsibilities.<font style="letter-spacing:0.2pt;"> </font>To ensure<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>our Supervisory Board can carry<font style="letter-spacing:0.05pt;"> </font><font style="color:#000000;">out</font> these<font style="letter-spacing:0.05pt;"> </font>functions<font style="letter-spacing:0.1pt;"> </font>properly,<font style="letter-spacing:0.05pt;"> </font>our Management<font style="letter-spacing:0.1pt;"> </font>Board must,<font style="letter-spacing:0.05pt;"> </font>among<font style="letter-spacing:0.05pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>duties,<font style="letter-spacing:0.05pt;"> </font>regularly<font style="letter-spacing:0.1pt;"> </font>report to our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board regarding<font style="letter-spacing:0.1pt;"> </font>our current<font style="letter-spacing:0.1pt;"> </font>business<font style="letter-spacing:0.05pt;"> </font>operations<font style="letter-spacing:0.1pt;"> </font>and future<font style="letter-spacing:0.05pt;"> </font>business<font style="letter-spacing:0.05pt;"> </font>planning<font style="letter-spacing:0.05pt;"> </font>(including financial,<font style="letter-spacing:0.1pt;"> </font>investment<font style="letter-spacing:0.1pt;"> </font>and personnel<font style="letter-spacing:0.05pt;"> </font>planning).<font style="letter-spacing:0.05pt;"> </font>In addition,<font style="letter-spacing:0.05pt;"> </font>our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board or any of its<font style="letter-spacing:0.05pt;"> </font>members<font style="letter-spacing:0.1pt;"> </font>is entitled<font style="letter-spacing:0.1pt;"> </font>to request<font style="letter-spacing:0.05pt;"> </font>special<font style="letter-spacing:0.1pt;"> </font>reports<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font><font style="color:#000000;">Management</font><font style="letter-spacing:0.1pt;"> </font>Board on all<font style="letter-spacing:0.05pt;"> </font>matters<font style="letter-spacing:0.1pt;"> </font>regarding<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Company, our legal and business<font style="letter-spacing:0.05pt;"> </font>relations<font style="letter-spacing:0.1pt;"> </font>with affiliated<font style="letter-spacing:0.15pt;"> </font>companies<font style="letter-spacing:0.1pt;"> </font>and any business<font style="letter-spacing:0.05pt;"> </font>transactions<font style="letter-spacing:0.15pt;"> </font>and matters<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>such affiliated companies<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>have a significant<font style="letter-spacing:0.15pt;"> </font>impact<font style="letter-spacing:0.1pt;"> </font>on our position<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>any time.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under German<font style="letter-spacing:0.05pt;"> </font>law, our shareholders<font style="letter-spacing:0.1pt;"> </font>have, as a general rule, no direct<font style="letter-spacing:0.1pt;"> </font>recourse<font style="letter-spacing:0.1pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>members<font style="letter-spacing:0.1pt;"> </font>of our Management Board or the<font style="letter-spacing:0.05pt;"> </font>members<font style="letter-spacing:0.1pt;"> </font>of our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board in the<font style="letter-spacing:0.05pt;"> </font>event<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>they<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>believed<font style="letter-spacing:0.05pt;"> </font>to have breached<font style="letter-spacing:0.05pt;"> </font>their<font style="letter-spacing:0.05pt;"> </font>duty of loyalty<font style="letter-spacing:0.05pt;"> </font>and care<font style="letter-spacing:0.05pt;"> </font>to us. Apart<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> when we are unable to fulfill our third party obligations, tortious conduct to board members </font>or other<font style="letter-spacing:0.05pt;"> </font>special<font style="letter-spacing:0.1pt;"> </font>circumstances,<font style="letter-spacing:0.15pt;"> </font>only we have the<font style="letter-spacing:0.05pt;"> </font>right<font style="letter-spacing:0.05pt;"> </font>to claim damages<font style="letter-spacing:0.05pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>members<font style="letter-spacing:0.1pt;"> </font>of our two boards.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may<font style="letter-spacing:0.05pt;"> </font>waive these<font style="letter-spacing:0.05pt;"> </font>claims<font style="letter-spacing:0.1pt;"> </font>to damages<font style="letter-spacing:0.05pt;"> </font>or settle<font style="letter-spacing:0.1pt;"> </font>these<font style="letter-spacing:0.05pt;"> </font>claims<font style="letter-spacing:0.1pt;"> </font>only if<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>three<font style="letter-spacing:0.05pt;"> </font>years<font style="letter-spacing:0.05pt;"> </font>have passed<font style="letter-spacing:0.05pt;"> </font>since<font style="letter-spacing:0.05pt;"> </font>a claim<font style="letter-spacing:0.1pt;"> </font>associated<font style="letter-spacing:0.1pt;"> </font>with <font style="color:#000000;">any</font> violation<font style="letter-spacing:0.1pt;"> </font>of a duty has arisen<font style="letter-spacing:0.05pt;"> </font>and only if<font style="letter-spacing:0.05pt;"> </font>our shareholders<font style="letter-spacing:0.1pt;"> </font>approve<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>waiver<font style="letter-spacing:0.05pt;"> </font>or settlement<font style="letter-spacing:0.15pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>a shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>with a simple<font style="letter-spacing:0.1pt;"> </font>majority<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>votes<font style="letter-spacing:0.05pt;"> </font>cast,<font style="letter-spacing:0.05pt;"> </font>provided<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>no shareholders<font style="letter-spacing:0.1pt;"> </font>who in the<font style="letter-spacing:0.05pt;"> </font>aggregate<font style="letter-spacing:0.1pt;"> </font>hold one-tenth<font style="letter-spacing:0.1pt;"> </font>or more<font style="letter-spacing:0.05pt;"> </font>of our share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>oppose the<font style="letter-spacing:0.05pt;"> </font>waiver<font style="letter-spacing:0.05pt;"> </font>or settlement<font style="letter-spacing:0.15pt;"> </font>and have their opposition<font style="letter-spacing:0.05pt;"> </font>formally<font style="letter-spacing:0.1pt;"> </font>recorded<font style="letter-spacing:0.05pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>meeting&#8217;s<font style="letter-spacing:0.1pt;"> </font>minute<font style="letter-spacing:0.1pt;">s</font>.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supervisory Board</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">German law requires that the Supervisory Board consists of at least three members, while a company&#8217;s articles of association may stipulate a certain higher number. Our Supervisory Board currently consists of four members.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we are not subject to co-determination, the members of our Supervisory Board are all elected by the shareholders&#8217; meeting in accordance with the<font style="letter-spacing:0.05pt;"> </font>provisions<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>SE Regulation<font style="letter-spacing:0.05pt;"> </font>and the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>Stock Corporation Act (<font style="font-style:italic;">Aktiengeset</font><font style="font-style:italic;letter-spacing:0.1pt;">z</font>). German<font style="letter-spacing:0.05pt;"> </font>law does not require<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>majority<font style="letter-spacing:0.1pt;"> </font>of our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board members<font style="letter-spacing:0.1pt;"> </font>to be independent<font style="letter-spacing:0.05pt;"> </font>and neither<font style="letter-spacing:0.1pt;"> </font>our Articles<font style="letter-spacing:0.1pt;"> </font>of Association<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Satzun</font><font style="font-style:italic;letter-spacing:0.05pt;">g</font>) nor the<font style="letter-spacing:0.05pt;"> </font>rules<font style="letter-spacing:0.05pt;"> </font>of procedure<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>our Supervisory Board provide<font style="letter-spacing:0.05pt;"> </font>otherwise.<font style="letter-spacing:0.05pt;"> </font>However, the<font style="letter-spacing:0.05pt;"> </font>rules<font style="letter-spacing:0.05pt;"> </font>of procedure<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board provide<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the Supervisory<font style="letter-spacing:0.05pt;"> </font>Board should<font style="letter-spacing:0.05pt;"> </font>have an independent<font style="letter-spacing:0.05pt;"> </font>member<font style="letter-spacing:0.1pt;"> </font>with expertise<font style="letter-spacing:0.1pt;"> </font>in <font style="color:#000000;">the</font><font style="letter-spacing:0.05pt;"> </font>field<font style="letter-spacing:0.05pt;"> </font>of accounting,<font style="letter-spacing:0.05pt;"> </font>internal<font style="letter-spacing:0.1pt;"> </font>control processes<font style="letter-spacing:0.1pt;"> </font>and auditing.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under European<font style="letter-spacing:0.05pt;"> </font>law, a member<font style="letter-spacing:0.1pt;"> </font>of a supervisory<font style="letter-spacing:0.1pt;"> </font>board<font style="letter-spacing:0.05pt;"> </font>of an SE may<font style="letter-spacing:0.05pt;"> </font>be elected<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>a maximum<font style="letter-spacing:0.1pt;"> </font>term<font style="letter-spacing:0.05pt;"> </font>to be specified<font style="letter-spacing:0.1pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>articles<font style="letter-spacing:0.1pt;"> </font>of association,<font style="letter-spacing:0.1pt;"> </font>which must<font style="letter-spacing:0.05pt;"> </font>not <font style="color:#000000;">exceed</font><font style="letter-spacing:0.05pt;"> </font>six<font style="letter-spacing:0.05pt;"> </font>years.<font style="letter-spacing:0.05pt;"> </font>Re-election,<font style="letter-spacing:0.1pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>repeated re-election,<font style="letter-spacing:0.15pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>permissible.<font style="letter-spacing:0.15pt;"> </font>The shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>specify<font style="letter-spacing:0.05pt;"> </font>a term<font style="letter-spacing:0.05pt;"> </font>of office<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>individual<font style="letter-spacing:0.1pt;"> </font>members<font style="letter-spacing:0.1pt;"> </font>or all of the<font style="letter-spacing:0.05pt;"> </font>members<font style="letter-spacing:0.1pt;"> </font>of our Supervisory<font style="letter-spacing:0.05pt;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">195</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Board which is</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shorter</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">than</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">standard</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">term</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of office</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and, subject</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to statutory</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">limits,</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">set</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">different</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">start</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and end dates</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">terms</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of members</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our Supervisory</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Board. Our Articles</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of </font><font style="color:#000000;">Association</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provide</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a term</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of approximately</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">five</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">years,</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">depending</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">date</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">annual general</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shareholders&#8217;</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">meeting</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">year</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in which the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">term</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">relevant</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">member</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to expire.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>may,<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>same<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>as it<font style="letter-spacing:0.05pt;"> </font>elects<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>members<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Supervisory<font style="letter-spacing:0.05pt;"> </font>Board, elect one or more<font style="letter-spacing:0.05pt;"> </font><font style="color:#000000;">substitute</font><font style="letter-spacing:0.1pt;"> </font>members.<font style="letter-spacing:0.1pt;"> </font>The substitute<font style="letter-spacing:0.1pt;"> </font>members<font style="letter-spacing:0.1pt;"> </font>replace<font style="letter-spacing:0.1pt;"> </font>members<font style="letter-spacing:0.1pt;"> </font>who cease<font style="letter-spacing:0.05pt;"> </font>to be members<font style="letter-spacing:0.1pt;"> </font>of our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board and take<font style="letter-spacing:0.05pt;"> </font>their<font style="letter-spacing:0.05pt;"> </font>place<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>remainder<font style="letter-spacing:0.1pt;"> </font>of their<font style="letter-spacing:0.05pt;"> </font><font style="color:#000000;">respective</font><font style="letter-spacing:0.1pt;"> </font>terms<font style="letter-spacing:0.1pt;"> </font>of office.<font style="letter-spacing:0.1pt;"> </font>Currently,<font style="letter-spacing:0.05pt;"> </font>no substitute<font style="letter-spacing:0.1pt;"> </font>members<font style="letter-spacing:0.1pt;"> </font>have been elected<font style="letter-spacing:0.1pt;"> </font>or have been proposed<font style="letter-spacing:0.05pt;"> </font>to be elected.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Members<font style="letter-spacing:0.1pt;"> </font>of our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board may<font style="letter-spacing:0.05pt;"> </font>be dismissed<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>any time<font style="letter-spacing:0.05pt;"> </font>during<font style="letter-spacing:0.05pt;"> </font>their<font style="letter-spacing:0.05pt;"> </font>term<font style="letter-spacing:0.05pt;"> </font>of office<font style="letter-spacing:0.1pt;"> </font>by a resolution of the<font style="letter-spacing:0.05pt;"> </font><font style="color:#000000;">shareholders&#8217;</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#000000;">meeting</font><font style="letter-spacing:0.1pt;"> </font>adopted<font style="letter-spacing:0.05pt;"> </font>by at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>a simple<font style="letter-spacing:0.1pt;"> </font>majority<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>votes<font style="letter-spacing:0.05pt;"> </font>cast.<font style="letter-spacing:0.05pt;"> </font>In addition,<font style="letter-spacing:0.05pt;"> </font>any member<font style="letter-spacing:0.1pt;"> </font>of our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board may<font style="letter-spacing:0.05pt;"> </font>resign<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>any time<font style="letter-spacing:0.05pt;"> </font>by giving<font style="letter-spacing:0.05pt;"> </font>one month&#8217;s<font style="letter-spacing:0.05pt;"> </font>written<font style="letter-spacing:0.05pt;"> </font>notice &#8211; or,<font style="letter-spacing:0.1pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>event<font style="letter-spacing:0.05pt;"> </font>of cause, giving<font style="letter-spacing:0.05pt;"> </font>written<font style="letter-spacing:0.05pt;"> </font>notice<font style="letter-spacing:0.05pt;"> </font>with immediate<font style="letter-spacing:0.15pt;"> </font>effect &#8211; of <font style="letter-spacing:0.1pt;"> </font>his<font style="letter-spacing:0.05pt;"> </font>or her<font style="letter-spacing:0.05pt;"> </font>resignation<font style="letter-spacing:0.1pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board elects<font style="letter-spacing:0.1pt;"> </font>a chairperson<font style="letter-spacing:0.1pt;"> </font>and a deputy<font style="letter-spacing:0.05pt;"> </font>chairperson<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>members.<font style="letter-spacing:0.1pt;"> </font>The deputy chairperson<font style="letter-spacing:0.1pt;"> </font>exercises<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>chairperson&#8217;s<font style="letter-spacing:0.15pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>and obligations<font style="letter-spacing:0.1pt;"> </font>whenever<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>chairperson<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>unable<font style="letter-spacing:0.05pt;"> </font>to do so. The members<font style="letter-spacing:0.1pt;"> </font>of our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board have elected<font style="letter-spacing:0.1pt;"> </font>Mr.<font style="letter-spacing:0.05pt;"> </font>Helmut<font style="letter-spacing:0.05pt;"> </font>Jeggle<font style="letter-spacing:0.05pt;"> </font>as chairperson<font style="letter-spacing:0.1pt;"> </font>and Dr. Ulrich <font style="color:#000000;">Wandschneider</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#000000;">as</font> deputy<font style="letter-spacing:0.05pt;"> </font><font style="color:#000000;">chairperson</font>,<font style="letter-spacing:0.1pt;"> </font>each<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>term<font style="letter-spacing:0.05pt;"> </font>of their<font style="letter-spacing:0.05pt;"> </font>respective<font style="letter-spacing:0.1pt;"> </font>membership<font style="letter-spacing:0.1pt;"> </font>on our Supervisory Board.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Supervisory<font style="letter-spacing:0.05pt;"> </font><font style="color:#000000;">Board</font> meets<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>twice<font style="letter-spacing:0.05pt;"> </font>each<font style="letter-spacing:0.05pt;"> </font>calendar<font style="letter-spacing:0.1pt;"> </font>half-year.<font style="letter-spacing:0.1pt;"> </font>Our Articles<font style="letter-spacing:0.1pt;"> </font>of Association<font style="letter-spacing:0.1pt;"> </font>provide <font style="color:#000000;">that</font><font style="letter-spacing:0.05pt;"> </font>a quorum<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Supervisory<font style="letter-spacing:0.05pt;"> </font>Board members<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>present<font style="letter-spacing:0.05pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>three<font style="letter-spacing:0.05pt;"> </font>of its<font style="letter-spacing:0.05pt;"> </font>members<font style="letter-spacing:0.1pt;"> </font>participate<font style="letter-spacing:0.15pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>vote. <font style="color:#000000;">Members</font><font style="letter-spacing:0.1pt;"> </font>of our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board are<font style="letter-spacing:0.05pt;"> </font>deemed<font style="letter-spacing:0.05pt;"> </font>present<font style="letter-spacing:0.05pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>they<font style="letter-spacing:0.05pt;"> </font>attend<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>via<font style="letter-spacing:0.05pt;"> </font>telephone<font style="letter-spacing:0.05pt;"> </font>or other (electronic)<font style="letter-spacing:0.15pt;"> </font>means<font style="letter-spacing:0.05pt;"> </font>of communication<font style="letter-spacing:0.15pt;"> </font>(including<font style="letter-spacing:0.1pt;"> </font>via<font style="letter-spacing:0.05pt;"> </font>video<font style="letter-spacing:0.05pt;"> </font>conference)<font style="letter-spacing:0.1pt;"> </font>or submit<font style="letter-spacing:0.05pt;"> </font>their<font style="letter-spacing:0.05pt;"> </font>written<font style="letter-spacing:0.05pt;"> </font>vote<font style="letter-spacing:0.05pt;"> </font>through another<font style="letter-spacing:0.05pt;"> </font>member.<font style="letter-spacing:0.1pt;"> </font>Additionally,<font style="letter-spacing:0.1pt;"> </font><font style="color:#000000;">our</font> Articles<font style="letter-spacing:0.1pt;"> </font>of Association<font style="letter-spacing:0.1pt;"> </font>allow<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>resolutions<font style="letter-spacing:0.1pt;"> </font>to be taken<font style="letter-spacing:0.05pt;"> </font>via<font style="letter-spacing:0.05pt;"> </font>telephone<font style="letter-spacing:0.05pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>(electronic)<font style="letter-spacing:0.15pt;"> </font>means<font style="letter-spacing:0.05pt;"> </font>of communications<font style="letter-spacing:0.15pt;"> </font>(including<font style="letter-spacing:0.1pt;"> </font>via<font style="letter-spacing:0.05pt;"> </font>video<font style="letter-spacing:0.05pt;"> </font>conference). </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Resolutions<font style="letter-spacing:0.05pt;"> </font>of our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board are<font style="letter-spacing:0.05pt;"> </font>passed<font style="letter-spacing:0.05pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>vote<font style="letter-spacing:0.05pt;"> </font>of a simple<font style="letter-spacing:0.1pt;"> </font>majority<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>votes<font style="letter-spacing:0.05pt;"> </font>cast<font style="letter-spacing:0.05pt;"> </font>unless otherwise<font style="letter-spacing:0.05pt;"> </font>required<font style="letter-spacing:0.1pt;"> </font>by law, our <font style="color:#000000;">Articles</font><font style="letter-spacing:0.1pt;"> </font>of Association<font style="letter-spacing:0.1pt;"> </font>or the<font style="letter-spacing:0.05pt;"> </font>rules<font style="letter-spacing:0.05pt;"> </font>of procedure<font style="letter-spacing:0.05pt;"> </font>of our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board. In the event<font style="letter-spacing:0.05pt;"> </font>of a tie,<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>chairperson<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Supervisory<font style="letter-spacing:0.05pt;"> </font>Board has the<font style="letter-spacing:0.05pt;"> </font>casting<font style="letter-spacing:0.05pt;"> </font>vote.<font style="letter-spacing:0.05pt;"> </font>Our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board is<font style="letter-spacing:0.05pt;"> </font>not permitted<font style="letter-spacing:0.1pt;"> </font>to make<font style="letter-spacing:0.05pt;"> </font>management<font style="letter-spacing:0.1pt;"> </font>decisions,<font style="letter-spacing:0.1pt;"> </font>but in accordance<font style="letter-spacing:0.1pt;"> </font>with European<font style="letter-spacing:0.05pt;"> </font>and German<font style="letter-spacing:0.05pt;"> </font>law and in addition<font style="letter-spacing:0.05pt;"> </font>to its<font style="letter-spacing:0.05pt;"> </font>statutory<font style="letter-spacing:0.1pt;"> </font>responsibilities,<font style="letter-spacing:0.2pt;"> </font>it<font style="letter-spacing:0.05pt;"> </font>has determined<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>certain<font style="letter-spacing:0.1pt;"> </font>matters<font style="letter-spacing:0.1pt;"> </font>require<font style="letter-spacing:0.1pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>prior<font style="letter-spacing:0.05pt;"> </font>consent,<font style="letter-spacing:0.05pt;"> </font>including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">entering into certain large transactions;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">creating or holding any interest in businesses (except wholly owned subsidiaries) or disposing of shares in businesses (except for a sale of JPT);</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">issuing shares from authorized capital, unless the shares are issued pursuant to a redemption of stock appreciation rights; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">acquiring treasury shares in return for valuable consideration.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supervisory Board Practices</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decisions<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>made<font style="letter-spacing:0.05pt;"> </font>by our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board as a whole, however decisions<font style="letter-spacing:0.1pt;"> </font>on certain<font style="letter-spacing:0.1pt;"> </font>matters may<font style="letter-spacing:0.05pt;"> </font>be delegated<font style="letter-spacing:0.1pt;"> </font>to committees<font style="letter-spacing:0.15pt;"> </font>of our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board to the<font style="letter-spacing:0.05pt;"> </font>extent<font style="letter-spacing:0.05pt;"> </font>permitted<font style="letter-spacing:0.1pt;"> </font>by law. The chairperson,<font style="letter-spacing:0.1pt;"> </font>or if he or she is<font style="letter-spacing:0.05pt;"> </font>prevented<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>doing so, the<font style="letter-spacing:0.05pt;"> </font>deputy<font style="letter-spacing:0.05pt;"> </font>chairperson,<font style="letter-spacing:0.1pt;"> </font>chairs<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>meetings<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Supervisory<font style="letter-spacing:0.05pt;"> </font>Board and determines<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>order<font style="letter-spacing:0.05pt;"> </font>in which the<font style="letter-spacing:0.05pt;"> </font>agenda<font style="letter-spacing:0.05pt;"> </font>items<font style="letter-spacing:0.1pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>discussed,<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>method<font style="letter-spacing:0.05pt;"> </font>and order<font style="letter-spacing:0.05pt;"> </font>of voting,<font style="letter-spacing:0.05pt;"> </font>as well<font style="letter-spacing:0.05pt;"> </font>as any adjournment<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>discussion<font style="letter-spacing:0.1pt;"> </font>and passing<font style="letter-spacing:0.05pt;"> </font>of resolutions<font style="letter-spacing:0.1pt;"> </font>on individual<font style="letter-spacing:0.1pt;"> </font>agenda<font style="letter-spacing:0.05pt;"> </font>items<font style="letter-spacing:0.1pt;"> </font>after<font style="letter-spacing:0.1pt;"> </font>a due assessment<font style="letter-spacing:0.1pt;"> </font>of the circumstances.<font style="letter-spacing:0.15pt;"> </font>Our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board may<font style="letter-spacing:0.05pt;"> </font>designate<font style="letter-spacing:0.1pt;"> </font>further<font style="letter-spacing:0.1pt;"> </font>types<font style="letter-spacing:0.05pt;"> </font>of actions<font style="letter-spacing:0.05pt;"> </font>as requiring<font style="letter-spacing:0.1pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>approval.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition,<font style="letter-spacing:0.05pt;"> </font>each<font style="letter-spacing:0.05pt;"> </font>member<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Supervisory<font style="letter-spacing:0.05pt;"> </font>Board is<font style="letter-spacing:0.05pt;"> </font>obliged<font style="letter-spacing:0.05pt;"> </font>to carry<font style="letter-spacing:0.05pt;"> </font>out his<font style="letter-spacing:0.05pt;"> </font>or her<font style="letter-spacing:0.05pt;"> </font>duties<font style="letter-spacing:0.05pt;"> </font>and responsibilities<font style="letter-spacing:0.2pt;"> </font>personally,<font style="letter-spacing:0.1pt;"> </font>and such duties<font style="letter-spacing:0.05pt;"> </font>and responsibilities<font style="letter-spacing:0.2pt;"> </font>cannot<font style="letter-spacing:0.05pt;"> </font>be generally<font style="letter-spacing:0.1pt;"> </font>and permanently<font style="letter-spacing:0.1pt;"> </font>delegated<font style="letter-spacing:0.1pt;"> </font>to third<font style="letter-spacing:0.05pt;"> </font>parties.<font style="letter-spacing:0.1pt;"> </font>However, the<font style="letter-spacing:0.05pt;"> </font>Supervisory<font style="letter-spacing:0.05pt;"> </font>Board and its<font style="letter-spacing:0.05pt;"> </font>committees<font style="letter-spacing:0.15pt;"> </font>have the<font style="letter-spacing:0.05pt;"> </font>right<font style="letter-spacing:0.05pt;"> </font>to appoint<font style="letter-spacing:0.05pt;"> </font>independent<font style="letter-spacing:0.05pt;"> </font>experts for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>review<font style="letter-spacing:0.05pt;"> </font>and analysis<font style="letter-spacing:0.1pt;"> </font>of specific<font style="letter-spacing:0.1pt;"> </font>circumstances<font style="letter-spacing:0.15pt;"> </font>in accordance<font style="letter-spacing:0.1pt;"> </font>with its<font style="letter-spacing:0.05pt;"> </font>control<font style="letter-spacing:0.05pt;"> </font>and supervision<font style="letter-spacing:0.1pt;"> </font>duties<font style="letter-spacing:0.05pt;"> </font>under applicable<font style="letter-spacing:0.1pt;"> </font>European<font style="letter-spacing:0.05pt;"> </font>and German<font style="letter-spacing:0.05pt;"> </font>law. We would bear<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> of </font>any such independent<font style="letter-spacing:0.05pt;"> </font>experts<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>are retained<font style="letter-spacing:0.1pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>Supervisory<font style="letter-spacing:0.05pt;"> </font>Board or any of its<font style="letter-spacing:0.05pt;"> </font>committees.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">196</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to Section</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107 para.</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 of the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">German</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock Corporation</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Act (</font><font style="font-style:italic;">Aktiengeset</font><font style="font-style:italic;letter-spacing:0.1pt;">z</font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">), the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">supervisory</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">board may</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">form</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">committees</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">among</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">members</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and charge</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">them</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">performance</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of specific</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tasks.</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The committees&#8217;</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tasks,</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authorizations</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and processes</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">determined</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">supervisory</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">board.</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Where</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">permissible</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by law, important</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">powers of the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">supervisory</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">board</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">also</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be transferred</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to committees.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By resolution,<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Supervisory<font style="letter-spacing:0.05pt;"> </font>Board has established<font style="letter-spacing:0.1pt;"> </font>an Audit Committee,<font style="letter-spacing:0.1pt;"> </font>a Compensation,<font style="letter-spacing:0.1pt;"> </font>Nominating<font style="letter-spacing:0.05pt;"> </font>and Governance<font style="letter-spacing:0.05pt;"> </font>Committee<font style="letter-spacing:0.1pt;"> </font>and a Capital<font style="letter-spacing:0.05pt;"> </font>Markets<font style="letter-spacing:0.1pt;"> </font>Committee.<font style="letter-spacing:0.1pt;"> </font>Set forth<font style="letter-spacing:0.05pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>table<font style="letter-spacing:0.05pt;"> </font>below are<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>current<font style="letter-spacing:0.1pt;"> </font>members of the<font style="letter-spacing:0.05pt;"> </font>Audit Committee,<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Compensation,<font style="letter-spacing:0.1pt;"> </font>Nominating<font style="letter-spacing:0.05pt;"> </font>and Corporate<font style="letter-spacing:0.05pt;"> </font>Governance<font style="letter-spacing:0.05pt;"> </font>Committee<font style="letter-spacing:0.1pt;"> </font>and the<font style="letter-spacing:0.05pt;"> </font>Capital Markets<font style="letter-spacing:0.1pt;"> </font>Committee.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.3%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Name of Committee</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.58%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.06%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Current Members</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.3%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audit Committee</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.58%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.06%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Ulrich Wandschneider, Michael Motschmann and Prof. Christoph Huber, M.D.</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation, Nominating and Corporate Governance Committee</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-left:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Motschmann, Prof. Christoph Huber, M.D. and Dr. Ulrich Wandschneider</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital Markets Committee</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-left:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Helmut Jeggle and Michael Motschmann</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Audit Committee</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Audit Committee consists of Dr. Ulrich Wandschneider, Michael Motschmann and Prof. Christoph Huber. Dr. Ulrich Wandschneider is the chair of the Audit Committee. The Audit Committee assists the Supervisory Board in overseeing the accuracy and integrity of our financial statements, our accounting and financial reporting processes and audits of our financial<font style="letter-spacing:0.1pt;"> </font>statements,<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>effective<font style="letter-spacing:0.1pt;"> </font>functioning<font style="letter-spacing:0.1pt;"> </font>of our internal<font style="letter-spacing:0.1pt;"> </font>control<font style="letter-spacing:0.05pt;"> </font>system,<font style="letter-spacing:0.05pt;"> </font>our risk management<font style="letter-spacing:0.1pt;"> </font>system,<font style="letter-spacing:0.05pt;"> </font>our compliance<font style="letter-spacing:0.1pt;"> </font>with legal<font style="letter-spacing:0.05pt;"> </font>and regulatory<font style="letter-spacing:0.1pt;"> </font>requirements,<font style="letter-spacing:0.15pt;"> </font>our independent<font style="letter-spacing:0.05pt;"> </font>auditor&#8217;s qualifications<font style="letter-spacing:0.15pt;"> </font>and independence,<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>performance<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>independent<font style="letter-spacing:0.05pt;"> </font>auditor<font style="letter-spacing:0.05pt;"> </font>and the<font style="letter-spacing:0.05pt;"> </font>effective<font style="letter-spacing:0.1pt;"> </font>functioning<font style="letter-spacing:0.1pt;"> </font>of our internal<font style="letter-spacing:0.1pt;"> </font>audit<font style="letter-spacing:0.05pt;"> </font>functions,<font style="letter-spacing:0.1pt;"> </font>and, subject<font style="letter-spacing:0.05pt;"> </font>to certain<font style="letter-spacing:0.1pt;"> </font>limitations,<font style="letter-spacing:0.15pt;"> </font>adopts<font style="letter-spacing:0.05pt;"> </font>and implements<font style="letter-spacing:0.15pt;"> </font>pertinent<font style="letter-spacing:0.1pt;"> </font>decisions<font style="letter-spacing:0.1pt;"> </font>on behalf of the<font style="letter-spacing:0.05pt;"> </font>Supervisory<font style="letter-spacing:0.05pt;"> </font>Board. The Audit Committee&#8217;s<font style="letter-spacing:0.15pt;"> </font>duties<font style="letter-spacing:0.05pt;"> </font>and responsibilities<font style="letter-spacing:0.2pt;"> </font>to carry<font style="letter-spacing:0.05pt;"> </font>out its<font style="letter-spacing:0.05pt;"> </font>purpose,<font style="letter-spacing:0.05pt;"> </font>include, among<font style="letter-spacing:0.05pt;"> </font>others:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">considering the commissioning of the audit engagement, as well as the compensation, retention and oversight of the independent auditor;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">evaluating the qualifications, independence and performance of the independent auditor;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">reviewing and pre-approving the audit and non-audit services to be performed by the independent auditor;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">reviewing and discussing with the independent auditor and management the annual audit plan, as well as critical accounting policies and practices to be used;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">reviewing and discussing with the independent auditor and management the adequacy and effectiveness of our internal accounting controls and critical accounting policies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">reviewing and discussing with the independent auditor and management the results of our annual audit;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">reviewing and discussing with the independent auditor and management any quarterly or annual earnings announcements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">reviewing any related party transactions and reviewing and monitoring potential conflict of interest situations on an ongoing basis for compliance with our policies and procedures; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">overseeing procedures for the receipt, retention and treatment of complaints received regarding accounting, internal accounting controls or auditing matters. </font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>limits<font style="letter-spacing:0.1pt;"> </font>of applicable<font style="letter-spacing:0.1pt;"> </font>European<font style="letter-spacing:0.05pt;"> </font>and German<font style="letter-spacing:0.05pt;"> </font>law, the<font style="letter-spacing:0.05pt;"> </font>Audit Committee<font style="letter-spacing:0.1pt;"> </font>shall<font style="letter-spacing:0.05pt;"> </font>have the<font style="letter-spacing:0.05pt;"> </font>resources and authority<font style="letter-spacing:0.1pt;"> </font>appropriate<font style="letter-spacing:0.1pt;"> </font>to discharge<font style="letter-spacing:0.1pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>duties<font style="letter-spacing:0.05pt;"> </font>and responsibilities,<font style="letter-spacing:0.2pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>authority<font style="letter-spacing:0.1pt;"> </font>to select,<font style="letter-spacing:0.1pt;"> </font>retain, terminate,<font style="letter-spacing:0.15pt;"> </font>and approve<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>fees<font style="letter-spacing:0.05pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>engagement<font style="letter-spacing:0.1pt;"> </font>terms<font style="letter-spacing:0.1pt;"> </font>of special<font style="letter-spacing:0.1pt;"> </font>or independent<font style="letter-spacing:0.05pt;"> </font>counsel,<font style="letter-spacing:0.05pt;"> </font>accountants<font style="letter-spacing:0.1pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>experts<font style="letter-spacing:0.05pt;"> </font>and advisors,<font style="letter-spacing:0.05pt;"> </font>as it<font style="letter-spacing:0.05pt;"> </font>deems<font style="letter-spacing:0.05pt;"> </font>necessary<font style="letter-spacing:0.1pt;"> </font>or appropriate<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>so discharging<font style="letter-spacing:0.1pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>duties<font style="letter-spacing:0.05pt;"> </font>and responsibilities, without<font style="letter-spacing:0.05pt;"> </font>seeking<font style="letter-spacing:0.05pt;"> </font>approval<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board or Supervisory<font style="letter-spacing:0.05pt;"> </font>Board. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All members of the Audit Committee<font style="letter-spacing:0.1pt;"> </font>qualify<font style="letter-spacing:0.05pt;"> </font>as &#8220;independent<font style="letter-spacing:0.1pt;"> </font>directors&#8221;<font style="letter-spacing:0.1pt;"> </font>as such term<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>defined<font style="letter-spacing:0.05pt;"> </font>in Rule 10A-3 under<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Exchange Act and Nasdaq Rule 5605. Additionally,<font style="letter-spacing:0.1pt;"> </font>our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board has determined<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>Dr. Ulrich<font style="letter-spacing:0.05pt;"> </font>Wandschneider<font style="letter-spacing:0.1pt;"> </font>qualifies<font style="letter-spacing:0.1pt;"> </font>as an &#8220;audit<font style="letter-spacing:0.05pt;"> </font>committee<font style="letter-spacing:0.15pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>expert&#8221;<font style="letter-spacing:0.05pt;"> </font>as that<font style="letter-spacing:0.05pt;"> </font>term<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>defined<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Exchange Act.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:8.55%;text-indent:-3.62%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Compensation</font><font style="font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">, Nominating and Corporate Governance Committee</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Compensation, Nominating and Corporate Governance Committee consists of Michael Motschmann, Prof. Christoph Huber, M.D. and Dr. Ulrich Wandschneider. Mr. Motschmann is the chair of the committee. The Compensation, Nominating and Corporate Governance Committee&#8217;s duties and responsibilities to carry out its purpose include, among others:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">preparing and discussing with management policies relating to the remuneration of the members of our Management Board;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">reviewing and supervising corporate goals and objectives for the remuneration of the members of the Management Board, including evaluation of the performance of the members of the Management Board in light of these goals and proposals to the Supervisory Board for remuneration based on such evaluations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">reviewing all equity-based compensation plans and arrangements and making recommendations to the Supervisory Board regarding such plans;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">assisting with identifying and recruiting candidates to fill positions on the Management Board and the Supervisory Board;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">considering any corporate governance issue that arises and developing appropriate recommendations for the Supervisory Board; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">overseeing the evaluation of the Supervisory Board and reporting on its performance and effectiveness. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:8.5%;text-indent:-3.59%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Capital Markets Committee</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Capital<font style="letter-spacing:0.05pt;"> </font>Markets<font style="letter-spacing:0.1pt;"> </font>Committee<font style="letter-spacing:0.1pt;"> </font>consists<font style="letter-spacing:0.1pt;"> </font>of Helmut<font style="letter-spacing:0.05pt;"> </font>Jeggle<font style="letter-spacing:0.05pt;"> </font>and Michael<font style="letter-spacing:0.1pt;"> </font>Motschmann.<font style="letter-spacing:0.1pt;"> </font>Mr.<font style="letter-spacing:0.05pt;"> </font>Jeggle<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>the chair<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>committee.<font style="letter-spacing:0.15pt;"> </font>The Capital<font style="letter-spacing:0.05pt;"> </font>Markets<font style="letter-spacing:0.1pt;"> </font>Committee<font style="letter-spacing:0.1pt;"> </font>advises<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Supervisory<font style="letter-spacing:0.05pt;"> </font>Board on issues<font style="letter-spacing:0.05pt;"> </font>in connection with capital<font style="letter-spacing:0.1pt;"> </font>measures<font style="letter-spacing:0.1pt;"> </font>and takeover,<font style="letter-spacing:0.05pt;"> </font>merger<font style="letter-spacing:0.1pt;"> </font>and acquisition<font style="letter-spacing:0.1pt;"> </font>activities.<font style="letter-spacing:0.15pt;"> </font>Its<font style="letter-spacing:0.05pt;"> </font>responsibilities<font style="letter-spacing:0.2pt;"> </font>include<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>following tasks:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">overseeing the activities of the Company relating to its capital structure and capital raising, including preparation for and implementation of public offerings and share issuances; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">overseeing the activities of the Company relating to takeovers, mergers and acquisitions activities.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Management<font style="letter-spacing:0.05pt;"> </font>Board and Senior Management</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Management Board consists of at least two members. Our Supervisory Board determines the exact number of members of our Management Board. Pursuant to the Articles, the Supervisory Board may also appoint a chairperson or a spokesman of the Management Board. Prof. Ugur Sahin, M.D. has been appointed the chair of the Management Board.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The members<font style="letter-spacing:0.1pt;"> </font>of our Management<font style="letter-spacing:0.1pt;"> </font>Board are<font style="letter-spacing:0.05pt;"> </font>appointed<font style="letter-spacing:0.05pt;"> </font>by our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board for<font style="letter-spacing:0.05pt;"> </font>a term<font style="letter-spacing:0.05pt;"> </font>of up to five years.<font style="letter-spacing:0.05pt;"> </font>They are<font style="letter-spacing:0.05pt;"> </font>eligible<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>reappointment<font style="letter-spacing:0.15pt;"> </font>or extension,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>repeated<font style="letter-spacing:0.1pt;"> </font>re-appointment<font style="letter-spacing:0.15pt;"> </font>and extension,<font style="letter-spacing:0.05pt;"> </font>after the<font style="letter-spacing:0.05pt;"> </font>completion<font style="letter-spacing:0.1pt;"> </font>of their<font style="letter-spacing:0.05pt;"> </font>term<font style="letter-spacing:0.05pt;"> </font>in office,<font style="letter-spacing:0.1pt;"> </font>in each<font style="letter-spacing:0.05pt;"> </font>case<font style="letter-spacing:0.05pt;"> </font>again<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>up to an additional<font style="letter-spacing:0.1pt;"> </font>five<font style="letter-spacing:0.05pt;"> </font>years.<font style="letter-spacing:0.05pt;"> </font>Under certain circumstances,<font style="letter-spacing:0.15pt;"> </font>such as a serious<font style="letter-spacing:0.05pt;"> </font>breach<font style="letter-spacing:0.05pt;"> </font>of duty or a vote<font style="letter-spacing:0.05pt;"> </font>of no confidence<font style="letter-spacing:0.1pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>shareholders<font style="letter-spacing:0.1pt;"> </font>in a shareholders&#8217; meeting,<font style="letter-spacing:0.1pt;"> </font>a member<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board may<font style="letter-spacing:0.05pt;"> </font>be removed<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>office<font style="letter-spacing:0.1pt;"> </font>by our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board prior<font style="letter-spacing:0.05pt;"> </font>to the expiration<font style="letter-spacing:0.1pt;"> </font>of his<font style="letter-spacing:0.05pt;"> </font>or her<font style="letter-spacing:0.05pt;"> </font>term.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The members of our Management Board conduct the daily business of the Company in accordance with applicable laws, our Articles of Association and the rules of procedure for the Management Board adopted by our Supervisory Board. They are generally responsible for the management of our company and for handling our daily business relations with third parties, the internal organization of our business and communications with our shareholders.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A member<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>management<font style="letter-spacing:0.1pt;"> </font>board<font style="letter-spacing:0.05pt;"> </font>of an SE governed<font style="letter-spacing:0.05pt;"> </font>by German<font style="letter-spacing:0.05pt;"> </font>law may<font style="letter-spacing:0.05pt;"> </font>not deal<font style="letter-spacing:0.05pt;"> </font>with or vote<font style="letter-spacing:0.05pt;"> </font>on matters<font style="letter-spacing:0.1pt;"> </font>relating<font style="letter-spacing:0.1pt;"> </font>to proposals,<font style="letter-spacing:0.05pt;"> </font>arrangements<font style="letter-spacing:0.15pt;"> </font>or contractual<font style="letter-spacing:0.1pt;"> </font>agreements<font style="letter-spacing:0.1pt;"> </font>between<font style="letter-spacing:0.05pt;"> </font>himself<font style="letter-spacing:0.1pt;"> </font>or herself<font style="letter-spacing:0.1pt;"> </font>and the Company,<font style="letter-spacing:0.05pt;"> </font>and a member<font style="letter-spacing:0.1pt;"> </font>of our Management<font style="letter-spacing:0.1pt;"> </font>Board may<font style="letter-spacing:0.05pt;"> </font>be liable<font style="letter-spacing:0.1pt;"> </font>to us if<font style="letter-spacing:0.05pt;"> </font>he or she has a material<font style="letter-spacing:0.15pt;"> </font>interest<font style="letter-spacing:0.1pt;"> </font>in any contractual<font style="letter-spacing:0.1pt;"> </font>agreement<font style="letter-spacing:0.1pt;"> </font>between<font style="letter-spacing:0.05pt;"> </font>the Company<font style="letter-spacing:0.05pt;"> </font>and a third<font style="letter-spacing:0.05pt;"> </font>party<font style="letter-spacing:0.05pt;"> </font>which is<font style="letter-spacing:0.05pt;"> </font>not disclosed<font style="letter-spacing:0.1pt;"> </font>to and approved<font style="letter-spacing:0.05pt;"> </font>by our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">198</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The rules</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of procedure</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our Management</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Board provide</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">certain</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">matters</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">require</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a resolution</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the entire</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Board, in addition</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to transactions</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which a resolution</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adopted</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">entire</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management Board is</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">required</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by law or required</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by our Articles</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of Association.</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In particular,</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">entire</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Board shall</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">decide</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on, among</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">others: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the budget plan for the following year, which is to be presented by the Management Board to the Supervisory Board by December 20 of each year;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">reporting to the Supervisory Board;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">all measures and transactions that require the Supervisory Board&#8217;s approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">all measures and transactions relating to a business area that is of extraordinary importance to us or involving an extraordinary economic risk;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">taking on new lines of business or discontinuing existing lines of business;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">acquisitions or sales of interests or holdings; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">certain large transactions.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Code of Conduct and Conflicts<font style="letter-spacing:0.05pt;"> </font>of Interest<font style="letter-spacing:0.1pt;"> </font>Policy</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted<font style="letter-spacing:0.05pt;"> </font>a Code of Business<font style="letter-spacing:0.05pt;"> </font>Conduct &amp; Ethics,<font style="letter-spacing:0.05pt;"> </font>or Code of Conduct, which outlines<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>principles of legal<font style="letter-spacing:0.05pt;"> </font>and ethical<font style="letter-spacing:0.1pt;"> </font>business<font style="letter-spacing:0.05pt;"> </font>conduct<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>which we do business.<font style="letter-spacing:0.05pt;"> </font>The Code of Conduct applies<font style="letter-spacing:0.05pt;"> </font>to all<font style="letter-spacing:0.05pt;"> </font>of our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board members,<font style="letter-spacing:0.1pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board members,<font style="letter-spacing:0.1pt;"> </font>directors<font style="letter-spacing:0.1pt;"> </font>of our subsidiaries<font style="letter-spacing:0.15pt;"> </font>and employees.<font style="letter-spacing:0.1pt;"> </font>The full<font style="letter-spacing:0.05pt;"> </font>text<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Code of Conduct is<font style="letter-spacing:0.05pt;"> </font>available<font style="letter-spacing:0.1pt;"> </font>on our website<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>https://www.biontech.de.<font style="letter-spacing:0.1pt;"> </font>The information<font style="letter-spacing:0.15pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>content<font style="letter-spacing:0.05pt;"> </font>appearing<font style="letter-spacing:0.05pt;"> </font>on our website<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>not incorporated by reference into this Annual Report<font style="letter-spacing:0.1pt;"> </font>and our website<font style="letter-spacing:0.05pt;"> </font>address<font style="letter-spacing:0.05pt;"> </font>is included<font style="letter-spacing:0.05pt;"> </font>in this<font style="letter-spacing:0.05pt;"> </font>report<font style="letter-spacing:0.1pt;"> </font>as an inactive<font style="letter-spacing:0.1pt;"> </font>textual<font style="letter-spacing:0.1pt;"> </font>reference<font style="letter-spacing:0.1pt;"> </font>only. Any amendments<font style="letter-spacing:0.1pt;"> </font>or waivers<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>provisions of the<font style="letter-spacing:0.05pt;"> </font>Code of Conduct for<font style="letter-spacing:0.05pt;"> </font>members<font style="letter-spacing:0.1pt;"> </font>of our Supervisory<font style="letter-spacing:0.05pt;"> </font>or Management<font style="letter-spacing:0.1pt;"> </font>Boards will<font style="letter-spacing:0.05pt;"> </font>be made<font style="letter-spacing:0.05pt;"> </font>only after<font style="letter-spacing:0.1pt;"> </font>approval by our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board and will<font style="letter-spacing:0.05pt;"> </font>be disclosed<font style="letter-spacing:0.1pt;"> </font>on our website<font style="letter-spacing:0.05pt;"> </font>promptly<font style="letter-spacing:0.1pt;"> </font>following<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>date<font style="letter-spacing:0.05pt;"> </font>of such amendment or waiver.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have also<font style="letter-spacing:0.05pt;"> </font>adopted<font style="letter-spacing:0.05pt;"> </font>a Conflicts<font style="letter-spacing:0.1pt;"> </font>of Interest<font style="letter-spacing:0.1pt;"> </font>Policy<font style="letter-spacing:0.05pt;"> </font>which sets<font style="letter-spacing:0.05pt;"> </font>forth<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>procedures<font style="letter-spacing:0.1pt;"> </font>by which we manage potential<font style="letter-spacing:0.1pt;"> </font>and actual<font style="letter-spacing:0.05pt;"> </font>conflicts<font style="letter-spacing:0.1pt;"> </font>of interest.<font style="letter-spacing:0.1pt;"> </font>Under the<font style="letter-spacing:0.05pt;"> </font>Conflicts<font style="letter-spacing:0.1pt;"> </font>of Interest<font style="letter-spacing:0.1pt;"> </font>Policy,<font style="letter-spacing:0.05pt;"> </font>which applies<font style="letter-spacing:0.05pt;"> </font>to all<font style="letter-spacing:0.05pt;"> </font>of our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board Members,<font style="letter-spacing:0.1pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board members,<font style="letter-spacing:0.1pt;"> </font>directors<font style="letter-spacing:0.1pt;"> </font>of our subsidiaries<font style="letter-spacing:0.15pt;"> </font>and employees,<font style="letter-spacing:0.1pt;"> </font>an actual,<font style="letter-spacing:0.05pt;"> </font>potential<font style="letter-spacing:0.1pt;"> </font>or perceived<font style="letter-spacing:0.1pt;"> </font>conflict<font style="letter-spacing:0.1pt;"> </font>of interest<font style="letter-spacing:0.1pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>be disclosed<font style="letter-spacing:0.1pt;"> when it first arises</font>.<font style="letter-spacing:0.1pt;"> </font>If<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>conflict<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>transactional<font style="letter-spacing:0.15pt;"> </font>in nature<font style="letter-spacing:0.05pt;"> </font>and involves<font style="letter-spacing:0.05pt;"> </font>a member<font style="letter-spacing:0.1pt;"> </font>of the Management<font style="letter-spacing:0.1pt;"> </font>Board or the<font style="letter-spacing:0.05pt;"> </font>Supervisory<font style="letter-spacing:0.05pt;"> </font>Board, the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>or Supervisory<font style="letter-spacing:0.05pt;"> </font>Board, as the<font style="letter-spacing:0.05pt;"> </font>case<font style="letter-spacing:0.05pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>be, with the<font style="letter-spacing:0.05pt;"> </font>abstention<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>conflicted<font style="letter-spacing:0.1pt;"> </font>member,<font style="letter-spacing:0.1pt;"> </font>shall<font style="letter-spacing:0.05pt;"> </font>decide<font style="letter-spacing:0.05pt;"> </font>whether<font style="letter-spacing:0.05pt;"> </font>to approve<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>transaction.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition,<font style="letter-spacing:0.05pt;"> </font>we have implemented<font style="letter-spacing:0.15pt;"> </font>compliance<font style="letter-spacing:0.1pt;"> </font>policies<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>describe<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>compliance<font style="letter-spacing:0.1pt;"> </font>management<font style="letter-spacing:0.1pt;"> </font>systems that<font style="letter-spacing:0.05pt;"> </font>have been implemented<font style="letter-spacing:0.15pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>us and our subsidiaries.<font style="letter-spacing:0.15pt;"> </font>Our compliance<font style="letter-spacing:0.1pt;"> </font>policies<font style="letter-spacing:0.1pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>designed<font style="letter-spacing:0.05pt;"> </font>to ensure compliance<font style="letter-spacing:0.1pt;"> </font>with applicable<font style="letter-spacing:0.1pt;"> </font>legal<font style="letter-spacing:0.05pt;"> </font>requirements,<font style="letter-spacing:0.15pt;"> </font>while<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>same<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>implementing<font style="letter-spacing:0.15pt;"> </font>high ethical<font style="letter-spacing:0.1pt;"> </font>standards<font style="letter-spacing:0.1pt;"> </font>that are<font style="letter-spacing:0.05pt;"> </font>mandatory<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>both management<font style="letter-spacing:0.1pt;"> </font>and each<font style="letter-spacing:0.05pt;"> </font>employee.<font style="letter-spacing:0.05pt;"> </font>The overall<font style="letter-spacing:0.1pt;"> </font>responsibility<font style="letter-spacing:0.15pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>compliance management<font style="letter-spacing:0.1pt;"> </font>system<font style="letter-spacing:0.05pt;"> </font>lies<font style="letter-spacing:0.05pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board. The Audit Committee<font style="letter-spacing:0.1pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>receive<font style="letter-spacing:0.1pt;"> </font>regular<font style="letter-spacing:0.1pt;"> </font>reports<font style="letter-spacing:0.1pt;"> </font>on the operation<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>compliance<font style="letter-spacing:0.1pt;"> </font>management<font style="letter-spacing:0.1pt;"> </font>system.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">199</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">D.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_6_D"></a><font style="text-decoration:none;Background-color:#auto;"></font><font style="color:#000000;"></font><font style="color:#000000;"><a name="ITEM_6_D"></a>Empl</font><font style="color:#000000;">oyees</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As<font style="color:#000000;"> of December&#160;31, 2020, we had 1,941&#160;full-time equivalent employees working for BioNTech, of whom 440 hold a doctoral degree or higher. The following tables provide breakdowns of our full-time equivalent employees as of December&#160;31, 2020 by function and by region: </font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Function</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical Research&#160;&amp; Development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Scientific Research&#160;&amp; Development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">624</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">657</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quality</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">211</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supporting Functions</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">286</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial&#160;&amp; Business Development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.16%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1,941</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Region</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mainz, Germany (Headquarters)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,161</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Munich, Germany</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Idar-Oberstein, Germany</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">254</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Halle, Germany</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Berlin, Germany</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marburg, Germany</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">268</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cambridge, United States</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.16%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1,941</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since<font style="color:#000000;"> December 2016, our workforce has grown by 300%. Within the next several years, two further new production sites are planned to be built in Mainz and Idar-Oberstein. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None<font style="color:#000000;"> of our employees has engaged in any labor strikes. We have no collective bargaining agreements with our employees, but we maintain a company agreement (</font><font style="font-style:italic;color:#000000;">Betriebsvereinbarungen</font><font style="color:#000000;">) with respect to certain topics at our Idar-Oberstein site. We have a workers&#8217; council at our Idar-Oberstein and Mainz sites. However, we consider our relationship with our employees to be positive and have not experienced any major labor disputes.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">E.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_6_E"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_6_E"></a>Share Ownership</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The share ownership information with respect to Management Board and Supervisory Board members is presented in Item 7 below. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7_MAJOR_SHAREHOLDERS_RELATED_PARTY_"></a><a name="ITEM_7_MAJOR_SHAREHOLDERS_RELATED_PARTY_"></a>Item 7. Major Shareholders and Related Party Transactions</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">A.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_7_A"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_7_A"></a>Major Shareholders</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <font style="color:#231F20;">following</font><font style="letter-spacing:0.05pt;"> </font>table<font style="letter-spacing:0.05pt;"> </font>presents<font style="letter-spacing:0.1pt;"> </font>information,<font style="letter-spacing:0.15pt;"> </font>as of December 31, 2020, regarding<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>beneficial<font style="letter-spacing:0.1pt;"> </font>ownership<font style="letter-spacing:0.05pt;"> </font>of our ordinary shares for:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">each person, or group of affiliated persons, known by us to own beneficially 5% or more of our outstanding shares;</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">each member of our Supervisory Board;</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">each member of our Management Board; and</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">all members of our Supervisory Board and Management Board as a group.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of ordinary shares beneficially owned by each entity, person, and member of our Supervisory Board and our Management Board is determined in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any ordinary shares over which the individual has sole or shared voting power or investment power as well as any ordinary shares that the individual has the right to acquire within 60 days <font style="color:#000000;">of December 31, 2020 t</font>hrough the exercise of any option, warrant or other right. Except as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all ordinary shares held by that person. All of our ordinary shares and ADSs representing our ordinary shares vote on an equal basis.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="color:#000000;"> percentage</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">of outstanding</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">ordinary shares is</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">computed</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">on the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">basis</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">of 241,521,065&#160;ordinary shares outstanding</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">as of December 31, 2020. This amount</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">excludes</font><font style="letter-spacing:0.05pt;color:#000000;"> 4,789,016</font><font style="color:#000000;">&#160;shares</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">held</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">in treasury. Amounts presented in this section include ordinary shares held in the form of ADSs. Unless</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">otherwise</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">indicated,</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">address</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">for</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">each</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">beneficial</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">owner is</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">An der</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Goldgrube</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">12, D-55131 Mainz,</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Germany.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;Name of Beneficial Owner</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Shares Beneficially Owned</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percentage Beneficially Owned</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5% Shareholders</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AT Impf GmbH <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,410,338</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47.37%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medine GmbH <sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,663,430</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.25%</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Members of the Supervisory Board and the Management Board</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prof. Ugur Sahin, M.D. <sup style="font-size:85%;line-height:120%;vertical-align:top">(3)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,663,430</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.25%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sean Marett <sup style="font-size:85%;line-height:120%;vertical-align:top">(4)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">985,936</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(9)</sup></p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Sierk Poetting <sup style="font-size:85%;line-height:120%;vertical-align:top">(5)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">654,387</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(9)</sup></p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. &#214;zlem T&#252;reci</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ryan Richardson</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Helmut Jeggle <sup style="font-size:85%;line-height:120%;vertical-align:top">(6)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116,687,524</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48.31%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Motschmann</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prof. Christoph Huber, M.D. <sup style="font-size:85%;line-height:120%;vertical-align:top">(7)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,202,040</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(9)</sup></p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Ulrich Wandschneider <sup style="font-size:85%;line-height:120%;vertical-align:top">(8)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,480</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(9)</sup></p></td>
</tr>
<tr>
<td colspan="3" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.28%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">All members of our Supervisory Board and Management Board, as a group</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">162,196,797</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">67.16%</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;color:#000000;">Information herein is based upon a Schedule 13G jointly filed with the SEC on February 16, 2021 by ATHOS KG, AT Impf GmbH, Helmut Jeggle and Thomas Maier. Consists of 114,410,338 ordinary shares held by AT Impf GmbH. The sole member of AT Impf GmbH is ATHOS KG, and, as a result, ATHOS KG is deemed to be the beneficial owner of the securities held by AT Impf GmbH. Helmut Jeggle and Thomas Maier are each general partners (</font><font style="font-style:italic;font-size:9pt;color:#000000;">Komplement&#228;r</font><font style="font-size:9pt;color:#000000;">) of ATHOS KG and may be deemed to be beneficial owners of the securities held by AT Impf KG. Each of Messrs. Jeggle and Maier disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. We are also aware that, since December 31, 2020, AT Impf GmbH has sold 2,000,000 of the ordinary shares it held.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:2.72%;text-indent:-3.03%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;color:#000000;">Information herein is based upon a Schedule 13G jointly filed with the SEC on February 16, 2021 by Medine GmbH and Prof. Sahin. The sole shareholder of Medine GmbH is Prof. Sahin, and, as a result, Prof. Sahin is deemed to be the beneficial owner of the securities held by Medine GmbH. Consists of 41,663,430 ordinary shares held by Medine GmbH, 2,552,040 of which are held for the </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="font-size:9pt;color:#000000;">benefit of a former colleague pursuant to a trust arrangement. Pursuant to this arrangement, Medine GmbH retains voting power, but not dispositive power, over such shares for so long as such shares are held in trust and accordingly Medine GmbH and Prof. Ugur Sahin, M.D. each may be deemed beneficially to own such shares.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:2.72%;text-indent:-3.03%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(3)</sup></font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;color:#000000;">Consists of the shares described in note 2 above. Prof. Sahin is the sole shareholder of Medine GmbH.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:2.72%;text-indent:-3.03%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(4)</sup></font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;color:#000000;">Consists of 985,936 ordinary shares held by RLG GmbH. Mr. Marett is the sole shareholder of RLG GmbH.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:2.72%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(5)</sup></font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;color:#000000;">Consists of 654,387 ordinary shares held by Tofino GmbH. Dr. Poetting is sole shareholder of Tofino GmbH.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:2.72%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(6)</sup></font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;color:#000000;">Consists of (a) the shares described in note 1 above, (b) 332,316 ordinary shares held directly by Mr. Jeggle, (c) 1,893,651 ordinary shares held by Salvia GmbH and (d) 51,219 ordinary shares held by Nils GmbH. Mr. Jeggle has no voting or dispositive power with regard to such shares described in note 1 above and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:2.72%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(7)</sup></font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;color:#000000;">Consists of 2,202,040 ordinary shares held by CHuber 2008 GmbH. Prof. Huber is the majority shareholder of CHuber 2008 GmbH.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:2.72%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(8)</sup></font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;color:#000000;">Consists of 3,480 ordinary shares held by beebusy capital gmbh.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:2.72%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(9)</sup></font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;color:#000000;">Less than one percent. </font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;color:#231F20;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Holdings by U.S. Shareholders</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate that <font style="color:#000000;">as of December 31, 2020, 30.46%</font> of our outstanding ordinary shares are held by 2&#160;U.S. record holders. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">B.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_7_B"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_7_B"></a>Related Party Transactions</font></p></td></tr></table></div>
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Agreements with TRON</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have a longstanding relationship with Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz (<font style="font-style:italic;">Translationale Onkologie an der Universit&#228;tsmedizin der Johannes Gutenberg Universit&#228;t Mainz gemei</font><font style="font-style:italic;color:#000000;">nn&#252;tzige</font><font style="font-style:italic;letter-spacing:0.1pt;color:#000000;"> </font><font style="font-style:italic;color:#000000;">GmbH</font><font style="color:#000000;">), or TRON.</font><font style="letter-spacing:-0.05pt;color:#000000;"> </font><font style="color:#000000;">TRON</font><font style="letter-spacing:-0.05pt;color:#000000;"> </font><font style="color:#000000;">is</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">a non-profit</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">limited</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">liability</font><font style="letter-spacing:0.15pt;color:#000000;"> </font><font style="color:#000000;">company engaged</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">in biopharmaceutical</font><font style="letter-spacing:0.2pt;color:#000000;"> </font><font style="color:#000000;">research.</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">Prof.</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Ugur Sahin, M.D., our co-founder</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">and Chief</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Executive</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Officer, co-founded</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">TRON</font><font style="letter-spacing:-0.05pt;color:#000000;"> </font><font style="color:#000000;">and served</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">as Managing</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Director</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">for</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Science</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">and Research</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">at</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">TRON,</font><font style="letter-spacing:-0.05pt;color:#000000;"> </font><font style="color:#000000;">until</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">his</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">resignation September</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">10, 2019, and is currently serving as a scientific advisor of TRON. Additionally,</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">Prof.</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Christoph</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Huber, a member</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">of our Supervisory</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Board, served</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">on TRON&#8217;s</font><font style="letter-spacing:-0.05pt;color:#000000;"> </font><font style="color:#000000;">supervisory</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">board</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">until</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">his</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">resignation</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">in April</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">2019. Prof. Ugur Sahin, M.D., our co-founder</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">and Chief</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Executive</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Officer, owns a significant amount of shares in TRON. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 1, 2015, we and certain of our subsidiaries entered into both a Master Agreement for Research Services<font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">and a License</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Agreement</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">with </font>TRON<font style="color:#000000;">.</font><font style="letter-spacing:-0.05pt;color:#000000;"> </font><font style="color:#000000;">During the year ended December&#160;31, 2020, the aggregate</font><font style="letter-spacing:0.1pt;color:#000000;"> </font>value of transactions related to these agreements with TRON amounted to &#8364;10.1&#160;<font style="color:#000000;">million</font><font style="letter-spacing:0.1pt;color:#000000;"> </font>pursuant<font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">to these</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">agreements (&#8364;10.0&#160;million during the year ended December&#160;31, 2019).</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Agreements with Santo Service GmbH</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<font style="color:#000000;"> </font>have<font style="color:#000000;"> </font>several<font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">agreements</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">with Santo Service</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">GmbH, or Santo Service,</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">pursuant</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">to which Santo Service provides</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">us with </font>certain<font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">real</font><font style="letter-spacing:0.05pt;color:#000000;"> </font>property<font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">and custodial</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">services.</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">Santo Service</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">is</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">wholly owned by AT</font><font style="letter-spacing:-0.05pt;color:#000000;"> </font><font style="color:#000000;">Impf</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">GmbH, one of our major shareholders.</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">During the year ended December&#160;31, 2020, the aggregate</font><font style="letter-spacing:0.1pt;color:#000000;"> </font>value of transactions with <font style="color:#000000;">Santo Service</font> amounted to &#8364;4.6&#160;million <font style="color:#000000;">pursuant</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">to these</font> agreements (&#8364;2.1&#160;million during the year ended December 31, 2019).</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Agreement with Medine GmbH</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 29, 2019, we entered into an agreement with Medine GmbH, or Medine, pursuant to which we acquired from Prof. Dr. Ugur Sahin, M.D. all of the<font style="letter-spacing:0.05pt;color:#000000;"> </font>outstanding<font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">shares</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">of reBOOST</font><font style="letter-spacing:-0.05pt;color:#000000;"> </font><font style="color:#000000;">Management</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">GmbH (subsequently renamed to reSano GmbH), or reBOOST,</font><font style="letter-spacing:-0.05pt;color:#000000;"> </font><font style="color:#000000;">which owned certain intellectual</font><font style="letter-spacing:0.15pt;color:#000000;"> </font><font style="color:#000000;">property,</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">in exchange</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">for</font><font style="letter-spacing:0.05pt;color:#000000;"> a </font><font style="color:#000000;">total</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">consideration</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">of &#8364;0.3&#160;million. Medine</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">is wholly-owned by Prof.</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Ugur Sahin, M.D., our co-founder</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">and Chief</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Executive</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Officer,</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">who </font><font style="letter-spacing:0.05pt;color:#000000;">was </font><font style="color:#000000;">also</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Managing Director</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">of reBOOST at the time of the acquisition</font><font style="letter-spacing:-0.05pt;color:#000000;"> </font><font style="color:#000000;">and is the Managing Director of Medine.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Series<font style="letter-spacing:0.05pt;"> A</font> 2018 Financing</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2018, we issued an aggregate of 22,587,912 of our ordinary shares to certain new and existing shareholders at a price of $11.99 per share for aggregate proceeds of $270.9 million. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the aggregate number of ordinary shares that we issued and sold in this transaction to our related parties and the aggregate purchase price for such shares: </font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Participant</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.68%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number of Ordinary Shares</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Aggregate Purchase Price ($)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.16%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.68%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AT Impf GmbH <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.68%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,002,812</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,997,612.58</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;color:#000000;">See &#8220;Major Shareholders&#8221; under this Item 7 for additional information about ordinary shares held by this entity or the parent company of this entity.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Series<font style="letter-spacing:0.05pt;"> </font>B 2019 Financing</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June and August 2019, we issued an aggregate of 12,465,288 ordinary shares (excluding 5,524,506 ordinary shares which were issued to a Hong Kong-based investor and subsequently transferred to us for no consideration) to certain new and existing shareholders at a price of $18.10 per share for aggregate proceeds of &#8364;1<font style="color:#000000;">98.6&#160;</font>million<font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">($225.6&#160;million).</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <font style="color:#231F20;">following</font><font style="letter-spacing:0.05pt;"> </font>table<font style="letter-spacing:0.05pt;"> </font>sets<font style="letter-spacing:0.05pt;"> </font>forth<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>aggregate<font style="letter-spacing:0.1pt;"> </font>number<font style="letter-spacing:0.05pt;"> </font>of ordinary shares<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we issued<font style="letter-spacing:0.05pt;"> </font>and sold<font style="letter-spacing:0.05pt;"> </font>in this transaction<font style="letter-spacing:0.1pt;"> </font>to our related<font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;">parties</font><font style="letter-spacing:0.1pt;"> </font>and the<font style="letter-spacing:0.05pt;"> </font>aggregate<font style="letter-spacing:0.1pt;"> </font>purchase<font style="letter-spacing:0.05pt;"> </font>price<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>such shares:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Participant</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number of Ordinary Shares</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Aggregate Purchase Price ($)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AT Impf GmbH <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,657,332</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,999,550.68</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;color:#000000;">See &#8220;Major Shareholders&#8221; under this Item 7 for additional information about ordinary shares held by this entity or the parent company of this entity.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Initial Public Offering</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October<font style="letter-spacing:0.05pt;"> </font>2019, we sold<font style="letter-spacing:0.05pt;"> </font>10,517,408 ADSs<font style="letter-spacing:-0.05pt;"> </font>representing<font style="letter-spacing:0.1pt;"> </font>10,517,408 of our ordinary shares to certain<font style="letter-spacing:0.1pt;"> </font>new and existing<font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;">shareholders</font><font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>a price<font style="letter-spacing:0.05pt;"> </font>of $15.00 per<font style="letter-spacing:0.05pt;"> </font>ADS<font style="letter-spacing:-0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>proceeds<font style="letter-spacing:0.05pt;"> </font>of &#8364;135.4&#160;million ($149.1 millio<font style="letter-spacing:0.1pt;">n</font>) in our initial public<font style="letter-spacing:0.05pt;"> </font>offering.<font style="letter-spacing:0.1pt;"> </font>The following<font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;">table</font><font style="letter-spacing:0.05pt;"> </font>sets<font style="letter-spacing:0.05pt;"> </font>forth<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>aggregate<font style="letter-spacing:0.1pt;"> </font>number<font style="letter-spacing:0.05pt;"> </font>of ADSs<font style="letter-spacing:-0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we issued<font style="letter-spacing:0.05pt;"> </font>and sold<font style="letter-spacing:0.05pt;"> </font>in this transaction<font style="letter-spacing:0.1pt;"> </font>to our related<font style="letter-spacing:0.1pt;"> </font>parties<font style="letter-spacing:0.1pt;"> </font>and the<font style="letter-spacing:0.05pt;"> </font>aggregate<font style="letter-spacing:0.1pt;"> </font>purchase<font style="letter-spacing:0.05pt;"> </font>price<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>such shares:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Participant</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number of ADS representing Ordinary Shares</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Aggregate Purchase Price ($)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AT Impf GmbH <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,800,000</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,000,000.00</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Helmut Jeggle <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,219</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">768,285.00</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;color:#000000;">See &#8220;Major Shareholders&#8221; under this Item 7 for additional information about ordinary shares held by this entity, the parent company of this entity or Supervisory Board member.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Global Offering</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 27, 2020 we issued 5,500,000 ADS each representing one of our ordinary shares at a public offering price of $93.00 per ADS for proceeds of &#8364;5.5&#160;million ($6.4&#160;million), which we refer to as the Underwritten Offering. On August 27, 2020, following the Underwritten Offering, we issued 16,124 ADS each representing one of our ordinary shares at a public offering price of $93.00 per ADS for proceeds of &#8364;16&#160;thousand ($19&#160;thousand), which we refer to as the Rights Offering.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.8%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Participant</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of ADS representing Ordinary Shares</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate Purchase Price ($)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.8%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:1pt;font-family:Calibri;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AT Impf GmbH <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">268,818</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,000,074.00</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;color:#000000;">See &#8220;Major Shareholders&#8221; under this Item 7 for additional information about ordinary shares held by this entity, the parent company of this entity.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">C.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_7_C"></a><font style="text-decoration:none;Background-color:#auto;"></font><font style="color:#000000;"></font><font style="color:#000000;"><a name="ITEM_7_C"></a>Inter</font><font style="color:#000000;">ests of Experts and Counsel</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_8_FINANCIAL_INFORMATION"></a><a name="ITEM_8_FINANCIAL_INFORMATION"></a>Item 8. Financial Information</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">A.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_8_A"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Consolidated Statements a<a name="ITEM_8_A"></a>nd Other Financial Information</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See<font style="color:#231F20;"> Item 18. </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">B.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_8_B"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_8_B"></a>Significant Changes</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.<font style="color:#231F20;"> </font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9_FER_LISTING"></a><a name="ITEM_9_FER_LISTING"></a>Item 9. The Offer and Listing</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">A.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_9_A"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Offer Listing <a name="ITEM_9_A"></a>Details</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">B.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_9_B"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_9_B"></a>Plan of Distribution</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not <font style="color:#000000;">applicable</font>. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">C.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_9_C"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_9_C"></a>Markets</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ADSs representing our ordinary shares have been listed on the Nasdaq Global Select Market under the symbol &#8220;BNTX&#8221; since October 10, 2019.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">D.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_9_D"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_9_D"></a>Selling Shareholders</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not <font style="color:#000000;">applicable</font>. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">E.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_9_E"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_9_E"></a>Dilution</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">F.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_9_F"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_9_F"></a>Expenses of the Issue</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_10_ADDITIONAL_INFORMATION"></a><a name="ITEM_10_ADDITIONAL_INFORMATION"></a>Item 10. Additional Information</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">A.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_10_A"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_10_A"></a>Share Capital</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not <font style="color:#000000;">applicable</font>. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">B.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_10_B"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Memorandum and Articles of <a name="ITEM_10_B"></a>Association</font></p></td></tr></table></div>
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">General</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were <font style="color:#000000;">incorporated</font><font style="letter-spacing:0.1pt;"> </font>as a German<font style="letter-spacing:0.05pt;"> </font>stock<font style="letter-spacing:0.05pt;"> </font>corporation<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Aktiengesellschaf</font><font style="font-style:italic;letter-spacing:0.2pt;">t</font>) with the<font style="letter-spacing:0.05pt;"> </font>legal<font style="letter-spacing:0.05pt;"> </font>name<font style="letter-spacing:0.05pt;"> </font>Petersberg 91. V AG<font style="letter-spacing:-0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font><font style="color:#000000;">laws</font> of the<font style="letter-spacing:0.05pt;"> </font>Federal<font style="letter-spacing:0.05pt;"> </font>Republic<font style="letter-spacing:0.05pt;"> </font>of Germany<font style="letter-spacing:0.05pt;"> </font>on June 2, 2008. We changed<font style="letter-spacing:0.05pt;"> </font>our name<font style="letter-spacing:0.05pt;"> </font>to <font style="color:#000000;">BioNTech</font> AG<font style="letter-spacing:-0.05pt;"> </font>on December<font style="letter-spacing:0.05pt;"> </font>11, 2008. Effective<font style="letter-spacing:0.1pt;"> </font>as of March<font style="letter-spacing:0.05pt;"> </font>8, <font style="color:#000000;">2019</font>, the<font style="letter-spacing:0.05pt;"> </font>date<font style="letter-spacing:0.05pt;"> </font>on which the<font style="letter-spacing:0.05pt;"> </font>change<font style="letter-spacing:0.05pt;"> </font>of legal<font style="letter-spacing:0.05pt;"> </font>form and company<font style="letter-spacing:0.05pt;"> </font>was registered<font style="letter-spacing:0.1pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>commercial<font style="letter-spacing:0.15pt;"> </font>register<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Handelsregiste</font><font style="font-style:italic;letter-spacing:0.1pt;">r</font>) of the<font style="letter-spacing:0.05pt;"> </font>local<font style="letter-spacing:0.05pt;"> </font>court<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">Amtsgerich</font><font style="font-style:italic;letter-spacing:0.05pt;">t</font>) of Mainz,<font style="letter-spacing:0.05pt;"> </font>Germany,<font style="letter-spacing:0.05pt;"> </font>we converted<font style="letter-spacing:0.05pt;"> </font>to a <font style="font-style:italic;">Societas</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">Europaea </font>with the<font style="letter-spacing:0.05pt;"> </font>legal<font style="letter-spacing:0.05pt;"> </font>name<font style="letter-spacing:0.05pt;"> </font>BioNTech SE. We completed<font style="letter-spacing:0.1pt;"> </font>our initial<font style="letter-spacing:0.1pt;"> </font>public<font style="letter-spacing:0.05pt;"> </font>offering<font style="letter-spacing:0.1pt;"> </font>in October<font style="letter-spacing:0.05pt;"> </font>2019. The principal<font style="letter-spacing:0.1pt;"> </font>legislation<font style="letter-spacing:0.15pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>which we operate<font style="letter-spacing:0.05pt;"> </font>and our shares<font style="letter-spacing:0.05pt;"> </font>are issued<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Council<font style="letter-spacing:0.05pt;"> </font>Regulation<font style="letter-spacing:0.05pt;"> </font>(EC) No 2157/2001 of October<font style="letter-spacing:0.05pt;"> </font>8, 2001 on the<font style="letter-spacing:0.05pt;"> </font>Statute<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>a European<font style="letter-spacing:0.05pt;"> </font>company (SE), the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>Law on the<font style="letter-spacing:0.05pt;"> </font>Implementation<font style="letter-spacing:0.15pt;"> </font>of Council<font style="letter-spacing:0.05pt;"> </font>Regulation<font style="letter-spacing:0.05pt;"> </font>(EC) No 2157/2001 of October<font style="letter-spacing:0.05pt;"> </font>8, 2001 on the<font style="letter-spacing:0.05pt;"> </font>Statute<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>a European<font style="letter-spacing:0.05pt;"> </font>company<font style="letter-spacing:0.05pt;"> </font>(SE) (<font style="font-style:italic;">Gesetz</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">zur Ausf&#252;hrung</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">der Verordnung (EG) </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;">NR.</font><font style="font-style:italic;letter-spacing:-0.05pt;"> </font><font style="font-style:italic;">2157/2001 des Rates vom 8. </font><font style="font-style:italic;">Oktober</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">2001 &#252;ber das Statut</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">der Europ&#228;ischen</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">Gesellschaft</font><font style="font-style:italic;letter-spacing:0.1pt;"> </font><font style="font-style:italic;">(SE)</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">(SE-Ausf&#252;hrungsgesetz&#8212;SEAG</font><font style="font-style:italic;letter-spacing:0.1pt;">)</font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) and the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">German</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock Corporation</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Act (</font><font style="font-style:italic;">Aktiengeset</font><font style="font-style:italic;letter-spacing:0.1pt;">z</font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">), in each</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">case</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as amended.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We <font style="color:#000000;">are</font><font style="letter-spacing:0.05pt;"> </font>registered<font style="letter-spacing:0.1pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>commercial<font style="letter-spacing:0.15pt;"> </font>register<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Handelsregiste</font><font style="font-style:italic;letter-spacing:0.1pt;">r</font>) of the<font style="letter-spacing:0.05pt;"> </font>local<font style="letter-spacing:0.05pt;"> </font>court<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">Amtsgerich</font><font style="font-style:italic;letter-spacing:0.05pt;">t</font>) in Mainz, Germany,<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>number<font style="letter-spacing:0.05pt;"> </font>HRB<font style="letter-spacing:-0.05pt;"> </font>48720. Our statutory<font style="letter-spacing:0.1pt;"> </font>seat<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>in Mainz,<font style="letter-spacing:0.05pt;"> </font>Germany,<font style="letter-spacing:0.05pt;"> </font>and our registered<font style="letter-spacing:0.1pt;"> </font>office<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>An der<font style="letter-spacing:0.05pt;"> </font>Goldgrube<font style="letter-spacing:0.05pt;"> </font>12, 55131 Mainz,<font style="letter-spacing:0.05pt;"> </font>Germany.<font style="letter-spacing:0.05pt;"> </font>Copies of our Articles<font style="letter-spacing:0.1pt;"> </font>of Association<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Satzun</font><font style="font-style:italic;letter-spacing:0.05pt;">g</font>) will<font style="letter-spacing:0.05pt;"> </font>be publicly available<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>commercial<font style="letter-spacing:0.15pt;"> </font>register<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Handelsregiste</font><font style="font-style:italic;letter-spacing:0.1pt;">r</font>) at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>local<font style="letter-spacing:0.05pt;"> </font>court<font style="letter-spacing:0.05pt;"> </font>of Mainz,<font style="letter-spacing:0.05pt;"> </font>Germany,<font style="letter-spacing:0.05pt;"> </font>electronically<font style="letter-spacing:0.15pt;"> </font>at www.unternehmensregister.de<font style="letter-spacing:0.15pt;"> </font>and as an exhibit<font style="letter-spacing:0.05pt;"> </font>to this<font style="letter-spacing:0.05pt;"> </font>Annual Report.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share Capital</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>registered<font style="letter-spacing:0.1pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>commercial<font style="letter-spacing:0.15pt;"> </font>register<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Handelsregiste</font><font style="font-style:italic;letter-spacing:0.1pt;">r</font>) in the<font style="letter-spacing:0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of &#8364;246,310,081, which is<font style="letter-spacing:0.05pt;"> </font>divided<font style="letter-spacing:0.05pt;"> </font>into 246,310,081 registered<font style="letter-spacing:0.1pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">Namensaktie</font><font style="font-style:italic;letter-spacing:0.05pt;">n</font>). All shares<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>with no par<font style="letter-spacing:0.05pt;"> </font>value<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">St&#252;ckaktien</font><font style="font-style:italic;letter-spacing:0.1pt;"> </font><font style="font-style:italic;">ohne Nennbetra</font><font style="font-style:italic;letter-spacing:0.05pt;">g</font>) with a notional<font style="letter-spacing:0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>attributable<font style="letter-spacing:0.15pt;"> </font>to each<font style="letter-spacing:0.05pt;"> </font>ordinary<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>of &#8364;1. Each issued<font style="letter-spacing:0.05pt;"> </font>ordinary<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>fully<font style="letter-spacing:0.05pt;"> </font>paid.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Form, Certification<font style="letter-spacing:0.1pt;"> </font>and Transferability<font style="letter-spacing:0.1pt;"> </font>of Shares</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The form<font style="letter-spacing:0.05pt;"> </font>and contents<font style="letter-spacing:0.05pt;"> </font>of our share<font style="letter-spacing:0.05pt;"> </font>certificates,<font style="letter-spacing:0.2pt;"> </font>collective<font style="letter-spacing:0.1pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>certificates<font style="letter-spacing:0.2pt;"> </font>and global<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>certificates<font style="letter-spacing:0.2pt;"> </font>are determined<font style="letter-spacing:0.1pt;"> </font>by our Management<font style="letter-spacing:0.1pt;"> </font>Board. A shareholder&#8217;s<font style="letter-spacing:0.15pt;"> </font>right<font style="letter-spacing:0.05pt;"> </font>to certification<font style="letter-spacing:0.2pt;"> </font>of its<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>excluded,<font style="letter-spacing:0.05pt;"> </font>to the extent<font style="letter-spacing:0.05pt;"> </font>permitted<font style="letter-spacing:0.1pt;"> </font>by law and to the<font style="letter-spacing:0.05pt;"> </font>extent<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>certification<font style="letter-spacing:0.2pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>not required<font style="letter-spacing:0.1pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>stock<font style="letter-spacing:0.05pt;"> </font>exchange<font style="letter-spacing:0.05pt;"> </font>on which the shares<font style="letter-spacing:0.05pt;"> </font>or rights<font style="letter-spacing:0.05pt;"> </font>or certificates<font style="letter-spacing:0.2pt;"> </font>representing<font style="letter-spacing:0.1pt;"> </font>them<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>admitted<font style="letter-spacing:0.1pt;"> </font>to trading.<font style="letter-spacing:0.05pt;"> </font>We are<font style="letter-spacing:0.05pt;"> </font>permitted<font style="letter-spacing:0.1pt;"> </font>to issue<font style="letter-spacing:0.05pt;"> </font>collective share<font style="letter-spacing:0.05pt;"> </font>certificates<font style="letter-spacing:0.2pt;"> </font>and global<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>certificates<font style="letter-spacing:0.2pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>represent<font style="letter-spacing:0.1pt;"> </font>multiple<font style="letter-spacing:0.1pt;"> </font>or all<font style="letter-spacing:0.05pt;"> </font>of our shares.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our shares<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>freely<font style="letter-spacing:0.1pt;"> </font>transferable<font style="letter-spacing:0.15pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>law.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Changes in Our Share Capital<font style="letter-spacing:0.05pt;"> </font>During the Last Three Fiscal<font style="letter-spacing:0.05pt;"> </font>Years</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>as registered<font style="letter-spacing:0.1pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>commercial<font style="letter-spacing:0.15pt;"> </font>register<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Handelsregiste</font><font style="font-style:italic;letter-spacing:0.1pt;">r</font>) amounts<font style="letter-spacing:0.05pt;"> </font>to &#8364;246,310,081, including an amount of &#8364;4,789,016 relating to 4,789,016 ordinary shares held in treasury. Since<font style="letter-spacing:0.05pt;"> </font>January<font style="letter-spacing:0.05pt;"> </font>1, 2018, our share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>has changed<font style="letter-spacing:0.05pt;"> </font>as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#231F20;">On February</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">1, 2018, our share</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">capital</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">as registered</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">with the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">commercial</font><font style="color:#231F20;letter-spacing:0.15pt;"> </font><font style="color:#231F20;">register</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">(</font><font style="font-style:italic;color:#231F20;">Handelsregiste</font><font style="font-style:italic;color:#231F20;letter-spacing:0.1pt;">r</font><font style="color:#231F20;">) was increased</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">by issuing</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">1,254,884 shares;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>On September<font style="letter-spacing:0.1pt;"> </font>12, 2018, our share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>as registered<font style="letter-spacing:0.1pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>commercial<font style="letter-spacing:0.15pt;"> </font>register<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Handelsregiste</font><font style="font-style:italic;letter-spacing:0.1pt;">r</font>) was increased<font style="letter-spacing:0.1pt;"> </font>by issuing<font style="letter-spacing:0.05pt;"> </font>32,373 shares;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#231F20;">On October</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">18, 2018, our share</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">capital</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">as registered</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">with the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">commercial</font><font style="color:#231F20;letter-spacing:0.15pt;"> </font><font style="color:#231F20;">register</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">(</font><font style="font-style:italic;color:#231F20;">Handelsregiste</font><font style="font-style:italic;color:#231F20;letter-spacing:0.1pt;">r</font><font style="color:#231F20;">) was increased</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">by issuing</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">186,715 shares;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#231F20;">On January</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">29, 2019, our share</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">capital</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">as registered</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">with the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">commercial</font><font style="color:#231F20;letter-spacing:0.15pt;"> </font><font style="color:#231F20;">register</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">(</font><font style="font-style:italic;color:#231F20;">Handelsregiste</font><font style="font-style:italic;color:#231F20;letter-spacing:0.1pt;">r</font><font style="color:#231F20;">) was increased</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">by issuing</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">282,678 shares;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#231F20;">On April</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">24, 2019, our share</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">capital</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">as registered</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">with the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">commercial</font><font style="color:#231F20;letter-spacing:0.15pt;"> </font><font style="color:#231F20;">register</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">(</font><font style="font-style:italic;color:#231F20;">Handelsregiste</font><font style="font-style:italic;color:#231F20;letter-spacing:0.1pt;">r</font><font style="color:#231F20;">) was increased</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">by issuing</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">131,933 shares</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">against</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">contributions</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">in kind (swap of shares</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">in our company against</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">shares</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">in one of our subsidiary</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">companies);</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#231F20;">On June 26, 2019, our share</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">capital</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">as registered</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">with the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">commercial</font><font style="color:#231F20;letter-spacing:0.15pt;"> </font><font style="color:#231F20;">register</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">(</font><font style="font-style:italic;color:#231F20;">Handelsregiste</font><font style="font-style:italic;color:#231F20;letter-spacing:0.1pt;">r</font><font style="color:#231F20;">) was increased</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">by issuing</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">666,123 shares;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#231F20;">On August 16, 2019, our share</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">capital</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">as registered</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">with the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">commercial</font><font style="color:#231F20;letter-spacing:0.15pt;"> </font><font style="color:#231F20;">register</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">(</font><font style="font-style:italic;color:#231F20;">Handelsregiste</font><font style="font-style:italic;color:#231F20;letter-spacing:0.1pt;">r</font><font style="color:#231F20;">) was increased</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">by issuing</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">333,310 shares;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#231F20;">On September</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">18, 2019, our share</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">capital</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">as registered</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">with the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">commercial</font><font style="color:#231F20;letter-spacing:0.15pt;"> </font><font style="color:#231F20;">register</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">(</font><font style="font-style:italic;color:#231F20;">Handelsregiste</font><font style="font-style:italic;color:#231F20;letter-spacing:0.1pt;">r</font><font style="color:#231F20;">) was increased</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">by issuing</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">206,595,492 shares</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">by way of a capital</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">increase</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">from</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">our funds;</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">thus,</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">no contribution</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">by investors</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">was made;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>On September 26, 2019, our share capital as registered with the commercial register (Handelsregister) was increased by issuing 3,038,674 shares;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#231F20;">On October</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">14, 2019, our share</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">capital</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">as registered</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">with the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">commercial</font><font style="color:#231F20;letter-spacing:0.15pt;"> </font><font style="color:#231F20;">register</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">(</font><font style="font-style:italic;color:#231F20;">Handelsregiste</font><font style="font-style:italic;color:#231F20;letter-spacing:0.1pt;">r</font><font style="color:#231F20;">) was increased</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">by issuing</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">10,000,000 shares;</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">205</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6, 2019, our share</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">capital</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as registered</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercial</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">register</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-style:italic;">Handelsregiste</font><font style="font-style:italic;letter-spacing:0.1pt;">r</font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) was increased</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by issuing</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">517,408 shares;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>On April 23, 2020, our share capital as registered with the commercial register (<font style="font-style:italic;">Handelsregister</font>) was increased by issuing 1,580,777 shares;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>On May 5, 2020, our share capital as registered with the commercial register (<font style="font-style:italic;">Handelsregister</font>) was increased by issuing 2,377,446 shares;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>On May 8, 2020, our share capital as registered with the commercial register (<font style="font-style:italic;">Handelsregister</font>) was increased by issuing 1,935,488 shares;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>On July 24, 2020, our share capital as registered with the commercial register (<font style="font-style:italic;">Handelsregister</font>) was increased by issuing 5,500,000 shares;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>On August 24, 2020, our share capital as registered with the commercial register (<font style="font-style:italic;">Handelsregister</font>) was increased by issuing 16,124 shares; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>On September 8, 2020, our share capital as registered with the commercial register (<font style="font-style:italic;">Handelsregister</font>) was increased by issuing 2,595,996 shares. </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Anti-takeover<font style="letter-spacing:0.05pt;"> </font>Provisions<font style="letter-spacing:0.05pt;"> </font>of Our Charter Documents</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Articles<font style="letter-spacing:0.1pt;"> </font>of Association<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Satzun</font><font style="font-style:italic;letter-spacing:0.05pt;">g</font>) do not include<font style="letter-spacing:0.05pt;"> </font>any provisions<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>would have a direct<font style="letter-spacing:0.1pt;"> </font>effect<font style="letter-spacing:0.1pt;"> </font>of delaying,<font style="letter-spacing:0.05pt;"> </font>deferring<font style="letter-spacing:0.1pt;"> </font>or preventing<font style="letter-spacing:0.1pt;"> </font>a change<font style="letter-spacing:0.05pt;"> </font>of control.<font style="letter-spacing:0.05pt;"> </font>However, in the<font style="letter-spacing:0.05pt;"> </font>event<font style="letter-spacing:0.05pt;"> </font>of a hostile<font style="letter-spacing:0.1pt;"> </font>takeover,<font style="letter-spacing:0.05pt;"> </font>we could<font style="letter-spacing:0.05pt;"> </font>use our authorized<font style="letter-spacing:0.1pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>to increase<font style="letter-spacing:0.1pt;"> </font>our share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>to issue<font style="letter-spacing:0.05pt;"> </font>new shares<font style="letter-spacing:0.05pt;"> </font>to an investor<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>a premium.<font style="letter-spacing:0.1pt;"> </font>An increase in the<font style="letter-spacing:0.05pt;"> </font>number<font style="letter-spacing:0.05pt;"> </font>of shares<font style="letter-spacing:0.05pt;"> </font>outstanding<font style="letter-spacing:0.1pt;"> </font>could<font style="letter-spacing:0.05pt;"> </font>have a negative<font style="letter-spacing:0.05pt;"> </font>effect<font style="letter-spacing:0.1pt;"> </font>on a party&#8217;s<font style="letter-spacing:0.1pt;"> </font>ability<font style="letter-spacing:0.1pt;"> </font>to carry<font style="letter-spacing:0.05pt;"> </font>out a hostile takeover.<font style="letter-spacing:0.05pt;"> </font>The provisions<font style="letter-spacing:0.1pt;"> </font>of German<font style="letter-spacing:0.05pt;"> </font>law relating<font style="letter-spacing:0.1pt;"> </font>to public<font style="letter-spacing:0.05pt;"> </font>bids<font style="letter-spacing:0.05pt;"> </font>and takeovers<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>require<font style="letter-spacing:0.1pt;"> </font>any such bids<font style="letter-spacing:0.05pt;"> </font>to be carried<font style="letter-spacing:0.1pt;"> </font>out in a manner<font style="letter-spacing:0.05pt;"> </font>designed<font style="letter-spacing:0.05pt;"> </font>to safeguard<font style="letter-spacing:0.1pt;"> </font>equal<font style="letter-spacing:0.05pt;"> </font>and fair<font style="letter-spacing:0.05pt;"> </font>treatment<font style="letter-spacing:0.15pt;"> </font>to all<font style="letter-spacing:0.05pt;"> </font>shareholders<font style="letter-spacing:0.1pt;"> </font>and give<font style="letter-spacing:0.05pt;"> </font>them<font style="letter-spacing:0.05pt;"> </font>a right<font style="letter-spacing:0.05pt;"> </font>to be bought out at<font style="letter-spacing:0.05pt;"> </font>an adequate<font style="letter-spacing:0.05pt;"> </font>compensation<font style="letter-spacing:0.1pt;"> </font>where a party<font style="letter-spacing:0.05pt;"> </font>acquires<font style="letter-spacing:0.1pt;"> </font>&#8220;control&#8221;<font style="letter-spacing:0.1pt;"> </font>(as<font style="letter-spacing:0.05pt;"> </font>such term<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>defined<font style="letter-spacing:0.05pt;"> </font>in such provisions)<font style="letter-spacing:0.1pt;"> </font>over<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>relevant<font style="letter-spacing:0.1pt;"> </font>company<font style="letter-spacing:0.05pt;"> </font>do not apply.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Future Changes to the Share Capital</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Authorized<font style="letter-spacing:0.05pt;"> </font>Capital</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the<font style="letter-spacing:0.05pt;"> </font>relevant<font style="letter-spacing:0.1pt;"> </font>law, the<font style="letter-spacing:0.05pt;"> </font>general<font style="letter-spacing:0.05pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>of a European<font style="letter-spacing:0.05pt;"> </font>stock<font style="letter-spacing:0.05pt;"> </font>corporation<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Societas</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">Europaea</font>) governed by German<font style="letter-spacing:0.05pt;"> </font>law can authorize<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board, with the<font style="letter-spacing:0.05pt;"> </font>consent<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Supervisory<font style="letter-spacing:0.05pt;"> </font>Board, to issue<font style="letter-spacing:0.05pt;"> </font>shares in a specified<font style="letter-spacing:0.1pt;"> </font>aggregate<font style="letter-spacing:0.1pt;"> </font>nominal<font style="letter-spacing:0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of up to 50% of the<font style="letter-spacing:0.05pt;"> </font>issued<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>of such company<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>the resolution<font style="letter-spacing:0.1pt;"> </font>becomes<font style="letter-spacing:0.05pt;"> </font>effective.<font style="letter-spacing:0.1pt;"> </font>The shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>authorization<font style="letter-spacing:0.15pt;"> </font>becomes<font style="letter-spacing:0.05pt;"> </font>effective<font style="letter-spacing:0.1pt;"> </font>upon registration<font style="letter-spacing:0.15pt;"> </font>in the commercial<font style="letter-spacing:0.15pt;"> </font>register<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Handelsregiste</font><font style="font-style:italic;letter-spacing:0.1pt;">r</font>) and may<font style="letter-spacing:0.05pt;"> </font>extend<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>a period<font style="letter-spacing:0.05pt;"> </font>of no more<font style="letter-spacing:0.05pt;"> </font>than<font style="letter-spacing:0.05pt;"> </font>five<font style="letter-spacing:0.05pt;"> </font>years<font style="letter-spacing:0.05pt;"> </font>thereafter.<font style="letter-spacing:0.15pt;"> </font>Under &#167; 4(5)<font style="letter-spacing:0.05pt;"> </font>of our Articles<font style="letter-spacing:0.1pt;"> </font>of Association<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Satzun</font><font style="font-style:italic;letter-spacing:0.05pt;">g</font>), the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board is<font style="letter-spacing:0.05pt;"> </font>authorized<font style="letter-spacing:0.1pt;"> </font>to increase<font style="letter-spacing:0.1pt;"> </font>our share capital,<font style="letter-spacing:0.1pt;"> </font>on one or more<font style="letter-spacing:0.05pt;"> </font>occasions,<font style="letter-spacing:0.05pt;"> </font>by a total<font style="letter-spacing:0.05pt;"> </font>of up to &#8364;91,812,171 by issuing,<font style="letter-spacing:0.05pt;"> </font>on one or more<font style="letter-spacing:0.05pt;"> </font>occasions,<font style="letter-spacing:0.05pt;"> </font>up to 91,812,171 new, registered<font style="letter-spacing:0.1pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>with no par<font style="letter-spacing:0.05pt;"> </font>value<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">Genehmigtes</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">Kapita</font><font style="font-style:italic;letter-spacing:0.05pt;">l</font>), in each<font style="letter-spacing:0.05pt;"> </font>case<font style="letter-spacing:0.05pt;"> </font>with consent<font style="letter-spacing:0.05pt;"> </font>of the Supervisory<font style="letter-spacing:0.05pt;"> </font>Board. This authorization<font style="letter-spacing:0.15pt;"> </font>expires<font style="letter-spacing:0.05pt;"> </font>on August 18, 2024.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any new shares<font style="letter-spacing:0.05pt;"> </font>issued<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>authorized<font style="letter-spacing:0.1pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>participate<font style="letter-spacing:0.15pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>profits<font style="letter-spacing:0.1pt;"> </font>starting<font style="letter-spacing:0.1pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>fiscal<font style="letter-spacing:0.1pt;"> </font>year for<font style="letter-spacing:0.05pt;"> </font>which the<font style="letter-spacing:0.05pt;"> </font>annual<font style="letter-spacing:0.05pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>statements<font style="letter-spacing:0.15pt;"> </font>have not yet<font style="letter-spacing:0.05pt;"> </font>been submitted<font style="letter-spacing:0.1pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>general<font style="letter-spacing:0.05pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>of registration<font style="letter-spacing:0.15pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>implementation<font style="letter-spacing:0.15pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>increase.<font style="letter-spacing:0.1pt;"> </font>Further<font style="letter-spacing:0.05pt;"> </font>details<font style="letter-spacing:0.1pt;"> </font>of a capital<font style="letter-spacing:0.1pt;"> </font>increase<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>authorized capital<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>be specified<font style="letter-spacing:0.1pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Conditional<font style="letter-spacing:0.05pt;"> </font>Capital</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant<font style="letter-spacing:0.05pt;"> </font>to &#167; 4(6)<font style="letter-spacing:0.05pt;"> </font>of our Articles<font style="letter-spacing:0.1pt;"> </font>of Association<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Satzun</font><font style="font-style:italic;letter-spacing:0.05pt;">g</font>), our share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>conditionally<font style="letter-spacing:0.1pt;"> </font>increased<font style="letter-spacing:0.1pt;"> </font>by &#8364;21,874,806 through<font style="letter-spacing:0.05pt;"> </font>issuance<font style="letter-spacing:0.05pt;"> </font>of new, registered<font style="letter-spacing:0.1pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>with no par<font style="letter-spacing:0.05pt;"> </font>value<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">Bedingtes</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">Kapital</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">ESOP</font><font style="font-style:italic;letter-spacing:-0.05pt;"> </font><font style="font-style:italic;">2017/2019</font>). The conditional<font style="letter-spacing:0.1pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>only be used to issue<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>holders<font style="letter-spacing:0.05pt;"> </font>of option<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>granted<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>our ESOP to members<font style="letter-spacing:0.1pt;"> </font>of our Management<font style="letter-spacing:0.1pt;"> </font>Board and to certain<font style="letter-spacing:0.1pt;"> </font>of our employees.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The conditional<font style="letter-spacing:0.1pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>increase<font style="letter-spacing:0.1pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>only be implemented<font style="letter-spacing:0.15pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>extent<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>stock<font style="letter-spacing:0.05pt;"> </font>options<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>our ESOP are<font style="letter-spacing:0.05pt;"> </font>exercised<font style="letter-spacing:0.1pt;"> </font>and <font style="letter-spacing:0.05pt;">such </font>stock<font style="letter-spacing:0.05pt;"> </font>options<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>not serviced<font style="letter-spacing:0.1pt;"> </font>by our providing<font style="letter-spacing:0.05pt;"> </font>treasury<font style="letter-spacing:0.1pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>or through<font style="letter-spacing:0.05pt;"> </font>cash<font style="letter-spacing:0.05pt;"> </font>payments. Any new shares<font style="letter-spacing:0.05pt;"> </font>issued<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>conditional<font style="letter-spacing:0.1pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>pursuant<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>said<font style="letter-spacing:0.05pt;"> </font>&#167; 4(6)<font style="letter-spacing:0.05pt;"> </font>of our Articles<font style="letter-spacing:0.1pt;"> </font>of Association (<font style="font-style:italic;">Satzun</font><font style="font-style:italic;letter-spacing:0.05pt;">g</font>) shall<font style="letter-spacing:0.05pt;"> </font>be entitled<font style="letter-spacing:0.1pt;"> </font>to dividends<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>beginning<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>previous<font style="letter-spacing:0.05pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>year<font style="letter-spacing:0.05pt;"> </font>in case<font style="letter-spacing:0.05pt;"> </font>they<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>created by the<font style="letter-spacing:0.05pt;"> </font>exercise<font style="letter-spacing:0.1pt;"> </font>of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subscription</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">until</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">start</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">annual</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">general</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">meeting</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company and otherwise from</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">beginning</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">year</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in which they</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">created</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as a result</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exercise</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stock</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">options.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant<font style="letter-spacing:0.05pt;"> </font>to &#167; 4(7)<font style="letter-spacing:0.05pt;"> </font>of our Articles<font style="letter-spacing:0.1pt;"> </font>of Association<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Satzun</font><font style="font-style:italic;letter-spacing:0.05pt;">g</font>), our share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>conditionally<font style="letter-spacing:0.1pt;"> </font>increased<font style="letter-spacing:0.1pt;"> </font>by &#8364;87,499,260 through<font style="letter-spacing:0.05pt;"> </font>issuance<font style="letter-spacing:0.05pt;"> </font>of new, registered<font style="letter-spacing:0.1pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>with no par<font style="letter-spacing:0.05pt;"> </font>value<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">Bedingtes</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">Kapital</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">WSV 2019</font>). The conditional<font style="letter-spacing:0.1pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>only be used to issue<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>holders<font style="letter-spacing:0.05pt;"> </font>or creditors<font style="letter-spacing:0.1pt;"> </font>of option<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>or conversion rights<font style="letter-spacing:0.05pt;"> </font>or those<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>an obligation<font style="letter-spacing:0.1pt;"> </font>to convert<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>warrant-linked<font style="letter-spacing:0.15pt;"> </font>or convertible<font style="letter-spacing:0.1pt;"> </font>bonds avail<font style="letter-spacing:0.05pt;"> </font>of their<font style="letter-spacing:0.05pt;"> </font>option rights<font style="letter-spacing:0.05pt;"> </font>or conversion<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>or where they<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>an obligation<font style="letter-spacing:0.1pt;"> </font>to convert,<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>extent<font style="letter-spacing:0.05pt;"> </font>they<font style="letter-spacing:0.05pt;"> </font>satisfy<font style="letter-spacing:0.1pt;"> </font>their obligation<font style="letter-spacing:0.1pt;"> </font>to convert,<font style="letter-spacing:0.05pt;"> </font>or to the<font style="letter-spacing:0.05pt;"> </font>extent<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we exercise<font style="letter-spacing:0.1pt;"> </font>a right<font style="letter-spacing:0.05pt;"> </font>to choose<font style="letter-spacing:0.05pt;"> </font>to grant<font style="letter-spacing:0.05pt;"> </font>our shares,<font style="letter-spacing:0.05pt;"> </font>in whole or in part instead<font style="letter-spacing:0.05pt;"> </font>of paying<font style="letter-spacing:0.05pt;"> </font>a monetary<font style="letter-spacing:0.1pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>due, and to the<font style="letter-spacing:0.05pt;"> </font>extent<font style="letter-spacing:0.05pt;"> </font>cash<font style="letter-spacing:0.05pt;"> </font>compensation<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>not granted<font style="letter-spacing:0.05pt;"> </font>in each<font style="letter-spacing:0.05pt;"> </font>relevant case<font style="letter-spacing:0.05pt;"> </font>or treasury<font style="letter-spacing:0.1pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>or shares<font style="letter-spacing:0.05pt;"> </font>of another<font style="letter-spacing:0.05pt;"> </font>stock-listed<font style="letter-spacing:0.15pt;"> </font>company<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>not utilized<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>servicing.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any new shares<font style="letter-spacing:0.05pt;"> </font>issued<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>said<font style="letter-spacing:0.05pt;"> </font>conditional<font style="letter-spacing:0.1pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>pursuant<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>said<font style="letter-spacing:0.05pt;"> </font>&#167; 4(7)<font style="letter-spacing:0.05pt;"> </font>of our Articles<font style="letter-spacing:0.1pt;"> </font>of Association<font style="letter-spacing:0.1pt;"> </font>shall<font style="letter-spacing:0.05pt;"> </font>carry<font style="letter-spacing:0.05pt;"> </font>an entitlement<font style="letter-spacing:0.15pt;"> </font>to dividends<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>beginning<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>year<font style="letter-spacing:0.05pt;"> </font>in which they<font style="letter-spacing:0.05pt;"> </font>are created;<font style="letter-spacing:0.1pt;"> </font>however, as far<font style="letter-spacing:0.05pt;"> </font>as the<font style="letter-spacing:0.05pt;"> </font>law permits,<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board can confer<font style="letter-spacing:0.05pt;"> </font>dividend<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>new shares<font style="letter-spacing:0.05pt;"> </font>in derogation<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>foregoing.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Preemptive<font style="letter-spacing:0.1pt;"> </font>Rights</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">German<font style="letter-spacing:0.05pt;"> </font>law generally<font style="letter-spacing:0.1pt;"> </font>provides<font style="letter-spacing:0.05pt;"> </font>shareholders<font style="letter-spacing:0.1pt;"> </font>with preemptive<font style="letter-spacing:0.1pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>when new shares<font style="letter-spacing:0.05pt;"> </font>convertible<font style="letter-spacing:0.1pt;"> </font>bonds, bonds with warrants,<font style="letter-spacing:0.05pt;"> </font>profit<font style="letter-spacing:0.1pt;"> </font>participation<font style="letter-spacing:0.15pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>or participating<font style="letter-spacing:0.15pt;"> </font>bonds are<font style="letter-spacing:0.05pt;"> </font>issued.<font style="letter-spacing:0.05pt;"> </font>This requirement,<font style="letter-spacing:0.15pt;"> </font>however, may also<font style="letter-spacing:0.05pt;"> </font>be satisfied<font style="letter-spacing:0.1pt;"> </font>by way of a credit<font style="letter-spacing:0.1pt;"> </font>institution<font style="letter-spacing:0.15pt;"> </font>subscribing<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.15pt;"> </font>and then<font style="letter-spacing:0.05pt;"> </font>offering<font style="letter-spacing:0.1pt;"> </font>them<font style="letter-spacing:0.05pt;"> </font>to the shareholders<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>purchase<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">mittelbares</font><font style="font-style:italic;letter-spacing:0.1pt;"> </font><font style="font-style:italic;">Bezugsrech</font><font style="font-style:italic;letter-spacing:0.05pt;">t</font>).</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further,<font style="letter-spacing:0.05pt;"> </font>it<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>possible<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>a shareholder<font style="letter-spacing:0.1pt;"> </font>resolution<font style="letter-spacing:0.1pt;"> </font>approved<font style="letter-spacing:0.05pt;"> </font>by three-quarters<font style="letter-spacing:0.15pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>voting<font style="letter-spacing:0.05pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>resolution<font style="letter-spacing:0.1pt;"> </font>to exclude<font style="letter-spacing:0.05pt;"> </font>preemptive<font style="letter-spacing:0.1pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>both where the<font style="letter-spacing:0.05pt;"> </font>general<font style="letter-spacing:0.05pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>itself<font style="letter-spacing:0.1pt;"> </font>resolves<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>new securities to be issued<font style="letter-spacing:0.05pt;"> </font>and in relation<font style="letter-spacing:0.1pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>authorized<font style="letter-spacing:0.1pt;"> </font>capital,<font style="letter-spacing:0.1pt;"> </font><font style="font-style:italic;">i.e.,</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font>an authorization<font style="letter-spacing:0.15pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board to, with the consent<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Supervisory<font style="letter-spacing:0.05pt;"> </font>Board, resolve<font style="letter-spacing:0.05pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>issuance<font style="letter-spacing:0.05pt;"> </font>of new securities;<font style="letter-spacing:0.15pt;"> </font>provided,<font style="letter-spacing:0.05pt;"> </font>however, that<font style="letter-spacing:0.05pt;"> </font>in each<font style="letter-spacing:0.05pt;"> </font>case the<font style="letter-spacing:0.05pt;"> </font>exclusion<font style="letter-spacing:0.05pt;"> </font>or the<font style="letter-spacing:0.05pt;"> </font>authorization<font style="letter-spacing:0.15pt;"> </font>to so exclude<font style="letter-spacing:0.05pt;"> </font>preemptive<font style="letter-spacing:0.1pt;"> </font>rights,<font style="letter-spacing:0.05pt;"> </font>respectively,<font style="letter-spacing:0.15pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>be justified<font style="letter-spacing:0.1pt;"> </font>by specific facts,<font style="letter-spacing:0.05pt;"> </font>in accordance<font style="letter-spacing:0.1pt;"> </font>with established<font style="letter-spacing:0.1pt;"> </font>case<font style="letter-spacing:0.05pt;"> </font>law of the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>Federal<font style="letter-spacing:0.05pt;"> </font>Court of Justice<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">BG</font><font style="font-style:italic;letter-spacing:-0.05pt;">H</font>). The German Federal<font style="letter-spacing:0.05pt;"> </font>Court of Justice<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">BG</font><font style="font-style:italic;letter-spacing:-0.05pt;">H</font>) considers<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>exclusion<font style="letter-spacing:0.05pt;"> </font>of subscription<font style="letter-spacing:0.1pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>justified<font style="letter-spacing:0.1pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>it<font style="letter-spacing:0.05pt;"> </font>(i)<font style="letter-spacing:0.05pt;"> </font>serves<font style="letter-spacing:0.05pt;"> </font>a purpose<font style="letter-spacing:0.05pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>company&#8217;s<font style="letter-spacing:0.05pt;"> </font>interests,<font style="letter-spacing:0.1pt;"> </font>(ii)<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>suitable<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>attaining<font style="letter-spacing:0.1pt;"> </font>such purpose,<font style="letter-spacing:0.05pt;"> </font>and (iii)<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>necessary<font style="letter-spacing:0.1pt;"> </font>and appropriate. Additionally,<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>management<font style="letter-spacing:0.1pt;"> </font>board<font style="letter-spacing:0.05pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>submit<font style="letter-spacing:0.05pt;"> </font>a written<font style="letter-spacing:0.05pt;"> </font>report<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>in which it presents<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>reasons<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>exclusion<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>subscription<font style="letter-spacing:0.1pt;"> </font>rights.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly,<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>our Articles<font style="letter-spacing:0.1pt;"> </font>of Association<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Satzun</font><font style="font-style:italic;letter-spacing:0.05pt;">g</font>), the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board may,<font style="letter-spacing:0.05pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>consent<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Supervisory<font style="letter-spacing:0.05pt;"> </font>Board, exclude<font style="letter-spacing:0.05pt;"> </font>such preemptive<font style="letter-spacing:0.1pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>in a capital<font style="letter-spacing:0.1pt;"> </font>increase<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>authorized<font style="letter-spacing:0.1pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>in the following<font style="letter-spacing:0.05pt;"> </font>circumstances:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>to exclude<font style="letter-spacing:0.05pt;"> </font>fractional<font style="letter-spacing:0.15pt;"> </font>amounts<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>subscription<font style="letter-spacing:0.1pt;"> </font>right;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>in the<font style="letter-spacing:0.05pt;"> </font>case<font style="letter-spacing:0.05pt;"> </font>of a capital<font style="letter-spacing:0.1pt;"> </font>increase<font style="letter-spacing:0.1pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>cash<font style="letter-spacing:0.05pt;"> </font>contributions,<font style="letter-spacing:0.1pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>issue<font style="letter-spacing:0.05pt;"> </font>price<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>new shares<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>not significantly<font style="letter-spacing:0.15pt;"> </font>lower<font style="letter-spacing:0.05pt;"> </font>than<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>market<font style="letter-spacing:0.1pt;"> </font>price<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>company&#8217;s<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>already<font style="letter-spacing:0.05pt;"> </font>listed<font style="letter-spacing:0.1pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>stock<font style="letter-spacing:0.05pt;"> </font>exchange at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>issue<font style="letter-spacing:0.05pt;"> </font>price<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>finally<font style="letter-spacing:0.1pt;"> </font>determined.<font style="letter-spacing:0.1pt;"> </font>However, this<font style="letter-spacing:0.05pt;"> </font>authorization<font style="letter-spacing:0.15pt;"> </font>shall<font style="letter-spacing:0.05pt;"> </font>only apply<font style="letter-spacing:0.05pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>provision<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>issued<font style="letter-spacing:0.05pt;"> </font>excluding<font style="letter-spacing:0.05pt;"> </font>subscription<font style="letter-spacing:0.1pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>in accordance<font style="letter-spacing:0.1pt;"> </font>with Section<font style="letter-spacing:0.05pt;"> </font>186(3) Sentence<font style="letter-spacing:0.05pt;"> </font>4 AktG may<font style="letter-spacing:0.05pt;"> </font>not exceed<font style="letter-spacing:0.05pt;"> </font>a total<font style="letter-spacing:0.05pt;"> </font>of 10% of the<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>either<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>this<font style="letter-spacing:0.05pt;"> </font>authorization takes<font style="letter-spacing:0.05pt;"> </font>effect<font style="letter-spacing:0.1pt;"> </font>or, if<font style="letter-spacing:0.05pt;"> </font>this<font style="letter-spacing:0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>lower,<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>this<font style="letter-spacing:0.05pt;"> </font>authorization<font style="letter-spacing:0.15pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>exercised.<font style="letter-spacing:0.1pt;"> </font>This limit<font style="letter-spacing:0.1pt;"> </font>of 10% of the<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>includes<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>which are<font style="letter-spacing:0.05pt;"> </font>issued<font style="letter-spacing:0.05pt;"> </font>or disposed<font style="letter-spacing:0.05pt;"> </font>of during<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>term<font style="letter-spacing:0.05pt;"> </font>of this<font style="letter-spacing:0.05pt;"> </font>authorization until<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>date<font style="letter-spacing:0.05pt;"> </font>of its<font style="letter-spacing:0.05pt;"> </font>exercise<font style="letter-spacing:0.1pt;"> </font>in direct<font style="letter-spacing:0.1pt;"> </font>or equivalent<font style="letter-spacing:0.1pt;"> </font>application<font style="letter-spacing:0.1pt;"> </font>of Section<font style="letter-spacing:0.05pt;"> </font>186(3)<font style="letter-spacing:0.05pt;"> </font>Sentence<font style="letter-spacing:0.05pt;"> </font>4 AktG. Shares<font style="letter-spacing:0.05pt;"> </font>which are<font style="letter-spacing:0.05pt;"> </font>used to service<font style="letter-spacing:0.1pt;"> </font>bonds with convertible<font style="letter-spacing:0.1pt;"> </font>or option<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>or convertible<font style="letter-spacing:0.1pt;"> </font>obligations<font style="letter-spacing:0.1pt;"> </font>are to be offset<font style="letter-spacing:0.1pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>10% limit<font style="letter-spacing:0.1pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>these<font style="letter-spacing:0.05pt;"> </font>bonds were issued<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>exclusion<font style="letter-spacing:0.05pt;"> </font>of shareholder subscription<font style="letter-spacing:0.1pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>in accordance<font style="letter-spacing:0.1pt;"> </font>with Section<font style="letter-spacing:0.05pt;"> </font>186(3)<font style="letter-spacing:0.05pt;"> </font>Sentence<font style="letter-spacing:0.05pt;"> </font>4 AktG during<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>entitlement<font style="letter-spacing:0.15pt;"> </font>period. Treasury<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>to be offset<font style="letter-spacing:0.1pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>10% limit,<font style="letter-spacing:0.1pt;"> </font>where they<font style="letter-spacing:0.05pt;"> </font>were disposed<font style="letter-spacing:0.05pt;"> </font>of by the<font style="letter-spacing:0.05pt;"> </font>company during<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>term<font style="letter-spacing:0.05pt;"> </font>of this<font style="letter-spacing:0.05pt;"> </font>authorization<font style="letter-spacing:0.15pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>exclusion<font style="letter-spacing:0.05pt;"> </font>of subscription<font style="letter-spacing:0.1pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>pursuant<font style="letter-spacing:0.05pt;"> </font>to or in analogous<font style="letter-spacing:0.05pt;"> </font>application<font style="letter-spacing:0.1pt;"> </font>of Section<font style="letter-spacing:0.05pt;"> </font>186(3)<font style="letter-spacing:0.05pt;"> </font>Sentence<font style="letter-spacing:0.05pt;"> </font>4 AktG;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>in the<font style="letter-spacing:0.05pt;"> </font>case<font style="letter-spacing:0.05pt;"> </font>of capital<font style="letter-spacing:0.1pt;"> </font>increases<font style="letter-spacing:0.1pt;"> </font>in exchange<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>contributions<font style="letter-spacing:0.1pt;"> </font>in kind, in particular<font style="letter-spacing:0.15pt;"> </font>in order<font style="letter-spacing:0.05pt;"> </font>to be able<font style="letter-spacing:0.05pt;"> </font>to offer<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>to third<font style="letter-spacing:0.05pt;"> </font>parties<font style="letter-spacing:0.1pt;"> </font>when purchasing<font style="letter-spacing:0.05pt;"> </font>companies,<font style="letter-spacing:0.1pt;"> </font>parts<font style="letter-spacing:0.05pt;"> </font>of companies<font style="letter-spacing:0.1pt;"> </font>or interests<font style="letter-spacing:0.1pt;"> </font>in companies<font style="letter-spacing:0.1pt;"> </font>as well<font style="letter-spacing:0.05pt;"> </font>as licenses<font style="letter-spacing:0.1pt;"> </font>or industrial<font style="letter-spacing:0.1pt;"> </font>property<font style="letter-spacing:0.05pt;"> </font>rights;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>in order<font style="letter-spacing:0.05pt;"> </font>to grant<font style="letter-spacing:0.05pt;"> </font>subscription<font style="letter-spacing:0.1pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>to new shares<font style="letter-spacing:0.05pt;"> </font>to holders<font style="letter-spacing:0.05pt;"> </font>of conversion<font style="letter-spacing:0.05pt;"> </font>or option<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>in respect<font style="letter-spacing:0.1pt;"> </font>of bonds issued<font style="letter-spacing:0.05pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>company<font style="letter-spacing:0.05pt;"> </font>or its<font style="letter-spacing:0.05pt;"> </font>subordinated<font style="letter-spacing:0.1pt;"> </font>domestic<font style="letter-spacing:0.1pt;"> </font>or foreign<font style="letter-spacing:0.05pt;"> </font>Group companies,<font style="letter-spacing:0.1pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>extent<font style="letter-spacing:0.05pt;"> </font>to which they<font style="letter-spacing:0.05pt;"> </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">207</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would be entitled</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">after</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exercising</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">their</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conversion</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or option</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or after</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fulfilling</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an agreed</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conversion</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obligation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>to implement<font style="letter-spacing:0.1pt;"> </font>an election<font style="letter-spacing:0.1pt;"> </font>dividend<font style="letter-spacing:0.05pt;"> </font>by which shareholders<font style="letter-spacing:0.1pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>given<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>option<font style="letter-spacing:0.05pt;"> </font>to contribute<font style="letter-spacing:0.1pt;"> </font>their dividend<font style="letter-spacing:0.05pt;"> </font>entitlements<font style="letter-spacing:0.15pt;"> </font>(either<font style="letter-spacing:0.1pt;"> </font>in whole or part)<font style="letter-spacing:0.05pt;"> </font>as a contribution<font style="letter-spacing:0.1pt;"> </font>in kind against<font style="letter-spacing:0.05pt;"> </font>issuance<font style="letter-spacing:0.05pt;"> </font>of our new shares;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>in capital increases, in each case if excluding subscription rights, according to the assessment by the Management Board, is expedient to the shares&#8217; successful placement in view of the requirements of eligible investors and if the discount by which the issue price of the shares may be below the current stock ex-change price at the time the Management Board adopts the resolution on using authorized capital, according to the assessment by the Management Board, does not exceed the extent necessary for a successful placement and in any case does not exceed 10% of either the latest available closing price at the time when the issue price is fixed or the volume-weighted average price over a period of up to five trading days ending on the day on which the issue price is so fixed;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>in case<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>to be issued<font style="letter-spacing:0.05pt;"> </font>to a member<font style="letter-spacing:0.1pt;"> </font>of our Management<font style="letter-spacing:0.1pt;"> </font>Board or to another<font style="letter-spacing:0.05pt;"> </font>person<font style="letter-spacing:0.05pt;"> </font>who is employed<font style="letter-spacing:0.05pt;"> </font>by us or one of our affiliates<font style="letter-spacing:0.15pt;"> </font>and a minimum<font style="letter-spacing:0.1pt;"> </font>holding<font style="letter-spacing:0.05pt;"> </font>period<font style="letter-spacing:0.05pt;"> </font>of at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>one year<font style="letter-spacing:0.05pt;"> </font>and the obligation<font style="letter-spacing:0.1pt;"> </font>to transfer<font style="letter-spacing:0.1pt;"> </font>back the<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>event<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>beneficiary<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>not employed<font style="letter-spacing:0.05pt;"> </font>by us or one of our affiliated<font style="letter-spacing:0.15pt;"> </font>companies<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>entire<font style="letter-spacing:0.1pt;"> </font>duration<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>holding<font style="letter-spacing:0.05pt;"> </font>period<font style="letter-spacing:0.05pt;"> </font>or any other<font style="letter-spacing:0.05pt;"> </font>agreed<font style="letter-spacing:0.05pt;"> </font>period<font style="letter-spacing:0.05pt;"> </font>is agreed<font style="letter-spacing:0.05pt;"> </font>upon. Additional<font style="letter-spacing:0.05pt;"> </font>restrictions<font style="letter-spacing:0.15pt;"> </font>with regard<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>issued<font style="letter-spacing:0.05pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>be agreed<font style="letter-spacing:0.05pt;"> </font>upon; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>in order<font style="letter-spacing:0.05pt;"> </font>to be able<font style="letter-spacing:0.05pt;"> </font>to satisfy<font style="letter-spacing:0.1pt;"> </font>an option<font style="letter-spacing:0.05pt;"> </font>to acquire<font style="letter-spacing:0.05pt;"> </font>additional<font style="letter-spacing:0.1pt;"> </font>ordinary<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>or American<font style="letter-spacing:0.05pt;"> </font>Depositary Shares<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>has been agreed<font style="letter-spacing:0.05pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>issuing<font style="letter-spacing:0.05pt;"> </font>banks in connection<font style="letter-spacing:0.05pt;"> </font>with a public<font style="letter-spacing:0.05pt;"> </font>offering<font style="letter-spacing:0.1pt;"> </font>of our shares<font style="letter-spacing:0.05pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>form<font style="letter-spacing:0.05pt;"> </font>of American<font style="letter-spacing:0.05pt;"> </font>Depositary<font style="letter-spacing:0.05pt;"> </font>Shares.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total<font style="letter-spacing:0.05pt;"> </font>number<font style="letter-spacing:0.05pt;"> </font>of new shares<font style="letter-spacing:0.05pt;"> </font>issued<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>authorized<font style="letter-spacing:0.1pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>and under<font style="letter-spacing:0.05pt;"> </font>exclusion<font style="letter-spacing:0.05pt;"> </font>of subscription<font style="letter-spacing:0.1pt;"> </font>rights pursuant<font style="letter-spacing:0.05pt;"> </font>to bullets<font style="letter-spacing:0.1pt;"> </font>one through<font style="letter-spacing:0.05pt;"> </font>three<font style="letter-spacing:0.05pt;"> </font>and six<font style="letter-spacing:0.05pt;"> </font>above may<font style="letter-spacing:0.05pt;"> </font>not exceed<font style="letter-spacing:0.05pt;"> </font>20% of the<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>capital,<font style="letter-spacing:0.1pt;"> </font>either<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>time that the amendment to the Articles of Association (<font style="font-style:italic;">Satzung</font>), resolved upon by the general meeting of June 26, 2020, came into effect or, if<font style="letter-spacing:0.05pt;"> </font>lower,<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>of utilization of the<font style="letter-spacing:0.05pt;"> </font>authorization.<font style="letter-spacing:0.1pt;"> </font>To be counted<font style="letter-spacing:0.05pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>the aforementioned<font style="letter-spacing:0.15pt;"> </font>20% limit<font style="letter-spacing:0.1pt;"> </font>are:<font style="letter-spacing:0.05pt;"> </font>(i)<font style="letter-spacing:0.05pt;"> </font>those<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>issued<font style="letter-spacing:0.05pt;"> </font>or to be issued<font style="letter-spacing:0.05pt;"> </font>to service<font style="letter-spacing:0.1pt;"> </font>conversion<font style="letter-spacing:0.05pt;"> </font>or option<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>or conversion<font style="letter-spacing:0.05pt;"> </font>or option<font style="letter-spacing:0.05pt;"> </font>obligations<font style="letter-spacing:0.1pt;"> </font>or tender<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>issuer<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>bonds, if<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>bonds have been issued<font style="letter-spacing:0.05pt;"> </font>during the<font style="letter-spacing:0.05pt;"> </font>term<font style="letter-spacing:0.05pt;"> </font>of this<font style="letter-spacing:0.05pt;"> </font>authorization<font style="letter-spacing:0.15pt;"> </font>up to the<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>of its<font style="letter-spacing:0.05pt;"> </font>exercise,<font style="letter-spacing:0.1pt;"> </font>excluding<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>subscription<font style="letter-spacing:0.1pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>of shareholders,<font style="letter-spacing:0.1pt;"> </font>as well<font style="letter-spacing:0.05pt;"> </font>as, to a certain<font style="letter-spacing:0.1pt;"> </font>extent<font style="letter-spacing:0.05pt;"> </font>(ii)<font style="letter-spacing:0.1pt;"> </font>treasury<font style="letter-spacing:0.1pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>have been disposed<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>exclusion<font style="letter-spacing:0.05pt;"> </font>of subscription<font style="letter-spacing:0.1pt;"> </font>rights during<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>term<font style="letter-spacing:0.05pt;"> </font>of this<font style="letter-spacing:0.05pt;"> </font>authorization<font style="letter-spacing:0.15pt;"> </font>(except<font style="letter-spacing:0.05pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>case<font style="letter-spacing:0.05pt;"> </font>of certain<font style="letter-spacing:0.1pt;"> </font>exceptions<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>resolution<font style="letter-spacing:0.1pt;"> </font>to item<font style="letter-spacing:0.05pt;"> </font>no. 8 of the general<font style="letter-spacing:0.05pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>of August 19, 2019).</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Corporate Purpose of our Company</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business<font style="letter-spacing:0.05pt;"> </font>objective,<font style="letter-spacing:0.1pt;"> </font>as described<font style="letter-spacing:0.1pt;"> </font>in &#167; 2 of our Articles<font style="letter-spacing:0.1pt;"> </font>of Association<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Satzun</font><font style="font-style:italic;letter-spacing:0.05pt;">g</font>), is<font style="letter-spacing:0.05pt;"> </font>to research<font style="letter-spacing:0.1pt;"> </font>and develop,<font style="letter-spacing:0.05pt;"> </font>as well<font style="letter-spacing:0.05pt;"> </font>as to manufacture<font style="letter-spacing:0.1pt;"> </font>and market<font style="letter-spacing:0.1pt;"> </font>immunological<font style="letter-spacing:0.15pt;"> </font>and RNA-based drugs<font style="letter-spacing:0.05pt;"> </font>and test<font style="letter-spacing:0.05pt;"> </font>methods<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the diagnosis,<font style="letter-spacing:0.05pt;"> </font>prevention<font style="letter-spacing:0.1pt;"> </font>and treatment<font style="letter-spacing:0.15pt;"> </font>of cancer,<font style="letter-spacing:0.05pt;"> </font>infectious<font style="letter-spacing:0.1pt;"> </font>diseases<font style="letter-spacing:0.1pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>serious<font style="letter-spacing:0.05pt;"> </font>diseases.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Shareholders&#8217;<font style="letter-spacing:0.05pt;"> </font>Meetings<font style="letter-spacing:0.05pt;"> </font>and Voting Rights</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant<font style="letter-spacing:0.05pt;"> </font>to our Articles<font style="letter-spacing:0.1pt;"> </font>of Association<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Satzun</font><font style="font-style:italic;letter-spacing:0.05pt;">g</font>), shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meetings<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>be held<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>our seat<font style="letter-spacing:0.05pt;"> </font>or in any municipality<font style="letter-spacing:0.15pt;"> </font>in Germany<font style="letter-spacing:0.05pt;"> </font>with more<font style="letter-spacing:0.05pt;"> </font>than<font style="letter-spacing:0.05pt;"> </font>500,000 inhabitants.<font style="letter-spacing:0.1pt;"> </font>Generally,<font style="letter-spacing:0.05pt;"> </font>shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meetings<font style="letter-spacing:0.1pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>convened<font style="letter-spacing:0.05pt;"> </font>by our Management<font style="letter-spacing:0.1pt;"> </font>Board, or our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board. Shareholders<font style="letter-spacing:0.1pt;"> </font>representing<font style="letter-spacing:0.1pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>aggregate<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>five percent<font style="letter-spacing:0.05pt;"> </font>of our ordinary<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>may,<font style="letter-spacing:0.05pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>to certain<font style="letter-spacing:0.1pt;"> </font>formal<font style="letter-spacing:0.1pt;"> </font>prerequisites,<font style="letter-spacing:0.15pt;"> </font>request<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>a shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting be convened.<font style="letter-spacing:0.05pt;"> </font>Shareholders<font style="letter-spacing:0.1pt;"> </font>representing<font style="letter-spacing:0.1pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>aggregate<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>five<font style="letter-spacing:0.05pt;"> </font>percent<font style="letter-spacing:0.05pt;"> </font>of our ordinary<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>or owning shares<font style="letter-spacing:0.05pt;"> </font>with an aggregate<font style="letter-spacing:0.1pt;"> </font>nominal<font style="letter-spacing:0.05pt;"> </font>value<font style="letter-spacing:0.05pt;"> </font>of at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>&#8364;500,000 may<font style="letter-spacing:0.05pt;"> </font>request<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>addition<font style="letter-spacing:0.05pt;"> </font>of one or several<font style="letter-spacing:0.1pt;"> </font>items<font style="letter-spacing:0.1pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>agenda<font style="letter-spacing:0.05pt;"> </font>of any shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting.<font style="letter-spacing:0.1pt;"> </font>Shareholders&#8217; meetings may be summoned either via publication in the German Federal Gazette (<font style="font-style:italic;">Bundesanzeiger</font>) or via mail or email, in each case generally at least 36 days before the meeting.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shareholders<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>participate<font style="letter-spacing:0.15pt;"> </font>and vote<font style="letter-spacing:0.05pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>they<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>registered<font style="letter-spacing:0.1pt;"> </font>as a shareholder with the<font style="letter-spacing:0.05pt;"> </font>Company&#8217;s<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>register.<font style="letter-spacing:0.1pt;"> </font>A shareholder<font style="letter-spacing:0.1pt;"> </font>who wishes<font style="letter-spacing:0.05pt;"> </font>to attend<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting&#8212;either<font style="letter-spacing:0.15pt;"> </font>in person<font style="letter-spacing:0.05pt;"> </font>or by proxy, which may<font style="letter-spacing:0.05pt;"> </font>also<font style="letter-spacing:0.05pt;"> </font>be appointed<font style="letter-spacing:0.05pt;"> </font>by us (<font style="font-style:italic;">Stimmrechtsvertrete</font><font style="font-style:italic;letter-spacing:0.15pt;">r</font>)&#8212;must<font style="letter-spacing:0.05pt;"> </font>register<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>meeting, which registration<font style="letter-spacing:0.15pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>occur<font style="letter-spacing:0.05pt;"> </font>no later<font style="letter-spacing:0.1pt;"> </font>than<font style="letter-spacing:0.05pt;"> </font>six<font style="letter-spacing:0.05pt;"> </font>days before<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>(or<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>a later<font style="letter-spacing:0.1pt;"> </font>date,<font style="letter-spacing:0.05pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>so determined<font style="letter-spacing:0.1pt;"> </font>by our Management<font style="letter-spacing:0.1pt;"> </font>Board).</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each share<font style="letter-spacing:0.05pt;"> </font>carries<font style="letter-spacing:0.1pt;"> </font>one vote<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>a shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting.<font style="letter-spacing:0.1pt;"> </font>Resolutions<font style="letter-spacing:0.05pt;"> </font>are,<font style="letter-spacing:0.05pt;"> </font>in accordance<font style="letter-spacing:0.1pt;"> </font>with our Articles<font style="letter-spacing:0.1pt;"> </font>of Association<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Satzun</font><font style="font-style:italic;letter-spacing:0.05pt;">g</font>), generally<font style="letter-spacing:0.1pt;"> </font>taken<font style="letter-spacing:0.05pt;"> </font>by simple<font style="letter-spacing:0.1pt;"> </font>majority<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>votes<font style="letter-spacing:0.05pt;"> </font>cast.<font style="letter-spacing:0.05pt;"> </font>However, under<font style="letter-spacing:0.05pt;"> </font>applicable<font style="letter-spacing:0.1pt;"> </font>German and European<font style="letter-spacing:0.05pt;"> </font>law, a number<font style="letter-spacing:0.05pt;"> </font>of resolutions<font style="letter-spacing:0.1pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>be passed<font style="letter-spacing:0.05pt;"> </font>by either<font style="letter-spacing:0.1pt;"> </font>a three-quarter<font style="letter-spacing:0.15pt;"> </font>majority<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>votes<font style="letter-spacing:0.05pt;"> </font>cast<font style="letter-spacing:0.05pt;"> </font>or a three-quarter<font style="letter-spacing:0.15pt;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">208</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">majority</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">share</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">capital</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">represented</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">meeting.</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fact</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in these</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cases</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">quorum</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is determined</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in relation</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">share</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">capital</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or shares</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">present</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(as</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">opposed to, for</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">example,</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">all</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shares</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eligible</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to vote)</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">means</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">holders</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of a minority</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our shares</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">potentially</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">control</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">outcome</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of resolutions.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Claims<font style="letter-spacing:0.05pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>Directors<font style="letter-spacing:0.05pt;"> </font>and Shareholders&#8217;<font style="letter-spacing:0.05pt;"> </font>Derivative<font style="letter-spacing:0.05pt;"> </font>Actions</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under German<font style="letter-spacing:0.05pt;"> </font>law, generally,<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>company,<font style="letter-spacing:0.05pt;"> </font>rather<font style="letter-spacing:0.1pt;"> </font>than<font style="letter-spacing:0.05pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>shareholders,<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>proper<font style="letter-spacing:0.05pt;"> </font>claimant<font style="letter-spacing:0.1pt;"> </font>in an action with respect<font style="letter-spacing:0.1pt;"> </font>to a wrong committed<font style="letter-spacing:0.1pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>company,<font style="letter-spacing:0.05pt;"> </font>or in cases<font style="letter-spacing:0.05pt;"> </font>where there<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>an irregularity<font style="letter-spacing:0.15pt;"> </font>in the company&#8217;s<font style="letter-spacing:0.05pt;"> </font>internal<font style="letter-spacing:0.1pt;"> </font>management<font style="letter-spacing:0.1pt;"> </font>or supervision.<font style="letter-spacing:0.1pt;"> </font>Therefore,<font style="letter-spacing:0.1pt;"> </font>such claims<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>only be raised<font style="letter-spacing:0.05pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>company represented<font style="letter-spacing:0.1pt;"> </font>by its<font style="letter-spacing:0.05pt;"> </font>management<font style="letter-spacing:0.1pt;"> </font>board,<font style="letter-spacing:0.05pt;"> </font>or, in the<font style="letter-spacing:0.05pt;"> </font>case<font style="letter-spacing:0.05pt;"> </font>of a wrong committed<font style="letter-spacing:0.1pt;"> </font>by a member<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Management Board, by the<font style="letter-spacing:0.05pt;"> </font>Supervisory<font style="letter-spacing:0.05pt;"> </font>Board. This concerns,<font style="letter-spacing:0.05pt;"> </font>in particular,<font style="letter-spacing:0.15pt;"> </font>claims<font style="letter-spacing:0.1pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>members<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board or the<font style="letter-spacing:0.05pt;"> </font>Supervisory<font style="letter-spacing:0.05pt;"> </font>Board.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">However, pursuant<font style="letter-spacing:0.05pt;"> </font>to German<font style="letter-spacing:0.05pt;"> </font>case<font style="letter-spacing:0.05pt;"> </font>law, the<font style="letter-spacing:0.05pt;"> </font>Supervisory<font style="letter-spacing:0.05pt;"> </font>Board is<font style="letter-spacing:0.05pt;"> </font>obliged<font style="letter-spacing:0.05pt;"> </font>to pursue<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>company&#8217;s<font style="letter-spacing:0.05pt;"> </font>claims against<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board, unless<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>interest<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>company<font style="letter-spacing:0.05pt;"> </font>keeps<font style="letter-spacing:0.05pt;"> </font>them<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>doing so. Further,<font style="letter-spacing:0.05pt;"> </font>the Management<font style="letter-spacing:0.1pt;"> </font>Board, or, if<font style="letter-spacing:0.05pt;"> </font>a claim<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>a member<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board, the<font style="letter-spacing:0.05pt;"> </font>Supervisory<font style="letter-spacing:0.05pt;"> </font>Board, is obliged<font style="letter-spacing:0.05pt;"> </font>to pursue<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>company&#8217;s<font style="letter-spacing:0.05pt;"> </font>claims<font style="letter-spacing:0.1pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>designated<font style="letter-spacing:0.1pt;"> </font>individuals<font style="letter-spacing:0.1pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>so resolved<font style="letter-spacing:0.05pt;"> </font>by a simple<font style="letter-spacing:0.1pt;"> </font>majority<font style="letter-spacing:0.1pt;"> </font>of votes<font style="letter-spacing:0.05pt;"> </font>cast<font style="letter-spacing:0.05pt;"> </font>during<font style="letter-spacing:0.05pt;"> </font>a shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting.<font style="letter-spacing:0.1pt;"> </font>With<font style="letter-spacing:0.05pt;"> </font>a simple<font style="letter-spacing:0.1pt;"> </font>majority<font style="letter-spacing:0.1pt;"> </font>of votes,<font style="letter-spacing:0.05pt;"> </font>shareholders<font style="letter-spacing:0.1pt;"> </font>can also<font style="letter-spacing:0.05pt;"> </font>request<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>a representative<font style="letter-spacing:0.15pt;"> </font>pursue<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>claim<font style="letter-spacing:0.1pt;"> </font>on behalf<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>company.<font style="letter-spacing:0.05pt;"> </font>The court<font style="letter-spacing:0.05pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>appoint<font style="letter-spacing:0.05pt;"> </font>such a representative<font style="letter-spacing:0.15pt;"> </font>upon the request<font style="letter-spacing:0.05pt;"> </font>of shareholders<font style="letter-spacing:0.1pt;"> </font>holding<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>10% of the<font style="letter-spacing:0.05pt;"> </font>company&#8217;s<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>or a participation<font style="letter-spacing:0.15pt;"> </font>of at<font style="letter-spacing:0.05pt;"> </font>least &#8364;1,000,000 in the<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>capital.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>company<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>unable<font style="letter-spacing:0.05pt;"> </font>to fulfill<font style="letter-spacing:0.1pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>third-party<font style="letter-spacing:0.15pt;"> </font>obligations,<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>company&#8217;s<font style="letter-spacing:0.05pt;"> </font>creditors<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>pursue<font style="letter-spacing:0.05pt;"> </font>the company&#8217;s<font style="letter-spacing:0.05pt;"> </font>damage<font style="letter-spacing:0.05pt;"> </font>claims<font style="letter-spacing:0.1pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>members<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board for<font style="letter-spacing:0.05pt;"> </font>certain<font style="letter-spacing:0.1pt;"> </font>wrongdoings.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under certain<font style="letter-spacing:0.1pt;"> </font>circumstances,<font style="letter-spacing:0.15pt;"> </font>shareholders<font style="letter-spacing:0.1pt;"> </font>can bring<font style="letter-spacing:0.05pt;"> </font>forward<font style="letter-spacing:0.05pt;"> </font>damage<font style="letter-spacing:0.05pt;"> </font>claims<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>company<font style="letter-spacing:0.05pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>its management<font style="letter-spacing:0.1pt;"> </font>on their<font style="letter-spacing:0.05pt;"> </font>own behalf.<font style="letter-spacing:0.05pt;"> </font>In order<font style="letter-spacing:0.05pt;"> </font>to bring<font style="letter-spacing:0.05pt;"> </font>forward<font style="letter-spacing:0.05pt;"> </font>such a claim<font style="letter-spacing:0.1pt;"> </font>one shareholder<font style="letter-spacing:0.1pt;"> </font>alone<font style="letter-spacing:0.05pt;"> </font>or together<font style="letter-spacing:0.1pt;"> </font>with other<font style="letter-spacing:0.05pt;"> </font>shareholders<font style="letter-spacing:0.1pt;"> </font>needs<font style="letter-spacing:0.05pt;"> </font>to hold at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>1% of the<font style="letter-spacing:0.05pt;"> </font>company&#8217;s<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>or a participation<font style="letter-spacing:0.15pt;"> </font>of &#8364;100,000 in the share<font style="letter-spacing:0.05pt;"> </font>capital.<font style="letter-spacing:0.1pt;"> </font>Additionally,<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>claimant(s)<font style="letter-spacing:0.15pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>comply<font style="letter-spacing:0.05pt;"> </font>with special<font style="letter-spacing:0.1pt;"> </font>claim<font style="letter-spacing:0.1pt;"> </font>approval<font style="letter-spacing:0.05pt;"> </font>procedures<font style="letter-spacing:0.1pt;"> </font>conducted before<font style="letter-spacing:0.05pt;"> </font>a competent<font style="letter-spacing:0.1pt;"> </font>court<font style="letter-spacing:0.05pt;"> </font>which will<font style="letter-spacing:0.05pt;"> </font>allow<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>pertinent<font style="letter-spacing:0.1pt;"> </font>request<font style="letter-spacing:0.05pt;"> </font>only if<font style="letter-spacing:0.05pt;"> </font>there<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>circumstances<font style="letter-spacing:0.15pt;"> </font>justifying<font style="letter-spacing:0.1pt;"> </font>the assumption<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>damage<font style="letter-spacing:0.05pt;"> </font>has been afflicted<font style="letter-spacing:0.15pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>company<font style="letter-spacing:0.05pt;"> </font>by improper<font style="letter-spacing:0.1pt;"> </font>conduct<font style="letter-spacing:0.05pt;"> </font>or a gross<font style="letter-spacing:0.05pt;"> </font>breach<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>law or the<font style="letter-spacing:0.05pt;"> </font>articles<font style="letter-spacing:0.1pt;"> </font>of association.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dividend Rights</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under German<font style="letter-spacing:0.05pt;"> </font>law, distributions<font style="letter-spacing:0.15pt;"> </font>of dividends<font style="letter-spacing:0.05pt;"> </font>on shares<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>a given<font style="letter-spacing:0.05pt;"> </font>fiscal<font style="letter-spacing:0.1pt;"> </font>year<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>determined<font style="letter-spacing:0.1pt;"> </font>by a process<font style="letter-spacing:0.05pt;"> </font>in which the<font style="letter-spacing:0.05pt;"> </font>management<font style="letter-spacing:0.1pt;"> </font>board and supervisory<font style="letter-spacing:0.05pt;"> </font>board submit<font style="letter-spacing:0.05pt;"> </font>a proposal<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>company&#8217;s<font style="letter-spacing:0.05pt;"> </font>annual general<font style="letter-spacing:0.05pt;"> </font>shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>held<font style="letter-spacing:0.05pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>subsequent<font style="letter-spacing:0.05pt;"> </font>fiscal<font style="letter-spacing:0.1pt;"> </font>year<font style="letter-spacing:0.05pt;"> </font>and such annual<font style="letter-spacing:0.05pt;"> </font>general<font style="letter-spacing:0.05pt;"> </font>shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting adopts<font style="letter-spacing:0.05pt;"> </font>a resolution.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">German<font style="letter-spacing:0.05pt;"> </font>law provides<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>a resolution<font style="letter-spacing:0.1pt;"> </font>concerning<font style="letter-spacing:0.05pt;"> </font>dividends<font style="letter-spacing:0.05pt;"> </font>and distribution<font style="letter-spacing:0.15pt;"> </font>thereof<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>be adopted<font style="letter-spacing:0.05pt;"> </font>only if the<font style="letter-spacing:0.05pt;"> </font>company&#8217;s<font style="letter-spacing:0.05pt;"> </font>unconsolidated<font style="letter-spacing:0.1pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>statements<font style="letter-spacing:0.15pt;"> </font>prepared<font style="letter-spacing:0.05pt;"> </font>in accordance<font style="letter-spacing:0.1pt;"> </font>with German<font style="letter-spacing:0.05pt;"> </font>law show net<font style="letter-spacing:0.05pt;"> </font>retained profits.<font style="letter-spacing:0.1pt;"> </font>In determining<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>profit<font style="letter-spacing:0.1pt;"> </font>available<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>distribution,<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>result<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>relevant<font style="letter-spacing:0.1pt;"> </font>year<font style="letter-spacing:0.05pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>be adjusted<font style="letter-spacing:0.05pt;"> </font>for profits<font style="letter-spacing:0.1pt;"> </font>and losses<font style="letter-spacing:0.05pt;"> </font>brought<font style="letter-spacing:0.05pt;"> </font>forward<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>previous<font style="letter-spacing:0.05pt;"> </font>year<font style="letter-spacing:0.05pt;"> </font>and for<font style="letter-spacing:0.05pt;"> </font>withdrawals<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>or transfers<font style="letter-spacing:0.1pt;"> </font>to reserves. Certain<font style="letter-spacing:0.05pt;"> </font>reserves<font style="letter-spacing:0.1pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>required<font style="letter-spacing:0.1pt;"> </font>by law and must<font style="letter-spacing:0.05pt;"> </font>be deducted<font style="letter-spacing:0.05pt;"> </font>when calculating<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>profit<font style="letter-spacing:0.1pt;"> </font>available<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>distribution.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shareholders<font style="letter-spacing:0.1pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>participate<font style="letter-spacing:0.15pt;"> </font>in profit<font style="letter-spacing:0.1pt;"> </font>distributions<font style="letter-spacing:0.15pt;"> </font>in proportion<font style="letter-spacing:0.1pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>number<font style="letter-spacing:0.05pt;"> </font>of shares<font style="letter-spacing:0.05pt;"> </font>they<font style="letter-spacing:0.05pt;"> </font>hold. Dividends<font style="letter-spacing:0.05pt;"> </font>on shares<font style="letter-spacing:0.05pt;"> </font>resolved<font style="letter-spacing:0.05pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>general<font style="letter-spacing:0.05pt;"> </font>shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>paid<font style="letter-spacing:0.05pt;"> </font>annually,<font style="letter-spacing:0.05pt;"> </font>shortly<font style="letter-spacing:0.05pt;"> </font>after<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>general shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting,<font style="letter-spacing:0.1pt;"> </font>in compliance<font style="letter-spacing:0.1pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>rules<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>respective<font style="letter-spacing:0.1pt;"> </font>clearing<font style="letter-spacing:0.1pt;"> </font>system.<font style="letter-spacing:0.05pt;"> </font>Dividend<font style="letter-spacing:0.05pt;"> </font>payment<font style="letter-spacing:0.05pt;"> </font>claims are<font style="letter-spacing:0.05pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>to a three-year<font style="letter-spacing:0.1pt;"> </font>statute<font style="letter-spacing:0.1pt;"> </font>of limitation<font style="letter-spacing:0.15pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>company&#8217;s<font style="letter-spacing:0.05pt;"> </font>favor.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Authorization<font style="letter-spacing:0.05pt;"> </font>to Purchase and Sell<font style="letter-spacing:0.05pt;"> </font>Our Own Shares</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may<font style="letter-spacing:0.05pt;"> </font>not purchase<font style="letter-spacing:0.05pt;"> </font>our own shares<font style="letter-spacing:0.05pt;"> </font>unless<font style="letter-spacing:0.05pt;"> </font>authorized<font style="letter-spacing:0.1pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>or in other<font style="letter-spacing:0.05pt;"> </font>very limited<font style="letter-spacing:0.1pt;"> </font>circumstances<font style="letter-spacing:0.15pt;"> </font>as set<font style="letter-spacing:0.05pt;"> </font>out in the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>Stock Corporation<font style="letter-spacing:0.05pt;"> </font>Act. The Company&#8217;s<font style="letter-spacing:0.05pt;"> </font>shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting held<font style="letter-spacing:0.05pt;"> </font>on August 19, 2019 authorized<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board until<font style="letter-spacing:0.05pt;"> </font>August 18, 2024, provided<font style="letter-spacing:0.05pt;"> </font>it<font style="letter-spacing:0.05pt;"> </font>complies<font style="letter-spacing:0.1pt;"> </font>with the legal<font style="letter-spacing:0.05pt;"> </font>requirement<font style="letter-spacing:0.15pt;"> </font>of equal<font style="letter-spacing:0.05pt;"> </font>treatment,<font style="letter-spacing:0.15pt;"> </font>to acquire<font style="letter-spacing:0.05pt;"> </font>treasury<font style="letter-spacing:0.1pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>up to a total<font style="letter-spacing:0.05pt;"> </font>of 10% of the<font style="letter-spacing:0.05pt;"> </font>Company&#8217;s<font style="letter-spacing:0.05pt;"> </font>share capital<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>relevant<font style="letter-spacing:0.1pt;"> </font>resolution<font style="letter-spacing:0.1pt;"> </font>or at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>authorization<font style="letter-spacing:0.15pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>exercised.<font style="letter-spacing:0.1pt;"> </font>These shares<font style="letter-spacing:0.05pt;"> </font>held<font style="letter-spacing:0.05pt;"> </font>by the Company (including<font style="letter-spacing:0.1pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>attributable<font style="letter-spacing:0.15pt;"> </font>to it<font style="letter-spacing:0.05pt;"> </font>pursuant<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>AktG) must<font style="letter-spacing:0.05pt;"> </font>never<font style="letter-spacing:0.05pt;"> </font>exceed<font style="letter-spacing:0.05pt;"> </font>10% of the<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>capital. The shares<font style="letter-spacing:0.05pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>be purchased<font style="letter-spacing:0.05pt;"> </font>(i)<font style="letter-spacing:0.05pt;"> </font>through<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>stock<font style="letter-spacing:0.05pt;"> </font>exchange,<font style="letter-spacing:0.05pt;"> </font>(ii)<font style="letter-spacing:0.1pt;"> </font>by means<font style="letter-spacing:0.05pt;"> </font>of a public<font style="letter-spacing:0.05pt;"> </font>offer<font style="letter-spacing:0.05pt;"> </font>directed<font style="letter-spacing:0.1pt;"> </font>to all shareholders<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Company, (iii)<font style="letter-spacing:0.1pt;"> </font>by means<font style="letter-spacing:0.05pt;"> </font>of a public<font style="letter-spacing:0.05pt;"> </font>invitation<font style="letter-spacing:0.1pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>shareholders<font style="letter-spacing:0.1pt;"> </font>to make<font style="letter-spacing:0.05pt;"> </font>a sales<font style="letter-spacing:0.05pt;"> </font>offer<font style="letter-spacing:0.05pt;"> </font>or (iv)<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Bill<font style="letter-spacing:0.05pt;"> </font>&amp; Melinda<font style="letter-spacing:0.05pt;"> </font>Gates<font style="letter-spacing:0.05pt;"> </font>Foundation<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>very<font style="letter-spacing:0.05pt;"> </font>limited<font style="letter-spacing:0.1pt;"> </font>circumstances<font style="letter-spacing:0.15pt;"> </font>as specified<font style="letter-spacing:0.1pt;"> </font>in the authorization.<font style="letter-spacing:0.15pt;"> </font>Such shares<font style="letter-spacing:0.05pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>not be purchased<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>trading<font style="letter-spacing:0.05pt;"> </font>purposes.<font style="letter-spacing:0.05pt;"> </font>The Management<font style="letter-spacing:0.1pt;"> </font>Board is<font style="letter-spacing:0.05pt;"> </font>authorized<font style="letter-spacing:0.1pt;"> </font>to use the<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>only as specified<font style="letter-spacing:0.1pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>authorization.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">209</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Squeeze-Out</font><font style="letter-spacing:0.05pt;"> </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">of Minority</font><font style="letter-spacing:0.05pt;"> </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Shareholders</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under German<font style="letter-spacing:0.05pt;"> </font>law, the<font style="letter-spacing:0.05pt;"> </font>shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>of a stock<font style="letter-spacing:0.05pt;"> </font>corporation<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>resolve,<font style="letter-spacing:0.05pt;"> </font>upon request<font style="letter-spacing:0.05pt;"> </font>of a shareholder<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>holds<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>95% of the<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>capital,<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>held<font style="letter-spacing:0.05pt;"> </font>by any remaining<font style="letter-spacing:0.1pt;"> </font>minority shareholders<font style="letter-spacing:0.1pt;"> </font>be transferred<font style="letter-spacing:0.15pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>majority<font style="letter-spacing:0.1pt;"> </font>shareholder<font style="letter-spacing:0.1pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>payment<font style="letter-spacing:0.05pt;"> </font>of &#8220;adequate<font style="letter-spacing:0.05pt;"> </font>cash<font style="letter-spacing:0.05pt;"> </font>compensation&#8221; (<font style="font-style:italic;">Ausschluss</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">von Minderheitsaktion&#228;re</font><font style="font-style:italic;letter-spacing:0.2pt;">n</font>). This amount<font style="letter-spacing:0.05pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>take<font style="letter-spacing:0.05pt;"> </font>into<font style="letter-spacing:0.05pt;"> </font>account<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>full<font style="letter-spacing:0.05pt;"> </font>value<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>company<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the time<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>resolution,<font style="letter-spacing:0.1pt;"> </font>which is<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>determined<font style="letter-spacing:0.1pt;"> </font>using<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>future<font style="letter-spacing:0.05pt;"> </font>earnings<font style="letter-spacing:0.05pt;"> </font>value<font style="letter-spacing:0.05pt;"> </font>method (<font style="font-style:italic;">Ertragswertmethod</font><font style="font-style:italic;letter-spacing:0.1pt;">e</font>).</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A squeeze-out<font style="letter-spacing:0.1pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>context<font style="letter-spacing:0.05pt;"> </font>of a merger<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">umwandlungsrechtlicher</font><font style="font-style:italic;letter-spacing:0.1pt;"> </font><font style="font-style:italic;">Squeeze-Ou</font><font style="font-style:italic;letter-spacing:0.05pt;">t</font>) only requires<font style="letter-spacing:0.1pt;"> </font>a majority shareholder<font style="letter-spacing:0.1pt;"> </font>to hold at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>90% of the<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>capital.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidation Rights</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Apart<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>liquidation,<font style="letter-spacing:0.1pt;"> </font>e.g., as a result<font style="letter-spacing:0.1pt;"> </font>of insolvency<font style="letter-spacing:0.05pt;"> </font>proceedings,<font style="letter-spacing:0.1pt;"> </font>we may<font style="letter-spacing:0.05pt;"> </font>be liquidated<font style="letter-spacing:0.1pt;"> </font>with a vote<font style="letter-spacing:0.05pt;"> </font>of the holders<font style="letter-spacing:0.05pt;"> </font>of at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>three-quarters<font style="letter-spacing:0.15pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>represented<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>which such a vote<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>taken.<font style="letter-spacing:0.05pt;"> </font>If<font style="letter-spacing:0.05pt;"> </font>we are<font style="letter-spacing:0.05pt;"> </font>liquidated,<font style="letter-spacing:0.1pt;"> </font>any assets<font style="letter-spacing:0.05pt;"> </font>remaining<font style="letter-spacing:0.1pt;"> </font>after<font style="letter-spacing:0.1pt;"> </font>all<font style="letter-spacing:0.05pt;"> </font>of our liabilities<font style="letter-spacing:0.15pt;"> </font>have been paid<font style="letter-spacing:0.05pt;"> </font>off<font style="letter-spacing:0.05pt;"> </font>would be distributed<font style="letter-spacing:0.1pt;"> </font>among<font style="letter-spacing:0.05pt;"> </font>our shareholders<font style="letter-spacing:0.1pt;"> </font>in proportion<font style="letter-spacing:0.1pt;"> </font>to their<font style="letter-spacing:0.05pt;"> </font>holdings<font style="letter-spacing:0.05pt;"> </font>in accordance<font style="letter-spacing:0.1pt;"> </font>with German<font style="letter-spacing:0.05pt;"> </font>statutory<font style="letter-spacing:0.1pt;"> </font>law. The German<font style="letter-spacing:0.05pt;"> </font>Stock Corporation<font style="letter-spacing:0.05pt;"> </font>Act provides<font style="letter-spacing:0.05pt;"> </font>certain<font style="letter-spacing:0.1pt;"> </font>protections<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>creditors,<font style="letter-spacing:0.1pt;"> </font>which must<font style="letter-spacing:0.05pt;"> </font>be observed<font style="letter-spacing:0.05pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>event<font style="letter-spacing:0.05pt;"> </font>of liquidation.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">C.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_10_C"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_10_C"></a>Material Contracts</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except as otherwise disclosed in this Annual Report (including the exhibits thereto), we are not currently, and have not been in the last two years, party to any material contract, other than contracts entered into in the ordinary course of our business.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">D.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_10_D"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_10_D"></a>Exchange Controls</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are currently no legal restrictions in the Federal Republic of Germany on international capital movements and foreign exchange transactions, except in limited embargo circumstances (<font style="font-style:italic;">Teilembargo</font>) relating to certain areas, entities or persons as a result of applicable resolutions adopted by the United Nations and the European Union. Restrictions currently exist with respect to, among others, Belarus, Congo, Egypt, Eritrea, Guinea, Guinea-Bissau, Iran, Iraq, Lebanon, Libya, North Korea, Somalia, South Sudan, Sudan, Syria, Tunisia and Zimbabwe.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For statistical purposes, there are, however, limited notification requirements regarding transactions involving cross-border monetary transfers. With some exceptions, every corporation or individual residing in the Federal Republic of Germany must report to the German Central Bank (<font style="font-style:italic;">Deutsche Bundesbank</font>) (i) any payment received from, or made to, a non-resident corporation or individual that exceeds &#8364;12,500 (or the equivalent in a foreign currency) and (ii) (with the exception of individuals residing in the Federal Republic of Germany) in case the sum of claims against, or liabilities payable to, non-resident corporations or individuals exceeds &#8364;5,000,000 (or the equivalent in a foreign currency) at the end of any calendar month. Payments include cash payments made by means of direct debit, checks and bills, remittances denominated in euros and other currencies made through financial institutions, as well as netting and clearing arrangements.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">E.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_10_E"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_10_E"></a>Taxation</font></p></td></tr></table></div>
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">German<font style="letter-spacing:0.05pt;"> </font>Taxation</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following discussion addresses certain German tax consequences of acquiring, owning or disposing of the ADSs. With the exception of &#8220;&#8212;Taxation of Holders Tax Resident in Germany&#8221; below, which provides an overview of dividend taxation and of capital gains taxation with respect to holders that are residents of Germany, this discussion applies only to U.S. treaty beneficiaries (defined below) that acquire the ADSs representing our ordinary shares.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This discussion<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>based<font style="letter-spacing:0.05pt;"> </font>on domestic<font style="letter-spacing:0.1pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>laws, including,<font style="letter-spacing:0.05pt;"> </font>but not limited<font style="letter-spacing:0.1pt;"> </font>to, circulars<font style="letter-spacing:0.1pt;"> </font>issued<font style="letter-spacing:0.05pt;"> </font>by German<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>authorities,<font style="letter-spacing:0.15pt;"> </font>which, e.g., are<font style="letter-spacing:0.05pt;"> </font>not binding<font style="letter-spacing:0.05pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>courts,<font style="letter-spacing:0.05pt;"> </font>and the<font style="letter-spacing:0.05pt;"> </font>Treaty<font style="letter-spacing:0.05pt;"> </font>(defined<font style="letter-spacing:0.1pt;"> </font>below).<font style="letter-spacing:0.05pt;"> </font>It<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>based upon tax<font style="letter-spacing:0.05pt;"> </font>laws in effect<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>of filing<font style="letter-spacing:0.1pt;"> </font>of this<font style="letter-spacing:0.05pt;"> </font>report.<font style="letter-spacing:0.1pt;"> </font>These laws are<font style="letter-spacing:0.05pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>to change,<font style="letter-spacing:0.05pt;"> </font>possibly<font style="letter-spacing:0.05pt;"> </font>with retroactive<font style="letter-spacing:0.15pt;"> </font>effect.<font style="letter-spacing:0.1pt;"> </font>For example,<font style="letter-spacing:0.05pt;"> </font>certain<font style="letter-spacing:0.1pt;"> </font>member<font style="letter-spacing:0.1pt;"> </font>states<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>European<font style="letter-spacing:0.05pt;"> </font>Union are<font style="letter-spacing:0.05pt;"> </font>considering<font style="letter-spacing:0.1pt;"> </font>introducing<font style="letter-spacing:0.1pt;"> </font>a financial<font style="letter-spacing:0.1pt;"> </font>transaction<font style="letter-spacing:0.1pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">Finanztransaktionssteue</font><font style="font-style:italic;letter-spacing:0.2pt;">r</font>) which, if<font style="letter-spacing:0.05pt;"> </font>introduced,<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>also<font style="letter-spacing:0.05pt;"> </font>be applicable<font style="letter-spacing:0.1pt;"> </font>on sales<font style="letter-spacing:0.05pt;"> </font>and/or<font style="letter-spacing:0.05pt;"> </font>transfer<font style="letter-spacing:0.1pt;"> </font>of ADSs.<font style="letter-spacing:-0.05pt;"> </font>In addition,<font style="letter-spacing:0.05pt;"> </font>in Germany,<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>example,<font style="letter-spacing:0.05pt;"> </font>there<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>currently<font style="letter-spacing:0.1pt;"> </font>ongoing discussions<font style="letter-spacing:0.1pt;"> </font>on an increase<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>top tax<font style="letter-spacing:0.05pt;"> </font>rate,<font style="letter-spacing:0.05pt;"> </font>which may<font style="letter-spacing:0.05pt;"> </font>also<font style="letter-spacing:0.05pt;"> </font>have an effect<font style="letter-spacing:0.1pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>consequences<font style="letter-spacing:0.05pt;"> </font>of acquiring,<font style="letter-spacing:0.1pt;"> </font>owning and disposing<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>ADSs.<font style="letter-spacing:-0.05pt;"> </font>There<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>no assurance<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>authorities<font style="letter-spacing:0.15pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>not challenge<font style="letter-spacing:0.1pt;"> </font>one or more<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>consequences<font style="letter-spacing:0.05pt;"> </font>described<font style="letter-spacing:0.1pt;"> </font>in this<font style="letter-spacing:0.05pt;"> </font>section.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">210</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, this discussion is based upon the assumption that each obligation in the deposit agreement and any related agreement</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be performed</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in accordance</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with its</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">terms.</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">does not purport</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to be a comprehensive or exhaustive</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">description</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of all</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">German</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tax</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">considerations</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be of relevance</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">context</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of acquiring, owning and disposing</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of ADSs.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The tax information presented in this report is not a substitute for tax advice. Prospective holders of ADSs should consult their own tax<font style="letter-spacing:0.05pt;"> </font>advisors<font style="letter-spacing:0.05pt;"> </font>regarding<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>consequences<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>purchase,<font style="letter-spacing:0.05pt;"> </font>ownership, disposition,<font style="letter-spacing:0.1pt;"> </font>donation<font style="letter-spacing:0.05pt;"> </font>or inheritance<font style="letter-spacing:0.1pt;"> </font>of ADSs<font style="letter-spacing:-0.05pt;"> </font>in light<font style="letter-spacing:0.05pt;"> </font>of their<font style="letter-spacing:0.05pt;"> </font>particular<font style="letter-spacing:0.15pt;"> </font>circumstances,<font style="letter-spacing:0.15pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>effect<font style="letter-spacing:0.1pt;"> </font>of any state,<font style="letter-spacing:0.05pt;"> </font>local,<font style="letter-spacing:0.05pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>foreign<font style="letter-spacing:0.05pt;"> </font>or domestic<font style="letter-spacing:0.1pt;"> </font>laws or changes<font style="letter-spacing:0.05pt;"> </font>in tax<font style="letter-spacing:0.05pt;"> </font>law or interpretation.<font style="letter-spacing:0.15pt;"> </font>The same<font style="letter-spacing:0.05pt;"> </font>applies<font style="letter-spacing:0.05pt;"> </font>with respect<font style="letter-spacing:0.1pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>rules<font style="letter-spacing:0.05pt;"> </font>governing<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>refund<font style="letter-spacing:0.05pt;"> </font>of any German<font style="letter-spacing:0.05pt;"> </font>dividend<font style="letter-spacing:0.05pt;"> </font>withholding<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">Kapitalertragsteue</font><font style="font-style:italic;letter-spacing:0.15pt;">r</font>) withheld.<font style="letter-spacing:0.05pt;"> </font>Only an individual<font style="letter-spacing:0.1pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>consultation<font style="letter-spacing:0.1pt;"> </font>can appropriately<font style="letter-spacing:0.15pt;"> </font>account<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>particular<font style="letter-spacing:0.15pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>situation<font style="letter-spacing:0.1pt;"> </font>of each investor.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">General</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the<font style="letter-spacing:0.05pt;"> </font>circular<font style="letter-spacing:0.1pt;"> </font>issued<font style="letter-spacing:0.05pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>Federal<font style="letter-spacing:0.05pt;"> </font>Ministry<font style="letter-spacing:0.1pt;"> </font>of Finance<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">BMF-Schreibe</font><font style="font-style:italic;letter-spacing:0.1pt;">n</font>), dated<font style="letter-spacing:0.05pt;"> </font>May 24, 2013, reference<font style="letter-spacing:0.1pt;"> </font>number<font style="letter-spacing:0.05pt;"> </font>IV C 1-S2204/12/10003,<font style="letter-spacing:0.05pt;"> </font>as amended<font style="letter-spacing:0.05pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>circular<font style="letter-spacing:0.1pt;"> </font>dated<font style="letter-spacing:0.05pt;"> </font>December<font style="letter-spacing:0.05pt;"> </font>18, 2018 (reference number<font style="letter-spacing:0.05pt;"> </font>IV C 1 &#8211; S 2204/12/10003),<font style="letter-spacing:0.05pt;"> </font>in respect<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>taxation<font style="letter-spacing:0.1pt;"> </font>of American<font style="letter-spacing:0.05pt;"> </font>Depositary<font style="letter-spacing:0.05pt;"> </font>Receipts,<font style="letter-spacing:0.05pt;"> </font>or ADRs,<font style="letter-spacing:-0.05pt;"> </font>on domestic<font style="letter-spacing:0.1pt;"> </font>shares,<font style="letter-spacing:0.05pt;"> </font>or the<font style="letter-spacing:0.05pt;"> </font>ADR<font style="letter-spacing:-0.05pt;"> </font>Tax Circular,<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>purposes,<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> should</font>, in light of the ADR Tax Circular,<font style="letter-spacing:0.05pt;"> </font>represent<font style="letter-spacing:0.1pt;"> </font>a beneficial<font style="letter-spacing:0.1pt;"> </font>ownership interest<font style="letter-spacing:0.1pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>underlying<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>of BioNTech and qualify<font style="letter-spacing:0.05pt;"> </font>as ADRs<font style="letter-spacing:-0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>purpose<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>ADR<font style="letter-spacing:-0.05pt;"> </font>Tax Circular.<font style="letter-spacing:0.1pt;"> </font>If the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>qualify<font style="letter-spacing:0.05pt;"> </font>as ADRs<font style="letter-spacing:-0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>ADR<font style="letter-spacing:-0.05pt;"> </font>Tax Circular,<font style="letter-spacing:0.1pt;"> </font>dividends<font style="letter-spacing:0.05pt;"> </font>would accordingly<font style="letter-spacing:0.1pt;"> </font>be attributable<font style="letter-spacing:0.15pt;"> </font>to holders of the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>purposes,<font style="letter-spacing:0.05pt;"> </font>and not to the<font style="letter-spacing:0.05pt;"> </font>legal<font style="letter-spacing:0.05pt;"> </font>owner of the<font style="letter-spacing:0.05pt;"> </font>ordinary<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">i.</font><font style="font-style:italic;letter-spacing:0.05pt;">e</font>., the<font style="letter-spacing:0.05pt;"> </font>financial institution<font style="letter-spacing:0.15pt;"> </font>on behalf<font style="letter-spacing:0.05pt;"> </font>of which the<font style="letter-spacing:0.05pt;"> </font>ordinary<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>stored<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>a domestic<font style="letter-spacing:0.1pt;"> </font>depository<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>ADS<font style="letter-spacing:-0.05pt;"> </font>holders). Furthermore,<font style="letter-spacing:0.1pt;"> </font>holders<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>should<font style="letter-spacing:0.05pt;"> </font>be treated<font style="letter-spacing:0.1pt;"> </font>as beneficial<font style="letter-spacing:0.1pt;"> </font>owners of the<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>of BioNTech with respect to capital<font style="letter-spacing:0.1pt;"> </font>gains<font style="letter-spacing:0.05pt;"> </font>(see<font style="letter-spacing:0.05pt;"> </font>below in section<font style="letter-spacing:0.05pt;"> </font>&#8220;&#8212;German<font style="letter-spacing:0.05pt;"> </font>Taxation<font style="letter-spacing:0.05pt;"> </font>of Capital<font style="letter-spacing:0.05pt;"> </font>Gains of the<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>Treaty<font style="letter-spacing:0.05pt;"> </font>Beneficiaries<font style="letter-spacing:0.15pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>ADSs&#8221;). However, investors<font style="letter-spacing:0.1pt;"> </font>should<font style="letter-spacing:0.05pt;"> </font>note<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>circulars<font style="letter-spacing:0.1pt;"> </font>published<font style="letter-spacing:0.05pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>authorities<font style="letter-spacing:0.15pt;"> </font>(including<font style="letter-spacing:0.1pt;"> </font>the ADR<font style="letter-spacing:-0.05pt;"> </font>Tax Circular)<font style="letter-spacing:0.1pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>not, e.g., binding<font style="letter-spacing:0.05pt;"> </font>on German<font style="letter-spacing:0.05pt;"> </font>courts,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>courts,<font style="letter-spacing:0.05pt;"> </font>and it<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>unclear<font style="letter-spacing:0.05pt;"> </font>whether<font style="letter-spacing:0.05pt;"> </font>a German<font style="letter-spacing:0.05pt;"> </font>court<font style="letter-spacing:0.05pt;"> </font>would follow<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>ADR<font style="letter-spacing:-0.05pt;"> </font>Tax Circular<font style="letter-spacing:0.1pt;"> </font>in determining<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>treatment<font style="letter-spacing:0.15pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>ADSs.<font style="letter-spacing:-0.05pt;"> </font>For the purpose<font style="letter-spacing:0.05pt;"> </font>of this<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>section,<font style="letter-spacing:0.05pt;"> </font>it<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>assumed<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>qualify<font style="letter-spacing:0.05pt;"> </font>as ADRs<font style="letter-spacing:-0.05pt;"> </font>within<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>meaning<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>ADR Tax Circular.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Taxation of Holders Not Tax Resident in Germany</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following<font style="letter-spacing:0.05pt;"> </font>discussion<font style="letter-spacing:0.1pt;"> </font>describes<font style="letter-spacing:0.1pt;"> selected</font><font style="letter-spacing:0.15pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>consequences<font style="letter-spacing:0.05pt;"> </font>of acquiring the ADSs,<font style="letter-spacing:0.1pt;"> </font>owning the ADSs and disposing<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>ADSs to a holder that is a U.S. treaty beneficiary.<font style="letter-spacing:-0.05pt;"> </font>For purposes<font style="letter-spacing:0.05pt;"> </font>of this<font style="letter-spacing:0.05pt;"> </font>discussion,<font style="letter-spacing:0.1pt;"> </font>a &#8220;U.S. treaty beneficiary&#8221;<font style="letter-spacing:0.15pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>a resident<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>United<font style="letter-spacing:0.05pt;"> </font>States<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>purposes<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Convention<font style="letter-spacing:0.05pt;"> </font>between<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Federal<font style="letter-spacing:0.05pt;"> </font>Republic<font style="letter-spacing:0.05pt;"> </font>of Germany<font style="letter-spacing:0.05pt;"> </font>and United<font style="letter-spacing:0.05pt;"> </font>States<font style="letter-spacing:0.05pt;"> </font>of America<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Avoidance<font style="letter-spacing:0.05pt;"> </font>of Double Taxation<font style="letter-spacing:0.05pt;"> </font>and the<font style="letter-spacing:0.05pt;"> </font>Prevention<font style="letter-spacing:0.05pt;"> </font>of Fiscal Evasion<font style="letter-spacing:0.05pt;"> </font>with respect<font style="letter-spacing:0.1pt;"> </font>to Taxes on Income<font style="letter-spacing:0.05pt;"> </font>and Capital and Certain Other Taxes of 1989,<font style="letter-spacing:0.05pt;"> </font>as amended by the Protocol as of June 4, 2008 (<font style="font-style:italic;">Abkommen</font><font style="font-style:italic;letter-spacing:-0.05pt;"> </font><font style="font-style:italic;">zwischen</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">der Bundesrepublik</font><font style="font-style:italic;letter-spacing:0.1pt;"> </font><font style="font-style:italic;">Deutschland</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">und den Vereinigten</font><font style="font-style:italic;letter-spacing:0.1pt;"> </font><font style="font-style:italic;">Staaten</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">von Amerika zur Vermeidung der Doppelbesteuerung und zur Verhinderung</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">der Steuerverk&#252;rzung</font><font style="font-style:italic;letter-spacing:0.1pt;"> </font><font style="font-style:italic;">auf dem Gebiet</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">der Steuern</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">vom Einkommen und vom Verm&#246;gen und einiger</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">anderer</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">Steuern</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">in der Fassung vom 4. Juni</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">2008</font>), hereinafter<font style="letter-spacing:0.15pt;"> </font>referred<font style="letter-spacing:0.1pt;"> </font>to as the<font style="letter-spacing:0.05pt;"> </font>&#8220;Treaty,&#8221;<font style="letter-spacing:0.05pt;"> </font>who is eligible<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> relevant </font>benefits<font style="letter-spacing:0.1pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Treaty.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A holder will be a U.S. treaty beneficiary entitled to full Treaty benefits in respect of the ADSs if it is, inter alia: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the beneficial owner of the ADSs (and the dividends paid with respect thereto);</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a U.S. tax resident corporation or individual;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">not also a resident of Germany for German tax purposes; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">not subject to the limitation on benefits (i.e., anti-treaty shopping) article of the Treaty that applies in limited circumstances. </font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Special rules apply to pension funds and certain other tax-exempt investors.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This discussion<font style="letter-spacing:0.1pt;"> </font>does not address<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>treatment<font style="letter-spacing:0.15pt;"> </font>of ADSs<font style="letter-spacing:-0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>(i)<font style="letter-spacing:0.05pt;"> </font>held<font style="letter-spacing:0.05pt;"> </font>in connection<font style="letter-spacing:0.05pt;"> </font>with a permanent establishment<font style="letter-spacing:0.15pt;"> </font>or fixed<font style="letter-spacing:0.05pt;"> </font>base<font style="letter-spacing:0.05pt;"> </font>through<font style="letter-spacing:0.05pt;"> </font>which a U.S.<font style="letter-spacing:-0.05pt;"> </font>treaty<font style="letter-spacing:0.1pt;"> </font>beneficiary<font style="letter-spacing:0.1pt;"> </font>carries<font style="letter-spacing:0.1pt;"> </font>on business<font style="letter-spacing:0.05pt;"> </font>or performs<font style="letter-spacing:0.1pt;"> </font>personal services<font style="letter-spacing:0.1pt;"> </font>in Germany<font style="letter-spacing:0.05pt;"> </font>or (ii)<font style="letter-spacing:0.1pt;"> </font>part<font style="letter-spacing:0.05pt;"> </font>of business<font style="letter-spacing:0.05pt;"> </font>assets<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>which a permanent<font style="letter-spacing:0.1pt;"> </font>representative<font style="letter-spacing:0.15pt;"> </font>in Germany<font style="letter-spacing:0.05pt;"> </font>has been appointed.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">211</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">General Rules for</font><font style="letter-spacing:0.05pt;"> </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">the Taxation of Holders</font><font style="letter-spacing:0.05pt;"> </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Not Tax Resident</font><font style="letter-spacing:0.05pt;"> </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">in Germany</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-German<font style="letter-spacing:0.05pt;"> </font>resident<font style="letter-spacing:0.1pt;"> </font>holders<font style="letter-spacing:0.05pt;"> </font>of ADSs<font style="letter-spacing:-0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>to German<font style="letter-spacing:0.05pt;"> </font>taxation<font style="letter-spacing:0.1pt;"> </font>with respect<font style="letter-spacing:0.1pt;"> </font>to German<font style="letter-spacing:0.05pt;"> </font>source income<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">beschr&#228;nkte</font><font style="font-style:italic;letter-spacing:0.1pt;"> </font><font style="font-style:italic;">Steuerpflich</font><font style="font-style:italic;letter-spacing:0.15pt;">t</font>). According<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>ADR<font style="letter-spacing:-0.05pt;"> </font>Tax Circular,<font style="letter-spacing:0.1pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>should<font style="letter-spacing:0.05pt;"> </font>be attributed<font style="letter-spacing:0.1pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>holder<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>purposes.<font style="letter-spacing:0.05pt;"> </font>As a consequence,<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>should be treated<font style="letter-spacing:0.1pt;"> </font>as German<font style="letter-spacing:0.05pt;"> </font>source<font style="letter-spacing:0.05pt;"> </font>income.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">German Withholding<font style="letter-spacing:0.05pt;"> </font>Taxation of Dividends<font style="letter-spacing:0.05pt;"> </font>of the U.S.<font style="letter-spacing:-0.05pt;"> </font>Treaty<font style="letter-spacing:0.05pt;"> </font>Beneficiaries<font style="letter-spacing:0.1pt;"> </font>of the ADSs</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally,<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>full<font style="letter-spacing:0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of a dividend<font style="letter-spacing:0.05pt;"> </font>distributed<font style="letter-spacing:0.1pt;"> </font>by BioNTech to a non-German<font style="letter-spacing:0.05pt;"> </font>resident<font style="letter-spacing:0.1pt;"> </font>holder,<font style="letter-spacing:0.05pt;"> </font>which does not maintain<font style="letter-spacing:0.1pt;"> </font>a permanent<font style="letter-spacing:0.1pt;"> </font>establishment<font style="letter-spacing:0.15pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>taxable<font style="letter-spacing:0.05pt;"> </font>presence<font style="letter-spacing:0.05pt;"> </font>in Germany,<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>to (final)<font style="letter-spacing:0.1pt;"> </font>German withholding<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>an aggregate<font style="letter-spacing:0.1pt;"> </font>rate<font style="letter-spacing:0.05pt;"> </font>of 26.375%<font style="color:#000000;"> (</font>that amount consists of 25% on dividends distributed plus solidarity surcharge of 5.5% on the amount of the withholding tax). The basis for the withholding tax is generally the dividend approved for distribution by our general shareholder&#8217;s meeting. German<font style="letter-spacing:0.05pt;"> </font>withholding<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>withheld<font style="letter-spacing:0.05pt;"> </font>and remitted<font style="letter-spacing:0.1pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>German tax<font style="letter-spacing:0.05pt;"> </font>authorities<font style="letter-spacing:0.15pt;"> </font>by (i)<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>disbursing<font style="letter-spacing:0.1pt;"> </font>agent<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">i.e</font><font style="font-style:italic;letter-spacing:0.05pt;">.</font>, the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>credit<font style="letter-spacing:0.1pt;"> </font>institution,<font style="letter-spacing:0.15pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>services<font style="letter-spacing:0.1pt;"> </font>institution, securities<font style="letter-spacing:0.15pt;"> </font>trading<font style="letter-spacing:0.05pt;"> </font>enterprise<font style="letter-spacing:0.1pt;"> </font>or securities<font style="letter-spacing:0.15pt;"> </font>trading<font style="letter-spacing:0.05pt;"> </font>bank (each<font style="letter-spacing:0.05pt;"> </font>as defined<font style="letter-spacing:0.05pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>Banking Act (<font style="font-style:italic;">Kreditwesengeset</font><font style="font-style:italic;letter-spacing:0.1pt;">z</font>) and in each<font style="letter-spacing:0.05pt;"> </font>case<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>a German<font style="letter-spacing:0.05pt;"> </font>branch<font style="letter-spacing:0.05pt;"> </font>of a foreign<font style="letter-spacing:0.05pt;"> </font>enterprise,<font style="letter-spacing:0.1pt;"> </font>but excluding<font style="letter-spacing:0.05pt;"> </font>a foreign branch<font style="letter-spacing:0.05pt;"> </font>of a German<font style="letter-spacing:0.05pt;"> </font>enterprise))<font style="letter-spacing:0.15pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>holds<font style="letter-spacing:0.05pt;"> </font>or administers<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>underlying<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>in custody<font style="letter-spacing:0.05pt;"> </font>and (a)<font style="letter-spacing:0.05pt;"> </font>disburses<font style="letter-spacing:0.1pt;"> </font>or credits<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>dividend<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>underlying<font style="letter-spacing:0.05pt;"> </font>shares,<font style="letter-spacing:0.05pt;"> </font>(b)<font style="letter-spacing:0.05pt;"> </font>disburses<font style="letter-spacing:0.1pt;"> </font>or credits<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>dividend<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the underlying<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>on delivery<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>dividend<font style="letter-spacing:0.05pt;"> </font>coupons or (c)<font style="letter-spacing:0.05pt;"> </font>disburses<font style="letter-spacing:0.1pt;"> </font>such dividend<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>to a foreign<font style="letter-spacing:0.05pt;"> </font>agent; or (ii)<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>central<font style="letter-spacing:0.1pt;"> </font>securities<font style="letter-spacing:0.15pt;"> </font>depository<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Wertpapiersammelban</font><font style="font-style:italic;letter-spacing:0.1pt;">k</font>) in terms<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>Depositary<font style="letter-spacing:0.05pt;"> </font>Act (<font style="font-style:italic;">Depotgeset</font><font style="font-style:italic;letter-spacing:0.05pt;">z</font>) holding<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>underlying<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>in a collective<font style="letter-spacing:0.1pt;"> </font>deposit,<font style="letter-spacing:0.05pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>such central<font style="letter-spacing:0.1pt;"> </font>securities<font style="letter-spacing:0.15pt;"> </font>depository<font style="letter-spacing:0.1pt;"> </font>disburses the<font style="letter-spacing:0.05pt;"> </font>dividend<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>underlying<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>to a foreign<font style="letter-spacing:0.05pt;"> </font>agent,<font style="letter-spacing:0.05pt;"> </font>regardless<font style="letter-spacing:0.1pt;"> </font>of whether<font style="letter-spacing:0.05pt;"> </font>a holder<font style="letter-spacing:0.05pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>report<font style="letter-spacing:0.05pt;"> </font>the dividend<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>purposes<font style="letter-spacing:0.05pt;"> </font>and regardless<font style="letter-spacing:0.1pt;"> </font>of whether<font style="letter-spacing:0.05pt;"> </font>or not a holder<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>a resident<font style="letter-spacing:0.1pt;"> </font>of Germany.<font style="letter-spacing:0.05pt;"> </font>Dividend<font style="letter-spacing:0.05pt;"> </font>payments, to the<font style="letter-spacing:0.05pt;"> </font>extent<font style="letter-spacing:0.05pt;"> </font>funded<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>BioNTech&#8217;s tax-recognized<font style="letter-spacing:0.15pt;"> </font>contribution<font style="letter-spacing:0.1pt;"> </font>account<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">steuerliches</font><font style="font-style:italic;letter-spacing:0.15pt;"> </font><font style="font-style:italic;">Einlagekont</font><font style="font-style:italic;letter-spacing:0.05pt;">o</font>), subject<font style="letter-spacing:0.05pt;"> </font>to certain<font style="letter-spacing:0.1pt;"> </font>prerequisites,<font style="letter-spacing:0.15pt;"> do not </font>form<font style="letter-spacing:0.05pt;"> </font>part<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>taxable<font style="letter-spacing:0.05pt;"> </font>dividend<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>but should lower<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>holder&#8217;s<font style="letter-spacing:0.1pt;"> </font>acquisition<font style="letter-spacing:0.1pt;"> </font>costs for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>ADSs. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>Treaty,<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>withholding<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>not exceed<font style="letter-spacing:0.05pt;"> </font>(i)<font style="letter-spacing:0.05pt;"> </font>15% of the<font style="letter-spacing:0.05pt;"> </font>gross<font style="letter-spacing:0.05pt;"> </font>amount of the<font style="letter-spacing:0.05pt;"> </font>dividends<font style="letter-spacing:0.05pt;"> </font>received<font style="letter-spacing:0.1pt;"> </font>by a U.S.<font style="letter-spacing:-0.05pt;"> </font>treaty<font style="letter-spacing:0.1pt;"> </font>beneficiary<font style="letter-spacing:0.1pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>than<font style="letter-spacing:0.05pt;"> </font>a company<font style="letter-spacing:0.05pt;"> </font>holding<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>which represent<font style="letter-spacing:0.1pt;"> </font>10% or more<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>voting<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>in BioNTech, and (ii)<font style="letter-spacing:0.1pt;"> </font>5% of the<font style="letter-spacing:0.05pt;"> </font>gross<font style="letter-spacing:0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>dividends<font style="letter-spacing:0.05pt;"> </font>received<font style="letter-spacing:0.1pt;"> </font>by a U.S. treaty<font style="letter-spacing:0.1pt;"> </font>beneficiary<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>a company<font style="letter-spacing:0.05pt;"> </font>holding<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>which represent<font style="letter-spacing:0.1pt;"> </font>10% or more<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>voting<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>in BioNTech. The excess<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>total<font style="letter-spacing:0.05pt;"> </font>withholding<font style="letter-spacing:0.05pt;"> </font>tax,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>solidarity<font style="letter-spacing:0.1pt;"> </font>surcharge,<font style="letter-spacing:0.1pt;"> </font>over<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>maximum<font style="letter-spacing:0.1pt;"> </font>rate<font style="letter-spacing:0.05pt;"> </font>of withholding<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>permitted<font style="letter-spacing:0.1pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>Treaty<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>refunded<font style="letter-spacing:0.05pt;"> </font>to U.S.<font style="letter-spacing:-0.05pt;"> </font>treaty<font style="letter-spacing:0.1pt;"> </font>beneficiaries<font style="letter-spacing:0.15pt;"> </font>upon application.<font style="letter-spacing:0.1pt;"> </font>For example, for<font style="letter-spacing:0.05pt;"> </font>a declared<font style="letter-spacing:0.1pt;"> </font>dividend<font style="letter-spacing:0.05pt;"> </font>of 100, a U.S.<font style="letter-spacing:-0.05pt;"> </font>treaty<font style="letter-spacing:0.1pt;"> </font>beneficiary<font style="letter-spacing:0.1pt;"> </font>initially<font style="letter-spacing:0.15pt;"> </font>receives<font style="letter-spacing:0.1pt;"> </font>73.625 (100 minus<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>26.375% withholding<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>solidarity<font style="letter-spacing:0.1pt;"> </font>surcharge).<font style="letter-spacing:0.1pt;"> </font>A U.S.<font style="letter-spacing:-0.05pt;"> </font>treaty<font style="letter-spacing:0.1pt;"> </font>beneficiary<font style="letter-spacing:0.1pt;"> other than a company holding ADSs which represent 10% or more of the voting shares in BioNTech </font>is<font style="letter-spacing:0.05pt;"> </font>entitled<font style="letter-spacing:0.1pt;"> </font>to a partial<font style="letter-spacing:0.1pt;"> </font>refund<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the German<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>authorities<font style="letter-spacing:0.15pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of 11.375% of the<font style="letter-spacing:0.05pt;"> </font>gross<font style="letter-spacing:0.05pt;"> </font>dividend<font style="letter-spacing:0.05pt;"> </font>(of<font style="letter-spacing:0.05pt;"> </font>100). As a result,<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>treaty beneficiary<font style="letter-spacing:0.1pt;"> </font>ultimately<font style="letter-spacing:0.15pt;"> </font>receives<font style="letter-spacing:0.1pt;"> </font>a total<font style="letter-spacing:0.05pt;"> </font>of 85 (85%<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>declared<font style="letter-spacing:0.1pt;"> </font>dividend)<font style="letter-spacing:0.05pt;"> </font>following<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>refund<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>excess withholding.<font style="letter-spacing:0.05pt;"> </font>However, it should be noted that there is uncertainty as to<font style="letter-spacing:0.05pt;"> </font>how the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>authorities<font style="letter-spacing:0.15pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>apply<font style="letter-spacing:0.05pt;"> </font>the refund<font style="letter-spacing:0.05pt;"> </font>process<font style="letter-spacing:0.05pt;"> </font>to dividends<font style="letter-spacing:0.05pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>with respect<font style="letter-spacing:0.1pt;"> </font>to non-German<font style="letter-spacing:0.05pt;"> </font>resident<font style="letter-spacing:0.1pt;"> </font>holders.<font style="letter-spacing:-0.05pt;"> </font>Further,<font style="letter-spacing:0.05pt;"> </font>such refund<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>anti-avoidance<font style="letter-spacing:0.15pt;"> </font>treaty<font style="letter-spacing:0.1pt;"> </font>shopping<font style="letter-spacing:0.05pt;"> </font>rule<font style="letter-spacing:0.05pt;"> </font>(as<font style="letter-spacing:0.05pt;"> </font>described<font style="letter-spacing:0.1pt;"> </font>below in &#8220;&#8212;Withholding<font style="letter-spacing:0.1pt;"> </font>Tax Refund for<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>Treaty<font style="letter-spacing:0.05pt;"> </font>Beneficiaries&#8221;).</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">German Withholding<font style="letter-spacing:0.05pt;"> </font>Taxation of Capital<font style="letter-spacing:0.05pt;"> </font>Gains of the U.S.<font style="letter-spacing:-0.05pt;"> </font>Treaty<font style="letter-spacing:0.05pt;"> </font>Beneficiaries<font style="letter-spacing:0.1pt;"> </font>of the ADSs</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The capital<font style="letter-spacing:0.1pt;"> </font>gains<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>disposition<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>realized<font style="letter-spacing:0.1pt;"> </font>by a non-German<font style="letter-spacing:0.05pt;"> </font>resident<font style="letter-spacing:0.1pt;"> </font>holder,<font style="letter-spacing:0.05pt;"> </font>which does not maintain<font style="letter-spacing:0.1pt;"> </font>a permanent<font style="letter-spacing:0.1pt;"> </font>establishment<font style="letter-spacing:0.15pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>taxable<font style="letter-spacing:0.05pt;"> </font>presence<font style="letter-spacing:0.05pt;"> </font>in Germany,<font style="letter-spacing:0.05pt;"> </font>would be treated<font style="letter-spacing:0.1pt;"> </font>as German<font style="letter-spacing:0.05pt;"> </font>source income<font style="letter-spacing:0.05pt;"> </font>and be subject<font style="letter-spacing:0.05pt;"> </font>to German<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>qualify<font style="letter-spacing:0.05pt;"> </font>as a Qualifying<font style="letter-spacing:0.1pt;"> </font>Participation.<font style="letter-spacing:0.15pt;"> </font>A Qualifying<font style="letter-spacing:0.1pt;"> </font>Participation exists<font style="letter-spacing:0.05pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>a holder<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>any time<font style="letter-spacing:0.05pt;"> </font>during<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>five<font style="letter-spacing:0.05pt;"> </font>years<font style="letter-spacing:0.05pt;"> </font>preceding<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>disposition,<font style="letter-spacing:0.1pt;"> </font>directly<font style="letter-spacing:0.1pt;"> </font>or indirectly,<font style="letter-spacing:0.1pt;"> </font>owned at least 1% of BioNTech&#8217;s share<font style="letter-spacing:0.05pt;"> </font>capital,<font style="letter-spacing:0.1pt;"> </font>irrespective<font style="letter-spacing:0.15pt;"> </font>of whether<font style="letter-spacing:0.05pt;"> </font>through<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>or shares<font style="letter-spacing:0.05pt;"> </font>of BioNTech. If<font style="letter-spacing:0.05pt;"> </font>such holder<font style="letter-spacing:0.05pt;"> </font>had acquired<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>without<font style="letter-spacing:0.05pt;"> </font>consideration,<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>previous<font style="letter-spacing:0.05pt;"> </font>owner&#8217;s<font style="letter-spacing:0.05pt;"> </font>holding<font style="letter-spacing:0.05pt;"> </font>period<font style="letter-spacing:0.05pt;"> </font>and quota<font style="letter-spacing:0.05pt;"> </font>would be taken<font style="letter-spacing:0.05pt;"> </font>into<font style="letter-spacing:0.05pt;"> </font>account.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>Treaty,<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>gains<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>disposal<font style="letter-spacing:0.1pt;"> </font>of a Qualifying<font style="letter-spacing:0.1pt;"> </font>Participation<font style="letter-spacing:0.15pt;"> </font>realized<font style="letter-spacing:0.1pt;"> </font>by a U.S. treaty<font style="letter-spacing:0.1pt;"> </font>beneficiary<font style="letter-spacing:0.1pt;"> </font>are,<font style="letter-spacing:0.05pt;"> </font>however, generally<font style="letter-spacing:0.1pt;"> </font>exempt<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>taxation.<font style="letter-spacing:0.1pt;"> </font>Pursuant<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>Treaty,<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>treaty beneficiaries<font style="letter-spacing:0.15pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>not subject<font style="letter-spacing:0.05pt;"> </font>to German<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>in relation<font style="letter-spacing:0.1pt;"> </font>to capital<font style="letter-spacing:0.1pt;"> </font>gains<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>disposal<font style="letter-spacing:0.1pt;"> </font>of a Qualifying Participation<font style="letter-spacing:0.15pt;"> </font>even under<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>circumstances<font style="letter-spacing:0.15pt;"> </font>described<font style="letter-spacing:0.1pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>preceding<font style="letter-spacing:0.05pt;"> </font>paragraph<font style="letter-spacing:0.05pt;"> </font>and therefore<font style="letter-spacing:0.1pt;"> </font>should<font style="letter-spacing:0.05pt;"> </font>not be subject<font style="letter-spacing:0.05pt;"> </font>to German<font style="letter-spacing:0.05pt;"> </font>taxation<font style="letter-spacing:0.1pt;"> </font>on capital<font style="letter-spacing:0.1pt;"> </font>gains<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>disposition<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>ADSs.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">German statutory law requires the disbursing agent to levy withholding tax on capital gains from the sale of ADSs or other<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.15pt;"> </font>held<font style="letter-spacing:0.05pt;"> </font>in a custodial<font style="letter-spacing:0.1pt;"> </font>account<font style="letter-spacing:0.05pt;"> </font>in Germany.<font style="letter-spacing:0.05pt;"> </font>With<font style="letter-spacing:0.05pt;"> </font>regard<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>taxation<font style="letter-spacing:0.1pt;"> </font>of capital gains,<font style="letter-spacing:0.05pt;"> </font>disbursing<font style="letter-spacing:0.1pt;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agent</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">means</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a German</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">credit</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">institution,</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">services</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">institution,</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">securities</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trading enterprise</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or securities</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trading</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bank (each</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as defined</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">German</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Banking Act and, in each</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">case</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a German</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">branch</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a foreign</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enterprise,</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">but excluding</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a foreign</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">branch</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of a German</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enterprise)</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">holds</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the ADSs</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in custody</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or administers</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ADSs</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">investor</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or conducts</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sales</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or other</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dispositions</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and disburses</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or credits</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">income</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ADSs</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">holder</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ADSs.</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The German</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">statutory</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">law does not explicitly condition</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obligation</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to withhold</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">taxes</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on capital</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gains</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">being</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subject</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to taxation</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in Germany</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">German statutory</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">law or on an applicable</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">income</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tax</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">treaty</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">permitting</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to tax</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such capital</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gains.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">However, a circular<font style="letter-spacing:0.1pt;"> </font>issued<font style="letter-spacing:0.05pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>Federal<font style="letter-spacing:0.05pt;"> </font>Ministry<font style="letter-spacing:0.1pt;"> </font>of Finance,<font style="letter-spacing:0.05pt;"> </font>dated<font style="letter-spacing:0.05pt;"> </font>January<font style="letter-spacing:0.05pt;"> </font>18, 2016, reference number<font style="letter-spacing:0.05pt;"> </font>IV C 1-S2252/08/10004<font style="letter-spacing:0.05pt;"> </font>:017, as most<font style="letter-spacing:0.05pt;"> </font>recently<font style="letter-spacing:0.1pt;"> </font>amended<font style="letter-spacing:0.05pt;"> </font>by circular<font style="letter-spacing:0.1pt;"> </font>dated<font style="letter-spacing:0.05pt;"> </font>September<font style="letter-spacing:0.1pt;"> </font>16, 2019, reference number<font style="letter-spacing:0.05pt;"> </font>IV C 1-S2252/08/10004<font style="letter-spacing:0.05pt;"> </font>:027, provides<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>taxes<font style="letter-spacing:0.05pt;"> </font>need not be withheld<font style="letter-spacing:0.05pt;"> </font>when the<font style="letter-spacing:0.05pt;"> </font>holder<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>custody account<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>not a resident<font style="letter-spacing:0.1pt;"> </font>of Germany<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>purposes<font style="letter-spacing:0.05pt;"> </font>and the<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>not subject<font style="letter-spacing:0.05pt;"> </font>to German<font style="letter-spacing:0.05pt;"> </font>taxation.<font style="letter-spacing:0.1pt;"> </font>The circular<font style="letter-spacing:0.1pt;"> </font>further<font style="letter-spacing:0.1pt;"> </font>states<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>there<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>no obligation<font style="letter-spacing:0.1pt;"> </font>to withhold<font style="letter-spacing:0.05pt;"> </font>such tax<font style="letter-spacing:0.05pt;"> </font>even if<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>non-resident<font style="letter-spacing:0.1pt;"> </font>holder<font style="letter-spacing:0.05pt;"> </font>owns at least 1% of the<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>of a German<font style="letter-spacing:0.05pt;"> corporation</font>.<font style="letter-spacing:0.05pt;"> </font>While<font style="letter-spacing:0.05pt;"> </font>circulars<font style="letter-spacing:0.1pt;"> </font>issued<font style="letter-spacing:0.05pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>Federal<font style="letter-spacing:0.05pt;"> </font>Ministry<font style="letter-spacing:0.1pt;"> </font>of Finance<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> generally </font>only to be adhered to by the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>authorities<font style="letter-spacing:0.15pt;"> </font>but are, for example, not binding on the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>courts,<font style="letter-spacing:0.05pt;"> </font>in practice,<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>disbursing agents<font style="letter-spacing:0.05pt;"> </font>nevertheless<font style="letter-spacing:0.1pt;"> </font>typically<font style="letter-spacing:0.1pt;"> </font>rely<font style="letter-spacing:0.05pt;"> </font>on guidance<font style="letter-spacing:0.05pt;"> </font>contained<font style="letter-spacing:0.05pt;"> </font>in such circulars.<font style="letter-spacing:0.1pt;"> </font>Therefore,<font style="letter-spacing:0.1pt;"> </font>a disbursing<font style="letter-spacing:0.1pt;"> </font>agent<font style="letter-spacing:0.05pt;"> </font>would only withhold<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>26.375% on capital<font style="letter-spacing:0.1pt;"> </font>gains<font style="letter-spacing:0.05pt;"> </font>derived<font style="letter-spacing:0.05pt;"> </font>by a U.S.<font style="letter-spacing:-0.05pt;"> </font>treaty<font style="letter-spacing:0.1pt;"> </font>beneficiary<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>sale<font style="letter-spacing:0.05pt;"> </font>of ADSs<font style="letter-spacing:-0.05pt;"> </font>held<font style="letter-spacing:0.05pt;"> </font>in a custodial<font style="letter-spacing:0.1pt;"> </font>account<font style="letter-spacing:0.05pt;"> </font>in Germany<font style="letter-spacing:0.05pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>event<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>disbursing<font style="letter-spacing:0.1pt;"> </font>agent<font style="letter-spacing:0.05pt;"> </font>did not follow<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>abovementioned guidance.<font style="letter-spacing:0.05pt;"> </font>In this<font style="letter-spacing:0.05pt;"> </font>case,<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>treaty<font style="letter-spacing:0.1pt;"> </font>beneficiary<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>be entitled<font style="letter-spacing:0.1pt;"> </font>to claim<font style="letter-spacing:0.1pt;"> </font>a refund<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>withholding<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>from the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>authorities<font style="letter-spacing:0.15pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Treaty,<font style="letter-spacing:0.05pt;"> </font>as described<font style="letter-spacing:0.1pt;"> </font>below in &#8220;&#8212;Withholding<font style="letter-spacing:0.1pt;"> </font>Tax Refund for<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>Treaty Beneficiaries.&#8221;<font style="letter-spacing:0.15pt;"> </font>A refund<font style="letter-spacing:0.05pt;"> </font>of taxes<font style="letter-spacing:0.05pt;"> </font>withheld<font style="letter-spacing:0.05pt;"> </font>on capital<font style="letter-spacing:0.1pt;"> </font>gains<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>disposition<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>which do not qualify as Qualifying<font style="letter-spacing:0.1pt;"> </font>Participations<font style="letter-spacing:0.15pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>also<font style="letter-spacing:0.05pt;"> </font>be claimed<font style="letter-spacing:0.1pt;"> </font>based<font style="letter-spacing:0.05pt;"> </font>on German<font style="letter-spacing:0.05pt;"> </font>statutory<font style="letter-spacing:0.1pt;"> </font>domestic<font style="letter-spacing:0.1pt;"> </font>law.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Withholding<font style="letter-spacing:0.05pt;"> </font>Tax Refund for<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>Treaty<font style="letter-spacing:0.05pt;"> </font>Beneficiaries</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.<font style="letter-spacing:-0.05pt;"> </font>treaty<font style="letter-spacing:0.1pt;"> </font>beneficiaries<font style="letter-spacing:0.15pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>eligible<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>treaty<font style="letter-spacing:0.1pt;"> </font>benefits<font style="letter-spacing:0.1pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Treaty,<font style="letter-spacing:0.05pt;"> </font>as described<font style="letter-spacing:0.1pt;"> </font>above in &#8220;&#8212;Taxation<font style="letter-spacing:0.05pt;"> </font>of Holders<font style="letter-spacing:0.05pt;"> </font>Not Tax Resident<font style="letter-spacing:0.05pt;"> </font>in Germany.&#8221;<font style="letter-spacing:0.05pt;"> </font>Accordingly,<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>treaty<font style="letter-spacing:0.1pt;"> </font>beneficiaries<font style="letter-spacing:0.15pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>in general entitled<font style="letter-spacing:0.1pt;"> </font>to claim<font style="letter-spacing:0.1pt;"> </font>a refund<font style="letter-spacing:0.05pt;"> </font>of (i)<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>portion<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>otherwise<font style="letter-spacing:0.05pt;"> </font>applicable<font style="letter-spacing:0.1pt;"> </font>26.375% German<font style="letter-spacing:0.05pt;"> </font>withholding<font style="letter-spacing:0.05pt;"> </font>tax (<font style="font-style:italic;">Kapitalertragsteue</font><font style="font-style:italic;letter-spacing:0.15pt;">r</font>) on dividends<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>exceeds<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>applicable<font style="letter-spacing:0.1pt;"> </font>Treaty<font style="letter-spacing:0.05pt;"> </font>rate<font style="letter-spacing:0.05pt;"> </font>and (ii)<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>full<font style="letter-spacing:0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of German withholding<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">Kapitalertragsteue</font><font style="font-style:italic;letter-spacing:0.15pt;">r</font>) on capital<font style="letter-spacing:0.1pt;"> </font>gains<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>disposition<font style="letter-spacing:0.1pt;"> </font>of ADSs.<font style="letter-spacing:-0.05pt;"> </font>The application<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>such claim<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>to be filed<font style="letter-spacing:0.05pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>Federal<font style="letter-spacing:0.05pt;"> </font>Central<font style="letter-spacing:0.05pt;"> </font>Office<font style="letter-spacing:0.05pt;"> </font>of Taxation<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">Bundeszentralamt</font><font style="font-style:italic;letter-spacing:0.1pt;"> </font><font style="font-style:italic;">f&#252;r</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">Steuer</font><font style="font-style:italic;letter-spacing:0.05pt;">n</font>) within four years after the end of the calendar year in which the capital gains or dividends have been received (<font style="font-style:italic;">bezogen</font>).</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">However, in respect<font style="letter-spacing:0.1pt;"> </font>of dividends,<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>refund<font style="letter-spacing:0.05pt;"> </font>described<font style="letter-spacing:0.1pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>preceding<font style="letter-spacing:0.05pt;"> </font>paragraph<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>only possible<font style="letter-spacing:0.05pt;"> </font>if,<font style="letter-spacing:0.05pt;"> </font>due to special<font style="letter-spacing:0.1pt;"> </font>rules<font style="letter-spacing:0.05pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>restriction<font style="letter-spacing:0.15pt;"> </font>of withholding<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>credit,<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>following<font style="letter-spacing:0.05pt;"> </font>three<font style="letter-spacing:0.05pt;"> </font>cumulative<font style="letter-spacing:0.1pt;"> </font>requirements<font style="letter-spacing:0.15pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>met: (i)<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>holder<font style="letter-spacing:0.05pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>qualify<font style="letter-spacing:0.05pt;"> </font>as beneficial<font style="letter-spacing:0.1pt;"> </font>owner of the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>an uninterrupted<font style="letter-spacing:0.1pt;"> </font>minimum<font style="letter-spacing:0.1pt;"> </font>holding<font style="letter-spacing:0.05pt;"> </font>period<font style="letter-spacing:0.05pt;"> </font>of 45 days within<font style="letter-spacing:0.05pt;"> </font>a period<font style="letter-spacing:0.05pt;"> </font>starting<font style="letter-spacing:0.1pt;"> </font>45 days prior<font style="letter-spacing:0.05pt;"> </font>to and ending<font style="letter-spacing:0.05pt;"> </font>45 days after<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>due date<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>dividends,<font style="letter-spacing:0.05pt;"> </font>(ii)<font style="letter-spacing:0.1pt;"> </font>the holder<font style="letter-spacing:0.05pt;"> </font>has to bear<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>70% of the<font style="letter-spacing:0.05pt;"> </font>change<font style="letter-spacing:0.05pt;"> </font>in value<font style="letter-spacing:0.05pt;"> </font>risk<font style="letter-spacing:0.05pt;"> </font>related<font style="letter-spacing:0.1pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>during<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>minimum<font style="letter-spacing:0.1pt;"> </font>holding period<font style="letter-spacing:0.05pt;"> </font>as described<font style="letter-spacing:0.1pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>(i)<font style="letter-spacing:0.05pt;"> </font>of this<font style="letter-spacing:0.05pt;"> </font>paragraph<font style="letter-spacing:0.05pt;"> </font>and has not entered<font style="letter-spacing:0.05pt;"> </font>into<font style="letter-spacing:0.05pt;"> </font>(acting<font style="letter-spacing:0.1pt;"> </font>by itself<font style="letter-spacing:0.1pt;"> </font>or through<font style="letter-spacing:0.05pt;"> </font>a related party)<font style="letter-spacing:0.05pt;"> </font>hedging<font style="letter-spacing:0.05pt;"> </font>transactions<font style="letter-spacing:0.15pt;"> </font>which lower<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>change<font style="letter-spacing:0.05pt;"> </font>in value<font style="letter-spacing:0.05pt;"> </font>risk<font style="letter-spacing:0.05pt;"> </font>by more<font style="letter-spacing:0.05pt;"> </font>than<font style="letter-spacing:0.05pt;"> </font>30%, and (iii)<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>holder<font style="letter-spacing:0.05pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>not be obliged<font style="letter-spacing:0.05pt;"> </font>to fully<font style="letter-spacing:0.05pt;"> </font>or largely<font style="letter-spacing:0.1pt;"> </font>compensate<font style="letter-spacing:0.1pt;"> </font>directly<font style="letter-spacing:0.1pt;"> </font>or indirectly<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>dividends<font style="letter-spacing:0.05pt;"> </font>to third<font style="letter-spacing:0.05pt;"> </font>parties.<font style="letter-spacing:0.1pt;"> </font>If<font style="letter-spacing:0.05pt;"> </font>these requirements<font style="letter-spacing:0.15pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>not met,<font style="letter-spacing:0.05pt;"> </font>then<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>a holder<font style="letter-spacing:0.05pt;"> </font>not being<font style="letter-spacing:0.05pt;"> </font>tax-resident<font style="letter-spacing:0.15pt;"> </font>in Germany<font style="letter-spacing:0.05pt;"> </font>who applied<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>a full<font style="letter-spacing:0.05pt;"> </font>or partial refund<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>withholding<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>pursuant<font style="letter-spacing:0.05pt;"> </font>to a double<font style="letter-spacing:0.05pt;"> </font>taxation<font style="letter-spacing:0.1pt;"> </font>treaty,<font style="letter-spacing:0.1pt;"> </font>no refund<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>available.<font style="letter-spacing:0.1pt;"> </font>This restriction generally<font style="letter-spacing:0.1pt;"> </font>does only apply<font style="letter-spacing:0.05pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>(a)<font style="letter-spacing:0.05pt;"> </font>the German<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>underlying<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>refund<font style="letter-spacing:0.05pt;"> </font>application<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>below a tax<font style="letter-spacing:0.05pt;"> </font>rate<font style="letter-spacing:0.05pt;"> </font>of 15% based<font style="letter-spacing:0.05pt;"> </font>on the gross<font style="letter-spacing:0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>dividends<font style="letter-spacing:0.05pt;"> </font>and (b)<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>holder<font style="letter-spacing:0.05pt;"> </font>does not directly<font style="letter-spacing:0.1pt;"> </font>own 10% or more<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>of BioNTech and is<font style="letter-spacing:0.05pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>to income<font style="letter-spacing:0.05pt;"> </font>taxes<font style="letter-spacing:0.05pt;"> </font>in its<font style="letter-spacing:0.05pt;"> </font>state<font style="letter-spacing:0.05pt;"> </font>of residence,<font style="letter-spacing:0.1pt;"> </font>without<font style="letter-spacing:0.05pt;"> </font>being<font style="letter-spacing:0.05pt;"> </font>tax-exempt.<font style="letter-spacing:0.1pt;"> </font>The restriction<font style="letter-spacing:0.15pt;"> </font>of the withholding<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>credit<font style="letter-spacing:0.1pt;"> </font>does not apply<font style="letter-spacing:0.05pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>holder<font style="letter-spacing:0.05pt;"> </font>has beneficially<font style="letter-spacing:0.15pt;"> </font>owned the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>one uninterrupted year<font style="letter-spacing:0.05pt;"> </font>until<font style="letter-spacing:0.05pt;"> </font>receipt<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Zuflus</font><font style="font-style:italic;letter-spacing:0.05pt;">s</font>) of the<font style="letter-spacing:0.05pt;"> </font>dividends.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In general,<font style="letter-spacing:0.05pt;"> </font>as previously<font style="letter-spacing:0.1pt;"> </font>discussed,<font style="letter-spacing:0.05pt;"> </font>investors<font style="letter-spacing:0.1pt;"> </font>should<font style="letter-spacing:0.05pt;"> </font>note<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>it<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>unclear<font style="letter-spacing:0.05pt;"> </font>how the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>tax administration<font style="letter-spacing:0.15pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>apply<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>refund<font style="letter-spacing:0.05pt;"> </font>process<font style="letter-spacing:0.05pt;"> </font>to dividends<font style="letter-spacing:0.05pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>ADSs.<font style="letter-spacing:-0.05pt;"> </font>Further,<font style="letter-spacing:0.05pt;"> </font>such refund<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>to the German<font style="letter-spacing:0.05pt;"> </font>anti<font style="letter-spacing:0.15pt;"> </font>treaty<font style="letter-spacing:0.1pt;"> </font>shopping<font style="letter-spacing:0.05pt;"> </font>rule.<font style="letter-spacing:0.05pt;"> </font>Generally,<font style="letter-spacing:0.05pt;"> </font>this<font style="letter-spacing:0.05pt;"> </font>rule<font style="letter-spacing:0.05pt;"> </font>requires<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>treaty<font style="letter-spacing:0.1pt;"> </font>beneficiary<font style="letter-spacing:0.1pt;"> </font>(in<font style="letter-spacing:0.05pt;"> </font>case it<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>a non-German<font style="letter-spacing:0.05pt;"> </font>resident<font style="letter-spacing:0.1pt;"> </font>company)<font style="letter-spacing:0.05pt;"> </font>maintains<font style="letter-spacing:0.1pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>own administrative<font style="letter-spacing:0.2pt;"> </font>substance<font style="letter-spacing:0.05pt;"> </font>and conducts<font style="letter-spacing:0.05pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>own business activities.<font style="letter-spacing:0.15pt;"> </font>In particular,<font style="letter-spacing:0.15pt;"> </font>a foreign<font style="letter-spacing:0.05pt;"> </font>company<font style="letter-spacing:0.05pt;"> </font>has no right<font style="letter-spacing:0.05pt;"> </font>to a full<font style="letter-spacing:0.05pt;"> </font>or partial<font style="letter-spacing:0.1pt;"> </font>refund<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>extent<font style="letter-spacing:0.05pt;"> </font>persons<font style="letter-spacing:0.05pt;"> </font>holding ownership<font style="letter-spacing:0.05pt;"> </font>interests<font style="letter-spacing:0.1pt;"> </font>in BioNTech would not be entitled<font style="letter-spacing:0.1pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>refund<font style="letter-spacing:0.05pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>they<font style="letter-spacing:0.05pt;"> </font>derived<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>directly<font style="letter-spacing:0.1pt;"> </font>and the gross<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>realized<font style="letter-spacing:0.1pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>foreign<font style="letter-spacing:0.05pt;"> </font>company<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>not caused<font style="letter-spacing:0.05pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>business<font style="letter-spacing:0.05pt;"> </font>activities<font style="letter-spacing:0.15pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>foreign<font style="letter-spacing:0.05pt;"> </font>company, and there<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>either<font style="letter-spacing:0.1pt;"> </font>no economic<font style="letter-spacing:0.05pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>considerable<font style="letter-spacing:0.1pt;"> </font>reasons<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>interposition<font style="letter-spacing:0.15pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>foreign<font style="letter-spacing:0.05pt;"> </font>company,<font style="letter-spacing:0.05pt;"> </font>or the<font style="letter-spacing:0.05pt;"> </font>foreign<font style="letter-spacing:0.05pt;"> </font>company<font style="letter-spacing:0.05pt;"> </font>does not participate<font style="letter-spacing:0.15pt;"> </font>in general<font style="letter-spacing:0.05pt;"> </font>commerce<font style="letter-spacing:0.1pt;"> </font>by means<font style="letter-spacing:0.05pt;"> </font>of a business<font style="letter-spacing:0.05pt;"> </font>organization<font style="letter-spacing:0.1pt;"> </font>with resources<font style="letter-spacing:0.1pt;"> </font>appropriate<font style="letter-spacing:0.1pt;"> </font>to its<font style="letter-spacing:0.05pt;"> </font>business<font style="letter-spacing:0.05pt;"> </font>purpose.<font style="letter-spacing:0.05pt;"> </font>However, this<font style="letter-spacing:0.05pt;"> </font>shall<font style="letter-spacing:0.05pt;"> </font>not apply<font style="letter-spacing:0.05pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>foreign<font style="letter-spacing:0.05pt;"> </font>company&#8217;s<font style="letter-spacing:0.05pt;"> </font>principal class<font style="letter-spacing:0.05pt;"> </font>of stock<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>regularly<font style="letter-spacing:0.1pt;"> </font>traded<font style="letter-spacing:0.05pt;"> </font>in substantial<font style="letter-spacing:0.1pt;"> </font>volume<font style="letter-spacing:0.05pt;"> </font>on a recognized<font style="letter-spacing:0.1pt;"> </font>stock<font style="letter-spacing:0.05pt;"> </font>exchange,<font style="letter-spacing:0.05pt;"> </font>or if<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>foreign<font style="letter-spacing:0.05pt;"> </font>company is<font style="letter-spacing:0.05pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>provisions<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>Investment<font style="letter-spacing:0.1pt;"> </font>Tax Act (<font style="font-style:italic;">Investmentsteuergeset</font><font style="font-style:italic;letter-spacing:0.2pt;">z</font>). Whether<font style="letter-spacing:0.05pt;"> </font>or not and to which extent<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>anti-treaty<font style="letter-spacing:0.1pt;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">213</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shopping</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rule</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">applies</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ADSs</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has to be analyzed</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on a case</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by case basis</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">taking</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">into</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">account</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">all</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">relevant</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tests.</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition,</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">interpretation</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of these</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tests</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">disputed</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and to date</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no published</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">decisions</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">German</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Court exist</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in this</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regard. It</font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> should be noted that a draft bill containing reforms to the German anti-treaty shopping rule is currently in the legislative process and might be passed into law still in 2021.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to the<font style="letter-spacing:0.05pt;"> </font>legal<font style="letter-spacing:0.05pt;"> </font>structure<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>ADSs,<font style="letter-spacing:-0.05pt;"> </font>only limited<font style="letter-spacing:0.1pt;"> </font>guidance<font style="letter-spacing:0.05pt;"> </font>from the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>authorities<font style="letter-spacing:0.15pt;"> </font>exists<font style="letter-spacing:0.05pt;"> </font>on the practical<font style="letter-spacing:0.1pt;"> </font>application<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>refund process<font style="letter-spacing:0.05pt;"> </font>with respect<font style="letter-spacing:0.1pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>ADSs and the respective limitations. Recently, the German tax authorities have indicated that for ADR programs (which are considered comparable to ADS programs) a collective tax certificate in connection with a withholding of tax amounts may no longer be issued by the domestic depositary of the shares upon request of the foreign depositary agents. Rather, individual tax certificates need to be issued which might delay a potential refund procedure. Moreover, the simplified refund procedure based on electronic data exchange (<font style="font-style:italic;">Datentr&#228;gerverfahren</font>) for claims for reimbursement based on ADRs has been suspended temporarily by the tax authorities.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Taxation of Holders<font style="letter-spacing:0.05pt;"> </font>Tax Resident<font style="letter-spacing:0.05pt;"> </font>in Germany</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This subsection<font style="letter-spacing:0.1pt;"> </font>provides<font style="letter-spacing:0.05pt;"> </font>an overview<font style="letter-spacing:0.05pt;"> </font>of dividend<font style="letter-spacing:0.05pt;"> </font>taxation<font style="letter-spacing:0.1pt;"> </font>and of capital<font style="letter-spacing:0.1pt;"> </font>gains<font style="letter-spacing:0.05pt;"> </font>taxation<font style="letter-spacing:0.1pt;"> </font>with regard<font style="letter-spacing:0.05pt;"> </font>to the general<font style="letter-spacing:0.05pt;"> </font>principles<font style="letter-spacing:0.1pt;"> </font>applicable<font style="letter-spacing:0.1pt;"> </font>to ADS holders<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>resident<font style="letter-spacing:0.1pt;"> </font>in Germany.<font style="letter-spacing:0.05pt;"> </font>A holder<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>a German<font style="letter-spacing:0.05pt;"> </font>tax resident<font style="letter-spacing:0.1pt;"> </font>if,<font style="letter-spacing:0.05pt;"> </font>in case<font style="letter-spacing:0.05pt;"> </font>of an individual,<font style="letter-spacing:0.1pt;"> </font>he or she maintains<font style="letter-spacing:0.1pt;"> </font>a domicile<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Wohnsit</font><font style="font-style:italic;letter-spacing:0.1pt;">z</font>) or a usual<font style="letter-spacing:0.05pt;"> </font>residence<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">gew&#246;hnlicher Aufenthal</font><font style="font-style:italic;letter-spacing:0.1pt;">t</font>) in Germany<font style="letter-spacing:0.05pt;"> </font>or if,<font style="letter-spacing:0.05pt;"> </font>in case<font style="letter-spacing:0.05pt;"> </font>of a corporation,<font style="letter-spacing:0.1pt;"> </font>it<font style="letter-spacing:0.05pt;"> </font>has its<font style="letter-spacing:0.05pt;"> </font>place<font style="letter-spacing:0.05pt;"> </font>of management<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Gesch&#228;ftsleitun</font><font style="font-style:italic;letter-spacing:0.15pt;">g</font>) or registered<font style="letter-spacing:0.1pt;"> seat </font>(<font style="font-style:italic;">Sitz</font>)<font style="letter-spacing:0.1pt;"> </font>in Germany.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The German<font style="letter-spacing:0.05pt;"> </font>dividend<font style="letter-spacing:0.05pt;"> </font>and capital<font style="letter-spacing:0.1pt;"> </font>gains<font style="letter-spacing:0.05pt;"> </font>taxation<font style="letter-spacing:0.1pt;"> </font>rules<font style="letter-spacing:0.05pt;"> </font>applicable<font style="letter-spacing:0.1pt;"> </font>to German<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>residents<font style="letter-spacing:0.1pt;"> </font>require<font style="letter-spacing:0.1pt;"> </font>a distinction<font style="letter-spacing:0.1pt;"> </font>between<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>held<font style="letter-spacing:0.05pt;"> </font>as private<font style="letter-spacing:0.1pt;"> </font>assets<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">Privatverm&#246;ge</font><font style="font-style:italic;letter-spacing:0.05pt;">n</font>) and ADSs<font style="letter-spacing:-0.05pt;"> </font>held<font style="letter-spacing:0.05pt;"> </font>as business<font style="letter-spacing:0.05pt;"> </font>assets (<font style="font-style:italic;">Betriebsverm&#246;ge</font><font style="font-style:italic;letter-spacing:0.1pt;">n</font>).</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ADSs<font style="letter-spacing:-0.05pt;"> </font>as Private<font style="letter-spacing:0.05pt;"> </font>Assets<font style="letter-spacing:0.05pt;"> </font>(Privatverm&#246;gen)</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>held<font style="letter-spacing:0.05pt;"> </font>as private<font style="letter-spacing:0.1pt;"> </font>assets<font style="letter-spacing:0.05pt;"> </font>by a German<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>resident,<font style="letter-spacing:0.1pt;"> </font>dividends<font style="letter-spacing:0.05pt;"> </font>and capital<font style="letter-spacing:0.1pt;"> </font>gains<font style="letter-spacing:0.05pt;"> </font>(other<font style="letter-spacing:0.05pt;"> </font>than capital<font style="letter-spacing:0.1pt;"> </font>gains<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>disposition<font style="letter-spacing:0.1pt;"> </font>of a Qualifying<font style="letter-spacing:0.1pt;"> </font>Participation)<font style="letter-spacing:0.15pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>taxed<font style="letter-spacing:0.05pt;"> </font>as investment<font style="letter-spacing:0.1pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>and are<font style="letter-spacing:0.05pt;"> </font>principally subject<font style="letter-spacing:0.05pt;"> </font>to 25% German<font style="letter-spacing:0.05pt;"> </font>flat<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>on capital<font style="letter-spacing:0.1pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">Abgeltungsteue</font><font style="font-style:italic;letter-spacing:0.1pt;">r</font>) (plus<font style="letter-spacing:0.05pt;"> </font>a 5.5% solidarity<font style="letter-spacing:0.1pt;"> </font>surcharge (<font style="font-style:italic;">Solidarit&#228;tszuschla</font><font style="font-style:italic;letter-spacing:0.15pt;">g</font>) thereon,<font style="letter-spacing:0.05pt;"> </font>resulting<font style="letter-spacing:0.1pt;"> </font>in an aggregate<font style="letter-spacing:0.1pt;"> </font>rate<font style="letter-spacing:0.05pt;"> </font>of 26.375%),<font style="letter-spacing:0.05pt;"> </font>which is<font style="letter-spacing:0.05pt;"> </font>levied<font style="letter-spacing:0.05pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>form<font style="letter-spacing:0.05pt;"> </font>of withholding<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">Kapitalertragsteue</font><font style="font-style:italic;letter-spacing:0.15pt;">r</font>). In other<font style="letter-spacing:0.05pt;"> </font>words, once deducted,<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>holder&#8217;s<font style="letter-spacing:0.1pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>liability<font style="letter-spacing:0.15pt;"> </font>on the dividends<font style="letter-spacing:0.05pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>be settled.<font style="letter-spacing:0.1pt;"> </font>Dividend<font style="letter-spacing:0.05pt;"> </font>payments<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>extent<font style="letter-spacing:0.05pt;"> </font>funded<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>BioNTech&#8217;s tax-recognized<font style="letter-spacing:0.15pt;"> </font>contribution account<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">steuerliches</font><font style="font-style:italic;letter-spacing:0.15pt;"> </font><font style="font-style:italic;">Einlagekont</font><font style="font-style:italic;letter-spacing:0.05pt;">o</font>), subject<font style="letter-spacing:0.05pt;"> </font>to certain<font style="letter-spacing:0.1pt;"> </font>prerequisites,<font style="letter-spacing:0.15pt;"> do not </font>form<font style="letter-spacing:0.05pt;"> </font>part<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>taxable<font style="letter-spacing:0.05pt;"> </font>dividend income<font style="letter-spacing:0.05pt;"> </font>but should lower<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>holder&#8217;s<font style="letter-spacing:0.1pt;"> </font>acquisition<font style="letter-spacing:0.1pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>ADSs.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holders<font style="letter-spacing:0.05pt;"> </font>of ADSs<font style="letter-spacing:-0.05pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>apply<font style="letter-spacing:0.05pt;"> </font>to have their<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>investment<font style="letter-spacing:0.1pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>assessed<font style="letter-spacing:0.05pt;"> </font>in accordance<font style="letter-spacing:0.1pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>general rules<font style="letter-spacing:0.05pt;"> </font>and with an individual&#8217;s<font style="letter-spacing:0.1pt;"> </font>personal<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>rate<font style="letter-spacing:0.05pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>this<font style="letter-spacing:0.05pt;"> </font>would result<font style="letter-spacing:0.1pt;"> </font>in a lower<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>burden<font style="letter-spacing:0.05pt;"> </font>in which case actually<font style="letter-spacing:0.1pt;"> </font>incurred<font style="letter-spacing:0.1pt;"> </font>expenses<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>not deductible.<font style="letter-spacing:0.1pt;"> </font>The holder<font style="letter-spacing:0.05pt;"> </font>would be taxed<font style="letter-spacing:0.05pt;"> </font>on gross<font style="letter-spacing:0.05pt;"> </font>personal<font style="letter-spacing:0.05pt;"> </font>investment<font style="letter-spacing:0.1pt;"> </font>income (including<font style="letter-spacing:0.1pt;"> </font>dividends<font style="letter-spacing:0.05pt;"> </font>or gains<font style="letter-spacing:0.05pt;"> </font>with respect<font style="letter-spacing:0.1pt;"> </font>to ADSs), less<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>saver&#8217;s<font style="letter-spacing:0.1pt;"> </font>allowance<font style="letter-spacing:0.05pt;"> </font>of &#8364;801 for<font style="letter-spacing:0.05pt;"> </font>an individual<font style="letter-spacing:0.1pt;"> </font>or &#8364;1,602 for<font style="letter-spacing:0.05pt;"> </font>a married<font style="letter-spacing:0.1pt;"> </font>couple<font style="letter-spacing:0.05pt;"> </font>and a registered<font style="letter-spacing:0.1pt;"> </font>civil<font style="letter-spacing:0.05pt;"> </font>union (<font style="font-style:italic;">eingetragene</font><font style="font-style:italic;letter-spacing:0.1pt;"> </font><font style="font-style:italic;">Lebenspartnerschaf</font><font style="font-style:italic;letter-spacing:0.15pt;">t</font>) filing<font style="letter-spacing:0.1pt;"> </font>taxes<font style="letter-spacing:0.05pt;"> </font>jointly. The deduction<font style="letter-spacing:0.05pt;"> </font>of expenses<font style="letter-spacing:0.05pt;"> </font>related<font style="letter-spacing:0.1pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>investment<font style="letter-spacing:0.1pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>(including<font style="letter-spacing:0.1pt;"> </font>dividends<font style="letter-spacing:0.05pt;"> </font>or gains<font style="letter-spacing:0.05pt;"> </font>with respect<font style="letter-spacing:0.1pt;"> </font>to ADSs) is<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>not possible<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>private<font style="letter-spacing:0.1pt;"> </font>investors.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Losses<font style="letter-spacing:0.05pt;"> </font>resulting<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>disposal<font style="letter-spacing:0.05pt;"> </font>of ADSs<font style="letter-spacing:-0.05pt;"> </font>can only be offset<font style="letter-spacing:0.1pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>gains<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>sale<font style="letter-spacing:0.05pt;"> </font>of any shares<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">Aktie</font><font style="font-style:italic;letter-spacing:0.05pt;">n</font>) and other<font style="letter-spacing:0.05pt;"> </font>ADSs.<font style="letter-spacing:-0.05pt;"> </font>If,<font style="letter-spacing:0.05pt;"> </font>however, a holder<font style="letter-spacing:0.05pt;"> </font>holds<font style="letter-spacing:0.05pt;"> </font>a Qualifying<font style="letter-spacing:0.05pt;"> </font>Participation,<font style="letter-spacing:0.15pt;"> </font>60% of any capital<font style="letter-spacing:0.1pt;"> </font>gains resulting<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>sale<font style="letter-spacing:0.05pt;"> </font>and transfer<font style="letter-spacing:0.1pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>taxable<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>holder&#8217;s<font style="letter-spacing:0.1pt;"> </font>personal<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>rate<font style="letter-spacing:0.05pt;"> </font>(plus<font style="letter-spacing:0.05pt;"> </font>5.5% solidarity surcharge<font style="letter-spacing:0.1pt;"> </font>thereon).<font style="letter-spacing:0.1pt;"> </font>Conversely,<font style="letter-spacing:0.05pt;"> </font>60% of any capital<font style="letter-spacing:0.1pt;"> </font>losses<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>recognized<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>purposes.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since 2021, the basis for the calculation of the solidarity surcharge (<font style="font-style:italic;">Solidarit&#228;tszuschlag</font>) has been reduced for certain individual persons being subject to tax assessments (other than withholding taxes), and in certain cases, the solidarity surcharge has been abolished. However, the abolition or reduction of the solidarity surcharge is not applicable to corporations. In addition, the abolition or reduction of the solidarity surcharge will not affect withholding taxes. Solidarity surcharge will still be levied at 5.5% on the full withholding tax amount and withheld accordingly. There will not be any separate refund of such withheld solidarity surcharge (regardless of the aforementioned exemption limits) in case the withholding tax cannot be refunded either.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Church tax<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>has to be withheld,<font style="letter-spacing:0.05pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>applicable,<font style="letter-spacing:0.1pt;"> </font>based<font style="letter-spacing:0.05pt;"> </font>on an automatic<font style="letter-spacing:0.1pt;"> </font>data<font style="letter-spacing:0.05pt;"> </font>access<font style="letter-spacing:0.05pt;"> </font>procedure,<font style="letter-spacing:0.05pt;"> </font>unless the<font style="letter-spacing:0.05pt;"> </font>holder<font style="letter-spacing:0.05pt;"> </font>of ADSs<font style="letter-spacing:-0.05pt;"> </font>has filed<font style="letter-spacing:0.05pt;"> </font>a blocking<font style="letter-spacing:0.05pt;"> </font>notice<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">Sperrvermer</font><font style="font-style:italic;letter-spacing:0.05pt;">k</font>) with the<font style="letter-spacing:0.05pt;"> </font>Federal<font style="letter-spacing:0.05pt;"> </font>Central<font style="letter-spacing:0.05pt;"> </font>Tax Office.<font style="letter-spacing:0.05pt;"> </font>Where church<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>not levied<font style="letter-spacing:0.05pt;"> </font>by way of withholding,<font style="letter-spacing:0.05pt;"> </font>it<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>determined<font style="letter-spacing:0.1pt;"> </font>by means<font style="letter-spacing:0.05pt;"> </font>of income<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>assessment.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ADSs</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">as</font><font style="font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </font><font style="font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Business</font><font style="font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> Assets</font><font style="letter-spacing:0.05pt;"> </font><font style="font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(Betriebsverm&#246;gen)</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In case<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>held<font style="letter-spacing:0.05pt;"> </font>as business<font style="letter-spacing:0.05pt;"> </font>assets,<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>taxation<font style="letter-spacing:0.1pt;"> </font>depends<font style="letter-spacing:0.05pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>legal<font style="letter-spacing:0.05pt;"> </font>form<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>holder<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">i.e</font><font style="font-style:italic;letter-spacing:0.05pt;">.</font>, whether<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>holder<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>a corporation<font style="letter-spacing:0.1pt;"> </font>or an individual).</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Irrespective<font style="letter-spacing:0.15pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>legal<font style="letter-spacing:0.05pt;"> </font>form<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>holder,<font style="letter-spacing:0.05pt;"> </font>dividends<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>aggregate<font style="letter-spacing:0.1pt;"> </font>withholding<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>rate<font style="letter-spacing:0.05pt;"> </font>of 26.375%. The withholding<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>creditable<font style="letter-spacing:0.1pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>respective<font style="letter-spacing:0.1pt;"> </font>holder&#8217;s<font style="letter-spacing:0.1pt;"> </font>corporate<font style="letter-spacing:0.1pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>or income<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>liability.<font style="letter-spacing:0.15pt;"> </font>Due to special<font style="letter-spacing:0.1pt;"> </font>rules<font style="letter-spacing:0.05pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>restriction<font style="letter-spacing:0.15pt;"> </font>of withholding<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>credits<font style="letter-spacing:0.1pt;"> </font>in respect<font style="letter-spacing:0.1pt;"> </font>of dividends,<font style="letter-spacing:0.05pt;"> </font>a full<font style="letter-spacing:0.05pt;"> </font>withholding<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>credit<font style="letter-spacing:0.1pt;"> </font>requires<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>following<font style="letter-spacing:0.05pt;"> </font>three<font style="letter-spacing:0.05pt;"> </font>cumulative<font style="letter-spacing:0.1pt;"> </font>requirements<font style="letter-spacing:0.15pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>met:<font style="letter-spacing:0.05pt;"> </font>(i)<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>holder<font style="letter-spacing:0.05pt;"> </font>must qualify<font style="letter-spacing:0.05pt;"> </font>as beneficial<font style="letter-spacing:0.1pt;"> </font>owner of the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>an uninterrupted<font style="letter-spacing:0.1pt;"> </font>minimum<font style="letter-spacing:0.1pt;"> </font>holding<font style="letter-spacing:0.05pt;"> </font>period<font style="letter-spacing:0.05pt;"> </font>of 45 days occurring within<font style="letter-spacing:0.05pt;"> </font>a period<font style="letter-spacing:0.05pt;"> </font>starting<font style="letter-spacing:0.1pt;"> </font>45 days prior<font style="letter-spacing:0.05pt;"> </font>to and ending<font style="letter-spacing:0.05pt;"> </font>45 days after<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>due date<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>dividends,<font style="letter-spacing:0.05pt;"> </font>(ii)<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>holder<font style="letter-spacing:0.05pt;"> </font>has to bear<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>70% of the<font style="letter-spacing:0.05pt;"> </font>change<font style="letter-spacing:0.05pt;"> </font>in value<font style="letter-spacing:0.05pt;"> </font>risk<font style="letter-spacing:0.05pt;"> </font>related<font style="letter-spacing:0.1pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>during<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>minimum<font style="letter-spacing:0.1pt;"> </font>holding<font style="letter-spacing:0.05pt;"> </font>period<font style="letter-spacing:0.05pt;"> </font>as described<font style="letter-spacing:0.1pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>(i)<font style="letter-spacing:0.05pt;"> </font>of this<font style="letter-spacing:0.05pt;"> </font>paragraph<font style="letter-spacing:0.05pt;"> </font>and has not entered<font style="letter-spacing:0.05pt;"> </font>into<font style="letter-spacing:0.05pt;"> </font>(acting<font style="letter-spacing:0.1pt;"> </font>by itself<font style="letter-spacing:0.1pt;"> </font>or through<font style="letter-spacing:0.05pt;"> </font>a related<font style="letter-spacing:0.1pt;"> </font>party)<font style="letter-spacing:0.05pt;"> </font>hedging transactions<font style="letter-spacing:0.15pt;"> </font>which lower<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>change<font style="letter-spacing:0.05pt;"> </font>in value<font style="letter-spacing:0.05pt;"> </font>risk<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>more<font style="letter-spacing:0.05pt;"> </font>than<font style="letter-spacing:0.05pt;"> </font>30%, and (iii)<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>holder<font style="letter-spacing:0.05pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>not be obliged<font style="letter-spacing:0.05pt;"> </font>to fully<font style="letter-spacing:0.05pt;"> </font>or largely<font style="letter-spacing:0.1pt;"> </font>compensate<font style="letter-spacing:0.1pt;"> </font>directly<font style="letter-spacing:0.1pt;"> </font>or indirectly<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>dividends<font style="letter-spacing:0.05pt;"> </font>to third<font style="letter-spacing:0.05pt;"> </font>parties.<font style="letter-spacing:0.1pt;"> </font>If<font style="letter-spacing:0.05pt;"> </font>these<font style="letter-spacing:0.05pt;"> </font>requirements<font style="letter-spacing:0.15pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>not met, three-fifths<font style="letter-spacing:0.15pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>withholding<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>imposed<font style="letter-spacing:0.05pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>dividends<font style="letter-spacing:0.05pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>not be credited<font style="letter-spacing:0.1pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>holder&#8217;s<font style="letter-spacing:0.1pt;"> </font>corporate income<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>or income<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>liability,<font style="letter-spacing:0.15pt;"> </font>but may,<font style="letter-spacing:0.05pt;"> </font>upon application,<font style="letter-spacing:0.1pt;"> </font>be deducted<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>holder&#8217;s<font style="letter-spacing:0.1pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>base<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the relevant<font style="letter-spacing:0.1pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>assessment<font style="letter-spacing:0.1pt;"> </font>period.<font style="letter-spacing:0.05pt;"> </font>A holder<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>to German<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>or corporate<font style="letter-spacing:0.1pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>tax and that<font style="letter-spacing:0.05pt;"> </font>has received<font style="letter-spacing:0.1pt;"> </font>gross<font style="letter-spacing:0.05pt;"> </font>dividends<font style="letter-spacing:0.05pt;"> </font>without<font style="letter-spacing:0.05pt;"> </font>any deduction<font style="letter-spacing:0.05pt;"> </font>of withholding<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>due to a tax<font style="letter-spacing:0.05pt;"> </font>exemption<font style="letter-spacing:0.1pt;"> </font>without qualifying<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>a full<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>credit<font style="letter-spacing:0.1pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>aforementioned<font style="letter-spacing:0.15pt;"> </font>requirements<font style="letter-spacing:0.15pt;"> </font>has to notify<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>competent<font style="letter-spacing:0.1pt;"> </font>local<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>office accordingly, has to file withholding tax returns for a withholding tax of 15%  in accordance with statutory formal requirements<font style="letter-spacing:0.1pt;"> </font>and has to make<font style="letter-spacing:0.05pt;"> </font>a payment<font style="letter-spacing:0.05pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>omitted<font style="letter-spacing:0.1pt;"> </font>withholding<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>deduction.<font style="letter-spacing:0.05pt;"> </font>The special<font style="letter-spacing:0.1pt;"> </font>rules on the<font style="letter-spacing:0.05pt;"> </font>restriction<font style="letter-spacing:0.15pt;"> </font>of withholding<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>credit<font style="color:#000000;"> </font>(and the corresponding notification and payment obligations)<font style="letter-spacing:0.1pt;"> </font>do not apply<font style="letter-spacing:0.05pt;"> </font>to a holder<font style="letter-spacing:0.05pt;"> </font>whose overall<font style="letter-spacing:0.1pt;"> </font>dividend<font style="letter-spacing:0.05pt;"> </font>earnings<font style="letter-spacing:0.05pt;"> </font>within<font style="letter-spacing:0.05pt;"> </font>an assessment<font style="letter-spacing:0.1pt;"> </font>period<font style="letter-spacing:0.05pt;"> </font>do not exceed<font style="letter-spacing:0.05pt;"> </font>&#8364;20,000 or that<font style="letter-spacing:0.05pt;"> </font>has been the<font style="letter-spacing:0.05pt;"> </font>beneficial<font style="letter-spacing:0.1pt;"> </font>owner of the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>one uninterrupted<font style="letter-spacing:0.1pt;"> </font>year<font style="letter-spacing:0.05pt;"> </font>until<font style="letter-spacing:0.05pt;"> </font>receipt<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Zuflus</font><font style="font-style:italic;letter-spacing:0.05pt;">s</font>) of the<font style="letter-spacing:0.05pt;"> </font>dividends.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the<font style="letter-spacing:0.05pt;"> </font>extent<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>withheld<font style="letter-spacing:0.05pt;"> </font>exceeds<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>liability,<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>withholding<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>be refunded, provided<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>certain<font style="letter-spacing:0.1pt;"> </font>requirements<font style="letter-spacing:0.15pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>met<font style="letter-spacing:0.05pt;"> </font>(including<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>aforementioned<font style="letter-spacing:0.15pt;"> </font>requirements).</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Special<font style="letter-spacing:0.05pt;"> </font>rules<font style="letter-spacing:0.05pt;"> </font>apply<font style="letter-spacing:0.05pt;"> </font>to credit<font style="letter-spacing:0.1pt;"> </font>institutions<font style="letter-spacing:0.15pt;"> </font>(<font style="font-style:italic;">Kreditinstitut</font><font style="font-style:italic;letter-spacing:0.15pt;">e</font>), financial<font style="letter-spacing:0.1pt;"> </font>services<font style="letter-spacing:0.1pt;"> </font>institutions (<font style="font-style:italic;">Finanzdienstleistungsinstitut</font><font style="font-style:italic;letter-spacing:0.3pt;">e</font>), financial<font style="letter-spacing:0.1pt;"> </font>enterprises<font style="letter-spacing:0.15pt;"> </font>(<font style="font-style:italic;">Finanzunternehme</font><font style="font-style:italic;letter-spacing:0.05pt;">n</font>), life<font style="letter-spacing:0.05pt;"> </font>insurance<font style="letter-spacing:0.1pt;"> </font>and health<font style="letter-spacing:0.05pt;"> </font>insurance companies,<font style="letter-spacing:0.1pt;"> </font>and pension<font style="letter-spacing:0.05pt;"> </font>funds.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In principle, dividends that a corporation receives from German or foreign corporations are subject to corporate income tax (and solidarity surcharge thereon) at a rate of 15.825% and also subject to trade tax of between 7.0% and 19.0% depending on the multiplier applied by the relevant municipality. However, with<font style="letter-spacing:0.05pt;"> </font>regard<font style="letter-spacing:0.05pt;"> </font>to holders<font style="letter-spacing:0.05pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>legal<font style="letter-spacing:0.05pt;"> </font>form<font style="letter-spacing:0.05pt;"> </font>of a corporation,<font style="letter-spacing:0.1pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>gains<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>in general<font style="letter-spacing:0.05pt;"> </font>effectively<font style="letter-spacing:0.15pt;"> </font>95% tax exempt<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>corporate<font style="letter-spacing:0.1pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>(including<font style="letter-spacing:0.1pt;"> </font>solidarity<font style="letter-spacing:0.1pt;"> </font>surcharge).<font style="letter-spacing:0.1pt;"> </font>Dividends<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>also<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>95% tax<font style="letter-spacing:0.05pt;"> </font>exempt from<font style="letter-spacing:0.05pt;"> </font>corporate<font style="letter-spacing:0.1pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>(including<font style="letter-spacing:0.1pt;"> </font>solidarity<font style="letter-spacing:0.1pt;"> </font>surcharge),<font style="letter-spacing:0.1pt;"> </font>inter<font style="letter-spacing:0.05pt;"> </font>alia,<font style="letter-spacing:0.05pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>holder<font style="letter-spacing:0.05pt;"> </font>held<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>10% of the registered<font style="letter-spacing:0.1pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Grundkapital</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">oder Stammkapita</font><font style="font-style:italic;letter-spacing:0.05pt;">l</font>) of BioNTech at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>beginning<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>calendar<font style="letter-spacing:0.1pt;"> </font>year, or Qualifying<font style="letter-spacing:0.1pt;"> </font>Dividends.<font style="letter-spacing:0.05pt;"> </font>Five percent<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>gains<font style="letter-spacing:0.05pt;"> </font>and five<font style="letter-spacing:0.05pt;"> </font>percent<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Qualifying<font style="letter-spacing:0.05pt;"> </font>Dividends<font style="letter-spacing:0.05pt;"> </font>are treated<font style="letter-spacing:0.1pt;"> </font>as non-deductible<font style="letter-spacing:0.1pt;"> </font>business<font style="letter-spacing:0.05pt;"> </font>expenses,<font style="letter-spacing:0.05pt;"> </font>respectively,<font style="letter-spacing:0.15pt;"> </font>and, as such, are<font style="letter-spacing:0.05pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>to corporate<font style="letter-spacing:0.1pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>tax (including<font style="letter-spacing:0.1pt;"> </font>solidarity<font style="letter-spacing:0.1pt;"> </font>surcharge);<font style="letter-spacing:0.1pt;"> </font>actual<font style="letter-spacing:0.05pt;"> </font>business<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.05pt;"> </font>incurred<font style="letter-spacing:0.1pt;"> </font>to generate<font style="letter-spacing:0.1pt;"> </font>dividends<font style="letter-spacing:0.05pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>be deducted.<font style="letter-spacing:0.05pt;"> </font>The acquisition<font style="letter-spacing:0.1pt;"> </font>of a participation<font style="letter-spacing:0.15pt;"> </font>of at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>10% in the<font style="letter-spacing:0.05pt;"> </font>course<font style="letter-spacing:0.05pt;"> </font>of a calendar<font style="letter-spacing:0.1pt;"> </font>year<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>deemed<font style="letter-spacing:0.05pt;"> </font>to have occurred<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the beginning<font style="letter-spacing:0.05pt;"> </font>of such calendar<font style="letter-spacing:0.1pt;"> </font>year<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>determination<font style="letter-spacing:0.15pt;"> </font>of whether<font style="letter-spacing:0.05pt;"> </font>a dividend<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>a Qualifying<font style="letter-spacing:0.05pt;"> </font>Dividend. Participations<font style="letter-spacing:0.15pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>of BioNTech held<font style="letter-spacing:0.05pt;"> </font>through<font style="letter-spacing:0.05pt;"> </font>a partnership,<font style="letter-spacing:0.1pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>co-entrepreneurships (<font style="font-style:italic;">Mitunternehmerschafte</font><font style="font-style:italic;letter-spacing:0.2pt;">n</font>), are<font style="letter-spacing:0.05pt;"> </font>attributable<font style="letter-spacing:0.15pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>respective<font style="letter-spacing:0.1pt;"> </font>partner<font style="letter-spacing:0.1pt;"> </font>only on a pro rata<font style="letter-spacing:0.05pt;"> </font>basis<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>ratio<font style="letter-spacing:0.05pt;"> </font>of its entitlement<font style="letter-spacing:0.15pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>profits<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>partnership.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital<font style="letter-spacing:0.1pt;"> </font>gains<font style="letter-spacing:0.05pt;"> </font>and dividend<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>of a German<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>resident<font style="letter-spacing:0.1pt;"> </font>corporation<font style="letter-spacing:0.1pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>to German<font style="letter-spacing:0.05pt;"> </font>trade<font style="letter-spacing:0.05pt;"> </font>tax<font style="color:#000000;"> </font>of between 7.0% and 19.0% depending on the multiplier applied by the relevant municipality.<font style="letter-spacing:0.05pt;"> </font>The aforementioned<font style="letter-spacing:0.15pt;"> </font>95% exemption<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>gains<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>applies<font style="letter-spacing:0.05pt;"> </font>also<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>trade<font style="letter-spacing:0.05pt;"> </font>tax purposes. However, the<font style="letter-spacing:0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of any dividends<font style="letter-spacing:0.05pt;"> </font>after<font style="letter-spacing:0.1pt;"> </font>deducting<font style="letter-spacing:0.05pt;"> </font>business<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.05pt;"> </font>related<font style="letter-spacing:0.1pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>dividends<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>not subject<font style="letter-spacing:0.05pt;"> </font>to trade<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>corporation<font style="letter-spacing:0.1pt;"> </font>held<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>15% of BioNTech&#8217;s registered<font style="letter-spacing:0.1pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>beginning<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>relevant<font style="letter-spacing:0.1pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>assessment<font style="letter-spacing:0.1pt;"> </font>period.<font style="letter-spacing:0.05pt;"> </font>In this<font style="letter-spacing:0.1pt;"> </font>case,<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>aforementioned<font style="letter-spacing:0.15pt;"> </font>exemption<font style="letter-spacing:0.1pt;"> </font>of 95% of the<font style="letter-spacing:0.05pt;"> </font>dividend income<font style="letter-spacing:0.05pt;"> </font>also<font style="letter-spacing:0.05pt;"> </font>applies<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>trade<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>purposes.<font style="letter-spacing:0.05pt;"> </font>Losses<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>sale<font style="letter-spacing:0.05pt;"> </font>of ADSs<font style="letter-spacing:-0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>not tax<font style="letter-spacing:0.05pt;"> </font>deductible<font style="letter-spacing:0.1pt;"> </font>for corporate<font style="letter-spacing:0.1pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>and trade<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>purposes.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With<font style="letter-spacing:0.05pt;"> </font>regard<font style="letter-spacing:0.05pt;"> </font>to individuals<font style="letter-spacing:0.1pt;"> </font>holding<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>as business<font style="letter-spacing:0.05pt;"> </font>assets,<font style="letter-spacing:0.05pt;"> </font>60% of dividends<font style="letter-spacing:0.05pt;"> </font>and capital<font style="letter-spacing:0.1pt;"> </font>gains<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>taxed<font style="letter-spacing:0.05pt;"> </font>at the<font style="letter-spacing:0.05pt;"> </font>individual&#8217;s<font style="letter-spacing:0.1pt;"> </font>personal<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>rate<font style="letter-spacing:0.05pt;"> </font>(plus<font style="letter-spacing:0.05pt;"> </font>5.5% solidarity<font style="letter-spacing:0.1pt;"> </font>surcharge<font style="letter-spacing:0.1pt;"> </font>thereon).<font style="letter-spacing:0.1pt;"> </font>Correspondingly,<font style="letter-spacing:0.1pt;"> </font>only 60% of business<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.05pt;"> </font>related<font style="letter-spacing:0.1pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>dividends<font style="letter-spacing:0.05pt;"> </font>and capital<font style="letter-spacing:0.1pt;"> </font>gains<font style="letter-spacing:0.05pt;"> </font>as well<font style="letter-spacing:0.05pt;"> </font>as losses<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>sale<font style="letter-spacing:0.05pt;"> </font>of ADSs<font style="letter-spacing:-0.05pt;"> </font>are principally<font style="letter-spacing:0.1pt;"> </font>deductible<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>purposes.<font style="letter-spacing:0.05pt;"> </font>Since 2021, the basis for the calculation of the solidarity surcharge (<font style="font-style:italic;">Solidarit&#228;tszuschlag</font>) has been </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reduced for certain individual persons being subject to tax assessments (other than withholding taxes), and in certain cases, the solidarity surcharge has been abolished, subject to the limitations described above in &#8220;&#8212;ADSs as Private Assets (</font><font style="font-style:italic;">Privatverm&#246;gen</font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)&#8221;. The dividend</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">income</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and 60% of the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">capital</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gains</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">generally subject</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to trade</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tax,</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which is</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fully</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or partly</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">creditable</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">against</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">individual&#8217;s</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">personal</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">income</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tax</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by a lump-sum</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">method.</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividends</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(after</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">deduction</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of business</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expenses</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">economically</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">related</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">thereto)</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exempt from</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trade</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tax</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">holder</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">held</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">least</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15% of BioNTech&#8217;s registered</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">share</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">capital</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">beginning</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the relevant</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tax</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assessment</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">period.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">German Inheritance<font style="letter-spacing:0.05pt;"> </font>and Gift<font style="letter-spacing:0.05pt;"> </font>Tax (Erbschaft-<font style="letter-spacing:0.1pt;"> </font>und Schenkungsteuer)</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transfer<font style="letter-spacing:0.1pt;"> </font>of ADSs<font style="letter-spacing:-0.05pt;"> </font>to another<font style="letter-spacing:0.05pt;"> </font>person<font style="letter-spacing:0.05pt;"> </font>by inheritance<font style="letter-spacing:0.1pt;"> </font>or gift<font style="letter-spacing:0.05pt;"> generally </font>should<font style="letter-spacing:0.05pt;"> </font>be subject<font style="letter-spacing:0.05pt;"> </font>to German inheritance<font style="letter-spacing:0.1pt;"> </font>and gift<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>only if:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.09%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<font style="letter-spacing:0.05pt;"> </font>decedent<font style="letter-spacing:0.05pt;"> </font>or donor or heir,<font style="letter-spacing:0.05pt;"> </font>beneficiary<font style="letter-spacing:0.1pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>transferee<font style="letter-spacing:0.15pt;"> </font>(a)<font style="letter-spacing:0.05pt;"> </font>maintained<font style="letter-spacing:0.1pt;"> </font>his<font style="letter-spacing:0.05pt;"> </font>or her<font style="letter-spacing:0.05pt;"> </font>domicile<font style="letter-spacing:0.1pt;"> </font>or a usual residence<font style="letter-spacing:0.1pt;"> </font>in Germany,<font style="letter-spacing:0.05pt;"> </font>(b)<font style="letter-spacing:0.05pt;"> </font>had its<font style="letter-spacing:0.05pt;"> </font>place<font style="letter-spacing:0.05pt;"> </font>of management<font style="letter-spacing:0.1pt;"> </font>or registered<font style="letter-spacing:0.1pt;"> </font>office<font style="letter-spacing:0.1pt;"> </font>in Germany<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>of the transfer,<font style="letter-spacing:0.1pt;"> </font>(c)<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>a German<font style="letter-spacing:0.05pt;"> </font>citizen<font style="letter-spacing:0.1pt;"> </font>who has spent<font style="letter-spacing:0.05pt;"> </font>no more<font style="letter-spacing:0.05pt;"> </font>than<font style="letter-spacing:0.05pt;"> </font>five<font style="letter-spacing:0.05pt;"> </font>consecutive<font style="letter-spacing:0.1pt;"> </font>years<font style="letter-spacing:0.05pt;"> </font>outside<font style="letter-spacing:0.05pt;"> </font>of Germany without<font style="letter-spacing:0.05pt;"> </font>maintaining<font style="letter-spacing:0.1pt;"> </font>a domicile<font style="letter-spacing:0.1pt;"> </font>in Germany<font style="letter-spacing:0.05pt;"> </font>or (d)<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>a German<font style="letter-spacing:0.05pt;"> </font>citizen<font style="letter-spacing:0.1pt;"> </font>who serves<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>a German<font style="letter-spacing:0.05pt;"> </font>entity established<font style="letter-spacing:0.1pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>public<font style="letter-spacing:0.05pt;"> </font>law and is<font style="letter-spacing:0.05pt;"> </font>remunerated<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>his<font style="letter-spacing:0.05pt;"> </font>or her<font style="letter-spacing:0.05pt;"> </font>service<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>public<font style="letter-spacing:0.05pt;"> </font>funds<font style="letter-spacing:0.05pt;"> </font>(including family<font style="letter-spacing:0.1pt;"> </font>members<font style="letter-spacing:0.1pt;"> </font>who form<font style="letter-spacing:0.05pt;"> </font>part<font style="letter-spacing:0.05pt;"> </font>of such person&#8217;s<font style="letter-spacing:0.05pt;"> </font>household,<font style="letter-spacing:0.05pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>they<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>citizens)<font style="letter-spacing:0.1pt;"> </font>and is<font style="letter-spacing:0.05pt;"> </font>only subject to estate<font style="letter-spacing:0.1pt;"> </font>or inheritance<font style="letter-spacing:0.1pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>in his<font style="letter-spacing:0.05pt;"> </font>or her<font style="letter-spacing:0.05pt;"> </font>country<font style="letter-spacing:0.05pt;"> </font>of domicile<font style="letter-spacing:0.1pt;"> </font>or usual<font style="letter-spacing:0.05pt;"> </font>residence<font style="letter-spacing:0.1pt;"> </font>with respect<font style="letter-spacing:0.1pt;"> </font>to assets<font style="letter-spacing:0.05pt;"> </font>located in such country<font style="letter-spacing:0.05pt;"> </font>(special<font style="letter-spacing:0.1pt;"> </font>rules<font style="letter-spacing:0.05pt;"> </font>apply<font style="letter-spacing:0.05pt;"> </font>to certain<font style="letter-spacing:0.1pt;"> </font>former<font style="letter-spacing:0.1pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>citizens<font style="letter-spacing:0.1pt;"> </font>who neither<font style="letter-spacing:0.1pt;"> </font>maintain<font style="letter-spacing:0.1pt;"> </font>a domicile<font style="letter-spacing:0.1pt;"> </font>nor have their<font style="letter-spacing:0.05pt;"> </font>usual<font style="letter-spacing:0.05pt;"> </font>residence<font style="letter-spacing:0.1pt;"> </font>in Germany);</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.09%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>transfer,<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>held<font style="letter-spacing:0.05pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>decedent<font style="letter-spacing:0.05pt;"> </font>or donor as business<font style="letter-spacing:0.05pt;"> </font>assets<font style="letter-spacing:0.05pt;"> </font>forming<font style="letter-spacing:0.1pt;"> </font>part<font style="letter-spacing:0.05pt;"> </font>of a permanent<font style="letter-spacing:0.1pt;"> </font>establishment<font style="letter-spacing:0.15pt;"> </font>in Germany<font style="letter-spacing:0.05pt;"> </font>or for<font style="letter-spacing:0.05pt;"> </font>which a permanent<font style="letter-spacing:0.1pt;"> </font>representative<font style="letter-spacing:0.15pt;"> </font>in Germany<font style="letter-spacing:0.05pt;"> </font>has been appointed;<font style="letter-spacing:0.1pt;"> </font>or</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.09%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>to such transfer<font style="letter-spacing:0.1pt;"> </font>form<font style="letter-spacing:0.05pt;"> </font>part<font style="letter-spacing:0.05pt;"> </font>of a portfolio<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>represents<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>transfer<font style="letter-spacing:0.1pt;"> </font>10% or more<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>registered<font style="letter-spacing:0.1pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>of BioNTech and that<font style="letter-spacing:0.05pt;"> </font>has been held<font style="letter-spacing:0.05pt;"> </font>directly<font style="letter-spacing:0.1pt;"> </font>or indirectly<font style="letter-spacing:0.1pt;"> </font>by the decedent<font style="letter-spacing:0.05pt;"> </font>or donor, either<font style="letter-spacing:0.1pt;"> </font>alone<font style="letter-spacing:0.05pt;"> </font>or together<font style="letter-spacing:0.1pt;"> </font>with related<font style="letter-spacing:0.1pt;"> </font>persons.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Agreement<font style="letter-spacing:0.05pt;"> </font>between<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Federal<font style="letter-spacing:0.05pt;"> </font>Republic<font style="letter-spacing:0.05pt;"> </font>of Germany<font style="letter-spacing:0.05pt;"> </font>and the<font style="letter-spacing:0.05pt;"> </font>United<font style="letter-spacing:0.05pt;"> </font>States<font style="letter-spacing:0.05pt;"> </font>of America<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the avoidance<font style="letter-spacing:0.05pt;"> </font>of double<font style="letter-spacing:0.05pt;"> </font>taxation<font style="letter-spacing:0.1pt;"> </font>with respect<font style="letter-spacing:0.1pt;"> </font>to taxes<font style="letter-spacing:0.05pt;"> </font>on inheritances<font style="letter-spacing:0.15pt;"> </font>and gifts<font style="letter-spacing:0.05pt;"> </font>as of December<font style="letter-spacing:0.05pt;"> </font>21, 2000 (<font style="font-style:italic;">Abkommen zwischen</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">der Bundesrepublik</font><font style="font-style:italic;letter-spacing:0.1pt;"> </font><font style="font-style:italic;">Deutschland</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">und den Vereinigten</font><font style="font-style:italic;letter-spacing:0.1pt;"> </font><font style="font-style:italic;">Staaten</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">von Amerika zur Vermeidung der Doppelbesteuerung</font><font style="font-style:italic;letter-spacing:0.1pt;"> </font><font style="font-style:italic;">auf dem Gebiet</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">der Nachlass-,</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">Erbschaft-</font><font style="font-style:italic;letter-spacing:0.1pt;"> </font><font style="font-style:italic;">und Schenkungssteuern</font><font style="font-style:italic;letter-spacing:0.1pt;"> </font><font style="font-style:italic;">in der Fassung vom 21. Dezember 2000</font>), hereinafter<font style="letter-spacing:0.15pt;"> </font>referred<font style="letter-spacing:0.1pt;"> </font>to as the<font style="letter-spacing:0.05pt;"> </font>&#8220;United<font style="letter-spacing:0.05pt;"> </font>States-Germany<font style="letter-spacing:0.1pt;"> </font>Inheritance<font style="letter-spacing:0.1pt;"> </font>and Gifts<font style="letter-spacing:0.05pt;"> </font>Tax Treaty,&#8221; provides<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>inheritance<font style="letter-spacing:0.1pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>or gift<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>can, with certain<font style="letter-spacing:0.1pt;"> </font>restrictions,<font style="letter-spacing:0.15pt;"> </font>only be levied<font style="letter-spacing:0.05pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>cases<font style="letter-spacing:0.05pt;"> </font>of (i)<font style="letter-spacing:0.05pt;"> </font>and (ii)<font style="letter-spacing:0.1pt;"> </font>above. Special<font style="letter-spacing:0.05pt;"> </font>provisions<font style="letter-spacing:0.1pt;"> </font>apply<font style="letter-spacing:0.05pt;"> </font>to certain<font style="letter-spacing:0.1pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>citizens<font style="letter-spacing:0.1pt;"> </font>living<font style="letter-spacing:0.05pt;"> </font>outside<font style="letter-spacing:0.05pt;"> </font>of Germany<font style="letter-spacing:0.05pt;"> </font>and former German<font style="letter-spacing:0.05pt;"> </font>citizens. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Taxes</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No German<font style="letter-spacing:0.05pt;"> </font>transfer<font style="letter-spacing:0.1pt;"> </font>tax,<font style="letter-spacing:0.05pt;"> </font>value-added<font style="letter-spacing:0.1pt;"> </font>tax,<font style="letter-spacing:0.05pt;"> </font>stamp<font style="letter-spacing:0.05pt;"> </font>duty or similar<font style="letter-spacing:0.1pt;"> </font>taxes<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>assessed<font style="letter-spacing:0.05pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>purchase,<font style="letter-spacing:0.05pt;"> </font>sale<font style="letter-spacing:0.05pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>transfer<font style="letter-spacing:0.1pt;"> </font>of ADSs.<font style="letter-spacing:-0.05pt;"> </font>Provided<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>certain<font style="letter-spacing:0.1pt;"> </font>requirements<font style="letter-spacing:0.15pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>met,<font style="letter-spacing:0.05pt;"> </font>an entrepreneur<font style="letter-spacing:0.1pt;"> </font>may,<font style="letter-spacing:0.05pt;"> </font>however, opt for<font style="letter-spacing:0.05pt;"> </font>value-added tax<font style="letter-spacing:0.05pt;"> </font>on transactions<font style="letter-spacing:0.15pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>otherwise<font style="letter-spacing:0.05pt;"> </font>tax-exempt.<font style="letter-spacing:0.1pt;"> </font>Net wealth<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">Verm&#246;gensteue</font><font style="font-style:italic;letter-spacing:0.05pt;">r</font>) is<font style="letter-spacing:0.05pt;"> </font>not imposed<font style="letter-spacing:0.05pt;"> currently </font>in Germany.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Material<font style="letter-spacing:0.1pt;"> </font>United States<font style="letter-spacing:0.05pt;"> </font>Federal<font style="letter-spacing:0.05pt;"> </font>Income<font style="letter-spacing:0.05pt;"> </font>Tax Considerations</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following<font style="letter-spacing:0.05pt;"> </font>discussion<font style="letter-spacing:0.1pt;"> </font>describes<font style="letter-spacing:0.1pt;"> </font>material<font style="letter-spacing:0.15pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>federal<font style="letter-spacing:0.1pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>considerations<font style="letter-spacing:0.15pt;"> </font>relating<font style="letter-spacing:0.1pt;"> </font>to the acquisition,<font style="letter-spacing:0.1pt;"> </font>ownership<font style="letter-spacing:0.05pt;"> </font>and disposition<font style="letter-spacing:0.1pt;"> </font>of ADSs<font style="letter-spacing:-0.05pt;"> </font>by a U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder<font style="letter-spacing:0.05pt;"> </font>(as<font style="letter-spacing:0.05pt;"> </font>defined<font style="letter-spacing:0.05pt;"> </font>below)<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>acquires<font style="letter-spacing:0.1pt;"> </font>our ADSs<font style="letter-spacing:-0.05pt;"> </font>and holds<font style="letter-spacing:0.05pt;"> </font>them<font style="letter-spacing:0.05pt;"> </font>as a capital<font style="letter-spacing:0.1pt;"> </font>asset.<font style="letter-spacing:0.05pt;"> </font>This discussion<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>based<font style="letter-spacing:0.05pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>laws of the<font style="letter-spacing:0.05pt;"> </font>United<font style="letter-spacing:0.05pt;"> </font>States,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Internal Revenue Code of 1986, as amended,<font style="letter-spacing:0.05pt;"> </font>or the<font style="letter-spacing:0.05pt;"> </font>Code, Treasury<font style="letter-spacing:0.05pt;"> </font>regulations<font style="letter-spacing:0.1pt;"> </font>promulgated<font style="letter-spacing:0.1pt;"> </font>or proposed<font style="letter-spacing:0.05pt;"> </font>thereunder,<font style="letter-spacing:0.1pt;"> </font>and administrative<font style="letter-spacing:0.2pt;"> </font>and judicial<font style="letter-spacing:0.1pt;"> </font>interpretations<font style="letter-spacing:0.2pt;"> </font>thereof,<font style="letter-spacing:0.1pt;"> </font>all<font style="letter-spacing:0.05pt;"> </font>as in effect<font style="letter-spacing:0.1pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>date<font style="letter-spacing:0.05pt;"> </font>hereof.<font style="letter-spacing:0.05pt;"> </font>These tax<font style="letter-spacing:0.05pt;"> </font>laws are<font style="letter-spacing:0.05pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>to change,<font style="letter-spacing:0.05pt;"> </font>possibly<font style="letter-spacing:0.05pt;"> </font>with retroactive<font style="letter-spacing:0.15pt;"> </font>effect,<font style="letter-spacing:0.1pt;"> </font>and subject<font style="letter-spacing:0.05pt;"> </font>to differing<font style="letter-spacing:0.1pt;"> </font>interpretations<font style="letter-spacing:0.2pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>could<font style="letter-spacing:0.05pt;"> </font>affect<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>tax consequences<font style="letter-spacing:0.05pt;"> </font>described<font style="letter-spacing:0.1pt;"> </font>herein.<font style="letter-spacing:0.05pt;"> </font>This section<font style="letter-spacing:0.05pt;"> </font>does not address<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>treatment<font style="letter-spacing:0.15pt;"> </font>of a non-U.S. holder,<font style="letter-spacing:0.05pt;"> </font>nor does it address<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>treatment<font style="letter-spacing:0.15pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>laws of any state,<font style="letter-spacing:0.05pt;"> </font>local<font style="letter-spacing:0.05pt;"> </font>or foreign<font style="letter-spacing:0.05pt;"> </font>taxing<font style="letter-spacing:0.05pt;"> </font>jurisdiction.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes<font style="letter-spacing:0.05pt;"> </font>of this<font style="letter-spacing:0.05pt;"> </font>discussion,<font style="letter-spacing:0.1pt;"> </font>a &#8220;U.S. Holder&#8221;<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>a beneficial<font style="letter-spacing:0.1pt;"> </font>owner of our ADSs<font style="letter-spacing:-0.05pt;"> </font>that,<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>federal income<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>purposes,<font style="letter-spacing:0.05pt;"> </font>is:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">an individual who is a citizen or resident of the United States;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a domestic corporation (or other entity taxable as a corporation);</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">216</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a trust if (i) a court within the United States is able to exercise primary supervision over the trust&#8217;s administration and one or more U.S. persons have the authority to control all substantial decisions of the trust or (ii) a valid election under the Treasury regulations is in effect for the trust to be treated as a U.S. person.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This discussion<font style="letter-spacing:0.1pt;"> </font>does not address<font style="letter-spacing:0.05pt;"> </font>all<font style="letter-spacing:0.05pt;"> </font>aspects<font style="letter-spacing:0.05pt;"> </font>of U.S.<font style="letter-spacing:-0.05pt;"> </font>federal<font style="letter-spacing:0.1pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>taxation<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>be applicable<font style="letter-spacing:0.1pt;"> </font>to U.S. Holders<font style="letter-spacing:0.05pt;"> </font>in light<font style="letter-spacing:0.05pt;"> </font>of their<font style="letter-spacing:0.05pt;"> </font>particular<font style="letter-spacing:0.15pt;"> </font>circumstances<font style="letter-spacing:0.15pt;"> </font>or status<font style="letter-spacing:0.05pt;"> </font>(including,<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>example,<font style="letter-spacing:0.05pt;"> </font>banks and other<font style="letter-spacing:0.05pt;"> </font>financial institutions,<font style="letter-spacing:0.15pt;"> </font>insurance<font style="letter-spacing:0.1pt;"> </font>companies,<font style="letter-spacing:0.1pt;"> </font>broker<font style="letter-spacing:0.05pt;"> </font>and dealers<font style="letter-spacing:0.1pt;"> </font>in securities<font style="letter-spacing:0.15pt;"> </font>or currencies,<font style="letter-spacing:0.1pt;"> </font>traders<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>have elected<font style="letter-spacing:0.1pt;"> </font>to mark securities<font style="letter-spacing:0.15pt;"> </font>to market,<font style="letter-spacing:0.1pt;"> </font>regulated<font style="letter-spacing:0.1pt;"> </font>investment<font style="letter-spacing:0.1pt;"> </font>companies,<font style="letter-spacing:0.1pt;"> </font>real<font style="letter-spacing:0.05pt;"> </font>estate<font style="letter-spacing:0.1pt;"> </font>investment<font style="letter-spacing:0.1pt;"> </font>trusts,<font style="letter-spacing:0.1pt;"> </font>partnerships<font style="letter-spacing:0.1pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>pass- through<font style="letter-spacing:0.05pt;"> </font>entities,<font style="letter-spacing:0.1pt;"> </font>corporations<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>accumulate<font style="letter-spacing:0.1pt;"> </font>earnings<font style="letter-spacing:0.05pt;"> </font>to avoid<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>federal<font style="letter-spacing:0.1pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>tax,<font style="letter-spacing:0.05pt;"> </font>tax-exempt organizations,<font style="letter-spacing:0.1pt;"> </font>pension<font style="letter-spacing:0.05pt;"> </font>plans,<font style="letter-spacing:0.05pt;"> </font>persons<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>hold our shares<font style="letter-spacing:0.05pt;"> </font>as part<font style="letter-spacing:0.05pt;"> </font>of a straddle,<font style="letter-spacing:0.1pt;"> </font>hedge or other<font style="letter-spacing:0.05pt;"> </font>integrated investment,<font style="letter-spacing:0.1pt;"> </font>persons<font style="letter-spacing:0.05pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>to alternative<font style="letter-spacing:0.15pt;"> </font>minimum<font style="letter-spacing:0.1pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>or whose &#8220;functional<font style="letter-spacing:0.1pt;"> </font>currency&#8221;<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>not the<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>dollar).</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<font style="letter-spacing:0.05pt;"> </font>a partnership<font style="letter-spacing:0.1pt;"> </font>(including<font style="letter-spacing:0.1pt;"> </font>any entity<font style="letter-spacing:0.05pt;"> </font>or arrangement<font style="letter-spacing:0.1pt;"> </font>treated<font style="letter-spacing:0.1pt;"> </font>as a partnership<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>federal<font style="letter-spacing:0.1pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>tax purposes)<font style="letter-spacing:0.05pt;"> </font>holds<font style="letter-spacing:0.05pt;"> </font>our ADSs,<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>treatment<font style="letter-spacing:0.15pt;"> </font>of a person<font style="letter-spacing:0.05pt;"> </font>treated<font style="letter-spacing:0.1pt;"> </font>as a partner<font style="letter-spacing:0.1pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>partnership<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>federal income<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>purposes<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>depend on the<font style="letter-spacing:0.05pt;"> </font>status<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>partner<font style="letter-spacing:0.1pt;"> </font>and the<font style="letter-spacing:0.05pt;"> </font>activities<font style="letter-spacing:0.15pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>partnership. Partnerships<font style="letter-spacing:0.1pt;"> </font>(and<font style="letter-spacing:0.05pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>entities<font style="letter-spacing:0.1pt;"> </font>or arrangements<font style="letter-spacing:0.15pt;"> </font>so treated<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>federal<font style="letter-spacing:0.1pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>purposes)<font style="letter-spacing:0.05pt;"> </font>and their partners<font style="letter-spacing:0.1pt;"> </font>should<font style="letter-spacing:0.05pt;"> </font>consult<font style="letter-spacing:0.05pt;"> </font>their<font style="letter-spacing:0.05pt;"> </font>own tax<font style="letter-spacing:0.05pt;"> </font>advisors.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In general,<font style="letter-spacing:0.05pt;"> </font>and taking<font style="letter-spacing:0.05pt;"> </font>into<font style="letter-spacing:0.05pt;"> </font>account<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>earlier<font style="letter-spacing:0.1pt;"> </font>assumptions,<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>federal<font style="letter-spacing:0.1pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>and German<font style="letter-spacing:0.05pt;"> </font>tax purposes,<font style="letter-spacing:0.05pt;"> </font>a holder<font style="letter-spacing:0.05pt;"> </font>of ADSs<font style="letter-spacing:-0.05pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>be treated<font style="letter-spacing:0.1pt;"> </font>as the<font style="letter-spacing:0.05pt;"> </font>owner of the<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>represented<font style="letter-spacing:0.1pt;"> </font>by those<font style="letter-spacing:0.05pt;"> </font>ADSs.<font style="letter-spacing:-0.05pt;"> </font>Exchanges<font style="letter-spacing:0.05pt;"> </font>of shares<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>ADSs,<font style="letter-spacing:-0.05pt;"> </font>and ADSs<font style="letter-spacing:-0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>shares,<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>not be subject<font style="letter-spacing:0.05pt;"> </font>to U.S.<font style="letter-spacing:-0.05pt;"> </font>federal<font style="letter-spacing:0.1pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>or to German<font style="letter-spacing:0.05pt;"> </font>tax.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">This discussion<font style="letter-spacing:0.05pt;"> </font>addresses<font style="letter-spacing:0.05pt;"> </font>only U.S.<font style="letter-spacing:-0.05pt;"> </font>Holders<font style="letter-spacing:0.05pt;"> </font>and does not discuss<font style="letter-spacing:0.05pt;"> </font>any tax considerations<font style="letter-spacing:0.1pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>than U.S. federal<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>tax considerations.<font style="letter-spacing:0.1pt;"> </font>Prospective<font style="letter-spacing:0.1pt;"> </font>investors<font style="letter-spacing:0.1pt;"> </font>are urged to consult<font style="letter-spacing:0.05pt;"> </font>their<font style="letter-spacing:0.05pt;"> </font>own<font style="letter-spacing:-0.05pt;"> </font>tax advisors<font style="letter-spacing:0.05pt;"> </font>regarding the U.S.<font style="letter-spacing:-0.05pt;"> </font>federal,<font style="letter-spacing:0.05pt;"> </font>state<font style="letter-spacing:0.05pt;"> </font>and local,<font style="letter-spacing:0.05pt;"> </font>and foreign<font style="letter-spacing:0.05pt;"> </font>tax consequences<font style="letter-spacing:0.05pt;"> </font>of the purchase, ownership, and disposition<font style="letter-spacing:0.1pt;"> </font>of ADSs.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Dividends</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>federal<font style="letter-spacing:0.1pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>laws, and subject<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>passive<font style="letter-spacing:0.05pt;"> </font>foreign<font style="letter-spacing:0.05pt;"> </font>investment<font style="letter-spacing:0.1pt;"> </font>company,<font style="letter-spacing:0.05pt;"> </font>or PFIC, rules<font style="letter-spacing:0.05pt;"> </font>discussed<font style="letter-spacing:0.05pt;"> </font>below, the<font style="letter-spacing:0.05pt;"> </font>gross<font style="letter-spacing:0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of any dividend<font style="letter-spacing:0.05pt;"> </font>we pay out of our current<font style="letter-spacing:0.1pt;"> </font>or accumulated<font style="letter-spacing:0.1pt;"> </font>earnings<font style="letter-spacing:0.05pt;"> </font>and profits<font style="letter-spacing:0.1pt;"> </font>(as<font style="letter-spacing:0.05pt;"> </font>determined<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>federal<font style="letter-spacing:0.1pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>purposes)<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>includible<font style="letter-spacing:0.1pt;"> </font>in income<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>a U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder<font style="letter-spacing:0.05pt;"> </font>and subject to U.S.<font style="letter-spacing:-0.05pt;"> </font>federal<font style="letter-spacing:0.1pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>taxation.<font style="letter-spacing:0.1pt;"> </font>Dividends<font style="letter-spacing:0.05pt;"> </font>paid<font style="letter-spacing:0.05pt;"> </font>to a noncorporate<font style="letter-spacing:0.1pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>constitute<font style="letter-spacing:0.1pt;"> </font>qualified<font style="letter-spacing:0.1pt;"> </font>dividend income<font style="letter-spacing:0.05pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>be taxable<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>a preferential<font style="letter-spacing:0.15pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>rate<font style="letter-spacing:0.05pt;"> </font>applicable<font style="letter-spacing:0.1pt;"> </font>to long-term<font style="letter-spacing:0.1pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>gains,<font style="letter-spacing:0.05pt;"> </font>provided<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>U.S. Holder<font style="letter-spacing:0.05pt;"> </font>holds<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>more<font style="letter-spacing:0.05pt;"> </font>than<font style="letter-spacing:0.05pt;"> </font>60 days during<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>121-day<font style="letter-spacing:0.05pt;"> </font>period<font style="letter-spacing:0.05pt;"> </font>beginning<font style="letter-spacing:0.05pt;"> </font>60 days before<font style="letter-spacing:0.05pt;"> </font>the ex-dividend<font style="letter-spacing:0.1pt;"> </font>date<font style="letter-spacing:0.05pt;"> </font>and meets<font style="letter-spacing:0.05pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>holding<font style="letter-spacing:0.05pt;"> </font>period<font style="letter-spacing:0.05pt;"> </font>requirements.<font style="letter-spacing:0.15pt;"> </font>Dividends<font style="letter-spacing:0.05pt;"> </font>we pay with respect<font style="letter-spacing:0.1pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>ADSs generally<font style="letter-spacing:0.1pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>be qualified<font style="letter-spacing:0.1pt;"> </font>dividend<font style="letter-spacing:0.05pt;"> </font>income.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder<font style="letter-spacing:0.05pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>include<font style="letter-spacing:0.05pt;"> </font>any German<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>withheld<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>dividend<font style="letter-spacing:0.05pt;"> </font>payment,<font style="letter-spacing:0.05pt;"> </font>as described<font style="letter-spacing:0.1pt;"> </font>above under &#8220;&#8212;German<font style="letter-spacing:0.05pt;"> </font>Taxation&#8212;General<font style="letter-spacing:0.1pt;"> </font>Rules for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Taxation<font style="letter-spacing:0.05pt;"> </font>of Holders<font style="letter-spacing:0.05pt;"> </font>Not Tax Resident<font style="letter-spacing:0.05pt;"> </font>in Germany,&#8221;<font style="letter-spacing:0.05pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>gross amount<font style="letter-spacing:0.05pt;"> </font>of dividend<font style="letter-spacing:0.05pt;"> </font>paid<font style="letter-spacing:0.05pt;"> </font>even though the<font style="letter-spacing:0.05pt;"> </font>holder<font style="letter-spacing:0.05pt;"> </font>does not in fact<font style="letter-spacing:0.05pt;"> </font>receive<font style="letter-spacing:0.1pt;"> </font>it.<font style="letter-spacing:0.05pt;"> </font>The dividend<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>taxable<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>holder when the<font style="letter-spacing:0.05pt;"> </font>depositary<font style="letter-spacing:0.1pt;"> </font>receives<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>dividend,<font style="letter-spacing:0.05pt;"> </font>actually<font style="letter-spacing:0.1pt;"> </font>or constructively.<font style="letter-spacing:0.15pt;"> </font>Because<font style="letter-spacing:0.05pt;"> </font>we are<font style="letter-spacing:0.05pt;"> </font>not a U.S.<font style="letter-spacing:-0.05pt;"> </font>corporation,<font style="letter-spacing:0.1pt;"> </font>the dividend<font style="letter-spacing:0.05pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>not be eligible<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>dividends-received<font style="letter-spacing:0.15pt;"> </font>deduction<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>allowed<font style="letter-spacing:0.05pt;"> </font>to U.S.<font style="letter-spacing:-0.05pt;"> </font>corporations<font style="letter-spacing:0.1pt;"> </font>in respect<font style="letter-spacing:0.1pt;"> </font>of dividends<font style="letter-spacing:0.05pt;"> </font>received<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>corporations.<font style="letter-spacing:0.1pt;"> </font>The amount<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>dividend<font style="letter-spacing:0.05pt;"> </font>distribution<font style="letter-spacing:0.15pt;"> </font>includible<font style="letter-spacing:0.1pt;"> </font>in U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder&#8217;s<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>be the<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>dollar<font style="letter-spacing:0.05pt;"> </font>value<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Euro payments<font style="letter-spacing:0.05pt;"> </font>made,<font style="letter-spacing:0.05pt;"> </font>determined<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>spot<font style="letter-spacing:0.05pt;"> </font>Euro/U.S. dollar<font style="letter-spacing:0.05pt;"> </font>rate<font style="letter-spacing:0.05pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>date<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>dividend<font style="letter-spacing:0.05pt;"> </font>distribution<font style="letter-spacing:0.15pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>includible<font style="letter-spacing:0.1pt;"> </font>in income,<font style="letter-spacing:0.05pt;"> </font>regardless<font style="letter-spacing:0.1pt;"> </font>of whether<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>payment<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>in fact<font style="letter-spacing:0.05pt;"> </font>converted<font style="letter-spacing:0.05pt;"> </font>into<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>dollars.<font style="letter-spacing:0.1pt;"> </font>Generally,<font style="letter-spacing:0.05pt;"> </font>any gain<font style="letter-spacing:0.05pt;"> </font>or loss<font style="letter-spacing:0.05pt;"> </font>resulting<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>currency<font style="letter-spacing:0.05pt;"> </font>exchange<font style="letter-spacing:0.05pt;"> </font>fluctuations<font style="letter-spacing:0.15pt;"> </font>during the<font style="letter-spacing:0.05pt;"> </font>period<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>date<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>dividend<font style="letter-spacing:0.05pt;"> </font>payment<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>included<font style="letter-spacing:0.05pt;"> </font>in income<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>date<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>payment<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>converted<font style="letter-spacing:0.05pt;"> </font>into U.S.<font style="letter-spacing:-0.05pt;"> </font>dollars<font style="letter-spacing:0.1pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>be treated<font style="letter-spacing:0.1pt;"> </font>as ordinary<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>or loss<font style="letter-spacing:0.05pt;"> </font>and will<font style="letter-spacing:0.05pt;"> </font>not be eligible<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>special<font style="letter-spacing:0.1pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>rate<font style="letter-spacing:0.05pt;"> </font>applicable to qualified<font style="letter-spacing:0.1pt;"> </font>dividend<font style="letter-spacing:0.05pt;"> </font>income.<font style="letter-spacing:0.05pt;"> </font>The gain<font style="letter-spacing:0.05pt;"> </font>or loss<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>be income<font style="letter-spacing:0.05pt;"> </font>or loss<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>sources<font style="letter-spacing:0.05pt;"> </font>within<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>United States<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>foreign<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>credit<font style="letter-spacing:0.1pt;"> </font>limitation<font style="letter-spacing:0.15pt;"> </font>purposes.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the<font style="letter-spacing:0.05pt;"> </font>extent<font style="letter-spacing:0.05pt;"> </font>a distribution<font style="letter-spacing:0.15pt;"> </font>with respect<font style="letter-spacing:0.1pt;"> </font>to ADSs<font style="letter-spacing:-0.05pt;"> </font>exceeds<font style="letter-spacing:0.05pt;"> </font>our current<font style="letter-spacing:0.1pt;"> </font>or accumulated<font style="letter-spacing:0.1pt;"> </font>earnings<font style="letter-spacing:0.05pt;"> </font>and profits, as determined<font style="letter-spacing:0.1pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>federal<font style="letter-spacing:0.1pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>principles,<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>distribution<font style="letter-spacing:0.15pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>be treated,<font style="letter-spacing:0.1pt;"> </font>first,<font style="letter-spacing:0.1pt;"> </font>as a tax-free<font style="letter-spacing:0.1pt;"> </font>return of the<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder&#8217;s<font style="letter-spacing:0.05pt;"> </font>investment,<font style="letter-spacing:0.1pt;"> </font>up to the<font style="letter-spacing:0.05pt;"> </font>holder&#8217;s<font style="letter-spacing:0.1pt;"> </font>adjusted<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>basis<font style="letter-spacing:0.05pt;"> </font>in its<font style="letter-spacing:0.05pt;"> </font>ADSs,<font style="letter-spacing:-0.05pt;"> </font>and, thereafter,<font style="letter-spacing:0.15pt;"> </font>as capital<font style="letter-spacing:0.1pt;"> </font>gain, which is<font style="letter-spacing:0.05pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>treatment<font style="letter-spacing:0.15pt;"> </font>described<font style="letter-spacing:0.1pt;"> </font>below in &#8220;&#8212;Gain on Sale,<font style="letter-spacing:0.05pt;"> </font>Exchange or Other<font style="letter-spacing:0.05pt;"> </font>Taxable Disposition.&#8221;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject<font style="letter-spacing:0.05pt;"> </font>to certain<font style="letter-spacing:0.1pt;"> </font>limitations,<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>withheld<font style="letter-spacing:0.05pt;"> </font>in accordance<font style="letter-spacing:0.1pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>Treaty<font style="letter-spacing:0.05pt;"> </font>and paid<font style="letter-spacing:0.05pt;"> </font>over<font style="letter-spacing:0.05pt;"> </font>to the German<font style="letter-spacing:0.05pt;"> </font>taxing<font style="letter-spacing:0.05pt;"> </font>authority<font style="letter-spacing:0.1pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>be creditable<font style="letter-spacing:0.1pt;"> </font>or deductible<font style="letter-spacing:0.1pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>a U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder&#8217;s<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>federal<font style="letter-spacing:0.1pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>liability. To the<font style="letter-spacing:0.05pt;"> </font>extent<font style="letter-spacing:0.05pt;"> </font>a refund<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>withheld<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>available<font style="letter-spacing:0.1pt;"> </font>to a U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>law or under<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Treaty,<font style="letter-spacing:0.05pt;"> </font>the amount<font style="letter-spacing:0.05pt;"> </font>of tax<font style="letter-spacing:0.05pt;"> </font>withheld<font style="letter-spacing:0.05pt;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">refundable</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not be eligible</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">credit</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">against</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a U.S.</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holder&#8217;s</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">federal income</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tax</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">liability.</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See &#8220;&#8212;German</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Taxation&#8212;Withholding</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax Refund for</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Treaty</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beneficiaries&#8221;</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">above for the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">procedures</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obtaining</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a tax</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">refund.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Gain On<font style="letter-spacing:-0.05pt;"> </font>Sale, Exchange or Other Taxable Disposition</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>PFIC rules<font style="letter-spacing:0.05pt;"> </font>described<font style="letter-spacing:0.1pt;"> </font>below under<font style="letter-spacing:0.05pt;"> </font>&#8220;&#8212;Passive<font style="letter-spacing:0.05pt;"> </font>Foreign<font style="letter-spacing:0.05pt;"> </font>Investment<font style="letter-spacing:0.1pt;"> </font>Company Considerations&#8221;, a U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>sells,<font style="letter-spacing:0.05pt;"> </font>exchanges<font style="letter-spacing:0.05pt;"> </font>or otherwise<font style="letter-spacing:0.05pt;"> </font>disposes<font style="letter-spacing:0.05pt;"> </font>of ADSs<font style="letter-spacing:-0.05pt;"> </font>in a taxable<font style="letter-spacing:0.05pt;"> </font>disposition<font style="letter-spacing:0.1pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>will recognize<font style="letter-spacing:0.1pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>gain<font style="letter-spacing:0.05pt;"> </font>or loss<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>federal<font style="letter-spacing:0.1pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>purposes<font style="letter-spacing:0.05pt;"> </font>equal<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>difference<font style="letter-spacing:0.1pt;"> </font>between<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>dollar value<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>realized<font style="letter-spacing:0.1pt;"> </font>and the<font style="letter-spacing:0.05pt;"> </font>holder&#8217;s<font style="letter-spacing:0.1pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>basis,<font style="letter-spacing:0.05pt;"> </font>determined<font style="letter-spacing:0.1pt;"> </font>in U.S.<font style="letter-spacing:-0.05pt;"> </font>dollars,<font style="letter-spacing:0.1pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>ADSs.<font style="letter-spacing:-0.05pt;"> </font>Gain or loss recognized<font style="letter-spacing:0.1pt;"> </font>on such a sale,<font style="letter-spacing:0.05pt;"> </font>exchange<font style="letter-spacing:0.05pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>disposition<font style="letter-spacing:0.1pt;"> </font>of ADSs<font style="letter-spacing:-0.05pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>be long-term<font style="letter-spacing:0.1pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>gain<font style="letter-spacing:0.05pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>the U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder&#8217;s<font style="letter-spacing:0.05pt;"> </font>holding<font style="letter-spacing:0.05pt;"> </font>period<font style="letter-spacing:0.05pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>exceeds<font style="letter-spacing:0.05pt;"> </font>one year.<font style="letter-spacing:0.05pt;"> </font>Long-term<font style="letter-spacing:0.1pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>gains<font style="letter-spacing:0.05pt;"> </font>of non-corporate<font style="letter-spacing:0.1pt;"> </font>U.S. Holders<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>taxed<font style="letter-spacing:0.05pt;"> generally </font>at<font style="letter-spacing:0.05pt;"> </font>preferential<font style="letter-spacing:0.15pt;"> </font>rates.<font style="letter-spacing:0.05pt;"> </font>The gain<font style="letter-spacing:0.05pt;"> </font>or loss<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>be income<font style="letter-spacing:0.05pt;"> </font>or loss<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>sources within<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>United<font style="letter-spacing:0.05pt;"> </font>States<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>foreign<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>credit<font style="letter-spacing:0.1pt;"> </font>limitation<font style="letter-spacing:0.15pt;"> </font>purposes.<font style="letter-spacing:0.05pt;"> </font>A U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder&#8217;s<font style="letter-spacing:0.05pt;"> </font>ability<font style="letter-spacing:0.1pt;"> </font>to deduct<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>losses is<font style="letter-spacing:0.05pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>to limitations.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Passive<font style="letter-spacing:0.05pt;"> </font>Foreign Investment<font style="letter-spacing:0.1pt;"> </font>Company Considerations</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not believe<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we should<font style="letter-spacing:0.05pt;"> </font>be treated<font style="letter-spacing:0.1pt;"> </font>as, and do not expect<font style="letter-spacing:0.05pt;"> </font>to become,<font style="letter-spacing:0.05pt;"> </font>a PFIC. Because<font style="letter-spacing:0.05pt;"> </font>the determination<font style="letter-spacing:0.15pt;"> </font>of our PFIC status<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>made<font style="letter-spacing:0.05pt;"> </font>annually<font style="letter-spacing:0.05pt;"> </font>based<font style="letter-spacing:0.05pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>factual<font style="letter-spacing:0.1pt;"> </font>tests<font style="letter-spacing:0.05pt;"> </font>described<font style="letter-spacing:0.1pt;"> </font>below, however, we cannot<font style="letter-spacing:0.05pt;"> </font>provide<font style="letter-spacing:0.05pt;"> </font>any assurances<font style="letter-spacing:0.1pt;"> </font>regarding<font style="letter-spacing:0.1pt;"> </font>our PFIC status<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>current<font style="letter-spacing:0.1pt;"> </font>or future<font style="letter-spacing:0.05pt;"> </font>taxable<font style="letter-spacing:0.05pt;"> </font>years<font style="letter-spacing:0.05pt;"> </font>or that<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>IRS will<font style="letter-spacing:0.05pt;"> </font>agree<font style="letter-spacing:0.05pt;"> </font>with our conclusion<font style="letter-spacing:0.05pt;"> </font>regarding<font style="letter-spacing:0.1pt;"> </font>our PFIC status.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<font style="letter-spacing:0.05pt;"> </font>we were classified<font style="letter-spacing:0.15pt;"> </font>as a PFIC in any taxable<font style="letter-spacing:0.05pt;"> </font>year,<font style="letter-spacing:0.05pt;"> </font>a U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder<font style="letter-spacing:0.05pt;"> </font>would be subject<font style="letter-spacing:0.05pt;"> </font>to special<font style="letter-spacing:0.1pt;"> </font>rules<font style="letter-spacing:0.05pt;"> </font>with respect<font style="letter-spacing:0.1pt;"> </font>to distributions<font style="letter-spacing:0.15pt;"> </font>on and sales,<font style="letter-spacing:0.05pt;"> </font>exchanges<font style="letter-spacing:0.05pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>dispositions<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>ADSs.<font style="letter-spacing:-0.05pt;"> </font>We will<font style="letter-spacing:0.05pt;"> </font>be treated<font style="letter-spacing:0.1pt;"> </font>as a PFIC for<font style="letter-spacing:0.05pt;"> </font>any taxable<font style="letter-spacing:0.05pt;"> </font>year<font style="letter-spacing:0.05pt;"> </font>in which at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>75% of our gross<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>&#8220;passive<font style="letter-spacing:0.05pt;"> </font>income&#8221;<font style="letter-spacing:0.05pt;"> </font>or at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>50% of our gross assets<font style="letter-spacing:0.05pt;"> </font>during<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>taxable<font style="letter-spacing:0.05pt;"> </font>year<font style="letter-spacing:0.05pt;"> </font>(based<font style="letter-spacing:0.05pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>average<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>fair<font style="letter-spacing:0.05pt;"> </font>market<font style="letter-spacing:0.1pt;"> </font>values<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>assets<font style="letter-spacing:0.05pt;"> </font>determined<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>end of each<font style="letter-spacing:0.05pt;"> </font>quarterly<font style="letter-spacing:0.1pt;"> </font>period)<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>assets<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>produce<font style="letter-spacing:0.05pt;"> </font>or are<font style="letter-spacing:0.05pt;"> </font>held<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>production<font style="letter-spacing:0.05pt;"> </font>of passive<font style="letter-spacing:0.05pt;"> </font>income.<font style="letter-spacing:0.05pt;"> </font>Passive<font style="letter-spacing:0.05pt;"> </font>income for<font style="letter-spacing:0.05pt;"> </font>this<font style="letter-spacing:0.05pt;"> </font>purpose<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>includes,<font style="letter-spacing:0.05pt;"> </font>among<font style="letter-spacing:0.05pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>things,<font style="letter-spacing:0.05pt;"> </font>dividends,<font style="letter-spacing:0.05pt;"> </font>interest,<font style="letter-spacing:0.1pt;"> </font>rents,<font style="letter-spacing:0.05pt;"> </font>royalties,<font style="letter-spacing:0.1pt;"> </font>gains<font style="letter-spacing:0.05pt;"> </font>from commodities<font style="letter-spacing:0.15pt;"> </font>and securities<font style="letter-spacing:0.15pt;"> </font>transactions,<font style="letter-spacing:0.15pt;"> </font>and gains<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>assets<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>produce<font style="letter-spacing:0.05pt;"> </font>passive<font style="letter-spacing:0.05pt;"> </font>income.<font style="letter-spacing:0.05pt;"> </font>However, rents<font style="letter-spacing:0.05pt;"> </font>and royalties<font style="letter-spacing:0.1pt;"> </font>received<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>unrelated<font style="letter-spacing:0.1pt;"> </font>parties<font style="letter-spacing:0.1pt;"> </font>in connection<font style="letter-spacing:0.05pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>active<font style="letter-spacing:0.05pt;"> </font>conduct<font style="letter-spacing:0.05pt;"> </font>of a trade<font style="letter-spacing:0.05pt;"> </font>or business<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>not considered<font style="letter-spacing:0.1pt;"> </font>passive<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>purposes<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>PFIC test.<font style="letter-spacing:0.05pt;"> </font>In determining<font style="letter-spacing:0.1pt;"> </font>whether<font style="letter-spacing:0.05pt;"> </font>we are<font style="letter-spacing:0.05pt;"> </font>a PFIC, a pro rata portion<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>and assets<font style="letter-spacing:0.05pt;"> </font>of each<font style="letter-spacing:0.05pt;"> </font>corporation<font style="letter-spacing:0.1pt;"> </font>in which we own, directly<font style="letter-spacing:0.1pt;"> </font>or indirectly,<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>a 25% interest<font style="letter-spacing:0.1pt;"> </font>(by value)<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>taken<font style="letter-spacing:0.05pt;"> </font>into<font style="letter-spacing:0.05pt;"> </font>account.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<font style="letter-spacing:0.05pt;"> </font>we were a PFIC with respect<font style="letter-spacing:0.1pt;"> </font>to a U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder,<font style="letter-spacing:0.05pt;"> </font>then<font style="letter-spacing:0.05pt;"> </font>unless<font style="letter-spacing:0.05pt;"> </font>such U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder<font style="letter-spacing:0.05pt;"> </font>makes<font style="letter-spacing:0.05pt;"> </font>one of the<font style="letter-spacing:0.05pt;"> </font>elections described<font style="letter-spacing:0.1pt;"> </font>below, a special<font style="letter-spacing:0.1pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>regime<font style="letter-spacing:0.1pt;"> </font>would apply<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder<font style="letter-spacing:0.05pt;"> </font>with respect<font style="letter-spacing:0.1pt;"> </font>to (i)<font style="letter-spacing:0.05pt;"> </font>any &#8220;excess<font style="letter-spacing:0.05pt;"> </font>distribution&#8221; (generally,<font style="letter-spacing:0.1pt;"> </font>aggregate<font style="letter-spacing:0.1pt;"> </font>distributions<font style="letter-spacing:0.15pt;"> </font>in any year<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>greater<font style="letter-spacing:0.1pt;"> </font>than<font style="letter-spacing:0.05pt;"> </font>125% of the<font style="letter-spacing:0.05pt;"> </font>average<font style="letter-spacing:0.05pt;"> </font>annual<font style="letter-spacing:0.05pt;"> </font>distribution received<font style="letter-spacing:0.1pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>holder<font style="letter-spacing:0.05pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>shorter<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>three<font style="letter-spacing:0.05pt;"> </font>preceding<font style="letter-spacing:0.05pt;"> </font>years<font style="letter-spacing:0.05pt;"> </font>or the<font style="letter-spacing:0.05pt;"> </font>holder&#8217;s<font style="letter-spacing:0.1pt;"> </font>holding<font style="letter-spacing:0.05pt;"> </font>period<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>ADSs) and (ii)<font style="letter-spacing:0.1pt;"> </font>any gain<font style="letter-spacing:0.05pt;"> </font>realized<font style="letter-spacing:0.1pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>sale<font style="letter-spacing:0.05pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>disposition<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>ADSs.<font style="letter-spacing:-0.05pt;"> </font>Under this<font style="letter-spacing:0.05pt;"> </font>regime,<font style="letter-spacing:0.1pt;"> </font>any excess<font style="letter-spacing:0.05pt;"> </font>distribution and realized<font style="letter-spacing:0.1pt;"> </font>gain<font style="letter-spacing:0.05pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>be treated<font style="letter-spacing:0.1pt;"> </font>as ordinary<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>and will<font style="letter-spacing:0.05pt;"> </font>be subject<font style="letter-spacing:0.05pt;"> </font>to tax<font style="letter-spacing:0.05pt;"> </font>as if<font style="letter-spacing:0.05pt;"> </font>(a)<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>excess<font style="letter-spacing:0.05pt;"> </font>distribution<font style="letter-spacing:0.15pt;"> </font>or gain<font style="letter-spacing:0.05pt;"> </font>had been realized<font style="letter-spacing:0.1pt;"> </font>ratably<font style="letter-spacing:0.1pt;"> </font>over<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder&#8217;s<font style="letter-spacing:0.05pt;"> </font>holding<font style="letter-spacing:0.05pt;"> </font>period,<font style="letter-spacing:0.05pt;"> </font>(b)<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>deemed<font style="letter-spacing:0.05pt;"> </font>realized<font style="letter-spacing:0.1pt;"> </font>in each year<font style="letter-spacing:0.05pt;"> </font>had been subject<font style="letter-spacing:0.05pt;"> </font>to tax<font style="letter-spacing:0.05pt;"> </font>in each<font style="letter-spacing:0.05pt;"> </font>year<font style="letter-spacing:0.05pt;"> </font>of that<font style="letter-spacing:0.05pt;"> </font>holding<font style="letter-spacing:0.05pt;"> </font>period<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>highest<font style="letter-spacing:0.05pt;"> </font>marginal<font style="letter-spacing:0.1pt;"> </font>rate<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>such year<font style="letter-spacing:0.05pt;"> </font>(other than<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>allocated<font style="letter-spacing:0.1pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>current<font style="letter-spacing:0.1pt;"> </font>period<font style="letter-spacing:0.05pt;"> </font>or any taxable<font style="letter-spacing:0.05pt;"> </font>period<font style="letter-spacing:0.05pt;"> </font>before<font style="letter-spacing:0.05pt;"> </font>we became<font style="letter-spacing:0.05pt;"> </font>a PFIC, which would be subject<font style="letter-spacing:0.05pt;"> </font>to tax<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder&#8217;s<font style="letter-spacing:0.05pt;"> </font>regular<font style="letter-spacing:0.1pt;"> </font>ordinary<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>rate<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>current<font style="letter-spacing:0.1pt;"> </font>year<font style="letter-spacing:0.05pt;"> </font>and would not be subject<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>interest<font style="letter-spacing:0.1pt;"> </font>charge<font style="letter-spacing:0.05pt;"> </font>discussed<font style="letter-spacing:0.05pt;"> </font>below),<font style="letter-spacing:0.05pt;"> </font>and (c)<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>interest<font style="letter-spacing:0.1pt;"> </font>charge<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>applicable<font style="letter-spacing:0.1pt;"> </font>to underpayments<font style="letter-spacing:0.1pt;"> </font>of tax<font style="letter-spacing:0.05pt;"> </font>had been imposed<font style="letter-spacing:0.05pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>taxes<font style="letter-spacing:0.05pt;"> </font>deemed<font style="letter-spacing:0.05pt;"> </font>to have been payable<font style="letter-spacing:0.05pt;"> </font>in those<font style="letter-spacing:0.05pt;"> </font>years.<font style="letter-spacing:0.05pt;"> </font>If<font style="letter-spacing:0.05pt;"> </font>we were determined<font style="letter-spacing:0.1pt;"> </font>to be a PFIC, this tax<font style="letter-spacing:0.05pt;"> </font>treatment<font style="letter-spacing:0.15pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>Holders<font style="letter-spacing:0.05pt;"> </font>would apply<font style="letter-spacing:0.05pt;"> </font>also<font style="letter-spacing:0.05pt;"> </font>to indirect<font style="letter-spacing:0.1pt;"> </font>distributions<font style="letter-spacing:0.15pt;"> </font>and gains<font style="letter-spacing:0.05pt;"> </font>deemed<font style="letter-spacing:0.05pt;"> </font>realized<font style="letter-spacing:0.1pt;"> </font>by U.S. Holders<font style="letter-spacing:0.05pt;"> </font>in respect<font style="letter-spacing:0.1pt;"> </font>of stock<font style="letter-spacing:0.05pt;"> </font>of any of our subsidiaries<font style="letter-spacing:0.15pt;"> </font>determined<font style="letter-spacing:0.1pt;"> </font>to be PFICs. In addition,<font style="letter-spacing:0.05pt;"> </font>dividend<font style="letter-spacing:0.05pt;"> </font>distributions<font style="color:#000000;"> </font>would not qualify<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>lower<font style="letter-spacing:0.05pt;"> </font>rates<font style="letter-spacing:0.05pt;"> </font>of taxation<font style="letter-spacing:0.1pt;"> </font>applicable<font style="letter-spacing:0.1pt;"> </font>to long-term<font style="letter-spacing:0.1pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>gains<font style="letter-spacing:0.05pt;"> </font>discussed<font style="letter-spacing:0.05pt;"> </font>above under &#8220;&#8212;Taxation<font style="letter-spacing:0.05pt;"> </font>of Dividends.&#8221;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>holds<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>any time<font style="letter-spacing:0.05pt;"> </font>during<font style="letter-spacing:0.05pt;"> </font>a taxable<font style="letter-spacing:0.05pt;"> </font>year<font style="letter-spacing:0.05pt;"> </font>in which we are<font style="letter-spacing:0.05pt;"> </font>classified<font style="letter-spacing:0.15pt;"> </font>as a PFIC generally<font style="letter-spacing:0.1pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>continue<font style="letter-spacing:0.05pt;"> </font>to treat<font style="letter-spacing:0.1pt;"> </font>such ADSs<font style="letter-spacing:-0.05pt;"> </font>as ADSs<font style="letter-spacing:-0.05pt;"> </font>in a PFIC, even if<font style="letter-spacing:0.05pt;"> </font>we no longer<font style="letter-spacing:0.05pt;"> </font>satisfy<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>and asset tests<font style="letter-spacing:0.05pt;"> </font>described<font style="letter-spacing:0.1pt;"> </font>above, unless<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder<font style="letter-spacing:0.05pt;"> </font>elects<font style="letter-spacing:0.1pt;"> </font>to recognize<font style="letter-spacing:0.1pt;"> </font>gain,<font style="letter-spacing:0.05pt;"> </font>which will<font style="letter-spacing:0.05pt;"> </font>be taxed<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>excess distribution<font style="letter-spacing:0.15pt;"> </font>rules<font style="letter-spacing:0.05pt;"> </font>as if<font style="letter-spacing:0.05pt;"> </font>such ADSs<font style="letter-spacing:-0.05pt;"> </font>had been sold<font style="letter-spacing:0.05pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>last<font style="letter-spacing:0.05pt;"> </font>day of the<font style="letter-spacing:0.05pt;"> </font>last<font style="letter-spacing:0.05pt;"> </font>taxable<font style="letter-spacing:0.05pt;"> </font>year<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>which we were a PFIC.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain<font style="letter-spacing:0.05pt;"> </font>elections<font style="letter-spacing:0.1pt;"> </font>by a U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder<font style="letter-spacing:0.05pt;"> </font>would alleviate<font style="letter-spacing:0.1pt;"> </font>some<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>adverse<font style="letter-spacing:0.05pt;"> </font>consequences<font style="letter-spacing:0.05pt;"> </font>of PFIC status<font style="letter-spacing:0.05pt;"> </font>and would result<font style="letter-spacing:0.1pt;"> </font>in an alternative<font style="letter-spacing:0.15pt;"> </font>treatment<font style="letter-spacing:0.15pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>ADSs,<font style="letter-spacing:-0.05pt;"> </font>as described<font style="letter-spacing:0.1pt;"> </font>below.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<font style="letter-spacing:0.05pt;"> </font>we were a PFIC, the<font style="letter-spacing:0.05pt;"> </font>rules<font style="letter-spacing:0.05pt;"> </font>above would not apply<font style="letter-spacing:0.05pt;"> </font>to a U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>makes<font style="letter-spacing:0.05pt;"> </font>an election<font style="letter-spacing:0.1pt;"> </font>to treat<font style="letter-spacing:0.1pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>as stock<font style="letter-spacing:0.05pt;"> </font>of a &#8220;qualified<font style="letter-spacing:0.1pt;"> </font>electing<font style="letter-spacing:0.1pt;"> </font>fund&#8221;<font style="letter-spacing:0.05pt;"> </font>or QEF.<font style="letter-spacing:-0.05pt;"> </font>However, we do not expect<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>a U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder<font style="letter-spacing:0.05pt;"> </font>would be able<font style="letter-spacing:0.05pt;"> </font>to make<font style="letter-spacing:0.05pt;"> </font>this<font style="letter-spacing:0.05pt;"> </font>election<font style="letter-spacing:0.1pt;"> </font>because<font style="letter-spacing:0.05pt;"> </font>we do not intend<font style="letter-spacing:0.05pt;"> </font>to provide<font style="letter-spacing:0.05pt;"> </font>to U.S.<font style="letter-spacing:-0.05pt;"> </font>Holders<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>required<font style="letter-spacing:0.1pt;"> </font>information<font style="letter-spacing:0.15pt;"> </font>to make<font style="letter-spacing:0.05pt;"> </font>a valid QEF<font style="letter-spacing:-0.05pt;"> </font>election.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">218</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we were a PFIC, the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rules</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">above also</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would not apply</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to a U.S.</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holder</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">makes</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a &#8220;mark-to-market&#8221; election</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with respect</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ADSs,</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">but this</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">election</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be available</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with respect</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ADSs</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">only if</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">they</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">meet certain</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">minimum</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trading</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">requirements</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to be considered</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;marketable</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stock&#8221;</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">purposes</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PFIC rules. Generally,</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shares</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of ADSs</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be treated</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as marketable</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stock</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">they</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;regularly</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">traded&#8221;</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on a &#8220;qualified exchange&#8221;</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">within</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">meaning</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of applicable</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Treasury</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulations.</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ADSs</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">generally</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be considered regularly</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">traded</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">during</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any calendar</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">year</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">during</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which they</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">traded,</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">than</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in </font><font style="font-style:italic;">de minimis</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">quantities,</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on at least</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15 days during</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">each</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">calendar</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">quarter.</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any trades</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have as their</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">principal</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">purpose</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">meeting</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">this requirement</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be disregarded.</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ADSs</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be marketable</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stock</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as long as they</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">remain</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">listed</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nasdaq Global</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Select</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Market</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and are</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">traded</font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> regularly</font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>makes<font style="letter-spacing:0.05pt;"> </font>a valid<font style="letter-spacing:0.05pt;"> </font>mark-to-market<font style="letter-spacing:0.2pt;"> </font>election<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>first<font style="letter-spacing:0.1pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>year<font style="letter-spacing:0.05pt;"> </font>in which the<font style="letter-spacing:0.05pt;"> </font>holder<font style="letter-spacing:0.05pt;"> </font>holds<font style="letter-spacing:0.05pt;"> </font>(or is<font style="letter-spacing:0.05pt;"> </font>deemed<font style="letter-spacing:0.05pt;"> </font>to hold)<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>and for<font style="letter-spacing:0.05pt;"> </font>which we are<font style="letter-spacing:0.05pt;"> </font>a PFIC will<font style="letter-spacing:0.05pt;"> </font>be required<font style="letter-spacing:0.1pt;"> </font>to include<font style="letter-spacing:0.05pt;"> </font>each<font style="letter-spacing:0.05pt;"> </font>year<font style="letter-spacing:0.05pt;"> </font>an amount<font style="letter-spacing:0.05pt;"> </font>equal<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>excess,<font style="letter-spacing:0.05pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>any, of the<font style="letter-spacing:0.05pt;"> </font>fair<font style="letter-spacing:0.05pt;"> </font>market<font style="letter-spacing:0.1pt;"> </font>value<font style="letter-spacing:0.05pt;"> </font>of such ADSs<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>holder<font style="letter-spacing:0.05pt;"> </font>owns as of the<font style="letter-spacing:0.05pt;"> </font>close<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>taxable<font style="letter-spacing:0.05pt;"> </font>year<font style="letter-spacing:0.05pt;"> </font>over the<font style="letter-spacing:0.05pt;"> </font>holder&#8217;s<font style="letter-spacing:0.1pt;"> </font>adjusted<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>basis<font style="letter-spacing:0.05pt;"> </font>in such ADSs.<font style="letter-spacing:-0.05pt;"> </font>The U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder<font style="letter-spacing:0.05pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>be entitled<font style="letter-spacing:0.1pt;"> </font>to a deduction<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>excess,<font style="letter-spacing:0.05pt;"> </font>if any, of the<font style="letter-spacing:0.05pt;"> </font>holder&#8217;s<font style="letter-spacing:0.1pt;"> </font>adjusted<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>basis<font style="letter-spacing:0.05pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>over<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>fair<font style="letter-spacing:0.05pt;"> </font>market<font style="letter-spacing:0.1pt;"> </font>value<font style="letter-spacing:0.05pt;"> </font>of such ADSs<font style="letter-spacing:-0.05pt;"> </font>as of the<font style="letter-spacing:0.05pt;"> </font>close<font style="letter-spacing:0.05pt;"> </font>of the taxable<font style="letter-spacing:0.05pt;"> </font>year,<font style="letter-spacing:0.05pt;"> </font>but only to the<font style="letter-spacing:0.05pt;"> </font>extent<font style="letter-spacing:0.05pt;"> </font>of any net<font style="letter-spacing:0.05pt;"> </font>mark-to-market<font style="letter-spacing:0.2pt;"> </font>gains<font style="letter-spacing:0.05pt;"> </font>with respect<font style="letter-spacing:0.1pt;"> </font>to such ADSs<font style="letter-spacing:-0.05pt;"> </font>included<font style="letter-spacing:0.05pt;"> </font>by the U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>election<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>prior<font style="letter-spacing:0.05pt;"> </font>taxable<font style="letter-spacing:0.05pt;"> </font>years.<font style="letter-spacing:0.05pt;"> </font>The U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder&#8217;s<font style="letter-spacing:0.05pt;"> </font>basis<font style="letter-spacing:0.05pt;"> </font>in such ADSs<font style="letter-spacing:-0.05pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>be adjusted<font style="letter-spacing:0.05pt;"> </font>to reflect<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>amounts<font style="letter-spacing:0.05pt;"> </font>included<font style="letter-spacing:0.05pt;"> </font>or deducted<font style="letter-spacing:0.05pt;"> </font>pursuant<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>election.<font style="letter-spacing:0.1pt;"> </font>Amounts<font style="letter-spacing:0.05pt;"> </font>included<font style="letter-spacing:0.05pt;"> </font>in income<font style="letter-spacing:0.05pt;"> </font>pursuant<font style="letter-spacing:0.05pt;"> </font>to a mark-to-market<font style="letter-spacing:0.2pt;"> </font>election,<font style="letter-spacing:0.1pt;"> </font>as well<font style="letter-spacing:0.05pt;"> </font>as gain<font style="letter-spacing:0.05pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>sale,<font style="letter-spacing:0.05pt;"> </font>exchange<font style="letter-spacing:0.05pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>taxable<font style="letter-spacing:0.05pt;"> </font>disposition<font style="letter-spacing:0.1pt;"> </font>of such ADSs,<font style="letter-spacing:-0.05pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>be treated<font style="letter-spacing:0.1pt;"> </font>as ordinary<font style="letter-spacing:0.05pt;"> </font>income.<font style="letter-spacing:0.05pt;"> </font>The deductible<font style="letter-spacing:0.1pt;"> </font>portion<font style="letter-spacing:0.05pt;"> </font>of any mark-to-market<font style="letter-spacing:0.2pt;"> </font>loss,<font style="letter-spacing:0.05pt;"> </font>as well<font style="letter-spacing:0.05pt;"> </font>as loss<font style="letter-spacing:0.05pt;"> </font>on a sale, exchange<font style="letter-spacing:0.05pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>disposition<font style="letter-spacing:0.1pt;"> </font>of ADSs<font style="letter-spacing:-0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>extent<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of such loss<font style="letter-spacing:0.05pt;"> </font>does not exceed<font style="letter-spacing:0.05pt;"> </font>net mark-to-market<font style="letter-spacing:0.2pt;"> </font>gains<font style="letter-spacing:0.05pt;"> </font>previously<font style="letter-spacing:0.1pt;"> </font>included<font style="letter-spacing:0.05pt;"> </font>in income,<font style="letter-spacing:0.05pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>be treated<font style="letter-spacing:0.1pt;"> </font>as ordinary<font style="letter-spacing:0.05pt;"> </font>loss.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The mark-to-market election applies to the taxable year for which the election is made and all subsequent taxable<font style="letter-spacing:0.05pt;"> </font>years,<font style="letter-spacing:0.05pt;"> </font>unless<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>cease<font style="letter-spacing:0.05pt;"> </font>to be treated<font style="letter-spacing:0.1pt;"> </font>as marketable<font style="letter-spacing:0.1pt;"> </font>stock<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>purposes<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>PFIC rules<font style="letter-spacing:0.05pt;"> </font>or the<font style="letter-spacing:0.05pt;"> </font>IRS consents<font style="letter-spacing:0.05pt;"> </font>to its<font style="letter-spacing:0.05pt;"> </font>revocation.<font style="letter-spacing:0.1pt;"> </font>The excess<font style="letter-spacing:0.05pt;"> </font>distribution<font style="letter-spacing:0.15pt;"> </font>rules<font style="letter-spacing:0.05pt;"> </font>described<font style="letter-spacing:0.1pt;"> </font>above generally<font style="letter-spacing:0.1pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>not apply<font style="letter-spacing:0.05pt;"> </font>to a U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder for<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>years<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>which a mark-to-market<font style="letter-spacing:0.2pt;"> </font>election<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>in effect.<font style="letter-spacing:0.1pt;"> </font>However, if<font style="letter-spacing:0.05pt;"> </font>we were a PFIC for<font style="letter-spacing:0.05pt;"> </font>any year<font style="letter-spacing:0.05pt;"> </font>in which the<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder<font style="letter-spacing:0.05pt;"> </font>owns the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>but before<font style="letter-spacing:0.05pt;"> </font>a mark-to-market<font style="letter-spacing:0.2pt;"> </font>election<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>made,<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>interest<font style="letter-spacing:0.1pt;"> </font>charge<font style="letter-spacing:0.05pt;"> </font>rules<font style="letter-spacing:0.05pt;"> </font>described above would apply<font style="letter-spacing:0.05pt;"> </font>to any mark-to-market<font style="letter-spacing:0.2pt;"> </font>gain<font style="letter-spacing:0.05pt;"> </font>recognized<font style="letter-spacing:0.1pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>year<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>election<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>made.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder<font style="letter-spacing:0.05pt;"> </font>of PFIC shares<font style="letter-spacing:0.05pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>file<font style="letter-spacing:0.05pt;"> </font>an annual<font style="letter-spacing:0.05pt;"> </font>information<font style="letter-spacing:0.15pt;"> </font>return<font style="letter-spacing:0.05pt;"> </font>on IRS Form<font style="letter-spacing:0.05pt;"> </font>8621 (Information<font style="letter-spacing:0.15pt;"> </font>Return<font style="letter-spacing:0.05pt;"> </font>by a Shareholder<font style="letter-spacing:0.1pt;"> </font>of a Passive<font style="letter-spacing:0.05pt;"> </font>Foreign<font style="letter-spacing:0.05pt;"> </font>Investment<font style="letter-spacing:0.1pt;"> </font>Company or Qualified<font style="letter-spacing:0.1pt;"> </font>Electing<font style="letter-spacing:0.05pt;"> </font>Fund). The failure<font style="letter-spacing:0.1pt;"> </font>to file<font style="letter-spacing:0.05pt;"> </font>IRS Form<font style="letter-spacing:0.05pt;"> </font>8621 could<font style="letter-spacing:0.05pt;"> </font>result<font style="letter-spacing:0.1pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>imposition<font style="letter-spacing:0.1pt;"> </font>of penalties<font style="letter-spacing:0.1pt;"> </font>and the<font style="letter-spacing:0.05pt;"> </font>extension<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>statute<font style="letter-spacing:0.1pt;"> </font>of limitations<font style="letter-spacing:0.15pt;"> </font>with respect<font style="letter-spacing:0.1pt;"> </font>to U.S.<font style="letter-spacing:-0.05pt;"> </font>federal<font style="letter-spacing:0.1pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>tax.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">U.S.<font style="letter-spacing:-0.05pt;"> </font>Holders<font style="letter-spacing:0.05pt;"> </font>are urged to consult<font style="letter-spacing:0.05pt;"> </font>their<font style="letter-spacing:0.05pt;"> </font>tax advisors<font style="letter-spacing:0.05pt;"> </font>as to our status<font style="letter-spacing:0.05pt;"> </font>as a PFIC,<font style="letter-spacing:-0.05pt;"> </font>and the tax consequences<font style="letter-spacing:0.05pt;"> </font>to them<font style="letter-spacing:0.05pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>we were a PFIC,<font style="letter-spacing:-0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>the reporting<font style="letter-spacing:0.05pt;"> </font>requirements<font style="letter-spacing:0.1pt;"> </font>and the desirability<font style="letter-spacing:0.15pt;"> </font>of making,<font style="letter-spacing:0.05pt;"> </font>and the availability<font style="letter-spacing:0.15pt;"> </font>of, a QEF<font style="letter-spacing:-0.05pt;"> </font>election<font style="letter-spacing:0.1pt;"> </font>or a mark-to-market<font style="letter-spacing:0.15pt;"> </font>election<font style="letter-spacing:0.1pt;"> </font>with respect<font style="letter-spacing:0.05pt;"> </font>to the ADSs.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Medicare<font style="letter-spacing:0.05pt;"> </font>Tax</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-corporate<font style="letter-spacing:0.1pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>Holders<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>individuals,<font style="letter-spacing:0.1pt;"> </font>estates<font style="letter-spacing:0.1pt;"> </font>or trusts<font style="letter-spacing:0.1pt;"> </font>and whose income<font style="letter-spacing:0.05pt;"> </font>exceeds<font style="letter-spacing:0.05pt;"> </font>certain thresholds<font style="letter-spacing:0.1pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>to a 3.8% tax<font style="letter-spacing:0.05pt;"> </font>on all<font style="letter-spacing:0.05pt;"> </font>or a portion<font style="letter-spacing:0.05pt;"> </font>of their<font style="letter-spacing:0.05pt;"> </font>net<font style="letter-spacing:0.05pt;"> </font>investment<font style="letter-spacing:0.1pt;"> </font>income,<font style="letter-spacing:0.05pt;"> </font>which may include<font style="letter-spacing:0.05pt;"> </font>their<font style="letter-spacing:0.05pt;"> </font>gross<font style="letter-spacing:0.05pt;"> </font>dividend<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>and net<font style="letter-spacing:0.05pt;"> </font>gains<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>disposition<font style="letter-spacing:0.1pt;"> </font>of ADSs.<font style="letter-spacing:-0.05pt;"> </font>A U.S.<font style="letter-spacing:-0.05pt;"> </font>person<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>an individual,<font style="letter-spacing:0.1pt;"> </font>estate<font style="letter-spacing:0.1pt;"> </font>or trust<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>encouraged<font style="letter-spacing:0.05pt;"> </font>to consult<font style="letter-spacing:0.05pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>advisors<font style="letter-spacing:0.05pt;"> </font>regarding<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>applicability<font style="letter-spacing:0.15pt;"> </font>of this<font style="letter-spacing:0.05pt;"> </font>Medicare<font style="letter-spacing:0.1pt;"> </font>tax to its<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>and gains<font style="letter-spacing:0.05pt;"> </font>in respect<font style="letter-spacing:0.1pt;"> </font>of any investment<font style="letter-spacing:0.1pt;"> </font>in ADSs.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Information<font style="letter-spacing:0.1pt;"> </font>Reporting<font style="letter-spacing:0.05pt;"> </font>with Respect<font style="letter-spacing:0.05pt;"> </font>to Foreign Financial<font style="letter-spacing:0.05pt;"> </font>Assets</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individual<font style="letter-spacing:0.1pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>Holders<font style="letter-spacing:0.05pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>be subject<font style="letter-spacing:0.05pt;"> </font>to certain<font style="letter-spacing:0.1pt;"> </font>reporting<font style="letter-spacing:0.1pt;"> </font>obligations<font style="letter-spacing:0.1pt;"> </font>on IRS Form<font style="letter-spacing:0.05pt;"> </font>8938 (Statement<font style="letter-spacing:0.1pt;"> </font>of Specified<font style="letter-spacing:0.1pt;"> </font>Foreign<font style="letter-spacing:0.05pt;"> </font>Financial<font style="letter-spacing:0.1pt;"> </font>Assets)<font style="letter-spacing:0.05pt;"> </font>with respect<font style="letter-spacing:0.1pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>any taxable<font style="letter-spacing:0.05pt;"> </font>year<font style="letter-spacing:0.05pt;"> </font>during<font style="letter-spacing:0.05pt;"> </font>which the<font style="letter-spacing:0.05pt;"> </font>U.S. Holder&#8217;s<font style="letter-spacing:0.05pt;"> </font>aggregate<font style="letter-spacing:0.1pt;"> </font>value<font style="letter-spacing:0.05pt;"> </font>of these<font style="letter-spacing:0.05pt;"> </font>and certain<font style="letter-spacing:0.1pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>&#8220;specified<font style="letter-spacing:0.1pt;"> </font>foreign<font style="letter-spacing:0.05pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>assets&#8221;<font style="letter-spacing:0.1pt;"> </font>exceed<font style="letter-spacing:0.05pt;"> </font>a threshold amount<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>varies<font style="letter-spacing:0.05pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>filing<font style="letter-spacing:0.1pt;"> </font>status<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>individual.<font style="letter-spacing:0.1pt;"> </font>This reporting<font style="letter-spacing:0.1pt;"> </font>obligation<font style="letter-spacing:0.1pt;"> </font>also<font style="letter-spacing:0.05pt;"> </font>applies<font style="letter-spacing:0.05pt;"> </font>to domestic entities<font style="letter-spacing:0.1pt;"> </font>formed<font style="letter-spacing:0.05pt;"> </font>or availed<font style="letter-spacing:0.05pt;"> </font>of to hold, directly<font style="letter-spacing:0.1pt;"> </font>or indirectly,<font style="letter-spacing:0.1pt;"> </font>specified<font style="letter-spacing:0.1pt;"> </font>foreign<font style="letter-spacing:0.05pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>assets,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>ADSs. Significant<font style="letter-spacing:0.1pt;"> </font>penalties<font style="letter-spacing:0.1pt;"> </font>can apply<font style="letter-spacing:0.05pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>Holders<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>required<font style="letter-spacing:0.1pt;"> </font>to make<font style="letter-spacing:0.05pt;"> </font>this<font style="letter-spacing:0.05pt;"> </font>disclosure<font style="letter-spacing:0.1pt;"> </font>and fail<font style="letter-spacing:0.05pt;"> </font>to do so. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.<font style="letter-spacing:-0.05pt;"> </font>Holders<font style="letter-spacing:0.05pt;"> </font>who acquire<font style="letter-spacing:0.05pt;"> </font>ADSs<font style="letter-spacing:-0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>cash<font style="letter-spacing:0.05pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>be required<font style="letter-spacing:0.1pt;"> </font>to file<font style="letter-spacing:0.05pt;"> </font>IRS Form<font style="letter-spacing:0.05pt;"> </font>926 (Return<font style="letter-spacing:0.05pt;"> </font>by a U.S.<font style="letter-spacing:-0.05pt;"> </font>Transferor of Property<font style="letter-spacing:0.05pt;"> </font>to a Foreign<font style="letter-spacing:0.05pt;"> </font>Corporation)<font style="letter-spacing:0.1pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>IRS and to supply<font style="letter-spacing:0.05pt;"> </font>certain<font style="letter-spacing:0.1pt;"> </font>additional<font style="letter-spacing:0.1pt;"> </font>information<font style="letter-spacing:0.15pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>IRS if (i)<font style="letter-spacing:0.05pt;"> </font>immediately<font style="letter-spacing:0.15pt;"> </font>after<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>transfer,<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder<font style="letter-spacing:0.05pt;"> </font>owns directly<font style="letter-spacing:0.1pt;"> </font>or indirectly<font style="letter-spacing:0.1pt;"> </font>(or<font style="letter-spacing:0.05pt;"> </font>by attribution)<font style="letter-spacing:0.15pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>10% of our total<font style="letter-spacing:0.05pt;"> </font>voting<font style="letter-spacing:0.05pt;"> </font>power or value<font style="letter-spacing:0.05pt;"> </font>or (ii)<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of cash<font style="letter-spacing:0.05pt;"> </font>transferred<font style="letter-spacing:0.15pt;"> </font>to us in exchange<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>ADSs,<font style="letter-spacing:-0.05pt;"> </font>when aggregated<font style="letter-spacing:0.1pt;"> </font>with all<font style="letter-spacing:0.05pt;"> </font>related<font style="letter-spacing:0.1pt;"> </font>transfers<font style="letter-spacing:0.1pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">219</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">applicable</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulations,</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exceeds</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$100,000. Substantial</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">penalties</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be imposed</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on a U.S.</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holder</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fails</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to comply</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with this</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reporting</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">requirement.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Information<font style="letter-spacing:0.1pt;"> </font>Reporting<font style="letter-spacing:0.05pt;"> </font>and Backup Withholding</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In general,<font style="letter-spacing:0.05pt;"> </font>information<font style="letter-spacing:0.15pt;"> </font>reporting,<font style="letter-spacing:0.1pt;"> </font>on IRS Form<font style="letter-spacing:0.05pt;"> </font>1099, will<font style="letter-spacing:0.05pt;"> </font>apply<font style="letter-spacing:0.05pt;"> </font>to dividends<font style="letter-spacing:0.05pt;"> </font>in respect<font style="letter-spacing:0.1pt;"> </font>of ADSs<font style="letter-spacing:-0.05pt;"> </font>and the proceeds<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>sale,<font style="letter-spacing:0.05pt;"> </font>exchange<font style="letter-spacing:0.05pt;"> </font>or redemption<font style="letter-spacing:0.1pt;"> </font>of ADSs<font style="letter-spacing:-0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>paid<font style="letter-spacing:0.05pt;"> </font>to a holder<font style="letter-spacing:0.05pt;"> </font>of ADSs<font style="letter-spacing:-0.05pt;"> </font>within<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>United States<font style="letter-spacing:0.05pt;"> </font>(and<font style="letter-spacing:0.05pt;"> </font>in certain<font style="letter-spacing:0.1pt;"> </font>cases,<font style="letter-spacing:0.05pt;"> </font>outside<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>United<font style="letter-spacing:0.05pt;"> </font>States),<font style="letter-spacing:0.1pt;"> </font>unless<font style="letter-spacing:0.05pt;"> </font>such holder<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>an exempt<font style="letter-spacing:0.05pt;"> </font>recipient<font style="letter-spacing:0.1pt;"> </font>such as a corporation.<font style="letter-spacing:0.1pt;"> </font>Backup withholding<font style="letter-spacing:0.05pt;"> </font>(currently<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>a 24% rate)<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>apply<font style="letter-spacing:0.05pt;"> </font>to such payments<font style="letter-spacing:0.05pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>a holder<font style="letter-spacing:0.05pt;"> </font>of ADSs<font style="letter-spacing:-0.05pt;"> </font>fails to provide<font style="letter-spacing:0.05pt;"> </font>a taxpayer<font style="letter-spacing:0.05pt;"> </font>identification<font style="letter-spacing:0.15pt;"> </font>number<font style="letter-spacing:0.05pt;"> </font>(generally<font style="letter-spacing:0.1pt;"> </font>on an IRS Form<font style="letter-spacing:0.05pt;"> </font>W-9)<font style="letter-spacing:0.05pt;"> </font>or certification<font style="letter-spacing:0.2pt;"> </font>of other<font style="letter-spacing:0.05pt;"> </font>exempt status<font style="letter-spacing:0.05pt;"> </font>or fails<font style="letter-spacing:0.1pt;"> </font>to report<font style="letter-spacing:0.05pt;"> </font>in full<font style="letter-spacing:0.05pt;"> </font>dividend<font style="letter-spacing:0.05pt;"> </font>and interest<font style="letter-spacing:0.1pt;"> </font>income.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Backup withholding<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>not an additional<font style="letter-spacing:0.1pt;"> </font>tax.<font style="letter-spacing:0.05pt;"> </font>A U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>obtain<font style="letter-spacing:0.05pt;"> </font>a refund<font style="letter-spacing:0.05pt;"> </font>of any amounts withheld<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>backup withholding<font style="letter-spacing:0.05pt;"> </font>rules<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>exceed<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>U.S.<font style="letter-spacing:-0.05pt;"> </font>Holder&#8217;s<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>liability<font style="letter-spacing:0.15pt;"> </font>by filing<font style="letter-spacing:0.1pt;"> </font>a refund claim<font style="letter-spacing:0.1pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>IRS.<font style="color:#000000;"> </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">F.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_10_F"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_10_F"></a>Dividends and Paying Agents</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">G.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_10_G"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_10_G"></a>Statement by Experts</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not <font style="color:#000000;">applicable</font>. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">H.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_10_H"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">D<a name="ITEM_10_H"></a>ocuments on Display</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to the informational requirements of the Exchange Act. Accordingly, we are required to file reports and other information with the SEC, including annual reports on Form 20-F and reports on Form 6-K. The SEC maintains an Internet website that contains reports and other information about issuers, like us, that file electronically with the SEC. The address of that website is www.sec.gov.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also make available on our website, free of charge, our Annual Report and the text of our reports on Form 6-K, including any amendments to these reports, as well as certain other SEC filings, as soon as reasonably practicable after they are electronically filed with or furnished to the SEC. Our website address is www.biontech.de. The information contained on our website is not incorporated by reference in this Annual Report and our website address is included in this Annual Report as an inactive textual reference only.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statements contained in this Annual Report regarding the contents of any contract or other document are not necessarily complete, and, where the contract or other document is an exhibit to the Annual Report, each of these statements is qualified in all respects by the provisions of the actual contract or other documents.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">I.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_10_I"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_10_I"></a>Subsidiary Information</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_11_QUANTITATIVE_QUALITATIVE_DISCLOS"></a><a name="ITEM_11_QUANTITATIVE_QUALITATIVE_DISCLOS"></a>Item 11. Quantitative and Qualitative Disclosures About Market Risk</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to various risks in relation to financial instruments, including currency risk. Our risk management is coordinated by our Management Board. We do not engage in the trading of financial assets for speculative purposes. The most significant financial risks to which we are exposed include the risks discussed below.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;color:#231F20;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Currency Risk</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to currency risk, as our income and expenditures are denominated in Euro and the U.S. dollar. As such, we are exposed to exchange rate fluctuations between these currencies. Cash inflows denominated in U.S. dollar occurred <font style="color:#000000;">from issuing ordinary shares in connection with public financing transaction, which includes our initial public offering in 2019 and the global offering in 2020 as well as from generating proceeds under our collaboration agreements.</font> We aim to match U.S. dollar cash inflows with U.S. dollar cash outflows where possible, and we do not hedge this exposure. Under our collaboration agreement with Pfizer, significant increases in cash balances, revenues and sales and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">marketing expenses denominated in U.S. dollars may occur with respect to commercializing</font><font style="color:#000000;"> our COVID-19 vaccine,</font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> while we would expect our development and operating expenses to remain, at least some extent, denominated in Euro.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We publish our consolidated financial statements in Euro. Revenue and expenses incurred in U.S. dollars will be translated into Euro when they are reported in our consolidated financial statements. As a result, any substantial future appreciation or decline of the U.S. dollar against the Euro could have a material effect on our revenue and profitability. As an example, if the U.S. dollar weakens by 5% against the Euro, monetary assets and monetary liabilities denominated in U.S. dollar as of December&#160;31, 2020 would decrease by &#8364;32.7 million, or 5%.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For additional information about our quantitative and qualitative risks, see Note 12 to the consolidated financial statements.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_12_DESCRIPTION_SECURITIES_OR_THAN_E"></a><a name="ITEM_12_DESCRIPTION_SECURITIES_OR_THAN_E"></a>Item 12. Description of Securities Other than Equity Securities</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">A.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_12_A"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_12_A"></a>Debt Securities</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">B.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_12_B"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_12_B"></a>Warrants and Rights</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">C.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_12_C"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_12_C"></a>Other Securities</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">D.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="ITEM_12_D"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="ITEM_12_D"></a>American Depositary Shares</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fees and Expenses</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:4.93%;width:90.07%;">
<tr>
<td valign="bottom"  style="width:48.06%;">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Persons depositing or withdrawing shares or ADS holders must pay:</p></td>
<td valign="bottom"  style="width:2.54%;">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:49.4%;">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">For:</p></td>
</tr>
<tr>
<td valign="top"  style="width:48.06%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)</p></td>
<td valign="top"  style="width:2.54%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.4%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates</p></td>
</tr>
<tr>
<td valign="top"  style="width:48.06%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$.05 (or less) per ADS</p></td>
<td valign="top"  style="width:2.54%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.4%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any cash distribution to ADS holders</p></td>
</tr>
<tr>
<td valign="top"  style="width:48.06%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A fee equivalent to the fee that would be payable if securities distributed to an ADS holder had been shares and the shares had been deposited for issuance of ADSs</p></td>
<td valign="top"  style="width:2.54%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.4%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Distribution of securities distributed to holders of deposited securities (including rights) that are distributed by the depositary to ADS holders</p></td>
</tr>
<tr>
<td valign="top"  style="width:48.06%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$.05 (or less) per ADS per calendar year</p></td>
<td valign="top"  style="width:2.54%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.4%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depositary services</p></td>
</tr>
<tr>
<td valign="top"  style="width:48.06%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Registration or transfer fees</p></td>
<td valign="top"  style="width:2.54%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.4%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transfer and registration of shares on our share register to or from the name of the depositary or its agent when an ADS holder deposits or withdraws shares</p></td>
</tr>
<tr>
<td valign="top"  style="width:48.06%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expenses of the depositary</p></td>
<td valign="top"  style="width:2.54%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.4%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cable and facsimile transmissions (when expressly provided in the deposit agreement)</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Converting foreign currency to U.S. dollars</p></td>
</tr>
<tr>
<td valign="top"  style="width:48.06%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Taxes and other governmental charges the depositary or the custodian has to pay on any ADSs or shares underlying ADSs, such as stock transfer taxes, stamp duty or withholding taxes</p></td>
<td valign="top"  style="width:2.54%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.4%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As necessary</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">221</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:4.93%;width:90.07%;">
<tr>
<td valign="top"  style="width:48.06%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any charges incurred by the depositary or its agents for servicing the deposited securities</font></p></td>
<td valign="top"  style="width:2.54%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.4%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As necessary</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The depositary collects its fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The depositary may collect any of its fees by deduction from any cash distribution payable (or by selling a portion of securities or other property distributable) to ADS holders that are obligated to pay those fees. The depositary may generally refuse to provide fee-attracting services until its fees for those services are paid. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the depositary may make payments to us to reimburse us for costs and expenses generally arising out of establishment and maintenance of the ADS program, waive fees and expenses for services provided to us by the depositary or share revenue from the fees collected from ADS holders. In performing its duties under the deposit agreement, the depositary may use brokers, dealers, foreign currency dealers or other service providers that are owned by, or affiliated with, the depositary and that may earn or share fees, spreads or commissions.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The depositary may convert currency itself or through any of its affiliates and, in those cases, acts as principal for its own account and not as agent, advisor, broker or fiduciary on behalf of any other person and earns revenue, including, without limitation, transaction spreads, that it will retain for its own account. The revenue is based on, among other things, the difference between the exchange rate assigned to the currency conversion made under the deposit agreement and the rate that the depositary or its affiliate receives when buying or selling foreign currency for its own account. The depositary makes no representation that the exchange rate used or obtained in any currency conversion under the deposit agreement will be the most favorable rate that could be obtained at the time or that the method by which that rate will be determined will be the most favorable to ADS holders, subject to the depositary&#8217;s obligations under the deposit agreement. The methodology used to determine exchange rates used in currency conversions is available upon request.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;color:#231F20;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Payment of Taxes</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ADS holders will be responsible for any taxes or other governmental charges payable on their ADSs or on the deposited securities represented by any of their ADSs. The depositary may refuse to register any transfer of ADS holders ADSs or allow him or her to <font style="color:#000000;">withdraw</font> the deposited securities represented by his or her ADSs until those taxes or other charges are paid. It may apply payments owed to you or sell deposited securities represented by his or her ADSs to pay any taxes owed and you will remain liable for any deficiency. If the depositary sells deposited securities, if appropriate, it will reduce the number of ADSs to reflect the sale and pay to ADS holders any proceeds, or send to ADS holders any property, remaining after it has paid the taxes.</p><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">222</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_II"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_II"></a>PART II</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_13_DEFAULTS_DIVIDEND_ARREARAGES_DEL"></a><a name="ITEM_13_DEFAULTS_DIVIDEND_ARREARAGES_DEL"></a>Item 13. Defaults, Dividend Arrearages and Delinquencies</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_14_MATERIAL_MODIFICATIONS_TO_RIGHTS"></a><a name="ITEM_14_MATERIAL_MODIFICATIONS_TO_RIGHTS"></a>Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_15_CONTROLS_PROCEDURES"></a><a name="ITEM_15_CONTROLS_PROCEDURES"></a>Item 15. Controls and Procedures</p>
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Disclosure Controls and Procedures</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As required by Rule 13a-15 under the Exchange Act, management, including our Chief Executive Officer (CEO) and our Chief Financial Officer (CFO), has performed an evaluation of the effectiveness of our disclosure controls and procedures. Disclosure controls and procedures refer to controls and other procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. Disclosure controls and procedures include, without limitations, controls and procedures designed to ensure that information required to be disclosed by us in our reports that we file or submit under the Exchange Act is accumulated and communicated to management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding our required disclosures.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the foregoing, our CEO and CFO have concluded that, as of the end of the period covered by this annual report, our disclosure controls and procedures were effective in ensuring that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in by the SEC&#8217;s rules and forms, and that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management to allow timely decisions regarding required disclosure. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f). Our internal control over financial reporting is a process designed by or under the supervision of the Chief Financial Officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external reporting purposes in accordance with International Financial Reporting Standards as issued by the IASB.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No system of internal control over financial reporting, including one determined to be effective, may prevent or detect all misstatements. It can provide only reasonable assurance regarding financial statement preparation and presentation. Also, projections of the results of any evaluation of the effectiveness of internal control over financial reporting into future periods are subject to inherent risk. The relevant controls may become inadequate due to changes in circumstances or the degree of compliance with the underlying policies or procedures may deteriorate. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2020. In making this assessment, it used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in &#8220;Internal Control - Integrated Framework (2013)&#8221;.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As permitted by the SEC, the Company has elected to exclude an assessment of the internal controls of acquisitions made during the year ended December 31, 2020, namely the acquisitions of BioNTech US Inc. as well as BioNTech Manufacturing Marburg GmbH. The acquired entities did not contribute to the Group&#8217;s revenues, they contributed <font style="Background-color:#FFFFFF;">&#8364;28.5&#160;million and &#8364;6.7&#160;million of operating loss, respectively, which are included within the &#8364;15.2 million of profit of the Group</font> during the year ended December 31, 2020 and constituted 3.9% and 5.7% of the Group&#8217;s total assets a<font style="Background-color:#FFFFFF;">s of December 31, 2020</font>. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on this assessment, our management has determined that the Company&#8217;s internal control over financial reporting as of December 31, 2020 is effective.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Attestation Report of the Registered Public Accounting Firm</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The effectiveness of our internal control over financial reporting as of December 31, 2020 has been audited by Ernst &amp; Young GmbH Wirtschaftspr&#252;fungsgesellschaft, an independent registered public accounting firm. Their report is included on page F-2. Ernst &amp; Young GmbH Wirtschaftspr&#252;fungsgesellschaft is a member of the Chamber of Public Accountants (<font style="font-style:italic;">Wirtschaftspr&#252;ferkammer</font>), Berlin, Germany.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Changes in Control over Financial Reporting</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no changes to our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Securities and Exchange Act of 1934) that occurred during the period covered by this form 20-F that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16A_AUDIT_COMMITTEE_FINANCIAL_EXPER"></a>Item 16A. Audit <a name="ITEM_16A_AUDIT_COMMITTEE_FINANCIAL_EXPER"></a>Committee Financial Expert</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Audit Committee consists of Dr. Ulrich Wandschneider, Michael Motschmann and Prof. Christoph Huber. Dr. Ulrich Wandschneider is the chair of the Audit Committee. All members of the Audit Committee qualify as &#8220;independent directors&#8221; as such term is defined in Rule 10A-3 under the Exchange Act and Nasdaq Rule 5605. Additionally, our Supervisory Board has determined that Dr. Ulrich Wandschneider qualifies as an &#8220;audit committee financial expert&#8221; as that term is defined under the Exchange Act.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16B_CODE_ETHICS"></a><a name="ITEM_16B_CODE_ETHICS"></a>Item 16B. Code of Ethics</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted a Code of Business Conduct &amp; Ethics, or Code of Conduct, which outlines the principles of legal and ethical business conduct under which we do business. The Code of Conduct applies to all of our Supervisory Board members, Management Board members, directors of our subsidiaries and employees. The full text of the Code of Conduct is available on our website at https://www.biontech.de. The information and other content appearing on our website are not part of this Annual Report and our website address is included in this Annual Report as an inactive textual reference only. Any amendments or waivers from the provisions of the Code of Conduct for members of our Supervisory or Management Boards will be made only after approval by our Supervisory Board and will be disclosed on our website promptly following the date of such amendment or waiver.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16C_PRINCIPAL_ACCOUNTANT_FEES_SERVI"></a><a name="ITEM_16C_PRINCIPAL_ACCOUNTANT_FEES_SERVI"></a>Item 16C. Principal Accountant Fees and Services</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ernst &amp; Young GmbH Wirtschaftspr&#252;fungsgesellschaft, or EY, has served as our independent registered public accounting firm for the years ended December&#160;31, 2020, December&#160;31, 2019 and December&#160;31, 2018 for which audited financial statements appear in this Annual Report. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <font style="color:#000000;">following</font> table sets out the aggregate fees for professional audit services and other services rendered by EY in the periods indicated: </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C5E0B3" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.12%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audit fees</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,354</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;578</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audit-related fees</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">444</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">721</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax fees</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All other fees</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">419</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.12%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total fees for professional audit services and other services</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,472</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,480</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audit fees relate to the audit of the financial statements as set out in this Annual Report, certain procedures on our quarterly results, fees for testing our internal controls over financial reporting during the six months ended December 31, 2020 and services related to our statutory and regulatory filings for our subsidiaries.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audit-related fees billed for assurance and related services are related mainly to the issuance of comfort letters in connection with our financing transactions. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax service fees were billed for services in conjunction with transactions, especially with </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financing and deal transactions</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other fees comprised fees for testing the implementation of our internal controls over financial reporting during the six months ended June 30, 2020.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Audit Committee evaluates the qualifications, independence and performance of the independent auditor as well as pre-approves and reviews the audit and non-audit services to be performed by the independent auditor. The external audit plan and fees for professional audit services and other services rendered by EY for the years ended December&#160;31, 2020 and 2019 were approved by the Audit Committee. The Audit Committee monitors compliance with the German and U.S. rules on non-audit services provided by an independent registered public accounting firm.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16D_EXEMPTIONS_FROM_LISTING_STARDS_"></a><a name="ITEM_16D_EXEMPTIONS_FROM_LISTING_STARDS_"></a>Item 16D. Exemptions from the Listing Standards for Audit Committees</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Please see &#8220;Board Practices&#8212;Supervisory Board Practices&#8212;Audit Committee&#8221; in Item 6C in this Annual Report for the information required by this Item 16D. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16E_PURCHASES_EQUITY_SECURITIES_BY_"></a>Item 16E.<a name="ITEM_16E_PURCHASES_EQUITY_SECURITIES_BY_"></a> Purchases of Equity Securities by the Issuer and Affiliated Purchasers</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16F_CHANGE_IN_REGISTRANTS_CERTIFYIN"></a><a name="ITEM_16F_CHANGE_IN_REGISTRANTS_CERTIFY"></a><a name="ITEM_16F_CHANGE_IN_REGISTRANTS_CERTIFYIN"></a><a name="ITEM_16F_CHANGE_IN_REGISTRANTS_CERTIFY"></a>Item 16F. Change in Registrant&#8217;s Certifying Accountant</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16G_CORPORATE_GOVERNANCE"></a><a name="ITEM_16G_CORPORATE_GOVERNANCE"></a>Item 16G. Corporate Governance</p>
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">German Corporate Governance Code</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The German<font style="letter-spacing:0.05pt;"> </font>Corporate<font style="letter-spacing:0.05pt;"> </font>Governance<font style="letter-spacing:0.05pt;"> </font>Code, or the<font style="letter-spacing:0.05pt;"> </font>Corporate<font style="letter-spacing:0.05pt;"> </font>Governance<font style="letter-spacing:0.05pt;"> </font>Code, was originally<font style="letter-spacing:0.1pt;"> </font>published<font style="letter-spacing:0.05pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>Federal<font style="letter-spacing:0.05pt;"> </font>Ministry<font style="letter-spacing:0.1pt;"> </font>of Justice<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Bundesministerium</font><font style="font-style:italic;letter-spacing:0.1pt;"> </font><font style="font-style:italic;">der Justi</font><font style="font-style:italic;letter-spacing:0.05pt;">z</font>) in 2002. The version currently in effect, dated<font style="letter-spacing:0.05pt;"> </font>December&#160;16, 2019,<font style="letter-spacing:0.05pt;"> was published </font>in the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>Federal<font style="letter-spacing:0.05pt;"> </font>Gazette<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">Bundesanzeige</font><font style="font-style:italic;letter-spacing:0.05pt;">r</font>) on March&#160;20, 2020. The Corporate<font style="letter-spacing:0.05pt;"> </font>Governance<font style="letter-spacing:0.05pt;"> </font>Code contains<font style="letter-spacing:0.05pt;"> </font>recommendations<font style="letter-spacing:0.15pt;"> </font>(<font style="font-style:italic;">Empfehlunge</font><font style="font-style:italic;letter-spacing:0.05pt;">n</font>) and suggestions<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Anregungen</font>) relating to the<font style="letter-spacing:0.05pt;"> </font>management<font style="letter-spacing:0.1pt;"> </font>and supervision<font style="letter-spacing:0.1pt;"> </font>of German<font style="letter-spacing:0.05pt;"> </font>companies<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>listed<font style="letter-spacing:0.1pt;"> </font>on a stock<font style="letter-spacing:0.05pt;"> </font>exchange.<font style="letter-spacing:0.05pt;"> </font>It<font style="letter-spacing:0.05pt;"> </font>follows internationally<font style="letter-spacing:0.15pt;"> </font>and nationally<font style="letter-spacing:0.1pt;"> </font>recognized<font style="letter-spacing:0.1pt;"> </font>standards<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>good and responsible<font style="letter-spacing:0.1pt;"> </font>corporate<font style="letter-spacing:0.1pt;"> </font>governance.<font style="letter-spacing:0.05pt;"> </font>The purpose of the<font style="letter-spacing:0.05pt;"> </font>Corporate<font style="letter-spacing:0.05pt;"> </font>Governance<font style="letter-spacing:0.05pt;"> </font>Code is<font style="letter-spacing:0.05pt;"> </font>to make<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>system<font style="letter-spacing:0.05pt;"> </font>of corporate<font style="letter-spacing:0.1pt;"> </font>governance<font style="letter-spacing:0.05pt;"> </font>transparent<font style="letter-spacing:0.1pt;"> </font>for investors.<font style="letter-spacing:0.1pt;"> </font>The Corporate<font style="letter-spacing:0.05pt;"> </font>Governance<font style="letter-spacing:0.05pt;"> </font>Code includes<font style="letter-spacing:0.05pt;"> </font>corporate<font style="letter-spacing:0.1pt;"> </font>governance<font style="letter-spacing:0.05pt;"> </font>recommendations<font style="letter-spacing:0.15pt;"> </font>and suggestions with respect<font style="letter-spacing:0.1pt;"> </font>to shareholders<font style="letter-spacing:0.1pt;"> </font>and shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meetings,<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>management<font style="letter-spacing:0.1pt;"> </font>and supervisory<font style="letter-spacing:0.1pt;"> </font>boards,<font style="letter-spacing:0.05pt;"> </font>transparency, accounting<font style="letter-spacing:0.05pt;"> </font>policies<font style="letter-spacing:0.1pt;"> </font>and auditing.<font style="letter-spacing:0.05pt;"> </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>no obligation<font style="letter-spacing:0.1pt;"> </font>to comply<font style="letter-spacing:0.05pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>recommendations<font style="letter-spacing:0.15pt;"> </font>or suggestions<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Corporate<font style="letter-spacing:0.05pt;"> </font>Governance Code. The German<font style="letter-spacing:0.05pt;"> </font>Stock Corporation<font style="letter-spacing:0.05pt;"> </font>Act (<font style="font-style:italic;">Aktiengeset</font><font style="font-style:italic;letter-spacing:0.1pt;">z</font>) requires<font style="letter-spacing:0.1pt;"> </font>only that<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>management<font style="letter-spacing:0.1pt;"> </font>board<font style="letter-spacing:0.05pt;"> </font>and supervisory<font style="letter-spacing:0.1pt;"> </font>board<font style="letter-spacing:0.05pt;"> </font>of a German<font style="letter-spacing:0.05pt;"> </font>company<font style="letter-spacing:0.05pt;"> </font>listed<font style="letter-spacing:0.1pt;"> </font>on a trading<font style="letter-spacing:0.05pt;"> </font>facility<font style="letter-spacing:0.1pt;"> </font>(such<font style="letter-spacing:0.05pt;"> </font>as a stock<font style="letter-spacing:0.05pt;"> </font>exchange)<font style="letter-spacing:0.05pt;"> which is </font>regulated<font style="letter-spacing:0.1pt;"> </font>and supervised<font style="letter-spacing:0.1pt;"> </font>by government<font style="letter-spacing:0.1pt;"> </font>authorities<font style="letter-spacing:0.15pt;"> </font>issue<font style="letter-spacing:0.05pt;"> </font>an annual<font style="letter-spacing:0.05pt;"> </font>declaration<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>either<font style="letter-spacing:0.1pt;"> </font>(i)<font style="letter-spacing:0.05pt;"> </font>states<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>company<font style="letter-spacing:0.05pt;"> </font>has complied<font style="letter-spacing:0.1pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>recommendations<font style="letter-spacing:0.15pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Corporate<font style="letter-spacing:0.05pt;"> </font>Governance<font style="letter-spacing:0.05pt;"> </font>Code or (ii)<font style="letter-spacing:0.1pt;"> </font>lists<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>recommendations<font style="letter-spacing:0.15pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the company<font style="letter-spacing:0.05pt;"> </font>has not complied<font style="letter-spacing:0.1pt;"> </font>with and explains<font style="letter-spacing:0.05pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>reasons<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>deviating<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>recommendations<font style="letter-spacing:0.15pt;"> </font>of the Corporate<font style="letter-spacing:0.05pt;"> </font>Governance<font style="letter-spacing:0.05pt;"> </font>Code (<font style="font-style:italic;">Entsprechenserkl&#228;run</font><font style="font-style:italic;letter-spacing:0.15pt;">g</font>). In addition,<font style="letter-spacing:0.05pt;"> </font>a listed<font style="letter-spacing:0.1pt;"> </font>company<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>also<font style="letter-spacing:0.05pt;"> </font>required<font style="letter-spacing:0.1pt;"> </font>to state<font style="letter-spacing:0.05pt;"> </font>in this<font style="letter-spacing:0.05pt;"> </font>annual<font style="letter-spacing:0.05pt;"> </font>declaration<font style="letter-spacing:0.1pt;"> </font>whether<font style="letter-spacing:0.05pt;"> </font>it<font style="letter-spacing:0.05pt;"> </font>intends<font style="letter-spacing:0.05pt;"> </font>to comply<font style="letter-spacing:0.05pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>recommendations<font style="letter-spacing:0.15pt;"> </font>or list<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>recommendations<font style="letter-spacing:0.15pt;"> </font>it does not plan<font style="letter-spacing:0.05pt;"> </font>to comply<font style="letter-spacing:0.05pt;"> </font>with in the<font style="letter-spacing:0.05pt;"> </font>future.<font style="letter-spacing:0.05pt;"> </font>These declarations<font style="letter-spacing:0.15pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>be made<font style="letter-spacing:0.05pt;"> </font>accessible<font style="letter-spacing:0.1pt;"> </font>to shareholders<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>all times.<font style="letter-spacing:0.1pt;"> </font>If<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>company<font style="letter-spacing:0.05pt;"> </font>changes<font style="letter-spacing:0.05pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>policy<font style="letter-spacing:0.05pt;"> </font>on certain<font style="letter-spacing:0.1pt;"> </font>recommendations<font style="letter-spacing:0.15pt;"> </font>between<font style="letter-spacing:0.05pt;"> </font>such annual<font style="letter-spacing:0.05pt;"> </font>declarations,<font style="letter-spacing:0.15pt;"> </font>it<font style="letter-spacing:0.05pt;"> </font>must disclose<font style="letter-spacing:0.1pt;"> </font>this<font style="letter-spacing:0.05pt;"> </font>fact<font style="letter-spacing:0.05pt;"> </font>and explain<font style="letter-spacing:0.05pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>reasons<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>deviating<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>recommendations.<font style="letter-spacing:0.15pt;"> </font>Non-compliance<font style="letter-spacing:0.1pt;"> </font>with suggestions<font style="letter-spacing:0.1pt;"> </font>contained<font style="letter-spacing:0.05pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>Corporate<font style="letter-spacing:0.05pt;"> </font>Governance<font style="letter-spacing:0.05pt;"> </font>Code need not be disclosed.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While<font style="letter-spacing:0.05pt;"> </font>in our opinion<font style="letter-spacing:0.05pt;"> </font>it<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>doubtful<font style="letter-spacing:0.05pt;"> </font>whether<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>above legal<font style="letter-spacing:0.05pt;"> </font>requirements<font style="letter-spacing:0.15pt;"> </font>and hence<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Corporate Governance<font style="letter-spacing:0.05pt;"> </font>Code currently<font style="letter-spacing:0.05pt;"> </font>apply to us<font style="letter-spacing:0.05pt;"> </font>as a company listing<font style="letter-spacing:0.1pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>Nasdaq Global<font style="letter-spacing:0.05pt;"> </font>Select<font style="letter-spacing:0.05pt;"> </font>Market,<font style="letter-spacing:0.05pt;"> </font>we issue<font style="letter-spacing:0.05pt;"> </font>the<font style="color:#000000;"> </font>annual<font style="letter-spacing:0.05pt;"> </font>declaration<font style="letter-spacing:0.1pt;"> </font>described<font style="letter-spacing:0.1pt;"> </font>above on a voluntary<font style="letter-spacing:0.05pt;"> </font>basis.<font style="letter-spacing:0.05pt;"> </font>Therefore,<font style="letter-spacing:0.1pt;"> </font>our Management<font style="letter-spacing:0.1pt;"> </font>Board and Supervisory Board comply<font style="letter-spacing:0.05pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>Corporate<font style="letter-spacing:0.05pt;"> </font>Governance<font style="letter-spacing:0.05pt;"> </font>Code except<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>such provisions<font style="letter-spacing:0.1pt;"> </font>which are<font style="letter-spacing:0.05pt;"> </font>listed<font style="letter-spacing:0.1pt;"> explicitly </font>in the<font style="letter-spacing:0.05pt;"> </font>annual<font style="letter-spacing:0.05pt;"> </font>declaration<font style="letter-spacing:0.1pt;"> </font>and for<font style="letter-spacing:0.05pt;"> </font>which they<font style="letter-spacing:0.05pt;"> </font>provide<font style="letter-spacing:0.05pt;"> </font>an explanation<font style="letter-spacing:0.1pt;"> </font>of non-compliance. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">225</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Differences</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> in Corporate Law</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The applicable provisions of the SE Regulation in conjunction with the German Stock Corporation Act as applied to a European stock corporation that has its legal seat in Germany differ from laws applicable to U.S. corporations and their shareholders. <font style="color:#000000;">Set</font> forth below is a summary of certain differences between the provisions of the SE Regulation in conjunction with the German Stock Corporation Act applicable to us and the General Corporation Law of the State of Delaware relating to shareholders&#8217; rights and protections. This summary is not intended to be a complete discussion of the respective rights and it is qualified in its entirety by reference to Delaware law and European and German law. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.93%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:4.93%;width:90.07%;">
<tr>
<td valign="bottom"  style="width:15.38%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.9%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40.16%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">European Union/Federal Republic of&#160;Germany</p></td>
<td valign="bottom"  style="width:2.44%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40.12%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Delaware</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.38%;">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Board System</p></td>
<td valign="top"  style="width:1.9%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.16%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A European<font style="letter-spacing:0.05pt;"> </font>stock<font style="letter-spacing:0.05pt;"> </font>corporation<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>choose to have a two-tier<font style="letter-spacing:0.1pt;"> </font>board<font style="letter-spacing:0.05pt;"> </font>structure composed<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board (<font style="font-style:italic;">Vorstan</font><font style="font-style:italic;letter-spacing:0.05pt;">d</font>) and the<font style="letter-spacing:0.05pt;"> </font>Supervisory<font style="letter-spacing:0.05pt;"> </font>Board (<font style="font-style:italic;">Aufsichtsra</font><font style="font-style:italic;letter-spacing:0.1pt;">t</font>). We have chosen<font style="letter-spacing:0.05pt;"> </font>this structure.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Management Board is responsible for running the company&#8217;s affairs and representing the company in dealings with third parties.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Supervisory Board of a European stock corporation under German law has a control and supervisory function. The Supervisory Board does not actively manage the company but certain Management Board actions require the approval of the Supervisory Board.</p></td>
<td valign="top"  style="width:2.44%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.12%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Delaware law, a corporation has a unitary board structure, and it is the responsibility of the board of directors to appoint and oversee the management of the corporation on behalf of and in the best interests of the stockholders of the corporation.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management is responsible for running the corporation and overseeing its day-to-day operations.</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">226</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:4.93%;width:90.07%;">
<tr>
<td valign="top"  style="width:15.38%;">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appointment and Number of Directors</font></p></td>
<td valign="top"  style="width:1.9%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.16%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under applicable European and German law, a European stock corporation governed by German law with a share capital of at least &#8364;3 million generally must have at least two members on its Management Board and the number of members shall be determined by or in the manner provided in the company&#8217;s articles of association.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Supervisory Board must consist of at least three but&#8212;depending on the share capital&#8212;no more than 21 Supervisory Board members, whereby the number of Supervisory Board members must be divisible by three if this is necessary for the fulfilment of co-determination requirements. The articles of association of the company must specify if the Supervisory Board has more than three members.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supervisory Board members are either appointed by the shareholders&#8217; meeting or delegated by one or more individual shareholders if so provided for in the company&#8217;s articles of association. If the Supervisory Board consists of fewer members than is required to meet the quorum for resolutions (either statutory or pursuant to the company&#8217;s articles of association), a competent court may appoint additional members as needed to meet the quorum. The provisions of German law in relation to employees&#8217; co-determination do not apply to the Company.</p></td>
<td valign="top"  style="width:2.44%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.12%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Delaware law, a corporation must have at least one director and the number of directors shall be fixed by or in the manner provided in the bylaws.</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:4.93%;width:90.07%;">
<tr>
<td valign="top"  style="width:15.38%;">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Removal of Directors</font></p></td>
<td valign="top"  style="width:1.9%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.16%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Members of the Management Board of a European stock corporation are appointed by the Supervisory Board for a maximum period of six years with an opportunity to be reelected. The articles of association may provide for a shorter term, which in our case is up to five years. The members of the Management Board may be reelected, even repeatedly. The Supervisory Board may remove a member of the Management Board prior to the expiration of his or her term only for cause, such as gross breach of duties (<font style="font-style:italic;">grobe Pflichtverletzung</font>), the inability to manage the business properly (<font style="font-style:italic;">Unf&#228;higkeit zur ordnungsgem&#228;&#223;en Pflichtaus&#252;bung</font>) or a vote of no-confidence during the shareholders&#8217; meeting (<font style="font-style:italic;">Vertrauensentzug</font>). The shareholders themselves are not entitled to appoint or dismiss the members of the Management Board.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under European law, a member of the Supervisory Board of a company may be elected for a term of up to six years. The articles of association may provide for a shorter term. Our Supervisory Board members are, if the general meeting does not resolve on a shorter term, elected for a period up to the end of the general meeting deciding on the discharge for the fourth financial year after the election. Reelection, including repeated reelection, is permissible. Members of the Supervisory Board may be removed with or without cause by way of a general meeting resolution, with the applicable majority requirement depending on the relevant company&#8217;s articles of association. </p></td>
<td valign="top"  style="width:2.44%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.12%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Delaware law, any director or the entire board of directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors, except (i) unless the certificate of incorporation provides otherwise, in the case of a corporation whose board of directors is classified, stockholders may effect such removal only for cause; or (ii) in the case of a corporation having cumulative voting, if less than the entire board of directors is to be removed, no director may be removed without cause if the votes cast against his removal would be sufficient to elect him if then cumulatively voted at an election of the entire board of directors, or, if there are classes of directors, at an election of the class of directors of which he is a part.</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.38%;">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vacancies on the Board of Directors</p></td>
<td valign="top"  style="width:1.9%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.16%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the law, vacant positions on the Management Board are filled by the Supervisory Board in accordance with the general rules of appointment, which provide that vacancies are filled by the simple majority of votes of Supervisory Board members present or represented by proxy at the vote (with, under certain circumstances, the chairman having a casting vote), unless otherwise provided by the company&#8217;s articles of association. In case of emergencies, a vacant position on the Management Board may be filled by an individual appointed by the court. Vacant positions on the Supervisory Board are filled in accordance with the general rules of appointment.</p></td>
<td valign="top"  style="width:2.44%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.12%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Delaware law, vacancies and newly created directorships may be filled by a majority of the directors then in office (even though less than a quorum) or by a sole remaining director unless (i) otherwise provided in the certificate of incorporation or by-laws of the corporation or (ii) the certificate of incorporation directs that a particular class of stock is to elect such director, in which case a majority of the other directors elected by such class, or a sole remaining director elected by such class, will fill such vacancy.</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">228</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:4.93%;width:90.07%;">
<tr>
<td valign="top"  style="width:15.38%;">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual General Meeting</font></p></td>
<td valign="top"  style="width:1.9%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.16%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A European stock corporation, which is governed by German law, must hold an annual shareholders&#8217; meeting within six months of the end of its fiscal year. The annual shareholders&#8217; meeting must be held at a location determined by the articles of association. If the articles of association do not provide for a specific location, the shareholders&#8217; meeting shall be held at the company&#8217;s seat or, if applicable, at the venue (in Germany) where its shares are listed.</p></td>
<td valign="top"  style="width:2.44%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.12%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Delaware law, the annual meeting of stockholders shall be held at such place, on such date and at such time as may be designated from time to time by the board of directors or as provided in the certificate of incorporation or by the bylaws.</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.38%;">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General Meeting</p></td>
<td valign="top"  style="width:1.9%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.16%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the law, extraordinary shareholders&#8217; meetings, in addition to the annual shareholders&#8217; meetings, may be called either by the Management Board, or the Supervisory Board. Shareholders holding at least 5% of the company&#8217;s share capital are entitled to request that an extraordinary shareholders&#8217; meeting be convened. In the event that the meeting is not then so convened, a competent court may order that the meeting be convened or authorize the shareholders or their representative to convene the meeting themselves.</p></td>
<td valign="top"  style="width:2.44%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.12%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Delaware law, special meetings of the stockholders may be called by the board of directors or by such person or persons as may be authorized by the certificate of incorporation or by the bylaws.</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.38%;">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notice of General Meetings</p></td>
<td valign="top"  style="width:1.9%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.16%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under applicable European and German law, unless a longer period is otherwise provided for in the articles of association or applies because of registration requirements stipulated in the articles of association, the shareholders must be given at least 30 days&#8217; advance notice of the shareholders&#8217; meeting. Such notices must at least specify the name of the company, the statutory seat of the company, and the location, date and time of the shareholders&#8217; meeting. In addition, the invitation must contain the agenda items as well as the Management Board&#8217;s and the Supervisory Board&#8217;s voting proposal for each agenda item and, depending on the circumstances, certain further information.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If all shareholders entitled to attend the shareholders&#8217; meeting are present or represented and do not object to the meeting being held, the formalities of calling and holding of a shareholders&#8217; meeting do not apply.</p></td>
<td valign="top"  style="width:2.44%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.12%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Delaware law, unless otherwise provided in the certificate of incorporation or bylaws, written notice of any meeting of the stockholders must be given to each stockholder entitled to vote at the meeting not less than ten nor more than 60 days before the date of the meeting and shall specify the place, date, hour, and purpose or purposes of the meeting.</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">229</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:4.93%;width:90.07%;">
<tr>
<td valign="top"  style="width:15.38%;">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy</font></p></td>
<td valign="top"  style="width:1.9%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.16%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A shareholder may designate another person to attend, speak and vote at a shareholders&#8217; meeting of the company on such shareholder&#8217;s behalf by proxy.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to Management Board meetings, a Management Board member may transmit its (written or verbal) vote via another Management Board member.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to Supervisory Board meetings, a Supervisory Board member may participate in voting by issuing a written vote to another Supervisory Board member or any third party entitled to attend the Supervisory Board meeting.</p></td>
<td valign="top"  style="width:2.44%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.12%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Delaware law, at any meeting of stockholders, a stockholder may designate another person to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period. A director of a Delaware corporation may not issue a proxy representing the director&#8217;s voting rights as a director.</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.38%;">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preemptive Rights</p></td>
<td valign="top"  style="width:1.9%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.16%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the law applicable to European stock corporations governed by German law, existing shareholders have a statutory subscription right for any additional issue of shares or any security convertible into shares pro rata to the nominal value of their respective holdings in the company, unless (i) shareholders representing three-quarters of the registered share capital present at the shareholders&#8217; meeting have resolved upon the whole or partial exclusion of the subscription right and (ii) there exists good and objective cause for such exclusion. No separate resolution on the exclusion of subscription rights is required if all shareholders waive their statutory subscription rights.</p></td>
<td valign="top"  style="width:2.44%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.12%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Delaware law, stockholders have no preemptive rights to subscribe to additional issues of stock or to any security convertible into such stock unless, and except to the extent that, such rights are expressly provided for in the certificate of incorporation.</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.38%;">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Authority to Allot</p></td>
<td valign="top"  style="width:1.9%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.16%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under applicable European and German law, the Management Board may not allot shares, grant rights to subscribe for or to convert any security into shares unless a shareholder resolution to that effect has been passed at the company&#8217;s shareholders&#8217; meeting granting the Management Board with such authority&#8212;subject to the approval of the Supervisory Board&#8212;in each case in accordance with the provisions of the German Stock Corporation Act.</p></td>
<td valign="top"  style="width:2.44%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.12%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Delaware law, if the corporation&#8217;s certificate of incorporation so provides, the board of directors has the power to authorize the issuance of stock. It may authorize capital stock to be issued for consideration consisting of cash, any tangible or intangible property or any benefit to the corporation or any combination thereof. It may determine the amount of such consideration by approving a formula. In the absence of actual fraud in the transaction, the judgment of the directors as to the value of such consideration is conclusive.</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:4.93%;width:90.07%;">
<tr>
<td valign="top"  style="width:15.38%;">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liability of Directors and Officers</font></p></td>
<td valign="top"  style="width:1.9%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.16%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under German law, any provision, whether contained in the company&#8217;s articles of association or any contract or otherwise, that purports to exempt a Management or Supervisory Board member from any liability that would otherwise attach to such board member in connection with any negligence, default, breach of duty or breach of trust in relation to the company is void. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under German law, members of both the Management Board and members of the Supervisory Board are liable to the company, and in certain cases to third parties or shareholders, for any damage caused to them due to a breach of such member&#8217;s duty of care. Apart from insolvency or special circumstances, only the company has the right to claim damages from members of either board. The company may waive claims for damages against a negligent Management or Supervisory Board member only after the expiry of three years.</p></td>
<td valign="top"  style="width:2.44%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.12%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Delaware law, a corporation&#8217;s certificate of incorporation may include a provision eliminating or limiting the personal liability of a director to the corporation and its stockholders for damages arising from a breach of fiduciary duty as a director. However, no provision can limit the liability of a director for:</p>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders;</p>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;</p>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;intentional or negligent payment of unlawful dividends or stock purchases or redemptions; or</p>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;any transaction from which the director derives an improper personal benefit.</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.38%;">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Voting Rights</p></td>
<td valign="top"  style="width:1.9%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.16%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the relevant European and German law, each share, except for statutory non-voting preferred shares (<font style="font-style:italic;">nicht stimmberechtigte Vorzugsaktien</font>), entitles its holder to vote at the shareholders&#8217; meeting with, in the case of no-par value shares, each share conferring one vote. While German law does not provide for a minimum attendance quorum for shareholders&#8217; meetings, the company&#8217;s articles of association may so provide. In general, resolutions adopted at a shareholders&#8217; meeting may be passed by a simple majority of votes cast, unless a higher majority is required by law or under the company&#8217;s articles of association.</p></td>
<td valign="top"  style="width:2.44%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.12%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware law provides that, unless otherwise provided in the certificate of incorporation, each stockholder is entitled to one vote for each share of capital stock held by such stockholder.</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.38%;">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shareholder Vote on Certain Transactions</p></td>
<td valign="top"  style="width:1.9%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.16%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under applicable European and German law, certain shareholders&#8217; resolutions of fundamental importance require the vote of at least three-quarters of the share capital present or represented in the voting at the time of adoption of the resolution. Resolutions of fundamental importance include, in particular, capital increases with exclusion of subscription rights, capital decreases, the creation of authorized or conditional share capital, the dissolution of a company, a merger into or with another company, split-offs and split-ups, the conclusion of inter-company agreements (<font style="font-style:italic;">Unternehmensvertr&#228;ge</font>), in particular domination agreements (<font style="font-style:italic;">Beherrschungsvertr&#228;ge</font>) and profit and loss transfer agreements (<font style="font-style:italic;">Ergebnisabf&#252;hrungsvertr&#228;ge</font>).</p></td>
<td valign="top"  style="width:2.44%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.12%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally, under Delaware law, unless the certificate of incorporation provides for the vote of a larger portion of the stock, completion of a merger, consolidation, sale, lease or exchange of all or substantially all of a corporation&#8217;s assets or dissolution requires:</p>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;the approval of the board of directors; and</p>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:69.85pt;;text-indent:-45.35pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;approval by the vote of the holders of a majority of the outstanding stock or, if the certificate of incorporation provides for more or less than one vote per share, a majority of the votes of the outstanding stock of a corporation entitled to vote on the matter.</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">231</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:4.93%;width:90.07%;">
<tr>
<td valign="top"  style="width:15.38%;">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Standard of Conduct for Directors</font></p></td>
<td valign="top"  style="width:1.9%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.16%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under applicable European and German law, both Management and Supervisory Board members must conduct their affairs with &#8220;the care and diligence of a prudent business man&#8221; and act in the best interest of the company. The scope of the fiduciary duties of Management and Supervisory Board members is generally determined by European and German legislation and by the courts. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statutory and fiduciary duties of members of the Management Board to the company include, among others:</p>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;to act in accordance with the law, the company&#8217;s articles of association and the rules of procedure for the Management Board, if any;</p>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;to report to the Supervisory Board on a regular basis as well as on certain important occasions;</p>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;to exercise reasonable care, skill and diligence;</p>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;to maintain a proper accounting system;</p>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;to not compete, directly or indirectly, with the company without permission by the supervisory board; and</p>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;to secure that no further transactions are made in case of insolvency. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statutory and fiduciary duties of members of the Supervisory Board to the company include, among others:</p>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;to effectively supervise the Management Board&#8217;s handling of the company&#8217;s affairs; </p>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;to evaluate and issue a resolution on certain transactions which can only be conducted by the Management Board after approval of the Supervisory Board;</p>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;to approve the company&#8217;s financial statements;</p>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;to appoint the Management Board members and to represent the company in transactions between the company and members of the Management Board; and</p>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-15.1pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;to approve service contracts between individual members of the Supervisory Board and the company.</p></td>
<td valign="top"  style="width:2.44%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.12%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware law does not contain specific provisions setting forth the standard of conduct of a director. The scope of the fiduciary duties of directors is generally determined by the courts of the State of Delaware. In general, directors have a duty to act without self-interest, on a well- informed basis and in a manner they reasonably believe to be in the best interest of the stockholders.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Directors of a Delaware corporation owe fiduciary duties of care and loyalty to the corporation and to its stockholders. The duty of care generally requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself of all material information reasonably available regarding a significant transaction. The duty of loyalty requires that a director act in a manner he reasonably believes to be in the best interests of the corporation. He must not use his corporate position for personal gain or advantage. In general, but subject to certain exceptions, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties. Delaware courts have also imposed a heightened standard of conduct upon directors of a Delaware corporation who take any action designed to defeat a threatened change in control of the corporation. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, under Delaware law, when the board of directors of a Delaware corporation approves the sale or break-up of a corporation, the board of directors may, in certain circumstances, have a duty to obtain the highest value reasonably available to the stockholders.</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:4.93%;width:90.07%;">
<tr>
<td valign="top"  style="width:15.38%;">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholder Actions</font></p></td>
<td valign="top"  style="width:1.9%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.16%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under German law, generally, the company, rather than its shareholders, is the proper claimant in an action with respect to a wrong committed against the company, or in cases where there is an irregularity in the company&#8217;s internal management or supervision. Therefore, such claims may only be raised by the company represented by its Management Board, or, in the case of a wrong committed by a member of the Management Board, by the Supervisory Board.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, pursuant to German case law, the Supervisory Board is obliged to pursue the company&#8217;s claims against the Management Board, unless the interest of the company keeps them from doing so.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Management Board, or, if a claim is against a member of the Management Board, the Supervisory Board, is obliged to pursue the company&#8217;s claims against the designated individuals if so resolved by a simple majority of votes cast during a shareholders&#8217; meeting. With a simple majority of votes, shareholders can request that a representative pursues the claim on behalf of the company.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the company is unable to fulfill its third- party obligations, the company&#8217;s creditors may pursue the company&#8217;s damage claims against members of the Management Board for certain wrongdoings.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under certain circumstances, shareholders can bring forward damage claims of the company against its management on their own behalf. In order to bring forward such a claim one shareholder alone or together with other shareholders needs to hold at least one percent of the company&#8217;s share capital or a participation of &#8364;100,000 in the share capital. Additionally, the claimant(s) need(s) to pass through special claim approval procedures.</p></td>
<td valign="top"  style="width:2.44%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.12%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Delaware law, a stockholder may initiate a derivative action to enforce a right of a corporation if the corporation fails to enforce the right itself. The complaint must:</p>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;state that the plaintiff was a stockholder at the time of the transaction of which the plaintiff complains or that the plaintiffs shares thereafter devolved on the plaintiff by operation of law; and </p>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;either (i) allege with particularity the efforts made by the plaintiff to obtain the action the plaintiff desires from the directors and the reasons for the plaintiff&#8217;s failure to obtain the action, or (ii) or state the reasons for not making the effort. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the plaintiff must remain a stockholder through the duration of the derivative suit. The action will not be dismissed or compromised without the approval of the Delaware Court of Chancery.</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Foreign Private<font style="letter-spacing:0.05pt;"> </font>Issuer<font style="letter-spacing:0.05pt;"> </font>Exemptions</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a &#8220;foreign<font style="letter-spacing:0.1pt;"> </font>private<font style="letter-spacing:0.1pt;"> </font>issuer,&#8221;<font style="letter-spacing:0.1pt;"> </font>as defined<font style="letter-spacing:0.05pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>SEC,<font style="letter-spacing:-0.05pt;"> </font>although<font style="letter-spacing:0.05pt;"> </font>we are<font style="letter-spacing:0.05pt;"> </font>permitted<font style="letter-spacing:0.1pt;"> </font>to follow<font style="letter-spacing:0.05pt;"> </font>certain<font style="letter-spacing:0.1pt;"> </font>corporate governance<font style="letter-spacing:0.05pt;"> </font><font style="color:#000000;">practices</font><font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Federal<font style="letter-spacing:0.05pt;"> </font>Republic<font style="letter-spacing:0.05pt;"> </font>of Germany,<font style="letter-spacing:0.05pt;"> </font>instead<font style="letter-spacing:0.05pt;"> </font>of those<font style="letter-spacing:0.05pt;"> </font>otherwise<font style="letter-spacing:0.05pt;"> </font>required<font style="letter-spacing:0.1pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>rules<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Nasdaq <font style="color:#000000;">Stock</font> Market<font style="letter-spacing:0.05pt;"> </font>LLC,<font style="letter-spacing:-0.05pt;"> </font>or Nasdaq, for<font style="letter-spacing:0.05pt;"> </font>domestic<font style="letter-spacing:0.1pt;"> </font>issuers,<font style="letter-spacing:0.1pt;"> </font>we follow<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Nasdaq corporate<font style="letter-spacing:0.1pt;"> </font>governance rules<font style="letter-spacing:0.05pt;"> </font>applicable<font style="letter-spacing:0.1pt;"> </font>to foreign<font style="letter-spacing:0.05pt;"> </font>private<font style="letter-spacing:0.1pt;"> </font>issuers.<font style="letter-spacing:0.1pt;"> </font>While<font style="letter-spacing:0.05pt;"> </font>we voluntarily<font style="letter-spacing:0.1pt;"> </font>follow<font style="letter-spacing:0.05pt;"> </font>most<font style="letter-spacing:0.05pt;"> </font>Nasdaq corporate<font style="letter-spacing:0.1pt;"> </font>governance<font style="letter-spacing:0.05pt;"> </font>rules, we intend<font style="letter-spacing:0.05pt;"> </font>to take<font style="letter-spacing:0.05pt;"> </font>advantage<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>following<font style="letter-spacing:0.05pt;"> </font>limited<font style="letter-spacing:0.1pt;"> </font>exemptions:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>exemption<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>filing<font style="letter-spacing:0.1pt;"> </font>quarterly<font style="letter-spacing:0.1pt;"> </font>reports<font style="letter-spacing:0.1pt;"> </font>on Form<font style="letter-spacing:0.05pt;"> </font>10-Q and providing<font style="letter-spacing:0.05pt;"> </font>current<font style="letter-spacing:0.1pt;"> </font>reports<font style="letter-spacing:0.1pt;"> </font>on Form<font style="letter-spacing:0.05pt;"> </font>8-K disclosing<font style="letter-spacing:0.1pt;"> </font>significant<font style="letter-spacing:0.15pt;"> </font>events<font style="letter-spacing:0.05pt;"> </font>within<font style="letter-spacing:0.05pt;"> </font>four<font style="letter-spacing:0.05pt;"> </font>days of their<font style="letter-spacing:0.05pt;"> </font>occurrence<font style="letter-spacing:0.1pt;"> </font>(however,<font style="letter-spacing:0.05pt;"> </font>we intend<font style="letter-spacing:0.05pt;"> </font>to furnish quarterly<font style="letter-spacing:0.1pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>information<font style="letter-spacing:0.15pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>cover<font style="letter-spacing:0.05pt;"> </font>of Form<font style="letter-spacing:0.05pt;"> </font>6-K);</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">exemption from compliance with Regulation FD, which generally requires that when a company intentionally discloses material-non public information, it do so through a public disclosure that is broadly available to all members of the public at the same time. However, we do furnish quarterly financial information and other </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">233</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">information on a more frequent basis under cover of Form 6-K, and intend to continue doing so. </font><font style="color:#000000;">Moreover</font><font style="color:#000000;">, we comply with other </font><font style="color:#000000;">other securities laws, such as rule 10b-5 (rule targeting securities fraud), among others</font><font style="color:#000000;">;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#231F20;">exemption</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">from</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Section</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">16 rules</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">regarding</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">sales</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of ordinary</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">shares</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">by insiders,</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">which will</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">provide</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">less data</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">in this</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">regard</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">than</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">data</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">provided</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">to shareholders</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">of U.S.</font><font style="color:#231F20;letter-spacing:-0.05pt;"> </font><font style="color:#231F20;">companies</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">that</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">are</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">subject</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">to the Exchange Act;</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#231F20;">exemption</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">from</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Nasdaq rules</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">applicable</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">to domestic</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">issuers</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">requiring</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">disclosure</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">within</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">four business</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">days of any determination</font><font style="color:#231F20;letter-spacing:0.15pt;"> </font><font style="color:#231F20;">to grant</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">a waiver</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">code of business</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">conduct</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">and ethics</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">to directors</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">and officers.</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">Although we will</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">require</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">board</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">approval</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of any such waiver,</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">we may</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">choose</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">not to disclose</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">waiver</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">in the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">manner</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">set</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">forth</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">in the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Nasdaq rules,</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">as permitted</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">by the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">foreign</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">private issuer</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">exemption.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore<font style="color:#231F20;">,</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">Nasdaq Rule 5615(a)(3)</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">provides</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">that</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">a foreign</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">private</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">issuer,</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">such as we, may</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">rely</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">on home country</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">corporate</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">governance</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">practices</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">in lieu</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of certain</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">of the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">rules</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">in the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Nasdaq Rule 5600 Series</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">and Rule 5250(d),</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font>provided<font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">that</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">we nevertheless</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">comply</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">with Nasdaq&#8217;s</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Notification</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">of Noncompliance</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">requirement (Rule</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">5625) and the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Voting Rights</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">requirement</font><font style="color:#231F20;letter-spacing:0.15pt;"> </font><font style="color:#231F20;">(Rule</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">5640) and that</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">we have an audit</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">committee</font><font style="color:#231F20;letter-spacing:0.15pt;"> </font><font style="color:#231F20;">that</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">satisfies Rule 5605(c)(3),</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font>consisting<font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">of committee</font><font style="color:#231F20;letter-spacing:0.15pt;"> </font><font style="color:#231F20;">members</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">that</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">meet</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">independence</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">requirements</font><font style="color:#231F20;letter-spacing:0.15pt;"> </font><font style="color:#231F20;">of Rule 5605(c)(2)(A)(ii).</font><font style="color:#231F20;letter-spacing:0.2pt;"> </font><font style="color:#231F20;">Although we are</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">permitted</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">to follow</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">certain</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">corporate</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">governance</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">rules</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">that</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">conform</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">to German</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">requirements</font><font style="color:#231F20;letter-spacing:0.15pt;"> </font><font style="color:#231F20;">in lieu</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of many</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Nasdaq corporate</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">governance</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">rules,</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">we comply</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">with the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Nasdaq corporate</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">governance</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">rules</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">applicable</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">to foreign</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">private</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">issuers.</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">We may</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">utilize</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">these</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">exemptions</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">for</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">as long as we continue</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">to qualify</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">as a foreign</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font>private<font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">issuer.</font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16H_MINE_SAFETY_DISCLOSURE"></a><a name="ITEM_16H_MINE_SAFETY_DISCLOSURE"></a>Item 16H. Mine Safety Disclosure</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">234</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_III"></a><a name="PART_III"></a>PART III</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_17_FINANCIAL_STATEMENTS"></a><a name="ITEM_17_FINANCIAL_STATEMENTS"></a>Item 17. Financial Statements</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Item 18. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_18_FINANCIAL_STATEMENTS"></a><a name="ITEM_18_FINANCIAL_STATEMENTS"></a>Item 18. Financial Statements</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <font style="color:#000000;">financial</font> statements are filed as part of this Annual Report beginning on page F-1. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_19_EXHIBITS"></a><a name="ITEM_19_EXHIBITS"></a>Item 19. Exhibits</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100.04%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:10.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:87.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:10.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:87.3%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">1.1*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="bntx-ex11_6.htm"><font style="text-decoration:underline;">Articles of Association of the Registrant</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">2.1</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1201935/000101915519000234/biontechdep.htm"><font style="text-decoration:underline;">Form of Specimen American Depositary Receipt (included in Exhibit 2.3)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312519241112/d635330dex42.htm"><font style="text-decoration:underline;">Registrant&#8217;s Specimen Certificate for Ordinary Shares (incorporated herein by reference to Exhibit&#160;4.2 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1201935/000101915519000234/biontechdep.htm"><font style="text-decoration:underline;">Form of Deposit Agreement among the Registrant, the depositary and holders and beneficial owners of the American Depositary Shares (incorporated herein by reference to Exhibit&#160;1 to the Registration Statement on Form&#160;F-6 (File No.&#160;333-233898), filed with the SEC on September&#160;23, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4*</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="bntx-ex24_790.htm"><font style="text-decoration:underline;">Description of Securities of the Registrant</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312519241112/d635330dex101.htm"><font style="text-decoration:underline;">Master Agreement for Research Services by and among the Registrant, BioNTech RNA Pharmaceuticals GmbH, BioNTech Diagnostics GmbH, BioNTech Protein Therapeutics GmbH, BioNTech Cell&#160;&amp; Gene Therapies GmbH, Eufets GmbH, JPT Peptide Technologies GmbH and TRON-Translationale Onkologie an der Universit&#228;tsmedizin der Johannes Gutenberg Universit&#228;t Mainz gemeinn&#252;tzige GmbH, dated January&#160;1, 2015 (incorporated herein by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312519241112/d635330dex102.htm"><font style="text-decoration:underline;">Confirmation Letter by and among the Registrant, BioNTech RNA Pharmaceuticals GmbH and TRON-Translationale Onkologie an der Universit&#228;tsmedizin der Johannes Gutenberg Universit&#228;t Mainz gemeinn&#252;tzige GmbH dated September&#160;15, 2016 (incorporated herein by reference to Exhibit&#160;10.2 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312519241112/d635330dex103.htm"><font style="text-decoration:underline;">Supplementary Agreement for IVAC Developments to the Master Agreement for Research Services by and among the Registrant, BioNTech RNA Pharmaceuticals GmbH, BioNTech Diagnostics GmbH, BioNTech Protein Therapeutics GmbH, BioNTech Cell&#160;&amp; Gene Therapies GmbH, BioNTech Innovative Manufacturing Services GmbH (f/k/a Eufets GmbH), JPT Peptide Technologies GmbH and TRON-Translationale Onkologie an der Universit&#228;tsmedizin der Johannes Gutenberg Universit&#228;t Mainz gemeinn&#252;tzige GmbH, dated November&#160;28, 2017 (incorporated herein by reference to Exhibit&#160;10.3 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312519241112/d635330dex104.htm"><font style="text-decoration:underline;">License Agreement by and among the Registrant, TRON-Translationale Onkologie an der Universit&#228;tsmedizin der Johannes Gutenberg Universit&#228;t Mainz gemeinn&#252;tzige GmbH, Johannes Gutenberg-Universit&#228;t Mainz, Universit&#228;tsmedizin der Johannes Gutenberg-Universit&#228;t and Ganymed Pharmaceuticals AG, dated January&#160;1, 2015 (incorporated herein by reference to Exhibit&#160;10.4 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">235</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100.04%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312519241112/d635330dex105.htm"><font style="text-decoration:underline;">Framework Collaboration Agreement by and among the Registrant, BioNTech RNA Pharmaceuticals GmbH, BioNTech Diagnostics GmbH, BioNTech Protein Therapeutics GmbH, BioNTech Cell&#160;&amp; Gene Therapies GmbH, BioNTech Innovative Manufacturing Services GmbH, JPT Peptide Technologies GmbH and TRON-Translationale Onkologie an der Universit&#228;tsmedizin der Johannes Gutenberg Universit&#228;t Mainz gemeinn&#252;tzige GmbH, dated August&#160;29, 2019 (incorporated herein by reference to Exhibit&#160;10.5 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312519241112/d635330dex106.htm"><font style="text-decoration:underline;">Amended Patent License Agreement by and among the Registrant, the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College and Uniwersytet Warszawski, dated May&#160;12, 2015 (incorporated herein by reference to Exhibit 10.6 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.7&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312519241112/d635330dex107.htm"><font style="text-decoration:underline;">License and Collaboration Agreement by and between the Registrant and Genmab A/S, dated May&#160;19, 2015 (incorporated herein by reference to Exhibit 10.7 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312519241112/d635330dex108.htm"><font style="text-decoration:underline;">Amendment No.&#160;1 to License and Collaboration Agreement by and between the Registrant and Genmab A/S, dated May&#160;18, 2017 (incorporated herein by reference to Exhibit 10.8 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312519241112/d635330dex109.htm"><font style="text-decoration:underline;">Amendment No.&#160;2 to License and Collaboration Agreement by and between the Registrant and Genmab A/S, dated August&#160;4, 2017 (incorporated herein by reference to Exhibit 10.9 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.10&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312519241112/d635330dex1010.htm"><font style="text-decoration:underline;">Amendment No.&#160;3 to License and Collaboration Agreement by and between the Registrant and Genmab A/S, dated May&#160;18, 2018 (incorporated herein by reference to Exhibit 10.10 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.11&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312519241112/d635330dex1011.htm"><font style="text-decoration:underline;">Collaboration and License Agreement by and between Sanofi S.A. and BioNTech RNA Pharmaceuticals GmbH, dated November&#160;2, 2015 (incorporated herein by reference to Exhibit&#160;10.11 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.12&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312519241112/d635330dex1012.htm"><font style="text-decoration:underline;">Amendment to Collaboration and License Agreement by and between Sanofi S.A. and BioNTech RNA Pharmaceuticals GmbH, dated December&#160;22, 2018 (incorporated herein by reference to Exhibit 10.12 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.13&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312519241112/d635330dex1013.htm"><font style="text-decoration:underline;">Development Agreement by and between Sanofi S.A. and BioNTech RNA Pharmaceuticals GmbH, dated March&#160;29, 2018 (incorporated herein by reference to Exhibit 10.13 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.14&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312519241112/d635330dex1014.htm"><font style="text-decoration:underline;">Collaboration Agreement by and among the Registrant, BioNTech RNA Pharmaceuticals GmbH, Genentech, Inc. and F.&#160;Hoffman-La&#160;Roche Ltd, dated September&#160;20, 2016 (incorporated herein by reference to Exhibit 10.14 to the Registrant&#8217;s Registration Statement on Form F-1 (File&#160;No.&#160; 333-233688),&#160;filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.15*&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312519241112/d635330dex1017.htm"><font style="text-decoration:underline;">First Amendment to the Collaboration Agreement by and among the Registrant, BioNTech RNA Pharmaceuticals GmbH, Genentech, Inc. and F. Hoffman-La Roche Ltd, dated June&#160;1, 2018 (incorporated herein by reference to Exhibit 10.17 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-239970), filed with the SEC on July 21, 2020)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.16*&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312519241112/d635330dex1018.htm"><font style="text-decoration:underline;">Second Amendment to the Collaboration Agreement by and among the Registrant, BioNTech RNA Pharmaceuticals GmbH, Genentech, Inc. and F.&#160;Hoffman-La&#160;Roche Ltd, dated December&#160;6, 2019 (incorporated herein by reference to Exhibit 10.18 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-239970), filed with the SEC on July 21, 2020)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.17*</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="bntx-ex417_789.htm"><font style="text-decoration:underline;">Joinder and Third Amendment to the Collaboration Agreement by and among the Registrant, BioNTech RNA Pharmaceuticals GmbH, BioNTech Manufacturing GmbH, Genentech, Inc. and F. Hoffman-La Roche Ltd, effective as of October 1, 2020</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100.04%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.18</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="bntx-ex418_411.htm"><font style="text-decoration:underline;">Fourth Amendment to the Collaboration Agreement by and among the Registrant, BioNTech RNA Pharmaceuticals GmbH, BioNTech Manufacturing GmbH, Genentech, Inc. and F. Hoffman-La Roche Ltd, effective as of October 26, 2020</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.19&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1015.htm"><font style="text-decoration:underline;">Patent Sublicense Agreement by and between CellScript, LLC and BioNTech RNA Pharmaceuticals GmbH, dated July&#160;14, 2017 (incorporated herein by reference to Exhibit 10.15 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.20*&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="bntx-ex420_412.htm"><font style="text-decoration:underline;">Second Amendment to Patent Sublicense Agreement by and between CellScript, LLC and BioNTech RNA Pharmaceuticals GmbH, effective as of August 1, 2020</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.21&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1016.htm"><font style="text-decoration:underline;">Patent Sublicense Agreement by and between mRNA RiboTherapeutics, Inc. and BioNTech RNA Pharmaceuticals GmbH, dated July&#160;14, 2017 (incorporated herein by reference to Exhibit 10.16 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.22*&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="bntx-ex422_413.htm">Second Amendment to Patent Sublicense Agreement by and between mRNA RiboTherapeutics, Inc. and BioNTech RNA Pharmaceuticals GmbH, effective as of August 1, 2020</a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.23&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1018.htm"><font style="text-decoration:underline;">Research Collaboration and License Agreement by and among the Registrant, BioNTech RNA Pharmaceuticals GmbH and Pfizer, Inc., dated July&#160;20, 2018 (incorporated herein by reference to Exhibit&#160;10.18 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.24&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1019.htm"><font style="text-decoration:underline;">Collaboration and License Agreement by and between the Trustees of the University of Pennsylvania and BioNTech RNA Pharmaceuticals GmbH, dated October&#160;9, 2018 (incorporated herein by reference to Exhibit 10.19 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.25&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1021.htm"><font style="text-decoration:underline;">Sublease Agreement by and among the Registrant and Universit&#228;tsmedizin der Johannes Gutenberg-Universit&#228;t Mainz, dated January&#160;14, 2013 (incorporated herein by reference to Exhibit&#160;10.21 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.26&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1022.htm"><font style="text-decoration:underline;">Amendment to Sublease Agreement by and among the Registrant and Universit&#228;tsmedizin der Johannes Gutenberg-Universit&#228;t Mainz, dated July&#160;5, 2014 (incorporated herein by reference to Exhibit 10.22 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.27&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1023.htm"><font style="text-decoration:underline;">Amendment to Sublease Agreement by and among the Registrant and Universit&#228;tsmedizin der Johannes Gutenberg-Universit&#228;t Mainz, dated June&#160;8, 2015 (incorporated herein by reference to Exhibit 10.23 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.28&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1024.htm"><font style="text-decoration:underline;">Amendment to Sublease Agreement by and among the Registrant and Universit&#228;tsmedizin der Johannes Gutenberg-Universit&#228;t Mainz, dated January&#160;18, 2017 (incorporated herein by reference to Exhibit 10.24 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.29&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <a href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1025.htm"><font style="font-size:11pt;text-decoration:underline;">Lease Agreement by and among the Registrant and Wolfram Richter, dated August&#160;17, 2011 (incorporated herein by reference to Exhibit 10.25 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.30&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1026.htm"><font style="text-decoration:underline;">Amendment No.&#160;1 to Lease Agreement by and among the Registrant and Wolfram Richter, dated February&#160;17, 2012 (incorporated herein by reference to Exhibit 10.26 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.31&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1027.htm"><font style="text-decoration:underline;">Amendment No.&#160;2 to Lease Agreement by and among the Registrant and Wolfram Richter, dated February&#160;1, 2013 (incorporated herein by reference to Exhibit 10.27 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.32&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1028.htm"><font style="text-decoration:underline;">Amendment No.&#160;3 to Lease Agreement by and among the Registrant and Wolfram Richter, dated March&#160;6, 2013 (incorporated herein by reference to Exhibit 10.28 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100.04%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.33&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1029.htm"><font style="text-decoration:underline;">Amendment No.&#160;4 to Lease Agreement by and among the Registrant and Wolfram Richter, dated December&#160;10, 2013 (incorporated herein by reference to Exhibit 10.29 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.34&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1030.htm"><font style="text-decoration:underline;">Amendment No.&#160;5 to Lease Agreement by and among the Registrant and Wolfram Richter, dated March&#160;29, 2016 (incorporated herein by reference to Exhibit 10.30 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.35&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1031.htm"><font style="text-decoration:underline;">Amendment No. 6 to Lease Agreement by and among the Registrant and Wolfram Richter, dated October 6, 2017 (incorporated herein by reference to Exhibit 10.31 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.36&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1032.htm"><font style="text-decoration:underline;">Lease Agreement by and among the Registrant and Wista-Management GmbH, dated April&#160;12, 2005 (incorporated herein by reference to Exhibit 10.32 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.37&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1033.htm"><font style="text-decoration:underline;">Amendment to Lease Agreement by and among the Registrant and Wista-Management GmbH, dated December&#160;27, 2018 (incorporated herein by reference to Exhibit 10.33 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September&#160;9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.38&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001776985/000156459020014536/bntx-ex435_184.htm"><font style="text-decoration:underline;">Amendment to Lease Agreement by and among the Registrant and Wista-Management GmbH, dated October 24, 2019 (incorporated herein by reference to Exhibit 4.35 to the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.39&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312520195911/d939702dex1038.htm"><font style="text-decoration:underline;">Amendment to Lease Agreement by and among the Registrant and Wista-Management GmbH, dated June 1, 2020 (incorporated herein by reference to Exhibit 10.38 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233970), filed with the SEC on July 21, 2020)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.40&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1034.htm"><font style="text-decoration:underline;">Loan Agreement by and between BioNTech Innovative Manufacturing Services GmbH and Deutsche Bank AG dated November&#160;21, 2017 (incorporated herein by reference to Exhibit 10.34 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September&#160;9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.41&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1035.htm"><font style="text-decoration:underline;">Loan Agreement by and between JPT Peptides Technologies GmbH and Deutsche Bank AG dated July&#160;18, 2018 (incorporated herein by reference to Exhibit 10.35 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.42&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1776985/000156459020014536/bntx-ex441_127.htm"><font style="text-decoration:underline;">Finance Contract by and between the Registrant and the European Investment Bank, dated December&#160;12, 2019 (incorporated herein by reference to Exhibit 10.43 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233970), filed with the SEC on July 21, 2020)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.43&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1776985/000156459020014536/bntx-ex442_125.htm"><font style="text-decoration:underline;">Finance Fee Letter by and between the Registrant and the European Investment Bank, dated December&#160;12, 2019 (incorporated herein by reference to Exhibit 10.44 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233970), filed with the SEC on July 21, 2020)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.44*&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="bntx-ex444_416.htm"><font style="text-decoration:underline;">Amended and Restated Collaboration Agreement by and between the Registrant and Pfizer Inc., dated March 17, 2020</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.45&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312520195911/d939702dex1046.htm"><font style="text-decoration:underline;">Antiviral Vaccine RDI Finance Contract by and between the European Investment Bank and the Registrant, dated as of June&#160;10, 2020 (incorporated herein by reference to Exhibit 10.46 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233970), filed with the SEC on July 21, 2020</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.46&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312520195911/d939702dex1047.htm"><font style="text-decoration:underline;">Finance Fee Letter by and between the Registrant and the European Investment Bank, dated June&#160;10, 2020 (incorporated herein by reference to Exhibit 10.47 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233970), filed with the SEC on July 21, 2020</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.47&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312520195911/d939702dex1048.htm"><font style="text-decoration:underline;">License Agreement by and between the Broad Institute, Inc. and BioNTech US Inc. (as successor-by-merger to Neon Therapeutics, Inc.), dated as of November&#160;13, 2015 (incorporated herein by reference to Exhibit 10.48 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233970), filed with the SEC on July 21, 2020</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.48&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312520195911/d939702dex1049.htm"><font style="text-decoration:underline;">First Amendment to the License Agreement by and between the Broad Institute, Inc. and BioNTech US Inc. (as successor-by-merger to Neon Therapeutics, Inc.), dated as of January 18, 2018 (incorporated herein by reference to Exhibit 10.49 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233970), filed with the SEC on July 21, 2020</font></a></p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">238</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100.04%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.49&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312520195911/d939702dex1050.htm"><font style="text-decoration:underline;">Second Amendment to the License Agreement by and between the Broad Institute, Inc. and BioNTech US Inc. (as successor-by-merger to Neon Therapeutics, Inc.), dated as of November&#160;14, 2018 (incorporated herein by reference to Exhibit 10.50 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233970), filed with the SEC on July 21, 2020</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.50&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1776985/000119312520289350/d21545dex12.htm"><font style="text-decoration:underline;">Sales Agreement by and among the Registrant, Jefferies LLC and SVB Leerink LLC, dated November 9, 2020 (incorporated herein by reference to Exhibit 1.2 to the Registrant&#8217;s Registration Statement on Form F-3 (File No. 333-249991), filed with the SEC on November 10, 2020)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:14.2pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.51*&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="bntx-ex451_414.htm"><font style="text-decoration:underline;">Advance Purchase Agreement by and among BioNTech Manufacturing GmbH, Pfizer Inc., and the European Commission, dated November 20, 2020</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:14.2pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.52*&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="bntx-ex452_415.htm"><font style="text-decoration:underline;">Purchase Agreement by and among BioNTech Manufacturing GmbH, Pfizer Inc., and the European Commission, dated February 17, 2021</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:14.2pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.53*&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="bntx-ex453_417.htm"><font style="text-decoration:underline;">Lease by and between the Pharmaserv GmbH and Novartis Manufacturing GmbH.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:14.2pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8*</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="bntx-ex8_418.htm"><font style="text-decoration:underline;">List of Subsidiaries of the Registrant</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">12.1*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="bntx-ex121_12.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">12.2*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="bntx-ex122_16.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">13.1*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="bntx-ex131_7.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">13.2*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="bntx-ex132_8.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">15.1</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="bntx-ex151_1103.htm"><font style="text-decoration:underline;">Consent of Ernst &amp; Young GmbH Wirtschaftspr&#252;fungsgesellschaft</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.INS</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Instance Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.SCH</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Schema Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.CAL</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.DEF</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Definition Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.LAB</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Label Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.PRE</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:87.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:94.2%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.72%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Filed herewith.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.72%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Certain information has been excluded from the exhibit because it both (i) is not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.</p></td></tr></table></div>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:4.93%;text-indent:-4.93%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">239</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a><a name="SIGNATURES"></a>SIGNATURES</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this Annual Report on Form 20-F on its behalf. </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:55.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="top"  BGCOLOR="#FFFFFF" style="width:42.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech SE</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:55.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:3.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:37.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:55.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 30, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:3.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:37.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;<font style="color:#000000;"> </font>Prof. Ugur Sahin, M.D.</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:55.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:3.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:37.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Prof. Ugur Sahin, M.D.</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:55.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:3.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:37.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
<td style="border:none;padding:0;"></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="INDEX_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a><a name="INDEX_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><font style="text-decoration:underline;">Reports of Independent Registered Public Accounting Firm</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_FINANCIAL_POSITI"><font style="text-decoration:underline;">Consolidated Statements of Financial Position as of December&#160;31, 2020 and 2019</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS"><font style="text-decoration:underline;">Consolidated Statements of Operations for the Years ended December&#160;31, 2020, 2019 and 2018</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQU"><font style="text-decoration:underline;">Consolidated Statements of Changes in Stockholders&#8217; Equity for the Years ended December&#160;31, 2020, 2019 and 2018</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><font style="text-decoration:underline;">Consolidated Statements of Cash Flows for the Years ended December&#160;31, 2020, 2019 and 2018</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-11</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><font style="text-decoration:underline;">Notes to Consolidated Financial Statements</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-12</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a>REPORT OF <font style="color:#000000;">INDEPENDENT</font><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a> REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Shareholders and the Management and Supervisory Boards of BioNTech SE</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Opinion on the Financial Statements</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk65513751"></a><a name="_Hlk65513751"></a>We have audited the accompanying consolidated statements of financial position of BioNTech SE and subsidiaries (the Company) as of December 31, 2020 and 2019, the related consolidated statements of operations, comprehensive income,&#160;changes in equity and cash flows for each of the three years in the period ended December 31, 2020, and the related notes&#160;&#160;(collectively referred to as the &#8220;(consolidated) financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020, in conformity with International Financial Reporting Standards as issued by the International Accounting Standard Board.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission &#8220;(2013 framework),&#8221; and our report dated March 30, 2021 expressed an unqualified opinion thereon.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Audit Matters</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated&#160;financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100.48%;">
<tr>
<td colspan="3" valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounting for cost-sharing and related revenue recognition under Genentech and Pfizer Collaboration Agreements</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:14.98%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:83.78%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:14.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Description of the Matter</p></td>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:83.78%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has been engaged in collaboration agreements (&#8220;agreements&#8221;) with Genentech and Pfizer. Upon entering into the agreements, the Company has recognized a contract liability. As of December 31, 2020, the Company has a contract liability of &#8364;82.3 million related to the Genentech agreement and no remaining contract liability related to the Pfizer agreement. Additionally, the Company recognized &#8364;49.2 million of revenue from the Genentech agreement and &#8364;118.0 million from the Pfizer agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company, Genentech, and Pfizer conduct research and development activities under these agreements. Revenue for both agreements is recognized based upon incurred costs as a measurement basis in the cost-sharing models. As explained in note 6 to the consolidated financial statements, the Company, Genentech, and Pfizer share certain internal and external research and development costs under the agreements. The Company&#8217;s research and development costs include external actual and estimated Clinical Research Organizations costs (&#8220;CRO&#8221;), external actual and estimated Contract Manufacturing Organization (&#8220;CMO&#8221;) costs, and internal employee costs. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Auditing the cost-sharing under the agreements was challenging because of the complexity of determining the eligible research and development costs under the respective agreements. The research and development costs include management&#8217;s judgment specifically for estimated third party CRO and CMO costs incurred during the reporting period. Additionally, management evaluates the research and development costs incurred and activities performed by Genentech and Pfizer to assess the eligibility for reimbursement through cost-sharing under the agreements.</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</a></p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100.48%;">
<tr>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:14.98%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:83.78%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:14.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">How We Addressed the Matter in Our Audit</p></td>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:83.78%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the accounting for the cost-sharing conducted under the agreements. We tested management&#8217;s evaluation of the agreements to determine eligible research &amp; development costs, tested their review of completeness and accuracy of those costs and tested their review of the underlying calculations. We also tested management&#8217;s controls of reviewing third party CMO and CRO costs incurred and eligibility to be included under the terms of the agreements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audit procedures included, among others, conducting interviews with program management, clinical operations and manufacturing personnel to determine the progress to date under the agreements and testing the eligibility of the Company&#8217;s research and development costs against the terms of the agreements. We met with Company personnel and reviewed meeting minutes to understand discussions held with Genentech and Pfizer during various committee meetings to test the completeness and accuracy of information obtained. Further, we tested the research and development activities reported by the Company, Genentech, and Pfizer for appropriate classification and disclosure by comparing the cost categories reported to those included in the agreements. Lastly, we obtained external confirmations from Genentech and Pfizer for the research and development costs incurred and evaluated the adequacy of the Company&#8217;s related disclosures.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:499.8pt;;">
<tr>
<td style="width:78.15pt;"></td>
<td style="width:4.4pt;"></td>
<td style="width:417.25pt;"></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Valuation of IPR&amp;D acquired within Business Combinations of Neon</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Description of the Matter</p></td>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As described in more detail in Note 5 to the consolidated financial statements, in May 2020, the Company completed its acquisition of Neon Therapeutics Inc. (Neon) for a purchase price of &#8364;89.9 million. As a result of the acquisition, the Company acquired in-process research and development (IPR&amp;D) assets including a neoantigen-targeting T cell platform that can be utilized to develop product candidates across several neoantigen-targeting non-engineered and engineered T cell therapies with BNT221 (NEO-PTC-01) being the most advanced program acquired. The lead program acquired is BNT222 (NEO-STC-01) a T-cell therapy candidate targeting shared RAS neoantigens. NEO-PTC-01 and NEO-STC-01 IPR&amp;D assets were accounted for as definite-lived intangible assets and valued at &#8364;28.8 million and &#8364;0.6 million, respectively.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Auditing the valuation of the IPR&amp;D assets was complex because of the significant estimation uncertainty in determining the fair value of the intangible assets. The fair value determination is based on a discounted cash flow model using certain assumptions containing high subjectivity, such as revenue growth, probability of technical success and discount rates. These significant assumptions are forward-looking and could be affected by future economic and market conditions. Further, the estimated fair value of the IPR&amp;D assets was sensitive to changes in these assumptions. </p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">How We Addressed the Matter in Our Audit</p></td>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We evaluated the design and tested the operating effectiveness of the Company&#8217;s controls related to the valuation of the IPR&amp;D assets. For example, we tested controls over management&#8217;s review of the significant assumptions used to calculate the valuation of the intangible assets acquired including forecasts of future cash flows, discount rate and review of the valuation model. <br /></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audit procedures included, among others, obtaining an understanding of management&#8217;s approach to developing the probability of technical success and evaluating the reasonableness by comparing to analyst expectations, historical results of similar products in development and industry trends. In addition, to evaluating the probability of technical success, we considered the phase of development of the IPR&amp;D project and third-party data regarding clinical trial success rates. We evaluated the reasonableness of the projected revenue growth used in the valuation by comparing assumptions to industry trends, such as patient population, market studies, and price ranges for similar drugs. Our procedures also included sensitivity analysis of the significant assumptions to evaluate the change in the fair value of the IPR&amp;D assets resulting from changing the assumptions. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, we involved our valuation specialists to evaluate the discounted cash flow model used by the Company and to test the discount rate utilized in the Company&#8217;s valuation. Lastly, we evaluated the adequacy of the Company&#8217;s related disclosures.</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"><a name="_Hlk65513936"></a>&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Ernst &amp; Young GmbH Wirtschaftspr&#252;fungsgesellschaft</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2018</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cologne, Germany</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 30, 2021</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">REPORT OF <font style="color:#000000;">INDEPENDENT</font> REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Shareholders and the Management and Supervisory Boards of BioNTech SE</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Opinion on Internal Control Over Financial Reporting</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited BioNTech SE&#8217;s and subsidiaries&#8217; internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission &#8220;(2013 framework),&#8221;<font style="font-weight:bold;"> </font>(the COSO criteria).&nbsp;&nbsp;In our opinion, BioNTech SE and subsidiaries (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on the COSO criteria.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67406950"></a>As indicated in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting, management&#8217;s assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of BioNTech US Inc. and BioNTech Manufacturing Marburg GmbH, which are included in the 2020 consolidated financial statements of the Company and constituted 10% and 6% of total assets and net assets, respectively, as of December 31, 2020 and 0% of revenues and constituted &#8364;35.7 million of net loss included within the &#8364;15.2 million total profit for the year then ended.&#160;Our audit of internal control over financial reporting of the Company also did not include an evaluation of the internal control over financial reporting of BioNTech US Inc. and BioNTech Manufacturing Marburg GmbH.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the <font style="color:#000000;">consolidated statements of financial position of the Company as of December 31, 2020 and 2019, the related consolidated statements of operations, comprehensive income,&#160;changes in equity and cash flows for each of the three years in the period ended December 31, 2020, and the related notes&#160;</font>and our report dated March 30, 2021 expressed an unqualified opinion thereon.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Definition and Limitations of Internal Control Over Financial Reporting</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Ernst &amp; Young GmbH Wirtschaftspr&#252;fungsgesellschaft</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cologne, Germany</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 30, 2021</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_FINANCIAL_POSITI"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_FINANCIAL_POSITI"></a>Consolidated Statement</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">s of Financial Position</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;163,490</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;89,434</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">226,968</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,044</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,988</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,018</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,045</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161,233</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total non-current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;651,724</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;237,496</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,120</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,722</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade receivables</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165,468</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,913</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other financial assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137,234</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,680</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,966</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,069</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">898</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">756</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,001</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,862</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,210,209</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">519,149</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,666,896</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;560,151</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,318,620</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;797,647</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity and liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">246,310</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,304</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital reserve</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,514,451</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">686,714</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Treasury shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,789)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,525)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated losses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(409,629)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(424,827)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other reserves</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,503</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,826</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,371,846</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;493,492</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest-bearing loans and borrowings</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">231,047</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,904</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other financial liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,476</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,498</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,892</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,109</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">566</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">281</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total non-current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;340,760</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;166,013</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest-bearing loans and borrowings</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,142</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,307</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade payables</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,288</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,498</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other financial liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,075</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,352</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government grants</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.5</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,951</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax provisions</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other provisions</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">903</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">762</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">299,583</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,583</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,061</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,490</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;606,014</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;138,142</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;946,774</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;304,155</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total equity and liabilities</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,318,620</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;797,647</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The </font>accompanying<font style="Background-color:#FFFFFF;"> notes form an integral part of these consolidated financial statements.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_OPERATIONS"></a><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_OPERATIONS"></a>Consolidated Stateme</font><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">nts of Operations</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:8.5pt;">
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands, except per share data)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research &amp; development revenues</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;178,849</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;84,428</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;101,837</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial revenues</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">303,476</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,161</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,738</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">482,325</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">108,589</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">127,575</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of sales</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.1</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59,333)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,361)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,690)</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.2</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(645,029)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(226,466)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(143,040)</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,512)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,718)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,041)</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.4</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(94,049)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,547)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,334)</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,358)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(739)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(720)</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other operating income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.5</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250,539</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,724</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,396</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(82,417)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(181,518)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(53,854)</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance income*</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.6</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,564</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,122</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,046</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance expenses*</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.7</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(62,946)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(326)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(48)</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expenses related to lease liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,003)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,718)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,721)</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share of loss of equity method investees</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(84)</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss before tax</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(145,802)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(179,440)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(47,662)</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161,000</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">268</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(600)</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Profit / (Loss) for the period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15,198</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(179,172)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(48,262)</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attributable to:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity holders of the parent</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,198</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(179,056)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(48,019)</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-controlling interests</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(116)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(243)</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Profit / (Loss) for the period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15,198</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(179,172)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(48,262)</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Earnings per share</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:8.5pt;">
<td colspan="3" valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted, profit / (loss) for the period attributable to ordinary equity holders of the parent**</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;0.06</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(0.85)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(0.25)</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* Foreign exchange differences on a cumulative basis are shown either as finance income or expenses and might switch between those two positions during the year-to-date reporting periods.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">** Numbers of shares for calculating the earnings per share for the years ended December 31, 2019 and December 31, 2018 have been adjusted to reflect capital increase due to 1:18 share split, which occurred on September 18, 2019.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ac<font style="Background-color:#FFFFFF;">companying notes form an integral part of these consolidated financial statements.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Statements of Comprehensive Income / (Loss)</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Profit / (Loss) for the period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15,198</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(179,172)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(48,262)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income / (loss)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other comprehensive income / (loss) that may be reclassified to profit or loss in subsequent periods, net of tax</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exchange differences on translation of foreign operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,096)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net other comprehensive income / (loss) that may be reclassified to profit or loss in subsequent periods</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(11,096)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other comprehensive loss that will not be reclassified to profit or loss in subsequent periods, net of tax</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remeasurement loss on defined benefit plans</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(273)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net other comprehensive loss that will not be reclassified to profit or loss in subsequent periods</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(273)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income / (loss) for the period, net of tax</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(11,369)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive income / (loss) for the period, net of tax</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;3,829</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(179,095)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(48,252)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attributable to:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity holders of the parent</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,829</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(178,979)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(48,009)</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-controlling interests</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(116)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(243)</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive income / (loss) for the period, net of tax</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;3,829</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(179,095)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(48,252)</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes form an integral part of these consolidated financial statements.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQU"></a><a name="CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQU"></a>Consolidated Statements of Changes in Stockholders&#8217; Equity</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity attributable to equity holders of the parent</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share capital</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital reserve</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Treasury shares</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated losses</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other reserves</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">currency</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">translation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">reserve</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-controlling interest</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total equity</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2018</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;166,764</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;8,922</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(197,753)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(27,206)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(23)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(49,296)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,090</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(48,206)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss for the period</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(48,019)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(48,019)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(243)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(48,262)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total comprehensive income</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(48,019)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(48,009)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(243)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(48,252)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of share capital</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,949</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">329,867</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">355,816</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">355,816</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share based payments</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,641</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7,641</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7,641</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Settlement of share-based payment plan</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">583</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,326</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,909)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2018</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;193,296</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;344,115</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(245,771)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(25,474)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(13)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;266,153</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;847</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;267,000</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss for the period</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(179,056)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(179,056)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(116)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(179,172)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total comprehensive income</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(179,056)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(178,979)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(116)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(179,095)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of share capital</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,126</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,748</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">49,874</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">49,874</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital increase Series B</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,990</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,390</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,525)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">198,855</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">198,855</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital increase initial public offering (referred to as IPO)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,517</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,743</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">143,260</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">143,260</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of non-controlling interest</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,375</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,644)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">731</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(731)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transaction costs</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,638)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(16,638)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(16,638)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share based payments</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,236</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">30,236</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">30,236</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;232,304</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;686,714</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364; (5,525)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(424,827)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;4,762</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;64</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;493,492</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;493,492</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Profit for the period</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,198</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15,198</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15,198</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive loss</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(273)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,096)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(11,369)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(11,369)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total comprehensive income</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15,198</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(273)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(11,096)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3,829</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3,829</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of share capital</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,006</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">860,960</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">736</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">875,702</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">875,702</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transaction costs</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,223)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(33,223)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(33,223)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based payments</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,046</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">32,046</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">32,046</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;246,310</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,514,451</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(4,789)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(409,629)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;36,535</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(11,032)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,371,846</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,371,846</p></td>
</tr>
<tr>
<td colspan="9" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.12%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* Numbers as of January 1, 2019 have been adjusted to reflect capital increase due to 1:18 share split which occurred on September 18, 2019.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The accompanying notes form an integral </font>part<font style="Background-color:#FFFFFF;"> of these consolidated </font>financial<font style="Background-color:#FFFFFF;"> statements.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a>Consolidated Statements of Cash Flows</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.62%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Profit / (Loss) for the period</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15,198</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(179,172)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(48,262)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(161,000)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(268)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">600</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before tax</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(145,802)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(179,440)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(47,662)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile loss before tax to net cash flows:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization of property, plant, equipment and intangible assets</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,744</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,896</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,984</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based payment expense</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,142</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,236</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,641</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net foreign exchange differences</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,275</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">459</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Gain) / Loss on disposal of property, plant and equipment</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">595</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">542</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance income</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,564)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,782)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,996)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on lease liability</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,003</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,717</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,721</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance expense</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,336</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">326</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Movements in government grants</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,951</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- </p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share of loss of an associate and a joint venture</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-cash income</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,749</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Working capital adjustments:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decrease / (Increase) in trade receivable and contract assets</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(247,886)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,939</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,732)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decrease / (Increase) in inventories</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,794)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,798)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,253)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Decrease) / Increase in trade payables, other liabilities, contract liabilities and provisions</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204,583</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(80,577)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,080)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest received</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,444</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,256</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,996</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest paid</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,628)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,044)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,769)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax received (paid), net</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">378</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(304)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net cash flows used in operating activities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(13,474)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(198,537)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(58,877)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of property, plant and equipment</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,033)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,592)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,901)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from sale of property, plant and equipment</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,241</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">705</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of intangibles assets and right-of-use assets</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,413)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,488)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,256)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses, net of cash acquired</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(60,643)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,056)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net cash flows used in investing activities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(144,848)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(77,115)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(66,452)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of share capital, net of costs</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">753,007</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">375,351</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">361,725</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from loans and borrowings</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">156,027</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,000</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,600</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repayment of loans and borrowings</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,566)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- </p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments related to lease liabilities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,743)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,061)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,148)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net cash flows from financing activities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;894,725</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;383,290</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;365,177</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase in cash and cash equivalents</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">736,403</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,638</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">239,848</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in cash and cash equivalents resulting from exchange rate differences</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,343)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(459)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at January 1</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">519,149</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">411,495</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172,106</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at December 31</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,210,209</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;519,149</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;411,495</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanyin<font style="Background-color:#FFFFFF;">g notes form an integral part of these consolidated financial statements.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a>Notes to the <a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a>Consolidated Financial Statements</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Corporate Information</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech SE is a limited company incorporated and domiciled in Germany. American Depositary Shares (ADS) representing BioNTech SE&#8217;s ordinary shares have been publicly traded on Nasdaq Global Select Market since October 10, 2019. The registered office is located in Mainz, Germany (An der Goldgrube 12, 55131 Mainz). The accompanying International Financial Reporting Standards (IFRS) consolidated financial statements present the financial position and the results of operation of BioNTech SE and its subsidiaries, hereinafter also referred to as &#8220;BioNTech&#8221; or the &#8220;Group&#8221;.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020 the following changes to the Group structure occurred:</p>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">On February 16, 2020, BioNTech Protein Therapeutics GmbH was renamed to BioNTech Delivery Technologies GmbH and the company&#8217;s registered office was changed from Mainz to Halle. </p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">On May 6, 2020, BioNTech SE acquired Neon Therapeutics, Inc., Cambridge, Massachusetts, United States (formerly Nasdaq: NTGN), or Neon. Under the merger agreement by and among BioNTech, Neon and BioNTech&#8217;s wholly-owned subsidiary, Endor Lights, Inc., New York, United States, Endor Lights, Inc. merged with and into Neon. The new subsidiary operates under the name BioNTech US Inc., is held indirectly via BioNTech USA Holding, LLC. as a wholly-owned subsidiary and serves as BioNTech&#8217;s headquarters in the United States.</p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">On July 17, 2020, BioNTech IVAC GmbH was renamed to BioNTech Manufacturing GmbH and on August 7, 2020, BioNTech Small Molecules GmbH was renamed to BioNTech Europe GmbH. </p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">On September 17, 2020, the liquidation process for BioNTech Austria Beteiligungen GmbH was initiated by a resolution of the shareholders. </p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">On October 15, 2020, BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. was founded and is a wholly-owned subsidiary of BioNTech SE. </font></p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Three new real estate entities have been founded in Germany: BioNTech Real Estate An der Goldgrube GmbH &amp; Co. KG, BioNTech Real Estate Adam-Opel-Stra&#223;e GmbH &amp; Co. KG and BioNTech Real Estate Haus Vier GmbH &amp; Co. KG, all Holzkirchen. All are partnerships wholly-owned by its limited partner BioNTech Real Estate Holding GmbH, a wholly-owned subsidiary of BioNTech SE. </p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">On October 31, 2020, BioNTech SE acquired Novartis Manufacturing GmbH, Marburg, Germany. The new production site operates under the name BioNTech Manufacturing Marburg GmbH, a wholly-owned subsidiary of BioNTech SE.</p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">On November 11, 2020, BioNTech UK Limited was founded and is a wholly-owned subsidiary of BioNTech SE.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">On December 15, 2020, reBOOST Management GmbH was renamed to reSano GmbH.</font> </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All entities listed above are included in the Group&#8217;s consolidated financial statements.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information on the Group&#8217;s structure is provided in Note 4. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements of the Group for the year ended December&#160;31, 2020 were authorized for issue in accordance with a resolution of the Supervisory Board on March 30, 2021.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Significant Accounting Policies</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.1</font></p></td>
<td valign="top">
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Basis of Preparation</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">General</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements have been prepared on a going concern basis in accordance with the IFRS as issued by the International Accounting Standards Board (IASB). </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech prepares and publishes its consolidated financial statements in Euros</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and rounds </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">numbers to </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">thousands</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or millions </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of Euros</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, respectively</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Accordingly, numerical figures shown as totals in some tables may not be exact arithmetic aggregations of the figures that preceded them</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and figures presented in the explanatory notes may not add up to the rounded </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arithmetic aggregations</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Segment Information</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Historically <font style="color:#000000;">BioNTech </font>reported four segments: Clinical, Technology Platform, Manufacturing and Product Sales &amp; External Services. In the course of the year ended December&#160;31, 2020, <font style="color:#000000;">BioNTech </font>leveraged the breadth of its immunotherapy technologies and used its expertise to mobilize these rapidly to address the COVID-19 pandemic. In December 2020, BioNTech&#8217;s COVID-19 vaccine was authorized or approved for emergency or temporary use or granted conditional marketing authorization in over 65 countries worldwide. Beginning in the fourth quarter, given the financial and operational significance of the activities to develop and then market, produce and transport the COVID-19 vaccine, BioNTech&#8217;s Management Board, as the chief operating decision maker (CODM), reviewed financial information presented on a consolidated basis. Decisions with respect to business operations and resource allocations are made by the CODM based on BioNTech as a whole. Accordingly, BioNTech operates and makes decisions as a single operating segment, which is also its reporting segment. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.2</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Basis of Consolidation</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements comprise the financial statements of BioNTech SE and its controlled investees (subsidiaries). </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group controls an investee if, and only if, the Group has</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.14%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">power over the investee (</font><font style="font-style:italic;font-family:Times New Roman;">i.e.</font><font style="font-family:Times New Roman;">, existing rights that give it the current ability to direct the relevant activities of the investee); </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">exposure, or rights, to variable returns from its involvement with the investee; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the ability to use its power over the investee to affect its returns. </font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally, there is a presumption that a majority of voting rights results in control. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group re-assesses whether it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The profit / (loss) and each component of other comprehensive income / (loss) for the period are attributed to the equity holders of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. When necessary, adjustments are made to the <font style="color:#000000;">consolidated </font>financial statements of subsidiaries to bring their accounting policies in line with the Group&#8217;s accounting policies. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated on consolidation.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Group loses control over a subsidiary, it derecognizes the related assets (including goodwill), liabilities, non-controlling interests and other components of equity, while any resultant gain or loss is recognized in the <font style="color:#000000;">consolidated </font>statements of operations. Any investment retained is recognized at fair value.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Summary of Significant Accounting Policies</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Business combinations and Goodwill</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Business combinations are accounted for using the acquisition method. The cost of an acquisition is measured as the aggregate of the consideration transferred, which is measured at acquisition date fair value, and the amount of any non-controlling interests in the acquiree.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill is initially measured at cost as the excess of the aggregate of the consideration transferred and the amount recognized for non-controlling interests and any previous interest held over the net identifiable assets acquired and liabilities assumed.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After initial recognition, goodwill is tested at least annually or when there is an indication for impairment. See Note&#160;2.3.13. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Group&#8217;s cash-generating units that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those units. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Where goodwill has been allocated to a cash-generating unit (CGU) and part of the operation within that unit is disposed of, the goodwill associated with the disposed operation is included in the carrying amount of the operation when determining the gain or loss on disposal. Goodwill disposed in these circumstances is measured based on the relative values of the disposed operation and the portion of the cash-generating unit retained.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Current versus Non-Current Classifications</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group presents assets and liabilities in the consolidated statements of financial position based on current or non-current classification. An asset is current when it is either: (i)&#160;expected to be realized within 12&#160;months after the reporting period or (ii)&#160;cash or cash equivalents, unless it is restricted from being exchanged or used to settle a liability for at least 12&#160;months after the reporting period. All other assets are classified as non-current. A liability is current when it is due to be settled within 12&#160;months after the reporting period. The Group classifies all other liabilities as non-current. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets and liabilities are classified as non-current assets and liabilities, respectively.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Fair Value Measurement</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is a market-based measurement. For some assets and liabilities, observable market transactions or market information is available. For other assets and liabilities, observable market transactions or market information might not be available. When a price for an identical asset or liability is not observable, another valuation technique is used. To increase consistency and comparability in fair value measurements, there are three levels of the fair value hierarchy:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.14%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Level 1 contains the use of quoted prices in active markets for identical assets or liabilities.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.14%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.14%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Level&#160;3 inputs are unobservable. </font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within this hierarchy, estimated values are made by management based on reasonable assumptions, including other fair value methods.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For assets and liabilities that are recognized in the financial statements at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the fair value hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the purpose of fair value disclosures, the Group has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy, as explained above.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.93%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.4</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Revenue from Contracts with Customers</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech generates revenues from collaboration and license agreements under which BioNTech grants licenses to use, research, develop, manufacture and commercialize product candidates and products. BioNTech determined that those collaboration and license agreements qualify as contracts with its customers. If the grant of a license is bundled together with the rendering of services, it is assessed whether these agreements are comprised of more than one performance obligation. A performance obligation is only accounted for as the grant of a license if the grant of a license is the sole or the predominant promise of the performance obligation. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the consideration in an agreement includes a variable amount, BioNTech estimates the amount of consideration to which BioNTech will be entitled in exchange for transferring the goods to the customer. At contract inception, the variable </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consideration is estimated based on the most likely amount of consideration expected from the transaction and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with respect the variable consideration is subsequently resolved. The estimated revenue is updated at each reporting date to reflect the current facts and circumstances.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a contract with a customer contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative-stand-alone selling prices.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each separate performance obligation, it is evaluated whether control is transferred either at a point in time or over time. For performance obligations that are satisfied over time, revenue is recognized based on a measure of progress, which depicts the performance in transferring control to the customer. Under the terms of its licensing arrangements, BioNTech provides the licensee with a research and development license, which represents a right to access BioNTech&#8217;s intellectual property as it exists throughout the license period (as BioNTech&#8217;s intellectual property is still subject to further research). Therefore, the promise to grant a license is accounted for as a performance obligation satisfied over time, as the licensee simultaneously receives and consumes the benefits of BioNTech&#8217;s performance.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Earnings based on the collaboration partners&#8217; gross profit, which is shared under the respective collaboration agreements are recognized based on the sales-based or usage-based royalty <font style="color:#000000;">exemption; </font><font style="font-style:italic;color:#000000;">i.e. </font>when, or as, the underlying sales occur, which is when the performance obligation has been satisfied. As described further in Note 3, BioNTech uses certain information from its collaboration partners, some of which is based on preliminary data shared between the partners and might vary once final data is available. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue arrangements that involve two or more partners who contribute to the provision of a specific good or service to a customer are assessed in terms of principal-agent considerations in order to determine the appropriate treatment for the transactions between BioNTech and the collaborator and the transactions between BioNTech and other third parties. The classification of transactions under such arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which BioNTech is considered the principal, which includes being in control of the good or service before such good or service is transferred to the customer, are accounted for as gross revenue. Any consideration related to activities in which BioNTech is considered the agent, are accounted for as net revenue.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue from the sale of pharmaceutical and medical products (<font style="font-style:italic;">e.g</font>. COVID-19 vaccine sales and other sales of peptides and retroviral vectors for clinical supply) is recognized when BioNTech transfers control of the product to the customer. Control of the product normally transfers when the customer gains physical possession and BioNTech has not retained any significant risks of ownership or future obligations with respect to the product. A receivable is recognized, as the consideration is unconditional and only the passage of time is required before payment is due. The transaction price is quoted in the relevant price lists in force at the date of customer placing the respective order for such products. Payments from customers are due within 20 days (Europe) or 30 days (non-Europe) after invoice.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contract Balances</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contract Assets</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A contract asset is the right to consideration in exchange for goods or services transferred to the customer. If BioNTech performs by transferring goods or services to a customer before the customer pays consideration or before payment is due, a contract asset is recognized for the earned consideration that is conditional.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Trade Receivables</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A receivable represents BioNTech&#8217;s right to an amount of consideration that is unconditional (<font style="font-style:italic;">i.e</font>., only the passage of time is required before payment of the consideration is due).</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contract Liabilities</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A contract liability is the obligation to transfer goods or services to a customer for which BioNTech has received consideration (or an amount of consideration is due) from the customer. If a customer pays consideration before BioNTech transfers goods or services to the customer, a contract liability is recognized when the payment is made or when the payment is due (whichever is earlier). Contract liabilities are recognized as revenue when BioNTech performs under the contract.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.5</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:normal;"></font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Government </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">G</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">rants</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government grants are recognized where there is reasonable assurance that the grant will be received and all attached conditions will be complied with. When the grant relates to an expense item, it is recognized as other income on a systematic basis over the periods that the related costs, for which the grant is intended to compensate, are expensed. When the grant relates to an asset, it is recognized as deferred income within the consolidated statements of financial position. Other income is subsequently recognized in profit or loss over the useful live of the underlying asset subject to funding. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.6</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Taxes</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Current Income Tax</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the reporting date in the countries where the Group operates and generates taxable income. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, current income taxes presented for the period include adjustments for uncertain tax payments or tax refunds for periods not yet finally assessed, excluding interest expenses and penalties on the underpayment of taxes. Due to the increasing complexity of tax laws and the corresponding uncertainty regarding the legal interpretation by the fiscal authorities, tax calculations are generally subject to an elevated amount of uncertainty. In the event that amounts included in the tax return are considered unlikely to be accepted by the tax authorities (uncertain tax positions), a provision for income taxes is recognized. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred Tax</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities are recognized for all taxable temporary differences, except: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">when the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">in respect of taxable temporary differences associated with investments in subsidiaries, associates and interests in joint arrangements, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future. </font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets are recognized for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, the carry forward of unused tax credits and unused tax losses can be utilized, except:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">when the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">in respect of deductible temporary differences associated with investments in subsidiaries, associates and interests in joint arrangements, deferred tax assets are recognized only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized. </font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year in which the asset is realized, or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recognition of Taxes</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current and deferred tax items are recognized similar to the underlying transaction either in profit or loss, other comprehensive income or directly in equity.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group offsets current tax assets and current tax liabilities if, and only if, it has a legally enforceable right to set off the recognized amounts and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously. Deferred tax assets and deferred tax liabilities are only offset when the Group has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same taxation authority on either (i) the same taxable entity or (ii) different taxable entities, which intend either to settle current tax liabilities and assets on a net basis, or to realize the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sales Tax</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expenses and assets are recognized net of sales tax, except when the sales tax incurred on a purchase of assets or services is not recoverable from the taxation authority.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The net amount of sales tax recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the <font style="color:#000000;">consolidated</font> statements of financial position.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.7</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Foreign Currencies</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group&#8217;s consolidated financial statements are presented in Euros, which is also BioNTech SE&#8217;s functional currency. For each entity, the Group determines the functional currency, and items included in the <font style="color:#000000;">consolidated </font>financial statements of such entity are measured using that functional currency. The Group uses the direct method of consolidation and on disposal of a foreign operation, the gain or loss that is reclassified to the <font style="color:#000000;">consolidated </font>statements of operations reflects the amount that arises from using this method.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Transactions and Balances</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transactions in foreign currencies are initially recorded by the Group&#8217;s entities at their respective functional currency spot rates at the date the transaction first qualifies for recognition.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In determining the spot exchange rate to use on initial recognition of the related asset, expense or income (or part of it) on the derecognition of a non-monetary asset or non-monetary liability relating to advance consideration, the date of the transaction is the date on which the Group initially recognizes the non-monetary asset or non-monetary liability arising from the advance consideration. If there are multiple payments or receipts in advance, the Group determines the transaction date for each payment or receipt of advance consideration.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Foreign Currency Translation</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On consolidation, the assets and liabilities of foreign operations are translated into Euros at the rate of exchange prevailing at the reporting date and their <font style="color:#000000;">consolidated</font> statements of operations are translated at exchange rates prevailing at the dates of the transactions.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The exchange differences arising on translation for consolidation are recognized in other comprehensive income. On disposal of a foreign operation, the component of other comprehensive income relating to that particular foreign operation is reclassified to profit or loss.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any goodwill arising on the acquisition of a foreign operation and any fair value adjustments to the carrying amounts of assets and liabilities arising upon the acquisition are treated as assets and liabilities of the foreign operation and translated at the spot rate of exchange at the reporting date.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.8</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:normal;"></font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Property, </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">P</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">lant and </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">E</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">quipment</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress is stated at cost, net of accumulated impairment losses, if any. Property, plant and equipment are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Such cost includes the cost of replacing part of the property, plant and equipment if the recognition criteria are met. All other repair and maintenance costs are expensed as incurred.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Useful life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7-33</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equipment, tools and installations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-15</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An item of property, plant and equipment initially recognized is derecognized upon disposal (<font style="font-style:italic;">i.e</font>., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the <font style="color:#000000;">consolidated </font>statements of operations when the asset is derecognized.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year-end and adjusted prospectively, if appropriate.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.9</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Leases</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of a contract, the Group assesses whether the contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, the Group assesses whether: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the contract involves the use of an identified asset&#8212;this may be specified explicitly or implicitly and should be physically distinct or represent substantially all of the capacity of a physically distinct asset. If the supplier has a substantive substitution right, then the asset is not identified; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the Group has the right to obtain substantially all of the economic benefits from use of the asset throughout the period of use; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the Group has the right to direct the use of the asset. The Group has this right when it has the decision-making rights that are most relevant to changing how and for what purpose the asset is used. In rare cases where the decision about how and for what purpose the asset is used is predetermined, the Group has the right to direct the use of the asset if either:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the Group has the right to operate the asset; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the Group designed the asset in a way that predetermines how and for what purpose it will be used. </font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At inception or on reassessment of a contract that contains a lease component, the Group allocates the consideration in the contract to each lease component on the basis of their relative stand-alone prices. However, for the leases of land and buildings in which it is a lessee, the Group has elected not to separate non-lease components, and instead accounts for the lease and non-lease components as a single lease component.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group recognizes a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of the costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received by the Group.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset and the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of property and equipment. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">incremental borrowing </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">interest rate implicit in the lease or, if that rate cannot be readily determined, the Group&#8217;s incremental borrowing rate. Generally, the Group uses its incremental borrowing rate as the discount rate.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease payments included in the measurement of the lease liability comprise the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">fixed payments, including in-substance fixed payments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">variable lease payments that depend on an index or a rate, initially measured using the index or rate as of the commencement date; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">amounts expected to be payable under a residual value guarantee; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the exercise price under a purchase option that the Group is reasonably certain to exercise, lease payments in an optional renewal period if the Group is reasonably certain to exercise an extension option, and penalties for early termination of a lease unless the Group is reasonably certain not to terminate early.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The lease liability is subsequently measured at amortized cost using the effective interest method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the Group&#8217;s estimate of the amount expected to be payable under a residual value guarantee, or if the Group changes its assessment of whether it will exercise a purchase, extension or termination option. When the lease liability is remeasured, a corresponding adjustment is made to the carrying amount of the right-of-use asset or is recorded in the <font style="color:#000000;">consolidated </font>statements of operations if the carrying amount of the right-of-use asset has been reduced to zero.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group presents right-of-use assets separately and lease liabilities in &#8216;financial liabilities&#8217; in the <font style="color:#000000;">consolidated </font>statements of financial position.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets or shorter lease term, as follows:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Useful life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2-25</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equipment, tools and installations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2-5</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Production facilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2-3</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Automobiles</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-4</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Short-Term Leases and Leases of Low-Value Assets</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group has elected not to recognize right-of-use assets and lease liabilities for short-term leases of machinery that have a lease term of 12 months or less or leases of low-value assets. The Group recognizes the lease payments associated with these leases as an expense in the <font style="color:#000000;">consolidated </font>statements of operations on a straight-line basis over the lease term.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.10</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Intangible Assets</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The useful lives of intangible assets are assessed as either finite or indefinite. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets with finite lives are amortized generally on a straight-line basis over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are at least reviewed at the end of each reporting period. The amortization expense on intangible assets with finite lives is recognized in the <font style="color:#000000;">consolidated </font>statements of operations in the expense category that is consistent with the function of the intangible assets.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the useful lives applied to the Group&#8217;s intangible assets is as follows:</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Useful life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intellectual property rights</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-20</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Licenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-20</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-8</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets with indefinite useful lives are not amortized, but are tested for impairment at least annually, or when there is an indication for impairment, either individually or at the level of a cash-generating unit (see Note 2.3.13 for further details). The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group has classified advanced payments on intangible assets as intangible assets, which are not yet ready for use. Advanced payments on intangible assets are tested for impairment on an annual basis.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An intangible asset is derecognized upon disposal (<font style="font-style:italic;">i.e</font>., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising upon derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the <font style="color:#000000;">consolidated </font>statements of operations.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Costs</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research costs are expensed as incurred. Development expenditures on an individual project are recognized as an intangible asset if, and only if, all of the following six criteria can be demonstrated by the Group:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the technical feasibility of completing the intangible asset so that the asset will be available for use or sale;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">its intention to complete the project;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the ability and intention to use or sell the asset;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">how the asset will generate future economic benefits;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the availability of resources to complete the asset; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the ability to reliably measure the expenditure during development.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to the inherent risk of failure in pharmaceutical development and the uncertainty of approval, management has determined that these criteria are not met in the biotech sector until regulatory approval has been obtained. The related expenditure is reflected in the consolidated statements of operations in the period in which the expenditure is incurred. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following initial recognition of the development expenditure as an asset, the asset is carried at cost less any accumulated amortization and accumulated impairment losses. Amortization of the asset begins when development is complete and the asset is available for use. It is amortized over the period of expected future benefit. Amortization is recorded in cost of sales. During the period of development, the asset is tested for impairment annually.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.11</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Financial Instruments &#8211; Initial Recognition and Subsequent Measurement</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">i) Financial Assets</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Initial recognition and Measurement</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets are initially measured at fair value. The Group&#8217;s financial assets mainly include trade receivables as well as other receivables that reflect BioNTech&#8217;s entitlement to cash. With respect to trade receivable, the Group has applied the practical expedient which means that they are measured at the transaction price determined under IFRS 15. Refer to the accounting policies in Note 2.3.4. Other financial assets are measured at amortized costs since they are held by the Group to collect contractual cash flows, which are solely payments of principal and interest. Gains and losses are recognized in profit or loss when the financial asset is derecognized, modified or impaired. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Derecognition</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e., removed from the Group&#8217;s consolidated statements of financial position) when the rights to receive cash flows from the asset have expired or have been transferred in terms of fulfilling the derecognition criteria. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Impairment of Financial Assets</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An allowance for expected credit losses (ECLs) is considered for all debt instruments of the Group. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all of the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For trade receivables and contract assets, the Group applies a simplified approach in calculating ECLs. Therefore, the Group does not track changes in credit risk, but instead recognizes a loss allowance based on lifetime ECLs at each reporting date. The Group has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment. In this analysis BioNTech also considered that governments and health ministries which are BioNTech&#8217;s customers established in connection with progressing the commercial activities of the Group with respect to BioNTech&#8217;s COVID-19 vaccine. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ii) Financial Liabilities</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Initial Recognition and Measurement</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings or as payables.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group&#8217;s financial liabilities include trade payables and other financial liabilities.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Subsequent Measurement</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The measurement of financial liabilities depends on their classification, as described below.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Financial Liabilities at Fair Value through Profit or Loss</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial liabilities at fair value through profit of the Group include the embedded derivative, which was bifurcated from the convertible note, as host contract, and is recognized as a separate financial instrument until it is extinguished upon conversion. Financial liabilities at fair value further include contingent considerations resulting from the Group&#8217;s business combinations. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gains or losses arising from fair value measurement adjustments of the embedded derivative and the contingent consideration are recognized in profit and loss within the consolidated statements of operations.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Loans, Borrowings, Trade Payables and Other Financial Liabilities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After initial recognition, interest-bearing loans and borrowings, trade payables and other financial liabilities are subsequently measured at amortized cost using the EIR method. Gains and losses are recognized in the <font style="color:#000000;">consolidated </font>statements of operations when the liabilities are derecognized as well as through the EIR amortization process.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortization is included as finance costs in the <font style="color:#000000;">consolidated </font>statements of operations.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This category generally applies to interest-bearing loans and borrowings.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Derecognition</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the <font style="color:#000000;">consolidated </font>statements of operations.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.12</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Inventories</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories are valued at the lower of cost and net realizable value.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs incurred in bringing each product to its present location and condition are accounted for as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">raw materials and supplies: purchase cost on a first-in/first-out basis; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">unfinished goods and finished goods: cost of direct materials and labor, including both internal manufacturing and third-party contract manufacturing organizations, or CMOs, and a proportion of manufacturing overheads based on the normal operating capacity, but excluding borrowing costs.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.13</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Impairment of Non-Financial Assets</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group assesses, at each reporting date, whether there is an indication that an asset may be impaired. Goodwill is tested for impairment annually as of October 1. Impairment is determined for goodwill by assessing the recoverable amount of each cash generating unit (or group of CGUs) to which the goodwill relates. If any indication exists, or when annual impairment testing is performed, the Group estimates the asset&#8217;s or CGU&#8217;s recoverable amount. The recoverable amount is the higher of an asset&#8217;s or CGU&#8217;s fair value less costs of disposal and its value in use. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. When the carrying amount of an asset or cash generating unit exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used. These calculations are corroborated by valuation multiples, quoted share prices for publicly traded companies or other available fair value indicators.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group bases its impairment calculation on detailed budgets and forecast calculations, which are prepared separately for each of the Group&#8217;s cash generating units to which the individual assets are allocated. These budgets and forecast calculations generally cover a period of five years. A long-term growth rate is calculated and applied to project future cash flows after the fifth year.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment losses of continuing operations are recognized in the <font style="color:#000000;">consolidated </font>statements of operations in expense categories consistent with the function of the impaired asset.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For assets excluding goodwill, an assessment is made at each reporting date to determine whether there is an indication that previously recognized impairment losses no longer exist or have decreased. If such indication exists, the Group estimates the asset&#8217;s or cash generating unit&#8217;s recoverable amount. A previously recognized impairment loss is reversed only if there has been a change in the assumptions used to determine the asset&#8217;s recoverable amount since the last impairment loss was recognized. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognized for the asset in prior years. Such reversal is recognized in the <font style="color:#000000;">consolidated </font>statements of operations unless the asset is carried at a revalued amount, in which case, the reversal is treated as a revaluation increase.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.14</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Cash and Cash Equivalents</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents comprise cash in banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.15</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:normal;"></font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pension</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The liability in respect of defined benefit pension plans is the defined benefit obligation calculated annually by independent actuaries using the projected unit credit method. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions of the respective employees, while the net interest on the net defined benefit liability or asset is recognized in finance expenses or finance income.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Provisions</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Group expects some or all of a provision to be reimbursed, for example, under an insurance contract, the reimbursement is recognized as a separate asset, but only when the reimbursement is virtually certain. The expense relating to a provision is presented in the <font style="color:#000000;">consolidated </font>statements of operations net of any reimbursement.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Share-Based Payments</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employees (and others providing similar services) receive remuneration in the form of share-based payments, which are settled in equity instruments (equity-settled transactions).</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cost of equity-settled transactions is determined by the fair value at the date when the grant is made using an appropriate valuation model, further details of which are given in Note 17. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These costs are recognized in cost of sales, research and development expenses, sales and marketing expenses or general and administrative expenses, together with a corresponding increase in equity (other reserves), over the period in which the service is provided (the vesting period). The cumulative expense recognized for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Group&#8217;s best estimate of the number of equity instruments that will ultimately vest.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.4</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Standards applied for the First Time</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020 several new and amended standards and interpretations became effective but did not have an impact on the consolidated financial statements of the Group. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Standards/Interpretations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Date of application</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to IFRS 3 Business Combinations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2020</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to IFRS 9, IAS 39 and IFRS 7 Interest Rate Benchmark Reform</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2020</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to IAS 1 and IAS 8 Definition of Material</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2020</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to References to the Conceptual Framework in IFRS Standards</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2020</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment to IFRS 16 Leases COVID-19-Related Rent Concessions</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 1, 2020</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.5</font></p></td>
<td valign="top">
<p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Standard issued but not yet effective</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The new and amended standards and interpretations that are issued, but not yet effective, up to the date of issuance of the Group&#8217;s financial statements and that might have an impact on the Group&#8217;s financial statements are disclosed below. The Group has not early adopted any standards and intends to adopt these new and amended standards and interpretations, if applicable, when they become effective. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Standards/Interpretations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Date of application</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to IFRS 4 Insurance Contracts &#8211; deferral of IFRS 9</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2021</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 Interest Rate Benchmark Reform &#8211; Phase 2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2021</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to IFRS 3 Business Combinations: Reference to the Conceptual Framework</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2022</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to IAS 16 Property, Plant and Equipment: Proceeds before Intended Use</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2022</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to IAS 37 Provisions, Contingent Liabilities and Contingent Assets - Onerous Contracts &#8211; Cost of Fulfilling a Contract Amendments to IAS 37</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2022</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual Improvements to IFRS Standards 2018-2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2022</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to IAS 1 Presentation of Financial Statements: Classification of Liabilities as Current or Non-current - Deferral of Effective Date</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2023</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IFRS 17 Insurance Contracts (issued on 18 May 2017); including Amendments to IFRS 17</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2023</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group does not expect a significant impact of the application of any of these amendments. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Significant Accounting Judgments, Estimates and Assumptions</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Group&#8217;s consolidated financial statements requires management to make <font style="color:#000000;">judgments</font>, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, the accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Judgments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the process of applying the Group&#8217;s accounting policies, management has made the following judgments, which have the most significant effect on the amounts recognized in the consolidated financial statements:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue from Contracts with Customers</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech applied the following <font style="color:#000000;">judgments </font>that significantly affect the determination of the amount and timing of revenue from contracts with customers:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Identification and Determination of Performance Obligations</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech generates revenues from collaboration and license agreements, which c<font style="color:#000000;">ontain multiple elements, including licenses to use, research, develop, manufacture and commercialize candidates and products, research and development services as well as obligations to develop and manufacture preclinical and clinical material and products. </font>BioNTech determined that those collaboration and license agreements qualify as contracts with its customers. <font style="color:#000000;">At inception of each agreement, BioNTech applies judgment when determining which promises represent distinct performance obligations. </font>If promises are not distinct, they are combined until the bundle of promised goods and services is distinct. For some agreements, this results in BioNTech accounting for goods and services promised in a collaboration and license agreement as a single performance obligation with a single measure of progress. For these combined performance obligations, BioNTech assesses which of these promises is the predominant promise to determine the nature of the performance obligation. <font style="color:#000000;">When licenses are granted, BioNTech determined that the grant of the license is the predominant promise within the combined performance obligations. </font>It is assessed that BioNTech grants their customers a right to access or a right to use BioNTech&#8217;s intellectual property due to the collaboration and license agreements. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Measurement of the Transaction Price</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech&#8217;s collaboration and license agreements often include variable considerations, which are contingent on the occurrence or non-occurrence of a future event <font style="font-style:italic;">(i.e.</font>, reaching a certain milestone). When determining deferred revenues of a collaboration and license agreement, BioNTech is required to estimate the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to the customer. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As there are usually only two possible outcomes (<font style="font-style:italic;">i.e.,</font> milestone is reached or not), BioNTech has assessed that the method of the most likely amount is the best method to predict the amount of consideration to which BioNTech will be entitled. At contract inception, the most likely amount for milestone payments is estimated to be zero. BioNTech has assessed that the likelihood of achieving the respective milestone decreases depending on how far the expected date of achieving the milestone lies in the future. At each reporting date, BioNTech uses judgment to determine when to include variable consideration in the transaction price such that it is highly probable that a significant revenue reversal in the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">amount of cumulative revenue recognized will not occur when the associated uncertainty with respect </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the variable </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consideration is subsequently resolved. BioNTech has concluded that future milestone payments are fully constrained at the end of the current fiscal year.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future milestone payments would become unconstrained at the satisfaction of the milestone event, specifically a development event, a regulatory approval or achievement of a sales milestone.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Allocation of the Transaction Price to Performance Obligations and Revenue Recognition as Performance Obligations are satisfied</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech allocates the transaction price to performance obligations based on their relative standalone selling prices, which are generally based on best estimates and interpretations of <font style="color:#000000;">facts and circumstances of each contractual agreement and may </font>require significant judgment to determine appropriate allocation. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront payments and reimbursement for expenses are initially deferred on BioNTech&#8217;s <font style="color:#000000;">consolidated</font> statements of financial position. BioNTech assessed that no significant financing component exists within its collaboration agreements since the overall business purpose of advanced payments is to support the payment structure other than to provide a significant benefit of financing. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For performance obligations in which the costs vary based on progress, an input-based measure considering cost incurred depicts most reliably the progress of the related research activities. In other cases, revenue recognition on a straight-line basis may most reliably depict BioNTech&#8217;s performance toward complete satisfaction. In case the contractual activities progress, the achievement of development milestones will be used to measure the progress toward complete satisfaction. <font style="color:#000000;">BioNTech evaluates the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net loss in the period of adjustment.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon successfully commercializing a pharmaceutical product, the collaboration and license agreements also provide for additional profit-sharing or tiered royalties earned when customers recognize net sales of licensed products as well as sales milestone payments. Revenue is recognized based on the sales-based or usage-based royalty exemption when, or as, the underlying sales occur, which is when the performance obligation has been satisfied. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Principal-Agent Considerations</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration agreements that involve two or more partners who contribute to the provision of a specific good or service to a customer are assessed in terms of principal-agent considerations. Under BioNTech&#8217;s current collaboration agreements, the allocation of marketing and distribution rights defines territories in which the collaboration partner act as a principal respectively. BioNTech recognizes revenue net based on the collaboration partners&#8217; gross profit in territories where the partner is responsible for supply and on a gross basis when directly supplying customers in its territories when control has been transferred. Amounts paid to collaboration partners for their share of BioNTech&#8217;s profits where BioNTech is the principal in the transaction are recorded as cost of sales. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Pfizer Agreement Characteristics</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to the collaboration with Pfizer, commercial revenue is recognized based on the collaboration partners&#8217; gross profit from COVID-19 vaccine sales, which is shared under the respective collaboration agreement. In determining commercial revenue pursuant to this collaboration agreement, BioNTech is reliant on the collaboration partner for detail regarding its gross profit for the period at hand. BioNTech has been informed by its collaboration partner that certain of the information it intends to provide BioNTech with regard to the gross profit will be, by necessity, preliminary and subject to change. This is mainly due to the fact that the partner&#8217;s financial reporting cycle differs from BioNTech&#8217;s. Pfizer&#8217;s subsidiaries outside the United States have a fiscal year-end of November 30; that is, the details on sales in these territories are required in advance of closing the respective reporting periods. As a result, BioNTech&#8217;s determination of its share of such gross profit for purposes of recognizing revenues will be subject to risks that amounts reported might vary from actual amounts reported once the collaboration partner&#8217;s final financial results are available. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the period covered in these consolidated financial statements, Pfizer has calculated gross profit for COVID-19 vaccine sales in the U.S. territory as well as shared preliminary gross profit for COVID-19 vaccine sales in territories outside the United States, both of which will be reconciled and finalized. The respective gross profit shares are calculated based on sales and include consideration of transfer prices. The latter includes manufacturing and shipping costs which </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-25</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">represent standard prices and include mark-ups on manufacturing costs as specified by the terms of the agreement. Manufacturing and shipping cost variances were considered as far as those have been identified. Nevertheless, those input parameters maybe adjusted once actual costs are determined. The sales for the U.S. territory</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, as reported by Pfizer,</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as well as </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sales preliminary reported</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">territories outside the United States </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have been used to estimate license obligations in terms of royalties and sales milestones</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Sales milestones and royalties are recognized as they are </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">earned </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by the partners. Sales milestones are shared equally, while royalty payments are shared on the basis of revenue in the territories for which the partners are responsible. </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">estimated </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">royalty fees applied to net sales reflect the </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">license </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obligation</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s to the extent currently identified from third party contractual arrangements</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in estimates are accounted for prospectively, when determined. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These estimated figures are likely to change prospectively in future periods as BioNTech receives final data from Pfizer. Those changes in BioNTech&#8217;s share of the collaboration partner&#8217;s gross profit will be recognized prospectively as changes to BioNTech&#8217;s commercial revenues. To the extent that Pfizer does not provide such preliminary information in the future, BioNTech&#8217;s provisional sales figures for territories outside of the United States will be subject to a greater level of estimation and judgment. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:1.09%;width:99.88%;">
<tr>
<td style="width:35.4%;"></td>
<td style="width:14.27%;"></td>
<td style="width:14.27%;"></td>
<td style="width:21.19%;"></td>
<td style="width:14.75%;"></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="bottom"  BGCOLOR="#FFFFFF">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2020</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-bottom:solid 1pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-bottom:solid 1pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">German territory</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-bottom:solid 1pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">U.S. territory</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-bottom:solid 1pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Territories outside the U.S.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-bottom:solid 1pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style=" border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#C6E0B4" style=" border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct product sales to BioNTech customers</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 20,553</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style=" border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 20,553</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#C6E0B4" style=" border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share of collaboration partner's gross profit</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 46,997</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style=" border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 141,480</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 188,477</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Input parameters used within gross profit share calculation</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:10pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Sales</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">reported</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">preliminary<br />reported</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Transfer price (manufacturing, shipping costs and respective variances)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">standard<br />prices</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">standard<br />prices</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">License payments</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">identified<br />royalty rate</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">identified<br />royalty rate</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer&#8217;s determination of manufacturing and shipping costs also affects the transfer prices that have been charged to COVID-19 vaccine supplies that it manufactures and supplies to BioNTech and may be subject to adjustment whenever manufacturing and shipping cost variances are identified. <font style="color:#000000;">Likewise, </font>BioNTech&#8217;s <font style="color:#000000;">own cost of sales and the respective gross profit share owed to </font>BioNTech&#8217;s <font style="color:#000000;">partner may be adjusted prospectively</font>, when changes are determined<font style="color:#000000;">. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the carrying amounts of the revenue recognition-related contract balances, see Note 6.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist of costs incurred in performing research and development activities, including personnel-related expenses, contract services and costs for purchased materials, laboratory supplies and non-capital equipment used in the research and development process. Research and development expenses include BioNTech&#8217;s share of expenses under the terms of collaboration agreements and 100% of the expenses for wholly-owned product candidates. Research and development expenses shared under collaboration agreements, which are initially incurred by the collaboration partners and subsequently charged to BioNTech, are recorded as purchased services classified within research and development. Cost reimbursements from partners for research and development expenses initially incurred by BioNTech and due to BioNTech under the agreements, are recorded as a reduction to purchased services classified within research and development expenses. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech has entered into agreements under which third parties grant licenses to BioNTech. Consideration paid under those agreements include upfront payments, development milestone payments and development expense reimbursements as well as sales-based milestone and royalty payments. Milestone payments are recorded when the specific milestone has been achieved. If those licenses grant access to technologies, both parties jointly perform research or development activities and both are exposed to significant risks and rewards of the activities. Costs incurred with the agreements are not treated differently from costs related to own product candidates. If the agreements grant BioNTech </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-26</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights to use certain patents and technologies, that </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">meet the definition of an </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">identifiable assets, they are treated as acquired intangible assets</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. This assessment is made based on the facts and circumstances of each contractual agreement. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The value of goods and services received from contract research organizations, or CROs, and contract manufacturing organizations, or CMOs, in the reporting period are estimated based on the level of services performed and progress made in the respective period. Amounts are recorded as accrued expenses if BioNTech has not received an invoice from the service provider. Advance payments for goods or services that will be used or rendered for future research and development activities are recognized as other current assets or other current financial assets respectively. The amounts are currently expensed as the related goods are delivered or the services performed. Management&#8217;s estimates are based on the best information available at the time. However, additional information may become available in the future and management may adjust the estimate in such future periods. In this event, BioNTech may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. BioNTech considers resulting increases or decreases in cost as changes in estimates and reflects such changes in research and development expenses in the period identified.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research costs are expensed as incurred. Development expenditures on an individual project are recognized as an intangible asset if, and only if, all of the six criteria can be demonstrated by the Group as shown under Note&#160;2.3.10 above. Due to the inherent risk of failure in pharmaceutical development and the uncertainty of approval, management has determined that these criteria are not met in the biotech sector until regulatory approval has been obtained. The related expenditure is reflected in the consolidated statements of operations in the period in which the expenditure is incurred.<font style="color:#000000;"> Sales-based milestone or royalty payments incurred under license agreements relating to self-developed intangibles after the approval date of the respective pharmaceutical product are considered as contingent considerations. These contingent considerations are recognized as expenses as incurred. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to initial regulatory approval, costs relating to production of products are expensed as research and development expenses in the period incurred. If pre-launch products are sold, the respective product gross margin may be higher compared to the expected recurring margin as the underlying costs will not be included in cost of sales.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimates and Assumptions</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are described below. The Group based its assumptions and estimates on parameters available when the consolidated financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Group. Such changes are reflected in the assumptions when they occur.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Business Combinations</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The allocation of the purchase price for business acquisitions to the identifiable assets acquired and liabilities assumed based on their respective fair values, requires use of accounting estimates and judgment. Acquired intangible assets are valued using valuation models such as the Multi Period Excess Earnings Method under which fair values are derived from future net cash flows, which are discounted to the acquisition date using an appropriate discount factor. BioNTech has estimated fair values of assets acquired, liabilities assumed and contingent considerations based on reasonable assumptions. BioNTech continues to collect information and reevaluate these provisional estimates and assumptions in accordance with IFRS 3. Any adjustments to these provisional estimates and assumptions is recorded against goodwill provided they arise within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statements of operations.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For further disclosures relating to business combinations, see Note 5.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Impairment of Non-Financial Assets</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment exists when the carrying value of an asset or cash generating unit exceeds its recoverable amount, which is the higher of its fair value less costs of disposal and its value in use. The fair value less costs of disposal calculation is based on DCF model less incremental costs of disposing of the asset. The value in use calculation is based on a DCF model as well. The cash flows are derived from the budget for the next five years and do not include restructuring activities that the Group is not yet committed to or significant future investments that will enhance the performance of the assets of the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-27</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CGU being tested. The recoverable amount is sensitive to the discount rate used for the DCF model as well as the expected future cash-inflows and the growth rate used for extrapolation purposes. These estimates are most relevant to goodwill and other intangibles with indefinite useful lives recognized by the Group. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The key assumptions used to determine the recoverable amount for the different CGUs, including a sensitivity analysis, are disclosed and further explained in Note&#160;11.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Share-Based Payments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Determining the fair value of share-based payment transactions requires the most appropriate valuation for the specific program, which depends on the underlying terms and conditions.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group has used valuation models like a binomial or Monte-Carlo simulation model for the measurement of the cash- and equity-settled transactions&#8217; fair value at the grant date considering certain assumption relating to, <font style="font-style:italic;">e.g.</font>, the volatility of stock price, the determination of an appropriate risk-free interest rate, expected dividends and the probability of reaching a minimum hurdle to exercise the relevant options. For awards which were granted prior to the initial public offering, at a time where no quoted market prices existed, the valuation model assumptions included the option&#8217;s underlying share price. For awards which were granted post the initial public offering, the grant date&#8217;s share prices on the Nasdaq Global Select Market were included in the valuation. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For further disclosures relating to share-based payments, see Note 17.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Embedded Derivatives</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Defining the fair value of the embedded derivative which was bifurcated from the convertible note, as host contract, requires significant judgment. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group has used the Cox-Rubinstein binomial tree model when determining the fair value of the conversion right. The primary inputs used in the model include stock price volatility, credit spreads, risk-free interest rate and foreign exchange forward rates. Stock price volatility is based on implied volatility for BioNTech, credit risk is model implied and adjusted for movement in credit spreads for B-rated corporates at each valuation date, the risk-free interest rate is based on currency specific time congruent IBOR and swap rates whereas the foreign exchange forward rates are based on observable market data. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For further disclosures relating to financial instruments, see Note 12.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Leases</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets are measured at the amount equal to the lease liability, adjusted by the amount of any prepaid or accrued lease payments relating to that lease.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant accounting judgments are required for the determination of the appropriate incremental borrowing rate, which is to be used in the calculation of the asset and liability that are recognized in the financial statements regarding the lease contracts.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the carrying amounts of right-of-use assets and the related lease liability, see Note 19.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Taxes</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group is subject to income taxes in more than one tax jurisdictions. Due to the increasing complexity of tax laws and the corresponding uncertainty regarding the legal interpretation by the fiscal authorities, tax calculations are generally subject to an elevated amount of uncertainty. To the extent necessary, possible tax risks are taken into account in form of provisions. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group does not recognize or impairs deferred tax assets when it is unlikely that a corresponding amount of future taxable profit will be available against which the deductible temporary differences, tax loss carry forwards and tax credits can be utilized. Significant management <font style="color:#000000;">judgment </font>is required when determining whether sufficient future taxable profit will be available against which the deductible temporary differences, tax loss carry forwards and tax credits can be utilized. This includes management&#8217;s assessment on the character and amounts of taxable future profits, the periods in which those profits are expected to occur, and the availability of tax planning opportunities. As a matter of policy, convincing evidence </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">supporting the recognition of deferred tax assets is required if an entity has suffered a loss in either the current or the preceding period</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, based on BioNTech&#8217;s <font style="color:#000000;">product-based business plan, including commercial supply commitments agreed with various governments and health ministries under which BioNTech either directly supplies the COVID-19 vaccine or, if they relate to territories which have been allocated to Pfizer, BioNTech will receive the profit share to which its eligible, it is now considered highly probable that taxable profits for the German tax group will be available </font>against which the tax losses can be utilized. On this basis, BioNTech has determined that a deferred tax asset with respect to the German tax group&#8217;s tax losses carried forward can be recognized. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the other hand, management has determined that deferred tax assets on tax losses carried forward that relate to subsidiaries which have a loss making history cannot be recognized. This includes the assessment that those subsidiaries neither have any taxable temporary difference nor any tax planning opportunities available that could support the recognition of deferred tax assets. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For further disclosures relating to deferred taxes, see Note 8.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Group Information</font></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Information about Subsidiaries</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements of the Group include the following subsidiaries: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">% equity interest</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Country of incorporation</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registered office</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech RNA Pharmaceuticals GmbH</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mainz</p></td>
<td valign="top"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Delivery Technologies GmbH</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Halle</p></td>
<td valign="top"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Diagnostics GmbH</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mainz</p></td>
<td valign="top"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Europe GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(previously BioNTech Small Molecules GmbH)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mainz</p></td>
<td valign="top"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Manufacturing GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(previously BioNTech IVAC GmbH)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mainz</p></td>
<td valign="top"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Manufacturing Marburg GmbH</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marburg</p></td>
<td valign="top"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n/a</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Austria Beteiligungen GmbH</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Austria</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vienna</p></td>
<td valign="top"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Innovative Manufacturing Services GmbH</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Idar-Oberstein</p></td>
<td valign="top"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reSano GmbH (previously reBOOST Management GmbH)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mainz</p></td>
<td valign="top"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JPT Peptide Technologies GmbH</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Berlin</p></td>
<td valign="top"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JPT Peptide Technologies Inc.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cambridge (previously Acton)</p></td>
<td valign="top"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech USA Holding, LLC</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cambridge (previously New York)</p></td>
<td valign="top"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Research and Development, Inc.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cambridge (previously New York)</p></td>
<td valign="top"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech US Inc.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cambridge</p></td>
<td valign="top"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n/a</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Pharmaceuticals Asia Pacific Pte. Ltd</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Singapore</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Singapore</p></td>
<td valign="top"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n/a</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech UK Limited</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Kingdom</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reading</p></td>
<td valign="top"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n/a</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Cell &amp; Gene Therapies GmbH</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mainz</p></td>
<td valign="top"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Real Estate Holding GmbH</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holzkirchen</p></td>
<td valign="top"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Real Estate Verwaltungs GmbH</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holzkirchen</p></td>
<td valign="top"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Real Estate GmbH &amp; Co. KG</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holzkirchen</p></td>
<td valign="top"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Real Estate An der Goldgrube GmbH &amp; Co. KG</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holzkirchen</p></td>
<td valign="top"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n/a</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Real Estate Haus Vier GmbH &amp; Co. KG</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holzkirchen</p></td>
<td valign="top"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n/a</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Real Estate Adam Opel Stra&#223;e GmbH &amp; Co. KG</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holzkirchen</p></td>
<td valign="top"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n/a</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, two entities were acquired: Neon Therapeutics, Inc. (subsequently renamed BioNTech US Inc.) and Novartis Manufacturing GmbH (subsequently renamed BioNTech Manufacturing </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-29</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marburg GmbH). Additionally, BioNTech UK </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Limited</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">., BioNTech Pharmaceuticals Asia Pacific Pte. Ltd, BioNTech Real Estate Haus Vier GmbH &amp; Co. KG, BioNTech Real Estate </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n der Goldgrube GmbH &amp; Co. KG and BioNTech Real Estate Adam Opel Stra&#223;e GmbH &amp; Co. KG were established.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During<font style="color:#000000;"> the year ended December&#160;31, 2019, two entities were founded in the United States: BioNTech USA Holding, LLC, a wholly-owned subsidiary of BioNTech SE, and BioNTech Research and Development, Inc. a wholly-owned subsidiary of BioNTech USA Holding, LLC. Additionally, reSano GmbH (previously reBOOST Management GmbH), was acquired through a share purchase which represents a related party transaction. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Parent Company</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATHOS KG, Holzkirchen, Germany is the sole shareholder of AT Impf GmbH, Munich, Germany and beneficial owner of the following percentage of ordinary shares in BioNTech at the dates as indicated. ATHOS KG via AT Impf GmbH has de facto control over BioNTech based on its substantial shareholding, which enabled it to exercise the majority of voting rights to pass resolutions at BioNTech&#8217;s Annual General Meeting, or AGM. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ownership of ordinary shares in BioNTech (in %)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Country of incorporation</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registered office</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AT Impf GmbH</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Munich</p></td>
<td valign="top"  BGCOLOR="#C5E0B3" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47.37%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50.33%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Entity with significant Influence over the Group</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medine GmbH, Mainz owned the following percentage of ordinary shares in BioNTech at the following dates as indicated: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ownership of ordinary shares in BioNTech (in %)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Country of incorporation</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registered office</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medine GmbH</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mainz</p></td>
<td valign="top"  BGCOLOR="#C5E0B3" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.25%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.38%</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5</font></p></td>
<td valign="top">
<p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Business Combinations</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Lipocalyx GmbH</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, BioNTech Delivery Technologies GmbH (previously BioNTech Protein Therapeutics GmbH), or BioNTech Delivery Technologies, a wholly-owned subsidiary of BioNTech&#160;SE, entered into an agreement to acquire all assets, employees and proprietary know-how of Lipocalyx GmbH, or Lipocalyx, and its related parties in exchange for a total cash consideration at an amount of &#8364;6.5&#160;million and additional contingent consideration estimated at the closing date of January 6, 2020 in an amount of &#8364;0.6&#160;million. The employees of Lipocalyx were transferred automatically to BioNTech Delivery Technologies with effect as of the closing date. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="color:#000000;"> Group acquired the assets of Lipocalyx and its related parties to combine the acquired technologies and the related know-how with already existing product candidates of the Group to improve their functionality and performance. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-30</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The final fair values of the identifiable net assets of Lipocalyx as at the date of acquisition were:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">recognized on</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">acquisition</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lipocalyx GmbH</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;896</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other intangible assets</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,978</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total identifiable net assets at fair value</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7,088</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;6,516</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration liability</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">572</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total consideration</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7,088</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated statements of operations include the result of Lipocalyx since the acquisition date. From the date of acquisition through December&#160;31, 2020, Lipocalyx contributed &#8364;1.7&#160;million as operating loss to the respective result of the Group. From the date of acquisition through December 31, 2020, Lipocalyx generated &#8364;0.2&#160;million of revenues. Given the timing of closing, the contribution to operating loss and revenues, if the transaction had occurred at the beginning of the reporting period, would not differ materially. Goodwill recognized is primarily attributed to the expected synergies and other benefits from combining the assets and activities of Lipocalyx with those of the Group. The goodwill resulting from the Lipocalyx acquisition during the year ended December 31, 2020 was allocated to the CGU Immunotherapies. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transaction costs of &#8364;17&#160;thousand relating to the acquisition have been expensed and are included in the general and administrative expenses in the consolidated statements of operations and are included in cash flows used in operating activities in the consolidated statements of cash flows.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The purchase <font style="color:#000000;">agreement</font> with Lipocalyx includes the following contingent cash considerations to the previous owners: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.09%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.04%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">&#8364;1.0&#160;million upon successful completion of a Phase 1 clinical trial designed to show and establish a sufficient safety margin justifying further development of the first pharmaceutical product relating to acquired technologies formulated in a manner covered by a valid granted claim in a major country of a patent within the assigned IP rights; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.09%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.04%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">&#8364;1.0&#160;million upon successful completion of the first Phase 2 clinical trial of the first pharmaceutical product relating to acquired technologies formulated in a manner covered by a valid granted claim in a major country of a patent within the assigned IP rights. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the <font style="color:#000000;">acquisition</font> date, the fair value of the contingent consideration was &#8364;0.6&#160;million. The contingent consideration is presented in &#8216;non-current financial liabilities&#8217; in the consolidated statements of financial position (see Note 12). </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">BioNTech US Inc. (previously Neon Therapeutics, Inc., or Neon)</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 6, 2020, BioNTech acquired Neon, a biotechnology company developing novel neoantigen-based T-cell therapies, to leverage Neon&#8217;s expertise in the development of neoantigen therapies, with both vaccine and T cell capabilities. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the acquisition date share price, the aggregate value of the merger consideration was &#8364;89.9&#160;million ($97.1&#160;million) financed by <font style="color:#000000;">issuing</font> 1,935,488 American Depositary Shares representing BioNTech&#8217;s ordinary shares as a stock transaction and including a de minimis cash consideration which was paid to settle Neon&#8217;s outstanding stock options. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-31</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The f</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">air values and values in accordance with IFRS 3 of the identifiable net assets of BioNTech US Inc. as at the date of acquisition </font><font style="color:#000000;">were</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as follows: </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">recognized on</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">acquisition</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech US Inc.</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;29,867</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,617</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,896</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets non-current and current</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,704</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,749</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;52,833</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade payables</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,723</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities non-current and current</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,793</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;19,516</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total identifiable net assets at fair value</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;33,317</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill from the acquisition</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,573</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consideration transferred</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;89,890</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issued, at fair value</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,548</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">342</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total consideration</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;89,890</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The intangible assets comprise two neoantigen targeted therapies, BNT221 (NEO-PTC-01) and BNT222 (NEO-STC-01), which were identified and recorded as in-process R&amp;D. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities relating to temporary differences of the assets acquired in the business combination were recognized at an amount of &#8364;&#160;8.0&#160;million. To the extent of those deferred tax liabilities assumed, deferred tax assets relating to temporary differences and tax loss carryforwards which existed as of the acquisition date were recognized. Since the conditions to offset were fulfilled, the deferred tax assets and liabilities were offset. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated statements of operations include the results of BioNTech US since the acquisition date. From the date of acquisition through December 31, 2020, BioNTech US contributed &#8364;28.5&#160;million operating loss to respective result of the Group. If the transaction had occurred at the beginning of the reporting period, &#8364;59.8&#160;million would have contributed to the operating loss. This amount includes expenses resulting from the merger and should not necessarily be <font style="color:#000000;">considered</font> representative of the future consolidated results of operations or financial condition on a consolidated basis. From the date of acquisition, BioNTech US did not generate any revenue and no revenue would have been generated if the transaction had occurred at the beginning of the reporting period. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill recognized is primarily attributable to the expected synergies and other benefits from combining two organizations with a common culture of pioneering translational science and a shared vision for the future of cancer immunotherapy as described above. The goodwill resulting from the BioNTech US acquisition during the year ended December 31, 2020 was allocated to the CGU Immunotherapies. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transaction costs of &#8364;1.1&#160;million relating to the acquisition have been expensed and are included in the general and administrative expenses in the consolidated statements of operations. In the consolidated statements of cash flows they are included in cash flows used in operating activities. The attributable costs of the issuance of the shares of &#8364;1.3&#160;million were recorded in <font style="color:#000000;">equity</font> as a deduction from the capital reserve and are included in cash flows from financing activities in the consolidated statements of cash flows. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-32</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Manufacturing Marburg GmbH (previously Novartis Manufacturing GmbH)</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 31, 2020, BioNTech acquired Novartis Manufacturing GmbH, a manufacturing facility in Marburg. Through the acquisition, BioNTech plans to produce its COVID-19 vaccine for global supply.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair values and values in accordance with IFRS 3 of the identifiable net assets of BioNTech Manufacturing Marburg GmbH, or BioNTech Marburg, as at the date of acquisition <font style="color:#000000;">were</font> as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">recognized on</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">acquisition</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Manufacturing Marburg GmbH</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,828</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,514</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,466</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets non-current and current</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,343</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,319</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;131,470</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions non-current and current</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,127</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade payables</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,105</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities non-current and current</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,383</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;46,615</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total identifiable net assets at fair value</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;84,855</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bargain purchase</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,002)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consideration transferred</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;77,853</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,853</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total consideration</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;77,853</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated statements of operations include the results of BioNTech Marburg since the acquisition date. From the date of acquisition, the transition into a GMP certified manufacturing facility for BioNTech&#8217;s COVID-19 vaccine was initiated rapidly. During this time, no revenues have been recognized and set-up, retooling and prepping expenses led to a &#8364;6.7&#160;million operating loss, which contributed to the respective result of the Group. Projecting the revenue and result of the joint company as if the acquisition had occurred at the beginning of the reporting period is impracticable, since BioNTech intends to use the facility for manufacturing its COVID-19 vaccine<font style="color:#000000;">. Information about revenues and net income generated by BioNTech Marburg before the acquisition were</font> <font style="color:#000000;">considered</font> <font style="color:#000000;">not to be useful as they are not </font>representative of the future consolidated results of operations or financial condition on a consolidated basis. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The contracting parties shared the understanding that the manufacturing facility is well-equipped to make an important contribution in BioNTech&#8217;s effort to develop and manufacture a COVID-19 vaccine. The possibility of acquiring a GMP certified manufacturing facility with well-established biotechnology drug substance and drug product manufacturing equipment as well as an experienced team was a very good opportunity for BioNTech to accelerate its efforts to scale-up the commercial manufacturing capacity for its COVID-19 vaccine production. The fact that the offer to sell and the need to acquire the facility overlapped at a convenient time, the underlying opportunities ultimately resulted in a bargain purchase of &#8364;7.0&#160;million which was recognized in other operating income. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transaction costs of &#8364;1.4&#160;million relating to the acquisition have been expensed and are included in the general and administrative expenses in the consolidated statements of operations and are included in cash flows used in operating activities in the consolidated statements of cash flows.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-33</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reconciliation of </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">G</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">oodwill</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amount of goodwill equals the acquisition costs adjusted by currency translation adjustments. The reconciliation of this carrying amount at the beginning and end of the reporting period is presented below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2020</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,978</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,469</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency differences</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,750)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;53,697</p></td>
</tr>
</table></div>
<p style="line-height:5pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="line-height:5pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:7pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6</font></p></td>
<td valign="top">
<p style="margin-top:7pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Revenue from Contracts with Customers</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.1</font></p></td>
<td valign="top">
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disaggregated revenue information</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Set out below is the disaggregation of the Group&#8217;s revenues from contracts with customers:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research &amp; development revenues from collaborations</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;178,849</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;84,428</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;101,837</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Pfizer Inc.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">121,597</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">14,348</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">7,173</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Genentech Inc.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">49,195</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">64,026</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">49,536</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Shanghai Fosun Pharmaceutical (Group) Co., Ltd</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">5,074</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2,983</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">6,054</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">45,128</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commercial revenues</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">303,476</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">24,161</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">25,738</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 vaccine revenues</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">270,490</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Sales to collaboration partner*</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">61,460</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Direct product sales to BioNTech customers</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">20,553</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Share of collaboration partner's gross profit</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">188,477</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other sales</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,986</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,161</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,738</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;482,325</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;108,589</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;127,575</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Represents sales to collaboration partner of products manufactured by BioNTech. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, revenues from contracts with customers mainly increased since revenues were recognized for the first time under two new collaboration agreements, which BioNTech entered into during the year ended December&#160;31, 2020 in order to develop a COVID-19 vaccine, and ultimately led to the recognition of COVID-19 vaccine commercial revenues. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, revenues<font style="color:#000000;"> recognized from two customers, Pfizer (&#8364;371.5&#160;million) and Genentech (&#8364;49.2&#160;million), </font>each account for more than 10% of total revenues. During the year ended December 31, 2019 revenues recognized from one customer, <font style="color:#000000;">Genentech (&#8364;64.0&#160;million), accounted for more than 10% of total revenues. D</font>uring the year ended December 31, 2018<font style="color:#000000;"> </font>revenues recognized from two customers, <font style="color:#000000;">Genentech (&#8364;49.5&#160;million) and Sanofi (&#8364;41.7&#160;million), accounted for more than 10% of total revenue. The geographic region which recognized revenues was mainly Germany (also the Country of BioNTech&#8217;s domicile) and is based upon the location will bills customers. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research &amp; Development Revenues from Collaborations</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of its BNT162 vaccine program against COVID-19, BioNTech collaborates with Pfizer and Fosun Pharma. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue from Pfizer was mainly derived from the collaboration and license agreement to develop a COVID-19 vaccine and, in addition, includes an amount of &#8364;3.5&#160;million revenue derived from the existing Influenza collaboration. During the year ended December&#160;31, 2020, a non-refundable upfront cash payment of &#8364;66.3&#160;million was received. A regulatory milestone payment of &#8364;51.8&#160;million became due, but has not yet been received. Both were fully recognized as revenue during the year ended December&#160;31, 2020. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-34</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fosun Pharma is the collaboration partner with whom BioNTech works together on the development of a COVID-19 vaccine in China. Through the collaboration agreement BioNTech is conducting clinical trials in China</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, using BioNTech&#8217;s proprietary mRNA technology</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and leveraging Fosun Pharma&#8217;s extensive clinical development, regulatory, and commercial capabilities in the country. Fosun Pharma has paid a non-refundable upfront cash payment of </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;0.9</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million and development milestones of </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;4.2</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;million that were recognized as revenue during </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">year ended December&#160;31, 2020</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other collaboration programs have been progressed during the year ended December&#160;31, 2020 and revenues of &#8364;52.1<font style="color:#000000;">&#160;</font>million have been derived from deferred upfront payments measured based on the costs incurred under the respective research programs. For certain collaboration programs, the commencement of trials has been delayed, partially due to slowed patient enrollment or other delays as a result of the COVID-19 pandemic. Accordingly, during the year ended December&#160;31, 2020, revenues from collaboration programs with Genentech and from the Influenza collaboration with Pfizer have generally decreased compared to the prior year periods. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenues recorded during the year ended December&#160;31, 2019 mainly included revenues resulting from collaboration and license agreements processed in the research and development phase. The amounts were mainly derived from deferred upfront fees received under the Genentech, Pfizer (Influenza) and Sanofi collaboration. The amounts were recognized as revenue as BioNTech performed under the agreement and measured based on the costs incurred under the respective research programs. Compared to the revenues recognized from collaboration and license agreements during the year ended December 31, 2018, revenues decreased since the revenue recognized in the year ended December&#160;31, 2018 included an amount of &#8364;33.2&#160;million collaboration revenue from the Sanofi collaboration for a reimbursement of 50% of CellScript sublicense costs pursuant to a separate sub-sublicense agreement dated December 22, 2018. This transaction only occurred in the year ended December&#160;31, 2018. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commercial Revenues</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech&#8217;s COVID-19 vaccine has evolved from the BNT162 program and has been authorized or approved for emergency or temporary use or has been granted conditional marketing authorization in over 65 countries worldwide, which resulted in recognition of revenues from the sale of pharmaceutical products for the first time. BioNTech is the marketing authorization holder in the European Union, and holder of emergency use authorizations or equivalent in the United States, United Kingdom, Canada and other countries in advance of a planned application for full marketing authorizations in these countries. BioNTech has marketing and distribution rights in Germany and Turkey. Pfizer has marketing and distribution rights worldwide with the exception of China, Germany, and Turkey. Fosun Pharma has marketing and distribution rights in China. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 vaccine manufacturing process leverages Pfizer&#8217;s and BioNTech&#8217;s manufacturing facilities, consequently responsibilities are shared between BioNTech and Pfizer. Whenever responsibilities in the manufacturing and supply process of the COVID-19 vaccine shift and the COVID-19 vaccine is transferred, it is sold from one partner to the other. During <font style="color:#000000;">the year ended December&#160;31, 2020, BioNTech has recognized &#8364;61.5&#160;million of revenues from selling </font>d<font style="Background-color:#FFFFFF;">rug product batches manufactured by BioNTech to Pfizer&#8217;s manufacturing site for fill and finish</font><font style="color:#000000;">. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon receiving a conditional marketing authorization, emergency or temporary use authorization, BioNTech and Pfizer started selling the product. The allocation of marketing and distribution rights defines territories in which the collaboration partners act as a principal respectively. For supplying BioNTech&#8217;s territory, Germany, BioNTech acquired COVID-19 vaccine from Pfizer and recognized &#8364;20.6&#160;million of revenues from direct COVID-19 vaccine sales during the year ended December&#160;31, 2020. The share of gross profit that Pfizer as collaboration partner has earned based on these sales is recognized as cost of sales. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on Pfizer&#8217;s COVID-19 vaccine sales in the collaboration partner&#8217;s territory, BioNTech is eligible to receive a share of the respective gross profit which represents a net figure and is recognized as collaboration revenue during the commercial phase. During the year ended December&#160;31, 2020, a gross profit share of &#8364;188.5&#160;million has been recognized. In order to determine our share of collaboration partner&#8217;s gross profits, BioNTech used certain information from the collaboration partner, including revenue from the sale of products, some of which is based on preliminary data shared between the partners and might vary once final data is available. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, &#8364;33.0&#160;million of revenues compared to &#8364;24.2&#160;million of revenues during the year ended December&#160;31, 2019, and &#8364;25.7&#160;million during the year ended December 31, 2018 were recognized from other sales transactions based on sales of diagnostic products, peptides, retroviral vectors for clinical supply, and development and manufacturing services that were sold to third-party customers. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-35</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenues from contracts with customers disclosed above were recognized as follows: </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Timing of revenue recognition</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Goods and services transferred at a point in time</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;108,840</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;16,955</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;22,828</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Goods and services transferred over time</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">373,485</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,634</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,747</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;482,325</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;108,589</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;127,575</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2019, BioNTech recognized revenue of &#8364;1.1&#160;million under a bill-and-hold transaction for which the customer already had obtained control. The bill-and-hold arrangement is substantive since the request to retain the product in BioNTech&#8217;s facilities until January 2020 was initiated by the customer. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.2</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Contract Balances</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade receivables</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;165,468</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;11,913</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">371,475</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">190,692</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade receivables are non-interest bearing and are generally settled within 20 to 30 days.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract assets are recognized for revenue earned from sales and services based on individual customer contracts of BioNTech Innovative Manufacturing Services GmbH. However, the customers&#8217; advance payments exceeded BioNTech&#8217;s transferred goods and services for which a conditional right to consideration exists. Therefore, only contract liabilities net of contract assets are presented as of December&#160;31, 2020 and December&#160;31, 2019, respectively. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities mainly include upfront fees received from BioNTech&#8217;s major collaboration and license agreements as well as advance payments received for future COVID-19 vaccine sales and other sales. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The contract liabilities from collaboration and commercial supply agreements as <font style="color:#000000;">o</font>f December&#160;31, 2020 comprise &#8364;131.8&#160;million remaining upfront fees from collaboration agreements, <font style="color:#000000;">&#8364;235.8&#160;million of advance payments </font>for future COVID-19 vaccine sales, which had been received during the year ended December&#160;31, 2020 or for which an unconditional right of consideration exists as well as &#8364;3.9&#160;million advance payments received on other sales (as of December&#160;31, 2019: &#8364;187.6&#160;million of remaining upfront fees from collaborations as well as &#8364;3.1&#160;million advance payments received on other sales). </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, the increase from payments received exceeded revenues recognized from contract liabilities recorded at the beginning of the year (during the year ended December&#160;31, 2019: decrease in contract liabilities since recognizing revenues from amounts which had been included in contract liabilities at the beginning of the year exceeded advance payments on other sales received). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Set out below is the amount of revenue recognized <font style="color:#000000;">for the periods </font>indicated:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts included in contract liabilities at the beginning of the year</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;58,895</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;84,112</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;59,583</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-36</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.3</font></p></td>
<td valign="top">
<p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Performance Obligations</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The contract liabilities allocated to the remaining performance obligations from collaboration or commercial supply agreements (unsatisfied or partially unsatisfied) as at year-end are as follows: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within one year</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;299,583</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;93,583</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">More than one year</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,892</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,109</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;371,475</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;190,692</p></td>
</tr>
</table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</font></p></td>
<td valign="top">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Income and Expenses</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.1</font></p></td>
<td valign="top">
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Costs of Sales</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.93%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of sales related to COVID-19 vaccine revenues</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;35,616</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost related to other sales</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,717</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,361</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,690</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;59,333</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;17,361</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;13,690</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, cost of sales mainly increased compared to the year ended December&#160;31, 2019 since costs were <font style="color:#000000;">recognized</font> for the first time with respect to BioNTech&#8217;s COVID-19 vaccine sales and included Pfizer&#8217;s share of gross profits earned by BioNTech in transactions, where BioNTech is the principal. Costs of sales do not include costs relating to production of pre-launch products since those are expensed as research and development expenses in the period incurred. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.2</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Research and Development Expenses</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchased services</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;359,880</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;65,552</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;42,079</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wages, benefits and social security expense</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,298</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,213</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,668</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory supplies</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,792</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,218</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,921</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,192</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,533</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,312</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IT costs</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,118</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,800</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,572</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease and lease related cost</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,725</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,527</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,404</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transport costs</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,135</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,081</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">668</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,889</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,542</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,416</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;645,029</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;226,466</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;143,040</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, r<font style="color:#000000;">esearch and development expenses increased compared to the year ended December&#160;31, 2019 due to an increase in research and development expenses from BioNTech&#8217;s BNT162 program. Research and development expenses include BioNTech&#8217;s share of expenses under the terms of the Pfizer collaboration agreement. Development costs, which are shared, are divided equally between BioNTech and Pfizer. The amount of shared development expenses, which were initially incurred by Pfizer and subsequently charged to BioNTech, were recorded as purchased services classified within research and development and the reimbursement from Pfizer for research and development expenses initially incurred by BioNTech were recorded as a reduction to research and development expenses. The increase was further driven by an increase in expenses for purchased laboratory supplies as well as an increase in headcount leading to higher wages, benefits and social security expenses. In addition, from May 6, 2020, the date of acquisition, the new U.S.-based subsidiary, BioNTech US Inc., contributed &#8364;21.0&#160;million to the research and development expenses of the Group. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2019, research and development costs increased compared to the year ended December&#160;31, 2018 based on an increase in wages, benefits and social security expenses due to an increase in headcount </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-37</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and the full-year reflection of the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee Stock Ownership Plan (&#8220;ESOP&#8221;) </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expenses during the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">year ended December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as well as higher development expenses spent on purchased services and laboratory supplies. </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.3</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Sales and Marketing Expenses</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchased services</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;10,929</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;247</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;794</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wages, benefits and social security expense</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,636</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,938</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,728</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,947</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">533</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">519</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;14,512</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,718</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;3,041</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, sales and marketing expenses increased compared to the year ended December&#160;31, 2019 due to an increase in purchased service, which we incurred in connection with progressing the commercial activities of the Group with respect to BioNTech&#8217;s COVID-19 vaccine. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.4</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">General and Administrative Expenses</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wages, benefits and social security expense</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;33,007</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;19,122</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;8,582</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchased services</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,022</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,419</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,177</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IT and office equipment</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,404</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,573</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,774</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,104</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,855</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,284</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance premiums</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,840</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,061</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Job advertisement expenses</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,897</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">548</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">861</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease and lease related cost</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,390</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,715</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,012</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research services</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,033</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory supplies</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,191</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">785</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">456</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract staffing</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,108</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">686</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">781</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,053</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,551</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,236</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;94,049</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;45,547</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;26,334</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, general and administrative <font style="color:#000000;">expenses increased compared to the year ended December&#160;31, 2019 due to higher expenses for purchased management consulting and legal services, an increase in headcount leading to higher wages, benefits and social security expenses and higher insurance premiums. In addition, from May 6, 2020, the date of acquisition, the new U.S.-based subsidiary, BioNTech US Inc., contributed &#8364;7.4&#160;million to the general and administrative expenses of the Group, respectively. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2019, <font style="color:#000000;">general and administrative </font>expenses increased compared to the year ended December&#160;31, 2018 based on an increase in headcount and the full-year reflection of the ESOP program expenses during the year ended December&#160;31, 2019 as well as a charge of &#8364;2.6 million in connection with certain withholding tax payments for intellectual property licenses related to prior years that was recorded during the year ended December&#160;31, 2019 but not during the year ended December&#160;31, 2018. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.5</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Other Operating Income</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government grants</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;239,017</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,547</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;4,228</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bargain purchase</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,002</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,520</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,177</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,118</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;250,539</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,724</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;5,396</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-38</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, the other income increased compared to the year ended December&#160;31, 2019. The increase mainly results from government grants for which BioNTech became eligible as part of an initiative by the German Federal Ministry of Education (<font style="font-style:italic;">Bundesministerium f&#252;r Bildung und Forschung</font>, or the BMBF) to support its COVID-19 vaccine program, BNT162. The BMBF funding was granted to accelerate BioNTech&#8217;s vaccine development, and to upscale its manufacturing capabilities in Germany. The funding will also compensate further costs that incur since the COVID-19 vaccine continues to be tested in clinical trials, for example to test it against new variants or to approve it for additional groups (pregnant women, individuals less 16 years), and because study participants will continue to be followed for two years to continue evaluating safety and efficacy. The proportion of the grant that related to expenses incurred by BioNTech is recognized as other operating income with an amount of &#8364;238.9 million; the proportion which was received and will compensate BioNTech for future expenses, has been deferred and is presented as government grant in the consolidated statements of financial position with an amount of &#8364;88.0 million. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table illustrates the changes regarding the government grants:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Received during the year</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">330,968</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,547</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,228</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Released to the consolidated statements of operations</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(239,017)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,547)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,228)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;91,951</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,951</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.6</font></p></td>
<td valign="top">
<p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Finance Income</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,564</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,781</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,996</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange gains, net</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,341</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,050</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,564</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;4,122</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;8,046</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2019, finance income included &#8364;2.3&#160;million foreign exchange gains. Foreign exchange differences on a cumulative basis, are either shown as finance income or expenses.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.7</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Finance Expense</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of financial instruments</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;3,048</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;326</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;48</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value adjustments of financial instruments measured at fair value</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,289</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange loss, net</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,609</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;62,946</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;326</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;48</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, finance expenses included &#8364;42.6&#160;million foreign exchange losses as well as &#8364;17.3&#160;million in expenses arising from fair value measurement adjustments of the derivative embedded within the convertible note. The increase in foreign exchange losses is mainly due to higher <font style="color:#000000;">balances in</font> U.S. dollar bank accounts<font style="color:#000000;"> and the weakening of the U.S. dollar when compared to the Euro</font>. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-39</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Employee Benefits Expense</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wages and salaries</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;160,655</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;98,568</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;54,149</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Social security costs</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,988</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,394</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,231</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pension costs</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">761</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">517</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">324</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;179,404</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;111,479</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;62,704</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The item wages and salaries includes, among other things, expenses for share-based payments.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Income Tax</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax for the years ended December&#160;31, 2020, December&#160;31, 2019 and December&#160;31, 2018 comprised current income taxes, other taxes and deferred taxes. BioNTech SE is subject to corporate taxes, the solidarity surcharge and trade taxes. The Company&#8217;s corporate tax rate in the reporting year remained unchanged (15.0%) as did the solidarity surcharge (5.5%) whereas the average trade tax rate (15.0%) changed. BioNTech USA Holding, LLC is subject to Federal Corporate Income Tax (21.0%) as well as State Income Tax in various state jurisdictions (average rate of 8.1%). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table illustrates the current and deferred taxes for the periods indicated: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current income taxes</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C5E0B3" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;17</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(296)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;600</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred taxes</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C5E0B3" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(161,034)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other taxes</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Income taxes</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(161,000)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(268)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;600</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-40</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table reconciles the expected income taxes to the actual current income taxes and deferred taxes as presented in the table above. The combined income tax rate of 30.79% in the year ended December&#160;31, 2020 (during the years ended December 31, 2019 and 2018: 30.78% and 30.99%, respectively) was applied to loss before taxes to calculate the expected income taxes. This rate consists of above outlined tax rates of BioNTech SE applicable to the Group. The slight decrease of the tax rate results from the Lipocalyx GmbH business combination. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before tax</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(145,802)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(179,440)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(47,662)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected tax benefit (based on BioNTech`s statutory tax rate of 30.79%, 2019: 30.78%, 2018: 30.99%)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,891</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,240</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,776</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Effects</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government grants exempted from taxes</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible expenses</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(770)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Add-back for trade tax purposes</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(595)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(110)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-tax effective bargain purchase</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,156</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-recognition of tax effect on share-based payment expenses</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,806)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,308)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax-effective equity transaction costs</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,229</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,121</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utilization of tax losses</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,165</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-recognition of deferred taxes on tax losses and temporary differences</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,961)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,197)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,634)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition of deferred taxes on tax losses not recognized in prior periods</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,231</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition of deferred taxes on temporary differences not recognized in prior periods</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,241</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effect from lower foreign income tax rate</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,304)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(102)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustment prior year tax</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(326)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">316</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credit</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,059</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other effects</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,821)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Income taxes</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;161,000</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;268</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(600)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-41</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred taxes for the periods indicated relate to the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">January 1,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="top"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recognized in P&amp;L*</p></td>
<td valign="top"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recognized in OCI</p></td>
<td valign="top"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses</p></td>
<td valign="top"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(655)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(2,370)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;8,637</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;5,612</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">596</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">329</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">971</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leases</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">512</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,091)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,593)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,543</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(174)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,369</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest-bearing loans and borrowings</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,741)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">195</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,546)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net employee defined benefit liabilities</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">169</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(63)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">698</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">804</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">187</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">886</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">419</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,492</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other (incl. deferred expenses)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,087</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,336</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,625</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax loss carryforward / tax credit</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,764</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,660</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,280</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">175,704</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred Tax Assets Net (before valuation)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;136,034</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;40,721</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(63)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;34,746</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;211,438</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation Adjustment</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(136,034)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">120,313</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(34,765)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(50,486)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred Tax Assets Net (after valuation)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;161,034</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(63)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(19)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;160,952</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Includes all changes in deferred taxes related to U.S. tax group other than those acquired in business combination</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">January 1,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recognized in P&amp;L</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recognized in OCI</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses </p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(90)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(565)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(655)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">596</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;596</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leases</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">306</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;512</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,441</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,898)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;23,543</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;187</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other (incl. deferred expenses)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,926</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,087</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax loss carryforward / tax credit</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,848</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,916</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;109,764</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred Tax Assets Net (before valuation)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;84,799</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;51,235</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;136,034</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation Adjustment</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(84,799)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(51,235)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(136,034)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred Tax Assets Net (after valuation)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated tax losses of the German tax group, German <font style="color:#000000;">entities</font> <font style="color:#000000;">not within the tax group </font>and U.S. tax group for the periods indicated amount to the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate Tax</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;596,359</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;356,044</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;179,264</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade Tax</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,561</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">352,341</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176,425</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal Tax Credits</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;756</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State Tax Credits</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-42</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accumulated tax losses related to the German tax group include &#8364;457.9 million of corporate income tax losses and &#8364;450.9&#160;million of trade tax losses. <font style="color:#000000;">Under German law, tax losses do not expire. </font>Deferred tax assets on tax losses had not been capitalized in previous years, as there was not sufficient probability in terms of IAS 12 that there would have been future taxable profits available against which the unused tax losses could have been utilized. <font style="color:#000000;">Following the authorization and approval of the COVID-19 vaccine for emergency or temporary use or having been granted conditional marketing authorization in over 65 countries worldwide, BioNTech re-evaluated previously unrecognized tax losses. Based on BioNTech&#8217;s product-based business plan, including commercial supply commitments agreed with various governments and health ministries under which BioNTech either directly supplies the COVID-19 vaccine or, if they relate to territories which have been allocated to Pfizer, BioNTech will receive the profit share to which it is eligible, it is now considered highly probable that taxable profits for the German tax group will be available against which the tax losses can be utilized. On this basis, BioNTech recognized deferred tax assets and liabilities with a net amount of &#8364;161.0&#160;million for the losses and temporary differences determined for the German tax group as of December&#160;31, 2020. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accumulated tax losses related to German entities not within the tax group include &#8364;1.7 million of corporate income tax losses and &#8364;1.8&#160;million of trade tax losses. With respect to those tax losses, no deferred tax assets have been capitalized, as there is not sufficient probability in terms of IAS 12 that there will be future taxable profits available against which the unused tax losses can be utilized.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accumulated tax losses related to U.S. tax group include &#8364;136.8&#160;million of corporate income tax losses and &#8364;60.9&#160;million of trade tax losses. The tax losses related to the U.S. tax group include &#8364;20.9&#160;million of federal losses that are expected to expire in 2033 and &#8364;115.9&#160;million of federal losses which have no expiration date and can be carried forward indefinitely. In addition, the U.S. tax group has state tax losses of &#8364;60.9&#160;million, which may be available to offset future taxable profit and that expire at various dates beginning in 2033. BioNTech&#8217;s forecast for the U.S. tax group does not provide sufficient probability for the use of existing tax loss carryforwards in the near future. Therefore, the requirements set out by IAS 12 are not fulfilled for the U.S. tax group. As of December&#160;31, 2020, deferred tax assets are only recognized up to the amount of deferred tax liabilities. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to accumulated tax losses, BioNTech had accumulated federal tax credits of &#8364;0.8&#160;million and state tax credits of &#8364;0.3&#160;million in the United States as of December 31, 2020. The tax credits in the United States will expire at various dates beginning in 2035 if they are not used.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Earnings per Share</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic earnings per share (EPS) is calculated by <font style="color:#000000;">dividing</font> the profit / (loss) for the year attributable to ordinary equity holders of the parent by the weighted average number of ordinary shares outstanding during the year.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted EPS is calculated by dividing the profit / (loss) attributable to ordinary equity holders of the parent by the weighted average number of ordinary shares outstanding during the year plus the weighted average number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 18, 2019, BioNTech effected a 1:18 share split by issuing 206,595,492 shares by way of a capital increase from its own funds; thus, no outside proceeds were received. This capital increase came into effect upon registration with the commercial register (<font style="font-style:italic;">Handelsregister</font>). The accompanying financial statements and notes to the financial statements including the EPS information below give retroactive effect to the share split for all periods presented.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-43</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table reflects the income and share data used in the basic and diluted EPS calculations:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Gain (loss) attributable to ordinary equity holders of the parent for basic earnings</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15,198</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(179,056)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(48,019)</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of ordinary shares for basic EPS</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">235,442</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">211,499</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">190,710</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effects of dilution from share options</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C5E0B3" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,085</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of ordinary shares adjusted for the effect of dilution</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">248,527</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">211,499</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">190,710</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Earnings per share</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">in EUR</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted, profit / (loss) for the period attributable to ordinary equity holders of the parent*</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;0.06</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(0.85)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(0.25)</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* Numbers of shares for calculating the earnings per share for the years ended December 31, 2019 and December 31, 2018 have been adjusted to reflect capital increase due to 1:18 share split, which occurred on September 18, 2019.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no other transactions involving ordinary shares or potential ordinary shares between the reporting date and the date of authorization of these financial statements. Share options were not included in the calculation of diluted EPS for periods in which they were antidilutive; i.e. for the periods in which a loss was incurred. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Property, Plant and Equipment</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td rowspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Land and buildings</p></td>
<td rowspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Equipment, tools and installations</p></td>
<td rowspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress and advance payments</p></td>
<td rowspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Acquisition and production costs</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;22,147</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;73,613</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7,091</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;102,853</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,269</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,700</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,623</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,592</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disposals</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(105)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(115)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency differences</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">999</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">999</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;29,469</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;83,206</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;29,652</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;142,329</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2020</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;29,469</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;83,206</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;29,652</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;142,329</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,927</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,093</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,013</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,033</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disposals</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,892)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(958)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,891)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,561</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,832</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,391)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency differences</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(638)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(690)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,400</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,817</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,302</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,519</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;61,264</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;142,418</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;81,618</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;285,300</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-44</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td rowspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Land and buildings</p></td>
<td rowspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Equipment, tools and installations</p></td>
<td rowspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress and advance payments</p></td>
<td rowspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cumulative depreciation and impairment charges</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;6,472</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;30,180</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;36,652</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,854</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,861</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,715</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disposals</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(79)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(79)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency differences</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;8,326</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;40,959</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;49,285</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2020</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;8,326</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;40,959</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;49,285</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,074</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,753</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,827</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disposals</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,683)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,724)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency differences</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;10,356</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;47,976</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;58,332</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td rowspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Land and buildings</p></td>
<td rowspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Equipment, tools and installations</p></td>
<td rowspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress and advance payments</p></td>
<td rowspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Carrying amount</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15,675</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;43,433</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7,091</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;66,200</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;21,143</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;42,247</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;29,652</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;93,044</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;50,908</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;94,442</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;81,618</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;226,968</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Intangible Assets</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td rowspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td rowspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concessions, licenses, in-process R&amp;D and similar rights</p></td>
<td rowspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Advance payments</p></td>
<td rowspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Acquisition costs</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;534</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;101,853</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,497</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;103,883</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,744</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,529</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,273</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disposals</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(133)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(477)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(610)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(146)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency differences</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,444</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,726</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,170</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,978</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;116,313</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,403</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;121,693</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2020</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,978</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;116,313</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,403</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;121,693</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,187</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,426</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,613</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disposals</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,435)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(643)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,078)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">233</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(233)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency differences</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,750)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,897)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,647)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,469</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,845</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,314</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;53,697</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;147,246</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;5,953</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;206,895</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-45</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td rowspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td rowspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concessions, licenses, in-process R&amp;D and similar rights</p></td>
<td rowspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Advance payments</p></td>
<td rowspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cumulative depreciation and impairment charges</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15,842</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15,842</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,502</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,502</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disposals</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency differences</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;32,260</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;32,260</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2020</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;32,260</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;32,260</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,627</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,627</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disposals</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,410)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,410)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency differences</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(72)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(72)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;43,405</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;43,405</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td rowspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td rowspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concessions, licenses, in-process R&amp;D and similar rights</p></td>
<td rowspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Advance payments</p></td>
<td rowspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Carrying amount</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;534</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;86,011</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,497</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;88,042</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,978</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;84,053</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,403</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;89,434</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;53,697</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;103,841</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;5,953</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;163,490</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Goodwill and intangible assets with indefinite useful lives</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For impairment testing, goodwill acquired through business combinations has been allocated to the cash-generating units (CGU) as shown in the following table: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CGU Immunotherapies</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">External Product Sales of JPT</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;53,163</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,444</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;534</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;534</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;53,697</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,978</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group performs its annual goodwill impairment test for the respective year as of October 1. As a result of the change to one reportable segment (Note 2.1), BioNTech evaluated the implications on its determination of CGUs for allocation of goodwill. As a result, two CGUs were identified: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">The Immunotheraopies CGU focuses on the development of therapies to address a range of rare and infectious diseases and includes BioNTech&#8217;s broad pipeline includes mRNA-based immune activators, antigen-targeting T-cells and antibodies, and defined immunomodulators of various immune cell mechanisms. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">The External Products Sales of JPT Peptide Technologies GmbH CGU includes the distribution of innovative peptide-based products to external customers.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">CGU Immunotherapies</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The recoverable amount of the CGU Immunotherapies has been determined based on a value in use calculation using cash flow projections from financial budgets approved by the Management Board covering a fifteen-year period. The projected cash flows have been updated to reflect the near-term effect from<font style="color:#000000;"> BioNTech&#8217;s COVID-19 vaccine. </font>The discount rate applied to cash flow projections is 8.9% and cash flows beyond the forecast period are extrapolated using a 1.0% growth rate that is the same as the long-term average growth rate for the biotech industry. It was concluded that the fair value less costs of disposal did not exceed the value in use. As a result of the analysis, management did not identify an impairment for this CGU.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-46</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">CGU External Product Sales of JPT Peptide Technologies GmbH</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The recoverable amount of the CGU External Product Sales of JPT Peptide Technologies GmbH has been determined based on a value in use calculation using cash flow projections from financial budgets approved by senior management covering a ten-year period. The discount rate applied to cash flow projections is 7.9% and cash flows beyond the forecast period are extrapolated using a 1.0% growth rate which is in line with industry standard. It was concluded that the fair value less costs of disposal did not exceed the value in use. As a result of the analysis, management did not identify an impairment for this CGU.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Key assumptions used in value in use calculations and sensitivity to changes in assumptions</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The calculation of value in use for both CGUs, Immunotherapies and External Product Sales of JPT Peptide Technologies GmbH, is most sensitive to the following assumptions:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.14%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Discount rates</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.14%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Growth rates used to extrapolate cash flows beyond the forecast period</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rates &#8722; Discount rates represent the current market assessment of the risks specific to the CGU, taking into consideration the time value of money and individual risks of the underlying assets that have not been incorporated in the cash flow estimates. The discount rate calculation is based on the specific circumstances of the Group and the respective CGU. It is derived from its weighted average cost of capital (WACC). The WACC takes into account both debt and equity. The cost of equity is derived from the expected return on investment by the Group&#8217;s investors. The cost of debt is based on the interest-bearing borrowings the Group is obliged to service. CGU-specific risk is incorporated by applying individual beta factors. The beta factors are evaluated annually based on publicly available market data. Adjustments to the discount rate are made to factor in the specific amount and timing of the future tax flows in order to reflect a pre-tax discount rate.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An increase in the discount rate to 9.4% (i.e., +1.5%point) in the CGU External Product Sales of JPT Peptide Technologies GmbH would result in a goodwill impairment as of October 1, 2020. With respect to the CGU Immunotherapies, no reasonable rise in the discount rate would result in an impairment.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Growth rate estimates &#8722; Rates are based on published industry research. Management recognizes that the speed of technological change and the possibility of new entrants (further market approvals) can have a significant impact on growth rate assumptions. The effect of new entrants is not expected to have an adverse impact on the forecasts, but could yield a reasonably possible alternative to the estimated long-term growth rate of 1.0%.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to both CGUs, no reasonable reduction in the growth rate estimate would result in an impairment. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In general, BioNTech concluded that no reasonable possible change of key assumptions on which the calculation of the recoverable amount is based would cause the carrying amount of the CGU to exceed its recoverable amount.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intangible Assets not yet Available for Use</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets not yet available for use did not exist in the years ended December&#160;31, 2020 and December&#160;31, 2019.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Non-Current assets by Region</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and December&#160;31, 2019, non-current assets comprised &#8364;89.2&#160;million respectively &#8364;3.8&#160;million intangible assets, property, plant and equipment, right-of-use assets and other assets of our subsidiaries incorporated in the United States respectively. The remaining non-current assets relate to subsidiaries incorporated in Germany.&nbsp;&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Financial Assets and Financial Liabilities</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.1</font></p></td>
<td valign="top">
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Capital Risk Management</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech&#8217;s capital management objectives are designed primarily to finance the Group&#8217;s growth strategy.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group&#8217;s controlling committee reviews the total amount of cash of the Group on a weekly basis. As part of this review, the committee considers the total cash and cash equivalents, the cash outflow, currency translation differences and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-47</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">refinancing activities. The Group monitors cash using a burn rate. The cash burn rate is defined as the average monthly net cash flow from operating and investing activities during a financial year.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at banks and on hand</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,210,209</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;519,149</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,210,209</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;519,149</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In meeting its financing objectives, the Group negotiates and enters into research cooperation agreements. In general, the aim is to maximize the financial resources available for further research and development projects.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech is not subject to externally imposed capital requirements. BioNTech&#8217;s capital management objectives were achieved in the reporting year.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No changes were made in the objectives, policies or processes for managing cash during the years ended December&#160;31, 2020 and December&#160;31, 2019. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.2</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Categories of Financial Instruments</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial assets at amortized cost</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Set out below, is an overview of financial assets, other than cash and cash equivalents, held by the Group as of the dates indicated: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="4" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial assets at amortized cost</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade receivables</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;165,468</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;11,913</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other financial assets</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137,234</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,680</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;302,702</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;13,593</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">302,702</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,593</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, other financial assets mainly include advance-payments received by BioNTech&#8217;s collaboration partner on future deliveries and payable to BioNTech. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial liabilities: Financial liabilities at amortized cost (including Interest-bearing loans and borrowings and other financial liabilities)</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Set out below, is an overview of financial liabilities, other financial liabilities and trade payables held by the Group as of the dates indicated: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="4" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Interest-bearing loans and borrowings</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Maturity</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;84,158</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;57,611</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible note - host contract</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">08/28/2024</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,457</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.50% &#8364; 50,000,000 secured bank loan</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/21/2026</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,176</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.15% &#8364; 10,000,000 secured bank loan</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/30/2027</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,032</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,000</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.08% &#8364; 9,450,000 secured bank loan</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/30/2028</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,877</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,600</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.90% &#8364; 3,528,892.48 secured bank loan</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">05/30/2039</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,489</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;240,189</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;74,211</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,142</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,307</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">231,047</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,904</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-48</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="4" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other financial liabilities</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Derivatives not designated as hedging instrument</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible note - embedded derivative</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;30,903</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial liabilities at fair value through profit or loss</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">572</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total financial liabilities at fair value</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;31,475</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other financial liabilities at amortized cost, other than interest-bearing loans and borrowings</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade payables</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,288</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,498</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other financial liabilities</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,076</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,352</p></td>
</tr>
<tr>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total other financial liabilities at amortized cost, other than interest-bearing loans and borrowings</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;176,364</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;30,850</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total other financial liabilities</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;207,839</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;30,850</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176,363</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,850</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,476</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="4" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total financial liabilities</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest-bearing loans and borrowings</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;240,189</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;74,211</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other financial liabilities</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;207,839</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;30,850</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;448,028</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;105,061</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">185,505</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,157</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262,523</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,904</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Interest-Bearing Loans and Borrowings</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2.15% and 2.08% Secured Bank Loan</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech maintains two secured loans with Deutsche Bank AG, or Deutsche Bank, to finance the buildouts of the JPT Peptide Technologies GmbH facility and BioNTech Innovative Manufacturing Services GmbH facility. The &#8364;10.0&#160;million secured credit facility, entered into with Deutsche Bank by the subsidiary BioNTech Innovative Manufacturing Services GmbH, bears interest at a rate of 2.15% and matures on December 30, 2027. The loan is repayable in equal quarterly installments of &#8364;0.3&#160;million commencing on June 30, 2020. As of December 31, 2020, the full amount under this facility is drawn down and the first three scheduled repayments have occurred. The &#8364;9.45&#160;million secured credit facility, entered into with Deutsche Bank by the subsidiary JPT Peptide Technologies GmbH, bears interest at a rate of 2.08% and matures on September 30, 2028. The loan is repayable by quarterly installments of &#8364;0.3&#160;million commencing on September 30, 2020. As of December 31, 2020, the full amount under this facility is drawn down and the first two scheduled repayments have occurred. Each of these facilities is secured by liens over property. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">EIB Manufacturing Financing &#8211; 3.50% Secured Bank Loan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2020, BioNTech entered into an agreement with the EIB for a &#8364;100.0&#160;million credit facility to partially support the development of BNT162 and fund expansion of the manufacturing capacity to provide worldwide supply of BNT162 in response to the COVID-19 pandemic. The credit consists of (i) a term loan in the amount of &#8364;50 million that may be drawn in a single tranche upon the achievement of certain milestone events (Credit A), and (ii) a term loan in the amount of &#8364;50.0&#160;million that may be drawn in a single tranche (Credit B). Credit B may only be drawn down after Credit A has been drawn down and upon the achievement of certain milestone events. The financing arrangement is to be secured by way of liens over certain of our property. On December 21, 2020, &#8364;50.0&#160;million from Credit A was drawn down. Interest is payable on the outstanding balance of Credit A at the cash interest fixed rate of 1% per annum quarterly in arrears, plus deferred interest at fixed rate of 2.5% per annum. The nominal amount must be repaid on December 21, 2026. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-49</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">June 2020 Private Placement &#8211; Convertible Note</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A fund associated with Temasek Capital Management Pte. Ltd., or Temasek, and another accredited investor, contributed a private investment which closed as of August 28, 2020 following the satisfaction of customary closing conditions. The private placement includes an investment in ordinary shares (see Note 16) and a &#8364;100.0&#160;million investment in a 4-year mandatory convertible note with a coupon of 4.5% per annum and a conversion premium of 20% above its reference price. As of closing, the convertible note has been classified as a financial liability according to IAS 32 because the conversion features of the note lead to a conversion into a variable number of shares and is measured at amortized costs since the fair value option was not applied. On initial recognition, the financial liability was measured at the present value of the contractually determined future cash flows discounted at the effective interest rate of 9.0%. The financial liability is subsequently measured at amortized cost by using the effective interest rate method until extinguished upon conversion. The conversion features provided for in the contract were identified as a combined embedded derivative since they share the same risk exposure and are interdependent. The embedded derivative was bifurcated from the convertible note, as host contract, and is recognized as a separate financial instrument. Based on the classification as derivative, the instrument is measured at fair value through profit and loss until it is extinguished upon conversion. The fair value of the embedded derivative is determined by modeling the stock price movement using the Cox-Rubinstein binomial tree model to derive the value of the conversion right. The primary inputs used in the model include stock price volatility, credit spreads, risk-free interest rate and foreign exchange forward rates. Stock price volatility is based on implied volatility for BioNTech, credit risk is model implied and adjusted for movement in credit spreads for B-rated corporates at each valuation date, the risk-free interest rate is based on currency specific time congruent IBOR and swap rates whereas the foreign exchange forward rates are based on observable market data.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other Financial Liabilities at Amortized Cost</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other financial liabilities at amortized cost mainly include provision for outstanding services and obligations derived from license agreements as well as CRO and CMO contracts. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.3</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fair Values</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair values of cash and cash equivalents, trade receivables, trade payables and other current financial assets and liabilities approximate their carrying amounts as of December&#160;31, 2020, largely due to the short-term maturities of these instruments.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The liabilities measured at amortized cost include four fixed-interest rate loans as well as a recently issued convertible note. As of December&#160;31, 2020, the carrying value approximates their fair values as there have been no significant changes in relevant interest rates since the inception of the respective loans and note. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair values of financial instruments measured at fair value are reassessed on a quarterly basis. The valuation technique used for measuring the fair value of the embedded derivative is based on significant observable inputs (Level 2).</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, the fair value adjustment derived from remeasuring the embedded derivative was recognized as finance expenses in profit or loss and amounted to &#8364;17.3&#160;million. The initial fair value of the contingent consideration determined at acquisition remains valid since no changes of the underlying performance criteria have occurred.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.4</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Instruments Risk Management Objectives and Policies</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group&#8217;s financial liabilities comprise of bank loans, lease liabilities, trade and other payables as well as the recently issued convertible note. The main purpose of these financial liabilities is to enable the Group&#8217;s operations. The Group&#8217;s principal financial assets include mainly cash and trade receivables that derive directly from its operations.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group is exposed to market risk, credit risk and liquidity risk. The Group&#8217;s Management Board oversees the management of these risks. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The controlling committee provides assurance to the Group&#8217;s Management Board that the Group&#8217;s financial risk activities are governed by appropriate policies and procedures and that financial risks are identified, measured and managed in accordance with the Group&#8217;s policies and risk objectives. The Management Board reviews and agrees policies for managing each of these risks, which are summarized below.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-50</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.5</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Market </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">R</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">isk</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate due to changes in market prices. Market risk comprises of three types of risk: interest risk, foreign currency risk and other price risk. Financial instruments affected by market risk include cash and cash equivalents. Interest risk as well as other price risk are not considered as risks for the Group.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The sensitivity analysis in the following sections relate to the position as of December&#160;31, 2020 and December&#160;31, 2019.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no material changes in the Group&#8217;s market risk exposures or changes in the way risk was managed and valued during the periods.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Foreign Currency Risk</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The Group&#8217;s exposure to the risk of changes in foreign currency rates relates primarily to the Group&#8217;s operating activities (when revenue or expense is denominated in a foreign currency).</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to reduce exchange rate risk, BioNTech makes every effort to generate expenses and income in the same functional currency. The Group does not hedge exchange rate risks.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amount of the monetary assets (the Group&#8217;s cash and cash equivalents) of BioNTech denominated in foreign currencies at the dates indicated are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.82%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.82%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. dollar Bank accounts</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;673,545</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;213,913</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other financial assets in U.S. dollar</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,573</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.82%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial liabilities in U.S. dollar</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,821</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;686,297</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;213,913</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables demonstrate the sensitivity to a reasonably possible change in U.S. dollar exchange rates, with all other variables held constant. The impact on the Group&#8217;s profit before tax is due to changes in the fair value of monetary assets. The Group&#8217;s exposure to foreign currency changes for all other currencies is not material.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">1 &#8364; =</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Closing rate</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average rate</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Currency</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Country</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. dollar</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2271</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1234</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1422</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1195</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change in U.S. dollar rate</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Effect on loss before tax</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Effect on pre-tax equity</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+5 %</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(32,491)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(32,681)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-5%</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;35,911</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;36,121</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-right:solid 1pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-left:solid 1pt #70AD47; border-right:solid 1pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+5 %</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-left:solid 1pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-right:solid 1pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(10,186)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-left:solid 1pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(10,186)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-5%</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;11,259</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;11,259</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.6</font></p></td>
<td valign="top">
<p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Credit Risk Management</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Credit risk is the risk that a counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The Group is exposed to credit risk from its operating activities, including deposits with banks and financial institutions, foreign exchange transactions and trade accounts receivable.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Trade Receivables and Contract Assets</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group&#8217;s exposure to credit risk of trade receivables and contract assets is primarily on transactions with corporate customers in the biopharma/biotech industry that operate in Germany or in the United States as well as <font style="color:#231F20;">governments</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font>which are BioNTech&#8217;s customers established in connection with progressing the commercial activities of the Group with respect to BioNTech&#8217;s COVID-19 vaccine. An analysis of the aging of receivables and the creditworthiness of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-51</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">customers is used to evaluate this risk at each reporting date. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group follows risk control procedures to assess the credit quality of the customers taking into account their financial position, past experience and other factors. The compliance with credit limits by corporate customers is regularly monitored by </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the outstanding trade receivables were mainly due from BioNTech&#8217;s collaboration partner Pfizer as well as the German government. To a smaller extent, BioNTech&#8217;s other customers are medical universities, other public institutions and peers in the biopharma industry, which all have a very high credit rating. Due to this customer portfolio, the credit risk on trade receivables and contract assets is very low. BioNTech has not incurred bad debt expense and does not expect that this will change with respect to the trade receivables recognized as of December 31, 2020. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally, trade receivables are written off if past due for more than one year and are not subject to enforcement activity. The maximum exposure to credit risk at the reporting date is the carrying value of each class of financial assets disclosed in Note 12.2. The expected credit risk on trade accounts receivables and other financial assets was estimated to be not material as of December 31, 2020 as well as December 31, 2019. The Group does not hold collateral as security. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Credit risk from balances with banks and financial institutions is managed by the Group&#8217;s controlling department in accordance with the Group&#8217;s policy. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Credit risk stemming from cash and cash equivalents is very low due to its demand feature and the high credit rating of the respective banks.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group&#8217;s maximum exposure to credit risk for the components of the consolidated statements of financial position as of December&#160;31, 2020 and December&#160;31, 2019 are the carrying amounts as illustrated in Note 12.1.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.7</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Liquidity Risk</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally, BioNTech has relied on the financing from shareholders and collaborators in order to ensure sufficient liquidity. Lack of external financial support could pose a risk of going concern. The liquidity management of BioNTech ensures the availability of cash and cash equivalents for operational activities and further investments through appropriate budget planning. In addition, a sufficient level of cash and cash equivalents, which is managed centrally, is always maintained to finance the operational activities.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group monitors liquidity risks using a liquidity planning tool.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ultimately, the responsibility for liquidity risk management lies with the Management Board, which has established an appropriate approach to managing short-, medium- and long-term financing and liquidity requirements. BioNTech manages liquidity risks by holding appropriate reserves, as well as by monitoring forecasted and actual cash flows and reconciling the maturity profiles of financial assets and liabilities.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risk Concentration</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentrations arise when a number of counterparties are engaged in similar business activities, or activities in the same geographical region, or have economic features that would cause their ability to meet contractual obligations to be affected similarly by changes in economic, political or other conditions. Concentrations indicate the relative sensitivity of the Group&#8217;s performance to developments affecting a particular industry.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to avoid concentrations of risk, the Group&#8217;s policies and procedures include specific guidelines to focus on the maintenance of an effective diversification in the sources of funding and distribution of cash deposits. Identified concentrations of credit risks are controlled and managed accordingly.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-52</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturity profile of the Group&#8217;s financial liabilities based on contractual undiscounted payments is summarized as follows:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2020</p></td>
<td colspan="4" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Less than 1 year</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1 to 5 years</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">More than 5 years</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest bearing loans and borrowings</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;3,173</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;12,643</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;66,730</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;82,546</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade and other payables</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,288</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;102,288</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,525</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,283</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,780</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;107,588</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">572</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;572</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other financial liabilities</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,076</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;74,076</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;188,062</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;39,926</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;139,082</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;367,070</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The mandatory convertible note, which was issued during the year ended December&#160;31, 2020 and which is expected to be settled in equity is excluded from the table above. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.8</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Changes in Liabilities arising from Financing Activities</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">January 1,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">New leases and disposals</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reclassification</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current obligations under lease contracts</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;3,485</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(12,743)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,719</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;8,684</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;3,982</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;6,127</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current obligations under lease contracts</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,126</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,331</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,444)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,982)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">78,031</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest-bearing loans and borrowings</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,600</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140,847</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,416)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">156,031</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible note - embedded derivative</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,614</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,289</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">30,903</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;74,211</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;141,718</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;35,050</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;4,240</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15,873</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;271,092</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">January 1,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">New leases and disposals</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reclassification</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current obligations under lease contracts</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,134</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(3,061)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,484</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,928</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;3,485</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current obligations under lease contracts</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,618</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,436</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,928)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">54,126</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest-bearing loans and borrowings</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,600</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,000</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16,600</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;56,352</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7,939</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;9,920</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;74,211</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">13</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Inventories</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials and supplies</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;44,283</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;8,201</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unfinished goods</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,380</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,888</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">457</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">633</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;64,120</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;11,722</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech has not pledged any inventories as securities for liabilities.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-53</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">14</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#000000;">Other</font><font style="color:#000000;"> Assets</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepayments on inventories</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,845</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">351</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepayments related to CRO and CMO contracts</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,140</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales tax receivable</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,155</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,536</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepayments related to service contracts</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,825</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,046</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,182</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;62,011</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;9,069</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,966</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,069</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,045</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Deferred Expenses</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred expenses from insurance contracts</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;13,845</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,758</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred expenses from CRO and CMO contracts</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,725</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,431</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,104</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;28,001</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;5,862</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,001</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,862</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16</font></p></td>
<td valign="top">
<p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Issued Capital and Reserves</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 18, 2019, BioNTech effected a 1:18 share split by issuing 206,595,492 shares by way of a capital increase from its own funds; thus, no outside proceeds were received. This capital increase came into effect upon registration with the commercial register (<font style="font-style:italic;">Handelsregister</font>). The accompanying consolidated financial statements and notes to the consolidated financial statements give retroactive effect to the share split for all periods presented. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Capital transactions during the year ended December&#160;31, 2020</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, the issued share capital of BioNTech increased by &#8364;14.0&#160;million. Each share has a nominal value of &#8364;1.00. As a result of the financing transactions, treasury shares decreased by &#8364;0.7&#160;million and capital reserve increased by &#8364;861.0&#160;million. Costs of &#8364;33.2&#160;million related to these equity transactions were recorded in equity as deduction from the capital reserve. The financing transactions that occurred during year ended December&#160;31, 2020 were as follows: </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Shanghai Fosun Pharmaceuticals (Group) Co., Ltd</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the BNT162 program, BioNTech entered a strategic alliance with Fosun Pharma to develop COVID-19 vaccine candidates in China. Fosun Pharma agreed to make an equity investment of &#8364;45.6&#160;million ($50.0&#160;million) for 1,580,777 ordinary shares in BioNTech via Fosun Industrial Co., Limited, Hong Kong. The increase in share capital with a nominal amount of &#8364;1.6&#160;million was subject to execution of share subscription documentation and approval from regulatory authorities in China and became effective with the registration with the commercial register (<font style="font-style:italic;">Handelsregister</font>) on April 23, 2020. As a result of the transaction the capital reserve increased by &#8364;44.0&#160;million.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Pfizer Inc., New York, New York, United States</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the collaboration between BioNTech and Pfizer, for the co-development of BNT162, Pfizer agreed to make an equity investment of &#8364;103.9&#160;million ($113.0&#160;million). The issuance of 2,377,446&#160;ordinary shares with the nominal amount of &#8364;&#160;2.4&#160;million was registered with the commercial register (<font style="font-style:italic;">Handelsregister</font>) on May 5, 2020. As a result of the transaction the capital reserve increased by &#8364;101.5&#160;million. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Neon Therapeutics, Inc., Cambridge, Massachusetts, United States</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech acquired Neon by issuing 1,935,488 ADS representing BioNTech&#8217;s ordinary shares with the nominal amount of &#8364;&#160;1.9&#160;million to former stockholders of Neon in the Merger. The capital increase was registered with the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-54</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercial register (</font><font style="font-style:italic;">Handelsregister</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) on May 8, 2020. As a result of the transaction the capital reserve increased by &#8364;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.6</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;million</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Global Offering</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 27, 2020 BioNTech increased its share capital by &#8364;5.5&#160;million ($6.4&#160;million) in conjunction with the underwritten offering of 5,500,000 ADS each representing one of BioNTech&#8217;s ordinary shares at a public offering price of $93.00 per ADS (&#8220;Underwritten Offering&#8221;). On August 27, 2020, following the Underwritten Offering, BioNTech increased its share capital by additional &#8364;16&#160;thousand ($19&#160;thousand) in conjunction with the rights offering of 16,124 ADS each representing one of BioNTech&#8217;s ordinary shares at a public offering price of $93.00 per ADS (&#8220;Rights Offering&#8221;). The Underwritten Offering and the Rights Offering are part of a single, global offering which BioNTech refers to as the Global Offering. The gross proceeds of the Global Offering were &#8364;436.3&#160;million ($513.0&#160;million) including &#8364;5.5&#160;million increase in share capital and &#8364;430.8&#160;million increase in capital reserve. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">June 2020 Private Placement &#8211; Equity Investment</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A fund associated with Temasek Capital Management Pte. Ltd., or Temasek, and another accredited investor, contributed a private investment. The private placement includes an investment in a 4-year mandatory convertible note (see Note 12) and an investment of &#8364;123.9&#160;million in ordinary shares. The issuance of 2,595,996&#160;ordinary shares with the nominal amount of &#8364;&#160;2.6&#160;million was registered with the commercial register (<font style="font-style:italic;">Handelsregister</font>) on September 8, 2020. As result of the transaction the capital reserve increased by &#8364;121.3&#160;million.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">At-The-Market Offering Program</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, <font style="color:#000000;">BioNTech </font>entered into a sales agreement (&#8220;Sales Agreement&#8221;) with Jefferies LLC and SVB Leerink LLC, as sales agents, to establish an at-the-market offering program, pursuant to which BioNTech may sell, from time to time, ADS representing ordinary shares for aggregate gross proceeds of up to $500.0&#160;million. During the year ended December&#160;31, 2020, BioNTech sold 735,490 ADSs, each representing one of its ordinary shares that had previously been held in treasury, under the Sales Agreement for aggregate gross proceeds of &#8364;76.5&#160;million ($92.9&#160;million). Re-issuing 735,490 ordinary shares was registered as decrease of &#8364;0.7&#160;million in treasury shares. As a result of the transaction the capital reserve increased by &#8364;75.8&#160;million. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Capital transactions during the year ended December&#160;31, 2019</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2019, the issued share capital of BioNTech increased by &#8364;39.0&#160;million. Each share has a nominal value of &#8364;1.00. As a result of the financing transactions the capital reserve increased by &#8364;359.2&#160;million. Costs of &#8364;16.6&#160;million related to these equity transactions were recorded in equity as deduction from the capital reserve. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2019, BioNTech issued 5,088,204 shares and increased its share capital by &#8364;5.1&#160;million. The cash investment of &#8364;80.0&#160;million was received in 2018. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 14, 2019, BioNTech acquired the remaining 5.5% of non-controlling interests in BioNTech Cell &amp; Gene Therapies GmbH previously held by Eli Lilly Nederland B.V. in exchange for issuing 2,374,794 new ordinary shares with an imputed nominal value of &#8364;1.00 each. This acquisition was recognized within equity and resulted in the derecognition of the non-controlling interest of &#8364;0.7&#160;million as well as an increase in share capital of &#8364;2.4&#160;million. The net effect of the transaction of &#8364;1.6&#160;million was recognized as a decrease in capital reserve. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the share capital issued in 2019, &#8364;12.5&#160;million related to a new financing round (referred to as the Series B round). As part of the Series B round, 12,465,288 ordinary shares (excluding 5,524,506 ordinary shares which were issued to a Hong Kong-based investor and subsequently transferred to BioNTech for no consideration; these shares are held as treasury shares) were issued to certain new and existing shareholders. As a result of the Series B round, the capital reserve increased by &#8364;186.1&#160;million.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 30, 2019, BioNTech entered into agreements with the Bill &amp; Melinda Gates Foundation under which BioNTech is required to perform certain research and development activities. The issuance of 3,038,674 ordinary shares with the nominal amount of &#8364;3.0&#160;million was registered with the commercial register (<font style="font-style:italic;">Handelsregister</font>) on September 26, 2019. As result of the transaction the capital reserve increased by &#8364;46.8&#160;million. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 10, 2019, BioNTech increased its share capital by &#8364;10.0&#160;million in conjunction with the Initial Public Offering. American Depositary Shares which represent ordinary shares were offered on the Nasdaq Global Select Market at </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-55</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a price of $</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.00</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. On November 6, 2019, BioNTech increased its share capital by &#8364;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;million upon the execution of the underwriter&#180;s option. American Depositary Shares which represent ordinary shares were issued at a price of $</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.00</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (under both issuances). The gross proceeds were &#8364;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143.3</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;million ($</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157.8</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;million) including &#8364;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;million increase in share capital and &#8364;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132.7</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;million increase in capital reserve</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">17</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Share-Based Payments</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2020, December&#160;31, 2019 and December&#160;31, 2018, the Group had the following share-based arrangements. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">17.1</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">BioNTech Employee Equity Plan (LTI and LTI-plus Program) (Equity-Settled)</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, BioNTech adopted the BioNTech Employee 2020 Equity Plan and the BioNTech 2020 Restricted Stock Unit Plan for North America Employees. Under the plans Restricted Cash Units, or RSUs, will be offered to employees based in Europe and the United States respectively. The plan to which employees based in Europe will be eligible, was communicated in December 2020. Since those employees obtained a valid expectation of the award as of the announcement date and started rendering services as of such date, BioNTech concluded that the service commencement date for the BioNTech Employee 2020 Equity Plan was December 17, 2020. This is the date as of which BioNTech started to recognize the expenses related to the services received. Since the BioNTech 2020 Restricted Stock Unit Plan for North America Employees had not been communicated in detail to employees based in the United States during the year ended December 31, 2020, no expenses have been recognized in the Consolidated Statements of Operations for the year ended December 31, 2020. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">BioNTech Employee 2020 Equity Plan for employees based in Europe</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Description of Share-Based Payments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The BioNTech Employee 2020 Equity Plan share-based payment transaction for employees based in Europe includes two programs, LTI and LTI-plus. The LTI program will be offered to all employees. The LTI-plus program intends to compensate employees who did not participate in the ESOP. Under both programs, RSUs will be offered to employees based in Europe. Both programs are classified as equity-settled because BioNTech has the ability to determine the method of settlement. The LTI will vest annually in equal installments after four years commencing on December 15, 2020. The LTI-plus will vest annually in equal installments after two years commencing on December 15, 2020. Moreover, the LTI-plus contains a non-vesting condition concerning 50% of the granted RSUs. These units will be awarded to the participant after the FDA fully approves BNT162b2. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Measurement of Fair Values</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech estimates the grant date fair value of the awards for services received in advance of grant date based upon the share-price at the reporting date. The estimate is revised at subsequent reporting periods until the date of grant has been established (refer to Note 22). An estimate for the number of equity instruments for which service conditions are expected to be satisfied is calculated considering a retention assumption and will be revised in case material differences arise. Ultimately, a true-up to the number satisfied until Settlement Date will be recorded. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reconciliation of Outstanding Share-Options</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Restricted Stock Units (expected to be allocated)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share price (in &#8364;)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected to be allocated under LTI Program</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">252,766</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66.43</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected to be allocated under LTI-plus Program</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">396,938</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66.43</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">649,704</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">66.43</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-56</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Expense recognized in the Consolidated Statements of Operations</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of sales</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;179</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">681</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,015</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">17.</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Management Board Grant (Cash-Settled)</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the beginning of 2020, the first year following the completion of BioNTech&#8217;s initial public offering (&#8220;IPO&#8221;), the current service agreements with BioNTech&#8217;s Management Board have provided for a short-term incentive compensation of up to a maximum of fifty percent of the annual base salary for the years 2020, 2021 and 2022. The amount of such short-term incentive compensation will depend on the achievement of certain company goals in the particular fiscal year, which goals will be set uniformly for all members of the Management Board. Fifty percent of the incentive compensation will be paid promptly upon achievement of the applicable company goals (first installment), with the remaining amount payable one year later, subject to adjustment relative to the performance of the price of the American Depositary Shares representing BioNTech&#8217;s ordinary shares during that year (second installment).</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each of the three yearly awards, the second installment of the short-term incentive compensation that is dependent on the price of the American Depositary Shares representing BioNTech&#8217;s ordinary shares, represents a cash-settled share-based payment arrangement. The fair values of the liabilities are recognized over the award&#8217;s vesting period beginning as of the service commencement date (January 1, 2020) until each separate determination date and are remeasured until settlement date. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, the Group recognized share-based payment expenses of &#8364;0.3&#160;million as research and development expenses and of &#8364;0.4&#160;million as general and administrative expenses in the consolidated statements of operations and &#8364;0.7&#160;million of other financial liabilities in the statements of financial position as of December 31, 2020.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">17.3</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Management Board Grant (Equity-Settled)</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Description of Share-Based Payments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From the beginning of 2020, the first year following the completion of BioNTech&#8217;s IPO, until the end of the term of the Management Board member&#8217;s employment agreement, the service agreements with BioNTech&#8217;s Management Board provide for a long-term incentive compensation in terms of a yearly grant of options to purchase BioNTech shares. The right to receive options in 2020, 2021 and 2022 represents an equity-settled share-based payment arrangement. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The options allocated each year will be subject to the terms, conditions, definitions and provisions of the ESOP and the applicable option agreement thereunder. The number of options to be allocated each year to Prof. Ugur Sahin, Sean Marett, Dr. Sierk Poetting, Dr. &#214;zlem T&#252;reci and Ryan Richardson is to be calculated based on a value of &#8364;750,000, &#8364;300,000, &#8364;300,000, &#8364;300,000 and &#8364;260,000, respectively, in each case divided by the amount by which a certain target share price exceeds the exercise price. The value used to calculate the number of options for Ryan Richardson increases to &#8364;280,000 for the year 2022.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The allocation of the number of issued options in 2020 occurred as of February 13, 2020 (allocation date). As of December 31, 2020, the assessment about options expected to be granted in 2021 and 2022 was based on estimated allocation dates in the middle of the years 2021 and 2022, respectively. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-57</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The share options allocated and expected to be allocated to BioNTech&#8217;s Management Board as of the dates indicated are presented in the tables below. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share options (expected to be allocated)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average exercise price (&#8364;)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted as of allocation date February 13, 2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">248,096</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.32</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected to be allocated as of estimated allocation date 2021</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,422</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.26*</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected to be allocated as of estimated allocation date 2022</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,463</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.27*</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">451,981</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">45.89</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Valuation parameter derived from the Monte-Carlo simulation model</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the awards with estimated allocation dates the numbers of options expected to be allocated have been derived from the Monte-Carlo simulation model. Those will be adjusted until the actual allocation has occurred and the number of options granted has ultimately been determined. The options will vest annually in equal installments over four years commencing on the first anniversary of the allocation date and will be exercisable four years after the allocation date.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The options will be subject to the terms, conditions, definitions and provisions of the ESOP and the applicable option agreement thereunder. The vested options can only be exercised if and to the extent that each of the following performance criteria has been achieved: (i) at the time of exercise, the current price is equal to or greater than the threshold amount (that is, the exercise price, provided that such amount increases by seven percentage points on each anniversary of the allocation date); (ii) at the time of exercise, the current price is at least equal to the target price (that is, (a) for the twelve-month period starting on the fourth anniversary of the allocation date, $8.5 billion divided by the total number of the ordinary shares outstanding immediately following the initial public offering (other than ordinary shares owned by BioNTech), and (b) for each twelve-month period starting on the fifth or subsequent anniversary of the allocation date, 107% of the target share price applicable for the prior twelve-month period); and (iii) the closing price for the fifth trading day prior to the start of the relevant exercise window is higher than the exercise price by at least the same percentage by which the Nasdaq Biotechnology Index or a comparable successor index as of such time is higher than such index was as of the last trading day before the allocation date. The options expire ten years after the allocation date. If they have not been exercised by that date, they will lapse without compensation.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Measurement of Fair Values</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Monte-Carlo simulation model has been used to measure the fair values at the (estimated) allocation dates of the Management Board Grant. This model incorporates the impact of the performance criteria regarding share price and index development described above. The parameters used for measuring the fair values as of the respective (estimated) allocation dates were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Allocation date February 13, 2020</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated allocation date&nbsp;&nbsp;2021</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated allocation date 2022</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average fair value*</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;10.83</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;26.85</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;26.61</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average share price</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;28.20</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 66.43*</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 66.43*</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;28.32</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 67.26*</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 67.27*</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility (%)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36.6%</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.0%</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40.7%</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (years)*</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.75</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.01</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.05</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate (%)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.61 %</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.88%</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.88%</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Valuation parameter derived from the Monte-Carlo simulation model</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The exercise of the option rights in accordance with the terms of the ESOP gives the Management Board members the right to obtain shares against payment of the exercise price. The per share exercise price of the options is the Euro equivalent of the arithmetic mean of the closing prices of the ten last trading days prior to the allocation date. For the award allocated as of February 13, 2020, the exercise price has been determined to be $30.78 (&#8364;28.32). For the awards with estimated allocation dates <font style="color:#231F20;">the exercise prices </font>of <font style="color:#231F20;">options </font>expected to be allocated have been derived from the Monte-Carlo simulation model.<font style="color:#231F20;"> Those will be adjusted until the actual allocation has occurred and the exercise price has ultimately been </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-58</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;">determined.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Expected volatility was based on an evaluation of the historical volatilities of comparable companies over the historical period commensurate with the expected option term. The expected term was based on general optionholder behavior for employee options. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reconciliation of Outstanding Share-Options</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The share options allocated and expected to be allocated under the Management Board Grant were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Allocation date February 13, 2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share options</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">outstanding</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average exercise price (&#8364;)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prof. Ugur Sahin, M.D.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,420</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.32</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sean Marett</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,968</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.32</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Sierk Poetting</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,968</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.32</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. &#214;zlem T&#252;reci, M.D.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,968</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.32</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ryan Richardson</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,772</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.32</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated allocation date 2021</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share options</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">outstanding (expected to be allocated)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average exercise price (&#8364;)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prof. Ugur Sahin, M.D.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,826</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.26*</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sean Marett</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,930</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.26*</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Sierk Poetting</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,930</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.26*</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. &#214;zlem T&#252;reci, M.D.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,930</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.26*</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ryan Richardson</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,806</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.26*</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Valuation parameter derived from the Monte-Carlo simulation model</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated allocation date 2022</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share options</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">outstanding (expected to be allocated)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average exercise price (&#8364;)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prof. Ugur Sahin, M.D.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,817</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.27*</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sean Marett</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,927</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.27*</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Sierk Poetting</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,927</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.27*</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. &#214;zlem T&#252;reci, M.D.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,927</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.27*</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ryan Richardson</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,865</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.27*</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Valuation parameter derived from the Monte-Carlo simulation model</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the share options allocated and expected to be allocated had a remaining weighted-average expected life of 4.63 years.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Expense recognized in the Consolidated Statements of Operations</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The expenses recognized for employee services received during the periods indicated are shown in the following table: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,514</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,246</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,760</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-59</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">17</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4</font></p></td>
<td valign="top">
<p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Chief Executive Officer Grant (Equity-Settled)</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Description of Share-Based Payments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2019, BioNTech granted Prof. Ugur Sahin, M.D. an option to purchase 4,374,963 ordinary shares, subject to Prof. Sahin&#8217;s continuous employment with BioNTech. The options&#8217; exercise price per share is the Euro translation of the public offering price from BioNTech&#8217;s initial public offering, &#8364;13.60 ($15.00). The option vests annually in equal installments after four years commencing on the first anniversary of the initial public offering and will be exercisable four years after the initial public offering. The option is subject to the terms, conditions, definitions and provisions of the ESOP and the applicable option agreement thereunder. The vested option rights can only be exercised if and to the extent that each of the following performance criteria has been achieved: (i) at the time of exercise, the current price is equal to or greater than the threshold amount (that is, the exercise price, provided that such amount increases by seven percentage points on each anniversary of the allocation date); (ii) at the time of exercise, the current price is at least equal to the Target Price (that is, (a) for the twelve-month period starting on the fourth anniversary of the allocation date, $8.5 billion divided by the total number of the shares outstanding immediately following the initial public offering (other than shares owned by BioNTech), and (b) for each twelve-month period starting on the fifth or subsequent anniversary of the allocation date, 107% of the target share price applicable for the prior twelve-month period); and (iii) the closing price for the fifth trading day prior to the start of the relevant exercise window is higher than the exercise price by at least the same percentage by which the Nasdaq Biotechnology Index or a comparable successor index as of such time is higher than such index was as of the last trading day before the allocation date. The option rights can be exercised up to ten years after the allocation date. If they have not been exercised by that date, they will lapse without compensation.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Measurement of Fair Values</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Monte-Carlo simulation model has been used to measure the fair value at grant date of the Chief Executive Officer Grant. This model incorporates the impact of the performance criteria regarding share price and index development described above in the calculation of the award&#8217;s fair value at grant date. The inputs used in the measurement of the fair value at grant date of the Chief Executive Officer Grant were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant date October 10, 2019</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average fair value</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;5.63</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average share price</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;13.60</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;13.60</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility (%)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.4%</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (years)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.37</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate (%)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.52 %</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility was based on an evaluation of the historical volatilities of comparable companies over the historical period commensurate with the expected term. The expected term was based on general optionholder behavior for employee options.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reconciliation of Outstanding Share-Options</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, no further options were granted or forfeited. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the share options outstanding had a remaining weighted-average expected life of 4.12 years.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Expense recognized in the Statement of Operations</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, the Group has recognized &#8364;11.3&#160;million of share-based payment expenses as research and development expenses in the consolidated statements of operations (during the year ended December&#160;31, 2019: &#8364;3.2 million).</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Employee Stock Ownership Plan (Equity-Settled)</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Description of Share-Based Payments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 15, 2018, the Group established a share option program that grants selected employees options to receive shares in the Company. The program is designed as an ESOP. The Group has offered the participants a certain </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-60</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">number of rights (Option Rights) by explicit acceptance of the participants. The exercise of the Option Rights in accordance with the terms of the ESOP, gives the participants the right to obtain shares against payment of the exercise price. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Option Rights vest over </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">four years</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> can only be exercised if the company has executed a public offering in the United States (IPO) and when the Threshold Amount</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> is met</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Threshold Amount means the exercise price provided that such price increases by </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eight</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> percentage points on the first and then each subsequent anniversary of the Allocation Date (September 26, 2018). The Option Rights can be exercised at the latest </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eight years</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> after the Allocation Date. If they have not been exercised by that date, they will </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">forfeit</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> without compensation</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Measurement of Fair Values</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the ESOP has been measured using a binomial model. Service conditions attached to the arrangement were not taken into account in measuring the fair value.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The share options can only be exercised by the grantee if the price of the share is equal or greater to the Threshold Amount as defined in the arrangement. Moreover, the option rights can only be exercised if the IPO has occurred. Both conditions have been incorporated into the fair value at grant date.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The inputs used in the measurement of the fair values at grant date of the ESOP was as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant date</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15 November 2018</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant dates</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">between</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">February 21 -</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">April 3, 2019</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant dates</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">between</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">April 29 -</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">May 31, 2019</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant date December 1, 2019</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average fair value</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7.41</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;6.93</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7.04</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;9.49</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average share price</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;14.40</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15.72</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;16.03</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;19.84</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;10.14</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15.03</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15.39</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15.82</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility (%)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46.0%</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46.0%</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46.0%</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46.0%</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (years)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.84</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.00</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.00</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.50</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate (%)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.05%</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.05%</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.05%</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.05%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility has been based on an evaluation of the historical and the implied volatilities of comparable companies over the historical period commensurate with the expected term. The expected term has been based on general option holder behavior for employee options.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reconciliation of Outstanding Share-Options</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Set out below is an overview of changes to share options outstanding and number of ordinary shares underlying these options that occurred during the periods indicated: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share options</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">outstanding</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number of ordinary shares underlying options</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average exercise price (&#8364;)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">658,109</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,845,962</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,511</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">261,198</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.17</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,237)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(310,266)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.85</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">655,383</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11,796,894</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.23</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">655,383</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,796,894</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.23</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,491)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(170,838)</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.81</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">645,892</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11,626,056</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.23</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the share options outstanding had a remaining weighted-average expected life of 3.73 years.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-61</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The share options </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">outstanding as of December 31, 2020 issued to the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management Board Grant were as follows:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share options</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">outstanding</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number of ordinary shares underlying options</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average exercise price (&#8364;)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prof. Ugur Sahin, M.D.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,686</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,830,348</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sean Marett</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,895</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">610,110</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Sierk Poetting</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,895</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">610,110</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. &#214;zlem T&#252;reci, M.D.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108,463*</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,952,334</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ryan Richardson**</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,306***</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149,508</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*&#160;&#160;&#160;&#160;&#160;Options fully vested on March 16, 2019, however these options will not become exercisable until September&#160;16,&#160;2022.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**&#160;&#160;&#160;Ryan Richardson was appointed to the Management Board as Chief Strategy Officer (CSO) and Managing Director on January 12, 2020. The share options granted on November 15, 2018 under the Employee<font style="letter-spacing:0.05pt;"> </font>Stock Ownership Plan were granted before his appointment to the Management Board. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***&#160;Options fully vested on October 10, 2019, however these options will not become exercisable until September&#160;16,&#160;2022.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The expenses recognized for employee services received during the periods indicated are shown in the following table:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of sales</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;869</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;896</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;114</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,120</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,016</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,786</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,975</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,008</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">728</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;17,075</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;27,028</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7,641</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">18</font></p></td>
<td valign="top">
<p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Other Liabilities</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities to employees</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;24,248</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;6,710</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,379</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">780</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;28,627</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7,490</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,061</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,490</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">566</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">19</font></p></td>
<td valign="top">
<p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Leases</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.1</font></p></td>
<td valign="top">
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Amounts Recognized in the Consolidated Statements of Financial Position</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Right-of-Use Assets</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following amounts are presented as right-of-use assets within the consolidated statements of financial position as of the dates indicated: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;80,875</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;54,956</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equipment, tools and installations</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Automobiles</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Production facilities</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,202</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Advance payments</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,800</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;98,988</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;55,018</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-62</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions to the right-of-use assets during the year ended December&#160;31, 2020 were &#8364;22.1 million (during the year ended December&#160;31, 2019: &#8364;10.0&#160;million) including advanced payments of &#8364;10.8 million related to embedded leases under contract manufacturing agreements that not yet commenced. Since the advanced lease payments have already been settled, the amounts are not included in the lease liability presented below.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Lease Liability</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following amounts are included in interest-bearing loans and borrowings as of the dates indicated: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;6,127</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;3,485</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,031</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,126</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;84,158</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;57,611</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group has various lease contracts that have not yet commenced as of December&#160;31, 2020. The future lease payments for these non-cancellable lease contracts are &#8364;2.8&#160;million for the year 2021 and &#8364;10.2&#160;million for the years 2022 and beyond.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Several lease contracts include extension and termination options. These options are negoiated by management to provide flexibility in managing the leased-asset portfolio and align with the Group&#8217;s business needs. Management exercises significant judgement in determining whether these extension and termination options are reasonably certain to be exercised.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">19</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.2</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Amounts Recognized in the Consolidated Statements of Operations</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Depreciation Charge of Right-of-Use Assets</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;4,628</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;4,614</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,751</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equipment, tools and installations</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Automobiles</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Production facilities</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,613</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total depreciation charge</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;6,290</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;4,679</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,846</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on lease liabilities</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,003</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,718</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,721</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expense related to short-term leases</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(included in other expenses)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">875</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">442</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">431</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expense relating to leases of low-value assets that are not short-term leases (included in other expenses)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total amounts recognized in profit or loss</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;9,468</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;6,929</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;5,088</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">19</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.3</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Amounts recognized in the Consolidated Statements of Cash Flows</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, the total cash outflow for leases amounted to &#8364;14.7 million (during the year ended December&#160;31, 2019: &#8364;4.8 million; during the year ended December&#160;31, 2018: &#8364;2.3&#160;million).</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">19.3</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Extension Options</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group has several lease contracts that include extension options. These options are negotiated by management to provide flexibility in managing the leased-asset portfolio and align with the Group&#8217;s business needs. Management exercises judgement in determining whether these extension options are reasonably certain to be exercised. The undiscounted potential future lease payments, which relate to periods after the exercise date of renewal options and are not included in lease liabilities, amount to up to &#8364;38.3 million until 2049.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-63</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">20</font><font style="margin-left:14pt;"></font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pension</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">s</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, BioNTech adopted a defined benefit pension plan through the acquisition of BioNTech Manufacturing Marburg GmbH in Germany. The defined benefit pension plan is a final salary plan for German employees, which requires contributions to be made to a separately administered fund.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The pension plan is governed by the employment laws of Germany and consists of a funded base plan and a non-funded supplement plan. The base plan through <font style="font-style:italic;">Pensionskasse</font> <font style="font-style:italic;">Hoechst</font> is a multi-employer plan. <font style="font-style:italic;">Pensionskasse</font> <font style="font-style:italic;">Hoechst</font> is a legally independent insurance company that is subject to the Insurance Supervision Act (<font style="font-style:italic;">BaFin</font>). Plan participants may elect to contribute a percentage of their income (between 1.5% and 2.5% of salary components up to the social security contribution ceiling). A &#8364;1.00 employee contribution results in an annual pension entitlement of &#8364;0.42. The aforementioned contributions include contributions to the <font style="font-style:italic;">Pensionskasse H&#246;chst</font> in the amount of &#8364;34&#160;thousand. Contributions in the amount of &#8364;0.2&#160;million are expected for the following financial year. Since the obligation of the sponsoring company is not limited to the payment of the contributions for the financial year, this is a multi-employer defined benefit plan, which is generally to be accounted for proportionally as such. However, pension fund benefits are financed in accordance with the financing methodology of the pension fund (<font style="font-style:italic;">Bedarfdeckungsverfahren</font>). Consequently, the actuarial valuation is performed to determine the present valuate of future contributions based upon the present value of future benefit obligation less plan assets for all employers and the level of the pension fund portfolio, not at the level of an individual insurer&#8217;s risk. The calculation of the contribution rates is based on the future coverage of the total obligation, so that all sponsoring companies pay the same contribution rates. Accordingly, the portion of the base plan financed through <font style="font-style:italic;">Pensionskasse</font> <font style="font-style:italic;">Hoechst</font> is not accounted for as a defined benefit plan, but as a defined contribution plan. There are no minimum funding requirements. It is not possible to withdraw the funds from the multi-employer plan or to transfer them to another pension fund. It is not possible to withdraw from the pension fund. Upon expiry of the plan, any underfunding is to be made up by the employer and therefore recognized as liability in the consolidated statement of financial positions; any remaining surplus would be used for charitable purposes. Both plans have been closed so that no further employees can obtain entitlements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the German Company Pension Act (<font style="font-style:italic;">Betriebsrentengesetz</font>) applies to the pension obligation, the pensions are subject to adjustments at least every three years by the increase in the consumer price index or by the net wage development of comparable groups of employees. Therefore, the pension obligation is subject to inflation risk. In addition, there is longevity risk as the pensions are paid for life. Part of the obligations is also based on the level of salaries, so that the obligations will also increase if salaries develop more strongly than expected. Plan assets benefits from pension funds are offset. In this case, there is a risk that the external pension provider will not be able to provide the benefits to the extent expected and that the payments to be made directly by the employer will therefore increase.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the defined benefit obligation recognized in non-current provisions:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Base plan</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,140</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplement plan</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,125</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;4,265</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the components of net benefit expense recognized in the statement of profit or loss for both plans: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Service cost</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;24</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net interest expense</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;30</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current service cost is included in the personnel expenses of the various functions of the respective employees, while the net interest is recognized in finance expenses or finance income.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-64</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">summarizes</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the components of remeasurements recognized in other comprehensive income</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for both plans</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Actuarial changes arising from changes in financial assumptions</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;227</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Experience adjustments</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;210</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Set out below is an overview of changes to the defined benefit obligation during the period indicated for both plans:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Defined benefit obligations</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,029)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Service cost</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net interest expense</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Benefits paid</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Actuarial changes arising from changes in financial assumptions</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(227)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Experience adjustments</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(4,265)</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The principal assumptions used in determining the defined benefit obligation for the Group&#8217;s plans are shown below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.34%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.36%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.34%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.80%</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Price inflation</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.00%</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rate of salary increase</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.50%</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pension increases for in-payment benefits</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.75%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sensitivity analysis</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The main actuarial assumptions that are used to calculate the provisions for post-employment benefits are the discount rate and the trend for future increases in post-employment benefit payments. A reasonably possible increase, or respective decrease, in the significant actuarial assumptions would have impacted the present value of the post-employment benefit obligations as of December&#160;31, 2020 as shown below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="3" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Quantitative sensitivity analysis</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate increase 0.25%</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(282)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate decrease 0.25%</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">309</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pension increases for in payment benefits 0.25%</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">475</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pension decreases for in payment benefits 0.25%</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(447)</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Duration</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The average duration of the German obligations are 35.92 years for the base plan and 19.77 years for the supplement plan.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-65</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Expected benefit payments</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following are the expected payments or contributions to the plans in future years:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="3" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Expected payments or contributions in future years</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less than 1 year</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;29</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 to 5 years</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">317</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">More than 5 years</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">340</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;686</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font></p></td>
<td valign="top">
<p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Related Party Disclosures</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.1</font></p></td>
<td valign="top">
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Parent and Ultimate Controlling Party</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATHOS KG, Holzkirchen, Germany is the sole shareholder of AT Impf GmbH, Munich, Germany and beneficial owner of ordinary shares in BioNTech. ATHOS KG via AT Impf GmbH has de facto control over BioNTech based on its substantial shareholding, which enabled it to exercise the majority of voting rights to pass resolutions at BioNTech&#8217;s Annual General Meeting, or AGM.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.2</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Transactions with Key Management Personnel</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Key Management Personnel Compensation</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Key management personnel at BioNTech has been defined as the members of the Management Board and of the Supervisory Board. Key management personnel compensation is comprised of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation of key management personnel of the Group</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term employee benefits incurred</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,627</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,847</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,161</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term employee benefits accrued*</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">740</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based payments</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,700**</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,151</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,163</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total compensation paid to key management personnel</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;24,067</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;19,998</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7,324</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:2pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Includes the fair value of the second installment of the short-term incentive compensation, which has been classified as cash-settled share-based payment arrangement was determined pursuant to the regulations of IFRS 2 &#8220;Share-based Payments&#8221;. This table shows the pro-rata share of personnel expenses for the respective financial year that are recognized over the award&#8217;s vesting period beginning as of the service commencement date (January 1, 2020) until each separate determination date and are remeasured until settlement date.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Includes expenses from a bonus arrangement agreed with Ryan Richardson in advance of his appointment to the Management Board. During the year ended December 31, 2020, the arrangement was modified from an all-equity share-based payment arrangement into a partly cash and partly equity settled share-based payment arrangement including 4,534 ordinary shares which have not yet been issued. </p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2019, BioNTech agreed to grant Prof. Ugur Sahin, M.D., BioNTech&#8217;s co-founder and Chief Executive Officer, an option to purchase 4,374,963 ordinary shares (see Note 17). </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management Board members participate in the Group&#8217;s ESOP program (see Note 17). </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Key Management Personnel Transactions</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A number of key management personnel, or their related parties, hold positions in other companies that result in them having control or significant influence over these companies. A number of these companies have entered into transactions with the Group during the year.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group purchases various goods and services from<font style="color:#231F20;"> Translationale Onkologie an der Universit&#228;tsmedizin der Johannes Gutenberg-Universit&#228;t Mainz gemeinn&#252;tzige GmbH, or TRON, an</font> institute which was co-founded by <font style="color:#231F20;">Prof.</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Ugur </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-66</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;">Sahin, M.D., </font><font style="color:#231F20;">the</font><font style="color:#231F20;"> </font><font style="color:#231F20;">co-founder and Chief</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Executive</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Officer</font><font style="color:#231F20;"> of </font><font style="color:#231F20;">BioNTech</font><font style="color:#231F20;">. </font><font style="color:#231F20;">Prof.</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Ugur Sahin, M.D.</font><font style="color:#231F20;"> served</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">as Managing</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Director</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">at</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">TRON</font><font style="color:#231F20;letter-spacing:-0.05pt;"> </font><font style="color:#231F20;">until</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;letter-spacing:0.05pt;">September 10, </font><font style="color:#231F20;">2019</font><font style="color:#231F20;"> and </font><font style="color:#231F20;">currently</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">serves</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">as </font><font style="color:#231F20;">scientific advisor at TRON and as </font><font style="color:#231F20;">a Professor</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">of Medicine</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">at</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">University</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">of Mainz. Additionally,</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">Prof.</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Christoph</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Huber, M.D., a member</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">of our Supervisory</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Board, served</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">on TRON&#8217;s</font><font style="color:#231F20;letter-spacing:-0.05pt;"> </font><font style="color:#231F20;">supervisory</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">board</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">until</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">his</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">resignation</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">in April</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">2019. </font><font style="color:#231F20;">Prof.</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Ugur Sahin, M.D., our co-founder and Chief</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Executive</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Officer, owns a significant</font><font style="color:#231F20;"> amount of</font><font style="color:#231F20;"> shares in TRON. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate value of transactions related to key management personnel were as follows for the periods indicated:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consulting services / patent assignment</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;25</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;56</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;25</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of various goods and services from TRON</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,105</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,968</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,160</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;10,130</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;10,024</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;11,185</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The outstanding balances of transactions related to key management personnel were as follows as at the periods indicated:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consulting service provider</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TRON</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,229</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,843</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,236</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,843</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.3</font></p></td>
<td valign="top">
<p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Other Related Party Transactions</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total amount of transactions with ATHOS KG or entities controlled by it was as follows for the periods indicated:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of various goods and services from entities controlled by ATHOS KG</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,296</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,071</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,431</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and other assets from entities controlled by ATHOS KG</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,349</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,748</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;4,645</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,071</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7,179</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The outstanding balances of transactions with ATHOS KG or entities controlled by them were as follows as at the periods indicated:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATHOS KG</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;500</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;51</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;500</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;51</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None of the balances are secured and no bad debt expense has been recognized in respect of amounts owed by related parties. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Events After the Reporting Period</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 12, 2021, BioNTech and Pfizer announced that the U.S. government has exercised its option to purchase an additional 100 million doses of the Pfizer-BioNTech COVID-19 vaccine. This brings the total number of doses to be supplied by the companies to the U.S. government to 300 million.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-67</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 17, 2021, BioNTech and Pfizer announced an agreement with the European Commission (EC) to supply an additional </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million doses of COVID-19 vaccine to the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> European Union member states. The EC has the option to request supply of an additional </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million doses.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021, RSUs under the BioNTech Employee 2020 Equity Plan were offered to employees based in Europe which determined the grant date fair value. Given that the share price had increased since the plan was established, a significant true-up in fair value occurred. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021, RSUs under the BioNTech 2020 Restricted Stock Unit Plan for North America Employees were offered to employees based in the United States. As from this date, BioNTech started recognizing expenses for this plan in the Consolidated Statements of Operations. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 12, 2021, BioNTech <font style="color:#000000;">Turkey T&#305;bbi &#220;r&#252;nler Ve Klinik Ara&#351;tirma Ticaret Anonim &#350;irketi</font>, translates as BioNTech Turkey Pharmaceutical Products and Clinical Trials Trading JSC, Istanbul, Turkey, was founded and is a wholly-owned subsidiary of BioNTech SE. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-68</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>bntx-ex11_6.htm
<DESCRIPTION>EX-1.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-ex11_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 1.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Convenience Translation. The German version is authoritative</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;line-height:20pt;margin-bottom:0pt;margin-top:0pt;margin-left:2.6%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLES OF ASSOCIATION OF BIONTECH SE</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">I.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">General provisions</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#167; 1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Company name, registered office and financial year</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The name of the company is &#8220;BioNTech SE&#8221;.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The company has its seat in Mainz, Germany.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The financial year is the calendar year.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#167; 2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Purpose of enterprise</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The purpose of the company is to research and develop, as well as to manufacture and market immunological and RNA-based drugs and test methods for the diagnosis, prevention and treatment of cancer, infectious diseases and other serious diseases.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The company may undertake all transactions and actions that are expedient for serving the company&#8217;s purpose. It is also entitled to establish and acquire other companies and to invest in other companies, as well as to manage such companies or to limit itself to the administration of the investment.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#167; 3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Announcements</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;margin-left:8.66%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of the company's announcements shall be made exclusively in the German Federal Gazette (Bundesanzeiger).</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">II.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Share capital and shares</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#167; 4</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Amount and division of share capital; deviating profit participation</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The company's share capital totals EUR&#160;232,304,250.00 and is divided across 232,304,250 no-par value shares.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Any entitlement of shareholders to the right of issuance of share certificates is excluded, to the extent permitted by law or unless certification is required under the rules applicable at a stock exchange where the shares or rights or certificates representing them are admitted for trading. Global certificates for shares may be issued. Form and content of these certificates shall be determined by the Management Board.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The shares are registered shares.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(4)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">In the event of a capital increase, the profit sharing of new shares may be determined in deviation from Section 60(2) Sentence 3 German Stock Corporation Act (</font><font style="font-style:italic;color:#000000;">AktG</font><font style="color:#000000;">).</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-align:justify;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(5)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;"></font><font style="color:#000000;"></font><font style="color:#000000;">The Management Board is authorized, subject to the consent of the Supervisory Board, to increase the company&#8217;s share capital in the period up to 1</font><font style="color:#000000;">8&#160;</font><font style="color:#000000;">August 202</font><font style="color:#000000;">4</font><font style="color:#000000;"> on one occasion or on multiple occasions by up to a total of EUR</font><font style="color:#000000;">&#160;</font><font style="color:#000000;">105,818,002.00</font><font style="color:#000000;"> </font><font style="color:#000000;">by issuing up to </font><font style="color:#000000;">105,818,002</font><font style="color:#000000;"> </font><font style="color:#000000;">new, no</font><font style="color:#000000;">-</font><font style="color:#000000;">par value </font><font style="color:#000000;">registered </font><font style="color:#000000;">shares </font><font style="color:#000000;">against</font><font style="color:#000000;"> contributions in cash or in kind (Authorized Capital). In principle, the shareholders are to be granted a right of subscription. The shares may also be assumed by one or more banking institution(s)</font><font style="color:#000000;"> or one or more co</font><font style="color:#000000;">mpanies op</font><font style="color:#000000;">erating according to Section 53</font><font style="color:#000000;">(</font><font style="color:#000000;">1</font><font style="color:#000000;">)</font><font style="color:#000000;"> se</font><font style="color:#000000;">ntence 1 </font><font style="color:#000000;">Banking Act (</font><font style="font-style:italic;color:#000000;">Kreditwesengesetz</font><font style="color:#000000;">; </font><font style="font-style:italic;color:#000000;">KWG</font><font style="color:#000000;">)</font><font style="color:#000000;"> or Section 53b(</font><font style="color:#000000;">1</font><font style="color:#000000;">) sentence 1 or</font><font style="color:#000000;"> </font><font style="color:#000000;">(</font><font style="color:#000000;">7</font><font style="color:#000000;">)</font><font style="color:#000000;"> KWG</font><font style="color:#000000;"> with the requirement that the shares are offered to the company's shareholders for purchase (so-called indirect right to subscription). The Management Board is authorized to exclude the subscription right of shareholders in one or more instance(s) of a capital increase as part of the </font><font style="color:#000000;">A</font><font style="color:#000000;">uthorized </font><font style="color:#000000;">C</font><font style="color:#000000;">apital, subject to Supervisory Board approval,</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:17.32%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">to exclude fractional amounts from the subscription right,</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:17.32%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">in the case of a capital increase against cash contributions, if the issue price of the new shares is not significantly lower than the market price of the company's shares already listed on the stock exchange at the time the issue price is finally determined. However, this authorization shall only apply subject to the provision that the shares issued excluding subscription rights in accordance with Section 186(3) Sentence 4 AktG may not exceed a total of 10% of the share capital either at the time this authorization takes effect or - if this amount is lower - at the time this authorization is exercised. This limit of 10% of the share capital includes shares which are issued or disposed of during the term of this authorization until the date of its exercise in direct or equivalent application of Section 186(3) Sentence 4 AktG. Shares which are used to service bonds with convertible or option rights or convertible obligations are to be offset against the 10% limit if these bonds were issued under exclusion of shareholder subscription rights in accordance with Section 186(3) Sentence 4 AktG during the entitlement period. Treasury shares are to be offset against the 10% limit, where they were disposed of by the company during the term of this authorization with the exclusion of subscription rights pursuant to or in analogous application of Section 186(3) Sentence 4 AktG;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:17.32%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">in the case of capital increases in exchange for contributions in kind, in particular in order to be able to offer the shares to third parties when purchasing companies, parts of companies or interests in companies as well as licenses or industrial property rights;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:17.32%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">in order to grant subscription rights to new shares to holders of conversion or option rights in respect of bonds issued by the company or its subordinated domestic or foreign Group </font></p></td></tr></table></div>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a> | 14</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:17.32%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;">companies, to the extent to which they would be entitled after exercising their conversion or option rights or after fulfilling an agreed conversion obligation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:17.32%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(e)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">to implement an election dividend (</font><font style="font-style:italic;color:#000000;">scrip dividend</font><font style="color:#000000;">/share dividend) by which shareholders are given the option to contribute their dividend entitlements to the company (either in whole or part) as a contribution in kind against issuance of new shares in the company;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:17.32%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(f)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">if shares are issued to one or more investors on one or more occasions or in connection therewith to shareholders by way of co-investments (within the meaning of the </font><font style="font-weight:bold;text-decoration:underline;color:#000000;">Annex to Section 4(5)</font><font style="text-decoration:underline;color:#000000;">)</font><font style="color:#000000;"> on the basis of agreements concluded by 30 June 2020 at an issue price (including any further payment agreed under the law of obligations) of at least USD 18.10 (to this extent, the more detailed provisions of the Annex to Section 4(5) shall apply) and, in doing so, the provisions of the Annex to Section 4(5) are complied with. However, this authority to exclude the subscription right pursuant to this letter f) shall lapse if the shares of the Company or the rights or certificates representing them have been admitted to trading on a stock exchange or any other multilateral trading system,</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:17.32%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(g)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">in case shares are to be issued to a member of the Management Board of the Company or to another person who is employed by the company or one of its affiliates and a minimum holding period of at least one year and the obligation to transfer back the shares in the event that the beneficiary is not employed by the company or one of its affiliated companies for the entire duration of the holding period or any other agreed period is agreed upon. Additional restrictions with regard to the shares issued may be agreed upon,</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:17.32%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(h)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">in a capital increase effected after introduction of the Company&#8217;s shares or certificates representing them to trading on a stock exchange or a multilateral trading system, if excluding subscription rights, according to the written declaration of an internationally renowned investment bank, is expedient to the shares&#8217; successful placement in view of the requirements of eligible investors and if the discount by which the issue price of the shares may be below the current stock exchange price at the time the Management Board adopts the resolution on using authorised capital, according to such declaration, does not exceed the extent necessary for a successful placement, and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:17.32%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(i)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">in order to be able to satisfy an option to acquire additional shares or American Depositary Shares that has been agreed with the issuing banks in connection with a public offering of shares in the Company in the form of American Depositary Shares.</font></p></td></tr></table></div>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a> | 14</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;margin-left:17.32%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total number of new shares issued from the Authorized Capital and under exclusion of subscription rights pursuant to sentence 4 lit. a) to c) </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and h) </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">above may not exceed 20% of the share capital, either at the time this authorization becomes effective or &#8211; if lower &#8211; at the time it is utilized. To be counted against the aforementioned 20%-limit are: (i) those shares issued or to be issued to service conversion or option rights or conversion or option obligations or tender rights of the issuer under bonds, if the bonds have been issued during the term of this authorization up to the time of its exercise, excluding the subscription rights of shareholders, as well as (ii) treasury shares that have been disposed </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under exclusion of subscription rights during the term of this authorization (except in the case of lit. b) para (v), (vi) or (vii) of the resolution to item no. 8 of the General Meeting of 19 August 2019).</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;margin-left:17.2%;text-indent:0%;font-weight:normal;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">The new shares participate in the profits as of the beginning of the first fiscal year for which the annual financial statements have not yet been submitted to the General Meeting at the time of registration of the implementation of the capital increase. The Management Board shall be authorized, with the consent of the Supervisory Board, to determine further details of the capital increase and its implementation. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(6)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The share capital is conditionally increased by up to EUR 21,874,806.00 by issuing up to 21,874,806 new registered no-par value shares each representing a notional value of EUR 1.00 of the share capital (Conditional Capital ESOP 2017/2019). The sole purpose of the Conditional Capital ESOP 2017/2019 is the grant of rights to holders of stock options issued by the Company under the authorisation granted by the General Meeting of 18&#160;August 2017 under agenda item5.a), also in the version of such authorisation as amended by resolution of the General Meeting of 19&#160;August 2019 on agenda item&#160;6.a) (together the &#8220;Authorisation 2017/2019&#8221;). The shares shall be issued at the strike price determined in accordance with the provisions of the Authorisation 2017/2019 in the version applicable at the time of its exercise. The conditional capital increase shall only be implemented to the extent that the holders of the stock options issued by the Company under the Authorisation 2017/2019 exercise their subscription rights and the Company does not service the stock options by delivering treasury shares or by a cash payment. The new shares shall be entitled to dividends from the beginning of the previous financial year in case they are created by the exercise of subscription rights until the start of the Annual General Meeting of the Company, and otherwise from the beginning of the financial year in which they are created as a result of the exercise of the stock options.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(7)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The share capital is conditionally increased by up to EUR&#160;87,499,260.00 by issuing up to 87,499,260 new registered no-par value shares, each representing a notional value of EUR 1.00 of the share capital (Conditional Capital WSV 2019). The conditional capital increase shall only be carried out to the extent that the holders or creditors of option rights or conversion rights or those under an </font></p></td></tr></table></div>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a> | 14</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;">obligation to convert under warrant-linked or convertible bonds issued in return for cash contributions and issued or guaranteed by the Company or by a subordinate Company group</font><font style="color:#000000;"> entity up to, and including, 18</font><font style="color:#000000;"> August 2024 based on Management Board authorisation as per the shareholder resolution conferring said authorisation passe</font><font style="color:#000000;">d at the General Meeting of 19</font><font style="color:#000000;"> August 2019 avail of their option rights or conversion rights or where they are under an obligation to convert, to the extent they satisfy their obligation to convert, or to the extent that the Company exercises a right to choose to grant Company shares, in whole or in part instead of paying a monetary amount due, and to the extent cash compensation is not granted in each relevant case or treasury shares or shares of another stock-listed company are not utilised for servicing. The new shares are issued at the warrant exercise price or conversion price to be determined in each case in accordance with the aforementioned resolution granting authorisation. The new shares shall carry an entitlement to dividends from the beginning of the financial year in which they are created; as far as the law permits, the Management Board can confer dividend rights for new shares in derogation of the foregoing and of section 60(2) AktG </font><font style="color:#000000;">and also for </font><font style="color:#000000;">a financ</font><font style="color:#000000;">ial year that has already ended</font><font style="color:#000000;">. The Management Board shall be authorised, subject to Supervisory Board approval, to determine the remaining details for implementing the conditional capital increase.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(8)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">To the extent that the above paragraphs provide for authorized or conditional capital, the Supervisory Board is authorized to amend the wording of the Articles of Association after expiry of the period for utilization of the authorized capital and in accordance with the extent of capital increases carried out on the basis thereof.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">III.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The executive bodies of the company </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#167; 5</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Two-tier system</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The company has a two-tier management and supervisory system consisting of a management body (Management Board) and a supervisory body (Supervisory Board).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The company's executive bodies are the Management Board, the Supervisory Board and the General Meeting.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">IV.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Management Board</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#167; 6</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Composition</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The Management Board shall consist of at least two persons. The members of the Management Board are appointed for a maximum term of five years. Reappointments are permitted.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The number of members of the Management Board is otherwise determined by the Supervisory Board. </font></p></td></tr></table></div>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a> | 14</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;"></font><font style="color:#000000;"></font><font style="color:#000000;">The appointment of deputy members of the Management Board is permissible.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#167; 7</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Management, representation</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The members of the Management Board shall conduct the business of the company in accordance with the law, the Articles of Association and the Rules of Procedure issued by the Supervisory Board.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The company shall be represented by two members of the Management Board or by one member of the Management Board jointly with one holder of a general commercial power of representation (</font><font style="font-style:italic;color:#000000;">Prokurist</font><font style="color:#000000;">). If only one member of the Management Board is appointed, the company will be represented by this individual alone. The Supervisory Board may grant one, several or all members of the Management Board sole power of representation. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The Supervisory Board may, by resolution, authorize members of the Management Board in general or in individual cases to conclude legal transactions simultaneously for the company and as representatives of a company affiliated with the company within the meaning of Section&#160;15 AktG as well as in individual cases simultaneously for the company and as representatives of a third party.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(4)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The Supervisory Board may appoint a spokesman or a chairperson of the Management Board</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(5)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Furthermore, the Supervisory Board shall issue rules of procedure for the Management Board and shall determine in particular which types of business may only be transacted with its consent.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#167; 8</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Passing of Resolutions</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The Management Board has a quorum if all members of the Management Board are invited and at least half of its members participate in the adoption of the resolution , unless otherwise required by mandatory law. Members of the Management Board may cast their vote in writing, by telephone, by telefax or by means of electronic media.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The resolutions of the Management Board are passed by a majority of the votes cast, unless otherwise stipulated by mandatory law with abstentions not to be taken into account. In the event of a tie the chairperson shall have a casting vote, if such person has been appointed. This does not apply to a spokesman of the Management Board who may have been appointed.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">V.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Supervisory Board</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#167; 9</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Composition, term of office and remuneration</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The Supervisory Board shall comprise of four members.</font></p></td></tr></table></div>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a> | 14</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Unless the General Meeting resolves on a shorter period when electing individual Supervisory Board members to be elected by it or for the full Supervisory Board, the Supervisory Board members shall be elected at the longest until the end of the General Meeting which resolves on the discharge for the fourth financial year after the election. The fiscal year in which the term of office begins is not included in this calculation. Re-election is possible.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The successor to a member who leaves the Supervisory Board before the end of his or her term of office shall only be elected for the remainder of the term of office of the member who has left the Supervisory Board.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(4)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">When electing Supervisory Board members, the General Meeting may for the same period elect a substitute member for several or all Supervisory Board members or as many substitute members as Supervisory Board members and determine the order in which they shall replace the Supervisory Board members who leave the Supervisory Board during their term of office for the remaining term of office.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(5)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Each member of the Supervisory Board may resign from office by submitting a written declaration to the Management Board. A period of one month must be observed.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(6)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">In addition to reimbursement of their expenses, the members of the Supervisory Board receive an annual remuneration of EUR 50,000, the chairperson three times this amount and the deputy chairperson one and a half times this amount. The chairperson of the Audit Committee receives an additional annual remuneration of EUR 20,000. The members of the Supervisory Board who are only members of the Supervisory Board for part of the fiscal year or who chair or deputy chair the Supervisory Board or the Audit Committee receive the respective remuneration pro rata temporis. The same shall apply if this provision or a specific version of this provision is only in force for part of the financial year. If the reimbursement of out-of-pocket expenses or the remuneration is subject to value-added tax, value-added tax shall be payable in addition.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#167; 10</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Chairperson and deputy</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The Supervisory Board shall elect a chairperson and a deputy chairperson from among its members for the duration of its term of office. In these elections the oldest member of the Supervisory Board in terms of age is the chairperson. The deputy shall have the rights of the chairperson if the latter is prevented from attending or delegates his or her representation to him or her.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">If the chairperson or his/her deputy departs prematurely from their office, then the Supervisory Board shall immediately hold a new election to cover the remaining term of office.</font></p></td></tr></table></div>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a> | 14</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#167; 11</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;"></font><font style="color:#000000;"></font><font style="color:#000000;">Convening and passing resolutions</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">As far as possible, the Supervisory Board shall be convened in each calendar quarter. It must be convened twice every calendar half-year.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The meetings of the Supervisory Board shall be convened by the chairperson verbally, by telephone, in writing, by fax or by email, stating the agenda.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The Supervisory Board constitutes a quorum if at least three members participate in the adoption of the resolution. A member shall also participate in the adoption of a resolution if he or she abstains from voting.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(4)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Resolutions require a majority of the votes cast by the members of the Supervisory Board not taking into account any abstentions. In the case of a tie, the votes of the chairperson of the Supervisory Board or, if he does not participate in the passing of the resolution, the vote of the deputy chairman of the Supervisory Board shall be the casting vote. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(5)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Resolutions of the Supervisory Board are in principle passed at meetings with personal attendance of the members of the Supervisory Board. Absent members of the Supervisory Board may submit their written vote through another member of the Supervisory Board. Unless the chairperson of the Supervisory Board states otherwise in the invitation due to special circumstances of the individual case, it is permissible for Supervisory Board members to participate and cast their vote in a face-to-face meeting by telephone. The Supervisory Board may also vote without convening a meeting by doing so in writing, by telephone, fax, video conference or email, or in a combined resolution. The chairperson shall decide on the form in which resolutions are to be passed. The Rules of Procedure for the Supervisory Board may stipulate that resolutions are to be postponed in individual cases to be specified in more detail.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(6)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Minutes shall be taken of the meetings of the Supervisory Board and signed by the chairperson of the meeting. If resolutions are passed outside meetings, the minutes must be signed by the chairperson of the Supervisory Board and forwarded to all members without delay.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(7)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The chairperson is authorized to on behalf of the Supervisory Board make the declarations required to implement the resolutions and to receive the declarations addressed to the Supervisory Board.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(8)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The Supervisory Board is empowered to resolve upon changes and amendments to the Articles of Association as long as such changes only affect the wording.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#167; 12</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Rules of Procedure</font></p></td></tr></table></div>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a> | 14</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;margin-left:8.66%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Supervisory Board may issue Rules of Procedure for itself within the framework of the statutory provisions and the provisions of these Articles of Association.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#167; 13</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Committees</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;margin-left:8.66%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Supervisory Board may form committees and may refer items for resolution to these committees within the scope of what is permitted by law.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">VI.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">General Meeting </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#167; 14</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Venue and convocation</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The General Meeting shall take place within the first six months of the expiry of the fiscal year at the registered office of the company or in a German city with at least 500,000 inhabitants.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The General Meeting shall be convened by the Management Board or by the Supervisory Board.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Extraordinary General Meetings shall be convened when the best interests of the company so require.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#167; 15</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Chairing the General Meeting, right to participate, participation of Supervisory Board members</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The General Meeting shall be chaired by the chairperson of the Supervisory Board or, in his/her absence, by his/her deputy or, in his/her absence, by  another person determined by the Supervisory Board. If no such determination has been made, the chairperson of the meeting shall be elected by the General Meeting. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Shareholders registered in the share registered are entitled to participation and the exercising of their voting rights in the General Meeting if they are registered in good time with the Company for participation. The registration to attend the General Meeting must be in German or English and must be received by the Company at least six days prior to the meeting, unless a shorter period, expressed in days, is provided for in the invitation to the General Meeting, at the address and in the form (written form, text form or another (electronic) form further specified by the Company) as stipulated in the said invitation The day of the General Meeting and the day of receipt shall not be counted.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The chairperson of the meeting shall determine the order of items on the agenda as well as the type and form of voting. The chairperson is authorized to limit the question and speaking rights of the shareholders, as appropriate and to the extent permitted by law. In particular, he/she is authorized, at the beginning or during the course of the General Meeting, to set a reasonable time limit for the entire General Meeting, for discussion of particular items on the agenda, or for any particular speech or question. Furthermore, the chairperson of the General </font></p></td></tr></table></div>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a> | 14</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;">Meeting</font><font style="color:#000000;"> may</font><font style="color:#000000;"> prematurely close the list of requests to speak and close the debate, as far as this is necessary for the proper </font><font style="color:#000000;">execution</font><font style="color:#000000;"> of the General Meeting.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(4)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The chairperson of the General Meeting may permit the video and audio transmission of the General Meeting in whole or in part, including a transmission via the Internet.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#167; 16</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Procedure, minutes</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Each share carries one vote. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Voting rights may be exercised by representatives. The power of attorney must be granted in text form by other means. The details shall be determined by the company. They will be announced with the invitation to the General Meeting.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The Management Board is authorized to provide for shareholders to vote without attendance in the General Meeting in written form or by way of electronic communication (postal vote) as well as participate in the General Meeting and exercise all or some of their rights in whole or in part by means of electronic communication without physical participation and without being represented by a proxy (online participation). The Management Board determines the details of the postal vote as well as the scope and procedure of online participation in the invitation to the General Meeting. Minutes shall be kept of the proceedings and shall be signed by the chairperson of the Supervisory Board unless a notarial record is required by law.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#167; 17</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Resolution</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Unless a larger majority is required by law or these Articles of Association, resolutions of the General Meeting shall be adopted by a simple majority of the votes cast. To the extent that statutory provisions also require a majority of the share capital present at the time the resolution is adopted, a simple majority of the share capital present shall suffice, unless a larger majority is required by law. In the event of an undecided vote, an agenda item shall be deemed rejected.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">However, unless a larger majority is required by law, resolutions to amend the Articles of Association require a majority of at least two thirds of the votes cast and of the share capital present, except where at least half of the share capital is present.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Should no majority be obtained in the first ballot in elections, the candidates with the two highest numbers of votes reached shall be put on a shortlist. If the election results in a tie between these two candidates, the decision shall be made by lot.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">VII.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Annual Financial Statements, appropriation of profits </font></p></td></tr></table></div>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a> | 14</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#167; 18</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Annual Financial Statements, Management Report</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The Management Board shall prepare the Annual Financial Statements and any Management Report as well as the Consolidated Financial Statements and any Group Management Report for the past financial year within the statutory period.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The Management Board shall submit the Annual Financial Statements and any Management Report as well as the Consolidated Financial Statements and any Group Management Report to the Supervisory Board immediately after they have been prepared, together with its proposal to the General Meeting for the appropriation of net profit.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The Supervisory Board shall examine the Annual Financial Statements, the potential Management Report of the Management Board, the Consolidated Financial Statements and any Group Management Report and the proposal for the appropriation of net profits and report the results of its examination in writing to the General Meeting. It must forward its report to the Management Board within one month of receipt of the documents. Should the Supervisory Board approve the Annual Financial Statements after examination, they shall be adopted unless the Management Board and Supervisory Board decide to leave the adoption of the Annual Financial Statements to the General Meeting.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#167; 19</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Retained earnings</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Should the Management Board and the Supervisory Board adopt the Annual Financial Statements, they may transfer amounts of up to half of the net profit for the year to retained earnings. In addition, they are authorized to transfer amounts to retained earnings of up to a further quarter of the net profit for the year as long as the retained earnings do not exceed half of the share capital or insofar as they would not exceed half of the share capital after the transfer.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">When calculating the portion of the net profit to be transferred to retained earnings in accordance with paragraph (1), allocations to the statutory reserve and accumulated losses carried forward shall be taken into account in advance.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The General Meeting resolves on the appropriation of profits retained resulting from the adopted Annual Financial Statements. It may allocate further portions of the profits retained to retained earnings, carry these profits forward to a new account &#8211; also by way of distribution in kind - or distribute them among the shareholders.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">VIII.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Legal disputes</font></p></td></tr></table></div>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a> | 14</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#167; 20</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Jurisdiction of the US Federal Courts</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;margin-left:8.66%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the case of litigation on the grounds of or in connection with federal or state capital market laws of the United States of America to be settled in front of a federal or state court of the United States of America only the United States District Court for the Southern District of New York or, in the case of it being replaced by any other first-instance Federal Court of the United States of America having judiciary over the borough of Manhattan, such court, shall be the competent court of jurisdiction, in each case insofar as this may be determined by these Articles of Association. This shall leave unaffected any exclusive international jurisdiction under German or European law of the court seated at the venue of the Company&#8217;s statutory seat.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">IX.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Expenses</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#167; 21</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Formation expenses</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The formation costs of the company shall be borne by FORATIS AG.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The company shall bear the expenses of the formation of the BioNTech SE by conversion of BioNTech AG into a European company (SE) in the amount of up to EUR 100,000.<br /></font></p></td></tr></table></div>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a> | 14</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:8.66%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Annex to Section 4(5) of the Articles of Association</p>
<p style="text-align:center;margin-bottom:9pt;line-height:14pt;margin-top:0pt;margin-left:17.32%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Stipulations which are to be fulfilled in the event of an exclusion of the subscription right<font style="font-weight:normal;"><br /></font>pursuant to Section 4(5) Sentence 4 Subsection (f) (the 'new investor clause')</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.65%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(i)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Ref8219519"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The portion of shares issued on the basis of the respective Management Board resolution on the utilization of the authorized capital (including the shares issued to shareholders on the basis of co-investments pursuant to item (iv)) does not exceed one tenth of the share capital existing at the time of the resolution. In the event that shares have already been issued previously using the authorization to exclude subscription rights in accordance with the new investor clause, said tenth shall be replaced by the aforementioned tenth less the fractions which the shares issued in each case represented in relation to the share capital existing at the time of the respective resolution of the Management Board.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.65%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(ii)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The issue price in US dollars (including any further payment agreed under the law of obligations) shall be converted into euros for the purpose of determining an issue price in euros on the basis of an exchange rate that is determined by the Management Board in its dutiful discretion and that is current at the time of the resolution on the issuance or, in the case of further payments agreed under the law of obligations, at the time of the request for further payment.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.65%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(iii)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Shareholders who hold a total of 60&#160;% of the company's shares and among whom are Medine GmbH, the AT Impf GmbH, at least one Fidelity fund and at least one Redmile fund, have approved the issuance of shares by declaration in text form. "Fidelity fund" or "Redmile fund" means any investment fund managed or advised by Fidelity Management &amp; Research Company or any of its affiliates or, respectively, by Redmile Group LLC or any of its affiliates on the basis of a contract.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.65%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(iv)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Ref8158431"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">In connection with any capital increase under exclusion of subscription rights pursuant to the new investor clause either (x) no shareholder nor any company affiliated with a shareholder will be given the opportunity to participate in the envisaged share issue, or (y) the company will announce the envisaged share issue to each shareholder by email notifying the number of shares that the respective new investor intends to subscribe for, the issue price per share (including any further payment agreed under the law of obligations) and the total issue price to be paid by the respective investor (including, if applicable, the further payment), will request each shareholder, with a deadline of at least one week, to make a binding declaration in text form as to the extent to which he/she </font></p></td></tr></table></div>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13 | 14</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.65%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.33%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;">himself/herself wishes to subscribe </font><font style="color:#000000;">for</font><font style="color:#000000;"> shares in the context of the relevant capital increase ("co-investment"), and offer those who have submitted the declaration in due time to conclude a corresponding subscription agreement by submitting a proper draft subscription form. Each shareholder may transfer or assign his or her right to co-invest to companies </font><font style="color:#000000;">affiliated </font><font style="color:#000000;">with him </font><font style="color:#000000;">or, in the case of an investment fund, to another investment fund advised directly or indirectly by the same investment advisor or by an investment advisor affiliated to the same. The invitation and the offer shall be restricted (in the cases set out in letters </font><font style="color:#000000;">b</font><font style="color:#000000;"> and </font><font style="color:#000000;">c</font><font style="color:#000000;"> below in the event that a determination of the relevant content is made) to the extent that;</font><font style="color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:25.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Ref8220670"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the pro rata amount of the share capital represented by the total shares to be subscribed for by way of co-investments in the context of the capital increase in question may not exceed the fraction set out in item (i) with the proviso that existing subscription requests are initially taken into account in proportion to the pro rata shareholdings and are otherwise disregarded to the extent that this amount would otherwise be exceeded, </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:25.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Ref8220403"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the pro rata amount of the share capital represented by the total number of shares to be subscribed for by way of co-investments within the framework of the capital increase in question may not exceed the amount determined in the invitation and the offer (which amounts to at least half of the total envisaged amount of the capital increase); in such a case, the provisions of letter a shall apply mutatis mutandis, and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:25.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">c.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Ref8220407"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the co-investment is subject to the condition that, upon penalty of exclusion from the co-investment, within a period of at least five banking days to be determined by the company, starting from the date of availability of the proper draft of the subscription form corresponding to the declaration (x) the company receives the duly signed subscription form in two originals , and (y) that the issue amount (in whole or the part claimed by the company) is fully paid.</font></p></td></tr></table></div>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a> | 14</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.4
<SEQUENCE>3
<FILENAME>bntx-ex24_790.htm
<DESCRIPTION>EX-2.4
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-ex24_790.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 2.4</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DESCRIPTION OF SECURITIES</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The following description sets forth certain material terms and provisions of ordinary shares and American Depositary Shares representing ordinary shares of BioNTech SE (&#8220;BioNTech,&#8221;, the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;) that are registered under Section 12 of the U.S. Securities Exchange Act of 1934, as amended. This description also summarizes certain provisions of our articles of association and German law as of the date of the filing of the Annual Report on Form 20-F of which this exhibit forms a part. This summary does not purport to be complete and is qualified in its entirety by the provisions of our articles of association filed with the Securities and Exchange Commission as an exhibit to the Annual Report on Form 20-F of which this exhibit forms a part, as well as to the applicable provisions of German legislation on stock corporations. We encourage you to read our articles of association and the applicable provisions of German law for additional information.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ordinary Shares</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were <font style="color:#000000;">incorporated</font><font style="letter-spacing:0.1pt;"> </font>as a German<font style="letter-spacing:0.05pt;"> </font>stock<font style="letter-spacing:0.05pt;"> </font>corporation<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Aktiengesellschaf</font><font style="font-style:italic;letter-spacing:0.2pt;">t</font>) with the<font style="letter-spacing:0.05pt;"> </font>legal<font style="letter-spacing:0.05pt;"> </font>name<font style="letter-spacing:0.05pt;"> </font>Petersberg 91. V AG<font style="letter-spacing:-0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font><font style="color:#000000;">laws</font> of the<font style="letter-spacing:0.05pt;"> </font>Federal<font style="letter-spacing:0.05pt;"> </font>Republic<font style="letter-spacing:0.05pt;"> </font>of Germany<font style="letter-spacing:0.05pt;"> </font>on June 2, 2008. We changed<font style="letter-spacing:0.05pt;"> </font>our name<font style="letter-spacing:0.05pt;"> </font>to <font style="color:#000000;">BioNTech</font> AG<font style="letter-spacing:-0.05pt;"> </font>on December<font style="letter-spacing:0.05pt;"> </font>11, 2008. Effective<font style="letter-spacing:0.1pt;"> </font>as of March<font style="letter-spacing:0.05pt;"> </font>8, <font style="color:#000000;">2019</font>, the<font style="letter-spacing:0.05pt;"> </font>date<font style="letter-spacing:0.05pt;"> </font>on which the<font style="letter-spacing:0.05pt;"> </font>change<font style="letter-spacing:0.05pt;"> </font>of legal<font style="letter-spacing:0.05pt;"> </font>form and company<font style="letter-spacing:0.05pt;"> </font>was registered<font style="letter-spacing:0.1pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>commercial<font style="letter-spacing:0.15pt;"> </font>register<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Handelsregiste</font><font style="font-style:italic;letter-spacing:0.1pt;">r</font>) of the<font style="letter-spacing:0.05pt;"> </font>local<font style="letter-spacing:0.05pt;"> </font>court<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">Amtsgerich</font><font style="font-style:italic;letter-spacing:0.05pt;">t</font>) of Mainz,<font style="letter-spacing:0.05pt;"> </font>Germany,<font style="letter-spacing:0.05pt;"> </font>we converted<font style="letter-spacing:0.05pt;"> </font>to a <font style="font-style:italic;">Societas</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">Europaea </font>with the<font style="letter-spacing:0.05pt;"> </font>legal<font style="letter-spacing:0.05pt;"> </font>name<font style="letter-spacing:0.05pt;"> </font>BioNTech SE. We completed<font style="letter-spacing:0.1pt;"> </font>our initial<font style="letter-spacing:0.1pt;"> </font>public<font style="letter-spacing:0.05pt;"> </font>offering<font style="letter-spacing:0.1pt;"> </font>in October<font style="letter-spacing:0.05pt;"> </font>2019. The principal<font style="letter-spacing:0.1pt;"> </font>legislation<font style="letter-spacing:0.15pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>which we operate<font style="letter-spacing:0.05pt;"> </font>and our shares<font style="letter-spacing:0.05pt;"> </font>are issued<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Council<font style="letter-spacing:0.05pt;"> </font>Regulation<font style="letter-spacing:0.05pt;"> </font>(EC) No 2157/2001 of October<font style="letter-spacing:0.05pt;"> </font>8, 2001 on the<font style="letter-spacing:0.05pt;"> </font>Statute<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>a European<font style="letter-spacing:0.05pt;"> </font>company (SE), the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>Law on the<font style="letter-spacing:0.05pt;"> </font>Implementation<font style="letter-spacing:0.15pt;"> </font>of Council<font style="letter-spacing:0.05pt;"> </font>Regulation<font style="letter-spacing:0.05pt;"> </font>(EC) No 2157/2001 of October<font style="letter-spacing:0.05pt;"> </font>8, 2001 on the<font style="letter-spacing:0.05pt;"> </font>Statute<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>a European<font style="letter-spacing:0.05pt;"> </font>company<font style="letter-spacing:0.05pt;"> </font>(SE) (<font style="font-style:italic;">Gesetz</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">zur Ausf&#252;hrung</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">der Verordnung (EG) NR.</font><font style="font-style:italic;letter-spacing:-0.05pt;"> </font><font style="font-style:italic;">2157/2001 des Rates vom 8. Oktober</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">2001 &#252;ber das Statut</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">der Europ&#228;ischen</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">Gesellschaft</font><font style="font-style:italic;letter-spacing:0.1pt;"> </font><font style="font-style:italic;">(SE)</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">(SE-Ausf&#252;hrungsgesetz&#8212;SEAG</font><font style="font-style:italic;letter-spacing:0.1pt;">)</font>) and the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>Stock Corporation<font style="letter-spacing:0.05pt;"> </font>Act (<font style="font-style:italic;">Aktiengeset</font><font style="font-style:italic;letter-spacing:0.1pt;">z</font>), in each<font style="letter-spacing:0.05pt;"> </font>case<font style="letter-spacing:0.05pt;"> </font>as amended.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We <font style="color:#000000;">are</font><font style="letter-spacing:0.05pt;"> </font>registered<font style="letter-spacing:0.1pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>commercial<font style="letter-spacing:0.15pt;"> </font>register<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Handelsregiste</font><font style="font-style:italic;letter-spacing:0.1pt;">r</font>) of the<font style="letter-spacing:0.05pt;"> </font>local<font style="letter-spacing:0.05pt;"> </font>court<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">Amtsgerich</font><font style="font-style:italic;letter-spacing:0.05pt;">t</font>) in Mainz, Germany,<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>number<font style="letter-spacing:0.05pt;"> </font>HRB<font style="letter-spacing:-0.05pt;"> </font>48720. Our statutory<font style="letter-spacing:0.1pt;"> </font>seat<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>in Mainz,<font style="letter-spacing:0.05pt;"> </font>Germany,<font style="letter-spacing:0.05pt;"> </font>and our registered<font style="letter-spacing:0.1pt;"> </font>office<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>An der<font style="letter-spacing:0.05pt;"> </font>Goldgrube<font style="letter-spacing:0.05pt;"> </font>12, 55131 Mainz,<font style="letter-spacing:0.05pt;"> </font>Germany.<font style="letter-spacing:0.05pt;"> </font>Copies of our Articles<font style="letter-spacing:0.1pt;"> </font>of Association<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Satzun</font><font style="font-style:italic;letter-spacing:0.05pt;">g</font>) will<font style="letter-spacing:0.05pt;"> </font>be publicly available<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>commercial<font style="letter-spacing:0.15pt;"> </font>register<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Handelsregiste</font><font style="font-style:italic;letter-spacing:0.1pt;">r</font>) at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>local<font style="letter-spacing:0.05pt;"> </font>court<font style="letter-spacing:0.05pt;"> </font>of Mainz,<font style="letter-spacing:0.05pt;"> </font>Germany,<font style="letter-spacing:0.05pt;"> </font>electronically<font style="letter-spacing:0.15pt;"> </font>at www.unternehmensregister.de<font style="letter-spacing:0.15pt;"> </font>and as an exhibit<font style="letter-spacing:0.05pt;"> </font>to this<font style="letter-spacing:0.05pt;"> </font>Annual Report.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share Capital</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>registered<font style="letter-spacing:0.1pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>commercial<font style="letter-spacing:0.15pt;"> </font>register<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Handelsregiste</font><font style="font-style:italic;letter-spacing:0.1pt;">r</font>) in the<font style="letter-spacing:0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of &#8364;246,310,081, which is<font style="letter-spacing:0.05pt;"> </font>divided<font style="letter-spacing:0.05pt;"> </font>into 246,310,081 registered<font style="letter-spacing:0.1pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">Namensaktie</font><font style="font-style:italic;letter-spacing:0.05pt;">n</font>). All shares<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>with no par<font style="letter-spacing:0.05pt;"> </font>value<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">St&#252;ckaktien</font><font style="font-style:italic;letter-spacing:0.1pt;"> </font><font style="font-style:italic;">ohne Nennbetra</font><font style="font-style:italic;letter-spacing:0.05pt;">g</font>) with a notional<font style="letter-spacing:0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>attributable<font style="letter-spacing:0.15pt;"> </font>to each<font style="letter-spacing:0.05pt;"> </font>ordinary<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>of &#8364;1. Each issued<font style="letter-spacing:0.05pt;"> </font>ordinary<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>fully<font style="letter-spacing:0.05pt;"> </font>paid.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form, Certification<font style="letter-spacing:0.1pt;"> </font>and Transferability<font style="letter-spacing:0.1pt;"> </font>of Shares</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The form<font style="letter-spacing:0.05pt;"> </font>and contents<font style="letter-spacing:0.05pt;"> </font>of our share<font style="letter-spacing:0.05pt;"> </font>certificates,<font style="letter-spacing:0.2pt;"> </font>collective<font style="letter-spacing:0.1pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>certificates<font style="letter-spacing:0.2pt;"> </font>and global<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>certificates<font style="letter-spacing:0.2pt;"> </font>are determined<font style="letter-spacing:0.1pt;"> </font>by our Management<font style="letter-spacing:0.1pt;"> </font>Board. A shareholder&#8217;s<font style="letter-spacing:0.15pt;"> </font>right<font style="letter-spacing:0.05pt;"> </font>to certification<font style="letter-spacing:0.2pt;"> </font>of its<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>excluded,<font style="letter-spacing:0.05pt;"> </font>to the extent<font style="letter-spacing:0.05pt;"> </font>permitted<font style="letter-spacing:0.1pt;"> </font>by law and to the<font style="letter-spacing:0.05pt;"> </font>extent<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>certification<font style="letter-spacing:0.2pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>not required<font style="letter-spacing:0.1pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>stock<font style="letter-spacing:0.05pt;"> </font>exchange<font style="letter-spacing:0.05pt;"> </font>on which the shares<font style="letter-spacing:0.05pt;"> </font>or rights<font style="letter-spacing:0.05pt;"> </font>or certificates<font style="letter-spacing:0.2pt;"> </font>representing<font style="letter-spacing:0.1pt;"> </font>them<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>admitted<font style="letter-spacing:0.1pt;"> </font>to trading.<font style="letter-spacing:0.05pt;"> </font>We are<font style="letter-spacing:0.05pt;"> </font>permitted<font style="letter-spacing:0.1pt;"> </font>to issue<font style="letter-spacing:0.05pt;"> </font>collective share<font style="letter-spacing:0.05pt;"> </font>certificates<font style="letter-spacing:0.2pt;"> </font>and global<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>certificates<font style="letter-spacing:0.2pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>represent<font style="letter-spacing:0.1pt;"> </font>multiple<font style="letter-spacing:0.1pt;"> </font>or all<font style="letter-spacing:0.05pt;"> </font>of our shares.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our shares<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>freely<font style="letter-spacing:0.1pt;"> </font>transferable<font style="letter-spacing:0.15pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>law.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Anti-takeover<font style="letter-spacing:0.05pt;"> </font>Provisions<font style="letter-spacing:0.05pt;"> </font>of Our Charter Documents</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Articles<font style="letter-spacing:0.1pt;"> </font>of Association<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Satzun</font><font style="font-style:italic;letter-spacing:0.05pt;">g</font>) do not include<font style="letter-spacing:0.05pt;"> </font>any provisions<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>would have a direct<font style="letter-spacing:0.1pt;"> </font>effect<font style="letter-spacing:0.1pt;"> </font>of delaying,<font style="letter-spacing:0.05pt;"> </font>deferring<font style="letter-spacing:0.1pt;"> </font>or preventing<font style="letter-spacing:0.1pt;"> </font>a change<font style="letter-spacing:0.05pt;"> </font>of control.<font style="letter-spacing:0.05pt;"> </font>However, in the<font style="letter-spacing:0.05pt;"> </font>event<font style="letter-spacing:0.05pt;"> </font>of a hostile<font style="letter-spacing:0.1pt;"> </font>takeover,<font style="letter-spacing:0.05pt;"> </font>we could<font style="letter-spacing:0.05pt;"> </font>use our authorized<font style="letter-spacing:0.1pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>to increase<font style="letter-spacing:0.1pt;"> </font>our share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>to issue<font style="letter-spacing:0.05pt;"> </font>new shares<font style="letter-spacing:0.05pt;"> </font>to an investor<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>a premium.<font style="letter-spacing:0.1pt;"> </font>An increase in the<font style="letter-spacing:0.05pt;"> </font>number<font style="letter-spacing:0.05pt;"> </font>of shares<font style="letter-spacing:0.05pt;"> </font>outstanding<font style="letter-spacing:0.1pt;"> </font>could<font style="letter-spacing:0.05pt;"> </font>have a negative<font style="letter-spacing:0.05pt;"> </font>effect<font style="letter-spacing:0.1pt;"> </font>on a party&#8217;s<font style="letter-spacing:0.1pt;"> </font>ability<font style="letter-spacing:0.1pt;"> </font>to carry<font style="letter-spacing:0.05pt;"> </font>out a hostile takeover.<font style="letter-spacing:0.05pt;"> </font>The provisions<font style="letter-spacing:0.1pt;"> </font>of German<font style="letter-spacing:0.05pt;"> </font>law relating<font style="letter-spacing:0.1pt;"> </font>to public<font style="letter-spacing:0.05pt;"> </font>bids<font style="letter-spacing:0.05pt;"> </font>and takeovers<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>require<font style="letter-spacing:0.1pt;"> </font>any such bids<font style="letter-spacing:0.05pt;"> </font>to be carried<font style="letter-spacing:0.1pt;"> </font>out in a manner<font style="letter-spacing:0.05pt;"> </font>designed<font style="letter-spacing:0.05pt;"> </font>to safeguard<font style="letter-spacing:0.1pt;"> </font>equal<font style="letter-spacing:0.05pt;"> </font>and fair<font style="letter-spacing:0.05pt;"> </font>treatment<font style="letter-spacing:0.15pt;"> </font>to all<font style="letter-spacing:0.05pt;"> </font>shareholders<font style="letter-spacing:0.1pt;"> </font>and give<font style="letter-spacing:0.05pt;"> </font>them<font style="letter-spacing:0.05pt;"> </font>a right<font style="letter-spacing:0.05pt;"> </font>to be bought out at<font style="letter-spacing:0.05pt;"> </font>an adequate<font style="letter-spacing:0.05pt;"> </font>compensation<font style="letter-spacing:0.1pt;"> </font>where a party<font style="letter-spacing:0.05pt;"> </font>acquires<font style="letter-spacing:0.1pt;"> </font>&#8220;control&#8221;<font style="letter-spacing:0.1pt;"> </font>(as<font style="letter-spacing:0.05pt;"> </font>such term<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>defined<font style="letter-spacing:0.05pt;"> </font>in such provisions)<font style="letter-spacing:0.1pt;"> </font>over<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>relevant<font style="letter-spacing:0.1pt;"> </font>company<font style="letter-spacing:0.05pt;"> </font>do not apply.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Future Changes to the Share Capital</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Authorized<font style="letter-spacing:0.05pt;"> </font>Capital</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the<font style="letter-spacing:0.05pt;"> </font>relevant<font style="letter-spacing:0.1pt;"> </font>law, the<font style="letter-spacing:0.05pt;"> </font>general<font style="letter-spacing:0.05pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>of a European<font style="letter-spacing:0.05pt;"> </font>stock<font style="letter-spacing:0.05pt;"> </font>corporation<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Societas</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">Europaea</font>) governed by German<font style="letter-spacing:0.05pt;"> </font>law can authorize<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board to, with the<font style="letter-spacing:0.05pt;"> </font>consent<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Supervisory<font style="letter-spacing:0.05pt;"> </font>Board, issue<font style="letter-spacing:0.05pt;"> </font>shares in a specified<font style="letter-spacing:0.1pt;"> </font>aggregate<font style="letter-spacing:0.1pt;"> </font>nominal<font style="letter-spacing:0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of up to 50% of the<font style="letter-spacing:0.05pt;"> </font>issued<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>of such company<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>the resolution<font style="letter-spacing:0.1pt;"> </font>becomes<font style="letter-spacing:0.05pt;"> </font>effective.<font style="letter-spacing:0.1pt;"> </font>The shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>authorization<font style="letter-spacing:0.15pt;"> </font>becomes<font style="letter-spacing:0.05pt;"> </font>effective<font style="letter-spacing:0.1pt;"> </font>upon registration<font style="letter-spacing:0.15pt;"> </font>in the commercial<font style="letter-spacing:0.15pt;"> </font>register<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Handelsregiste</font><font style="font-style:italic;letter-spacing:0.1pt;">r</font>) and may<font style="letter-spacing:0.05pt;"> </font>extend<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>a period<font style="letter-spacing:0.05pt;"> </font>of no more<font style="letter-spacing:0.05pt;"> </font>than<font style="letter-spacing:0.05pt;"> </font>five<font style="letter-spacing:0.05pt;"> </font>years<font style="letter-spacing:0.05pt;"> </font>thereafter.<font style="letter-spacing:0.15pt;"> </font>Under &#167; 4(5)<font style="letter-spacing:0.05pt;"> </font>of our Articles<font style="letter-spacing:0.1pt;"> </font>of Association<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Satzun</font><font style="font-style:italic;letter-spacing:0.05pt;">g</font>), the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board is<font style="letter-spacing:0.05pt;"> </font>authorized<font style="letter-spacing:0.1pt;"> </font>to increase<font style="letter-spacing:0.1pt;"> </font>our share capital,<font style="letter-spacing:0.1pt;"> </font>on one or more<font style="letter-spacing:0.05pt;"> </font>occasions,<font style="letter-spacing:0.05pt;"> </font>by a total<font style="letter-spacing:0.05pt;"> </font>of up to &#8364;91,812,171 by issuing,<font style="letter-spacing:0.05pt;"> </font>on one or more<font style="letter-spacing:0.05pt;"> </font>occasions,<font style="letter-spacing:0.05pt;"> </font>up to 91,812,171 new, registered<font style="letter-spacing:0.1pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>with no par<font style="letter-spacing:0.05pt;"> </font>value<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">Genehmigtes</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">Kapita</font><font style="font-style:italic;letter-spacing:0.05pt;">l</font>), in each<font style="letter-spacing:0.05pt;"> </font>case<font style="letter-spacing:0.05pt;"> </font>with consent<font style="letter-spacing:0.05pt;"> </font>of the Supervisory<font style="letter-spacing:0.05pt;"> </font>Board. This authorization<font style="letter-spacing:0.15pt;"> </font>expires<font style="letter-spacing:0.05pt;"> </font>on August 18, 2024.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any new shares<font style="letter-spacing:0.05pt;"> </font>issued<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>authorized<font style="letter-spacing:0.1pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>participate<font style="letter-spacing:0.15pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>profits<font style="letter-spacing:0.1pt;"> </font>starting<font style="letter-spacing:0.1pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>fiscal<font style="letter-spacing:0.1pt;"> </font>year for<font style="letter-spacing:0.05pt;"> </font>which the<font style="letter-spacing:0.05pt;"> </font>annual<font style="letter-spacing:0.05pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>statements<font style="letter-spacing:0.15pt;"> </font>have not yet<font style="letter-spacing:0.05pt;"> </font>been submitted<font style="letter-spacing:0.1pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>general<font style="letter-spacing:0.05pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>of registration<font style="letter-spacing:0.15pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>implementation<font style="letter-spacing:0.15pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>increase.<font style="letter-spacing:0.1pt;"> </font>Further<font style="letter-spacing:0.05pt;"> </font>details<font style="letter-spacing:0.1pt;"> </font>of a capital<font style="letter-spacing:0.1pt;"> </font>increase<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>authorized capital<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>be specified<font style="letter-spacing:0.1pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Conditional<font style="letter-spacing:0.05pt;"> </font>Capital</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant<font style="letter-spacing:0.05pt;"> </font>to &#167; 4(6)<font style="letter-spacing:0.05pt;"> </font>of our Articles<font style="letter-spacing:0.1pt;"> </font>of Association<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Satzun</font><font style="font-style:italic;letter-spacing:0.05pt;">g</font>), our share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>conditionally<font style="letter-spacing:0.1pt;"> </font>increased<font style="letter-spacing:0.1pt;"> </font>by &#8364;21,874,806 through<font style="letter-spacing:0.05pt;"> </font>issuance<font style="letter-spacing:0.05pt;"> </font>of new, registered<font style="letter-spacing:0.1pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>with no par<font style="letter-spacing:0.05pt;"> </font>value<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">Bedingtes</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">Kapital</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">ESOP</font><font style="font-style:italic;letter-spacing:-0.05pt;"> </font><font style="font-style:italic;">2017/2019</font>). The conditional<font style="letter-spacing:0.1pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>only be used to issue<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>holders<font style="letter-spacing:0.05pt;"> </font>of option<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>granted<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>our ESOP to members<font style="letter-spacing:0.1pt;"> </font>of our Management<font style="letter-spacing:0.1pt;"> </font>Board and to certain<font style="letter-spacing:0.1pt;"> </font>of our employees.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The conditional<font style="letter-spacing:0.1pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>increase<font style="letter-spacing:0.1pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>only be implemented<font style="letter-spacing:0.15pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>extent<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>stock<font style="letter-spacing:0.05pt;"> </font>options<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>our ESOP are<font style="letter-spacing:0.05pt;"> </font>exercised<font style="letter-spacing:0.1pt;"> </font>and said<font style="letter-spacing:0.05pt;"> </font>stock<font style="letter-spacing:0.05pt;"> </font>options<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>not serviced<font style="letter-spacing:0.1pt;"> </font>by our providing<font style="letter-spacing:0.05pt;"> </font>treasury<font style="letter-spacing:0.1pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>or through<font style="letter-spacing:0.05pt;"> </font>cash<font style="letter-spacing:0.05pt;"> </font>payments. Any new shares<font style="letter-spacing:0.05pt;"> </font>issued<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>conditional<font style="letter-spacing:0.1pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>pursuant<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>said<font style="letter-spacing:0.05pt;"> </font>&#167; 4(6)<font style="letter-spacing:0.05pt;"> </font>of our Articles<font style="letter-spacing:0.1pt;"> </font>of Association (<font style="font-style:italic;">Satzun</font><font style="font-style:italic;letter-spacing:0.05pt;">g</font>) shall<font style="letter-spacing:0.05pt;"> </font>be entitled<font style="letter-spacing:0.1pt;"> </font>to dividends<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>beginning<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>previous<font style="letter-spacing:0.05pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>year<font style="letter-spacing:0.05pt;"> </font>in case<font style="letter-spacing:0.05pt;"> </font>they<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>created by the<font style="letter-spacing:0.05pt;"> </font>exercise<font style="letter-spacing:0.1pt;"> </font>of subscription<font style="letter-spacing:0.1pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>until<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>start<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>annual<font style="letter-spacing:0.05pt;"> </font>general<font style="letter-spacing:0.05pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Company and otherwise from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>beginning<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>year<font style="letter-spacing:0.05pt;"> </font>in which they<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>created<font style="letter-spacing:0.1pt;"> </font>as a result<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>exercise<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>stock<font style="letter-spacing:0.05pt;"> </font>options.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant<font style="letter-spacing:0.05pt;"> </font>to &#167; 4(7)<font style="letter-spacing:0.05pt;"> </font>of our Articles<font style="letter-spacing:0.1pt;"> </font>of Association<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Satzun</font><font style="font-style:italic;letter-spacing:0.05pt;">g</font>), our share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>conditionally<font style="letter-spacing:0.1pt;"> </font>increased<font style="letter-spacing:0.1pt;"> </font>by &#8364;87,499,260 through<font style="letter-spacing:0.05pt;"> </font>issuance<font style="letter-spacing:0.05pt;"> </font>of new, registered<font style="letter-spacing:0.1pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>with no par<font style="letter-spacing:0.05pt;"> </font>value<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">Bedingtes</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">Kapital</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">WSV 2019</font>). The conditional<font style="letter-spacing:0.1pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>only be used to issue<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>holders<font style="letter-spacing:0.05pt;"> </font>or creditors<font style="letter-spacing:0.1pt;"> </font>of option<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>or conversion rights<font style="letter-spacing:0.05pt;"> </font>or those<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>an obligation<font style="letter-spacing:0.1pt;"> </font>to convert<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>warrant-linked<font style="letter-spacing:0.15pt;"> </font>or convertible<font style="letter-spacing:0.1pt;"> </font>bonds avail<font style="letter-spacing:0.05pt;"> </font>of their<font style="letter-spacing:0.05pt;"> </font>option rights<font style="letter-spacing:0.05pt;"> </font>or conversion<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>or where they<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>an obligation<font style="letter-spacing:0.1pt;"> </font>to convert,<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>extent<font style="letter-spacing:0.05pt;"> </font>they<font style="letter-spacing:0.05pt;"> </font>satisfy<font style="letter-spacing:0.1pt;"> </font>their obligation<font style="letter-spacing:0.1pt;"> </font>to convert,<font style="letter-spacing:0.05pt;"> </font>or to the<font style="letter-spacing:0.05pt;"> </font>extent<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we exercise<font style="letter-spacing:0.1pt;"> </font>a right<font style="letter-spacing:0.05pt;"> </font>to choose<font style="letter-spacing:0.05pt;"> </font>to grant<font style="letter-spacing:0.05pt;"> </font>our shares,<font style="letter-spacing:0.05pt;"> </font>in whole or in part instead<font style="letter-spacing:0.05pt;"> </font>of paying<font style="letter-spacing:0.05pt;"> </font>a monetary<font style="letter-spacing:0.1pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>due, and to the<font style="letter-spacing:0.05pt;"> </font>extent<font style="letter-spacing:0.05pt;"> </font>cash<font style="letter-spacing:0.05pt;"> </font>compensation<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>not granted<font style="letter-spacing:0.05pt;"> </font>in each<font style="letter-spacing:0.05pt;"> </font>relevant case<font style="letter-spacing:0.05pt;"> </font>or treasury<font style="letter-spacing:0.1pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>or shares<font style="letter-spacing:0.05pt;"> </font>of another<font style="letter-spacing:0.05pt;"> </font>stock-listed<font style="letter-spacing:0.15pt;"> </font>company<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>not utilized<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>servicing.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any new shares<font style="letter-spacing:0.05pt;"> </font>issued<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>said<font style="letter-spacing:0.05pt;"> </font>conditional<font style="letter-spacing:0.1pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>pursuant<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>said<font style="letter-spacing:0.05pt;"> </font>&#167; 4(7)<font style="letter-spacing:0.05pt;"> </font>of our Articles<font style="letter-spacing:0.1pt;"> </font>of Association<font style="letter-spacing:0.1pt;"> </font>shall<font style="letter-spacing:0.05pt;"> </font>carry<font style="letter-spacing:0.05pt;"> </font>an entitlement<font style="letter-spacing:0.15pt;"> </font>to dividends<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>beginning<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>year<font style="letter-spacing:0.05pt;"> </font>in which they<font style="letter-spacing:0.05pt;"> </font>are created;<font style="letter-spacing:0.1pt;"> </font>however, as far<font style="letter-spacing:0.05pt;"> </font>as the<font style="letter-spacing:0.05pt;"> </font>law permits,<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board can confer<font style="letter-spacing:0.05pt;"> </font>dividend<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>new shares<font style="letter-spacing:0.05pt;"> </font>in derogation<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>foregoing.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preemptive<font style="letter-spacing:0.1pt;"> </font>Rights</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">German<font style="letter-spacing:0.05pt;"> </font>law generally<font style="letter-spacing:0.1pt;"> </font>provides<font style="letter-spacing:0.05pt;"> </font>shareholders<font style="letter-spacing:0.1pt;"> </font>with preemptive<font style="letter-spacing:0.1pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>when new shares<font style="letter-spacing:0.05pt;"> </font>convertible<font style="letter-spacing:0.1pt;"> </font>bonds, bonds with warrants,<font style="letter-spacing:0.05pt;"> </font>profit<font style="letter-spacing:0.1pt;"> </font>participation<font style="letter-spacing:0.15pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>or participating<font style="letter-spacing:0.15pt;"> </font>bonds are<font style="letter-spacing:0.05pt;"> </font>issued.<font style="letter-spacing:0.05pt;"> </font>This requirement,<font style="letter-spacing:0.15pt;"> </font>however, may also<font style="letter-spacing:0.05pt;"> </font>be satisfied<font style="letter-spacing:0.1pt;"> </font>by way of a credit<font style="letter-spacing:0.1pt;"> </font>institution<font style="letter-spacing:0.15pt;"> </font>subscribing<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.15pt;"> </font>and then<font style="letter-spacing:0.05pt;"> </font>offering<font style="letter-spacing:0.1pt;"> </font>them<font style="letter-spacing:0.05pt;"> </font>to the shareholders<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>purchase<font style="letter-spacing:0.05pt;"> </font>(<font style="font-style:italic;">mittelbares</font><font style="font-style:italic;letter-spacing:0.1pt;"> </font><font style="font-style:italic;">Bezugsrech</font><font style="font-style:italic;letter-spacing:0.05pt;">t</font>).</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further,<font style="letter-spacing:0.05pt;"> </font>it<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>possible<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>a shareholder<font style="letter-spacing:0.1pt;"> </font>resolution<font style="letter-spacing:0.1pt;"> </font>approved<font style="letter-spacing:0.05pt;"> </font>by three-quarters<font style="letter-spacing:0.15pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>voting<font style="letter-spacing:0.05pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>resolution<font style="letter-spacing:0.1pt;"> </font>to exclude<font style="letter-spacing:0.05pt;"> </font>preemptive<font style="letter-spacing:0.1pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>both where the<font style="letter-spacing:0.05pt;"> </font>general<font style="letter-spacing:0.05pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>itself<font style="letter-spacing:0.1pt;"> </font>resolves<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>new securities to be issued<font style="letter-spacing:0.05pt;"> </font>and in relation<font style="letter-spacing:0.1pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>authorized<font style="letter-spacing:0.1pt;"> </font>capital,<font style="letter-spacing:0.1pt;"> </font><font style="font-style:italic;">i.e.,</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font>an authorization<font style="letter-spacing:0.15pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board to, with the consent<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Supervisory<font style="letter-spacing:0.05pt;"> </font>Board, resolve<font style="letter-spacing:0.05pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>issuance<font style="letter-spacing:0.05pt;"> </font>of new securities;<font style="letter-spacing:0.15pt;"> </font>provided,<font style="letter-spacing:0.05pt;"> </font>however, that<font style="letter-spacing:0.05pt;"> </font>in each<font style="letter-spacing:0.05pt;"> </font>case the<font style="letter-spacing:0.05pt;"> </font>exclusion<font style="letter-spacing:0.05pt;"> </font>or the<font style="letter-spacing:0.05pt;"> </font>authorization<font style="letter-spacing:0.15pt;"> </font>to so exclude<font style="letter-spacing:0.05pt;"> </font>preemptive<font style="letter-spacing:0.1pt;"> </font>rights,<font style="letter-spacing:0.05pt;"> </font>respectively,<font style="letter-spacing:0.15pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>be justified<font style="letter-spacing:0.1pt;"> </font>by specific facts,<font style="letter-spacing:0.05pt;"> </font>in accordance<font style="letter-spacing:0.1pt;"> </font>with established<font style="letter-spacing:0.1pt;"> </font>case<font style="letter-spacing:0.05pt;"> </font>law of the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>Federal<font style="letter-spacing:0.05pt;"> </font>Court of Justice<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">BG</font><font style="font-style:italic;letter-spacing:-0.05pt;">H</font>). The </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">German Federal</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Court of Justice</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-style:italic;">BG</font><font style="font-style:italic;letter-spacing:-0.05pt;">H</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) considers</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exclusion</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of subscription</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">justified</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">it</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">serves</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a purpose</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">company&#8217;s</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">interests,</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">suitable</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">attaining</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such purpose,</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and (iii)</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">necessary</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and appropriate. Additionally,</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">management</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">board</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">must</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">submit</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a written</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">report</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shareholders&#8217;</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">meeting</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in which it presents</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reasons</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exclusion</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subscription</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly,<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>our Articles<font style="letter-spacing:0.1pt;"> </font>of Association<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Satzun</font><font style="font-style:italic;letter-spacing:0.05pt;">g</font>), the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board may,<font style="letter-spacing:0.05pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>consent<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Supervisory<font style="letter-spacing:0.05pt;"> </font>Board, exclude<font style="letter-spacing:0.05pt;"> </font>such preemptive<font style="letter-spacing:0.1pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>in a capital<font style="letter-spacing:0.1pt;"> </font>increase<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>authorized<font style="letter-spacing:0.1pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>in the following<font style="letter-spacing:0.05pt;"> </font>circumstances:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#231F20;">to exclude</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">fractional</font><font style="color:#231F20;letter-spacing:0.15pt;"> </font><font style="color:#231F20;">amounts</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">from</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">subscription</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">right;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#231F20;">in the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">case</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of a capital</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">increase</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">against</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">cash</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">contributions,</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">if</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">issue</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">price</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">new shares</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">is</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">not significantly</font><font style="color:#231F20;letter-spacing:0.15pt;"> </font><font style="color:#231F20;">lower</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">than</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">market</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">price</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">company&#8217;s</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">shares</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">already</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">listed</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">on the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">stock</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">exchange at</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">time</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">issue</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">price</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">is</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">finally</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">determined.</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">However, this</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">authorization</font><font style="color:#231F20;letter-spacing:0.15pt;"> </font><font style="color:#231F20;">shall</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">only apply</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">subject</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">to the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">provision</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">that</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">shares</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">issued</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">excluding</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">subscription</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">rights</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">in accordance</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">with Section</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">186(3) Sentence</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">4 AktG may</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">not exceed</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">a total</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of 10% of the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">share</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">capital</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">either</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">at</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">time</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">this</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">authorization takes</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">effect</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">or, if</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">this</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">amount</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">is</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">lower,</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">at</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">time</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">this</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">authorization</font><font style="color:#231F20;letter-spacing:0.15pt;"> </font><font style="color:#231F20;">is</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">exercised.</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">This limit</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">of 10% of the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">share</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">capital</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">includes</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">shares</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">which are</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">issued</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">or disposed</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of during</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">term</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of this</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">authorization until</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">date</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of its</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">exercise</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">in direct</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">or equivalent</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">application</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">of Section</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">186(3)</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Sentence</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">4 AktG. Shares</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">which are</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">used to service</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">bonds with convertible</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">or option</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">rights</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">or convertible</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">obligations</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">are to be offset</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">against</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">10% limit</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">if</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">these</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">bonds were issued</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">under</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">exclusion</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of shareholder subscription</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">rights</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">in accordance</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">with Section</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">186(3)</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Sentence</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">4 AktG during</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">entitlement</font><font style="color:#231F20;letter-spacing:0.15pt;"> </font><font style="color:#231F20;">period. Treasury</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">shares</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">are</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">to be offset</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">against</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">10% limit,</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">where they</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">were disposed</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of by the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">company during</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">term</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of this</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">authorization</font><font style="color:#231F20;letter-spacing:0.15pt;"> </font><font style="color:#231F20;">with the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">exclusion</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of subscription</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">rights</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">pursuant</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">to or in analogous</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">application</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">of Section</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">186(3)</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Sentence</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">4 AktG;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#231F20;">in the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">case</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of capital</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">increases</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">in exchange</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">for</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">contributions</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">in kind, in particular</font><font style="color:#231F20;letter-spacing:0.15pt;"> </font><font style="color:#231F20;">in order</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">to be able</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">to offer</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">shares</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">to third</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">parties</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">when purchasing</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">companies,</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">parts</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of companies</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">or interests</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">in companies</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">as well</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">as licenses</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">or industrial</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">property</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">rights;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#231F20;">in order</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">to grant</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">subscription</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">rights</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">to new shares</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">to holders</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of conversion</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">or option</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">rights</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">in respect</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">of bonds issued</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">by the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">company</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">or its</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">subordinated</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">domestic</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">or foreign</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Group companies,</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">to the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">extent</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">to which they</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">would be entitled</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">after</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">exercising</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">their</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">conversion</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">or option</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">rights</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">or after</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">fulfilling</font><font style="color:#231F20;letter-spacing:0.15pt;"> </font><font style="color:#231F20;">an agreed</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">conversion</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">obligation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>to implement<font style="letter-spacing:0.1pt;"> </font>an election<font style="letter-spacing:0.1pt;"> </font>dividend<font style="letter-spacing:0.05pt;"> </font>by which shareholders<font style="letter-spacing:0.1pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>given<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>option<font style="letter-spacing:0.05pt;"> </font>to contribute<font style="letter-spacing:0.1pt;"> </font>their dividend<font style="letter-spacing:0.05pt;"> </font>entitlements<font style="letter-spacing:0.15pt;"> </font>(either<font style="letter-spacing:0.1pt;"> </font>in whole or part)<font style="letter-spacing:0.05pt;"> </font>as a contribution<font style="letter-spacing:0.1pt;"> </font>in kind against<font style="letter-spacing:0.05pt;"> </font>issuance<font style="letter-spacing:0.05pt;"> </font>of our new shares;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>in capital increases, in each case if excluding subscription rights, according to the assessment by the Management Board, is expedient to the shares&#8217; successful placement in view of the requirements of eligible investors and if the discount by which the issue price of the shares may be below the current stock ex-change price at the time the Management Board adopts the resolution on using authorized capital, according to the assessment by the Management Board, does not exceed the extent necessary for a successful placement and in any case does not exceed 10% of either the latest available closing price at the time when the issue price is fixed or the volume-weighted average price over a period of up to five trading days ending on the day on which the issue price is so fixed;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#231F20;">in case</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">shares</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">are</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">to be issued</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">to a member</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">of our Management</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">Board or to another</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">person</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">who is employed</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">by us or one of our affiliates</font><font style="color:#231F20;letter-spacing:0.15pt;"> </font><font style="color:#231F20;">and a minimum</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">holding</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">period</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of at</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">least</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">one year</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">and the obligation</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">to transfer</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">back the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">shares</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">in the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">event</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">that</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">beneficiary</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">is</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">not employed</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">by us or one of our affiliated</font><font style="color:#231F20;letter-spacing:0.15pt;"> </font><font style="color:#231F20;">companies</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">for</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">entire</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">duration</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">holding</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">period</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">or any other</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">agreed</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">period</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">is agreed</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">upon. Additional</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">restrictions</font><font style="color:#231F20;letter-spacing:0.15pt;"> </font><font style="color:#231F20;">with regard</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">to the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">shares</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">issued</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">may</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">be agreed</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">upon; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>in order<font style="letter-spacing:0.05pt;"> </font>to be able<font style="letter-spacing:0.05pt;"> </font>to satisfy<font style="letter-spacing:0.1pt;"> </font>an option<font style="letter-spacing:0.05pt;"> </font>to acquire<font style="letter-spacing:0.05pt;"> </font>additional<font style="letter-spacing:0.1pt;"> </font>ordinary<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>or American<font style="letter-spacing:0.05pt;"> </font>Depositary Shares<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>has been agreed<font style="letter-spacing:0.05pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>issuing<font style="letter-spacing:0.05pt;"> </font>banks in connection<font style="letter-spacing:0.05pt;"> </font>with a public<font style="letter-spacing:0.05pt;"> </font>offering<font style="letter-spacing:0.1pt;"> </font>of our shares<font style="letter-spacing:0.05pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>form<font style="letter-spacing:0.05pt;"> </font>of American<font style="letter-spacing:0.05pt;"> </font>Depositary<font style="letter-spacing:0.05pt;"> </font>Shares.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">number</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of new shares</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issued</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authorized</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">capital</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and under</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exclusion</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of subscription</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights pursuant</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to bullets</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one through</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">three</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and six</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">above may</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not exceed</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20% of the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">share</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">capital,</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">either</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">time that the amendment to the Articles of Association (</font><font style="font-style:italic;">Satzung</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">), resolved upon by the general meeting of June 26, 2020, has come into effect or, if</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lower,</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">time</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of utilization of the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authorization.</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To be counted</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">against</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the aforementioned</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20% limit</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are:</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">those</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shares</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issued</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or to be issued</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to service</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conversion</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or option</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or conversion</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or option</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obligations</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or tender</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issuer</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bonds, if</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bonds have been issued</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">during the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">term</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of this</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authorization</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">up to the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">time</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of its</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exercise,</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">excluding</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subscription</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of shareholders,</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as well</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as, to a certain</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">extent</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">treasury</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shares</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have been disposed</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exclusion</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of subscription</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights during</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">term</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of this</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authorization</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(except</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">case</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of certain</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exceptions</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">resolution</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to item</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no. 8 of the general</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">meeting</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of August 19, 2019).</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shareholders&#8217;<font style="letter-spacing:0.05pt;"> </font>Meetings<font style="letter-spacing:0.05pt;"> </font>and Voting Rights</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant<font style="letter-spacing:0.05pt;"> </font>to our Articles<font style="letter-spacing:0.1pt;"> </font>of Association<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Satzun</font><font style="font-style:italic;letter-spacing:0.05pt;">g</font>), shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meetings<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>be held<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>our seat<font style="letter-spacing:0.05pt;"> </font>or in any municipality<font style="letter-spacing:0.15pt;"> </font>in Germany<font style="letter-spacing:0.05pt;"> </font>with more<font style="letter-spacing:0.05pt;"> </font>than<font style="letter-spacing:0.05pt;"> </font>500,000 inhabitants.<font style="letter-spacing:0.1pt;"> </font>Generally,<font style="letter-spacing:0.05pt;"> </font>shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meetings<font style="letter-spacing:0.1pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>convened<font style="letter-spacing:0.05pt;"> </font>by our Management<font style="letter-spacing:0.1pt;"> </font>Board, or our Supervisory<font style="letter-spacing:0.05pt;"> </font>Board. Shareholders<font style="letter-spacing:0.1pt;"> </font>representing<font style="letter-spacing:0.1pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>aggregate<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>five percent<font style="letter-spacing:0.05pt;"> </font>of our ordinary<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>may,<font style="letter-spacing:0.05pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>to certain<font style="letter-spacing:0.1pt;"> </font>formal<font style="letter-spacing:0.1pt;"> </font>prerequisites,<font style="letter-spacing:0.15pt;"> </font>request<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>a shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting be convened.<font style="letter-spacing:0.05pt;"> </font>Shareholders<font style="letter-spacing:0.1pt;"> </font>representing<font style="letter-spacing:0.1pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>aggregate<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>five<font style="letter-spacing:0.05pt;"> </font>percent<font style="letter-spacing:0.05pt;"> </font>of our ordinary<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>or owning shares<font style="letter-spacing:0.05pt;"> </font>with an aggregate<font style="letter-spacing:0.1pt;"> </font>nominal<font style="letter-spacing:0.05pt;"> </font>value<font style="letter-spacing:0.05pt;"> </font>of at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>&#8364;500,000 may<font style="letter-spacing:0.05pt;"> </font>request<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>addition<font style="letter-spacing:0.05pt;"> </font>of one or several<font style="letter-spacing:0.1pt;"> </font>items<font style="letter-spacing:0.1pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>agenda<font style="letter-spacing:0.05pt;"> </font>of any shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting.<font style="letter-spacing:0.1pt;"> </font>Shareholders&#8217; meetings may be summoned either via publication in the German Federal Gazette (<font style="font-style:italic;">Bundesanzeiger</font>) or via mail or via email, in each case generally at least 36 days before the meeting.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shareholders<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>participate<font style="letter-spacing:0.15pt;"> </font>in and vote<font style="letter-spacing:0.05pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>they<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>registered<font style="letter-spacing:0.1pt;"> </font>as a shareholder with the<font style="letter-spacing:0.05pt;"> </font>Company&#8217;s<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>register.<font style="letter-spacing:0.1pt;"> </font>A shareholder<font style="letter-spacing:0.1pt;"> </font>who wishes<font style="letter-spacing:0.05pt;"> </font>to attend<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting&#8212;either<font style="letter-spacing:0.15pt;"> </font>in person<font style="letter-spacing:0.05pt;"> </font>or by proxy, which may<font style="letter-spacing:0.05pt;"> </font>also<font style="letter-spacing:0.05pt;"> </font>be appointed<font style="letter-spacing:0.05pt;"> </font>by us (<font style="font-style:italic;">Stimmrechtsvertrete</font><font style="font-style:italic;letter-spacing:0.15pt;">r</font>)&#8212;must<font style="letter-spacing:0.05pt;"> </font>register<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>meeting, which registration<font style="letter-spacing:0.15pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>occur<font style="letter-spacing:0.05pt;"> </font>no later<font style="letter-spacing:0.1pt;"> </font>than<font style="letter-spacing:0.05pt;"> </font>six<font style="letter-spacing:0.05pt;"> </font>days before<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>(or<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>a later<font style="letter-spacing:0.1pt;"> </font>date,<font style="letter-spacing:0.05pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>so determined<font style="letter-spacing:0.1pt;"> </font>by our Management<font style="letter-spacing:0.1pt;"> </font>Board).</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each share<font style="letter-spacing:0.05pt;"> </font>carries<font style="letter-spacing:0.1pt;"> </font>one vote<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>a shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting.<font style="letter-spacing:0.1pt;"> </font>Resolutions<font style="letter-spacing:0.05pt;"> </font>are,<font style="letter-spacing:0.05pt;"> </font>in accordance<font style="letter-spacing:0.1pt;"> </font>with our Articles<font style="letter-spacing:0.1pt;"> </font>of Association<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">Satzun</font><font style="font-style:italic;letter-spacing:0.05pt;">g</font>), generally<font style="letter-spacing:0.1pt;"> </font>taken<font style="letter-spacing:0.05pt;"> </font>by simple<font style="letter-spacing:0.1pt;"> </font>majority<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>votes<font style="letter-spacing:0.05pt;"> </font>cast.<font style="letter-spacing:0.05pt;"> </font>However, under<font style="letter-spacing:0.05pt;"> </font>applicable<font style="letter-spacing:0.1pt;"> </font>German and European<font style="letter-spacing:0.05pt;"> </font>law, a number<font style="letter-spacing:0.05pt;"> </font>of resolutions<font style="letter-spacing:0.1pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>be passed<font style="letter-spacing:0.05pt;"> </font>by either<font style="letter-spacing:0.1pt;"> </font>a three-quarter<font style="letter-spacing:0.15pt;"> </font>majority<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>votes<font style="letter-spacing:0.05pt;"> </font>cast<font style="letter-spacing:0.05pt;"> </font>or a three-quarter<font style="letter-spacing:0.15pt;"> </font>majority<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>represented<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>meeting.<font style="letter-spacing:0.1pt;"> </font>The fact<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>in these<font style="letter-spacing:0.05pt;"> </font>cases<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>quorum<font style="letter-spacing:0.05pt;"> </font>is determined<font style="letter-spacing:0.1pt;"> </font>in relation<font style="letter-spacing:0.1pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>or shares<font style="letter-spacing:0.05pt;"> </font>present<font style="letter-spacing:0.05pt;"> </font>(as<font style="letter-spacing:0.05pt;"> </font>opposed to, for<font style="letter-spacing:0.05pt;"> </font>example,<font style="letter-spacing:0.05pt;"> </font>all<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>eligible<font style="letter-spacing:0.1pt;"> </font>to vote)<font style="letter-spacing:0.05pt;"> </font>means<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>holders<font style="letter-spacing:0.05pt;"> </font>of a minority<font style="letter-spacing:0.1pt;"> </font>of our shares<font style="letter-spacing:0.05pt;"> </font>could<font style="letter-spacing:0.05pt;"> </font>potentially<font style="letter-spacing:0.1pt;"> </font>control<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>outcome<font style="letter-spacing:0.05pt;"> </font>of resolutions.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Claims<font style="letter-spacing:0.05pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>Directors<font style="letter-spacing:0.05pt;"> </font>and Shareholders&#8217;<font style="letter-spacing:0.05pt;"> </font>Derivative<font style="letter-spacing:0.05pt;"> </font>Actions</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under German<font style="letter-spacing:0.05pt;"> </font>law, generally,<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>company,<font style="letter-spacing:0.05pt;"> </font>rather<font style="letter-spacing:0.1pt;"> </font>than<font style="letter-spacing:0.05pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>shareholders,<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>proper<font style="letter-spacing:0.05pt;"> </font>claimant<font style="letter-spacing:0.1pt;"> </font>in an action with respect<font style="letter-spacing:0.1pt;"> </font>to a wrong committed<font style="letter-spacing:0.1pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>company,<font style="letter-spacing:0.05pt;"> </font>or in cases<font style="letter-spacing:0.05pt;"> </font>where there<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>an irregularity<font style="letter-spacing:0.15pt;"> </font>in the company&#8217;s<font style="letter-spacing:0.05pt;"> </font>internal<font style="letter-spacing:0.1pt;"> </font>management<font style="letter-spacing:0.1pt;"> </font>or supervision.<font style="letter-spacing:0.1pt;"> </font>Therefore,<font style="letter-spacing:0.1pt;"> </font>such claims<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>only be raised<font style="letter-spacing:0.05pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>company represented<font style="letter-spacing:0.1pt;"> </font>by its<font style="letter-spacing:0.05pt;"> </font>management<font style="letter-spacing:0.1pt;"> </font>board,<font style="letter-spacing:0.05pt;"> </font>or, in the<font style="letter-spacing:0.05pt;"> </font>case<font style="letter-spacing:0.05pt;"> </font>of a wrong committed<font style="letter-spacing:0.1pt;"> </font>by a member<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Management Board, by the<font style="letter-spacing:0.05pt;"> </font>Supervisory<font style="letter-spacing:0.05pt;"> </font>Board. This concerns,<font style="letter-spacing:0.05pt;"> </font>in particular,<font style="letter-spacing:0.15pt;"> </font>claims<font style="letter-spacing:0.1pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>members<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board or the<font style="letter-spacing:0.05pt;"> </font>Supervisory<font style="letter-spacing:0.05pt;"> </font>Board.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">However, pursuant<font style="letter-spacing:0.05pt;"> </font>to German<font style="letter-spacing:0.05pt;"> </font>case<font style="letter-spacing:0.05pt;"> </font>law, the<font style="letter-spacing:0.05pt;"> </font>Supervisory<font style="letter-spacing:0.05pt;"> </font>Board is<font style="letter-spacing:0.05pt;"> </font>obliged<font style="letter-spacing:0.05pt;"> </font>to pursue<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>company&#8217;s<font style="letter-spacing:0.05pt;"> </font>claims against<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board, unless<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>interest<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>company<font style="letter-spacing:0.05pt;"> </font>keeps<font style="letter-spacing:0.05pt;"> </font>them<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>doing so. Further,<font style="letter-spacing:0.05pt;"> </font>the Management<font style="letter-spacing:0.1pt;"> </font>Board, or, if<font style="letter-spacing:0.05pt;"> </font>a claim<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>a member<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board, the<font style="letter-spacing:0.05pt;"> </font>Supervisory<font style="letter-spacing:0.05pt;"> </font>Board, is obliged<font style="letter-spacing:0.05pt;"> </font>to pursue<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>company&#8217;s<font style="letter-spacing:0.05pt;"> </font>claims<font style="letter-spacing:0.1pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>designated<font style="letter-spacing:0.1pt;"> </font>individuals<font style="letter-spacing:0.1pt;"> </font>if<font style="letter-spacing:0.05pt;"> </font>so resolved<font style="letter-spacing:0.05pt;"> </font>by a simple<font style="letter-spacing:0.1pt;"> </font>majority<font style="letter-spacing:0.1pt;"> </font>of votes<font style="letter-spacing:0.05pt;"> </font>cast<font style="letter-spacing:0.05pt;"> </font>during<font style="letter-spacing:0.05pt;"> </font>a shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting.<font style="letter-spacing:0.1pt;"> </font>With<font style="letter-spacing:0.05pt;"> </font>a simple<font style="letter-spacing:0.1pt;"> </font>majority<font style="letter-spacing:0.1pt;"> </font>of votes,<font style="letter-spacing:0.05pt;"> </font>shareholders<font style="letter-spacing:0.1pt;"> </font>can also<font style="letter-spacing:0.05pt;"> </font>request<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>a representative<font style="letter-spacing:0.15pt;"> </font>pursue<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>claim<font style="letter-spacing:0.1pt;"> </font>on behalf<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>company.<font style="letter-spacing:0.05pt;"> </font>The court<font style="letter-spacing:0.05pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>appoint<font style="letter-spacing:0.05pt;"> </font>such a representative<font style="letter-spacing:0.15pt;"> </font>upon the request<font style="letter-spacing:0.05pt;"> </font>of shareholders<font style="letter-spacing:0.1pt;"> </font>holding<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>10% of the<font style="letter-spacing:0.05pt;"> </font>company&#8217;s<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>or a participation<font style="letter-spacing:0.15pt;"> </font>of at<font style="letter-spacing:0.05pt;"> </font>least &#8364;1,000,000 in the<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>capital.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>company<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>unable<font style="letter-spacing:0.05pt;"> </font>to fulfill<font style="letter-spacing:0.1pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>third-party<font style="letter-spacing:0.15pt;"> </font>obligations,<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>company&#8217;s<font style="letter-spacing:0.05pt;"> </font>creditors<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>pursue<font style="letter-spacing:0.05pt;"> </font>the company&#8217;s<font style="letter-spacing:0.05pt;"> </font>damage<font style="letter-spacing:0.05pt;"> </font>claims<font style="letter-spacing:0.1pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>members<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board for<font style="letter-spacing:0.05pt;"> </font>certain<font style="letter-spacing:0.1pt;"> </font>wrongdoings.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under certain<font style="letter-spacing:0.1pt;"> </font>circumstances,<font style="letter-spacing:0.15pt;"> </font>shareholders<font style="letter-spacing:0.1pt;"> </font>can bring<font style="letter-spacing:0.05pt;"> </font>forward<font style="letter-spacing:0.05pt;"> </font>damage<font style="letter-spacing:0.05pt;"> </font>claims<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>company<font style="letter-spacing:0.05pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>its management<font style="letter-spacing:0.1pt;"> </font>on their<font style="letter-spacing:0.05pt;"> </font>own behalf.<font style="letter-spacing:0.05pt;"> </font>In order<font style="letter-spacing:0.05pt;"> </font>to bring<font style="letter-spacing:0.05pt;"> </font>forward<font style="letter-spacing:0.05pt;"> </font>such a claim<font style="letter-spacing:0.1pt;"> </font>one shareholder<font style="letter-spacing:0.1pt;"> </font>alone<font style="letter-spacing:0.05pt;"> </font>or together<font style="letter-spacing:0.1pt;"> </font>with other<font style="letter-spacing:0.05pt;"> </font>shareholders<font style="letter-spacing:0.1pt;"> </font>needs<font style="letter-spacing:0.05pt;"> </font>to hold at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>1% of the<font style="letter-spacing:0.05pt;"> </font>company&#8217;s<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>or a participation<font style="letter-spacing:0.15pt;"> </font>of &#8364;100,000 in the </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">share</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">capital.</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally,</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">claimant(s)</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">must</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">comply</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with special</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">claim</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">procedures</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conducted before</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a competent</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">court</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which will</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">allow</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pertinent</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">request</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">only if</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">there</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">circumstances</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">justifying</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the assumption</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">damage</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has been afflicted</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">company</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by improper</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conduct</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or a gross</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">breach</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">law or the</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">articles</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of association.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dividend Rights</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under German<font style="letter-spacing:0.05pt;"> </font>law, distributions<font style="letter-spacing:0.15pt;"> </font>of dividends<font style="letter-spacing:0.05pt;"> </font>on shares<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>a given<font style="letter-spacing:0.05pt;"> </font>fiscal<font style="letter-spacing:0.1pt;"> </font>year<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>determined<font style="letter-spacing:0.1pt;"> </font>by a process<font style="letter-spacing:0.05pt;"> </font>in which the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board and Supervisory<font style="letter-spacing:0.05pt;"> </font>Board submit<font style="letter-spacing:0.05pt;"> </font>a proposal<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>company&#8217;s<font style="letter-spacing:0.05pt;"> </font>annual general<font style="letter-spacing:0.05pt;"> </font>shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>held<font style="letter-spacing:0.05pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>subsequent<font style="letter-spacing:0.05pt;"> </font>fiscal<font style="letter-spacing:0.1pt;"> </font>year<font style="letter-spacing:0.05pt;"> </font>and such annual<font style="letter-spacing:0.05pt;"> </font>general<font style="letter-spacing:0.05pt;"> </font>shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting adopts<font style="letter-spacing:0.05pt;"> </font>a resolution.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">German<font style="letter-spacing:0.05pt;"> </font>law provides<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>a resolution<font style="letter-spacing:0.1pt;"> </font>concerning<font style="letter-spacing:0.05pt;"> </font>dividends<font style="letter-spacing:0.05pt;"> </font>and distribution<font style="letter-spacing:0.15pt;"> </font>thereof<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>be adopted<font style="letter-spacing:0.05pt;"> </font>only if the<font style="letter-spacing:0.05pt;"> </font>company&#8217;s<font style="letter-spacing:0.05pt;"> </font>unconsolidated<font style="letter-spacing:0.1pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>statements<font style="letter-spacing:0.15pt;"> </font>prepared<font style="letter-spacing:0.05pt;"> </font>in accordance<font style="letter-spacing:0.1pt;"> </font>with German<font style="letter-spacing:0.05pt;"> </font>law show net<font style="letter-spacing:0.05pt;"> </font>retained profits.<font style="letter-spacing:0.1pt;"> </font>In determining<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>profit<font style="letter-spacing:0.1pt;"> </font>available<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>distribution,<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>result<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>relevant<font style="letter-spacing:0.1pt;"> </font>year<font style="letter-spacing:0.05pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>be adjusted<font style="letter-spacing:0.05pt;"> </font>for profits<font style="letter-spacing:0.1pt;"> </font>and losses<font style="letter-spacing:0.05pt;"> </font>brought<font style="letter-spacing:0.05pt;"> </font>forward<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>previous<font style="letter-spacing:0.05pt;"> </font>year<font style="letter-spacing:0.05pt;"> </font>and for<font style="letter-spacing:0.05pt;"> </font>withdrawals<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>or transfers<font style="letter-spacing:0.1pt;"> </font>to reserves. Certain<font style="letter-spacing:0.05pt;"> </font>reserves<font style="letter-spacing:0.1pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>required<font style="letter-spacing:0.1pt;"> </font>by law and must<font style="letter-spacing:0.05pt;"> </font>be deducted<font style="letter-spacing:0.05pt;"> </font>when calculating<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>profit<font style="letter-spacing:0.1pt;"> </font>available<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>distribution.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shareholders<font style="letter-spacing:0.1pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>participate<font style="letter-spacing:0.15pt;"> </font>in profit<font style="letter-spacing:0.1pt;"> </font>distributions<font style="letter-spacing:0.15pt;"> </font>in proportion<font style="letter-spacing:0.1pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>number<font style="letter-spacing:0.05pt;"> </font>of shares<font style="letter-spacing:0.05pt;"> </font>they<font style="letter-spacing:0.05pt;"> </font>hold. Dividends<font style="letter-spacing:0.05pt;"> </font>on shares<font style="letter-spacing:0.05pt;"> </font>resolved<font style="letter-spacing:0.05pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>general<font style="letter-spacing:0.05pt;"> </font>shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>paid<font style="letter-spacing:0.05pt;"> </font>annually,<font style="letter-spacing:0.05pt;"> </font>shortly<font style="letter-spacing:0.05pt;"> </font>after<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>general shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting,<font style="letter-spacing:0.1pt;"> </font>in compliance<font style="letter-spacing:0.1pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>rules<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>respective<font style="letter-spacing:0.1pt;"> </font>clearing<font style="letter-spacing:0.1pt;"> </font>system.<font style="letter-spacing:0.05pt;"> </font>Dividend<font style="letter-spacing:0.05pt;"> </font>payment<font style="letter-spacing:0.05pt;"> </font>claims are<font style="letter-spacing:0.05pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>to a three-year<font style="letter-spacing:0.1pt;"> </font>statute<font style="letter-spacing:0.1pt;"> </font>of limitation<font style="letter-spacing:0.15pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>company&#8217;s<font style="letter-spacing:0.05pt;"> </font>favor.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Authorization<font style="letter-spacing:0.05pt;"> </font>to Purchase and Sell<font style="letter-spacing:0.05pt;"> </font>Our Own Shares</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may<font style="letter-spacing:0.05pt;"> </font>not purchase<font style="letter-spacing:0.05pt;"> </font>our own shares<font style="letter-spacing:0.05pt;"> </font>unless<font style="letter-spacing:0.05pt;"> </font>authorized<font style="letter-spacing:0.1pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>or in other<font style="letter-spacing:0.05pt;"> </font>very limited<font style="letter-spacing:0.1pt;"> </font>circumstances<font style="letter-spacing:0.15pt;"> </font>as set<font style="letter-spacing:0.05pt;"> </font>out in the<font style="letter-spacing:0.05pt;"> </font>German<font style="letter-spacing:0.05pt;"> </font>Stock Corporation<font style="letter-spacing:0.05pt;"> </font>Act. The Company&#8217;s<font style="letter-spacing:0.05pt;"> </font>shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting held<font style="letter-spacing:0.05pt;"> </font>on August 19, 2019 authorized<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board until<font style="letter-spacing:0.05pt;"> </font>August 18, 2024, provided<font style="letter-spacing:0.05pt;"> </font>it<font style="letter-spacing:0.05pt;"> </font>complies<font style="letter-spacing:0.1pt;"> </font>with the legal<font style="letter-spacing:0.05pt;"> </font>requirement<font style="letter-spacing:0.15pt;"> </font>of equal<font style="letter-spacing:0.05pt;"> </font>treatment,<font style="letter-spacing:0.15pt;"> </font>to acquire<font style="letter-spacing:0.05pt;"> </font>treasury<font style="letter-spacing:0.1pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>up to a total<font style="letter-spacing:0.05pt;"> </font>of 10% of the<font style="letter-spacing:0.05pt;"> </font>Company&#8217;s<font style="letter-spacing:0.05pt;"> </font>share capital<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>relevant<font style="letter-spacing:0.1pt;"> </font>resolution<font style="letter-spacing:0.1pt;"> </font>or at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>authorization<font style="letter-spacing:0.15pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>exercised.<font style="letter-spacing:0.1pt;"> </font>These shares<font style="letter-spacing:0.05pt;"> </font>held<font style="letter-spacing:0.05pt;"> </font>by the Company (including<font style="letter-spacing:0.1pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>attributable<font style="letter-spacing:0.15pt;"> </font>to it<font style="letter-spacing:0.05pt;"> </font>pursuant<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>AktG) must<font style="letter-spacing:0.05pt;"> </font>never<font style="letter-spacing:0.05pt;"> </font>exceed<font style="letter-spacing:0.05pt;"> </font>10% of the<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>capital. The shares<font style="letter-spacing:0.05pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>be purchased<font style="letter-spacing:0.05pt;"> </font>(i)<font style="letter-spacing:0.05pt;"> </font>through<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>stock<font style="letter-spacing:0.05pt;"> </font>exchange,<font style="letter-spacing:0.05pt;"> </font>(ii)<font style="letter-spacing:0.1pt;"> </font>by means<font style="letter-spacing:0.05pt;"> </font>of a public<font style="letter-spacing:0.05pt;"> </font>offer<font style="letter-spacing:0.05pt;"> </font>directed<font style="letter-spacing:0.1pt;"> </font>to all shareholders<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Company, (iii)<font style="letter-spacing:0.1pt;"> </font>by means<font style="letter-spacing:0.05pt;"> </font>of a public<font style="letter-spacing:0.05pt;"> </font>invitation<font style="letter-spacing:0.1pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>shareholders<font style="letter-spacing:0.1pt;"> </font>to make<font style="letter-spacing:0.05pt;"> </font>a sales<font style="letter-spacing:0.05pt;"> </font>offer<font style="letter-spacing:0.05pt;"> </font>or (iv)<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Bill<font style="letter-spacing:0.05pt;"> </font>&amp; Melinda<font style="letter-spacing:0.05pt;"> </font>Gates<font style="letter-spacing:0.05pt;"> </font>Foundation<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>very<font style="letter-spacing:0.05pt;"> </font>limited<font style="letter-spacing:0.1pt;"> </font>circumstances<font style="letter-spacing:0.15pt;"> </font>as specified<font style="letter-spacing:0.1pt;"> </font>in the authorization.<font style="letter-spacing:0.15pt;"> </font>Such shares<font style="letter-spacing:0.05pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>not be purchased<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>trading<font style="letter-spacing:0.05pt;"> </font>purposes.<font style="letter-spacing:0.05pt;"> </font>The Management<font style="letter-spacing:0.1pt;"> </font>Board is<font style="letter-spacing:0.05pt;"> </font>authorized<font style="letter-spacing:0.1pt;"> </font>to use the<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>only as specified<font style="letter-spacing:0.1pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>authorization.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Squeeze-Out<font style="letter-spacing:0.05pt;"> </font>of Minority<font style="letter-spacing:0.05pt;"> </font>Shareholders</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under German<font style="letter-spacing:0.05pt;"> </font>law, the<font style="letter-spacing:0.05pt;"> </font>shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>of a stock<font style="letter-spacing:0.05pt;"> </font>corporation<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>resolve,<font style="letter-spacing:0.05pt;"> </font>upon request<font style="letter-spacing:0.05pt;"> </font>of a shareholder<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>holds<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>95% of the<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>capital,<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>held<font style="letter-spacing:0.05pt;"> </font>by any remaining<font style="letter-spacing:0.1pt;"> </font>minority shareholders<font style="letter-spacing:0.1pt;"> </font>be transferred<font style="letter-spacing:0.15pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>majority<font style="letter-spacing:0.1pt;"> </font>shareholder<font style="letter-spacing:0.1pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>payment<font style="letter-spacing:0.05pt;"> </font>of &#8220;adequate<font style="letter-spacing:0.05pt;"> </font>cash<font style="letter-spacing:0.05pt;"> </font>compensation&#8221; (<font style="font-style:italic;">Ausschluss</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">von Minderheitsaktion&#228;re</font><font style="font-style:italic;letter-spacing:0.2pt;">n</font>). This amount<font style="letter-spacing:0.05pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>take<font style="letter-spacing:0.05pt;"> </font>into<font style="letter-spacing:0.05pt;"> </font>account<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>full<font style="letter-spacing:0.05pt;"> </font>value<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>company<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the time<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>resolution,<font style="letter-spacing:0.1pt;"> </font>which is<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.1pt;"> </font>determined<font style="letter-spacing:0.1pt;"> </font>using<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>future<font style="letter-spacing:0.05pt;"> </font>earnings<font style="letter-spacing:0.05pt;"> </font>value<font style="letter-spacing:0.05pt;"> </font>method (<font style="font-style:italic;">Ertragswertmethod</font><font style="font-style:italic;letter-spacing:0.1pt;">e</font>).</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A squeeze-out<font style="letter-spacing:0.1pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>context<font style="letter-spacing:0.05pt;"> </font>of a merger<font style="letter-spacing:0.1pt;"> </font>(<font style="font-style:italic;">umwandlungsrechtlicher</font><font style="font-style:italic;letter-spacing:0.1pt;"> </font><font style="font-style:italic;">Squeeze-Ou</font><font style="font-style:italic;letter-spacing:0.05pt;">t</font>) only requires<font style="letter-spacing:0.1pt;"> </font>a majority shareholder<font style="letter-spacing:0.1pt;"> </font>to hold at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>90% of the<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>capital.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidation Rights</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Apart<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>liquidation,<font style="letter-spacing:0.1pt;"> </font>e.g., as a result<font style="letter-spacing:0.1pt;"> </font>of insolvency<font style="letter-spacing:0.05pt;"> </font>proceedings,<font style="letter-spacing:0.1pt;"> </font>we may<font style="letter-spacing:0.05pt;"> </font>be liquidated<font style="letter-spacing:0.1pt;"> </font>with a vote<font style="letter-spacing:0.05pt;"> </font>of the holders<font style="letter-spacing:0.05pt;"> </font>of at<font style="letter-spacing:0.05pt;"> </font>least<font style="letter-spacing:0.05pt;"> </font>three-quarters<font style="letter-spacing:0.15pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.1pt;"> </font>represented<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>shareholders&#8217;<font style="letter-spacing:0.15pt;"> </font>meeting<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>which such a vote<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>taken.<font style="letter-spacing:0.05pt;"> </font>If<font style="letter-spacing:0.05pt;"> </font>we are<font style="letter-spacing:0.05pt;"> </font>liquidated,<font style="letter-spacing:0.1pt;"> </font>any assets<font style="letter-spacing:0.05pt;"> </font>remaining<font style="letter-spacing:0.1pt;"> </font>after<font style="letter-spacing:0.1pt;"> </font>all<font style="letter-spacing:0.05pt;"> </font>of our liabilities<font style="letter-spacing:0.15pt;"> </font>have been paid<font style="letter-spacing:0.05pt;"> </font>off<font style="letter-spacing:0.05pt;"> </font>would be distributed<font style="letter-spacing:0.1pt;"> </font>among<font style="letter-spacing:0.05pt;"> </font>our shareholders<font style="letter-spacing:0.1pt;"> </font>in proportion<font style="letter-spacing:0.1pt;"> </font>to their<font style="letter-spacing:0.05pt;"> </font>holdings<font style="letter-spacing:0.05pt;"> </font>in accordance<font style="letter-spacing:0.1pt;"> </font>with German<font style="letter-spacing:0.05pt;"> </font>statutory<font style="letter-spacing:0.1pt;"> </font>law. The German<font style="letter-spacing:0.05pt;"> </font>Stock Corporation<font style="letter-spacing:0.05pt;"> </font>Act provides<font style="letter-spacing:0.05pt;"> </font>certain<font style="letter-spacing:0.1pt;"> </font>protections<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>creditors<font style="letter-spacing:0.1pt;"> </font>which must<font style="letter-spacing:0.05pt;"> </font>be observed<font style="letter-spacing:0.05pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>event<font style="letter-spacing:0.05pt;"> </font>of liquidation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Differences</font><font style="color:#000000;"> in Corporate Law</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The applicable provisions of the SE Regulation in conjunction with the German Stock Corporation Act as applied to a European stock corporation that has its legal seat in Germany differ from laws applicable to U.S. corporations and their shareholders. <font style="color:#000000;">Set</font> forth below is a summary of certain differences between the provisions of the SE Regulation in conjunction with the German Stock Corporation Act applicable to us and the General Corporation Law of the State of Delaware relating to shareholders&#8217; rights and protections. This summary is not intended to be a complete discussion of the respective rights and it is qualified in its entirety by reference to Delaware law and European and German law. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94%;">
<tr>
<td valign="top"  style="width:16%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">European Union/Federal Republic of Germany</p></td>
<td valign="top"  style="width:42%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Delaware</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Board System</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A European<font style="letter-spacing:0.05pt;"> </font>stock<font style="letter-spacing:0.05pt;"> </font>corporation<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>choose to have a two-tier<font style="letter-spacing:0.1pt;"> </font>board<font style="letter-spacing:0.05pt;"> </font>structure composed<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Management<font style="letter-spacing:0.1pt;"> </font>Board (<font style="font-style:italic;">Vorstan</font><font style="font-style:italic;letter-spacing:0.05pt;">d</font>) and the<font style="letter-spacing:0.05pt;"> </font>Supervisory<font style="letter-spacing:0.05pt;"> </font>Board (<font style="font-style:italic;">Aufsichtsra</font><font style="font-style:italic;letter-spacing:0.1pt;">t</font>). We have chosen<font style="letter-spacing:0.05pt;"> </font>this structure.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Management Board is responsible for running the company&#8217;s affairs and representing the company in dealings with third parties.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Supervisory Board of a European stock corporation under German law has a control and supervisory function. The Supervisory Board does not actively manage the company but certain Management Board actions require the approval of the Supervisory Board.</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Delaware law, a corporation has a unitary board structure, and it is the responsibility of the board of directors to appoint and oversee the management of the corporation on behalf of and in the best interests of the stockholders of the corporation.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management is responsible for running the corporation and overseeing its day-to-day operations.</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appointment and Number of Directors</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under applicable European and German law, a European stock corporation governed by German law with a share capital of at least &#8364;3 million generally must have at least two members on its Management Board and the number of members shall be determined by or in the manner provided in the company&#8217;s articles of association.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Supervisory Board must consist of at least three but&#8212;depending on the share capital&#8212;no more than 21 Supervisory Board members, whereby the number of Supervisory Board members must be divisible by three if this is necessary for the fulfilment of co-determination requirements. The articles of association of the company must specify if the Supervisory Board has more than three members.</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Delaware law, a corporation must have at least one director and the number of directors shall be fixed by or in the manner provided in the bylaws.</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="right";>
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94%;">
<tr>
<td valign="top"  style="width:16%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">European Union/Federal Republic of Germany</p></td>
<td valign="top"  style="width:42%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Delaware</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supervisory Board members are either appointed by the shareholders&#8217; meeting or delegated by one or more individual shareholders if so provided for in the company&#8217;s articles of association. If the Supervisory Board consists of fewer members than is required to meet the quorum for resolutions (either statutory or pursuant to the company&#8217;s articles of association), a competent court may appoint additional members as needed to meet the quorum. The provisions of German law in relation to employees&#8217; co-determination do not apply to the Company.</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Removal of Directors</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Members of the Management Board of a European stock corporation are appointed by the Supervisory Board for a maximum period of six years with an opportunity to be reelected. The articles of association may provide for a shorter term, which in our case is up to five years. The members of the Management Board may be reelected, even repeatedly. The Supervisory Board may remove a member of the Management Board prior to the expiration of his or her term only for cause, such as gross breach of duties (<font style="font-style:italic;">grobe Pflichtverletzung</font>), the inability to manage the business properly (<font style="font-style:italic;">Unf&#228;higkeit zur ordnungsgem&#228;&#223;en Pflichtaus&#252;bung</font>) or a vote of no-confidence during the shareholders&#8217; meeting (<font style="font-style:italic;">Vertrauensentzug</font>). The shareholders themselves are not entitled to appoint or dismiss the members of the Management Board.</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Delaware law, any director or the entire board of directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors, except (i) unless the certificate of incorporation provides otherwise, in the case of a corporation whose board of directors is classified, stockholders may effect such removal only for cause; or (ii) in the case of a corporation having cumulative voting, if less than the entire board of directors is to be removed, no director may be removed without cause if the votes cast against his removal would be sufficient to elect him if then cumulatively voted at an election of the entire board of directors, or, if there are classes of directors, at an election of the class of directors of which he is a part.</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under European law, a member of the Supervisory Board of a company may be elected for a term of up to six years. The articles of association may provide for a shorter term. Our Supervisory Board members are, if the general meeting does not resolve on a shorter term, elected for a period up to the end of the general meeting deciding on the discharge for the fourth financial year after the election. Reelection, including repeated reelection, is permissible. Members of the Supervisory Board may be removed with or without cause by way of a general meeting resolution, with the applicable majority requirement depending on the relevant company&#8217;s articles of association.</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="right";>
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94%;">
<tr>
<td valign="top"  style="width:16%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">European Union/Federal Republic of Germany</p></td>
<td valign="top"  style="width:42%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Delaware</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vacancies on the Board of Directors</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the law, vacant positions on the Management Board are filled by the Supervisory Board in accordance with the general rules of appointment, which provide that vacancies are filled by the simple majority of votes of Supervisory Board members present or represented by proxy at the vote (with, under certain circumstances, the chairman having a casting vote), unless otherwise provided by the company&#8217;s articles of association. In case of emergencies, a vacant position on the Management Board may be filled by an individual appointed by the court. Vacant positions on the Supervisory Board are filled in accordance with the general rules of appointment.</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Delaware law, vacancies and newly created directorships may be filled by a majority of the directors then in office (even though less than a quorum) or by a sole remaining director unless (i) otherwise provided in the certificate of incorporation or by-laws of the corporation or (ii) the certificate of incorporation directs that a particular class of stock is to elect such director, in which case a majority of the other directors elected by such class, or a sole remaining director elected by such class, will fill such vacancy.</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual General Meeting</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A European stock corporation which is governed by German law must hold an annual shareholders&#8217; meeting within six months of the end of its fiscal year. The annual shareholders&#8217; meeting must be held at a location determined by the articles of association. If the articles of association do not provide for a specific location, the shareholders&#8217; meeting shall be held at the company&#8217;s seat or, if applicable, at the venue (in Germany) where its shares are listed.</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Delaware law, the annual meeting of stockholders shall be held at such place, on such date and at such time as may be designated from time to time by the board of directors or as provided in the certificate of incorporation or by the bylaws.</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General Meeting</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the law, extraordinary shareholders&#8217; meetings, in addition to the annual shareholders&#8217; meetings, may be called by either the Management Board, or by the Supervisory Board. Shareholders holding at least 5% of the company&#8217;s share capital are entitled to request that an extraordinary shareholders&#8217; meeting be convened. In the event that the meeting is not then so convened, a competent court may order that the meeting be convened or authorize the shareholders or their representative to convene the meeting themselves.</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Delaware law, special meetings of the stockholders may be called by the board of directors or by such person or persons as may be authorized by the certificate of incorporation or by the bylaws.</p></td>
</tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="right";>
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94%;">
<tr>
<td valign="top"  style="width:16%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">European Union/Federal Republic of Germany</p></td>
<td valign="top"  style="width:42%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Delaware</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notice of General Meetings</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under applicable European and German law, unless a longer period is otherwise provided for in the articles of association or applies because of registration requirements stipulated in the articles of association, the shareholders must be given at least 30 days&#8217; advance notice of the shareholders&#8217; meeting. Such notices must at least specify the name of the company, the statutory seat of the company, and the location, date and time of the shareholders&#8217; meeting. In addition, the invitation must contain the agenda items as well as the Management Board&#8217;s and the Supervisory Board&#8217;s voting proposal for each agenda item and, depending on the circumstances, certain further information.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If all shareholders entitled to attend the shareholders&#8217; meeting are present or represented and do not object to the meeting being held, the formalities of calling and holding of a shareholders&#8217; meeting do not apply.</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Delaware law, unless otherwise provided in the certificate of incorporation or bylaws, written notice of any meeting of the stockholders must be given to each stockholder entitled to vote at the meeting not less than ten nor more than 60 days before the date of the meeting and shall specify the place, date, hour, and purpose or purposes of the meeting.</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proxy</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A shareholder may designate another person to attend, speak and vote at a shareholders&#8217; meeting of the company on such shareholder&#8217;s behalf by proxy.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to Management Board meetings, a Management Board member may transmit its (written or verbal) vote via another Management Board member.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to Supervisory Board meetings, a Supervisory Board member may participate in voting by issuing a written vote to another Supervisory Board member or any third party entitled to attend the Supervisory Board meeting.</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Delaware law, at any meeting of stockholders, a stockholder may designate another person to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period. A director of a Delaware corporation may not issue a proxy representing the director&#8217;s voting rights as a director.</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preemptive Rights</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the law applicable to European stock corporations governed by German law, existing shareholders have a statutory subscription right for any additional issue of shares or any security convertible into shares pro rata to the nominal value of their respective holdings in the company, unless (i) shareholders representing three-quarters of the registered share capital present at the shareholders&#8217; meeting have resolved upon the whole or partial exclusion of the subscription right and (ii) there exists good and objective cause for such exclusion. No separate resolution on the exclusion of subscription rights is required if all shareholders waive their statutory subscription rights.</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Delaware law, stockholders have no preemptive rights to subscribe to additional issues of stock or to any security convertible into such stock unless, and except to the extent that, such rights are expressly provided for in the certificate of incorporation.</p></td>
</tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="right";>
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94%;">
<tr>
<td valign="top"  style="width:16%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">European Union/Federal Republic of Germany</p></td>
<td valign="top"  style="width:42%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Delaware</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Authority to Allot</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under applicable European and German law, the Management Board may not allot shares, grant rights to subscribe for or to convert any security into shares unless a shareholder resolution to that effect has been passed at the company&#8217;s shareholders&#8217; meeting granting the Management Board with such authority&#8212;subject to the approval of the Supervisory Board&#8212;in each case in accordance with the provisions of the German Stock Corporation Act.</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Delaware law, if the corporation&#8217;s certificate of incorporation so provides, the board of directors has the power to authorize the issuance of stock. It may authorize capital stock to be issued for consideration consisting of cash, any tangible or intangible property or any benefit to the corporation or any combination thereof. It may determine the amount of such consideration by approving a formula. In the absence of actual fraud in the transaction, the judgment of the directors as to the value of such consideration is conclusive.</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liability of Directors and Officers</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under German law, any provision, whether contained in the company&#8217;s articles of association or any contract or otherwise, that purports to exempt a Management or Supervisory Board member from any liability that would otherwise attach to such board member in connection with any negligence, default, breach of duty or breach of trust in relation to the company is void. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under German law, members of both the Management Board and members of the Supervisory Board are liable to the company, and in certain cases to third parties or shareholders, for any damage caused to them due to a breach of such member&#8217;s duty of care. Apart from insolvency or special circumstances, only the company has the right to claim damages from members of either board. The company may waive claims for damages against a negligent Management or Supervisory Board member only after the expiry of three years.</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Delaware law, a corporation&#8217;s certificate of incorporation may include a provision eliminating or limiting the personal liability of a director to the corporation and its stockholders for damages arising from a breach of fiduciary duty as a director. However, no provision can limit the liability of a director for:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:39.5pt;;text-indent:-15pt;;text-align:left;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="color:#231F20;font-family:Times New Roman;">&#160;&#160;&#160;&#160;&#160;any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:39.5pt;;text-indent:-15pt;;text-align:left;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="color:#231F20;font-family:Times New Roman;">&#160;&#160;&#160;&#160;&#160;acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:39.5pt;;text-indent:-15pt;;text-align:left;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="color:#231F20;font-family:Times New Roman;">&#160;&#160;&#160;&#160;&#160;intentional or negligent payment of unlawful dividends or stock purchases or redemptions; or</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:39.5pt;;text-indent:-15pt;;text-align:left;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="color:#231F20;font-family:Times New Roman;">&#160;&#160;&#160;&#160;&#160;any transaction from which the director derives an improper personal benefit.</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="right";>
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94%;">
<tr>
<td valign="top"  style="width:16%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">European Union/Federal Republic of Germany</p></td>
<td valign="top"  style="width:42%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Delaware</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Voting Rights</font></p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the relevant European and German law, each share, except for statutory non-voting preferred shares (<font style="font-style:italic;">nicht stimmberechtigte Vorzugsaktien</font>), entitles its holder to vote at the shareholders&#8217; meeting with, in the case of no-par value shares, each share conferring one vote. While German law does not provide for a minimum attendance quorum for shareholders&#8217; meetings, the company&#8217;s articles of association may so provide. In general, resolutions adopted at a shareholders&#8217; meeting may be passed by a simple majority of votes cast, unless a higher majority is required by law or under the company&#8217;s articles of association.</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware law provides that, unless otherwise provided in the certificate of incorporation, each stockholder is entitled to one vote for each share of capital stock held by such stockholder.</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shareholder Vote on Certain Transactions</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under applicable European and German law, certain shareholders&#8217; resolutions of fundamental importance require the vote of at least three-quarters of the share capital present or represented in the voting at the time of adoption of the resolution. Resolutions of fundamental importance include, in particular, capital increases with exclusion of subscription rights, capital decreases, the creation of authorized or conditional share capital, the dissolution of a company, a merger into or with another company, split-offs and split-ups, the conclusion of inter-company agreements (<font style="font-style:italic;">Unternehmensvertr&#228;ge</font>), in particular domination agreements (<font style="font-style:italic;">Beherrschungsvertr&#228;ge</font>) and profit and loss transfer agreements (<font style="font-style:italic;">Ergebnisabf&#252;hrungsvertr&#228;ge</font>).</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally, under Delaware law, unless the certificate of incorporation provides for the vote of a larger portion of the stock, completion of a merger, consolidation, sale, lease or exchange of all or substantially all of a corporation&#8217;s assets or dissolution requires:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:39.5pt;;text-indent:-15pt;;text-align:left;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="color:#231F20;font-family:Times New Roman;">&#160;&#160;&#160;&#160;&#160;the approval of the board of directors; and</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:39.5pt;;text-indent:-15pt;;text-align:left;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="color:#231F20;font-family:Times New Roman;">&#160;&#160;&#160;&#160;&#160;approval by the vote of the holders of a majority of the outstanding stock or, if the certificate of incorporation provides for more or less than one vote per share, a majority of the votes of the outstanding stock of a corporation entitled to vote on the matter.</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Standard of Conduct for Directors</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under applicable European and German law, both Management and Supervisory Board members must conduct their affairs with &#8220;the care and diligence of a prudent business man&#8221; and act in the best interest of the company. The scope of the fiduciary duties of Management and Supervisory Board members is generally determined by European and German legislation and by the courts. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statutory and fiduciary duties of members of the Management Board to the company include, among others:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:39.5pt;;text-indent:-15pt;;text-align:left;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="color:#231F20;font-family:Times New Roman;">&#160;&#160;&#160;&#160;&#160;to act in accordance with the law, the company&#8217;s articles of association and the rules of procedure for the Management Board, if any;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:39.5pt;;text-indent:-15pt;;text-align:left;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="color:#231F20;font-family:Times New Roman;">&#160;&#160;&#160;&#160;&#160;to report to the Supervisory Board on a regular basis as well as on certain important occasions;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:39.5pt;;text-indent:-15pt;;text-align:left;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="color:#231F20;font-family:Times New Roman;">&#160;&#160;&#160;&#160;&#160;to exercise reasonable care, skill and diligence;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:39.5pt;;text-indent:-15pt;;text-align:left;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="color:#231F20;font-family:Times New Roman;">&#160;&#160;&#160;&#160;&#160;to maintain a proper accounting system;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:39.5pt;;text-indent:-15pt;;text-align:left;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="color:#231F20;font-family:Times New Roman;">&#160;&#160;&#160;&#160;&#160;to not compete, directly or indirectly, with the company without permission by the supervisory board; and</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:39.5pt;;text-indent:-15pt;;text-align:left;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="color:#231F20;font-family:Times New Roman;">&#160;&#160;&#160;&#160;&#160;to secure that no further transactions are made in case of insolvency. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statutory and fiduciary duties of members of the Supervisory Board to the company include, among others:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:39.5pt;;text-indent:-15pt;;text-align:left;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="color:#231F20;font-family:Times New Roman;">&#160;&#160;&#160;&#160;&#160;to effectively supervise the Management Board&#8217;s handling of the company&#8217;s affairs; </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:39.5pt;;text-indent:-15pt;;text-align:left;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="color:#231F20;font-family:Times New Roman;">&#160;&#160;&#160;&#160;&#160;to evaluate and issue a resolution on certain transactions which can only be conducted by the Management Board after approval of the Supervisory Board;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:39.5pt;;text-indent:-15pt;;text-align:left;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="color:#231F20;font-family:Times New Roman;">&#160;&#160;&#160;&#160;&#160;to approve the company&#8217;s financial statements;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:39.5pt;;text-indent:-15pt;;text-align:left;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="color:#231F20;font-family:Times New Roman;">&#160;&#160;&#160;&#160;&#160;to appoint the Management Board members and to represent the company in transactions between the company and members of the Management Board; and</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:39.5pt;;text-indent:-15pt;;text-align:left;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="color:#231F20;font-family:Times New Roman;">&#160;&#160;&#160;&#160;&#160;to approve service contracts between individual members of the Supervisory Board and the company.</font></p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware law does not contain specific provisions setting forth the standard of conduct of a director. The scope of the fiduciary duties of directors is generally determined by the courts of the State of Delaware. In general, directors have a duty to act without self-interest, on a well- informed basis and in a manner they reasonably believe to be in the best interest of the stockholders.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Directors of a Delaware corporation owe fiduciary duties of care and loyalty to the corporation and to its stockholders. The duty of care generally requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself of all material information reasonably available regarding a significant transaction. The duty of loyalty requires that a director act in a manner he reasonably believes to be in the best interests of the corporation. He must not use his corporate position for personal gain or advantage. In general, but subject to certain exceptions, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties. Delaware courts have also imposed a heightened standard of conduct upon directors of a Delaware corporation who take any action designed to defeat a threatened change in control of the corporation. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, under Delaware law, when the board of directors of a Delaware corporation approves the sale or break-up of a corporation, the board of directors may, in certain circumstances, have a duty to obtain the highest value reasonably available to the stockholders.</p></td>
</tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="right";>
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94%;">
<tr>
<td valign="top"  style="width:16%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">European Union/Federal Republic of Germany</p></td>
<td valign="top"  style="width:42%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Delaware</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="right";>
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94%;">
<tr>
<td valign="top"  style="width:16%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">European Union/Federal Republic of Germany</p></td>
<td valign="top"  style="width:42%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Delaware</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholder Actions</font></p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under German law, generally, the company, rather than its shareholders, is the proper claimant in an action with respect to a wrong committed against the company, or in cases where there is an irregularity in the company&#8217;s internal management or supervision. Therefore, such claims may only be raised by the company represented by its Management Board, or, in the case of a wrong committed by a member of the Management Board, by the Supervisory Board.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, pursuant to German case law, the Supervisory Board is obliged to pursue the company&#8217;s claims against the Management Board, unless the interest of the company keeps them from doing so.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Management Board, or, if a claim is against a member of the Management Board, the Supervisory Board, is obliged to pursue the company&#8217;s claims against the designated individuals if so resolved by a simple majority of votes cast during a shareholders&#8217; meeting. With a simple majority of votes, shareholders can request that a representative pursues the claim on behalf of the company.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the company is unable to fulfill its third- party obligations, the company&#8217;s creditors may pursue the company&#8217;s damage claims against members of the Management Board for certain wrongdoings.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under certain circumstances, shareholders can bring forward damage claims of the company against its management on their own behalf. In order to bring forward such a claim one shareholder alone or together with other shareholders needs to hold at least one percent of the company&#8217;s share capital or a participation of &#8364;100,000 in the share capital. Additionally, the claimant(s) need(s) to pass through special claim approval procedures.</p></td>
<td valign="top"  style="width:42%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Delaware law, a stockholder may initiate a derivative action to enforce a right of a corporation if the corporation fails to enforce the right itself. The complaint must:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:39.5pt;;text-indent:-15pt;;text-align:left;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="color:#231F20;font-family:Times New Roman;">&#160;&#160;&#160;&#160;&#160;state that the plaintiff was a stockholder at the time of the transaction of which the plaintiff complains or that the plaintiffs shares thereafter devolved on the plaintiff by operation of law; and </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:39.5pt;;text-indent:-15pt;;text-align:left;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="color:#231F20;font-family:Times New Roman;">&#160;&#160;&#160;&#160;&#160;either (i) allege with particularity the efforts made by the plaintiff to obtain the action the plaintiff desires from the directors and the reasons for the plaintiff&#8217;s failure to obtain the action, or (ii) or state the reasons for not making the effort. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:39.5pt;;text-indent:-15pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:24.4pt;;text-indent:0pt;;text-align:left;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the plaintiff must remain a stockholder through the duration of the derivative suit. The action will not be dismissed or compromised without the approval of the Delaware Court of Chancery.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">American Depositary Shares </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Bank of New York Mellon, as depositary, will register and deliver the American Depositary Shares, or the ADSs. Each ADS will represent one share (or a right to receive one share) deposited with The Bank of New York Mellon SA/NV as custodian for the depositary in Germany. Each ADS will also represent any other securities, cash or other property which may be held by the depositary. The deposited shares together with any other securities, cash or other property held by the depositary are referred to as the deposited securities. The depositary&#8217;s office at which the ADSs will be administered and its principal executive office are located at 240 Greenwich Street, New York, New York 10286. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You may hold ADSs either (i) directly (a) by having an American Depositary Receipt, or an ADR, which is a certificate evidencing a specific number of ADSs registered in your name, or (b) by having uncertificated ADSs registered in your name, or (ii) indirectly by holding a security entitlement in ADSs through your broker or other financial institution that is a direct or indirect participant in The Depository Trust Company, or DTC. If you hold ADSs directly, you are a registered ADS holder, or an ADS holder. This description assumes you are an ADS holder. If you hold the ADSs indirectly, you must rely on the procedures of your broker or other financial institution to assert the rights of ADS holders described in this section. You should consult with your broker or financial institution to find out what those procedures are. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Registered holders of uncertificated ADSs will receive statements from the depositary confirming their holdings. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As an ADS holder, we will not treat you as one of our shareholders and you will not have shareholder rights. European and German law governs shareholder rights. The depositary will be the holder of the shares underlying your ADSs. As a registered holder of ADSs, you will have ADS holder rights. A deposit agreement among us, the depositary, ADS holders and all other persons indirectly or beneficially holding ADSs sets out ADS holder rights as well as the rights and obligations of the depositary. New York law governs the deposit agreement and the ADSs. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of the material provisions of the deposit agreement. For more complete information, you should read the entire deposit agreement and the form of ADR. Those documents are filed as exhibits to the registration statement of which this prospectus forms a part. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dividends and Other Distributions </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">How will ADS holders receive dividends and other distributions on the shares? </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The depositary has agreed to pay or distribute to ADS holders the cash dividends or other distributions it or the custodian receives on shares or other deposited securities, upon payment or deduction of its fees and expenses. You will receive these distributions in proportion to the number of shares your ADSs represent. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Cash<font style="font-style:normal;">. The depositary will convert any cash dividend or other cash distribution we pay on the shares into U.S. dollars, if it can do so on a reasonable basis and can transfer the U.S. dollars to the United States. If that is not possible or if any government approval is needed and cannot be obtained, the deposit agreement allows the depositary to distribute the foreign currency only to those ADS holders to whom it is possible to do so. It will hold the foreign currency it cannot convert for the account of the ADS holders who have not been paid. It will not invest the foreign currency and it will not be liable for any interest. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before making a distribution, any withholding taxes, or other governmental charges that must be paid will be deducted. The depositary will distribute only whole U.S. dollars and cents and will round fractional cents to the nearest whole cent. <font style="font-style:italic;">If the exchange rates fluctuate during a time when the depositary cannot convert the foreign currency, you may lose some of the value of the distribution.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Shares.<font style="font-style:normal;"> The depositary may distribute additional ADSs representing any shares we distribute as a dividend or free distribution. The depositary will only distribute whole ADSs. It will sell shares which would require it to deliver a fraction of an ADS (or ADSs representing those shares) and distribute the net proceeds in the same way as it does with cash. If the depositary does not distribute additional ADSs, the outstanding ADSs will also represent the new shares. The depositary may sell a portion of the distributed shares (or ADSs representing those shares) sufficient to pay its fees and expenses in connection with that distribution. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Rights to purchase additional shares.</font><font style="font-style:normal;"> If we offer holders of our securities any rights to subscribe for additional shares or any other rights, the depositary may (</font><font style="font-style:normal;">i</font><font style="font-style:normal;">) exercise those rights on behalf of ADS holders, (ii) distribute those rights to ADS holders or (iii) sell those rights and distribute the net proceeds to ADS holders, in each case after deduction or upon payment of its fees and expenses. To the extent the depositary does not do any of those things, it will allow the rights to lapse. </font><font style="font-weight:bold;font-style:normal;">In that case, you will receive no value for them.</font><font style="font-style:normal;"> The depositary will exercise or distribute rights only if we ask it to and provide satisfactory assurances to the depositary that it is legal to do so. If the depositary will exercise rights, it will purchase the securities to which the rights relate and distribute those securities or, in the case of shares, new ADSs representing the new shares, to subscribing ADS holders, but only if ADS holders have paid the exercise price to the depositary. U.S. securities laws may restrict the ability of the depositary to distribute rights or ADSs or other securities issued on exercise of rights to all or certain ADS holders, and the securities distributed may be subject to restrictions on transfer. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other Distributions.<font style="font-style:normal;"> The depositary will send to ADS holders anything else we distribute on deposited securities by any means it thinks is legal, fair and practical. If it cannot make the distribution in that way, the depositary has a choice. It may decide to sell what we distributed and distribute the net proceeds, in the same way as it does with cash. Or, it may decide to hold what we distributed, in which case ADSs will also represent the newly distributed property. However, the depositary is not required to distribute any securities (other than ADSs) to ADS holders unless it receives satisfactory evidence from us that it is legal to make that distribution. The depositary may sell a portion of the distributed securities or property sufficient to pay its fees and expenses in connection with that distribution. U.S. securities laws may restrict the ability of the depositary to distribute securities to all or certain ADS holders, and the securities distributed may be subject to restrictions on transfer. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any ADS holders. We have no obligation to register ADSs, shares, rights or other securities under the Securities Act. We also have no obligation to take any other action to permit the distribution of ADSs, shares, rights or anything else to ADS holders. <font style="font-weight:bold;">This means that you may not receive the distributions we make on our shares or any value for them if it is illegal or impractical for us to make them available to you.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deposit, Withdrawal and Cancellation </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">How are ADSs issued? </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The depositary will deliver ADSs if you or your broker deposits shares or evidence of rights to receive shares with the custodian. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will register the appropriate number of ADSs in the names you request and will deliver the ADSs to or upon the order of the person or persons that made the deposit. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">How can ADS holders withdraw the deposited securities? </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You may surrender your ADSs to the depositary for the purpose of withdrawal. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will deliver the shares and any other deposited securities underlying the ADSs to the ADS holder or a person the ADS holder designates at the office of the custodian. Or, at your request, risk and expense, the depositary will deliver the deposited securities at its office, if feasible. However, the depositary is not required to accept surrender of ADSs to the extent it would require delivery of a fraction of a deposited share or other security. The depositary may charge you a fee and its expenses for instructing the custodian regarding delivery of deposited securities. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">How do ADS holders interchange between certificated ADSs and uncertificated ADSs? </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You may surrender your ADR to the depositary for the purpose of exchanging your ADR for uncertificated ADSs. The depositary will cancel that ADR and will send to the ADS holder a statement confirming that the ADS holder is the registered holder of uncertificated ADSs. Upon receipt by the depositary of a proper instruction from a registered holder of uncertificated ADSs requesting the exchange of uncertificated ADSs for certificated ADSs, the depositary will execute and deliver to the ADS holder an ADR evidencing those ADSs. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Voting Rights </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">How do ADS holders vote? </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ADS holders may instruct the depositary how to vote the number of deposited shares their ADSs represent. If we request the depositary to solicit your voting instructions (and we are not required to do so), the depositary will notify you of a shareholders&#8217; meeting and send or make voting materials available to you. Those materials will describe the matters to be voted on and explain how ADS holders may instruct the depositary how to vote. For instructions to be valid, they must reach the depositary by a date set by the depositary. The depositary will try, as far as practical, subject to the laws of the State of New York and the provisions of our articles of association or similar documents, to vote or to have its agents vote the shares or other deposited securities as instructed by ADS holders. If we do not request the depositary to solicit your voting instructions, you can still send voting instructions, and, in that case, the depositary may try to vote as you instruct, but it is not required to do so. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Except by instructing the depositary as described above, you won&#8217;t be able to exercise voting rights unless you surrender your ADSs and withdraw the shares. However, you may not know about the meeting enough in advance to withdraw the shares.<font style="font-weight:normal;"> In any event, the depositary will not exercise any discretion in voting deposited securities and it will only vote or attempt to vote as instructed or as described in the following sentence. If (i) we asked the depositary to solicit your instructions at least 30 days before the meeting date, (ii) the depositary does not receive voting instructions from you by the specified date and (iii) we confirm to the depositary that: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we wish the depositary to vote uninstructed shares; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we reasonably do not know of any substantial shareholder opposition to a particular question; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the particular question is not materially adverse to the interests of shareholders, </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the depositary will consider you to have authorized and directed it to vote the number of deposited securities represented by your ADSs in favor of any resolution that we proposed in the invitation to the shareholders&#8217; meeting. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote your shares. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. <font style="font-weight:bold;">This means that you may not be able to exercise voting rights and there may be nothing you can do if your shares are not voted as you requested.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to give you a reasonable opportunity to instruct the depositary as to the exercise of voting rights relating to deposited securities, if we request the depositary to act, we agree to give the depositary notice of any such meeting and details concerning the matters to be voted upon at least 30 days in advance of the meeting date. </p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fees and Expenses </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94%;">
<tr>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Persons depositing or withdrawing<br />shares or ADS holders must pay<font style="font-style:normal;">:</font></p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">For<font style="font-style:normal;">:</font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:24.5pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$.05 (or less) per ADS</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any cash distribution to ADS holders</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A fee equivalent to the fee that would be payable if securities distributed to you had been shares and the shares had been deposited for issuance of ADSs</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Distribution of securities distributed to holders of deposited securities (including rights) that are distributed by the depositary to ADS holders</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$.05 (or less) per ADS per calendar year</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depositary services</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Registration or transfer fees</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transfer and registration of shares on our share register to or from the name of the depositary or its agent when you deposit or withdraw shares</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expenses of the depositary</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cable and facsimile transmissions (when expressly provided in the deposit agreement)</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:24.5pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Converting foreign currency to U.S. dollars</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Taxes and other governmental charges the depositary or the custodian has to pay on any ADSs or shares underlying ADSs, such as stock transfer taxes, stamp duty or withholding taxes</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As necessary</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any charges incurred by the depositary or its agents for servicing the deposited securities</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As necessary</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.43%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The depositary collects its fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The depositary may collect any of its fees by deduction from any cash distribution payable (or by selling a portion of securities or other property distributable) to ADS holders that are obligated to pay those fees. The depositary may generally refuse to provide fee-attracting services until its fees for those services are paid. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the depositary may make payments to us to reimburse us for costs and expenses generally arising out of establishment and maintenance of the ADS program, waive fees and expenses for services provided to us by the depositary or share revenue from the fees collected from ADS holders. In performing its duties under the deposit agreement, the depositary may use brokers, dealers, foreign currency dealers or other service providers that are owned by or affiliated with the depositary and that may earn or share fees, spreads or commissions. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The depositary may convert currency itself or through any of its affiliates and, in those cases, acts as principal for its own account and not as agent, advisor, broker or fiduciary on behalf of any other person and earns revenue, including, without limitation, transaction spreads, that it will retain for its own account. The revenue is based on, among other things, the difference between the exchange rate assigned to the currency conversion made under the deposit agreement and the rate that the depositary or its affiliate receives when buying or selling foreign currency for its own account. The depositary makes no representation that the exchange rate used or obtained in any currency conversion under the deposit agreement will be the most </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">favorable rate that could be obtained at the time or that the method by which that rate will be determined will be the most favorable to ADS holders, subject to the depositary&#8217;s obligations under the deposit agreement. The methodology used to determine exchange rates used in currency conversions is available upon request. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payment of Taxes </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You will be responsible for any taxes or other governmental charges payable on your ADSs or on the deposited securities represented by any of your ADSs. The depositary may refuse to register any transfer of your ADSs or allow you to withdraw the deposited securities represented by your ADSs until those taxes or other charges are paid. It may apply payments owed to you or sell deposited securities represented by your ADSs to pay any taxes owed and you will remain liable for any deficiency. If the depositary sells deposited securities, it will, if appropriate, reduce the number of ADSs to reflect the sale and pay to ADS holders any proceeds, or send to ADS holders any property, remaining after it has paid the taxes. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tender and Exchange Offers; Redemption, Replacement or Cancellation of Deposited Securities </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The depositary will not tender deposited securities in any voluntary tender or exchange offer unless instructed to do by an ADS holder surrendering ADSs and subject to any conditions or procedures the depositary may establish. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If deposited securities are redeemed for cash in a transaction that is mandatory for the depositary as a holder of deposited securities, the depositary will call for surrender of a corresponding number of ADSs and distribute the net redemption money to the holders of called ADSs upon surrender of those ADSs. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If there is any change in the deposited securities such as a sub-division, combination or other reclassification, or any merger, consolidation, recapitalization or reorganization affecting the issuer of deposited securities in which the depositary receives new securities in exchange for or in lieu of the old deposited securities, the depositary will hold those replacement securities as deposited securities under the deposit agreement. However, if the depositary decides it would not be lawful and practical to hold the replacement securities because those securities could not be distributed to ADS holders or for any other reason, the depositary may instead sell the replacement securities and distribute the net proceeds upon surrender of the ADSs. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If there is a replacement of the deposited securities and the depositary will continue to hold the replacement securities, the depositary may distribute new ADSs representing the new deposited securities or ask you to surrender your outstanding ADRs in exchange for new ADRs identifying the new deposited securities. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If there are no deposited securities underlying ADSs, including if the deposited securities are cancelled, or if the deposited securities underlying ADSs have become apparently worthless, the depositary may call for surrender or of those ADSs or cancel those ADSs upon notice to the ADS holders. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amendment and Termination </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">How may the deposit agreement be amended? </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may agree with the depositary to amend the deposit agreement and the ADRs without your consent for any reason. If an amendment adds or increases fees or charges, except for taxes and other governmental charges or expenses of the depositary for registration fees, facsimile costs, delivery charges or similar items, or prejudices a substantial right of ADS holders, it will not become effective for outstanding ADSs until 30 days after the depositary notifies ADS holders of the amendment. <font style="font-weight:bold;">At the time an amendment becomes effective, you are considered, by continuing to hold your ADSs, to agree to the amendment and to be bound by the ADRs and the deposit agreement as amended.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">How may the deposit agreement be terminated? </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The depositary will initiate termination of the deposit agreement if we instruct it to do so. The depositary may initiate termination of the deposit agreement if: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>60 days have passed since the depositary told us it wants to resign but a successor depositary has not been appointed and accepted its appointment; </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we delist the ADSs from an exchange in the United States on which they were listed and do not list the ADSs on another exchange in the United States or make arrangements for trading of ADSs on the U.S. </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">over-the-counter</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> market; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we delist our ordinary shares from an exchange outside the United States on which they were listed and do not list the shares on another exchange outside the United States; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the depositary has reason to believe the ADSs have become, or will become, ineligible for registration on Form F-6 under the Securities Act; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we appear to be insolvent or enter insolvency proceedings </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>all or substantially all the value of the deposited securities has been distributed either in cash or in the form of securities; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>there are no deposited securities underlying the ADSs or the underlying deposited securities have become apparently worthless; or </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>there has been a replacement of deposited securities. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the deposit agreement will terminate, the depositary will notify ADS holders at least 90 days before the termination date. At any time after the termination date, the depositary may sell the deposited securities. After that, the depositary will hold the money it received on the sale, as well as any other cash it is holding under the deposit agreement, unsegregated and without liability for interest, for the pro rata benefit of the ADS holders that have not surrendered their ADSs. Normally, the depositary will sell as soon as practicable after the termination date. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the termination date and before the depositary sells, ADS holders can still surrender their ADSs and receive delivery of deposited securities, except that the depositary may refuse to accept a surrender for the purpose of withdrawing deposited securities or reverse previously accepted surrenders of that kind that have not settled if it would interfere with the selling process. The depositary may refuse to accept a surrender for the purpose of withdrawing sale proceeds until all the deposited securities have been sold. The depositary will continue to collect distributions on deposited securities, but, after the termination date, the depositary is not required to register any transfer of ADSs or distribute any dividends or other distributions on deposited securities to the ADSs holder (until they surrender their ADSs) or give any notices or perform any other duties under the deposit agreement except as described in this paragraph. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Limitations on Obligations and Liability </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Limits on our Obligations and the Obligations of the Depositary; Limits on Liability to Holders of ADSs </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The deposit agreement expressly limits our obligations and the obligations of the depositary. It also limits our liability and the liability of the depositary. We and the depositary:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>are only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith, and the depositary will not be a fiduciary or have any fiduciary duty to holders of ADSs; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>are not liable if we are or it is prevented or delayed by law or by events or circumstances beyond our or its ability to prevent or counteract with reasonable care or effort from performing our or its obligations under the deposit agreement; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>are not liable if we or it exercises discretion permitted under the deposit agreement; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>are not liable for the inability of any holder of ADSs to benefit from any distribution on deposited securities that is not made available to holders of ADSs under the terms of the deposit agreement, or for any special, consequential or punitive damages for any breach of the terms of the deposit agreement; </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have no obligation to become involved in a lawsuit or other proceeding related to the ADSs or the deposit agreement on your behalf or on behalf of any other </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">person;</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>may rely upon any documents we believe or it believes in good faith to be genuine and to have been signed or presented by the proper person; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>are not liable for the acts or omissions of any securities depository, clearing agency or settlement system; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the depositary has no duty to make any determination or provide any information as to our tax status, or any liability for any tax consequences that may be incurred by ADS holders as a result of owning or holding ADSs or be liable for the inability or failure of an ADS holder to obtain the benefit of a foreign tax credit, reduced rate of withholding or refund of amounts withheld in respect of tax or any other tax benefit. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the deposit agreement, we and the depositary agree to indemnify each other under certain circumstances. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Requirements for Depositary Actions </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before the depositary will deliver or register a transfer of ADSs, make a distribution on ADSs, or permit withdrawal of shares, the depositary may require:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>payment of stock transfer or other taxes or other governmental charges and transfer or registration fees charged by third parties for the transfer of any shares or other deposited securities; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>satisfactory proof of the identity and genuineness of any signature or other information it deems necessary; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>compliance with regulations it may establish, from time to time, consistent with the deposit agreement, including presentation of transfer documents. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The depositary may refuse to deliver ADSs or register transfers of ADSs when the transfer books of the depositary or our transfer books are closed or at any time if the depositary or we think it advisable to do so. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Your Right to Receive the Shares Underlying your ADSs </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ADS holders have the right to cancel their ADSs and withdraw the underlying shares at any time except:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>when temporary delays arise because (i) the depositary has closed its transfer books or we have closed our transfer books, (ii) the transfer of shares is blocked to permit voting at a shareholders&#8217; meeting or (iii) we are paying a dividend on our shares; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>when you owe money to pay fees, taxes and similar charges; or </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of shares or other deposited securities. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This right of withdrawal may not be limited by any other provision of the deposit agreement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Direct Registration System </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the deposit agreement, all parties to the deposit agreement acknowledge that the Direct Registration System, or DRS, and Profile Modification System, or Profile, will apply to the ADSs. DRS is a system administered by DTC that facilitates interchange between registered holding of uncertificated ADSs and holding of security entitlements in ADSs through DTC and a DTC participant. Profile is a feature of DRS that allows a DTC participant, claiming to act on behalf of a registered holder of uncertificated ADSs, to direct the depositary to register a transfer of those ADSs to DTC or its nominee and to deliver those ADSs to the DTC account of that </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DTC participant without receipt by the depositary of prior authorization from the ADS holder to register that transfer. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with and in accordance with the arrangements and procedures relating to DRS/Profile, the parties to the deposit agreement understand that the depositary will not determine whether the DTC participant that is claiming to be acting on behalf of an ADS holder in requesting registration of transfer and delivery as described in the paragraph above has the actual authority to act on behalf of the ADS holder (notwithstanding any requirements under the Uniform Commercial Code). In the deposit agreement, the parties agree that the depositary&#8217;s reliance on and compliance with instructions received by the depositary through the DRS/Profile system and in accordance with the deposit agreement will not constitute negligence or bad faith on the part of the depositary. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shareholder Communications; Inspection of Register of Holders of ADSs </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The depositary will make available for your inspection at its office all communications that it receives from us as a holder of deposited securities that we make generally available to holders of deposited securities. The depositary will send you copies of those communications or otherwise make those communications available to you if we ask it to. You have a right to inspect the register of holders of ADSs, but not for the purpose of contacting those holders about a matter unrelated to our business or the ADSs. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Jury Trial Waiver </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The deposit agreement provides that, to the extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our shares, the ADSs or the deposit agreement, including any claim under the U.S. federal securities laws. If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable in the facts and circumstances of that case in accordance with applicable case law. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.43%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You will not, by agreeing to the terms of the deposit agreement, be deemed to have waived our or the depositary&#8217;s compliance with U.S. federal securities laws and the rules and regulations promulgated thereunder. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.15
<SEQUENCE>4
<FILENAME>bntx-ex415_13.htm
<DESCRIPTION>EX-4.15
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-ex415_13.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4.15</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THE SYMBOL &#8220;[***]&#8221; DENOTES PLACES WHERE CERTAIN IDENTIFIED</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</p>
<p style="text-align:center;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#282828;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FIRST AMENDMENT TO <font style="color:#3D3D3D;">THE </font>COLLABORATION AGREEMENT</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#282828;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">T<font style="font-variant: small-caps;">his</font> FIRST <font style="font-weight:normal;">AMENDMENT TO THE COLLABORATION AGREEMENT </font>("First Amendment") <font style="color:#161616;font-size:11pt;font-weight:normal;">i</font><font style="color:#3D3D3D;font-size:11pt;font-weight:normal;">s </font><font style="font-size:11pt;font-weight:normal;">made and entered </font><font style="color:#161616;font-size:11pt;font-weight:normal;">into</font><font style="color:#3D3D3D;font-size:11pt;font-weight:normal;">, </font><font style="font-size:11pt;font-weight:normal;">effective </font><font style="color:#3D3D3D;font-size:11pt;font-weight:normal;">as of </font><font style="font-size:11pt;font-weight:normal;">June </font><font style="color:#161616;font-size:11pt;font-weight:normal;">1, </font><font style="font-size:11pt;font-weight:normal;">2018 </font><font style="font-size:11pt;">("Amendment Effective </font><font style="color:#161616;font-size:11pt;">Date"), </font><font style="color:#161616;font-size:11pt;font-weight:normal;">by </font><font style="font-size:11pt;font-weight:normal;">and between BioNTech RNA Pharmaceuticals GmbH, a </font><font style="color:#161616;font-size:11pt;font-weight:normal;">limit</font><font style="color:#3D3D3D;font-size:11pt;font-weight:normal;">ed </font><font style="font-size:11pt;font-weight:normal;">liability company organized </font><font style="color:#161616;font-size:11pt;font-weight:normal;">under </font><font style="font-size:11pt;font-weight:normal;">the </font><font style="color:#161616;font-size:11pt;font-weight:normal;">laws </font><font style="font-size:11pt;font-weight:normal;">of Germany </font><font style="font-size:11pt;">("RNP") </font><font style="font-size:11pt;font-weight:normal;">and BioNTech AG, a </font><font style="color:#3D3D3D;font-size:11pt;font-weight:normal;">stock </font><font style="font-size:11pt;font-weight:normal;">corporation organized under the </font><font style="color:#161616;font-size:11pt;font-weight:normal;">laws </font><font style="font-size:11pt;font-weight:normal;">of Germany </font><font style="font-size:11pt;">("BNT") </font><font style="font-size:11pt;font-weight:normal;">(RNP and BNT colle</font><font style="color:#505050;font-size:11pt;font-weight:normal;">c</font><font style="font-size:11pt;font-weight:normal;">tively, </font><font style="color:#3D3D3D;font-size:11pt;">"</font><font style="color:#161616;font-size:11pt;">BioNTech")</font><font style="color:#3D3D3D;font-size:11pt;">, </font><font style="font-size:11pt;font-weight:normal;">and Genentech, Inc., a corporation organized under the </font><font style="color:#161616;font-size:11pt;font-weight:normal;">l</font><font style="color:#3D3D3D;font-size:11pt;font-weight:normal;">aws </font><font style="font-size:11pt;font-weight:normal;">of the State of </font><font style="color:#161616;font-size:11pt;font-weight:normal;">D</font><font style="color:#3D3D3D;font-size:11pt;font-weight:normal;">e</font><font style="color:#161616;font-size:11pt;font-weight:normal;">lawar</font><font style="color:#3D3D3D;font-size:11pt;font-weight:normal;">e </font><font style="font-size:11pt;">("GNE") </font><font style="font-size:11pt;font-weight:normal;">and F. </font><font style="color:#161616;font-size:11pt;font-weight:normal;">Hoffmann-La </font><font style="font-size:11pt;font-weight:normal;">Roche </font><font style="color:#161616;font-size:11pt;font-weight:normal;">Ltd</font><font style="color:#3D3D3D;font-size:11pt;font-weight:normal;">, </font><font style="font-size:11pt;font-weight:normal;">a corporation </font><font style="color:#3D3D3D;font-size:11pt;font-weight:normal;">organized </font><font style="color:#161616;font-size:11pt;font-weight:normal;">und</font><font style="color:#3D3D3D;font-size:11pt;font-weight:normal;">e</font><font style="color:#161616;font-size:11pt;font-weight:normal;">r </font><font style="font-size:11pt;font-weight:normal;">the laws of Switzerland </font><font style="font-size:11pt;">("Roche") </font><font style="font-size:11pt;font-weight:normal;">(GNE and Roche, collectively</font><font style="color:#505050;font-size:11pt;font-weight:normal;">, </font><font style="font-size:11pt;">"Genentech"). </font><font style="font-size:11pt;font-weight:normal;">BioNTech and Genentech are sometimes </font><font style="color:#161616;font-size:11pt;font-weight:normal;">r</font><font style="color:#3D3D3D;font-size:11pt;font-weight:normal;">efe</font><font style="color:#161616;font-size:11pt;font-weight:normal;">rr</font><font style="color:#3D3D3D;font-size:11pt;font-weight:normal;">ed </font><font style="color:#161616;font-size:11pt;font-weight:normal;">to herein </font><font style="font-size:11pt;font-weight:normal;">individually as </font><font style="color:#3D3D3D;font-size:11pt;font-weight:normal;">a </font><font style="color:#3D3D3D;font-size:11pt;">"</font><font style="color:#161616;font-size:11pt;">Party</font><font style="color:#505050;font-size:11pt;">" </font><font style="font-size:11pt;font-weight:normal;">and collectively as </font><font style="color:#161616;font-size:11pt;font-weight:normal;">th</font><font style="color:#3D3D3D;font-size:11pt;font-weight:normal;">e </font><font style="color:#3D3D3D;font-size:11pt;">"Part</font><font style="color:#161616;font-size:11pt;">ies ."</font></p>
<p style="text-align:center;margin-top:20pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#282828;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BACKGROUND</p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#282828;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, <font style="font-weight:normal;">the </font><font style="color:#161616;font-weight:normal;">Parti</font><font style="color:#3D3D3D;font-weight:normal;">es </font><font style="font-weight:normal;">entered </font><font style="color:#161616;font-weight:normal;">into </font><font style="font-weight:normal;">a Collaboration Agreement dated as of September 20, 2016 </font><font style="color:#161616;font-weight:normal;">pur</font><font style="color:#3D3D3D;font-weight:normal;">s</font><font style="color:#161616;font-weight:normal;">uant to </font><font style="font-weight:normal;">which </font><font style="color:#161616;font-weight:normal;">BioNTech </font><font style="font-weight:normal;">and Genentech agreed </font><font style="color:#161616;font-weight:normal;">to </font><font style="font-weight:normal;">collaborate </font><font style="color:#161616;font-weight:normal;">in </font><font style="color:#3D3D3D;font-weight:normal;">the </font><font style="font-weight:normal;">research, </font><font style="color:#161616;font-weight:normal;">d</font><font style="color:#3D3D3D;font-weight:normal;">evelopmen</font><font style="color:#161616;font-weight:normal;">t, </font><font style="font-weight:normal;">and commercialization of Collaboration Products (the </font><font style="color:#3D3D3D;">"Agr</font><font style="color:#161616;">eement</font><font style="color:#3D3D3D;">");</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#282828;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="color:#505050;">, </font><font style="color:#161616;font-weight:normal;">the Partie</font><font style="color:#3D3D3D;font-weight:normal;">s </font><font style="color:#161616;font-weight:normal;">have </font><font style="font-weight:normal;">agreed to amend </font><font style="color:#161616;font-weight:normal;">the </font><font style="font-weight:normal;">Agreement </font><font style="color:#161616;font-weight:normal;">to </font><font style="font-weight:normal;">add </font><font style="color:#3D3D3D;font-weight:normal;">a </font><font style="font-weight:normal;">patent </font><font style="color:#161616;font-weight:normal;">to </font><font style="font-weight:normal;">the </font><font style="color:#161616;font-weight:normal;">li</font><font style="color:#3D3D3D;font-weight:normal;">st </font><font style="font-weight:normal;">of BioNTech Core </font><font style="color:#161616;font-weight:normal;">Patent</font><font style="color:#3D3D3D;font-weight:normal;">s </font><font style="font-weight:normal;">as set forth herein</font><font style="color:#505050;font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#161616;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOW <font style="color:#282828;">THEREFORE, </font><font style="color:#282828;font-weight:normal;">for good and valuable consideration, the </font><font style="font-weight:normal;">r</font><font style="color:#3D3D3D;font-weight:normal;">ece</font><font style="font-weight:normal;">ipt </font><font style="color:#282828;font-weight:normal;">and </font><font style="color:#3D3D3D;font-weight:normal;">sufficiency </font><font style="color:#282828;font-weight:normal;">of which </font><font style="font-weight:normal;">i</font><font style="color:#3D3D3D;font-weight:normal;">s </font><font style="font-weight:normal;">hereby </font><font style="color:#282828;font-weight:normal;">acknowledged, </font><font style="font-weight:normal;">the </font><font style="color:#282828;font-weight:normal;">Parties agree as follows:</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#161616;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I <font style="color:#3D3D3D;">. </font><font style="font-weight:bold;color:#282828;">Schedule 1</font><font style="font-weight:bold;color:#505050;">.</font><font style="font-weight:bold;color:#282828;">20 BioNTech Core </font><font style="font-weight:bold;">Patents. </font><font style="color:#282828;">Schedule </font>1.20 <font style="color:#282828;">shall be deleted and replaced </font>in it<font style="color:#3D3D3D;">s </font><font style="color:#282828;">entirety with </font>the revised <font style="color:#282828;">Schedule </font>1<font style="color:#505050;">.</font><font style="color:#282828;">20 attached </font>her<font style="color:#3D3D3D;">e</font>to.</p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#282828;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. <font style="font-weight:bold;">Survival </font><font style="font-weight:bold;color:#161616;">of </font><font style="font-weight:bold;">Agreement Terms. </font>All terms and conditions of <font style="color:#3D3D3D;">t</font><font style="color:#161616;">he </font>Agreement not modified by this First Amendment shall continue in full force and effect <font style="color:#161616;">in </font>accordance with <font style="color:#161616;">their terms. </font>All <font style="color:#161616;">capitalized terms </font>not otherwise <font style="color:#161616;">defined herein </font><font style="color:#3D3D3D;">shall </font>have the same definition as <font style="color:#161616;">in the </font>Agreement. In the event of any conflict between <font style="color:#3D3D3D;">the</font> terms <font style="color:#3D3D3D;">a</font><font style="color:#161616;">nd </font>conditions of this First Amendment and the Agreement, <font style="color:#161616;">the </font>terms and conditions <font style="color:#3D3D3D;">set </font>forth <font style="color:#161616;">in this </font>First Amendment shall control with respect <font style="color:#161616;">to the </font>subject matter hereof.</p>
<p style="text-align:center;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#161616;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[Signature <font style="color:#282828;">page </font>follows <font style="color:#3D3D3D;font-weight:normal;">- </font>the rest of <font style="color:#282828;">this </font>page intentionally left blank]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#1F1F1F;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IN WITNES<font style="color:#4D4D4D;">S </font><font style="color:#363636;">WHEREOF, </font><font style="font-weight:normal;">the Pa</font><font style="color:#4D4D4D;font-weight:normal;">r</font><font style="font-weight:normal;">ties h</font><font style="color:#4D4D4D;font-weight:normal;">ave exec</font><font style="font-weight:normal;">ut</font><font style="color:#4D4D4D;font-weight:normal;">e</font><font style="font-weight:normal;">d this First </font><font style="color:#363636;font-weight:normal;">Amendment by their </font><font style="font-weight:normal;">respe</font><font style="color:#4D4D4D;font-weight:normal;">c</font><font style="font-weight:normal;">tiv</font><font style="color:#4D4D4D;font-weight:normal;">e </font><font style="color:#363636;font-weight:normal;">officers hereunto duly authorized, </font><font style="font-weight:normal;">on the </font><font style="color:#363636;font-weight:normal;">Amendment Effective Date.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="top"  style="width:48.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">GENENTECH, INC.</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:48.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BIONTECH RNA</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:48.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:48.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PHARMACEUTICALS GMBH</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:48.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:48.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:42%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:42.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:48.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">F. HOFFMANN-LA ROCHE LTD</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:48.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BIONTECH SE</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:42%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:42.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:48.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">F. HOFFMANN-LA ROCHE LTD</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:48.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:42%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#2D2D2D;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Core Patents</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:59.93%;">
<tr>
<td style="width:10.96%;"></td>
<td style="width:23.55%;"></td>
<td style="width:25.42%;"></td>
</tr>
<tr>
<td rowspan="2" valign="bottom"  style=" border-top:solid 0.75pt #343434; border-bottom:solid 0.75pt #343434; border-left:solid 0.75pt #282828; border-right:solid 0.75pt #343434;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#161616;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">No.</font></p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #343434; border-bottom:solid 0.75pt #2B2B2B; border-left:solid 0.75pt #343434; border-right:solid 0.75pt #030303;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#161616;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sole<font style="color:#484848;">l</font>y <font style="color:#2D2D2D;">owned </font>BioNTech <font style="color:#2D2D2D;">Core</font></p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #343434; border-bottom:solid 0.75pt #030303; border-left:solid 0.75pt #030303; border-right:solid 0.75pt #2B2B2B;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#161616;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In-Licensed <font style="color:#2D2D2D;">Bio</font><font style="color:#484848;">N</font><font style="color:#2D2D2D;">Tech </font>Co<font style="color:#484848;">r</font><font style="color:#2D2D2D;">e</font></p></td>
</tr>
<tr>
<td valign="bottom"  style=" border-top:solid 0.75pt #2B2B2B; border-bottom:solid 0.75pt #383838; border-left:solid 0.75pt #343434; border-right:solid 0.75pt #2F2F2F;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#161616;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #030303; border-bottom:solid 0.75pt #383838; border-left:solid 0.75pt #2F2F2F; border-right:solid 0.75pt #2B2B2B;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#161616;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents</p></td>
</tr>
<tr>
<td valign="bottom"  style=" border-top:solid 0.75pt #444444; border-bottom:solid 0.75pt #282828; border-left:solid 0.75pt #282828; border-right:solid 0.75pt #0F0F0F;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#161616;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #383838; border-bottom:solid 0.75pt #4B4B4B; border-left:solid 0.75pt #0F0F0F; border-right:solid 0.75pt #2F2F2F;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #383838; border-bottom:solid 0.75pt #4B4B4B; border-left:solid 0.75pt #2F2F2F; border-right:solid 0.75pt #2B2B2B;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#161616;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:29.96%;">
<tr>
<td style="width:12.53%;"></td>
<td style="width:17.43%;"></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  style=" border-top:solid 0.75pt #343434; border-bottom:solid 0.75pt #343434; border-left:solid 0.75pt #282828; border-right:solid 0.75pt #2B2B2B;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#161616;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Neoepitope Prediction Algorithm</font></p></td>
</tr>
<tr>
<td valign="bottom"  style=" border-top:solid 0.75pt #444444; border-bottom:solid 0.75pt #282828; border-left:solid 0.75pt #282828; border-right:solid 0.75pt #0F0F0F;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#161616;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #383838; border-bottom:solid 0.75pt #4B4B4B; border-left:solid 0.75pt #0F0F0F; border-right:solid 0.75pt #2B2B2B;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#161616;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.82%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.16
<SEQUENCE>5
<FILENAME>bntx-ex416_11.htm
<DESCRIPTION>EX-4.16
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-ex416_11.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-right:1.11%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">Exhibit 4.16</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">THE SYMBOL &#8220;[***]&#8221; DENOTES PLACES WHERE CERTAIN IDENTIFIED</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</p>
<p style="margin-top:10pt;text-align:center;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECOND AMENDMENT TO</p>
<p style="margin-top:0pt;text-align:center;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THE COLLABORATION AGREEMENT</p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This SECOND AMENDMENT (the &#8220;<font style="font-weight:bold;">Second Amendment</font>&#8221;) is made and entered into, effective as of December 6, 2019 (the &#8220;<font style="font-weight:bold;">Second Amendment Effective Date</font>&#8221;), by and between BioNTech RNA Pharmaceuticals GmbH, a limited liability company organized under the laws of Germany (&#8220;<font style="font-weight:bold;">RNP</font>&#8221;) and BioNTech SE, a European stock corporation (&#8220;<font style="font-weight:bold;">BNT</font>&#8221;) (RNP and BNT collectively, &#8220;<font style="font-weight:bold;">BioNTech</font>&#8221;), and Genentech, Inc., a corporation organized under the laws of the State of Delaware (&#8220;<font style="font-weight:bold;">GNE</font>&#8221;) and F. Hoffmann-La Roche Ltd, a corporation organized under the laws of Switzerland (&#8220;<font style="font-weight:bold;">Roche</font>&#8221;) (GNE and Roche, collectively, &#8220;<font style="font-weight:bold;">Genentech</font>&#8221;). </p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Parties entered into a Collaboration Agreement, dated as of September 20, 2016, as amended on June 1, 2018, pursuant to which BioNTech and Genentech agreed to collaborate in the research, development, and commercialization of Collaboration Products (the &#8220;<font style="font-weight:bold;">Agreement</font>&#8221;).</p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, BioNTech and Genentech wish to modify certain terms of the Agreement with respect to [***] (i) certain RNA manufacturing projects within the CMC Development Plan and (ii) development of the commercial upstream manufacturing process. </p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Defined Terms</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Section 1.20 is hereby deleted in its entirety and replaced with the following:</font></p></td></tr></table></div>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="DocXTextRef24"></a>&#8220;&#8216;<font style="font-weight:bold;">BioNTech Core Patents</font><a name="DocXTextRef24"></a>&#8217; means (a) the Patents listed on <font style="text-decoration:underline;">Schedule 1.20</font>, (b) [***] and (c) all Patents claiming priority to any of the Patents described in clauses (a) or (b), or claiming priority to a priority document thereof.&#8221;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Section 1.27 is hereby amended by adding the following sentence to the end of the Section:</font></p></td></tr></table></div>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref453531682"></a><a name="_Ref453531682"></a>&#8220;For clarity, BioNTech Know-How [***].&#8221;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">c.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Section 1.59 is hereby amended by adding the following clause to the end of the Section:</font></p></td></tr></table></div>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;; <font style="font-style:italic;">provided</font>, however, that, notwithstanding anything to the contrary in this Agreement or the MDSA, Collaboration Know-How [***]&#8221;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">d.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The following definition is hereby added to the Agreement as Section 1.331:</font></p></td></tr></table></div>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;&#8216;<font style="font-weight:bold;">External Sequencing Party</font>&#8217; means an entity other than BioNTech or Genentech that is selected by Genentech to conduct some or all of the Sequencing Manufacturing Project.&#8221; </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">e.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The following definition is hereby added to the Agreement as Section 1.332:</font></p></td></tr></table></div>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;&#8216;<font style="font-weight:bold;">RNA Manufacturing Know-How</font>&#8217; means all Know-How that is discovered, generated, conceived or reduced to practice by a Party (or any authorized Third Party acting on a Party&#8217;s behalf) solely or jointly in the course of conducting the RNA Manufacturing Projects.&#8221;</p>
<p style="text-align:left;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">f.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;"></font><font style="color:#000000;"></font><font style="color:#000000;">The following definition is hereby added to the Agreement as Section 1.333:</font></p></td></tr></table></div>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;&#8216;<font style="font-weight:bold;">RNA Manufacturing Projects</font>&#8217; means the work packages for the Collaboration Products concerning RNA manufacturing process, [***] set forth in <font style="text-decoration:underline;">Schedule&#160;1.333</font>.&#8221;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">g.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The following definition is hereby added to the Agreement as Section 1.334:</font></p></td></tr></table></div>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;&#8216;<font style="font-weight:bold;">Sequencing Manufacturing IP</font>&#8217; means the Sequencing Manufacturing Know-How and all Patents that claim any such Sequencing Manufacturing Know-How.&#8221;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">h.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The following definition is hereby added to the Agreement as Section 1.335:</font></p></td></tr></table></div>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;&#8216;<font style="font-weight:bold;">Sequencing Manufacturing Know-How</font>&#8217; means all Know-How that is discovered, generated, conceived or reduced to practice by Genentech or by the External Sequencing Party on a Party&#8217;s behalf (whether solely or jointly with a Party) in the course of conducting any activities in connection with the Sequencing Manufacturing Project.&#8221;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">i.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The following definition is hereby added to the Agreement as Section 1.336:</font></p></td></tr></table></div>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;&#8216;<font style="font-weight:bold;">Sequencing Manufacturing Project</font>&#8217; means the development of the upstream portion of the Manufacturing Process for Commercial Manufacturing [***].&#8221;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Exhibits</font><font style="color:#000000;">.&nbsp;&nbsp;The schedule attached hereto as Exhibit A is hereby incorporated into the Agreement as </font><font style="text-decoration:underline;color:#000000;">Schedule 1.333</font><font style="color:#000000;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Amendment of the CMC Development Plan</font><font style="color:#000000;">.&nbsp;&nbsp;For each RNA Manufacturing Project, the Parties hereby agree that they will (a) agree upon a written project plan for such RNA Manufacturing Project, which will set forth the scope of work to be performed by each Party, deliverables, time schedule and budget (including required FTEs, equipment and other resources), (b) promptly amend the CMC Development Plan to include such agreed-upon project plan for such RNA Manufacturing Project, and (c) conduct such RNA Manufacturing Project in accordance with such project plan.&nbsp;&nbsp;Notwithstanding the foregoing, in the event that the Parties are unable to agree on such written project plan [***]. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Decision-Making</font><font style="color:#000000;">.&nbsp;&nbsp;Section 2.8.2(g) is hereby amended by adding the following clause to the end of the Section:</font></p></td></tr></table></div>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;margin-left:3.33%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;[***]&#8221; </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Sequencing Manufacturing by the External Sequencing Party</font><font style="color:#000000;">.&nbsp;&nbsp;The following provision is hereby added to the Agreement as Section 7.4:</font></p></td></tr></table></div>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;margin-left:3.33%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Sequencing Manufacturing by the External Sequencing Party<font style="font-weight:normal;">.</font> </p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;margin-left:3.33%;text-indent:3.33%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.4.1<font style="margin-left:36pt;">Sequencing Manufacturing Project</font><font style="font-weight:normal;">. Notwithstanding anything to the contrary in this Agreement (including Sections 7.1 and 7.2) or the MDSA, Genentech shall have the sole right and responsibility for the performance of the Sequencing Manufacturing Project, at its discretion (subject to Sections 7.4.2 and 10.2.5), and may use the External Sequencing Party to conduct some or all of the Sequencing Manufacturing Project.&nbsp;&nbsp;Genentech shall ensure that the Sequencing Manufacturing Project is designed to deliver, and shall use commercially reasonable efforts to deliver, [***].</font></p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;margin-left:3.33%;text-indent:3.33%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.4.2<font style="margin-left:36pt;">Use of External Sequencing Party by BioNTech</font><font style="font-weight:normal;">.&nbsp;&nbsp;If in connection with BioNTech&#8217;s Development of a BioNTech Indication or BioNTech&#8217;s Development or Commercialization of Reversion Products pursuant to Section 14.5.4, in each case, in accordance with (and subject to the terms and conditions </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;margin-left:3.33%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">of) this Agreement,&nbsp;&nbsp;BioNTech desires to use the External Sequencing Party that Genentech is using to perform the sequencing for the upstream portion of the Manufacturing Process for Commercial Manufacturing [***], Genentech will [***] in the case of BioNTech Indications, or [***] in the case of Reversion Products.&#8217;</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">6.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Costs</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The following provision is hereby added to the Agreement as Section 8.2.8:</font></p></td></tr></table></div>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">RNA Manufacturing Project Costs</font>.&nbsp;&nbsp;BioNTech shall be solely responsible for, and shall bear, all CMC Development Costs incurred by or on behalf of BioNTech or Genentech in the performance of activities pursuant to a RNA Manufacturing Project.&nbsp;&nbsp;In the event that Genentech incurs CMC Development Costs in connection with an RNA Manufacturing Project, such costs shall be reported to, and reimbursed by, BioNTech as part of the reconciliation process set forth in Sections 8.2.6 and 8.2.7.&nbsp;&nbsp;Genentech may offset the amounts of any invoices for such reconciled costs not paid in accordance with Section 8.2.7 from any payments due to BioNTech pursuant to Sections 8.4.1 and 8.7.&nbsp;&nbsp;Notwithstanding the foregoing, for any portion of such CMC Development Costs that both (a) are incurred by or on behalf of Genentech in excess of [***] percent ([***]%) of the budget set forth in the CMC Development Plan for activities allocated to Genentech pursuant to such RNA Manufacturing Project, and (b) have not been approved by BioNTech in advance, Genentech shall bear such portion of the CMC Development Costs.&nbsp;&nbsp;For clarity, the costs of implementing any processes or developments made under an RNA Manufacturing Project into the Manufacturing Process for a Collaboration Product shall be Shared Development Costs.&#8221;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The following provision is hereby added to the Agreement as Section 8.2.9:</font></p></td></tr></table></div>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Sequencing Manufacturing Project</font>.&nbsp;&nbsp;Genentech shall be solely responsible for, and shall bear, all Development Costs incurred by it and its Affiliates for the performance of the Sequencing Manufacturing Project by Genentech, its Affiliates or the External Sequencing Party.&#8221;&nbsp;&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">7.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Intellectual Property</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The following is provision is hereby added to Section 10.2.1 as subsection&#160;(d):</font></p></td></tr></table></div>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;[***]&#8221;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The following provision is hereby added to the Agreement as Section 10.2.5:</font></p></td></tr></table></div>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;[***]&#8221; </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">8.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Survival of Agreement Terms</font><font style="color:#000000;">.&nbsp;&nbsp;All terms and conditions of the Agreement not modified by this Second Amendment shall continue in full force and effect in accordance with their terms.&nbsp;&nbsp;All capitalized terms not otherwise defined herein shall have the same definition as in the Agreement.&nbsp;&nbsp;In the event of any conflict between the terms and conditions of this Second Amendment and the Agreement, the terms and conditions set forth in this Second Amendment shall control with respect to the subject matter hereof.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">[Remainder of the page intentionally left blank; signature page follows.]</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the Parties have each caused this Second Amendment to be executed by their duly authorized representatives.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="top"  style="width:48.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">GENENTECH, INC.</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:48.24%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BIONTECH RNA</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:48.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:48.24%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PHARMACEUTICALS GMBH</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:48.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:48.24%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:42%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:42.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:48.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">F. HOFFMANN-LA ROCHE LTD</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:48.24%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BIONTECH SE</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:42%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:42.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:48.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">F. HOFFMANN-LA ROCHE LTD</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:48.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:42%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.04%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:6.67%;text-indent:-6.67%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit A</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:14.5%;"></td>
<td style="width:24.38%;"></td>
<td style="width:44.42%;"></td>
<td style="width:12.52%;"></td>
<td style="width:21.43%;"></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Work Package</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Objective</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Key Deliverables</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Target</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Completion</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Target</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Implementation</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#D9EEFF" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.17
<SEQUENCE>6
<FILENAME>bntx-ex417_789.htm
<DESCRIPTION>EX-4.17
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-ex417_789.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4.17</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">JOINDER AND THIRD AMENDMENT TO THE COLLABORATION AGREEMENT</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This JOINDER AND THIRD AMENDMENT (the &#8220;<font style="font-weight:bold;">Third Amendment</font>&#8221;) is made and entered into, effective as of October 1, 2020 (the &#8220;<font style="font-weight:bold;">Third Amendment Effective Date</font>&#8221;), by and between (1) BioNTech RNA Pharmaceuticals GmbH, a limited liability company organized under the laws of Germany (&#8220;<font style="font-weight:bold;">RNP</font>&#8221;) and BioNTech SE, a European stock corporation (&#8220;<font style="font-weight:bold;">BNT</font>&#8221;) (RNP and BNT collectively, &#8220;<font style="font-weight:bold;">BioNTech</font>&#8221;), (2) Genentech, Inc., a corporation organized under the laws of the State of Delaware (&#8220;<font style="font-weight:bold;">GNE</font>&#8221;) and F. Hoffmann-La Roche Ltd, a corporation organized under the laws of Switzerland (&#8220;<font style="font-weight:bold;">Roche</font>&#8221;) (GNE and Roche, collectively, &#8220;<font style="font-weight:bold;">Genentech</font>&#8221;) and (3) BioNTech Manufacturing GmbH, a German limited liability company having its principal place of business at An der Goldgrube 12, 55131, Germany (&#8220;<font style="font-weight:bold;">BMG</font>&#8221;),</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">each a &#8220;<font style="font-weight:bold;">Party</font>&#8221; and together the &#8220;<font style="font-weight:bold;">Parties</font>&#8221;.</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, BioNTech and Genentech entered into a Collaboration Agreement, dated as of September 20, 2016, as amended on June l, 2018 and on December 6, 2019, and as supplemented by letters between BioNTech and Genentech dated June 1, 2020, June 24, 2020 and August 3, 2020, pursuant to which BioNTech and Genentech agreed to collaborate in the research, development and commercialization of Collaboration Products (as amended and supplemented, the &#8220;<font style="font-weight:bold;">Collaboration Agreement</font>&#8221;).</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, BioNTech and Genentech further entered into a Manufacturing Development and Supply Agreement, dated as of September 20, 2016, pursuant to which BioNTech and Genentech agreed to collaborate on CMC development and related activities in support of (i) clinical supply of Collaboration Products that are Personalized Products through BioNTech&#8217;s Clinical Facilities and (ii) commercial supply of Collaboration Products that are Personalized Products through a joint Manufacturing Network (as such terms are defined in such agreement) (as amended, the &#8220;<font style="font-weight:bold;">MDSA</font>&#8221;).</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, on the Third Amendment Effective Date, pursuant to an intra-group reorganization, RNP transferred the business and assets relating to its manufacturing operations to BMG, a wholly-owned subsidiary of BNT (the &#8220;<font style="font-weight:bold;">Manufacturing Asset Transfer</font>&#8221;). RNP further proposes to transfer all the assets, obligations and liabilities retained by it following the Manufacturing Asset Transfer (including the Collaboration Agreement and the MDSA) to BNT on 1 January 2021 (the &#8220;<font style="font-weight:bold;">Asset Transfer</font>&#8221;).</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, BioNTech and Genentech, therefore, wish to modify certain terms of the Collaboration Agreement with respect to the above transactions and to join BMG as a party to the Collaboration Agreement. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Addition of BMG as a party to the Collaboration Agreement</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">BioNTech hereby represents and warrants that BMG is a wholly-owned subsidiary of BNT.&nbsp;&nbsp;Each of BMG and RNP will continue to be wholly-owned subsidiaries of BNT through the effective date of the Asset Transfer.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">BMG (i) shall be made a party to the Collaboration Agreement; (ii) accepts and agrees to be subject to all terms, conditions and obligations of the Collaboration Agreement, including those amendments as set out in Sections 2 to 4 of this Third Amendment, and as may be further amended from time to time in accordance with its terms; and (iii) shall be entitled to the rights and benefits </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.83%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="font-family:Times New Roman;color:#000000;">and subject to the duties and obligations of BioNTech, as applicable, in each case as fully as if BMG were an original signatory to the </font><font style="font-family:Times New Roman;color:#000000;">Collaboration </font><font style="font-family:Times New Roman;color:#000000;">Agreement </font><font style="font-family:Times New Roman;color:#000000;">as </font><font style="font-family:Times New Roman;color:#000000;">a BioNTech party; and</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">c.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">all references in the Collaboration Agreement to &#8220;BioNTech&#8221; shall collectively mean RNP, BNT and BMG.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Change in Control</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">The words &#8220;BNT or RNP&#8221; in Section 1.42 (&#8220;Change in Control&#8221;) and Section 1.46 (&#8220;Class A Competition Change in Control&#8221;) of the Collaboration Agreement shall be deleted and replaced with the words &#8220;BNT, RNP or BMG&#8221;.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">The words &#8220;BNT and RNP&#8221; in paragraph (a) of the definition &#8220;Change in Control Firewall&#8221; in Schedule 1.43 (Firewalls) of the Collaboration Agreement shall be deleted and replaced with the words &#8220;BNT, RNP and BMG&#8221;.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Manufacturing Development and Supply Agreement</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The words &#8220;That certain Manufacturing Development and Supply Agreement entered into by and among RNP, BNT, GNE and Roche as of even date herewith and effective as of the Effective Date (the &#8220;<font style="font-weight:bold;">Manufacturing Development and Supply Agreement</font>&#8221;)&#8221; in Section 7.1 of the Collaboration Agreement shall be deleted and replaced with the following:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;That certain Manufacturing Development and Supply Agreement by and among RNP, BNT, GNE and Roche dated as of September 20, 2016 and amended on October 1, 2020 to join BMG as a party thereto (as may be further amended from time to time, the &#8220;<font style="font-weight:bold;">Manufacturing Development and Supply Agreement</font>&#8221;)&#8221; </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Intellectual Property: Ownership; Assignment and Cooperation: Inventorship</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 10.2 of the Collaboration Agreement shall be amended by adding the following new paragraph (e):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;If BMG or any of its employees generate or create any BioNTech IP or Collaboration IP pursuant to or in connection with any activities carried out by it or any of them under this Agreement, BMG shall assign to, or shall procure that such BioNTech IP or Collaboration IP is Controlled by, BNT. BMG shall further comply with Section 10.2.2 to ensure that all necessary assignments and documentation are executed to implement the provisions of this Section 10.2(e).&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Notices</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:11pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:11pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:0pt;margin-bottom:11pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Section 15.8.1 of the Collaboration Agreement is amended by deleting the final sentence in Section 15.8.1 and replacing it with the following:</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;For clarity, notice to Genentech shall require notice to both GNE and Roche, and notice to BioNTech shall require notice to each of BNT, RNP and BMG.&#8221;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Section 15.8.2 is amended by adding the following paragraph after &#8220;BioNTech AG&#8221;:</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.83%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:11pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"></p></td></tr></table></div>
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;If to BMG, to:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.96%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Manufacturing GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.96%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An der Goldgrube 12</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.96%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55131 Mainz</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.96%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: Managing Director</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.96%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fax: +49-6131-9084390</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:22.96%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with a copy of any notice to (where applicable) BNT, RNP or BNG (which shall not constitute notice) to:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.96%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.96%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech SE</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.96%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An der Goldgrube 12</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.96%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55131 Mainz</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.96%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: VP Legal</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.96%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fax: +49-6131-9084390&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">6.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Corporate Names</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 1.97 of the Collaboration Agreement shall be amended by adding the following at the end of the Schedule:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;For BMG:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.31%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;BioNTech Manufacturing GmbH&#8221;&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">7.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;">Assignment</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 15.4 of the Collaboration Agreement, each Party hereby consents to the assignment of the Collaboration Agreement by RNP to BNT in connection with the Asset Transfer, provided that both the Collaboration Agreement and the MDSA are assigned to BNT pursuant to such Asset Transfer, and provided further that RNP remains a wholly owned subsidiary of BNT through the effective date of such Asset Transfer.&nbsp;&nbsp;If the Asset Transfer is not consummated prior to March 31, 2021, or if RNP is no longer a wholly-owned subsidiary of BNT at any time prior to such Asset Transfer, this consent shall have no force or effect.&nbsp;&nbsp;RNP agrees to provide notice of and documentation relating to such transfer (subject to Genentech&#8217;s reasonable and good faith review and comment) to Genentech not less than 10 Business Days prior to the effective date of the Asset Transfer.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">8.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;">Survival of Agreement Terms</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All terms and conditions of the Collaboration Agreement not modified by this Third Amendment shall continue in full force and effect in accordance with their terms. All capitalized terms not otherwise defined herein shall have the same definition as in the Collaboration Agreement. In the event of any conflict between the terms and conditions of this Third Amendment and the Collaboration Agreement, the terms and conditions set forth in this Third Amendment shall prevail with respect to the subject matter hereof.</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">9.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;">Governing Law and Dispute Resolution</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Governing Law and Service. Sections 15.6.1 and 15.6.2 of the Collaboration Agreement shall apply to this Third Amendment </font><font style="font-style:italic;font-family:Times New Roman;color:#000000;">mutatis mutandis</font><font style="font-family:Times New Roman;color:#000000;">.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.65%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Dispute Resolution. Section 15.7 of the Collaboration Agreement shall apply </font><font style="font-style:italic;font-family:Times New Roman;color:#000000;">mutatis mutandis</font><font style="font-family:Times New Roman;color:#000000;"> to any controversy, claim, legal proceeding or other dispute arising out of or relating to this Third Amendment.</font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Remainder of the page intentionally left blank. Signature page follows.</font>]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the Parties have each caused this Third Amendment to be executed by their duly authorized representatives.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">GENENTECH, INC.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By<font style="text-decoration:underline;"> /s/ Beth Odeh-Frikert</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Beth Odeh-Frikert</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Head Alliance &amp; Asset Management, SSF</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">F. HOFFMANN-LA ROCHE LTD</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By<font style="text-decoration:underline;"> /s/ Stefan Arnold</font></p></td>
<td valign="top" >
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By<font style="text-decoration:underline;"> /s/ Melanie Wick</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Stefan Arnold</p></td>
<td valign="top" >
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Melanie Wick</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Head Legal Pharmaceuticals</p></td>
<td valign="top" >
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Authorized Signatory</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">BIONTECH SE</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By<font style="text-decoration:underline;"> /s/ Sean Marett</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Sean Marett</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Management Board Member</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">BIONTECH RNA PHARMACEUTICALS GMBH</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By<font style="text-decoration:underline;"> /s/ Dr. Sierk Poetting</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Dr. Sierk Poetting</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Managing Director</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">BIONTECH MANUFACTURING GMBH</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By<font style="text-decoration:underline;"> /s/ Dr. Sierk Poetting</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Dr. Sierk Poetting</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Managing Director</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By<font style="text-decoration:underline;"> /s/ Jan K&#252;rschner</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Jan K&#252;rschner</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Managing Director</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.18
<SEQUENCE>7
<FILENAME>bntx-ex418_411.htm
<DESCRIPTION>EX-4.18
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-ex418_411.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">Exhibit 4.18</p>
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">EXECUTION VERSION</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THE SYMBOL &#8220;[***]&#8221; DENOTES PLACES WHERE CERTAIN</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">COMPANY IF PUBLICLY DISCLOSED</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FOURTH AMENDMENT TO</p>
<p style="margin-top:0pt;text-align:center;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THE COLLABORATION AGREEMENT</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This FOURTH AMENDMENT (the &#8220;<font style="font-weight:bold;">Fourth Amendment</font>&#8221;) is made and entered into, effective as of October 26, 2020 (the &#8220;<font style="font-weight:bold;">Fourth Amendment Effective Date</font>&#8221;), by and between BioNTech RNA Pharmaceuticals GmbH, a limited liability company organized under the laws of Germany (&#8220;<font style="font-weight:bold;">RNP</font>&#8221;), BioNTech Manufacturing GmbH, a limited liability company organized under the laws of Germany (&#8220;<font style="font-weight:bold;">BMG</font>&#8221;) and BioNTech SE, a European stock corporation (&#8220;<font style="font-weight:bold;">BNT</font>&#8221;) (RNP, BMG and BNT collectively, &#8220;<font style="font-weight:bold;">BioNTech</font>&#8221;), and Genentech, Inc., a corporation organized under the laws of the State of Delaware (&#8220;<font style="font-weight:bold;">GNE</font>&#8221;) and F. Hoffmann-La Roche Ltd, a corporation organized under the laws of Switzerland (&#8220;<font style="font-weight:bold;">Roche</font>&#8221;) (GNE and Roche, collectively, &#8220;<font style="font-weight:bold;">Genentech</font>&#8221;). </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Parties entered into a Collaboration Agreement, dated as of September 20, 2016, as amended on June 1, 2018, December 6, 2019 and October 1, 2020, and as supplemented by letters between the Parties dated June 1, 2020, June 24, 2020 and August 3, 2020, pursuant to which BioNTech and Genentech agreed to collaborate in the research, development, and commercialization of Collaboration Products (the &#8220;<font style="font-weight:bold;">Agreement</font>&#8221;).</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, BioNTech and Genentech wish to revise the schedule of RNA Manufacturing Projects. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Schedule</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="text-decoration:underline;color:#000000;">Schedule 1.333</font><font style="color:#000000;"> is hereby deleted in its entirety and replaced with the schedule attached hereto as Exhibit A.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Survival of Agreement Terms</font><font style="color:#000000;">.&nbsp;&nbsp;All terms and conditions of the Agreement not modified by this Fourth Amendment shall continue in full force and effect in accordance with their terms.&nbsp;&nbsp;All capitalized terms not otherwise defined herein shall have the same definition as in the Agreement.&nbsp;&nbsp;In the event of any conflict between the terms and conditions of this Fourth Amendment and the Agreement, the terms and conditions set forth in this Fourth Amendment shall control with respect to the subject matter hereof.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">[Remainder of the page intentionally left blank; signature page follows.]</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:left;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parties </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">each </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">caused this </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fourth</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Amendment</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to be executed by their </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">duly </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authorized representative</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:50%;text-indent:-50%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="top"  style="width:47.12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BIONTECH SE</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top"  style="width:47.18%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BIONTECH RNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.68%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:47.18%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PHARMACEUTICALS GMBH</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.68%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:39.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:39.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.68%; border-top:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.74%; border-top:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:39.68%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:39.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.68%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:39.68%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:39.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.68%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.68%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:47.12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BIONTECH MANUFACTURING GMBH</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.68%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:39.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.68%; border-top:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:39.68%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.68%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:39.68%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.68%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.68%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:47.12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">GENENTECH, INC.</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.68%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:39.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.68%; border-top:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:39.68%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.68%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:39.68%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.68%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.68%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:47.12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">F. HOFFMANN-LA ROCHE LTD</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.68%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:39.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:39.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.68%; border-top:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.74%; border-top:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:39.68%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:39.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.68%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:39.68%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.44%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:39.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:50%;text-indent:-50%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:8.33%;text-indent:-8.33%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">EXECUTION VERSION</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit A</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#9FC5E8" style="padding-left:0pt;padding-Right:0pt;width:22.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  BGCOLOR="#9FC5E8" style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  BGCOLOR="#9FC5E8" style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  BGCOLOR="#9FC5E8" style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  BGCOLOR="#9FC5E8" style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:22.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:22.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:22.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:22.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:22.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:22.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:22.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">[***]</font></p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:22.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:22.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:22.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:22.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:22.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:22.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:22.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:22.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:25.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.20
<SEQUENCE>8
<FILENAME>bntx-ex420_412.htm
<DESCRIPTION>EX-4.20
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-ex420_412.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Exhibit 4.20</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Execution Copy</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">THE SYMBOL &#8220;[***]&#8221; DENOTES PLACES WHERE CERTAIN</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">(ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">COMPANY IF PUBLICLY DISCLOSED</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">CELLSCRIPT, LLC</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-size:12pt;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">Second Amendment to Patent Sublicense Agreement</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk33462627"></a><a name="_Hlk35876924"></a>This is the Second Amendment ("Second Amendment") to the Patent Sublicense Agreement which became effective on July 19, 2017, as amended in the First Amendment which became effective on February 10, 2020 (together, the &#8220;Agreement&#8221;) by and between CELLSCRIPT, LLC, a <a name="_Hlk35876924"></a>Wisconsin company (&#8220;Cellscript&#8221;) and BioNTech RNA Pharmaceuticals GmbH, a German corporation (&#8220;Company&#8221;). This Second Amendment is effective as of August 1, 2020 ("Second Amendment Effective Date"). Cellscript and Company may herein each be referred to as a "Party" or collectively as the "Parties".</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk52783247"></a>WHEREAS, The Trustees of the University of Pennsylvania (&#8220;Penn&#8221;) is the ultimate recipient of amounts of money that are payable by Company under the terms of the Agreement after the Second Amendment Effective Date; and</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Parties wish to amend the Agreement in order to assure more timely payment and less risk of loss for said certain amounts of money that are payable to Penn by Cellscript or by Cellscript&#8217;s sublicensor, mRNA RiboTherapeutics, Inc, (&#8220;mRNA&#8221;) from Company&#8217;s payments to Cellscript under the terms of the Agreement; and</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, unless otherwise defined herein, capitalized terms will have the definitions given them in the Agreement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in consideration of the mutual obligations contained in the Agreement and in this Second Amendment, and intending to be legally bound, the Parties agree as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.91%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Hlk42869688"></a><a name="_cp_blt_2_9"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="_cp_blt_2_9"></a> From and after the Second Amendment Effective Date, all payments owed by Company to Cellscript under the Agreement shall be owed and paid directly to Penn, including but not limited to payments under sections [***]. &#160;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.83%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.91%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">All references to payments to Cellscript&#160;are understood to mean payments to Penn.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.83%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.91%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">All information, and reports concerning payments, including inventories, required under the Agreement shall be sent to both Cellscript and Penn, including under sections [***].&nbsp;&nbsp;Such information shall be delivered to Penn at pcifin@upenn.edu with paper copies to: </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.81%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.83%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Penn Center for Innovation</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.83%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">University of Pennsylvania </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Execution Copy</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.83%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3600 Civic Center Boulevard, Floor 9 </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.83%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Philadelphia, PA 19104 </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention:&nbsp;&nbsp;PCI Finance</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.83%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.91%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Penn is a third-party beneficiary of the Agreement.&#160;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.83%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.91%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Under Section 6.3 termination, a failure to pay Penn is a failure to pay Cellscript.&#160;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.91%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">6)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Under Section 6.7, the obligations to pay Penn shall survive termination of the Agreement for any reason.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.91%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">7)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">All amounts payable by Company to Penn pursuant to this Second Amendment shall be in U.S. Dollars and shall be subject to the same instructions, terms, conditions and deadlines for payment as stated with respect to payments to Cellscript in the Agreement, except that all such payments to Penn shall be paid to &#8220;The Trustees of the University of Pennsylvania&#8221; as follows:</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:64.26%;">
<tr>
<td style="width:37.89%;"></td>
<td style="width:26.37%;"></td>
</tr>
<tr style="height:10.45pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">By ACH/Wire:</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">By Check (lockbox):</font></p></td>
</tr>
<tr style="height:10.45pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:11.1pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:10.45pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:10.45pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:10.45pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:32.05pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Payment should include the necessary amount to cover any bank charges incurred.</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.91%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">8)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The Agreement, together with this Second Amendment, constitute the entire agreement between the Parties.&nbsp;&nbsp;All other terms and provisions of the Agreement, except as expressly amended by this Second Amendment, remain in full force and effect. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.86%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.91%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">9)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">This Second Amendment may be executed in two or more counterparts, each of which shall be deemed an original and together shall be deemed one and the same instrument.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.86%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.91%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">10)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Hlk52463542"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Each Party&#8217;s respective Notice Address, as provided under Section 15.6 of the Agreement is hereby updated and replaced by the Notice Address listed on the signature page of this Second Amendment.</font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"><a name="_Hlk46247834"></a><a name="_cp_text_1_11"></a>&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Remainder of Page Intentionally Left Blank;</font> <font style="font-style:italic;">Signature Page Follows</font>]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_12"></a><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Execution Copy</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">P</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arties, intending to be legally bound, have caused this </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Amendment to be executed by their duly authorized representatives.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk46306595"></a>CELLSCRIPT, LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:3.77%;"></td>
<td style="width:3.24%;"></td>
<td style="width:24.61%;"></td>
<td style="width:15.26%;"></td>
<td style="width:12.02%;"></td>
<td style="width:41.18%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td colspan="2" valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Gary A. Dahl, Ph.D.</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notices to:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CELLSCRIPT, LLC</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gary A. Dahl, Ph.D.</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">726 Post Road</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and CEO</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Madison, WI 53713 USA</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: President</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BioNTech RNA Pharmaceuticals GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.94%;"></td>
<td style="width:3.21%;"></td>
<td style="width:24.32%;"></td>
<td style="width:14.41%;"></td>
<td style="width:12.43%;"></td>
<td style="width:40.69%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td colspan="2" valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Dr. Sierk Poetting</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notices to:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CELLSCRIPT, LLC</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gary A. Dahl, Ph.D</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An der Goldgrube 12</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and CEO</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55131 Mainz, Germany</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: Dr. Sierk Poetting</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.22
<SEQUENCE>9
<FILENAME>bntx-ex422_413.htm
<DESCRIPTION>EX-4.22
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-ex422_413.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Exhibit 4.22</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Execution Copy</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Hlk51670658"></a><font style="text-decoration:none;">THE SYMBOL &#8220;[***]&#8221; DENOTES PLACES WHERE CERTAIN</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">(ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">COMPANY IF PUBLICLY DISCLOSED</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">mRNA RiboTherapeutics, Inc.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-size:12pt;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">Second Amendment to Patent Sublicense Agreement</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk33462627"></a><a name="_Hlk35876924"></a>This is the Second Amendment ("Second Amendment") to the Patent Sublicense Agreement which became effective on July 19, 2017, as amended in the First Amendment which became effective on February 10, 2020 (together, the &#8220;Agreement&#8221;) by and between mRNA RiboTherapeutics, Inc., a <a name="_Hlk35876924"></a>Wisconsin company (&#8220;mRNA RiboTherapeutics&#8221;) and BioNTech RNA Pharmaceuticals GmbH, a German corporation (&#8220;Company&#8221;). This Second Amendment is effective as of August 1, 2020 ("Second Amendment Effective Date"). mRNA RiboTherapeutics and Company may herein each be referred to as a "Party" or collectively as the "Parties".</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk52783247"></a>WHEREAS, The Trustees of the University of Pennsylvania (&#8220;Penn&#8221;) is the ultimate recipient of amounts of money that are payable by Company under the terms of the Agreement after the Second Amendment Effective Date; and</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Parties wish to amend the Agreement in order to assure more timely payment and less risk of loss for said certain amounts of money that are payable to Penn by mRNA RiboTherapeutics from Company&#8217;s payments to mRNA RiboTherapeutics under the terms of the Agreement; and</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, unless otherwise defined herein, capitalized terms will have the definitions given them in the Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in consideration of the mutual obligations contained in the Agreement and in this Second Amendment, and intending to be legally bound, the Parties agree as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.88%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Hlk42869688"></a><a name="_cp_blt_2_9"></a><a name="_Hlk52785949"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="_cp_blt_2_9"></a> From and after the Second Amendment Effective Date, all payments owed by Company to mRNA RiboTherapeutics under the Agreement shall be owed and paid directly to Penn, including but not limited to payments under sections <a name="_Hlk52785949"></a>[***]. &#160;&#160;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.88%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">All references to payments to mRNA RiboTherapeutics&#160;are understood to mean payments to Penn.</font></p></td></tr></table></div><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.88%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">All information, and reports concerning payments, including inventories, required under the Agreement shall be sent to both mRNA RiboTherapeutics and Penn, including under sections [***]. Such information shall be delivered to Penn at pcifin@upenn.edu with paper copies to: </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:15.57%;width:39.61%;">
<tr>
<td valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Penn Center for Innovation</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">University of Pennsylvania</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3600 Civic Center Boulevard, Floor 9</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Philadelphia, PA 19104</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention:&nbsp;&nbsp;PCI Finance</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.88%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Penn is a third-party beneficiary of the Agreement.&#160;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.88%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Under Section 6.3 termination, a failure to pay Penn is a failure to pay mRNA RiboTherapeutics.&#160;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.88%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">6)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Under Section 6.7, the obligations to pay Penn shall survive termination of the Agreement for any reason.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.88%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">7)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">All amounts payable by Company to Penn pursuant to this Second Amendment &nbsp;&nbsp;shall be in U.S. Dollars and shall be subject to the same instructions, terms, conditions and deadlines for payment as stated with respect to payments to &nbsp;&nbsp;&nbsp;&nbsp; mRNA RiboTherapeutics in the Agreement, except that all such payments to &nbsp;&nbsp;&nbsp;&nbsp;  Penn shall be paid to &#8220;The Trustees of the University of Pennsylvania&#8221; as follows:</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:65%;">
<tr>
<td style="width:38.32%;"></td>
<td style="width:26.67%;"></td>
</tr>
<tr style="height:10.45pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">By ACH/Wire:</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">By Check (lockbox):</font></p></td>
</tr>
<tr style="height:10.45pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:11.1pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.45pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.45pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.45pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:32.05pt;">
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Payment should include the necessary amount to cover any bank charges incurred.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.88%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">8)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The Agreement, together with this Second Amendment, constitute the entire agreement between the Parties.&nbsp;&nbsp;All other terms and provisions of the Agreement, except as expressly amended by this Second Amendment, remain in full force and effect. </font></p></td></tr></table></div><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.88%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">9)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">This Second Amendment may be executed in two or more counterparts, each of which shall be deemed an original and together shall be deemed one and the same instrument.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.88%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">10)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Hlk52463542"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Each Party&#8217;s respective Notice Address, as provided under Section 15.6 of the Agreement is hereby updated and replaced by the Notice Address listed on the signature page of this Second Amendment.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"><a name="_Hlk46247834"></a><a name="_cp_text_1_11"></a>&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Remainder of Page Intentionally Left Blank;</font> <font style="font-style:italic;">Signature Page Follows</font>]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the Parties, intending to be legally bound, have caused this Second Amendment to be executed by their duly authorized representatives.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk46306595"></a>mRNA RIBOTHERAPEUTICS, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.01%;"></td>
<td style="width:26.84%;"></td>
<td style="width:9.11%;"></td>
<td style="width:13.02%;"></td>
<td style="width:44.01%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Gary A. Dahl, Ph.D.</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notices to:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mRNA RiboTherapeutics, Inc.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gary A. Dahl, Ph.D.</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">726 Post Road</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and CEO</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Madison, WI 53713 USA</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: President</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BioNTech RNA Pharmaceuticals GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:6.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:26.9%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Dr. Sierk Poetting</p></td>
<td valign="top"  style="width:9.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notices to:</p></td>
<td valign="top"  style="width:44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech RNA Pharmaceuticals GmbH</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:26.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Sierk Poetting</p></td>
<td valign="top"  style="width:9.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An der Goldgrube 12</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:26.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Managing Director</p></td>
<td valign="top"  style="width:9.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55131 Mainz, Germany</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: Dr. Sierk Poetting</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.44
<SEQUENCE>10
<FILENAME>bntx-ex444_416.htm
<DESCRIPTION>EX-4.44
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-ex444_416.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4.44</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">THE SYMBOL &#8220;[***]&#8221; DENOTES PLACES WHERE CERTAIN</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">COMPANY IF PUBLICLY DISCLOSED</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;text-transform:uppercase;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;font-variant: normal;">Amended and Restated collaboration AGREEMENT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by and between</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:11pt;font-style:normal;font-variant: normal;">Pfizer inc.</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:11pt;font-style:normal;font-variant: normal;">biontech SE</p>
<p style="text-align:center;margin-bottom:66pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 17, 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"><a name="_Hlk62066068"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-align:justify;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:left;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:-7.69%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="3" valign="top"  style="width:92.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:11pt;font-style:normal;font-variant: normal;">Contents</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:92.48%;">
<p style="margin-bottom:0pt;text-align:left;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:92.48%;">
<p style="margin-bottom:0pt;text-align:left;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:11pt;font-style:normal;font-variant: normal;">Clause</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:11pt;font-style:normal;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:0pt;text-align:left;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:87.46%;">
<p style="margin-bottom:0pt;text-align:left;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td colspan="2" valign="top"  style="width:87.46%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Definitions</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td colspan="2" valign="top"  style="width:87.46%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Scope and Spirit of Collaboration</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Scope of Collaboration</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Spirit of Collaboration</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reviewing of and Commenting on Documents</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Escalation</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td colspan="2" valign="top"  style="width:87.46%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Licenses</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research Licenses.</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Licenses for Commercial Manufacturing.</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory Dossier Licenses.</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercialization Licenses.</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional Licenses.</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.6</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trademark Licenses</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.7</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublicensees</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.8</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Current Licenses.</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.9</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third Party Agreements</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.10</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Implied Rights</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.11</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exclusivity</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.12</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to Commercialization Territories.</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.13</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expansion of the Territory.</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td colspan="2" valign="top"  style="width:87.46%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments, Funding, Financial Matters</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront Payment</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity Investment</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory Milestone Payment</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sharing of Development Costs</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third Party Funding</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounting Principles</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.7</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercialization Costs</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercialization Sales Milestones</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross Profit Sharing.</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.10</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third Party License Payments</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
</tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:44.12%;"></td>
<td style="width:11.74%;"></td>
<td style="width:44.13%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-i</a>-</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.11</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Taxes.</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.12</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency, Source of Payments</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.13</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Method of Payment</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.14</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Record Keeping and Audits.</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.15</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Guaranty of Success.</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.16</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Other Compensation</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.17</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Late Payment</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.18</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Double Counting</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</p></td>
<td colspan="2" valign="top"  style="width:87.46%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and Development Plan</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Scope of Development and Updating of Plans</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and Development Plan</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allocation of Responsibilities.</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Materials and Permitted Activities.</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human Materials</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</p></td>
<td colspan="2" valign="top"  style="width:87.46%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract Governance</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alliance Managers</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Program Directors</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joint Steering Committee.</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.4</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other Committees</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.5</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Committee Decision-Making</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</p></td>
<td colspan="2" valign="top"  style="width:87.46%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.1</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development of Manufacture Process</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.2</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacture of Candidates Products</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quality Requirements</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.4</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing Agreements</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.5</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allocation of Responsibilities</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.6</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quality Audits</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</p></td>
<td colspan="2" valign="top"  style="width:87.46%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development, Regulatory and Pharmacovigilance</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development Matters</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.2</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory Matters.</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.3</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmacovigilance and Pharmacovigilance Agreement.</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.4</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product Complaints and Returns</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.5</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical Trial Register</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.6</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory Exclusivity</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:468pt;;">
<tr>
<td style="width:206.5pt;"></td>
<td style="width:54.95pt;"></td>
<td style="width:206.55pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-ii-</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.7</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liability</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.8</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Objection Right</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.9</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Personal Data</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</p></td>
<td colspan="2" valign="top"  style="width:87.46%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercialization</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual Plans.</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Commercialization Responsibilities</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.3</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Commercialization Responsibilities:</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.4</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales Force.</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Training Materials, Promotional Materials and Other Product Information</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.6</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pricing, Reimbursement and Market Access</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.7</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase Agreements with Governmental Authorities</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.8</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product Packaging Configurations</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.9</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product Orders; Invoicing; Distribution and Sales</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.10</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Returns</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.11</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recalls and Withdrawals</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.12</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Co-branding</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.13</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vaccine Technical Committees</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.14</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diligence and Performance Standards</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.15</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management of Representatives</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</p></td>
<td colspan="2" valign="top"  style="width:87.46%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medical Affairs</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Global Medical Activities</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medical Science Liaisons.</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Training and Medical Education Materials</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unsolicited Medical Requests</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medical Information Content</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medical Affairs Studies</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</p></td>
<td colspan="2" valign="top"  style="width:87.46%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.1</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patent Committee</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.2</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ownership of Intellectual Property</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.3</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patent Rights.</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.4</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enforcement of Patent Rights.</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.5</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other Actions by Third Parties</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.6</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purple Book Listings</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.7</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allegations of Infringement and Right to Seek Third Party Licenses</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p></td>
</tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:468pt;;">
<tr>
<td style="width:206.5pt;"></td>
<td style="width:54.95pt;"></td>
<td style="width:206.55pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-iii-</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.8</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third Party Infringement Suits</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.9</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product Trademarks</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.10</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Packaging and Labeling Rights and Licenses</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.11</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Implied Licenses</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.</p></td>
<td colspan="2" valign="top"  style="width:87.46%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidentiality, Publications and Press Releases</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.1</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidentiality</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Authorized Disclosure</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.3</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential Treatment of the Terms and Conditions, SEC Filings and Other Disclosures</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.4</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Residual Knowledge Exception</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.5</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Public Announcements; Publications.</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.6</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-Disclosure in the Fosun Territory</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.7</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obligations in Connection with Change of Control</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.</p></td>
<td colspan="2" valign="top"  style="width:87.46%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Representations and Warranties</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.1</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mutual Representations and Warranties</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.2</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mutual Covenants</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.3</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Representations and Warranties of BioNTech</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.4</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accuracy of Representations and Warranties.</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.5</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Covenants</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.6</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Covenants</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.7</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notifications</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.8</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Representation by Legal Counsel</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.9</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech&#8217;s Knowledge</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.10</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disclaimer</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.11</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compliance Certificates</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.</p></td>
<td colspan="2" valign="top"  style="width:87.46%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government Approvals; Term and Termination</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.1</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government Approvals</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.2</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.3</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Termination for Cause by a Party</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.4</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Termination by Pfizer for Convenience.</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.5</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.6</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Termination Following Certain Violations.</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.7</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exclusion of termination rights</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.8</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effects of Expiration or Termination</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.9</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for Insolvency</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p></td>
</tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:468pt;;">
<tr>
<td style="width:206.5pt;"></td>
<td style="width:54.95pt;"></td>
<td style="width:206.55pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-iv-</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td colspan="2" valign="top"  style="width:87.46%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change of Control</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.1</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change of Control</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.2</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effects of Change of Control</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.</p></td>
<td colspan="2" valign="top"  style="width:87.46%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Limitation of Liability, Indemnification and Insurance</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.1</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Consequential Damages</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.2</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indemnification by Pfizer</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.3</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indemnification by BioNTech</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.4</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Procedure</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.5</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.</p></td>
<td colspan="2" valign="top"  style="width:87.46%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Miscellaneous</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.1</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assignment</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.2</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further Actions</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.3</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Force Majeure</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.4</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interpretation</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.5</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notices</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.6</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.7</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Waiver</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.8</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Severability</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.9</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Descriptive Headings</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.10</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Global Trade Control Laws</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.11</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dispute Resolution</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.12</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Governing Law</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.13</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consent to Jurisdiction and Venue</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.14</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entire Agreement</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.15</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Flu Collaboration</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.16</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Relationship of the Parties</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.17</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Counterparts</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.18</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Third Party Rights or Obligations</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.02%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:7.58%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.19</p></td>
<td valign="top"  style="width:79.88%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conflicting Terms</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:92.48%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit A Research and Development Plan</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:92.48%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit B Pfizer Anti-Bribery and Anti-Corruption Principles</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:92.48%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit C Pfizer&#8217;s Corporate Policy regarding Animal Care and Use (v. 1.2, June 18, 2017)</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:92.48%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 1.21 Candidates</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:92.48%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 1.45 Current Licenses</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td>
</tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:468pt;;">
<tr>
<td style="width:206.5pt;"></td>
<td style="width:54.95pt;"></td>
<td style="width:206.55pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-v-</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="3" valign="top"  style="width:92.48%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 1.49 Developing Countries List</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:92.48%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 1.50 Development Budget</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:92.48%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 1.94 Manufacturing Plan</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:92.48%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 4.5 Potential Third Party Funders</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:92.48%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 4.9.5 Form of Quarterly Consolidated Report and Illustrative Gross Profit Calculation</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:92.48%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 6.5.2 Decision-Making Rights</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:92.48%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:36pt;;text-indent:-36pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 8.1.1 Responsibilities delegated to Pfizer in the USA or other countries in the Territory where it is the Lead Development Party</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:92.48%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 8.3 Pharmacovigilance Agreement Term Sheet</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:92.48%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 9.7.1 Idemnification Terms</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:92.48%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 12.5.1 Public Announcements</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">148</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:92.48%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 13.3 Disclosures</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:92.48%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 13.9 BioNTech Management with Knowledge</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">182</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:92.48%;">
<p style="margin-bottom:3pt;margin-top:3pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 13.11 ABAC Compliance Certification</p></td>
<td valign="top"  style="width:7.52%;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;text-align:left;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-align:justify;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:468pt;;">
<tr>
<td style="width:206.5pt;"></td>
<td style="width:54.95pt;"></td>
<td style="width:206.55pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-vi</a>-</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:11pt;font-style:normal;font-variant: normal;">Amended and Restated COLLABORATION AGREEMENT</p>
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Amended and Restated Collaboration Agreement (the &#8220;<font style="text-decoration:underline;">Agreement</font>&#8221;) is entered into with effect as of March 17, 2020 (the &#8220;<font style="text-decoration:underline;">Effective Date</font>&#8221;), by and between Pfizer Inc., a corporation<font style="font-weight:bold;"> </font>organized and existing under the laws of Delaware and having a principal place of business at 235 East 42nd Street, New York, New York, 10017 United States (&#8220;<font style="text-decoration:underline;">Pfizer</font>&#8221;) and BioNTech SE, a corporation organized and existing under the laws of Germany and having a place of business at An der Goldgrube 12, D-55131 Mainz, Germany (&#8220;<font style="text-decoration:underline;">BioNTech</font>&#8221;). Pfizer and BioNTech are sometimes referred to herein individually as a &#8220;<font style="text-decoration:underline;">Party</font>&#8221; and collectively as the &#8220;<font style="text-decoration:underline;">Parties</font>&#8221;. </p>
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, BioNTech owns or otherwise Controls (as defined below) certain patents, patent applications, technology, know-how, scientific and technical information and other proprietary rights and information relating to the identification, research and development of Candidates<font style="font-weight:bold;font-style:italic;"> </font>(as defined below) in the Field (as defined below) for delivery via Delivery Technology (as defined below);</p>
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_203"></a><a name="_cp_text_1_203"></a>WHEREAS, Pfizer has extensive experience and expertise in the development and commercialization of pharmaceutical and biopharmaceutical products; </p>
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_209"></a>WHEREAS, in view of the current COVID-19 crisis, Pfizer and BioNTech<a name="_cp_text_2_209"></a> wish to engage in expedited collaborative research and development pursuant to the Research and Development Plan (as defined below) to identify and develop Candidates for inclusion in the Product, seek expedited regulatory approval for such Product, and launch such Product in all countries of the Territory (as defined below) as quickly as reasonably possible; </p>
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Pfizer and BioNTech wish that Pfizer Commercializes the Product in all countries of the Territory, subject to BioNTech having the right to exclusively Commercialize the Product in the BioNTech Commercialization Territory;</p>
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, BioNTech and Pfizer have entered into a Collaboration Agreement effective as of March 17, 2020 (the &#8220;<font style="text-decoration:underline;">Original Collaboration Agreement</font>&#8221;) to govern their collaboration in the Development, Manufacturing and Commercialization of the Product in the Field;</p>
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, under Section 4 of Original Collaboration Agreement BioNTech and Pfizer have agreed upon a term sheet setting forth material terms for Commercialization of the Products which shall form the basis of a definitive commercialization agreement to be entered into after the signing of the Original Collaboration Agreement; </p>
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, BioNTech and Pfizer have decided to integrate the definitive terms of such commercialization agreement into the Original Collaboration Agreement and to replace the Original Collaboration Agreement by this Amended and Restated Collaboration Agreement which shall now include also the definitive terms for the commercialization of the Product; and</p>
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, in addition, BioNTech and Pfizer wish to amend or modify some of the terms of the Original Collaboration Agreement such that they are restated in their amended form in this Agreement.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW THEREFORE, in consideration of the premises and the mutual promises set forth herein, and intending to be legally bound, the Parties hereby agree to amend and restate the Original Collaboration Agreement as follows: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-transform:none;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref473723080"></a><a name="_Ref276112391"></a><a name="_Toc62256024"></a><a name="_Toc59107051"></a><font style="text-decoration:none;"></font><font style="text-decoration:underline;text-transform:uppercase;">Definitions</font></p></td></tr></table></div>
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As used in this Agreement, the following capitalized terms will have the meanings set forth below:</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref518672571"></a><a name="_Ref268685212"></a>1.1<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Affiliate</font><a name="_Ref268685212"></a>&#8221; means any entity directly or indirectly controlled by, controlling, or under common control with, a Person, but only for so long as such control will continue. For purposes of this definition, &#8220;control&#8221; (including, with correlative meanings, &#8220;controlled by&#8221;, &#8220;controlling&#8221; and &#8220;under common control with&#8221;) means (a) possession, direct or indirect, of the power to direct or cause direction of the management or policies of an entity (whether through ownership of securities or other ownership interests, by contract or otherwise), or (b) beneficial ownership of more than 50% of the voting securities or other ownership or general partnership interest (whether directly or pursuant to any option, warrant or other similar arrangement) or other comparable equity interests of an entity; <font style="font-style:italic;">provided</font>, <font style="font-style:italic;">however</font>, that where an entity owns a majority of the voting power necessary to elect a majority of the board of directors or other governing board of another entity, but is restricted from electing such majority by contract or otherwise, such entity will not be considered to be in control of such other entity until such time as such restrictions are no longer in effect. Notwithstanding the foregoing, for the purposes of this Agreement, AT Impf GmbH, having its place of business at Rosenheimer Platz 6, 81669 Munich, Germany, and any entity that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with AT Impf GmbH (other than BioNTech SE or any entity that is directly or indirectly controlled by BioNTech SE) (collectively, the "Impf Group") shall not be considered Affiliates of BioNTech.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref44418715"></a>1.2<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Agreed Product Component</font>&#8221; is defined in Section 6.4.1.2.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Amendment Signing Date</font>&#8221; means 29 January 2021.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Annual Regional Commercialization Plan</font>&#8221; means, with respect to a Commercialization Region and having regard to the objectives and principles of the Global Commercialization Plan, the applicable plan as may be established by the applicable RCC, and as updated from time to time by the applicable RCC, in each case pursuant to Section&#160;9.1, for the applicable Calendar Year during the Term. It is acknowledged that if each Party has countries within its Commercialization Territory that lie within the same Commercialization Region, two separate Annual Regional Commercialization Plans may exist with each covering only those countries within one Party's Commercialization Territory.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Anti-Corruption Laws</font>&#8221; means all applicable anti-bribery and anti-corruption laws and regulations, including the U.S. Foreign Corrupt Practices Act of 1977, the U.K. Bribery Act 2010, and the local laws and regulations of any countries in which Candidates or Products, payments or services will be provided or procured under or pursuant to this Agreement.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.6<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Applicable Data Protection Law</font>&#8221; means all applicable personal data protection laws, rules and regulations, including the EU General Data Protection Regulation (&#8220;GDPR&#8221;).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="text-decoration:underline;">Bankruptcy Code</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means Section&#160;101(35A) of Title 11 of the United States Code, as amended, or such other legislation, Law or code with effect in another jurisdiction to which </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or its Affiliates is subject having equivalent or reasonably similar purpose or provisions to the foregoing.</font></p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Binding Obligation</font>&#8221; means, with respect to a Party (a) any oral or written agreement or arrangement that binds or affects such Party&#8217;s operations or property, including any assignment, license agreement, loan agreement, guaranty, or financing agreement, (b) the provisions of such Party&#8217;s charter, bylaws or other organizational documents or (c) any order, writ, injunction, decree or judgment of any court or Governmental Authority entered against such Party or by which any of such Party&#8217;s operations or property are bound.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.9<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Biologics License Application</font>&#8221; or &#8220;<font style="text-decoration:underline;">BLA</font>&#8221; means an application requesting permission from the FDA to introduce, or deliver for introduction, a biological product into interstate commerce, or any similar application or submission for marketing authorization of a product filed with a Regulatory Authority to obtain Regulatory Approval for such product in a country or group of countries, including an MAA.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.10<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">BioNTech Commercialization Territory</font>&#8221; means (a) Germany and Turkey, until such time, on a country by country basis, a BioNTech Territory Exit Option is exercised by BioNTech in respect of one or both of those countries and (b) those countries, on a country by country basis, which become Pfizer Exit Countries (if any). </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.11<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">BioNTech Commercial Materials</font>&#8221; means any and all BioNTech Promotional Materials, BioNTech Training Materials, and all other literature or other information related to the Product and, in each case, created and provided by or on behalf of BioNTech hereunder.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.12<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">&#8220;BioNTech House Marks</font>&#8221; means (a) the corporate logo of BioNTech, (b) the trademark &#8220;BioNTech&#8221;, (c) any other Trademark, trade name or service mark (whether registered or unregistered) containing the word &#8220;BioNTech&#8221;, and (d) any other corporate logo or Trademark used by BioNTech to identify BioNTech or its Affiliates; and all intellectual property rights and goodwill associated with any and all of the foregoing in clauses (a) through (d).</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.13<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">BioNTech Improvement</font>&#8221; means any Research and Development Program Technology, regardless of inventorship, that is a modification or improvement made to the RNA Technology or RNA Process Technology and (a) would also be applicable to one or more candidates or products in addition to or other than the Candidates or Products (b) is not predominantly directed to the Pfizer Technology and (c) could have reasonably been developed without the aid, use or application of Pfizer Materials, Pfizer Improvements or Pfizer&#8217;s Confidential Information or any improvements or enhancements thereto. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref263801536"></a><a name="_Ref135585870"></a>1.14<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">BioNTech Know-How</font>&#8221; means <a name="_Ref263801536"></a><a name="_Ref135585870"></a>[***]. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref516490003"></a>1.15<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">BioNTech Materials</font>&#8221; means any tangible materials (but not information about or contained in such materials) owned or Controlled by BioNTech that relate to or embody the BioNTech Know-How or BioNTech<a name="_Ref516490003"></a> Patent Rights.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref36313092"></a>1.16<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">BioNTech Patent Right</font>&#8221; means any Patent Right (other than Pfizer Patent Rights or Patent Rights jointly owned by BioNTech and Pfizer pursuant to Section 11.2) in any form and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">whether pending or issued that (a) is Controlled by </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or any of its Affiliates as of the Effective Date or comes into the Control of </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or any of its Affiliates during the Term (other than, in either case, through the grant of a license by Pfizer) and (b) claims any </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Know-How.</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref518672708"></a>1.17<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">BioNTech Technology</font>&#8221; means the BioNTech Patent Rights, BioNTech Materials, BioNTech Know-How. For avoidance of doubt, BioNTech Technology includes all Intellectual Property Rights Controlled by BioNTech pursuant to the Fosun<a name="_Ref518672708"></a> Agreement.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref35892129"></a><a name="_cp_text_1_215"></a><a name="_cp_text_1_216"></a><a name="_Ref488157529"></a>1.18<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">BioNTech Third Party Agreement</font>&#8221; means any agreement between BioNTech (or any of its Affiliates) and any Third Party (such Third Party, a &#8220;<font style="text-decoration:underline;">Third Party Licensor</font><a name="_cp_text_1_215"></a>&#8221;) that (a) relates to any of the BioNTech<a name="_cp_text_1_216"></a> Technology or Research and Development Program Technology, or (b) otherwise grants a license or otherwise transfers any right to practice under any Patent Rights or Know-How, in each case that relate to the Candidates or Products or activities under this Agreement. For clarity, all Current Licenses shall be deemed BioNTech<a name="_Ref488157529"></a> Third Party Agreements hereunder and all Current Licensors shall be deemed Third Party Licensors hereunder.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk35512827"></a><a name="_Ref488157542"></a>1.19<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Biosimilar Notice</font>&#8221; means a copy of any application submitted by a Third Party to the FDA under 42 U.S.C. &#167; 262(k) of the Public Health Service Act (or, in the case of a country of the Territory outside the United States, any similar law) for Regulatory Approval of a biopharmaceutical product, which application identifies a Product as the Reference Product with respect to such product, and other information that describes the process or processes used to manufacture the biopharmaceutical product.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref516495962"></a><a name="_Ref517695228"></a>1.20<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Business Day</font><a name="_Ref516495962"></a><a name="_Ref517695228"></a>&#8221; means a day other than a Saturday, Sunday or bank or other public holiday in New York, New York, USA or Mainz, Germany.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref36411444"></a><a name="_Ref36212476"></a><a name="_Hlk519522288"></a><a name="_Hlk35512854"></a>1.21<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Candidate</font><a name="_Hlk519522288"></a>&#8221; means an immunogenic composition in the Field that comprises Unmodified RNA Technology, Modified RNA Technology or Replicon Technology<a name="_Hlk35512854"></a> that (a) is Developed pursuant to the Research and Development Plan, (b) is Controlled by BioNTech as of the Effective Date or from time to time during the Term or (c) is Exploited by any of the Parties or their Affiliates pursuant to this Agreement. Those Candidates Controlled by BioNTech and existing as of the Effective Date are set forth in <font style="text-decoration:underline;">Schedule 1.21</font>.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.22<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Calendar Quarter</font>&#8221; means the respective periods of three consecutive calendar months ending on March 31, June 30, September 30 and December 31.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.23<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Calendar Year</font>&#8221; means any twelve (12) month period beginning on January 1 and ending on the next subsequent December 31.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.24<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Capex Costs</font>&#8221; means any capital expenditure costs associated with (a) the Research and Development Program or (b) the build-out, establishment, construction, expansion or investment in any Manufacturing facilities. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.25<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Change of Control</font>&#8221; means, with respect to a Party (a) the acquisition of beneficial ownership, directly or indirectly, by any Person (other than such Party or an Affiliate of such Party, and other than by virtue of obtaining irrevocable proxies) of securities or other voting interest of such Party representing of the combined voting power of such Party&#8217;s then outstanding securities or other voting interests, (b) any merger, reorganization, consolidation or business combination </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">involving such Party with a Third Party that results in the holders of beneficial ownership (other than by virtue of obtaining irrevocable proxies) of the voting securities or other voting interests of such Party (or, if applicable, the ultimate parent of such Party) immediately prior to such merger, reorganization, consolidation or business combination ceasing to hold beneficial ownership of at least fifty percent (50%) of the combined voting power of the surviving entity immediately after such merger, reorganization, consolidation or business combination, (c) any sale, lease, exchange, contribution or other transfer (in one transaction or a series of related transactions) of all or substantially all of the assets of such Party to which this Agreement relates, other than a sale or disposition of such assets to an Affiliate of such Party or (d) the approval of any plan or proposal for the liquidation or dissolution of such Party (other than in circumstances where such Party is deemed a Debtor pursuant to Section&#160;</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.9</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">).</font></p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.26<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Clinical Trial</font>&#8221; means a human clinical study conducted on sufficient numbers of human subjects that is designed to (a) establish that a pharmaceutical product is reasonably safe for continued testing, (b) investigate the safety and efficacy of the pharmaceutical product for its intended use, and to define warnings, precautions and adverse reactions that may be associated with the pharmaceutical product in the dosage range to be prescribed or (c) support Regulatory Approval of such pharmaceutical product or label expansion of such pharmaceutical product. Without limiting the foregoing, Clinical Trial includes any Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial or other expedited clinical trial conducted by or on behalf of one or both Parties in connection with this Agreement.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.27<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">CMC</font>&#8221; means chemistry, manufacturing and controls.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.28<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Combination Product</font>&#8221; means a product comprising a Candidate or Product in combination with one or more other therapeutically active ingredients (which includes any prophylactic activity) that are co-formulated as part of the same dosage form or packaged and administered to patient together. For the avoidance of doubt, adjuvants, including molecular adjuvants, are not considered therapeutically active ingredients for the purposes of this definition regardless of whether or not such adjuvant is packaged together with a Candidate or Product but in a separate container.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.29<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">&#8220;Commercialization Activities&#8221;</font> means those activities to be performed by each Commercializing Party with respect to the Commercialization of the Product in the Commercialization Territory, including those under Section&#160;9 of this Agreement.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.30<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Commercializing Party</font>&#8221; shall mean, as applicable, (a) Pfizer (including Pfizer&#8217;s Affiliates) with respect to the countries included within the Pfizer Commercialization Territory or (b) BioNTech (including BioNTech&#8217;s Affiliates) with respect to the countries included with the BioNTech Commercialization Territory.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.31<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Commercialization Territory</font>&#8221; shall mean either the Pfizer Commercialization Territory or the BioNTech Commercialization Territory, as applicable.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.32<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Commercialize</font>&#8221; or &#8220;<font style="text-decoration:underline;">Commercializing</font>&#8221; means to market, promote, distribute, offer for sale, sell, have sold, import, have imported, export, have exported or otherwise commercialize a compound or product. When used as a noun, &#8220;Commercialization&#8221; and &#8220;Commercialized&#8221; means any and all activities involved in Commercializing. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref488157701"></a><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.33</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="text-decoration:underline;">Commercially Reasonable Efforts</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means, with respect to the efforts to be expended by a Party with respect to any objective, those reasonable, good faith efforts to accomplish such objective as such Party would normally use to accomplish a similar objective under similar circumstances, in particular taking into account the then-current urgency of the COVID-19 crisis. With respect to any efforts relating to the Development, Regulatory Approval or Commercialization of a Candidate or Product by a Party, generally or with respect to any particular country in the Territory, a Party will be deemed to have exercised Commercially Reasonable Efforts if such Party has exercised those efforts normally used by such Party having regard to the circumstances, in the relevant country, with respect to a compound or protein, product or product candidate, as applicable (a) of similar modality Controlled by such Party, (b) to which such Party has similar rights, (c) which is of similar market potential in such country, and (d) which is at a similar stage in its development or product life cycle, as any Candidate or Product, in each case, taking into account all Relevant Factors in effect at the time such efforts are to be expended. Further, to the extent that the performance of a Party&#8217;s obligations hereunder is adversely affected by the other Party&#8217;s failure to perform its obligations hereunder, the impact of such performance failure will be taken into account in determining whether such Party has used its Commercially Reasonable Efforts to perform any such affected obligations.</font></p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.34<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Committee</font>&#8221; means one of the JSC, RCC, Patent Committee, Joint Safety Committee, JMC, JFC and JCC, and &#8220;<font style="text-decoration:underline;">Committees</font>&#8221; means any two or more of the foregoing.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.35<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Compassionate Use Purposes</font>&#8221; means, with respect to the Product, providing Product under any compassionate use or expanded access programs or other gratis donations, but excluding any sales of Product for cash or non-cash consideration under any Emergency Use Authorization. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.36<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Competitive Product</font>&#8221; means a pharmaceutical product that incorporates an immunogenic composition comprising RNA in the Field that is intended to be, has been, or is being Exploited by a Third Party. For avoidance of doubt, Competitive Product does not include Product (a) Commercialized by or on behalf of BioNTech in the BioNTech Commercialization Territory pursuant to this Agreement; or (b) Commercialized outside of the Territory in accordance with the terms of the Fosun Agreement.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.37<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Compliance</font>&#8221; means the adherence by the applicable Party and its Affiliates in all material respects to all applicable Laws and Party Specific Regulations, in each case with respect to the activities to be conducted by or on behalf of that Party under this Agreement.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref263791183"></a><a name="_Ref265015277"></a>1.38<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Confidential Information</font>&#8221; means, with respect to each Party, all Know-How or other information, including proprietary information and materials (whether or not patentable) regarding or embodying such Party&#8217;s or its Representatives&#8217; technology, products, business information or objectives, that is communicated by or on behalf of the Disclosing Party to the Receiving Party or its permitted recipients, on or after the Effective Date, but only to the extent that: (a) such Know-How or other information in written form is marked in writing as &#8220;confidential&#8221; at the time of disclosure, (b) such Know-How or other information disclosed orally or in non-tangible form is identified by the Disclosing Party as &#8220;confidential&#8221; at the time of disclosure or within 30 days thereafter, or (c) such Know-How or other information (regardless of the form of disclosure) is disclosed in circumstances of confidence or would be understood by the Parties, exercising reasonable business judgment, to be confidential. Confidential Information does not </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">include any Know-How or other information to the extent the Receiving Party can demonstrate by competent proof that such Know-How or other information (a) was already known by the Receiving Party (other than under an obligation of confidentiality to the Disclosing Party) at the time of disclosure by or on behalf of the Disclosing Party, (b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party, (c) became generally available to the public or otherwise part of the public domain after its disclosure to the Receiving Party, other than through any act or omission of the Receiving Party in breach of its obligations under this Agreement, (d) was disclosed to the Receiving Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to the Disclosing Party not to disclose such information to the Receiving Party or (e) was independently discovered or developed by or on behalf of the Receiving Party without the use of any Confidential Information belonging to the Disclosing Party.</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joint Know-How shall be deemed Confidential Information of either Party and either Party shall be deemed the Receiving Party in respect of Joint Know-How.</font></p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Contract Interest Rate</font>&#8221; means one-half of one percent (0.5%) plus the rate for deposits in U.S. Dollars for a period of three-months as published by the ICE Benchmark Administration Limited, a United Kingdom Company (&#8220;LIBOR&#8221;); measured at 2 p.m. London/England time on the date payment is due. If the three-month LIBOR has been permanently discontinued, it will be replaced by a comparable or successor quoting service approved by the Parties. Interest will be calculated on a 365/360 basis.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.40<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Control</font>&#8221; or &#8220;<font style="text-decoration:underline;">Controlled</font>&#8221; means with respect to any Intellectual Property Right or material (including any Patent Right, Know-How or other data, information or material), the ability (whether by sole, joint or other ownership interest, license or otherwise, other than pursuant to this Agreement) to, without violating the terms of any agreement with a Third Party, grant a license or sublicense or provide access or other right in as provided in this Agreement, to or under such Intellectual Property Right or material.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.41<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Conversion Costs</font>&#8221; means [***]. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref518672841"></a>1.42<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Copyright</font><a name="_Ref518672841"></a>&#8221; means any copyright rights pertaining to the promotional materials and literature created or utilized by or on behalf of a Commercializing Party in connection with the Commercialization of Products in the by that Commercializing Party in its Commercialization Territory.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.43<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Cover</font>&#8221;, &#8220;<font style="text-decoration:underline;">Covered</font>&#8221; or &#8220;<font style="text-decoration:underline;">Covering</font>&#8221; means, with respect to (a) a given Candidate or Product and Patent Right, that a valid claim of such Patent Right would, absent a license thereunder or ownership thereof, be infringed by the making, sale, offer for sale or importation of such Candidate or Product and (b) a given Candidate or Product and Know-How, that such Know-How would, absent a license thereunder or ownership thereof, be misappropriated or misused by the use or making of such Candidate or Product.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.44<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Current Good Manufacturing Practices</font>&#8221; or &#8220;<font style="text-decoration:underline;">cGMP</font>&#8221; means all applicable standards and applicable Laws relating to manufacturing practices for products (including ingredients, testing, storage, handling, intermediates) promulgated by the U.S. Food and Drug Administration and any other governmental authority (including, European Union or member state level and Japan), including, but not limited to, standards in the form of applicable Laws, guidelines, advisory opinions and compliance policy guides, and current interpretations of the applicable </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authority or agency thereof (as applicable to pharmaceutical and biological products and ingredients), as the same may be updated, supplemented or amended from time to time, in each case of those jurisdictions in which the products are Manufactured.</font></p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref36411363"></a><a name="_Ref35959654"></a><a name="_Ref36220046"></a><a name="_cp_text_1_218"></a><a name="_cp_text_1_220"></a><a name="_cp_text_1_221"></a><a name="_cp_text_1_222"></a>1.45<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Current Licenses</font><a name="_cp_text_1_218"></a>&#8221; means any agreement (a) that BioNTech<a name="_cp_text_1_220"></a> or its Affiliates has entered into prior to the Effective Date with a Third Party and (b) pursuant to which BioNTech<a name="_cp_text_1_221"></a> or its Affiliates are (i) granted rights to any BioNTech<a name="_cp_text_1_222"></a> Technology as of the Effective Date or (ii) granted a license or otherwise transferred any right to practice under any Patent Rights or Know-How, in each case that relate to the Candidates or Products or activities under this Agreement. BioNTech&#8217;s Current Licenses are disclosed on <font style="text-decoration:underline;">Schedule 1.45</font>. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.46<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Current Licensor</font>&#8221; means any Third Party that is a party to a Current License.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.47<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Delivery Technology</font>&#8221; means the BioNTech Know-How applicable to formulating nucleic acids to enable the delivery of such nucleic acids to target cells <font style="font-style:italic;">in vivo</font>. For clarity, Delivery Technology does not [***].</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.48<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Develop</font>&#8221;, &#8220;<font style="text-decoration:underline;">Developed</font>&#8221; or &#8220;<font style="text-decoration:underline;">Developing</font>&#8221; means to discover, research or otherwise develop or improve a process, compound or product, including planning and conducting non-clinical and clinical research and development activities prior to grant of a Market Authorization Approval or any research or development conducted after receipt of a Market Authorization Approval, including those required by any Regulatory Authority to maintain any Market Authorization Approval. When used as a noun, &#8220;Development&#8221; means any and all activities involved in Developing.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref36503015"></a><a name="_Ref44355504"></a>1.49<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Developing Countries Territory</font>&#8221; means, to the extent BioNTech or any of its Affiliates receive Third Party funding from [***] to fund Development or Manufacturing of the Candidates or Products pursuant to this Agreement, those countries listed in <font style="text-decoration:underline;">Schedule 1.49</font> which are also defined in the relevant funding documents as &#8220;Developing Countries&#8221;; <font style="font-style:italic;">provided</font> that if prior to the execution of such funding documents, the price of any medicinal product (including the Product) in any country within <font style="text-decoration:underline;">Schedule 1.49</font> is made relevant as a reference price for the sale of the Product in any country outside of the countries listed within <font style="text-decoration:underline;">Schedule 1.49</font>, then such country shall be automatically removed as a country within <font style="text-decoration:underline;">Schedule 1.49</font>, unless otherwise mutually agreed in writing by the Parties. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref37004189"></a>1.50<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Development Budget</font>&#8221; means the budget to be agreed and updated [***] by the JSC pursuant to Section 5.1 for all activities, costs and expenses that are to be funded as Shared Development Costs. The Development Budget existing on the signing of this Amended and Restated Collaboration Agreement is attached hereto as <font style="text-decoration:underline;">Schedule 1.50</font>. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.51<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">EMA</font>&#8221; means the European Medicines Agency or any successor agency thereto.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.52<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Emergency Use Authorization</font>&#8221; means an emergency use authorization, or any analogous approval for emergency situations, granted by a Governmental Authority or Regulatory Authority to warrant limited or conditional distribution of a pharmaceutical or vaccine product, including any granted pursuant to &#167;564 of the FD&amp;C Act (or any equivalent or comparable authorization granted by a Regulatory Authority elsewhere), in each case which is separate from a Market Authorization Approval.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.53</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="text-decoration:underline;">European Union</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;">EU</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means the countries of the European Union, as it is constituted as of the Effective Date, which consists of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and, notwithstanding its departure from the European Union, shall for the purposes of this definition include the United Kingdom of Great Britain and Northern Ireland.</font></p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.54<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Expedited Trial Pathway</font>&#8221; means a Clinical Trial protocol or pathway recognized or authorized by any Regulatory Authority for the emergency or expedited approval of medicines for human use, as opposed to a traditional Clinical Trial.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.55<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Exploit</font>&#8221; means to Develop, Manufacture, Commercialize, use or otherwise exploit. Cognates of the word &#8220;Exploit&#8221; will have correlative meanings.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.56<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">FD&amp;C Act</font>&#8221; means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules and regulations promulgated thereunder.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.57<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">FDA</font>&#8221; means the United States Food and Drug Administration and any successor Governmental Authority having substantially the same function.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk35520575"></a><a name="_Hlk519582324"></a>1.58<font style="margin-left:36pt;"></font><a name="_Hlk35520575"></a>&#8220;<font style="text-decoration:underline;">Field</font><a name="_Hlk519582324"></a>&#8221; means immunogenic compositions comprising RNA encoding a SARS-CoV-2 polypeptide or fragment thereof, including naturally occurring or engineered variants thereof, for prophylaxis against COVID-19 in humans.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk35513188"></a>1.59<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">First Commercial Sale</font>&#8221; means, with respect to the Product in a given country in the Territory, the first shipment of the Product by the applicable Commercializing Party to a Third Party in such country for end use or consumption of the Product pursuant to an Emergency Use Authorization in such country or after grant of a Market Authorization Approval of such Product in such country or, if earlier, the invoicing of a Third Party for such shipment, excluding, however, any shipment or invoicing or other distribution of the Product for use in or for (a) a clinical trial, a Compassionate Use Purpose, named patient programs, sales under a treatment IND, test marketing, or any non-registrational studies or (b) any similar instance where the Product is supplied at or below the Commercializing Party&#8217;s Manufacturing Costs (excluding any margin) for such Product.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.60<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Flu Collaboration License</font>&#8221; means the separate research collaboration and license agreement between, inter alia, the Parties for the development and commercialization of immunogenic compositions comprising RNA that encodes at least one Antigen for prophylaxis against influenza in humans dated July 20, 2018, as amended. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.61<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Fosun</font>&#8221; means Shanghai Fosun Pharmaceutical Industrial Development, Co. Ltd, a company incorporated in China, and having a place of business at No. 1289 Yishan Road, Shanghai, China.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.62<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Fosun Agreement</font>&#8221; means the Development and License Agreement concluded between BioNTech and Fosun on March 13, 2020.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.63<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Future License</font>&#8221; means an agreement approved by the Parties (a) that BioNTech or its Affiliates enters into on or after the Effective Date with a Third Party or (b) that Pfizer or its Affiliates enters into on or after the Effective Date with a Third Party; which in the case of (a) and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) grants a license (sublicensable in accordance with the licenses granted hereunder) to that Third Party's (&#8220;</font><font style="text-decoration:underline;">Future Licensor</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rights </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development, Manufacture or </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercialization of the Candidates or Products by </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and Pfizer in the Field, and which license is applicable to the Candidates or Products. </font></p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.64<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">GAAP</font>&#8221; means the then-current generally accepted accounting principles in the United States as established by the Financial Accounting Standards Board or any successor entity or other entity generally recognized as having the right to establish such principles in the United States, in each case, consistently applied.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.65<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">GEIA</font>&#8221; means the German Employee Invention Act.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.66<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">GEIA Technology</font>&#8221; means all BioNTech Technology and Research and Development Program Technology invented by employees of BioNTech or its Affiliates (solely or jointly with employees of Third Parties) under the jurisdiction of GEIA.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.67<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Global Commercialization Plan</font>&#8221; means, the global plan established by the JCC pursuant to Section&#160;9.1 with respect to the Territory as a whole, and as may be updated from time to time by the JCC for each Calendar Year during the Term, and from which any Annual Regional Commercialization Plan shall be derived.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.68<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Global Trade Control Laws</font>&#8221; include, but are not limited to, the U.S. Export Administration Regulations; the U.S. International Traffic in Arms Regulations; the economic sanctions rules and regulations implemented under statutory authority or President&#8217;s Executive Orders and administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Control; European Union (EU) Council Regulations on export controls, including Nos.428/2009, 267/2012; other EU Council sanctions regulations, as implemented in EU Member States; United Nations sanctions policies; all relevant regulations and legislative instruments made under any of the above; other relevant economic sanctions, export and import control laws, and other laws, regulations, legislation, orders and requirements imposed by a relevant Governmental Authority.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.69<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Government</font>&#8221; or &#8220;<font style="text-decoration:underline;">Governmental Authority</font>&#8221; is to be broadly interpreted and includes (a) any national, federal, state, local, regional or foreign government, or level, branch, or subdivision thereof; (b) any multinational or public international organization or authority; (c) any ministry, department, bureau, division, authority, agency, commission, or body entitled to exercise any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power; (d) any court, tribunal, or governmental arbitrator or arbitral body; (e) any government-owned or controlled institution or entity; (f) any enterprise or instrumentality performing a governmental function; and (g) any political party.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.70<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Government Official</font>&#8221;, to be broadly interpreted, means (a) any elected or appointed government official (e.g., a member of a ministry of health), (b) any employee or person acting for or on behalf of a government official, Governmental Authority, or other enterprise performing a governmental function, (c) any political party, candidate for public office, officer, employee, or person acting for or on behalf of a political party or candidate for public office, (d) any member of a military or a royal or ruling family, and (e) any employee or person acting for or on behalf of a public international organization (e.g., the United Nations). For clarity, healthcare </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">providers employed by Government-owned or -controlled hospitals, or a person serving on a healthcare committee that advises a Government, will be considered Government Officials.</font></p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref43806330"></a><a name="_Ref58960650"></a><a name="_Ref488159828"></a>1.71<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Gross Profit</font>&#8221; means [***].</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.72<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">GxP</font>&#8221; means, collectively, all relevant good practice quality guidelines and regulations, encompassing such internationally recognized standards as Good Manufacturing Practice (GMP), Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Good Distribution Practice (GDP), and Good Review Practice (GRP). </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.73<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">HCP</font>&#8221; or &#8220;<font style="text-decoration:underline;">Healthcare Professional</font>&#8221; includes any physician, nurse, pharmacist, or other person who may administer, prescribe, purchase or recommend pharmaceutical products or other healthcare products.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.74<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">House Marks</font>&#8221; means the Pfizer House Marks or the BioNTech House Marks, as the case may be.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.75<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Human Material</font>&#8221; means any biological samples of one or more Subjects collected, provided or utilized by BioNTech during the Research and Development Plan pursuant to this Agreement.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref488159830"></a>1.76<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">ICF</font>&#8221; means an informed consent form that was approved by a qualified Institutional Review Board or Independent Ethics Committee (&#8220;<font style="text-decoration:underline;">IRB / IEC</font>&#8221;) in accordance with all applicable Laws and recognized international standards for the protection of human research subjects. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.77<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">IFRS</font>&#8221; means International Financing Reporting Standards, as in effect from time to time, together with its pronouncements thereon from time to time, consistently applied.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.78<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">IND</font>&#8221; means an Investigational New Drug Application submitted under the FD&amp;C Act, or an analogous application or submission with any analogous agency or Regulatory Authority outside of the United States for the purposes of obtaining permission to conduct Clinical Trials.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.79<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Intellectual Property Rights</font>&#8221; means any and all (a) Patent Rights, (b) proprietary rights in Know-How, including trade secret rights, (c) proprietary rights associated with works of authorship and software, including copyrights, moral rights, and copyrightable works, and all applications, registrations, and renewals relating thereto, and derivative works thereof, (d) other forms of proprietary or intellectual property rights however denominated throughout the world, other than trademarks, service marks, trade names, trade dress, domain names and other indicators of origin.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Internal Compliance Codes</font>&#8221; means a Party&#8217;s internal policies and procedures intended to ensure that such Party and its Affiliates comply with applicable Laws, Party Specific Regulations, and such Party&#8217;s applicable internal policies and procedures, including such policies and procedures regarding compliance with such Party&#8217;s ethical, medical and similar standards.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk40816818"></a>1.81<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Joint Commercialization Committee</font>&#8221; or &#8220;<font style="text-decoration:underline;">JCC</font>&#8221; has the meaning defined in Section&#160;6.4.1.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.82</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="text-decoration:underline;">Joint Steering Committee</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;">JSC</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means the steering committee described in Section </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3.1</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Joint Know-How</font>&#8221; means any Research and Development Program Know-How, whether or not patentable, made or created jointly by (a) BioNTech or any of its Representatives and (b) Pfizer or any of its Representatives, which does not constitute BioNTech Know-How, Product Know-How or Pfizer Know-How. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.84<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Joint Patent Rights</font>&#8221; means Research and Development Program Patent Rights that claim or disclose any invention included in Joint Know-How. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref488158123"></a>1.85<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Joint Steering Committee</font>&#8221; or &#8220;<font style="text-decoration:underline;">JSC</font>&#8221; means the steering committee described in Section 7.3.1 of this Agreement, and in the event the JSC is dissolved pursuant to Section 6.3.6 but this Agreement survives, all references to the JSC shall mean the Joint Commercialization Committee.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.86<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Joint Technology</font>&#8221; means the Joint Know-How and the Joint Patent Rights.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.87<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Know-How</font>&#8221; means any proprietary invention, discovery, development, data, information, process, method, technique, technology, result, cell line, cell, antibody or other protein, compound, probe, nucleic acid, (including RNAi) or other sequences or other know-how, whether or not patentable, and any physical embodiments of any of the foregoing or any information contained in any of the foregoing. Know-How does not include Patent Rights, Copyrights, Product Trademarks, Pfizer House Marks or BioNTech House Marks.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.88<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Law</font>&#8221; means any law, statute, rule, regulation, order, judgment or ordinance of any Governmental Authority, including all applicable Anti-Corruption Laws, Applicable Data Protection Laws, accounting and recordkeeping laws, and laws relating to interactions with HCPs and Government Officials. For the avoidance of doubt, any specific references to any applicable Law or any portion thereof shall be deemed to include all then-current amendments thereto or any replacement or successor law, statute, standard, ordinance, code, rule, regulation, resolution, promulgation, order, writ, judgment, injunction, decree, stipulation, ruling or determination thereto.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.89<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">MA Holder</font>&#8221; means, on a country by country basis within the Territory, the Party (or its Affiliate or designee under its control) that holds the Regulatory Approval required for the Commercialization of the Product in such country.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.90<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Major EU Market Country</font>&#8221; means any of France, Germany, Italy, Spain or the United Kingdom.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.91<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Major Market Country</font>&#8221; means the Major EU Market Countries, the United States and Japan.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref488158132"></a>1.92<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Manufacture</font>&#8221; or &#8220;<font style="text-decoration:underline;">Manufacturing</font>&#8221; means to make, produce, manufacture, process, fill, finish, package, label, perform quality assurance testing, release, ship or store, and, for the purposes of further Manufacturing, distribute, import or export, a compound or product or any component thereof. When used as a noun, &#8220;Manufacture&#8221;, &#8220;Manufactured&#8221; or &#8220;Manufacturing&#8221; means any and all activities involved in Manufacturing a compound or protein, device or product or any component thereof.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref58330564"></a><a name="_Hlk519587668"></a>1.93<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Manufacturing Costs</font>&#8221; means [***]. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref36504755"></a><a name="_Ref36504813"></a><a name="_Ref44355584"></a>1.94<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Manufacturing Plan</font>&#8221; means the plan for establishing Manufacturing and the Manufacturing facilities, as well as the Manufacturing obligations of each Party, in respect of the Candidates and Products, as such plan may be updated and modified from time to time pursuant to Section 5.1 and Section 6.4.4. The Manufacturing Plan existing on the signing of this Amended and Restated Collaboration Agreement is attached hereto as <font style="text-decoration:underline;">Schedule 1.94</font>. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_699"></a>1.95<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Manufacturing Variances</font><a name="_cp_text_1_699"></a>&#8221; means [***].</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref44589759"></a>1.96<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Market Authorization Approval</font>&#8221; means the approval by all relevant Governmental Authorities of a Marketing Authorization Application in a given country or regulatory jurisdiction (but which will not include any Pricing and Reimbursement Approvals).</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.97<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Marketing Authorization Application</font>&#8221; or &#8220;<font style="text-decoration:underline;">MAA</font>&#8221; means an application to a Governmental Authority for approval to market the Product (but excluding Pricing and Reimbursement Approval) in a country or a regulatory jurisdiction including a BLA or an application for conditional use approval.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.98<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Medical Activities</font>&#8221; means MSL Activities and Global Medical Activities.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_335"></a><a name="_cp_blt_2_334"></a>1.99<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Medical Science Liaison</font>&#8221; or &#8220;<font style="text-decoration:underline;">MSL</font>&#8221; means a field-based colleague that is part of a Party&#8217;s medical organization (whether or not such field-based colleagues are titled as such within the respective Party&#8217;s medical organization) and who will have no responsibility for promotion, detailing or marketing of the Product.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.100<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Materials</font>&#8221; means the Pfizer Materials or the BioNTech Materials, as the context requires.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.101<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Modified RNA</font>&#8221; means an mRNA that has been modified by the incorporation of one or more modified nucleosides, excluding the 5&#8217; CAP.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.102<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Modified RNA Technology</font>&#8221; means [***].</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_370"></a><a name="_cp_text_1_371"></a><a name="_cp_text_2_372"></a><a name="_cp_text_2_373"></a>1.103<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">MSL Activities</font><a name="_cp_text_2_370"></a>&#8221; means, for each country in the Territory, <a name="_cp_text_1_371"></a>those activities not related to the promotion, detailing, or marketing of the Product, but which are otherwise <a name="_cp_text_2_372"></a>set forth in the relevant medical section of the Annual Regional Commercialization Plan, if any, approved for such country, or where no such plan exists as determined by the applicable Commercializing Party, consisting of the following activities: (a) HCP-facing field-based medical communication activities utilizing Medical Education Materials and medical content approved by the applicable Commercializing Party to support the safe and effective use of the Product for approved indications, including indications authorized under an Emergency Use Authorization, or as permitted under applicable Laws other indications identified by the Commercializing Party for its Commercialization Territory; (b) responses to UMRs; (c) scientific exchange activities utilizing medical resources approved by the applicable Commercializing Party created for such purpose; (d) field-based medical support at medical congresses, including drafting post-congress summary reports for internal use; (e) gathering field-based customer insights for internal use and (f) other non-promotional activities approved for MSLs pursuant to the Parties&#8217; compliance policies and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_373"></a>local laws and regulations. </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For clarity, MSL Activities specifically exclude Global Medical Activities.</font></p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.104<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Mutation</font>&#8221; means [***].</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref43806303"></a>1.105<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Net Sales</font>&#8221; means with respect to a Product [***]</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.106<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Packaging Configuration</font>&#8221; means the number of vial boxes, vials per box, and doses of Product per vial in the commercial packaging presentation of the Product for sale or use in the Territory.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.107<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Packaging and Labeling</font>&#8221; means primary, secondary or tertiary packaging and labeling of Product (in its commercial packaging presentation) for sale or use in the Territory, including insertion of materials such as patient inserts, patient medication guides, and professional inserts and any other written, printed or graphic materials accompanying the Product and any brand security or anti-counterfeiting measures included in the packaging elements for the Product considered to be part of the finished packaged Product, and all testing and release thereof.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.108<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Party Specific Regulations</font>&#8221; means all non-monetary judgments, decrees, orders or similar decisions issued by any Governmental Authority specific to a Party, and all consent decrees, corporate integrity agreements, or other agreements or undertakings of any kind by a Party with any Governmental Authority, in each case as the same may be in effect from time to time and applicable to a Party&#8217;s activities contemplated by this Agreement.<font style="font-weight:bold;font-style:italic;color:#C00000;"> </font></p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.109<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Patent Rights</font>&#8221; means any and all (a) issued patents, (b)&#160;pending patent applications, including all provisional applications, non-provisional applications, substitutions, continuations, continuations-in-part, divisions and renewals, applications sharing a priority claim and all patents granted thereon, (c) patents-of-addition, reissues, reexaminations and extensions or restorations by existing or future extension or restoration mechanisms, including patent term adjustments, patent term extensions, supplementary protection certificates or the equivalent thereof, (d) inventor&#8217;s certificates, (e) other forms of government-issued rights substantially similar to any of the foregoing and (f) United States and foreign counterparts of any of the foregoing.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.110<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Patient or HCP Support Program Trademark</font>&#8221; means any Trademark (whether or not registered) which is solely for use on, with, or to refer to a Party's patient or HCP support programs or patient assistance programs relating to the Product (where such Trademark does not incorporate a Product Trademark, the Pfizer House Marks or BioNTech House Marks, as applicable), and all intellectual property rights and goodwill associated with the foregoing.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.111<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Person</font>&#8221; means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or political subdivision or department or agency of a government.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.112<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Personal Data</font>&#8221; means any information relating to an identified or identifiable natural person as further specified in Art. 4 no. 1 of the GDPR.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.113</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="text-decoration:underline;">Pfizer Commercial Materials</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means any and all Pfizer Promotional Materials, Pfizer Training Materials, and all other literature or other information related to the Product and, in each case, created and provided by or on behalf of Pfizer hereunder.</font></p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.114<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Pfizer Commercialization Territory</font>&#8221; means the Territory, except for countries within the BioNTech Commercialization Territory from time to time. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.115<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Pfizer Exit Countries</font>&#8221; means, on a country by country basis, those countries out of the United Arab Emirates, South-East Asia and the Developing Countries Territory where Pfizer elects, pursuant to this Agreement, not to Commercialize the Product pursuant to any Pfizer Country Exit Option as described in Section&#160;3.12.2. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.116<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Pfizer House Marks</font>&#8221; means (a) the corporate logo of Pfizer, (b) the trademark &#8220;Pfizer&#8221;, (c) any other Trademark, trade name or service mark (whether registered or unregistered) containing the word &#8220;Pfizer&#8221;, (d) any other corporate logo or Trademark of Pfizer used by Pfizer to identify Pfizer or its Affiliates; and all intellectual property rights and goodwill associated with any and all of the foregoing in clauses (a) through (d).</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.117<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Pfizer Improvements</font>&#8221; means any Research and Development Program Technology, regardless of inventorship, that is a modification or improvement to the Pfizer Technology and (a) would also be applicable to one or more candidates or products in addition to or other than the Candidates or Products, (b) is not predominantly directed to the Candidates or Products or the RNA Technology or RNA Process Technology and (c) could have reasonably been developed without the aid, use or application of BioNTech Materials, BioNTech Know-How or BioNTech&#8217;s Confidential Information or any improvements or enhancements thereto. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.118<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Pfizer Know-How</font>&#8221; means [***].</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.119<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Pfizer Patent Right</font>&#8221; means any Patent Right (other than Patent Rights jointly owned by BioNTech and Pfizer pursuant to Section 11.2) in any form and whether pending or issued that (a) is Controlled by Pfizer or any of its Affiliates on the Effective Date or that comes into the Control of Pfizer or any of its Affiliates during the Term (other than, in either case, through the grant of a license by BioNTech), and (b) claims any Pfizer Know-How.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.120<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Pfizer Quarter</font>&#8221; means each of the four (4) successive thirteen (13) week periods, the first such thirteen (13) week period (a) with respect to the United States, commencing on January 1 of any Pfizer Year and (b) with respect to any country in the Territory other than the United States, commencing on December 1 of any Pfizer Year. Wherever non-country specific timelines are specified in this Agreement in reference to a Pfizer Quarter, such reference shall be deemed to be made to the Pfizer Year applicable in the United States. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.121<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Pfizer Technology</font>&#8221; means the Pfizer Patent Rights, Pfizer Materials and Pfizer Know-How.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.122<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Pfizer Year</font>&#8221; means the twelve (12) month fiscal periods observed by Pfizer (a) commencing on January 1 with respect to the United States; and (b) commencing on December 1 with respect to any country in the Territory other than the United States.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.123</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="text-decoration:underline;">Phase I Clinical Trial</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means a Clinical Trial that generally provides for the first introduction into humans of a pharmaceutical product with the primary purpose of determining safety, metabolism and pharmacokinetic properties and clinical pharmacology of such product, in a manner that is generally consistent with 21 CFR &#167; 312.21(a), as amended (or its successor regulation), provided, however, a Phase I Clinical Trial does not include any study generally characterized by the FDA as an &#8220;exploratory IND study&#8221; in CDER&#8217;s Guidance for Industry, Investigators, and Reviewers Exploratory IND Studies, January 2006, irrespective of whether or not such study is actually performed in the United States or under an IND. A so-called Phase I/II Clinical Trial shall be deemed to be a Phase I Clinical Trial unless such trial, when completed, allows Pfizer to proceed directly to a Phase III Clinical Trial.</font></p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.124<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Phase II Clinical Trial</font>&#8221; means a Clinical Trial, the principal purpose of which is to make a preliminary determination as to whether a pharmaceutical product is safe for it intended use and to obtain sufficient information about such product&#8217;s efficacy, in a manner that is generally consistent with 21 CFR &#167; 312.21(b), as amended (or its successor regulation), to permit the design of further Clinical Trials.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.125<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Phase III Clinical Trial</font>&#8221; means a pivotal Clinical Trial with a defined dose or a set of defined doses of a pharmaceutical product designed to ascertain efficacy and safety of such product, in a manner that is generally consistent with 21 CFR &#167; 312.21(c), as amended (or its successor regulation), for the purpose of enabling the preparation and submission of an NDA.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref488158251"></a>1.126<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Price Approval</font><a name="_Ref488158251"></a>&#8221; means, in any country where a Governmental Authority authorizes reimbursement for, or approves or determines pricing for, pharmaceutical products, receipt (or, if required to make such authorization, approval or determination effective, publication) of such reimbursement authorization or pricing approval or determination (as the case may be).</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.127<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Product</font>&#8221; means any pharmaceutical product in a formulation suitable for administration to humans that [***]. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.128<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Product Component</font>&#8221; means any component or consumable additional to the Product (e.g., diluent, needles or syringes) that are supplied by on behalf of a Commercializing Party for use in the administration of the Product to a patient, other than where such components or consumables are supplied through a separate sale or as part of the same sale, but where the customer is charged for such components or consumables at cost or at greater than cost thereof.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.129<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Product Know-How</font>&#8221; means any Research and Development Program Know-How that is predominantly directed to the composition of matter, treatment with, or the delivery of, Manufacture, form, formulation, or use of a Candidate or Product in the Field and is not generally applicable to compositions or products in addition to or other than a Candidate or Product. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.130<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Product Materials</font>&#8221; means all raw or intermediate materials (including, without limitation, active pharmaceutical ingredients and excipients, vectors, plasmids and mRNA), labeling or packaging materials and components needed for the Manufacture and supply of a given Candidate or Product. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.131<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Product Patent Rights</font>&#8221; means any Patent Right that claims any invention included in Product Know-How. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.132</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="text-decoration:underline;">Product Shipping and Storage Costs</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">means</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.133<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Product Technology</font>&#8221; means the Product Know-How and Product Patent Rights.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.134<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Product Trademarks</font>&#8221; means any Trademark, (whether registered or unregistered) selected with the mutual consent of the Parties through the JCC which is solely for use on, with, or to refer to the Product (other than Pfizer House Marks and BioNTech House Marks, as applicable), and all intellectual property rights and goodwill associated with the foregoing, but excluding any Patient or HCP Support Program Trademark.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.135<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Professional Requirements</font>&#8221; means (a) FDA&#8217;s regulations and guidelines concerning the advertising of prescription drug products, (b) the American Medical Association&#8217;s Guidelines on Gifts to Physicians, (c) the ACCME Standards for Commercial Support of Continuing Medical Education, (d) the European Federation of Pharmaceutical Industries and Associations (EFPIA), (e) the Pharmaceutical Supply Chain Initiative (PSCI) Pharmaceutical Industry Principles for Responsible Supply Chain Management, (f) the relevant Codes and Guidelines established by PhRMA relating to marketing practices and (h) all other accepted national and international pharmaceutical industry codes of practice in and for the relevant countries in the Territory.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.136<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Professional Sales Representative</font>&#8221; or &#8220;<font style="text-decoration:underline;">PSR</font>&#8221; means a pharmaceutical sales representative employed (either full time or part time) by or on behalf of a Party or its Affiliates to promote and deliver details for the Product.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.137<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Prosecution and Maintenance</font>&#8221; means (a) the preparation, filing, and prosecution of patent applications and maintenance of Patent Rights, as well as re-examinations and reissues with respect to such Patent Rights, together with the conduct of interferences, post&#8211;grant proceedings (including post-grant review, inter-parties review, and derivation proceedings in the U.S.) and the defense of oppositions with respect to such Patent Rights and (b) the preparation, filing, and prosecution of Trademark applications and maintenance and renewal of Trademarks, the handling of office actions, objections or rejections issued by trademark offices, and the defense of oppositions with respect to such Trademark application or Trademark; and &#8220;<font style="text-decoration:underline;">Prosecute and Maintain</font>&#8221; has the correlative meaning.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.138<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Public Health Service Act</font>&#8221; or &#8220;<font style="text-decoration:underline;">PHS Act</font>&#8221; means the United States Public Health Service Act (42 U.S.C. 201 <font style="font-style:italic;">et seq</font>), as amended from time to time (including any rules and regulations promulgated thereunder) or any subsequent or superseding law, statute or regulation.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.139<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Recall Costs</font>&#8221; means actual costs incurred by a Party or its Affiliates as the direct result of a recall or withdrawal of the Product in a country in the Territory, such as administrative costs associated with administering the recall or withdrawal, notification, packing, shipping, distribution and destruction costs, Product replacement costs and reimbursements, penalties payable to customers and other payments to Third Parties as a direct result of such recall or withdrawal, but will not include internal costs to the extent such costs are not included in Manufacturing Costs or indirect costs such as loss of reputation or goodwill or loss of indirect profits.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.140<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Regional Commercialization Committee</font>&#8221; or &#8220;<font style="text-decoration:underline;">RCC</font>&#8221; means any of the regional committees established pursuant to Section&#160;6.4.2.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.141</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="text-decoration:underline;">Regulatory Approval</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means all technical, medical and scientific licenses, registrations, authorizations and approvals (including conditional use approvals and approvals of INDs, NDAs, MAAs, BLAs, supplements and amendments, pre- and post- approvals and labeling approvals) of any Regulatory Authority, necessary or useful for the use, Development, Manufacture, and Commercialization of a pharmaceutical or biopharmaceutical product in a regulatory jurisdiction, including commercially reasonable Price Approvals and commercially reasonable Third Party reimbursement approvals, including for the avoidance of doubt any </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emergency Use Authorization</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.142<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Regulatory Authority</font>&#8221; means, with respect to a country in the Territory, any national (e.g., the FDA), supra-national (e.g., the European Commission, the Council of the European Union, or the European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council or other Governmental Authority involved in the granting of any license, approval or authorization (including a regulatory approval or emergency use authorization) to Develop, Manufacture, Commercialize or Exploit pharmaceutical products in such country.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.143<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Related Agreement</font>&#8221; means the Pharmacovigilance Agreement entered into or to be entered into or amended pursuant to Section 8.3.3, supply agreements and quality agreements entered into or to be entered into or amended pursuant to Sections 7.4.1 and 7.4.2, and any other agreements entered into or to be entered into between the Parties or their Affiliates in connection with the Development, Regulatory Approval, Manufacture or Commercialization of a Candidate or Product. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.144<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Relevant Factors</font>&#8221; means all relevant factors that may affect the Development, Regulatory Approval or Commercialization of a Candidate or Product, including (as applicable): [***].</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk519684304"></a><a name="_Hlk35513349"></a>1.145<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Replicon</font><a name="_Hlk35513349"></a>&#8221; means an RNA molecule(s) that comprises a gene encoding a polymerase that can, when the RNA molecule(s) is introduced into a cell, replicate the same or a different RNA molecule(s), that also comprises a gene or a sequence encoding at least one non-human polypeptide that is capable of eliciting an immune response (an &#8220;<font style="text-decoration:underline;">Antigen</font>&#8221;) and does not comprise the full set of genes required to make an infectious virus and is capable, when introduced into a cell, of expressing detectable levels of the encoded Antigen. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.146<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Replicon Product</font>&#8221; means any Product comprising Replicon Technology.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.147<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Replicon Technology</font>&#8221; means the BioNTech Know-How applicable to Replicons. For clarity, Replicon Technology does not include Modified RNA Technology, Unmodified RNA Technology or Delivery Technology.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.148<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Representatives</font>&#8221; means (a) with respect to Pfizer, Pfizer, its Affiliates, its Sublicensees and subcontractors, and each of their respective officers, directors, employees, consultants, contractors and agents and (b) with respect to BioNTech, BioNTech, its Affiliates, its Sublicensees and subcontractors, and each of their respective officers, directors, employees, consultants, contractors and agents.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref44333030"></a>1.149<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Research and Development Plan</font>&#8221; means the research and development plan to define the Development activities pursuant to the collaboration anticipated under this Agreement </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(including, for the avoidance of doubt, any post-Marketing Authorization Approval Development activities</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> but excluding any Medical Activities and Medical Affairs Studies</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) as may be amended from time to time pursuant to Section </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The Research and Development Plan existing on the signing of this Amended and Restated Collaboration Agreement is attached hereto as </font><font style="text-decoration:underline;">Exhibit&#160;A</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.150<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Research and Development Program</font>&#8221; means the program of collaboration between the Parties to Develop and Manufacture (but not Commercialize) Candidates and Products in the Field, including the activities described in the Research and Development Plan.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_224"></a>1.151<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Research and Development Program Know-How</font><a name="_cp_text_1_224"></a>&#8221; means any and all Know-How, Candidates and Products, whether or not patentable, made or created solely by or on behalf of either Party or its Representatives in the conduct of activities under the Research and Development Plan, made or created jointly by or on behalf of (a) BioNTech or its Representatives and (b) Pfizer or its Representatives in the conduct of activities under the Research and Development Plan. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.152<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Research and Development Program Patent Rights</font>&#8221; means any and all Patent Rights claiming or disclosing any invention included in Research and Development Program Know-How.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.153<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Research and Development Program Technology</font>&#8221; means the Research and Development Program Patent Rights and Research and Development Program Know-How.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.154<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Residual Knowledge</font>&#8221; means knowledge, techniques, experience and Know-How that (a) are, or are based on, any Confidential Information of the Disclosing Party and (b) are retained in the unaided memory of any authorized Representative of the Receiving Party after having access to such Confidential Information. An individual&#8217;s memory will be considered to be unaided if the individual has not intentionally memorized the Confidential Information for the purpose of retaining and subsequently using or disclosing it. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_227"></a><a name="_cp_text_2_229"></a><a name="_Ref488216132"></a>1.155<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">RNA</font>&#8221; means ribonucleic acid.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.156<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">RNA Process Technology</font>&#8221; means the BioNTech Know-How used to Manufacture Candidates or Products.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.157<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">RNA Technology</font>&#8221; means Replicon Technology, Unmodified RNA Technology, Modified RNA Technology and Delivery Technology that is, in each case, used by BioNTech in the Research and Development Program.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.158<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Sales Manager</font>&#8221; means a full or part time employee of a Commercializing Party (or a its subcontractor) that is responsible for the direct supervision of the PSRs of or on behalf of such Commercializing Party who detail the Product in the Territory under this Agreement.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.159<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Shared Development Cost</font>&#8221; means [***]. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.160<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Signing Date</font>&#8221; means April 9, 2020.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.161<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">South-East Asia</font>&#8221; means [***]. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.162<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Subject</font>&#8221; means the individual donor of the Human Material or of the original tissues from which the Human Material was derived.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.163<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Sublicensee</font>&#8221; means any Person to whom a Party grants or has granted, directly or indirectly, a license or sublicense of any of the same Intellectual Property Rights licensed to such Party by the other Party under this Agreement in accordance with Section 3.7. For the avoidance of doubt, distributors used by a Commercializing Party to Commercialize Product in a country or region shall not be regarded a Sublicensee.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.164<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Tax</font>&#8221; means all corporation tax, advance corporation tax, income tax, capital gains tax, value added tax, customs and other import duties, inheritance tax, purchase tax, capital duties, social insurance contributions, foreign taxation and duties and all penalties, charges and interest relating to any of the foregoing or resulting from a failure to comply with the provisions of any enactment relating to any of the foregoing.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.165<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Territory</font>&#8221; means worldwide, except for the People's Republic of China (including Hong Kong SAR and Macau SAR) and Taiwan. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.166<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Third Party</font>&#8221; means any Person other than Pfizer, BioNTech or their respective Affiliates.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref411999026"></a>1.167<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Third Party License</font>&#8221; means a Current License or a Future License.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.168<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Third Party License Payment</font>&#8221; shall mean a payment due to a Current Licensor or Future Licensor pursuant to a Current License or Future License, as applicable, that is [***]. For the avoidance of doubt, [***].</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.169<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Trademark</font>&#8221; means any trademark, trade name, service mark, service name, brand, domain name, trade dress, logo, slogan or other indicia of origin or ownership, including the goodwill and activities associated with each of the foregoing.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref59059021"></a>1.170<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Transfer Price</font>&#8221; shall mean [***] of such Candidate or Product, subject to any different percentage between [***] as determined by the JCC through mutual consent, to be applied for Products to be supplied to the Developing Countries Territory or to take account of any supply requirements of any Governmental Authority within the Territory or pursuant to the terms and conditions of any funding agreement with a Third Party Funder [***]. </p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.171<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">United States</font>&#8221; or &#8220;<font style="text-decoration:underline;">U.S.</font>&#8221; means the United States of America and its territories and possessions.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.172<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Unmodified RNA</font>&#8221; means an mRNA that [***].</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.173<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Unmodified RNA Technology</font>&#8221; means the BioNTech Know-How applicable to Unmodified RNA. For clarity, Unmodified RNA Technology does not include Replicon Technology, Modified RNA Technology or Delivery Technology.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.174<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Unsolicited Medical Request</font>&#8221; or &#8220;<font style="text-decoration:underline;">UMR</font>&#8221; means unsolicited requests for medical information from any Third Party communicated to a Party in any manner addressing on-label use, off-label use or unapproved indications of a Product or Candidates under Development.</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.175<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">UPC Agreement</font>&#8221; means the treaty Agreement on the Unified Patent Court signed 19 February 2013, as may be amended or superseded from time.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.176</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="text-decoration:underline;">Vaccine Technical Committee</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means a duly established and recognized multidisciplinary group of national medical and public health experts responsible for providing independent, evidence-based advice and recommendations to ministries of health or other relevant government policy makers on issues related to immunization and vaccines in a particular country or region.</font></p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following terms are defined in the section of this Agreement listed opposite each term: </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:73.78%;">
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Defined Term</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Section in Agreement</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquirer</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.2.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition Program</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.1.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional Commitment Country</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.12.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional Patent Jurisdictions</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.3.1.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Affected Party</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preamble</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alliance Managers</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual Net Sales Level</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audited Party</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Auditing Party</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.14</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.14</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BARDA</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Benefit Plans</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.16.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preamble</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Deferred Development Costs</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Enforcement Patent Rights</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.4.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Indemnified Party</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech JSC Members</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Medical Training Materials</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Promotional Materials</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5.3</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Prosecution Patent Rights</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.3.1.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Territory Exit Option</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.12.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Training Materials</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Branded Prescription Drug Fee</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.11.5</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Budget Deviation</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.4.1.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capex Funding</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change of Control Party</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.7</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercialization Materials</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.12</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercialization Region</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.4.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercialization Sales Milestone Payment</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compliance Committee</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.4.5</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consequential Damages</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitive Product Infringement</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.4.3</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Continuing Party</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.3.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Croda</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.4.2.4</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Croda Agreement</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.4.2.4</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cure Plan</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.8.3</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:73.78%;">
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debtor</font></p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_field_47_251"></a>14.9.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Declining Party</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.3.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Payment Period</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disputed Matter</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.5.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disclosing Party</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enforcement Action</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.4.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preamble</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity Investment</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive Officer</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.5.4</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expedited Milestone Refund</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.10.2.3</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Force Majeure</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.3</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fosun Territory</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.13.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTO Action</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.7.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Global Medical Activities</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hiring Party</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.16.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impf Group</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Incremental Withholding Taxes</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.11.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indemnified Party</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_field_47_255"></a>16.4.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indemnifying Party</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_field_47_257"></a>16.4.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Infringements</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.9.7.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Infringement Claim</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_field_47_259"></a>11.8</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment Agreement</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IRB / IEC</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.76</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JCC</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.4.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JFC</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.4.3</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JMC</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.4.4</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JSC Chair</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Key Patent Jurisdictions</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.3.1.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lead Development Party</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lead Party</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lead Regulatory Party</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.2.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_table_16_260"></a>Licensed Activities</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.7.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Litigation Conditions</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.4.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.16.3</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medical Affairs Studies</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medical Education Materials</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3.4</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medical Information Content</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MSL Activities</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NHP</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.16.3</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NHP Indemnitees</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.16.3</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notice of Dispute</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_field_47_264"></a>17.11.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notified Party</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9.3</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Original Collaboration Agreement</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preamble</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Party or Parties</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preamble</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patent Committee</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patent Term Extension</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.3.4</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Paying Party</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.10.2.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preamble</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:73.78%;">
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Country Exit Option</font></p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.12.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Indemnified Party</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.3</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer JSC Members</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Materials</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Medical Training Materials</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Promotional Materials</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5.3</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Training Materials</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmacovigilance Agreement</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.3</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pricing and Reimbursement Guidelines</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.6.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prosecution Proceedings</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.3.5</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Program Director and&#160;Program Directors</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Promotional Materials</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5.3</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proportional Adjustment</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.10.2.3</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receiving Party</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reference Product Sponsor</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.4.6.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory Approval Milestone </p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Relevant Line Item</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.4.1.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reporting Party</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9.3</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted Market</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.10.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted Parties</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.10.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted Party List</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.10.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Review Period</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.5.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROW</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Standard Conversion Cost</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.93</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Standard Product Materials Cost</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.93</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Termination Effective Date</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.8.5.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Terminated Product Data</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.8.6.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Terminated Territory</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.8.5.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third Party Claim</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.4.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third Party Funder</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third Party Licensor</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.18</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third Party Royalties</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.10.1.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transfer Price True Up Period</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9.4</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront Payment</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VAT</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.11.2</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Violating Party</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.6.1</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Withholding Taxes</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.11.1</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-transform:none;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc62256025"></a><a name="_Toc59107052"></a><font style="text-decoration:none;"></font><font style="text-decoration:underline;text-transform:uppercase;">Scope and Spirit of Collaboration</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256026"></a><a name="_Toc59107053"></a><font style="text-decoration:none;">2.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Scope of Collaboration</font><font style="text-decoration:none;">. Subject to the terms and conditions of this Agreement, the Parties shall (a) cooperate in good faith to conduct their respective activities under the Agreement; and (b) establish one or more committees as described in Section&#160;6 of this Agreement to oversee and coordinate the Development, Manufacture and Commercialization of Candidates and Products in the Territory. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref59004180"></a><a name="_Toc62256027"></a><a name="_Toc59107054"></a><a name="_Ref58314699"></a><font style="text-decoration:none;">2.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Spirit of Collaboration</font><font style="text-decoration:none;">. Without prejudice to the terms and conditions of this Agreement, each Party shall endeavor, in good faith, to conduct themselves in the collaboration hereunder, in all material respects, in the spirit of (i) honest and constructive good faith cooperation and (ii) with appropriate transparency between the Parties</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256028"></a><a name="_Toc59107055"></a><a name="_Ref58314701"></a><font style="text-decoration:none;">2.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Reviewing of and Commenting on Documents</font><font style="text-decoration:none;">. Subject to Section 2.2, but without prejudice to the terms and conditions of this Agreement, to the extent either Party has the right or obligation to review, comment or approve any documents, filings or other activities of the other Party pursuant to this Agreement, such Party shall endeavor to conduct such review, or provide its comments or approval (where required), within a timeline that is reasonable under the circumstances, and the Party requesting such review, comment or approval shall endeavor to make such request in a timely manner, in each case in order to endeavor to mitigate or avoid unreasonable disruptions or delays. Where comments have been requested, the requesting Party shall, in good faith, consider all reasonable comments made by the commenting Party in the requesting Party's further preparation or pursuit of such document, filing or activity. Where appropriate, and to the extent time permits, the Parties may discuss any material comment made by the other Party. The foregoing provisions however shall be interpreted in the general spirit of the collaboration set forth in Section 2.2 and the Parties recognize that the foregoing is not intended to (a) cause any unreasonably delay or impede or burden a Party's actions, activities or pursuit of the objectives under this Agreement, (b) modify any rights of a Party or decision making right set forth elsewhere in this Agreement, nor (c) give rise to any breach of this Agreement unless there is repeated, material and persistent uncured noncompliance with its provisions which has been raised through written notice and through the escalation procedure under Section 2.4.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref59091949"></a><a name="_Toc62256029"></a><a name="_Toc59107056"></a><font style="text-decoration:none;">2.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Escalation</font><font style="text-decoration:none;">. Without prejudice to the terms and conditions of this Agreement, to the extent one Party reasonably believes in good faith that the other Party is in material noncompliance with its obligations under Section 2.2 or 2.3, it shall escalate the relevant issues to the JSC or JCC, as applicable, and if such a relevant issue cannot be unanimously solved in such committee within [***], it shall be escalated to the Executive Officers for further discussion and resolution. </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-transform:none;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref35515787"></a><a name="_Ref35517986"></a><a name="_Toc62256030"></a><a name="_Toc59107057"></a><font style="text-decoration:none;"></font><font style="text-decoration:underline;text-transform:uppercase;">Licenses</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766477"></a><a name="_Toc519764370"></a><a name="_Toc519873368"></a><a name="_Toc35600532"></a><a name="_Toc62256031"></a><a name="_Toc59107058"></a><a name="_Ref35360974"></a><a name="_Ref135582937"></a><a name="_Ref135583144"></a><a name="_Ref263792560"></a><a name="_Ref468518398"></a><a name="_Ref519004462"></a><a name="_Ref519627766"></a><font style="text-decoration:none;">3.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Research Licenses</font><font style="text-decoration:none;">.</font><font style="text-decoration:underline;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref35438116"></a><a name="_Ref35517798"></a><font style="text-decoration:none;">3.1.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Research License from BioNTech to Pfizer</font><font style="text-decoration:none;">. Subject to the terms and conditions of this Agreement, effective as of the Effective Date, BioNTech on behalf of itself and its Affiliates hereby grants</font><font style="font-weight:bold;text-decoration:none;"> </font><font style="text-decoration:none;">(and will procure that its Affiliates grant) to Pfizer a sole license under the BioNTech Technology to use, have used, Develop, have Developed, Manufacture, and have Manufactured [***] Candidates and Products within the Territory [***]. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref35438105"></a><a name="_Ref36760180"></a><font style="text-decoration:none;">3.1.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Research License from Pfizer to BioNTech</font><font style="text-decoration:none;">. Subject to the terms and conditions of this Agreement, effective as of the Effective Date, Pfizer on behalf of itself and its Affiliates hereby grants (and will procure that its Affiliates grant) to BioNTech a sole license under the Pfizer Technology to use, have used, Develop, have Developed, Manufacture, and have Manufactured [***] (a) Candidates and Products and within the Territory [***] and (b) Candidates or products identical to any Product within the Field for their Development (but not Manufacture) outside the Territory by or on behalf of BioNTech (including by Fosun or its Affiliates) pursuant to the Fosun Agreement. With respect to (b) above, such license shall (i) exclude and prohibit the disclosure and license by BioNTech of Pfizer Technology used for Manufacture or formulation of the Candidate </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">or Products, other than to the extent necessary for </font><font style="text-decoration:none;">Fosun</font><font style="text-decoration:none;"> or its Affiliates to undertake fill/finish of a product identical to any Product in </font><font style="text-decoration:none;">the </font><font style="text-decoration:none;">Fosun</font><font style="text-decoration:none;"> Territory or to comply with information requirements of the China National Medical Products Administration (or equivalent), relating to such product required under applicable Law; and (ii) automatically terminate on the termination or expiration of the </font><font style="text-decoration:none;">Fosun</font><font style="text-decoration:none;"> Agreement and will, unless earlier terminated, survive the termination or expiration of this Agreement in those circumstances described in Section </font><font style="text-decoration:none;">14.8.6.5</font><font style="text-decoration:none;">.</font><font style="text-decoration:none;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref35525023"></a><a name="_Ref35452761"></a><font style="text-decoration:none;">3.1.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Scope of Research Licenses</font><font style="text-decoration:none;">. Each of the licenses granted under Section 3.1.1 and 3.1.2 is (a) a sole license, such that the applicable licensor Party shall not grant a Third Party (unless it is necessary for the Third Party undertaking a fee-for-service Development or Manufacturing activity on its behalf pursuant to this Agreement) a license under the same Intellectual Property Rights for any Exploitation within the Field and within the Territory in respect of any product, whether or not it is a Candidate or Product; (b) royalty-free; (c) sub-licensable in accordance with and subject to Section 3.7; (d) non-assignable, in whole or part, other than where a Party's benefit under this Agreement may be assigned pursuant to Section 17.1<a name="_Ref35525023"></a><a name="_Ref35452761"></a>; and (e) granted subject to the provisions of this Agreement, and for the duration of the Term or until termination or expiry of this Agreement if earlier, unless otherwise specified herein. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref37060558"></a><a name="_Toc62256032"></a><a name="_Toc59107059"></a><font style="text-decoration:none;">3.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Licenses for Commercial Manufacturing</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref36236058"></a><font style="text-decoration:none;">3.2.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">License from BioNTech to Pfizer</font><font style="text-decoration:none;">.</font><font style="font-weight:bold;text-decoration:none;"> </font><font style="text-decoration:none;">Subject to the terms and conditions of this Agreement, effective as of the Effective Date, BioNTech on behalf of itself and its Affiliates hereby grants (and will procure that its Affiliates grant) to Pfizer a non-exclusive license under the BioNTech Technology to Manufacture and have Manufactured Candidates and Products for use within the Territory and, subject to Section 3.4, Commercialization within the Territory in any indication. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref36760189"></a><a name="_Ref36236130"></a><font style="text-decoration:none;">3.2.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">License from Pfizer to BioNTech</font><font style="text-decoration:none;">.<a name="_Ref36236130"></a> Subject to the terms and conditions of this Agreement, effective as of the Effective Date, Pfizer on behalf of itself and its Affiliates hereby grants (and will procure that its Affiliates grant) to BioNTech a non-exclusive license under the Pfizer Technology to Manufacture and have Manufactured (a) Candidates and Products for Commercialization within the Territory in accordance with Section 3.4 in any indication and (b) Candidates and products identical to any Product within the Field for their use and Commercialization outside the Territory by BioNTech or Fosun and its Affiliates pursuant to the Fosun Agreement. With respect to (b) above, such license shall (i) exclude and prohibit the disclosure and license by BioNTech of Pfizer Technology used for Manufacture or formulation of the Candidate or Product, other than to the extent necessary for Fosun or its Affiliates to (x) undertake fill/finish of a product identical to any Product in the Fosun Territory or (y) comply with information requirements of the China National Medical Products Administration (or equivalent), relating to such product required under applicable Law; and (ii) shall automatically terminate on the termination or expiration of the Fosun Agreement and will, unless earlier terminated, survive the termination or expiration of this Agreement in those circumstances described in Section 14.8.6.5. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">3.2.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Scope of Commercial Manufacturing Licenses</font><font style="text-decoration:none;">. Each of the licenses granted under Section 3.2.1 and 3.2.2 is (a) royalty-free; (b) sub-licensable in accordance with and subject to Section 3.7; (c) non-assignable, in whole or part, other than where a Party's benefit under this Agreement may be assigned pursuant to Section 17.1; and (d) granted subject to the provisions of </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">this Agreement, and for the duration of the Term or until termination or expiry of this Agreement if earlier, unless otherwise specified herein.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256033"></a><a name="_Toc59107060"></a><a name="_Ref36237650"></a><font style="text-decoration:none;">3.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Regulatory Dossier Licenses</font><font style="text-decoration:none;">.</font><font style="text-decoration:underline;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref37059688"></a><font style="text-decoration:none;">3.3.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">License from BioNTech to Pfizer</font><font style="text-decoration:none;">. Effective as of the Effective Date, in respect of the Drug Master Files, Regulatory Approvals and Regulatory Documentation (as each is defined in the Fosun Agreement), BioNTech hereby grants to Pfizer a sole license to rely upon and make reference to such Drug Master Files, Regulatory Approvals and Regulatory Documentation (and the data referenced therein), to use the same in respect of any application for, and maintaining, any Regulatory Approvals (as defined in this Agreement) filed by Pfizer pursuant to this Agreement in respect of Candidates or Products. The</font><font style="font-weight:bold;text-decoration:none;"> </font><font style="text-decoration:none;">license granted under this Section&#160;3.3.1 is (a) royalty-free; (b) sub-licensable in accordance with and subject to Section 3.7; (c) non-assignable, in whole or part, other than where a Party's benefit under this Agreement may be assigned pursuant to Section 17.1; and (d) granted subject to the provisions of this Agreement, and for the duration of the Term or until termination or expiry of this Agreement if earlier, unless otherwise specified herein. BioNTech shall procure disclosure of such Drug Master Files, Regulatory Approvals and Regulatory Documentation upon Pfizer's request. Without limiting any of the foregoing, but subject to Section 3.11, BioNTech shall be permitted to use such Drug Master Files, Regulatory Approvals and Regulatory Documentation (to the extent not comprising Pfizer's Technology or Pfizer's Confidential Information) with respect to any application for or maintenance of any Regulatory Approvals outside the Field.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref36235743"></a><a name="_Toc62256034"></a><a name="_Toc59107061"></a><font style="text-decoration:none;">3.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Commercialization Licenses</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref36237458"></a><a name="_Ref35525025"></a><font style="text-decoration:none;">3.4.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">License from BioNTech to Pfizer</font><font style="text-decoration:none;">. Subject to the terms and conditions of this Agreement, BioNTech on behalf of itself and its Affiliates hereby grants (and will procure that its Affiliates grant) to Pfizer an exclusive (even as to BioNTech) license under the BioNTech<a name="_Ref35525025"></a> Technology to Commercialize and have Commercialized Products within the Pfizer Commercialization Territory in any indication.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref36760196"></a><a name="_Ref36237461"></a><font style="text-decoration:none;">3.4.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">License from Pfizer to BioNTech</font><font style="text-decoration:none;">. Subject to the terms and conditions of this Agreement, Pfizer on behalf of itself and its Affiliates hereby grants (and will procure that its Affiliates grant) to BioNTech a license under the Pfizer Technology to Commercialize and have Commercialized (a) Products within the BioNTech Commercialization Territory in any indication, which license shall be granted on a sole basis; and (b) products identical to any Product within the Field but outside the Territory by BioNTech or by Fosun or its Affiliates pursuant to the Fosun Agreement. With respect to (b) above, such license shall (i) be sole; (ii) royalty-bearing; (iii) exclude and prohibit the disclosure and license by BioNTech of Pfizer Technology used for Manufacture or formulation of any Candidate or Product, other than to the extent necessary for Fosun or its Affiliates to (x) undertake fill/finish of a product identical to any Product in the Fosun Territory or (y) comply with information requirements of the China National Medical Products Administration (or equivalent), relating to such product required under applicable Law; and (iv) shall automatically terminate on the termination or expiration of the Fosun Agreement and will, unless earlier terminated, survive the termination or expiration of this Agreement in those circumstances described in Section 14. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">3.4.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Scope of Commercialization Licenses</font><font style="text-decoration:none;">. Each of the licenses granted under Section 3.4.1 and 3.4.2 is (a) sub-licensable in accordance with and subject to Section 3.7; (b) non-assignable, in whole or part, other than where a Party's benefit under this Agreement may be assigned pursuant to Section 17.1; and (c) granted subject to the provisions of this Agreement-and for the duration of the Term, unless otherwise specified herein. Furthermore, [***].</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref37258844"></a><font style="text-decoration:none;">3.4.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Financial Provisions for Commercialization</font><font style="text-decoration:none;">. The license under: </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">3.4.4.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Sections&#160;3.4.1 and 3.4.2(a) is royalty-free, but each is subject to the Gross Profit share set out in Section&#160;4.9; and </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref37186374"></a><font style="text-decoration:none;">3.4.4.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Section 3.4.2(b) shall be royalty bearing at a rate of (i) [***] percent of net sales of the product(s) sold pursuant to the Fosun Agreement where such product(s) is Covered by any Pfizer Patent Right or any Joint Patent Rights; or (ii) if, or when, (i) does not apply, then [***] percent of net sales of the product(s) sold pursuant to the Fosun Agreement where such product(s) is Covered by any Pfizer Know-How or any Joint Know-How; with in each case of (i) or (ii) above, net sales having the same definition, </font><font style="font-style:italic;text-decoration:none;">mutatis mutandis</font><font style="text-decoration:none;">, to Net Sales under this Agreement, with references under such Net Sales definition to &#8220;a Party&#8221; meaning BioNTech, its Affiliates and their respective licensees and &#8220;Product&#8221; meaning a product as described above, and with sales and royalty reporting every Pfizer Quarter, payments on a Pfizer Quarter basis, and Pfizer having audit rights comparable with those under this Agreement); </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;">, </font><font style="font-style:italic;text-decoration:none;">however</font><font style="text-decoration:none;">, that (x) during the period in which a generic or biosimilar equivalent to such product(s) is Commercialized in any part of the territory that is the subject of the Fosun Agreement, the royalty under (i) above shall be reduced by [***]; or (y) if the gross profit share earned by BioNTech in connection with sale of products under the Fosun Agreement is lower than the royalty amount to be paid to Pfizer hereunder in respect of those same sales, then no royalty shall be payable hereunder for those sales. The foregoing royalty obligations shall commence on the first commercial sale of the product(s) sold pursuant to the Fosun Agreement, and extend (x) with respect to the royalty under (i) for so long as such product(s) is Covered by any such Patent Rights (until such Patent Right expires, is surrendered, or is otherwise irrevocably revoked or declared invalid), and (y) with respect to the royalty under (ii), the [***] anniversary of the date of the first commercial sale (having the same meaning, </font><font style="font-style:italic;text-decoration:none;">mutatis mutandis</font><font style="text-decoration:none;">, to the definition of First Commercial Sale herein) of such product(s) in the territory that is the subject of the Fosun Agreement; and in each case, such provision shall survive the termination or expiry of this Agreement. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc519764372"></a><a name="_Toc519873370"></a><a name="_Toc35600533"></a><a name="_Ref35360976"></a><a name="_Toc62256035"></a><a name="_Toc59107062"></a><a name="_Hlk35356792"></a><font style="text-decoration:none;">3.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Additional Licenses</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref516776496"></a><a name="_Ref36315008"></a><font style="text-decoration:none;">3.5.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Additional License To Pfizer</font><font style="text-decoration:none;">. Without limiting any other license or sublicense granted under this Agreement and subject to the terms and conditions of this Agreement, BioNTech on behalf of itself and its Affiliates, effective as of the Effective Date, hereby grants</font><font style="font-weight:bold;text-decoration:none;"> </font><font style="text-decoration:none;">(and will procure that its Affiliates grant)</font><font style="font-weight:bold;text-decoration:none;"> </font><font style="text-decoration:none;">to Pfizer a non-exclusive, royalty-free, fully paid-up, sublicensable license under all BioNTech Improvements and Product Technology that were solely or jointly made or invented by Pfizer Representatives to use, have used, Develop, have Developed, Manufacture, have Manufactured, Commercialize, have Commercialized and otherwise Exploit any products or processes outside the Field. In addition to the obligations set forth in Section 3.11 for the avoidance of doubt, the license granted in this Section 3.5.1 shall not include or imply a right of Pfizer to use </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">any of </font><font style="text-decoration:none;">BioNTech&#8217;s</font><font style="text-decoration:none;"> Confidential Information (that is not a </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Improvement or Product Technology) outside the Field.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref518245680"></a><a name="_Toc484766479"></a><a name="_Ref263792397"></a><font style="text-decoration:none;">3.5.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Additional License To BioNTech</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">3.5.2.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Without limiting any other license or sublicense granted under this Agreement and subject to the terms and conditions of this Agreement, Pfizer, effective as of the Effective Date, hereby grants</font><font style="font-weight:bold;text-decoration:none;"> </font><font style="text-decoration:none;">to BioNTech a non-exclusive, royalty-free, fully paid-up, sublicensable license under all Pfizer Improvements that were solely or jointly invented by BioNTech Representatives to use, have used, Develop, have Developed, Manufacture, have Manufactured, Commercialize, have Commercialized and otherwise Exploit any products or processes outside the Field.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref36238240"></a><font style="text-decoration:none;">3.5.2.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Without limiting any other license or sublicense granted under this Agreement and subject to the terms and conditions of this Agreement, Pfizer, effective as of the Effective Date, hereby grants</font><font style="font-weight:bold;text-decoration:none;"> </font><font style="text-decoration:none;">to BioNTech a non-exclusive, royalty-free, fully paid-up, sublicensable license under Pfizer&#8217;s interest in the Research and Development Program Technology to use, have used, Develop, have Developed, Manufacture, have Manufactured, Commercialize, have Commercialized and otherwise Exploit any products or processes outside the Field. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">3.5.2.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">For the avoidance of doubt, the licenses granted in this Section&#160;3.5.2 shall not include or imply a right of BioNTech to use any Pfizer Confidential Information (that is not a Pfizer Improvement or Research and Development Program Technology) outside the Field, but remain subject to the obligations set forth in Section 3.11.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">3.5.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">The licenses granted pursuant to Section 3.5.1 and Section&#160;3.5.2 may be sublicensed by the licensee Party pursuant to the terms of those applicable licenses, </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that (a) the sublicensing Party shall be responsible for failure by its Sublicensees to comply with the relevant terms and conditions of this Agreement applicable to such licenses and (b) [***] without BioNTech's prior consent (such consent not to be unreasonably withheld). For the avoidance of doubt, Section 3.7 shall not apply to the sublicensing of those rights licensed under this Section 3.5.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256036"></a><a name="_Toc59107063"></a><font style="text-decoration:none;">3.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Trademark Licenses</font><font style="text-decoration:none;">. Trademark Licenses are set forth in Section 11.9.5.</font><font style="text-decoration:underline;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc519764373"></a><a name="_Toc519873371"></a><a name="_Toc35600534"></a><a name="_Toc62256037"></a><a name="_Toc59107064"></a><a name="_Ref62658646"></a><a name="_Ref35517839"></a><a name="_Ref43137879"></a><font style="text-decoration:none;">3.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Sublicensees</font><font style="text-decoration:none;"><a name="_Ref43137879"></a>. Either Party shall have the right to grant sublicenses and, as applicable, sub-sublicenses under and subject to the rights granted to it under Sections 3.1 to 3.4 and 11.9.5 to (a) its Affiliates; (b) permitted Third Party subcontractors which such Party uses to undertake services for, or to perform its obligations under this Agreement; (c) Sublicensees in respect of Manufacturing, provided that, other than where a sublicense is required by a Governmental Authority or pursuant to a Third Party Funder agreement, the sublicensing Party shall (i) discuss the proposed use of a Third Party with the other Party, and take into account any reasonable views, objections or comments with respect to the proposed Third Party; (ii) impose industry standard obligations of confidentiality and non-use on the Third Party with respect to the other Party's Confidential Information, and limit the disclosure of that other Party's Confidential Information so far as is reasonably necessary; and (iii) not, where Pfizer is the sublicensing Party, [***] without BioNTech's prior consent (such consent not to be unreasonably withheld); and (d) distributors of the Product in the Territory; and (e) in the case of BioNTech, and subject to the restrictions </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">in Sections&#160;</font><font style="text-decoration:none;">3.1</font><font style="text-decoration:none;">, </font><font style="text-decoration:none;">3.2</font><font style="text-decoration:none;">, and </font><font style="text-decoration:none;">3.4</font><font style="text-decoration:none;"> and the terms of Section </font><font style="text-decoration:none;">12</font><font style="text-decoration:none;"> and excluding any rights under Section </font><font style="text-decoration:none;">11.9.5</font><font style="text-decoration:none;">, </font><font style="text-decoration:none;">Fosun</font><font style="text-decoration:none;"> and any of </font><font style="text-decoration:none;">Fosun&#8217;s</font><font style="text-decoration:none;"> Affiliates pursuant to the </font><font style="text-decoration:none;">Fosun</font><font style="text-decoration:none;"> Agreement for Commercialization in the Field outside the Territory. In respect of any and all such sublicenses (or sub-sublicenses):</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">3.7.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">the sublicensing Party shall be responsible for failure by its Sublicensees to comply with the terms and conditions of this Agreement;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">3.7.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">the rights sublicensed under the sublicense may not be further sublicensed by the Sublicensee;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">3.7.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">the sublicensing Party shall notify the other Party in writing of any sublicenses granted to Third Parties (other than Fosun); </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">3.7.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">in the event of a sublicense in respect of the Commercialization of Product, shall provide a copy of the relevant sublicense agreement to the other Party upon request which may be redacted to delete provisions not applicable to the calculation of Gross Profits; </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;">, </font><font style="font-style:italic;text-decoration:none;">however</font><font style="text-decoration:none;">, that the Sublicensing Party shall not be required to provide copies of any sublicense agreement between such Sublicensing Party and its Affiliates; </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">3.7.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">unless otherwise agreed between the Parties on a case-by-case basis, all sublicenses shall automatically terminate (and the sublicensing Party shall ensure that all sublicenses automatically terminate) upon termination (for whatever reason) or expiry of a license granted hereunder, but only to the extent necessary to terminate the sublicense in so far as it corresponds to any terminated or expired licenses granted in this Agreement; and</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref263792572"></a><a name="_Ref468645854"></a><a name="_Ref135582911"></a><a name="_Toc484766480"></a><font style="text-decoration:none;">3.7.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">in respect of Trademarks, the Party granting the sublicense shall ensure that all goodwill arising from use of the sublicensed Trademarks enures<a name="_Ref263792572"></a><a name="_Ref468645854"></a><a name="_Ref135582911"></a><a name="_Toc484766480"></a> for the benefit of the Party that owns the applicable Trademark.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766484"></a><a name="_Toc519764377"></a><a name="_Toc35600535"></a><a name="_Toc62256038"></a><a name="_Toc59107065"></a><a name="_Toc519873375"></a><font style="text-decoration:none;">3.8</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">BioNTech<a name="_Toc519873375"></a> Current Licenses</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref36716729"></a><a name="_cp_text_1_297"></a><font style="text-decoration:none;">3.8.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Maintenance of Current Licenses</font><font style="text-decoration:none;">. BioNTech will maintain in full effect and will perform all of its obligations in a timely manner under each of the Current Licenses. Absent Pfizer&#8217;s prior written consent (which may be provided, conditioned or withheld in Pfizer&#8217;s sole discretion), BioNTech<a name="_cp_text_1_297"></a> will not terminate, modify or amend any Current License in any manner that would adversely affect any of the rights granted or that may be granted to Pfizer under this Agreement or that would impose any obligations upon Pfizer hereunder (including any increase in Third Party License Payments) that are in addition to those obligations that would exist under this Agreement based on the Current Licenses as they exist on the Effective Date or adversely affect BioNTech&#8217;s ability to perform its obligations under this Agreement. Further, BioNTech will not take any action or omit to take any action that would cause it to be in breach of any Current License or that would give rise to a right of any Current Licensor to terminate the applicable Current License. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">3.8.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Communications and Performance</font><font style="text-decoration:none;">. Notwithstanding anything to the contrary in this Agreement, BioNTech will use Commercially Reasonable Efforts to facilitate any communications between Pfizer and any Current Licensor required for Pfizer to exercise the rights granted to it pursuant to this Section 3 and will use Commercially Reasonable Efforts to cause each applicable Current Licensor to perform all of its obligations under the applicable Current License.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref518673089"></a><a name="_Ref36220890"></a><a name="_Hlk386982174"></a><font style="text-decoration:none;">3.8.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Breach of Current License by </font><font style="font-weight:bold;text-decoration:none;">BioNTech</font><font style="text-decoration:none;">. If </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> receives notification of any actual or potential breach or otherwise becomes aware of its breach of any Current License (and if uncured, such breach could</font><font style="text-decoration:none;"> </font><font style="text-decoration:none;">give rise to the termination of the applicable Current License), then </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> will immediately notify Pfizer of such breach. To the extent that any act or omission on the part of Pfizer is the cause of such breach of a Current License, Pfizer will take all actions and provide </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> with all cooperation necessary to cure such breach, in each case as reasonably requested by </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"><a name="_Hlk386982174"></a> and at Pfizer&#8217;s sole cost and expense. To the extent that Pfizer is not the cause of such breach of </font><font style="text-decoration:none;">a </font><font style="text-decoration:none;">Current License, </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> will have the first opportunity to cure such breach in accordance with a plan to be mutually agreed upon by the Parties in writing</font><font style="text-decoration:none;">, acting reasonably</font><font style="text-decoration:none;"> (each, a &#8220;</font><font style="text-decoration:underline;">Cure Plan</font><font style="text-decoration:none;">&#8221;). If </font><font style="text-decoration:none;">(a) </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;">, at any time, is not using diligent efforts to cure such breach pursuant to the applicable Cure Plan or (</font><font style="text-decoration:none;">b</font><font style="text-decoration:none;">) </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> is unable to cure such breach in accordance with the applicable Cure Plan or it becomes reasonably apparent that </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> will not be able to cure such breach pursuant to the applicable Cure Plan, then Pfizer may, at its election and in its sole discretion and without prejudice to its other remedies against </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;">, act </font><font style="text-decoration:none;">reasonably </font><font style="text-decoration:none;">to cure such breach and </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> will take all actions and provide Pfizer with all cooperation to cure such breach, in each case as directed by Pfizer. Further, if Pfizer is not the cause of such breach of a Current License, then </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> will, at Pfizer&#8217;s sole election, (i) reimburse Pfizer for all out-of-pocket costs and expenses incurred by or on behalf of Pfizer or any of its Representatives in connection with curing such breach; or (ii) permit Pfizer, under the Agreement, to offset any such costs and expenses incurred by or on behalf of Pfizer or any of Pfizer&#8217;s Representatives in connection with curing such breach against Pfizer&#8217;s future payment obligations to </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> (or any of its successor or assigns) under this Agreement.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref36220894"></a><a name="_Ref517348565"></a><font style="text-decoration:none;">3.8.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Termination of any Current License</font><font style="text-decoration:none;">. In the event that any Current License is terminated by the applicable Current Licensor and this Agreement, as of the effective date of such termination, has not otherwise expired or been terminated, Pfizer, to the extent permitted by such Current License (or if not permitted or addressed in such Current License, to the extent permitted by the applicable Current Licensor), will have the right without prejudice to its other remedies against BioNTech, at Pfizer&#8217;s election, to convert the sublicenses granted under this Agreement by BioNTech to Pfizer under such Current License to a direct license from the applicable Current Licensor to Pfizer on the terms and conditions contained in such Current License (with Pfizer assuming the applicable obligations of BioNTech thereunder) or such other terms and conditions as may be negotiated by Pfizer and the applicable Current Licensor; </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that Pfizer shall negotiate in good faith reasonable terms and conditions, including with respect to royalties or other payments due in connection with the Candidates or Products. In the event Pfizer enters into any such direct license with a Current Licensor pursuant to this Section 3.8.4, BioNTech will, at Pfizer&#8217;s sole election and without prejudice to its other remedies hereunder:</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">3.8.4.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">in respect of royalties and other payments payable by Pfizer under such direct license to the Current Licensor, to the extent such royalties and payments are due in connection with the Candidates or Products hereunder, reimburse to Pfizer the difference between (a) the amount that is payable under any direct license with Pfizer and (b) the amount that would have to be reimbursed by Pfizer to BioNTech in accordance with Section 4.10.1 with respect to the Current License if the Current License had not been terminated; or</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">3.8.4.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">permit Pfizer to offset any such reimbursement amounts (to the extent not reimbursed pursuant to clause (a) above) against Pfizer&#8217;s future payment obligations to </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> (or any of its successor or assigns) under this Agreement </font><font style="text-decoration:none;">(including </font><font style="text-decoration:none;">BioNTech&#8217;s</font><font style="text-decoration:none;"> share of Gross Profits) </font><font style="text-decoration:none;">until Pfizer has fully recovered all such reimbursement amounts</font><font style="text-decoration:none;">. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref517369278"></a><font style="text-decoration:none;">3.8.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Consents and Waivers</font><font style="text-decoration:none;">. BioNTech represents, warrants and covenants to Pfizer that, to the extent any terms and conditions of this Agreement do not (or will not at any time during the Term) conform to any requirements relating to the grant of sublicenses under any Current License, it has obtained the irrevocable consent (or, if applicable, the waiver of any resultant conflict) from the applicable Current Licensor that is necessary to permit the activities contemplated under this Agreement, including such that BioNTech may grant the applicable sublicenses granted or to be granted hereunder and perform all of its obligations hereunder and Pfizer may exercise all of its rights and perform all of its obligations hereunder, in each case, without breaching the applicable Current License. In the event that any provision in any Current License which conflicts with this Agreement or adversely impacts the activities contemplated under this Agreement comes to the attention of either BioNTech or Pfizer or which otherwise, at any time during the Term, would cause the representation, warranty and covenant set forth in the preceding sentence to be untrue, BioNTech<a name="_Ref517369278"></a>, in consultation with Pfizer, will obtain any and all additional required consents or waivers from the applicable Current Licensor(s) which may be necessary to align the conflicting provision(s) of the applicable Current License with this Agreement and to permit the activities contemplated by this Agreement.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">3.8.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Exceptions to the Fosun Agreements</font><font style="text-decoration:none;">. If BioNTech (as opposed to Pfizer) has breached the Fosun Agreement [***]. In addition, in respect of the Fosun Agreement (i) [***]; and (ii) [***].</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">3.8.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Reduction in Royalties</font><font style="text-decoration:none;">. [***]</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256039"></a><a name="_Toc59107066"></a><a name="_Toc35600536"></a><a name="_Ref35522309"></a><a name="_Toc484766485"></a><a name="_Toc519764379"></a><a name="_Toc519873377"></a><a name="_Ref263792542"></a><a name="_Ref263793244"></a><font style="text-decoration:none;">3.9</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Third Party Agreements</font><font style="text-decoration:none;">. Subject to Section 4.10, each Party will be solely responsible for all obligations (including royalty and payment obligations) that relate to Candidates, Products, BioNTech Technology or Pfizer Technology under its or its Affiliates' own agreements with Third Parties that are in effect on or prior to the Effective Date, including the Current Licenses for which BioNTech has sole responsibility.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc35600537"></a><a name="_Toc62256040"></a><a name="_Toc59107067"></a><font style="text-decoration:none;">3.10</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">No Implied Rights</font><font style="text-decoration:none;">. Except as expressly provided in this Agreement, neither Party will be deemed to have granted the other Party (by implication, estoppel or otherwise) any right, title, license or other interest in or with respect to any Patent Rights, Know-How, Trademarks or other Intellectual Property Rights or information Controlled by such Party.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256041"></a><a name="_Toc59107068"></a><a name="_Ref516518839"></a><a name="_Toc519764380"></a><font style="text-decoration:none;">3.11</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Exclusivity</font><font style="text-decoration:none;">.</font><font style="font-family:Arial Narrow;text-decoration:underline;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref518288844"></a><a name="_Ref35600145"></a><a name="_Ref35962728"></a><a name="_Ref35527744"></a><a name="_Ref35419331"></a><a name="_Toc519764381"></a><a name="_Ref35452217"></a><font style="text-decoration:none;">3.11.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Mutual Exclusivity</font><font style="text-decoration:none;">.<a name="_Ref35452217"></a> Except if otherwise permitted by the unanimous consent of the JSC, during the Term, neither Party shall, and shall procure that its Affiliates shall not, itself or with or on behalf of a Third Party, Develop, have Developed, Manufacture, have Manufactured, Commercialize, have Commercialized or otherwise Exploit or have Exploited any [***] in the Field within the Territory, except that each Party may continue any agreement existing as of the Effective Date with a Third Party for non-clinical research within the Field with academic institutions and </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">consortia.</font><font style="text-decoration:none;"> For avoidance of doubt, the foregoing exclusivity obligation shall not apply to (a) </font><font style="text-decoration:none;">[***]</font><font style="text-decoration:none;">; (b) </font><font style="text-decoration:none;">[***]</font><font style="text-decoration:none;">;</font><font style="text-decoration:none;"> </font><font style="text-decoration:none;">(c) </font><font style="text-decoration:none;">[***]</font><font style="text-decoration:none;">; or (d) </font><font style="text-decoration:none;">[***]</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">3.11.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Exclusivity of the Licenses</font><font style="text-decoration:none;">. Without prejudice to the licenses granted by BioNTech pursuant to this Section 3, BioNTech shall not, and shall procure that its Affiliates shall not, grant any license, permission, waiver, covenant not to sue, or other right to use or Exploit any of the BioNTech Technology within the Field and within the Territory that would conflict with or erode any of Pfizer's rights hereunder. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref37010593"></a><font style="text-decoration:none;">3.11.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Exclusivity in the Product</font><font style="text-decoration:none;">. Except pursuant to this Agreement, neither Party shall, and shall procure that its respective Affiliates shall not, itself or with or on behalf of a Third Party, Develop, have Developed, Manufacture, have Manufactured, Commercialize, have Commercialized or otherwise Exploit (a) any Candidate Controlled by BioNTech as of the Effective Date within the Field; or (b) any Candidate that, as a consequence of the Development under this Agreement, becomes Controlled by BioNTech after the Effective Date, for any field; or (c) any Product for any field or application; in each case (a), (b) and (c) other than for non-clinical research purposes, or within the Field pursuant to the Fosun Agreement.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256042"></a><a name="_Toc59107069"></a><font style="text-decoration:none;">3.12</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Adjustments to Commercialization Territories</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref43145991"></a><font style="text-decoration:none;">3.12.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">BioNTech Territory Exit Option</font><font style="text-decoration:none;">: BioNTech shall have the option to opt-out of Commercializing the Product in any country of the BioNTech Commercialization Territory (excluding any Additional Commitment Country which has become part of the BioNTech Commercialization Territory pursuant to Section 3.12.2), whereupon Pfizer shall take over Commercialization of the Product in any such country (the &#8220;</font><font style="text-decoration:underline;">BioNTech Territory Exit Option</font><font style="text-decoration:none;">&#8221;). BioNTech may exercise the BioNTech Territory Exit Option, on a country by country basis, upon no less than [***] prior written notice to Pfizer, </font><font style="font-style:italic;text-decoration:none;">provided, however</font><font style="text-decoration:none;">, that the Parties agree upon a transition plan within the first [***] of such notice, which plan may require BioNTech to conduct distribution, Commercialization, promotional and supply activities beyond the expiration of the [***] period, however. In the event of any such option exercise, (a) the Parties will work together to transition to Pfizer the responsibilities for distribution, Commercialization and promotion of the Product and (b) as of the option exercise effective date, the Pfizer Commercialization Territory under this Agreement shall be extended accordingly and (c) prior to Pfizer fully transitioning as the exclusive distributor and licensee in the applicable country, where the Product has already been launched, BioNTech shall ensure that the Product continues to be supplied in such country.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref43145920"></a><font style="text-decoration:none;">3.12.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Pfizer Country Exit Option</font><font style="text-decoration:none;">: On a country by country basis in relation to [***] that obliges Commercialization of the Product in such country; (each such country under (a) and (b) being an &#8220;</font><font style="text-decoration:underline;">Additional Commitment Country</font><font style="text-decoration:none;">&#8221;), BioNTech shall request in writing from Pfizer a decision as to whether Pfizer wishes to Commercialize in such Additional Commitment Country in accordance with the Commercialization requirements [***] of its receipt of such notice or [***] prior to the date of the planned initiation of Commercialization following full Market Authorization Approval (for clarity, not Emergency Use Authorization or any conditional Market Authorization Approval)</font><font style="color:#FF0000;font-size:10pt;font-family:Arial;text-decoration:none;">&#160;</font><font style="text-decoration:none;">in such Additional Commitment Country [***] If Pfizer notifies BioNTech that it wishes to Commercialize the Product in such Additional Commitment Country, then Pfizer shall Commercialize the Product in such Additional Commitment [***].</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref43192998"></a><a name="_Toc62256043"></a><a name="_Toc59107070"></a><font style="text-decoration:none;">3.13</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Expansion of the Territory</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref43192058"></a><font style="text-decoration:none;">3.13.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Right of First Negotiation to Expand into Fosun Territory</font><font style="text-decoration:none;">. If the Fosun Agreement expires or is otherwise terminated for any reason, BioNTech shall promptly (and in any event within [***] of the earlier of expiration or termination of the Fosun Agreement or BioNTech receiving notice of expiration or termination of the Fosun Agreement) notify Pfizer in writing and Pfizer shall [***] such rights to be exercised by Pfizer within [***] of Pfizer&#8217;s receipt of BioNTech&#8217;s notice provided in accordance with this Section&#160;3.13.1.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">3.13.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Election; Negotiation</font><font style="text-decoration:none;">. If Pfizer elects to negotiate for such rights in the Fosun Territory, the Parties shall in good faith and acting reasonably exclusively negotiate for a period of no less than [***] after Pfizer&#8217;s notice of its intent to negotiate for those rights and BioNTech shall disclose to Pfizer if, at any time during such period, BioNTech is concurrently negotiating with one or more permitted Third Parties for such rights; provided, however, that BioNTech shall not be required to disclose the identity of such Third Party.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">3.13.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">BioNTech Negotiation </font><font style="text-decoration:none;">[***]. Prior to exhaustion of Pfizer&#8217;s exclusive negotiation right, BioNTech shall not engage in negotiations for, or license, or grant any option to the Product for the Fosun Territory [***]. The terms and discussions around, as well as the existence of, any negotiation activities between Pfizer and BioNTech shall be confidential information of each Party which neither shall disclose to a Third Party. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">3.13.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Interim Assistance in Fosun Territory</font><font style="text-decoration:none;">. During the period from termination of the Fosun Agreement until BioNTech concludes an agreement for the commercialization of the Product in the Fosun Territory with a Third Party (and provided that neither BioNTech nor Fosun are able and willing to distribute the Product in the Fosun Territory during such time period), Pfizer shall be free but not obligated) to distribute Product in the Fosun Territory (pursuant to the Regulatory Approval held for the Product by or on behalf of BioNTech) if it believes it is necessary or desirable at such time, for public health reasons, for the Product to be made available in the Fosun Territory (which sales shall be included in the Gross Profits calculation). For clarity, Pfizer shall have no obligation to distribute or Commercialize the Product in the Fosun Territory.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-transform:none;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc62256044"></a><a name="_Toc59107071"></a><a name="_Ref35894969"></a><a name="_Ref36513334"></a><a name="_Ref37056795"></a><a name="_Ref37104468"></a><font style="text-decoration:none;"></font><font style="text-decoration:underline;text-transform:uppercase;">Payments, Funding, Financial Matters</font><font style="text-decoration:none;text-transform:uppercase;">.</font><font style="text-decoration:underline;text-transform:uppercase;"> </font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref457071593"></a><a name="_Ref459573476"></a><a name="_Toc462394210"></a><a name="_Toc62256045"></a><a name="_Toc59107072"></a><a name="_Ref36410750"></a><a name="_Ref452681251"></a><a name="_Ref452506224"></a><a name="_Ref111883201"></a><a name="_Ref453532040"></a><a name="_Toc484766504"></a><a name="_Toc519764398"></a><font style="text-decoration:none;">4.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Upfront Payment</font><font style="text-decoration:none;">. The Parties acknowledge and agree that Pfizer made a one-time, non-refundable (without limiting Pfizer&#8217;s right to claim for damages under this Agreement) payment of Seventy-Two Million US Dollars (US&#160;$72,000,000) to BioNTech on or about 21 May 2020 (&#8220;Upfront Payment&#8221;) , which payment has been and shall be dedicated to activities to be performed under the Research and Development Plan.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256046"></a><a name="_Toc59107073"></a><a name="_Ref36410790"></a><a name="_Hlk36243781"></a><font style="text-decoration:none;">4.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Equity Investment</font><font style="text-decoration:none;"><a name="_Hlk36243781"></a>. The Parties acknowledge and agree that Pfizer and BioNTech entered into an "Investment Agreement" on 9 April 2020 in conjunction with this Agreement pursuant to which Pfizer subscribed for shares in BioNTech in consideration for an investment amount of One Hundred and Thirteen Million US Dollars (US&#160;$113,000,000) based on a price per share of US&#160;$47.53, subject to the conditions as prescribed in such Investment Agreement (&#8220;Equity Investment&#8221;).</font><font style="text-decoration:underline;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256047"></a><a name="_Toc59107074"></a><a name="_Ref36285957"></a><font style="text-decoration:none;">4.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Regulatory Milestone Payment</font><font style="text-decoration:none;">. Within the later of (a) [***] of the date upon which either BioNTech or Pfizer first obtains all Regulatory Approvals required for the Commercialization of the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">Product in a Major Market Country in the Territory or (b) following achievement of the milestone under (a) above </font><font style="text-decoration:none;">[***]</font><font style="text-decoration:none;"> after the Amendment Signing Date, Pfizer shall pay </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> a one-time, non-refundable (without limiting Pfizer&#8217;s right to claim for damages under this Agreement) milestone payment of </font><font style="text-decoration:none;">[***]</font><font style="text-decoration:none;"> US Dollars (US&#160;$</font><font style="text-decoration:none;">[***]</font><font style="text-decoration:none;">) (&#8220;Regulatory Approval Milestone&#8221;).</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256048"></a><a name="_Toc59107075"></a><a name="_Ref62385677"></a><a name="_Ref35879968"></a><font style="text-decoration:none;">4.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Sharing of Development Costs</font><font style="text-decoration:none;">.</font><font style="text-decoration:underline;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref452675399"></a><a name="_Ref453318941"></a><font style="text-decoration:none;">4.4.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Shared Development Costs</font><font style="text-decoration:none;">. Except as otherwise provided herein, each Party shall bear fifty percent (50%) of all Shared Development Costs.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref36285846"></a><font style="text-decoration:none;">4.4.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">BioNTech Deferred Development Costs</font><font style="text-decoration:none;">. The Parties acknowledge and agree that from the Effective Date until December 31, 2020 (the &#8220;</font><font style="text-decoration:underline;">Deferred Payment Period</font><font style="text-decoration:none;">&#8221;), BioNTech's share of the Shared Development Costs incurred in accordance with the binding parts of the Development Budget, Research and Development Plan and the Manufacturing Plan, and this Agreement were initially funded by way of an interest free repayable loan from Pfizer (&#8220;</font><font style="text-decoration:underline;">BioNTech Deferred Development Costs</font><font style="text-decoration:none;">&#8221;). BioNTech shall make a payment to reimburse Pfizer the BioNTech Deferred Development Costs incurred during the Deferred Payment Period within [***] of receipt of Pfizer's invoice for the same. The Parties shall exchange reasonable documentation of all relevant Shared Development Costs in accordance with Section 4.4.4 applicable to such invoice. Pfizer may offset any BioNTech Deferred Development Costs (to the extent not reimbursed to Pfizer), against Pfizer's future payment obligations to BioNTech (or any of its successors or assigns) under this Agreement. Following the end of the Deferred Payment Period, BioNTech shall thereafter itself fund its share of the Shared Development Costs in accordance with Section 4.4.4. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">4.4.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Budgeting of Shared Development Costs</font><font style="text-decoration:none;">. The Parties shall agree on, at least once per Calendar Year, and regularly update (if required), the Development Budget through the JSC. As soon as either Party determines that it is likely to overspend on the binding part of the Development Budget that is allocated to that Party by more than [***], it shall inform the JSC accordingly, and shall only be entitled to incur such overrun costs as Shared Development Costs pursuant to Section 4.4.1 and 4.4.2 upon the JSC&#8217;s mutual consent.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref452676682"></a><a name="_Ref36287476"></a><a name="_Ref37116841"></a><font style="text-decoration:none;">4.4.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Reporting and Reconciliation</font><font style="text-decoration:none;">. After the end of the Deferred Payment Period, all Shared Development Costs incurred in accordance with the binding parts of the Development Budget shall initially be borne by the Party incurring such costs and shall thereafter be subject to reimbursement in accordance with this Section 4.4.4. Each Party shall report to the other Party, within [***] after the end of each Pfizer US Quarter, the Shared Development Costs incurred by such Party during such Pfizer Quarter. Such report shall specify in reasonable detail all amounts included in such Shared Development Costs during such Pfizer Quarter (broken down by activity), and out-of-pocket costs shall be allocated to the extent possible to a specific activity in the applicable binding part of the Research and Development Plan. Each such report shall enable the receiving Party to compare the reported Shared Development Costs against the applicable binding part of the Development Budget previously approved by the JSC, on both a quarterly basis and a cumulative basis for each activity. The Parties shall seek to resolve any questions related to such accounting statements within [***] following receipt by each Party of the other Party&#8217;s report hereunder. Following such resolution, BioNTech shall prepare a reconciliation report for the Shared Development Costs for such Pfizer Quarter (including as against the binding parts of the Development Budget) and shall either (a) deliver an invoice to Pfizer for any amounts due to BioNTech as a result of reconciliation or (b) notify Pfizer that it should issue an invoice to </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> for any amounts due to Pfizer as a result of reconciliation.</font><font style="text-decoration:none;"> Any such invoice from </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> to Pfizer shall be payable within </font><font style="text-decoration:none;">[***]</font><font style="text-decoration:none;"> from receipt by Pfizer. </font><font style="text-decoration:none;">A</font><font style="text-decoration:none;">ny such invoice from Pfizer to </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> shall be payable within</font><font style="text-decoration:none;"> </font><font style="text-decoration:none;">[***]</font><font style="text-decoration:none;"> </font><font style="text-decoration:none;">from receipt by Pfizer.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">4.4.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Capex Costs</font><font style="text-decoration:none;">. Notwithstanding anything else in this Agreement, each Party shall be solely responsible for its own Capex Costs and any capital expenditures required in connection with this Agreement.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref35878799"></a><font style="text-decoration:none;">4.4.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Other Costs</font><font style="text-decoration:none;">. Except as expressly set forth otherwise in this Agreement), each Party will bear all costs and expenses it incurs in connection with its activities under this Agreement.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256049"></a><a name="_Toc59107076"></a><a name="_Ref35879970"></a><a name="_Ref35878855"></a><font style="text-decoration:none;">4.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Third Party Funding</font><font style="text-decoration:none;">.</font><font style="text-decoration:underline;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref36719402"></a><font style="text-decoration:none;">4.5.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Third Party Funders</font><font style="text-decoration:none;">. Pfizer and BioNTech shall, in good faith and acting collaboratively, seek funding from one or more Third Parties for such Third Party to provide financial support to the collaboration between the Parties under this Agreement (each, a &#8220;</font><font style="text-decoration:underline;">Third Party Funder</font><font style="text-decoration:none;">&#8221;). For each potential Third Party Funder, the Parties will agree on (a) the Party to lead the communications and discussions with such Third Party Funder (the &#8220;</font><font style="text-decoration:underline;">Lead Party</font><font style="text-decoration:none;">&#8221;) and (b) the activities, costs or expenses for which funding support shall be sought (e.g. funding for Development costs, funding in support of a Party's Capex Costs (&#8220;</font><font style="text-decoration:underline;">Capex Funding</font><font style="text-decoration:none;">&#8221;) or both). An initial list of potential Third Party Funders and their allocation as between the Parties is set forth in </font><font style="text-decoration:underline;">Schedule 4.5</font><font style="text-decoration:none;">. Notwithstanding the foregoing, Pfizer shall be entitled to secure funding from, and shall be the Lead Party in discussions with [***], in the event that Pfizer, in its sole discretion [***] and BioNTech shall be entitled to secure funding from, and shall be the Lead Party in discussions with [***], in the event that BioNTech, in its sole discretion, chooses to seek funding from [***]. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref36511521"></a><font style="text-decoration:none;">4.5.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Discussions with Funders</font><font style="text-decoration:none;">. The Lead Party will lead any discussions with such Third Parties in any country, provided that the Lead Party will provide regular updates to the JSC and keep the JSC reasonably informed of the status and any developments in such discussions, and shall, at the other Party&#8217;s reasonable request, update the other Party on any such discussions. The Lead Party shall conduct any such discussions and draft and file any applications for any Third Party Funding in good faith and acting reasonably with respect to its requests for such funding. Where legally possible and unless otherwise agreed between the Parties, each application for any Third Party funding shall be made in both Parties&#8217; name unless the Parties have agreed in advance pursuant to Section 4.5.1 that such application shall be in respect of one Party&#8217;s Capex Funding alone, in which case such application may be made in that Party's own name alone. The Lead Party shall not enter into a written agreement with any Third Party Funder without prior written consent of the other Party (such consent not to be unreasonably withheld, conditioned or delayed) unless the Parties have agreed in advance pursuant to Section 4.5.1 that such agreement shall be in respect of that Lead Party's Capex Funding alone, in which case the Lead Party can conclude such Third Party Funder agreement without consent from the other Party. Notwithstanding the foregoing, (a) Pfizer shall be entitled to seek any funding from [***] without requiring BioNTech's consent; (b) BioNTech shall be entitled to seek any funding from [***] without requiring Pfizer's consent; and (c) neither Party shall agree as a party to any agreement with any Third Party Funder or in consequence of such agreement to commit any particular allocation of supply of Product for any country or government without the prior consent of the JCC pursuant to Section 7.4.2.5. Pfizer and BioNTech acknowledge and agree that there is no guaranty that any Lead Party will be successful </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">in securing any funding from any Third Party Funder or that any specific amount of funding will be obtained.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">4.5.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Allocation of Funds and Balancing Payment</font><font style="text-decoration:none;">. To the extent possible, any Third Party funding to the extent it relates to activities in relation to which the Parties have agreed to treat the associated Development costs as Shared Development Cost shall be shared equally between the Parties. If such sharing is not possible, a balancing adjustment shall be made in favor of the other Party to the Shared Development Costs to reflect [***] percent of such funding that that Party receives from the Third Party Funder provided that doing so does not breach any applicable Laws or the terms of such funding. Each Party shall promptly report to the other Party in writing if and when it receives any payments from any Third Party Funder funding that relates to activities, costs or expenses that are Shared Development Costs.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">4.5.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Not Applicable to Loans</font><font style="text-decoration:none;">. For the avoidance of doubt, this Section 4.5 shall not apply to any traditional loans provided by any Third Party to a Party provided that (a) such loans are repayable by the borrower Party and not, directly or indirectly, by the other Party; (b) this Agreement, any other agreement ancillary to this Agreement, the BioNTech Technology, Product Technology and Product are not provided as security for, or otherwise encumbered by way of, such loan (excluding, for clarity, any tangible assets). Each Party shall be entitled to seek any such loans from any Third Party without any obligations to the other Party.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">4.5.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Documentation</font><font style="text-decoration:none;">. To the extent the conditions agreed by the Lead Party with any Third Party Funder require the disclosure or delivery of specific documentation relating to Shared Development Costs (e.g. invoices from Third Parties or calculation of internal costs) in order to obtain funding or reimbursement for such Shared Development Costs from such Third Party Funder, upon the Lead Party&#8217;s request, the other Party will use Commercially Reasonable Efforts to provide such documentation to the Lead Party within [***] from the request, </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that the Lead Party shall pay all reasonably necessary costs and expenses of the other Party which are directly incurred in connection with provision of any documentation to the extent it is beyond the documentation or the efforts required pursuant to Section 4.4.4, </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;">, </font><font style="font-style:italic;text-decoration:none;">further</font><font style="text-decoration:none;">, [***].</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256050"></a><a name="_Toc59107077"></a><a name="_Ref37260654"></a><a name="_Ref519717084"></a><a name="_Ref453532066"></a><font style="text-decoration:none;">4.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;"><a name="_Ref453532066"></a>Accounting Principles</font><font style="text-decoration:none;">. Each Party shall determine Shared Development Costs using its standard accounting procedures, consistently applied and in accordance with GAAP or IFRS, as applicable (provided that the application of such procedures results, on balance, in outcomes that are fair and equitable to both Parties taking into consideration the interests of both Parties as reflected in this Agreement). All personnel costs of either Party or its Affiliates are excluded from Shared Development Costs.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256051"></a><a name="_Toc59107078"></a><a name="_Ref36055668"></a><font style="text-decoration:none;">4.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Commercialization Costs</font><font style="text-decoration:none;">. Each Party will be solely responsible for the costs it incurs in Commercializing the Product within its respective Commercialization Territory and such costs shall not be included in the calculation of Gross Profits as described in Section 4.9 below.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc40858292"></a><a name="_Toc40859602"></a><a name="_Toc40860263"></a><a name="_Toc40863021"></a><a name="_Toc40863719"></a><a name="_Toc40864118"></a><a name="_Toc62256052"></a><a name="_Toc59107079"></a><a name="_Ref39508642"></a><a name="_Ref43485329"></a><font style="text-decoration:none;">4.8</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Commercialization Sales Milestones</font><font style="text-decoration:none;">. Pfizer shall pay BioNTech the following one off Commercialization Sales Milestone Payments within [***] of the end of the Pfizer Quarter in which the annual Net Sales of the Product within the Territory pursuant to this Agreement in a Pfizer Year first achieve the relevant level described below. For the avoidance of doubt, the Parties recognize that more than one Commercialization Sales Milestone Payment may become due in any particular Pfizer Quarter or Pfizer Year; however, each of the Commercial Sales Milestones Payments set forth below shall be payable one </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">time only, regardless of the number of Pfizer Years in which the applicable Annual Net Sales Level is achieved.</font><font style="text-decoration:none;"> </font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:12.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestone</p></td>
<td valign="top"  style="width:35.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual Net Sales Level</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc40858293"></a>in the Territory</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc40858294"></a>(US$)</p></td>
<td valign="top"  style="width:52.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.71%;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amount to be Paid to BioNTech </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc40858297"></a>(US$) (each a &#8220;<font style="text-decoration:underline;">Commercialization Sales</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Milestone Payment</font>&#8221;)</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="top"  style="width:35.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc40858298"></a>$[***]</p></td>
<td valign="top"  style="width:52.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc40858300"></a>$[***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="top"  style="width:35.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc40858301"></a>$[***]</p></td>
<td valign="top"  style="width:52.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc40858303"></a>$[***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="top"  style="width:35.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc40858304"></a>$[***]</p></td>
<td valign="top"  style="width:52.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc40858306"></a>$[***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="top"  style="width:35.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc40858307"></a>$[***]</p></td>
<td valign="top"  style="width:52.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc40858309"></a>$[***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="top"  style="width:35.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc40858310"></a>$[***]</p></td>
<td valign="top"  style="width:52.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc40858312"></a>$[***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="top"  style="width:35.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc40858313"></a>$[***]</p></td>
<td valign="top"  style="width:52.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc40858315"></a>$[***]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:7.69%;font-size:9pt;"><a name="_Ref43304536"></a><a name="_Toc62256053"></a><a name="_Toc59107080"></a>&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">4.9</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Gross Profit Sharing</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref43485409"></a><font style="text-decoration:none;">4.9.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Sharing of Gross Profits</font><font style="text-decoration:none;">. Subject to Section 4.4.2, BioNTech and Pfizer will share the Gross Profits generated through the Commercialization of the Product in the Territory pursuant to this Agreement on a fifty-fifty (50:50) basis calculated on a Pfizer Quarter basis.&nbsp;&nbsp;In reflecting that principle, it is agreed that all Product Shipping and Storage Costs incurred for Products, as well as Agreed Product Component costs incurred in acquiring or Manufacturing Agreed Product Components supplied or provided to customers in connection with Commercialization of the Product (if applicable) shall be shared on a fifty (50:50) basis.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref39495969"></a><a name="_Ref40719557"></a><a name="_Ref43302776"></a><font style="text-decoration:none;">4.9.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Calculation of Net Sales</font><font style="text-decoration:none;">. In calculating Net Sales for the purposes of this Section&#160;4, [***].</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref43485489"></a><font style="text-decoration:none;">4.9.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Quarterly Reporting of Net Sales and Payments</font><font style="text-decoration:none;">. Within [***] after the end of each US Pfizer Quarter, each Party (a &#8220;</font><font style="text-decoration:underline;">Reporting Party</font><font style="text-decoration:none;">&#8221;) shall deliver to the other Party (a &#8220;</font><font style="text-decoration:underline;">Notified Party</font><font style="text-decoration:none;">&#8221;) a report setting forth, for the most recent Pfizer Quarter, the following information, on a country-by-country and Territory-wide basis: [***]. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref43485548"></a><a name="_Ref59045665"></a><a name="_Ref44332229"></a><font style="text-decoration:none;">4.9.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Manufacturing Variances and True-Up of Transfer Pricing</font><font style="text-decoration:none;">. Each Party shall, [***]. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref43649711"></a><font style="text-decoration:none;">4.9.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Quarterly Consolidated Report</font><font style="text-decoration:none;">. Within the later of (i) [***] after exchange of all the reports and amounts pursuant to Section&#160;4.9.3 or (ii) [***] of the end of the applicable US Pfizer Quarter, Pfizer shall prepare and provide to BioNTech a consolidated report, with respect to the applicable Pfizer Quarter, setting forth:</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref43653183"></a><font style="text-decoration:none;">4.9.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Payment of Gross Profit Share</font><font style="text-decoration:none;">. To the extent Pfizer, with respect to any Pfizer Quarter, is to make a payment to BioNTech for its Gross Profit portion as set forth in the consolidated financial report prepared pursuant to Section&#160;4.9.5, such payment shall be made by Pfizer to BioNTech as provided in Section&#160;4.13. To the extent BioNTech is to make a payment to Pfizer for its Gross Profit portion as set forth in the consolidated financial report prepared pursuant to Section&#160;4.9.5, such payment shall be made by BioNTech to Pfizer as provided in Section&#160;4.13. Such payments under this Section&#160;4.9.6 for any Pfizer Quarter shall be made within [***] after </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">Pfizer, pursuant to Section&#160;</font><font style="text-decoration:none;">4.9.5</font><font style="text-decoration:none;">, delivers to </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> the consolidated financial report for such Pfizer Quarter.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc40858318"></a><a name="_Toc40859604"></a><a name="_Toc40860265"></a><a name="_Toc40863023"></a><a name="_Toc40863721"></a><a name="_Toc40864120"></a><a name="_Toc62256054"></a><a name="_Toc59107081"></a><a name="_Ref62483452"></a><a name="_Ref39586683"></a><font style="text-decoration:none;">4.10</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Third Party License Payments</font><font style="text-decoration:none;">.</font><font style="text-decoration:underline;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref43809136"></a><font style="text-decoration:none;">4.10.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Third Party Royalties</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref43485620"></a><font style="text-decoration:none;">4.10.1.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;"> [***]. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">4.10.1.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Following the consolidated financial report for each Pfizer Quarter prepared by Pfizer and delivered to BioNTech pursuant to Section&#160;4.9.5 above [***].</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">4.10.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Other Third Party License Payments</font><font style="text-decoration:none;">. Subject to Section&#160;3.8.4, for Third Party License Payments due under Third Party Agreements, the following rules, as applicable, shall apply:</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">4.10.2.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;"> [***];</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref43485677"></a><font style="text-decoration:none;">4.10.2.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;"> [***]; and</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref39586753"></a><font style="text-decoration:none;">4.10.2.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;"> [***].</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">4.10.2.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;"> [***].</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">4.10.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Exclusion of Certain Payments</font><font style="text-decoration:none;">. [***].</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref43653644"></a><a name="_Ref44336490"></a><a name="_Toc62256055"></a><a name="_Toc59107082"></a><a name="_Ref518669081"></a><font style="text-decoration:none;">4.11</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Taxes</font><font style="text-decoration:none;"><a name="_Ref518669081"></a>.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref37116928"></a><a name="_Ref518040856"></a><font style="text-decoration:none;">4.11.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Withholding Taxes</font><font style="text-decoration:none;">. The Parties agree to use reasonable efforts to cooperate with one another and use commercially reasonable efforts to avoid or reduce, to the extent permitted by applicable Law, tax withholding or similar obligations in respect of royalties, milestone payments, and other payments made by the paying Party to the receiving Party under this Agreement (&#8220;</font><font style="text-decoration:underline;">Withholding Taxes</font><font style="text-decoration:none;">&#8221;). If Withholding Taxes are imposed on any payment under this Agreement, the liability for such Withholding Taxes shall be the sole responsibility of the receiving Party, and the paying Party shall (a) deduct or withhold such Withholding Taxes from the payment made to the receiving Party, (b) timely pay such Withholding Taxes to the proper taxing authority, and (c) send proof of payment to the receiving Party within [***] following such payment. Each Party shall comply with (or provide the other Party with) any certification, identification or other reporting requirements that may be reasonably necessary in order for the paying Party to not withhold Withholding Taxes or to withhold Withholding Taxes at a reduced rate under an applicable bilateral income tax treaty. Each Party shall provide the other with commercially reasonable assistance to enable the recovery, as permitted by applicable Law, of Withholding Taxes or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing the cost of such Withholding Taxes under this Section&#160;4.11.1 (Taxes and Withholding). Notwithstanding the foregoing, if as a result of any assignment or sublicense by the paying Party, any change in the paying Party&#8217;s tax residency, any change in the entity that originates the payment, or any failure on the part of the paying Party to comply with applicable Law with respect to Withholding Taxes (including filing or record retention requirements), Withholding Taxes are imposed that would not otherwise have been imposed (&#8220;</font><font style="text-decoration:underline;">Incremental Withholding Taxes</font><font style="text-decoration:none;">&#8221;), then the paying Party shall be solely responsible for the amount of such Incremental </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;"><a name="_Ref518040856"></a>Withholding Taxes and shall increase the amounts payable to the receiving Party so that the receiving Party receives a sum equal to the sum which it would have received had there been no such imposition of Incremental Withholding Taxes.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref37117254"></a><font style="text-decoration:none;">4.11.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Value Added Tax</font><font style="text-decoration:none;">. All payments between the Parties under this Agreement are exclusive of applicable statutory value added tax or similar taxes (&#8220;</font><font style="text-decoration:underline;">VAT</font><font style="text-decoration:none;">&#8221;), if any, which shall be listed separately on each invoice. If and to the extent any VAT will become payable due to any supplies or services rendered under this Agreement and if and to the extent such VAT is to be paid by the Party providing the supply or service to the competent tax authorities, the receiving Party shall pay an amount equal to such VAT to the providing Party upon receipt of a valid invoice allowing for the recovery of such VAT.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">4.11.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Taxes of Co-Entrepreneurship</font><font style="text-decoration:none;">. If and to the extent the Parties are considered to be partners of a co-entrepreneurship for tax purposes because of their collaboration governed by this Agreement and taxes allocated to the co-entrepreneurship (e.g. German trade tax, but excluding any taxes imposed on or with respect to net income other than German trade tax) are owed by either of the Parties, such tax (as well as any related cost of reporting and preparation of relevant tax returns) shall be [***]. In deviation of the foregoing, if and to the extent such tax (including related cost) is increased or reduced by circumstances that are exclusively attributable to one of the Parties (Causing Party) (in particular due to so-called special trade tax effects), any increased tax (including related costs) shall exclusively be allocated to and be borne by the Causing Party and any saved tax shall be credited to the Causing Party. The Parties shall cooperate in good faith to agree on a mutual tax filing position for their collaboration governed by this Agreement in due course after the Effective Date. Each Party shall have the right to assign any or all of its contractual position under this Agreement to a wholly owned corporate subsidiary (&#8220;</font><font style="text-decoration:underline;">Blocker Entity</font><font style="text-decoration:none;">&#8221;) provided that the relevant Party (i) remains secondarily liable for any liabilities of the Blocker Entity under this Agreement in respect of the contractual position assigned and (ii) shall indemnify the other Party from any taxes triggered by the transfer of such contractual position to the Blocker Entity.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">4.11.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Other</font><font style="text-decoration:none;">. Except as otherwise set forth in this Section&#160;4.11, each Party shall be solely responsible for the payment of all Taxes imposed on such Party&#8217;s income arising directly or indirectly from the activities of the Parties under this Agreement and each Party shall be solely responsible for taxes based on, imposed on or calculated by reference to any employees employed by that Party. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref40732330"></a><a name="_Ref43485857"></a><font style="text-decoration:none;">4.11.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Branded Prescription Drug Fee</font><font style="text-decoration:none;">. Under the provisions of the U.S. Patient Protection and Affordable Care Act, Pub. L. No. 111-14 (as amended), Pfizer is subject to the annual fee on prescription drug manufacturers, hereinafter referred to as the &#8220;</font><font style="text-decoration:underline;">Branded Prescription Drug Fee</font><font style="text-decoration:none;">&#8221;. [***]</font></p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62256056"></a><a name="_Toc59107083"></a><a name="_Ref62658876"></a><a name="_Ref268768035"></a><a name="_Ref36048581"></a>4.12<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Currency, Source of Payments</font>. All amounts payable and calculations under this Agreement will be in United States dollars [***]. As applicable, all costs and expenses will be translated into United States dollars at the exchange rate used by the relevant Party for public financial accounting purposes. If, due to restrictions or prohibitions imposed by national or international authority, a given payment cannot be made as provided under this Section&#160;4.12, the Parties will consult with a view to finding a prompt and acceptable solution. If the Parties are unable to identify a mutually acceptable solution regarding such </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">payment, then the Party owing the relevant payment may elect, in its sole discretion, to deliver such payment in the relevant jurisdiction and in the local currency of the relevant jurisdiction.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256057"></a><a name="_Toc59107084"></a><a name="_Ref62658878"></a><a name="_Ref43653023"></a><a name="_Ref263796447"></a><font style="text-decoration:none;">4.13</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Method of Payment</font><font style="text-decoration:none;">. Except as permitted pursuant to Section&#160;4.12, each payment hereunder will be made by electronic transfer in immediately available funds via either a bank wire transfer, an ACH (automated clearing house) mechanism, or any other means of electronic funds transfer, at the paying Party&#8217;s election, to such bank account as the receiving Party will designate in writing to the other Party within [***] of the Signing Date, and thereafter at least [***] before the payment is due. All invoice or billing related questions in relation to Pfizer should be referred to Pfizer&#8217;s Accounting Department at [***] or go to the Accounts Payable Invoice Portal at [***]. Unless otherwise specified herein, each invoice is payable within [***] of receipt of the relevant invoice.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256058"></a><a name="_Toc59107085"></a><a name="_Ref62385690"></a><a name="_Ref62483501"></a><a name="_Ref135583354"></a><a name="_Ref518596921"></a><font style="text-decoration:none;">4.14</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Record Keeping and Audits</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref46484886"></a><font style="text-decoration:none;">4.14.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Record Keeping</font><font style="text-decoration:none;">. Each Party shall keep and maintain and shall cause its Affiliates to keep and maintain books and accounts of record in sufficient detail to enable the determination of [***] and any other financial provisions of or applicable to this Agreement. Such records will be maintained for up to [***] after the end of the year to which they pertain or such longer period of time required under a Current License, insofar as applicable to the rights sublicenses pursuant to such Current License. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">4.14.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Right to Audit</font><font style="text-decoration:none;">. Upon [***] prior notice from a Party (the &#8220;</font><font style="text-decoration:underline;">Auditing Party</font><font style="text-decoration:none;">&#8221;), the other Party (the &#8220;</font><font style="text-decoration:underline;">Audited Party</font><font style="text-decoration:none;">&#8221;) will permit an independent certified public accounting firm of nationally recognized standing selected by the Auditing Party and reasonably acceptable to the Audited Party, to examine [***] the relevant books and records of the Audited Party and its Affiliates (and where possible, its subcontractors) as may be reasonably necessary to verify the amounts reported by the Audited Party in accordance with Sections&#160;4.4 to 4.10. An examination by the Auditing Party under this Section 4.14 will occur not more than [***] and will be limited to the pertinent books and records for any Calendar Year ending not more than [***] before the date of the request. The accounting firm will be provided access to such books and records at the Audited Party&#8217;s or its Affiliates&#8217; facility(ies) where such books and records are normally kept and such examination will be conducted during the Audited Party&#8217;s or its Affiliates&#8217; normal business hours. The Audited Party may require the accounting firm to sign a reasonably acceptable non-disclosure agreement before providing the accounting firm with access to the Audited Party&#8217;s or its Affiliates&#8217; facilities or records. Upon completion of the audit, the accounting firm will provide both Pfizer and BioNTech the same written report disclosing any discrepancies in the reports submitted by the Audited Party, and, in each case, the specific details concerning any discrepancies. No other information will be provided to the Auditing Party. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref46484905"></a><a name="_Ref268773546"></a><a name="_Ref276112434"></a><font style="text-decoration:none;">4.14.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Underpayments/Overpayments</font><font style="text-decoration:none;">. If such accounting firm concludes that there are errors in how Shared Development Costs, Third Party funding, BioNTech Deferred Development Costs, Net Sales, Gross Profits, Transfer Prices, Third Party License Payments, Expedited Milestone Refunds or Proportional Adjustments have been calculated, allocated, paid or reclaimed, then adjustments shall be made in accordance with the accounting firm's recommendations in a reconciliation of such amounts and any overpayment or underpayment by the Audited Party shall be rectified either by a refund to, or payment by, the Audited Party from or to the Auditing Party</font><font style="font-weight:bold;text-decoration:none;"> </font><font style="text-decoration:none;">within [***] of the date the Audited Party receives such accountant&#8217;s written report. Further, if the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">amount of any overpayment or overallocation to the Audited Party exceeds more than </font><font style="text-decoration:none;">[***]</font><font style="text-decoration:none;"> of the amount that was properly payable due or allocated to the Audited Party, then the Audited Party will reimburse the Auditing Party for the Auditing Party&#8217;s out-of-pocket costs in connection with the audit.</font><font style="text-decoration:none;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref276112439"></a><font style="text-decoration:none;">4.14.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Confidentiality</font><font style="text-decoration:none;">. Notwithstanding any provision of this Agreement to the contrary, all reports and financial information of the Audited Party or its Affiliates which are provided to or subject to review by the Auditing Party will be deemed to be Confidential Information of the Audited Party and subject to the provisions of Section 12.1. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766498"></a><a name="_Toc519764392"></a><a name="_Toc519873388"></a><a name="_Toc35600541"></a><a name="_Ref43643933"></a><a name="_Toc62256059"></a><a name="_Toc59107086"></a><font style="text-decoration:none;">4.15</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">No Guaranty of Success</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">4.15.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Pfizer and BioNTech acknowledge and agree that any milestone payments payable hereunder: (a) have been included in this Agreement on the basis that they are only payable or otherwise relevant if a certain Product is successfully Developed or Commercialized in accordance with the applicable milestone or event, as applicable; (b) are solely intended to allocate amounts that may be achieved upon successful Development or Commercialization of such Product as applicable, between Pfizer and BioNTech; (c) are not intended to be used as a measure of damages if this Agreement is terminated for any reason; and (d) will only be triggered, and will only be relevant as provided, in accordance with the terms and conditions of such provisions. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">4.15.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Pfizer and BioNTech further acknowledge and agree that nothing in this Agreement, or in any document or presentation provided by Pfizer to BioNTech prior to the Effective Date will be construed as representing any estimate or projection of (a) the successful Development or Commercialization of any Product under this Agreement, (b) the number of Products that will or may be successfully Developed or Commercialized under this Agreement, (c) the number of countries in the Territory in which the Product will receive Regulatory Approval, (d) anticipated sales or the actual value of any Products that may be successfully Developed or Commercialized under this Agreement or (e) the damages, if any, that may be payable if this Agreement is terminated for any reason.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">4.15.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Neither Party makes any representation, warranty or covenant, either express or implied, to the other Party that (a) it will successfully Develop, Manufacture, Commercialize or continue to Develop, Manufacture or Commercialize any Product in any country, (b) it will secure Regulatory Approval for the Product in any country in the Territory, (c) if Commercialized, that any Product will achieve any particular sales level, whether in any individual country or cumulatively throughout the Territory or (d) it will devote, or cause to be devoted, any level of diligence or resources to Developing, Manufacturing or Commercializing any Product in any country, or in the Territory.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc40858324"></a><a name="_Toc40859610"></a><a name="_Toc40860271"></a><a name="_Toc40863029"></a><a name="_Toc40863727"></a><a name="_Toc40864126"></a><a name="_Toc62256060"></a><a name="_Toc59107087"></a><a name="_Ref415046591"></a><font style="text-decoration:none;">4.16</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">No Other Compensation</font><font style="text-decoration:none;">.<a name="_Ref415046591"></a> Other than as explicitly set forth in this Agreement, neither Party will be obligated to pay any additional fees, milestone payments, royalties or other payments of any kind to the other Party under this Agreement or any Related Agreement.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc40858325"></a><a name="_Toc40859611"></a><a name="_Toc40860272"></a><a name="_Toc40863030"></a><a name="_Toc40863728"></a><a name="_Toc40864127"></a><a name="_Toc62256061"></a><a name="_Toc59107088"></a><a name="_Ref62484222"></a><a name="_Ref411998645"></a><font style="text-decoration:none;">4.17</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Late Payment</font><font style="text-decoration:none;">. Any payments or portions thereof due hereunder which are not paid when due will bear interest at the Contract Interest Rate, compounded annually, calculated on the number of days </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">such payment is delinquent. This Section&#160;</font><font style="text-decoration:none;">4.17</font><font style="text-decoration:none;"> will in no way limit any other remedies available to either Party.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc40858326"></a><a name="_Toc40859612"></a><a name="_Toc40860273"></a><a name="_Toc40863031"></a><a name="_Toc40863729"></a><a name="_Toc40864128"></a><a name="_Toc62256062"></a><a name="_Toc59107089"></a><a name="_Ref62483511"></a><a name="_Ref415046685"></a><font style="text-decoration:none;">4.18</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">No Double Counting</font><font style="text-decoration:none;">. There will be no double counting of any payments, costs or revenue item in the calculation of any amounts under this Agreement or any Related Agreement, and to the extent a cost or expense has been included in one category or sub-category, it will not be included in another; similarly, to the extent any revenue has been taken into account in one category or sub-category it will not be taken into account in another. For clarity, [***].</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-transform:none;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref135583527"></a><a name="_Ref135583539"></a><a name="_Ref135584498"></a><a name="_Ref135584575"></a><a name="_Ref135584648"></a><a name="_Ref263793222"></a><a name="_Ref263793596"></a><a name="_Ref263796187"></a><a name="_Ref35881431"></a><a name="_Ref35356157"></a><a name="_Ref35528208"></a><a name="_Ref59008609"></a><a name="_Toc62256063"></a><a name="_Toc59107090"></a><font style="text-decoration:none;"></font><font style="text-decoration:underline;text-transform:uppercase;">Research and Development Plan</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766500"></a><a name="_Toc519764394"></a><a name="_Toc519873390"></a><a name="_Toc35600543"></a><a name="_Toc62256064"></a><a name="_Toc59107091"></a><a name="_Ref135582732"></a><a name="_Ref263792247"></a><a name="_Ref263796559"></a><a name="_Ref37257341"></a><a name="_Ref37022651"></a><font style="text-decoration:none;">5.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Scope of Development and Updating of Plans</font><font style="text-decoration:none;"> Pfizer and BioNTech will collaborate during the Term to conduct research to identify, Develop and evaluate Candidates and Products within the Field in accordance with the binding parts of the Research and Development Plan, the Development Budget, the Manufacturing Plan, and the terms and conditions set forth in this Section 5. The Research and Development Plan may be modified by agreement and approval of the JSC pursuant to Section 6, provided that the JSC shall have no right or authority to (a) modify the Research and Development Plan in a way not permitted under Section 6.3; or (b) modify the Research and Development Plan so as to amend the contractual provisions of this Agreement. The Parties acknowledge and agree that the initial [***] of each of the Research and Development Plan, the Manufacturing Plan and the Development Budget have been agreed between the Parties, the first [***] of each binding upon the Parties and the second [***] indicative but non-binding. At least [***] prior to the expiration of such initial [***] binding period, the JSC shall decide and mutually agree on the following [***] period of each of the Research and Development Plan and the Development Budget which period, upon agreement, shall be binding upon the Parties subject to Section 6.3.4. At least [***] prior to the expiration of the initial [***] period following the Effective Date, the JSC shall establish a rolling [***] process to decide on and update each of the Research and Development Plan and the Development Budget for subsequent [***] periods, each of which shall be updated by the JSC no later than [***] prior to the expiration of the then binding [***] period.</font><font style="text-decoration:underline;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256065"></a><a name="_Toc59107092"></a><a name="_Ref37270323"></a><a name="_Toc484766501"></a><a name="_Toc519764395"></a><a name="_Toc519873391"></a><a name="_Toc35600544"></a><a name="_Ref263793443"></a><font style="text-decoration:none;">5.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Research and Development Plan</font><font style="text-decoration:none;">. The Research and Development Plan shall (a) include a broad non-binding overview of the first [***] of the planned Development program (specifying in reasonable detail all material Development activities) to generate the preclinical, clinical, CMC, regulatory and other information required for submitting a marketing authorization application for Regulatory Approval for the Candidate or Product and to achieve such Regulatory Approval for the Candidate or Product in one or more selected country(ies) of the Territory; (b) include a more detailed and binding part of the plan for the initial binding period described in Section 5.1, which will be updated in accordance with Section 5.1; and (c) set forth those obligations assigned to each Party with respect to the performance of the Development activities contemplated by such Research and Development Plan. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256066"></a><a name="_Toc59107093"></a><font style="text-decoration:none;">5.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Allocation of Responsibilities</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref518636087"></a><font style="text-decoration:none;">5.3.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">General</font><font style="text-decoration:none;">. Each Party will use Commercially Reasonable Efforts to perform its obligations and activities identified under the binding parts of the Research and Development Plan or as allocated to it by the JSC in a professional manner in accordance with any target dates set forth in Research and Development Plan. Further, each Party will perform its obligations under the binding parts of the Research and Development Plan or as allocated to it by the JSC in compliance with all Laws applicable to its activities under the Research and Development Plan.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref37281340"></a><a name="_Ref35966013"></a><a name="_Ref37021140"></a><a name="_Ref36052264"></a><a name="_Ref36756856"></a><font style="text-decoration:none;">5.3.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Mutations</font><font style="text-decoration:none;">. If and to the extent Mutations of the SARS-CoV-2 virus arise [***]. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref36756859"></a><a name="_Ref37021449"></a><a name="_Ref135583007"></a><a name="_Ref468669222"></a><a name="_Ref518673689"></a><a name="_Ref516496784"></a><font style="text-decoration:none;">5.3.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Label Extensions</font><font style="text-decoration:none;">. If a Party wishes to extend the label or approved indication of any Product Developed hereunder to other indications (including any outside of the Field), it may so notify the JSC. In such event, the JSC shall discuss such label extension in good faith. If the JSC agrees by unanimous consent that Development should be undertaken to support the label extension, the Parties shall include the Development activities required to be undertaken to support such label extension in the Research and Development Plan and, if appropriate, amend the Field accordingly to cover such extension. Any external cost or expense (other than Capex Cost) incurred by either Party (or its Affiliates) solely and specifically in connection with such Development activities [***]. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref37258142"></a><a name="_Ref135582896"></a><a name="_Ref268773578"></a><font style="text-decoration:none;">5.3.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Subcontractors</font><font style="text-decoration:none;"><a name="_Ref135582896"></a><a name="_Ref268773578"></a>. Either Party may subcontract its responsibilities under the binding parts of the Research and Development Plan or those allocated to it by the JSC without the other Party&#8217;s prior written consent; </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that such Party shall be responsible for the management of all permitted subcontractors (which will include any Affiliate of a Party). The engagement of any Third Party subcontractor by a Party shall be in writing. The engagement of any subcontractor (whether Affiliate or Third Party) shall not relieve such Party of its obligations under this Agreement or the binding parts of the Research and Development Plan. Any agreement between the Party or its Affiliate and a subcontractor pertaining to the Research and Development Plan activities shall be consistent with the provisions of this Agreement including (a) an obligation to assign all Intellectual Property Rights generated during its performance of such Research and Development Plan to the Party free of any encumbrance such that the Party may fulfil its obligations hereunder and (b) terms and conditions under which such Third Party is obligated to preserve the confidentiality of the Research and Development Program, Research and Development Program Technology and any Confidential Information are at least as restrictive as those described in Section 12.2.1. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref35457043"></a><font style="text-decoration:none;">5.3.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Flexibility of Resources</font><font style="text-decoration:none;">. Due to practical consequences arising from the outbreak of the virus that is the subject of the Field, it may become difficult or temporarily impossible (including as classified as a force majeure event) for a Party to fulfil all of its responsibilities under the Research and Development Plan or as allocated to it by the JSC. Accordingly, a Party, in its effort to collaborate, may therefore agree to swap, substitute or perform any of the other Party's responsibilities that were allocated to it in the Research and Development Plan or by the JSC. The JSC shall be responsible for coordinating any such changes, which must be finally approved in writing by the Parties where the change results in a Party taking on additional financial cost and responsibility. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref36049552"></a><font style="text-decoration:none;">5.3.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Personnel Matters</font><font style="text-decoration:none;">. Each Party acknowledges and agrees that it is solely responsible for the compensation of its personnel assigned to the Research and Development Plan, and shall be responsible for withholding all national, state, local or other applicable taxes and similar items for such personnel. Each Party also shall be responsible for all other of its employer related obligations, including providing appropriate insurance coverage and employee benefits, and making all other deductions required by law affecting the gross wages of each of its employees. BioNTech personnel assigned to the Research and Development Plan activities are not nor shall they be deemed to be employees of Pfizer, and Pfizer personnel assigned to the Research and Development Plan activities are not nor shall they be deemed to be employees of BioNTech.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref263793539"></a><a name="_Ref475165052"></a><a name="_Toc62256067"></a><a name="_Toc59107094"></a><font style="text-decoration:none;">5.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Materials and Permitted Activities</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref263792126"></a><font style="text-decoration:none;">5.4.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Transfer</font><font style="text-decoration:none;">. From time to time during the Term, Pfizer shall provide BioNTech with tangible chemical or biological materials (the &#8220;</font><font style="text-decoration:underline;">Pfizer Materials</font><font style="text-decoration:none;">&#8221;) and BioNTech may provide Pfizer with BioNTech Materials for the other Party&#8217;s use in accordance with binding parts of the Research and Development Plan. The Party providing its Materials represents and warrants to the other Party that, as of the date of delivery of the Material (a) to the providing Party&#8217;s knowledge, such Party has the right to provide such Material to the other Party for the uses in accordance with the binding parts of the Research and Development Plan, (b) the Materials comply with any requirements set forth in the Research and Development Plan or otherwise mutually agreed between the Parties (if any) in writing and (c) to the providing Party&#8217;s knowledge, the use of the Materials authorized herein does not infringe any Third Party rights. Except as expressly set forth in the preceding sentence, the Materials are provided by the providing Party on an &#8220;as-is&#8221; basis without any representation or warranty of any type, express or implied, including any representation or warranty of merchantability or fitness for a particular purpose, each of which is hereby expressly disclaimed by the receiving Party.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref276112460"></a><font style="text-decoration:none;">5.4.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Title to Materials</font><font style="text-decoration:none;">. All right, title and interest in and to the providing Party&#8217;s Materials (including any modifications or progeny thereof) will remain the sole and exclusive property of such Party notwithstanding the transfer to and use by other Party of the same. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref276112465"></a><font style="text-decoration:none;">5.4.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Permitted Activities</font><font style="text-decoration:none;">. Notwithstanding anything to the contrary in this Agreement save for each Party&#8217;s exclusivity obligations and restrictions (including those at Sections 3.1 and 3.11), nothing in this Agreement shall be deemed to prevent or restrict in any way the ability of either Party or its Affiliates to conduct any activities in the Territory, which activities would be allowed under any safe harbor, research exemption, government or executive declaration of urgent public health need, or similar right available in law or equity if conducted by a Third Party. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref519674268"></a><font style="text-decoration:none;">5.4.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Return of Proprietary Materials</font><font style="text-decoration:none;">. Upon termination or expiration of the Term, each Party receiving the other Party&#8217;s Materials hereunder shall, either destroy or return all unused Materials to the providing Party.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256068"></a><a name="_Toc59107095"></a><font style="text-decoration:none;">5.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Human Materials</font><font style="text-decoration:none;">. To the extent a Party holds and controls Human Materials that have been collected as part of any Clinical Trial in relation to the Product or a product identical to the Product, upon the other Party's reasonable request for access to such Human Materials for purposes of obtaining Marketing Authorization Approval or other Development purposes for, in the case of Pfizer, the Product or, in the case of BioNTech, a product identical to the Product in the Fosun Territory, the Parties shall negotiate in good faith with respect to an agreement under which the Party holding and controlling such Human Materials could provide such Human Materials. </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;">6.</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-transform:none;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref58495523"></a><a name="_Toc62256069"></a><a name="_Toc59107096"></a><a name="_Ref263792275"></a><a name="_Ref135582785"></a><font style="text-decoration:none;"></font><font style="text-decoration:underline;text-transform:uppercase;">Contract Governance</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256070"></a><a name="_Toc59107097"></a><a name="_Ref248138385"></a><a name="_Ref37116739"></a><a name="_Ref519776476"></a><font style="text-decoration:none;">6.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Alliance Managers</font><font style="text-decoration:none;">. Each Party will appoint a (i) single individual to act as the primary point of contact between the Parties to support the activities under the Research and Development Plan and the Manufacturing Plan and (ii) single individual to support matters relating to the Commercialization of, and regulatory and Compliance issues regarding pharmaceutical products (all persons under (i) and (ii) being the &#8220;Alliance Managers&#8221;). A Party's Alliance Manager for Research and Development and Manufacturing may be the same or different than the Alliance Manager for Commercialization. Each Party </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">may change its designated Alliance Managers at any time upon written notice to the other Party. The Alliance Managers will:</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.1.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">act as a key point of contact between the Parties to facilitate a successful collaboration hereunder;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.1.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">use good faith efforts to attend (either in person or by telecommunications) and actively participate in all meetings of the JSC or JCC, as applicable, and as agreed by the Alliance Managers, any meetings of any RCC or any subcommittees established hereunder, but will be non-voting members at such meetings; and</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.1.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">be the first point of referral for all matters of conflict resolution and bring disputes to the attention of the JSC in a timely manner.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256071"></a><a name="_Toc59107098"></a><a name="_Ref248138992"></a><a name="_Ref519776463"></a><font style="text-decoration:none;">6.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Program Directors</font><font style="text-decoration:none;">. Each Party will appoint a program director to oversee all activities conducted under the Research and Development Plan and all activities related to Commercialization, including regulatory and Compliance activities (each, a &#8220;Program Director&#8221;). A Party may appoint a different Program Director for activities under the Research and Development Plan and activities related to Commercialization. Each Party may change its designated Program Director at any time upon written notice to the other Party. The Program Directors will coordinate the efforts of their respective Party in conducting activities under the Research and Development Plan. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref516781036"></a><a name="_Toc62256072"></a><a name="_Toc59107099"></a><font style="text-decoration:none;">6.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Joint Steering Committee</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref248138725"></a><a name="_Ref46485225"></a><font style="text-decoration:none;">6.3.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Composition</font><font style="text-decoration:none;">. As of the Effective Date, the Parties will establish a Joint Steering Committee, comprised of at least [***] representatives of BioNTech (including the Alliance Manager for BioNTech) and at least [***] representatives of Pfizer (including the Alliance Manager for Pfizer). The JSC representatives for each of Pfizer and BioNTech will be referred to herein as the &#8220;</font><font style="text-decoration:underline;">Pfizer JSC Members</font><font style="text-decoration:none;">&#8221; and the &#8220;</font><font style="text-decoration:underline;">BioNTech JSC Members</font><font style="text-decoration:none;">&#8221; respectively.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Party may replace its representatives to the JSC at any time upon notice to the other Party, <font style="font-style:italic;">provided that</font> at all times an equal number of representatives from each Party are appointed to the JSC and each Party shall be responsible for ensuring any replaced representative is fully briefed and apprised of the Research and Development Program. Each Party shall procure that its JSC representatives shall make themselves available to attend JSC meetings upon reasonable notice and in accordance with this Agreement. Each Party may invite non-voting employees and consultants to attend meetings of the JSC. All members of the JSC and any invitees of either Party described above will agree in writing to be bound to obligations of confidentiality and assignment of Intellectual Property Rights no less restrictive than those that bind the Parties under this Agreement.<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref248138868"></a><font style="text-decoration:none;">6.3.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Committee Chair</font><font style="text-decoration:none;">. The JSC will be chaired by a BioNTech JSC Member (the &#8220;</font><font style="text-decoration:underline;">JSC Chair</font><font style="text-decoration:none;">&#8221;). BioNTech may replace the JSC Chair at any time upon notice to Pfizer. The responsibilities of the JSC Chair will be:</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.3.2.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">to notify each Party at least [***] Business Days in advance of each JSC meeting;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.3.2.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">to collect and organize agenda items for each JSC meeting; and</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.3.2.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">to prepare the written minutes of each JSC meeting and circulate such minutes for review and approval by the Parties and identify action items to be carried out by the Parties.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref519242905"></a><font style="text-decoration:none;">6.3.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Meetings</font><font style="text-decoration:none;">. Until the initiation of a Phase I Clinical Trial or Expedited Trial Pathway, the JSC shall meet at least weekly, unless otherwise unanimously agreed. Thereafter, the JSC will meet on at least bi-weekly basis (or less or more frequently as the JSC so determines), either in-person or by audio or video teleconference. Meetings of the JSC will occur at such times and places as mutually agreed by the Parties. Any sub-committees or working groups established in accordance with Section 6.3.4 may meet via audio or video teleconference on a regular basis and in-person at such times and places as the Parties may agree. Meetings of the JSC will only occur if at least two representatives of each Party are present at the meeting or participating by teleconference or videoconference. Each Party will be responsible for, and will not be entitled to any reimbursement from the other Party with respect to, any and all personnel costs or expenses (including travel expenses) which are incurred by or on behalf of its personnel in connection with participation in any JSC meetings or sub-committee or working group meetings, or any other travel required to be undertaken by either Party&#8217;s personnel in connection with the performance of the Agreement. The JSC Chair will use good faith efforts to (a) prepare and circulate to BioNTech and Pfizer each JSC meeting agenda on or before the day prior to the scheduled date for each JSC meeting and (b) circulate for review and approval by BioNTech and Pfizer written minutes of each JSC meeting within [***] Business Days after such meeting. The Parties will agree on the minutes of each meeting promptly, but in no event later than the day before the next meeting of the JSC.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref468599083"></a><font style="text-decoration:none;">6.3.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Responsibilities</font><font style="text-decoration:none;">. The JSC will coordinate and provide operational and strategic oversight of the Development and Manufacturing activities to be performed under the Research and Development Plan and the Manufacturing Plan by each Party and, within such scope will:</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref43642204"></a><font style="text-decoration:none;">6.3.4.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">review and approve all proposals of whether to seek funding from a Third Party Funder, and the terms of any proposed agreement with a Third Party Funder, which (with the exceptions specified in Section 4.5.2 for [***] and [***]) will require unanimous consent of the JSC;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref43486014"></a><font style="text-decoration:none;">6.3.4.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">monitor and assess the progress of activities under the Research and Development Plan and the Manufacturing Plan;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.3.4.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">decide on the Candidates or Products that will be studied in the Clinical Trials;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.3.4.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">decide on the design of the Clinical Trials, including the protocol governing the Clinical Trials;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref517692480"></a><a name="_Ref35435405"></a><a name="_Ref35437246"></a><font style="text-decoration:none;">6.3.4.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">decide on and revise and approve any revisions of the Research and Development Plan and the Development Budget (including in accordance with the mechanism described in Section 5.1 and any adjustments pursuant to Section 5.3.3 and 5.3.5), each of which shall require unanimous consent of the JSC except as expressly set forth in Section 6.4.9; </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.3.4.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">discuss any Intellectual Property Rights of a Third Party which may be relevant to Candidates and Products;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.3.4.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">oversee the Development of Manufacturing processes relating to the Candidates or Products, establishment of Manufacturing capacity, and endorse a strategy for Manufacturing Candidates and Product for both the Clinical Trials and planned Commercialization;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.3.4.8</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">review and discuss all preclinical data and data arising from Clinical Trials investigating the Candidate or Product in the Territory, including adverse events;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.3.4.9</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">review and discuss all preclinical data and data arising from Clinical Trials under the Fosun Agreement, including adverse events;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.3.4.10</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;"> form such other Committees and sub-committees as the JSC may deem appropriate within its area of responsibility, such as a Joint Development Committee and the like, </font><font style="font-style:italic;text-decoration:none;">provided </font><font style="text-decoration:none;">that</font><font style="font-style:italic;text-decoration:none;"> </font><font style="text-decoration:none;">the JSC may, with unanimous consent, delegate decision-making authority (that is within the JSC's own authority) relevant to such committee&#8217;s and sub-committee&#8217;s area of expertise only;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.3.4.11</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;"> address such other matters relating to the activities of the Parties under the Research and Development Plan as either Party may bring before the JSC, including any matters that are expressly for the JSC to decide as provided in this Agreement; </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref36299038"></a><font style="text-decoration:none;">6.3.4.12</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;"> review and discuss any proposals by either Party relating to permitting a Third Party to perform research involving the Product;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.3.4.13</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;"> agree on a Development Budget, as well as any amendments to such budgets, provided that the Development Budget and any amendments to it shall require unanimous consent of the JSC;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.3.4.14</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;"> discuss, collaborate on and oversee any applications for Regulatory Approvals in respect of the Candidates and Products, both within and outside the Territory; </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref36408426"></a><font style="text-decoration:none;">6.3.4.15</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;"> discuss, collaborate on and agree on mutations pursuant to Section 5.3.2 or any label extension pursuant to Section 5.3.3, each of which must be agreed by unanimous consent of the JSC; and</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.3.4.16</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">attempt to resolve any disputes between the Parties with respect to (a) the performance of activities under the Research and Development Plan on an informal basis or (b) matters before the Patent Committee, in each case subject to Section 6.5.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref220999343"></a><font style="text-decoration:none;">6.3.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Limits on JSC Authority</font><font style="text-decoration:none;">. Notwithstanding any provision of this Section 6 to the contrary, (a) each Party will retain the rights, powers and discretion granted to it under this Agreement and no such rights, powers, or discretion will be delegated to or vested in the JSC unless such delegation or vesting of rights is expressly provided for in this Agreement or the Parties expressly so agree in writing, (b) except with respect to modifications to the Research and Development Plan permitted as set forth in Section 6.3.4.5, the JSC will not have the power to amend this Agreement or otherwise modify or waive compliance with this Agreement in any manner and (c) neither Party will require the other Party to (i)&#160;breach any obligation or agreement that such other Party may have with or to a Third Party to the extent such obligation or agreement existed prior to the Effective Date or (ii)&#160;perform any activities that are materially different or </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">greater in scope or more costly than those provided for in the Research and Development Plan then in effect.</font><font style="text-decoration:none;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref50560844"></a><font style="text-decoration:none;">6.3.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">JSC Term</font><font style="text-decoration:none;">. The JSC may be dissolved upon mutual agreement between the Parties.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256073"></a><a name="_Toc59107100"></a><a name="_Ref43819534"></a><font style="text-decoration:none;">6.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Other Committees</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref43485985"></a><a name="_Ref58588835"></a><a name="_Ref58583066"></a><font style="text-decoration:none;">6.4.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Joint Commercialization Committee</font><font style="text-decoration:none;">. The Parties shall establish a Joint Commercialization Committee (the &#8220;</font><font style="text-decoration:underline;">JCC</font><font style="text-decoration:none;">&#8221;) to (a) develop and oversee strategies on a global level for the Commercialization of the Product in the Territory, including reviewing and overseeing Packaging and Labeling and establishing global pricing guidelines, and marketing and patient access programs and strategies for the Product, (b) establish and oversee the implementation of a Global Commercialization Plan and, if the JCC so elects, review and oversee any Annual Regional Commercialization Plans in accordance with Section 9.1.1, and oversee the Commercialization Activities under the collaboration, in each case ((a) and (b)), on a global and, as applicable, on a Commercialization Region basis, and (c) establish and, if appropriate, amend guidance for the appropriate Packaging Configuration that may be used by either Commercialization Party, </font><font style="font-style:italic;text-decoration:none;">provided </font><font style="text-decoration:none;">that the Parties acknowledge and agree that [***]. The JCC shall be composed of [***] senior executives of each Party; </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that the total number of representatives may be changed upon mutual agreement of the Parties (so long as each Party has an equal number of representatives). One representative of each party on the JCC shall be designated by such Party to be a co-chairperson of the JCC. As part of its responsibilities, but subject to the decision making processes at Section 6.5.4 in the event agreement cannot be reached, the JCC shall also perform the following:</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref58588857"></a><a name="_Ref59037503"></a><a name="_Ref62211560"></a><a name="_Ref59046361"></a><font style="text-decoration:none;">6.4.1.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Within each annual planning cycle, the JCC shall discuss and seek to agree on the forward-looking Gross Profit budget for the following year to be set forth in the applicable Global Commercialization Plan by reference to the following year&#8217;s profit and loss forecast [***]. Relevant items for such review and discussion shall include: [***]. <a name="_Ref59046361"></a>Each Party shall promptly notify the JCC if it becomes aware that there is a deviation in the immediately preceding Pfizer Quarter of more than [***] of the actual Gross Profit as compared against the budget for the Gross Profit in the profit and loss forecasts pursuant to the above (a &#8220;</font><font style="text-decoration:underline;">Budget Deviation</font><font style="text-decoration:none;">&#8221;) and specify the reason for such Budget Deviation. Following such Budget Deviation notice, the JCC shall discuss the reasons for such deviation on a Relevant Line Item by Relevant Line Item basis and seek to agree on any potential measures to be taken to address and improve the situation. In addition, from [***] onwards, the Parties shall review, each Pfizer Quarter, the profit and loss statement compared to the Gross Profit level pursuant to (i) and (ii) above for such Pfizer Quarter and such year-to-date against the equivalent Pfizer Quarter in the previous year and the equivalent year-to-date period in the previous year.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref62145021"></a><a name="_Ref62472169"></a><font style="text-decoration:none;">6.4.1.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">The JCC shall review, discuss and agree by mutual consent all aspects relating to Product Components in any market or region, including [***].</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref43486025"></a><a name="_Ref44671743"></a><font style="text-decoration:none;">6.4.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Regional Commercialization Committee(s)</font><font style="text-decoration:none;">. The JCC may elect, at its discretion, to establish individual regional commercialization committees for the following regions located within a Party's Commercialization Territory (or such regions as may be amended by Pfizer from time to time): [***], (each a &#8220;</font><font style="text-decoration:underline;">Commercialization Region</font><font style="text-decoration:none;">&#8221;) in the Territory (each an &#8220;</font><font style="text-decoration:underline;">RCC</font><font style="text-decoration:none;">&#8221;), </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that </font><font style="text-decoration:none;">[***]</font><font style="text-decoration:none;">.</font><font style="text-decoration:none;"> </font><font style="text-decoration:none;">Each RCC will oversee and monitor the activities of the applicable Commercializing Party for such Commercialization Region. Each RCC will review the Annual Regional Commercialization Plan for the Commercialization Region for which such RCC is responsible, </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that</font><font style="text-decoration:none;"> </font><font style="text-decoration:none;">[***]</font><font style="text-decoration:none;">. To the extent an RCC is not established for a Commercialization Region (i) within the Pfizer Commercialization Territory, Pfizer shall establish its own Commercialization plan for such Commercialization Region, or (ii) within the </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Commercialization Territory, </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> shall establish its own Commercialization Plan for such Commercialization Region, </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that in each case of (i) and (ii), any such Commercialization Plan must </font><font style="text-decoration:none;">not be inconsistent</font><font style="text-decoration:none;"> with the global positioning and the Global Commercialization Plan agreed in the JCC</font><font style="text-decoration:none;"> or pursuant to Section </font><font style="text-decoration:none;">6.5.4</font><font style="text-decoration:none;">. Each RCC shall be composed of </font><font style="text-decoration:none;">[***]</font><font style="text-decoration:none;"> representatives from each Party. One of the Pfizer representatives on each RCC established for Commercialization Regions within the Pfizer Commercialization Territory shall be designated by Pfizer to be the chairperson of such RCC and one of the </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> representatives of each RCC established for the Commercialization Regions within the </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Commercialization Territory shall be designated by </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> to be the chairperson of such RCC; </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that for any RCC established for a Commercialization Region that incorporates countries in both the </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Commercialization Territory and the Pfizer Commercialization Territory, the chairperson of such RCC shall be designated by the Party having more countries in its Commercialization Territory in such Commercialization Region unless the JCC elects to establish two RCC's for such Commercialization Region where each such RCC only has responsibility for countries with in either the </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Commercialization Territory or the Pfizer Commercialization Territory, but not both.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref43486095"></a><font style="text-decoration:none;">6.4.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Joint Finance Committee</font><font style="text-decoration:none;">. The Parties shall establish a Joint Finance Committee (the &#8220;</font><font style="text-decoration:underline;">JFC</font><font style="text-decoration:none;">&#8221;) to work with the other Committees to assist in financial, forecasting, budgeting and planning matters as required, including (a) assisting the JCC and the Joint Manufacturing Committee established pursuant to this Agreement in developing the long-range forecast for commercial supply of the Products; (b) recommending and approving procedures, formats and timelines consistent with this Agreement for reporting pursuant to Sections&#160;4.9 and 4.10 financial data and assist in resolving differences that relate to the financial terms of this Agreement; provided that no Party shall be required to make any material changes to its internal accounting and reporting systems and standards; (c) reviewing calculations of the amount of any payments to be made by the Parties (or their Affiliates) hereunder, reviewing the reconciliation of payments; (d) coordinating audits of financial data where appropriate and required or allowed by this Agreement; and (e) establishing the inter-party procedures, contracts (if necessary), and financial structure necessary to effect that economic result contemplated by this Agreement and monitoring and maintaining such structure. Furthermore, the JFC shall establish reporting procedures for the sharing of information reasonably required by the other Party for its financial reporting. Such reporting shall as a minimum include reasonable detail with respect to [***]. The JFC shall be composed of [***] representatives from each Party, wherein one representative has expertise on research and development matters and the other on commercial matters, </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that the total number of representatives may be changed upon mutual agreement of the Parties (so long as each Party has an equal number of representatives).</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref43486161"></a><a name="_Hlk62831017"></a><font style="text-decoration:none;">6.4.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Joint Manufacturing Committee</font><font style="text-decoration:none;">. The Parties shall establish a Joint Manufacturing Committee (the &#8220;</font><font style="text-decoration:underline;">JMC</font><font style="text-decoration:none;">&#8221;) to plan, decide on, develop, amend, revise and oversee the execution of the Manufacturing Plan, to help the Parties establish adequate Manufacturing </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">facilities, capacity and capability for the Product</font><font style="text-decoration:none;">, to </font><font style="text-decoration:none;">address such other matters relating to the activities of the Parties under the </font><font style="text-decoration:none;">Manufacturing</font><font style="text-decoration:none;"> Plan as either Party may bring before</font><font style="text-decoration:none;"> it and, subject to Section </font><font style="text-decoration:none;">6.5</font><font style="text-decoration:none;">, to </font><font style="text-decoration:none;">attempt to resolve any disputes between the Parties with respect to the performance of activities under the </font><font style="text-decoration:none;">Manufacturing</font><font style="text-decoration:none;"> Plan on an informal basis. </font><font style="text-decoration:none;">The JMC</font><font style="text-decoration:none;"> </font><font style="text-decoration:none;">shall agree and decide on an initial Manufacturing Plan within </font><font style="text-decoration:none;">[***]</font><font style="text-decoration:none;"> of the Amendment Signing Date.</font><font style="text-decoration:none;"> </font><font style="text-decoration:none;">The JMC shall work with the JCC and the JFC in respect of Manufacturing activities. The JMC shall be composed of </font><font style="text-decoration:none;">[***]</font><font style="text-decoration:none;"> from each Party, provided that the total number of representatives may be changed upon mutual agreement of the Parties (so long as each Party has an equal number of representatives).</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref43486198"></a><font style="text-decoration:none;">6.4.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Compliance Committee</font><font style="text-decoration:none;">. Pfizer and BioNTech agree to establish a Compliance Committee (the &#8220;</font><font style="text-decoration:underline;">Compliance Committee</font><font style="text-decoration:none;">&#8221;) promptly after the Amendment Signing Date. The Compliance Committee shall be comprised of [***] from each Party or such other number as may be mutually agreed by the Parties, provided that each Party at all times shall have an equal number of representatives on the Compliance Committee. The Compliance Committee shall report to the JCC. Subject to the terms and conditions of this Agreement, the Compliance Committee shall have overall responsibility for resolving discrepancies between the Parties&#8217; respective compliance policies; managing compliance with corporate integrity agreements and deferred prosecution agreements (or similar agreements/settlement documents) to which either of the Parties are subject; and ensuring a process to monitor the Parties&#8217; activities under this Agreement for compliance with all applicable Laws relating to healthcare and all Anti-Corruption Laws.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.4.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Committee Membership &#8211; General</font><font style="text-decoration:none;">. Each Party will ensure that the members appointed by it to serve on any Committee, including the JSC or JCC, have, as applicable: (a) the appropriate level of seniority and decision-making authority commensurate with the responsibilities of the Committee to which they are appointed; and (b) a range of expertise, as applicable, in the Commercialization of pharmaceutical or vaccine products to enable an efficient cross-functional Committee structure. If any Committee member becomes unwilling or unable to fulfil his or her duties hereunder, then the Party that appointed such member will promptly appoint a replacement by written notice to the other Party. Further, each Party may replace any of its designated Committee representatives at any time on written notice to the other Party. The chairperson or co-chairpersons, as applicable, of each Committee will be responsible for calling meetings, preparing and circulating an agenda in advance of each meeting of such Committee; provided that the Committee chairperson(s) will call a meeting of the applicable Committee promptly upon the written request of the most senior representative from the other Party serving on such Committee to convene such a meeting.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.4.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Secretary; Minutes</font><font style="text-decoration:none;">. Each Committee will have a secretary (who need not be a voting member of such Committee), which will alternate yearly between the Parties. The hosting Party&#8217;s secretary (or designee) for a given Committee will be responsible for preparing reasonably detailed written minutes of all meetings of such Committee that reflect, without limitation, material decisions made, action items identified and unresolved matters discussed at such meetings. The initial draft of the meeting minutes for a given Committee meeting, reflecting key decisions, action items and unresolved matter, among other details, will be completed by the end of such meeting and circulated to the Committee&#8217;s members for subsequent review and approval.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.4.8</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Meetings</font><font style="text-decoration:none;">.</font><font style="text-decoration:none;"> Each Committee will meet at such times as it elects to do so; </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that the JCC and each RCC will meet at least once every </font><font style="text-decoration:none;">[***]</font><font style="text-decoration:none;">, via teleconference or videoconference or otherwise (with at least </font><font style="text-decoration:none;">[***]</font><font style="text-decoration:none;"> per calendar year being in person if feasible), or as otherwise agreed by the JCC or the relevant RCC, as applicable. Additionally, either Party may call a meeting of the JCC or any RCC at any time; provided that the requesting Party provides at least </font><font style="text-decoration:none;">[***]</font><font style="text-decoration:none;"> prior written notice to the chair of such Committee and such notice includes a proposed agenda for such meeting. Any and each subcommittee established hereunder will establish a meeting frequency and meeting protocol necessary to coordinate and conduct the activities for which it is responsible, as mutually agreed by the Parties. Any in-person meetings of the JCC and any RCC will be held on an alternating basis between a location designated by </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> and Pfizer, unless otherwise agreed by the Parties. Each Party will be solely responsible for its own expenses relating to attending and participating in all Committee meetings. As appropriate, other employee representatives of the Parties may attend such meetings as non-voting participants, but no Third Party personnel may attend unless otherwise agreed by each of the Parties. All Committee meetings will be conducted in English, and all documents (including all Committee meeting minutes and Annual Regional Commercialization Plans) will be in English.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref46773553"></a><font style="text-decoration:none;">6.4.9</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Reporting</font><font style="text-decoration:none;">. Each Commercializing Party will keep the JCC or applicable RCC informed of progress and results of the Commercialization Activities and Medical Activities for which such Commercializing Party is responsible through its members on such Committee at each regularly scheduled meeting thereof and as otherwise provided herein.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.4.10</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">No Authority to Amend or Modify</font><font style="text-decoration:none;">. Notwithstanding anything herein to the contrary, no Committee will have any authority to amend, modify or waive compliance with this Agreement or any Related Agreement. Subject to Section&#160;17.6, the Parties agree to periodically review the operation of the JCC and the provisions of Article 9 and mutually agree any changes which are considered necessary or appropriate in light of prevailing circumstances and to ensure the Agreement, its operation and that of the JCC continues to comply with applicable Laws</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref58495666"></a><a name="_Toc62256074"></a><a name="_Toc59107101"></a><a name="_Ref46910334"></a><font style="text-decoration:none;">6.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Committee Decision-Making</font><font style="text-decoration:none;">.</font><font style="text-decoration:underline;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref46501966"></a><font style="text-decoration:none;">6.5.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Consensus Decision Making</font><font style="font-style:italic;text-decoration:none;">.</font><font style="text-decoration:none;"> Each Party shall procure that its respective Committee members shall act reasonably and in good faith to take action by unanimous consent of the Parties, with each Party having a single vote, irrespective of the number of Committee representatives actually in attendance, </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that at least [***] from each Party is in attendance at any meeting in which a decision is made.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref46761296"></a><font style="text-decoration:none;">6.5.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Joint Steering Committee Deadlocks</font><font style="text-decoration:none;">. If, despite good faith efforts, the JSC is unable to reach unanimous agreement on a particular matter, within [***] after the JSC first meets to consider such matter, or such later date as may be mutually acceptable to the Parties (each such matter, a &#8220;</font><font style="text-decoration:underline;">Disputed Matter</font><font style="text-decoration:none;">&#8221;), then: </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.5.2.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">[***]; and </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.5.2.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">[***]; and </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.5.2.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">[***].</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:9.09%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Parties agree that the JSC will further refine the details of the decision-making rights and processes in accordance with <font style="text-decoration:underline;">Schedule 6.5.2</font> and the terms of this Agreement.</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.5.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Regional Commercialization Committees Deadlocks</font><font style="text-decoration:none;">. All deadlocks arising in any RCC will be referred to the JCC for resolution and the JCC shall attempt to resolve such matter within ten (10) Business Days of the matter being referred to it.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref43486418"></a><font style="text-decoration:none;">6.5.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Joint Commercialization Committee Deadlocks</font><font style="text-decoration:none;">. Either Party may elect to refer a deadlock arising in the JCC (including deadlocks referred to it by the RCC) to [***]. If [***] are not able to resolve the dispute, then:</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.5.4.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">[***];</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.5.4.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">[***]; and </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.5.4.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">[***],</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;">provided<font style="font-style:normal;"> that [***].</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref46936505"></a><font style="text-decoration:none;">6.5.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Joint Manufacturing Committee Deadlocks</font><font style="text-decoration:none;">. All deadlocks arising from the JMC will be referred to the Parties' respective [***] for resolution and such respective [***] shall use good faith efforts to discuss and resolve such deadlock within [***] of the matter being referred to them. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref52995362"></a><font style="text-decoration:none;">6.5.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Other Deadlocks</font><font style="text-decoration:none;">. All deadlocks arising from any other Committee described in Section 6.4 shall be referred to the JSC or JCC, depending on whether the issue subject to the deadlock is primarily related to Research and Development or Commercialization, for resolution and the JSC or JCC, as applicable, shall attempt to resolve such matter within [***] of the matter being referred to it, </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that the JSC or JCC, as applicable, may elect to consult with members of the other Committee (that is, the JCC or JSC, as applicable), or include such members in decision-making, where such matter is related to the expertise of such other Committee or its members.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.5.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Dispute Resolution</font><font style="text-decoration:none;">. For the avoidance of doubt Section 6.5 concerns resolution of any committee deadlocks relating to operational matters to be determined by the applicable committee, and any other dispute or deadlock, including any dispute as to questions of contractual interpretation under this Agreement, shall only be determined and resolved pursuant to Section 17.11.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;">7.</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-transform:none;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref35946508"></a><a name="_Ref36052567"></a><a name="_Ref46928535"></a><a name="_Ref46928695"></a><a name="_Ref59043286"></a><a name="_Toc62256075"></a><a name="_Toc59107102"></a><a name="_Ref516585039"></a><a name="_Toc484765950"></a><a name="_Toc484766016"></a><a name="_Toc484766082"></a><a name="_Toc484766506"></a><font style="text-decoration:none;"></font><font style="text-decoration:underline;text-transform:uppercase;">Manufacturing</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc519764401"></a><a name="_Toc519873397"></a><a name="_Toc35600548"></a><a name="_Toc62256076"></a><a name="_Toc59107103"></a><a name="_Ref36761110"></a><a name="_Ref516667488"></a><font style="text-decoration:none;">7.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Development of Manufacture Process</font><font style="text-decoration:none;">. BioNTech and Pfizer shall jointly Develop a scalable process for Manufacture of Candidates and Products in the Field in the Territory in accordance with the binding parts of the Research and Development Plan and the Manufacturing Plan.</font><font style="text-decoration:underline;"><a name="_Ref516667488"></a> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref519680106"></a><a name="_Toc519764402"></a><a name="_Toc519873398"></a><a name="_Toc35600549"></a><a name="_Toc62256077"></a><a name="_Toc59107104"></a><a name="_Ref37013993"></a><a name="_Ref516584404"></a><a name="_Ref516585271"></a><font style="text-decoration:none;">7.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;"><a name="_Ref516584404"></a><a name="_Ref516585271"></a>Manufacture of Candidates Products</font><font style="text-decoration:none;">. Each Party will use Commercially Reasonable Efforts to perform its obligations and activities identified under the binding parts of the Manufacturing Plan or as allocated to it by the JSC, or the JMC, once established, in a professional manner in accordance with any target dates set forth in the Manufacturing Plan. Further, each Party will perform its obligations under the binding parts of the Manufacturing Plan or as allocated to it by the JSC or the JMC, once established, in compliance with all Laws applicable to its activities under the Manufacturing Plan. Pfizer and BioNTech </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">will collaborate in the build-up of Manufacturing capacity for the Manufacturing of Candidates and Products for clinical and commercial purposes in accordance with the binding parts of the Manufacturing Plan and the terms and conditions set forth in this Section&#160;</font><font style="text-decoration:none;">7</font><font style="text-decoration:none;">. The Manufacturing Plan may be modified by unanimous consent of the JSC or the JMC, once established, pursuant to Section&#160;</font><font style="text-decoration:none;">6</font><font style="text-decoration:none;">. Unless otherwise agreed in the Manufacturing Plan, at a minimum Pfizer will be responsible for the build-up of its Manufacturing site(s) in the USA for quantities of Product to be agreed as part of the Manufacturing Plan and the commercial supply agreement for such site, and at a minimum </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> will be responsible for the extension of its Manufacturing sites in Mainz and </font><font style="text-decoration:none;">Idar</font><font style="text-decoration:none;">-Oberstein for quantities of Product to be agreed as part of the Manufacturing Plan and the commercial supply agreement for such sites. </font><font style="text-decoration:none;">[***]</font><font style="text-decoration:none;"> The Manufacturing Plan may also consider one or both Parties engaging Third Party contract manufacturing organizations as a source of Manufacturing. In addition, promptly after the Effective Date, the Parties will agree on a technology transfer plan and continue to perform the technology transfer that the Parties have already started prior to the Effective Date to enable Manufacturing by Pfizer. For the avoidance of doubt, to the extent the technology transferred under this Agreement is identical to the technology to be transferred pursuant to the Flu Collaboration License, the Parties shall cooperate to minimize any duplication of technology transfer efforts under the Flu Collaboration License that unreasonably would be duplicative, wasteful or unnecessary.</font><font style="text-decoration:none;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256078"></a><a name="_Toc59107105"></a><a name="_Ref44600749"></a><font style="text-decoration:none;">7.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Quality Requirements</font><font style="text-decoration:none;">. Each Party that undertakes or subcontracts any Manufacturing activities in respect of the Candidates or Products, whether for the purposes of this Agreement, the Clinical Trials or pursuant to the commercial supply agreements shall ensure (a) that all Manufacturing activities are undertaken in accordance with (i) applicable cGMP standards, applicable Laws, and other regulatory and manufacturing good practice (including record and sample keeping, deviation reporting, testing and quality requirements and post-marketing regulatory guidelines from the FDA and the EMA); (ii) the requirements of the applicable quality agreement; and (iii) the requirements of the applicable supply agreement entered into pursuant to Section&#160;7.4, and (b) that such Product manufactured by it is (i) in conformance with the specifications therefor in effect at the time of shipment by such Party to the other Party or to any Third Party distributor or customer, such that the Product is not, at the time of shipment from such Party to the other Party or to any distributors or customers in the Territory, adulterated or misbranded within the meaning of the FD&amp;C Act or any analogous applicable Law outside of the United States; and (ii) in conformance, at such time of shipment by such Party, in all material respects with the certificates of analysis accompanying such Product when shipped.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256079"></a><a name="_Toc59107106"></a><a name="_Ref37023723"></a><font style="text-decoration:none;">7.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Manufacturing Agreements</font><font style="text-decoration:none;">.</font><font style="text-decoration:underline;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref37115567"></a><font style="text-decoration:none;">7.4.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Clinical Supply</font><font style="text-decoration:none;">. Within [***] following the Effective Date, the Parties shall enter into an agreement for clinical supply, as required to ensure the Clinical Trials planned can proceed on the timelines set forth in the binding parts of the Research and Development Plan. All clinical supply of Candidates and Products shall be charged as Shared Development Costs at the Manufacturing Costs. In addition, the Parties have agreed on quality agreements with respect to such clinical supply agreement.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref37115569"></a><font style="text-decoration:none;">7.4.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Commercial Supply</font><font style="text-decoration:none;">. Furthermore, the Parties will negotiate in good faith and mutually agree on one or more commercial supply agreement(s) and quality agreement(s) simultaneously with the negotiation of the Commercialization Terms. The commercial supply agreement(s) shall be in accordance with the following commercial terms:</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">7.4.2.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">The Manufacturing Party shall be entitled to charge (i) the Transfer Price for each batch of Product delivered in accordance with the relevant commercial supply agreement, or (ii) where intermediates, drug substance or bulk drug product is supplied for Manufacturing the Product, the Manufacturing Costs (as further defined in Section 1.93) for any such intermediates, drug substance or bulk drug product, but in each case of (i) and (ii), all supplies shall be made by the Manufacturing Party on a buy/sell model. Such Transfer Price (or Manufacturing Cost) shall be invoiced by the Manufacturing Party upon delivery of the Products and shall be payable by the other Party within [***] from receipt of such invoice.  </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">7.4.2.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">The Transfer Price (or Manufacturing Cost) shall be adjusted on a yearly basis for all commercial supply agreements in accordance with relevant cost developments.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref58970118"></a><a name="_Hlk59037212"></a><font style="text-decoration:none;">7.4.2.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">The Parties will work together, subject to and observing applicable Laws, and agree the volumes of Product Materials to be purchased from Third Party suppliers for the purposes of this Agreement and to [***] of either Party to source the other Party's requirements for such Product Materials for its Manufacturing activities pursuant to this Agreement, which sourced Product Materials shall then be sold, at cost, to that other Party [***]. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref62224047"></a><a name="_Ref59054969"></a><font style="text-decoration:none;">7.4.2.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">[***].  </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref47449174"></a><font style="text-decoration:none;">7.4.2.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">The Parties will cooperate and use Commercially Reasonable Efforts to manufacture or cause to be manufactured and continuously supply the Product for distribution and use in the Field by customers and patients in the Territory. The JCC shall determine, by mutual consent, the allocation of supplies of Product in the Territory on a fair and equitable basis, subject also to any applicable Law, export controls, any government supply obligations, supply obligations included in any Third Party Funder agreements, supply obligations pursuant to advance purchase agreements, including agreements with any Governmental Authority, as well as supplies reasonably required by BioNTech for product identical to the Product in the Fosun Territory; </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;">, </font><font style="font-style:italic;text-decoration:none;">however</font><font style="text-decoration:none;">, that the allocation of supplies required for the purposes of this Agreement shall take precedence over supplies for other uses, which priority shall be the primary consideration for such determination. Notwithstanding the foregoing, neither Party will have liability to the other Party by virtue of any shortage or allocation.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">7.4.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">The supply agreements to be entered into between the Parties pursuant to Sections 7.4.1 and 7.4.2 shall include appropriate accounting mechanisms to allow for true-up payments in respect of (i) Manufacturing Costs, including to account for any mark up on the Manufacturing Costs of Product Materials where permitted in the definition of Manufacturing Costs or costs paid to Third Party manufacturers for the manufacture and supply of Candidates or Products or components thereof, and (ii) Manufacturing Variances. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256080"></a><a name="_Toc59107107"></a><a name="_Ref56421479"></a><font style="text-decoration:none;">7.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Allocation of Responsibilities</font><font style="text-decoration:none;">. Section </font><font style="text-decoration:none;">5.3.1</font><font style="text-decoration:none;"> and Sections </font><font style="text-decoration:none;">5.3.4</font><font style="text-decoration:none;"> to </font><font style="text-decoration:none;">5.3.6</font><font style="text-decoration:none;"> shall apply </font><font style="font-style:italic;text-decoration:none;">mutatis mutandis</font><font style="text-decoration:none;"> in respect of each Party's responsibilities under the Manufacturing Plan</font><font style="text-decoration:none;">.</font><font style="text-decoration:none;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref58516064"></a><a name="_Toc62256081"></a><a name="_Toc59107108"></a><font style="text-decoration:none;">7.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Quality Audits</font><font style="text-decoration:none;">. The Parties shall negotiate in good faith and mutually agree on appropriate and customary audit rights of the other Party and any relevant Third Party contractor of such Party with respect to manufacturing quality matters in the commercial supply agreement(s) or quality agreement(s). </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;">8.</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-transform:none;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc62256082"></a><a name="_Toc59107109"></a><a name="_Ref36046796"></a><a name="_Ref36742703"></a><a name="_Ref37021753"></a><a name="_Ref37024803"></a><a name="_Ref37024823"></a><a name="_Ref43642899"></a><a name="_Ref43656611"></a><a name="_Ref43656651"></a><a name="_Hlk35512845"></a><a name="_Ref36996199"></a><a name="_Ref36050274"></a><a name="_Ref35520176"></a><font style="text-decoration:none;"></font><font style="text-decoration:underline;text-transform:uppercase;"><a name="_Ref36996199"></a><a name="_Ref36050274"></a><a name="_Ref35520176"></a>Development, Regulatory and Pharmacovigilance</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256083"></a><a name="_Toc59107110"></a><a name="_Ref37115415"></a><font style="text-decoration:none;">8.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Development Matters</font><font style="text-decoration:none;">.</font><font style="text-decoration:underline;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref37236050"></a><a name="_Ref37114806"></a><font style="text-decoration:none;">8.1.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Allocation of Development and Regulatory Responsibility</font><font style="text-decoration:none;">. The Development of Candidates and Products shall be conducted by the Parties, under the direction and oversight of the JSC (and, as applicable, the Joint Development Committee), in accordance with the applicable Research and Development Plan and Development Budget. Pursuant to the initial Research and Development Plan, the Parties shall identify a strategy for Development of the Candidates and Products in the Territory that identifies the Party that is leading the clinical Development of the Candidates or Products in a country in the Territory (the &#8220;</font><font style="text-decoration:underline;">Lead Development Party</font><font style="text-decoration:none;">&#8221;). Notwithstanding the foregoing, the Parties have agreed that (a) Pfizer shall lead the clinical aspects of Development of Candidates and Products in the USA, and (b) BioNTech shall lead the clinical aspects of Development of Candidates and Products in the EU. BioNTech shall be the sponsor and IND/CTA holder for all Clinical Trials in the Territory, in each case, subject to a mutually agreeable strategy with respect to the Development of Candidates and Products. For any Clinical Trial for which Pfizer is the Lead Development Party (but is not the sponsor of such Clinical Trials), BioNTech shall have delegated to Pfizer operational and day-to-day Development activities, decision-making authority and responsibility for such Clinical Trial, including those activities described in </font><font style="text-decoration:underline;">Schedule 8.1.1</font><font style="text-decoration:none;">, subject to a protocol approved by unanimous consent by the JSC. For avoidance of doubt, the Lead Development Party shall conduct its Development activities in collaboration with and with active review of the other Party. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref62386147"></a><font style="text-decoration:none;">8.1.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Appointment of Lead Development Party for Future Clinical Trials</font><font style="text-decoration:none;">. At any time during the Term, the JSC may determine by mutual consent that additional clinical Development of the Candidate and Product are warranted and, in such event, unless otherwise agreed by the JSC, (a) Pfizer shall be the Lead Development Party for each additional Clinical Trial in the USA, (b) BioNTech shall be the Lead Development Party for each additional Clinical Trial in the EU and (c) the JSC shall mutually agree on the appointment of one of the Parties to be the Lead Development Party for each additional Clinical Trial on a Clinical Trial-by-Clinical Trial basis in a country or region in the Territory other than the USA and EU (&#8220;</font><font style="text-decoration:underline;">ROW</font><font style="text-decoration:none;">&#8221;), and subject to the mutually agreed upon strategy. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">8.1.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Clinical Trials</font><font style="text-decoration:none;">. In respect of Clinical Trials for the Candidates or Products pursuant to this Agreement, the following shall apply:</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">8.1.3.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-style:italic;text-decoration:none;">GxP Standards</font><font style="text-decoration:none;">. Subject to Section 8.1.3.8, BioNTech as the sponsor for any Clinical Trial in respect of any Candidate or Product pursuant to this Agreement shall ensure the Clinical Trial is conducted in accordance with GxP and all applicable Laws, and will provide to the other Party any significant GxP or non-compliance issues relating to the protocol for such Clinical Trial, which arise or may be identified through monitoring, </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">8.1.3.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-style:italic;text-decoration:none;">Monitoring Plans</font><font style="text-decoration:none;">. A high-level strategy for monitoring Clinical Trials in respect of any Candidate or Product pursuant to this Agreement will be agreed by the JSC within </font><font style="text-decoration:none;">[***]</font><font style="text-decoration:none;"> following the Effective Date. The Lead Development Party of the Clinical Trial will notify the other Party if there are any amendments required to such monitoring plan, and provide such other Party with an opportunity to review and comment on any such amendments, and any amendments shall only be made following approval by the JSC.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">8.1.3.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-style:italic;text-decoration:none;">Sponsor Oversight Plan. </font><font style="text-decoration:none;">The Parties shall mutually agree on a sponsor oversight plan to set forth the accountabilities and oversight of all Clinical Trials conducted by the Lead Development Party, consistent with that certain GCP Quality Agreement, dated December 10, 2020, including Appendix D, Roles and Responsibilities.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">8.1.3.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-style:italic;text-decoration:none;">IRB/IEC Approval</font><font style="text-decoration:none;">. BioNTech as the sponsor and Regulatory Approval holder of the Clinical Trials shall ensure that the Clinical Trial is approved by and subject to continuing oversight by an appropriate Institutional Review Board (IRB) or Independent Ethics Committee (IEC), except that BioNTech shall delegate this responsibility to Pfizer for any Clinical Trial for which Pfizer is the Lead Development Party. The Lead Development Party shall provide documentation of both the initial IRB/IEC approval of the final protocol to the other Party and annual renewals of that approval if such renewals are required. To the extent a Party receives notice of any withdrawal or suspension of IRB/IEC approval during the Term, it will promptly inform the other Party. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">8.1.3.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-style:italic;text-decoration:none;">Informed Consent</font><font style="text-decoration:none;">. BioNTech as the sponsor and Regulatory Approval holder for each applicable Clinical Trial will obtain informed consent for each Clinical Trial subject in accordance with the applicable informed consent document and applicable Law and will inform and obtain express consent from each Clinical Trial subject that the data, including Personal Data, arising from such Clinical Trial may be used in accordance with the terms of this Agreement (including its export from the European Union and its processing by Pfizer or other Third Parties in accordance with the terms of this Agreement and Law), provided however, that BioNTech shall delegate this responsibility to Pfizer for those Clinical Trials for which Pfizer is the Lead Development Party. Notwithstanding the foregoing, the Lead Development Party will share the informed consent document with the other Party for such other Party&#8217;s review and comment prior to its use in a Clinical Trial in a country in the Territory.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">8.1.3.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-style:italic;text-decoration:none;">Sponsorship</font><font style="text-decoration:none;">. Where the Lead Development Party (or its Affiliate or designee) is not the sponsor of a Clinical Trial or Regulatory Approval holder, such Lead Development Party shall not represent to any Third Party, including any Clinical Trial subjects, that the Lead Development Party or its Affiliates are a sponsor.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">8.1.3.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-style:italic;text-decoration:none;">Reporting</font><font style="text-decoration:none;">. BioNTech is solely responsible for any and all safety reporting and regulatory obligations associated with the conduct of the Clinical Trial for which it is the sponsor, including, but not limited to, obtaining and maintaining Regulatory Approvals for the conduct of the Clinical Trials, provided, however, that BioNTech shall delegate the safety reporting and regulatory obligations associated with the conduct of each Clinical Trial in the Territory to Pfizer subject to Section&#160;8.3.7.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref37236249"></a><font style="text-decoration:none;">8.1.3.8</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-style:italic;text-decoration:none;">Delegation</font><font style="text-decoration:none;">. Notwithstanding the responsibilities of </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> as IND/CTA holder or sponsor of Clinical Trials, where Pfizer is the Lead Development Party for a Clinical Trial Pfizer shall conduct its activities in compliance with </font><font style="text-decoration:none;">GxP</font><font style="text-decoration:none;"> and applicable Law with respect to each of the activities which have been delegated to Pfizer pursuant to </font><font style="text-decoration:underline;">Schedule</font><font style="text-decoration:underline;"> </font><font style="text-decoration:underline;">8.1.1</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref43283474"></a><a name="_Toc62256084"></a><a name="_Toc59107111"></a><font style="text-decoration:none;">8.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Regulatory Matters</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref37115147"></a><font style="text-decoration:none;">8.2.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Lead Regulatory Party</font><font style="text-decoration:none;">. The JSC shall agree on a strategy to allocate operational responsibility for regulatory activities relating to each Candidate or Product to one of the Parties (the &#8220;</font><font style="text-decoration:underline;">Lead Regulatory Party</font><font style="text-decoration:none;">&#8221;) which shall, as a default initial allocation, be by reference to the country or region where such Party is the Lead Development Party. The JSC&#8217;s initial allocation shall be that Lead Regulatory Party for regulatory activities relating to each Candidate or Product in the EU shall be BioNTech, and the Lead Regulatory Party for regulatory activities relating to each Candidate or Product in the USA shall be Pfizer. Subject to the JSC&#8217;s mutual consent to seek Regulatory Approval in one or more countries or regions in the ROW, Pfizer shall be the Lead Regulatory Party for regulatory activities relating to each Candidate or Product in such country or region in the ROW. If the JSC cannot agree on whether Regulatory Approval shall be sought for any country or region in the ROW, the Party that wishes to seek Regulatory Approval in such country or region shall be entitled to be the Lead Regulatory Party for regulatory activities relating to each Candidate or Product in such country or region and seek such Regulatory Approval at its own cost. The JSC may vary from the foregoing allocations by mutual consent. The other Party shall cooperate with the Lead Regulatory Party, at its reasonable request, with respect to any regulatory matters for which the Regulatory Approval holder is responsible or to whom regulatory matters have been delegated. Notwithstanding the foregoing, for matters relating to any Vaccine Technical Committee, Price Approval or reimbursement approval in a country, such matters shall be handled by the Party in whose Commercialization Territory such country is located irrespective of whether they are the Lead Regulatory Party. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref37115184"></a><a name="_Ref49784477"></a><a name="_Ref43295247"></a><font style="text-decoration:none;">8.2.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Regulatory Communications and Filings</font><font style="text-decoration:none;">. The Lead Regulatory Party shall use Commercially Reasonable Efforts to prosecute to grant and maintain all applications for Regulatory Approvals for the Product, including any supplements or amendments thereto and all Regulatory Approvals obtained therefrom. The Lead Regulatory Party shall make all filings with the Regulatory Authority that are necessary to maintain the Regulatory Approvals for the Product in good standing, including any regulatory reporting. In accordance with Section 8.2.1, each Party shall cooperate with the other Party with respect to any and all regulatory matters for which the other Party is responsible pursuant to this Agreement or the Research and Development Plan. Unless exigent action is required with respect to a given filing before a Regulatory Authority concerning a Candidate or Product, or a material communication with a Regulatory Authority concerning the same, the Lead Regulatory Party shall provide the other Party with copies of all filings relating to such Marketing Authorization Application prior to submission within a reasonable amount of time (but not less than [***]) to allow such Party to review and comment on such filings, and the Party submitting such filing shall consider all comments and proposed revisions from the other Party in good faith prior to submission. The Lead Regulatory Party shall consult with the other Party regarding, and keep the other Party informed of, the status of the preparation of all Marketing Authorization Applications and the prosecution or maintenance thereof, including any material communications that it receives with respect to the same. The Lead </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">Regulatory Party shall provide to the other Party copies of all final Marketing Authorization Applications and filings relating thereto that it submits</font><font style="text-decoration:none;"> within </font><font style="text-decoration:none;">[***]</font><font style="text-decoration:none;"> from filing (unless access to such </font><font style="text-decoration:none;">Marketing Authorization Applications </font><font style="text-decoration:none;">or filing is reasonably required earlier in which case the Lead Regulatory Party shall make such </font><font style="text-decoration:none;">Marketing Authorization Applications and filings</font><font style="text-decoration:none;"> available earlier than </font><font style="text-decoration:none;">[***]</font><font style="text-decoration:none;"> to the extent reasonably possible)</font><font style="text-decoration:none;">. The foregoing provisions of this Section </font><font style="text-decoration:none;">8.2.2</font><font style="text-decoration:none;"> shall also apply to material and substantive communications with Regulatory Authorities.</font><font style="text-decoration:none;"> Both Parties will cooperate with respect to any and all regulatory matters with respect to the Product, including the implementation of any of the foregoing in any country in the Territory. For the avoidance of doubt, where Pfizer is the Lead Regulatory Party, all filing, prosecution and maint</font><font style="text-decoration:none;">en</font><font style="text-decoration:none;">ance activities to be made by Pfizer under this Section </font><font style="text-decoration:none;">8.2.2</font><font style="text-decoration:none;"> shall be made in the name of </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> or its Affiliate</font><font style="text-decoration:none;">, unless otherwise agreed pursuant to Section </font><font style="text-decoration:none;">8.2.6</font><font style="text-decoration:none;">, and Pfizer shall submit </font><font style="text-decoration:none;">or make available </font><font style="text-decoration:none;">to </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> with</font><font style="text-decoration:none;">in </font><font style="text-decoration:none;">[***]</font><font style="text-decoration:none;"> </font><font style="text-decoration:none;">copies of all filings and other </font><font style="text-decoration:none;">material </font><font style="text-decoration:none;">correspondence submitted to any Regulatory Authority, Governmental Authority or Government Official worldwide in </font><font style="text-decoration:none;">BioNTech&#8217;s</font><font style="text-decoration:none;"> name or on </font><font style="text-decoration:none;">BioNTech&#8217;s</font><font style="text-decoration:none;"> behalf</font><font style="text-decoration:none;"> in connection with such Regulatory Approvals and applications therefor</font><font style="text-decoration:none;">.</font><font style="text-decoration:none;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">8.2.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Requests by Associations or Competitors</font><font style="text-decoration:none;">. The JCC shall, in good faith, seek to agree and align on the types of complaints, inquiries or other requests for information with respect to the Product from any trade or industry association or any competitor that may merit standard responses. Either Party shall use such standard responses in response to any such complaint, inquiry or request on which the JCC aligns. Furthermore, either Party will promptly notify the respective other Party if it or its Affiliates receive any complaint, inquiry or request, including situations for which such standard responses are not applicable or appropriate. If such standard responses are not sufficient, where such complaint, inquiry or request relates to or primarily impacts only one Party's Commercialization Territory, such Party will have control and discretion with respect to determining the appropriate response thereto, subject to applicable Law; </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;">, </font><font style="font-style:italic;text-decoration:none;">however</font><font style="text-decoration:none;">, that if any such complaint, inquiry or request (i) relates to the safety or efficacy of the Product, subject to the terms of the applicable Pharmacovigilance Agreement</font><font style="text-decoration:underline;">,</font><font style="text-decoration:none;"> the Party that is the applicable MA Holder will have control and discretion (having regard to the other Party's input and recommendations) with respect to determining the appropriate response thereto or (ii) relates to or impacts both Parties' Commercialization Territory, the Party in receipt of such complaint, inquiry or request shall refer it to the JCC and the JCC will have control and discretion with respect to determining the appropriate response thereto, subject to applicable Law. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">8.2.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Regulatory Meetings</font><font style="text-decoration:none;">. The Lead Regulatory Party shall consult with the other Party reasonably in advance of the date of any anticipated meeting with a Regulatory Authority relating to any Marketing Authorization Applications or Regulatory Approvals in respect of any Candidate or Product for which it is responsible and shall consider any timely and reasonable recommendations made by the other Party in preparation for such meeting. The Parties agree that the Lead Regulatory Party shall lead interactions with respect to countries or regions in the Territory for which such Party is the Lead Regulatory Party. Upon the request of the other Party, and to the extent legally permissible and not opposed by the relevant Regulatory Authority, the Lead Regulatory Party shall permit the other Party to attend any and all meetings with the applicable Regulatory Authority concerning the Candidate or Product. [***] </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">8.2.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Manufacturing Matters</font><font style="text-decoration:none;">. Where a Party is the Lead Regulatory Party and responsible for preparing and maintaining the filings for Regulatory Approval, the other Party shall </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">provide all reasonable assistance to the Lead Regulatory Party in such filings, including preparation of the CMC portions of the Common Technical Document in English and supporting ancillary cGMP documents and analytical data as required to meet specific regulatory filing and approval requirements. Each Party shall promptly provide the other with copies of material written correspondence as reasonably necessary to permit each Party to comply with its relevant regulatory obligations described in the Agreement or as otherwise reasonably requested.</font><font style="font-weight:bold;text-decoration:none;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref58971899"></a><a name="_Ref43294957"></a><font style="text-decoration:none;">8.2.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Ownership of Regulatory Filings, Regulatory Approvals and Pricing and Reimbursement Approvals</font><font style="text-decoration:none;">. The Parties shall discuss through the JSC which Party shall apply for and hold the Regulatory Approvals directed to a Candidate or Product in each country in the Territory. Notwithstanding Section 6.5.2, if despite good faith efforts, the JSC is unable to reach unanimous agreement on which Party shall apply for and hold the MAA or Marketing Authorization Approvals directed to a Candidate or Product in any country in the Territory, then BioNTech shall have final decision making authority in that respect, </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that Pfizer shall not be required to apply for and hold any MAA or Marketing Authorization Approval in a country unless Pfizer and its Affiliates are already Commercializing a Pfizer vaccine product in such country and are permitted to hold an MAA or Marketing Authorization Approval for the Product in such country. The Parties acknowledge that, unless otherwise determined pursuant to this Section 8.2.6 or required under applicable Law, all Regulatory Approvals directed to a Candidate or Product in a country in the Territory and all applications therefor shall be made and/or held in the name of and owned by BioNTech or its Affiliate. For clarity, if under the applicable Law of any country BioNTech or its Affiliate is allowed to apply for a Regulatory Approval even though, at the time of such application, BioNTech or its Affiliate does not fulfil the requirements under applicable Law to hold such Regulatory Approval in such country, BioNTech or its Affiliate shall be allowed to file such application, </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that BioNTech reasonably believes that it will fulfill all such requirements within such time period as will not unreasonably delay approval of the applicable Regulatory Approval. In addition, the following principles shall apply:</font><font style="font-weight:bold;text-decoration:none;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref58312532"></a><font style="text-decoration:none;">8.2.6.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Where BioNTech or its Affiliate has applied for and/or holds in its own name any MAA or Marketing Authorization Approval directed to a Candidate or Product in a given country in the Territory, it may, upon giving reasonable notice to Pfizer, elect with Pfizer's agreement to transfer to Pfizer or any of its Affiliates such Regulatory Approval (or the relevant application therefor) in such country and Pfizer or its Affiliate will not withhold its agreement to such transfer if Pfizer or any of its Affiliates is already Commercializing a Pfizer vaccine product in such country and is permitted to hold such MAA or Marketing Authorization Approval in such country.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref62659122"></a><a name="_Hlk55926989"></a><font style="text-decoration:none;">8.2.6.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Where an MAA or Marketing Authorization Approval directed to a Candidate or Product in a given country in the Territory is held by Pfizer or its Affiliate after it has been (i) applied for or obtained by Pfizer or its Affiliate or (ii) transferred to Pfizer or its Affiliate pursuant to Section 8.2.6.1 above, BioNTech, in its sole discretion, may at any time request in writing that Pfizer transfers or transfers back, as applicable, such Regulatory Approval (or application therefor) to BioNTech or its Affiliate and, upon such written request, the Parties will mutually agree on the date of the transfer or transfer back, as applicable, of such Regulatory Approval (or application therefor) to BioNTech or its Affiliate, </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that such date shall be no later than six (6) months after BioNTech&#8217;s request and BioNTech has fulfilled all necessary requirements under applicable Law to </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">hold such Regulatory Approval (or application therefor)</font><font style="text-decoration:none;"> at the time of transfer or transfer back</font><font style="text-decoration:none;">.</font><font style="text-decoration:none;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">8.2.6.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Recognizing that the transfer of the foregoing responsibilities or the responsibilities described in Sections 8.2.1 and 8.2.2 and Regulatory Approvals, as the case may be, requires time, coordination and effort, the Parties will agree a reasonable transition plan for each such transfer (including specifications for the transfer period) and during the transfer period BioNTech or Pfizer, as applicable, shall continue to use Commercially Reasonable Efforts to maintain the Regulatory Approvals in good standing and continue to perform its obligations as Lead Regulatory Party or owner of the Regulatory Approval (or application therefor), unless determined otherwise in the relevant transition plan. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">8.2.6.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">A Party that is a Regulatory Approval holder under this Agreement shall procure that its Affiliates conduct all activities in connection with such Regulatory Approvals in accordance with this Agreement.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">8.2.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Notice of Regulatory Investigation or Inquiry</font><font style="text-decoration:none;">. If any Regulatory Authority (i) contacts a Party with respect to the alleged improper Development, Manufacture, or Commercialization of a Candidate or Product in the Territory, (ii) conducts, or gives notice of its intent to conduct, an inspection at a Party&#8217;s facilities used in the Development or Manufacturing of a Candidate or Product, or (iii) takes, or gives notice of its intent to take, any other regulatory action with respect to any activity of a Party that could reasonably be expected to adversely affect any Development, Manufacture or Commercialization Activities with respect to a Candidate or Product in the Territory, then such Party shall promptly notify the other Party of such contact, inspection or notice. The inspected Party shall provide such other Party with copies of all pertinent information and documentation issued by any such Regulatory Authority within [***] of receipt, and, to the extent practicable, the JSC or appropriate subcommittee. Such other Party shall have the right to (a) be present at any such inspection where reasonably practicable, and (b) review and comment upon in advance any responses of the inspected Party that pertain to a Candidate or Product or a Party&#8217;s activities hereunder.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref37279707"></a><a name="_Toc62256085"></a><a name="_Toc59107112"></a><a name="_Ref37236598"></a><a name="_Ref37114868"></a><font style="text-decoration:none;">8.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Pharmacovigilance and Pharmacovigilance Agreement</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">8.3.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">As soon as practicably possible following the Signing Date the Parties shall form a Joint Safety Committee to (a) review and approve each investigator&#8217;s brochure for the clinical Development of Candidates and Products, (b) review and approve all aggregated data Drug Safety Update Reports, annual IND reports, and other period reports to Governmental Authorities information regarding patient safety (including adverse drug) experiences that are or may be associated with Candidates or Products, (c) review, discuss and agree the outputs of each Party&#8217;s periodic Candidate and Product related benefit/risk analysis, and (d) such other patient safety-related activities as the Parties may delegate to it from time to time.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">8.3.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">So long as BioNTech holds the necessary INDs/CTAs/Regulatory Approvals and is acting as sponsor in a country or region in the Territory, BioNTech may initiate clinical Development of the Candidates and Products in the EU prior to the Parties entering into a pharmacovigilance agreement. In such circumstances BioNTech shall be responsible for collecting, monitoring, evaluating, sharing and reporting to applicable Governmental Authorities in the EU information regarding patient safety (including adverse drug) experiences that are or may be </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">associated with Candidates or Products. </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> shall be responsible for maintaining a suitable safety database.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref43822062"></a><font style="text-decoration:none;">8.3.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">The Parties acknowledge and agree that they have entered into a pharmacovigilance agreement covering pharmacovigilance responsibility relating to Development Activities and shall update such agreement or enter into a new pharmacovigilance agreement with respect to Commercialization Activities (each a &#8220;</font><font style="text-decoration:underline;">Pharmacovigilance Agreement</font><font style="text-decoration:none;">&#8221;), in each case reflecting the applicable terms set forth in Section&#160;8.3.7 and </font><font style="text-decoration:underline;">Schedule 8.3</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">8.3.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Following the filing of the IND for Candidate(s) with FDA:</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref47520652"></a><font style="text-decoration:none;">8.3.4.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">should BioNTech require Pfizer to take over certain activities in relation to collecting, monitoring, evaluating, sharing and reporting to applicable Governmental Authorities, but excluding Ethics Committees, information regarding patient safety (including adverse drug) experiences that are or may be associated with Candidates or Products in the EU, the Parties shall agree and execute an amendment to the Pharmacovigilance Agreement to (i) reflect the additional activities and responsibilities the Parties have agreed Pfizer will perform in the EU, and (ii) set out the procedures the Parties have agreed upon to allow for the reconciliation of BioNTech&#8217;s safety database with Pfizer&#8217;s safety database. The effectiveness of the amendment shall be conditional upon BioNTech delivering to Pfizer (x) confirmation from the relevant Governmental Authorities in the EU that they have accepted an amendment to the clinical trial protocol for any on-going clinical trial of Candidates or Product in the EU to reflect the necessary changes (as agreed with Pfizer) in responsibilities and contact information for collecting, monitoring, evaluating, sharing and reporting of information regarding patient safety (including adverse drug) experiences, and (y) written confirmation from BioNTech that it has amended the relevant clinical trial agreements to reflect the change in pharmacovigilance provider and trained the investigators on the new reporting procedures; and,</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref47520664"></a><font style="text-decoration:none;">8.3.4.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">BioNTech through their agreement with Fosun shall ensure that Fosun, via BioNTech, deliver to Pfizer (x) a copy of a due diligence report on Fosun&#8217;s safety data reporting system reasonably acceptable to Pfizer in terms of findings made, (y) a copy of the pharmacovigilance agreement between BioNTech and Fosun which, inter alia, provides for delivery to Pfizer of fully assessed, translated (into English) CIOMS forms for all SAEs: Death / life threatening SUSARs &#8211; 5 Business Days from Day 0 (Day 0 being receipt by Fosun from the clinical investigator), or 10 days for all other SAEs, [***] and (z) details of the quality management system used with Fosun to ensure that if late inbound reports are received BioNTech can request root cause analysis and implementation of corrective and preventive actions by Fosun. The Parties agree that prior to Fosun&#8217;s commencement of clinical activities by Fosun, BioNTech shall have entered into a written agreement with Fosun, reflecting the foregoing.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">8.3.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">The Pharmacovigilance Agreement and each amendment to it from time to time shall set forth the responsibilities and procedures for (i) collecting, monitoring, evaluating, sharing and reporting to applicable Governmental Authorities information regarding patient safety (including adverse drug) experiences that are or may be associated with Candidates or Products in the countries covered by that agreement and (ii) providing regulatory information to and support </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">of the other Party with regard to regulatory obligations, provided, that, each such agreement shall include the following guiding principles: acting as </font><font style="text-decoration:none;">BioNTech&#8217;s</font><font style="text-decoration:none;"> delegate for regulatory interactions, Pfizer shall primarily control the regulatory process and regulatory interactions in the countries covered by that agreement, provided, however that the Parties shall work together collaboratively to further the purposes of the collaboration and the activities described in this Agreement. Subject to the proviso in the foregoing sentence, to the extent there is any conflict between the terms and conditions of the Pharmacovigilance Agreement (as amended from time to time) and this Agreement with respect to safety or regulatory matters, the Pharmacovigilance Agreement shall control.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">8.3.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Audits</font><font style="text-decoration:none;">. Each Party shall have the right, at its sole cost and expense, to perform audits of the other Party&#8217;s pharmacovigilance, regulatory, and environmental, health and safety activities concerning any Candidates or Products under this Agreement, including each Party&#8217;s oversight of any Third Party contracted to perform pharmacovigilance, regulatory or environmental health and safety activities as outlined in this Agreement and in compliance with applicable Laws, which audit right is exercisable once per Calendar Year (or more frequently for material cause) during the Term, </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;">, </font><font style="font-style:italic;text-decoration:none;">however</font><font style="text-decoration:none;">, that the auditing Party shall notify the other Party of the identity of any Third Party auditor, such other Party may require such Third Party auditor to sign a customary confidentiality agreement in form and substance reasonably acceptable to such other Party and the auditing Party shall not use such Third Party auditor without the prior consent of the other Party, such consent not to be unreasonably withheld, delayed or conditioned. Upon request, BioNTech shall provide Pfizer with a copy of its latest audit report on Fosun&#8217;s pharmacovigilance activities.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref37115066"></a><font style="text-decoration:none;">8.3.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Global Safety Database and Safety Reporting</font><font style="text-decoration:none;">. Subject to the Pharmacovigilance Agreement entered into as described in Section&#160;8.3.3 as amended from time, Pfizer shall maintain the global safety database for the Candidates and Products pursuant to this Agreement, </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that (a) BioNTech will hold a safety database to meet its sponsor responsibilities and regulatory responsibilities in the EU and any other countries or markets in the BioNTech Commercialization Territory and to hold safety data reports received from the Fosun Territory; (b) information shall be exchanged between Pfizer and BioNTech as described in the Pharmacovigilance Agreement to ensure alignment of information between the databases; and (c) BioNTech will delegate to Pfizer its responsibilities for the collection, processing, assessment and safety reporting to Regulatory Authorities for (i) all Clinical Trial(s) conducted pursuant to this Agreement and the Research and Development Plan thereunder in the Territory upon the approval of the IND for Candidate(s) with FDA and (ii) upon Regulatory Approval of the Marketing Authorization Applications or grant of Emergency Use Authorization, adverse event and other safety information relating to the Candidates or Products. Notwithstanding the foregoing, such responsibility can only be delegated to and Pfizer can only accept this responsibility if, with respect to safety information arising from clinical trials, the Clinical Trial sites for the Candidates and Products are reporting the safety data and, with respect to safety information from Commercialization Activities and Medical Activities, BioNTech and its Affiliates are reporting the safety data, in each case, including all individual Serious Adverse Events, translated into English, to Pfizer and for so long as Pfizer has access to all safety data, including all individual Serious Adverse Events, translated into English for any and all active Clinical Trials for the Candidates and Products, including products identical to Candidates or Products conducted under the terms and conditions of the Fosun Agreement (or subsequent agreements with other development partners) and for all Commercialization Activities and Medical </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">Activities conducted by or on behalf of </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> to allow Pfizer to meet its regulatory obligations as Lead Regulatory Party in the Territory.</font><font style="text-decoration:none;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">8.3.8</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Procedures and Training</font><font style="text-decoration:none;">. Each Party will, at its sole cost and expense, put into place and cause its Affiliates to put into place, appropriate procedures, including the provision of adequate training to all applicable Representatives, to ensure full and timely compliance with its obligations under each of (a) this Section&#160;8.3 and (b) the Pharmacovigilance Agreement.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256086"></a><a name="_Toc59107113"></a><font style="text-decoration:none;">8.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Product Complaints and Returns</font><font style="text-decoration:none;">. The Parties&#8217; rights and obligations with respect to non-conformance and returns of Products shall be governed by, as and to the extent applicable, Sections&#160;9.3.1.2, 9.3.2.2, 9.10, 9.11, and Section&#160;16 of this Agreement, and the applicable sections of the clinical supply agreement, the commercial supply agreement(s), any global quality agreement, any pharmacovigilance, in each case, where such agreement is related to the Product so affected. In addition, BioNTech may forward any product complaints received by it to Pfizer for further processing, reporting, closure and other related activities in the BioNTech Commercialization Territory to fulfill BioNTech&#8217;s responsibilities for complaint handling on BioNTech&#8217;s behalf in accordance with procedures that are agreed by the Parties.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256087"></a><a name="_Toc59107114"></a><font style="text-decoration:none;">8.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Clinical Trial Register</font><font style="text-decoration:none;">. BioNTech shall, in accordance with Law and its internal policies, register, and publish the summaries and results of, Clinical Trials relating to the Candidate or Product on a clinical trial register maintained by it (or an equivalent register), or as otherwise required by Law. If Pfizer is the Lead Development Party for a Clinical Trial, Pfizer shall prepare such summaries and results in accordance with its internal policies and in a timely manner so as to allow the summaries and results to be published within the mandatory time period, and provide such summaries and results to BioNTech for review and comment. Pfizer will give reasonable consideration to any such comments. BioNTech shall publish such summaries and results on a clinical trial register maintained by it (or an equivalent register), within the mandatory time period. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256088"></a><a name="_Toc59107115"></a><font style="text-decoration:none;">8.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Regulatory Exclusivity</font><font style="text-decoration:none;">. The JCC shall oversee the process of applying for and securing exclusivity rights that may be available under the applicable Law of countries in the Territory, including any data or market exclusivity periods such as those periods listed in the FDA's Orange Book or Purple Book (as applicable) or periods under national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83 (including any pediatric exclusivity extensions or other forms of regulatory exclusivity that may be available), and all international equivalents.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256089"></a><a name="_Toc59107116"></a><a name="_Ref62483548"></a><a name="_Ref37260780"></a><font style="text-decoration:none;">8.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Liability</font><font style="text-decoration:none;">. Subject to Pfizer and its Affiliates compliance with (i) the obligations set forth in Sections 8.1.3.8 above, Pfizer and its Affiliates, employees, agents or representatives will not be liable to BioNTech or its Affiliates in respect of any act, omission, default or neglect on the part of Pfizer, its Affiliates, or their respective employees, agents or representatives in connection with the activities undertaken as a Lead Regulatory Party where such activities are undertaken in good faith, unless liability arises from Pfizer's or its Affiliates, employees, agents or representatives gross negligence or willful misconduct.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256090"></a><a name="_Toc59107117"></a><font style="text-decoration:none;">8.8</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Objection Right</font><font style="text-decoration:none;">. Notwithstanding any other provision of this Section&#160;8, where a Party is the MA Holder, it shall have the right to object to or oppose any intended action of the other Party if such objecting Party reasonably and in good faith believes the other Party&#8217;s intended action is contrary to applicable Law and carries a material risk that if such action is taken, it will result in a material negative impact on approvability of a Market Authorization Application or continued approval of a Marketing Authorization Approval for the Product or sanctions or fines from the relevant Governmental Authority. In </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">case of an objection or opposition by the MA Holder pursuant to the preceding sentence, the Parties shall promptly discuss the relevant issue in good faith and the objected or opposed intended action shall not be initiated or shall be put on hold until the Parties have reached an agreement on how to ensure compliance with applicable law. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256091"></a><a name="_Toc59107118"></a><font style="text-decoration:none;">8.9</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Personal Data</font><font style="text-decoration:none;">. The Parties agree that any processing of Personal Data pursuant to this Agreement will be in their capacity as independent controllers with respect to such Personal Data. To the extent the Parties shall be required to share Personal Data in connection with this Agreement, the Parties shall enter into a legally binding written agreement governing the Parties relationship and their processing activities as required by Applicable Data Protection Law.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;">9.</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-transform:none;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref43644299"></a><a name="_Ref46928315"></a><a name="_Ref59043209"></a><a name="_Toc62256092"></a><a name="_Toc59107119"></a><a name="_Toc484765952"></a><a name="_Toc484766018"></a><a name="_Toc484766084"></a><a name="_Toc484766514"></a><a name="_Toc519762587"></a><a name="_Toc519764414"></a><a name="_Toc519774929"></a><a name="_Toc519873410"></a><a name="_Toc36024665"></a><a name="_Toc35600550"></a><a name="_Ref263795066"></a><a name="_Ref263795414"></a><a name="_Ref263797045"></a><a name="_Ref264825354"></a><font style="text-decoration:none;"></font><font style="text-decoration:underline;text-transform:uppercase;">Commercialization</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref46928273"></a><a name="_Toc62256093"></a><a name="_Toc59107120"></a><a name="_Ref43642285"></a><a name="_Ref44661991"></a><font style="text-decoration:none;">9.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Annual Plans</font><font style="font-style:italic;text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref46781294"></a><font style="text-decoration:none;">9.1.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Preparation of Annual Plans</font><font style="text-decoration:none;">. The JCC shall prepare a Global Commercialization Plan (which will include a projected budget for Gross Profit for the applicable year set on a global and Major Market by Major Market basis) and will update such plan at least once per year. If the JCC agrees to establish one or more RCCs, each RCC shall prepare an Annual Regional Commercialization Plan which shall have regard to the Global Commercialization Plan's objectives and principles, and update such plan at least once per year for its respective Commercialization Region and submit the same to the JCC for review and approval solely in respect of those aspects where such local plans deviate from the Global Commercialization Plan. The Global Commercialization Plan (and updates made thereto) shall be prepared and reviewed in accordance with the timing for Pfizer&#8217;s global operations planning process, which timing shall be communicated by Pfizer to BioNTech sufficiently in advance to enable the Parties to prepare and approve the Global Commercialization Plan and updates thereto in accordance with such timing. Each Annual Regional Commercialization Plan that is to be prepared or reviewed by a RCC shall be prepared and reviewed for such year in accordance with (a) the timing for Pfizer&#8217;s operations planning process for the applicable Commercialization Region(s) within the Pfizer Commercialization Territory, which timing shall be communicated by Pfizer to BioNTech sufficiently in advance to enable the Parties to prepare and review such Annual Regional Commercialization Plan reasonably in advance of its implementation and (b) the timing for BioNTech&#8217;s operations planning process for the applicable Commercialization Region(s) within the BioNTech Commercialization Territory, which timing shall be communicated by BioNTech to Pfizer sufficiently in advance to enable the Parties to prepare and review such Annual Regional Commercialization Plan reasonably in advance of its implementation. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.1.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Content of Commercialization Plans</font><font style="text-decoration:none;">. The Global Commercialization Plan will include [***]. It is expected that only certain aspects of the Global Commercialization Plan shall be updated each Calendar Year, to adjust the plan for annual variations including the forecasts for Units of Product to be sold during each Calendar Quarter of the applicable year.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256094"></a><a name="_Toc59107121"></a><font style="text-decoration:none;">9.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Pfizer Commercialization Responsibilities</font><font style="text-decoration:none;">. In the Pfizer Commercialization Territory, Pfizer, subject to Section&#160;</font><font style="text-decoration:none;">9.14</font><font style="text-decoration:none;"> and at its own cost, shall (or shall cause its Affiliates, sublicensees or subcontractors to);</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.2.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">be responsible for commercial distribution of the Product and those other activities normally undertaken by the commercial distributor of a pharmaceutical product (in each case consistent with Commercially Reasonable Efforts), including, but not limited to:</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.2.1.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">rejecting or accepting and fulfilling Third Party orders for Products and selling Products;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.2.1.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">subject to Section&#160;9.6, applying for and negotiating for pricing and reimbursement of the Product;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.2.1.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">conducting all customer contracting pertaining to the Product;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.2.1.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">consulting with BioNTech whether to implement and, if so decided by Pfizer or BioNTech, as applicable in accordance with Section&#160;9.11, implementing any recalls or market withdrawals of the Product; and</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.2.1.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">managing and responding to medical information requests;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref43643293"></a><a name="_Ref47519772"></a><font style="text-decoration:none;">9.2.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">manage and oversee product liability claims pertaining to Products distributed by it for use by its customers or patients in the Pfizer Commercialization Territory, and be responsible for the costs and Liabilities of all product liability claims solely to the extent that the injuries underlying such claims are caused by the breach or default, negligence or intentional misconduct of Pfizer, its Affiliates or any of its or their Representatives, and shall indemnify and hold harmless BioNTech and its Affiliates, Representatives from such costs;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.2.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">be responsible for promoting and detailing the Product in each country or region, as applicable, of the Pfizer Commercialization Territory using Commercially Reasonable Efforts and in a manner not inconsistent with the strategy and Global Commercialization Plan established by the JCC and, if applicable, the Annual Regional Commercialization Plan established by any applicable RCC, provided, however, that in no event will Pfizer, its Affiliates or any of their respective sublicensees or subcontractors be required to conduct any such activity in a manner that is inconsistent with Pfizer&#8217;s or its Affiliates&#8217; own promotion or its detailing practices, policies or procedures for Pfizer&#8217;s or its Affiliates&#8217; other products, consistently applied;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.2.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">subject to Sections&#160;9.5 and 10.3, be responsible for training its medical and field sales personnel;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.2.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">ensure that its sales, medical and other representatives comply with all applicable regulatory, professional and legal requirements governing Product marketing, promotion and detailing activity, including all Anti-Corruption Laws;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.2.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">subject to Section&#160;9.5.3, ensure that promotional materials developed by Pfizer are not inconsistent with the global messaging and global positioning platform approved by the JCC in the Global Commercialization Plan and in compliance with all Pfizer policies, the relevant Regulatory Approvals and applicable Laws;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.2.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">comply with the standards and requirements set forth in Section&#160;</font><font style="text-decoration:none;">9.4.2</font><font style="text-decoration:none;">;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.2.8</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">subject to the Pharmacovigilance Agreement, be responsible for maintaining the global safety database and managing pharmacovigilance reporting in accordance with the Pharmacovigilance Agreement, in each case on the behalf of the MA Holder(s);</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.2.9</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">not actively solicit any orders for the Product from within the BioNTech Commercialization Territory; </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.2.10</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">sell the Products in its own name and on its own account, subject to the profit sharing mechanism set forth in Section 4.9 above;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.2.11</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">invoice its customers and collect receivables in accordance with good industry practice, and</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref46506136"></a><font style="text-decoration:none;">9.2.12</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">ensure through an active monitoring program that its personnel and other representatives fully comply with all applicable regulatory, professional and legal requirements governing Product Commercialization Activity.</font></p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer shall not be obliged to commence its detailing and promotional efforts in a country of the Pfizer Commercialization Territory until after the Product has received a Market Authorization Approval (as opposed to an Emergency Use Authorization) and recommendations from the applicable Vaccine Technical Committee in such country. For clarity, other Commercialization Activities and Medical Activities may be conducted by Pfizer, at its sole discretion, prior to Regulatory Approval of a Product to the extent permitted by applicable Law in order to prepare for promotion, marketing and sale of Products once such Regulatory Approval is obtained and Pfizer shall not be obligated to commence any detailing and promotional efforts in violation of applicable Law.</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256095"></a><a name="_Toc59107122"></a><font style="text-decoration:none;">9.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">BioNTech Commercialization Responsibilities</font><font style="text-decoration:none;">:</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.3.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">General Responsibilities</font><font style="text-decoration:none;">. BioNTech, at its own cost, shall </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.3.1.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">in accordance with the Pharmacovigilance Agreement, promptly forward to Pfizer for handling all adverse event and associated safety information it or its representatives receive pertaining to the Product; </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref43643310"></a><font style="text-decoration:none;">9.3.1.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">be responsible for and indemnify and hold harmless Pfizer and its Affiliates, representatives, personnel and subcontractors, against the costs and Liabilities of all product liability claims, except to the extent such costs and Liabilities are the responsibility of Pfizer pursuant to Section 9.2.2; </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.3.1.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">except to the extent Pfizer becomes the MA Holder for any country (including pursuant to Section&#160;8.2.6 this Agreement), fulfill the obligations of the MA Holder and shall maintain the Regulatory Approvals for each Product and not diminish the label or indication for any Product without Pfizer&#8217;s prior consent; and</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.3.1.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">ensure through an active monitoring program that its personnel and other representatives fully comply with all applicable regulatory, professional and legal requirements governing Product Commercialization Activity.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.3.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">BioNTech</font><font style="font-weight:bold;text-decoration:none;"> Commercialization Territory Responsibilities</font><font style="text-decoration:none;">.</font><font style="text-decoration:none;"> In the </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Commercialization Territory, </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;">, subject to Section&#160;</font><font style="text-decoration:none;">9.14</font><font style="text-decoration:none;"> and at its own cost, shall (or shall cause its Affiliates, sublicensees or subcontractors to):</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.3.2.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">be responsible for commercial distribution of the Product and those other activities normally undertaken by the commercial distributor of a pharmaceutical product (in each case consistent with Commercially Reasonable Efforts), including, but not limited to </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:30.77%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:none;">rejecting or accepting and fulfilling Third Party orders for Products and selling Products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:30.77%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:none;">subject to Section&#160;9.6, applying for and negotiating for pricing and reimbursement of the Product;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:30.77%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:none;">conducting all customer contracting pertaining to the Product;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:30.77%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:none;">consulting with Pfizer whether to implement and, if so decided by Pfizer or BioNTech, as applicable in accordance with Section&#160;9.11, implementing any recalls or market withdrawals of the Product; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:30.77%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:none;">managing and responding to medical information requests;</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref43643328"></a><font style="text-decoration:none;">9.3.2.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">manage and oversee product liability claims pertaining to Products distributed by it for use by its customers or patients in the BioNTech Commercialization Territory, and be responsible for the costs of all product liability claims as set forth in Section 9.3.1.2; </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.3.2.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">be responsible for promoting and detailing the Product in each country or region, as applicable, of the BioNTech Commercialization Territory using Commercially Reasonable Efforts and in a manner not inconsistent with the strategy and Global Commercialization Plan established by the JCC and, if applicable, the Annual Regional Commercialization Plan established by any applicable RCC, provided, however, that in no event will BioNTech, its Affiliates or any of their respective sublicensees or subcontractors be required to conduct any such activity in a manner that is inconsistent with BioNTech&#8217;s or its Affiliates&#8217; own promotion or its detailing practices, policies or procedures for BioNTech&#8217;s or its Affiliates&#8217; other products, consistently applied, or if no such practices are established across multiple commercialized products, then in a manner compliant with applicable Law and consistent with established industry practices for promotion and detailing; </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.3.2.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">subject to Sections&#160;9.5 and 10.3, be responsible for training its medical and field sales personnel;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.3.2.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">ensure that its sales, medical and other representatives comply with all applicable regulatory, professional and legal requirements governing Product marketing, promotion and detailing activity, including all Anti-Corruption Laws;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.3.2.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">subject to Section&#160;</font><font style="text-decoration:none;">9.5.3</font><font style="text-decoration:none;">, ensure that promotional materials developed by </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> are not inconsistent with the global messaging and global positioning platform approved by the JCC in the Global Commercialization Plan and in compliance with all </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> policies, the relevant Regulatory Approvals and applicable Laws; </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.3.2.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">comply with the standards and requirements set forth in Section&#160;9.4.2;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.3.2.8</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">not actively solicit any orders for the Product from within the Pfizer Commercialization Territory; </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.3.2.9</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">sell the Products in its own name and on its own account, subject to the profit sharing mechanism set forth in Section 4.9 above;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.3.2.10</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">invoice its customers and collect receivables in accordance with good industry practice, and</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.3.2.11</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">ensure through an active monitoring program that its personnel and other representatives fully comply with all applicable regulatory, professional and legal requirements governing Product Commercialization Activity. </font></p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;margin-left:15.15%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech shall not be obliged to commence its detailing and promotional efforts in a country of the BioNTech Commercialization Territory until after the Product has received a Market Authorization Approval (as opposed to Emergency Use Authorization) and recommendations from the applicable Vaccine Technical Committee, if any, in or for such country. For clarity, other Commercialization Activities and Medical Activities may be conducted by BioNTech, at its sole discretion, prior to Regulatory Approval to the extent permitted by applicable Law of a Product in order to prepare for promotion, marketing and sale of Products once such Regulatory Approval is obtained and BioNTech shall not be obligated to commence any detailing and promotional efforts in violation of applicable Law.</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc40858260"></a><a name="_Toc40859570"></a><a name="_Toc40860231"></a><a name="_Toc40862989"></a><a name="_Toc40863687"></a><a name="_Toc40864086"></a><a name="_Toc62256096"></a><a name="_Toc59107123"></a><font style="text-decoration:none;">9.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Sales Force</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.4.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Maintenance of Sales Force</font><font style="text-decoration:none;">. Within its respective Commercialization Territory, in each Major Market Country, the applicable Commercializing Party will use Commercially Reasonable Efforts to provide and maintain, at its respective sole cost and expense (following Regulatory Approval of the Product in such country), (a) a well-trained internal or external sales force of PSRs sufficient to promote the Product in accordance with the applicable Annual Regional Commercialization Plan, if there is one or if not, in accordance with the Global Commercialization Plan and (b) an adequate number of well-trained internal or external Sales Managers to oversee all of such Commercializing Party&#8217;s PSRs and other sales force Representatives. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref39647285"></a><a name="_Ref43657233"></a><a name="_Hlk39391480"></a><font style="text-decoration:none;">9.4.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Pfizer Policies and Standards</font><font style="text-decoration:none;"><a name="_Hlk39391480"></a>. Pfizer will ensure that during the course of its promotion of the Product in the Pfizer Commercialization Territory, its respecting Sales Managers, PSRs and other sales and promotion representatives are governed by promotional standards and are subject to policies that (a) require them to limit the claims of efficacy and safety for the Product to those which are consistent with the Pfizer Promotional Materials approved by Pfizer and the Pfizer Training Materials; (b) require such individuals to use only the Pfizer Promotional Materials approved by Pfizer; (c) do not permit such individuals to add, delete or modify claims of efficacy </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">or safety contained in such Pfizer Promotional Materials or to make any other changes in any such Pfizer Promotional Materials; (d) include the manner in which employees and other representatives should handle unsolicited requests for information related to off-label uses of the Product; and (e) are designed to ensure compliance with applicable Laws</font><font style="text-decoration:none;">.</font><font style="text-decoration:none;"> In addition, Pfizer will ensure that its marketing, promotion and detailing of the Product will be in adherence to all applicable Laws, Anti-Corruption Laws, Party Specific Regulations, Pfizer&#8217;s Internal Compliance Codes, Professional Requirements and the applicable Annual Regional Commercialization Plan, if there is one, and any updates thereto, in each case to the extent applicable in such country.</font><font style="text-decoration:none;"> </font><font style="text-decoration:none;">Pfizer shall provide </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> with access to copies of its </font><font style="text-decoration:none;">global </font><font style="text-decoration:none;">foundational headquarters level policies that have worldwide applicability to </font><font style="text-decoration:none;">the </font><font style="text-decoration:none;">promotion and </font><font style="text-decoration:none;">C</font><font style="text-decoration:none;">ommercialization</font><font style="text-decoration:none;"> of the Product</font><font style="text-decoration:none;">. </font><font style="text-decoration:none;">[***]</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref39647493"></a><a name="_Ref43658853"></a><font style="text-decoration:none;">9.4.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">BioNTech Policies and Standards</font><font style="text-decoration:none;">. BioNTech will ensure that during the course of its promotion of the Product in the BioNTech Commercialization Territory, its respecting Sales Managers, PSRs and other sales and promotion representatives are governed by promotional standards and are subject to policies that (a) require them to limit the claims of efficacy and safety for the Product to those which are consistent with the BioNTech Promotional Materials approved by BioNTech and the BioNTech Training Materials; (b) require such individuals to use only the BioNTech Promotional Materials approved by BioNTech; (c) do not permit such individuals to add, delete or modify claims of efficacy or safety contained in such BioNTech Promotional Materials or to make any other changes in any such BioNTech Promotional Materials; (d) include the manner in which employees and other representatives should handle unsolicited requests for information related to off-label uses of the Product; and (e) are designed to ensure compliance with applicable Laws. In addition, BioNTech will ensure that its marketing, promotion and detailing of the Product will be in adherence to all applicable Laws, Anti-Corruption Laws, Party Specific Regulations, BioNTech&#8217;s Internal Compliance Codes, Professional Requirements and the applicable Annual Regional Commercialization Plan, if there is one, and any updates thereto, in each case to the extent applicable in such country. At least [***] prior to Commercialization of the Product in the BioNTech Commercialization Territory, or such shorter period as may be agreed by the Compliance Committee, BioNTech shall provide Pfizer with BioNTech&#8217;s policies in relation to promotion and Commercialization of the Product for Pfizer's review and compliance audit. Within [***] after any change of such policies, BioNTech shall provide Pfizer with a copy of any changed compliance policies.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref414619659"></a><font style="text-decoration:none;">9.4.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Compliance of Personnel</font><font style="text-decoration:none;">. If information comes to a Party&#8217;s attention that provides such Party with a reasonable basis to believe that any Sales Manager or PSR of the other Party or its Affiliates has (a) violated any applicable Law as it relates to promoting or detailing of the Product or (b) failed to comply with the terms of this Agreement in respect of its Commercialization Activities, then, with respect to either (a) or (b), such Party will have the right to (i) request that the other Party immediately assess the performance of such individual and (ii) exercise any other rights or remedies available to it under this Agreement, at law or in equity. The other Party will (A) promptly use Commercially Reasonable Efforts to evaluate and resolve such issue in accordance with its internal policies or as it may otherwise deem appropriate, (B) to the extent permitted by applicable Law, keep the first Party informed of the progress of, and information learned during, such evaluation and (C) within [***] of the first Party bringing such information to the other Party&#8217;s attention, provide the first Party, to the extent permitted by applicable Law, with a reasonably detailed written report summarizing any steps taken toward </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">resolution of the matter, unless such other Party has received an opinion from counsel that such disclosure would waive any applicable privilege attaching to information or written report.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc40858261"></a><a name="_Toc40859571"></a><a name="_Toc40860232"></a><a name="_Toc40862990"></a><a name="_Toc40863688"></a><a name="_Toc40864087"></a><a name="_Toc62256097"></a><a name="_Toc59107124"></a><a name="_Ref412004533"></a><font style="text-decoration:none;">9.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Training Materials, Promotional Materials and Other Product Information</font><font style="text-decoration:none;">.</font><font style="text-decoration:underline;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref39385579"></a><a name="_Ref39389413"></a><a name="_Ref43486536"></a><a name="_Ref411995344"></a><a name="_Ref413993082"></a><a name="_cp_text_2_679"></a><a name="_Hlk39384724"></a><a name="_Ref411995362"></a><font style="text-decoration:none;">9.5.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Pfizer&#8217;s Training Obligations</font><font style="text-decoration:none;">. Pfizer or its Affiliates, at its cost and risk, will develop (as necessary or desirable to address local requirements or customs and market strategies and needs) and design training materials, for use by its PSRs and Sales Managers in particular countries within the Pfizer Commercialization Territory (the &#8220;</font><font style="text-decoration:underline;">Pfizer Training Materials</font><font style="text-decoration:none;">&#8221;). The Pfizer Training Materials shall be in compliance with applicable Law, consistent with the applicable Regulatory Approvals for the Product and, except where necessary to comply with applicable Law, not be inconsistent with the global Commercialization strategy for the Product established by the JCC as reflected in the Global Commercialization Plan. Upon BioNTech&#8217;s reasonable request, Pfizer shall provide BioNTech with access to the Pfizer Training Materials&nbsp;&nbsp;developed specifically for the Product for use in the Major Markets in the Pfizer Commercialization Territory for BioNTech to review, and Pfizer shall take into account any reasonable comments made by BioNTech in relation to such Pfizer Training Materials. <a name="_cp_text_2_679"></a>Utilizing such Pfizer Training Materials, Pfizer will be responsible, at its own cost and risk, for preparing and delivering training to its PSRs and Sales Managers<a name="_Hlk39384724"></a> with respect to the Product and the detailing thereof. Such training shall occur (a) prior to the provision by such PSR or Sales Manager of any detailing or promotional activities with respect to the Product and (b) periodically thereafter in each country in the Pfizer Commercialization Territory as is consistent with Pfizer&#8217;s practices for periodic training of its Sales Managers and PSRs or as may be otherwise needed to update such training based on new information. Pfizer shall share the Pfizer Training Materials with BioNTech for BioNTech&#8217;s use, subject to Section&#160;9.5.2 and at its sole risk, in the BioNTech Commercialization Territory; </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;">,</font><font style="font-style:italic;text-decoration:none;"> however</font><font style="text-decoration:none;">, that Pfizer shall not be liable to BioNTech for any inaccuracy or error in the Pfizer Training Materials.<a name="_Ref411995362"></a> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref40473170"></a><a name="_Ref414973225"></a><font style="text-decoration:none;">9.5.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">BioNTech&#8217;s Training Obligations</font><font style="text-decoration:none;">. Utilizing the Pfizer Training Materials where applicable, BioNTech or its Affiliates, at its cost and risk, will adapt (as necessary or desirable to address local requirements or customs and market strategies and needs) and design training materials, for use in particular countries within the BioNTech Commercialization Territory (as so adapted and designed, the &#8220;</font><font style="text-decoration:underline;">BioNTech Training Materials</font><font style="text-decoration:none;">&#8221;). BioNTech shall ensure that the BioNTech Training Materials shall be in compliance with applicable Law, consistent with the applicable Regulatory Approvals for the Product and, except where necessary to comply with applicable Law, not be inconsistent with the global Commercialization strategy for the Product established by the JCC as reflected in the Global Commercialization Plan. Utilizing such BioNTech Training Materials, BioNTech will be responsible, at its own cost and risk, for preparing and delivering training to its PSRs and Sales Managers with respect to the Product and the detailing thereof. Such training shall occur (a) prior to the provision by such PSR or Sales Manager of any detailing or promotional activities with respect to the Product and (b) periodically thereafter in each country in the BioNTech Commercialization Territory as is consistent with BioNTech&#8217;s practices for periodic training of its Sales Managers and PSRs or as may be otherwise needed to update such training based on new information.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref39387391"></a><a name="_Ref39647097"></a><a name="_Ref412003958"></a><a name="_Hlk52997407"></a><font style="text-decoration:none;">9.5.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Promotional Materials</font><font style="text-decoration:none;">. All written sales, promotion and advertising materials relating to the Product, and other media and materials used to promote the Product or educate the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">public regarding the Product or any indication treated with the Product (collectively and including translations, &#8220;</font><font style="text-decoration:underline;">Promotional Materials</font><font style="text-decoration:none;">&#8221;) will be prepared by Pfizer for the Pfizer Commercialization Territory (the &#8220;</font><font style="text-decoration:underline;">Pfizer Promotional Materials</font><font style="text-decoration:none;">&#8221;) and by </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> for the </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Commercialization Territory (the &#8220;</font><font style="text-decoration:underline;">BioNTech</font><font style="text-decoration:underline;"> Promotional Materials</font><font style="text-decoration:none;">&#8221;) and, Pfizer or </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;">, as applicable, will determine, in its discretion, but subject to the requirements set forth below in this Section&#160;</font><font style="text-decoration:none;">9.5.3</font><font style="text-decoration:none;"> and in Section&#160;</font><font style="text-decoration:none;">9.12</font><font style="text-decoration:none;">, the content, the quantity and the method of distribution of all such Promotional Materials within its respective Commercialization Territory. All such Promotional Materials prepared by a Party shall (a) be owned (as to Copyright) by such Party; (b) not be inconsistent with the global messaging platform approved by the JCC as reflected in the Global Commercialization Plan (c) be in compliance with the applicable Regulatory Approval(s) for the Product and applicable Law, and (d) be reviewed and approved for use in a manner consistent with such Party&#8217;s normal procedures for reviewing and approving promotional materials for its other Products, consistently applied (or in the case of </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> in accordance with procedures consistent with applicable Laws and industry standards for review and approval of promotional materials for pharmaceutical and vaccine products), and in any event, in accordance with procedures to ensure that such Promotional Materials meet the requirements set forth in clauses (b) and (c) above.</font><font style="text-decoration:none;"> Pfizer and </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> shall coordinate to ensure there is consistency of approach by </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> of its Promotional Materials for Germany compared with Pfizer&#8217;s Promotional Materials for the rest of the EU. In connection with the performance of its Commercialization Activities in each country of the Pfizer Commercialization Territory, Pfizer will and will cause its Affiliates and Representatives, including Pfizer&#8217;s sales managers and PSRs, to use only the Pfizer Promotional Materials provided by Pfizer for use in such country and to not use such Pfizer Promotional Materials for any other purposes other than its Commercialization Activities under this Agreement. In connection with the performance of its Commercialization Activities in each country of the </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Commercialization Territory, </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> will and will cause its Affiliates and Representatives, including </font><font style="text-decoration:none;">BioNTech&#8217;s</font><font style="text-decoration:none;"> sales managers and PSRs, to use only the </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Promotional Materials provided by </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> for use in such country and to not use such Pfizer Promotional Materials for any other purposes other than its Commercialization Activities under this Agreement.</font><font style="text-decoration:none;"><a name="_Hlk52997407"></a> </font><font style="text-decoration:none;">On an item-by-item and country-by-country basis, and upon the written request of </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> and with Pfizer&#8217;s prior written approval (such approval not to be unreasonably withheld or delayed), Pfizer hereby licenses </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> to use, reproduce, copy, modify, distribute and display such Pfizer Promotional Materials in accordance with this Agreement and compliance with applicable Law, </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> will not use such Pfizer Promotional Materials for any other purposes other than its Commercialization Activities under this Agreement.</font><font style="text-decoration:none;"> For clarity, </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> may combine requests for Pfizer&#8217;s approval for the use of several items in various countries in one written request.</font><font style="text-decoration:none;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc40858263"></a><a name="_Toc40859573"></a><a name="_Toc40860234"></a><a name="_Toc40862992"></a><a name="_Toc40863690"></a><a name="_Toc40864089"></a><a name="_Toc62256098"></a><a name="_Toc59107125"></a><a name="_Ref39503703"></a><a name="_Ref43656867"></a><a name="_Ref411995676"></a><font style="text-decoration:none;">9.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Pricing, Reimbursement and Market Access</font><font style="text-decoration:none;">.</font><font style="text-decoration:underline;">  </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref39585276"></a><font style="text-decoration:none;">9.6.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Guidelines</font><font style="text-decoration:none;">. The JCC shall establish </font>a global pricing strategy, launch sequencing and a range of suggested prices and any discount strategies, rebates or managed entry strategies, which price ranges and strategies may differ by region or country, for each Product in the Territory (collectively, the &#8220;<font style="text-decoration:underline;">Pricing and Reimbursement Guidelines</font>&#8221;) which will be submitted by the JCC to each of the Parties as recommended but non-binding guidance.<font style="text-decoration:none;"> All sales of Product shall be made in accordance with the applicable Pricing and Reimbursement Guidelines [***].</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.6.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Pricing Meetings, Submissions &amp; Negotiations</font><font style="text-decoration:none;">. Subject to Section </font><font style="text-decoration:none;">8.2</font><font style="text-decoration:none;">, the Commercializing Party having rights to Commercialize in a specific country or region of its Commercialization Territory will be solely responsible for conducting all meetings and negotiations with, and the preparation of all materials and submissions for, national and local Governmental Authorities, health insurance providers (e.g., managed care, sickness fund), retail and hospital pharmacies, other formulary segments (e.g., sub-national and local payors) and other Third Party payors relating to any pricing, tenders, direct procurement contracts, inclusion on formularies, coverage or reimbursement with respect to Products in each such country or region, and shall have the right to hold in its name and control all applications, registrations, licenses, authorizations, approvals required for such purposes. All such pricing meetings, submissions and negotiations shall be planned and conducted by each Party in compliance with applicable Law, Anti-Corruption Laws, applicable pharmaceutical industry guidelines, applicable Internal Compliance Codes and Party Specific Regulations.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256099"></a><a name="_Toc59107126"></a><a name="_Ref62567762"></a><a name="_Ref47980223"></a><a name="_Toc40858264"></a><a name="_Toc40859574"></a><a name="_Toc40860235"></a><a name="_Toc40862993"></a><a name="_Toc40863691"></a><a name="_Toc40864090"></a><font style="text-decoration:none;">9.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Purchase Agreements with Governmental Authorities</font><font style="text-decoration:none;">.</font><font style="text-decoration:underline;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref62568279"></a><font style="text-decoration:none;">9.7.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">After the Amendment Signing Date, in negotiating any agreement with a Governmental Authority for such Government Authority to purchase the Product, [***] such Party will notify and promptly meet to discuss with the other Party the results of such negotiation prior to concluding and entering into such agreement. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref59055814"></a><a name="_Hlk62580998"></a><font style="text-decoration:none;">9.7.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">In any event, prior to entering into any agreement with any Government Authority in a Major Market Country after the Amendment Signing Date, for such Governmental Authority to purchase or have purchased from the Party negotiating such agreement or for such Party to otherwise supply Product to such Governmental Authority, to the extent permitted and provided the receiving Party has the necessary security and infrastructure in place as may be required by the Governmental Authority (provided that, where permitted, such security and infrastructure requirement shall be communicated to the receiving Party by the negotiating Party in writing reasonably in advance of any need for such security and infrastructure by the receiving Party), the applicable Party negotiating such agreement shall make a substantially negotiated draft version of such agreement available to the other Party for review and comment, and that other Party shall make available its comments (if any) to any such draft agreement to the Party negotiating such purchasing or supply agreement within [***] of its receipt of such draft agreement. The Party negotiating such purchasing or supply agreement shall consider the other Party&#8217;s comments in good faith when finalizing its negotiation of such purchasing or supply agreement with such Government Authority. In addition, each Party shall promptly submit to the other Party a copy of any such purchasing or supply agreement concluded with any Government Authority prior to the Amendment Signing Date to the extent permitted under such agreement (and, where required, shall use good faith efforts to obtain relevant consents of the Government Authority to allow such sharing of such agreement).<a name="_Hlk62580998"></a> Notwithstanding the provisions of Section 12.1, the Party receiving any agreements with Government Authorities that are provided pursuant to this Section 9.7, including any drafts provided hereunder, shall treat such agreements as the providing Party&#8217;s Confidential Information and shall hold such agreements, including any drafts provided hereunder, strictly confidential in perpetuity and shall only disclose those aspects of such agreements to those Representatives of the receiving Party having a need to know.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256100"></a><a name="_Toc59107127"></a><font style="text-decoration:none;">9.8</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Product Packaging Configurations</font><font style="text-decoration:none;">. The Parties shall each provide to the JCC current information regarding their respective Product Shipping and Storage Costs associated with all current and proposed Packaging Configurations for which they are responsible. [***]</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256101"></a><a name="_Toc59107128"></a><font style="text-decoration:none;">9.9</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Product Orders; Invoicing; Distribution and Sales</font><font style="text-decoration:none;">. With respect to Product in each country of a Party&#8217;s Commercialization Territory, the applicable Commercializing Party will have sole control and responsibility with respect to (a) receiving orders and order processing, including, rejection or acceptance and fulfillment of orders, (b) invoicing, (c) collection and receivables, (d) distribution and (e) effecting all sales of Product in the Commercialization Territory (provided that the foregoing shall not prevent or be breached by the unsolicited supply of Product by one Party from an EU country within its Commercialization Territory to an EU country outside of its Commercialization Territory in response to an unsolicited order). </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc40858265"></a><a name="_Toc40859575"></a><a name="_Toc40860236"></a><a name="_Toc40862994"></a><a name="_Toc40863692"></a><a name="_Toc40864091"></a><a name="_Toc62256102"></a><a name="_Toc59107129"></a><a name="_Ref62483563"></a><a name="_Ref415045667"></a><a name="_cp_text_1_778"></a><font style="text-decoration:none;">9.10</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Returns</font><font style="text-decoration:none;">. With respect to Product in each country of a Party&#8217;s Commercialization Territory, the applicable Commercializing Party will have sole control and, subject to Sections&#160;9.2.2, 9.3.1.2 and 9.3.2.2<a name="_cp_text_1_778"></a>, responsibility with respect to handling all returns of the Product and destruction of non-saleable or returned Product. Any and all costs associated with returns of Product, including accruals for returns of the Product sold during the Term will be included as a deduction from gross sales in the calculation of Net Sales pursuant to Section&#160;4.9.2.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc40858266"></a><a name="_Toc40859576"></a><a name="_Toc40860237"></a><a name="_Toc40862995"></a><a name="_Toc40863693"></a><a name="_Toc40864092"></a><a name="_Toc62256103"></a><a name="_Ref62483571"></a><a name="_Toc59107130"></a><a name="_Ref412003809"></a><font style="text-decoration:none;">9.11</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Recalls and Withdrawals</font><font style="text-decoration:none;">. In the event that either Party believes that a recall or withdrawal of a Product is advisable in any country of the Territory, it shall promptly consult with the other Party with respect thereto. After such consultation, Pfizer will have the sole right and authority to make any decision to initiate a recall or withdrawal of the Product in any country of the Pfizer Commercialization Territory and BioNTech will have the sole right and authority to make any decision to initiate a recall or withdrawal of the Product in any country of the BioNTech Commercialization Territory, </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;">, </font><font style="font-style:italic;text-decoration:none;">however</font><font style="text-decoration:none;">, that in each such case, with respect to (a) any lot or batch of Product manufactured by a Party, its Affiliates or any of their respective subcontractors, in the event that such Party, after consultation with the other Party, determines that such lot or batch of Product should be recalled in one or more countries of the other Party&#8217;s Commercialization Territory, it shall so notify such other Party and such other Party shall promptly institute a recall of such lot or batch of such Product, and (b) if the Party that is the MA Holder in a country in the other Party&#8217;s Commercialization Territory determines in good faith, after consultation with the other Party and its legal counsel, that a recall is required in such country by applicable Law, it shall so notify such other Party and such other Party shall promptly institute a recall. Subject to the foregoing and Sections&#160;9.2.2, 9.3.1.2, 9.3.2.2 and 16.3, the Commercializing Party will have sole control, responsibility and discretion with respect to implementing any and all such recalls or withdrawals in each country of such Party&#8217;s Commercialization Territory, </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that where the Recall Costs are to be borne by the other Party the Commercializing Party shall use Commercially Reasonable Efforts to mitigate any such Recall Costs. The Recall Costs of any such recall or withdrawal will be borne by BioNTech, except to the extent that the recall or withdrawal of Product is attributable to the (i) breach or default of Pfizer or its Affiliates or any of its or their Representatives under this Agreement or in its Manufacturing, handling or storing of the Product that is the subject of the recall or withdrawal, or (ii) negligence or willful misconduct of Pfizer, its Affiliates or any of its or their Representatives, in which event Pfizer will if such recall or withdrawal is in a country in the Pfizer Commercialization Territory, bear or, if such recall or withdrawal is in a country in the BioNTech Commercialization Territory, reimburse BioNTech and its Affiliates for such Recall Costs. If there is any </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">recall or withdrawal, then the Commercializing Party will implement any necessary action, and the other Party will provide any and all assistance as reasonably requested by the Commercializing Party.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc40858267"></a><a name="_Toc40859577"></a><a name="_Toc40860238"></a><a name="_Toc40862996"></a><a name="_Toc40863694"></a><a name="_Toc40864093"></a><a name="_Ref62062520"></a><a name="_Toc62256104"></a><a name="_Toc59107131"></a><a name="_Ref414602619"></a><a name="_Ref38893629"></a><a name="_Hlk62566775"></a><a name="_Toc40858268"></a><a name="_Toc40859578"></a><a name="_Toc40860239"></a><a name="_Toc40862997"></a><a name="_Toc40863695"></a><a name="_Toc40864094"></a><a name="_Toc62256105"></a><a name="_Toc59107132"></a><font style="text-decoration:none;">9.12</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Co-branding</font><font style="text-decoration:none;">. As of the Amendment Signing Date, the Parties agree on the following co-branding provisions to govern the future use of the Pfizer House Mark and BioNTech House Mark:</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:0%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">Where permitted by applicable Law and consistent with the applicable Regulatory Approval, subject to Section&#160;11.9.4, the Parties shall include on (a) Product Packaging and Labeling for the Product in the Territory, (b) all Promotional Materials to be distributed in the Territory by the Commercializing Party&#8217;s Sales Managers and PSRs and (c) those Medical Education Materials related solely to the Product to be distributed in the Territory by the Commercializing Party&#8217;s MSLs (the materials described in each of (a), (b) and (c), the &#8220;</font><font style="text-decoration:underline;">Commercialization Materials</font><font style="text-decoration:none;">&#8221;), both the Pfizer House Mark and the BioNTech House Mark, with both House Marks being clearly visible to the customer and having equal prominence;</font><font style="font-style:italic;text-decoration:none;"> provided </font><font style="text-decoration:none;">that: </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref62565935"></a><font style="text-decoration:none;">9.12.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">with respect to Commercialization Materials distributed in connection with the Product Commercialized under an Emergency Use Authorization issued by the FDA or by a Regulatory Authority in reference to the Emergency Use Authorization issued by the FDA, then on a country by country basis:</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">(a)</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">[***]; and</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">(b)</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">[***];</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.12.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">[***]</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref62566256"></a><font style="text-decoration:none;">9.12.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">[***].</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">[***]</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.13</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Vaccine Technical Committees</font><font style="text-decoration:none;">. Pfizer shall have the right to seek all recommendations for use of the Product from the applicable Vaccine Technical Committees throughout the Pfizer Commercialization Territory and BioNTech shall have the sole right to seek all recommendations for use of the Product from the applicable Vaccine Technical Committees throughout the BioNTech Commercialization Territory.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc40858269"></a><a name="_Toc40859579"></a><a name="_Toc40860240"></a><a name="_Toc40862998"></a><a name="_Toc40863696"></a><a name="_Toc40864095"></a><a name="_Toc62256106"></a><a name="_Toc59107133"></a><a name="_Ref40524487"></a><a name="_Ref43656837"></a><a name="_Ref44342777"></a><font style="text-decoration:none;">9.14</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Diligence and Performance Standards</font><font style="text-decoration:none;">. Each Party&#8217;s obligations to Commercialize the Product in its respective Commercialization Territory (and to undertake any Medical Activities in its respective Commercialization Territory) [***]. For clarity, [***], provided that a Party&#8217;s Commercialization Activities or Medical Activities in such country shall remain subject to this Article 9 and Article 10, including compliance with all applicable Laws, including Anti-Corruption Laws and provided further that if one Party does not actively Commercialize the Product in any such country which is part of its Commercialization Territory, the other Party may, through written notice to such Party, notify such Party that it desires to discuss taking over Commercialization in such country and, in such event, the Parties shall discuss in good faith whether such country shall be added to the Commercialization Territory of the other Party; </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that the Party that is entitled to Commercialize in such Commercialization Territory shall have no obligation to agree to add such country to the Commercialization Territory of the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">other Party. </font><font style="text-decoration:none;">Notwithstanding the foregoing, the Parties acknowledge the provisions of Section&#160;</font><font style="text-decoration:none;">4.15</font><font style="text-decoration:none;"> and that neither Party guarantees the success of the Product.</font><font style="text-decoration:none;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc40858270"></a><a name="_Toc40859580"></a><a name="_Toc40860241"></a><a name="_Toc40862999"></a><a name="_Toc40863697"></a><a name="_Toc40864096"></a><a name="_Toc62256107"></a><a name="_Toc59107134"></a><font style="text-decoration:none;">9.15</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Management of Representatives</font><font style="text-decoration:none;">. Each Party will have sole authority and responsibility for recruiting, hiring, managing, compensating (including paying for all benefits, wages, special incentives, workers&#8217; compensation and employment taxes), disciplining, terminating the employment of and otherwise controlling the Representatives provided or engaged by or on behalf of such Party or its Affiliates for performance of its Commercialization Activities and other obligations under this Agreement; </font><font style="font-style:italic;text-decoration:none;">provided that</font><font style="text-decoration:none;"> all such Representatives will be, to the extent relevant to the activities to be performed by such Representatives, subject to written obligations of confidentiality and invention assignment substantially consistent with the relevant provisions of this Agreement prior to, and as a condition of, such Representatives performing any such Commercialization Activities, </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;">, </font><font style="font-style:italic;text-decoration:none;">further</font><font style="text-decoration:none;">&#184; that to the extent that ownership of all relevant inventions of such Representative vests in such Party or its Affiliates, no such written obligation of invention assignment are required. Each Party will respectively provide for the day-to-day management of its or its Affiliates&#8217; Sales Managers, PSRs, MSLs and other Representatives involved in any Commercialization Activities, including furnishing administrative support, financial resources, equipment and supplies.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;">10.</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-transform:none;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref46398463"></a><a name="_Toc62256108"></a><a name="_Toc59107135"></a><font style="text-decoration:none;"></font><font style="text-decoration:underline;text-transform:uppercase;">Medical Affairs</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc40858272"></a><a name="_Toc40859582"></a><a name="_Toc40860243"></a><a name="_Toc40863001"></a><a name="_Toc40863699"></a><a name="_Toc40864098"></a><a name="_Toc62256109"></a><a name="_Toc59107136"></a><a name="_Ref413990576"></a><a name="_Ref412004740"></a><a name="_Ref39925054"></a><a name="_Hlk52997629"></a><font style="text-decoration:none;">10.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Global Medical Activities</font><font style="text-decoration:none;">. The Parties shall, but only using Commercially Reasonable Efforts in accordance with its obligations pursuant to Section&#160;9.14, undertake their respective global medical activities [***]<a name="_Hlk52997629"></a> (&#8220;Global Medical Activities&#8221;). The medical affairs section of the Global Commercialization plan will address medical strategies and guidelines; </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;">, </font><font style="font-style:italic;text-decoration:none;">however</font><font style="text-decoration:none;">, that each Party will have final say on its own Global Medical Activities. A copy of any article or abstract that relates directly to the Product which has been published in a scientific, medical, academic or industry publication by either Party under its Medical Activities for its respective Commercialization Territory shall be provided to the respective other Party after its publication. All such Global Medical Activities shall be planned and conducted by each Party in compliance with applicable Law, applicable pharmaceutical industry guidelines, applicable Internal Compliance Codes and Party Specific Regulations. Each Party will bear its own internal costs associated with planning, conducting and attending any such Global Medical Activities.</font><font style="text-decoration:underline;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc40858273"></a><a name="_Toc40859583"></a><a name="_Toc40860244"></a><a name="_Toc40863002"></a><a name="_Toc40863700"></a><a name="_Toc40864099"></a><a name="_Toc62256110"></a><a name="_Toc59107137"></a><font style="text-decoration:none;">10.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Medical Science Liaisons</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Hlk40257660"></a><font style="text-decoration:none;">10.2.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">BioNTech Medical Science Liaisons</font><font style="text-decoration:none;">. In each country of the BioNTech Commercialization Territory where BioNTech determines the use of MSLs are appropriate in connection with the Product, BioNTech shall, at its sole cost and using its Commercially Reasonable Efforts, provide and maintain MSLs to engage in MSL Activities pertaining to the Product in such country, each in accordance with the medical portion of the applicable Global Commercialization Plan and the applicable Annual Regional Commercialization Plan, if any, for such Commercialization Region. Each such BioNTech MSL may be either a full-time or a part-time employee of BioNTech or its Affiliates or an employee of a Third Party company or agency that provides temporary employees to BioNTech or its Affiliates pursuant to a contract between BioNTech or its Affiliate and such Third Party company or agency and in each case, such BioNTech MSL will remain exclusively under the authority of BioNTech<a name="_Hlk40257660"></a> or its Affiliate and be subject to all required training and Compliance requirements. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">10.2.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Pfizer Medical Science Liaisons</font><font style="text-decoration:none;">. In each country of the Pfizer Commercialization Territory where Pfizer determines the use of MSLs are appropriate in connection with the Product, Pfizer shall, at its sole cost, but only using Commercially Reasonable Efforts in accordance with its obligations pursuant to Section 9.14, provide and maintain MSLs to engage in MSL Activities pertaining to the Product in such country, each in a manner not inconsistent with the medical portion of the applicable Global Commercialization Plan and the applicable Annual Regional Commercialization Plan, if any, for such country. Each such Pfizer MSL may be either a full-time or a part-time employee of Pfizer or its Affiliates or an employee of a Third Party company or agency that provides temporary employees to Pfizer or its Affiliates pursuant to a contract between Pfizer or its Affiliate and such Third Party company or agency and in each case, such Pfizer MSL will remain exclusively under the authority of Pfizer or its Affiliate and be subject to all required training and Compliance requirements.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_cp_text_1_832"></a><a name="_cp_text_1_833"></a><a name="_cp_text_1_838"></a><font style="text-decoration:none;">10.2.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">MSL Activities</font><font style="text-decoration:none;"><a name="_cp_text_1_832"></a>. Each Party will, <a name="_cp_text_1_833"></a>and will cause its respective Affiliates to, ensure that, in each country within its Commercialization Territory, the activities of such Commercializing Party&#8217;s MSLs are (i) aligned with guidelines established by the applicable Commercializing Party across its product portfolio, consistently applied (</font><font style="font-style:italic;text-decoration:none;">e.g.</font><font style="text-decoration:none;"><a name="_cp_text_1_838"></a>, related to internal and external interactions), or if the Party does not have such guidelines, then consistent with industry standards for such governing MSL Activities, and (ii) not inconsistent with the global medical strategy for the Product as set forth in the medical portion of the applicable Global Commercialization Plan or the medical strategy for the Product in such country as set forth in the applicable Annual Regional Commercialization Plan. Each Party will, and will cause its Affiliates to, ensure that, in each country within its Commercialization Territory, its MSLs only use Medical Education Materials approved by the applicable Commercializing Party for use in such country.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc40858274"></a><a name="_Toc40859584"></a><a name="_Toc40860245"></a><a name="_Toc40863003"></a><a name="_Toc40863701"></a><a name="_Toc40864100"></a><a name="_Toc62256111"></a><a name="_Toc59107138"></a><a name="_Ref412004544"></a><font style="text-decoration:none;">10.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Training and Medical Education Materials</font><font style="text-decoration:none;">.</font><font style="text-decoration:underline;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Hlk39590429"></a><a name="_Ref43486958"></a><a name="_Ref413993095"></a><a name="_Ref412003750"></a><a name="_Ref39590105"></a><font style="text-decoration:none;">10.3.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Pfizer&#8217;s Training Obligations</font><font style="text-decoration:none;">. Pfizer or its Affiliates, at its cost and risk, will develop training materials for its MSLs, for use in particular countries within the Pfizer Commercialization Territory (the &#8220;</font><font style="text-decoration:underline;">Pfizer Medical Training Materials</font><font style="text-decoration:none;">&#8221;). The Pfizer Medical Training Materials shall be in compliance with applicable Law, consistent with the applicable Regulatory Approvals for the Product and, except where necessary to comply with applicable Law, not be inconsistent with the global medical strategy for the Product established by the JCC as reflected in the medical affairs section of the Global Commercialization Plan. Utilizing such Pfizer Medical Training Materials, Pfizer will be responsible, at its own cost and risk, for preparing and delivering training to its MSLs with respect to the Product. Such training shall occur (a) prior to the provision by such MSL of any MSL Activities with respect to the Product and (b) periodically thereafter in each country in the Pfizer Commercialization Territory as is consistent with Pfizer&#8217;s practices for periodic training of its MSLs or as may be otherwise needed to update such training based on new information. Pfizer will share, at BioNTech&#8217;s risk, such Pfizer Medical Training Materials (to the extent such materials are solely related to the Product) for BioNTech&#8217;s use, subject to Section&#160;10.3.2, in the BioNTech Commercialization Territory; </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;">,</font><font style="font-style:italic;text-decoration:none;"> however</font><font style="text-decoration:none;">, that Pfizer shall not be liable to BioNTech for any inaccuracy or error in the Pfizer Medical Training Materials.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref40020503"></a><font style="text-decoration:none;">10.3.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">BioNTech&#8217;s Training Obligations</font><font style="text-decoration:none;">. BioNTech or its Affiliates, at its cost and risk, will develop (as necessary or desirable to address local requirements or customs and medical strategies and needs) and design training materials, for use in particular countries within the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Commercialization Territory, including by adapting and modifying the Pfizer Medical Training Material (the </font><font style="text-decoration:none;">&#8220;</font><font style="text-decoration:underline;">BioNTech</font><font style="text-decoration:underline;"> Medical Training Materials</font><font style="text-decoration:none;">&#8221;</font><font style="text-decoration:none;">). </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> shall ensure that the </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Medical Training Materials shall be in compliance with applicable Law, consistent with the applicable Regulatory Approvals for the Product and, except where necessary to comply with applicable Law, not be inconsistent with the global medical strategy for the Product established by the JCC as reflected in the medical affairs section of the Global Commercialization Plan. Utilizing such </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Medical Training Materials, </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> will be responsible, at its own cost and risk, for preparing and delivering training to its MSLs with respect to the Product. Such training shall occur (a) prior to the provision by such MSL of any MSL Activities with respect to the Product and (b) periodically thereafter in each country in the </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Commercialization Territory as is consistent with </font><font style="text-decoration:none;">BioNTech&#8217;s</font><font style="text-decoration:none;"> practices for periodic training of its MSLs or as may be otherwise needed to update such training based on new information.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">10.3.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Communication with MSLs</font><font style="text-decoration:none;">. Subject to this Section&#160;10.3, each Party will, directly or through its Affiliates, have full and sole responsibility for the dissemination of all information regarding the Product to its MSLs. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref412003542"></a><a name="_cp_text_1_884"></a><a name="_cp_text_1_886"></a><a name="_cp_text_1_888"></a><a name="_cp_text_1_889"></a><a name="_cp_text_1_892"></a><a name="_cp_text_1_893"></a><font style="text-decoration:none;">10.3.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Medical Education Materials</font><font style="text-decoration:none;">. All written medical educational materials to be provided to healthcare professionals relating to any condition treated with the Product, and other media and materials used to educate the public regarding the Product or any indication treated with the Product (collectively and including translations, &#8220;</font><font style="text-decoration:underline;">Medical Education Materials</font><font style="text-decoration:none;"><a name="_cp_text_1_884"></a>&#8221;) will be prepared by Pfizer for use in the Pfizer Commercialization Territory and by BioNTech for use in the BioNTech Commercialization Territory. <a name="_cp_text_1_886"></a>Subject to applicable Law, Pfizer will determine the content, quantity and method of distribution of all such Medical Education Materials and other Pfizer Commercial Materials for use in the Pfizer Commercialization Territory in its sole discretion and BioNTech will determine the content, quantity and method of distribution of all such Medical Education Materials and other BioNTech Commercial Materials for use in the BioNTech Commercialization Territory in its sole discretion, provided that, in each case, all such Medical Education Materials and Pfizer Commercial Materials or BioNTech Commercial Materials, as applicable, will be in compliance with applicable Law. Pfizer and BioNTech<a name="_cp_text_1_888"></a> each will provide the other copies of the <a name="_cp_text_1_889"></a>Medical Education Materials it prepares, and the other Party shall be free to utilize all or part of such Medical Education Materials in the design of the Medical Education Materials it will prepare solely for use in and distribute solely by its or its Affiliates&#8217; MSLs and other employees, as permitted by applicable Law and such Party's Internal Compliance Codes, in its Commercialization Territory. Each of Pfizer and BioNTech<a name="_cp_text_1_892"></a> will, <a name="_cp_text_1_893"></a>and will cause its respective Affiliates and its and their respective Representatives, including each MSL and other Representative to, as applicable, (a) use all Pfizer Commercial Materials solely in connection with Pfizer&#8217;s MSL Activities under this Agreement, (b) use all BioNTech Commercial Materials solely in connection with BioNTech&#8217;s MSL Activities under this Agreement, (c) not create or modify, distribute or use sales, promotion or any other material relating to the Product other than the Medical Education Materials or other approved materials per each respective Party&#8217;s Compliance policies, and requirements under local labeling, Regulatory Approval and applicable Law. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc40858275"></a><a name="_Toc40859585"></a><a name="_Toc40860246"></a><a name="_Toc40863004"></a><a name="_Toc40863702"></a><a name="_Toc40864101"></a><a name="_Toc62256112"></a><a name="_Toc59107139"></a><a name="_Ref412003672"></a><a name="_Hlk52997836"></a><a name="_Hlk56600825"></a><font style="text-decoration:none;">10.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Unsolicited Medical Requests</font><font style="text-decoration:none;">.&nbsp;&nbsp;Pfizer will have the exclusive right to respond to all Unsolicited Medical Requests received from HCPs, patients, payors or other customers in the Pfizer Commercialization Territory and BioNTech will have the exclusive right to respond to all Unsolicited Medical Requests received from HCPs, patients, payors or other customers in the BioNTech </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">Commercialization Territory. </font><font style="text-decoration:none;">In the event a Commercializing Party or its Representatives receives an UMR from an individual within and concerning a country in the other Commercializing Party&#8217;s Commercialization Territory, such Commercializing Party (i) will log all Unsolicited Medical Requests it or any of its Representatives receives in accordance with its respective policies and procedures in effect in each country within its Commercialization Territory, (ii) will, and will use Commercially Reasonable Efforts to cause its respective Affiliates and their respective Representatives to, communicate promptly to the other Party all UMRs so received concerning that other Party&#8217;s Commercialization Territory, by contacting the other Party&#8217;s medical information function in the applicable country, and (iii) to the extent practicable, shall refer the individual making such Unsolicited Medical Request to the other Party for response in accordance with referral instructions that such other Party has previously provided and that are then in effect. The applicable RCC for each such country or if there is no RCC for such country, the Party in whose Commercialization Territory such country is located, will be responsible for reviewing such policies and procedures related to logging UMRs as well as determining the manner by which a Party will communicate UMRs to the other Party as provided above, including points of contact for each such country. If any gaps or significant differences between the applicable policies and procedures of </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"><a name="_Hlk56600825"></a> and Pfizer related to the logging of UMRs in a given country are identified, then each Party will promptly consult with applicable internal personnel and each other to determine how such policies and procedures are to be reconciled. </font><font style="text-decoration:none;">Each party will share analytics such as inquiry volumes and topics on a monthly basis or other mutually agreed upon timeframe. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256113"></a><a name="_Toc59107140"></a><a name="_Ref58356309"></a><font style="text-decoration:none;">10.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Medical Information Content</font><font style="text-decoration:none;">. Pfizer shall be responsible for preparing all medical information standard response documents, content and frequently asked questions (FAQs) documents to be used in the context of the Commercialization of the Product or Product Materials in the Territory (such medical information individually or collectively, &#8220;Medical Information Content&#8221;) and shall make such Medical Information Content available to BioNTech within [***]. [***].</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256114"></a><a name="_Toc59107141"></a><a name="_Ref51488437"></a><font style="text-decoration:none;">10.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Medical Affairs Studies</font><font style="text-decoration:none;">. Either Party shall have the right, at its own expense, to plan, design, recruit, monitor and conduct studies (other than Clinical Trials) relating to the Product, including surveillance studies, epidemiological studies, or other non-interventional studies where the effectiveness of the Product is not an endpoint nor are such studies used to support Regulatory Approval of the Product or expansion of the Product label (&#8220;Medical Affairs Studies&#8221;), </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that (i) such study shall be conducted in compliance with applicable Law and all applicable Professional Requirements and (ii) solely to the extent that data arising from any such study is of application exclusively to the Product, such data shall be owned by BioNTech, and Pfizer shall make such data available to BioNTech upon completion of the relevant study, and Pfizer shall be free to use and sublicense (through multiple tiers) such data (on a royalty free and irrevocable basis) for any purpose. The Party conducting such studies shall keep the other Party reasonably informed regarding the results of all such studies. In the event that the other Party desires to use the data from any such study in the Commercialization of the Product in its Commercialization Territory, the Parties shall discuss in good faith a cost-sharing arrangement with respect to costs of such studies in consideration for a license to use such data from such study.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;">11.</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-transform:none;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref43660314"></a><a name="_Ref59043520"></a><a name="_Toc62256115"></a><a name="_Toc59107142"></a><font style="text-decoration:none;"></font><font style="text-decoration:underline;text-transform:uppercase;">Intellectual Property</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc519764415"></a><a name="_Toc519873411"></a><a name="_Toc35600551"></a><a name="_Toc62256116"></a><a name="_Toc59107143"></a><a name="_Ref519243414"></a><a name="_Toc484766516"></a><a name="_Ref135582504"></a><a name="_Ref135585235"></a><a name="_Ref263796758"></a><a name="_Toc484765954"></a><a name="_Toc484766020"></a><a name="_Toc484766086"></a><a name="_Toc484766520"></a><a name="_Toc519762588"></a><a name="_Toc519764424"></a><a name="_Toc519774930"></a><a name="_Toc519873415"></a><a name="_Ref135583512"></a><a name="_Ref135584703"></a><a name="_Ref135585297"></a><a name="_Ref263793569"></a><a name="_Ref468947752"></a><a name="_Ref518291079"></a><a name="_Ref519269750"></a><font style="text-decoration:none;">11.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Patent Committee</font><font style="text-decoration:none;">. Within the first [***] following the Effective Date, or as otherwise agreed by the Parties, the Parties will establish a patent committee (the &#8220;Patent Committee&#8221;), comprised of at least [***] of BioNTech and at least [***] of Pfizer (which [***] may be replaced by either Party at any time through written notice to the other Party). The Patent Committee shall coordinate all activities in </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">relation to Patent Rights applicable to the terms of this Agreement. In particular, the Patent Committee shall:</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc519764416"></a><font style="text-decoration:none;">11.1.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">coordinate all activities in relation to the filing and prosecution of Patent Rights relating to this Agreement pursuant to Sections&#160;11.2.1 and 11.3.1 of this Agreement,</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc519764417"></a><font style="text-decoration:none;">11.1.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">discuss any actual, potential or suspected infringement of such Patent Rights pursuant to Section 11.4.1, </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc519764418"></a><font style="text-decoration:none;">11.1.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">regularly review which BioNTech Patent Rights may be relevant to Candidates and Products; and</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc519764420"></a><font style="text-decoration:none;">11.1.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">discuss and consider any potential Future License, including in meetings where relevant attorneys and business personnel of the Parties are invited to participate in such discussions and considerations, </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that the decision for any agreement to become a Future License shall only be made on mutual agreement by the Parties<a name="_Toc519764420"></a>.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref36308609"></a><a name="_Hlk519522881"></a><font style="text-decoration:none;">11.1.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">The Patent Committee shall meet (either in-person or by audio or video conference) as often as determined by the Patent Committee as well as upon the reasonable request of either Party. It is acknowledged that particularly in the case of any Enforcement Action the Patent Committee may need to meet at very short notice and be required to expedite and make decisions very quickly and the Parties shall procure that the Patent Committee shall meet urgently as quickly as reasonably required in connection with any Enforcement Action. The Patent Committee will be chaired by a Patent Committee member chosen by mutual agreement. The Patent Committee shall operate in good faith and acting reasonably. Sections 6.3.2 and 6.3.3, unless otherwise mutually agreed between the Parties, shall apply </font><font style="font-style:italic;text-decoration:none;">mutatis mutandis</font><font style="text-decoration:none;">. <a name="_Hlk519522881"></a>The Patent Committee will use good faith efforts to reach agreement on all matters properly brought before it. If, despite such good faith efforts, the Patent Committee is unable to reach unanimous agreement on a particular matter, such matter shall be escalated to the JSC for final resolution and decisions of the JSC in this regard must be made by unanimous consent.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc519764421"></a><a name="_Toc519873412"></a><a name="_Toc35600552"></a><a name="_Toc62256117"></a><a name="_Toc59107144"></a><a name="_Ref62483583"></a><a name="_Ref519347103"></a><font style="text-decoration:none;">11.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Ownership of Intellectual Property</font><font style="text-decoration:none;">.</font><font style="text-decoration:underline;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref35521050"></a><a name="_Ref135582798"></a><a name="_Ref516778969"></a><a name="_Ref263796800"></a><a name="_Ref265016256"></a><a name="_Ref468600778"></a><a name="_Ref518043618"></a><font style="text-decoration:none;">11.2.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Ownership of Product Technology</font><font style="text-decoration:none;">. [***]</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref518310204"></a><font style="text-decoration:none;">11.2.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Ownership of BioNTech Improvements and Pfizer Improvements</font><font style="text-decoration:none;">. As between the Parties, (a) BioNTech will own all BioNTech Improvements and (b) Pfizer will own all Pfizer Improvements.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref35890333"></a><a name="_cp_text_2_407"></a><a name="_Ref517384859"></a><font style="text-decoration:none;">11.2.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Ownership of other Research and Development Program Technology</font><font style="text-decoration:none;"><a name="_cp_text_2_407"></a>. Except for BioNTech Improvements, Pfizer Improvements and [***]<a name="_Ref517384859"></a>, the ownership of other Research and Development Program Technology, will be allocated based on inventorship as defined under the Laws of the United States. Notwithstanding the foregoing, during the Term, and without prejudice to Section 11.3 the Parties (through the Patent Committee) shall cooperate and discuss in good faith with respect to the timing, scope and filing of any Patent Rights claiming or disclosing any Research and Development Program Technology.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref518310202"></a><a name="_Ref263784882"></a><a name="_Ref263784933"></a><a name="_Ref263784953"></a><a name="_Ref263784958"></a><a name="_Ref263796763"></a><font style="text-decoration:none;">11.2.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Ownership of Joint Technology</font><font style="text-decoration:none;">. Subject to Section 11.2.1, 11.2.2 and 11.2.3, the Parties will jointly own any Joint Technology. Subject to (a) the grant of licenses or sublicenses </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">under Section </font><font style="text-decoration:none;">3</font><font style="text-decoration:none;">, (b) </font><font style="text-decoration:none;">BioNTech&#8217;s</font><font style="text-decoration:none;"> representations, warranties and covenants under Section </font><font style="text-decoration:none;">13</font><font style="text-decoration:none;"> and (c) the Parties&#8217; other rights and obligations under this Agreement (including Section&#160;</font><font style="text-decoration:none;">3.11</font><font style="text-decoration:none;">), each Party will be free to exploit, either itself or through the grant of licenses to Third Parties (which Third Party licenses may be further sublicensed), Joint Technology throughout the world without restriction, without the need to obtain further consent from or provide notice to the other Party, and without any duty to account or otherwise make any payment of any compensation to the other Party.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref475159684"></a><a name="_Toc484766517"></a><a name="_cp_text_1_412"></a><font style="text-decoration:none;">11.2.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Ownership of Other Intellectual Property</font><font style="text-decoration:none;">. Except as set forth in Sections 11.2.1, 11.2.2, 11.2.3 and 11.2.4<a name="_Ref475159684"></a><a name="_Toc484766517"></a>, <a name="_cp_text_1_412"></a>each Party will own all right, title and interest in and to any and all Know-How, Patent Rights or other Intellectual Property Rights that such Party owns as of the Effective Date or otherwise develops, creates or acquires pursuant to activities under this Agreement during the Term. For the purposes of determining ownership under this Agreement, as applicable, inventorship will be determined in accordance with United States patent laws. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc519764422"></a><a name="_Toc519873413"></a><a name="_Toc35600553"></a><a name="_Ref518373201"></a><a name="_Toc62256118"></a><a name="_Toc59107145"></a><font style="text-decoration:none;">11.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Patent Rights</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref135584745"></a><font style="text-decoration:none;">11.3.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Filing, Prosecution and Maintenance of Patent Rights. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref516825148"></a><a name="_Ref518674138"></a><a name="_Ref135584729"></a><a name="_cp_text_2_420"></a><font style="text-decoration:none;">11.3.1.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-style:italic;text-decoration:none;">Prosecution by BioNTech</font><font style="text-decoration:none;">. BioNTech will have the first right, and a Commercially Reasonable Efforts obligation, to file, Prosecute and Maintain the BioNTech Patent Rights owned by BioNTech or its Affiliates and any Product Patent Rights, and Patent Rights claiming BioNTech Improvements (together the &#8220;</font><font style="text-decoration:underline;">BioNTech Prosecution Patent Rights</font><font style="text-decoration:none;">&#8221;) at BioNTech&#8217;s<a name="_cp_text_2_420"></a> sole expense using counsel of its own choice reasonably acceptable to Pfizer in Australia, Canada, the member states of the European Patent Convention including the Major EU Market Countries, Japan, the United States, Brazil, Russia, India, Mexico and South Korea (&#8220;</font><font style="text-decoration:underline;">Key Patent Jurisdictions</font><font style="text-decoration:none;">&#8221;). Upon request of Pfizer, BioNTech shall file one or more BioNTech Prosecution Patent Rights in one or more jurisdictions other than the Key Patent Jurisdictions (&#8220;</font><font style="text-decoration:underline;">Additional Patent Jurisdictions</font><font style="text-decoration:none;">&#8221;), and BioNTech will have the first right, and a Commercially Reasonable Efforts obligation, to file, Prosecute and Maintain such BioNTech Prosecution Patent Rights in such Additional Patent Jurisdictions at Pfizer&#8217;s sole expense (until such time as Pfizer elects not to maintain such Patent Rights in such Additional Patent Jurisdictions whereupon BioNTech can elect to abandon or surrender the same or to continue the Prosecution and Maintenance of such Patent Rights at its own expense) using counsel of its own choice reasonably acceptable to Pfizer. BioNTech will keep Pfizer advised on the status of the preparation, filing, prosecution, and maintenance of the Patent Rights included within BioNTech Prosecution Patent Rights in all the jurisdictions where filed. Further, in respect of any jurisdiction, BioNTech will (a) allow Pfizer a reasonable opportunity and reasonable time to review and provide comments to BioNTech&#8217;s patent counsel regarding relevant substantive communications to BioNTech and drafts of any responses or other proposed substantive filings by BioNTech before any applicable filings are submitted to any relevant patent office (or Governmental Authority) with respect to any BioNTech Prosecution Patent Rights and (b) reflect any reasonable and timely comments offered by Pfizer in any final filings submitted by BioNTech to any relevant patent office (or Governmental Authority) with respect to any BioNTech Prosecution Patent Rights. If BioNTech elects not to file a Patent Right included in the BioNTech Prosecution Patent </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">Rights in any Key Patent Jurisdiction or Additional Patent Jurisdiction or elects to cease the prosecution or maintenance of one or more Patent Rights included in the </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Prosecution Patent Rights in any Key Patent Jurisdiction or Additional Patent Jurisdiction and, as relevant, no Third Party has agreed to continue the prosecution or maintenance of such Patent Rights under agreements concluded before the Effective Date, </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> will provide Pfizer with written notice of its decision not to file, not to Prosecute and Maintain not less than </font><font style="text-decoration:none;">[***]</font><font style="text-decoration:none;"> before any action is required to avoid abandonment or lapse. In the event of any such notice, if Pfizer elects to file or continue such prosecution or maintenance in the name of </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> at Pfizer&#8217;s sole expense, (x) Pfizer shall be entitled to do so and take all steps in such Prosecution and Maintenance at its sole discretion; (y) </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> will reasonably cooperate to promptly transfer the necessary files and execute the necessary forms regarding such transfer and (z) Pfizer will keep </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> advised on the status of such filing, Prosecution and Maintenance and will reasonably consider any comments made by </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> in connection therewith. If Pfizer elects not to file or continue such prosecution or maintenance, then </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> may immediately abandon, allow to lapse, or omit to prosecute such Patent Right, as the case may be. </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> will promptly, and no later than </font><font style="text-decoration:none;">[***]</font><font style="text-decoration:none;"> after written request by Pfizer, by written notice to Pfizer update </font><font style="text-decoration:underline;">Schedule </font><font style="text-decoration:underline;">13.3.4</font><font style="text-decoration:none;"> to identify all </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Patent Rights to be added thereto.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref263796853"></a><a name="_Ref517385331"></a><font style="text-decoration:none;">11.3.1.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-style:italic;text-decoration:none;">Other Patent Rights. </font><font style="text-decoration:none;">Except as provided in Section&#160;11.3.1.1, each Party will have the sole right, but not the obligation, to file, Prosecute and Maintain the Research and Development Program Patent Rights or other Patent Rights that it solely owns under this Agreement or to which it otherwise has control of prosecution rights in its sole discretion, provided that at a Party&#8217;s reasonable request, the other Party will provide status or other requested information for any Research and Development Program Patent Right and will consider in good faith any recommendations made by such Party in regard to the filing, prosecution or maintenance of any such Patent Right.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref37279420"></a><font style="text-decoration:none;">11.3.1.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-style:italic;text-decoration:none;">Reference of Research and Development Program Know-How. </font><font style="text-decoration:none;">If a Party chooses to file, and thereafter Prosecute and Maintain, Patent Rights after the expiration of the Term, including any extension to the Term, that Party may use or incorporate Research and Development Program Know-How in the filing or prosecution of such Patent Rights filed after the Term, if it determines in its sole discretion that it is necessary or useful to use or incorporate such Research and Development Program Know-How.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref480471102"></a><a name="_Ref263791213"></a><a name="_cp_text_2_431"></a><a name="_cp_text_2_436"></a><a name="_cp_field_47_441"></a><font style="text-decoration:none;">11.3.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Joint Patent Rights</font><font style="text-decoration:none;"><a name="_cp_text_2_431"></a>. In the event the Parties make any Joint Know-How, the Parties will promptly meet to discuss and determine, based on mutual consent, whether to seek patent protection thereon. Neither Party will file any Joint Patent Right without mutual consent. Unless otherwise agreed between the Parties, if the Parties decide to seek patent protection for any Joint Know-How: (a) BioNTech will have the first right, but not the obligation, to prepare, file, Prosecute and Maintain any Joint Patent Right predominantly relating to the RNA Technology or RNA Process Technology throughout the world, and (b) Pfizer will have the first right, but not the obligation, to prepare, file, Prosecute and Maintain any other Joint Patent Right throughout the world, in each case of (a) and (b) with the respective provisions of Section <a name="_cp_text_2_436"></a>11.3.1.1 to apply </font><font style="font-style:italic;text-decoration:none;">mutatis mutandis</font><font style="text-decoration:none;"><a name="_cp_field_47_441"></a> except as provided in this Section 11.3.2. The non-filing Party will reimburse the filing Party for 50% of the costs reasonably incurred by the filing Party in preparing, filing, prosecuting and maintaining such Joint Patent Rights, which reimbursement will be made pursuant to, and </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">within 75 days of, invoices (including supporting documentation) submitted by the filing Party to the non-filing Party no more often than once per Pfizer Quarter. The non-prosecuting Party will cooperate with the prosecuting Party in taking reasonable measures to control costs and non-prosecuting Party shall be responsible for 100% of (x) any fees or costs related to any correspondence of outside counsel with or instructions to outside counsel by such Party (or any of such Party&#8217;s Representatives) which is independent of joint prosecution efforts, or (y) any patent office fees, and associated counsel/agent fees and costs, for extensions which are not incurred at the request of, and not due to the actions of, the prosecuting Party. If, once the Parties have agreed to prepare and file an application of Joint Patent Rights, either Party (the &#8220;</font><font style="text-decoration:underline;">Declining Party</font><font style="text-decoration:none;">&#8221;) at any time thereafter declines to participate in the preparation, filing, prosecution or maintenance of any Joint Patent Right or share in the costs of filing, prosecuting and maintaining any Joint Patent Right, on a country-by-country basis, the Declining Party will provide the other Party (the &#8220;</font><font style="text-decoration:underline;">Continuing Party</font><font style="text-decoration:none;">&#8221;) with 30 days prior written notice to such effect, in which event, the Declining Party will (A) have no responsibility with respect to the filing, prosecution or maintenance of the applicable Joint Patent Right after the end of such 30 day period, (B) have no responsibility for any expenses incurred in connection with such Joint Patent Right after the end of such 30 day period and (C) if the Continuing Party elects to continue filing, prosecution or maintenance, the Declining Party, upon the Continuing Party&#8217;s request, will execute such documents and perform such acts, at the Continuing Party&#8217;s expense, as may be reasonably necessary (1) to assign to the Continuing Party all of the Declining Party&#8217;s right, title and interest in and to such Joint Patent Right and (2) to permit the Continuing Party to file, Prosecute and Maintain such Joint Patent Right at its sole expense. Where such Joint Patent Right is assigned to Pfizer as the Continuing Party, </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> will retain a non-exclusive, sublicensable, perpetual, irrevocable, royalty-free, fully paid-up worldwide right and license to practice and exploit such Patent Right for any and all purposes excluding, during the Term, in the Field; and where such Joint Patent Right is assigned to </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> as the Continuing Party, it will be excluded from the definition of </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Patent Rights, and Pfizer will retain a non-exclusive, sublicensable, perpetual, irrevocable, royalty-free, fully paid-up worldwide right and license to practice and exploit such Joint Patent Right for any and all purposes.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref263796981"></a><a name="_Ref469051642"></a><a name="_Ref519034501"></a><font style="text-decoration:none;">11.3.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Prosecution by Third Party Licensors</font><font style="font-style:italic;text-decoration:none;">. </font><font style="text-decoration:none;">Except in the ordinary course of filing continuation applications, BioNTech shall not decline to pay for or participate in the filing, prosecution or maintenance of any Patent Right under any BioNTech Third Party Agreement in any Key Patent Jurisdiction (or other country to the extent doing so may result in BioNTech&#8217;s loss of license to such Patent Right in such country), to the extent BioNTech is obligated to pay for, or has the right to participate in, such filing, prosecution or maintenance, that is included in the BioNTech Patent Rights and that, in Pfizer&#8217;s reasonable opinion, covers any Candidate, Product or [***] in the Field in the Territory, and the loss of which would result in loss of right to or would materially diminish the overall protection of such Candidate or Product, without Pfizer&#8217;s prior written consent, not to be unreasonably withheld or delayed.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref519257331"></a><font style="text-decoration:none;">11.3.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Patent Term Restoration and Extension</font><font style="font-style:italic;text-decoration:none;">. </font><font style="text-decoration:none;">Upon the request of either Party, the Parties will (through the Patent Committee) reasonably discuss patent term extension and supplemental protection certificate strategies in relation to Patent Rights Covering Candidates or Products at any time. Notwithstanding the above, within the time period specified by applicable Law upon receiving Regulatory Approval for a Product in any country in the Territory, [***].</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref519269515"></a><a name="_Hlk519523150"></a><font style="text-decoration:none;">11.3.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Clarifications</font><font style="font-style:italic;text-decoration:none;">.</font><font style="text-decoration:none;"> For clarity, prosecution under this Section 11.3 includes opposition, revocation and post-grant review proceedings before the granting patent office or other patent office proceedings ("</font><font style="text-decoration:underline;">Prosecution Proceeding</font><font style="text-decoration:none;">"). If such Prosecution Proceedings are concurrent with Third Party litigation under Section 11.4<a name="_Hlk519523150"></a> and are applicable to or part of a coordinated enforcement of such rights, the prosecuting Party and the enforcing Party shall work together and closely align their prosecution and enforcement strategy in accordance with Section 11.5 (including the right for one Party to have final control as stipulated in Section 11.5). </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref62484305"></a><font style="text-decoration:none;">11.3.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Liability</font><font style="font-style:italic;text-decoration:none;">.</font><font style="text-decoration:none;"> To the extent that a Party is obtaining, Prosecuting or Maintaining a Patent Right or otherwise exercising its rights under this Section 11.3, such Party, and its Representatives, will not be liable to the other Party in respect of any act, omission, default or neglect on the part of any such Party, or its Representatives, in connection with such activities undertaken in good faith. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766518"></a><a name="_Ref273099482"></a><font style="text-decoration:none;">11.3.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Recording</font><font style="text-decoration:none;">. If either Party deems it necessary or useful to register or record this Agreement or evidence of this Agreement with any patent office or other appropriate Governmental Authority(ies) in one or more jurisdictions, the other Party will reasonably cooperate to execute and deliver to such Party any documents accurately reflecting or evidencing this Agreement that are necessary or useful, in such Party&#8217;s reasonable judgment, to complete such registration or recordation. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">11.3.8</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Joint Research Agreement</font><font style="font-style:italic;text-decoration:none;">. </font><font style="text-decoration:none;">This Agreement shall be understood to be a joint research agreement under 35 U.S.C. &#167; 103(c)(3) for pre-AIA Patent Rights and 35 U.S.C. &#167; 100(h) for post-AIA Patent Rights entered into for the purpose of researching, identifying and Developing Candidates and Products.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref135584777"></a><a name="_Ref263796833"></a><a name="_Toc62256119"></a><a name="_Toc59107146"></a><a name="_cp_text_2_445"></a><font style="text-decoration:none;">11.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Enforcement of Patent Rights</font><font style="text-decoration:none;"><a name="_cp_text_2_445"></a>.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref519036958"></a><a name="_Ref519354339"></a><font style="text-decoration:none;">11.4.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Notification of Infringement and Decision about Enforcement Actions</font><font style="text-decoration:none;">. Each Party will promptly notify the other (through the Patent Committee) in the event of any actual, potential or suspected infringement of a patent under the BioNTech Patent Rights or Research and Development Program Patent Rights by any Third Party. In the event of any such notification, the Parties will (through the Patent Committee) discuss in good faith the relevant actual, potential and suspected infringement and the risks and chances of success as well as chances of settlement connected with the institution of any litigation or other step to remedy infringement (any such steps, or threat of or assertion or enforcement of a Patent Right being an &#8220;</font><font style="text-decoration:underline;">Enforcement Action</font><font style="text-decoration:none;">&#8221;) taking into account the possible uses of the relevant Patent Rights by each Party, its respective Affiliates or its or their licensees and the revenues relating to or impacted by such Patent Rights, with the goal to agree on whether or not any Enforcement Action should be taken and, if yes, to closely coordinate so far as reasonably possible their respective efforts and strategies. The Parties acknowledge that time shall be of the essence in connection with any Enforcement Action and each shall move urgently and expeditiously to discuss and seek agreement on any actual or proposed Enforcement Action. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref519248016"></a><a name="_Ref519271981"></a><a name="_Ref135584780"></a><a name="_Ref268772185"></a><a name="_Ref271024140"></a><a name="_Ref517389371"></a><a name="_Ref517390216"></a><a name="_Ref518674260"></a><a name="_Hlk35439583"></a><font style="text-decoration:none;">11.4.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Enforcement of BioNTech Patent Rights and Product Patent Rights</font><font style="text-decoration:none;">. Subject to Section 11.4.1, and unless otherwise agreed between the Parties on a case-by-case basis, as between Pfizer and BioNTech, BioNTech shall have the first right, but not the obligation, to institute any Enforcement Action in connection with the BioNTech Patent Rights [***] in the Field </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;"><a name="_Hlk35439583"></a>in the Territory (the &#8220;</font><font style="text-decoration:underline;">BioNTech</font><font style="text-decoration:underline;"> Enforcement Patent Rights</font><font style="text-decoration:none;">&#8221;), and any such Enforcement Action will be at </font><font style="text-decoration:none;">BioNTech&#8217;s</font><font style="text-decoration:none;"> expense including </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> indemnifying and holding harmless Pfizer and its Affiliates from and against any adverse cost award, where Pfizer or its Affiliates consent to join any such Enforcement Action upon </font><font style="text-decoration:none;">BioNTech&#8217;s</font><font style="text-decoration:none;"> request, or where required by Law or where Pfizer or its Affiliates are enjoined by the counterparty. </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> shall not name as a party Pfizer or its Affiliates in any Enforcement Action without Pfizer's prior written consent. In any event, </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> will not, without the prior written consent of Pfizer, enter into any compromise or settlement relating to such litigation that (a) admits the invalidity or unenforceability of any </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Enforcement Patent Right or (b) requires </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> to abandon any </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Enforcement Patent Right. Upon the request of </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;">, Pfizer shall have the sole discretion to decide whether or not to join as a party in any such Enforcement Action, and where it elects to do so it shall, at </font><font style="text-decoration:none;">BioNTech&#8217;s</font><font style="text-decoration:none;"> expense, join and cooperate with </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> in such Enforcement Action. Pfizer will have the right to consult with, and provide comments to, </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> about such Enforcement Action (irrespective of Pfizer or its Affiliate being a party to such Enforcement Action), and to participate in and be represented by independent counsel in such Enforcement Action at Pfizer&#8217;s own expense, and </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> shall take into account any reasonable comments provided by Pfizer in such Enforcement Action. Neither Party will incur any liability to the other Party (other than that related to a Party&#8217;s indemnification obligation pursuant to Section&#160;</font><font style="text-decoration:none;">16</font><font style="text-decoration:none;">) as a consequence of any Enforcement Action initiated or pursued pursuant to this Section&#160;</font><font style="text-decoration:none;">11.4</font><font style="text-decoration:none;"> or any unfavorable decision resulting therefrom, including any decision holding any </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Enforcement Patent Rights invalid or unenforceable.</font><font style="text-decoration:none;"> Any infringement recoveries resulting from such litigation or steps relating to a claim of Third Party infringement, after deducting </font><font style="text-decoration:none;">BioNTech&#8217;s</font><font style="text-decoration:none;"> out of pocket expenses (including counsel fees and expenses including any adverse cost award) in pursuing such claim, will be treated as Gross Profits for the purposes of this Agreement.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref37116546"></a><a name="_cp_text_2_449"></a><a name="_Ref518674295"></a><a name="_Ref517693964"></a><font style="text-decoration:none;">11.4.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Pfizer's Enforcement Rights</font><font style="text-decoration:none;">. In respect of an infringement of any BioNTech Enforcement Patent Right in the Field in the Territory in connection with a Competitive Product (&#8220;</font><font style="text-decoration:underline;">Competitive Product Infringement</font><font style="text-decoration:none;">&#8221;), if, following (a) discussion of any potential Enforcement Action pursuant to Section 11.4.1 and (b) a subsequent written request by Pfizer to initiate any Enforcement Action in connection with such Competitive Product Infringement, BioNTech does not initiate any Enforcement Action in connection with such Competitive Product Infringement within thirty (30) days following receipt of such notices, or as soon as possible and in any event no later than ten (10) Business Days if preliminary injunction proceedings are a potential or likely recourse to remedy the infringement), or ten (10) days before the time limit, if any, set forth in the applicable Laws for the filing of such actions, Pfizer shall have the right, but not the obligation, in place of BioNTech to institute any Enforcement Action in connection with such Competitive Product Infringement and any such Enforcement Action will be at Pfizer&#8217;s expense and the provisions set forth in the first paragraph of this Section 11.4.2 shall apply </font><font style="font-style:italic;text-decoration:none;">mutatis mutandis</font><font style="text-decoration:none;">. Pfizer&#8217;s rights with respect to an Enforcement Action for BioNTech Enforcement Patent Rights other than Product Patent Rights shall be limited to (i) Major Market Countries; (ii) Enforcement Actions in countries in which a Competitive Product (or part thereof) reasonably believed to be designated for any Major Market Country is Manufactured; and (iii) Enforcement Actions in Belgium, Ireland or the Netherlands that are in parallel with Enforcement Actions in any of the Major EU Market Countries. <a name="_cp_text_2_449"></a><a name="_Ref518674295"></a><a name="_Ref517693964"></a>[***]</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">11.4.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">BioNTech Enforcement outside the Field and/or outside the Territory</font><font style="text-decoration:none;">. Subject to Section 11.4.1 and unless otherwise agreed between the Parties on a case-by-case basis, as </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">between Pfizer and </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;">, </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> shall have the sole right, but not the obligation, to institute any Enforcement Action outside the Field and/or outside the Territory in connection with any </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Enforcement Patent Rights), and any such Enforcement Action will be at </font><font style="text-decoration:none;">BioNTech&#8217;s</font><font style="text-decoration:none;"> expense including </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> indemnifying and holding harmless Pfizer and its Affiliates from and against any adverse cost award, where Pfizer or its Affiliates consent to join any such Enforcement Action upon </font><font style="text-decoration:none;">BioNTech&#8217;s</font><font style="text-decoration:none;"> request, where required by Law or where Pfizer or its Affiliates are enjoined by the counterparty. </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> shall not name as a party Pfizer or its Affiliates in any Enforcement Action without Pfizer's prior written consent. In any event, </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> will not, without the prior written consent of Pfizer, enter into any compromise or settlement relating to such Enforcement Action that (i) admits the invalidity or unenforceability of any </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Enforcement Patent Rights or (ii) requires </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> to abandon any </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Enforcement Patent Rights. Upon the request of </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;">, Pfizer shall have the sole discretion to decide whether or not to join as a party in any such Enforcement Action, and where it elects to do so it shall, at </font><font style="text-decoration:none;">BioNTech&#8217;s</font><font style="text-decoration:none;"> expense, join and cooperate with </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> in such Enforcement Action. Pfizer will have the right to consult with, and provide comments to, </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> about such Enforcement Action (irrespective of Pfizer or its Affiliate being a party to such Enforcement Action), and to participate in and be represented by independent counsel in such Enforcement Action at Pfizer&#8217;s own expense, and </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> shall take into account any reasonable comments provided by Pfizer in such Enforcement Action. Neither Party will incur any liability to the other Party (other than that related to a Party&#8217;s indemnification obligation pursuant to Section </font><font style="text-decoration:none;">16</font><font style="text-decoration:none;"> or otherwise in this sub-section) as a consequence of any Enforcement Action initiated or pursued pursuant to this Section </font><font style="text-decoration:none;">11.4.3</font><font style="text-decoration:none;"> or any unfavorable decision resulting therefrom, including any decision holding any </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Enforcement Patent Rights invalid or unenforceable.</font><font style="text-decoration:none;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">11.4.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Pfizer Patent Rights</font><font style="text-decoration:none;">. Pfizer shall have the sole right, but not the obligation, to institute litigation or take other steps to remedy infringement in connection with any field in respect of any Patent Rights that it solely owns including any Pfizer Patent Right. In the event that any such Patent Rights are based on inventions made or created solely or jointly by BioNTech, its Affiliates or its Representatives acting on BioNTech&#8217;s behalf, BioNTech shall provide reasonable assistance to Pfizer at Pfizer&#8217;s expense in connection with such litigation.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref468629984"></a><font style="text-decoration:none;">11.4.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Biosimilar Notices.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">11.4.6.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-style:italic;text-decoration:none;">BioNTech Cooperation</font><font style="text-decoration:none;">. Upon Pfizer&#8217;s request, BioNTech and Pfizer will use Commercially Reasonable Efforts to assist and cooperate with each other in (A) establishing a strategy for responding to requests for information from Regulatory Authorities and Third Party requestors and (B) preparing submissions responsive to any Biosimilar Notices received by Pfizer or BioNTech; </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that BioNTech will make the final decisions with respect to such strategy and any such responses.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref37117159"></a><a name="_cp_text_1_453"></a><a name="_cp_text_1_457"></a><font style="text-decoration:none;">11.4.6.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-style:italic;text-decoration:none;">Compliance with Biosimilar Notices</font><font style="text-decoration:none;"><a name="_cp_text_1_453"></a>. The MA Holder will have the sole right in its discretion to comply with the applicable provisions of 42 U.S.C. &#167; 262(l) (or any amendment or successor statute thereto), any similar statutory or regulatory requirement enacted in the future regarding biologic products in the United States, or any similar statutory or regulatory requirement in any non-U.S. country or other regulatory jurisdiction, in each case, with respect to any Biosimilar Notice received from any Third Party regarding any Product that is being Commercialized in the Field in the Territory in </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">the applicable jurisdiction, and the exchange of information between any Third Party and such MA Holder pursuant to such requirements; </font><font style="font-style:italic;text-decoration:none;">provided that</font><font style="text-decoration:none;">, prior to any submission of information by MA Holder to a Third Party, the other Party will have the right to review the patent information included in such proposed submission, and to make suggestions as to any changes to such patent information that Pfizer reasonably believes to be necessary; </font><font style="font-style:italic;text-decoration:none;">provided further</font><font style="text-decoration:none;"><a name="_cp_text_1_457"></a> that MA Holder will determine the final content of any such submission. In the case of a Product approved in the United States under the PHS Act (or, in the case of a country in the Territory other than the United States, any similar Law), to the extent permitted by applicable Law, the MA Holder, as the sponsor of the application for the Product, will be the &#8220;reference product sponsor&#8221; under the PHS Act. The MA Holder will give written notice to the other Party of receipt of a Biosimilar Notice received by MA Holder with respect to a Product, and MA Holder will consult with the other Party with respect to the selection of </font><font style="text-decoration:none;">any </font><font style="text-decoration:none;">Patent Rights to be submitted pursuant to 42 U.S.C. &#167; 262(l) (or any similar law in any country of the Territory outside the United States); </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that the MA Holder will have final say on such selection of Patent Rights. Such other Party agrees to be bound and will cause its Affiliates and use Commercially Reasonable Efforts to cause all Third Party Licensors to be bound by the confidentiality provisions of 42 U.S.C. &#167; 262(l)(1)(B)(iii). In connection with any action brought by such other Party under this Section </font><font style="text-decoration:none;">11.4.6</font><font style="text-decoration:none;">, such other Party, upon the MA Holder&#8217;s request, will reasonably cooperate and will cause its Affiliates and use Commercially Reasonable Efforts to cause all Third Party Licensors to reasonably cooperate with MA Holder in any such action, including timely commencing or joining in any action brought by MA Holder under this Section </font><font style="text-decoration:none;">11.4.6</font><font style="text-decoration:none;">.</font><font style="text-decoration:none;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">11.4.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Unified Patent Court</font><font style="text-decoration:none;">. In respect of BioNTech Enforcement Patent Rights, for each and every such Patent Right having effect anywhere within any member state that was or is, from time to time, a signatory to the UPC Agreement, BioNTech shall have the sole discretion to decide whether to (a) opt in or opt out (and to opt in again), pursuant to Article 83 of the UPC Agreement, of the Unified Patent Court system; and (b) elect if such Patent Rights should, during their prosecution, be designated as a Unitary Patent or a European Patent. The other Party shall promptly do all things necessary and execute all documents and make all necessary elections required to give effect to such decision(s) or election(s).</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">11.4.8</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Settlement Cross-Licensing</font><font style="text-decoration:none;">. If pursuant to a bona fide settlement of any Enforcement Action or Infringement Claim controlled by Pfizer, Pfizer, with BioNTech&#8217;s prior written consent, which shall not be unreasonably withheld, conditioned or delayed, grants to a Third Party (that was a party to the Enforcement Action or Infringement Claim) any sublicense to any of the Patent Rights licensed to Pfizer under this Agreement in respect of that Third Party&#8217;s Competitive Product, then Pfizer shall pay to BioNTech (a) at a minimum, if such sublicense includes any of the rights granted to Pfizer under a Current License or future BioNTech Third Party Agreement (subject to Section 3), all royalties due by BioNTech to the relevant Third Party for such sublicense under any Current License and Future BioNTech Third Party Agreement in respect of licensed sales of such Third Party Competitive Product and (b) all other royalties received by Pfizer shall be deemed Gross Profits. For the avoidance of doubt, should the Third Party as part of the same agreement grant any cross-license to Pfizer (sublicensable to BioNTech for the purposes of this Agreement) for any Candidates or Products, such cross-license shall not be deemed "non-cash" consideration for the purpose of the Net Sales definition.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_cp_blt_1_461"></a><a name="_Toc62256120"></a><a name="_Toc59107147"></a><a name="_Ref475143644"></a><a name="_Ref519253307"></a><a name="_Ref488158590"></a><a name="_cp_text_1_462"></a><font style="text-decoration:none;">11.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Other Actions by Third Parties</font><font style="text-decoration:none;">. Separate from Prosecution Proceedings, each Party will promptly notify the other Party in the event of any legal action by any Third Party involving any </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Enforcement Patent Rights of which it becomes aware, including any nullity, revocation, declaratory judgment, interference, </font><font style="font-style:italic;text-decoration:none;">inter </font><font style="font-style:italic;text-decoration:none;">partes</font><font style="text-decoration:none;"> reexamination, reexamination or compulsory license proceeding. The right to defend against any such action shall be with the Party controlling the filing, Prosecution and Maintenance of the affected Patent Right (as determined in accordance with Section&#160;</font><font style="text-decoration:none;">11.3.1</font><font style="text-decoration:none;">), and the provisions of Section&#160;</font><font style="text-decoration:none;">11.3.1</font><font style="text-decoration:none;"> shall apply </font><font style="font-style:italic;text-decoration:none;">mutatis mutandis</font><font style="text-decoration:none;"> in respect of such defense.</font><font style="text-decoration:none;"> If any such action has been instituted by any Third Party in response to, or in connection with, any Enforcement Action pursuant to Section&#160;</font><font style="text-decoration:none;">11.4</font><font style="text-decoration:none;">, or any Enforcement Action is to be pursued as a consequence of such action being instituted by any Third Party, the Party controlling the Enforcement Action and the Party controlling the defense shall work together and closely align their enforcement and defense strategy, which may include the (joint) appointment of the same patent counsel for all concurrent Third Party litigation and patent office proceedings taking into account the impact on enforcement and potential for revenues relating to such Patent Rights, and in the absence of agreement, the enforcing Party shall have the final say over the Prosecution Proceedings in so far as the Prosecution Proceeding will adversely impact the ongoing enforcement of such right, subject to having given good faith consideration to the comments and suggestions of the prosecuting Party. Further details of such joint proceeding may be agreed between the Parties from time to time.</font><font style="text-decoration:none;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256121"></a><a name="_Toc59107148"></a><a name="_Ref36327058"></a><font style="text-decoration:none;">11.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Purple Book Listings</font><font style="text-decoration:none;">. To the extent of any BioNTech Enforcement Patent Rights, the Parties shall cooperate with each other to enable BioNTech to make filings with Regulatory Authorities, as required or allowed in connection with (a) in the United States, the FDA&#8217;s Purple Book and the Biologics Price Competition and Innovation Act and (b) outside the United States, under the national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83 or other international equivalents thereof within the Territory. Pfizer shall consider BioNTech&#8217;s reasonable requests in connection therewith, including meeting any submission deadlines, in each case, to the extent required or permitted by applicable Law.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_cp_blt_1_472"></a><a name="_cp_blt_2_471"></a><a name="_cp_blt_1_474"></a><a name="_cp_blt_2_473"></a><a name="_Toc62256122"></a><a name="_Toc59107149"></a><a name="_Ref135584941"></a><font style="text-decoration:none;">11.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Allegations of Infringement and Right to Seek Third Party Licenses</font><font style="text-decoration:none;">.</font><font style="text-decoration:underline;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref37116567"></a><a name="_Ref135582658"></a><a name="_Ref135582852"></a><a name="_Ref264836378"></a><a name="_Ref480490971"></a><a name="_Ref518674362"></a><font style="text-decoration:none;">11.7.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Notice</font><font style="text-decoration:none;">. If either Party becomes aware that the Development, Manufacture, Commercialization or use of any Candidate or Product, the practice of any BioNTech Technology or Research and Development Program Technology in the Field, or the exercise of any other right granted by BioNTech to Pfizer or any of its Affiliates or Sublicensees hereunder (collectively, the &#8220;</font><font style="text-decoration:underline;">Licensed Activities</font><font style="text-decoration:none;">&#8221;) is alleged by a Third Party to infringe, misappropriate or otherwise violate such Third Party&#8217;s Patent Rights or other Intellectual Property Rights or either Party otherwise identifies any Third Party Patent Rights or other Intellectual Property Rights that may be relevant to such Licensed Activities (collectively, an &#8220;</font><font style="text-decoration:underline;">FTO Action</font><font style="text-decoration:none;">&#8221;), such Party will, as soon as reasonably practicable, notify the other Party in writing and the Parties will discuss the FTO Action in good faith to determine and agree upon a resolution of the same.<a name="_Ref135582852"></a><a name="_Ref264836378"></a><a name="_Ref480490971"></a><a name="_Ref518674362"></a> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">11.7.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Option to Negotiate</font><font style="text-decoration:none;">. If the Parties determine that to resolve the FTO Action it is necessary or useful to obtain a license under one or more Patent Rights or other Intellectual Property Rights Controlled by a Third Party, then [***] will negotiate and enter into a license or other agreement with such Third Party in close coordination with the other Party. If the Parties do not agree that a license from a Third Party is necessary or useful to resolve the FTO Action, the Party who considers a license is necessary or useful to resolve the FTO Action shall be entitled to </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">negotiate and enter into a license or other agreement with such Third Party, but shall do so keeping the other Party reasonably informed. </font><font style="text-decoration:none;">[***]</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref49446044"></a><font style="text-decoration:none;">11.7.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Option to Challenge</font><font style="text-decoration:none;">. Other than in response to an Infringement Claim, if a Party determines that to anticipate, mitigate or resolve an FTO Action, it is useful or advisable to pre-emptively challenge one or more Patent Rights or other Intellectual Property Rights Controlled by a Third Party by filing suit or bringing an action, including any nullity, revocation, declaratory judgment, interference, </font><font style="font-style:italic;text-decoration:none;">inter partes</font><font style="text-decoration:none;"> reexamination, reexamination or compulsory license proceeding, then either (a) BioNTech, where the FTO Action predominantly impacts use of BioNTech Technology; or (b) Pfizer, where the FTO Action predominantly impacts use of Pfizer Technology, will, as applicable, have the first right (but not the obligation) to control such suit or action, and any such suit or action shall be at the controlling Party's expense and if that Party does not commence such suit or action the other Party may (but shall not be obliged) to do so. The controlling Party shall, however, be entitled to consider its own contractual obligations to Third Parties that would be impacted when challenging any Patent Rights or other Intellectual Property Rights pursuant to this Section 11.7.3, and if it elects not to pursue any such action then the other Party shall be entitled (but not obliged) to do so. The foregoing shall not preclude or impede a Party from taking any such pre-emptive action in connection with a different product. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_cp_blt_1_476"></a><a name="_cp_blt_2_475"></a><a name="_Toc62256123"></a><a name="_Toc59107150"></a><a name="_Ref62483719"></a><a name="_Ref268767480"></a><a name="_Ref480490253"></a><a name="_Ref519347195"></a><font style="text-decoration:none;">11.8</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Third Party Infringement Suits</font><font style="text-decoration:none;">. Each of the Parties will promptly notify the other in the event that any Third Party files any suit or brings any other action alleging patent infringement by Pfizer or BioNTech or any of their respective Affiliates or Sublicensees with respect to the</font><font style="font-weight:bold;text-decoration:none;"> </font><font style="text-decoration:none;">Development, Manufacture, Commercialization or use of any Candidate or Product or the practice of any BioNTech Technology or Research and Development Program Technology (any such suit or other action referred to herein as an &#8220;Infringement Claim&#8221;). In the case of any Infringement Claim against Pfizer (including its Affiliates or Sublicensees) alone, or against both Pfizer and BioNTech (including their respective Affiliates), Pfizer will have the right, but not the obligation, to control the defense of such Infringement Claim, including control over any related litigation, settlement, appeal or other disposition arising in connection therewith. BioNTech, upon request of Pfizer, agrees to cooperate with Pfizer at Pfizer&#8217;s expense. BioNTech will have the right to consult with Pfizer concerning any Infringement Claim and to participate in and be represented by independent counsel in any associated litigation in which BioNTech is a party at BioNTech&#8217;s own expense. If Pfizer elects to control the defense of any Infringement Claim and BioNTech is obligated under Section&#160;16.3 to indemnify Pfizer (including any Pfizer Indemnified Party) with respect to such Infringement Claim, then (a) Pfizer will bear 100% of its own attorneys&#8217; fees incurred in investigating, preparing or defending such Infringement Claim notwithstanding the provisions of Section&#160;16.3 and (b) BioNTech will otherwise indemnify Pfizer and any applicable Pfizer Indemnified Parties to the full extent provided for under Section&#160;16.3, provided that Pfizer shall not enter into any compromise or settlement with the Third Party in respect of such Infringement Claim without BioNTech&#8217;s prior written consent (such consent not to be unreasonably withheld, conditioned or delayed) where such compromise or settlement requires the payment of monetary penalty or damages that are indemnified by BioNTech under this Agreement. In the case of any Infringement Claim against BioNTech alone, Pfizer will have the right to consult with BioNTech concerning such Infringement Claim and Pfizer, upon request of BioNTech, will reasonably cooperate with BioNTech at BioNTech&#8217;s expense. Neither Party will enter into any compromise or settlement in respect of an Infringement Claim admitting or implying that the</font><font style="font-weight:bold;text-decoration:none;"> </font><font style="text-decoration:none;">Development, Manufacture, Commercialization or use of any Candidate or Product or the practice of any </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Technology or Research and Development Program Technology infringes Third Party patents without the other Party&#8217;s written consent.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc40858335"></a><a name="_Toc40859621"></a><a name="_Toc40860282"></a><a name="_Toc40863040"></a><a name="_Toc40863738"></a><a name="_Toc40864137"></a><a name="_Toc62256124"></a><a name="_Toc59107151"></a><a name="_Ref47473297"></a><font style="text-decoration:none;">11.9</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Product Trademarks</font><font style="text-decoration:none;">.</font><font style="text-decoration:underline;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">11.9.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Trademark Selection, Clearance and Registration</font><font style="text-decoration:none;">. The Parties shall collaborate to develop a list of potential Trademarks to be used to identify the Products in the Territory. Such list shall be submitted to the JCC for review and the JCC shall, by mutual agreement, select one or more of such potential Trademarks as the Product Trademark for use in identifying the Products in the Territory, </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that no such Product Trademark shall be confusingly similar to any Trademark that either Party or any of its Affiliates then use or have filed or registered in any country in or outside of the Territory (except as permitted by such Party). BioNTech, in consultation with Pfizer, shall be responsible for the creation, filing, registration, and Prosecution and Maintenance of the Product Trademarks, </font><font style="font-style:italic;text-decoration:none;">provided </font><font style="text-decoration:none;">that all out-of-pocket costs and expenses associated therewith (including law firm and service provider costs) as well as costs of any Third Party claims arising from said filing, registration, Prosecution and Maintenance or use of the Product Trademarks shall be shared equally between the Parties (but not as Shared Development Costs). Pfizer, in consultation with BioNTech, shall undertake the searching and clearance of all potential Product Trademarks, </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that all out-of-pocket costs and expenses associated therewith (including law firm and service provider costs) shall be shared equally between the Parties (but not as Shared Development Costs) and Pfizer and its Affiliates, employees, agents or representatives will not be liable to BioNTech, its Affiliates or licensees in respect of any act, omission, default or neglect on the part of Pfizer, its Affiliates, or their respective employees, agents or representatives in connection with such searching and clearance activities. BioNTech and Pfizer will each perform such actions at the same level of quality as would be performed for their own Trademarks, respectively. BioNTech shall select a reputable law firm (subject to the approval of Pfizer, such approval not to be unreasonably withheld) to instruct, manage and interact with local Trademark agents throughout the Territory and to act as a single point of contact for BioNTech and Pfizer with respect to the filing and Prosecution and Maintenance of applications for and the registration and maintenance of the Product Trademarks in each country of the Territory. BioNTech shall keep Pfizer reasonably informed of the status of the actual and prospective Trademarks filings, prosecution and registration status and any office actions, oppositions or objections received. BioNTech shall not withdraw, surrender, allow to lapse or otherwise permit any Trademark application or registration to cease to have effect in respect of the Product Trademark anywhere in the Territory without Pfizer&#8217;s consent (which shall not be unreasonably withheld or delayed). Furthermore, with respect to any office actions, oppositions or other objections received, BioNTech shall consult and cooperate with Pfizer, and take Pfizer&#8217;s comments reasonably into account, regarding the strategic approach and costs to handling such matters. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref43828911"></a><a name="_Ref62659552"></a><font style="text-decoration:none;">11.9.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Title</font><font style="text-decoration:none;">. Unless otherwise decided by the JCC by mutual agreement, BioNTech will own all right, title and interest in and to the Product Trademarks in the Territory. If the JCC decides to adopt one of the Pfizer pre-existing Trademarks (if offered by Pfizer) as a Product Trademark, then BioNTech shall be responsible for preparing and recording all Trademark assignments necessary to transfer ownership of such Product Trademark to BioNTech, and BioNTech shall bear all costs related thereto including legalization costs, and such Trademark shall be deemed a Product Trademark according to the provisions of this Agreement (including with respect to BioNTech&#8217;s responsibility for the same).&#160;The Product Trademarks will not use, be comprised of, or incorporate </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">all or any part of either Party&#8217;s House Marks without such Party&#8217;s prior written consent, which may be provided or withheld in such Party&#8217;s sole discretion. Neither Party will, nor will cause its Affiliates to: (a) challenge any application for a Product Trademark approved by the JCC or the registration thereof in any country in the Territory; (b) file, register or maintain any registrations for any trademarks or trade names that are identical to or confusingly similar to any Product Trademark, in any country without the express prior written consent of the other Party; or (c) authorize or assist any Third Party to do any of the foregoing.</font><font style="text-decoration:none;"> Each Party shall own all right, title and interest in any Patient or HCP Support Program Trademarks developed and/or used by or on behalf of such Party in such Party's Commercialization Territory.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">11.9.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Domain Names</font><font style="text-decoration:none;">. The Parties shall also collaborate on the selection and registration of domain names incorporating the Product Trademarks. Unless otherwise determined by the JCC by mutual agreement, BioNTech will register, maintain and manage such domain names and will own all right, title and interest in and to such domain names and similar electronic media references. BioNTech shall ensure that all such domain names are timely registered and renewed as necessary to support websites in the Territory related to the Product Trademarks, or for defensive purposes, regardless of which Party operates such websites. All costs in connection with the registration and maintenance of such domains shall be shared equally between the Parties (but not as Shared Development Costs).</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref39655102"></a><font style="text-decoration:none;">11.9.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Required Use and Compliance</font><font style="text-decoration:none;">. Each Party will not and will cause its Affiliates to not use Product Trademarks or the other Party&#8217;s House Marks in a way that might materially prejudice their distinctiveness or validity or the goodwill of the other Party therein. Each Party will not and will cause its Affiliates not to use any trademarks or trade names so resembling any of the Product Trademarks as to be likely to cause confusion or deception. Each Party will and will cause its Affiliates (a) to include, where possible, the trademark registration symbol &#174; or &#8482;, as appropriate, in connection with the use of any Product Trademark or (as requested) the other Party&#8217;s House Marks; and (b) not to use any Trademarks or trade names so resembling any of the other Party&#8217;s House Marks as to be likely to cause confusion or deception.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref411999275"></a><font style="text-decoration:none;">11.9.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Trademark Licenses.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Hlk39655754"></a><font style="text-decoration:none;">11.9.5.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-style:italic;text-decoration:none;">To Pfizer</font><font style="text-decoration:none;">. Subject to the terms and conditions of this Agreement, for the Term BioNTech hereby grants to Pfizer and its Affiliates (i) a non-exclusive, royalty-free license to use the BioNTech<a name="_Hlk39655754"></a> House Marks in the Pfizer Commercialization Territory solely as set forth in Section&#160;9.12 and (ii) an exclusive (even as to BioNTech), royalty-free, fully paid-up, non-assignable and sublicensable license to use the Product Trademarks in the Pfizer Commercialization Territory, in each case, solely in connection with the exercise by Pfizer or its Affiliates of Pfizer&#8217;s rights or obligations under this Agreement or the performance by Pfizer or its Affiliates of Pfizer&#8217;s Commercialization Activities.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref415046915"></a><font style="text-decoration:none;">11.9.5.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-style:italic;text-decoration:none;">To BioNTech</font><font style="text-decoration:none;">. Subject to the terms and conditions of this Agreement, Pfizer hereby grants to BioNTech and its Affiliates a non-exclusive, royalty-free license to use the Pfizer House Marks in the BioNTech Commercialization Territory solely as set forth in Section&#160;9.12 in connection with the exercise by BioNTech or its Affiliates of BioNTech&#8217;s rights or obligations under this Agreement. In addition, to the extent the JCC decides in accordance with Section 11.9.2 that Product Trademarks shall be owned by Pfizer, Pfizer hereby grant to BioNTech and its Affiliates for the Term an exclusive (even </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">as to Pfizer), royalty-free, fully paid-up, non-assignable and sublicensable license to use the Product Trademarks in the </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Commercialization Territory solely in connection with the exercise by </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> or its Affiliates of </font><font style="text-decoration:none;">BioNTech&#8217;s</font><font style="text-decoration:none;"> rights or obligations under this Agreement or the performance by </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> or its Affiliates of </font><font style="text-decoration:none;">BioNTech&#8217;s</font><font style="text-decoration:none;"> Commercialization Activities.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref415046924"></a><font style="text-decoration:none;">11.9.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Respect of Trademarks</font><font style="text-decoration:none;">. Pfizer will not have, assert or acquire any right, title or interest in or to any BioNTech House Marks or Product Trademarks (unless ownership is otherwise decided by the JCC in accordance with Section 11.9.2), or the goodwill pertaining thereto, and BioNTech will not have, assert or acquire any right, title or interest in or to any Pfizer House Marks or the goodwill pertaining thereto, except in each case for the limited licenses explicitly provided in this Agreement. Pfizer will maintain necessary quality standards with respect to Pfizer's use under license of Product Trademarks and each Party will maintain necessary quality standards with respect to the use by such Party of the other Party&#8217;s House Marks pursuant to the licenses granted under Section&#160;11.9.5, as applicable. Each Party recognizes and agrees that no ownership rights are vested or created by the limited licenses granted pursuant to Section&#160;11.9.5 and that all goodwill arising by virtue of the use of (i) the Pfizer House Marks including use by any sublicensee will inure to the exclusive benefit of Pfizer; and (ii) the BioNTech House Marks and the Product Trademarks including use by any sublicensee (unless ownership is otherwise decided by the JCC in accordance with Section 11.9.2) inures to the exclusive benefit of BioNTech.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">11.9.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Infringement.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref43829904"></a><a name="_Ref47473158"></a><font style="text-decoration:none;">11.9.7.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-style:italic;text-decoration:none;">Monitoring and Infringements</font><font style="text-decoration:none;">. Each Party will monitor the Product Trademarks and House Marks against infringing uses in the Territory relating to the Product (including (i) with respect to domain names, unauthorized online activities and other digital handles and (ii) with respect to the Product Trademarks and with respect to either Party's House Marks as used on the Product or Product Packaging and Labeling, unauthorized uses amounting to counterfeiting or unlawful product diversion) (collectively, &#8220;</font><font style="text-decoration:underline;">Infringements</font><font style="text-decoration:none;">&#8221;)) and will promptly notify the other Party of any infringement or threatened Infringement thereof of which it becomes aware. BioNTech will use Third Party watch services, as necessary, to monitor filings for Third Party Trademarks that may be similar to the Product Trademarks, and will, in consultation with Pfizer, defend the Product Trademarks against oppositions, cancellations, nullity or other legal actions filed by Third Parties and will promptly, in consultation with Pfizer, undertake to oppose, cancel, nullify or take other appropriate action, where reasonable, against confusingly similar or identical Third Party Trademarks filed for products or services related to those claimed by the Product Trademarks, or where the Third Party use would be dilutive of the Product Trademarks. BioNTech will have the right to determine what action, if any, to take in response to any such Infringement or threatened infringement of any Product Trademark in the BioNTech Commercialization Territory, and Pfizer will have the right to determine what action, if any, that BioNTech should take in response to any such Infringement or threatened Infringement of any Product Trademark in the Pfizer Commercialization Territory, recognizing that in all cases such actions legally may need to be filed or brought in the name of the trademark owner (BioNTech). The Parties will cooperate in good faith to formulate an agreed-upon process for such actions. Each Party shall keep the other Party reasonably informed of the status of such oppositions, </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">cancellations, Infringements, threatened Infringements and other actions. Each Party shall not withdraw, surrender, allow to lapse or otherwise permit any Trademark application or registration to cease to have effect in respect of the Product Trademark without the consent of the other Party (which shall not be unreasonably withheld or delayed). All costs in connection with any activities under this Section </font><font style="text-decoration:none;">11.9.7.1</font><font style="text-decoration:none;"> (including law firm and service provider costs) shall be shared equally between the Parties (but not as Shared Development Costs).</font><font style="text-decoration:none;"> Each </font><font style="text-decoration:none;">P</font><font style="text-decoration:none;">arty shall be exclusively responsible for and have the exclusive right (at its sole discretion) to take or not take any action with respect to its House Mark.</font><font style="text-decoration:none;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref411999301"></a><a name="_Ref46755498"></a><font style="text-decoration:none;">11.9.7.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-style:italic;text-decoration:none;">Responsibility for Protection</font><font style="text-decoration:none;">. Unless otherwise agreed between the Parties, the Parties will mutually agree upon the protection and maintenance of the Product Trademarks, including all enforcement against Infringements or threatened Infringements and defense thereof. The Parties recognize that anti-counterfeiting activity may involve law enforcement actions or customs authority seizures based on the Product Trademarks and/or based on either or both Party&#8217;s House Marks as they appear on the Product or Product Packaging and Labeling, and the Parties will cooperate in good faith to create anti-counterfeiting strategies and processes -- as well as anti-diversion strategies and processes -- for the Products throughout the Territory. The Parties will also cooperate to formulate an agreed-upon process to handle and support such anti-counterfeiting actions brought by law enforcement authorities including but not limited to customs seizures and criminal actions. Each Party will provide all assistance reasonably requested by the other Party in connection with the maintenance, enforcement and defense of the Product Trademarks in the Territory. The foregoing obligations shall apply to all trademark uses including with respect to domain names, online activities and use of other digital handles. All costs and expenses (including law firm and service provider costs) in connection with any activities under this Section 11.9.7.1 and 11.9.7.2 anywhere in the Territory shall be shared equally between the Parties (but not as Shared Development Costs).</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">11.9.7.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-style:italic;text-decoration:none;">House Marks</font><font style="text-decoration:none;">. Each Party will have sole control and discretion with respect to protecting and maintaining its respective House Marks, including all enforcement and defense thereof. To the extent that anti-counterfeiting or anti-diversion activity for the Product must be based on a Party&#8217;s House Marks, the Parties will cooperate in good faith on decisions relating to control of such actions, and costs of same shall constitute the sole cost of the applicable Party whose House Mark is in issue.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256125"></a><a name="_Toc59107152"></a><font style="text-decoration:none;">11.10</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Packaging and Labeling Rights and Licenses</font><font style="text-decoration:none;">. Subject to the terms and conditions of this Agreement, for the Term each Party hereby grants to the other Party and its Affiliates a non-exclusive, royalty-free license under any Intellectual Property Rights it Controls in the Packaging and Labeling selected for the Product solely for use in connection with (i) Commercializing the Product in the Territory; and (ii) Commercializing a product identical to the Product in the Fosun Territory.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc40858336"></a><a name="_Toc40859622"></a><a name="_Toc40860283"></a><a name="_Toc40863041"></a><a name="_Toc40863739"></a><a name="_Toc40864138"></a><a name="_Toc62256126"></a><a name="_Toc59107153"></a><font style="text-decoration:none;">11.11</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">No Implied Licenses</font><font style="text-decoration:none;">. No right or license under any Pfizer Technology, BioNTech Technology, BioNTech House Mark, Pfizer House Mark, Product Trademark, or any other Intellectual Property Right or Trademark of a Party is granted or will be granted by implication as a result of the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">respective rights of the Parties under this Agreement. All such rights or licenses are or will be granted only as expressly provided in this Agreement.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;">12.</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-transform:none;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref36312602"></a><a name="_Ref37017877"></a><a name="_Ref37261085"></a><a name="_Toc484766521"></a><a name="_Toc519764425"></a><a name="_Toc519873416"></a><a name="_Toc35600555"></a><a name="_Ref43883186"></a><a name="_Ref59043252"></a><a name="_Toc62256127"></a><a name="_Toc59107154"></a><font style="text-decoration:none;"></font><font style="text-decoration:underline;text-transform:uppercase;">Confidentiality, Publications and Press Releases</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256128"></a><a name="_Toc59107155"></a><a name="_Ref62567670"></a><a name="_Ref135582716"></a><a name="_Ref263791424"></a><font style="text-decoration:none;">12.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Confidentiality</font><font style="text-decoration:none;">. Except to the extent expressly authorized by this Agreement, the Parties agree that, during the Term and for [***] years thereafter (except to the extent a longer period is required by a Current License applicable for such Confidential Information disclosed pursuant to that Current License), each Party (the &#8220;</font><font style="text-decoration:underline;">Receiving Party</font><font style="text-decoration:none;">&#8221;) receiving any Confidential Information of the other Party (the &#8220;</font><font style="text-decoration:underline;">Disclosing Party</font><font style="text-decoration:none;">&#8221;) hereunder will: (a) keep the Disclosing Party&#8217;s Confidential Information confidential; (b) not disclose, or permit the disclosure of, the Disclosing Party&#8217;s Confidential Information; and (c) not use, or permit to be used, the Disclosing Party&#8217;s Confidential Information for any purpose other than as expressly permitted under the terms of this Agreement (including under any license or right of use granted hereunder).</font><font style="text-decoration:underline;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766522"></a><a name="_Toc519764426"></a><a name="_Toc519873417"></a><a name="_Toc35600556"></a><a name="_Toc62256129"></a><a name="_Toc59107156"></a><a name="_Ref276053229"></a><a name="_Ref135585280"></a><a name="_Ref135585441"></a><a name="_Ref263797003"></a><font style="text-decoration:none;">12.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Authorized Disclosure</font><font style="text-decoration:none;">.</font><font style="text-decoration:underline;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref268767512"></a><font style="text-decoration:none;">12.2.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Disclosure to Party Representatives</font><font style="text-decoration:none;">. Notwithstanding the foregoing provisions of Section 12.1, the Receiving Party may disclose Confidential Information belonging to the Disclosing Party to the Receiving Party&#8217;s Representatives who (a) have a need to know such Confidential Information in connection with the performance of the Receiving Party&#8217;s obligations or the exercise of the Receiving Party&#8217;s rights under this Agreement and (b) have agreed in writing to non-disclosure and non-use provisions with respect to such Confidential Information that are at least as restrictive as those set forth in this Section 12.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref273099587"></a><font style="text-decoration:none;">12.2.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Disclosure to Third Parties</font><font style="text-decoration:none;">. Notwithstanding the foregoing provisions of Section&#160;12.1, each Party may disclose Confidential Information belonging to the other Party to the extent such disclosure is reasonably necessary:</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">12.2.2.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">in conducting the activities contemplated, or exercising rights under this Agreement;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref264999973"></a><font style="text-decoration:none;">12.2.2.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">to Governmental Authorities to the extent useful, to (a) obtain or maintain Regulatory Approvals (including fulfilling post-approval regulatory obligations) for any Product within the Territory; or (b) obtain or maintain any Regulatory Approvals for a product comprising a Candidate in the Field outside of the Territory; (c) to ministries of health, Vaccine Technical Committees or similar public health or scientific bodies for purposes of securing vaccine recommendations, tenders, direct procurement contracts or responding to relevant requests for information; (d) complying with applicable governmental regulations with respect to performance under this Agreement or (e) in order to respond to inquiries, requests or investigations (i) relating to Candidates or Products or this Agreement within the Territory; or (ii) relating to any product comprising a Candidate in the Field outside of the Territory; </font><font style="font-style:italic;text-decoration:none;">provided, however</font><font style="text-decoration:none;">, that BioNTech may not disclose any Pfizer Confidential Information to Fosun or its Affiliates without the prior written consent of Pfizer, other than to the extent necessary for Fosun or its Affiliates (or such other collaboration partner in or for the Fosun Territory) to undertake fill/finish of a product identical to any Product in the Fosun Territory or to comply with information requirements of the China National Medical Products Administration (or equivalent), relating to such </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">product required under applicable Law, in each case so far as such use is licensed under Sections&#160;</font><font style="text-decoration:none;">3.4.2</font><font style="text-decoration:none;">(b) or </font><font style="text-decoration:none;">3.4.4</font><font style="text-decoration:none;">(b); </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">12.2.2.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">to outside consultants (including any professional advisor), potential acquisition partners (including any potential successors in interest), private investors or financing sources, contractors, advisory boards, managed care organizations, and non-clinical and clinical investigators, in each case to the extent useful to develop, register or market any Candidate or Product within the Territory; </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that the Receiving Party will obtain the same confidentiality obligations from such Third Parties as it obtains with respect to its own similar types of confidential information; </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">12.2.2.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">in connection with filing or prosecuting Research and Development Program Patent Rights, Product Patent Rights or Trademark rights as permitted by this Agreement; </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">12.2.2.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">in connection with any prosecution or litigation actions or defenses undertaken pursuant to Section&#160;11 or any other litigation directly related to a Candidate or Product in the Field in the Territory;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">12.2.2.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">subject to the provisions of Section 12.5.2, in connection with or included in scientific presentations and publications relating to Candidates or Products, including abstracts, posters, journal articles and the like, and posting results of and other information about clinical trials to clinicaltrials.gov or PhRMA websites; </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">12.2.2.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">by either Party in respect of Confidential Information belonging to the other Party (including the terms of the Agreement) to any bona fide or potential subcontractor under this Agreement in connection with the Development, Manufacture or Commercialization of the Candidate or Product in the Territory, in each case who has agreed in writing to non-disclosure and non-use provisions with respect to such Confidential Information that are at least as restrictive as those set forth in this Section 11.1; and </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">12.2.2.8</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">to the extent necessary or useful in order to enforce its rights under this Agreement.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">12.2.2.9</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">to the extent otherwise required by applicable Law or agreements with Governmental Authorities; </font><font style="font-style:italic;text-decoration:none;">provided that</font><font style="text-decoration:none;"> if a Party is so required by applicable Law to make any such disclosure of the other Party&#8217;s Confidential Information it will, except where impracticable for necessary disclosures (for example, in the event of medical emergency), give reasonable advance notice to the other Party of such disclosure requirement and will use its reasonable efforts to secure confidential treatment of such Confidential Information required to be disclosed; or</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">12.2.2.10</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">to the extent mutually agreed to by the Parties.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding anything herein to the contrary, each Party acknowledges and agrees that the use by a Party of the other Party&#8217;s Confidential Information disclosed under the Related Agreements or the Flu Collaboration License in the performance of this Agreement is not a breach of the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">confidentiality obligations under this Agreement, the Related Agreements or the Flu Collaboration License, and vice versa. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766523"></a><a name="_Toc519764427"></a><a name="_Toc519873418"></a><a name="_Toc35600557"></a><a name="_Toc62256130"></a><a name="_Toc59107157"></a><a name="_Ref263784993"></a><a name="_Ref263794589"></a><a name="_Ref265016554"></a><a name="_Ref516782177"></a><font style="text-decoration:none;">12.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Confidential Treatment of the Terms and Conditions, SEC Filings and Other Disclosures</font><font style="text-decoration:none;">. The Parties agree that the terms and conditions of this Agreement will be Confidential Information of each Party, and such material terms and conditions will not be disclosed, except (a) as otherwise permitted under Section&#160;12.2. Notwithstanding the foregoing, either Party may disclose the terms of this Agreement and make any other public written disclosure regarding the existence of, or performance under, this Agreement, to the extent required, in the reasonable opinion of such Party&#8217;s legal counsel, to comply with (a) applicable Law, including the rules and regulations promulgated by the United States Securities and Exchange Commission or (b) any equivalent Governmental Authority, securities exchange or securities regulator in any country. Before disclosing this Agreement or any of the terms hereof pursuant to this Section 12.3, the Parties will consult with one another on the terms of this Agreement to be redacted in making any such disclosure, with the Party disclosing pursuant to this Section 12.3 providing as much advance notice as is feasible under the circumstances, and giving consideration to the comments of the other Party. Further, if a Party discloses this Agreement or any of the terms hereof in accordance with this Section 12.3, such Party will, at its own expense, seek such confidential treatment of confidential portions of this Agreement and such other terms, as may be reasonably requested by the other Party and limit its disclosure of such Confidential Information to only that required to comply with applicable Law.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766524"></a><a name="_Toc519764428"></a><a name="_Toc519873419"></a><a name="_Toc35600558"></a><a name="_Toc62256131"></a><a name="_Toc59107158"></a><a name="_Ref263796096"></a><font style="text-decoration:none;">12.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Residual Knowledge Exception</font><font style="text-decoration:none;">. Notwithstanding any provision of this Agreement to the contrary, Residual Knowledge will not be considered Confidential Information for purposes of this Section 11.1; provided that, for clarity, a Party&#8217;s rights to Residual Knowledge hereunder shall not include the right to practice any Patent Right owned or Controlled by the other Party that claims such Residual Knowledge unless otherwise expressly granted in another provision of this Agreement or in another agreement between the Parties.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766525"></a><a name="_Toc519764429"></a><a name="_Toc519873420"></a><a name="_Toc35600559"></a><a name="_Toc62256132"></a><a name="_Toc59107159"></a><font style="text-decoration:none;">12.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Public Announcements; Publications</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref59101886"></a><a name="_Ref135585397"></a><a name="_Ref263801694"></a><a name="_Ref47712273"></a><a name="_Ref62547122"></a><font style="text-decoration:none;">12.5.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Announcements</font><font style="text-decoration:none;">. Except as may be expressly permitted under Section&#160;12.3, neither Party will (i) make any public announcement about this Agreement without the prior written approval of the other Party (such approval not to be unreasonably withheld, conditioned or delayed); or (ii) make any public announcement which otherwise relates to the performance or subject matter of this Agreement or to the Product without having given to the other Party prior notice of such public announcement (including its wording and reasonably relevant information) and a reasonable time period to comment on such public announcement, taking into account the circumstances surrounding such public announcement. As a general rule, a Party shall provide an initial draft for the other Party&#8217;s review and comments, and the other Party shall have two (2) Business Days to review and provide comments to such initial draft and the Parties shall work promptly and collaboratively in preparation for release of the public announcement, reasonably taking into account the other Party&#8217;s comments. In the event of an urgent announcement that relates to an</font><font style="color:#FF0000;text-decoration:none;"> </font><font style="text-decoration:none;">unknown or unplanned event, such that the review period referenced above is not practicable, a Party shall endeavor to provide the other Party with as much notice as reasonably possible and the Parties shall work promptly and collaboratively in preparation for release of the public announcement, reasonably taking account the other Party&#8217;s comments. Unless the Parties mutually agree otherwise in writing, every public announcement made by either Party shall include a statement that is substantially identical to the statement set forth on Schedule 12.5.1. Nothing in this Section shall prevent a Party from advertising for promotional purposes the Product in its </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">respective Commercialization Territory and such </font><font style="text-decoration:none;">advertising </font><font style="text-decoration:none;">do</font><font style="text-decoration:none;">es</font><font style="text-decoration:none;"> not require review and approval as set forth in this Section </font><font style="text-decoration:none;">12.5.1</font><font style="text-decoration:none;">, </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that such </font><font style="text-decoration:none;">advertising is</font><font style="text-decoration:none;"> in compliance with other terms and provisions of this Agreement and applicable Law</font><font style="text-decoration:none;"> and that a statement substantially identical to the statement set forth in Schedule </font><font style="text-decoration:none;">12.5.1</font><font style="text-decoration:none;"> shall be included</font><font style="text-decoration:none;">, </font><font style="text-decoration:none;">to the extent</font><font style="text-decoration:none;"> permitted under Applicable Law, also into all advertisements issued pursuant to this sentence</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref135585312"></a><a name="_Ref263791624"></a><font style="text-decoration:none;">12.5.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Publications</font><font style="text-decoration:none;">. During the Term, each Party will submit to the other Party for review and approval (such approval not to be unreasonably withheld, delayed or conditioned) any proposed publication or public presentation proposed by a Party or its Affiliates or any of their respective Representatives that relates to the activities conducted under this Agreement, including the Research and Development Plan; </font><font style="font-style:italic;text-decoration:none;">provided </font><font style="text-decoration:none;">that notwithstanding the requirement for approval (a) neither Party shall be prevented from submitting any publication or making a presentation in respect of a Clinical Trial for which the Party is either the IND holder or the Lead Development Party to the extent such publication or presentation is required under applicable Law or such Party&#8217;s internal publication policies, but such publishing Party shall not disclose the other Party's confidential information in respect of its technology and Intellectual Property Rights, and shall take on board and reasonably consider any reasonable requests of the other Party with respect to such proposed publication or presentation; (b) the Party whose approval is sought shall not unreasonably withhold or condition such approval; (c) nothing shall prohibit a Party from making any press release or statement where required pursuant to applicable Law or stock exchange rule, subject to such publishing Party shall take on board and reasonably consider any reasonable requests of the other Party with respect to such proposed publication or presentation and (d) neither Party is required to obtain the prior consent of the other Party with respect to presentations made to any Vaccine Technical Committee, nor shall the Party making such presentation be required to submit the presentation to the other Party prior to making such presentation to any Vaccine Technical Committee.</font><font style="font-weight:bold;font-style:italic;text-decoration:none;"> </font><font style="text-decoration:none;">Each Party&#8217;s review and approval will be conducted only for the purposes of identifying if confidential information should be modified or deleted so as to preserve the value of the technology owned by such Party or its Affiliates and the rights granted to each Party hereunder. Written copies of such proposed publication or presentation required to be submitted hereunder will be submitted as soon as practically possible before submission for publication or presentation (the &#8220;</font><font style="text-decoration:underline;">Review Period</font><font style="text-decoration:none;">&#8221;). The reviewing Party will provide its comments with respect to such publications and presentations within [***] of its receipt of such written copy. The Review Period may be extended for an additional [***] in the event a Party can, within [***] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Each Party will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section&#160;12.5.2, including International Committee of Medical Journal Editors standards regarding authorship and contributions.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256133"></a><a name="_Toc59107160"></a><a name="_Ref36991477"></a><font style="text-decoration:none;">12.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Non-Disclosure in the Fosun Territory</font><font style="text-decoration:none;">. For the avoidance of doubt, nothing in this Agreement authorizes or permits BioNTech to disclose to Fosun, its Affiliates or any other collaboration partner in or for the Fosun Territory any Pfizer Confidential Information without the prior written consent of Pfizer other than to the extent necessary for Fosun or its Affiliates (or such other collaboration partner in or for the Fosun Territory) to undertake fill/finish of a product identical to any Product in the Fosun Territory or to comply with information obligations required by the China National Medical Products </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">Administration or equivalent, relating to such product in accordance with applicable Law, in each case so far as such use is licensed under Sections </font><font style="text-decoration:none;">3.4.2</font><font style="text-decoration:none;">(b) or </font><font style="text-decoration:none;">3.4.4</font><font style="text-decoration:none;">(b).</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766526"></a><a name="_Toc519764430"></a><a name="_Toc519873421"></a><a name="_Toc35600560"></a><a name="_Toc62256134"></a><a name="_Toc59107161"></a><a name="_Ref517351091"></a><font style="text-decoration:none;">12.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Obligations in Connection with Change of Control</font><font style="text-decoration:none;">. If a Party is subject to a Change of Control or if a Party or any of its Affiliates acquires or merges with a Third Party during the Term (&#8220;Change of Control Party&#8221;), such Change of Control Party will, and it will cause its Representatives to, ensure that no Confidential Information of the other Party is released to (a) any Affiliate of the Change of Control Party that becomes an Affiliate of the Change of Control Party as a result of the Change of Control or (b) any other Representatives of the Change of Control Party (or of the relevant surviving entity of such Change of Control) who become Representatives of the Change of Control Party as a result of the Change of Control, unless such Affiliate or other Representatives, as applicable, have signed individual confidentiality agreements which include equivalent obligations to those set out in this Section 12. Upon occurrence of a Change of Control, the Change of Control Party will promptly notify the other Party, share with the other Party the policies, procedures and technical and organizational measures it plans to implement in order to protect the confidentiality of the other Party&#8217;s Confidential Information prior to such implementation and make any adjustments to such policies and procedures that are reasonably requested by the other Party.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;">13.</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-transform:none;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref265015612"></a><a name="_Ref265016354"></a><a name="_Ref59043358"></a><a name="_Toc62256135"></a><a name="_Toc59107162"></a><font style="text-decoration:none;"></font><font style="text-decoration:underline;text-transform:uppercase;">Representations and Warranties</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766528"></a><a name="_Toc519764432"></a><a name="_Toc519873423"></a><a name="_Toc35600562"></a><a name="_Toc62256136"></a><a name="_Toc59107163"></a><a name="_Ref263795179"></a><a name="_Ref468633620"></a><font style="text-decoration:none;">13.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Mutual Representations and Warranties</font><font style="text-decoration:none;">.</font><font style="font-weight:bold;text-decoration:none;"> </font><font style="text-decoration:none;">Each of BioNTech and Pfizer hereby represents and warrants as of the Amendment Signing Date to the other Party that:</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766529"></a><a name="_Ref468639385"></a><a name="_Ref135585520"></a><a name="_Ref263795195"></a><a name="_Ref263797027"></a><a name="_Ref263797066"></a><font style="text-decoration:none;">13.1.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">it is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.1.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">the execution, delivery and performance of this Agreement by such Party has been duly authorized by all requisite action under the provisions of its charter, bylaws and other organizational documents, and does not require any action or approval by any of its shareholders or other holders of its voting securities or voting interests;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.1.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">it has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.1.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">this Agreement has been duly executed and is a legal, valid and binding obligation on each Party, enforceable against such Party in accordance with its terms; and</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.1.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">the execution, delivery and performance by such Party of this Agreement and its compliance with the terms and provisions hereof does not and will not conflict with or result in a breach of or default under any Binding Obligation existing as of the Effective Date.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref58515757"></a><a name="_Ref58515770"></a><a name="_Ref58515784"></a><a name="_Ref58515798"></a><a name="_Toc519764433"></a><a name="_Toc519873424"></a><a name="_Toc35600563"></a><a name="_Toc62256137"></a><a name="_Toc59107164"></a><a name="_Ref265016598"></a><a name="_Ref273099895"></a><a name="_Ref468633634"></a><a name="_Toc484766530"></a><font style="text-decoration:none;">13.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Mutual Covenants</font><font style="text-decoration:none;">.<a name="_Ref265016598"></a><a name="_Ref273099895"></a><a name="_Ref468633634"></a><a name="_Toc484766530"></a> In addition to the covenants made by the Parties elsewhere in this Agreement, each of BioNTech and Pfizer hereby covenants to the other Party that, from the Effective Date until expiration or termination of this Agreement it will perform its obligations under this Agreement in compliance with applicable Laws.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc519764434"></a><a name="_Toc519873425"></a><a name="_Toc35600564"></a><a name="_Toc62256138"></a><a name="_Toc59107165"></a><a name="_Ref518373508"></a><a name="_Ref519143349"></a><a name="_Ref517456314"></a><font style="text-decoration:none;">13.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Representations and Warranties of BioNTech</font><font style="text-decoration:none;">. As of the Signing Date, BioNTech hereby represents and warrants to Pfizer that, unless otherwise disclosed in Schedule 13.3 (or otherwise as accepted to have been disclosed between BioNTech&#8217;s external counsel and Pfizer&#8217;s external counsel other than in writing), and provided that those provisions of the Current Licenses set forth in Schedule 1.45 shall be </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">deemed disclosed against the representations and warranties given by </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> at sections&#160;</font><font style="text-decoration:none;">13.3.1</font><font style="text-decoration:none;">, </font><font style="text-decoration:none;">13.3.2</font><font style="text-decoration:none;">, </font><font style="text-decoration:none;">13.3.4</font><font style="text-decoration:none;">, </font><font style="text-decoration:none;">13.3.10</font><font style="text-decoration:none;"> and </font><font style="text-decoration:none;">13.3.11</font><font style="text-decoration:none;"> of this </font><font style="text-decoration:none;">Agreement and provided further that all disclosures made under the Flu Collaboration License shall be deemed disclosed also under this</font><font style="text-decoration:none;"> Agreement:</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref265014898"></a><a name="_Ref276052922"></a><a name="_Toc484766531"></a><a name="_Toc519764435"></a><a name="_Toc519873426"></a><a name="_Ref265016628"></a><a name="_Ref273099898"></a><a name="_Ref273102596"></a><font style="text-decoration:none;">13.3.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">as of the Signing Date, except with respect to BioNTech Technology Controlled by BioNTech pursuant to a Current License, BioNTech or its Affiliates are the sole and exclusive owner of the BioNTech Technology, and all BioNTech Technology is free and clear of any claims, liens, charges or encumbrances;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref518312480"></a><font style="text-decoration:none;">13.3.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">as of the Signing Date, BioNTech has, and to its knowledge will have, the full right, power and authority to (a) grant all of the right, title and interest in the licenses and other rights granted or to be granted to Pfizer, Pfizer&#8217;s Affiliates or Pfizer&#8217;s Sublicensees under this Agreement and (b) perform its obligations under this Agreement;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref468632504"></a><font style="text-decoration:none;">13.3.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Schedule 1.21</font><font style="text-decoration:none;"> sets forth a true and complete list of all Candidates relevant to the Field discovered, developed or Controlled by BioNTech or its Affiliates on or prior to the Signing Date; </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref36312739"></a><font style="text-decoration:none;">13.3.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">as of the Signing Date, (a) </font><font style="text-decoration:underline;">Schedule 13.3.4</font><font style="text-decoration:none;"> sets forth a true and complete list of all Patent Rights (i) owned or otherwise Controlled by BioNTech or its Affiliates or (ii) to which BioNTech or its Affiliates have been granted or otherwise transferred any right to practice under, in each case of (i) and (ii), that relate to the Candidates, the Products, the BioNTech Technology, or the Parties&#8217; activities in the Research and Development Program, (b) each such Patent Right is in full force and effect and, so far as BioNTech is aware, valid and enforceable, (c) BioNTech or its Affiliates have timely paid, or caused the appropriate Third Parties to pay, all filing and renewal fees payable with respect to such Patent Rights; (d) BioNTech Controls all Patent Rights listed in </font><font style="text-decoration:underline;">Schedule 13.3.4</font><font style="text-decoration:none;">; and (e) other than those licensed hereunder, there are no other Patent Rights owned or Controlled by BioNTech that Candidates or Products would infringe;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref59042113"></a><a name="_Ref517978829"></a><font style="text-decoration:none;">13.3.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">as of the Signing Date, BioNTech is not aware of any material adverse event, or medical or scientific concern or doubt regarding the safety, contraindications or effectiveness of the use of the BioNTech<a name="_Ref517978829"></a> Technology or the Candidates that have not previously been disclosed in writing to Pfizer; </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.3.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">to BioNTech&#8217;s knowledge as of the Signing Date, (a) no Third Party (i) is infringing any BioNTech Patent Right or (ii) has challenged or threatened in writing to challenge the ownership, scope, validity or enforceability of, or BioNTech&#8217;s or any Current Licensor&#8217;s rights in or to, any BioNTech Patent Right (including, by way of example, through the institution or written threat of institution of interference, nullity or similar invalidity proceedings before the United States Patent and Trademark Office or any analogous foreign Governmental Authority);</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref265014911"></a><font style="text-decoration:none;">13.3.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">as of the Signing Date, BioNTech has independently developed all BioNTech Know-How and BioNTech Materials or otherwise has a valid right to use, and to permit Pfizer, Pfizer&#8217;s Affiliates and Pfizer&#8217;s Sublicensees to use, the BioNTech Know-How and BioNTech Materials for all permitted purposes under this Agreement;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref517465680"></a><a name="_Hlk517987150"></a><font style="text-decoration:none;">13.3.8</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">except with respect to BioNTech Technology Controlled by BioNTech pursuant to a Current License, BioNTech or its Affiliates have obtained from all inventors of BioNTech Technology existing as of the Signing Date, valid and enforceable agreements assigning to </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> or its Affiliates each such inventor&#8217;s entire right, title and interest in and to all such </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"><a name="_Hlk517987150"></a> Technology (</font><font style="text-decoration:none;">except to the extent applicable Law provides that all right, title and interest in and to such </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Technology automatically vests in </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> or its Affiliates by operation of law</font><font style="text-decoration:none;">);</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref44357957"></a><a name="_Ref518672420"></a><a name="_Ref263801732"></a><font style="text-decoration:none;">13.3.9</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">in respect of BioNTech Technology solely or jointly owned by BioNTech existing as of the Signing Date, neither BioNTech nor its Affiliates are subject to any funding agreement with any government or Governmental Authority;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref36312923"></a><font style="text-decoration:none;">13.3.10</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">as of the Effective Date (a) there are no BioNTech Third Party Agreements other than the Current Licenses set forth in </font><font style="text-decoration:underline;">Schedule 1.45</font><font style="text-decoration:none;">, (b) true and complete copies of each Current License (other than the Fosun Agreement) have been provided to Pfizer, (c) except as provided in the Current Licenses, no Third Party has any right, title or interest in or to, or any license under, any BioNTech Technology in the Field, (d) no rights granted by or to BioNTech or its Affiliates under any Current License conflict with any right or license granted to Pfizer or its Affiliates hereunder and (e) BioNTech and its Affiliates are in compliance in all material respects with all Current Licenses;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref518312557"></a><font style="text-decoration:none;">13.3.11</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">as of the Signing Date, to BioNTech&#8217;s knowledge, the use by BioNTech or Pfizer (or their respective Affiliates or Sublicensees) of the BioNTech Technology in accordance with this Agreement, and the Development, Manufacture or Commercialization of those Candidates listed in </font><font style="text-decoration:underline;">Schedule 1.21</font><font style="text-decoration:none;"> or Products incorporating such Candidates in accordance with this Agreement (a) does not and will not infringe any Patent Right of any Third Party or (b) will not infringe the claims of any published Third Party pending Patent Right when and if such claims issue;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref518312559"></a><font style="text-decoration:none;">13.3.12</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">as of the Effective Date, there is no (a) written claim, demand, suit, proceeding, arbitration, inquiry, investigation or other legal action of any nature, civil, criminal, regulatory or otherwise, pending or, to BioNTech&#8217;s knowledge, made or threatened (irrespective of whether or not in writing) against BioNTech or any of its Affiliates or (b) judgment or settlement against or owed by BioNTech or any of its Affiliates, in each case in connection with the BioNTech Technology, the Current Licenses, any Candidate or Product or relating to the transactions contemplated by this Agreement;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref518672453"></a><a name="_Ref518312614"></a><a name="_Ref518312594"></a><font style="text-decoration:none;">13.3.13</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">as of the Signing Date, BioNTech and its Affiliates (a) have claimed and remunerated all employee inventions of their respective employees comprised within the GEIA Technology in accordance with the provisions of the GEIA;<a name="_Ref518312594"></a> and (b) are entitled to unrestrictedly claim all rights to employee inventions of their employees comprised within the GEIA Technology; </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref44358953"></a><font style="text-decoration:none;">13.3.14</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">as of the Signing Date, BioNTech has obtained all necessary assignment documents for the BioNTech Technology inventions in its files and maintains written track records of the proper claiming of any inventions made by employees of BioNTech, its Affiliates or Third Parties included in BioNTech Technology or Research and Development Program Technology by the employer and/or the proper assignment of the inventors of their rights in the invention, including the right to claim priority to said invention, to the employer;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.3.15</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">as of the Signing Date, BioNTech has no knowledge of (a) any inequitable conduct or fraud on any patent office with respect to any of the BioNTech Patent Rights or (b) any Person </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">(other than Persons identified in the applicable patent applications or patents, as inventors of inventions disclosed in the </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Patent Rights) who claims to be an inventor of an invention disclosed in the </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Patent Rights;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.3.16</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">as of the Signing Date, BioNTech and its Affiliates are not, and to BioNTech&#8217;s knowledge, no Current Licensor or Representative of BioNTech (in each case, as applicable) is, debarred by any Regulatory Authority or the subject of debarment proceedings by any Regulatory Authority and, in the course of the discovery or pre-clinical development of any Candidate or Product, BioNTech and its Affiliates have not and, to the knowledge of BioNTech, no Current Licensor or Representative of BioNTech (in each case, as applicable) have used any employee or consultant that is debarred by any Regulatory Authority or, to the knowledge of BioNTech, is the subject of debarment proceedings by any Regulatory Authority; </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref518376830"></a><font style="text-decoration:none;">13.3.17</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">BioNTech, its Affiliates, and to BioNTech&#8217;s knowledge, all third parties and Representatives acting on BioNTech&#8217;s behalf, have and will comply in all material respects with all applicable Law and accepted pharmaceutical industry business practices in connection with this Agreement, including, to the extent applicable, the FD&amp;C Act (21 U.S.C. &#167; 301, et seq.), the Anti-Kickback Statute (42 U.S.C. &#167; 1320a-7b), Civil Monetary Penalty Statute (42 U.S.C. &#167; 1320a-7a), the False Claims Act (31 U.S.C. &#167; 3729 et seq.), comparable state statutes, the regulations promulgated under all such statutes, and the regulations issued by the FDA, consistent with the &#8216;Compliance Program Guidance for Pharmaceutical Manufacturers&#8217; published by the Office of Inspector General, U.S. Department of Health and Human Services;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.3.18</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">with respect to any Candidates, Products, or payments or services provided under this Agreement, BioNTech, its Affiliates, and to its knowledge all third parties and Representatives acting on BioNTech&#8217;s behalf, have not taken and will not during the Term take any action directly or indirectly to offer, promise or pay, or authorize the offer or payment of, any money or anything of value in order to improperly or corruptly seek to influence any Government Official or any other person in order to gain an improper advantage, and has not accepted, and will not accept in the future such payment;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref499624497"></a><font style="text-decoration:none;">13.3.19</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">BioNTech, its Affiliates, and to its knowledge all third parties and Representatives acting on BioNTech&#8217;s behalf, have and will continue to comply with the laws and regulations of the countries where it operates, including Anti-Corruption Laws, accounting and record keeping laws, and laws relating to interactions with HCPs, Governments and Government Officials; </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref518674708"></a><font style="text-decoration:none;">13.3.20</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">BioNTech has implemented a compliance and ethics program containing adequate systems, policies, and procedures for the detection, investigation, documentation, and remediation of any allegations, reports, or findings related to a potential violation of Applicable Law with respect to the Products, payments, and Services under this Agreement. Such policies and procedures should set out rules governing interactions with HCPs and Government Officials, the engagement of third parties, and where appropriate, conducting due diligence, and the investigation, documentation, and remediation of any allegations, reports, or findings related to a potential violation of Applicable Law;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.3.21</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">BioNTech has implemented policies and procedures, including but not limited to anti-corruption policies and procedures, commensurate with its current risk profile, and shall review said policies from time to time setting out rules governing interactions with HCPs and </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">Government Officials, engagement of Third Parties, including, where appropriate, due diligence (&#8220;Policies&#8221;), and its Policies will mandate a robust set of internal controls, including accounting controls designed to ensure the making and keeping of fair and accurate books, records and accounts, on its operations around the world and apply worldwide to all its employees, subsidiaries, and Third Parties acting on its behalf to provide reasonable assurance that </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;">, its subsidiaries and such Third Parties will comply with Laws, including but not limited to Anti-Corruption Laws to the extent required by such Laws. </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> will reasonably monitor and audit its operations and the operations of its Affiliates with the purpose of ensuring compliance with its Policies and the effectiveness of its Policies at the reasonable assurance level and make necessary changes from time to time and in response to identified issues, in particular as</font><font style="text-decoration:none;"><strike> i</strike></font><font style="text-decoration:none;">ts business activities expand;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.3.22</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">the Impf Group does not own or Control any Intellectual Property Rights used by BioNTech or that BioNTech may reasonably require or be useful to exploitation of any of the RNA Technology.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.3.23</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">BioNTech has been provided with a copy of Pfizer&#8217;s International Anti-Bribery and Anti-Corruption Principles and has communicated such principles to all persons acting on its behalf in connection with this Agreement, including its employees, agents, contractors, or subcontractors.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc35600565"></a><a name="_Toc62256139"></a><a name="_Toc59107166"></a><font style="text-decoration:none;">13.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Accuracy of Representations and Warranties</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.4.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">BioNTech will take no action which would render any representation or warranty made by BioNTech and contained in Section 13.1 or Section 13.2 inaccurate or untrue; </font><font style="text-decoration:underline;">provided</font><font style="text-decoration:none;"> that such covenant shall not apply to representations and warranties expressly given as of the Effective Date;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.4.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">BioNTech will promptly notify Pfizer of any lawsuits, claims, administrative actions, regulatory inquiries or investigations, or other proceedings asserted or commenced against BioNTech or its Representatives involving in any material way the ability of BioNTech to deliver the rights, licenses and sublicenses granted herein; </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.4.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">BioNTech will promptly notify Pfizer in writing of any facts or circumstances which come to its attention and which cause, or through the passage of time may cause, any of the representations and warranties contained in Section 13.1, Section&#160;13.2, Section 17.10 or otherwise in this Agreement to be untrue or misleading in any material respect at any time during the Term; and in addition to the foregoing, with regard to any of the representations under Section 17.10, BioNTech will suspend all affected activities (including making any related payments) under this Agreement, unless and until Pfizer determines that such activities may be resumed; </font><font style="text-decoration:underline;">provided</font><font style="text-decoration:none;"> that such covenant shall not apply to representations and warranties expressly given as of the Effective Date; and</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.4.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">BioNTech undertakes to inform Pfizer if it becomes aware that a Government or Government Official has become an owner of at least one (1) percent of BioNTech&#8217;s shares or has come into a position of authority or control within the structure of BioNTech that includes influence over decisions with respect to any Products, payments, or services provided under this Agreement.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766532"></a><a name="_Toc519764436"></a><a name="_Toc519873427"></a><a name="_Toc35600566"></a><a name="_Toc62256140"></a><a name="_Toc59107167"></a><a name="_Ref488240720"></a><font style="text-decoration:none;">13.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">BioNTech</font><font style="text-decoration:underline;"> Covenants</font><font style="text-decoration:none;">. </font><font style="text-decoration:none;">In addition to the covenants made by </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> elsewhere in this Agreement, </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> hereby covenants to Pfizer that, from the Effective Date until expiration or termination of this Agreement:</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref265016671"></a><a name="_Ref276051242"></a><font style="text-decoration:none;">13.5.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">BioNTech will, at all times during the term of this Agreement, maintain its licenses, consents, authorizations or registrations to do business and continue to make any notifications as may be necessary or required by local Laws, regulations, policies, or administrative requirements in order to provide the Products or Services encompassed within this Agreement, and will ensure that providing such Products or Services will not be inconsistent with any other obligation of BioNTech;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_cp_text_1_494"></a><font style="text-decoration:none;">13.5.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">BioNTech will not, and will cause its Affiliates not to (a) license, sell or assign (other than in a connection with a permitted assignment of this Agreement by BioNTech pursuant to Section 17.1) or otherwise transfer to any Person (other than Pfizer or its Affiliates or Sublicensees pursuant to the terms of this Agreement) any BioNTech Technology or Research and Development Program Technology (or agree to do any of the foregoing) or (b) incur or permit to exist, with respect to any BioNTech<a name="_cp_text_1_494"></a> Technology or Research and Development Program Technology, any lien, encumbrance, charge, security interest, mortgage, liability, assignment, grant of license or other Binding Obligation, in each case of (a) and (b) that is inconsistent with the licenses and other rights granted (or that may be granted) to Pfizer or its Affiliates under this Agreement;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref517695468"></a><a name="_cp_text_1_495"></a><a name="_cp_text_1_496"></a><font style="text-decoration:none;">13.5.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Except as explicitly permitted under this Agreement, BioNTech will not (a) take, or omit to take, any action that diminishes the rights under the BioNTech<a name="_cp_text_1_495"></a> Technology or Research and Development Program Technology granted (or that may be granted) to Pfizer or Pfizer&#8217;s Affiliates under this Agreement or (b) take, or omit to take, any action that is reasonably necessary to avoid diminishing the rights under the BioNTech<a name="_cp_text_1_496"></a> Technology or Research and Development Program Technology granted (or that may be granted) to Pfizer or Pfizer&#8217;s Affiliates under this Agreement (for the avoidance of doubt, BioNTech shall not be in breach of the covenants set forth in this Section&#160;13.5.3 due to any reasonable act or position taken in connection with the filing, prosecution, maintenance, defense or enforcement of BioNTech Technology or Research and Development Program Technology as permitted in Section 11);</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref517465395"></a><a name="_cp_text_1_497"></a><a name="_cp_text_1_499"></a><font style="text-decoration:none;">13.5.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">BioNTech will (a) not enter into any BioNTech<a name="_cp_text_1_497"></a> Third Party Agreement that adversely affects (i) the rights granted (or that may be granted) to Pfizer, Pfizer&#8217;s Affiliates or Sublicensees hereunder or (ii) BioNTech&#8217;s ability to fully perform its obligations hereunder; (b) not amend or otherwise modify any BioNTech<a name="_cp_text_1_499"></a> Third Party Agreement (including any Current License) or consent or waive rights with respect thereto in any manner that (A) adversely affects the rights granted (or that may be granted) to Pfizer or Pfizer&#8217;s Affiliates or Sublicensees hereunder or (B) BioNTech&#8217;s ability to fully perform its obligations hereunder; (c) promptly furnish Pfizer with true and complete copies of all (1) amendments to the Current Licenses and (2) BioNTech Third Party Agreements and related amendments executed following the Effective Date (in each case with redactions only in respect of sensitive information which is not relevant for the purposes of this Agreement); (d) remain, and cause its Affiliates to remain, in compliance in all material respects with all BioNTech Third Party Agreements; and (e) furnish Pfizer with copies of all notices received by BioNTech or its Representatives relating to any alleged breach or default by BioNTech or its Representatives under any BioNTech Third Party Agreement within ten (10) Business Days </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">after receipt thereof (in each case with redactions only in respect of sensitive information which is not relevant for the purposes of this Agreement); and</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_cp_text_1_500"></a><font style="text-decoration:none;">13.5.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">BioNTech<a name="_cp_text_1_500"></a> will not enter into or otherwise allow itself or its Representatives to be subject to any agreement or arrangement, other than the Current Licenses, which limits the ownership or licensed rights of Pfizer or its Affiliates with respect to, or limits the ability of Pfizer or its Affiliates to grant a license, sublicense or access, or provide or provide access or other rights in, to or under, any Intellectual Property Right or material (including any Patent Right, Know-How or other data or information), in each case, that would, but for such agreement or arrangement, be included in the rights licensed or assigned (or that may be licensed or assigned) to Pfizer or its Affiliates pursuant to this Agreement </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.5.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">BioNTech and its Affiliates will maintain or obtain valid and enforceable agreements with or from all inventors of BioNTech Technology or Research and Development Program Technology who are employed by or otherwise acting on behalf of BioNTech or its Affiliates assigning to BioNTech or its Affiliates each such inventor&#8217;s entire right, title and interest in and to all such BioNTech Technology or Research and Development Program Technology (except to the extent applicable Law provides that all right, title and interest in and to such BioNTech Technology or Research and Development Program Technology automatically vests in BioNTech or its Affiliates by operation of law).</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.5.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">BioNTech will unrestrictedly claim and remunerate (and procure that its Affiliates will unrestrictedly claim and remunerate) all employee inventions of their respective employees comprised within the GEIA Technology in accordance with the provisions of the GEIA.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.5.8</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">In respect of GEIA Technology created after the Effective Date to which Pfizer shall obtain a license hereunder, BioNTech will use Commercially Reasonable Efforts (and will procure that its Affiliates use Commercially Reasonable Efforts) to conclude agreements with BioNTech employee inventors regarding the respective inventions by which the respective inventors: (a) waive the employer&#8217;s obligation to release the employee invention and to enable the employee inventor upon request to apply for foreign Intellectual Property Rights for such foreign countries in which it does not intend to apply for Intellectual Property Rights (Sec. 14 GEIA); and (b) waive the employer&#8217;s obligation to notify the employee inventor and to transfer the right in the invention to the employee inventor at the latter&#8217;s request and expense, if it does not intend to pursue the application for the grant on an Intellectual Property Right for the invention any further or if it does not want to maintain the Intellectual Property Right granted for the job-related invention (Sec. 16 GEIA); and (c) waive the employer&#8217;s obligation to acknowledge protectability of the invention in case the employer decides not to file a registration, but to keep the invention secret (Sec. 17 GEIA); </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.5.9</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">To the extent BioNTech Technology or Research and Development Program Technology is created after the Effective Date by inventors employed by or acting on behalf of BioNTech&#8217;s or its Affiliates&#8217; Third Party subcontractors, BioNTech will (a) use Commercially Reasonable Efforts (and will procure that its Affiliates use Commercially Reasonable Efforts) to obtain valid and enforceable agreements with their respective Third Party subcontractors imposing on their Third Party subcontractors the obligation to claim the rights in the invention in accordance with applicable Law and to conclude agreements with its employee inventors assigning to the respective Third Party subcontractor each such inventor&#8217;s entire right, title and interest in and to all </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">such </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Technology or Research and Development Program Technology (except to the extent applicable Law provides that all right, title and interest in and to such </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Technology or Research and Development Program Technology automatically vests in the Third Party subcontractor by operation of law) and, (b) to the extent GEIA applies to such </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Technology or Research and Development Program Technology, use Commercially Reasonable Efforts to obtain a waiver of inventor in his rights in Sec. 14, 16 and 17 GEIA;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.5.10</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">with respect to any BioNTech Technology or Research and Development Program Technology to which Pfizer shall obtain a license hereunder that is made after the Effective Date in the jurisdiction of the GEIA by an inventor on behalf of BioNTech or its Affiliates who is employed by a university pursuant to Sec. 42 GEIA (e.g. university professors, research assistants), BioNTech will use Commercially Reasonable Efforts (and will procure that its Affiliates use Commercially Reasonable Efforts) to obtain valid and enforceable trifold agreements with such inventor and the respective university by which the university (a) waives its entire right, title and interest in and to that BioNTech Technology or Research and Development Program Technology made by the inventor, (b) the inventor assigns its rights, title and interest in and to that BioNTech Technology or Research and Development Program Technology to BioNTech or its Affiliates, (c) the inventor waives its rights pursuant to Sec. 14, 16 and 17 GEIA as well as (d) waives its negative publication right (Sec. 42 Nr. 2 GEIA) vis-a-vis BioNTech or its Affiliates;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.5.11</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">with respect to animals used in conducting activities under this Agreement, BioNTech will, and will cause its Affiliates and permitted subcontractors to, comply with its policies on animal care and use which shall be no less strict than Pfizer&#8217;s Corporate Policy regarding Animal Care and Use, attached hereto as </font><font style="text-decoration:underline;">Exhibit C</font><font style="text-decoration:none;"> (except where in conflict with applicable Law);</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.5.12</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">with respect to Human Material used, including collection or transfer, by BioNTech, its Affiliates or permitted subcontractors in conducting activities under this Agreement, (a) such use shall be in accordance with the binding part of the Research and Development Plan and shall be within the scope of and consistent with its ethical approval policies, (b) BioNTech will, and will cause its Affiliates or permitted subcontractors to, handle and use the Human Material in accordance with all applicable Laws and the ICF, which shall permit Pfizer to use the Human Material for the research purposes contemplated by this Agreement, (c) BioNTech will provide the ICF to Pfizer upon request by Pfizer, (d) the Human Material will be used for research purposes only and not be used for treatment of or administration to humans and (e) if BioNTech procures any Human Material from a Third Party such as a sample bank, it will ensure that the collection and transfer of the Human Material and the use of the Human Material for purposes of the Research and Development Plan is in accordance with all applicable Laws and recognized international standards for the protection of human research subjects; </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref46401063"></a><font style="text-decoration:none;">13.5.13</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">BioNTech shall, at all times, maintain and enforce a compliance and ethics program containing adequate systems, policies and procedures for the detection, investigation, documentation, and remediation of any allegations, reports or findings related to a potential violation of applicable Law, including Anti-Corruption Laws, with respect to the Candidates, Products, payments and services under this Agreement, which policies shall be not less strict than Pfizer&#8217;s Anti-Bribery and Anti-Corruption Principles attached hereto as </font><font style="text-decoration:underline;">Exhibit B</font><font style="text-decoration:none;">. Such policies and procedures should set out rules governing interactions with HCPs, Government Officials, the engagement of Third Parties, and where appropriate, conducting due diligence, and the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">investigation, documentation and remediation of any allegations, reports or findings related to a potential violation of applicable Laws, and </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> shall, upon Pfizer's request, require any persons acting on behalf of </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> in connection with this Agreement to complete anti-corruption compliance training provided by Pfizer, and will notify Pfizer of any persons that require or may require such training during the Term;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref46401081"></a><font style="text-decoration:none;">13.5.14</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">if BioNTech finds, following an investigation, credible evidence of a violation of any applicable policies and procedures that are designed to ensure compliance with any applicable Laws, including any criminal, civil or administrative laws or regulations, or violations of policies or procedures related to scientific misconduct or data integrity, BioNTech shall promptly inform Pfizer of the occurrence and the steps taken by BioNTech to remediate the occurrence; </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.5.15</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">in it undertaking, sponsoring, or having regulatory oversight over any Clinical Trials, BioNTech shall ensure and procure that all documentation for such Clinical Trials shall comply with, and take advantage of, any applicable Laws that serve to limit product liability claims and losses having regard to the pandemic status of COVID-19, including any requirements under any declarations pursuant to the Public Readiness and Emergency Preparedness (PREP) Act in the USA or any equivalent, similar or comparable legislation in the Territory;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref46401124"></a><font style="text-decoration:none;">13.5.16</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">In connection with its activities under this Agreement, BioNTech agrees to comply with all Applicable Laws, including all applicable Anti-Corruption Laws; and BioNTech has not taken, and will not during the term of this Agreement, take any action directly or indirectly to (i) offer, promise, provide, or authorize the offer or provision of money or anything of value, in order to improperly or corruptly seek to influence any Government Official or any other person in order to obtain or retain business or any other improper business advantage; (ii) request or accept any such improper payment; or (iii) cause a violation of any applicable Anti-Corruption Law. For example, this includes providing any inducement for such Government Official or person to approve, reimburse, prescribe, or purchase a Product, to influence the outcome of a clinical trial, or otherwise to benefit BioNTech&#8217;s business activities improperly;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref46401141"></a><font style="text-decoration:none;">13.5.17</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">BioNTech agrees, at all times during the term of this Agreement, to: (i) maintain truthful and complete documentation supporting, in reasonable detail, the work and services performed and any expenses incurred in connection with this Agreement; and (ii) maintain financial books and records that timely, fairly, accurately, and completely reflect all financial transactions, in accordance with all Applicable Laws, including applicable Anti-Corruption Laws (for example, invoices, reports, statements, books, and other records), and shall maintain such books and records during the term of this Agreement and for five years after final payment has been made under this Agreement;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref46401162"></a><font style="text-decoration:none;">13.5.18</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">In connection with any audit or any investigation regarding any potential violations of Applicable Laws related to this Agreement, including all applicable Anti-Corruption Laws, BioNTech agrees to permit, during the term of this Agreement and for five years after final payment has been made under this Agreement, Pfizer&#8217;s external auditors access to any non-privileged relevant books, documents, papers, and records of BioNTech involving transactions related to the Products, payments, or services provided under this Agreement; and</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Hlk44659539"></a><a name="_Hlk44659719"></a><font style="text-decoration:none;">13.5.19</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">BioNTech<a name="_Hlk44659719"></a> agrees, from the beginning of the Commercialization Activities onwards until the end of the Term, to maintain and enforce adequate policies and procedures </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">describing the materials and information that may be distributed or discussed by </font><font style="text-decoration:none;">BioNTech&#8217;s</font><font style="text-decoration:none;"> employees, contractors, subcontractors, or agents related to the Products, and the manner in which such persons should handle unsolicited requests for information related to off-label uses of the Products. Such policies and procedures should be designed to ensure compliance with applicable Laws and regulations. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc519764437"></a><a name="_Toc519873428"></a><a name="_Toc35600567"></a><a name="_Toc62256141"></a><a name="_Toc59107168"></a><a name="_Ref35895506"></a><font style="text-decoration:none;">13.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Pfizer Covenants</font><font style="text-decoration:none;">. In addition to the covenants made by Pfizer elsewhere in this Agreement, Pfizer hereby covenants to BioNTech that, from the Effective Date until expiration or termination of this Agreement, </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.6.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">In connection with its activities under this Agreement, Pfizer will, at all times during the term of this Agreement, maintain its licenses, consents, authorizations or registrations to do business and continue to make any notifications as may be necessary or required by local Laws, regulations, policies, or administrative requirements in order to provide the Products or Services encompassed within this Agreement, and will ensure that providing such Products or Services will not be inconsistent with any other obligation of Pfizer;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Hlk517999704"></a><font style="text-decoration:none;">13.6.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Pfizer and its<a name="_Hlk517999704"></a> Affiliates maintain or will obtain valid and enforceable agreements with or from all inventors of Pfizer Improvements or Research and Development Program Technology who are employed by or otherwise acting on behalf of Pfizer or its Affiliates valid and enforceable agreements assigning to Pfizer or its Affiliates each such inventor&#8217;s entire right, title and interest in and to all such Pfizer Improvements or Research and Development Program Technology (except to the extent applicable Law provides that all right, title and interest in and to such Pfizer Improvements or Research and Development Program Technology automatically vests in Pfizer or its Affiliates by operation of law), and Pfizer and its Affiliates have made or will make any payments owing to any such inventors in respect of any Pfizer Improvements or Research and Development Program Technology or any other Person that is required in connection with the creation or exploitation of or transfer of rights to such Pfizer Improvements or Research and Development Program Technology; </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.6.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">with respect to Human Material used, including collection or transfer, by Pfizer, its Affiliates or permitted subcontractors in conducting activities under this Agreement, (a) such use shall be within the scope of and consistent with its ethical approval policies, (b) Pfizer will, and will cause its Affiliates or permitted subcontractors to, handle and use the Human Material in accordance with all applicable Laws and the ICF, (c) Pfizer will provide the ICF to BioNTech upon request by BioNTech, (d) the Human Material will be used for research purposes only and not be used for treatment of or administration to humans and (e) if Pfizer procures any Human Material from a Third Party such as a sample bank, it will ensure that the collection and transfer of the Human Material and the use of the Human Material for purposes of the Research and Development Plan is in accordance with all applicable Laws and recognized international standards for the protection of human research subjects; and</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref519110590"></a><a name="_Ref519110687"></a><font style="text-decoration:none;">13.6.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Pfizer will comply with the provisions of the Current Licenses set forth in </font><font style="text-decoration:underline;">Schedule&#160;1.45</font><font style="text-decoration:none;"> in respect of BioNTech Technology sublicensed to Pfizer under the respective Current Licenses insofar as Pfizer is using such BioNTech Technology; </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.6.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Pfizer shall comply with its Anti-Bribery and Anti-Corruption Principles attached hereto as </font><font style="text-decoration:underline;">Exhibit B</font><font style="text-decoration:none;"> and its Corporate Policy regarding Animal Care and Use, attached hereto as </font><font style="text-decoration:underline;">Exhibit C</font><font style="text-decoration:none;">; and</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.6.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">in it undertaking, sponsoring, or having regulatory oversight over any Clinical Trials, Pfizer shall ensure and procure that all documentation for such Clinical Trials shall comply with, and take advantage of, any applicable Laws that serve to limit product liability claims and losses having regard to the pandemic status of COVID-19, including any requirements under any declarations pursuant to the Public Readiness and Emergency Preparedness (PREP) Act in the USA or any equivalent, similar or comparable legislation in the Territory.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref44659709"></a><font style="text-decoration:none;">13.6.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">In connection with its activities under this Agreement, Pfizer agrees to comply with all applicable Laws, including all applicable Anti-Corruption Laws; and Pfizer has not taken, and will not during the term of this Agreement, take any action directly or indirectly to (i) offer, promise, provide, or authorize the offer or provision of money or anything of value, in order to improperly or corruptly seek to influence any Government Official or any other person in order to obtain or retain business or any other improper business advantage; (ii) request or accept any such improper payment; or (iii) cause a violation of any applicable Anti-Corruption Law. For example, this includes providing any inducement for such Government Official or person to approve, reimburse, prescribe, or purchase a Product, to influence the outcome of a clinical trial, or otherwise to benefit Pfizer&#8217;s business activities improperly;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.6.8</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Pfizer agrees, at all times during the term of this Agreement, to: (i) maintain truthful and complete documentation supporting, in reasonable detail, the work and services performed and any expenses incurred in connection with this Agreement; and (ii) maintain financial books and records that timely, fairly, accurately, and completely reflect all financial transactions, in accordance with all applicable Laws, including applicable Anti-Corruption Laws (for example, invoices, reports, statements, books, and other records), and shall maintain such books and records during the term of this Agreement and for five years after final payment has been made under this Agreement;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.6.9</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">In connection with any audit or any investigation regarding any potential violations of applicable Laws related to this Agreement, including all applicable Anti-Corruption Laws, Pfizer agrees to permit, during the term of this Agreement and for five years after final payment has been made under this Agreement, BioNTech&#8217;s external auditors access to any non-privileged relevant books, documents, papers, and records of Pfizer involving transactions related to the Products, payments, or services provided under this Agreement; and</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.6.10</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Pfizer agrees, from the beginning of the Commercialization Activities onwards until the end of the Term, to maintain and enforce adequate policies and procedures describing the materials and information that may be distributed or discussed by Pfizer&#8217;s employees, contractors, subcontractors, or agents related to the Products, and the manner in which such persons should handle unsolicited requests for information related to off-label uses of the Products. Such policies and procedures should be designed to ensure compliance with applicable Laws and regulations; </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc519764438"></a><a name="_Toc519873429"></a><a name="_Toc35600568"></a><a name="_Toc62256142"></a><a name="_Toc59107169"></a><a name="_Ref441668734"></a><font style="text-decoration:none;">13.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Notifications</font><font style="text-decoration:none;">. During the Term: </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.7.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">BioNTech will promptly notify Pfizer in writing or orally in the event that it learns of:</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.7.1.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">any prior art or other facts that BioNTech believes would result in the invalidity or unenforceability of any of the claims included in any of the BioNTech Patent Rights or Research and Development Program Patent Rights; or</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.7.1.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">any inequitable conduct or fraud on the patent office with respect to any of the BioNTech Patent Rights or Research and Development Program Patent Rights; or </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_cp_text_2_501"></a><font style="text-decoration:none;">13.7.1.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">any Person (other than Persons identified as inventors of inventions disclosed in the BioNTech Patent Rights or Research and Development Program Patent Rights) who claims to be an inventor of an invention disclosed in the BioNTech<a name="_cp_text_2_501"></a> Patent Rights or Research and Development Program Patent Rights; and</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Hlk50034629"></a><font style="text-decoration:none;">13.7.1.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">any material lawsuits, claims, administrative actions, government inquiries or investigations, or other proceedings related to the activities contemplated under this Agreement or under any Related Agreement to the extent such notification is permitted under applicable Law, except to the extent that BioNTech&#8217;s counsel reasonably believes that such disclosure to Pfizer could violate applicable privacy laws or have a significant adverse impact on BioNTech&#8217;s legal position or defense (including the loss of attorney-client privilege) with respect to any such lawsuit, claim, administrative action, government inquiry or investigation, or other proceeding. In the event that BioNTech determines that disclosure could violate applicable privacy laws or have a significant adverse impact on its legal position or defense, BioNTech shall promptly notify Pfizer that it is exercising its right not to disclose.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.7.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Pfizer will promptly notify BioNTech in writing or orally in the event that it learns of any material lawsuits, claims, administrative actions, government inquiries or investigations, or other proceedings related to the activities contemplated under this Agreement or under any Related Agreement to the extent such notification is permitted under applicable Law, except to the extent that Pfizer&#8217;s counsel reasonably believes that such disclosure to BioNTech could violate applicable privacy laws or have a significant adverse impact on Pfizer&#8217;s legal position or defense (including the loss of attorney-client privilege) with respect to any such lawsuit, claim, administrative action, government inquiry or investigation, or other proceeding. In the event that Pfizer determines that disclosure could violate applicable privacy laws or have a significant adverse impact on its legal position or defense, Pfizer shall promptly notify BioNTech that it is exercising its right not to disclose.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766533"></a><a name="_Toc519764439"></a><a name="_Toc519873430"></a><a name="_Toc35600569"></a><a name="_Toc62256143"></a><a name="_Toc59107170"></a><a name="_Ref35966534"></a><font style="text-decoration:none;">13.8</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Representation by Legal Counsel</font><font style="text-decoration:none;">. Each Party hereto represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption will exist or be implied against the Party which drafted such terms and provisions.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc519764440"></a><a name="_Toc519873431"></a><a name="_Toc35600570"></a><a name="_Toc62256144"></a><a name="_Toc59107171"></a><a name="_Ref518986131"></a><font style="text-decoration:none;">13.9</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">BioNTech&#8217;s Knowledge</font><font style="text-decoration:none;">. All references in this Section&#160;13 to BioNTech&#8217;s knowledge (or equivalent) shall refer to the actual knowledge after reasonable internal inquiry of BioNTech&#8217;s management comprising those individuals set forth in </font><font style="text-decoration:underline;">Schedule 13.9</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766534"></a><a name="_Toc519764441"></a><a name="_Toc519873432"></a><a name="_Toc35600571"></a><a name="_Toc62256145"></a><a name="_Toc59107172"></a><a name="_Ref135585485"></a><font style="text-decoration:none;">13.10</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Disclaimer</font><font style="font-weight:bold;text-decoration:none;">.</font><font style="text-decoration:none;"> THE FOREGOING REPRESENTATIONS AND WARRANTIES OF EACH PARTY ARE IN LIEU OF ANY OTHER REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR ANY IMPLIED WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE, ALL OF WHICH ARE HEREBY SPECIFICALLY EXCLUDED AND DISCLAIMED.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256146"></a><a name="_Toc59107173"></a><a name="_Ref44355743"></a><font style="text-decoration:none;">13.11</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Compliance Certificates</font><font style="text-decoration:none;">. Each Party agrees to complete and submit to the other, on an annual basis for the Term, a certification in the form set out in&nbsp;&nbsp;Schedule 13.11 (an ABAC Compliance Certification).</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;">14.</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-transform:none;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref135585535"></a><a name="_Ref59005694"></a><a name="_Toc62256147"></a><a name="_Toc59107174"></a><a name="_Toc484766538"></a><a name="_Toc519764445"></a><a name="_Toc519873436"></a><a name="_Toc35600573"></a><font style="text-decoration:none;"></font><font style="text-decoration:underline;text-transform:uppercase;">Government Approvals; Term and Termination</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256148"></a><a name="_Toc59107175"></a><a name="_Ref488160034"></a><font style="text-decoration:none;">14.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Government Approvals</font><font style="text-decoration:none;">. Each of BioNTech and Pfizer will cooperate with the other Party and to make all registrations, filings and applications, to give all notices and to obtain as soon as practicable all governmental or other consents, transfers, approvals, orders, qualifications authorizations, permits and waivers, if any, and to do all other things necessary or useful for the consummation of the transactions as contemplated hereby including the collection of Human Material.</font><font style="text-decoration:underline;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766539"></a><a name="_Toc519764446"></a><a name="_Toc519873437"></a><a name="_Toc35600574"></a><a name="_Toc62256149"></a><a name="_Toc59107176"></a><a name="_Ref263792351"></a><font style="text-decoration:none;">14.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Term</font><font style="text-decoration:none;">. The term of this Agreement (the &#8220;Term&#8221;) will commence on the Effective Date and shall continue, unless terminated earlier in accordance with this Section&#160; 14, for so long as either at least one Candidate or Product is being Developed for use in the Territory or a Product Commercialized anywhere in the Territory.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc519873438"></a><a name="_Toc484766540"></a><a name="_Toc519764447"></a><a name="_Toc35600575"></a><a name="_Toc62256150"></a><a name="_Toc59107177"></a><a name="_Ref263794696"></a><a name="_Ref263797210"></a><a name="_Ref43392342"></a><a name="_Ref46525294"></a><a name="_Ref46928404"></a><a name="_Ref51419014"></a><font style="text-decoration:none;">14.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Termination for Cause by a Party</font><font style="text-decoration:none;">. Either Party may terminate this Agreement for cause, at any time during the Term, by giving written notice to the other Party in the event that such other Party commits a material breach of its obligations under this Agreement which, taking into account the breached obligation and the effect of the breach, has a material detrimental effect on the overall total value and fundamental purpose of this Agreement, and such material breach remains uncured for at least one hundred and [***], in each case measured from the date written notice of such material breach is given to the other Party; </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;">, </font><font style="font-style:italic;text-decoration:none;">however</font><font style="text-decoration:none;">, that if any breach is not reasonably curable within [***] and if the Party accused of breach is making a bona fide effort to cure such breach, such termination will be delayed for a time period either to be agreed by both Parties (which non-breaching Party's consent shall not be unreasonably withheld or conditioned) or in the absence of agreement for such reasonable additional period required to cure the breach (having regard to the nature of the breach and steps required to cure it) in order to permit the Party accused of a breach a reasonable period of time to cure such breach. If the alleged material breach relates to the non-payment of any amount due under this Agreement, the cure period will be tolled pending resolution of any bona fide dispute between the Parties as to whether such payment is due. For the avoidance of doubt, a Party&#8217;s failure to use Commercially Reasonable Efforts to Commercialize the Product in its </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">Commercialization Territory may constitute a material breach of this Agreement if such failure is a material default that has materially diminishes the overall total value and fundamental purpose of this Agreement.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766541"></a><a name="_Toc519764448"></a><a name="_Toc519873439"></a><a name="_Ref58515862"></a><a name="_Ref58515891"></a><a name="_Toc62256151"></a><a name="_Toc59107178"></a><a name="_Ref263794712"></a><a name="_Ref36285066"></a><a name="_Ref36759433"></a><a name="_Ref36934195"></a><a name="_Ref43391184"></a><font style="text-decoration:none;">14.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Termination by Pfizer for Convenience</font><font style="text-decoration:none;"><a name="_Ref43391184"></a>. [***], Pfizer may terminate this Agreement, on a country-by-country basis or in its entirety for convenience upon [***] prior written notice [***] (which notice period may be shortened by BioNTech in BioNTech&#8217;s sole discretion through written notice to Pfizer at any time after BioNTech&#8217;s receipt of such termination notice) without any liability to BioNTech.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256152"></a><a name="_Toc59107179"></a><a name="_Ref37010753"></a><a name="_Ref37186539"></a><font style="text-decoration:none;">14.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Termination by Pfizer for [***]</font><font style="text-decoration:none;">. [***]</font><font style="font-style:italic;text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref412001725"></a><a name="_Toc62256153"></a><a name="_Toc59107180"></a><font style="text-decoration:none;">14.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Termination Following Certain Violations</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref412001446"></a><font style="text-decoration:none;">14.6.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Cause for Termination following Certain Violations</font><font style="text-decoration:none;">. Subject to Section&#160;14.8, this Agreement may be terminated at any time during the Term by either Party immediately upon written notice to the other Party (the &#8220;</font><font style="text-decoration:underline;">Violating Party</font><font style="text-decoration:none;">&#8221;) if:</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">14.6.1.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">the Violating Party is convicted of violating any Anti-Corruption Law in connection with the performance of its obligations under this Agreement and such violation materially adversely affects the ability of either Party to perform its Commercialization Activities or Medical Activities;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">14.6.1.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">the Violating Party enters into a settlement or other resolution that includes an admission of liability under any such Anti-Corruption Law in connection with this Agreement and such admission of liability materially adversely affects the ability of either Party to perform its Commercialization Activities or Medical Activities;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">14.6.1.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">the Violating Party materially breaches any of its covenants, contained in Section 13.5.14, 13.5.16, 13.5.17 or 13.5.18, or violates any Anti-Corruption Law in connection with its Commercialization Activities or Medical Activities and such violation materially adversely affects the ability of either Party to perform its Commercialization Activities or Medical Activities (provided that the term &#8220;material&#8221; shall be interpreted taking into account each Party's responsibilities under the Agreement);</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1152"></a><a name="_cp_text_1_1152"></a>provided that in each case, that the Violating Party has not cured (such cure to be pursuant to Section&#160;14.6.2, as applicable) such material breach or violation within ninety (90) days after written notice delivered by the non-Violating Party to the alleged Violating Party requesting cure of the breach.</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref412001434"></a><font style="text-decoration:none;">14.6.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Cure of Violations of Anti-Corruption Laws</font><font style="text-decoration:none;">. With respect to any breach resulting in a right of termination under Section&#160;14.6.1, such breach may be cured by taking all of the following actions to the extent relevant to such breach:</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">14.6.2.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">diligent investigation of the facts relating to such breach or violation by the Violating Party and, to the extent not covered by any opinion from the Violating Party&#8217;s counsel that such disclosure would waive any applicable privilege attaching to such findings, the sharing of the investigation&#8217;s findings with the other Party;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">14.6.2.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">appropriate disciplinary action by the Violating Party (which may include termination) with respect to any of its directors, officers or employees who the Violating </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">Party believes was responsible for or involved in the breach or violation, or any related violation of the Violating Party&#8217;s compliance and ethics program;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">14.6.2.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">appropriate remedial action by the Violating Party, which may include termination of any contractor, agent, sub-contractor, customer, other Person or vendor that the Violating Party believes was responsible for or involved in the breach or violation or termination of any business or relationship that the Violating Party believes was obtained through bribery; and</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">14.6.2.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">presentation to the other Party of the Violating Party&#8217;s plan for resolution or remediation of the breach or violation and informing the other Party that the Violating Party has initiated activities under such plan (</font><font style="font-style:italic;text-decoration:none;">e.g.</font><font style="text-decoration:none;">, through the applicable Committee(s) or other applicable mechanism under this Agreement) unless the Violating Party has received an opinion from counsel that such disclosure would waive any applicable privilege attaching to such plan.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256154"></a><a name="_Toc59107181"></a><font style="text-decoration:none;">14.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Exclusion of termination rights</font><font style="text-decoration:none;">. Save for the rights expressly set out in this Agreement, neither Party may terminate this Agreement prior to expiry of the term under any common law right or other remedy.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766542"></a><a name="_Toc519764449"></a><a name="_Toc519873440"></a><a name="_Toc35600577"></a><a name="_Ref58975580"></a><a name="_Toc62256155"></a><a name="_Toc59107182"></a><a name="_Ref62483642"></a><a name="_Ref276112498"></a><font style="text-decoration:none;">14.8</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Effects of Expiration or Termination</font><font style="text-decoration:none;">.</font><font style="text-decoration:underline;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref516844692"></a><a name="_Ref36760298"></a><a name="_Ref263793945"></a><font style="text-decoration:none;">14.8.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">General</font><font style="text-decoration:none;">. Upon the expiration or termination of this Agreement, with regard to the Product in the countries that are the subject of such expiration or termination, the Parties acknowledge and agree that, except as otherwise expressly set forth in this Agreement and subject to Section 14.8.8, each Party&#8217;s rights and obligations under this Agreement will terminate in their entirety (including all rights and licenses and sublicenses granted by either Party to the other Party hereunder, and all sublicenses granted to Affiliates or Third Parties under the rights granted hereunder) with respect to the Terminated Territory from and after the Termination Effective Date.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref518044537"></a><font style="text-decoration:none;">14.8.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Termination for Cause by a Party</font><font style="text-decoration:none;">.<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup>In the event that a Party terminates this Agreement for cause pursuant to Section 14.3<a name="_Ref518044537"></a> or upon its expiration, all rights and obligations of each Party hereunder will cease (including all rights and licenses and sublicenses granted by either Party to the other Party hereunder, and all sublicenses granted to Affiliates or Third Parties under the rights granted hereunder), except as otherwise expressly provided herein.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">14.8.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Termination for Pfizer&#8217;s Convenience</font><font style="text-decoration:none;">. Upon Pfizer's termination of the Agreement as a whole pursuant to Section 14.4, (a) Pfizer shall pay for all Shared Development Costs (i) incurred by either Party in accordance with the binding portions of the Research and Development Plan, Manufacturing Plan and Development Budget up to the date notice is served to terminate by Pfizer; and (ii) that are irrevocably committed to by a Party prior to the date notice is served to terminate by Pfizer in accordance with the binding portions of the Research and Development Plan, Manufacturing Plan and Development Budget, and which costs cannot be refunded, reduced or otherwise allocated to another project; and (b) Pfizer shall pay for all future Development costs that are irrevocably committed to by BioNTech in accordance with the binding portions of the Research and Development Plan, Manufacturing Plan and Development Budget prior to the date notice is served to terminate by Pfizer, and which costs cannot be refunded, reduced or otherwise allocated to another project.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">14.8.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">No Effect on Related Agreements</font><font style="text-decoration:none;">. Unless explicitly agreed otherwise, termination or expiration of this Agreement shall not affect any other agreements concluded hereunder, including the Manufacturing agreements pursuant to Section&#160; 7.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">14.8.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Termination-specific Definitions</font><font style="text-decoration:none;">. Solely for purposes of this Section&#160; 14:</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref412004018"></a><font style="text-decoration:none;">14.8.5.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">&#8220;</font><font style="text-decoration:underline;">Termination Effective Date</font><font style="text-decoration:none;">&#8221; means the effective date of expiration or termination with respect to the Product in the applicable Terminated Territory.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref412004012"></a><font style="text-decoration:none;">14.8.5.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">&#8220;</font><font style="text-decoration:underline;">Terminated Territory</font><font style="text-decoration:none;">&#8221; means (i) in the event of termination pursuant to Section&#160;14.4, those countries regarding which such termination has occurred (to the extent this Agreement is not terminated with respect to the entire Territory pursuant to Section 14.4) or (ii) in the event of expiration or any other termination, the entire Territory.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref412001622"></a><a name="_Ref46756244"></a><a name="_Ref46761179"></a><font style="text-decoration:none;">14.8.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Return of Rights and Materials</font><font style="text-decoration:none;">. BioNTech will have the sole right, as between the Parties, to Develop, Manufacture, Commercialize and otherwise exploit the Product in and for the Terminated Territory. Accordingly, upon the Termination Effective Date for such Product, or such earlier time as is indicated in this Section 14.8.6, the Parties will undertake the activities set forth below; </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;"> that in the event that BioNTech terminates this Commercialization Agreement pursuant to Section 14.3, the remedies provided for in this Section 14.8.6 shall be taken into account to reduce any damages calculation awarded in any action relating to Pfizer&#8217;s alleged material breach of this Agreement:</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref39568023"></a><font style="text-decoration:none;">14.8.6.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-style:italic;text-decoration:none;">Cessation of Activities. </font><font style="text-decoration:none;">Pfizer will, except as required under this Section&#160;14.8 or as required by applicable Law, immediately cease all of its Commercialization Activities in or for the Terminated Territory as of the Termination Effective Date, and (x) if BioNTech terminates this Agreement pursuant to Section 14.3 or Pfizer terminates this Agreement pursuant to Section 14.4, BioNTech shall be entitled to request from Pfizer to purchase, or re-purchase, as applicable, any or all of the inventory of Product then owned by Pfizer that is of appropriate quality for sale or resale by BioNTech (provided</font><font style="font-style:italic;text-decoration:none;"> </font><font style="text-decoration:none;">that if Pfizer is obligated to supply Product pursuant to Section 14.8.6.5, BioNTech shall be obligated to first purchase, or re-purchase, as applicable all such inventory of Product then owned by Pfizer of such saleable quality prior to Pfizer manufacturing or having manufactured for it Product pursuant to Section 14.8.6.5) and (y) if Pfizer terminated this Agreement pursuant to Section 14.3, then Pfizer shall be entitled to require BioNTech to purchase, or re-purchase, as applicable, any or all such inventory of Product then owned by Pfizer of such saleable quality, and in each case of (x) or (y) with the understanding that (i) the Party having such option may exercise such option by providing written notice thereof to the other Party within [***] after the Termination Effective Date, and upon exercise of such option, (ii) Pfizer shall promptly ship such inventory of Product to BioNTech or its designee, and (iii) BioNTech shall pay Pfizer the Transfer Price (or cancel any outstanding unpaid invoices) for such inventory of Product, including all shipping costs.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref412004000"></a><a name="_Ref43487459"></a><a name="_cp_text_1_1154"></a><font style="text-decoration:none;">14.8.6.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-style:italic;text-decoration:none;">Product Data. </font><font style="text-decoration:none;">Pfizer, upon BioNTech&#8217;s written request and subject to any applicable obligations to Third Parties, will promptly transfer to BioNTech copies of all data, reports, records, and other Know-How specified in such request that (i) solely relate to the Product, (ii) was generated by or on behalf of Pfizer or its Affiliates under this </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">Agreement, (iii) is reasonably necessary for </font><font style="text-decoration:none;">BioNTech&#8217;s</font><font style="text-decoration:none;"> continued Commercialization of the Product in the Terminated Territory, and (iv) is at the time of such request in Pfizer&#8217;s or its Affiliates&#8217; possession and Control (&#8220;</font><font style="text-decoration:underline;">Terminated Product Data</font><font style="text-decoration:none;">&#8221;), provided that Pfizer shall not be obligated to provide to </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> any such Terminated Product Data where Pfizer or its Affiliates are restricted from doing so by Applicable Law or the terms and conditions of any agreement between Pfizer or any of its Affiliates and a Third Party. The Terminated Product Data will be provided in the form in which Pfizer or its Affiliates has maintained such Terminated Product Data; </font><font style="font-style:italic;text-decoration:none;"><a name="_cp_text_1_1154"></a>provided</font><font style="font-style:italic;text-decoration:none;"> </font><font style="font-style:italic;text-decoration:none;">that</font><font style="text-decoration:none;"> Pfizer will not unreasonably withhold its consent and cooperation, if necessary, in connection with </font><font style="text-decoration:none;">BioNTech&#8217;s</font><font style="text-decoration:none;"> (or its designee&#8217;s) further Commercialization of the Product in the Terminated Territory to obtain original hardcopies or duplicate copies thereof.</font><font style="text-decoration:none;"> </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> shall not disclose the Terminated Product Data to any Third Party, except to the extent necessary for </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;">, after the Termination Effective Date, to Commercialize the Product in the Terminated Territory and, for clarity, </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> shall have no right to use or to permit any Affiliate or Third Party to use any or the Terminated Product Data outside of the Territory (except in accordance with the licenses granted under this Agreement).</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">14.8.6.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-style:italic;text-decoration:none;">Transfer or Destruction of Confidential Information</font><font style="text-decoration:none;">. Pfizer will promptly transfer to BioNTech, or destroy upon BioNTech&#8217;s request (and certify such destruction to BioNTech), all Confidential Information of BioNTech, except to the extent that Pfizer (i) must retain such Confidential Information in order to perform its obligations under this Section&#160;14 or to comply with applicable Laws, (ii) is permitted to retain such Confidential Information pursuant to the terms and conditions of this Agreement or (iii) has received such Confidential Information pursuant to the Flu Collaboration License or (iv) has a need to retain or use such Confidential Information for purposes of exercising its rights or performing its obligations under the Flu Collaboration License. BioNTech will promptly transfer to Pfizer, or destroy upon Pfizer&#8217;s request (and certify such destruction to Pfizer), all Confidential Information of Pfizer, except to the extent that BioNTech (i) must retain such Confidential Information in order to perform its obligations under this Section&#160; 14 or to comply with applicable Laws, (ii) is permitted to retain such Confidential Information pursuant to the terms and conditions of this Agreement or (iii) has received such Confidential Information pursuant to the Flu Collaboration License or (iv) has a need to retain or use such Confidential Information for purposes of performing its obligations under the Flu Collaboration License.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref415304304"></a><a name="_cp_text_1_1156"></a><a name="_cp_text_1_1163"></a><font style="text-decoration:none;">14.8.6.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-style:italic;text-decoration:none;">Use of the Pfizer House Mark</font><font style="text-decoration:none;">. Following the Termination Effective Date, BioNTech will not use the Pfizer House Mark in connection with the Commercialization of the Product, including on any Packaging and Labeling, Promotional Materials or Medical Education Materials; </font><font style="font-style:italic;text-decoration:none;"><a name="_cp_text_1_1156"></a>provided <a name="_cp_text_1_1163"></a>that</font><font style="text-decoration:none;"> BioNTech may use any and all then-existing inventory of Packaging and Labeling, Promotional Materials and Medical Education Materials bearing the Pfizer House Mark for such time, if any, in a country within the Territory as may be required to receive any required Regulatory Approvals in such country in the Territory in connection with the removal of the Pfizer House Mark from such Packaging and Labeling, Promotional Materials or Medical Education Materials and a reasonable sell-off period thereafter (not to exceed [***]), in each case, if permitted by applicable Law; </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;">, </font><font style="font-style:italic;text-decoration:none;">further</font><font style="text-decoration:none;">, that, promptly following the Termination Effective Date, BioNTech promptly will seek such Regulatory Approval in each applicable country </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">in the Territory for the removal of the Pfizer House Mark from any existing supplies of such Packaging and Labeling, Promotional Materials and Medical Education Materials bearing the Pfizer House Mark, and </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> will implement the same within </font><font style="text-decoration:none;">[***]</font><font style="text-decoration:none;"> following its receipt of such approvals.</font><font style="text-decoration:none;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref58975868"></a><font style="text-decoration:none;">14.8.6.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-style:italic;text-decoration:none;">Continuation of Pfizer Licenses</font><font style="text-decoration:none;">. Except in the event of Pfizer&#8217;s termination of this Agreement pursuant to Section 14.3 or 14.9.1, (a) [***], (b) [***], (c) [***], and (d) [***].</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">14.8.6.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-style:italic;text-decoration:none;">Exclusivity</font><font style="text-decoration:none;">. In the event of Pfizer's termination pursuant to Section 14.3 or 14.9, the Parties' obligations pursuant to Section 3.11.3 shall survive the termination or expiration of this Agreement for a period of [***] years provided that BioNTech shall not be prevented from using the Product within the Field. In the event of Pfizer&#8217;s termination pursuant to Section 14.4 or 14.5, [***]. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">14.8.6.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-style:italic;text-decoration:none;">Transition Plan.</font><font style="text-decoration:none;"> In the event of any termination of this Agreement, the Parties shall prepare and agree upon a written transition plan setting forth the responsibilities of each Party and the timeline for the transition to BioNTech of the responsibilities for distribution, Commercialization and promotion of the Product in the Pfizer Commercialization Territory. Such transition plan will provide for a transition as quickly as is practicable, provided that transition planning and activities may begin prior to the Termination Effective Date and such transition shall be completed within twelve (12) months after the Termination Effective Date. Such transition plan shall not be inconsistent with this Section 14.8.6. Each Party (i) will use its Commercially Reasonable Efforts to complete the activities required of it under such transition plan in a timely manner, and (ii) bear its own costs in undertaking such activities.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">14.8.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Accrued Rights.</font><font style="text-decoration:none;"> Subject to Section 14.8.6, Expiration or termination of this Agreement for any reason will be without prejudice to any right which will have accrued to the benefit of either Party prior to such expiration or termination or are attributable to activities prior to such termination or expiration, including damages arising from any breach under this Agreement. Expiration or termination of this Agreement will not relieve either Party from any obligation which is expressly indicated to survive such expiration or termination. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref263794980"></a><a name="_Ref263794998"></a><a name="_Ref268685088"></a><a name="_Ref273099837"></a><a name="_Ref46759216"></a><font style="text-decoration:none;">14.8.8</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Survival Period</font><font style="text-decoration:none;">. The following sections, together with any sections that expressly survive or are intended to survive after expiration or termination, will survive expiration or termination of this Agreement for any reason: Sections 1 (Definitions), 3.5 (additional licenses), 3.7 (Sublicenses) (only to the extent the relevant licenses survive), 4.9 (Gross Profit Sharing) and 4.10 (Third Party License Payments), but only in relation to any Pfizer Quarter in which sales have occurred prior to the termination or expiration, 4.11 (Taxes), 4.12 (Currency, Source of Payments), 4.13 (Method of Payment), 4.14 (Record Keeping and Audits), 4.17 (Late Payment), 4.18 (No Double Counting), 5.4.2 (Title to Materials), 5.4.4 (Return of Proprietary Materials), 8.2.6.2 (Transfer of Regulatory Filings by Pfizer), 8.7 (Liability), 9.2.2, 9.3.1.2 and 9.3.2.2 (Product Liability), 9.10 (Returns) and 9.11 (Recalls), but, in each case of 9.2.2, 9.3.1.2, 9.3.2.2, 9.10 and 9.11, only in relation to sales of Product that occurred prior to termination, 11.2 (Ownership of Intellectual Property), 11.3.1.2 and 11.3.1.3 (Filing, Prosecution and Maintenance of Patent Rights), 11.3.2 (Joint Patent Rights), 11.3.6 (Liability), 12 (Confidentiality), 14.8 (Effects of Termination), 14.9 (Provision for Insolvency), 16.1 (No Consequential Damages), 16.2 </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">(Indemnification by Pfizer), </font><font style="text-decoration:none;">16.3</font><font style="text-decoration:none;"> (Indemnification by </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;">), </font><font style="text-decoration:none;">16.4</font><font style="text-decoration:none;"> (Procedure), </font><font style="text-decoration:none;">17</font><font style="text-decoration:none;"> (Miscellaneous) and, to the extent an Enforcement Action or Infringement Claim is active, live or pending at the time of expiry or termination, Sections </font><font style="text-decoration:none;">11.4</font><font style="text-decoration:none;"> or </font><font style="text-decoration:none;">11.8</font><font style="text-decoration:none;">, as applicable. </font><font style="text-decoration:none;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766543"></a><a name="_Toc519764450"></a><a name="_Toc519873441"></a><a name="_Toc35600578"></a><a name="_Toc62256156"></a><a name="_Toc59107183"></a><a name="_Ref62483653"></a><a name="_Ref135585699"></a><a name="_Ref273099867"></a><a name="_Ref276112501"></a><a name="_Ref263790738"></a><a name="_Ref263794962"></a><a name="_Ref265015261"></a><font style="text-decoration:none;">14.9</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Provision for Insolvency</font><font style="text-decoration:none;">.</font><font style="text-decoration:underline;"> </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref273099815"></a><a name="_Hlk37010385"></a><font style="text-decoration:none;">14.9.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Termination Right</font><font style="text-decoration:none;">. BioNTech will be deemed a &#8220;</font><font style="text-decoration:underline;">Debtor</font><font style="text-decoration:none;">&#8221; under this Agreement if, at any time during the Term (a) a case is commenced by or against BioNTech under the Bankruptcy Code, (b) BioNTech files for or is subject to the institution of bankruptcy, reorganization, liquidation or receivership proceedings (other than a case under the Bankruptcy Code), (c) BioNTech assigns all or a substantial portion of its assets for the benefit of creditors, (d) a receiver or custodian is appointed for BioNTech&#8217;s business or (e) a substantial portion of BioNTech&#8217;s business is subject to attachment or similar process; </font><font style="font-style:italic;text-decoration:none;">provided, however</font><font style="text-decoration:none;">, that in the case of any involuntary case under the Bankruptcy Code, BioNTech will not be deemed a Debtor if the case is dismissed within 60 days after the commencement thereof. If BioNTech is deemed a Debtor, then Pfizer may terminate this Agreement by providing written notice to BioNTech. If Pfizer terminates this Agreement pursuant this Section 14.9.1, then: (i) all licenses granted to Pfizer under this Agreement will become irrevocable and perpetual, and Pfizer will have no further obligations to BioNTech under this Agreement other than (A) those obligations that expressly survive termination in accordance with Section&#160;14.8.8 and (B) an obligation to pay royalties with respect to Net Sales of Products in an amount equal to 100% of the amount that would otherwise have been payable under this Agreement, such amount to be paid in accordance with and subject to the other terms of this Agreement governing the payment of royalties; (ii) such termination will not be construed to limit BioNTech&#8217;s right to receive payments that accrued before the effective date of such termination; (iii) Pfizer will have the right to offset, against any payment owing to BioNTech as provided for under clause (i), above, any damages found or agreed by the Parties to be owed by BioNTech<a name="_Hlk37010385"></a> to Pfizer; and (iv) nothing in this Section 14.9.1 will limit any other remedy Pfizer may have for any breach by BioNTech of this Agreement.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref153096685"></a><font style="text-decoration:none;">14.9.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Rights to Intellectual Property</font><font style="text-decoration:none;">. All rights and licenses now or hereafter granted by BioNTech to Pfizer under or pursuant to any Section&#160;of this Agreement, including Sections&#160;3.1.1, 3.2.1, 3.3, 3.4.1, 3.5.1 and Section 9 hereof, are rights to &#8220;intellectual property&#8221; (as defined in the Bankruptcy Code). The Parties hereto acknowledge and agree that the payments provided for under Sections 4 and all other payments by Pfizer to BioNTech hereunder or under this Agreement do not constitute royalties within the meaning of Section&#160;365(n) of the Bankruptcy Code or relate to licenses of intellectual property hereunder. If (a) a case under the Bankruptcy Code is commenced by or against BioNTech, (b) this Agreement is rejected as provided in the Bankruptcy Code and (c) Pfizer elects to retain its rights hereunder as provided in Section 365(n) of the Bankruptcy Code, then BioNTech (in any capacity, including debtor-in-possession) and its successors and assigns (including any trustee) will provide to Pfizer all Intellectual Property Rights licensed hereunder, and agrees to grant and hereby grants to Pfizer and its Affiliates a right to access and to obtain possession of and to benefit from and, in the case of any chemical or biological material or other tangible item of which there is a fixed or limited quantity, to obtain a pro rata portion of, each of the following to the extent related to any Candidate or Product, or otherwise related to any right or license granted under or pursuant to this Agreement: (i) copies of pre-clinical and clinical research data and results; (ii) all of the following (to the extent that any of the following are so related): BioNTech Materials, cell lines, antibodies, assays, reagents and other biological </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">materials; (iii) samples or Candidates and Products; (iv) </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> Technology, Product Technology, and RNA Technology, (v) laboratory notes and notebooks; (vi) Candidate and Product data or filings, and (vii) rights of reference in respect of filings for and Regulatory Approvals, all of which constitute &#8220;embodiments&#8221; of intellectual property pursuant to Section&#160;365(n) of the Bankruptcy Code, and (viii) all other embodiments of such intellectual property, whether any of the foregoing are in </font><font style="text-decoration:none;">BioNTech&#8217;s</font><font style="text-decoration:none;"> possession or control or in the possession and control of any Third Party but which </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> has the right to access or benefit from and to make available to Pfizer. </font><font style="text-decoration:none;">BioNTech</font><font style="text-decoration:none;"> will not interfere with the exercise by Pfizer or its Affiliates of rights and licenses to Intellectual Property Rights licensed hereunder and embodiments thereof in accordance with this Agreement and agrees to use Commercially Reasonable Efforts to assist Pfizer and its Affiliates to obtain such Intellectual Property Rights and embodiments thereof in the possession or control of Third Parties as reasonably necessary or useful for Pfizer or its Affiliates or Sublicensees to exercise such rights and licenses in accordance with this Agreement. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref516828681"></a><a name="_Ref516827478"></a><font style="text-decoration:none;">14.9.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">No Limitation of Rights</font><font style="text-decoration:none;">. All rights, powers and remedies of Pfizer provided in this Section 14.9 are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at Law or in equity (including the Bankruptcy Code) in the event of the commencement of a case under the Bankruptcy Code involving BioNTech<a name="_Ref516828681"></a><a name="_Ref516827478"></a>. To the extent equivalent rights exist under the Bankruptcy Code existing from time to time in the jurisdiction where BioNTech is established the foregoing provisions shall be interpreted in accordance with such equivalent rights, and where such equivalent rights to not exist Pfizer shall be entitled to avail of itself all remedies and rights available to it as a creditor and licensee of Intellectual Property Rights under such local Bankruptcy Code.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;">15.</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-transform:none;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref59043866"></a><a name="_Toc62256157"></a><a name="_Toc59107184"></a><a name="_Toc519764452"></a><a name="_Toc519873443"></a><a name="_Toc35600580"></a><a name="_Ref518045476"></a><a name="_Ref518293992"></a><a name="_Ref36395228"></a><font style="text-decoration:none;"></font><font style="text-decoration:underline;text-transform:uppercase;">Change of Control</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256158"></a><a name="_Toc59107185"></a><a name="_Ref37116718"></a><font style="text-decoration:none;">15.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Change of Control</font><font style="text-decoration:none;">. If a Change of Control occurs with respect to a Party and a Third Party during the Term, or if a Party or any of its Affiliates acquires or merges with a Third Party during the Term, (in either case such Party being the &#8220;Affected Party&#8221;): </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref37116663"></a><font style="text-decoration:none;">15.1.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">if such Third Party is, at the time of such Change of Control or acquisition or merger, conducting activities that would cause the Affected Party or one of its Affiliates to violate Section 3.11.1 (such activities, a &#8220;</font><font style="text-decoration:underline;">Acquisition Program</font><font style="text-decoration:none;">&#8221;), then such Affected Party or such Third Party shall be permitted to continue such Acquisition Program and such continuation will not constitute a violation of Section 3.11.1; </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">15.1.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">the provisions of Section&#160;12.7 shall apply and no Confidential Information of the other Party or its Affiliates may be disclosed to the Third Party and shall not be used in any Acquisition Program (if any) and the Affected Party shall implement and maintain, in accordance with such Affected Party&#8217;s internal commercially reasonable practices, an information and personnel barrier between the working teams involved in the day to day conduct of such Affected Party&#8217;s internal program of Development and Manufacture of Candidates and Products under this Agreement, and any activities of the Third Party, including under any Acquisition Program; and</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">15.1.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">if BioNTech is the Affected Party, then [***].</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256159"></a><a name="_Toc59107186"></a><a name="_Ref36412211"></a><font style="text-decoration:none;">15.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Effects of Change of Control</font><font style="text-decoration:none;">. In the event of a Change of Control of BioNTech by during the Term, the following provisions of this Section 15 shall also apply:</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref357670044"></a><font style="text-decoration:none;">15.2.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">BioNTech Intellectual Property</font><font style="text-decoration:none;">. All BioNTech Technology and Research and Development Program Technology, Controlled by BioNTech immediately prior to such BioNTech Change of Control shall continue to be BioNTech<a name="_Ref357670044"></a> Technology and Research and Development Program Technology licensed to Pfizer for purposes of this Agreement. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref518675013"></a><font style="text-decoration:none;">15.2.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Existing Acquirer Intellectual Property</font><font style="text-decoration:none;">. Patent Rights and Know-How that were Controlled by the entity acquiring BioNTech or such entity&#8217;s Affiliates that were not Affiliates of BioNTech prior to such BioNTech Change of Control (collectively, the &#8220;</font><font style="text-decoration:underline;">Acquirer</font><font style="text-decoration:none;">&#8221;) shall not be included within the licenses granted to Pfizer hereunder. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">15.2.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Independent Intellectual Property</font><font style="text-decoration:none;">. Patent Rights and Know-How that, following such BioNTech Change of Control, are developed, made or otherwise acquired or Controlled by the Acquirer outside of the Research and Development Plan, or the Manufacturing Plan or outside of conducting Commercialization or regulatory activities pursuant to this Agreement and without use of Pfizer&#8217;s Technology, Pfizer's Confidential Information, Research and Development Program Technology, BioNTech Improvements or BioNTech Technology shall not be included within the Research and Development Program Technology or BioNTech Technology or BioNTech Third Party Agreements (it being understood, however, for the avoidance of doubt, that all BioNTech Technology, Research and Development Program Technology, and Intellectual Property Rights developed by BioNTech or the Acquirer in the course of, or used by BioNTech or the Acquirer under the Research and Development Plan, used in the Manufacture of the Candidates or Products by BioNTech, or used by BioNTech in its Commercialization or regulatory activities, shall be licensed to Pfizer pursuant to the licenses set forth in this Agreement).</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">15.2.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Research and Development Program Technology</font><font style="text-decoration:none;">. No Research and Development Program Technology Controlled by Pfizer including Pfizer Improvements shall be licensed or sub-licensable to the Acquirer, and no Confidential Information of Pfizer or its Representatives shall be disclosed to the Acquirer, in each case without the prior written consent of Pfizer. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc519764453"></a><a name="_Toc519873444"></a><a name="_Toc35600581"></a><font style="text-decoration:none;">15.2.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Effect on Certain Agreement Provisions</font><font style="text-decoration:none;">. From and after the effective date of a BioNTech Change of Control by a Specified Person, the Acquirer shall not be considered an &#8220;Affiliate&#8221; for the purposes of this Agreement, provided that the Acquirer does not engage in any activities otherwise restricted under Section 3.11 using any Research and Development Program Technology, Pfizer Technology, Pfizer Improvements or Confidential Information of Pfizer.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;">16.</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-transform:none;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref135585735"></a><a name="_Ref268768230"></a><a name="_Ref268772216"></a><a name="_Ref468638852"></a><a name="_Ref263794398"></a><a name="_Ref59043320"></a><a name="_Toc62256160"></a><a name="_Toc59107187"></a><font style="text-decoration:none;"></font><font style="text-decoration:underline;text-transform:uppercase;">Limitation of Liability, Indemnification and Insurance</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766545"></a><a name="_Toc519764455"></a><a name="_Toc519873446"></a><a name="_Toc35600583"></a><a name="_Toc62256161"></a><a name="_Toc59107188"></a><a name="_Ref62483669"></a><a name="_Ref263797100"></a><a name="_Ref135582630"></a><a name="_Ref135582695"></a><a name="_Ref135585751"></a><font style="text-decoration:none;">16.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">No Consequential Damages</font><font style="text-decoration:none;">. Except with respect to liability arising from a breach of Sections 11 or 12, from any willful misconduct or intentionally wrongful act, or to the extent such Party may be required to indemnify the other Party under this Section 16, in no event will either Party or its Representatives be liable under this Agreement for any special (only as related to indirect, incidental or consequential damages), indirect, incidental, consequential or punitive damages, whether in contract, warranty, tort, negligence, strict liability or otherwise, including loss of indirect profits or revenue suffered by the other Party or any of its Representatives. Without limiting the generality of the foregoing, </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">&#8220;consequential damages&#8221; will be deemed to include, and neither Party will be liable to the other Party or any of such other Party&#8217;s Representatives or stockholders for any damages based on or measured by loss of projected or speculative future sales of the Products, any development, regulatory, launch or sales threshold milestone payments due or any other unearned, speculative or otherwise contingent payments provided for in this Agreement.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766546"></a><a name="_Toc519764456"></a><a name="_Toc519873447"></a><a name="_Toc35600584"></a><a name="_Toc62256162"></a><a name="_Toc59107189"></a><a name="_Ref62483676"></a><a name="_Ref263791139"></a><a name="_Ref263791532"></a><a name="_Ref263795233"></a><a name="_Ref265014650"></a><a name="_Ref276112509"></a><a name="_Ref468638879"></a><a name="_Ref475137640"></a><a name="_Ref36410243"></a><font style="text-decoration:none;">16.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Indemnification by Pfizer</font><font style="text-decoration:none;">. Pfizer will indemnify, defend and hold harmless BioNTech, each of its Affiliates, and each of its and its Affiliates&#8217; employees, officers, directors and agents (each, a &#8220;</font><font style="text-decoration:underline;">BioNTech Indemnified Party</font><font style="text-decoration:none;">&#8221;) from and against any and all claims, causes, or allegations (whether threatened or pending), judgments, expenses, damages, liabilities, obligations, fees (including the reasonable fees of attorneys and other consulting or testifying professionals), costs and losses (collectively, &#8220;</font><font style="text-decoration:underline;">Liabilities</font><font style="text-decoration:none;">&#8221;) that the BioNTech Indemnified Party may be required to pay to one or more Third Parties resulting from or arising out of (a) use of the Pfizer Technology, Pfizer Materials, and/or Pfizer Know-How disclosed by or on behalf of Pfizer in accordance with the rights licensed under this Agreement infringing a Third Party Patent Right or misappropriating a Third Party trade secret, (b) use of the Pfizer House Marks in accordance with the rights licensed under this Agreement or (c) the material breach by Pfizer of any of its representations, warranties or covenants set forth in Section 5.4.1, Section 13.1 or Section 13.2 or Section 13.6; except, in each case, to the extent caused by the negligence, recklessness or intentional misconduct of BioNTech or any BioNTech Indemnified Party or to the extent BioNTech indemnifies Pfizer under this Agreement. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766547"></a><a name="_Toc519764457"></a><a name="_Toc519873448"></a><a name="_Toc35600585"></a><a name="_Toc62256163"></a><a name="_Toc59107190"></a><a name="_Ref62483683"></a><a name="_Ref263792049"></a><a name="_Ref263794385"></a><a name="_Ref263795250"></a><a name="_Ref268768253"></a><a name="_Ref276112511"></a><a name="_Ref468638884"></a><a name="_Ref475137802"></a><a name="_Ref135582881"></a><a name="_Ref135585717"></a><a name="_Ref135585763"></a><a name="_cp_text_2_526"></a><font style="text-decoration:none;">16.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Indemnification by BioNTech</font><font style="text-decoration:none;">. BioNTech will indemnify, defend and hold harmless Pfizer, its Affiliates, Sublicensees, contractors, distributors and each of its and their respective employees, officers, directors and agents (each, a &#8220;</font><font style="text-decoration:underline;">Pfizer Indemnified Party</font><font style="text-decoration:none;">&#8221;) from and against any and all Liabilities that the Pfizer Indemnified Party may be required to pay to one or more Third Parties resulting from or arising out of (a) use of the BioNTech Technology [***], BioNTech Materials, and/or BioNTech Know-How disclosed by or on behalf of BioNTech in accordance with the rights licensed under this Agreement infringing a Third Party Patent Right or misappropriating a Third Party trade secret, (b) the Candidates or Products in accordance with the rights licensed under this Agreement, save to the extent the Liabilities are in respect of (i) the exploitation of Pfizer Technology, Pfizer Materials, and/or Pfizer Know-How in accordance with the rights licensed under this Agreement infringing a Third Party Patent Right or misappropriating a Third Party trade secret or (ii) [***]; (c) use of the BioNTech House Marks in accordance with the rights licensed under this Agreement, (d) rights or obligations under the GEIA relating to inventions made by employees of BioNTech or its Affiliates or Third Party Licensors in relation to BioNTech Technology or Research and Development Program Technology used in any Candidate or Product; or (e) the material breach by BioNTech or any of its Representatives of any of its representations, warranties or covenants set forth in Section 8, Section 13.1, Section 13.2, Section 13.3, or Section 13.5<a name="_cp_text_2_526"></a>; except, in each case, to the extent caused by the negligence, recklessness or intentional misconduct of Pfizer or any Pfizer Indemnified Party or to the extent Pfizer indemnifies BioNTech under this Agreement.</font></p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc484766548"></a><a name="_Toc519764458"></a><a name="_Toc519873449"></a><a name="_Toc35600586"></a><a name="_Toc62256164"></a><a name="_Toc59107191"></a><a name="_Ref62483689"></a><a name="_Ref276112512"></a><a name="_Ref135582599"></a><a name="_Ref135582613"></a><a name="_Ref263791471"></a>16.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Procedure</font>. </p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref273100003"></a><font style="text-decoration:none;">16.4.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Notice</font><font style="text-decoration:none;">. Each Party will notify the other Party in writing in the event it becomes aware of a claim for which indemnification may be sought hereunder. In the event that any Third Party asserts a claim or other proceeding (including any governmental investigation) with respect to any matter for which a Party (the &#8220;</font><font style="text-decoration:underline;">Indemnified Party</font><font style="text-decoration:none;">&#8221;) is entitled to indemnification hereunder (a &#8220;</font><font style="text-decoration:underline;">Third Party Claim</font><font style="text-decoration:none;">&#8221;), then the Indemnified Party will promptly notify the Party obligated to </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">indemnify the Indemnified Party (the &#8220;</font><font style="text-decoration:underline;">Indemnifying Party</font><font style="text-decoration:none;">&#8221;) thereof; </font><font style="font-style:italic;text-decoration:none;">provided, however,</font><font style="text-decoration:none;"> that no delay on the part of the Indemnified Party in notifying the Indemnifying Party will relieve the Indemnifying Party from any obligation hereunder unless (and then only to the extent that) the Indemnifying Party is prejudiced thereby.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref268767495"></a><a name="_Ref185177954"></a><font style="text-decoration:none;">16.4.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Control</font><font style="text-decoration:none;"><a name="_Ref185177954"></a>. Subject to either Party&#8217;s right to control any actions described in Section&#160;9 (even where the other Party is the Indemnifying Party), the Indemnifying Party will have the right, exercisable by notice to the Indemnified Party within [***] after receipt of notice from the Indemnified Party of the commencement of or assertion of any Third Party Claim, to assume direction and control of the defense, litigation, settlement, appeal or other disposition of the Third Party Claim (including the right to settle the claim solely for monetary consideration) with counsel selected by the Indemnifying Party and reasonably acceptable to the Indemnified Party; provided that (a) the Indemnifying Party has sufficient financial resources, in the reasonable judgment of the Indemnified Party, to satisfy the amount of any adverse monetary judgment that is sought, (b) the Third Party Claim seeks solely monetary damages and (c) the Indemnifying Party expressly agrees in writing that as between the Indemnifying Party and the Indemnified Party, the Indemnifying Party will be solely obligated to satisfy and discharge the Third Party Claim in full (the conditions set forth in clauses (a), (b) and (c) above are collectively referred to as the &#8220;</font><font style="text-decoration:underline;">Litigation Conditions</font><font style="text-decoration:none;">&#8221;). [***] after the Indemnifying Party has given notice to the Indemnified Party of its exercise of its right to defend a Third Party Claim, the Indemnified Party will give notice to the Indemnifying Party of any objection thereto based upon the Litigation Conditions. If the Indemnified Party reasonably so objects, the Indemnified Party will continue to defend the Third Party Claim, at the expense of the Indemnifying Party, until such time as such objection is withdrawn. If no such notice is given, or if any such objection is withdrawn, the Indemnifying Party will be entitled, at its sole cost and expense, to assume direction and control of such defense, with counsel selected by the Indemnifying Party and reasonably acceptable to the Indemnified Party. During such time as the Indemnifying Party is controlling the defense of such Third Party Claim, the Indemnified Party will cooperate, and will cause its Affiliates and agents to cooperate upon request of the Indemnifying Party, in the defense or prosecution of the Third Party Claim, including by furnishing such records, information and testimony and attending such conferences, discovery proceedings, hearings, trials or appeals as may reasonably be requested by the Indemnifying Party. In the event that the Indemnifying Party does not satisfy the Litigation Conditions or does not notify the Indemnified Party of the Indemnifying Party&#8217;s intent to defend any Third Party Claim within [***] after notice thereof, the Indemnified Party may (without further notice to the Indemnifying Party) undertake the defense thereof with counsel of its choice and at the Indemnifying Party&#8217;s expense (including reasonable, out-of-pocket attorneys&#8217; fees and costs and expenses of enforcement or defense). The Indemnifying Party or the Indemnified Party, as the case may be, will have the right to join in (including the right to conduct discovery, interview and examine witnesses and participate in all settlement conferences), but not control, at its own expense, the defense of any Third Party Claim that the other party is defending as provided in this Agreement.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">16.4.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Settlement</font><font style="text-decoration:none;">. The Indemnifying Party will not, without the prior written consent of the Indemnified Party, enter into any compromise or settlement that commits the Indemnified Party to take, or to forbear to take, any action. The Indemnified Party will have the sole and exclusive right to settle any Third Party Claim, on such terms and conditions as it deems reasonably appropriate, to the extent such Third Party Claim involves equitable or other non-monetary relief, but will not have the right to settle such Third Party Claim to the extent such Third Party Claim </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">involves monetary damages without the prior written consent of the Indemnifying Party. Each of the Indemnifying Party and the Indemnified Party will not make any admission of liability in respect of any Third Party Claim without the prior written consent of the other party, and the Indemnified Party will use reasonable efforts to mitigate Liabilities arising from such Third Party Claim.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766549"></a><a name="_Toc519764459"></a><a name="_Toc519873450"></a><a name="_Toc35600587"></a><a name="_Toc62256165"></a><a name="_Toc59107192"></a><a name="_Ref468638805"></a><a name="_Ref265016171"></a><a name="_Ref276112518"></a><font style="text-decoration:none;">16.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Insurance</font><font style="text-decoration:none;"><a name="_Ref265016171"></a><a name="_Ref276112518"></a>. Each Party agrees to obtain and maintain, during the Term, commercial general liability insurance, including products liability insurance (or clinical trials insurance, if applicable), with minimum &#8220;A-&#8221; A.M. Best rated insurance carriers to cover its indemnification obligations under Section 16.2 or Section 16.3, as applicable, in each case with limits of not less than the equivalent of [***] U.S. Dollars (US&#160;$[***]) per occurrence and in the aggregate. All deductibles and retentions will be the responsibility of the named insured. As soon as reasonably possible, but in any case (i) prior to commencing clinical trials, with respect to clinical trials insurance in a country or (ii) prior to the First Commercial Sale, with respect to commercial general liability and products liability policies in a country, BioNTech will amend its existing insurance policies in such a way that (a) Pfizer and its Affiliates will be indemnified as principal or will be added as additional insureds on BioNTech&#8217;s commercial general liability and products liability policies (or clinical trials insurance, if applicable) and (b) Pfizer and its Affiliates will be provided a waiver of subrogation on BioNTech&#8217;s commercial general liability and products liability policies (or clinical trials insurance, if applicable). BioNTech represents and warrants that, as of the Amendment Signing Date, Pfizer and its Affiliates have been added as additional insureds to BioNTech&#8217;s primary pharma products liability insurance for the development, production and distribution of the covid19-vaccine taken out after the Effective Date for an amount equivalent to [***] U.S. Dollars (US $[***]) per occurrence and in the aggregate, and Pfizer Inc. and its Affiliates are provided a waiver of subrogation under this policy.&nbsp;&nbsp;BioNTech undertakes to use reasonable efforts to have Pfizer and its Affiliates named as additional insureds on BioNTech&#8217;s secondary pharma products liability insurance for the development, production and distribution of the covid19-vaccine. Should BioNTech be successful in reaching agreement with its pharma products liability insurers to name Pfizer and its Affiliates as additional insureds and provide them with a waiver of subrogation, BioNTech will report this and any increase to the insurance premiums to Pfizer. If there will be an increase in BioNTech&#8217;s insurance premiums as a result of making the requested change to BioNTech&#8217;s secondary pharma products liability insurance for the development, production and distribution of the covid19-vaccine, Pfizer shall confirm its desire for Pfizer and its Affiliates to be named on such policies and shall indemnify BioNTech against such increase in insurance premiums. For U.S. exposures, additional insured status on BioNTech&#8217;s pharma products liability&nbsp;&nbsp;insurance for the development, production and distribution of the covid19-vaccine shall be via form CG20101185 or its equivalent. Pharma products liability coverage shall be maintained for three years following termination of this Agreement. To the extent of its culpability, negligence or indemnification obligations, all coverages of BioNTech will be primary and non-contributing with any similar insurance, carried by Pfizer.</font><font style="font-style:italic;text-decoration:none;"> </font><font style="text-decoration:none;">Notwithstanding any provision of this Section 16.5 to the contrary, Pfizer may meet its obligations under this Section 16.5 through self-insurance. Neither Party&#8217;s insurance will be construed to create a limit of liability with respect to its indemnification obligations under this Section 16. A minimum of thirty (30) days written cancellation notice shall be given to the other Party for any cancellation, non-renewal or material change of coverage.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:11pt;font-style:normal;font-variant: normal;">17.</font></p></td>
<td valign="top">
<p style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-transform:none;font-weight:bold;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref475170664"></a><a name="_Ref488228681"></a><a name="_Toc62256166"></a><a name="_Toc59107193"></a><font style="text-decoration:none;"></font><font style="text-decoration:underline;text-transform:uppercase;">Miscellaneous</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766551"></a><a name="_Toc519764462"></a><a name="_Toc519873453"></a><a name="_Toc35600589"></a><a name="_Toc62256167"></a><a name="_Toc59107194"></a><a name="_Ref265016683"></a><a name="_Ref468633723"></a><a name="_Ref135585807"></a><a name="_Ref263795273"></a><font style="text-decoration:none;">17.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Assignment</font><font style="text-decoration:none;">. Neither this Agreement nor any interest hereunder will be assignable by a Party without the prior written consent of the other Party, except as follows: (a) subject to the provisions of </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">this Agreement in respect of Change of Control, as applicable, a Party may assign its rights and obligations under this Agreement by way of sale of itself or the sale of the portion of its business to which this Agreement relates, through merger, sale of assets and/or sale of stock or ownership interest, </font><font style="font-style:italic;text-decoration:none;">provided that</font><font style="text-decoration:none;"> the assignee will expressly agree to be bound by such Party&#8217;s obligations under this Agreement and that such sale is not primarily for the benefit of its creditors, (b) such Party may assign its rights and obligations under this Agreement to any of its Affiliates, </font><font style="font-style:italic;text-decoration:none;">provided that</font><font style="text-decoration:none;"> the assignee will expressly agree to be bound by such Party&#8217;s obligations under this Agreement and that such Party will remain liable for all of its rights and obligations under this Agreement. In addition, Pfizer may assign its rights and obligations under this Agreement to a Third Party where Pfizer or its Affiliate is required, or makes a good faith determination based on advice of counsel, to divest a Product in order to comply with Law or the order of any Governmental Authority as a result of a merger or acquisition, </font><font style="font-style:italic;text-decoration:none;">provided that</font><font style="text-decoration:none;"> the assignee will expressly agree to be bound by Pfizer&#8217;s obligations under this Agreement. Each Party will promptly notify the other Party of any assignment or transfer under the provisions of this Section </font><font style="text-decoration:none;">17.1</font><font style="text-decoration:none;">. This Agreement will be binding upon the successors and permitted assigns of the Parties and the name of a Party appearing herein will be deemed to include the names of such Party&#8217;s successors and permitted assigns to the extent necessary to carry out the intent of this Agreement. Any assignment not in accordance with this Section </font><font style="text-decoration:none;">17.1</font><font style="text-decoration:none;"> will be void.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766553"></a><a name="_Toc519764463"></a><a name="_Toc519873454"></a><a name="_Toc35600590"></a><a name="_Toc62256168"></a><a name="_Toc59107195"></a><a name="_Ref468951114"></a><font style="text-decoration:none;">17.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Further Actions</font><font style="text-decoration:none;">. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of the Agreement.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766554"></a><a name="_Toc519764464"></a><a name="_Toc519873455"></a><a name="_Toc35600591"></a><a name="_Toc62256169"></a><a name="_Toc59107196"></a><a name="_Ref62741503"></a><a name="_Ref519683571"></a><font style="text-decoration:none;">17.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Force Majeure</font><font style="text-decoration:none;">. Each Party will be excused from the performance of its obligations under this Agreement to the extent that such performance is prevented by force majeure (defined below) and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse will be continued so long as the condition constituting force majeure continues and the nonperforming Party takes Commercially Reasonable Efforts to remove the condition. For purposes of this Agreement, &#8220;force majeure&#8221; will include conditions beyond the control of the Parties, including an act of God, voluntary or involuntary compliance with any regulation, applicable Law or order of any government, war, act of terror, civil commotion, labor strike or lock-out, epidemic, failure or default of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm or like catastrophe. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766555"></a><a name="_Toc519764465"></a><a name="_Toc519873456"></a><a name="_Toc35600592"></a><a name="_Toc62256170"></a><a name="_Toc59107197"></a><font style="text-decoration:none;">17.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Interpretation</font><font style="text-decoration:none;">. Except where the context expressly requires otherwise, (a)&#160;the use of any gender herein will be deemed to encompass references to either or both genders, and the use of the singular will be deemed to include the plural (and vice versa), (b)&#160;the words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; will be deemed to be followed by the phrase &#8220;without limitation&#8221;, (c)&#160;the word &#8220;will&#8221; will be construed to have the same meaning and effect as the word &#8220;shall&#8221;, (d)&#160;any definition of or reference to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (e) any reference herein to any Person will be construed to include the Person&#8217;s successors and assigns, (f) the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;, and words of similar import, will be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) all references herein to Sections, Exhibits or Schedules will be construed to refer to Sections, Exhibits or Schedules of this Agreement, and references to this Agreement include all Exhibits and Schedules hereto, (h) the word &#8220;notice&#8221; means notice in writing (whether or not specifically stated) and will include notices, consents, approvals and other written communications contemplated under this Agreement, (i) provisions that require that a Party, the Parties or any committee </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">hereunder &#8220;agree,&#8221; &#8220;consent&#8221; or &#8220;approve&#8221; or the like will require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (excluding e-mail or instant messaging, but a signed PDF document being acceptable), (j) references to any specific law, rule or regulation, or article, section or other division thereof, will be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof, and (k) the term &#8220;or&#8221; will be interpreted in the inclusive sense commonly associated with the term &#8220;and/or&#8221;.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766556"></a><a name="_Toc519764466"></a><a name="_Toc519873457"></a><a name="_Toc35600593"></a><a name="_Toc62256171"></a><a name="_Toc59107198"></a><a name="_Ref263795298"></a><font style="text-decoration:none;">17.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Notices</font><font style="text-decoration:none;">.<a name="_Ref263795298"></a> Any notice or notification required or permitted to be provided pursuant to the terms and conditions of this Agreement (including any notice of force majeure, breach, termination, change of address, etc.) will be in writing and will be deemed given upon receipt if delivered personally or by facsimile transmission (receipt verified), and upon delivery if mailed by registered or certified mail or courier. Where delivery occurs outside normal working hours, notice will be deemed given at the start of normal working hours on the next Business Day. Notice shall be given to the Parties at the following addresses or facsimile numbers (or at such other address or facsimile number for a Party as will be specified by like notice, </font><font style="font-style:italic;text-decoration:none;">provided, however</font><font style="text-decoration:none;">, that notices of a change of address will be effective only upon receipt thereof):</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All correspondence to Pfizer will be addressed as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notices: [***]</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with a copy to:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notices: Pfizer Legal Division</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To help expedite Pfizer&#8217;s awareness and response, copies of notices may be provided to<font style="font-weight:bold;"> </font>Pfizer by email but must be supplemented by one of the following methods: (a) personal<font style="font-weight:bold;"> </font>delivery, (b) first class certified mail with return receipt requested, or (c) next-day delivery by<font style="font-weight:bold;"> </font>major international courier, with confirmation of delivery. Electronic copies may be sent via<font style="font-weight:bold;"> </font>email to [***].</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All correspondence to BioNTech will be addressed as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech SE</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766557"></a><a name="_Toc519764467"></a><a name="_Toc519873458"></a><a name="_Toc35600594"></a><a name="_Ref62229295"></a><a name="_Toc62256172"></a><a name="_Toc59107199"></a><font style="text-decoration:none;">17.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Amendment</font><font style="text-decoration:none;">. No amendment, modification or supplement of any provision of this Agreement will be valid or effective unless made in writing and signed by a duly authorized officer of each Party.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766558"></a><a name="_Toc519764468"></a><a name="_Toc519873459"></a><a name="_Toc35600595"></a><a name="_Toc62256173"></a><a name="_Toc59107200"></a><font style="text-decoration:none;">17.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Waiver</font><font style="text-decoration:none;">. No provision of this Agreement will be waived by any act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party. The waiver by either of the Parties of any breach of any provision hereof by the other Party will not be construed to be a waiver of any succeeding breach of such provision or a waiver of the provision itself.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766559"></a><a name="_Toc519764469"></a><a name="_Toc519873460"></a><a name="_Toc35600596"></a><a name="_Toc62256174"></a><a name="_Toc59107201"></a><font style="text-decoration:none;">17.8</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Severability</font><font style="text-decoration:none;">. If any clause or portion thereof in this Agreement is for any reason held to be invalid, illegal or unenforceable, the same will not affect any other portion of this Agreement, as it is the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">intent of the Parties that this Agreement will be construed in such fashion as to maintain its existence, validity and enforceability to the greatest extent possible. In any such event, this Agreement will be construed as if such clause of portion thereof had never been contained in this Agreement, and there will be deemed substituted therefore such provision as will most nearly carry out the intent of the Parties as expressed in this Agreement to the fullest extent permitted by applicable Law.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766560"></a><a name="_Toc519764470"></a><a name="_Toc519873461"></a><a name="_Toc35600597"></a><a name="_Toc62256175"></a><a name="_Toc59107202"></a><font style="text-decoration:none;">17.9</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Descriptive Headings</font><font style="text-decoration:none;">. The descriptive headings of this Agreement are for convenience only and will be of no force or effect in construing or interpreting any of the provisions of this Agreement.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766561"></a><a name="_Toc519764471"></a><a name="_Toc519873462"></a><a name="_Toc35600598"></a><a name="_Toc62256176"></a><a name="_Toc59107203"></a><a name="_Ref488320195"></a><a name="_Ref488318477"></a><font style="text-decoration:none;">17.10</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Global Trade Control Laws</font><font style="text-decoration:none;">. The Parties acknowledge that certain activities covered by or performed under this Agreement may be subject to Global Trade Control Laws. Each of the Parties will perform all activities under this Agreement in compliance with all applicable Global Trade Control Laws. Furthermore, with respect to the activities performed under this Agreement, each of the Parties represents, warrants and covenants that:</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc519764472"></a><a name="_Ref518675126"></a><font style="text-decoration:none;">17.10.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Each Party will not, for activities under this Agreement, (a) engage in any such activities in a Restricted Market; (b) involve individuals ordinarily resident in a Restricted Market; or (c) include companies, organizations, or Governmental Authorities from or located in a Restricted Market. &#8220;</font><font style="text-decoration:underline;">Restricted Market</font><font style="text-decoration:none;">&#8221; for purposes of this Agreement means the Crimean Peninsula, Cuba, the Donbass Region, Iran, North Korea, Sudan, and Syria, or any other country or region sanctioned by the United States or European Union. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref518675163"></a><font style="text-decoration:none;">17.10.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Each Party represents and warrants that it is not a Restricted Party and is not owned or controlled by a Restricted Party. With respect to activities performed under this Agreement, neither Party will engage or delegate to any Restricted Parties for any activities under this Agreement. Each Party will screen all relevant Third Parties involved by such Party in the activities under this Agreement under the relevant Restricted Party Lists. &#8220;</font><font style="text-decoration:underline;">Restricted Parties</font><font style="text-decoration:none;">&#8221; for purposes of this Agreement means any individual or entity on any of the following &#8220;Restricted Party Lists&#8221;: the list of sanctioned entities maintained by the United Nations; the Specially Designated Nationals List and the Sectoral Sanctions Identifications List of the U.S. Treasury Department&#8217;s Office of Foreign Assets Control; the U.S. Denied Persons List, the U.S. Entity List, and the U.S. Unverified List of the U.S. Department of Commerce; entities subject to restrictive measures and the Consolidated List of Persons, Groups and Entities Subject to E.U. Financial Sanctions, as implemented by the E.U. Common Foreign &amp; Security Policy; the List of Excluded Individuals / Entities published by the U.S. Health and Human Services&#8217; Office of Inspector General; any lists of prohibited or debarred parties established under the U.S. Federal Food Drug and Cosmetic Act; the list of parties suspended or debarred from contracting with the U.S. government; and similar lists of restricted parties maintained by the Governmental Authorities of the countries that have jurisdiction over the activities conducted under this Agreement.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_cp_text_2_543"></a><font style="text-decoration:none;">17.10.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;"><a name="_cp_text_2_543"></a>Neither Party will knowingly transfer to the other Party any goods, software, technology or services that are (a) controlled under the U.S. International Traffic in Arms Regulations or at a level other than EAR99 under the U.S. Export Administration Regulations; or (b) specifically identified as an E.U. Dual Use Item or on an applicable export control list of another country. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Hlk53001071"></a><font style="text-decoration:none;">17.10.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">In the event that any of the representations in this Section 17.10 changes, the Party changing its representation will immediately inform the other Party and suspend all related </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">activities until the Parties agree to </font><font style="text-decoration:none;">lift the suspension and move forward.</font><font style="text-decoration:none;"> </font><font style="text-decoration:none;">For clarity, any and all activities pursuant to this Agreement which are not affected by such change in representation in this </font><font style="text-decoration:none;">S</font><font style="text-decoration:none;">ection</font><font style="text-decoration:none;"> </font><font style="text-decoration:none;">17.10</font><font style="text-decoration:none;"> shall continue without interruption</font><font style="text-decoration:none;">.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766563"></a><a name="_Toc519764473"></a><a name="_Toc519873463"></a><a name="_Toc35600599"></a><a name="_Ref59037340"></a><a name="_Toc62256177"></a><a name="_Toc59107204"></a><a name="_Ref135585823"></a><a name="_Ref263793844"></a><a name="_Ref263795446"></a><a name="_Ref263805344"></a><a name="_Ref468587474"></a><font style="text-decoration:none;">17.11</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Dispute Resolution</font><font style="text-decoration:none;">. If any dispute or disagreement arises between Pfizer and BioNTech in respect of this Agreement, they will follow the following procedures in an attempt to resolve the dispute or disagreement: </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref263791643"></a><a name="_Ref468645635"></a><font style="text-decoration:none;">17.11.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">The Party claiming that such a dispute exists will give notice in writing (&#8220;</font><font style="text-decoration:underline;">Notice of Dispute</font><font style="text-decoration:none;">&#8221;) to the other Party of the nature of the dispute.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">17.11.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Within thirty (30) days of receipt of a Notice of Dispute and in advance of any meeting pursuant to Section 17.11.3, the receiving Party will provide a written response to the other Party&#8217;s claims regarding the dispute.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref263795328"></a><a name="_Ref480460443"></a><a name="_Ref263795387"></a><font style="text-decoration:none;">17.11.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;"><a name="_Ref263795387"></a>Within forty-five (45) days of receipt of a Notice of Dispute, the Executive Officers will meet at a mutually agreed-upon time and location or via teleconference for the purpose of resolving such dispute to discuss the dispute or disagreement.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_field_47_554"></a><a name="_cp_field_47_554"></a>Notwithstanding any provision of this Agreement to the contrary, either Party may immediately initiate litigation in any court of competent jurisdiction seeking any remedy at law or in equity, including the issuance of a preliminary, temporary or permanent injunction, to preserve or enforce its rights under this Agreement. The provisions of this Section 17.11 will survive for five (5) years from the date of termination or expiration of this Agreement. </p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766565"></a><a name="_Toc519764474"></a><a name="_Toc519873464"></a><a name="_Toc35600600"></a><a name="_Toc62256178"></a><a name="_Toc59107205"></a><font style="text-decoration:none;">17.12</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Governing Law</font><font style="text-decoration:none;">. This Agreement is governed by, and all disputes arising under or in connection with this Agreement shall be resolved in accordance with, laws of England and Wales, without regard to conflict of law principles thereof.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766566"></a><a name="_Toc519764475"></a><a name="_Toc519873465"></a><a name="_Toc35600601"></a><a name="_Toc62256179"></a><a name="_Toc59107206"></a><a name="_Ref468662700"></a><a name="_Ref480460666"></a><a name="_Ref516826391"></a><a name="_cp_text_1_576"></a><font style="text-decoration:none;">17.13</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;"><a name="_cp_text_1_576"></a>Consent to Jurisdiction and Venue</font><font style="text-decoration:none;">. The Parties irrevocably submit to the exclusive jurisdiction of the courts of England and Wales as regards any claim, dispute or matter (whether contractual or non-contractual) arising out of or in connection with this Agreement (including its formation). Notwithstanding the foregoing, this clause shall not prevent either Party from being entitled to seek urgent interim or emergency relief (such as a preliminary injunction) before any other court of competent jurisdiction in respect of any claim, dispute or matter (whether contractual or non-contractual) arising out of or in connection with this Agreement (including its formation).</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766567"></a><a name="_Toc519764476"></a><a name="_Toc519873466"></a><a name="_Toc35600602"></a><a name="_Toc62256180"></a><a name="_Toc59107207"></a><a name="_Ref268773400"></a><a name="_cp_text_2_586"></a><font style="text-decoration:none;">17.14</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Entire Agreement</font><font style="text-decoration:none;">. This Agreement constitutes and contains the complete, final and exclusive understanding and agreement of the Parties and cancels and supersedes any and all prior negotiations, correspondence, understandings and agreements, whether oral or written, between the Parties respecting the subject matter hereof and thereof, including (a) that certain [***] (which is hereby terminated effective as of the Effective Date, </font><font style="font-style:italic;text-decoration:none;">provided that</font><font style="text-decoration:none;"><a name="_cp_text_2_586"></a> such Confidential Disclosure Agreement will continue to govern the treatment of Confidential Information disclosed by the Parties prior to the Effective Date in accordance with its terms), (b) that certain [***] (which is hereby terminated effective as of the Effective </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">Date, </font><font style="font-style:italic;text-decoration:none;">provided that</font><font style="text-decoration:none;"> the terms of this Agreement shall also apply to all activities made under the </font><font style="text-decoration:none;">[***]</font><font style="text-decoration:none;">) and (c)</font><font style="text-decoration:none;"> [***]</font><font style="text-decoration:none;"> (which is hereby terminated effective as of the Effective Date). </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc62256181"></a><a name="_Toc59107208"></a><font style="text-decoration:none;">17.15</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Flu Collaboration</font><font style="text-decoration:none;">. Except as provided in Section 7.2, nothing in this Agreement varies, amends or otherwise supersedes or replaces the provisions and rights under the Flu Collaboration License, and the Flu Collaboration License and this Agreement shall be treated as separate arm's length transactions.</font></p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62256182"></a><a name="_Toc59107209"></a><a name="_Ref43398117"></a><a name="_Toc484766568"></a><a name="_Toc519764477"></a><a name="_Toc519873467"></a><a name="_Toc35600603"></a><a name="_Toc59107210"></a><a name="_Toc62256183"></a>17.16<font style="margin-left:36pt;"></font><font style="text-decoration:underline;"><a name="_Toc59107210"></a><a name="_Toc62256183"></a>Relationship of the Parties</font>.</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">17.16.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Independent Contractors</font><font style="text-decoration:none;">. Both Parties are independent contractors under this Agreement. Nothing herein contained will be deemed to create an employment, agency, joint venture or partnership relationship between the Parties hereto or any of their agents or employees, or any other legal arrangement that would impose liability upon one Party for the act or failure to act of the other Party. Neither Party will have any express or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any respect whatsoever. Additionally, the Parties expressly agree that this Agreement is not intended to be treated as a partnership for taxation purposes.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref414600312"></a><a name="_Ref43487719"></a><font style="text-decoration:none;">17.16.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Personnel</font><font style="text-decoration:none;">. Each Party acknowledges and agrees that all of its personnel, including its Sales Managers and PSRs, are not, and are not intended to be or to be treated as, employees of the other Party or any of its Affiliates, and that such individuals are not, and are not intended to be, eligible to participate in any benefits programs or in any &#8220;employee benefit plans,&#8221; as such term is defined in section 3(3) of the Employee Retirement Income Security Act of 1974, as amended, that are sponsored by the other Party or any of its Affiliates or that are offered from time to time by the other Party or its Affiliates to their own employees (the &#8220;</font><font style="text-decoration:underline;">Benefit Plans</font><font style="text-decoration:none;">&#8221;). All matters of compensation, benefits and other terms of employment for a Party&#8217;s personnel will be a matter solely between such Party and its personnel. Each Party will be solely responsible and liable for the payment of all compensation and benefits under any such Benefit Plan to its personnel. A Party will not be responsible to the other Party (the &#8220;</font><font style="text-decoration:underline;">Hiring Party</font><font style="text-decoration:none;">&#8221;) or to any Sales Manager or PSR used by the Hiring Party to promote or sell the Product for any compensation, expense reimbursements or benefits (including vacation and holiday remuneration, healthcare coverage or insurance, life insurance, pension or profit-sharing benefits and disability benefits), payroll-related taxes or withholdings, or any governmental charges or benefits (including unemployment and disability insurance contributions or benefits and workmen&#8217;s compensation contributions or benefits) that may be imposed upon or be related to the performance by the Hiring Party and its Sales Managers and PSRs of its obligations under this Agreement, all of which will be the sole responsibility of the Hiring Party, even if it is subsequently determined by any court or any Governmental Authority that such individual may be deemed a common law employee of the non-Hiring Party or any of its Affiliates.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref414463576"></a><font style="text-decoration:none;">17.16.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Indemnification</font><font style="text-decoration:none;">. Each Hiring Party will indemnify, defend, and hold harmless the non&#8209;hiring Party (the &#8220;</font><font style="text-decoration:underline;">NHP</font><font style="text-decoration:none;">&#8221;) and its Affiliates, and the NHP&#8217;s and its Affiliates&#8217; directors, officers, employees and agents (collectively, the &#8220;</font><font style="text-decoration:underline;">NHP Indemnitees</font><font style="text-decoration:none;">&#8221;) from and against any claims, liabilities, costs, expenses, damages, penalties, compensation or attorney fees (&#8220;</font><font style="text-decoration:underline;">Losses</font><font style="text-decoration:none;">&#8221;) that may be incurred or payable by any such NHP Indemnitee resulting from or in connection with any claim or other cause of action asserted by or on behalf of any Sales Manager or PSR of the Hiring Party arising out of the execution or performance of this Agreement that is based on or with respect to:</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_DV_M1168"></a><font style="text-decoration:none;">17.16.3.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Losses that the NHP or its Affiliates may incur resulting from any claims for benefits that any of the Hiring Party&#8217;s Sales Managers or PSRs may make under or with respect to any NHP Benefit Plans;</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_DV_M1169"></a><font style="text-decoration:none;">17.16.3.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">any payment or obligation to make a payment to any Hiring Party Sales Managers or PSRs relating in any way to any compensation, benefits of any type under any Benefit Plan, and any other bonus, stock option, stock purchase, incentive, deferred compensation, supplemental retirement, severance and other similar fringe or employee benefit plans, programs or arrangements that may be sponsored at any time by either Party or any of its Affiliates, even if it is subsequently determined by any court, the IRS or any other Governmental Authority that any of the Hiring Party&#8217;s Sales Managers or PSRs may be deemed a common law employee of the NHP or any of its Affiliates; </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_DV_M1170"></a><font style="text-decoration:none;">17.16.3.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">the payment or withholding of any contributions, payroll taxes, or any other payroll&#8209;related item by or on behalf of the Hiring Party or any of its Sales Managers or PSRs with respect to which the Hiring Party or any of its Sales Managers or PSRs may be responsible hereunder or pursuant to Applicable Law to pay, make, collect, withhold or contribute, even if it is subsequently determined by any court, the IRS or by any other Governmental Authority that any of such Hiring Party&#8217;s Sales Managers or PSRs may be deemed a common law employee of the NHP or any of its Affiliates; and</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_DV_M1171"></a><font style="text-decoration:none;">17.16.3.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">failure of the Hiring Party to withhold or pay required taxes or failure to file required forms with Governmental Authorities with regard to compensation and benefits incurred or extended by a Hiring Party to its Sales Managers or PSRs.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_DV_M1172"></a><font style="text-decoration:none;">17.16.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:none;">Improper Conduct</font><font style="text-decoration:none;">. Notwithstanding anything to the contrary in this Section&#160;17.16, a Hiring Party will have no liability to any NHP Indemnitee to the extent attributable to any discriminatory, harassing or retaliatory acts of the NHP, or any tortious acts (including acts constituting assault, battery or defamation) by the NHP, with respect to any Sales Managers or PSRs of the Hiring Party, or any breach by the NHP of this Agreement. Nothing contained in this Section&#160;17.16 is intended to affect or limit any compensation payable by a Party to the other for the services rendered by a Party pursuant to this Agreement. </font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766569"></a><a name="_Toc519764478"></a><a name="_Toc519873468"></a><a name="_Toc35600604"></a><a name="_Toc62256184"></a><a name="_Toc59107211"></a><font style="text-decoration:none;">17.17</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Counterparts</font><font style="text-decoration:none;">. This Agreement may be executed in two (2) counterparts, each of which will be an original and both of which will constitute together the same document. Counterparts may be signed and delivered by facsimile or digital (e.g., PDF) file, each of which will be binding when received by the applicable Party.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Toc484766570"></a><a name="_Toc484766952"></a><a name="_Toc519764479"></a><a name="_Toc519873469"></a><a name="_Toc35600605"></a><a name="_Toc62256185"></a><a name="_Toc59107212"></a><font style="text-decoration:none;">17.18</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">No Third Party Rights or Obligations</font><font style="text-decoration:none;">. No provision of this Agreement will be deemed or construed in any way to result in the creation of any rights or obligation in any Person not a Party to this Agreement, and this Agreement does not give rise to any rights under the Contracts (Rights of Third Parties) Act 1999 to enforce any term of this Agreement. However, Pfizer may decide, in its sole discretion, to use one or more of its Affiliates to perform its obligations and duties hereunder, </font><font style="font-style:italic;text-decoration:none;">provided that</font><font style="text-decoration:none;"> Pfizer will remain liable hereunder for the performance by any such Affiliates of any such obligations.</font></p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;"><a name="_Toc62256186"></a><a name="_Toc59107213"></a>&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:9pt;text-align:justify;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">17.19</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Conflicting Terms</font><font style="text-decoration:none;">. In the event of any inconsistency between the terms or definitions of this Agreement and the terms or definitions (as applicable) of any Related Agreement, the terms of this Agreement will control for purposes of this Agreement except to the extent such Related Agreement specifically provides that specified terms in such Related Agreement control; </font><font style="font-style:italic;text-decoration:none;">provided</font><font style="text-decoration:none;">, </font><font style="font-style:italic;text-decoration:none;">however</font><font style="text-decoration:none;">, that any actions by a Party required for compliance with its obligations under the other Related Agreements will not constitute a breach under this Agreement and any actions by a Party required for compliance with its obligations under this Agreement will not constitute a breach under any of the Related Agreements.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="font-style:italic;">Signature page follows</font>)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62824704"></a>IN WITNESS WHEREOF, authorized representatives of the Parties have duly executed this Agreement as of the Amendment Signing Date to be effective as of the Effective Date. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;width:40%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">PFIZER INC.</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;width:40%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">BIONTECH SE</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;width:40%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;width:40%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;width:40%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;width:40%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;width:40%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;width:40%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;width:40%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:bold;"><a name="_cp_text_1_28"></a><a name="_cp_text_1_32"></a>&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Signature page to Amended and Restated Collaboration Agreement]</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62256187"></a><a name="_Toc59107214"></a><font style="text-decoration:underline;">Exhibit A<br /></font><font style="text-decoration:none;">Research and Development Plan</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.9%;">
<tr>
<td style="width:7.86%;"></td>
<td style="width:23.8%;"></td>
<td style="width:22.26%;"></td>
<td style="width:25.18%;"></td>
<td style="width:20.79%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk37858478"></a>[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62256188"></a><a name="_Toc59107215"></a><font style="text-decoration:underline;">Exhibit B<br /></font><font style="text-decoration:none;">Pfizer Anti-Bribery and Anti-Corruption Principles</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer has a longstanding corporate policy that prohibits colleagues or anyone acting on our behalf from providing any payment or benefit to any person or entity in order to improperly influence a government official or to gain an unfair business advantage. Pfizer is committed to performing with integrity, and acting ethically and legally in accordance with all applicable laws and regulations, including, but not limited to, anti-bribery and anti-corruption laws. We expect the same commitment from the consultants, agents, representatives or other companies and individuals acting on our behalf (&#8220;Business Associates&#8221;), as well as those acting on behalf of Business Associates, in connection with work for Pfizer. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Bribery of Government Officials </p>
<p style="margin-top:6pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most countries have laws that forbid making, offering or promising any payment or anything of value (directly or indirectly) to a government official when the payment is intended to influence an official act or decision to award or retain business. Under Pfizer&#8217;s policies, &#8220;government official&#8221; is broadly interpreted and includes: (i) any elected or appointed government official (e.g., a member of a ministry of health); (ii) any employee or person acting for or on behalf of a government official, agency, or enterprise performing a governmental function; (iii) any political party, candidate for public office, officer, employee, or person acting for or on behalf of a political party or candidate for public office; or (iv) an employee or person acting for or on behalf of a public international organization (e.g., the United Nations). &#8220;Government&#8221; is meant to include all levels and subdivisions of governments (i.e., local, regional, or national and administrative, legislative, or executive). Because this definition of &#8220;government official&#8221; is so broad, it is likely that Business Associates will interact with a government official in the ordinary course of their business on behalf of Pfizer. For example, doctors employed by government-owned hospitals would be considered &#8220;government officials&#8221; under Pfizer&#8217;s policies. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. Foreign Corrupt Practices Act of 1977 (the &#8220;FCPA&#8221;) prohibits making, promising, or authorizing the making of a payment or providing anything of value to a non-U.S. government official to improperly or corruptly induce that official to make any governmental act or decision to assist a company in obtaining or retaining business, or to otherwise obtain an improper advantage. The FCPA also prohibits a company or person from using another company or individual to engage in any of the foregoing activities. As a U.S. company, Pfizer must comply with the FCPA and could be held liable as a result of acts committed anywhere in the world by a Business Associate.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Anti-Bribery and Anti-Corruption Principles Governing Interactions with Governments and Government Officials </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Business Associates must communicate and abide by the following principles with regard to their interactions with governments and government officials: </p>
<p style="text-align:left;margin-bottom:5pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Times New Roman;">Business Associates, and those acting on their behalf in connection with work for Pfizer, may not directly or indirectly make, promise, or authorize the making of a corrupt payment or provide anything of value to any government official to induce that government official to make any governmental act or decision to help Pfizer obtain or retain business. Business Associates, and those acting on their behalf in connection with work for Pfizer, may never make a payment to or offer a government official any item or benefit, regardless of value, as an improper inducement for such government official to approve, reimburse, prescribe, or purchase a Pfizer product, to influence the outcome of a clinical trial, or otherwise improperly to benefit Pfizer&#8217;s business activities. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="color:#000000;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#000000;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">Business Associates, and those acting on their behalf in connection with work for Pfizer, need to understand whether local laws, regulations, or operating procedures (including requirements imposed by government entities such as government-owned hospitals or research institutions) impose any limits, restrictions, or disclosure requirements on compensation, financial support, donations, or gifts that may be provided to government officials. Business Associates, and those acting on their behalf in connection with work for Pfizer, must take into account and comply with any applicable restrictions in conducting their Pfizer-related activities. If a Business Associate is uncertain as to the meaning or applicability of any identified limits, restrictions, or disclosure requirements with respect to interactions with government officials, that Business Associate should consult with his or her primary Pfizer contact before undertaking their activities. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Times New Roman;">Business Associates, and those acting on their behalf in connection with work for Pfizer, are not permitted to offer facilitation payments. A &#8220;facilitation payment&#8221; is a nominal, unofficial payment to a government official for the purpose of securing or expediting the performance of a routine, non-discretionary governmental action. Examples of facilitation payments include payments to expedite the processing of licenses, permits or visas for which all paperwork is in order. In the event that a Business Associate, or someone acting on their behalf in connection with work for Pfizer, receives or becomes aware of a request or demand for a facilitation payment or bribe in connection with work for Pfizer, the Business Associate shall report such request or demand promptly to his or her primary Pfizer contact before taking any further action.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Commercial Bribery </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bribery and corruption can also occur in non-government, business to business relationships. Most countries have laws which prohibit offering, promising, giving, requesting, receiving, accepting, or agreeing to accept money or anything of value in exchange for an improper business advantage. Examples of prohibited conduct could include, but are not limited to, the provision of inappropriate gifts or hospitality, kickbacks, or investment opportunities offered to improperly induce the purchase of goods or services. Pfizer colleagues are not permitted to offer, give, solicit or accept bribes, and we expect our Business Associates, and those acting on their behalf in connection with work for Pfizer, to abide by the same principles.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Anti-Bribery and Anti-Corruption Principles Governing Interactions with Private Parties and Pfizer Colleagues</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Business Associates must communicate and abide by the following principles with regard to their interactions with private parties and <font style="color:#000000;">Pfizer colleagues:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Times New Roman;">Business Associates, and those acting on their behalf in connection with work for Pfizer, may not directly or indirectly make, promise, or authorize the making of a corrupt payment or provide anything of value to any person to induce that person to provide an unlawful business advantage for Pfizer. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Times New Roman;">Business Associates, and those acting on their behalf in connection with work for Pfizer, may not directly or indirectly, solicit, agree to accept, or receive a payment or anything of value as an improper inducement in connection with their business activities performed for Pfizer. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Times New Roman;">Pfizer colleagues are not permitted to receive gifts, services, perks, entertainment, or other items of more than token or nominal monetary value from Business Associates, and those acting on their behalf in connection with work for Pfizer. Moreover, gifts of nominal value are only permitted if they are received on an infrequent basis and only at appropriate occasions. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Reporting Suspected or Actual Violations</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Business Associates, and those acting on behalf in connection with work for Pfizer, are expected to raise concerns related to potential violations of these International Anti-Bribery and Anti-Corruption Principles or the law. Such reports can be made to a Business Associate&#8217;s primary point of contact at Pfizer, or if an Associate prefers, to Pfizer&#8217;s Compliance Group, by e-mail at <font style="color:#000000;">corporate.compliance@pfizer.com</font> or by phone at 1-212-733-3026.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;"><br /></font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62256189"></a><a name="_Toc59107216"></a><font style="text-decoration:underline;">Exhibit C<br /></font><font style="text-decoration:none;">Pfizer&#8217;s Corporate Policy regarding Animal Care and Use (v. 1.2, June 18, 2017)</font></p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BACKGROUND</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer is dedicated to helping people and animals live longer, healthier lives through the discovery and development of breakthrough medicines and therapies. Animal-based biomedical research in the pharmaceutical industry remains a vital component of the discovery, evaluation and regulatory processes, which lead to the development of products <font style="color:#000000;font-size:10pt;">that</font> save or improve human lives throughout the world. Pfizer&#8217;s Animal Care and Use <font style="color:#000000;font-size:10pt;">policy</font> reflects our absolute commitment that all animals used by our business are treated humanely. This means that any research involving animals is conducted only after appropriate ethical consideration and review. This review ensures that we provide a high level of care to all animals used, and that a scientifically appropriate and validated alternative to the use of animals is not available.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Why We Conduct Animal-based Biomedical Research</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer is ethically and legally obliged to rigorously evaluate potential new medicines and therapies. Many of these evaluations can be, and are, <font style="color:#000000;font-size:10pt;">accomplished</font> by techniques that do not require the use of animals. However, given the <font style="color:#000000;font-size:10pt;">present</font> state of scientific knowledge, testing potential new medicines and therapies in animals is frequently critical to their evaluation, and is required by regulatory authorities worldwide to ensure the quality, efficacy and safety of the medicines we discover.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pfizer&#8217;s Commitment to Ethical and Humane Treatment of Animals</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer accepts its responsibility to use animals in a humane and ethical manner and expects all Colleagues to treat animals with respect. We approach the use of animals in our business with a high level of humane and ethical concern for those animals. All use is carefully planned and conducted in such a way as to minimize or avoid pain, distress, or discomfort to the animals. Every proposed use is thoroughly evaluated before being undertaken as the health and well-being of all animals under our care is a primary concern. Similarly, we expect any Third Party organization we engage to conduct animal-based research on our behalf to adhere to this Policy and to comply with all applicable laws and regulations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pfizer&#8217;s Commitment to Alternatives to Animal-based Biomedical Research</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer is fully committed to the development and use of scientifically validated alternative testing methods that are acceptable to regulatory authorities and do not compromise patient safety or the effectiveness of our medicines. Pfizer continues to engage and lead cross-industry efforts aimed at developing and refining new in-vitro testing and predictive informatics-based systems that hold promise for future reduction of animal usage. Pfizer works directly with regulators and through pharmaceutical trade organizations to increase the recognition and acceptance of alternative models where such alternatives can be used appropriately.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">POLICY</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For as long as it remains necessary to use animals in the discovery, development, evaluation and production of new medicines, we commit to maintaining high standards in the humane treatment of these animals. Significantly, we <font style="color:#000000;font-size:10pt;">embrace</font> the principles known as <font style="color:#000000;font-size:10pt;">the</font> &#8220;3Rs&#8221; of animal research first proposed in 1959 by Russell and Burch to describe the use of alternatives in animal research. These are:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Replacement <font style="font-weight:normal;">of animal experiments with non-animal experiments such as mathematical models, computer simulations, and in-</font><font style="color:#000000;font-size:10pt;font-weight:normal;">vitro</font><font style="font-weight:normal;"> biological systems wherever appropriate; and where animals must be used;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Reduction <font style="font-weight:normal;">of the numbers of animals </font><font style="color:#000000;font-size:10pt;font-weight:normal;">used</font><font style="font-weight:normal;"> in each study, and of the number of studies involving animals, to the absolute minimum </font><font style="color:#000000;font-size:10pt;font-weight:normal;">necessary</font><font style="font-weight:normal;"> to obtain valid results and achieve our research objectives; and</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Refinement <font style="font-weight:normal;">of </font><font style="color:#000000;font-size:10pt;font-weight:normal;">procedures</font><font style="font-weight:normal;"> involving animals to minimize the potential for pain and distress.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the 3R&#8217;s, and to further assure we maintain high standards for our animals, we have adopted the following guidelines:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;text-align:justify;margin-top:0pt;font-family:Segoe UI Symbol;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Segoe UI Symbol;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">When animal experimentation is necessary, great care is taken to choose the most appropriate animal species for the research and to optimize the study design to ensure that the results will be as meaningful as possible.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;text-align:justify;margin-top:0pt;font-family:Segoe UI Symbol;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Segoe UI Symbol;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Non-human primates will only be used when scientifically justified, for example in cases where other species will not provide sufficiently close analogues to the biological pathways and responses expected in humans.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;text-align:justify;margin-top:0pt;font-family:Segoe UI Symbol;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Segoe UI Symbol;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">All studies are carefully designed to gain the maximum information from the fewest number of animals possible.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;text-align:justify;margin-top:0pt;font-family:Segoe UI Symbol;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Segoe UI Symbol;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Each proposed use of animals is reviewed and approved by a panel of objective experts prior to performing any experiments to ensure that the use of the animals is consistent with sound scientific practices and ethical considerations.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;text-align:justify;margin-top:0pt;font-family:Segoe UI Symbol;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Segoe UI Symbol;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Our standards of animal care and welfare meet or exceed those required by applicable local, national, or international laws and regulations.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;text-align:justify;margin-top:0pt;font-family:Segoe UI Symbol;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Segoe UI Symbol;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">We regularly monitor our animals for signs of ill health or distress and take prompt action wherever appropriate. We make veterinary care available to our animals at all times.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;text-align:justify;margin-top:0pt;font-family:Segoe UI Symbol;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Segoe UI Symbol;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Our veterinarians and scientists evaluate every proposed animal procedure with an emphasis on eliminating or minimizing any potential for pain or distress which may be experienced by the animals.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;text-align:justify;margin-top:0pt;font-family:Segoe UI Symbol;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Segoe UI Symbol;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">We train all Colleagues involved in the care, welfare and use of animals to ensure (a) that they are competent in the care of the animals and in the procedures required to complete the proposed work; (b) that they are aware of the ethical issues involved in the use of animals; and (c) that they demonstrate respect and humane treatment towards the animals in their care.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;text-align:justify;margin-top:0pt;font-family:Segoe UI Symbol;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Segoe UI Symbol;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">We expect our contract research organizations, collaborators and vendors to maintain similar high standards. Parties conducting animal based research for Pfizer at their facilities are required to adhere to this Policy and to comply with all applicable laws and regulations. We perform welfare audits of Third Party facilities in accordance with our quality assurance policies.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:10pt;text-align:justify;margin-top:0pt;font-family:Segoe UI Symbol;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Segoe UI Symbol;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
<td valign="top">
<p style="margin-bottom:10pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Because respect is a key tenant in our use of animals, we have also established standards regarding the use of animals in the marketing of Pfizer products. If advertisements featuring animals are used, any animal shown should be healthy and in a natural or appropriate setting. Non-human primates should not be used in the advertising of Pfizer products, and other wild animals will also not be used unless they are shown in their natural setting or portrayed through animation or computer-generated graphics.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Policy represents Pfizer&#8217;s commitment to high-quality animal care and welfare throughout our business, and to the replacement, reduction and refinement of the use of animals in research. We are equally committed to bringing important and safe new medicines to patients.</p><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62256190"></a><a name="_Toc59107217"></a><font style="text-decoration:underline;">Schedule </font><font style="text-decoration:underline;">1.21</font><font style="text-decoration:underline;"><br /></font><font style="text-decoration:none;">Candidates</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:12.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:23.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:29.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:23.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:29.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:23.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:29.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:23.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:29.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:23.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:29.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:23.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:29.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:23.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:29.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:23.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:29.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:23.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:29.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:23.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:29.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62256191"></a><a name="_Toc59107218"></a><font style="text-decoration:underline;">Schedule 1.45<br /></font><font style="text-decoration:none;">Current Licenses</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62256192"></a><a name="_Toc59107219"></a><font style="text-decoration:underline;">Schedule&#160;1.49<br /></font><font style="text-decoration:none;">Developing Countries List</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62256193"></a><a name="_Toc59107220"></a><font style="text-decoration:underline;">Schedule&#160;1.50<br /></font><font style="text-decoration:none;">Development Budget</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62256194"></a><a name="_Toc59107221"></a><font style="text-decoration:underline;">Schedule 1.94<br /></font><font style="text-decoration:none;">Manufacturing Plan</font></p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62256195"></a><a name="_Toc59107222"></a><font style="text-decoration:underline;">Schedule&#160;4.5<br /></font><font style="text-decoration:none;">Potential Third Party Funders</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62256196"></a><a name="_Toc59107223"></a><font style="text-decoration:underline;">Schedule&#160;4.9.5<br /></font><font style="text-decoration:none;">Form of Quarterly Consolidated Report and Illustrative Gross Profit Calculation</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU10"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62256197"></a><a name="_Toc59107224"></a><font style="text-decoration:underline;">Schedule&#160;6.5.2<br /></font><font style="text-decoration:none;">Decision-Making Rights</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:60pt;">
<td valign="middle"  BGCOLOR="#E2EFDA" style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#E2EFDA" style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#E2EFDA" style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#E2EFDA" style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#E2EFDA" style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#E2EFDA" style="width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:15pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:39pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:79.5pt;">
<td colspan="10" valign="middle"  BGCOLOR="#F2F2F2" style="width:100%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:57.75pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.95pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:57.6pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.95pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:63.75pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.95pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:65.25pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:9.95pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:39.95pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.95pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:39.95pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left";>
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:60pt;">
<td valign="middle"  BGCOLOR="#E2EFDA" style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#E2EFDA" style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#E2EFDA" style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#E2EFDA" style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#E2EFDA" style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#E2EFDA" style="width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:40.9pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font></p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:49.9pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:49.9pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:49.9pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:30.6pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:43.15pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:19.9pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:9.95pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:47.25pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:9.95pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:39.95pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:9.95pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:39.95pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:9.95pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:39.95pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:9.95pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:39.95pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left";>
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:60pt;">
<td valign="middle"  BGCOLOR="#E2EFDA" style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#E2EFDA" style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#E2EFDA" style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#E2EFDA" style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#E2EFDA" style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#E2EFDA" style="width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:39.95pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font></p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:48.75pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.5pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:15pt;">
<td valign="middle"  style="width:20.5%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.24%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:14.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:1.96%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:20.52%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:48.75pt;">
<td colspan="10" valign="middle"  BGCOLOR="#F2F2F2" style="width:100%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62256198"></a><a name="_Toc59107225"></a><font style="text-decoration:underline;">Schedule 8.1.1<br /></font><font style="text-decoration:none;">Responsibilities delegated to Pfizer in the USA or other countries<br />in the Territory where it is the Lead Development Party</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62256199"></a><a name="_Toc59107226"></a><font style="text-decoration:underline;">Schedule 8.3<br /></font><font style="text-decoration:none;">Pharmacovigilance Agreement Term Sheet</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62256200"></a><font style="text-decoration:underline;">Schedule 9.7.1</font></p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Indemnification Terms</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font><font style="font-weight:normal;">[***]</font></p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:9pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Schedule 12.5.1<br /></font><font style="text-decoration:none;">Public Announcements</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">148</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62256201"></a><a name="_Toc59107227"></a><font style="text-decoration:underline;">Schedule 13.3<br /></font><font style="text-decoration:none;">Disclosures</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:8pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p><a name="_AEIOULastRenderedPageBreakAEIOU12"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">[***]</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150</a></p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font></p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:36.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font></p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font></p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">154</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font></p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font></p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">156</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font></p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.85pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td rowspan="3" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.4pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.4pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.45pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.4pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.4pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:3.75pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font></p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:6pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.95pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.25pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.15pt;">
<td rowspan="3" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="3" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:5.15pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:24.6pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font></p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font></p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.8pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:7.75pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.75pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:9.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:10.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font></p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font></p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.65pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.65pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.65pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.65pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.65pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.65pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.65pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:17.65pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font></p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font></p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:18.4pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font></p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:18.35pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font></p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.95pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:14.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:14.1pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:15.3pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:15.25pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:15.3pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:15.25pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:15.3pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:15.25pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:15.3pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:15.25pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:15.3pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:15.25pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:15.3pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:15.25pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:15.3pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:15.25pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:68.95pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font></p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.1pt;">
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:13.7pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font></p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:23.25pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:23.25pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">169</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font></p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font></p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.85pt;">
<td rowspan="2" valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:100.95pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font></p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:36.85pt;">
<td valign="top"  style="width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:7.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:8.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:13.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172</a></p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62256203"></a><a name="_Toc59107229"></a><font style="text-decoration:underline;">Schedule 13.9<br /></font><font style="text-decoration:none;">BioNTech Management with Knowledge</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173</a></p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62256204"></a><a name="_Toc59107230"></a><font style="text-decoration:underline;">Schedule&#160;13.11<br /></font><font style="text-decoration:none;">ABAC Compliance Certification</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]<font style="color:#000000;"> </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:48.1%;">
<tr>
<td style="width:8.27%;"></td>
<td style="width:13.53%;"></td>
<td style="width:16.67%;"></td>
<td style="width:9.64%;"></td>
</tr>
<tr>
<td colspan="2" valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPANY NAME:</p></td>
<td colspan="2" valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NAME:</p></td>
<td colspan="2" valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TITLE:</p></td>
<td colspan="2" valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DATE:</p></td>
<td colspan="2" valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174</a></p>
<p style="line-height:1pt;margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.51
<SEQUENCE>11
<FILENAME>bntx-ex451_414.htm
<DESCRIPTION>EX-4.51
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-ex451_414.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">Exhibit 4.51</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THE SYMBOL &#8220;[***]&#8221; DENOTES PLACES WHERE CERTAIN <br />IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM <br />THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, <br />AND <br />(ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE <br />COMPANY IF PUBLICLY DISCLOSED</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">EN</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ANNEX <br />to the <br />COMMISSION DECISION <br />of 11.11.2020 <br />approving an Advance Purchase Agreement on COVID-19 vaccines</p>
<p style="margin-bottom:63pt;margin-top:1pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:63.82%;">
<tr>
<td valign="top"  style="width:37.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gzpp5ykc3xex000001.jpg" title="" alt="" style="width:145px;height:72px;"></p></td>
<td valign="bottom"  style="width:62.08%;">
<p style="margin-top:26pt;text-align:justify;margin-bottom:0pt;margin-left:18pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EUROPEAN COMMISSION</p>
<p style="margin-bottom:4pt;text-align:justify;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Directorate-General for Health and Food Safety</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ADVANCE PURCHASE AGREEMENT (&#8220;APA&#8221;)<sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup> for the development, production, <br />priority-purchasing options and supply of a successful COVID-19 vaccine for EU Member</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">States</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font>The European Commission<font style="font-weight:normal;">, acting on behalf and in the name of the Member States set out in Annex III (hereinafter referred to as &#8220;Participating Member States&#8221;),<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup>:</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">being represented for the purposes of the signature of this APA by Ms Stella Kyriakides, Commissioner of Health and Food Safety</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on the one part and</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font>Pfizer Inc.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Incorporated in Delaware (Registration Number 0383418) with its registered address at 235 East 42nd Street, 10017 New York City, NY (UNITED STATES)</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">appointed as the leader of the group by the members of the group that submitted the joint tender (hereinafter referred to as <font style="font-weight:bold;">&#8220;Pfizer&#8221;</font>)</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Manufacturing GmbH</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-right:1.55%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Registered with the commercial register of the lower court (<font style="font-style:italic;">Amtsgericht</font>) of Mainz, Germany under HRB 47548, with its registered address at An der Goldgrube 12, 55131 MAINZ, GERMANY</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(hereinafter referred to as <font style="font-weight:bold;">&#8220;BioNTech&#8221;</font>)</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as a member of the group (collectively &#8216;<font style="font-weight:bold;">the Contractor&#8217;</font>), represented for the purposes of the signature of this APA which has the form of a framework contract by <font style="color:#000000;">[***]</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on the other part,</p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup></font></font></p></td>
<td valign="top" style="width:92.02%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">This APA is based on the agreement between the Commission and the Member States as approved by Commission Decision C(2020) 4192 final on approving the agreement with Member States on procuring Covid-19 vaccines on behalf of the Member States and related procedures.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:4pt;text-align:justify;margin-bottom:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup></font></font></p></td>
<td valign="top" style="width:92.02%;">
<p style="margin-top:4pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"><font style="color:#000000;">As provided for in Article 4(5)(b) of Council Regulation (EU) 2016/369 of 15 March 2016 on the provision of emergency support within the Union as amended by Council Regulation (EU) 2020/521 of 14 April 2020 activating the emergency support under Regulation (EU) 2016/369, and amending its provisions taking into account the COVID</font><font style="color:#000000;font-size:9pt;">&#8208; </font><font style="color:#000000;">19 outbreak.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HAVE AGREED</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the <font style="font-weight:bold;">special conditions and the general conditions of this APA </font>and the following Annexes and Attachments:</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annex I <font style="font-weight:normal;">&#8211; Model for Vaccine Order Form</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annex II <font style="font-weight:normal;">&#8211; Agreement between the Commission and Member States on procuring Covid-19 vaccines on behalf of the Member States and related procedures, annexed to the Commission Decision C(2020) 4192 final of 18 June 2020</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annex III <font style="font-weight:normal;">&#8211; Participating Member States</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annex IV <font style="font-weight:normal;">&#8211; Subcontractors</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annex V <font style="font-weight:normal;">&#8211; Participating Contractor Affiliates</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attachment 1 &#8211; Specifications</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attachment 2 &#8211; Delivery Documentation</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attachment 3 &#8211; Delivery Specification</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attachment 4 &#8211; Labelling and Packaging Specifications</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attachment 5 &#8211; Return and Disposal of Product Materials</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which form an integral part of this APA.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The full content of the Attachments will be provided as soon as possible after Authorisation has been obtained and prior to the first shipment <font style="color:#000000;">[***]</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This APA sets out:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">the procedure and conditions by which the Commission and the Participating Member States will pay for the services and/or supplies from the Contractor;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">the provisions that apply to any Vaccine Order Form which the Participating Member States and the Contractor may conclude under this APA; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">the obligations of the parties during and after the duration of this APA.</p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All documents issued by the Contractor (end-user agreements, general terms and conditions, etc.) except its tender are held inapplicable, unless explicitly mentioned in the special conditions of this APA. In all circumstances, in the event of contradiction between this APA and documents issued by the Contractor, this APA prevails, regardless of any provision to the contrary in the Contractor&#8217;s documents.</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:14pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Table of Content</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.47%;"></td>
<td style="width:9.82%;"></td>
<td style="width:77.48%;"></td>
<td style="width:0.11%;"></td>
<td style="width:5.13%;"></td>
</tr>
<tr>
<td colspan="4" valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:10.8pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENT </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="4" valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:10.8pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.SPECIAL CONDITIONS</p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr style="height:18.75pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.1</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Order of Priority of Provisions&nbsp;&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:2pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr style="height:18.7pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.2</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Definitions&nbsp;&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:2pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr style="height:18.75pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.3</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject Matter </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:2pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr style="height:18.45pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.4</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entry into force and duration of the APA </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:2pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
</tr>
<tr style="height:18.75pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.5</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Implementation of the APA </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:2pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr style="height:18.7pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.6</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supply of the Vaccine </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:2pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr style="height:18.5pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.7</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prices </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:2pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr style="height:18.7pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.8</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment Arrangements </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr style="height:18.7pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.9</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Communication Details </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr style="height:18.5pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.10</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Project management </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr style="height:18.5pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.11</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exploitation of the results of the APA </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:2pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr style="height:18.7pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.12</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indemnification </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:2pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr style="height:18.7pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.13</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Applicable Law and Settlement of Disputes </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:2pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr style="height:18.75pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.14</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other Special Conditions </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:2pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
</tr>
<tr style="height:18.45pt;">
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:12pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.</p></td>
<td colspan="3" valign="top" >
<p style="margin-top:3pt;text-align:justify;margin-bottom:0pt;margin-left:14.4pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GENERAL CONDITIONS FOR THE FRAMEWORK CONTRACT FOR SERVICES </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
</tr>
<tr style="height:18.75pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.1</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Definitions </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
</tr>
<tr style="height:18.7pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.2</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roles and responsibilities in the event of a joint tender </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
</tr>
<tr style="height:18.5pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.3</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Severability </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
</tr>
<tr style="height:18.7pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.4</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision of services and supplies </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
</tr>
<tr style="height:18.75pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.5</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Communication between the parties </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
</tr>
<tr style="height:18.7pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.6</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liability </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
</tr>
<tr style="height:18.5pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.7</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conflict of interest and professional conflicting interests&nbsp;&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:2pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr style="height:18.95pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.8</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Representations and warranties </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:2pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr style="height:18.45pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.9</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidentiality </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:2pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr style="height:18.75pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.10</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Announcements and publicity </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:2pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr style="height:18.7pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.11</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Processing of personal data </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:2pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
</tr>
<tr style="height:18.5pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.12</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subcontracting </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
</tr>
<tr style="height:18.7pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.13</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
</tr>
<tr style="height:18.75pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.14</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:2pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assignment </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:2pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr style="height:18.7pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.15</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Force majeure </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr style="height:18.7pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.16</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suspension of the implementation of the APA </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr style="height:17.35pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.17</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Termination of the APA </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.47%;"></td>
<td style="width:9.82%;"></td>
<td style="width:77.48%;"></td>
<td style="width:0.11%;"></td>
<td style="width:5.13%;"></td>
</tr>
<tr style="height:17.35pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</font></p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.18</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Invoices, value added tax and e-invoicing A </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr style="height:17.35pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.19</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments and guarantees </p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr style="height:17.35pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.20</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recovery </p></td>
<td colspan="2" valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
</tr>
<tr style="height:17.35pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.21</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Checks and audits </p></td>
<td colspan="2" valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr style="height:17.35pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.22</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Relationship of the parties </p></td>
<td colspan="2" valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
</tr>
<tr style="height:17.35pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.23</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Waiver </p></td>
<td colspan="2" valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
</tr>
<tr style="height:17.35pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.24</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further documents </p></td>
<td colspan="2" valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
</tr>
<tr style="height:17.35pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.25</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Headings </p></td>
<td colspan="2" valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr style="height:17.35pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.26</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Electronic Delivery and Storage </p></td>
<td colspan="2" valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr style="height:17.35pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.27</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entire Agreement </p></td>
<td colspan="2" valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr style="height:17.35pt;">
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:13.45pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.28</p></td>
<td valign="middle" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:7.65pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs </p></td>
<td colspan="2" valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr style="height:17.35pt;">
<td colspan="3" valign="top" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANNEX I: MODEL FOR VACCINE ORDER FORM</p></td>
<td colspan="2" valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
</tr>
<tr style="height:61.2pt;">
<td colspan="3" valign="top" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANNEX II: AGREEMENT BETWEEN THE COMMISSION AND MEMBER STATES ON PROCURING COVID-19 VACCINES ON BEHALF OF THE MEMBER STATES AND RELATED PROCEDURES, ANNEXED TO THE COMMISSION DECISION C(2020) 4192 FINAL OF 18 JUNE 2020</p></td>
<td colspan="2" valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
</tr>
<tr style="height:17.35pt;">
<td colspan="3" valign="top" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANNEX III: PARTICIPATING MEMBER STATES</p></td>
<td colspan="2" valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
</tr>
<tr style="height:17.35pt;">
<td colspan="3" valign="top" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANNEX IV: SUBCONTRACTORS</p></td>
<td colspan="2" valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
</tr>
<tr style="height:17.35pt;">
<td colspan="3" valign="top" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANNEX V <font style="font-size:11.5pt;">&#8211; </font>PARTICIPATING CONTRACTOR AFFILIATES</p></td>
<td colspan="2" valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td>
</tr>
<tr style="height:17.35pt;">
<td colspan="3" valign="top" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATTACHMENT 1: SPECIFICATION</p></td>
<td colspan="2" valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:17.35pt;">
<td colspan="3" valign="top" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATTACHMENT 2: DELIVERY DOCUMENTATION</p></td>
<td colspan="2" valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:17.35pt;">
<td colspan="3" valign="top" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATTACHMENT 3: DELIVERY SPECIFICATION</p></td>
<td colspan="2" valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:17.35pt;">
<td colspan="3" valign="top" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATTACHMENT 4 : LABELLING AND PACKAGING SPECIFICATIONS</p></td>
<td colspan="2" valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:17.35pt;">
<td colspan="3" valign="top" >
<p style="margin-bottom:1pt;margin-top:3pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATTACHMENT 5: RETURN AND DISPOSAL OF PRODUCT MATERIALS</p></td>
<td colspan="2" valign="bottom" >
<p style="text-align:right;margin-bottom:1pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">S</font><font style="text-decoration:underline;font-size:12pt;">PECIAL </font><font style="text-decoration:underline;">C</font><font style="text-decoration:underline;font-size:12pt;">ONDITIONS </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.1<font style="margin-left:36pt;">O</font><font style="font-size:9.5pt;">RDER OF </font>P<font style="font-size:9.5pt;">RIORITY OF </font>P<font style="font-size:9.5pt;">ROVISIONS</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If there is any conflict between different provisions in this APA, the following rules must be applied:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The provisions set out in the special conditions and Article II.6 of the general conditions (Liability) take precedence over those in the other parts of the APA.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The other provisions set out in the general conditions take precedence over those in the Annexes and Attachments.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The provisions set out in the APA take precedence over those in the Vaccine Order Forms.</p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.2<font style="margin-left:36pt;">D</font><font style="font-size:9.5pt;">EFINITIONS</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following definitions shall apply to this APA:</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Additional Order&#8217;<font style="font-weight:normal;">: has the meaning set forth in Article I.6.2;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Additional Product&#8217;<font style="font-weight:normal;">: has the meaning set forth in Article I.6.2;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Adjusted Delivery Schedule&#8217;<font style="font-weight:normal;">: has the meaning set forth in Article I.6.3(ii);</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Advance Payment&#8217;<font style="font-weight:normal;">: has the meaning set forth in Article I.8.1</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-right:0.66%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Affiliate&#8217;: <font style="font-weight:normal;">means in relation to a body corporate, any other entity which directly or indirectly Controls, is Controlled by, or is under direct or indirect common Control of that body corporate from time to time;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-right:0.66%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Authorisation&#8217;<font style="font-weight:normal;">: means a Conditional Marketing Authorisation and/or Marketing Authorisation that permits the Products to be placed on the market in the European Economic Area;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-right:0.66%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Best Reasonable Efforts&#8217;<font style="font-weight:normal;">: </font><font style="font-weight:normal;color:#000000;">[***]</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-right:0.66%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Conditional Marketing Authorisation&#8217;: <font style="font-weight:normal;">means a conditional marketing authorisation granted by the European Commission as referred to in Article 14-a of Regulation (EC) No 726/2004;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8216;<font style="font-weight:bold;">Confidential Information&#8217;</font>: means any information disclosed to or obtained by one party to the other party, either directly or indirectly, or which the disclosing party indicates in writing at the time of disclosure to, or receipt by, the recipient is to be considered confidential or proprietary, or which such recipient knows or ought reasonably to know is information of a confidential or proprietary nature, including the terms of this APA and any Vaccine Order Form. Confidential Information shall not include any information (i) the receiving party can prove was known to it prior to the date of disclosure; (ii) the receiving party can prove was lawfully obtained from a third party without any obligation of confidentiality; (iii) is or becomes part of the public domain other than through any act or omission of the receiving </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">party; or (iv) is independently developed by the receiving party without use of or reference to the disclosing party&#8217;s Confidential Information, as evidenced by the receiving party&#8217;s records;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Conflict of interest&#8217;: <font style="font-weight:normal;">a situation where the impartial and objective </font><font style="font-style:italic;font-weight:normal;">Implementation of the APA </font><font style="font-weight:normal;">by the Contractor is compromised for reasons involving family, emotional life, political or national affinity, economic interest, any other direct or indirect personal interest, or any other shared interest with the Commission, the Participating Member State or any third party related to the subject matter of the APA;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Contracted Doses&#8217;<font style="font-weight:normal;">: has the meaning set forth in Article I.6.2;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Control&#8217;: <font style="font-weight:normal;">means the possession by a person or an entity, directly or indirectly, of the power to direct or cause the direction of the management and policies of the other person or entity (whether through the ownership of voting shares, by contract or otherwise) and </font>"Controls" <font style="font-weight:normal;">and </font>"Controlled" <font style="font-weight:normal;">shall be interpreted accordingly;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Delivery Price&#8217;<font style="font-weight:normal;">: has the meaning set forth in Article I.8.2;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Delivery Schedule&#8217;<font style="font-weight:normal;">: means the Interim Delivery Schedule or the Adjusted Delivery Schedule, as applicable;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Effective Date&#8217;<font style="font-weight:normal;">: has the meaning set forth in Article I.4.1;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Force majeure&#8217;: <font style="font-weight:normal;">any unforeseeable, exceptional situation or event beyond the reasonable control of the parties that prevents either of them from fulfilling any of their obligations under the APA, </font><font style="font-weight:normal;color:#000000;">[***] </font><font style="font-weight:normal;"> </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Formal notification&#8217; <font style="font-weight:normal;">(or &#8216;formally notify&#8217;): form of communication between the parties made in writing by mail or email, which provides the sender with compelling evidence that the message was delivered to the specified recipient;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Fraud&#8217;: <font style="font-weight:normal;">an act or omission committed in order to make an unlawful gain for the perpetrator or another by causing a loss to the Union's financial interests, and relating to: i) the use or presentation of false, incorrect or incomplete statements or documents, which has as its effect the misappropriation or wrongful retention of funds or assets from the Union budget, ii) the non-disclosure of information in violation of a specific obligation, with the same effect or iii) the misapplication of such funds or assets for purposes other than those for which they were originally granted, which damages the Union's financial interests, it being understood that the Union&#8217;s financial interests are impacted under this APA only by reason of the Advance Payment;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Good Manufacturing Practice&#8217;: <font style="font-weight:normal;">means the current practices for manufacture required by the standards, rules, principles and guidelines set out in Directive 2001/83/EC (as amended by Directive 2004/27/EC), Directive 2017/1572, Directive 2003/94/EC and EudraLex - Volume 4 of the Rules Governing Medicinal Products in the EU entitled &#8220;EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use&#8221;;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Implementation of the APA&#8217;: <font style="font-weight:normal;">the purchase of services or supplies envisaged in the APA through the signature and </font><font style="font-style:italic;font-weight:normal;">performance of </font><font style="font-weight:normal;">Vaccine Order Forms;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Indemnified Persons&#8217;: </font><font style="font-weight:normal;">has the meaning set forth in Article I.12.1; </font><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Interim Delivery Schedule&#8217;</font><font style="font-weight:normal;">: has the meaning set forth in Article I.6.3;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Irregularity&#8217;: <font style="font-weight:normal;">any infringement of a provision of Union law resulting from an act or omission by the Contractor within the meaning of Article 1(2) of the Council (EC, Euratom) Regulation 2988/95 of 18 December 1995 on the protection of the European Communities financial interests (in OJ 23.12.95, L 312/1) , which has, or would have, the effect of prejudicing the Union&#8217;s budget, it being understood that the Union&#8217;s financial interests are impacted under this APA only by reason of the Advance Payment;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-right:0.66%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Latent Defect&#8217;<font style="font-weight:normal;">: means a defect causing the Product to not conform to the applicable Specifications that the relevant Participating Member State can show was present at the time of delivery of the Product and which could not have been detected by the Participating Member State, its designee, or their personnel at delivery through visual inspection;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-right:0.66%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Law(s)&#8217;<font style="font-weight:normal;">: means, collectively, all applicable supranational, national and local laws, common laws, statutes, ordinances, codes, rules, regulations, orders, decrees or other pronouncements of any government, administrative or judicial authority having the effect of law;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Losses&#8217;: <font style="font-weight:normal;">has the meaning set forth in Article I.12.1;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-right:0.66%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Marketing Authorisation&#8217;<font style="font-weight:normal;">: means the marketing authorisation (other than Conditional Marketing Authorisation), in respect of the Product granted by the European Commission, as amended or varied from time to time, that allows the Product to be placed on the market in the European Economic Area according to applicable Law;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Non-Complying Product&#8217;<font style="font-weight:normal;">: has the meaning set forth in Article I.6.14;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Notification&#8217; <font style="font-weight:normal;">(or &#8216;notify&#8217;): form of communication between the parties made in writing including by electronic means;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-right:11.08%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Participating Contractor Affiliate&#8217;<font style="font-weight:normal;">: means an Affiliate of Pfizer or BioNTech as identified in Annex V;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Product&#8217;<font style="font-weight:normal;">: means the Vaccine;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-right:1.55%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Product Materials&#8217;<font style="font-weight:normal;">: means all packaging materials and components needed for delivery of the Product;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Professional conflicting interest&#8217;: <font style="font-weight:normal;">a situation in which the Contractor&#8217;s previous or ongoing professional activities affect its capacity to implement the APA or to perform a Vaccine Order Form to an appropriate quality standard;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Record&#8217;: <font style="font-weight:normal;">means books, documents, and other data, of all matters relating to performance of obligations under this APA;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Related person&#8217;: <font style="font-weight:normal;">any natural or legal person who is a member of the administrative, management or supervisory body of the Contractor, or who has powers of representation, decision or control with regard to the Contractor;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Specifications&#8217;</font><font style="font-weight:normal;">: means the specifications for the manufacture, testing and testing procedures, and supply of the Product as set out in Attachment 1 (Specifications), and as such specifications may be amended, supplemented or otherwise modified by the Contractor and communicated to the Commission;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Taxes&#8217;: <font style="font-weight:normal;">has the meaning set forth in Article II.18.1;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Term&#8217;<font style="font-weight:normal;">: means the term of the APA set out in Article I.4.2 of the APA;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Thermal Shipper&#8217;<font style="font-weight:normal;">: has the meaning set forth in Article I.6.8;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Third Party Claim&#8217;: <font style="font-weight:normal;">has the meaning set forth in Article I.12.4.</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Vaccine&#8217;<font style="font-weight:normal;">: BNT162b2, a nucleoside-modified messenger RNA (modRNA) vaccine that encodes an optimized SARS-CoV-2 full-length spike glycoprotein (S) for which a rolling submission for BNT162b2 has been initiated with the European Medicines Agency;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Vaccine IP Rights&#8217;<font style="font-weight:normal;">: has the meaning set forth in Article I.11</font>.<font style="font-weight:normal;">; and</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Vaccine Order Form<font style="font-weight:normal;">: has the meaning set forth in Article I.5.2I.3.</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except where the context expressly requires otherwise, (a) the use of any gender herein shall be deemed to encompass references to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b) the words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without limitation", (c) the word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall&#8221;, (d) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (e) any reference herein to any person shall be construed to include the person's successors and assigns, (f) the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;, and words of similar import, shall be construed to refer to this APA in its entirety and not to any particular provision hereof, (g) all references herein to Articles, Annexes or Attachments shall be construed to refer to Articles, Annexes or Attachments of this APA, and references to this APA include all Annexes and Attachments hereto, (h) the word &#8220;notice&#8221; means notice in writing or by email (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this APA, (i) provisions that require that a party or parties &#8220;agree&#8221;, &#8220;consent&#8221; or &#8220;approve&#8221; or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (including e-mail), (j) references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.3<font style="margin-left:36pt;">S</font><font style="font-size:9.5pt;">UBJECT </font>M<font style="font-size:9.5pt;">ATTER</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The subject of the call for tenders SANTE/2020/C3/043 is securing the purchase of certain vaccine doses for the Participating Member States.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By Decision </font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C(</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020) 4192 final of 18 June 2020, the Commission approved the agreement with Member States on procuring COVID-19 vaccines on behalf of the Member States (&#8220;the Decision&#8221;). This agreement is based on Article 4(5)(b) of Regulation (EU) 2016/369 of 15</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 2016 on the provision of emergency support within the Union<sup style="font-size:85%;line-height:120%;vertical-align:top">3</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup> (&#8220;the ESI Regulation&#8221;) which provides that the Commission may grant emergency support in the form of procurement on behalf of the Member States based on an agreement between the Commission and Member States. In order to implement such action, the Commission is running procurement procedures on behalf of Participating Member States, with a view to signing EU-level APAs with vaccine manufacturers. In view of its importance, this APA will be approved for signature on behalf and in the name of the Participating Member States by a separate individual Commission decision.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor is currently in Phase 3 clinical development of the Vaccine and is using its Best Reasonable Efforts to secure Authorisation of such vaccine candidate by the Commission, expected at the earliest in December 2020.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission, on behalf of the Participating Member States, wishes to purchase the Vaccine during the pandemic period through this APA. It acknowledges that the clinical development might not be successful or regulatory approval may not be obtained and subsequently an authorised Vaccine may not be available.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the basis of this APA, the European Commission commissions the Contractor to commit to produce and deliver in priority 200 million doses of the Vaccine which shall be ordered by the Participating Member States (via specific Vaccine Order Forms) at the price and conditions, including timeframe, agreed under this APA.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In case the Contractor succeeds to develop a safe and effective Vaccine according to the terms laid down in this APA, the Contractor or an Affiliate of the Contractor shall supply to the Participating Member States the agreed doses of the Vaccine pursuant to the Vaccine Order Forms.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Vaccine Order Forms shall be signed by the Contractor and shall incorporate by reference this APA.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.4<font style="margin-left:36pt;">E</font><font style="font-size:9.5pt;">NTRY INTO FORCE AND DURATION OF THE </font>APA</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.98%;text-indent:-7.98%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.4.1 The APA enters into force on the date on which the last party signs it (<font style="font-weight:bold;">&#8220;Effective Date&#8221;</font>).</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.98%;text-indent:-7.98%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.4.2 The APA is concluded for a period of 24 months with effect from the Effective Date (<font style="font-weight:bold;">&#8220;Term&#8221;</font>).</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.98%;text-indent:-7.98%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.4.3 Contractor and the Participating Member States may not sign any Vaccine Order Form after the APA expires.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The APA continues to apply to such Vaccine Order Forms after its expiry. <font style="color:#000000;">[***].</font></p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">3</sup></font></font></p></td>
<td valign="top" style="width:92.02%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;font-size:8pt;">OJ L 70, 16.3.2016, p.1, as amended by Council Regulation (EU) 2020/521 of 14 April 2020 activating the emergency support under Regulation (EU) 2016/369, and amending its provisions taking into account the COVID</font><font style="color:#000000;font-size:9pt;">&#8208; </font><font style="color:#000000;font-size:8pt;">19 outbreak, OJ L 117, 15.4.2020, p. 3.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.4.4 Renewal of the APA</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The APA will expire automatically at the end of the Term, unless it is extended in mutual written agreement between the parties. Renewal does not change or postpone any existing obligations.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.5<font style="margin-left:36pt;">I</font><font style="font-size:9.5pt;">MPLEMENTATION OF THE </font>APA</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.5.1 Period of provision of the supplies</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The period for the provision of the supplies starts to run as foreseen in Article I.6.3.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.5.2 Implementation of the APA</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The APA shall be implemented following signature between the Commission and the Contractor as follows:</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to guarantee the right of the Participating Member States to acquire Vaccine doses in a given timeframe and at a certain price and conditions, the Commission will pay the Advance Payment.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor shall use Best Reasonable Efforts to build manufacturing capacity or utilise existing capacity to be capable of manufacturing and supplying the Product to the Commission in accordance with the provisions of this APA.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor agrees to supply an initial total number of 200 million Vaccine doses to Participating Member States collectively, upon their order, in accordance with this APA and the respective Vaccine Order Forms.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participating Member States shall place orders for supplies of 200 million Vaccine doses in total in accordance with the allocation communicated by the Commission to the Contractor pursuant to Article I.6.3, by sending the Contractor a completed copy of Annex I (<font style="font-weight:bold;font-size:10pt;">&#8220;</font><font style="font-weight:bold;">Vaccine Order Form</font><font style="font-weight:bold;font-size:10pt;">&#8221;</font>) in paper format or emailed pdf <font style="color:#000000;">[***]</font>. This Vaccine Order Form shall be signed by an authorised representative of the Participating Member State and the Contractor.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] <font style="color:#000000;">the Contractor must send back to the Participating Member States the duly signed and dated Vaccine Order Form in paper format or emailed pdf.</font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6<font style="margin-left:36pt;">S</font><font style="font-size:9.5pt;">UPPLY OF THE </font>V<font style="font-size:9.5pt;">ACCINE </font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.1 Creation of the Vaccine</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the term of this APA, and subject to the successful development and authorisation of the Vaccine as set out in this APA, the Contractor shall use Best Reasonable Efforts to supply or have supplied the Product to the relevant Participating Member States, and the Participating Member States shall purchase the Product, subject to and in accordance with the terms and conditions of this APA.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.2 Product </font><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">supply</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the Effective Date, the Commission orders 200 million doses (<font style="font-weight:bold;">&#8220;Contracted Doses&#8221;</font>) of the Product on behalf of the Participating Member States to be delivered if the Contractor succeeds to develop a safe and effective Vaccine according to the terms laid down in this APA.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The parties acknowledge that the Commission may wish to place an additional binding order (the <font style="font-weight:bold;">&#8220;Additional Order&#8221;</font>) for a maximum of up to 100 million doses of the Vaccine. The parties also agree that such Additional Order may be placed by the Commission only after (i) being advised by the Contractor that the Contractor has availability of supply of such additional requested doses at the time of the proposed Additional Order (the <font style="font-weight:bold;">&#8220;Additional Product&#8221;</font>) (ii) the Contractor agrees, in its sole discretion, to allocate the Additional Product to the Commission (iii) the Contractor confirms how many doses can be delivered and by when (iv) the Commission confirms the required allocation between Participating Member States and (v) <font style="color:#000000;">[***]</font>. The Additional Order will be placed by way of an additional Vaccine Order Form and, as such, be subject to the same terms and conditions set forth in this APA.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission shall communicate to the Contractor the allocation of the Contracted Doses supplied pursuant to the initial order and any Additional Product among the governments of the Participating Member States. <font style="color:#000000;">[***]</font> The parties acknowledge that should resale to any third country take place, the Participating Member State reselling doses has an obligation to reimburse the Commission the Advance Payment per dose paid by the Commission to the Contractor.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.3 Supply mechanism</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vaccine supply in Europe will primarily come from <font style="color:#000000;">[***] </font>manufacturing site <font style="color:#000000;">[***] </font>and shall incorporate RNA produced at <font style="color:#000000;">[***] </font>manufacturing sites including sites operated by the following sub-contractors <font style="color:#000000;">[***]</font>.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to points (i) to (v) below, it is estimated that the order will be delivered as set out in the table below (the <font style="font-weight:bold;">&#8220;Interim Delivery Schedule&#8221;</font>) assuming Authorisation being granted by <font style="color:#000000;">[***]</font>. The Interim Delivery Schedule and logistics will be further refined <font style="color:#000000;">[***]</font> by the Contractor after the Commission has communicated how to apportion the 200 million Vaccine doses amongst the Participating Member States pursuant to the provisions of this Article I.6.3.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Interim Delivery Schedule is as follows (subject to the limitations set forth below):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:4.19%;width:311.75pt;;">
<tr>
<td style="width:81.1pt;"></td>
<td style="width:49.7pt;"></td>
<td style="width:56.4pt;"></td>
<td style="width:62.15pt;"></td>
<td style="width:62.4pt;"></td>
</tr>
<tr style="height:13.2pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.75pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quarter</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:5.75pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Doses (million)</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">No doses will be shipped to the Member States prior to the Contractor receiving Authorisation.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">If Authorisation is received after <font style="color:#000000;">[***]</font> then the Interim Delivery Schedule will shift accordingly and be adjusted to reflect the delay between <font style="color:#000000;">[***]</font> and the date of Authorisation (<font style="font-weight:bold;">&#8220;Adjusted Delivery Schedule&#8221;</font>).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;">[***]</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vi)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;">[***]</font></p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the avoidance of doubt, the Participating Member States will not have the right to terminate the Vaccine Order Forms <font style="color:#000000;">[***]</font> in the event that the Commission has not exercised its right to terminate the APA.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Vaccine is successfully developed and obtains Authorisation in the foreseen time-line <font style="color:#000000;">[***]</font> the Contractor shall use Best Reasonable Efforts to ensure that the doses are supplied in accordance with the Interim Delivery Schedule, or if applicable, the Adjusted Delivery Schedule. Allocations shall be made pursuant to Article I.6.3(iv) in case of insufficient supply to deliver the full amount of Contracted Doses.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within <font style="color:#000000;">[***] </font>following the Effective Date, the Commission shall communicate to the Contractor a table how to allocate the 200 million Vaccine doses amongst the Participating Member States.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Participating Member State shall have a commitment to purchase the number of Vaccine doses as set out in the above-mentioned allocation table and to sign a Vaccine Order Form to this effect as set out below.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To operationalise the ordering of the Vaccine, each Participating Member State will enter into a Vaccine Order Form. Each Vaccine Order Form will specify in particular the number of doses that the Participating Member State will purchase from the above-mentioned allocation table, the price of all Vaccine doses pursuant to Article I.7, and the liability and indemnification undertakings by the Participating Member State (which will be incorporated by reference from the APA into the Vaccine Order Form). <font style="color:#000000;">[***] </font>For the avoidance of doubt, the Contractor shall have no obligation to supply any Vaccine doses to any Participating Member State where there is not a Vaccine Order Form , including provisions related to liability and indemnity (which will be incorporated by reference from the APA into the Vaccine Order Form executed by the Participating Member State and the Contractor). It is agreed that the Contractor may discharge its obligations under the Vaccine Order Form acting with one or more Participating Contractor Affiliates.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.4 Manufacturing</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor confirms that it is in possession of all necessary manufacturing authorisations to undertake the manufacturing of the Vaccine.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.5 Legal and regulatory filings and requests</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor shall ensure that all Product is properly labelled and packaged in accordance with the provisions of Article I.6.8 and Good Manufacturing Practice and in accordance with the applicable EU legislation on information on packaging (Title V of Directive 2001/83/EC).</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the above, <font style="color:#000000;">[***]</font>, the Contractor shall comply with all conditions (in the relevant timescales) set out in the Authorisation (where applicable), subject to any exemption, exception or waiver of requirements for the Product granted or permitted by the Participating Member State (including but not limited to serialization).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.6 Clinical trials and licensure</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor will use Best Reasonable Efforts to obtain Authorisation. <font style="color:#000000;">[***]</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.7 Waiver</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission acknowledges and agrees that the Contractor&#8217;s efforts to develop and manufacture the Vaccine are aspirational in nature and subject to significant risks and uncertainties. Notwithstanding the efforts and any estimated dates set forth in this APA, the parties recognize that the Vaccine is in Phase 3 clinical trials at the date of signature of this APA and that, despite the diligent efforts of the Contractor in research, and development and manufacturing, the Vaccine may not obtain Authorisation or may not be delivered (despite the Contractor&#8217;s obligation to use Best Reasonable Efforts pursuant to Articles I.6.1 and 1.6.6 of this APA) due to technical, clinical, regulatory or manufacturing, shipping, storage or other challenges or failures.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.8 Packaging, labelling and shipping</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the date of execution of this APA, the Vaccine is expected to be supplied in a thermal shipping box in accordance with Schedule 4 (Labelling and Packaging Specifications) (<font style="font-weight:bold;">&#8220;Thermal Shipper&#8221;</font>) containing up to <font style="color:#000000;">[***].</font> The costs of packaging, packing materials, addressing, labelling, loading and delivery to the agreed Participating Member States&#8217; delivery point of the Vaccine <font style="color:#000000;">[***]</font>.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All deliveries shall be accompanied by the documentation specified in Attachment 2 (Delivery Documentation) (which may be updated from time to time by the Contractor upon notice to the Commission), and shall be in accordance with, and subject to, the delivery specification set forth in Attachment 3 (Delivery Specification). The Product shall be labelled and packaged in accordance with the packaging specifications set forth in Attachment 4 (Labelling and Packaging Specifications)</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Final specifications including package size and labels will be communicated to the Commission and to the Participating Member States prior to delivery. All specifications shall be consistent with any conditions set out in the Authorisation and applicable Law.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.9 Storage, transport and product acceptance</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on current knowledge and subject to updating based on Authorisation, the Vaccine is expected to be a two dose regimen in a concentration liquid formulation that needs to be stored frozen at temperatures between <font style="color:#000000;">[***].</font> The Vaccine must be thawed on the day of administration and stored at <font style="color:#000000;">[***].</font> </p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] <font style="color:#000000;">Final storage specifications, based on the Authorisation received, will be communicated to the Participating Member State prior to delivery.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.10 Delivery</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor will deliver the doses ordered by each of the Participating Member States to one or more locations selected by the Participating Member State in accordance with the procedure set out in this Article I.6.10 and the Vaccine Order Form. <font style="color:#000000;">[***]</font> For the avoidance of doubt, the Participating Member States shall bear all costs and expenses for operating these distribution hubs and for use of the Vaccine, including, but not limited to, those for storage and distribution of the Vaccine after delivery, local duties and local QA testing.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The duly authorised representative of the Participating Member State shall sign to confirm receipt of delivery (the current proposed format of which is as set out in Attachment 2 (Delivery Documentation)). The person signing for receipt must ensure the contents of the delivery match the accompanying shipping documentation proof of receipt.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor shall deliver the Product <font style="color:#000000;">[***]</font> to the location agreed pursuant to this Article I.6.10.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor and the Participating Member State shall agree the location(s) for delivery of shipments of the Product; provided that (i) each location meets the requirements set forth in Attachment 3 (Delivery Specification), and (ii) all locations shall be agreed upon by the Contractor and the Participating Member State at least <font style="color:#000000;">[***]</font>. <font style="color:#000000;">[***]</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-right:15.07%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All shipments of Product <font style="color:#000000;">[***].</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-right:15.07%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.11 Product handling</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon delivery of the Product, the Participating Member State shall store and handle the Product in the manner set forth in the Specifications set forth in Attachment 1 (Specifications), instructions in Attachment 3 (Delivery Specification) and the instructions provided by the Contractor to ensure stability and integrity of the Product.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participating Member States shall be solely responsible and liable for the proper storage, handling, distribution, transportation, administration, use and disposal of the Product in their country following delivery of the Product to the Participating Member State or its designee. Without prejudice to the generality of the foregoing, the Participating Member States ensure that: (a) recipients of the Product shall follow the return and disposal instructions in Attachment 5 (Return and Disposal of Product Materials) (as updated by the Contractor and communicated to the Participating Member State from time to time) when disposing of open and unused Product and its packaging components; and (b) such return and disposal complies with Laws regarding pharmaceutical waste, medical waste, or hazardous waste, as appropriate.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Participating Member States shall be responsible for and shall ensure that any equipment used to deliver the Product, for example <font style="color:#000000;">[***]</font> are stored in an appropriate clean and secure location to protect and maintain the functionality of such equipment (in controlled conditions, with no exposure to weather or pests, etc). Within <font style="color:#000000;">[***] </font>of receipt of the Product, subject to Article I.6.14, the Participating Member State shall take the necessary measures to enable the collection by the Contractor of all such equipment, including <font style="color:#000000;">[***]</font> in accordance with the Contractor&#8217;s instructions, consistent with the provisions of Attachment 5 (Return and Disposal of Product Materials).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor may provide Safety Data Sheets and other agreed information to Participating Member States </font><font style="color:#000000;">[***]</font><font style="color:#000000;">.</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.12 Title to Product and risk of loss</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.13 Quality tests and checks</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.14 Rejection of Product; Disposal of rejected shipments</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Participating Member State must visually inspect the Product <font style="color:#000000;">[***]</font> following the instructions set out in Attachment 3 (Delivery Specification) and may reject any specific delivery of the Product or doses therein that does not conform <font style="color:#000000;">[***]</font> (<font style="font-weight:bold;">&#8220;Non-Complying Product&#8221;</font>) by providing notice to Pfizer Customer Service following an agreed protocol: <font style="color:#000000;">[***].</font> </p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Without prejudice to the right to refer the matter to the dispute resolution procedure set out in Article I.13.2 and the provision on <font style="color:#000000;">[***]</font>, replacement of Non-Complying Product <font style="color:#000000;">[***]</font>. The provisions of this Article I.6.14 shall survive termination or expiration of this APA.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.15 Maintenance and retention of Records</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each party shall maintain <font style="color:#000000;">[***]</font> with respect to its activities under this APA as required by Laws.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participating Member State will maintain a quality system for receipt, inspection, storage, traceability to further delivery points, and recall activities. If the Participating Member State does not have a quality system for the activities defined, the Contractor may share details of a proposed quality system for the Participating Member State&#8217;s compliance.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.16 Diversion issues</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All Product delivered to a Participating Member State shall be: (a) stored securely by the Participating Member State; and (b) without prejudice to Article I.6.2, distributed by the Participating Member State in a secure manner appropriate to the transportation route and destination, in each case (a) and (b) to guard against and deter theft, diversion, tampering, substitution (with, for example, counterfeits) or unauthorised resale or export out of the Participating Member State, and to protect and preserve the integrity and efficacy of the Product. <font style="color:#000000;">[***]</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.7</font><font style="margin-left:36pt;">P</font><font style="font-size:9.5pt;">RICES</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The price of the Vaccine to the Commission and the Participating Member States for the 200 million Contracted Doses will be <font style="color:#000000;">[***]</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.2%;width:99.67%;">
<tr>
<td style="width:33.22%;"></td>
<td style="width:33.14%;"></td>
<td style="width:33.31%;"></td>
</tr>
<tr style="height:26.65pt;">
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.75pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:26.65pt;">
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.8<font style="margin-left:36pt;">P</font><font style="font-size:9.5pt;">AYMENT </font>A<font style="font-size:9.5pt;">RRANGEMENTS </font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.8.1 Advance Payment</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission agrees to pay <font style="color:#000000;">[***] </font>to the Contractor (the <font style="font-weight:bold;">&#8220;Advance Payment&#8221;</font>). The Advance Payment <font style="color:#000000;">[***]</font> shall be counted as a payment towards the Delivery Price as defined below.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission shall pay to Contractor the Advance Payment, on behalf of the Participating Member States, <font style="color:#000000;">[***] </font>after the date of Contractor&#8217;s invoice in respect thereof.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.8.2 Delivery Price</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the Advance Payment is made, the remainder of the contracted price per dose (the <font style="font-weight:bold;">&#8220;Delivery Price&#8221;</font>) for the Contracted Doses is to be paid by the Participating Member State to the Participating Contractor Affiliate <font style="color:#000000;">[***].</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The full contracted price per dose for any Additional Order (as set out in Article I.7 above) is to be paid to the Participating Contractor Affiliate <font style="color:#000000;">[***].</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participating Contractor Affiliate may claim the payment of the balance in accordance with Article I.8.2. The Participating Contractor Affiliate must send an invoice in paper format or emailed pdf for payment of the balance due under a Vaccine Order Form for each provision of supplies to the Participating Member States.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Invoices shall be established by the Participating Contractor Affiliate for a given order of supplies and for an identified delivery scheduled within the Vaccine Order Form.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participating Contractor Affiliate may not send an invoice to a Participating Member State before it receives from the Participating Member State <font style="color:#000000;">[***]</font> in respect of which such invoice is established, which <font style="color:#000000;">[***]</font>.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participating Contractor Affiliate must send an invoice in paper format or emailed pdf or by electronic systems for payment due under the Vaccine Order Form accompanied by the following:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;">[***]</font></p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each invoice must contain the following information:</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<font style="margin-left:36pt;">Name of the Participating Member State concerned</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<font style="margin-left:36pt;">APA and Vaccine Order Form number/reference</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<font style="margin-left:36pt;">Order reference</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<font style="margin-left:36pt;">Billing address</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<font style="margin-left:36pt;">Product </font><font style="color:#000000;">[***]</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<font style="margin-left:36pt;"></font>Quantity <font style="color:#000000;">[***]</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<font style="margin-left:36pt;"></font><font style="color:#000000;">[***] </font>reference and date</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<font style="margin-left:36pt;">Price</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<font style="margin-left:36pt;">Any applicable taxes, transportation charges or other charges provided for in the Vaccine Order Form</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<font style="margin-left:36pt;">The ship-to destination</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<font style="margin-left:36pt;"></font><font style="color:#000000;">[***]</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<font style="margin-left:36pt;">Participating Contractor Affiliate name and bank account.</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participating Member States must approve the submitted documents or deliverables as conforming to the above requirements and pay <font style="color:#000000;">[***]</font>. Any payment which falls due on a date which is not a business day may be made on the next succeeding business day. Any dispute by a Participating Member State of an invoice shall be provided to the Participating Contractor Affiliate in writing (along with substantiating documentation and a reasonably detailed description of the dispute) <font style="color:#000000;">[***].</font> A Participating Member State will be deemed to have accepted all invoices for which the Participating Contractor Affiliate does not receive timely notification of disputes, and shall pay all undisputed amounts due under such invoices within the period set forth in this Article I.8.2. The parties shall seek to resolve all such disputes expeditiously and in good faith.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to all other remedies available under this APA or at Law, if a Participating Member State fails to pay any undisputed amounts when due under this APA, the Contractor <font style="color:#000000;">[***].</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission and the Participating Member States shall not, and acknowledge that they will have no right, under this APA, any Vaccine Order Form, any order, any other agreement, document or Law, to withhold, offset, recoup or debit any amounts owed (or to become due and owing) to the Participating Contractor Affiliate, against any other amount owed (or to become due and owing) to it by the Contractor or an Affiliate.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.8.3 Bank account</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments by the Commission must be made <font style="color:#000000;">[***] </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.9<font style="margin-left:36pt;">C</font><font style="font-size:9.5pt;">OMMUNICATION </font>D<font style="font-size:9.5pt;">ETAILS</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the purpose of this APA, communications must be sent to the following addresses:</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By derogation from this Article I.9, different contact details for the Commission, the Participating Member States or the Contractor may be provided in Vaccine Order Form.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.10 P<font style="font-size:9.5pt;">ROJECT MANAGEMENT</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer, BioNTech and the Commission will each nominate a project manager that will be the sole contact point for and responsible for managing the overall relationship between the parties. Each Participating Member State shall in addition appoint an expert to work on APA implementation at Participating Member State level. Project meetings with the Commission and Participating Member State experts will be held regularly on a timeframe to be determined following execution of the APA to report, amongst other things, on progress of clinical studies, licensing activities, manufacturing status, forecast and deliveries. Details specific to each Participating Member State such as logistics and payments shall be handled directly by the respective Participating Member State experts.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.11 E<font style="font-size:9.5pt;">XPLOITATION OF THE RESULTS OF THE </font>APA<sup style="font-size:85%;line-height:120%;vertical-align:top">4</sup><font style="font-family:Times New Roman Bold;"><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup></font><font style="font-size:7pt;"> </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission acknowledges and agrees <font style="color:#000000;">[***]</font> (collectively, the <font style="font-weight:bold;">&#8220;Vaccine IP Rights&#8221;</font>). <font style="color:#000000;">[***] </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All rights not expressly granted by the Contractor hereunder are reserved by the Contractor.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.12 I<font style="font-size:9.5pt;">NDEMNIFICATION</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.12.1<font style="margin-left:36pt;"></font>The Commission, on behalf of the Participating Member States, declares that the use of Vaccines produced under this APA will happen under epidemic conditions requiring such use, and that the administration of Vaccines will therefore be conducted under the sole responsibility of the Participating Member States. <font style="color:#000000;">[***]</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.13 A<font style="font-size:9.5pt;">PPLICABLE </font>L<font style="font-size:9.5pt;">AW AND </font>S<font style="font-size:9.5pt;">ETTLEMENT OF </font>D<font style="font-size:9.5pt;">ISPUTES </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.13.1<font style="margin-left:36pt;"></font>This APA shall be governed by the laws of Belgium.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">4</sup></font></font></p></td>
<td valign="top" style="width:92.02%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;font-size:8pt;">This article must be adapted with care. In particular where the FWC is in essence only a licence on pre-existing materials (with no actual production of new materials specifically for the Union), as is the case for instance for a subscription contract to a database service provider, this article must be adapted accordingly. All information is in the Explanatory note on IPR on: </font><font style="font-size:8pt;">http://myintracomm.ec.testa.eu/budgweb/EN/imp/procurement/Documents/ipr-note-en.pdf</font><font style="text-decoration:underline;color:#0000FF;font-size:8pt;">.</font><font style="color:#0000FF;font-size:8pt;"> </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.14 O<font style="font-size:9.5pt;">THER </font>S<font style="font-size:9.5pt;">PECIAL </font>C<font style="font-size:9.5pt;">ONDITIONS</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor shall keep the Commission and the Participating Member States informed <font style="color:#000000;">[***]</font> during the pharmacovigilance or vaccine monitoring programmes in relation to the Vaccines which are the object of this APA <font style="color:#000000;">[***]</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Signature page follows)</p><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:49.19%;"></td>
<td style="width:2.66%;"></td>
<td style="width:48.15%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the Contractor,</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the Commission, on behalf and in the name of the Participating Member States,</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stella Kyriakides</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commissioner of Health and Food Safety</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature:</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature:</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Done at&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Done at&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In duplicate in English</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.<font style="margin-left:36pt;">GENERAL CONDITIONS FOR THE FRAMEWORK CONTRACT</font></p>
<p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;margin-left:43.08%;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">FOR SERVICES</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.1 D<font style="font-size:9.5pt;">EFINITIONS</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All definitions are contained in Article I.2</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.2 R<font style="font-size:9.5pt;">OLES AND RESPONSIBILITIES IN THE EVENT OF A JOINT TENDER</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of a joint tender submitted by a group of economic operators and where the group does not have legal personality or legal capacity, one member of the group is appointed as leader of the group.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.3 S<font style="font-size:9.5pt;">EVERABILITY</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each provision of this APA is severable and distinct from the others. If a provision is or becomes illegal, invalid or unenforceable to any extent, it must be severed from the remainder of the APA. This does not affect the legality, validity or enforceability of any other provisions of the APA, which continue in full force and effect. The illegal, invalid or unenforceable provision must be replaced by a legal, valid and enforceable substitute provision which corresponds as closely as possible with the actual intent of the parties under the illegal, invalid or unenforceable provision. The replacement of such a provision must be made in good faith between the parties. The APA must be interpreted as if it had contained the substitute provision as from its entry into force.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.4 P<font style="font-size:9.5pt;">ROVISION OF SERVICES AND SUPPLIES</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.4.1</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">All periods specified in the APA are calculated in calendar days, unless otherwise specified.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.4.2</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Contractor must immediately inform the Commission of any changes in the exclusion situations as declared, according to Article 137 (1) of Regulation (EU) 2018/1046.</p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.5 C<font style="font-size:9.5pt;">OMMUNICATION BETWEEN THE PARTIES</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.5.1 Form and means of communication</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any communication of information, notices or documents under the APA must:</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.98%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>be made in writing in paper or electronic format in the language of the contract;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.98%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>bear the APA number and, if applicable, the Vaccine Order Form number;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.98%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>be made using the relevant communication details set out in Article I.9; and</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.98%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>be sent by mail or email.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a party requests written confirmation of an e-mail within a reasonable time, the other party must provide an original signed paper version of the communication as soon as possible.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The parties agree that any communication made by email has full legal effect and is admissible as evidence in judicial proceedings.</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.5.2 Date of communications by mail and email</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any communication is deemed to have been made when the receiving party receives it, unless this APA refers to the date when the communication was sent.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E-mail is deemed to have been received by the receiving party on the day of dispatch of that email, provided that it is sent to the e-mail address indicated in Article I.9. The sending party must be able to prove the date of dispatch. In the event that the sending party receives a nondelivery report, it must make every effort to ensure that the other party actually receives the communication by email or mail. In such a case, the sending party is not held in breach of its obligation to send such communication within a specified deadline.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mail sent to the Commission or the Participating Member State is deemed to have been received on the date on which the department responsible referred to in Article I.9 registers it.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Formal notifications <font style="font-style:normal;">are considered to have been received by the receiving party on the date of receipt indicated in the proof received by the sending party that the message was delivered to the specified recipient.</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.6 L<font style="font-size:9.5pt;">IABILITY</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.6.1</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">During the term of this APA, <font style="color:#000000;">[***]</font>.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.6.2</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;">[***]</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.6.3</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Commission and the Participating Member States shall <font style="color:#000000;">[***]</font> to mitigate both (1) the damages that would otherwise be recoverable from the other pursuant to this APA and the Vaccine Order Forms, and (2) any costs, fees, expenses or losses that may be incurred by the Commission or the Participating Member State, or for which the Contractor may be responsible, under this APA and/or any Vaccine Order Form, by taking appropriate and reasonable actions to reduce or limit the amount of such damages, costs, fees, expenses or losses.</p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.6.4 Limits on liability</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.86%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:0.12%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Taking into account the unprecedented nature of the current COVID-19</p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:15.95%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">situation and the exceptional circumstances under which the Vaccine shall be delivered, the parties explicitly agree that <font style="color:#000000;">[***].</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;">[***]</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The aggregate liability of the Contractor and its Affiliates towards the Commission arising out of or relating to this APA and/or the Vaccine Order Forms (whether arising contractually or extracontractually), shall not exceed <font style="color:#000000;">[***]. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate liability of the Contractor and its Affiliates towards any of the Participating Member States arising out of or relating to this APA and/or the Vaccine Order Form concluded with that Participating Member State (whether arising contractually or </font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">extracontractually</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">), shall not exceed </font><font style="color:#000000;">[***]</font><font style="color:#000000;">.</font></p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:15.95%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.6.5 No limitation of liability</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.98%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;">Nothing in this APA excludes or limits the liability of either party for:</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.98%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.6.6 Waiver of sovereign immunity</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Participating Member State represents that it has adequate statutory or regulatory authority and adequate funding appropriation to undertake and completely fulfil the indemnification obligations pursuant to Article I.12 of this APA.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.6.7 Recall</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of a recall of the Vaccine, <font style="color:#000000;">[***]</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.7 C<font style="font-size:9.5pt;">ONFLICT OF INTEREST AND PROFESSIONAL CONFLICTING INTERESTS</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.7.1</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Contractor must take all the necessary measures to prevent any situation of <font style="font-style:italic;">conflict of interest or professional conflicting interest</font>.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.7.2</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Contractor must <font style="font-style:italic;">notify </font>the Commission in writing as soon as possible of any situation that could constitute a <font style="font-style:italic;">conflict of interest or a professional conflicting interest </font>during the Implementation of the APA. The Contractor must immediately take action to rectify the situation.</p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.98%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission may do any of the following:</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:7.98%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>verify that the Contractor&#8217;s action is appropriate;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.98%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>require the Contractor to take further action within a specified deadline;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:7.98%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>decide not to award a Vaccine Order Form to the Contractor. II.7.3 The Contractor must pass on all the relevant obligations in writing to:</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.98%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>its personnel which is directly involved in the performance of this APA;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.98%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>any natural person with the power to represent it or take decisions on its behalf;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.98%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>third parties involved in the Implementation of the APA, including subcontractors.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor must also ensure that the persons referred to above are not placed in a situation which could give rise to conflicts of interest.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.8 Representations and warranties</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.8.1 Mutual representations and warranties</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The parties each represent and warrant to each other the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Organization and authority. They have full right, power and authority to enter into this APA and to perform their respective obligations under this APA;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">No conflicts or violations. The execution and delivery of this APA by such party and the performance of such party&#8217;s obligations hereunder (i) do not conflict with or violate any laws existing as of the date of entry into force of the APA and applicable to such party and (ii) do not conflict with, violate, breach or constitute a default under, and are not prohibited or materially restricted by, any contractual obligations of such party existing as of the date of entry into force of the APA; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Valid execution. Such party is duly authorised to execute and deliver this APA, and the person executing this APA on behalf of such party is duly authorised to execute and bind such party to the terms set forth herein.</p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.98%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above warranties shall also be given by the Participating Member States in respect of the Vaccine Orders Forms and their obligations contained therein.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.8.2 Warranties of either party</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor warrants to the Commission and the Participating Member States that:</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of any breach of the Contractor&#8217;s warranties or undertakings relating to the Vaccine, the Commission&#8217;s and the Participating Member States&#8217; <font style="color:#000000;">[***]</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission warrants that the APA is awarded and each Vaccine Order Form is concluded in accordance with applicable Laws.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.8.3 Anti-bribery/anti-corruption</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The parties represent and warrant that, beyond the mutual consideration set forth in this APA, neither they nor their agents have provided or requested, or will provide or request, any additional incentive or benefit to or from the other party or its agents to induce either party to enter into this APA or perform any part of this APA.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor has not made, and will not make, in the performance of this APA directly or indirectly any payment, offer, promise, or authorisation of payment of money or anything of value to a government official, political party, candidate for political office, or any other person, and has not sought and will not seek improperly or corruptly to influence any government official, political party, candidate for political office, or any other person, in order to gain an improper business advantage.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.8.4 No other warranty</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except to the extent set out expressly in this APA, all conditions, warranties or other terms which might have effect between the parties or be implied or incorporated into this APA (whether by statute, common law or otherwise) are hereby excluded to the fullest extent permitted by applicable Law. <font style="color:#000000;">[***]</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.9 C<font style="font-size:9.5pt;">ONFIDENTIALITY</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.9.1</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Neither the Commission, a Participating Member State nor the Contractor shall, at any time, without the disclosing party&#8217;s prior written consent, disclose to any third party any of the other party&#8217;s Confidential Information.</p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.9.2<font style="margin-left:36pt;"></font>The Commission, the Participating Member State and the Contractor shall:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">use such Confidential Information solely for the purposes for which it was provided;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">take all reasonable precautions to prevent any unauthorised use or disclosure;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">not disclose or distribute any Confidential Information to any third party except as and to the extent authorised in writing to do so by the disclosing party.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.9.3</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The receiving party shall be permitted to disclose Confidential Information that is required or requested to be disclosed by a governmental authority pursuant to applicable law in connection with any other legal or administrative proceeding, provided that it (i) notifies the disclosing party of any such disclosure requirement or request as soon as practicable and (ii) furnishes only that portion of the Confidential Information which, in the opinion of the receiving party or their legal counsel, is responsive to such requirement or request and (iii) asks the court or other public body, if applicable, to treat the Confidential Information as confidential.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.9.4</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The receiving party shall disclose Confidential Information only to such of its representatives who have a need to know such Confidential Information to fulfil its obligations under this APA; provided, however, before any disclosure of Confidential Information, the receiving party shall bind its representatives receiving such Confidential Information to a written agreement of confidentiality at least as restrictive as contained in this APA; and prior to any disclosure, the receiving party shall instruct its representatives of the confidential nature of, and to maintain the confidentiality of, the Confidential Information. The receiving party shall be responsible for all actions of its representatives, including any breach of the terms hereof, regardless of whether or not such representatives remain employed or in contractual privity with the receiving party.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.9.5</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Notwithstanding the foregoing, in all cases, <font style="color:#000000;">[***]</font>, and (b) the Contractor may disclose Confidential Information to their Affiliates without prior written consent of the Participating Member States.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.9.6</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The confidentiality obligations set out in this Article II.9 are binding on the Commission, the Participating Member State and the Contractor during the </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Implementation of the APA and for as long as the information or documents remain confidential unless:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">the disclosing party agrees to release the receiving party from the confidentiality obligation earlier;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">the Confidential Information or documents become public through other means than a breach of the confidentiality obligation;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">the applicable Law requires the disclosure of the Confidential Information or documents.</p></td></tr></table></div>
<p style="margin-top:11pt;text-align:justify;margin-bottom:0pt;margin-left:7.98%;text-indent:-7.98%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.9.7 The Contractor must obtain from any natural person with the power to represent it or take decisions on its behalf, as well as from third parties involved in the Implementation of the APA a commitment that they will comply with this Article. At the request of the Commission, the Contractor must provide a document providing evidence of this commitment.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.98%;text-indent:-7.98%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.9.8 Neither this APA nor the performance by either party hereunder shall transfer to the receiving party any proprietary right, title, interest or claim in or to any of the disclosing party&#8217;s Confidential Information (including, but not limited to, any intellectual property rights subsisting therein) or be construed as granting a license in its Confidential Information.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.98%;text-indent:-7.98%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.9.9 The provisions of this Article II.9 shall survive the termination or expiration of this APA for [***], except with respect to any information that constitutes a trade secret (as defined by the applicable Law), in which case the recipient of such information will continue to be bound by its obligations under this Article II.9 for so long as such information continues to constitute a trade secret, but in no event for a period of less than <font style="color:#000000;">[***]</font> specified above.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.98%;text-indent:-7.98%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.9.10 The Contractor acknowledges that the Commission is subject to requirements laid down under Regulation (EC) 1049/2001.The Commission commits that it will consult with the Contractor on any disclosure request concerning documents containing Confidential Information as provided for in Article 4(4) of said Regulation.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.10 A<font style="font-size:9.5pt;">NNOUNCEMENTS AND PUBLICITY</font></p>
<p style="margin-top:11pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The parties shall consult together on the timing, contents and manner of any press release relating to the execution of this APA. Other than the foregoing, no party shall make, or permit any person to make, any public announcement concerning the existence, subject matter or terms of this APA or a Vaccine Order Form, the wider transactions contemplated by them, or the relationship between the parties, without the prior written consent of the other party (such consent not to be unreasonably withheld or delayed), except (i) as required by law, any governmental or regulatory authority (including, without limitation, any relevant securities exchange), any court or other authority of competent jurisdiction; or (ii) on terms that are consistent and do not go further than the matters covered in any agreed press release. For clarity, unless consent is granted pursuant to this clause II.10, no announcement or disclosure will include or infer <font style="color:#000000;">[***]</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A party shall not use the name, trade name, service marks, trademarks, trade dress or logos of the other party in publicity releases, advertising or any other publication, without the other party&#8217;s prior written consent in each instance, provided, however, that consent is granted for public announcements pursuant to above sub-clause (ii) in this Article II.10.</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.11 P<font style="font-size:9.5pt;">ROCESSING OF PERSONAL DATA</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.11.1 Processing of personal data by the Commission</p>
<p style="margin-top:11pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any personal data included in or relating to the APA, including its implementation, shall be processed in accordance with Regulation (EU) 2018/1725. Such data shall be processed solely for the purposes of the implementation, management and monitoring of the APA by the data controller. For the purpose of this provision, the data controller for the Commission shall be the Director-General of the European Commission's Directorate-General for Health and Food Safety. The data protection notice <font style="color:#000000;">is available at</font><font style="text-decoration:underline;color:#000000;"> </font><font style="color:#000000;">https://ec.europa.eu/info/data-protection-public-procurement-procedures</font><font style="text-decoration:underline;color:#000000;"> </font><font style="color:#000000;">en.</font><font style="text-decoration:underline;color:#000000;"> </font></p>
<p style="margin-top:11pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor or any other person whose personal data is processed by the data controller in relation to this APA has specific rights as a data subject under Chapter III (Articles 14-25) of Regulation (EU) 2018/1725, in particular the right to access, rectify or erase their personal data and the right to restrict or, where applicable, the right to object to processing or the right to data portability.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should the Contractor or any other person whose personal data is processed in relation to this APA have any queries concerning the processing of its personal data, it shall address itself to the data controller. They may also address themselves to the Data Protection Officer of the data controller. They have the right to lodge a complaint at any time to the European Data Protection Supervisor.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.11.2 Processing of personal data by the Contractor</p>
<p style="margin-top:11pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The processing of personal data by the Contractor shall meet the requirements of Regulation (EU) 2016/679 and be processed solely for the purposes set out by the Controller.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.12 S<font style="font-size:9.5pt;">UBCONTRACTING</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:11pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.12.1</font></p></td>
<td valign="top">
<p style="margin-top:11pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Contractor may not subcontract and have the APA implemented by third parties beyond the third parties already mentioned in its tender without <font style="color:#000000;">[***]</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.12.2</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">In the case of subcontracting, the Contractor remains bound by its contractual obligations and is solely responsible for the <font style="font-style:italic;">Implementation of the APA</font>.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.12.3</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Contractor must ensure that the subcontract does not affect the rights of the Commission and the Participating Member States under this APA.</p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.98%;text-indent:-7.98%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.13 A<font style="font-size:9.5pt;">MENDMENTS</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:11pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.13.1</font></p></td>
<td valign="top">
<p style="margin-top:11pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any amendment to the APA or a Vaccine Order Form must be made in writing before all contractual obligations have been fulfilled. A Vaccine Order Form does not constitute an amendment to the APA.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.13.2</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">No amendment can make changes to the APA or a Vaccine Order Form that might alter the initial conditions of the procurement procedure or result in unequal treatment of tenderers or contractors.</p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.14 A<font style="font-size:9.5pt;">SSIGNMENT</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neither this APA nor any interest hereunder will be assignable by a party without the prior written consent of the other party, except as follows: <font style="color:#000000;">[***].</font> </p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.15 F<font style="font-size:9.5pt;">ORCE MAJEURE</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.15.1</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">If a party is affected by <font style="font-style:italic;">Force majeure</font>, it must immediately <font style="font-style:italic;">notify </font>the other party, stating the nature of the circumstances, their likely duration and foreseeable effects.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.15.2</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">A party is not liable for any delay or failure to perform its obligations under the APA or Vaccine Order Form if that delay or failure is a <font style="font-style:italic;">result of Force majeure</font>. <font style="color:#000000;">[***].</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.15.3</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The parties must take all necessary measures to limit any damage due to <font style="font-style:italic;">Force majeure </font>and shall use commercially reasonable efforts to avoid or minimize the delay in performance of their respective obligations affected by <font style="font-style:italic;">Force majeure</font>.</p></td></tr></table></div>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.16 S<font style="font-size:9.5pt;">USPENSION OF THE IMPLEMENTATION OF THE </font>APA </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.16.1 Suspension by the Contractor</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Contractor or a Participating Contractor Affiliate is affected by <font style="font-style:italic;">Force majeure</font>, it may suspend the provision of the services under a Vaccine Order Form.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor or the Participating Contractor Affiliate must immediately <font style="font-style:italic;">notify </font>the Commission of the suspension. The <font style="font-style:italic;">notification </font>must include a description of the <font style="font-style:italic;">Force majeure </font>and state when the Contractor or the Participating Contractor Affiliate expects to resume the provision of services.</p>
<p style="margin-top:11pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor or the Participating Contractor Affiliate must <font style="font-style:italic;">notify </font>the Commission as soon as it is able to resume <font style="font-style:italic;">performance of the </font>Vaccine Order Form, unless the Commission has already terminated the APA or the Vaccine Order Form.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.16.2 Suspension by the Commission or the Participating Member State</p>
<p style="margin-top:11pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Financial Regulation, the Commission or the Participating Member State may suspend the Implementation of the APA or performance of a Vaccine Order Form or any part of it:</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;">if the procedure for awarding the APA or a Vaccine Order Form or the Implementation</font> of the APA proves to have been subject to Irregularities, Fraud (in the sense of the Financial Regulation) or breach of obligations;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in order to verify whether the presumed Irregularities, Fraud (in the sense of the Financial Regulation) or breach of obligations have </font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">actually occurred</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission or the Participating Member State in question must formally notify the Contractor of the suspension and the reasons for it. Suspension takes effect on the date of formal notification, or at a later date if the formal notification so provides.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission or the Participating Member State in question must notify the Contractor as soon as the verification is completed whether:</p>
<p style="margin-top:11pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;">it is lifting the suspension; or</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">it intends to terminate the APA or a Vaccine Order Form under Article II.17.1, (f) or (i).</p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor is not entitled to compensation for suspension of any part of the APA or a Vaccine Order Form. For the avoidance of doubt, the Contractor shall not be under any obligation to deliver any Contracted Doses during the suspension period, and the Delivery Schedule shall be adjusted to take into account the period of such suspension. Equally for the avoidance of doubt, the Contractor shall complete the delivery of any Contracted Doses that were already in transit on the date of the formal notification or at the later date indicated in the formal notification.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.17 T<font style="font-size:9.5pt;">ERMINATION OF THE </font>APA</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.17.1 Grounds for termination by the Commission</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission may terminate the APA or the Participating Member State may terminate any on-going Vaccine Order Form (depending on whether the event affects the APA or the Vaccine Order Form) solely in the following circumstances:</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>[***]</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>if the Contractor does not implement the APA or perform the Vaccine Order Form in accordance with material aspects of the APA or the Vaccine Order Form (as applicable) or is otherwise in material breach of another substantial contractual obligation;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;">[***]</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>if the Contractor or any person that assumes unlimited liability for the debts of the Contractor is in one of the situations provided for in points (a) and (b) of Article 136(1) of the Financial Regulation<sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup>;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">if the Contractor or any Related person is in one of the situations provided for in points</p></td></tr></table></div>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup>&nbsp;</font>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;font-size:8pt;">Regulation (EU, Euratom) 2018/1046 of the European Parliament and of the Council of 18 July 2018 on the financial rules</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.02%;margin-left:7.98%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-top:1pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">applicable to the general budget of the Union, amending Regulations (EU) No 1296/2013, (EU) No 1301/2013, (EU) No 1303/2013, (EU) No 1304/2013, (EU) No 1309/2013, (EU) No 1316/2013, (EU) No 223/2014, (EU) No 283/2014, and Decision No 541/2014/EU and repealing Regulation (EU, Euratom) No 966/2012, OJ L 193 of 30.7.2018, p.1</font><font style="text-decoration:underline;color:#0000FF;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1544791836334&amp;uri=CELEX:32018R1046</font><font style="color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-top:1pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;color:#0000FF;"></font><font style="color:#000000;"></font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.98%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) to (h) of Article 136(1) or Article 136(2) of the Financial Regulation;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">if the procedure for awarding the APA or the Implementation of the APA prove to have been subject to Irregularities, Fraud (in the sense of the Financial Regulation) or breach of obligations;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">if the Contractor is in a situation that does constitute a Conflict of interest or a Professional conflicting interest which would have a material adverse impact on the performance of the APA;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">in case of a change regarding the exclusion situations listed in Article 136 of Regulation (EU) 2018/1046 that calls into question the decision to award the contract;</p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>[***]</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.17.2 Grounds for termination by the Contractor</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor may terminate the APA or any on-going Vaccine Order Form solely in the following circumstances:</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>if the Commission or the Participating Member State does not implement the APA or perform the Vaccine Order Form in accordance with material aspects of the APA or the Vaccine Order Form (as applicable) or is otherwise in material breach of another substantial contractual obligation, <font style="color:#000000;">[***].</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>[***].</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.17.3 Procedure for termination</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A party must <font style="font-style:italic;">formally notify </font>the other party of its intention to terminate the APA or a Vaccine Order Form and the grounds for termination.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The other party <font style="color:#000000;">[***]</font> following the date of receipt to submit observations, including the measures it has taken or will take to continue fulfilling its contractual obligations. Failing that, the decision to terminate becomes enforceable the day after the time limit for submitting observations has elapsed in the event the grounds giving rise to termination have not been cured.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the other party submits observations, the party intending to terminate must <font style="font-style:italic;">formally notify </font>it.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.17.4 Effects of termination</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within <font style="color:#000000;">[***]</font> date of termination, the Contractor must submit any invoice required for services that were provided before the date of termination. <font style="color:#000000;">[***].</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The termination or expiration of this APA shall not affect the survival and continuing validity of Articles I.1, I.2, I.4, I.6.7, I.6.9, I.6.11, I.6.12, I.6.14, I.6.16, I.7 to I.9, I.11 to I.14, II.3, II.5, II.6, II.8.2, II.8.4, II.9 to II.11, II.15, II.17.4, II.18 to II.28, Attachment 3 (Delivery Specification) and Attachment 5 (Return and Disposal of Product Materials) or of any other provision which is expressly or by implication intended to continue in force after such termination or expiration.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expiry or termination of this APA for any reason shall be without prejudice to either party&#8217;s other rights and remedies or to any accrued rights and liabilities as the date of such expiry or termination; </font><font style="color:#000000;">[***]</font><font style="color:#000000;">.</font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.18 I<font style="font-size:9.5pt;">NVOICES</font>, <font style="font-size:9.5pt;">VALUE ADDED TAX AND E</font>-<font style="font-size:9.5pt;">INVOICING </font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.18.1 Invoices and value added tax</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Invoices must contain the Contractor&#8217;s or the Participating Contractor Affiliate&#8217;s (or leader&#8217;s in the case of a joint tender) identification data, the amount, the currency and the date, as well as the APA reference and reference to the Vaccine Order Form.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Invoices must indicate the place of taxation of the Contractor or the Participating Contractor Affiliate (or leader in the case of a joint tender) for value added tax (VAT) purposes and must specify separately amounts not including VAT and amounts including VAT.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission is exempt from all taxes and duties, including VAT, in accordance with Articles 3 and 4 of the Protocol 7 of the Treaty on the Functioning of the European Union on the privileges and immunities of the European Union.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is understood and agreed between the parties that any prices stated under this APA and Vaccine Order Form are exclusive of any VAT or similar tax and all other taxes which are incurred as a result of manufacturing and supplying the Product (including custom duties, levies and charges and all local taxes) (<font style="font-weight:bold;">&#8220;Taxes&#8221;</font>), which shall be added thereon as applicable. Where Taxes are properly chargeable on any amounts payable under this APA or Vaccine Order Form, the party making the payment will pay the amount of Taxes, as specified on the invoice, in accordance with the laws and regulations of the country in which the Taxes are chargeable.</p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.19 P<font style="font-size:9.5pt;">AYMENTS AND GUARANTEES </font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.19.1 Date of payment</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The date of payment is deemed to be the date on which <font style="color:#000000;">[***]</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.19.2 Currency</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments are made in euros or, for non-Eurozone countries, the local functional currency of the Participating Member State. For non-Eurozone countries, the Vaccine Order Form shall set forth the Delivery Price in the local functional currency converted from euro at the exchange rate existing one (1) day prior to the Effective Date of the APA as of 4:00pm London time published in Bloomberg FX Fixings (BFIX), such rates being found via Bloomberg or the website <font style="color:#000000;">www.bloomberg.com/markets/currencies/fx-fixings.</font> </p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.19.3 Costs of transfer</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The costs of the transfer are borne as follows:</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Commission or the Participating Member State in question bears the costs of dispatch charged by its bank;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">the Contractor or the Participating Contractor Affiliate bears the costs of receipt charged by its bank;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">the party causing repetition of the transfer bears the costs for repeated transfer.</p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.19.4 Suspension of the time allowed for payment</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission or the Participating Member State in question may suspend the payment periods specified in Article I.8 at any time by <font style="font-style:italic;">notifying </font>the Contractor or the Participating Contractor Affiliate (or leader in the case of a joint tender) that its invoice cannot be processed. <font style="color:#000000;">[***]</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suspension takes effect on the date the Commission or the Participating Member State in question sends the <font style="font-style:italic;">notification</font>. The remaining payment period resumes from the date on which the requested information or revised documents are received or the necessary further verification, including on-the-spot checks, is carried out. <font style="color:#000000;">[***]</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.19.5 Interest on late payment</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On expiry of the payment periods specified in Article I.8, the Contractor or the Participating Contractor Affiliate (or leader in the case of a joint tender) is entitled to interest on late payment at the higher of (a) the rate applied by the European Central Bank for its main refinancing operations in euros (the reference rate) <font style="color:#000000;">[***]</font> (or such centralized bank reference rate set forth in the Vaccine Order Form) and (b) <font style="color:#000000;">[***]</font>%. The reference rate is the rate in force, as published in the C series of the <font style="font-style:italic;">Official Journal of the European Union</font>, on the first day of the month in which the payment period ends.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suspension of the payment period as provided for in Article II.19.4 is not considered as giving rise to late payment.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on late payment covers the period running from the day following the due date for payment up to and including the date of payment as defined in Article II.19.1.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.20 R<font style="font-size:9.5pt;">ECOVERY</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.20.1 Recovery procedure</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In all cases where the recovery procedure as described in the Financial Regulation applies, the parties shall follow the procedure set out in this Article.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before recovery, the Commission or the Participating Member State in question must formally notify the Contractor of its intention to recover the amount it claims, specifying the amount due and the reasons for recovery and inviting the Contractor to make any observations <font style="color:#000000;">[***]</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If no observations have been submitted or if, despite the observations submitted, the Commission or the Participating Member State in question decides to pursue the recovery procedure, it must confirm recovery by formally notifying a debit note to the Contractor, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">specifying the date of payment. The Contractor must pay in accordance with the provisions specified in the debit note.</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Contractor does not pay by the due date, the Commission or the Participating Member State in question may, after informing the Contractor in writing, recover the amounts due:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">by offsetting them against any amounts owed to the Contractor by the Commission or the Participating Member State in question;  by taking legal action.</p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.20.2 Interest on late payment</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Contractor does not honour the obligation to pay the amount due by the date set by the Commission or the Participating Member State in question, the amount due bears interest at the rate indicated in Article II.19.5. Interest on late payments will cover the period starting on the day after the due date for payment and ending on the date when the Commission or the Participating Member State in question receives the full amount owed.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any partial payment is first entered against charges and interest on late payment and then against the principal amount.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.21 C<font style="font-size:9.5pt;">HECKS AND AUDITS</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.21.1</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Commission and the European Anti-Fraud Office may check or require an audit on the Implementation of the APA. This may be carried out either by OLAF&#8217;s own staff or by any outside body authorised to do so on its behalf, provided that the auditor may not be a competitor of the Contractor.</p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.98%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Such checks and audits may be initiated at any moment during business hours during the provision of the services and up to <font style="color:#000000;">[***]</font> starting from the payment of the balance of the last specific contract issued under this APA.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.98%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The audit procedure is initiated on the date of receipt of the relevant letter sent by the Commission. Audits are carried out on a confidential basis.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.21.2</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Contractor must keep all original documents stored on any appropriate medium, including digitised originals if authorised under national law, for a period of <font style="color:#000000;">[***]</font> starting from the payment of the balance of the last specific contract issued under this APA.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.21.3</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Contractor must grant the appropriate right of access to sites and premises where the APA is implemented,<font style="color:#000000;"> [***]</font> needed to conduct such checks and audits. The Contractor must ensure that the information is readily available at the moment of the check or audit and, if so requested, that information is handed over in an appropriate format. The auditor must, insofar possible, comply with all applicable and reasonable security measures notified to Commission by the Contractor subject to this not creating any material obstacles for the performance of the auditor&#8217;s tasks.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.21.4</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">On the basis of the findings made during the audit, a provisional report is drawn up. The Commission or its authorised representative must send it to the Contractor, who has <font style="color:#000000;">[***]</font> following the date of receipt to submit observations. The Contractor must </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">receive the final report within </font><font style="color:#000000;">[***]</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">following the expiry of the deadline to submit observations.</font></p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.98%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the basis of the final audit findings, the Commission or the Participating Member State in question may recover all or part of the payments made in accordance with Article II.20 and may take any other measures which it considers necessary.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:34pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.21.5</font></p></td>
<td valign="top">
<p style="margin-top:34pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">In accordance with Council Regulation (Euratom, EC) No 2185/96 of 11 November 1996 concerning on-the-spot checks and inspection carried out by the Commission in order to protect the European Communities&#8217; financial interests against fraud and other irregularities and Regulation (EU, Euratom) No 883/2013 of the European Parliament and of the Council of 11 September 2013 concerning investigations conducted by the European Anti-Fraud Office, the European Anti-Fraud Office may carry out investigations, including on the spot checks and inspections, to establish whether there has been fraud, corruption or any other illegal activity under the contract affecting the financial interests of the Union. Findings arising from an investigation may lead to criminal prosecution under national law.</p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.98%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The investigations may be carried out at any moment during the provision of the services and up to <font style="color:#000000;">[***]</font> starting from the payment of the balance of the last specific contract issued under this APA.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.21.6</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Court of Auditors and the European Public Prosecutor&#8217;s Office established by Council Regulation (EU) 2017/19398 (&#8216;the EPPO&#8217;) have the same rights as the Commission, particularly right of access, for the purpose of checks, audits and investigations.</p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.22 R<font style="font-size:9.5pt;">ELATIONSHIP OF THE PARTIES</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The relationship hereby established between the Contractor and the Commission is solely that of independent contractors. Neither party has authority to act or make any agreements or representations on behalf of the other party. This APA is not intended to create, and shall not be construed as creating, between the parties, the relationship of principal and agent, employer and employee, joint venturers, co-partners, or any other such relationship, the existence of which is expressly denied.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.23 W<font style="font-size:9.5pt;">AIVER</font></p>
<p style="margin-top:11pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A waiver by any party of any term or condition of this APA in any instance shall not be deemed or construed to be a waiver of such term or condition for the future, or of any subsequent breach thereof. All remedies specified in this APA shall be cumulative and in addition to any other remedies provided at Law or in equity, except where expressly otherwise agreed.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.24 F<font style="font-size:9.5pt;">URTHER DOCUMENTS</font></p>
<p style="margin-top:11pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each party hereto agrees to execute such further documents and take such further steps as may be reasonably necessary or desirable to effectuate the purposes of this APA.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.25 H</font><font style="font-size:9.5pt;">EADINGS</font></p>
<p style="margin-top:11pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Headings of Articles or other parts of this APA are included herein for convenience of reference only and shall not constitute a part of this APA or change the meaning of this APA.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.26 E<font style="font-size:9.5pt;">LECTRONIC </font>D<font style="font-size:9.5pt;">ELIVERY AND </font>S<font style="font-size:9.5pt;">TORAGE</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delivery of a signed APA by reliable electronic means, including facsimile or email (with receipt electronically confirmed), shall be an effective method of delivery of the executed APA.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This APA may be stored by electronic means and either an original or an electronically stored copy of this APA can be used for all purposes, including in any proceeding to enforce the rights or obligations of the parties to this APA.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.27 E<font style="font-size:9.5pt;">NTIRE </font>A<font style="font-size:9.5pt;">GREEMENT</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This APA, together with any Annexes and Attachments, which are hereby incorporated by reference, constitute the entire agreement of the parties with respect to its subject matter and merges and supersedes all prior discussions and writings with respect to thereto.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.28 C<font style="font-size:9.5pt;">OSTS</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each party will bear its own legal costs in preparing and concluding this APA.</p><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:34pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">A</font><font style="text-decoration:underline;font-size:9pt;">NNEX </font><font style="text-decoration:underline;">I: V</font><font style="text-decoration:underline;font-size:9pt;">ACCINE </font><font style="text-decoration:underline;">O</font><font style="text-decoration:underline;font-size:9pt;">RDER </font><font style="text-decoration:underline;">F</font><font style="text-decoration:underline;font-size:9pt;">ORM</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Vaccine Order Form is submitted by:</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:3.99%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">The Government of [&#8226;]</font>] (the &#8220;<font style="font-weight:bold;">Participating Member State</font>&#8221;), represented for the purposes of signing this Vaccine Order Form by [<font style="font-style:italic;">forename, surname, function, department of authorising officer</font>],</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to:</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:4.79%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Add details for Contractor]</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participating Member State and Contractor are together referred to as the &#8220;<font style="font-weight:bold;">Parties</font>&#8221; and each individually as a &#8220;<font style="font-weight:bold;">Party</font>&#8221;.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:13pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:13pt;"><font style="font-size:12pt;">Contractor and the European Commission, acting on behalf of and in the name of the Participating Member States, entered into an Advance Purchase Agreement for the purchase and supply of Contractor&#8217;s Vaccine for EU Member States dated [&#8226;] 2020 (the &#8220;</font><font style="font-weight:bold;font-size:12pt;">APA</font><font style="font-size:12pt;">&#8221;), the terms of which are binding on the Participating Member States and must be read in conjunction with this Vaccine Order Form.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:13pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:13pt;"><font style="font-size:12pt;">The APA provides that each Participating Member State will submit to Contractor a Vaccine Order Form through which Contractor shall make available and deliver to the relevant Participating Member State a proportion of the Contracted Doses or Additional Order as applicable, in accordance with the allocation provided by the Commission pursuant to Article I.6.3 of the APA and at the price and conditions as set out in the APA.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:13pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:13pt;"><font style="font-size:12pt;">In accordance with Article I.5.2 of the APA, the [name of Participating Member State] hereby places its order for its full allocated portion of the Contracted Doses or Additional Order (as applicable).</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Article I</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subject matter</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">This Vaccine Order Form is submitted by [name of the Participating Member State] to Contractor in accordance with the terms of the APA, and forms an integral part of the APA. The terms and conditions of the APA are incorporated into this Vaccine Order Form by reference. In the event of contradiction between this Vaccine Order Form and the APA, the terms of the APA prevail regardless of any provision to the contrary. Any capitalised terms in this Vaccine Order Form will have the meaning attributed to them in the definitions list included in Article I.2 of the APA.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">This Vaccine Order Form relates to the order for the Participating Member State&#8217;s full allocated portion of the Contracted Doses or the relevant Additional Order (as applicable) as set out in the allocation provided by the Commission to Contractor pursuant to Article I.6.2 of the APA. The submission of this signed Vaccine Order Form </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by the Member State to Contractor constitutes a binding order by the Member State for the purchase of its full allocated portion of the Contracted Doses or the relevant Additional Order (as applicable) as follows</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:12.76%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">[Name of the Member State] will purchase [insert amount] number of doses of [Contracted Doses] [Additional Order] of the Vaccine, on the basis of the following delivery schedule: [<font style="color:#000000;">[***]</font>].</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:12.76%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Delivery Price of Contracted Doses is [insert price here] euros per dose excl. VAT.</p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:16.75%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total amount payable by the Participating Member State for the [Contracted Doses] [Additional Order] is [insert amount], excluding [insert applicable percentage]% VAT.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">By signature of this Vaccine Order Form, the undersigned Member State warrants to Contractor that:</p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:12.76%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a<font style="margin-left:36pt;">it is irrevocably and unconditionally bound by the terms of the APA (as concluded by the Commission on behalf and in the name of the Participating Member States), including the indemnification obligations and the liability, limitation of liability and exclusions terms set out therein;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:12.76%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b<font style="margin-left:36pt;">the provisions of the APA are enforceable against it in accordance with its terms;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:12.76%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c<font style="margin-left:36pt;">it shall indemnify the Indemnified Persons in accordance with Article I.12 (</font><font style="font-style:italic;">Indemnification</font>) of the APA;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:12.76%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d<font style="margin-left:36pt;">it has full right, power and authority to </font>enter into this Vaccine Order Form and to perform its respective obligations under it;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:12.76%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e<font style="margin-left:36pt;">the person executing this Vaccine Order Form is duly authorized to execute and bind the undersigned Participating Member State to the terms set forth herein and incorporated by reference.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;">[***].</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Participating Member State represents and warrants that all necessary permissions and approvals have been or will be obtained prior to the time for performance by the Participating Member State, to authorise performance of all of the obligations contained herein.</p></td></tr></table></div><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:14pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Article II</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delivery, Supply</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:24pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:24pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:24pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;"></font><font style="text-decoration:underline;">Delivery Address</font>. The Delivery Address for the Participating Member State is as follows:</p></td></tr></table></div>
<p style="margin-top:14pt;text-align:justify;margin-bottom:0pt;margin-left:16.75%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;font-size:12.5pt;">&#8226; </font><font style="font-style:italic;">- Member State to enter location of its distribution hub</font>]</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;"></font>Supply of the Products</p></td></tr></table></div>
<p style="margin-top:13pt;text-align:justify;margin-bottom:0pt;margin-left:8.77%;margin-right:6.2%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor shall supply the Products as further described in the APA: [<font style="font-weight:bold;">Note: </font>Include any additional details concerning the supply here.]</p>
<p style="text-align:center;margin-top:26pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Article III</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Invoices; Notices</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:13pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:13pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:13pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;"></font><font style="text-decoration:underline;">Invoice and Payments</font>. Contractor shall invoice the Participating Member State in accordance with the terms of the APA. All payments to Contractor or its designated Affiliate shall be made in accordance with the terms of the APA.</p></td></tr></table></div>
<p style="margin-top:13pt;text-align:justify;margin-bottom:0pt;margin-left:8.77%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment shall be made in the following currency pursuant to the provisions of Article II.19.2: [to be completed].</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:13pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:13pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:13pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;"></font><font style="text-decoration:underline;">Notice</font>. Any notice given under this Vaccine Order Form must a) be made in writing in English in paper or electronic format; b) bear the APA number and the number of this Vaccine Order Form; c) be made using the relevant communication details set out below with respect to the Member State and Contractor (as applicable); d) be sent by mail and email:</p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:13.56%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Participating <font style="text-decoration:underline;">Member State</font>:<font style="text-decoration:underline;"> </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:16.75%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Name of Participating Member State</font>]</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:16.75%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Full official address of Participating Member State</font>]</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Full name of addressee physical person (contact person)</font>]</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Function of addressee physical person (contact person)</font>]</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:16.75%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E-mail: [<font style="font-style:italic;">complete email of addressee physical person (contact person)</font>]</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Contractor</font>: <font style="text-decoration:underline;">[Add details] </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Article IV.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Entry into Force and Duration</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">This Vaccine Order Form shall enter into force on the date of signature by the Parties and will remain into force until termination of the APA, or if the APA expires, until the last delivery of Product <font style="color:#000000;">[***]</font>.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Article V.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Applicable Law and Settlement of Disputes</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">For the avoidance of doubt, Article I.13 (<font style="font-style:italic;">Applicable Law and Settlement of Disputes</font>) of the APA shall apply to any dispute arising out of the implementation of or in connection with this Vaccine Order Form and the Participating Member State irrevocably agrees to be bound by the provisions set out therein.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Signature page follows)</p><a name="_AEIOULastRenderedPageBreakAEIOU8"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:34pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</font></p>
<p style="text-align:left;margin-top:26pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the <font style="font-weight:bold;">Participating Member State</font>, </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">forename/surname/position</font>]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="top"  style="width:27.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature:</p></td>
<td valign="top"  style="width:0.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:72.5%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:27.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:72.5%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Done at [<font style="font-style:italic;">place</font>], [<font style="font-style:italic;">date</font>]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For acceptance of the Vaccine Order Form,</p>
<p style="margin-top:14pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Contractor],</p>
<p style="margin-top:14pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">forename/surname/position</font>]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="top"  style="width:9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:30%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:30%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Done at [<font style="font-style:italic;">place</font>], [<font style="font-style:italic;">date</font>]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The invoice will be paid only once the Contractor has returned the signed Vaccine Order Form.</p><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">ANNEX II: A</font><font style="text-decoration:underline;font-size:9pt;">GREEMENT BETWEEN THE </font><font style="text-decoration:underline;">C</font><font style="text-decoration:underline;font-size:9pt;">OMMISSION AND </font><font style="text-decoration:underline;">M</font><font style="text-decoration:underline;font-size:9pt;">EMBER </font><font style="text-decoration:underline;">S</font><font style="text-decoration:underline;font-size:9pt;">TATES ON </font><font style="text-decoration:underline;font-size:9pt;">PROCURING&nbsp;&nbsp;</font><font style="text-decoration:underline;">C</font><font style="text-decoration:underline;font-size:9pt;">OVID</font><font style="text-decoration:underline;">-19 </font><font style="text-decoration:underline;font-size:9pt;">VACCINES ON BEHALF OF THE </font><font style="text-decoration:underline;">M</font><font style="text-decoration:underline;font-size:9pt;">EMBER </font><font style="text-decoration:underline;">S</font><font style="text-decoration:underline;font-size:9pt;">TATES AND RELATED PROCEDURES</font><font style="text-decoration:underline;">, </font><font style="text-decoration:underline;font-size:9pt;">ANNEXED TO THE </font><font style="text-decoration:underline;">C</font><font style="text-decoration:underline;font-size:9pt;">OMMISSION </font><font style="text-decoration:underline;">D</font><font style="text-decoration:underline;font-size:9pt;">ECISION </font><font style="text-decoration:underline;">C(2020) 4192 </font><font style="text-decoration:underline;font-size:9pt;">FINAL OF </font><font style="text-decoration:underline;">18 J</font><font style="text-decoration:underline;font-size:9pt;">UNE </font><font style="text-decoration:underline;">2020 </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Agreement</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preamble</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Having regard to Article 4(5)(b) of Council regulation (EU) 2016/369 on the provision of emergency support within the Union1as amended by Council regulation (EU) 2020/521 of 14 April 2020 activating the emergency support under regulation (EU) 2016/369, and amending its provisions taking into account the COVID-19 outbreak (hereinafter &#8220;ESI&#8221; or &#8220;ESI regulation&#8221;);</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The European Commission (&#8220;the Commission&#8221;)</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following Member States: (XXX), hereinafter referred to as &#8220;the Participating Member States&#8221;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Together referred to as &#8220;the Parties&#8221;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agree on the Following:</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Article 1: Objective and mandate of the Commission</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the basis of the present agreement, the Commission is mandated to conclude, on behalf of the Participating Member States, Advance Purchase Agreements (&#8220;APA&#8221;) with vaccine manufacturers with the objective to procure vaccines for the purposes of combatting the COVID 19 pandemic at Union level.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Annex to this agreement sets out the negotiating directives for this purpose.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Article 2: Acquisition of vaccine doses</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is the Participating Member States, and not the Commission, that shall acquire vaccine doses from the manufacturers on the basis of the APAs unless otherwise agreed. All relevant vaccination policies shall therefore remain matters for the Participating Member States.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Article 3: APAs containing a right to acquire vaccine doses</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Where the Commission concludes an APA in conformity with the present agreement that provides the right for the Participating Member States to acquire vaccine doses, the use of such a right shall take place by means of the conclusion of contracts between the Participating Member States and the vaccine manufacturers. There shall be no obligation for any Participating Member State to conclude such a contract on the basis of the APA. The APA shall contain a clause to this end.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Article 4: APAs containing an obligation to acquire vaccine doses</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Where the Commission intends to conclude, in conformity with the present agreement, an APA containing an obligation to acquire vaccine doses, it shall inform the Participating Member</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">States of such intention and the detailed terms. In case a Participating Member State does not agree with the conclusion of an APA containing an obligation to acquire vaccine doses or its terms, it has the right to opt out by explicit notification to the Commission within 5 working days after the Commission has communicated its intention to conclude the APA. All Participating Member States not having opted out within the period of 5 working days are deemed to have authorised the Commission to negotiate and conclude the APA with the vaccine manufacturer in their name and on their behalf.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Article 5: The legally binding nature of APAs</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once concluded, the terms of the APA shall be legally binding on the Participating Member States, except for those who have exercised their right to opt out.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Article 6: Responsibility and liability</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The present Agreement regulates only the division of potential liability and indemnification between the Commission and the Participating Member States. It does not regulate the extent to or the conditions under which potential liability of the vaccine manufacturer may be taken over or indemnified under the APAs.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission shall be exclusively responsible for the procurement process and the conclusion of APAs including any liability arising out of the conduct of the negotiations.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Participating Member States acquiring a vaccine shall be responsible for the deployment and use of the vaccines under their national vaccination strategies, [and shall bear any liability associated with such use and deployment. This shall extend to and include any indemnification of vaccine manufacturers under the terms and conditions of the relevant APA for liability related to the use and deployment of vaccines normally borne by such manufacturer.]</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Article 7: Obligation not to negotiate separately</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By signing the present Agreement, the Participating Member States confirm their participation in the procedure and agree not to launch their own procedures for advance purchase of that vaccine with the same manufacturers.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In case an APA containing an obligation to acquire vaccine doses has been concluded with a specific manufacturer, the Member States having made use of the opt-out provided under the present Agreement can enter into separate negotiations with the same manufacturer after the APA under the present Agreement has been signed.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annex</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Initial considerations</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A permanent solution to the COVID-19 crisis is most likely to be brought about by the development and deployment of a safe and effective vaccine against the virus. Every month gained in the deployment of a vaccine will save many lives, many jobs and billions of euros.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therefore, it is the objective of the present Agreement that the EU takes steps to secure sufficient supplies of a safe and effective vaccine for Member States.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Structure and purpose of the procurement</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work on a COVID-19 vaccine is challenging for many reasons: the shortened development timeframe, the large upfront costs for manufacturers, the high failure rate during clinical trials. If vaccine producers follow their usual practice of making investments in production capacity only when they are sure of a viable product, this will result in considerably longer waiting times for a vaccine. Investments need to be made now in order to ensure that vaccines are being produced at the scale required as early as possible.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the present agreement, this challenge will be addressed through concluding EU-level Advance Purchase Agreements (&#8220;APA&#8221;) with vaccine manufacturers when necessary, to secure access to vaccine candidates where they are successful, including up-front EU financing to de-risk essential investments to increase the speed and scale of manufacturing successful vaccines. Funding for the up-front payments will come from the Emergency Support Instrument (ESI).</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Parties understand that developing a safe and effective vaccine is a highly complex process and the risk of failure in any such venture is very high. Therefore, the aim is to put in place APAs with a number of manufacturers of leading vaccine candidates, to maximise the chances of having access to at least one successful vaccine.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission will invite all vaccine manufacturers to manifest interest. In general, the Commission will give priority to negotiating specific APAs with those manufacturers that (a) have entered or have firm plans to enter clinical trials still in 2020, (b) have the capacity to develop a successful vaccine and (c) have a proven capacity to produce at scale already in 2021.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Process and governance</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to run the procurement centrally and efficiently, the European Commission will set up a steering board for the process subject to Article 6 of the present Agreement. It will be co-chaired by the European Commission and a Participating Member State with experience in the negotiations and production capacities for vaccines. The steering board will include senior officials from all Participating Member States to assist and provide guidance throughout the evaluation process.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The co-chairs of the steering board will propose a team of a limited number of experts with relevant experience for the ongoing negotiations from six Participating Member States with production capacities for vaccines. These experts will join with the European Commission in a negotiation team (&#8220;joint negotiation team&#8221;), which will work on a continuous basis as one </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unit. That joint negotiation team will start work immediately building on previous contacts with individual companies by the European Commission and Participating Member States. In order to launch negotiations with a specific manufacturer, there needs to be support from at least four Participating Member States. The joint negotiation team will make its best effort to take the advice of the steering board into account in the negotiations and will report back to the steering board on a regular basis on the progress made in negotiating with individual companies.</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For compliance with the applicable rules, all members of the steering board and the joint negotiation team will obtain the status of experts associated to the procurement process as provided in the Financial Regulation. Given their access to highly sensitive business information, all those members will be required to sign strict confidentiality and no-conflict-of-interest agreements.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assisted by the steering board, the European Commission will then decide which of the resulting APAs should be concluded, in particular if financing under ESI is insufficient to finance all relevant packages. The Commission will only consider those APAs for financing where at least four Participation Member States have expressed agreement. Before making any final decisions, the Commission</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will seek independent scientific advice on the state of progress and the available data on quality, safety and efficacy for the vaccine candidate in question.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should financing under ESI be insufficient, Participating Member States can decide to top up ESI funding to make up the gap to finance all packages. In such a case where there are opportunities to conclude further APAs but money from ESI is no longer sufficient, Participating Member States will have the opportunity to express their interest in such opportunities. If at least four Participating Member States express interest, those Participating Member States will make use of the possibility of a voluntary contribution to ESI to the required amount allowing the Commission to proceed with signing the APA only on behalf of those Member States that have expressed interest and contributed the funds to ESI.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For full transparency, the European Commission will report to the IPCR at least once every two weeks on overall progress more generally.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Advanced Purchase Agreements and conditions</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To conclude APAs, the joint negotiating team will negotiate funding packages with individual vaccine producers in return for the right to buy a specific number of vaccine doses in a given timeframe and at a certain price.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As outlined in the present Agreement, the European Commission also has the possibility to conclude APAs including an obligation to procure the vaccine if it becomes available, where the conditions (notably the pricing) of those APAs make this worthwhile and in line with the conditions in the present Agreement. If in such a case the distinction between upfront payments and purchase price is difficult to draw, the Commission will share the total cost related to the vaccine purchase but will in any case contribute no more than [50%] of the total cost.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Funding provided up front will be considered as an advance payment for any eventual purchase by Member States, thus reducing the amount that Member States will have to pay when eventually purchasing that vaccine.</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The up-front payments under the APAs shall be used by manufacturers to de-risk the necessary investments related to both vaccine development and clinical trials, and the preparation of the at-scale production capacity along the entire vaccine production value chain in the EU required for a rapid deployment of millions of doses of an eventual vaccine. The relevant payments should be structured according to the need of the manufacturer, but subject to the state of the vaccine development, in particular relying on transparency of the associated clinical data and its assessment, at the time of payment. This is in order to avoid obligations to pay in situations where the development work has shown a vaccine candidate likely to be unsuccessful.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The purchase price of the vaccine, as well as the amount of funding provided up front will take into account a transparent estimation of production costs (supported by independent audits where available), as well as the resources already granted from other public sources. Under the APA, the manufacturer can be asked to provide ex post proof supported by independent audits concerning the activities financed by these payments.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aim of the negotiation is to conclude APAs with individual companies under the best possible conditions. These APAs should specify details with respect to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Payments to be made, such as payment amounts, payment schedules, type of payments requested and the use of those payments related to de-risk investment, financing clinical trials, providing working capital and scaling-up production capacity;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-size:12pt;">Delivery details of the vaccine if successful, such as price per person immunised (or alternatively, number of doses required per person immunised and price per dose), quantity of doses to be delivered and delivery timeline following approval;</font></p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:23.93%;text-indent:-7.98%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-size:12pt;">Any other relevant conditions, such as production capacity built or used in the EU or liability arrangements.</font></p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For liability arrangements, the joint negotiation team will make its best effort to limit what is required by individual companies for the purpose of indemnification to be included in the terms and conditions of the APA.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The APAs will contain provisions to clarify the law applicable to both the APA and resulting purchase orders as well as the competent courts. The Participating Member States agree that each APA negotiated by the Commission on their behalf with a vaccine manufacturer will have the same applicable law for all Participating Member States, and that the courts corresponding to that applicable law will be competent to hear disputes arising from that APA.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When taking a decision to finance individual APAs, the European Commission, in consultation with the steering board, will take into account the following elements: any available data on quality, safety and efficacy of the vaccine at time of negotiation of the contract, speed of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delivery at scale, cost, risk-sharing, diversification of technologies, capacity to supply through development of production capacity within the EU, possible flexible future use of any capacity funded, engagement at an early stage with EU regulators with the intention to apply for an EU marketing </font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authorisation</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for the candidate vaccine(s), commitment to supply vulnerable countries.</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The procedure outlined above complies with the ESI Regulation and the Financial Regulation. The latter is aligned to the European procurement Directives, which also provide the basis for national procurement rules. Participating Member States may rely on the procedure run by the European Commission to directly purchase vaccines from the manufacturers as and when any of the vaccines becomes available based on the conditions laid down in the APA. Access to vaccine doses will be allocated to Participating Member States according to the population distribution key.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the negotiations with the pharmaceutical industry under the present Agreement, the Commission will promote a Covid-19 vaccine as a global public good. This promotion will include access for low and middle income countries to these vaccines in sufficient quantity and at low prices. The Commission will seek to promote related questions with the pharmaceutical industry regarding intellectual property sharing, especially when such IP has been developed with public support, in order to these objectives. Any vaccines available for purchase under the APAs concluded but not needed and purchased by Participating Member States can be made available to the global solidarity effort.</p><a name="_AEIOULastRenderedPageBreakAEIOU10"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:5pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">A</font><font style="text-decoration:underline;font-size:9pt;">NNEX </font><font style="text-decoration:underline;">III: P</font><font style="text-decoration:underline;font-size:9pt;">ARTICIPATING </font><font style="text-decoration:underline;">M</font><font style="text-decoration:underline;font-size:9pt;">EMBER </font><font style="text-decoration:underline;">S</font><font style="text-decoration:underline;font-size:9pt;">TATES</font></p>
<p style="margin-top:6pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany </p>
<p style="margin-top:6pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">France </p>
<p style="margin-top:6pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Italy</p>
<p style="margin-top:6pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Spain</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Austria </p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Greece </p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cyprus </p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Malta </p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denmark </p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sweden </p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finland </p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ireland </p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portugal </p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Belgium </p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Luxembourg </p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Netherlands </p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Poland </p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Romania </p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bulgaria </p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Slovenia </p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Croatia </p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Czech Republic </p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hungary </p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Slovakia </p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lithuania</p>
<p style="margin-top:6pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Latvia </p>
<p style="margin-top:6pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estonia</p><a name="_AEIOULastRenderedPageBreakAEIOU11"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">A</font><font style="text-decoration:underline;font-size:9pt;">NNEX </font><font style="text-decoration:underline;">IV:</font><font style="text-decoration:underline;"> SUBCONTRACTORS</font></p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p><a name="_AEIOULastRenderedPageBreakAEIOU12"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANTE/2020/C3/043 - SI2.838335</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:19pt;margin-top:37pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">A</font><font style="text-decoration:underline;font-size:9pt;">NNEX </font><font style="text-decoration:underline;">V </font><font style="text-decoration:underline;">&#8211; </font><font style="text-decoration:underline;">PARTICIPATING CONTRACTOR AFFILIATES</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.87%;">
<tr>
<td style="width:34.52%;"></td>
<td style="width:65.34%;"></td>
</tr>
<tr style="height:13.2pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:12.85%;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Country</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:14.62%;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Participating Contractor Affiliate</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Europe GmbH</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">France</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer SAS</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Italy</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer S.r.l.</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Spain</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer S.L.U.</p></td>
</tr>
<tr style="height:12.95pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Austria</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Corporation Austria GmbH</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Greece</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Hellas SA</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cyprus</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Hellas SA</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Malta</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Hellas SA</p></td>
</tr>
<tr style="height:12.95pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denmark</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer ApS</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sweden</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Innovations AB</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finland</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Finland Oy</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ireland</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Healthcare Ireland</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portugal</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Biofarmac&#234;utica Sociedade Unipessoal, Lda</p></td>
</tr>
<tr style="height:13pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Belgium</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer SA</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Luxembourg</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Luxembourg S.A.R.L.</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Netherlands</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer BV</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Poland</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Trading Polska sp. z o.o.</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Romania</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Romania SRL</p></td>
</tr>
<tr style="height:12.95pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bulgaria</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Export B.V.</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Slovenia</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Export B.V.</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Croatia</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Export B.V.</p></td>
</tr>
<tr style="height:25.65pt;">
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:11pt;text-align:justify;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Czech Republic</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer PFE, spol. s r.o.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After 1/12 shall be merged into Pfizer, spol. s r.o.</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hungary</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Gy&#243;gyszerkereskedelmi Kft.</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Slovakia</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Export B.V.</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lithuania</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Export B.V.</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Latvia</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Export B.V.</p></td>
</tr>
<tr style="height:13.45pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estonia</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Export B.V.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;"><font style="text-decoration:underline;">Attachment 1: Specifications</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]<font style="font-weight:bold;text-decoration:underline;font-variant: small-caps;">Attachment 2: Delivery Documentation</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;"><font style="text-decoration:underline;">Attachment 3: Delivery specifications</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;"><font style="text-decoration:underline;">Attachment 4: labelling and packaging specifications</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.52
<SEQUENCE>12
<FILENAME>bntx-ex452_415.htm
<DESCRIPTION>EX-4.52
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-ex452_415.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4.52</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSITIVE</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:center;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">THE SYMBOL &#8220;[***]&#8221; DENOTES PLACES WHERE CERTAIN</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:center;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:center;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:center;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">(ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:center;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">COMPANY IF PUBLICLY DISCLOSED</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:27.84%;">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><img src="g30rn3tljakw000001.jpg" title="" alt="" style="width:148px;height:77px;"></p></td>
<td valign="top"  style="width:72.16%;">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:12pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EUROPEAN COMMISSION<br /><font style="font-size:8pt;">Directorate-General for Health and Food Safety</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PURCHASE AGREEMENT (&#8220;PA&#8221;)<sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup><font style="text-decoration:none;color:#auto;font-size:11pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top"><strike Style="text-decoration:none;"></strike></sup></font> for the further development, production, <br />purchasing options and supply of the successful COVID-19 Vaccine for EU Member<br />States</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NUMBER &#8212; [<font style="font-style:italic;Background-color:#D9D9D9;">complete</font>]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">The European Commission</font>, acting on behalf and in the name of the Member States set out in Annex III (hereinafter referred to as &#8220;Participating Member States&#8221;),<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup><font style="text-decoration:none;color:#auto;font-size:11pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top"><strike Style="text-decoration:none;"></strike></sup></font>:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">being represented for the purposes of the signature of this PA by Ms Stella Kyriakides, Commissioner of Health and Food Safety</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on the one part and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Pfizer Inc.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Incorporated in Delaware (Registration Number 0383418) with its registered address at 235 East 42nd Street</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10017 New York City, NY (UNITED STATES)</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">appointed as the leader of the group by the members of the group that submitted the joint tender</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(hereinafter referred to as <font style="font-weight:bold;">&#8220;Pfizer&#8221;</font>)</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Manufacturing GmbH</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Registered with the commercial register of the lower court (<font style="font-style:italic;">Amtsgericht</font>) of Mainz, Germany under HRB <font style="Background-color:#E6E5EA;">47548</font>, with its registered address at An der Goldgrube 12</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:3pt;margin-bottom:3pt;text-align:justify;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-style:normal;text-decoration:none;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup></font>  </font></font></p></td>
<td valign="top" style="width:92.02%;">
<p style="margin-top:3pt;margin-bottom:3pt;text-align:justify;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"><font style="text-decoration:none;"></font><font style="color:#000000;">This PA is based on the agreement between the Commission and the Member States as approved by Commission Decision C(2020) 4192 final on approving the agreement with Member States on procuring Covid-19 vaccines on behalf of the Member States and related procedures.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:3pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-style:normal;text-decoration:none;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup></font>  </font></font></p></td>
<td valign="top" style="width:92.02%;">
<p style="margin-bottom:3pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"><font style="text-decoration:none;"></font><font style="color:#000000;">As provided for in Article 4(5)(b) of Council Regulation (EU) 2016/369 of 15 March 2016 on the provision of emergency support within the Union as amended by Council Regulation (EU) 2020/521 of 14 April 2020 activating the emergency support under Regulation (EU) 2016/369, and amending its provisions taking into account the COVID&#8208;19 outbreak.</font></p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55131 MAINZ, GERMANY</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(hereinafter referred to as <font style="font-weight:bold;">&#8220;BioNTech&#8221;</font>)</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as a member of the group (<font style="Background-color:#D9D9D9;">collectively</font> &#8216;<font style="font-weight:bold;">the Contractor&#8217;</font>), represented for the purposes of the signature of this PA which has the form of a framework contract by [***].</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on the other part,</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HAVE AGREED</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the <font style="font-weight:bold;">special conditions and the general conditions of this PA</font> and the following Annexes and Attachments:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annex I<font style="font-weight:normal;"> &#8211; Model for Vaccine Order Form</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annex II <font style="font-weight:normal;">&#8211; Agreement between the Commission and Member States on procuring Covid-19 vaccines on behalf of the Member States and related procedures, annexed to the Commission Decision C(2020) 4192 final of 18 June 2020</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annex III<font style="font-weight:normal;"> &#8211; Participating Member States</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annex IV<font style="font-weight:normal;"> &#8211; Subcontractors</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annex V<font style="font-weight:normal;"> &#8211; Participating Contractor Affiliates</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attachment 1 &#8211; Specifications</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attachment 2 &#8211; Delivery Documentation</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attachment 3 &#8211; Delivery Specification</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attachment 4 &#8211; Labelling and Packaging Specifications</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attachment 5 &#8211; Return and Disposal of Product Materials</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which form an integral part of this PA. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***].</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This PA sets out:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">the procedure and conditions by which the Participating Member States will pay for the services and/or supplies from the Contractor;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">the provisions that apply to any Vaccine Order Form which the Participating Member States and the Contractor may conclude under this PA; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">the obligations of the parties during and after the duration of this PA.</p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All documents issued by the Contractor (end-user agreements, general terms and conditions, etc.) except its tender are held inapplicable, unless explicitly mentioned in the special conditions of this PA. In all circumstances, in the event of contradiction between this PA and documents issued by the Contractor, this PA prevails, regardless of any provision to the contrary in the Contractor&#8217;s documents.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-variant: normal;font-weight:bold;font-style:normal;text-transform:none;"><font style="font-family:Times New Roman;font-variant: normal;border-bottom:double 2.5pt;font-style:normal;text-transform:none;">Table of Content</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="3" valign="top"  style="width:95.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENT</p></td>
<td valign="bottom"  style="width:4.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.32%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:38pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.</p></td>
<td colspan="2" valign="top"  style="width:90.4%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:36pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SPECIAL CONDITIONS</p></td>
<td valign="bottom"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.1</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Order of Priority of Provisions</p></td>
<td valign="bottom"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.2</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Definitions</p></td>
<td valign="bottom"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.3</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject Matter</p></td>
<td valign="bottom"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.4</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entry into force and duration of the APA</p></td>
<td valign="bottom"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.5</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Implementation of the APA</p></td>
<td valign="bottom"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.6</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supply of the Vaccine</p></td>
<td valign="bottom"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.7</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prices</p></td>
<td valign="bottom"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.8</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment Arrangements</p></td>
<td valign="bottom"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.9</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Communication Details</p></td>
<td valign="bottom"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.10</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Project management</p></td>
<td valign="top"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.11</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exploitation of the results of the APA</p></td>
<td valign="top"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.12</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indemnification</p></td>
<td valign="top"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.13</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Applicable Law and Settlement of Disputes</p></td>
<td valign="top"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.14</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other Special Conditions</p></td>
<td valign="top"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.32%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:38pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.</p></td>
<td colspan="2" valign="top"  style="width:90.4%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:36pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GENERAL CONDITIONS FOR THE FRAMEWORK CONTRACT FOR SERVICES</p></td>
<td valign="bottom"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.1</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Definitions</p></td>
<td valign="top"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.2</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roles and responsibilities in the event of a joint tender</p></td>
<td valign="top"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.3</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Severability</p></td>
<td valign="top"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.4</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision of services and supplies</p></td>
<td valign="top"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.5</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Communication between the parties</p></td>
<td valign="top"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.6</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liability</p></td>
<td valign="bottom"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.7</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conflict of interest and professional conflicting interests</p></td>
<td valign="bottom"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.8</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Representations and warranties</p></td>
<td valign="bottom"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.9</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidentiality</p></td>
<td valign="bottom"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.10</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Announcements and publicity</p></td>
<td valign="middle"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.11</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Processing of personal data</p></td>
<td valign="middle"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.12</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subcontracting</p></td>
<td valign="middle"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.13</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments</p></td>
<td valign="middle"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.14</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assignment</p></td>
<td valign="middle"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.15</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Force majeure</p></td>
<td valign="middle"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.16</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suspension of the implementation of the APA</p></td>
<td valign="middle"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
</tr></table></div>
<p style="margin-bottom:12pt;margin-top:12pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.17</font></p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Termination of the APA</p></td>
<td valign="middle"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.18</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Invoices, value added tax and e-invoicing</p></td>
<td valign="middle"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.19</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments and guarantees</p></td>
<td valign="middle"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.20</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recovery</p></td>
<td valign="middle"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.21</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Checks and audits</p></td>
<td valign="middle"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.22</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Relationship of the parties</p></td>
<td valign="middle"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.23</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Waiver</p></td>
<td valign="middle"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.24</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further documents</p></td>
<td valign="middle"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.25</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Headings</p></td>
<td valign="middle"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.26</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Electronic Delivery and Storage</p></td>
<td valign="middle"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.27</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entire Agreement</p></td>
<td valign="middle"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:13.3%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:72pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.28</p></td>
<td valign="top"  style="width:82.42%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:45pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs</p></td>
<td valign="middle"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:95.72%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANNEX I: MODEL FOR VACCINE ORDER FORM</p></td>
<td valign="bottom"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:95.72%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:36pt;;text-indent:-36pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANNEX II: AGREEMENT BETWEEN THE COMMISSION AND MEMBER STATES ON PROCURING COVID-19 VACCINES ON BEHALF OF THE MEMBER STATES AND RELATED PROCEDURES, ANNEXED TO THE COMMISSION DECISION C(2020) 4192 FINAL OF 18 JUNE 2020</p></td>
<td valign="bottom"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:95.72%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANNEX III: PARTICIPATING MEMBER STATES</p></td>
<td valign="bottom"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:95.72%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANNEX IV: SUBCONTRACTORS</p></td>
<td valign="bottom"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:95.72%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANNEX V PARTICIPATING CONTRACTOR AFFILIATES</p></td>
<td valign="bottom"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:95.72%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATTACHMENT 1: SPECIFICATION</p></td>
<td valign="bottom"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:95.72%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATTACHMENT 2: DELIVERY DOCUMENTATION</p></td>
<td valign="bottom"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:95.72%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATTACHMENT 3: DELIVERY SPECIFICATION</p></td>
<td valign="bottom"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:95.72%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATTACHMENT 4 : LABELLING AND PACKAGING SPECIFICATIONS</p></td>
<td valign="bottom"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:95.72%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATTACHMENT 5: RETURN AND DISPOSAL OF PRODUCT MATERIALS</p></td>
<td valign="bottom"  style="width:4.28%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;text-transform:uppercase;font-weight:bold;font-size:14pt;font-variant: small-caps;font-style:normal;"><font style="text-decoration:none;">I.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="border-bottom:double 2.5pt;text-transform:none;">Special Conditions </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">I.1<font style="margin-left:36pt;"></font>Order of Priority of Provisions</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If there is any conflict between different provisions in this PA, the following rules must be applied:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The provisions set out in the special conditions and Article II.6 of the general conditions (Liability) take precedence over those in the other parts of the PA.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The other provisions set out in the general conditions take precedence over those in the Annexes and Attachments.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The provisions set out in the PA take precedence over those in the Vaccine Order Forms.</p></td></tr></table></div>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">I.2<font style="margin-left:36pt;"></font>Definitions</p>
<p style="text-align:justify;margin-top:14pt;margin-bottom:0pt;margin-right:0.66%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following definitions shall apply to this PA:</p>
<p style="text-align:justify;margin-top:14pt;margin-bottom:0pt;margin-right:0.66%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Additional Order&#8217;<font style="font-weight:normal;">: has the meaning set forth in Article I.6.2;</font></p>
<p style="text-align:justify;margin-top:14pt;margin-bottom:0pt;margin-right:0.66%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Additional Product&#8217;<font style="font-weight:normal;">: has the meaning set forth in Article I.6.2;</font></p>
<p style="text-align:justify;margin-top:14pt;margin-bottom:0pt;margin-right:0.66%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Affiliate&#8217;:<font style="font-weight:normal;"> means in relation to a body corporate, any other entity which directly or indirectly Controls, is Controlled by, or is under direct or indirect common Control of that body corporate from time to time;</font></p>
<p style="text-align:justify;margin-top:14pt;margin-bottom:0pt;margin-right:0.66%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Authorisation&#8217;<font style="font-weight:normal;">: means a Conditional Marketing Authorisation and/or Marketing Authorisation that permits the Products to be placed on the market in the European Economic Area;</font></p>
<p style="text-align:justify;margin-top:14pt;margin-bottom:0pt;margin-right:0.66%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Best Reasonable Efforts&#8217;<font style="font-weight:normal;">: [***];</font></p>
<p style="text-align:justify;margin-top:14pt;margin-bottom:0pt;margin-right:0.66%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Conditional Marketing Authorisation&#8217;: <font style="font-weight:normal;">means a conditional marketing authorisation granted by the European Commission as referred to in Article 14-a of Regulation (EC) No 726/2004;</font></p>
<p style="text-align:justify;margin-top:14pt;margin-bottom:0pt;margin-right:0.66%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8216;<font style="font-weight:bold;">Confidential Information&#8217;</font>: means any information disclosed to or obtained by one party to the other party, either directly or indirectly, or which the disclosing party indicates in writing at the time of disclosure to, or receipt by, the recipient is to be considered confidential or proprietary, or which such recipient knows or ought reasonably to know is information of a confidential or proprietary nature, including the terms of this PA and any Vaccine Order Form. Confidential Information shall not include any information (i) the receiving party can prove was known to it prior to the date of disclosure; (ii) the receiving party can prove was lawfully obtained from a third party without any obligation of confidentiality; (iii) is or becomes part of the public domain other than through any act or omission of the receiving party; or (iv) is independently developed by the receiving party without use of or reference to the disclosing party&#8217;s Confidential Information, as evidenced by the receiving party&#8217;s records;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:14pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Conflict of interest&#8217;:</font><font style="font-weight:normal;"> a situation where the impartial and objective </font><font style="font-style:italic;font-weight:normal;">Implementation of the PA</font><font style="font-weight:normal;"> by the Contractor is compromised for reasons involving family, emotional life, political or national affinity, economic interest, any other direct or indirect personal interest, or any other shared interest with the Commission, the Participating Member State or any third party related to the subject matter of the PA;</font></p>
<p style="text-align:justify;margin-top:14pt;margin-bottom:0pt;margin-right:0.66%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Contracted Doses&#8217;<font style="font-weight:normal;">: has the meaning set forth in Article I.6.2;</font></p>
<p style="text-align:justify;margin-top:14pt;margin-bottom:0pt;margin-right:0.66%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Control&#8217;:<font style="font-weight:normal;"> means the possession by a person or an entity, directly or indirectly, of the power to direct or cause the direction of the management and policies of the other person or entity (whether through the ownership of voting shares, by contract or otherwise) and </font>"Controls"<font style="font-weight:normal;"> and </font>"Controlled"<font style="font-weight:normal;"> shall be interpreted accordingly;</font></p>
<p style="text-align:justify;margin-top:14pt;margin-bottom:0pt;margin-right:0.66%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Delivery Price&#8217;<font style="font-weight:normal;">: has the meaning set forth in Article I.8.2;</font></p>
<p style="text-align:justify;margin-top:14pt;margin-bottom:0pt;margin-right:0.66%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Delivery Schedule&#8217;<font style="font-weight:normal;">: has the meaning set forth in Article I.6.3</font></p>
<p style="text-align:justify;margin-top:14pt;margin-bottom:0pt;margin-right:0.66%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Effective Date&#8217;<font style="font-weight:normal;">: has the meaning set forth in Article I.4.1;</font></p>
<p style="margin-bottom:0pt;margin-top:14pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Force majeure&#8217;:<font style="font-weight:normal;"> any unforeseeable, exceptional situation or event beyond the reasonable control of the parties that prevents either of them from fulfilling any of their obligations under the PA [***];</font></p>
<p style="margin-bottom:0pt;margin-top:14pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Formal notification&#8217; <font style="font-weight:normal;">(or &#8216;formally notify&#8217;): form of communication between the parties made in writing by mail or email, which provides the sender with compelling evidence that the message was delivered to the specified recipient;</font></p>
<p style="margin-bottom:0pt;margin-top:14pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Fraud&#8217;:<font style="font-weight:normal;"> an act or omission committed in order to make an unlawful gain for the perpetrator or another by causing a loss to the Union's financial interests, and relating to: i) the use or presentation of false, incorrect or incomplete statements or documents, which has as its effect the misappropriation or wrongful retention of funds or assets from the Union budget, ii) the non-disclosure of information in violation of a specific obligation, with the same effect or iii) the misapplication of such funds or assets for purposes other than those for which they were originally granted, which damages the Union's financial interests, it being understood that the Union&#8217;s financial interests are impacted within the framework of this PA as the Union is engaging resources into the coordination and preparation of the PA, resulting from Decision C(2020) 4192 final of 18 June 2020 which approved the agreement with Member States on procuring COVID-19 vaccines on behalf of the Member States (&#8220;the Decision&#8221;), this agreement being based on Article 4(5)(b) of Regulation (EU) 2016/369 of 15 March 2016 on the provision of emergency support within the Union<sup style="font-size:85%;line-height:120%;vertical-align:top">3</sup></font><font style="font-weight:normal;text-decoration:none;color:#auto;font-size:11pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top"><strike Style="text-decoration:none;"></strike></sup></font><font style="font-weight:normal;"> (&#8220;the ESI Regulation&#8221;) ;</font></p>
<p style="text-align:justify;margin-top:14pt;margin-bottom:0pt;margin-right:0.66%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Good Manufacturing Practice&#8217;: <font style="font-weight:normal;">means the current practices for manufacture required by the standards, rules, principles and guidelines set out in Directive 2001/83/EC (as amended by Directive 2004/27/EC), Directive 2017/1572, Directive 2003/94/EC and EudraLex - Volume 4 of the Rules Governing Medicinal Products in the EU entitled &#8220;EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use&#8221;;</font></p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-top:3pt;margin-bottom:3pt;text-align:justify;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-style:normal;text-decoration:none;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">3</sup></font>  </font></font></p></td>
<td valign="top" style="width:92.02%;">
<p style="margin-top:3pt;margin-bottom:3pt;text-align:justify;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"><font style="text-decoration:none;"></font><font style="color:#000000;">OJ L 70, 16.3.2016, p.1, as amended by Council Regulation (EU) 2020/521 of 14 April 2020 activating the emergency support under Regulation (EU) 2016/369, and amending its provisions taking into account the COVID&#8208;19 outbreak, OJ L 117, 15.4.2020, p. 3.</font></p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Implementation of the PA&#8217;:<font style="font-weight:normal;"> the purchase of services or supplies envisaged in the PA through the signature and </font><font style="font-style:italic;font-weight:normal;">performance of </font><font style="font-weight:normal;">Vaccine Order Forms;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Indemnified Persons&#8217;:<font style="font-weight:normal;"> has the meaning set forth in Article I.12.1;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Irregularity&#8217;:<font style="font-weight:normal;"> any infringement of a provision of Union law resulting from an act or omission by the Contractor within the meaning of Article 1(2) of the Council (EC, Euratom) Regulation 2988/95 of 18 December 1995 </font><font style="Background-color:#FFFFFF;color:#000000;font-family:inherit;font-weight:normal;">on the protection of the European Communities financial interests (in OJ 23.12.95, L 312/1)</font><font style="font-weight:normal;"> , which has, or would have, the effect of prejudicing the Union&#8217;s budget, it being understood that the Union&#8217;s financial interests are impacted within the framework of this PA, as the Union is engaging resources into the coordination and preparation of the PA, resulting from the Decision which approved the agreement with Member States on procuring COVID-19 vaccines on behalf of the Member States, this agreement being based on Article 4(5)(b) of the ESI Regulation;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:14pt;margin-right:0.66%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:14pt;margin-right:0.66%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Latent Defect&#8217;<font style="font-weight:normal;">: means a defect causing the Product to not conform to the applicable Specifications that the relevant Participating Member State can show was present at the time of delivery of the Product and which could not have been detected by the Participating Member State, its designee, or their personnel at delivery through visual inspection;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:14pt;margin-right:0.66%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Law(s)&#8217;<font style="font-weight:normal;">: means, collectively, all applicable supranational, national and local laws, common laws, statutes, ordinances, codes, rules, regulations, orders, decrees or other pronouncements of any government, administrative or judicial authority having the effect of law;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Losses&#8217;:<font style="font-weight:normal;"> has the meaning set forth in Article I.12.1;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:14pt;margin-right:0.66%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Marketing Authorisation&#8217;<font style="font-weight:normal;">: means the marketing authorisation (other than Conditional Marketing Authorisation), in respect of the Product granted by the European Commission, as amended or varied from time to time, that allows the Product to be placed on the market in the European Economic Area according to applicable Law;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:14pt;margin-right:0.66%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Non-Complying Product&#8217;<font style="font-weight:normal;">: has the meaning set forth in Article I.6.14;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Notification&#8217;<font style="font-weight:normal;"> (or &#8216;notify&#8217;): form of communication between the parties made in writing including by electronic means;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:14pt;margin-right:0.66%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Participating Contractor Affiliate&#8217;<font style="font-weight:normal;">: means an Affiliate of Pfizer or BioNTech as identified in Annex V;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:14pt;margin-right:0.66%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Product&#8217;<font style="font-weight:normal;">: means the Vaccine;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:14pt;margin-right:0.66%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Product Materials&#8217;<font style="font-weight:normal;">: means all packaging materials and components needed for delivery of the Product;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Professional conflicting interest&#8217;:<font style="font-weight:normal;"> a situation in which the Contractor&#8217;s previous or ongoing professional activities affect its capacity to implement the PA or to perform a Vaccine Order Form to an appropriate quality standard;</font></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:14pt;margin-right:0.66%;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Record&#8217;:</font><font style="font-weight:normal;"> means books, documents, and other data, of all matters relating to performance of obligations under this PA;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Related person&#8217;:<font style="font-weight:normal;"> any natural or legal person who is a member of the administrative, management or supervisory body of the Contractor, or who has powers of representation, decision or control with regard to the Contractor;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Specifications&#8217;<font style="font-weight:normal;">: means the specifications for the manufacture, testing and testing procedures, and supply of the Product as set out in Attachment 1 (Specifications), and as such specifications may be amended, supplemented or otherwise modified by the Contractor and communicated to the Commission;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Taxes&#8217;:<font style="font-weight:normal;"> has the meaning set forth in Article II.18.1;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Term&#8217;<font style="font-weight:normal;">: means the term of the PA set out in Article I.4.2 of the PA; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Thermal Shipper&#8217;<font style="font-weight:normal;">: has the meaning set forth in Article I.6.8; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Third Party Claim&#8217;:<font style="font-weight:normal;"> has the meaning set forth in Article I.12.4.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Vaccine&#8217;<font style="font-weight:normal;">: the medicinal product, being </font><font style="font-weight:normal;color:#000000;">BNT162b2, a nucleoside-modified messenger RNA (mRNA) vaccine that encodes an optimized SARS-CoV-2 full-length spike glycoprotein (S) for which Authorisation has been granted, including any subsequent variations approved by the Commission. [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Vaccine IP Rights&#8217;<font style="font-weight:normal;">: has the meaning set forth in Article I.11; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8216;Vaccine Order Form<font style="font-weight:normal;">: has the meaning set forth in Article I.5.2.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except where the context expressly requires otherwise, (a) the use of any gender herein shall be deemed to encompass references to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b) the words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without limitation", (c) the word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall&#8221;, (d) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (e) any reference herein to any person shall be construed to include the person's successors and assigns, (f) the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;, and words of similar import, shall be construed to refer to this PA in its entirety and not to any particular provision hereof, (g) all references herein to Articles, Annexes or Attachments shall be construed to refer to Articles, Annexes or Attachments of this PA, and references to this PA include all Annexes and Attachments hereto, (h) the word &#8220;notice&#8221; means notice in writing or by email (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this PA, (i) provisions that require that a party or parties &#8220;agree&#8221;, &#8220;consent&#8221; or &#8220;approve&#8221; or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (including e-mail), (j) references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;"><font style="font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">I.3</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">Subject Matter</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The subject of the call for tenders SANTE/2021/C3/005 is securing the purchase of certain vaccine doses for the Participating Member States.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following the Decision, taken in accordance with Article&#160;4(5)(b) of the ESI Regulation, the Commission is running procurement procedures on behalf of Participating Member States, with a view to signing EU-level Advance Purchase Agreements (&#8220;APAs&#8221;) with vaccine manufacturers. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An APA between the Parties was signed on 20 November 2020. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In compliance with Article 164(l)(d) as well as Annex I, Point 11.1(c) of the Financial Regulation, the Commission launched on 12 January 2021 a negotiated procedure without prior publication of a contract notice for the procurement of additional doses of vaccines. This procedure was justified by the need to quickly secure additional doses of vaccines to reach a turning point in the epidemic. This PA is for such additional doses, and while it is organised following the Decision it is entirely separate from the APA between the Parties.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In view of its importance, this PA will be approved for signature on behalf and in the name of the Participating Member States by a separate individual Commission decision.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Conditional Marketing Authorisation for the Vaccine was granted on 21 December 2020.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission, on behalf of the Participating Member States, wishes to purchase the Vaccine during the pandemic period through this PA. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the basis of this PA, the European Commission commissions the Contractor to commit to produce and deliver 200 million doses of the Vaccine which shall be ordered by the Participating Member States (via specific Vaccine Order Forms) at the price and conditions, including timeframe, agreed under this PA, with the option to obtain a further 100 million doses of the Vaccine subject to the conditions set out in this PA.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor or a Participating Contractor Affiliate shall supply to the Participating Member States the agreed doses of the Vaccine pursuant to the Vaccine Order Forms. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Vaccine Order Forms shall be signed by the Contractor and shall incorporate by reference this PA.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">I.4<font style="margin-left:36pt;"></font>Entry into force and duration of the PA</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.4.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The PA enters into force on the date on which the last party signs it (<font style="font-weight:bold;">&#8220;Effective Date&#8221;</font>).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.4.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The PA is concluded for a period of eighteen (18) months with effect from the Effective Date (<font style="font-weight:bold;">&#8220;Term&#8221;</font>).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.4.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Contractor and the Participating Member States may not sign any Vaccine Order Form after the PA expires.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The PA continues to apply to such Vaccine Order Forms after its expiry. [***].</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.4.4</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Renewal of the PA </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The PA will expire automatically at the end of the Term, unless it is extended in mutual written agreement between the parties. Renewal does not change or postpone any existing obligations.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">I.5<font style="margin-left:36pt;"></font>Implementation of the PA </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.5.1<font style="font-weight:normal;margin-left:36pt;"></font>Period of provision of the supplies</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The period for the provision of the supplies starts to run as foreseen in Article I.6.3. </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.5.2<font style="font-weight:normal;margin-left:36pt;"></font>Implementation of the PA</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The PA shall be implemented following signature between the Commission and the Contractor as follows:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor shall use Best Reasonable Efforts to obtain manufacturing capacity or utilise existing capacity to be capable of manufacturing and supplying the Product to the Commission on behalf of the Participating Member States in accordance with the provisions of this PA.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor agrees to supply an initial total number of 200 million Vaccine doses to Participating Member States collectively, upon their order, in accordance with this PA and the respective Vaccine Order Forms.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participating Member States shall place orders for supplies of 200 million Vaccine doses in total in accordance with the allocation communicated by the Commission to the Contractor pursuant to Article I.6.3, by sending the Contractor a completed copy of Annex I (&#8220;<font style="font-weight:bold;">Vaccine Order Form</font>&#8221;) in paper format or emailed pdf [***]. This Vaccine Order Form shall be signed by an authorised representative of the Participating Member State and the Contractor.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] the Contractor must send back to the Participating Member States the duly signed and dated Vaccine Order Form in paper format or emailed pdf.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">I.6<font style="margin-left:36pt;"></font>Supply of the Vaccine</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">General</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the term of this PA, the Contractor shall supply or have supplied the Product to the <font style="color:#000000;">relevant Participating Member States</font>, and the<font style="color:#000000;"> Participating Member States </font>shall purchase the Product, subject to and in accordance with the terms and conditions of this PA.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Product supply</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the Effective Date, the Commission orders 200 million doses (<font style="font-weight:bold;">&#8220;Contracted Doses&#8221;</font>) of the Product on behalf of the <font style="color:#000000;">Participating Member States</font> [***] according to the terms laid down in this PA<font style="font-size:11pt;">. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The parties acknowledge that the Commission may wish to place an &#8206;additional binding order (the <font style="font-weight:bold;">&#8220;Additional Order&#8221;</font>) for a maximum &#8206;of up to 100 million doses of the Vaccine. The parties also agree that such Additional Order may be placed by the Commission only after (i) being advised by the Contractor that &#8206;the Contractor has availability of supply of such additional requested doses at the time of the proposed Additional Order (the <font style="font-weight:bold;">&#8206;&#8206;&#8220;Additional Product&#8221;</font>) (ii) </p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the C</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ontractor</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> agrees, in its sole discretion, to &#8206;allocate the Additional Product to the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commission</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (iii) the Contractor confirms how many doses can be delivered and by when</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (iv) the Commission confirms the required allocation between Participating Member States and (v)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The Additional Order will </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be &#8206;placed by way of </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an additional</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Vaccine Order Form and, as such, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be &#8206;subject to the same terms and conditions set forth in this </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PA</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission shall communicate to the Contractor the allocation of the Contracted Doses supplied pursuant to the initial order and any Additional Product among the governments of the Participating Member States. [***] </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Supply mechanism</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vaccine supply in Europe will primarily come from [***] manufacturing site [***] and shall incorporate RNA produced at [***] manufacturing sites including sites operated by the following sub-contractors:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Delivery Schedule is as follows (subject to the limitations set forth below):</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:3.99%;width:61.17%;">
<tr>
<td valign="top"  style="width:28.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:6pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quarter</p></td>
<td valign="top"  style="width:22.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:26.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:22.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:28.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:6pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Doses (million)</p></td>
<td valign="top"  style="width:22.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:26.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:22.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Delivery Schedule and logistics will be further refined [***] by the Contractor after the Commission has communicated how to apportion the 200 million Vaccine doses amongst the Participating Member States pursuant to the provisions of this Article I.6.3. [***].</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">[***]</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">[***]</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the avoidance of doubt, the Participating Member States will not have the right to terminate the Vaccine Order Forms [***] in the event that the Commission has not exercised its right to terminate the PA. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor shall use Best Reasonable Efforts to ensure that the doses are supplied in accordance with the Delivery Schedule, the estimated monthly and weekly schedules and the dates set out in the Vaccine Order Forms. [***] Allocations shall be made pursuant to Article I.6.3(i) in case of insufficient supply to deliver the full amount of Contracted Doses. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within [***] following the Effective Date, the Commission shall communicate to the Contractor a table how to allocate the 200 million Vaccine doses amongst the Participating Member States. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Participating Member State shall have a commitment to purchase the number of Vaccine doses as set out in the above-mentioned allocation table and to sign a Vaccine Order Form to this effect as set out below. </p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To operationalise the ordering of the Vaccine, each Participating Member State will enter into </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vaccine Order Form</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vaccine Order Form </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will specify in particular the number of doses that the Participating Member State will purchase </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">above-mentioned </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">allocation </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">table</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the price of all Vaccine doses pursuant to </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Article </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.7</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and the liability and indemnification undertakings by the Participating Member State</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (which will be incorporated by reference </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from the PA in</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to th</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vaccine Order Form</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">).</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the avoidance of doubt, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the C</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ontractor</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall have no obligation to supply any Vaccine doses to any Participating Member State </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">where there is not a</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vaccine Order Form</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, including provisions related to liability and indemnity</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (which will be incorporated by reference </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from the PA in</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vaccine Order Form</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> executed by the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Participating Member State and the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractor</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. It is agreed that the Contractor may discharge its obligations under the Vaccine Order Form </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">acting with</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> one or more</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Participating </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractor Affiliate</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.4</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Manufacturing</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor confirms that it is in possession of all necessary manufacturing authorisations to undertake the manufacturing of the Vaccine. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.5</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Legal and regulatory filings and requests</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor shall ensure that all Product is properly labelled and packaged in accordance with the provisions of Article I.6.8 and Good Manufacturing Practice and in accordance with the applicable EU legislation on information on packaging (Title V of Directive 2001/83/EC). </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the above, [***] the Contractor shall comply with all conditions (in the relevant timescales) set out in the Authorisation (where applicable), subject to any exemption, exception or waiver of requirements for the Product granted or permitted by the Participating Member State (including but not limited to serialization).</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.6</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Clinical trials and licensure</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.7</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Waiver</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission acknowledges and agrees that the Contractor&#8217;s efforts to continue to develop and manufacture the Vaccine are aspirational in nature and subject to significant risks and uncertainties. Notwithstanding the efforts and any estimated dates set forth in this PA, the parties acknowledge that the Vaccine might not be delivered fully according to the Delivery Schedule due to technical, clinical, regulatory or manufacturing, shipping, storage or other challenges or failures.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.8</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Packaging, labelling and shipping</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the date of execution of this PA, the Vaccine is expected to be supplied in a thermal shipping box in accordance with Attachment 4 (Labelling and Packaging Specifications) (<font style="font-weight:bold;">&#8220;Thermal Shipper&#8221;</font>). [***]. The costs of packaging, packing materials, addressing, labelling, loading and delivery to the agreed Participating Member States&#8217; delivery point of the Vaccine [***].</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All deliveries shall be accompanied by the documentation specified in Attachment </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (Delivery </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ocumentation)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (which may be updated from time to time by </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Contractor</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> upon notice to the Commission), and shall be in accordance with, and subject to, the delivery specification set forth in Attachment </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Delivery Specification)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The Product shall be labelled and packaged in accordance with the packaging specifications set forth in Attachment </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Labelling and Packaging Specifications)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Final specifications including package size and labels will be communicated to the Commission and to the Participating Member States prior to delivery. All specifications shall be consistent with any conditions set out in the Authorisation and applicable Law.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.9</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Storage, transport and product acceptance</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] Final storage specifications, based on the Authorisation received, will be communicated to the Participating Member State prior to delivery. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.10</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Delivery</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor will deliver the doses ordered by each of the Participating Member States to one or more locations selected by the Participating Member State in accordance with the procedure set out in this Article I.6.10 and the Vaccine Order Form. [***] For the avoidance of doubt, the Participating Member States shall bear all costs and expenses for operating these distribution hubs and for use of the Vaccine, including, but not limited to, those for storage and distribution of the Vaccine after delivery, local duties and local QA testing.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The duly authorised representative of the Participating Member State shall sign to confirm receipt of delivery (the current proposed format of which is as set out in Attachment 2 (Delivery Documentation)). The person signing for receipt must ensure the contents of the delivery match the accompanying shipping documentation proof of receipt.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor shall deliver the Product [***] to the location agreed pursuant to this Article I.6.10. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor and the Participating Member State shall agree the location(s) for delivery of shipments of the Product; provided that (i) each location meets the requirements set forth in Attachment 3 (Delivery Specification), and (ii) all locations which are additional to those approved in advance by the Contractor prior to the Effective Date shall be agreed upon by the Contractor and the Participating Member State at least [***].</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All shipments of Product [***], or such other amount as notified to the Commission from time to time by the Contractor in accordance with the terms of this PA. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.11</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Product handling</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon delivery of the Product, the <font style="color:#000000;">Participating Member State</font> shall store and handle the Product in the manner set forth in the Specifications set forth in Attachment 1 (Specifications), instructions in Attachment 3 (Delivery Specification) and the instructions provided by the Contractor to ensure stability and integrity of the Product. </p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The </font><font style="color:#000000;">Participating Member State</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shall be solely responsible and liable for the proper storage, handling, distribution, transportation, administration, use and disposal of the Product in </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">their </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> following delivery of the Product to </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="color:#000000;">Participating Member State</font><font style="color:#000000;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or its designee. Without prejudice to the generality of the foregoing, </font><font style="color:#000000;">the Participating Member State</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ensure that: (a) recipients of the Product shall follow the return and disposal instructions in Attachment </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (Return </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Disposal </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product Materials</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(as updated by the Contractor and communicated to the </font><font style="color:#000000;">Participating Member State</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> from time to time) </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">when disposing of open and unused Product and its packaging components; and (b) such return and disposal complies with Laws regarding pharmaceutical waste, medical waste, or hazardous waste, as appropriate.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Participating Member State<font style="color:#000000;">s shall be responsible for and shall ensure that any equipment used to deliver the Product, for example [***], are stored in an appropriate clean and secure location to protect and maintain the functionality of such equipment (in controlled conditions, with no exposure to weather or pests, etc). Within [***] of receipt of the Product, subject to Article I.6.14, the Participating Member State shall take the necessary measures to enable the collection by the Contractor of all such equipment, including [***], in accordance with the Contractor&#8217;s instructions, consistent with the provisions of Attachment 5 (Return and Disposal of Product Materials).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor may provide Safety Data Sheets and other agreed information to <font style="color:#000000;">Participating Member State</font>s [***]. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.12</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Title to Product and risk of loss</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.13</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Quality tests and checks</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.14</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Rejection of Product; Disposal of rejected shipments</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Participating Member State must visually inspect the Product [***] following the instructions set out in Attachment 3 (Delivery Specification<font style="color:#000000;">) and </font>may reject any specific delivery of the Product or doses therein that does not conform [***] (<font style="font-weight:bold;">&#8220;Non-Complying Product&#8221;</font>) by providing notice to Pfizer Customer Service following an agreed protocol: [***]. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Without prejudice to the right to refer the matter to the dispute resolution procedure set out in Article I.13.2 and the provision on [***], replacement of Non-Complying Product [***]. The provisions of this Article I.6.14 shall survive termination or expiration of this PA.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.15</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Maintenance and retention of Records</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each party shall maintain [***] with respect to its activities under this PA as required by Laws.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participating Member State<font style="color:#000000;"> will maintain a quality system for receipt, inspection, storage, traceability to further delivery points, and recall activities. If </font>the Participating Member State<font style="color:#000000;"> </font></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">does not have a quality system for the activities defined, </font><font style="color:#000000;">the Contractor</font><font style="color:#000000;"> may share details of a proposed quality system for </font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Participating Member State</font><font style="color:#000000;">&#8217;s compliance.</font><font style="color:#000000;"> </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.6.16</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Diversion issues</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All Product delivered to a <font style="color:#000000;">Participating Member State</font> shall be: (a) stored securely by <font style="color:#000000;">the Participating Member State</font>; and (b) without prejudice to Article I.6.2, distributed by the <font style="color:#000000;">Participating Member State</font> in a secure manner appropriate to the transportation route and destination, in each case (a) and (b) to guard against and deter theft, diversion, tampering, substitution (with, for example, counterfeits) or unauthorised resale or export out of the Participating Member State, and to protect and preserve the integrity and efficacy of the Product. [***].</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">I.7 Prices</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The price of the Vaccine to the Commission and the Participating Member States for the 200 million Contracted Doses and any Additional Order will be [***]. </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">I.8 Payment Arrangements</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.8.1<font style="font-weight:normal;"> </font>[***]</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.8.2<font style="font-weight:normal;"> </font>Delivery Price</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <font style="font-weight:bold;">Delivery Price</font> for the Contracted Doses and any Additional Order is to be paid by the Participating Member State to the Participating Contractor Affiliate [***]. [***] </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participating Contractor Affiliate may claim the payment of the balance in accordance with Article&#160;I.8.2. The Participating Contractor Affiliate must send an invoice in paper format or emailed pdf for payment of the balance due under a Vaccine Order Form for each provision of supplies to the Participating Member States.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Invoices shall be established by the Participating Contractor Affiliate for a given order of supplies and for an identified delivery scheduled within the Vaccine Order Form.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participating Contractor Affiliate may not send an invoice to a Participating Member State before it receives from the Participating Member State [***] in respect of which such invoice is established, which [***].</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participating Contractor Affiliate must send an invoice in paper format or emailed pdf or by electronic systems for payment due under the Vaccine Order Form accompanied by the following:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each invoice must contain the following information:</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<font style="margin-left:36pt;">Name of </font>the Participating Member State concerned<br />-<font style="margin-left:36pt;">PA and </font>Vaccine Order Form number/reference<br />-<font style="margin-left:36pt;">Order reference</font></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<font style="margin-left:36pt;">Billing address</font><br />-<font style="margin-left:36pt;">Product</font> [***]<br />-<font style="margin-left:36pt;">Quantity</font> [***]<br />-<font style="margin-left:36pt;"></font>[***] reference and date</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<font style="margin-left:36pt;">Price</font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<font style="margin-left:36pt;">Any applicable taxes, transportation charges or other charges provided for in the </font>Vaccine Order Form</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<font style="margin-left:36pt;">The ship-to destination</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<font style="margin-left:36pt;"></font>[***]<br />-<font style="margin-left:36pt;"></font>Participating Contractor Affiliate name and bank account.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participating Member States must approve the submitted documents or deliverables as conforming to the above requirements and pay [***]. Any payment which falls due on a date which is not a business day may be made on the next succeeding business day. Any dispute by a <font style="color:#000000;">Participating Member State</font> of an invoice shall be provided to the Participating Contractor Affiliate in writing (along with substantiating documentation and a reasonably detailed description of the dispute) [***]. A <font style="color:#000000;">Participating Member State</font> will be deemed to have accepted all invoices for which the Participating Contractor Affiliate does not receive timely notification of disputes, and shall pay all undisputed amounts due under such invoices within the period set forth in this Article I.8.2. The parties shall seek to resolve all such disputes expeditiously and in good faith.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to all other remedies available under this PA or at Law, if a <font style="color:#000000;">Participating Member State</font> fails to pay any undisputed amounts when due under this PA, the Contractor [***].</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission and the Participating Member States shall not, and acknowledge that they will have no right, under this PA, any Vaccine Order Form, any order, any other agreement, document or Law, to withhold, offset, recoup or debit any amounts owed (or to become due and owing) to the Participating Contractor Affiliate, against any other amount owed (or to become due and owing) to it by the Contractor or an Affiliate.[***]</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.8.3<font style="font-weight:normal;"> </font>Bank account</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments by the Commission must be made [***]</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">I.9 Communication Details</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the purpose of this PA, communications must be sent to the following addresses:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By derogation from this Article I.9, different contact details for the Commission, the Participating Member States or the Contractor may be provided in Vaccine Order Form.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">I.10 Project management</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer, BioNTech and the Commission will each nominate a project manager that will be the sole contact point for and responsible for managing the overall relationship between the parties. Each Participating Member State shall in addition appoint an expert to work on PA implementation at Participating Member State level. Project meetings with the Commission and Participating Member State experts will be held regularly on a timeframe to be determined </p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">following execution of the PA to report, amongst other things, on progress of clinical studies, licensing activities, manufacturing status, forecast and deliveries</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Details specific to each </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Participating </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Member State such as logistics and payments shall be handled directly by the respective </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Participating </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Member State experts</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">I.11 Exploitation of the results of the PA</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission acknowledges and agrees [***] (collectively, the <font style="font-weight:bold;">&#8220;Vaccine IP Rights&#8221;</font>). [***] All rights not expressly granted by the Contractor hereunder are reserved by the Contractor.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">I.12 Indemnification </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission, on behalf of the Participating Member States, declares that the use of Vaccines produced under this PA will happen under epidemic conditions requiring such use, and that the administration of Vaccines will therefore be conducted under the sole responsibility of the Participating Member States. [***] </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">I.13 Applicable Law and Settlement of Disputes </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This PA shall be governed by the laws of Belgium.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">I.14 Other Special Conditions</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor shall keep the Commission and the Participating Member States informed [***] during the pharmacovigilance or vaccine monitoring programmes in relation to the Vaccines which are the object of this PA [***].</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:13.96%;"></td>
<td style="width:36.72%;"></td>
<td style="width:2.99%;"></td>
<td style="width:13.33%;"></td>
<td style="width:33%;"></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the Contractor,</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the Commission, on behalf and in the name of the Participating Member States,</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[forename/surname/position]</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Done at [<font style="font-style:italic;Background-color:#D9D9D9;">place</font>], [<font style="font-style:italic;Background-color:#D9D9D9;">date</font>]</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Done at [<font style="font-style:italic;Background-color:#D9D9D9;">place</font>], [<font style="font-style:italic;Background-color:#D9D9D9;">date</font>]</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In duplicate in English.</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;text-transform:uppercase;font-weight:bold;font-size:14pt;font-variant: small-caps;font-style:normal;"><font style="text-decoration:none;">II.</font><font style="text-decoration:none;text-transform:none;"> </font><font style="border-bottom:double 2.5pt;text-transform:none;">GENERAL CONDITIONS FOR THE FRAMEWORK CONTRACT FOR SERVICES</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">II.1 Definitions</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All definitions are contained in Article I.2</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">II.2 Roles and responsibilities in the event of a joint tender</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of a joint tender submitted by a group of economic operators and where the group does not have legal personality or legal capacity, one member of the group is appointed as leader of the group.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">II.3 Severability</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each provision of this PA is severable and distinct from the others. If a provision is or becomes illegal, invalid or unenforceable to any extent, it must be severed from the remainder of the PA. This does not affect the legality, validity or enforceability of any other provisions of the PA, which continue in full force and effect. The illegal, invalid or unenforceable provision must be replaced by a legal, valid and enforceable substitute provision which corresponds as closely as possible with the actual intent of the parties under the illegal, invalid or unenforceable provision. The replacement of such a provision must be made in good faith between the parties. The PA must be interpreted as if it had contained the substitute provision as from its entry into force.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">II.4 Provision of services and supplies</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.4.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">All periods specified in the PA are calculated in calendar days, unless otherwise specified.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.4.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Contractor must immediately inform the Commission of any changes in the exclusion situations as declared, according to Article&#160;137&#160;(1) of Regulation (EU) 2018/1046.</p></td></tr></table></div>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">II.5 Communication between the parties</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.5.1<font style="font-weight:normal;"> </font>Form and means of communication</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any communication of information, notices or documents under the PA must:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">be made in writing in paper or electronic format in the language of the contract;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">bear the PA number and, if applicable, the Vaccine Order Form number;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">be made using the relevant communication details set out in Article&#160;I.9; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">be sent by mail or email.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a party requests written confirmation of an e-mail within a reasonable time, the other party must provide an original signed paper version of the communication as soon as possible.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The parties agree that any communication made by email has full legal effect and is admissible as evidence in judicial proceedings.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.5.2<font style="font-weight:normal;"> </font>Date of communications by mail and email</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any communication is deemed to have been made when the receiving party receives it, unless this PA refers to the date when the communication was sent.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E-mail is deemed to have been received by the receiving party on the day of dispatch of that e-mail, provided that it is sent to the e-mail address indicated in Article&#160;I.9. The sending party must be able to prove the date of dispatch. In the event that the sending party receives a non-delivery report, it must make every effort to ensure that the other party actually receives the communication by email or mail. In such a case, the sending party is not held in breach of its obligation to send such communication within a specified deadline.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mail sent to the Commission or the Participating Member State is deemed to have been received on the date on which the department responsible referred to in Article&#160;I.9 registers it.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Formal notifications<font style="font-style:normal;"> are considered to have been received by the receiving party on the date of receipt indicated in the proof received by the sending party that the message was delivered to the specified recipient.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">II.6 Liability</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.6.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">During the term of this PA, [***].</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.6.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">[***]</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.6.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Commission and the Participating Member States shall [***] to mitigate both (1) the damages that would otherwise be recoverable from the other or the Contractor pursuant to this PA and the Vaccine Order Forms, and (2) any costs, fees, expenses or losses that may be incurred by the Commission or the Participating Member State, or for which the Contractor may be responsible, under this PA and/or any Vaccine Order Form, by taking appropriate and reasonable actions to reduce or limit the amount of such damages, costs, fees, expenses or losses.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.6.4</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Limits on liability</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Taking into account the unprecedented nature of the current COVID-19 situation and the exceptional circumstances under which the Vaccine shall be delivered, the parties explicitly agree that [***]</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">[***]</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The aggregate liability of the Contractor and its Affiliates towards the Commission arising out of or relating to this PA and/or the Vaccine Order Forms (whether arising contractually or extra-contractually), shall not exceed [***]. </p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate liability of the Contractor and its Affiliates towards any of the Participating Member States arising out of or relating to this PA and/or the Vaccine Order Form concluded with that Participating Member State (whether arising contractually or </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">extra contractually</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">), shall not exceed</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">[***]</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.6.5</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">No limitation of liability</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Nothing in this PA excludes or limits the liability of either party for:</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.95%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.6.6</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Waiver of sovereign immunity </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Participating Member State represents that it has adequate statutory or regulatory authority and adequate funding appropriation to undertake and completely fulfil the indemnification obligations pursuant to Article I.12 of this PA. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.6.7</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Recall</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of a recall of the Vaccine [***]. </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">II.7 Conflict of interest and professional conflicting interests</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.7.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Contractor must take all the necessary measures to prevent any situation of <font style="font-style:italic;">conflict of interest or professional conflicting interest</font>.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.7.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Contractor must <font style="font-style:italic;">notify</font> the Commission in writing as soon as possible of any situation that could constitute a <font style="font-style:italic;">conflict of interest or a professional conflicting interest</font> during the Implementation of the PA. The Contractor must immediately take action to rectify the situation.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission may do any of the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">verify that the Contractor&#8217;s action is appropriate;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">require the Contractor to take further action within a specified deadline;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">decide not to award a Vaccine Order Form to the Contractor.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.7.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Contractor must pass on all the relevant obligations in writing to: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">its personnel which is directly involved in the performance of this PA;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">any natural person with the power to represent it or take decisions on its behalf;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">third parties involved in the Implementation of the PA, including subcontractors.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor must also ensure that the persons referred to above are not placed in a situation which could give rise to conflicts of interest.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-variant: normal;font-weight:bold;font-size:12pt;font-style:normal;text-transform:none;">II.8<font style="font-variant: small-caps;"> </font>Representations and warranties</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.8.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Mutual representations and warranties</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The parties each represent and warrant to each other the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Organization and authority. They have full right, power and authority to enter into this PA and to perform their respective obligations under this PA;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">No conflicts or violations. The execution and delivery of this PA by such party and the performance of such party&#8217;s obligations hereunder (i) do not conflict with or violate any laws existing as of the date of entry into force of the PA and applicable to such party and (ii) do not conflict with, violate, breach or constitute a default under, and are not prohibited or materially restricted by, any contractual obligations of such party existing as of the date of entry into force of the PA; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Valid execution. Such party is duly authorised to execute and deliver this PA, and the person executing this PA on behalf of such party is duly authorised to execute and bind such party to the terms set forth herein.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above warranties shall also be given by the Participating Member States in respect of the Vaccine Orders Forms and their obligations contained therein.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.8.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Warranties of either party</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor warrants to the Commission and the <font style="color:#000000;">Participating Member State</font>s that: </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of any breach of the Contractor&#8217;s warranties or undertakings relating to the Vaccine, the Commission&#8217;s and the Participating Member States&#8217; [***]. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.95%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission and the Participating Member State warrant that the PA is awarded and each Vaccine Order Form is concluded in accordance with applicable Laws.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.8.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Anti-bribery/anti-corruption</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The parties represent and warrant that, beyond the mutual consideration set forth in this PA, neither they nor their agents have provided or requested, or will provide or request, any additional incentive or benefit to or from the other party or its agents to induce either party to enter into this PA or perform any part of this PA.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor has not made, and will not make, in the performance of this PA directly or indirectly any payment, offer, promise, or authorisation of payment of money or anything of value to a government official, political party, candidate for political office, or any other person, and has not sought and will not seek improperly or corruptly to influence any government official, political party, candidate for political office, or any other person, in order to gain an improper business advantage.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.8.4</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">No other warranty</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except to the extent set out expressly in this PA, all conditions, warranties or other terms which might have effect between the parties or be implied or incorporated into this PA (whether by </p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">statute, common law or otherwise) are hereby excluded to the fullest extent permitted by applicable </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">L</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">aw. </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">II.9 Confidentiality</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.9.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Neither the Commission, a Participating Member State nor the Contractor shall, at any time, without the disclosing party&#8217;s prior written consent, disclose to any third party any of the other party&#8217;s Confidential Information.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.9.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Commission, the Participating Member State and the Contractor shall:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">use such Confidential Information solely for the purposes for which it was provided;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">take all reasonable precautions to prevent any unauthorised use or disclosure;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">not disclose or distribute any Confidential Information to any third party except as and to the extent authorised in writing to do so by the disclosing party.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.9.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The receiving party shall be permitted to disclose Confidential Information that is required or requested to be disclosed by a governmental authority pursuant to applicable law in connection with any other legal or administrative proceeding, provided that it (i) notifies the disclosing party of any such disclosure requirement or request as soon as practicable and (ii) furnishes only that portion of the Confidential Information which, in the opinion of the receiving party or their legal counsel, is responsive to such requirement or request and (iii) asks the court or other public body, if applicable, to treat the Confidential Information as confidential.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.9.4</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The receiving party shall disclose Confidential Information only to such of its representatives who have a need to know such Confidential Information to fulfil its obligations under this PA; provided, however, before any disclosure of Confidential Information, the receiving party shall bind its representatives receiving such Confidential Information to a written agreement of confidentiality at least as restrictive as contained in this PA; and prior to any disclosure, the receiving party shall instruct its representatives of the confidential nature of, and to maintain the confidentiality of, the Confidential Information. The receiving party shall be responsible for all actions of its representatives, including any breach of the terms hereof, regardless of whether or not such representatives remain employed or in contractual privity with the receiving party.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.9.5</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Notwithstanding the foregoing, in all cases, (a) [***], and (b) the Contractor may disclose Confidential Information to their Affiliates without prior written consent of the <font style="color:#000000;">Participating Member State</font>s.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.9.6</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The confidentiality obligations set out in this Article II.9 are binding on the Commission, the Participating Member State and the Contractor during the Implementation of the PA and for as long as the information or documents remain confidential unless:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">the disclosing party agrees to release the receiving party from the confidentiality obligation earlier;</p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">onfidential </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nformation or documents become public through other means than a breach of the confidentiality obligation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">the applicable Law requires the disclosure of the Confidential Information or documents.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.9.7</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Contractor must obtain from any natural person with the power to represent it or take decisions on its behalf, as well as from third parties involved in the Implementation of the PA a commitment that they will comply with this Article. At the request of the Commission, the Contractor must provide a document providing evidence of this commitment.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.9.8</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Neither this PA nor the performance by either party hereunder shall transfer to the receiving party any proprietary right, title, interest or claim in or to any of the disclosing party&#8217;s Confidential Information (including, but not limited to, any intellectual property rights subsisting therein) or be construed as granting a license in its Confidential Information.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.9.9</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The provisions of this Article II.9 shall survive the termination or expiration of this PA for [***], except with respect to any information that constitutes a trade secret (as defined by the applicable Law), in which case the recipient of such information will continue to be bound by its obligations under this Article II.9 for so long as such information continues to constitute a trade secret, but in no event for a period of less than [***] specified above.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.9.10</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Contractor acknowledges that the Commission is subject to requirements laid down under Regulation (EC) 1049/2001.The Commission commits that it will consult with the Contractor on any disclosure request concerning documents containing Confidential Information as provided for in Article 4(4) of said Regulation.</p></td></tr></table></div>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">II.10 Announcements and publicity</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The parties shall consult together on the timing, contents and manner of any press release relating to the execution of this PA. Other than the foregoing, no party shall make, or permit any person to make, any public announcement concerning the existence, subject matter or terms of this PA or a Vaccine Order Form, the wider transactions contemplated by them, or the relationship between the parties, without the prior written consent of the other party (such consent not to be unreasonably withheld or delayed), except (i) as required by law, any governmental or regulatory authority (including, without limitation, any relevant securities exchange), any court or other authority of competent jurisdiction; or (ii) on terms that are consistent and do not go further than the matters covered in any agreed press release. For clarity, unless consent is granted pursuant to this Article II.10, no announcement or disclosure will (i) include or infer [***]. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A party shall not use the name, trade name, service marks, trademarks, trade dress or logos of the other party in publicity releases, advertising or any other publication, without the other party&#8217;s prior written consent in each instance, provided, however, that consent is granted for public announcements pursuant to above sub-clause (ii) in this Article II.10.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">II.11 Processing of personal data </p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;"></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.11.1<font style="font-weight:normal;"> </font>Processing of personal data by the Commission</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any personal data included in or relating to the PA, including its implementation, shall be processed in accordance with Regulation (EU) 2018/1725. Such data shall be processed solely for the purposes of the implementation, management and monitoring of the PA by the data controller. For the purpose of this provision, the data controller for the Commission shall be the Director-General of the European Commission's Directorate-General for Health and Food Safety. The data protection notice is available at https://ec.europa.eu/info/data-protection-public-procurement-procedures_en. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor or any other person whose personal data is processed by the data controller in relation to this PA has specific rights as a data subject under Chapter III (Articles&#160;14&#8209;25) of Regulation (EU) 2018/1725, in particular the right to access, rectify or erase their personal data and the right to restrict or, where applicable, the right to object to processing or the right to data portability.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should the Contractor or any other person whose personal data is processed in relation to this PA have any queries concerning the processing of its personal data, it shall address itself to the data controller. They may also address themselves to the Data Protection Officer of the data controller. They have the right to lodge a complaint at any time to the European Data Protection Supervisor.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.11.2<font style="font-weight:normal;"> </font>Processing of personal data by the Contractor</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The processing of personal data by the Contractor shall meet the requirements of Regulation (EU) 2016/679 and be processed solely for the purposes set out by the controller.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">II.12 Subcontracting</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.12.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Contractor may not subcontract and have the PA implemented by third parties beyond the third parties already mentioned in its tender [***].</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.12.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">In the case of subcontracting, the Contractor remains bound by its contractual obligations and is solely responsible for the <font style="font-style:italic;">Implementation of the PA</font>.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.12.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Contractor must ensure that the subcontract does not affect the rights of the Commission and the Participating Member States under this PA.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.12.4</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">[***]</p></td></tr></table></div>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">II.13 Amendments</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.13.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Any amendment to the PA or a Vaccine Order Form must be made in writing before all contractual obligations have been fulfilled. A Vaccine Order Form does not constitute an amendment to the PA.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.13.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">No amendment can make changes to the PA or a Vaccine Order Form that might alter the initial conditions of the procurement procedure or result in unequal treatment of tenderers or contractors.</p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;"><font style="font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">II.14</font><font style="font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;"> </font><font style="font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">Assignment</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neither this PA nor any interest hereunder will be assignable by a party without the prior written consent of the other party, except as follows: [***] </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">II.15 Force majeure</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.15.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">If a party is affected by <font style="font-style:italic;">Force majeure</font>, it must immediately <font style="font-style:italic;">notify</font> the other party, stating the nature of the circumstances, their likely duration and foreseeable effects.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.15.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">A party is not liable for any delay or failure to perform its obligations under the PA or Vaccine Order Form if that delay or failure is a <font style="font-style:italic;">result of Force majeure</font>. [***]</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.15.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The parties must take all necessary measures to limit any damage due to <font style="font-style:italic;">Force majeure </font>and shall use commercially reasonable efforts to avoid or minimize the delay in performance of their respective obligations affected by <font style="font-style:italic;">Force majeure</font>.</p></td></tr></table></div>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">II.16 Suspension of the implementation of the PA</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.16.1<font style="font-weight:normal;"> </font>Suspension by the Contractor</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Contractor or a Participating Contractor Affiliate is affected by <font style="font-style:italic;">Force majeure</font>, it may suspend the provision of the services under a Vaccine Order Form.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor or the Participating Contractor Affiliate must immediately <font style="font-style:italic;">notify</font> the Commission of the suspension. The <font style="font-style:italic;">notification</font> must include a description of the <font style="font-style:italic;">Force majeure</font> and state when the Contractor or the Participating Contractor Affiliate expects to resume the provision of services.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor or the Participating Contractor Affiliate must <font style="font-style:italic;">notify</font> the Commission as soon as it is able to resume <font style="font-style:italic;">performance of the </font>Vaccine Order Form, unless the Commission has already terminated the PA or the Vaccine Order Form.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.16.2<font style="font-weight:normal;"> </font>Suspension by the Commission or the Participating Member State</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Financial Regulation, the Commission or the Participating Member State may suspend the Implementation of the PA or performance of a Vaccine Order Form or any part of it:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">if the procedure for awarding the PA or a Vaccine Order Form or the Implementation of the PA proves to have been subject to Irregularities, Fraud (in the sense of the Financial Regulation) or breach of obligations;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">in order to verify whether the presumed Irregularities, Fraud (in the sense of the Financial Regulation) or breach of obligations have actually occurred.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission or the Participating Member State in question must formally notify the Contractor of the suspension and the reasons for it. Suspension takes effect on the date of formal notification, or at a later date if the formal notification so provides.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission or the Participating Member State in question must notify the Contractor as soon as the verification is completed whether:</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">it is lifting the suspension; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">it intends to terminate the PA or a Vaccine Order Form under Article&#160;II.17.1, (f) or (i).</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor is not entitled to compensation for suspension of any part of the PA or a Vaccine Order Form. For the avoidance of doubt, the Contractor shall not be under any obligation to deliver any Contracted Doses or the Additional Order during the suspension period, and the Delivery Schedule shall be adjusted to take into account the period of such suspension. Equally for the avoidance of doubt, the Contractor shall complete the delivery of any Contracted Doses or Additional Order that were already in transit on the date of the formal notification or at the later date indicated in the formal notification.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">II.17 Termination of the PA</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.17.1<font style="font-weight:normal;"> </font>Grounds for termination by the Commission</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission may terminate the PA or the Participating Member State may terminate any on-going Vaccine Order Form (depending on whether the event affects the PA or the Vaccine Order Form) solely in the following circumstances:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">[***] </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">if the Contractor does not implement the PA or perform the Vaccine Order Form in accordance with material aspects of the PA or the Vaccine Order Form (as applicable) or is otherwise in material breach of another substantial contractual obligation; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">[***]</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">if the Contractor or any person that assumes unlimited liability for the debts of the Contractor is in one of the situations provided for in points (a) and (b) of Article&#160;136(1) of the Financial Regulation<sup style="font-size:85%;line-height:120%;vertical-align:top">4</sup><font style="text-decoration:none;color:#auto;font-size:11pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top"><strike Style="text-decoration:none;"></strike></sup></font>;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">if the Contractor or any Related person is in one of the situations provided for in points (c) to (h) of Article&#160;136(1) or Article&#160;136(2) of the Financial Regulation;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">if the procedure for awarding the PA or the Implementation of the PA prove to have been subject to Irregularities, Fraud (in the sense of the Financial Regulation) or breach of obligations;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">if the Contractor is in a situation that does constitute a Conflict of interest or a Professional conflicting interest which would have a material adverse impact on the performance of the PA;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">in case of a change regarding the exclusion situations listed in Article&#160;136 of Regulation (EU) 2018/1046 that calls into question the decision to award the contract;</p></td></tr></table></div>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:3pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-style:normal;text-decoration:none;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">4</sup></font>  </font></font></p></td>
<td valign="top" style="width:92.02%;">
<p style="margin-bottom:3pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"><font style="text-decoration:none;"></font><font style="color:#000000;">Regulation (EU, Euratom) 2018/1046 of the European Parliament and of the Council of 18 July 2018 on the financial rules applicable to the general budget of the Union, amending Regulations (EU) No 1296/2013, (EU) No 1301/2013, (EU) No 1303/2013, (EU) No 1304/2013, (EU) No 1309/2013, (EU) No 1316/2013, (EU) No 223/2014, (EU) No 283/2014, and Decision No 541/2014/EU and repealing Regulation (EU, Euratom) No 966/2012, OJ L 193 of 30.7.2018, p.1 </font><font style="text-decoration:underline;color:#000000;">https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1544791836334&amp;uri=CELEX:32018R1046</font></p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">[***]</p></td></tr></table></div>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.17.2<font style="font-weight:normal;"> </font>Grounds for termination by the Contractor</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor may terminate the PA or any on-going Vaccine Order Form solely in the following circumstances:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">if the Commission or the Participating Member State does not implement the PA or does not perform the Vaccine Order Form in accordance with material aspects of the PA or the Vaccine Order Form (as applicable) or is otherwise in material breach of another substantial contractual obligation, [***]</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">[***].</p></td></tr></table></div>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.17.3<font style="font-weight:normal;"> </font>Procedure for termination</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A party must <font style="font-style:italic;">formally notify</font> the other party of its intention to terminate the PA or a Vaccine Order Form and the grounds for termination.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The other party [***] following the date of receipt to submit observations, including the measures it has taken or will take to continue fulfilling its contractual obligations. Failing that, the decision to terminate becomes enforceable the day after the time limit for submitting observations has elapsed in the event the grounds giving rise to termination have not been cured.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the other party submits observations, the party intending to terminate must <font style="font-style:italic;">formally notify</font> it. </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.17.4<font style="font-weight:normal;"> </font>Effects of termination</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within [***] date of termination, the Contractor must submit any invoice required for services that were provided before the date of termination. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The termination or expiration of this PA shall not affect the survival and continuing validity of Articles I.1, I.2, I.4, I.6.7, I.6.9, I.6.11, I.6.12, I.6.14, I.6.16, I.7 to I.9, I.11 to I.14, II.3, II.5, II.6, II.8.2, II.8.4, II.9 to II.11, II.15, II.17.4, II.18 to II.28, Attachment 3 (Delivery Specification) and Attachment 5 (Return and Disposal of Product Materials) or of any other provision which is expressly or by implication intended to continue in force after such termination or expiration.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expiry or termination of this PA for any reason shall be without prejudice to either party&#8217;s other rights and remedies or to any accrued rights and liabilities as the date of such expiry or termination [***].</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">II.18 Invoices, value added tax and e-invoicing </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.18.1 Invoices and value added tax</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Invoices must contain the Contractor&#8217;s or the Participating Contractor Affiliate&#8217;s (or leader&#8217;s in the case of a joint tender) identification data, the amount, the currency and the date, as well as the PA reference and reference to the Vaccine Order Form.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Invoices must indicate the place of taxation of the Contractor </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or the Participating Contractor Affiliate </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(or leader in the case of a joint tender) for value added tax (VAT) purposes and must specify separately amounts not including VAT and amounts including VAT.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is understood and agreed between the parties that any prices stated under this PA and Vaccine Order Form are exclusive of any VAT or similar tax and all other taxes which are incurred as a result of manufacturing and supplying the Product (including custom duties, levies and charges and all local taxes) (<font style="font-weight:bold;">&#8220;Taxes&#8221;</font>), which shall be added thereon as applicable. Where Taxes are properly chargeable on any amounts payable under this PA or Vaccine Order Form, the party making the payment will pay the amount of Taxes, as specified on the invoice, in accordance with the laws and regulations of the country in which the Taxes are chargeable. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">II.19 Payments and guarantees </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.19.1 Date of payment</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The date of payment is deemed to be the date on which [***].</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.19.2 Currency</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments are made in euros or, for non-Eurozone countries, the local functional currency of the Participating Member State. For non-Eurozone countries, the Vaccine Order Form shall set forth the Delivery Price in the local functional currency converted from euro at the exchange rate existing one (1) day prior to the Effective Date of the PA as of 4:00pm London time published in Bloomberg FX Fixings (BFIX), such rates being found via Bloomberg or the website <font style="color:#auto;text-decoration:underline;">www.bloomberg.com/markets/currencies/fx-fixings</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.19.3 Costs of transfer</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The costs of the transfer are borne as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">the Commission or the Participating Member State in question bears the costs of dispatch charged by its bank;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">the Contractor or the Participating Contractor Affiliate bears the costs of receipt charged by its bank;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">the party causing repetition of the transfer bears the costs for repeated transfer.</p></td></tr></table></div>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.19.4 Suspension of the time allowed for payment</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission or the Participating Member State in question may suspend the payment periods specified in Article&#160;I.8 at any time by <font style="font-style:italic;">notifying</font> the Contractor or the Participating Contractor Affiliate (or leader in the case of a joint tender) that its invoice cannot be processed. [***]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suspension takes effect on the date the Commission or the Participating Member State in question sends the <font style="font-style:italic;">notification</font>. The remaining payment period resumes from the date on which the requested information or revised documents are received or the necessary further verification, including on-the-spot checks, is carried out. [***]</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.19.5</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest on late payment</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On expiry of the payment periods specified in Article&#160;I.8, the Contractor or the Participating Contractor Affiliate (or leader in the case of a joint tender) is entitled to interest on late payment at the higher of (a) the rate applied by the European Central Bank for its main refinancing operations in euros (the reference rate) [***] (or such centralized bank reference rate set forth in the Vaccine Order Form) and (b) [***]%. The reference rate is the rate in force, as published in the C series of the <font style="font-style:italic;">Official Journal of the European Union</font>, on the first day of the month in which the payment period ends.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suspension of the payment period as provided for in Article&#160;II.19.4 is not considered as giving rise to late payment.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on late payment covers the period running from the day following the due date for payment up to and including the date of payment as defined in Article&#160;II.19.1.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">II.20 Recovery</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.20.1<font style="font-weight:normal;"> </font>Recovery procedure</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In all cases where the recovery procedure as described in the Financial Regulation applies, the parties shall follow the procedure set out in this Article.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before recovery, the Commission or the Participating Member State in question must formally notify the Contractor of its intention to recover the amount it claims, specifying the amount due and the reasons for recovery and inviting the Contractor to make any observations [***].</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If no observations have been submitted or if, despite the observations submitted, the Commission or the Participating Member State in question decides to pursue the recovery procedure, it must confirm recovery by formally notifying a debit note to the Contractor, specifying the date of payment. The Contractor must pay in accordance with the provisions specified in the debit note.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Contractor does not pay by the due date, the Commission or the Participating Member State in question may, after informing the Contractor in writing, recover the amounts due:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">by offsetting them against any amounts owed to the Contractor by the Commission or the Participating Member State in question;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">by taking legal action.</p></td></tr></table></div>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">II.20.2<font style="font-weight:normal;"> </font>Interest on late payment</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Contractor does not honour the obligation to pay the amount due by the date set by the Commission or the Participating Member State in question, the amount due bears interest at the rate indicated in Article&#160;II.19.5. Interest on late payments will cover the period starting on the day after the due date for payment and ending on the date when the Commission or the Participating Member State in question receives the full amount owed.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any partial payment is first entered against charges and interest on late payment and then against the principal amount.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;"><font style="font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">II.21</font><font style="font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;"> </font><font style="font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">Checks and audits</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.21.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Commission and the European Anti-Fraud Office may check or require an audit on the Implementation of the PA. This may be carried out either by OLAF&#8217;s own staff or by any outside body authorised to do so on its behalf, provided that the auditor may not be a competitor of the Contractor.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Such checks and audits may be initiated at any moment during business hours during the provision of the services and up to [***] starting from the payment of the balance of the last specific contract issued under this PA. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The audit procedure is initiated on the date of receipt of the relevant letter sent by the Commission. Audits are carried out on a confidential basis.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.21.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Contractor must keep all original documents stored on any appropriate medium, including digitised originals if authorised under national law, for a period of [***] starting from the payment of the balance of the last specific contract issued under this PA.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.21.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Contractor must grant the appropriate right of access to sites and premises where the PA is implemented, [***], needed to conduct such checks and audits. The Contractor must ensure that the information is readily available at the moment of the check or audit and, if so requested, that information is handed over in an appropriate format. The auditor must, insofar possible, comply with all applicable and reasonable security measures notified to Commission by the Contractor subject to this not creating any material obstacles for the performance of the auditor&#8217;s tasks.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.21.4</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">On the basis of the findings made during the audit, a provisional report is drawn up. The Commission or its authorised representative must send it to the Contractor, who has [***]following the date of receipt to submit observations. The Contractor must receive the final report within [***] following the expiry of the deadline to submit observations.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the basis of the final audit findings, the Participating Member State in question may recover all or part of the payments made in accordance with Article&#160;II.20 and may take any other measures which it considers necessary.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.21.5</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">In accordance with Council Regulation (Euratom, EC) No 2185/96 of 11 November 1996 concerning on-the-spot checks and inspection carried out by the Commission in order to protect the European Communities&#8217; financial interests against fraud and other irregularities and Regulation (EU, Euratom) No 883/2013 of the European Parliament and of the Council of 11 September 2013 concerning investigations conducted by the European Anti-Fraud Office, the European Anti-Fraud Office may carry out investigations, including on the spot checks and inspections, to establish whether there has been fraud, corruption or any other illegal activity under the contract affecting the financial interests of the Union. Findings arising from an investigation may lead to criminal prosecution under national law.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The investigations may be carried out at any moment during the provision of the services and up to [***] starting from the payment of the balance of the last specific contract issued under this PA.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">II.21.6</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Court of Auditors and the European Public Prosecutor&#8217;s Office established by Council Regulation (EU) 2017/19398 (&#8216;the EPPO&#8217;) have the same rights as the Commission, particularly right of access, for the purpose of checks, audits and investigations.</font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">II.22 Relationship of the parties</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The relationship hereby established between the Contractor and the Commission is solely that of independent contractors. Neither party has authority to act or make any agreements or representations on behalf of the other party. This PA is not intended to create, and shall not be construed as creating, between the parties, the relationship of principal and agent, employer and employee, joint venturers, co-partners, or any other such relationship, the existence of which is expressly denied.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">II.23 Waiver</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A waiver by any party of any term or condition of this PA in any instance shall not be deemed or construed to be a waiver of such term or condition for the future, or of any subsequent breach thereof. All remedies specified in this PA shall be cumulative and in addition to any other remedies provided at Law or in equity, except where expressly otherwise agreed.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">II.24 Further documents</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each party hereto agrees to execute such further documents and take such further steps as may be reasonably necessary or desirable to effectuate the purposes of this PA.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">II.25 Headings</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Headings of Articles or other parts of this PA are included herein for convenience of reference only and shall not constitute a part of this PA or change the meaning of this PA.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">II.26 Electronic Delivery and Storage</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delivery of a signed PA by reliable electronic means, including facsimile or email (with receipt electronically confirmed), shall be an effective method of delivery of the executed PA. This PA may be stored by electronic means and either an original or an electronically stored copy of this PA can be used for all purposes, including in any proceeding to enforce the rights or obligations of the parties to this PA.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">II.27 Entire Agreement</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This PA, together with any Annexes and Attachments, which are hereby incorporated by reference, constitute the entire agreement of the parties with respect to its subject matter and merges and supersedes all prior discussions and writings with respect to thereto. </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;font-variant: small-caps;font-style:normal;text-transform:none;">II.28 Costs</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each party will bear its own legal costs in preparing and concluding this PA.</p>
<p style=" clear:both;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><br /></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-style:normal;text-transform:none;"><font style="font-size:12pt;font-family:Times New Roman;border-bottom:double 2.5pt;font-variant: small-caps;font-style:normal;text-transform:none;">Annex I: </font><font style="font-size:12pt;font-family:Times New Roman;border-bottom:double 2.5pt;font-variant: small-caps;font-style:normal;text-transform:none;">Vaccine Order Form</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Vaccine Order Form is submitted by:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.99%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">The Government of [&#8226;]</font>] (the &#8220;<font style="font-weight:bold;">Participating</font> <font style="font-weight:bold;">Member State</font>&#8221;), represented for the purposes of signing this Vaccine Order Form by [<font style="font-style:italic;">forename, surname, function, department of authorising officer</font>],</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:4.99%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Inc, incorporated in Delaware (Registration Number 0383418) with its registered address at 235 East 42nd Street, 10017 New York City, NY (UNITED STATES) (&#8220;<font style="font-weight:bold;">Pfizer</font>&#8221;);</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:4.99%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:4.99%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Manufacturing GmbH, registered with the commercial register of the lower court (Amstgericht) of Mainz, Germany under HRB 47548, with its registered address at An ger Goldgrube 12, 55131 Mainz, Germany (&#8220;<font style="font-weight:bold;">BioNTech</font>&#8221;),</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:4.99%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Pfizer and BioNTech together the &#8220;<font style="font-weight:bold;">Contractor</font>&#8221;, represented for the purposes of signing this Vaccine Order Form by [***]).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participating Member State and Contractor are together referred to as the &#8220;<font style="font-weight:bold;">Parties</font>&#8221; and each individually as a &#8220;<font style="font-weight:bold;">Party</font>&#8221;.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8212;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">Contractor and the European Commission, acting on behalf of and in the name of the Participating Member States, entered into a Purchase Agreement for the purchase and supply of Contractor&#8217;s Vaccine for EU Member States dated [&#8226;] 2021 (the &#8220;</font><font style="font-weight:bold;font-family:Times New Roman;">PA</font><font style="font-family:Times New Roman;">&#8221;), the terms of which are binding on the Participating Member States and must be read in conjunction with this Vaccine Order Form.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8212;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">The PA provides that each Participating Member State will submit to Contractor a Vaccine Order Form through which Contractor shall make available and deliver to the relevant Participating Member State a proportion of the Contracted Doses or Additional Order as applicable, in accordance with the allocation provided by the Commission pursuant to Article I.6.3 of the PA and at the price and conditions as set out in the PA. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8212;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">In accordance with Article I.5.2 of the PA, the Participating Member State hereby places its order for its full allocated portion of the Contracted Doses or Additional Order (as applicable).</font></p></td></tr></table></div><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Article I</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subject matter</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.72%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">This Vaccine Order Form is submitted by the Participating Member State to Contractor in accordance with the terms of the PA, and forms an integral part of the PA. The terms and conditions of the PA are incorporated into this Vaccine Order Form by reference. In the event of contradiction between this Vaccine Order Form and the PA, the terms of the PA prevail regardless of any provision to the contrary. Any capitalised terms in this Vaccine Order Form will have the meaning attributed to them in the definitions list included in Article I.2 of the PA.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.71%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.72%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">This Vaccine Order Form relates to the order for the Participating Member State&#8217;s full allocated portion of the Contracted Doses or the relevant Additional Order (as applicable)<font style="font-size:11pt;"> </font>as set out in the allocation provided by the Commission to Contractor pursuant to Article I.6.2 of the PA. The submission of this signed Vaccine Order Form by the Participating Member State to Contractor constitutes a binding order by the Participating Member State for the purchase of its full allocated portion of the Contracted Doses or the relevant Additional Order (as applicable) as follows</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:12.7%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Participating Member State will purchase [insert amount] number of doses of [Contracted Doses] [Additional Order] of the Vaccine, on the basis of the following delivery schedule: </p></td></tr></table></div>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:83.3%;">
<tr>
<td valign="top"  style="width:19.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:20.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:20.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:20.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:20.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:16.69%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:12.7%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Delivery Price of [Contracted Doses] [Additional Order] is [***].</p></td></tr></table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:16.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total amount payable by the Participating Member State for the [Contracted Doses] [Additional Order] is [insert amount] [***].</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.71%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.72%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">By signature of this Vaccine Order Form, the undersigned Participating Member State warrants to Contractor that:</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.71%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.91%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a<font style="margin-left:36pt;">it is irrevocably and unconditionally bound by the terms of the PA (as concluded by the Commission on behalf and in the name of the Participating Member States)</font>, including the indemnification obligations and the liability, limitation of liability and exclusions terms set out therein;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:16.69%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.91%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b<font style="margin-left:36pt;">the provisions of the PA are enforceable against it in accordance with its terms;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:27.92%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.71%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c<font style="margin-left:36pt;">it shall indemnify </font>the Indemnified Persons in accordance with Article I.12 (<font style="font-style:italic;">Indemnification</font>) of the PA;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.71%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d<font style="margin-left:36pt;"></font>it has full right, power and authority to enter into this Vaccine Order Form and to perform its respective obligations under it;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.71%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</font><font style="margin-left:36pt;">the person executing this Vaccine Order Form is duly authorized to execute and bind the undersigned </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Participating </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Member State to the terms set forth herein and incorporated by reference.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.71%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.72%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">[***]</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.71%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.72%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Participating Member State represents and warrants that all necessary permissions and approvals &#8206;have been or will be obtained prior to the time for performance by the Participating Member State, to authorise performance of all of the obligations contained herein.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.71%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Article II</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delivery, Supply</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.91%;text-indent:-11.19%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.72%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;">Delivery Address</font>. The Delivery Address for the Participating Member State is as follows: </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.71%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.95%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">&#8226; - Participating Member State to enter location of its distribution hub</font>]</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:15.95%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.72%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Supply of the Products</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor shall supply the Products as further described in the PA: [<font style="font-weight:bold;">Note: </font>Include any additional details concerning the supply here.]</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:8.71%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Article III</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Invoices; Notices</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:12.03%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.72%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;">Invoice and Payments</font>. Contractor shall invoice the Participating Member State in accordance with the terms of the PA. All payments to Contractor or its designated Affiliate shall be made in accordance with the terms of the PA.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.71%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.71%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment shall be made in the following currency pursuant to the provisions of Article II.19.2: [to be completed].</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:8.71%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.72%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;">Notice</font>. Any notice given under this Vaccine Order Form must a) be made in writing in English in paper or electronic format; b) bear the PA number and the number of this Vaccine Order Form; c) be made using the relevant communication details set out below with respect to the Participating Member State and Contractor (as applicable); d) be sent by mail and email: </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:13.98%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Participating <font style="text-decoration:underline;">Member State</font>:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.64%;text-indent:7.98%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Name of </font><font style="font-style:italic;Background-color:#D9D9D9;">Participating</font><font style="Background-color:#D9D9D9;"> </font><font style="font-style:italic;">Member State</font>]</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.64%;text-indent:7.98%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Full official address of Participating Member State</font>]</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.64%;text-indent:7.98%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Full name of addressee physical person (contact person)</font>]</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.64%;text-indent:7.98%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Function of addressee physical person (contact person)</font>]</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.64%;text-indent:7.98%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E-mail: [<font style="font-style:italic;">complete email of addressee physical person (contact person)</font>]</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.64%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:13.98%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Contractor</font>:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.98%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">[Add details]</font></p><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Article IV.</font><font style="margin-left:36pt;"></font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Entry into Force and Duration</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">This Vaccine Order Form shall enter into force on the date of signature<font style="font-size:9pt;"> </font>by the Parties and will remain into force until termination of the PA, or if the PA expires, until the last delivery of Product [***].</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Article V.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Applicable Law and Settlement of Disputes</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.96%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.96%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">For the avoidance of doubt, Article I.13 (<font style="font-style:italic;">Applicable Law and Settlement of Disputes</font>) of the PA shall apply to any dispute arising out of the implementation of or in connection with this Vaccine Order Form and the Participating Member State irrevocably agrees to be bound by the provisions set out therein. </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Signature page follows)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:122.75pt;">
<td colspan="2" valign="top"  style="width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the <font style="font-weight:bold;">Participating</font> <font style="font-weight:bold;">Member State</font>,</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">forename/surname/position</font>]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature:_____________________</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Done at [<font style="font-style:italic;">place</font>], [<font style="font-style:italic;">date</font>]</p></td>
</tr>
<tr style="height:202.7pt;">
<td valign="top"  style="width:52.2%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For acceptance of the Vaccine Order Form,</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractor,</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature: _______________________</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Done at [<font style="font-style:italic;">place</font>], [<font style="font-style:italic;">date</font>]</p></td>
<td valign="top"  style="width:47.8%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The invoice will be paid only once the Contractor has returned the signed Vaccine Order Form.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-style:normal;text-transform:none;"><font style="font-family:Times New Roman;border-bottom:double 2.5pt;font-variant: small-caps;font-style:normal;text-transform:none;">ANNEX II: Agreement between the Commission and Member States on procuring Covid-19 vaccines on behalf of the Member States and related procedures, annexed to the Commission Decision C(2020) 4192 final of 18 June 2020</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Agreement</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preamble</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Having regard to Article 4(5)(b) of Council regulation (EU) 2016/369 on the provision of emergency support within the Union1as amended by Council regulation (EU) 2020/521 of 14 April 2020 activating the emergency support under regulation (EU) 2016/369, and amending its provisions taking into account the COVID-19 outbreak (hereinafter &#8220;ESI&#8221; or &#8220;ESI regulation&#8221;); </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The European Commission (&#8220;the Commission&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following Member States: (XXX), hereinafter referred to as &#8220;the Participating Member States&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Together referred to as &#8220;the Parties&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agree on the Following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Article 1: Objective and mandate of the Commission</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the basis of the present agreement, the Commission is mandated to conclude, on behalf of the Participating Member States, Advance Purchase Agreements (&#8220;APA&#8221;) with vaccine manufacturers with the objective to procure vaccines for the purposes of combatting the COVID 19 pandemic at Union level.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Annex to this agreement sets out the negotiating directives for this purpose.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Article 2: Acquisition of vaccine doses</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is the Participating Member States, and not the Commission, that shall acquire vaccine doses from the manufacturers on the basis of the APAs unless otherwise agreed. All relevant vaccination policies shall therefore remain matters for the Participating Member States. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Article 3: APAs containing a right to acquire vaccine doses</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Where the Commission concludes an APA in conformity with the present agreement that provides the right for the Participating Member States to acquire vaccine doses, the use of such a right shall take place by means of the conclusion of contracts between the Participating Member States and the vaccine manufacturers. There shall be no obligation for any </p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Participating Member State to conclude such a contract on the basis of the APA. The APA shall contain a clause to this end. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Article 4: APAs containing an obligation to acquire vaccine doses</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Where the Commission intends to conclude, in conformity with the present agreement, an APA containing an obligation to acquire vaccine doses, it shall inform the Participating Member States of such intention and the detailed terms. In case a Participating Member State does not agree with the conclusion of an APA containing an obligation to acquire vaccine doses or its terms, it has the right to opt out by explicit notification to the Commission within 5 working days after the Commission has communicated its intention to conclude the APA. All Participating Member States not having opted out within the period of 5 working days are deemed to have authorised the Commission to negotiate and conclude the APA with the vaccine manufacturer in their name and on their behalf. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Article 5: The legally binding nature of APAs</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once concluded, the terms of the APA shall be legally binding on the Participating Member States, except for those who have exercised their right to opt out.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Article 6: Responsibility and liability</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The present Agreement regulates only the division of potential liability and indemnification between the Commission and the Participating Member States. It does not regulate the extent to or the conditions under which potential liability of the vaccine manufacturer may be taken over or indemnified under the APAs. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission shall be exclusively responsible for the procurement process and the conclusion of APAs including any liability arising out of the conduct of the negotiations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Participating Member States acquiring a vaccine shall be responsible for the deployment and use of the vaccines under their national vaccination strategies, and shall bear any liability associated with such use and deployment. This shall extend to and include any indemnification of vaccine manufacturers under the terms and conditions of the relevant APA for liability related to the use and deployment of vaccines normally borne by such manufacturer.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Article 7: Obligation not to negotiate separately</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By signing the present Agreement, the Participating Member States confirm their participation in the procedure and agree not to launch their own procedures for advance purchase of that vaccine with the same manufacturers.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In case an APA containing an obligation to acquire vaccine doses has been concluded with a specific manufacturer, the Member States having made use of the opt-out provided under the present Agreement can enter into separate negotiations with the same manufacturer after the APA under the present Agreement has been signed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annex</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Initial considerations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A permanent solution to the COVID-19 crisis is most likely to be brought about by the development and deployment of a safe and effective vaccine against the virus. Every month gained in the deployment of a vaccine will save many lives, many jobs and billions of euros.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therefore, it is the objective of the present Agreement that the EU takes steps to secure sufficient supplies of a safe and effective vaccine for Member States. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Structure and purpose of the procurement</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work on a COVID-19 vaccine is challenging for many reasons: the shortened development timeframe, the large upfront costs for manufacturers, the high failure rate during clinical trials. If vaccine producers follow their usual practice of making investments in production capacity only when they are sure of a viable product, this will result in considerably longer waiting times for a vaccine. Investments need to be made now in order to ensure that vaccines are being produced at the scale required as early as possible.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the present agreement, this challenge will be addressed through concluding EU-level Advance Purchase Agreements (&#8220;APA&#8221;) with vaccine manufacturers when necessary, to secure access to vaccine candidates where they are successful, including up-front EU financing to de-risk essential investments to increase the speed and scale of manufacturing successful vaccines. Funding for the up-front payments will come from the Emergency Support Instrument (ESI).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Parties understand that developing a safe and effective vaccine is a highly complex process and the risk of failure in any such venture is very high. Therefore, the aim is to put in place APAs with a number of manufacturers of leading vaccine candidates, to maximise the chances of having access to at least one successful vaccine.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Commission will invite all vaccine manufacturers to manifest interest. In general, the Commission will give priority to negotiating specific APAs with those manufacturers that (a) have entered or have firm plans to enter clinical trials still in 2020, (b) have the capacity to develop a successful vaccine and (c) have a proven capacity to produce at scale already in 2021. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Process and governance</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to run the procurement centrally and efficiently, the European Commission will set up a steering board for the process subject to Article 6 of the present Agreement. It will be co-chaired by the European Commission and a Participating Member State with experience in the negotiations and production capacities for vaccines. The steering board will include senior officials from all Participating Member States to assist and provide guidance throughout the evaluation process. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The co-chairs of the steering board will propose a team of a limited number of experts with relevant experience for the ongoing negotiations from six Participating Member States with production capacities for vaccines. These experts will join with the European Commission in a negotiation team (&#8220;joint negotiation team&#8221;), which will work on a continuous basis as one </p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unit.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">That</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">joint</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">negotiation</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">team</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">start</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">work</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">immediately building</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">previous</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">contacts</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">individual</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">companies</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">European</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commission and</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Participating</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Member</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">States.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">order</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">launch</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">negotiations</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">specific manufacturer,</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">there</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">needs</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">support</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">least</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">four</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Participating</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Member</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">States. The</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">joint</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">negotiation</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">team</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">make</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">best</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effort</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">take</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">advice</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the steering board</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">into</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">account</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">negotiations</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">report</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">back</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">steering</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">board</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a regular basis on the progress made in negotiating with individual companies. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For compliance with the applicable rules, all members of the steering board and the joint negotiation team will obtain the status of experts associated to the procurement process as provided in the Financial Regulation. Given their access to highly sensitive business information, all those members will be required to sign strict confidentiality and no-conflict-of-interest agreements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assisted by the steering board, the European Commission will then decide which of the resulting APAs should be concluded, in particular if financing under ESI is insufficient to finance all relevant packages. The Commission will only consider those APAs for financing where at least four Participation Member States have expressed agreement. Before making any final decisions, the Commission will seek independent scientific advice on the state of progress and the available data on quality, safety and efficacy for the vaccine candidate in question. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should financing under ESI be insufficient, Participating Member States can decide to top up ESI funding to make up the gap to finance all packages. In such a case where there are opportunities to conclude further APAs but money from ESI is no longer sufficient, Participating Member States will have the opportunity to express their interest in such opportunities. If at least four Participating Member States express interest, those Participating Member States will make use of the possibility of a voluntary contribution to ESI to the required amount allowing the Commission to proceed with signing the APA only on behalf of those Member States that have expressed interest and contributed the funds to ESI.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For full transparency, the European Commission will report to the IPCR at least once every two weeks on overall progress more generally.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Advanced Purchase Agreements and conditions</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To conclude APAs, the joint negotiating team will negotiate funding packages with individual vaccine producers in return for the right to buy a specific number of vaccine doses in a given timeframe and at a certain price. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As outlined in the present Agreement, the European Commission also has the possibility to conclude APAs including an obligation to procure the vaccine if it becomes available, where the conditions (notably the pricing) of those APAs make this worthwhile and in line with the conditions in the present Agreement. If in such a case the distinction between upfront payments and purchase price is difficult to draw, the Commission will share the total cost related to the vaccine purchase but will in any case contribute no more than 50% of the total cost. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Funding provided up front will be considered as an advance payment for any eventual purchase by Member States, thus reducing the amount that Member States will have to pay when eventually purchasing that vaccine. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The up-front payments under the APAs shall be used by manufacturers to de-risk the necessary investments related to both vaccine development and clinical trials, and the preparation of the at-scale production capacity along the entire vaccine production value chain in the EU required for a rapid deployment of millions of doses of an eventual vaccine. The relevant payments should be structured according to the need of the manufacturer, but subject to the state of the vaccine development, in particular relying on transparency of the associated clinical data and its assessment, at the time of payment. This is in order to avoid obligations to pay in situations where the development work has shown a vaccine candidate likely to be unsuccessful.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The purchase price of the vaccine, as well as the amount of funding provided up front will take into account a transparent estimation of production costs (supported by independent audits where available), as well as the resources already granted from other public sources. Under the APA, the manufacturer can be asked to provide ex post proof supported by independent audits concerning the activities financed by these payments. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aim of the negotiation is to conclude APAs with individual companies under the best possible conditions. These APAs should specify details with respect to: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Payments to be made, such as payment amounts, payment schedules, type of payments requested and the use of those payments related to de-risk investment, financing clinical trials, providing working capital and scaling-up production capacity;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Delivery details of the vaccine if successful, such as price per person immunised (or alternatively, number of doses required per person immunised and price per dose), quantity of doses to be delivered and delivery timeline following approval; </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.97%;text-indent:-3.99%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.97%;text-indent:-3.99%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Any other relevant conditions, such as production capacity built or used in the EU or liability arrangements. </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For liability arrangements, the joint negotiation team will make its best effort to limit what is required by individual companies for the purpose of indemnification to be included in the terms and conditions of the APA.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The APAs will contain provisions to clarify the law applicable to both the APA and resulting purchase orders as well as the competent courts. The Participating Member States agree that each APA negotiated by the Commission on their behalf with a vaccine manufacturer will have the same applicable law for all Participating Member States, and that the courts corresponding to that applicable law will be competent to hear disputes arising from that APA.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When taking a decision to finance individual APAs, the European Commission, in consultation with the steering board, will take into account the following elements: any available data on quality, safety and efficacy of the vaccine at time of negotiation of the contract, speed of delivery at scale, cost, risk-sharing, diversification of technologies, capacity to supply through development of production capacity within the EU, possible flexible future use of any capacity funded, engagement at an early stage with EU regulators with the intention to apply for an EU marketing authorisation for the candidate vaccine(s), commitment to supply vulnerable countries. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The procedure outlined above complies with the ESI Regulation and the Financial Regulation. The latter is aligned to the European procurement Directives, which also provide the basis for national procurement rules. Participating Member States may rely on the procedure run by the European Commission to directly purchase vaccines from the manufacturers as and when any of the vaccines becomes available based on the conditions laid down in the APA. Access to vaccine doses will be allocated to Participating Member States according to the population distribution key.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the negotiations with the pharmaceutical industry under the present Agreement, the Commission will promote a Covid-19 vaccine as a global public good. This promotion will include access for low and middle income countries to these vaccines in sufficient quantity and at low prices. The Commission will seek to promote related questions with the pharmaceutical industry regarding intellectual property sharing, especially when such IP has been developed with public support, in order to these objectives. Any vaccines available for purchase under the APAs concluded but not needed and purchased by Participating Member States can be made available to the global solidarity effort.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-style:normal;text-transform:none;"><font style="font-size:12pt;font-family:Times New Roman;border-bottom:double 2.5pt;font-variant: small-caps;font-style:normal;text-transform:none;">Annex </font><font style="font-size:12pt;font-family:Times New Roman;border-bottom:double 2.5pt;font-variant: small-caps;font-style:normal;text-transform:none;">II</font><font style="font-size:12pt;font-family:Times New Roman;border-bottom:double 2.5pt;font-variant: small-caps;font-style:normal;text-transform:none;">I</font><font style="font-size:12pt;font-family:Times New Roman;border-bottom:double 2.5pt;font-variant: small-caps;font-style:normal;text-transform:none;">: Participating Member States</font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">France</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Italy</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Spain</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Austria</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Greece</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cyprus</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Malta</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denmark</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sweden</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finland</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ireland</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portugal</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Belgium</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Luxembourg</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Netherlands</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Poland</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Romania</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bulgaria</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Slovenia</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Croatia</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Czech Republic</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hungary</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Slovakia</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lithuania</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Latvia</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estonia</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-style:normal;text-transform:none;"><font style="font-size:12pt;font-family:Times New Roman;border-bottom:double 2.5pt;font-variant: small-caps;font-style:normal;text-transform:none;">Annex </font><font style="font-size:12pt;font-family:Times New Roman;border-bottom:double 2.5pt;font-variant: small-caps;font-style:normal;text-transform:none;">I</font><font style="font-size:12pt;font-family:Times New Roman;border-bottom:double 2.5pt;font-variant: small-caps;font-style:normal;text-transform:none;">V</font><font style="font-size:12pt;font-family:Times New Roman;border-bottom:double 2.5pt;font-variant: small-caps;font-style:normal;text-transform:none;">: SUBCONTRACTORS</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]<br /></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-style:normal;text-transform:none;"><font style="font-size:12pt;font-family:Times New Roman;border-bottom:double 2.5pt;font-variant: small-caps;font-style:normal;text-transform:none;">Annex V </font><font style="font-size:12pt;font-family:Times New Roman;border-bottom:double 2.5pt;font-variant: small-caps;font-style:normal;text-transform:none;">&#8211;</font><font style="font-size:12pt;font-family:Times New Roman;border-bottom:double 2.5pt;font-variant: small-caps;font-style:normal;text-transform:none;"> </font><font style="font-size:12pt;font-family:Times New Roman;border-bottom:double 2.5pt;font-variant: small-caps;font-style:normal;text-transform:none;">PARTICIPATING CONTRACTOR AFFILIATES</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:34.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Country</p></td>
<td valign="top"  style="width:65.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Participating Contractor Affiliate</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:65.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Europe GmbH</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">France</p></td>
<td valign="top"  style="width:65.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer SAS</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Italy</p></td>
<td valign="top"  style="width:65.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer S.r.l.</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Spain</p></td>
<td valign="top"  style="width:65.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer S.L.U.</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Austria</p></td>
<td valign="top"  style="width:65.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Corporation Austria GmbH</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Greece</p></td>
<td valign="top"  style="width:65.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Hellas SA</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cyprus</p></td>
<td valign="top"  style="width:65.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Hellas SA</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Malta</p></td>
<td valign="top"  style="width:65.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Hellas SA</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denmark</p></td>
<td valign="top"  style="width:65.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer ApS</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sweden</p></td>
<td valign="top"  style="width:65.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Innovations AB</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finland</p></td>
<td valign="top"  style="width:65.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Finland Oy</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ireland</p></td>
<td valign="top"  style="width:65.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Healthcare Ireland</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portugal</p></td>
<td valign="top"  style="width:65.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Biofarmac&#234;utica Sociedade Unipessoal, Lda</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Belgium</p></td>
<td valign="top"  style="width:65.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer SA</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Luxembourg</p></td>
<td valign="top"  style="width:65.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Luxembourg S.A.R.L.</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Netherlands</p></td>
<td valign="top"  style="width:65.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer BV</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Poland</p></td>
<td valign="top"  style="width:65.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Trading Polska sp. z o.o.</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Romania</p></td>
<td valign="top"  style="width:65.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Romania SRL</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bulgaria</p></td>
<td valign="top"  style="width:65.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Export B.V.</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Slovenia</p></td>
<td valign="top"  style="width:65.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Export B.V.</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Croatia</p></td>
<td valign="top"  style="width:65.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Export B.V.</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Czech Republic</p></td>
<td valign="top"  style="width:65.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer PFE, spol. s r.o.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After 1/12 shall be merged into Pfizer, spol. s r.o.</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hungary</p></td>
<td valign="top"  style="width:65.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Gy&#243;gyszerkereskedelmi Kft.</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Slovakia</p></td>
<td valign="top"  style="width:65.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Export B.V.</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lithuania</p></td>
<td valign="top"  style="width:65.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Export B.V.</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Latvia</p></td>
<td valign="top"  style="width:65.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Export B.V.</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estonia</p></td>
<td valign="top"  style="width:65.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Export B.V.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-variant: normal;font-style:normal;text-transform:none;"><font style="text-decoration:none;">In addition, any Contractor Affiliate which is involved in the sale or distribution of Product which is resold or donated by a Participating Member State shall be deemed to be a Participating Contractor Affiliate.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-style:normal;text-transform:none;"><font style="font-size:12pt;font-family:Times New Roman;border-bottom:double 2.5pt;font-variant: small-caps;font-style:normal;text-transform:none;">Attachment</font><font style="font-size:12pt;font-family:Times New Roman;border-bottom:double 2.5pt;font-variant: small-caps;font-style:normal;text-transform:none;"> 1: SPECIFICATION</font><font style="font-size:12pt;font-family:Times New Roman;border-bottom:double 2.5pt;font-variant: small-caps;font-style:normal;text-transform:none;">S</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]<br /></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-style:normal;text-transform:none;"><font style="font-size:12pt;font-family:Times New Roman;border-bottom:double 2.5pt;font-variant: small-caps;font-style:normal;text-transform:none;">Attachment</font><font style="font-size:12pt;font-family:Times New Roman;border-bottom:double 2.5pt;font-variant: small-caps;font-style:normal;text-transform:none;"> 2: Delivery Documentation</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-style:normal;text-transform:none;"><font style="font-size:12pt;font-family:Times New Roman;border-bottom:double 2.5pt;font-variant: small-caps;font-style:normal;text-transform:none;">Attachment</font><font style="font-size:12pt;font-family:Times New Roman;border-bottom:double 2.5pt;font-variant: small-caps;font-style:normal;text-transform:none;"> 3: Delivery Specification</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-style:normal;text-transform:none;"><font style="font-size:12pt;font-family:Times New Roman;border-bottom:double 2.5pt;font-variant: small-caps;font-style:normal;text-transform:none;">Attachment</font><font style="font-size:12pt;font-family:Times New Roman;border-bottom:double 2.5pt;font-variant: small-caps;font-style:normal;text-transform:none;"> 4: Labelling and Packaging Specifications</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-style:normal;text-transform:none;"><font style="font-size:12pt;font-family:Times New Roman;border-bottom:double 2.5pt;font-variant: small-caps;font-style:normal;text-transform:none;">Attachment</font><font style="font-size:12pt;font-family:Times New Roman;border-bottom:double 2.5pt;font-variant: small-caps;font-style:normal;text-transform:none;"> 5: Return and Disposal of Product Materials</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.53
<SEQUENCE>13
<FILENAME>bntx-ex453_417.htm
<DESCRIPTION>EX-4.53
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-ex453_417.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62055695"></a>Exhibit 4.53</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">THE SYMBOL &#8220;[***]&#8221; DENOTES PLACES WHERE CERTAIN</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE</p>
<p style="text-align:center;margin-bottom:11pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">COMPANY IF PUBLICLY DISCLOSED</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Lease</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">concerning</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:11pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Areas and Spaces in Buildings H028 and H030</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(Buildings H028 and H30 are hereinafter jointly</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">referred to as &#8220;Building H028&#8221;)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at the Behringwerke Site in Marburg</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emil-von-Behring-Strasse 76, 35041 Marburg</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- hereinafter referred to as the &#8220;<font style="font-weight:bold;">Lessor</font>&#8221; &#8211;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="text-align:center;margin-top:11pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Novartis Manufacturing GmbH</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emil-von-Behring-Strasse 76, 35041 Marburg</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- hereinafter referred to as the &#8220;<font style="font-weight:bold;">Lessee</font>&#8221; &#8211;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <font style="font-weight:bold;">Lessor</font> and <font style="font-weight:bold;">Lessee</font> are also referred to individually as a &#8220;Party&#8221; or</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">jointly as the &#8220;Parties&#8221;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Preamble</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Section 1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Leased Object</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The <font style="font-weight:bold;">Lessor</font>, in its capacity as the owner, leases to the <font style="font-weight:bold;">Lessee</font> the areas and spaces marked in green within the Buildings H028 and H030 (Buildings H028 and H30 will be hereinafter also referred to jointly as &#8220;Building H028&#8221;) shown in <font style="font-weight:bold;text-decoration:underline;">Annex 1.4</font>) (&#8220;Site Plan&#8221;), at the Behringwerke Site, Emil-von-Behring-Strasse 76, 35041 Marburg, including the traffic areas and ancillary areas, to the extent that these traffic areas and ancillary areas are marked in &#8220;green&#8221; instead of &#8220;grey&#8221; in <font style="font-weight:bold;text-decoration:underline;">Annex 1.1)</font> (hereinafter jointly referred to as the &#8220;<font style="font-weight:bold;">Leased Object</font>&#8221;).</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The areas and spaces marked in green in <font style="font-weight:bold;text-decoration:underline;">Annex 1.2)</font> (hereinafter referred to as the &#8220;<font style="font-weight:bold;">Additional Areas</font>&#8221;) will be included in the Lease as from 01.01.2025. However, by way of deviation from the previous sentence, the Additional Areas will be included in the Lease as early as 01.01.2024 if the <font style="font-weight:bold;">Lessor</font> informs the <font style="font-weight:bold;">Lessee</font> in writing of the earlier lease start date by no later than 31.12.2022.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From the date of inclusion of the Additional Areas in the Lease, the <font style="font-weight:bold;">Leased Object</font> will comprise the areas and spaces as shown in <font style="font-weight:bold;text-decoration:underline;">Annex 1.3)</font> to this Lease.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The technical areas marked in blue may be jointly used by the <font style="font-weight:bold;">Lessee</font> free of charge for the installation of the <font style="font-weight:bold;">Lessee</font>&#8217;s own technical equipment, depending on the space available. </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The external roof areas, fa&#231;ade surfaces and external parts of the building are not included in the Lease. The <font style="font-weight:bold;">Lessee</font> is permitted to use these roof areas and fa&#231;ade surfaces free of charge in agreement with the <font style="font-weight:bold;">Lessor</font> only if they are required in order to fulfil the purpose of the Lease as set out in Section 2 of this Lease.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Components of the <font style="font-weight:bold;">Leased Object</font> include its building construction, facilities and installations, only insofar as and to the extent that these are listed in <font style="font-weight:bold;text-decoration:underline;">Annex 2.1), Annex 2.2) </font>(Additional Areas) and <font style="font-weight:bold;text-decoration:underline;">Annex 2.3).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the building construction, facilities and installations are not listed in Annex 2.1), Annex 2.2) (Additional Areas) and Annex 2.3), they do not form part of the <font style="font-weight:bold;">Leased Object</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">More specifically, the Lease does not cover the extension to the <font style="font-weight:bold;">Leased Object</font> for pharmaceutical purposes (building construction, facilities and installations) carried out in the <font style="font-weight:bold;">Leased Object</font> by the <font style="font-weight:bold;">Lessee</font> and the previous lessees, [***].</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Lease also does not cover &#8211; and it is therefore not listed as leased in <font style="font-weight:bold;text-decoration:underline;">Annex 2.1), Annex 2.2) and Annex 2.3) </font>&#8211; the necessary infrastructure for energy and media transmission, such as supply lines, from the output terminal of the main distributor, and from the first shut-off valve in the central energy room. This infrastructure is in the possession of [***], and the <font style="font-weight:bold;">Lessee</font> will agree with [***] on the usage and transfer of this infrastructure outside the scope of this Lease.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The <font style="font-weight:bold;">Lessee</font> is permitted sole use of the area for storing waste containers allocated to Building H028 as per <font style="font-weight:bold;text-decoration:underline;">Annex 1.4)</font> and listed as such therein, on the eastern side of Talstrasse, to the north of Building H028, and joint use of the area to the south of Building H028 with the other users of Building H028, free of charge and in accordance with all applicable legal provisions, more specifically to an extent that corresponds to the proportion of the <font style="font-weight:bold;">Leased Object</font> surface area provided to the <font style="font-weight:bold;">Lessee</font> in m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">&nbsp;&nbsp;</sup>in relation to the surface area of all leasable areas in Building H028.</p></td></tr></table></div>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 2</a> of 20</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The description of the <font style="font-weight:bold;">Leased Object</font> in this Lease merely constitutes an agreement on quality rather than a guaranteed characteristic.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The <font style="font-weight:bold;">Lessor</font> is authorised to have the technical equipment available in the <font style="font-weight:bold;">Leased Object</font>, in particular fire alarms and fault indication systems, including the infrastructure necessary for these, and to install, reposition, dismantle, extend, operate, and renew them. The <font style="font-weight:bold;">Lessor</font> is authorised to enter the <font style="font-weight:bold;">Leased Object</font> at any time for this purpose in agreement with the <font style="font-weight:bold;">Lessee</font> or arrange for it to be entered by appointed third parties. In the event of imminent danger, entry is authorised even without agreement; however, the <font style="font-weight:bold;">Lessor</font> must notify the <font style="font-weight:bold;">Lessee</font> after it has carried out the work.</p></td></tr></table></div><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 3</a> of 20</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Section 2</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Purpose of the Lease, Value Added Tax,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Orders, Requirements, Approvals</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) </font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The <font style="font-weight:bold;">Lessor</font> provides the <font style="font-weight:bold;">Lessee</font> with the <font style="font-weight:bold;">Leased Object</font> for the purpose of carrying out pharmaceutical activities, using its own expansions and the <font style="font-weight:bold;">Lessor</font>&#8217;s expansions, which the <font style="font-weight:bold;">Lessee</font> purchases directly from the previous lessee independent of this Lease. The areas leased in Building H030 are leased only for the storage of the goods described in more detail in <font style="font-weight:bold;text-decoration:underline;">Annex 8)</font> to this Lease.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) </font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">If special installations, fittings (for example floor coverings or air conditioning units) or structural amendments beyond those set out in <font style="font-weight:bold;text-decoration:underline;">Annex 2.1), Annex 2.2) </font>(Additional Areas) and <font style="font-weight:bold;text-decoration:underline;">Annex 2.3) </font>are required for a special use within the scope of the agreed purpose of the Lease, it is the responsibility of the <font style="font-weight:bold;">Lessee</font> to arrange for these within the framework of the existing building permit, at its own risk and expense, and to obtain any necessary further approvals. In the event of termination of the Lease, Section 14 of this Lease will apply.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <font style="font-weight:bold;">Lessor</font> approves these installations, fittings or structural amendments within the framework of the existing building consent. However, the <font style="font-weight:bold;">Lessor</font> assumes no liability for the suitability of the provided rooms and areas for a renovation and for special use by the <font style="font-weight:bold;">Lessee</font>, and more specifically it assumes no liability for compliance with the public-law provisions applicable to the operation envisaged by the <font style="font-weight:bold;">Lessee</font>, the accident prevention regulations, the VDS [<font style="font-style:italic;">German corporate security and safety</font>] and T&#220;V [<font style="font-style:italic;">German technical inspection association</font>] guidelines and the availability of the supply, disposal and sanitary facilities required for use by the <font style="font-weight:bold;">Lessee</font>. It is up to the <font style="font-weight:bold;">Lessee</font> alone, at its own expense and risk and under its own responsibility, to provide all necessary conditions, and in particular comply with the public laws (e.g. building consent) and technical and structural requirements for the amendments to the <font style="font-weight:bold;">Leased Object</font> in the areas and spaces provided, made by the previous lessees and the <font style="font-weight:bold;">Lessee</font> and any amendment to be made by it in the future, and for the usage envisaged by the <font style="font-weight:bold;">Lessee</font>, and to meet the requirements imposed by authorities at its own expense. If installations, fittings or structural amendments require an adjustment to the building consent, these require the consent of the <font style="font-weight:bold;">Lessor</font>, which will only refuse this if there is an important reason to do so.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The <font style="font-weight:bold;">Lessee</font> commits to putting in place and maintaining the required fire protection in the <font style="font-weight:bold;">Leased Object</font> with respect to the extension already carried out or to be carried out in the future by it or by third parties, at its own expense. This also applies accordingly to all future amendments to be made in the <font style="font-weight:bold;">Leased Object</font> by the <font style="font-weight:bold;">Lessee</font> itself.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The Lease is for business purposes within the meaning of the German Value Added Tax Act.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <font style="font-weight:bold;">Lessee</font> declares that it and any future sublessees will use the <font style="font-weight:bold;">Leased Object</font> exclusively for revenues that do not preclude input tax deduction by the <font style="font-weight:bold;">Lessor</font> (Sections 9 (2) of the German Value Added Tax Act, 27 (2) of the German Value Added Tax Act). Where requested to do so by the <font style="font-weight:bold;">Lessor</font>, the <font style="font-weight:bold;">Lessee</font> will provide it with suitable evidence of the fact that it and any future sublessees are using or have used the <font style="font-weight:bold;">Leased Object</font> exclusively for revenue that does not preclude input tax deduction by the <font style="font-weight:bold;">Lessor</font>. The <font style="font-weight:bold;">Lessee</font> warrants that it will impose on any future sublessees the obligation to use the <font style="font-weight:bold;">Leased Object</font> exclusively for revenues that do not preclude input tax deduction by the <font style="font-weight:bold;">Lessor</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the <font style="font-weight:bold;">Lessee</font> or any future sublessees generate revenues in the <font style="font-weight:bold;">Leased Object</font> that preclude input tax deduction by the <font style="font-weight:bold;">Lessor</font> contrary to the above provision, it must notify the <font style="font-weight:bold;">Lessor</font> of </p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 4</a> of 20</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">this immediately. In this case, it is obliged to compensate the </font><font style="font-weight:bold;">Lessor</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for any proven disadvantage</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> suffered by it as a result of the lost input tax deduc</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tion. The </font><font style="font-weight:bold;">Lessee</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> is obliged to produce any rele</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vant evidence requested by the T</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ax </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uthority.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">A change of use in accordance with paragraph (1) above requires the prior written consent of the <font style="font-weight:bold;">Lessor</font>, to which the <font style="font-weight:bold;">Lessee</font> has no entitlement.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">Official orders and requirements and necessary approvals which are exclusively based on or required due to the general quality and/or location of the <font style="font-weight:bold;">Leased Object</font> must be fulfilled or obtained by the <font style="font-weight:bold;">Lessor</font> at its own expense, for the entire term of the Lease.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If official requirements and/or the obtaining/retention of official permits results from the <font style="font-weight:bold;">Lessee</font>&#8217;s personal or special operational circumstances or from the special circumstances of its commercial operations, the <font style="font-weight:bold;">Lessee</font> will be solely responsible for the related measures and costs.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To this extent, the <font style="font-weight:bold;">Lessee</font> must also fulfil any official orders and requirements issued in relation to the <font style="font-weight:bold;">Leased Object</font> during the term of the Lease at its own expense, even if they are directed at the <font style="font-weight:bold;">Lessor</font>. The <font style="font-weight:bold;">Lessor</font> will provide the <font style="font-weight:bold;">Lessee</font> with the necessary and reasonable support in this regard.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Section 3</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Term of the Lease</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)<font style="margin-left:36pt;">The </font>Lease begins</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- on 01.07.2019 for the areas described in more detail in <font style="font-weight:bold;text-decoration:underline;">Annex 1.1).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- for the Additional Areas, in accordance with the provision laid down in Section 1 (2) of the Lease. The date from which the Additional Areas will also be included in the Lease will be agreed by the Parties in an amendment to this Lease which complies with the written form requirement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For all areas as a single unit, the Lease will end on 31.12.2034 (&#8220;Fixed Lease Term&#8221;) without any Party being required to give notice to terminate.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The <font style="font-weight:bold;">Lessee</font> has the right by unilateral declaration to extend the term of this Lease after expiry of the Fixed Lease Term for a period of five years on three consecutive occasions (&#8220;<font style="font-weight:bold;">Option Right</font>&#8221;) and the provisions of the Lease will continue to apply. The extension of the Fixed Lease Term by five years in each case will be hereinafter referred to as the &#8220;<font style="font-weight:bold;">Extended Period</font>&#8221;. The adjustment of the rent excluding utilities during the Extended Periods is provided for in Section 6 of this Lease. The <font style="font-weight:bold;">Lessee</font> must declare in writing to the <font style="font-weight:bold;">Lessor</font> that it is exercising its Option Right no later than 12 months before expiry of the Fixed Lease Term, and otherwise no later than 12 months before the end of an Extended Period. The date of receipt of the declaration by the <font style="font-weight:bold;">Lessor</font> will be the decisive date.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)<font style="margin-left:36pt;">Tacit extension of the </font>Lease pursuant to Section 545 of the German Civil Code is excluded.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 5</a> of 20</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Section 4</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Uninterrupted Possession of the Leased Object, Handover of Additional Areas, Contractual Compliance</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">As regards the areas described in more detail in <font style="font-weight:bold;text-decoration:underline;">Annex 1.1),</font> the <font style="font-weight:bold;">Lessee</font> is already in possession of the <font style="font-weight:bold;">Leased Object</font>. The Parties confirm that the <font style="font-weight:bold;">Lessee&#8217;s</font> possession will be maintained without interruption.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">As regards the Additional Areas described in more detail in <font style="font-weight:bold;text-decoration:underline;">Annex 1.2),</font> the Parties agree that these areas will be handed over to the <font style="font-weight:bold;">Lessee</font> by the <font style="font-weight:bold;">Lessor</font> in accordance with the start of the Lease, either on 01.01.2024 or 01.01.2025.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The <font style="font-weight:bold;">Lessee</font> acknowledges that the <font style="font-weight:bold;">Leased Object</font> is suitable for the purpose of the Lease.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Section 5</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Rent</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The monthly net rent excluding utilities (graduated rent) owed by the <font style="font-weight:bold;">Lessee</font> is the net rent excluding utilities agreed in <font style="font-weight:bold;text-decoration:underline;">Annex 4.1)</font> until the inclusion of the Additional Areas in the Lease.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">As soon as the Additional Areas are included in the Lease pursuant to <font style="font-weight:bold;">Section 1 (2),</font> the <font style="font-weight:bold;">Lessee</font> will owe the net rent excluding utilities for all leased areas depending on the Additional Areas are included in the Lease, as agreed in <font style="font-weight:bold;text-decoration:underline;">Annex 4.2)</font> (from 01.01.2024) or <font style="font-weight:bold;text-decoration:underline;">Annex 4.3)</font> (from 01.01.2025).</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Lease is extended beyond the end of the Fixed Lease Term by the exercise of the Option Right pursuant to Section 3 (2) of this Lease, the monthly rent excluding utilities will be adjusted pursuant to the provisions in Section 6 of this Lease.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">With respect to the net rent excluding utilities and with respect to all operating costs pursuant to Section 7, the <font style="font-weight:bold;">Lessee</font> additionally pays value added tax at the valid rate during the performance period, i.e. currently 19%.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The monthly net rent excluding utilities, including the advance payment for operating costs pursuant to Section 7, must be paid to the Lessor, without charges and in advance, by the third working day of the relevant month at the latest, into the account at [***].</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The <font style="font-weight:bold;">Lessee</font> may only set off claims against the <font style="font-weight:bold;">Lessor</font>&#8217;s payment and exercise a right of retention only if it has recognised or legally determined counterclaims. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:7.98%;text-indent:-7.98%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Section 6</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Rent Adjustment if Option is Exercised</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Only in the event that the Lease is extended beyond 31.12.2034 (&#8220;Fixed Lease Term&#8221;) by the exercise of the option (Section 3 (2)), the following applies to the adjustment of the rent excluding utilities from 01.01.2035 onwards:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">Starting on 01.01.2035, the minimum monthly rent will be adjusted automatically on 1 January of each year on a percentage basis, in accordance with the change to the Consumer Price Index for Germany (2010=100). The first adjustment will take place on 01.01.2035 based </p></td></tr></table></div>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 6</a> of 20</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">change in the index</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for the month of December 2034 compared with </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the month of December 2033. The following adjustments will take place accordingly with effect from 1 January, in accordance with the change in the index for the December of the previous year compared with</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the December of the year preceding the previous year.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">If the Consumer Price Index determined by the Official Statistics Office for the Federal Republic of Germany is discontinued, not replaced by another index or changed to another benchmark index, the amended index will replace the index referred to in paragraph (1). Moreover, the Parties mutually undertake to agree a corresponding provision that comes closest in economic terms to the provisions agreed herein.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">In the event of a change to the index, which leads to an adjustment of the rent pursuant to paragraph (1), the <font style="font-weight:bold;">Lessor</font> will notify the <font style="font-weight:bold;">Lessee</font> of this immediately in writing, without the notification and obligation for the <font style="font-weight:bold;">Lessee</font> to pay the adjusted rent being a prerequisite for payment. However, until the notification, no late payment interest will be owed by the <font style="font-weight:bold;">Lessee</font> or <font style="font-weight:bold;">Lessor</font>. A failure to notify or a delayed notification does not entail a waiver of the right to adjust the rent.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The Parties jointly assume that pursuant to Section 3 (1) of the German Price Clause Act of 7 September 2007, the indexation clause agreed in this Lease is admissible and no Party within the meaning of Section 2 (1) of the German Price Clause Act is inappropriately disadvantaged.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">If Section 3 (1) of the German Price Clause Act is inapplicable and/or the indexation clause is inadmissible, the Parties undertake to agree an admissible provision that comes closest in economic terms to the indexation clause agreed in this Lease.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Section 7</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Operating Costs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">As a general rule, the <font style="font-weight:bold;">Lessee</font> bears all operating costs in addition to the net rent excluding utilities. Operating costs are costs charged to the <font style="font-weight:bold;">Lessor</font> on an ongoing basis as a result of its ownership of the property or the intended use of the <font style="font-weight:bold;">Leased Object</font>, the building (comprising Building H028 North, Building H028 South and Building H030), its facilities and installations, and the property. The operating costs to be borne by the <font style="font-weight:bold;">Lessee</font> include the operating costs pursuant to <font style="font-weight:bold;text-decoration:underline;">Annex 5.1</font><font style="font-weight:bold;">)</font> to this Lease, provided that the <font style="font-weight:bold;">Lessee</font> has not rented the Additional Areas. From the date of inclusion of the Additional Areas, <font style="font-weight:bold;text-decoration:underline;">Annex 5.1</font><font style="font-weight:bold;">)</font> will apply instead of <font style="font-weight:bold;text-decoration:underline;">Annex 5.2</font><font style="font-weight:bold;">),</font> since from this date, the <font style="font-weight:bold;">Lessee</font> will no longer be supplied with energy and media in Building H028 South by the <font style="font-weight:bold;">Lessor</font> within the framework of this Lease, and the <font style="font-weight:bold;">Lessee</font> will enter into separate energy and media supply contracts in order also to supply Building H028 South and/or include the delivery point H028 South in any existing energy and media supply contracts. The operating costs to be borne by the <font style="font-weight:bold;">Lessee</font> also include the operating costs labelled as &#8220;<font style="font-weight:bold;">Basic Infrastructure Costs</font>&#8221; and &#8220;<font style="font-weight:bold;">Drainage Costs</font>&#8221; in <font style="font-weight:bold;text-decoration:underline;">Annex 5.1</font><font style="font-weight:bold;">)</font> and <font style="font-weight:bold;text-decoration:underline;">Annex 5.2</font><font style="font-weight:bold;">),</font> charged to the <font style="font-weight:bold;">Lessor</font> on an ongoing basis as a result of the operation of the Behringwerke Site.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">If public taxes are newly introduced or if the <font style="font-weight:bold;">Lessor</font> is charged new operating costs within the meaning of this Lease by fulfilling legal obligations in relation to the <font style="font-weight:bold;">Leased Object</font> arising after conclusion of the Lease, these may be allocated pursuant to this Lease and a corresponding adjustment made to the advance payment for operating costs. The adjustment of operating costs referred to in <font style="font-weight:bold;text-decoration:underline;">Annex 5.1</font><font style="font-weight:bold;">)</font> and <font style="font-weight:bold;text-decoration:underline;">Annex 5.2)</font> and the creation of new operating costs, which concern neither public taxes nor the fulfilment of legal obligations in relation to </p></td></tr></table></div>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 7</a> of 20</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="font-weight:bold;">Leased Object</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> arising after conclusion of the </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may only take place </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">while taking </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the principle of sound financial management into account. The </font><font style="font-weight:bold;">Lessor</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> will inform the </font><font style="font-weight:bold;">Lessee</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> immediately of any adjustments to operating costs.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">If the <font style="font-weight:bold;">Lessor</font> provides services within its own business operations which, if performed by third parties, would be charged as part of the operating costs pursuant to this Lease, the <font style="font-weight:bold;">Lessor</font> may issue a cost estimate for these services in an amount which corresponds to appropriate consideration, plus the value added tax applicable to these services during the period of performance insofar as applicable (e.g., where agreed, supply of energy and media at the prices applicable to the site, lift maintenance)</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">Unless precluded by mandatory provisions, the operating costs will be allocated according to the proportion of surface area held by the <font style="font-weight:bold;">Lessee</font> in relation to the total surface area of the building. The ratio between the <font style="font-weight:bold;">Lessee</font>&#8217;s proportion of surface area and the total surface area of Building H028 before inclusion of the Additional Areas, agreed only for the purpose of allocating the operating costs, is agreed by the Parties with binding force in <font style="font-weight:bold;text-decoration:underline;">Annex 3.1)</font> to this Lease. The ratio between the <font style="font-weight:bold;">Lessee</font>&#8217;s proportion of surface area and the total surface area of Building H028 after inclusion of the Additional Areas, agreed only for the purpose of allocating the operating costs, is agreed by the Parties with binding force in <font style="font-weight:bold;text-decoration:underline;">Annex 3.2)</font> to this Lease. </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The areas described in more detail in <font style="font-weight:bold;text-decoration:underline;">Annex 1.1)</font> and located in Building H028 North are supplied with energy and media not within the framework of this Lease, but instead on the basis of the supply contracts to be entered into by the <font style="font-weight:bold;">Lessee</font> outside of this Lease.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The areas described in more detail in <font style="font-weight:bold;text-decoration:underline;">Annex 1.1)</font> and located in Building H028 South are supplied with energy and media within the framework of this Lease only until the inclusion of the Additional Areas in the Lease. From the time of inclusion of the </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional Areas, the <font style="font-weight:bold;">Lessor&#8217;s</font> obligation under this Lease to supply the <font style="font-weight:bold;">Lessee</font> with energy and media in Building H028 South will end.<font style="margin-left:36pt;"></font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Parties agree that the supply limit/transfer point for all energy and media supplied is the outlet of the relevant shut-off devices and/or output terminals of the <font style="font-weight:bold;">Lessor&#8217;s</font> main distributor in the central energy room. The distribution/onward transfer of energy and media in Building H028 South to the areas rented by the <font style="font-weight:bold;">Lessee</font> will be agreed between the <font style="font-weight:bold;">Lessee</font> and [***] outside of this Lease.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until the time of inclusion of the Additional Areas in the Lease, the costs for supplying H028 South with energy and media will be billed based on consumption, as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each type of energy and media, an assessment of the total energy and media quantities supplied to Building H028 South will be drawn up based on information from the <font style="font-weight:bold;">Lessor</font>&#8217;s metering points.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">According to the <font style="font-weight:bold;">Lessee&#8217;s</font> share in the relevant energy and media consumption determined in this manner, the supply costs will be allocated within the framework of the operating costs billing.</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 8</a> of 20</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As soon as H028 South is fully rented by the <font style="font-weight:bold;">Lessee</font>, the following applies:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each type of energy and media, an assessment for the total energy and media quantities supplied to Building H028 will be drawn up based on information from the <font style="font-weight:bold;">Lessor</font>&#8217;s metering points. The <font style="font-weight:bold;">Lessee</font> will enter into energy and media supply contracts with the <font style="font-weight:bold;">Lessor</font> or third parties in order to supply the <font style="font-weight:bold;">Leased Object</font>, if this has not been done already. If and to the extent that energy and media supply agreements are already in place between the <font style="font-weight:bold;">Lessor</font> and <font style="font-weight:bold;">Lessee</font>, these may be extended to include the delivery points in Building H028 South.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">For the future, the <font style="font-weight:bold;">Lessor</font> may change the allocation criteria at its discretion in agreement with the <font style="font-weight:bold;">Lessee</font>. </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The operating costs labelled as &#8220;Basic Infrastructure Costs&#8221; and &#8220;Drainage Costs&#8221; in <font style="font-weight:bold;text-decoration:underline;">Annex 5.1</font><font style="font-weight:bold;">)/</font><font style="font-weight:bold;text-decoration:underline;">Annex 5.2</font><font style="font-weight:bold;">)</font> will be determined for the billing year pursuant to the agreement set out in <font style="font-weight:bold;text-decoration:underline;">Annex 5.1</font><font style="font-weight:bold;">)/</font><font style="font-weight:bold;text-decoration:underline;">Annex 5.2</font><font style="font-weight:bold;">),</font> and allocated to the <font style="font-weight:bold;">Lessee</font> in accordance with the arrangements described and agreed in <font style="font-weight:bold;text-decoration:underline;">Annex 5.1)/Annex 5.2).</font> The Basic Infrastructure Costs and Drainage Costs are not subject to the monthly advance payment for operating costs <font style="font-weight:bold;">(</font><font style="font-weight:bold;text-decoration:underline;">Annex 5.3</font><font style="font-weight:bold;">));</font> instead, they are billed for separately by the <font style="font-weight:bold;">Lessor</font> and reimbursed by the <font style="font-weight:bold;">Lessee</font>. </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">If there are fire alarms and fault indication systems or any other technical fittings required for the operation of the building &#8211; except for access control installations &#8211; located in areas used jointly with other lessees of Building H028, the costs of these installations will be borne by the <font style="font-weight:bold;">Lessee</font> in proportion to the spaces used exclusively by it compared with the total surface area of Building H028 <font style="font-weight:bold;text-decoration:underline;">(Annexes 3.1 and 3.2)).</font> The same applies to lightning protection.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The <font style="font-weight:bold;">Lessee</font> will pay monthly advance payments for operating costs, which will be determined as follows if they are not those operating costs labelled as &#8220;Basic Infrastructure Costs&#8221; and &#8220;Drainage Costs&#8221;:</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each calendar year, the <font style="font-weight:bold;">Lessor</font> will estimate a planned amount of the operating costs, adjusted to account for the operating costs actually incurred for the previous year, and invoice the <font style="font-weight:bold;">Lessee</font> on a monthly basis for 1/12 of this amount, plus value added tax, as an advance payment for the operating costs.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">Energy and media consumption will be invoiced for on a monthly basis. No advance payment has been agreed.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">After expiry of the billing period (calendar year), when invoicing for operating costs, the <font style="font-weight:bold;">Lessor</font> will determine all operating costs incurred during the billing period. The <font style="font-weight:bold;">Lessor</font> will compare the operating costs actually incurred with the advance payment for operating costs paid by the <font style="font-weight:bold;">Lessee</font> and will notify the <font style="font-weight:bold;">Lessee</font> of the result when invoicing for the operating costs.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">Any difference between the amount of the advance payment and the amount of the invoice in the <font style="font-weight:bold;">Lessor</font>/<font style="font-weight:bold;">Lessee</font>&#8217;s favour must be settled by the <font style="font-weight:bold;">Lessor</font>/<font style="font-weight:bold;">Lessee</font> within three (3) months after receipt of the invoice by the <font style="font-weight:bold;">Lessee</font>, plus the value added tax applicable at the time of payment.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The <font style="font-weight:bold;">Lessee</font> must notify any objections to an invoice in writing to the <font style="font-weight:bold;">Lessor</font> within three (3) months after receipt of the invoice; otherwise, any objections to the accuracy of the invoice will be excluded unless (i) the <font style="font-weight:bold;">Lessee</font> is not responsible for the delay in asserting the </p></td></tr></table></div>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 9</a> of 20</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">objections, or (ii) the </font><font style="font-weight:bold;">Lessor</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> did not </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">specifically </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">refer to </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the cut-off point and the consequences of its expiry in the invoice letter.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the <font style="font-weight:bold;">Lessee</font>&#8217;s request, the <font style="font-weight:bold;">Lessor</font> will grant the <font style="font-weight:bold;">Lessee</font> access to the invoicing documents in the <font style="font-weight:bold;">Lessor</font>&#8217;s business premises during usual business hours, by prior appointment within four weeks after receipt of the invoice.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">If the <font style="font-weight:bold;">Lessee</font> moves out during the invoicing period, in the event of doubt, the apportionment for the next invoice due will take place in proportion to the leasing period compared with the invoicing period.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The current advance payment amounts as at the start date of the Lease are appended to this Lease as <font style="font-weight:bold;text-decoration:underline;">Annex 5.3</font><font style="font-weight:bold;">).</font> The Parties agree that in the event of an amendment to the advance payment amounts, <font style="font-weight:bold;text-decoration:underline;">Annex 5.3</font><font style="font-weight:bold;">)</font> will not be adjusted and no new annex to the Lease will be created; instead, a simple notification of the amendment (e.g. in the form of a bill) by the <font style="font-weight:bold;">Lessor</font> will be sufficient.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The <font style="font-weight:bold;">Lessor</font> must provide the <font style="font-weight:bold;">Lessee</font> with the invoice no later than by the end of the 12<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> (twelfth) month after the end of the invoicing period. After expiry of this period, any subsequent claim by the <font style="font-weight:bold;">Lessor</font> is excluded, unless the <font style="font-weight:bold;">Lessor</font> is not responsible for the delay in asserting such claim.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Section 8</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Operator Liability</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The <font style="font-weight:bold;">Lessee</font> must create and maintain all the conditions required to operate its business at its own expense (operator liability).</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Requirements of the trade inspectorate or other authorities must be fulfilled by the <font style="font-weight:bold;">Lessee</font> at its own expense, to the extent that corresponding requirements are specifically associated with the business of the <font style="font-weight:bold;">Lessee</font> or its activities in the <font style="font-weight:bold;">Leased Object</font>, even if they are directed at the <font style="font-weight:bold;">Lessor</font>. Section 2 (6) of this Lease is not affected by this.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <font style="font-weight:bold;">Lessee</font> will conduct its business in the <font style="font-weight:bold;">Leased Object</font> in accordance with applicable laws and in accordance with the requirements of national and international authorities.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The <font style="font-weight:bold;">Lessee</font> shall hold the <font style="font-weight:bold;">Lessor</font> harmless against all claims asserted against the <font style="font-weight:bold;">Lessor</font> by third parties as a result of a breach of the operator liability requirements that apply to the <font style="font-weight:bold;">Lessee</font>.</p></td></tr></table></div><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 10</a> of 20</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Section 9</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Warranties, Liability</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The <font style="font-weight:bold;">Lessee</font> is aware that the <font style="font-weight:bold;">Leased Object</font> is located on an industrial site, and that annoyances typical of industrial sites may be caused during the term of the Lease, such as emissions from neighbouring users, works on supply lines, roads, neighbouring buildings and plots.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The strict liability of the <font style="font-weight:bold;">Lessor</font> to compensate for initial defects is excluded.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The exclusion of liability for initial defects also applies to rights and entitlements in relation to rectification of defects, deterioration, termination and rights of retention of the <font style="font-weight:bold;">Lessee</font>, unless the <font style="font-weight:bold;">Lessee</font> was not aware of the defect at the start of the Lease or it is not responsible for it and the <font style="font-weight:bold;">Lessee</font> can prove its unawareness or lack of responsibility.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">If a defect occurs in the <font style="font-weight:bold;">Leased Object</font> after the start of the Lease and the <font style="font-weight:bold;">Lessee</font>, as a general rule, is entitled to warranty claims in relation to this defect, the provisions laid down by Sections 536 et seqq. of the German Civil Code will apply in accordance with this Lease.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">If the <font style="font-weight:bold;">Lessor</font> delays rectifying the defect, the <font style="font-weight:bold;">Lessee</font> may rectify the defect itself and demand compensation for the expenditure incurred in this regard.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The <font style="font-weight:bold;">Lessee</font> will only be entitled to a rent reduction if the appropriate timeframe set for the <font style="font-weight:bold;">Lessor</font> by the <font style="font-weight:bold;">Lessee</font> within which to rectify defects has expired without action. Section 9 (2) of this Lease remains unaffected.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">Claims for compensation by the <font style="font-weight:bold;">Lessee</font>, to the extent not excluded by this Lease, including claims arising from pre-contractual obligations and unlawful acts, can only be asserted if they are based on the intent or gross negligence of the <font style="font-weight:bold;">Lessor</font> or its vicarious agents.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">All liability exclusions and limitations contained in this Lease also apply to the benefit of the organs, representatives and vicarious agents of the <font style="font-weight:bold;">Lessor</font>.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">If the <font style="font-weight:bold;">Lessor</font> supplies energy and media within the framework of this Lease that are to be invoiced as operating costs, the following liability provision will apply regardless of the item supplied:</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the causes of an interruption or erratic supply are due to the electricity supply network operated by the <font style="font-weight:bold;">Lessor</font> as the operator of the electricity supply network for the Behringwerke Site, the <font style="font-weight:bold;">Lessor</font> is liable vis-&#224;-vis the <font style="font-weight:bold;">Lessee</font> in accordance with Section 18 of the German Network Connection Ordinance.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Section 10</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Maintenance, Cosmetic Repairs,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Structural and Technical Amendments</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The allocation of obligations set out below is based on the circumstance that the <font style="font-weight:bold;">Lessee</font> is entitled to organise the internal fittings in the <font style="font-weight:bold;">Leased Object</font> at its own risk to the greatest extent in accordance with its operational requirements, and to take over the fixtures and </p></td></tr></table></div>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 11</a> of 20</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conversions of the previous </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lessee</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under its own responsibility. The allocation of obligations was also taken into consideration when calculating the rent excluding utilities.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <font style="font-weight:bold;">Lessor</font> is only responsible for the maintenance, repair, upkeep, and inspection (hereinafter referred to as &#8220;Maintenance&#8221;) of the <font style="font-weight:bold;">Leased Object</font> within the defined limits pursuant to Section 1 of the Lease, namely the building envelope and the load-carrying components (&#8220;Roof and Structures&#8221;), and the installations, facilities, and fittings of the <font style="font-weight:bold;">Leased Object</font> described in more detail in <font style="font-weight:bold;text-decoration:underline;">Annex 2.1), Annex 2.2)</font> (Additional Areas), and <font style="font-weight:bold;text-decoration:underline;">Annex 2.3),</font> as well as for maintaining and repairing the circulation and ancillary use areas not included in the Lease (marked in &#8220;grey&#8221; in <font style="font-weight:bold;text-decoration:underline;">Annex 1.1), Annex 1.2),</font> and <font style="font-weight:bold;">Annex 1.3))</font> and any other communal technical installations, facilities and areas. This does not affect the exclusion of liability for initial defects pursuant to Section 9 of this Lease. Major maintenance and repair measures to be taken by the <font style="font-weight:bold;">Lessor</font>, i.e. such measures that may significantly affect the operations of the <font style="font-weight:bold;">Lessee</font>, will be agreed in good time with the <font style="font-weight:bold;">Lessee</font> beforehand. Prior agreement will not be required in the event of imminent danger.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except in relation to the house connection, there is no obligation to maintain energy and media distribution infrastructure located within the building, as this infrastructure is not owned by the <font style="font-weight:bold;">Lessor</font> and does not form part of the <font style="font-weight:bold;">Leased Object</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At its own expense, the <font style="font-weight:bold;">Lessee</font> is responsible for the maintenance, repair, upkeep and inspection of the facilities, installations, and fittings within Building H028, to the extent that these are not listed in <font style="font-weight:bold;text-decoration:underline;">Annex 2.1), 2.2), and 2.3)</font> as part of the <font style="font-weight:bold;">Leased Object</font> but are located in the areas provided to the <font style="font-weight:bold;">Lessee</font>/in the spaces used by the <font style="font-weight:bold;">Lessee</font>. The <font style="font-weight:bold;">Lessee</font> is more specifically responsible for the maintenance, repair, upkeep and inspection of the fixtures and conversions carried out by the previous lessees and by the <font style="font-weight:bold;">Lessee</font> itself at its own expense. All works to maintain the operational readiness and operational safety of these facilities, installations, and fittings that are required by law and/or necessary according to the manufacturer&#8217;s instructions are the responsibility of the <font style="font-weight:bold;">Lessee</font> and must be carried out at its own expense.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cosmetic repairs (e.g. replacing the wallpaper, paint and cleaning the carpets) in the <font style="font-weight:bold;">Leased Object</font> are the responsibility of the <font style="font-weight:bold;">Lessee</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The <font style="font-weight:bold;">Lessor</font> is responsible for maintaining an appropriate physical appearance of the fa&#231;ade of the <font style="font-weight:bold;">Leased Object</font>. The <font style="font-weight:bold;">Lessor</font> will carry out modernisation work on the fa&#231;ade of Building H028, as described in <font style="font-weight:bold;text-decoration:underline;">Annex 9)</font> to this Lease.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The <font style="font-weight:bold;">Lessee</font> is authorised to carry out structural or technical amendments to the <font style="font-weight:bold;">Leased Object</font> with the prior consent of the <font style="font-weight:bold;">Lessor</font>, to the extent not already acknowledged in Section 2 (2). For the <font style="font-weight:bold;">Lessor</font> to provide its consent, questions on the effects of the planned measures in terms of planning permission (including statics, fire protection, construction physics) and significance in terms of site development (including effects on the neighbourhood, environment and infrastructure) must be answered and a realistic assessment of the operational significance of the measures must be obtained. A joint approach is required in this regard.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the <font style="font-weight:bold;">Lessor</font> approves structural and/or technical amendments, before the measures are implemented, by means of follow-up management, the type and extent of the amendments must be documented in a manner that complies with the written form requirement, as well as &#8211; where agreed &#8211; a waiver by the <font style="font-weight:bold;">Lessor</font> of the right to demand, at the end of the Lease, </p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 12</a> of 20</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">restoration by the </font><font style="font-weight:bold;">Lessee</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the condition of the </font><font style="font-weight:bold;">Leased Object</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> prior to the structural and/or technical amendment and the obl</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">igation to maintain it.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">In accordance with the areas key agreed pursuant to <font style="font-weight:bold;text-decoration:underline;">Annex 3.1) and 3.2),</font> the <font style="font-weight:bold;">Lessee</font> will bear the costs of the adaptation of the technical building equipment of Building H028 by the <font style="font-weight:bold;">Lessor</font>, if and to the extent that adaptation is necessary, in order to allow simultaneous use of the building by the <font style="font-weight:bold;">Lessee</font> and other companies based in the building, regardless of which part of Building H028 the adaptation is carried out in.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Section 11</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Company Sign</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p>
<p style="text-indent:36px;"></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">Taking the conditions on site into account, after agreement with the <font style="font-weight:bold;">Lessor</font>, the <font style="font-weight:bold;">Lessee</font> may affix its own company signs at its own expense only to the buildings or parts of buildings for which it has sole use. These costs will be at its own expense. If official permits are required for the affixing of these signs, the <font style="font-weight:bold;">Lessee</font> will obtain these and bear the associated costs.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <font style="font-weight:bold;">Lessee</font> is responsible for fulfilling the public safety obligation for signs affixed by it.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">(Hanging) internal communication and information boxes or boards installed outside of the areas for which the <font style="font-weight:bold;">Lessee</font> has sole use are subject to agreement between the <font style="font-weight:bold;">Lessee</font> and <font style="font-weight:bold;">Lessor</font> depending on the type of design, size and installation site.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">If it is necessary to remove company signs pursuant to paragraphs (1) or (2) for works at the site or on the <font style="font-weight:bold;">Leased Object</font>, the <font style="font-weight:bold;">Lessee</font> will bear the costs of the removal, storage and reinstallation, including the resulting repairs to the facility required. At the end of the Lease, the <font style="font-weight:bold;">Lessee</font> must remove the company sign at its own expense and rectify any damage caused by the affixing, operation and removal.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">If the <font style="font-weight:bold;">Lessor</font> installs standardised company signs, the <font style="font-weight:bold;">Lessee</font> may participate in the costs for affixing and maintaining these installations on a proportionate basis.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Section 12</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Technical Building Services, Supply and Disposal</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The <font style="font-weight:bold;">Lessor</font> is responsible for ensuring the proper technical connection of the <font style="font-weight:bold;">Leased Object</font> to the currently existing supply and disposal systems at the site. Except as provided for in Section 7 (5) concerning the supply of H028 South, the <font style="font-weight:bold;">Lessee</font> will be responsible for the supply of the <font style="font-weight:bold;">Leased Object</font> with the energy and media required for its use at its own expense by entering into separate energy supply contracts with the <font style="font-weight:bold;">Lessor</font> or third parties. The <font style="font-weight:bold;">Lessee</font> will be responsible for sufficiently heating the <font style="font-weight:bold;">Leased Object</font> using the air conditioning installations installed by it in the <font style="font-weight:bold;">Leased Object</font> for the purposes of production. Irrespective of their invoicing as operating costs or their supply within the framework of energy supply agreements, the delivery of energy and media takes place from the output terminal of the main distributor and from the first shut-off valve in the central energy room.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Lease does not cover the infrastructure required for the onward transfer of energy and media in the building, such as electricity and water supply lines and these are not, therefore, included in <font style="font-weight:bold;text-decoration:underline;">Annex 2.1), Annex 2.2),</font> and <font style="font-weight:bold;text-decoration:underline;">Annex 2.3). </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 13</a> of 20</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This infrastructure is in the possession of [***] and the <font style="font-weight:bold;">Lessee</font> will agree with [***] on the usage and &#8211; if it rents all floors of Building H028 - transfer of this infrastructure outside the scope of this Lease. If this is not successful or if the infrastructure is not made available, this circumstance does not entitle the <font style="font-weight:bold;">Lessee</font> to terminate this Lease.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The <font style="font-weight:bold;">Lessee</font> will use the supply and disposal lines, e.g. for electricity, gas, nitrogen, compressed air, and water/wastewater only to the extent that no overload is caused. Any additional needs can be covered by the <font style="font-weight:bold;">Lessee</font> by extending the lines and necessary technical installations at its own expense after obtaining the <font style="font-weight:bold;">Lessor</font>&#8217;s prior written consent, which may only be refused for an important reason.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">If it is necessary to convert devices or equipment, equipment parts and auxiliary equipment belonging to the <font style="font-weight:bold;">Lessee</font> because of a legally required change to the way energy is obtained, the costs of converting these devices or equipment, equipment parts and auxiliary equipment will be borne by the <font style="font-weight:bold;">Lessee</font>. Any claims for compensation by the <font style="font-weight:bold;">Lessee</font> and entitlements to rent reduction are excluded in this case.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Section 13</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Insurance Policies</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">As at the handover date, the <font style="font-weight:bold;">Lessor</font> holds all risks property insurance, including building fire cover, as well as business liability insurance with a minimum coverage amount of EUR 10 million. The costs of these insurance policies are included (proportionately where necessary) in the operating costs pursuant to Section 7 of this Lease.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">From the commencement of the Lease, the <font style="font-weight:bold;">Lessee</font> is obliged to take out a liability insurance policy which provides cover for rental damage with a minimum coverage amount of EUR 10 million, as well as all insurance policies necessary for the operations pursuant to Section 2 of this Lease. Comprehensive insurance coverage or policies that provide for an excess to be paid by the <font style="font-weight:bold;">Lessee</font> fulfil this requirement.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of an increase to the previously insured risk, the <font style="font-weight:bold;">Lessee</font> must extend its insurance coverage without being requested to do so. The same applies to the <font style="font-weight:bold;">Lessor</font>&#8217;s insurance obligation under paragraph (1).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">All insurance coverage must be maintained throughout the entire term of the Lease, either by continuing the relevant insurance policy or by taking out new comparable insurance policies. The determining factor is whether insurance coverage exists throughout the entire term of the Lease.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">At the request of the other Party, each Party must produce certificates for the insurance policies to be taken out by it, which also state the amount of the excess and, when requested to do so at any time, provide evidence of payment of the premium where required.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">Each Party undertakes to notify the other Party immediately if it becomes aware of missing or insufficient general or special insurance protection. This applies in particular in circumstances whereby the risk may be changed or increased, particularly where installations, structural amendments or changes of use take place.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The <font style="font-weight:bold;">Lessee</font> will notify the insurer and the <font style="font-weight:bold;">Lessor</font> immediately of any damage event and ensure that, to the extent possible and reasonable, no changes are made to the damage site before </p></td></tr></table></div>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 14</a> of 20</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the insurer&#8217;s inspection. </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nevertheless, the Parties are obliged to </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">take any measures required in order to reduce the damage or reduce consequential damage. The Parties will take these measures in agreement with each other and with the relevant insurer.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 15</a> of 20</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Section 14</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">End of the Lease, Handover Obligation,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Restoration to the original condition</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">At the end of the Lease, the <font style="font-weight:bold;">Lessee</font> must return the <font style="font-weight:bold;">Leased Object</font> in accordance with the provisions of this Lease, swept clean and free from materials which may cause danger, significant disadvantages or significant pollution for individuals or the general public within the meaning of Section 3 of the German Federal Emissions Act (hereinafter referred to as &#8220;Contamination&#8221;), unless </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Contamination was not caused by the <font style="font-weight:bold;">Lessee</font> or by previous lessees.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">If there is Contamination in the <font style="font-weight:bold;">Leased Object</font> or in the parts of the building made available for use free of charge, the <font style="font-weight:bold;">Lessee</font> must also indemnify the <font style="font-weight:bold;">Lessor</font> fully during the term of the Lease if claims are made against the <font style="font-weight:bold;">Lessor</font> for investigations, decontamination or any other measures in relation to the Contamination, and it must also indemnify the <font style="font-weight:bold;">Lessor</font> against any claims from third parties in connection with such Contamination, unless the relevant Contamination was caused before 01.01.2005.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The <font style="font-weight:bold;">Lessee</font> is obliged to do the following at the end of the Lease:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.15%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8212;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Calibri;">have all facilities, installations, and fittings (even those installed in the </font><font style="font-weight:bold;font-family:Calibri;">Leased Object</font><font style="font-family:Calibri;"> by previous lessees) located in Building H028 (including H030) in the areas used by the </font><font style="font-weight:bold;font-family:Calibri;">Lessee</font><font style="font-family:Calibri;">/in the spaces used by the </font><font style="font-weight:bold;font-family:Calibri;">Lessee</font><font style="font-family:Calibri;"> professionally removed at its own expense, unless these are identified in </font><font style="font-weight:bold;text-decoration:underline;font-family:Calibri;">Annex 2.1), Annex 2.2),</font><font style="font-family:Calibri;"> and </font><font style="font-weight:bold;text-decoration:underline;font-family:Calibri;">Annex 2.3)</font><font style="font-family:Calibri;"> to the Lease as part of the </font><font style="font-weight:bold;font-family:Calibri;">Leased Object</font><font style="font-family:Calibri;">, including their connections to the </font><font style="font-weight:bold;font-family:Calibri;">Leased Object</font><font style="font-family:Calibri;">;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.15%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8212;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Calibri;">remove its movable fixtures at its own expense;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.15%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8212;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Calibri;">have all structural and technical amendments to the </font><font style="font-weight:bold;font-family:Calibri;">Leased Object</font><font style="font-family:Calibri;"> (also to the extent carried out by previous lessees) professionally removed at its own expense and restore the structural and technical condition of the </font><font style="font-weight:bold;font-family:Calibri;">Leased Object</font><font style="font-family:Calibri;"> identified in </font><font style="font-weight:bold;text-decoration:underline;font-family:Calibri;">Annexes 1.1), 1.2), </font><font style="font-family:Calibri;">and </font><font style="font-weight:bold;text-decoration:underline;font-family:Calibri;">1.3)</font><font style="font-family:Calibri;"> and in </font><font style="font-weight:bold;text-decoration:underline;font-family:Calibri;">Annex 2.1), Annex 2.2),</font><font style="font-family:Calibri;"> and </font><font style="font-weight:bold;text-decoration:underline;font-family:Calibri;">Annex 2.3).</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unless the <font style="font-weight:bold;">Lessor</font> has waived this obligation in writing in an amendment to this Lease.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">If the <font style="font-weight:bold;">Lessee</font> does not fulfil its obligation to return the <font style="font-weight:bold;">Leased Object</font> pursuant to Section 14 of this Lease within the requisite period, then for each day of the delayed handover, it must pay the <font style="font-weight:bold;">Lessor</font> 1/30 of the most recently paid monthly advance payment for operating costs, plus the value added tax applicable at the time of payment.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <font style="font-weight:bold;">Lessor</font>&#8217;s right to claim for compensation due to additional damage is not excluded.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The Parties will draw up a written handover report concerning the return of the <font style="font-weight:bold;">Leased Object</font>.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Section 15</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Force majeure</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If and to the extent that a Party is prevented from fulfilling its contractual obligations due to force majeure, it will be released from such obligations. It will notify the other Party immediately of the circumstances of the force majeure and make efforts to remedy these circumstances. If necessary and possible, the Parties will agree on the required adaptive measures.</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 16</a> of 20</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Section 16</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Confidentiality</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The Parties mutually undertake to maintain confidentiality in relation to all information that they obtain in relation to the conclusion of this Lease and its performance, including all economic framework conditions and the provisions laid down in this Lease, as well as any business and operational secrets that may become known. This means that the relevant information must not be disclosed to third parties without prior written consent of the other Party.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Excluded from this is the disclosure of information to third parties appointed by a Party for the implementation of the Lease, however only to the extent strictly necessary for the implementation of the Lease.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">However, it is a requirement that such third parties (e.g. lawyers, tax advisors, brokers, experts, tradesmen, group companies, etc.) either are subject to professional secrecy obligations or are required in turn to maintain confidentiality.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing confidentiality obligation applies for a period of up to ten (10) years after the end of the Lease.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">Excluded from the confidentiality obligation under paragraph (1) is information which the Parties have obtained prior to conclusion of the Lease and independent of the implementation of the Lease, and information that can be obtained by one of the Parties from generally accessible sources, without either Party having caused such information to be accessible through a breach of the confidentiality obligation.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The confidentiality obligation does not apply if one of the Parties discloses the necessary information as a result of a legal or official order or in legal proceedings to safeguard its legitimate interests. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Section 17</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Guarantees</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) </font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">Within 14 days after the signing of this Lease, in order to guarantee all claims of the <font style="font-weight:bold;">Lessor</font> against the <font style="font-weight:bold;">Lessee</font> under this Lease, the <font style="font-weight:bold;">Lessee</font> will provide a guarantee that is directly enforceable on first request, issued by a German bank or public savings bank [<font style="font-style:italic;">Sparkasse</font>] in accordance with the appended template (<font style="font-weight:bold;text-decoration:underline;">Annex 6),</font> for an amount equal to three times the monthly rent excluding utilities at the start of the Lease, plus the advance payment for operating costs at the start of the Lease, plus value added tax.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">If the <font style="font-weight:bold;">Lessee</font> does not provide a rental guarantee in the due and proper form within the agreed timeframe and after a deadline extension has been granted, the <font style="font-weight:bold;">Lessor</font> is authorised to extraordinarily terminate the Lease without notice.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3) </font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">Six months after the end of the Lease, the <font style="font-weight:bold;">Lessor</font> will return the guarantee to the <font style="font-weight:bold;">Lessee</font> if and to the extent that the <font style="font-weight:bold;">Lessor</font> does not assert against the <font style="font-weight:bold;">Lessee</font> or the guarantor any claims arising from the Lease and secured by the guarantee.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 17</a> of 20</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Section 18</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Subletting, Transfer of Use</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The <font style="font-weight:bold;">Lessee</font> may only transfer the use of the <font style="font-weight:bold;">Leased Object</font> to a third party and/or sublet it with the consent of the <font style="font-weight:bold;">Lessor</font>. The <font style="font-weight:bold;">Lessor</font> is obliged to permit a transfer of use to third parties if the third party is not a competitor of the <font style="font-weight:bold;">Lessor</font> and there is no other important reason for refusing permission. </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Section 19</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Consideration, Averting Dangers</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) </font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The Parties agree that the foregoing provisions are only viable if they act considerately at the request of the other Party, taking into account other companies operating on the site and more specifically, undertake to seek amicable solutions to issues that cannot be foreseen and are not contractually provided for in detail.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">This applies in particular to measures implemented by the Parties in accordance with the provisions laid down in this Lease under their own responsibility and at their own expense, and for official and other orders, which can only be complied with by mutual agreement.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">In the event of imminent danger, the <font style="font-weight:bold;">Lessee</font> must comply with the instructions from the site security and fire services. It will also impose this obligation on its staff and on third parties appointed by it.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The attachment, placement or storage of items of any kind (boxes, goods, etc.) outside of the <font style="font-weight:bold;">Leased Object</font>, particularly on the shared traffic routes, is only permitted in the designated storage/parking areas.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The <font style="font-weight:bold;">Lessee</font> will receive a copy of the parking rules (<font style="font-weight:bold;text-decoration:underline;">Annex 7</font>) and ensure that its employees and visitors comply with the parking rules and support the <font style="font-weight:bold;">Lessor</font> as far as possible in enforcing the parking rules.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Section 20</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Entire Agreement, Written Form</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">This Lease contains all agreements made between the Parties. There are no additional agreements, ancillary agreements, or undertakings. If, contrary to the previous sentence, additional agreements, ancillary agreements, or undertakings do exist, these are hereby rescinded.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">Amendments and supplements to this agreement and its annexes, and all declarations of intent under this Lease, must be made in writing in order to be valid. This also applies in the event of an amendment to this written form clause.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The Parties undertake not to terminate this Lease early by invoking any non-compliance with the written form requirement. This applies not only to the conclusion of this Lease, but also to any addenda, amendments or supplements hereto. If the written form requirement is not complied with for amendments and supplements, the Parties further undertake to rectify this immediately.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The Lease is drawn up in two counterparts; each Party receives one copy thereof.</p></td></tr></table></div>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 18</a> of 20</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Section 21</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Entry to the Leased Object, Public Safety Obligation, Annexes,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Partial Invalidity, Place of Jurisdiction, Competition Clause</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The <font style="font-weight:bold;">Lessor</font>, its representatives, experts, and interested parties may enter the <font style="font-weight:bold;">Leased Object</font> after providing sufficient notice and during business hours in order to check its condition for re-letting or sale purposes or for another important reason, subject to agreement and taking the legitimate interests of the <font style="font-weight:bold;">Lessee</font> into consideration.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If regulatory requirements apply to parts of the <font style="font-weight:bold;">Leased Object</font> (for example GMP rules), entry by the <font style="font-weight:bold;">Lessor</font> is only authorised if these requirements are complied with. The <font style="font-weight:bold;">Lessee</font> will provide the <font style="font-weight:bold;">Lessor</font> with comprehensive information on the rules to be complied with and the necessary measures in good time.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of imminent danger, they must be granted access at any time of day or night. In this case, in the event of absence, the <font style="font-weight:bold;">Lessee</font> must provide the corresponding access options or leave keys in an accessible place known to the <font style="font-weight:bold;">Lessor</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If required, the <font style="font-weight:bold;">Lessor</font> and its appointed parties are also authorised to enter the <font style="font-weight:bold;">Leased Object</font> at any time of day or night in agreement with the <font style="font-weight:bold;">Lessee</font> (the agreement must be documented for example by providing a corresponding access authorisation card) in order to access energy rooms, communications hubs, main and single-floor distribution boards for telephones, main and single-floor fire alarm distribution boards, battery facilities and electroacoustic installations, as well as any other premises used to supply the <font style="font-weight:bold;">Leased Object</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When entering the <font style="font-weight:bold;">Leased Object</font>, the <font style="font-weight:bold;">Lessor</font> must give the necessary and requested consideration to the <font style="font-weight:bold;">Lessee</font>&#8217;s operations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The <font style="font-weight:bold;">Lessee</font> is subject to the public safety obligation within the leased areas and technical areas used by it alone, to the extent that these are indeed used by the <font style="font-weight:bold;">Lessee</font> alone. If technical areas are used by both the <font style="font-weight:bold;">Lessee</font> and <font style="font-weight:bold;">Lessor</font> (Section 1 (3) of the Lease), both parties are equally bound by the public safety obligation and are jointly and severally liable vis-&#224;-vis third parties in the event of a breach of the public safety obligation.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">All annexes constitute a component of this Lease. </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">On the date on which it comes into force, this Lease replaces all existing oral and/or written ancillary agreements between the parties concerning the leasing of areas and spaces in Building H028, therefore also the Lease concerning H028 North of 25.06.2016, together with its amendments.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">This Lease is independent of further leases entered into between the contractual parties.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The laws of the Federal Republic of Germany apply to this Lease and the tenancy provided for therein. If any translations of the Lease are created, the German version will prevail.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7) </font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">In relation to any disputes resulting from this Lease, the courts of Marburg will have jurisdiction, as far as legally permitted.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 19</a> of 20</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">If a provision of this agreement or a future new provision is fully or partially ineffective or unenforceable, or loses its validity or enforceability at a later date, or if a loophole is discovered in this agreement, this will not affect the validity of the other provisions. To replace the ineffective or unenforceable provisions or to close the loophole, an appropriate provision will be agreed on in the proper form, which, as far as legally permissible, comes closest to what the Parties intended when entering into the Lease, or to what they would have wanted&nbsp;&nbsp;in accordance with the purpose of the agreement if they had considered the matter.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9) </font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">There is no competition clause.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">The following are annexes to this agreement:</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:-7.98%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:7.98%;width:91.91%;">
<tr>
<td style="width:20.24%;"></td>
<td style="width:71.67%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 1.1)</font></p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Plans for the Leased Object, (H028 North, H030 and H028 South <font style="text-decoration:underline;">without</font> Additional Areas, i.e. only floors 1 - 2)</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 1.2)</font></p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Plans for the Leased Object (only Additional Areas, i.e. only H028 South, floors 1 - 2)</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 1.3)</font></p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Plans for the Leased Object after leasing of the Additional Areas (H028 North, H030 and H028 South <font style="text-decoration:underline;">including</font> Additional Areas)</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 1.4)</font></p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Site plan</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 2.1)</font></p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">List of installations, facilities, and fittings for the Leased Premises (H028 North, H030, and H028 South without Additional Areas, i.e. without floors 1&nbsp;&nbsp;- 2)</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 2.2)</font></p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">List of installations, facilities, and fittings for the Leased Premises (only Additional Areas, i.e. only H028 South, floors 1 - 2)</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 2.3)</font></p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">List of installations, facilities, and fittings for the Leased Premises (H028 North, H030, H028 South, floors 1 - 6)</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 3.1)</font></p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Lessee&#8217;s share of the total area for the building, without Additional Areas</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 3.2)</font></p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Lessee&#8217;s share of the total area for the building, with Additional Areas</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 4.1)</font></p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Net rent excluding utilities, without Additional Areas, from 01.01.2020</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 4.2)</font></p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Net rent excluding utilities, with Additional Areas, from 01.01.2024</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 4.3)</font></p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Net rent excluding utilities, with Additional Areas, from 01.01.2025</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 5.1)</font></p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Services covered by operating expenses H028 North, H028 South (without floors 1-2 H028 South), and H030, i.e. including energy and media supply</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 5.2)</font></p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Services covered by operating expenses H028 North, H028 South (with floors 1-2 H028 South), and H030, i.e. without energy and media supply</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 5.3)</font></p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Initial advance payment for operating expenses</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 6)</font></p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Rental guarantee template</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 7)</font></p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">General entrance and parking rules for the Behringwerke Site</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 8)</font></p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">List of the goods only to be stored in Building H030</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 9)</font></p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Description of the fa&#231;ade renovation</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.94%;"></td>
<td style="width:49.94%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marburg, <font style="font-family:Lucida Handwriting;">25.07.19</font></p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marburg, <font style="font-family:Lucida Handwriting;">25.07.2019</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Novartis Manufacturing GmbH</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 20</a> of 20</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 1.1)<br /></font><font style="font-weight:normal;">[***]</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of: 26.06.2019</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 1</a> of 7</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 1.1)<br /></font><font style="font-weight:normal;">[***]</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of: 26.06.2019</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 2</a> of 7</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 1.1)<br /></font><font style="font-weight:normal;">to the Lease concerning areas and spaces in buildings H028 and H030<br />between Pharmaserv GmbH<br />and Novartis Manufacturing GmbH</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of: 26.06.2019</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 3</a> of 7</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 1.1)<br /></font><font style="font-weight:normal;">[***]</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of: 26.06.2019</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 4</a> of 7</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 1.1)<br /></font><font style="font-weight:normal;">[***]</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of: 26.06.2019</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 5</a> of 7</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 1.1)<br /></font><font style="font-weight:normal;">[***]</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of: 26.06.2019</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 6</a> of 7</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 1.1)<br /></font><font style="font-weight:normal;">[***]</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of: 26.06.2019</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 7</a> of 7</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 1.2)<br /></font><font style="font-weight:normal;">[***]</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of: 26.06.2019</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 1</a> of 2</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 1.2)<br /></font><font style="font-weight:normal;">[***]</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of: 26.06.2019</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 2</a> of 2</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 1.3)<br /></font><font style="font-weight:normal;">[***]</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 1.3)<br /></font><font style="font-weight:normal;">[***]</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 1.3)<br /></font><font style="font-weight:normal;">[***]</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 1.3)<br /></font><font style="font-weight:normal;">[***]</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 1.3)<br /></font><font style="font-weight:normal;">[***]</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 1.3)<br /></font><font style="font-weight:normal;">[***]</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 1.3)<br /></font><font style="font-weight:normal;">[***]</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Appendix 1.4</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.96%;"></td>
<td style="width:49.93%;"></td>
</tr>
<tr>
<td colspan="2" valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BILINGUAL KEY</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DE</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EN</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Anlage 1.4)<br /></font><font style="font-weight:normal;">zum Mietvertrag &#252;ber Fl&#228;chen und R&#228;ume in Geba&#252;de H028 zwischen Pharmaserv GmbH und Novartis Manufacturing GmbH</font></p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 1.4)<br /></font><font style="font-weight:normal;">to the lease concerning areas and spaces in building H028 between Pharmaserv GmbH and Novartis Manufacturing GmbH</font></p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Geba&#252;de H034</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building H034</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Geba&#252;de H030</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building H030</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Geba&#252;de H033</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building H033</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lageplan</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Site plan</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Abstellfl&#228;che f&#252;r Abfallcontainer H028 Nord</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Storage area for waste container(s) H028 north</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">H028 Nord</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">H028 north</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Geba&#252;de H028 gesamt</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building H028 entire</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">H028 S&#252;d</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">H028 south</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Abstellfl&#228;che f&#252;r Abfallcontainer H028 S&#252;d</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Storage area for waste container(s) H028 south</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Geba&#252;de H021</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building H021</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stand: 26.06.2019</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of: 26.06.2019</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Seite 1 von 1</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 1 of 1</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.1</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="6" valign="top"  BGCOLOR="#E7E6E6" style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">List of Fixtures, Equipment and Fittings of the Leased Property, Building H028 (North)</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Leased Object</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Fixtures, Equipment and Fittings)</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Notes</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Technical Identification of the Equipment</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No entry &#8211; for all parts of the equipment</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entry &#8211; only for the part of equipment stated</p></td>
<td valign="top"  style="width:19.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Room</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Location of the fixture/equipment</p></td>
<td valign="top"  style="width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Performance data / properties</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="6" valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">List of Fixtures, Equipment and Fittings of the Leased Property, Building H028 (North)</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Leased Object</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Fixtures, Equipment and Fittings)</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Notes</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Technical Identification of the Equipment</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No entry &#8211; for all parts of the equipment</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entry &#8211; only for the part of equipment stated</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Room</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Location of the fixture/equipment</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Performance data / properties</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at: 26/06/2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOM-FAC-REM-KIM</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 12</a> of 5</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.1</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="6" valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">List of Fixtures, Equipment and Fittings of the Leased Property, (H030)</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Leased Object</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Fixtures, Equipment and Fittings)</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Notes</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Technical Identification of the Equipment</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No entry &#8211; for all parts of the equipment</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entry &#8211; only for the part of equipment stated</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Room</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Location of the fixture/equipment</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Performance data / properties</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at: 26/06/2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOM-FAC-REM-KIM</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 13</a> of 5</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.1</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="6" valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">List of Fixtures, Equipment and Fittings of the Leased Property, Building H028 (South, levels 3-6)</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Leased Object</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Fixtures, Equipment and Fittings)</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Notes</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Technical Identification of the Equipment</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No entry &#8211; for all parts of the equipment</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entry &#8211; only for the part of equipment stated</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Room</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Location of the fixture/equipment</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Performance data / properties</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="6" valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">List of Fixtures, Equipment and Fittings of the Leased Property, Building H028 (South, levels 3-6)</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Leased Object</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Fixtures, Equipment and Fittings)</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Notes</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Technical Identification of the Equipment</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No entry &#8211; for all parts of the equipment</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entry &#8211; only for the part of equipment stated</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Room</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Location of the fixture/equipment</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Performance data / properties</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at: 26/06/2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOM-FAC-REM-KIM</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 14</a> of 5</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.2</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">List of Fixtures, Equipment and Fittings of the Leased Property, Building H028 (South, levels 1-2)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:19%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="top"  style="width:19%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Leased Object</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Fixtures, Equipment and Fittings)</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Notes</p></td>
<td valign="top"  style="width:19%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Technical Identification of the Equipment</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No entry &#8211; for all parts of the equipment</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entry &#8211; only for the part of equipment stated</p></td>
<td valign="top"  style="width:19%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Room</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Location of the fixture/equipment</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Performance data / properties</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH<font style="margin-left:36pt;"></font>As at: 26/06/2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOM-FAC-REM-KIM<font style="margin-left:36pt;">Page </font>15</a> of 2</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.2</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="6" valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">List of Fixtures, Equipment and Fittings of the Leased Property, Building H028 (South, levels 1-2)</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Leased Object</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Fixtures, Equipment and Fittings)</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Notes</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Technical Identification of the Equipment</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No entry &#8211; for all parts of the equipment</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entry &#8211; only for the part of equipment stated</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Room</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Location of the fixture/equipment</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Performance data / properties</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH<font style="margin-left:36pt;"></font>As at: 26/06/2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOM-FAC-REM-KIM<font style="margin-left:36pt;">Page </font>16</a> of 2</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">List of Fixtures, Equipment and Fittings of the Leased Property, Building H028 (North)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:19%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="top"  style="width:19%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Leased Object</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Fixtures, Equipment and Fittings)</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Notes</p></td>
<td valign="top"  style="width:19%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Technical Identification of the Equipment</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No entry &#8211; for all parts of the equipment</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entry &#8211; only for the part of equipment stated</p></td>
<td valign="top"  style="width:19%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Room</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Location of the fixture/equipment</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Performance data / properties</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.98%;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH<font style="margin-left:36pt;"></font>As at: 26/06/2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOM-FAC-REM-KIM<font style="margin-left:36pt;">Page </font>17</a> of 5</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="6" valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">List of Fixtures, Equipment and Fittings of the Leased Property, Building H028 (North)</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Leased Object</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Fixtures, Equipment and Fittings)</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Notes</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Technical Identification of the Equipment</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No entry &#8211; for all parts of the equipment</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entry &#8211; only for the part of equipment stated</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Room</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Location of the fixture/equipment</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Performance data / properties</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH<font style="margin-left:36pt;"></font>As at: 26/06/2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOM-FAC-REM-KIM<font style="margin-left:36pt;">Page </font>18</a> of 5</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="6" valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">List of Fixtures, Equipment and Fittings of the Leased Property, (H030)</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Leased Object</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Fixtures, Equipment and Fittings)</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Notes</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Technical Identification of the Equipment</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No entry &#8211; for all parts of the equipment</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entry &#8211; only for the part of equipment stated</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Room</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Location of the fixture/equipment</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Performance data / properties</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbHAs at: 26/06/2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOM-FAC-REM-KIMPage 19</a> of 5</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="6" valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">List of Fixtures, Equipment and Fittings of the Leased Property, Building H028 (South, levels 1-6)</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Leased Object</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Fixtures, Equipment and Fittings)</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Notes</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Technical Identification of the Equipment</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No entry &#8211; for all parts of the equipment</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entry &#8211; only for the part of equipment stated</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Room</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Location of the fixture/equipment</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Performance data / properties</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***] </p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="6" valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">List of Fixtures, Equipment and Fittings of the Leased Property, Building H028 (South, levels 1-6)</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Leased Object</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Fixtures, Equipment and Fittings)</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Notes</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Technical Identification of the Equipment</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No entry &#8211; for all parts of the equipment</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entry &#8211; only for the part of equipment stated</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Room</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Location of the fixture/equipment</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Performance data / properties</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH<font style="margin-left:36pt;"></font>As at: 26/06/2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOM-FAC-REM-KIM<font style="margin-left:36pt;">Page </font>20</a> of 5</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 3.1)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease of Space and Premises in the H028 and H030 Buildings</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#BFBFBF" style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Proportion of the total area allocated to the Lessee </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">H030 Building </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:85%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:4pt;margin-top:4pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. The total area of the H030 Building is</p></td>
<td valign="top"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,217.08 m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.66%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:85%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. The proportion of the total area of the H028 Building (H028 North entire building and H028 South 3rd - 6th floors) allocated to the Lessee is </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,267.65 m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at: 26.06.2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOM-FAC-REM-KIM</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 21</a> of 2</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 3.1)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease of Space and Premises in the H028 and H030 Buildings</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#BFBFBF" style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Proportion of the total area allocated to the Lessee </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">H030 Building </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:85%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:4pt;margin-top:4pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. The total area of the H030 Building is</p></td>
<td valign="top"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:4pt;margin-top:4pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86.54 m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.66%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:85%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:4pt;margin-top:4pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. The proportion of the total area of the H030 Building allocated to the Lessee is </p></td>
<td valign="top"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:4pt;margin-top:4pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86.54 m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at: 26.06.2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOM-FAC-REM-KIM</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 22</a> of 2</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 3.2)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease of Space and Premises in the H028 and H030 Buildings</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#BFBFBF" style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Proportion of the total area allocated to the Lessee </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">H028 Building </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:85%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:4pt;margin-top:4pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. The total area of the H028 Building is</p></td>
<td valign="top"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,217.08 m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.66%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:85%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. The proportion of the total area of the H028 Building (H028 North entire building and H028 South entire building) allocated to the Lessee is </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,217.08 m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at: 26.06.2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOM-FAC-REM-KIM</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 1</a> of 2</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 3.2)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease of Space and Premises in the H028 and H030 Buildings</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#BFBFBF" style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Proportion of the total area allocated to the Lessee </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">H030 Building </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:85%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:4pt;margin-top:4pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. The total area of the H030 Building is</p></td>
<td valign="top"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:4pt;margin-top:4pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86.54 m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.66%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:85%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:4pt;margin-top:4pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. The proportion of the total area of the H030 Building allocated to the Lessee is </p></td>
<td valign="top"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:4pt;margin-top:4pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86.54 m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at: 26.06.2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOM-FAC-REM-KIM</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 2</a> of 2</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 4.1)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease of Space and Premises in the H028 and H030 Buildings</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#BFBFBF" style="width:100%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basic rent (graduated rent) euros/month net</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">H028 Building excluding additional space with effect from 01.07.2019</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(H028 North, H028 South 3rd &#8211; 6th Floors) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease period</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Euros/month</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.07.2019 &#8211; 31.12.2019</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2020 - 31.12.2020</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2021 - 31.12.2021</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2022 - 31.12.2022</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2023 - 31.12.2023</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2024 &#8211; 31.12.2024</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2025 - 31.12.2025</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2026 - 31.12.2026</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2027 - 31.12.2027</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2028 - 31.12.2028</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2029 -31.12.2029</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2030 - 31.12.2030</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2031 - 31.12.2031</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2032 - 31.12.2032</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2033 - 31.12.2033</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2034 - 31.12.2034</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at: 26.06.2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOM-FAC-REM-KIM</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 1</a> of 2</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 4.1)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease of Space and Premises in the H028 and H030 Buildings</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#BFBFBF" style="width:100%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basic rent (graduated rent) euros/month net</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">H030 Building with effect from 01.07.2019</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease period</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Euros/month</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.07.2019 &#8211; 31.12.2019</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2020 - 31.12.2020</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2021 - 31.12.2021</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2022 - 31.12.2022</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2023 - 31.12.2023</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2024 &#8211; 31.12.2024</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2025 - 31.12.2025</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2026 - 31.12.2026</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2027 - 31.12.2027</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2028 - 31.12.2028</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2029 -31.12.2029</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2030 - 31.12.2030</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2031 - 31.12.2031</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2032 - 31.12.2032</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2033 - 31.12.2033</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2034 - 31.12.2034</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at: 26.06.2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOM-FAC-REM-KIM</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 2</a> of 2</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 4.2)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease of Space and Premises in the H028 and H030 Buildings</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#BFBFBF" style="width:100%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basic rent (graduated rent) euros/month net</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">H028 Building excluding additional space with effect from 01.01.2024</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(H028 North, H028 South 3rd &#8211; 6th Floors, entire H028 South with effect from 01.01.2024) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease period</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Euros/month</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.07.2019 &#8211; 31.12.2019</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2020 - 31.12.2020</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2021 - 31.12.2021</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2022 - 31.12.2022</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2023 - 31.12.2023</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2024 &#8211; 31.12.2024</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2025 - 31.12.2025</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2026 - 31.12.2026</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2027 - 31.12.2027</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2028 - 31.12.2028</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2029 -31.12.2029</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2030 - 31.12.2030</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2031 - 31.12.2031</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2032 - 31.12.2032</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2033 - 31.12.2033</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2034 - 31.12.2034</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at: 26.06.2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOM-FAC-REM-KIM</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 1</a> of 2</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">A</font><font style="text-decoration:underline;font-size:10pt;">nnex 4.2)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease of Space and Premises in the H028 and H030 Buildings</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#BFBFBF" style="width:100%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basic rent (graduated rent) euros/month net</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">H030 Building with effect from 01.07.2019</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease period</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Euros/month</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.07.2019 &#8211; 31.12.2019</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2020 - 31.12.2020</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2021 - 31.12.2021</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2022 - 31.12.2022</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2023 - 31.12.2023</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2024 &#8211; 31.12.2024</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2025 - 31.12.2025</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2026 - 31.12.2026</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2027 - 31.12.2027</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2028 - 31.12.2028</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2029 -31.12.2029</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2030 - 31.12.2030</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2031 - 31.12.2031</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2032 - 31.12.2032</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2033 - 31.12.2033</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2034 - 31.12.2034</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at: 26.06.2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOM-FAC-REM-KIM</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 2</a> of 2</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 4.3)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease of Space and Premises in the H028 and H030 Buildings</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#BFBFBF" style="width:100%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basic rent (graduated rent) euros/month net</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">H028 Building excluding additional space with effect from 01.01.2025</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(H028 North, H028 South 3rd &#8211; 6th Floors, entire H028 South with effect from 01.01.2025) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease period</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Euros/month</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.07.2019 &#8211; 31.12.2019</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2020 - 31.12.2020</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2021 - 31.12.2021</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2022 - 31.12.2022</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2023 - 31.12.2023</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2024 &#8211; 31.12.2024</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2025 - 31.12.2025</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2026 - 31.12.2026</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2027 - 31.12.2027</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2028 - 31.12.2028</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2029 -31.12.2029</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2030 - 31.12.2030</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2031 - 31.12.2031</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2032 - 31.12.2032</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2033 - 31.12.2033</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2034 - 31.12.2034</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at: 26.06.2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOM-FAC-REM-KIM</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 1</a> of 2</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">A</font><font style="text-decoration:underline;font-size:10pt;">nnex 4.3)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease of Space and Premises in the H028 and H030 Buildings</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:98.36%;">
<tr>
<td style="width:98.36%;"></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#BFBFBF" style=" border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basic rent (graduated rent) euros/month net</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">H030 Building with effect from 01.07.2019</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease period</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Euros/month</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.07.2019 &#8211; 31.12.2019</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2020 - 31.12.2020</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2021 - 31.12.2021</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2022 - 31.12.2022</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2023 - 31.12.2023</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2024 &#8211; 31.12.2024</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2025 - 31.12.2025</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2026 - 31.12.2026</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2027 - 31.12.2027</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2028 - 31.12.2028</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2029 -31.12.2029</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2030 - 31.12.2030</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2031 - 31.12.2031</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2032 - 31.12.2032</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2033 - 31.12.2033</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***] </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01.01.2034 - 31.12.2034</p></td>
<td valign="top"  style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; [***]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at: 26.06.2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOM-FAC-REM-KIM</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 2</a> of 2</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">A</font><font style="text-decoration:underline;font-size:10pt;">nnex 5.1)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease of Space and Premises in the H028 and H030 Buildings</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#BFBFBF" style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Service charges</p>
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">as defined in Article 7 of the Lease are</p>
<p style="margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#BFBFBF" style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top"  style="width:45%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top"  style="width:45%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top"  style="width:45%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td valign="top"  style="width:45%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="top"  style="width:45%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</p></td>
<td valign="top"  style="width:45%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</p></td>
<td valign="top"  style="width:45%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at: 26.06.2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOM-FAC-REM-KIM</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 1</a> of 4</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">A</font><font style="text-decoration:underline;font-size:10pt;">nnex 5.1)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease of Space and Premises in the H028 and H030 Buildings</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#BFBFBF" style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Service charges</p>
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">as defined in Article 7 of the Lease are</p>
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#BFBFBF" style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</p></td>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td rowspan="7" valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</p></td>
<td colspan="2" valign="top"  style="width:90%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at: 26.06.2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOM-FAC-REM-KIM</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 2</a> of 4</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">A</font><font style="text-decoration:underline;font-size:10pt;">nnex 5.1)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease of Space and Premises in the H028 and H030 Buildings</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#BFBFBF" style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Service charges</p>
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">as defined in Article 7 of the Lease are</p>
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#BFBFBF" style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:95%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at: 26.06.2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOM-FAC-REM-KIM</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 3</a> of 4</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">A</font><font style="text-decoration:underline;font-size:10pt;">nnex 5.1)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease of Space and Premises in the H028 and H030 Buildings</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#BFBFBF" style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Service charges</p>
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">as defined in Article 7 of the Lease are</p>
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#BFBFBF" style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td rowspan="2" valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</p></td>
<td valign="top"  style="width:95%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:95%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</p></td>
<td valign="top"  style="width:95%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.</p></td>
<td valign="top"  style="width:95%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.</p></td>
<td valign="top"  style="width:95%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at: 26.06.2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOM-FAC-REM-KIM</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 4</a> of 4</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">A</font><font style="text-decoration:underline;font-size:10pt;">nnex 5.2)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease of Space and Premises in the H028 and H030 Buildings</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#BFBFBF" style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Service charges</p>
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">as defined in Article 7 of the Lease are</p>
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#BFBFBF" style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td rowspan="5" valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</p></td>
<td colspan="2" valign="top"  style="width:90%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]<font style="font-weight:bold;"> </font></p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at: 26.06.2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOM-FAC-REM-KIM</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 1</a> of 4</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU25"></a>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">A</font><font style="text-decoration:underline;font-size:10pt;">nnex 5.2)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease of Space and Premises in the H028 and H030 Buildings</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#BFBFBF" style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Service charges</p>
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">as defined in Article 7 of the Lease are</p>
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#BFBFBF" style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.6</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:90%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at: 26.06.2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOM-FAC-REM-KIM</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 2</a> of 4</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">A</font><font style="text-decoration:underline;font-size:10pt;">nnex 5.2)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease of Space and Premises in the H028 and H030 Buildings</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#BFBFBF" style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Service charges</p>
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">as defined in Article 7 of the Lease are</p>
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#BFBFBF" style="width:50%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td rowspan="2" valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</p></td>
<td valign="top"  style="width:95%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:95%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</p></td>
<td valign="top"  style="width:95%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</p></td>
<td valign="top"  style="width:95%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</p></td>
<td valign="top"  style="width:95%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at: 26.06.2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOM-FAC-REM-KIM</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 3</a> of 4</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">A</font><font style="text-decoration:underline;font-size:10pt;">nnex 5.3)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease of Space and Premises in the H028 and H030 Buildings</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:98.36%;">
<tr>
<td style="width:98.36%;"></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#BFBFBF" style=" border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Advance payment of service charges euros/month net</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">H028 Building</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#BFBFBF" style="width:100%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364; <font style="font-size:10pt;font-weight:normal;">[***]</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at: 26.06.2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOM-FAC-REM-KIM</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 1</a> of 2</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">A</font><font style="text-decoration:underline;font-size:10pt;">nnex 5.3)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease of Space and Premises in the H028 and H030 Buildings</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#BFBFBF" style="width:100%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Advance payment of service charges euros/month net</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">H030 Building</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:100%; border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364; <font style="font-size:10pt;font-weight:normal;">[***]</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at: 26.06.2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOM-FAC-REM-KIM</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 2</a> of 2</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 6)</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease of Space and Premises in the H028 and H030 Buildings</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;text-transform:uppercase;font-size:11pt;font-style:normal;font-variant: normal;">Standard</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;text-transform:uppercase;font-size:11pt;font-style:normal;font-variant: normal;">Rent guarantee</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Novartis Manufacturing GmbH</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Emil-von-Behring-Strasse 76</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">35041 Marburg </p>
<p style="text-align:right;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- hereinafter called &#8220;<font style="font-weight:bold;">Lessee</font>&#8221; -</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Emil-von-Behring-Strasse 76</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.98%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">35041 Marburg</p>
<p style="text-align:right;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- hereinafter called &#8220;<font style="font-weight:bold;">Lessor</font>&#8221; &#8211;</p>
<p style="text-align:right;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">concluded on ___________ a Lease for Commercial Premises on the site in Emil-von-Behring-Strasse 76 in 35041 Marburg (leased premises: space and premises in the H028 Building). The provision of a guarantee by the <font style="font-weight:bold;">Lessee</font> from a bank approved for business transactions in the EU had been agreed to ensure the performance of the contractual obligations of the <font style="font-weight:bold;">Lessee</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With this proviso, we </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">_______________ [Bank],</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">herewith assume with regard to the <font style="font-weight:bold;">Lessor</font>, including its successors (hereinafter <font style="font-weight:bold;">Beneficiary </font>in each case) all existing and future claims, including conditional and/or limited claims, which the <font style="font-weight:bold;">Beneficiary </font>has or will have<font style="font-weight:bold;"> </font>against the <font style="font-weight:bold;">Lessee </font>under or in connection with the aforementioned Lease (including claims for damages for breach of duty, non-performance or in lieu of performance, </p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;border-top:Solid 0.75pt;padding-top:1pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FOR-KIM-0026-06</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 1</a> of 2</p></td>
</tr>
</table></div>
<p style="border-top:Solid 0.75pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">claims in respect of delay or unjust enrichment), with the unconditional, unlimited and irrevocable guarantee up to an amount that corresponds to three times the applicable monthly rent inclusive of service charges plus value added tax (&#8220;maximum amount&#8221;). The aforementioned basis of calculation currently establishes a maximum amount of </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">&#8364; </font><font style="font-weight:normal;">[***]</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(in words: </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]).</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumption of claims entails waiving the pleas of contestability and set-off, unless the counterclaim for set-off made by the Lessee is either undisputed or expressly acknowledged or legally binding, and waiving the plea that the creditor first proceeds against the debtor (Section 771 German Civil Code). This guarantee applies regardless of any other guarantees and other collateral, which are provided by a third party as additional security for claims by the <font style="font-weight:bold;">Beneficiary</font>. The creation of a collective guarantee (joint and several liability) pursuant to Section 769 German Code is thus excluded. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will make a payment to the <font style="font-weight:bold;">Beneficiary </font>on receipt of the first written request from the <font style="font-weight:bold;">Beneficiary </font>and may only be called upon to make payment of money. The guarantee expires when this document is returned to us by the <font style="font-weight:bold;">Beneficiary</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The laws of the Federal Republic of Germany shall apply to this guarantee. If this guarantee is translated, the German version shall prevail. The courts in Marburg shall have exclusive jurisdiction to hear any legal disputes that may arise out of this guarantee.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">______________, on _________________</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">______________________________</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;border-top:Solid 0.75pt;padding-top:1pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FOR-KIM-0026-06</p></td>
<td valign="top"  style="width:20%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 2</a> of 2</p></td>
</tr>
</table></div>
<p style="border-top:Solid 0.75pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 7)</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:98.69%;">
<tr>
<td style="width:54.51%;"></td>
<td style="width:44.18%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 2</a> of 10</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parking Regulations_Site_Behringwerke_2017.docx</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;text-transform:uppercase;font-size:11pt;font-weight:normal;font-style:normal;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:98.69%;">
<tr>
<td style="width:54.51%;"></td>
<td style="width:44.18%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 3</a> of 10</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parking Regulations_Site_Behringwerke_2017.docx</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:98.69%;">
<tr>
<td style="width:54.51%;"></td>
<td style="width:44.18%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 4</a> of 10</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parking Regulations_Site_Behringwerke_2017.docx</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 8)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease of Space and Premises in the H028 and H030 Buildings</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#BFBFBF" style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Inventory H030 Building</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:19.85pt;">
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Material</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Substances</p></td>
</tr>
<tr style="height:19.85pt;">
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:19.85pt;">
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:19.85pt;">
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:19.85pt;">
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:19.85pt;">
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:19.85pt;">
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:19.85pt;">
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:19.85pt;">
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:19.85pt;">
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:19.85pt;">
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:19.85pt;">
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:19.85pt;">
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:19.85pt;">
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:19.85pt;">
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:19.85pt;">
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:19.85pt;">
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:19.85pt;">
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:19.85pt;">
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:19.85pt;">
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:19.85pt;">
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:19.85pt;">
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:6.2%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50.02%;"></td>
<td style="width:49.98%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at: 26.06.2019</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SO-FAC-REM-KIM</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 5</a> of 6</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 9)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease of Space and Premises in the H028 and H030 Buildings</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#BFBFBF" style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Scheduled works on the leased premises </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">excluding the H030 Building</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Objectives</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;"><br /></font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50.02%;"></td>
<td style="width:49.98%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at: 26.06.2019</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SO-FAC-REM-KIM</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 1</a> of 6</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 9)</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50.02%;"></td>
<td style="width:49.98%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at: 26.06.2019</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SO-FAC-REM-KIM</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 2</a> of 6</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 9)</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50.02%;"></td>
<td style="width:49.98%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at: 26.06.2019</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SO-FAC-REM-KIM</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 3</a> of 6</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2.3</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Lease for areas and rooms in the buildings H028 and H030</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between Pharmaserv GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Novartis Manufacturing GmbH</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annex 9)</font></p>
<p style="text-align:right;margin-bottom:10pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-size:10pt;">***]</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50.02%;"></td>
<td style="width:49.98%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaserv GmbH</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As at: 26.06.2019</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SO-FAC-REM-KIM</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 4</a> of 6</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8
<SEQUENCE>14
<FILENAME>bntx-ex8_418.htm
<DESCRIPTION>EX-8
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-ex8_418.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 8</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;width:79.48%; border-bottom:solid 1pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subsidiary</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;width:3.86%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.5pt;width:16.66%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Jurisdiction of<br />Incorporation</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:79.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Cell &amp; Gene Therapies GmbH</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:79.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Delivery Technologies GmbH</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:79.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Diagnostics GmbH</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:79.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Europe GmbH</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:79.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Innovative Manufacturing Services GmbH</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:79.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Manufacturing GmbH</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:79.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Manufacturing Marburg GmbH</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:79.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech RNA Pharmaceuticals GmbH</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:79.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">resano GmbH</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:79.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JPT Peptide Technologies GmbH</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:79.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Real Estate Verwaltungs GmbH</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:79.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Real Estate Holdings GmbH</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:79.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Real Estate GmbH &amp; Co. KG</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:79.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Real Estate An der Goldgrube GmbH &amp; Co. KG</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:79.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Real Estate Adam Opel Strasse GmbH &amp; Co. KG</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:79.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Real Estate Haus Vier GmbH &amp; Co. KG</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:79.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Austria Beteiligungen GmbH</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Austria</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:79.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Pharmaceuticals Asia Pacific Pte. Ltd.</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Singapore</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:79.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech UK Limited</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Kingdom</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:79.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech USA Holding LLC</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:79.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Research and Development, Inc.</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:79.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech US Inc.</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:79.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JPT Peptide Technologies, Inc.</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:79.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Turkey T&#305;bbi &#220;r&#252;nler Ve Klinik Ara&#351;tirma Ticaret Anonim &#350;irketi</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:16.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Turkey</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>15
<FILENAME>bntx-ex121_12.htm
<DESCRIPTION>EX-12.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-ex121_12.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 12.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Ugur Sahin, certify that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have reviewed this annual report on Form 20-F of BioNTech SE; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(c)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(d)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee of the company's board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 30, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Prof. Dr. Ugur Sahin</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Prof. Dr. Ugur Sahin</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>16
<FILENAME>bntx-ex122_16.htm
<DESCRIPTION>EX-12.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-ex122_16.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 12.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Sierk Poetting, certify that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have reviewed this annual report on Form 20-F of BioNTech SE; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(c)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(d)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee of the company's board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 30, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Dr. Sierk Poetting</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dr. Sierk Poetting</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>17
<FILENAME>bntx-ex131_7.htm
<DESCRIPTION>EX-13.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-ex131_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 13.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The certification set forth below is being submitted in connection with the Annual Report on Form 20-F for the year ended 2019 (the &#8220;Report&#8221;) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Ugur Sahin, certify that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 30, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Prof. Dr. Ugur Sahin</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Prof. Dr. Ugur Sahin</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>18
<FILENAME>bntx-ex132_8.htm
<DESCRIPTION>EX-13.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-ex132_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 13.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The certification set forth below is being submitted in connection with the Annual Report on Form 20-F for the year ended 2019 (the &#8220;Report&#8221;) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Sierk Poetting, certify that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 30, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Dr. Sierk Poetting</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dr. Sierk Poetting</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>19
<FILENAME>bntx-ex151_1103.htm
<DESCRIPTION>EX-15.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-ex151_1103.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 15.1</p>
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consent of Independent Registered Public Accounting Firm</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:18pt;margin-top:6pt;text-indent:0%;color:#333333;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in the Registration Statement (Form F-3) of BioNTech SE and in the related Prospectus of our report dated March 30, 2021, with respect to the consolidated financial statements of BioNTech SE,&#160;and the effectiveness of internal control over financial reporting of BioNTech SE, incorporated by reference in this Annual Report (Form 20-F) for the year ended December 31, 2020.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#333333;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Ernst &amp; Young GmbH Wirtschaftspr&#252;fungsgesellschaft</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#333333;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cologne, Germany</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#333333;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 30, 2021</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gdc15tqwxkbk000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdc15tqwxkbk000011.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "> F # 1$  A$! Q$!_\0
M'@ !  (" P$! 0            @)!@<#! 4* @'_Q !9$  !! ("  0# @8*
M#0D%"0 $ @,%!@$'  @)$1(4$Q4A%C$7&"(C05<9)#(U-U%WE9;4)3-"5%9V
MD;&TMM+5UB8T-E-88GF3F HI0X&41%)A<7.7LK.U_\0 '0$!  (" P$!
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M+&ENR,ZD63^#*R(K47'FD,^X#AXUM?MDR6<QL>*NBI%(\H$$4C/)T@EWZ@W
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MDN0"GQ*Z\[(2+2*X#$CQ\B?%L E.Z>?:K)?$U:+L=^K6GG@  [-B6/K>,@
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M&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FM:;2TQJ#>,"'5MTZKUUMNLQ\JU.
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MDG'$CA!!L/%%F%O-CBBC#MJ=?))(>4AIAAAI"G'GG5I;;;2I:U)3C.<<@$D
M DD\ #R23\ !\R==6945G=E5%4LS,0JJJCEF9CP H )))X \G4"+#XD?7MZ=
MDJ=HN/V?V]O$02L*4@.J]#.VA"0QB<8QAFQ;561":7KV4O*2R0W+;&&*%7GT
MO"X7Z4+E5PUP()+1AQ\3 %7O2B!W!^<<'#67\>1TPD'Y'P>*?/OG"F9ZN(2_
MN6W&W1)#MZHV0BB?]K/D.J+%P'GPPENJRGXKKS4[>\26^X\Z/TZT9I4%?Y;,
MAV,[,$3TZIA6?R/<4S0NN;U&"E)3Y+4/^$9Y&<YRTLAA:<YSV]GPL7Z[D;5D
M_,4Z05.?PDM3Q,1^/9'X ZZC);XN?SKMG$XM#\'S>>,TW'RYJX>E<C#?A[<?
MN)77+\J\5XG\YF^>'K#_ 'YP&C5'8^Q^G^)*I)6Y:Q\3'Z,KQ%-9_3Z/T<XZ
ML"/ZEEV_'VBDG_9]E?C_  CKGM^H;>?;-FQ?N/HW-S__ -SZ4KD_G[8_-K\Y
MD/%:KW[9)K/03:;#/Y;L;#VCL#IF4,0GZY:!)EJ]N6-9(<_<H]XXVPC.?-;N
M<8\L\\8%_ ?+0$_!F2I94?VP5ZS$#Y\>?N&N"_J'![Q@V?D /)2.QF<7(X^Y
M#)#E(PQ^760H^9UUU]W=R:V_+[,=$>PFN8A&?43?-(EUCM=K^/%;_P"=2,FW
MK%X';<='C(\WG'R=0)]+"'77$MH1C*GT97F_G+*U)F^45D/0F8_)5[_-=F/W
M"Q]VNIW7DZ/]'=HYFE$/M7,4T&XJ:@?:=Q0*Y)$'QZFQH\<D@:E%H_LUH#LG
M#E3>C-LTS9 \:KX4W'P4JA-DK1'Q%-9#ME0D$A6NI'X<2I&8^RPT4:E6/++&
M.:-JE;I,%M5Y82WV2Z^XX^^.0<I(/Q1F'XZL&)SV'SD32XG(U;RQ^)4AD'?@
M;GCHLUGZ;%9^?'1/%&X_:ZWIS5U+:<::<::<::<::<::<::<::<::\.QV:MT
MZ%/LENL$'5:[%,Y)E)^QRP$'"QHZ<XPH@^5DR!00V4YSC&72'VV\9SCS5SLB
M/(P2-&D=O"HBEV8_<%4$G]X:Q3SP58GGLS15X(QU233R)%$@^]Y)"J*/Q8@:
M@K(>)SU3./+A=02NS.T$\$0L8B.ZM:=V1O&.;<;SY+RY>:A7B-:L-H5Y86Z3
M=66V\9PXXI+/FYB4&$O@!K"PT4/D&]8AJG_FI'$Q_,(R3\O.JB^_=NN[18R2
M_GYD)5DV_C+V60$?'FW6@:@!^+6AQSR?'G7!CN=V%G_SM \-/MO*BY_M9%_M
M75[4[CF/I^7\OLN^B9)E&?/S2DD-A_R_=L-JQE..?HVFGZ[FL>I^Z&.]8'^$
ME4 _O<C[B=<?HHS4WFGL7<DB_MKEC;^./Y^B?,-(!^=0W[G7]SV\[4Q/Y^U^
M&/V2& 3^4X[3=O=2;V?A&/JK+44)O:*)><QCS]+258RM6/3A7UQGG/T?0;Q'
MFZ9)_P!TK9"(?+XL:K #\?PT_1+N"/S8V'G0GS-;);;MO^]&N8C8G\-<*O$R
MT?5_KO767:3K"/\ N<S.]>N>PXRFH<Q]5H?V-00-@ZY#0TGS<>*-MHX3*,>I
MPE/FG"GT):D_G6>C>/[6K<A:0_FAE,,YY^0$?)^0UP=]XFO_ $7HY_ CX=W+
MX2['5''QZKU-+E!0/B6:R% \EO(U,K6&XM2[LKK=MT]LRA[2K#F4)^>T"V0=
MMC&W5IRK Y)<&<:T*6GR4ET,E3)3*T+;=90XA:<1L]:Q6?MV8)8'_:31M&Q'
MW@,!R/N(Y!^(.K/0R>.RL LXR_3R%<\?74K,-F,$_L6:%W"M\>5;A@000"#K
M9',.M[3C33C33C33C33C33C33C33C33C34-MN=]^LFH;6]K4BZR&S=QMX6E&
MD-$U:P[KVW[A"DIR-)4_7<?.D556<JQG!-T?K4?A/Y2S$IRG.9&OBKMB/O=M
M8*_^^;4B5J_G]K),5$GYHPY_#58R6\,#C;!HFT]_)_+$XBO-E<ES]TE:DDS5
M_P"VM&"/[W'C6M4=C>]>Q_RM/]#1=?0AGUC;9VUWY5==F)9S]$$FZSTY!;RM
M0WG]<K!E92#/;QC'J9_*^F?V/%P_SQE>ZP^U'0J23#]Z>PU5#^=58'[]:/TW
MNV[YQFT%IQ-]BQN/,UZ+\<_::CC(<O87G]I))$X^8US)B_%<D\X6[=?#YIJ5
M?7(@VM>Q>Q7&?/\ N,2A&TM:-D>7W?%S"C>KS\_A(\O+G'5@5_J67D_$S4X>
M?^2()N/\,_=KGM^H<GDV]FU?W*T,W>('W=PY"@#^?M#G[AHJ-\5V+SZVKAX?
M-U2GZX$)U[V,ULX]_$C,F/LK:+8_G_UN(4GT_P#5*^[#JP+?U/+Q_B)J<W'_
M "3#!S^;K'YQIV_4./R+6S;?[EJ6;H$C[NX+^0"_G[3?F.N%?93O%K?\O<O0
MAZ\0@?E\RMW4C>M1VD0IO'T44'K/;$/HVZ$)QGRS@*)?L!ZD>>4M97C#:N?8
ML7-_.V6$3'X1Y"K) /S&>!K,7P^;!!SX_'74YW=E'SD]G&W$OV[.W,O6R#<?
MMA1R,6)M$?N(C._[GGQK:>G>]W67=-H3KF'O9-$W E*,%:/W16K#IG<0[ZLJ
MPH<:A;&CJ_+V#X64*PZ94T3\9C^Y/5CZ\P6,5>K)WFB[M?XBU6=+-8C[S+"7
M5/S2=#?/C4CC-W8'*6/8HKAJ9+]EBLI!-B\F#\PM.\D,LP'!Y>N)H_N<ZF!R
M.U9=.--.--.--.--.--:+[ ]CM3]9J6U==J3Q :)62'KU-J<#&EV38&R+A(9
MPW$TG7%*B4/SEPM<L^I#0L9%C.)8;RL^3(CXL8L\?:J4[%V7M0(#TJ7DD<A(
M88Q]J6:5N$CC4?%F/D^ZH+$ Q.9SF.P-46LA,R]R18*M:%&GN7K+^(ZM&K&#
M+9L2'@+'&IX'+R%(U9Q#H;5/;3N9C$SV'L]GZC=?)''Q8KK/I^T8!WK=X9[&
M/AYW]O.!=]Q3&)(;UXD-8:;("?'$/7&V#8D@6*\*F1-C'X[W::)D+8^U=L1D
MU8F__*57\2%3\)[(/)4%(5!Y-87';CW/];FK$^V\,_F/!8RQT9>U$?A],9>$
M]54..>NABV1E5NB:Z[ J)MZ9T#I3KO5D4O2&L*;K&N>I#A053A18XB6*1A6/
MF-@E<(7+V27<]2LD3,^?)2I*E*608ZK.<YC+-NS<?N69Y)W^1D8D*/N1?LHO
MW*@51\AJUXO#8K"UQ5Q-"K0@^++7B5#(WGWYI.#)/(>23),[R,3R6.MO<U]2
M6G&FG&FG&FM2[CT/IGL'57:3NW65,V=6',K6U&V^#"E<QQ*\8Q\PA#GF_F,!
M+->E*AY>$+CY05:$.#%M.(2K&Q7M6:D@EK3R0/\ MHW*\C[F \.OWJP*GYC4
M=D\1B\S7-7*T*M^#XA+,*R=MOV\3D=<,@X!66)DD4@%6!&H0$Z>[8=-L*FNM
M%JL7:O0<?^=E.K6Z;:H[;]/AVDYPM/7K?5@==/G4QPZ6DQVLMS%2PQ H:@(.
M_0Q)3#.9,6:&1]V[&E"V?LWJT?%>1C\/;*B^%Y/QFK!2">IHFX)-4;&;BVQ]
M;@K$VX<.GF3;^4L=>2K1#X_0N8F)>;H7CHH91I RKT178B5&I?\ 7OLIJ?LW
M3R[;J^9-61!2;U<O='L\655]D:PN(65(DZ5LFD2B6IJI6>->;=;=#/9R,:VW
M@^'-DXIX8]^/MTK%*01SJ.'7KBEC8203QG[,L$J\K)&P\@@\CX,%;D"RX;.8
M[/5FLT)6ZHI##;J3QM!>H65^W5O5).):UA#R"CCI8#KB:2,JYWUS4U+Z<::<
M::<::<::_#CC;+;CSSB&FFD*<==<4E#;;:$Y4MQQ:LX2A"$XRI2E9PE*<9SG
M.,8XUP2 "20 !R2?  'Q)/R U6Q-]LMN=F;!,:Y\/^$K4K6H62+@+WW1V.";
M(:&J,B(\L25AM.5\ F/D>P]YBUMD)61#2<5JV#D&16IJW2BB%Q?)I<?7I(LV
M69UD90\6-A(6W(".5:R[!EJ1-X\,K3LO)6->.=4:7<62SLTM+9T4$D$4C0V]
MT7D=\16=&*218R!"CYJW&0P)BDBQ\3A1+9D),>M@:N\/[3%6M(6U]R&V3M;O
MYC\]^&7L*0%<3H$IQ:'W6=84+ @^MM0P[)6%KC@*!5HD\=A>&#IB4<3DA>&?
M+69$,%8)0J'Q[-3!C#CX?7R\F:RW'Q,TC+SY55^&MVALW%U["9')M/N',+Y^
MD\TR6GA8^2*%/I6CC8PW/0E*O$R@\/)(?>,ZN1>K;IQIIQIIQIKR)ZOP-JAY
M&NV>$B+'7Y<984M!3T:',0\H&[_;1)&,D&2 C1G/+'K8)8=:7Y?E(SSLCO&P
M=&9'4\JZ,593]X8$$'\0=8YH8;$3P6(HYX95*R0S1K+%(I^*O&X9'4_,,"-5
MZ3'0R4TT<;=N@&SG^L]@<)>E)'1DTQ(W3J)?BW'%$$"2^I734%ZL+DG,,CKM
M>DY.H% ,X4\1 3WFH9R77*K9 BRT NIP%%I2(LA$!XY6P!Q. /V%I9 ?@'3X
MZI<NT),6[6MG7VP4W49'Q,H>UMNXQ)9EDQQ<''M(>%]HQ4E9D'EH9OLG8FB>
MY#5POB.O?86A&=<.T; !)XFNK!*LS-*VQ$1R,*.N/7[9#3 <3LNNMM?MJ1A,
M,1E]J:?<#V:KAH"=/<PVL=VXO:ZDHN420#,BE9:[-\(K<)):%_D'Y:&3P8Y#
MR!K=Q&YA9MC#9JFV#W $9UI32"6KD8T^W9PUX!8[\ 'O21=,=RMY6Q70*7,W
MN1FK7IQIIQIIQIIQIIQIJ&_87N' ZCM45I;6-+F^P?:*UQOS2K:(HI@@945"
M+<0.F\[;N1J'H#4&M6"'6FG+3:/,N4>7[.K0=B.2Z,U(T\<]B-K,\BU*,;=,
MEN4$AFXY[5>,$-9G('/;C\ >79!YU6,UN:''6(\50JRYG/V(^Y7Q%1E5HXB>
M!;R5IN8<91#$ V+'O2'W:\,[@J-.QG1Z[;_)%N'B$;,3N=>7V9&,ZPZZ>FJ=
MU-I#K:DO"B2M<22/9]\RX#F%958]M&DPKZG7D1]$AQ_AM\V6RD50&/$0>S>"
MK7INF3(2\^"5?@QU%/[2N PX!,S'48FT[699;.\[_P!*'D.F I&6KMRJ0>56
M2#J%C+R)\YLD[0DD]%.(<:L-K-7K-+@HVKTZNP53K,,,D.'KM9B(^!@HH1'G
MZ!8V(BQQ8\$9'GGTL"CM-)\\^2<>?(=W>1F>1VD=CRSNQ=F/WLS$DG\2=72"
MO!5A2O5@AK01+TQP01I##&H^"I'&JHBC[E4#7N\ZZS:<::<::<::B;O;I-U[
M[ 2XMULE5,I6X(A.<UG?NHY@S6.\:N0E&&V7HW8M7R'*R0PZ4^28*T8L-8>3
ME:#(,EM:T*D*N3MU%,:2"6NWVZEA1/5D'Q(:%^57G]M'T./DPU7<OM7#9B5;
M<]=JN3B_6,QC96H9:N1\"EVOTR2*/]QL=ZN1X:)AXU')_=/9KI"I+':S)/9#
MK&,K#3?;2@5+ .T=4QR<_D$=E-15AA\6:K83&<XD-P:J!;$#9#6?;:'$)+5(
MIW!6I9/^</U'=/\ ]WRR=4$YX\^QV'(*N3\*]@\GGB.5N.G4&<IGMJ>-PELY
M@5\#<5.MTY#'I\FSN-KJ5E@4?;R>/0*@7KLU(@QDU9#5[16KM782WTZ?A[55
M;)&B3-?LE>DA)B#FXD]E+X4E%2@#KX9P13*TNL$C/.-.(5C*59QR&DC>)VCD
M1HY$8JZ.I5E8>"K*>""#\0=7B"Q!:ABLUIHK%>>-989X9%EBEC<=221R(2CH
MP(*LI((^!U[W.FLVG&FG&FG&FG&FNH>>#% FRDH:)&QD:(0?(R)Y+(8( (;*
MR"S32R%MCBB"L-N/D$/N-LL,H6XZM*$J5CD L0J@LS$!5 )))/   \DD^ !Y
M)UU=TC1I)&5(T5G=W8*B(H+,S,Q"JJJ"68D  $D\:K<*[;[F[0R1]5Z 4^O'
MT00TF)L'='<($NC1@1 K[@<DQI&F@/Q5G["30#[1;+4['2%;U4-(B(0[<)QE
M[VRID8^M1 DRTCB4@,F-KE?:F!'*FS(0R4U/CE"KV"I/$:'@ZHS;DRF?=Z^S
M:T+U%9HYMTY-)1B$*DK(,550QSYJ5"& E22#'AU'-J4'IUD]6\.73\I,Q]\[
M1V.Y=U=IAO8.9L788L2:U[7I!2?-[\'N@HL<#3%' 2[G+@6!ZC)SPOTR[8RW
MLN/N=),Q853%12/&0$<%*8*S./EWK;%K,I^_F14/[0?#6Q7V3C9)4N;@GM;I
MR"GJ$V:99:4#_$^Q8>-4Q=1.?*\5I)EX',['DF?,9%QL+'B1,-' Q,7'L(%
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M+MIP:K-K6,IU^KJ#B(Q<Y3]C6*Q1;<D(AETF/=.B;:4.T:PT2,ZZ*XXE]#)
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M+;333:<(;;;;1C"$-H1C"4(3C"4IQA*<8QC&.0Q//D^2?))^>KN      !P
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M"_\ FTCIKK;%E[UND:=G&,K]E/6FKZZJA2,82@AFQK$6XC)"$KF<2>PF1O\
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M,.U]3IC6^EAK(=]K38*T[,2U*RI#K#<2B5PY?[2=-.A_"C,"#X9?^7MNCD_
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MUN$Q)=J17495E7PPX40="E-LH5G>S$JRY&P(S]379:D ^0AJ**\?'X,(^O\
M$L3P.>-5_9-*6GMG&O9'ZNR4<F:R+'GK:_F)7R-GK)\EHVL=@<_!8E'RUT-Q
M]W>O-/DRZU:HXVV!5Z?BE$R61:_BM"VF)F1787V1D_+ )(E8VQ#AKC"QQ_2B
M79$<BR7B$M+3\I[B_*LV%@=S7MK8C$[MW=DL<UR"[-M?'5;559*4<K9&.!YK
M]>Q92E'%.;EB&N::1122+8DA5G%EM"LL0:ZU=(5E@(:R\:1B;NI[/P9"%$O?
M[?9\]7=Z.CW^-: GN[O22=#2;8M60L@!,/7C]N2$=K-0DQFP.,M;-$=(7/89
ME ["]$,-["C75D!3CL:VFT#%K$QAN,B_*_PQL3TX/3SU5:W37'O9JQX:FUBJ
MMU$DQ+S0KE#)![7'/&^.=E4SI,C52RR*3&SQ;?EC66<X=XIS>"R2/5[<_4>G
M)H')Z95=H>F_'RR.8N+*DIX\^6[>=#Y.Q.2LWHZI&VR:FZ;:ER,C6-4/6"2L
M4=#GT_7UA261+*D2)@. /DZO3Y5#BC&8<LZ%AGTA/OC*ZQ?EC81ZTT\.PO51
MJ=49&*Q-'BJ35JZXX)9R\<LBY8Q1B@O;L9%7(]E!26R$!#:ZRT]MO8#3181K
M4\M*P&D6D;$LS))4QTZEAW'D:-I:U.0<L4+PPDJ2NO?)[3]-YXMI1?7P&6/K
M2I&/;6[3-<&&P;E@I<-49<3*\R3A #TWKP. K4BTK+3LC3AHB()P]#-!CIC'
M_+>V76B@EDVMZ@P0WHC8JR25\1'%;@AMV(C-79LT$GBBO06HC)&61+<,Z<B:
M.0#:.*Q$\A_46-EEJLT;?40/)7:>G# Z-[A:)IJ KQ.IZ3)4$*,##T#72DNU
M?2:=,>O<MH*&E3[%9*=<GKB=4M:&%S=NA(W%5H%I58'I5;LA8HF(DDURH37N
MW9(*/.1$PY+8Y*6%YQ^6MM6.U/BQL_U(2[22_%9Q_L>,6U5CII+:R<<U3Z9$
ML*58ZT]B\KQJL*02S6 HC=EQOC<'*!?DJXJ06)Z=H76BK,)[*J*U"P+!4B2<
M)*M>I*'+A9%BA;APIRU?B/=<M;0+=9A:>=4AX2'1\@JC:J/70!F'G7AHH<2,
M8GV?:A'2B5!#Y%$SAXM3C3"'2?-O.YB?RN-M[BE@;'[!]2;T5JX:;7X<5C[5
M6.=$CFL]ZQ!E)5'LE61;=L<EX*OU\BK'PQV>YCZ CJ">C3Z$3M5N[#!TI+(8
MHNW"2GNR3<QQ]*\/+[B\OXUB$=XIG7X(R/)1=9:PM)4ZW:FRY[5OL6&EQ+1[
M$F&U'6%ER%4V2?76F&GBU .14Z,LI!DD?'R+DHGY2U=DE:3TD]7H&2$20QS;
M6CCDN,;ST#!34W>9YEFKWRR+Y"XS)#[=.94P+F<,XD*9C%.(E#2E<A481*1"
MP:0B7W%(LUB&;@$6(#_5D+9@OQ9>KC33#[DHMMDI*%C/+M.NT-$(<#,D6UL.
M*N&$.I7'QT@<A3>584&"82G.6!GEHPK^4Y7>26)/1_UD>6!F6:-=IHTD+)9K
M4W65!>+1LENY3JL' *V;=: \2SQ*W!S>$559LUB K@%&.1J!7#1R3*5)EX8&
M*&:4$<\QQ2./=1B.SCQ6.M"B7PDDF*,%<:9*$Q8:!DD9XAU;##3[&+;\5EQY
MYMQEIMQ"5..MK;1A2T*QC"?RI<>L$-H^DWJ\*UB.26"P=L0"">**-999(9C?
M[<D<43I)(Z,RI&RNQ"L">XRV(+O&,MBS)&RK)&+];K1F8HJNG<ZE9F5E4, 2
MP*CR"-<P7BH=;Y( >4CER4A&%DI#%D0IVB%@DF+C\2R11RV+8X.\2J*SB32P
MVXIW,?G!N$^VS\7F*U^57B:5N:A=]+/5FG>KP&U/2M;<JU[<%9;AQS6)J\V1
M2:* 9 &B9G18Q<'LI;O^YKO%D\7-$D\.4QTL$CB-)HKM>2)Y##[0(TD60HSF
MO]>%!+&'ZWCH][7<1XH/7M3T>RL>>3F3:AR $HDJ2MTX6P/>W@B0&OM6C)K4
MT]C+,.ME66Y1[&6@UNK\\8PK^5MMSBR[^F_JBD-&;(U\A*,#09:,N'C$V8CL
M\Y55AFQ,)[V1BE>-Z4?#VNRIZM=_;J',2^WT>9UKO"/:H>9DN-T5'B'7S(MI
M_=KLG(G;W8BQ\:GA0+]5]F5:.N%0D/F$-)8<2A2VU,%"DL+RV4"<,O\ .#&"
MNXRAUI7FE2<H>8<>&=9><^B=F[RV_OW;U'<^V;OMV*OAPC,C0SUYX6,=BI;K
MO[\%JO("DD;<J1TRQ/+!)%*^V1P>-0:Z^H_!%WP[EZ-1CVM:W# ZN[G4,!OZ
MC,S%K'D--[P2SE6,9;=(MNN*?:364*6C!MS?*4EG):/B^@6_U1BL=:^+UWGQ
MLI^?3&19J\_FCFDC'X1<#G@\4C#?[&[NW/B?LP9.&ANBF@^R); ?%Y8#GX$V
M:-:RP'CKMLW ZAS8OR'U=M5RG-_AL\32*">Q[NG]'^OV+*EOR]++.^.TTA*P
M,:^YA6<H?+K.EM?SZ1E)3EP1G9CV<+:P1E)$P/U-A&/PDR=OHY^^I1578?F>
MS,GYS!\#P"*2X^E=]QH?>J[4PW?X^0R^X'DAC)'P+U\72FZ?'*KD">1U<-8U
MR'U=M8O:;O2Z,*P==;?5Z>$4XXR*9:9^)KXI+S3>776F")8L1IYQMK&77$-K
M4I#>,K5C"?KS(D4LI(BCDD(\D(C.0/O(4'C6O8MU:BJUJS7K*Q(5K$T<*L0.
M2%,C*"0/) ^ \ZJ;\7K]\O"^_P#%@ZE?Y[OR=V_\,W_Q!D?Y(M><^I7ZYL#^
M^)MW_P":U+?OUKF[;0T 16Z#7C;//-W"MRF8J/RQ[M8(N3F27FFWWF<._!44
MRI:&U*<PWE3GHRAM:DX=OV8*N0$MB18HS#*G6W/3U'I(!(!XYX/D^.=2GJ)C
M+^6VXU7'5I+=@7:LO9BZ>LQIW S ,R\]/4.0.3QYXX!U0\!L:>\.;=.G=J;_
M -4; %B916P&HB-C&(5,C*>TJ;D&>H7,C+!BY]B3<(9U]*WT9^ ZO*,Y7A"%
MV;,9"G<H35:TZ3/,8_*'E8^W+'+R_P #[P0A> ?///''GYBR>[QZ,YO;N8W7
M@LPT5XY9:T-1*O<D%>FD$Y!L684^K?(UCQU>5+'P0 VR*;NZ.[Z;7V)8=)5J
MZ'R[YK,V=5)X0)N>A8=_ 48(682%('0N(ELK" !R$2F?;M(826T+ZT85^0_Y
M0GY/_JI?]4\[GL)@+VZ,3NBY!;H7Z$D,GLI-6"!L?D%FFC:B*1A[4$T_33>H
ML#).'$T,/T)Z7^LNT?52&XN$-VCD\<.Y<Q&2A6.W%5:01Q7$EKO/4F@E=@G$
M5AIHI.5EB0-&\GT*:)I,SKG4='I=A)05-0D4XB16V[\=IA\T\R2^7M/_ +EY
MJ+08B-:=1^:6V(E37YO*>?=WI!M/*;&]-=I;5S=A;.5Q..=+K1R=Z.&:U<LW
MO8HI?A+%CULK1CD7W'2NK1_5E=>J,>22/]?]?EK;7/2=<:^%[>_0'NE*[OW'
M*Q76G;,K%RFT]@249)QE7*/CI&./MDL6"<":+ET8H0L5YI\=]EQ;;C3B5)5G
M&>3*3P]"_6+]D?$\'X?<=?DYNST>]4+&ZMRV*^QMQ6*\^?S$\$\%"2:&:&;(
M6)(I8I8^I)(Y(V5T=6*LI!!U]'%#[;U7IQU\ZT:1V)4+4?M.L:.UF+=ZK'?+
M!W:62BL1[:XV:*++PWB;QZ%.?*QTNY::]*RR1?BL8=ST\'9R8ELQR1Q0F1UC
M9^HF0@^2H4?9!\%B?CR #P>/O';.[:^PMD;'VYF*%TYRAM7!PY*@G:5\?*E"
M!7@LN[](L @\PIU%0/?9.5ZK(]3[3J.YZ'![$I)1!$#.-O>AHUE(TC'F"/N"
MGQDF*AQY YP)+3C3R6WGQW4X02(02(^P0[$6ZDU*Q)6G $D9^(/*LI\JZG@<
MJP\CD CX$ @@>OX?+T\YCJ^3H,S5[ ;@2*$EC=&*212H"P62-P5;AF4^&1F1
ME8[&YK:D]5R]UF_P4[IZ6]L ,>V;IFZ1NN.TR4?F&"M/=IU!48=V:)1Y96!5
MMU :BL B"?,<1?S!Y*F\OO)?F,;^J*V2H$_KE8W8 ?E8H\RD*/ODK&PAX^/N
M\_ $4G=(^CLIM;<2^Z*N4&#R##P&QNX>BHIE8?L*^53&S+U<JOOGQR>;&N0^
MKMIQIJNCJ.C\*7:'O=V1-_;# >TZ_P!1-<J?S\9<92>MT$E^[ICWL>:&Q9S=
M]^V+DUIOTY617A$/IRL1"U3&0^HHXJF/B8'R$W'CF6Z_U75^*U88>.?D_(^U
MP*3ML?2&?W=G&\A<A#MND3YZ*F#AYM!#\ LN6N7NL#XF%0?*:L7Y#ZNVH?\
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M*%0<+R23NKG;4[K1_97^ 7:O^)\E_F1SR3UY_I.>HO\ <Q?_ )%UV3[0_?\
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M&AA!64,#L-)Q^Y;990AMO&/W*4XQ^CD2Q+$LQ)+$DD_$D^2>?O)U<$18T5$
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MZLK4N7RON18JN/LQ8R&4C_\ $N22VF/[ZRQ_P:I>T?U1;WADF\O;W5=J!O\
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M2L+.()1!. '1X93#%86.6.14DC9H)X9D#*.N*6.1>4=2?8OO_0:Z?XIV/_\
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M;;&4H*?OL8S(4;R*?_T]NTR_,]+<> =6'\B-733C33C34.^Y'[P:9_E\HO\
MH4_SY@_*B_H-Z5_WY=H?]US.NZ?'][_*-3$Y]/ZZ:@[V+\/3KCVBO@VR-I1M
MN=M(U? K7N("UEQ KT9&E'EAX="RP4RE]IR1)3EUC#.'$91\1"UIRO/1HU8\
MGX_#QJ@;G]-=L;MR"93+Q73;2M'5ZZUQX4:*)Y'3JCZ77J4RN.5Z>1QR"1SK
M:V@=!Z9ZC41_6^N'WX.ORMBDK:0FU6;YA('3)X45&%DH(/6PE+* HB,&2.(P
MRPW\'XJT*)(?>=Y50HX'PU,;<VY@]EXYL7BV:O6FM2W&]LM]R22>2.&)V#2%
M0 (X(E"HJJ.GD@LS,9!!G!2#." #!3A\J4C#X9#1+.5I\O4G#K*UH]2?/'J3
MZO/'GCSQSMJR))'*O7&Z2+Y'4C!UY'Q'*DCQ\]:9[*_P"[5_Q/DO\R.>2>O/
M])SU%_N8O_R+K*GVA^__ "'7NZ-_@6U'_)I1O]68SDQZ1_TJO37^X+:/_@%#
M7!^)_.?Y=;3YZ'KC3C33C35>'AJJ^T.G]S;=;\L@;Z[B=K=I0:_O6]6&MO3V
MMZJ0M7GGUX)K>O(HAAS'Y#@C@ZVO-I2%9F,U[EFM7^=3'4*[?=U^SI-)Q_RY
MFY'R/(/G5+V+]=C,IDA]C+[FW%D(C\S7&2FHUV_'J@I1L"/!4@CQQK(/$ZK<
MI9>@_9_$&Q[F9J.N7-JQ3&//UN2&F)N'VZ(EG"<94HCX])1D9*,96I_#:4)R
MK.,9Z81U3*T>K[,DWL[?FLJU<_Q2^?PUFWY!)/L_/]D=4M:B<A&!Y)?%RQY)
M0!Y][JJCIX\]7''G4SZE9HNZ56LW&#>]Q"6ROPUFAR/I^?BYZ.&E(][\G.4_
MG1"F5_3.<?E?3.<<C9$:.1XV\-&[(P^YD)4_QC5HKSQVJ\%F(]45B&*>)OVT
M<R+(A_?5@=8[MFG-['UAL37#DRU7\;"HULI.9ET1,A\K;M,"?!.R*(]1L;[Y
M839ZB$#>^%2\MM*%/MI5E7.([,52:":1D';E20*\BQ]?;97*AFY^X D \<_#
M6'(5?;J%VCW.U[94L53+T=SMBQ"\1?HZDZBH?D+UKR1QR-1?A^I L%,ZRG(_
M: F2Z;U13U'M+9=6;?8M-(;*K1C5C@DM6P9RHVIMV",3\0YRX1*FY-O"HS*@
M,++VFS=9EG4M!Q+?^D$XM1@I+PXZ&Y4]R/WQX';;Q]KSX@8]L]J6A*EWWJNW
M?T-V U;D6*G5783Q<6%]FL POY;VF/B3RAZ!U83>NA59N5QLU^8VCF"L5MV;
MHS9TV(+7FRJJ9-Z([#F[W@I1< ]:4/XMLY'(K6K)JU-RS>54RL"I'B6WWT-A
MY8MP01QI"6KND<-J!2;,8D"6J8JLH?I([:GKG5.G]=<\MQ\=6YLZ*U9GMK=:
M&:S?Q%^517ZJ[2XC--EX9.T9P?:)HQ!CY; D'ZE@'3&"P"8E8_#<ID]JJ!TX
MC;1050U[KSMEK_52_LZ,3,UMCM?"V:J3,G:3_M,PS=':)4;E8X:MC,!UA$B^
M0!,6!X\\#U$9$W)"MAK/-8RRS4)I_P!4H%<T&215C7CF,2R1HTA)DXX*IT@^
M-:?8E>;'18L7Y$K4Z6XJ6//LX:6 ;BAL5I9+#]]1:-.M:FB@4+7#DI),7= 3
M)?JMUU"ZO5N\5$'8?VW@[;>';\&],13(UDBI:7KT#&60*3M3TY+S%QBER<+D
MBH*LCQ<W3:LN,H+<Y,5ZM5](&E?R]:\\4A>O$T<7:/38C*,JNS(5C]U8VZ6X
MDZ.%E?JEZ5=WYG=O8+Z @MUDMM;ALVS<0RQ=,\<DD,,<Z26#+++:C,D7-8SE
MI:U<QTQ+)#!#T;YOI@F:-<\8*&SG-3L6,8P^U]?[#F?][F@+-8^!8@)/@ 2Q
M^?\ M:L&EB,$^<4+]M#?2V&9S^?:^G_(:YX^OY7\><8_^?'M-;S^J(/'D_6Q
M^/EY][[R!^_IK+/>!_WV-_Y[7^UQ[56_WQ!_SL?_ )M-/>!_WV-_Y[7^UQ[5
M6_WQ!_SL?_FTT]X'_?8W_GM?[7'M5;_?$'_.Q_\ FTU_4EBJSA*21U*5G&,)
M2\WG.<Y^F,8QA7GG.?T8QSD6*[$!9X22> !*A))^  #<DZ:[',VFJ\-F*^VW
MB;=5ZLQG\WI#K%V4W+,Y_=)P5LRTZFU%4&E8Q_:GGQ@-@.C+5C'QF0ST)S^:
M5C,Q!]5A+[G_ &U>I5E_-!'8L2?GX+0\_=ROWZI=_P#56_-OUQQQBL!G<G+\
M_>OV,;C:P_ E4N%2?B%<#X:L/Y#ZNFJ\?#Y5\D5W6UL]G+)>O>^_8@A #GY+
MHT-MPBM[Y@WTMY_*]F8+M%Q0;O[ES#3J4YSEI6,3&7][Z,F \38FF.1\"U</
M5<?G!@'(^7.J7LSB+]%-$^&I;PS1Z#\1'DC!F(FX_:LN0]T_ \$#X'5AW(?5
MTU7EWLLGR _5 R3;+'/3T+MV$8-I]BU#&6454Q%5*$,(AXW<.T=:0+4BU$R\
MDJ,OC*+8FA2OR]9]??8GT8=E\4G6)SPAZ&KN1(EED/2TC#J-:"9RO4J]47U9
ME7GI<%#JE[MG[+XY>J=#-%DHE:M/C(YU[D=:%FBCR=^C#UB.63HMJ+/LDG07
MA(F'.@/%Y^DCX7V/O\O%@ZE?7/W_ 'W?[^;6W_AF_P#B#(_R1:A?4K]<V!_?
M$V[_ /-:N,Y7M>G:Z4D5D&//-2C#B@PBBDH5G.,+R.PMW",YQ]<85E'EG./K
MC&>:UV<U:=NTJAS6K3SA"> QAB>0*2/(#%>"1\.=-0U3V5N?JQE4-6,H]6/4
ME(TJE64^?UQA69=6$JSCZ85E"L8S]?3G[N?,P];]S\CJQF!*\CD"#( D<^0&
M.28 D? E2 ?/2?AK+T#\?XO\VIK8SYXQG^/&,_Y<<^H5/(!^\ _PC6+12L)Q
ME2LX2E.,J4I6<8PG&,>><YSGZ8QC'USG/TQC@D*"S$  $DD\  >223X  \DG
MX::^2;Q_:S/=T&M#/==/GVP']-2VPX>Q581H80&:S>%4YL"QU3)DB.N8>CR*
ML_&'(4&AY\61!+B<OB-GN9\KV#^5KZ*/O"YLV7.V:DMJ>*I2W';HF+;5R[%,
MT IPY$2O/&)Y)28+EJG6QL@C8BX1)7,OB?K1L[/;DIX>YA8'O'%M=6U0B=1,
MR6Q6*688V91*8C79)$4M+TR(8T*B3C /"QU[&>%?IK<^_O$!!+I3&[):D574
MNC@E 679T\_2VK1(3MF)K$;,-B0#?PK ,"*JR2D*L5H<K,M[/,K6T2OT-NS:
M>*]2;F/HC%U,LV*2S*UVV)(Z]1;9@5HUF'#OW# A9(UDY*@J"$E*>>[0SM#T
M7P64W#OJS-03.3U*F*P5017,K=DI+8EFG%-)ECA"+.J]RS-76,<B9D::LLOT
MH]+^X77+MY0)2;Z]FGB"4\]B/M%*L,4B"M54*E\%&1SDK&LFR8;HDRD<YT"4
MC)63CRW0SQ4F8, ,&'K=K9S[*CKXI:->E3XE>H*9+59.9"\Q1F"N7$DG5()5
M60=:DCI9"?</3_U,VKZEX^SD-M6K#-2ECBR%"] *V0HO,KM ;$*R31&.=8Y#
M#-!/-"YCEC$G<BD1)D<TM7[4._$)NJ->]%^W5J]:T%"=>-L1T1\/&5.+L5CI
MLM6ZTPA./REK(L$O&,(0CS6M3F$HQE6<8S(XB+O93'Q\<@W(&;G]HDBN_G\$
M5CJL[SM>Q;2W)8Y(9<)DDBX^)GFJR00 ?,EII(U 'DD\#SK?6F*8O7&GM4:\
M<0EM=#UK1:8MM&<90VNKU>+@U(3G'TRE.0<I3G'TSC&/+Z<U+,G>L6)OCW9I
M9.?OZY&;_+J8Q=7V'&XZD1P:E&I5X'R]GKQQ<?\ 8ULKF'6]JO#PNU?)NIP6
MJ2,8;F.OFY>Q6@YH=.?- SNMMY7R.@FVOT_ >IS]:,'SY82I@IM3>5-9;6J7
MSGO7S./LVZU.VI^_O58F?GX^1('!_$??JE[ /:VZF/;]<PV4S>'E'[7V'+W(
MX1^8U3 Z_N6''CC5A_(C5TU6OWCT/?[Q8:_L2E0Y]H8#KK5;EX6*:47*A>SD
MI*1$/$CV_42<.5\U>8?;":>>'<&0ZMK+;ZEM_!WY7'H]O/=N:PN]]J8RYN&&
MKA(\%D\5CD:SD:GLMZ]>K7:U).9[<-CZ1EAF2HDLL+P)(T9CE9X\B$ 'D\'^
M7_7_ %\ZJUV%U6W?>VJZ O6>QH^-A[-7+40XC7UQ7*9D:E9(.SPGLGFVF8_(
M^2X=;)H<K'28[BWPI(=+!L0Q@CY@V9L[U0VE)FK@]*/4*[=R6"S6WX$;:^62
M@*6X<)E<%E/:HWPDMT3BODDEJV<==H3(D-JC,TU7)3&&+R^-.56G$9TAAKW:
M=YR%<SF;'W:MZMVV69(>CN5BLL<\,Z$O%.@22LG7L3\!VZ?U1[,_H+9_]V<I
M7\R/U5_L:[]_ZHY__0-2_(^\?PC6C(#IIO\ @90]&*/?)6J'6;:%N+@YO4,O
M*D2<GL:7:FPPSI N+<*8CZF6]*B!XCB!<RL*_$Q9C+.(7W)_K.7Q/J)EL?48
M^C/J50W#4P6P]N5\KC,;NNA#0H;+H28RS9ITZU".O+<W#6CQ\]CVV&?Z/R<.
M0R%::4Y,P5*O4P,U2>4"]!/0ENYW(25;-.&=YY\S86S''--(6D2&A(UB.,PL
MG?K/!!*BBL'EVC4>MFX*E6(&M"ZEV4ZU"Q8@"B$:^L8WO"&6DX+/6PU&?#:>
MD"\O&D)1G./CON9\\^?GF@[D]/?5S<>?R^=L>F>_XY,ID+-Q86VMN*?V6&60
M^S4TFDH=<D5.N(JL);@]J%!P..-3F/J1X^C4I1LK+6@CB+A53N.JCN2E5]T-
M-)U2OQ^R<ZT?NCHEN[:Y%G-$H>R*X78M3VG4Y*TZ[M)C$E$68.4='>F&<1PZ
MU_9FR/Q,_#H'?2\K TO&9)%%GSL\]5],&]4?3VO@JECT<]0,U7PWJ%@?4*!3
MMG.UI:.1P=C'QS18Z0XZ9%^G,'%D</DFGA:-38QUY89[&(JC58W)M7Z?>[*E
MU:4EO WL"Y"=Q9J]V.=D:P.I"?8KK5[=<(X8]NQ"75+4G&*W[P\^P5YE[S+/
MPVU1_ME!TF,983K*P,%P!-.(V*0$['3($:(0X&*N\L-M"E"NXE8P"3A)U1H,
M\XH*P;0S7J%M3';4Q\7H#O>7]#.4W1=EF^@-RR5\O#N2+9<5E;N-MT+$*VK
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M5"1QRB5_X#MT_JCV9_06S_[LY\\?S(_57^QKOW_JCG_] U?>1]X_A&IQ])]
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MU1V2).J1@C%5(4\>E^-+V!_6C8O\D=_4>:/Z8?UI_LA9O_!H_P"AZS\#[A_
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M9>4.P_(E! ^X0\6SA4GMM1)+E(#)%&]C#7:\1E=8T,LIB5%+-^)Y/') !/'
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M2Y1"L_?V<#JA^JKN+_Z9KE_6.1/Z&KW^[X[_ *;%JX_S5MO?\';G_P 06_\
M/I^S@=4/U5=Q?_3-<OZQQ^AJ]_N^._Z;%I_-6V]_P=N?_$%O_/I^S@=4/U5=
MQ?\ TS7+^L<?H:O?[OCO^FQ:?S5MO?\ !VY_\06_\^OYGQO^I^<>6=5=Q,XS
M]^,]9KEG'_\ ?Q^AJ]_N^._Z;%I_-6V[_P ';G_Q!;_SZXG/&[ZH*;<0UJWN
M*.XMM:$/M]8[;EQI2DYPEQ"7'%MJ4C.<+2EQ"V\YQC"T*3YXR_0U>_W?'?\
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MT5^E864P((X9^4> I,-]5/NGLZP=5^N6Z#*C3XZS;=WKG3FP;![*<_!OJV$
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GU+9DK":S9>);DMGNRUXGCJ1S*\E>"(SR RPY'ZL6G&FG&FG&FO_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>gdc15tqwxkbk000018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdc15tqwxkbk000018.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &U F4# 1$  A$! Q$!_\0
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MP8Z=,'*C.KCC88V/A"D*]TB%J6,B:W>@:M;GKND<;POV/'$S/&CJ &5&?EB
MW/M+'XNYONCUKIS8P[;1ZS9U[%FW7O5ELP6;D4,%J>"5F:*2>&N%AC=HRI*Q
MI&OL/A1$F-9UYB9-XXQCC&.,8XQCC&.,8XQCC&.,8XQG\5C"DY3GS\E8SC/H
MJ4E7EG'EGR4G.%)S_H4G.%8S\^,XS\_&,\EG7+N1VCC]C:_$M.\-D$: ;[-^
M)SI^,/(6.1?F[1'TSJJDVC5%-G5PRGU]#$ZXE$IMDA[. R#I8M((9K]KA,!6
M$$%] N:VB:;F.K )EHZ*SR(Q$8S9GE2Q*KJ?M[3!0A@<*J\=\9[O@Y\M]/\
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M&<.:[3UT/JMV>66"9T2@D0A;UCP?7K/@R2O$O!:6&-2%B\^'D4\=W:1U7?\
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M;5H=VK_ONN29"1K-M'#I8:%!+%+3(.1EK711T+!4=UBCLEI%TX;QP\,DDJ?
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M /-'&(0B3.%4-(JAV"@%CP,YS.AM&QS^;7'TQJABTJ,V*Q*LK.NJ@T?58+?
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MO00R1'R%+8S"]0B+A+V97I*RWB\8)O5Q:2,R1>/X#]K1AHSX?B&1A(Z<Q@$
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M+W/>F1$T3)B@ L]#6:>_%,0V7%-2O+$.6WAF4-*D3P-&'GH4 GA504*"6'\
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MZ>EM+NPFZ?N0P6NNZG6$.OISAX**#3]35]G7JL]NN1)>W74EB_&DJ25:]<&
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M_P#..S/QKSSW1N?Y<_\ 4C_L91_R;?0E^\2I]+=0_K?.+.\);P\B4.4/F];
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MJ2/J%/&OLQ9QV7#::>GOO37T/-#0XQ$B+[R)9CS'&')L)EB%*>DH;YZ%)_\
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M:$VR>23GU!T[HZG36CUFBI%FK:VJE=7?[N9^2\\[CD@/8G>29E7X"M(50!0
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M<SG"'$X5A*O/&*5K5'4,L2$'G@\$>PD'V\'R((RJ?=[^M(89KTR2*%)7[2W
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M8NY?%L311\CNYS7>]][M)Z_ZQ4;M651:Y]$V!\&FPE>#!D3[TB<73*E685,
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M$H9/%S7O98A4Y/K6'9*FP)FP'"45M3I%].;;UXY"Y(/+F,MQQYF)NY?:#[>
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M-CPQ\4V,?FRGQJ%N$&(T5J2M]]V VVXN:TTVI<5#:U/I;2A6<6#'( 6,;A0
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ML 49.G6OS^5>\3/S_=_8IZ-^?_K^!.R?/]SYOW>8MW]H-)_T^S_G8\V;1?\
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M41&=3?Z;K:%]DLMN.Y9298[F]37\^%"!/5DY/VR-<I5PS$#XE5@?E#=W'E_
MO/\ KRKGQ&_U?8?\X=;_ /IEAY]7_P#[.G_X_7O_ .7G47_%.G<^6OV8/_PH
MJ_Z7Z?\ H&XRI?3>EU;6$;FLDJR)K@#26JW]I6)485@\<*PU7.GT,<*!AE%
MS3[SQZ["GR4^63B0Q :.0GKS*DMQ!\W]O[MWU1Z4:Q>+)>MBI'R_AHA\">PS
MN_8_ $==PJA2SN54< EE_.;IWIP[VOU'<>X*=7IK1MO+A2 6K4\9V.NU4,%6
ML9ZRLS6ME TTKS)'7KI+*>]Q'%)VN^M$YTFC4LZ#9Y=M&;4U%6-MQ)[E9=K:
M@4>TV*Z@Q@&<UDP:2LEZ%)G$/69?BJ6AQQEN-G,)]W-&OO\ KWKBM$(7J7):
M;+XHE\0PQP.TBGL3X/V]5XX/''//P@,R.JNE_>T-#+%=DOP;S04M_',:34C5
M2];V5:"K*OK%D>-QK)9N>]"02H3[4S9ZCO \[\%[WHN_ZJW]="QDCI8U5XM(
MM1B(?L)B=2K;"-*A5PB1A0B<J9FJSZU/1 E$W?:$B"HX4RI<02REKD7I"U%7
M7WZERK&D*[%)S+"@"H)Z[1=\JH. HE6=.X*."Z.Y\W.?>'[%;KW<]4],;O1;
MRU/?FZ4LZY*-^RSRV'UNTCN&"G-.Y9YC2EU]@1/(S.M>:&#GPX8P,X[3[7JA
MCQ$.NEQ"6*6Y7 59I4>801!.PU0G,6Z^+((;A2(,<@O#L26PE[,6(XB0VYZK
MS<RAQ"=!7[@_Z_\ NS*](DSKZ<.ABLCJ%U^I [69>WQ-GN5?CCCCO7X+<?=#
MR/(\LK'8L*<];3==<(RE2I&\ZX?]@4J6IEQ#=$M<)\@I>4YB9D>N>8:5E;GM
M:TYPK"5-H4I-SX__ %_^C/G])I#T';C,DA5NKZ$K(7;M+G3[(&0KSP7/ !8_
M"\O;GJ0H?8[42*13&IMPDJG(JM=;EJ<K=P?<5*2(AI?RX_@$YAY>7L+RIW#B
M\.*\UX6K&?2S8/M/\)S]#-/)W:C5,S%F;6T69F[BS,:L1)8GS))\R3YD^W,5
M[R=I6.J&@I^Q!LBFYO5FL%;U]JJ%L GD+3)MYMTSU,*9;"/MHMV%5:V'8,6Z
MS/H(0'<! ,UEF7'E/,*Y,Z#4G<;!:S"?U>**6S;:LG?.M>%>6$*]KAII7*0Q
M JP\2125(!S4?2=UNO072TVVB;7>ZENY3U&CCVT_JVMDVE^3LCDOS"6$QT:5
M=+&PNLLL3>K59561'9#FG&]/%JI&ONO?5?=='CT\N0WYY7&R56QGVHCE<UQK
M^-ES>(P-(:GPO>.QA9Y&=>T,8KVB*?MCKCS<4A#'2F%S=#H^Q9V6VHSF9%U_
MVF*:*,L);-@\4'<%6[:K1_W188<&.'@<J6!SG?5'I[UFIZ3Z&ZDUB:^Q+U5_
M[1N4;EI8VJ:?4IW=305F66/QMS#:'N1JH#WI:V#%@DL<,BF0MX>)IKO5G:#K
MIIH.9U^:U]LH15S>R;?+/H8,!!FXU>Z]'D:;$]NCL$H4LHV@[?G94:3[BHQ@
M&?Q[,Q*]<O&H=*V;>JV=YTLQV:KRQU8%CY21Z7PKZSGM)1E7[77 (\2=)(_,
MKQDMU+Z:-1I.MND.G:]G56-5NJ]&SN+\EL)9K0]1'P.F9=='XJK/').!9VI>
M-_5=98JV^8T?ENWJOB*U2R^(!9>H+<BD_!.$/,4FO6".<0Y=)V^*4)'7"Z5X
M@'5/PB-3U5DO* @B?NYMUR_Z_N854R8J2.CQJ)>FIHNG(MT5L>,S)/)&8R(%
MUT[O#!*K]GG-XJ+)(O>1ZM9@D[5X8MD4?2]1N>E>[Z/P^L]0CBL:VI;2T#LI
M>J-;!#?V52:L9>$UYIV'JU9O!!.UU.RK&20O"B6:<U;.T8XQCC&0'VL_5=[)
M?S![A_L\L7,NA_AU+^-UOYY,A^H?V@WG\C[/^A3Y#WAI_P 'OTJ_HQ:7_J&$
MYD;K]M]E_';'\ZV1G0O[B^E?Y U7]#BR..^G[\7AG?T[!G]WG?G+VJ_O&Z_D
MI_Z74S"ZO_;/H3_2Y/\ @FZS?B]4P+L.I&Z78F_7!3\5$0@U[*+G)<:1(9DI
M2Y!-CRP>:UEUAO#T,H,GP)37IL2HC[+BVU144K0R+*GW2'D>;#XB/:K*P]OD
M58$'S!S;KM.&_5FIV!S#.H20=L;\@,&X*31RQ..5'*21NC#E64@D9&4GK=JS
MU6D$A14VIO\ 7:'+$ZFF5B=D>_6P!.G9H)>O9;>:EPYXDK5\1X,E$V(]+C2H
M(XN,ECS ^)/9OB[8YM=S"07"&L!QR'=9?&5O+@JRR<D<$ @LK J2,CFZ?UG&
MG$,3U6T*M%JWK/X;5X)*GJ,M?@AD>*6MVHP=2RLD<L;I-&D@UJUUX:6@M8;O
MK^[*Y/N[TZM$)%G&UTP=R1@_#EZNN4YFSR">66BKS,*J//#(U?R_@1F2Y[Q?
M;?<2EKF;-N[<]5ZKB("0!&=4[3X7?XIC"\]HYD 8OQW<#@'-=U_H[T>MW,&X
MKR7"]>1K$<$LWB)ZZ8#4%EI>T2LJ52T2P$^%W'Q""1QFWFPM-T+:1FB&KL&C
MFW]='6[+6H\R&,DL13<<@'*P2*'ID"20@2H)$"-?;D!9PI^5&3,#DW9X$J5%
MS8Z&S+ LJ1,5$R]CD%@2O#*5X!"D$,?)@P!X9>&56&UW]32V4U*:Y$LQU\XL
MUU9(V59EDAE20%XVD1DD@C8-"\3,O?%(7@EEB?HI77S7DB^[#V.ADQ$L6TP(
M #=/92>?=Y+X+5NW4\"69B2&)&8)4?6KN>$XS$=:'2VW(DF<.E3X,:4W6+DW
M@PP?!*5W=XN5^$OB/'(Z\@CE2\2-YCN'F P#$&PVAH->O[ "9+&RA@AN=LGV
MN3U:M:J02A65NR6.M<GB^"1&P*,\;.BL(:J_07KW3K]I?9P*!;(UTT#KG6.I
MM:%U69YQ8J@:FK.P:?6:[.:]EPV7BRZ]M"WP;"N?AYXRY*&D'W$DP069!R7V
MUR2&U S1F*Y//8G7L^ZFL/#([CS^"0\$93C[G@@?!=PT16Z&T-2]J-E!':6Y
MHM?K=7KI?66)BHZNO?JUJ[CMXE5H-E;2<R=S3%XW8^)!"Z;J<C,W#'&,<8QQ
MC'&,TK.=!]!6"J5BAS&KJQ1J60V_+JE4'VR1"' 8&]J[L"I[-KX^8S%P<;#G
M*_M&\C8>5EEEJ_',1TUXJ,]PUSW1)IMK:2/*/",L@K!Y#&"S&H\,D#$$]G<C
MP1,?@]KE3WJ>]^[3YNA]'/6K4G%P4J<FU>K62TR1P)NZ]ZKLH(V"^-X4U?97
M8DYE,L"S#U>6(P5_"E74/6/3FC+3=[EK2J0ZX>V&+J8:UR!\<>/:*CZ0_9':
MQF?&$P1S)8L-:M1(?FS'$E+3-$LB11 W*@!AK$;'L7K-J.*.>0NL+2-'R6)4
MRA._@L6[5)C#=B]J!BS!06/,GJ>F]1I;-RWKJJUY[\=:*TR+&@E2FU@UO$6)
M(Q++&+,D?K,WBV7B6**29DAC"S_S$R=QQC'&,<8QQC(M:T[24[;<W=)B2B&P
M454G2!96<^VX@#4S<FI$#($4VU'9=R.GEJ2$,MQR;Y% <J[8)=>P(5;;2DQ?
M]9E]7]5!"PF1964#[N1!($=N2?A*LKKRH7N7L#]WAQ]L:-33&U.Y96>_ZK)3
MCE=@1#5F:K)+!& H/AO+3AF"R-((I3.\'A&U9\6*&^G.F&*"C646-9(M,C;3
MKVWQ8IHZK*A%JJV[BG8D*S!FO179K@:-M@R1L"H!%^>X[$?2!<E*!1XPYG(]
MTK/C&<E#*8'KLW9]U')56F_(! [C74)RH'!^&!WDL8H=(Z@41K56RM-=G!M8
MXQ.>8K-;<R[^%4<J7,*;2:2?LD+DJ1 6,"K&.?ISJ3I_1&R=H[6UY$L ^W;F
M)'#&QG)AQV8-L14Y?K=LA9%X9EAN,Q,&V2^6[ J1'PT[&$&5!G52!X\0R/\
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M^[J__P 7'N=I/WQI]%7_ .K/??-U[_FSF_._I_\ KQ\;_P 33^1^/??NZO\
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M?-U[_FSF_._I_P#KQ\;_ ,33^1^/??NZO_\ %Q[G:3]\:?15_P#JQ[YNO?\
M-G-^=_3_ /7CXW_B:?R/Q[[]W5__ (N/<[2?OC3Z*O\ ]6/?-U[_ )LYOSOZ
M?_KQ\;_Q-/Y'X]]^[J__ ,7'N=I/WQI]%7_ZL>^;KW_-G-^=_3_]>/C?^)I_
M(_'OOW=7_P#BX]SM)^^-/HJ__5CWS=>_YLYOSOZ?_KQ\;_Q-/Y'X]]^[J_\
M\7'N=I/WQI]%7_ZL>^;KW_-G-^=_3_\ 7F#6'0?=SQ!2U= ]T*=0^JW48%8
M]HM/66B[$9VYM'>Q.ND(Y4-6ML;,!01=-$ZT9)Q81.:"J;<@B6>C.1)CB'D!
MSPBXEO6:A7?6RRW]@R,D=Z6$UX*JN.UG@@8F5IN"P#R<!>00..Y&Q9]/U5UG
M)!#U16I]/=-PS1V+&AIW1LMAMY('$D4&QOQ)'6CH!U5WAK!GE(*N01%+'<<P
MPS&99C1F6H\>.TVPPPPVAIEAEI&&VF66F\)0VTVA*4-MH2E"$)PE.,8QC'-<
M)Y\SYD^9)^/.F@!0%4     #@ #R  'D !Y #V9#W8+1%![+Z?NNE-EQ9SU4
MNH]F.[-$3,C;!7C V;&,5NV5@HE#BA5GJE@@#;  (8:>1&*#HRWX\F-ZZ,[D
MT[<U&S%:@(\2(D\,.Y'5@5>.1?+NCD0LCKR.5)X(/!R,W.HI[W66M5?5C7M(
M%+1MV30RHZRP6().#X=BO,D<T+\'MD1201R#I%7[EXG>@(#% M&A->=Y@X9M
M,&M[OHFYJOH781X1%QAF$_M36^R!CE91<'6DX45+4BX2 \US"9*!;,A^0EN3
M>/1VR9H[<VK9CR]66L]J%6/F? FA;O\ #'^*LD?</9SP!SJD-KKW3(M.QIZ7
M5L<0"0;:IM*^GNS1*.%.QHWHS7]:(_ODE2T8G^Z$:L2!W_QI/$ _DM[)]\3K
M=_C^4>HZG\>)]'7/ZLO>^#K+_-_/^<VC_MX^-)X@'\EO9/OB=;O\?QZCJ?QX
MGT=<_JQ[X.LO\W\_YS:/^WCXTGB ?R6]D^^)UN_Q_'J.I_'B?1US^K'O@ZR_
MS?S_ )S:/^WCXTGB ?R6]D^^)UN_Q_'J.I_'B?1US^K'O@ZR_P W\_YS:/\
MMX^-)X@'\EO9/OB=;O\ '\>HZG\>)]'7/ZL>^#K+_-_/^<VC_MX^-)X@'\EO
M9/OB=;O\?QZCJ?QXGT=<_JQ[X.LO\W\_YS:/^WCXTGB ?R6]D^^)UN_Q_'J.
MI_'B?1US^K'O@ZR_S?S_ )S:/^WCXTGB ?R6]D^^)UN_Q_'J.I_'B?1US^K'
MO@ZR_P W\_YS:/\ MX^-)X@'\EO9/OB=;O\ '\>HZG\>)]'7/ZL>^#K+_-_/
M^<VC_MX^-)X@'\EO9/OB=;O\?QZCJ?QXGT=<_JQ[X.LO\W\_YS:/^WCXTGB
M?R6]D^^)UN_Q_'J.I_'B?1US^K'O@ZR_S?S_ )S:/^WCXTGB ?R6]D^^)UN_
MQ_'J.I_'B?1US^K'O@ZR_P W\_YS:/\ MX^-)X@'\EO9/OB=;O\ '\>HZG\>
M)]'7/ZL>^#K+_-_/^<VC_MX^-)X@'\EO9/OB=;O\?QZCJ?QXGT=<_JQ[X.LO
M\W\_YS:/^WCXTGB ?R6]D^^)UN_Q_'J.I_'B?1US^K'O@ZR_S?S_ )S:/^WC
MXTGB ?R6]D^^)UN_Q_'J.I_'B?1US^K'O@ZR_P W\_YS:/\ MX^-)X@'\EO9
M/OB=;O\ '\>HZG\>)]'7/ZL>^#K+_-_/^<VC_MX^-)X@'\EO9/OB=;O\?QZC
MJ?QXGT=<_JQ[X.LO\W\_YS:/^WCXTGB ?R6]D^^)UN_Q_'J.I_'B?1US^K'O
M@ZR_S?S_ )S:/^WCXTGB ?R6]D^^)UN_Q_'J.I_'B?1US^K'O@ZR_P W\_YS
M:/\ MX^-)X@'\EO9/OB=;O\ '\>HZG\>)]'7/ZL>^#K+_-_/^<VC_MX^-)X@
M'\EO9/OB=;O\?QZCJ?QXGT=<_JQ[X.LO\W\_YS:/^WCXTGB ?R6]D^^)UN_Q
M_'J.I_'B?1US^K'O@ZR_S?S_ )S:/^WCXTGB ?R6]D^^)UN_Q_'J.I_'B?1U
MS^K'O@ZR_P W\_YS:/\ MYTIW8?B?[N@O4:E];=:]+F2[:H9G>.T=UU/>]CJ
MPV3C+$N=KS5>LAF0QNW16G,R SUUN RNM2VTJ(P)C2<,NUI#HZQ$LMV;9%?-
M:L%:2HCD>P2V)F[EC/\ C"*,OQ[&&6I;O7VU0U*NBH]+"4=LNVV&UK;>>O&W
MDSTM?0C\*6RH/,1M6HX0PY=' X.Y76_K[1NL&H*QIZ@++3A@+)$D9LUDFY*6
MZ]7&Q$)!NX7RY&%I2X6M-M/S9Q<M,4E#2')"(4%F*.B0XC$;=N2WK,EF7M5G
MX"QH.V.*- %CBC7_ !4C0!5'M\N2222=HT>FJ:#6P:RGXCQP^))+/._B6;=F
M=VELV[,I\Y+%F9WED;@ %NU J*JB=.8N2V.,8XQCC&.,8XQCC&.,8XQCC&.,
M8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQC
MC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,
M8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQC
MC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,
M8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQC
MC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,
M8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQC
MC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,9JYVT[6U/IUJP_N?
M8=!V=;->5(.X9MAK74"ED<UUE=FJ%3&1)T2UWFFR)1 X4N,98J,(02QF$'/2
MI[D#$2(F=GZ_7R;*PE6&:".:1NV-9C*.\]DDC$&.*4 *L9[BW;YL@'/)XUKJ
MGJ>KTEK)]Q?H[&U0J0F:U-02I)X ]8JU8T=+-VHS2326U,2Q"0=D4[.4[%#]
MR [2Z=FPH[EVM0#31J9%'E(-0VW>=95VU3@!<&W8A-DB#Q=Z/QG@A$;B>J/*
MQ.]:A\(=CRH\=T3+2W0]"R"?"C>RH)4R5XIWC#J_8R$M$A#*W'(XXX9""0PR
M]!U+J713<M0:B9T25*FTNZZO:>"6 6(K"QQW9U,,D7>58/R##.K*IB<#)B/8
MOKX'&0S1;>VFQ8<@X>9@%B.SZ3"&3GJJ\F-:&H<^2<:BR7*W(6B.>0RZM0=Y
M:6B&([BL)S0M.XS%5JV68=A*K!*6'B#F/D!>1WCS3G[H?<\YD2=0:&&-)I=W
MJ(HG,ZI+)LJ:1NU4]MD([3!6-=B%G ),)/$G:<C3L;W0T3UGU1L?;5KLC-SA
M:L$!C]KI6M#5,L6Q60QPK4A<0E&K)*U@$JB(Q>:L3>>E3X:/=!@?-CJD8GP&
MY5^GK+=VQ#6C0Q-.S(DDZR)#W*LC$%Q&_G]JD7@*3W*P\NT\1W4'5^DZ=U>Q
MVEJPMM-7#%/:IZZ:I8OK#-)5C61:TEF#X(]=K2$LZ#PI8W7N[XPT@W/LGH+7
MH:^'+CN'7(.-K&MS[9?X<FX@%FJH#&KBL2I1@%'(.EXJ_;IP\5'C+A^T3#!(
M:)B-/D"$.,]9BI6YGB2*O,YG<1Q$1OVR.W/ 5^.T^0+$\\!59CP 2,^YU%HJ
M$-V>WMM?"NMKO:O(UN S588RJLTL"R&53WO'$JE.YY9(XE!DD13AM([?:4O!
MS:0YBQ1*Z U4WJIPEL*UGZ4(H-BQN"J)MM7;K)I-KE25OQXJL"R<>P#J^_[Y
M\XHELLPE4I-R776HD@8H7>QZQVPQI*TJ>KR>')WKX8'!/PE*,X[/-BI\LQ*7
M5>GNS;.-;"00:P:PR7[,].*C8]U:WK585YO668LJ_:Y%GC@/B_!B$J_"R37M
MYZ2CV 54Y&XM6,6HZ]7XX2M/;!J35@,R+9$R0JS H,LNDB1>LL#&9M?:B1GE
MF8F,R1R9+./3Y8%6R4:05IS&G>6<0R=BB,\2%F[>T=A\GY([3Y-QDB=UIUGB
MJMMM8+4Q@6&L;]43RM97OK+%"9?$D-A/AP!%)E7X4?<//)3Y8R3QQC'&,<8Q
MQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,Q^T3;$."2I54 P;
M*?2\/9@!R9Q5;'/^UD8D25)GFT"3KT&&,A/R2DE48,3F/,PUQH<*1*>9;57&
M$9@)'*)PQ+*O>1PI( 7N0$L0%'+*.3R2!EBR\\<+-5@2Q/R@2*2;U>,]TBJS
M/,(IRB1HS2,5AD<A"J(S$#*WM%>)Q1=CT>W;8VY6JWU_U/4]Y7_KB_<[%L:9
M9%2]LTPI6X0L3@=%U\%8BB+E%+EY88O(*X7&?KRQY >RZ3A.<FK6CEAECKUW
M>W8DJPW1$D(3BO*KLS=QF;EHRJAE"^8?D$]ISGNE](]+84[>TVM>OHM74W5_
MIYKEC8-8[MI3EK)%%X:T(0L5Q99FAE:3E37['0-*A$\#?$(Z7F AJR#.PU#G
M :]39VP2Q:.X67"8IHDN&KYT\R][K]&?$K1RPAA%K0/]JDU0A/9B6)@8]AQ"
M,1M/LU=8VIRAWE6%5/;SXK*SHA^%Y&1$9H^>!(!RA;)R/KSI"6&:Q%OJ+P05
M)+\LJF4HM2&6&"><-X?#K6FGABM"/N:K(X6PL9Y R$)W<ZIV7,)NO;JJIR40
MLUSJ$0<*:,SR[A[78,+9KQ'4'C"W"K,.K5RR5XZ8,/PVPT00<$$5D/9",1UV
MAM7?3GOJR*%CCE);M"A)G>.(]Q;MYD>-T5>>XNC+V\@C+\/6/3%CL%?<59FD
ML7*BQQ"9YC/0AALW5,*Q&4+6KV()Y9601+#/%)W]DB$PKJ'Q*^O]WKUF*;./
M -)&*YM_:.JO<)^QN'<R8NL]IUW3CM\F$80(>U7:D>OMOJU>@E+%'&C63)\6
M)<).S9&&\95G27(G18$>TKUX)^]$[>#/ ]GP@"Q[Y$AC=RJ$L51F"\#(?4^D
M317:]F793P::6OMMEK/ GL&?N77;.OJ#=:1(8Q!5GO6ZM=)9UCC6:Q%$9"[
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MH;"* D$*N*=&F'Y<\+KY!+!)VL2I8LJ]X^Y(Y]G(XSY/1=K9I29MG>EK-O\
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MJ\L8<;:<^;S_ /XC3:__ "FT*\TXZW!)XT,,O''BQ1R<#N\N] W'PTC?X_\
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MDU^22?,D^W*8_1QTM$B111;>..-%CCCCZDZB1(T0!41$7:!515 554 *
M,Y?R4'3W^*]A/O@]KOSCYY[O;'Y:GT?0^KY7]CSIK[W=?G-U'^M,?)0=/?XK
MV$^^#VN_./CW>V/RU/H^A]7Q]CSIK[W=?G-U'^M,?)0=/?XKV$^^#VN_./CW
M>V/RU/H^A]7Q]CSIK[W=?G-U'^M,?)0=/?XKV$^^#VN_./CW>V/RU/H^A]7Q
M]CSIK[W=?G-U'^M,?)0=/?XKV$^^#VN_./CW>V/RU/H^A]7Q]CSIK[W=?G-U
M'^M,?)0=/?XKV$^^#VN_./CW>V/RU/H^A]7Q]CSIK[W=?G-U'^M,?)0=/?XK
MV$^^#VN_./CW>V/RU/H^A]7Q]CSIK[W=?G-U'^M,?)0=/?XKV$^^#VN_./CW
M>V/RU/H^A]7Q]CSIK[W=?G-U'^M,?)0=/?XKV$^^#VN_./CW>V/RU/H^A]7Q
M]CSIK[W=?G-U'^M,?)0=/?XKV$^^#VN_./CW>V/RU/H^A]7Q]CSIK[W=?G-U
M'^M,?)0=/?XKV$^^#VN_./CW>V/RU/H^A]7Q]CSIK[W=?G-U'^M,Z\GX7&I@
M,-XGH/=7:WKYLF(A3]?OM<[)[BV#$C$&<>LA-6>@[:N5VI5TK6926E%JV5%,
MME(F'8R)\%U;<MFI=Y88]MNM0N0GR>*2G7B)'Q]DM>.*6-^/N75CVG@\$<@V
MY.@-=$IDT^UZBTMY1S#<@WNTNJKCS46*>RM6ZEJ#NX,D$D8$BC@.AX83%TCW
MWL'<5(V%2MWP HWL+UQVB<T?N?X-M.1:S9S84:'L%8V758,C/M4"M;+I-AK]
MJ@P9"6UCYTLH,0TAF"WCF-LZD5>6&2L6:I<@6U6[_-T5BR/"Y'D7AD1XR1]T
M K?'DGTKN+NSJ7:NU2*/=:/82ZG:> "M>>:*.*:"]75OA)!>J3PV$1N#&[21
M\<(,W2Y&YM..,8XQFMO8P')6,K-R&U0;<C%-/C"HH.2=*,(5/CD(SL5^.^(;
M2\T]'Q[1(]80D*&>3.([L*2Y)3A/$?31J9Y*>AZDI=.TNI]ETWMZ-_7:R]/>
MK1F]7N035YXYM?$'CDKQBU,'NV/4.8U@>K/)94"S8',88(KM&ZNH(/)\^" 0
M>?:5/':P/')X Y&FO<W>LB[%A>J=(7;W';0]9@6X]LX=L3?H*DAQ=N*S@T<
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MYWO*,O8XQE;77O\ A,?$@S_GQJ7H/C'_ %8R![%YSC_V^7)BW^TVG_C&U_\
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M*RY;3YY5#Q::VOT?-:)#JTI8<Q;70B>&32O/XH!(2RB]CGY/$B *?P^&_P#
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MO$AS&,QY"Y$:4U%Z&A8EDFADF$M::LIA=8YH3. ADB9DD7O[.^,<KY"0D>8
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M$&$:.E"L2'/,R,RS$Z)'G2GV8\PK*SF22DLH0].D9R]*6ZY^ESP*J^:JJ\\
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M5LPD@/W@<&5%_P :*3[H%>0I)1O,>?4O25Z/=ET/NK*^KS2:"U8DDU&Q5&>
MPR,72E/*!VQW*RGPG1^TS*GCQ QMPM=HO85^!P!HH+>+>'%ARWOX0-%V4T/@
M"COFC/OH;#B368\$MYM-Y]XQFVIGFVC]N_03Y3+0PN69HHV9E[&9D4EE^]8D
M$E?R'R_)F@Q;"_ D<4%ZY#%#+X\4<5F:-(I_+[=&B.%27R'VQ0'\AY^6=HO;
MFUW(K\%S9VPUPI+)R/)AKNED5%D1[/(Q*LC#\=1++3K-AE8Q).-.(4@M(QAZ
M>F0YCTN4^K5^0? AY'80?"3D&,<(0>W_ !!Y)]Z/9QEP[;:%2AV6P*,)E9#<
ML%66RW=84KXG!%AOA3 CB5O-^XYLUT1Z&[L[Z;E!ZWUD )QJC')P'-F[1?'O
MJJ6N*PIU*R! D14E$.2??A)?36JNW(P3/D,(0VA@<P2)P,';;:KJ:SS3NID*
MGP( 1XDTG'D%7VA >.]_N47Y6*J=CZ)Z(W/7&WAU^M@D6HLD9V6R9#ZKKZQ/
M,DDDAX1IV0-ZO6#>)/)P %C$DB6S^.)X3UHT!<X?9+KS22AKKK-I=+K=T&@8
MCQ*7J(U0JJ(I<4F;BQ&5/MTZS@P(LBY9U(5"@VIPU$,+%MD*\DCKW2W4"6XC
M2N2A;@DE>)G( L++(TI523_?(V=E[/:8^PKW$/QU+TT>BZSH[B=1:"G+-H'I
MTZ]R*!3(VJFHU8J:23*@[A4LPP1R&QP42SXRRF,20!_.X*MMK!#2P8'9["&$
M'TL).BA1HD.&FDQL/8C)+08DEF*23'Q(?PQB8T]AK#SV&_1PXOTMR:*-V5GC
M1F3GL9D5F7GV]I()7G@<\<>S.!16[4$<L,-FQ##/VB>**:2..;MY[?%1&"R=
MO<W;W@\<GCVG,O9W=NB/*?G,;=V@Q-E28\R5,9OUK;E29D0?@3%EOR$%DO/2
M8PO&!L=]Q:G61^,0VU)CX]7RWZK6(X-: @ @#P8^ ">XCCMXX+?"(^7S]N98
MW6X5VD7;;-79E=G%^T'9TC\)'9A+R66+[6K$\K'\ $+Y9V>K-3[K[2;6&T'6
M58MVVMJWDFIS$:)[69+39$E]'MQZPF)KBVX R*I[VHW93TZ,-'1_632<]AA*
MW<4V+%6A7:6>2.O!$OM/"J !Y(BC[ICQPB("S'R4$^67-9J]SU-M(Z6NK6]K
MM+LG/:O?-*[,1WSV)G)"1KSW36)W6.->6D=1R<]'W?\ \""\:NZ6=>+=H<0[
MLW<^BZ27%=BPM4AR)QB_1[&?*7F79:4.;8;GG<:[.GC5=C#FH63INE*$SVX;
M<P'*B2]+U'5<4^SN1VV\"M;E5J3.0%B**(@DIY(0S(J.6Y[%E[ASPP(^A.N_
M0E<UO1V@M:.([';Z2G+'U!#61GFOK8FDNO8IQ@!Y_4)YIH$C">/-3,;A>^$H
MWF !V2V4DE+E5L_8JB75&EB)T@&4) 22HCRDHG"Y;T!^))S&=6RA,N$\KU3B
MFDX>:SE&,8WIDCE4!T21>0P#*KKR/8P!!'(^(_[,^;(;%NE([5Y[%27M:)VA
MED@D[2>'B<QLC=I(X9#Y$CS'EG?1=L[4@L1HT+9FP(<:$(S7X<>+<K''8B <
MO-R<A(S31)#; C,AEI_(UI*8>7FFW?4^FA*L4&O7)),$));O),2$E^..XGM\
MVX\N[V\?'E]=KM$54397T1(O 15N6%58.X/X*J) %B[@&\, )W 'CD<YUC+=
MZVC;XD1A%LV)?;61BCX,9I)>VVZR%I.41H4**TGW@8,$'\X;CQH[29$AW.$-
M-(5Y)3RK[57C)^UPPQJ6)^#'&BCS))\E51[23P![3EH"[L[:HHM;"]:D5$4>
M+:M6)6X5$4?;)I9&/"JH[F/D ,_T!O ]\/>U]&.MU@,[:@-BMY;\+!+5=Z^E
MQI]VE5FO0IT>BTD@^PMUAXX.2;L)H\J.[EB(0L*@B<O*#*FR^1=4[B/:W46N
M2U6HKQQ/[!*[D&650?,(W8BISYE4[O+NX'W9Z&.@K7173T\NU01;K>2PVKL
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M?4=_IM5NZ?=W"KMM?4V-</QQWK#;BFC5^/8ZJ&'Q$9 7Q#^EOU6-#_9E5/\
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M=Z[-T+.Q5B'97MF?/7+Q3"@JM:__ +FHJBO<30E#"$.)S0Q]9\#R\$S>#X?
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MR_<".."8U>]7\FP[Z[*L,_$=7ZW*?^=AO]@7/IY3_P#S>CY^7_7RQ,918E,
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M;;;3A#;;:,82A"$)QA*$(3C"4I3C&$XQC&,8QCGF9*J% 50%50%55  4 <
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M'MNQ )2K#84F2N5.3Z4UN$6QX&WA $6P4^.%]D.PC %J,^9(\1N)T+<%ED)
MX&:+T1/)KO=#HRZ[&WTU(!KWD/+7>G+3,^ILH3QW^K)W:ZP$Y6&2LBLW<XYM
M!Y!YOV.,8XQE?'B!=:=W]AP_7\OH<_JZ!<="[QA[D8KVX?A6S2;/(@T:YU*
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M2[];# JER;-3NJK&%,C*C&>#G@N54F1>2H/EFG_2SJSV%T+8S<S<>V]<6>G
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M@8D=P7@? &<%FU'I#U76>[ZCT73=2^+\URL9]AU,T<=ZB)8_4>[6M((JIII
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MA>L2VY]'66Q,W=-)4EM4/&?S)>5:$]9))"22SNI=B22Q)YS$/DB?#V^@:?\
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MK;L$B&$RE^U2S'OADC 51[3W.#YD#@'S]@.D>D;1[#J7HS=:/5I')>V,=2.
M32K#"#%?JV7:21N>U1'"X':K,6*CMX)(KYG=./$#)[PL=H@WN[@M:'[#MB!
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M.+=],6DHR[**33;UUUD^\KS2QIJ^R1NGK=2KLFB5]FDO8GKD4L7B1QO*O*A
MP8+"TOQ:;C6V.Z='LPUQ5ZJEY[T!^IUV'U<,JEO,]4NO%=WN/JVS("K&D\^8
ME"RLF2^4C X(LK":]UMSAI;.'6\H=/Q.=9*A^U/%JFV$1D82\W[CU#) W9V!
M0R@!2Q93\+AER(?TI6ZZ]84[,9-VK>ZT@Z7N1UH338=,:"ONXZVQC]8$[2M%
M*SM*L*12H/"#QR_"&\74?OT.WT6IFG;/2+6%W>WI'K]MBY2)$:M#*E8*WN34
MJKP[LVBLLV@B5F:_'VN.UK\GEZ(V4!W2R5T#)A.LOODF8K8ZDU%ELI+&U7UJ
MY7B +M(CUK'A>!+]K"B8QGQE\^UXD=P1P =SZ6ZYCW<M34V:=J'<C3:':6V9
M:\=6>OM]4;IV5("S)*]".THH2$J)8;EBO R$,9!"G='Q";AU>[=@:"7=C@=!
MT;K"YV+V-)&TL==;QL$B4WE4M)UO7M=3/N]3CUW!<U:!XJ ;SZQ0^P%X94TR
M_4QY1;.3K-/'?U[RJ"]N6\*4 :0Q10@59;3S/VQ2%^U8RQ7XT4JOPR.8?J_K
MRWTWU7!0E*P:.GTV=_L&CIQW+E^27=T]-7H5^^[56OXLUI(HYO/PYYDEF4U8
MY2N(WSQ;*Y6M_CXC;1$5IC6%6[N".R=7(5N"1OH?:G4=RH^F*I)6$:2*)0[&
MS;(,D-(=EXA%X94%F>NL36S4:-=BZ>=ZC'E6LSR:MJ4@<B)J^Q\7X4JE>Y2G
MAGN''*E6X[QVDXE[TIUZV]C0!X]1K:O6474-9ZZ27H=GTJ:G,5.5)_"D2P+2
M-"2W;*DL/?ZLXF58SH'BF;>/[F6!LHM=>I,_MD/UU7ZPNAU<U<5Z[,=79V[8
MU2LA^!M$6$#V'!:1%Q%M8B-9FD1AS4$B.])Z4])O2Z&NE;N1@\JZ\SO()I%B
M\9;XJF1$-=F9.P'F-O#/+$AO9Q'T?25M9]N8+,7J]-^J4UT%8TJTULT)>F7W
M2U;$\>RBAAG\5E[;42V0%18Y(^2S-L50/&4T'L()',0M5;N >]T]=7JXU98.
MNXL(@/[+W0Y0*4>-'16PC .EUP)8Z_.;MQ:USQ>!T1V"N!'*3IT8>YAS=-VX
M6*FQ5?M]=[^PS$J:,:2RJJ-"K2NR.IC6,-W'GDJ 6R>H^ES1WX4E36;F#QAH
M&KBPE!4>/J.Y/0ISS3Q7Y8:=>&Q7<6Y;3Q^&IC,:RNZIDI;%\0$>[T C=O-6
M50J%NFUJH88ZZ:NV@(=59[OLJ0Q9E4ZLYKM-(F'C+YN)6"=I@Q Q?U!"LQ%$
M5EQP]3Q&-8AT[#;G73R*T5>1/79X&^UQ0<Q^(_?*JA>PR*A++\%SQVL1VF3V
M'72'H9>JM95EAN;2M,O3^LV41-F[L&6QZI6]7J22F4S+7DLHL,O:]93(98X^
M9%[7JEW/=VQT\MO9@Y .;)'TX-?;S$7K>NP)]@N%1AQ2M[I](%@AY-I@ONH!
MK^56*ALP6/BA*RSN!NP@*^^N! =?CT[#6>K[*.BI6 RM#$1-(0D<A*PR2LY7
MX-9YA))"Q+/ZOV._F1S=Z8ZO.TZ3M=1S)/L8ZD-ZZIUU='GMU$66[4I10)*%
MEW$%!JU78QQK#6&V$\$#%(R5P6H^+AUNOABB!J8!V-=7KA2!.RB4BAAQ5U:I
ME!,[/&:B9LUCA5\Q+.L-"K7,*S;<(P'38J35:I935L#B)48<))W9.GKL2RM(
MT,7A2M"HE9HO$E6!K!1"ZA/A1A1&W=V2R2(L;,"67"J^E/IZ[+2BIP["Z;=.
M+8R-1ACN"I1FV4>J%FPD$K3J(K32O:B\$3TZM6S-:BB98XI.$GQ8]=D*5K2_
M5GKEV8M5;W?>:=0=(3AM:H0V)M0S?AFTB-::K96S[# @DRD9U*:CV85,+,%*
MDNPTOWW%CK.2&AOOO?F$L\+W:,;U8I);09YF-=8F@5^]4A=N/[H4HP4B3LE[
M">T%J/LH:^2GKK];I_J*U7W-VI1TSQUJ,2;.:]%LY:PKRV;\$'=_[*F6Q$\J
MRU3/4\9%,S"/#KIXOU%1J:V[$UEI';AY8NT :37REI#"Q%$GV(GNZ)H4S$(V
MD6=)CHA:M6V4T435')L8S9:U*'&!;L<<LU.K]V+IR4V(X9[5=.Y'D=8V9I0B
MU3;4K&RJ2LD0X\0 K&X*MRW8'Q+?I6I>Y5K8:[3;6?P[,%.O+9ACBI26)=TN
MCF22S'-)&LM>TPE]6+K+8K-'+&RH9G@XH3Q7*C2#O8.N[5$W.U66@;Y[;U^N
MU2HTBKU^?7-4=1],4G;FR9! I,VB9$VV4,&GEQ*^9Q)K1*Y'C$$;BI5\8.(&
M8OK=/R2I3>!HHXYJFN=Y))7</8V-F6O  H@5HPQ0%UX=8D4MXCL0IHA])]6E
M/OJ^SBN6K%'>=4P5ZM2E6@DKZOI;3T]KL6DD;9S16FBCG[8)@U>2W/,D?JD$
M4<DRRGK_ ,5[0VR]W5#3-7HVUY#-YOE5U]7=E/#Z:S1YI:^:13OZDR_9LW3-
MV:''J(M/F\_46G!A9281!IE'I2$X\W3]N"K):DEKCPHI)G@[I3*%BM>J2#GP
MO")67XA)YKYCY,DJ'I0T>QW-345J6T87;U:A7V)CJ"D\M[3#>TG[?6_7!'/2
M(\VJ@QRD)( /A9:%R"SI6.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,96_XI
M/9O:74GK4*VWJ*6'CV9S<6KZ/*:/ 4V(?( W4VL06] >EV/)R2CLY3(&.QY&
M,)DHPAZ-+;7EGDUH:,&PO-7L!C'ZM/*.QRC!XD[E\_,<$^3 CV>P@^><^])7
M4>SZ6Z=BVNJ:%;)VVLI,)X/6(V@N3^#+Q&"K>(H/=&5;[H<,K@]N8E:O$FUG
MU_+6.M[A=V;85 @8#:=B,/Z^#U0IJ_4=TW=7.M53DW@,\3#2RIN;M*48L+T.
MOU]LB/UVC,V<-R8B#X%@N)I9[BH]80)WL\")XS2">Q%5>]((6[6 05PB<N_!
MF/"MVEBF+:](6NT4UBMMFV-@PPU]E8E-"*K)K-5=W%?IZHUV(R0O+,^R::<I
M! )(Z [WC\58TGT-NGC";.J?5W;[K Z.=[/5LUVA/U$B,JH9O7U<U7H#> ;5
MPXSL""4LHV41FV#)A@7B+4T/S7YS<XFJ,)BQXS,R6BZ=@DOUP24HNM!)%:1O
M&>Q<JM8*Q%48*$[2W,G XX7EB21I%STL;&KTUM66-9^I*\G4MBK)'5A%"OK-
M%NHM9'-?26S&TCS^*L?;5#.SB23MB555]EQ'BLQ*'9=J ]GU&];#F1.PY+35
M##:]IM%K"PSP#KU7]PS8I,O9MP>SV& 3;9L4V'8'(X"='=?9&R*^AM+'JL%M
M 98Z[P210@TQ8E>:25^[ON/6':J5^493V IRZG@L'^78XO2<E*SLX-C4NWW3
M?2:BE#0J4JQA,&@AV[K)+9VQ6PDBK8=)RM=U++$U<<+Q,5(\5W26Q+SI:BU3
M6VY)D_=J>O>0<B6&JD%0I'8V@7G9-:)2Q;EN67+5FF5S7=D8V1;*U",@*V>3
M!#1IQ9YV<X.QI=!:ABM2R35@*OKG> TA[O4I8H9%5O#"AY'F0PQN5=T[F(4=
MO=*T_2?IK]W3TJNOV[ON?<'P&:&JGA#J"A=V-:1XS;,LE>I7U]@;"U726"O/
MV0H\Q,ACC[N%XBQK2W;+4FAJ&4JOP:>D,PMIG9P><8;@;!9FTG8.-*SIWIPX
M(^[W[KLK8!/4P(3-6?L>V2FKAA%4"L2S")][6Z9;6OL6Y5D[P.8$5E4M#Q+#
MZR!P28H;GA+89AVI76<KS(%XP>K.OYM/U1JM'1DJ^KLP39SO$\HCO*]._P"X
M\C_ 2.[>T'K\FK@B<SV-I+K8Y.RLTOB;B[W[I:VZ[;#T/KG9 *UAIW8"3+&U
M:Q$$ 15+%6&(1K$#-..V\D;CUZ/=);%DD&18!@B\HX+J]B8!2BEA76@%DCJF
MLGNPVYH7C84P&D0=[2LA5SXB1JA<Q H%9^/@-(A8!/$>/;-WUAKM!?TFOV$-
MJ%]ZS1UK$@@BIQ3K)6C]4GMR3+ MQUL--% LC&:*K9$#26/5X+&M5=\7+1-Q
MKU*.U/6&^3:]M6097=(PVJ1"CL;;<)XV8YA=8.2#B +1$;%U69EF:O.(M6H<
MFQ4:*H,Z0LBH8[-?IVW&\B23U$%=&>RQE8^K]O@?WQ>SO[6-A KA2A[)3W<1
M\G7H/2GI;<%.:KK=W/[J6(J^F44T5=J91LF_N:=YA )(TU<SRUGD%E!8I+X1
MDL=B?$IXM>K0MDL==-:#[&5_X+W/3>LC)6R =>@H@C:&_ 5%L>M: ?%2]BYM
M8(\\)NKTBTIFUS$>K.5&U1)#LN;%'QB/J]/6&1'6W3;Q(K,ZK&\KEH*CRI-,
MC"'PW3NB'9P_+^)&0 "Q6B3TI:R&Q8KS:/?U_5KFHULTMF&A"L6RWD-&QKJ,
M\37_ %J"9HKA:SWU^VL:EI&+.L:R0CV"\6<\ IV^2% U;>]8)U%UST[NJ98=
MFT >4N8,QM3<\76N*Z5U 5V!0%R&A+<,O">D9N$=$Z3(:L(A^:!AC%VG)I]/
MHTE433Q3^L7+-4)#,5C=:]8S=ZV%AFX[N5;CPSP!V-PY;PXC>^E&:&IO'H:V
M]KO<G0:C</8V-".2W#+M-NNO\"74RWZ!81!)59O6U#LPGB9X4C]9G&^>+[UL
MH+U^S/K&T2@ZFS.R8D,4%":UEC8!WJ5\#U[L$U=F=:83\9P7'N#4JM3+&@+
MLS-?L*F9,/" 63V+%TY=F$7;) K2"BSJS/\ :4V/B"JTA$9![C'\-4[BG>G(
M/P^R8O>E?IVBU[OK;*2.HW444,D45?MO3=*^J'<15@]E&4QBT&KO8$,=@03\
M,OVGQMJ^J?;FE=M!FS9U3J-WI,W5-_9U_9 MZ:K*9[DV;3ZQ>!90>_4[):13
MXZ>"M8[.$J(HFQIC4N-(BH2VR\_@7]?+KV@$DD4HL0^,C1=_' DDB92)$1@P
M>-OBX(X(/R;1TSU33ZHCV3U:MRF^KO"A9ANBOWEWJ5KL<B-5L68FC>"U'_\
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M[>1<L#&_ENN;CDVG,VQ/XM1:_K<;R;.V/!0WY0A289"*D,)Q"N#;;%1PMEE
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M-QL54(+/"B,0@>%!_>UE\8)_>_9XOVSY2WF3EY^A>E9)7G?5!I9+CWW?US8
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M))''.1U_3ZG:^%[J:O7;+P%F2'U^E6N>"MA0EA8O6(I/#6=%5)@G E50KA@
M,CIW2O4,5/+(?U+UO&E([QQDXEVAZQASV9&T@<<!96BR5BFY#;VQ:W"B!#B)
MF,+MP.)'&S\$($=ME%_UK8,J\6+K*>TK]MG*_:&[T[?A<?:7/<O'][8]PX)Y
MS .GZ5B>7NU?3\<BM,)^:6N1U;9PK!8$O,08-L($6&8/YVX46-_$10!\4Z/Z
M=RX0U"-0=:90^W*#"Q"$T#5ST*SJI8TA7:\.&IP)4P:54Q$XJ"#0XN).00V8
M0&06XL61)86]:V(+?W1=#1][-]MG!C\5@[EOA<KXC!7<GCO8!CR0#E(TW2;)
M&!JNG6CM>#%$!1UI2R:D<D%>.,>%VS>JPO+#"B]W@QO)&@568')FZWUM;D0K
MZR T>B52XD2I#KHV*H29%3@ A)4= K,*QI8PX"B!@1XW!B!6)D5D<),E8K,9
MF&1EH>H+W?.(O:XE)D,1:7[8792SE.?AEG1"6()9E4DD@<9(K]/!DNB#3!J:
MK4CMB*CW54@BEC2LE@+S L,$\R+"KJ(XII5"A)'!C]>C.I%8G O@\ U7JE-7
M-U>_3 >N9-9U<'LBP7K54=_8(*IJ!P;E709B5"L%3B6:-.&#K) $%1>&Y3"?
M67O6]A(&[WL6.]9(@\PDG:/O_OHA>3N,3NH*2%"&*%E;RS ]Q>EJSP^KP:S6
M>K35KSPZ]JVMAL^#R:37X:O@I;KPRLD]5;"O''82*6/AE\_CM#8O5>?O7K]K
MO9=;HEVVG9G-KV+25F,T^L7-FEE=/!P5@V1)@6^8P0>UX<$#"8*2Z\TZ,DR\
MJ80A];D1S#""&^*ER:!Y8Z\?JZ6D65X_$6RSI"#&"/&5F5Q[& ^3@^?FRV'3
M+[O1:_8UZ5S9V3M+&FLS5*UP4Y=3%#/L&CMNLAH3Q1R0L2#$S>0#$H>WD3P'
M2=F15M<3*GUMD+W39'S=7IS51UV1B["L^OFR5@=LC0J*+DPBQ"GO-SY#=DEM
M*R&,RVH;!!@R5B1I8/LR))Q)='JJ!7E,DRF&.7M0)W%@5$GD.P'X2@GM*J2*
MG@Z.#5M>]7IYCN+#35J@JZ^1;]BB)+!L")8V25ZK!V%A@?"F8*)%FE16CC>*
M>@?7C31K>%]U#H!>N*L)$-.2JQJS6)^5)#56PM2AD*NC(@U#AJ/3SDE9N.+#
M^TN@I+4LI#B-2677,7JONO<LK5AL7/'=F\GGG0!G3@EV)^!XBCM+-P&' )XR
M/W1Z&T&HFW5[5Z,ZZK%$"];6ZZ=FAK3AHTKQI'S,M29O&6*'N,+!I$0,I.11
MN#J1X>=GWEJJ'=].!P-M(T-VY52?7*=%JVO:S7]8[%B;!;ER+,+$Q1NJ;*>O
M-_E$9)&L%:?8MD)P1%6,D<@C(<!&16V.XCJ6#%99XQ+X4@>3Q)G:>$PD!&8M
M.B10@ .LB0>3($+$Y%[;I7H.SN]8MW4106WHFW5DKU%K4*\&MOI?#M9CB6/5
MV)KMYI&DK2U+&P'B1V))TB1!M9MX-U:A5/8?8W8&L-4;$9UB"E7:XW-JA46]
M6R%"T]!(6'$ALG+AR",DQ0X:"9 - 1/]Z"WU/M!F43Y2&7X^NUXR0TX9[$)G
M<11Q>++%&38(3CM! "RGA6/':W^,>!R-GVL7325;_4%[7:O8+K8&N6[@I4KM
MI$U*26.X2,C2-+20220H'\2,DB$!V .IMHW)X;FJM$Z3[(6;0^N:AI+?5="Z
MYJMV1UXIF1H+7&RDR"PT/?XP<)*F4_6%C8(3"92*3B_!J,[-=8L,:$6),0I<
MA'5W4]NU2CM326JCM-)%ZY)W/-#PK-"6<"29. JE3WD %"5!(U>SM_1]K-)I
M^H+.DH5=-O*\-"M<&AI^'#K]CW21Q7UAA9ZFML+(TDJRKZNI<K85)9 C9UM'
ML_TYZYMP-/V+5+(VN;+*V6K"ZM2M6TPK2+U^Q[J:GW\E_P!Z@4O(@B)A:G)5
M9\0HG!0F8,@QJZ,9=F#6A;=J"CLKO-A+'<\"I(TDL\JRP^-8DA7X3CN5C85^
M[M/DQ+GR;NS-V74G273XCU5C6+'7V,MBM%6IZRI+3NFAJJE^0^% WA21)JY*
MQB,B#OCC6O$"T:QC8;4D?K!V"U]IG>VLZ1K6VT_,*3>=+VQW7(B"0JJ['+=D
MERE69, 8AJE&IQ1,G)WV-@42=)MR,S_3D)4K.'8-ZG-9J3RSQR<B*S'XS$2=
M@X59"KE95"\=O)9>TCCRR>U2]-[VAJ-WK:6NM5"C7=1:.OB22MZPQ:66L)8$
MFIS/(&\?L6*0R!N_EO/-DN86;#CC&.,8XQCC&:W6+N3U"J!>97[9VJZW5<\.
M=4P0"6+>6L0A>"^A64K9F#25HC3(SJ%8RE3;S*%I5C.,XQG&>9J:W82*'CH7
M9$/F&2K.RG^!E0@_ZCD'/U-TW6E:&SU#HZ\R$AXI]M0BE0@\$-')85E(((((
M!YSI/CW]'OKE=4_O#ZB_%_*O<K:?BV_\SL?H\M>^[I3]\_3WTUK?K./CW]'O
MKE=4_O#ZB_%_'N5M/Q;?^9V/T>/?=TI^^?I[Z:UOUG'Q[^CWURNJ?WA]1?B_
MCW*VGXMO_,['Z/'ONZ4_?/T]]-:WZSCX]_1[ZY75/[P^HOQ?Q[E;3\6W_F=C
M]'CWW=*?OGZ>^FM;]9Q\>_H]]<KJG]X?47XOX]RMI^+;_P SL?H\>^[I3]\_
M3WTUK?K./CW]'OKE=4_O#ZB_%_'N5M/Q;?\ F=C]'CWW=*?OGZ>^FM;]9Q\>
M_H]]<KJG]X?47XOX]RMI^+;_ ,SL?H\>^[I3]\_3WTUK?K./CW]'OKE=4_O#
MZB_%_'N5M/Q;?^9V/T>/?=TI^^?I[Z:UOUG'Q[^CWURNJ?WA]1?B_CW*VGXM
MO_,['Z/'ONZ4_?/T]]-:WZSCX]_1[ZY75/[P^HOQ?Q[E;3\6W_F=C]'CWW=*
M?OGZ>^FM;]9Q\>_H]]<KJG]X?47XOX]RMI^+;_S.Q^CQ[[NE/WS]/?36M^LY
MY$?&HZX=:MN]MM6;IZO=D^KY:-V8M8>C;C:$[SU;)#:\OZ<,L)VS:<CK0ZD+
M2SM:8=F6HRZRW&C6&NRY4N5(-7,?%?Z)TS>NU]?/5O4KRFC&TM;NJSAIHO,^
MKQ\Q_"D1R BCDE'' "QDCY3],/2VEVO56KW'3>[T$J]1VH:.V$6VU[14;WD!
MM+/AV#X52:LK/:E("K/79F9IK:*WIZZT;L\.+JOHG6>@=:]O^J<>IZUK40'&
MDN=@M/-33A-2G)M@M!7#5P]6HS:3THE8"RF_)KV\B^EA+<=+3:-%NUMS?MSV
MY]=?,D\A<CU2R0H]B(O,?W,:!47\BC/I'IS8=#],Z36Z+7]2]/+5UU9(%8[G
M6!YI/-Y[,O%GCQK,[23R\>7?(W: O $Z?'OZ/?7*ZI_>'U%^+^8ON5M/Q;?^
M9V/T>3?ONZ4_?/T]]-:WZSCX]_1[ZY75/[P^HOQ?Q[E;3\6W_F=C]'CWW=*?
MOGZ>^FM;]9Q\>_H]]<KJG]X?47XOX]RMI^+;_P SL?H\>^[I3]\_3WTUK?K.
M/CW]'OKE=4_O#ZB_%_'N5M/Q;?\ F=C]'CWW=*?OGZ>^FM;]9Q\>_H]]<KJG
M]X?47XOX]RMI^+;_ ,SL?H\>^[I3]\_3WTUK?K./CW]'OKE=4_O#ZB_%_'N5
MM/Q;?^9V/T>/?=TI^^?I[Z:UOUG'Q[^CWURNJ?WA]1?B_CW*VGXMO_,['Z/'
MONZ4_?/T]]-:WZSCX]_1[ZY75/[P^HOQ?Q[E;3\6W_F=C]'CWW=*?OGZ>^FM
M;]9Q\>_H]]<KJG]X?47XOX]RMI^+;_S.Q^CQ[[NE/WS]/?36M^LX^/?T>^N5
MU3^\/J+\7\>Y6T_%M_YG8_1X]]W2G[Y^GOIK6_6<?'OZ/?7*ZI_>'U%^+^/<
MK:?BV_\ ,['Z/'ONZ4_?/T]]-:WZSD^TC85!V8#;LVM[Q4-@5MYQ3+-@I%E"
MVL&Z\A*5+:;+ 9L^ MQ"5H4I"9&5)2M.<XQA6//$EAE@;LFBDA<>?9*C1M_U
M7 /_ &9,5+M._$)Z-NM<@)X$U2>*Q$2/B$D+NA/\!S+^6\R<<8R+-A[STEJ%
M<1K;&XM6:P<((R[ ;V'L&I4I<UO"E(RY$192XQ4E&%I4G*V<+3Z25)\_/&<<
MOPU;-CGU>M//Q[?!ADEX_A[%;C(^[MM5K2HV.SU] N.4%V[6JEASQRHGDC[A
MSY<CGSR,/CP]*_K?=7?M_P!3_BWE_P!S-E^+[WS2Q^CS ]]?2W[Y-!],:[ZS
MCX\/2OZWW5W[?]3_ (MX]S-E^+[WS2Q^CQ[Z^EOWR:#Z8UWUG'QX>E?UONKO
MV_ZG_%O'N9LOQ?>^:6/T>/?7TM^^30?3&N^LX^/#TK^M]U=^W_4_XMX]S-E^
M+[WS2Q^CQ[Z^EOWR:#Z8UWUG'QX>E?UONKOV_P"I_P 6\>YFR_%][YI8_1X]
M]?2W[Y-!],:[ZSCX\/2OZWW5W[?]3_BWCW,V7XOO?-+'Z/'OKZ6_?)H/IC7?
M6<?'AZ5_6^ZN_;_J?\6\>YFR_%][YI8_1X]]?2W[Y-!],:[ZSCX\/2OZWW5W
M[?\ 4_XMX]S-E^+[WS2Q^CQ[Z^EOWR:#Z8UWUG'QX>E?UONKOV_ZG_%O'N9L
MOQ?>^:6/T>/?7TM^^30?3&N^LX^/#TK^M]U=^W_4_P"+>/<S9?B^]\TL?H\>
M^OI;]\F@^F-=]9Q\>'I7];[J[]O^I_Q;Q[F;+\7WOFEC]'CWU]+?ODT'TQKO
MK.4W^-@&Z6]VNJ1 O1NT?5XEOS0Z2M\U<B%O?5#Q6T"\Q6E7C6T?#=J6](=M
M0J!&G@H;2%/2;> KL-#D>-.G*7LG3#[+5[!5EHWEJ6^V*QS5G[4;D^%.?M?E
MX;$AS\4;N?,@9R3TQT>E^LNEY):6^T$F\TGBWM;V;;7&6S'VCUS7+Q8)8VHD
M5X4'FUN"NH*J[\QWX$5;Z<=/NM;VT]G]F>LX/?\ V$;@'K&,-[PU;!/4+7D+
M+KE+HLR'-M#<T06E)??M=L@/-PYC1(D,!&(B9M4:4F]U7)L=C=%>"E=>G3Y5
M&6K.4EF/]]E!"<,HX$<9\QPK.IXDR/\ 0EK^F>D^G3L]EO-##O-^(YYXY=KK
MTGHZ].33I,K6 \4CAC:M(0C"22.&9>^J.+U/CP]*_K?=7?M_U/\ BWFJ^YFR
M_%][YI8_1YVOWU]+?ODT'TQKOK./CP]*_K?=7?M_U/\ BWCW,V7XOO?-+'Z/
M'OKZ6_?)H/IC7?6<?'AZ5_6^ZN_;_J?\6\>YFR_%][YI8_1X]]?2W[Y-!],:
M[ZSCX\/2OZWW5W[?]3_BWCW,V7XOO?-+'Z/'OKZ6_?)H/IC7?6<?'AZ5_6^Z
MN_;_ *G_ !;Q[F;+\7WOFEC]'CWU]+?ODT'TQKOK./CP]*_K?=7?M_U/^+>/
M<S9?B^]\TL?H\>^OI;]\F@^F-=]9Q\>'I7];[J[]O^I_Q;Q[F;+\7WOFEC]'
MCWU]+?ODT'TQKOK./CP]*_K?=7?M_P!3_BWCW,V7XOO?-+'Z/'OKZ6_?)H/I
MC7?6<?'AZ5_6^ZN_;_J?\6\>YFR_%][YI8_1X]]?2W[Y-!],:[ZSCX\/2OZW
MW5W[?]3_ (MX]S-E^+[WS2Q^CQ[Z^EOWR:#Z8UWUG'QX>E?UONKOV_ZG_%O'
MN9LOQ?>^:6/T>/?7TM^^30?3&N^LY(^O=_Z(VW+D#]4[KU)LZ?$:R_+A:]V1
M3KI+BLISC"GI$:MF23S+2<YQC+CB$HQG.///SXY9FJ6JX#6*UB 'R!FADB!/
MR NJ@YFTMQJ-DS)KMKK;[J.62E>K6F4?*RP2R$#\I'&2WS'R2QQC'&,<8QQC
M'&,I!V;X1)>_,=E8:MLUB<[NW=LO;-7M=FK5Z(V^I +/NC4^[+?JXTPULA%%
ML5609U.,"5R=\"XE@A#),#UA-$,$L.:VF#J)8?4B*[KZM5%>2.-XECD>.M8J
MQV$)A\9).VP7<>*49@?@\MW+QG9>BJ:\O42':UG]V=RVTK6K->[);JP6-QJ]
MQ;ULRC8"E8K"75QPUW]32=(V3F0)"8IOG0O".LU'MH*PJVIK.V!8L3< 6;0K
MSJVP6"D@HEZ[*Q.TE&M5&#"]@U90BYT>\#0P8@F9*E5^T!P(=^6.CXB8%J\E
MZACEC=/ GC8^K,)8K")*YBI&A+'*S0OW12Q%F' #QLS<,>>X*/HLLTK4,_NG
MK;4*+MXFHW=9/8IPI>ZB7J6E9IQ17ZIAN4KL<,,G<S06HH(6>->P19JM9?!X
M[&4PAJ_-?M>M]TNE-OZ*,7.2NCCJ=4]:U;4W6>ZZ!DS\5@[L7TSM=G^\Z?.1
M4Z<S#7#AAG(HT3'A"PHKD@G4=*43]Z3U0M:TD0\5I))Y+%Z*X!WI#\!QVRCQ
M)2>2_FW+,V:Q9]$W4%1];ZO:U^X:7;:26XQI1U*FOK:OINYH6?U::_S/ _B5
M7%6H$*)"5CB5(X8LG,EX*1].L;1K"M=DI @;=.LH/2%WD3ZN5/#+U;J;4=5U
MBBW^=6#-JG1*<2K;6OR8A1"DD1LHO0Y]2IY&(Z_3R5@N6*O4Z>.D[T@S1WGM
M1<.JM%%+)8>6$2+&#(KF8-Q*"%F$DB^4@2.;D]#U@:VUK:W4+11W.FX-+<+U
MI9HKMJG4UE:E?DK2V76I)7%"2(O3D1IJ,E6I(A:F]BWS#OA ;2,D+&:7O/6"
MR]@OO?G8#Z2.I29FNJG=X*!0*>\+=K):VS8S\#7\NC*((R1F%&[$R70Q)@P\
MC%^]/$ZC@143U6?M2'4PCML!7[=7--*&[UC4]TPFX/:%[.WR+=WP:I_11LYI
M+$QW6M,L][KF^WB:J2:N9.LJ-*H8S6EM.K1T7IE_MCRBPLH#(OAGQ.:&\'6]
M,RI;QSLF-=?-%N][YDX$H!V">AP^[E)I(.=+K\LAL I(C&J'8*N2)PW9TZ6@
MO',Y<D/,36Y"I=+]21$ +2/"+J0JM,I0G5RR. X$(!65) IX [2H\B/97#Z)
MKP=FL=11EII>MFEF@HS).B=94Z<$C5VDO2%)J,]:25"[N)1-RQ5PQ;&]B>"G
M9-@:]KM9QNF@UNQ/:COFJK].B:]O]AK1$E;X6FH"=KU@!:]O%GJ]?I,33 F#
M88@H@(K,T:18BCA@U\,_-L%<'4Z0RN_JTSH+$-B$&:%758S:;U=W2LO?$#:8
MH6#2 J2S$/VIC[#T/6+]"O6]V*->P=3>U=YUH7K%>22VFHC]U*T%K:RF"\RZ
MB))UCDBK/'(J1Q1F(O/MSW5\/:U=KCE=*C=G5VHH$=6]X]<YGM]6(D5RI>Z(
M57AKM\=J.:9Q'C5U58;?:!.R9#I'W@XSDO"S$2]*CM9MX]>KJT#R=U^K='$B
MJ *ID(C)*'DOXA!8 =O:#VGG@;5UAT':ZHG@E395ZOA],[KI]^^K))W/N%K*
M;:@3#M6N:P982S%^\CQ4[>YOIIWP^;#J;K3W1T!%OM5?5VK>OCH4H.K,X6'H
M&;]H^K:8F>O#-SW,F?=WP;^%&,1'Q'O-Z;D2ZJ#ZGWJZL[=+%W66_"D_]GB(
M,K.&:;P;4ED?"X^#W=_AGD-V@=WGSVCW4]"6-7T[UAHUO56]\[7C#)'7>*&A
MZ]I:VH?NA#GQO#]7]9^ 8O%+^$>SCQ#FNG>FUQJNG].]=MOGM8[5TIJ_3M;T
M\0K*JJ9@.6X<.UY<M?V<J5;G$B<96+=#L !SW2E2$5]NN/XBD9\HOB4.MVME
M%+9L7:Z3U[4]E[*OXBGPR98I8U7@*?M91_A?XY<<@!>&S-1TC;JZG4Z#;3ZW
M9Z?6:FOJ7K>JS(;<<="Y1L2RB221?[J2> ^$.! *Y[9':7NCUBA>$2D7)ZOU
MN3M>-L74W6O=&W;S$J>T0I*PF+;JO8U-K>O*QIPJ7R57&4/UY2J[&KT8K*@S
MH9X5&'C5U\1"8<:<SCU%W"\XKF&Q=K5HC)7<(L=B&5YI+*KV\\S2OWE0P*'N
M/>Q/EK:>BKPVZ:K-M%OZOIW;[6ZE;90R6)K6LV%."A6U,LOB=ICH4X%KK*R.
ML\2I&88D!!N3K59KE,KX:IU  %JM6KHV('K];K@N$$ @Q,!E,>",$"!K$: -
M'PV$(9BPX<=F.PTE+;3:4XQCFMR2/*[22.TDCL6=W8L[L?,LS,26)/M)/)SK
ME>M7IP0U:D$-:M7C6*"O7C2&"&) %2.**,*D<:* %1%"J!P!G=\HR]CC&.,8
MXQE0/:E5W[I=P('A_5V[6?7?7[6^JA&Z^X5AHQ60!N&PH]R,S VMNOPVQP\H
M(UL+9(HPC:+Q+@Y2\;K/_>=B;"=;<1+V&AX6MUYVSQ)-;FG:MKEE :.$QJ&F
MN%#Y.R$B.(-]RX[N#Y$<UZ@-OJCJ9.C8;5BEIJ.NBVO4L]20PVKJVI7BHZ:.
M=2)*\4ZQO8MNGPI8.(E9#SW;757PY.@M,!0*Z#Z9]9UCAK"([#I[3-"MIEY#
M:<(2X1L=K!FK$7E92G'K)A8I-ENY_2=?6KY^8#[G;2,7;97@6/)"69HU_P!2
M1NJ*/R*H&;%7Z(Z.JPI!%TOH>Q  #-JZ=F4\#CEY[$4L\K>7F\DCL?C)S(OB
M'='/J9=4?N[:A_!_*?=;:_C/8?/;/Z3+WO0Z3_>OT[]":WZMCXAW1SZF75'[
MNVH?P?Q[K;7\9[#Y[9_28]Z'2?[U^G?H36_5L?$.Z.?4RZH_=VU#^#^/=;:_
MC/8?/;/Z3'O0Z3_>OT[]":WZMCXAW1SZF75'[NVH?P?Q[K;7\9[#Y[9_28]Z
M'2?[U^G?H36_5L?$.Z.?4RZH_=VU#^#^/=;:_C/8?/;/Z3'O0Z3_ 'K]._0F
MM^K8^(=T<^IEU1^[MJ'\'\>ZVU_&>P^>V?TF/>ATG^]?IWZ$UOU;'Q#NCGU,
MNJ/W=M0_@_CW6VOXSV'SVS^DQ[T.D_WK]._0FM^K8^(=T<^IEU1^[MJ'\'\>
MZVU_&>P^>V?TF/>ATG^]?IWZ$UOU;'Q#NCGU,NJ/W=M0_@_CW6VOXSV'SVS^
MDQ[T.D_WK]._0FM^K8^(=T<^IEU1^[MJ'\'\>ZVU_&>P^>V?TF/>ATG^]?IW
MZ$UOU;'Q#NCGU,NJ/W=M0_@_CW6VOXSV'SVS^DQ[T.D_WK]._0FM^K8^(=T<
M^IEU1^[MJ'\'\>ZVU_&>P^>V?TF/>ATG^]?IWZ$UOU;'Q#NCGU,NJ/W=M0_@
M_CW6VOXSV'SVS^DQ[T.D_P!Z_3OT)K?JV/B'='/J9=4?N[:A_!_'NMM?QGL/
MGMG])CWH=)_O7Z=^A-;]6Q\0[HY]3+JC]W;4/X/X]UMK^,]A\]L_I,>]#I/]
MZ_3OT)K?JV/B'='/J9=4?N[:A_!_'NMM?QGL/GMG])CWH=)_O7Z=^A-;]6Q\
M0[HY]3+JC]W;4/X/X]UMK^,]A\]L_I,>]#I/]Z_3OT)K?JV/B'='/J9=4?N[
M:A_!_'NMM?QGL/GMG])CWH=)_O7Z=^A-;]6Q\0[HY]3+JC]W;4/X/X]UMK^,
M]A\]L_I,>]#I/]Z_3OT)K?JV/B'='/J9=4?N[:A_!_'NMM?QGL/GMG])CWH=
M)_O7Z=^A-;]6Q\0[HY]3+JC]W;4/X/X]UMK^,]A\]L_I,>]#I/\ >OT[]":W
MZMCXAW1SZF75'[NVH?P?Q[K;7\9[#Y[9_28]Z'2?[U^G?H36_5L?$.Z.?4RZ
MH_=VU#^#^/=;:_C/8?/;/Z3'O0Z3_>OT[]":WZMCXAW1SZF75'[NVH?P?Q[K
M;7\9[#YY9_28]Z'2?[U^G?H36_5LT![==**YU&K-J[S>'[6Q>A]OZ1"RK_L?
M4]$0NN:5[$ZEJ3;AJ]T"Z:X%^A68)9FLQS!2I6"N!X1:*982TVE9*0*+ Y77
M[-]@Z:O;.UJO:8106)?AV:=B3X,4L<S?;"I<HLBNY4K_ /=[U?3>I.E8>FX+
M'5O1L$>HV>JB:Y>UM,&#5[O75@9;=.U1C^T+*(!+)6F@B6191QYN8Y(K;-3[
M(K^X]6ZWVY4U/*J^T:'4=AUW,C"4R< [F 'V(6F2E&5)1)1"(L)D(2K.$/86
MCS^;FOSPO7GFKR?=P2R0OQ[.Z-RC<?DY!XSI&NO0[/7T=E7Y]7V%.M=@Y]OA
M6H4GC[N/\;L<<CXCSFM??#>5_P!+:<KXK3:1N-Z[\VM0NN>DYQN,F8#KU^V=
M+F-KNIN(I+B98V@U(1:;N[#<8D1IKU?8@S&'(DE]/,W558;-EFL]WJM6"6Y9
M"GAGB@ ^UJ>1PTLC1Q \@COY'F!D%U=MKFKUD,>L[/=?<;"II-4\J]T4-R^S
MCUJ53SW1TZT5BVRD,',(1E*L<Z'37AO=4]6C')UKUE6=_;:/>A/V+O??P 1M
M7:>P;&\VG!(R1/7**:6#ARG4^42M5OW8 &1&XT5B&M3*I#M=C<WYVXCGDJ5U
M\H:M1VKP1)_BJ$B*!R![7?N<DDD^?&6M9T1T]KXR]BA!N-C+PUW;[F&/8[&[
M,?NY9)K2RF)6/W,$'APQJ%54\N3-_P 4GJI]67KY]C&N/PWS%]?O?AMOYS-_
M;R5][G3WXBTWT71_08^*3U4^K+U\^QC7'X;X]?O?AMOYS-_;Q[W.GOQ%IOHN
MC^@Q\4GJI]67KY]C&N/PWQZ_>_#;?SF;^WCWN=/?B+3?1=']!CXI/53ZLO7S
M[&-<?AOCU^]^&V_G,W]O'O<Z>_$6F^BZ/Z#'Q2>JGU9>OGV,:X_#?'K][\-M
M_.9O[>/>YT]^(M-]%T?T&/BD]5/JR]?/L8UQ^&^/7[WX;;^<S?V\>]SI[\1:
M;Z+H_H,?%)ZJ?5EZ^?8QKC\-\>OWOPVW\YF_MX][G3WXBTWT71_08^*3U4^K
M+U\^QC7'X;X]?O?AMOYS-_;Q[W.GOQ%IOHNC^@Q\4GJI]67KY]C&N/PWQZ_>
M_#;?SF;^WCWN=/?B+3?1=']!CXI/53ZLO7S[&-<?AOCU^]^&V_G,W]O'O<Z>
M_$6F^BZ/Z#'Q2>JGU9>OGV,:X_#?'K][\-M_.9O[>/>YT]^(M-]%T?T&/BD]
M5/JR]?/L8UQ^&^/7[WX;;^<S?V\>]SI[\1:;Z+H_H,?%)ZJ?5EZ^?8QKC\-\
M>OWOPVW\YF_MX][G3WXBTWT71_08^*3U4^K+U\^QC7'X;X]?O?AMOYS-_;Q[
MW.GOQ%IOHNC^@Q\4GJI]67KY]C&N/PWQZ_>_#;?SF;^WCWN=/?B+3?1=']!C
MXI/53ZLO7S[&-<?AOCU^]^&V_G,W]O'O<Z>_$6F^BZ/Z#'Q2>JGU9>OGV,:X
M_#?'K][\-M_.9O[>/>YT]^(M-]%T?T&/BD]5/JR]?/L8UQ^&^/7[WX;;^<S?
MV\>]SI[\1:;Z+H_H,?%)ZJ?5EZ^?8QKC\-\>OWOPVW\YF_MX][G3WXBTWT71
M_08^*3U4^K+U\^QC7'X;X]?O?AMOYS-_;Q[W.GOQ%IOHNC^@Q\4GJI]67KY]
MC&N/PWQZ_>_#;?SF;^WCWN=/?B+3?1=']!CXI/53ZLO7S[&-<?AOCU^]^&V_
MG,W]O'O<Z>_$6F^BZ/Z#'Q2>JGU9>OGV,:X_#?'K][\-M_.9O[>/>YT]^(M-
M]%T?T&/BD]5/JR]?/L8UQ^&^/7[WX;;^<S?V\>]SI[\1:;Z+H_H,A_;OAR]/
MMLADLLZ6IFJ+P*SF92=PZ- !]1;=UZ?92I0VPU.\T>"'+,2QDG*)30\BX1!3
M%H]42%3([CC2LFON=C7;_"9+$3>4M:T[6*TR?XR212EE(8>1(X8>T,#P<C-E
MT1TSL8N!JZNNMQ_"J[/4PQ:W94IA_>YJUNHD4BM&W#!'+Q/QQ)&Z\C/CT.W'
MLR^TG:&I-[DX9W?/5?;1O16Q[;!@M"H^R80\.#M>N]LM!F?-D.O86OK-7RI0
M>RK##%B9.>R,Q8*HL9IM:T$4L%BJI2I>KK:AC)[C"2S)-7+'S;P948 _>%>2
M3SGG2&SOW*FPUVWD6;<=/[*;47K"((UO*D45FEL1$OP8_7:5B"21!P%G$W:J
MIV@;T\B\VW'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&
M,<8RJ;K9\_BP>)IY_P";5/1S&/\ JQFE;)SG&/\ 1C.?GSC_ $_/R?N_M!I/
M^GV?\['G/-'_ /$3KS^3NDOZ+?RUGD!G0\<8QQC'&,<8QQC'&,KZ\3W>^S^N
MO4&\[#U&I<"WN&*Q5T6=N(U-731UD)I@S;&TQ):?BXE)_:@XZ1*:6U$)F(<O
M"''F6FU9E"&.:RB2>:\,W;]\5'(7^#XS\H!&<2_9"=8]0]#>C#<;OI@M#LVM
M:_7C8+$LQU5>_8$,U]4=7C$@^#5@DD4K%8M12@%T0'S>=._%E[$:(V9%F;DO
MU[WCJ<_*1'N-?N-@F6:Q!V'G4_\ A!2"QV4_*@$1>,K<Q7\S6*^9BY>@O-0)
M:X)@9.6==#-&1$B12#[EE4*I_(P X(/R\<@^?GY@_!WHM_9*=<=&]0)+U3NM
MSU?TW=D";2EM;TVPO549O\-U%F[(\D$]?DMZEXT=*W'W0NL,AAM5_8?K795&
MW!1JYLC6]C'6REVP>V3"'!CF5L26%Y4VZR\TM*)$(A"D(=A$ALUIB>,GL2(,
MZ/'EQWF4:U)&\3LCJ593P0?_ %Y@^T$>1'F,_4;0;_3]4:>AOM#?@V6IV4"V
M*=NNQ*2(>0R.K /#-$X:*Q7E5)J\R/#-&DB,HSGE&3&.,8XQCC&.,8XQE*7B
M>^*+ ZUPB.D-$E!Y;?I"-AL_8$(BDQ>HX,IK"T.26'T2(1"\S&%I=&!933T4
M/'<;+&V',+@#2$I0H>/]MF!$(^Y7S!D/\/M"#XR/:?('R)'R9^R$_9$0] Q3
M](]'6(+/6DT86[= CL5NF89%!!D1P\4^XE0AJ]217CJHRV;B-W0UYZ_/">[X
M]JKYVSK&GMC[$MFVZ/LD?<'##-NDJ-RZE, U8Q9X-B$%'V\S!43VL2T$E#,2
MFPKK)C&6X62+([*<S8TZZ5VE1%C>,KQV^08,P4J1[#[>0>.?+V\<YQ3]C9Z9
M/2/N?27K^E][O=EU-I]]!M&M)M)#<EUDM+76MA#>JV''BUH_%K+4DKB05'2U
MY0F=("/5AS7\_1['&,<8QQC'&,<8QQC(#[6?JN]DOY@]Q?V>6+F70_PZE_&Z
MW\\F0_4/[G]Y_(^S_H4^0]X:G\'OTJ_HQ:7_ *A!.9&Z_;;9?QVS_.MD9T+^
MXOI7^0-5_0XLC?Q OWR/#5_VA-&_L%["<O:G^\[G^2)OZ54S!ZR_P_H7_3.K
M_P &W662\ALWG'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQ
MC'&,<8QQC'&,<8QQC'&,K:ZA?KK>*C_/?UR_NE:IY,[#]K-%_%KG]/GS1NFO
MW4^D+^5]+_X<UN62\ALWG'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQ
MC'&,<8QQC'&,<8RJ;K9_"O\ B:?S5=&_ZE;)Y/W?V@TG_3[/^=CSGFC_ /B)
MUY_)W27]%OY:SR SH>.,8XQCC&.,8XQD#]E[?:J-I:Y62FY<9.1&1S#4]EK#
MSPJ)/*0X,\FTWE*\>MBQ)#N6WLIRF(XI,Q>/0CJYQKT_]3]1]'^B?JO?=*>)
M'N*T-*&.Y%&)9=;6N;"K4N[&.,JP\2K6FD:.4J16<K:;X,#9>KJKRHK^P\^7
MRD D _[/]?L^/*>ZAOBU0'2P38LB;MC6]PAR@M]H5XGR; *L 4DG+1!#22SL
MO$(AZM>7&9+/H86ZAM,C"T83E'YJ>C#]D;Z1/1_U+#M=AO\ =]5::Q,/=G3;
MK;7+_K$3L#)9H3WI;#4-E%]W%/%Q',5$-I)83PMW;:75[S6W-3M*5:[K[]>2
MK;J6(4D@L02J5DBEC(X=&!_A4\,A5@&%0?>[HCC1"8V\='R9UVZO7:=Z(DLK
MUDHYJPW+<\\T.^8QE;S'J'EXB@CLK]$@GU,">[DDJ+*,_LAT!U_T[Z1>G:'4
M?3E^.[1NQ\@CA)H9D \>I;@Y+5;U5CV6:S^:GMDC:2"2*5OR9]/WH V7HKV,
MFYTT=B_T/>L<5[)[I9]'/,Q\/7;%^"6@8GLH;!N!. *]@K;538EGP:NSNT];
M=G:=H<5,F'-6;F)%HEAJ#V79,<,:@5HF4BW4"CSS[KGQ$"&H]@6UC$4J 0Y@
M@R[*&!Y8[9MG!') TQ $D0!#?*"P':?E!Y\OD/L]IYSOV*_I!ZCT/I!U?1M:
M66YT[U58LQ7M8W=(E6U#0L6(]M3'/]SS1"JJ72OVNQ2#>,C20598/8_S6<_4
MW'&,<8QQC'&,KG\4KLOL'JUU2+WC5[>(]SM-M!ZY%V-4=,O%,181QTA,M"([
MB5,+FQHH-T:(<E)7&C&2@Z4\S*2Q[(_FZ^!+%@+)]RJEROW_ &D +_!R>3\H
M!'QYPK]D3U_N_1UZ-[6WZ>7LVVQV5315[YC\4:H7H+DTNQ","AECCJ-!5:4&
M-+=B"1DD">$_BWHE$V7OS98JF4P4<V!LK8!Q[##&'G9Y4N5GNNS"18L2F.Y]
M6RWYR2APX4DMQH<9N62)2VF&GGD[0[I"A=R$1!_  !Y  #_8 /X!GY1:;3;_
M *TW];5:JM<W>_W=QNQ.YIK-JS,S2V+-FQ*QX4<R6+ERQ((XHQ+8L2JBNX]'
MVH]6T;P_*/.H6N20VV]F;5 :A[DW-";2]&J+65-OO:WUR[(:PY%AP9+:,%B>
M6VIDZ?'3-GMLSV!@NI_GK^R=_92OHY;?07HZOJ-Y&S0;SJ"LR2)H^/@R:_7O
M\..3='S2W9'<FI4F"'G9&1Z'ZV>@GT$Z?T4:;UBR(=EU;LX$&XVX0]JH2LGN
M9K.]1)#K(9%5F8A)ME.BV;*I&E6K7V^Z6[BVD<VIFGG++8;?72P8O/(8/D9I
MIP,\/92_&)QID]V1)B-O2LM#7F$O)B/K(MK6RJ0AE:>4?L3?2GZ1MQZ1STMN
M-_N^I]%LM5L[MT;N];VTFIEI1B:#85[=R2>Q626RT="6$2K6F>\CM&9TB=>\
M6XHQ%W*JH00!V@+SR?8> .?E^7R^3+9.?I9D;CC&.,8XQCC&.,9 ?:S]5WLE
M_,'N'^SRQ<RZ'^'4OXW6_GDR'ZA_:#>?R/L_Z%/D/>&G_![]*OZ,6E_ZAA.9
M&Z_;?9?QVQ_.MD9T+^XOI7^0-5_0XLC?Q OWR/#5_P!H31_[!>PG+VI_O.Y_
MDB;^E5,P>LO\/Z%_TSJ_\&W662\ALWG'&,<8QQC'&,<8QQC'&,<8QQC.-,F1
M!T.40GR&8<&#'?ES)<AQ+4>-%C-J>D2'W5YPAMEEI"W'%JSA*$)RK.<8QST
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M+M@5!5@LGX==99I:[1VE@D3ZK]'?H@]'OH[M6['2G3\-"W<C[+%V>U<V%UX
MZN*L=G86+,D%7N"O)! 8TF:.)[ E>-6&D%$HEIV;:8%4JD!TF8).94I2LJQ&
MAQL*3[43)RLI7B+!BX7A<B0YYYRI2&FD/27F67/RGZ-Z-ZC](/4=+IOINE)L
M-KL)"S,Q8058 P]9V&PLD,*].N&#SSOR266*)9;$L44G77=8U+,> /\ :?D
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MRQUEKM_<V^RV&QK=4;2/^[X8B?1ITCLX*&IJ;/9FK6K[.WL!;AA$;23Q7XO
MNRP206Y"D@B$=PG69"6_%:\2]M'I>@WJ;HPA/IK6XOT4T?9"4^DXXI;BU>6,
M>DM:E+5GS4I6<YSGFN7?V@TG_3[/^>CSL>A_^(?77'L]S>DN.23_ /9+_P 9
M\S_"?,Y:[R SHF.,8XQCC&.,8XQCC&.,8XQCC&.,9XL?\J/_ '^^K7\T-Q_K
MFUSIG0G^"W_XQ%_-G/C_ /9+?MUTQ_)=W^EID2>!=^K7XP7]$;__ (+?_,GJ
MG_#NF_Y1_P#]U/(KT)_N>]*_^BP_H.]SSMA?_'(G_P#J<#__ &FN;B_W#?\
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MTVBAWS;6X;3LE,?OF[5 _;$&B]FR.GI&T=:N6YN4+K-/ +PBL4&J)J,Y,&=
M'R)\=^ C"^ATMKJXJM6-]M''-%7K1P@ZGQ&U[^$HLBO/X7!DED\Y)I#(.06
MX;/E;?\ 0_65S<;F[7Z*L6J5[:;:SL O6[58NJ(!=FDU)V>N]9#1UZD'E5HU
M?5'"/&C2 IP;C>M7\*[XF?S>7_V4]&OF_P!'_@3LGYN:W=_:#2?]/L_YV/.R
MZ+_XB==_R;TE_1;^6M<@,Z)CC&.,8XQCC&.,8XQCC&.,8XQCC&49>.!U ZD=
M@M34#9'8[L<'ZJV36Y(J#HVRRXA5LB6&-9419Q6DR*%!GC;%;G\K#LEAN:W)
M43 (;+3EQ)8^3-:YM72VQV-.Q-!2I-?2<*TL"MX90IR%E$Q#)&/A%6[QVO\
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MN^*]?:@1N+G4@/0PMZ32"6JH6ALD*&1K#E8"RZQ9;$:V&X?799A"9-MD"Z1
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M<,:=U'82RX["?)ME1,^8+&Y^6TIS++%"!!_UDN9(=<2>:Q$^WP_^Z20#_8
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M,8XQCC&.,8XQCC&.,8XQCC&>0_N9X2W<.9V,VO<]545.V:+L6]VJ_!CXZVU
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M D\4ECY,&#&$6B4=CW)-+L'C>2S;1HH();!+2S2]C"O3G"=K)Y-)':K$LG<
MH()+1A<Q:GI Z8BMUZFHTMB*YL-C2UBK'3U]$30ML]YK38,D4Y[H*ES3;9$B
ME"2&5D9$6&RTZQ0,\:6A9&=?S9BN90 /TV9=>QMA@A26!='@R>N.V-_UT;KR
M+(.+L!ZP2QVK_0F#B(1T6B#8QK:+ V6:DQ&LANF9>ZXBORZ2>%20NO=*PNUZ
M;F8]G8B=T_D5?GN1O@E>"8R/TP4?#T4TU?B">F]SJ"PD,GA4D;I_:;VO'05I
MO6)YWCUG#1R0&,)9B G$H9!<1JS9 [;%,A7477KG5HLT@>&^Y+[7)57L;#H
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DXQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>gdc15tqwxkbk000017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdc15tqwxkbk000017.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "; B\# 1$  A$! Q$!_\0
M'@ !  (" P$! 0            @)!@<#! 4* @'_Q !7$  !! ("  0#! (*
M"PT'!0 $ @,%!@$'  @)$1(3%!4A%A<B(R0Q&!DR05=8EIC5U@HS-#<Y45EX
ME[;74E158G9WD9.4L;72TR4F)S9"0V$X4U9QM__$ !T! 0 " P$! 0$
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M?5)HG!CD0_@RG;U4@['43E\'C,Y"D61K"1H6[E6U&SP7J,X^[8HW(2EBI.I
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MDS5JU('3^S>O8$49"G3).:MU"E8?X"'&9;<>=D/E;V&T8QZV\8SZL?1A*TY
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M]N;8M?7:]G[5&8:-;ZU:)48[$2&P4LO84,3LZ['LFU32T 0E;;TZ/,W*4;Q
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M2R9.Q$TT-,]06.Z\:AR6'YAP!VCD8(S!V5&95(4G6R/OC\8G^)?U,_G.S_\
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M00AWBS33'VAA!!!FU/$%%$O*0R..PRA;KSSJT-M-H4M:DI3G.(< D@ $DD
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M/&2'7>ZR =?C$O$D%_=;;=;)6G'R\M>)>^!<KQ95 !([^[9!0-@+:KR2QL/
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MU>J+4_N"[5G8-\8R13(8B0L59T-J[1C* 2V[Q(CQD2>SJ\"XFB,1RS,31[@
MTD/#CK$+XK'MD]DT\<$8]HWL_C%>)XHO_3CIQ@$>U/:.X]_!9AWS&"6VXC<@
ML=Q.8W#V<?:OVFO>\')VX+MP>Z"(O/!A\?B $83.(XW7'I:90G+NN4601#@T
M@9CL!IF+CWC&]I:WD'DN##C!"WZI>Z26<4P"(UEQ<M[;#*B2&OB2W<X9#']T
MI[.&F5YYRQ^U;V72L5B]I/0,C!))"L?6/3KL(X8VEED(7(DA(HD>61ONI&C.
MQ"J2)W8_@?YCKHP_8359)9L;-;'U3&&B#AF-NQ^SZU+1)8IJRV4I8/(7#/\
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MG($-B 1PA)YQ;RO2R,&(RL@DAU7_ -+;++:W'%?O)3G//H!8A0-R2  /J3X
M_E.L7=8T:1V"HBL[L?154%F8_J !)U\ZW1G;NR*]TTJ4QJ9J/![->)[VN[/;
MOK4Q98[$I&ZTJA5Q/'OFZ;'#N.-,S8-#I%7K>:U7GB6@I^Z6^B09:DQDD?E%
MORD$+9&06231P>/HUG5#Q:=Q&##61OT&FED?F^VZ1QRN-V4;^+='W[Z=,UGQ
MO!,_U]U%GLM#-.G<2A6:VZW,K/$>(E2G4KP>[P%E6:U9IPL1&[[9[5:OIZM
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M(0Y4'<+\Q&WG68_""?[V'_ZEO_R\U^[U_P"H0_X)/]773K$[F(+\G#_1A_\
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M\UZ/]:*]R:Z=_IUC_P"_'_1OJC>TO_D)U-_V<?\ 30ZGMK?^]W0O^1=6_P#
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M4]_7PZ?B-3ZY$ZN&JU?&&_P9O<#_ )KT?ZT5[DUT[_3K'_WX_P"C?5&]I?\
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MNX3Y,D28J/@65(<RMP0-8RVTM8.<4_\ RX_X:V2ZI_+3 XJU)<BZ1^ PV\5
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M%W+':DEH&*ILEE2XW1K!"#YNTH6PK]D]XKO^2TU[_/OUM_LZY$>Y8']_)O\
M)<W_ )NKG\?]H?\ :]I_YX4/]AT_9/>*[_DM->_S[];?[.N/<L#^_DW^2YO_
M #=/C_M#_M>T_P#/"A_L.O$U%K?NEOGO!J?M'V6Z_P!#ZQ5'06GMJ4*O5B%W
M9$[LL5_L.U3:\ETO)5=KT%&P$-!QT*ZX]DW*C735#-#-%L%OO165B;&U<98H
MTK<MV2W8@E9VK-62)( _CYW8NS%@!MXVW)(V ;5C:/5.8ZLQW4&=PU3 5L-C
M,A3@KQ9:+*SW9\B\.[<H((8X8H4B)//YRY4*&#,8[>>5_7I.J^^]SN-D&]:>
MI8.?B"NQ.]:M.WD-&,^IC1'7F1C=U;1-)<QY^P!-2E<H>M'E*QZ7WMBCB_B]
M[*%2^*WA%W('P*=61(C_ /JK@:M !^+*KRSCUV$)/C;<4WJX^_-@NG$\MFLM
M7FMJ/48C"R1Y7(.?P262"G0)^IO*OG?;5@G(C5RU7]WF<^[>P]3NTF,J9CM"
M]A(:N;%-5]1@=.=BXLS1]OD3DISAS %=MMGUO<SB$>I(8=5(*>;4RRM2);%_
M;)?H^K6JC/"/J;%-A:C4?K>-)H@/J9 -4WJP^XS=.]0>D>'S,4%YS]U,7FXV
MQ5EV^O""S/1M.1]U*[,1L"18#R)U<M.--4T][:\YVF[Q]1.B5ZD3!NNDO1[[
MV<W'4HYX@96XR=8S,9%4?75C+'>8<;I8LZ3B=G(Y&74S/DPGR#D(^)E ;'BG
M%'%Y'*1#>XLD5*O(=OS83J3+,@(/VI7Y%/CCY]59E/F/5T)Z@ZLZ:Z1MNRX2
M2I=SV3K(2OQ-J$L4=2E.P((JK,W>F0;]WP/E=(Y$LCC;=:Z[&M0-?Z[V:*@Z
M]M2!U/ 1,/,ZMC(IG5N!(5G&Y8B/&M@XL;KNNLEE!8IZ&1]A8:@GVX^EK9>"
MP[#&.-SS>XC,\#SLS+.S=_=OS9B8]S,^P/<\P_."9/75X2S8@C$,.%GCBAR$
M..ACBEQ\<:X_C$/B<:+858Z4 9D]V %S:$A*I!3?"JCL2[S9[MHD.L,Z%9%[
M*B==/RK+M4CIJ,H9ZG_F-\D92UOULV5K%6]AC,F!5W9PV5R8QFMQTGE@M(_E
MOLOZTZIZVK=3'JOHO)] G#9FU1QD&4>S(,S6B&Z3UP]2OR8$!&MPK+C9RRM6
MMN%<)U6OL)8)H*!N333PUII8O=HY*U:0GN69))Y(VD@AV!>*$R3-N.W$Y!VS
M26MEJL46? 6#KK9IJ!G-J2.IIJ(F)G5DG$R.JRPRF"MR2D<9;'A3]=2;/Z"1
M3GV7MA/-&>@FEY9]WR]26.-&#I<176NMA659U83@C:LK",$3+ZB0;0[CQ+OM
MKEDLV)HWAFPD\L,V0?'2QRRX^2-\>R,&R<B-8*O1D'R-68&Z0VS5=M]5P=!X
M!SK%W4[F=$Z3)&E==ZE7=;=B]+U23>?)<U&K;A,NB\:[KQA#S[KU+5/BXF(
M!>6OE&5E8<R;(R,I)F3&5?W[&XW*2J/?)'FIV9!L/>/=PO:E< #:3@>+GSR\
M>BA5%'Z/@. ZHZGZ1J2,V$K04,WBZ\A+'&_$FF%NE"S$DU>\G=A0[=K=M^;N
M\C91X9_]^SQ4O\_^Y_ZA4KF&:_H7!?\ 94?^EDUOZ$_IM[0O_;&S_P#1U=6U
M\@->CZQRX.B,5&TOR&1$@,UR;=-R>T ^#@1N,*63DUF5-C8MX3#.%Y):DI$
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MG&FJ]/$=ZY;1WGJG75XZ_KBU=B^KVY*=V*TS$S9+84)=9VEI/&F=<3)SSS#
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MG&Y.JGEA*<>6,8_0_P![&/+FG:Q_8>O^ O?_ /==H?%#P/;;+L/_ .J=-_\
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M@:PL>TK/1XE^#.W'<FMA7L)B2D'((^Z_(XROR%DCH!XA<3"2D^##QSUE)B!
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M*D,I:*571BK %=U.Q (\ZTQ^PZZB_P 5CKC_ *#]9?U8YT?$<A_7US_&I_\
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M>Z];[$B*O*0MD! +MX+!\-5[$0+ W-;)+$@6PV15#R&YD<AX**D3VF5"Y6X
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MZT=?(V5G*.=(V"&(U/8.M=ELE5$?<V$F!^Q.PY3J]0G'8M-;:F8!EU\-RQ6
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MHT=B#3L_*%^_WS4CW]X[W'N'[OQ%LD$WX'9^\W;,NVYA'#@&);7,?9I7./\
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M\UF()L!#XM@*(>,L4ZO7$<0Z1I(\<$+UJ:S+$\G<+C(NTXD+ E]H2K%PO((
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MGW,H;5A'NNM-^KR];B$^:L?5!9@H]6( ]?4G;Z G^8$_JUA(XCC>1MRL:,Y
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>gdc15tqwxkbk000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdc15tqwxkbk000010.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $Q E\# 1$  A$! Q$!_\0
M'@ !  (" P$! 0            8( 0<$!0D#"@+_Q !S$  ! P," P(&"0D-
M$P@(!04% P0& 0('  @1(3%!40D4%19A<1(3%U16@9&A\#=5E)67L=+4UA@D
M)3925Y.6P='7X?$B)B<R,S0U.$5&1V5U=G>RM;;5(RA$9&9G=(1#6&)C@X6&
MAT)3<K?"&9*DM-/_Q  < 0$!  (# 0$              0($ P4'!@C_Q !9
M$0 ! P,!!0((!@L-" (" @,! @,1  0A,042$T%18? &%")Q@9&AT3)25)2Q
MP0<5(S-"DM+3U.'Q%B0U0U-58W)T@I.BPA<E-$1B<[*T)C9%9(.$I*/B_]H
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M--\IYSP3C,O"HQ&,CQ^,X7*Y"SCO9<[;8 1F1!7;O9D'':0=%XC=)2PZ4SP
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MO4@@Z9&2J 4UQW/@YL-]S;SZ&!?J:3X9WCE^O:CJGK2\V6X]]J[;A&XFY#K
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M(*EO6A+B+A7W1MZZ+3S:R74)!0V4D\%@EL_#>WB$JP"$[B2>91F<F5 *DS&
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M>S"HF( #5L23.( UG'6LD?#3R\I.3IJ-:\V[<591VD1BN0@:V+]L,(R>;Q#
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M1PYDFS'+TN=C<A#")4HK#8K,FY^+$BX<:Q,"7#64)I)7BW)"E6J3 S56@J0
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MK!%Z4W"7U-(6!;MVJVE%82XTBT1:*!4E25I*VTS*2-U1D8 %0&#)S@ C(D!
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MLK3"I(WTJ)"L.(8((!"BHD&0/**2=#."@'7LYS7!5\'#B6N7Y)EZR0D'9J7
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M=W=W?N:F.S&GGT_55F1RP0(CGH(.(Z]4\^E.VOH]=:_)P]?"G'XN>KW]??%
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M/3]'NI3S-D'ZZD^^P<9_P=:4IYFR#]=2??8.,_X.M/3'J^L&E8\S9!^NK/\
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M4!<Q8I2T/1XZ%%,?N>16Q+9#JON-^\VHV0:1;.H<<W+I5TVIU:EV+2PE#EN
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MV,G,#XVLA+@]/)Q&\W&&H<\X1;WJ^3W!)0>JI[<V4LL^LK8K\VDOWYE8+O\
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M:,D*W519MO;;KZ(M4:J7^TMT_8))UOOK99QNNXL]<:=^ST5Q+<<<*-]:G A
M;05*4K<0@F&T E0"4RK=2   3'.>+R[^G7X^VOT_<T[]>_?%8X',=O9(\VI
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MB_+S(L0CY&1G;" L*P3$O'L=AT0J59L%Q;EXW*26T[)%*/;6BQ>K9M99?''
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MQ<W28WMRV8)$C20(!S!S!BJ#!!U@@P><$&-#K&L&-8JF$MV4SK)3,X2R'E"
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M+&<<8M0,94JLK/P3$> ,F3,#G/)):V60B61#/3?)1R3Y$ Y.7R;FK#^8LN&
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M<;R+V\.?7I[*O#NMX\;E*_/WX:KA[L&&^_W-B?#EQ_OG>_-WUUI7?\7CX_\
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MVV)7KO&R*VKPU_%.A.O*)/GQG33(KQEO8>U5I2I-D[' >N05+;1++%D-HNK
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M +94)WTBDQYUK3C_ &)NY</5ZNSKKI/"/^!;_P#[;7_L,ZY]_P!%>B?8N_\
MM]H,8M+[.-?%SC3/H Q KU.R_7<M3+$0]PRV^X!=':TF5,B6PNN$J6V%'=R7
MM*@ARGG)')*B%U]J-X=H]Q]41:S\K6)%*)W7>96PL3;N^-F%[_W+@\4W4[HY
M*'BI9F/AJ2]O;VZ2FOU"-V#O:SB)WHQI^#'G(5,QC(\TLS3;/1G/N?'LRQUN
M A$6<X4D -%-D]#.(B,P;"]P^,!TGDL1NQ[.#$J4D\]QK9/9:^(,@ V=-6A\
M5%&;6ZZ)M22W=6S5JBTM T]9.NBY0J#(<5=.V=PIM#G%:2C<9?++82I:F90I
M9(XB@,Q&ZF"DJG.H.\4DB9 $ X&2#J=2!W(#&Q0['W^2\ 2PHVQ;#]P;P#M7
MC;UI,2;(H-.$L R!0ACQT4*-"+"&D,CQ/+$/D)9\F[#(8CD\^<@;ZQA)!B5Q
M6\$.<"\;3XP[:!=^L%I!2I";I 2^$C=+B65V[B4IA7C+;06.(24C PH"2GR]
M!,;^#RG=(C_J"9$U9K"V<LD7[2,W%X?CTFZR1A> RQ[%&9AP5EAR<9*LA!"9
MKB9JP0'AWZF3+)JNHUR)%0=5T$CQ"X8%?>S5L1:Z%S:LC:%LEQX<&Y>;#A2$
MM(;9XH:WFU%2P&"T)9<5'D *4(UQ4!OB2 %*$D  !,@2,Q$:$X UT-5LC9C(
M^Y+*VWP02SF?S'AC'VZ9$L)R6RQ8&@PG*JHG;G+L@O $B&I@&(EZTQW-Q7D9
MB<C[,<@V>22T.06>3F&7%$MYQ+-BQ=J%HFVN7K H+"KA3JF J\;9#B"5J4"\
MT2O<63(05)AIP).1A(5Y !*--XF 5@2,ZD9S.!T.>FS'.L^8]F.Z:\&?<'L?
MSG+F8 K;'12"M"S(4\B> ,(2T-+!QY=-P77\>+)$ E0]MUL:43<K+(,*'$E7
MZEMVK1YNP"D!#K5O;*+X=*2H.7ETVILH!"1N@A6_\/R0"=W #=(&!(2DR#U6
MH$&(S.3S![)J$S'<1GK*TL$8I3S>O64E9O")-+($RPU:!?[<9G%_"#[5H%&H
MY<47:-',W%"(-))"Z?H&2+Y*3-:.)@_=JPN511B.YF[*U8;+YM0&TLN(0\;G
M?%ZVYLB_>6L)REE2G$-A, %&&P XAPJNZD"=WD<[P.\.&LG&@DC7Z"#5N#&X
M3=:RV].4!T-D3F<CIXOCM/<JZ$8NNA[QT&W9KX/3?%<2HR=O+U"AV$,4Y 2N
M"PQG$TU2BKL24%M4DKF?7BSL#>"74!I30>-D%/\ $2%6 NB$W!06]U#IW %.
M%SR0%)49G'=3O22(B=T3/P-Z)B(G S.(/4ZA.;B-VV*'P0O+\JJ3*&6S[)<>
ME[IQAV-B5(UCK .^3;SB:5Y$?N8\,OO5<2C DXRC()6LBR;AQK(0RD$1%"%@
MKYX_V$V>S[@*2U;\-TM,K: N5J#CUWLN\N&V %D8;NVF$-^5O*4I2'"H+ 38
M220$F<1!U*FE*CG@+@#,S@ZP-9%-V>7ALBR=F8GF'(XH ;QWD8'C"-"<<1.\
M74!'_"'98Q* R&+#3Y&,QX88CF%U,=JR&42]]0>, D&,QEX:2MVB(UUSHV?;
M*1;VPMF5+2^PM]Q3S@4%N;'M[A3"E,EQ:DN7(>W$-@$K2IIM2"5$7< W0 "2
M4[Q).3PD$C$X)G03.!V1+'>X[<%D\IB2<3[(ALA>;$EH4-A*D29M(AD-W"=_
M&)8PTFJS*^(1Q+SRIBD@VD%#(H)&&OD]O0\)"L!#IRA=RW%C9VZ;EIEE(W5I
M=+O$)<9#FRKE9:'W1PEHOI*-U2UF3NJ45 &BDI 5 TDS,D2V3&"8!,B"9.1J
M0*W)$=U6ZJ8Q0TV$Y*4>3([^9C:3E3W#$ ]-I^5<L;K<=XEG.&TVQ@;8RF]H
M?'LHE+_VF3*%Y,&\SK9@2.)@YG';&NL[L^P:6A2F(:2+XM?OHJ^V-O;V#]PU
M<RE4M;SS;:?N>ZA?$X:4A;:ZA2D08@>5!*OA)""0HXQ)C3WU"IMODW,0B284
MAZLQ-DI<TRDO!Y:W>8HB >*Y8B0W>;DS;\2E"RK=B8E:\C2QM!QTO+M<?C<?
M0:$K$*2(]*7;*0QR)V\K6RK%YN[<#24H+ =:(N'5.6[BMFL7:6X)2V$%YU3:
M2^IYUP)*$M@H6Y600DA1Q&Z% S\$E 5&H$28R23&!,FO539Q4G=@U'RO5_<]
MIEG<9;6I.KBKOQ2S<1E.T;3BYI17Q:@VC2UC2G_)6L:-K6__ "%$]?/[1W?&
MO)B/%[+X,1/B5OO:8G>F><S.:X3$XCX*-/ZB:M'K1J4TI32E5^WHT(W;5=R=
MHBCFXK7;YD:@RC*]S8\J_KC<C1I1K>TI5W8XJX]KHC<VMJO:I[&J-*J4MX]I
M;1]M+#>C=W]F[TP1N\*WF=X 1&LX P21FLD_#3,1*?-&-?/S^JO-1MC[-.TV
M*73ZQ]C+;)!<FGL1P.;.\/O)]FV,XJC[%A/C9_.1AIE")A @R5R@JXA6,'+B
M^#O8Z"'.&AR0OC%&C% 3V9>M=H.I9BXOW6$7#K2;A+5JY<+4II*+1)8<4HH0
MGB/"' M1!0A*9)5EY*B-5$ P#"29*?)P3I!.N=!$YX\*W=;FC<LQ2SE,S5CY
MTN4P<.@^+?<(),+=TF/YOEDY$,DYF5)$6+DU +HWBUFADVL=#OPB&.KF-'T]
M:%(_)PK!"N[-LD-7!;:WTI%T7;@7:5>(.M6R'6+8)20EXN/DL;ZPKCS#)2M"
MC5*4PJ.4RK>$I( (3&AD^3)D'\'(JRL9E>9RFQ:-Y/R-*UL@9%R MA>8K,WL
M&CH!I%FDEG&.6KN,,  48WN<I"D;R))0D9J[*4).W+BQ5@P:L&##0<;MAM1;
M##?!99%RW(=6LN%#3Q#A6HXWO)3NIA, :DDG$@;Q P!O 9F8!SR_9U,DTT)D
M=S>X. P:!Y:RT>? LC2#9QDHNW"XPBL;J-$3C.62XI*<;/K41*Z9>-H#(1$)
M$5O+)W$KR=KZ]PX;QHH@#:=DD6-F\X];6Z0ME&TF 57"U[RVK1EQM\;Q\E16
MZXA(&-T  %Q)6<I2#*4@8=$$DP4I24F3I)*@-<#K6B<<94SO#QH+)P^>2V .
M+<73<VSA;:,HW0>7Y+9^"\VB2^$ '( B+=LT%!LK%R\D!"L:-:*$6,@8I6WJ
MJE$%MMZWM75.,%E#WW=E!=*X=:8.W-H-O+"TD$[R%-I6L@X*"=$UF4I)B!J)
M,Y XJP?-(B9DQG'*U&1=T>XS&NYG!V!4,K2Z6NC<BQ#',@+&\0XZCP0X#S H
M;H5F$>N!"24D=^8[M^"#L3GL8/ @Y!@RCYY]/I4Y)MG6BQ865Q875WXNAL)1
M<+:W;EY:D*M@B&EE12V"Z M>Z>(\I)4M"6FPE0P"4J0M1 3 ,9)@B)!F!D9Y
MSJ !%:AQ/N#R[%8;CUH?W &81'".-<#B,I;GS^*!\YE8"4LHAN#=/8=(D7@!
MT&2*J3B,"H8[-2D._=VN!BL=M73F<T%EK>=^TMW'7RBR2ZM+UVIBQ1<*:;6@
MKLX=1"PLHX2U/!#9 A061PFE"J4B9"9,KA$P")3!$1B,P-?,FK4;<<\[N9UD
MK&\@RF7\A1F6Y1A>(I1AA3%K0"E&U3?@\HQN=/2ZR0O;*S4:^:9=J0C#<&:?
M.6HEB3)Q\K1X99CKQ>A>VFSV6'D,)WW&V'+A%SQRLK"=KN6*&RA/W)0-ONK*
MD@%2@E:=U)(5BI*0DQF$E6],DPZ49&!E.<= 0()%9WC;NLK8AW2X?QCC\Z<8
ML"<BP(V/15]!(RO$IA',HY;N@\S>-9&X1.SXV5BL=MO*5K%VL%BL*421?3"5
MG5RHJ+N<MF[.MKG9]T^\E)4E%T4.!USB-+8MRZV"@;C*4N+\G[HIU;F0VVD)
M4L$)!2LF  %09R"$E0QIGMDGDF,UIB-;GMVC #$+,H9H\V(ID*%[;\ES#-5,
M(QVB^!1>4D=T;8O'D0R MV"(,B$HPUB>)7G)<)(N Y#)!5Q6C&TE&6X;G786
M"EN<"VXCC+E\PW;>-+'C:K?Q H<*MX*!#=S<.!#:DA:6$""0YO90C,)DA2T@
M;WPBDMQTR=Y6 8\G)P9]&]A;HV^V?8">R1=^Z.NX,@X*N2@TJ'(+O%B1%159
MR(.**F12BE;J74&E%%'["RMK5U?<LE?6O3;5"!M&[" D(#I"0E25I  $ +1"
M5 ?&2(5J,&L'/AJ\_9]6/5BK<ZZ^L*:4II2FE*:4JU^(/TFI?Y1?_P"LGKV3
MP*_@)K^T7$_CCZHKL+;[T/ZQK:.OK*V*\Z8?M*\'CE-QE7'T2QE'92KB8B;P
M1E,7:4R71$"3F&1XIO*D\)>%"!E!L7=',CR:)Y1DS@4_)WK/WK, 9?48M5H^
MW4K>SC9AMF<@Q$=4Q<RM&@,URW<6&N;R.9-"@[-$[7DRTPG+8\UD2)VUY(:3
M&3-20RI*H%8:66$^2K1B39HBI4**>#JV6F&0$>^P/'KF\9VW_F0PU6QR9CW+
M?;94J),JXB</A\E:OB48=/@S6U]4FX>$W[!R9$/2#@3(I Q)J5NV+[=<'0?)
M%^6X3B^(P[(*L$NQFN=B@VR.IN814\WDUH1T%#W,P#FB1MJB\;D7 I0LVMI>
MT;OTF2RS912M.$_!\;.3(N4!BF$0SX;-1.9P<I;KR*;W5-"]P\Y Y(S0U=KT
MD]'/"?S&, "A=9)9-PBW%M@HU5B"I>,O1W&*5%,B[1]AXMU,K)[C>.^6\IQW
M<H<D8)N>GY"73@!EJ$P".[D'H&)QT\YDYFX[",>X[CI.D0$JOPK)D&!QBP6X
M/U:%5*^QKP>FQ_+@>TX7P<BY:3(HKD)9U8?RM!#KQW*\/@L,OTB2#.2QJ2"Q
MI7#X4'!C<"(HL0WDT>FU+QM,HDNI12I\,V,;40[AFY&X<"ME1\GP-,F5/+,L
M51;R+;!&FL1P(^3;+GU6WM.- 3)JW!C:I5%K/4+#)5D0-<2%5*T+BC9=X-S.
MV*I/.L68GCDSQ7G\"?C+DNB:RFS8+Q%ME5_,3L;QPV.'AY/$L05R\&=3&X'B
M]M"(^_D[%I*&K1PI:/(54K<<,VD[-C2+0M%8+%YPWB^5\ES-0J]FDHR,E?F"
M20ES@_*122D)!*9#;))0K#D'\ D+:3+%;Q=UA)I<V9%O'5*J5V>/-B^US%CO
M'KV&8W?-%L3RYQ.<:)F\C93F+*#21;'A3$Z3F,CIE-CX\4/&8X-$H>  -6MD
M?C89Q:@ %C;V[91%2JD;@_!3;)'\,D!^T<-P;$T97&L@9ND)&5S@K%R>%8/F
MYCN?R)BULVD^16\8Q#C^89%!7RXZ\AC,,.CKIR>*#Q5BA8C<JI6E\(X7\')O
MEG&&WVV'+,,G6%MFF8GVXD_AUO$YP4F<UW&S5F=0B&;<C94S"54R#.8ZLE>0
M+!"J@H\SF<@C@MY;D%^*CEH"U2O=72E-*4TI32E0'*>48%A/',SRUE*1M8CC
MO'L?(2F8R9XW?O&X4$+1JN]>WLQ31^3>53LIP3:#F3M\Z5NL0:MEEU+$[E*F
MK)XW(LVA!I?<HT?-6[QLI>DLA?>W<I6+HWW(.$TET;KD[[;KDEDDUDZUK8HG
M9?2ZVBE<G2E-*5#F/U09/_F;!>W_ !WD7LX_/[&G'AUNX<+5*_/UX:KZL&&Z
M]V-B??7^^=[3L]>M*[_B_P"__I'U^?VU^?OLXF'/!G.B-KGT;VS0?IKS_P 1
M[@#PLL4;9*G$K+Q5/%.5(M'Q;YZ2,LF)V0X>,8YBMK=A>JHFU31;W!@='-ME
MJ;$2V13NK:V;VVV\*'#)WE&-U0 U$E.Z.1C$#2!VUY=LCP@?9>=3M.^NW;4;
M)VO:6[3BW'T(?N=C/[,M-U!)W(26&)$<-E"0?)3%7>E.]?$9\M(&:A<@ZB9>
M<YQ3J.6AWL$E<9RS;B.BT, 7M_$K5+1RN945Y Z$^RLL2+))2I[9XU8BYLY2
M\@DC>,$KQ ^"4 )&DQOCK/,R<U]S=^'&R+AZX07G%6KU_MX<(V,!6R[SP<;M
MK*W(* H-_;I*KE3,X> NE^4 JODOO4Q.Y-^)K&"*D,NF(%NH-4B%+D+L<5VW
M5A\I!^+U8^V7,2^5DFA$@,I6E"3AL@;6I?1NDK;"\F<:3&GX);@\OC9C0P)G
M6HKPWV2M_=+SBK(WK">$;))!V:?!KQ.[8CAE6X[M8-NN-;TNJ0E]0.X#750W
M<WMR"J1"2/C)7RHL]V>^<,<O@KJ^D?;X)8EQ,W7M*)+.&A?RM1PW(,TF:%E[
MM"Y.Q?BZHJDC0ZV(,G5J1NZ;H(,$3)DY/,8QRX;/PH\'&39W*WGN+Q/ XW-M
MX@L^+IV$AYJ^AU)4A[BA:7$!  6C="O+D#ZP;>%B!)E'"$I>(TR?9CIS&7>0
MS4*D!1$1<.SI(I8Q .TH:=B$C(CB.-WH@4@D-+IC/:QZ$6-I7!'+^VT'42"<
MG=W9(.(63&(,$:1YC FK8>&.QTHMG;M:?MG]K56J]HOV=PZADM;>NKM%NH65
MQ9W3K3FS5L,I#;W#W6Q:/I+"G(I?AK*,&BVX@AD:1-$0T:).<DWA7H:,)J(0
M0K*Q$A9Q*3"8BJ2*U10AI8D-*- Z1DFZ8(L+$V9%^Z;(KK<*%)#A)B/*@Q@3
M,$)R1'(>HU\7L;:MC:^$;NTKA(8MW5;4+*V;8%.SW;QJY;M;IBSXKI";)YQM
MU#(>=4V$ (<<6D$WR_-E8,;I/;52K>5RA#'F) ):;33&TH,-,@HPN%2<)+H@
M^CH.:PIXLB?.DV1))I)#%\2)T76>&*)DA0U6G/Q4><A*1*DDS (((!$Y,YD&
M>P5]Y^[3820YO.HN[I&SMCVSU]>[+NGD[0%E973%Y:.6[%[9+(N+EQMU+=P\
M;)W>*GH<:;-0^)[J=N[&%[>6,U:OI$1QH4@]RX 1#WC,(&1#120 2I<T%-&R
M@I\4'F'HHXT(00P$=35=%<M)V PLBU;VXAU ")S$2D" ,$$Q.H.A21O 9@YK
M3M/"OP<18^#K=\A=RYLQVQFW9LG$,LH9M+BW=>?MWGG&7'6WEM/I<V>ZRN^*
M2]=MMO!"1")[NU!)1O+E(#)TQ^09,]PBU%3"'165Q9R;'P\?+DY<_7,2V53"
M57%5+"X@*Z.%"[ E(V36ZU8>BC1>YS%.C=5ND!1W((21@#.3)G023)&HK2O_
M  O83;;7&SKH-[0NE[#;:O+*TN[53[=HW>>..+>O+J[NR\>,RPX^\\V[<H00
MIL#>*]#;K,XJY1S3.9C#)W(R\/EE4WC!L\H4$JC6Y$ P#DP3EBZ4I;6J39I<
M.=7M[U63MG?>@BJJV65LOP=<WEJ*5'=.<R(P 1ZAGERR)KH/"S;BMJ;:VA>6
M5_<O65V0MM*^*TII+C#;+ENMM1@%"$;BBE2FU(.ZE105 ]]A_+<'C.!Y1 W<
MU*8\E+V1S@H<O'0 ?,D\G1>08Y;1N.1!VH^<(LFEL?D;8B_2J9JDT&^<%YX.
MXM.#4+*D+ 01.Z943"9*@4P!)Q@]8B9$FMC8VV+&UV!=6*[UW9UVY<WSUP6M
MGM7PVI:W&S46]M9J+J@V@6UREQQ*GH0UQS<-*X[8JVCO==MT$LH/9'SQXN[A
M(G)S2/OY!$'2ID2RE6"[HG'0KBER?F\E:RG;9M5<?&A B,LF]S4@FB4=7E"B
MW+Q6Q$$F-Z"0>:( /ICECJ3D_6K\+/!ME-@FWN+AY5BUM5##EQ:++S35WL(V
MELPH1P &[Y*2INV99MD(*7$I=6773#OS4>*"Z3]TWGIG'DV-1C :\WR"TQ@/
MF+Z>+0[%9N*Y0A!,40O:-']YV5$!I?VXU2Z-R-0;8L7<HU:LK[YQ$3\+=)"
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M7;M:UJS1</'-Z:"5]UC9HW7<KW4M2;(JJWV)W;+R%./MH2)4MFT2D2!)-LR
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M13@G$))F.SISZR1'M]%=B#S"CE/%1/(>WY@.GQ5-V:"AXWD-:;X3L\Z8T<6
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MJ& Y)S3+29-P[61R"43)E:.I"\]OT(GOD>:G?OI4F->#MWOXAE!$WM]A "2
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MDDDW29M5JMJVU?>)(N'-+E:4]CUCSB%K46FRRV=W[EQ%. %(B2I62=3G22!
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M,G_S-@O/_P"=Y%^+E^[ZM*5^?OPU?'W8,-\.ON;$_5^FAY]/CZ=>&G=_Q?\
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M7VAS_.DNVX2.4S\R,R5.&!B;HX^,6M)"Q7EP@:-;+1M*1$36WW:L/-$53]Q
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MA -JV;=B;2V7<M(?6IY#6XY<OH2VEZY6AQP(;>1NE+8WL0G>"5N!8)"L4A
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M66&"V;,X'Q4Q;3F2X_8 _<SQIBITD^L3>HNWDC,S[.73D?7.I[(5!93N9\*
M>V^Y,DQ7,6>!KG)&QLAFA)&);>X)'3F!)GF?=>C!L(A(>0CN(+YPL<A6"KY
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M(GJ8';D5*=O&XX;N%>YD\DQ2310;BS(8J"()30#(XA*W][[&D$GKIR=ATL"
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M(2XE !N PM*'F%O)_?@L5+#*G4$H%R0T%DI;*E)E8!D7AKF(YQJF?A[DP5#
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MQ%3CUR\5Y6MO7+;+K/"95QE/J6X57"5'QAP.KE"'DLJ4%@;CBFE.)2D("MT
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M9)'X.6)RC&0/%);/>="$6A4EBI+&HTU3$,G X_B$%C,KB$1QP/@\HQ28@$E
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MGTF<<XSUF.58Z4[N-:UIRK7T\^%>'/NIP^/GI]??U>?]53=B>IF-=.8.[CM
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MA[ZY]_/MU..GY-;^I[/_ /N^B*F.G9JKW^T0:>-I\_S@RY^AURZ=/SUZ/O\
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M%A014>@9)C1"B]I!^/$+EA2)-ZU;JMF"I,>FZ52O>-J**5W.E*:4II2NH<2
M T-C(T[."&LC-,B1(. <$F2)LL.#7LDR[\8*47M?/V0I0D.L).FJ"J#&]^RM
M=*)7.D***5'[\FXW3G"6,;\@PBS)*X^XLACV^6 ;9PL*L3O5O)I1.K^AY0?:
MDG>I<]L'U;6IV7WU4I;;6M%*[XY(X]&&K=])#H:/,GA,6$:/#A1B):NC)M\B
M,"B&[A^NW17)ER3EN/%L$K[G1!\X1:-$EG"J:=RE10OE_$L?B2\_/91QT$@C
M4JZ!.9J7FT:&Q)L;9%7()X'7D;TFB'1*M#;-V'=#U'EKMN5:N1ZJ-CM!5&U2
MN'"LWX6R4NV:XYR]B^?N7EI>YHVA4_BDJ7=6@*![CMS9$$6?J+VA+9" J7JE
M;=0;0X'J\JC0FR]O4K:&E*:4KII#(X]$A#N02L\%C($?[1X^;D)1B%$,O&G*
M+)KXV2)+MF3;QEXX;M$/;EK/;G*Z*"?LE5;++E*[G2E-*4TI32E-*4TI32E0
MYC]4&3_YFP7_ &WD7LX\/FIQ[Z\*<%*_/UX:KA[L&&^_W-B?#]L[WGK3N_XO
M^]_IK\_?9Q^^^#/+R-L&9&(.S>L_JJAYS9UD$+ G,XLFN)S#H?C@%EDIC\1+
MWBF1AD"/MACMN=>1]Z"8-O:FC8NQ5>VMRB]]MJE?%:.JUMI=P%E023O(/DA1
M2"=X ]1&(D<_9FO,WO W:+.SU7XO=D/%O9K&UW=GLWKAVDWL^X2TM-PNV7;M
MIA"7FU+W7E:G<WL5#,=;8LR9&EBL0;1 W%GK:&%<A/7TQCLM%LFD/$M%G5QN
MUNQCQ4V0;D5$?$ U@<.26+$E4F;))6ZM_L,4MK4J((\DJR"  .<P=9QUY=NE
MLWP7VUM.[59"T?M%ILGMHN.7MO>--HLV6RHO;K=N\\XEU0X;*66G2\Z4H0DD
MF(;9A/,:[IJT:8IR4]6?L5BHVQK I8K>2$-K62JQ=@E41:LY&IHD1RRCVQ*J
M*21!C>I<GXTC[9-Q?Q5'0B$GEF=-(S/T5I#8>VE+;2G96TW"XVIYK<V?>'BM
M(W"I]L<&5MA+B"7!A*7$&!O)G@1_%62Y6@.>1Z S$L-*R%G%&)AG'"ZP5:2/
MG*35J$\L6LZC4R*CE6Q+Q11U:O9==_-66TIR@0HZ)5!,2 8F=)TD\Q7';[)V
MG=I0NWV?>NM/7*+5MY%L^657+BPE# >W.$'%+@;A6% D@@1GM99A+*L+-Y !
MF('*;E,7EUP\X),(\:>! "R5]]&[P@6L86M&8TFWI8_$/WES=$F-7;OFMRC9
M9.^M*%)*I2?)("B 2!T,X Y$$Y(Y:5S7>PMK63VT&'MG71.RGE,7SC=L^MBW
M4DPEQQX-[C;;J8<:<6$AUI2'$2@A1ZDGBC*04<Q,&,;3\2))NF# :4)PZ1,1
MQ!\5LHJ,9L7CD<DV=NR25UJC!NW546>)UI>VL4MK2M9NJ DI5&DP0,Z=D]Q7
M [LG:K#2'W=F;099=4TAIYZSN6VG''AO-(0I;00M;J?O:4E17@H!S':P_"F3
MIVID%".Q RZ<8MCY*1SIHJ-?I/ +06]38.FCMEXK>[3+^-WJIVB[T;7=MC,B
MY6L2:C""[8&U*WH3\$;RA':-<'/ZSRD<UIL3:=\=HIM[-Y2]E6SESM!!:<#C
M"67$H4E;6X5AW?*@&BD*(2XI02AIQ:>H2Q7DY=VNP1QS/%GS8A>)<LTXA(%'
M;<JF'5/JC%F]@^JR)!,"BL;49J66N+!":I*J=&=EZUK=5\56H'P2>WEG0\]-
M8C7A&RMJ*4ML;-OU+0X6EH\3N%*2Z&3<%LI2V5)<\6!N"@@*#(+H2&P5#)G%
M64([<TL/XWGP.\@5\@C[#$.D0RY\=]@FI0*SH]'(U<EO8*I7^34:*/*V*)W>
MT^QOMK44*$ I4,P)!&>@QKI@57ME;5MMP7&S=H,%QW@-AZSN&BX_ (8;WV@%
M/04_<D@K@@[N03]Z8ARQ<3,A;<89$N+QQNV=2$5;"I+4F!;/&Z[MFY,L:#?&
MAC=VT:NG399ZD@FLW;+KI77IHJ767<7D!*I&HA1(\XU]=9?:?:_%>8&R]H\6
MV0%7#0LKGBVZ5)4IM;Z.'OMI4A"U)4L)"DH4H&$DIZ*2PB:0VHSSPB,GBGEI
MG:1#><@ J#\K#ZTLX/1E2C1KX^SK51.M'37VU&OL[.%_\U;6L*5)U!$Z2"/I
MK6N;&]L^$;VSNK,/HXS N;9VW+S>/+:+J$!Q$J$+3.2,Y!J,<*4]%/77M]'[
MO74K6T&D#/,]L1.-1@DC.8$B7J[.79RZ?3U?%I20,Q'FB//R//!Z'&516?W_
M .+[^I/?OGV14U)Q !@9(G(!GKF#/4 $UCO[>/+A3AZOO\:]>VNK0\P)R8CS
M:Y(.))DSV:9IRY\?3QKTY?R<JU]&I[.\G]?OJB(/(3ST@P,$3KH3)ZXJ\/@\
M_P"V5"_YJ3"G6O:(N]-/W>WEUUTOA'_ M_\ ]MKS?\0SYO;(TQ7HGV+O_M]H
M<9M+[30_<"9$Q]?,CG7M5)Y]AF"3:-,)E-<8PW(V0T48S#V4GD<5CTVG#=@^
MN50C\:;E7C,[)D61,Q>HB*%V/;&SXI=?8WL</JU5\I;9N76G"TT^ZRR>(Z6T
M.+::)$;[A2"A!*4QO*B0G6!7Z@ )!@$@9, D#M/33V5IY8_L:?&<C97<&MJ#
MN01*]H/RWDE8CB!<S&5"XEY$F#+(TQ46O?!;R8(B0C#1M)B+:YZ)?/ J-BK-
MTNVOV=S:H0Q;[E^$. JMF-VX"5A*@XHLMQ"@E:0XHH284D*.4@B^7 'E0=!G
MSF!V')[:X<-IL_GV&HUE&N.<+Q[$@"6$7T8(3:&8S"QN,R6&2>_$PZ3B'"MC
MF.!7:[N)B@\2.#WR#Y<.C&F+11O6UH/;Y.':3-RXP'[E=PML!Q+3CREN(=1X
MRI"P(6L .K4XE22 HK)G*B.\#$DDC,$Y!$P="=="*D;*9;.<A-W8L=*ML\X:
M%1#CQ\<R.8MDS8D!SC-1+5UXXS0=/4G@C,&14@;=Q[>FHRR!-4Q**OE<Y8SM
MIQEO:3!"BW?-%*QNJ*'T%*[1I1$$@0JV9*SC++15\%$U(4,PH9Z$92#[4@GS
M":UG7<+LQPSF,I#Q37&<'R!D8M 03V6Q<1C\$UR/+9.^S:% Q9]+1;QBX.22
M.F,&9" %F9^^R@ Y>,!6N*DR+AFUY_%-IW5LE:B^ZRPAU:6W%/++#2!;+6X&
MU A"%INFEI*?AIWEQNI!.6ZLB8*HG&20/),YY'>'GU.!-24_GO:>/CDIR,2>
MXI*3&.X^6W(R*"C">*9+F6K''N/DI C([0PB0D5"DEC</=M!@>0M#+H:T:$6
M#<9);0I!J[6XT6FT"MME*;A+2GO$D.J2^BVEYXME&\I W4.. J4@I"B0HE&^
M"!(5@9C>W ?* DJB-, G41YQ6PHQ3;)*9\J.C#/!Y3+<#"#'A &*;X_>Y.@
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MH*+W)V*ND$[KE;=U32KBZMV$%(6\W8M)*R0D*7;L(!40"0F3)(!,9@Z50)4
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M;*V=?0QPD%QZ[=?N'U>6$M*XBG?E&MZ,''Y=,90D&/I*8OLC.$0T/;5.#7-
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M9+QT@[=EY4;YKK;-J\CA-,/M-EJ_02"R% W:K=:/@I!<"%6^ZM3JUNJ2LD+
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MJ'T"N'K@J4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5:_$'Z34O\
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M32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E6OP_^DU+_ "B__P!9/7LG@5_
M37;<7'_F!]5=A;?>AVJ/NK:.OK*V*:4II2FE*:4II2FE*:4II2FE*:4II2FE
M*:4II2FE*:4II2FE*:4II2FE*AK'ZH,GY?WFP3GPZ_HWD7EQX<^'=[*O#CTM
MX\;E*\"O#/C"1#+V'[F ]\]M2QN1M5N:-'#FU.Z^3OJV44N13OI96ZEMU;:7
M<*W<*\.E=:ET%'<@$QO3 )CX/3.<Q7A'V:+&]O'/!SQ.SN;H-HVMQ#;V[SX0
M5'9VX%\)"]W?"5;LQ.Z8F"#XS>;L@KU!&>77]#'OS\$>'[FM/<7\16O0^OZ_
MUUX=]I-M:'8^U"1DCQ"Z G3/W*,DY@QB8DD4I'9!6G"@(QRX]!;W_P#X>GTT
MI73<7INJ]"3]!!_8>RGVDVU!'VIVGK,_:^[@ SH.#DY..W7%8I'9!7^X1GU>
M2WOQ\>"'/C7KV5^^W%_%5RSNGW?J[*#8>VB#&R-IC/.PNM ><,YUY^;3)>;L
M@K3^P1CC_DU]Z>VB%*T[?53CV:NXOFE1_NGW4&Q-LQ!V1M,ZS^\+L>:/N.F?
M1)'93S=D''AY",]]/T+?5X\J?^YZ>KAZ.E>+<7\57XIJ?:3;1TV1M223KLZZ
M/+3[T==,#/+I6?-V0<:U\A&>5/K8]^/G[1QY=O9STW%_%5^*?=67VDVU/\$;
M3T^076NNO!,1I&>N<T\W9!7A^@1CGQI_8Q[PKW_^@Y^CUZ;B_B*_%-!L/;)(
M_P!T;3/X)!L+HXSG[R)R ><SII2L=D':",\*]ODQ[3Y_:*?2G/3<7\57XI_;
MGZO6^TFV3KLC:FAR;"ZP=" 0SYNLCEUQ2.R#ZQF>RG"@Q[7G7_X'3G\7#UZF
MXL?@K/H_5//V==9]I-LB/]T;3@'^;[H@2>1+,F><'!$Z8K/F[(*_W",_$,?<
M.7_P/Y=7<7\57XI]W[:HV)MKGLC:F8TV?=Q(\[6 -3(&D]9>;L@[01FO7^Y;
MWIZO:*^BO'[U*\--Q?Q5?BGW?34^TFV?YHVIH==GW?.<'[D21I.I'I(&/-V0
M4YT!&>ZE/)C[A7I_[CA2OJ^/T-Q?Q5?BGIYO=[Y]I-M9_P!T;3SR\0NXS']#
MC2-!'72L^;L@X_V",U_^5O>//K_Z#LI3Y*=NFXKXBOQ3[JR^TFV1KLC:A[?$
M+L^?(:!Z<IQS@1CS<D'.E01GA7C2E*BWM.[EQ]H]-.'HK\D*%?$4>7P3S]&G
M6I]I-M9'VHVF1H!]K[O0D9D,1V@#KV4\W9!Q_L$9Z\/[%O:\J].'!&O7OKPX
M\J\>%.&FXO'D'\4X'9CT>WLJ#8>V9'^Y]J9Y^(79,])#7;J8D]@BGFZ?Y?H$
M8Y5^M;WKW?U#EPX4[NS3<7\17;"3[<?KJG8>V,_[GVGS_P#QUT(,&=6I\V@&
M!-72V#,G8/<2'(&FC@0/3B\M34?%$%1[.Q145=8E9>Y=)I(6WJ75I:G;6^VM
MUW"VWG773^$#+KFQKY"&G%K*&MU*4*6I1%PR<) 43 DF- "9@37WWV--E[3M
M?"NU=N-GW]NT+6^2IQ^S?:;!X!"05K;2D$G DR3 $C->Z/G5%_A(!^W _P#&
M->4^(7WR*[^;/?D5^D]U7Q3ZC3SJB_PD _;@?^,:>(7WR*[^;/?D4W5?%/J-
M/.J+_"0#]N!_XQIXA??(KOYL]^13=5\4]=#IUIYU1>O22 *__.!WXQIXA??(
MKOYL]^12#T/J-/.J+\/TR >'^6!_W_&=/$+[Y%=_-GOR*%*N:59["/53SJC'
MPC _;@?^,:>(7WR*[^;/?D4W5?%5ZC6/.J+_  D <_\ ' [GQZ?](]&GB%]\
MBN_FSWY%-U7Q3ZCK6?.J+_"0#]N!_P",:>(7WR*[^;/?D4W5?%/J-/.J,<_Y
MY /'_+ _Y_SQIXA??(KOYL]^13=5\4SYCKRY<Z>=48^$8'[<#_QC3Q"^^17?
MS9[\BFZKH?4:>=47^$@'[<#_ ,8T\0OOD5W\V>_(INJZ'U&GG5%_A( [O[,#
M^O=_7&GB%]\BN_FSWY%-U7Q3RY'4^CU4\ZHQ\(P/VX'_ (QIXA??(KOYL]^1
M3=5\4]-#KTIYU1CX1@?MP/\ QC3Q"^^17?S9[\BFZKXI]1IYU1CX1@?MP/\
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M_(J;JOBJ]1]W>#TIYU1?X2 ?MP/_ !C3Q"^^17?S9[\BFZH:I(]!IYU1?X2
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2I32E-*4TI32E-*4TI32E?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g30rn3tljakw000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g30rn3tljakw000001.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #T <X# 2(  A$! Q$!_\0
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MEHH 3 ]!^5&!Z#\J6B@!!T'T'\J6D'0?0?RI: "BBB@ HHHH **** "BBB@
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M(L^592;MR1.P/R."0,9'I7Z4_LP_&"+Q_P"%8='U.Y4Z]HT202B1_P!Y<HN
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M#W:BBBLS0**** "BBB@ HHHH **** "BBB@ HHHH 0=!]!_*EI!T'T'\J6@
MHHHH **** "BBB@ HHINY1U9?S% #J*@>ZMHSA[B!#Z/+&I_5A6)?>+?#>FA
MFO-9L(0F=V;B,XQU^Z3^E '145Y;<_&CX:6BL\WBK3P%." Y)S_GWZ5RNI_M
M*?"?3D)'B.WG<#.Q"!CTSR>M.S[/[A77='OE%?(>H?MA_#VV5C:AKQ@3\J2
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M46A_3_R?^2"\WTM\O\SL+_\ ;CLL_P"@:._(X\Q,\YXZC^5>?:O^V]XUP_\
M9.GZ8C9.SSX4/'49!3DX]#7I-A^Q;X(M3NU;QNJL",(ES H'LWFRQ\G.>,]J
M]#L?V=_@?HT*1ZAJ^FWC0 %WFN[0LWKN"S.>>X&2>XIWI]K[:6].MOZ\PM-^
M7W?H?&E_^UQ\7-5+-YEI"" "MLI55'L%7 SR>!WK#/QH^-&M#SK:34YAG8#:
MF7!W=N!U_P BOO\ 3PO^S=H+"1HM$E(&TH9(I%.,]5!0Y_X%1)\4?V<_"RM'
M##IMNL;9(M[-9!N&?NYG;ICV[47[1E?T2TT_'_(5GUG^+?IV]3\^5MOC[XHE
M)(\5VPE)(</,$(//R].,?ED5KV7P1^.FNR>7-=ZVFYL,;QY"I!X).<]<_E7W
M-<?M>?!&QC9+6]E>2+Y4B2RCB7@8X8,?Y<\\UR]]^VY\/8A_H<;2MGHY(/I_
M>'-%Y?R^6K]'_5O^ %H]9?UI_7_#,^=K+]C+XL:D@EN=<L($)!9+A\,W7! +
M9/3KCTKT32OV&7DA3^WM6@EG&-[0,=I_(^O^36AJ/[<:@-_8_AZ&\_N9=LD'
MIG#_ *_I7&W/[;WC^X#)9>!U^;A)(4:1A^&3@_Y^J]_R_JWG^72_D'N>;_I>
MG]7\CVW3?V(/A?%"AU"6_EN!C<8'V)Q]2>_/2O1M)_9<^%FDHB1Z;)/L& ;@
MJY/UX]!BOB:?]J'XUZN[+9^&M6M]_"F.TDV@G(&,>GY527Q=^TSXD<26LFL6
MRL,A'AE4 9R._J?IBBTOYNVW_ _KO8=X](_@C])+'X3_  XT-(RN@:8HCSA[
MB./GN2<@9K46_P#AUH6=D_AW3C'R=GV>(KCO\H]OQK\S;;P=^U9XJ=;>/5[U
M<9_U[21J!WR2X& ."<\#FMW3OV5OC;K<Q'BO6O*C?[[PWCG(SSP)?<_X"AQ[
MS_X:VN_?;Y:W!2?2/].WE_6C/NS6/CS\--&CF>3Q#9SF$']W!*I+;>/DZ\<<
M<?E7S]XC_;@\$6WF6N@:=?7=VK% \B%HRYX0+M3!R?7/^.-HG[#&@CR[C7/$
M>H2S#EHTEE<$XZ'<^,9]S7T%X:_9M^%_AY( =#M]0EAP?,NHPV]EQAF'))SS
MP12]Q=W_ $OE;=?.X_?:Z+\_N_0^/KCXU?M#?%.>;2O#GAZ32])G&(]0B@,3
M[7P%8L%7H&-=YX,_9&USQ RZE\7_ !/?:N[E;B&RCN"^PGD1R M@<'D'ISQF
MON:W@\/>&[<0P+IFD6\:<*7@M@$ ]796(P.!D^U>(^.OVF_AIX+DFL3J8U/5
M54B*ULMLJNX!P-ZL<\^@^I%',WI%6]/EKY>?^066G,[^NW3[_P!>J/6O"O@C
MPOX&TV&RT+3+2PAM8BK7"Q(DSJ!\SRRXSR!\W..OJ:\4^+'[2OAGP(QT300?
M$?BBZ BLK2PQ/''<,0 )@H/W21G.!^'-?..H?$[XW_'Z[;1?!&CW/A?1@YCF
MOW22$3V[$AW\PL,_+R.1CL<5]'?"/]FWPWX"*ZUKK?\ "1>)I@LLMY?9F%O.
MV&?RM[-DAN >E*R6LG=]MWWU_7\PNWI'9=?\D<!X ^#'B;XD:K;_ !!^,5Q+
M,6D%WIOAS=_HL0)W1B>$\#:,9R.2"*^K]?\ $7ASP%H3WNI3VNEZ;8P,((!M
MB#",$K!;Q@?>8\  8R:Y?XE?%KPG\,-)DN]7NDEO2C)9:5:E)+J>8+B*/R5.
M]%+8'W>G''!KYS\.^!_&_P >]9M/&7Q%271O!\$@GT;P\K,GVN)'^1KF+(^\
MN"=P&2#[T6;]Z6D>EE^6_D/;1:M[Z_F_Z\BSI=KXH_:.\01:MK,4^C?#31[L
MRZ;98,4^JLCJ0TZD+YD;X^4MGY?I7V1INFV6D65OI^G6\=K:6T:QQ0Q*%554
M!<X&.3CDU':6FF:!IL5K;1V^GZ;80A5'RQ0PQ1C&YF.U1P.6/T]!7S)J?Q1\
M1_$;QS;>%/AK"SZ#H]Y'+K_B$@K&QA/[VV@D#;67.5X/S=?3"UELK)?<O5_U
M^8:1WW=OF_\ )'U;134!5$4G<555+'^(@ $_B>:=4E!1110 4444 %%%% !1
M110 5P'Q*\"V?Q#\+7_AZ[<Q-<0R"WD!QLF*_*3ZCCG\Z[^O$_COKVM>%O!<
MOB/0Y2EUI,AN6C!P)D7:2AYQC /6FKW5M[B>SNKH_)GQ9X/\8?!+QI$K_:+*
MYTV[$^F:C%E$N4A<LJEQP4/0]<U]>WT'A_\ :F^';WL)M[+XH>'K+YE&U3J/
ME1DM\O\ &64#!R><#GMZ+I>J>"/VKOAP;2Z-O;>+[.V;KL6YBNXE?&SHS0M)
M@-CIC=TSCX-DA\=_L]^/89)TEM;NRNON*6%O>V@DY()(5\Q9]??BMKM^4EM^
M'IIY_JC/;S@_Z^_^O3L_@M\3]0^%_B"^\ ^,[=_^$:U*233-6L;I3Y<!.86G
MC5@  7;.>*O?$3PIK'P#\?Z=X]\-LT_A#79%U""2WYMVTZ3#FU<K\O(;:5/>
MO6?B/X+\-_M">!T^)'@%(H_$]A LNO:7"0L\CQ_/(ZQQ@,3N4G..<=ZYSX*^
M.K'QUX=U#X(?$P*]YM>'0KJ^PLMG<\K#;AGRR@$ 8R.GK1T;ZW7,F_G?L^C[
M_<'9-_X7KUM;_+R9SGQ%M1I][X<_:!^&PQ'??9Y_$%K;<+IK*%>82!?N&1LY
MX&:_1_X1_$73OB9X+TKQ%9.!++"D=W"6_>1S(BAF9>H#GD$^]?F_X$N;OX/^
M-]=^#OQ!@:3PAXDEDA%U<KF'=<,RVK6[R9&T*5.4P.:[GP)J^H?LU_%.3P]J
MD[7/@3Q9,)-,NV8_9;:*=U,7E.3LW ,,@8Z>E)Q3BEU^R_+3T].OW@G9WM9/
M22[/3[E^6JMU/TVHJO:7<%];07EK(LUO<Q)-#(IRKQN,J01QTJQ6)J%%%% !
M1110 4444 %%%% !1110!^;FI_$+]G+13#'!X/\ MW_$MT^1'RIRK6ZLJ>O[
ML84^NWGFLJ/]I_X8:'&%TCX80N!PBO%&^W!ZG(_J?3I7(W/[(OQ&NY[6666T
ML[=--T]29#&-CBW0,AY',; JPXY!S6]8?L<ZFBYU3QAHL3MTC\Z,,HX)R-PZ
M#/\ GFMKQ76^NFK_ ,_P?^9DN;HK?)(ENOVTIEXTGP7I^GJ.%'V6($+C &<9
MX_0_E7,7?[8GQ"F<M8"WM(V'RQQP@8XQT7G@UZE8_LK?"NVDC'B'QQ8_NU'V
MA(KF,'('S8^<#&1_GD5U-I\%?V8=%<--XLL92@SLDOT8G'J%#Y)Q2]U6T_"_
M;_/^M$'O]7;YV[?Y_P!=?E6__:F^,=TC*FMW$2R9&$BFZ$]MH]..M<E<?'3X
MOZJP276=4D] D%T./J%ST[U]ZQR?LP:!&KQSZ9??9VR$.U]Y4CJ3@G/TY_.K
M%S\<_P!G_2/+6#P]IDO&%,-A:,5&/5HG8_B::[J#\]EV"SZS7WM]4?GTUS\6
M_%+#RSK5R\I! 5KJ/)_I_7D5K6GP=^.NL?/;Z-K<S,!]ZZN!\O;K^)]Z^UY?
MVMOA!IKM]B\+D",X#0VMJA/NNVW''XUC7?[<WA2(LFG^'[M(QPNY.X]E4 <=
M.*+RZ1]=5Y?\-_P]A6CUE^#/FW2OV6OC)JF'U&RU*P9CR)+B5L<]3GZUZ+8?
ML2^+K@(U_KY0O]]93NV9'.<CG!/X_A6[J'[<EXR,=.TN.-LG;YT ;C\8S_GU
MKCKO]M_QRY46UMIRK_$3;KNR?3$>>/RH]_\ NK;O_6H_<7=_U\OZ\['I=E^P
MI GE/=^*8G8',J"W8Y'=<^61[9!KTK3OV-/AQ;E3J"B\(10QV[,L.K<@<?\
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M#[T_^(%^+;LEP3FB3M:SPOEL_K'Y=.^@UXK^':]Y\3X*U]W3Q3WM_P!.-_\
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M48'H/RI:*+OS_K_AE]P"8'H/RHP/0?E2T47?G_7_  R^X!,#T'Y5V'PS5?\
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M)?@KP!\.6CGOK;3-7,-O+=2Q(#]GMD\R/,DF,#ALG&,<U'_P2Z_;!\"_L8?
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M_!+6P1?3^&5GF.&CN[6))RS>C"+)/(ZD<XX-:$/CKX;>+D5=22V7?@;=5B6
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MWBI&F^ >(^:32^J4_7_>*/D_R/Y,CV^B_P A24=,#T5?_0117^I9_G*%%%%
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MQ]K1]K"G-TY--Q<H*ZUMJ%%%%>H<05V/PS_Y*C\/O^QIT7_TOAKCJ['X9_\
M)4?A]_V-.B_^E\-8XG_=<7_V"U__ $W(Z<'_ +WAO^O]+_TM'^KM\$?^2/?#
M#_L1/"__ *9[2O4:\N^"/_)'OAA_V(GA?_TSVE>HU_C!C_\ ?L;_ -A>)_\
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M_P!>7<+KI%?.[_R[?GW9^A47PS_9*A01_P!OZ<V.I.I/SVYQ:GTZ5HVO@?\
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M?U\_07NKI)??Y>O]?(Z:.;]HK0HLZE<6&M,A))M8%)=1Q@87OQCZYJ5OC/\
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MV2LDNBLD>*T5[5_PR[^UG_T;'\7/_":O_P#XS1_PRY^UH>G[,7Q<_P#":O\
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MCB;/Y@YK\0K'4OC]:VZ1+;^,B!G[PF./F/M5[^W/V@AP(/&0'TFJ_9^?X?\
M!,_:>7]?<?M%+HNB7',NEZ;(?5K2W.?J0G/XUSM_\./!.IDM<^'].8DY/EV\
M2<_@GYU^2EAXS_:'L$V+I_BN?WE64D?F":VX/BG^T;:1LD>@^(9"Q!R\4A(
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MI&?3->X5#TZ6\BELNOG:Q#Y$#!=T$3855&Z)#A0. ,KP!V'04GV6V_Y]X/\
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MHV_[3?G_ /6HHH -O^TWY_\ UJ-O^TWY_P#UJ** #;_M-^?_ -:C;_M-^?\
M]:BB@ V_[3?G_P#6HV_[3?G_ /6HHH -O^TWY_\ UJ-O^TWY_P#UJ** #;_M
M-^?_ -:C;_M-^?\ ]:BB@ V_[3?G_P#6HV_[3?G_ /6HHH -O^TWY_\ UJ-O
M^TWY_P#UJ** #;_M-^?_ -:C;_M-^?\ ]:BB@ V_[3?G_P#6HV_[3?G_ /6H
KHH -O^TWY_\ UJ-O^TWY_P#UJ** #;_M-^?_ -:C;_M-^?\ ]:BB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>gdc15tqwxkbk000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdc15tqwxkbk000008.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 'M ET# 1$  A$! Q$!_\0
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M9'5VE;3!T=(V1597=(.3E+.UMM/4U=;P&%B$I,/Q-V5WA9:BIK+"Q,7&_]H
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MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,IEN&XF7O28/7/>F*?0;D1
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M%=B%1D#'P,CG>+Y.#.,K%J^0\VO?.5;MS/2E/)$:J>UK*FPVI)A9,(JZ>,J
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M,UI>S8-:45.V &WR"29HDJ),>8#Y/HG ;6J4C;'$L/G1[:X@2KTPPC+4)BC
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MO?W_ .[_ $7V;[/_ +)_<OIOH?[S\6=5'M^-J=_9V?$P=_J=OI]GJ+W]_?\
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ML5HDB"'=&M/\&W,"WX/F/<E,5<%2"6E)!)OK:O4L>V*=BQD"*!;@<N!M_@^
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M:QQ6" !$UMQ.]J7)R4I4"4!BE24 6ZO!+:GBKPKW2S2+&B_JS'@<GZ*/=B?
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MQ'BEFU*Q(;(G!_4+5<D$2[D_/OF^>[F1#WOZK QIPTILQVVDXXX#/8BC=^.
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MC,A]F =64D>S @^1G/#;K3RV8(9XI9J4B16XD<-)6DDB2>-)D!YC9X9(Y4#
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MK+I*EN]MK%^]:W->S\-MI(*DLJ:3;?!VXYH# ].K)=;73"*Q*HALQK%6K(Q
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MK62RI:1(T$@.)J$NVG'2Z)+>+LP/LGM5-S@N4O+3)7.3N3I)*SYAJNG[ =)
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MAW>D*P9 >.2Q!(XR/@^SP5EJ%=H)FI1Z-$5Z(19AHK>UN1HS"VQC%MMH\4Q
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M8.]PHQ.:N2D(5,5+6H"6I9A(DU[-+;DC8'U88E:!32L,B,[%9B8E?ANZ*59
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M/]I;N*T+N4ZTLJWCA,]\TTQH?\Q$YWE)4K6[=*3]&$7LWI1$VS])THVJ] -
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M47_Q'I#_ .MC-#M&J;-J>MYW9LZ]1SJ9OAT"B;]+)*J/KGA 0 M#&VJ'!84
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MOQO?CSXWX_IE>((]P1_,$9Z2&5ORLK<?H0?^;/JSYF6-[UK6][WXUK\[WO\
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MV0%9_30J*YZ,44C5VB"]^1%I'UQC,ZL-/X%\9_Z]&J '^?LTV7VWX HZ\?\
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MM[\U:1/ZQ4D#HY2WGG[2+0>\:8@88-9)JS3Q\&-Y(WKS*Z\.%+*64A@"K<H
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M=NWYB"*/U'%]Z[_I[IZW+-'J+M/=;&[!!-+7.RFUIUL5:C/- \<OPH%^6U-
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M69-+4;T+T\)96VQ-(2TRACMF3?4OB:<%QUC22@X<O5-3Q@LUZU6V V8D>""
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MC"+O[+2?#OVS,J-\2OMSEE"E=%:NW6DDEF:DKVXZ$R2S9Y+:JE,1A CBTH6
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M5EF4HL5C@4YK=Y&LD"RMW^;Q"/RZ-5*6R2)KC\.AK[()DXI4+>06H7-Y;4E
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MU1"0N1-B0M8M1@*T0D5+%:9&$M,41XR6"-;OHD=R>2 ?XIW '^1]OY#.+?\
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M 4+"(PHC"=CA?1%3X(0\B7O">A^\']7O^?U>[SG1)T#I)6:5Y+QL.[6&L>M
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ML.ET=5=6IQAE8!E(^.O>"#R#_?E.VLTU?IS[6YH)9()H]W9:.6%VCD1OZ/\
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M W;7;Q5L1]L&QD#5V2KLT-6? /QRC^& /!^A\>/]/_Y>#XR07%__ %L]9?\
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M*(YXMQ^(3'C $A2K1.("1F#2J- YMN"E37+QX>7:S\\'RSWC"?/L3VUT/'N
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MS#  ,4^GU9P4P!C"$:C:?H:H!J-$!%O6S=D -+&=HO0ME!, (?MT,.]Q('^
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MWI_:AH*6AN[2YJ(Z.ZK;J.U1CBDG,]6GL*:1\3$*JE;[R=ZD.'C3CP3D)/\
M1(3C_C$^Q?\ QW=__:7-_P 8/]K0?\4?^;/+O_M=]K_[<_VE?^%;/_T[GQ./
MHYKY*B4,4V[QZWED4<@?3/D<<I@<I1.Z >]?,C4$NSD\MHP&AUX\+&M<3K?C
M8TYFM>W;XWCRL$*L/8A?(/Z_3-4_^ILEO1/4VGVM?:+L=?..RW2GV321683^
M:)UL3V82&_[)!*OU*')>VAZ?]23CCUMXNBKF]US6K.8P'-[FV 2O3]]0SR/]
M5+5RXQQT6G6N,A>C%B]W4[ 2#:E<H$E3IR=$D%:4L.LWKD!G//@^!Y';]/T'
MMGHV^^R#IW:_9O!]F.OGM:71UC3:&> 1V;??6N_'RRRM/PDLURT9);,G"@O*
MYC1%[47O=B<YU3<-+)Z(MB-IIS!26-C:-DK]G(EY2J/(243:_M;@WFD+F5\3
M?$(TA<VJ2#2]'*$HA&HE*E.=@LCH_J(>UN2?'\?<$'P1_ Y;MUT7T_U)TPG2
M?4-)-KJEJU:_;,6BF62G$L4%N":%DEJVD[2R2P.K+W/&2T3NC5CIO1=BT/$>
MCIWL'JVJHV<<:>".,TT3Z1I]GCV8864)B(BQ8P>X6_:)0F/4"#XV>><9[C!=
M1NLW'?#"Y]N2O_GY_P#-_#/"X_\ 4R:_6EX^FOM(^T#I^DS,ZTJNT01(78LP
M4U%H KR?!=&<^[N[<L>@53Z.G.4-G[7:-JS.V>D9DS*4JQOW<,E3.T>+6(3O
MJ$2E6T)D!2YYTF4?S=-[\]NK*=O]JEJ.#L6A8O=E*E45(@??L'!_TGV_F!S^
MA_68Z?\ ]39T5K-Q7W^_V?4/6VSK/')">I+R6*:R1-WQ/)62%9;/IO\ ,(;=
MJQ58_GKMYYL'N&FFRX2864Y/*YFU"Y<@ER7:%.G/^M4( B"!&?H_>OC(,]WD
M0R_YFO'XSRO[1OLWH_:-%TU%=V5K6CIKJ*IU% :L4,ILSU%=5KR^M^2)^\]S
M)\XX\9^A67NX!/'!!_T9V7/2,RSCMST?"+QC?V&6)!%+$GR&L4B0A* \L2H>
M@^\:0XP @G)%'L %<W*-#2JP! /82U1"54G\X^TO[+NE_M2TGW3U!7:.Q7[Y
M-5N*HC79:JPP'<]>1U99*\W:JVJ<P:"PH5B$GB@GAQ9 XX/]Q^H_^SZYFZDK
MA%4E>QVO6YR5.Z..@<@$N*THHA2H^Y/+B\CV:41O90/B-<1D@]F_R66$6_W;
MWDG]GO1E7[/>C]/T?2NV-C6TZWEBN6HXXIYOCME<V3^HD7X:]CW&B7M]T12?
M).%7M4+[\<_\IYS 4O3393#9*6QL>EST7*9:X2U0:O3ITXTJEP3I$XTA.D^]
MA&06%($01C_F;V,6M_C6LBOLT^S:C]FM'?4:.RM[--]U%<ZBFDMQ0Q-!-<AK
M0M7C$/AHD%92K-\Y+'GV&%7M!'//))_TY!V\?3=EER6O,[-0=M=.5HCEKBG7
MD06$RMR01:.A(;D2#:1G2$OJ4HA.:)&)88$"<K6U"DX7MWL6Q;]32R$15]"%
MN!QW,O)/\3G@_57V)['J7J#9[R'[4>N]''L9DE35:O8SPT*02"*'TZT:VHU1
M&,9D("+\[L>//.<H_P!$A./^,3[%_P#'=W_]I<S^,'^UH/\ BC_S97__ +7?
M:_\ MS_:5_X5L_\ T[F\UEZ84PKNQH'/E?=W54T2PJ7QV5*(A)9>Z*H]*"6%
MV2.AC ^)C) >6H:78";:%P)&2: Q*>: 18];V'>+V@RLOH0KW CN5>".1[CQ
M[C)71?83LM-NM3MY/M9^T#9QZO94M@^NO;*>2G?6I8CG:G;C:VX>O8$?I3*5
M8-&[ @\\9+[JGC2A^QHHW1>Z(TJ6*&$U6?%9='UWV:8Q0]> H"[;,[? K(&E
M7!(3[6-3L@=&94:F2*3VXQ4C2'D:8II(3RC<<^X/E3_,?^4<'^.>C]?_ &9]
M)?:5KX:'4]&25ZC2/K]C3F^%V6O>4*)36L=LB&.4(GJ5[,-BM(R1R/"9(HW2
MOY'Z.BF.D%M<'[NZ[B<=2AT4WLB.:& (1)P?@HDL+0L8D.@E@\!UHAM3@_'[
M2PZ_&NDW>?)KPD_J5Y_Y^<\?B_U-CTD$&J^UG[1M=3C';#5BV95(D'Y4 K25
M(N /[,*#]%&;#'_2EFK&_,CV;Z@G73L6SN[:ZF-;A,W8Q Y ;UI*L;>M+%(Q
MA,2+ D[3J0" +0R3!AV$6M^-XFV""/AX1R".0HY'/Z>/?.RG_J?MI5MU;3?;
M#]HU@5K$$Y@FVEAHIQ#*LAAE4W2#'(%['!!Y5B.#DT)#R1'9#V3!.R3I<])Y
M-!*L658DAA2%"-B7MZP^8G"=5"\>_N!:P&YBI"$DK6R=Z1$;WO\ F&>-(F(@
M:#M':S=W=YY'Y?'Z?NYZ=<^SNE<^TO4_:6VQM)>U.@DT$>L6*(U)89'V3FP\
MI_&$H.RD 5?D_"3]6R7&:<]$R*797*4>[*IDZF9-*WF&-ATG8I/MZ8D2)>OT
M>Q?6?"ETG<-Z3_"?]8+Y!^?>'V!]O]=YN@F,#]X 8\$<'V\\?IGGWVE_9_3^
MTOIENF;VPLZR!K]2_P#$U(HI9N^IZO;'V3?)VOZI[C[C@<9*%N1A;F]"W@&(
MP"%&E1@,%K6A&!2D (",6M?C0A:!H6]:_&M[_'XS2?))_7+[#&(88H02PBC2
M,$^Y"*%!/\3QSGV8S9C&,8QC&,8QC&,8QC&,8QC&,8QD">LN.7FU)9%^CN=)
MPFH_L6L&PUJAMD&HSUL.L:'C4A7+J;O2/(]A-EU:O:@.QIU  F/\+=#"Y%&A
M[5)QHE<MK]DM>.2E<B-K6SMW20@@2PR<<"S5<^(YT'T/"2+RC\ \BG]1=,R[
M"S!N]);74]34(S'6O%"]6[6+!WUFW@7S9HRL.5(YFJR$3P'N4HVETSZC,4,E
MS=0W9,4-XZZ=V'25/%;$<2":GM<TDP*44AHBWSA@B<T97(\9'TS"L<4$N;UJ
MO[&8W.:M"H6#V6=-)Z9M:Z3[QI>"9(5)L0<CGLM5Q^)&R^>6 :,@=W< >,Y=
M7UO7-E-/U-7/3.__ "BM=<#7; J>WUM1LCQ7M12'CMA9TLHS>D8W92QLI"+0
MM:$'>A!%K0@B#O6]"UO7G6];U^-ZWK\ZWK\;UD+EZS]QC&,9![I#O^B.>7M-
M6B12]79T6^;VFA_--)(@SJW7UP&7[R1.[.VF&)8(PE _O;C))JJ9FY(V$JUB
M;3@8G^E,DZ>IM7$,Y"UJ:>9+MD^E70?7M9O,K_14B#,6(!X!Y%3W?66HTLJT
M5:7:[N;Q6T6J7XS93.1R/4BC)6I"!\SSVVBC5 S N1VGD%%\JW+<-N1OK_O<
MQA/LF(B-6<]\Q15R$^U-S 4N*]IC\X.(O"2RKU4)]EDNL\$1MG8%19@(>#X$
M[&H9NFU?K5Z[Z_5=P@D\6[LB]MB]Q^X![PU0>>V+GN<?M/)8-&ZGI[9[/90=
M2]8&%KU8E]+H*\AFUV@#C]L[GY;VW9>!+<X]*%@16':(FCM R#R_8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,9#+I?B;E#HM_2V'?T;=#7E/"S*B4R!JN*
MTJG(>H'*GX(Q5[)OX?SR&M\F8GZ0.NDY;(_%N!;@N<M(2BC1*BR!25+9WZ:&
M&HZ]IE%@(U>"P5EC3]LGJQ2,C*@Y+(1P%Y/MSE7WW2G3N\F6[N()#*M4ZTS1
M;/8:X2T[$O)IS_!W*J3PS32<"*8.'=^P ]W!VGGGC+GOEMWE\AIR*R1KD$[:
MHJPR=^E]GVE:+RM880!T!$V-,Y6?,I@K:F=C"\N043<TFH4N@J-!,+,"G3:)
MUV]C;O+&EF1&2)I'1(X((%#R]OJ.5@CC#,W:.6;D^/'N>>C2]+Z7I^2S-K*\
M\<UN.O#8FL[#8;"5X:@D%:)7OVK+1Q0^K)V)&47YO(/"\;!??+=*]+E1+5M1
MY^<%T#6/"R(2"(6%8E7RM@%(D)+9(4B&65C*HA(]-;\A3)4[RSFN9K4Y:1HC
M%:,TY$D,)QJ7K-+U/AW0"4()$DAAGC?L;N0F.>.1.Y"25;M[EY(!X)YW;CI_
M5;X5OO*&9WIM*U::M=NZ^Q#ZZ".=5LT+%:?TYD"K+$9#&_:I9254CEO/G%_'
M_--B*E%)1L3)8+% =,"1A=[@LFQ%L!K26/H5WT$3A]@3R5IZ^BDGD$/#O9D<
M:65$\K(R))HY1II,()W6]EL+L(^)?NB>;O+K6AA$L\:<<R20Q1F61$D]G9BH
M?G@=V1^EZ7Z:T5UFU4'I78J?HK#)L[UUJ="S,'[*U6Y<L+2KV)ZH\P1Q)*U?
MMY(B*B5KS"(C(I!#Y8^1QH=9+7RYW<H0^+D1)[G%E[^QK8R]JV16,.S4!SK'
MW)<T+A$B#]0A5&D&>0B_'"LLB))&CLJ3!5E0$A9 C!U##ZA7 8<^Q .6*6K6
MFFK6)8(Y)Z;R25974&2N\T+P2M$Q\H9(9'C?C\R,0<AO9WII\?6_(9[(9Q!)
MT=NTG<U_L:-QR^[^@T FKVJ3(4C@Z2"N819T>@JQ<[D-B +TH_3X#'@U,%4Y
M;4JQ&'CD8-UL:ZPK%+$/AU[('>K4EEB4$D*DTL#R@*6/:._Y>>!P/&5B_P!"
M]-;.>Y/;J6S]X2F:]!!N-Q4I6Y65%>2>C5OPTW:58T$I]'F4KW2=S<DYCFGF
M#D6!R=SM^AESI/9,VI974ATV?N@[5Z '%2V^0H SB#M"JQK'GR*(KBI%&6LB
M4M[2!L<AJF5$D=/<!,65K"[=V$J"O:"Q(3'8]):D%3O+(3%*PAAB,@[)&,9;
MN'#DK[YMT73_ $W3L/LM0\MRQ&MC7&W-NMCN37"3)\74C:[>N)6<3P1BPD8C
MD[HE63\H&3+=&Q ]-CBSNJ4M:V.R%6V.2([6]DJT"].8E6)3=!V$6RU"<TPH
MS01:W[1[\;UO\Y'*Q5E93PRD,I'T(/(/]QRSR1I+&\4BAHY$:-U/LR."K*?X
M%20<JHE/I8^FG7S.TES)FEL)C[RA;J08")#V!TI'F=Q99<O 2V4XSDN%W)$:
MIDDCD$L"2 (PC1.BHD&RVPX9/D,\F]W4S-Z;1RNK-;<IKJ3L'C7YK+%:Q(9%
M]Y3Y4?O#G//+'V>]"TXHQ:CM58)4351";J;>P1/%9<"/61!]JJ-#._ 6F@[)
M& XC)'BTR.1YFB4>8HI'$!35'HRS-<>86L@1HR&UF94)#:UH"1'F&G"*1H4Q
M"<L1QIANP%ZV88,>]BW!.[2.TCGN=V9V8_5F)+'QX\DD^,]!AABKPQ5X$$<,
M$4<,,:\\)%$@2-!R2>%10HY)/ \G(X7MQ?S[T=,(S8-GQZ8BG$0CCK#V*60*
MW;=J-^)BSVX)'5SCZQPJJ<0T]V:E+DA3+?I'42THI07[R=%[&/W=E796Z<;P
MP/'Z4CK(\<M>O84R("JN!/%(%8 D<KQD'M^E]-O+,%R_#:^+K025H;%/9;+6
MS"O*ZR20N^NMU3)&SHK]LG< PY'')R-O*7)_IS1VS3)-S&L%*YYRJ\RBKR6K
M^T1<]J-E'/<@9!LLFCK7"IO94HC,7/7,IRMD-/0,Q97N2NC6G4Z7M*\A'VW[
M^X>#LNCTXKZQSEO@ZT!M*K!XW:6*"-WX8!QRWU5N.UAS!].].=$07S/H7^)N
M=/2V->(_OO:;&/4RS1&*>".K:OV(*Y>(M$2L0'RR1JW?&X6Q*+PF(PK]1?I*
M.-$=_5LH=IM)OM*(E']]ES]]/]YD;G\00_5.[G](F^M6F^3C_@+]XM^W61#R
MR2]GJ.S^G&L2=Q)[(TY[47]%7D\#V'.76O5K5?7^&@C@^)L26K'IH$]:S-V^
MK/)Q^:23M7O<^3P.<VC->=&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8R/?2K?RZ]UNO8.MA4H.K''8OJT]Z+X<W17Z@H M 6)EDR4I$:%T1A,V
M-(Y(5"=R0&"">D4D&Z"/772-Y9E?7_$^N/8U1(TG!]QQ&"2I^JD$$>"",AMZ
MF@EHO#U']U'7O^8;=ZJ5N0..X-:941UY^5U970^58'SE%KI)?32I1<-!REZP
ME@\N(TIHBVRO8;<R7H:B&?6_R(+3!+-8K):49/R>W8?MLI2H=%>2 E?$ G1%
MI";JR.;_ $]#>)\M,];X.TWT^:6!H6/\F0MSY]_?R22?H35/V=._:9<Z?56X
M2E5VJ;K41_[W4V$5^)!SQP8["IQXXX XYFK[=ZC>>IN7^9*+]6^D;W8>A/U^
M&26ZW<QTLG6U .'1Y2^LR1[8F^7E-3P[3':%8@;TJX,1V \LHQ(F<=J0)@;A
MK:"T;MZUT_9JM4]+LK&]9(L>HX1BK-&618^0Q(]3D>Y ')X&ZKW\O4.@T&H^
MT?4[>'<_&^OLDT.K#:PU(&FC66)+0CEDM=CHBO\ #<'@J).X*+6C?3PN*R@_
M%TUZC'65K-)@=@71"JC('RY"WI,;KVJ&Y]0U''R9*Y-)Y6]E#1_JX@8P;W\Z
MD_SOS _>]:'_ !+3T(&^DD_JWI5X^JFPW8&Y^OI_R ]\]$/1>SO>-]UMU%L8
MSX>MKS4Z?JR@_F25=9"MAXR/!3XD<_5CDPN?>3N<N5V)3'Z J&'ULF<=A$].
M;2B-62J1F!%[PG2F:/)[E+I0>$?DP!S^]N(RQB&(L0-B%YC[=^Y?</;L23$?
ME5B!&G\(XE"QQC^"*,LNFZ=TG3T+0Z;6UJ*OQZLD:%K$Y'GFQ:E+V;#<^>9I
M7(/)'ODALX\FL8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QE)/K#<\6)<
ME"WS8$^F8 <^T)4Z:RX!3\+<'YK=IS94=="GN83.W'4@+?H]EB400K6NNXJR
MK%"4+H[NDO>UA;DV,:-+9NG;D-:U4BBC_K=JP89K$H4K% Z]L<==?FX>20AI
M9& /"K&H[2Q/E7VF:6[L]/N+ERUQIM/K1>IZRJ\T<EN_!()K-K92*$[HJU9&
MCI5XF91))):E821Q*MDW,M8V/4,+<H-,;C67=#&QW+%3,KE"$S^)B"M%#<C-
M:XU9,I"K,23][85(E*%NFH&YJ='MB+;SY"6L>_K%Q\+=GAL2"6.N*TC+_68T
M/X!F!/<\$?',2N."T7+*C\A.$X47G0T+VMJO4M;-MK6CD'W78L(?CTH%%,<%
MZQW%;DT+=R):$<<DL00S=\O<[=Z?_OOV)Z_2_P!I_4WVEQ_3OW_ZS3%]]^C.
M^T?>MM^MK_M/W#Z?[C]#K:SZ/YOIM;.]F<J]O<O?W=G<._MX[NWGYNWGQW<<
M\<^.??QDQ-ZOI2^AZ?K^F_H^MW>EZO:?3]7L^?T^_CO[/F[>>WSQG\]J/A*>
MQ;U 6-[3])39J[#L#D=_NA;T.$"MPB,EM."73&V":P=VJ92Z)6%TH0^'6/"X
M6V5J4H;EC''8G'7UI>4$L0J'A3;FVL4FH9/@HCKHM@E9:?($J025I'BE%@*7
M6V)(99&GX8.\CHRF,]N>,KTE;K]8Q2KO;4?4UWIN;:/N@&>O/L*>U@BM59=:
MTBPR:=JUZK52@&1H8*T$L4T=E#*W]$2;2@*=.%882:K"25I4:F),3IS5&BPZ
M/,3IS3U1I!(S?<(HDQ2H,*+V$ SS1!V8*H'CD\<\<^.?)X^G)X')_N'\L]I7
MN[5[B"W [BH(4MQY*@EB 3[ L2!X)/OG#^C:TL2X:R75M7=IK*;-ECJTM<TG
M3$V[6S5'7!QXOUHUUXX"6)DT5G#^UZVS,TS4IG;]+ 6JW= V&NZ=M4)>FG-#
M7G$TT L^FK-%$YXB,P_9M,."9(D;YFC!7U. I8*3S$[NC=V=!Z-+8-K#8DCC
MM6XH^^TM$G^M1TG+!:]J:/\ "BM,LGP_<TB1F149:F/2^Y#8Z>L/H=QI*<R6
MJVJGNT>AZ>LJI]B52R#6S5ND[7.:<"Z(7UV^KC<_@;'8,:*8[/:CSW=WC:%9
M%Y,D?4BM*J:;!O-@UB&F+,26&LZVG9AL>(Y:\_+16>"B\212O"Y:%AVJY#H5
M((;SKH'IJ'67=T^JMSZZ/6=4;K6W]=RUFIL=>5CN:OU%FD[H+E2&[7$5^,M+
M) C5["S*RM'>[E5SUS*-O5BY.(LF V+T1>TK,L& 5#+.=5-/4PE*<X[#H/"O
MXRU2#H"43 U$\?43">SB,FRV/I7_ /V+2P^ @*;&9(6ZN;R[G6C07_1E@IU8
M_1EL1W/B;)[7EEE^'L&HD7*\1Q1/Z;%/F,DOS-R%5<\F^T3IP7J=W=;>R;M+
M6V=(VLU:B2&M4JC::[[YL62DO-JY;KFS"LWX:UJ?$<2B2261K5>>:DE5'P =
M<R.W95<K4R/SB&OI!.T:<4XC]>#)1!CT(E<H(5&FV$Z1DPM>G)G3DD;'IW:3
MFU*\IECFW*GMV@;EA+4WK)7CK,ZKZR1$^D\WGOEC0C\)9/!,0+*K=Q4A2%7T
M/2ZVQJJ9I3[*QLXXII/@YKBJ;<-(A?1J6+ 8F[) 0ZK;D6.62,QK*KR(TLF=
MO"OI1:U62VNH?9L@IUXER5$SFV+$D*-=+&!B/=$.Y2"+#7FEIV>1O$9 [,3)
M)_:I41-Q<T\E1(UBUJ3IC<:LT=>>.:2!+*QDMZ,A(C=PI]/U.WRR*_:[)X]0
M*4) 8G-NVIV-AK[%*M?FUDME4C-VLB-9AA,B?$"N7^6*:6 2113\,U=W6=%9
MXU4U$<J\-4U67<74#;38Y#1SQ0TPYDF$345\X%E FM-6%1L=CDLJFT$+VG=4
M<[B<OF-1RF1G.KL49+66;+7"8L$B;I L=53A8+^TLSZNBUGMM+:CO1R>L.?3
MLPV7>.>!E*F*2.*Q&@53Z;1@1NA0*!YOT]TGK*'5F_36>MJ9-1:T-JLU-P/B
MM7<U,$%G77UE61;E:S:UMB<R2 V(K;O9@FCG:1GO.RKYZSC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QFG6#84(JB%26QK)E++"H+#VI0]2:4R%<2W
M-#.V)=:^10J5';UKW#&(LA,G+T8I6*SB$:,D]4>22/9%%+/(D,*-)+(P5$0%
MF9C] !_I)]@.2> ,YKEVIKJL]Z]8BJU*T;2V+$[A(HHU]V9C_'@*!RS,0J@L
M0#5N@MKM+U ?[YS<<LXMY'7"&%NZ(G<1)>>C;L9A^ A=Z;JZ1%EM%8PIY3;.
M$T3R=E*Y*M1J6J0QQE3"TH1E3K5];J#Q= V>P'O4BD[:59O[-B=.6GE4\<Q1
M<("&1V]B?/TV75/67SZ,MTMTV_[/=7*PEWFUB/\ E-9KYQZ5"K*O/I6[@>=T
M,<T,*^5'9:X]*[C"%.X9E-JW5])VD=HL3K;?53^XW[.GA25YV6K.W/!N$7:S
M2AB$80&.1EE)3C%[RB@C"$6N:;>[*1?2BF%* <]M>@BU(E!]Q^$%=O'CYW8\
M9)T?L^Z7JR?$VJ+;S8'CU-EU#,^YMR,/9B;AD@C(/) @@B4'R!SDX&2MZ[C2
M$+9'(%"V!M"7\(6]DBS&U(0D_P#8@I$*$A/HO_N>B_;_ ,F1;33.>YY9'/OR
MTC,>?UY))RV14:4">G!3JPQ\<=D5>*-./T[40+Q_#C.-6CQ?R1=2-2BM3FND
MIMI4'81KWFMXJ)])WO7MV8AD:=L3O[:?[=[#I0W.24_0=[#HS6M[UG3!LMA6
M/,%VS'_!9I.T_P T+%&_X2G(O8=+].;5678Z+56^[W>6C7,H^G*S",3(?XHZ
MG^.0V6<$W?S,'<C].WHJ3P]K; Z-URAT<_R2X><']&G%[PL$5>WM:XV?3)I^
MMC]KM&GYY2FG 2D*FLI)H\S)(;6K=/9N*:2%O^KZ2)6NH3[O(J@06?\ <NBD
M<DACX&5END-MHN9^BMW/61//]'=Y-/L]',H//HUY96?8:LGZ25YI4Y"JT87N
M.=[Y=[=8KQE3]1MJP-]YRZS@C?IRG'/\Z5IUBI<RZ-$G#.ZHEZ4LADM:MUAP
M1 (DT=U\R$W7PN[<A 8B5+N2]JWJQK:@E2YKY6[8K<7@!N.?2L1\EJ\PY_(_
M@^ZD^0)?0=5P[:Q-J=A3FTG45- ]O36V5F>+GCXS765 BV-%B"!/#Y0^)8TY
M4M.?(O+;C&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,XST= !6OSU>]7
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M<@VE?3[7]>RA'.(32,QLC]:5M'IBUIE:=B?"'64LKK;J]-&Q+3%D:B+S:;E
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MO1LH28Y!V35YD8QV*MB,^8[%697@GC/E9$8>1P3V+.?)/*RW@7]A_JDR5_\
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MUXT6U!K>C#9,8Y [*K<F>)87*#I!5$STWV535G-2C2U L@+NNEK8@=OB4#E
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MC6W/;8XLKNB3.32[H%;6Z-RPH)Z1>W+TYB1:B5$CUL!R94F--(/*'K83"C!
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M9'56_*S*P#<CD<$C@\CSX^F7>.Q7E=XXIX9)(^?4CCE1W3@]I[U5BR\-\IY
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M:Q&)RS#E(RA;Q-(H9XH3Q-+&KR1HR([#N&<N2V>HL\D[9H23BC1$&[(/T68
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M1EN/#Z2=T)-BG)!)\2_:?37L8F(]R=TH5>3SP>T9S9*97_ZJC&AD/IR=F('
M)8B$]"SA\+T;_ATNC*#]2-@M>?'\P#DTI!D_]V"#QYW^,EM$Q3<:XCW-J)?[
MG/8?^1CSE-^T*))NB.J$?CM&GMRCGV[X$]>/^_U(UX_CQD>>9I[)N'&NDJCM
M]X<WCDBY(_""^<;AD*PY:JHB:RMC;UZ;F:V7Q8(1FH<M7*3DU#3QV._NQ.BJ
MPD*L:A%&EJKLNQ1[0V;%=5785WE^,K(.!;C1R#=KJ.!Z@ !M0J.3YG0<>H!#
M:*W8Z335ZW92O+TYM(JHT>SG8LVHM6(D==#L97)(K.[%=/;D;Y1QKYG++79K
MALKN>EXQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC/C<6Y [MZ]I=$:=P;'1&J;G% L* >D7(%I TRQ&J(
M,T(LY.I3FF$GE&!$ PH8@"UL.]ZSZ"5(920RD$$'@@@\@@_0@^0<Q=$D1XY%
M5TD5D=& *LC JRL#X*L"00?!!XRJOT\Y"LYUFUI>FE8BY0%ZH<]?8/+[N[J/
MD469R--'U:KB>T*L\7SNCW3SZH<*WEFO84%.4C8MHBCD91QY<[MT%R*#=0@=
MMH"&\JCQ#L(D DY '"K80+-'Y/)+<GGQGGG1<S:2WL.A+KGU=07NZ"20\M>Z
M;M3,U?M8^9)=9,ST;/@ !8>T%>3EL&0.>BXQC&,9!"]'UTI7IV ]&2*#S>14
MPDH>>U/-Y= &$V:KJU=WJP:_F+7)9;"V4P^;JH.-MC3L2Z2&(1Z4;CAY9*N0
MH6UD$>[II6JJV:,M-)8DLFW%8BCE;TA,J0S1LD<K<1"7EU*I(\??[(6;A34=
MO-)JM]3W<U2W/JUU%S76[-.$VGHR2W:=F.>S5B+6FJ%()!)-6AL& @-,B1=T
MBRL:;<JM]KHNWV>R(*Y52:S&R$-DI)6QFP4+$G"(2EV-E05WV0AO2: 9I6J.
M6EE)!EF%J1%#+&$/ U>PLWPS02BQW!/0,;^KWGV41\=Q8_0 <GZ988]CKYJ0
MV45ZH^N,1G%Y;$1J>B.>Z4V._P!((O![F+ *00W!!R(%:S3^T=UM"+YK2+RX
MVAZXYWO"L4EN2-F'%HU9DLM6R>=90TCJMM>S4DLED3:FFH9"-?/]QU!"78YP
M9PPY]E!!JU0AD9XO@]?+4G>,6IKE6<UT;U'AC@@N1MZ[)S''(S6$XB[S*O#>
MHB<#NK5&U]^=1U-O0KV3J*.EVU%=E/$:\%^QL;VEGC^[XY2MFQ7CCULQ>YZ"
M5)"\7PLU@%RG/_4FL61S-D@W M-NAB>\>S3ED2>W)N&$Q35'-J,0=7G;#R$&
MA_0IS(K]?"(H%9M)]]DKZ-,T*#5[4:1FW2PI&\NVLJ#5UH$BJWM/</\ BM=?
M()/J<2R=O/8B<L &!SCZYNSVHJG1^KD*[;J@M6E=""VNT2_]-]E+[]BFOWU*
MW=V^M8F[8F+QE<L7@D)C5:PB'5U#&TIFB$"B[!#(LTD[WLILCL8:DC*RH"][
M_<(*1N1)B-"%^X7Q^X6]BWO>0\LKS2R32-W22R/)(Q]V=V+,?[R2<NU.K!1J
M5J55!%6IUX:M>,>T<,$:Q1(/]RB*.?KQG-#^6^9%*52A4\Z42H1+13 :Q&?4
M5?FI58[#,1G3\2E.9'A$GBG)K<WFS 1H![DQB!&-ZVM$E(V#<+]X$$7+0(]/
M@BQ-R/1Y$/![_P#)=S>G_8Y/;QR<X#T_H65D;2:AD?XHLIUM(JWQI4W>Y3#P
M?BRB&UR#\044R]_:./:MYCYL<C'4UQY[HY>:^C?#'PQ;4\"5&/)DG=61^DAC
MJ,]@,$XCD+Y&HX\O@E>SA.SK'V1Q7[4+&I <0%ZZO:!<M#L[0O%B4=O8K(G;
MP_R]BNZKQQVJ[ <!B#];0:)S(7TNI<S>J92VNIL93/)%-.9"827]::""67NY
M]22&)WY:-"#AS'S:[&%'.G/U)N)A#D_/)(EM5P95['B521LF,G=M:.8AZ^YR
M*7,K/*7Q?O6U;K(FMO>UQQ[DD(4@"]=4<+<M*"J+XL2CY8T:)%\/^5(V:-1[
M*C%0 I(P^AT<A!DTVJ<K)-*.[7U&XEL3QVK$GF$_B3V8HK$S_FDGC25R9%##
M[$_.G/J-0<L1493Z%:H"J"<N0UI#$2XS2Z9EV0L]RQ*RE*?<JL0DF?'CT;H1
MLU)*E0][?BP+P_#<N$=IM62HX^4SRE?$7HCP6X\0DQ#Q^R/I_D\9DNDTJ,73
M4:Q';N#.E"JCGOM"\W++$&^:Z!</GS; L'\8!\\=\X\\[/2JMT/3.U2']*?1
M*=U?"-J$GZ#:G9B@_P!,?MCV:1^C6-_?6:*;*$']/-3T[-[1]&D<5A)SXRYP
M1\79X/J<CUY>#ZS*TO([O/JLB-)_;95+<E1P^X])RK?<^K[D^'[&^[ZG<OP<
M<D-3M/I<CX6*:6*OP?P8Y9$C[5=@?:FYXH%&C"W(Z0J-(VAB9D#"VI:XAZ=N
M!"#67]-FP\" EG D#&3(Y_M?,8@DZ;!L?^Q DVV_^[Y\-RV3W&U8+>IZO<9I
M"WJAN\2=W=SWA_G[N>[N^;GGSGU=+IT7TUU6M6,5C3$:T:PC%0Q>@:W8(@GP
MY@_!,/'IF'\+M[/ES"J>5.8%K6%C6\Z48L9@N#V[?:5=3P12VF.DF;$3))'(
M]$>Q&)E"Z0,[8VM;XK/+,/=F]M;TB\Q00B2@*S%^\&[Q<M!N$7N%B4,%C8N@
M!#\@(S,R >%+,1P2<U-T]H'C]%])J7B[YI/3;75&0R6(UBG<J82I>:)$CE8@
MF1$17)"+QY+.5^8UZ[[HMYUHU4Y?=%SYM>=4\$&K$].;^QRMR>!J-L/RF.J^
M3QF.R%:XC$)8J>F-J<SSAK$"8XL+]X#M%RT!VA>/B)>.T(T87CO_ "A'= /8
M*S*/!(P_3V@=^]])J6?U'F[SKJ9?U7FALO+W>CSZCV*\$[OSW-+#'(Q+(I&P
M(J"HQM-1GMU-58WG-\@=96A-10"*I#$DG?9&VS!YD) B&HO9;TZRYF9I4X.0
M?"Q7)69H?3CANK6A5I\#;M-R&LV""BQD&:0\HJ-&J'EORK&S1A?8(S*/E8@[
MDT^HC*%-7KT,<TEA"E.NI6Q-.EJ692(QQ+)9BBLNX^9IXHYB3)&C+]3;2-,L
MJ&,M;-4M:L[7"U:A?$&QI@T9;6Z+KE<A;Y>J5Q] B;"$C0H42UI:94><@)(&
M;)6IL?ABVZH$BLGXUJRQ=FL3,T@ D9I79G 1HP')8EAZ;-'P21V,R?E)&91Z
MG5Q)!'%K:$4=5B]:..I D==FG2RS0HL86)C9CCL$H 3/'',?Q$5AU#-&2&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&1;ZCYG1=!1^-N\<DJFK[YJ=V/E]
M"W6S)"U3W7DO&GTG5)%Z,8BRY-7DR1 #'[(@;B9MHED=-&2:$AS1-#DW]]"\
M:;NKH)ZEA?3MUF/"S1\\@@_N31GYX91\T;_JI937^H-$NYA@D@G;7[C72&SJ
M-K$H:6E9[>UE=3P)Z5I?P;U1SZ=B$D$"18W2K7D[H.3//JW69 [C@IU1W=.>
M*X:TV?#?*M5%7JS:.LZ0%HY95DA4E@_5%:3NN)P"4Q!?L7W-M V2*-R,E.^1
M]5L^<OU$7I^"6O*+%:/9RF"3P'6"S I,<Z#S'/%-&4D'Y6[D="5<<>?].[J>
M7[1[U/9U&UNVM]*U8[]7YFKRWM3L)PMG7S-^WHW*5P6*S_M$].>"<+-"_-]V
M53/8,AKUK_NPXF_YY48_]!E_9):_]GL_^YK_ /C53*QU'_C/2O\ WSU__F3N
M,B9U-'Y,KGW?];,[4Y/,SOWCNJY16C$T[&![L^&5.[6=&;IJF)B",HU4_I4$
MQ:$_V\@T&]G70T& &7]0J,*[Z+H(=3,S*L=38SI,S?D@DL+ ]:Q)X\(3$YY/
M/BLWZ#*[U!#.]SK&C'')+:W'3.OL488R1-L*NNDOP;37UO(+3*MF)>P<>=I$
M>?F8CH#9$=V=U79\1FEG7W4S]&F*I;*Y%B]?V#*:J@^J&;8E"D4P$?5Y&@P.
M=2IMN/\ 5T7M>/6O!Y<IB<*D-7HVYK82G="H,TM)Z-""2*"K81VL0["26%)Y
M?BFDD,?$Y_%BC-?TWKO!)&))4G+%RK#.R.M\?U#?K6K^XUTT$6NO=-P4[MG7
MU/N=*U5+/-!3\';L1[/XFOL8=C4LM7JS4%2.$2(QT*P;0MZ+G35T>;,/IQBN
M8Z&1F9.0)\T7"U\$=EM#1#G&(1F9.R884I7-][-&H24[MZY%%$S<O?R%;@@B
M7\;SSXWNA@KOZ06$66K>H\:^BU9MMK6:02O$IY)NU&]7M8-)RJ< R?"@2<=W
M8;*NUJ26^=9#M#5KVI!<BV471_4\455ZU>U*.%&CV\?P@E1UKJCS!G2M]ZDP
M3<8&^Q; '0TXLN-SBJYTT&24F:P.)RJ/26!HG9$4L3&+71\;W0(W6(R4;4!;
M#586X4@.97YL0RN/1%[$[H6OROJCH1-[U?TGU-6ZMW^OK]'SW9UU&NLO4UW4
M"["*)!%M:Q7B1J_;V2@ET>(SQ1-VNLQOFONW'IUA?UQJW+(9+4:2PV8:LD/J
M R+.D@+U[!0/5;L$W9+$+$,$OJ1QR>RYYVY6;ZO;TL(X*MN L0_=,KY>*TYY
M@R#6M;-=I+<=D1>';0$!\ZV,P+$N?%X@!\B$2A-T'7N\9-=/*#M:\K_LZJSV
MY3_92O"\G/\ QPH_F<HGVE2L.C]E3B\VMQ+0TM1/K)/M+U>KV ?4B)Y7X'GA
M#D[9/4]>3BKW&F9O%FJ75J\Q0N%/,4?DX5K:Z1XM"4@ C5%[]HM&%E$$FIU9
M B5:-820M1'IU9!!Q<6D\T4XLQR-',LGJK(AX97YYY']Y\@^".0002,MT^NI
M6Z#ZNW7CLT9:XJRUYE[XY( @3L8'SX !# AE8!U(8 B D'LF;\&2F/T9T=)G
M>9\OR1T11GG;JF3*1+'* JUQP4D?HGI=[,\!3+BA"(:*UN=QV0U2].%(PS%0
M@E18%CO+2PQ;6-[5.-8KR*7N4(QPLP'E[5%!YX]VGK#DQGEXP8_"TZI>M](6
M(=1N[$MK03R)!I.H;#=STV<]L.HWTQ_*X/;%0VC\1VE[8;3)9 :6T#6_/YU^
M=;_.MZ_SR#R_8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,9"+H#K-SCDU_LY\TQ1!=G5CJVIEYT8.6GI*VI"
M/N>O:ELGHB6MX3=Q&,DE;$N9H>BV98%@C+*;HLU (5C?$,I4UZO'\9=D-6@K
M$>IP#-:=?>&G&>/4<^S2'\&'R78D=AJNXZBD@M?<FBKIM>H9$5C7+E:.IAD\
M+>W5F,-\- /S155YN7>.RO&%)F2C.Z(4A=A/W2-87TW_ ,6>8I8YV1=/JN6D
M2Z_HN26LQ,3W&VCCWFNNXVK-02BJG)X>M0^51:+))!%61&H,9R"K+LMW4ILM
M%:0CMI35&]"]&L-;0P%?42!F61MC=F< QSA5]5'<I(QX;F"%0<\EVE59/6WF
MOVZ?>6@LR7=I]HFP$GPMC8PQ2P1],Z.C Q2QKGEE%6Q7KK-6B!,8%_82,,N5
MX@]0*-]0(4=;VI#WGG;KEAB[,_V!SI8B%?&Y(<VN;8G<4TYKQ,_%)5TH@;LG
M.TJ",@)SS%C1#:9.G(-*2.+I6]GJ7HDS02+<U[2,D5R$AT#*Q'I3%.0DJ^WT
M63\R$^0OIW2?6<'4"+1V%:72=20UXY[FDNH\$YCD176W268*UBG("#R.9:YY
MCG52%>2Q3(?+MC&,8QD57;B/EA\L0VSW2G8XID"MY)E#LS_4/)5<R&:I!!$W
MV%)ZE)<RZODUCM?@6FNP7V(.$P0>_P!R=Y ,E,,CO79WUA$ LN$"F-6X7UDB
M/YH8[!7UTA;]Z%)!&?JOD\UZ3I7I^6Z;\FL@:9I18DB[I12FMK^2[8UPD%">
M\G^3NS5GLI^[*" 1JO6?:L&YE*8(*Q,3E<O2]DA$@I7FR!F%J9W.G0S8R271
MWV !Y$%KMK&6<LDU@20"5D:6I YG)MN*Q&)"+/7ZR6\7E9UK4H?-F[+XBB4>
M2J^QEF;P$A3EF9E![0><Y^H^J:FA$-2&&3:;V]RFKT5,AKEN3R!))QR*E*/@
MM/<G"Q1QHY7O92N:[QCRK,:J7SSH;HV1-=A]AWX%O.M&4M(#-Q.O(HVC$=%J
M+J4A3K9[57,* 8$*@_>]+YE("S9&^G*SPM_TFS97XK BITT,.NJ=P@1OVDTC
M>'M6"/S32_0>T:'L0 <\Z.E^GK6O>YNMW/'=ZFW'8=A8BY^&I5D/-?4:T-\T
M=&J#Y;P]F8&>4LW9VSVR)RX8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,95YZF<%>HG':A[GK2,[?+4X@GQ-EO2-I
M1%CDLTYV>4"Z,] 0!&K#H!FP#@[NLF","DPU*D51DXTA,-2JWH<YI)5D>QJY
MG[:^SB,*EC^'%<4AZDQ'^^J(SP.2' YX&4'KNI+6@UO5M&#U=ATI<%Z58U'K
MVM)*CU]S35O!/-21K* DJ'KDA2S<&QF"S>*V7"XI8<%>T4DADXCS/*XJ_MQF
MS$3PP/R AR:G!,+>@CT6J1J23= ,  TK8MEG%EF@& ,/+%)#))#*I22)VCD0
M^ZNA*L#_ "(R[5+=>]5KW:DJ3U;<,=BO,AY26&9 \;J?T96!X/!'L0"",B_U
MK_NPXF_YY48_]!E_9W:_]GL_^YK_ /C53(#J/_&>E?\ OGK_ /S)W&=PMBM4
M4V1LTJ:V&..-LU8.22RD7J2JI WM<>L)PA[]%T8GI7%ES<]*8B\)GHYLES&
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M\_DB7QSY/SN6?R1W<>,GM#TKJNG_ %IJRS6ME;\W]QL9C;VMYO!_'M. 5CY
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ME^(L21QP?%:+<[GX25A$6-RD=2M>Y&$0#XV!^(C\C=CM7U!WH--56_1ZJ95
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M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9ZS"2CM:T:46;H._(=&
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M#<\%E5_3DX"RQR+RIC$%][>Y-U\$L9G#O.B$&_:3,(6@8HMV!"V@O\ W)X$
M3+7E^%H4X2BANL&402>. M&J3(;(EPQ&&=O9K-A^S<:JT?/IREI-=*W^9-\T
MU3D\D+*)HAX'J(,@1-U7T[\MB)^K]0OM:JI#7ZEJQ_3UZ8]&EN @X!DJ-3MO
MY8U9W\M*2B>HZ'Z2;W%74%AM,B=& SZ:6PI<2NC-D05P"+19K9.ZXDR5IFT.
M7DG;V1LE_8T(3C [$D,4%;"8+AM4;5)@+$+(K_LY01)#*/UBF0M%(/K\C'@>
M_&3^HZ@U&]1VUEV.>2$]MFJX>"]4?P"ENC86.W6<$\<30IR?RDCSG)K3X3JB
M8S)QM^J7N8\P7\X;T<MN.@W%'%G"5*2A".(+M6"K$+E6MP-PE&RQ*R+"B;TY
MB)+^%O>6P?M/!T0;6Q'$M:=8[U1?:M;4NL8/N8)05GK-^AAD1>?S*P\9';#I
M'76;3[+7RVM!N'\OL].ZUWL,.2!L*C))0V:<GYA=K2R<>$EC/!&@:MON7G;^
MZWC2K9UK7:+]O\9>4TA<?MA,A+_E@6S3F.8/8_NRX>]A.6G4_84G/-#\@V^"
MD:]J4&WX?5W/-6RVOF/_ %-?)>N3^D5Z-/E7Z*+,* ?O3'W/']Y=6:7Y=MJX
M^HZ2?^N?3RB'8J@\=UK0VICZC>Q9M;=G8^>RF/"COM)=C<U]"K53%5]K,#A-
MFS8@/M7R,MQ@EN1P\HO0SR)#54X11^?M D_[@F'K(^6C'LL8B%)Q8??ODLZZ
M[4 >>NXB;\LZ<2UW'T*3Q%XFY_@_/Z@9,:KJ;1;IVAH;&%[2>):$X>ILH"!R
M1/KK:PW8N/J7@"G@\,1YR36<63V,8QC&0?Z7[KKF@92TTY$XO+NA>GY8AVNA
MW.%/IB'>;G(1_& J2SMT.&%@JR!E&'D#72^9*D9!:(1ZYM0.Y2-6$F3I:N:W
M&;,CQTZ*-VR7+!*Q ^?DB7\\\O@@1Q@GG@,5Y&53>]74=/8CUE:O9W6_L)WU
M='K%62VR> )[<A/HZ^F"1WV;3*H7ED23M8#A2:D/4GZ/UIVO?IM@XUA3AY&7
M2O([$SRRR4K>=^XE-*NC+&;70I-(T8=B*5F5Y"4K(>;L!B94,!/D[K-G2T_E
MJTGV,HX_K6P9HX2P]^RG"R\H3QQZTI;CD$><B%U/7.\_$V^^AZ7JOSQJNFXH
MK-Y4/LMC=WHY LZCPQI5%B)X*MP/FR@/22YH=]:-LVQ.O+K=-^/E>[1Z\O=<
MY'#U^=C%J+3&)H"_(OWZ+3H""2]ZT$HHLO6@:Q^_[J^(8=?67Z)!KZH4?\>-
MS_I)/]_.;/\ 6XT4GF_=ZEVLGUEV'4NX=S_/X>U60?R5% ^@ SP,]*BJHYK9
M])=(=O\ /R\KP8EW7O4MB/K)L\O?N(^Z1>TE5@L3TC"+00FHER78#2O( F%&
M;T<%]^SOXLTM9;'L?6HQ*W'^;) (F4_7D'_DY&?#]GFO@\ZK>=6:9QY4T^H+
MTT7(]O4K[!KL,JCZJZ^1XY'OF%6*/4]Y-T)T6JX9ZCU.-_R&NB-LCS-176C&
MUE^!B/94#8<;4EJB:T0#=[:BDL3ELE6!()1;^I4C]N0&DO\ R@2::P?REG:U
M0=OT9F_K$'<W'S?/'&"2? &:G;KWIT&1FJ]<:Q.3(L<,6HZCBC]R8DC)UNQ]
M-0?PPM6Q.W 3YF/$S>:.L:3ZRB+A*:ADBE2MCCAMBGL!D[6KBMFUC)RMF 51
M:Q(,[A)>HR\I3R%2?7U!)K:X#2*36=Q<DI6U&1MVA9H2".P@ <=T4J,)()T/
M!$D,J\I(I!!\'D<@,%/C+1HNHM5U%6>QK9V9H']&Y3GC:O?H6!R&KW:DG$M>
M52&'S H_:QB=U'=DD<X\G,8QC&,8QC&,P<CDT;AS*ODDND#'%HZUD[4.;](W
M9 QLK<G#_B/7NCFH2H4A.O\ ,U0>6#7^8LR1'D8)&C2.QX5$4LS'] J@DG^0
MS5//!6B>>S-%7AC'=)-/(D42*/<O)(511_%B!D%7#U%*SF*U5'N4*]M+LZ4$
M*#4 EU(L!2>FVQ>6/9>@R+HJ;J8S32-)[@&?(*/2F5NV@ECV0RJ1:T'<J-//
M& ]^:#6Q\ \67YLL#_8IQ![)/^[2-?\ .&5%^MJ%IV@Z=I;#JBP"4[]3"!JX
MW!X_'W=MJ^K5>>>?0L691P>(F/C-'FD6ZTL"-.DVZSZ=K_ANCD!&UK]".>9(
MB(F29G%_,TGGO6UGM[2FCII8M (6#JRO8<J_)I3=-!;V!2/;&^OA=8M?2FVE
MICPDMR,F,M^L6O@9B_ZCXB64?K%]!RVJ_4=R"2UU'OJ72>I1>Z:II9U%I8SY
M[;G4>PCB6'CV;[OI56]Q';/ALY'1TNAS4D<X_P"E9R6ADI<G-%N6]EWF"7PZ
MJ)$IV/6S'Y;9,Q)=.A.HUH%19NR]1LLR)J#_ &[3V*VIQZ&'HM1R,5?>[ IZ
M8_#UU7TY+"?3L$$7;3HCCW[_ )Q]82<C-38K1I)#]GW3BS_$'^L]4;<6:VNF
M;QS.]ZT)-UU _()'H UF/'%Z,'-/LPNA:DM"."ZAG$^]2SNS0@/=9\UPN-('
M2,5ZY&!!]*]0WGQJ6GUI3+ WA.2&GW#=[P\RXA F&\(Y<K/)&BS9!\78@?X&
M*+2ZORL]V61E>8>>4DML/6L,>#Q7K*L1;Y3&.><Y[_W/K;\'W_;N===7>)J.
MCJUTD@I.?RRU=+&YH:N%.03L]M++9" R+:8@KF2NN(/TNC:*WO5DM=DKBFU;
MLB(KS@&DWQ\>F29R,PT"ABBEE/D:3DV#U+82A3M($%;0=H0UV0N0@6Z:WQL$
MN4ZQK2)&YKZ"!IK 4^MMK2HK1I[-)"KDPT(0.>9Y6,Q!X[D8*,SVE::S FR^
MT3814=8TBBET=JI998K4Q(,-:_+ /C.H+I/:/@:D:40ZAO2F3N;/*UUZZ8U<
MVROL *CBOA9O^UQBM.*X%_<+[Z&V>$*6*0&R$5;C&X,Z*0)@%)&OF"FOK'A8
M0H/2V#*?H&U:QI?M<".=DUW&RVI[I)]G+\U2GQYDEA,XX8H>2UZSPHX!A3N(
M8MB[V=>ECJ7NZ6Z23TZ]'I>GRNXW7<.VM3O+1_$B68<+'H-9W2.&*7;!1'A7
ML=?\RS?J--$'3I2O4%%\HPC30=27 3 !K0MJQO8ADGQ:2]1@CGM87A4B$0F<
M6/G]B,45]$32D09BHE[ZE4)D/-+>BHF04IFM7Y>X6ML_<2&;D.E'O^=01X:V
M_$TGGTQ&A!,G3T-O?K6DWE--1T[4],ZKHZ 1K&Z1$&O/U (/P964A9(=/#S2
MK$+\2UJ92$M/)))3$E)TY19"<@LLD@@DL)1)))0= ****!H("RRP!" LL =!
M '6@AUK6M:R!)Y\GR3Y)/UST$ * J@     <  >  !X  \ #VSV8S[C&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,K6D
M7IJP:2.4]<5EH34G=@7'T-=KB0G;([H*&4=(<ZN',TN;T S49@OL;)!%^W2-
M)U/SKBI22!:ZN#HUB&S[FDW<J+$H@C/I5J=526?S'2N"[&3P1\[2CM<C@=GA
M0K?-E$GZ$J6)+DC;"V/C-INMLX6.#Y)]YI)-#9C0E3^#%3?U( W<XL /)))'
MS'FM.GI65L[()&VJ+5GX$\H:K(:7/9+?&=& +L[DJ'\=/1R,0VXP))J&O(8W
M2!KT:!0 N9*5BM6%6RB)9"<UWTRLC""'E&@9>2_^0V$FQ4'YAR#-(4/L?3
M^;ECIE^SVC*D\;;&X%L1WHY.$K\@7^FZW3$I4E#QVT:J31@A@+3.S=T1$0^&
M:>DY6$X;98W+[;LMMU-S;E*?U+2CAX3Q-%XU?1M6R]K;].+"Y$(Q)VSGV"N;
M.N-)5J$JY9)@'Z4IW%N SY1]03QF-A7A;TA6[ QDX[JMBU8B8]K#GEK<JL/
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MROVN!(DL5>+N1P5#J6 [25S.#H/7P67M"S-+)+'L(Y!/7ISJ#=VNPW"2P>K
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M!('=R0#S^F<.VO=6ZG5;+:2?T<G36T+E]XDBV<;2I3K26&C1FG<*SB/M4D<
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MQ,^LM<G\B?$166!'-=3X$[O*%U0^=?2.3:XI/^XK$*]"K)__ (B=4D5$&?\
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M^?U[T51O,;$9XT-@YNK!=;4[VG._UI([8O@2:+I510/Y9:E!1/D)FQ&EF:$
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M.6)@Z.ONI'_(01R"#R&!((()&<>PH4]I2LZ_85X[5.W$T-B"4<I(C?RX*LI
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MR'#)0E_^H%,(Y9O:\2.I?EN(O2.4U9P^:XDN4EL)Y;%1:R.3SK1Q;S1M2P*
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2&,8QC&,8QC&,8QC&,8QC&?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>gdc15tqwxkbk000015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdc15tqwxkbk000015.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &+ EX# 1$  A$! Q$!_\0
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M@?3]YQ;9QB#&\^?4;N!\#J$X5FL>:-Z%NPMDU3=0I;0ZHP*Y6D,37!T]MAR
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M@UNWLVJE"::G0L[&9>P&M3EK16O$S@3RP-;DCA>:&'ODAA+<S3*D0X#EEH:
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MI3-Y71XZ%RY'&VT6A]JK6KD??]M:)K'BGG,*W$RNSIL8QD;=AL=NJ'+[U9J
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MCPJJ68GX!5'))_8 YSC  \]NNO6JR6*JS.0=MYUNP6TIL+RF]RK5T0#3]71
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M8\H**#I#D0@-)0)=N9E09\&6R[%F0Y+34B-(:<9>;0XA2=3UU>S90RZZ^RL
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MW1E<Y&O!L]6=7TG+L[M1]?I]50TWL\M&C0VL>OU=*&Y9FO60;\UZ2ZMJ!*-
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M D'"3[[SS[LXFY*DN/.NN+=VMQ:M[I;%B<(L\\TPB4)&)97D$:CT"H'8A%
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M,8QC&,8QC&,8QC&,8QE0_4$_,,\V?Z)/D;_8_<<L-3^FNL_="E_28\YKK/\
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M[D[222@1B?>R#TK:VUC411;VK+7VVOEEUMR212(K\E3M1=G4<@>6M?C*3JX
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M2ZV/3Z?5ZF(@QZS74Z"L!P'%2O'!W\?6_9WGGU))))))S9[ZQ;95&N<:@3(
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M[C@JQH9-5PTS<ZI8ZV]9@Q&KC3#]A=K4S8@4=GPUO8#KMA-VRH\D-@P=A*M
M)."WD]Y/==?&ZN$979>SO'<R<[=VAZBCZGZ<HB6G/#6O:P7_ #I'+%L6K!XX
MQ78QS<2P2BU6G@-B)X$D,Y@;QQRUIYWXU=FOL()T.C5VX< )=]],)/!+@6-+
MDT^R<"\C@/U&122WV"DR0)F(H5(Z)TICZQ5@$5T3\D-6!V.C'I<AF;-=K1%H
M99([:U-W[5&J@2);IL5\B^8!T/<(H3VNQ#<L'[BH!HJ.BVEQ8KU.&SI7W70
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M5HOM33!1*T?,;.4)&11ZCO2_)KD7A[UB_>(=.?N_<@L8%]GAD&NJN14<*F6
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M:2)9>.\1NRJSQANQF1&(+*I'.#J''+!XP,^2'E;3*PQVSN%HZL*N/.B9H[;
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MMA0)+MWNQ\T/OL_ [VD^[+<>\6Y]>><J>HH(JO0?4M>$QF*+IWJ!$6&+P0Q
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M2K=<":65#><<AI[24[.6LDRU#:9C+'"&)+S$M4"?1H-=,MB>85J4!#6KDG+
M%O41QK]U-8D_4QKR?7EB.1W<]U!U'%HEJ:W7TSL][?!BU.EK%8RR1@*UFS(
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M5)=;8C1H[*-N//R'W5(:99:;2IQUUQ24-H3M2E:3K>\S +$*H))(  '))/H
M /4DGT 'QS%W2-&DD=8XT4N[NP5$11RS,S$*JJ 26)  ')/&0 YY7^/*G'6Q
M/3PUOTPXMF1(YY".=*A1GFE;0\S*(<_%66#&>87K:)#+\AMQA:5(>2A25:U8
M_-&R_5U)(>?4"RT=5B#Z@A;+Q,01Z@@<$>H],Y0]=])$D5]W6V':Q5GU,=G<
MQ(RGAE>;507(D92"&5W5E((8 C-MI/=^-=&*N5ZE],IQVSLL*E2:BR:B1;E$
MBH]OO2IM0GKB6:%&U[%?O\H4RU^2K6E_DJ]FF?7W:R"2>K-'$3P)BA,+'ZEF
M7F)C^0.3D_6]4=.[>P:FNW.OLW57O>@MF--C&GW\FOE*7(T^/O/ J^A]?0YR
MK\HN+7/T_NG6+U!_$*N3)W,RLE!7SI\6ZXA+0._TUE:UE^]\W")4V/!]6HT9
MV2;L*(B(<&S"FR)"<[$6NR.G;FC9BVT":G8N!.H*ZN^_JT4GZFK.WW3P2GA4
M)Y,9X4 _:^SBM_JK71M^?K/IJ!GHR,).K>GX !%<J@\R[BC%Z)#L:B]TLP0*
MMB/R.Y4F8R]=.9=*I/8^>TWJG-[!"M-$O]=&6FJGQZE;CD@Y:,B5%=VVO2'H
MLEO2]QYT"4VS-'3F9$"<PQ+COLHY^>&6O-)!,ACEB=DD0_%64\'\A'T@CD,.
M""00<](H7JNSI5=A1F6Q4N0QV*\R?<R12*&4\'U5ASPR, R,"C ,"!O.:LEX
MQC&,8QC&,9#_ '([)J5 (6T370=DL(N=7APB ;@,3M2/M':@ :8/A)>G"M:G
M$6Y#;,%M96!&<)H'KEK>:8U'<D54$DJQL[(C!RQ4D<=B.P)]#Z+QR?=)[>>.
M.>16;:9JU-[,<$,\T;PI$DJ!^[SV(8F1.7C]YPP"CR(I<(6Y [36+RQ+D3WI
MI>8)<I5H]+F3O%'RI=W6X[H=W<",GG_16X#LY%?)F@\,P1@(C%#@N"9+MB#,
MV>+64(O0W)CTZ@H3=:Y5?R ;"@._WO4^:'GCO56*@\JK%5[E ;M / H.HY'F
MZ$ZEDDKK59^G>H#X%,1[%]CNA"_ADEB65T"R31I+*(I6>/R2%2YL9XQ?FU^/
M7\QW)OZA ,AWOT;<_;5C_BOEYH/TBTO[DZ[^APY..1<ML8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,U _=15<L5'K,Z!9I4_H!8L&#2PU5L)
ML(-DAJX5L\I^V'Q0Z6'IP]^ (D1!I"RS1D0J:>@A![LDE-8CKV)$SI*X* 0J
MK,&D168,ZQ@1HQ#2$%@6" E5!8\ <Y&FM1P35('2=GN2211-%7FEB1HH)+#&
MS-&C15D*1,J/.T:R2E(D+.X7-OS7DG&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,9S0]4_P#\D.'?TX_"S^W^G9=:/]$V_P!R]E_19,X7Y0/TIU7^MG2O
M_.JF=+\I<[K&,8QC(.\D^^4WQ?X;TCNU\U)?K_/:^X3T)'Z]XM93DN1'$U:H
M!&_=7\4Y;[-/$UL.WM.V]D2D=3VT,)<6F52J27K4-6+@/,X7N/W*( 6DD;_1
MC0,[?Z*GCURIWFXJZ#4WMO<[C#2A,GC3UDGE8B.O6B'!YFLSO'!$../)(O/
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M*[(^Q_6S<65.JE@Y)20E+M@"!*ME=IDJ&W+W?ZP3<KK!1=8)2SC4!DB<>9:
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M^R23ZS7T)PO;=G&PNRSU#-66*H9!90>YQ[P$:?%NX@L0/H/:2JJ?I/<QXY'
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M_O%CG"=7#Q;OH&XOI*G4TU('Z?%L-)M(YE_881)S^P/R9<'OLOR1AT\>YXO
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MJ=Y# @[8J]C:R[:I=C@C'"112RZ9;KH@"M;MVIB.^5V/U1VLZCT7A7 ^HMW
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MUG889BL,QH[:6F([3;##2->Q+;+*--MMIU_N2A"4IUK_ --:R@/KZGXG/10
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M:JUCB".>$-%.OECDD1H^^&5 X4NC(",P?%GQ8"+9N1;Z=TCK=PY862BYV_J
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M'H;S*YI5Z>]?#O+;ESKH87J?,^A@10RPNUFY!AAL%IPI6#*FAME!D =C,P"
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MY![56>5R%$E1R;=4L>%<2$+)((XVZ5Y2YW6:H[1*0_+=GO4^KO37W%O/2W0
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MEF;%&/FZG"GU*-(F"&"4UXDY%'R%.*D1,4BL%;#0LT:QF)?)S9C:16>,L@[
MJ%%D*R$!BH"@D976XEFM:T2:U+D<-B:RMR0U^-78BK21PSI'*?,TLRS2UE>N
MI:-9'+E48G)7R/ECD1SYA_GIXH9(3NE=.%])Z+30=?JP.M566.XZ.G AH"?/
M7*'Q )E=%T6%S;=:CMD)V<J)F''HPII EJ*/8D ),BJ!! T$,C/(SR!K)#LX
M'#%U\O:PCC2-8U8)RWO<G*UVFI322N]Z_'>NU8H:\4%=DUB/#'"[]R+#*:GD
MC>S8FGDL21M*5C'C"1K+F1\LL8QC&,8QC&,8QC&,8QC&,TF1TOG$2TQZ/*Z!
M28UUEL$I42GR+4"9M,J,&B,SS$B/7W)Z2S[ J#(CS23K413<&(^S(E*:9=0M
M6T03%#*(93&"H,@C<H"Q(4%^.WEB"%'/J00,B-?HK8%1KM1;;"1EJFQ"+#+$
MH>4K 7\I$:,'<A2$4AFX!!S2>9]P#]<J8?H%'J=Q(\_M=$B]"H=R=8KK(N]
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M2*QS>@FBAYII?5)]CY%Q[J[A  'E0H,Z!%%:[54JE,U)W);38I4&"])C$2\
M8J--KIXHXG"LY>&2:953GV<)8L5P'8$ABWLTD@XX]P$CD*6RSI=3:ZY9MP&6
M*!(;U>C3EDF ^<'GUFLV1>&-D1D6/YUK5F[BP\S(A97E2/+7>WV_P??_  Z_
M_;[M_P#[;^[>0,Z/&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9_
M-[UK6][WK6M:]N][^[6M:_AWO?\ NUK&,YD^DXW]IO&.T>0$K2MF/+#R,\B/
M(<BMSVJ<T/LG3SE3I<=#BO:K<.+SZE5-H<U[?=CPO@M)UK:5;W=[_P!R]'4'
MW-"G3ICCX=R0))*?V3-+)W'Z3G!_)T/:-!8W+?Y7J+=[O=.3\>R>_-6JKS]Z
MM*K6"#]2G:H^&=-\I,[S&,8QC&,9@2]JJX"8)''K(!"$#\C40% +F!PV8:EJ
MEP("8HF+,D,ODI"IQ09"TS#0\YN61@1M)^-,CH<S6-W#,B.P0<N54L%'!/+$
M A1PK'UX]%)^ .:9+%>%XXYIX8GF;MA225$>5NY$[8U9@7;ODC3A03W.B_%E
M!SV89NQC&,8SQO$1\>9#'2)T-@@13*4/@O2F&ID],)#;DU4.,M:7I28C;K3D
MK;"%ZCH=;4[[B5IWOZ%)!8 D+QW$ \#GX<GX#GZ.?CF)=%949U#OW%$+ ,_8
M 6[5)Y;M!!;@'@$<\<Y[,^9EC&,^;KK3#3CSSC;+++:W7775I;:::;3M;CCC
MB]Z2AM"=;4M:MZ2E.M[WO6M;WC/A( ))  !))/  'J22?0 #XG/..(CS ^"6
M$SH9044AQ2(PF.E,31Y$?-81)A3H,V,MV-+ARXSK<B+*CN.,2&'$.M+6VM*M
M_2"I*L"K*2&4@@@@\$$'U!!]"#Z@Y\1TE1)(W62.15>.1&#HZ. RNC*2K*RD
M,K*2""""0<]24)0G2$)2A*?NTE.M)3K_ '_=K6M:U_\ IK/F9<<>@]!GZQC&
M,8QC.??E=ZA% \>;8)X;SFFV;R7\MK?%T_3/&WE2F)-C:CNMH<:L72K$MN2(
MY;2FFW6I4L_8D+D)'N?4XHF4*9FD(=M0U$MN-K4TB4M?&>)+D_HG/WD"<AIY
M/0@(GIS[I8,0#QG476E+2V8]31JV-[U'97NJZ/7=K3A2.1/>F/,6OJCD%II_
M>[#WK&T89EK?%\'/+_S UJP^H9Y)FJ30R?[\UX<>)!LA0.>1![WY6@O5.L-+
M<NO3778ZD,FA<25%!QB<=4NNFOE'4-IF'9Z_7>YJ*2RRCT^<=@HEF)]/>@K^
MD4'!Y[6(+%3PZ\\\TB])]2]2_;NM-[-4J/ZCIGIN9Z5)4/\ W6PV(_/=\E2!
M*BLD(D7NAD[3QE[.&^#_ (A^-D6''XCXZ\IH4N$AM#5B@U2 3NCNFM>QM4Z]
MGD%;F26C[]I<(GI2]*4M6E:4M>]U=K9["X2;-RQ*#\4,A6+U^/$2=L2_^E!]
M'U9UVIZ4Z;T2JNITNNILH $R5D>T>/AWVY1)9D/Y7E;+49!SH,8QE1.Z^ _A
MIY*QIC?:/'#EEN(S4KTY:FJU%K5[:VO[]KB7^J?0[I#5[^M.?[,=:2IQ*5+2
MK>LL*NVV5(CV:Y/&!\$+EXOWXI.^,_OKG-[?H_I?>AAM-'K[+M\; @6"V.?7
MW;E?Q6E]?7W9AR?CSE))7A_YQ^&6MV#P1\AC'?.8#/WZ5X>>7A]RRM.#6O9M
M0CCW=EZBV&E2F(_Q(M= V1>ZJP^XF8=(D?A:9=LQL=7L?<VM-:D[>@V.O01^
MOWUFKZK*">"[I[_ X15^.<HW375G2_,W2.ZEW&O3U;IGJ28SCL'J8]9MSQ/5
M8#E889^:X)[I7?C+4>)7G[RSRB+6#F!0#:.$>35!:_\ ZE^,_6HV@O1JWMI+
M7QC%?VXB/$OE+=V\T\/M=>2I#D"4.G%!H9)4>W(@7]3/15)U9+5*7_(W:Y[H
M7Y^"O\3%(/4&-_U08*6[6XZ'ISK'7[^2:A)#8U&^IC\_Z+8KXKL''',L'/"W
M*IY!2S!R"C(\B1>1 <=Y.\";,=6YCY&6F'9NN<XX"DM<PGCJ,9!0*X)ZU*D1
M&8GD',ALCTD;^6H8+9>3$!SOKIX X^0L?/1!VV+AUN?E1ME8)J<92O-;[8VN
M,6+M7 /-0$GB)97[06':C\*DK(G+C7O]/Y=CK]Y86QLJ.F$MJ+21B%((]DS*
M%W3*(_)<EIP^0K"WFEA+//2BFL]D#PAQ#SUZWUGR%I;L_DEQJWCQWM;-<\?*
MX2Y?>E=#.5<#7;=;S?E7=+=]/BT?GW,+$['KE.KO/#TZ5>2<,L"NVV $9?TN
MS2;6JKUZD@%B)[E4=]MQ8B\*NSI&M&*/N,LLZ M(\J@1*5:+ES[R5.IZQV6R
MW54OK;5?2;DB#2P/K[AO2UX8+-F;J&W9[%J4=?.RP58*4[-;D22&WQ"I\<_6
M>+*C38T>;"D,2X<MAJ5$EQ76Y$:5&D-I=8D1WVE+:>8>:6AQIUM:FW&U)6A2
MDJUO="002"""#P0?0@CX@CZ",]'5E=596#*P#*RD%64CD,I'(((/((]"/49]
M\^9]QC&,8QC&,8QC&,8QC&,8QC&,8QC&1#+D5V;W<' V?Z7&M=>Y98"FJS#9
MM\;D):OV>T@H&S!V8D3]@R_0 I&L_*UZ Z<^U84 :/RVQ.Q)E4S4@!Q59NR$
MQO81>\F,V%=(W/:H[O*L+*_+D)XV=4!;N7C*UF@?;Q)YKRV(=?-)[.HLKK9(
M;%B%/+,PC]DDN1/7[84,OM$4,LS"/QRELE[(^66,8R((7/2-"D X/'F*?6ZR
M;ZI;K]UZ'8XUI/$SK%V8LY^Q2Z9,39([(*SD^A$ A1U9-@I7(H'1L<.!Q'W1
MKD20TPF#&R9'=8(XJY0HBH8RBH)!V'O180R@#M<MVL7(!!K$I/3,*:P58*\N
MPLW-DDZV)I)5M">:=JK>=1#/)=>*0EQ) L/E1(5)0KMM+NP^[BYI6&(M8!N%
M:;74_D[K5S-/*3)E1/DZ_*)C1IZ+#ED*Z8<%/%JP>BMN#K#7Y$(R.>=AR4+U
MKEB,3!2T;\I')S%(LB@2('"ED) =>[M=#[R."I'(R35MI;C:18K$(6Q8K]EJ
MO+6D9JTTD+2)',JL\,AC,D$R@I-"5E0E&!S<LUY*QC&,8QC&,8QC&51\Q.WW
MOQ_Y7$OE,"U=^*]:PM8M%TN#%@,USED"S;?$@;U8Z=5ECC]IJ3=UD5FN6Y0B
MR IM0 6&9?/=.0JQ.!3Y^NJQ6YS%(S\^-GCBC[5><IPSQ)(X98Y/&'>/N1A(
MZ"+W"X<<[U-MKFFUZVZL5=E-F&O8M61-+!KTL<Q0W)ZU<I-8K"TU>"SXYX6K
M0S/<^VI7>)ZM\W\/+7>[R-Z[=0@7EE,O/1O'KS3_ '*6'I$F]\I\FH')Y]-[
MA3&G&AS -JKWB.Y4X5L(LD'I1B;!Z'$E5Y'VKBFX$Z;8QQ1-7B9IY(H;FL\Y
M $-BB; DK2\$]_?']L,:D *#"0_N%#S]'IBQ;N)LK446OJV[VEZJ^;@6:YKM
M^FM>IMJH*H(17MJ:Z67#L976\K0_GE9DO#Q3@-0X'5Q5#HAFX*Y_6(9,31J,
M<,QB-?HM>*$]E%5P'MH;#+$A(U>FX(#[8E;21KH9K04(0@#'9,5^LLVY+<C2
MRK'YI"K2RJI#RNJ]O>WJ55C\6\2QJ[>\X9@".LU6FK::O%3IRV?8JZ/%4J2R
MAX:D#OW^"+A%DDCC]$A]JDL/!$!%$Z1\J='N?AGP:]-\ZAG:Y.DB.=6--A9#
M32;MCB6]IGDM^XI"K-\FW!NR';%41U#Z7;84 #]7AQV)9!<OWU?&FM2]L6RM
MQ&8HX#3)V%E4(8R9XK)>(1]BI(988R7[2>!Q]7$.UTMI[@HK- [1T;'G6)Y#
M.MD#6W=4M>XUH3RS5DIW[*)#Y%4,_=SZL&]9KP]X(6M0N[Q:<R M0@C>B\,L
M(6TY[A3HB.>+L1%(XTP8%1I[9#DG,2P*= @PYM;GT@1H%(@07BT(E\78VUC:
M(R%XV6)2K?>P^;L'*E6(XL3JP)(<2MW GM*YS=,Z>6S';6J(;,3W)$ECX/$E
MWV(SN$E66-7#ZW7R0NB(\#U(O"R*9%>H]1\=O)OQEM?!>=<#+PB7&8Q"F">B
MEY<R419L1#Y*O0^H]"Z<%N9>PFJZVUR[D, !SX7RDYK5H[WU\Q?+F_70$$B%
ML]A)<I7H[<UM2MDK(T*@ %!RY@A@:)41_M]@O,9U]RK76*(.Y#)S=;2[_0V-
M/1T\JR:Q7JQW969G$[]D";"[L(K4D\L &OUB0TH]=,/:-QLY;EHPPH\4_5;*
M'/0\8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,T'JQ*0&Y=TDO$5M$
MH50;B2C*3OV*3(@UXC*94G?^[>G&D[UO_=O7MS=7 :Q I^#31 _L%U!R'L':
M.A>D7T:.G9=2/B&2%V''[XRI?I=#8XGTZ_#"+&2E#;OCOS4DK2=>S6Y!FOQ3
M$M7_ /TN5.>6K?\ O4K>\G[QBVWV1/\ XN9?WE<J/_89SGR?H(^B>EE7X'24
M'_?EA65O_P G/.7RRJSK\8QC&,8QE<.Q<=L?0+SS:YU<M JYBAE@;B;*@F7;
MG/U9R\58_P!"I1FJ;A$*I=05Q UB%&#N%TBCE ML(9<ZJ:B%8R5(F5["1131
MR*SK*K^YVKP)/$Z0R+)R)(FC=R7"]R31DQ2*5RCV>KGNVZ-J"1()*DD)\_DE
M#&O[77FNU9:_8]>W#:A@58C+XY:5E([5>59!Z5\J_BAV\#0X%63V<I"(C:N&
MID.3 Z-U%X=%@B_'L;RV/8!D1<N&V(,"^FB]=:@P(K"X\V60E0II)DC'A&FY
M;WZK2E_9E(:1I2&AAY+-;:<HQX/<K0-[.2?4  A2.5RFK].[:&FE?YTD61*\
M=4.EW8%52/31Z]9HU++XI([\8V2(H*N[LK.) LN8.]\4\EP$J0D);[Y?(%RN
MY*7+C!>TW:J.@1DNT>2Y>-OZV\+.S*T]'K74./! #-?#M5.":Y&/DGU1@T 3
M#)9Q6:3@=\<41BB '=6B?O8)24^Z"@?EX++N6;R%;!"<L6(T7-5O86/BLW+B
M6K3LRQ;2U6,*-8WTJ_;C',T!6#8:R&$0Q+7276HTQ6%(TDG+KW'.VWCI40_4
M>BIJM);@5 ?-$0+QT&O$)\<7<PUEL2'H(5,@8Q*G#PSP)@H)E")1 98)X\PV
M[&A:V3BU[%6*$I)"9)>9"&,<3JI:-D3CNX) +=Q5NX!E#+Z_<V^SU>UMWEEK
M7O9Z@6LCQI;NP.ZQV8IYN5B[D#.D1A$D;1%XYG24,%YDU7E7CCVJDEF7S/8"
M:VI9/1(Z;%VVPG#<W;/$^;<M@-O";P%.5LW-@&>?/V9!FQ19\J0NRS7'H_U-
MAV<1SL7*\J\+ HX7A%:-%4<V9IVX:-E= 5F"=J$#A!Z]IX$?7:/:U)0TVSD(
M:3R2RQV9Y96XU5'7HICMQ2P3,DM,V/-,KLQG<E?(IDDPQ7QH[RRZ<BU3KSPL
M>9L_2#ZYB;W?A$U"K;T"^781(0-#0T#8<U,._P#V<)M#7H<.&U3 A(<F1LBR
M/K.:W:A"&2OW%$A3CQ1,#XX8HF!+'N(YB[P6Y),C _<]SZI-%N 95K;(QI+8
MO3%O:[D;_GF[;MQ$1Q((T8)<\#A"JJ*L+Q\]X2#(!O'+N8BP""*NNDR->B3R
MLBQ5,CTWJ4UFX#)K8)$ .X=F.22M5^CSUVNR1R@+WY4F:Z* RVG0+TI$/%KE
M9E8"NJN54+(((.48=W<W:. _>/&A5_0#N8</QSG%H]O'-&_SD[PJ\C3UWO[!
MA:C?P]D1E8F2OXG-B=9(?>9S'"P,+-V^>O\ CIY"UJ#26E]GF7 X&L\$C<+5
M8^A]-8E6H,)NG*C#45JN*6;J0MNPU:N]+!G1,40WN&[;AL<6?^A_: 65^O<I
MR&7\[")7C*QQI# 1&[13J3W^Y(W:[P,K%O7QMW)W=C+\ATFZ@2J/G1K,L5A'
MLV)KEX/8BCM:Z4*(?MM:/SP07XIHUBY4V4$<_B\T<EKN-4J?S;D/*^=%)<2>
M2H/.*12B$^!\;Y&=-JM9& I,R'J0VS(U%E/0%OL)>:;=2TXE+B=+UO(%F43V
M)YE!"S32R@'CD"1V< \<CD<\'C.AU=1Z&LUU&1E>2E1J5'=.>QVK5XX6=>X
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M&\3$#:[51VO\V=X[M?KV*BP%6S94H8TD["#!@T*.@!PP^")$"H<8<+%#(C$
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MY.K74^Z&[K=8]7Z7V2#3M)J])?U=:A(FGO7;0D,%O6VIY7MOL/#<$<I+PPP
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M\-3?S3)_BL?/?7?XB4?]\*W_ $?'X1OJ9?R:/.?V]*9_H=CV/2_AJ;^:9/\
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M3'6UOC]DHT9B-.5%6TJ3';TP[M36U(WD'8*R!F"OVEE!(#=O/;W#Z>WDD<_
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MB;:2P9GEZ56B4TNP@0[7T,DY4P8\_/:2!??");E..H2(>=&ZUJ&XMG>Q;%A
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M$*/*"FJP*DA9<5\6[*I<VT5A$L23.E#)K0NPIR"-9Z@XC@E'( 8&PSNRRMZ
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M@HC"V)R:O]OI:NG"Q4N;,=K]J;BP <V!3AH:KC,);;RL794\A@$!D'=W,H(
M8\L1W^(> L .].2P,A9VWU-+7I1B"*6;V5;YV$=8^/Q1RLK.T2=L8?V?VQC?
MCC9F,-@*D3)5CBKQX2Z^+]6NEZ(= <M5P!EB)9HV^/$2AVP#Q%/++1QZ1,E!
M2(Z? <(2J7;"$&0:C-0STM,0%$)%2 JLUD<'RBO21Q"+QQNH7M!8'O[?/'9"
MAU(/:)8P0I)4<L54%W+:;?3]:W;>X;%F*1Y1,R1,GA,GS?/K"S1.CH7:I8=&
ME4+,P6%9)'CKP)%I:/"FB:7$6Y;K>Y\K+$2U>Q%<;7)V'L?CO9FFGG4!-.?#
MD2_&NE19'PU(7\D8LZ&5-2) >2%V_.<OK]KC]0P_5^G<EQ.0"Q^ NR$<\^JH
M?ONZ)]BE/E";-D]K1M\(/>\4^DL $^+G@MHJJMP0>R6< @F)HL7'\&*A&%QA
MJ.H=-VMH4X&D$=IH29LJ!(C>/T"4QO3=)1#8TZ.\<J;&0XU$T\VLO9G]NN?-
MC6Q67SI)R3X(!R0P'VW@$&V0?67D\&Y(?CQ[J>GH>[6.D:P14^<-AR(S$S\4
MP[(PTRL/2H%7E-)57E5!'EL'GWH_'F:[X95&M2*9,AWZ^2)M F%B=9?F?9C>
MFR)VWTR[%UE&(E>AL%84XQ3O@J@OH1J,//%-0'XA2( *AL'V4CB0&*("4*K@
M=_JJQRQ* 2Y*D+)SR/B4'/NEU;=#TO7@:JZ7+9:DTCP%O!Z/+9JVY/(%A02*
MTM7CL/':DTG:RR+#)%MW(?%FC\7LHRPU0U9'T!ZN2J(X44<$O1&Q1"F^/M%2
MI]^**B3)$J&$\<*5N*YM]#2996RK6PN-)$Q0VNQ>ELQF.14]YUD+#NY[EDMR
M^@+$ %KDG/ISPJ>O/<6DZWIZIJ[$<]:6<B*O)6CCD,941/5TM,<E8U=F2+1U
M.TEN.Z2?D=K1K%9K(67V,8QC&5.D^9G%Q/EY^!593/V9["5YA7^J45HNZQ'$
M]!$%R=K&$@=<EJ6GW[77OLI()RP3Z422 65]1$;FH%FT#9XUMEM?\Y(O?76=
MX)>WDM"RK&5=Q^MOY H<>BL.&X[D[N=;J?5Q]2_8M/+X-G)KX=C4$I"QW8I)
M+,<D4#$^MB'V9I&A/O/$W?'W".7LMCD#.BSE];(Z>^^JAS^IS-:GT3P:\?97
M8)<32?BP]=\\C"Q:C4G96.Y[S#LFL\LI]P-@'E-_&@SK)N5%6AUM2T7D9]DT
M4T@])=I;%<'Z?9::K++VGX\//+&KCX%5X/H>,X&R/GCY0:=9O?I])Z9MFR_%
M?GG=RRTZGD!].ZOKJMJ6$_%6L=R^H)%T^Z<)JO?ZX'J]PGGX@L,?BV5AL"?L
M-?6^4@,O-P%S'JZ9"R)C$1;ZY+4.8](@_-H8EJC;DQ8SS/([*OMITC&HWDVB
MF4N)9X:-&\TT;+QXREZ*5(^" W>@#GX$]I(/7[#64MK$D%Z.26*.59U6.S9K
M?;$!"%FK2Q,ZKW$A'+)W=K=O<JD597Z:WCE$9?V_ ^$%9ARD?09;L]5%&LN%
MV[-+FQ:3)-*I8V7L\Q]?>*Q@D>=HLY,+*E:FS)LA^G&MZY/(_-'VA=N.)!H]
M&)>>WL ,@K^1QV>X%9B.WA>./3*C[#^F%!YUD8A"L# UBQ[&H,@G9EJ-)[(C
M>5?,9%A#B0M)W=S,3KAGI71/*BEW'H8SISOC-X*UZOV(C/[)$'!G>P=[I->@
M37;3>JO,M0HS6^0<,F#8A!\+;'JV?Z#?@:/M+6MT(+)"EC?H<->/7-!7DC.Q
MVY\2&%N5@KS-VA%D6)E:Q;+<%XE=((7/C?S,&5*F:]=ZAK6KL=\Z'I&&&=WV
M:I$=EMZL*.9[==[$<L&MU#(KF*RT$UVY"//!['$T4LNN\DJO5NCT/CE#KEGM
MGA+XL(JHRH\#Y;38[97RBZ#0*C6-2 1;I?0[D,ML'B0N96!42:U4@PXCTQ#4
MN,FQ],KMEF2*G%VSR5X9;$SI'L[W>TMN>0]M&*:1^'6&&(Q&RP=B#(S" D'Q
MPL@\AT:ZO?N5=72@L6>E>G_9XZVFU]8>3?W:=6OW127[MF.RNJB:O&K"O$CW
MQW+YKT,[FNL?2N9]"Z09\DO#OF_9>MF*M>?">RQNI0^XW@EU=[@/D'TY8X1S
M*GHZ-(:<N,F-;Z7(Z(3Z)4=GBK,&MB*79:K&!P[E%=,[A/#"E+8SUJZO%LT,
M!JQ"O[73@Y:>3P#B,>.00K#)V+R[2I(7:-NV$U&[?DW?35'9[*2"YTK.NQ3:
MVY-B=-N;_9'1J^W,#986:K77NUO,X6"*K8KB);2F6X%"\HC]:L/->5]_\;;M
MXUD+M)BT2A6G=AYA>>%'[M#$O285!K5LHENFV&MS"\$9.^PD/HG/Z"FQH@:#
M#$_:%<4(_72T4=)IZEV.Z(@99H^R>*TD18 RO'+&$<*6'E,,TO9W=S>YRPZ:
MGOYH)J.OW.CM:)[3+3IV//0MZB:VL99*<%FI9:>!I$C?V1;M*F)PGBC^WE83
M=K*S.JSE]QN/K@WJ:>2O'(6M1*)Y8<@JGF!5AZ$_+#1O5:69B\;[@P.:U[&W
MB=LA.\UNIM>_:\]*<DR=>U.I'N7EDFUI*5D^LM"Q)KW/Q8P2+[15Y_T8SYHU
M^@#@?5G ZM?F?KS>ZQ/=J=1:VOU+73CB--A5E76;8)]!DL(=?:E^DL6;Z\Z?
MJ4E"5+6I*4)3M2E*WI*4I3KVJ4I6_9K2=:UO>][W[-:^_>4>=]F/^LA_XU&_
MKT7^]S+L?[UOXI_JS#R1_KB?QE_KQ]9#_P :C?UZ+_>X['^];^*?ZL>2/]<3
M^,O]>/K(?^-1OZ]%_O<=C_>M_%/]6/)'^N)_&7^O'UD/_&HW]>B_WN.Q_O6_
MBG^K'DC_ %Q/XR_UX^LA_P"-1OZ]%_O<=C_>M_%/]6/)'^N)_&7^O'UD/_&H
MW]>B_P![CL?[UOXI_JQY(_UQ/XR_UX^LA_XU&_KT7^]QV/\ >M_%/]6/)'^N
M)_&7^O'UD/\ QJ-_7HO][CL?[UOXI_JQY(_UQ/XR_P!>/K(?^-1OZ]%_O<=C
M_>M_%/\ 5CR1_KB?QE_KQ]9#_P :C?UZ+_>X['^];^*?ZL>2/]<3^,O]>:CT
M 6!OU$NM$E6*&.BW6IV*I2B$>5">D08UC$3 \B7':=>2TY(CLS%O,H=W\/;J
M$:<TI'M3O9"7AEBE",QBD20 @@$HP8 GCX$CUR-=BBN4[=-IEC6U6GK,ZE2R
M+/$T1903P2H8D ^G(]?3*TS_ !5HAFU@KT>Z)]7M ROTFC$&IHVI3:B2Y[0&
MK.NNUMNI%6"<2,0@FK<<M,:US)94XP>G/L?&<J_P*U'FB],L;PK#VHSRR@@R
M"19I>SO?R+P2I6-4,8"H4'P[^7-"W3M22Q#;FNF6>.&I4</'7:L]*F+'@@%:
M0.JR)+:FL+9=I)1*Y4DU^V!=))>(@V /E+KO3&2Y;=1(TP$@K."5:/47SEBY
M:?:Z,(GB0%A?G7;G)[DU5O-%08'RES;#!=!%C\.N.@=5+:-@S,.^ J/(LK]H
M:0R=B3IX6#,@6*9+#Q2]K#A"'5"X;R19.F41&,%_RR>SO5B$CQ5UK--/KY_;
MHWC@G+VJ4VNKVZ@EC;NF0Q23+"8?9MP,>)U FG)QT7T5P3(T2U,KJ7X%2,O
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MXU&_KT7^]QV/]ZW\4_U8\D?ZXG\9?Z\?60_\:C?UZ+_>X['^];^*?ZL>2/\
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M]:X%Y[)TNPE%.^Q.WFZQ;*2C6MK0S\/?NNID^TZL>BZR9@?B9=@S./R1F*M
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/C&,8QC&,8QC&,8QC&?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>gdc15tqwxkbk000019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdc15tqwxkbk000019.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &3 F$# 1$  A$! Q$!_\0
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M?^7 -OJVI:803G'**ZIJ"C:(L8H1,R&F4R)TMUZTVI[)*M4>B5:-15 ^!>Q
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MW(I>&TNPEU\E2S*T424K=]HGGU<<_N6H(YG>2 0R$2S5?)VLWBJV>[5(&0,
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M+IIT?'E3Y3JDM1(++RY<IY26H[+KBM)WKETFWA1I)-=;5%'+,(F;M'TDA>2
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MTXA=@[K&O6*2=K<?O\& 0PS2ER0/'%*_W,;E=IH?1*+U  BT\\M82XUY<N3
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M.U##-#)&K 31S1K)&Z(WO@2*P95;W@" ?7-[LL:N\C+&D89G=V"JBJ"69F)
M55 )))  ').8>'>:41&-&A]PJTX,_-T-8+0[ )DC'B.VOF-0&I[$M<5R;MC]
M^U%0[M_;7[YIOW/RLE&*4,5,<@8#N*E&#!>>.2".>.?3GX<^F:$NTY(Q,ENL
M\1?QB5)XFC,G'=V!PY4OQZ]O/=QZ\<9L$.9$(Q(I ?*C3H$Z,Q,A38;[4F),
MB26DO1I462RI;,B-(96AUA]I:VG6EI<;4I"M;W@002""""001P01Z$$'U!!^
M(S>CI(BR1LKHZJZ.C!D=& 965E)#*P(*L"0000>,PN[A4DV#52W::YJU*3I:
M:SLV,U8%(W%7/TK07<KZEM.X+;DS2M1O3<5"Y'K\%*EZR\<G9Y/&_C_;]K=G
MQX^ZX[?B0/C\3Q\<T^UU?/[+[37]J/J*WFC\_'87Y\/=Y/N 7^Y^X!;X>N;'
MF&2,Q:C85#Y2,LN+1)!Q&)YN.J?$2^'@RFY+T:84:V[IP?$DM0ICK$B6EEEY
MN))6VM26'=IR[&X4]K<.2J'@\,1QR%]/>(Y'(')'(^L9K,T(:53+&&A57F4R
M+W1(P8J\HYYC5@CE6?@$(Q!]T\>Z/(8EL,2HK[,F+)9;D1I,=Q#S$AAY"7&7
MV'FU*;=9=;4EQMQM2D+0I*DJVG>MYB002"."/0@^A!'Q!&9JRLH92&5@&5E(
M*LI'(((]""/4$>A'J,PQ^UU:J-19%ILH"M,37U1H3Q\R.#-2Y*&EOKCQ7",F
M,B0^AAMQY332EN):;6YM.D)5O6:1R2<B-'<CU/8I;@?#D\ \9IGM5JH5K-B"
MNKGM1IYHX0S <E5,C*&( )X')X]?AGZ?M%9C;)ZDV(%'V%&1S9C3Y<>UL2&E
MIDJB%B>G)"?D!DI,.8J//E?"BOIB2=MNJTP[[H1N>WA'/<Q1>%/O,..57T]6
M'(Y ]1R/3U&>M9KKY.Z>%?#&LTO=*@\4+=Q663EO<C8(_:[<*>UN#[IXR;,^
M#(W&U'F17]S8NY\/3,AEW<N#KX'K,C:0M7QXNOFHOK(:]]G7S+'JO]^;][$J
M1SR".#VGD'T/KZ'ZCZ'T^/H?JS8'1NWM=6[U[UX8'N3T]]>#[R^\OO#D>\/7
MU&>K/,RQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&<U?+W
MV=5<\EK\*Z8!M^Z):9&A N[Z=&?4X-C##M-Q&B4;2'X[T.R012$#V%N[D#Y\
M:(.CO-PE1G),C-7X'!]1]'_K]W/B?RB?(W2ZVVU?>5-C\U7W]G@VG=!YXKM:
M'MC6=.'1HKT-<"%"W?#,D<",(O&TC]!*93Z_S^IUVD50>V+K=5#P08: U]NF
M((]A$=GXCF]>\_(=TC;TJ2[[STJ2X])?6MYU:U8?'U.?7M;KJ>HU]/5Z^%:]
M*A7BJUH5^"10H$7D_%G;CND=N6D<L[$LQ)V;&3LAOI/+YEZGJF1BL:!K=:?!
MZ0_'=>W\=PO")(>VIM:=?"VB.XTO7I[Z5[0K6EZVK2?G_5_1<_4MDV(;T-4?
M-$FN"R1/)]L-^O<23E67A.V)T;T+ E2 P)XCS0&4\A@/<*_#Z2P//[G S:J'
M4'J=$L$9Z:W.^LVLO8FEM-*9^"R23%0W&6E2U^\XWJ-O:UIW[N]K]$Z^SUW=
M],Z&300[6*2PEGYQWE_;(R1M'XX[8@5(6#,W<Z"'EF!"\MP!Z<G.*/QAP3SW
M2,__ $N/3^3/+UKE5$[ES.\<AZ<"CV6@]$KA&K6D+(4XUJ6+),[:<7'DLJ1(
M@D(;GPIPLE$<:FC"4:*0A/,RHS+J.KKV):L\5F!NR:%UDC;X\,I^D? J?@RG
MT920?0Y%VFLI;K77=5L8%L4;]>2M9A;D=\4B\'M8>\DBGAXY%(>.15="&4$?
MY)>G_P#X7&^IMQ1SC/E%3WJ(_*>>"Q.F5$W#M@N&MS:F!Q*=5U$!!R1&;VEM
MTO&@ $3%ZVZD+!UOX6OH4'7<7C7VFA)Y0 &,$BF-C])42<,@/[4E^/AW'XY^
M6-E_[--[VJ0Z?J6HU)F8PILJDR6HD)]V.22L9(IV4>AE6.N'/KX4^&1Y_P U
MU\E/\Y;AW_@E]_\ 2LW?9W2_ ;7_ $XO_%E?_P"[5U%_A%I?\S>_18_YKKY*
M?YRW#O\ P2^_^E8^SNE^ VO^G%_XL?\ NU=1?X1:7_,WOT6/^:Z^2G^<MP[_
M ,$OO_I6/L[I?@-K_IQ?^+'_ +M747^$6E_S-[]%C_FNODI_G+<._P#!+[_Z
M5C[.Z7X#:_Z<7_BQ_P"[5U%_A%I?\S>_18_YKKY*?YRW#O\ P2^_^E8^SNE^
M VO^G%_XL?\ NU=1?X1:7_,WOT6/^:Z^2G^<MP[_ ,$OO_I6/L[I?@-K_IQ?
M^+'_ +M747^$6E_S-[]%C_FNODI_G+<._P#!+[_Z5C[.Z7X#:_Z<7_BQ_P"[
M5U%_A%I?\S>_18_YKKY*?YRW#O\ P2^_^E8^SNE^ VO^G%_XL?\ NU=1?X1:
M7_,WOT6;72__ ,+?UQZQ#4]$\I^<C:DF0VLN]2Z79C=B=BH7I3T8;&.2*^,8
MD2&]*:;FR94AN&M>I"A\Y+>XKNN3KNN$;PT)FDX/:))45.?H+%0[$#XD #GX
M<CXB53_]FG:FQ'\X=3:^.KW RFG3LS6"H/JL:SM!&K,/0.S,$)[C&_':?]8O
MC?X\<Q\4^*T3@O'Q#PBB4 6N .U-?1++E9TN4^1-6(]/0S'1//6 O+FEBLEN
M/&C;ERULP8<$>S%A1_G]VY/L+4MNRP:69N3P.%4 !51!Z\(B@*HY)X'))8DG
M]1=/:#6],:>CH]3$8J5&(I'WD/+*[LTDUB=P%#SSRN\LK!57N8A%1 J+B/*O
MB4_R(X7<N3"SL2MDK$L!)A%B$5Z9!8? V(4>TU*8CK0_\&6D<J)MYG:UQU/)
M?TR_IO;+D93P0<J.ONEY>L>E=ET_!:CI37#4>*Q+&TD2/4N06NV1$(?MD$)C
M[EY*%@_:W;VFD$3V:QQB[\OL;O4A.QM*X20Y679;KTS<Z6;G4VXU7ZH-2J>E
MC0MMRUIG?#E.MRU('JC^YI4O3T7,O^+Z1Q_ 0<^71?(G:7::*ZV^K^'6=*3:
M"RBTY/+)9FUNRU_G@YE""!3L!+Q(1(1"4X^V=T=L?"_QN+>+?(9?.C=F'6HD
M0N9JV2" J%)A06-$H 88S"93+6J0]M# 5N0Z\M#.M.R5L(;4AA+[V+'D\CZL
M^@?)GT78Z$Z=DTUJ[#?GFV5G8/-7C>.)//%6@6)1(>]N$JJ[,0OO.5 (4,UM
MLQSZ%C&,8QC&,8QC&,8QC&,8QF-,QR4P05B!B388O*&SHXHP] 04:%$GXKK4
M$DZ,<?BMD6X,I34I<!R3'1,2UN.I]I+FW$Y*0&4LO<H8%EY[>X ^J]WKQR/3
MG@\?',)5=HY%B<12,CK'*4$@C<J0CF,E0X1N&["P#<<$CGG.=WXN/M(/_J6T
M[_\ 0MSW]KV6_MFF_P"!9?SI+^K9Q/S'UQ_AW6__ #2I?_K+'XN/M(/_ *EM
M._\ T+<]_:]CVS3?\"R_G27]6Q\Q]<?X=UO_ ,TJ7_ZRQ^+C[2#_ .I;3O\
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MVM13+)JZ$\5IM?K)VX"-2I5MI72Q:5B5BN75M7$Y'A>(GC+8]CHO7TBA%O\
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M:>[/1M0B6>W)#'-)S#%Y:Q"*J61YA&:[N,W)?F!17CA*O J3TNSDX-P9H<5
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M7)KU-L(T[#9JLBB5^H(IT5DB1A1I5;KE K08F$)VF8>ME<C01%.D!YP)-M-
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M3(D-ZQ(DKPO9,<%2Y=>&K&W:]NRM*O8-2FC>Z]NR(JRL"#*.UN-D_&>\;?\
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MV'=/?@EG\[;?]?Q^(#XJ?H':OUU=T_:5CYUO_?4_)ZWZ''V'=/?@EG\[;?\
M7\?B ^*GZ!VK]=7=/VE8^=;_ -]3\GK?H<?8=T]^"6?SMM_U_'X@/BI^@=J_
M75W3]I6/G6_]]3\GK?H<?8=T]^"6?SMM_P!?Q^(#XJ?H':OUU=T_:5CYUO\
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MVGFEH<;6I"M;W5D%258$$$@@C@@CT((/J"#Z$'X9UJ.LBJZ,KHZAT="&5U8
MJRL"0RL""""0000>,]6>9EC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QE!.$B&?('R(Z_Y.VQO
M10%QZ]7GQJ\9Q,K7S VJQ>?S=53OO3AS*_6.BYW[J0^R<\=--)5*@T+G(P7
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M^R:=:.;%/"]2Y,U4?4J?#F1)8IR1I2-LKW(C.N(6G:%;2O7O?@WY;[^CE_\
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M'W>Z9$/K(H-X<J\ZO&,8QC&,8QC&,8QC&,8QC&,9S"\X+/UCFG5?$!=/['>
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M3$92I4>9(I6MR1)!6L%*C"?:MN&7:N9B\$TBBF*MX VXL37T];MR@#_/@@3
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MN*6IX9]48XRUFO'8AG6P3#V&,Z1T/S<[%W/LO"/'+G.Y_!3YWMHFG]1LU7M
MVP*>!= \'#7DO0GZA8;%S&;"?FU<B4C3CX<E56XI0S1P8DCN;3;P6;A;(=96
MJUK=V;MMHE5I($DC*</%M4HR^1$G! D"D(PDY5)69>)8EYAW^L=ONMOI.G]?
MWZ2>;=15-E9K68Y^8+W1<W4=%JD]C6NA>M)(CSPR5>R2:G#%)WU+LH2&^4>T
MFOE.)\UOMR(] N]%N/BI0"3-'MIVKF)^NK]#\\C_ (Z0;G8;G3N6U%"1XD$[
M!3+T%HL1IP*+C0HX E9Y*B)"5/I894GBC6&*6/83*98TD5?9X=2MQHDBDGD]
M6<'COE/O,275!VBIU?RAW:DNNO7)+]RC;Z9HR"G:FK2R?.E_K>;I]+EBW4UE
M0".*%D[O#20&&-46"2RWDD[Q<GN-AO\ S^O6RUT8ES:QDT$FC%)+SXQ2:#FB
MS! 0ZCY^*U'1*B3OD-$QKK\,<0^G38FB@L62U+'1N3L1I#,\<<JS(O;VRJ.T
M,&4-\.3P1SVMP2.0>UF'!/VS5VY[U""U:I2:^Q()!-3E=9'A>*62(CO4+W(_
MC\D99(Y/&Z^6.*3NC61,TY88QC&,8QC&,8QC&,8QC&,8QC&,8QC*(]<J/1^
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MGDP\J6^-JYUMLU78+KJHP0LA!$:U&F)T]K!+=N-0L=JQ&H9V"I-(JAI%[)&
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MQC&,8QC&,8QC&,8RF?L]OXFW#/Z/F_ZXV/+';?W1M?OU_P!&F<QT9_>QJ/\
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M;CG@\,C!ASZ\',IC-V,8QC&5,E>7%0B>5\;Q5>KAO1.578<I-[TZQ^#C-T(
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MVS//HF,8QC&4/\BP,'H7E7XG<[)(U)$?@3Y2VHW%5K2V]1Y7/Z]S2&ZXUO\
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M@K';F=W"QC!Z!9_L'%>F$BK=:?;^;U$H946=&-N+C2(CT\[4'V;_ %DLZU6
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MYN D2'WW=T^IUEAUS;T=W>]6T(L)3V7 #W8Y%L\#@-<K.(YI !P.9HV@G?@
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M7*+YI1'(D8X4N<NO3Z8*W9&D] J?X7,](>KO;1SI:ME=FG(<&OAY_P"XK((
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MIZ53'CYL<?*[JDVHU"3,3((0)L]>FTWMRZ_(PYC^G!XY4.%!8C!6!<9FNMM
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M=X/*HWSOJ=[<6XC6&:\*]BE6$\:S64J%5L649$]BZ4WDT<C*29FDV6LY5HS
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M7+Y]9KIN>?-1J2\_7Y*\;\_RYNN>Y.QC&4K\^?X7P.!7?O\ PO[CXX5KW/\
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M::;2E#:$I2E.DZUK,"2223R3ZDGU))^))S>JJJA5 55 554 *J@<  #T  ]
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MXY9X^Y8YI$;!$_!'E9<2/!SKCU1X2*J)"FCH2SM7>1!&E*A?*5-?@N2*8\_
MDOB[^0F.QX+L8.^9$ABD@4](V:^M9+M;"$LL< 9I!(S=C@LRR12@'B0<@-$
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M\3(WW_1^1^3Y;T_Q?GW..BM*^S^7TVG6]^NOMWK7IO>5)^[3]Q_^[D3;>_\
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MTE.]YZ 20 "22  !R23Z  #U))^ S%F5%9W941%+.S$*JJHY9F)] H ))/H
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M,?:>_O![2O;\>[GTXXYYRT2U6DK+=6>(U'A6RMGO40FNR"03>0D*(S&>_O)
M"^I(&>L(>!V4:R8KAD38!$AR4S'*A",,J-?>@RWX$UIF= >?BNN0YT:3"E(0
MZI4>7'?CO:0\TXA/C(Z-VNK(PX)5E*MP0"#P0#Z@@CZP01F<,\-B,35YHIXF
M+!989$EC8HQ1P'0LI*.K(P!]UE*G@@C,MF.;<8QG@@E!A3YSZ81@$?I\^2+G
M_(RX\OY$G#VG4L=,^7<<^6GQ=K1J3$>]R0QM:=.MI][7KZ59>.Y2O(##D$<J
M?@PY^(/T$>AS!)8Y>_QR))XW:*3L=7[)$X[XW[2>UUY'<AX9>1R!GOSS,\8Q
MFONVRJL1;#.?LU?9A5*4N#:YCID<W%K,UL? +N0[#(7)TT%E(%%19-<<DN,Z
MD>2@35(U&F1W7,_'(2@$;DR#F,=K<R#N*\H./>'<K+RO([E(^(.:#:K!9W-B
M )58I9<S1A:SB-)2D[%N(6$4L<A60J?'(C\=KJ3L&89OQC&,8S7Q=MJIR8^.
M"V:OF"$5J0_*@"S(XA,C,1"Y&ORGGXL22\^RU&/!RX20XXA*&2XLB-<VF;!D
MLM9M'(H#,CJ#QP64@'E5<<$C@\HRL/K5E;X$'-$5JM,[1PV8)74,62*:.1U"
M2R0,65&) 6>*6%B1P)8Y(SPZ,!_7+75VHA:>[9 #<$ 1^D'9KA@<B(%+?P/^
MY9:2J3ID<1_NA _@4Q;,G^'0_P!Z_A+/OO')RJ]C\NO<@[6Y9?7WE''++Z'U
M'(]#]1P;58)+(;$ 2"3Q3.98PD,ON_:Y6+<1R>^GN.0WOKZ>\.?X+ME5.2-1
M MEKY>4I)9>HPLR.(2-H &GZV=5IF))=<VD+8HTD 65I/H--1WQ<S;,YIQA)
MHW4<LCJ/=]64@>^H=/4C]DA#K^V4AAR/7$=JM,W9#9@E?[:>V.:.1N()FKSG
MM5B?M-A6@E]/M<RM$_#@KFP9AF_&,8QC&,8QC&,8QC&,93/V>W\3;AG]'S?]
M<;'ECMO[HVOWZ_Z-,YCHS^]C4?Y"3_6)LN9E=G3XQC.>ODX^4F=F@5];UB+U
MQ?*15A*56H=+H7.I:!@R^D ]@.7*8=C3+5JI+78JP/9+@Y%:^B+2:F1#3KWS
MSX2XHA159QV+)YV19)()9ART(9%C"$1^3A)&[7$G=PH*CT#\'U&TK;=*Y,\M
M<ZN.Q)5J[&EKW$4=UX;$UMIE:R:I-BM&LL35O"?,Z3$][0]"LI\[S*7>"O\
M@MZU_KH^>7_&+VO+/:_V^M_Q9JO^KJV<?T3_ '-VO_+#K?\ [6;C,=?"8^!Y
MY<O(EYL8<*J7B3W2SDR$UYN/#&C_ -T/E$:;/E/N;2VQ&CQF'77WG%)0VTVI
M:E:2G>5)X[Q^)6//\*_^>0=A+''\H>IDFD6*&GT;U!;ED<A4BC^<].DDCL>
MJ*JDLQ/  //&4HMT0[VKH'C5YF6Y). +MGE[R2B>.E3F_,14UOA3J;>XY;YX
MU>VTHLO834$?:I2WVGGX59@5> Q+<C;6E&/Q*L1^R 7\2^OK\?7G.#N)8WNR
MZ5ZYO>6*&YUIIM=TQ3?O45NGV%TF[+$> +6[GCBMN64M'4CIQJY7D#MSFW/O
M6,8QC&4K\*/WP7Y-S/OU-\T_)-6E?XVA]O9":WZ_GUK0OW=;U]GHG68IZ]W[
MYOY#QG"]">L/5;_M^NNJ?X?%=$'\T('_ )8YU^]>=_DVW]WS7#?&^5Z?XWP#
M/88WO>GY_3U]WU^WT^[/!]VW[U?^]_Z],\UGI\H?58_;]/\ 2[_N]L^[3G_9
MEU,SSN\U.YT.D=&"/UKH%0K-VK\GU^.%M8,:?&+5M.TZ<^2*1I3"7DZWOX;R
M$)=;WZ*;6E6M;UX0#Z$<C(=[74-G7:KLJ56_6?[J"Y7BL1$_#GQRJZAA]# =
MP^((.<L?-'Q)IO'O%GNMGXM?^K<JKL&AEE%^3B;G,L?([#"GN,0YP]5-NB;"
MBN*FID_#;EU">!7#UZ:89]U+:$:W4!6*DCT^ /H?H^!^'\&?(NNNC*.DZ1Z@
MMZ+9;C3UH]=.9M/#?DLZ6S'(522,T;PLBJ7#=JO2DK=GT+P!Q8\;=/-GD(\?
M NG%N>^0=8'0HL5-BX;:MT2]QA\)AMG3Q'FW2Y&PQ4BIM&MJCUV_(TXYK?R\
M1/O::1ERX^(#?C'H?XCZ?RYU$5_KS2Q11WM%K.I:D4:+[3T_<.OV"QQJ!W2:
MO:MX)I2!]Q6V([C]R@Y[17KP*\Q/'FF^-G&N9]#OC?+[6,%FH#372PYJD@":
M?PK/.M/!+H='Q*6882AU,9U4&P/+9ELOL.MH6W]N*,H503P?AZCCZ_X/Y<YK
MY.^M^FJ/2VCU6SV(U-R&&:(#:P3T*TO%RP5:"_8B2A,O![6,=DE75E(!&=6P
MIT)8QT<O7C H\)EI]^*4"D(A0=)1]F_>CS8+S\9Y/IO6_>;=5K[=?;FW/L$%
MBO:B6:M/#8A?[B6"5)HF_>R1LRM_ 3F5QF[*5]D_?_-;PICZ^WY6H^5956O\
M7X59YD+;5O\ D]?JSB=;U]OWZ^[?VX'[M!^)O]G].<+N_>Z[Z$7]K2ZOF/XN
MVKJ8@?\ ],1G]\Z/R.;<ID_GA^5/C!)UO^3:>Q5AOU]=?;K_ -Y]^OMP_P %
M_?K_ #YY\H/IJ].X_P![ZOZ3?^+=U!_MRZ>9YW>,8QC&4K\1_P"$WGS9)_Y;
MRZL(OU_ET$Y+R&-K7\^D[=4G^3UUO7W^N8KZE_WW\RJ,X3HSWMAUY+\>[K2S
M%S_D--I5X_@)(Q%_(]HJ<^W_ .(\*ZKZZ_E^3[G<O3?\_N_/;_[/>^W[]8X]
M_G_% _E.>IZ?*98_QNA:7_T=07_TG]/T9=3,L[K&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC.:U1IMW\7/.NTPZM4['8/&CSFDD[\4DUT1.*"^(>5=1K7Q
M+:7L28,=QL%3>^TH'%(OV">XXPGI=97#>5!0?84]=2217M5&7D1+NK B4.P5
MK-"1_M:IR?>DJ2N5"#U\+\^I4YPU:K;T'5MA:]>>;1=6L]R1H8WD34]0UH";
M,L_8I$-7<58D<S.>T7X.P]GG!;I3E+G<XQC&,9_C2\E^_P#(WO(OKOTGIE$&
MRH/=O:/118^RW&M50C#*GO%NK\]%Z/0; 5&R:FQ9NRA[96JP_:6PJ#RHK)0?
M\860@S9'?UJ-GV:$FM.RM4Z?[VCADE4B/9RSR>,HK"4Q5&CDD$7?V<E6X96
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M@E%I 4D,+#S5:/U@>%B7GH8VP#%U1ZNQH)8N3'Q97D<T_FP1S/.;2S>-D=#
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M)2A.DHU]F;?L?WPSJ^MHHXHNC8XD6.*'KCII(XT4*D<:O8B1$4 !552%55
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M\;7-?R^NNZT+7V;_ .CO\K[_ /\ WA_N>?J93_\ 4,\^47^]Z _2.HNER/\
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M6$_E"K/W#L$@C/:+6?N;>=@;[1?E#Q>X^[]J6[GXX3@FU?R)=D4_J[&E>O\
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M1Q](7G3QV=28MX;#]!;AD!X<X*#/ @Z3Q:NGN21.VC38Z.BR+'OZD4*2[,9
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MF#TMR=32!X+%(4B(;!G8KEK]1SFU>'6V5[20@1O42=Q\?9X?:.]G[>U08.)
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F,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8S_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>gdc15tqwxkbk000022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdc15tqwxkbk000022.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $A 0\# 1$  A$! Q$!_\0
M'@ !  (" P$! 0            @)!@<$!0H# @'_Q  X$  !! (" 0,# @4"
M!@$%   % @,$!@$'  @)$1(3%!4A%B(7(S$R01@E"B0S0E%2)C0Y8G)U_\0
M'0$!  $% 0$!              4" P0&!P$("?_$ $P1  (" @$# @,& @8&
M! T%  $" P0 !1$&$B$3,10B00<5(S)184)B"!8S4G&!)#13<I&A)4-4@A<U
M1&-D<X.2DZ*QLM$VL\'#\?_:  P# 0 "$0,1 #\ ]_'&,<8QQC'&,<8QQC'&
M,C/V_P FAW7;;-TK]ULE'*ZTUQL[8D"?6RJ@SD\G6]7798*$5FM90_D3 L,D
M39EQ&WFFIY"OCH1%,H2^0@2\[7=IN5XWB259YH(6#KW *\\7>5!\=Q0,G/N
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M3 %2Y"(WU?M8>FBA4YQCXUS1@Z5EZ&QC6X%K6K%=9!*L$TD0D  #A&*]W +
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M\CT4AQIQ+D:9$D(9F0)K,B#.CQYD9]AO]-YH9:\KPS1M%+&Q5T<<,K#Z$?\
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M'<]RD_8;#I8X5;RAI?ZT7CY6EO5U4XXDJST6'L].0V48?SP6Y5;N_G2RJ_\
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M9T0G)&CY!* EQ$$@_#CNSH2'L92\F)+<;5(C)=QG.'$LN(PO&<X5C..:Z&8
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M'JPLJR1DCU(I?-_XH=I=Z/'GWA7TJV=5R S4A>W#8VYZS>YC\37VN(5AG,A
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M5"AL93Z)SC&+VRG2SL+MB/S'-9F="?=D:1BK'^9QPS?N3F%TQ0GU?3NCUUH
M6:>KHUYT!Y6.:.O&LD2'R"D3<QH1X[$'&=#=N\G5C7]J.4H]M>+.LM4E9@W&
M#2JI>]E,T><E.%N0;X3US5[4)H\YAI27Y,.V3@\F+'6B1(::86ES-46KORQK
M(M<A'',9EDB@]4?K$LSQM*"? ,8;D^!YRU:ZLZ?IV):LVQ5YZ[=ME*M>W>%1
MN.2MN2E7L1U& ^9ELO$RK\Q 7SD@:%L&B;3J8B]ZUN-9OM+/L9DA;54#0^P
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M@U[%?\>T'T>!^G9V_J,@'U.LB?T).LMY&.>WX9^I(ED_3M]5E%[GZ<_$=_\
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M/UY<J$5K<P%"%V"JL6#3$&V4^S%K%,G#DD),-BG!R1$T<GQ^PV,%J%8H(C"
M[%XS''V'BQ:FCE5PY9)"MEHY45 &[0?490J+L7372^PU%^6WL+<=YFAB$-E;
M-GUD[];J:5JG+ T*QSUQ/JTLU;$L[/'ZC(*L3O+-)91R&S>\<8QQC'&,<8QQ
MC'&,<8QQC("]_P#N8/ZHZLDQ*K[3F^+X.EP=756*.>/OB\O31X!_8U@!0\_5
M2ZW6C!T*-%AT*9F;#V :I^KZ\YFP6^&N/+:G6M?G!D^6I$P,[E@@;P6$*.?
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M:000E_D$LQ41H6Y +<A7("- ]2[2QI]1-=K1QM,):M<2SI*]6FMJS%7>_<2
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M(F<F?7ZJ(SE)(I!&NS:-1=B)D$$M?X$'M<G\:-Y? X,@4E."I.15#J7K&VE
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MD8 CN4E3PP*L.1]&4E6'L5)!Y!(RS/7@LQF*Q#'/$6C?TY461.^*198G"L"
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M?:BPX4.*TM^3+ER7UH9CQH[*%O/OO+0TRTA;CBTH3G./0"Q"J"22  !R23X
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MXA2<09'!(\'@D>""/'CP1R"/T()!]QF_JP=58!@&4, RE& (YX96 96'/E6
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M+K3M-Y9CC"E-B\-FQ6JPT+BL'IR1Q3<KSWN6X V]_IP\G(C/R"?);0;1G/\
M6)>NCU 8;QZ_U4W,I.S*VYC&/^U#D1W.?\N\QOC-(WYM++'^\6SE/_*6!_\
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M,I#6,K8#5NY@9,QSUCL(^7#69%L1Z*WXCGM:N4_PV5%RKS]%$L02=//@L\;
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M\S7VYA!K:6#X&(GL]8 2;&SSP 9+'!9"QX(B@[50GM4D'S P=%)>*[3KF_\
M?]R/FQ\#([0=,ZOM!8K5UI98IUB7E'M['UGF11(Z1G-;CR%X\E9%ZAZ/+G=
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M99!@=)L9E:YKXX0B5@6$A9]K L/$@CHR$LQD<AK5E[<[V)$B1Y."PAC6*/D
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M92K&<XSC.,XSZ<LYG \^1Y!\@CZY^N,9#+R)V^^4'HIVSN6LWYT.[U[0^Q2
M0D,RX@D%^.O3$$K .=:SAQB?7Q*YYN')1^Z+(@-R$XSEKTY):>.*7:4(Y@&B
M>U"&4^S_ #CM1OU5VX4CZ@D?7-7ZULW*?2/4=J@76W#I[SPO'SZD7$#!YD(\
MAX8R\JL/RL@;Z9L7J5KW5FK>L^C:7I6&*C:R':QITJJRA#;&(YZ"7!0BZK5(
MD,8]").U/S7;"5*NJ<D%")&3.D.N.OJ7FSL)IY[MJ6R6,[3R"3NYY4JQ7TP#
M[+& $5?954 #@9G=.4M?K]%J:FJ6-:$="L:[1@=LR21+(;#,OYY+#,9I)"29
M'=G))/.0R,# ]$\PFOEZU98@E]X]-]E&NR003A,>*2@ZUO\ 2!FE]DV6%'PE
MJ38TD#5KH@P]+0J:Z%;>$I>7'BI;;DE9I>G9?6Y*U=E"M-V\E3/#*UF!&/LA
M"I*R#QW\-QR?.KRQQ5/M+I? A4DVW3%^7>11\!9%H7*D>KO3JOO.'FLU(YG'
M<8@T0)5>!:KR!SH6.,96=V@USO[5/:*G=Z.O>MX^^\0='3>O.\-%QC\&KWPS
MKJ/>U;'KEVU*3,Y; $[C5C4X^W/J1F7 Q9A,UL<)D?=G([\.;HS5+%&35W)O
MA.;0N5;10R1+,8O1>*=5^=8Y%"<2*#V,.YOEY!T3?T=SK^H*O5NEHKN.S4OI
M=MJ5F2O<EI"Y\=!:UTDO$$EFO*\P>O*Z>O&X2-O4[2NS]&>1/JOO:QIUU!N\
M[5>ZVEM1B6@=]@2&G-SC2+O]!B*=<D0?U'+3C\J<I<^S0O;ZY3,5[5^VQ:T]
M^JGK&(3UO=;=1Q9K,H_B]2/GL'_K A_;,_4=:]/[>?X)+;Z_:C@2:?;POK-I
M&Y_@%:T$]=A]35>=/J&(R<7(O-LQQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8Q
MQC'&,<8QQC'&,<8QQC'&,<8S5F\-N5?0>G=G[KNKN6JMJRBV:]&DH<0V_+B5
MP5))8&PLK]4K(E7F&A@UG&%*D3Y<9AM"UN)3F_5KO;L05H_SSRI$OZ NP'<?
MV4'N/Z '(_;;*OI]9?VMH\5]?4L6Y?/!98(VD[%Y_CD*A$'!)=E !)XSSS^/
MRU=L.S6ISV>M3J-6$NPM\L&Y^X_?FYUA9%UZ]6][^7I7JC1SJ6\6QS4=6:#Z
MW_6QQU6NZ@2#65=7CSID@7+F[?MXZ%&PGQH]<5(4KZ[51. !%&/]9OS)Y3XA
MRTWI*/6D5H_4(4,,XOT;8ZBWVNF^XB->^ZMS;3J?K&U 7)N63_XJZ>J3 ?$G
M6UQ'1%N4FC6>*<P!W9"]K] \6?2&H!S+-PTK7^P%UMK#F+WM[LFQ'W;MF[$)
M#/PRRY.X7>.1?#S9"<)RENGQZU B+;9<A0X[K27,0$N]V<C*8[+U(X_[*O2)
MK5XE'LJQQ$!E_P#6%R>2"2/&=$I_9_TI6CE%G50;FU9!^+V6]5=KL;3L.&DD
MM6U=HV(XX%80(I *(I .81XU<E:#/[?]68=A,VW5'5+L2G7FD3%A(/F"X#7U
MHUW3]ALZK?-RW'II>)JLE99E;#R2+\@A&"Y'"W7?IA\-IJ[NN)AK[Y18Y[]/
MUK*HH57ECEDA]<(. IG5 [< *6Y8>2<Q>A?4IOU+T^L\UG7]/;OX+52SN998
M:5BC5O#7F5N6E77R6'@B9R7$7IQD]J*!:'R#S?LX9$</,#YXDM!B$Q12'*'$
MAL^.S,@$!\UA<:9!FQ)"'&)427'=<8DQWVULOLN+:<0I"E8SZ"5(92592"K
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M[X9 ?8\H0"1_$&'TS8.E=W_6#1TMBZ>C;[7J[*J1VO4V=1S7OUG3DE.RPCE
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M&.,8XQCC&4W3="30'=CLL4HFH;)$"UOIWK [I.UXH9S]+.]C:K?-O7*5+ 7
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-'&,<8QQC'&,<8S__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>gdc15tqwxkbk000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdc15tqwxkbk000006.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #B C<# 1$  A$! Q$!_\0
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M/A[PD2_.MX-O^992[97IY#(L!^2J[0B/3W[[S<^S_'W/PXQRT^NG23/W=O(
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MV17+>C%J5"1'HTLC"%812K&J@7=6=+)#&6X6MMK"@UP+3N!CG634((4:DT/
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M_GSS[]%2GT/N#9$?.*XW<B TB/G;7<R-(\Z1'W9R(=W+NT\>/HU-*?0^X,&
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M()L"UQ##'+,=I;S3HS@/RW^)GN_+_N"(]FP>Z><;#S$.>W8+JAF_S 7DV<Y
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MSO80R;5!A%F2&L[V+S?&VI-JD>$Z-!M[[_$P/JO_ '!P&=MP]TA^+'TP>K0
M$"2!-\U=&UA)<$2V*(&6>V25Q/#,F#=L5'FG1D=_?>XF $!]/UP-@W 1P+GS
M#D/<.!V'0X<(-R0M3)A2 T1I>>-#AP@W)!'&3E(%CD1H=*#PG1GE[[_$QCH/
MO_7!Y"&=_P#">=M^T1QMC3JA3R(<@@Y<X$P'+H,(5S>0Y; *YP,A,L&GFFQK
MTO\ $QG.,#?^X(9SGE_A(, /P9'(=VBP\4FP6K7NSD;PCJ:+#Q2)@M6YSD5D
MN=/-/C(<KO<3.<>G^X(AUSO[I\N_H(#ZPO4&I3Y')0F^&;'(WJ#4I\CDH3?#
M-CD7FG1G.]WN)@.OZ/\ <#/7.,.0_ .P; .0#&)U0D"3EG%LV$9XF;$AU.J,
MC-N1A25/>92)#J?-.B_(+O<3'R_7    =QW!S^'(<@^'4ZF>7;)FPC.$;GLH
M,)NR!P)DAJ(SA&7V5'FG1D!Q[[_$SV"(\0%P0QN.<C[I=G9USC(:O5";X@"=
M+9W]":-7JPV9E"7:5SUR31J?-.C0[C=_B8'KM?ZX(\PYX]TL=0SUZX'8=.KA
MXQ$D3.IX HV)N<JG5&N*(DZ&S/ %9&SN*X^:;&1' W>XF! ?^?ZX._7D+GCK
MOG;'WZ<(3L<Y$93?,923$94X0G+S9$<UQ&4D^B?-.C(8_+>XF,X -K_7  =\
M"("'NERWV#< $-@[)U0602 7G"E(\PSP4PZ=4%D%">2E3G(9X*<Z>:=&O2_Q
M,X <8]_^X.V^^,N?>&^ #U=75PKB0Q?.UAP,,GGE.KA7$AB^=K#@89//+9S@
MS@2*W@7R8T,AFLD)]\MC.]OSJ6.TP>,UVO@AHT>ZCP>>J JD31HH*"OP*2Z"
MZ #%%.O0_(L+<=]O._&";?<^P$.:SZ/PC#M-^()]UO. D$D@+==AA6$&P0GC
MW5NQK[*NRK4*_/$O:FP4Y@<!F,(=72JY-!TB/>&9F8U+,PHZKB6QM2X2*3@L
M5I50EIW6[3 H<5J9*M.+84SPI.JPGH(/4[/%WW^FN^MBSV6NS,YI>%DMZ OT
M2DTRL@AEKY12J0.Z&'*D\?ERB&-HN"UJ0,!T@1ND46K"&]M6NZF-KJ5%!S?[
M6-4J>/'COK[^(R_##PW12%ORB$K)<JEDY8[81AE:':&Q8M.X/J!S<"JE;]-G
MJ.QUF9R$; >)U1[B7XPVA(G((-,K+I!2M8+9>R(61N&\0U*T6BN UQU[.<XW
M5,RV"(/#-';GHXA,9ZMMF2CBS\\/K\[+8G;]\=FQ]AS4]Q:04^XI+4[K3'9'
ME2MO+ 7'@E^K.PVZ\0AZZ,QB:(7-0@CLIC[>RO[84@>'IA5HGMF3UJB6Y;2I
M2N-*I!4=6:G]LGD*::#JU!8*5:5$GC%$CIA)3TT!*"F7W=\F25J87=.PT*2T
M%#H8V%UBI3M@JJZ$A*HPHM.8< DDU5UT5TTJ5D.E*:4II2FE*:4II2FE*:4I
MI2O.?B&N)>*VMT)D0IO!((O$Y#"$#]8J-1F!0%W4RV<-QJ&./MJZ7*2M:Y6L
ME3T_.L>>8_2!Q5)C0\/%515".,+%8J5N_;)!.&RWL+07,?$4DN&FC3.7-7QM
M;R&MN<I."$D7I2WH$U-!*9"*\3J4A=%% ^UZ2ZJZ::ZJJ05!P]9/KK.=*M-*
M4TI32E8K.]X1,@QG,5D(  <Q$6A8  &-\B.P=^E*U^X%@$."[A1"H! 0X>K1
M (" @(#Y"LG,!W^/?MWT'CQZO1%*VKTI32E-*4TI32E-*4TI32E-*4TI32E-
M*4TI32E-*4TI32E-*4TI5.7_ /T))9ZV#_6=EUU'3_[B])?DFU]5:N^_>NV_
MFC^MAJEJNF.?TN,B'^=UY9[^WEKR//&[>Y?=6J+86"NJ7=+K9?/Z=*CKR'.V
M>><XVYB.=\"'J'-.F5PI5DG-@%#!YA8JN5PI5DG-@%#!YA8J".>0XWSOCKV!
MN.=^G9GF.@"N'"AY:F HSU5A0!7#A0\M3 49ZJPICD&P#W>K&?@V'OSD,!OH
M3<R1QYM=LC@D68H3<R1QYM=LC@D68H.^W,,C@,[Y'.X[CG ]<]<\MM!$V*#*
MA!0("8R62O-!$V*#*A!0("8R62O-!Y;8YXR&-^G,-@SG..SU:"\NS1<9V,E)
M/7G07EV:+C.QDI)Z\Z9#KC<.79MW=_(!'8.6,Z(Y.#?6>/"Y DW:HCDX-]9X
M\+D"3=JH#EWAGER$.>!^_P!G+U:IOP*O<&S'HUOSJF_ J]P;,>C6_.N6!JZ[
MAGD&0R..N<;!CEN&!'<<:Q8PY05<HH/).2[P6! =8L8<H*N44'DG)=X+ @.H
MY;YP(\]N_?\ CZ8S@>S5O"8%IX1ZLVF-:MX3 M/"/5FTQK4!C(Y$=LY[^G7_
M +_4.J6@@)MPSR_9S%4M! 3;AGE^SF*G&1Z#G'+ED>?,.?,=@SGER'4:&83O
M="UC:PDI7N*C0S"=[H6L;6$E*]Q4\QVZ[ .0^';KM@-P#;&>6=2PG*2$>R<I
M9@F6KJI83E)"/9.4LP3+5U4;@(@.!'<>NW(=LX#O[P#'=JP0"&! RFXE,\.!
M+XU8(!# @93<2F>' E\:CF(=G_>.W/<=\ (COG5L#K^P3:!#( A5; Z_L$V@
M0R (53R$0[<@.X ': 9#;(<L;AOC.-M2X>B(@DZ$HRC=P8:<U+AZ(B"3H2C*
M-W!AIS4#MT[PR.X<N>,#\'?W#JB<^!0@WLV.WAQ%43GP*$&]FQV\.(J>?,1P
M.0VWR.W+(==L9SC'34M8!A&80FZ.4M)O.I:P#",PA-T<I:3>=-^?;CEC/TWJ
MQD=MOCV'DBVCNU[GFT)GND71;1W:]SS:$SW2+@ 0'GL&_3/Q .=\[;]=M"01
M:3&:[R%"F,IH2"+28S7>0H4QE-!R/<(YVV -LYS\.<=G/F(CH$.(&<DRDNQ/
M6U@!0(<0,Y)E)=B>MK "@;B'>(<A'IZ@V#ION'/MT, \ ;@9\S)SB#;2A@'@
M#<#/F9.<0;:4SCJ "'4 Z9P(<M^W(B(XQUSHGD2#D3FF#>-$  WDJ(FX)>1.
M:8+RT@ 7R5-\Y#GOV??$1SR >8!RY;CI"1M&OH "N18F]X%(2-HU]  5R+$W
MO H([CCGD.8#MZ^P '';N&V ' @(#LC8B>6I(>D&60P @.R-B)Y:DAZ099#'
M5K'MG;ES6VN#FA1N#V:H)9D:M420H=#DI(J5)" HTRFM6<20 GFD$@8;2328
M;X 445U S367:$-!*,$ =HBG"V7:(.0E$) =P%6%PY?GS?+?/Y8S!OV_E5V_
MUZ'Y&?>.^0ONXQI]S["L]P]_OF7W1@C3[GV-;/Z^PKL*ULO/POP*^<EHDDQ7
MOI9M-FKK65! W'(2D@,5V5D,<'5\+J4(5"DF1L*Z#LZR.K"CJ$Z-2)IZA,I,
MH3B0I5CV<M<QV6ME#K7QU:Z.C9$&BA![LOAJ<]]?W X\Y<\R-]4)4Z1,H>Y$
M\*U[T[GITJ8@YQ7*3"2"2ZJ2Z5/!KH;U6&@%_4<#:;CMJ=]88'<1FN.1'G)L
M9GIA?W1D;'MK1MTA:GQN<T2YJ\%\/55%4DE**%B9(>4H*$H?"5.V^7LSJJJ>
M#6WJ>^[%>AJDDH8VE@=&>5H;.LI$5;[94W!CEMWFS[!-BTZ>.4R1(K:[<OJV
M.IV!#($T7&HI"YU,WN@B+.%37QZV_4+*KOLU:ICLG;A@MG&U[HYLT>/?STBU
MYK2F.1U<@DCQ)E8**T25&FJ I:\J""/%IR_!3%DTU^&8%==2K5.5\#W#)7>R
M;\0-5LFRNY%RF- QSU>:H6GM\GI:58JVIT6MAZ@Q,G>$/AGIJ%K=2B]L)3ZR
MEI:FJ@FLI2L_\V:P?HKB?VD9_+:4IYLU@_17$_M(S^6TI3S9K!^BN)_:1G\M
MI2GFS6#]%<3^TC/Y;2E/-FL'Z*XG]I&?RVE*>;-8/T5Q/[2,_EM*4\V:P?HK
MB?VD9_+:4IYLU@_17$_M(S^6TI6GW&K;/AXM[:6HELB9+!<]Q=$,EM$UQ.+3
M5^=IM,+7K4=QS()[2B*%T-5-DN:(XOCS\WN-!;>L87-R ^FLHDRHM3QX\=]8
M]P<VDX8KU6]+63.V#8^W:9969=:8Q2X4(E3:_68DERC'J00^'H$\S:&SW,70
MN%.9,4*41X!3^"D7JB#:2';PE"E;Q>;-8/T5Q/[2,]7U;LVTI3S9K!^BN)_:
M1G\MI2GFS6#Y>]7$\=GM(S^6T0NIUI3S9K!^BN)_:1G\MI2GFS6#]%<3^TC/
MY;2E8Q-^&NQ!,,EQQ-K8I0:5&'\PNL$9F::Z&I752("!V<@(9#&^=^>^HU(N
M]'DG!"C-P*3*NBJTJX-N!JQ$FX2N&>0N3?)/=!ZL7:US7"GDSD034K60UG//
MJ+*H,\ NFHVNJH**?I:0'P0#&O.M[_R;]&[[O6\[WCZ<\JMECWG:XMMCV>[]
M/[[L=A@Q8F\.QV6#$,.#9S !(0K5Q[I@QXB<6TVP+M@VAP#_ -/!#L=:]^R$
M\,O#A8-MM)<F:QGB&<;+-SI.6BX)MG9)<A7($LFDD?1--J?;Z:".[:^>T5<M
M.J0)5AU1C,@<U20YV$@@:3J=OHSR$W7HC%ML>Z=.^4^+'M\.#!BQ[UTQM=[6
M#9XNN=G@P;UU\& [0A8L6#",>(>XZV$$4P;K@P-;3;S)ZVT..T9VNP!)L>&G
M/ W:UEGG$Y:ZI5(%]QB$#R:LN7%!;[TU2I,PD</\-8O*1_62Z8-EI'VSM5WG
M1Z:G>N-6R23)OGI,?=F]U6L"AV5$?6=&[AL^C=TP[IL]MO6\8<&/:8OJN^[;
M%O&\$[3&=H1BVN*3AP];JX,-L&$#!A>'"#7/@P#!AZHQ8L4DO%?3YM3JZ_I&
M#AFL('ZED3SV^TC/Y<1^_P ]];Z&G'MUK.GFS6#]%<3^TC/Y;2E/-FL'Z*XG
M]I&?RVE*GS9K">BN)_:1G\MI2J^B]L>&&73*Y4%:;5L8/=J72-M$H%4T5DHQ
M5RB,():U^YJ@%=8K"@:G)."BL2R?$J@,)"FH*/#%2K!\V>PGHLBGVD9TY?\
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M>SA<U(65M3U@K!RS_P"+#ORY?3YSSVQN/74($H"Z_"B]Y2M+@942,9'B%>_
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M3< R'0(YB8 (LLD$PB;@&0ZGM[0Y8'ID1# ]HY#H/>.1'$TT-V,T 6- CF.
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MLS!&CFIZXW$0R 8WQM@=AY_Q" CV8"<8 *)<.6)%O6"!JS., %$N'+$BWK!
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M!_G#C.?@UY'8X_\ A$29PMH2D<ZUA PWD$"YSTX*=>RN/A!L&:<=OA4YZ\A
M0W'EWCSYCH0)NXA%6%PC [Q82!5($W<0BK"X1@=XL) H(@/Z:GMWJ#(#V .=
M\]^WPZ#MT@$ A7((CLG(,101K$0"B(1(5QPGLH(A^NH^"H #UB&>O=TZ (Z
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M'I@?S0;[!C?;^W,;#2L,V/>F)+B?%A8:5AFQ[TQ)<3XL(#8<=1V$!V[<CR
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M[%5J:,MPTN3RHNJ24NDLC7GFN,DE#C31#*@]OR%\5+G92'A5 56J\12/BRJ
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M7\&FS^;Z4K%YQ8"R),+EQQ=J8)285%W\PNNB-M@5TUTM*L::J1 @!"H! !#
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M<VJ6(4:B# $"\$FVI-S:H$1R =.0\@VZAOL& 'ET$1QTU4$3G<7,Y&)+(OF
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MONWZ.WSHK:[4DG<M^PX<.\;,8#U1UQL\6T =PTQ+SK9P8CBPC$<)PDWPFX]
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M]8#MV[8$=]]$-<XR !(/(B=)8$11#7.,@ 2#R(G26!$4#?;KWAD!P ],9S2
MB&X] YYV&)RX%$,C-I8B 8&9LI&)RX%$,C-I8B 8&9LI@?X_C'<<[[<]PWR(
MB'(,@&J/5W" HFT&$ "9*)JCU=P@*)M!A  F2B:G8 $,?%G(;8 1Y"/,>[.V
MP"&I)(+[TC+(%P+#CG)!J22"^](RR!<"PXYR0:4CT$0P/S"&_+NV]0]NF(9@
M%CV@Q?C/,:4Q#, L>T&+\9YC2G:. $<ACKZ@V'&W3'9OCD+0,@(O+F9#G-ZP
M[AH&0$7ES,ASF]8=P'ICO#&^/@ZB.=^X< /+09O@7#[<@%'$,B]!F^!</MR
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M0Z@(@/: B [".E*QRKA&X8:FI]8JK"VLJ9)0H=%<E9ZH>SBV2!4^!X+RI>D
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M#_9KZ@6#5L@AV 16Q3S=K&>BN&=OYS)_F^]RU:+V7/CMO3S=K&>BN&?<9/\
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M)2)DI(,N7"ZU[$I$R4D&1YYP/+<1SMGU;9[<AD-^6B%LKP(RYRM$9BB%DQ>
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MXS)9'L#IMO\ %C(9$>G,>P<AL0U.<QJ9:* SL-0C)#4YS&IEHH#.PU",M\[
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MU?AS]#,!^X*;YM*5C,UX7.'<B&RX\FS<"H-*C#^8772Q)O"IKH:E=5-0;!N
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M5KV5X3LBR$R]N99N[$H6^LD^,() D\0: $DU*OL]OCYM?K]BM8;F-7#ZXO\
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M=*8.G(,T!D1Y!MR'EIU1GA"YDR[F2 !>\$7IU<TA:Y,YDHE#4/).GO-6JY#
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MNQ=/EY!Q3/[H"SO'GY$_?[.[&;UL2:%QKRL_!XVKQWR8_8)[,YXU/NU=,/\
M(2*!MZ0%F<;8#/D2 ]GP;@&-))G"#/<9E-:Z,YNGNB; S.<ZIK70-YV>[-TL
M?XB17D&WO@*Q#_4K8 QOD-@Y[;:$GX,C-*<U/&-3;@>+X(SFWJ(UC7B:GW9N
ME^T2*[XW\OU8AV!OY%8QS#IMMRVT9.5F-#D25UF38K671XCD GP.I@EDV.K1
MJ!>;I?M$BO(0_1 6<\<O\2=@WY?[>0$Y8="<NULN1!4CTAUL@-5E>]V;7)/<
M:>[-T_VB13;MN K =A_]R<XY!S$,ASU&?@B>9$B8:!-[-'C1XO@@OF1(=F@2
M.WOJ!>;I;?D$B@XV_1 6!MGNA(_V[=9#K3%Y[<KXM.ZJ.OI<N4_74^[-U-_R
M!Q3D.?R?K.0!V>1(8V''JSC6+Q1 O$DR2[O43Z<JGNH@7@\7JY9#+8?94@]7
M2_:)%?!Z_D_5CC/+ #"1SUZ!VZI;][,J44LR#EZ>%4]9A@ REG&9ZPK$K%2F
M]DI:Y2=>>WK'!3VZ6OK?#SFE^K<U,EB:5S6DM3XYM-2,L6!0I1%IJJ"JUJ@U
M=37[>J0LX'4H2YA)_"$$PC[[*ULQI8MB\!)OGZ3 2,02&D" 6ZO/;'/IM@,Y
MSN(CGXN@ACEMK.7;.64E  7?F"[S6<NV<LI*  N_,%WFN60SD-Q#'=D0SG(^
MKOQZ]8HI& 7Q0-HY\'RK%%(P"^*!M'/@^50 9'81SOC?'J'D.PACGV;9Y:I*
MN H</F#(D%VUE7JDJX"AP^8,B07;65>FPCVYP&,XR.VX]<9R.>?JT+ T3+30
MF!DT@K<Z%@:)EIH3 R:05N=2'/ED,<L8Z] R.V0 1$,^K4-KHN[>690E$@ K
MG4-KHN[>690E$@ KG4"&-@#(CUWQRSL.>GPY^]J@N24!E#NO=!9]B]-4%R2@
M,H=U[H+/L7IH(@/3KMMUVSC&XYZYQG;J&@!&>4SE*;@+)-3D: $9Y3.4IN L
MDU.1H'=MCMSG;F&,#S'(ASQ@>S8<W+T2FQ;%@@;-C61S<O1*;%L6"!LV-9@=
MN@9Q3SY\@Z<NF_KU1.93Q6YG.^<<JHG,IXK<SG?..5<MP[L8YXQG&>H\PR(>
MK&^0#.,'BW9M-9"Q0/-PB5C!XMV;360L4#S<(E0(Y'<>6<[=^, &W+GV_"&J
M K"Z4\&R9O;3L-4!6%TIX-DS>VG8: (X_C$ #D AN(=V=L8'KT#0@/U DW+@
M'BI;&69H0'Z@2;EP#Q4MC+,UEW#E^?-\OW1F$/BM7;_^PATY:]#\C/O'?/RT
MGOW?8>'G>L]Q]_OG^_P'OW?8G]ASO6S^OL*["M3>(+BZA?#O,87#)-&90^+Y
MNRUOC>J8@:A2)$Y=U+1VH$I7[?<$AWCO=B\#*Y?W$HVCW,:W7Z;VT"1.H4\>
M/17S60XV[%7V<(C&8V\NK;/9=&J907#'%@>SS65*;0X*TK8^RMK;ET%;I(N9
MFT^0H8PHDU$@5Q_P'E.VF-P@ITI66\3'$4U<-T4B,C<H]Y2'S:X;#;AG1GRN
M*0=J3.KZA>'$E>]RJ9N+8Q-#6G3LJFBLX]14<<J-2IDY)AAP84\>/'JK6DOV
M3:TH1:.2E5;JZZ=&_62NC>H5-+0QJ(^6EM1-6R /<5:YI0^TQ&4.[F_N9*IG
M=HZ\+XM5&#$,H<GMN:79L-4J5MG8&^C#?V'N\E:&M2P.46F,BM],8ZJ=6)^,
M8)?%CRBG9MH?(RXNK"[IP+4I%2=<W+C2ZR5-!9Y:=64H3$J5>.E*:4II2FE*
M:4II2FE*:4II2OS--*(*,/.,H*))+K---,J"@LLHND:S#*ZZA"FFBBD!JJJJ
M$ II 1$0 -*5\R-S;G!(E7H%Z-8A6IR52-8F4DGIE29072:0H3G%UU%G$G%5
MT&%&EU54&454UTB-(@(J5]'CR?JQ7[Y1\^E*>/)^K%?OE'SZ4IX\GZL5^^4?
M/I2GCR?JQ7[Y1\^E*>/)^K%?OE'SZ4K%9V<2,(F0 :6.8K(0P%= B/\ @A7R
M#//4.A*!@G3C,!4]%:^\"IA5/!APJ!49334'#Y:+--584U /D,R!@0R @.1P
M(=O3.L1B&9$, DX9&K0R$Y&\T;-V1>>R?IK:SQI/U6C]]#\+5ZV'X6'O'MJ+
MGWFGC2?JQ?[Z'X6G6P_"P]XJT\:3C/CB\=OC0Q__ -:=;"UUL+T8=1<^\^VG
MC21Y'%C_ /:A^%IUL(OBPCM%%S[SRU\7O3QI/U6C]]#\+3K8?A8>\>VBY]Y]
MM/&D_5B_WT/PM.MA^%A[Q1<^\^VGC21Y'%C_ /:A^%IUL(OBPCM%%S[S[:>-
M)^JT?OH?A:=?!\+#_2'MHLY[SZFJ@3B0_P"%+YAG^[4A@!Z_FM4$&T\B(YS0
MB]^\^V*>.(V_NQ> Z>,HZ=N1S]_'+4(=R5I81[5K0>))])J?'D_5BOWRCY]9
M5:>/(^K%?OE'SZ4IX\CZL5^^4?/I2GCR?JQ7[Y1\^E*>/)^K%?OE'SZ4IX\C
MZL5^^4?/I2I\<3C/C2L=OC*<?QZ5&&F'IG4>/(^K%?OE'SZ5:>/)^K%?OE'S
MZ4JG;_'$C:65@!I8B(L& "N@1'\D[+L 9UU'3_[B])?DFU]5:F_?>NV_FX?Z
M^&J7J-+ZUT#^9Y5T]E0[X_V=-]>1B^-1.$,C^23&O[=)U@8$KW)DG7$;"V6N
M;R51XVC.U5&VP!X0;8[<#D<<^T!Q@>V]4"YU9].<#CD0V-*L/P@Y9C/O6AR(
MN-(\;1^OH !S^FIWYAS$1$>?7[VKU1'#7Y@$!;+TT]SJ"19GV0+9#OIXVCGX
M='+;%5(8WQV\NGP]NB'M<OGQ<OA0=6S'%EOOXF_!<GC"^VC[,,=O;G.._EV]
M8C\+T#CV+L[LA.F,=X[."[+CN>-+_748V''A!L'+J/7;?KCJ XU5Q[=?H$QQ
MB0#3_B%C+DEQI"<.'%@:CQM'+PZ-\?IJ=^??G?.-L;;:+QI;V.7,U?<ZCOM:
MVMG.<U(FEB/YNC(AC\V'WM^0]F_,>W4 07%V]?'C&50((,7X>GVQ(%/'4#CZ
M>CF'Z>GF'9TZYQCKIU5Z1;(G.63DW4@6.',25<]YT;[*";0.PUT9SUK#;/0
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M"(:1B[B0RO100#EC./AYB.1QD1P'_K;#T#?0$W:?98!!H!G^;(S,4!-VGV6
M0: 9_FR,S%.8"&1'N'(;[X^^.^?TV SOH8(* XA&(?H$+\%E10P04!Q",0_0
M(7X+*BF.>0 < /4,9WQ@/C$0^$0SMH[(D,C(M0V>X ]@*FCLB0R,BU#9[@#V
M J:8YCG.,X$,[=>F=^H?3;CSWSH[!)I@J<LU&1]S M"H[!)I@J<LU&1]S M"
MIL 9R CMC80]6X=V?AYCMI)*1 EL@\X/%=EA-))2($MD'G!XKLL)IOS'EG8=
MO7MS#(\Q[<"&<["BPNI$\IL4+#1@I2$6%U(GE-BA8:,%*0W';/(?CR(]-\YS
MOD1VSL.^4"5<=R SA)0@)S$) E7'<@,X24("<Q"9WY /(=\C\>1#(@'/H&!V
M ,Z*+D7$(=R!0)MF6))5%%R+B$.Y H$VS+$DJFW0<\\  =.7+U9ZYQ@>W"<P
MK,DYWOS62;&C3F%9DG.]^:R38T<;X ,9SOTWQW[[@ #WY'?OL,EI1G#X1!)'
M!".%ADM*,X?"()(X(1PG<>8AU[ #D 9'U@. VZ;;;ZD"P.6I-R4.1#,W,S%2
M!8'+4FY*'(AF;F9BI$ 'ED0W#X $!V$=NT R(=.P1U 2+H&_:01($Z$H'/4"
MH"1= W[2") G0E YZ@5&VX8VYAS'H&<=1 >>1P& V$,Y"S!<V-AF4\@19!EF
M04C9@N;&PS*>0(L@RS(*1C #C [B([#_ &'OYCZM5D-B !/A<+#G59#8@ 3X
M7"PYU(8^FZ;9QMRY[;#UP'0>O<$+]SG*<MVF1DSF,N)A?N<Y3ENTR,F<QEQ+
MIR'.,A@=^>PB',1W'?L'X09W":+$6D V @1J.PL[A-%B+2 ; 0(U'80XP.X=
MG(<YYB..G9RZ=- V(.MPE8 G/6^>= V(.MPE8 G/6^>= ]6,;YQR#(8[1$<@
M.=]MP[M#S;A.Y1>@ 1"B8/&AYMPG<HO0 (A1,'C0>6PYW#X=N78.-@Y<^8!G
M<+R%![)OJ')O:Q*@+R%![)OJ')O:Q*AZ\<\8Z@'J#<,#TZYQV:<G9O(GF8+&
M>1#UIR=F\B>9@L9Y$/6LNX<OSYOE^Z,P_%[U< QV]._7H?D;]X[Y^6GO\WV#
MTSK/<??[Y_O\'?YML7IG6CW'O.+K0,F<GL"*W+Q9:8RYH@%YVFX4#";-Q=<B
M@<4"%K%I)L@9DA$><' E;'W.H\L^I,[N,=4%&%T5J:BOL.5=AX\=WKK<O@IF
M%Y[A6%C\_O75&RW68*UKY"6Z.1<R)%H+9FT)R(68YM5;N\4E.3R@3UR$"BSB
M 0MKNW-AR8I6B4C4I7D$H]DLXKX$RQQ[D<+3SH(%)[Y*+DMB**4QTJX,3E*>
M;/?#@*5Y-35H(LT0IEC<@HNB_$ HJ*20E2X+"R:7,0THL_'CZ=:RB3>RZW7M
M\T&3&8VAM;6B?T5I'.&6\;IRXKWLUB=$DD3SQU9Y<PQQ^A\D*=7%JH60.DAU
M3UU(*53>8G<G-O=BD3QX\:WJ+QRMR\$(UW;E[*[=$AP>7=;;BT$7CT04WJC#
MXQN,QD;^0ZS%CD=EVJV]"6=1^(JXL-(-L^?5\W3(EBHMK);Z#'U;$Z43@"11
M>(OK:[FOHB7LM<\GPM]2.Q#&P*5L @=R&1I07'3K53K0YQ>IU?V2:.I\(5M-
MO66I[6IVQI52<Z//*QO1J7QNH7-E+D:U*I^?,91QOZHO7IIPJ7<;.+2PEM[P
M2>%,#4\4/+LJ+:$=:MY:(_*HNZ.T=,<HN]N+6VTN!%1(*J4CVRBO9U:5:I*:
MGQZ;C/;RE40\>/!FMKJB"*_#\(DJKQG@>'X1=(^'XL<T>%D!\(*!R-(#D*1$
M1#&1TJT$@@?"R26/AU4U5YHI'PZJ,#155D!\*JD0 :1'(TX# A@,*5/B2O"\
M+Q1?A8J#/@4YQ6.:PSCE6(9J#E4.XY'?2E=6DC[&A=W)^1M+>F>G=*W(71U)
M2E4+UZ)I%74V)%*FFD#34R"M>MK2D55>*),5J3**0K/,JJ4K4SC)NE&K7(>'
MLVX#K#66UDPXBX[%[F.4]);O)M+'T-N+HSMA/4.#I70C9E::X<*A2MM=*JZ3
M*'!.F1DU :LIRJ9\O#^;+.\5DW%3>:NU=@QNW&Y$Q(6<J7V6K6RAPI2+HZ5
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M++2>(J% +P(875F?9DU7&2*4;BYL\ZA[BW-Y)K>YL@._9UDO!X,Q:?8(K9.
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M:WHFTY92@EB(M1'GHU"4>@-K2KDRC3QX[ZGC6Q]?B57K1I5JG+_B 6CE@B.
M 6 1$>0!Y3LNXZZCI_\ <7I+\DVOJK4W[[UVW\T7_GX?'LJD_'%9 ?&4#L'*
MND1Y5!T'X]>1%'KR/P;F+/U5JO"<.$=;#[TF2(]WZ+=I/*H\:4.?[I1OR *J
M0$,9P&1VY '+??&^C2D1<DL%W*!=R;Q#BG6 7NL,7)Q @NY0+N3>(<4\:7G8
MRCM'-='/8<9$0R&>S';OC58S(S"#M()0L5JU:*O6PD3BPY@(Y2&@U&KTBGC"
MN7C"\;_IZ/O;]1P&1#D'9R.Q:,:S^P%H&YUO.OAOUL+Y^OD&4#<ZWCQI6!$3
M*,]GAASSTW';&,B @.V.N@,@ ^JP'86)@@B7E5ZV%@#%A6K%EG(EN"")>52!
MA89R87C&?S=//&V!SD!#EU_VZA(*1EKL<L6(-\OFJ''@*6(-J^3EBQ!OE\U0
M!A?U0L,=?#I#?/<(\NF-@Y]H:I(D D\+QVZF"Y-M*O7PY8G:&#'?F8+DVTH!
MA8X'PR^F?IZ0'(=?S0#OW8WY\MQ( (>JS"TTB+N+7@<>$,=<9J00CEF(XN+7
MB?&EYQXVC<>8549Y8WP.^!'GZQ 1VQ&+Q L25=P[,"W80)<ZV"[PP+'%%W#L
MP+=A E@,+V'QE'3 >'2/+EG([!D?7C/>.A(D1FS:]TKE#DUP%#CP2.MAS98%
M[I7*')K@*>,*Z&EASR UA_$'P=1'X0U>M=RE(47N7J\@.PTZ^',@V1!'K)YY
M =AJ!,+W_NE \OT](<@'OP/+OSGM'0$0D+\<P>8ST2F!5&/#'NL(OF#<CM%^
M"6@KEXXL-@,+SD<_3TX'X<@ CL&^WQYS(-[(+49VD@2=0N"6+P&3B"04ACLD
M@28GN2@#2^AE 9VR-=/7 9# @.>\>@9[<"A=1*'!D LF. UT3IQ8,\6$J4",
MNL462%P&96C>,+$?_"%AW^'2';D<B'/U!V8Y:, 7>61Y!#%:,S*.M.OA ]\#
MP8.B"&*W,ZN] ,+#_A:.6_TX;".VV!W'EVAW\M"0=+Q:0)EF!?0\+T./"<\-
MXG#($RS OH>%ZGQI.<^,HV#;Z>GI@.0XWZ^OEV:CA/#)GM9N"8R]>M3K!+K8
M),SJS<$QEZ]:CQI08_NM&V_YND>H[;#V"/3UXS@*VS$L"5D)G-K/DTS>OA+G
M#+%P,A,\0,^33,":7UKHQC&/#I^? ;AD Y<MA#5!PY$-MQ^TP43>\@U1BP98
M\+;;'[3!1-[R#4^,*Y>-HP CCZ>G(!GGL(9R(<L#C8=M1BZ&3F"5:6D'F'(G
M*=?#=X60'(DJTM(&[#D34>,+^J4 '/\ \)3WXZA\.-\8P&0'58U!-K#@]>QP
MVRB*O7P_"PDVRX/,]CAME$4\:5C_ ,(6(]OAAG<.>?"[>F,]N!SHP[@#1A0;
M+EFUHPJ=;"_?80-'A4&RY9M:,*I\:5^OHQM^GI$0P 9QZP  Y8SUQJ1\(.<T
M"R4YR))NUDZG6P_#PN<T"R4YR))NUDZ>-+ 1P87OV54X#IR$<;^OED>6-&(<
M$:F2#(D3%[70$NG6PPR 1KBD@R)$Q>UT!+J!,*^J4;^#SKIV^_G <L"'8.>6
MJ#FX'6MG\SL6#FE5&/#\+#'6L1,]S,%L22%4B85]4+'.^YE',<9W >GP<]N6
M=08AJLH!,2H+D]MINJ@QX?A81E&@8%S=<[2;"LPX<:J:GB^0TB%0>^,P[@("
M'Z%< [!'ERY],:]$\C/O'?/RT_V?82T&[M37)N!>/?%/^?P2V_N?8YPZ[DJ=
MQN"W$N@GD]#\EK=W:,N+88EA\K>$JQ&7#V9 :>G7-#(O1&>+6)%"<TNE0)Q1
MA0@:70%5 U?7D W *U#[J[!R1IQY_-ZZR,+\6V , KDP '( M[/P /@",Z
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M@]2-VF+O;*/.DM?BD)#W*'"P[XLD#N2V'MZIN*<G@^#UN"XM"I:6H])0I4&
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M<X_\OL=<_<3$S3S+<_BF[?(;+]2GF[V!]!UH/DXAV?C]Q<Z'HWH\O[AW.?\
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M(0<K%(D2IA4F45G"0G()&L2R2Z:>?8[OL-W&+#L-CL]CAQ'K8L.RP8<&$XD
MR,( )0 =T!7+L]CLMB"-EL]GLAB/6(V>##@!Q(!D80 T 'PK*]<U<E-*4TI3
M2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*
M4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI3
M2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*
#5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>gzpp5ykc3xex000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzpp5ykc3xex000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !Q .0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "JLDIGE-M$&P.))!T7U ]^GYTEY<.N+>W(-S
M)]T?W1W8^@_K4?RC;8VV[Y3^]?T'4\_WCQ^= %^BBB@ HHHH *9/GR),9SM.
M,?2GTV0D1.1UVF@"CI&H"^LP6/[Y/E<>OO\ C6A7%QS20RQWT&>"/-QT#=\C
MT.?U-=C%*DT2RQG*,,@T /HHHH **** "BBB@ HHHH **** "BBB@ HHI"RJ
M,LP'U- "T57:_M$^]<PC_@8J!M9T].MRI^@)_E0!?HK,;7K+I'YLI]$C/]:/
MM][.,6VGNN?XYSM _"@#29E12S$!1U)/2LYK^:[<QZ<BL!]Z>0'8/8>M,:SN
MY4+:A?!(1R4B^4'ZFB*8LGD:1 @C7K,X(3/MW)]Z '!3 S6]N_FWLO,LS#[H
M]3_05,K+!BSMLM+U9B,XSU9CZ_XBHU LV,<9-Q?2C+,W\SZ*/2GJ8[3Y,^=>
M2<GU8GO[+Q^E %ZBBB@ HHHH *;(2L;$=0":=3)6VPNV <*3@]Z .1()C-[:
MIF$C_2(0>%/?\#GCT_"M+1;H6\WV-GW0R#? Y_4?7^N:H F &YM%,EC)_K8C
M_#ZJ?SX-((VC>)(7)R?,M)/7U0^_]?K3$=?1533]0CU"$N@*NN ZGL?\*MTA
MA1110 4444 %%%% '-/XHDS\EL@'N^:9_;^H3?ZJ%/\ @*$TBKJJ_=@@A^J1
MK_.G8U(_ZW5+>(>GF@?RIB$^UZ]+PJ3+_P!L@/YBI4MM;F_UUQ+$OJ&']#4)
MB!_UNNC'^RS-_6H_(TD',NHS2'_90_U!H N?V43S=:JX]<O_ (FD_L[15_UE
M]O/?]Z/Z55!T*/J+F7Z\?X43ZCHME:373Z=+Y,*%W<@L HY)ZFA)MV0;%S_B
MGH.FUS[[V_\ K4W^T]/0_P"C6$4C>R<_^@US(^*?A6/_ %42#T/E-_\ $T[_
M (6WHG\$L:_6.3_"MOJU;^1_<9>WI?S+[SIQJ]^P_P!'TM@O^Z<?R%31_P!L
MW1Q(PM4/=5!/\ZY,?%327'.J6L?_ &[3$_\ H-+_ ,+(\/2_Z[Q*ZC^[#92#
M]=M'U:M_(_N8_;TOYE]YV)TRUA_?7MP\VWH;A_E'X4T75Q>R^58?NK91_P ?
M 3(^@!Q7(KX^\"1'S6U&>YD'(\R"5C^JXIQ^*7ARX.T:F;.(="+=W8_^.X H
M^K5OY']P>WI?S+[SL&VV*^1:CS;N4Y8MRQ]6;V_*IML5A 7)+RL?O'[TC'M_
M]:N+_P"%G>$;.$K:7SRRN?F=X9.3ZL2N33[?XD>#8W\^;5FEN2.7-M+Q[ ;>
M!1]6K?R/[@]O2_F7WG>45QO_  M3P=_T%&_\!I?_ (FC_A:G@[_H*-_X#2__
M !-+ZM6_D?W![>E_,OO.RHKC?^%J>#O^@HW_ (#2_P#Q-)_PM3P=_P!!1O\
MP&E_^)H^K5OY']P>WI?S+[SLZ;(=L3G;NPI./6F6MS%>6D-U VZ&:-9$;&,J
M1D'\J?(0(G+#*A22*Q-3EKA&LG6\L 7LY5W.O5?0J?S[T>5$'6 .?LEP-\+D
M_P"K?TS^G.*<HFT]?/LV^T:?)\SJ>>.A#>AI'2&.(O&6?39SS_>A?_ZWZBF(
M=:73Q3BY9!')&_EW*@8RI_C/OG-=."" 0<@]"*YLK<&2-)BCSA?W$G\,Z=T/
MU'/XU:LKUK6#&R2:U!PI R\1_NL/ZTAFW144%S#<IOAD5U[X/3ZU+0 4444
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M4WM9J+[/7^NER5AXS4Y0EI'OU.!HHHKUSE"@]**#TH ^K/#?_(K:1_UY0_\
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MT//(^M<W<0_9[B2$2Q3;#CS(FW*WT/<5X^4K#T'4PE*JYRB[OF=VN;7\[O\
MS.O%>TGRU9123[>1%0>E%!Z5[)R'U9X;_P"16TC_ *\H?_0!6C(H>-E)P"""
M:SO#?_(K:1_UY0_^@"M&1=\3)G&X$9KY&?Q,^EA\*,#RM4TI2B 7=J!R",\>
MF.WZU' J/(;K1Y/+E ^>U<]1[?Y_*GPQZKI+;=K7%N.<(<\?S%22I::OB2SD
M6"]4Y.05;]/Y\U)1'$\5Q<[K5?L5\,YB<?++ZC^=/AVI*RPS'3[CJ\$@RA]U
MILSNT/V?5X2C=([G&0#^%31R30PB._MS>P]4F0"0?E3 F>*5V#7.GQRM_P ]
M;=\']<']:<)8EP?-O8/]]&(_4$5!']@D&+*\^ROG[I9AS_NDXJY&E_'R9HIQ
M[_)_(&D 1SO(<0WMM-_LD<_H?Z4LD3,<RV,,A_O(PS^H'\Z61F?BXT\N/4%7
M'ZX/Z5"18KUAEMSZJCH/S7B@"Y;JJQD*DB#/W9&R?YFBF6A4Q-LN/.7=P<YQ
M[44 <D+^W'33[?\ $L?ZT]=33.%T^S_%"?ZU<4:J.EW;K_P-/\*<#JO0ZG;#
M_MHO^%,1 NH3'[NG67_?O_Z]64O=2/W+&U'T _QHQJ??5K7_ +^#_"C_ $X]
M=:MA])!_A0!*MSK;?<M(!],?_%5E>+9-:;P=K(F@A6(V<N\@C(&TY[UI!+P_
M\QN#\&%9/BR*Y'@_6"^L1R#['+E 1\WRGBKI?Q(^J)G\+/G>BBBOK#YL5&*.
MKC&5.1D9'Y5H7=YJ>J6+75Y<O<103[=TC997D!.!WP=AXZ#\:SJ["S\916WA
M5M*:W#W;(Q%R8D.QA]P8Q\W&?F/(SWKS\?*K3Y)T:2G*Z7:R>[V?3M]SV-Z"
MC*\9RLK?><?14Z6D\MI/=HA,,+*LC>A;./Y&H.M=RDFVD]O^',6F@HHZU;E@
MNM+N;>1QY<CQI<1$C(*L,@X/7Z42FD^7J]@2OKT+J2:QH.GV=W;W#6T-\?,C
M:%@&?RS_ !=\#=T/!K(9MSLQ &3G &!^5=KK_CBWU;17TZVL1;&(JL4NQ#O3
MHXQC]WG@\$],5Q->=E<J]2G*KB:2IS;?:[7V;M>5EOO?;8Z,2H1:C3E=?U<*
M#THH/2O3.8^K/#?_ "*VD?\ 7E#_ .@"M&12\;*K;200#Z5G>&_^16TC_KRA
M_P#0!6B^[RVV?>P<?6OD9_$SZ6'PHQ<ZUIZ')CN8EYW,><?H?YTQ+O3-7=4F
MB:&Y)^5EZY]B/ZU*+[5[?B>P$H'>,]?RS3'O=)O3MNX##)W+I@_F*DHLM;W]
MLA E6]A(^:.88;'L?\:J6GV::1AI]S-:2_Q1$;E_(\58@M&4;M/U,L!_ Y$B
M_P#UJ)DDD_X_M+6;'_+2 @D_@<&@"1X;SI/:VMX!T/W6_(\579;2(YDTV:$]
MRD@'\FI4:TB'RS7UJ!_"P; _,$5,MTA^YJ\1]G5?_K4 0)J%ANV)>W43=,$E
MOY@U<A:249@OS(/^FD0_IBE5II1@3V<X]-I']336M6;_ %EA9O[@X/\ Z#_6
M@"Y$)@I\TQEL]44@?SHIEK&(XBH@\GG[H;(HH Y80Z/GFYG_ "_^QIXAT//-
MU/\ D?\ XF@-*.NB*?\ MF]/$C@?\@)3_P!LV_PIB 0Z#WNI_P C_P#$T\0^
M'_\ GYE/X-_A2><?^@ /^^&_PI1,O?P^?^^#_A0,>(O#W_/9S]=W^%97BN+0
MQX0U@P/F46<NSYFZ[3BM7SX^_A]O^^#_ /$UF>)<W7A?5+>W\/S>?+:R(GEQ
M$MN*G& !DFKI?&O4B?PL^=Z*UO\ A%O$7_0OZO\ ^ ,O_P 31_PBWB+_ *%_
M5_\ P!E_^)KZGVD.Z/GO9S[,R:*UO^$6\1?]"_J__@#+_P#$T?\ "+>(O^A?
MU?\ \ 9?_B:/:0[H/9S[,Z.S\<&V\.2::]Y=RW$L+@7#<M$VP!5#9SC(/8]>
MM0> $T=]0N+C5OE:W7S%GE<",;OEPV3R3GCBL/\ X1;Q%_T+^K_^ ,O_ ,31
M_P (MXC_ .A?U?\ \ 9?_B:\6>3X54*M&A+D=3=JU_TZ:=CK6(K<\93C?E+_
M (C^P:9XMSI#S01(RR&>.3D[OF+(0>F#Q6AXG\;#7])>VBDN86\_A!\JR1<X
MW8)R>1GMQ6!_PBWB/_H7]7_\ 9?_ (FC_A%O$7_0OZO_ . ,O_Q-:+*\++V,
MZTN:=):2;U?K_6A+K5ESJ,;*70R:*UO^$5\1_P#0O:O_ . ,O_Q-'_"*^(_^
MA>U?_P  9?\ XFO6]I#N<WLY]F9-!Z5K?\(KXC_Z%[5__ &7_P")H/A7Q'C_
M )%[5_\ P!E_^)H]I#N'LY]F?2WAO_D5M(_Z\H?_ $ 5HR%A$Y3[P4X^M4/#
M\;Q>&M*CE1XY$LXE9'4JRD(,@@\@U?=BJ,P&2!D#UKY2?Q,^BA\*.=35]5BX
MGM2<=28C5D:[8S+LNH6'KOCR/ZTHUJ[QSI4_Y'_"E_M>5QA])N#_ ,!)_I4E
M#-N@W!&QXXV[,I*$5(+6Y4?Z#J1=>WF2!A_*HS>0/]_1)C_VP'^%-+6#==&N
M1](2/Y4 6D_MF,_/]FE7U&<_TJ=9[H\2V+L/]DI_5JH(;)?NV.H1_P"Z''\C
M4@FA[)JB_@YH LNMLPS+IQ/UA5OY9IHBT_M:/&3_ '8'7^0I@F7M/J*_6 G^
M:FGB?GBYO#_O6Q_H@H MP>4L9$>_;GHQ;(_.BBW8O&29&;GJT94_D:* "BBB
M@ HHHH *4=1110!)1114C"BBB@ HHHH **** %HHHJA!1110 4'I110!#111
70 4444 %%%% !1110!(GW?QHHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>gdc15tqwxkbk000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdc15tqwxkbk000007.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '$ EX# 1$  A$! Q$!_\0
M'@ !  (# 0 # 0            @)!08'! $" PK_Q !6$  !! ,!  $# P$#
M!0H(!Q$% @,$!@ !!P@1"1(3%!4A%A<B,1@C)$%1&3(S.%AA=9:WU"4F-#E"
M4E.V)U5Q=GB1DIC1TM<**#6!D[$V8GF"H:>X_\0 ' $!  ,! 0$! 0
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MY.0%_.]1>E^D5POVVFN+VA/ZP'P\(W,;8?=CL]2D*3^3)7GUE#VJP_B5@?\
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M)[32OUYX0*O"CO61,N,8QC&,8QC&,8QC&,8QFD=)YQ2>OT&W\OZ171]LHE[
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M-FM.C1S5YXUEAEC;V9)(W#(ZG[A@1E?\;R=Z)\V?\2'N M[F[&U[B>6?4?\
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MS,268DDDD\DDGW))]R3[DYOT1(T2.-%CCC541$4*B(H"JB*H"JJJ %4
M<9[,^9ZQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&5^>?/^/S]1
M+_H;QQ_V9WO+>W_K3I_^'LO^FAS&:7_#'UM_Q7IC_J%S+ \J,V>,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8RKOK-6L'@OHMI]2\B"DS7E_H!=Z
MQ>P>(UV(].>H)>3]B2'J[DU?B(6XF9":0E[O%.#,?-K ,;OD&$[8PA!9"\KR
M+MH8Z%AE6]$H3767/ E4?EH6'/V/TJR-_-L?$2$8<8#8UYO2%ZQZ@UL4DN@N
MR&;U+JH%+FG*>.WJ'70K]&4#G;UHQ_*(0;B*9XG\EE-:LM?N5=!6ZIFAECJ]
MG$#C]=L 68P1$&PA:(U.&%1D^,MR/,@SX;[,F+)8<6T\RXAQ"MI5K>4KH\;M
M'(K(Z,4=&!#*RGAE8'W!!'!!S=03PVH(;->6.>O8C2:":)@\<L4BAXY(W4D,
MCJ0RL#P001F;SSG7&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,96[Z5O-R])]3F>%>%6(I6(
M$84*-^R>U5R1M@CR?E]B;6Z*Y!2BC7W(@]L[2.;D-1YF][D<]YVHC<?TSI0E
M6?BZI114H!M+:*Y+,FNJR#E;$Z>S6)5^]6L2"1])I@(N>%?,/O;=K>[!O26H
MGDKHL<<OJ?:P-UDUU"8<Q:VI(/9=KM4# -[FE2[V2IDDKC)Z4&A4WEM*JW.>
M>5P74:/2@8^N5:M!H^HHP,%%QT1H4**UK:E;TVTC6W7GENR9+RG),IYZ2ZZZ
MNIFEEGEDFF=I)96+R.QY9F8\DD_^P>P'L  ,U].G5U]6O1I01UJE6)(*\$2]
M8XHHU"HBC]P'N22S'EF)8DG;LYY)QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8ROSSY_Q^?J)?]#>./\ LSO>6]O_ %IT_P#P]E_TT.8S2_X8
M^MO^*],?]0N98'E1FSQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&?1QM#J%M.H0XVXA3;C;B=+0XA>MI6A:%:VE2%)WM*DJUO2M;WK>MZWC! ((
M(Y!]B#[@@_4$95I7M+^G1V,90Y"E,>$O0=VW"YO-<7O]K\F=XM\]U_\ LWEJ
M<W^,/PGL9N0Z_09"5-B>>]&FR*F\R/!6@*_&O7_TYKM,/?:U(N9E_I;"I&./
M,O'YK590!,..TT($G)=&!_/X>?1.SCIGV]([JUUHO_L?IS<67)^!;[1:C9RM
MS3;GQTKSM6(2&Q"5M.RBS] QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8RFGZJG:NN>>>C>/>F
M<"JI[J'7R+WH_EE:Y'6(1^S%K S?>8#"3=[F4"L1YYRUU?E5IIM3LEGU"'.*
MB#7E0M3QCAEN3FCT-:O<AV,-MU@KK\%.]ARJ*GBG9?%Y7(2-YXY)$3D^[#GA
MNO&?F/\ "%M=EI;OIJ_IZTVPV3G>:^#75TEL2S"YKXW%QJ<"O-8KZ^Q5K3V.
MB'JAZ=XS*#DE_IV!(54XX4K#/'O0E .)L+MLZ'TST?6:A5+YZ&ZG=$N$[YU.
M4( 7BWGHRYA-EJ*B%:H@%8,-H#7 D>4-#?Z+"W#&2RLAL4Y5Z>.&"D\DD5.O
M%\L-<,T4:'A23RA;LW9V(+>]YZ*B6OK)*XUFYIRB8V+M_>05J]S=;"T#)<V#
M10V[,REI %Z6%A\4?B@A4QQ<+/\ RIS98QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,9HO3:D:O?/[?3ZY>['S&P6$%.&A.@U)L6_8J>5>:W^@
M/"XQJ$0%2WH,E+;KD*?$<CS(^GHJU,_FT^WU@D6*:.1XDG1&#-#)VZ2+]T8J
M0PY'W!Y!X/VXR)?K2VZ=FM!;GH330ND5VL(S/6D(^2:-94>-BC<$HZE7'*GC
MGD4E<0Y)]2ZV^N^_ ^JQPG$*78I'G6=U?TWS.4W^7MH'C .P"@]?X<&)1I6Z
M3.ZHJ6U,ZF^3_6R.:P(Q2N!_U3M@!S\TUJQI8]=4:N7M2H+@@I3CVJO99"SV
MF4CRBOU_DX4 3$J[>R.,_*M5K?75CU+N8M@L.JJSMHWV.^HL.=K#JX9HXX=3
M$ZL:C[#L&V!D[M019((BYGAE%]^93/V#&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC(X>LZV;N?!;W2A'" /I.)<(&JU:.0G[^/YHFR5,KO;!
MIT+:2P8N+C6<6W^(C76YTBN-I*1X\QBU ID2-+U,H.L5N*5K34C&W=+"0F?I
M(ONO:-65BC'Y7(#GJ3^S<$C*/U%!+:U%NK%J(=XME1!8ULUQ* GK2'B4Q6)(
MI(Q/&.'A#M /(%86(64-E0W@WJ?IGH/K?FWGKTP(Z]REGR'R7L!OF[/7I#8&
M^^G15H+U"@4BUVUNO%"](Z3-XM0Y-@K5KLE7L%D$F;8=#W9U40I.>8@:':P4
MH:$UNDU>?\0GK+.:_P \-%D6266.,N%EA6S*$>-)$5EC1H^2H!;\W](;#>W?
M4='3;Z/9:X>F];LY:*[(B&WOX[$E6G5L6/!)+5O/JJ;35[,T$T\<MB:*V>LC
MD)_01F2S]DQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8S5[M=*MSBG6GH%X-P:U3:57R]IM-@)N_A@!
M@ *"^2+$I;FM*5IF'"C//KTA*W%Z1]C2%N*2C?2**2:2.&)2\DKK&B*.2SL0
MJ@?VDY'M6J]&M8N6Y4@K589+%B9SPD4,*%Y'8_HJJ3^I^@]\@IXSI%IZS:[3
M[U[,#G!;UVH&Q7>"4(XW^.?P[RXU,25J(*3"VIQ(Z_\ 6I*8_3>HKTXY(8DS
M*U45*8:J6X^[392QUTCU59@T59N]N9#[6KQ'61@?O#7]X(/L0'D_V3,EZ8J6
M-C8L>K]I"\5O:1"#3TYOSZGT^&\E:$I[B.YLFZW]@>20S5ZQ(%;@V)Y3YM<8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QD/_ &/Y^L?9:37;IR2?
M!K7IC@IY?3O/%PF_+4-NVQ8:XIOGEHD-K9>=YSUVO;ET.]C]O:C[@$8AS\+L
M\ .^RQUMM*TKQ6 7HVU\%R,?7QD\K-&/M-7?B6(_7D%.>KMF:]3::?:58+6M
M=*^^T\QOZ6TWLHLA>LM*P1P31V4/:G<3GCHZS<%X8^.C>:._5STOQVL=5 #Y
MU=FSU$@-WHQKX19>:])JT]\#?N<VF-M+3D8]3[-"("9/Y&64SH[44M$0H>1A
MNN<;M1Z5EX'(<#J\4J_DFAD >*9#]UD0AA[G@\J?<')VBW$&]UE?80H\#/WA
MM5)?:>C>KN8;E&POL5FJV$>)N0 P"R+RCJ3WK(F6^,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&>54^"B6B N9%3.<1IQN$J0RF
M6XWO3RM.(C;7IY2-ICO[TI*-IWIA[>M_#:_M^\'CG@\?3GCV_P _T^X_SYY[
MIVZ=E[GW"]AV(]_?KSS]C]OL?T.:0YUKE30R>:=Z;SYL.*N".>DRSESKB!@Z
M_.S8@UJCSYZB6HL.X.$9\& BM2'6S2YLR)%3"V_(9;7U^'G[!?!-V:/S!?&_
M8Q<$^4#KR8^ 3W'R\ GG@9%.QUX1Y3?IB..R*4DAM0!$N%E05'?OU6R7=$$#
M$2]F5>G+ 'VA>D<[LB&UUZ^TL\ATF<"-+"VD&40X9K$I$&RB&U09S^EDZ]-<
M;AG("=[E"92T1Y[4=Y24;^-!,GL\,J$*C'M&Z_*XY1O<#Y7'NA^C#W'(SU%>
MI3@&"Y5F!DEB!BL12 RUV"SQCHYYDA8A94_-&Q <*<W3.62L8QC&,8QE9_H3
M6_7_ *5KGC<?\S.'<6_I#MOL>0CY4/M!%R5HUP?S=,5K[FY#-K*CD=6Z.+=:
MVARD5NMB)#S;-RVTY=U/]+J3[(^UJSY*VN']*,<=;5T#Z_(K&O"?\:[M_L>8
M3<__  EWL'IA/GU.K^&VOJ8C\EB0OY=1HW^S"Q)'^(WHR.#4@@B8@6LLOUK6
MM:UK6M:UK6M:UKXUK6OXUK6M?QK6M?X:RDS=Y\XQC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QG/2'6^4B+%6*@5Z;SX9;+L2+!:95R%SKD.P
MVTP :T^=%5D+()-DCQ(*SO3I:"+C2I(YO>ES&F4[UO?85YV1Y%@F:.)5:5Q&
MY2-7/",[!>J*Q]E+$!C].<A/LM=%/7K27Z4=BW))%5KO:@6:S+".9HX(F</-
M)$/>1(U9D'Y@,Y?8_6?$:O9N;TLF<LW]6=>)]0"\Y!,\YZ'^HLA7C#!65TV#
MJ9(K$<4'?JL4(5DR?Z@("43H\)U\2N>U]BU=TU]ITGD")XZRP/,_FAX1;)40
M'@2%F\A90.@;CGYN,@3^H]57GHU9)I_B=E)?BHPBE=YGDU:R-?3L8%CB-=8I
M&/F>,.%)C+CC/=TGTYRSD?%(_H"_O6@!SA<ZIC9K\BGV!5E#$+K:1M(!03%-
M1"W:(D]RW&1=?FCTBW9PV=+TJ=&8B1YDF-\@HSV+1IP^-YN)& $B=&6*-I7*
MR\^,CQJS@]@& ]B20#ZO;[7ZW5+N;AL0T2U9&+5IC/$]NQ'5A26J$^(5S9EC
MA9/&7C=N74*KLOEF>MO/(L79BQSI ^NLTGH@+D]TAV,5809FH=#M34!^JUJR
M!"0B.6#O6QDJ*=J9&9#;"VIHJ+>KI(FR1A+?#7VV**L)?RPM8C*,CK)"A(=T
M96*MXRK>10>T?5NZKU/'QO4>ECCGDEO)"*MV'76DGCFBEK7; 0UZ\\4D:R1-
M9$L9K.RB.R)(S \@=">N5[HM MQBQUVK7>IV*Q4Z8T/M]>"V$22/5,@^TA]B
M#9PT26Z2 3'V'6GV8I:+$?=9=;=;;4VXA6X[PRQJCR12(DH[1NR,J2+^J,1U
M<?O4D98PW:=F6>"O;KS3UF"688IHWFKN0&"3Q*QDA8J0P615)!!XX.;EG/)6
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&5G7U/\ D9^NP_88
M6MP/.'M"R5WG/;8J/\T&YMZ?5'8!\CZ^MI/RP,$]C'1H_);_ #DM1(R[A"YL
M:*3%OSISJ[N+_3+7M6/O<UJ/-5/]*>CR6L5^?JS5V/GA'N?&9E4>PS"7/_@O
MZDCV:_)I/5$\%':J.1%1W_40ZW9<#Y4CV<:KK;C\*/B4H2NW+N39CE)F[QC&
M,8QC&?52DHU]RU)2G7QK:E;TG6OG>M:_G?QK^=[UK7^W>]:_QQCGCZ^V:^>M
M]2JH8]8[/:*[7*]56E/6@Z>-C0X:MLHC1IJW3Q0A)CP0[28<R)+4X0?CH3&E
M1G][TT^TM7M8Y'9$1'=Y/9%569G]R/D4 EO<$>P/N"/MG&:S7KQ33SV(8(:X
MYL332QQQ0 *K$S2.RI$.K*W+E?E93]",P<3JW+I[@1J#TF@S7;*5+ JXW$N-
M=DN6 V!8W).!PB&2*U%2H:-K<@L/@:?ECF-;=F,LMZ^[/1@G';F&4=%5WYC<
M=%<\*S>WRJQ]E)X!/L"<XKL->YB"7J;&>22* +9A8S2Q#M+%%PY\DD2_-(B<
ML@]V &;D/(CRT**2%3H9,=-91(A$!\EF;"EQW-?*'XLJ,MQB0RO7\H=:<6A6
MOYTK><RI4E6!5A[$$$$?V@^XR4CI(BR1NLB. RNC!D8'Z%64D$'[$$C/9GS/
M6,8QC&,8QC&,8QC&,8QC&,8QC&,8SE%T[=S"AV)JD'K@";Z(0IEJOE=YPDR(
MCW6V5^FQ%3#CU;$$YX],]UAI*OL2N3':VEJ5)<>:@CR,J)(BJSRIY$C?PB2.
M)YNK&*-Y#PO=E!X!_L/V'') -=:VM"G,*LUF$77JV+D-+R1BU8AJKWF,$;N@
M=E'V[#V#,2$1V6'=E^H*&#<T\Y^@(=".3.&].@6J;VV8B*0FWOSS"KQ '5S1
MZU@1<68Q)$<MZ!/F4_L[33GYZREF6>&/DX@*5$(V*:AFGN5#*HM0%!5'($5P
MN&=5C9B"&GA DK?U^0C!2P*YJ?UE%%0TFY6G*VJOK8;:L [6]*D+Q5Y9K$,:
M.&CU]QVK;, AH.&FC,BPLK\"ZER[TK>!WMNAU:R=DZ@;BTK@71O*%Q(V6;6Z
M)>"SXBCE;E3()>)(K'(MR"%^Y.LR9<2F%$&53M)X!$VFH3)XF-+@GI1'62R)
M6@0RVX;\80/-$O:58Y&4]['RPS]4^I,E9';]J QI[^OWMI/552"?9["5:NGO
M>GK+SM!3MR&.I)9JK(I@UO9[FN,LI'58Z^TFA3BLSQK,/S_QKH5#MG19?1JU
M5[>Y8O0W3^XT7I98K%EW*IU;IXM3,&D3(21T^1%ME!&3'^41=!CTJJ2>;BQ,
MR'8/RM_THBNMV898X1"\D82G!5E@52(Y)(#R90>P!CE8"<ED$@F9@4X_:9I=
M-K+M2Q=:[!7LF;<W]K3O2.K6:]>^A5*C($<K9I1,=<OBE:NU&.-EFY'PXX/T
M#P'<;-<+Q<*]<:T'BWOT!YZ] %:)+=*/5S5^XGZ*1TDM?V23 1,QJWW7C=<H
M?(WHNABH$%P/(+.D)[:&V)4J+;1)''&\;L8JENFLHZ]_#9I^%8BI;CQQ6'FL
M ]N3V"\#[5%WT?9L6K5F&U!$EO<:7<24V,AA^,U.[%^2X'$086;6L@J:TKT*
M(8C*7?CANI<U\Q7KF/*KG1Y\2A]!EP#?JBZ49R7(D.-6ZU]S[R2[U3)=L"FP
M38JM2J:8>'")3T8M:6I;T+1J(J%\(&IX3WHI[$<H\L(*T(I0H \<=6JM201L
MK=G\BAF'*H1SU//YLL*&AMT-?9J.M2ZR2^H+54L219L;?<2;BLUB*6+QP-5E
M9(V*R3ABOE4I[(.#,<F[_P"8?,/EGG?'Z:=AS.6FO&DKT"_2Y6SUCZR\*L7,
MJ!VV"+&@HY\A)#BJ)7CUKN$E[^ET'VD!&QL\S\V@$6E&>I>O7IK$BD3C9"IY
M!T2N&2>:LS%N@#-*Z1Q@=^OS]@O[-EJ%UVXT.@]/4M;6F#Z^7TN=RU4^:?8F
M.>A3VJQI$LSF*.I#-9LLWPXE'B"/)S8ADV_H7K+I',>E>SK0S90=EX3Y.YY2
MC-B#V"NQUV*Q=9N8:\6AKE7-#55_9]LN11_]CE<C;M$6WD)MKNY>)N0T[%8'
M0N<-"&>#6Q]&2W?FE5&5ST2O&T2>>97[?4_$.>AC 2('C@]FDW?45[7WO4]@
M3PSZCT[2JRS1S0@SS;&U';G&NHR5Q&053\,@4SK9=[%N12RE0BRCY3ZNYYTI
MUH-*VY7;1#NF^165K7[@1I0_NPRLS+1<>/5Z_3! *!<['2HHLS!.$1 YL(@R
M((@$S=6*))#LP;%":#EA\Z&+XA/H)#59PD=EX@S&-)2RLJL>_1@_'0AC?Z[U
M#2O$1-S#82U^&SCYWJIMXZ[6+.L@N-'$EJ:JL<J2R1)X1+&\/?SJT0DY'D1Y
M<=B5%?9DQ9++4B-)CNH>CR([R$N,OL/-J4VZRZVI+C3K:E(<0I*DJVG>MY!(
M()!'!'L0?8@CZ@C+Y6# ,I#*P#*RD$,".001[$$>X(]B,YWSGD'.N3.7M^@5
MW025TZ_GNHWV>\5-G"5FO5D1#8*&R!*P$BL_[=0QPX8+%1Y+ 4 ''P P$<-%
M0HT-KM-8FL>(2OV$$*01#JJA(DY*J BJ/JS,S$%G8EG9F).0J.MI:XVS3@\3
M7[DVPN.9)97GMSA%DE>29Y'_ "1I''&&$4,2)%"B1JJCI6<<G8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,9A++8PM.KE@MUDGMBZ[5@A6QGR;K;[S
M0X*$@/DRL]QF*T_)=;AP8K\A;<=AY]:6]I9:<<VE&_2(TCI&@[.[*B+[#EF(
M51R>![D@>Y SE//%6@FLSN(X*\4D\TA!(2*)#)(Y"@L0J*6( )]O8$Y 6Y?4
M<YI3)G [S,JQ:?Y2[]48ME%>IQY2*[4J,Z8(AA=<<Z/4E0DGZ?4IY$^%#'+D
M9>B1J38SH$+;A@IR43D!K:/332BW$)%%^HY4T2I\DH4,9!#)STDD559TC7DR
MHKM&S<*&Q]KUM0JMI[;5Y']/;BLL\?J".136J&5XHX#>K]?-6K.\T44MJ4HM
M6>:&*S'&6<Q5VF>X>C^B5BP3;"7N/0>X>,/9/ O1!*D<PC%$)[-X>[6.!'13
M OF-/^T??54^H6"PZ5^,'82P^T<N<,1Y3IPE.9E7"UJ4,B!%CBJ['6VZ8EG*
M_P FV=8NK%IY.6B\DB)QRR*4GZD! I&)EVV[NP3M-+:N[;TOZGTVZDJ4%D_T
MT])[5(I8UCU]7Y+GPU::?GB&:1;&O\JL978-/GJ_FKGGJZMQ:N?YE:B?+)_?
M"UHJYX9#5RZW\P%V#D,<K*ZM0UVMVIVVM&X/>_LL<0P"&3"\Z?)+/Z#&*U-(
M-SJFO>FH.9$GC$XJJDB,?/'.R6"HKR^/R1NIJ?LRCL% ZCLK@==CL=%2]0P+
M7FH6)->^XDL5YHU-"SKTFUHD;8U#9-:S!*FWXG26%&E9VD(BDA9P_"#_ -/#
MT5=(/FBN]3ZA4^PP>"]5]-S;->"-LN/*;[TWDO>N:6*D1F7GZ)42R1'0%R+>
M1E72:T2;&&9(Y^7M4YNQ2XD24FWIQ&Z\$#US:@HA(ECCGBAGJS)*?:61>T7[
M,"(<<J"!P"@)J)_1>[MIH8-AL*^S33[#?-8MO8LZ^[?UVWH3U%!-2M+XKG-I
MVM.)!'*T9;YA,R)+'U7YZ[=Z:\SB^3D"G,Q=YE=BYQ?K.Y^[69%1;J'-^U#>
MG"JP.)MU)\L4+/5^N5^M2S,NOAXTDK^O/Z'1F/PB%0*%NM2NM.JS&(5YHD^5
M/)Y)JQA:0@OU5>[NX4,Q"\+V)Y;-%ZATNUWVBCUSR4$MMLZ-R<F2?X85J.UC
MOQUT<5VDDD,,$-=I6AB5I.\WC4<19%?K/@7LMMZ[.[)^HJILMV7W3Y([WV2K
MASKT>OU#B/D>MN :74ZY(/#A,B\6XX61"LMIGS(=6@K95($CX3NQ,!\K/@VU
M:.L*W#JM;5["I6=E!>2SL'#2R/U+"*-%Y1%!D/W+?,0N?V/H_:6=D^S[5YI-
MIZN].;C9UXYBL-;5>FX/%5KP-,D;6[,LH2>P[+70CF-%/C0R=DA>=[(%]G>Q
MN@7H?7XOECL=/\O=7M)(X]#>BG>A\9$7BJDZR\->0XVT&B#ZMSNVW C-6RW*
MCBP%>;B%Q]BL6QD8W$?6ZZ&(L;U:2]!&%Y!2&RT4BOV_K%I)HXP/H6=^5*)S
M9II9XO5/J:Y:2%?3^SK:#8V'E*%9KNLBN5I(#&00(U2O1LV78J&6.&'K*DTW
MCX#XI[IUXKRWH7JWM'0+9S_CUHM?:/5HMJZGX-D#M^<4E>CB:WR&KU$Y#<+U
M.5SD11PO1K))KY08O;70J^+WJ0F<H/7IFRJUQ/#KZT,<UF-*U!C$C(QN=86D
ML22*>LGF:5H4#J1^Q=OMV>G]+;;9/KKOJ':7+-/63V-KZBC%J99HQHO)=CKZ
MV"M,IEK-2BJQ79VADC/%V&,]N_BAD1Y$^H]2.^U\9&ZE&I_);\QP"I^B[FS"
MO@ZPT.CT6Y6DQ6 <&]6Z9'#P^?7YQ(V ;*<^L+K\P./.PV6C9B1!+;A0MAII
M*C,8#)8B^+>G'S$4EEECC5W,48+F:$$LBS)[,RGY5Y'-UZ;];U-Q#&NP6MK;
M@T]?=VE6W'-4J5+5B6"%+EEA&M*X0B2R4IR6B290)9627I9 -*#34&,4#D8)
M89,1MV&1&RX\^#*;TI2-N1I<5QV.^C2T*1M;3BD_<E2?GYUO64S*RDJP*L/J
M&!!']H/N,VZ2)*BR1NDB,.5=&#HP^G*LI((Y]O8Y[L^9[QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&<M[;Q^E]_Y+T'C'0X*Y]-Z/6"-9--L+TU.B(F
MM_,(P)D[2O<$X!(MPS8$BA.WAID?!GL?#T9&]=ZUB6I8ALPGB6%U=>?<'CZJ
MP^Z..5=?HRD@^QROVNLJ[G6W-7=3O5O0/!*![.O8?++&W]":%PLL,@]XY41Q
M[J,\? J_U>I<;YY5.X6D%>>IUBN1:];KO74$&A]REAE.#H5L>CDX\:5$-6(5
M&@%['#2VN)$L,PI''/R1[<9]S[;>"2Q-)5C:*!W+QQ/QS$&^8Q@J2"J,2J'V
M)0*2 >1GG3P[&MK*5?:V(;>PKP+#8MP=PEIHN46P5D5666>-4DG3W59FD5&9
M I/3R908$'S2QDA"%"AL23/($B,IB%!@P84=R7,F2Y<E;;$>-%BLO2)#[JT-
MLL-..N*2A"E:X*K,0J@LS$   DDD\  #ZDGV&3Y)$B1I)76.-%9W=V"HB*"S
M,S,0%55!9B2  "3[#(*=%^H+R$%4OZOYL[(Z4"&W7A58NA^('N T73:QZ1<;
MA<FZN/3.J[".ET.P%)@V%$FT8C)AS9$S<=)B*N+-<B6D.IL-((Y@(6:.T\:%
MHRTCTO>Q7/#GPS(H8E95!'')4\CG)7?66MBK_$42UZ)+>HKVIEBLI'5K[PA-
M=L4[UQ\=3FD9$5ZCLK,W'D7JY6.]O]%^HR/9S5"I-CBE3443XWZ94^; J;!B
MB;=2.HWI_F_IZ@6XB2&R+]2++S89O?4Q)AFP B53$O#-6.-/@#36I<R.G16L
MLTJ%5+;&"29Y"6CE@B$U*6,*1%+',W[!E*.)&!\?#,O%-9W>_?9RU*LRR2K'
MZ8OUJ,-5!'9J;"XU'?T[+NAMU;%",'81RB:%Z\;1^=76.7MY.6^6^O%X?D6Q
M=)I!6VW#B_H;T%6>Q'>I6*(?-=)X+-&]GIO*^A+F60T5,F"3FIG'KO!'DVX=
M@AD6;(3?8@FDH41^V+U=3L$AD6..S3J/72!.BPVPU:6>'A%5%'M8B)4E"I10
M2OY?&O\ 3^RD7TW/>J26+.KW6Y@V<NPG6:6]IVCVM377.TTLDDKD-K+:I+UF
M1Q/(567COO/7?%O?>A.>P(H:\<Z%UWV9P2^\UO0,F2N,A%9Z&T^<JG(>BB]Z
M"38Q%<#CYF)2^@0X<>K(*_TE240F9#H289,<H-E4B&N[13,^MMQ3Q.JQ_M(3
MTDL0GYE*\V$\D)/D*^24D@,$65L_2VXNGU*L5NE'!ZHT]NC;BDDM-\/=!EKZ
MV['^R99.FLE6K<517\GPU0*"8GEE_'?@_J<#EKE0'6^ESN@CO;%2]2USK;Y>
MS5^[-@WR8")T48>*":W,9F7E7)M6WA->-AQ@(*6H<JNS28P&7'3?UGW\5@,X
MD,<@A.LDH/7ZH\18*_A9%+KQ'\1X[;JS,RS!PK,K#CX?2.P77FLEFJ]Q/55;
MU!!L6DGAM"$R0K=CFDC@<-;_  WXG40S1)%%)3:%GCBE1^^W_4!Y?Z5O-'I5
M&\YTR"6HM8&2+43KE<M@6C'#=DHIVD+JW+'G39$.''<[O7-%]5JVB@E4@[4^
MC/<OM,-(T77"+[_/4STHI9);DA65V$:R/&TJ(DJRB2<!%9FFBF\$G4\+)")X
MSRSJ,E>L:&]MU*M7254DJ5T:P\$%F*I-+/4EJ&OKR97CB2E;HG8U_)&3-6NG
M7V%Z1P2%O=Z0[;VKFP[R17JZX3K)BTG"=J[E92T*J5\"$YK0^76$H=JQZVW-
MZ_T.J6.PW@C2![,I=H,$TPAUD(B9I%B,^M?FE6K3'8._5UC18ZR*9'=II9T5
M9$CB\4LB)$LIXZ*O)16X)&>M[M=I13TY# 9();$TEC;6)%KPPQ4:FOGDFKS6
M+1NTZ\\UMZB*QL22=(YWB>158G?:=ZQ*H[Q.\\W.L,FS;W/J%;>=7FF*:'P.
MN/\ [^_1^XK"U:PDDJ"0>.6= TL=TY9RDM=;+R4,17B81AFP<Y->OP@N1R=5
M$TL<T4ON8!T\M7M(B\,UF/LJ<(H[J/?JQZ3*WJ*0;=M+:KB:4TZEBE;J\(FQ
M/F-7;&*O-)^R763^.27FQ(Q@E/"EXAYI*<H[#SKMM)JO0N;6)L]5[I7HMJKD
MAZ"2"$9U>FOOQ8I;8([#&FXT%^3&D,,2I(]J/(6RO<=QU'VKW"L5YJLLD,Z=
M)(W,;CE6 <<$KV4LI(!!(!Y'(YR\UVSI;6K7NT9Q-7M0K8@8H\3O Y*K)X9E
M254+*P#,@!(/!.=,SAD_&,8QC&,8QC&,8QC&,965[']&=P 3+MQSE'-.EC[2
M39IX+G=[_LPM\WF-JL]J.T!P /*=Q SI%=YR-NI*;:>(362X1DS6+"3%7^78
M@%881,=N]=3JL(K$\T+(ID>:+SQB:..-)>Y6JZ]YVB4):'5BKH#$$>0D#!^I
M]WM86MZS74;R6)!6AI6_@++T+%BQ-3,*2;:%V@HQVW:QJ7$L0EKSR1W&FAK@
M,< *\-0NQD^ASN@A;=0./WDC1+_1>16XK%(7[@G1)5<L,7KCG(;+3[H;'\K1
M/L\'E5IK\RJG2 J%8:]T0=#KJJ3?)C)?VVT-=81"T<UF)98I;$:D16H0Z&N+
M"21J9^J&>-Q(@8H\1[^6(%>4?I--G)=>[%9IZRV].Y4UMF17N:BZ89UV)UL]
M:U,E#O837V(6KS/&DT-U$@^%ML); :/Q/EO.)U@)4^G#19"S6RZW<K,<5*(O
M_P!2=&/0[/>)@Q1.1,T"CV:PCAQHP,!:'#)Q6!#)2(;DYA$C51+9GF"+)(S!
M(XXE'L!TA4I$&X [=$)52W+!20#P>,V-35Z^B\SUJL<;SV+5N1OF<^>[*L]I
MHS(S>%9YD266.'I&\B+(5+@-G4\X989Q>_\ I'SORAUV/U+O7&.;2&/^&CWW
MJ%(J#[6]?ZG&; <'NIW_ !O^-IUOY_CXR3#2N6 #!4LS _0Q02R _P!Z*1E7
M<WFEUQ(V&WU=$CZBY?J5B/[1-*AR/\GZG'T\8C^XSOM+S:MS2MI^Z-UFH36/
MG6_C^)4,F_%VG_8K3WV[U_.M_&2QI-N1S^&W/[X'!_S$ _\ -E,WKWT4K=3Z
MIT1/^3L:SK_RDD9?[^<Z)4/</C"_OM1*5ZS\VV><]M*6QH;MO-YI12E[UI"=
MBVK)L@E2M[UI*51DJWO?QK7SG&36;*(<R:^Z@'])JTP7_E=./^?)M;U9Z7N,
M%J>H]'8<\<)%M:+R$GZ#QB?OS^[KSDG8LJ+.CLS(4EB9$DMI>CRHKS<B.^TO
M7RAUE]I2VG6UZ_E*T*4E6OYUO>LA$$$@@@CV(/L1_:,OU974,K!E(Y#*05(_
M4$<@C^S-6NW/J/T@-JOWVI@;<&23!FVAYX;&(L1S58*L'*V8B_J&U+B%0!F-
M'*AB,934P809;EPWF7TZ7GN*:6%N\4C1MU924)!*NI5U/'U5U)5E/(8'@@C(
MUNE4O1>&Y6ALQ>2*4)-&KA98)!+!*O8$K)#*HDB=>&C<!E(/OD4+9XLK4POS
MR=4K$?$ .;]8Z+V"LT!LI##583T?ME@MLWI/4=S1];G60W<:^.Z3TF9RL20*
MQZY7K)9]RIR)4,:#9"V$>S<+,)$1GFKPUI)NI:1H*R1B&#@N$2-S! )V5>[H
MG X+-VSUCTM TE-JT\\4-+8WME7IB18J\5W:S67O7^R0-/-9A2]>;7QR2B"&
M>QV;LL<(BAIQ"Y=N\BHY3YZ=J\.<(=[+W_AU,$D991T7$KD6R=TZSY4C.KCN
ML)K$GLE%$2*V_>H\>Y@*()J58B' <HL4+1JK8V8JVP^(N!R&%:I:E8=>S.4J
MU[Y^_?X:9NXB/C>5I'*LJA3)F-5:VWIL:[3-75XSL]SJ:L;M(T:PK/M]CZ>4
MD,OPYV=.)H#;"VH:<=:NDL32/(M>ZG7S\:^=:UOXU\ZUOYUK?^O6M[UK>]?/
M^&_C7S_LU_AF:S]2SYQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9H7
M49/28?.[G*X\,J1CJ+%<*NT,9>YQ(;4)MG1#=4(CV"6(9=)-C'9FFD2=1=QW
M%HWM'ZR$E6Y376 0F:,6&D6 NOE:(*9 G/S% WR]N.>.>?[#],AWVO+2M-K(
MZTM\02&I';>1*SV I\:S-$"XC+<!NI4D>W=/S"CQBU=U],@!7HGS3U>XT[M=
MTI]D\\=V\E=A,6BT\FB]TYR-*0NF\EL=7CJ(/\2LS\67/M//^L54=7*L._:F
M4WV%/&]*@PQNG,=6B[5+M>.2M'(ERI?KJD=@U9F!@L)(>HM("%CEKN7<\GQ,
M&A);\H%C;[Z"/=Z+8VJNUM5I]+MO3>SEL6-<NVI)(M_73UU+-JIRKM8I[&LD
M$"!%^+1X[R*D[>&^''>=,=(I1VRBGO/-CZO;ND\[X4W6119%,J_6ZBZSV'B-
MD-'-%@!CCUEO1ZRV.#10=8'K"O(%/Q[C._$U'AU=O:>8PRJC?&)7CAFM]V4R
MO7D_D]I%3JRV$B1$,KNW8=@8Q]3KM1Z3-$7JLL\9TLVPLWJ6H^'CD^%K[*N1
ML]5/+-Y(9-9/<EGG2I% IB(C*VG "K-2F\KYOS[]&NF4FMUZ7"J];I+)6"+C
M:.N5*H#F!-8K\RP/(=-D18,?&9CCXQ A)0Q\+=U_GG77%ULEB:;GRRNX,CRE
M2QZ>21BSN$_*&8DDD <\YJ:NOHT^IJU8(62O!5$B1KYC6K((X(6F(,KQQ(H5
M%=V ]S]22=Z>>9C,NR)#K3##*%.O/O.(:9:;1K:EN.N+VE#:$)UM2EJ5I*=:
MWO>]:SB!S[#W)]@!]\EDA02Q  '))/  'U))]@,C3<O:OCKG;[L2]^K/.51G
M,J6EP=8.U<X%DTK;W\+1H9+L;<]3B-_PIM$=2];_ (VGYR='K-C,.8J%R1?Z
MR5IF7^]@G4?WG**UZI],TF*W/4.CK..04GVM&.3D?4>-IP_(_0+SG,6?J=?3
MP??U&1[2\W)<VK2?N>ZO4X['SO?Q\[E2"+472?\ :O;WVZU_.]_&=CI-N!S^
M&W/[H')_S $Y7CU[Z*+=1ZIT?/[]C65?^4SA?[^<[M0O4'FGJK[,7F'H;AW1
M94C>DL1:+UBAVR4ZK>]:^QN,!/3WU+^=ZU]FF_NUO?QO7SD6:C=K\F>G:A ^
MIEKRQC_.Z 9<4]_HMB0NOW6IO,WT6IL:=EC^X+#,YY_=QSG<\BY;9'+MODS@
M'H*LW:L='YV)?1T,(S7+?8:WMZGW(Z#CEH9Y@*6MM:<&'#(!)L= *R:R;EDJ
MR5E0V-&0Q%A*F53*M^W4DBDAE;]BW>-'XDC5BI0LL;]E5NK%0Z!74'Y64\'*
M3:^G--N8+5>]2C(NQ""S-!S6M31"19A%+9@,<LL/E1)&KRM)7D91Y8G'MD"^
MR^";H(X_ZQY;S.84M%(]#7OI'HBN0*4W5*?U3FGHE\WRCH7)_P"GREBL56II
M3GM=Z3SJQV8EJ88"$MS+I$%,C=C8,TTW;5]M$UBA/.%CEIQ04W,O>2O/3"6(
M;'=4CDD$SPS1H.%9>L18MV(4Y#:>D+4>L]1:^@TD]7=6[VZ@6J*U;84-V9==
M=UWADFGK5I*<-ZE//)WEB?M:6,)XT>4:]PSJOH2^]SW4>63*0."^;.;[LGNN
MSCWH^N:=S]M])H]2EF^1U>QS89&+4ZWS]T/_ %1=;U6AQ S5$$(=?6 D2)I&
M";]6J].*KY)Q*S79^FJ0_P _6UD,CA+$B @R23!ND<3E5?J7#@!2G'4[#=7-
ML:U!JB1:.B9_5LZ,/@=KZJO5*S2ZVO.ZNE:"D8_B+=N!'EKB1(1"Q:1))_\
ME_UMROU54TV*@DM?K&GK RN$IHLD78857M).EE+IS8V9#5]?0^83;&'FQ0%Z
M&"HC,QK<1LP,KYA]P,Q4WM?/0DZ3+[$(>>5[(719%CF56?PSA&!>)F/'OU9U
M^8[#0>H]?ZAK>>F_S S KQ)XYEKV)*LEJC-+%#\;0:>-EAMQQJ&'42QPR-XA
M*/(.:#&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9P/TCWH-YMYJ[U*T
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MBW^O7Z[7TY$\=^)![>2YH)Y9))/LSOK+=E@ 2M3CV$Q.+]XX_P"B*8Q?^*]
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MEJ?N:=TX)(E"EW5M&OT5,F[<;^ZQ@U<K1+9MRQT*C>ZRV.?),/O\-67F:?\
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M94E25)=VO[-I5K>E?&]90V+%>I#+8MSPU:\*EYI[$J00Q(/JTLLC*D:C[L[
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MOQA_D8C>>.;9?C E%UEG&H*'6QK,<I\93%A;OGK,?Q*6PUX;"5KLU)H)8TT
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M@L06)X "#ZL2>!P.23E^ZUXB]J00QF.-C)9<(A2)!V8O,W'6-0.S=F"@#D\
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MI2VTTVE*&T)2E*=)UK64A))))Y)]R3[DD_4DYNU4* J@*J@*JJ  H X  'L
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M&,8QC. =KZ?8*G.K-&I$FK";?; ]SN!"Y7MN3(I'->9<W; JOG0CXZ(4 R+
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MZB!3[<V!'_/FLX@X_,6+Q^4)_EFMYP!]3R57ERH.BW?0+K6L<? )M('V!?\
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M6%-MMLMH::0AIII"6VVVTI0VVVA.DH0A"=:2A"$ZTE*4ZTE*=:UK6M:RGS:
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MB8# ]^1(FC+SP\Q_O3)7JC,Q@+&CM/4!^\Q*K]RZ?!]&RZ@W*] 0J2A&UL:
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MED#)*U<1OR?R,W'OQG!KMY!CGKJW;:A>(?.X8MD>[7*Z%H8S8X60'6:MW?\
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M68$,#W@GC9Z]J$K-7EDB8-G;LBY:XQC&,97UX6^$WWZBC37\Q4>_[HIC>O\
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M7?'YT)P9-E189!$EAI4.5)8CR=-NO-H5T;:;)%#O!55&XZNVIHJI[#E>&-4
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MUE 'JRAE/!K?1E(93]"I!'L1A/1'I^52T=O?R*'DC+)ZN]2.HDAD:*5"5VQ
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M6%H3G\:WIZ"2ITJ&^E6M*0\PXE>ONUO++=J%VU_CZ26'G7Z>ZV.)U/M[<$2
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MM57)NPX*8]R^)HCIQ!SQ&%DY@B =O@JT(8>YZ>.U'-8/'\^).LG'9P)@U7J
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M1R!&DK3Q6XTH-0FOE9FIR)_O"ZM<[\3^M+FX]IAX'YU["Z.5O?QMPW*H9R
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M2U$7;BFF[34J\5%LQ0!*.0KS^XVB5BGLC]VB%5%UPQ5YI_C)1Z- J2&3SSO
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M()'")V[]4['JI?D]B!P"?N>?8?3-;K7EDU]*2>4S3O5@::8Q"#RRF-?)((@
M(U=^S(HY 4CAF'#'H.<<FXQC&,9PGU#R!KO_ )P[MQ)S;2'>J<FOM&@2'OC2
M()BPUHB/"$_E7]U+@LP]!(M+5_=0[%0K>MZUO62J-CX2Y5L_XBQ%*0/NJ."R
M_P#C+R/[\J-_K!N='M]5R =CKKE1&/'"2SP.D4GO[?LY"CC]"N:[XT[$[W[R
MKP3KDW3B#EOYI6W+A%>^=/C;^&B:KO0P\C2O[^I 6\"+ )D)<TEU+T->G4-N
M:4A/O95_A+]NN/R1SOXS^L+'O"P_<T3(PX]N#[<C.'IC9_C'I[3[)OYVS0@-
ME3]8[D2>&[$WW[16XYHVY]^5/.=UN%MKU"JEEN]L(I$5>H BMDL)-4>5+U #
M!83Q$C*U$@,2I\Q;,2.ZMN'!BR9LIS28\2._(<;:7%CC>61(HU[/(RHB\@<L
MQ 4<D@#DGZD@#ZD@9;V;,-.O/;L/XZ]:&2>:3JS=(HD+NW5 SL0JDA45G8_*
MJEB :MP7K!,;J_1.OWCDKP'B'4KU0_+Z++=[!"09WNBUOIQU 071 02YP[L;
M<MYWH02U55%G$N"IT@%S\.W;.V+NW*ZI>-0YKPUXK':U!%+>Z1H>H\KP+V:5
MWC,2^-8623QL& >9C'5$5B3 Q>H>NQN[*WKC#JMA;J:#SVYE$O\ )(-A,(HZ
MD45I;<IL2W(K%<3Q&-VBIQ_$[4V]=6["7YQPF'S,?>JGV*]<^\TDK#3IY/DH
M4;(+UDC8*KT 8D+2*)2;'5#G2>:&RMV"P**:Y%S>"%D/DV90 %2*]?9<\J]'
M6:V9S%)7BFNJL@6PS .$>)NTLLJ2+#.BQL95L3,P"\,TKQ +EE)2U"T$MUMG
M;IZ*2:LSZZ*,R0/-!<015*=6:M+>HS26XEJ2ZVDD;-(&ABJ0W&>0XRQ<B]"]
MPN9[N]!O4_SHP2BB*>$H9BOVL/:^G\]ISI2>"-=,F-7#7]G!N;8;/<9%18B\
M_EVFN5,@.3?1A4M*74*EZ2Q4JQI5EB6X5+2/*KQM'#-)U#+"#%^V4)'&).9A
M&\@/B*J/))SFUNYVUJ;;T[;Z19%BK15)(+$=B_2K&1XIKS"R/@9FFL6365:9
ML05W3XQ))&^%K31XZ"Z-6N<UX+UFVQ;Q?8:C.S%DAQXK#4F)*/E9E>@..PPU
M<C$Y@&M2 X A8&Z[7OZEGBY-@6!#.$U#8U;8:%YG:O&8HCUZH>?8A%#G@LY4
M.X9PG=^@8)V;KR=3K(KL%*&+8V5MVU\ODG55 96FD:%"5CA61H8#%"\PAA\[
MQM-X8C)T6FWL?JM=6F\]LEVK-RZ 3Z%QFA^B; L?WWJ/)_Z8I_42I]FM\QX/
M5.=3!PJ?;J>.!J'2[,05"L-XL!"OP"95A%C:56L-ZW_A+J^A?57H+TD_IW=[
M1_76_G]/5MAK-;6MT];-6EH0/<VDE@%YD+WUM35H2OPFNKW+@[>!8I\2]I[-
M:796&,KQZ6GZ@L1MNMCKI%K;!K/@U^EKT62(V:Z5S#\3)UEN6YJT+R 6.U>W
M+B9NPR(O0J39S<BU$^2]%DT%NX36HC)&TAY-.IG0J]/,-CX\6"H\+ 7P;5[%
M-AQHD8P> $C34 8DEH9#W=E4!AE11&MB$2^,<]48220N%Y)/1GB9T!)*JP7D
M]>3L-7+,5N59Y6L2:ZZU,67"A[$35JMR%Y BJAFCAMI7G=5599H9)0D8?QK^
M97A8QPT:-4Z^=(Y;NU3WBEO$T$R$: 60E*TG4XIL/:ZW:X=6,E-Z6\8/4!%1
M.FISKA4L2FE?LG(^K:;JJR10S^,<1M*K=T4?1>T;QF15^BI+Y%4?*H"^V?)-
M3&999:UN]0^(<R68Z<L0AGD;\\GCL06%KRR>YEFI_#32L?)([2<..CTREUKG
MU>AU:ICE#0\-V;*TAZ:0*D)Q$I.D%#!DT:+RIYD\>-E9<PJ</&I\\P:*RY9(
MG.E39+SZ^,LKS.9)#RQX'L H 4!5554!415 544!54 * !QDVK5@I0K7K)TB
M4NW!9Y'=Y':266661GEFFED9I)9I7>661F>1V9B3M.<\D9I3/.:+'OTKJ3%5
M#,]$FUS^D9=O:AH0;DUO<R$06)>E)^-N1W)8P6X]M2=O/)%C&775L#H3;'4S
M2F(0&1C"'\@CY^4/P1V _7AFX^P[,1[L>8HHU!<;8"O$+K0?#-9"@2M!V5S&
M6^ZEHXR?N1&@)(10-USEDK&,97C]19?];4CA/F2)O\Y#U-Z8Y%0C$!CY5-5R
MWGQU/<^R$&T:_P![":H',286<^O6VFU6&*RO^])1O+C3#Q2VKQ_+0I6)E)^G
MGF3X6L/[?-.K ?7Y"?MF*];'XJIJ-"ON_J#?:RG(@]V_#Z4PVVS<#^H*=!XG
M8^P\ZCZL,L.RGS:XQC*_NB<R]+W>5''DY4LA76.OBSI\>-LPP3!.5*N^P^0]
M#YA/JVV"@PB'53_-83H-4Z,*F?M*K5=W!$R!&LCZ6#S=O#/2B!( #FNRHQ1F
M*2/KK$,PDY5@WDO-#)"P[>.+L"4'*9C;M#?6V5'=GA&SCFF1+$<:2UH/4VMN
MT&K\.C1_#:**[6O1N(S8MF)D$YXF&\=+I/<G^H3E<[V2!\UEA.$@]N5B70P,
M]D;7)/HC^T87!DRTQ[!$A(B67DNQK:'D?HY+4UVL+'K2:<D<H):O@'FZM,'M
MOQ()F!9Q3\+'KRA)*6.?U''DY^7B7>J[8[!_@N\-!HM1%S7:G"X2!MU\=&C-
MQ,J!9]:(QR.K!S7Z?M2W#X=.]Y* MM$+%:4FV*TLCJ1%LG+M?J;T]SSRL_\
MB>^[>XVP['40_I5Y(S330-(HQ%'HC+KLH$/BRC)JNQX2/J9. .D_M$);_P#?
MV\+4@2"7Y4GGN&)JDJ^KO#Q)/8\HKEP5GH?-;-+T\??GY?&NPCWS!.!%XY$0
M*8&BC7+DZS[=CD2<0++LC@G6KZBOSW;7SY]Z+!BS?: NAM$OW(DY)FEY82T^
M02&Y,B/-87)IIJ:?ELF(QEJQ>%?6%5+!.W[+N/'+P21K6EXZKP%#1[$< @\2
M*%'4KTZ/7]5K(ZQ/,8OY8(7-BF2J*_JF.F).[EGD:*QZ:?DAP6JS/,PE$HGV
M[G==];P^CP(=Z)6A_G,:P0B00O&.\\E$6&6HL:3;QG0VU3]/D:S97BDR)4&P
M ,\:!303L9.Z<,DB3;?B5]>86,0C$Q0JRE)0/OXVA/7Y9$ZCR=G575N29&#*
M95*#U&MY%MO.:2S+)%(LU-G4!5:S'='?EX)S(RU1#%-+"\)7^3(T<P_/H/./
M0/0"ML%GF;)* 1^V<<+@X@FT5<12C?-:KZ YM?GB41ENP,7"+8 /,@]LKEJ%
MSHH >=.;8E0(MO5*$$:RAFJ0K&R% _PME6+)(TBS25)X0">OC*M,T;QL.Y5?
M8F/AA)YNT=S<DL)*)VA&UU<D2QV*\=26C7W-&XSJ/,+*S0T(K,%B-EA2:7AD
M6R6B>#0JYR;U31!Q\-SN')J[DJ'VFT4J6NQ4T@);Z"<Z/WPM6AO6'RY&P$I-
M1*5&T\:E5I%: 7"8#.UDW"GJJ$&22?L?5[%"4HTY$G!K)* DJMX5AJ+(U<*J
M*)%D2R'[O'W5U(\AZ](<&M]0U$FBI*T!9=I8JOYZSQ_&37MS)!'L3*\TC5GK
M6-6T'P\%EXIH)E=JRLYGZ,BI>B/[0(UH&PNFQJ*>!<WC'JC9^EU.9:@0R#>.
MSD+W71CH.S[KD&R_AM_+)8RRPB9@@4H5)+UR=>6+!L9%F<?)3\/C8P&5'F*2
M)!((V+15A$[=D#LG,<X9"JA990XB*<D3A6W1NK81;Z5)H:*S5K%ZL]B)$M[2
M2W!&89_ D_%G7LDZ/*\E.I) UM9N@;%52F>SX0Z+/M5QGG[;!Z!S)4N ^0IT
M&F6*B#^,<X&WUMIRO+"$JU.E]<WT6P-F=AS_ .I=C0("J!)JQB*T"]/+K2Q"
M1A(S%-P0LAD25K,S1?G[AU%?PIT[)QR3Y@ZDOSK5?5*HKV+336%N4.R%JJ59
MZ::NBEP P&&2N[;+XZ82^.;DJB?!-!*HAL$RHS98QC*\/J%K_H$3YF].H^([
M'F3U)S:R7(DG6]N0>1]<9,>>^HR'-:_G< 6%ZI%M1'_T6XU9V^XIMIEQQ%QJ
M/VS7:/U-ZC,D:_K8KE;D _>6: Q@?J_W/ S%^M#\''H=\/E&B]04)[,@^J:[
M9"72[!C_ )$<6Q6P_P!@(.3P 2+#\I\VF,8QC&>>7%9FQ9,*2E2X\N.]%?0A
MQUE2F9#:FG4I>96V\TI2%JUIQIQ#J-[TIM:5ZTK7T$@@CZ@\C^T9\90RLK?1
M@5/!(]B.#[@@CV^X((^QSD4:^\DYA$@<YAD'@X^CQJU28(V,(MAB '=7JD J
MI3]G&AQ.*[8YK5XH[ >NODW[(3BFX4R/"DQDR9#4@PV)R9B QE+R%BT:EN/*
MTDG7LIZ#Q2EGZA 5(YYX&5JW-=05*2N8DJ+!51%BLRI$3\+%7K>4)(IG<6ZH
MB@,AGD6565&4,PU*1ZZ\^1FY#[MZE;C0X,PA/FLTCH4F .CC 2K,802GQJH[
M"&S 0!F:4L(V<_'(U^*).J-18*@!I,#H-?;/ $0Y)"@&6$,2S^->JF3DAWX5
M" 0Y9>I/9>8S>H],H9C;;JJ,[N*MQD18XC/+Y'6N41H85>29'*O"L4QE5/#+
MTRQ7T3Q51*'5'+%LT<-EE!00&)4;D<582T1R\N;_ &E JL%4EAL&1S"ZKG'1
MK4\0*W77GY<MK\P_]7Y6G:X,G3JJ+W=S)&O12(OS=G7J2)XN%8AF[\ >S<=)
M-UJO(E<S^66:4PPPK6M3&>53;/[(1UY/*B-0M=Y8P\<9A)9@63MH_.O8W*.A
M5Z@'TD?Z;>N%5$'"E<L ZY0+,",GZ_SFP ZX.&RJ7';M6S".E@((0H.E1F+3
M.E08U,CV61(G,"NLVML0O,G7OXY&0.AC9&5&F5W9A(?'U\+%E8$H 3(4 ':)
M2]3ZZ[!3F#^ V:T4TD$R6DL0R3PTIH84C:J!8\HO0I$Z,HL.R+56=F98]3D^
MD.5=*'C@UR$F!$]VRD$5D<+(=-&V,=9*M+]'ICF"):IU@,:JH,D%\YWUY@D.
MF$22]+,5FQUZ!^%#1WH*5B!BT3*PZ+Y&*P,A204N559)&21@UV($$*OY71SS
M\L9MYKKZ)%9CDC<V)!7CC>]'.D]=MX!+))7@BEKPR1:2X5D1G<CRP3PIP!+U
M4'Z1X/%B @46Z"8LA0RNL#A0N#9B<1UTK"C;'!@<_P#8&=G""5.L0U#X[/[X
MS*>C128R"1E-P]QWI6R6<Q,1RY9F,8(ZGYF8=SU'WY_+QR5)4<Y8P[S4*L4*
MV8U;I"J1QI8D7F15Z11/X1Y7]PO0#RABJO&KL%R1>0\N\8QC&,8QE>)5?]K'
MU-ZD-8WJ37_'OE^QV<JZQOY;B=3]4VR#7*V/F;WO>DS!W,N.6Z>VUI.G$1+A
M'<TY^.2XVJX7^3Z21C[/L;R(O/W@H1EW8?N,]A%)_6,^WT.8N0_B/KRL@^:'
MTUH)[$A'T78>H;*00(Y^G:.AK++@>Q"VE//!(SI'I;B?<NH6.K$^3=2"\W&0
M14@7:2$<7*UT_074U1<O6^96R<H[3Z8[TUR&!KEKMAOGUI*UH*&;G5N,\2?1
MN%PI6JL"2+8@:=BP:-2P\';CJKSH.DD@@!=XXUFC5V;AR%'O.WNJVU^>O)KM
MA%11(S'8=8V^/\7?RR04+#^:M5-\K#!8L2T[$D$40>!3(04DW0PTZNTBG "C
MK;Y0+5P HG(9:'L-2"4 5%BSY"&1(X0+:2_+:>>^P:)&0$_?\1!\-C\<=N%*
MP>61U]E:1V4<D\ L2!RQ9CP/;YF)_4D^^7U2)X:M:&0@R15X8Y" BAI$C578
M"-(XQRP)XCCC0<_*BCA1M><\D97'Z"=_R>_9WG?TU\?IN>]Q%M>,>X2=;^R*
M+-G3LBW^9;L0TC2&]-0^@/V[ETHE,7^.-_:L'1M>D,-(U<U/Y7K;E'ZS56_$
MJH^[(B>.]$/[81'. /\ $/\ J<Q&Y/X+ZHTN^_+2VT8],;=OHL<LTIL:"TX]
MAPEUK.O9V_+^(Q_898YE-FWS V:K5BZ!)U:N-< VRN%&TM$Z_9A \\$(M)6E
MQ+4X44CRH$MM+B$.)1(8<3I:4KUK[DZWKVDCQ,'C=XW7W5T8HR_V,I!']QSC
M/7KVHG@M00V8)!Q)#/$DT3CGGAXY%9&'/OP0??,72.=<^YF*<!<WHE-Y^#>D
MKF.AJ16 E4%.S'$I0Y+<' 8,"(N2M*4I6^IG;JDI3I2MZUK6?99IIV[S2R3-
MQQVE=I&X_3ER3Q^[G.=2E2H1F&C4JTXBW8Q5*\5>,L?JQ2%$4L?UXYS82X@2
M?%D AT6.-!2T.0/*B"\*,2%DX$MM3,J"0'S&GHDV')96MJ1&DM.,O-J4AQ"D
MJWK?E69&#(S*RD%64E64CZ$$<$$?8CWSO)%'-&\4T:2Q2*4DBD17CD1APR.C
M JRL#P58$$>Q&<WHW!>(<R+.GN=<AYK1SCT-8U1FJTJN@BJ!;CC;JQ#! </C
MRXP?;K3;NA,=UH<EQ"5HC)4G6\ZRVK,Z]9K$TJ\]NLDKNO;CCMPS$%N/;L?F
MX^^0:FGU-"0S4M;1J3%#'Y:]6"*01D@F(.B!EBY /C!"<CGKG6<X98XQC&,9
M$7V%!Z;9:.$H?->"T3MDNW%9#4N;U*!4[!SWGLN!'0L%8C]4LA87),_D(2M[
M3/$ZF/UP="+F&QEE+L@Z3;+#7&!)7EFM2UA&HX$#2)-,"?F1)$4]?E'T;@.Q
M52R*6ECS?J5+\]2*G1T]3:M9D8,VP2O-2I-& 89YJ\\D9EY=O9H^S0(LDHCL
M2+%4LUZ^<..T#TR-E@273.8W>*#0NFV"SA:\;(]E-\WY=4Y_F](_F_7)=@TD
M5S/I@P"NSW0-!@G7AQB^7EF:B*[TX3(KMQ<LRT6#+!/$6_:)&SHM99IY!=YF
MKA/FF@+A(F+*"L4)!X@/DQFDUE/>QM"]^C<6$&K-8C@E?:2T:%:31^.ELFFX
MCHWTB^(LQHDI26W<#\-?C:#KG+/1;I>B%/2?:[V'*/<6&6BJ<AITR!5>9R[K
M=+'S<-<_VZW6/=RM 8GW"+7&G:7=J^#$T:M\PLO]I>C%1F#Q@XJ#CV*865:5
M6)E%ED>S(#),(HTF:/M&GBC9:I<B6)W,KSIX>L@)*O9:_=&2I)O-I<CD.KCL
M5];5=*U![5J>C%:\=F?XJS$^V6 &K;AA2I!0G%_RUF2-)(ND>%]];<&H3#[-
MSGH?%8FB4F?6R8.PO=OKMOMKLB[NS#EBD4KB6H<:Q2+%_4BQUQX^Z?-PR[5D
M@VM\<0BMN\-I\/V]ZTT-D\!75D^%>./B(!4$EGDH$Z=H[/12O0Q\@G)WI/\
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M+>1(2+98K4FB#*^/@#J_*EDRB;RXU22D4<S*6!N#\>KG=#3DAB YY&MO,.1
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M1;7I?:>FC$:+6&1=I/7F>X)/C8 S1&NBK!XP&#,3*/;B.-[^D>JY,=.8A]T
M5O72HOJ0?(_;^(;4D8.],0N!Q'(OV-=7A:GIHRN&(DC]+W&8+/VN6I4<5L;K
M9"9%Z@\1@)JO)X30([6OS&DUIN?]3G@R_$\$^_41C\W;Y:*Y_!M\4+X7;PP"
M\OJ!&\>I_FTWRZ=2OML5[BI^$]D!ZB4V&/$?C^?(6_Z3B+/*Z_+C=M# =]4'
M^I(B(XKC>HS(5ST;U;C76!_Y]M]+3^[PN?EN.PA:8FD#56* >G.,OUN3&:4[
M\CW_ $%<&JS^ T">;/Y_@J]FNQ_F/E:9;);GYNA4 B0$Y[L_P<B=MFZ[6*$[
M%/4"\1ZSJ(CO-CJ]DG)%_P#:)3DUB1A.$\R3.0T#*.?K;?I1E+B[:YI/OH%!
M*TS/1Y/]0UQ*0ZP&*^BO4'*O3!&<+9D=><D-+JD[F2J>*W^LU)F#[ ^3?EL/
M0MP9R/?B,1@5'XC%)>/B@.RTZ,](!N*_!\@F\C>W *!>#SV'VS_!V]HV'?<1
M"2P^\D#?A1(BEW?J#7;YWC!V1(-9Z'PT?S=F28R%@4Z/*;B'CB;PZO=U&ANB
M##=CZBKIK-3O9RFFB=@K8F^]$ZQU<.(O, UT4S5>A0Z1>.Q6Z8.;$5[GC9F%
M.(MG6Y9 O,(Z@6MD+3U6:$HD'@,D22*J.T4,%=FB*PK)"98J\8/9YNI5>O 4
M#-!J?3#ZF';QQ7DFGV!OBO;FJRR301W+NQV,4=M);LM>ZM2WL[+((H:0E1W$
MH9Y'DR/DKZ<%9J38ZF\]$2JY6;-Z*H'<XC?,7(50YIP"931<2O=)CU"D6NXG
MRHV+Z#H1GH]--P:*V\)#OV,0EROQXHN4?G2QN7D[23/W=*<M0^?F2>VLK%X3
M)*D:*34E6"53+PS!&^<DA!2MZ&KU@E:E$T%>?=T]NHH%*U#3/5C6"\M:I8LS
M2(NYIRWJLJ5!XXFGB_8*L;3-O1+Z><QSJ2>C@.SO A\?TK6_2 ^@O5 N>J8H
MX->[VS9X0317HBRU;DW0=V_]64W7"0JG1+O6YUW@T1J5<BXV+S7<#P>%ZP<F
MD](R^14D9#\(8RW6'JXB:KPO=6D,3B(R\1*QF/Z+?\0%Z':&%%WL&\2F:TLU
M>.5#N%L)%Y+OD@:U'MNS^!XZJVX'MK3[6I8UXHY](R.]RJD\R=[4%>>I=%[3
MSURWS^4V V<MHCI'GRT^=Z8:L[!OM,X;JU\]K%AB$94^O10(FT2@<*+%"55&
M]26I(]0D6)9_AG_:RUIO&+"*J-#;CN2*A6L&\<TB$!7+L@8DO)],JC_!NIUU
M77G:1$UJFUI&R^NFEFLQ7M+9TE66P)=H\?Q%*O.KN\*PQV&A15BK_F$[/)_F
M-?F$1U4/JYPK@QTOID#H[:8%/W3H]><A\CY9RMX0U%_J:RHGMRM<Q:L.YJ5C
MU(DFY4-45[45,R15;"]\<T#>,QF& PGF3R=^;$\X;\B=>/.5X^;GKSR.>!KO
M3NA_ (]C'\4MD7[Z7@$K?#+ 5UNOUYB5?/.&#? ";MRG!E9"IZ]VE=D#-%C&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,\D^=%&09A*>\F-
M!'Q)$Z9(7\_8Q%B,K?D/+^W6U?:TRVM:OC6]_"=_&M[_ (SZ 6( ]R2 !^I/
ML,\NZQHTCGJB*SL3]E4$L?[@"<T_E_2J?V3G%&ZQSXB^8HO1ZJ$NM/+2!I(.
M\4K=C'L% Q%8LQ$@E8/ZV!)8DICSX<:4VAQ.G64*_C.D\,E::6O, LL+M'(H
M96"NAZL.RDJ>"".02/WY%U]ZMM*-38TG,M2]7BM5I&C>(R03H)(G,<JI(G=&
M#!756 /N <WO.63,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QF$,66N5YT.R?
M/A ;UA+1@ !HP5@C'3AV8EQ<0*';FOL*)EI2&75QAT+3\Q]+3BFF5:0K>O2H
M[]BB,X12[]5+=5'U9N >JC[D\ ?KG*6>"$Q"::*(S2+#")9$C,LS<E8H@Y'D
MD8 E47ECP>![9Q&U\LY9T+T7RSI<VYR=]<\\5>[ZKU,$6*N? ^M]H8&ACQ6T
MUAP=,L"X1Y--@Q Q)<L?%;?#2M#5_FV1_+*CGL0TYX!$/A[DD7>1D?YGK%F1
M8WY"<IY&+  GAAV_H\5-C7Z^[N]??>TWXEI:]OP58YH/D@V@CBFDL5RC3%)O
MA46*0LBAHF\9Y\G,?H/TTO/X^>N9&.]12RV;KQH8,58JZJ %35?31GUR"$P-
M[J'Z]X9![18"Q7[BTXF5DA)6J_+*/CX\5#$L[NVP *P<]65FZ-RQ>DFO=C^T
MX#-615^4*H8=PH)/-,GH331N66;8<>:"9$\\)2+X??2^I(8T_DW8QIM9I)/V
MC/(T3>%Y&0*!YPOT]/,E(L%'4BRW-FWB$U7^S=PQ;:S^]1BO+>O=)] "C%>&
MKK<=@N3%6?K5]27;D#BHYRI&MP)X[28<.<Q];<7I4E^2/QMY/-UC?J5GKPU&
M5SW/4-'7BZ^ZGNO(/NP/R+T7H:LU0B>T+,7P_P "9+,'E637[._N8Y84, $D
MD=C97/(&21#6EZ.G"JX[AYY\A\B\OSSLODZ+(/BV"B\MY]+$%BT<J.9#<CAV
M.+6I<9:QS1/]XFO6VQ$;!.E$I229 DX\F/&:9BL,1;>PL7E43]"4FGF#*I5B
MU@H7!^;KU'C0( HZ@?4\G+;2^FM;H'E;7"=%FIZ^DT4D@DC$6M6=8&7E!)Y7
M-F=YG9V\COR H"@:,GP5Q_1",158NCN.1O6I+VHAAPO5U17.V%0,VLS'WD?T
M=IQ=56$(SH2:[^73:?U"G_U6Y+;+S77\5L]>O2'C\/76?E?GX57$@'\Y_.=P
M#W_=QQQR,ACT?K.ZR&:\2OJ.3U2 9*_4[66%X')XJ@_#F*1T\ ('S<]NP!&E
MH^GSY=YWSRGAC)NRA^9<4&=-:&_U%9ZN$ A>7= HAZC7*BVL^BNB)!"CPJ:<
M)0V;!8BS]X'PF8R9=[?A06F4=?Q>]--(RJC3VF@YZ)(SM/#*DL<L:=V"RF1%
M/1%\1//$7N<B_P 3-!2I5HI99XJ&JCOB/S6*\4,6OMTYJEJI8F$$;/42K+(H
MFGE-N- O:V50 =,H'B;DE"F\J(12USL2N1\TZ)R6N,GY-2U#+47I\&@#+$.M
M#%=I]?2:F?MG,*3$C'-;C&9.A+TTU/+DBYF:0X3;.Q*)P5C3XB:&=^@DY66
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MC*8VG[=LJJ5*" 5-J3O^=*0J!M*M;_GYUOY_G.5R7SW+4_\ CK,\O_G)6?\
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MXNZ/2H?$N<3)6O\ 5MRT]T+31V_GYW)K[V_C>D*RWI_L=7M+''!F^%U\;?\
M&R&U,!_Y.JH/_"&8O=?RWU;Z1UH^9*(V_J.RGV7X6JNII,WV][&VD9/OVA/Z
M989E1FTQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&::J@UA?0&NGJB2MW)FHN
M49N?^Z$]0TUIXN@ZY#_9=2_V;<A1-M#_ .Y[@;)Z;3J+J7J+O;.^GE?Q&#D>
M,R>4CJO/?KUY[<=N./Z//'WXYR*:=<W!?ZM\4*YJA_))U\!D\I7Q=O%SW]^_
M3OQ\O;J2,W'XUOX^=:W\;^=?\V_C>OG7^S?QO>O_ )-[U_KSGDK/G&,\DN!"
MGH;:FQ6)334N'/0T^VEUO4T=)9F0)7V*UM*GX4R/'EQ'%:VJ/*CQY+6T/,-+
M1]!(^A(]B/;V]B."/[""0?U!(/L3GED5P RA@&5P".1V1@R-Q^JLJLI_HLJL
M." 1ZOC7S\_&OGX^/GX_GX_Q^/G_ !^/G_5GS/6/C7S\_&OGX^/G_7\?[/G_
M &8QFK7.F +_ %V;5K*R0=$SWQ4IW8@X<K)1F6#+P3PB7 /5HB(.#94 N-A3
M6'QY&,Y]['XW-K8<>:<Z12O"XD3KV'8#LBNI#J48%'5D8%20>0?\X!R/:JPW
M('KSB0QN8V/BFFKR!HI$FC9)H'CF1DD16!1U^G!Y4D'7Z]R2DU@_%LPJ/8%%
MH0=P+'46N]VL ]*'I3TF29<"GK"2"OV^4V]L7*N[X]RX2*\S#K+IQ5>A1!C/
MM[$LB=&*=2W;Y8HD;V  7LB*PC''81 ^,.2_3N2V<(-;4KSK8C$_D6(Q#R6[
M<T?NQ+2^*::2(V6!\;6RALM %KF7P(L8Z3\:^?GXU\_[?C^?X^?C^?\ F^[?
M_P!>_P#;O.&3\;UK?Q\ZUOXW\Z^=?/QOXWKYU_LW\;WKY_V;WK_7C&/C7SK?
MQKYU\ZUOX_G6M_'SK6_]7S\:^?\ ;\:_V8QC>M;_ (WK6]?/S_.M?XZW\ZW_
M /+K?\_/^/S_ #_CC&-ZUOX^=:W\;^=?/^K?^'SK_9OXWO7_ .O&,?&OY_C7
M\_SO_G^?]N,8UK6M:UK6M:UKXUK7\:UK7^&M:_U:UC&?.,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,97[Y\WO_ "^/J(Z^=_&@WCCX
MU_JU\\SO?S\?[/G_ %Y;V_\ 6G3_ /#V7_30YC-+_ACZV_XKTQ_U"YE@65&;
M/&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,97
MCY[WOJ7N;VSVI7Q+!\K'\?\ '5&FI^=,IE4L%,[3U_3&M_[]:K?U^N )SNDZ
MW^JIOX-K<U'0EJXN?L-7K*OT:<V-C*/W2N*U?G_R==W'[I/WGG%Z7_3#U;ZJ
MVOYHM>FL],U'^W:K$^UV74?OL;."%S_6J\>_7VL.RGS:8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9ROCO9*1W.HS+E0Y
M)!P<+N=\Y\:@F![H@V#N'-;@9H]N!EQ<C>WX4N =!S--I7O:94!R&084N-,8
M6KO9K2U9!'*!RT<4RE3V5XYHUEC=6'L0R,/[#R#[@Y7ZS9U-M6:U39RD=JY3
ME25#'+#9HV9:EF&6,\E&2:%N.?9D*NO*L">J9PRPQC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&5^>?/^/S]1+_H;QQ_V9WO+
M>W_K3I_^'LO^FAS&:7_#'UM_Q7IC_J%S+ \J,V>,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&:9T>^5[EG/;UTVW2M0:KSNG66\
MV69O:=?I0-4#33I9_7W[2G:FH$!]:=;5K[E:TGY_G.D,3SS101CF2:1(D'ZO
M(P11_G(R+>N0Z^E;OV6ZUZ56>W.W]6&O$TTA_N1#QD5/IV4.PTSR7S<Y>(NX
MW3.U/6CT=U+3FE:EIOWH"RE.JEQ\W[DIW^HK<:S#ZDE/VZTU& 1V-?.FM;W/
MW$J2;"98CS!6Z4X/T\51%@4C]SE#)_:YS/>BJ<]7TY1EMKUO[0V-YL.>>PN;
MF>38RQMSQ[P"PE;C@<+"H^V3>RLS5XQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,975P]7]B/NWT_PA[_1:GZ) 5[V7RQG^
M$Q4VE*!7(O1@2,MS[5*E(/!N97^1%8VXG\O02<S[4;V_O+BU_*M51M_62F[Z
MV<_?Q^]BFQ ' '1IXN2>>(5&8G4_Z5>KM_J#\M?=PP>I]>/M\0!'K=W$O/U8
M314+A4<^]V1OURQ7*?-MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,K\\^?\?GZB7_0WCC_LSO>6]O\ UIT__#V7_30YC-+_
M (8^MO\ BO3'_4+F6!Y49L\8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,KM^H>ZOHU:XCX]&N+41]?=EK]*MS,=6T2HW ^;ZUU?
MOQ+2][TVW%(4RKL<\=6]I2%3.ACHZ4+=D-)W<:?]C):V)^FNK/+&?M\7-_)Z
M@_M$LGF'[H2?H#F*]:$WH-5Z:0\OZEVD%6RH_,NGH_Z8[A_T"O5KBD2?;O=0
M<<D98>VVAI"&FD(;;;0EMMMM.D(;0C6DH0A"=:2E"4ZTE*4ZUI.M:UK6M:RG
MS:@   #@#V 'L !] !GWQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC*[OJ$Q9?. 7&/9H*+(?*^.NF,W.[MPFG)$TEYR
MZ#$3S[T.,;CH3M,A :HDH'4$MN_W4SN9P'6]Z?;:5JXU!$S6=:Y 78P&*+GC
M@783YJ9Y/T[2 P<C[3G[<YBO6:M1AU?JB)6,GIF^MJWT'+2:.XOP>ZCX'YA%
M6=-@%/MWH(?J!EA$.9$(1(L^!)8FP9T9B9"F176Y$67$DM)>CR8S[2E-/,/L
MK0ZRZVI3;C:TK0K:=ZWE0002"""#P0?8@CZ@C[$9LU97571@R.H964@JRL.5
M92/8@@@@CV(]QGISYGK&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC*_//G_ !^?J)?]#>./^S.]Y;V_]:=/_P /9?\ 30YC-+_A
MCZV_XKTQ_P!0N98'E1FSQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8RN;AV_P"W_P!P^B?0;G^E43S>(UXUXZZK^_$DW1$T7?O3
MMJA-N_=]DA%GUS_EFY\;2=;>YS8H.E[^Z2E5S:YIZRG3^DMUOQ*R/<$1\-%1
MC;]W3RV.#S_/(?L,Q&I_TY]6;O<GYJFCC_BQK#_1:UVCN;ZPO/W%CX/7]E^]
M&=>?<Y8SE-FWQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&8:QUX);J\>JEE&Q3-<LX8I7CX><C\L(J$-07QI4;+;^=?
MDBSH,E^+(1\Z^]IU:?G7SGI':-UD1BKHRNC#ZJRD,K#]X(!&<IX(K,$U:=%E
M@L12031L.5DBE0QR(P^ZNC%2/T.02^GM8S=8HU_\B7PE*(]%\77%OD39$DY]
MY*W<0(0?Z@\X=!=5K[DNZ.<N>'U@F_IUY6[?2+6R\O3K"]9:[=%>6+8Q "'9
M1_$$+^6.T#UNP_NZS\R*/\7+&?OF2]&3RUZESTW;=GN^E[(UH>0\R6=4Z>;1
MW3^OEUYCKR'D_P IJ603RIRP;*C-EC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QE?GGS_C\_42_Z&\<?]F=[RWM_P"M.G_X>R_Z
M:',9I?\ #'UM_P 5Z8_ZA<RP/*C-GC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,C'[#[M+\Z^?+ST*OCM'^BRVQE$XW44Z0[)NO:>
MB$XM-Y95HT92M+E((W P+<)I:TM48'&*D%I_!#>4F=KJHN6XH7/2$=I;,GVB
MK0J99Y"?MUB5NO/U8JOU(RA]3;=M)IK=V%!-=81U-96]N;6TNR+5U]<#[A[4
ML9DXYZQ+(Y]E.9GRKPJ)YL\_<QXTR04<*U2OZ>N5H=4M<FY=&L4R59ND768Z
M[K3[DJW7DP?L#NW_ )<;_<$L[W]K2=:\7[1N6Y[/'59'XC3Z".% $AC 'MQ'
M$J)_=SG3T]J%T6FH:L/Y9*\/-J<_FM7IW:Q>M,?J6LVY9ICS[COQ]LD'D3+K
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC*V_6JO\FSOG%O<D'>XE%4D;YG]8;1K[8C/(+Y8T.<MZH3WKY0VCC'6R
M<9LH0VVX_&HO1+@ZI;<:%O:;K7_RVI9U9]Y1VO:_]38B3^45U'W^)KJ>H^\L
M,8^^8?U&?P+<:OU8GRU#X]#ZB^RC6W)^=?L)/T_"]E(HD?W*U+UHDA4)%DFM
M_/\ .OYUO^=;U_KRES<8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,97YY\_X_/U$O\ H;QQ_P!F=[RWM_ZTZ?\ X>R_Z:',9I?\
M,?6W_%>F/^H7,L#RHS9XQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC*VI"O\JKWC%A-[W/X?X!UHE/7K_.B+=[$Z+67&1D+Y^'H<_?
M ^1'9!!_[%-R15UZK 2XE$VO_P";NA_(-43]+6V^4?9H]=#("Q^H(^+L( /L
MT4#?9\P[?_"'U<J_GU/H[]HY^L=GU-=@(C3[J_X/K9F<\>\=K8Q\\/![62Y2
MYN,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QFHW^B53J%&N'-[T'C6"F7RLFZA:@DQ/W1B@"PCI HK"=^/A2/U
M$*4\A+K>TNLKVEUI:'4(5KI%+)!+'-$Q22)UDC8?570AE/\ <1D:Y3K["I9H
MW(EFJW():UB)ORR0SHT<B'[CLK$<CW!]P00#D,/"-]M8<->_(/7C$@OVCR.0
M$TO^HB:M:(=6X67BOR.#]D3O?SJ7*/U&$JJ75YIZ6N-T>G6M$QY#DEA*[+:Q
M1L\6QKJ%K; -+T7Z06EX^+K?;@)(WDC]AS#+'Q]#F7](W+$<=STULI6DVGIQ
MXZOFD_/L=3(K'4;/_+::LGP]I@3Q>K6 Q!89/W*G-CC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,K\\^?\?GZB7_0WCC_ +,[WEO;
M_P!:=/\ \/9?]-#F,TO^&/K;_BO3'_4+F6!Y49L\8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,C#Z\] /^<^*E[=70[=LZG:BP7F/"Z!
M]_VO=![7?I6PE K"4Z6VO]OT2<6=L\E"T?ME0"6 NM:6X"]ZG:^H+EE8W;QP
M(K3VIOM#6B'::3[^_7Y4''S2,B_?*#U+N6TFJELP1?$["Q)%0U%/[W=K<;Q4
MZ_U!Z>0^:PP(\=:*:4^R9D/*' F/-G#JIS2097;+DMPM<NKWZ0CX(='[!>24
MFT=+O9!Q2$/N+L%K)$'A[4C[W1P1L4'0O]..82GS?MF[:DF"^./Y8Z\7VAKQ
M*(X(A]ODC502/S-V;ZL<Z>G=.NCU->B938L\R6=A<8?/=V5N1K%ZVY^O,UB1
MR@//CB$<0^5!DCLAY=XQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,97K[:IMJYT9H/NCD02<=Z)YQ@EAO5J8$
M;^XKV7RP>?8G]1HT>.C;:B=HHKT*+UGF<9YU6OZDK9$'&96JVR$KM]9)',LN
MKL,$AN%6@D;\M:^H*P2G^JDH)KS'^HX<_P V,QGJJK8I2T_5NMA::]I$DCV%
M:(?M-GZ?F97V%10./)8J%%V-!2?Y^!X5!^)8&<5(NM6Z13JMT"CFX-EIMVKX
MBTU:P#7/S0#( [!8)"B41>])5MF7"DLO)2M*'4?=]CJ$.)4C59+%)#))#*I2
M2)VC=&'!5U)5@?[",U=2U7O5:]VI*D]6W#%8KS(>4EAF021NI_1D8'W]Q]"
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M+>L-5_4"^,<&R=;<D10QS0LUMHYZHC,(F1F+=9 B@2A.0H4@,!P$D^:;:O\
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M2)IIYI#\J(OV '+.[L0D<:!GDD98T5G95,*?,O,K[V[IJ?<GHZLD*M9YH4B
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M=R&>O.C-#9KLP #F"Q'+%W  ?IV '/ [OD7+?&,8QC&,8QC&,8QC(M>CO65
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M(EGC4A)A%)^TC$@8(X#KPP!SC'0-_/T). [W_._\F[P#_P"]'GS),7^%=O\
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MMM'5L>&5XO/6ECN^6O-T9?)#)U7O$_*/U7LIX&97Z6__ !(^8_\ SV]$:_\
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M)]ASQR?89^9^IYD&NE621%EL>@_X,C$CN \QC]62/+XU8]I/&&#2=0>H8%N
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M#A29,DA.6YIB,PZJ/$G2_P $*1]T0B*[=9Y1!$VJD1YBC2= ]FLH/1.6;W(
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M)_\ 677?^';+_HJ&-?\ X>>IO_H]Z7_ZWZBRN#K_ /YH3ZHG_P!)CWW_ /\
M7=QRX@_P@TG_ ('J?_P?%F(V/_Q:^O\ _P"?/6?_ /L=K+ .P_\ '-^F'_\
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MY0];6HXJP+V=GX8Z8B20RCX>N/Q260J$E)"*@*D]UE5P3_SA'U"?_F%XF_\
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=,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>gdc15tqwxkbk000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdc15tqwxkbk000003.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_X0!*17AI9@  34T *@    @  P$:  4
M   !    ,@$;  4    !    .@$H  ,    !  (        #P     $   /
M     0  _]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$!_\  $0@ 9 )5 P$1  (1 0,1 ?_$ !\   $$ @,! 0
M       &!P@) 04"! H#"__$ &\0   & 0($ 04)!@\("1(' 0$" P0%!@<(
M$0 )$B$3%!4Q05$7&!DB5V&1EM46(UEQ@=<H,C<X5598E)67H='3U/ *)"4F
M)T>QP34V0E)E=7>8X1HS-#E%1DAG:'B%HK.TMK>X\3I$5&-DA[+%_\0 '@$
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MZC1YFU,?A =8WUJQO^;3@_A"][_F:Q?H^H_U[1\0=I?RFJ?G2/U&CS-J8_"
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M7GK0G7F7$++,1L@PN6,D8^%J%2@D)Z:MLBHKC;J7CT47L<W1;M_[Y66?)B4
M AP!+H7C%\058HU\UE^!8-+38RZ=!E0WZ34W950K]7J+E+@4./PJ24,R'9#3
MI4^YS90E&3ZI"M=<[::RHBZ$VR]5YBJ_+;C0^D^E"0TJ.N2Y+<YQ\I;9;2DE
M"N#BE+" ,Y&DM#ZI?NAB[#-5_FOZH)^.JC"-E)Y2#LM0EEV<7,.RL8V318L,
M1N'\C'.'I@9B^C&SQJ@[ [9PJDL0Q2JDSQ,>,NGRJ;"G;6VS"DU>1)B4Y,R.
MB*T_*B,&2_&7)>KB(T60EA*GDLRW6''6AU&4N((.N5G;G:Z0B4N/7ICXAQS+
M?#+X<4(R7A'6\A"62IY+;ZDLN!H*4VM0"P-(?*FLJZ8RIM/R GKZUT7.I7.<
M7@HZ3@9[%\2N5VU>M&+E)&'N./ZW,R[M)9ZD;S;#,'K]5$#K(H'(7?AS6AO_
M .*FZJU6;=D4S;"W*W184><_!J4>HSPMB4U(=8=<ET*;4H<.,X(SH]*ER&F4
M+'%9!!UP56P=O:;2A6D/5R; #JV'E-/-QW&W$(2OBA$MII3KCB3\BTA*EO'D
MEL%0[*&8U,9BB,^0&G@^MC7F[N-EAG4M"NV=LPPHT<"W@#6(C=[&_<<%@C$'
M;0HMFDU(1;:'4?B5J#OJ Q@3H/B:\1<W;NH;E]7:EBATJ7Z/4&G:=</480FJ
M?!+SJ):7# D.1W@IYV"Q(7+Z *PWR]76Z3MS8\6KT>DK%<4NM-(<BN)D,$CJ
MLNOH*V!B2$(2TIIYP-%#3X+:E).--ZKK*U"1B.6QM.I/F+4Y7""F/E<BEG;K
M@ARWAX[(4XTB6KDDA7ZI.,UG\-'NR6.4@S+(2)(<"K 0IUD2F<;7B"WTFJLP
M4J[-F:RC<$W"S:BZ?1;G0JH2[>IS\]U'2J#L)Q,.4ZPJG,U%"7(XF*2@=09T
MEKL6TF5U9N12[G9<HM+;J\I!E1' J&J3TED+8"^DYT$/S$-N)RN,RI8QE*S.
M?S1J6,!3I\P/6*=,Y2G3.6U8W$#IG*!R' ?<U[@<H@8!]8" [!Q7%7]D*WP2
MI2%42QD+;6MM:%4^H\D.-J*'$*_CV.2%I4DXR,CS/GJ16-B+/?9:?;EU-;;K
M:'$*$E&%)6D*!'R!\P<Z/,VIC\(#K&^M6-_S:<8_A"][_F:Q?H^H_P!>UM^(
M.TOY35/SI'ZC1YFU,?A =8WUJQO^;3@_A"][_F:Q?H^H_P!>T?$':7\IJGYT
MC]1H\S:F/P@.L;ZU8W_-IP?PA>]_S-8OT?4?Z]H^(.TOY35/SI'ZC1YFU,?A
M =8WUJQO^;3@_A"][_F:Q?H^H_U[1\0=I?RFJ?G2/U&CS-J8_" ZQOK5C?\
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M*IJ\+4OE.UE?^';,HM/H-%5]3<CT3T"F0Y,&-Z4R3EY_T>4X''>: IS"PD8
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M^O?T^G??MZ?3W[>SU#\_!V\_Z._EH^_^_P"C0'07L _D 3=@^;YNWXN,_O\
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M]_\ 9YZ-9W+MON.WH])O3]/!D?OG/Y/,:-4A?W1&.W*KS<)1^-]VN"]AW_\
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M>9$>%"IBHS2REL9#:G75)Q@E2U?>PIKIS+M<L=9JVR9Z@K(W:OC=#I)*(JX
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MUMQ*E!"N"1C&,CSU(JUZ_P#6"PTVZ?[FUS=8&]GM=NSU'6&7)'5[QY1E4[+
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M1;X9<9<QQ>?YTV2%,I]8 )]JTY;_ -:WNJ8R&DP*82'I#O>L0.Y<9B(;[];
M02RZ5$%:D@)PDDD!U&$WDU'33C/%JFE#666V5;..1KY+M_>SY*,T3KEEIM;A
M8I=%Z6)%!=RI(1CHBK0AO&12*54X%*H3>PF]]Z4"^Z#=%/MR0])E5:DVS$B)
M?BR(J"]2JQ*FS.:WFT!"$QG 4*)/46>* 0"=2M=.QNX%8L:#0(D* :@Q<$BI
M.I74XJ$"*] A1TE*ROIJ<ZS"LM\QQ0.1.2 (^QE2SFVMOG=;23K!!@#Q\OXA
M=.F0C'%-<KD$Q\((SKW'Q2=0>KXP#Z."];UM^N>'R)MU3Y+R[G9HEL0%1W(L
MEJ*)-)D4U<L&8MH,%M*8KA2M*B%Y2$C)(#*F>'#<Y^W(5+3 IGI4<L%W^W$$
M(^3>F.*XJ+N">,AOL<#*5^L1Q)=AX?+"[5<B>D[61UGCG#4I1TV9&#=91DHB
M4.H8L  HGZ/C=P !$1]'>MMJ4>;2+VLRNSDMHI]%:I"9ZVW ZZ@PW.3Y:9 "
MG0 ?5 (*_,>[4@T[9*^8UU6K678L$0J1835MRU?",/J)J H51@%"6^KU%H])
ME-CJI26NF2KEV(TZF#;?D"@XES_4+%I4UFHS>1,/H4RM(-M,F2W2*\\E=(F<
M,BY=(Q1T&C?R!FN;RE<Y$?$*"0&$YB@+Y=>;<WIN&^$J_M!4KC@U*(_A?75$
M8?A*<6Y%* \VK@PM26R.9[92%'CI1VGV;O:T+@O^IUF+#;CW)0JW!IH8J$62
MI4F=+>=CMN!IQ73"FUI"EJPE"PH$E "U??(]ROMGT[:5,;Q.E36<K:,2+W-2
MYME=,>3$&S4LY=$)Q@+)XI$@WD.IBF8ZODYS"F</#,'6( +E36X'QJUJ[ XO
MX$G4^^X[#Y:5UE.W#%>8IH,<?*)"W#AQ2AAH$%> "=.BY]L;KJM;V5J$2-$+
M-AQ(S5?ZDZ,V6EMF,5ICI4H+D%);5_@DD*'=!4< QXL,9F:01O";;27K$.:?
M=02L<!M.&12>(FP.H+D5!-&;(B4# ).O;K] >@>'/M;=]%M15C_##KS(H53W
M!E5 MQW'^DS<4A#E*4D- J<+B$CK)0DEDY"AKA&U5W"#NY',>)SO&]&:W0P)
MK!ZM/:J<N2HOJ)"6'@R\A73<X]\I'K#!T%(K.;X0TD>2TE:PT?*$V@(^'IRR
M&OU'144.??PXP>DOQPVW[B&X!WX2/$]<5-W3^H[ZD'5RO@9=95/,QE^!TT34
M4X,! D-)+JB8KO(HRE.$@_9 B#KD\-NY]45!,:!32F-'<0LJJ\!)ZBEH7Y*>
M3\F$H\\YSVQW&G)(&5RMET1TGZR.I84Q#]#7D;L)07W#?S7_ /N$]6_<?1MQ
M6%BT*XW2:I"4U%$B5)ISC ]*24E,5Q:G>1XC!R$X]X)]VNVE>''<F'9=V4%Z
M%3_3ZQ/MR5$0*K *%-TQ=35)*G _P04"4R>*U!2\JX@X /)<,JKM6R)=*&LD
M#)'=B??35D?T+'0,3N$7MW!,?1OW].W;CKEVK67:!1J<VU',F ]*<?!D)2CB
MZ24<5$'D>_?&E>X?#]N%4MN+"M>-$@*JENU&Z9-1;54H:$(:JTB$[#*'ENAI
MTE++G4#:E%L\0<YR'LJ]\O$3IKU*XO=Z5=: 6S)Z.,TJDW)IAR<=FY&K6EW+
MR_E;XL09NQ%)FLF*7E!B L<3$(/440%\V/"?H2K5-2X-BDW12*M-+2NL$085
M7C2WW$\1EQ88964MI!4I6 /=J0:=M'>,387XNU18AN,W/&JJ&O3HQC"(W5H<
MQ2UR0OI<NDPX VA2CRQDX/:!HX]U!"(B&D35]W$1_6\W[;V_L?\ D]''H2/$
M#MPE(_C]0(  R*3/P<=O_P!AIAN; [@K6M8A0<+4I0S58(.%$GRZJL>?O.IC
M:0['D7#=Q=3EYTI:S6;%:D9>@BBPTRY*DE/+[CC2<JT&3PVL4<P)KRT@V365
M$.ALB<RZH@1,P\5#W*KE/N??:W;^I3JG+<ID.@LR7WFGF9(=@3);\@(AN-I?
M6E+;R,$)]8@\ K6ZT=AMP*)?OU13H,(4_P"!JQ3PIJJ07'"],MY^FQ\MAT*
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M5<>6$'<7F!S5.LHM",TE:PU5&KAZJJ"NG+(B  1=%H5/83Q8=1A,DIV#]*4
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M5%Q25%#9QS4D'N\.")K)N/KEDJ:L>D_66C'VC35D_%\4HVTT9(=J*6VU4-"
MB&RJ246)T&:D@F<BSU0/ 03V55,4@B(+#>ZEGIH42 9DH26;^<K[B#3YI":8
MJXI%2ZG(,E*G?0W$JZ*27.?)'$D:2!M?=GPP]-]%BF.NSHU#21.C\O3&K<8I
M93@D$I])0L<\!!3Q6#C(+2-8;,Z2E),?29K$ L%$O&TCMIPR*(D66;BFF5(
MB]U2]1OC&* @  /?T;P/<M6A56P-WK=B.*54[ROQJO4-M;;C;3U-166YJG7G
ME(XL.".E1Z3F'"LH2$G*BF+*YX?]Q*C8EN6\S#I_PC3*O7)TM'PI"Z2&ITR0
M]'X/*=0AQ2D/(*T@#AW"E<L)*AM*&79>'BV3/2=K&,NT7CSK ?3;D=,H$;NB
MJ*B4PQ>QA G4( &_5L&W#/M-M5'J],F3<)9B63>5!<*"5J^$*W;K]-@(2A()
M4VJ6L(==!"6T'J'L-.7<396^KFM;:VE4J)!<F6G:$ZB5E+E0CLMM3949II"&
M7'%I2^GF@Y<;R@=\GR*MQ'*95:/T5SZ4-9 IE5$PB&FO(XCL9-0N_2$5N/QC
M &W;MN/$8VQ:=9IE7@S)C3"8\9#J7"W(2M>5M(2G", G[#!\L$Y]A&F]LYL%
MN#9&XUOW-6H<%NETUZ4N2XS4H<EU"7H,R.@!AAU;CBBZX@ )Q@<B<8TE+)&Y
MBD4V?D>D[6*<R4XS?J@?3=D5, ;HJ+'4,7JC/C& %2CT;[B&^WH[RGLWRLJ_
MZQ<5?*6*7-M^XZ>PN/REO*EU3HB&A3+0Y(2L->LLY2A1',I2>03*7X>-QX>X
M2KE7"I_P:;@GU/G\*02YZ+)DR76E=(/=3D4.I)24I*>_8D<2[F7K#DFX:<L6
MXT@M*&LQ>UU/+^4;I,-E],V2FS1*"M<%3X^(52>K114'#A1Q#/@5;)&,HB4A
M#* 0%"[ROX=;MHNVZ;N%U/NQ?AB<EZ#Z-'?F\VPY)/RGH[2PTKBXDD*/GV[X
M[R'4=G+VD4R5$9B0U/.7W=EP)!J,0!5.J\RGRHBDJ+@3U2B,XEQHE*T+3@I
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M4^GP&HTIM'43\J@.(44.(RA2,$$G($+73X?-Q:S9=A4*+"IYGVXFOIJ*556
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MG)XJ3G/'&2.^GK@DLMQY(<'.D_6.462481?ITUY',!3-O"!7;:+$3%#PQVV
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MF6T:RBE(*A65DEYS;N'K^$R.[GV-;>H)-A622$[BMR17C9VJW=M0!$RB/2H
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MO#+S$BU;G3:E5.@0YEU@(B0YP?$.FS)S,M^,VE;4%#+DE1<0CIH?>1';("U
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M+- MD+#)PJ\ 4RPK ^!>5\E6101\AZT5 #RL&Y $X1% E3K9AW;OK5:'5&K
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MV^U59S]8KME/7_28;=)GI]+MQFG2JKZ1Z0ZRW&8?7#AOJ3&D/-.\TA"DI4H
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M]QY9\M6>WO\ \UKPR>[IQ2/_ $6J9[_?SW_%YZ<<1_1_:U1#<-L/Q8;CZO\
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M_P!VK,?^YXI_MW[<*]@Y5XEJJA.<_4=MZ1[!WN6Z?(^6<)[^W&//MJ*-X_\
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M6G?\XOP]_P#1,#^+X+J0S^7'X/O:<7*>P\F33_Z.V3;#]/W;6#?_ $#O_+W
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M34\&V_\ B'C 0_&7/...X>OMOZ0]&X;^D.(SMS_<5P'!.(E.S@9Q_;B$>_\
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M_2Q1>#1JIR\MD'?]U.XM1=)D61-I=M^Z:@;D$1Q*S+W /:0PA^7V[<.J\*;
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MZ")K!]1[T5U2EM%7=*B2#WU;HTTS8"^[R'R[[E%-]TR+28J1]T\TI>?FAVC
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MEDN.HPI1:;R?43A!ZR*A59.:Y:-0D*]#NZJ:V90:#75F#<T-Y*SAV*K5MYO
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M]\R?-D#M5;8:\\];&Y\VC40M5K%F+">)Z3E3%<[G=KIDQC7RQTU#WB,RIF7
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M-<59'8X)Q$>UNX,"U[;WII4FGRY*[XH]%@PWF7&DI@KA7%\(J7)0YW<2M'J
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MN!'04.J9]12ST%$</5]8#MJ7+AZ#=BL],0YBI-5'0D   QB)I"J)0'L'48
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M@_'6^R%*:0]-;<(6A"BV%G 4 G4V^&O=FD[7[TB^JE3*A4H"Z57H@B0E,(E
MS64*2Y\LM+9"$L*Y)Y@DJ3A7GJL#1GR^+]I@R+D>T6J\5.?,SIWW*OHZ#;RP
M&(^?V> 637;NGK=N5=NEY$<IQ.BBJ83%V3  $>*/;OWI]6%M;V;<L4[T*H[?
M5.UFJA/=E!Z+.4[=$&GH,-#;"7$CK/H62]QXH2K()(U:CQ"^*2U]Y;0MZ@42
MW:Y2U&O-UAF74G()0N/&IE0;4A;,=UY2'%E])1A:DX2<J]FK?=&^*[!@>2SA
M0[.]C)21O67+=FF.=0IG)FC2 N'FMK'1KP7:""GG1#S:HHZ!(JC4I5$P374'
MJV]$MKKI8HMX5'9B3%=<K=$L^@WB]56%I539$*HH;I"(S2%A,A$EM^ XZKF%
M-K:<04JY!0U3C>^^*9N*UM]6:1&F1(]M6)0K&EMSPR'7JE1/2G9,ECHN.),-
MP2D!I2RATE*N;:>VF3YEND^WZJI#3C$4^R0%??T^^RDVH2P)OA;OTQ3B%SH)
MKL$7"B"A$V*ABB= Y5#'(03$#<W'QO17A'NW:.T412[*O6X:I"BRR\EIB$:;
M :J#CCR2A:W0XVE2$);P>0'GGM('A6WLH6S#6YLBNTJJ5-BX[=C4UHTPQN<5
MP*FI#CB)+C0<2I<A (0L%"0I6#V&M)S"=/U@U"P4G0(.>B8!]%#C.Q.7\JBZ
M6;G:PTP9!9!%-J05#+*G=I>%U 4O20_4)>W%6-Y+C;L_Q&;F7"]%5.:I^T6W
M;;D9MU++BS/O6-3&RE:P4^J]*0XL%.> (2,D:QX:=TJ5M5<*+IJE-G5.-+BW
M-26XL%;#;P=GQ$K;=67E! ;0EH\P%9]V=6!YOK;^=IZ+ALH@0M==DG7A5Q.F
M*K6/05.HFAT)J??C>@H*=!/6)@XG#QHV!5[XVHCU&ER8##>WM;9W JC<UQYI
M4RF6_!F/RHL-33#P$QU*L,A\-M%79;B!W%;;3FM0ZFI#B5J,UI4)KC@\7'W$
MA)7W'JC'<C)]P.H>Y]Q=(Y(U!Z9<_L99I&PE)Q=EM%S NVRRLH_/9ZF[(AX"
MZ)@:I%; L K"IN)^G9,!WW!J[O;L4VNVE8\V+29K4;=#9S<.L4X/O,!VF--V
M1)JW0FH1R#JU-J#?)A82%Y/9.-3AM_?D.U]JMU=M),&5)J-TW-9S\>HL+:3"
MB)HU6:<=#R%GK+4]T\-\ 0#CD1Y*>S,^'['FW1E;\-5=Y%L;%?,6_<]%/IA1
MRG%(/G:""B)WJK5NX<)MPZ!*<Z3=8Y1,'WLVVW$S;+T"5(\->V] 0ZR)+VV]
MOQD.J*@P%.TUA0*BD*7Q 7ZQ2DGL<#.F5MO>U,V_WKMN^:O'F2:7;EUHJDV/
M 2TN8ZPPMP*3'0\XTTISN" XZVD^U2?,1"L>A3)J43@ARYLU12:8<PMF^DVH
MQ%)199T^OV*6]+CG<,GYO1*X:M'[=1VZ!THS5%L)03*901*6.MO=IKAV3V]N
MF;<,REU,TRH[G7HXQ279*NI"J\'TB+#0[*BL?Q@)CJ2\HMA""H!!7YZFNB^(
M.U&).YR!2*VXY?>X5BW-1T\8:$L1;<O)VOR6)RC)66WWHSJ6FNBE]'6SR4$@
M$IG2)@2QZ;,"AB^T3$/.2;25K<\61@P=@R596*TN)1B42O4$%B.$T5B$<I]
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MPL=1&4'T%[CS[^KG)QRQD^6I)Q&2,=DS#-KFOM+*B>BPZ951M,$"1E"NC]1
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M4IFQE**C@ !U)))/D,=\ZCI/Y"H)Z[BXA+Q3S'1QW9TU2A984124-6#$*FH
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M[>.2<\DR9!4D=\E2<CDG&4Y&1IUHW)..BYCLC@U^I0('I\&0BPVJ"!(QP?R
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M7"A!<*.!64@K4@I)*%*/<H)_T2>/WM8*C^4Y_'D#/X>^@G+3Y?FWZS33CVW
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M^2>H=NPCV_P7\W&5I2I:%+2E2D$<%*2"I!43DH5CD@G R4D$^W.LY/D"0/:
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M^7X/?WFNG'UA^I/3_4.WI\U[^K^;C?TVPOJ!" XH!"E\1S4E/K!)5]D0%)!
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>gdc15tqwxkbk000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdc15tqwxkbk000001.jpg
M_]C_X  02D9)1@ ! @$ W #<  #_[@ .061O8F4 9      !_^$ 2D5X:68
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ME^/'(IH<Y(PL<1Y45*UU*=-Y+%/=!2]11C;B)M)Y/'9:0SMAR\#7)VZ/KC2
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MNMJLFTJCQ+ Q1F"VG;,KI*!D1I  AO- 9/(?2W(%^0G-#40'25.&.*0*1!T
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MNY7Q@^H'-EIZY5M8-UL7%D*(1'+;]B"$O>M%I(U.=O381ONA)T+R!2^QU/W
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M6];]CV-X10V\\YN,S02>(NP#GE23V=B)FB\I4'']O9[!"I4SHVH7=UOMWWE
M=?T?A]C"*'7SJ65"D3C^+\+L%Y6A'O0"W%/'V- 87H)GX_EA3V\*P[V8$/8'
M:7_%%O?;VZ[NR*MT\ZOC#'"AE_%NN(2J*V/9BB>6>B-*"$.M&=HT/D<5,)V
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M"# XBSL[65]Q)6YEDC8^:0M,0.R5P+XNU(YS>[+=I:P:MW!UD^NZ\@8>I%P
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MCN6D -+G5+=I;7[G0&AK34=53TJ/L>=<6@\.7<)G&0]]R1N+I&Q0E@D=)WM
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MG/=<%K2]U27;:]HUU->@$](%2J3CL/QF3Q@O,7DHK>/'M+Q!$6-$/>[6;6[
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MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%.7&>5UQ
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MN:(NC^[B!)SU1Y1B)&2#99901C_&-W^9O#9#)7\-U;F$1PT(W.<"3N#M:,(
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MQVCAY?;L6A#*\K;W\6]Z +_%[X>WV?QM=OL1DO!8#]PN'M_A-#OH%JM-K_W
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MC7M2\/)J!O+'HDD2M6J5"+!K9IQH^\,4VW-8AK0TW41('27-J?.:4%3Y@!Y
MJ%+P+FDDKI&8FZC8YQ(:V-^UH)J&C<7.H.@;G.=3I).J^#T8>1'T*V3YIN_M
M;/WX\P_PF'ZX+'\G_-O\KO/<RGHP\B/H5LGS3=_:V/CS#_"8?K@GR?\ -O\
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MI OAR2<'K'EU9CMLCA*G!1W6M$U$JU!X#599YB9((B*L'\<QTCI(+IAW.<X
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M836TG\&5O^\6JT6G)H;D RV>2@)ZI+64_P V)!\]7$BO4WN0](G,6Q6$NR<
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MQ_\ RVP_.-L^;V$3[.;C_P#EMA^<;9\WL(GV<W'_ /+;#\XVSYO81/LYN/\
M^6V'YQMGS>PB?9S<?_RVP_.-L^;V$3[.;C_^6V'YQMGS>PB?9S<?_P ML/SC
M;/F]A$^SFX__ );8?G&V?-[")]G-Q_\ RVP_.-L^;V$3[.;C_P#EMA^<;9\W
ML(GV<W'_ /+;#\XVSYO81/LYN/\ ^6V'YQMGS>PB?9S<?_RVP_.-L^;V$3[.
M;C_^6V'YQMGS>PB?9S<?_P ML/SC;/F]A$^SFX__ );8?G&V?-[")]G-Q_\
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MQ_\ RVP_.-L^;V$3[.;C_P#EMA^<;9\WL(GV<W'_ /+;#\XVSYO81/LYN/\
M^6V'YQMGS>PB?9S<?_RVP_.-L^;V$3[.;C_^6V'YQMGS>PB?9S<?_P ML/SC
M;/F]A$^SFX__ );8?G&V?-[")]G-Q_\ RVP_.-L^;V$3[.;C_P#EMA^<;9\W
ML(GV<W'_ /+;#\XVSYO81/LYN/\ ^6V'YQMGS>PB?9S<?_RVP_.-L^;V$3[.
M;C_^6V'YQMGS>PB?9S<?_P ML/SC;/F]A$^SFX__ );8?G&V?-[")]G-Q_\
MRVP_.-L^;V$3[.;C_P#EMA^<;9\WL(GV<W'_ /+;#\XVSYO81/LYN/\ ^6V'
MYQMGS>PB?9S<?_RVP_.-L^;V$3[.;C_^6V'YQMGS>PB?9S<?_P ML/SC;/F]
MA$^SFX__ );8?G&V?-[")]G-Q_\ RVP_.-L^;V$3[.;C_P#EMA^<;9\WL(GV
M<W'_ /+;#\XVSYO81/LYN/\ ^6V'YQMGS>PB?9S<?_RVP_.-L^;V$3[.;C_^
M6V'YQMGS>PB?9S<?_P ML/SC;/F]A$^SFX__ );8?G&V?-[")]G-Q_\ RVP_
M.-L^;V$3[.;C_P#EMA^<;9\WL(GV<W'_ /+;#\XVSYO81/LYN/\ ^6V'YQMG
MS>PB?9S<?_RVP_.-L^;V$3[.;C_^6V'YQMGS>PB?9S<?_P ML/SC;/F]A%GK
M+POJABB,SA*1XL,UCG"5F2.I2N4$G&)2V-]1R%,-J"%J+2I#SUR$L)PQ%&"$
M5VAUW>W>\(N/N&\D^L/U#.3U\L'&R^)HT+XJYR&0FP.+V*VU;"HE"V^4 BS.
MVL*-8L0IE 4(3DQ(AF&'KU0N\>H---$88+JTEEQS#V,3[V)I:X ;BTO<74J2
M>GS^8= 7R):YWQ-YIG[R'!7DK7QN<[NV2"*-C _8T-!(&F@U)<>EQ)J59;T/
M?61?ISL7ZT$6^<&:7QCPOVIGN1^DIWT9\<OA<WY4S[)/0]]9%^G.Q?K01;YP
M8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M3/<C])/1GQ
MR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23T9\<OA<WY4S[)/0]]9%^
MG.Q?K01;YP8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M
M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23T9\<OA<WY4
MS[)/0]]9%^G.Q?K01;YP8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$
M6^<&/C'A?M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23
MT9\<OA<WY4S[)/0]]9%^G.Q?K01;YP8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?
M61?ISL7ZT$6^<&/C'A?M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQ
MX7[4SW(_23T9\<OA<WY4S[)/0]]9%^G.Q?K01;YP8^,>%^U,]R/TD]&?'+X7
M-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%
M^M!%OG!CXQX7[4SW(_23T9\<OA<WY4S[)/0]]9%^G.Q?K01;YP8^,>%^U,]R
M/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M3/<C])/1GQR^%S?E3/LD
M]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23T9\<OA<WY4S[)/0]]9%^G.Q?K01;YP
M8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M3/<C])/1GQ
MR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23T9\<OA<WY4S[)/0]]9%^
MG.Q?K01;YP8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M
M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23T9\<OA<WY4
MS[)/0]]9%^G.Q?K01;YP8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$
M6^<&/C'A?M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23
MT9\<OA<WY4S[)/0]]9%^G.Q?K01;YP8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?
M61?ISL7ZT$6^<&/C'A?M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQ
MX7[4SW(_23T9\<OA<WY4S[)/0]]9%^G.Q?K01;YP8^,>%^U,]R/TD]&?'+X7
M-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%
M^M!%OG!CXQX7[4SW(_23T9\<OA<WY4S[)/0]]9%^G.Q?K01;YP8^,>%^U,]R
M/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M3/<C])/1GQR^%S?E3/LD
M]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23T9\<OA<WY4S[)/0]]9%^G.Q?K01;YP
M8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M3/<C])/1GQ
MR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23T9\<OA<WY4S[)/0]]9%^
MG.Q?K01;YP8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M
M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23T9\<OA<WY4
MS[)/0]]9%^G.Q?K01;YP8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$
M6^<&/C'A?M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23
MT9\<OA<WY4S[)/0]]9%^G.Q?K01;YP8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?
M61?ISL7ZT$6^<&/C'A?M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQ
MX7[4SW(_23T9\<OA<WY4S[)/0]]9%^G.Q?K01;YP8^,>%^U,]R/TD]&?'+X7
M-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%
M^M!%OG!CXQX7[4SW(_23T9\<OA<WY4S[)/0]]9%^G.Q?K01;YP8^,>%^U,]R
M/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M3/<C])/1GQR^%S?E3/LD
M]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23T9\<OA<WY4S[)/0]]9%^G.Q?K01;YP
M8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M3/<C])/1GQ
MR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23T9\<OA<WY4S[)/0]]9%^
MG.Q?K01;YP8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M
M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23T9\<OA<WY4
MS[)/0]]9%^G.Q?K01;YP8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$
M6^<&/C'A?M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23
MT9\<OA<WY4S[)/0]]9%^G.Q?K01;YP8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?
M61?ISL7ZT$6^<&/C'A?M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQ
MX7[4SW(_23T9\<OA<WY4S[)/0]]9%^G.Q?K01;YP8^,>%^U,]R/TD]&?'+X7
M-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%
M^M!%OG!CXQX7[4SW(_23T9\<OA<WY4S[)/0]]9%^G.Q?K01;YP8^,>%^U,]R
M/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M3/<C])/1GQR^%S?E3/LD
M]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23T9\<OA<WY4S[)/0]]9%^G.Q?K01;YP
M8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M3/<C])/1GQ
MR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23T9\<OA<WY4S[)/0]]9%^
MG.Q?K01;YP8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M
M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23T9\<OA<WY4
MS[)/0]]9%^G.Q?K01;YP8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$
M6^<&/C'A?M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23
MT9\<OA<WY4S[)/0]]9%^G.Q?K01;YP8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?
M61?ISL7ZT$6^<&/C'A?M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQ
MX7[4SW(_23T9\<OA<WY4S[)/0]]9%^G.Q?K01;YP8^,>%^U,]R/TD]&?'+X7
M-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%
M^M!%OG!CXQX7[4SW(_23T9\<OA<WY4S[)/0]]9%^G.Q?K01;YP8^,>%^U,]R
M/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M3/<C])/1GQR^%S?E3/LD
M]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23T9\<OA<WY4S[)/0]]9%^G.Q?K01;YP
M8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M3/<C])/1GQ
MR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23T9\<OA<WY4S[)/0]]9%^
MG.Q?K01;YP8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M
M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23T9\<OA<WY4
MS[)/0]]9%^G.Q?K01;YP8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$
M6^<&/C'A?M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23
MT9\<OA<WY4S[)/0]]9%^G.Q?K01;YP8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?
M61?ISL7ZT$6^<&/C'A?M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQ
MX7[4SW(_23T9\<OA<WY4S[)/0]]9%^G.Q?K01;YP8^,>%^U,]R/TD]&?'+X7
M-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%
M^M!%OG!CXQX7[4SW(_23T9\<OA<WY4S[)/0]]9%^G.Q?K01;YP8^,>%^U,]R
M/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M3/<C])/1GQR^%S?E3/LD
M]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23T9\<OA<WY4S[)/0]]9%^G.Q?K01;YP
M8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M3/<C])/1GQ
MR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23T9\<OA<WY4S[)/0]]9%^
MG.Q?K01;YP8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M
M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23T9\<OA<WY4
MS[)/0]]9%^G.Q?K01;YP8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$
M6^<&/C'A?M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23
MT9\<OA<WY4S[)/0]]9%^G.Q?K01;YP8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?
M61?ISL7ZT$6^<&/C'A?M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQ
MX7[4SW(_23T9\<OA<WY4S[)/0]]9%^G.Q?K01;YP8^,>%^U,]R/TD]&?'+X7
M-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%
M^M!%OG!CXQX7[4SW(_23T9\<OA<WY4S[)/0]]9%^G.Q?K01;YP8^,>%^U,]R
M/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M3/<C])/1GQR^%S?E3/LD
M]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23T9\<OA<WY4S[)/0]]9%^G.Q?K01;YP
M8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M3/<C])/1GQ
MR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23T9\<OA<WY4S[)/0]]9%^
MG.Q?K01;YP8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M
M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23T9\<OA<WY4
MS[)/0]]9%^G.Q?K01;YP8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$
M6^<&/C'A?M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23
MT9\<OA<WY4S[)/0]]9%^G.Q?K01;YP8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?
M61?ISL7ZT$6^<&/C'A?M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQ
MX7[4SW(_23T9\<OA<WY4S[)/0]]9%^G.Q?K01;YP8^,>%^U,]R/TD]&?'+X7
M-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%
M^M!%OG!CXQX7[4SW(_23T9\<OA<WY4S[)/0]]9%^G.Q?K01;YP8^,>%^U,]R
M/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M3/<C])/1GQR^%S?E3/LD
M]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23T9\<OA<WY4S[)/0]]9%^G.Q?K01;YP
M8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M3/<C])/1GQ
MR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23T9\<OA<WY4S[)/0]]9%^
MG.Q?K01;YP8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M
M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23T9\<OA<WY4
MS[)/0]]9%^G.Q?K01;YP8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?61?ISL7ZT$
M6^<&/C'A?M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQX7[4SW(_23
MT9\<OA<WY4S[)/0]]9%^G.Q?K01;YP8^,>%^U,]R/TD]&?'+X7-^5,^R3T/?
M61?ISL7ZT$6^<&/C'A?M3/<C])/1GQR^%S?E3/LD]#WUD7Z<[%^M!%OG!CXQ
MX7[4SW(_23T9\<OA<WY4S[)/0]]9%^G.Q?K01;YP8^,>%^U,]R/TD]&?'+X7
M-^5,^R3T/?61?ISL7ZT$6^<&/C'A?M3/<C])/1GQR^%S?E3/LE7!]<^NS7O)
M^&<*7CD=915ZWI7*J715@/N:-/2%1$&A3*Y.H<$4Q4JEB"(.X14ZY!V:G4)%
MQJ4!B78]IUII1VXQO%9K%V3;#'[TB?0G81J:#HZQVQU$5UZ1I!S2>+MEGXN*
MRWT_QO=P%[&]^UPV-+WDAY)#'?:7:@AQ%6UVO(-C_5UOV\>9?]G4E_OD9,T^
M9?X3;?PQ_$*G/!/_ %?E/Y%W\^U=DV<V7T\F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3"+G6Y(_]2+P _P"$>9_FMS9RXV7^B[O^T-^C"N)9S_KE
MAO\ EK_XE\J!>KK?MX\R_P"SJ2_WR,F3',O\)MOX8_B%4[P3_P!7Y3^1=_/M
M79-G-E]/)A$PB81,(F$3")A$PB81,(F$6*3>1.\3BSM(&&!RNS79N E$C@T(
M60=!*7X2A<F2&EM*NR)G7T*)&B(/&I-\N>$0=D$CT7LP[991F2)C9) Q[VL:
M?JG;J#U=K7.\V@/K+7NYY;:W=-##)<2-I2.,QA[JD#0ROCCTZ3N>W0&E30'4
M]2G6=JGD4\6E':6XE\U)Y(J7;%#M9,=;XIQY02!@2I7%2TGE)V-ZY*-CK(7(
MMR1FD^1-A*U9L8-ZT5OV.VP77&KBS;&^YN+9C)31IK)0Z5Z1&0!3K- N<XKQ
M1QV;EN(,5C<K-/:MK*T,M@YH!(]BZZ!<:@C:P.=YE<?AWSOXW<Z8D^RJ@)>L
M=5$26)&^:P^2,ZJ-S6'K'$HXYN"],JO9A9J-Q+3F^ L1'JT)IA)I03MG$G%E
MQN2Q5[BI!'=M #A5I!JT^6A\WD-#\PJS\8Y?@^76S[C#2ESHB ]CFEKV$]&Y
MIZC0T<TEI((K4$"XN1JLZHMS?ZAW'WI_--9N]\!G2@FU9*X1V.IX)&TTA5(R
M64ML.D,B>=+GAD3IF-A*>4HC@DF*' [QM:3)3]A'H,KB\/>9=SVVFRL;:G<:
M=-: :'4T/F\I"J/+.:X7AD=O)F.^(N)"UHC:'$;:;G.JYH#6[A6A+C7LM.M+
MPI%1"U*F6IA"&F5IR52<8BS"1#(4%A-*$(HX!9Q0A%CUO81A"(/X-ZUOV,BR
M"#0]*MK7![0YOL2*KZ,_%^IA%Y;XX*VEE=W1 QNDF7-K6X."*-L9S*G>I"K1
MI#5"=C:#Y([QZ.DNCL<7HA.->O0H@FF!V>H)*T(P/I@#G!I(:">DUH/.: F@
M\P)\@*QRO='$Z1C'2/:TD-;M#G$"H:W<YK:GH&YS6U.K@-5K[X;=3.E>;-H7
M#3U?5Y=D!G%&@$&>H+788 U)TR\B0K8NM:4"F%63/-*U[>[MYH#>]HLGNA[0
M&#[<E\E@[K%P1W,SXGQ2^QV%QZJU[36]2IG%^>8KE>0NL9907<-W:?=!,V,
M'<6$ LEDJ0X&O0/(2MC&0RNZPF&6/![#.F9$)DC=)15]-G6N)B-L$:<0R3AB
M0M3@]QLY4(H"90XLQ+TG JT0,T*=3L:<P03R3BR\LD,L(:96EN]H<*];36A^
M;33RC7H(6I:WUI>F46DC9##*8GTZ&R- +FUZ"6[A6E:&K3J"!FV8EMIA$PB8
M1,(M>G/#J0U+T\T<$>;IK&[I/%["4KVQEE=7,];OC.E?FTK:H^/.R>4VC"WY
M(Y#;]>4EC B-2&%=N@G[, ,L,QBL+<9@O;;/B;(S4AQ<#0]8HUPIU=-?,J5R
M_G.-X4V&7*V]W);S$AKXFQ.:'#7:=\K' TU'9((ZZ@A7X975.^L[2]I '%I'
MAL0.J8M2$ %!:=P2E*R0'@*,.+"<$L[6A:",0="[>S>]>SD2YI8XL/2#3UE<
M8I&S1-E;7:YH(KTT(JO3SRLB81,(F$5$.,W46X[<LKPO>@*G%.A37C\O6(I2
MMDD6 SQN0%-C\;&'5QB+@6YKEIZ-M?RO)A@<DS8I-V+1A))I6A&!E;[#7F/M
M8KNXV=U,-*&I%145%.L:Z$CRZJH8'F^$Y'EKS#8[OO?=DXAY<S:UU';"6&I-
M [3M!A/2 1JKWY%*WIA$PB81,(F$3")A$PB81,(F$3")A$PB81:\>2G4RX^\
M:[/<:36LMFV[;\?KN16U+Z\IUDBKF\PNN(K%7::O4FD3A/)K7L9+&5'&<Q02
MV)5ZIZ5!-(\%&9Y03WYBRPEY>P"Z!9';EX8'/) <XD  ;6N/2>D@-&M3HJ5G
M>>87!7[L4]EQ<Y-D#IGQPM87,B8PO<]QD?&SV+:A@<7FHHTU%;/\;[_@O*6D
M:^OZM$\E20>R6E4[,*68,AD=D:<I"[.+&L)<VH9RHLH9;BUG:+-(.4)%1.@'
MISC2#"S!:-[:2V%T^TGV]ZPT-#4=%=#ZA]4=! *G\'F;3D&)AS-@)!:3M):'
MMVN%"6FHUZP=02"-6D@@J;\U5+)A$PB81,(F$5#G;J,<=F;G"R]/Y7\?!7D^
M,0'A.X)XN4;7Z9:=$E$\2QM6_>ZH7<+TIB"82X)A;:8V@!O19BL!_:5J6;AK
MQV+.7&SWJ#2E>UT[:TI2E=.FOFHJA)S?"1<L9PQW??&SV;J[/M8.PR!I=7=N
M+!NJ&EO47 Z*^.1*MZ81,(F$3")A$PB81,(HAO>W"Z(JF9VXK@$\LEH@3*OD
MTBCM;ZA1DJ)C3,C4.;^^)$L]FL"95R=C:TAB@X@I>):< '=3D'F[T7O8M+?W
MW<-MP]C'/- 7;J5.@'9:XZGS4\I"C<ODAB,=+DG0S3Q0L+G-BV;]K02YP$CX
MVG: 20';C]2"=%!W!CG/4O4"J617+34=L6,QB,V*[5DO06:TQIF?C7YFC41E
M2I6D2Q673-O,:#&^9I0%F#5%G;.+-ULH(0@&/;RN*N,1<-MKES'2.8'=DDBA
M)'6&Z]D]2B.(\NQO,\:_*8MD\=O'.8B)0UKMS6L>2 Q[QMH\==:UTZ"?>YG<
MRZBX*4N=>5T)Y@X1CXS,L/;F>",J)\DSS(7TIP5HT*!,ZN\?9B EM[2J4&&K
M%R4G19&PZ&(T198_&-QMQE;GWK;;1)M))<:  >H">L= *S<IY1C>(XLY;*"5
MUOWC6!L;0Y[G.J0 "YK>@$DN<!0>6@,X5/9L4NFL:^MV"*%BN&6;#H[.HLI<
M4"AK7G,,H:DKPUC6-ZH(3T:G:16'O@WV]@NWLV+79O>K<026T[[>6G>L<6FF
MNH-"I;'7]OE;"')6A)M;B)LC"00=KP'"H/0:%2#F%;J81,(F$3")A$PB81,(
MF$6$S>QX/6Y,8/G$D;HX&:3:,5Q$P+A&[/D,XF*[W/CD;:4J<H]2L<7 X(Q[
MT &PD)B3E!PBR"33 98H99BX1-+MK2X^9HZ2?_'30#4K4N[ZTL1&;N1K!+*R
M)E>ETCS1K0!J2?G %QH 2*,\UNII3_ V<5;#+EJV]GE+<>E),(FU>LE:/4/5
MNK:Y-K<^,2X;]:L7DS<Z,>GQO4'^(V>3&IUH-IC3QEJ $RF,PESE8I);:2(&
M+V37%P-""0=&$$&AZZZ:TTK4N5<\QG#[NWM<I;WCFW5>[?&V)S"00'-.Z9CP
M6[FD]BA#AM)(<!L<R&5X3")A$PB81,(F$53N9W,NHN"E+G7E=">8.$8^,S+#
MVYG@C*B?),\R%]*<%:-"@3.KO'V8@);>TJE!AJQ<E)T61L.AB-$66.0QN-N,
MK<^];;:)-I)+C0 #U 3UCH!5<Y3RC&\1Q9RV4$KK?O&L#8VASW.=4@ %S6]
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M6U6\_@/+"NHX^R>@6FM(LRISRF9@J@Y[<WRT!,XY'N7SY)9A3D(;0G9V9C<
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MONMN5#0SJ^0<$DM=5E$@5<>]1V*2M8NI1TKJ'0R3 21Q#+CRPHI*8_G+0M(
MB4IS%0QEYK7$V&6DN[2VB[F> GNW!SCNH2.V'%PUITMVTKT&BT<MS#D'#K?#
M9C*71O+'(M:;F-T43.ZW-8\F Q,8ZC0\]F4R%VP=II<2*V]3XBQUO6YX%UD&
M];921F0#IV?0],4= 52:G))*[6G$,=5M:1]U@+C#A'#1P%$IV?(6R0*SU.QA
M4'')0ITQ&[@S".+W<_=1EXWM/LNV UKAN(<#]41V2T4Z #4F#Y^+Y_BOA[#W
MY<BW?W,C!]K(A<^:1A,33&6=$;361LA)KN);M:/O]8P:7J,HNF\SJY,^6*_M
M$TMI..43'46:7V5.!*FDMEK'[XBQ*+1-O4K3>P)@FYF2IR]>R!/['9O\X:YK
MS>N#0QA:S05( [?1N)/KN/JKWXW1RP-P<3I'SS-EF&]^P.>:P:N[MC& GKVL
M \C58@?-OG/0O5]J;B'=UL5[;%5WTQ,;V9#XI5K/"FFKS9>T2W2!HALDV-7.
MY"&-2*+A 8O>EZKW41#&/2-":,!9&G\5XJ[X[)D;6-\=Q$2*EQ<74(U(]B*@
M]#0*'K/7-^E?+</XEVW&LM<PW./O&-=L9$U@BWM?0,=K([:YFKGN.]M3M82
M,HM[J7O-@]1:PN&C1R@@W!VE:(@TF73.]Y0=2Q$CL*U$Z&-H4$-9%M_-4@@*
M%H9'Z6 ,-0$(=N[DG9UXBU)!8@F)\=OA&PX9F2= ^ZN97BD8WT:S74]V0ZI
MZ:T!(T/7GR7/);WF\_%X\A#B<59PN+[A_<;I)@&@,:;@.C :Y]2T-WN#'T<
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MB+-D36$-HXO+B0V=N;?4&Z@W&:7\%>0Y-IUD&F.6@$[^;Q>:*R9EK;%8N63
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M73-V1)CA&')&UQET@7')21B$,E., !"%L.][JN3O79&_EO7"F]V@\@  :/5
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M%@-#I<'%U ^.3U7]D);(ED?C(!7D-(M$A3]J E4>8F)4+ "$'L([AP\F-O\
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MQ>X??H-Y$U(ZU;,XS8DL?$0U4OK28-,F9I8>2XIU;4LKR:RT:,YM.*&0I)7
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M]'-CE(G%J?227T*96EV7M(H/#L6]1>#RN/M;:XQ&0=6SD+J/:'$:C:=*;A4
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MD-"1<B$6E$L7H_*S1DI#-F[$'<XWD,98LN/?KC'</91CPTN(!!J&T!H:T.M
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M[+FGXB<7^:U4=6;DGS-G7$2>-5-W<UVZT,/DMK<9G25LQ$@D,5D\85OC&AO
MTK2AU*A04II*90H E5+@=XT1!9AVKMD;[&7''X,;%<,-S$6$]B4 T!!H=G5N
MKJ-0/+HN$\:P'*L=XC7_ "B\QLS<7=MF#:36I>W<YCV%S1/TG90@$T+AK0$J
M(^%_#7GM0QW4Z=)SPYF8E/+ZM)\@JYO9KCXQ+_)I-)G.?@;&.2JAW8F+;4X"
M+#"><L $XL!* _00C-$04;L9/)8F[%BV*Y;2W>W=5DO0 VI'8U]CT><>=1O%
MN+\PPYS\EWBY=V3@D$0;/:FCWF2C7'OQ0?;*EVNC3TF@-]^A5QDY*</N.=KT
MKR3IEUK%]7W6X6C'7DR;57,6.1M,G@L%B9S8C%7T\ECD@=6%9 !&J=+DZ4@P
ME>1X!AHPGA*B>57UED;V.YLI0]@BVD;7@@ASC7M- H=VE*]!KU*X>$> SO&<
M'<XK.VKK>9UV96N[R%[7!\<;*#NY'D%ICJ=P (<*$ZTM3U6*RN2[^#EOTI0]
M6NUL6+:OQ7BS>T-TIK^()6!"EDK9*7*4OCM8DLB3:)I1IXYY*$A&8J7FK%A&
MM$:3Z4*$^A@)[:URD=U=R".&.IJ0XUT(  :":ZUUH* ZUH#8O$2PRF6XE<XK
M$6[KF^N-C T/C8&@.#R]QD>P4 ;2C27%SAI3<X:,;LX'<^[&Z1G$_A"S<19:
MGN&F[VD\UF"E9;_&<$4U&DFK<5,R]M=@76(Y:;(?TSE$ED^"$U.<S+?'T H2
M(U7:;7+8F'D-QE'7#?>TD0:.Q+6O8K4;.K9\\4ZZ<DRO$.8WWAMCN)Q8V09.
MUO'R/)FM=FT=\6D'O]=W?@ 4J"Q]:#879_U%>&7/#DS2_36A=7<2)09(>,E7
MDAM$I_M[C@UI6V6)DM?1$,5;S_TQ&@>1F$U8-UTL3[$D]SW=$#8]+ K4B/#A
MLEB;&YO9)[ANR=_9HR0U':-?8:>SI3IJ#U4)W.;<7Y?GL7@K7'XV3O["W^V[
MIK8 / C9L![[M?<M^X:;7L%=V]K;(=6?A3RNY,V9P?Y6\=:D!+)=2"QF?9K1
M,MGM=0Z6M*E/)HG83<U*I*HE:JO%AS>O;5;6[&-[TN*+."68B$M)$(P.GQ_)
MX^Q@NL?>2;8Y:AL@:X@Z%I-*;M="*M'GH5.^(_%>19Z_Q/(L);=Y<VA:Y]N^
M2)CP0YD@!<7F,T(+'EKW &A9O&JB:%\6NHFIZR,&YZVQQ7:D5;N: ABD*6L+
MHJ22D5ZS/]..%8(PK#IC,8))9DLA9SD2H?5")H("I\)3ML3JM!3EGYY;_##C
M;\3;SDS@U&YCQN(>'=0<!NI1M3IIN(UI&VO'N;.\3X>89''-%BX;7"*>%W=M
M= 8A7>^-SRRH,A:P5H[NP[L@Y7.^,'-%5UOHCSG9N*4N=Z A(S8&)[(M3CLG
M?GQC/J"55*KGC;&7*X6]T3LX5TGVXD)%(27,QO(UXB<I4/:4'B*^Q@XN[%.N
M&B[=VJ;)* [P_:2&$5TI4:5ZZ:K8N\!REWBQ'RV+'2NPT7VO=WMMN<WN7PF0
M,,P(;5^X T=M&K0X[1Z<;X/\W:0ZR%L<LZUK* 6#2UZ-SHU&V&_6,SQQ#6S;
M+T\.->U[["0G'3N4/L86Q8W25N;DX4;L TG0W)O\0T2;R_*8NZXW'CYWO9<Q
M$':&D[BVM*.]B :ZDZC7LGKR0<3Y7B?$^YY'8V\,V*NVD=XZ5K1$'AFXNC^Z
M/<PL-&M&U]161E3M\.R>*G,YWZW4,YP,O%>7.?'Z#KV^&#?P6EQX2/KTRE5>
M_5DNG;=&%UOIG<EC X2 3@0D4 )=#FTC6QIB51FTI?J&_P 8WB[L6ZX:+QXW
M4VR4!W!VTG92NE*C2O61JL5]QWE,GBO%RR+'2NPL3@S=WML'.;W3HC(&&8';
M5VX T>6C5H<=HJYP5D<SBG7?ZC[Y"J]7V@J1QWD-MXA[$_1E@EB]EW?%0=X<
M/-FSM&H6X/X';237DSJ\,R0201YGE>C2RR3M_*LBDXI9-E>(QNCH2"178_IV
M@NI2NH#C6FG6*_Q&>ZM_%[.2VL#KAP9<[F-<UKRWWQ#[#O"UA=6FCWL%*G=4
M '8YTT^$-]T%;_-OG%R#@XFNW^1TFG<AAU"Q26PJ1R%FCCU,7JQU,<72@#\C
MKHR32!W,;V]O[7DIN3 2>(J5%A.%LB&S>4M+NWM<79NK;0M:#(0X D -K2FZ
M@%2>S4UT&FMWX)Q/,8;)Y7EF:AVY.^DD<RW8]CG-:Y[I2TOW"+>YVUK>V&BE
M7.%=*2]/WIK\LFJ+]1NC.3]"2"GX=SBBS:*+V2BL:CYXV0&2Q9RLYZ9"9"S0
M^SW23. =ND\2&E^2H1E'>0&%FF)M&!,U)Y?-8]TEE=6,PDDM7:MVO:7 AH-"
M6@=#3TGKZU5>&<%Y'';YS$9^S?;6N6C&R42P2"-S#*YNYK)2\ZR BC:':02V
MM58WIE4WU6N(,%<^&<QHNJ-54@D<A=(+RB571'%[17S?(U);E(0,E6M:1ZFM
MBFFNZM2O:$3DBBQ.EQIP5JK1 R^[IYRYP&1E&2CED]\%H#HMAJZF@JXT:W2@
M)!=I2@JIO@6+\1.-6CN+W5I;?%S7N,=V9VEL8<:NVQ .DE[1+F-<V(;B=[J$
M4Z&RPB 66 1@SA  $(CC-%Z,-$$.M;,,T2645H8]Z[=]T(0]N_8UK7L93EVH
M:"G2N=NW.#_-:#]9\OG;159P.TZUL2.-[,XNDELAGA396"X=(M=**W"8-2@1
MTSD"1G4,I;T!,Q-Z\;BF%M'LY&:+9Y5QM\IC)>-?%5T]\<['5 #2XN[9?H>@
M5KMJXBG30]"XIDN)\JM/%+TOQ%O#<6,[ TETK6"(]P("7@]MP:6A](VNW#LU
M:34>->G%7F9)^M+4W-",\7I4_P!"U?J,0U?)$]G\?FUU?VU+%Y1&W>9LL6>+
M=1OA+0D4RT1Y*5660X'IDN^TD!I@2]>[2_QL?&9,8^=HNY*FFV0@&H(!(92N
MG2-*E8LOQ[E%QXIVW*8,?(_#V^QA=WMN"X!CVN>UCI@[:"^H!HX@= )HOPX*
M<2>8E8]63E#RJM7B]*(=1W))INJ.M;VNL_C^^.$12S.P8?8# NE\>B-MR%Y-
M)7HX1M <4V%.!A"Q>5O?:0 TX#*Y#&S\?@L+>=KKJ L)&V0 T:6FA+ /JJZT
MT'ET7GB/&^3V'B-D.0Y''R18F^;.T.,MNXL#Y&2-+VLF<[41[2&!U'.'4"1B
M/"[AGU).EWR,NJ&T11L"Y.\6K@>6]0TR%]O"+5/N+ 9U#M\47Y\V[)I',D3L
MTL[V8D>DS?'7<MPV44-.=KPP[WDR>2PN=LXI;N5\%_&-0&%]:TJ!2@H2*M)<
M*=86MQ;B_.?#_-W5KB+2&_X_=.!#G3LAV;2[8YU0YX(:XB0-B>'4&TZ*TG66
MXP<N.57#JH:,JFM#;MMC=L-5E6'(X[(ZNKJ"1D,>C$M;E34A3V3/HL]G(5SE
M.PIV,LDMT4!;FHT;FK"JV4-9H\;OL?89*2ZN']U;]V6M!#G.-2#7LM(Z&]KH
MU/9%.BP>*& Y)R+C%MB,=![[R/OD2R.:Z**-NUCP0!+(QU"9*1@!YVL/>.W4
M+MB_$5EMIBX:TW7\UK]TIBW:\I*(5<I8I6]027)TDJ@L%:XHFDJ9SKN431A<
MHRXN;=I4G",XM9LC\4],4/\ %W#9%UN_)231/$MN^4NJ X:.<32C@T@@:>3R
M%7?C462AXO:V5U"ZUR4%HR(M>Z-X#XXPP.!C>]I82*C4.ITM!7-E$NFIU1W/
MAMSVI:QJBKIYM2_[.@=F'VE*KOCKW95Q+(#,&5[]P&42$];'D;6Z&)5+BB7R
M1X9#4AAAJ4QO_P L"I;[I)F\$W)6ES#(\6\+'-VAA#6;FD5/74: AK75Z:Z4
M/"[;@GB!)Q?,8J^MH'9"]N(Y>]?.UTLQC>UVUM*M -"YKI7L()+2SM;F9+U%
MZRN:EN@WQSJ2^80RU_85=6[6T65QYFFB&<CTW(6>R!MZYX<V= 0PH7I6$X6S
M4:!8[)"0: (*TP8QE$^,-/;77*YKBT<7POC<:ENWK;T FM/.0#YEL<WL,IBO
M""QQN8B9#>P7,3"UKQ)H&RT+BT;0X];6N>!IVR20)=N'C-RWY_=.OII\6(+4
M*:&01KK[C38D[Y!O%@0!5 $L+9J&3QR+EL\7*D)5MNLK-99<:J<D(X\F0IG!
M,60G7JR!B5%Z]M?8_$9F]OY9-TI?(UL8:[=N,E34TV 5% =U2-2 =%)9/ \D
MYEPG \>M+816;8;622Y=)&8PQMN&LVLW=\7[7DN;W8:' !KW [A/O53Z7MSV
MZR<1[1X7*T*JWN'#1'XI%XI)'QJ8U<BC4*&QN\$<61]>!-T>)E4;?XZ'8R5Q
MZ-(L*6B'XY(D^BS]3 YVVMWW$&3!][W))) )H75#@0-:$'JJ13H-=)GQ#X!E
M,E%C<AQ8@Y/%M:QC'.#2YK-IC+7.HW>US>AQ:'!U:C;0[0^+,QYF64UH)7RI
MIF"\:U#<QJ&<^L(M9#5;;U+90-0A\>;.;VRMNX_!HTF(1FZ;&9&[/JP[RT0U
MJLO:<LLZ"OX\; XQV$KYP37<6E@ _<@$U<?*2&C30:J_\>NN47T;;CD-K#8N
M:PM[IDHF<]]1]L+FC;&T4.UC7R..[M.&T \X]'].3J9\7Z9Z@?$F!\>*[GD)
MY&,)[7%;P<;NA+0B7,D<:I0B2M,;@AS@7)#Y1.6R0A2)C7P3 WM"TL9J@U03
MH.A7.ZS.#OKFSR$LSV2PFI9L<=21J74I1I%3MW$C04*XAB>#\\X_B\UQNSLH
M)K2^91DYG8T%K0\ -CKNWR!U 9.[:QU2XN'3>KA]P:Y0(^D%>_!>U*Q'3=Q/
MJ"SD</6R:95S*HA)SIBL^,;$,IVK.9354T)BG!-I"N$L3DF$>($XD"D.A #%
M9'*V)Y%%E;=_>6P+:T#@130Z.:VOE%/4-%;N,\2Y WPTO.(Y&W]ZY-[90PN?
M$]C]YW-UB>\M%1M=N I6H#M0O7X"4'SIX\]-NYN-=H\:FM-)&*&V]'*LB<9M
MJM'^=6O);:6O(R'-8XJ)6SUC7</B8G[>SQ*WM:Y."?1II:8@U,2E<?.7N\5>
M9J*]@G.PN87$L<&L#*:4H7.)IU- 'E-26Y.'8?EV%X+=8+(6#1.R*9L3&S1.
MDF=,7:DE[8HF,W:UD<YPJ0T%H:^GG$;I-\GY'TWN3_"'D)5RRC9[*K<:;VIV
MP72=U;,H0ND[7'HFR(XZ\DUM.)E)&T ]1=00K.,0>$6E<M'$[-.(V0*1R/(+
M%F:@REG()8FQF-[0U[74))J-S6@].FO2-=#55GC?ASGY^#9#B>:MS:7DER+B
M&0R1/C+PUC0UW=2/</8$.);2CJBI%%?KICQGJDTG5T+XIWQ0=71" U*X^Y##
MR&>+=CDL<G.LTSRL6E15@JN!J7A:^/6DF]H6YS=7*-E-S><G,/1+3TQI"B(S
MDF"NIW7]I+(Z:05,880 ZG27.I0=9 #JFM" :BX\"M_$'%8^+CN8L[>*SMG4
M;<NF:\F(.)V-AC+BYU.RUSW1!K2TECRTAV\7*NNLKDL@_3LZHBF'=3^(6;6U
M72V;<L4+8)HOF86ZT+Y)+2H7)GI]1Q. ,;88YFM3%,2%*4A(4^J(HC8@)4_B
M$J2B24Y'0)<S@A)8R0/D;%;G6,,-!4 5<32I&M=N\NJ=16I^<;3A/B ZUS]M
M?P6\EWD0-MP^9I<_8]S@R-HK1KZ@ 2&%L=!4. #1/[9PZYO-70N7\&'/C>!;
M?"V1*(W'8Q&;@J9<8EB[E?"B]5DUGCS(9/%(2PDHQ:4-)2!E>)(L/,,1GB"4
M U6%!J.R6+=RH95LU+0-J26/Z>[[O:T %Q\M7!HZ1Y*S,?&.61^$9XC)8US!
M?M:QLT)HPW'O@R2.<]D;::L#6/E<26G0%VS9-TDZPNVAN$=74%?M/OM2SVI3
M9<TJ N,MK*8L\L12.=RN9H7F.N-<3>7[(3I4<@+3*27$M">!26+P@G%=ANX7
MD,]K=Y22[M)!)%)0Z!P(HT-H=S1Y*BE=/(KSX;X_+8?BEOALS;/MKRV+P:OB
M>UX=(]X<TQ2/T < 0[::]%1JM85)\*NH9TW^=%ZV'Q=I*&<H>-'(IZ7*%[2Z
M7-$:D<XH@6R-1(HVHD2V2^4NJ9WK]9(G!+XS:SOY;DU[-'HDA4<443.7.3P^
M:Q44-]*Z"]A'2&%X.E#2FE'4!U+:&FI UH.*XKS7@W+KN]X_:19# WSR2#.R
M$L!<7-W%U2'1ESA5K) YE30.( MIU9N-'/KDQPFBM74NY,<ILEWL-.]W? X;
M*6>"L\EARH#TK00F.R*:*(BB?XI"'52AT;MU/0*7H*$"P9 3>Q(&/X_>XFQR
M;I[D%L(91CB"X@Z5<0VM"X5Z*@5I7K5D\1\#S'/<4CQ^+<R2^=.'3QL>V-KF
M'<1&USRP.9&2VN\M+]H<17LJF$RX'=0=SYZ=/_E W<=J50Q:DJHJ>NI/#(A=
M[:@B58(Z\/EK:>B?'QZCZ>2N>E+;)/+2-1V.O123_P !WE7D^G!9)QY;$-Q-
MY8F:4R2R/<"6&KMU.@ T'13M.;7ITK05:ZXAS23F&&S[+&U%O:6T,3V,G 9$
M(]XHYSFAQJ';AW4;PWV':V[W6VZA?$>V>7D0O6$6-Q$;;BD93XZIN%EY0*QZ
MLATRJM$OCS#Y."WRI=((.M_1VDFA2Y2>0W&2E:Y(#NX)L2K"2%>X_#Y&WQTD
M4L-P8V4'?,<UQ:[4^PH'=JE!KM /U1%0K)S7C>2Y+;7=I?8UMU.'D6-Q'+$Q
M\(+6T[[>Z,]V'[B0WO7.:?N;7 .6R_A31\HXU\4*$HF:R8J7RNL*Z9(P^OB8
M9IB :],$P\QL:#3R4R@YBC^E&F] ,PLHP:-*4(8 "WL.H/)W4=[D);N)NV.1
MY('7ZI\YZ3YRKWQ7$W&"X[9XB[D[VYMX&L<X=%1U-K0[6UVMJ =H%0%:'-%6
M!,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(N=;DC_ -2+P _X1YG^
M:W-G+C9?Z+N_[0WZ,*XEG/\ KEAO^6O_ (E\J!>KK?MX\R_[.I+_ 'R,F3',
MO\)MOX8_B%4[P3_U?E/Y%W\^U=DV<V7T\F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$6G[J0=8>A.!J%R@K*)%;_ "1-1:VW58S.7AML0,6)]FH'>T'U
M*6H P)0@& \#67WG9:4(&] 3D'!5AL6%XY=Y8B5U8[*OLB-3YFCK]7H'G(HN
M9\Y\3</P]CK2*ESG*:1-.C*C1TKA7:.O8.VX4T:#N''*+JW\]A<EO2EW>3Y\
M>NP+;\4@A&&IOB:%7I7JOOT<!/TQ[B6]Z]GV/='9_P#E>U>U^_*LZ/Z/8GWE
M[P[H=UTU^KK^ZW=-?G=5*:+YC^4CF'Q[Z0^^W^^^C9_[.RM>[[KV.S_U5[6[
M?VEV)]-_K&T)SO1MT#D T%.<D"TV@JZP>W,KW)FQR<C9RMRJI\5"*W("=%%B
M.,:SM =D@ F;\-0G*$K%SG-<<N\43*RLEE^Z U;YGCJ]7H/F.B^F^#>)V'Y>
MUMG-2USE-8G'22G287'V7E+#VQKHYHW+<1E<734PB81,(F$3")A$PB81,(F$
M3")A$PBK9R]HJ2\FN.=IT'&; :JP/M:-*X:\3%V@RBPPMT:> ^3OY3?'4\T@
MFMNJUO$,HA28M$6F$/O[)-WK6M;N.NV6-['=O89!&ZH =MU'1KM=IYJ:^507
M)<1/GL'<8>"9MN;B,L<\QF2C7:.HW?'J1H"74'30JOW3=X03K@%3KE13M><=
MNF!%R)RE$2.3TXLK.4L#D_F%FOZ1T=_TM3ULD3,><G :D+T@1*DQHSN^H/+$
M241N9K*19>Y%TV)T4NT ]O<"!T4&QI!\NI!TT'7#<&XG=\-QCL1)=LNK/>7L
MI 8GM+O9 GOI YNE0-K2#6KB* ;%,AE=DPB81,(F$3")A$PB81,(F$3")A$P
MB81,(M*_&GI56]QUYR6;S?!RTA<PD5V+)F1:4#-XR.3$RKXO/9HPS9\8X@[E
M\B75=%EZ)QC2,#>N4%.O@@*_R@E5WAZ%9KW/6]YBV8OWNYK(J;7=Z":M!:"1
MW8KH34"GF(7+,#X>9+"<MN.6#)12SW9?WL?O4M:62/;(YK'>^26$%K=KB'TI
MJ':K=1E974TPB81,(F$3")A$PB81,(F$6N/J7\#Y+U#*;BM)-]VM=*Q9IG*:
M>21:=5)UEO,A<&=K7MD<0-Q_Z2H"ECS<CT]+#5>A$K3E9FT^@&)P%&A4S.$R
MK,/<NNC$99"W:.WM J:FO9=7H%.BFO3U4?GG$)^:XN/$LNVVMNV82./<]ZYQ
M:"&@'O8PT#<XG1Q)VT+0#NLAQ.IJ<<>>/]9T=.K'C]JGU/$H[7L7E[!72RLM
MJ(/#8^U1R+(GQ@53^Q"UL@1-[9H*A>0K2DJM;!OR4L81C-TLA<Q7EV^ZB88Q
M(XN(+MW:))-#M;IKH*&GE4[QS%W>%PUOB;N=EP;:-L;'MC,58V-#6!S3)+5P
M U<" ?W(-2;&9IJ;3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(N=;DC_U(O #_ (1YG^:W-G+C9?Z+
MN_[0WZ,*XEG/^N6&_P"6O_B7RH%ZNM^WCS+_ +.I+_?(R9,<R_PFV_AC^(53
MO!/_ %?E/Y%W\^U=DV<V7T\F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81>+(
MY)'H>P/$JECXT1F,1YN5O#](7]Q2-#(RM* D:A:Y.KHO.3HD"%(0 0S#31A
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MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBYUN2/\
MU(O #_A'F?YK<V<N-E_HN[_M#?HPKB6<_P"N6&_Y:_\ B7RH%ZNM^WCS+_LZ
MDO\ ?(R9,<R_PFV_AC^(53O!/_5^4_D7?S[5V39S9?3R81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PBY>O6@O\ </Q=_M<F/YFDY>N#?UN?^3'\9< \?O\
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M--6EU=.C33C/+N6<?Y1Q/*LM;>6YQ]LQ[6W)C88&W ;V-A+^]W=H 2-BV#>
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MJTKHI;T;6Y-QNEB%0I2["<+S<X6]MK*.^?L,<C]@:TU<':Z. % ="" 20="
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MUH:ZG7M<ZGJJF0>(F%D;:SW4-W:XV^>6P7$K8Q%(X&@'8E?)'N^I,K(P1KT
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M&OENOOJJ$\K'(Z^.BU(D'*%L)E#1%I&VHI-J_#(4C$C4.WE!:UR<V]I4D$[
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MZ89#NJ-P#97-:QIH'/D<QH<YC02YS0;>3KJ-<?(;%^,CJW$3JPIKS!9(I(Z
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MD[U*EK4F0LJ12^$J"=:"1K2@H1NKR7'Y1F6=?V/>=U*P5>PD!M  0YPIM;0
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M)Z0M)G4%5H;7Z//2/JJK$P)A/IR\UDPQ:+LO8X2-XD<5JM_@<K;&U, 9AF_
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MCS%(C2M;&(66PC;>\2$%M&R:>-Q+F$NU(>3]0YKJ[2"-=>A:W(;F3!^,AO\
M*7,UE87,3 RX8V,[6&%K/_>BE8&]ZTM>=E6@EU1JKRJ^(_3>9.*?+-F,Y)6I
M9E$\H+MJ\,YY%NDNJ-]KJ*7Z_2Y5MHF<!E$ AU>P<;6RRF4(?C2H(*5L:<H8
M4.C21I'$E)%C(9I]_;N[F-EW!$[;& \.,8&K7!Q<ZI .WH=U];2;:[C?!HN.
MY*(WUQ/B,A=Q=Y<E\+HV7#GFCXWQLCCHU[V]Z0#&!V*@M>&QKTS">7O#WG\5
MT\[>F<<Y%U&U4'(+&JNRFTLN0.57UL]N#28TB9I&O$;)81#YDZQ1$A<(L>>I
M0A7D-RA$(2<(%"G-G/B[(XCXXMFNAN#,&O:=-SA6M1T.(!)#M#2H.N@T.!CD
MO&>9>A63E9?8UMFZ6&4=HQ1.(IM<>U&QY8UKHB2W<&.9V:.=TZ91UWQ,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBYUN2/\ U(O #_A'F?YK<V<N
M-E_HN[_M#?HPKB6<_P"N6&_Y:_\ B7RH%ZNM^WCS+_LZDO\ ?(R9,<R_PFV_
MAC^(53O!/_5^4_D7?S[5V39S9?3R81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(H2L_C1QQNU
MV;W^Y^/])6Z^M+=[D-3U9]4P2?.S8T^4GK?<MO<96PNRQ$W>6*3#? +&$KQ3
M!"[O>%O>]J"]O;5I9;32QL)J0U[F@GRT!"BLA@<'EI&S92RM+F9K=H=+#'(0
M*UH"]I(%230:5*]>7T11]@P5AJ^>TU5,WK.*^X_Q7KN7UW$)+!8W\7FPYD8/
M<&)/+.M8&?W#9E)B1'Y.G+\F2F"*+[H!;#OS'=W4,IGBED;.ZM7!Q#C4U-2#
M4U.IKTE9+G#XF]M&8^\M;>6PCV[(WQL=&W:-K=K'-+6[6DM;0"@T&BQ>NN*'
M%JH)(7,JEXUT#5TO*1JFXJ55U3E=PF2%MZ\( KD);Y&HXV.8$:P)8=&E:-T
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MKBVH\AH14>JL][C,;D@P9&W@N!&[<SO(V/VN_=-W [3YQ0K_  &F:?!8J>X
MU16H;;2,P8ZEM(,%B^K%31\*8:,+$GF^FO4F)9@HS!%:2A5:(T6+8>[W=]F?
MOOFY[GWMWC_>]:[=QVU\NVM*^>B?%>,]_#)^]H/C(-VB7NV=Z&TIM$E-VVFE
M*THOFE%&4G.)I';(FE/59+[$A_A_%*>RBOHD_P TB_@FB/)^+LI=FA6^,GA'
MBV,/DQY7='O>]>SB.ZNHHG0Q22-A=TM#B&GU0#0_-7FXQ&*N[IE]=6MO+>Q>
MPD?&QSV=?9>6ES?F$+V8/5U9UBE/0UM74%KU$J[OE2.#Q&/Q-*I[JA4J#XZ=
MA;T!1W=5+CS-=[6^PPX8OPC%O?F6>><UG>]Y'[HD_166TQ]A8-++&"&%AZ1&
MQK =2>AH'62?5)\JJ=U,R7MRX'<GXO&(?/)[*YS5$H@L5B=;P666'*'>12M
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M6@\BT6\4XLV%ULW&X\6[W-<YHMX=KG,#@UQ;LH2T/<&DBH#G4I4U_P ;X/\
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M],01I')5[/*(A$3HO)5N]C"N1HP*&X1P-GIMIBC@H4O/[XV)N"['=X+8Z@/
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M+'XIBG9:$ZPV&#$MB[*Y!YAQ[>B@J]YZ.R#0:G0$])\VHYOR'GKK3/1<1XY
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MKXY%G!8K2!CD:T \!24)^A&^*&QLX_8W-Y<8NU?(+Z!M0YQ;L?2FX;0T%NI
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MU"1M:WH&M%S7P]YSG.78._R-U;VYOK9Q$4<0<P2'NRX-)>^2A<ZC:U %>A7
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MV)+J4J:RMU7/^;#T=O\ ;'CM_P#;)1G-? ?Z?R7\&3^;*D?$7_J-QG^5MO\
M[IJQOG!#XM%/6(.%2R-1YH85,T0TQ,)8<TH4Z$4AE*B8V<Q*9"[>3@+TL=U+
M0P(B#3QZV88!,#O;WO7;GO%R22<.N@\DAI>!7J%&F@\U2?76#EEM;V_C7BG0
M,:QTH@>^@ W/+Y6EQITN+6M!/2:!8@BHRDY)ZRA9U4R*G:L?ZN6L?N\LK9ZK
MZ).L!5OCGQ)B$Q<GE3#US0?'CW9PES@>ZGJ!IMG&N1YBD0MG#$/>4W5TSA4=
MPR203@TW!Q#J"4@"M:TII2O1IT+6;B,5/XZW&.GM;=^/+-QB=&PQEQLV/+BP
MC:27DO)I4N)=TFJR?K6<68)Q Y'\9^HO6]/Q%Y@8+0CK5>U:F1II.@[S)6(\
MM\8'13'QIA-213.(VW.*(]1LH*<IQ0)#]ZVI/%L>/C-_+D;*?#32.$O=DL=4
M[@#H17I[)H?4)'0%G\5./6?&LY8<WL;:)UG[X:+B+:.[<YO::2VE 9&AS2:4
M#FM/LCKNKXNUIQ\O7DG;/4+@<&A"L4D9XY4-1V0TL#80JES3&VH]79%L!7$%
M;,52B12.2FPTYP,[%H6N(!3:$$@XT)E9OI[RULH\1*]_9)>]I)T)/99Z@ WT
MZ*OKTKJG'[#"Y?.W/-+.&([VMAAE#15X:*RS5ZWN<XP%Q[6R';T$U_WU@8I%
MY/TY.4ITEC;!(3HQ7*^31HU\9VYV-CTD0*$Q"&0,9B].H$TOB,A6: I6GV6>
M6 T>@CUH6^UQR21F9@#'$!SZ&AI4>0^4>9?OB9;V]QP?(&>-CS' 7-W-!VN%
M*.;4&CA4T(H14K4]TW'J-<7NB-8/,FM:QKA/R'C\(OE*GLW<)CNIFZ:(LEQ0
M1U))I.4V!D$BC4><$Z%7[FJ5(TI@4!8.P.@A$&P9IK[[D[,;.]_O-SH^SN-!
MV=:"M 2*BH%=5SG@TL''_"B;E%A;P#-LBN )>[;O/VTAH>^FYS6D-=M)H=H"
MJ(&+IT_0[,Y_GNB\/-)=?>I\CY-^Z*W=XF.0+_+K(3-^D<!A,H#'=,",TWW*
M$I.;/%#XO@Z-WK8)#O">4?%  ^+!#M[KZBG=[J[>BM>NE?.JV+=K?";TR+CZ
M4F\[P753W]??'=;>]]GMV@G94MKK2O1U,<%+GE/(;AYQRNF< 2!F5@U7&7J5
M&H2PDHULA"E\@=W1.F  LM&4[+T8U6B ZV CQO##L6@Z%NB96VCL\E-;1?<V
M2$#U.D#YG0OH+B.4N,UQFQRMW3WU-;L<^G074HX@=52*TZJT7.[S@A\6BGK$
M'"I9&H\T,*F:(:8F$L.:4*="*0RE1,;.8E,A=O)P%Z6.ZEH8$1!IX];,, F!
MWM[WKMRX8N223AUT'DD-+P*]0HTT'FJ3ZZXIRRVM[?QKQ3H&-8Z40/?0 ;GE
M\K2XTZ7%K6@GI- L2Y@4S%I'ZPU2T%8#W*LD=GQJ.O,W>ZR4 ATG=E;M +%#
M,5B=]:BR5[0_S)C;!(%3ND&2ZDZ/$I3J"E@2U ,N.N9&</EE?1YC)#0[4"CF
MTT/2 34 Z=1%-%K<FQ=O/XU6MI"76[;B-KI'1'8\DQR[R'#5KGM&TO;1XKN:
MX.HY9YTDV5NKGJP]2/AW'PKE7'(,8NA6*KI.[.<QC:P4;M^OH4@V\)92J=Q2
M!0=$YJM;U2A<)0I7)1Z I,._#F'D#G3<?LLB^GOS<SM  '5CCI2E-6@@#0'H
MHMSPWB98^(N=XQ#4X/NYSW3R7M.V:-@W!Y.X['N:2ZI<-'$J/*C:J9Z0761M
MR&6%&X^Q\=[EJ252RI)B]-J9S75]&W5 NEQ#2Q/+D ;@F;M/,3>X@), T9[A
MKR'9Y@O9WO-<.N>1<;CDA<3>1R / --Q&E2!YBU_FUHM'&QXOPT\3[FUO6,9
MA+JV>^%[@"8VD%]&N.H&YDD-*U=V*DJ<.=21YZ9/2UT[T3#FKC_>7,Z[D)UR
MO->M22,/%?%60V6-:*BLXLXMZ5"ICS35K B#$&0A* @+>C\L4IM$+#S3QZN*
M+<YGMMTXS6MM%V XU#MI:W<?*7'MNKTF@-0**7Y<V7@7A]WN(B;99?*78[]T
M8#'1]Z)93$P@ M$31W,8%-HW.;1SB3GO'&B^1D-O7IZ7=P_XJ6/55%+JCB,4
MY>R*16/QH;6*^8Y,&EI7);N>H_".04Y?Y_*$XWU6_;<UJ$J1&[+3D:",':G#
MBO;JRDM+RUR-PR2[$A,(#9*QD$]@%T;0T:!M =O2?.MS!XC-VN7PN6XSCI[?
M$&V8R\<Z6U#;AKP")W-CN9'2/&XR;W-$AHT4([*J;S M&7<0>=W)QRYVT?)9
MU2O)]V/;./G+6!F+DMM<>8FD97%!'2J FVEB04=7Q1L?0ER..)%K,>Y*$^U)
MVU:0[P5DACH(\CBH&XJ5K+F 5DB=39(:BO>-ZZD=EQ!IT:$:5ODV0N>-<OOY
M.7VDDV*R#B+:\CJ)K9@:0WWO)4;2P.I+$',+B-QW--'>/UY8[5+DBZ4<Y@Q<
M1F2*PX=(FXZT6^+(6M?:T!9D''$R#*WLPY/MV6,>FV2K%*%O7&G!;PN:@ 0A
MV:;WO7%'W#3D(I=S2QP.VM=CCWFZG56H )'30+'XOP8Z1O';NT[J5D\3AWH8
M 9HVBV[LNTJ6T<XM:XG;O<.LKKMKVLJWJ.,IX75%?0BL8<D4JUJ6)U[%&&%Q
ME,L<#MJ%ZM.Q1M VM9*E:?O8SC E:&8/?:+>]^SG/)IYKA_>W#W/D\KB7'US
M4KZ3LK"QQL M<=#%;VH)(9&QK&@G4D-: *GKTU7._P W;3E/('K1<2.!TX[B
M_C,Q($<^EM8+!#-BEJ27<&G,^\IL!H&68W2QD;BHPC1I6U:4>D#V*M[_ /%&
M=VXXN".SXU<9:+2^)VAW6T;FM[)ZCJ22->CR+BG+,A<9KQ2QO$+O7 L:)'Q'
MV$SN[DDK(WH>T;&M#7 CV7[HKY.&]B+ZGZRG,C@!%D[<HXE2N,NTA::84$:/
M@$"?#8!7\E>DL-BRO2MF8XXZ@DCDVKFA,40W'$C)["P@3%E9^Y*$7'&[;+R5
M^,&N +_JG#<X"IZ210$$Z]/E7GC%Z_'>*&4X;;AIXW)&7" _<XW=W&YP8PU:
MUIW.:Y@ :132C0%KTZ8U;P)ZCG7&KMXB3$[0=JJ26%MD8<V\E>TH-PAWNMWA
MJA(G5!-\G715X8D2QN4!WH]&L2$GE# :6 >IC.S2L?BYFN(E,@J1T]H,!]<$
M@^4$A4O@5C9RP<MLI8V.M&VSZ,(J!W;IW,(!ZV.:US3TM< 0:@%6?Z5D5C4R
MZ#G/)DEC$TR-G [<H'T#:](4[BB ]Q*A:ZE<7=RTZDLPL#E'9.RHW!$?K6C$
MRU*4<7L)A81:T<](^/E=HZ,EKJ1"HTT,C@1ZA!(/E!HI[P\MX+KP@S$5RQKX
MMUTZC@"-S+>)['4/6U[6N:>D. (U"ASI8=/-'U ^F^\,<GN6;U>HKWEJXN=7
MN$1-<E3;&5+7&JY>)L[.$4(?X\TR"42M$ZE)$#BK&<='A-Q!R+NA/<4Z[8SV
M8.(S0='$V0/MP'5I4U+@T5H2 *5('LJD'H!$9X>\*9S/@SH;BZEMW09(F(LJ
M0PAL3I"6;FASW@@-<:F/:"SI>U_9<6#PRRR^^,SPP!!WS!=XP?=#H/?,%V:[
MPQ=G;O?].\YLOJ "@HN-#I/FOC#UT^5+9<P%!5F/!7)](FT]E]Y<=*3[*8)&
M)0W".T'L3JX0A6G)3"=>&-N%KP_ZD6LZ3R ,?Q6!UM]P'=='DVD?QJ5\Z^7_
M  Z,L/BYD8\I7W^[WT!NZ=_>M=4>8QAQ%--O1HNS+.;+ZA7'AZSS$)&T/G#E
MQ;&D:"J&F(V/$&),UD%IHVPR-*LB!XVDAO1@+1M U$;3) I2^Z )I"$82M;"
MG'H/1N#2,<RY:XUN"YI->DC77SZUKZOG7S+X^6T\<N+?&W;CFQRL:!HUK@6:
M4&@JT"GE#33H*ZX:_5M2^!PE>QB)&R+8C&U;.-/V>3C:E+,B.;Q$=W>P^")(
M,&P]GL=WLSGLP<)7!_L@XU]6J^D;-T;[.)\-.Z,;2VG10M%/G+D'Z="%VE'K
M!?*V3U\2H/A3+87+IRG#BB (3<)G<9@[,Q9JA0 CP=E.E@+$9Q.M[#LW8>^'
M8M!WV]$S);'Q"WCF^ZED0:.NH /SFU7S3PADEQXSY&XL@3:MFO#(1T;2\MU/
MGD+2/+TJS'K%5 22'J.._4+J;QF>=TW+H]"I:^MB8(E3<!*]F2^I9>J&$.BP
MDQV8)U2 9ANA[-,=$97^*'6LTN&W;)!-A[C6*1I< ?4H\?-%#\PJ>\;<-/;&
MRYIC:MO+65K'N U%';X7G^"\%NO27M"VP\1;K9.>TDKSE6RE>%7=8U,T,4::
M1!":E2\AK7CC(_W.(!HMCTH4U)$!-T92+"3# ;4OC\E'V#)%VU_(VKL2Q]@[
M[M)(23_\;"0SZ\U<1Y&L/6NC<:RL7,)X.0Q?U*WMFM:WJ%S,UKI_5,+-L37
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M-#;PM= &P!LG==\&SS0M$E0#WC"Z1KGZ4 ;3>_TM(YR^@_$*(U_S:8W9IN*
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MVBDD(:XDB@^I )H 32H'2!10=S>CB7A!!E<%%%;Y2ZMK=CY8V-:\EXH9'.:
M7/ +@USB2USMP->FG_*E 7PPZ;O3)YF4 --7O*"1OD%D<ZM1F":7,+<*LJLY
M)9$E0VX]E#3+K+9CG1*0G$E>1+0DI3AD$B 6(??D;!WQGFK[&W=7V+0X-:>A
MFUP:-@^I--:BFNI59Y"P<6X-@>48:D'()'QNDF;[.;O8G2N$SM#*VH H_=0$
M@4%:]@=?R8R:P.$S(Y(!O-EL1C<F-0%G"4%HC'YF1.HTA9XBRA'@3"5[!H>P
MAV+0>WLUV]F<ZFC[J9\5:[7$>L:+Z8LK@W5G%=$;3)$U].FFYH-/F57.GRXA
M]62#EWS)A,CG@^=5CS/C?,)(W\<)M"(^.ON!T9B,0)<0V49;[FLE!L(?^QT$
M!H;(RQI'I<N>TPG$8='%.6KECY+AF.MI6-]ZPMF [QKCNG)--NP4W#34N<6@
M--.BBXCR2VQ\W)<I:3S?&]]+8O<+:2-O=X]K&5[WOB7]V[7L-BC#W.>W>=1(
MJQ\%.:%XTQT$^5%OMDP?'R<U!=;I3]0O3TH]VCZ^99LWT$TMIK>-UTL+VFA[
MK9[BXMY!P#DX%.RR=E^!V UO97&VMSRRWMW- BDB#W@:;BTR$UIY0T _34#Q
M'E.6Q?@]D<G'*]]W;71AA<X[N[:\6X%*UT897.:#45H*4T5F.#G3]B?*CBAT
M_P#EI7EU2"I.1$/FLEL6Y+O8D"J76;>X?TCK$LQKRQYFIE#"_+PD#B)+<D,<
MS79&A1>,3M"H*4#[VCE,O)89"[Q\T0DLW-#6,.C8^SHYK:$==32A)H:BBGN)
M<,MN0\=PW)+*Z?;9N*5\L\[07RW'VTA\<KR]KC[ -!<7M:VHV.!*\^W[@(Y2
M=>.,\,[U"DD7&ZH(>XIX[24GT4KKNQ;(7T>GM+<DFT34@-:9DXHQ/':W$N 3
MR$P&@DP@LLPT_1W[;VYL.*.R5KV;V1PJ\>R:W?MHT](&FM.FIKU4\9/)CD'B
M_'Q?+T?@K:(AL#]8Y93!WNZ1AT>1N[(=4#8" "37).3]=6[T<>F3R%:Z?Y$S
M>>*; NAF9J?='5L4-"GCM!9P<0C41N'&J9/)S=KT+*SJ"BW%.)N) O5!5D(D
MQX1C,\V,UMR3.0NN86L#(B7@&O>.;UG0=9Z-=!0DA9\_8Y+PQX%>QXR]EF=-
M=-;"2-IMHY-"UE7OU#6D!PVC<=P8TU)ACC33/)9,R=+[D1PHXM67&5B2/L*W
MF?;+W9?&QE9>4D,L<<5=YD_R<E!R%?IU8:YD<G"1J6HR2LR1\;-')P!(*.3E
MID^S>W-D7WUGDYV.!)[E@;(3$6U  ^UAK:@-KM<6G74@U,5@L7G6Q<?S?%<?
M/&X,:;Z9TMJUMVR78Y[GTN722%I,I9WK!(RK10%H:WVJ5_ZF;D?_ &;'_P!P
MM/YYN?\ 1$/\/_\ 2/6;%?\ 7F^_D/\ ^'A59*,G4]ZC5\]39RLFB[(Y+6>R
MQETKWBLW1N24JRM7%#:B06&EB4JC.KAN>JU<0?6J1Q>/G#>HPF<G,9I"P2O8
M-*PE+-VZBBPUI8M@E9! 7!TM0\F71M0=C'U!!=V74'13HT@,1=WG-\QGI+ZT
MGO[]L9CM UT#1:5=(&/;WT\)8X.9&=\0<^H=NINH[+NJI"N0!'1NXJK^:\'3
MH>5E7WXAKE7*GI[A\WEYT0<HY9NTZL<TB;U)4IYLQ8(FP&/&O+AG+US64H5:
MV<$.]8\#+9GDEP,8^MA)#NH 6BM6_4D#H)=330&@T6SXAVN9;X88Y_*H@.16
M]X(B]SF2/V%LM#O8YP[;61E_:JYS 7:K9_PQZ=Z1XD?3]Y_N%U3P%BQGB9%6
MV;PWQW!TBTS3SBGTC5#VEF]T'T+=!(K7C%(=$>YB)L&G=U*!*O4=Q?M:I6P>
M2S!:R[Q B9W+K@[3T%NU]23I5Q<1TDZ D#2@%_XMPELL^&YD^ZF]_1XU@D9J
M6/$D(# VKJ1LC:ZFUK:/+6O=1^]S]+_+F/UXGXC\VS(G9"GG7:-+WK7<GD//
MJ90Z/P>1T\[2:S(>QMU)5#8R1;,YQ::PA2!:H6E(5;)#FI*K$H0[T>(A(=9<
M>^8Y&U[QGO2"6)P$ )<'@-)+WM[+6=5*ASR10Z5*Y;R2&R'&LL;:<Y?(6MW&
M]V0>QL;H2^5C1!#*"^24UW%P:Z.%@=N9K1IOER_7GW-ZN7%+6M<".P[,:*OX
M^O;3/I:W-[W+6I]57E7,*7O[8_+4IKD@?W:)JSV]:N*, K7)E)X#S#-'&]^)
MQP%MS-UO;U9 7R M&@([MSJ$=% =0.@$"G0KAR9YRG@A'D<C2>_;;VSA(\!S
MPXSQ,+@XBH<6$M<X&K@2"34UA]AGY7#+H"U[R$X]PV&5QR!N!K;:UD=U1*(1
MYEL8]&\VQ.$YSR[R]N;D[\[NC:P-AR1M4*E!HV\X\LTG81E WK8=%\9<M?9W
MCG/M(R7!A)+=&-T )H!4U-.GK49#>#B_@W#FL+%%!F;IHB=.QC6RT=-)VG/
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MKA,[0RMJ */W4!(%!6OO];(14AY@=,&V8DT,$+L>TF.O9 JD)#6D7* .X9_
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M*'B6RQ0VA5N'N>=)Y.XJUVTWE"C2;1^BM&C"#0M^LA>R9"]DO)-'/=6G30=
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MUKQBYR,3&6Y;ND;:FL@C;MC&TW)VD"I>:G>:4# "#^T[Z43;:_%_C%3%C72
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M^<#CGET<38>[>^FC&S2&5X>UK>SV(XR6DZ@ZC=*666266226 HHH 2RBBPA
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MGI"E>+<3R6"AB@RN4FR$-L*0,,;(F1C;MUH7R2$-):S?(6L::-94 BRO+O\
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M/M==:#IZ-?+05_)^%V2RO%[/BMQE(A9V4A<UXM#O<*$,#JW1'9#WBH W MJ
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M0L51/]";D"4HW59*4::*C"Z(#I L K">2V)D9ZL,='9VKK&6[DE>U['AK6[
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MO9T(<ZIVP9R5ZT<IXZTOPTO<[BBT2Z$\P*]02EO(*Y!J&1^@4IV4T+WB+."
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MGJN!M,59F?W!WM$662Z/3T<> I"VF[ >(F1N.+P6[()GW;6P3D4+HR"-P!:
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M)5TB=:JA?Q6B,*+9"QB4$HG=R7G."8A.WB&,7=EY^*L@-NXW31!.0-SF4H2
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M&.T<:M#=P!UV@DFO1IZE;!GF-YKXEX>ZX](VYQEBV*6::/M1,V2F78YXTWN
M:-GL@7"HT=2&4EW4^C]9>DDQ6V9"4,0 W&5F.5K9$VHXT78"+C:UPA5$#'U2
MH*:BWTJ:HS6;9 C=#V[ \CUVJ-Z+WM&UN3PEL88XR5W4H:[>\+JTZ:;=?4UZ
M%%-RN,9X[R73YXA;;>ZWEP#>\%J(RS<33=W@+*5]GV?9:+].A18T"<^I%U#
MH)A'5(K.>)S(*["6ZI.]-V9-<<E?#U\7T(T.WHDID<"5@O [XM)1;-[/#"(6
MG*H96X6SJT]@-#M/8G8!KY-=/57[X17UG)SG-!DK#[X=(Z+4?;&B9SB6?NNR
M0[3JUZ%TG<T8G(I[P[Y8P6'M*Q_ELTXTWM$XNQ-Q(E#@]2*1U=*6=D:4) -;
M&>L<G-8424#6M[$,>M:_#E)QDC(<E;RR$"-L\9)\@#@2?F!=TY3;3WG&,C:6
MS2^YEL+AC&C4N<Z)[6@#RDD +GJZ*6T]V=,_EOPB9"I:QVO("N1\??75PB<@
M;HE!5-DUO&H-$TT@E2I&G:_=UT=SEHM-28P]Q*3M*LQ24G+VG&?<.35M<W;Y
M1VTVX[L@5!+MKBXT'30"FITU%"=:<7\*]N5X'DN*1"1F1?[Y:XEC@R,RQ-C8
M'/(IN)W=@5< QQ<&C:362GYHDI_HR\M.#,[;E\1YE+;E=(:Q<;%K<:;<T],E
M4EK(XE^AD#2EF/LPCI;6T.>A.;>6J2!*:QC"8((T^C=ZYB-QR6WRL1#L:(PX
MR5[#:!VCG= -2-#0Z^JH#&73<9X79+B5XTQ<H-T6-M2/M\F]T7:9&.T]M [M
M-!%&$U]C7<35_3QE[YT2&3A!9K823:ZJH);)6YL5[)T?$[6?)]);N@K$K5>/
MLI*LC4C=T;2XC*.\(0"U -"$2/>A5R?,1MY.<I ?^'[P GRL#0QQ^: 2/F=:
MZ=C^%7,OA2SB=^T#(FV>X _43.D=/&TGJ+7%K'4--'"M"M0L*X06-R Z%LQM
M.R4SDZVW7*8J7T6G=$&TKQ'J)XX/UB=^(@3CV!P&-8CGT[/*+[H=JP::P>$/
M:8DP5BERD-IREL$! MWZ/H=#)(&Z_P#I9ZG:UU*YI:\3OLSX1RY"^#G9* ;[
M<$4<VWMG2=BG3J)+@@=?VL4.T%;ZN!2*VJ>Z<3==,]9G>R.0<QILV]I%'@IS
M$[Y,7A@J5F8ZHAA*1,6K4I7=56<"CC<<6 &QB=!J#=$@$;LH-3RQM[G,FVA(
M99MDV ]0!>2]WJ;G./J478.'LR6,X.W*WC73YJ6U]\.;]4]S86MA905(<8HX
MFD?NZF@K1<M=W\@9SS3Z=_(2\;M16Q97)!KY-Q!(N<0U])DE)<?J.0-J<IO8
MH&N$G%!H:)\E[F:D=22%)DF<AI4ACD TE/I:.]VMI%C,Q#:VIC99& T[0WR/
M\KOJC0"HTVBIVZFB^?LMF;OE7";W+947,^<;?L!/=O$%O  *-C-.[9N>2'@'
MO74:7@ANXW;ZGMG0E\Z%/3HC9#P-NDZPGCLV-T6DK8[1.4._Z(:#D4)L-V9(
MY)T+2]/47CLC<$9(G=*0<UG@<$9Q*@PE8F,-B\'!*SE5Z\BK/MA)!! WR!S0
M2*@$@'0ZZ$$5!5KY]?VDWA'@X&NVW!%L QP+'N[FW='(6M> YS&N+1O +#N:
M02'-)Z->G5-H+.N#'$]PKZ21V2L[+Q^J"(.1L;7HUJ9FD\5KR-LTDC+B6C&+
MW+?&%V3&)U:,T)9Z<T.PC!K>4W,Q2Q96X$S7-<9GD5ZP7$@CR@CH*[?PBZM+
MOB..?92,DB990L.T@AKV1M:YIIT.:006G4'I6@/I'FE<';%ZC7$+D>H402VW
MDINDM:() 6>4NN=C9$-F-)[G6Z7N&J)FH<DKJ@7IB6_:M0H3*#A]S6DBG8+;
MR'_\4ALLC9=NW&CJ?4$[31WDZ"-::@>4+C?AN1Q.]SG&LX3#DGT=$'5K.UHE
M%8ATOJ"UP#:D@DT[+J2'ZLL:YQVJN0L0D$1G[&MD<IB-BQUZ=J_F2"%/T6-C
MQ+0!0USQ0R AJAQ,4&EF$H?+M+5240E"<HTDE085AYOM?/#(QS"&M+2 YNX&
MM=6UK3STH#H=2%N^ QD@QU[;313,>^1DK7&-XC<S;MTD+=A-=0W=N([300'$
M;3NKSRGNKA_PMEMLT(R>6SU3*(W#-2DUFU($58L\B Y"<+!7-1R=2W*/<\Q
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M(G[0?ZH_.OT9/O37\"@OK-_R]X] _P :^]?A$_:#_5'YU^C)]Z:_@4%]9O\
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M) 7O]KX&PB>D2#Y("]_M? V$3TB0?) 7O]KX&PB>D2#Y("]_M? V$3TB0?)
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M"]_M? V$3TB0?) 7O]KX&PB>D2#Y("]_M? V$3TB0?) 7O\ :^!L(GI$@^2
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M/_>$^WJY?_1QQM\S[/\ UPX]",3[9<?7,_HT^7GE_P &QON<_P#>$^WJY?\
MT<<;?,^S_P!<./0C$^V7'US/Z-/EYY?\&QON<_\ >$^WJY?_ $<<;?,^S_UP
MX]",3[9<?7,_HT^7GE_P;&^YS_WA/MZN7_T<<;?,^S_UPX]",3[9<?7,_HT^
M7GE_P;&^YS_WA/MZN7_T<<;?,^S_ -<./0C$^V7'US/Z-/EYY?\ !L;[G/\
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MWJY?_1QQM\S[/_7#CT(Q/MEQ]<S^C3Y>>7_!L;[G/_>$^WJY?_1QQM\S[/\
MUPX]",3[9<?7,_HT^7GE_P &QON<_P#>$^WJY?\ T<<;?,^S_P!<./0C$^V7
M'US/Z-/EYY?\&QON<_\ >$^WJY?_ $<<;?,^S_UPX]",3[9<?7,_HT^7GE_P
M;&^YS_WA/MZN7_T<<;?,^S_UPX]",3[9<?7,_HT^7GE_P;&^YS_WA/MZN7_T
M<<;?,^S_ -<./0C$^V7'US/Z-/EYY?\ !L;[G/\ WA/MZN7_ -''&WS/L_\
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M?^\)]O5R_P#HXXV^9]G_ *X<>A&)]LN/KF?T:?+SR_X-C?<Y_P"\)]O5R_\
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MCYYQ79I.,YJ(97,)8NW8PA6#U[&M_C=$X+;MV3W9]D2U@]0:GUZCUE\V>/\
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M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB_H/<7OV:.._\
M874GY@1_.#Y#^OS_ ,L_^,5_0S ?X%9?V2'^;:ITS34LF$3")A$PB81<Q7K
MW^O7&C_9.R/],1/.C<$^Y7/\)GT'+YG_ .X'^LXO^!<?1A7/%E^7SJF$3")A
M$PB81,(F$7V-[>O=EZ)J:D2MS='-6F;VUM;TQRQ>X+UAP$R-$B1I@&*%:M6H
M,"6446$0S!BT$.M[WK6?CG-:TN<0&@5)/0 O<44DTC886N?,]P:UK027$F@
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MM!#K6KE;PQVT#((0!$QH ]0+B&5R%UE<G/D;TN-W-*Y[JDD@D^QUUHWV('4
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M0MDUU#&@ZZ'4"NHT/E7B?E/)KJ+N+K(W\D-6G:ZXE<VK2'--"\BK7 .:>D$
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M;+-)( :4J ]Q -"14:T*_"7<A;^L"'-%=SR\;@FU?Q\*<+#!I=9DTDD.9 I
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M?]$#^UR_[BW,94EU],(F$7*%U\OVEZ@_L+1_G_-\Z=P?^H3?RW^Z%\L>/O\
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MEQD;2YMX)#V'21/8UVE>R7- =IKI711;FPHQ,(F$3")A$PB_H/<7OV:.._\
M874GY@1_.#Y#^OS_ ,L_^,5_0S ?X%9?V2'^;:ITS34LF$3")A$PB81<Q7K
MW^O7&C_9.R/],1/.C<$^Y7/\)GT'+YG_ .X'^LXO^!<?1A7/%E^7SJF$3")A
M$PB81,(F$5W. W.JT.G]>B>Y*Y;VV3M[FS*8I/X ^*#T;/-HDL4I5IC>-P3%
MGJ65X;W!$2J0+RBS1)CR^Z,L].8>G.B\OBH,O:^]IB6N!JUPZ6G_ ,P>L?\
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M&8!*I# TJ@*H8"#SP3!L1')2!=[2I6441W!^)W!2O)I)HL).Z"NZ@!(Z0TN
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MK@"#YB%X>>U@7VFMS@2A2.AR!84V."A8D0.)J4\M"M5-P4@W!,D5C!I.I4(
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M;;97'EB;#4K3'FMD8TZ=,RL11!84B4HKN)][[-[T+>>.6VUO:8**VM1M@9<
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MWV5-%\LPB)TK1,2V$N&XC4AM=2!UD#H7:K?I+17O6.Z1M=4BN$UT['^/!S=
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M6)P4NPW:/!B%1,2Z-/YCHM/4B<6\Y,O$H4'&;.V,TS8O<>&Q\5W[^:U_OO\
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MU5AQ7*L]A;*7&X^?;CYR"^-S(Y&%PI1P;*QX:X4:=S:&K6FM0*9U+NH+S+L
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M)(54EZ\77VYJ8DR*76G4JJV^+ELN2:*N!=D.3<%VJ"92"8,<_<&EZ?V93MI
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M:KP)YU .5-F4"P<79M-X8\43$TS0GBD"+HJ@FDJ*F,FC-('.,R!EK!NE<?D
M@*#PJ')&O)<%@%:D*@XT*I1HWW#A[""[-]$UPNG$U=WDAK7R@N((\Q%-!IH%
MKWO-^29'$MP5Y-$_$L: V/WO; ,VB@+"V$.8X D;FD.H3KJ:_GQ[Y^<J>*\"
MF58T7/8O#H18IR@V?,Z^EZ.G!DT)4MIK.8V2EWL"MY4]OK !L4GDE-RE28@)
M J4>&2':@_9B\Q&/OYFSW;'.E9[$[WMIUZ!K@ ?.!7H\B_,+S;DO';)^/P\[
M(;20DO;W%N\OJ*=ITD3G.%- "2 *@  KVH=U&N6T#HU1QHC<TKLJAEQIZETJ
M]WXX\:I1&'M:>[)GT3E($\HJ%Y42%V)=T*902K6F*%)!B1/LL8/)R>YYDPN.
MDNO?KVO]]CH<))01I32CQ04TH--3Y5F@Y[R>WQ?Q)%-!\4'IA-K:.C/:W5+7
M0$..ZCJFIJ >D!2:BZ@_(CDG>O$\SE'<M<BB5*W16TDC<RDW'JJ L]:-#')F
M52KVXMM3P:$2^05\F2MY9BZ.$KR42X"8OM" PHDTK [#V5C:7'O")_>2Q.!:
M)'U=4'HWN< [71U*CYM%)6_-LYR#.8P\CO(/>UK>12-D?;P@1;7-.O=1QO,9
MH-S-X:: FFT.&]^:<V^$<RL!Y<+TZ=W3=7U9.Y<LW87)>/<K.($]M9SCDG6G
MG.EJ@J&"P=PY-FS%V3*1+C&X.BWY*N-V6H4E&@&>&J18S*1P 6MY>B=K1MB,
M4S6@CZG>7=W0>7V)'0.I=BN>3\2NLM(<KA\ [&R2.+[L7=C+(YIJ>\[EL9N2
M]VE6^S#CJ[3<N1^?GPY3.YJIKM$Y-M?J);)#X,W/*C:MX;X<:\K#(RB=56_9
M4N25E$06>9_Z9H1;_ISH4(E$+!.09MHW4Z-U-:?-7S/D39.R$[L<"W'F9_=
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M&H!<T$Z%PZ5L@ZB_3T;^!OH^JFFZ%5QM5_UZNL-L4KJS+K1;'F\CW!,1(5B
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MHF8XN(NLZK=(Y(3'@X@"L7NN0:F2B,.*+4&%A3FZ]U++#;OEA:U[VBM"XM!
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M[J('LE9_'#"0.N+/E]@6.M+R,1O<TM+7.#=T3PYM0[?'4!P)!;&*:++N%O\
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MQN!8[+K4D35R3<[#4/J7R!W^.!]369[O)U[=HE,!L/1N.C"?)0%% 2Z+T4$
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M+;;\[SBK+/8ZQ>JZLFHU]0SYZ O:YPX.-FQ-I!,9^SO-2DF15$6@<1N)#BM
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M,CGI%&&K*NO90QM\>EP((SS4^#6&W(&!-$O#F$7GD_G&QA5Q-L0(#"VY0W$
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MB0C,'L8M$IDQ92=.5K8OQ0%A" &O8#K6M:UDZ!047.7N+WE[J5))T  U\@
M \@  '0 M@UQ=2B[N0]45C6U[PBF+8DE-)0H*TO*6Q22BN>/-Y:5M2%H'!T:
M)JU0:;I-@:21G D3 [^5J-;/4>,>(1FX>VP=K9SR36KY8V2^R8"-A]=I<.GZ
MEPH-!17S)^(F8S5A;V>7@LKFXM?N4[XWF9IH!4D2"-_0"1)&YKG %S20O'I+
MJ'W33E 6+Q8=XM5=Y<>K,6J7AYK"[&&4N[<TR-8L:W ^2Q:1P6:5].&%Z\O9
MR%!8RG79)"K0E!18% Q&[]W.&M;B[9?L=)%=L% YA J.BA#FN!%-.CHTZ%KX
MKGF8QN%GX[/';7N'G)+H[AKW4+CN+FN9)&]I+ANKNJ']IM':KV>&'4BMS@Q/
M9K9E2UI2<AE\QBB. D+K#:;*<DD/@:1R2/!D2B;1%+1AK44@<'1L1J%*EP)<
M',X]+HS:K1AZP2GQDL);92)L-P^41M=N[):-SNC<26$UI4 "@ TI0"F;C?B#
ME>+W<M[C[>S?<2QB,=XV4B.)IJ(HVMF8 VH!)<'/<ZKG/+BXG+ZLZHT]IZG[
M[HF'<:^+P*UY)N\E=+39G)+R*7*7 B2$GI-,K2[^D84Z,K6Q(#]D(=DFZ5A"
M'0SCSSNTS>*? 0W%Q#=23S]]  &'[7I3K([NAJ>FJVK+Q)R%ACKS%6UACA8W
M[Y'3-(NCN,HVN /OJK1MT&TBG3TZK6)D\N<IA$PB81,(F$3"+KZZ%O[&#[_;
MI./S8@.<HYG_ (P/Y%OT7+[#\$?]$#^UR_[BW,94EU],(F$7*%U\OVEZ@_L+
M1_G_ #?.G<'_ *A-_+?[H7RQX^_X[8_V1W\XY:*LNRX(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+^@]Q>_
M9HX[_P!A=2?F!'\X/D/Z_/\ RS_XQ7]#,!_@5E_9(?YMJG3--2R81,(F$3")
MA%S%>L#?Z]<:/]D[(_TQ$\Z-P3[E<_PF?0<OF?\ [@?ZSB_X%Q]&%<\67Y?.
MJ81,(F$3")A$PB81?<UKQM;DW.9111QC<N2+RR3];$2:-(H+4 *."'81;*,$
M7V"UK>M]F\\O:'M+#T$4]=9K:=UM<1W+0"Z-[7 'H):0:'S::KK,Y(\C>-G)
M/J$]-/GM&.1%*1NJ8['(>QVE'Y98L>:K$JF41N42J:F,,K@*E21,BDRH<P-1
M!>0-_N"$UN,&-8$)Z/RGGEG9WUEA[W%202FX<XEI#26N! %0[V/U-:5W:]'3
M3Z<R^9X]FN:8/EUMD+)F/BA<)6OF8V2,]HM:Z,G>"3(026A@V&K@2T.\&G;J
MXVN?7LG7*QDY04$IHE\@CJ_+)U))Z15K;'UJ^GV2N4L55'7 D@"6324]]0Z.
MT5'#7LDI"< P\TDTM40FR7-M>CBD=@Z";WTUX&T-W5HXNKV-U!0_5;=>BHH3
MJ8S*X'Y7;OD+<C8'%26WLS*(PUW=1,#:R[&O<2TG[49 T>S+7=D<_O,P_P!Q
M^;'(64))/#9PA>^0-A64PRJ!3Z(V9&9&Q2V>.LS8'5)+(6^2%D5*'!K<B3%!
M U&EB,\0R%11*@LPL-OQPWXN*(M<PB%K"'-+2"&AI%' '3J/0>K1<4Y/)[UY
ME=W\;X9HW7\D['1R,E:YKI72-.Z-SFU(I5I(<WH< 5U@R/E%Q4LOJR\0>8K-
MREX[M-*ZXA3.%JW&56_!X](&*:'K+'= Q291I<]!=X Z;;9H08 ;Z6W)%)I)
MB=.<<I\,D?/F6.0AP-QCG6\YN??#7:,<010"H(%':CZFOEZ%]*2Y[C5WSRQY
M+'D\>,;\621'=/&UP>YY> YI=5AVGZL-U&W5VBHCQ*3<@93SGZP;'QZ157R-
MI^X3;?D4YJZ+7' AI[UA%P6/, US^C.XV&2.D(A4G3PRQW,]2X+CEA;1HT]$
ML0;<=EE$2V2-HS%XTW9DAN8]@:XL=]K+&MW;F$!SA5HH!2O2#3IIO$FY:7E?
M)_BD6U]BYS*]T3)HS[X$TDIA$<S7&.,ECW[W.)V5VN9N]C4?J-U-SWJKB=0U
M)3OB;*./'"R@7I[61(A=;E=<@9 MGTT>7%>OD]O6+5^VIB(7*7V;.)+('4?8
M$I9;D:G!I49KOADL-<8F?(2W,5PV;)S 5[#HQM:!HQKJGH:*]IQTKHJISG'<
MPL>+VF*N,6^PXK8NJ*SQ7+S*\N[<LD5 *ND<&@1L;5Y&O9 K5T?>55<\/^<<
M M"W%9K16[S'Y97LJDA*!0YBBJ>6("]-LA.1) &+36Y$^H$H5HB &'%(3#C
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M6[V/=WDCRQSJFNT.> *].H:!T]%1UK+B>-82Z\9LH)HHNYM8HYHXMHV][)'
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M'D2@TW.+B(S&'&FZH "M2Y==7D4[\B([RL<.._$D^]HK6JRHF2:>X/(8LM+
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M1"=.04$9IQYQH]!  .MB$+>M:UVY^$AH+G&C0O<<<DLC8HFETKB  !4DG0
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M6-81VNE?&'AEQ/PMS?''7G,;Z"WRPN7M#'WD<![L-86G8YP-"2[M4H:4ZE=
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M +%_^^^'GXWIZEH\!_U-;_Z;]F/ZW[#I'L/_ )?:_P!_1=0W*C_<:_?YG_\
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M;_67_.:3_6#_ .Y_VYE;[,KZ%X+_ -5>2?U?ZGV'W3V0]FMLF9%W):N>2/\
MS&>$G^J/^8I[_G3_ %H_S7(O\P?^S_\ JG_9WLQN]F%Q;EW_ %:XY]P^Y3^R
/^Z>QD]A_YK:-F1=I7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>gdc15tqwxkbk000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdc15tqwxkbk000004.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %- >P# 1$  A$! Q$!_\0
M'P   0,% 0$!              4'" (#! 8) 0H+_\0 >1    8"  ($!@</
M#0<,#0P# 0(#! 4&!P@ $1(3%"$)%2(Q05$6.&%W>('P%Q@C-#4V-SEQD:&Q
MMK>X"B0E)R@R,W:TM<'1X1DF2'1UE_$I149'4E576&=HA[)49&5F<X.$A8:6
MF*>S0D-$4U9B<GF4E:6HQV.2_\0 '@$!  $$ P$!              $" P0%
M!@<("0K_Q !T$0 " 0($ @0&"@P'!P\(!@L! @,$$0 %!A(3(0<B,4$4(U%A
M<? 5,C,T=H&1H;'!"!8D-39U=[.TM='A%R4W0G2R\28G0T1%<G-&1U)35%56
M5V1E9F>"A;8X8F.#A)25I D8EJ*CI<3&*(>2D\+#AJ;%_]H # ,!  (1 Q$
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M7-X G!XJ;HY0S+U;TQGZIDOTJWJ+E#1RLD)<5Y5O&@KLP_ R!XAL_<N!=@7
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M*XS 9@^6FJ-J _<@E0R ^[&.PX6_D$5W^J9K\S0GW"FCE8,2NW&$I3P";,2
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MD-2T14F8K+#NB4EPOJ_ZIEOS=M).CZ.5D21=T84=<H;,2'3/)R#V(9).$@'
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M!XZ+DU3O$H1+R1;6/6MD&_5*^0BRBD3\X_5173J0W$3ALS(]4,:#D6O4 /S
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MSTGZ<9%0^K6'?>&=?CQUQCU_O;/_ (21?1G.-CIG[[]&OY(JS\[H;R8PZ-_
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M6ONI[/9Y_D*MX<A+HWA[D.6L?FJ%298]1MCJ0DDWT6@T:KRQYYTD1X].<K!
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MXW>9^UUC^.*/],S+&QTE[?H%Y_ZW^;\^W_(6DN?G^3&]Q(_M<:X!_P!^E_\
M3ZH_)7W?7[GKXT#W^V+6?XNR[Y/",C]'9V]_DQI])>UZ*>5_[I=;\O\ V#6G
MT]_GOCIYX/KZZM4/1^Z.V _)?-_N#_6/HX\T].]O8[I7^ FD/UAI#SCS<^[O
MQYTZ9OO75?E6U-^FZB[_ *N\@>?$P=Q.7]SQR\'H_NB\D'Q?/!#][NXYKT1?
M>W1'Y)Z#_P /OY3V^7OY>FW1W0QSZ9=#>4Z\IO3V2>;S^7O[,<?ZSR^=ESOR
M'G^ZGQOZ?^ZNMWW/D/')<XO_  EZ3/+EH#._T37%N_S>4?%CV5JGGJG6-_\
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M714(CSS*W\-E73N;HT5)LJR:F17=(VC@WNKLJ%0S &9>QN4,92&1LEN6&2*
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MKS.67AZL/%EY9Y26O(XMXW-A8<^0[K#D>6/9>D:"A-1T)@T-&>)T=YRTEZ2
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M932::O+*;ZGJ0;R.;BV1\C=N8YGD>7,\N9QDZJH:%<XZ70M%1@)T/93(@%+
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M4,TW&R/QLOX+9N>;OVC[9+'MYD6%CV\ASY#$9C04/@'2&? J2Z=,>A$0^#0
MJK/T3[D4\.ZH=[W5; AW[=S7M7..CBN,Q@6/8EZNS83!,"LVY0("C^M H! !
M/R0. FZ8!R X"(&Y\^*J*67A9 .++SR[4Q/C'-R(:VQ-R;D6%B>8L+6(&+.H
MZ*B%7TG6HJ0"/4O1(J6I8!L5\PT\'50(^0<,0X7DX8[@;G%V]QL<5OLIT8YB
M7JJ3 F1Y-&Q>J,-7F!$R?)+R#"8 $3$Y#S !'F/+B,NEE/VFGBRF^956Z\CF
M_P!VTM@W/G8'D#R%^0%\5ZJH:(+T\6HJ,</2>4-'MI8!L)T]FURG4ZC$B]UL
M;@$F_/"M98R-+8,I!XN8 "> HE4@ S; !%1>9(Z2A0!( *H/1*'3  ,/0+S$
M>B7E8HY930Y&3++<ZIJ%),C\UX>2\CSYCK'D?*;#&SU%04(U%TB!:&C 7H<R
M]U5:6 !7\,UYUP @"OU5ZPLW5'6[+8+R,C0?1X>+V'+YVR=6$.QMQ 5@4KX
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MS_SG\4Y=[TTS\**G^KD6,K5AMG/2^?)T.92?_O\ 2/Z_'A09_7A$^\"KYO\
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MR'GUEOKM'YWJ6.KT"T6B:V=H^AR.G@49_IZ,U-+Q]+VKE,E:HB0E(E\'F*5
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M5X^[;+&A5 :=R*EC*-D9"/:]5+%;2R^*3)X[D5S(83<MVI"V6K)"]:=*A\Y
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M2YWI)HZ%AX<2[RLD<0J8[TR-,K,^V.0BS:[!:S1V= 4H#]$KJRT0STY[)5U
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M7/RXR:A]6L.^\,Z_'CKC'K_>V?\ PDB^C.<;#3//-^C4_P#5%6?G=#8PZ-_
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M8Z=IN%#H>GKQ.<QKN*Z>Q66SBF*^T"6F$?$4%R$#>V)QQ.EJ-:FNH<J&KHA
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MNLO W/SD>Q=8*YILM@Q7OPN"M7-.\8E]BD.CXT%2O5\R ](BHBQ[.F9-+DW
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M#Z@_E)UY?L_@FTOS[/\ &](_3\?D\V.C9OY4Y_RAZE_5N;X@WD,/V:M'/O\
MW7[0?-_WWQ/J[^?N_<'CO#3WWORW\F[^3_>RJ\O+]G;CN;)C_<S2^;IBI?\
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M:$<KWL000>PW'QRX3?,?G?:<7MK01#;>?.(=H1Z12&R->C 8>1^8%$# 8IA
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M?F;R3>28.B/(1Z(]W<(!R'-4<?;0=C?A'&1U6-_&YQYCR]&-MHZ>'=T. S1
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MK ><!@0#Y\7(Y98B3%+)$6%F,4CQEAVV)0J2+\['E?#.!X/O1<.CRU!UO#H
M)2<L.4,.@4>7,I.4'Y)1Y!S O(!Y!W=P<J>%%S\7'S-SU%YGGS/+F>9YGRGR
MXK%55#;:JJ1L!5+3RC8K6NJ6?JJ;"ZK8&PN.0L!X/O1<.B :@:W@!.8DY8<H
M8= 1 0$2<H/R>8"(#T>7,!'GSYCPX47/Q<?6 #=1>8'8#RY@6%K]EL!550V6
MJJD<,DI:HF&PM?<4L_5)N;D6O<W[<>AX/S1@H@)=0M<"B43&*(8=H@"!C<^D
M8!"$[C&YCTA#O-S'F(\QYSPHN^.,W !NBD$#L!!%B!86\EA;LP\*JA:U54BS
M%A:HF%F:^YA9^3-<[F',W-R;G%?S@&CG1 GSHNN?0 XJ 3YC]%Z *"(B*@%\
M2='K!$PB)^72YB(\^8B/$<&&]^##>UK\*.]NRQ.VY6UA;LL +6&(%14 W%14
M7#%P>-+<,3<L#OY,3S+#F;GGSQ0/@_-&!$1'4+7 1$P'$1P[1!$3@("4XB,)
MWG*)2B!A\H!*7D(=$.4\*+_:X^0M[1+6YW%K6L;FX[#<W[3B?"JKF/"JD@L'
M(,\I!<6LYZ_-AM6S'F-JV/(6!\'[HR//GJ%KB/2$IC<\.T01,8G+H&,(PGE&
M)T2] 1YB7D'1$.0<.%%_M47*X'BTL >T ;>0-S<#MN;WP-55&]ZFI.X@M>>4
M[BMMI:[\RMAM)N5L+$6%O1\'[HR/2YZA:XCTP #\\.T0>F !R #\X3RP .X
M-S  [@[N(X47+Q40MV6C06]%EY>>UK]^!JJH[KU-2=]MX,\I#V%@&!?K #D
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MW;KW-R";W()!-L6Q\']HV81$VH>N1A$_6"(X>HHB*G/GU@B,)WJ<^\#CY0"
M#SY@'$\*(=D40L+#Q:<A:VWVOM;<MO9;NQ5X34VL*FH W;[">4#>#??8/[:_
M/=VWYWOCWYP#1P2'3'477,4U# =0@X?HO04.7H]$RA?$G1.8O0)R,8!$.@3D
M/DEY.##<'@PW (4\*.Z@WN%.VX!W-<"P.YK]IO!J:@DDU%022&),TI)86LQ)
M?FPL+,>8L+$6%J!\'WHN/2YZ@:WCTNCTN>'*&/2Z(@)>ES@_*Z(@ EZ7/HB
M"'+EQ/"C%K1H+7MU%Y7[;<N5^_$FJJFW;JJI._:7O43'<4]J6N_6V_S;WMW6
MQ6'@_P#1L 4*&HFN0%6*!52AA^B@54H ( 54 A.2A0 PAR. AR$0\P\N(X,/
M+Q,1*\U)C0E3VW4E;J;@&XMS \F(:IJ6)+5%0Q8 ,6GE8L + ,2Y+ "X -P
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M!RY<N'"CY>+3J^UZB\O1RY=I[/+@:JJ.^]54GB6WWJ)COL !ON_6L  +WL
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M^?')X]W?Y_EZ.Z<,;'K1[:K;#U#1];1^[^Q^3N_A>_T88U>N>V>W*_CEA?\
M,E6N&&-GTM^RKO5\(FC_ *,6">'9AC8=/_LA;W]W+]V7,_F%P)W_ !^?AB!Z
M;\S]/9\79AM?!BARQQLY[N_&Y _^^&9_T</JP7L'H'T8<WP>?M4*M[Y.RGZ2
M^8.&)QA:"]VB^(?<J-Q[_P#TOMON?T?%PQ![#Z/7R?2,6M3/M<^&?@P17Y#J
M<,3ANIO[4%)__E_N?S#FX@_6/I&&' W"^UR9N^#'+?D8EQ.(/8/2O9Z1A0WT
M]I3DC_$<7_G*H?#$XS-_O:UC[_&G_/\ ]K?!X?CY<0>SXQ](Q'D]/+Y#A/\
M""_8:QM\+K2W]*/%?$XGR>O<>WU[;8V':+[*.BWPL7GZ,.R/#$=X]!^E<>[#
M>V'T*]_++'Z*&>>&)Q;SE[:W1W_+VPGYEY'AAWV_MQ9RI[=[43S_ &+=J/\
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MO0;';:RQ[7:2,IJVXA6CE/F0YE45539X<KK-P*S5''ZKEF8KA,Q2$>I-U%B
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M?M\WKZ_LQ%K@=W9W]EB._G?Z\9V[.ZVNUAU"R% 15HMRTHX9XX(DDOA[,C!
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MPIF!!*(@/SX&M/>'O@M?E]WW.?$X8878\Y_9!JSY9@_=3T;_ .4/_P!ALE@
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M@?FI[?\ D9'9S[1R[/*.5^?W#[P_8/KWO_ZL?I%8QX]VX^+I[#Z#A)WM^L;
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ML.N$45B_DLXY09S:D0-,/T'#N,;8$?,T'_9Q$YVJ,FX0!4.@5V8OT3C+ )(
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M%N%]KDS=\&.6_(Q+C(Q1?E\GF[3;"AOI[2G)'^(XO_.50^&)QF;_ (\M:_\
MIXT_#_\ MQ@_S?+S<PXANPVY<L/)Z]Q[?7MMA/\ ""_8:QM\+K2[T<_\*/%?
MWN_T_>[^7$X>3X_)Y#;M^KGC8=HOLHZ+#W>VQ>>?W=8MD>?Q\/-Z]^([QZ#]
M*X]V&]L/H5[^66/T4,\\,3BUG+VUVCG^7MA/7S^PM(_(>?N>GEPP[_7^SO\
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M!HYM4QW/UKH^>T*<^QY*SCVVU:XT20DFTTK4;YCVV3-'NL$A-LTT6LW'LK%
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MCQ=G%IOL/2#1D>0=)V(R+,CMT8K9L9<Z8+N# BF)E! O ,IY @^@@_1AS\A
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MW "B=,% $O%OB1BX,B7!((+K>]SR(OV^;N[,38GN/Q V^6WS]_IQXWVJU?\
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M_L] QHVE]!HCC3:8<.*54EW!;UMV0%UJW#JK 5OL-F=) H*'9&/T44DTTT@
MW),A"$)R*4  .T>GZ_/_ &?%AB*NN=)IBW@[,+/%:C5U7:FGM'<*.E*_$G<'
M7-AZ/4,N=8S05#*F/S.90QA.8X](3<^8\?-74E54CI!SU!/-M&JLP 42N ![
M)R]G6%@.RW9;D!CG]*JG+HCM!/@QYV _F'GZ]F)/MJ#11\%C'/AI=2%Z.A44
MY%X-<AQ="Y-@!JJ+@7'8NM%<5/H@J]+K!/Y8CTN_CZ4KV#T#Z,< /(GT\_WX
MKVDH-%1\&'FM\C2ZDD]3TPM+A-XE7(=-R1P7$:ZA5TW!615BJ@< .54#@<#<
MC 8#=_$2>YR?Z-_ZIM\^+]+[ZI//54UP;=AGCN/)V<L?"S(0\2$2SY14841>
M5OO!@T 1Z4U$E$>EU//O 1 P>80Y@//F/'CV@J*@U\0,\W-IK@ROS\3+V]8_
M7C[8],>6Y=%T1:_DBR^ACD32.9LCI24ZNK"FY,K+'=6'<5-QW''VI;.46DHX
M^J)T:=54CFSYK,F)DZ]$$,*:VP.-T5DS&*S 1(JBH=)0@^2=,YR& Q3" ];]
M#-34/TG::1YYF0U5;=6D<J0,OK"+@FQ M?GWB^/D!FZ*,NF(4 [4%P #[9>S
MNOB0V[=+IT-4<"2$/4ZS%/T]RM3B)O8V!BF+M,JF9:V10I'+5HDL0JA!$AP*
M< ,41*;R1'CZ%M[4^CU[QZ]QQP;R?/\ (<= ^)PQ ?8;PC&!=:=HM;=3K^RO
M#N^;*O4V4-8Z[#1K^C8X/,2QJU15LI3#J:8OJ\ADJW(O*E2E(Z*FNVS;!X20
M",9IE=G88GQPPPTN<\YXKUKQ9:,U9KM1:5C*F#!A9;,:&L-@"-&R6.(J4*'B
MBJQ,Y//!>V&>B8X.P1;KJ!=@Y==0S1<.$6&+]KR5)UG)6+<>M<6Y*M<?DDMR
M-)9)K,9!N<>XO]B<0VE&H9)DG]@CIB,-<%7!HFIA"0D^+V4;N$7WBY$I'!V&
M'3X88.&&#AA@X88YF,O".3UHRWDK&6+]$MQ\M06*,U2^";=F"F(:X-<:-K?7
ME(8+"\0-<-AZM=582$;3K%\]=&IJ;H[45>R,G*Y 1,PQTSX88ACC7V]VV7O
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MA\< >V;WM]\G"?WOG=L>?+^SEQ[4QQ7%&G_U6VZ^&)E+\FJ!PPQ7I7];&?\
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M^]LWH3^LN) [V_6-@?X9FI?YYZUQ]$6[#Z#C@GD]>X]OKVVQ-T1 H"8P@!0
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MQ?1Z^?T>?EAC-P+<]JL3I9B+,Z-91D1R-GS)>6(KQ;EW7(>Q0MV=1R\?'/\
MM64F_1DVI6:@/2M^O:E,8G4N5@YB$_%\?+]M_FPQ>U]N^U&(JI;X":T9RG).
M+#F7,^1VBT9EW7$448G).2;'=(EDX[5E1N<L@QCYE!K(E3*=N5XDJ5LNX1Z"
MQF&+6N5SVIPWC%Q1Y[1G*4G(+9$S%< =1.7=<CM"L,CY6N=\BFPB[RFU6%VQ
MC+(T:2 =4")7R#@&ZJZ )KJ/B_=AC"P':MJ\2ZS8\PE-:-Y1D;!4<;(4Q_*1
M>7=<S1#B03CUVIW+0SK*3=X+/K50$IEFJ2PD 1%(IN1>&&$JCS>V%7T]K>NC
MS1[)KBT0^O3/$+B;;9=UT&!4G&] +4SR*)E<HIOQBQ?!V@ICLB.^R]_9@5^A
M</B_?AC$MDIME/Z66+6AKH_DQ*UR^M$CA1O/.,NZZA7R6![C-:DIRBID\H'D
M0ARR)P=',1B9Z#+RBM#+?0>'KZ_NPQ[G24VRREIODC6^&T@R8PM-RP)+XGCY
MR2R[KJ6 ;33^EFKB,B\,VR@XD"Q978@LJ9%DLZ*W[RMCJ_0^(/.X[B/7U]3(
MY$'R'&JYP8[;9.QPWIL+I/DEA(I7C#UH,ZD\NZ[%9BSQWE:D7R50 S7)[AQV
MI[&UAXTCPZD$C/EVP.54$!563Q:^!JNAK:5"JO4TD\"ER=H:6-D!>P8[02+V
M!-KVOV&4(5U8\PK7\_?C:<YR.U^4:[2X>&TBR<Q7K6;,%Y,=J267-="I+P^+
MLKU*_33%N+;*3DXR3^,@'32-*J1-L9\LW*Y<-VXJ+DZ]R#1.8Y3FU-7SU-')
M% 9-R1-,7.^-T&W="BGFPO=AR'+&;-5))&456N?+:PL?6WSVQL6QMKVKS+ X
MUB(/1K*,6K2\YXERC(*2N7=<@3=0M LZ,W*,&?9,I.3#)O&R8I,"K%2:F7$
M<.4$^9^.S<8&&ZRLUVSOLGAI[&Z39+:)8YS-7<CRY'V7-=0.]B(>N6V'<,HX
M&^4%BFD5'%@:J)%<F;MNI1<"9P4X)D4@^OQ<Q\^'[/C[NS]^-:R;7-O;IG_3
MW+<7I7D-M":ZY*R1=;5&O\NZ\EE)IA<<-7''$>UKY6^3%VIWK:6L31Z\"0<,
M4 CD7!D55G()-U)]?7Y,,.CE28VOOVPFO.7F&C^364'B"L9RA)R->9<UT&5D
MG.4&6/FT,K% CE)1H*+$]2?FDA=N6QRE7:=F(Y$RH)<=U/E%1G>6^!4TD44G
M'CEW3,X3:@<$=1'-S<6Y>7F.^_3RK$^YMQ%B+"WSW^;%U>;VM4V2QGF@FC^3
M@@:3BC+-"D(LV7-<PEW<G?[#B^7C';,H92,S%DT;T>23?&6=(KE5=,@016(9
M<Z.MTEINLR UIJIJ>;PD0A. 9#;A\2^[B1I;VPM:_?\ '74SK-MV@BU[WPF7
MQ_ME;=D*YF=II#DQK PV$K'C%Q%N<N:ZC+*R\Q>ZY:6[]$J>43,QCDV4.Y;K
M&.Z(Y!TH@!&YTA45)Q;I>Z/\UZ0<JRFARJJH*26@KIJJ5J]YT1XY(!&JQF"G
MJ&WAA<AE4;3>Y( QE9771T,LDDBNP= H"6O<&_.Y'+&HQT5MRTV,G\Q*Z4Y'
M/ 2V#ZOC%&-3RWKN$LG,P5_MEL</E2FR@+,(U5C/M6Z!B.C.1=HN 4;$2!-5
M2.B'H_S;H^RS-J'-:J@JI*^MAJ8GH)*AT5(X3&5DX]-3D,2;@*&%NT]V(S2N
MCKIHY(T= D90APM_;$W!!/(^?#B8GG]K,?9GS3DA_H]E![$Y+KV)X>(8M,N:
MY>,&*]!:W!&45D05RDFV*D[-86@L!;KKG."+D7!$!!(%>WL:S"5#O=KV&7L\
MY#<:19.-%Y6GZ!*PK-'+FN@OH]"I8]B:B^3DP4RB1 JKA_'JN&O95G)#-#IF
M5,DL)DBO7U]?WL*F Y[:[$MSV,LDQH]D^19YCRG7KU (1V7-<^T1D9#X?QOC
MQ9K+@XRD@D1\K+4V1>)%9G=(>+W+(QURN3+MT6&%+!MLVLQ;9]CIR7T;RA(-
M\S9YD,K02,=EW7,5HN%=XVQK3"1\MVG*2!"R99"ER#HQ69W34&;EF(.!6,LB
MBPQJNHCW;37JJY<@;/I%DF:<Y"V4SQFF-6@LNZ[F190&5;T_M4+%ONWY09G"
M7CV3M-O)E;E69E=%/V5TX2Y*C'Q?1_;R]& Y #R8VW6"V[58-PQ#XUL.C>49
M:4CK;EF?5?PV7-<S,#M+_ER]9 C$D^VY3:.!<,XJTLVCXHH@F#]NY*@HLW!)
M=2<,8^M-IVMPKKM1L.6#1O)\I.5>$G8M[)Q&7==#12ZTK.3<HDHU,\RBT=F3
M31DT4U!5;)&ZU-0"E$H%,9ABC"=FVNQGJS0<$2^CF3WUBJF(&6.WTO'9=US-
M#.)-M7CPYWK47.4F[XS 5S J456B3@4N?- #^3P!M8V[.=OJPQ'N0HNXSO3Y
MWKNGIA?"VIQKNKB LP?+NOOB L\ICP:B$@94N3!D/%(/Q[0*@,1>=D\KL@K?
M0N/):= 6J%UBFHCFF1&D74:9P8N-7\<TZYD*PIM\ "<;AC:%XNS?RXENMCDO
MLU!X%X-PI=_!X>[JVOM O[;LO?N^(]\@<Z63:[*6J^0L#0VCF3V%BMV(GN/6
M,Q)Y=US+#-Y-S DB2/79FV4G#T&)5BBJ846BK@$N7) 3^3QZU/,D^4G'&OW=
MF,K9*U[5YHP!;,20.C>4(N:GF]01:R,OEW7(L8D-=MM;GW)EQ9Y3=.@!=K#.
M$D 3;G^CJ(@IT$Q.H2,,9&R]PVIS9B<:! :-Y1BI$<DX,N0/)C+FN0,_%^+<
MX8[R=,MA['E-TL#Q_#4]^RC !(4323EH5RLW:BLY2@\[BWQ]W[?B(L>S#R7[
MOV$?7C$V;M.UF;Z'5*I7]',H13V S?@+*#EQ,9=US*U6A\39CIF19I@B+/*3
MM3QE(Q5;=LXPITRMAD%VY73ANW%5=.<,*F8+OM1D6XZZ6*+T9RDR:X<S4ODN
M=1?Y=UR*XDXA7$&5\>E8Q(-\IKIFD E;[&/#%=J-6W8&;XP.!<%006?%]'GY
M]OK?TX=]_3\]OV8P,QVO:O)&0]<K?&:.918,<.9%N5PGFS_+NN7:Y)A8\,9(
MQNT;1(-\IK(G=HR]RCGK@KM5JB$<V>&35.Y*BW6T.H\KGSC*IJ"G>..222%E
M>4L$M'(&:Y178&P-NJ>=OBO02"*3>P) !%AV\_3A(M$UM=.9MU^R<VT?R<E$
MXD?9.=3;%?+>N82,B2[T)U5(XL6">4U6YC-7K@KAX#I=L!6Q3&1,JIR2'0Z4
MTM79!5U-14STTR34W!58&E+!N*CW(DB06LA%]Q-R.5KD7:FH695"AA9K\[6[
M"/E^K&P7*Y[4V383"&7VNC.4D(3%].S+7)>-<9=UQ"4?N\CEH 12T<">4U&@
MMV7L3?>,!<.6ZA>T->SIN.:P)<\QB8#W+:D^T+3.?SC64@KS? <CB<T2.7=<
M?'!IIYD2+MY) H!E/L?BLK!BHW.877:NUG(!6PI=)4&&*(NX;5,-H+KG-31K
M*1Z_9L&X[Q<TB29=UR\<(3%/O.1[0_D' &RF5F$:Z97&.0:&3='="Y;/ 6;I
M)%046CG]'KW\Q\F&&1M]>V]LNS>2<WHZ69#:U^YXLQ-1(^*6RUKR>8;2- FL
ME24H[=E)E#L163Q*YQY&!D72RYE&SSKT$"@B9;Q_]E7]CKJCIZ;19TYG60Y0
M--)G"U?LTU>#.<Q>A:'@"BHZH%4\&?B<0QF[+MW<[<ITWGM/DOA?'BFE\(X6
MWA;.KP^)>^YAV[QV>3Y-SUZ4VTPYE'/%YF=)<E2L9E9KBA&&:QF6]=BO8\]#
MB+/'28R1'64D4 *Z5FVQV(M5W F337[0" E3 _87V-G1+G?0OT;_ &F9_F.5
MYI7C/\US;PK*#5&DX%='1K%'>LIZ:;BJ:=RXX10!EVLQO;7Y]F46:Y@]9#&\
M:-%''MDV[@8P03U218]HY^G#A8UNNU%)RYL;D)_HSE-W&YEM>/I^!9-,NZX]
MNC&U1Q95J*^1E@6RFDW*NXDH-RZ:=D7=$,R50,L=)<5$2=_<[]G=YN1O\I_=
MY3C38IP==-J,6O<W.9?1G*<@3)^=;CE.(+'9=UQ$S"'L<168]JPD0<Y3;@$D
MBK"N3N"MA7;%341%-RH83E)/KZ]OK\N&/< W7:G$L1DN.FM&<I2*MVSSFC*K
M!2,R[KB*;6%R3>I.T1#!YVK*;8P2;)D^20D2HE5:E<D.5LY<)=%46&*M>;MM
M1AZD62L3>C.4Y-W-9FSYDE!>+R[KB+=*)ROFB]9(A&2O:LJ-U/&$?$6ADRE"
MD(9L610<D:+N6P).%&&-=U^GML,2X$?8GF]'LFR$TZLF<IDLC%Y=UT-&$0RE
ME/(%[ATA%UE%NY%6/C;:Q:2/ZWZ /6[HK8SA J2RJ]B.5^?=R^N_R889G%%1
MW!H6JV/L#R>E^0'=CJ6!JYBI_+,<MZ]FA'$W#T-K57#]H=QDY!\:,4?('71,
MLS1="U$HG;$5YIAY%S?['_568:IS+/(<UR%::LSNJS**.2:O$PAGK)*A%D5<
MO=!*$8!@LC+N! 8CF>3PYW3QTB4YBE++%PRP"6N5L2.L.0OYNSL[L.^C,[8I
MZ9M=;1T>R8-J;ZT,\*&G/FNZZ^(#6%MC!&D&DRF'*'C'Q.:23%R4XLNV=B$#
MBTZ_FAQZY L /(+8XQCW,LWMCDC3W(6ND5H]DUE:+?@"9Q*QFY#+NN@0+:;D
MJ*K5TI%V9OE%=^6+(]."ZAD62KH&W,2MC*_0N(8$JRBUV5EY^5@1]?[CBY X
MBF@D()6*:&4@6N1'(KD"_*Y"V%[#SC'SA.O! >$H78(-2ZV,BJ).(A8QC9EQ
M)T!+'R#)XL!>5IZ724(U,4G,O(3F+TNB7F(=#TW15G<%2D[5^6%4,A(#55SN
MC= !>GMVL+DGEYSCZ&:^^S T)JS0NI]+46F]5T]9GF15F5T]15)E(IH9ZB'A
MI).8LSEEX2GFQCC=R.Q<?0;F%GMOD2KPD%$Z49'9.(O)N(;LJK(9;UW(BI'X
M]RA4KS*-DQ;90<'%X\CJ^Z:L"F(5$SU9 '"S=$5%B<2T!T&:FTGK#*-15V99
M)/2Y?-4230TLU:\[B6FG@41B6AACN&E!):1; &US88\)5^<T]5224Z1RJSA0
M&;;86(//F?)Y#AZ\PRVRNP9\.TX=0K_C>-KVQ>#,EV&XVS)^#)&'B*SC?($3
M:IU0\?4\ASL\]=K1\>LBQ:L8Q<RKI1(J@II"=0OJ8BX(_9^_Z/1CCF.F!R$4
M(=-0A5$U"F(HF<H'(<AP$IB'*8!*8IBB(&*(" @(@(" \3AC6:92*7CBKP]'
MQY4*O0Z77FIF4!4*9 1-7J\&R,LJX,TAZ_!M&,3&-3+K++F;LFB"0K+*J"3I
MJ',+#&KUW!^%J@\K,A4\08NJ[^EKW-S3GU=H%3A'E3<Y'?!)Y"<5ES&Q+9:!
M7ODD4LA<U8L[52T/@!W.&?. !3AAA03Q/BQ%O?V:6-,?I-,KO7$EE)JG3:Z1
MODJ1=Q;:#=O[^@6-!*Y/74(S:0[AU8BR*ZT6U;1ZBAFB"2)6&-4AM<L$5.$J
MD%0L.XLQVVQVPMS+%RE%QS3*PIBLU[:N&ML=XW)$0C5&F.K 5RH>;/ )L F3
MB/C0KLIC%,PQQJIO@9[^TQMA'7>^93UKE<.80R51LB-<K4[5]U6=Q+\YQ]>4
M,@,#6;,\CE"?BX>TVR;:IDR!>X"LEGK$T=3!"]D4EECIL,=C+UJ]K/E"XQN1
M,EZ[8+R)D"'*B6(O5ZQ'0+;<8HK<2"W+&V>?K\A-L2H"FF*(-7R0)"0@D O1
M+R88<U"DTQK;GN0&U1K#>^25?85.1NR$!%(VY_58I\[DXNM/;(FT+,NJ_&R4
M@_D&$,N]4CF;YZ[=MVR:[E90[#%%-HM(QU"A6L?4ZJT2N!(RTN$!3:]$5B%"
M6GI%S,3DH$5",V+$)&9EGCN4EGO4=ID9%TY>O%5G*ZJIF&&X;ZQZV-,F*YI:
MZ]X.;9C76.Y7RRWQ-0D<F+.%#=-1=6^)P!;2HLH?RSJGE1.8WE&,(]_###X\
M,,14VIRWEG#$!5+;0(.@2=8<69E!WZ8O WDZ-,BY(3=3;%D*-#3D@I",#(':
MR)NPJ&(\?Q@JJ,X_M\@THW6E17*I&X<!SNY2+')(J&P(\:42*.]@9' +#D&K
M"AHW90S2H5.P;;,ADC1V%R#>-7:5[7/#C;:K'L8ZP;:Y4@<%X[S)+Q^-Z][+
M9:;@7$.I7,D6!2:792\R$;8ZFU47J<LTJSFI0SFW.U+6PBY1O' 8 9BY%!JX
MO&-S44E.@O)51TPX9MNBGF*(ZR-?8(UDFA0=K@N R[KJM!*B*HE)NE.\MY!<
MK)&BEE,:V+%V"2D]J'82K%;,V9F[;F\XZUTH.;ZG&P%G?24Y(0]M;'J\RUJ3
M1>+/,1TFG+O7]MC;'1X^,FHE5@[FFT3D)VFN0Q6U;DD54EPM2L$D@L 8ZBG2
M=&D?8I$D,4T9,BI(4WJYVH868W ;8RF]R--RSAB5DAF,150&:Z2/&X",R*]K
M EA,@L+KNW #9L@;29 A<?8#MU7J-4=#EZN.Y^PV%NTR]DBDU%9O!P\LQC6(
MXYQJZMTHA8%9)XG$3DW7JHS%&)5Z]L#UVW9%NSIPJEX+L L;.IDC8,[!H5"=
M4LB';(TG6>[*EE4DMLL0/Q:83]4L9$0JC@A583DOU@KL T00[4(#/=F  +(^
MS6WMYP'%84D8^C1MA:9(CWJLW-*0V1%V#69)'QHQ,!%0T17G=ECG,L_DNTE5
ML[!DHVCV+AH+-:44%-L91X1+$M^HCF&,E3)42"&HD5%D4F% )(8H69FL6JHV
M7Q<<K"N'KP1RNRKNDA65K,%AC>:%))#&X$K6CDEE4;184[JQ#/&&6LQ[1WN@
M67%L$RJM<K3._4ME8W,S<(?*=Q;%LCIZS:N*!%_,EIUG:$FXU%P9VL[EI!HB
M_3$@QK5PFW>K(5%$\.GI5D$D<4D2Q.H96J4DEG1Y(^(%1!&D4;-N;EQE+;44
ML:%=C1P5+(5>593+&2I%.T:0,JO8[V,C2N%(0#Q+ %F8*%'-6R=WQSF*H8TC
M8.L1L)8J[ R[>UVBNY?L!+',2D](14C5JXCCNDSL?&R4&Q9-))RI995F=9*:
M:'*S3:LGKKBB$"2I>%K@(\("BP>1)"^^178K"!'L"$EB S!G*(5W5R=2GCE'
M,N)BQ_FQM&(BBL@)E)DWL5ZJW"%5WMN"ZKG/<*\8OV!J^%:]CFN2[272HLFX
MGIVUGBG<G'6BP'K;R+KS K4&_CXCYRS4CBO'JB964?//Y1JS8HL7+JJF19I"
MC/LVS+"R@%GVR"G*3+;D417JI9%%R$I-EQ)50 Q/>*#BJ-S-$\B@D*A:/C[H
MBQYJQ*4T:%MH+5BOS2GGMF7G:_)-8VHA\"Q6)U)FORAJTFWF48ZY.W[QK)2U
M10GK"$Y%PKRE0L5!P]AG9$&4[)M7ZQJ1+E7.U++0G:(IU$QE#,$,<EB#RVQ"
MGFD,K,UE8&58454-[26&^6T8F:T21L.MOCW "QW2F94$5@;H1'O8LW(L5)"Q
MJSLN*[424+LC-8.FQQ6XBO9'7V<9,I7&VQEDAV%A@V:K6(F(=3'<A4'EE&;*
MZ!%FCD)@N>.E('M;%@Z?,22-,"F5)"1;AM."ZV*L$2HGCL&X=K14\RRE3(%,
M$K7W*T:S,.&8[ D21Q,%868;I(87-U#=4O/#PPP5FXJCVI#X28;;J7G<\IX3
MCHNJ.IL<C62)4C$'C]0Q<4-Z0G.5;)2%O255JT@[E+ F9H\I\>"\^C&2;=7L
M:/BIV\>50KQ58WLT<-8TUP0(9X:CATT1!&Z031@,[QW$;2@,5X+JT2E8FL;D
M/)2"*PN98I8@U2Q'+A-#(S*@D(WB$@7,\96Y@?8[(N2LC.J);K-K(SDZ]:,D
M0MDJ%&N-]E\C]75):4C(QNE6K14ZL5@+=))@^F)=1=^T=H%.I%-.S/4'*",!
MHED-V)IPY$9#*LIE2-BQ-F1$.]"C*7+E+E1VQ->.4Q^U\<JJ9.JS1F(RC: &
M#NX*L"K; @?FQ ./*CMQ>)G-%EQ@.&)&Z5.!M+BM/,H8[F6;8M:>^-F4>5A;
ML:W]2K7HX1:$K&/IFQT=K=*VG&N22I72#94B04P S1<1NIR(5CSCD8!N0M>2
M"[*$M.BJ&8 R6NPKF CD**P;D&9.R1%(![?<IK@L5X3EF"D!+\BC:S[?Y#S?
MDS(V/K3BL*8>BKVL)-0&=M3<5CQ8WI:U:CYQ:9B&,;87\ZK/6ADHM4W+ANFX
MIKM5 BK&28.U*PJ-1FI60%A%$U@K &9WJ>)"$-I;Q1QPL3LYEG!"$QJ8D'#J
M1#8LID=0UU!,:JFR3=<H!(Q<K=K!62Q;9(P4M>]L;UFT^5XZP4>I8Q?8]JBD
MC$/W5Q;V=G8W'73;<MMD6L8":U#K"1XUL=Q4[LM%9%9=-Z:5@XYFBS>O[3\J
M&6J5D210+1NP9(B8&E#23)=)$9U8#@[BB1L9=DCK&*E"BLBIR'DB>1@712LD
M@694*1PMUUD"L#>0!'9UX)D56;%6']M[9E3%N3K+'U&BSE]H&-GUKA*O1+9<
MISV:SC EMBBMD(^U8TQ_+Q\3*6ZGR,/&N&B,RJX #B01_69WU=0K)!)/&C+U
MP$CD!)1'&Y3,5'$!2SAP(0Q,4JJO%C>-:8 'GBAE==K$!Y8R-IL4W&.Y,9!2
M2-U)EV@21EF$;K(65IN]V;)1:YJ/,3T>[P$1292:@+;C9SE!A#*6N(@FTI(U
MF90R!1H"0.=@]<IQJR4.BZE7JZB*$-'R4D28CX2OAKPYG,@C"3JD<C+NCD@:
M:CB-2$1C(41*B>8JMV9*&?;R9'Q0I/$B0K<M$6EB!VR12\*KD$!9APPS-3Q1
M!F*J'JXBQ%BI<_$&XF1,GZX9'S.GBQ)68IQHQG!-6#2X,8FR/%H>"6L3M.$F
M85&YG8T^6D9/Q@VB8Z4>3#&+%I!"ZFC+,D8J$6**!U?W:1%)9=P2)Q3WJ"L9
M+;$>6:(H=C%J9W!$4B/BJ+KS21'F(XI'NIV[I$>J"TX9[*'DCA@D#W*@52 K
MO1DQB5[<K)4WJE><^#B<K>Q5J2KT7$13J.ND9&R:,M!4EU.6->O2D,VO1XVH
M3MCL$4]C8Z-=/IPM65/"N%!>@=O35@0)$Z'>)6EL/;$1H9#$UE[YPJQJIL5=
MA(UH"KM53@32O&QVA$0EAR!<L5D4;NZ)1QF87NAX:@SJR#,+N+D$=;X3,SC%
M[2)GK/D^M8_KD;/,\C,6,K%V1:,12MK6KQM)F\G/4FKEW(QHPD?5'3UVM#/)
M=NO['Q+(A<J(UCFIXHW#<8U6XD%BBTYKGB.V,,?NBGI89^L$$*5 ,I C)-$1
MXD=1(>R!:<BPVAGE\$21"TA5;PSU$D75+\5H=L=W<*'+L6P%[@,%5?(J=?K4
MID&?G0B6-&3@LPQB-G<@YE"EA8-I*X_;7V$D7#*/%R68LE(2@FA45W+U1.+.
ME(EM2!D:)40R%UW,@9 Q 1G8A[F- M@2)BG*X8HUL(K.LS.PC$;;58@[><B(
MH96"N^XL0."'-[, ZAL-G<=T<FUK#L3DHVM,]$6P+8SK<UC&W9#QW'-GR3N/
MDE7#RMY>B[#+8O;&AGS Z$BVM\M7GAG+=Q E9H6%Q&,7D261HMI#+*);W.QH
MRD:2)(0;B:)MX4"G,KR'>T*OPG4U(-PDW<BFPJ5NZR!I&C9+ !HI++O!G$:(
M"G%*"16'N9]RKGC+#F$,BQ-$JLT\S S2(]EI&P2D32*9+NVT<Z3(]<.HU"7?
MQS%FXFI9PNJE$J23*KO&,5UDU-0<>XF8".H,"L"!!QTD8;>*$X3N$0G<K/ T
MCPHQWF3A1%=Q<I,0#PM*X8$3&)HT*L8]W&2,O)[4@3I%%(Z@H SR[@B@G*RA
MMEEVL47"<O2<*-;%;,M40MNEF2TS(RL/1%T4*Y(R9)+V+QTB^>QC&#D9Z51>
M=-@63<P[&NQIW,[-LVO%<\?"JJB!3=((S(78$;M@9GA)'560[!!&Q)#S2QN%
M,*2LM,1#P12L;M)-P0JC;R8A$F ;KE+L)76VZ.)) Q$AC#8,ENO),*EEZ6F&
MV*L?W/']>H,W4<;WB\'"S9"5FZ+ WB>:0R$>FFK(-I5U,.:#19*LM;(1[:8A
M\N^;*% (LLS(L3E48U!&82TO#B!XQACECB7JFY6HF#&:)67A&)H09 6D,1.L
M(]WB=](L[32<H5D<2$@FX\5#L"S$L)5?B 1]5>(F9RVLV!Q/?6L*SH&,EJ[9
M*Y6+#0&,T&4SW*YR,Q+(QTSC^.-6ZO,5AK=()#IOG'CB3B8DB3^).LY3CPF)
M.+1QAJIJ9G5BM9%!NC[)*:29DDJT+[5V0Q@.X+7O>X5=A>DM>F2H *;Z:64K
M)R,<T<*2)3N%NVZ9V,:$*?:FVYKHKG9&V5O-;V 98;K=5KB\:A7Z!/S<U)QF
M7;)(B2ZSL]%*LT4L:XXMM>K:D>A!*+-W%UL,*C(G<BX*"$8R<OAHB DDD!-H
MXZA8+BX+ Q)+O#R!(;^, *<3<@"O)M62.]4@*11O_/DBDDL;64HQ0*54M(02
M"=P2S<U3<R. WUOVAS]2=@RXCEJ1BY>)D+K08VJ(,OFIJW*ZTFWRB3>>LT N
MG5EZ*DI0(Y19S9"3-DC$P7BY----)(\,K+J5>-((Y"JE7F64(3>-(Z05$<YW
M@ Q22G@6%VW))MW/LC94>*CXB E&B5XRP'7E-087I[*2PE" 3"ZA=LD5R%XC
MQKE@VRR7$[9I8 :8E5D*N[>5A",L*4=<5'<G#R*$4K9K>G8F\(M0F4571E'G
M.,?3",BL-6EVIEB2<I#QYHIP)FD5SL""1F/9PE2&N9"^\ .99:>E5>&2 M:@
MZTD4JK-0.#'&Z]8OM4+VEY&GI$*KMN4"135#L7 NU*WM8W1VV^!V#R)-;%V#
M%+VK0M<J,):E:_'NW]4S*_G;3&)U"/L*5FB[<SHJ6)63%U(/EXY)JXMKDZ/B
MUPW<.22RI8Y)!:5"[W#6J?%@;3'P99(TWM)M#\5$6<",'JR*BEG5K1/XIE"V
M(/@YWWW!N,BLX"Q[BAB9FB)DMUD+,%1E);^M[=92LNSESUX0Q:PC5XA[,HQ#
MZ3;W- 8^"90UY6A[G8YHT*6KOH:;EZW5!3CZ])+2:$5D.) G:9&%FD$JH4$U
M/+*LB"2-9R4-PL<B24J0Q/?K,T@EG)9!;Q0*JT6Z7$S6AEB0JS(YI^LI4EUD
M21YG2Q*@1$*H#D<U<,5D9(\9.O\ LOG;(N638^R!0Z#'LF)<DM[*I2VV5!D:
M@\IMB)"UEU-R=MJD53'4;?&I%I*() 6*8? FJUZI)VU2DGC%$!)%)(21:GBE
M0\@IG>2,-2'=9C,D;ER0NSQ,IW%#"\M,H:-U0VN:AXB.9)A6*1A4K:XX9D18
M[,0WC4!4.)4C5,0[76NY2V1%;S78RNQE'96YRZJ,#1<[25ZBUJ]9?$K)I(2$
MCCIA5Y]Q(,Q;OP0IRLLLNF_;.XHDC$IJ2)K8/W)X18NS14[JJ @"6=+M P>T
MA:*4F%G"!0R.[A$(M<*_=)@!"JLLR;W*]:.(D"8;24"R(.*JER2K*@)?MR=<
M=H+UF>)MDS-56$8R,32U;7'8ZB:WEZ"MS)Z*[Y)K7)B:R32*C6I)XLNQ4BNU
M0!ED3R*:ZR:8L$Q6XJ<;*=Y5/%=%C(*<D9G@,Q0*;RWO8*0I&WF;%E!H7K5*
M0GQ<;/*NYP2P6.=8A(2/%@%27*%MPN%!.UR-8UQW&R#F>IY<G)G%2+*3Q?6[
M%)J,6!;/7&[BUQ,Y<FS6A.%KU#Q)QD%8*$@)%Q.,P6C45)=;KT6@%;(J53B.
M*D>I259=K%4(!5957B!Y54WD5!L22Q4L4G11>1)%$H"U6E.P,8:V\L-S176
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MVZ2M2W1:9DYB>.24LU]NQ(ZB2,)R +5#0I!%=MO%F7<P%QBN(!WJ$D.PPNB
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M*VJQQU=S*DU-F* GHHK5JP1Q(ZG7*E=CWB**:!@EH2*)PW%("VEBKGD" F%
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M062T31;[!YMISN!J^/DFDE!LWZMZL#NX4^%;,X]S,J29&RT$.]=EVQMK245
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MT9VR5@*X=E4:^=-9NHQ<'9K%=1KF8&^Y)MQ9F%%3IN0;E9.,&6JW /:HEV,
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M123<R9!8"G<2NB7W1\E522Z-;E^/MM*TIU]=4ZL/Z]*UB]WB6"SW&S9)ILA
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MFA1XGCX2NRN51RS&\0FC97=C$V/.6-+#Q.K.R4=@H)L#6QRNLL;\7:KHC%5
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M:-TEZ:Q&AJ:=BW$+TZ2GB7=B9::.4%0\6X21/U58%'CZRAG!96FF96@J% V
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M=XA1@O#CG,S)M%Y"3&=A<W9 IB0IP]NQ@76S,S&M.H78%M[0&%&O;AW#CB6
M =CQ&#![AAM4]46PZ6 <'M,#U:7K+.P%GT9:?7GA.C5*M46K-1=DR9J(HL:Q
M',Q>*+"R[6[DIIW*RCAPN=/M:;)%HS;UM(62-"/<PXW7//>Y>VWDJ@%C[4 L
MQ9W+.Q.* MG=[^WV7%ARV+M'/VQY64 G:JJJH% YZ=MK4\GWG'\!6<7UE6>D
ME[[4I:3?M;K5:@\K;"O2R$R6701NM&R!6;(0KEFDBO!RD L18BG7H'1=(H+H
MV+-QH6[%CXS%NJPNU/+$JE&5@P<R;;@@QDAP05&+H(X<P/-G5%5;$7\;&[$.
M""A4)N["&%T(L2#$?(BMOP7KSCFHV.M5(D]7\F*7-_C5BCCSL%XI"<[-&&!3
MDJGB>K5:#G7#J3CIR9=U[' !U#=Q&.IL3RCF9XKE=&DI05$HCIY(9([LJKQ:
M:KIX67<9/%PJ4WJ!%&S$QJ-K;9(C1PE6X;8TDT<D4AL7+13T<TVX+MO)*5D"
M%C(ZCQI(*=28>G+5XSUQQNB[1C68=EFU6$7$Q3&(90<,XLLPO"U\B$=%0;1X
MK Q2C2)<S*<-%GG'+-6768MUWJA OS@@P@L79:2D5W)/C'6FB#. 2=BL1<)>
MRCD HZHLQG<9F"A ]14.J WV!YG;;NL-Q!)YD$]Q9R-[,%NC@>[YDMM']B>&
M8"V14>SD#6NY$M&.JS=7:1&$J%=K<2_NU(NQVT3&6!=K,2R"+)J6206%(KTJ
M;=U&RV&%;B2N  . PC]KUZG=$8GE&T[HDC$R%#VLZ,5<)M.3O7AQJ26/&4N#
M?J06?BK'S%I9'X1#_P U4=;@N&$R,)05JJ^'L7UR\HQ#:Y05#JT1:&\"DR0A
M6\['PS-K)HQ:<:U81Q623I)4B L&$>R,0H':L&2!DVJ67.RO*[(258@W(87.
MT;B S.RKNOM5G<JM@68BYQHE*H%(M8OM%U)";V*!BH52P3:'9556:Y"J#8:[
M>=9=>LFV)>VY$POC>[6=RR".<3UGJ<1,RBT?U:")F"CQ\V66,R.DV;$5:B;J
M%BMT 53/U2?1L* A+* I9@S$<B64J5)\I!52#W$ ]HQ=)) !)( ( N>0.ZX'
MD]LW9_LCY3CEKNS RL+FJ,&"RS(LHR2B6[:A5%@O@^+A*CD!C*P39Q'VM2Y)
MPUI)1U8A%DN=Q7U+7.(N'+Y%HT: C%LWU=,6:J!D8R.U1!(C.>JT+54YJE?A
MCBF3?N6':I+-NW.2%43,%%.M@(XTBFC9$Y/O6GA%*T8<B(*5]U!=0HX910I9
MA[NQ3[1;-EL66FM6N#92+$^/:_$P@8YB';F4&*M%D"UGF[;/X/N,XO#QDVE!
M*L4:Y<8$Q8-S/OHM!"248R+FNCX:YDSD,5>HB8@V3;"CQ$,^W8QD$<=9"/&,
M!+/2MNCABFXE%5SRU8SR9:>< @[[S21G:J!BZ;"7II21$"R03H1)(\0C[=]_
M+W?P<^+6)QQ*O44*V\<58;G6X:)2@\PTAG:[U4K-*DA"35AB*RXHM8FH^=A$
MY]1_,,ZGC^0?NZR@6O,Y*.&/<65I&25H9/[U T@*<U4,:X(O)DEJEI&:94OU
MP84>=HS+L4B:8 27B4*H$QL.9M'3.S7 :.E%240M>ZGBN45Q'N<<*(W3:S%8
ME,OTK&V]%@G[59,<1[!UE="@NS6B*HRV780)7&[:50F(^<<4LDU&X?5.@DR:
MR'S15I-O)/AC$H9)HZ!@2W0BZNE^M,U<B;39]\=0Y$545V\W*@4JVD+H:9'[
M&X-56.LC6 X<5$_,75EE1%WTUPW-0Q:H)V!6\(9"21Q>S9#E4(4Y# 8ARE.0
MQ1YE,4P )3 (><! 0$!](#Q!!!(/(@V(\A&* 00".8(N#Y0<-M"89Q+6[C(9
M#@<;TJ)O<J,D:1N#&N1;>R.S3"Z;J6%68(V!]SDW"22S_HKE[6=,AE^LZ!>4
M)XM65.HK#:P7D&7=OVFW:NX!K'EN :UP")?QA5GZQ4@J6%]I"E 1?L(0E+CG
MM)%[$@N7PPP<,,'##!PPP<,,'##!PPP<,,'##!PPP<,,<_O"32E3KVO3*U6Y
ME*/651R%7K2Q!LTI3N"2DH2+L#T@W(F0ZU;ZB6NN69'K!/QG7GZB]A=P+2/,
MRD7#5^UI4 U5$I9$W3/'OD"F-5E@EBD8[P>N(W8Q!2CF0*!(BEB;B@F&J #-
M>*/JQE@Y*U,#I8JRV02*G&+;D6'B$HYVJ6-R<YAKYJ!AN+K,,-S8RN6'L%"X
MJ0A8^OUK/"<$ZNZ2D:W5Q E2*^SISEO&K7^%GF35A7Y-K#,5)6/>'?&3/<G1
MN-2[H^*W@AF,3,X,2BF%ZAMQNKTY(*)V'B+PU1C&4HA?Q545?A@3)'Q@%.\M
M*IX(L.R>YCD/MD*.'9D60.W^84)*8U*U+AJG>K?8+H%M67KD2>&,>*DY&DR#
MJ9EJY:BY RYC-=L;':$*XK$*K9,B2,T_3:NU!9S;M0[YE5.2U92R!N+MHXJA
MI39?"8%6A+U95GC DJ@Z!XPK/PZJ<';:20(UVTE;&R<'?42T_#4F\$K^&*E.
MIVO>.%@75PR)OIX"G(I&>JF ()W6,)8MK[^1L,N]B:1 ,G4C;'$8ZL3I=)BD
M"AY9>&GK5%'<E,(I_K&RS[<B9$R$F)'HBZ5KJ"&E8@W 6-0Q)+-LC1=\C%(]
MTKVWRL(T#2,[*H4C%F'FFXKLW/*^P6"IOE=^&@5W"QINV1KO;;&%4FX.%#(V
M%\6Y<\4CD>DPUL/!]M)%JR*:Q5VS64!N65C1<-5FZ[B'ERLVA9>%<J+1,J5J
MV+(,W)4$@+8'58./;  >4, =P#J;JX5NLH<,%;FMCSQ>W-MVW(%]PL2"K6(W
M*PLR,02"RD$CD3;EARD$$&J"+9JBDV;-TDT&[=!,B*"""1 321123*5-))(A
M2D33(4I"$*!2@   <2S,S%F)9F)9F8DLS$W))/,DGF2>9/,XI50JA5 55 55
M L  +  #D !R '8,<V-E\SU2MYM1K%]UAI%\<5VOU6;I64[1*14@P@R3D\_8
MJO[L=A3[1)XTI\7+L6ZK"?LPMX^1E$7ZT4F9>)7<)J9!+/ML(W:>GIS( #=)
MB0MFN 9SXQ:> LKNQLI4/N-<_4A5B3)'PZB;9;L>%4+V0F[1 %#/*!L5=NX,
M5L(];-1R,)MWC2GU1EBRH5J"KF(II**0<S<3 RL="W]K$1U:OU=AG[2FNXB)
MD+.G/UQ>PP2SR&18-U:NL+B2D@9WJ-BU2S.9F:.KC4 7*G>E'"LD>XD)6P1\
M6)=EI.--E*7,6[;;JK"C  0&6GJ26;M6RU<\B2;0"U',ZI(^XE#'%FK6X@4-
MVP]'H\WH\WQ>YQ8/8>[%6.&B$?;<7;YTZLLJ$F^H[S*/BM*XR496(JQR$A(Q
M,5-2+Z$A*]@4Z;J$9%MB1R2RF5(Z05C8&UR;PR9X5PT<54"^W1NIM@J4C[V9
M((*@$N!PPG6AC+!=R!:VBY,972.:P *LBD.6>GDD![ TT\6U48[RS6>2V[:Q
M:EJ;E51)'[F<4XC!PPQCNVS9VV6;/&R+QLJ02K-7"*;A%<GGZM1%4IDU $0#
MD4X"41 /N\0>0O:Y7K #MW+S4CR," 0>T&Q&';R[C<&_98BQ!\Q!(([Q<8YS
M:C[(5K+67<C5&*U\K&,)NO/;4VG)>OQZ;>PQ;:,&F/HECD4/8A7_ !=-V96T
M2I48]M)S"(RE/L0(KOFC=*36O11@T@E61-O#IV9(R>'Q'DJ$,*WVDM!''&QN
M@(XK K& AE3^+J3$1N;?( S6XFP+&>*?;=25BUB&LR\)@6+.(^D/%K#!PPQ'
M7;A*>7UESBE6%G3>P'QQ9 BE6,P>!=E=]A.).SRJ<O7S-E3 !BE+[(( KD1[
M*>=AR+FD6UN6WBK@%?"J3>"N\&,54)D4Q[X^*#&&!AXB<8$Q[ANQ=A]LW9?@
MU&TDVL_ DV'=M?AV?:>+L?A6XFUMMC""MUN!CM5K,KDR@9:94]&YL;;,O<<V
M9?6:5BXF!BHJ5&TR5LM6UCHJE5(YCP;R*S7(S=@Z_@5*^=-%214OSR+&:9B2
MO!F=U)D"HK\1!&LD9"$[V("*>+<]@C:U[$(=^*J@,98%C(V%F8,LG$9'&]1L
M7FQ 6P-R74D++73FW8AO6-IZS8;/8W$ ]NT@E+O;3F6(SG*O)]K"P**JAKG"
MY6S S1;I1@1:"$(-H;*L02,N:':D>$</*G#".&]@K"1D&PH?=65RQ*+Q"64C
M<&>P4(2-FT4J5,DMK[QL5NON  2Z +<[  ;VVK<L6Y[KX<+83$\IF7'Q:E$3
ML?#.VUDKEC%K/L)&6J-G0@) CY:IW6(B9>!D92K3A"BA),VLJVZ9B('73>M4
MUV#JP1XR)[(XC=F,<@)1P\,D5R 19XC()H6(8+-'&Q4VY7@P"2IUE,B!0Z&S
MH1(DG(_[%PABE'(M%)(H92;XB#F3"5HQYK+CVA@I.6^1@\O$LDA;Z)&Y@,.(
MXV<?VJ3,_H]*Q5>HO*TM5*LG+HTF'K$?<71VL'(E>R97,3'+L25R,&EI>LZ"
M*&2)IF#R22,*:50LO#*@B=B( [JZQIPR^Z11(8C6T=9R0\5HY%@78B*!44]S
M&7!*F%4:I81E&ED#A-JN4PU^:9.4@]4M<IC)\3+UYI#WB8;V",R!7<D9$J$C
M'&B[Q&U:6RG59:_-LGMVDX@:)L5<B9VS3DI4+,[A8J::KG8"X93,4X\.[8ID
MH I4@2"&I:*E+I%+$%3PJ*TJI,00\8J$W"5UD$0 B*I"[V"U9*NI9&EA62:S
MLC[F%/)U-\=Q8\)A>-3&S[NM71S/A'7-JPR=VE*ATZ0%!]DO%B-[C+6WME=2
M8-Y&2H5TGTAB92 **3BJOI%Y*3<,V*#-5\Z(Z?J/)JD8U$I)VL:44I)VM,IM
M3MX0LH"B.J8PWF=$4LTL@('9B()%X( 4$&K-4 -PBL&J/N?8Q;B4PXP$2NS*
M%BC9>=B(=[NXKH=%QUKIC'.U[E\E3=>B):M5*T3%-I)*FFTCY2AI,)FTQ%]O
MS)A)6,%F,? /SQ<Z23DZU/V95<T%&H*/D(=_"*R>4*J2FAF>5[!CMCCJI7-.
M#UQ/-"LD8(W 5(IIW?>$1[L2F*"->V+PR,(B]4!G,:+Q=JE>##(Z2@67Q(FB
M1"AD9>PN&_%WS(\7^*'$P[BOF>TWQ:ZL+)*-GG+#V/1W8UYJ/0 $&4HJWZL[
M]JB'5-W0JI)B8A2B.17;O#*K>%#^$3%@A+)N,C7VLP!(OV$@$]I /+&)3;?!
MX-M]O"2U[ VVBW86'R,PM_.;M/&W?^0IMZV,AX9Y(Y,@[-48>ELJ<Z,_H:./
MI:47G[2RF1JY9//V/ECV!F>;CG,H,W6UT&]@K%-%VG*PZ;Z'?6*&PK(W"@N:
MRB!#^V,*3'<8[;_%&6*Q(C9CMJHC'*TB*F34,!2LC;2O@]625W6$CI$0LHZG
M7X3-;KJ+212;XPI9NZJ/,$40,(B;JD^8CT>8CT YB/0\CF(]X]#R>?[WNY<4
MMS9N[F>7/ES\_/Y>?EQ;7VJ\[]4<^7/EV\N7R<L<;MCZ'$2&^V-I1S8;NK89
M*U8J?Q)*XS/D1&J0L.M$N7C)_4*[D9G8:%!RTE6B@M<Y[&<Q36;6T7%W+RQS
MO(_Q1<R]E6IFZBNP:I9F8E4"ME\2K$TP+1PD;9=L<HC:7P@<$\8QR&JL7=31
M'=M BC4*.3%A63EI%C(1I[B6(L8VDV^"H)!P5E4ZW+TE_;-_HZ]UE+/<8Y@<
MT03)Y!S%7S!5Z0RJ,?3*LD]E("(+;(S$4_5G,@RM9'%CEX,B[Q6QRLK'M)JR
M5R%-(4T.U6#D=5H\P,AD-B"8*R.%'CD+"+<9(UCX*[B*:E955IJJ55:-T>SD
M74T6S9>S6J8)9622, RD*I$@E.U>+4*[%4@CQVJEC*DBI,Z#(DDL2/>F1CE
M 4WZI6R@ILE $B@"1T< 0. IG 2J#Y!OWHV9"0CE5WL$8A#V.0#93V^V/+L/
M;BI+;UNQ4;ENP[5%Q=AYP.>.9N#<UO;WGP,<7O6+"6.9Y_&6!&??LYVN2-\1
M23@E%#1SZ!4K<?,K-Y-CU39XFZ4*GXN5YJIJMQ*4;T061)B"053>P7K!GXT>
M\/:UNNV\EKGB*+]8W%N0M&T7+M<!"PV%5,;;&2_.^T6 7M4FUE!PS>OUWE8O
M<B1BX>H5:PS]AF<PHW5W66^"(N,;5=OD.1B:C*TZ2@JS7KFF_CXV#>K7VOV&
MYV2P2:L>_D48B53!&7931#=3NI#!#2Q22RW/5J6DIY&;;'U7I'2>-E4(SQM5
M4+NP#\2>JK 652"+BH9(D[=T"P3*$;?<K4K)&RE]Z(PIZR-%NAA@[2F*4Y3$
M.4#%, E,4P 8IBF#D)3 /,! 0$0$! 0$!Y#Q;(!!!%P>1!["/(<.SLPR4EBW
M%&.*+?G=1QC0:Z@I2[B23:PL!'5EO)QSU*7GI:,?O8*.*\0CY64>/GT@9NDL
MIVEVN](@JZZ/.U.Q6EF7F42!@([MMVQ1R;% 4W 7?)M"\U,CE;%V)NP#?51/
M>TCSJ3+8%]TCQ!GNWMF(CCON/6X:!KA5M!#P8U#<P4/;;?(ELRJEJ@*R]@B6
M:DY&K(UNOSCZ:MHU.!EKN^4:V.#:2LZ[=H2+1BG*.!6(XDWBR1V+9KL)6=86
MA=R[K4,9'<+'+*XXC[Y8KL48/-,2%)17D=;LW6QB<GF$@4*IB(1%)=(QXF*R
M26&X&."!;L-Q2*,@*.6.KO&)B]@X88.&&#AACFQX11S#-*W1DW,):#/YBPL(
M=]?(S&]AO\+C:J'<+.96PO$(-@EUCYT_3BXDD,:S0;A\U>J/TDY D6HS7M&Q
MGC4MPP0S-(5)!V0U!CA!%KF68HK<VX?4D*6!.+P)$$A #D6"1A@&NTM.))#>
M^T1Q!W4V&\AH@X+8D)IA(NI36O&KIVP6CS%;3S1N#AJZCEG[!A:)IE'3:D4^
M(5Y"C/,6Z$SXD=*.UX<'P1JK]^=L9VMF5';"2+,U)2.R7#<-VIHF:/<.3\,D
MKNLM[=GEQ(N7% -PL\ZJUBN]1*X5]I)MN%C:Y'>#8V#1;_/$VU2QLE*/;-6*
MT[N3Y&7R'092"A,B4IT2O2*\4O4)BPY$QW'Q;V56278K/3+6CJR 1)>J/F:S
MEY'X?+PA-S/&.!,5>-E5GD$E/XEBV[Q;1F21@8W!,2@E.1.4+\"2P#$R1!E<
M,4$96:\@"@'>K\-%/$0@2,5W6*XDKK]$R45BZM*.\DW?*4=+QD9-5VQ9'"I+
MW5&"DHI@NTC[!,TIHS@;"^24%=<\PW24,X!P"0O'Y$2/%\N;DVTHBNMPQ0,J
MM<EENC6VLJD(=H4-MW%0Q).-$05#*7*L%L'8,00-K$,+DAF!8 EMMR UK /7
MQ9Q<QQP\(I,M8[+55:!=303Z2Q9,-FJ[W'SRZ)8X>L%[#;VV0JF\2S=BI:$N
M#F+J%@CT7$)#6F26\61[9PLP!=@PEU,KM42E"%*/E["4@[D;PAHQ3J5+,8J@
M2AIU$>TI$UV=BD9N2 &"*Z[N5;>/< DBF*'QC@@+Q(& $):0%6F) 5 \@T[;
M%@_/DQB:TWQH%P9XXP@6X6Z'QO25W];6>9&E4JU9,$QF0<IL,@M9::D#"UO,
M5157K\(YNRY/7\^JP8$O0!O#F$0$;>R-'&HY,5JMB>)8QGB'+Y'YR!@(T0S
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M(.779)=H@\4;W(97J'#@!RYJ!M'$67>@\&!W0JH,3M&@>-0TYFJ<JYYH&4I
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M:X%FF]=M7KEF[D.H%\Y8J=B6<':E(B6P$4,S"^YT,;&Y-T.TLEB2 C[5+J
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MZJ=UA=G>-9NO(55B2 DM,D31D,2O*6*-T8#J))4A5$LHE2J;QD:HAX1X:H[
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MT,=VJ/3(T536!F!U7D7"OUQ5?0D2X9S&QB%HSMZSOR[FDCFB<B_8&2HJ!86
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M5<?J ^(W=V%PRF@.ZM5P";UE!$&/5/*616I-DQCB'A9Y1U)</'NWI8",O55
MBEV6O]S5LFT.;->&)A4!XP\@\%6[20JA#FROSW =IT>])(>F"G-,GE@ % _D
MAY8%#N*!O/R#N#GR#@>T\K<SR[;<^SXL4#L'._(<[6OR[;=U_)BYQ&)P<,,'
M##!PPP<,,'##!PPP<,,'##!PPP<,,'##!PPP<,,'##!PPP<,,'##!PPP<,,'
M##!PPP<,,'##!PPQKMO?,XRIVB2D# 5A'UV;?/C"5V<"LVD:Y<.3"2/,5^<
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M18F*7;Q(R;HRD @Q+IPV-UM(OD.R4!98]PLPCE50LL8.R0 !U.'B  * %*
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7,'##!PPP<,,'##!PPP<,,'##!PPQ_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>gdc15tqwxkbk000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdc15tqwxkbk000014.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '8 D # 1$  A$! Q$!_\0
M'P !  (" P$! 0$           <(!@D$!0H# @$+_\0 5Q   00#  $" P,&
M" H%"08'! (#!08  0<($1()$Q05%B$8(C%9F-<*%QDV05AXMQHC,E%789:7
MU=8D,U*3U"4F-4)B<925I"=#4X&1TG)S=K&RP?#_Q  > 0$  04! 0$!
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M 4"2%H>+K?6;,<=F.Q%%2K:5TQ?M3-I,3V+;:YK-W2Y%6K\K+'4V>&OQ*V[
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MX61IRZ.16%P(9,"-"G\TBI:!H$N''0Y0,<F>J$%.S$' 6!8BYN.AI$J*8/2
MYL?!U&\5=6LR,LO=$@8AN0G97F4E@3PD=%=TWXE@&(W\YZO36@I)!+'I=6)Z
MQJ-7,*&$1/1CDAIRJD3(G>K12RQ0S%3*D3M&KA#QSK@?"GQ:C(0FMQ_&ZV'
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MPW8DGWG-\TZB=.HU:7=FL^K0K&;$RQK+,P\O*ZPI'$K.Q+<8T5%WV4;#(/\
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MK!@&4AE8 AE(((/D$$>"#\",L21R1.\4J/')&S))'(I1T=3LR.C ,K*00RL
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M>X:[WI.G*%B== T6LLS114X7,2:E9K1*>Y?MJ1+//*KM7$PJ1.L**#KZ>9*
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M=1TR35XTTU[WROINK6NS')H]B2.C9-2Y3-.9[#+4OF![,T,<T5S'^W]6A.X
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M$"\X^ARODLLW:)(^W(]AQ5C'#?@CAP X>+?D$<+I,7_>%I-@&]P81\2?BV_
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M/_D?,W]L[1_^8:E_DU?UC(#]R!UQ]\O2G^7J_P#X9C_!VO*+_37P/_XGH?\
MR/C]L[1_^8:E_DU?UC'[D#KC[Y>E/\O5_P#PS'^#M>47^FO@?_Q/0_\ D?'[
M9VC_ /,-2_R:OZQC]R!UQ]\O2G^7J_\ X9G, _@ZWDDX6PB4[KP\,!2TZ))
M:OLD6TWZZ]RV B*Q%,D+TGUVEMR0&2K>M:VZG6_=JEO2?I04\-.U!F^ 8UD4
M_C83.1_DG+L/V'_632*)^J>F8XB1S>%=5GD5?B5B>E75R/@#*@/\(9O&\!_A
MA<7\%1S['%R1G2^QSL=N*FNG3T:/%[!BG%MNDPE,K[),@W6HHQYEAV16[)RT
MQ).,MH)E?H6QX\?GW4G5M_J$K$ZK4HQMSCJ1N7Y.-P))Y2%,KJ"0NR)&@/A.
M1+'Z>]%/H1Z:]%R2W*\TNM=16H>Q9UNW"D/:@)#/6TZHKRBE!(RJTQ::Q8F*
M@//V@D2;+LU3.T8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC(;F.$<[L'40.N3<<1*6>+C1  13'VWH(=\!UUP*6U&J']SDH+IY2!
MW'27!&5):*;#2<RT6CE^I^A_HC6O2%3])>K49M0Z@T^A6I4Z]J9)=(@EIR22
M5=2%%H>3ZC7$K+!)).]>(K'8CJK;BCLK[N=MOADR9U#/,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,H=X/\ \XO.O^WCU+^ZWB62VJ?0TG^*
M8/[1:S4>E/MW5O\ *[4/[OTK+XY$YMV,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8R)NS<A@NV5%FGV"1E(P%B;CIQ),0H5)6W@$%,;9W]6.2U\MX8TEO
MW?+]S;NVGM>]+:FG.;^E+T9Z1Z5^FHNF-:NZA0J1:M1U83Z::XL&2FL\1B/K
M,,\?"6"U.G+ARCD,<HY!#&_H8KOM\1M_W_YP,S.GT^MT*NQM5J<4/#P<4SID
M4,=._P =[_%TDEY6U/%&$N>KQ19"W""'E*<=<4K?KFU=,],:%T=HE'IWIS3H
M-+TG3HA%7JP+[R?,D\\C;R6+4[[RV+,S/-/*S22.S'?/-]_?F39/8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8RAW@__.+SK_MX]2_NMXEDMJGT-)_BF#^T6LU'I3[=U;_*[4/[OTK+XY$Y
MMV,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&4.\
M'_YQ>=?]O'J7]UO$LEM4^AI/\4P?VBUFH]*?;NK?Y7:A_=^E9?'(G-NQC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8RAW@__ #B\
MZ_[>/4O[K>)9+:I]#2?XI@_M%K-1Z4^W=6_RNU#^[]*R^.1.;=C&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QE#O!_\ G%YU_P!O
M'J7]UO$LEM4^AI/\4P?VBUFH]*?;NK?Y7:A_=^E9?'(G-NQC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8R _*._V7E?C[U3HE.>8
M8L]0K#TS#+)$%.'46.6+K3#PIKC(SR"4+6/M+K[&M?-TK3[*DZ<3ET8DGMP0
MR>4D?BVQ(\$'SN//CW_'\1]V0_4%R?3]&U"[5(%BM7,L7)5<%E9?9*N0IY E
M?)'O]X/D0#R[RYGYQ<-69FL,3]OG>B=#@V8=^=J-!MU0I-+Z94.;D.]'@YV<
M1&.="KI=SC9JT5VDEGHD:FJ*GZL$9(6VI5B:RY]/1>3K)PC6*%N022:.266&
M28"%D3D(7$;*CR@%9.22$".1UA]/ZDEE,5>6 369KMV(1M+6IV:U6K>K46-V
M&:41FY UI);$-5F#U^W-71GLUJ\OYH7G8%>I#GT*/RF4#F>B5"D]/BQW;W2Q
M8]CF%RCN32C\SN9L!==!.MU1#ZW$EVBA1RB3VP(YPJ&DIG<W6&9E+I9B69C.
MI6&22!CVI23/&;"\.*!R(Y#781RML"3LRKQ?BI]6K;>E$NG2)+>K5+\:FW55
M!0M)I\AE[LS0HUFLNHQ-8IINX12T3R=V 2YMQ_RXCNS])K]*KE:!'AY6HW6R
M%SZ[2S(.?.KE2\8;S$LP@X$6L&;CY6O^3$-I^49E&1$F5Z2>AW9J&?CI4^W9
MT\UH&E=R6$D2!.WMX>2]$Q8EMU97I-[/$G9U#<6Y*N5IO4D>J7H:D$"B.2O:
MG:8SASO!6T&W&(51"LL<D.NQ;R!U7E"YC[L121XFO7GI%$U;H07/0(\*[5ZI
MVBZ0<I+S,?(58VLU4/DLB5)#&",/,2\F:SUV!U'Q *EQ$F"%-2L;;7PQ@GC;
MT6E,'B:8DQO(D3*JD.)'-@!2-]U4>KMNQ]H,R*T8).T=;ZOC:O<2DJ);AKV+
M44DLJ/7:O773G:164$2R.-2A[<:_-2(LLD=EE52V7/>:J7I*QQ".=F LP\J?
M ;F6[. 40@G?1/(3DD8<Q%NPJ&'M/W7Q[GB5L/&Z;8K,]"RBW'Y-$A71Z!IF
MRHQF!+*'X\#L1V:=@CD'W^U7$\@;EU91XXN<@]4@R3Q^I.@BD>$RB=68-Z]K
M6FHXC,6QWM:+,Q#-LL$T4AW</"O4-^;31OSH1%3F020HBK22;(F2A"2)-QX'
MQ$L4RRY#.1Z @6R8/RUJ8Z'VR'EZD(*VLL"B-#P)\K4=-X^UW%(+2+PV;QL=
M012&#;G9M/D.WCPT?D[NJT#JI7)B%>562."3O\XBTA*=-SRJ8N'%>4/4=8 @
MG9XK  0+"\G;2OFVR'818@/G;CJ/E7,>3 E+ 7!V,&7KU\\;Z;",MAF5C</)
MQ5@#\B8BT"V&"FYFNGP$:B2KDS/"'LO92NF;H6,VQWBV*H&0J\5V1CN'Y!D-
M-D*,BNKMQ=4((RY)U4%F6-*6_BT'CDG:*=9(;>AU8@%:OVI(YEUJ.PL\,LL#
MPH)()9E<$<E[S+T;>(SG$33XM-@7:WJI92OOL*9'0;S%<\M'SMQ1P< 4+,S$
M7;?%&PP+T:\@0='V^ /*%1=ACYRNQ8:;M$TS2-P[8DC':(+;OIX'(%P55H[Z
M/R!)]ABH9"CM4>I^=N.C%6C[QL&O.WK2LD1$'49?MNL)666.QT[-"4(51WD$
MC1S)+"G5QWG/#.5:FS ]&L,[]Y)&DT]!#A\=''MVZSPW%9C;D_&L!NMP<&X!
MV>)+%FVMOAF$!(&8$''GZT5)>G2VYR*943@LLFVS$=M&M+LC$^VV]9MU.Q )
M))*.!;3JN,P5I!4FF[[U*W+FB.+-B/2Y-YHPA$4)35(G64%E8J %59H&>W7*
M>@,=1Y_7;RQ&.PVYIHY!44Z4@[Z"1B)4Z$E163D,C:.$:DXTM(1JA W# _D$
MNA!.NK%9CIXNQ*\7(-QVV8#;<,H93MYV.Q&XW.QW&Y]^;'I]P7Z<%L1F+NAN
M498/P>.1XI%#@+S4.C<7XJ679BBDE1(>6LS<8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,H=X/\ \XO.O^WCU+^ZWB62VJ?0TG^*8/[1:S4>E/MW5O\ *[4/[OTK
M+XY$YMV,8QC&,8QC&,8QC&,8QC&,8QC&,8RGGD7V7H_';7&6"*#&FN01?/+-
M,=<'CHER1O-&"U(@ 1'7*TPSHA,] TA\AU_H=3?C2RWZFZ1:8%Y1U2)K%PD:
M=:&Q&R,2MAID6N2P$4IXDM7D)VX-+[H9 P D';<;2!XM:UO4[VF6(YHE673H
MZ5B34E2/G;J('1(]2@ W[T-1B3=K&-F:N6L0GG6->UBK/F:/&Q].!>IDM9):
M>LE<YO\ :*3PX?W7DR]<+YO)E6",1'ON5J!)F>Z0,]"2+31[,I7PG2$#A.3%
M7'FJ_D[D9&[JHJH\W'8M\T(K4RA&+#FP6JR,I(*L1Y;C(5QAU0(XZRFK)/)-
M/!1#\UBWMO;TFB[31A"8(6EU:&:*0"0/"I.R&2!9<R:\I(N<IO(K=%5^V1K]
M\EZLU(Q1D#*#P[/WDI-JL28H.[RL Q6;(R(;!_3&DU(TN3"<;8^T HY3I 6K
M?J++)8C9XR(E<A@ZEO9EC3D8E?FFX?<"0!2-]BW@YEC7XY:VG68X;"&W)7#Q
MM#(L8[]6Q,(UMR0BO.%:+9VKNSH0.:IN4R-(WST!,AB)PGEDB((F-$,%9:MH
M!19)<ES;@G6X\%QM4.,P/K=,[] M&E?4O)&L\#,Q([1T2X!8R+S:4P8()U)Y
M$'YL@ +/;KLV_([_ #M1MAMY1U;PVZ9@1]7J\33-I[JH1&4"RC,SR4='U)$.
M\2A?\%UB$.VYXV(9(P'C*SGEO^=D9&%RH$[SIZ-)B3KY%O.-W ,@!1_.6O+H
M.P?],?A -MADV3P_N$="$N,:>-B+=4Y<P2,D/M>O1X:4S!2DW+D(F [9!VF^
M3RGCF?(348RP]P:-U!9>+FH]71H\B2TF1HWN1D^LJ4YT?V2)-[1B796GZ:LI
M$VV[1V:\C*C]V%.Z#\V(8JXP]/70SQGK;/&5BG2CM@&7&FS,;/\ 'H(S=B>9
MBG-5N+>=[?34PYS>YDB6DF9:&1'CF;@=S]!TUA&TG=!$:AY%X'<*R6''#VO;
M;:M)R!XA1Q;<CEQNIU3$UJ*L:C*;,KP59#,I1Y(YM-A;O$1GL1L=5J]IQW3(
MXDB"!NSWN,#YQ0T@$J7;YA:P((0"N[EY::D8V*#AYBW$\GBJRT9(NMN0"*U*
MSG6!0V[2J<0A$73;K9MQ2H$*%-GJFTME/'OQEBS\54%BZQB=GXC<.9%6 DQ\
M?I21IRYE@M*=5QNAD%"PD2I!W))7CC6*6RVG1UU9]C$())M1518,HVCJVIS'
MV5B>;H[;YNOPL/<TR/-Y:KR%9K-H?-($MU.M1<;9JWR-WKIT>&F)^U*S*",P
M<=.B,27VVK3DJ)$B&1(OVG):@*H],#-%M,KK))& #')&&1[ @!/+9U)9E)''
MZ))#'9>5JSU4T45KG1DKO7KV&9ELUK#I/!IQU)HU$8D@D411RJ).Z1W%C5D7
MF_9LA3^U*Z%!]!FZ36A[!]T6[,-!1@]MA6Y:R62JVB^TZ1J\K';2LNDR:IZB
MJ9:<FV'!M-3(Z'7&Y.)L$7%X<M7LO"DKE.YP+DQMQ1)$BD5U;W2KQE_>G?V2
M1NK(S3E;5/78KDM6!9O5A.L*+9B[L\U>Q;K/!)'MRJ2=ZIL.Z"-I0"1)'-''
M!TAYT4X2&7;!*=*25-!Y:/VN8F-62KP<D#S.1CN@+BYX.N6PZOR<R2J>YM.P
MLO$1^EG0[!]>EE)+:DWA@<D:7(6$9D42F<UE3A(RF93%R4O&'"CA.C*Q&S;.
MO@J.40_5M58C86M))533QJLLO?KQ.E%TN=N98+#PR2,9J,T4D:>U$K0R>T)"
MJ9&GRH,;Z?\ Q:DTZN[(E N>,5>7C>ACR\))3]^L'D0"&F2EXVNDC1-<<@^!
MNE RBFWYAVSV^ IQ5=%/)^I11Z@.QWQ(_LF;N*T)5E2*.FQXJS@L_.WL5\*(
MXWE#E1MF0.H&]?\ 436@+2+2%>2.Z)8GFN3:TB\Y8X&6. Q:.620@R&Q9AJM
M"KMRS._'OOZ/(.,L%BBJ7)U2N1&J*T(]/28CDZ:==N54#KR12H4%AX:.;BJ[
MTJN /DIF3TES3$RT*WN,$CY25M6ZGJA1&D61V[I(13Q BL35]PQV)Y/ Y XC
M9"I/M$JN7HVL#68YIXZLE>"+U0*9G4S,]K3J>I<6B0%4$<-Z!"PE?E*)0HX*
MCR6)S#R:QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8R-N@W;F]?^CK70'PR$V&+F)IN"*K\C9FRH&K&U]F>G9&.CXN6;%K]>D+'
M6D2LW*,CQ,65+Q7U1;+A(_NO0Q3/N\((X,J\@ZIL\@?B@+,N[N$?BJ[LP5M@
M=CF#<M48>->X5;O1RRB%H7G#0UGA$TSHD<@6&!YX.Y+(%CC:2/DP++G?MUZF
MRA"9L2(K94B/(%.#SPD;#E'A3( [E9*)'D?IGULRL<.(Y!/+VO;XS(BHI_6F
MF%#)IYR*.)9PI ]@LP!4GF 1N/9)/(?7OR'OWR\(:LA[JQP,ZNW&54C9UE13
M Q5]B1(BJ82=]U"F,^!QS'Z'R'G7.*91*%6*M%,5[FL=$QM-;-"$/.B$0D0S
M QYS<B0PHMR:3$,-A$SCKJI<]'S'#C"'GGG'*I;$TTLLKNW.9F:38D!N3<B-
M@=N/+R%^B/@  ,LU--I4JM2I!7C$-%(TK!D5WC[48B1P[#D9>V K2D]Q_)=F
M))/272P\7X7$:MUEBX6GQ46+,'N3,)13C]PT:#&-.SLH8NI5^1)AHD>,!$9D
MI4Q D?I#4>"^3MUP)A=<:6;3=M"TC,5'%I0.3$G@H[C@,Q))51NWO('O.6K4
MVEZ3'ZS/'%6CC65S+%49^U&B S2,:\+M%&$5!)(W%-@BEM^(SO("O<NM42Q,
MQ-*KK@#LI(O(U)T1$&<S,Q<G-1<B^3$SL)'2H4D/)$3S*WBPF"5J./>;4MF0
M<=?H=YXV*M*^X51[,O(<2J,H#(S*5*A"-B1X7^"-KL,&GV(Q+'5@*&1R.=01
M,)8WEC<M'+$DB.KM,-V4-[;D>')..=#G>$\R%^MZ#'U&"$7"VNS*()I^I!O4
M+1@#K;:Y)U4="G?+;A0#Y6>)T[[7UI)E#!FWG%&JRY"EJ<GLF1B&C3Q)L>4K
M".-?+#?F0J#;Z@#XVRQ=FTB@O.XE:%>U9L<FK<QVJB/9LR$I$^PB1Y)FWV)Y
M2,H)YY(/W#HVTZ1NF53:-:]ND?=V(]NM>R.;]-)^C]/3Y</$M^GIZ>R+CD_Y
M(0VFK/=E_P"4D_RV_P"E^'_I-_E-]9S-]3J;;>JU]OJ[$6W[P?P?JBC'_P#K
M3^ NWT?I-,*0TT34:P0VR\^0RV_ Q3R&B"E"+*?:0X(I+;Q*X\!;[J=:6\H(
M13BE;&9V@)9021)("0 2'8$@;[ ^?<-SM^,_7GIJUF #5H& +$ PQD L5+$;
MKX+%$+'WDHI/T1M^7*/2GGRBG:?5G23B_KS2'*_$K?,.^8X]]84\H3;A!?SG
MG7?J'5+>^8ZXOW^Y:M[=V78#N2; ; <VV \> -_ \#P/'@9X:E4EF-:N6=N;
ML88]V?<GDQX[LVY)Y'<[DG??/O\ ="I^SY?W7KOR_I8\+Y?V)&^SZ.)=9?BQ
M/;]-[?I8U\8=Z/8]/E!NL,N#H;6TC:?.Y)[^X_O)^DWO/@GW^\@G<_'?SGOJ
MU;;;U>#;BB[=J/;C&0T:[<?HHP!0>Y2 5V(&=L!'@10C0$8"'' L;<VR& ,R
M&(SMYU;[NVAQT-LM[=?=<><]B->]UQ;BO5:U;W26+'=B6)]Y))/@;#R?/@>/
MQ9=1$C4)&BH@WV5%"J-R6.RJ !N22?'DDD^3G,SS*L8QC&,8QC&,8QC&,8QC
M&,8QC&,8QG0SMJJ]68239K) UP97KM)$[,1T0PK2?Q5M+L@0.WOVZ_'?HK\/
MZ<K2.20[(CN?J12Q_J!RS-8KUQRGGA@4_OII4C']+LHS7?X.=5Y>Y:/-P9'2
M*$LB6\Y.F2<4PBX5Y3TG&O\ ,N,#L2$>UJ1VLP%Y\8AEHL9+C#CK#S:'-K:6
ME,QJD$_;TL]F79=*@5CVWV#">R2#X\$ @['SL1]>:7TIJ% V.J@+U/>3JR^Z
M#UF'=T-'3%#H.>[*65@&&X)4@'<'-EB%H<0EQM:7&UITM"T*TM"TJUZI4E2=
M[2I*M;UO6];WK>OQUO(3-Z!W\CR#Y!'QS]8QC&,8QC&,8QC&,8QC&,8QC&,8
MQD7F]!Y<%>2((V0C&[F()J&D3UPIKC46,[!2=YU S-P1&KA(=Q==B#[5]A2D
MT(_N,::EMA_)+#>(OB&<Q<P&[9/(#D-V/)8N:Q\N3>VP3DJD<CQWW! P'N:>
MMMHG>,6E7M.YB8B-3$]KLRV>V8HB88WL=F253VP)..S*3F3E9K!*G'W:_ D+
M)^S5NO.1,>ZHC[)<8?B%..*'5MW[,=&&>C5*VKZ-P=AP;;:FF]IM\Y!XYN .
M7CD?'+<-XW_?;D-]>YWS),%=MR886Y<"28T/+MD&,D[>>V54I_!(!7;89^E5
MBM+CPHE=>@UQ<8[I^-C51("H^/?2EY*7@@]C['$=2D@A.G&&VUZ2^]K6_1U?
MN\YON6YMR;PS<CN1X\$[[GW#W_4,>KP%$C,,/;C.\:=M."'R-T7CQ4[,PW4
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M<CR%19W/N**<XSJOI=-VX^D=!:):ZFU ;J;9AF73XO/'N"- D\T*MX::9Z,
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M:_3^<)M/^=/I^&6EZRU<'<K38?4T+[?^[,I_KS*?T%]$NNROK41_A)?A+?\
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M=:UHA))))))))).Y)/DDD^22?><^AU5454151$4*B* JJJC9551L%50
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MC&,8QC&,8QC&,8QC&,8QC&,8SS)_"=&UYA?$Y^(;\0&=U]JP5-LB^'\3+?\
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MD_LW^+_[N\>NZ=]QH/RR_P#I\?(74WW\7_S)T_\ J./R:_,7]8]TG]F_Q?\
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MQ[I/[-_B_P#N[QZ[IWW&@_++_P"GQ\A=3??Q?_,G3_ZCC\FOS%_6/=)_9O\
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M#N1\<^?/5KE_TW=01:;J4NE3PZ%7:6W!6J6WX"CHP,9BN12P[.9HMVX\UX@
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MW&@_++_Z?'R%U-]_%_\ ,G3_ .HX_)K\Q?UCW2?V;_%_]W>/7=.^XT'Y9?\
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MIV4ZCI[P@]^6-.+V:\17VN[\U'9KA=V,]=(T ,I.6.^&)YW5CS[\7ZMTUHD
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M7CRY2:VN4B1HJX1S5.%K'D_$!W=5RTS6:S?ZU9;%4"XR0J<C(R)O.Z'+"2"
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MR$#YWC\'<D.W_6W'D\5Y <S\=X/D0S%_7:SY5D0SHG-.@7Y[["L$NS58BUQ
MS#S[SYT/$VX=1TR()'($\/I1M<:NT<[4YKK6-XNVJD]F>&(<D7FR,3[@S9.H
M=,]5W#9LU9)MI(.KET<OJO*SIT>LT=%BTY1<]8>0*UVC=N'LSRBO'8C5226C
MCS\OQV[9SXKH[\/9[%S'N78_B&5'N'(5-6JUS=9Z+S)SGW%>=]7J726JA*R<
M.V*+78CI-ZW!6?2!R7:W3I&/<*^P'1J_:%RK+V>4:3U:^D25;'S<:O#/W;,U
M>2$R*K;EVABYQ^0'E4[<P7S&T35:;WVCL3T-5U/K.MJVF[6+$T%ZAZCI5'4:
MUY:TDD0"PQ7K8BL>R6@JR)R[)6'N.D>*'F1(WJ]"U"T=23S,GM'7)ZJCL>1M
MHBY%[F4MX(B<<Y]%%E(OH<PI3/DI&@7]<6>7MH3T(MQ.]2YAH#]$-_3EBB,D
M<!G%>NDA-.,@3+JAL3,!VBO_  )C#R \^(_H@'+E[IWJ>2W;6M8U 4&U74IJ
MZC6YXW-"3I!=,I1LPMK+XUV-+IC9ME\V6^=9E.->-NO)&*\O^?UOM4KY-2NJ
MBJKUJQ28EVJE@YM-W/\ (OY8)9P;O%L]BAKMKF$9T>!O-K@YUKA5HK$OU6RC
MS+_2OJ[ =&!W+OJ;:?,]9:2B3N/&IB=)EB^4I^V8F]6:+OM"\4;KZTCK G#L
M^P#EC0QK<?4M.#5)->D]6]7@GD6U7FH2VOV+Z>LZ6HQJ<5OU".]%;L13#2;%
M>34)UD-[E,Z+]>O>)?G1:K=W25JERZ@$%<;7YONT'0'DI;*_'1-=Z%P3GD1X
MPMA1 %]$%K@M8[S7K#:]!QP##E<"-20^P^,:1$H\K:AI<<=59(H"8H],[N]*
M-F9X;<S7MV,1+F2HZ1[LQ#D;;@CEGNI].=6V+.K25K6H(EJQU6:G#7;,*1PW
M='I1:"$C2XH@6OK$,UCBB@P*W(@JYB7%[MX/^7%I[[>^TGUV)M]5E.@^ E_L
MG'K5;ZD)$]SWX\\_D*W?%S%ABB%V"LW"B7J4!Z-SE#DTS1+D1 G1U\B)0,J,
M U7%J>GI4BK!VCD6+5HDL1QR%JOKDJO%Q1APDCEB4PS>QW8PX:)E(8Y8M=)]
M1V-9N:H\,=FM+=Z/NSZ;8LUEBU;Y%IO!;[L\9,\%JI;=+U'YT5+30M'<CD5D
M46D>\,;]$=VK/DGRA+G.92Z=@EW?+#EAQ<$]&=IYS!=?L/3.2="!W%2QT&%U
MRD/?=Z(1)%FCE25(DYZM&F,JBXYN2PAJ4357I6-IEBKKZA. W*M,]=(+$)Y*
M'->7VVX@;+*%<#VFXSYZ8MQ:O!KNG T9+6I2?LBT]FA,>J4HM1FO:==7MRM"
MFI5&[,8D9@TE22:!F!CC#Y#QC@WD#S+S+D.[NQ$8_0?)7CK3/DA$L'Q0!=,[
M+3[)*3/,I4;YEOL;UV3"T^R3W)C).(8AQM56$YX^T&ZJ-D&!:+-NI/IJU.3=
MZE9)IL0Q$E:1%693\VG:Y2(M@!N1[C2C<!AE_3-(UBAU0^KF*,T]=TL+KD8>
M-&K:I5GDEH2+O9G-KM59YM.9XQ$!7AI$*Q1U7%>D>-?:;'?H26 BGK.73/B4
MP?DT8\5:2JJ-/<2D_',[G$7]#*I7H4HBDV5R%KLE ;^;.#0M,(D0XDL26@QI
M^Y#=K)$RLW 2Z*U$ ()"ME;@F;=?>!(G)U;PA:0 L"K%,>]H6J37(I4C,[5>
MN8M>8FPU=9M*DT-Z,?&3?B6JV#%#)"=Y1%59UC99(5FJA*>)7Q K]R+H%+Z&
M#,%FV&[>"MVJ429V2O75%2EN&=/G++VZ68F;=,GLF66P04)23&9HB-2'?K#]
M)+3,'7%.R\/$9RZAI,5B&6$J D>IQR$5GB[BV8$CJKQC4;(C-*"H;>)-U5G]
MEFUV3ISK&[IERI=20O/;Z2MUXWU2&WZM)I.H23ZK(LMF1P\\T,-5Q*R!;D_&
M26&#>2*.:.>_#ZLUKY+;?'GR6H[<N[/]U[_U,_R7HEG@X^V6J[7>1BK-SCR6
MU':DQ9/FO:HPV/CXLV!I4._3H8BO"CQ#.J=+%PXV/+JZ1V([E*7CPJU(!2E1
MVC2.)2DU+?8B:J068/*PD;GNQ[JA\DZ71L]C3;.BZ[4$IFU?6-0?7:EB)+-B
MU;DCGHZ[P[BR4=5C=$C>*K&:T30*(E%61HE[3HGA_P"5G6?#0/Q[Z5:H69[#
M2H_K728CL4&)&ACVKR$B>W3]QX!>(D9JWUPRF3VHQH&TVC9@,K5Q"+=)QK8C
MID.,RFF'4:%?4C;@C9:TIKPM7?<]NHU9([D3'MOW$Y%HTXE9"(U;E[1.7;W3
M74.I=,+HMZQ%+J=:/4KL>IQ*B+8UF/59;6C6XU%F%JLP0)8L<DDKJUAT"EHP
MN2_>N?>1?392,NDI19N-MX_BO4*3TVB4CLTIQUN=[#+]AYS<WV*AV2LCR);4
M+SF'JE_.0<*.M4S WUJIE($(L-@$C<:*6G K1+*K1F])+!++66QQKK6FC!DK
M.0.4SR1 @GV7B[@W"*6DK=/6[[QVI*DL=E>GZU6_3J:I)I@EU.34Z5HBMJE=
M9&$=**O<<.J_.PW!7;@9I@FS/(7-[QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&4.\'_YQ>=?]O'J7]UO$LEM4^AI/\4P?VBUFH]*?;NK?
MY7:A_=^E9?'(G-NQC&,8QC&,8QC&,8QC&,8QC&,8QC&:8?/[SNZ[XN][FJ)4
M)FOC0J_$,CK=("L=.^U8 ON)??Z)QVEP71+>V;#!T?D<\FW_ $UEM4_/U4*N
MRKL<<NY!M.-0DCLFDZ57O5%ED5RWRB*\I23BPJBI+9E:&/BYEL+V]T1$D+KR
M';.Q8<OZQZNU+0-8EIUI85B/3;:E46>KW86U9M8J:95ANV0T2U--F]9XV+,T
MU=()"CFT@(B>>+O\26D<XB.TR$[RCJUE9\=E%U[K%@HE<5)T>/Z) UOC5EL=
M1CK;*O14(QMT/LT<W42+!(0S]E)J-R9V''L#UDVTXD6C2S-65)ZZ&YL\"3/Q
ME,+O81)#&H9O?6;N!0P021G=B7$<Q:ZXJ4H]5>73M0G&B%H=1FIP=RHEV*#2
M[$]:.S(8XANFJ)ZL9GB:=JUH<4 KO8K9W_XFMG@+!T$2B!R5"C^4<B\V4=2C
MK#2ZW?;)6.K>,TEX]/0LS5Q!+[6J_;H,NJ=JW/*B"K=#LRZE1T<^;!' R+9&
M;4T1&6$RE93/8TPP,DCQ))7NK;YJY,3O&PDK<.0C;C[1V8$;06L]>6()[JU%
M>HFG:9U5\H1S58+D\&HZ#)HIBD@5;D$-B%ZVJ][M-9B$F\:,\+I(#=-CSGJ<
M@Q9I2$YY=I>GUOK$EPI70W":G#5%[JM>Z;"\CL,!((.L:[#%,#6Z7>U$NL0D
MR=8(Z$EWHB.*)=KPM@C?DN0%%::)9'@6UV1W&D$#P-81QLG!B8U'(%E"%EYL
M '*;0.K*[K/)%2M25H-1DT@W2U:*L=1@O1:=/"X>;O1A;,C",K%*TR0RF)&8
MPK-!Z?B[^.&J?"W<RO\ 0X6-L?(*1V&O1%AC8F&L]FAKX\S%1P5.CB9;<9='
M86UGP]/MSU4G)A=8FI5@R3%;K;),\WE?L>N=QX@\+,EB6N[(6:-&B'(F1@O*
M+E&&DC$B+S52%/,A#%_MD:'ZK%;:&[$D^FU-3@BF2.*Q/%<V2-:Z-)V[)BL/
M%6LFM++ZO+(K2*( TPM7:/*J'J/&H'KT]SOH$ F>NTES]NI7"*U1Y\&;C)RT
M0#1Y@EKW%22J]9RJJX11#0HDN5N %BIYD?!MM3JM@X$=!I++5TFA?C$LW<B;
MNH498W(!3<<XQ)\\"P$924%B4\[!8ZABK:9%J4]*Y!W;4E,5K,?JLR31RV(0
MS+8[;F&PU<M4=(VDLI-69(@)?8K1%_%8XE*2%*6F@=1$J%SBO&";3=3!JB@&
M C?++GU]OW-E34.Q:R)Y1,<QSN=BK8S$1\JS&D_3D@%2HSJ5*SCH-D++\] 9
M(FO+VP9-W.GRPQ3\6*! #WT9"Q4D;@A2,@D](6E.]0^IZ@M:W'H$HM,M;A#'
MU'2N7*)EB%AIN2"E-'8$:2!&XLC2*<R?P_\ ,2U^4'8.R-CULR Y2QX^^)O=
M..PMB8@1[@Y$^0(78Y/1,Y(5^7F $#R\+2:I("Q1*UR%>/,F0R236/I5-VM0
MTY*->L2X><V[]6PR%C'RJ&NNRAU4[JTD@+#V7 4@ [Y?Z:ZFL:_J>IA8&ATX
M:-TYJ^F13+$MDQZRFIR<IGADD3:2*I7=8V/.%VE5F=>)&!<W^+%RKIC_ #=
M7'^Q0$=U%[QB^Q9B55SAQN.B_+.TW*A<PEI(2-O,F6G;-TI,K'SP0PQC\=%K
M&F?8_P#,W'9>FT"Q#WM[%9S +W)5[V[&A''-.JDQ >8I R$D;L"OCWYB4?2)
MI]\T>.FZG FH'0#%))ZB0D?4=BU3T^5UCMR-XM5)$F0*Q2,K+L=RF5]\:/B
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MH!P]CU<,L'$!0%[(9A&$"A>3%0"QWS'Z7T&5&2;3*\O<CN1S%NZ3,NHO'+J
ME+2L\OKDD,36.Z\C2"*)79EC0#LCO$+QKDB)HHWD=9=>L%Z@>GRN]+E6FW^D
MUMZ/)C;^RPS(ML 7-U^)C7IFS1[8LS9' AUV,R5VWK>4C4+JA0+$@"1- OT?
M$+@@P[[;F,!F"H=U0$\ N^7&Z;T-S*S:; 3-;BU"3;N#>]"49+@ <!;1,49E
MG0++.44S-)MG!'\+_%H:G-\\UQ2FD4)B&DH 2E2+)\K50(Z7AA*Z?N-@),XN
M+C9!V !"@VIH 4>9$B!6(X0]@-M+.JCJ5XR=[UF02EE<R@A9"R,77=U 8@.2
MW$DJ6/(@GSE Z7Z?6L*7R55:FL3PK5</)72.2-87[<+NT<;F%5B$B*LBQ@(K
MA?&9Q9?'KC%RI]0H-LH$19*I0K''W"I1DV])22XBTQC,J,/84219SLL7+NC3
MLV-(G2!Q9$P-,RH\LLUF1,0]:2W9BDDECF9))4,<C+LO*,E3P( XA040J  %
M*J5V*C;*GT72[5:M3LTXYZ].=+-:.4O(8[""11/W&<R-*5FE5W=V:02R"0L'
M;?!X;PQ\7Z_]A:A^.5D)%97R]<$TAZ9<9COXE8V8B.4(:8?E'65LT*,L,\%7
M&'D.L L3,HA+:OKB=N76U*\W+E9D//OAOH[GUDJUCSQW^=9$+D>257ZAF+%T
MOH$/:[6F5T['J'9 ,I"?):2QZ< #(1M3CFF6 $$()9 ![;;Y?S#QNX?Q9Z7)
MY5SN&HQ,Y7("GR1$"])CONU2I[E?NC6V'5GNN P=0:FY46HQ8"A@JN"<]'P+
M,>#M(Z;<]RU9"B>9I0KO(.?$_.2<>XY\>6DXJ9&.YD(!?<^<R=/T/2=*,C:=
M2BJ-+!#6<PF12:U;N>K0*2Y*0UA+(M:-.*5T=DA"+XS#8CPM\7(!N!:A.-UB
M*;JR><HKJ 'IH9,*CD$W+V7EK<=IJ43],US^P3\S,U-IOT;A)&2++!2R\[M6
M7&U*\W/E9=NYWN>X4\O6%5)]_9\]U$59/X2J ?&8L72^@0B$0Z97C%<4A $,
MJ]H:;-)8T\)M)[(ISS2RU@/$,DC,@!.<N.\._&>(37/LOD=>CR*?+=$G*K(B
M$S;$S797K8ZQNH%0TXW*IF([[_H==<MK(IS8\Z6\^=(-/FOND+\.HW6Y\K#D
M2+"L@(4JZUSO &4KQ;L_\62-T'A2!XRI.F="C[';TV!#6DNS5W5I1+!)J((O
MM%*).ZGKFY-D*X$S$O(&8DY(TOQ?F$ZY"$RU2#,D:Y5=T>%FU%2;5C J2IVI
M69V :LK!S4^N.?L%%J,L2R]).?5&P8CQ"G=[?^;96S.G+C(0'D[K+LO R<)(
M^90CAR"2R*#Q\!SM\,SI-+H3&)I*ZL\%?U6*7E()TKF:M8,(G#B;@9JE:0@N
M=VB4G?SORJ[R3G-2OU^ZE7*L%%= ZDW7FNAV@=\]4A;D5,%<95TS.GBW1B?N
M[&N.QT+OY"=Q@+SX8>V1WW6U^/8FDAB@>0M#!S[*$#:/N'E)Q\;CFVQ;S[1
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M*RT+^]#92I-M].!#[.1#_A(I']3AG]H!?[ELS?VK/_QS_P#+O_CLU[]V4_\
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MUC]#C_"E^T_U3>7_ .\.U_\ !L?L'K?\_G_ZJ/\ UL?N@M4^]RA^76/T./\
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M;2%.OOD$!14:/K9<M(@":V_ES2-'OZW;%2A%S?;E)(Y*PP1[[=R9]CQ7?P
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M2M#QPB/E)3]40DF1(^8::4\[V/3::4*-:JBA>W$O/ZVE8<I7/UEG+'\ V V
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M,^TXJ21Q(B2 ,!(BN ZE& =0P#(P#*VQ&ZL RG<$ C-5LP/5L3UI&C:2O-+
M[0RI-"SPNT;-%-&6CEC+*2DL;,DB[,A*D',?RK+.;,_AG?$QZO\ #LZOJ7B-
MG7'B%Q.#;ZUR5PSY8LP*W[1TVJJJ(5]+#7R&%]?H#_1L2:$;U!SFU!J#,BX7
M6M%@U>#BVT=F,'U>QMY4^_@^WEHF/O'O4^TOG<'?.@^O-1Z)U'N1\[6DVG4:
MEII;99%'LBS6Y'C%<B7Z#>%F4=F;V>#Q>UGJOQ4/$RR< MDQQ'OM4E>F6GGJ
MR*!6VU2 =L&F+)&,I!4N/(#1H2:K[1ZI$D1Y[?TY4<ZRO:_9O2N9?(FHP3?X
M14D6**3:23P4V5MMP03NK'8 [>0=_&?07I#]*>AZ?Z/NI-5T#6J[:N=$E^3(
MU+K:AM7E2O!,$*CC/4:P+'$G97AV.X!!\[M3HLO>([H4T%)1@[?/*?N^3WVL
M](Z*/BUVJLU%3<9])'GH)DES-NB=J;.>!8V,HDA1?N9]BY-W$9C4@^V_;7;;
M8'BS#?<C8;*?<#^+/S%TK1+>MU]?N0V*T:Z!I!UR_P"M/8$L]8ZIINDE:W:K
MSB2R;FK5-UF>!#&9)#+NFQD:-\>9R5C6)06\\]TP_P!(!Y3IMTFXMO-W"27+
M[!$=U]RU-)&($AGCT$Z>5Z#DA,J;3(NN LT&< \>$F_;,G[SZ X[GZ?UMM_,
M?AYS8:_0%VU62U'K>@=M^HH.EP&DU<.NKV3;[$3 :.5$<D51YQ)R.T<D*%18
M9H$Q/K'(K/QJ<CH"TEPQ$A(@&2;*8@DY3@XX-CG*UO9P4K'1$M'J+*@"9&+4
M7'M,RD$9%34>Z0#(,.[KBE64$J"-B =P/BH;P02#X8 ^=P=P0",B>JND]2Z0
MNUZ&J2TY+%B":RJU))RT<<.H7=./?AM5ZEJ RRT)+%8RP*MFE+5N0-)#.C95
M'SW\GNB>2_0^;P]MD9"2:Y%R^I<\B1%N/$?:,TX$P?8+.XSZJV_/V=\B-8E#
M-)^><F(CVU>[0[>LZST/I\%'1C80*)+UBQ/*_@$)%(\$<9;^!&(V=0?"F1S\
M3DWUYU_K?7[],KJD\]AM!Z>H:+$K,SFQ;0?X7J#+Y+W-080"Q+MSF,$0._!<
MCYOQ O:.DVGE<A.0(]HA.)E]P@-@-2DW&7BO#<M_C70#6S8T-W91140V1 M.
MH9=2U:6]QY;8P(LS)Q$R=;K>JPW%CD,,FH#3Y.12-Z\IM^I\I5=ALJOM(02#
MV3R7=BB/2OH[U4:U?T&6U52_5Z9DZGJ=I9[,.J5$T/Y>$5*2&,\Y'KAZBL%;
M:\.U(J11V9Z^-=U\7>D<&MP%-FV6+-)F@7\S:JFP?)H%5RWJG1..7O1#:1=/
MH#BKCS"S/CR.V]#E5QR(ER/H'RRHT"[IVKU=1@:>,F%%:LOSQ5"?7*=:]6V.
M^W)X+<0*;[B4.@Y!0[875/0VL]*ZA%IUE5O321:M(3026<1G0M=U?IW5.8"<
MA'!J.B7'2;;@]-J]A^T\CPQ8-;^5&U'F7(^F/S AH?7&[R[&Q3(S[9<.FBV)
M%;.^O?<5ME[9I2_J!/IM*TD?6_G[;<]$9D075GMWJ@1E:B:P=R1QD-F+NKQ'
MO'$>#O[S[M\B]0T&73]$Z>UMK"2Q]0KJC0P*C+)7&E7!3E[KDE6[KGG'P'A!
M[6Q\9_>9<9N73NI43DH0[59L70).' B"K@DF!BAQIO:5 S)Q)0^E,Q#S*M/,
MG:;4.^E3>VG-I7I6+=^"I3L76/>BK*[.(-I'+1_2C4*?+@^"OO'G<>,]T3IO
M4M<UW2] B04KFK35XZ\FH!ZL"1V?,5F5Y$!6NRD,LNQ1]QQ)W&2OSWQ7/Z%6
MIR0$Z! Q5TJ4G; [ES63@+:/8ZV)2*-U'I%B?)D7HEBMDR(]0X]=36(8>843
MLUF,C370'Y%*F<.UK"U98U:M(\$Z0M7MK+"8I38L4ZL0"AS,JF>]74N8]N)9
MU#!?,]I'0DNKTK4L>KU:^I:?-?CU+19ZE]+E*/3-+US6;C/,T"TWF73^G=2D
M2LECF95@@E:%I@5V1?"&E>B>,'Q.)'QJESVGF;8KJ')[\)%DODP,A)<[@+)<
MH*QA-NML+>VR95'FHHTD4<T6(L<FT\R-LLQC6J];)5U?I)=51=C#ZI<K,X D
M5+,L4$D3$$^\3 NH)4O$I!/$'.R?8^3ZQT/Z;9NB[$JLM_Y<T'58X)&>I+-I
M%2YJ56[$&52W&2@RP2.B2I7N3*RH7D3/9OG"L_1[&,8QC&,9X6?.CQNZKX)^
M1?0(^$:DHSE_2WK&[0+ V$T=5K;SV?D6Y9ZBS@YPY<++&5<E$>',04N*YO1T
M1#6<<%IDB$-R9AD6:,$[%AMR'Q#?6/B.7D@CX$C?WC/R;]+/1'4/HEZVUB&H
ML\&@:XUUM'NB)9=/U+1KDRV'TBVDJ25+,FGN(8K5.S&WSM:K?2%4>I+E=:7Y
M7=GI8C,2W/ V.N"5F\58"K6F*&D:]'@WRI=6I\@\*"+]GKVY% =KZ27  DOD
M00)]D,^HAS8];D>Y<:-6\G??=3ON=]U*-\=_?P4'X[#W[^<TK2_2'U1I<:5U
MMQ7J4='5M/AT_4*Z3TH8M7T[J'39FCB3LDM7AZIUR6G$[O4BFO2\ZTL+-"VZ
M_P""OXJ]#Z!UFV^;G90I,V()%LP=)EK6RMZ1Z'=[B0M%MNS6SD*6?$QH#LM&
M.2>V_II*:G'D D+<@Y%I&);F"J(D/GQOL?HJ/<OCW'P/'P _",^IOL7.@-<U
M;J/4?2MU*EAX'COQ:59OJQL:SJNIN5U'54:4<I:T$#6:[3[=NQ9MNL+DU)U&
MX7S3X@78Z]#WREPS;A=29,&L$9%!MH()@B%((1),CC-I4^J'(0\HI"$+=^C-
M<)W[6@7-[Q(I/.S'??W$GX_5Y^O_ #_CSZ-]+72D^HTJFM:;7[DVF)+%=@A3
M>1Z3D2+.B*-V]5D#F15!;MS-)X6)LUO$]'M)[<FB2+9D=RLE!S9#I8R-O(FZ
MY'%143+LN-?)5]8R$<6A]+WSA#G7]DG"D$(:=;R-A]7UC^D@G_,/\WNS@LFN
MZC,MA9Y5G]9GIVW:1!R%NA!)6JVE9>)[J0S2APW**9G,DT<CA67^Q?1[)#[J
MVP5A(53@I\"$4H;:E-#V;Z[[6T_OYNMOK=^TC-LN;]%#[>]6MI^6U[!4'?Q[
M]M_P[>[_ #9[7UV_5^3C"8E.EQ78:A,>Y5+_ 'O6>9Y#FS=^7BQV*<O9(XKM
M:OQ=YY9NQ=68ZO;@6WH"N+;*D91X!MABT604%(03>T?+TP=(:<TW+SQJ&U?.
M)9TL[>S9/YKEJ1@B\0=B?=Y\@;_U#X#^KW9TCT=Z+J/4_4B=3:E$#4T]EEFM
M&%8UU#48H1%"/ "RSA@MN[,JGG(O*;YVSR/BS^*KX/7GPB\L>AUN1@3FN3=
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MUIYEJ2MMRF4,OMPU>B]/-_->VT^:>4Z+$PP,G-'Q\<5C7K];3J[6;4G"-?
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MLW+3JBSZA?GV#6KMDHO>F8 !52&)(J\,,,?._2-TW-U+T_)'30/J-&9;M1
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MGZ$_\7VD?]?JGZ_FQ\V^O^H?Z,?DI^/7^B^#_P#B9G_B>/W.?H3_ ,7VD?\
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M=+;<;7K:5H6A6MI6A:=[2I*M;TK6]ZWK>MY0#MY'@CR"/AD\0&!5@&5@0RD
M@@C8@@^""/!!\$92^V?#G\&+M,%3]A\7.1.RIKBWS"8NLM5Q!1#JO>Z20)7'
M(D-XEY>]N/$N#J?><4IQUQ:U*5N>AZHZA@C$<6KW@BC90\QEV ]P#2\V  \
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MTMM---I4MQQ:DH0A.U*WI.M[QE+ND:-)(RHB*SN[L%1$4%F9F8@*J@$LQ(
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M:MN"".246'CZU:H58?6""#[B,W%_#C^-M>+KT6K<,\OWH23^^DD'7J?VB,C
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MX,>[[>KF"-%'N[?$,I]G?<'VN._G-<724'44EWU"(5CIT16SM!O\HB_8L2,
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IQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QG_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>gdc15tqwxkbk000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdc15tqwxkbk000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (L!>P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F2RQPQ/+*ZI&@+,S'
M]:?7FGQ%U34OM:Z>T;0V! 96!XF/N?8]OQ]*#*M55*',9WB_Q?)K4K6=FS)I
MZ'Z&4^I]O0?C].3HHJ3PJE2527-(****" HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ]F\"_\B;8?]M/_1C4WQMJE[I&A)<V,WE3&=4+;0W!!]0?2G>!?^1-L/\
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MIXIT?0UFT\ZCJK6EK;QK'':X+Y0>F/F]!GGI7(W;Z?;>*M.FT**YMH2\9'F
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M_D>3_P"*H_X07PW_ - [_P CR?\ Q5%@_L^KW7]?(\9HKV;_ (07PW_T#O\
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MP@OAO_H'?^1Y/_BJ/^$%\-_] [_R/)_\518/[/J]U_7R/&:*]F_X07PW_P!
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M_P )UX6_Z#ME_P!_*/\ A.O"W_0=LO\ OY7S#11]7CW#^TI]D?3W_"=>%O\
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M^@[9?]_*/^$Z\+?]!VR_[^5\PT4?5X]P_M*?9'T]_P )UX6_Z#ME_P!_*/\
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M\>X?VE/LCZ>_X3KPM_T';+_OY1_PG7A;_H.V7_?ROF&BCZO'N']I3[(^GO\
MA.O"W_0=LO\ OY1_PG7A;_H.V7_?ROF&BCZO'N']I3[(^GO^$Z\+?]!VR_[^
M4?\ "=>%O^@[9?\ ?ROF&BCZO'N']I3[(^GO^$Z\+?\ 0=LO^_E'_"=>%O\
MH.V7_?ROF&BCZO'N']I3[(^GO^$Z\+?]!VR_[^4?\)UX6_Z#ME_W\KYAHH^K
MQ[A_:4^R/I[_ (3KPM_T';+_ +^4?\)UX6_Z#ME_W\KYAHH^KQ[A_:4^R/I[
M_A.O"W_0=LO^_E'_  G7A;_H.V7_ '\KYAHH^KQ[A_:4^R/I[_A.O"W_ $';
M+_OY1_PG7A;_ *#ME_W\KYAHH^KQ[A_:4^R/I[_A.O"W_0=LO^_E'_"=>%O^
M@[9?]_*^8:*/J\>X?VE/LCZ>_P"$Z\+?]!VR_P"_E'_"=>%O^@[9?]_*^8:*
M/J\>X?VE/LCZ>_X3KPM_T';+_OY1_P )UX6_Z#ME_P!_*^8:*/J\>X?VE/LC
MZ>_X3KPM_P!!VR_[^4?\)UX6_P"@[9?]_*^8:*/J\>X?VE/LCZ>_X3KPM_T'
M;+_OY1_PG7A;_H.V7_?ROF&BCZO'N']I3[(^GO\ A.O"W_0=LO\ OY1_PG7A
M;_H.V7_?ROF&BCZO'N']I3[(^GO^$Z\+?]!VR_[^4?\ "=>%O^@[9?\ ?ROF
M&BCZO'N']I3[(^GO^$Z\+?\ 0=LO^_E'_"=>%O\ H.V7_?ROF&BCZO'N']I3
M[(^GO^$Z\+?]!VR_[^4?\)UX6_Z#ME_W\KYAHH^KQ[A_:4^R/I[_ (3KPM_T
M';+_ +^4?\)UX6_Z#ME_W\KYAHH^KQ[A_:4^R/I[_A.O"W_0=LO^_E'_  G7
MA;_H.V7_ '\KYAHH^KQ[A_:4^R/I[_A.O"W_ $';+_OY1_PG7A;_ *#ME_W\
MKYAHH^KQ[A_:4^R/J>#Q7H-S9W-W#JMJ]O:[?/D5^(]QPN?J:K?\)UX6_P"@
M[9?]_*\4\,_\D[\:_P"[9_\ HQJXRDJ";>I<L?-*+LM?\V?3W_"=>%O^@[9?
M]_*/^$Z\+?\ 0=LO^_E?,-%/ZO'N1_:4^R/I[_A.O"W_ $';+_OY1_PG7A;_
M *#ME_W\KYAHH^KQ[A_:4^R/I[_A.O"W_0=LO^_E'_"=>%O^@[9?]_*^8:*/
MJ\>X?VE/LCZ>_P"$Z\+?]!VR_P"_E'_"=>%O^@[9?]_*^8:*/J\>X?VE/LCZ
M>_X3KPM_T';+_OY1_P )UX6_Z#ME_P!_*^8:*/J\>X?VE/LCZ>_X3KPM_P!!
MVR_[^4?\)UX6_P"@[9?]_*^8:*/J\>X?VE/LCZ>_X3KPM_T';+_OY1_PG7A;
M_H.V7_?ROF&BCZO'N']I3[(^GO\ A.O"W_0=LO\ OY1_PG7A;_H.V7_?ROF&
MBCZO'N']I3[(^GO^$Z\+?]!VR_[^4?\ "=>%O^@[9?\ ?ROF&BCZO'N']I3[
M(^GO^$Z\+?\ 0=LO^_E'_"=>%O\ H.V7_?ROF&BCZO'N']I3[(^GO^$Z\+?]
M!VR_[^4?\)UX6_Z#ME_W\KYAHH^KQ[A_:4^R/I[_ (3KPM_T';+_ +^4?\)U
MX6_Z#ME_W\KYAHH^KQ[A_:4^R/I[_A.O"W_0=LO^_E'_  G7A;_H.V7_ '\K
MYAHH^KQ[A_:4^R/I[_A.O"W_ $';+_OY1_PG7A;_ *#ME_W\KYAHH^KQ[A_:
M4^R/I[_A.O"W_0=LO^_E'_"=>%O^@[9?]_*^8:*/J\>X?VE/LCZ>_P"$Z\+?
M]!VR_P"_E'_"=>%O^@[9?]_*^8:*/J\>X?VE/LCZ>_X3KPM_T';+_OY1_P )
MUX6_Z#ME_P!_*^8:*/J\>X?VE/LCZ>_X3KPM_P!!VR_[^4?\)UX6_P"@[9?]
M_*^8:*/J\>X?VE/LCZ>_X3KPM_T';+_OY1_PG7A;_H.V7_?ROF&BCZO'N']I
M3[(^GO\ A.O"W_0=LO\ OY1_PG7A;_H.V7_?ROF&BCZO'N']I3[(^GO^$Z\+
M?]!VR_[^4?\ "=>%O^@[9?\ ?ROF&BCZO'N']I3[(^GO^$Z\+?\ 0=LO^_E6
M;/Q7H.H/*MIJMK,T4;2R!'SM0=6/L*^6*[/X<_\ '_KG_8%N?_9:4J"2O<NG
MCYRDHM(]K_X3KPM_T';+_OY1_P )UX6_Z#ME_P!_*^8:*?U>/<C^TI]D?3W_
M  G7A;_H.V7_ '\H_P"$Z\+?]!VR_P"_E?,-%'U>/</[2GV1]/?\)UX6_P"@
M[9?]_*/^$Z\+?]!VR_[^5\PT4?5X]P_M*?9'T]_PG7A;_H.V7_?RC_A.O"W_
M $';+_OY7S#11]7CW#^TI]D?3W_"=>%O^@[9?]_*/^$Z\+?]!VR_[^5\PT4?
M5X]P_M*?9'T]_P )UX6_Z#ME_P!_*/\ A.O"W_0=LO\ OY7S#11]7CW#^TI]
MD?3W_"=>%O\ H.V7_?RC_A.O"W_0=LO^_E?,-%'U>/</[2GV1]/?\)UX6_Z#
MME_W\H_X3KPM_P!!VR_[^5\PT4?5X]P_M*?9'T]_PG7A;_H.V7_?RC_A.O"W
M_0=LO^_E?,-%'U>/</[2GV1]/?\ "=>%O^@[9?\ ?RC_ (3KPM_T';+_ +^5
M\PT4?5X]P_M*?9'T]_PG7A;_ *#ME_W\H_X3KPM_T';+_OY7S#11]7CW#^TI
M]D?3W_"=>%O^@[9?]_*/^$Z\+?\ 0=LO^_E?,-%'U>/</[2GV1]/?\)UX6_Z
M#ME_W\H_X3KPM_T';+_OY7S#11]7CW#^TI]D?3W_  G7A;_H.V7_ '\H_P"$
MZ\+?]!VR_P"_E?,-%'U>/</[2GV1]/?\)UX6_P"@[9?]_*/^$Z\+?]!VR_[^
M5\PT4?5X]P_M*?9'T]_PG7A;_H.V7_?RC_A.O"W_ $';+_OY7S#11]7CW#^T
MI]D?3W_"=>%O^@[9?]_*/^$Z\+?]!VR_[^5\PT4?5X]P_M*?9'T]_P )UX6_
MZ#ME_P!_*/\ A.O"W_0=LO\ OY7S#11]7CW#^TI]D?3W_"=>%O\ H.V7_?RC
M_A.O"W_0=LO^_E?,-%'U>/</[2GV1]/?\)UX6_Z#ME_W\H_X3KPM_P!!VR_[
M^5\PT4?5X]P_M*?9'T]_PG7A;_H.V7_?RC_A.O"W_0=LO^_E?,-%'U>/</[2
MGV1]/?\ "=>%O^@[9?\ ?RC_ (3KPM_T';+_ +^5\PT4?5X]P_M*?9'U+9^+
MO#U_=QVMIJ]I-/(<)&CY+'VK:KYG^'G_ "/^C_\ 78_^@FOIBL:D%!V1W86N
MZT7)HI7?^M'^[4%3W?\ K1_NU!7.]SK"BBBD,**** "BBB@#RGXU?Z[0_P#K
MG-_-:\JKU7XU?Z[0_P#KG-_-:\JKTJ/\-'SV,_CR_KH%%%%:G*%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5V;_P#)&8_^P]_[0-<979O_
M ,D9C_[#W_M U$NAM2^UZ'&44459B%%%% !1110 4444 %=KX'^'_P#PF5I=
MS_VG]C^SNJ;?L_F;LC/]X8KBJ]F^"T?G:%K<6<;Y%7..F5-9U).,;HZ,+3C4
MJJ,E=$/_  HS_J8__)'_ .V5YOXIT+_A&O$=WI'VG[3]GV?O=FS=N16Z9./O
M8Z]J](_X49_U,?\ Y(__ &RL/P9X=M+3XIS:)>QPW\-N)4/G0@JY X.TY%1&
M>[O<WJT-H\G+=[WN>=T5[FEQX-@\?/X63PO:/)*QWW+Q(0LA7=M52.%QQQC!
M[=ZY6Y\"6<_Q<;0H5,>FD"Y9%8Y6/;DKG_>X^AJE474REA6OA=];?,\VJQ8P
M1W6H6UM+.MO'+*L;S/TC!(!8\C@=>M>NZIJ/@B'Q0OA1O#-NJ"1(#>Q(H9)#
MC';+ $\DGUX-5/B!H^F67C[PS;6NG6D$$TD8EBB@55?,H!W #!XXYH52^EAO
M#63:DG9V. \4:)9:#J<=K8:S;ZM$\(D,\&W:K$L-O#-SP#U[UB5ZYXHT?2[?
MXO\ A^RATVSBM)88S) D"B-R7D!RH&#T'Y5L:[<^#?#WC&STI_"]G/-?>6)'
M\E-D(8[5VH1C.>3C'X]*2J:+J5+"IN3NDD['A=%>F^-O!%H/B'I>FZ7&EK!J
M2J61.D9#'<0.PP,X]:ZV\T_0M"U2TT2W\!2ZA:,%$U^+/S=F3UW;26QU/(Q3
M=565B5A)7:;M;0\%HKU/4/AK:K\3+32X-Z:3<1&Z(W<JJG#(#UZXY]&]JZ@V
M.A-XA/AT^ )!88\K^TQ9G&[']_;G';=NZ_G0ZJZ!'!S;?,[:V/!**]7\-^$;
M+2_BU>Z-=6T5Y9+;-+"MS&K@J=I'!SR,D9]JC\776A'69?!ND>'+*"ZGN8XO
M[0*+NC=V!(4;<X&['48[#@4_::V1/U9J/-)VUM\SRRBO=K_3-$\)R66E6W@6
M?68V0-/>"T\XKDD9W;3EN,XR,9%<WXE^'5E'\0=(L+$M!8:H6<H.3'L&YPN?
M;&,]":2JIE3PDXK1W_X)Y;77>.?!'_"%R6*_VC]L^U!SGR/+V[=O^T<_>_2N
MV\0ZGX%T/6E\,S>&;=X5"I<7:J%>'<!@AL;FX().X?C5?XY?Z_0_]V;^:4E-
MN2*>'C"G-MW:M\CR.O2M!^#FIZG81W6H7R:=Y@W)$83(X'^T,C!]LURW@6TB
MOO'&D03#,9N Y'KM!8#]*ZSXS:M>MXCATL3NMFELLGDJV%9B3R1WZ#&>GXU4
MF^;E1%&$%3=6:OTL9OBWX7ZEX9L&U"&Y2_LT_P!:RIL:/W*Y/'N#7"5T]IX^
MUVT\.3Z&)HY;6560M.F]U1A@J"3C'X=Z[7P=X7T[3/ Q\27NAOK5[/DPVBQ>
M9A=VT?+@CMDG!P/U7,XKW@]E"K/]UHK:^1Y'77-X(V_#I?%O]H_>./LOD?\
M34Q_?W>V>E=CXF\,Z=KO@:;7[3P_)H6HV>3+:M"8@RC&[C !&#D,!VQ3)/\
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MX<_\?^N?]@6Y_P#9:XRNS^'/_'_KG_8%N?\ V6HG\)M0_B(XRBBBK,0HHHH
M**** "BBB@ HHHH [#P;\/-0\7Q272SI:64;;/.=2Q9O15XSC/7(KHM5^"E_
M:6,DVGZI'>S(N[R6@\HM[ [B,_7%3_#OQ7HK>%I_#&LW9L<L_ES>88PRMR?G
M_A(.>O'2MFU\":KHEK-<>"/%!V2KGRIU21'^C8(!_P" _C7/*<E+>QZ5*A2E
M334>;OKJOD>'$%6((((."#VI*]8^%FD6^J:MXC37=/MKFZC=-XN($8HY9]V,
MC .1V]*V?#*>#/%<VJ:':^'+:&&T7;'<E09)5SMW;L;@<^YSFK=6S>FQA#"N
M:3O:][?(\.HKW#PU'X,UG5]0\*P^&X<64;#[7,JM)+M8(QW8W Y((P?RZ5PG
MART\*Z5XMU-/$EP3:V,KQV\3Q,_G,&(RVT'H!T/!S352]]"98:UO>5F<578^
M#O G_"6:;?WG]I?9?LAQL\C?OX)Z[ACI7HNCV'A[QQHNHJ_A!-($8Q#,L C+
M@@X96"CD8Y'(Y'7-9?P=_P"1:U__ 'A_Z :F51\KMHT:T\,E4CS:IW_ XOP_
MX(_MWPCJNO?VCY'V 2'R/(W>9LC#_>W#&<XZ&N1KUSX?_P#)(O%7^[<_^B!7
MD=7%MMF-:$8P@UU1Z-X4^%?_  D_AVWU;^V?LWG%QY7V7?C:Q7KO'IZ5R-OX
M?N+CQ:OA\-B8W9MF<+G;AL%L>@ )_"O8O ^H?V7\)+2^+!5AD9G)_N^>=WZ9
MI8/#2P_&6\U=U_T9+(78;LKL/+_'A7/XUE[1INYU/"PE&#BM7:_S.(\6_"W_
M (1?P_-JO]L_:?+95\K[+LSN..N\_P J\[KWCQW>G4?A E\00;E8)L'MN8'^
MM95YI_AGX;>'+%M2T6'5M6NQEEG (R -V"P(51D#IDTX5';75D5L-#G]S2*2
M9XY78WG@3[)X A\4_P!I;_-"G[-Y&,;FV_>W?TKI/$WA_0O$?@7_ (2SP_8B
MQEAYGMXP I4'## X!'WLCJ.WI=UC_D@-E_NQ?^C*;J7M;N3'#J/-S:Z71X[1
M7MR^'=,\%^'+#_BDI/$6I7(!G*V_G!#@%N=K!0,X QSCZU@_$+P=9+8Z5K>C
MV$E@U_(D,MDZ;-CN,K\O\)X((Z=/Q:JINQ$\)*,;WU70\OHKV;6H_"GPVL=/
ML9_#\&KWEP-TLLZJ3@8!;Y@<<]%  XZ^O+^()?!VI>)]%D\.PE?-N(UNH/(*
MQ$%E['OU! &#_-JI?H*>'Y-')7[' T5Z1\8-,L-,UG3H["QMK1'MR66WB6,,
M=W4X%6/B_I6G:9#H)L+"UM#*LWF>1"L>_'EXS@<]3^="J)V\Q3P[CSZ_#;\3
MG?&W@C_A#H].;^T?MGVT.<>1Y>S;M_VCG.[VZ5R->U?%337UC4O"&G1MM:YD
MEBW?W0?*R?P'-7K_ $[0_#-Y9Z1;^ Y]4MB@,]\MGYQ3)ZYVDL>Y&1CC'I41
MJ>ZK[F]3"IU)<NB5OR/!Z*[;XF>%+;POK\7V!2EE=QF2-"V=C X91[=#^-<3
M6T6I*Z..I!TY.,N@4444R HHHH **** "BBB@#I_AY_R/^C_ /78_P#H)KZ8
MKYG^'G_(_P"C_P#78_\ H)KZ8KDQ'Q(]G+OX;]2E=_ZT?[M05/=_ZT?[M05R
M/<]$****0PHHHH **** /*?C5_KM#_ZYS?S6O*J]5^-7^NT/_KG-_-:\JKTJ
M/\-'SV,_CR_KH%%%%:G*%%%% !1110 4444 %%%% !1110 4444 %%%7-(@C
MNM:L+>9=T4MQ&CKDC*E@".*0TKNQ3HKVOQ%X8^'?A?4K0ZE9W 6[ CC@2:0H
MN#S(Q+9 ^8#KVX'6J_B#P?X$\(:BEWJPNY+6[PD%DC,=A&-[;@0Q RO?/7KP
M!FJJ?0ZG@YJ]VM-]3QRO2/\ A2GB3_G]TK_O[)_\;JK\3_".F^&+S3YM*#I;
M7J/^Z9BVPKMZ$\X.X=?2O4/'/A_Q+KDEB?#^L?V>L0<3#[3)%OSMQ]P'.,'K
MZU,JFS74TI89)S4U=JVWF>3:Y\+?$6A:;+?R_9+F"%=TGV:0DHHZG#*.![54
M\+^ =5\6V,]WI\]G&D,GELL[LI)P#QA3ZUZ_I45_X.\(7\OBS6EON&9=TC/Q
MC[@9N6)/:L#X.7"VGA#6+EE++#.9"!U($8-+VDN5LOZK3]I%/2Z>AY##IES+
MK,>E,HBNGN!;%9#@(Y;;SC/0U?\ %'A>]\):G'87\MO)+)")@8&8KM)8=P.?
ME->E^,O#\,_BCP]XMTS$EK=W=L)V3IDLNQ_Q'!]P/6L'XU_\CE9_]@]/_1DE
M7&=VC&IAU3A)OHU;T,'PMX U?Q=93W=A+:10PR>63<.PW-C/&%/0$?G6#JNF
M7.C:K<Z==J!/;R%'VG@^X]B.1]:]F?4O^%;_  ^T"$KBYN)XWN%.-V"=\GY#
M"_B*YOXRZ,L.KV>MP*##>Q[)&4<%UZ$GW4C_ +YI1J-RUV'5P\8TKKXE:_S/
M,:***V.(**** "BBB@ HHHH **** "BBB@ HHHH **** "NS?_DC,?\ V'O_
M &@:XRNS?_DC,?\ V'O_ &@:B70VI?:]#C****LQ"BBB@ HHHH **** "O9O
M@M'YVA:W%G&^15SCIE37C-%1./,K&U"K[*?/:Y[!_P *,_ZF/_R1_P#ME0^%
M/#'_  B7Q:M]-^V?:\V;R^9Y6SJ#QC)]/6O):*GDDU9LT]M234H0LT^YZC_S
M<#_V]?\ M*M/6==@\/\ QO2ZNV"6TEND,KG^ ,O!^@(&?;->-U?T6_@TS5[>
M\N;&&^@C8[[>8 JX((/4'GG(]P*'3_*PXXGI:WO7/7M5^'\,WCA/$SZO:Q:5
M+<1SD%OG9\C"J>AW-WSWQ@U!\2?^2C^$_P#KK%_Z.%9%MXJ^&MM>QW\?A>^2
M[1@ZXP45ATPIDQ^E<AXR\42^+=>;4'A\B)$$4,><E4!)Y/J22:B,9-ZFU6K3
MC!\MKMWT/2O%W_);?#7_ %PB_P#1DE8WQ$_Y*WI7_;M_Z,->745:IVL83Q/,
MFK;NY[3\1=630_B)X;U*5=T4"$R ==I8@D>^":Z75(?$NM7EO?>&/%-G!I,J
M#>#"DFWU*G:<_0D8KYQHI>RT1?UQWDVM'YV_$]9C\47&B?$RS77/$%OJMO%$
M\#7,42H(-_8[1C(*KGDX!KL=0L/%]WJLEWIGBZSM]%D&^,_9HY&3CH/EPP]]
MU?.M%#I=A1Q;2::ZWW?YGKW@R]O+WXMW)O=5AU22&S>(74*!5< J>  !P2?\
M:Y#Q)?+IGQ6NK]E++:ZDLQ4=2%8''Z5R%%6H6=S.5=RAR^=SZ-U,Z_XB-IJ/
MA#Q-:0:=(@$J/"CX.3E@2I.>Q4XQBN&U37[S0?B)HLFM>(H-8BLF?<T,"QF
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M.J:;&\=AJ5Y:QN<NL$[(&/N >:7LDDK;C^N.4I<^S*5%%%;'$%%%% !1110
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M4HPY=7^13HHHK8X@HHHH **** "BBB@ HHHH **** "BBB@#L_#/_)._&O\
MNV?_ *,:N,KL_#/_ "3OQK_NV?\ Z,:N,J([O^NAM4^&'I^K"BBBK,0HHHH
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M-O\ &C_A9VH?\^%M^;?XT>WD'+@^[.4_X4QXE_Y^=,_[_/\ _$4?\*8\2_\
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M?XT>WD'+@^[.4_X4QXE_Y^=,_P"_S_\ Q%'_  ICQ+_S\Z9_W^?_ .(KJ_\
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M.U#_ )\+;\V_QH_X6=J'_/A;?FW^-'MY!RX/NSE/^%,>)?\ GYTS_O\ /_\
M$4?\*8\2_P#/SIG_ '^?_P"(KJ_^%G:A_P ^%M^;?XT?\+.U#_GPMOS;_&CV
M\@Y<'W9RG_"F/$O_ #\Z9_W^?_XBC_A3'B7_ )^=,_[_ #__ !%=7_PL[4/^
M?"V_-O\ &C_A9VH?\^%M^;?XT>WD'+@^[.4_X4QXE_Y^=,_[_/\ _$4?\*8\
M2_\ /SIG_?Y__B*ZO_A9VH?\^%M^;?XT?\+.U#_GPMOS;_&CV\@Y<'W9RG_"
MF/$O_/SIG_?Y_P#XBC_A3'B7_GYTS_O\_P#\175_\+.U#_GPMOS;_&C_ (6=
MJ'_/A;?FW^-'MY!RX/NSE/\ A3'B7_GYTS_O\_\ \11_PICQ+_S\Z9_W^?\
M^(KJ_P#A9VH?\^%M^;?XT?\ "SM0_P"?"V_-O\:/;R#EP?=G*?\ "F/$O_/S
MIG_?Y_\ XBC_ (4QXE_Y^=,_[_/_ /$5U?\ PL[4/^?"V_-O\:/^%G:A_P ^
M%M^;?XT>WD'+@^[.4_X4QXE_Y^=,_P"_S_\ Q%'_  ICQ+_S\Z9_W^?_ .(K
MJ_\ A9VH?\^%M^;?XT?\+.U#_GPMOS;_ !H]O(.7!]V<I_PICQ+_ ,_.F?\
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M\+;\V_QH]O(.7!]V5-&^&>N:?X3\1:7--8F?41;B$K(Q4;'+'<=O'!]ZY_\
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M+;\V_P :/;R#EP?=G*?\*8\2_P#/SIG_ '^?_P"(H_X4QXE_Y^=,_P"_S_\
MQ%=7_P +.U#_ )\+;\V_QH_X6=J'_/A;?FW^-'MY!RX/NSE/^%,>)?\ GYTS
M_O\ /_\ $4?\*8\2_P#/SIG_ '^?_P"(KJ_^%G:A_P ^%M^;?XT?\+.U#_GP
MMOS;_&CV\@Y<'W9RG_"F/$O_ #\Z9_W^?_XBC_A3'B7_ )^=,_[_ #__ !%=
M7_PL[4/^?"V_-O\ &C_A9VH?\^%M^;?XT>WD'+@^[.4_X4QXE_Y^=,_[_/\
M_$4?\*8\2_\ /SIG_?Y__B*ZO_A9VH?\^%M^;?XT?\+.U#_GPMOS;_&CV\@Y
M<'W9RG_"F/$O_/SIG_?Y_P#XBC_A3'B7_GYTS_O\_P#\175_\+.U#_GPMOS;
M_&C_ (6=J'_/A;?FW^-'MY!RX/NSE/\ A3'B7_GYTS_O\_\ \11_PICQ+_S\
MZ9_W^?\ ^(KJ_P#A9VH?\^%M^;?XT?\ "SM0_P"?"V_-O\:/;R#EP?=G*?\
M"F/$O_/SIG_?Y_\ XBC_ (4QXE_Y^=,_[_/_ /$5U?\ PL[4/^?"V_-O\:/^
M%G:A_P ^%M^;?XT>WD'+@^[.4_X4QXE_Y^=,_P"_S_\ Q%'_  ICQ+_S\Z9_
MW^?_ .(KJ_\ A9VH?\^%M^;?XT?\+.U#_GPMOS;_ !H]O(.7!]V<I_PICQ+_
M ,_.F?\ ?Y__ (BC_A3'B7_GYTS_ +_/_P#$5U?_  L[4/\ GPMOS;_&C_A9
MVH?\^%M^;?XT>WD'+@^[.4_X4QXE_P"?G3/^_P __P 11_PICQ+_ ,_.F?\
M?Y__ (BNK_X6=J'_ #X6WYM_C1_PL[4/^?"V_-O\:/;R#EP?=G*?\*8\2_\
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MO\:/^%G:A_SX6WYM_C1[>0<N#[LY3_A3'B7_ )^=,_[_ #__ !%'_"F/$O\
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MO\:/;R#EP?=G*?\ "F/$O_/SIG_?Y_\ XBC_ (4QXE_Y^=,_[_/_ /$5U?\
MPL[4/^?"V_-O\:/^%G:A_P ^%M^;?XT>WD'+@^[.4_X4QXE_Y^=,_P"_S_\
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MQZX%0UI:)K=SH%\UW:I$\C1F,B4$C!(/8CTH'&U_>V$_L#6?^@1?_P#@,_\
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MTMO_ $,US==)HG_(G^)OI;?^AFN;H-:GPP]/U84444&04444 :.@?\C)I?\
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M1G^0-<)'K]U%XB.MK'#]I+L^TJ=F2".F<]_6F7FN7MYKC:QN6"[+*P,(("D
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MM&LC*V]0<]#G'&>.*#.A6A3;4M5T^1HVGVCQ5X\O)+:_EM(U5L2P.0QB4A0
M1Z\'\:Z#PQ!ID'B2]AL[2_>YA#K/>73YW'<,CC@D]<GGBO.-)U:[T6^6\LW"
MR %2&&0P/8^U= _Q&UQYXI MJBQDDQK&=K\8YYS^1%!5*O37O2WO<Z'P>\8\
M8>)8R1YK3L5'? D;/\Q7$VVF:])K-U!:)<?;D+><8WV'KSD\<$_G4+:]>_VX
M^KP%+>Z=MQ\H?+[\'/7WK<D^)&N/"46.SC8C&]8SD?FQ'Z4$^TISBE)M6;_$
MY6YAGMKF2&Y1TF1B'5^H-14^65YI7EE8M([%F8]23U-,I'(]] HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *Z1O^2;)_V%?_ &D:YNND;_DFR?\ 85_]
MI&@UI?:]#FZ***#(**** "BBB@ HHHH **** "BBB@#T;X=30W.D:EI9?;*S
M%\=RK*%R/IC]17+KX-UTZD+(V,@^;!FQ^[ SUW=/?'7VK(L[VYT^Z2YM)FBF
M3[K+_GFNI_X63K?E[?*LLX^_Y;9_]"Q^E,ZHU*4X*-2^A%XA\*6VFZSI^FV%
MS++-='!60 E 2 #QVZ_E77^*!X;%I::/JE_-:I JO''"I/ !49^5O>O.;77[
MVVUP:Q(4N;P9.Z<$C)&.@([5#J^K7.M:B][=!!(X VH"%4 8XR30-5Z<8RY5
MOT\CT?6(;#7_  (XTRY:[6Q ,<C@[R4'.<@'.TGM5+P-<O9>"M7NXPID@>21
M0PX)6,$9]N*Y+0O%-_X?AGBM4@DCF(++,I(!Z<8(Z_TI+#Q->:=I%[IL$-O]
MGN]^_<K%EW+M.#GT]<T%K$0<U/9VM_D>@^&/%C>)(9[.4K:7ZKE6B&01Z@-G
MD>A__5Q#6L=GXU:+Q1(TL.YC-*V[YQM.TC;SC.WITZ=JP[&]GTZ^AO+9MLT3
M;E/]#['I6AKOB.Y\0O#)=VUK')$" \*L"1Z')/%!$L1SP7/NON9L>(/^$,_L
MB3^QO^/W<NS_ %W3//WN.E/^&?\ R,EQ_P!>C?\ H:5QE:>AZY=>'[U[NTCA
M>1XS&1*"1@D'L1SP*"(5E[53:2MV(];_ .0_J/\ U]2_^A&H=.N%M-3M+E\E
M89DD./0$&H[JX>[NYKF0*'FD:1@O0$G)Q45(Q;]ZZ/2_'NBW>KQV6HZ;&;J-
M8R&$7)*GD$#O^'M6/H_@4S:5<WNLO-8JB[HQ@9"@9)8'^7!X-9FC^,M7T6W^
MSP/'+ /NQS*6"_3!!I-9\8:MKEO]GN'BB@)RT<*D!O3.233.N52A)^T:=^W0
M[+PF;1_A],LT$ES$K2">&'[[<YQP1SC'>JUKX@\/V.C7<=AHFJI9SAED8Q[T
MSC!R2Y KC-$\1:AH$KO92+L?[\<@RK?Y]JT=3\=ZSJEF]J_D01R#:_D(06'I
MDDT#CB8\BZ-*VQT&A?\ )+=1^DO\A4:_\D=?_>_]KBN7M/$][9Z!-H\<5N;>
M8,&9E;>-W7!SC]*0>);P>&CH7E0?92<[]IW_ ']_7..OM0)5X6M_=M\SJ+/Q
M1;R:):V_B+0YI;>,!([CR=RG QGG&#CT-5_%?AK2K?0HM9TL/ CLO[IR<,&]
M W(/]*S['X@:W8VJ09M[A4&U6G0EL?4$9K.USQ-J6OE!>.BQ1G*Q1+A0?7N2
M: G6IRIV>K]/U,>BBBD<04444 %%%% !1110 4444 %%%% '2:)_R)_B;Z6W
M_H9KFZZ31/\ D3_$WTMO_0S7-T&M3X8>GZL****#(**** "BBNZ^&/\ R%+[
M_K@/_0J#2E3]I-1[G"T5TZ^&KWQ#KFM&SD@7[/<N6$K$$Y9L8P#_ '34DGP]
MUR*R-R1;LP7<85D)?Z=,9_&F/V%1ZI71RE%=6/A[KILOM&VW#;=WD&0[_ITQ
MG\:S=#\,WVOBZ^R/"AMMN]9203G.,8!_NFD+V-1-*VYC45U<GP]UR*R-R1;L
MP7<85D)?Z=,9_&@?#W739?:-MN&V[O(,AW_3IC/XTQ_5ZO\ *SE**V-"\-WO
MB"6>.UD@C:  MYQ(ZY] ?2F:3H%UK.J2Z?;R0K+$K,QD8A>" >@/K2)5.3M9
M;F516SIWAF]U/6[O2H9;=9[7?O9V(4[6"G&!GJ?2M5/ASKCQ,Y:U4C.$:0Y/
MZ8Y]Z"HT:DE=(Y&BK*Z?=OJ/]GI [7?F&/RAUW#J*Z8_#?7/)\S?:%L9\OS#
MN^G3'ZT"C2G/X4<A16E9Z'>WFN+H^U8+LEE(FR I +<X!["MU/AQK;M("]HH
M0X!:1OG]Q\O\\4!&C4E\*.0HKJ;3X?ZY="0LD%OL8K^^<C=CN, \>]8=UI-[
M9ZJVFR0,;H,%"+SNSTQZYH%*E.*NT4J*Z]/AQKC0"0O:(Q&?+:0[OIP,?K7,
MW.G7EI?FQGMW2Z#!?+QDDGIC'7/M0.=*<-9(K45UC?#O71:>=BV+[<^2)#O^
MG3&?QK8^)D9FN](B7 9_,49]RE,OZO-0<I:6L>=T5KZ]X<O/#LD"7<D#F8$K
MY3$XQZY ]:?K7AB]T*UM[BZEMW2<X41,Q(XSSD"D9NG-7NMC%HKT+XG?ZK1_
M]V7_ -DK)M/AYK=W:I.3;0;QN$<SL&'U 4XIFD\/-5'".MCDZ*Z33O"EZ?%,
M>EW:1*T>)I S':\8(S@CU'T_"MWQ_P"''14U.V%O%96T"0F)<AL[ST &,?,.
M] +#S<'/L>?45T^F^ ]9U*T6Y406\;C*"=B"1ZX /ZUEZSH&H:%.L=[$ '^Y
M(ARK_0_XTB'2G&/,UH9E%=;%\.]9FCAD2:SV2IO!,C?*, C/R]>>U5K+P1JU
M_<7,<+6^RWD,33,YV,PZ@<9./I0/V%7^4YNBNBU?P5JVC6;74PAFA7[[0L3M
M]R"!Q7.T$3A*#M)6"BBB@D**** "ND\&_P#'WJG_ &#9OZ5S==)X-_X^]4_[
M!LW]*#6A_$1S=%%%!D%%%% !1110 4444 %%>E_#J;[/X<U*?;N\N4OC.,X0
M&I-+^(7]J:E!9?V-(!*X4LDN_;GN1M' [TSJCAX.,7*5K^1YA177>/=*@M/$
M<*V,2JUU&&,,8_CR1P/?^>:$^'.N/;B4FU1B,^4TAW#VX&/UH,WAY\SBE>QR
M-%6CIUX-1_L\V\GVO?L\K'.:Z4?#?7#"',EF&(SY9D.X>WW<?K2)C2G/X4<A
M16A#HFHSZN=+2V;[8K89#_#CN3TQ[UMWGP]UNTM&G'V>?:,F.%R6Q]"!F@(T
MJDDVEL<I16QH7AN\\0FX%I) GD!2WFL1G.<8P#Z5J'X=ZZ+3SL6Q?;GR1(=_
MTZ8S^- 1HU)*Z6AR=%=OX \/B[OYKV\AB>&W)C\J4'<LG!SC&..>M9_BOP[>
MV6O,V(Y3J%Q*\$<.2V"V<$8'/S#IFF4Z$U3]H<Q177I\.-<: 2%[1&(SY;2'
M=].!C]:P4T6];6DTF6,07;N$Q(> 3[C/'TI$RHU(VNMS.HKK)_A[J]M!<3RS
MV2Q0*69C(V" ,G'R_P ZY.@4Z<H?$K!17L6J^(O^$<\/:;<?9?M'FHB;?,V8
M^3.>A]*CT?6;7QK8WD%YI9BB0 $LV]3GT; P13.KZI'FY%/7T/(:*[3P.NKI
M<ZDNBM8, 4#M=[^1EL$;?QK&T3PO?Z];7$]F\ $!P5D8@L<9XP#2.?V,FERZ
MWO\ @8E%=7+\/-<BLVN/]&=E7<85D)?Z=,9_&L/2-&O=;O/LUE&&8#<S,<*H
M]2:!.E.+2:W*%%>F>%/".IZ!KZW%T8)(6A9=T3DX/&,Y -4+/^TO^%C:M_97
MV3[1A\_:MVW;E<_=YSTIFOU:22<M+NQP5%='#X?U'Q#XBU2%9+5+F*:1YB68
M)NWD';P3C/K5I/AUKCP&0FU5NT;2'<?TQ^M(S5"H]8JYR5%7+72[V\U+^SX(
M&:ZW%"G3:1USZ8KH9?AUK<1C^:U<.P4E'8[,]S\O3Z9H%&E.2O%')45?UG2+
MC1-0:RN7B>15#$QDD<_4"J%!#3B[,****!!1110 4444 ;G@_P#Y&W3O^NA_
MD:]LKQ/P?_R-NG?]=#_(U[931ZV7_P -^I2N_P#6C_=J"I[O_6C_ ':@J'N>
M@%%%%(84444 %*OWA]:2E7[P^M &=X\_Y$^\^L?_ *&M>-U[)X\_Y$^\^L?_
M *&M>-UHSQ<?_%7H%%%%(X@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'F?[.W[V/Z4#>(@]=O>O\CJ=7NI_^%HZ?%YKB--BJH8X (.?SK2:.)_BBID
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M"BBB@ KI/!O_ !]ZI_V#9OZ5S==)X-_X^]4_[!LW]*#6A_$1S=%%%!D%%%%
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MEMW7!S^0JMH_B/\ LGQ!/JOV7S?-W_NO,VXW'/7!_E0)5H+DUV;.U\-QP_\
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MS_H5%_\  ]_\* ]G'^9?C_D<W172?VWX<_Z%1?\ P/?_  H_MOPY_P!"HO\
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MT;_GYO\ _OXG_P 11_PK/1O^?F__ ._B?_$46#ZC6/*J*]5_X5GHW_/S?_\
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M]"HO_@>_^% >SC_,OQ_R.;HKI/[;\.?]"HO_ ('O_A1_;?AS_H5%_P# ]_\
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M;@6]U^Z?/H,\-^!-=;0 4444 >;?$'_D/0?]>J_^A-7*5U?Q!_Y#T'_7JO\
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M^-(****# **** "BBB@ HHHH **** "BBB@ HHHH **** /0O"W_ "3;7/\
M>F_]%+5WP]>R:=\-FO(OOPLS@'OA^GXU@Z#KFG67@C5=.N+C9=SF7RX]C'=F
M-0.0,#D&I++7M-B^'D^EO<XO6#XB\MN<MD<XQT]Z9Z-.I%):_99U@L;?6-7T
M;Q+8X(P5F'?:58#/N#P?_K5EP64-Y\6+]IT#_9X5F0'IN"1@'_QZL3P/XJ@T
M8S6>H2E+1_G1]I;8W<8 )P?Z>])-XJM[+Q]<ZO:DW%G,JQMA2I9=B@X!QR"O
M?TH&ZU.48R?>[^X[RWA\1?VY))=3V+Z6Y8+"N=ZKV/W>3TSDXZUQ ^V^&_'.
MH-I&GS75O&0)88HV("N P' ./;Z58N7\!7-Y-?RW%P[S9=H K@;CR2..OXXK
M(\/>);;0==N)8()1IL_RF,L&=0.A]R.>/>@*E2+<4WUWO<Z0:QX,\1RA;RT$
M%S*P&YX]C,?]]?ZUROB[PZOA[4DCAD9[:9=T9?[PQU!_Q]ZZS^T_ /VS^T-B
M?:<[\>3)U]=N-N:Y+Q;XB7Q#J:20HR6T*[(PV,GU)_SVH(KN+IOF:<NEOU.B
M^%W^MU3_ '8O_9J\]KL? 6N:=HLE^=0N/)$H39\C-G&[/0'U%<=085))T8)>
M84444CG"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KT3X6_\Q;_MC_[/
M7G=>B?"W_F+?]L?_ &>FCIP?\>/]=#T2BBBF>X%%%% !1110 4444 %%%% !
M1110 4444 %%%% %/5-+L]9L'LKZ+S(7YQG!![$'UKE%^%>@"3<9[]ESG895
MQ_Z#G]:[>B@""TM+>PM(K6UB6*")=J(O85/110 4444 %%<?>>*[ZW\?V^@I
M%;&UDVY<JV_E2>N<?I3D\4WS?$63P\8K?[(JY#[6\S_5!^N<=3Z4 ==1110
M4444 <QK?@/1==O6O)Q/#.^-[P.!N]R"",T_0O!&C^'[O[7;+-+< $+).X)7
M/7& !7244 %%%% !1110 4444 %%%% !1110 4444 %%%% '&?$S_D6[?_K[
M7_T!Z\JKU7XF?\BW;_\ 7VO_ * ]>54F>+COXP4444CD"BBB@ HHHH ****
M"BBB@ HHHH *Z32O'&KZ19):1^1-"G""9"2H] 01Q7-UZ+IWP[L[K1(9[BXN
M8[Z6'?M!4*I/(R,9XR,\_E3-Z$:LI/V9S&M>+]4UVW%O<M%'!G)CA4@,>V<D
MFL&G21O#*\4BE71BK*>Q'6FTC*<Y2=Y/4***Z23PNL'@[^W);@M)(5\N)1P
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU&#X$L+"S4@M)/;!'3'<$J,GT 'XT 5-3_Y+-9?\ _\ 0#4D?_);YO\ <_\
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MSFK6GW.DZSX#@TJXU6WLI4P'\U@"-K9X!(SD4%J?OOE>KC^([1Y#-\,]4E8
M,YF8X]ZGT2]AT_X8K=W$"SI$681L.&;S?ES_ ,"Q6?IE[86WP^U*R-];^=F9
M40RJ&?T(&<\U9T*\T67P!'INI7\$7FED9/,&]29"5.WKP<'I0$):K77E+&F7
MT/CO0+ZWO[6)+FW'RM&#A20=K#/(Y!XS_.J6@0VOAOP8WB"6U6>\E^YN[ MM
M4#T]34EO=:)X-T"\%GJ<-_>W/W3$0<G!"Y )P!DGD^M4O#VL:5J?A=_#NKW'
MV8K_ *N9FP"-VX<G@$'L>U N977,USV?W]#4TB_@\>Z;>6FI6<*74*@I+&.F
M<X(SDC&.>>:J^$K2#1/#-]KMQ;K+=(7"@_PA>, ]LMWI;*ZT/P3IET]KJ<6H
MW\XPOE$$<9QT) '/.3S5/PGK>GW&AW>A:O<B%9BQ25VP,-UY/ (///K0"DN:
M/.US6?\ P#HO!WB,^(9KMY[."&ZB5<R1 _.I)P#GGCZ]ZS/AW_R%-<_WU_\
M0GJWX9C\/>')+B--=M9YI@"TC2*JA0> .<9Y]:R_ FHV-GJ6LM=7EO LCJ4,
MLJJ&Y;ID\]:"HR?-3YWKJ2^ M*2/1;K6$M4NKW<RV\;$#H.Q/0DGKZ5L2Z??
M^(M"NX=>TN&UO$4FWEC96&<<8P21T&?7-<WX+U^SBTJZT:^NVL_,+-#<*VW;
MD<_-V(QD$^M3Z@EI8:9-(WCB^N;C!\M8+G<#Z J&/YY%!-.4%25MK:ZHU/"4
M/E^#HYM$2T?46)\UI\]<G@XYZ=*QO&5UJTVF)'JFA0Q.K#_3(GW 'VQT!Z8)
MJIH&FZ-/IPGC\2RZ;J!X;<XC"_J,C\:VM?UVQL_"<FF-JR:M>3+L\Q<$#GJ<
M<#';DG- K\U&S=M.ZM_PYYK1112/-"BBB@ HHHH **** "BBB@ HHHH *['X
M:_\ (RR_]>K?^A+7'5V/PU_Y&67_ *]6_P#0EH-L-_%B>KT4451[X4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4KO_6C_=J"
MI[O_ %H_W:@K-[C&3(TD$B(=K,I /H<5X=_PJ+X@_P#0['_P,N*]TKA/BQXJ
MO?"O@_S--)6_O9UM87 R4R"2P]\# ]R*$!P9^$_CU9!&WCH!VZ*;V?)_"NR^
M'O@CQ-X7U:ZN=<\0'4H)8/+2/SY'VMN!SA^.@-<?#\ +Z]MOMFI^)W&JR@.Y
M\DRA7]"Y8%OKQ72?"K6]:AU76?!GB"<W-WI)#0SEBQ:,G&"QY(Y4C/.#CM3>
MP'J-%%%2,\V^(/\ R'H/^O5?_0FKE*]!\7:1;W^JQ2S:O9V;" +Y<Q.2-S<_
M3G]*P/\ A&K+_H9-,_[Z;_"K6QX>(I2=631SM%=%_P (U9?]#)IG_?3?X4?\
M(U9?]#)IG_?3?X4&'L9_TT<[171?\(U9?]#)IG_?3?X4?\(U9?\ 0R:9_P!]
M-_A0'L9_TT<[171?\(U9?]#)IG_?3?X4?\(U9?\ 0R:9_P!]-_A0'L9_TT<[
M171?\(U9?]#)IG_?3?X4?\(U9?\ 0R:9_P!]-_A0'L9_TT<[171?\(U9?]#)
MIG_?3?X4?\(U9?\ 0R:9_P!]-_A0'L9_TT<[171?\(U9?]#)IG_?3?X4?\(U
M9?\ 0R:9_P!]-_A0'L9_TT<[171?\(U9?]#)IG_?3?X4?\(U9?\ 0R:9_P!]
M-_A0'L9_TT<[171?\(U9?]#)IG_?3?X4?\(U9?\ 0R:9_P!]-_A0'L9_TT<[
M171?\(U9?]#)IG_?3?X4?\(U9?\ 0R:9_P!]-_A0'L9_TT<[171?\(U9?]#)
MIG_?3?X4?\(U9?\ 0R:9_P!]-_A0'L9_TT<[171?\(U9?]#)IG_?3?X4?\(U
M9?\ 0R:9_P!]-_A0'L9_TT<[171?\(U9?]#)IG_?3?X4?\(U9?\ 0R:9_P!]
M-_A0'L9_TT<[171?\(U9?]#)IG_?3?X4?\(U9?\ 0R:9_P!]-_A0'L9_TT<[
M171?\(U9?]#)IG_?3?X4?\(U9?\ 0R:9_P!]-_A0'L9_TT<[171?\(U9?]#)
MIG_?3?X4?\(U9?\ 0R:9_P!]-_A0'L9_TT<[171?\(U9?]#)IG_?3?X4?\(U
M9?\ 0R:9_P!]-_A0'L9_TT<[171?\(U9?]#)IG_?3?X4?\(U9?\ 0R:9_P!]
M-_A0'L9_TT<[171?\(U9?]#)IG_?3?X4?\(U9?\ 0R:9_P!]-_A0'L9_TT<[
M171?\(U9?]#)IG_?3?X4?\(U9?\ 0R:9_P!]-_A0'L9_TT<[171?\(U9?]#)
MIG_?3?X4?\(U9?\ 0R:9_P!]-_A0'L9_TT<[171?\(U9?]#)IG_?3?X4?\(U
M9?\ 0R:9_P!]-_A0'L9_TT<[7HGPM_YBW_;'_P!GKG?^$:LO^ADTS_OIO\*Z
M_P #6,6EF_$%[!?^9Y>[[.2=F-W7/KG]*:.C"TY1K)O^M#MZ*K_:'_Y]Y*/M
M#_\ /O)3/9+%%5_M#_\ /O)1]H?_ )]Y* +%%5_M#_\ /O)1]H?_ )]Y* +%
M%5_M#_\ /O)1]H?_ )]Y* +%%5_M#_\ /O)1]H?_ )]Y* +%%5_M#_\ /O)1
M]H?_ )]Y* +%%5_M#_\ /O)1]H?_ )]Y* +%%5_M#_\ /O)1]H?_ )]Y* +%
M%5_M#_\ /O)1]H?_ )]Y* +%%5_M#_\ /O)1]H?_ )]Y* +%%5_M#_\ /O)1
M]H?_ )]Y* +%%5_M#_\ /O)1]H?_ )]Y* +%%5_M#_\ /O)1]H?_ )]Y* +%
M%5_M#_\ /O)1]H?_ )]Y* +%%5_M#_\ /O)1]H?_ )]Y* +%%5_M#_\ /O)1
M]H?_ )]Y* +%%5_M#_\ /O)1]H?_ )]Y* +%%5_M#_\ /O)1]H?_ )]Y* +%
M%5_M#_\ /O)1]H?_ )]Y* +%%5_M#_\ /O)1]H?_ )]Y* +%%5_M#_\ /O)1
M]H?_ )]Y* +%%5_M#_\ /O)1]H?_ )]Y* .4^)G_ "+=O_U]K_Z ]>55[+XH
MTF;Q'IT5C&PMW682AI1P< C''^]^E<G_ ,*QU#_G_MOR;_"DSR\70J3J7BCA
MJ*[G_A6.H?\ /_;?DW^%'_"L=0_Y_P"V_)O\*+'-]5K?RG#45W/_  K'4/\
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M^%'_  K'4/\ G_MOR;_"BP?5:W\IPU%=S_PK'4/^?^V_)O\ "C_A6.H?\_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUZK_ .A-7*5:V/G\5_&D%%%%!@%%%% !1110 4444 %%%% !7HG_ #1K_/\
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M*1S!1110 4444 %%%% !1110 5Z)\+?^8M_VQ_\ 9Z\[KT3X6_\ ,6_[8_\
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MD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KT3X6_\ ,6_[8_\
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M5>;_ (^[?_@7\JL4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.7:[*LZ@ !/E)V?[76M_PAKM_P"(] 34-1T2YT:X:1D-I<;MX /!^95//TH
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M^3OV;\=LX./RH UZ*Q/"'B'_ (2OPII^N?9?LOVM"WD^9OV88K][ ST]*VZ
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MC'XUV,^E7>FZA:1:'I^GP6. ;BY91YBX//)Y/'U[]*R?&BG_ (3#P^V/E,B
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M''IDU.FLZI%"(8]2O$B P$6=@ /IFC^R-3_Z!UW_ -^&_P */[(U/_H'7?\
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ME_*C[-!_SR7\JEHH 8D,<9RB!3TXI]%% !1110 4444 %%%% !1110 4444
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M?U%:U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!2N_]:/\ =J"I[O\ UH_W:@K-[C"B
MBBD,**** "E7[P^M)2K]X?6@#.\>?\B?>?6/_P!#6O&Z]D\>?\B?>?6/_P!#
M6O&ZT9XN/_BKT"BBBD<04444 %%%% !1110 445=@TC4[J%9K?3KN:)NCQP,
MRG\0*!I-[%*BK\FB:M%&7ETN]1%&2S6[@#]*JV]M<7<HBMH)9I",A(T+'\A0
M#BUI8BHJTFFWTET]JEE<M<(,M"L3%U'N,9'457DC>*1HY$9)$)5E88*D=01Z
MT"LT-HHHH ***M6VF7]ZA>UL;F=1U,43,/T% )-[%6BI9[>>UE\JXADAD'.V
M12I_(U%0 444\0RM$TJQN8U(#.%. 3TR: &4444 %%6(K"\GMI+F&TGDMX\[
MY4C)5<#)R>@XJO0%F@HJQ]@O/L?VS[)/]E/_ "W\L[.N/O=.O%5Z ::"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ KU?X:_\BU+_ -?3?^@K7E%>K_#7
M_D6I?^OIO_05IH[,#_%.QHHHIGLA1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% '._9I_P#GA)_WP:/LT_\
MSPD_[X-=%101R'._9I_^>$G_ 'P:/LT__/"3_O@UT5% <ASOV:?_ )X2?]\&
MM73$>.V8.K*=Y.",=A5VB@:C8QF\*:(_BE/$S66=82/REN/-?A<$8VYV]">U
M)I'A/1-!U74M3TVR\B\U.0RW<GFNWF,6+9PQ('+'H!UK:HH*.?'@?PXOBT>*
M5TQ5UH9/VE97')0H3LW;<[21T]^M9NL?"KP7K^K7&J:GHOGWMP099/M4R[B
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M>P;.S]<_G7.^-O#6IR^();ZUM);F&XVD&)=Q4@ $$#GMG/3F@MQ=*$E2WO\
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M6L%%%%!D%%%% !1110 4444 %>K_  U_Y%J7_KZ;_P!!6O**]7^&O_(M2_\
M7TW_ *"M-'9@?XIV-%%%,]D**** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM!O-'NWE2WNXS'(T) < ^A((S^%1^&] M?"_A^ST6RDFDMK52J-,P+D$D\D
M#OZ4 >=:Y\);L^ O#6GZ->0_VSX><SP22C$<KLP=Q[98 C/I@]<B'7/#?C7X
MF7>DV/B31+30M(L9Q/<LEXL[W) Q\@7[H(R.>F<\XQ7L%% 'F6I^$];N/C]H
MWB:*RW:/;6;12W/FH-K&.88VYW'EUZ#O1\+?">M^'/$WC2\U:R^SP:E>++:/
MYJ/YBAYB3A22.'7KCK7IM% 'E/PX\$:UI-OXTMM8LQ:IJTS?9R94<.C"09^4
MG'WAUQ5GX0Z/XJ\*Z;)X=UO0XK>R@:26/4$O$?S69EPH0<@8W')QT Q7IM%
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MG6%6ASU(1;U13_L#PY_T!E_\"'_QH_L#PY_T!E_\"'_QJY101[.'\J^Y%/\
ML#PY_P! 9?\ P(?_ !H_L#PY_P! 9?\ P(?_ !JY10'LX?RK[D4_[ \.?] 9
M?_ A_P#&C^P/#G_0&7_P(?\ QJY10'LX?RK[D4_[ \.?] 9?_ A_\:/[ \.?
M] 9?_ A_\:N44![.'\J^Y%/^P/#G_0&7_P "'_QH_L#PY_T!E_\  A_\:N44
M![.'\J^Y%/\ L#PY_P! 9?\ P(?_ !H_L#PY_P! 9?\ P(?_ !JY10'LX?RK
M[D4_[ \.?] 9?_ A_P#&C^P/#G_0&7_P(?\ QJY10'LX?RK[D4_[ \.?] 9?
M_ A_\:/[ \.?] 9?_ A_\:N44![.'\J^Y%/^P/#G_0&7_P "'_QH_L#PY_T!
ME_\  A_\:N44![.'\J^Y%/\ L#PY_P! 9?\ P(?_ !H_L#PY_P! 9?\ P(?_
M !JY10'LX?RK[D4_[ \.?] 9?_ A_P#&C^P/#G_0&7_P(?\ QJY10'LX?RK[
MD4_[ \.?] 9?_ A_\:/[ \.?] 9?_ A_\:N44![.'\J^Y%/^P/#G_0&7_P "
M'_QH_L#PY_T!E_\  A_\:N44![.'\J^Y%/\ L#PY_P! 9?\ P(?_ !H_L#PY
M_P! 9?\ P(?_ !JY10'LX?RK[D4_[ \.?] 9?_ A_P#&C^P/#G_0&7_P(?\
MQJY10'LX?RK[D4_[ \.?] 9?_ A_\:/[ \.?] 9?_ A_\:N44![.'\J^Y%/^
MP/#G_0&7_P "'_QH_L#PY_T!E_\  A_\:N44![.'\J^Y%/\ L#PY_P! 9?\
MP(?_ !H_L#PY_P! 9?\ P(?_ !JY10'LX?RK[D4_[ \.?] 9?_ A_P#&C^P/
M#G_0&7_P(?\ QJY10'LX?RK[D4_[ \.?] 9?_ A_\:/[ \.?] 9?_ A_\:N4
M4![.'\J^Y%/^P/#G_0&7_P "'_QH_L#PY_T!E_\  A_\:N44![.'\J^Y%/\
ML#PY_P! 9?\ P(?_ !KH-#M+.RL6BL;86\1D+% Y;G YR?PK+K9TK_CT;_?/
M\A07"$4[I(O4444S8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX\9/P_G6%6[J/_'C)^'\ZPJT,9[A11102%%%% !1110 4444 %%%% !1110
M5YS9:OXMU66<6$_FB$@-\D2XSG'4#T->C5Y3HCZ\CWSZ*&(!!FVJA/\ %MX;
MGUZ4%1-;_A(O$6B7\":RH:&0\@JG3N05XR*Z/79K^.\M1::K96:'[Z7#*&DY
M'3(-<?I<-UXLU9!J>H ^1R8F&&([A0 !]:T_'/\ R&-*_'_T(4#MJ7_$VLW^
MGZYIUO:S^7%-C>NQ3GYL=QZ5T<>H64LY@CN[=YAUC64%ORS7$^.8S-KNFQ!B
MI=0NX=LM3?%/AZST6PMKW3S)%*DH0G>23P2&]CQVH%9:'?.ZQH7=@J@9+,<
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M"K0QGN%%%%!(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6
MSI7_ !Z-_OG^0K&K9TK_ (]&_P!\_P A05'<O4444S0**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVMH2C,"2V>*L44#44@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
2%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>gdc15tqwxkbk000021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdc15tqwxkbk000021.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &K EX# 1$  A$! Q$!_\0
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M?'D0?<<X8)(<30MT:0A$&VU>XXY!E,2T(7O7KI"UL..)2KT^_P!U6];]/O\
M3TP59?G K_&"/^_/$DCD!,<B2 >1*,K 'Z"5)XSNYYE>,8QC&,8QC&,8QC&,
M8QC&,8QC&,8SH3RHL4F,HH2@#4S)3,&&J?,CPTRITC>],0XVY#C>GY3^TJTS
M':]YYS>M^XA7IO*@K-SVJS<#D\ G@#WD\>X#Z3Y9;>6*+M\22./O8(G>ZIW.
MWN1>XCN8_!1R3\!G9U(85IA27F5)D_\ @V].(WJ1ZMJ>U\#>E>COY)*G?R?O
M?DTJ7_DZWO*>/]GO_5\/^_*^X>7F/:^;YCVO+GR^GR\_+X>>=1LP(=FJ'-%!
MSA!"EI7 ;G1ES4*;UM3B514N[?2I"=;4O6T:VG6M[5Z:UE7:P'<5;M^G@\?Z
M_=E FB+^&)8S(.04#J7!'O';SSY?'RQ.,"!:FTDB@X<I[2E-)G3HT13J4[UI
M2F]2'6]KTG>]:5M/KK6]ZUO\^L!6;YJLW'T G_NP\L4?'B21Q\^[O=5YX]_'
M<1SQG8C3(DV.B7#E1I<1SW]MRHS[3\=>FUJ;<VAYI2VU>XM"T+]%;]U:5)5Z
M;3O6O""#P00?H(X/^HY4KJZAD964\\,I#*>#P>""0>""#^L9UQI@298U*$%!
MQ6,K:]:D#9L:<QO;;JV7-:=BNNM[VV\VXTOT5^*ZVMM7HI"M:]964\,K*?H8
M$'S'(]_TCS_BRF.:*8=T4L<J^?M1NKCR)4^:DCR((/T$$'SS]^K"OC_*_4Q_
MS7S&XGRWSL;X_P UI'Q-QO@_$^)\QIO\IMGW?B:1^-[ON_?GG:W'/!XXYYX/
M''/'/\7/ES]./%B[NWQ(^[N[>WO7N[N.>WCGGNX\^/?QYYZ&>9<QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&4>]G/&01\2.:=3E:T]9O(S9_P F+J27
MZ;E$K'W4Y-Z A$E?^ENO5\N!IHEC6M('U^M!Q;"41X+2$RFY]G83UQY)3[*4
M:CW*E51%Y?Y;J\C'\IW9CYG-3Z)4/TW0V#><^[\;>VI#QWR3[>5K@[C_ .Q@
MEAJQ#W)!!%&/909EOEK+N$NA$AU$EN12-0CC.FV!Z/I2I#8NOG(S@B,CTWK3
M:W9D,E9&GMZ6GX=*E1]ITJ0A6OE3^J8L]46>BMA1Z.LO7O=+P:[T@[J6$,TR
M:[1[BO)K:Z\$"-I;56_OHI"'!3I.S 5!F5ANU8('!?S#\QJ/UL//_80OT^WD
M\<PO,'I5 JMW@?#2V?$QY4EAM7O)A$F_>C%H'KO>][^0)L2XGO;^]>F=+_,K
M6=E]'O6%/K[HKISJ^EV+'N]9!9GA0]PJWTYK[*ESR233V$-FKR?-O"[O<1EB
M1#&[(?R3_L]X/\HX.59ZA&12?.OQ;NXG7R[_ &CG/;>"WEIO7HDW#IXF!VWG
M$^9K7IM;]-E5[I, 4ZKUTRST0TU]VY*?3HT!\757HF\Q6FK6XN?R3(QJS@?Y
MT/ 6'Q\%3\,U&^HJ=6]/VX_9;:4MKI[8'_6K6B3:T7?Z35:"\D9_)%V4?E9>
M+(O-KQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8RNOE71*_>N$]'28
MIJKN7K-'Z&?HHN-7I]J,1[M,YK<Z>-F5X"+B$"!$\Z/M982/:AP)<K2BBUQ6
MDR4LNMYE"5XK</;)X2O+"DK%Q&IB$T<C!W8@*O,:L22![/F>.1D!U/2@NZ38
M":IZY+7IWYZ42P/9E6X^OMU(G@@C21Y)REJ6*,(C-S(2H[N"*?\ BAQF[UGV
M8E4"<SIT_D/E%8O">OT#XUAKA7G=L&=CJO)B]<I;]M&'X B?!,5JVD-M;,DH
M"):X;,7:Y<H9"&Z9DMA9BDWDC3R"S03:/-PCK-&U:2PKRB-D+ J\:_-4\<D^
M08MSJ72^HNUO1O5AUM234]2S]'UZ7-BO+0M1;>MJY:]1K44\<3I-7M/QXLD?
M<5"\LT:1\0]7M6:B>SQY83XMX_W:1YO>./C3J."#'N26J'<*MUG[#,5OL[\@
MB>"115Y.V@S,LUD$"6YEJ8ZO970MK'";+!5LFQD/V2[BPMJY%\EW;O+NEB-H
MY*_B]];A4<M$J*(T9N(S7C#1LT9]DQ=?UFCT%K)-1H;C=9=/].=L$,^KLK;K
M;3U):^X)DFA6*[/9F:S8BB#6AM+)AM)%80^(M-/,JD>0_7Y72K9*H'6^O/6O
MP.Z76JC8*YXZ]9'SG]FO-[A%[H'-RX]?+JE*E7ZMTD.96YK=,JD\R&K$FX:K
ML>+(>(RI/6RTZXAC$U:L(]K"\B/=K,H[=7;BEG1O6)0(7E9!_"R!7<1]Y( &
MH]6T]]M9+]MJ.TVIL]$[*O4L5]!M$<^-UEH[U'72QG6U7>]7I0SD_P!AU9)H
M:S6Q756,C;BO&CH?DA8^Y]_J?8!)R5SP(8.F.0W5FLN52JRZH0Z1<10&FD@=
M@YY4K9!O]2KX6"U/)QK9T.J7FMR@5Y&2Z^DW%BD]<O0TDJU)*S()G5%L1^)X
MD@D6"-GD#)-)&89'8E08X9(G#Q$/VDKUGIV_U!8W6\J[:*9J$$L\NJN+7-6L
M]6386XH*DD$^OJVDO58(4621;>PJW:[0W8W@$RK)>S(G-UQC&,8QC&,8QC&,
M8QC&,8QC&,8SY7I>T*TWM*5[2K2%*3M24K]-^[M2=*3M2=;]-[3I2=[U]VE:
M_/C!YX/'D?@??P?XO+G-1/@72(]:\;N><Y\J.97@OY1\V[3TWH_1CY+FMV.%
MR?4F>IW"T0^Q!>C00"Q5G#'J8^(2&,AS\UHT 2SS.!$FEHFJ@G8MM*9+LTU"
M>):$]6"&%!/$BBOX$49K-"S]R-')W=ZL@*/^/8A3XF<JZ'IBMT]0U_4NMNR]
M2Z_;[+8;">377)I9=D-E;LKMH=@D!BLPSTVB$,L,[B:#C7(CRKZKGB\D(=VY
M_P"876"O0.>=0-\5\WN$)Z^I<2D=2NPKC_5^>PYE='\\N<;7/!HZ@D[5Q1VL
M5U^M3/FYIBW\[;BQTR9Y]E$JJP*DVMKK#- EK5VO5^#+!$UFO,0YFB/C,9A'
M9\1^]> L<Q)X">5G5ONZ/5FSEO4-E-I^L]'\JGLI[*Y%J=I01JZ4+B_)\<=&
M2WIVK5S7<L\MK7]JAGG7NJ#[);DG:.6=+\7Y/;N(=8Y]$C^%9_FW/CP;E-^I
MX8?86.M%[3T.E>5D<P#W.%7B/[@DWQ<V<77*44KY W&&:*6N2A,>1Z@L5IX+
MXJVJ\Q.S2>96L0R,4-=8X9=>5?AHCYK95 \JL%+=L8\]4]%NKW&LV/31W.FV
ME!%Z.GU]">+5WJD,=@;26SL*?4ZRP]\5U>(IM/-.:].6"298Q+:8=O\ 2AFE
M9]#8QC&,8QC&,8QC&,8QC&,8QC&,8QC-81P!9*[[1GH]][95+);^&W'Q6JM"
MXB7B46R=%IU9-,VTM*[-0B@FO ["@%:;\AZKE-.E!T9-[!"X0"!-+/UY8F#.
M(R2::&*K(D=J*_)-:4RI#(Z&-!6F5G=.^.(B1>%)\)V+D*'#-S>:"S7](&PO
M;BK8M:6WTS5HZ:9:5B_4K3"W*VWHR1P0SB"S>!K2\RQJ+L$20(\K5S$L*^5P
MSK-$9\<^K^,W*>IJH?@3<^+AQW&*]5.H2;CT'F%XJ^N>]8J56Y]%I1J-T5NH
M\FM-3W7[2S9W?L;9:IT$5-CRRR$9E:]J\INU[UBOXNVBLLUIY(/#AGBD\:O)
M),95,1DL1R=\?8#*DD3 A<A^IX]I17I_:=.:O9^I=$7-1#'J(*NR>W?UMVMZ
MAM*M:@E.8; 5-7:K&"RMD^IV:MZ-U:4<937RPY-U^U>6OF;=P/!>P6#B-LOG
MLT[/<K+1N*]*@=LG4KF#EB)7.U>,-C?K*(Y*^T2S2:=$Z%71(LQ:IU,)GH\!
M0>0%(R6)+7V*\>OUL3VZR6HX]TD23686JK).(Q''>02<K#*@D,+LRQK*J%NX
M,!FH]4:K:VNJ>KKL&CVT^FM7?1W9MV:6GV,>XDIZUK$ERSTY8-<+)>HV346_
M7BCEM/3DG5#"\+L-C/M;N4M],\-KZ8I/*+-T;K!DMX]A:VQ5.<6NZW]JJ"O(
MSF-_LL*$ #@RE@!#V @<L9LVMCA_Q4"HT4TIQ^",BM0W3UCP-C&LMA(8%2XS
MF2:.*(R-3GB0EV94=B[*L?M'YQ*>18YO_I4U?RETC=FI:NSL-I--H8JXJZ^U
M<OBK%O\ 6WK")!%#)8AC6&*2:R/#CY$2K-R8XU&7^T XY;YOA39Z)XT4L@@;
M*Z+3;S?.9T(;*&V&\<Q,]>@]![O60 )I,2<\6N4 G92)JJQFF9MFC2C=68'2
MI)E(B5;U%F(;..6](I(AEBBFE(9(IUKM%5=V\QVQL$"R'D(0LG< O<,SKK46
MGZ/LT>G:<GAOL*=V]KJ,;1SW=;-MH[V\K00#M=I;<<EEYJJA7LJTU98V:80O
MCWDE>;!4&Z;U;Q'YG;!I>_\ 1>/\O[YTD!Q&YI/!.+#P'5'ZN0B4TES&SEBZ
M:5=S $59B [F5IG52M'9HF:V+7&3-K-5*))#)!L9XRL,-B>I"]J/L>RSU^]3
M()T5?%B5V0&>,22*&!;GA\?J&[/4%39]*ZZU'->OZG6[S80::X)X=/'!M&K.
ME236V99?4[LT,=EX]=9>M6G>)Q$5$E;7G;J!Y"->01;H)#F?3#5G8\\?#[J9
M'H->\=NK?9 JBL^S'M%#OO20U>T!U+32H?8UM!"HU172QAF5#KA8DP24A[<S
M%-3]46$3P*AU.R@$+W*_B+XF\CEA@9^\CQ36Y96[?:4%U7M\LT*U1WR[Z2_+
MKMC-97K?I79RWZ^@VGJDHK^C>S1N[&&#P.[U--N1!+'XOXJ9DKRR"0ALW)>$
M]R[_ '#E]C3Y*""D#I55OLBHOF'HT2+5[N/%TJCR=WCG;:>=<M-,TVP&2!EW
MZ7;*DQ9*W:6;/5),\A!!#G\UO:15(IT]293#)").T$F2)FEE'A3?CIU\1%51
MS'(4>/PY. SL,ZYT=;WMO6V/PABD38UKQJM*55:UR..G2;UW7@:_63"G/-),
M?#LU18KVELU6>1((VRXF1N;9C&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QE
M$/!0BU0*I=?$$\K4"[^*UJ+580.?_).V'@5F-F;!X^7X0UO:M20LNA/QZ*3D
MQG'F85]H-R#.;:7 0C<KM1XTD>Q3VHK\:R,WO[+:(JVX6/E[8E!E4$ F*:-O
M/GG-1Z2<4Z]KIJ8A+?3UB2O'&?(S:>>66;37(Q^5"U,BH[*2%N4[49X*#+&1
M^;-F)]U+W^IT*TDC<W:@*YC6R7R8..,8'CZZ]))U]R0.C-.LR",F5!U+TZ0,
MDI+4%KW6VW>,0=!Q[2[U9L^M.FNC.H;VVM<Z=K47RAZMJ(-?%2I:.6QL-(TU
M*O'+%/=FGIBRLEW:[">.I'VHDNZ>)VA!&\BA?,_#VN>2P ;@_ #GCR4#DYB'
MCER*Y\7#'JJ;- S5:F%7C0%N Z25-"OR=-M2AZ_G83+<J&^VRR_IY#D=34QN
M0Y\L[\^M4;5_03Z,>J_1/JMSTWMMMJ-MH+6RFVVDCI27S;U$MCLCLT7-NK&E
MFK*D<4RRH\#1VDG<UY/76:O58E24JRA@P'#<@<'CW'R/O]_\G'T><1,$FNZ>
M=0^57UIG4#PQH-R!V0['WIP=.\B>X,5=MJGQ)>O>:?)\PY$&(SK8PQO?R,GL
M%<A2'$S8DZ(Q]'E?5=6>_P I=E-&R(?(BG5,G,A'YL]A@(R??ZNY'D0<TD.-
MMU:C0GOI]+T[44\J^:/N]LM<"LK^XR4-;&[V57YAV<"L0RNHO?D5FW8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC*U=W\<8/
M6RE6Z)3KD9XYWOG<<A$Y]V2JPH1*=#$%7&)!BC7FL$MH#]'Y?8)42')-TDXM
MCX<Z+&.5<Q5[/$A'XV;5NFNLD,D:V:DQ!FK.2H++R%EB<<M#.@)"2J#Y$I(L
MD9*&#V^D3925[M:U+K-O2#K2V==%D=8I"IEJ6X'XBO4)F56EJRD<.JRP2U["
MI,L91NI^=5)3H1=_%?GW9I$?6FVKSP/MX6IP#B=?=J9/YSV^%69M,?7O7O.B
M8/1>B,,:W^2.RM_BZOF#52^U%?FK _\ 56ZK2,OZEFJEQ+^IC#"3\5'O. NP
MZMJCP[?3]+:,OD+>GVL5=)A^<]+:I7:JQ\^8TNWE'EQ,WPZ1)KSI[HTNOR!E
M#\,*!/3N,=LP:Y1NX>1,T<YKTEQ*='8K(GD/,";[2ML1[=/*=@D0-J<D0JS%
MFHB3V/5.KJGOYEV4H\UC:,U:8/P,A\1K,RCWF-17!\@7(Y!H<=6[8&$QT^EZ
M;^S+8BM+MMTZ'YRUE$$>MH2$>0LO)LRG)*5U8*XM+R+D=!X;00G-N;!?HE8"
M?./I2_,F%2Y@N5F/DSUFLQXF]*+V6UV4Q*F&K)9#4R87-EYDH@0E/2'E*S L
M6);4K33-W.W \@%554!41$4!4C10%1% 55   &;!K=;3U-.*C1B\*"+N/FS2
M2RRR,9)IYYI"TD]B>1FEGGE9I)9&9W8DY)66<SL8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QFD3M7EUY%
M<O\ :S\AX$U<-2.$=$'TF*F@NUZN:84Q;QI8+*+).I$)LJIL*V"G2C+NS.V4
M-QECML_(N/LN2L5:"372S=GXY"_M]S?DD'CCGM^:>../]N?(_5GI-ZZZ>_JE
M>F.BUV@?H[>0ZB,:5J5#L*;.O:J261<%47_&BV5=K"-ZUV!8_ [?"9T.[O(K
M/KC-:7F-Y"].J5H.\SH9?[*L)H$DW]=&QF5V999J 4-,LBYDM,F/%;E)&11'
MN,P535IF3OE)3$UR$_#^7.K/3/U9I_ZHSH3T6ZJIJ6Z>VKZ1-R;M2:>Y9&UF
MM-:EKSQV8176K3B3U<"-U]865['C1%84Q]M$PT.TL13S06(J=F6"6$J'62&,
MR1JO<C@^*ZB-N!WE7(C*2=KC9;GU'F1C&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,@7NODCS'Q[@5[[:23AFW7>?(#\XY900$^Z]4Z6:B,:DRQM
M)I(=+A$D@>PMN0:.3-CJO6HKK4ZS'0T%Q,G>74I3W"_A!%CB :>>9Q%7@4^0
M,LK>RO<00BCEW(X1&/ED'NNH=;H4@]<:>:U==HM?K:,$ES9[&9%[GCITX09)
M/#7AIIG\.M70A[,T2'NR"V^Z^=)I'U6N^!U3#@W-?&C#>J>758J?0UQE:]YK
M4JM\^Y-V"G0IZV]IVN&OI;C;#N]LO2T;2I:<KU35+[,FVD9_<37UTDD//QX>
M:Q6D*_K\#DCSXR%&ZZUF EK]$U88#[2Q[/JJM5O]I\P&KT-5MJB/[N4.Q(!Y
M!89ZU0\VZ?%L[/.?)&CVKQ'Z5*@DR(8?V0C5=\WO,('"=)G)/-NV5LT4YO:'
M PII14I7B!:MWH>,1()SJ?&'1)4MJF35R&/QJ4L>PA!56-99/&B+D*@FK.JS
M1]S$*KA7B+$*)"Q -ZGUC5%I==U!1M=+;)TD>"+;25C0O)"ADF;7;BM-+K[3
M11 RR5WEKWHX@TDE18U+B(Y'M!K)VDA- >!'CS;/*)B)+D#9O=K&71QGQ7%S
M([JHDQ0SJ-D&3SO3W14K7^.0N64VRQ)+7PUQCR6'?FF\@:A*P#[6W'1Y 854
M4V+S @$<P(0L 8'R,\B$>?*<C@XAZRGVCM#T?I;&_56*/MYY1J^GXV!*L8[\
M\;S;#PV^<NNJV$(X*S 'NSMHXK[3;HO^/] \UN.<!2[^*NH>-'C@.N^HK6]_
MY.NB>09RR2)K^D?B+E-<[$I<<_+L1H>O1C7GK.DA\HM99M_^TNW6BY/T^#41
M /U#QFX'D2WORH:OKR[[=WJG6:?G_P##:+1QVNT?1Z[N9K!9O\84H^3YA5]V
M<^_"CR:1KYF/[3_RO25_RM/2*'XP2Q/Q=_?Z[!KXFB/MKU_,Q\Q[NM?BZ5Z9
MY\ITO<=)0[?H$MT-_P!OUGG_ &9[^"N^'M#K[J/Q/?R:F@:/G_,G4]O'ZN>,
MZ[G+/:B\QUN=2/*SQ]\G(R/QG*IY"\(?XX9?9;_&4U!Z+P<VZ)CSY&M?#:D3
M^5R832MZ^-'5I6W6_1/HY_*6A;I'ZRG:]84'Z3#;7N('Q G!/P/TTG7]?T/;
MJ=0Z;?*/?7W6H.LE('P2]J)3&'/N#/KV4$^8/O'*!]HE!Y]8!%#\X>+7/PPM
M1N<R) WJUE1E_P#&>W%)"O=BP0'D+5FFJV$(3$)7*0)Z8*H$YAC;3*OBRU;8
MUXVG,R-+K+,6R11W/%&K178U'O+TW]M@#Y<P-,#[Q[/GGL/6J4IHZ?5>KM=+
MV)7$<-NQ(ES0V9#\U(=U %@B=N"PCOQTG X'!8\9L?CR(\N.Q+B/LRHLIEJ1
M&DQW4/1Y$=Y"7&7V'FU*;=9=;4EQIUM2D.(4E25;3O6\AB""01P1Y$'R((]X
M(S>%8, RD,K ,K*00P(Y!!'D01Y@CR(SFQGN,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8S^<OVN-TUXV>;_AGY4JJC=O; U<Q"6 <
M(J#)-[H-CE$%14ED0B7R4F.WTA$B-)5 FI:>2QMR,\U[S>YK7)X]6U7[NWN8
M'GCGCO4#GCD<_,^GS_5GPI_5-;7\ O2[Z*O2.=<NS6EKK,)I-.:HMG2WY9S&
M+(AG\&1%WPDCD,,H1PA:-EY!V3>(?M'N0^5W+^D=&0&,<U>Y+*%M7BO')<8V
M]$A'VGU5\H*FBV6G"<4Q+A$1<9I0Z',T1@NLJC;:=C/O:GUCN=3T)H]CU)U'
M>2GI=76-JY<\.60HGB1PI&D,2R2RS33S0P0Q1JS2RS1HHY;/HOT-^F/3^F/7
M;2SK-=:U&PTUFO!L-9;GALLD=R.62I:AL1",2P3>KVH^7AA=)*\@*%2CM#Q:
MR\]\G?+KE,D+!.)K\%(E^?\ 46V1[I0E0))V]0EKCL/S/?$27H V!/BRU(V1
MA(E0GX[;+_JO\^=?Z0NF?2W_ %6/HWZ@Z2K;**E2U-RA9FV=>&M):LZK5=5;
M#UN&&*Q89(1!/7AC>9HYC)#R8$X4OVRQ4#T)()_-?&@EX1B.3#8AF16\O-&>
M,"1".'C9D/DQS;?GZ,9AXQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,9X%JM59HU;.7&YV /5*G61<PU8K)82,00#""![*I
M$XD4)SG6(<&%%80MU^1(=;:;0G>U*UE<<;RND42-))(P1$0%F9F/ 55')))]
MP&6+-JM2KS6[D\-6K6C>:Q8GD6*&&*,%GDED<JB(J@EF8@ 920?Y==JZTTDS
MXN>(=MZ'S^1K2P_5^Y= '^,])N,5>O?CEJ0$*U3H78"U?F,*;D#SYGE-;%%H
M[K<D/)(PUHE*DSKJM?V;^QCAF'SJ]6$WI8S\5E99(:RN#R&1;#LI!#!3Y9IJ
M=5;C: 3=-=*6K]%O.':;J_'T[3MJ?FRTX9*U_;2P,O#1SS:NM%*I#0M(A#'Y
M(>8/7N1-J+^5GB7;>7<^9U[Q?K_&KZ-\D^<T^.G\9XI?(06LT/KE=K\5K2GI
M]FC<G,5X0PAR4=)BH3;DI/HUM:Q[.OV$<\WY-:S"U*:0_FQ%I)J[N?<(S85V
M/DBL?+/9.J]KJAXO4W2UK6T1_"[747H^H=?47XR74AK4=K! H]J2RNKE@B4%
MII(T!8<O3_:+\ J9H50>0JLGECV:QA!]BKW)/&2%!Z49^@F8S,H/9;A:XA"-
MS_G-3FQY<&:D[=K2'T\+F,DQD(G'4GW_ "#3VY%:6QV4*R,4>Q=)@7O7D,D<
M9'BS2 @CMB1N&':Q4Y?O=<:6"2*KJVFZDV5B&.>OKM J;"0PRJ&BL6+*.*5*
MLZLCB:W8B!C8/&KKF#LM>U3[5KYIV=XQ^#U6F_E(XOZ4=\L>V#D:]/1HM.T7
MYGQR#)<3Z[6T,1<([#F]>[.DH:W\Q<_]15O+B]M''O;N6A6;]:CMFLD?Y7AD
MCX GV<4#TA;3VB^@Z3KMYB/PYNHMJ@^B1_$H:Q&/T1BRH/Y; >UW$^&7E>4U
M\Q;/:A^2DDAO[][I?)_&"B"4J]/S-"F>1&UZ;U]VM)?(2'=ZUZN/N+WM>>?*
M-!?X/24PO_M;%Z9OY6-A1_J4#Z ,K_!?J*3VK'7^^9__ -EUV@J1_P D8UDI
MX_RG8_2<^%^,/G[4O\:YY[24A;?E?1R/6O('Q@X];A$]2/OU&FV+EW]$-KBM
MO>FDN2FI4YQM/O;:C;6KWM/7M3)Y3:81\^]ZEZQ&P_6$G]8C/'T<+R?><\^0
M>L:WM4NN'L]OFL&ZT&LLQ/\ XKSZ[Y,LJ#\6#.1\%SS)/E5YF^/.OB^7/B=$
MO] B^JB?>/"0J<Z6*"QO\I1&U\!N$4;U\(*@QT.3"Y*J3>D1Q["'O73B6FWI
M-7J&MM_]'WS%*?FU=FJPLQ_-CMQDUW8GR42"$L>/<20*#U#U1I>3U)TZMRFO
MF^WZ5DEOQQ+[^^QIK*Q[.)$ +2O6:\J 'W@ F\/%^Z\?\B:- Z3Q'H=9Z32B
M*U,-FJU/3)U#G-H0N0)-#W4L%:\=AZ<;T0 GH(TR/4M*)L&.O>DY&6:MBG*T
M%J%X95\RKCWCX,K#E74\'AT+*?@3FUZO;ZS=5$O:J[7O57\A+ _=VN/G1RH>
M)(9EY'?#,B2H?)T!R6,Q\D<8QC&,8QC&,8QC&,XGWV8K#TF0ZVQ'CM./OO.J
MTAIEEI&W'77%JWI*&VT)4M:E;UI*=;WO?IK/0"2 !R2> !\2?<,\9@JEF(55
M!9B?(  <DD_  >9S7[X+UM/5!)?SKO,;9'I/D['<+\]>)-[==YCXOZ)R9'%.
M:U;3VO\ BF&=J^AO3;ZY":AN66^VR?()?,Q@P)$&7VK^KLNJB/$%$A9@/^OO
M=H%F:3CYQ23N@BYY[(D 7@L_.B=%5_E.&7K6ZOB;'J-3-0,GM'7=-^*S:?7U
M>[^"2>L(]C=[ OK%ZR[2=RQ0!)C[?Y,#N0W #38 B!<C<ZFW"Y6,+$-J@E:3
M7PS<)@#>;2TV.)N0><R3SS@.RF(,0K9 D5YVWCJH>J51OY2L8M6D;$;R%C&H
MDCB1BO*RNW)>)/:7F8)[:*2J.0(S(LDD0>=VN]CUMF&LD:697K6;,\2R]LE2
M&(((;=@!'*46F/A3RHLD\2DV8Z\U:M<D@@M[G0WRJYOTWQ#\E(,7O%"F5F-I
MKN]:KZ1]:9M,AAN;]GQ\^7))_!Z/S%Z>++U>\!G2@TN-6P.LTMF[![5 ,90F
M:A/!L:1]5E$A_L5WY?PP>WN90%YAGX99(CVLK E!X31E86;70]3:_8],;Y%V
M]*2NO;N*\(2%+) <1Q2,9.W8:]GCEK6XC(DB%4G86HK"2RUX.7^QW3@(NNWI
MH4STKA]LNWCMTGZ$,C!0D^V<6L4RE)LP<1";9@B1=YKH\!?!XN"PQ"&1+.R/
MB,M,1FT:L;6%(K;/%W>!:CBNP=S%F6.T@E\-F))9HG9X2Q)+&/DGDYG]&W[-
MS1QP7O#^4M/:NZ'8F&-889+6HLO3]9BB0!(H[T$<%Y(T 6-+(C4 *!EOLCLV
MK,78N]+E6:52HMOJ\FY08^IDVI,'Q+UFAQ-I0O4J4!;EJ*QX^T.-KT^[%0UM
M*T*][T5K>[ABE""4QR",G@2%&"$_0'X[2?Y<QEN5&L-46U6:VB][U5GB-A%(
MY#- &\15X(/)4#@^_,HRWF3G@6FJUB\5TQ4;I70=MJEA@OBSU:LHJ"< FALE
M/NR(!4038DP)\-Y/W.1Y3#K2_N]Y&_365QR/$ZR1.T<B$,CHQ5U8>XJRD$']
M8.6;%>"W#+6M0Q6:\R&.:">-)894;WI)'(&1U/Q5@0<U36#GO3_9D/2>B<)8
MM_7/!!AYTAU3QI<E$+5?/&@0M:GBG2?'"=/?DF#7-0Z-N$[CQ8A*E*#0VYIR
MD2HS#A&#"GEF@W8$-KPZ^UX"P70!'%=;W+#= ':L[?-CLJ!W'A)03VD\\FIW
M^@RUW4+9V72()?8:(L]BYHHSYO>T;.3)+0B'+V=4[-X2AI:C*"\:[3*)>Z?T
M^F5CH?/K&+MU(N84?8JO90DE,L6:"E(Z),*=$?3Z;VAUI>O?:<2V_'=TY'DM
M,R&G&D04L4D$CPS(T<L;%'1APRLIX((_^P?>/+.@4[=6_5KW:4\=FI:B2>O/
M$P:.6*0!D=2/@0?,'@J>58 @@99EO,G&,8QC&,8QC&,8QC,<MUNK5"K)NY7$
MS"KU8K@]\H:,D7-MQ(,*.GU6XOW4K===6K:68T6.V]*F27&8D1A^2\TTNI59
MV"J"S,> ![R3F!M-IK])KKFVVUN&AKM? ]FY;G;MBAAC'+,> 69B>$CBC5Y9
M9&2*)'D=5-9SGD9TE%?(74)P7=4Y\-B;(OWGR-ZG6>#B-BOQ=I+OBF171[;7
M8*]+1Z,WJMU RTI6D2A$96TZ5?$$?=V--W/SQV01M,>1\ >45C[S[#,O \FS
MG=SK[J$4)]Q3Z)^3-'7B-A]SU_U+KNB:IK>7%J2LM7?[370GD>QNM?JK:'RE
MJQDCF-J/YMV*XG6ZZ.Y/3[F:>B2"4*O<G[S72]I-BH>DJFE:L&[-4N ,6D=$
M;6AR1/"$Y<%I#C*G9*-/-;76]55'=XK*O/!:2$A0WT,8GF[2>/+D<_JS7M-Z
M8;^VNK0K],:G;W'BDL14.F.MJ%K97*L0!EM:RIU=J^ADV=>)2&DGIV)($#)W
M2#O7FWG,NHUSJH<F2!QC8<C73DJKVZIVH8H+;*=9H<6%/?!V(4IV0VQ)6,)"
MR\"9!ESQ!D*4&&@I(B*(1)CV/)&T9 ;@AAW*RGN5E/(Y4_Q@@@\$$$$ @C.J
M=.]2:_J:I9L4X[E2Q0NRZW::O9UC3VFIV,,<,[T[]8LZI(U>Q6MP2PRSU;=.
MS6N4[%BK/%*_A])[97>=EA-1B@K9T/H]@@R"H+FG/!<4M:98B*^F(^>*22I$
M)5J?6D35I@:LUWL=;!2"&]C8<^41U\IGJ1,X+<JB+Y&1R0O/O[1P&9VX\^U%
M9N/,CCSS#Z@ZPH:&U5U4=+:;[J"]!)9I=/:&M%:V<M2-Q$]VS)9L4]9J=>)B
M(!L=SL-=2DL?V/%/)8'A96>]>7]ZY^60)N-8\5^;DG8Z)K=4ZWYF-U3H"8#F
MDJ1*F5FJ\(Z$.B,>XI.U3$V24-TO:4IG*0K3VKZ5E<<HUB0<D=T=4LG(^AFE
M0D_J[>?U?#.=[KTJ[K16A5VVM]&G3]ED$RZSJGTMKK-X(&X(EEUVLZ)WL$2=
MI',HV$E<$@>,5/?F:TKS "%!X<W>JHU6Z4>)1PHKLM O=1[3P9XS+DLP8PPA
MT2ER6RE36].D1X:"=[IE3KOSDJ'!V;T0DM0]TM68%@C=S*.XQ.C13=H\^1&X
MX;R\^$9F\B>W@<Y+ZCTK4K,%6YNM8FOT]VQ'4K=6Z/=:OJ_HE[<LBPQU[&^U
M$BV-6S321PBQNM3K*'BRQ0^N>/(L67'S%SK.,8QC&,8QC&,8QC&:)?;W\UEV
M/QRY9TJ!!>F+YMT]T84=996Y]-K]\!26),^0M*=Z9B[/5RM#U+7M*=R9\1'Y
MU:R6U#A9Y(S^7'R/UE#[O]3,?X@<^.?ZL[02W^A.G-_#"TIT/4+5[#*I/@4M
MS3='F<CYL9NT:$!)]\DT8S2;[/LU<J^6ZD*9'$FJ1T*CPXL\@MEY@;,+U&YU
MLH.TP\YI+,YR"B9-:D(C[=5#40C;?^#\PUIWY@_JW[LM7T)M#%W%=EU9H-?9
M[02! $O[1?$(\E4V=77[>[@%PH')XSEW]1&FVBZ\ZC85+0TESI6QXMPQ2+4;
M8T]KJQ5C68@123+7MWOQ:%G5'+$*OOW'>(])Z_8^_IG4CI56JK >MFRT5!?E
M\BW;@,+B0P<A+[K=^KGS:Y+Y96VW?<C:8T^EOX;ON:4KY _J.H^F[OI.UW'3
MNR;=:3I[?;*SN1OT]29)3'JQVZCY%[H>8MK%7#'92>V#+Q[?AK^B^TK[ES(U
M;:TZ]=V01P2:EK$B *.0T_RE"'Y=6?RA3@$+P>WN.VS[">4?]8CFO_JZ3/YW
M9^JOBT/T.?[:/YKD'ZIO_P"_5']R-_2N95<&.X!>.$FJ>3J=X[7"CQE#9TL)
MNFU8_(^T$9V5%6-D6 []G-.UM4D>V4<)6!(X@E!WZ$=2WJL3+<9JM94R+)%6
M)/< WB2(.P\'N")W^WP>WA.X>SWI\\7K@W$6JD%)ZMO;HJ&)I(O5:TS>.I=2
MAFE\#FOW()"\_AOQ-X,X'J[UK@U'S6ME_@6"Q66O4(?#YS?XBA0Q^01I3/2H
MYR*KG$E X3=(Y.RUY2H[I<J1.BA4TG3YDBG$ (BP)CV-C-,FLCB9$1IB9H3W
M,.V4P%#XP[FBX1_,*JHQ42#Q [)RAUQ*G6%J]'//9@I(FOO*8HV9Z8V*SJ=>
MPCBN+)8K^R999)HHWEJ.U22"*?B=;KTU5I75*\[=VA\>WOB(4FRPQ3_S8L>:
MDL)D$!8Z=N/#41A"Y+BQT4FN%"<),QD3W(41<A49J,E\/Q'\+DQAB$+>3%0>
M%8CD\%AYD<G@GCD\<YN-3UDU8#<$:VVB1K"1'NBCF8!I(XW[4,B1L3&LA1#(
M%#E$+=HR7*,R,8QC&,8QC&,8QC&,8QC&,8QC&,8QD;=*ZU2.3P!<NW3Y^YUA
M(*$56L5X(8M=RMYA$=R6L75JE7(),^;DL16G)<]R'!7#$P&W21B5 &LORV[D
M<3R$]H'"CEF8A40<\<LS$ <GR YY)\E!/EFO]0]4:?IB"M+M)YO&OSFKK-=0
MIV]GMMK;$;2FMK-7KX;%ZY(D2M+,T4)AJP*UBW+!71Y5K]=/+,[1 _VHM7C[
M=J'4%/:99L?6>K>-'+HLM2D[4CX#-A[4MZ*XZA.U-PS?T<CK6M_'A,;UO67D
MK*Y[5F5V_-CCGDX_C[8O/CZ5[A]!S1=OZ4+NEJ?*6SZ%W&DU7<$78=4=3>CS
MIN*4D$J$2]U>S1,X\UBN>J3CS\2%.,P\_P"5%/Z'S?1*P4/K%)Y]/,U:82Z>
M'FT7H?.HP );@92Q3IW1O'OH74QP*O-"H<QLR4.N@X40<N5]6?'Q?CO-PN_J
M;)J25M63):M7]75F\)WK30:Z?8UDVTZ-,:\B21ZOUPP-"6E$YA\-6;C*:_I0
MT6VU8V&WTO4FGT :*XW44+Z7J'IX"A9AM"6?>=";SJ>M5H++$GKL^P:G5CJ>
M,;S0U_$87U8>9DLLR(SK3\=]IMYA]AQ#K+S+J-+:=9=;VI#C3B%)6VXA6T+1
MO2D[WK>MY(9UI'21%DC97C=5='1@R.C ,K*RDJRLI!5@2"""#QD!VCR.IPBR
ME:/3:[?NR7H"^B)8*OR:N-'&ZW.<9;D-C+7=CI*M<QJ)ER.\Q(0"M%X#FE17
MVIFA^XB]/Y>6!BH=V2)".5:0D=PYXY5 &D8?K5"/(CGG-'V77^IJ["UIM3K]
MYU;NJ+B*]K>EZ"W%U\Y19%K;/<7;&NZ<U=MHW21:6RW-6X8W640>$>_, 5Y2
MVN*9V$(>-O0]%$N:0[7A?5?%PK<HWKO7_?JMKO$24\ZG6_>7%&R2,M?IM,5B
M4YM"%W/5UXY$\?'YQCL!3\/G>"1_*>!D&?25LX[?J<_H^WPLAN&HUNIO1M9V
MT?\ EZS\-HI'8?&*M)8E;W1)*Q53,G-^W4/J$XL""R#0.Z5V/'EV3GMXKIBE
M7T##EN+9BDI=9L,2%-F IC[3K$"SA?JE7)O-.MC34M3:])M20O& Q *-Y*Z,
M'0D?#N4D!OI4\,/B!FV]/]8Z3J2:U2IR7*>WH1QR[#0[FA;T^[I12LR16)==
M?BAFEI2NK)!LJGK.ML.K+7N2E6XES+6;3C&,UY]/!Q_*/S"&<*L[:2G"?%^D
MT;N'3:B^GWPW2NU]!/66/Q.L6N(YK31FK\R#4*Q=+G5V0E\63M9OG,\FR^@$
MB,[,0-ZAK6MI[-N_++5@D'/=!5A1#:DC/Y,D[RI '^<L:3A2"_(T+90+U+U9
M'I+(\32=-TJ6YV-5OX'8[B_/973UK2GRFK:V&C8V+UVYCDM3:^216$ 4VU[?
MU0-Q7EMQZ0:( 8+=<#RY8UFQD9 H:8-)9<6* ;F0X1.<R\9E(1";>A"RDB+I
MQ4WZ?+:C.M*CZL#69XX5#GO8 E%#,J_E/P2H(4>?!90?=W D'-LVNPBU>OLW
M9'A001LT8G<QQR2@'PX>Y4D<&1AV@I'(5Y+]C!2,JXUY ]$=O,>XQ!4XB#+$
MH'-C/BS$&),]HJ3M9A;/W[J!61!EJ "IM::M(IHA6V)Q>FWNAHI-DYST*SVS
MHM IMESC4A$1C+ .JF9;Y/;6D[SV10*".]@Y1N'(66&7Q4FA2.&:1-?&XNFV
M+2QO)#)(E&7I]4$NSKF!/&N;"0JWA1M )XP\ >2K;J>JSTKD]F[2JSXCPCGE
M3\1/,KHW"J'60-6Y'Y64VQ>3-!&!Q \6U6NL<\-5*F]RJ,)V''0\]73HR[\X
MOE7#/._*5N<Y?885B('=AP8=RU+)L-;#:E=Y+&OD2C,S,6[Z\RR259#R?)T:
M*:%V][CP2Q+<DQVEHUNENK;^DI00UM5U-3L=1:^&*)(UJ[.A-5J;JI&57^UY
MTNZ^]6A)"UY&O+"JPE$391D+G0LQFSW6FTF/#EW*VUFI12$M,"!)LYX4!CSI
MR]>J(<-XK+B-R9:]?>F.RI;RM??I&\K2*24D1QO(0.2$1G('TD*#P/UG,>Q<
MJ4U1K=JO561@D;6)XH%=S[D0RLH9C\%')_5F2)4E:4K0I*T+3I2%IWI25)5K
MU2I*M>NE)5K>MZWK>];UOUU]V49D \^8\P?,$?'/K&,UY=Z\(Y;MW)>2_AU9
MAGCSY7:;3)-SV(3W]#OD+'B*<?33?(JB#?A1+%'([6_$A]&%1X_1*H]*23@$
MR.H$4?J8J;,>&M+9(URAYA5Y'K%,GC\;3E;DJ1[S"Q,,G'!4<DYI>XZ58VWW
MO3,Z:7J'CNE=5/R9N@O)%7=TX^%G5^2JWHPMVN6$B2/V*F2OXG^58SR/"6L!
M9*H0Y)Y!<@*QJGWSA-BE,2K!SNTOQ]R(,\=/9TB/:^=W"&A9KGU\%)4(LX1>
MG&E,SXL^%%Q[]!J31ND@L4[*F2I:0$)-&#P00?..:,GMFB;VHV^D$$R/3O4,
M>\BL0SUWUNYULBU]QJ)V#34K!7N1T<<+8I65!EI7(QX5B+S'#JZK;;(_-CQC
M&,8QC&,8QC&>%: J;)6K%75/JBI/@BP54E&O>7'25@2(.WTZ]=>JF=/_ !$Z
M]=>NTZUZZ_/E2-V.C\<]C*W'T]I!X_V99LP^L5[%?N[?'AEA[AYE?%C9.X?Q
M=W.4F\&.@C(?@%QERP%1%++<,Y#$XITUPTZTS!H?0_'L8OE%[C'F7G(VXC(N
MR4V;,3&D*CKD"WX3[*ML3(SSDIM82=O9[%:1;5@VH.WGF6&XWK$14^?/<D@'
M(YX8$'S!S3NB;T:]#Z?QY(JLVFU::;8^*0$I;#0Q_)=U)E)4J([%1V"G@M&R
M,O(=2<?X1HE$J<1CG%9ZIKOG8!P&V=CZ5W7FESK4:B%WA"%G2A>79*50(%])
M@"1DR!Y]4J]N=O4/0^I1RM:Y!3!$2KU6NTR'QGK^JUF:.O!5FC<RKW'M50DD
MIA5PJO-(_;Y\R%7L2L7JU'B+65:,&P&WV:0V-G>V]&U M20Q RR2M/5II<DA
M>66&E7A[_9[*XD@UM6-:]Q>2\I \7J**76C%G(U^+)<FP6+27;+*$+D1X_U-
M@4YJ)$2,$3RC<X\D#$2T! S"TT95!M?JL8/7A4=8L/9D\5U0.1P?#7M[N">T
ML.3W,%X3N/+N%#2,\A9VV;7:^'5UO58))W@5BZ+8D$GA<JOB",]J^'&\@>;P
M5XAA:1DKQPUUCACJ][/Y]%HH7=.RC_QJKW[RN[EU"@R=>NFRU"A%1?+:K9HJ
M=^F]#KD-YHBX"7?36I8D]!G)]4RDJWG[<>'+4K'^$J:^K!,/S9BK6)$/ZXVG
M\-O?PR$<^6:QT,WK-'=;=/.KO.I]SLJ##W2T$EBUM6RO_L[D>N%N(_EQ3HX\
MF&2YYE]-+\:\3/)#J%;(:%VVF<5Z,6H\SX:'G-7_ %5B4:@QH\=S2D2IDZY2
M <&#$VE7S<R2Q'TE6W=)WC:V!;.PI0..8Y+,*R@G@>#W@S$GX!8@[$_  G)3
MJ[8S:GI?J#95G\.W4T]^6DW'<?7O5I%HJJGYSR6VA2-?RG95X/.:D>I>*'->
M?^,5M(\WHPL1W/E_/+#TGG_7!4&*OL7].-4KDVR#+S-Z)\%RUGK+8;;#2NU2
M29.7JV0R)(081+%D'XBLNIM[4VTB\>P[5+-B.O/69V]5]3ED$;0B#GPTCCB;
M\6%4>&55EX8<YJVYZ+U%'I"[\FZR"+>:O56=CKMM%$AW/R[3JR68;S['M]<L
M6;-Q ;32ROZVDLL,RO%(R'>=S2Y0.C<YH'01<J+-&7JE56XCID%6EPI<&S H
M!J+)B*TMS2HS[$UMQC?Q%^K2D[]]7Y]QD\9AFFA8$&*62,@^\%'*D']8(\\W
M_76TV&OHWXF5X[M.M;C=/-'2S"DRLIY/LLK@CS/E\<S;+69F?F]:WK>MZUO6
M];UO6]>NMZW]V];UO[MZWK\^L8S5)SR!KP%\MQW$(6OI_B#YFG[&<XC ]=MA
M.$>434:79KIR(0E?I%"T/M8B.5O%"",O-0QEZ%6:O@A,=DNA3D],WRMKVM'S
MV.M1%LG\JU1Y"1V&^+2UF*Q2MQR8F1W8E?+GE)/P/ZD35+['375$T\NJ3W1:
MC?A6GM:V,>2Q4]K$)+=.)2%2W%8ABC42#G:YD#G0\8QC&,8QC&,8QC&,K%Y+
M-M2Y/CJ,))2Y6B7DQSU-DCNZTJ+(T) W2R4U$I"OQ%H;Z@$H<F,ES6T[(,0]
MIUMS2,R(/^O(^<*[]OT^;(&X_P#X9?\ DYSG/I#599.@JU@=VNL>D31#8(W\
M$XJTMOL-2)0?995ZCIZ62-6\C.D/'M 9C'/*T.\@+[;^N]$2S8@'-NJ7CG7&
M^>S_ '9-;IY#E-D)46S='+A'/>B%.CG[@%/O5TV5CO.5*DMU]-5;&3C-C)F_
M78PHL2>RTD:/*_N9A(H=4!X!$84KW 'AWY)) 4".T.OK]=;O:=5;X)?H]/\
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ME^KG13EA(\6\8^3OT,"EQMF0ZS>+3V>88A!Y+Z5MCI/1+52:C72<]6M1])J
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M-2)-CLW#/*"7T3ED/F?2'9/Q7I5NJ1"J5^Q&B&IC[=N;K%!O,J./+224364
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M+]",>(K ';W1MR6'9YZ-U;KK-22#J_31,^WTD3>N5H_+Y:T7=XE[6R#\N:)
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M/EY9LER%S><8QC&,T"^UFN=JH'9@MJI9XE6K%!\<ZI"B&!,A46<Q$/></C2
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M[2][<.?-B#QYC-G_ .%WX[_[0T_LK=OX;S]$ODZY]0?^W'_SY'?A)I?TW_\
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M(-RGU?G7(EE[7-DR'%>JG'W7'%[VI6][D-Y)XFWV)_-MRQ#Z L#>"H'T +&
M!\!QFM] U_5NB^F4^,NGIW')][2WXQ>E8_2SRV'9C\6).7NR*S;L8QE$?:6[
MWKPTZ7Z;WKUMG"$[]/N]=*\A.5I5K?\ S*3O:=Z_-O6]ZW]V\D]/_;\?^8N_
M[C8S3>OO[EKG^G:'_P#2#5Y3;PKN5JO7(+(:N!XE8BL;O_DS7X\\I(5)DLA*
MUWWH8.OBFW%?>F"&#0(0H;'U^3B0(D:(SI+++:$VMS#%!;B2&-8U-#6R%5'
M+R48'D8C\YW8LQ^+$D^9SSH2]<V&EM3WK$MJ9.H^JJRR3-W.M>KU%LH*T(/U
M<$$:0Q+[DC147A5 %>"-TM9?VB &FDCY*;5:9Y*^%DNJ@7Y"EC0,FV<4\LG[
M*^-C_<EATVZ,'K(KUZ[D?)Q]+_%;3K4M3AB33B98U$LVOW E<#VG$5S5B,,?
MB$#-V_1R?IS3=M>N3=>FC+8EDIT>I.A7IUV8F*N]S1]8-::)?<K3M%$9#[V\
M->?<,_H^S6\[+C&,8QFMHFC[+^UQJ,MK\C&[![/^YB2"&_Q4S#/%^^U(H$D/
M)UZ:<>C".M6*/IY?JYIE3+6E?#0E.IE?;Z?D!\S7VT;+^I;-216'\1:!#_'S
M].:-)_8_I'K,ODNSZ.M))Q^5)JMQ6>$GZ2L>RG')^' \_+C9+D-F\XQC&,8Q
MC&,8QC-;?GVKZ%U#V;M[<_\ !0?GC4:A,5O[DLIZMQOLU!'O+7O\5.G#Q0./
M;UO\9R1/8;;W[Z]:W,ZGVX-S%\6U4DH_7ZO8KRD?]@,?X@<T;K'\5L.AKA^;
M#U?7K-^H;'5[2FA^CSFDB3S]Y< 9LDR&S><8QC&,TP^U^\<C%TY[![Y7;U"!
M/U!'+.86FF%JRX::NM>M'D_Q&R 8]:,Q38E^K6MF\@0,9$N; LPLH(G3AFQ@
M^:N,68V+0VHTD:K)$S=PM68I5D[?"D376XW,B%'\2,PNYX4QLK -W,.5/*?2
M?HY[5*/<5KL<)A.IU=NI+6,WKE>QU1H[==:TRSPFK:6]6KKWO'9CEA>2+PD<
MI*MA;$P]*KYV-';4Z_(#$V&&D?>IQYZ$^VVVG7W?C+6I*=?\^]9K$1 DC)/
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M4IC%Z3.ENJ=_'T[LXUU'2E/J&_0:O+)0,]D]1;#5:K7$UB$7P(%L&4LQ60!
M7N/8>Q661JMBL#(P[+/AI*.QW0$I')*.V0+XB'NY[&4L%;E1MMS]&<P\C[J+
M'0I-*GL<NDBXEP<*5;33Y96FVDUW5K"*O*!KKD>7%9LSU&U8V:A((QGQ$>U.
M!GC#2Q;<Q.[T!A$H,X8Q]LG(7W]_AMX7/F"4$O89 "&,?<%]KC,#9+?:FZZU
MHDMF2MPTOD!7]:A]=\,E64632]8%1I%:);1A,P,0<90RHTSVEM>J7-:T0O\
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M-Z]W:=I]/3W?3[O=]/3T^[T],P,^BN!QQP...../+CW<<>[CCX9JNEL-T7I
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MM Q/ZE[PY_R?/RS4>N:-B]TSL&I+W;#7&ONM>!YL;FFLQ;&)$'Q:;U=H /\
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MT,J.T<T+$121=KF/LT_&'G//:=1GAG0;-)JX <)G623V/L->?L!&.PGZB;=
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M0Z=6+3;@YI8HS9X9=,YJ58>:I)MKT\MQ9X94M/%9EKR<O+)&W@AHQ"3#(K$
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M/EG7;[<2'6"',=^3GE,2L[ASND.PU)_@-KXE1!O&F&N=[Z!(&18;?8Q-@,C
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M-[9&JNVZD>T38=,2RR3P5(X*^YAL4+5=I6@CEM/.(JT<"B&8EA%WO$6C^0O
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M:YEM1ZR6#^Q=HI=-O<EH4.5>@K(TEN&2.9) KTU7QKJUX660O5YOS/I'O7X
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M[$WM[7M+TC=,M?UH'0G6BM\M=#\.>A+(\-MET-;:E*2%+ :N'FG:907I]W;
M)*I,N/ E'F98^!W'CQ?@OL,/H]ISW >X^\^UY9Y0GI=4V."(3SF]M[4#X<PC
M6^>2$Z:4.O1);VM[2G:4H8]-O,J1M2'O?UN)MUS>TZC]?Z1NEVJ:L+T#UI&'
MU?HN1 >A)5$)K]5WN%;M!"K5<&PC(60APU1I96*8->;S'C1G@(#^-/O0]TGO
M'Y:\#S]_N;CC.&;T^J:$D5[YM?E(^SE\D_"USJ1M2X\_JT=IN)[NTZ1\7;WH
M0D,*5IMAI.GY"D2/<;W19])/2HUUR4^C_K5T&EZLM-$.@I2TE>SZ0X*XJ=C
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MWO\ M5_N,?\ I)=8?WEZ:_8;3^E,?\)]\U/]A_B[_P!@=8_FSC\!=;^EWO\
MM5_N,?\ I)=8?WEZ:_8;3^E,?\)]\U/]A_B[_P!@=8_FSC\!=;^EWO\ M5_N
M,?\ I)=8?WEZ:_8;3^E,?\)]\U/]A_B[_P!@=8_FSC\!=;^EWO\ M5_N,?\
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MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QE2?+GLG2>(UWGMGYU'IA+4ZW7!BV
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M (\_ZO\ ZY\S?U2-#93:[IO80I+)JZ-C817NP,4@LVUI^IS3=O("NL%B%)'
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MJ!A+I)&R*4ONY(+!BBHZ/&SJ:IQ?9^2=W.M7$OY"]$,RJ>>/E*RJ; 8FD0$
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MN1I6GI+?XFGE1OR.9%?H7T'_ "I4[=UK_P"Z+0* .N[7FE;T9SQZP!QN._\
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MTDW)Z:#7/++4COS6JL\;-<@FUXB@6.(%O6&L&X16:'DE)_@2%X8D#-9ZXO\
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MU[3^9X^;]H'^@/#G]K^U_P $8XU/YVQ_9UOO,=W6'U'37VO:?S/'S?M _P!
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M%!7@4)''$D<,,2CYJ1HH1% ^"(!Q]&1KTRB>/7E%$D\QZ$!BV4R ;U81VI$
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MC&,8QC&,8QC*<^ O^:M0/]Y.Q_VV]&R0VG]NR?YNM_NL.:ST?_<_4_TC:?\
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MDPQ8;5'HCX./"@QI*)R^C=<I_$JS$8VY/CO/2G;Y>ZY&G-LL.H'B9,DU*<1
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M=OC7+D[26+$@'LKXCE8UX2)4C 435F-DIC&,H+Y@4I2BPFVCF"YJ>6K5E&$
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MUBHP$J7E$L<\XFB?8PQ0VIHV>1T,SI!%VF5)%5DY[.'D#R-S;AW/N4E;":J
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MPC-O3M-#O*5>&U1CH6O&U]R::("X;1I6ZEEH*EFEL*TU*9^P*9(.*\R3NDX
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MGX[?QY#JCT>V?1?/#U_Z+HITUVDEEN;_ -&RSR'2[+762(]I9Z9CF9TT&W6
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M^-Y"SW,:1NG4.T] :CM='[]V&P*NG6KI'B*2Y$$/G'(T.!7*F/6AK0NET\6
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MV"@RU;#1NB(I_6*-RSI#@M*MZA;NG(S ]GU4E S3"UL;H[?U\_#DCS/T<\$
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M^M:D"8B%Q<;\<G>/X5!^,'YZ#W2 ?2ON?^0^665SOF8^,8R!^>_B]K\A4?\
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MP=G6_P#[NR_07]Z^[_1[WT7_ ,_N:_U9QM?QO]4')\?4O0W"#_BG:=;3D?\
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M+7LN-D?FS8QC&,8QC&,8QC&,9K1]L-_R;OD[Z_F^@T3^UBA9G:_^V&_T6_\
M[A9SGWI3_N"W_/N[-=_Q:AEY-!.CJH804/O5<A72/H:HA:GJ"_-#38;+_P 2
M5%CU+5SBNP79,'X<)N4JRS-1GDKF?+O>_J,W&TC E>L/"?PA5A58_&'<O$*
M<R>%PW!')XC7GW>7OS=7CO-75$MP+:#@O8--FB=0Y+*M?UI2A9.%#>.W:>6[
M3SVC(Y\"V/6@ 0'605!J4.,3;L5:D5EV>5.2I#'N"I(^S)/PVP30V1Z/28RP
M!C9)OWF=/PM[2\G(!C$;@HQD)'8X?A5 /M IV'NY'D#WKQ[^#EQTL&Q"Z3QI
M657$T!@+R2L1^+9)_&41!#YLIAD[QY<K[\^10^WQS=JEE[,)* ""QRJ@%B5=
MT7.K#;$5ULF@L:582";1LA+4S*CK;%5[Z>TVY%VF9\73[7C&,J@5&5QW>(Q?
MN#\D=O:O8.SM'(/M/W>_RX\T:65EL-)/')"Y3U:):YC: !2)!)+XS^L=[<,"
M$A[ "OM<\B*359ZX$J/U ;?:]+Z(XRB+8K9'YN_L))@LF=RHY*/SS5Y^,]/&
M ]K#[1]L?61[RB2=)^&D<K5-Q$VHVPZGUU*>Q4>)*W4&K@E[K%JG$A%?85V$
M7XRYKF+$IX?=/39H%*E$;*%BOM2-<WH!>YY2[ZD? !\4-P:?K7/!B_%\BR.'
MXE\_X//GI_.S?6FJ"=I700]6G4^:0,QCS%568+R2;L%EB'''$OM$/T &*D)=
M;LP>>-L+1L>\F \Q"D1&9F075_2VJ](FEI;'3[-M=U'II_E3HOJ[7NKV-'M
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M7OLTO_+E']<3H/\ PQZ;_?%'[['^$I]GS_75\8OWTT+^_,?(FX_O9>^S2_\
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M9LU+O4+O/KYI4222K+#;@E03(D\)=H)5[HR[;H,US.HXQC&,8QC&,8QC*<^
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M\B,D3^B+D_\ LPYY^Q5;_NW-Y]8L?7S?M7_YLM_).J_O9K_L5;[O']$7)_\
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MC&,8QC&,8QC&,8QC&,9U9[<UV#,:&R8\(BY%D-P)DN(N?%B35LK3%DR8#<N
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M' !YM>X  <<X7M3R4%026(4@<LS%F;R7WLQ+$^\L23R?/)\UKTUK7^K6M?\
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MJN_/@LV+<?3F@CLR*V2^67(9TNT:MD<\UYQV]G=S%(.WQ03'S[/EX@!*<_/
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M#5]./M[+ZW4#3BJAK5^9/D:[7O0/;YY$\DTE6"*8J(HQ!XJ11QO,T@E3O_B
M [L*K(=%P(\TC<V*4JU<8E<_!B!9#CU^IMFCGDW>GI7[X5TH9%L.TLA!-A"@
M9JGD38>% CM6.Q[+V*>Q>HSMX2SF998[(F=F6S%*A3PI?RNU&_&J4=6\4*S$
M]B=LIO>E(-W'7B%N37+KY:=K4-1ABC?57JED3^NU?^J,DT8-.1)H9(O5'FA5
M +%CQ;>1TO(891)=0_(0RVE]]MKX#;SR4)TZZAC;CVV4.+TI:6MNN_#UO2/B
M+]/>W&GCD\>0^ ]_ _C\N<VM>0 &(+ #N(':">/,@<G@$^?')X]W)SFQGN,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MR+>U]BI/ >7VWKO0Y,^/5*?$A.S&Q,!TJ9)D#!:!7J[7P8QE2%D#UELA837@
M</;K#4DL3ALO28S*W'VZ))88(;%FS/#4J5*UF[<MV9!%6J4Z<$EJW;L2MY1U
MZM:&6>:0^211LWPS"V-^#5TYKMD2-'%X:B.&,RSS33RQUZU>"(<&2>S8EB@A
M3D=TLB*2 >12/V8G<*[?>+S^2O +52>G\B+&S-TI5QC T$6*[UGH?1;91+(+
M(U@_9ZZ8#%XT<R)<>@&790X_7#8TA$C? B/38S1]9]*>D'7?A1T5O:O46AEM
M2ZSU^K#>J^%L-=7J"W3L5-G4HWJT\<<]:PJSU8Q-6M5[$+212JV:_P!(RS04
MGTM^E:UNUUS26K-*WZLS^J[2]?L4K,,U.Q;JS0RA)X6,4[-%8K3Q2JA52VR[
M);-MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&5N\PJ76;_ .+O=ZY;1FBPA/-;)8FH^I<Z ]&/4J$JYU,Q#G#)4(A"
M(@+4 #'1DN)*9>C$!T9Y*_Q/3=25X+9-*U#%9IWDDH7:L\:35[5*]&U2Y5GB
MD#)+!9K32P31NI5XY&5@0<ANHH([&CV:2@D1U)+,95WC>.Q3 MU9HY(V22.6
M"S!%/$Z,&62-6!\LU6>P#FRNA^,70>[W-]P_UF\])E4BT7&7OX<LA4N;,O.T
MD R/B_ #"QX.1<+1,;:$C8&YL\X0GDE3)KVW]6:_072/HUJITKT/I*W3^A2:
M;:>H5I+,_B;"^L26[<]J]/:NV9I8JE6 -8L2>%7K05X1'!%'&ND>BS97M_I[
MG4&WL/=V]NWZA/<D"(S4]<&:G72&)8Z\,<+V[,G$,4?B2SRRREY&+9ODRYG4
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
:,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>gdc15tqwxkbk000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdc15tqwxkbk000002.jpg
M_]C_X  02D9)1@ ! @$ W #<  #_[@ .061O8F4 9      !_^$ 2D5X:68
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@/-9.W!PV<D^;YDDI ?4$%
M$*0Y5D-\HI18<\@%U8JDNUW*Z^G%U0 E&"@3 40":AAB/@$..%B+;*V(F>-K
M97\%E.556Y?/Q]I-_M^TRMK22T+8I:FS&TU773YS$?,GHY&S9KWM1R)3.1'(
MCDBB.5(Q@JI=(J^!OMEZ0M=_&R2O9)4<$[N%'_37IUTNR>-J/W4? WVR](6N
M_C9)7LDIP3NX/Z:].NEV3QM1^ZCX&^V7I"UW\;)*]DE."=W!_37IUTNR>-J/
MW4? WVR](6N_C9)7LDIP3NX/Z:].NEV3QM1^ZCX&^V7I"UW\;)*]DE."=W!_
M37IUTNR>-J/W4? WVR](6N_C9)7LDIP3NX/Z:].NEV3QM1^ZCX&^V7I"UW\;
M)*]DE."=W!_37IUTNR>-J/W4? WVR](6N_C9)7LDIP3NX/Z:].NEV3QM1^ZC
MX&^V7I"UW\;)*]DE."=W!_37IUTNR>-J/W4? WVR](6N_C9)7LDIP3NX/Z:]
M.NEV3QM1^ZCX&^V7I"UW\;)*]DE."=W!_37IUTNR>-J/W4VIB<%3:=L/AFN4
M^_M?QB#>=3>7#H1-U2*(;%*)*N3/F0RH8T5%P<S&8)?*V%LQ,,;Y7MRY6M\M
MG!.[AO69_MTTVHK2IZR;564LJ5/EO5$F3XJC7(Y81ID2,$N15.^>GZM@_9XH
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M-?K%?;IWE^T>J? N_";[#C$5D>0H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M$.A&&]"H(@2#WWL<W=D(!V*)[4-I^GH7C8I'RH]1&L\&XK1@HY%MBE1<[QC
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MM'O;FCELZ.39<FV)*2GS68;(/ES$<V*HJHZ6][;BI!4C%-H@RMLHQ0"@% *
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MK)3L%[')!45/5%%2XJ*BHJHJ*:O7H:HH"UXFD&S>#7US>H<>IIUK;9N,!HP
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MFE16V.^D_'T;O&77>!VZ;R)VHCQ@$@E!VN'JKC5D@$_VI)C8Y]:%<ACP_+R
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M4OZYZIE9-C%WZRJ$<'D36R)P"#&45E;8;)<9INDCK:41"B8X &U@I'D?,01
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MVR)'!.7& 21C*$GH!W$]CED<Y<0_6@GVK75TR<DQK5DU>"YKICD3@O:HQ)6
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MJ.5516X'BFPR?JRR5+B 1N)'FKT.*B6N<,]G;,R$D'":/'</Q>[AT)22E?8
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MJUCTPU3":J7H.2\<BVMT-SNWG]!.E5$BFJI%3.S=(;(E36S):RY_-63*F4O
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MPAYR;+\YE-)YO3LM>73J]78+73FMPG1PG8*.1,)T5BL(K%8G]-EB<2-E) "
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MV!5#4&P5P9R824 "39Q+-I7-IX=B6 %L")H4"W($)GAEY.J]%GN<][J-7O\
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MWXF%5M=^+$O,M0CA<@SB'K,>*[@%=BLPE:,MDU%EJ;J'SL(,YE!KG$09#.N
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M:4S$%X1)Q(W6AQP:3CT>(SE86SRZE,,ZCD\4Y).,Q.5$HT3:YI+3\+ %A".
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M9C#4S3#LFTNJS\0?#_WQ]R;;GZ-TR>1E,[V3TJGXQF,-3-,.R;2ZK/Q!\/\
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M$PKW?2C?F[O?L+#5S98"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M372,^I\S_4I?R$PKW?2C?F[O?L+#5S98"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H"5-"_YK$>_MY+'Y9) K]:R_P!'D?-I/R3"TL/Z+E]]_P H
MXN#4EL* 4 H!0"@% * 4 H!0"@*I'?Y\3:_-2?'Y7H]K<3Z/7\\GO7%8[Z89
M\V?[]A:VM,LQ0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@.
M'G&@_!H%^T*/^4!%KK9'U%K?GLGWJGYR_P!PGT&[\RS]IE'F!KA3\5B@% *
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M2>RG,ZY/O+FOL>1(_)[8;2U2VU=:HV"$Q'VXWV8IM%.;,+N,S)2&YG$X@\2
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M5C=]7J]6Q")!($%-7@Y\4<+6$'5]5E_4IF1H\I2XD+YFA@MJ3IK>+8>8VW;
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M OSK9\J*E7Y^(X9FV?*1 ^JL9"O<(Q;+]7GXWOCG^K;Y+U2:-+'1RSUBCO\
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M([_/B;7YJ3X_*]'M;B?1Z_GD]ZXK'?3#/FS_ '["UM:99B@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% <S]Z=>NE,[67"7??WB]]36/&N^;
MM!WS]8=[JR&XN9VF[=M[KKKSM7U'EZ[#ZGU3G\F7-YM^SHI7"Z"UZQA@U<E?
M83[9\A\Y.BNNM7)T;X?FW.)"KPF!PF#P<QLSVF&R,<#!]LD(QNP@M#_@)?\
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M^QN#531WHDK[.Z.CM"?HY;_ZPWV537'2?ID[[&X-5-'>B2OL[HZ.T)^CEO\
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M(V4(SLIO"&)YE!';K<?:-##W,JL&,)4A:4U=@OA$.BD <766P.'<R9(RHY8
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MO,9=%@.?%H$M+98$)/8[X4!< 2\G%P<+8 (ZP/G?$,)_!!X\F&=^3%7QM_\
MO?+8QZRYD/$?ZR_:7[2[/?O_ +8\S_G@EZ32Y>C6DLQ&Z1-2$N8L$2I1$O+L
M).1+Z7IB>,WQHH=M*V#]#"@% * P;DSL&A*>=[AXVQ+7ORBC9%@[?5X?XX^.
M.605O_3:UZI-)'HRPJEZJU$27]\Y6)?2^Y$54[\ 9RKL"@% * 4 H!0"@% 8
M5M96S;J!G:^&5LT5*RMD$-D9"O;(B!>UPS&6..0^%^7Y,[VM?*WR\GRU2:-/
M29HY9[T5JHZBD+%KE>U8RFWGJB*]-IRHBN2["Z2[VR]\S579 H!0"@% * 4
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MGB";&/$DV<)-B]]T0V[Y"VZ.J&[;MX XFC:1$;EV2W+D"'&-$CXR:3\A)M)
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M )0$6NMD?46M^>R?>J?G+_<)]!N_,L_:91Y@:X4_%8H!0"@% * 4 H!0"@%
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M3JK(XB;-&EAP/&8IL5Y@5HY2$+EVE!$5$E:".)H8A^^(1<H*K%^KW#P"/9E
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M\?E>CVMQ/H]?SR>]<5COIAGS9_OV%K:TRS% * 4 H!0"@% * 4 H!0"@% *
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M)5.=B* 4 H!0$>AQ)%(4H&)N"C*/0IH-,X..S4O!LMMX2@9C\)4Q7 F,8?\
MBFV=8S.#6L+',4S(W<E8U:PM@^J6YU 2%0"@% * 4 H!0"@.=.R?]H!PTO\
MSD_D50JN:+Z(K?\ D^_4X>WOKI8/^>^0:=%JICN!0"@% * 4 H!0"@% * 4
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MHBP2_<O=\_Q6V6UQ072$QER?X31GL.M*[; 9ZM*K$3G2,XF^C=\:^@!-\XO
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M(Q53@WL9<1$3Q;L<DF,;%&.2ZJ*BJD42"+<NHOK*B'U2YI/MDV(VV&A.'=3
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M[<A=@MSV(E4W#PZ]@&(IL5!QTN.SX1-Z'[[Q _W*W'-JS9N)[TVAFH>=H'A
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MMKL QFV(79:G)KO3))[^=AV4]$,_'T8)(R^I73T55+'"MK%4D524[]84!LD
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MODJFT<7"T>H'*JK&BD755KE^";?<U&M5=M6M:U;Z(B7"7>V7OF9JY(% * 4
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ME_N$^@W?F6?M,H\P-<*?BL4 H!0"@% * 4 H!0"@% * 4!?+1?1=\[BOG_\
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MW,\<RIMG-HTX#+> S8XCARCW%P(F#M5BQ5;Q2;+8!!5.$\#=BAH<$0"PU *
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MVAQWXH\S7\:LS^//_"Z:R?X"S>(_&&K_ /C;0X[\4>9K^-69_'G_ (7363_
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MAJ__ (VT.._%'F:_C5F?QY_X7363_ 6;Q'XPU?\ \;:''?BCS-?QJS/X\_\
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M8:O_ .-M#COQ1YFOXU9G\>?^%TUD_P !9O$?C#5__&VAQWXH\S7\:LS^//\
MPNFLG^ LWB/QAJ__ (VT.._%(,E:,>U$F:H7\X4GJ?;*='JD<BN[.O;$.O\
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MBI=1;J'J@X:_$H)3T22H/G!5*I\UIY7$JV7,:R"*$I5)% O\3/\ R8!9]%@
M[Y#@8VQP4,,;C VMG80/'VES/O7>KU>J[?\ V_YH/._*TLE,T=TB>UFDS&P8
M]8(VJ:B7TO(DY$2+V)<<D7L2&$UG9>O<^_"@% * P;DMRH2G;Y/_  U_\8<0
MK;_'P_5,!6R$"_\ 7:W+5)I)=L*IO?![+E9LI]^VZWOH#.5=@4 H!0"@% *
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MU%K?GLGWJGYR_P!PGT&[\RS]IE'F!KA3\5B@% * 4 H!0"@% * 4 H!0"@%
M71TDU E';&42*>RS*@T6HT5!-5GG*(6)@()FA!&,3)+%&, B%\S;R-YE[W3R
MP0F&>.>'5L\@P0\Q,2(KEP6W_8]6UL^%4^E>;/S?6UIQ;3%H7/IK.IGM=-J4
MBBRU1<)J2UN1G+"+(+XOMU@B)'VO(J=DCHZ2D9J2DL9I::13LU=:'",K"KD1
M*A%LE)6,@%R@!A2/7"ZJ/G@$'AF+EE>V&-K\EMQ$@D+Y_1.3+65*;*5SGJUJ
M)A.NN=!(1<J(B*JWU@B7=@R52>@H!0&$<E[V0E.]KWM?K:_RXB8A7M]7C^H)
MERXX?^N]4>DBJEA5*I%%X/85&[*;*W$)2^9NKP@4 H!0"@% * 4 H#"-J][M
MQ O>][WNB)5[WR$Q&RO?K$#EO<7'DQ%O?_WK?)E^K5)HTJKHY9ZK%5YE(OJC
ME^";]\EQW?2XM\EWME[YFZNR!0"@% * 4 H!0"@% <V]F?[1#AB?YC=?\BS7
MJXHOHFM[TGWYQUN?6NQ/PZO]G4Z253G8B@*K[QHC8<NG6S3>>,?GY40%R$Y#
M2AX\2HN<$TJ;L4#[;/ED)*3HN:C9>+B>!_-=$+9@ERB8;%P$PL+S<;!WSQ \
M0")I-)3?T_X$SQ%X>TYYJ$.1OQ.(0W*92'I%* <IXO*<827FE%!.5XTSB\F]
M70U7XIJ A;OF429AKAC'1,C:B#@(+E8#.ZEQ%L,PR?#4+N[4G=I#%AS@Z\1&
M$I-Q-Z1[:98M"6I 79L4V/'ZD(7AD8/-RNTD3MDGEP;BY&\C1/ /G9GB6(X$
MJ0MPSI-)P'P0IX96M +8G9ZQS+O#&WHC38""UIF//S0S8PI?;YR4'/'\GL]%
M7CY^"V8E+IK$Y<KEWP((Q4C<P*A]4Y .\_$3U9XA";H#M+!.BTBZ]M:.TO7L
M['>MVN\/:VR-&LY-]GHA%#3,&"UM@Q=OEADYKP[)(*)$IF7CU-S.B& @,,RH
MV775 >?B0.%[*&P^I_%"4(1U%?<=0I'+#T3G'A^07).M[RBIUB;7Z_0RWA=O
M#<6ZSR$U&RY@A)B))9QM.$/M!B4D9>$+F"]E,0 ,QF!;?0SAGNR,=L^(8K;*
MZ7,@UKH](N9N_P#'I<+6T-REFML=/\(2 WI2ULB=&)L->57LBPP(ZGFBEFHD
M@BJH//1AQ"/72B!B(!S)X:6L.Z4*D]1$.$=7-O\ 7K99=X5?$O@V3)#=.K&S
M$6-Y&V9=\ISN_-1DV1Y2>,=-^.TTR4#+H9Q&/'5+M6EBB%L,Q C H80@$F-#
M1[>=*X7+A'9[#V,&2GHYM"4[=O1%LZ-S-KF[%-&@QQ+:/LRMH>3_ )A?SMV]
ME&>2!M-4GJY6D@V1GP1+ YB%PQPA4LB!W6X&T9J$8;-<8&R?KI-&O4023M8R
M9$UW39(UWEB!V<X(?&8QU&0QXU)/]EM5((H:9D2ZD&W"UBYYMD\BY4RGI]K!
MEL /1G0"@.=.R?\ : <-+_SD_D50JN:+Z(K?^3[]3A[>^NE@_P">^0:=%JIC
MN!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * KI-OX2]/_P XMS?T2MHZW*7X"I_,I\K**.UOT^S/GS_V.K*":V?@/C_]
MK3W[MJ=?FC3GZW6A\X=]HH;*^CI/X"$XURA8"@% * 4 H!0"@% 5Y-_SL$#\
MWEW?E)9-=(SZGS/]2E_(3"O=]*-^;N]^PL-7-E@* 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@)4T+_FL1[^WDL?EDD"OUK+_ $>1\VD_),+2P_HN
M7WW_ "CBX-26PH!0"@% * 4 H!0"@% * JD=_GQ-K\U)\?E>CVMQ/H]?SR>]
M<5COIAGS9_OV%K:TRS% 5(C[1G6B+=I)@W/8[/=Z3L;/B*DMV7GL:FJ<EY#>
MR,WBR61;)(_%[BDA6B8GBTR".$72,RB&7$22V8X1/($,R9Q%F*@MO4 4 H"!
M9WUHB+9 @U2<HISTQ/,59..!DNZ,Y=EZ")(9ZLI)1I!5C#6E."WU'$D( 2VA
M'AB)\$HJA 'R8N8!C 0+*^%YBL(; -IB&&8[@IH8,B-4A234?-1-K:HH.)V/
M"07FZ7"H!EPE%TOJ19#7G5(,@.Y2"* X&59;5%!2,8@AV$'RMAC:Q55;XA E
M&H H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!P\XT'X- OVA1_P H"+76R/J+
M6_/9/O5/SE_N$^@W?F6?M,H\P-<*?BL4 H!0"@% * 4 H!0"@% * 4!<?3+3
M*1-Q)$P;K=P&06&@C%3$A2$8*Y#)K;31LKY8D2..5PPU1T*@8>>)(ECG:][V
MN*+? '#/.THBN7!;?]CU?9\*I]&\W/FYM7S@6KP$B,FQY*IP\^%QJ7\!D;CI
MKD]JV\B>,ZY?]DL+0M'>O\=H,7Q>@@H+700;\W'EQ&4E=2&QPL?7EX_; ,14
M7%00.V0X^5K6Y+8AAXX!8!AX;36HQ((?T#L&P;*T9LJ58UC2DDT,E((B7U79
M<Y;[GN6ZYRW57N00E6LBX% * 4!A7%;G(BE;DSRY2]_DP#!%SO\ 58_)B&.*
M"#E?_P!&66-JI=(VX5B5+8*OY/81KEOI>1SFM7UW(@2^9JKH"@% * 4 H!0"
M@% 89N8\UO(./)E;FHR7CR9AA!9VY"(%N3,( 08 /*W_ &XX9YX6O\EKWM\M
M4VCB8.CU U45(44BXJ-:OP3;[6JYJ+MHUSFI>152Z2[VR]\S-7) H!0"@% *
M 4 H!0"@.;>S/]HAPQ/\QNO^19KU<47T36]Z3[\XZW/K78GX=7^SJ=)*ISL1
M0"@% * KR#JG 9?952V^"8...PRQ'J)%RD_+N9XYE3;.;1IP&6\!FQQ'#E'N
M+@1,':K%BJWBDV6P""J<)X&[%#0X(@%AJ 4 H!0"@% * 4!SIV3_ +0#AI?^
M<G\BJ%5S1?1%;_R??J</;WUTL'_/?(-.BU4QW H!0"@% * 4 H!0"@% * 4
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M[V^2U\LK_P"&]_U:R9;EDM8C5LBA541-F=]N:J_97OJ2GGBLQ$1,RLXRD_\
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MN'\V3SV<#@6'8%M?=#?"F CAN*/[(,4M\^IXM@NGIQ1!,V=A8;$H=[8E#O,
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MCZ_LD16'K$)Q)OB\F/O:CB=/N6%AO@_WBZ>-8DU@/S<E]O>.QM,7#'I1/))
M[+>TCKB&NQXD/40D$BJ1L(R72%&]@DX8L,:,6'B"0O>-'[6Z3L]R!W5XKLR+
MR#O1H3K[+^PLW:BZ63['VQJ$N[ PG);E@LPF[3@I[6"@M(=DU)&=D!OV3>JF
M3B&C+]AF^X%82Q=3)*9/$4I4(B8/=]7W0M_N>K[AR]XCF]SUC+=J.DZ I]W,
M:J[KON)PL(UENTL2A)#7CMZ0WLLPG3=VF[:]%$AF1?>/W&C-\GWWN:0$105L
M7TJX%T3-$L6$ -S"-]-GV2.]M%;(DWQ>3'WM1Q.GW+"PWP?[Q=/&L2:P'YN2
M^WO'8VF+ACTHGDD@=EO:1UQ#78\2'J(2"15(V$9+I"C>P2<,6&-&+#H)"]XT
M?M;I.SW(%PX%V2V4<NIW$UGY,V7VI6^+%"H.\3-=NDAEX.]VL-@@D5]468$?
MK>U15T5<!C !EQ2E@69RTW0T%*=*D*("H=O5$4'&TP2-Y/5>]6R1'U>R52D+
M:O8Y*U*TDF8KQ 2*/'\X\4'A]$XP6(9W_P!B9V<;;C9X1\M)^XC!V#D^465"
M&+P)"2,VR;C6F"K!K:7'H2O9-ZBGI8Q&QN+D;UR/J]6X3[,#TR,?3+8B,>(K
M"4ZHBVW)*ULCG4S8K7-=>TV;%2.\=J#*I/$ZL;8@HJ@-\U IUK.AM,!<C)/:
M::7/O8L<Q;I[$SD-D.E8$U3%5BD"42Z=9ZQ)% * 4 H!0"@% * 4 H!0"@%
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M(-.BU4QW H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M,V/480]H%,XZ-=FS>M.Y(<!:.79Q7XX[PMB_>&;'J,(>T"F<=&NS9O6G<D.
MM'+LXK\<=X6Q?O#-CU&$/:!3..C79LWK3N2' 6CEV<5^..\+8OWAFQZC"'M
MIG'1KLV;UIW)#@+1R[.*_''>%L7[PS8]1A#V@4SCHUV;-ZT[DAP%HY=G%?CC
MO"V+]X9L>HPA[0*9QT:[-F]:=R0X"T<NSBOQQWA;%^\,V/480]H%,XZ-=FS>
MM.Y(<!:.79Q7XX[PMB_>&;'J,(>T"F<=&NS9O6G<D. M'+LXK\<=X6Q?O#-C
MU&$/:!3..C79LWK3N2' 6CEV<5^..\+8OWAFQZC"'M IG'1KLV;UIW)#@+1R
M[.*_''>%L7[PS8]1A#V@4SCHUV;-ZT[DAP%HY=G%?CDCZ5QWLP?UN8QIO;*-
M9OI(BS)N)9),0"FK8Q;,*5WP";SR4Q9$(YF+&SH8@UK7"QZEB)8.W.MCSK_I
MUDZBX"3^1=#F\J'Y2\G!,@GM=A+D=F^65B4]I+9DO!J&(D7_ -U_;=_;+3^:
M_;+WKF?]&Q)]I]3PU%D7<9^*6O-[4Z2SB?\ J#S7[9>]<S_HV)/M/IPU%D7<
M9^*.;VITEG$_]0>:_;+WKF?]&Q)]I].&HLB[C/Q1S>U.DLXG_J#S7[9>]<S_
M *-B3[3Z<-19%W&?BCF]J=)9Q/\ U!YK]LO>N9_T;$GVGTX:BR+N,_%'-[4Z
M2SB?^H/-?ME[US/^C8D^T^G#461=QGXHYO:G26<3_P!0>:_;+WKF?]&Q)]I]
M.&HLB[C/Q1S>U.DLXG_J#S7[9>]<S_HV)/M/IPU%D7<9^*.;VITEG$_]0>:_
M;+WKF?\ 1L2?:?3AJ+(NXS\4<WM3I+.)_P"H/-?ME[US/^C8D^T^G#461=QG
MXHYO:G26<3_U!YK]LO>N9_T;$GVGTX:BR+N,_%'-[4Z2SB?^H/-?ME[US/\
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MXHYO:G26<3_U!YK]LO>N9_T;$GVGTX:BR+N,_%'-[4Z2SB?^H/-?ME[US/\
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M,W<&;K>[2_5Y>Z.\F7_3?^+5L=ETSGH[V7^LS=P9NM[M+]7E[H[R9?\ 3?\
MBU;'9=,YZ.]E_K,W<&;K>[2_5Y>Z.\F7_3?^+5L=ETSGH[V7^LS=P9NM[M+]
M7E[H[R9?]-_XM6QV73.>CO9?ZS-W!FZWNTOU>7NCO)E_TW_BU;'9=,YZ.]E_
MK,W<&;K>[2_5Y>Z.\F7_ $W_ (M6QV73.>CO9?ZS-W!FZWNTOU>7NCO)E_TW
M_BU;'9=,YZ.]E_K,W<&;K>[2_5Y>Z09*S5DDG)FJ%U65NW-C4Z/4FG6[Q4%.
M[6*IC4?:'$BL\I8QE<[VOSM?+K?/D#%Y>3*]N2O1*^Q9DB;S>@X+!:Q7?EYC
ML)B3I>$RZGBX7E)=38*JOHK7EU]G\/7<)A54Q&_D6-P7+1U<'W%NX/DK<79*
MIZV?@/C_ /:T]^[:G7Y,TY^MUH?.'?:/*ROHZ3^ A.-<H6 H!0%>=ND\LK:H
M;.I1QG%)$**>O,TIYJ/SZL$@D7R6.QNY2P[..+HV6(**4<P0ER0AO.]L2V ]
MQ+WY,:WK+56VE3N1RL5)\OQD2*M\=+L-F%^!DQ8/18PNI=VCS9Z0,:8B&P&N
M:ZLP/_=T&\T+.QGF<WOIZ@M\AMP$0-A!8IZC':P34R2?FXU/,<+%6N6*AXF$
MP8[@"#:^> ==_:TVE6BGM9/MQTW =XLY7+)CLHY%2\GWL5N+"*F[.>Q6*B.G
M*[:=>]?U7SUI5\R- 4 H!0%>3?\ .P0/S>7=^4EDUTC/J?,_U*7\A,*]WTHW
MYN[W["PU<V6 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * E30O\
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M'2?P$)QKE"P% * P+J;*(]6PXV:YB."FW':@K#9<":)F*$&H(B\GF$I5(YB
M9AC!X&R!L0.^6&6.5K9<MKVO\M9RICY,QLV6L)C7(J+M*BQ3[(18+$I#''"R
MX>4/OIK2=%6H\-QY(;*5RRZU'DTFWVF<"$IEKY8V'(*!4QB*%B8 SS!&P^7
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M^15"JYHOHBM_Y/OU.'M[ZZ6#_GOD&G1:J8[@4 H!0"@% * 4 H!0"@% * 4
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MLQ-E=?%^T_:&RZKJV;5',N/M)<+M8@AMDF8U?9PW)S)9BD^%R-B4.-"2%G:
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MJ*D+NPFPMS9V80N[&P2O-/#DFF3&[/+<:VU#%8Y385J:X)3QQ4M:51XA$G+
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MME!USDZZ91_I^J$RNG[X  ;Y)@D']8L_T_,7<DUF:/J"W+#A,Y)XMK!!EQ"
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M]EM:W_XWU7^'Y:I-&FX.CEGM@B0HI"02,$_)-\KQO#=V[I+O;+WS-U=D"@%
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M&3(ZUK!M:AM<VVH#2S"Q**XNJ"O")+%E)J,1*"W(BK=D[%>%"S!2KG1L<@[
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M9=^0 XIRE^-9'=45$&BW-<%>96A.)934=SH% 9 +T>C.46P.U%XW8PFJ!P'
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M21F0N 9!Y!*K4>B&1<2 ?MU(04/'(RF*(666-LLN9E>^/+RVK!;A)(5 * 4
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MY;U1Z,*CM&[/<U45JT,B"H]9B+^29=28MUZ;3UNNOK=4EWME[YFZO"!0"@%
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MI75 QDCI& @ADR9*%\L,, .CX'$;TT4)/9$1H,P".]T2"@QXY6^N,..)8?\
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M>K3I(_"4E2(UQF3Y,"TQ3+>P>DR$W 06DQ&8C!D]T/%VM=M6$<.+2&)I-EA
MQ,F>V9 $/KFX&(2>%[Q(]>'N^B>G<E:X-=@E-)>'_I;'DCN>8)(;4WN1E:?K
M!GSE&U9,MJO++-AAPS0SWVXTU.6DXV\!VF8*DCA<H.*9OBE@?=!G#4XA, 21
MK0\T5%U*D-/@?=+?/:!5N^=O-DC#R=+;W C]R,Q ;9A\.;461G&K.UHFGL:-
M*RHJFC@BODF@Y<[ 0Z)D3 K!'_!WXH32UTD:"%!#T$-#NOA9R3PXDESDMJ=A
M<?\ XC(<V2#)F$LJA$;1*V9=.;Z))ILOBAABF,S9M.PRZ^+AG<^LP+0P#P=)
M.C:9WH]95UOX;TU%YP<4,2@MSN][J[GVLU DEKQ7'<=R4FZU/M;U1NI20V2J
ME&X"TP#QE<CHTU%@\(=$*G!0Q+' -^U*X<>_\-S!PQ1Y%>FG($/<-Z!MD=7L
MEYBB3&Y)-G:+)&3(80XX<X[26VPQVO%;Y$2(?3^W)>RXYB*<=!,F"XBE@J8E
MT@#7]Q>'9Q!9OECB4K\9MW3.[(W3;.A;1CL^_P#8R;$!T-,II/)[FD3-;>;9
M;^GSQ2+'9"L\#)<,H16#.*3F5!$ZX-]4RQ# O9H_K=M3$.R_$5FJ=D'7UMM[
M;V6XQE*-D^)9@D:6EEM9L"%6A"1A*?!9XP!!9'#%1(L FL8"$#1F^ I\8E>U
M\2V!TR!R%<_!PXG<VJ4@OK8+8""G5,KUU];+*,R$HSE-[]:YJ8X9W!B/;B*S
MZ7#F6OT9L>,H&>RC%V""M-5 O@;0 !;GL3[B,Y88@ :[M["&S"=-4B SY(>F
MJ7,V_6Z7"+D",M1H'?KRD&9"B=JW-42MN6)( 5I!1(E<+PC!I,]LGE53/EF8
M& 1*@Y9F3)3 GG8T!; ?A>;TDYZ9BJU7OJ:D0W'W&+E;B7I+J<"G,+IDUPL*
M;F:_$!T1JHQJG,YF-9 =[-%?1\N0-!.U0)*V)LN<&N0NFB$%@"P1+0C<^*0=
MYLM<9LB1BJ"R4F<SPU#2T MJ8$%+.U;N;TX;(82LCJS#=3=)%,YS0[]Z61 B
MYBB4D"7%&3Q>>(G9 4=8W"LXC\?S$T9 *EM5WNDD.(_$F_[A5)3W=V;D"4C
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M4(-/O8Z0/=*M6ML^@EU+[3J*IKX8%Y):N<W@T:KG/PHX6$J-@U((B^V/2?\
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MB</U>'=(P;GJ]6P49UBX N^,<L/2"#Y6=NJ9..M<]4^(_K#),BQ9.\W&Y%4
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M"@% 2IH7_-8CW]O)8_+)(%?K67^CR/FTGY)A:6']%R^^_P"4<7!J2V% * 4
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M\T/F?E:)2VZ0Z1,:_2=[?$9<<VE:J7D5(HZ<J7'O151J18Q883G]E*]C[\*
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M #WR#3HM5,=P* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M-%';<<2*_P!RR@\VZ&J&+H 3?P16^60CQE87R16Q<<?1LRPJ.TZGF\JJ7"7
M2Y)<L'/<K5PE5S6HQJP\;"PG82(UBK%$PE26S'8.%M;&W<VTN>OLW$(,U"V0
M<,\<5MZ.-NOB3\8-F;A::P;-M6(G'(SF<#%:CBDYT$[8+2*R!7$JL-L.01JA
M%2IX9&+EPC(^(PV5Q!3 XHNW:E!+HM&V,>R7SR5:,Z4YZ-1'.1B+<5T$<J1B
MJ(Y5A<380SF,P)"(J)AI,<D8;4#NS7'&J* 4 H!0"@% * 4 H!0"@% * E30
MO^:Q'O[>2Q^620*_6LO]'D?-I/R3"TL/Z+E]]_RCCB#JQLA)T0[NM#6;B!+6
M[L#;82;/KV'9DKK+]D26.'[O<ULLI)6V'&,.HYHT:A[6M5:C+,)(N:.W$IM*
MADZFA K!E1&-W &];EV"(6A_.U'%"#A[C@::-).VLBP]KNXG')>A<UZU(\VH
MH;M9DQO1"8+[8$\2/% ;A'%+%C$@FR[-35)13"8B7@04+ F\@E>P><02$-GU
M;GV1&[W"E7$CGW#7#B8\0 A(KPXG"_KZWM,82DM'MK?O-M&R8ZU?FB:G^OL@
M.<'HUD#:ABFVU$!=9%3PC9)OMYRI".%A?/!#QQR_9$$@B^J^HBMU#I-M'L!N
M+IUP/%5,7-CFM/&]R!I4^I(<^T$:F0S+<3VJG$A!2LR-M4,I22,Y#'6;F16^
MW5<4F1.+JH+DN]:VP*'P0B-C%=KV0J[!HW$6W6V#C[1C1I-A&0G.A.-PR-PU
M&]LG,)1;.".\4K-#BC\[>-"3IQ4L5T)YR*EDS2HXS?5,C0*", $/;+!>"%QR
M1J845V_MD*MSUBP;H7GLP?[PW$T?-Z4YTSBZ6N'-,DPOF'%6=)C=T/GI(;,L
ML]EHCH;,..I\K,9L93)MLC8##!!2DP#,84<?+"Y@R8%%P2]'U;!DMR'JVSB)
MKOQ3=K6?'FK6\*B_IHD!S;S:M\=F;92AUW/-S/&,FBYM"%9R/#68C&L5+IT\
MRX;*,MK-B[;/A-@BD=\&9SKA7Z_-V#%PF*;1%W;-&>O$QW#T^U)F9?:4VSK)
M+QFC@/:)<06SRDM\+\LGHQVJVAV+1M?Y6?D?COTPX@HW:IE*D8NJIK41\"31
M114*V1!,+WR'R$12_"Z#T6\+J2'ZD[8\4W2M:?\ +,F1AI_*&JQN&')-<BO&
M87\G(.Q&LC9DUWM)3E61U=R2(\0$Q^%CY\OVV5#V9 !5P*ENH$PBY<*%A E#
MM;6)(H!0%4CO\^)M?FI/C\KT>UN)]'K^>3WKBL=],,^;/]^P@O;7?-QZX[(Z
MVZW-J)62YUG8C X91'=+TU*4!-!:,([I0$5<C>)'-G#TF,Z0Y^*-U8&7BC06
M59GW54XI?$D>',97"PU4;%(Q+)5@598W&'9,URDUHT.1"L-;7_8S8K9G2:#Y
MY1)96RC^<DSZ^M]P&7><7H\262U%B*V6Z\$4V7:K@2W:IK7; #G&B23;J!C.
M<!4]7?W",)('$3A*\3B16K"O">=>W4D[&2(B*VI/%=V ?LV+^W3J<8+L3->9
MAET^["<^PN^XW61I7-L)@-%(!8JT+(9/-*R,' ,R(8)<OD9A$N;'J@(W2]VH
M>Y,\;/\ &!T\DY92Y2@N&]MN%2^MF4?7G':22)?B192CTELQ/B21U.-54HSH
MXCZ5!8^,!74R:.W\BY<0U?+!54QAC ]I@D/6W!&ZG?+I2YQ'MI&?Q%-H-:8^
M@V&'?$6IVA9S:=T#NV=77'KI>BRN8.-2:MT[-)USE $L($H,O%$&(7'+@$B:
MH95LC*D."62<8P;B=W[HC=*LL[^\-NAX,N1W>7TM027>5PD4_BOI*>-M H"]
MOFO9[EF<X8943>&M>/:!>3NM%,R26 @E$N>ZW*ABE2G70N9(K8>")*+'PFGJ
M']XTE)/8KS?PN@+5NF1[HSK5Q$'63Z8ISK\/7C8,DA%QB"-CCJMF74Y8:[E<
M)<(JCBB%4M42[W-C*J:9M=.I@W(Q]7J01]DMW)W',8#&D&0^T$)'7;KW 3]T
M[B_8Z8C<D MEX,5[;LD412C,!@Q4*Q%=%DQ!9)!R$1'<=,.QO")]A^:G@*F0
M8N.$X%V"WR,*Y$RS3XL^P;P7MZ4YMZ F7RFZ 3?+$6R\/&FQY%QN1R-ABP>X
MY;9CLC9H.>&&&==KL?:XG)K>,-D(:PJ4.K8&@SI\('+#-@ILJ(E^M$-J%?<>
M!BTUJK?AUOA*+G5T1*P@V>S.P[)/$4DDD9&A##N5HGA!SMQVHRZ<.)"RWEAL
MIRDDJ*:+CG80/,(3+%4@2BQ.#VZF]4M3MPJ=P]T6@\)@CA/FZ6R^IG#19\1R
M"\X2>X2KE.R+#+9GE4?D8O%M.5?<LC22WU!<"*B'1D<LSDD$@$7,!JBQ=2S@
MGM4O^J!$=DV10@%^J/%?X>>C[*VRWD.-+4[2]V[';X&R&\>WAPC-2ZN.\BW8
M43Y$57!+XHBF.O2O@MJ8A("]C [9OBF"!!))8F"6BY"/J]5\7;QZBJP,CAQP
MN#4Q; /7B@2N[]H)ZDR(E?;Z0]:-9U-S.M" .,9C03<RAR*MQ^V6RQFI%Z*"
MI2VXUE/2U<)$%5Q4E$)X&#(V1<,P+FMR%SU?\8F*72NC(W.E?1D&;)!-WD:=
M-2MC^)0Q->-+'?M!/LCXLJ*F N1@FEI)E1Y[)OMH3G(P, O"?T592H]&.@J:
M8HY"D<2QPFEFP#N4JV/?]7J\ CX#I?GO#+[SFP_!L :KEY<<<,F(-*;EJJI/
M;38"%K\M3,12' <8+(/B--T SC)\<,95Q<:NG89-U,NCYE[ J>:@;+D,L<%-
MNX3$Z1UB2* 4 H!0"@% * 4 H!0''#BU_@Y</\EIS^&:)79TGU M+YU(]^P^
M$>>SZ*G_ .G3??M/*;7S\_"HH!0"@% * 4 H!0"@% * 4 H#H5H3OL\M/7EV
ML4^V#HA)T* 6;T9> MA#"48$L&!D[VAB.)@ 4<!0##&PX%\L %(#"P0M\,\
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MMUH?.'?:*&ROHZ3^ A.-<H6 H!0"@% * 4 H!0%<54$0QM,DEP39@@*/KB]
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M15UF*0$'#6K*1!6XK. A@?S.B.?-P%Q?V(LH@%,0RV"*B!@H?X2&J4.2<KR
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M6]%4VDN7XEJ'+&+6W6HW9O)Z_>\!EV)P:H$C6+H^C]ES=LJBNV*'7.KBCB>
M%2",YD:J5LJ4N7FIA #B0#E&BPR'D8&,&^HJ;9.GT\X8N*2-EL@2G6^$[2NM
MGU#Y\V53K*F-EHZ7"9P:K*^#=\)A(YMZX]$5$@J+%8EJ'.<JJC8*B7+L+E[9
MC]DE1J\+36V.7Y#LA1.L2K%:Q!^IZYINSB;0=*&82343*Z]B[BAQQ NYINDX
MJO%">G/5@C=APBJ@9%$!5"R@2SR*WUYFD=?/DS9-2DJ8V=4I/<KFK'#1,&"0
M<B(U6W(0BB76JBW3%9[W-5KH*BNPO7]7W"#H6X)&N,*F87+$IKV8?K(@Z$9N
MUU;L8R$J0&=9CAB+895=2W*;6>)AK:^-)[*?;Q3=60@9HLLDS1;$F &&)8*Y
MG QMU6EU?5MFQDT[)LZ=+FJYJ3,)'RT:C%;&:YJ01MY6JBQ7N0R?4O?%51J.
M546-V^E[9-U=/".BUW:J,C3M3V8VXQB.,GE'KFCG/%T0<=<S,0(H/FEB.8U3
M3JU *JCJ++::SF5,%S"D0/.,0--*DQE45/P$)B^4K2>IE6B^U&T]+SF8UR.\
M69!RO1$<Y83$5'*D;B*C;JJC<*ZD)4*DQ9N"W"5%C?V;ZW_N=PD3;WAC0;NJ
MYBCNEA^34C+86O$E:T'AV"Y&6A@++#E(\AJC@55 JK1ZX "[K*JB ".6')8E
M"67.S",E3!>^(./A9>D599$M95*R2K%GMF^,CE@YJ*B(D')XL%NQBNTJ+=,9
M<YTNXU$]LB^NG_$YFI_"SD1][L[(QY(B!LJU=(7YJ-K/K.2EY"D+50(W-C:@
M1,3RZXQY%2B@Z_)#?;[W*X@%;J2"U6RLW$)F;!FTT :V1KH%TCD2+(IY\AU.
MZUV5,V:K%;.@Q9BK!S5N-56WX.>YMU+CE2Y[\,ULIKFX/"HY5A=N1O*FQ<[Z
MG41#UY#?VW3%E!^:UI,:HVE+=>L<ZP2>6?[:=MY,9TG,N.DO,Z5;2>6#<3&!
M9&*2N)0J<L89"8B9%3A$V/@:-A <Z^NX&S'T\FH68^K<U\UF"K<!S7.6_&#L
M*+5BFQ%%1()'P5T&8+71PKZ=Z/A.A-49Y"@% * 4 H!0"@% * 4 H"5-"_YK
M$>_MY+'Y9) K]:R_T>1\VD_),+2P_HN7WW_*..8(7!G+R;J)(_# EV2YJCO3
MEFS^X)C@YXP4YX0+N&08[?TN+\_H402$4DV&Y*66HI0%*QT7$ 5&+)Y%82NU
MN5C0ENODTMFJI?2^I:HFV3V8X-D6JCSFV:7)M;M^ZMIIV:C,C9Q[9+)W5H*8
MVM$+*7T5U%8CCIOHFK"/ C/9:VY&\3.*0H+*S6C(H-L;'\ ^7"Y'*EZ^%:BW
MR_Z_K%%3NE77Z=W>F#.6<-;TUVHS$EHZ702+Q4$9_LHXS'TC.85!1$='-(SJ
MN."JF"9(F0*@JQ( 4L& #80 2(W(;!,"J)+AA,9/XCBIQ."VR>SV,W+,:8PB
MI1_D8UTSA8Q"."J0<845=H\M<_. $@A.I++JEE'!RXN.YH*V%U*Y;+,ODB1
M_-7X8+06=_5;B+#;2[8$IB5X44-;!&4D*>O"3%I& %%>&>&47I(1#7,"3TTF
M3?(W;LNMA.C%U G\<<;*O6MNMJ(L%B(&]09P_D"&#"4XW!LIM!L7*K(C!Z0]
M#,Z;*.&'I&F&#V+( S?/.HHRG2G0HURCM75A8:*0<-++W)NU8.Y)@ !HT.2Z
MH5$16$-@0V2JS/X:3ZTQU3VJ@34.:IRFYS;B.B2%$<_LTL:]69T(R7/Q)?*R
MKL1F+$L)PD\5HA80^$=,-LN.J!CG"A0NFE$P$8^;M*+=BHA<@EXZ=:V0.R]7
M=?85UQCH,7!CP=&#*BYLYF.7KPXELMOD4(%34,LA!LA%-6R)W-&<[YYWS,#9
MY7O>]^6H58J2394 4 H!0%4CO\^)M?FI/C\KT>UN)]'K^>3WKBL=],,^;/\
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MX"L3 HK'6HP.P@E22V8U<$.OIYQBYV^R)C-"GY4C[%Q-1;(*QMD/=1SP-F"
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M$5+UY4BFR2G^WGSA.1')S&"IEEY,_7X.6[7@TPO6"C__ )E9X$SR5\*;I/\
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M0"@% <V]F?[1#AB?YC=?\BS7JXHOHFM[TGWYQUN?6NQ/PZO]G4Z253G8B@%
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M>S_NMW3IG"MRCAF>R\@SP#H.:F^@]G_=;NG3.%;E'#,]EY!G@'0<U-]![/\
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M\7*Q!JK8.0]W,QRCD\QXSV[NEH0PT9(ZS:DC=*7OS2NV"H8[<]Z$4(ZRW?\
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M\O!1N#12$@C%EHD)34AP;O&EPO8"W6^U6ZA+O;+WS-5=D"@% * 4 H!0"@%
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MN[*W/U*E&.WY*\0;)PA-D?1B6N,^7+!\G,Z92;?'R+"F220;QC18= ^;B6;
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MQ/PZO]G4Z253G8B@*Y[?E%XYJGL>$V'LYHY< <(2<=2'LS0FN,YV\=3F>KJ
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MG1\SQ,BDR-KB,S9IU'B;.9N%M8&\Y]5FC)3!D1TR9(<6GFLQPXL=32F-_(R
MTV99\M!<P:IM3ZF>45XV.!C@!%C VBXDS_V@@O4=4W++MQC@;Y;^Z:N+8)MZ
M[P?E,^P#3@S6'&?69(0 KB;ZU"3:>\7+Z@::"EBAL8%&'76^*8-%Q\.NDK "
M((Q4YQXB#PX&$I3!LJOEWK.6GW$$+/9M91)K*[8;=[GC?",6.\59UQ:[X951
MUU'G9O+%TQ]I)1630\$D+,LVQ6R*:.F3(&Z: [*[^;0.3AR1D?W;)1<RY<T5
MVWE1?)0UK/K:CG%&0]7=NVM#K0"&#=3,>S73(R/,9VDTNR W$IO&2B8D&,<%
M+,^9#42 'QZF[2<1Z<U/ATH#XXA2R5.;QO/BEQ5()YDZXZMH]F&%I1,S\+1V
M^8:(+\;/"Z>]U9&9MTH[9RBNM"[W38./:S-8!S7C0$80%Q$.+ANJ5B9H09/&
MLD62/'6A^N6T3O=$[N=KQ"P]B5!T2/*B',4AN1I%]-MB5%T1(WT6, $E6+LE
MT16*VEE3$-64C@0F!!- ^V3M@C,_[%<./<B?]A6,W+LOCF[!:G,W7)SMN"FR
M9UK:+!9NQ<4IQ#.1<VT2G0)XR8>8C85W>35G"80%(ZY&UB532=R1(8X!Z8I?
MV)EZ-'D*V&9H;M=L(B!IQ$[A(L0/#1M%9HYDWB)D81PB,^;FP?(-E%+OA;$?
M+-"P*97SMU$<:W.O8"A7& >BT_N"MN8\7K%CQ@9=5(;5<C,:S*>BA;=S0/)\
MB)2:AC.(Y#$HRO&)S)6S)%E(EBEN<[G8N: P&R+';#%P *V\6R/-C6SPJN(
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MCN1'CJM(FRV_44ISC>4;J\XRS'F]L/H IA7$5XP0[E2K7V19K7##-"GY+@8
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M@)KQ5X@B*/XT5'8G-0N.4:Q!S'V6WD4VO$FV4-"A)X1K,7 F&)EB#;"V5[7
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MILQG4W$M<0V\YF=K#"39<""BN8@N);D1T99160244M+<"8YU(L>+@"8!&P%
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M3';1<K74V^RDP@WTLL1!+II<L$$3+A XXV##PQL!M,)ZV:Z:U(RJW=<X"A6
M6^O'05)<0H3BQBQ6C+*B7#$"+GU5,8J$@DE$Z $-GC@*-AGGCCG>UKVM>] ;
MV_H^84K,UPQU*+(:$DQ\[DX1'=C%?S:1G@S7.DC989C);A;#A)**(M)PN8>-
M\@#( H65\;7OC\EJ KR0T$T32DU'1DS2O4I.2&\SGM': E$-<8=)IJ''\F!J
M@,CL9'(EV:&53&=( 2X=Q6TP'' DJXG![&@Q;"B<X"DT&\'>#X>W6E?9<>/M
M+%>''"TXF1H"UV;>BS*9)S5EU0RX7LXVT_HIDF\E.5N(;@<JG*KF-N,5&9B
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MW@3(^'!-C<ZSH6]B3'37G$T?NY.C(L*3C8@Y]6W ODH^*&$ZZ..58Y55BLV
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MR_N)F(.D1#OAA][[H[B4U/TBZ/\ &2L<:T6%E_<3,0Q2%L%$A=$1P#+N%P,
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M=@@?F\N[\I+)KI&?4^9_J4OY"85[OI1OS=WOV%AJYLL!0"@% * 4 H!0"@%
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MBJ%5S1?1%;_R??J</;WUTL'_ #WR#3HM5,=P* 4 H!0"@% * 4 H!0"@% *
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M/YG^/A_C=3^KY/\ U?+5%I-#,-5A0AP6S&%]+\+O@)2^9VKT@4 H!0"@% *
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MX&$..#B8 SZF*)AS<\LZJFF4=0^FFP5[%A%%BB[**B[2I!4"I!8$E5KD"@%
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M^#0+]H4?\H"+76R/J+6_/9/O5/SE_N$^@W?F6?M,H\P-<*?BL4 H!0"@% *
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M $KD&*!SV)[=S5Q(=I_[L/NZQFU 4.[93HRN+2V3ZHMLAY/6*4];AUBK[ +
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M7+ER.V8T[4P7OA%[6W/85?6/WXFFDVH,></K;P=B0W&K"#96E6R(S,BEIH2
MW8T 4B2>WGIC*I")R!0!K8RBSG6W$O(N[2Q,-9+=>]3&-9V$+V#:/6O:D^VZ
M9)TV8_#JY6$]55706+<!7W\!R*OB*N#<BB7Q(F3'3VQ5557)=V=J_M=PYQ\(
MG33;T4G&>P^OA9#T;@^0.&5"\8YF7$C,>3$N>-DC9!#5C>UXD'17+*4FV,CM
MP6P9=4<"JB.DV.!AD?(\T<R#>^TGM6RT690UL:RL97O?<5S%ERHJG \(]B[-
M]&HYB1\5;B*>]3,EQ5C_ !GI,5>\GDQ5/8BAZ@8)CI:B:)F;'KA7FZYEEMDS
MQ<\M-)J*S';1H0XL**G@&B-=P/>2W EIY($]B7#[8.%:4!K!=5,G# X@@F7S
MRMJ&U54^H8US6N5+CG(Y;B(EU4:Q%581N-:FPB(AH.5%=%+WJ[WL$MUJD"@%
M * 4 H!0"@% * 4 H!0$IZ'6ROJK']L,L<<[K4M6PRSQOGCCEYXI!YN66%LP
M[YXVO^K:V6-[V_[;5^M9?Z/(^;2?DF%G8?T7+[[_ )1QY*9984L.K^[&#ZL)
M4/3W+>VYW<.36A+K$A>!YJDYYVE^/N(NYI3EU>=I:,6DZC[ +&F@!VW(FU<5
M.Q,EC!4$IED-F"#?T6^L?5=+5(;'JN$[Q2TY>A';7B.S%#4([U/'A[2I$\%$
M"[CV&U:V[DK=%Z;+HS]9@Y!JQ?:8HM4=\)%@=H,D1=-&C;LQ5$%(.CWP+FPL
M\[X99-5+BK>]7J]C9(<BJD-DZ/Q[P[7OK5Q6HZVFU2+GT#1K;XV\98V6@_)'
M<#=*QAM*1@Z44]FS&EL%<)IIN/RDK(KU4"3A!&)DS!9PV+ES0>&0Y0 OC&XL
M;_J]2F4+I$;<+ODG_>@7W-)F#-G@H16>' 6U639PRU7V+O"QF;B\S,Z2!6YY
MV<8PO'X2#9JI!@2SBS4<6YD:PL5L>N9RP"RA=CO$;/KDGR.R'%LWQ,-8=FX&
MCO=^$9TUAGQXP?L"F['Q3(Z7K*Z-/LFE(A!YR!##A=AQPZ]FCDJ+J>A@HBC'
MZJ([#.!H$1;328>!@8"4O04;,3$\,IY*K;XA_&J?[NA+;)C,::Y4BB7HB=[]
MTSVP9#>DAC0]#!5D/HPT%1TPRDEEAR%W'R!)B 'E=?< =[C)1(Z%@)GA"W;B
M>J\2EP@GAKK^$;\,[B]I4_13/$()N<V<1?80\#L9KC.D"(Z_!<R)CG66@Y$9
M8F6/F.@N+MRBI1FQQ,)FAE1*O<+$^6*]<ENK3%%<B[$?MD7<&&S [0\*QLRJ
MS.&OHFU)OLH!RJW]5812WB66# IM:('RK"10RR6NF1A1QAUU)3+ %CN66>>5
MS00G+EE^K?%U\E+Q?JH)% * 4!5([_/B;7YJ3X_*]'M;B?1Z_GD]ZXK'?3#/
MFS_?L*";:X**UQ:]*E*0DASKL!ZLZ<[B[?D$)L,%WR<JJDV)+FAB#4]8;D=,
M!NNE\/\ ?#-8DN'KI!%(3E-0 %5,\BY>Q@4#++62XWN^K[I8K?.9NDV@J3OR
MC;];/[\IV\,=-:==Z5V<)-T9>&O;IA]BRW#VO10B7U/3WJW'SK7CL],@26TT
M, ^(ALQW]ICZD&5)C)=SH8I80J[4%3U?<"=V^1TPG1L=,*KQII)CK2W<,MM[
MQ"'.7U1U21)RU(GN!HUC74%CQHEPU'\M/V3I;8#&B!E-C 9\K3D.()55/NPV
M*GA]52A;\O,13;]7JB+QV$@U+V8X6>GL<P@HP,T)J@+5J T-DH#_ (3?NQTX
M;2RS(26S0;D2*5J!%^D"N73$AU2R;%(=<XOPT61$+/!2/#XXACAAPL%7N$I%
M$[I4/@PSD8UJU-C*)9*UAWS!GJ3#FP&X>[+Y=&A^V['9[%DY^*[ID=ZHJ.*N
MP>04):?HX]T=!0VXRRSB/*MK7S+BC9 Y892OC78[!%ZX3MPN$R2929_$RV27
M82D>.]@-L]KI&/)L<;DPU-<0HI>&V2TDJ*-;$97*2-%S977>PQXY2,E8^52@
MSH  ZL83LQ"8_5;!E5+FUW 3U'^G6S^I<'RW%NLCCB^8'&^3D;*R1(\XR,]H
M;DG*^89!JRPU3\@,N()XS14%FL-&P"BH8)(40VF"9 2AB)@FDA&3Y7(MW:\
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M]&V(3TTLLLKOI/8(O6P( *0"-8(G@"&$%@&!D"/!$X91%27%G/7MQ+*RY-@
M-IEM8=>QVTKS53^P&!-RIY^3!%)VS6M'0UESDG8;#70L,\23AQP*]LP3?6!'
MK<#,)O!AX;B+&421"A:_*[?94!92UE!W>]/>R2"\(?\ /LO)#DEX.-),1Y?)
M24R07ZIHH=CP:<KE\,BA@X4PM@4/G@3 %_8?A^,8 B]C0M##)08YBR-6Z0:C
M'93:*=9HZ AIH?, + 8Y9BF#)D83+(8R:,""FCAH00<P(*,(()D!)% * 4!S
MIV3_ +0#AI?^<G\BJ%5S1?1%;_R??J</;WUTL'_/?(-.BU4QW H!0"@/B4B
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MQASBU.C,X[_ICSH;9>ZBS_I)I/LPIP-%EG<7^,.<6IT9G'?],>=#;+W46?\
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MUL4A%1C::2E)IZU1PG*D<Q&M'RU^178R])CI*JCD2<N:"I$T<N4,\\J:&!$
MY2B<6_>#;#99V:8K$4:Q(45/][\0Z&]BM>') LK2%L/K]KCKM$*2I-5\SPN*
MVP[*8!-!VWP=!M)0E0RR[MX+*V.!4-Q#7%)6 J_PV^)EL)K=PV.'OJ]K,VH;
MP=;;X<&]/$ D=X3DTGT^&^KL2 YSF\-%B1G)#$DJ*S:"Z'VN(1D(PX31Q6 1
M2^00ED@]?.^-@-,+<0*56IN7Q!N*KJ?'T)LLXO<(_0[;R2HJF!F.UQ]]Y)UC
M,^[J9)-RL%VQ8:(/4%,-9@%'>>++!<?!**X72Q #.(Q0#J=M-QR)UA'8?7DJ
MQDO69YP9*<S</V-)&B$!N2\M;%0VB[QQJY7J1.2_+.#P:D61;)I,VUCQEMM$
MHU7B86F\1&/J1Q"R%( G0)*X#B&F-::^.HA,]!0T5,1^+/.95!;R86+M] )8
M!(Z9<J0+ETL@*72B%Q;VM?J);.P>-[WL'E?ZFX'&E?@K9OAEO[=R=]A=&(,*
M;]3CIYOU,D&\2O3_ &&V8?J+E(J/&YZ2YB,O:(9K>(J>QW>F);AZ_35E*;3:
M3@3";D23R0A087, "Y7"Y'G^,)VE>"]'TZ'VVK/W@H</+:!";$NEW<6U]-;D
MO%O725F4I4+1SC9VW<DMIIPR:=2L2YRZXAR )@V*8$ PSQ ^?C'ZD;!'-AV?
MQ -V-"M4]_\ 4&!(PA=ON1M1GL/M+&6P$)W2C:,MS)(+/8)5T,>(G^RA)-<R
MF.71E$BYUI81DX@&<-)X.(P08%9D619,,;KVVL&)G[;.C?WKM9X>@[WQS.9.
M_H$E81$;]X*S/%A S0\-I3:!P<G:NW_PGMK:RH(%D/R"T![J: 4!S;VU,CIV
MY>@"LA 8K3Y3BNV.;+98F=B +P.&HU9Q-;*"KYB^*<A61FT.;4;9F,K8CY%;
M 8<H@F-JZK1ZGLZIHJV7:E0M-30E>.C'3+N$L$P6W;NV<#I4M3+TCL>HH9?#
M5TM*M62\)&(Z,N6UT7+<3!:L>[>0L7YP]E/=Y3O6>U.R:W<SZ%=L/ZM-W#=S
MKI?V4SK$O='G#V4]WE.]9[4[)IF?0KMA_5INX,ZZ7]E,ZQ+W1YP]E/=Y3O6>
MU.R:9GT*[8?U:;N#.NE_93.L2]T></93W>4[UGM3LFF9]"NV']6F[@SKI?V4
MSK$O='G#V4]WE.]9[4[)IF?0KMA_5INX,ZZ7]E,ZQ+W1YP]E/=Y3O6>U.R:9
MGT*[8?U:;N#.NE_93.L2]T></93W>4[UGM3LFF9]"NV']6F[@SKI?V4SK$O=
M'G#V4]WE.]9[4[)IF?0KMA_5INX,ZZ7]E,ZQ+W1YP]E/=Y3O6>U.R:9GT*[8
M?U:;N#.NE_93.L2]T></93W>4[UGM3LFF9]"NV']6F[@SKI?V4SK$O='G#V4
M]WE.]9[4[)IF?0KMA_5INX,ZZ7]E,ZQ+W1YP]E/=Y3O6>U.R:9GT*[8?U:;N
M#.NE_93.L2]T></93W>4[UGM3LFF9]"NV']6F[@SKI?V4SK$O='G#V4]WE.]
M9[4[)IF?0KMA_5INX,ZZ7]E,ZQ+W1YP]E/=Y3O6>U.R:9GT*[8?U:;N#.NE_
M93.L2]T></93W>4[UGM3LFF9]"NV']6F[@SKI?V4SK$O='G#V4]WE.]9[4[)
MIF?0KMA_5INX,ZZ7]E,ZQ+W1YP]E/=Y3O6>U.R:9GT*[8?U:;N#.NE_93.L2
M]T></93W>4[UGM3LFF9]"NV']6F[@SKI?V4SK$O='G#V4]WE.]9[4[)IF?0K
MMA_5INX,ZZ7]E,ZQ+W1YP]E/=Y3O6>U.R:9GT*[8?U:;N#.NE_93.L2]T></
M93W>4[UGM3LFF9]"NV']6F[@SKI?V4SK$O='G#V4]WE.]9[4[)IF?0KMA_5I
MNX,ZZ7]E,ZQ+W1YP]E/=Y3O6>U.R:9GT*[8?U:;N#.NE_93.L2]T></93W>4
M[UGM3LFF9]"NV']6F[@SKI?V4SK$O='G#V4]WE.]9[4[)IF?0KMA_5INX,ZZ
M7]E,ZQ+W1YP]E/=Y3O6>U.R:9GT*[8?U:;N#.NE_93.L2]T></93W>4[UGM3
MLFF9]"NV']6F[@SKI?V4SK$O='G#V4]WE.]9[4[)IF?0KMA_5INX,ZZ7]E,Z
MQ+W1YP]E/=Y3O6>U.R:9GT*[8?U:;N#.NE_93.L2]T></93W>4[UGM3LFF9]
M"NV']6F[@SKI?V4SK$O='G#V4]WE.]9[4[)IF?0KMA_5INX,ZZ7]E,ZQ+W1Y
MP]E/=Y3O6>U.R:9GT*[8?U:;N#.NE_93.L2]T></93W>4[UGM3LFF9]"NV']
M6F[@SKI?V4SK$O='G#V4]WE.]9[4[)IF?0KMA_5INX,ZZ7]E,ZQ+W2%I+>LX
MGI-U8LXH8)(%BLTOT\B7#?C>4NW#B*ZB;0YI2!G8J/EUB&IY\[&YD3D"!YO+
ME?Y:A]FZ+R9#^9VDZ=A<&U_Y"8W EK.EX<RZGC8-SQ4NK&X5]5:&DDVOH.=V
M>V5@U$US/RS'8<Q*.JP9=Q?%PKOC+<2%TKWK9^ ^/_VM/?NVIU^/M.?K=:'S
MAWVCWLKZ.D_@(3C7*%@* 4!"DX0LQY>8SY27 EM8LO+4?.IHHS\7FTAN$\QN
MW*.I%@5Y+LN " ELD8X<L<OCCF%B+F!CS\N3'&^.Y1UD^EG,=+5V DQ'*U%5
M,*"I<6&W"!+55%3OGFZTSFV4-H=U8_A%;V$X+N#1@!]7D$B'I2PI#)3Y)^$>
M@'2::BM3%]FS#,1$DVGCB67Q$,X=S)DLA@2W5P,^N ^]M6EI[.LA]8R3:JS)
M[,'\NYJRV8>RN#XRKY.$B16$8+<-R;+8R5A(V;A+Y5Y-T]6%?-C2% * 4!7%
M5*%3^TR21/%BYTD=UQ>A0X3-@AF"ILJ8D5E@F"QDN-CF$.7'"SOCGAE:^.6-
M[VO:]KUTLM5;HB]S5@Y+3E_(S#0=]*,^;N]^P\J$#R8)PZ(2X_&T^KD4Z_(+
M]UXX@RNPF:DN>+!!VP7B8S)S8:($8)84?NB-5UO-5&S<ECI F6/]KBPY?_PF
M5\^=AV-9(2W:FQ;.M&9/=)GT>$Y4?=P\%5PUPD>BJL(*JI%8WSH7IP\R3+F*
M[!5B;.S=N[):%^\9O=N-I*VA25UMZJJC'U*F;1YIO$NF1I+I-T2$S-V$]#5"
M!!NK)B>3B6SG+%I4%5Q'53*<L%EW,4KS$Q.L$-U;0DZ)V1/D4[F.J4G5,JH<
MV+F0:LA518IP<7(^Y!$5%;=\9UR'FE-+5C5\;"<CME+BMCW-G['=-\FCBU[K
MQC(VWB DH6K:VVM;]\H U70 %&-I93EQRLK9$@HF&TJ*ZJ6G8\0)NA@#9%;'
MC8)&Y1;Q"%ZD13KBX=1\*31BR:B32N<ZH29444R<L'L5$=*A%$3@XP=L)&+=
ME70NX-D2W-:OC76*M]+Z1[FS ^P;BZ[;HJ$*EJZ'KBJ/F.>,^U>&-)BPFQI)
MR0UGO&[J'M@!)S';AJ=UE5CMZE+$C6&14^JN<CG>X>?-QM;+#+%-&;,>]'-6
M>DF99;JIB*]BJUS?O'+P:(YJW+J(Q;YES>6JW,+!65A)=2_M7KOV#^X[XK&[
M;W1-1P\D_5<-QSAQ#MB-&WV;M$\ME$0)+C&QG!H20TD^^PRD?0C^&2$<$4DL
MX95@U"QD$, T0ZAF*/-1HU9$E]5=J>#DT4JH;X[(Q?[9JKP5W8@J(D(+%%C<
MQ=)E)A0PKC$<EU-F%R]W>X;'$7%YV)GB.]0&>SV?"K1V,G\ONVJOMWN%GOUS
MPLW4?2I774T_WM,(A*35>@BC*PA,D&!@.YC&+>L.*,)=2ZF& -Y5.B]#1SZF
M;-=-=0REIT:U'-28JST2^Y6*V#+MYB85Q/%OH=3L8KG+%6)@]_QDC?AL=ZZ0
M4[N-_MHX$YL/*(V-KJVFL[>$R^^(@$@R,Q)2=S@0'Y%CR<31=,="+Z#,,?$G
M(T5\VT#7:\YBF)IDJ&;"&RR-8@W#,;DK1"S&.?)J7SW3&6DVFBUS$16O1'(Z
M"L=!R8212*HL-B-S-*66BP<JQ2;@[%Y=F\IER/'3V!CF)]A9-FN,H=> K6T
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M)TM9:-1\MR+[7"<Y'HBJD+QY/8U):.9%=M=B,+T+Z>&Z=+:Y\\10"@% * 4
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M^;R\E\K\G^&]>DAW R62;^ U$\"0[OLJ9-_W/X+4;F.\D/TS_P#%/I^/;_\
M@I?CT_\ L[7IPW<)_J@_@?Z[_P#B#X]O_P""E^/3_P"SM.&[@_J@_@?Z[_\
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MJDT:1J:.6>C(HSF4B$4<U8<$V'BN\9O>=XR7ENDN]LO?,U5V0* 4 H!0"@%
M* 4 H#FWLS_:(<,3_,;K_D6:]7%%]$UO>D^_..MSZUV)^'5_LZG22J<[$4!0
MO<K4ET3<_=6-D89<+;:VS&F<C.IXQ88>^)WO"?#'E9HBQW.$-O@VF):ZKMY#
MD9FB 9EUDB0/'4972R1H,N/B&("(!QIC?@L[P)VT3C>+OW,G=HZ]OC8";)-D
MZ/(RXC>QRC#$B1A,[Y?+E>,8(NFJQK@V5:(UY](3TS+'7.7GM?545:N.M)U[
MFA"H1$#J"#P7.&V6B*+8,)P$X"$:PNF28W(W3$[8;9M.7T%CS,(*+*\7&7\2
MF4O(#BAN0Q3 N2LS%14.M4[D*)<1/OU3/G ;=)G"2X>,NN6[K?&MZ0841VE'
ML>*R<W'Y*[":#IC.* VMC'$4OA@L)^-EC/R)&:,R4DR1:BTG'VZ$=(AFNL[F
M>46X&.EO@_<.B<I3>TU25KH"K2;(C^A24W8Y424YM8_7DD:[(AYM0R^4Y&8D
MDMIOMUT,AOJ9DF$=32A0<V7,"X&\A["9VN!.>NNBVL6J:UL X(/8SD;RKM*^
M34F3R,YY?FB5"[^?Q^ZQVT=8R?+,A/A.;ZNLAKHP9X1)"(=? AE@C%A R93$
M #$:V</74+4AHJT?P9$YE%8BLBN)L!LQ[R1+$T-9N,]XF@#SS8K!09K?4AI<
M:Q^]#Q0N.LH#>"3$96&)ELS98;,L7N&!IS:X6VBC3A.:M>$>$!LHHV&9R#',
MN(RU*DT.=PN2-6BDBH+(C-/D1S2*KR.SHUCY%,"E&XWD-6349O%QQ0TTL5Q%
M$MD!F6WPV=,FA-6>P+;BA72Y,,M*+V0L# R_-PK%=3?A1#;S>B7!\Q 9D@:(
M7ZKQVG-%*R25-:0CZF3-IQ8W@8L: #&Q V+'0#4/'97/;JT-D//OFN6=V3AR
M=;^R:%I LT<6!YU<(?R==X:#F3O%PLB]^6+?LZ>U7*4Z_P"H7N'<"XU * YM
M[._VA?# _P _NC^0E)JXH_HBM[\GWZG'6Q]<+%_ K?DY9TDJG.Q% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H"N,X?A-
MTZ_..<_]$7:>MVE^ J?S*?*RBCM;]/LSY\_]CJR@^MGX#X__ &M/?NVIU^9]
M.?K=:'SAWVBALKZ.D_@(3C7*%@* 4!H,K- M(,722PCJL$@DWNP7@T#:X,4*
M* **6<K>448=6%('Q B)T).".W&R!&RQ"$MAS<[VQO>]>U--614RYZ)A*Q[7
M0O1@J+#UR46"Q/.EI-+$J[-[7IL1.F=."$X&=";Q(OXCT*VJ[S6S#[!CE3&&
M2Q6J4=3P.-UD)>9DL!BY3B594ZW(F!B)?/,N:ZYKO+7IZ>S[,6JERK729.8K
M?R[F\$W#3[Z"1<L%7 1816"K=2!MS6,9+PD;-1R^5>]BZ>FNOGIIB@% * KB
MJE@SNTR23&R,8!&]<7H6%S*&S1 UB&/(K+"SR+'B(Q<Z2,8XY7O@*"(&*'ER
M9898Y6M>W2RU5NB+U2^EIR^[_<S-A;BF@[Z49\W=[]A5L/@_:!8,2;(R&BZ3
ME)B;(.!,=L[-U;VQV]7RLI.Q)72CE*NIW#K<\'SRBYAEM/ '-*'5<39VX.&)
M@07#''&WEK1;7#29Z3):3I"*DM4DR$P$5(0;"7<2%Y+R;!;<YG82.BF$V]<2
MY]@^!Q\&OAXNT1^C..(I&53$I*L6KDCFA]K=O,3CX5X3232)$R@YS@,[A&5@
MTP$XYG9-R&SSZ@+; :W*,&&)C,O2JW)2,1DUB)+1Z-_(R?%28L7HGY.YA+?V
M[UX)4SDA!4N1A<39O[&R9%T\(+09ZJ,BJSGC*4E11EJ3FQ,TBFLMM=P"HCIE
M%D]M.\QZ'K$IY+8 J[1Q6!L4RX%@@R&&(.(&.&)8M8*)>E%M2DEMES):)*EK
M+;^1D7&.AA-3\G>6%W;NQOJ0E1-2"(J7$@EQMY;^P;%CPJM%[-F4FGG$SN,)
M<RS6V]D'\:.;![(G7,;GMI*AQ90I=;;T.2Z.\8_?P!\_G<91;Y]+,' L0PC&
M0H0(6&'GK';'"2YJ36HZ5*64W\E*@DMR05BMP,%S;EYR+#8OJ.'FQ18I%$@E
MQ+VU>N^N8I+X2&A:'@QP4&+9#0"\:3&Z]@6"50=H=KD0FTIB>UDK%SOE$)I<
MW%"I-14L$@/&P..'6@&(YO$$(.QXY8?)VD]M/P\.8QRS)22W1DR5PF-C!JQE
MW42/?O1O)!SB;=BJ74A>2\GK&=1>%IH\W(D0H10(I=J.PVJ\7V_&H(G3_L:4
M?K3<DHIUDF2Q&I+P,MXRVV4:0D_(0-<2B*X72E7KDQ<R6%R,F+B8/TBM=]2M
M8^:U9SFM:L9<K!5&+%D68& JM7VJJV*7(+<0A9\U78:JD80O)"YW(0/D?/"C
MT+D18(K3BA-5*#ID Y:LIJ:S9IGR-VP0UY%*FBAJ)2;-CN46LTBS04,3HHAH
M' E;,T9SN.-EF/R"5,G26VI#5:R<EV=PRJZ7+<JS/+5SF*Z*;%VXEQ+A+9\U
MJ01?OHWD6[MW4/S9W">T)8QYP'D:%EL_@ZH'2]8G CO.<=@Y&:JG B"D)J(W
MHQ&9LA2JZ&G@WFV22"^2;S"6 Z<:PN:+"!&<\QLIFZ2VU.1J/G(F#.6:BMER
MFJDQ555?A-8CHK%8W8*EQ8I<"SYKKZWG1O(EW;BB&ZEN'#IF7B1W0F-$!A79
M3\>J!)#L4W-)DNNR4U>06B EE&:]LYU<S]5IO*NIDD44J71#X#B",HQ8#$$E
MF %RX7\EM^UEJFUG"PG,8K6HC6(Q&NCA-X-&I+@Z*JY%;!RW5B8\-,PL*-U$
MA>2$-J%[OW+IA0>&#I" TYB9&,/JXK=GJ2&M,<G &IDG4ZHJLNLPQ8XWY3;[
M@.28.X8_D4 YA@,86V\:2E(\,$'F:&&R##OCEK#:_"RIW"IPDEBL9XDM$1CK
M[%1&0<W^RY%1-A$)X:9%%C[5()<2]M=U.XIK*-PE-"VZ:;1Q"B=]) K.GY8V
ME;09#97:,L32M@%\-,!6)/!3PIHQ("KY\LD@@YXB!YE>H9"AV"L&8'Q$]'Z3
M6U,1R/FL7#DI*6,J3=EI&#/@[R1[_=N(2M1-5(*J76X-Y+VU>-RCSAG:211)
M++ER/H5NVW_'BG+JJT%@O),N'"B2-/"@:5I6(YMU2?IULJ: ZE$^.-VL-DQT
MTCF-GUF 7Y^7+Y3](+7J9#J:?.PI+T8BI@,N\&D&74;%%1-E%BNRJD+.F.16
MJMQ8;6Q>/G+<,32!.BEKPJAPR<:K!8[A>[F8P++E>:F2[6.>DD,^6?B>RY+:
M4BHLEM-J.M/5#!,ZAIZN6114\;(I<KUM?J52ND-KNJ75;YJ.G/:U'83);FNP
M?:JYBM5BN1;J.5JNC=C$<--PL-5BY=M$7[%XWMEZ(:J1Q,["V 847BM"3HOA
MDGKRP#S>?TF);2:T*D+Y"E8[3(O*O(.+<4 ,]GUY>V:-F+FH8XF\L[FL<1K>
M$ZV;2J*5]%/F85/,F\(Z+6*Y9GE*_!PX['MKUR]<(6;,5JL58M58^OMQOF^L
MO5Z#H^D\W,;59QHI(1AMKS1**ZB\7TXTYN-UVNH-\/-.9#5<CF5VBP+/EX%P
M%)>%0R">,N'"I<4_F8R+@7#\IUI5D^GYK->BR,)'01K455:F"U7*B(YV"VXW
M"5<%%6$(J8J]RMP57Q8^K[FT3]6B8B@% * 4 H!0"@% 2IH7_-8CW]O)8_+)
M(%?K67^CR/FTGY)A:6']%R^^_P"4<<@BW"DW1USUNV:T<TSDZ/$W7N;I:D:7
M(*F879K8W4O973)=DS)(4QR*%CKK%CK2]AFHQG;@<4DY&.+S'+*A>^*>IBC@
MC7%+YJJ+ZO8]7<+2"D9O[A&<0!$V-X5\LLUZP9MDD\.Z-IA2Y-=^X^V^T 4J
M[7R1L-'1=DRDIJXKC@':ZT9,LB=+W,IJ9BM+Y.Y8;(K@4(A86MDPH0AL"&V=
M5D!J\1Y3>VO*V_8MTC2&HRYZ=KI>;78NQ<R&/-;")N)S,2-!J148-:<MLO*S
MP3[.95<!W-8":!+,<,%*+W!+C8G2**0[JH(72'XOX8)K3R5.)K+FGA./14W?
M!HQBM-?7U[.QRQ;%K!G5)QEM(EISA.%I,&4LVNU9 3GTEJ=@TYN'#';%/%*W
MP#*7+9ED;J*2J%58!X3NU+&X=V@6O\C@ZT9[-<,;9-DSU!*JTIBE9;B";2;6
M5'>;6&U(KG5==VH\8<N[$21U,AU1/;SUQ3S2:14+6,XC#)X*(/T>? [E%7T(
MF>#6=M:ZV'L!+S?WB7EY#;@43CZUNJ1]U7:I/)?;+Q5)'UIE:9$MCH)>R<W1
M%]I"-EQF4@N9&"#*BF[@!RKXW$O$(V'?,@[M.N-!',3\/^$=87/PWWHUM/\
M7^.FTYW7M\Y-A5]86I^;K'3F6$]F@QX+AN,F8.VX520C9)CB+F1PR:Q,!J2F
M6LKEBYP.(PO;),(GH=32YHHG$"AY0%5CI4D5+G%0< J5'4C0( 89A0&+$@@"
M1<4X+C<3(,'# +"^7)AC;&UK5B2?;0"@% * JD=_GQ-K\U)\?E>CVMQ/H]?S
MR>]<5COIAGS9_OV%:=YM-)=V%F"!9<A,6-(XDR&%MM8M78D)_2+'\T1TUU)T
MC*\QMD1%;#.>#(V$BU_MI%3$S-A.7)&31#AHPIW4@1B8 !G6:J(EV)8JBQ*"
MQ=P<9[C.7H> ">41JL#:O;G[@;S1"LXOA\)LQ2:]=DVX[B+5A^3T/&(SK18;
M69"RZ1.V;G355Q&UHC?$,-&)9A99&)P_5X=TC!N>KU;!1K6/@"[X1RPM'H/E
M5VZJ$X[UTU2XC^L,F2)%L[3::D0^'O\ K,FFL'K'#35=7F@G8GHJ3W61RQ+G
M'$1NJ&.K\@Q3$$.YG%%2$#*%V)?+1WA@;N:^;8Z"2_+2KJJI1IIWP[G#P_5O
M&-Y#E4P^'*GHZZGJK!EM+0%^#&^W1SSF*-I/ 64,94*=J!C!D<%35KX8!BE5
M(03U7MP0+3/[AXS,X^(AM'L\AOB,2\,;8:#E]3'615N^J\GL5TH-WD&BJS>0
M2:3DU'(WU41UA&C1PRLD3)/$CF5#(&;F['"<HY()'8W?ND04XV1_P(^(HS6A
M*C1.+^EBD"[N"RN<*-L'RLV3D2%+N+*3%-S(TOKQ<75<WABBGT)0R'-)A?/,
M<D;RL3P&-!A]?BE<B^" 1(>$PZUP)N)8I1O,L? &-&L/.5PDM4^&DF*XNR$^
M6[7N+7PW'!I<E@\0PTLSYR*O][JAB42@Q\A\.87N(9MU<6Q:,*Y#N;NZ3#V2
MT[IX(^T3N,2&TAGQ!B)'FW4A\.F9]GW(')4EKDC0P]M&VVTTEQL^!2>,*-M,
MF5K2:89I7!,5EU08IUN8"C#9$5"]PP \E>BK'U;&X1@K"!=O5/039*+71Q>5
M&7V[JHO-_B S@LR7&+?Q><E2FWAFDXV4<CE69$\MA4B&(!0TX1OD2ID0%'55
M+$SFJ&REA ,2H9P[&$ER-Y/N;@@I;3AX:S3%JM&DI1])[O**+159R>3LU_BQ
M.E%]SDF:\0<HI;<(MR'DF8Y/:#$?KS2":ZF*:P4+'DP,-N%E?!%*CG"J>";'
MQ58DH7_J"10"@% * 4 H!0"@% * 4 H!0"@% * X><:#\&@7[0H_Y0$6NMD?
M46M^>R?>J?G+_<)]!N_,L_:91Y@:X4_%8H!0"@% * 4 H!0"@% * 4 H#[TI
M54T)33UI%4#J2L))TJI):HFFAB2@G*!(; R3/$3A;,,P5-E3 >.88F&6.>&>
M-KVO:]J7SVIZBHI*AE52O=+J9;D<Q[55KFN:L4<U4NHJ+=14/5OPWN)"F;')
MB?#TPJ!))G9))=32U03J))/E5/) WR$/$0\;!ERKQ*EP[YG26%L<#&&.1DMC
M;"PP)?VES/O'W]A=O[I^YO-'YW*?3*G;8=N.;+THEMN+<:VI:U+KV)>28B79
MDM+]U[$P<)K.O=>Y]U% * 4!@G->V*"J7RRQQM8M?ERS,9E,+?5X?+D9#M?,
M&W_XUOEJBTF5&V#5*Y41."OJ]9:7TOO2ZWOH#.U>@4 H!0"@% * 4 H#"-F]
MLFVW[XY8Y8W1$F]LL#&9O#*UR!>]LL#0EK"&<;V_4$R^JSM\M_EO5'HPJ.T;
ML]S516K0R(*CUF(OY)EU)BW7IM/6ZZ^MU27>V7OF;J\(% * 4 H!0"@% * 4
M!S;V9_M$.&)_F-U_R+->KBB^B:WO2??G'6Y]:[$_#J_V=3I)5.=B* 4!YV]M
M>.1+>KVRN\\)$]'VI);&T(AV*-BI1DDGMB8:KD<D+R4H-%/-F&?&ZEK8H$!Y
M-;>#IS-V0S+C+I9PFG&.19!,YEBI@"3&MQBI-D_;69=:H;TU2I";<2Q5JIL?
MG+ ^RQ%FA']:-C@6DN."0EEJ.6&"Q5OO.*6.YQ5K-LEUE4NN IQ@ L>",7"P
M$ A>,N/4NSVW6\,P]9D-BC;1:R;;;#:%N-[3H9,VDE/U/<;I;;R3)V;*=")H
MQ"CD/)S8'7TDHCC/XF>(!V",&B8M\[8 <AN&_N+LLP)"X>,SS3)>VVP;WW%T
M\W2V?)(#LXE;Y6-:5=TP5'S\,.9)>>M#@U#4,&'@M]YI(=(+HCN5$=KK!TV*
M2(=;EPBQD#K;K)NAM)Q"M'>'N:E,5+B*0MX)Z>LD+:MKG+\AM1REM1]=CSOF
M!UB"+[;:$;.Z*C2B]&RV8R.)R2M+0YU!7 C)A=S&43I<L!2;A6<8N9XZX9_#
MS8:PV7KO%MS-L4<038AYN.=-B76V% A"^K,TS,;4%%P2ZZ&)-;C=3Q6DM#";
MS4212X9/JI0,(ZH)9+ ,>@.JT#\:Q&V@V$U_B:%(*2K,F=X$C#81"79?FP.(
M9A=[,?C;>*N[L]?8D48M76#L )!S@:MD)X%RD@)*L241!QBI VGE!#N0%7WG
MQ4YFV&T%V*X@46-!OP2\=!S;:EM.BQM;-*DD*KO)D%==(3SJ]N_ *]$,1GHH
M?)".$R]\"V8*W8@K*)-3;:^/8F8R,@>CJ-7XB2G'3!DYLW&NVY'935?C?N9L
M%8Q=$=Z$0<*5<>P HP-AKD%$/G\S//'G<O)E>WRT!NM * YM[._VA?# _P _
MNC^0E)JXH_HBM[\GWZG'6Q]<+%_ K?DY9BN(3.VW4*R#H^V-:WGKBUT;:/9P
M'6)W#SE LFS&IMI3689F>949^-R[!V<@ J,03RL*F4PTDFL<Q# BF&9P.@V+
M9%S%0B1N;)V"K AE%XD[]U9V%EC6/B7C1(B'&U#"+L5"NQ6NC"EHNSIRCA9F
M%KP0895M>1UN=94:DYI$IR&VD@FW4I<=PKF$6@,T^]A;Y%<)A%+@CMDSG.++
MJN<<.K"4P )JDY(VDE"68I2G"S=;MCU*\:N>%DIQXO\ 1)4:Q>(C#UC]W-QY
M(P26I(ZZG)1M&*7.JJC<JG)ID:F"L(J(H3GK+OWJ?N&NN9M:]2<?>:VU6NVW
MX;)+,9RS&W;R.GDHKB0SY.81F4F*RRDG18[%)M'P4QSMP150#^97/J!L2UK7
MO"HJ"*&J@\2[3,524DH:2W:F&D/::^EKB$7X&V%;B>U]D,D-'<Q1BNQ77XJ3
M4IJI"N@. D;3W,HC%FHI &0\BJD-:],%1%##P_Q4M")Z<;(;D43\5= <EI\H
M*,=O46.Y;;L0/FT+'%DM*B8TIR=+!1(:<+D9)5 -*)U)*KPJIBB88JN)?)-%
M"-YL%1%"M[-XN\8.39"=$T\L-].U!B355BSZF21>,MCR,SN-4>$J&8T*#%8L
M=$7MMR.ACNT^$&$S#;12'.7>F8^ B8>&RMD5ME@7/[7_ !$? 2BY.+GJN0.:
MO@LU-GB1BFSNQ<A:SD,F]K-LB4<L82#%C->3J?*9*49JT1%)39Z\C&&J&!DC
MGD0LI=8&Q%K(/!#3U!1+1@[8B63B+>/6&=955H5C20E15D1-:RD^DU-7(TE=
MB(<@,5$7RC57GS#+X?S';#$G5E-YR*!4BHJ[,4EY.3S)PO@8&#R, V$A45+X
MBA LVSWN5#$_0$>/H,#J.LT[;&AZS8QZ$VGQGL,S1UULO9094ZY2<1DL]&[J
M:ZLILK,T?:%FFF'TM#-AC9K69H(R5!R1$6]M"*_9.8$G<8V3('UEXB*C+>[W
M"M3=T=3Y F-M0Q!"JS'!&RY*"=!Y THXIJI"+FWX7)75G-._("4;MTH^'@D&
M/EZBN=4Q#PA41/ (G;Y#<&T#EU@B]6;ZG#*GL7(#49!Q9?8\>NQ)@UF&W.G@
M+:X\QHB%F8Y(2^A-U+$R *(!=ZX'591R #$4DXJ*.<)E1$54VA%51%.?+1W]
MVP7DMH:ZJS-AY)W/>&\TV:8$I136#(RUK!BW8.B!1V%<>RH49&Y/09!,MH>-
M 2B-9KW? 8H;U,YD;+0@(%QA)5L+NQ#V2(F06-S-Z7SJ=+,Z0^T-<&(^]1\]
MCD;85N3$VY =+2EV1-7GV_6H]&%#2BS98:BQ$B&[6Y'W;]-=2X$[@BH+A3R>
M28:$ 4!P&"VYW1%2:I W+G-)V.X6#.;$<QHEP3O:)(Y63%!X++P.36R%]OZC
M2QL>V6PU&VGI2*SB)0N?818LJ*Z@?/#"8Y#%0DH'+/$^#"I"/<4E%]@Z=5B2
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * KC.'X3=.OSCG/_1%VGK=I?@*G
M\RGRLHH[6_3[,^?/_8ZLH/K9^ ^/_P!K3W[MJ=?F?3GZW6A\X=]HH;*^CI/X
M"$XURA8"@% <N.)6I[FN%G'X.UBCC7%[LB88<E]L3,>G"9W!#[B1FVMHF#:/
M'(^/MH3)1RN0;ZT='.J',#LEB6+"6$M?/ZGH]'V62V8E9:$R>R=*FL5B2Y:/
M1518HCD6Y=5$1$V;I[2N#1<)ZN146Y!$7PQ.=.M[4V+%ES7!NR#J%P@(D8C'
MD-A&0W_K!(#0'G%IY(&895,!B\AVL3;EA',8ZFC*H  UQC#>43Y8/$3,;&U[
MZO=1)2U$R356I-G/EO\ %FL=P;HW\/O>V2-YR(NP>CW2X*K73%<NVEQ>_=]2
MGI=KY\:HH!0"@*\F_P"=@@?F\N[\I+)KI&?4^9_J4OY"85[OI1OS=WOV%AJY
MLL!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!*FA?\UB/?V\EC\L
MD@5^M9?Z/(^;2?DF%I8?T7+[[_E'''7>CB];.1SH7L!Q%]20-9[0+%&QB1!,
M;%YOCF5WVKS*C(4X7URE23AE-K3)")./$(E* QBZ$7N76\S:6ABC&12XBB&$
MG^BM1$[I:Q\!\T7\3O>^:C6^[&@E\:$[&$M9FS#KEA+=V*HAET?4247:_3^2
M:X8#<3=2]MGP;&?*3F(&..NMU^*A1%+_ "FDLQF*7Q%(U%[Z^KU=\A70)-U/
MXGNS&["7$D>,D[KUK;N+$DWN;7[B)ZNSA"LI/A?:3Q0XUD:16^ZH95F_L/&I
MMK1M(F$1*!5+55(@\ K!K&(]KCY(V99:8.RMY/5_P)CX2/D_='BZ*7$^=O#&
M+2EPXL7FVM#@]R )3'TVV:P;"BYQI!;\=!1*,@A\0,55((/;5>L/DZ,13!BQ
M<+ELBWSRYEL53P").2SQ$MRVKQ@H)T/6V-ILMPI,;&D5:5VNQI5=ZUN+%:9'
M364E<.=Y013O:Z,VO%DD+I' LVFV6P57 93C&)PR<+& S"<!,$OI>AZMPB*^
MN2?IENOM?,4X<5.!I&;4)R6[M%Y+CQCPQE%#5=L&EY/RD6*C<C)B<_1)!EZ;
MBJ&8+'C!1/&4B@^(6 (8QK$GGEF&5P00F-PK_!7$6XDEB'$G:>SVLL XS!PW
M%^/'VX,=?%I\*453Y";VC1=F)0845NB0W F+Z9.B#&Y0D< .JJ<$EG#9L J;
M3DNQO <"41!%3N+$LHLJ<(LC>9HV6 7!'LL,5J2,R%P#(/()5:CT0R+B0#]N
MI""AXY&4Q1"RRQMEES,KWQY>6U8+<))"H!0"@% 52._SXFU^:D^/RO1[6XGT
M>OYY/>N*QWTPSYL_W["/]M-JUJ+92UEU6B)/)K.Q>W+M=":U3*@$74$.)(BC
M%$"<\TSP[4?-22QE=/9J,9*IZ0G]6 P5G&JD2^0G4NK6K5:B7UO%DNTE\I7J
ME..U?$R4IHE.+-BW7JKJ="LRN_7^$U5EQW!+\F?9YV0H?--:29@EY8E*-Y C
MYN1"YGB%<NEH#11D%<'"*&!LE@AU0,L'*HB;!"14KX_7_P 0UW<3)CZ:,#B!
M/IF),0<.0IL;N(M-B$=2C<9)\^G5,5FQR1;IJ1( =#]1&;(;D33RTKI&2H,<
M";A>P9)0(&,[F T$O['J^Z(JA\.M_&]D&1N" B\0-Y1LC*NSPD5SF9[Q&J35
M<&6NNR%'0L1^&_1RP5CQU&;KJ<>*. "EV%ZH<<2P DEA@PQ>NRY&QN['JN#"
MA<V2*=R^))NQ 3!D./RLMV1),T"T(AN?-NY>(QO&(@DW;N[ KS:;\ ZH(++5
MV4[6TVF2^5D-2$6L4? JY!$T\2 3#I<S80]4P;ZO5L[@BIVF;F\AU6V,1M0E
M2(1D;8HV#E(2RVQ'VGC-1(UL#LF=4F[%SV0L% VK64E@NAY-'M;@J!.*^08@
M^*-U%>&A6HB1C<"*I#NQVX$NJ6]FD^G6MRL@(R.^Y+DMX;(OY32RJN>-Q'KT
MS0E^0V%'@"LFGDH>QM].AL-AP+8-LA$XZL"$" N"D05LTHC?%BHC=@A,_%*V
M#D/5'A_[1;&12[VNR9"B*-#[L:2L[XY-2JDGU\$Z1)(K4"9Q1_1OD85WJKG0
M$@B;$4!@4XV=#-"$5' &Y$QBE\E3F!Q$-G]S=<=;^%''0NS<S1WN%LI,<:,W
M8=S0-K!&TXN119"9&YN1MK7&@Z[A:]SZ[%@U%R>2N"B%&NDX#E\A\#"ED:+@
MBVRF"17:$2K;VX@F_#3X,LM;.7V5>*A+\K;LI\3<-Z3VY%NMSRV D.)Y EE
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M;TPN8P-Y F"I.P/7&<HY+UV,(>QN$05#GEI1J<L\5_1=#CDA+L$)FKT1[/\
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M(!:#0!S2&JD9E3;^?QLJ(,CM%'&$RM;Y+9!8J3@4L0L\"!##/',QGCEEED&
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M 4 H#FWL[_:%\,#_ #^Z/Y"4FKBC^B*WOR??J<=;'UPL7\"M^3EG22J<[$4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M*XSA^$W3K\XYS_T1=IZW:7X"I_,I\K**.UOT^S/GS_V.K*#ZV?@/C_\ :T]^
M[:G7YGTY^MUH?.'?:*&ROHZ3^ A.-<H6 H!0$1S^Y%]FP/-CO:EFU=T-2(Y(
M<C;L],3&3.NOH3-651'L[,2@8QK)M=L2H?7]@L,A+E>?S;7OR6K9H9;)M;)E
M3,+@W36(N#?@KD18=W:[I+8*Y$6]$\X&FW$6E^:]@X%;)[C":ASTDR [VW<[
M $?:K/2,9*=J:HAV43+>3EY<3!C+9/(Y7G&#@9O# 6Y<H, )F%EE<3#OK4L*
MDI**?,;9=5)>QCH3'3FO8U4V51%NHNQ#95%-N;)1C%7@WMALJL4]@]3=?.#3
M% * 4!4"16Z[G'M$TR[0D)1CLV7@-X#&E!.;S:<0A\M>0V7A8F(7<R>H%B^&
M(N5L^>'CCGRX\G+R7KL[-J:.FT3G.K:9M2Q;1EHC5>]D%X&9=BQ45=J"W"HJ
M94Z9:<O@IBRX2'Q@C5CX[/*1?L&\^:Z;?>><_JOB?R;K0SM8/94KCZC'/?FM
M9TE^\EXH\UTV^\\Y_5?$_DW3.U@]E2N/J,<<UK.DOWDO%'FNFWWGG/ZKXG\F
MZ9VL'LJ5Q]1CCFM9TE^\EXH\UTV^\\Y_5?$_DW3.U@]E2N/J,<<UK.DOWDO%
M'FNFWWGG/ZKXG\FZ9VL'LJ5Q]1CCFM9TE^\EXH\UTV^\\Y_5?$_DW3.U@]E2
MN/J,<<UK.DOWDO%'FNFWWGG/ZKXG\FZ9VL'LJ5Q]1CCFM9TE^\EXH\UTV^\\
MY_5?$_DW3.U@]E2N/J,<<UK.DOWDO%'FNFWWGG/ZKXG\FZ9VL'LJ5Q]1CCFM
M9TE^\EXH\UTV^\\Y_5?$_DW3.U@]E2N/J,<<UK.DOWDO%'FNFWWGG/ZKXG\F
MZ9VL'LJ5Q]1CCFM9TE^\EXH\UTV^\\Y_5?$_DW3.U@]E2N/J,<<UK.DOWDO%
M'FNFWWGG/ZKXG\FZ9VL'LJ5Q]1CCFM9TE^\EXH\UTV^\\Y_5?$_DW3.U@]E2
MN/J,<<UK.DOWDO%'FNFWWGG/ZKXG\FZ9VL'LJ5Q]1CCFM9TE^\EXH\UTV^\\
MY_5?$_DW3.U@]E2N/J,<<UK.DOWDO%'FNFWWGG/ZKXG\FZ9VL'LJ5Q]1CCFM
M9TE^\EXH\UTV^\\Y_5?$_DW3.U@]E2N/J,<<UK.DOWDO%'FNFWWGG/ZKXG\F
MZ9VL'LJ5Q]1CCFM9TE^\EXH\UTV^\\Y_5?$_DW3.U@]E2N/J,<<UK.DOWDO%
M'FNFWWGG/ZKXG\FZ9VL'LJ5Q]1CCFM9TE^\EXH\UTV^\\Y_5?$_DW3.U@]E2
MN/J,<<UK.DOWDO%'FNFWWGG/ZKXG\FZ9VL'LJ5Q]1CCFM9TE^\EXH\UTV^\\
MY_5?$_DW3.U@]E2N/J,<<UK.DOWDO%)'TKB:>5/6YC'43:UTMI-%69-Q 12\
M31 J E<P)7?!<R)B>5&T.>%N=-A9CWMGE>V&0M\,>3#'&UOTZRHI> DKP#8<
MWE??/N)P3()?V$N%E8E)6K9DM4JGHD7_ 'DORW?V2T_F7V.]\IX>I>$?)2IY
MQ2Y!N^?NEKS.OZ6_>2\4>9?8[WRGAZEX1\E*<XI<@W?/W1S.OZ6_>2\4>9?8
M[WRGAZEX1\E*<XI<@W?/W1S.OZ6_>2\4>9?8[WRGAZEX1\E*<XI<@W?/W1S.
MOZ6_>2\4>9?8[WRGAZEX1\E*<XI<@W?/W1S.OZ6_>2\4>9?8[WRGAZEX1\E*
M<XI<@W?/W1S.OZ6_>2\4>9?8[WRGAZEX1\E*<XI<@W?/W1S.OZ6_>2\4>9?8
M[WRGAZEX1\E*<XI<@W?/W1S.OZ6_>2\4>9?8[WRGAZEX1\E*<XI<@W?/W1S.
MOZ6_>2\4>9?8[WRGAZEX1\E*<XI<@W?/W1S.OZ6_>2\4>9?8[WRGAZEX1\E*
M<XI<@W?/W1S.OZ6_>2\4>9?8[WRGAZEX1\E*<XI<@W?/W1S.OZ6_>2\4K2<B
M6>[;B-Y-OM@ZLEG/6EXG@W'YI8?L.$F!RBQ0!42R;9L]K<P3!H7 >X]\.KXY
M!6PMES,LK7VTGTW,57@6X/"I<PG>2Z[?*YU)6YV8G.GQYL^[@2_+9<]J66\R
M^QWOE/#U+PCY*5J<XI<@W?/W2QYG7]+?O)>*/,OL=[Y3P]2\(^2E.<4N0;OG
M[HYG7]+?O)>*/,OL=[Y3P]2\(^2E.<4N0;OG[HYG7]+?O)>*/,OL=[Y3P]2\
M(^2E.<4N0;OG[HYG7]+?O)>*/,OL=[Y3P]2\(^2E.<4N0;OG[HYG7]+?O)>*
M/,OL=[Y3P]2\(^2E.<4N0;OG[HYG7]+?O)>*/,OL=[Y3P]2\(^2E.<4N0;OG
M[HYG7]+?O)>*/,OL=[Y3P]2\(^2E.<4N0;OG[HYG7]+?O)>*/,OL=[Y3P]2\
M(^2E.<4N0;OG[HYG7]+?O)>*/,OL=[Y3P]2\(^2E.<4N0;OG[HYG7]+?O)>*
M/,OL=[Y3P]2\(^2E.<4N0;OG[HYG7]+?O)>*/,OL=[Y3P]2\(^2E.<4N0;OG
M[HYG7]+?O)>*/,OL=[Y3P]2\(^2E.<4N0;OG[HYG7]+?O)>*/,OL=[Y3P]2\
M(^2E.<4N0;OG[HYG7]+?O)>*/,OL=[Y3P]2\(^2E.<4N0;OG[HYG7]+?O)>*
M/,OL=[Y3P]2\(^2E.<4N0;OG[HYG7]+?O)>*/,OL=[Y3P]2\(^2E.<4N0;OG
M[HYG7]+?O)>*/,OL=[Y3P]2\(^2E.<4N0;OG[HYG7]+?O)>*/,OL=[Y3P]2\
M(^2E.<4N0;OG[HYG7]+?O)>*/,OL=[Y3P]2\(^2E.<4N0;OG[HYG7]+?O)>*
M/,OL=[Y3P]2\(^2E.<4N0;OG[HYG7]+?O)>*/,OL=[Y3P]2\(^2E.<4N0;OG
M[HYG7]+?O)>*/,OL=[Y3P]2\(^2E.<4N0;OG[HYG7]+?O)>*/,OL=[Y3P]2\
M(^2E.<4N0;OG[HYG7]+?O)>*/,OL=[Y3P]2\(^2E.<4N0;OG[HYG7]+?O)>*
M/,OL=[Y3P]2\(^2E.<4N0;OG[HYG7]+?O)>*/,OL=[Y3P]2\(^2E.<4N0;OG
M[HYG7]+?O)>*5Y?42.<::60VIBFTO)28M-97&+*+[BZ(RZ0@XIMU$SD!FAW;
MV#:5^V)JP7-S/ BY@"AX9 WQS^6_<6344$O0ZOG55-+FTJ5,J,MSWHBK%(+A
M(J.14CL+L=U3A[>LUU5I'24E9/:YCY$Q<*9*DN:D(K!6/:K%BJ)=<BJBP5+I
MO71DA;PN@WU':U^1]<UG71GLBFX^?CFQJC9G2*/JE#R0Z,D+>%T&^H[6OR/I
MG71GLBFX^?CC5&S.D4?5*'DAT9(6\+H-]1VM?D?3.NC/9%-Q\_'&J-F=(H^J
M4/)#HR0MX70;ZCM:_(^F==&>R*;CY^.-4;,Z11]4H>2'1DA;PN@WU':U^1],
MZZ,]D4W'S\<:HV9TBCZI0\D.C)"WA=!OJ.UK\CZ9UT9[(IN/GXXU1LSI%'U2
MAY(=&2%O"Z#?4=K7Y'TSKHSV13<?/QQJC9G2*/JE#R0Z,D+>%T&^H[6OR/IG
M71GLBFX^?CC5&S.D4?5*'DAT9(6\+H-]1VM?D?3.NC/9%-Q\_'&J-F=(H^J4
M/)#HR0MX70;ZCM:_(^F==&>R*;CY^.-4;,Z11]4H>2,6MZUPL615<SWTPB-U
MNEGQ^HAP9KID(+U(H*)U,/$FT+&\L\^;R6L%>PE[W^I^JY*U*^V=&95!/FYG
MIUP9+U@D^I55@U5@B-F82Q_L^-M73RG:)66DIR\XHU@U?_246UW)4? ?21UH
MA84D3%[ZX/PZH5+B<S.#=<+98<\'#+FY6&:%QK98\O)?G_5<OZORUZT]KZ,O
MIV.6R*=%5C5AP]1M)MOCX;NV9,T2LM6(O.*.\G_I*+DCZ^C)"WA=!OJ.UK\C
MZ]LZZ,]D4W'S\<SU1LSI%'U2AY(=&2%O"Z#?4=K7Y'TSKHSV13<?/QQJC9G2
M*/JE#R1+;#AL\V$@<G&,N)+>01SXIHR48<6PZDI RGD 7"&,#@-]M%R8A^Y8
M(+'+/*UQ.9CA:]^2UJ]&6MH\B>)9,B'<GU&.6U#8-5225EV97I*D*Z*I*IZ5
MK8W(K!DM$C"%V_>-V[P)4]/;@\08Z[A5EG>P>R9/'U&.;F:[:[3F\3(Q!W@2
MIZ>W!X@QUW"IG>P>R9/'U&.,UVUVG-XF1B#O E3T]N#Q!CKN%3.]@]DR>/J,
M<9KMKM.;Q,C$'>!*GI[<'B#'7<*F=[![)D\?48XS7;7:<WB9&(.\"5/3VX/$
M&.NX5,[V#V3)X^HQQFNVNTYO$R,0PZ\P9-Q1U#(S.:\: L!?JI?./H_%Q%QY
MV/U%PP$'JN=N7_LQ^6JBW[8T;;8U0ZHL61-DI+NL6=5.1R12XK6S,)?6NDI9
M=M1^DYO$R,0S'>!*GI[<'B#'7<*K?.]@]DR>/J,<C-=M=IS>)D8@[P)4]/;@
M\08Z[A4SO8/9,GCZC'&:[:[3F\3(Q!W@2IZ>W!X@QUW"IG>P>R9/'U&.,UVU
MVG-XF1B#O E3T]N#Q!CKN%3.]@]DR>/J,<9KMKM.;Q,C$'>!*GI[<'B#'7<*
MF=[![)D\?48XS7;7:<WB9&(.\"5/3VX/$&.NX5,[V#V3)X^HQQFNVNTYO$R,
M0=X$J>GMP>(,==PJ9WL'LF3Q]1CC-=M=IS>)D8@[P)4]/;@\08Z[A4SO8/9,
MGCZC'&:[:[3F\3(Q!W@2IZ>W!X@QUW"IG>P>R9/'U&.,UVUVG-XF1B&)06#)
MV2$BY%IS7BI?))3LBY7"/H_"P+ W)@W" Q"'0>K!X@A\F-L<_JK6MR7^6JG1
M^V-&W6#1.I[%D2J=:22K6).JFHQO!MP6HUTS":C4@B-=XR0@MTR=9=M82_\
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MF.X% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MF4*V%SRZD"$'S<,>=F/X28Z9!$PE58)&"16,$BJK!.ZJKMJ>"W5B9NL * 4
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M($#3MPMH3F[0-"X;)&3IRAC6E';S;8QLK$JI%63U<,:M,00TB1PK.658CE(
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M*KFB^B*W_D^_4X>WOKI8/^>^0:=%JICN!0"@% * 4 H!0"@% * 4 H!0"@%
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MB\9?UZC&=]?=;)(G#OU,I3E2I1V1145891IMQ(:8@F#EC]M]\)0!P*0SB3E
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M?JL!.-V21'P<CZVB10MYKL:@1*L-B)&VVSW>4,.*5(F7<D.D_BF9XD,S&9,
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M>EJ%OLA\^1]."F_V?"NX/Z9M(^TJ+>S<4^-1X'FPJ:GGE$:6(;$!($S)T7
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M@41@LC8H(A/$0,MC<7*UL+7RJ8+&&R(I?+1%S !L  T5'!,E3((9@L9+B8#
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MK;Y+U2:-+'1RSUBCO^RD74<CT7\DV[AM\5\?*2XZ^EQ27>V7OF:J[(% * 4
MH!0"@% * 4!S;V9_M$.&)_F-U_R+->KBB^B:WO2??G'6Y]:[$_#J_P!G4Z25
M3G8B@% * 4 H!0"@% * 4 H!0"@.=.R?]H!PTO\ SD_D50JN:+Z(K?\ D^_4
MX>WOKI8/^>^0:=%JICN!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M-,"+I$2$IVCL^1W)#4.*R.TK&57!;#3S:4.*FF+=5N8% ]1E * 4 H!0"@%
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MP;,>Y#9.<KQXXV[R-H;,.WB3!+ +6;K'UKEZ.'>\]9MI&5"*DG3E)9N.WE
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M;-\FZ/.O%OI*8'CBW>Z-.!G>0[P*.<4_ELWR;H\Z\6^DI@>.+=[HTX&=Y#O
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M\VG8D_B*7E"Z&HNUFF^X"@NMQH16UF:]T/#KW%F/-E,8NKK:)C@'U9:0!$W
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M@(M=;(^HM;\]D^]4_.7^X3Z#=^99^TRCS UPI^*Q0"@% * 4 H!0"@% * 4
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M3([8#:,2 Z73DQHT8Q99/9)+90^UR GF% V. 3P'-&!!"JJWPB(A8BH)% *
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MZ>=D419(G<DX-VL%TJ2*IX!<W \EGARPULP1,L+TQW!3G9R,XVX;'$VT;/\
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M_%W1)*A\^OMO8AX2&SY#8\E&T;89!+K"XG"LG$TBK*6 C@%L1KA&4XW?D%Q
MQ"OQ.M^&NO; R4[&+J05@O6;BN1EH"^(K::3,COFYY1C,PVO*,U9'9,FG'HT
M6F4D!LJFP:4<,)9AEF2BT!<X4"S3LTT,XK 554MC]@ME=L.%=Q"EU6US9T5O
M4[Q/!-7VBYG+,\?),9-B/M6MB@&TM;3.I7D)U1@L]^!1E K#A7$-DMU49:>
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M)#4.*R.TK&57!;#3S:4.*FF+=5N8% ]1E * 4 H!0"@% * 4 H!0"@% * 4
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MAHV1QZF.(Y$=4R'QO?JE\N=?EWF6U:3)#*;A$=*EI!F$QCW,2,?$>YJO9_\
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MT"_:%'_* BUULCZBUOSV3[U3\Y?[A/H-WYEG[3*/,#7"GXK% * 4 H!0"@%
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M.=OU,K6ORU2:-(C='+/:D()12+R.1/@F[#T1Z=YZ(Y+SD18DN]LO?,U5V0*
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M7$&2'A-*;.Y*9)&=[05"I81!.N%>5!4"Q(I@G7*ADRN((%\@0L0 0@,+B98
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M--@N.1#>@.MQE!:SC66XIB@R\NXV'-)4H#Q*'@F7$@'$4T;&<1 P:%#$#!#
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MS896B[M?3P:"/#FJ0Z<BN^,VNT71A)*,.FR"(^^VUU1*0K%6X. +(#?L@F\
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ME'&>8[*R+?"[='0PU6]!4?\ VHO]>IG"MRCAF.RLBWPNW1T,-5O05'_VHO\
M7J9PK<HX9CLK(M\+MT=##5;T%1_]J+_7J9PK<HX9CLK(M\+MT=##5;T%1_\
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M+;2'3+K$<I1D1G#D>M(BH0-U\B""0HO.)1;JF]D!?E9P)CO3EI(>JR24T_'
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MD#O'UU6U%ULML8M,"4RYS%:5W6HYFE95NJY!C@Y9 %R97'J>03#2-ZY=^R3
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M*1DHX=3"^9+,Q892$/J.8YD7JAK,.P086!)GZ 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M6*1$3KW7D9"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M^UJW"NM;I0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MJN;*8]);I;F+"4CILM52;A-1\U5:YJ1:V6J(JS($W4TH2--K-QO*TB/IU/\
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MH<))?PDI]R,6/@F$G=@EVY T.O8T10"@% * 4 H!0"@% * 4 H!0"@% * 4
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M]%%AMH6-KV176%7NLRT6HRM8R6YS8QP>$ELFHU?[2->B.38=%(K?(LK8*P4
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MU9)Z0IRE*\+Z^EUF+1)G!*R\L/S)?)QT:<#4;;37%-H1A'<F/ B8D,X[RYE
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M&GMIK6JD'L;]_@N5S;ZMP5B1'6R4PH!0"@% * 4 H!0"@% * 4 H!0"@% *
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@+GZ*_A7E+\S#?G^A9.U5EJ_H\OYS(^6EG4Z(_2-1_I=H?L-065A\&%Q
M^,X,%L)D@VB2^[4KY.;OKR3\6IF<#D)YB-,)U]M[72,FN*\\$_%1Q.?ZID2N
M+8;]BOG6C5+4IHS&DCP_-60A?A@MC"%V.#&$+ITEAMLQWG6A:^!S#.D^.'#!
MPL.9P>%&Y#A,"XMQ;RW#J9IZ%O6/QGH0C;:&SM<S?@QY;9N!C*K@;R".*EQJ
M]8ODY.37"UG>"CEW4I0D=4UE))(H?7(K<1QS@">4")C9];506AFI-&YLZAP6
MS9K)2.1%6ZYKFQ14C@H^XY5N82P5RQ2Z?2;"9IF_SH4]+;J3'V=25-:^4KFR
MU5)4R5-@YCX<*Z1&9+8EU9<MRLE0:Y$:DM<-V.I/C1;BY2>UD)H,9]<0;96)
MW0S6VF*K6>#E&.1Q)I!5;FVZFK.&S;=+8++R,0*M-H'4#(]VP/@G CP?/P*F
MM6V)TB<U[94736T<MR*JHK4NL@LE$2*+!55SL*$$5(;*=!H=0VC136/JD;+I
M)MMUC<"6US'NBVH15K7.=@S&*J-23+X.*+P3T>J>*4_:ME/*(-O]6R!.;-2"
M,:+>[[N)3#&YW$/75_Q\NBO-LXPWN*Q1!2Y-MB+Y5HFFTQEE1RQ.V&-@ II<
M06X=C5@]42HIZ]5E5+GI(16.^$:Y$:N%)=LP5<)[4N7\+N<S+D37V9:6CR,J
MK+DRIEHO9/EPYK,DO?,:LNLEWF(K45DA[T1V"B+)=L.@S8ITJ\P\.))631^9
MM>?,6B0A&BQ"2HH=\>G>P9Q$NBHB<[]>C1?,5$9VP"4&L&%Y\)92XHV0.9D4
MT-USD8Q$W*%C*>VL%.#GI-68Y'I<G2XQ54F;*L6&"Q5[D+A1Z2SJNT- G3)R
M55GOI)=+*?3K@OHJB#D1KJ9R11DYL<.<UBQ1$5DR*W3A177'PL4 H";-;F2\
MI$GN(FBP&FY'NZE%_-PT0;;21%)Q+IPJB* 2\M&RR2D%C9X8JC(289.FQ,0[
MX%B9<482^(8>>5M2OFRY-%-F37-:Q&+=541+J02ZNVJHB;:K OM%Z:HJ](Z&
M12RWS)RU4M<%K5<L&O1SE@B*L&M17.6\C455N(IW7XN.U,Z:M[F;@LB-H694
M+9['H#8;RUL4$V9.%E&98L,1PW$E;2T!R/=^+\;)S>LJ7S(&S+20DH?$TEAX
M"CV,@BY9\KH_9])7V=339\UTW@%54EQ9@L=A*J11&HZ,+J8;EN+M'U[SCZ3V
MWHUI-:=+9U+*I6U[);5JL";PLYB26-<C'OF+*1&JJM594MJHJ)%<.ZMUG- L
MR+D[<(1%(-MK-)5;?"[3T%>59@8CE7!FLM,N+TDN^4V/D!,<K 6!=@6866@A
MTL %73S:28O8X)EC@#?EJ6U=,VFM%RN<Y'5T41CD2**YV"KE5')P:PNW%C>V
M3MV61:RVCHS+9+E2YDBPU;,6?+>Y9:ME2$>V6C72U2H2,&^.U6IANNP@OS+3
MCNB[A<"6=3RBYTY8DJ&<H]E237.Y<%%WO)7";1)N@M679$!LEEW>[R2LIBEE
M(([E<UF;ZH&(%<3&V%I:W#LZU:5$:K63$<QJ)!J>-%58V[!(0A#8@8SW.D:3
MZ(VBO#-?.I9LF=,F.C,>O MP)=1,2"/?AX2JCK[T<J)%")M;C.\;@7.-Z$$L
M;..-S%6E(2#'89)?DM?724A)SR6B;4;[/P)GSJ@3?1&/2Y4)/(D^8I!(N1;$
M$.Q80"V6Q6)9;664L)#6X35?<:B8,$BKMMN%&*K<PH[,2ML5=+'S=+T>^N?,
M1LU*=$?,>K7QG8#92(JJV9@<&K6-@]&++5$P7,C(6N"<S9",Z%H[9('5+AUC
M\.E^IVX:2G%SPT/ SHT&$\S,F*DL)Y&QAK)\U)JV7*J1$^?P"6,2V.!@CG8"
MV')XUJS9/.W3%A:_/6K*7[[ 5R8. OML"%Q42YL+=+'1]DBMEV-*I4P]#EL.
M:VJ;?D\,UK,/AD3\FDY%BL7>-[=6K")2V5)(V/A/A"<,N98^,OMMN!CRML"
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M-:C41LJ"HU(01SH+%54\PE=X?FT4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M;.S\\]%62Z*Q)\R5,23+H^#<Y6K@MF8+%1CEA!'JC7*C5NJC7+"XIT*<46O
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M5ZKD!Z,-.>@_'4_*CX0'$4]WC\;4&^TRGIE\VW:7ZO5<@/1AIST'XZGY4?"
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MXDL#/60!4L!JR+?T<IYCYDFH<C9BQ5N!,P<+9<B8%Q5V8+!5NPC%2YM'S?\
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M4UJL'+^XF8@]$7G#[/\ CZ;EA\"?BJ>ZS^._7+VO4UJL'+^XF8@]$7G#[/\
MCZ;EA\"?BJ>ZS^._7+VO4UJL'+^XF8@]$7G#[/\ CZ;EA\"?BJ>ZS^._7+VO
M4UJL'+^XF8@]$7G#[/\ CZ;EA\"?BJ>ZS^._7+VO4UJL'+^XF8@]$7G#[/\
MCZ;EA\"?BJ>ZS^._7+VO4UJL'+^XF8@]$7G#[/\ CZ;EA\"?BJ>ZS^._7+VO
M4UJL'+^XF8@]$7G#[/\ CZ;EA\"?BJ>ZS^._7+VO4UJL'+^XF8@]$7G#[/\
MCZ;EA\"?BJ>ZS^._7+VO4UJL'+^XF8@]$7G#[/\ CZ;EA\"?BJ>ZS^._7+VO
M4UJL'+^XF8@]$7G#[/\ CZ;EA\"?BJ>ZS^._7+VO4UJL'+^XF8@]$7G#[/\
MCZ;EA\"?BJ>ZS^._7+VO4UJL'+^XF8@]$7G#[/\ CZ;EA\"?BJ>ZS^._7+VO
M4UJL'+^XF8@]$7G#[/\ CZ;EA\"?BJ>ZS^._7+VO4UJL'+^XF8@]$7G#[/\
MCZ;EA\"?BJ>ZS^._7+VO4UJL'+^XF8@]$7G#[/\ CZ;EA\"?BJ>ZS^._7+VO
M4UJL'+^XF8@]$7G#[/\ CZ;EA\"?BJ>ZS^._7+VO4UJL'+^XF8@]$7G#[/\
MCZ;EC6CO!PXE!@S=$)ZP+B@HM4.Z.OA);_B)4!3E,<V<6 B8AU/D R1&%R35
M, 7]B$SM:PEK7O;*U[6VIEMV73RY<Z=.1LJ>W#8JH[QFHJMC"$4\9JI!8+<V
MH&JOFTTXF/=(ET#W39*X#T29)7!<OC0BDR"^*Y%N*J7=N)\WP7>)W[ICN\;X
MN\NJ\=9;#Z0WP.Q1Z+=/NS9N_E<H/@N\3OW3'=XWQ=Y=4UEL/I#? [%'HMT^
M[-F[^5R@^"[Q._=,=WC?%WEU366P^D-\#L4>BW3[LV;OY7*#X+O$[]TQW>-\
M7>75-9;#Z0WP.Q1Z+=/NS9N_E<H/@N\3OW3'=XWQ=Y=4UEL/I#? [%'HMT^[
M-F[^5R@^"[Q._=,=WC?%WEU366P^D-\#L4>BW3[LV;OY7*#X+O$[]TQW>-\7
M>75-9;#Z0WP.Q1Z+=/NS9N_E<H/@N\3OW3'=XWQ=Y=4UEL/I#? [%'HMT^[-
MF[^5R@^"[Q._=,=WC?%WEU366P^D-\#L4>BW3[LV;OY7*#X+O$[]TQW>-\7>
M75-9;#Z0WP.Q1Z+=/NS9N_E<H/@N\3OW3'=XWQ=Y=4UEL/I#? [%'HMT^[-F
M[^5R@^"[Q._=,=WC?%WEU366P^D-\#L4>BW3[LV;OY7*#X+O$[]TQW>-\7>7
M5-9;#Z0WP.Q1Z+=/NS9N_E<H/@N\3OW3'=XWQ=Y=4UEL/I#? [%'HMT^[-F[
M^5R@^"[Q._=,=WC?%WEU366P^D-\#L4>BW3[LV;OY7*#X+O$[]TQW>-\7>75
M-9;#Z0WP.Q1Z+=/NS9N_E<H/@N\3OW3'=XWQ=Y=4UEL/I#? [%'HMT^[-F[^
M5RAC2W!UXE!U04TDKJTYAU)%ZR[:D@WE%V1@AVQ R,D>N<._KE#ZZ+XWSP_P
MVM6Q,MNRY-/+JIDYJ2)V%@+!WC8"P=L12"W+L.X>+/-KIQ,G/IV4$Q9TN&$F
M'*BW"2+8_E-E+IDO@N\3OW3'=XWQ=Y=5KZRV'TAO@=BGMZ+=/NS9N_E<H/@N
M\3OW3'=XWQ=Y=4UEL/I#? [%'HMT^[-F[^5R@^"[Q._=,=WC?%WEU366P^D-
M\#L4>BW3[LV;OY7*#X+O$[]TQW>-\7>75-9;#Z0WP.Q1Z+=/NS9N_E<H/@N\
M3OW3'=XWQ=Y=4UEL/I#? [%'HMT^[-F[^5R@^"[Q._=,=WC?%WEU366P^D-\
M#L4>BW3[LV;OY7*#X+O$[]TQW>-\7>75-9;#Z0WP.Q1Z+=/NS9N_E<H/@N\3
MOW3'=XWQ=Y=4UEL/I#? [%'HMT^[-F[^5R@^"[Q._=,=WC?%WEU366P^D-\#
ML4>BW3[LV;OY7*#X+O$[]TQW>-\7>75-9;#Z0WP.Q1Z+=/NS9N_E<H/@N\3O
MW3'=XWQ=Y=4UEL/I#? [%'HMT^[-F[^5R@^"[Q._=,=WC?%WEU366P^D-\#L
M4>BW3[LV;OY7*#X+O$[]TQW>-\7>75-9;#Z0WP.Q1Z+=/NS9N_E<H/@N\3OW
M3'=XWQ=Y=4UEL/I#? [%'HMT^[-F[^5R@^"[Q._=,=WC?%WEU366P^D-\#L4
M>BW3[LV;OY7*#X+O$[]TQW>-\7>75-9;#Z0WP.Q1Z+=/NS9N_E<H/@N\3OW3
M'=XWQ=Y=4UEL/I#? [%'HMT^[-F[^5R@^"[Q._=,=WC?%WEU366P^D-\#L4>
MBW3[LV;OY7*#X+O$[]TQW>-\7>75-9;#Z0WP.Q1Z+=/NS9N_E<H/@N\3OW3'
M=XWQ=Y=4UEL/I#? [%'HMT^[-F[^5R@^"[Q._=,=WC?%WEU366P^D-\#L4>B
MW3[LV;OY7*#X+O$[]TQW>-\7>75-9;#Z0WP.Q1Z+=/NS9N_E<H/@N\3OW3'=
MXWQ=Y=4UEL/I#? [%'HMT^[-F[^5R@^"[Q._=,=WC?%WEU366P^D-\#L4>BW
M3[LV;OY7*#X+O$[]TQW>-\7>75-9;#Z0WP.Q1Z+=/NS9N_E<H/@N\3OW3'=X
MWQ=Y=4UEL/I#? [%'HMT^[-F[^5R@^"[Q._=,=WC?%WEU366P^D-\#L4>BW3
M[LV;OY7*#X+O$[]TQW>-\7>75-9;#Z0WP.Q1Z+=/NS9N_E<H/@N\3OW3'=XW
MQ=Y=4UEL/I#? [%'HMT^[-F[^5R@^"[Q._=,=WC?%WEU366P^D-\#L4>BW3[
MLV;OY7*#X+O$[]TQW>-\7>75-9;#Z0WP.Q1Z+=/NS9N_E<H/@N\3OW3'=XWQ
M=Y=4UEL/I#? [%'HMT^[-F[^5R@^"[Q._=,=WC?%WEU366P^D-\#L4>BW3[L
MV;OY7*#X+O$[]TQW>-\7>75-9;#Z0WP.Q1Z+=/NS9N_E<H/@N\3OW3'=XWQ=
MY=4UEL/I#? [%'HMT^[-F[^5R@^"[Q._=,=WC?%WEU366P^D-\#L4>BW3[LV
M;OY7*#X+O$[]TQW>-\7>75-9;#Z0WP.Q1Z+=/NS9N_E<H/@N\3OW3'=XWQ=Y
M=4UEL/I#? [%'HMT^[-F[^5R@^"[Q._=,=WC?%WEU366P^D-\#L4>BW3[LV;
MOY7*#X+O$[]TQW>-\7>75-9;#Z0WP.Q1Z+=/NS9N_E<H/@N\3OW3'=XWQ=Y=
M4UEL/I#? [%'HMT^[-F[^5R@^"[Q._=,=WC?%WEU366P^D-\#L4>BW3[LV;O
MY7*#X+O$[]TQW>-\7>75-9;#Z0WP.Q1Z+=/NS9N_E<H/@N\3OW3'=XWQ=Y=4
MUEL/I#? [%'HMT^[-F[^5R@^"[Q._=,=WC?%WEU366P^D-\#L4>BW3[LV;OY
M7*#X+O$[]TQW>-\7>75-9;#Z0WP.Q1Z+=/NS9N_E<H/@N\3OW3'=XWQ=Y=4U
MEL/I#? [%'HMT^[-F[^5R@^"[Q._=,=WC?%WEU366P^D-\#L4>BW3[LV;OY7
M*#X+O$[]TQW>-\7>75-9;#Z0WP.Q1Z+=/NS9N_E<H/@N\3OW3'=XWQ=Y=4UE
ML/I#? [%'HMT^[-F[^5R@^"[Q._=,=WC?%WEU366P^D-\#L4>BW3[LV;OY7*
M#X+O$[]TQW>-\7>75-9;#Z0WP.Q1Z+=/NS9N_E<H/@N\3OW3'=XWQ=Y=4UEL
M/I#? [%'HMT^[-F[^5R@^"[Q._=,=WC?%WEU366P^D-\#L4>BW3[LV;OY7*#
MX+O$[]TQW>-\7>75-9;#Z0WP.Q1Z+=/NS9N_E<H/@N\3OW3'=XWQ=Y=4UEL/
MI#? [%'HMT^[-F[^5R@^"[Q._=,=WC?%WEU366P^D-\#L4>BW3[LV;OY7*%@
M]8.%_OC#TJJPDDZ[.-JX2=KYN7#K$R-N1@F^^&2GYIEL 6:35+=K'8=N6-K0
MQ(7' 8QU(MA?#]D%PMR<NG76[9-33IP$YKL"=)>ZXZXULZ7%;J;'A+JP- -+
M[,M%RUU$^7SBBK9,N+I:X4V915",8D'K!706ZL$VU0]0L$_\@FOY2YO_ "UR
M#7X?\X'UOK?PI?R4L_2-F_HB?AS/E'$Q5QQO"@% * 4 H"O.Q?\ NJ)?SAH4
M_AF3KI-&OA:S_3:GY-30M#VDK\_+]^A8:N;-\4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * E_1#^:% G[QP?W24:_7M1\*O>3V$
M+6P_HBG_ #2%MJ\"U% * 4 H!0"@% * 4 H!0"@% * 4!6O5'\%[I_.4W-_I
M@SI6W6_#-_,RODF%58_Z(_YU5?M,TV)K[/ZTOA_R+%#+V'@UWRE#Y8\=EJ-6
MO+3!7W_%Q-+,X$E,W(K-27 ;<3)+)QP7$(<13+%<01<K8YWME>UJU(*6IHZ9
MO9I"M1R6F%'W(U55HC./4.-2DI)FPT1GXY-2,*$FCA, L]RKO%;([U$!62>>
M*5B:N>OB;!O8+D%PYR"@EQYS9#,<,)0E60Y<C%AQ>D9G@U:2'F_6JUV$F")A
MDZ34L%!X+BJ1;Q+-/.)I@(>PAC&X0@ F.?)EAE:TP410A]Q[XZ.,]@MJ5W;N
M9JBUHM>F9 -G22X]B(A1&"[!%0)9,)@;:>*F\"K=7<U$!N*.8%BID6XV! Q?
M#EL +S4%A'8$4O;)/L?2)'\LLQO2/%;Z9TF1X[2%E1J/R/G.B/-F.9,R%% L
MHMYT-P\I(:T0N.!GA88L.*'S\,K<O+:]0"+D;;359QR$ZHC;VS&OJ[*S%%+@
M/>,4:9HY5)"9PYSJ?6@+J99)R#N1O"FNJX=3Q-E@;Y\ZW)R\MJF"[1$4+!5!
M(H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * AB+_\
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M% * AB+_ /G&<?Y1B7\"&K72VY]&V7\S=\O-.?L;Z0M+YVWY&63/7-'0"@%
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M;3@51'R\PUYN(P7:\@.$9-F,,A@*?<73<I_[Z-B7QA(QA]H0GHIQ5M+M=F(
M]XX<G2KPD%P*Z>LR2]\GJJNO!)CQMFA\0$3-M -C$PH@6S,BK=[%+$1P/=+0
M"@% * AAD_A?F_\ ^FO\&#==):?U=LO_ #/RJ'/V=]/6E_E_DU)GKFSH!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@*ZS;^$O3_ /.*<W]$K:.M
MRE^ J/S*?*RBDM;]/LSY\_\ 8ZLHE!/_ "":_E+F_P#+7(-?F[S@?6^M_"E_
M)2RBLW]$3\.9\HXF*N.-X4 H!0"@% 5YV+_W5$OYPT*?PS)UTFC7PM9_IM3\
MFIH6A[25^?E^_0VV<(1CW8J,W-#\JEG4H1^\B0J6Z4=HR3),5GEY&- BEE%
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M.V6-HJ*>=25#Z6H3!GRWJUR118.:L%2**J+!4OHJH'-5CE:[VR*;U7B0* 4
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M"9513%-.- 'D]13SP&!DD?('2V8I8V3-EA<1 A0\LL!,,K98WO:]KUB9'V4
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MWJVD,D.,<M\-Z2RL.\6Q01- W>:EE&XX;1VABQV-S7(,Z]'!JDG25'K@356
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M325"UCJ.6'P)#VL(7RM6+KYDEXMW6)(H!0"@% * 4 H!0"@% * 4 H!0"@%
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MAX-A<WXW.UM.[$\/C>O;.>F2I<1+9MN&F3)SA@>;)GU<C,X!(,].2R$08TO
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M)53.8K9,Y%5BK]\C5@JHE^$5OP@NQ$E6N1$54N+>);K6(% * 4 H!0"@% *
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M*-J"(1-F&D8PL23;8#MP8:Y/.W6Y?DR!O^QX?XML5O[9*7C<:@D4 H!0"@%
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M/36+8N#W-J21?NC>X+%<L2<)SB:Z\3,ZL=+M@39$Y,[FF'9^28X8UG:V(P5
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M8P3,8X#88B88CDS@0!LJ-;'+ZL,7# 3#+EQRQME:]J _:@% * AAD_A?F_\
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M9=48B.I9?J&J  .XJBN55 5QCF:=AF25PR 'H<H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% 5UFW\)>G_
M .<4YOZ)6T=;E+\!4?F4^5E%):WZ?9GSY_['5E$H)_Y!-?RES?\ EKD&OS=Y
MP/K?6_A2_DI916;^B)^',^4<3%7'&\* Y@;MR?,&NPD-L+3KA\-3;J0Y/SD
M^;2U"18IA%L,]#80+8-J9I5=TBA8!.%W.@T[^K$R(0ES1D @HFQ,[V+Y\_H[
M(D4U=PL^U:Y]-(EX-U&OF*Y71A!&WFI@W5O76HE\]I36/BLQ^"U.XJ^P;SH8
M^]FW^4E!4VJTM9.D[_*FV@21F6T)28,N"O)I8@.(4DZU1S1P;%0BE@5<0Z3
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M\O\ )J3/7-G0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MP:('9T Q_-K;8^C4QZ'(ZR\6LMCQW,,IY2VHO%2NBJ! =Z(SAZ]6 R!*Y4F
M1$)6.97PS*6%N"%86V8_GI963:V=)?.K)-8Y&N3"ELP$:D4\54^S&&S?78BH
M>Z8Y%<Y'K"^B0]:\AV?KDC7% 5AVI33JNU8Q3T]PJ[6-F=@(8"!74$% ,*J?
MGF[RV&)@F"YT-QHF8P.65L\;&"8X=\L;<['+'EQOU6B4UDFKJYDR6R<Q+.J8
ML>KT:[\FMQ58YCH=YR+W2KM66Z9(EL8]TMRSY7C-P55/'2]A-<WPHIM'FBD#
MWI)V\7M9?ZNE:F>;.[)L_?UW[X9<QJNF5.]I^0'FBD#WI)V\7M9?ZNE,\V=V
M39^_KOWP<QJNF5.]I^0'FBD#WI)V\7M9?ZNE,\V=V39^_KOWP<QJNF5.]I^0
M'FBD#WI)V\7M9?ZNE,\V=V39^_KOWP<QJNF5.]I^0'FBD#WI)V\7M9?ZNE,\
MV=V39^_KOWP<QJNF5.]I^0'FBD#WI)V\7M9?ZNE,\V=V39^_KOWP<QJNF5.]
MI^0'FBD#WI)V\7M9?ZNE,\V=V39^_KOWP<QJNF5.]I^0'FBD#WI)V\7M9?ZN
ME,\V=V39^_KOWP<QJNF5.]I^0'FBD#WI)V\7M9?ZNE,\V=V39^_KOWP<QJNF
M5.]I^0'FBD#WI)V\7M9?ZNE,\V=V39^_KOWP<QJNF5.]I^0'FBD#WI)V\7M9
M?ZNE,\V=V39^_KOWP<QJNF5.]I^0'FBD#WI)V\7M9?ZNE,\V=V39^_KOWP<Q
MJNF5.]I^0'FBD#WI)V\7M9?ZNE,\V=V39^_KOWP<QJNF5.]I^0'FBD#WI)V\
M7M9?ZNE,\V=V39^_KOWP<QJNF5.]I^0'FBD#WI)V\7M9?ZNE,\V=V39^_KOW
MP<QJNF5.]I^0'FBD#WI)V\7M9?ZNE,\V=V39^_KOWP<QJNF5.]I^0'FBD#WI
M)V\7M9?ZNE,\V=V39^_KOWP<QJNF5.]I^0'FBD#WI)V\7M9?ZNE,\V=V39^_
MKOWP<QJNF5.]I^0'FBD#WI)V\7M9?ZNE,\V=V39^_KOWP<QJNF5.]I^0'FBD
M#WI)V\7M9?ZNE,\V=V39^_KOWP<QJNF5.]I^0'FBD#WI)V\7M9?ZNE,\V=V3
M9^_KOWP<QJNF5.]I^0'FBD#WI)V\7M9?ZNE,\V=V39^_KOWP<QJNF5.]I^0'
MFBD#WI)V\7M9?ZNE,\V=V39^_KOWP<QJNF5.]I^0'FBD#WI)V\7M9?ZNE,\V
M=V39^_KOWP<QJNF5.]I^0'FBD#WI)V\7M9?ZNE,\V=V39^_KOWP<QJNF5.]I
M^0'FBD#WI)V\7M9?ZNE,\V=V39^_KOWP<QJNF5.]I^0'FBD#WI)V\7M9?ZNE
M,\V=V39^_KOWP<QJNF5.]I^0'FBD#WI)V\7M9?ZNE,\V=V39^_KOWP<QJNF5
M.]I^0'FBD#WI)V\7M9?ZNE,\V=V39^_KOWP<QJNF5.]I^0'FBD#WI)V\7M9?
MZNE,\V=V39^_KOWP<QJNF5.]I^0'FBD#WI)V\7M9?ZNE,\V=V39^_KOWP<QJ
MNF5.]I^0)4TIAJ1E356$3Y+;/8%NE#3,!$ 1$9MZK#I:;AVP/X];DA7!K.NK
M68-KVY>4P<'$Y;W^JY.2UOU345,GA5_[>5>39F[2?_4+.Q+/JULFG5*ZJ1.#
M3[VF^W3EH_,7*'OF[*>*VGW]5&O#G,GH\GPS>4+3-]7TZJWM-^[CS%RA[YNR
MGBMI]_51ISF3T>3X9O*#-]7TZJWM-^[CS%RA[YNRGBMI]_51ISF3T>3X9O*#
M-]7TZJWM-^[CS%RA[YNRGBMI]_51ISF3T>3X9O*#-]7TZJWM-^[CS%RA[YNR
MGBMI]_51ISF3T>3X9O*#-]7TZJWM-^[CS%RA[YNRGBMI]_51ISF3T>3X9O*#
M-]7TZJWM-^[CS%RA[YNRGBMI]_51ISF3T>3X9O*#-]7TZJWM-^[CS%RA[YNR
MGBMI]_51ISF3T>3X9O*#-]7TZJWM-^[CS%RA[YNRGBMI]_51ISF3T>3X9O*#
M-]7TZJWM-^[CS%RA[YNRGBMI]_51ISF3T>3X9O*#-]7TZJWM-^[CS%RA[YNR
MGBMI]_51ISF3T>3X9O*#-]7TZJWM-^[CS%RA[YNRGBMI]_51ISF3T>3X9O*#
M-]7TZJWM-^[CS%RA[YNRGBMI]_51ISF3T>3X9O*#-]7TZJWM-^[CS%RA[YNR
MGBMI]_51ISF3T>3X9O*#-]7TZJWM-^[CS%RA[YNRGBMI]_51ISF3T>3X9O*#
M-]7TZJWM-^[CS%RA[YNRGBMI]_51ISF3T>3X9O*#-]7TZJWM-^[E>M8H6D@]
M&[E&+;<["HX>&PNW)/(HG-K5$4N,83]KII(&U43)7UB5#5CZX:+9G36. N)7
M T8$Q+ ER]@BX6W65$E)R?D)2_DI6S-R3/\ ZA5V19]6M(__ +ZJ3_NJG[VF
MZ3-_PY87S%RA[YNRGBMI]_51K4YS)Z/)\,WE"TS?5].JM[3?NX\Q<H>^;LIX
MK:??U4:<YD]'D^&;R@S?5].JM[3?NX\Q<H>^;LIXK:??U4:<YD]'D^&;R@S?
M5].JM[3?NX\Q<H>^;LIXK:??U4:<YD]'D^&;R@S?5].JM[3?NX\Q<H>^;LIX
MK:??U4:<YD]'D^&;R@S?5].JM[3?NX\Q<H>^;LIXK:??U4:<YD]'D^&;R@S?
M5].JM[3?NX\Q<H>^;LIXK:??U4:<YD]'D^&;R@S?5].JM[3?NX\Q<H>^;LIX
MK:??U4:<YD]'D^&;R@S?5].JM[3?NX\Q<H>^;LIXK:??U4:<YD]'D^&;R@S?
M5].JM[3?NX\Q<H>^;LIXK:??U4:<YD]'D^&;R@S?5].JM[3?NX\Q<H>^;LIX
MK:??U4:<YD]'D^&;R@S?5].JM[3?NX\Q<H>^;LIXK:??U4:<YD]'D^&;R@S?
M5].JM[3?NX\Q<H>^;LIXK:??U4:<YD]'D^&;R@S?5].JM[3?NX\Q<H>^;LIX
MK:??U4:<YD]'D^&;R@S?5].JM[3?NX\Q<H>^;LIXK:??U4:<YD]'D^&;R@S?
M5].JM[3?NX\Q<H>^;LIXK:??U4:<YD]'D^&;R@S?5].JM[3?NX\Q<H>^;LIX
MK:??U4:<YD]'D^&;R@S?5].JM[3?NX\Q<H>^;LIXK:??U4:<YD]'D^&;R@S?
M5].JM[3?NX\Q<H>^;LIXK:??U4:<YD]'D^&;R@S?5].JM[3?NX\Q<H>^;LIX
MK:??U4:<YD]'D^&;R@S?5].JM[3?NX\Q<H>^;LIXK:??U4:<YD]'D^&;R@S?
M5].JM[3?NX\Q<H>^;LIXK:??U4:<YD]'D^&;R@S?5].JM[3?NX\Q<H>^;LIX
MK:??U4:<YD]'D^&;R@S?5].JM[3?NX\Q<H>^;LIXK:??U4:<YD]'D^&;R@S?
M5].JM[3?NX\Q<H>^;LIXK:??U4:<YD]'D^&;R@S?5].JM[3?NX\Q<H>^;LIX
MK:??U4:<YD]'D^&;R@S?5].JM[3?NX\Q<H>^;LIXK:??U4:<YD]'D^&;R@S?
M5].JM[3?NX\Q<H>^;LIXK:??U4:<YD]'D^&;R@S?5].JM[3?NX\Q<H>^;LIX
MK:??U4:<YD]'D^&;R@S?5].JM[3?NX\Q<H>^;LIXK:??U4:<YD]'D^&;R@S?
M5].JM[3?NX\Q<H>^;LIXK:??U4:<YD]'D^&;R@S?5].JM[3?NX\Q<H>^;LIX
MK:??U4:<YD]'D^&;R@S?5].JM[3?NX\Q<H>^;LIXK:??U4:<YD]'D^&;R@S?
M5].JM[3?NX\Q<H>^;LIXK:??U4:<YD]'D^&;R@S?5].JM[3?NX\Q<H>^;LIX
MK:??U4:<YD]'D^&;R@S?5].JM[3?NX\Q<H>^;LIXK:??U4:<YD]'D^&;R@S?
M5].JM[3?NYID6QJ\<5R5T_.<Y+/G$M]!%CS@4$R+P5EPC#-A!.AG5<!NQXW&
MV"8*%C.!0.Q%.)AW+EP[B8YC7$%$[*T+2HZ6R[-;.HJ>>KJ5RHKEF^*G#3$P
M4P9B7-F[%8K?.;LZS*R=7UZ,KJEBMJ4151),7+P4M8K^31(HBP\5$2")<C%5
MF'S8O+TX2)]@,;R4JGSY9O9='OI_*EQF:T.TJO>R>3'FQ>7IPD3[ 8WDI3/E
MF]ET>^G\J,S6AVE5[V3R8\V+R].$B?8#&\E*9\LWLNCWT_E1F:T.TJO>R>3'
MFQ>7IPD3[ 8WDI3/EF]ET>^G\J,S6AVE5[V3R8\V+R].$B?8#&\E*9\LWLNC
MWT_E1F:T.TJO>R>3'FQ>7IPD3[ 8WDI3/EF]ET>^G\J,S6AVE5[V3R8\V+R]
M.$B?8#&\E*9\LWLNCWT_E1F:T.TJO>R>3'FQ>7IPD3[ 8WDI3/EF]ET>^G\J
M,S6AVE5[V3R8\V+R].$B?8#&\E*9\LWLNCWT_E1F:T.TJO>R>3'FQ>7IPD3[
M 8WDI3/EF]ET>^G\J,S6AVE5[V3R8\V+R].$B?8#&\E*9\LWLNCWT_E1F:T.
MTJO>R>3'FQ>7IPD3[ 8WDI3/EF]ET>^G\J,S6AVE5[V3R8\V+R].$B?8#&\E
M*9\LWLNCWT_E1F:T.TJO>R>3'FQ>7IPD3[ 8WDI3/EF]ET>^G\J,S6AVE5[V
M3R8\V+R].$B?8#&\E*9\LWLNCWT_E1F:T.TJO>R>3'FQ>7IPD3[ 8WDI3/EF
M]ET>^G\J,S6AVE5[V3R8\V+R].$B?8#&\E*9\LWLNCWT_E1F:T.TJO>R>3(L
M:; =!B39;(A2V]RAE/[PNNE0 FT,CBOUVWS(P'7V S<$*X=8!X]3"ZB&'RXW
M^KYU_EJ]M"UZ!EB6?-=9]*YC^'@U5FP9"8B+@PF(OC7UBJW;T$*6ALNM?;%=
M+;75+7LX&+D25%T6*J1BR'BWD@B7+\24_-B\O3A(GV QO)2J+/EF]ET>^G\J
M769K0[2J][)Y,>;%Y>G"1/L!C>2E,^6;V71[Z?RHS-:':57O9/)CS8O+TX2)
M]@,;R4IGRS>RZ/?3^5&9K0[2J][)Y,>;%Y>G"1/L!C>2E,^6;V71[Z?RHS-:
M':57O9/)CS8O+TX2)]@,;R4IGRS>RZ/?3^5&9K0[2J][)Y,>;%Y>G"1/L!C>
M2E,^6;V71[Z?RHS-:':57O9/)CS8O+TX2)]@,;R4IGRS>RZ/?3^5&9K0[2J]
M[)Y,>;%Y>G"1/L!C>2E,^6;V71[Z?RHS-:':57O9/)CS8O+TX2)]@,;R4IGR
MS>RZ/?3^5&9K0[2J][)Y,>;%Y>G"1/L!C>2E,^6;V71[Z?RHS-:':57O9/)C
MS8O+TX2)]@,;R4IGRS>RZ/?3^5&9K0[2J][)Y,>;%Y>G"1/L!C>2E,^6;V71
M[Z?RHS-:':57O9/)CS8O+TX2)]@,;R4IGRS>RZ/?3^5&9K0[2J][)Y,>;%Y>
MG"1/L!C>2E,^6;V71[Z?RHS-:':57O9/)CS8O+TX2)]@,;R4IGRS>RZ/?3^5
M&9K0[2J][)Y,>;%Y>G"1/L!C>2E,^6;V71[Z?RHS-:':57O9/)CS8O+TX2)]
M@,;R4IGRS>RZ/?3^5&9K0[2J][)Y,>;%Y>G"1/L!C>2E,^6;V71[Z?RHS-:'
M:57O9/)CS8O+TX2)]@,;R4IGRS>RZ/?3^5&9K0[2J][)Y,>;%Y>G"1/L!C>2
ME,^6;V71[Z?RHS-:':57O9/)CS8O+TX2)]@,;R4IGRS>RZ/?3^5&9K0[2J][
M)Y,>;%Y>G"1/L!C>2E,^6;V71[Z?RHS-:':57O9/)CS8O+TX2)]@,;R4IGRS
M>RZ/?3^5&9K0[2J][)Y,>;%Y>G"1/L!C>2E,^6;V71[Z?RHS-:':57O9/)CS
M8O+TX2)]@,;R4IGRS>RZ/?3^5&9K0[2J][)Y,>;%Y>G"1/L!C>2E,^6;V71[
MZ?RHS-:':57O9/)CS8O+TX2)]@,;R4IGRS>RZ/?3^5&9K0[2J][)Y,>;%Y>G
M"1/L!C>2E,^6;V71[Z?RHS-:':57O9/)CS8O+TX2)]@,;R4IGRS>RZ/?3^5&
M9K0[2J][)Y,>;%Y>G"1/L!C>2E,^6;V71[Z?RHS-:':57O9/)CS8O+TX2)]@
M,;R4IGRS>RZ/?3^5&9K0[2J][)Y,>;%Y>G"1/L!C>2E,^6;V71[Z?RHS-:':
M57O9/)CS8O+TX2)]@,;R4IGRS>RZ/?3^5&9K0[2J][)Y,>;%Y>G"1/L!C>2E
M,^6;V71[Z?RHS-:':57O9/)CS8O+TX2)]@,;R4IGRS>RZ/?3^5&9K0[2J][)
MY,>;%Y>G"1/L!C>2E,^6;V71[Z?RHS-:':57O9/)CS8O+TX2)]@,;R4IGRS>
MRZ/?3^5&9K0[2J][)Y,>;%Y>G"1/L!C>2E,^6;V71[Z?RHS-:':57O9/)CS8
MO+TX2)]@,;R4IGRS>RZ/?3^5&9K0[2J][)Y,>;%Y>G"1/L!C>2E,^6;V71[Z
M?RHS-:':57O9/)CS8O+TX2)]@,;R4IGRS>RZ/?3^5&9K0[2J][)Y,>;%Y>G"
M1/L!C>2E,^6;V71[Z?RHS-:':57O9/)CS8O+TX2)]@,;R4IGRS>RZ/?3^5&9
MK0[2J][)Y,>;%Y>G"1/L!C>2E,^6;V71[Z?RHS-:':57O9/)CS8O+TX2)]@,
M;R4IGRS>RZ/?3^5&9K0[2J][)Y,>;%Y>G"1/L!C>2E,^6;V71[Z?RHS-:':5
M7O9/)CS8O+TX2)]@,;R4IGRS>RZ/?3^5&9K0[2J][)Y,>;%Y>G"1/L!C>2E,
M^6;V71[Z?RHS-:':57O9/)CS8O+TX2)]@,;R4IGRS>RZ/?3^5&9K0[2J][)Y
M,>;%Y>G"1/L!C>2E,^6;V71[Z?RHS-:':57O9/)CS8O+TX2)]@,;R4IGRS>R
MZ/?3^5&9K0[2J][)Y,>;%Y>G"1/L!C>2E,^6;V71[Z?RHS-:':57O9/)CS8O
M+TX2)]@,;R4IGRS>RZ/?3^5&9K0[2J][)Y,>;%Y>G"1/L!C>2E,^6;V71[Z?
MRHS-:':57O9/)CS8O+TX2)]@,;R4IGRS>RZ/?3^5&9K0[2J][)Y,>;%Y>G"1
M/L!C>2E,^6;V71[Z?RHS-:':57O9/)CS8O+TX2)]@,;R4IGRS>RZ/?3^5&9K
M0[2J][)Y,@N5V$YTZ3=3[FY8>JS8Y.KU3B^)\FT\+)ILYJ-M$& L%.LF\5OF
M?3LK<X+$7J@%[W^KPRM7HEK4,Z1-X.SZ:5@M8Y<%9OC(DZ5%BX4Q?%=LP@[:
M5"KKK,K)-?9_"5U1,PJJ8U,))?BJM'5P>F"Q/&;L1BW;12L4$_\ ()K^4N;_
M ,M<@U^4?.!];ZW\*7\E+,+-_1$_#F?*.)BKCC>% * 4 H!0%>=B_P#=42_G
M#0I_#,G72:-?"UG^FU/R:FA:'M)7Y^7[]"(N)@R&8_>'UN>DOIHMAZ)29K%.
M;K34QV("4XT]/=+1C%T.%J.4D26"APL47VPOIY<\GG \<3!(X &,#G@)ACE;
M1L&=.D6U2NDO<QRU$MJJU5151ST14N;"I<5+RI<4M)"JV<U46"X2>R>:#A0L
M1HN'9_ASMDQ';1T5E*-=!6K-[%<<+%C9\CQ-T.08\()JJM3:O)C7B5(S5XB.
M ]LE=N' ',KGC1\[D N @D\#0_T'22=-EV?73$>ZLIIE:LMR3()S56NBB2T5
M7K!]YKD5C4@D6+&";M2JX#UBKT5\+OWL%V+JW]NY>O&*BLVM2!)?"B=[ 9$
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M@% * E_1#^:% G[QP?W24:_7M1\*O>3V$+6P_HBG_-(6VKP+44 H!0"@% *
M4 H!0"@% * 4 H!0%:]4?P7NG\Y3<W^F#.E;=;\,W\S*^2855C_HC_G55^TS
M2RE:A:B@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H"&(O\ ^<9Q_E&)?P(:M=+;GT;9?S-WR\TY^QOI"TOG;?D99,]<
MT= * 4 H!0"@% * 4 H!0"@% * 4 H!0$,,G\+\W_P#TU_@P;KI+3^KME_YG
MY5#G[.^GK2_R_P FI,]<V= * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M#!TJ[RH 86$:/4%&U77#B_KNJ%MA=D2S\B(R?)@)QA+9THEY="DP@TK)Y8(
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MT*?PS)UTFC7PM9_IM3\FIH6A[25^?E^_0QVX4WG]=M<Y%E1%"2QG21LTV<Q
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MQ$%!D5T%FLKGT\+(X6S4S*&(>P"&,)F(Y>(J((6G8O"$X34LD$2<8W9BU**
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M^9/O\FH(ADDL+77Z9;.YT!+-VN3L!OVT"A)39XI7#$$0IOEY*C:4$K;)G/F
MTUPI2;"[D.L&#7(\T%\+Z"G-\HYG([PE!8""QQ4U<ZD% TTJ*3(%CEC!HP!S
M$-.658^V.XYD7MB,^)_L>R&@HQDAQ\[(TWX&+-G6PB]--H>V!<!=IWV'X@L-
M2*QE7SHNDXLX&V<EG12R.)VH+#8D;=JZ Z2\-AAO"8.$!IP45)TG>SZG76Z
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M1C5N*^^F$YSG0N7HPO;20Q=,5R8,$1J*JW.[]DN%568"@% * 4 H!0"@% *
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MX4W"*X7SR)%L)GXLVUC!GK:7 \:",+EVH.X#.Z>Q#E-)9040<ZHHR8FHJ-;
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M@% * 4 H!0"@)?T0_FA0)^\<']TE&OU[4?"KWD]A"UL/Z(I_S2%MJ\"U% *
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ME4.?L[Z>M+_+_)J3/7-G0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M(DW"3I,:#VA,WO8XU%?>C72G8V3TCQ4B"-1&;R(GDUE)5I/C),>@#B)*3L.
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MUJFM.D?3:G?NW1JW8'0Z?>(/,;#OHT9GVA(?6J:TZ1]-J=^[=&K=@=#I]XA
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MB"%K6N87DC'CCQAU?L> 4VR8*+:FG)YH9-5PBZ^A8.%))@*."<I!!J*?@:L
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M1!JS"II01<N\YRVK<*4C'"4"- ^Y26:"VF6R0'N@@+2IC@*I'%Y:*AE,PRI
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M% * 4 H"&(O_ .<9Q_E&)?P(:M=+;GT;9?S-WR\TY^QOI"TOG;?D99,]<T=
M* 4 H#@MQ*.*3/NOFXD!:/ZH,AAF)/D*+I*G-^/N>8"W DV."S&CC!(4!&NS
M =:FBH.-76E9"Q5AC"XFA.,DA'RA,@>(XC*(>00$S#<9C3:;(T5@=/IW3G9-
M3\U1GC9[7$)_ZZ[*$8^?#6A$P^VPON,Z*Y&K#R>K(J#(# /)R@EXN1(5L^HW
MR"OA@*"+F!S6U,X\<[.^3]4#NUB-"#9UZFCA7O'B RVM0U!6P3CD*-UYCRVX
M(W6RJ$F-R2)C6G#'91+0<U4WB$V3!Y/+=5%&,];EQ1[ =Y-?=^M7=I5&.4Z"
MW>_'EC+4*B;#1^MG("V#9;/7HCP>JC'V#CR?+]BQL,Q'43CG2A<2R,?/E5PV
M2R"/@DQ" X!D0#%3QQ'=+M9I43X7FZ;23*?QI&:CE6B]F5)+E:L<ME]O K'[
M(<\UR,T6:OQQ S9>#U.A)B6HO16021\WG;  7._+0%<W'QQ^&>TE=Y(3DFN3
M$A3CV=T/6)Y@&M/]T>I-_8!S=O,FY%!PX'KT(2R=Z\$VSHA,N&)G8R"#U0/+
M(/,/+,#:I(XQ_#YB!RMMG2=*4JLAT/(M-IIGHB_J'N03/.P'7 XXR$WW;(=X
M RLO"1X.TC]SH92XHF80.(H-A0A@<Q -Z=G%2T!9+9@=Y.#8UOXM?9-@@RO$
MZTCM.1W02-10*=;Z4+*K]R:[-6,X9C!.6'20(GG"\\4!&3SX]RIDR$8#%#P
MH)Q5N,H6U(-HK(U3?$22!-+"V3U\AK8J/9 A"=7VTVVDS^JAETA")SBQG=',
M2,.9"+? ,K 3;/J2XM&TX+,Q=,!+EQAZ ] % * 4 H"&&3^%^;__ *:_P8-U
MTEI_5VR_\S\JAS]G?3UI?Y?Y-29ZYLZ 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MM"JB]\0\!:O>.*>+S,R'K 5UH9_#.1\&"81I(G!@[02GM'(<>+$QM$\GJ4<
M-+.+(7C%9=[3C5PIH:^0.+&*;UPN!$QQ$H,1. &SF*)>OB&V==6*3=B<R&<G
MOU6(KSZ(M5O$WHNIA? HFK3L+)!,%QJR>5#)IP98BHK& PP0>)<#' /.UK!X
M6MS;0L(W+Q*7KM\VJH H!0"@% * 4 H!0%:]4?P7NG\Y3<W^F#.E;=;\,W\S
M*^2855C_ *(_YU5?M,T\NP/#ME[>+B<<=F$)%O,^OVI>V+PT,57 \W-J5+>*
M'LG'NLB02$?+6@S81T",>-&2N)TB%$\GFH88.85813AP=*)B8%LE(IK13V/8
M+2!TC?W!'=KUW 0-K\=R3F5V?O7&FXK-8+NA(X\[M]I1I%848HVO)=XB3<BG
MPV<CAY&CB*:+%"I=*R4#.&:<<$%N8J<.*0]5XA&P6)%,+\!27(V>FKK@=^ZL
M5OUMZZ[A;0[:*C73M.7BS34B#;<I!5 E..[KXFYSJ[U$P@DF5/%%4,29\<H*
M9+YF CEBHF!MAK&.SZMT8*0AL$LX\%R5DCAH3-PLVKNXG@P [B+F9\,K#PUI
ML['M$L6N^0$U_J3/=:J0GAJ6E16;9D Z5;RF!9M!D@%'/K\FJ]1+6"B*;5TF
M!+NX?"$;FXK/T!-/]ZPTNS+H:!B43526=74N;M;IC2G*P6PQ95;;_P!9W=*I
M0WWLN^[2)**2%9Y&#K</%@1@S9H8'$:\1BJJNR(0N%<=A> ><FE\N%>;6W($
M9Q_<;1\U%T-)VM[<&CF$,=-W*H.8TTHP;#1DN/&NSXQEU2513AY%2$U,&(JH
M8!G(Z<##R+"9(^'V/L$8)NNQW!/=LS-[BALQD;<IT=L_B?+T8.I\)3EUX\XQ
MZ-7(R2S4(.$\A*Z;-D<BKY58(,XN&D%Q R6*1<V<R.76+YE.LHPKEZ[ZD)1(
M$RZ^\-":]49JV,F6)-O>8@;0,^+EZ88I!UY;Q\?I#Q-&Z*R/.9"3E=DOFD]A
M->1NT-L55KN$NYL^M#%P2ZZ2&"!4 9PD5?&0C!@EPDHOIM-&VG"Y7=,N(S*X
M[\F"8XT=[+EN7&.SF3'*YU<\\E9;CEQW9K,/."-DMZ--$+(>2H52QS2&85"1
MC$ 04L)B)GC<1;EXF[#NE,Y"X$QJ98XGXW+6TJ8K[2SFM:<*-YM9T F6C%[5
M2M&QB(T/-H*!E*<7>NJR8O"@#F7.+W\E#:B<,\XF*G%P@2N&6&OJ[\2,'[!H
M.\' 5F'==W[N+B]O4QFDC;M0UJS#SK*WT^55]U-4MJP_V7)+>=!-Q$=K6DW%
M19>3C;AZRF%B@$B@98^%@6#!N5RS,PKKD$O>K=)ALK?+.0QP;&C#&Y\V;C$G
M#K@^73-3F2IDZ]D?2YH/&9(FV(*M8BAKCFA.?UB3S+J8$,.Y4+"'3K/P)&%@
M&Q@3 FY2PN69G-A)M>KU>K8$%+.<*[0]:X;6G;1U,6)B2YTP9CTDUTI;^3(Q
M-Q-D.1DM\+,@FDH^US4E2G84TE+KB.AAFPU$+ 0I<'"X%A \QAH58DD40APR
MWYKECNXQ89VW<K(@7;Y^S7,[=9"=&A424=?IGGAL+:,\7"P9H-/T>QYFDG"H
ME%]-2LV^54R2JF \Q7ZW$,@C3A)LH1 Y_H_]WF?*%$NR\<%-Y4=26MG-"X+T
M==CQ<6KA]3S2@HA6L!5Z6RB84V62CZNY)%;XYRYDJ?4A\R[A.9J>9LT7MVKO
M.&L/6W=TC!/J>']WO>\J#;"'I.W?10UN9(4TFC]F.*)=7E!@+,2R9H?=LYQ%
M*Q+-X;+2PG.I/6!$Q1[=((Y8ID/B>!ZV42N17+(RPU]7A&"6YVNX19[<UQ:@
M3#L!+<&2ML%JVI.L%8,2OIDU)1U=EQC2"W6PWWPQUC6%V2N9-(.)TXU0UQ,5
MKO)1549?-F10!KD>M4XK$4O0)@2GJ[PUUC6/>F:ML427(W'B^4-;80UM:^O+
M+UR+19A&S>@ @FIS%44EWMF6#+%N2S*B*N!E(3&,AIX>!DD&2Q)A$1,#I712
M&QZMT(FSLDF:HZ*G-;Y_V%V"5I-;CF7]@&U%K?<;>C>)0X0:CA7HZ"<.2E-$
MI-9*?KN9[VV!? SAZU4'&C);3*9(Q F4R31!0<S8I71N!$@5:;?"Y94R:=<2
M/1J?<7879NTVZ&S,OBO@ N6LNC!S&_&K/L8OEIGU<%3(K9F-3YI)3L!A<,P\
MC[=&+"8XW#SQQE52YLW"$B6$>6K.]S\@&0(K7M[HM)R"OL51C!E26V-/G*@(
M+?;+A0<VRY'J^8ZMMN=,2)-@B0,-DFJ99>0&@FG1\C/>L.(&7ZA&$B7DNQ)A
MX"NNNO#FW_UF@2(]=HWXB<#H4?:_0<%$T1)J#H*]$@$=UX@!H6<O2_<??!64
MY+<6#85EL<%()FV\WL72;(+ I(;%,Q(&F%MH@@19KWP,E1H03K3JAL]M,B3W
MJSJU(*;,#:AZ+]>CNOEIPEM.=CL?8;VVO=Z[/,]KLO8XO-T65>UR5WJ$#1PF
M'<^&>"O<&F%X?5_Q$"Z"UP]G%.6H6XFJFY,N,*;\=NW3(KB5GQ'4)."' F>&
MZ4UMA,+ %KN>=)O&75F&E1I)>:&=LJ$<+DDA/ &+YC #'#3"O"!HTR\-^8)$
MEKA[++,V2BME:_</9VM!\LR#G'K*[WVX)&=;?C97B8VN.Z44_:9B)I123VFO
MG3+<%+M>^2.MF,C1[MR!>Y/)A78[8@:I*/"(PEC9*6Y(<NP0IS7R=-E-:MMI
M(@]0C$V>D?.8-6VV@-Y@(K/G\&4D\LUH;/B---.GD')G'52QD$7 JL%BI@4O
M>4?#U>K:(P3+;%Z(\1>=]7V; 1'BI(;.>Q=^O1S2W-QW0R+G:H2ZRE!X**['
ML1'HNO++>BU*8;3;1L!&7 #:<L7>)<GA<]8($<X6-8QA>ODP/ICO4"8I VXU
M@D>='@X7_%_#RBEX(,</Q\HJ*V';LON'+B,(S)DV -1TF))=-CR,V$T,#J6T
MT\KU CD;7#624#@CIR8;4,E6YW5]7J[ZD(EWN'7ZL#(4 H!0"@% * 4!#$7_
M /.,X_RC$OX$-6NEMSZ-LOYF[Y>:<_8WTA:7SMOR,LF>N:.@% * 4!Q:V6T8
MVGF'BS:K;FM4*!">O$%:_P S02[ %V6Y%39E7 9T1U!/6G(AL-.@%<8^?>48
M&!S*$C+L"LK\E[B#$+X8VR Y!ZI<"'B,:U*^OQ,XX]*'JU-=-#]Z-,6^=+3/
M.C;<+S/;+/Z<)584B+*>+JZOIK;*%W#):>DK"4 94,TTD7,'BYM3%ZF0R DK
M5;AO[(<-B0]2=PMR7%JB1U@T%X8$MZI[&+$>R%/LK.LTAYR3),L9R6UHVPU+
M1QW6@]K%--)J*/D9"- AF#HH61NQ0($\!>SA6<->+X]TV>K!QEV:'?!$BS[)
M+XU:7(LGV>]?',U=1B4F2*XM?68B2+!#^BQ]J#*4Q)!<#J!RP4Q$]; <X)D0
M.^&)<(N!6C=/@331+\D[?)$ RDS+0;O[ FJT$3&Z-BI?G:19W@DIK-)C:=%W
M1':F[4*65O8<R^6DW^MA"[L>3<,DU7/KG,^;!_U>P'X[]?W?MY[12AOH^8QE
MIKMM)V9UUU7,Q(D/%PO(D;:&\^JBI=N,F;W>;06NM7!(6A5+LWK+1.YY4RLZ
M5NXB;ED&6&& EO=CA:;?RI/O#_DR!#^N;H;.FVH&V,"NLS-4N23&;RDV1=H=
M?5F#SSOL58>M\N(Y0DEJ0P+A/G13%S:L:.F@>M2]P\3!@"D#(_N\>QX*?I'Y
MYC>OLMHL7Z)N'A[[6PFG;:;FPU'[VC4I-SLEV/I)9S_@YB1R\Y)Q"..8(1;C
MMT)Z8VSN:>$%90N9Q*JI(#;=B.!5NZ=PVXCK7AYZHK\0[";U:V[V-59F&1YO
M94A-M9B N$$[X55221#LW6&;*@.7+9(;@$7U(R2+%<RXR7GF;N9+ >MDMD8R
M+@9' @0#>0(61H L/F:+@F+X8W'" -"EB8ID$,7EM@)D"%EGC:U[X8WOS; ?
MM0"@% 0PR?POS?\ _37^#!NNDM/ZNV7_ )GY5#G[.^GK2_R_R:DSUS9T H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0%=9M_"7I_^<4YOZ)6T=;E
M+\!4?F4^5E%):WZ?9GSY_P"QU91*"?\ D$U_*7-_Y:Y!K\W><#ZWUOX4OY*6
M45F_HB?AS/E'$Q5QQO"@% 4>XCJZV6_IO,AQVM1!=J.=3$= R+NR8#FOC00S
M;F<"6WB3M=LYIALBJQ4VFN94\3AQ6*"XFL0@K@A\N0UK7N+ 9,?:LI)3G,<B
MJMQG".5$155K9:W'JL((U>_L'I*15F)"_':C]C9.=/#5F+1<JX--];M=5R'#
M$@M?6N5%YQ1#K)+*M+,70ZXP%9CYR(['8NAJR^E.I8>BLNAD2+B6S-G/S<,@
MP.<44#V -_I!2VPLNKKJY)O .J&(CYK$8^8D'8+6I!%1&PBK6I@;-]J1]I[9
MWC/>CH*Y+JI!5OP_X)<^P=]ZX@U2K^UBV&W6E&:R*G+2L&0GZ&C&2>WDHTM+
M!JP+N+"W"(IA+#,R;,"6PYN&&%KWRRO:UOU:ZO1&0M35U4A',8KK.J4B]R-:
MD9=]7+<1-M2LM28DJ3+>J.5$GRKC455]NFPETS72+2O1+L-ZE'GV'7AJU-Z9
M9O69>Z>F<&9*?Q;]P=(M*]$NPWJ4>?8=-6IO3+-ZS+W1G!F2G\6_<'2+2O1+
ML-ZE'GV'35J;TRS>LR]T9P9DI_%OW!TBTKT2[#>I1Y]ATU:F],LWK,O=&<&9
M*?Q;]P=(M*]$NPWJ4>?8=-6IO3+-ZS+W1G!F2G\6_<'2+2O1+L-ZE'GV'35J
M;TRS>LR]T9P9DI_%OW!TBTKT2[#>I1Y]ATU:F],LWK,O=&<&9*?Q;]P=(M*]
M$NPWJ4>?8=-6IO3+-ZS+W1G!F2G\6_<'2+2O1+L-ZE'GV'35J;TRS>LR]T9P
M9DI_%OW!TBTKT2[#>I1Y]ATU:F],LWK,O=&<&9*?Q;]P=(M*]$NPWJ4>?8=-
M6IO3+-ZS+W1G!F2G\6_<'2+2O1+L-ZE'GV'35J;TRS>LR]T9P9DI_%OW!TBT
MKT2[#>I1Y]ATU:F],LWK,O=&<&9*?Q;]P=(M*]$NPWJ4>?8=-6IO3+-ZS+W1
MG!F2G\6_<'2+2O1+L-ZE'GV'35J;TRS>LR]T9P9DI_%OW!TBTKT2[#>I1Y]A
MTU:F],LWK,O=&<&9*?Q;]P=(M*]$NPWJ4>?8=-6IO3+-ZS+W1G!F2G\6_<'2
M+2O1+L-ZE'GV'35J;TRS>LR]T9P9DI_%OW!TBTKT2[#>I1Y]ATU:F],LWK,O
M=&<&9*?Q;]P=(M*]$NPWJ4>?8=-6IO3+-ZS+W1G!F2G\6_<'2+2O1+L-ZE'G
MV'35J;TRS>LR]T9P9DI_%OW!TBTKT2[#>I1Y]ATU:F],LWK,O=&<&9*?Q;]P
M=(M*]$NPWJ4>?8=-6IO3+-ZS+W1G!F2G\6_<'2+2O1+L-ZE'GV'35J;TRS>L
MR]T9P9DI_%OW!TBTKT2[#>I1Y]ATU:F],LWK,O=&<&9*?Q;]P=(M*]$NPWJ4
M>?8=-6IO3+-ZS+W1G!F2G\6_<'2+2O1+L-ZE'GV'35J;TRS>LR]T9P9DI_%O
MW!TBTKT2[#>I1Y]ATU:F],LWK,O=&<&9*?Q;]P=(M*]$NPWJ4>?8=-6IO3+-
MZS+W1G!F2G\6_<'2+2O1+L-ZE'GV'35J;TRS>LR]T9P9DI_%OW!TBTKT2[#>
MI1Y]ATU:F],LWK,O=&<&9*?Q;]PE'3#9I);^K4*(PD-;*JV:>S00,E% @I[+
M",;OU\>SZHGJ94G<N< ^KY.?A?DYUKV_[*_4D^C<LU5X23>3[]-I"SL6TF-L
MJG3@JA?R:7I3]PL[TLT7T%;6_1X?W85>/,G923OVEIG-F1J>*?N#I9HOH*VM
M^CP_NPJ<R=E)._:,YLR-3Q3]P=+-%]!6UOT>']V%3F3LI)W[1G-F1J>*?N#I
M9HOH*VM^CP_NPJ<R=E)._:,YLR-3Q3]P=+-%]!6UOT>']V%3F3LI)W[1G-F1
MJ>*?N#I9HOH*VM^CP_NPJ<R=E)._:,YLR-3Q3]P=+-%]!6UOT>']V%3F3LI)
MW[1G-F1J>*?N#I9HOH*VM^CP_NPJ<R=E)._:,YLR-3Q3]P=+-%]!6UOT>']V
M%3F3LI)W[1G-F1J>*?N#I9HOH*VM^CP_NPJ<R=E)._:,YLR-3Q3]P=+-%]!6
MUOT>']V%3F3LI)W[1G-F1J>*?N#I9HOH*VM^CP_NPJ<R=E)._:,YLR-3Q3]P
M=+-%]!6UOT>']V%3F3LI)W[1G-F1J>*?N#I9HOH*VM^CP_NPJ<R=E)._:,YL
MR-3Q3]P=+-%]!6UOT>']V%3F3LI)W[1G-F1J>*?N#I9HOH*VM^CP_NPJ<R=E
M)._:,YLR-3Q3]PK[K-M D),<N0KG"VS9ZXNP6VBG8=*@9\*!7#!:VJF98#)B
MF "=\ U).P/V+G +_5E3@0H.?)F'E6W64;EG(O"2?@I7WZ9-A5V1:3$I'IP5
M3^E5/]T_I,WN%@NEFB^@K:WZ/#^["K4YD[*2=^TM,YLR-3Q3]P=+-%]!6UOT
M>']V%3F3LI)W[1G-F1J>*?N#I9HOH*VM^CP_NPJ<R=E)._:,YLR-3Q3]P=+-
M%]!6UOT>']V%3F3LI)W[1G-F1J>*?N#I9HOH*VM^CP_NPJ<R=E)._:,YLR-3
MQ3]P=+-%]!6UOT>']V%3F3LI)W[1G-F1J>*?N#I9HOH*VM^CP_NPJ<R=E)._
M:,YLR-3Q3]P=+-%]!6UOT>']V%3F3LI)W[1G-F1J>*?N#I9HOH*VM^CP_NPJ
M<R=E)._:,YLR-3Q3]P=+-%]!6UOT>']V%3F3LI)W[1G-F1J>*?N#I9HOH*VM
M^CP_NPJ<R=E)._:,YLR-3Q3]P=+-%]!6UOT>']V%3F3LI)W[1G-F1J>*?N#I
M9HOH*VM^CP_NPJ<R=E)._:,YLR-3Q3]P=+-%]!6UOT>']V%3F3LI)W[1G-F1
MJ>*?N#I9HOH*VM^CP_NPJ<R=E)._:,YLR-3Q3]P=+-%]!6UOT>']V%3F3LI)
MW[1G-F1J>*?N#I9HOH*VM^CP_NPJ<R=E)._:,YLR-3Q3]P=+-%]!6UOT>']V
M%3F3LI)W[1G-F1J>*?N#I9HOH*VM^CP_NPJ<R=E)._:,YLR-3Q3]P=+-%]!6
MUOT>']V%3F3LI)W[1G-F1J>*?N#I9HOH*VM^CP_NPJ<R=E)._:,YLR-3Q3]P
M=+-%]!6UOT>']V%3F3LI)W[1G-F1J>*?N#I9HOH*VM^CP_NPJ<R=E)._:,YL
MR-3Q3]P=+-%]!6UOT>']V%3F3LI)W[1G-F1J>*?N#I9HOH*VM^CP_NPJ<R=E
M)._:,YLR-3Q3]P=+-%]!6UOT>']V%3F3LI)W[1G-F1J>*?N#I9HOH*VM^CP_
MNPJ<R=E)._:,YLR-3Q3]P=+-%]!6UOT>']V%3F3LI)W[1G-F1J>*?N#I9HOH
M*VM^CP_NPJ<R=E)._:,YLR-3Q3]P=+-%]!6UOT>']V%3F3LI)W[1G-F1J>*?
MN#I9HOH*VM^CP_NPJ<R=E)._:,YLR-3Q3]P=+-%]!6UOT>']V%3F3LI)W[1G
M-F1J>*?N#I9HOH*VM^CP_NPJ<R=E)._:,YLR-3Q3]P=+-%]!6UOT>']V%3F3
MLI)W[1G-F1J>*?N#I9HOH*VM^CP_NPJ<R=E)._:,YLR-3Q3]P=+-%]!6UOT>
M']V%3F3LI)W[1G-F1J>*?N&OQ--2<95Y56_-Y,Q<-=?09P)-,Q:Z EI-Q+-E
M"3<@%Q+ZUR,I!P;,E<8,(:V.8A80,6UN8)C>_8VA8TRMLNS7-J*.7@4KD_*3
MY<M5_+3%BU'*D4NWTN1BAS5GVQ+IK0KXR*M^'4M7Q),QT/R4M(.@EQ;D8+L0
M79)G\]:;Z/9F]53L["JFU9G],LWK4K&+?6&3T6T.K3<4>>M-]'LS>JIV=A4U
M9G],LWK4K&&L,GHMH=6FXH\]:;Z/9F]53L["IJS/Z99O6I6,-89/1;0ZM-Q1
MYZTWT>S-ZJG9V%35F?TRS>M2L8:PR>BVAU:;BCSUIOH]F;U5.SL*FK,_IEF]
M:E8PUAD]%M#JTW%'GK3?1[,WJJ=G85-69_3+-ZU*QAK#)Z+:'5IN*//6F^CV
M9O54[.PJ:LS^F6;UJ5C#6&3T6T.K3<4>>M-]'LS>JIV=A4U9G],LWK4K&&L,
MGHMH=6FXH\]:;Z/9F]53L["IJS/Z99O6I6,-89/1;0ZM-Q1YZTWT>S-ZJG9V
M%35F?TRS>M2L8:PR>BVAU:;BCSUIOH]F;U5.SL*FK,_IEF]:E8PUAD]%M#JT
MW%'GK3?1[,WJJ=G85-69_3+-ZU*QAK#)Z+:'5IN*//6F^CV9O54[.PJ:LS^F
M6;UJ5C#6&3T6T.K3<4>>M-]'LS>JIV=A4U9G],LWK4K&&L,GHMH=6FXH\]:;
MZ/9F]53L["IJS/Z99O6I6,-89/1;0ZM-Q1YZTWT>S-ZJG9V%35F?TRS>M2L8
M:PR>BVAU:;BCSUIOH]F;U5.SL*FK,_IEF]:E8PUAD]%M#JTW%(K:<KD"DFRV
MIY,F4Q\%;O#ZF3*QTY#"D1ZP;YDOGVU(!E+F$[KF^7. ZK:W5@[7RQY;6J^M
M"P)LRQ+/D)54"++X>ZM1+1KL*8B^*Y5@Z%YT+RW%*6AMN4RV*Z<M/6JC^!N)
M(F*Y,%BIXS81;'8C?2ZA*GGK3?1[,WJJ=G854.K,_IEF]:E8Q=:PR>BVAU:;
MBCSUIOH]F;U5.SL*FK,_IEF]:E8PUAD]%M#JTW%'GK3?1[,WJJ=G85-69_3+
M-ZU*QAK#)Z+:'5IN*//6F^CV9O54[.PJ:LS^F6;UJ5C#6&3T6T.K3<4>>M-]
M'LS>JIV=A4U9G],LWK4K&&L,GHMH=6FXH\]:;Z/9F]53L["IJS/Z99O6I6,-
M89/1;0ZM-Q1YZTWT>S-ZJG9V%35F?TRS>M2L8:PR>BVAU:;BCSUIOH]F;U5.
MSL*FK,_IEF]:E8PUAD]%M#JTW%'GK3?1[,WJJ=G85-69_3+-ZU*QAK#)Z+:'
M5IN*//6F^CV9O54[.PJ:LS^F6;UJ5C#6&3T6T.K3<4>>M-]'LS>JIV=A4U9G
M],LWK4K&&L,GHMH=6FXH\]:;Z/9F]53L["IJS/Z99O6I6,-89/1;0ZM-Q1YZ
MTWT>S-ZJG9V%35F?TRS>M2L8:PR>BVAU:;BCSUIOH]F;U5.SL*FK,_IEF]:E
M8PUAD]%M#JTW%'GK3?1[,WJJ=G85-69_3+-ZU*QAK#)Z+:'5IN*//6F^CV9O
M54[.PJ:LS^F6;UJ5C#6&3T6T.K3<4>>M-]'LS>JIV=A4U9G],LWK4K&&L,GH
MMH=6FXH\]:;Z/9F]53L["IJS/Z99O6I6,-89/1;0ZM-Q1YZTWT>S-ZJG9V%3
M5F?TRS>M2L8:PR>BVAU:;BCSUIOH]F;U5.SL*FK,_IEF]:E8PUAD]%M#JTW%
M'GK3?1[,WJJ=G85-69_3+-ZU*QAK#)Z+:'5IN*//6F^CV9O54[.PJ:LS^F6;
MUJ5C#6&3T6T.K3<4>>M-]'LS>JIV=A4U9G],LWK4K&&L,GHMH=6FXH\]:;Z/
M9F]53L["IJS/Z99O6I6,-89/1;0ZM-Q1YZTWT>S-ZJG9V%35F?TRS>M2L8:P
MR>BVAU:;BCSUIOH]F;U5.SL*FK,_IEF]:E8PUAD]%M#JTW%'GK3?1[,WJJ=G
M85-69_3+-ZU*QAK#)Z+:'5IN*//6F^CV9O54[.PJ:LS^F6;UJ5C#6&3T6T.K
M3<4>>M-]'LS>JIV=A4U9G],LWK4K&&L,GHMH=6FXH\]:;Z/9F]53L["IJS/Z
M99O6I6,-89/1;0ZM-Q1YZTWT>S-ZJG9V%35F?TRS>M2L8:PR>BVAU:;BCSUI
MOH]F;U5.SL*FK,_IEF]:E8PUAD]%M#JTW%'GK3?1[,WJJ=G85-69_3+-ZU*Q
MAK#)Z+:'5IN*//6F^CV9O54[.PJ:LS^F6;UJ5C#6&3T6T.K3<4>>M-]'LS>J
MIV=A4U9G],LWK4K&&L,GHMH=6FXH\]:;Z/9F]53L["IJS/Z99O6I6,-89/1;
M0ZM-Q1YZTWT>S-ZJG9V%35F?TRS>M2L8:PR>BVAU:;BCSUIOH]F;U5.SL*FK
M,_IEF]:E8PUAD]%M#JTW%'GK3?1[,WJJ=G85-69_3+-ZU*QAK#)Z+:'5IN*/
M/6F^CV9O54[.PJ:LS^F6;UJ5C#6&3T6T.K3<4>>M-]'LS>JIV=A4U9G],LWK
M4K&&L,GHMH=6FXH\]:;Z/9F]53L["IJS/Z99O6I6,-89/1;0ZM-Q1YZTWT>S
M-ZJG9V%35F?TRS>M2L8:PR>BVAU:;BCSUIOH]F;U5.SL*FK,_IEF]:E8PUAD
M]%M#JTW%'GK3?1[,WJJ=G85-69_3+-ZU*QAK#)Z+:'5IN*//6F^CV9O54[.P
MJ:LS^F6;UJ5C#6&3T6T.K3<4>>M-]'LS>JIV=A4U9G],LWK4K&&L,GHMH=6F
MXH\]:;Z/9F]53L["IJS/Z99O6I6,-89/1;0ZM-Q1YZTWT>S-ZJG9V%35F?TR
MS>M2L8:PR>BVAU:;BCSUIOH]F;U5.SL*FK,_IEF]:E8PUAD]%M#JTW%'GK3?
M1[,WJJ=G85-69_3+-ZU*QAK#)Z+:'5IN*//6F^CV9O54[.PJ:LS^F6;UJ5C#
M6&3T6T.K3<4>>M-]'LS>JIV=A4U9G],LWK4K&&L,GHMH=6FXH\]:;Z/9F]53
ML["IJS/Z99O6I6,-89/1;0ZM-Q1YZTWT>S-ZJG9V%35F?TRS>M2L8:PR>BVA
MU:;BCSUIOH]F;U5.SL*FK,_IEF]:E8PUAD]%M#JTW%'GK3?1[,WJJ=G85-69
M_3+-ZU*QAK#)Z+:'5IN*05*TJ$5B3=4,0V7*!'M=.CU5\[JT>N),Q-AI^HVT
M0F9%.N:*X6/*QJU^:7+!\HHV7R8VO7HEA3::1-PJFA?AM8SQ*B6Z"NG2_&=!
M?%8GWSEN)LE776S+J*^S\&GK&X%5,?XTA[8HVCJO%;%/&<OWK4NKL%8X)_Y!
M-?RES?\ EKD&OREYP/K?6_A2_DI9YV;^B)^',^4<3%7'&\* _P QRQSMRXY8
MY6MEEC>^-[7M;+#*^&>/+;E^JPSQO:]O^R]N2@.=FX!7;-+8.UCA0)GU$CZ(
M1HXC;"-CVPK-4#C/C[ BYB=]AEV>%)350&TX6.O1T*= 3RM@\,0C%P^K7YO/
ML)?66MF.G4TM\FJF5?"/P^#=!SKB\&DM$2*.1T%5>_ZWK+P%5J*CE='8V=J!
MS&X,Z)UE,SZ%BN?^$U(T<!-I0&DEH:!P\FQ?)^"^;'(AL]==P]@L5!1CPI<
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0%=9M_"7I_^<4YOZ)6T=;E+\!4?F4^5E%):WZ?9GSY_P"QU91*"?\
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M/Y\DN(H;0&?&L-LN3YRSB>,TTFUV\<6B:0:<*D0;R*6L$@M,FN*)/'J@9,
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MKJ5!T0R^])QCM%>S>?#^9;4CI>3?//-2O%9-DL0, %D-QG0.NR$IP;'2>SP
MQ0TNS?;J7F0#.GL ,L,3YVQ@JJM\DPL@:2ZRR5KP^M4%^.32-K[)BL^UA]1S
M&K^DN&R3C,2B]%Z09*)'%N(GBQW0&WW^['2I&%E+!/!IBD$>'+& !"PN8-T5
M(@A#*UPJ-&G'IVGZ!K\8OY9U'2CR:<3XB4]E=HCH!4LBF@#R*V\'F8F<21;L
M5%.E0AB;=R5[H)04+#,(GAEAC>R*DP(?7^!3PLG-K*PM-UC6A4&UGC-^..3V
MA$Y787:!*1BC^=>(N"RZ%=32II).-UJ-PAQ,"O;8Z>#3PQ1,"F(&(F=LD5A#
M8$"0'WP?^'_(\7ZUPLY8FD,"+=/QD-0UN9C1VDVRCM+BUQ-<T9.-A\)64>SB
MUSBM)+:,'1[ISG4Q3KA(XCBX@' \1,[9(JI$#I*G$ $M/()A;,X*63B94@7$
M45%06% 0 H!@7"S/JRL:/*JH<S##M<4R:&&,#Y\N8F>>>5\KP2?90"@% * 4
M H!0"@% 5KU1_!>Z?SE-S?Z8,Z5MUOPS?S,KY)A56/\ HC_G55^TS3BYM/O1
MN7JYL'M^[%MPNM]Q\V8@V,=6E<6Q8@03(.N<KN6$-=PWZX(HEM20V:)MO$FS
M<:.9"57 K8&5TXT%]MYX%B14D>"YHG@C4A&&QZO#ZKI9Q6/KG)_>'<O9J5.'
MSQ)=>9GEG/8=IJW"AT;W<(R8:9D8M8VP)"V,DM R=D1)H\2M=DH!V.K!DL#C
M7#5"1]P@DBPW7JJH7OB+2"(GJ[NX$6Z;BY>(GM)J_)G&<36.\FQ<U&C@X*$5
M17):I#,%)Z_#:'MI'P!1VNYZNAJ16@+<Q$(T(.'K!K8/D=Q62PPRH660V.9N
MQM"+EC>^Z0BK!#J%P;4M20N(-QUD-9D17EI51-D]6D90DEQ$V80<CQ-I6N01
M =8<I..FZT&& Y1LR]\5"R.D)*=UYB)< D4#YI</%VQZMA#)#DHJ;B[JPLS^
M*M/;.WCF -^L'CP-/6!):3H;&LKM:QR!$5TQ1$!U/NBNB!5-?0"0;2=Q F,(
M@GD@B6.$2AD(($X<4QE/)$PDNWO^&Z8JL%[O_$E)\\3/?PG NX[U9^XBZ;6H
M&_O B7HS'+JQBG5Y:)*VL:TX&@V+L!REB<) )"U9/[=#F U@C9/7LC%K8YG\
M@K=3HC47P[FZ2JP\!KZ'Q2>(0Q=IT9*=NV#KD&,6C_>#B/"C4XY58=UC3"+\
M@5WB.HP2=;N7VM"S8>!:2F\9.IY8L<0E)#(9$4['KDF:,BC#B1!,&/=^T(K&
M'<)DBKBB;Y/Y6BIV*<K.((#<B4.+)"IF%V_&L)A&-*$S2YI.TS$DJ1V;4HN5
M':HNE!6&Z5L[ Y&-O%"/&5,+J!$EAU(F/E@HJP]5]?5WR(K!5)^USG7BE33P
MJ]<=TD;:K.19AGN-XF*'H30V/JC%<B+IY)DEZ&I.<&MSX?\ %BA%ZIL9($8I
MMK)K;<S>.M6V:5G@6  &SS-B0B-O0NP)NW]@[LZ42<#,VJ4%2<#([RER[M8:
M>>,R+(K!;D6R YE N.:3E0R^(^9Z>E-!K.\FHDQ2RD622P*78X )D4PL7R#K
M!R06!*7BT502* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * AB
M+_\ G&<?Y1B7\"&K72VY]&V7\S=\O-.?L;Z0M+YVWY&63/7-'0"@% * \G/&
M!BMU[/\ &$T;U=DMQQDZ-?U+4S:::6=%3WC^75%#3)1C=-3UXL\7 HQELI#R
MXIN\FJ-0IFC*R8903*0G=?$,NO,%(47 ""H*XQ^U._D6Q%$>Q$<:IFHNW?X4
MO$"GN0V\SXKD8FH(;JA&29^A9,04PX^)ND)NJK.7T)B$C9HJ>2!C.!S,;F&.
MIYAX! 4GX6J#*"9L]PO%K5XA$B+L8N?W>Z4E=EJ<GM!46F(ZW^A[,OLFV"4F
M@,]U1^Z5-,/D4T%)L=P5\!TL#(,;' P&7ZT% ] '#@XM,S[3PLU-DYN)H(3
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MQO 8#TET H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M51+MY([!$&G<R\3*1Y*10=IHITV;$+*;%4'$2>.N$P."1UY861LB@+9&#(+
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MY55<!$:Q=B%SOP6,/6O&0='"2T->3@?3H7XND0=7DF8FU/[RR(;0[7(:<I3
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M(Z W&\F$D5"0TD@#@6(I:0D)H!9/34XD7#Q#" !#P"#PQMCCC:UN2H!F: 4
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M^LIZ,JK:8C]<%DDJI&4].-*91-"-#E"XXP@6($?SWPX-+=G91(S).$)E'J_
M$-K-A;,AOB3&LV)%;#&=Y9_,EL31'C->;>CR=6VSWH3"4TL@\TI=*)YO"P@
M8=Z S<T: Z?[#+TTN>8H107FX-B((1=:)E515IWHIM[0LW',LO)":9C-N.)'
MLD'4IRKHQH%93[%%W#(,MC8YS"93$ #3=@>&3I?L^_(PDR8HU>:B]86C)WP[
M%*NQ]@MC8;"8<<2 W5-H/ENMY'AJ6F AD^^]I*PJ6I&^MKGSB=B"6%'R!+E\
M @-';?" X>K.3->$QJP@XF]EJHBNQJP4NH^P&R9!YM!BOA6/++KC-2?I>7\'
ML_(F63BH;PS:3B4%9MX%#8Y7 CB6&%!S ^*:>#;PX=@7=(#XDO7LZ*O2FYH[
M?+]#8DV;"0^W'#(,3%1R$<22,RX@E=BLTE)K13S8Y8JY"I !<L6-#A9&L@QQ
ML<P.FI8# J7 *A9#9!%@0@ \C)DP<,98 X8AX9#G#@HYLT-?''ZL07/,3/+E
MRRROE>]Z _:@% * AAD_A?F__P"FO\&#==):?U=LO_,_*H<_9WT]:7^7^34B
M^0-'==90V4B_;IYH\HGIYA<D=3(P<J5L?LBU6LT4M7S3LW*E$8F:<M(D0&4I
M[61B6#A*F4$8!Q!$BX:G@;# !QPYLZ B:?>%7I)L](4PRA-C"E5U.Z?(R;<,
M2WDF;7;;L5LNZ)6D>**J#' C"CZ<VJPD9F%E@L*>%3TY,*%C9]043(^ HZHH
MB&@,4A<(_0QMO!M/Q)B^2 W2T)-;DT-]0.;3;9JQ<G+3=C3&'Q)'&25:<3R,
MI/-Z1QABF.]0-%QC+XPPP%<.2F8PQ%L!_1GA&</L\U7(SU*#5=737$-$PA=4
M6IQV%6GLP2\#'UQ4A9(A21U65SDA0 VXL/N=3$0DICJC>34VZB:Z@!A8P+;,
M"Y4=0DP(JC82*F7@\P&R8#7+'U9PRE*+XDM8../(QDK+J_,[Y>3CF%P.L6QC
MFA+!U=,*A4,(#  P'@7 Q# T/5?4:"=+8W.Q'KL@O-K1Z>=[E?>;?>$R31,]
MR;H>:AFLNT^C*TVR#(BX@%G(X#!A4.DR)DN2,JYTV?S"R.'#0XP$.JO#$T@7
MU&5U%QPR=<]IGC^8(N>B0Z98FISM4BQ]@EX%TSBD1LS%Z1E%I0J9EESE05)P
M'F:20%!44 0S X^8P>&>(&CY<(+0#OF[\08FD$BY,GO%\H#*:5M#M>D9&Y8A
MM.34B/Y@4"R7.!,FHS&F)*4$5..T<,1QK);,8)1.FPS)C$4#8V[PK](&M"93
M7A+C60!HH39WQV91T9>V6VA=;A0)QNHFE@Z_&Y(CIF99D=N&%I94CIQ3)$58
MNF*IQ3/CG"PXI\[F.!(VPNA6L^T3QB1_RXWY/R=\#E',4AY:B_9'92 !8\N\
M6^<:3F/MPM 4N1F1*+BLU% =+S4;A9'\4T;,K@-B!ED'<",8$X4VC^L<@0O)
MT*Q[*+6=FO,=NN(X;[:;5[:/MKLB,'L:/J#F811@2%.+J82FU%%3/8G+$CZ8
M: +G2*>8!Q#'3$X0J!.4K:;P)-4Z0ALC(21(AZ7]<C)PW#:XW9ZGU@-YI&%7
M,3%?$&CB/Y-:\:.COK("W3UJRPCJ&*TD<B<>L8(8XE[ 1>A\-74MN'MFE1'1
M9S+JFXI; ML8IC;B[CGU*0; E4]+*F03ZA/9HVRE%/;B471"IMOYI1DHW0<4
M@$3!,MUI0&R(O#_U=;NHXFBR,V)*(ZP9-_O0"8.&Q^R@JX09EA0,L&.DRL8E
MP6849C!%2V),-%*+X*6&F7R(X@6)YY@9 8H+ARZH"1V_HO<#;EN0FW)!N/3[
MA59?VHVKFB1DU0B1>..N+%!@3#+,UO.6XH/QR[%$PK(8S66T85+51Q#A;(,R
M)F+<##JG#(T[4&1$,>D&E+S(;D%N)ZO..1HGVQVVAEU$WW)';?O^D1U/Z)IR
M9;\DJ2'CWQ*?;%Q.525ULU=5/=4-7Z]-=6 RSWX<>J$BMG7YI.UOS$?2-7Y
M6Y9AH4EM?MD@KZ1*KB5#ZRKR<\':WIN2G7+<B&5%94L\5MWG5U3!Q653 (?
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MEQDCDSTP;3\J1O7XXZTVO^?]>?%&2?+:F'HAD[2XR1R8P;3\J1O7XXZTVO\
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M??Q3^3_XE\0/YJ_A_P </^H;^)C[^*?R?_$OB!_-7\/^.'_4-_$Q]_%/Y/\
MXE\0/YJ_A_QP_P"H;^)C[^*?R?\ Q+X@?S5_#_CA_P!0W\3'W\4_D_\ B7Q
M_FK^'_'#_J&_B8^_BG\G_P 2^('\U?P_XX?]0W\3'W\4_D_^)?$#^:OX?\</
M^H;^)C[^*?R?_$OB!_-7\/\ CA_U#?Q,??Q3^3_XE\0/YJ_A_P </^H;^)C[
M^*?R?_$OB!_-7\/^.'_4-_$Q]_%/Y/\ XE\0/YJ_A_QP_P"H;^)C[^*?R?\
MQ+X@?S5_#_CA_P!0W\3'W\4_D_\ B7Q _FK^'_'#_J&_B8^_BG\G_P 2^('\
MU?P_XX?]0W\3'W\4_D_^)?$#^:OX?\</^H;^)C[^*?R?_$OB!_-7\/\ CA_U
M#?Q,??Q3^3_XE\0/YJ_A_P </^H;^)C[^*?R?_$OB!_-7\/^.'_4-_$Q]_%/
MY/\ XE\0/YJ_A_QP_P"H;^)C[^*?R?\ Q+X@?S5_#_CA_P!0W\3'W\4_D_\
MB7Q _FK^'_'#_J&_B8^_BG\G_P 2^('\U?P_XX?]0W\3'W\4_D_^)?$#^:OX
M?\</^H;^)C[^*?R?_$OB!_-7\/\ CA_U#?Q,??Q3^3_XE\0/YJ_A_P </^H;
M^)C[^*?R?_$OB!_-7\/^.'_4-_$Q]_%/Y/\ XE\0/YJ_A_QP_P"H;^)C[^*?
MR?\ Q+X@?S5_#_CA_P!0W\3'W\4_D_\ B7Q _FK^'_'#_J&_B8^_BG\G_P 2
M^('\U?P_XX?]0W\3'W\4_D_^)?$#^:OX?\</^H;^)C[^*?R?_$OB!_-7\/\
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M0"@% * AB+_^<9Q_E&)?P(:M=+;GT;9?S-WR\TY^QOI"TOG;?D99,]<T= *
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M8-9R)\5RY(:#D^G.: (MQ"<2Q&+$>:>R,EXZ8Q!)F%L1.*&1;98!BY989VQ
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MU&JBX6$D9;%BF!.8J(CX,5;D#SP'M<]LU/RE^*I%%3U[T=AR;-P]0E?.S3%
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MB Z^R>]UA1X9N@)*7Y>58;F-"AJ4MT8#NQG4MN,YL6EM!OL.1Y78 9)%Q[9
M. ?$T<(C%P^JC)P@!)A03Q;_ /Q(A&_>.C7"S@E6@_:;;4N#"KBR:KS2DQ]%
MMG)4UZ<L![$JZH^'RY7U;7V=7<,FDX^V\6HY)NCKI*D-",*)@@GC=HU0QU\5
MS!".O;$8DH=X*\S(4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0$,1?_SC./\ *,2_@0U:Z6W/HVR_F;OEYIS]C?2%I?.V_(RR9ZYHZ 4
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H#S#;@<-#;V7-FIEDIC,)$4VB\'B95T$^8?;.31S1
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M#4@U$4_:6A=F5EC:)6=95H-1E;3T<J6]$5'(CFM1%2**J+=V46!/52=.* 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MY,Q].<W)R.*F\J/TE:,_ =8]7@WM>IJ1HKE+0WTGDQZ<YN3D<5-Y4?I*T9^
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M)Y,>G.;DY'%3>5'Z2M&?@.L>KP;VO4U(T5REH;Z3R8].<W)R.*F\J/TE:,_
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M * 4!ET#_?J)^VZ;_M@-8O\ :+WE/63\,S\)/9,161Y"@% * 4 H!0"@% *
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M!0"@% * 4!EUO_Q@/[4('[A)M8MO>NOLJ>LWVR?@M]ZAB*R/(4 H!0"@% *
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* [(<+_\ ?$K_-8?_P#1]V<KUF?1<_\ .TWRS3O-"_T2U/F$_P#9:DTSC,_S
MUE[]YR5_"5WU,[VDGYO+]XAY><#ZQ/\ P5^4F'**O$X@4 H!0"@% * 4 H!0
M"@% * 4 H#+IO_@U_P#:@']W42L77T[_ -I3UE^U?^#_ /,TQ%9'D* 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!EUO_P 8#^U"!^X2;6+;
MWKK[*GK-]LGX+?>H8BLCR% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M@% * 4 H!0&74O\ P:!^U W[NK=8MOKW_M(>LSVK/P?_ )G&(K(\A0"@% *
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MA&9VC()2)'7$4GMB55 1-"(1DX6"ZT603HJP'B,D!%&8I))9QF1%4'.V9;'
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M-X=2E#2B=C,%JS[3)%42+*8KM-N5&1#R"E""O1OE5[K!/**9LRH&"I#$S8/
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M2=,557!5$68R4BW,%5541:^6@R;+QWE+]H=E.\38BX 92A:/G;YN\1A,\P\
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M8-R.QYL%NP3,B\^HX+&SLALM%C![*CL89-/%P /FWFW"*&.L-<L2'$QP&$/
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M!4;XTI(JZY@N547Q3GZ6U[4F$\V(F.^4('+NM<?K*34)#:L[1!)"%9/4%D/
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M1S51$6\J^+&*0++Z48-8CPE>(!':U+NO37D+8 _&2G$[!>.R$#,Y[.0G'+S
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M0+$NJ<O-QY.J];\[DY/J>7DY;\G+>$2">N9/=A+'N(G@1$^T?'4F(H!0"@%
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MM#R)&\F8XU5\Q_\ Y!-ZQ(_=Q\,7@\^^%-OCU'/L$IK[:'D2-Y,QQJKYC_\
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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ML7P]#=CFBXT=C2JEN-&C17D5ZIT*IQ]80UEL.)!3R1[KTP$2*$\"UQ ,4H?
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M::SQ9DC)CJ92("T5@JZV^_TQ(=@"A@<1<N:8- 6Q/@WP- YC #!#9XF:%^*
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M\Q&@M]8=S"'/&F*Z51&2V@53E!QLLRJ&1$D\*'F:3A# N1?,.XF=[KUX%I0
M 2P()8L"$7+EP@P    \ @0 0L+!A @A!VQP#"#PQMCCCC:UK6MR6H#]: 4
MH!0"@% * 4 H!0"@% * 4!P^XH)Q-,QB5#(NU><@Q6?1P5!/6.O.M&N:LU'-
MRHJ)UUED'VN#M\MNI<@?+:OFNB-303[8MQE':597S9=I.;,ES\/ I'P^ D8=
MS@TOI@>*?E__ ' /E/T98DN=,FN2V$1R.C"6O 3O%9'[WO7#AY7='Y&% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M^UX5\%_W"?72D_T>F]F:4NCGZ-/^=S?90WJOA1T(H!0"@% * 4 H!0"@% *
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MHZW+ ;'"M&A3!1RK&;+N(R&$J_E+B-BF$NQ%(PB@_IST>2_;4RY'^[E;%_\
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M:U/X)F(/B;Z+>\$@>+#_ /)*G#R^[O7;@]+?FX[6I_!,Q!\3?1;W@D#Q8?\
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M6I_!,Q!\3?1;W@D#Q8?_ ))4X>7W=Z[<'I;\W':U/X)F(/B;Z+>\$@>+#_\
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ML+/U-<7!YG4W8,A'A*2"*J^.BK=@C5P%@N'=27#7='G;-K@W[6W+]?P7-N[
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MT'Y)&C@@P6$L2G(2=.S$DC75W1S&Z$*""=?,BL.>F?'#X8+7&R&O<F<6$XD
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MV(6LWA3V> HM\B9!/$RY+"AWSA?:IM_\?N!+_<]7W3M'6!D* 4 H!0"@% *
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MD(J.1426O#R_$;&^G=0\MM=X?AL4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4!VQX.,[; ILJYP@V4%1?L*J>!E;=P)HSD 0BC,7$3FNU,4C%
MLBY3!6.86!&2[7Y5 2]Q L<10Q<\LV*J.@FSZH^KO;1^D?\ ;[I-I2RV':-4
MTI]3HVJ*^8JK!*55BJ/:Y;D)CD@LK[Y8O;!6S%=ZBJV3]DB@% * 4!J)WF]_
MC;Y>I\_O1>W-Y>J]5YO;E@<[F<G[!U/EY.=SOJ^7F\WY.=5+/AK%2WL+F55M
MQ^%H[VQ"]&-V]"Y$UG?IC-O@W^^EFW5=&R* 4 H!0"@% * 4 H!0"@% * 4
MH#6&C_NHW^^=[?PS7ZY?1#Z)G?ZI:7_N-49/O^LGL(;/74&(H!0"@% * 4 H
M!0"@% * 4 H!0&K.O_((G[Z6[^Z05<OI5\!1?ZI2?+-)2_X?8-IKJ"!0"@%
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M@T/^Y6[F4S?6Y-PSQ9F68.G%J;Z<&A_W*W<RF;ZW)N&>+,RS!TXM3?3@T/\
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MS5?3%;_IR_M-,>*?2=#\X?\ L\\ZAU]G.P% * 4 H!0"@% * 4 H!0"@% *
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MPX#^I71OLZNWTK&'QVHO] ;]\;&]V%3AG>2GA^X/ZE=&^SJ[?2L8?':B_P!
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M% * 4 H!0&K.O_((G[Z6[^Z05<OI5\!1?ZI2?+-)2_X?8-IKJ"!0"@% * 4
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MP<V"L(B*7BV$N[00! L9(\PS%*3:C^/G(8;)!KK"^(<!/NQ8>8A0%J-QI-@
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M2(JN!1*MELN-Z.,R01B ZB< ;[.9R4O.YV+8Q<MEB43$HB=4CX]\0"P PV>
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MFS)#VI:Z(U):Q5J<#.N3+EQ^W?/.[77GY!% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% >C+@JQ+L4@EG-)BDLFFUKPZ2HX28SUDJ,8S?CG R
MP+!NUL%Q10>T1%(P R '4<;98*5\;%[!B]1ZJ6SE(Y782>UV>[_PV_6[WZ[_
M -O%A:64=-.M:JF.DZ+5#?R<EZ*JS9EQ.&8BJG!M1$P5=_>W+BHUKD]!-;)^
MGQ0"@% * U0X+>SX;H/5<;6$:CS%N#U\,'D)<)78>-A;)N-NMS>(/5N2X^7U
M9?GVPQ^0;.J>>^&D%++C<6CJEAAJD83*2[P=YT(PPUNLC!+DQQK.7_NV)_\
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M8\4^DZ'YP_\ 9YYU#K[.=@* 4 H!0"@% * 4!"<O0&QIE4XR<RZ*N-U^0T]
M7U&$BLX\42GFT%,8MDE.5+)'CR>JIYYK/UL#CI"ZEG"IDDHIX][9AV&"+C R
MBP(5";*@D4 H!0"@% ?B8#S& '!#,#%!!01 PS1?$#(<MGGAECB8 Q- &2N0
MP.5^=C80,0.^5K<['*W+:X$.P/ K"UV9)MEL2RX>R7'4XW^]W@[E@9QOJ1I$
M>)[MBZWZ^7$8P"S5W&MF;88_L88!,D3  )$@"Q(L6+!2JQ6(1($T5 % * 4
MH!0"@% * K7JC^"]T_G*;F_TP9TK;K?AF_F97R3"JL?]$?\ .JK]IFEE*U"U
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H#SP<8-%5TJ)"9E2CQ'91
M=7V4-'DM83%,N?,OHGDRW7S7(J@ J!W-/.B\ZW*%G@!E;GW^HK@-&*"MH[5M
M>;569(L^5/KW/ES9<QKW5C<O,1'N5CUO8+D8O]D_,7^X.5-EZ,2G3)#9+76N
MBHJ*BK,3@9WCK!5@J[2P//'79GY"% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@.Q?#:X;1_8$^F37-:8;38/33=AV^WQ[#$S\KGR8U[9!AY6N&
M8*L<J8#O@:-87QS.YXY%R^5N088+)C%>O]CV>XGVU]9+M[]"^:#S0/TD?+TE
MTEEJW1]JQE2EN+4JFRNRDE%OK_>7D\6*KZI4]/()) DEI9(HFIB:4+)Z<G)Y
M8$F03R!,' N3)$B9? ,N5*%2X>(888>..&&&-L<;6M:UJVD1$2"7C]I2Y;)3
M&RI34;+:B(B(D$1$N(B(EQ$1+B(EX^NAF* 4 H!0&K&^?W[-[DSSMAWK/'G!
MV$)6"RS[;,;F9Y@B964<\\+<ZV.05K@86RRL+>V60/+43L+/U-=7!YG4W(LA
M'A*2"JB^.JI=@K4P$BN'=67'7='G;-K@W[6W+]?P7-N[ VFK<V!0"@% * 4
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M1<[K",#;!;:*X> ,13$<PN07]JIF74H6XQ)@F <!1DQ2!SS"RRL,!GE<(7'
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M/X)S]5Q5_0M'^<G_ /VCC[+^NUK_ #.@]FL.DU4YV H!0"@% * 4 H!0"@%
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MRYLOGU0N:!", "<W+#G@C88B!9\S/''/'G896OR7M:]O^VU:ZHJ+!;Z$'[4
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MM2LBKI1/8;K9YS%4P,I "F9(\P\E$E(EEU>V2M5+Y$44[;UB2* 4 H!0"@%
M* 4 H!0"@% >>#C!C*PD2$\5%?C=9+A;*&L$PHQA2@BTB%.\MU\U/?\ B7)E
MA G-C\G/L+D+G\F7U5<!HQ,K7VK:[:JILJ?*;7N26VD5JS93?(K,%K52HVT<
MKEA&Z?F+_<&LU=&)7"/D/1+72"2X834X&=<F7$\?;C$\\==F?D(4 H!0"@%
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M7WI=8FVY+K;Z74-:LN4<U5O<&[9A]ZNRE[O[%\VVKHV10"@% * 4 H!0"@%
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M;=>XM;$-*120VD9)2RY2R\Q#YMO1J8!5\PWRN$B""?''*)ES1@  B8$$PQP
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M_G*;F_TP9TK;K?AF_F97R3"JL?\ 1'_.JK]IFEE*U"U% * 4 H!0"@% * 4
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M_9C#.U#Y3^+F8@Z;&N7A6[_4Q-WLZIS"JVF[]F,,[4/E/XN9B#IL:Y>%;O\
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M/>,*DL7_ ";L_?VZ/]KPKX/_ +A/KI2?Z/3>S-*71S]&G_.YOLH;U7PHZ$4
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M?2Q*+,A*,WW+\C'%=-8,:M=8>CR4T%I.]]JJ8V6^3%45I3*M%A(3F>"Y9.(
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MZ98+^AU-WQ8)^4I+B_?178AXMQ<*[@FN[]*9<_NW[6W+]?[6WL&U5;FP* 4
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MRFYO],&=*VZWX9OYF5\DPJK'_1'_ #JJ_:9I92M0M10"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * \ZO%Z50%&*<0 I-.OW)-V:-%!D0T@**,%'@EF6
M[.5K%#9W/(%< !YO_B .0._,_4^6OG.B=;+JK8MN4RUIEI+)M%S5E.DOE)1+
M#]':YUR<B7\-GBW#\O\ ^X&8DS1B6B5"SL&V$3!5JMX+\C.\1%7VT-M+AY[J
M[H_(HH!0"@% * RJ$A+3G6DIN-Q*4%Q?7% JE(R,E%1CRDJ*1X; N3(D29?
M0<R:,CB8X8888WRRRO15@;-'1U5H54NBHI;YM7->C6,:D7.<MQ$1$V3UE\.C
MAT(NKZ*4E"4"B>N3ZN)]^2W*">38P33P/-'04$?'J@!EQF0!+AJ2D'>^/-OD
M6+9=0ZJ*:]I<N'CO]ML)M?=_X)W?W1YJ/-12Z$TJ6K:J,FZ3S675OMD-6_+E
MKY6P]Z7_ &K?%BKNK=>Q]I% * 4 H!0"@-2?^..;$>N.>(>>&32<F.6 I,51
M"SQNCG+98B)X%\1CX>5ODN#A>V0MOJ;?+>J72-$71ZO1R(K5HI]Q6J]%_).O
ML2Z]-MJ777DNJ:U9=HYJ+>X-VQ'[U=A+_>V;QMM71LB@% * 4 H!0"@% * 4
M H!0"@% * U(YCCW]MO*^(=\[-)ZXXYW)BYBXXY+# OEC@H6OU$J'G?"U\@<
MK<X>^..6/R Y<M+/1-8:58)A<RJKN"JK\+1WGWFHMR+5NO@BI<8IK._3&+L\
M&_8_M2]G8[VS?V%-MJZ-D4 H!0"@% * 4 H!0"@% * 4 H!0&L-'_=1O]\[V
M_AFOUR^B'T3._P!4M+_W&J,GW_63V$-GKJ#$4 H!0"@% * 4 H!0"@% * 4
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M9*F3:!7+:%>_Q:NG<D)E=43&I%LQ41R-<B.;?8Z+7(CD5$EVDUGQ]I5WD_\
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M $3=FJ^G>:OZ8K/]/=^T4QK.^E+/^=/_ &6I.H=?:#LQ0"@% * 4 H!0"@%
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M4]>3";T93RC=VE2*F6#-%@'(P)$06L^V:M!A"6L835=-(J)02UPQP Q,<L;
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MU&_WS/7^&2]7+Z'_ $3._P!4M/\ ]RJS)]_UD]A#9JZ@Q% * 4 H!0"@% *
M4 H!0"@% * UET?Y!&_?,@?N@'7+Z5? 47^J4GRS3)NSWE-FKJ#$4 H!0"@%
M * 4 H!0"@% * 4 H!0'.J!/[2/B(_R1Z&_N5LG5S5_0M'^<G^S+.(L?Z\VW
M\VL_V*HZ*U3';B@% * 4!7?:/:J$M,H@6YZV(7G6TXF;)DN"Z'<UXHEN70FL
M7, &Q[+;H2(<8S_<#<:A;$GE@86#I0!**C" A#& Q!P<! *LQIQ>]!I=<#M9
MC#E"3%"06;#J9L";BU8U1VZ9TNN6&%GK?)*D6,(D><$M^29D;I\ V$.&(TDI
M;SR*B8C\WJ.5A+@;U!_$[T6V.U;E/=*&Y\3'9K1">3Y#E.2#+*DQJ9LXQ'#;
M(.UWDU!EO-EMZ01SZ>WU0L8 +ETD890N8##*8CBYXX7 P;%XKF@\AZP'MST6
M=#*+K 67@6PF2](\23A$" ]G 9/C)!9(BPC+$:LIP2\=-+A4=/"Q:Q-8ZHI%
M3!3'E,EQ@@P,RG<3'4)1+*^-W+,R0Y49D+4FB1:Z]1MO69.RM&[<.HR<NR"T
MM?7=!2).#X9"4><!0(=61F^?(89BWM<7Z@3F :)KKQ?M"ML16 +K_(<Q/YN2
MB\S,=L62.ASN>U897'V4**!TPTO/@]=?6Y#Z8O!@I8]NMSBX7$N*'U*UKB98
MX7 ORS)':;_/O],;)E7'.Q@^3,</(%7:CL:]B3L*MMLNX0LE#.A$1@'2D"-]
MX)XX*JDY'DD>XV001G,4$<,,#>: 4 H!0"@*S2Y^'36?]L9+_<%#KM]'OJM;
M?X%-[]YQUN_62Q_PZCWC"I+%_P F[/W]NC_:\*^#_P"X3ZZ4G^CTWLS2ET<_
M1I_SN;[*&]5\*.A% * 4 H!0"@% * 4 H!0"@% * U'+\/\ I_\ RZ/7^B;L
MU7T[S5_3%9_I[OVBF-9WTI9_SI_[+4G4.OM!V9XQ.&;*##UXA'CFZ(S,Y"#"
MW(E7?3=-1A_6I<N(7F.9DC8B-VPQX?<$0,3J>2_);7=BTE##9JR.";3$M)M9
M44#!1-Y3=@*6\9C=Z48,W)XQ6$3;[SO'SA@2,^'](FO</-;<>2$ML$I=6Y@A
ME&F]*;,48R&*E'RP; <A^Z^UBQ')%"+GLC9Y.RSP+C! >CSBE; ;1)O#LWLE
M,H4@Z'X'3]6W_($![505OG,"5.IQS9HI!9@590FZV-:XI;J ;>SK,)H& 23*
M*H >ZZ#)865 #N8 @'G)UXXG!V+HZW;L^MWMN9T925P=N'7L.JD8NVO+R)L*
MV=DG0A14VIL$B=WR4+)P,/G\';(Q3%]YE$T6[?(#C'C!/([@#E<"#9?WWV1:
M.@7$*1A=XIU:3I@KBI:S(NOKE2]M9Z ?"5&4KLU;55YF-N4'_*"M-,N0VJ,]
M%451/ <:TO(YTD3S62P.%@[#X ?T].(4Z(BG^7'7'_$LFIR(\+<>36^(8R;[
MGWZDN0X_/Z+.A/EU<EO!Q-EQRRMMF2XB.+3:3BIM?7 %4LC!%\2Y0T3Q%'Q&
M O+!^UW%>>S^XB\@,694$38Z!3/$W;,D:A.F>)Q?TS!@IC!Q<.EB_"&BZM"R
MM#L01W$:TW +)#P).'*TCC.*R>H&S)T9,(F@/OX-TLQB^^-'JR[$G95ZSX\)
M)_N^3#PD=VS',+GD][&MFSFP#;>LX1HFJK_7%E:)*;76DQ9/&6L1,C%6Y< ^
M7+A%RQ/,$N!#_$KV<F6+=_N-ZTV3NWM='LGPVV>'XZN'U!;;VPFXN@+L^RL6
MA5=?C+C>"!W\.TY1[[2J^J9&659+44K%*-G#(:98,B&,3 Z!:W.^?]A.+1Q9
MXIMMK/)1SZXQ[HAL1$6L3(VH=QF.P]AFY$:"\YGC %MK3X<:65@I5FM0%:S]
M:Q#K5'S+K@14?,F8+IHI<#GGKYNEO2?B1UG8OW8D+.2C/"4VLF?B!O78:3'T
M^&KIUM\RYM=Y%@F1VJYPW9T9)/S;!0=!2V0VTI/!-)>)-7P03 F 1X8"$I#F
M^:&=PTN*/LXA<2"62;M0(_X<+/U?8J!QF'1M#/4:R7BN18V]MGF?'@;<>66$
MG(LWO$->/H98U?)8NC G+8IZ$6+YD+@=5.*])PVN4!:],^/=P=^WC*6X<3;J
M;1Q?*#<VSD=L0Y@YF'H^U'V03D1QPYFDR:Z$Y0=;1(*<6Q^B.0NU0G*[%$ZI
MAJ*-8LBC <O)DXA,FO@OIN[7=Q")F8CAD3^[X3[,<A$&3N;(,1)#JW"CN-)6
MSB%Q'6HR)':J"E2ZK/=F@BXETXH245XX2S+&<#85S  @%X. INZ_Y XB<(Q2
MZ-SI/GUO3YP<FA.LC-24=H';-284W/*3D7N^";5;#R>;G38Z>J5'61ZQQKH(
M"5@32RF0XI.V(.0E@/;30"@% * 4 H!0"@% * 4!775S\&CF_.*W _I:S;6Y
M7?#M_,R?DF%)H_\ H$SY]6_MD\X!_P!X<8[HER<N$>VF[#.W<EM2'MX8XG.?
MW1K)!&W3O,QK!99?2TMS.M/EW65D*"XUGNEE4@V,5*-Q9!>Q+F@G"8 >0A4?
M+3+LH:R&4L05OUQZ76U]<>)<XH2V$TB;T+ZV/A_ZL\2_8EWR_)R+":2P'$VR
M<FRY'$E2BO%@Y%&'*)J@O*MDC!*P#$)&<4<N&($!/,6Z0R5M7_=:FWJD>B*;
M(MVSUQ8*V\6 R)3AJ8(<E)M[$PI("W,32+,5"?C1:ZVY1GRUE?M&G+"0"H)8
MHZT.6#,6.E3(98#T.<.[&;'#JW'$S[.LTW'VS6PC;:$M3FR3Q.R8;9[L.,5J
MM5(:PZ((F)1QLGT=F-9,[9)9@+$8BMB'L,\<,KY!X@7CH!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H#RC<8P[@;FUKX8R(*^[E,7P5S3Q4H=-LPLL%PC>[,"
M%&&%Q4PT_G<^QC"V&&?5.2UODK@]%JAL^MM=J6HZTL"U)C58LM9?,X-;_P!J
MBJJ\(C+^&D$7"O7#\5_[AWX5OTB</PT&3DA"'!^.W\GW87X]TX^UV!^>10"@
M% * 4 H"SVGT=3W(\]LA/UQ,**-(R,HA+@#O*B"%DQE)A83 %1<#E.6!, !M
M\, Q<$P7%#&Q4,1NM+ CY#V!SR:BJOBWSL] ;)TGM?2>FE:)*^7:TMZ/2:EQ
MLEJ7'/F+!4P(+!S51<.. C7*Y&K[C4D)2+I28 M'2JDL IY()6421+-,)GU(
M,L'@>.E$X0V?$3RIHUCGF&!D.-<+#*V-Q,^3G7VC^D4ALYLAC:AR/J$:B.<B
M8*.=#QE1L78**L51,)8)<BM\R%#U% * 4 H!0&K/G# 1E/ ,3#$7 1K.##,/
M,G91P$PS23>.6&2?<P4L>QSM?DN#<4*PMOJ>?CR\MJ;2)K7Z/US7(BM6CG(J
M*W#BG!NN8&$W#CY.$W"O821B:U8B+2346]P;MB/WJ[$4CWHI';-IJY-D4 H!
M0"@% * 4 H!0"@% * 4 H!0&K&\,+O5OB7PQOG@UGAAB)<G;//# 168V6>&*
MAUQC<KB)</&]P>I9V'OC;+GX=1Y!*:>UJZ04KH)A)1U21P8P19E)%,/"\6,$
M\7!7#@BX3<"#M9R)SMB[/!OV/[4O9C<[T+NVD+NTU<FR* 4 H!0"@% * 4 H
M!0"@% * 4 H#66E_NHW^^9Z_PR7JY?0_Z)G?ZI:?_N569/O^LGL(;-74&(H!
M0"@% * 4 H!0"@% * 4 H!0&LNC_ ""-^^9 _= .N7TJ^ HO]4I/EFF3=GO*
M;-74&(H!0"@% * 4 H!0"@% * 4 H!0"@.=4"?VD?$1_DCT-_<K9.KFK^A:/
M\Y/]F6<18_UYMOYM9_L51T5JF.W% * 4 H#B_P#WA9]L=C\';>,%Z/)J- 9\
M1"IL1EA.API" *[WPKC 'TEFM<-6.%,E]UJ9!(-CETXI88X,"5&SP#RQ#SOB
M!YX^'O.#!C_B?Z]2D!L9'>[$+)/!\8"#/NVTBK;!))_#(0FFP#BJ'"&<GQ0'
M'^N".BKL@X%$T8!71KO8'-;R .J(@H9X10 I=%"RWM:6MN["K(?\=X:#;Z\*
MN/N((#*19^M$%A-6;8FB90BM\1HA+X!^R-A)DA[S73FNI-ZXH:UB:#+IERMS
M.=L,P)5UJ&!='#5_NX>R"$JEI6UPX=NW\B*^^;4CHWC(2U *D\IR,J<5RM*\
M>M 18=Z,2C).Q,*PELTX0T$F+0)G +(N:PRS ] J[QF6K*FVDJ1&QXFU*D?4
MR(]?79*#FXH37W03G5"\4,EX8%6T-'CC7$_6XXQV+/KH7;)N.;(,/HM8X3R+
M#Y'\LN8#8"B?]T+9Z4\=!3*@-LP=D-NHJC-T=R-I8HCQ8ML>/Q9)>J K-^05
MUO(:$0D J=?S=:2J5P"=XZT5/$QC':JY(#$X": [P:(<([4CAVO^2I,U^13(
M3NE9!Q072IJ["U\0#(  CT7WJHV;9^)X1C%5:R*KF51/)CM\B8 :H91NI68"
M6"; &-& .G] * 4 H!0%9I<_#IK/^V,E_N"AUV^CWU6MO\"F]^\XZW?K)8_X
M=1[QA4EB_P"3=G[^W1_M>%?!_P#<)]=*3_1Z;V9I2Z.?HT_YW-]E#>J^%'0B
M@% * 4 H!0"@% * 4 H!0"@% :CE^'_3_P#ET>O]$W9JOIWFK^F*S_3W?M%,
M:SOI2S_G3_V6I.H=?:#LQ0"@% * 4 H!0"@.>\.\.B.H5WNV<X@3?F2=UV4=
MM&ZS6Q*L>.@W#8\08)D;HR&W(Y[UTY!AAOR*CF64WD2Q,OF(Y3-CF!D810L<
M'ZB*"!T(H"(9^A=L;&0G*4#O17=Z$T9<9#@8+E5F$X1VJ[B:(Y2 J:I9HBX"
M"9Q*&1"H^6&6 P)@J8"RR!, C ""!9@4ITDX46L6B4BNZ7HN R6Y.=[*QC<R
M[<H<U%@G @P\EU/<YQNA-#3'6K5V/EW(^X$DJ9$4EM(55D.Q? $$X$6Y0;@=
M-* 4 H!0"@% * 4 H!0"@% * 4!775S\&CF_.*W _I:S;6Y7?#M_,R?DF%)H
M_P#H$SY]6_MD\L56F78H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% >
M4OC(=L_/6TNV/>#U+J3W[7=Y/6_7W6/;TCU/OXZA]5WW\O+U?JGU?,YG+7#:
M,\[YY:W.LV8&<YF!S3!P\"#8<[A_ZGRXW88)^+/]Q'"9_H^$X&'!SH<'?AAM
M^$_^IM]R!QXKK3\\"@% * 4 H";]?-?)*V8DI(C",$BY]7/WL95%0S84)":R
M$$*&&?<;C/AABV(I9&PN-ODQR%'%RP!!P$&$##RE$5RP0Z31716V-,;8EV-8
MTO"GNNN<L49+8B^-,F.NP:D>^Y8-:BN5$7V5:G:G1KJ-&I9C,8M8^M'[%CKY
M?)TL$$NO1=""RQN;-WQR%N12"-Q<\"!##/((H%E?Y1!A!QQ=EK4:D$/Z!:#Z
M#V/H)8Z699B850Z"SIRHB/G/1+ZWX-2*HQB+!B;;E<YUHJR.T% * 4 H!0"@
M-4??-[QWES^I\SO4<7.ZKU7J7-[4'.=U7J'[/U/D_P ;F?5\GZGRU2Z20U=K
M\*&#S*?&,8?!.OPNPVX7=JZ:U9^B38WN#=[U3:ZNC9% * 4 H!0"@% * 4 H
M!0"@% * 4!JASF]_#=Y>I\_O4>7-Y>J]5YO;=B<[F<G[!U/EY.=SOJ^7F\WY
M.=5+/AK%2WL+F55MQ^%HXPV(7HQNWH7(FL[]+9M\&_WTLVNKHV10"@% * 4
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M_<)]=*3_ $>F]F:4NCGZ-/\ G<WV4-ZKX4="* 4 H!0"@% * 4 H!0"@% *
M4!J.7X?]/_Y='K_1-V:KZ=YJ_IBL_P!/=^T4QK.^E+/^=/\ V6I.H=?:#LSG
M)#?%JX?.P6VKZT9AO8'%^;11HIR&COF.$N+)J+D6^?BE4$1'^&9D54C@A%I@
M%OK(=RF0P"V* 8,WQ#+YBYYXVN!T;H!0"@% * 4 H"JZ+NIK@O;=.K1(B]'
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M3-BY)09 WWC-V:UGYE=K*F"/XS7&:Z)"0V:D* .;J"5!+AE"YH@&;PS#,E,
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M=H_7M6$%HYU]'*GP;MAB*]>\Q%<MYJ*L#7K/T2;')NV_)7:N^"[M&TU<FP*
M4 H!0"@% * 4 H!0"@% * 4 H#5C>.-WJW\OJ>=9K/#&W*$;OGS<E9C7RYHV
M =R >/+A;EQ$SQ&SOR7#MECB+?&FGHFL%*ZY'F=5L.C\)2;*)@)>O.5'+<5B
M*B/AKN_2V?FW[?E2_6\-W:V3::N38% * 4 H!0"@% * 4 H!0"@% * 4!K+2
M_P!U&_WS/7^&2]7+Z'_1,[_5+3_]RJS)]_UD]A#9JZ@Q% * 4 H!0"@% * 4
M H!0"@% * UET?Y!&_?,@?N@'7+Z5? 47^J4GRS3)NSWE-FKJ#$4 H!0"@%
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M!0&HY?A_T_\ Y='K_1-V:KZ=YJ_IBL_T]W[13&L[Z4L_YT_]EJ3J'7V@[,4
MH!0"@% * 4 H!0'/J/.'9'\:[_3;Q$D>:9Y494GY@MJ,W]&BT9A86&.\]ED$
MLDSD]$3DV%$N34X9N")=C 0^3I%&,##"6-9& NIA!@=!: C69HK;TY1')T,.
MQ1="0UY78+MCIPJK(<2@T7@FHKQ0SR I'FRYDO/ \AKA4H?SS+&,.=U,6UKY
M8YX\N&0% -)>$7JSHI*BO-L8AC+\HJ<<J42EG48AC3N#[I; 6W UG2NHN2%I
MMK#K V76;5EUE)8^2DXB2TJEK%KA%C( (Y@,8#J30"@% * 4 H!0"@% * 4
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M*ZZN?@T<WYQ6X']+6;:W*[X=OYF3\DPI-'_T"9\^K?VR>6*K3+L4 H!0"@%
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M3';B@% * 4 H!0"@% * 4 H!0"@% * 4!6:7/PZ:S_MC)?[@H==OH]]5K;_
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M648@EM@F@B[@:#P3VHYWHU#?*$8",$U)'6%5(4"XG.+&Q;X"8X 6_H!0"@%
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M.OM5Z?!N^\;!S_P4NNO)=4UJS]$F_FW;$?O5V$NKWDOFTU<FR* 4 H!0"@%
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M#<EU.8)%9!EB(BK<,/')!'CF1)+;RNUP1G,$ 7.6/AB#B@BWL#8*P8@@%WZ
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M+4@>2W)KM)S!V>8S?8C.>@NRZ:W1H,CU%:(2-DKN(%S+R.J%"&=@"A0\J_\
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M2''K;+%$Y"C9)/IY%#9K6&2"3ND@HDNT9/*CJ"N4+.AQDB Y[ B"?-]:9&S
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MH;TCYO24IN-H-M19T?G)>V+V/V'+16U5@%)*K#>AU)V!EF3D>'4A7((! H;
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MJ4U$G=H63QZ\F,T>;G_QEW4I>,/-QI-[ABCZA6SW4IJ).[0LGCUY,9H\W/\
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M55?9M10,M*R6OGR)DM%6<KD17L5J*J<'=1(Q5-F\><_2Z1-DOE)0VDBN:J?
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
..!0"@% * 4 H!0"@/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>gdc15tqwxkbk000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdc15tqwxkbk000005.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_X0!*17AI9@  34T *@    @  P$:  4
M   !    ,@$;  4    !    .@$H  ,    !  (        #P     $   /
M     0  _]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$!_\  $0@!60$S P$1  (1 0,1 ?_$ !\  0 " @,! 0$!
M       '" 8)! 4* 0,""__$ '(0   & @$! P0)"PH/"0L-  $" P0%!@ '
M"!$2$R$)%#%!%18W46%V@;7P%R(V.'%U=Y&AM+8*&",D-'1XL<'1)28G*#(S
M-4)%57.SM^'Q0T1'5UAD<H;4&2DY1E)696>%EK)B8V:#E)67I*:GT];7_\0
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MKH*UR,O,STW$Z>A74/2&CV7?*.E :*/VD=(3C]0!*K)V*0BXMY+O#J+K,$1
M.U%%+F$3")A%27RDD'*67@+R_@81LF\EI7C]LII'M57K".37<J5M[W:1G\HZ
M8QS0#B'3OWKQLV3_ +)5=,@"8*/$89*G#Z^GB ,M11U4,8<0 9)8'L8"3D 7
M.%R<@%\O%V.'2T@7TN18+S!?KG*1_B>=_P#OO6/_ /HF>;'][!RL_P";<(_U
MW1_6L$_D_B7]B+_S6K=3P\U%NZ?X+<+K-J]IKIM>=;[6W5M5* VA8I-G796N
MWG8>]$XU \]KR,O I/SP]WCI0A6J+QN4Y%&CA9)8IP+Z*;*8?4X3LOLWA58U
MK*S#, P?#ZMK'B1C:FCPZGIIVLD;XKVB6-P:\9. !&16<4[#'!!&[)T<$4;@
M,[.9&UI%[YBX.:[NY^3=V9;YZH7>6MM0GK389BZR^YX0=G<B=<49BZO6Q(2\
MK+4V+U%:J:IL5M68Z!CJK'P>S4V,3."Q0LSXD:^57CLOUO/U:7^GRJ;WT!_A
MY%:O:'$R;O>S;3?(Z<KD<6:_6SIQJZR+_P!G8Q'1]AV7+38IO2-EU$5)1M>6
MJ<**;Q0Q'#9X+U1$IR**Q1075N!^UV%4OS"1MNLJ];XC6%/UMH:STQA+G492
MFN=@VG9M)VCL$LI!H@C:6%CL**'L+#HSL>U:)2RR<HZ-.N&J!._U^A=M/\%+
MX,K58VLSFM35.>JNB(;;<]/M9@;U"S6E-LO-R.+%K%-E#JQKY[=K+(O4')IV
M2KQZ\J*,\T-).TPC\(MHV$3")A%YN_U3CK*[[-X;<?FE&AVTR[KG+6 L$JW<
MV&L5P$8H^C]Z0(.$G5KFH)BY4"2FXY(6C=VH\%-51P5 R#==1/+=A\8HL"VE
MH<3Q!TC*2".L;(Z.-TKP9J2:%EF-S-WO:#;09\%9-HJ"HQ+":FCI6M=/*ZG+
M ]X8/O=1%([QC<7#6FP.IR7BG8\6=_2S]C&,Z%'J.Y!\S9MB?5-TZ/;7<N4D
MDB]E/89SCU.< [)$SG'T%(81 !W'CW*5LKB&!XQ0T]15.J*W"ZZE@:ZCF:TS
M5%-+%&'/<+-;ON;=VC;DZ76!87LAC5+B6'U,L< BIJRFFD(G8[[W%*Q[R&C,
MG(^+_6-AK9?Z:%DU-R*KFYKA;=)6'3[*D;>>49_L-QL9G;)"U51Y5 2BI1>F
M0D&BE#V<L_64A9H-YVQ5HD-*J!( I(H(^9K<WK;"@6I\-][V&"@M4[?M]#JV
MJ*));GDJG9M)V2U?5:EG&TYFW+,73]:V4EK7ZD\@(BW/"][&*68CB0(00("1
M"K8[]_0G?OFK(\1>-,OQAK.QZF_V1/[%C+1M&;N-74GF=+8+0-<>14)%QL6=
MK1Z%0(=%\"44'GZ32+/&)E2:%C"-2 NF<GDMWZUK0\OYQ^WER"X]<=(K1.J;
MEMV<I7)IO<+) 4=@WDIB.K*FD-T53V8.T<.V8*-$IVRPC%8R:AE$S/DS]CL%
M.8MGQVCGK\-FIJ<-=*]\+FAS@T69*UY\9V0R'U+8O)5M)A>R6VV&XYC$DL5!
M2P8A'*^&%\\@=4T,\$0;''XQO)(T$C07)RNO+9)^3E\H1+LG$6VX3\ATEY G
MFB2SRIQ[=HB=P8J8*.5SS@E103$>VLJ("":8";H/3IF'8?LSBM-7T=1)%$(X
M:F&60B=I(8R1KG6:#GD-/,NDMK>6_8'&-E=H\)HZW$'5F)8)BE#2M?AE3&QT
M]5130PM=(X68#)(T.><@,R=5[[N0VL;W>6VM[?JE_4VNS]/W]*\U)E?E)=O2
MK E(5V?I-FK]A?0#.2F8E-[6;3*.(R7CHN4693+./[Q@NT5<]G9*XH[]^_F5
M4K1H/FU-6Z8NB5CXTN)S9>EY;4%]=J'V/$MJ*UE['(OT)"BQB=>FRW=Q7X60
M*BDM97U.)8)-J"KEE#-G!B(N_P!:+)]?\"_J6\B:)NFI;HV.[KT!67<#/T2Q
MJ4)_&N"-*16:+6HV#?):T2M[:MQ\97$ESQ+^\."-'Z[M[&"@O*2IG9/)Y>^2
MZ/GMP]V[RCEZ0MKJVU*OQ,-4K17IA.=M>PJ-),964M-%L$3.LY'5[)*8NT01
MK69.-EM;7.=3US(NG418)2NSDQ"1"\8[ZV]2:=^]EC-O\G_<+/7G$:C;:3'2
M3IARF(^="PDW+68=;SV'K*^UMA/I>9(JS%?;+4 [.YL7*G[>3=(>9D="4QTX
M6R-^-_L\PLBR^N\3=QGU)MEK/OM,U7<=MWS5>1=';T-"RNM6PUUU[/5&TU>(
ML2CZ$@9^0B9F3J*4?99)K#E?H1\FN[8M73QF@DM%/+QX]'?ZK\5R;#JKG/)7
M_7.Z$W7%B0OM2C]C5]>G.9?:D+3HBOW%"O$C@86MM4)F=M,HU<PR[IXN_K%6
M;@F[39H)*]P+I4G?OFHTK? 39]/ONKY*-MNN9N-JK/7KF0VG,!9V>XZ-*P4C
M,SNSH'4+%K'O(&)HNY)N746M,*O88I [7NT)5E8#1T2=DS[]\O2G>W#OT+;)
MA%JK\H%$14YO_A''S49'2[ [KD8L9E*,FS]F95+7]9[I4S9VFJB*B?:-W9Q)
MVB=H>R(=1PBK3L:F4Z"O_%&0A*G6H9^7F!H9$CV*@HN/=E25GW9%D@<M&J*P
M)JDZD4(!^R<O4I@$/#"+XF;?6KK34DZY 7RTP]\YA<J=IUD[UG/2K2EW*JP_
M(^'&M2B:@@+.B7N,/1K)3&1S(Q1["QMG=.0-.PJ)1ZM3VFW<!0XWZ.SJ^KMX
MK.:-N+EAL2,J-<@-\;77@K+L1FTE=R%TMJ.)NT2HWXP;%V5=-?QT;-Z:/048
M&L[AK4%5FLU*:]D9WV/=KUE>S2\XLC/@[]_X'3-1\G1;7TC7KU]"G*Y;KY#6
M'COKB0D=*VAE/N7O&.7D]D/V>M)R%G)J1V;KE"VBUUP62EK97WR#=Q+2H/)"
MFQ;>N';&>L'K%9FT73(H:TCLGFH$WJ:6OVYMD7./L,7I9Y::S,Z=U)7H87NT
MM)7&Z6Y-9S6=5PEBCVE-MT##LH)NG.(.H]1\[86I[83.F"#)Y;_P3R=/K\WJ
M[-5''U7N?<%26=T-N3:%MFU]8Z+N)Z@XTAIYI''M&W*;LE[<81-*)U*RGRQM
M&D*E77$%&&EQFV$K*/D[;,6",?Q<+'0/:>G+U:)Y.X.OE\UNM26;D=R0W7,O
M&&L-E["HU,5V(M#L;K7]1TA255BZWPSC=G2;2,+LO6=FBPC)#>:,E"24C(5Y
MR].M[)5F"?1O9C56KC;09Y^33SGT:62]A<B_4.VWJSU^I99K/D%R6LN]-6Q$
M]:+8B]F)B@QT]I$VL*ZRI$GJ*7T*\M%NW8^N)Z82X1%JC=O$9P*"+38#*I,T
M%?:LXUX[DG:5@:KY_9]GV9]B</I[G^/3DJ^6?EURU8.-JQ-2V58)^[,JZ,M<
M:=/ZPK-:8<>6[C?3.B2TO4)R+TS;9B6C:OJ<Z]S;/[=5]Z%3D"K6!]#66&2+
M4,'OWL?2#YDZ.COWU"D&K[EYIR]:IUE=[<L,@A4HBI6!?VH:UJ<A"[F92G)"
M(H+]K<9>W\>Z%.'(.NG4DL,EK"F:?(=9LWM+-FG&@JT7CY?M[Z\$^D^89G[,
M[^?-99L'<.X*SO3;=>?;0N?'_7 ;7L#NH6^C:(J=_=;(N##7/'T:_KV?;S%"
ML:\[!RY9>WBN[AW59NLLI')1,7LF$;01&989]G5DG'0'MX:VXA;@&"JB[%DL
MMVA66:-U51.U48G%0Z)#'$S)5195H83"(BU46540']B.H<Q!,,45!O*O!U\F
MESH ?$!XP;> 0'T" U"2 0'X!#P'('0]A]2MV,$C",4(-B,.KB"#8@^QI<P>
M';P7@R"OP(A_<2'^2-9].G7WNXZ=?D#Y,H=X])\Z\4ONMBH)OB>(WL1^.5-[
MVZI<LN.?3V>HWB-0IW8ODM?)P5*!UK1]K).=Y;/]DZ-LJ3FH77$A$L[GR4,3
MVVR<#3+ZZ81C)PFS58F/59%L,HE'-Q!N*B:Z5<W0?D\>SO9>R>P;W/V&V+>]
MSG/?LELTY[R2Y[G.P:B+G.)-W%Q-W$FYS.JL8G%<S>-^L]OUFK[(D78Z1US1
M'5.HE;K$'(ZUB5=L[#V-*6@T7<[3J6][,G(71=,/"05)391GL:RC:TPD9S7$
MI'N J16=N_U>;)99E?OZOM^M3UH_?7+)SQS/+O=?R&_+89MM5:N[DBI"J1,
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M7Q?@Z:MGK9=F];H.V;I)1!RU=))N&SA!4HD51705*=)9)0AC$434*8ARB)3
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M4<M!B$#*BGE&;7@%S7V(:^-VL<C2?%<T@YEOM20:FBKJFAJ&5-+(Z*5IR+2
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M<ZAG@?#S(+9&\XPEKGAX9*]FYSYA+XV;S(7R-C+FEX=</! D#!5C+N3>X\X
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M'KUUL;'A:P-S<Y+V._J6S2 HM.16_)!DLD=0E6UW!JN ZH+E/Y]/2$A'&#J
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M+ED9G"S0-/:-NXVT.Y<6*]2A2E(4I"%*0A"@4A"@!2E*4.A2E*'0"E*
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MH55)A%^:R*+A%5NX237073.BN@L0JJ*R*I1(HDJF<#$434(8Q#D.42G*(E,
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MS77H:^)[;N(CJF/C<T< )81+ONMD3S40.1R6O>V>2S\HM47_ +'N^%W(Z84
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M\'W#=PBJ<0GWCND'QG4=.-UK[D. ]F2L!&Z0\%7NDY/GG<=B&(M&0,D%%%O
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M_9*8W9Z]D!'P$BIKR]\JQIKAQMDFH+QKW9=IGC5B'M)I"II5<T61E-*OD6R
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M?9K3_C37_G9IA%H$\N>/]?&/X'M?_G=E]?OY2S^V'Y(]97F3X67PKCY,X/\
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M9C/QBU=>)5&**XB%8^UV&V6AFHQ4 R"C>QV>P3J9BB66EW[_ ,X<J AU/:5
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M@'4?*FTB[31;-7#A=IN-I;FQ%L[#S9])YN>2"Z@5\.:8 %;XN    !HNO@
M'0  &$0   !X  !Z SI;PA"3A7(V222>3G#"23<DFFH222<R2=2K[C( APD
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MF+YRE56M$>[AIK\*VN_TOA\TQR:_"+L#\M=E?W[0*U4/X[1_G5/\ZQ65\HB
M!R&$0  $:+6>H]/$>B\OTZCZ^GJ][-N^%2XGE2W220W9S"-T$FPO)6WL-!?C
M;57/:( 8C<  FGBN;"YLZ2USJ;7-KZ74K<$  --<HQZ!U&NH]1]?0*K<NG4?
M@ZCT][J.9MX-9/\ ('EC%S885&0. O@N/7L.NPOV!5>!#^9XH;9\V 3;.PBG
ML#QR)-KZ7*U?9QNL77J=H?V#TSXJ5WYH9Y[/;-^]W /T+A?[# MIP?@(?BH_
MU LKR]*:F$3")A$PB81,(F$3")A$PB81,(F$6E#RE5_M^I-]:HOM?F=U52.5
MU+;8*4L.A8[3J]J/V+/'296%C=;NT9O6J^UI%)-1ZDE'PT#+(/RF<'DUV@F;
ME(MI7'6U!>M"Z;NA9B?L!;7K6FV L[:CU96R3!)>!8OBR<ZI1ZW3Z:I*O2K
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M_>I= 1GY%K,^J9K?_C!I'_O7 _\ ;\Y!^X>-?YGQ3_5]7_Z*QGF9?^2D_P#
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MWO=[N_6VAVVL-PPNI-65]ULVES["]4#:NU:U;:JZ"X["TTSNC" @Y6HP:CI
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>gdc15tqwxkbk000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdc15tqwxkbk000012.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &) F # 1$  A$! Q$!_\0
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M00KM_,N/S?5VOQ#'&S<D(C\V2XH:U!8IQNLC6*C5H:\=K'/)&$>2&W!*V/\
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M'CZ)KR/R@>)+; =R1W.H7D/)]P'C:DF1XDNY.9(MNME\]Q?G(W#MV4F<92K
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MG^JH]G+_ '9N@O\ /R,_ZV7_ *#S'_1UO_V+:UO_  @\$?\ 6C#?YY'\]/\
M54>SE_NS=!?Y^1G_ %L?0>8_Z.M_^Q;3_A!X(_ZT8;_/(_GI_JJ/9R_W9N@O
M\_(S_K8^@\Q_T=;_ /8MI_P@\$?]:,-_GD?ST_U5'LY?[LW07^?D9_UL?0>8
M_P"CK?\ [%M/^$'@C_K1AO\ /(_GI_JJ/9R_W9N@O\_(S_K8^@\Q_P!'6_\
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M\.NGXA@]=-5>I%=0AM[PU!#9S=*&Q%'-$_G//'*H=&Y:D[+S*P(.S*&&X[,
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MKQD(J\77=J13(Z#%1RLJN9 55#F&EO*I@)0RR3YEE=@[B2C;8.X&P9ANP9@
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M\)IG3,U]G&?WZQO_ ,4Z^/\ R=_EN,O_ .'G%W^HKJZ^Q/\ ZZ+PE?XU7?\
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M,!'"E*"'G]*7(4J5RQ/,S,>>0ETA0 *L<40Y1SR2L_N'[.K^H"X)OV*/#_\
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M=O2?"Y%%'?;NS,% \22 .YURGRWQ,?)=Q3R@L0F(8@#<\J9_%.[?<J!F8^H
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MGUL-A[!^ T[OW_#^/'3]_P /Y]-A[!^ T[OW_#^/'3]_P_GTV'L'X#3N_?\
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MJZ?O^'\^MOL/8/P&G=^_X?QXZ?O^'\^FP]@_ :=W[_A_'CI^_P"'\^FP]@_
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M>3K 7&LM-)?!MK*LXADJ5T;K8R+$RLD,%*.&(O6A5N6&-(UF9W1%4A!FX!#
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M?%(L1O.]-E\XA$W3/)#)4ZY:411L7:!XXW*I(PL2V!"G,:QLE:>2N:'D'O\
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MC\*4I"E(0I2D*4"E*4 *4I2AR*4I0Y !0     .0!Y!F (U  '8 ; #8  >
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M:2"9EW*RSA82$ 55U5%3]2AS&'$?FE8O+))(YVW=V+L>4!1NS;D[* HW/8
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MM/:Y=[,P=M^541)=P9C<50QDKX_*5L[=M6GESF<@L06I,AEN56G,TL#R)$L
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M4X=U.'*RLD(Q:R4^T*TC;"V<1ZU39,01AGD)+P3^G$)$RL8NOC+:SD5F&%&
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M13=D,HT.JHR77*0CI,AU&YS" +D*8Z8F* CFAFKV*Y G@FA+<P EC>,DKMS
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M4C/(ZIS.\CN5ZA4OS*'"JYCZS32RRMR#V!]P9KM;?3D'L#[@QIK7AQ%@'^J
M]F]Y!^=W&9S\@_X)Z9DTPG]1W&_]LX8_E"UJ!Y_^KGR?_P!KXM_DRIK8?R#V
M!]P9"]3S3D'L#[@QIIR#V!]P8TTY![ ^X,::<@]@?<&--4Q[+Q,=Y/7S5 _E
MR1,H4S@PCY !&Y.I<XB/ER(F8>8@'VYBSWJ=;M/8B1O#DY@TI/L6)>:1C[@I
MU0TB)]I@#[-^_P" [_#7:9HV27 #0=-GGJ1O,CIZBA!LU"C^C26EE6QU"?WQ
M$1 ?4',?+,NM5S>0 ..P&3G0]UFLI'C8&'J9)+SPEU/M5#[MSVU;,^^_(CM[
MSLH/W%CO\-_=JN)4;9+KD(158C '['\VZ<F /?Z/C%2B(!]@&$/8.;:/A+B^
M;OYKAZGNLY&:5A_FM.1?P;;WZ\ZDG?9$'LW8G^)==TNM=AF#ZTC2DA^T"I3:
M_P!PF*AS_P#A^[,D<$<5'[5WA]/N3(R;?K(BW_ :\YYO_-?@Y_VC^/74>:ZM
M[)6'D).4K:K*.L=<=K),&LDDZ4Z)MBF4J9UU3I!]94!-U!^2 \AY\LMR<&YV
MI-CKER]B9*]3+XB>2.M!<29N7)554(TLCIXN-^8#L.Q!U2QF;8-T]N93Z(8'
MLP]I(_5\1K)3.R:KTQIIC33&FF--6O=;K4]<U2=O-ZGH^KU"L,%)2PV*66\/
M%P\:B8I5W\@XZ3%;LT.LIG#A3DD@GU*JF(D0YRW(HI)Y$BB0R22'E1%^TS>H
M >LGU#6-<N5<?5GNW9XZU2LAEGL2GEBAC&V[R-X*B[[LQ[*.Y( )U<B2A5DD
MU2=8$53(H0%$U$5.DY0,7K25*15(_(0ZDU2$4(/,IRE, @%O60"" 1X$ C<$
M'8^T'8C[B 1Z]4=:S5]O-&KKB78MYHK&/DACEURHKBRE9!Q$QJQ.]Z2'\=)-
M7#%LF0YEE7*?=%3$QB=5?3<KSA24W9>8#<;JH9A^I2"?=W]1U:-B!9C7:5%F
M"1R=,G9N261HHSW['GD1D4 [EAL!X:KF4:O:Z2LE'MWS.,7?LD9*12=KQ\>J
MZ03?/D8_P_CUF;0YRKNDF7BVOBU$$SD;>);]\).^3ZO0K$%@"578,P!V!;?8
M$^ WV.V_CL=O#5!DC5TC9T$D@=HXRRAW$?+SE%)YF"<R\Y4$+S+OMN-=W/-5
MZ8TU8&P]J:\U/$>G]D6V(IT*#2PR!Y.:6.W9I,*G69BY69^NN5,Y&[*"JL!-
M3\H[7%-NSC(UVY64*1(<O0UYK#<D$;2-NB\JC<\TCK&BCVEY'55 [DD;:P;^
M3H8N+KY"U%4AY)Y#),Q5!'5K2V[+LVQ"I!6@FGE=ME2.-F) &K](<BA"*)F
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MLQN?X6R[_B=]OU;^P:N!KKF_O^0NW=;KJ)N7,$O&SK],/MY@(1S$1#U!R5.
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M'S&*-%M<,7'5W^D5$@:3A^RD8$:1PQY2;EB+B=K=%ANS9OD*VJC4G$JZDH^
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M]3.Y6;)YI/%)<)PW''?EIS >$5[(/CJ['<;CF7P+$;'RE*0I2$*4I"E I2E
M"E*4H<BE*4.0 4     #D >09"-F]A_ ZZ6"H[ @ =@!MVU^L;'V'\#IN/:/
MQ&L#-Z<$\9-VQOOWA@E(+AWXIX-0SE"]0\+W5'VLP.;KD*)OJGPQF3:\5B>
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M>'ZM0/I3A^1T?0U!D9->5MT[)5A2<.DZ<C"Q_*PQ)RQL2R,8J!BHFY YE%4
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MR1A9%$D$ZI)TF:56B99B\?EC=?R/EVGS=RL@CJ*D/DDE#$(\:[BUN1LY*41
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M@1---,@ 0B9" !2$* %*4 *4   #+)))))W)[DGN23XDG6:JJJA5 55 554
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M')UVB-$CBCY",)P44L%@#U<TU9K;DLB53[0,HT6( ^0IF /,,MP>OAP;:?\
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M]Q5__AKK<>4?^K[C#_"'*?ZU)K^DOPZ?U/FB?_0WK#]Y,'G%;G].6_[IG_\
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M'IXE&&,A@+?M9*O2*B02;XSS^Z+)6MY;$GJ;&5R@RMP2J=&MOTBC7EM@RR]
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MJ,:NLK&)EUV3-9XW%H[6:MU733K(IX9PHD0Z[?O""8A^Y5$R?64QBFZ>HHB
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M6#2 JMTKK1R9<5E9.1D6LK$J*D;IIB5!JU1!\C^,6[TZ_F*8$#GRT\56_F+
MM0&M!B\'Q'B8)C+U'N6[D-ZB\BQ(G+'!#&+,8YY"[2=RH WVM$LQ[; *Z[[^
M)(()V]GC[]9/9VO5W3&FF--,::8TTQIIC33&FF--,::8TTQIK6CV??\ 35[3
M+]G]:_X"=$9NLO\ D,+_ 'IC_P!9M:@G!O[H\>?X8S_R1B-;+LTNIWIC33&F
MF--,::8TTQIIC33&FF--,::AW9W]$&NOURL7[WG&<^XU_=+A/^[<K_)4^J#^
M5B^]OXAKHY@:RMA[!^ TQIL/8/P&M<_!I^:N)[M,98W(5%N);740)O6(IP/#
MEJMND01]A <&  ^SF(?I2K/=L/PDGJ&)M/\ KDRMPG^+4"X3 ;B+RA2'N3Q#
M0B]O:' XU1_'K8QD5U/=A[!^ TQIL/8/P&F--A[!^ TQIL/8/P&F--A[!^ T
MQIL/8/P&F--A[!^ TQIL/8/P&F--A[!^ TQIL/8/P&M;7'C_ .,W:/ _PK)<
MU6FV>(9#;E_9F_&,WNJN%Z)':$U%RJ0<^3&<O1]<Q9#*!T*KK @7D<_>HRSA
MO]J4^(LR0-Z.+-*JWYRW<Q(*<;H?THZWG;^X#<]NQY_QH!D<CP?PTH!7)YU<
MI>78%6QG#L7TC-'(/T)KGF$>Y\2>4=SN-DN1/70-A[!^ TQIL/8/P&M?_&WN
M2_E<4+A&X>)48WB/XE"R;1K:FY1<?@,TO$F20V;O.532.F9LYAV+GZ/Z]1<+
ML?35[D62<>Z5<1*[163\/4*W+9SF4CY\3B>0F$[#Z1R#@FGCD)WW61AU;1 ;
MIUD;F79P1!^,,I=YJ7"^!D$>?X@ZBK94;_0V)B(&0S,G+L5:)&Z%$$IU;CH$
M8M&5.5.CM+4#AWU12M-:QB?1%,HL.E%1J2ARK/Y!P8ZCJ5GIIX!$QD;!895P
M\FYV24(4[^5?.W1BD[P"%TN1R%G*7;%^V_//9D+N1V50 %2*-?S8HD"QQK^:
MBJ/5J2X?#T<%C*F*Q\73J4XA'&&V:21B2TDTS[#J3SR,\TTA&[R.S'QVU*^8
M6MGL/8/P&F--A[!^ TQIL/8/P&F--A[!^ TQIL/8/P&F--A[!^ TQIL/8/P&
MF--A[!^ TQIL/8/P&F--A[!^ TQIL/8/P&F--A[!^ TQIL/8/P&F--A[!^ U
M\,8"@)C"!2E 3&,80 "@ <Q$1'R  #S$1\@#&V_8=SKPA0-R% 'B3L!JV(R[
MTN;F'->AK?5Y>P,FQWKR#C)^)?S#1FDLBW4=N8QJ[5>H-DW#A! ZZJ!$B++H
MI&.!U"%->>M8CC$LD$T<3'E61XG6-F() #LH4G8$[ [[ GU:QX[=*:5H(;-6
M69%+-#'-$\JJ"%+-&K%U4,0"2  2!XD:\E_;.\.FTN$CC%IG:/:8C#.ZG9;#
M5Y*VKD:K.(NJ;0@X]O .(ZRH-A24;U7:%;9)(B^*ND9S-KV9BJZ8/'\'XWLG
M!]C%\7\)Y'@3,L1U*MFO&%8+++2F8RI-79@0;./L$2(I5E54@;DD190OR7Y9
M>'LMP;QK0\I>#BYZL]FI-;;E9H:N4@C6NT5I4(*U,I60*7#+S3-9C+(\D'/,
MVMMAVGM)Z0CO+4T16=*VF@ND:I;8Z.VA:R[ V&BP.A+NM96"9JT96$:=19-C
M+2+VFWMXRM]DA[ [>.:[&ULB-B//?.'%G"N)\FUB3A7B-Y>(Z^1CEOX:Y<X=
MQUG%8&Q,CUX<Y4J9&:Y])9"":"!,GB$DHT;=.-([DMPM4%688?+7?*C1'$.%
MAJX&WCF2G?BAS%U<EE5B*SOB;,].*HM''2QS2O1R,B7;<%F1WK150MGSFTWZ
M#*(D:)(:EUYNC232V7JPT&Z3C"E#M*NVFUU)S9(:7@@J=,/L^:V!M21LL%),
M8_8$,1DG8&\2_=SEVM(1T)6)3E64\E.1XSAR53CF/AKRD9#&8ZG=X7J4<N_#
M_$-*GD#3LP/#E+0X>BQ'"=>A9$\_#MQ+:T)K,:XW"XM[-W*ULROF&P\E"?AN
MIGN&8+^0M8_*3''#-8^[=I-;@GA\PIG+S9'.2VZTD<66K=$6XX)&MY&Z(:]*
M;+OA_P"S&L>W8Z[R/$ Y4AM:7>^A/.XNUZNA8;B VO!M4X5RT7N4R$XM$ZSB
M$#QR%8AHJ-U] 7E*O1+>621H%F5+).>@\->3O&<-9;@SB:.WG\5F>#L/#0P?
M"."XOM3<"<,2*;GG#5T6LN4S-K(37+63RGGV?R=&>[>LU)Y\KBEAIP2+&\(Y
M#B*CFJW$4=3Z*SF2:S>GR. K1\4YZN!7,8NRM8>GB:T2P1T:L-?$5;R5:T<Z
M)CKK-/)O'UOJ[6^G:HRHVJ:+5-=T^/.HLUKE.@XZ B2.5^CQ+U1I'(()N9!X
M8A5'TBY!9\]5#OG;A941./0[EVYD)WM7K4]NP^W--8E>:0@>"\SDD*N^RJ-E
M4=E &NGXO$8O"4XL?B,=3QM&'?IU:5>*O I.W,W3B507;8<[MN[GNS$]]7YF
M+K8;#V#\!IC38>P?@-4=_)N$GC2(B8U>:G'Y%%6T<W.1 B;9(0*J]?O%?Q+%
MDF<Q4Q64 QE%3 DDFH?F 8-BW,MB"A0J2Y')V5>2&I$RQJL,9 >S:GD^KK5T
M8A>H^Y=R$168]K4CJFP"<S'<@ #P'K)]0WV'Z]=I:$V6R3\2M 5^42Y=1V4/
M-KIR*1?6(!Z38M6CA0I?T":Y.\,'20?,O/(DQ7&-9.M)C,3=3;=J]#(RK;0>
M) \\K0UY67]%9%YB-E/<:HYW'<QH?<I[_$:ZD;.LI)99F!7#&3:^3R'DT#LI
M1J/M5:J\C&3\P$%D151$#%Y*<Q ,Q:F2KVY)*^TU:[!_3%"Y$U>Y ?W\+]V7
MV21EXSN-F[ZN(\;]@ &'BI&S#P/A^L:K.;#5S8>P?@-,:;#V#\!KDU?(,&LU
M<8A\J#:?D9P9)HW<%%,S^$1CF35FLR4-]1T5 Z+H%DTC&4;@/-0A0ZN61P3;
MJPW\_0LOT<I;R;78(I04:UC8ZE:""2N[>C.(FBGZB1EFB!W=0-]L0$"20'LQ
M;<;]MUV[;>W;O_\ HU-F=(U<UU'S%I)LW4>_;INF3Q!1NZ;K%ZDUD52B4Y#!
M[P'R$! Q1Y&*(& !"Q9K07*\U6U$D]>Q&T4T4@W22-P596'O!\1L0=B"" =>
M$ @@^!UCTDT=5"9&H2:JJ[10BCBIRBX\Q?QB?+KC%U.0%-)1("5,P!R,X:=T
MX B8>0\E\VGP&0."N.\E=U>7!W93N;5-/M4I7/9KE$$*P&QE@Y)0JCL43<K=
M-]N^_38^+#U@]N[#^+;7V)5.RL=GC$QYM95*D6$Y/T*+Y"U,HE8Q0#R 7:":
M!U!]9S( /K PC7C)&KY?,4D_(W5X;RK+^;'9CSE>C(P'@#/&L18^+&+?U'>E
M@%E8#P8(^WL/,%\/?XZR/SKVJ],::8TTQIIC33&FF--,::8TTQIIC33&FM:/
M9]_TU>TR_9_6O^ G1&;K+_D,+_>F/_6;6H)P;^Z/'G^&,_\ )&(ULNS2ZG>F
M--,::8TTQIIC33&FF--,::8TTQIJ']F>=AUS^N5C_>\YSGW&O[I<)_W;E?Y)
MGU0?RL/WM_$-=;D'L#[@S UEZ<@]@?<&--:Y>#("M.)WM,H<Y0*NAQ,Z]FC$
M$/K WL/#EJITV/Y_H5"MSF+]@ASY>62K/=\1PE(.X.)M1[^K>+*W P_43L=0
M'A+T>(O*%$>S#B&C+MZ^6? XUE/W$+V_7K8UR#V!]P9%=3[3D'L#[@QIIR#V
M!]P8TTY![ ^X,::<@]@?<&--.0>P/N#&FG(/8'W!C33D'L#[@QIIR#V!]P8T
MTY![ ^X,::UMZ_*&U>U"X@+>?\9#\*W#EJW1<2FH'>-BWC>,P^W)=)!F(@)$
MY!O4837<6],7I43:NTTN8@X7*$LM?M+@_&0=NIF<K<R+D=F\WQT:T($;]Z9Y
M+3K[2-_4-0"C_P 9>47-VSWAX;P..PT7K47,Q*V5N.OJ$BUH:,;^!"L!^<VM
MDG(/8'W!D3U/]6?L&]U/5M%N&R;S*MX&FT.M3-MM$PY_F4=!P$>O)R3D2% 5
M%E$VK93N6Z13KN5A3;H$464(0U^K6FN68*E=#)/9FC@A0>+22L$0>[=B-R>P
M&Y/8:Q;UVMC:5K(7)5AJ4J\MJS*WA'# C22-MXDA5.RC=F.RJ"2!K!;@&U[:
MK6WOG&[N6(7C=R<6!XV:KU=DR@=WJ'ASBN]/IC530#"8&+Q:$<$O%Y\(1CZ5
MMM@.:49 _B2J#(^)K,$#5N'J#J]#"AHY94^S>RK[?2%TGL742#S>MS<W)!$.
M1N5]M0W@FC:LK=XORT31Y;B;IRP02#T\7@HM_HG&KO\ 88PMYY<Y0O4LSGJ+
MSQ@ZV,\@]@?<&174\TY![ ^X,::<@]@?<&--.0>P/N#&FG(/8'W!C33D'L#[
M@QIIR#V!]P8TTY![ ^X,::<@]@?<&--.0>P/N#&FG(/8'W!C33D'L#[@QIJ/
MH+:6OK-L'8.JX*QM)*_:KCZ7*;!KR+5^5:LLMAM9E]33O7JK-.+56FV5?E7B
M;1D^=/&C5!%>00:)/F!G65)2M0U:MV2%EK77L)5E)7:9JIC6<*H8N!&TB*2R
MA6)(4L5;;!AR5&Q>O8V&PLEW&QU)+T 5]ZZ7EE>J7<J(R9DAD<*CLRJ%9U4.
MA;#S8/:%ZZ2M\MJ?AGH=VXR-S0ZW@IFJZ13CE:#2GYA.5)':&[YE=KK.BIBL
MDLU<(#+34XR=I&;.H)-00#-[5X6M&!+N7LU\#0<<R39'G%FPG;<T\=&&MV#L
M0P/)'&RG=9#J*WN.J M2XSAZG<XKRT3<DM?$!#1J/WV&1S$I7'U!N"K+U9IE
M8<K0@ZM@FL.TDWCR=[,W[J[A J;OZWT X<:<WVOLWT<X#F9A/;EVLS)7(J:;
M (IG?TK7)FP& #-7AN7>GO&WPGCO1J8VYG)U_P#*LK.:5/G'Y\="FQE>,^I;
M%H$_G*/#6,,=Q_F?2R&;QW"U9_\ R' U5R>0Y#^9-E<DH@CE [%ZE$K^B_KU
MVT^RQX9+#TN-X3>_^*"4 >H9'B#X@=GVUL)N?,Q2U6!GJI14VXC^0R3JQ6:)
M?JH()E  SP\99B+<8Z/&X=/T,7C*<!'J'U\L<]G?]]U^8^))U6/)OP]/Z68F
MS?$4GB7SF<R-I??^UH9JU,#]Z*P4>  &LF-.\(W"_P /LHM.Z3T%JG65A<Q2
MT$ZLM1I4)%V9U"N'+-XXB75C2:#..8YR[CV#IPS7?J-UW+)HNJF=5NB<FGO9
MS,9-!%D,E=MQ!Q((9[$CPB0!E#B(MTPP5V4,%! 8@=CJ08KA?AW!R--B,)C<
M=.T9A:Q5J0QV&B9E9HFG"]9HV9$9D+E69%8@D ZF6W4ZJ7^L3M*N]<A;;4;-
M&N8>PUNPQS66A9F,=D%-RQD8YZDLV=-U2^LBJ9@ P%.7I.4I@P()YJLT=BM+
M)!/"X>*:)V22-U\&1U(((]Q]WAK:W*=7(59Z5ZO#;IVHVAL5K$:RP31.-F22
M-P592/41X[$=P->?_:_\CP:?DKA(VGAJXB]H<-;*944&0JJ,:ML&'9MU5!.:
M,@9 MOH]G;190Y"FVL$_:%BGZA\4*?=I)]+K>4VS)6CKYW"8[.=+8QRS!(7+
M@;"1T>O:@,GM:**'MZO;\_Y;^AXQ$ER6WPSQ'E>&4G)ZE58VOPJA.YB@<7*-
MI8O8MBQ:(/YVVP&R[@][/?4_"/5:3'H6?8.X+O2&LTC"WG9ULL$RVKZMB!P2
M9-0:$XF'=)U\1TU>/8WQD!%?21:)D)*-DK')-I)^5Q"\SFSE;UVY%CL9B_I#
MHBTN.I5H)[20<O26[=2%+=T*51^2:0PAXXW2%#&G+TW@_P G^+X2J48O/,EF
M;E!9Q7NY2Y9G2LUGF$QQ^/:9Z./YT=XN>O%YR8I)8Y+$BRR!LZGSUE&M5GS]
M=%JT;EZUEUA I"!S  ^P1,8QA I"% 3G.)2$*8P@ QVQ8@J0R6+,J0PQ+S/(
MYV51X#WEB=@JJ"S,0J@L0-3MF"@LQV ]>J*G.2#A$'C.EW%W'"7K*^2AR)@L
MD/F59LT<.47ZZ1B_6*8C7J,7S(4V827KLL?G$'#W$$]3;F%A*"J)$VW$D4$L
MT=J5"-B"L&[ [JI[ V>N/$)(1[0O\0WW.JM&23&7:)O6"I5D#B8@\R&34253
M'I50714*51%=(P"51)0I3E'[.0@(Y52Y7O0+8K2=2-BRGLR.CH=GCDC<!XY$
M/9D=0P]FQ!-U65QS*=Q_OV.N_P @]@?<&9.JM=:GK(,MD2:+H2%5FJLR]%*'
M$"]0Q3]T,@Q1$>74H)7;9X=,G,13**G+D0PA[PW+'7XNNQ3E1)D<+6-)V.W-
MYC:F-JM&3XOM8BL,B[DHI?;96(Q6[3'?\Y!R_J\1_MV^\ZG+.GZJU:5JID-;
M$$_&D4:R37F:-FV)@0E(Y7S$#(. #F=$1$>]:K=;=4!'J3 _2<NBS?#N.SL2
MBRC0VX=S3R-8B*]3?U&*8#=HR3Z<$G-%(">9>;9A2RAN_<$># [$?K&HB*O*
MU^32KMM(B#IP)BPT\@GW4;8"$_0 4>96,L4HAW\>8W(YAZVICIG2 W.V:_B+
MB8K.<AFE)&/R<2=.IE%'YNW<5KRC;JU6.S'TH"Z,G-6DA'HR; ^"MZF^3?Q_
MQW#R#V!]P9L=7]4F7A6<PBF1?O$'+90KAA(-#B@_CG1! 4W+-R3D=)0I@*(@
M B10  JA3!Y9A7J$-Y$$A>.:%Q+5M0,8[-2<?9FKRKZ2." 2/LML P(VU0\:
MN-CX^HCL0?:#JX*Q?7C%VWKEX.DF[6,",/9DR A&38^HC=X'\SC9@0]:)A!L
M[,!O#& W013>8/BJ>">+$<2/&EF1A%0S"J(J>2/YL4XWY:F0/KC)$,[;]$@E
M4?&W:,A9/6=E?U-[-_8WP[ZE_.@ZN:MRT5B-MD8:-D053$BI'3%\V,";Z-?(
M^:#UDL(&[M9,1$! 0$BB9C)J%,0PAFHS6%IYVD:=L.I5UGK686Y+-.S'N8K-
M>38\DB$D=P5=2R."K$:I90PV/;U@CQ!]1&K$;TDU8CY.0?2ZL],2LK4D%GZC
M)%@1)BQGXX&S1!JBHL1/ZZRJSA0J@ X6.!Q3)T &1JOPW]"5;=JQ??)W[U_!
M1R6GKQU@E:ME*@@@CAC>15]*2225PPZLC!N1>4#5(4C<LW.Q*C<@#L#V';X_
MQ#4O9/-7-,::8TTQIIC33&FF--,::8TTQIIC33&FM:/9]_TU>TR_9_6O^ G1
M&;K+_D,+_>F/_6;6H)P;^Z/'G^&,_P#)&(ULNS2ZG>F--,::8TTQIIC33&FF
M--,::8TTQIJ']E_T1:Y_7*Q_O><YS_C/OD^$O7^WLK_)4^J#^5B^]OXAK@Y#
M[!^X<Q>1?9\3\]96X]H_$:AK?41O26US(DX<[92*AM:/?QDO!*[(KCVQTBPH
M1KD'#^GV,D6[:3$-&V5 HQSBR0OBI:$(H+MBS76  +G8[Z-2TOTI!8GILKI(
M*LHBL1%UV6>(N&C=XCZ8BDV20CE8@:U.;3+RT)!@;=.KDT>.6$WX&L5)Q&W,
M]6<1NLL4=A?JS/%S20[\R*3K0E0VW&AQ%\:O$WI>7TYLOA+KF\77#AL'B@OC
M*><@:%JVFZ6_H=@J6CMFU\K-I/\ X=7<13XV$N,.]9RL#6(J[HO8EPZCWA4^
MD6/H#%X#$7TO5,U+CERM7$5FB'IS7["V8Y\A4E+F/Z.#SM)#(K))*]8JX#+O
MQ6D.*\_Q;Q#B9<5?X8KYAL!>XBNI,WU5?$U'I3U</D8.19_IAHJJ0VHG26&O
M';#QEXV&O2B4@E "@!N10  ZA,8>0!R\S&$3&'VF,(B(^8B(YRGE7V:^@-Q[
M1^.M=]@W]N'?W$>ZT1PJ2L+6M=:*M$.;BFXA)2#:6M@G/M5VTDMPXZMC'H^B
M)6^R$< ([(LJXN6VM8R0!L0A+@+)F:418K'XW%#)9F.2:UD89!AL8DC0MTR"
M@RMQU]-*RO\ TI"-FMNN_P"0YFUSJSQ#E\_Q(V!X4F@JX[!6H?V5<0S0):C$
MZE93PYBHI/J9K\D?;(V267'1N%&ULHFMB/(?8/W#D7Y%]GQ/SUT7<>T?B-.0
M^P?N''(OL^)^>FX]H_$:<A]@_<..1?9\3\]-Q[1^(TY#[!^X<<B^SXGYZ;CV
MC\1IR'V#]PXY%]GQ/STW'M'XC3D/L'[AQR+[/B?GIN/:/Q&G(?8/W#CD7V?$
M_/3<>T?B-.0^P?N''(OL^)^>FX]H_$:UN]F> W#7?$%Q"'_- <2G%UO[8<$^
M.'4NI0ZG:OP-T)F*@^9FK.!UH15J ?BC>,670 $G!0R5<6*(;6,QFVWT3A,;
M5D4> LS0^?V6[>MI;9#>OT0#N03J >3TBS1SF<;QX@XHS5Z)CMN:5:S]%4EW
M]:K#0!4[#?G+#LPULBY#[!^X<BO(OL^)^>I_N/:/Q&M8W&>4_$GO?0O 5'B9
MS3ITZ/$EQ5)IB84C:+UG8&A*7KZ2*'24[;<.UD8V+>()KHO2U^JSBZ95&YE0
M&78!1B<=D>)&'+8B!Q6&/K^D;<3><64[]FHTB[J2I4R31CL=M<\XM/T_F<+P
M7&=ZDY&?XDV/H_0^/G7S2C)ZN7*9)8XV7<-T*TQ *DZV;D3!,A4TTP(0A2D(
M0A0*0A"@!2E*4H !2E   I0      #ED1*@]SW)[DDGO\=="!4  %0!V &P
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MN''(OL^)^>FX]H_$:<A]@_<..1?9\3\]-Q[1^(U;4H#1.RT5:8(4\"G/*D>
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MH&(HDH03$.F<H@8IRB)3 (" B&=/CDCFC26&1)8I55XY(V5XY$8;JZ.I*LK
M@JRD@@[@ZKU0K3^= ?KM7?WPQ>:W,_TB/[OQ'\K4M>'P_6/XQJXLVNO=,::8
MTTQIIC33&FF--,::8TTQIIC33&FM:/9]_P!-7M,OV?UK_@)T1FZR_P"0PO\
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M&R>[\?Y]-,;)[OQ_GTTQLGN_'^?33&R>[\?Y]-,;)[OQ_GTU\,8"@)C"!2E
M3&$1Y   ',1$1]0 'F(YX>F 22  -R2W@!XGQTUQZPBRR*;J_/R=;^?,LA#%
M4#F,76VRYTF:"(#S[M60,F9^\4*/X[O$0Y% @E&]P306S'-Q197FM90R1X\/
MW-+$12LE>*,'?D:V5-J=E/I\\8[<I!MQ^EO(?%OL]OLKZA]Y\3J7#%*<IBF*
M!BF 2F*8 $IBB'(2F >8" @/(0'R$/(<GI 8%6 (((((W!![$$'L01V(/CJY
MJ%WM!GZT91:D.D)"(ZCJA4IA4R0M0.83G2@YCD<6Z8B/XII($4;I_6$' =0
M'.;7">2Q):3AR:*U1YF?Z"R#F,PACS,F-R YC$I)/3@MJ\*=]I1OVM\K+]CT
ME_0/;;[F^>X&J9'V9D[=C%/D'4%.D#\9"S"7A'9O6'6S.810D$#<C"FLS55
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M J$TS?\ $YMZMMEH1-LB[J4RRB)A*2!L_6E:!GK2F$K% OF[0M&%,X4B&"I
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MRRSK*TZ!]WQ^6--.@?=\?EC33H'W?'Y8TTZ!]WQ^6--8$\?NC-B; U[4-U:
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MX#36,O%IKZ0OVHWP0[=1W+562;6EJS1*)UWC=DV>,Y-LB0H"910L>^7>)HD
M5%U6::"0&44*4WS]_1+\#W>-/)E<&*@>SD^'+T'$=:K"I::W!4@M5LA7B5=V
M>04;D]J.)0TDTM6.&-3)(H.35D"2C?L''*3["=B/B-OUZTPY^4.MOIC33&FL
MM>#C7TA:=K,;0+=0(&C)KR;UV)1!%24<M7#.(CTU.7(7 K+'D3%#F!6[!0#B
M054NOZ:_H5^"+W$?E(J<1&%QA>#TFOV[+*1%)D;-:>KC**/X&<R2O>8#<+#2
M<.5,L7/BVY L17\Y^P'N\2?]GWD:W!Y^HNP]@_ :U.K4O-0C[[49ZH23EZP;
MS; [9*4BU$D9:$D$CD=1-@AEUT7"+:;K\J@RFH9TJW73:RC!HX,BJ"8D-?K3
MM5L16(PO/$X<!AZ+#P9' V)2124< C=6(W&^L6[4CO5)ZDK.BSQE1)&0)87!
M#13PLP8+-!*J30L58+(BL0=MM02JPV&-MA[-==,/-D[&KAHY:JVB&VZI&Z,;
M3T1#6NM-+V?7]NGG,IJNSR<'=+*RG I= V8]0CY)%BK9K:K$1CQO*DRU$PLJ
MV'K1N&ZL)JA[15FC<PB>-56Q&'B0IUIJXW4D1Q\[ QUJ^1\ZBL6\2V1OUS&:
MMF+*F+"K-%%9KK>-"U.\F,LR0V["3>9T<DZQR!#9M&*-A+>O*A+5YM9IBUR3
M26N^P+$I;;B\B4W#2&:OO0T16XF!KJ2YQ>)0M:K%?A(1J[7%!W,O&;^SO&K&
M2G'C5&.Y"V+LRLJ<D,,8A@1MF<('>0M(? O))(\C ;A>81J2J*=;K&TY:J6)
M;4B2W;U@V[CQ!EA63HQ5XH:X8\XAKUH(858\K3,CV75)9W44Q71>IEV=>8*4
MN.\)4VU.9UM(CB22]#--?(RJ%);,5$GQ%4D*R2;DS1276)&ZSH7( +A%!5*@
M7K8,C"9MYFF:4[+Z;6"IG+>CW,O(O.?6!MX$@T'"8IDKH:<?)56FE8!I!T4H
M"44E0AP0M;K2&(;[*6YOM*I'6/P_::48MHT^OX0S%E'3<0S;_FP"LXRR@Y"P
M,6A@=@=LVFO%+#)IH&3*\.")U^L[9L9+WZ0N<Q;KONS(['T?2:/;ILWH]RFP
MY2=^7N!MN=Z3@<.46,T(>1(YH47T_0BL<W713S;JLW,3( 1SG8G<JNW[+H+3
MI12,-!A5A03D$FXN?&.Q;)2\%"5:62:^)=*^&3EJO7(:LRB:'=DD:ZR"#> M
M%KNFJPW[AW^O<;\I.W*-RDCRIOL!OR2R/(N_V9&YUV8 CWZ"Q';]HPGE$@7F
MYVY1+##6E"\S'EZM:O#7EVVZE=.@_-$S*;YK%-K%,2E$*O#M89&:E#S<JFT%
M;I>RRC-E'J/U@554YN#LHYBV.<O3U)-$"B ] 9CRRR3E3,QD*)R(6 ]% S-R
MCMX<S,?O)UFUJ=:F)5K0K")I3-*%+>G*42,N=R?2*1HIVV[*/9JYLM;#V#\!
MK)TQL/8/P&FF-A[!^ TTQL/8/P&FJ%-V6&KY$ADW8)KN1Z6;%!-1U(/3^H"-
M&+<JCE<1-R*)BI]V4P@!SEYAFNR&4Q^,">=RA99CRUZT2-/;L-ZE@K1*\TA)
M[;JG*I(YF7?5+,J^)^X>)/W =]6HXO4H10"I5)9J4Q"J$+8K%7:V\.F83 53
MT>]>J.R%-TFZ143)S$! >D0$ TT_$%N*0(<**NZ+(J9G,X;#661MPK>9VK36
M5#$'8R1IOL0=B"!X#(W=87(]IV'S_P!_U:[+>_-T2H'L,1(5]LY.":$LH=I*
MUY4XG%,"!.1*[IFF83E,41<=PF42FZE $I@"]'Q#'&D,F4Q]G&03GEBR'/6O
MXAV+% HRF/EL5D)<%=YC$H(.[#8[><_*=I%,9[?:\-SZMQVU?I#D4(51,Q3I
MG*4Y#D,!B'(8 ,4Q3%$2F*8H@)3 (@(" @/+)&O(RAEY65@&5EV*LI&X(([$
M$=P1V([C5S7ZSW8>P?@--,;#V#\!IIC8>P?@--,;#V#\!IIC8>P?@--,;#V#
M\!IIC8>P?@--,;#V#\!IIC8>P?@--6S74RN]FSB[CD)X:J1+:.(;S I)9^^7
M?N4P'U',9DV;G4+Y]!03$>0B Z_"(L_%^3ED YL?A*$-4'U+?LV9+,J#])C6
MAB9AWY5"[[$[V_&4D^I !^L]S\-M_P"?4O9T'5S3&FOAB@8!*8 ,4P"4Q3
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M3AVR'J EGP&0D=Z3;]SYA9/-/CY#W*IO)5+MN\:J-6^5E[QGM^@Q.WZCX@_
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MXR>.S2L%7 >2'K0Q+;ACF@>U6#5C/&K\PP2X?>#[=6K./.Q[HVKLB6WS#OM
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M/M#<W!.7?4B_)>T0KY'/+_\ DGSD?N#X^6>_34Z_E.&.*D]NV*ZW^KV9B?U
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MA]EH[<!28<OBJLS)[5.J616[D=_:.Q_'5.3E[A2PZWRCB[5A+S5<=VF2V1*
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M=:[,MV)I\?DXAM#DZ#F"VFVVR2E?0LPG8!H;"R(5W4!=]]4L@;OX,/!AV/\
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M.<P%* B(!G3\\=J](GL!E\623ZOVTFOC?R:J6RN?5069N!^,E55!)8G!V@
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M*O&31*/4?HMX5$[TRJ6]S/$]G,5TJF".M$'620([2-(Z@A?28+RH-R>78DL
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M9 'L_;#:_8]JYQ>O/Q$-V./&8N^$.14YM1:N,!4]0 :4=:_<HE3YB'-44A
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M:JTQIIC35ISMYJM</W$I,M2/1'I3C&PG?RBIQ_)(2.9%7><SCY%,9(I.?K.
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MF_ATJL?/8EW_ /-Q-XCVC5)95\2!_O[/'5I'O%BF?J5&G/3(G\BS5K4&!C@
M?R5DF'2M,/43!Y@)6[7F'Z( Y<])^R#,Y+T<#P]8Z3>&2SS'%4P#W62.IRRY
M&S&P[@B"#?\ 2\-Z>=C]A#_";L/]I(]7MUU352R3?,UMN+]5 _F:%JY!KT6!
M1_*06=)G5F'R(^K\:\1YAY=/KYCP[ELEWS_$-N2-MRV.PBG$T=CXQ23HTF0L
MQGP].S'N/S1WW<C'[3G;V+Z(_'Q.KDA:O7JZ3HA8=C'B("!UD42BZ5Y^OOWB
MG6[7$?M%990??F\QN#Q&'4KC<?5J$[AY(XP9Y-^YZMA^:>7<^N21CJI45?
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M_#EC]C9]?$'$I_\ RFB_Z-5?]_?KWD_?O_E?S?[^K7WZ!(?;:;L/_O$J'[5
MO+_)C]C2]M\[Q*=O_P![R+^/+&NG)^^?_*.GT :_;9;L/_O.^+^TZ<?L9C]>
M:XE/_P"6[0_BVTY/WS_Y1U]^@#'[;#=1_P#>V7+]O/\ 0+E^'+RSW]C,'KR_
M$A__ "]D!_HRK_O^K3D'Z3_Y9T#7\;]LY=1_3N5@#]J^+\,?L9K>O*<2'_\
MN++C_1M#3IC])_\ +;YZ^_@^B!_*EKD;].[6G_H+*  ?Y.6/V+TOSLCQ&WW\
M2YS;X7AIR#])_P#+.GX/((?RGUL/[>J[6P>?Z?*8#]/'[%L=Z[>?;[^)<_\
M[,B- B@;>E_E-_L.GX.JV/Y2EE-^JNEO\_NG ]>/V*XKURYIOOXDXA_V9,:=
M-??_ )3?/7Z_!U5OM3G3?JKA<#?MIX<#A/##U94_?Q#Q ?X\IKSIH?4?\IO^
M]I^#FI__ *M+#^JM-J-^VFAST<*84?UO(?KSF</\>2.O>FGL/^4WST_!S4?M
M8OQ_56&QF^SEY]4L//\ RY[^Q3"?V"V?ORV7/\=\Z\Z:>S_WF^>OOX.J?_N8
MX']5,SAOVTD.>?L3P/\ S2<_PLEE&_TKAU[TT\-OBWSU]_!S3?\ <<1_52,L
M?]L^'_OYY[^Q3 ^NBQ^^Y?;^.T=!&@\%^)^>GX.:7]L$B/ZIT_-^V=CC]B?#
MW_1L9^^:T?XYSITT_1_CU]_!S21]=>9&_5&<&_;+CC]B7#G_ $37/WF8_P <
MATZ:?HCX_/3\'-'^VLQ9OU2(F_;''GGO[$^&_7AZ1^^,G^,G3II^B-??P=47
M[:I"&_5,4C_M@'V9Y^Q+AD^.#QI^^M&?XP=.FGZ(T_!S0A\QI]=,/M-$LS#_
M /U)#GO[$N%_7P_B#_"H5F_CC.@C0>"+^&N0->T,/53:O_E@XTW_ $MAST<*
M<,#_ /9["_KQE,_QPZ]Y$_17\!K]EH-%+ZJ95/TQKT2(_>+01RL<+<,CN.'<
M'_V30_\  TY$_17_ "1\M<@4>E!ZJ?5@_2K\2'_TF5CAKAP>& PH^[%41_\
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H&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC37_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>gdc15tqwxkbk000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdc15tqwxkbk000013.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %! ET# 1$  A$! Q$!_\0
M'P !  (" @,! 0            @)!@<%"@(#! $+_\0 6!    8#   $ P(%
M# D2!P    (#! 4& 0<("1$2$Q05(18B%R,Q0988&B0R.%%55Y33U=<*)3-"
M6&%WE;89)C0V-SE#4E-68G1U>(&7M;<U5'*BH[.T_\0 '0$!  (" P$!
M          4& P0! @<("?_$ & 1  $$ 0," @0&"! +!04)  (  0,$!081
M$A,A%#$'(D%1%2,R0F%Q%C-28H&1DM$(%R0T4U15<G.4H;&RP=35)34V-T-C
M=':TM? F@H.BX3A$9).V165UAI6CL\+Q_]H # ,!  (1 Q$ /P#O\ B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B]+AP@T06=
M.ED6S9LBHX<.'"A$4&Z")#*++++*&*FDBDF4RBBBABD(0IC&-@N,Y!F=W9F;
M=W[,S=W=W\F9EP[L+.1.PB+.Y$[LS,S-N[N[]F9F[N[]F90-MGB5<JQ5AD*3
MK:QW'IG848KE!]1>5=>VO?DFQ7+G)5D9>P4:/?4"N+-CER1VE9KC"J-3%4RX
M*F5%<R4M'A;Y ,DP1TH2[M+?FCJ"[>QQ"5VF/?V<(RWW;;S;>H6-=:>CG.I1
MGLYZ[&^QU-/4K&8D!VWW:6:H!TX'';UFL6HG'OOLS.[<%CJWL^T^3O6WAJ[%
M;0ZWWF;_ 'QT/HS3[Y4F?KC+JN522W-8(T_EDOJ2>1Y%,9R;'EG)<XSV\!C8
M^T^:A<O:U2G:LM^ Y&K _P" EB;4.J+'K4M#70C?Y)Y?-8G&F[??0UI,I,'U
M$&Z]GX:_$L1\W"O!V@G2&<8S\O9=QNTY(N/[XOQ#SF-&.44QY_3&5$4\YQG&
M5<8S@V'AL*_;X4MM]\^,9V_$UW?_ *\D^%==-W?2&&)NWJ!JPV-O?W+ ,#_5
MNS>S?VKUF['Z;IGFON+PWNA8V*+]%)K1&P-)]$(I9Q^W4S78JY4J_KH)X\C?
ML.F.GBI<^3=DLIC*>'P=1D[5LS3(ON;4-FG_ .<HY8M_KD9O>ZX^R;/5>^3T
M/F@C]LN(NXK-,WT]".U5N$S?>52)_F@[]ELG4WB <G[?LZ.O8G:*-&VLIE-(
MVG=TU^RZ0VP5VH;),L6E$VI$U2;G'"9RF(<U:0FFOJ(?T.3E(;.,,^)OUX^L
M4#RP?MBL<=J#;WO+7*0!;;[MQ\V]ZWL=K+3N3L-2BR#5<B^S?!F4@L8K(\G^
M8-3(15Y929^V\ RCOY$ZF8(U6A 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 10JZ"[*BM9W1IH?3-%F
M.C>IYR-2E(S2],D6D:QID&Y].$+QO"_/$W$#J*AXR=/X=_-D<V&PJK-VE4K<
MVJN8Z,G3QI3Q/:LRC3H 7$K,K.[R&WG%5B;8[$O9^P[ &SO(8LRJV9U/'0M#
MB,74DS>H)0:2/%U3$!JQ%V&WEKA,\.-I[NVQR\IYMV&M!,[OMJ:/X6NF_5T+
M7X@^VG6[E%54GS/F?6SF=U]R53E"'*NW8OJLT>-K;O!]'KESG%AV[+/XYUA1
M4C:EQ3?T(8SOE(JC/'B*[5F\GNSL$N0D]CNQNSQU6=OF5Q9V\^J[]U'!I*UF
M':QK/(EEG=V,<%1>6EIRJ^[.('7$ALY8@?\ TV2E.,MWXU(V[*P>GTJFZ\KT
M=4:!4JS1ZI$)80BJS4(&+K5?C$<8QC"4?#0S5E',T\8QC'H;MDR_3'T^@B))
M9)C>260Y9"[D<AD9D_O<B=R?\+JYUJM6E"%:G7@J5XFXQP5H8X(8V]P11"("
MWT"++)QT6= 1 1:JV]HS3>_JNM2]UZPH^TJNMA3TQ%VK<9/HLU52X+EY%JOF
MZKJ'DD_(IF\I%+LY%JH0BK9TDJF0Y<]>U9J&TE:>6 V^=$9 [_06S[$WO$F=
MG]K*/R6)QF8@>KE<?4R$#[_%VX(YV%W^=&YBY1FWF,D;B8OLXDSLSJ#;GFWI
M_DSSG>+]D2>Y=5Q_XU[QQTA<Y&;10C4O(QHW070LZ>3N>OGR+9(K2%JVS7-Z
MH9U5CX,^K2."+IRK7:.0]3)0C6G?LV2I1,.Y>^W3#C',S[[E) T4W;RD\E4R
MP>?TY\;I>])E,>'<],YRT<K-&VWJ8?,R]2U2-A;C%7O%;IN[[<J[>LI.\W=8
M:RZ68V)C74K#1]HZ_=-XK;.C-D1>:OMO5<TX3PH@TM-9655^(B)%//Q%>M\"
MYEJC9F?[(A9IV9-RBWT;N/GHN#FX2P3,Y5[4)<Z\X-YN![-L0_/C-ADC?L8M
MNV\]@]14,Z$X0--4R%,FCR.)O1^'R6/E=MV&Q7=WWC-N\-F$I:U@?6AE/8F:
M3@T5/("("("("("("("("("("("("("("("("("("("("("("("("("("("(
M"("("("("("("("("("("("("("("("("("("("("("("("("("("("("("(
M"("("("("("("("*O_IKH+9DYL5CQWR2O&&Z'LL&VL>RMHRL>2;I?*6JI-4[
M9+8-JCS&*UL&RK-@CIMI_6:ZR>9V005L]DPTIL4N>3EJ-2 (7R.08O!@;A!
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M-SI1N<-F[0V2G63].#%4\L85QG.I/^O:WU-_2)>\^C-W;]#UZ5]O+QMW?_\
M2\.H$B07RFII]:7#9%IJO.#6^Q[IBQK^JF,93SN8%6%*[@R1U>33706501Q*
M)Y1;M,X>)Y4*;!RF]7XW&<Z-/Y=K^&?^<E]*>G[?X"]#OT:&KLWU-3P^RPGC
MJQW6I]"4B>UXS</[:S;6HL:U:Q*DXLH1U4IMJ^R2,226.X]#!9R<V<)F]DI<
MK9\L)YSC)=_6TG_<_IBJS^AVW_3;TUMY]#._\AR2NT_5"]D?\T9W_P JY#^C
M1 K]+=S^G\7_ *+;NC-R=/VK9$'"7>FO\5-V5[B:>OZ2^KB48W39KJHO$Y-1
MNU0*OAV1NB1LK[_Q953HII%5,1=$N1<M^[/M]6RL*!9%7;XJ6/@^++O:T?N2
M.NMF\V;)B'6/[HS?T?I+4\]EPEG^]/EDT>M_/'EG!%S^6<?EQ,8+ODHHW\IH
M+L)?2TM*P'\[L_?MNRI7I"]72UJRW8Z-_!WXR;S$ZF<QTV[?]P2'ZG?NRL2$
M.KJ@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(OG=NVK!JY?/G+=DR9MUG3QX[63;
MM6C5NF95PY<N%C$20;H)$.JLLJ<J:293'.8I2YSCEF=W9F9W=WV9F[N[OY,S
M>UW74B$!(S(1 1<B(G81$1;<B(GV9A9F=W=WV9N[JO.P^(96KI.2="XNU?;N
MT;Y%O%(R7GM=O&-8YWILBEG'NHW?H^Q)9H95D4_4L:'H!-A657"2B"<)A?'I
MQ+AB#B!I<E/'C8G;D(3,YW)&_P!52!^K]'*;H@V[.Y;=U3)]:06II*>E\?9U
M1<C)XY)J1!7PM61O-K><G;PF[>;QTFNS]G;H[KBB\H=1="?LSLGIN2K=0>?>
M7YNX[=3VIJ"=J;[BD1=]WNE"[QV&U=M<F0E4(.1U="NE,J>W#8;'RB;MX^C4
M[8ZD)R-Y7<BPV)=V^=%6;]2PNS]QY-.3?=;]VQ_8[G\SZ^IL])!6+SP>FBFQ
MU/B_9XK>6)VRUT2'L;0GCXB??XKB^RF#I7G31/.5>-5]&:GHVKX=?T&D"U.
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M@7M%KN'E2L7RLYTK2PDVQ85V?#!S%/<%R[&>[@1J_"G"TYOBWJ\WEA:()VM
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MCY%IBRSS669MH&1LW@*KX"OUO"#:>U&UDA.2-WCZ;1"X;"PMR-R=F9I"<7X
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MX[-N,$K5\]B[%R2Y#U W8J]ZF<KA#.[S\ABA8RZ3=!7GBKKUI 1 1 1 1 1
M1 1 1:-Z$YVUATWKMUKC:,4[<,B/V5@J]F@GZT%>-=W6'/E>NW_7EK9XQ)52
MYUQYG#J*F&!_KCWF$@@^B7K^/=;52Y/1F:: F9]G P-N44T1=CAFC?U9(C;L
M0O\ 0[.Q,SM$YK"T,]2*CD(R<.8S5YX3>&W2M1]X+E*P/QE>U 7K1R@_O V.
M,S HJZ*Z#V?IO9L'R!V;*-7]]FRND.=.E$6*,)3.H8*,3]S,%,MDL_+Z7T-
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MB8VF""7H" B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B BB;UMS)CH>I5Z7IMCQK7
MH73\TK>^>-R-6WO/J%>DVWL+QTND0N3S>N;TP+FK[*J#@J\?8JVZ/[C4\E'Q
M3AK(8^]X.0QD#KT[ ]*Y6=]FFBWW9Q?YDT1?&0R-L0&S=]G)GKNH\#\-5H9*
ML_@,SC)7N87*".YT[;#Q<)&9MY:-L/U/?JEN$\!/N/4",A\^2.E\]$4J>97"
MMXUOO[44]G7G0VH'#CWWE V$T;E7PZBUCFR>9U]=H_*=KUM;4#+Q]CJ[Y Z3
MI208RB#7C(4O!R@\9]>I8#K4[+-LTT+OML3?-FB+>.:-^X&S]MG%W:<SOPW5
MF&S!X',8V;P6:QA%N5*Z([\HW?O+3M!M8HV6W">N;.Q.82",KQH*Q("("("(
M"("("("("("("("("("("("("("("("("("("("("*K#<*SGOO?,ORO7UUC<
ME: L,2[[ LK%50C3<>SF66D]6.4(F01,5->NP>/EULW\HS466]@]?UTNI&.9
M.:P)VLS8FJ-\V_PA; FQP.W>O ^X27R;V&7K1U-V\^<S;\07G^2=]89B33\+
MN^G,--&6I9Q=^&3OAQE@T[&;=B@A]2QF>+N_%X*+\'DFVM(:M6S)LW9LVZ#1
MFT02:M&C5)-!LU;()E20;MT$BD21012(5-)),I4TTRE(0N"XQC$&[N[N[N[N
M[[N[]W=W\W=_:[J_B(@(B(L(BS"(BS,(BS;,(LVS,S,VS,W9F[,O>.%R@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(JZ^P-4WS7=T@NZN<8!U.[@U5 F@-T:
MLB,%34Z8YW;N3R<]2<(8Q@J^T=?FR[N&FY;R,[-*I25,7(^C;,1JA,8Z>*:,
M\7<)AKV"YUIR_P#<KCMQ"7?]@E[1V1WVX\96V(.]*U+C[=*U#JW"0E-DL?#T
M<ICXO/.X1BZDU5A;L60I>M9Q<GRNHTE4N4<_%II:GVG1-WZVI6V]93[6ST+8
M-?866L3;3.<$=QS]/U83<('\EV,BQ7*M'RT8[(D^BI1J\C7Z"#QJNB2-L02U
M9I:\X.$L)N!B_L=O=[Q=MG$F[$+L3.[.RM&.R%3*T:N2H3#8IW(0GKRCY$!M
MY.S]P,'W"2,F8XY!*,V8Q=FV$,*W4!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!
M$!$!$!$!$!$!%!WM3>UYI$31]!:!49K]3=+R4E3-4'=(X>1^M:['M4U]D;]M
M;;ZDQ5]35]R62:MUBJ?:&Y/:M6F[5[\R<I)RF-JQ2E+;M[M1I"TD^S[/,;OM
M#4C?9_C+!ML[M\B-C-]N*J>J<O;J1U,/AG$M09TY*N.<AYQT( %GO9FR/EX?
M&PDT@B^_7M'7KL)=0MM[\\:&HW-&H*=IS7Z3L\+5F2IG\W++Y>6.Y6B5<JRE
MLO5MDS^:TK:[C8'<A/ST@KG/O/WRI$"(M$F[='4N6I;MB2S+MRD=MA%M@CC%
MF&.*,?(8XP80!F\F9O;NZF,+B*F"QM;&4F)XJXNYRR/SGM6)">2Q;LR/WDL6
M9B.:8W\S-]MA9F;=8UE*("("("("("("("*M7L3Q,M7<B;&JNL9&HS6P[')-
M&<S<$:_+Q\>:E0$@O[;!54CINZQ*S[Y!->0:U]16)QF/^#=.)1LE(M#*8SD8
M'9G9W]K[>Q>6ZV]*N(T7DZ>*EISY*U* 3W1K31Q^ K2%M&1,8GUK$@L4@5G>
M'XO@92@,H.]DC9=-TW0=)8/A)RBDNGA5,Z2F$UB%4)A1)0I5$C^DV/6FH4IR
M&\RF+@V,X&1>H"3&(FV^Q"Q-NSB^Q-NVXOL[/L_=G9G9^S]U[LY\OKGZ8Q]<
MYS^8%V3SQ],>?US^3'[_ )?O!O\ R^2)Y_E_Q?3/^+\_U_\ #.,_^(;_ ,G9
M$!%^9SC&,YSG&,8QYYSGZ8QC'Y<YS^;& 1<;F:A\?3,M&8SCZ9QE^U^G_P"4
M=N!?<E^)_P RZ=2/]D#\H?SI\ZAOX6C/Y>U_G0X']R7Y+_F3J1_L@?E#^=/G
M4-_"T9_+VO\ .AP/[DOR7_,G4C_9 _*'\Z?.H;^%HS^7M?YT.!_<E^2_YDZD
M?[('Y0_G3YU#?PM&?R]K_.AP/[DOR7_,G4C_ &0/RA_.GSJ&_A:,_E[7^=#@
M?W)?DO\ F3J1_L@?E#^=/G4-_"T9_+VO\Z' _N2_)?\ ,G4C_9 _*'\Z?.H;
M^%HS^7M?YT.!_<E^2_YDZD?[('Y0_G3YU#?PM&?R]K_.AP/[DOR7_,G4C_9
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MS=8>/$T6\_$&Q)12CMGG"P2031,)2PRQB;F(/)&8,11%PE87)F8GC/U#9MW
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MF'(T:UOBW^C.:(3DB^N*1RC?Z1=;K&LI5 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 15O]RI_A>VSQIR!C\? [9V\]W;M]EY96;/M-<M-HS8"T!,-B?7,7;]NR6H
MX%;W3%3<-C2"&"J8PKE*9Q?ZGKY+(_/KUVJUG\G:S>=X>8O]U'6:P7MV?COM
MNRH^K&^$LCI?37RH<CDCRN2#?<3QFGQCNO#*/MCLY*3&PDS]B'FW?OM9 (97
MA 1 1 1 1 1 1 1 1 1 10G\0W5TYL_D[9B](+[>U]2)1706EY!-,RCR/VSH
MR20V/4",?3G&2K3Z\"XJ+GZXPK&6)^W/DI%C&Q)X><8+\+2_K>QRIV6WV8J]
MIGADY?0#$TC?? SJJZTQ\M_3M]ZG;(XUH\SBS;?D&2Q)M>K<-O;,4+UB]\<Y
MM[5)#3FS8+=.I-8;@K&?];VTM?T_8,*7*F%3I1MPK\?/M&ZI\%+^/;(ORMW!
M<D(<BZ2A#D(<IB8TK,!5K$]<_EP320E]<9N#NWT/MNWT*<QE^+*8VADX/M.0
MIUKL7??:.S"$PL[^\6/9_)V=G9V9^RV0,*WD!%77K<GVX\4#J"TKX_%Z*Y7Y
MRTW#XS]XA7FV+CM7;=O43SGSRFLNT@-?)NRE\BJI,X[.<9,EYXF)OBL'1C;_
M -ZO7+)?57C@KQM^,Y7;ZR5*H_JO7V?L/Y8C3V#QD7T'D;61R-EV]SD$-)C]
M[!']RK%!#JZH"*H'Q;^R9?G[643J+7,LK%;/V\R?F>S+%;*,E4-?-SY8R4DQ
M5(8JK.7LKTRL)#/TOQC1LSL+MJJUDFD>X)BE/BVS>;^WW-_U^)>*^F77$VF\
M3#A<9,\.6S4<CG/&3C+2QHOTY98R;N$UH^5>"1NX %DP<90C)NIKG.<YSG.?
M/.?KG.?KG.<_ESG(U%\<H"("+D(F*DIV5C(.&8NI28F9!G%148Q1.X>R,E(N
M4VC%BT;IX,HNZ=NEDF[=%,N3JJJ$(7&3&Q@%DAAEL315X(SFGGDCAABC%RDE
MEE)@CC 6[D9F3"(MW=W9F7=RX7Y;C>3= 5K7YTFJUXE\%M6S9=#T*?,+E)MT
M?BF*#DOG[T77&J;> BC$]"3A%BI)^RDZDG?KW0'B+-[?-_K_ .NR^]O1_I&'
M1NG*N-V K\VUO*SCL_5O2B/.,3;Y4-46&O#ML)#&\O%CE/>8P[J[("("("*N
MOPS"XKFD]LZ<3QZ6//?7?56H(,F<_>2JS7<%AO=/;YQ^1--M5+W"MFJ./NH,
MDFR)/(A"XQ,9OU[->R_G<Q]"P7TF]<(I'_\ F1%O[WW?VJDZ$^(Q61QC?)PV
MI-0XV+Z*XY.>W6'_ +M>W$+,W9A9F]BL4$.KL@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(JZJ87%X\4W>4Z;[[;0/&VD];LBGQDV&\SO;:&R]A6-5'.?HFH[A]7
M4A)?!,>K)&:&3G\CE*)B3XK!50]MO(V9G^D:L$,(-^ IY=OK?W*E5=[?I RT
MK]QP^F,52#?YLN7OW[EAV]W*/'U&+;[AM]]VVL5$.KJ@(@(J8_$_\4N4X:O.
MGM=:[K%2O%KL>,W/9D;9,RAS0VMR2.(Q@SACQ,K&886:T.6L]F.DI+$DRB48
M4JSF#D4Y- R-[TCI -0U[UJU--7AB_4]0HN'QEKAS(I&,"Y10L4?(0X$;F[-
M(+@^_P X>F_TYS^B_*:=P^(HT,I?N?X2S4-SKN];"M-T(HZSU[$'2O7CCM=&
M:9IHH!K<CK3-,'&V^@WBM;,H]0V+39%.6J=YK4+;*Y))^6"O(6?CF\G'+F+C
M)LI*F:N4_>0-GW$%L'14QA1,V,4JS7EJ6)ZLX\)J\LD,HO\ -DC)P)OI;=GV
M?VML[>:^@,5DZ6:QF/R^.F:Q0RE.M?IS-Y25K<(3PD[=^).!CR%^XEN+]V=5
M?^*IXC\QPA6=9Q6MH6GVO;.Q)EW(8AKDE+/(:(H%?*0DS*NVD%,0<B5]+RCM
MC$P"AWR;4V&\\ZRDZ4B_8-;M':6#44ML[4D\-*K&P\X' 9#LR?:P8I D'B ,
M1R-Q=^\;;MRW7B'IU],=CT64<+!AJV/OY_,69)6K9$;$E:OB:C,UFQ)'5L5I
M6EGFDBKU'>5@]6S(XR=!P>Q#0>Y:MT+IG6VZJ8I@U>V-5(RQM6^52+K1;QPG
ME&9@7BJ>"D-(UV:0D(*3P3'H+(1SDI?,I<9%8R5&;&7[5"?[;5F.)WV=F-F?
M<)!9^_&6-QD#?YI,O7M*:CHZNTWAM2XTMZF8H0W #DQ%!(8\;%61Q[=:G9&6
MK,S=FEA-F[,H6>*%WF[X3TI 6*FQU9L.W-A6<D!0Z_;$I%W"DCHI).0MUEE(
M^)E(22?,(AFK'Q::+269'+,V*'64,LU2<H*3VD=.-J*_+%.<T5*K%U+,L/%I
M.1NXP1 1A( E(3$>Y 7Q<4C,S.[.WFWIP]*DGHMTU4N8Z&E<U!E[S5,54OC-
M)6Z, M-D+D\5>>M-)%7C*&!ACGC=K%RN3N0"8O);CSI&#ZSYSUGO2&2:L7-M
MA,)6F#:*F53K=VAU3Q=M@B^Z<[G#9G--71XI1WZ7#R%7C) Q?2\)G,5G,5)A
MLI;QTCD302;PR$VSRUS9CAD[=MRC)N?'L,C&/F+LKIZ/-95=?:.PFJ*PA$60
MK;7JL9.34\E7)X+]7UG<^$5F.1X'DV.2L4,VVTC.^JO$7[(2XCYNFMJ1C.%F
MMA3$Q&4[6-;G\.U8F6M4IE5TNYEFT<\82*T/!0+&6F7I&CQF9RLU917QS)63
M0<$W-+X)\_E8Z9E)'6",Y[<L>W,(0V9F!R$A8Y)"",7(2V8B/B3 [*!],/I%
M'T9Z,LYV".M9R]BQ!CL)3M]0H+%^=R,CG"&2*8J]6K%8LRM')&YE''!U8BG
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M%/+N398EG;?*^(%!V0C=VBBJBG+KX,W<$?1*I4\\(;OS?R;LWU^_\'\_U+Z
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MR/;;-)-TV^?I7?2'CHK$=/4%.6"Q&;-2NS52&2$I Y=&5B C;S:2 W<W<>,
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MR=*/X[56U9([B0EHA9L?\'=SE%<F45=OVC%)1W59A\J;W'LQ#-GK%XM[CA[
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M%5'^Y W?J0/[&.M+RA)MW?81+YS*&TCE;%['R4,F[-G<#-\$Y@/;)/ +>'R
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MQ,.4R.H<EJC)8U\(%C%T<-1QLL]>Q=DKU+-NX=[(E4.:M',<EOI5X(YYBBA
MNH3$>RN+'J:MR B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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MN1-NU:MD"$1;MT$R)(I$*FF0I"XQC$[N3N1.Y$[N[N[N[N[^;N[]W=_:[K<
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0@(@(@(@(@(@(@(@(@(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>gdc15tqwxkbk000016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdc15tqwxkbk000016.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $X E4# 1$  A$! Q$!_\0
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M1>N;K/JUV)8MHBFI.)4ANFI@95P+95!-,_?*&2*43ZX<U,N,*90U+JF7'E+
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M?)\K?TG/_>GOVS'ZXV*?[LY!_P#*9'^SMQN?KKX]!#2$-(0TA#2$?F!<1/\
MS@<Z_P"6/)W]-IO7V*6_-I?[!K]VF/QME7^E,I??YS^T.1AS6T<"&D(:0C,F
M)LWVK#L;DZ+K4=7WZ&5J=$4FPGG&LBY691<-D*EY);.(8S"5C2(2"DY18EHN
MJ^3D&QHIS(HIM4GBK9\TQ>80\65+*@67"XFR0 5*:=9(55)JFRZHT%#: -:
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M2JKN42I+.YC$ A#MK6V9-FY$LCDJ5M.E-M"76E-*0D,T3:8$N5H6IE3R5!L
M!.=+=K=%LFL<L;+LJ6)0.)8><DYIJ:0\X9L*=+,ZK*"6GF6YIN46@S*B5+3+
MIF+ 2VE]*4@"B'[HCG/PMI5;1&/6?EKX?$.'9P1"'GSDB8)HO9Q87R"Z3:'!
MX_)L=&W6W04=8N_6CV438I,C>#3>JIO4[=C)?<54Z;$UMH$J3>HA%6E;B]E1
M;0I2+B5(%54J#CVSY0!?LHEDY_)8R418<.;:27;,RU5TV)Q"'WVT.WI0AYRR
MV%D+%39]TDSJV4P^\7A*/)2^'(N'A8R3D763G"%HC:WCZ8QE6T;-5RY*3H[5
M>'JTPHD$C3:O49.7?LV,A87LPX(N+B.Q<O5^BG 'U*44@,BP5.I>787F<X0I
MQ-:.+<"02E 2#=IVUY0(D+34NI4@AMM"E*G"'D,RCDDT'6=M[626V'"+4NRP
MMQ02IY3A%]G6'BG35X(*)PFP:\^\>IY4LF1KY*RT!"13".AOF?*CCNJS+.>F
M)NR5TDTXF;]+K3,?5TF-FEBL8^)?)LU)M_=,G_\ 4')U02!F4--)2I1)5?G'
M5I*4I2NS9:39*]PDDJ%;(X[N60=CTMD5LNJ5MUZ;FEK:;0E",)>58=2ZXX\R
M%ER97G$,A+SEE#:K)=78;OBRRZI=<%WR-?QT#-\/56QC5J$A%I21X95+$ZIE
MJW+ST1*2LDRD)=V<PA,J()L6#PGS"#!F43 .HDV,W,-$%29E3RG*TM?+]^E*
M@ 0D5W.)&LQQCEF=VQDZ90I+3F3&I1J7"+9;.TC5I;C:UK2I:O\ B4"4JT)3
M&1;?QW9'L^/'&)8O'V)J)C/R8J$_$TVGQ=V"/KTO5KS9\B.GT6^L]\LTVNK;
M++:GREC"9E98B<>RB(NMDKS%@1$^3>3VD.YY3K[KI2M*G'%-U4E:$-@$(:0D
M!"4"S92FI*E+MDUCE3&R*9?E3)(E)*5E,XPZW+RZ)@):6R^_,E2%/3+SBB\Z
M^LNYU;E$I;0UFDH BYG'=(<YK2]BG$:YC)C)V*<XC;$LX:PMG'R/D^)J>HMC
MNJD<FYN#DA4X"0Q]"^4Y-X5[T-!>1).#8#+-SM:#)4L$I3:>*4B530J1>)1+
MJ&P:-CO@ZK.4I4@6;%#796RO**ENN9J42MUW*KQ*4/;E>5W)=R8* I\W-*E6
M\P%6K(*\X7:BS7)CNF^87RC]2&Q?@NH%DQR<[?(05>OKUJZG,NY'Q=E6Z6!=
MM:\CV5%9^[MV)X)9HQ4*:OLXV3FXM.%%HI%$B:IR2P*6GIAPIS(!6IH;EAIY
MEM.X:1N0A]0)[XD)-JMJUJYLNGEV\W)9.E\YMPK#3<TH*=GIN2G9AXA^;>!6
MI^1:(2?D@A;B W9* W<TEW5_-TK(QKUWBO!ZK:(M<%>HZ*<(YED&R%QK67BY
MMAIX\A*9E?V%RLSNJLD5..=S:\(6 E7$$2+(R8PA8JB<C2Z4J2'I@6D*;41M
M<50IC:ZDT3+A(JW9)(2%%:0LFI5:V7LTR@XM"U263R&WFYE"#M]:4OM3PR@A
MVTN?6ZHB8M@)6XIL-++80 EK-XU8]T6S3'DAGB%3Q:-LB$JI!*7P\-;!M$MC
MBE9<;YMKV*9(I;J2NA3FMZ9L55I"/@&%\=PS)K!N+HI')^!'4Y+8-H6WK!MJ
M#=I!0EUQ@RRGA5NW;+1(LE9:"B5!L&E.&G93/I2V0Q)EYL,-;9*'\^N4EIX9
M19DETF SF$S*4&VEI,RIM(;5,%%T7!C_ +IQG+'4BPE(>GXR7>1EFR?;6"YC
MY5@G*$ME;(#/(MA15?4S*=7?OH1&69A%I5N2=/*_,5UPYBK=&V4JA525=R3+
MO)*5+>LJ0TA0^14"EEHM)N<96 JR:VP M*]TA2(VE-E^491:%MR\HI3;LXZ@
MDSK9"YV93-.@JEYQA2VPM-@-+*FEM$H?0[B.OF=F7MCG)FPR71_)&=E9&9?]
M$;(,FG391XL^==%9MB)MVC?PZZG@6S=,B""?>I)$*F0I0[-*0E*4BM$@)%22
M: 4%2:DGC)J=,>7<<4ZXXZNEIQ:G%60$IM+45&RD !(J30   7 4BE:F*0TA
M'Z2/<Z/^87P??_9VQ1U_6?%_D'J:^3Y6_I.?^]/?MF/UQL4_W9R#_P"4R/\
M9VXW/UU\>@AI"&D(:0AI"/'%E;\S[<6-XRCDFZQF7N&UK&V^_7&T1[9_:,A)
MOV[*P6*1EFC=ZFAC1P@F\2;NTTW)$7"Z15BG*FLJ0 .;WS&R>0;99;4S.$H:
M;0HAMHBJ4 &GRPJ*BXFEVB/S_._DMV03$Y-S")O) 0_-3#R N8F@H)==6M(4
M!)$!0"@" 2 :T)QBP?E<WB_].7AB^^O)'XKM:]M63^ G=/\ PFO)_P ?EU<<
M<;N3[(O#,C>DS?X&'RN=Q?\ IR\,7WUY(_%=IVU9/TL3O--'_P"<0[D^R+PS
M(WI,W^!B/RN;Q@>G+PQ??7DC\5VH[:I#@)SFFO)_QOCCAW)]D7AF1O29O\#$
M/E<WB_\ 3EX8OOKR1^*[4]M63^!G>+Y)KW]WKAW)]D7AF1O29O\  P^5SN+_
M -.7AB^^O)'XKM1VU2' 3G-M>^AW)]D7AF1O29O\##Y7.XO_ $Y>&+[Z\C_B
MNT[:I#@)ROV37MSW\(=R?9%X9D;TF;_ P^5SN+_TY>&+[Z\D?BNT[:I#@)SF
MVO?0[D^R+PS(WI,W^!B/RN;Q@>G)PQ_?5DC\5VI[:LG\!.\TU[^'<GV1>&9&
M])F_P,0^5S>+_J\V7ABW\7EKR1^*[3MJR?P$[CP36'/X\7KAW)]D7AF1O29O
M\##Y7-XO_3EX8OOKR1^*[3MJR?P,[S37OX=R?9%X9D;TF;_ P^5SN+_TY>&+
M[Z\C_BNT[:LG\!.\TU[^'<GV1>&9&])F_P ##Y7.XO\ TY>&+[Z\C_BNT[:L
MG\#.\TU[^'<GV1>&9&])F_P,/E<WB_\ 3EX8O%^NO)'7XOV+M0-E63^ G/(T
MT?\ YA#N3[(O#,C>DS?X&'RN;Q?^G+PQ??7DC\5VG;5(<!.<VU[Z'<GV1>&9
M&])F_P ##Y7-XO\ TY>&+[Z\D?BNU/;3D_@9WFFO?P[D^R+PS(WI,W^!A\KF
M\7X]69>&+[Z\D?BNU';5(<!.4^R:]F>_C#N3[(O#,C>DS?X&+TM/YGOXM)N#
MQQ&MLO\ #8DM4*6^KT@=Q:,AE2<.W.0[[;"+,A3QFH8[4K"T,6YSK$04!X@[
M("0HD266HC91()4Z2S.44L*3\DU@&FTW_+W&J3KNH>*.0]^2S9 XW*)3.9(J
MS+J;768FZ%1FIEX6?]B-4V'4U)IN@H4H 39?RN;Q?^G+PQ<NO^RO)'+_ /U=
MJ_;5(<!.<VU[Z./W)]D7AF1O29O\##Y7-XO_ $Y>&+[Z\D=G7_Y+NS3MJD.
MG.::]]#N3[(O#,C>DS?X& _F<[B_#KS+PQ!Z]KR/V]7_ )+NW4]M63^ G>::
M]_#N3[(O#,C>DS?X&'RN;Q?^G+PQ??7DC\5VG;3D_@9WFFO?P[D^R+PS(WI,
MW^!A\KG<7_IR\,7WUY(_%=IVTY/X&=YIKW\.Y/LB\,R-Z3-_@8?*YW%_Z<O#
M%]]>1_Q7:=M63^ G>::]_#N3[(O#,C>DS?X&'RN;Q?\ IR\,7WUY(_%=IVTY
M/X&=YIKW\.Y/LB\,R-Z3-_@8?*YO%_Z<O#%]]>2/Q7:CMJD. G.::]]#N3[(
MO#,C>DS?X&'RN;Q?^G+PQ??7DC\5WJA[.I[:<G\#.\TU[^'<GV1>&9&])F_P
M,/E<WB_].7AB^^O)'XKM.VK)^EF=YIKWXAW)]D7AF1O29O\  P^5SN+_ -.7
MAB^^O)'XKM1VU2&EB<YIH_\ S"'<GV1>&9&])F_P,/E<WB_].7AB^^O)'XKM
M.VJ0X"<YMKWT.Y/LB\,R-Z3-_@8?*YW%_P"G+PQ??7DC\5VG;5(<!.<TU[Z'
M<GV1>&9&])F_P,/E<WB_ZO-EX8M_%Y:\D?BNU/;5D_0S.\TT/_G,.Y/LB\,R
M-Z3-_@8?*YO%_P"G+PQ??7DC\5VH[:I#@)SFVO?0[D^R+PS(WI,W^!A\KG<7
M_IR\,7WUY([>K_R7=NX:GMJR?P,[S37OX=R?9%X9D;TF;_ Q>T1^9\.+1A1;
MI65<O<-AWMBE:<^9KI6C(8M$4Z^-A%V1R<V,RJD46\ED.C FDJ4PIK>$,EL3
MO\SLHD,XA69FZ!"T_-M5JHH(H,]>!9-;](--$;H_)9L@$N\T9S)%IQQA:3MB
M;LT:2\%5)D@03G4TH#6AK2D63\KG<7_IR\,7WUY(_%=K3MIR?P,[S37OXP[D
M^R+PS(WI,W^!B/RN;Q@<_P#EEX8N77_97DCEZ_\ R7:CMJD-#$YS30_^8P[D
M^R+PS(WI,W^!B'RN;Q?^G+PQ??7DC\5VI[:LG\!.\TU[^'<GV1>&9&])F_P,
M1^5S>,#TY.&/[ZLD?BNU';5(:&)SFFA_\QAW)]D7AF1O29O\##Y7-XP/3EX8
MOOKR1^*[4]M63^ G>::]_#N3[(O#,C>DS?X&(?*YO%_Z<O#%]]>2/Q7:CMJD
M. G.;:]]#N3[(O#,C>DS?X&(_*YO& /5F7AB'_\ ->2/Q7:GMJR?P$[S37OX
M=R?9%X9D;TF;_ Q#Y7-XO_3EX8OOKR1^*[3MIR?P,[S37OX=R?9%X9D;TF;_
M  ,1^5S>,#TY.&/[ZLD?BNU';5(:&)SFFO?&'<GV1>&9&])F_P #$/E<WB_]
M.7AB^^O)'XKM3VTY/X&=YIKW\.Y/LB\,R-Z3-_@8?*YO%_Z<O#%]]>2/Q7:C
MMJD. G.;:]]#N3[(O#,C>DS?X&'RN;Q?CU9EX8A__->2/Q7:GMJR?P$[S37O
MX=R?9%X9D;TF;_ P^5SN+_TY>&+[Z\D?BNT[:<G\#.\TU[^'<GV1>&9&])F_
MP,/E<WB_].7AB^^O)'XKM.VK)_ SM/LFO9G_ .,.Y/LB\,R-Z3-_@8?*YO%_
MU>;+PQ;^+RUY(_%=IVTY/X&=YIKW\.Y/LB\,R-Z3-_@8?*YO%_Z<O#%]]>2/
MQ7:=M63^ G>::]_#N3[(O#,C>DS?X&+MNOYGKXM;%,LY!GF#AJ120J="@S$=
M6G(A%3.JQ1:Y6GJI2I8R5*+==[$N%VAA,"AVBB!U4T53'2)FWLHD$I(+,X25
MNJN;:INW5* ^>U*ONN(IQQL_^2O9"ZL+$YD>@:80:S$V-TTPVTJ@VD;K2#9.
M)30D FD6G\KF\8'IR<,?WU9(_%=J_;5(<!.<TUASWJ]<8]R?9%X9D;TF;_ P
M^5S>,#TY>&+[Z\D?BNU/;5D_@)WFFO?P[D^R+PS(WI,W^!B'RN=Q?^G+PQ??
M7DC\5VG;5D_@)WFFO)_Q_P#+CAW)]D7AF1O29O\  P^5S>+_ *_-EX8MO'Y:
M\D?BNT[:LG\#.\TU[^'<GV1>&9&])F_P,1^5S>,#TY.&/Q_KJR1U>/\ 8NT[
M:LG\#.\TU[^'<GV1>&9&])F_P,/E<WC ].7AB^^O)'XKM1VU2' 3G-M>^AW)
M]D7AF1O29O\  Q#Y7-XO_3EX8OOKR1^*[3MJD. G.::]]#N3[(O#,C>DS?X&
M'RN;Q?\ IR\,7WUY(_%=J>VG)_ SO-->_AW)]D7AF1O29O\  P^5SN+_ -.7
MAB^^O(_XKM.VK)_ SO-->_AW)]D7AF1O29O\##Y7.XO_ $Y>&+[Z\C_BNT[:
MLG\#.\TU[_Q_!N=R?9%X9D;TF;_ P^5SN+_TY>&+[Z\D?BNT[:LGZ6)WFFC_
M /.(=R?9%X9D;TF;_ P^5SN+_P!.7AB^^O(_XKM1VU9/X"<YIK'0/GOC5#N3
M[(O#,C>DS?C\!A\KG<7_ *<O#%]]>2/Q7:=M4AP$YS;7OH=R?9%X9D;TF;_
MP^5SN+_TY>&+[Z\C_BNU/;5D_@9WFFO?^+EY7<GV1>&9&])F_P ##Y7.XO\
MTY>&+[Z\D?BNT[:LG\!.\TU[^'<GV1>&9&])F_P,/E<WB_\ 3EX8OOKR1^*[
M3MJR?H9G>::]^8=R?9%X9D;TF;_ P^5S>+_TY>&+[Z\D?BNU';5D_0Q.'_\
MJ:\G_&,.Y/LB\,R-Z3-_@8];7"ABJ=P;PSX'PY9W\/*V+&&*:31YN2KZSMS!
MOI.N0+*,>.HEP_9Q[U:/67;G.U4=,6BYTA*95ND<1('AYYY$S.3+Z H(>?<<
M2%@!02I1("@"H T-X!(XX^ZY$DG<FY'R9D]]3:WI.1EI9U314IM2V6DH46U*
M2A102#9*D))&($; ZXL=I#2$-(0TA#2$8V<;=(<"(_\ 3*^KN('-RY#N/7U]
M0<];C >(1@<3XS''V<N7C >KGU\^OL ?LAMS$-Y^/CUQ$0[T-QVV]0=P$ Y\
M@$=^L0WV#GMOOV;:0@(]7/;U.8;#RY;>,.?;V>( TA#;?JVZ]MP#Q!L&X;".
MX[AU;<P]4-/CX_PA\:XCV<]AY]?(1YCU^J'+U.W<!V$00B':'+EN&_B'KY[=
M0<M]^?+GXATA$1#;KY<^L-M^7/EZO+K#?KVWW -(1 /&&_+Q!V["._6/4/\
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M$.S;2$=4%;XULPW'CSXF^'F/I4]6*1BCAOGK+BR/O&*LC5Y+(&1ZC9R1<MD
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M ! 2@.^X .D(^3((*#WYT4U#EV[TYDR&$ (<JA-A,41*!5"@H4 V #E P?-
M @]L(XP:-0() :MP()B&.0$$@()D>\\$;O0* "9($R]X/[7O0[W;8NR'BB(-
MFI3)F*W0 Z)2$1,")"F1(0#]Z5,0+N0J8',!"E$ (!C=[L B H1:<_CFBVN=
MI=HL=7B9B>QU+3$Y291XW[]Q7)>?A'];F9".#<J)7,E!RDA&N3JD5$[=VJ
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MZM'\(PK>NY1\0<=ES#%?JS:I7ND@O6Y*?R8ZKM<K]-X88R*X@LV9ID\:<.D
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M$V3#ODRB $[T>^*40V,4!!"/HS9NH("9NDH)5BK@8R1#""Q [TJP=\4=EBE
M"E4#YL"@ %';K0B/1FVX"+=$=OFB?G1.0BJ"^X;%W ?#E*L(@(#X4 5$1,'?
M:0CC,Q8F$HG9M#;)BB BV2$2IB!BF3+N0?F#%44 2!R$%#[E^:$!4'QXZ^V$
M1,Q9"*G?-&QO"'*=0101'PBA3@<#GW*/?' P=^ F$3 8 -UAN"$1Z(U$3FZ*
MW$3%3*8? I@)R(F 42''8 $$A* I ;D00 2 7ELH-0A4ZS'T#9J50BI6R *)
MBJ*:G@4P4)X8QC+ 0X!WQ?"F,8R@@(>$.(B??F.D(Y_'L'5OMR'J$0#??K$?
M%]GQ;:0C(,?\XM/J=+_Y U@K$^,^V-TX#Q#V1UC]T)[J)0>Y[6#&=?N>+KAD
M);)D/8YA@XK$O"QB48E7'L6R71=EE0$ZRCD\HF=(R/S)"I' _,Q==QDO(SF5
M$/+0\AH,J2DA:5**BH$U%"*4I'C-E6S26V*O2;,Q)/S9G&W7$EEQM 0&E(20
MJV"2255%-4==?RRO@S_LTY8^^NG^]UVO:C,>&,\VOICRG=>R=^AYWTACHA\L
MKX,_[-.6/OKI_O=.U&8\,9YM?3#NO9._0\[Z0QT0^65\&?\ 9IRQ]]=/][IV
MHS'AC/-KZ8=U[)WZ'G?2&.B.1'\TIX-6621#AJRN455")@(VNH" "<P% 1V+
MOL CN.AV)3 !.W&;O_QKZ8#\KV3B0.P\[?\ _P ACJQ*VS\T-80K5JLU=<</
M>57*\#8)B%6<)6.HE176BI%PQ562*=3ORI+';B<A3;& I@ P=\&I1L6F%(0K
M;;-%)2JEARMXKK\7KUQ#WY6,GMNNMG)$X2VXM!(F&+[*BFH%G30F\ZA%OA^:
M-,%A_P";KEKL#]<E/Z@#;SS?U?%OS$!U?M5F/"V?,7&?=;R?^AYSTACJP'\T
M:8+'_P W;+75M^N2G\_7_//] >/;3M5F/"V?,7#NMY/_ $/.>D,=6'RQK@O_
M +.N61Y;!O9*>.W_ .IMV>+3M5F/"V?(A8_C$]UO)WZ(G>?8\NCXXH?+&>"N
M0?U.N6N75_9+3^O[IVCS$.W3M5F/"V?,<Z?CV1W6\G_H><](8ZO^</EC3!?+
M_P '7+/+JVLE.#[/]O\ [-.U68\+9\Q?3#NMY/\ T/.>D,=6 ?FC7!8?^;ME
MKJV_7)3_ .(3CR]33M5F/"V>;7TP[K>3_P!$3GI#'D^C\<</EC3!?_9URSU;
M#_9)3^?_ .IZWK[<]PY:=JLQX6SYBX=UO)_Z'G/2&.K ?S1I@L?_ #=<LAU!
M^N2G]@[^><_6-N':.^G:K,>%L^8OIAW6\G_H><](8ZL/EC3!8!RX=<LAOR'^
MR.G<_P#]3_O]?K=JLQX6SYBX=UO)_P"AYSTACJP^6-,%[[_U.N6OOEI_,?5_
M/.?+D/(-PY=H[NU68\+9YM?3#NMY/_1$YZ0QY?H_'%$?EC7!7(/ZG3+&P;\O
M+)3^>_;^F=>W5U[?Q.U68\+9\J%GQ<G+QP[K>3_T1.>D,=7"G12(?+&F"_\
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M4J+8(!-2*D @&G"$L^6'9@(.:9<;:=42 4K=SF;!23:():<!4 4I4D)40I2
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MQ4DA1)NQO(MJ4!4$$4"J"AH*8$&@[SDP.4A"J'!10I"@=0"]X!S@  8X$ 3
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ME$'+95)9$X<CIG*8.0ZQ(()!N(-"-1$9D4)!Q%QB?TA#2$-(0TA$TG\Z.O\
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M)HE0-U=T3=&0L$%-;'>DE55 D6JTLHJD7BXU/'%E4?A8RJ>XVK*.1+/.N:S
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MMM3DZM+G7M\D[MT&K!6&0E9"0W1-NH2E(H0E)3BXDD$I4*J;6A6YLI":$;D
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M8A*Q2"=SON1X8RSNQ62*1CK/93!$9+>0MBR15VU6H0E(K:J256C7<D@64H.
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ME3YS$<10I6NKPM]C%KB^5MZ%_M,HRG+ X?+3-AC"V:,C'029AFRL)2I (6+
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M &!%"1J)\M+HS(H2-1I%=$I1 0$I1 =]P$ $!W'<=_7'F/C'GI"(@  &P!L
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M&QW"QK;S(W)5XO'U,GZ%!O%[1-8CELBQ9W%>LTQY,UNJ76N8^EIER%D<TP;
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M.&7'F%FYVN)'61+<OC=N9!VV!*FJS;P\ 5)K(&,_;-O(\4!:-GP],;MA21=
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M$E$WE1O<4=6%O=37$X 5R:LV^.FX,K]N99C(D8%?Q[ATQ<MW"O#<2$+4D&T
M=RK?)-Z5<5I)!IB*T(!NCCJ%E1 -0#<=8Q!NUBAC*^J16&D(:0AI"&D(F'7Z
M87ZG:?YHCK1WOA]FU^Z1%E8CZJ/V$Q+ZSBL-(0TA%#8V: DYR>K3"59NYZL)
MQ*M@BD5.^=Q*<\@X=0YWB>P>#+(MVCE5L.X]^1$X\MM200 2+C6AUTQY(FAH
M#H-:>3&)B.G(68<3+2)EXN4=5V4"$L#:/?M7KB#F1C8Z8"(F$6RJBD;)C$2\
M3* Q>%1=#'2<>]\%T9ZV54$$4)! (J*C$5(J-8J"*C2",1$4-UV-XXQ4BH\H
M(\8,5340BS<B4.NY2H5SQK;T';FJWVKSE/L;=@_=Q3Y:$L4:XBI--G)L547L
M>Z.S=*E0>M%DG+942K(J$4(4P2E10I*ABE04/&#4>L1()201B""/&#41A6*X
M2L4MFCYG9WN1<HIR-0R#072F7,E6_([D],R@E3TKE7"N;+)O%DXR0\HT JW1
M3.4T<X(^<,3H+2+LZNA>62"+"**2H6$)1ND6K)W(%XMGQW5PBV<5HLIO!W*0
M+TUH;A_6/DNPB]L*8"QGP^UH*CB^(>P\&$52H4&[Z:E)I;R/Q]1*YC:KIB[E
M73IR91G4JI"L5US*BL]<-U'[LZKQRNL>JW%.&JB":J-P O4I2SA_64?%A$*4
M5&IUDW"EZB5'#C,6)0,%X$X7I^ZY'BW$O%6+,=@HE0G[5>KO:;A)2SUY:I6/
MQS2V+^SR<JX0:C;\AR[>%:@<SEQ)V58'CQQWR'@;*<<="4FA#840$I2F@H"M
M1L@:$BI.@>.LE2U@ WA(40  *7 J-W$!71=&<+ED"FX^;1;NY6!E (S;Z2C(
M<7?ASJ2DC$52R7B28L$&R*Z[IVUJ50LT\=NBD=4S"%>G3*<Z8$-F$E5:"M*$
M\0)"03_ZE >,Q4 FM!6EY\I ]I \L7CUZB(AI"&D(:0AI"&D(V(KWZAQ'^+V
MO\B77KY/\UE_LD>R.[8^9:^HGV1Y+_S3!^R3PH?6/E'^?JCKZ%L1^8G?M6OV
M%Q\._*_^>Y$^ZS?[YF/,/KU\?'8:0AI")IC\^L_JIO\ RQ-0<#XC$IQ'C'MB
M^,N?LK9._P H5T_I)):HS\TU]FC]D1O-_G<U]X>_>*C'NM(X\-(0TA#2$-(0
MTA#2$-(0TA#2$-(0TA#2$-(0TA#2$>V/N*W]S_QK]=N3_P"G,Q^7;KXEL\_I
M]?W26]BX_0?Y/O\ =B5^WG/[0OXTQVNZ\9'M8:0AI"&D(:0AI"&D(:0BVKC3
M:ID*L35+O%?BK35+$R/'S<!--$GT;(M#'(H";ANJ42B9)9-)PV6)WB[5TBBZ
M;*).$4E22E2DD*22E0-00:$&)!((()!&!&,2&/\ '5&Q55F%)QS5H>G56-5>
MN&D+"-2M6A7<F\7D9-\N.YEGDC)R#EP^D9%XJN^?O%UG3MPLNH<XRI2EJ*E$
MJ4<2>*X>0"X# 0)*C4DDZSQ1>FJQ$-(0TA#2$-(0TA$TG\Z.O\(V_P!=K1/S
M;GUF_P"_$_1/C3[%1*ZSB(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&
MD(F'7Z87ZG:?YHCK1WOA]FS^Z1%E8CZJ/V$Q+ZSBL-(0TA'7WFCA'L&8<LR,
MU-KL5\93V0:%8[%"L[A:ZQ*S$%3^'G/V/RQ[X]9"-<.$T\CY!H4TE&'EP8.F
M$0\?.^^78-H]YR&W@V@ 5"PE0!LI(!4XVJZM?H)4*TQ(IKC5+ED75"@E0!H*
M J6@W5K]%)ONH3=KC46D=SOSO 1MV5DGM-<W:1Q->7T-<1RUE)):P<1=GX>N
M&;&L'<;<:%90DP0:U=,8Y6E6]M0DY"823N,?88Z-9S9138[*F6S9H%60M(*;
M"+FDNO+*4UJ+TK;%F@&Y()I&BG474%UH5%D'<!:U$"MPJ"FZ[ C#&YL#<#?$
MU1(NOP]ANL="U^7S!*N[] (Y0F;BXC<(HN<6Y%KE>K+^+QUC6#/)FR90;76Y
M.#:U6!C"4++%K45EYF4(L:5AR8:54A-5! "24)'RGRB22"I9[Q:2"5'=(3<!
M2A;J#6XFB19-D#=44FI%3=94#CWR!H$6U@'N=7$%!IHUGB!OZM\I3C(E!FKV
MS)F6UOPR6WJE*S)%V.[O4(:B4&7C)N[6:Y4Q[.Q$I9K(O/1\0#2QS+U&OQJ4
MA+DRV;VDV5!"PG<)%BTI!"152@0D!5#1-FM4B\T*>1>4)H;*@G<@!))307E6
M !%:"F@7F)N&X$N*_H45&3MS@'5S/BFL5=WGYSF_+$G:H1K'<*#+"T_B-''J
MT$G V"M3.7D)++;J^.IUC)NWL^YG'%?-<(UA(#&V&JDV39SA5F@V@ _+%87:
MK4$-T0$@4 % 0DD0+J+S2ZT2$!*0#\I:"BJ\C<[FS313"&2.#[C7R=-QN0G+
MNB52ZH9F1NT16X[/MUE,?U"%0POPVT5F_E69\/1LO;)%K<<06V>3\J<GC"?B
M&%FD64195S6Z?=-2'F$ IHI2<W9KFTA1^4=41\X0D$+2+PL$@$@614EQM-1>
M04TK8%>^<-!NKA10%X4#05%T9ZXE.$[,.6,]U^^U]&J2$0RM_#G9H2\S65,@
MU^:Q/'8ER(WM-WKM=Q1%PDC1[F2WD3+8&\I-3$6NK-(-&TJW5/6JE),*-/(0
MVI)M E+H*0A)"RM!2E162%)LX4 -UX[Y0BB%I2D@UK18("00JT* E5013"X&
M[#$QI]4NYQ\8T7C2PUJ;RC%R5F-(3SJ)?RF5YF;:O;.\X5>*G#+G*;=PSQ56
M).N6>X77,U"?3YW#VR3"D17G,@\F'4E#L4I;94RR5A00:4 (" " '6G B]P@
MA*4* P )%  21H7FRH&FKZ(! SC2K.)J $*PH*FZXT&:<X\"W$K=82WQE3R6
MW7A(/*,6XQK37.09J";V/"[ISE&[3E4N,E(TRZQ#.1C<C9/@6T3'NJS9HMW3
M\(4(BCQA(KD+%T;F&DE)*+R@A2@@$I7N$A2=TGZ*"30IHIQ5Q%QJEU LU%]#
M55+PJB0"*%)P2;P0:J/'64L/"WG/%F-V5F;7.V3_ !0/9GA\QABB^1TMD+)Y
M(A-;&4-B;(;R^"S@(F%9U:(:R5]O,I=K!"0+&8E:[5)J>=I6,\/$FD.MK59L
MI2S1U:TFR@G=E:0DU)*C1"0E)- 5 "S4B0XA1I0!NBU*!HFIM%0 H:GZ(H";
MB12@J.WVJUQA3ZO6ZE%'>*1=6@8>N1JD@[7D'ZC"$CV\8S.^?N3J.7KPS=JF
M9R[<*'7<K"=94YE#F,/")*B2:5))-,*F\T%UWDCCDU).LDW7"_BT17M1$0TA
M#2$;$5[]0XC_ !>U_D2Z]?)_FLO]DCV1W;'S+7U$^R/)?^:8/V2>%#ZQ\H_S
M]4=?0MB/S$[]JU^PN/AWY7_SW(GW6;_?,QYA]>OCX[#2$-(1-L W?,@$0* N
MVX"([[!NL3F.P".P=8[ (^(!'EJ#@?$8E/?)\8]L;$Y6Q_4U<HY)4/G'%K<Z
ME^N)SMUHC-9ED#'L4B8R*IF^'UT!42$1(<4%UD1,41354)WIQXK3KF:;_P!F
M?/R:+PJ6H=R+[Y@'E /%':34JP9J9)RE) E]XD%O*-15Q5QID\BHP-"1J)%\
M6#YG=0]/?%/[SYP_$UK3/.>"O^=+?B(PVI+_ *3D>;RE_P!NAYG=0]/?%/[S
MYP_$UIGG/!7_ #I;\1#:DO\ I.1YO*7_ &Z'F=U#T]\4_O/G#\36F><\%?\
M.EOQ$-J2_P"DY'F\I?\ ;H>9W4/3WQ3^\^</Q-:9YSP5_P Z6_$0VI+_ *3D
M>;RE_P!NAYG=0]/?%/[SYP_$UIGG/!7_ #I;\1#:DO\ I.1YO*7_ &Z'F=U#
MT]\4_O/G#\36F><\%?\ .EOQ$-J2_P"DY'F\I?\ ;H>9W4/3WQ3^\^</Q-:9
MYSP5_P Z6_$0VI+_ *3D>;RE_P!NAYG=0]/?%/[SYP_$UIGG/!7_ #I;\1#:
MDO\ I.1YO*7_ &Z'F=U#T]\4_O/G#\36F><\%?\ .EOQ$-J2_P"DY'F\I?\
M;H>9W4/3WQ3^\^</Q-:9YSP5_P Z6_$0VI+_ *3D>;RE_P!NAYG=0]/?%/[S
MYP_$UIGG/!7_ #I;\1#:DO\ I.1YO*7_ &Z'F=U#T]\4_O/G#\36F><\%?\
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MFOVCWXGI83PS?([[J%D;]/(OJPZ.EZ.:_:/?B>EA/#-\CONH61OT\B^K&P$
M %A(H ,4X P:@!B]\!3 "1>8 <I3;#UAWQ2CXP =>LE!258 (-&D7BM#=B*@
M'E /%'<L_--WUW";Q75Q@'U1Y+?S3!^R3PH?6/E'^?JCKZ#L1^8G?M6OV%Q\
M._*_^>Y$^ZS?[YF/,/KU\?'8:0AI")IC\^L_JIO_ "Q-#@?CV7\D2G$>,>V+
MXRY^RMD[_*%=/Z226LV?FFOLT?LB-YO\ZF?O#W[Q48]UI''AI"&D(:0C)3W#
M.8(V B;7(XHR4PJ\\I%)05D>T6T-8":5G1($(G$S"\6G'2*DR*J011&;E8T@
M*A : MWY=\A,,%:D!]DK1:MH#B"M-GOK20JJ;/TJ@4TTCEJR?/H:;?7)3:&'
M2@-/*EGDM.%SYL-N% 0LN5%BR3:KN:Q8DE$RD,X*TEXV0BG9V[=V1M),W#%P
M=H\1*X:.2HNDTE#-W2!R+-U@**:Z)RJ)&,0P&'0$*%4D$5(J""*@T(J-(-QU
M&.,M"VS96A2%4"J+24FRH I50@&B@00<"""+HK51HUVO\F>%H=/M-VF$VRCU
M2)J-?EK))ILT1*55V=A#-'KHK9(QR HN9($B"<H&. F#>JW&VA:<<0VFM+2U
M)0*G 540*G5&C$M,32RW+2[TPX 5%MAIQY82,5%+:5*H*BII05BWQ9/ =FCQ
M:.0?D7.U.R%!7I97*9Q34;F;=YX8JY%"F(=(2 H4Y1*8H& 0U>H(J"*4K713
M775&5E5JS9-JI%FAM5&(IC4:12L?;".D)5QT.+8/9)V#=Z\%JP:KO' -(UFX
MD9%UX!NFHKT=A'M'3]ZOWO@FK-LX=+F3014.6"0D5) %0*D@"I( %3I)( &D
MD 7F)2E2S90E2U44JB05&RA)6M5 ":)2E2E'!*02: $Q%>-D6K-C(.6#UNPE
M <C&OEVJZ+.1!FMT=X+%RHF5%V#1<00<BW.IX!8?!J]X?YG0$$D @D4J 145
MO%1HJ+Q7&!0L)2HI4$KK844D)59-%62115DW&A-#<;XDM3%8:0AI"&D(:0AI
M"/;%W%7^Y_XV]6W9/_IS,:^);//Z?7]TEO8N/T%^3[_=F5XYB<_M"X[7M>,C
MVT-(0TA#2$-(1;%PN],Q[!.;1?[=6*/662B"3RQ7"?BJS!-%7*@(MDW,O-.V
M4>@HX6,5) BK@AE5# 1,#&$ U*4J4;*4E1. 2"2:8W"IB0"30 DZ@*GD$52/
MFX:6AVEABI>,DX!^P2E6,Y'OVKR'>Q:Z .D))I)ME5&3E@LV,5PD\17.W40$
M%2*"F(&T(()!!!!H01>#A0C&M=$10UI2_"FFNJ/N1EHJ'C7<S+2<?%P[!JH^
M?2TB\;,HUDR2)X15X[?.5$FK=JFF J*.%E2)$)\T8X%YZ@ DT ))P O)\D "
M;@*G4(^TY*.5D740D_9*2S)DQDGL6FZ0/(M(Z47D6T8_=,BJ"Y;LI%S$2S=B
MZ52(@[7BY%)NHHHR<E24-*TNO%=%12H\E17QB%#2M+KQ7144J/)45\8B=TA#
M2$-(0TA#2$-(0TA$TG\Z.O\ "-O]=K1/S;GUF_[\3]$^--WD5\>6)76<1#2$
M-(0TA#2$-(0TA%-DYF(A4VRLQ*QL2D\=IL&:DF^:L$W3]9-55%DV.Z52*N[5
M20743;)"991-%4Y2"5,X@ )P!/BA&-*OQ!8%N[28?TO-V(;>PKP1XS[VKY*I
MD^T@PEGA(^*&8<Q,T[1C DWZA&,>+TZ'37AR-FWA%C 0;EMQ) 4VM)-: H4"
M:7FE1?08ZHL4J&*5"N%016ZNK5?XKXOQY;JI'%E#R%GKS$D)(143-'>34:U+
M$2DZ9@2#C90R[D@,)"9/*Q9(IF[%)S(FDF!6::PO&X*5H;KC>"1<;P*U(U@4
M-=5#$4-UQOK2[&F-/%IBX=1$0TA#2$-(0TA#2$3#K],+]3M/\T1UH[WP^S9_
M=(BRL1]5'["8E]9Q6)=V[:1[1T_?NF[)BR;K.WKUVLFV:-&C9,RSATZ<+&(B
MW;MT2'5665.1-),AE%#%*41!CA"*>E8J^NO#-D9R'6<6-@XE:\W2DV2B\[&-
M$V:SN2ADB+BI*,&J,C'JN'C$J[=%-^S444*5T@)YH;[C<:&[ WW'4;CR&%#J
MPQXHFW<E',%XUJ^D&3-S,O3QL0W=ND&Z\K(IQ[^6481J2RA%'SU.*BY.3.U:
ME57)'QS]Z9,&S1PJG%#?=A>>(5I4^4@>,P_AC$[I"/DYR)E,<YBD(0ICG.<P
M%*0A0$3&,81 "E* ")C"(   (B.VD(HGEHK/@JZOY8H+P%O411J:WDO'^"M"
MSB,<S;=*NJ=([R;47AF;R71)&F<F5C&CE^0#-$%5230WW'<]]<;KP+]5Y OT
MD#&%#?<;L>*^E^J^[QQ8D[GK!E7E(B#LV9\3UV;GW;QA!0\[D6GQ$I-OHZ<=
MUB091$?(3#=W).V-ECW]>>-F:*RS:<9.XE<A'[99N2P;<()#:R!>2$*( ("@
M20*#<D'Q$'"+!*C@E1\0.JNK40?$:Q?3JTUAC8(BIOK' L[38&4G(P%:=2\>
MWL$Y'PO1?)E_$0RS@DC),HGIK+R3=,FRZ##I;7I2B72$N_K0D%0!L@@$T- 3
M@"< 30TUTBM#0FAH*5.@5PJ>.AIXHKVHA#2$2+64C'KN28,I%@[?0RZ#679M
M7;=P[BG3IFWD6S:2;I*'68KN(]TU?((NB)*+,W+=RF4R"R9S*&Z[&\<8J14>
M4$>,&%#JQPXXXF\W#.Y!>):R\8YE6K4KYS&-W[1:0;LCO7L:1XNR35,Y2:GD
M8V1CRN%$BI&>L'K4#BNU7334.-#0X'D/L(/E&N%#C0TU^OV7Q4](0TA#2$-(
M1L17OU#B/\7M?Y$NO7R?YK+_ &2/9'=L?,M?43[(\E_YI@_9)X4/K'RC_/U1
MU]"V(_,3OVK7["X^'?E?_/<B?=9O]\S'F'UZ^/CL-(0TA$TQ^?6?U4W_ )8F
MD2G$>,>V+XRW^RMDW_*%=/Z226LV?FFOLT?LB-YO\[FOO#W[Q48]UI''AI"&
MD(:0CMJ0XKN'R:CUJ@^@X.LN"T3A%KLUD]<^9[(WR+5,:L\.J9<QG.4"1GIJ
MI5Z83F*@B[@K?6J)&,'[*COX8ZBI[>A83=.J4F4J+B5*6"Y/+2S27065O%_,
M/)=2E*U)LK(4VIQ1!=2K_AE,>U3EK);C:9=3+;*DR^0VG)PJR@[MIF33(F=E
M7953KLNVX'& MM]F60E29=3=Y?#D5"8S5PA3B>/75ND<5VN-BH[#4##P[?"]
MQ)>*98*E77L5/V')UE=5:)1O>'V0%@V;C'T%9; ]F6[ R<95HH[1Q)VJJ6)U
M.="$O()VPI2C,-YMQ+C@4E+*0M1:?.Z.>4A%DJJI:Z@(E4_D5P2BIA<D\E"9
M!M+8R>_MEAUADMNNSKQ:;$S()HVDRK3KJG FB&$62M^QK5DG!MGK4UC&GYNQ
MWABUR@XHM5[S#1,;97HV%,F62G%R-'S$/"U.A8V+D"LH,(RRTR3B$O,HKE8L
M%KA;))/XRN+##23[1#4PA2'ER[KZ$YY#;#CK#LPRAPM$*4XZ[FEDE#@5\NM2
M6U(2%+W0&#TWD]YMR48RC)R#R]I/3$_+2D]+9.FW6!-)<;;8EI3;+00EV74@
M;0::=>;>4I#6X6O(N,,G84QQ)T#B)M'?34]8,_6&B1V7,K4!A-2%NQZA,HV^
MW9ZEJHBUL[V1LS";EQJ#YXRBYV59UYT:(C%Y.P1KEN3-UI]U+DLFY*99+BF&
M'2@-NV<VW+(75%E"DIM@%2$E0M&B"(Y,G-2,HY+95>HMQW*;LLB=GI8.J?E0
MX'W\IK8LOJ6\EQ886I*75I:44-E;J5 <-+S?P;TWRMS,N7&TTP:4P\,QK./<
M9V^AY+CI>0X=,DT?-#?(.2"T!BVGH3+V39U@KCH[%]=!J<+*QSY>'Q8S@Y"M
M+EL3RRL)SR"7+16ZZVZR4B;:<E\VUG24J892K/;ENVH$!3Y4E8,91R&PEE;F
MTW0F7+89E9.8EIQ*UY)FY?* FIS:J0XW/SKJ#*E*YC,-+0HHDTMJ9-,9YJX-
M*LZ3%C%XFNR,AE>)!VM8,"N1:QN&Y[*+Z5L;=G /JLM'P-BA\9NF4&\5@%GT
MDVD6CI:JR\F_2832HR\\L&I>;HRJ@3,WJ?0R$HW86"I*G@5BW9!!&<2FI2*I
MRAD)DBRB1F N<1:+N3"0W(.3CBW0EI3)0VZB44AM6;*U)6"6'%J2AR)M/*_
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M";M3^S15HY)<8*E4#2""X&R6B4!)+905I"%%5P= JE125"H  *=;39)N0+W
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MZMMGJZA;DM:HD(S>)H@VB3,I52MD*IF0:"H !(%#00*VJW!-F\FB;S\L#2M
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M5 .;LH4H!*B4!="4BMU395@:H6D)LJI>I2KP2 ;-$D@ U2%8@ W5N.!QS5<
M<8\ZG).+9;\_56)*RP?"X^KZO$.W6M=8HLCQ?Y0G\L1]_FJS<WT;;<J5?A;<
M8W@):ZN):WN79DEXNHW.[6=H^GWMRXR"*);/SA4<W<5!A(19JD$(4]:(31-U
M+24BZ+%;8I0()W94;%Q(:2$V016R7+1H0-!(2+HJ-<Q%QFXF7K5MCY+.V7"1
MLT+NZT&7SM6IV6L=:JN?):+I<-5!OU[A*DTF%\ R;"6L3B5L,"6\K0N]^GI#
M("B:BXK87:!#:*@V56% )4IL%1-E)) =!"0 ;-=R+$"IM51N4ZB$D4)14UH*
MTMW#&F@68U0O6!NZ=HTJ3>TR#R5'9(MJ@VN4EJ3FBCI3P9+@,*8@K=$5M\NZ
MSMBF-F*8PL\!=(><6EB93C7[=NW3=X<F6<O'6FM:AR5M7E%D7 *0JE@N.%5D
M9M=%4*2*6"-#@H4F]MBOT:"Z]*J!-I9-!8-]X-UDBMRKB#E^,X=^+:DO;I'P
MU5XAE\5'S-<+/;*G1^)"K0>3,HU&U9TXF[Z97#MSFLR1;BB=(87W!LQ8XZ;N
MV'I"5;5N\Q2+]-^_4+9:%UE5DDM6\VD J:)2A0;93\HD(HJ]+@%$K JDTH+J
MVVR!4HM60 2@D)(0VG= )O-RZ$!6BMP%+QC\ <=BK",LTIDK-#.[(M8ZHHQK
M#-T ZAHRBR'#UDJ)=R$I!NWHT:QY1@\HO,:%D;R^KKQT^N4$M9H0OE5D; XD
M(+DO4I"463NJYLUM9U)H"!:""BW1(4-R0#> (6VL E-!?WIJ56TW5QLD6B!4
M7&A-:1MOP'UOB$J.&I. XBV]I2L;.\2HU->]V+RP7E[3EH6O* ZL_>YXXH"1
M3D]L&U!&QY,^Y!*:#",D$R4M!\CCZJXS!;*P6Z4LBU9%$VJG#Y-GZ-FOR:;Z
M]]WQR=*2K<4I2^@H*U.&X;K=2^P/+B=U=81G#2$;$5[]0XC_ !>U_D2Z]?)_
MFLO]DCV1W;'S+7U$^R/*O^:0*1=+;D7A:6JM0M%F294K)B;Q6OP$M,IM%%IV
MIF1(Y/&M')4#JE(<R951(8Y2&$H"!1V]_L4<;;9G+;B$5=:(MK2FHLJO%2*X
MB/BGY6I:8?G,C%AAYX)E9L*+32W DEUJ@44)-*Z*XQYJ/,:R_P"E3DG[QK1_
MNO7K=L,<.SSB.M'R+:$_X%-^C/=2'F-9@]*G)/WBVC_=>HVQ+\.SSJ.M#:$_
MX%-^C/=2'F,Y@]*G)/WBVC_=>FV)?AV>=1UH=CY_P*;]&>ZD33+#67P>-!'%
M.20 '3<1$:-9]@#PI.8CY%[ 'KZ&88H?EV<.$1JN^ER:XE,A/U'^Q3>(_P#M
MGM?U(O3*^'\MKY2R2LCBW(RR*U_N*J2J5(LRB2J2EBD3IJ)J$C!(=,Y! Q#E
M$2F*(&*(@(#K-J88#357V1\FC%Q&]']:-IJ0GC-3)$E-$%]X@B7>((+BKP;%
MXU&+!\QG,'I4Y)^\6T?[KUIMB7X=GG4=:,.Q\_X%-^C/=2'F-9@]*G)/WBVC
M_=>FV)?AV>=1UH;0G_ IOT9[J0\QG,'I4Y)^\6T?[KTVQ+\.SSJ.M#L?/^!3
M?HSW4AYC.8/2IR3]XMH_W7J<^QPS7.(ZT.Q\_P"!3?HSW4AYC67_ $J<D_>-
M:/\ =>FV&.'9YQ'6AM"?\"F_1GNI#S&<P>E3DG[Q;1_NO4;8E^'9YU'6AV/G
M_ IOT9[J0\QG,'I4Y)^\6T?[KU.V&,,\U75G$=:'8^?\"F_1GNI#S&LP>E3D
MG[Q;1_NO3;#'#LX5^<1AK[["&T)_P*;]&>ZD/,:S!Z5.2?O%M'^Z]1MB7X=G
MG4=:'8^?\!G/1GNI#S&<P>E3DG[Q;1_NO3;#'#L\XC1C]+1#L?/^!3?HSVC'
MZ&B'F-9@]*G)/WBVC_=>FV&.'9YQ'6AM"?\  IOT9[J0\QK+_I4Y)^\:T?[K
MTVQ+\.SSJ.M#:$_X%-^C/=2'F-9@]*G)/WBVC_=>FV)?AV>=1UH=CY_P*;]&
M>ZD/,:S!Z5.2?O%M'^Z]-L2_#L\ZCK0VA/\ @4WZ,]U(>8SF .O%.2?O%M'^
MZ]-L,#%]GG$=:'8^?\!G/1GNIQCEAYC.8/2IR3]XMH_W7IMB7X=GG4=:'8^?
M.$E-G_\ 6>ZD>S3N-E:L=?X#,<QD] 3<))(VO)9U8^7BG\:^2(M=I=1$ZC1Z
MW17(15,Q5$S&3 IR& Y1$!WU\8V<_*Y=6MOY1.U)86D;M-0%U%4U%1IOC[YL
M!9>;V-2J'&G6UA^;JE:%I4*S"R*I4 147BZAQCM+Z([]#./N*GO=>/S;G!K\
MU71'L["]ZKS3T0Z([]#./N*GO=,VYP:_-5T0L+WJO-/1#HCOT,X^XJ>]TS;G
M!K\U71"PO>J\T]$.B._0SC[BI[W3-N<&OS5=$+"]ZKS3T0Z([]#./N*GO=,V
MYP:_-5T0L+WJO-/1#HCOT,X^XJ>]TS;G!K\Q71"PO>J\T]$.B._0SC[BI[W3
M-N<&OS5=$+"]ZKS3T0Z([]#./N*GO=,VYP:_-5T0L+WJO-/1#HCOT,X^XJ>]
MTS;G!K\U71"PO>J\T]$.B._0SC[BI[W3-N<&OS%=$+"]ZKS3T0Z([]#./N*G
MO=,TYP:_,5T0L+WJO-/1#HCOT,X^XJ>]TS;G!K\Q71"PO>J\T]$.B._0SC[B
MI[W3-N<&OS5=$+"]ZKS3T0Z([]#./N*GO=,VYP:_,5T0L+WJO-/1#HCOT,X^
MXJ>]TS;G!K\U71"PO>J\T]$.B._0SC[BI[W3-.<&OS%=$+"]ZKS3T1-)M771
M7(=&<;BHVV#P*FX[>&WV#O>S<-_7UH&W,VY\FOOD?15_7XOX?XS879.Y5BG0
M=2HE>B._0SC[BI[W6>;<X-?F*Z(BPO>J\T]$.B._0SC[BI[W3-N<&OS%=$+"
M]ZKS3T0Z([]#./N*GO=,VYP:_-5T0L+WJO-/1#HCOT,X^XJ>]TS;G!K\U71"
MPO>J\T]$.B._0SC[BI[W3-N<&OS%=$+"]ZKS3T0Z([]#./N*GO=,VYP:_,5T
M0L+WJO-/1#HCOT,X^XJ>]TS;G!K\Q71"PO>J\T]$.B._0SC[BI[W3-N<&OS5
M=$+"]ZKS3T0Z([]#./N*GO=,TYP:_,5T0L+WJO-/1#HCOT,X^XJ>]TS3G!K\
MQ71"PO>J\T]$.B._0SC[BI[W3-N<&OS%=$+"]ZKS3T0Z([]#./N*GO=,VYP:
M_-5T0L+WJO-/1#HCOT,X^XJ>]TS;G!K\U71"PO>J\T]$.B._0SC[BI[W3-.<
M&OS%=$+"]ZKS3T0Z([]#./N*GO=,VYP:_,5T0L+WJO-/1#HCOT,X^XJ>]TS;
MG!K\U71"PO>J\T]$3#EHZ\(7]#./G=I_T*G8U1 ?VOCUHXVX5"B%_-M#O5:&
MD Z-8BRD+J-RKO4?1.]'%$OT1WZ&<?<5/>ZSS;G!K\U71%;"]ZKS3T0Z([]#
M./N*GO=,TYP:_,5T0L+WJO-/1#HCOT,X^XJ>]TS;G!K\Q71"PO>J\T]$.B._
M0SC[BI[W3-N<&OS%=$+"]ZKS3T0Z([]#./N*GO=,TYP:_,5T<1Y(6%[U7FGH
MAT1WZ&<?<5/>Z9MS@U^8KHA87O5>:>B'1'?H9Q]Q4][IFW.#7YJNB%A>]5YI
MZ(=$=^AG'W%3WNF;<X-?FJZ(6%[U7FGHAT1WZ&<?<5/>Z9MS@U^8KHA87O5>
M:>B'1'?H9Q]Q4][IFW.#7YJNB%A>]5YIZ(=$=^AG'W%3WNF;<X-?FJZ(6%[U
M7FGHAT1WZ&<?<5/>Z9MS@U^8KHA87O5>:>B'1'?H9Q]Q4][IFW.#7YJNB%A>
M]5YIZ(=$=^AG'W%3WNF;<X-?FJZ(6%[U7FGHAT1WZ&<?<5/>Z9IS@U^8KHA8
M7O5>:>B'1'?H9Q]Q4][IFW.#7YBNB%A>]5YIZ(=$=^AG'W%3WNF:<X-?F*Z(
M6%[U7FGHC8& *8L)%%,42F*P:@8I@$# ()%W 0'80$.T!UZV4!$JP"""&D5!
M%"+M1CN600TV"*&PFX^**;8QV.TY[#WBP]>P[@*?Y=GK]6N8@=]<#ACY8+K4
M:J>N+<[X?HAW$1WYCX_'R$-^KKVVWY;ZO0:AR12IUP[XVP#N(=8_MM^T>OQ"
M ]>_C]72@PH/)3'IA\7_ ,>*/G<?&8.0AS$>8\_5#;D(;!S]7U9H/CR= Y(1
M'<=P#<=]^6QA$ YAV;_Z0'U^R*#"@OXKKM=T,<>F.981\,ON;8!44#M#D!M^
MP>8COU]8=>X#RTH*UH/CR>3Q>I'#N;K PCR]GUO& ]H^+?<.P9H-4(=\(=8C
MN'(>W?;??D ; /( #8-*#4/BO2>4PJ=?Q\ 0[XP=HCN!NKEU!ZNWC\>W+M$-
M1075 XJCIPA$0$=@#OAV !'K$-]]N77X^L.7+GV[Z4&H<D(@(B/[80#;?K'G
ML [[;#RY[_Z.0Z4&H<FGXIR0^/)A ##S^:,.W/K'D(^/F.P^(?'S[.:@U#D&
M&KQ0@ FYB(FY\@YCU\^7,>?:/K[?94&H:\-.N$0W, [[CU\MQ_+EZH;!VAJ:
M#4(1]"(\QW$0Z^1MNL.77S#U W'GV;=<4&H<@OB:G"IY3=IB',=Q P]>^^XA
MMMMMX]O4 /%X^I0:AR>/I]L1\>SXY(B(CSV,/(=^?Y>KU<Q';80W#G-!JA$
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MMJ:#4(1$1, CN([<MQW$?4ZQY;^+EN'LZB@& Y/9"(B([CS'Q[;COSV]7?F
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MP$1\>VW-0:A_A\5A\& B.X\Q#<-^9A[=AYB(\^O</6Y^(5!J'QA[3\&%>,_
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MZO$(1:3K^/CRZX?ZQNQ+]#[(.:R?^/A\F?X;^8A0,Q@.W+^M50Y#V?\ CCU
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MEN @H)HD&T%@(-A0Q%0O$A)K?2E*V#( M*5=9T"\*HDA)&(J%8FE#HB^<?\
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MSS[CC+ 2C-I#3:E%*;#>X10;A%4)HDD19>HKXN(W887T%3\5!CKH]1G<P?\
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M\\VJU;)&D3/;!;+--.^DBITF3GI5ZMW[AZNH>2M:@ I2B$TL@DD)H !350)
MNT 0*E$ $D@8"N%P%VJX"*(SP%A]G3)W''E K;O'E@D*_(/*,^BF3JIMS52&
MJ4'6FL;!G0Z"P9032CUI6+;()%*R?1R;U Q%]CEG.+M!=HVA6BJ[K=%1-3B:
MVC7B-(FVJH54U%;]-Y)-_'4^2Z*32.%WARQK..;+C[!V+J78'LPSGW4S6:7!
M0TDXFHUM96<=)*NV+)%8SJ.:7*V-6"@F_03:QS*#8$DI!R125.NK%%.+4 *4
M*B12ZH\ME-==!6!6M5Q4HW4O-;KN@1>1,0XL3>STB3'E.![:6UL9V1QY7XT3
M3C2^>0WEV:RA1;B1ZWMHUZ#/8T5RG3F5(MFK(%<*) ;5;:Z 6E4%"!4W%-;)
M'U:FFJII$6E7"INI2_"E:4\5;HE8C"F(8"DIXVA,:4F)H"3Z&E$Z='UR+:UT
MDE774.]@) L6BW*U![".Z] N(IUX/P\>K#19VITA8-O!"M95:*E%5"+1)K0@
M@BNH@FNNIUQ)4HFT5&M"*UOH00>6IY3%4B<:4J)KE"JQ8)E(Q>,O(A2E#+H(
MR#J"?0<,ZK\=+,EU4OT/*HQ#^08@];D1.#=^[13!-%<R>H*E$J-2"JMJEU:F
MI!IHK0TPJ!$$DUO[ZM>,$U(.L5UQ9-CX9N'JWU]&J6C"N,Y^MMH2EUMK"RU/
MA'L>T@<<$FTJ%$-&Z[,Y&K"GHV2PH5YNW!,D6WG)9!J":,@Z(K8.N)-0M8-5
M&H4:DJI:)-;RJR*UQH*X1(6L&H40:DU!TJI7EH*^(1\.^&+AT?V:-N;O!V*U
MK7#0#6K1-@&C5TDK&UQE".ZRSA63M-@15M'-*V_>5YLV2$J:$&X4B4@*P$&X
M3G7:%.<79)M$6C0FM:XXUOKKOQA;70BTJA-3><:UKXZW^.+ODL18NF'U>DY3
M']1?R%3B8V"K3UU!1ZSJ#A8:Q5FW1$5&K'0%1JPBK13:K8(YJF8$64Q 1;]L
M1)RU34"H6L5 4JA))O-Y(*23K)2I0)T@D:8BTJ^\WFIO-YH0:^,$@ZP36/N
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ME):GUJPS+#R[R4Q&LK\[4C-)A3:W6UVTK!LAQ(+EE%" 4YPI*U)(J0H!1 -
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M,ID&TFG8%.8=V%.)D@EW0.F*<\_67>3*:"@"4DHY5.L_* .3B J[!FKOK[J
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MA-^B[3$K:=;#9<;<;#K8=:*T*0'&BI2 XV5 !;96A:0M-4E2%)K5) E--5*
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M%6\DV+H\K,O"3[>PF*"F;3> '#56[ ;4T--$;E:JV1WU#<!0SG=:0:W*O.Z
M0I IO=RHX:<*"Z,<U;N4N,*H6RMV.3[XXCY)S%MZRT>M8AVK5:U&6!_9"0/3
MG1%W4F8[UV@W!VD>): S8('6B7$JL[E7%U3BU4JA-;RHBNZ50"O%AQF^@(%T
M7,PHTW(K>3C>2FS7D\=_%=%PY/[F=2,C-&Z#7*5NI;U%6LII6&LP%59V^&8P
M.(:1AQPM2[HBR;VVES[R!HD:_0?PLV2"&05*-BJMI2AZX6&JB:4@UL)(H=R2
M;))<6YNDULJ%5FXBNHBJJU2\4_1!H#B203;*P2,"*G2*W7$5->S!,G@TR)]^
M<_>$*3OU#=\H?O2@7OSFV#OCFVW,;8-S"([!KBQC'WI"&D(:0B:3^='7^$;?
MZ[6B?FG/K-_WXGZ)PQ3X\%8?QB5UG$0TA#2$-(0TA&-,F8RC<FI49&2D'3 M
M&R53\EL^C(H+ ]DJ<Z7>,H]R#@# FU<*K;JK);+I"F0R1@,&X62HIM4^DE2?
M(H4,2#2M-*2.44K&I*G 1#1B^.+!1LK6:EWO$55QI7L?VE&LU.<:1[K'C+/L
M"O*3%:F&2\9-%L]5XC+Y$/F??L3QSU&&FXU\B[:+)N=ML$V@I"5)6I94FJA6
MWFR*$&HLEI)&-;P12-,Z=U:2%!:E*(J1WUDT!%XH4"F.FO%1Z[W.NN4YW6&5
M7S+D!I1X>R4Z_6"GR<#C^34N&2*=0E,;M[8\L:58CY:#0E:Z+9>3K5;\BX1*
M88H.(="*BEY&%?V,T2%5;25%*D!55;E"E6K-+5#0X$WT-Y)OB2\34E(J00#4
MW))K2E:&_3CKT4J]:[G9AV@QT/%8Q5;XW8*4;#%0R,SJ%0JL,SRC)X'NU/NU
M"OEA;1S%F1M=4EJ[,PLS+MA4/.0UI41DP<KU^OKLJF96HDKW9M.%)4I1L!Q)
M2I(J3N;P0-!3=B:P7E$DJW1JHIJ2;-L$$"_O;P::QQFM(:=S-P6I>+E-V66N
M=JQW:,A6[*,9AYW.R,)4Z?<+?4*K2E5*_)U=]"6)*!@8*)M\?5ZPK(FA8.*R
M/8H%FV+!LH./CYVTY1- D+2A*+= 5%*5*50A514D@J-*DI!Q)K.>504"0H "
MU2I(!K@:BI-"32I(!QC<O#.,VV&L74O%,=.2=@A,?Q!:M6'TT)5)1M3XEPNV
MIL$]= =1636J]6)$5D9EXHI)398@LO**'D7KHPXN+SBU+( *C4@86CWQ&JTJ
MII@*T%T9J5:454 )-33"IQ/%4U-,!6@NC)VJ16&D(:0AI"&D(F'7Z87ZG:?Y
MHCK1WOA]FU^Z1%E8CZJ/V$Q+ZSBL-(0TA&LUQP7>Y?,;_*5+S0[HT79JE1*7
M>J2:@5NSM;-#46=N\LW!K/2CE"3K[F2:WV9C7*[(BW@2D:NT2^&2$#:I<2$6
M5(M$*4I*K1%"H)& N-+(-\7"A9LE-:%1!J10J"1@,>]!C6F4[F%B:6J$E4G%
MYO"::V*L-T"#=-1C&I*[:,0/,4R 9)8MD$$SFFKXO@;"K:Z1Q7:#9Q&T)!"'
M<Q+Z5>R>M1-+"@JRFY:U$7WA=O<DZDYQPIU%5X-*1?/*J#0=\I7&0JUN:XT3
M;53C-]0*1FWAGX.ZKPT/UI>%ML[:I60I9*I,.YEC&->FNE,@W;(K^72Z&07*
M0N92[NF)&[UW)O!91S)>3EI:55>2+C-UXNBA2$@*J*?52@#R!/$+Z    56X
M5BE  #44\0%/4,*#BI2-2WW<EZW,+54L_G^]S\?3,<O<;5UI+4VB/'4+!GP=
M>>'F-:P$LXCU7U9BT,?7)-_.1-</%%N%[B$K/9'3YJX3@F6PG"*T;2"5A9H5
M $YQ+I)%;S;% 3WJ#9&LZ"8I6B *FIH2*FT%FNN\&E< :#7%7R9P5Y6R=Q%6
M:*>OT(3A0NT_.WR\MFEJJ[RPSMFLG"\_X:Y)2!8JXL1M-6D?(ES'F0BEKI.U
MELG#*60DFNK,FH<5"'T(:!I5Y("4[DA(2'0[>;="*U^B%7T(NMF$NI2@756
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MJR"0=(J*$FMP\H8 =\A0QN**7 ZC05BZLQ]STP5?L7QN+<65NE\.$/'71:\
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MVTM*NO-WQY?+#N?["/\ E/('_2Y3W47@/"-PK  "/#UAC8=P 1Q[5MA$-]P
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MY3R!_P!+E/=1.%X3N$\^PEP#A,WS12 ):%4S?-J"8"$#:/'YHXD,!2]9A*8
M 1*.TVE:S\?'MUF'<_V$?\IY _Z7*>ZBSG^#>".,DG<4\PIAA-W'N&;63.GB
MV+<L(IS(D0/&H2TJU@%HN*6DNDH)1J<@\;&D'*A6K,%W.Z01:5K/Q\?%3#M
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M$WYB>B*DFFFBF1)(A4TDR@1-,A0*0A2AL4I2AL % .0  ; &MTI"0$I 2E(
M  H !<  +@ (N      !0 7  8 #0!'WJ8F,!,>'^#:=ZHI8I]PZ:.(U2*5\
M(@W;LV\,A4&46S>1K<B<?-H),*9&-W(2[=T"RJ[QZ@5FZ,V4:H1QI<.U6*H4
M%9RS*,V]=BX:-CT)$8UK%R42T7;-;&V&**Q75D?"OI9^=J]6=1AW\S)+G9F!
M9(B*$9#ME%3MD7$1J\LXCQC)!5ZHY8LV11>I.8^2CGC4Z"J:B* .$9)105T2
M@J1=,JA=P,H0R$8H-PQU %8XZ$M(MTX]%HD4A6,,<X&94\M.(JS6.Q%2-4>-
M3.'\P9D*9Y9Z9J#HXMV22)D(N6!P/5:[8JS8HYV_35K(J':LR^#09*+J5MC6
MU70MV?1FY73M)F=Y(+G064>N7!@.8A$R@*$<,UP_4R;E5IEPHZ;R#FP-9]T\
M9(LFC]=1O+V:6.T&3;MTY%-!P-E.T452=$<E;QD:*2R:J 'TB*7U^!XHEW'#
MW75B 1*P61J8CIR*;E)T@I(&BW9+(1Q$NI)PBL_?"<;(HN,PZ<*3BCV.8R#F
M1</COW#U$Q?\%0&%<8ST)&.W18"8"0.V9.E7,@]B#RR>\DBSEI!RZ>K,7#]1
M[+E;/#N!1D))YX)4C3P#9)",;&X;:6F9J,>X7B@0=LG*Q6,=#(E<="5F%$S?
M,,2^ ?(A-.PCY1'O7L68149J)F57!016(\OQ4]-..D<,9PUU>,0DR(3DT5P_
M7KJR2K<C)BS0"N-$&" .H9F@C$3"[UHW(H\>2S-VZ3EC&G(U6/E"HN$43%6)
M@&ME>/G@SMF^:%NZ@VR,B9BUKDPV0KP)2[1&.!H$BJE)5EA+MV<T,BP0=KOT
M2-^A.2MDD(OFSX[AK::O*2P@8];62<L/ M6A4TW24O RY7*":B2O1%@/ IM2
M*-C$43;/'92' QBF*A&.XCA\AXM=JX/8I!^L@-<%1PZBH,SS:K/FSN,38/18
MF<PR2Y&Y4)<L8H@I)@5 RBJ943I+(13VO#/5F;)HQ2F)(Z+6-=Q^SE!J\,KX
M9K.,D5/#NO#/6R2J,^[6F6S-VW3F)!O'OQ,S49IETA'VOPUUIPFB16>EE!)'
M-6"BYFL61V/0:FK4D#M7;9JW<1B#AHX6<2K2.4;)RBA6B*QB-V:9#(4Z?77V
MQ<$A@2F2D=6(U^+MZA5HA.(8DD#%ED01*[K#E0S=O,>2"<<18E6:M56T?T=N
MH@[>"L15=45A1!&.BHI6+84X9*PH<JAIZ4.8CYNY 5HZ$7,*;>PIV@%3&48F
M$TX:3)T,+&/]=$Z]M")G*D7I HF/I+A@I:!D?!2LVBFD_M3\4VJB#( 6MA67
M35$RL2-D0<(J1Z ).'"+H3MEGK94A@=>%20C)T?C6)9T<]$65(XC%Y!S(NO!
M1L:Q;*F>60]E<LTXILW+'(1YW*AV@-"HF(#,W>',HH)E#(&_U>HUBQX[AVI\
M0Z3>1KZ68+-CUY9HBQ418QR;FO&AC)K.XIDFWC97IX0C<'1)-LZ!%507D>9G
M((,W;=$4_P ],?+?AVJJ!3)!-V8$$(I@SB$&\D:/3A9:-9,6S:PLPC09F7?%
M=LU9;HD@9Y&#(24B8S0R"Y44T3%^6C'J%N8U=M)R/1G-8L+*PMW4='M$BJ.6
M2BQB$3;N0<I-Q435%-10 4(8QE%/ =\9,$D(Q?$<,M8B6,HW+8K J[DW42[Z
M20S=JR04BTC(& T$W(6%=D>IG.N)'C)8D9(F+)0)8ET@U,W0BODP'6ROY!\,
MY9=U%T9"#;(2)F+6MRZ*%8 LDS1CP:!)"G(U.,E6[*;\D6+5RJ_;HMP8N0:I
M(1=%TQ?&7<]>/(2#M@,"SFV)%(I)!HX.A.LD&;SHBW>G\CE.];)B11$BIDRB
M8S?P#LC9XW0BTJ_P^U:O*'<M)*4!Z,%.0B+I(Q$3-"SRT6Y<J(@85U%VJ3B*
M2.2'D57\2X35.W?M'B)2D!")"(X;*7%)QXF<+/'<8X!TR>K,(TR[10LY)6!,
MC)59NX=-4&\A)K':D*Y.JB"2!_#'<%,N=$$5KQ@CE^/;% K_  M5B/@V+.;<
MI3CLD?3$Y2,!A%LJT_>TXK0R*2;1*+.9NTDS-"HR3D&YW3@R[N0\$1RY.D5$
MQ76O#S#JL6CF9E'CZRA"MF[Z2[Y XC.^3#.??2K*049%D6ZR[QL:.1=E\&Y1
MAU 0(4AB% J%/BIBX:9B?R-QMY1;0:*7%W8EI^00AF;4(?8+6E8VT:DV4BX]
MLLU,1JV:O3&BVW2._<J>#!0_A3(CX^.F*&SX;Z?'(.D8^2F61EDZF1N5J=LW
M8-S59@W8 HM#((IQ$D>4*@9VY/)LG2C*35&5B5&$DB@[31,3Y, 5HCQZ[\G+
M+L(-G$&V1D3,6M=F6B%?\!,M$HX&82"R,E6V,NW9S0R$>@[7?(D;="< V20^
M/CX\<5Z[XG87M!@$E(%9.FD&\@%56,3'&179/I^JV!=,B+M-=5J47%4:H$!L
MX2.F1TNNDHDZ2:K(H1;E?X>JI7D81LC+3[Y"*;RJ"Z<B\Z85\,DM)K%60*L!
MDX)9N,LY\*: 3CBR*B$:YD2N746Q610BKT_"L+35(-\TFYZ3FHE@UB7<I+.N
MD)3$6TBX**1:NH1'H\"T433K4([3=1D:S73?LQ<%-LX73.A'#:<'U^T2]BFE
MWJC9Y80,980C(IT""RS>D,72A5'#87!^D1M$CF!3@LFZ:HOY,[-VW64;J-D(
MMJ&X9ZC!,X5LPEI(%8AW6WAGZK2*.]?+5E]9W;1=RJ5FF!G:B5G<L1<'*J5)
MHU;$(B(@810BJ3W#W5K'8I:>E)&2=$E8]:./'O"-I),J2L.WB2*.7<F1XZDE
MV8MRO6#E\=9TW7.*9G"K=%HDV1!%?\/$1_&+?<\,M=>RLPNI)G8Q;H1/%MXN
M.BFSYF+B5?S#MJJ]!@"GD21P_4(TATSBP Y$'ZJ0OFZ:ND!\<=P^+HG4N'.N
MF<R:"RPMH0X27D8R9E:F SFRPTU$6Q^\:FC4&C=:7:R44S.@CTHJB598NEE^
M_?/6Q43%:IN'U*?DE]:62\:6O#"3+"/:E22&6*XG7=775:"9.+:E8P40C6")
M1<<A(.VX'?.%BM6:GA!70B"?#W2$WC5ZF>0:J(N%G#I2*5)!/I R[*-:'Z1+
M098Z63/X2,3>^&;/45A=KKG,H('$ND13C^/X^7BTWQ+$X>Z\!8DBEAL/@F"C
M8L@FS.PB0G63.,A(EHQ>J1;1HLT31:0QR I$*QYN\EI5(@)I+-RMD3&5ZE6$
M:C&%A6;E1Q&-#J)Q17/A%GK-@+APLUCW$@NLLX?HQJ"R4>P5=&.Z*S:I X7<
M+"=04(NG2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(
70TA#2$-(0TA#2$-(0TA#2$-(0TA'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>gdc15tqwxkbk000020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdc15tqwxkbk000020.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %N ;0# 1$  A$! Q$!_\0
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M5Y7$I4E66U>&%>5>,9SE*O#.,^"O#/AG&?R9X2M"BH)4E10=JPE0)0K 5M4
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M>C\DI"T8Y?1O(W>'3N_*!SYX'7KGSJ9M37V^BNR\K@(.R$6N3M9,I2IX51.
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MSUMOAG8MM^SPD]5I&.K5TBK#(RON !L3<A7I@6 %*=(RE!QN+.N.D!W$*?\
M;9%5)Y4IIK.'<)P*X?<:H^N=2+LT.^::FP]/ZLM]YGW02(,==VFV2YQ[*P\[
M(PB=*&H5P9S+K9?#!C*GE9;;^,B\]'4@#>A>%(.U)"B % JR!G;W=P(.#XI\
M:[!U)U_MZ+WV@PB*L$(% .2K&PR93! XS[101[;4>8MY7IRQ1DKA@D7#2R<X
M<9^9I7Z3&7N9KT9M"\5+7QF;FRK7?;-"M"KDUK:3<T/L1Y+4F),0W#?6\=ET
MD2KCR)$<LJD;5M>L O8SS#"0\PME24K0M73 2H**5>\#)3@9SG'3(\ZW$\]2
M:QE6-B_Z8*R_P?B_RA#<^;0_MJ7;\5&?Z9 JW3]<N?@T?II*Y\.P-8_MT$S&
M?_XZ8S_SXQQ,^VI:?Q4>_ID^H*^NF_P2OTFOJ\?G>U#_ ,6T_P G)Y#4OV?Z
M"^]O7]$HY]<Q_H=_4--M?MFT_G_R\#_SP/\ \.3:Z_OSH'\9F?UX]'_EQ_PH
MJ&^OVM5C]/:_^KR?)>)_]Z;'^-5J_F9U)7R$?A4?UU5;_P#S837]]PW\JB<K
M<4_L,N'[HM_]-9I+^85]*?UA7*[1_-18_P!X1_\ ."\O]:_8/>/WL:_78J9_
MZW7]Y_NJ.?KI7.?_ -%W_P"4^#UX<D__ &*__(JC_P"K_P#N?]BOG6'YIZ[^
M\!'^67QHS[!K1^]3GZ7J@Q];H^\_WUQF@?S7P?\ ?4S_ "L9RRX6_87;/PUP
M_I\BI8GS"?I5^L:I-"_M:L_Z>V#_ #$9RAPQ_O1>_P :;M_-PZ1?D+_"K_JI
MJ/\ ;+N#]/3OU@[C0?\ ??7WXTROYV11CY<C\*:C1?SN[?\ _-;^3G.1TS]G
MFOO_ .!_T-=0:^N)'^9^BH1/],!:/T""_78?D(7VT[S^*T?^E0*BGZZ<_!)_
M2*2W],!5_P! C?UV8XF_;3LWXK2/Z5/HKZZ;_!*_2:C>OIMS4'_G1_Z8]O'&
MIOL[T#]-[_HC=0=^N(_^?^BH;<_;+I_]/0?U@'C7G]]] _C3%_G8]1?^7'_"
MBN&[._FY&_M60+^2IK')^)7][+#[M66?]26*MKM]82/P;G\TNOS2>=[5XDUZ
MCO@7?TF_>/\ 2*L_]%#^<\\?/[TC]P_^?C5W?Z)GV%\0_P!WQ?\ 5K]>7'G0
MU<(5Z?\ X)7](;\1K]'K!_ZF[=SY9KC[(=,_A6OZ<S7;?HU?:MXO?N:9_P#A
MV=7F Y]3KB2O3=\.#_N(/Q%?W\WQ_P"H+5W/ENIOL[TW^#M_^L9==I\'?_T:
M.+W[IU3_ /A2R5YD>?4JXLKVG_S/M_2F27Z6V'^63.<HZO\ MN:K_%W2_P"B
M?7IIZ*OVK(W[\7?^D"MP-/\ ING;']XU7_TQ0F>?-;!]L377[GL/\L!DUT6W
M]<R/H:_4%0J7Y[MI_O95_P"2P.2V+[9&M_W'9/Z!$HCZY>^\1^@5$'^F"F/X
M.6?Y6C.31OMJ7#\46_Z?#J(^NE?@1^M4)S\_=*_0Z6_RI;D+G]L_3G[P3_TS
MJ*^N6_P:_P!-1V'^=+37]^6C]3CN-5_9KP]/_M[W_1XG^^I7?KB,?PG\@'^^
MH;CSX2VILX_+C8\)G_D)'XU_]?Z%_&^V_P \W49'BQ^'1^FH[]_:?$_IA!?Y
M)O'%+['X/[_VS]$BDKY"/PJ/ZZY'?'YK++_QX3^7XOEWQ/\ L)O'WUN_UI"J
M,KYA?^;^NFJV_?FBG?T3;_5F.7.J/L#N?[Q)_F&ZBY];J_!?[-(S\RH/\&+'
M_19/$/[7<;\3&O\ 4@J*/K=/X%/Z@IIW\UM6_>\S^43N.'_V%63]R/\ ]*DT
MC_,M_>UPG7O\V<=_:D9?]=7GF-X5'.C8?NESQ_\ W*S_ %U)$^83]*OUC4K1
M7^U5Y_A&L/ZM&<EX9_6.I?QON_\ ,P:1O!W\.Y^A-1U5^W+<?Z7M?Y4EQHC[
M(.('[_H_3+J+/SDC\(/U:5#\]>U_[PJW\DA<6'[8VN/W)8_Z!&J#?US(^AK]
M04#_ *825_@X;_E:-Y"/]M:=^**/Z=#H/KL_@/\ ;%1G?S]4?/\ Y(S'_O7_
M ./)KG]L[39__8-P_P#._P"^HJ^N6_P:_P!-?.QOSGZ8_?"R_JT7R&KOLRX=
M_NN]?S$&H._/QOI<_534=Q_[::H_A'@_UAGD.(/U[H;\;K;_ #K=)'BQ^'1^
MFH[^^E,C,_\ E=!_\QG)N*733T,^R_6S_P >HR?FT_A$?K5R6]_S66;_ (T-
M_+T9R[XG?81>OIMO^MH-1D_,.?0/UA59>L>.H9OP_P#L>C/_ "!LYS_Z,<N-
M3?8%<OW@']&147?F%_@S^BHQ'YEX_P#@T8_Z,IX@?:[B_B<W_J841];I_ I_
M4%0TU^:ZJ_WB;_*1_'#W["['^YI'],DU"-\PW]!_6-<%UZ_-H!^^<M^M9YC.
M%/V'1?W9/_GS4L3YA/TJ_6-?.C<>$??,8_)C8]AQ_P C$=QPUZ1-3C_[87?^
M:ATC>#OX=S]":CJS]NFX_P!+!_\ WER&B?LBX@_OZU_YRC/SLC[]/Z#4-8?M
M_P!S_I#$_P"1+\:,^RGB'^^L#]2=1GYV1]^G]!J^//I-7-8-0'8W5AW922CQ
MYDE3$M%,4B-F<AJQ#&6%,E'H0,T5ZF7?;D$#N"#'K&0$^\II2'\CNMOJY,L_
M'_AK.XVR[.Q=))$^*WI:#=E1"+/*O0FQ6T1FI7,+O*?D-*C1YBXR(;SI;4A\
ML.(>54[$\E2GSMVEM(VY.\8).2,8Q@_LLCV5"R=C=61W9.* )F2$L0T812Y2
M92'E4,#8%GR+;@SQ7J8=]N*22V*6<V,L,=Y+REO889<>2O7'_AK;^-L2SR+I
M) M\5S2\^ZIB%5HAWHS93;D9Z5S0[RH[[J8TF6B,N(RZ'"MX--..IAV)]2TR
M!MVALC;D[SG)R!C'ACH5 ^ZIVWNP^LJIO.C14I)'+73G),:T&! +*"AGY@)M
M##+[B7$O$.#(<;=.0 .7D9*LM*PHIMT=N?B3QZX=:6XK::LUSGSEO:><E,7Z
M5#@JDPK2]<8R.4W(<2XEYY;*'$.2TPH\LQPHMJ!D(=90$)YU33Z=H2@+[JB0
MI6X;<CIC&?V1'N\LSNPF_M<5.\:TB39(L\N#G(FT3'R<5)S,?#F>S+#>=>]9
MI#KQ8>,&,C"Y?>4(XR\I*4D#^K6XR\<^'^DM5Z,M,Z?+FR[?<+=?;EZIC)FL
MP+;+[-(BO/N\]I*UR(N)33$;M#QC.,O%L(?9+D#">?Y:T[4AMS)"R058Z$)Z
M'WCK@9&*^NRN_-;PT)00DRK\P3-R%?O0+<,-@G&:LMDY(TH\M]T5#23<NYP(
M.I7NG/1>RMEM*,95-QOXX\/K!;M',+N,BZ/7E^T:MAMVB.F2?@\ZU*3'N+RG
MWHK;2)96H1V2LR5\ITJ90$9)<)Z0G:G:G8X,E9(&4YR!@*R?#W>^JKL-O[6C
M>I(0L27>E?N@MAR=:&CA5.%/ 1LD.J0*,;(6,F/2(^VX"ZT4MLC)Z'AFV7%#
M%98K<8^.7#R#P\LEP;N;]S1K5MB?8(]MC<V4]"A2VNV2)+<AR*B$F*\E4-UN
M2XV_VM#K"&EJCR.4<AO2$N-)VI*2-Q62$@@YQT"B<@9&!C'B1D9K=H]AM8+T
M(-9AY@@L:ZBN0L#'CB*^;/2<:X/\U%)$=6TD3Y7E*<&//O)'_#B*'=(2:(I^
MZUWQWX<M\(HFIV[I(E1-5-.VVS08\4FZO3X"VA<HST1UQI,8VX@"4Z^\A@<V
M,IAUY,N*IZ*H;S@<8&T*"0"HD[!G&#D GKUQTST/L-/V0^K_ -C9]JOG!'M?
MD'W/OEWM,_./M=]G/0^4^S]3T_-Z/\\/=>X]E[#\-[CS_@N0_N[\.?[B'PL]
M:2.Q^KO@?V#LI];?"3U-M]5]DYG+YG)^K>T=H['V/XWM&[N4[(]CL^$[^5C.
M>YC;MW9QG&>GAGW5#5_8?6#>A";,1+DBC4H5N%GH]\-7S9J3DW"/E(HPC;CB
M"_FF5*P&\R^H?\ 6HAT=(9:F8Z&X\<.7>$4S4[ESD1HFE66K9>(,B*1=69\]
M3HML9F(TXZB2;B2H1'67U,'E25/NLIBR5,DPWFPA@A)44D!0/<./$Y(! &>N
M1GV Y&:'KSV UHYJ2<+,EGXK[GK9<G9!I$7*"F@)*2(5'DA-C+)2?@LAUL!I
MH9Q9&#W&1W6F\DBJ>M>#W'/AY.X=WJX.W*1;$:);?G7Z/<HW+E-0YTQ[L4B*
MW'<DHF)E/K3#:;CNK>$Q;3#C3:I$<NP;A/,);:5M6I15@H)VGJ21W@DC ZG(
MQCP)P:I>M>_M;3$)?@URA$.3"'6"]G-S(V!_]BR&04DR;"QGBT/>RRUC!0R5
M>Z3ZS.6V7<*SE-#@CQSX?:@MNL6$W"5:7K*]>-6S6[Q&3'/P>:;C"3<651GI
M;;J8A0D2& L24\UK8RX%$I)AO1TA*]JN8X=I021E6,).X)Z_R>^OCKUV!UO;
M+QLJ)$D#(XN=FY:TP^9D5 +$A#A>],-=:>20^AI\0+*C7ABO0=P(T^\G"DCO
M^G)P:X[</]6ZJUG:(4R; EW"X7*_6XW>,W#9GVV()$F6ZRZF0^EMR-%W2W6)
M/9W1&;>>2E26'N6$)YCF.*VJ#CF<())3GH K*1YD#IGK4C3_ &)UG:]YWB*C
M3Y!I5S>C1JN8<!D4*7?APW4/--+RZM\9PI+:W0$G#BJ)3C#/@V6XT.Y1X:\?
M>'>JN*VI+-;9EP;=U&Y$8L$R;"[-"NKUMC.!QIA9>6^PN0A"W(:9L>*7PD-=
MV2MIA;L+S*G7U;"E>WNI)*DXZ=[ICS^Y)_-4FM]D=62/9*4 &E#,C34<-2HJ
M;4'A,,;/H/CVFV6B/6R1@4LD98HAS@J!7G5M+PY@9U#^:5C](3AK<>-DNT1[
MC-*+E'9TO;[PN(E-GF7@3(K;;+4@/F0&),AHQHTMR*B,ZZIM0=##B7C'L+Z5
MJD';M+8&S)WC&"204@= .H"B?=[%F[):LC.R,6"5*&8&A(TFERTV@+"H8&>6
M<>VZRZ1ZV"%"AD$)%,-:$<%8>0ZKU%#M+?Q"_>D+PUMO&N':)-PF[+9'>TO<
MKPB(E5GA7<RY+;C+T@OB06(TAT1Y4MN*Y&9<2XHN%EM;H""\M:9 V[0V0$9.
M]63D$#&W&#D95D^SPJ;N+L5K2I[QH\5)'2+RJ8](L6@P #W040_,!LI99=7A
MY#Y+@J%H=/0".4H=*LLXPX6VZ,W5XE\?>'FE>*FFK+<9=P==TX[*9O\ +@P1
M)A6IVY1F@TV\OG(??7'0M#LQ,&/*+"5%K"Y*'&$0["\\II])0$HW=U1(4K/3
MIT(_.1^:IW8;L%KBIW?6D44<;*%0<U$6N7S"C-&L@PYOLC G5O+)';>?+"PD
MU@<;+SF1'&'E^1)#'J5>,O'?A_I/5.C+3+ESKC*M\^VW^XFSQFIC$&V2Q'DQ
M'77ER6$N.R8A3+98C<]PQG&G5!(>9YD>Q//\M:2E(;<R=Y4"K'0A("3Y].N.
MOY:XWMCOS7,=1JU'#R1,T98AP+O'-Q R7DXK3T?)MB2)*RGA$L>]6ZI(PRLY
M+SEA_P!9EG",95=<9..&@;/%T-#1.E7>3J"78M4V]NTQT/CU#(+Z(MPD+DOQ
M$,IE*6H,,%1DDLO<QEL)!-K/A/2(4M*=J>6T]NWDCJEI>4C:%=>H]WOK\[#G
MJI7A]7I/^#/LNJZ]Z=]P1K"21@ZUW6N1,#'!,X?,.):IQ[Y+N$K<9::$#;4T
MHLAUU"6\OL-(PMY]IM?('I8\1--:!M-C1?GW^UZB4;99H$-D/RYDA$R*X^XE
M*W&6FXT1"VU27W74)0766T[W7FVU=[>B)'<D:.XAH1@?5\7*E$A(_P#1DC&<
M GKCR!KS8<Z_K@FO2U\'&WU^G_#_ /B,R$_(-ALKC2(QI&,*=(>/G]5VR+B1
MVAV\*=6HPQ2D)5Y<-H;9(?=6A@9]QOX9Q:U38]+733,Z]3FXK1N%F@-H +LA
MV9>KW'MUL8;81EQ2I<LJ0A1 ;2AJ0\XM#4=Y:.W?1H2I7"WB\$C/U+-/Y$Z<
MG$]?H_EP/$BO-+S[G7$5>D+X<-VKN/@\_$7UVLS+5IR)O&WLA.-J2V5".Z6U
MS$./#/\ U;<>%-$\"1\^5U+1##S>'4>OECX1J;5MC'&G3FAURBWJ,Z;M.IVH
M:VU)1)M#FH;I;%NQWNJ%NQI<;$A@[7$MOL.MAQ'.+/:O!U"O^C+Q><QW>UZI
M1GV'X)V,]?I!Z?0?=GS>\^[UQ57L%^ IMBG5CK^/1IXQZ,E;#:+6N)+);;3$
MONAR!1;@CIF'LJ%(6QE:F,D,MCNJ;4RE_#ZV&G>#>(G%'2EB](^]:'O$A^WW
M6[:7TX[;I4AMM-K?6S%G2UQE2P\51WRP%*;[0RVRXI!:2]SEM-N>GGHJQG#P
MEBR!M*%7J\IV@G>-LE.21C&.OD2?=6TS679;5M@WQ=!19 \06VIC0*]+R(21
M(R0)AH]IEU.75$*?#29[9U<>HX<?U\>FTYZ!+K3"_@N@_2)X;Z@XLZCML69/
MBLW\0XMENMPB(BVV>_;(:6W$AU4A3\5,H,N+A*FQHX> 0VODON-LKZ/["\TI
MU]6TI6$=U))6G:G!STVG_-4:^-7]EM:6?L!:@ 7Y9ABZYBH:L2AH+; ,E(1H
M@XB6L^!*RA<2;HZL1621FU/Y6TT0@0AU#.9- ^D1P\U)Q@O=I@NW1E&IEP;9
M8+G,AMLP;C-AQVHZ6AB0N5&$];)%N,F,V7BMMMY,9YQ#2HF"\VIQ]1004I!2
M"2I.,9)Z8_,34N)[.:O*[)E"-%27R^2C6Z$%/Y$:Q$/3WS8-+2_/[G)*8H@A
MC(K,BH;#>75MO.(;!SDQ-.V^D;PXE<;GK6U(N/99L=&D8E\5%:%I>O!N$=#9
M#G:>TIM[S[79FIZHP:+BT.K#<,F4(]A>2I3YVXY8&S)WC!S[,>&>F<].F3TJ
M%T[.:PA.QD0(63**!K Q]0GIMD-I<6!,N$'CD8RI122W@XT@CT)$ED5?IN,O
MY';);1ZF6J?2-X=6;C1!M<MZYJC6),K3EXO+,5I=L@W1;TEA\*)DIE.QH#[I
M9G2&HRPVXVZ642&T<RG875J0^"G ;.$9.Y05U&.F/H&:J=W=D==5'=%%B#5R
MQJZ.4=FTEQH;) D<J;$ RPRTI933IKXC.$D'H%:7AE#B66E$&)>%:K\5?2$T
M#I/B=IJRS#=)CFF)$CX02[=%9D1+>JZ1HBFFDJ7):=EO1FMKTQ$9IP,I6&FU
M/2D.QFX=A=>+3R2A(1O(2K.5 X'3 P/#ID]?<.IF=B^Q6NJS9];1?KR,V1%S
M%>N\BN$''?8'@BL#G J2Z46(EXTX'*#1149\N1G67'WF/6:PNIQJX_Z"TM?]
M%6U3EPO+\6;9M4S%69B.\S'M$I+4N&OFR945+LJ9$4B7'CH)'9G&G'76N:T%
MC!=D!"@4H#;H5W]V5;3U P#X'(R?/I[<3.R?8G7,?5:*,&6=.$6A4'>8]J+'
M;SZ=:_&VV2S,F/B>V?*>P^.P$K&2$OB%(*2+Z:<KGXW<?= V>PZ1;8D3KT]J
M-NUZL@-6N.V2W85F0AF7+,Q^*&'9#J7F68AS(#T:0B0B.$!2BH+L@%(*4<MP
M9*B<$I\0-H/M'7PQU&:K-]]C]:N:9A9&.,/E%;):9*KH(HJ$EM,0<T&J87+)
M>?;: ]@4*[&K3AQ];QZ5(%2^,T^4U<<6O2 X?,<,K+=8DB=<_AVVF18X42,V
M):&;3<HXN:[DE]]IJ%V*2RY 6D./*>F)4F,E]AMZ0T7"=?2ZR"E!3M!4K./$
M*&,#)R!GZ",^0JHOG9363O7H6RC%R)&+8(_58N&0(TF8;FXX<?$F.<RHG PS
M,<A8[Y)."G6E,&!+&]PHIE"JVK/2%X>#@U$U0S(N$A&HVW]/VZTMQFQ=4W:"
MRUZPCRVER!'CMP4+9=D2!)<;4S*BKC\\R&DJBJ&ZO>QE(.SJO)V8/0$=,]>N
M!@'IUQ2,[*ZR3UM^T[A<DC$?$CZZ?A<B-?.56I=>RTT(RS[GVS@KXS;LDT?D
MI+'L67_/E)K+@24'TA>'G]Q ZK7(N"&X<5G1;MH,9KUNK42K1AN(TUVCLRV'
MHZ')[<TR4L&&T[N*9;2XB0ANIVQ^Z5<H#=D[, ;2?#/CTQC/4>76H:?[+:S8
MT9(V TJ2#^YXVP!/Q+@C2Y1TJ;.,S"HBVFR5,&HE'/58'<60/AEP4I9V!!F<
MOYAPY](7AXKA/<M127[A"1HI+$.\VQV,TNY+D763(]4HM[;4A3$M-Q<#K+"U
M/LAI<>0N9V9AHO$B&ZURF24J)& L9V]/$GID8'CT/NR:XWKEV+UPK6%GS(EG
M0[] 8-L$V,:,A3K\2:9AL8B+]L\\DU;ACPT=D?.67DGE"M91ELAIY5EP7X_:
M FZ%U&_+D3K2YHN/(O5WC3HZ%.NVV3)#3$BW=F>?3+4N4ZQ!+)+3J9DF.V4%
MMYMU4J(3L=+;1*5E2B I.<9)S@Y Q@=?/H":E=;.Q>NIEC8T>2_(0) )UDV(
MO,N.RAERL#C!Y.?;=#(+PHV.;8R\6#X>IEEQ*PU%X;(]"3@AQ_T%J!O6D-UV
M?8WK>]>]9K-V892V[I^.Q&5,D-N1'Y0,F$VUS9,/',+2TKBF2$/\F(@NQP<E
M*^8\2-N>A7@ '('L\?T=,R^O_9#7ELV5L*&:5*1#]LDS)^OOS XPXQ@42/(G
M&M/.,&$>S,;C\.GI:>QZ*AAR/QC#Z$,N4^#GI!Z$U;KC5EF9]96I^^2Y=VL[
MUV9CLQYD6VL2Y<M"W&)4CLLE$)#LP-O -EAA[XX/)2TH83K',<44J"U@X3G*
M<]!G(&>N!T\SX>=4VJNS.M[1OZU@!*F!A[RY%1%8DS@FF0SSHP-D5+3J4DN%
M!XE'6%?*\OL84]E;+92 R'<,\H</O2+X?ZFXOWNU0S=8[>J'(-LT_<IL1IJ'
M<)D*.W'2VI*9"Y,47!QD^KB^PE3I6TW(3%?<2U0P76E.ODH(4$92"=R=H .>
MF#[\'Z,U*C.T&L2.R9 [;\I\KD(UN@B6#(K.(IV<S+");?SGW7N40[[[&1FI
M%0^,>=QM]UEH'S%II0/20X=2.-SMM;<N?8I;"=(QK\8S/JMV[FX,-MN9$@RD
MVQY]OL[<]4<#>I#SC3<,JE)=@="C(RG'*QR^N_&0K/AC.,]W/Y<]*7CL_K*"
M[%0XI;LLX!5&9"HS\VP(RN.!EW73AB<IQDI)9 <621Z$B0T/E:%L$9$9,0A"
MW(ZL])#AY9.,\&V2E7-<33_:].7F],1F5V^%<UN28\CNF0F4]%MTATLSWVF"
MI"V7S&:E)0E2XB"\M2'P4@!"@$'.X@]01TQU]A(]^*J=Y=D]>5+<U&B"L2\@
MJBF&.6@N+%'?%!5-BQSC# ^7"V5G/B,(2^>AA'D92XEEEP@M#PS5?BQZ0VA-
M)\3=,V64FZSUZ6D/JU!+ML=AZ-!5=(\)QEIHN265S'H[(2],2PDI:2XEIM;T
MI+L=N @NO%IX*2D(WD)5G*@1CI@8'4=,^/CT&"9W8OL=KRM636L8VN1GGXV6
MKE[/=A6!W!V8$M+!P'D=+*$P\=( *;.&&QA*/;.L./D,9>;2JIQK](+0FE[Y
MHNW W&]OQY=EU7+7:&8[C,>SRT-2X9#LJ3&#LN9#4W+CQDX1V=QI;S[)<;"H
M&"Z_L4"E :=R0K/>*3U P#X$8S[<U]=D^QFN@JE1A0"#YPFU8A;S'M1P[:<,
M5SS%M-$G*+>'R,22^D@=D+RK?2^$6@K V$(4Y4XW<?\ 0=IT_I%N,[.O3VIF
M;9JR U;F6D\JQ*4^VU)F*EO1^0^^\E]AJ)M6\EZ+)3($<(25Q5"=?"D@I1L<
M&2HG!*>N!@'W=?8:K=\=E-;/:8A)*-?D9-S93;9$!'L#--F#-04T)F85,X=(
MPT#D$H9V-REMPG))V,^TP^(AXMJXXL^D)P_:X866[0G;A<CKQL/V6!'CMHEL
MM6BZ1Q=570.O):A]BDL.0%)2X^I^6#V4/QD.R6XKA.O!UD%*2G *CG;U(4,8
M&3D=? 8'CCI51=^S6M'>O(ME&?DR%6H0FH1T(D5E,NS.1X8^)-D]&2<BCCQ[
M3HI+Y*"7DK8.!4.EY9*&\5M4^D1P]'!F)JAEVXR!J)N3IR!9T1V4W5N[P8[7
M;V9B%2.S,,PFW([[TA,AU"F9<13 =7(0BBH;J][&4@[,%1SMP1@$=,G/T>1S
M4(GLUK1'6[-G<>DVU1L8/KI^$R*SF7<M+E?4A@=A'N?:K"?%:>DFS\DH:P$P
M^E:4G-*"Y+;_ $B.'W]Q!>JENW% @QV=&/68QVC=5:A<M*N3':1VCLRXKT=M
MV>B:9*6NR,OA03,:5#H(;J=L?*2>4.^"=N -I/AGQ\L9ZCR.:AIWLUK4?1LE
M/'O282M=(8"G8E8S+DD01.'F*A,1"$$^@:B2<RZ.VMQX7VSHI*S<#"MI)<<-
M_2(X?*X4734,MRXPO@0F/&O-K<CM.7%U^[RY/JA-M2V^6):;@X'&&UK>8##C
M#ZY@CQVP^LB$ZR&V<I43NPH9">A)).1D8!]_NS7&]<>QVNLZRM*9-\^'(H Q
MMCF1BQVW'"H@LQ#([\5D=YS!;JC7Q8Y0[F!W$FF"-X\S3Z7L67!;T@=!3-#Z
MD=FN3[0[HN+)OEUC3&&W''[9(DI99?MQCO.)DN*EO1X)87R7!+E1D *;=2[4
M$078Z6VR4K*E$ IR!DY.#GPZ9Z^P?DJ7UN[(:\F4['CS')"OOBG6;8WFEF6?
M1=K(PPSA[B' WRO$^.98R^4#A.5+95YPW"\-$>C)P1](+0FH#K:&^;A8W83E
M\UH571IGE.V"*RRY-=0Y$?D_5<)ILO2(>TJ4TK?%7)V/<H(+L<*RI*^8[D;<
MC!7@ './$],_GQ7'Z.[0ZUF;]LQ@I4I ,6 B3M42=+CL(&=BZ\#*2DF@K(A)
M2Q3&HMM\]MCRNMNLBOMI(]SZ+#UEPH])'A]?-7ZUB/\ K.R-W)5QU!;IEU88
M3&>M]DAS[C< \8LB2N-*;MS3\U#)2XAQJ.\@/"1RF78]@=9+CFY*^8M'1.<@
MD[1\H ')('MZ^&,FJW0'9"A7/;EY@1&9B-(O<F@ZK/28XS;)V(D>2??%(R.6
M1D,U\5:R16EX6RZEAUE1#92F&'KO@YZ0>B=8\1M2V"(Q=K?)U3,[3I]ZXL1T
M,SA;F)K[T=TL27U1)3L;?(CMN!3;B6EM*>1)++#L#!<8YKI4E06I)(3G*?+S
M'7J?+\V.M9X\Z^JG6O6 Z%Q4+LT*TYNBWZ;%3K$\!7OE:D2R_:&)-#B"Y/)B
MF,B,NH;:?.:&P04,A3:&!'G<$-</V7T,K;:>(434GPL6]I6VWEF]0K$+>I%R
M5V:6F7$M<BX]J+)BM.(;0]+;CID2&$*;2S&=<$AN^5-);*=G?*=I5GIU&"H#
M'C[!X#VGPJ-BZ&14]LT^TXNBQZ=+SK\](U[,6I<LC)A:C3HD23P8EC KSKCK
M8YCHV2!!W$MJ8+=:]P[&^>AE;;SQ"F:D^%CC&EKG>7KU.L?JY2[DDRI2IDRV
MQKCVM+(C/.K<0S+<CE^,PM+:FI+K?/<)F[6PG9E82$YSW3CH"1X^S(\SGJ/"
MJ_:71T/8.S)*ZQ]V5!Q%CD$R<]$N1.3362W/)[]429[QEGRGK2MY"2V%8!>=
M6K'NV<('1><1O1 BZXX@3]6PM7*L]LOTU-PO5M7;#+EM25[.VJMDKM;36)JD
MJ=2F2RH0WG%J':6@AA,&YA0V$%&2D82<X&/+(QY>[Q]WC4_</2*/V';0K)6K
M?]F!UQ<%#RT>=%N2^?1K\6'!@E@/(.#SZORF/"'=%(QA"WV%$^Y3ZRFDU^*?
MHBP=<ZGB7^P:H^#K"[=9[7<X,NW+N?Q-DM\6T0Y,%U,R*>9ZMA16'([X"%.L
MF1V@%U3:34PH24J1N.5$$''RB5$'H?,GJ/HQ4S;/2.*N[=*S5+:NNNU6K1%.
M)Q*QZI5N3CH?#F!9+*F"@E,2F?7?]TVE.1"O,SAI(/HJR_/Q+]$6V:O1I(Z;
MU,NPN:;TY;-*OBXP3<D7"!:PX(T\EF1#4S<?CGNTH2DQI.YKEB)RE%XW,*-^
MY&0I2EC!Q@J\NN<CV$G(]]?>PND<-9:3KVMUNV/1$I0HLR(S)24?DT:=&DY,
MF;.=?&8*9< >3+GR!8F&726VV"LA.X=]-HEN;7'HBVG4&DM#V"PZF=M=PT7;
MI=L[?/@F9'O#%PN#]VF./1V9+*X3PNDR;)C<IQ]"&9)BN!S8T^B")92M:E)R
M%D' ."G "1]/0 'P]ONKZLO2.$E=3U"AQEN?$L-1DIN718RXWU0Y4NR8!Q,,
M/Q;1B%A#J3%1: 5M%DN#-A>#R2G"77,37_T1;1<N&NE]%V_4ST:]Z8GW:YHO
MLF!S8EQDWX0Q=6GK<W*2J*PH6ZW(AJ;DON1T1,."0M]U=$S"'%+*.ZH)&T'J
M-N<8..OB<]//W5']A'!_<9^YQ]K2/M+]I_MA]JOEOXE\T^7_ "KY;\H][Y_E
M/L/O//[WWGO?Q[S>E_.[C_HBV?\ N4_ +X3O^OOA#\*?A'V =D]8]A]6]@]5
M]JW^K.Q=S=VSM7:_JS=ROJ"G;%<W?L[NW;MSU\<YW8\<^6,8Z>/6H5KI'!Q6
MJ+?0Y.VD%V&W2,+++L8D;Z0<477/?8AF1XMTQ2S!TIE91!ZG2QW"D&^#.!'!
MF7.1L'HC6>V\-=3Z+N&IGY-[U/.M5S7?HT'E1;;)L0EBU-,VUR4I4IA N-Q1
M,4Y)8<DHE_%B,MAI=%2R7$K">ZD*&TGJ0K&>N.G@,=#C'GFFO>D<)6:3L*M6
M2V/S$G?HL*(^91L?[$:#&BY,:; ='&?*?</?S, 1Y9?K.CMN,"I":2UYW27(
M:']$:T:>TCKC3]_U*]=;AK2WQ+89\"#V-BSL6ZX,7:$XQ'>DOKF/>M(<*5)Y
MKC"%M1TQ&PV%NON%S%*6A24 !!)P3G.04GK@8Z$X\>O7W5\ZFZ1P]';NF;5;
M';([:JM+4\?$9'JB&XR-F,-8*D4J?+.4_*?@&?:H4G @OE=PXDW+J<L2\-/1
M&M6CT:L.H]3.7]S4FG+GI9@6^ ;6W;X%T"!)G O29JGKC\2R8R5 1HVUT.(F
M<U)9.RRO9M3M"5!9R<Y(\!TQ@>.?,]/#'7XT_P!(HK7=M-LECM^;2PB+G(>)
MCA(I</C#%@BS(0XJ0>5(&J4]\ID#!FAA\)0V\_@GW"LM(:Y+PM]$6VZ%U-+O
M]]U0=2-)M]XM=L@QK:JUA+-[M\JT3),UU4Z85.FV39<=MAD!"'7A(YZBVANH
MNRRM(2E.WJDDD@_)(4 .@\P.OGCPZU(U=T>CM>[+CKL==G9Z)KIZI* A\1&
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MS;DAV3+D*E3X\.\=M;$2++?<=4D*MS[L5"RTVM>$+;@F8I+81L!4$[0K=TZ
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MFN_P>Y.NAELAF?H[L/K+84;)";'3_12,[JBUC4K:D4XYGQ\L%KT'=);?X/\
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M,Q13[K<387'6T1,B1E+^6;15FF)2M9#6UM$)Q1#G@BX*VQ5>'4*/R@.\@?*
MK.-:]L#SK#*#-+LE_4,5E)BD;I.ET*<O#!._:E;*4_%*40U() :<5WL6Y_\
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MROI:DNO.LMH8@LSVU)47$OM2'@RV4%(.!N"PHJPH*2D;2%%2:*^(-N<F6B%
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M<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4KSV_%#^*%V$ZU;L*T-IF'J=4:
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MI(WJOO)QG&<8=&G:Y'$,K_*V\TVXGP4G&>92R.%J[VU23C,QALD?L77 TO\
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MV<IOE&7VSFY7S>=RN2/NMFSE]-NS.>NZM85IA@ZN3K#MLH34V0Z?$/;'['V
MS!/)/Q/:.T&4-_,Y^T(^+Y>.M8X1GPO=:1%\8O &W]O#MPU\[8["J580G7"X
M2OS/<:#5#;1&<()H),_,1X.7GRZNT=,X?CEH"9*).;8+S(7AOKRFBT8T<[V;
M<RXO+^Y:;:O<P0 Z$)4K #F$]>\0!D;< WPWMS4U,Q%UNJ0S.U1<(D8>KRRP
M]JUDM7))4J"I]YM!4I<8+>W-G8E2EA*M_2I/X06FY77\CK@C;NX40DEU6U?U
M#=)9SK],DWK74NS/NI5F59>727!\6]^:4]'2T@X*Y%DQ#RFQX80Y#9R:J=1R
M4O)?$:,5IN#]QP>=M+\ACLZTD!T'EA("D@'<%#JH@D59N<*;2Y 7;U76[!ES
M3%LTH5#L/,%OM5R]9QG03#*>UJ>*FW5E):4TK"64K 6+PK^&]IM=O.M";%<&
MA7-O;K["1%>0N%S&0>\-^Z^1KV^W4=QV+<*, ;'<EK/7*R>Z_'Q%LL,N8\](
M1#%?@X*V%ZDAL(V-D]GC0U+[VY<6(]SFFCWL!6=K:W!A1;0D#"MZUY8\/K09
M:Y7/EA!NUXOS,<<GEL7F^0.P39B26BM: DNR8\994VU*?=62XTEAEC(G2?7F
M$T9UNI_6BL7&Z$URC:^<UO7[F\7%1]]"AT@DQT?*,R</% Q@]BB1R$. R8\0
MTA!@HY;@JW,+PNSE3%2YKDU;;86Z]SEM@*4T59!*2E2BHH41U25'H2,UGK-8
M&;+IZ)IV-+EJCPH!M\>6I33<U#(;4VVX'&FD-B0TE0*'$M ;TI44DYS@.!\'
MO58U-O5--WINF48V11>O])M\P0)JQF;E%=<]GKVM3K*^<-KUI9UEF;#AE-PF
M9GYK*65+LH=*'$RL@V<%ECJ-\N-.")%3R79CC: 7]J1-8Y#K8'.Z(2CYM*=J
M482E("1@Z.CA/;!$FQ%WN\.BX0K##E/*3; \X=/W(W.))4M,!)<D//X$MY[F
MNR,N+<6IU86B\ ?PW=?QM]$V5&;8VE'6P/M]L'N0.:.W0W66+SM#70FK[C4V
M0S::6-BG$U>/";C4D-DV"--0^6B;><?3Z-N;V\IDL*CL*;-N9MI!YN>4P\7V
MG,AP'F!Q1W>"%# *?;ED\/H+<Y-Q;NER;E(U7.U<E:1!*4S;E;TVR7%"%Q%I
M[(J*A ;R"^VL%?.42,8G[-^&/L: 1JZB:6OQ<GK>GPG8T^7-V!K#1VWRK!9=
M_P"SJ]L6PU.SU&WFZF!Q0R# 3?\ M2?LH\@+EB)F*FA<>/.2&08OC"^>[)9"
M7G%0DH#+\J.&T1&%LH<;<;$A7. 4/%#9![R7>I0-7N/#BX,"VPK1.6Y B,Z@
M<=7.MMENJI$F^W)BX2(LF++7:T=A4M"\[9$A+B-K3T4%M+SF5E(^'^* )N:7
ML&R9NO3O:.E^MORET.'I#^O@MQV?4@^L-CW;5LI:J7(WZOPLNA*Y6.KQD^\!
MB2"CB3!51V38(C'NW<DQDH82M$!WZD<=4Z'3&;D%]EI]+;H96I/R5+"-V"0#
MG"QL\/0J4(N[K]P>CO:EAYOD."U"5 1=Y-K3;;A-MKDF&Y.8:= +K;"GBCF(
M;4M!1O95<OK?TCI'6F[)N]8O-YLQC?7?1_6IF/L^*Q[%NE:!C"HJERV50M?B
M2EV4P>0D%SY*B/EIKQ"%!QD>AAMOE";='9K7*6TTV.V2II4CF9YLQ04XGO+4
M-@PG8,;ACJHY-9'3VC8>G9G;8TV;)7Z@LNG0W)[-L$.Q-K:AN_$L-*,A:7%\
M]6[EK)!0VV!BLU.8RMPIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*\E_Q]JGF-[-ZHN+;?D8M.E1(EQ>,>&'
MI"JW.TK(<RK]U> +#%-*Q^XAIO\ J\V*SJRPXG]B[G\BDIZ?G2?SUYI^FC;>
MS\0=-W1*<(N.DVHRC^S?MUUN)6H^_DS8R/H0FM$_,M7'=>L_X!EV+F.M.U*.
M4^M]%)V\[(1R5JSGVD;;ZO"/>T:Q^1#/S6$EC<8QCZOG$*SGZX\-=NZ 'VUC
M[MO!]Y2H]?S$#\E>E?H7W9R5H'4=G<65BTZG4^P"2>7'NENB*Y2?(([3#DNX
M'W;RR?&M[/,378M.*5BWWC_I*>X/_P"RWV!_]4UMY?6S^^5O_=T3^D-UK^K/
ML5U-^+]Y_P!72:Q)^"!_W+/J9]]YO]C^Q?K_ /C/L?[W_P#=_H?\'[G,AJ;^
M_D_[YG^C,_I\:UOA1]K[3GG\3-_UI._1X5BKTP<QN+XY/Q,=SA9]W!::UCK;
MKP$_C\(T%*F-TQJ9%2O^A2_BQZAMWF2GP4VE;[2ORJ\U]<OJ?3%EC'HN2^]+
M(\,I',*3]&R2W_(?96O:6/K/BSKRZ)[S-L@0+*A7B$.*$4.I!\CSK;)SCPR0
M?&LF_B#7$PV]5&C-OKQ%P5=Q/OL)5G#;DO-F%BX6\C&?!Q8L=&C^W6K&<M)/
M*2CPPZYYO*/TWM52I>L-,:.;>6+=9[&+V^RE1#:[G=I<J,E3J0<+7'@P&N0I
M0RVF;(",<U>[[Q"2 A2\=5*QGW) _K)_-6OCG#]7M<_OT;W/7WX?M7;QXOWO
MXPO69"F\?T68Z,%E7Y$GPQ]<MC(BFLN9_(G"L>.<9YZ]>@=&[/PBU')(P)%V
MU3)!]I%OL$-/TY,8@>/45\BXJGF*T3&\3(UYII&,_P#5MN3'G#^0)_E%>E'G
M2U;[3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI
M3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE>
M<S^:#ZEDBJ=9KVVUX8BK#LBI%O8Q_1YL$;5)F.:6K_[O[,RBVL?_ 'KV>9JS
M*[SZ/:E"@/O2H']85PKZ;=LWVWA_>$I^MIU^MCJP/'MK%ME,)4?\GU?(*1_E
M+KS%<SU>?->GW^9[L.?8GL[G/CZ6;3K'"/\ >^IB)N7J^']ORY9\?[7EY@;S
M\MC[US]*:]"?0CW>J>().=GK'3VWV;NS77=^7!1G\E>BOF%KN>G%*LYV)I1V
MR>OV]-=1;.2)*_:<V=2HYA/Y7SK329N"$9Q]<?5P@]M&/KCZJ_+RYANAB9%>
M5T2S)8=)/D&W4K/\@K&7J*N=9KM";&5S+9/BH'M7(BNLI'Y2L"M"WPN._P#H
M7K/\&:N739=UKX5BZ]&;CIAVO7YD$.Z6:\%; MMXIE*A8!YWYJ])V*-ML$,T
M\D-8@ Z9*6D718R(E" ]IOEIES=1K;8:642TQG ]M):0T&6VG'5+'=VH4VLD
M9R3A*05*2#\@X?ZRL]BX8,2KA+90]95W.*N&7$)E/RS,DRXL1IDGF%QYN0RD
M';M2-[BRE#;BDY1? RT3>:%U9M_8?;XCP^X>ZVU+)V)M.3!UBR":Y8WW7:=@
MMESS+2B9]W/7L#S.+6F.NPK3WD?;=;39:HE-.SFXD<YCVUA$1O!R-Z .9@]/
MD80T?++1QT(K/\);1+AZ?DWJY)*;GJJX/WN1N3M6&7U$QMP]CH4[,0/$(E@'
M!R!+[S8<QOR1ROQ\JJS6\M>/[C?M74Y\/[7JI<S_ '?'GC?Z886.-$XJSM5I
MZP%O/[#D.I./=S O\N:^TP_F1]\K]-8>\Y:JZJX4^-BU;M^#7J1K'JYF.Q/9
M3?9[2?ODCL:+H99,>:3C_O:733UBB.*QX.$(6VC/G3X<]F?0QC=D]'L33T[7
M*O(2?-7:-02X1Q[>D+"O8!7R#7A[5K7AS;!US=+G=ECR2FTVPN(6?9E;VU&?
M%73K7HNY]WK?Z<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4K3;\<ZH?:+I.//(:\SE"W!1K&MW&/%38LD#9*8XE2OW&G";0%YL9^
MF7&V?W<)YD[2K;*Q^S;6G\V%?[-<K^F!;.W<)6Y@3DV;5%GGE0'5+<AF?:E
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M>H89U]*EH6S]FPS+6&UA>5 CW%,:ZAET);+?N=P=4&^#7">$V-K470=A= \
M7[E#;N4AP#VJ7*"2?NBWN'0U\ZL5D7;;AJBY2>LR^Z@ERB20I2($4]BMK15Y
MIY#2I"1GN"3R\ I(K9YSZ%6RTXI3BE.*4XI3BE.*59'5'8K4.[[!L^K:SLLE
M/SNF;<_0MEAETN]5A%7N S:7B*^^;;*U!@2,@R.MHE:(<J10D5\8KS^W)'=<
MNI$*3%0PX^A*$R6PZP0ZTYS&ST"P&UK(23D J Z@CQ!K#6N_VJ\OW*-;I#C[
MUHEF#<4+AS8W9I:0%*84N5'90XL)(4>4IP;5)5G"@3>[EK69IQ2G%*<4IQ2G
M%*<4IQ2N%>L< /8HZHOS,8S:)>%F;'%UYPT=$S(0%=.@HR=F1([+F"GXR(D;
M/7 I$UMI0XA4W%L/+0X:PE<P0LH+@2KEI4E"EX.T+6%J0DGP"E)0L@>)"5'R
MJB9#"9#<53S8DNLO2&V"M(><8CK8;?>0WG<IMIR3'0XL#:E3S2205ISS7):K
M4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3
MBE.*4XI3BE6\V[4$["U1LZ@K1AU-XU[=*@IM7AY7$V6MR4-E&?'Z>"L&^7/C
M]/KR=I6QQM?[!:%?Z*@?ZJP>I[6+YIK4-E*0L7>QW:UE)\%"? D1-I^GFXK\
MYM25(4I*DY2I.<I4E6,X4E6,^&4JQGPSC.,X\,XS]<9^F>;K7A8002"""#@@
M]""/$$>1%9!=?^U._>KLX=.Z.V-+TIZ7P.F<BVV8^7KD\@7*_;_.:W."2,(<
M\.AU]L0YP'YB"V00D$P;+[F547H[,@ .H"L>!ZA0^A0((^C.#Y@UNNBN(VM.
M'DMZ9I"_2K2J5RQ,CI0Q*@S UNY?:H$QI^(\ML+6EIY3//92XYR76RM1.S:G
M_'E[<0F6&;52M*745'EP^^[7;17YA_"?Z+*2XBW)B65+_+G.(!:<*\,I1C'W
MN;!5HC'.U;J#Y=Y*@/R%.?\ XJZ!M?IE<38FQ%RM.D[NV,;UK@W"%*7CQP[%
MN8C))\_J(C/@ .E;D>B'Q6M9]R;/G5TW4"]3[=5&ERD3 D33-AKEP%C&<D2B
M:U-^QB#$RX0C;TH3 GQ:'$1;))04C)H!/4-C)=O<BIY@4'&\@$XVJ23X;ADC
M!\-P/CX@9&>J.#GI(:?XIW#X.R[6[IO4YCNR(T)R6B= NC<=.^0($SDQ71*:
M:2N0Y">C)4(Z''&GY 9>+>U[F/KI&G%*ZY/W&I51K+]GL]?KS6$Y7YYN8CXO
M&4_7/BGWI#.5^/AX)PC"LJS]$XSGZ<P-ZU3IK3;1?U#J&R6-H)W;[O=(5N21
M_D]K?:W9\@G)4>@!-3)0I71*5*^@$_HK5YW0["4/9,/!4&BF?/VHFP)L$K8&
MF'F8Y+XL=(1HT=&N$-M.G>=,F0^44TW@/&&1DC/E>H[ECSN]+#CAHS7MJLVB
MM'2O7;=MO:;W<KXVRZU!0]'@SK?'@0''T-N3-XN#[TF2VV(H#49,=Z27'>3D
M(K"VR5K[N4[0GQ."023CP\!@>/CG&.NO7G#U7U>CC6(7RW6NO8[P\N0*/4PL
MI_J9%@0&,X_P>3GO#P]B=@T#H>#C'8M(::B8]G9[-"9Q_P#!6"=.7'#[5K/Y
MU&K03>J>P9\U+G0_:N7@(DV3/+BX)&F]822(6/(*=>"BD2)P633T1PZVQ$F&
M*442EG#Q"E.K7G.^(?AA*0J %J"0%+[2\G<0.JMHZ#)ZX'0>58!VWWE;KBVM
M0.,MJ<6IMKU9!<Y2%*)2WO4G<O8DA.Y7>5C)ZDUQ?W'NRG]F#,_Q':F_ZCR;
MM$+]KA_&GZI^K;Y_VD<_[JM_]FGW'NRG]F#,_P 1VIO^H\=HA?M</XT_3U;?
M/^TCG_=5O_LT^X]V4_LP9G^([4W_ %'CM$+]KA_&GZ>K;Y_VD<_[JM_]FGW'
MNRG]F#,_Q':F_P"H\=HA?M</XT_3U;?/^TCG_=5O_LT^X]V4_LP9G^([4W_4
M>.T0OVN'\:?IZMOG_:1S_NJW_P!FLC*M'3417HB,L=C=MTZ$&VQ*65Z+CX1V
M9+3G/J'+B8I#<<!ESQQCVX:$LHPG'E^N<YS9N*2I:E(1RT$Y2C<5;1[-RNI^
MDUFHZ'6V6T/O&2ZE(#CY;0T75>:RVWW$9_8IZ5Y\#>MW:=$QV??@-6[7KV-H
M?%>TYOF%E*Y8A:M)3O7$$^# V+/)EH&W1TM'!.U^*E&3JX42!8SQC VQ8A]]
MSR,;@)L H@A;\=?(T_)B*2X@N)1-4E191M4VI*B%E)"P"@8/>]OP9>GM3A[4
MBH]MN;'K+BA:+VR['D)C./Z>0MA%P>YK$IMUM!8:<2Y'4I#[B5("6E$X%)2N
MN?<RL62F$)J.]TP05H^*#5Y\0W94G,!)T]L"N/G]0(/Y9)7TYI<?]IB$.U1@
M0=4C4)?"RIY4)A&2>'9EM6VZ.9%WJ;L3B"&$I^J65@7)9(9'>V##A/=<2<)W
M>%0AV#5T>1#4(E\#*)7$F.^E=Q<=1ZIGL+7I1GEN3E@H[0L&*E">9$="E/<D
M]XVJDNJW?4/4LX/ 5CL:C8Z>EG2I,2[]VB;<)7VZUQN*/>V_*I*-V8N.58 -
M9N/BN3)3F*Y)0K3\3#$E.I0&JY1/M!DH*UPN1ZSNFX=F3CU<_&/9DX# .Q3^
M#M'?2K"E #K6+7IG7"+6^EF-J#UA\#]'!H^N'BLZJM]V0;LZ%KN1;[0BW%22
M\H]G<9"FF5*.$'*L?3O<$+LXE_-"V_(:^#^)E8]W.V-FZ0F*;CJK=^O84%\B
M: DKV')&0H^Q1LG3.N!8 A(4H'[U$2Y(/!(*QQDVTP<<V.'C8T1@CE+YG;VI
MA65DI9*0LLG"7BL$I.-V,XV9-IU8C4FXP;LY 1Q%D7@R$S&>Q_!B98$L\@(<
MG(<4RFX)WNV]#"@AU&\-%Q2 O&.H]9?B40FJ(6.H@F[JAMV=Z9=NZ+;IBS;:
M?.9QM.9[$E6O1T8S(R-\EXR%M3NH&I.,I5MAE!"TXR;%8/G80T@I2;]R=95R
M%J=,5R,BYVYUM*(X![.B&&Y*MH:2I;8D%)=;5DN!)VH4 *UV+ISB(S:V6X2;
MS%NSVD-60I;TFZE8]9O7]4JRMAQR<ZVS*-J#K<.4UL3$4\E*WV5%6-M6M]?;
M''Z<=@8Y$/N0&Y;*K.R9RE:XOWV5B;#0[%8]71L2)2->"U:TSK%<K(MW#,D(
M3YK8VSV+))SDXR^)!EQ!'->?>8-QAD*C%MA;*'7F>8I#R$/J477BXV@K66B$
MK"4$<M*$'<H*%?4;? N"=)7YL-7=N7<8UP?AV^=V9E^#)D6UMI,*WIC27DQX
MR9J%.,\R0%B2Z^\E265M*K DCJAV=K>JNBRHX;L>2-9]:35:[V04=M*1O>RX
M'<4CUOKNJ:-LNL1.PMH#UMA5#N4?9CAI*J36(V!L$G6]E!1D@37HLV/RXN$%
M<BZ[C"!;?2NU++"665QA-7(=86MF.5_&MEM)2XC<M"5L%0"R#I"M,:DCVS16
MQ.H%)DV]Z/K9ENY.3;DQ=G-/Q[7!N,9J?<A&3V&6W)6ER(Z&V)#D>XH;<4PV
MM'?Y'1W=22*[=1!Z][$;V:B;5,=/-]@[&JT-0B*Q8NL0>M(;7UY8BK8 '$3U
M?V*Q,V<R/8K*8K&W)F*VI&N%QT8Y-,44RK8D6Y0[((FYM-QB*9<6\%HG%]3S
M6YM14A;)2@*W[NSH5'5@JVF^<LNL'%:K:6;V;V&I+VDKVBX1FH*XTC3:+<S
MFI:E(0T_'N"7I*VQ'Y7K5YJYME;;1>%C;57MC46:^'XC847V1$'VKV$F&-A:
M.F9J'B#&VXOJ(7#W:CT^+IFPS')BCS5KI#-SE8VQ6A>;E=R+/:(^)<^TK:92
MZ0MAY-W+*H9,>&CDRDI4L$JN(4T\XIUD;74MN\M)0W\4T$-E?<.W"RF+A">T
M)VYK4*$W2_NB?977FFE@-:44S,A1&X<]:G83TJ$)CK<B2>US#(E(:/:$\SAM
M:=2/B UTO6]NFJ[:R.P#WPM^PFBZSMV3NU<FY'5^\IS=LM<=,0EWM!MK=/\
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M4MP;&@0T>7RIS'QUNEAXUUM/[C3X"!GV?ZK3B,_N\W-A6]AE?[)I!_*4C/\
M+7A]Q M/J+7>LK,$;$6S5%]A-)Q@<ABYR41U)'[%; ;6G_)4*L=RK6H4XI5Q
MM0;-L.F-I:_VO5'E-6#7ULA+5')PXIILM<0<R2_&E*1XY4!*BH?C)!G.%((!
M+(8<0MMQ2<R.MI=;6VKP6DI/NR/'Z0>H]XK.Z7U!.TIJ*R:DMJBF;9+E$N+
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MN<PK4#1-=+=6MMNMN3]_)2Z7.'_AI6O(PR;9-WPG8><?80+5AVVDG[1@AY;
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M+4B&'%8^;A7B$^V\K/D#,AVY&/ E8\P,^6+6FR+EJ"^U?9>OIEZOW*G2C4O
MRS"&W%#%(0XRXAQEU*VB!2Q7GPS!G4J:)$(?8<QE#BN9]Q"74*;6,I4,$?\
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M1_("3^2OG'%S23FN>&^KM-1VP[-G6IQZVMG *[I;G&[E;6PHD;.=-B,LJ7G
M0XK<"G(/@/E(N3A)(^&F8XZ(EXHPB/DXN3$? D8X\1U;!81P13;1(A8SZ%LD
M#$--O,NH4VXA*TYQC;P00"""",@CJ"#X$'S!KQ<D1Y$1]Z++8>C2HSKC$B-(
M;6R^P\THH=9>9<2EQIUM:2A;:TI4A0*5 $$5=.M;VV+4];G:DB#H;%"D[U ;
M)D(8ZKUV2=*N-896-"2CLH=&ORWIA"O$B_+4FIC'QRBFR0WL/N9534RA3@<(
M.\(4V"%$=U7B, X_+C/0>RMB@:POMML+VF8ST7U-(O$*_O17K?!?4Y=+>@MQ
M)"I+S"Y.UIM;C?9P\(ZT.N!QI6\UW5,!V3[N[>L%JA*19-L[-N,BP99SZ=3Q
M 0,GK99%3)3:H./C:M7&7&F6O<R!ZHH#S8]8A["UJ6J7+$1M*2M+;:1W0I1)
MQXX&25*\? 9-980M>\7-3S;C$M$_4NH+H^AVX/VNUMLLEXH2V'Y9AL1[= 2I
M*$\Q]XQF<]Y:MQ).P;4G7_6/5Z[EZMNMW8OO<<VM*L-RHVN5YLE(Z[:\;)CF
MW8W9EM!4J-QL6X2\E7V(Z(9\X\6 *2K+SS,W!GRW'WIN,3Y? ]$YEA:+='UG
M85.NK20IY"XUV82XE.,AA$AUELN'H77&T#O9 [R]&GA'#X:ZI?>U#<&IVOIM
MCE-N6NUN=JMVF+:M^$ZZS<9J/BG[O,<2RD(;RQ&::=#:WQ(:?7DYSQ_KN"G%
M*N#*;/MLRR&U(/Q3V8ZHL46.?Q7X-LL"K#-O,M1@92(]+XZL,$DCK/;<Q)/,
M$D,/&+:><2K>;EQ$U/=FHK4YVV.F#IAG1T%\6.T(DPM.1VWF6[?%D(A)=8(9
MD2&5S&U)G.,OO,N25MNK290A SA.,JWGO+ZJZ')RH@^ Z'IT'3H*RY^'Q J,
MV9;["I&5,0=-R!A7A]ZV9.2X*V%>/[BE"Q$@A./W4J7_ %.=.>A!9E2M?ZIO
MBD;FK1I7L05CHW*O%SB+9.?)1CVN:D>U)55I-.&TI]J\_F!_WBMNW/3NL93B
ME.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4
MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3B
ME6)V;U@ZZ;F-S*;4TAJ^]S*D(:S/6*F01UA]%M.$-LXL"@TS6&4)PE*6<'8:
M3A*?!'WJ?"LV^^T,-NN('CA*B$Y^C./Y*T[4'#W0NJG3(U'I'3UYE%(3VV=:
MH;T[:D82CMQ:$L( Z! >VC Z=!6(N_/A>=<;UI38-)T=KG6.C=K3<4.Y0]K!
MT&$LAM1LD7)@S #RQ9X:30N*DU@9A)Q([>"TPLD>X!E!R!EIO8=R<8E,NR=T
MIA"CS6%+4D.(4DI/5)'>3NWHSTW)3NR,BM,N/ GAHNVS(]ET=IFTW)QM)AW)
M5FB3E19#;B'6U;)K<A.Q91RG=H"PTM900L)(L(!UO^+AM> C]4;-[!=3^HFH
MPAFXRP3/22E7=_;%P"0C#4@F%D]@"0\%J]4NE.'1IJH,#RT00MQ2 7QDI#7D
M>UZ>C*+\>'/G/Y);1<G&1';)^3N2R5*>V]<I<RE0QU![PO(VG.(,F*U:'[II
MC2=H:2&W/@=!D(FOHQA88,E#,>W<WQ#L5"7&E$X2I/=.?G7#I-UQZKZQE=5:
MKH B8BUK67L2Q6EW[47C:,R_ZJBY_8=JD4*D+%)D/D%$M-J]M%Q3Q1"8*-BF
M'/1QK6HD,:LB3+=J&-&NELG1UQ)-ME,H=@+BN#"H_9E@HV8"<'!<"DH7OWI2
MH;UIW3=HTM$,6T1^25JYLF6XHNSIK_4E^9*5\8\X2I1 .UMO<H--MI.VK);&
M^'Y"R))$CK&UJK^'5*<17;(T_(QC*E9SG#8DT-E<F,,W],);,#ER,^.<J+SX
M83GA#7?H26B<^_.X>ZD59.8I:TV._-O3[>VI62&XUU8*KA'CHZ!*946Z/D$D
MR#@).VMS2,!Q.?\ *3@'_1\,_00/=6LW;U?3I+?>H^L]SFHE>W]Z-O.ZPK\,
MB9."L+3!)8CBW)YZ'#A8;&'P24X3.&QR\X1A6$^5:,Y^&RO0OXZM,RI,&SV&
M\Q8AP])M^H[<RCP!!2W=U6N0K(((^)!]H!K$S=8V"W7>V6*9,6S<[N"8$?LL
MEP/!)4D[GFFG&&L%"A\:XCPZ9!&<H87HSOJ3?0U(1U;KK*E8\Y,K8PR4-I\?
MOL^G!)F'EJQC\B<(QC.?#&5)QXJQ;6GT/.,]P>0W-@V&Q-%0"Y%ROL60E"?-
M0;LR;HZH@>"0D9. 5)&5#.JF,CP*E?>I/^UMK9;UZT+%Z'K!\8S)JG9Z?*'-
ML$QD? C#JQ&G&@@01O4=6V"#A\E3:WW7'WWR2'U^BAQH4?O_ ('<&+=P:T[,
MMS5P5>+U>I#$R]W3D"*RXN,VMN)#AQ][BT0X27I!;4\ZMYYZ1(?5R4.(C,V#
M[Q>4#C:E.0D>)Z^))]IP/H]_C60'/ME4*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*\WOQ%O^[=?"
MA_>V4_Z0VCFXV?[&K]]*?U$5\/UK]M?AU^#=_G9%>C"4FH>#&R9-2T;#B8\?
M$J4/%CQL>'USXOENLM8\,?7/BKZ<^?W&ZVNT,&5=KE M<49S)N,R/"8&!DY>
MDN--C ZG*N@K[B$E71()/N!/Z*X.O[ H=L)?"JUUJ5E,&;RZ0) 6.'F"6&DJ
M2A3KK$>80ZVUA:DHRXI&$84K"?-XY\.8BR:UT;J60]$TYJW3-_E1T%Q^-9;[
M:[I(9;"@@N.LP93[C;84I*2M20D*(3G)Q45(6D94A21[5)('\HKMW-FJ6G%*
M<4IQ2G%*<4IQ2G%*Q?H/;'7^S2ZX_2J]=INE6C8VS]6@;/$&JKU'"M>I&[OF
MU)L'H6YVVUJ+=*U[9(^%E9ZJ1XLH7B(4VIL*P0A9]^[;WF OFK:2ZVRQ(+!+
M@=4W(+7+V9;Y;BL/(*DH<)2-WFA0&MP=40+BJ.J&Q,>AR;A<K8BXI3&,-$JU
M"9VH2,2C*C-E4"0VRZ_&;0ZH-$$(?96YD8W-PSS1K[,O%NL1K:'I%YL\1;0#
M+@R3&W37$NY0*VL-22D+?RVE0RDOXSEK.%<LBA0(!2H%71((.3UQTZ=>O3IY
M]/&M@#S)"U!ULI; +A"TD(!2%@K(.$@H(4"<920KPZU%4U#(!%DURT8B--4,
M@*04>*D$M9BL($0*7EW#!"BEJ2@9+3B\OJ5A+6%9SC'&U62G:K<,Y3@Y&/'(
M\1CS]E.<R$)<+K8;7M"'-Z=BROHD)5G:K<>B<$Y\LU]N2\4R\4.])Q[1 +#)
M1S#AHR'@QB%+0.24TIS"QV'UMK2R\\E#;JD+2A2LISC$-JC@A)()(!P>I&,@
M>TC(R![10NM)*DEQL%"0I8*T@H2K(2I0)RE*B" 3@'!QX5.%.".2ZH(L4Q+#
MN&'E"D-$)9>RRT1AEW+2UX;=RP^P_AM?@O++S3GAY'$*R((\01GJ,C&>I'Z0
M1](-3)6A>2A25@'!VJ"L' 5@X)P=JDJP?(@^!%57(5-3BE.*4XI3BE.*4XI3
MBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*
M4XI3BE.*4XI3BE.*4XI73KW?ZGK6O$6FZ2[</##NM#^NMD@ET@M_"\CAB"B-
M/$DE/X;<RAIII7E0VX\YEMEIUQ&K:QUIIK0-C?U'JNYMVJU,.-L<Y3;S[CTE
M[=R8L:-&;=D2)#NQ92VTVHA"''5E#3;BTS(0IQ6U R?ZO:<U@+>/B%@LJ>%U
MS17C?#S):F+>7@1G*D_3"L0<2XZ\ZTO/WR%+FPW?)X86PA2LX1Q9K#TXH32G
M8^A-'/2R-R6[IJ>2(S.1D!0M%M<=>=;4>\DKNT5S;@+92HD)OD03XN+_ "('
M^T?[)K6QM^>7O#<E$W[>HV,<VIJ^-?B==6>&0;$%4P,DHHU[,'@8[\":H@PA
M291]1$FVASTFC$-XPC'.6H_2IXXZBCRH(UG(T_;9:BIVWZ7CL65(R,83<&$+
MO13M  2Y=%@8R!N))L7],6*5<X5YE6YF3<[<V6X4MY3BU1TJ4I1Y;>\,!94I
M1YG*W]<!6  *&2E929*6=,24A*FN?]D,DC"#BG/W?OR"G'75?7Z_?+SSX-<+
MG<KM(5,NMPG7.6OY<JX2WYDA?GWGY+CCJNO7JHUG0 !@  >P# K+'HU^?R,_
M1JR_JC?.E_0\^W1!_%Z__P PU5M,^9/WR?TUM$V-IHK84X/-,[CW7K] \8Q&
MYA=<VR'@H-]3))9&9$@0^L3+[DF]@O [Y&"D-K&%$;2PA32EN>NC,@,I*>SQ
MG<JSN>;4M0Z 8!"T@)&,XQXD]:U6;;%3'4NBYW2'AL(Y4*0TTT<*4K>I*X[I
M+AW8*MP!2E(QTZ]!_8OR']D[VI_C&K/^H7*O;1_B4'^!7_Q:L_4*_P!OM0?Q
MV/\ \G3]B_(?V3O:G^,:L_ZA<=M'^)0?X%?_ !:>H5_M]J#^.Q_^3I^Q?D/[
M)WM3_&-6?]0N.VC_ !*#_ K_ .+3U"O]OM0?QV/_ ,G3]B_(?V3O:G^,:L_Z
MA<=M'^)0?X%?_%IZA7^WVH/X['_Y.G[%^0_LG>U/\8U9_P!0N.VC_$H/\"O_
M (M/4*_V^U!_'8__ "=/V+\A_9.]J?XQJS_J%QVT?XE!_@5_\6GJ%?[?:@_C
ML?\ Y.LBZO!+K->B8!R<GK*N*#;$5/6@QB0L,KEOQ_&Y8T80 <DQ?CX..M!C
MI5X8_!XSXYS9K5O6I>U*-QSM0"$)]R022![LFLTPT6&6V2Z\^6TA/.?4%O.8
M^Z<4E*$J4?,A*?HK2!:NC]BH]NLW9NJ5,CK;+SVK^Q$CW:J];V*')]?NP")G
M4=V A)F(UXW)'8!N)-TD(2YRD@?$5*+@<!V,=#UJDS&IJ8VENZ(=;1!<<$Y*
M7X:;8XMDIF1-LAHJ2I[:-S8;"FD@*<4O*#AM(*4?&I&C'X<Q_4D:*=/.OVZ_
MN:RC1[@ARQ7T/6N8AEYN '%A$Q4QQF8ZXMF*TSLD)W2G5I>=Q*ZT]/=_[&ZY
MZFW1IG7VL!H65Z+=/=2-4DZ]$US.S]DZVW[";DG]Q2RJ:Y"C"7/641'.Q%;
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M'NLEH*F3ES5*6Y(<F\Q29+4@.QEH2PA#"$Q(@8&6\A*WP05EO)!'=.!D#'3
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MN:H99O\ $=[?ZK%B]8H]8LOM*^HTZ9;@!:XJT#LK<=$>1 4'TQG*RRTQ^02
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M9128M);(JK_Y'\3*Y/$?A+2;*RE0N,,J\$CI<=^6I1ATOS5O2-G<:>1PR3J
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MJN"RP(L7I9G(8*(TE,T/*G]Y$D2-SK_Q*F5F$<L<D?(Z9W[MN?'[K/B/#W>
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M5R72ADB8^U*XQT-3N7"T*]P^OQ!P?G.$X&6?CO'USJ)RSQ=509R]/ZL%\?U
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MK2XT\TXG"VW6G$94AQMQ"L+0M&<I4G.%)SG&<9Y(1CH>A'0@^5500H!22""
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M;M5?X+3_ /#W'_EZ>Y[N_P# O5;_ !GVW_JCQBV_LIW^C'_MTW:J_P %I_\
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MK(.OS$V7"7H<V".T(*?5UQ4'F>P'V:M(-)TS-L.MV1=<(B;5:#L1+RFK H^
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M:1)$"!C#/R):64E'O,,H:=-)2,VR.D@I:%/O)89:9PXXK#3;:/*G&))R20
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M6<=;^AO9KN]Q5;O35LGN6>'9+S'E75,1\VZ/(D,M)8CNS-G9T2'CGELESFK
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MV!9D'*>\OAE.<1<[(_+G59S]<)8C/%><^&$Y^F.9!K@UZ-/#0HDWN#I2+(;
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MI;CL\C_ /?P2_P"S3UK:_P!LH'\<C_\ $I]V_2W]=[5_^/\ 5/\ 2W'9Y'^
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M'2PLVU(29="PN;,,)LKZW,Y)C1BMMI&QK=%M;KI#+JN2)$&.^_(+@6H;"\X
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M=^-^5J._'ANZ][&3C.<9J[1#B-\H-Q8Z P5%D(8:3R2L@K+6$CEE1 *MF-Q
MSG%4J-?4)KTO3I%0;]# V&?)6H9'HX#DUS0F&O*%CT\"S+BY8;"/##$FM9[7
ME*5EW,><]U^-<ZYSWU=<IVG/7KE/=/\ D]/"I! @C&(<0;0D)Q'9&T(<+R .
MYT"7274X^2X2L84<U3LZSUN/C"6-?4AA*?/Y4LU2!;PGU$2;;GAA "<8]1$W
M,H7X?T2)>32KQP>5AV)??/B\Z?I<7_D^_P#R4_Z*?8*@+=;TC"8,-(Z]!%8
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JBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>44
<FILENAME>bntx-20201231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Instance Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-30T14:14:26.4316036+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : a6c3372c9f8947078f9b74c1e02df132 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xbrli:xbrl xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:bntx="http://www.biontech.de/20201231" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="bntx-20201231.xsd" />
  <xbrli:unit id="U_xbrlishares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217EUR">
    <xbrli:measure>iso4217:EUR</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217EUR_xbrlishares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:EUR</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U_xbrlipure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_bntxEntity">
    <xbrli:measure>bntx:Entity</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_bntxOperationSegment">
    <xbrli:measure>bntx:OperationSegment</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_bntxReportingSegment">
    <xbrli:measure>bntx:ReportingSegment</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_bntxCountry">
    <xbrli:measure>bntx:Country</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_bntxNeoantigenTargetedTherapy">
    <xbrli:measure>bntx:NeoantigenTargetedTherapy</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_bntxCustomer">
    <xbrli:measure>bntx:Customer</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_bntxLoan">
    <xbrli:measure>bntx:Loan</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD_xbrlishares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U_utrY">
    <xbrli:measure>utr:Y</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_bntxDose">
    <xbrli:measure>bntx:Dose</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_bntxState">
    <xbrli:measure>bntx:State</xbrli:measure>
  </xbrli:unit>
  <xbrli:context id="C_0001776985_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_20210330">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_bntxAmericanDepositarySharesEachRepresentingOneOrdinaryShareMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">bntx:AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_bntxOrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareOfOneMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">bntx:OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareOfOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:ResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:ResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:ResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:CommercialMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:CommercialMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:CommercialMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_20190918_20190918">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-09-18</xbrli:startDate>
      <xbrli:endDate>2019-09-18</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullAccumulatedOtherComprehensiveIncomeMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullOtherReservesMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_bntxForeignCurrencyTranslationReserveMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">bntx:ForeignCurrencyTranslationReserveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullNoncontrollingInterestsMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullAccumulatedOtherComprehensiveIncomeMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullNoncontrollingInterestsMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_bntxForeignCurrencyTranslationReserveMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">bntx:ForeignCurrencyTranslationReserveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullOtherReservesMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullAccumulatedOtherComprehensiveIncomeMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullOtherReservesMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_bntxForeignCurrencyTranslationReserveMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">bntx:ForeignCurrencyTranslationReserveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullNoncontrollingInterestsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullNoncontrollingInterestsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_bntxForeignCurrencyTranslationReserveMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">bntx:ForeignCurrencyTranslationReserveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_bntxCapitalIncreaseSeriesBMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">bntx:CapitalIncreaseSeriesBMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_bntxCapitalIncreaseSeriesBMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">bntx:CapitalIncreaseSeriesBMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_bntxCapitalIncreaseSeriesBMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullTreasurySharesMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">bntx:CapitalIncreaseSeriesBMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_bntxCapitalIncreaseSeriesBMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">bntx:CapitalIncreaseSeriesBMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_bntxCapitalIncreaseSeriesBMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">bntx:CapitalIncreaseSeriesBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullOtherReservesMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullTreasurySharesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullAccumulatedOtherComprehensiveIncomeMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullOtherReservesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_bntxForeignCurrencyTranslationReserveMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">bntx:ForeignCurrencyTranslationReserveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullOtherReservesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_bntxForeignCurrencyTranslationReserveMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">bntx:ForeignCurrencyTranslationReserveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullTreasurySharesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullTreasurySharesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullAccumulatedOtherComprehensiveIncomeMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullOtherReservesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_bntxForeignCurrencyTranslationReserveMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">bntx:ForeignCurrencyTranslationReserveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxLipocalyxGmbHMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">bntx:LipocalyxGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">bntx:BioNTechUSIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechManufacturingMarburgGmbHMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">bntx:BioNTechManufacturingMarburgGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeEquityPlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ChiefExecutiveOfficerGrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullGeographicalAreasAxis_countryDE_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_20200101_20200930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_20201201_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullBuildingsMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullBuildingsMember_srtRangeAxis_ifrs-fullTopOfRangeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_srtRangeAxis_ifrs-fullTopOfRangeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfAssetsAxis_ifrs-fullBuildingsMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfAssetsAxis_ifrs-fullBuildingsMember_srtRangeAxis_ifrs-fullTopOfRangeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfAssetsAxis_bntxEquipmentToolsAndInstallationsMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfAssetsAxis_bntxEquipmentToolsAndInstallationsMember_srtRangeAxis_ifrs-fullTopOfRangeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfAssetsAxis_bntxProductionFacilitiesMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:ProductionFacilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfAssetsAxis_bntxProductionFacilitiesMember_srtRangeAxis_ifrs-fullTopOfRangeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:ProductionFacilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfAssetsAxis_ifrs-fullVehiclesMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfAssetsAxis_ifrs-fullVehiclesMember_srtRangeAxis_ifrs-fullTopOfRangeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfIntangibleAssetsOtherThanGoodwillAxis_bntxIntellectualPropertyRightsMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">bntx:IntellectualPropertyRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfIntangibleAssetsOtherThanGoodwillAxis_bntxIntellectualPropertyRightsMember_srtRangeAxis_ifrs-fullTopOfRangeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">bntx:IntellectualPropertyRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrs-fullLicencesMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrs-fullLicencesMember_srtRangeAxis_ifrs-fullTopOfRangeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrs-fullComputerSoftwareMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrs-fullComputerSoftwareMember_srtRangeAxis_ifrs-fullTopOfRangeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullGeographicalAreasAxis_countryDE_ifrs-fullSalesChannelsAxis_ifrs-fullGoodsSoldDirectlyToConsumersMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SalesChannelsAxis">ifrs-full:GoodsSoldDirectlyToConsumersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSalesChannelsAxis_ifrs-fullGoodsSoldDirectlyToConsumersMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SalesChannelsAxis">ifrs-full:GoodsSoldDirectlyToConsumersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullGeographicalAreasAxis_countryUS_ifrs-fullProductsAndServicesAxis_bntxCollaborationAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:CollaborationAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullGeographicalAreasAxis_bntxOutsideUSMember_ifrs-fullProductsAndServicesAxis_bntxCollaborationAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">bntx:OutsideUSMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:CollaborationAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxCollaborationAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:CollaborationAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRNAPharmaceuticalsGmbHMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechRNAPharmaceuticalsGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechDeliveryTechnologiesGmbHMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechDeliveryTechnologiesGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechDiagnosticsGmbHMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechDiagnosticsGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechEuropeGmbHMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechEuropeGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechManufacturingGmbHMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechManufacturingGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechManufacturingMarburgGmbHMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechManufacturingMarburgGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechAustriaBeteiligungenGmbHMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechAustriaBeteiligungenGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechInnovativeManufacturingServicesGmbHMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechInnovativeManufacturingServicesGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxReSanoGmbHMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:ReSanoGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxJPTPeptideTechnologiesGmbHMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:JPTPeptideTechnologiesGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxJPTPeptideTechnologiesIncMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:JPTPeptideTechnologiesIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechUSAHoldingLLCMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechUSAHoldingLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechResearchAndDevelopmentIncMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechResearchAndDevelopmentIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechUSIncMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechUSIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechPharmaceuticalsAsiaPacificPteLtdMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechPharmaceuticalsAsiaPacificPteLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechUKLimitedMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechCellAndGeneTherapiesGmbHMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechCellAndGeneTherapiesGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateHoldingGmbHMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechRealEstateHoldingGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateVerwaltungsGmbHMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechRealEstateVerwaltungsGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateGmbHAndCoKGMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechRealEstateGmbHAndCoKGMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateDerGoldgrubeGmbHCoKGMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechRealEstateDerGoldgrubeGmbHCoKGMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateHausVierGmbHCoKGMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechRealEstateHausVierGmbHCoKGMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateAdamOpelStraeGmbHCoKGMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechRealEstateAdamOpelStraeGmbHCoKGMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRNAPharmaceuticalsGmbHMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechRNAPharmaceuticalsGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechDeliveryTechnologiesGmbHMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechDeliveryTechnologiesGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechDiagnosticsGmbHMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechDiagnosticsGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechEuropeGmbHMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechEuropeGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechManufacturingGmbHMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechManufacturingGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechAustriaBeteiligungenGmbHMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechAustriaBeteiligungenGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechInnovativeManufacturingServicesGmbHMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechInnovativeManufacturingServicesGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxReSanoGmbHMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:ReSanoGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxJPTPeptideTechnologiesGmbHMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:JPTPeptideTechnologiesGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxJPTPeptideTechnologiesIncMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:JPTPeptideTechnologiesIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechUSAHoldingLLCMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechUSAHoldingLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechResearchAndDevelopmentIncMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechResearchAndDevelopmentIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechCellAndGeneTherapiesGmbHMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechCellAndGeneTherapiesGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateHoldingGmbHMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechRealEstateHoldingGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateVerwaltungsGmbHMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechRealEstateVerwaltungsGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateGmbHAndCoKGMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechRealEstateGmbHAndCoKGMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxNeonTherapeuticsIncAndNovartisManufacturingGmbHMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:NeonTherapeuticsIncAndNovartisManufacturingGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_bntxReSanoGmbHMember_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechUSAHoldingLLCAndBioNTechResearchAndDevelopmentIncMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechUSAHoldingLLCAndBioNTechResearchAndDevelopmentIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">bntx:ReSanoGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_bntxATImpfGmbHMember_srtOwnershipAxis_bntxBioNTechMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:OwnershipAxis">bntx:BioNTechMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">bntx:ATImpfGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_bntxATImpfGmbHMember_srtOwnershipAxis_bntxBioNTechMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:OwnershipAxis">bntx:BioNTechMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">bntx:ATImpfGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_bntxMedineGmbHMember_srtOwnershipAxis_bntxBioNTechMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:OwnershipAxis">bntx:BioNTechMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">bntx:MedineGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_bntxMedineGmbHMember_srtOwnershipAxis_bntxBioNTechMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:OwnershipAxis">bntx:BioNTechMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">bntx:MedineGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxLipocalyxGmbHMember_20200106_20200106">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">bntx:LipocalyxGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-06</xbrli:startDate>
      <xbrli:endDate>2020-01-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxLipocalyxGmbHMember_20200106">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">bntx:LipocalyxGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxLipocalyxGmbHMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">bntx:LipocalyxGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxLipocalyxGmbHMember_ifrs-fullItemsOfContingentLiabilitiesAxis_bntxPhaseOneClinicalTrialMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">bntx:LipocalyxGmbHMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ItemsOfContingentLiabilitiesAxis">bntx:PhaseOneClinicalTrialMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxLipocalyxGmbHMember_ifrs-fullItemsOfContingentLiabilitiesAxis_bntxPhaseTwoClinicalTrialMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">bntx:LipocalyxGmbHMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ItemsOfContingentLiabilitiesAxis">bntx:PhaseTwoClinicalTrialMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200506">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">bntx:BioNTechUSIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-05-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_ifrs-fullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrs-fullIntangibleAssetsUnderDevelopmentMember_20200506_20200506">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">bntx:BioNTechUSIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-05-06</xbrli:startDate>
      <xbrli:endDate>2020-05-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200101_20200101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">bntx:BioNTechUSIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-01-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200506_20200506">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">bntx:BioNTechUSIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-05-06</xbrli:startDate>
      <xbrli:endDate>2020-05-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechManufacturingMarburgGmbHMember_20201031_20201031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">bntx:BioNTechManufacturingMarburgGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-10-31</xbrli:startDate>
      <xbrli:endDate>2020-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechManufacturingMarburgGmbHMember_20201031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">bntx:BioNTechManufacturingMarburgGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxPfizerIncMember_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:PfizerIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:ResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxPfizerIncMember_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:PfizerIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:ResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxPfizerIncMember_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:PfizerIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:ResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxGenentechIncMember_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:GenentechIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:ResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxGenentechIncMember_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:GenentechIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:ResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxGenentechIncMember_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:GenentechIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:ResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxShanghaiFosunPharmaceuticalGroupCoLtdMember_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:ShanghaiFosunPharmaceuticalGroupCoLtdMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:ResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxOtherMember_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:OtherMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:ResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxOtherMember_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:OtherMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:ResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxOtherMember_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:OtherMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:ResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxCOVID19VaccineRevenuesMember_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:CommercialMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxSalesToCollaborationPartnerMember_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:SalesToCollaborationPartnerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:CommercialMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxDirectProductSalesToBioNTechCustomersMember_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:DirectProductSalesToBioNTechCustomersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:CommercialMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxShareOfCollaborationPartnersGrossProfitMember_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:ShareOfCollaborationPartnersGrossProfitMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:CommercialMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxOtherSalesMember_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:OtherSalesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:CommercialMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxOtherSalesMember_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:OtherSalesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:CommercialMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxOtherSalesMember_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:OtherSalesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:CommercialMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxPfizerIncMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:PfizerIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxGenentechIncMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:GenentechIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxSanofiSAMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:SanofiSAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxGenentechIncMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:GenentechIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxGenentechIncMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:GenentechIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxPfizerIncMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:PfizerIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxGenentechIncMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:GenentechIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxSanofiSAMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:SanofiSAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxGenentechIncMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:GenentechIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxGenentechIncMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:GenentechIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxFosunPharmaMember_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:FosunPharmaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:ResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullIntangibleAssetsWithIndefiniteUsefulLifeAxis_bntxCellscriptSublicenseMember_ifrs-fullMajorCustomersAxis_bntxSanofiSAMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:SanofiSAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis">bntx:CellscriptSublicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:CommercialMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxRevenuesFromSellingDrugProductBatchesToPfizersManufacturingSiteMember_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:RevenuesFromSellingDrugProductBatchesToPfizersManufacturingSiteMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:CommercialMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxBioNTechMember_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_srtStatementGeographicalAxis_countryDE_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:CommercialMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:BioNTechMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxRevenueFromShareOfCollaborationPartnersGrossProfitMember_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:RevenueFromShareOfCollaborationPartnersGrossProfitMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:CommercialMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxOtherSalesTransactionsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:OtherSalesTransactionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxOtherSalesTransactionsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:OtherSalesTransactionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxOtherSalesTransactionsMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:OtherSalesTransactionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullPerformanceObligationsAxis_ifrs-fullPerformanceObligationsSatisfiedAtPointInTimeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullPerformanceObligationsAxis_ifrs-fullPerformanceObligationsSatisfiedAtPointInTimeMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullPerformanceObligationsAxis_ifrs-fullPerformanceObligationsSatisfiedAtPointInTimeMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullPerformanceObligationsAxis_ifrs-fullPerformanceObligationsSatisfiedOverTimeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">ifrs-full:PerformanceObligationsSatisfiedOverTimeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullPerformanceObligationsAxis_ifrs-fullPerformanceObligationsSatisfiedOverTimeMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">ifrs-full:PerformanceObligationsSatisfiedOverTimeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullPerformanceObligationsAxis_ifrs-fullPerformanceObligationsSatisfiedOverTimeMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">ifrs-full:PerformanceObligationsSatisfiedOverTimeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMajorCustomersAxis_bntxBioNTechMember_ifrs-fullProductsAndServicesAxis_bntxBillAndHoldTransactionMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:BioNTechMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:BillAndHoldTransactionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_srtRangeAxis_ifrs-fullBottomOfRangeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_srtRangeAxis_ifrs-fullTopOfRangeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxOtherSalesTransactionsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:OtherSalesTransactionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxOtherSalesTransactionsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">bntx:OtherSalesTransactionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMaturityAxis_ifrs-fullNotLaterThanOneYearMember_ifrs-fullPerformanceObligationsAxis_bntxUnsatisfiedOrPartiallyUnsatisfiedMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">bntx:UnsatisfiedOrPartiallyUnsatisfiedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMaturityAxis_ifrs-fullNotLaterThanOneYearMember_ifrs-fullPerformanceObligationsAxis_bntxUnsatisfiedOrPartiallyUnsatisfiedMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">bntx:UnsatisfiedOrPartiallyUnsatisfiedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMaturityAxis_ifrs-fullLaterThanOneYearMember_ifrs-fullPerformanceObligationsAxis_bntxUnsatisfiedOrPartiallyUnsatisfiedMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">bntx:UnsatisfiedOrPartiallyUnsatisfiedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMaturityAxis_ifrs-fullLaterThanOneYearMember_ifrs-fullPerformanceObligationsAxis_bntxUnsatisfiedOrPartiallyUnsatisfiedMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">bntx:UnsatisfiedOrPartiallyUnsatisfiedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullPerformanceObligationsAxis_bntxUnsatisfiedOrPartiallyUnsatisfiedMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">bntx:UnsatisfiedOrPartiallyUnsatisfiedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullPerformanceObligationsAxis_bntxUnsatisfiedOrPartiallyUnsatisfiedMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">bntx:UnsatisfiedOrPartiallyUnsatisfiedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxPurchasedServicesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:PurchasedServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxPurchasedServicesMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:PurchasedServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxPurchasedServicesMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:PurchasedServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxWagesBenefitsAndSocialSecurityExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:WagesBenefitsAndSocialSecurityExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxWagesBenefitsAndSocialSecurityExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:WagesBenefitsAndSocialSecurityExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxWagesBenefitsAndSocialSecurityExpenseMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:WagesBenefitsAndSocialSecurityExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxLaboratorySuppliesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:LaboratorySuppliesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxLaboratorySuppliesMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:LaboratorySuppliesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxLaboratorySuppliesMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:LaboratorySuppliesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAndAmortisationMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAndAmortisationMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAndAmortisationMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxITCostsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:ITCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxITCostsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:ITCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxITCostsMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:ITCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxLeaseAndLeaseRelatedCostMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:LeaseAndLeaseRelatedCostMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxLeaseAndLeaseRelatedCostMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:LeaseAndLeaseRelatedCostMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxLeaseAndLeaseRelatedCostMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:LeaseAndLeaseRelatedCostMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxTransportCostsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:TransportCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxTransportCostsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:TransportCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxTransportCostsMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:TransportCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxOtherIncomeExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:OtherIncomeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxOtherIncomeExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:OtherIncomeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxOtherIncomeExpenseMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:OtherIncomeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechUSIncMember_20200506_20200506">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechUSIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-05-06</xbrli:startDate>
      <xbrli:endDate>2020-05-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullOfficeEquipmentMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullOfficeEquipmentMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullOfficeEquipmentMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxInsurancePremiumsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:InsurancePremiumsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxInsurancePremiumsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:InsurancePremiumsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxInsurancePremiumsMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:InsurancePremiumsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxJobAdvertisementExpensesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:JobAdvertisementExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxJobAdvertisementExpensesMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:JobAdvertisementExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxJobAdvertisementExpensesMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:JobAdvertisementExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxResearchServicesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:ResearchServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxResearchServicesMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:ResearchServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxResearchServicesMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:ResearchServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxContractStaffingMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:ContractStaffingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxContractStaffingMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:ContractStaffingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxContractStaffingMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:ContractStaffingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxNatureOfExpensesAxis_bntxGeneralAndAdministrativeExpensesMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:NatureOfExpensesAxis">bntx:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxGovernmentGrantsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:GovernmentGrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxGovernmentGrantsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:GovernmentGrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxGovernmentGrantsMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:GovernmentGrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxBargainPurchaseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:BargainPurchaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxBargainPurchaseMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:BargainPurchaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxGovernmentGrantsMember_srtStatementGeographicalAxis_countryDE_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:GovernmentGrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_srtStatementGeographicalAxis_countryDE_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-fullUnusedTaxLossesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-fullTemporaryDifferenceMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:TemporaryDifferenceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-fullTemporaryDifferenceMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:TemporaryDifferenceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxFixedAssetsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:FixedAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxInventoryMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:InventoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxLeasesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:LeasesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxContractLiabilitiesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ContractLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxProvisionsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ProvisionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxOtherDeferredTaxesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:OtherDeferredTaxesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-fullUnusedTaxCreditsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bntxValuationAdjustmentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">bntx:ValuationAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxFixedAssetsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:FixedAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxInventoryMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:InventoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxLeasesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:LeasesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxContractLiabilitiesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ContractLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxInterestBearingLoansAndBorrowingsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-fullNetDefinedBenefitLiabilityAssetMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:NetDefinedBenefitLiabilityAssetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxProvisionsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ProvisionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxOtherDeferredTaxesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:OtherDeferredTaxesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-fullUnusedTaxCreditsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bntxValuationAdjustmentMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">bntx:ValuationAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxFixedAssetsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:FixedAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxInventoryMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:InventoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxLeasesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:LeasesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxContractLiabilitiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ContractLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxInterestBearingLoansAndBorrowingsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-fullNetDefinedBenefitLiabilityAssetMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:NetDefinedBenefitLiabilityAssetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxProvisionsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ProvisionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxOtherDeferredTaxesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:OtherDeferredTaxesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-fullUnusedTaxCreditsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bntxValuationAdjustmentMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">bntx:ValuationAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxFixedAssetsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:FixedAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxLeasesMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:LeasesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxContractLiabilitiesMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ContractLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxProvisionsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ProvisionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxOtherDeferredTaxesMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:OtherDeferredTaxesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-fullUnusedTaxCreditsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bntxValuationAdjustmentMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">bntx:ValuationAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxFixedAssetsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:FixedAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxInventoryMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:InventoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxLeasesMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:LeasesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxContractLiabilitiesMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ContractLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxProvisionsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ProvisionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxOtherDeferredTaxesMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:OtherDeferredTaxesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-fullUnusedTaxCreditsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bntxValuationAdjustmentMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">bntx:ValuationAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxGermanTaxGroupMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:GermanTaxGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxGermanTaxGroupMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:GermanTaxGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxGermanEntitiesNotWithinTaxGroupMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:GermanEntitiesNotWithinTaxGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxGermanEntitiesNotWithinTaxGroupMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:GermanEntitiesNotWithinTaxGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxUnitedStatesTaxGroupMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:UnitedStatesTaxGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxConstructionInProgressAndAdvancePaymentsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxConstructionInProgressAndAdvancePaymentsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxConstructionInProgressAndAdvancePaymentsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxConstructionInProgressAndAdvancePaymentsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxConstructionInProgressAndAdvancePaymentsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxConstructionInProgressAndAdvancePaymentsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxConstructionInProgressAndAdvancePaymentsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxConstructionInProgressAndAdvancePaymentsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-fullGoodwillMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxAdvancePaymentsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxAdvancePaymentsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-fullGoodwillMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-fullGoodwillMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxAdvancePaymentsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxAdvancePaymentsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-fullGoodwillMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-fullGoodwillMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxAdvancePaymentsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-fullGoodwillMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxAdvancePaymentsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-fullGoodwillMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxAdvancePaymentsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-fullGoodwillMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxAdvancePaymentsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullConsolidatedStructuredEntitiesAxis_bntxCGUImmunotherapiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ConsolidatedStructuredEntitiesAxis">bntx:CGUImmunotherapiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullConsolidatedStructuredEntitiesAxis_bntxCGUImmunotherapiesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ConsolidatedStructuredEntitiesAxis">bntx:CGUImmunotherapiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullConsolidatedStructuredEntitiesAxis_bntxExternalProductSalesOfJPTMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ConsolidatedStructuredEntitiesAxis">bntx:ExternalProductSalesOfJPTMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullConsolidatedStructuredEntitiesAxis_bntxExternalProductSalesOfJPTMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ConsolidatedStructuredEntitiesAxis">bntx:ExternalProductSalesOfJPTMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullConsolidatedStructuredEntitiesAxis_bntxCGUImmunotherapiesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ConsolidatedStructuredEntitiesAxis">bntx:CGUImmunotherapiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullConsolidatedStructuredEntitiesAxis_bntxExternalProductSalesOfJPTMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ConsolidatedStructuredEntitiesAxis">bntx:ExternalProductSalesOfJPTMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullGeographicalAreasAxis_countryUS_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_ifrs-fullSubsidiariesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullGeographicalAreasAxis_countryUS_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_ifrs-fullSubsidiariesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfFinancialAssetsAxis_ifrs-fullTradeReceivablesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfFinancialAssetsAxis_ifrs-fullTradeReceivablesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfFinancialAssetsAxis_bntxOtherFinancialAssetsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:OtherFinancialAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfFinancialAssetsAxis_bntxOtherFinancialAssetsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:OtherFinancialAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_ifrs-fullLeaseLiabilitiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_ifrs-fullLeaseLiabilitiesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBorrowingsByNameAxis_bntxConvertibleNoteHostContractMember_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">bntx:ConvertibleNoteHostContractMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBorrowingsByNameAxis_bntxThreePointFiveZeroPercentageSecuredBankLoanMember_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">bntx:ThreePointFiveZeroPercentageSecuredBankLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBorrowingsByNameAxis_bntxTwoPointOneFivePercentageSecuredBankLoanMember_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">bntx:TwoPointOneFivePercentageSecuredBankLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBorrowingsByNameAxis_bntxTwoPointOneFivePercentageSecuredBankLoanMember_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">bntx:TwoPointOneFivePercentageSecuredBankLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBorrowingsByNameAxis_bntxTwoPointZeroEightPercentageSecuredBankLoanMember_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">bntx:TwoPointZeroEightPercentageSecuredBankLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBorrowingsByNameAxis_bntxTwoPointZeroEightPercentageSecuredBankLoanMember_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">bntx:TwoPointZeroEightPercentageSecuredBankLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBorrowingsByNameAxis_bntxOnePointNineZeroPercentageSecuredBankLoanMember_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">bntx:OnePointNineZeroPercentageSecuredBankLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBorrowingsByNameAxis_bntxConvertibleNoteHostContractMember_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">bntx:ConvertibleNoteHostContractMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBorrowingsByNameAxis_bntxThreePointFiveZeroPercentageSecuredBankLoanMember_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">bntx:ThreePointFiveZeroPercentageSecuredBankLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBorrowingsByNameAxis_bntxTwoPointOneFivePercentageSecuredBankLoanMember_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">bntx:TwoPointOneFivePercentageSecuredBankLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBorrowingsByNameAxis_bntxTwoPointZeroEightPercentageSecuredBankLoanMember_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">bntx:TwoPointZeroEightPercentageSecuredBankLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBorrowingsByNameAxis_bntxOnePointNineZeroPercentageSecuredBankLoanMember_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">bntx:OnePointNineZeroPercentageSecuredBankLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxOtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember_ifrs-fullClassesOfLiabilitiesAxis_bntxConvertibleNoteEmbeddedDerivativeMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">bntx:ConvertibleNoteEmbeddedDerivativeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxOtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember_ifrs-fullClassesOfLiabilitiesAxis_ifrs-fullContingentConsiderationMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxOtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxOtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxTradePayablesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:TradePayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxOtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxTradePayablesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:TradePayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxOtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxOtherFinancialLiabilitiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxOtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxOtherFinancialLiabilitiesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxOtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_deiLegalEntityAxis_bntxDeutscheBankAGMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bntx:DeutscheBankAGMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_deiLegalEntityAxis_bntxDeutscheBankAGMember_ifrs-fullBorrowingsByNameAxis_bntxTwoPointOneFivePercentageSecuredLoanMember_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechInnovativeManufacturingServicesGmbHMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">bntx:TwoPointOneFivePercentageSecuredLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bntx:DeutscheBankAGMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechInnovativeManufacturingServicesGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_deiLegalEntityAxis_bntxDeutscheBankAGMember_ifrs-fullBorrowingsByNameAxis_bntxTwoPointOneFivePercentageSecuredLoanMember_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechInnovativeManufacturingServicesGmbHMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">bntx:TwoPointOneFivePercentageSecuredLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bntx:DeutscheBankAGMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechInnovativeManufacturingServicesGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_deiLegalEntityAxis_bntxDeutscheBankAGMember_ifrs-fullBorrowingsByNameAxis_bntxTwoPointZeroEightPercentageBankLoanMember_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxJPTPeptideTechnologiesGmbHMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">bntx:TwoPointZeroEightPercentageBankLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bntx:DeutscheBankAGMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:JPTPeptideTechnologiesGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_deiLegalEntityAxis_bntxDeutscheBankAGMember_ifrs-fullBorrowingsByNameAxis_bntxTwoPointZeroEightPercentageBankLoanMember_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxJPTPeptideTechnologiesGmbHMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">bntx:TwoPointZeroEightPercentageBankLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bntx:DeutscheBankAGMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:JPTPeptideTechnologiesGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_deiLegalEntityAxis_bntxEuropeanInvestmentBankMember_ifrs-fullBorrowingsByNameAxis_bntxThreePointFiveZeroPercentageSecuredBankLoanMember_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">bntx:ThreePointFiveZeroPercentageSecuredBankLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bntx:EuropeanInvestmentBankMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_deiLegalEntityAxis_bntxEuropeanInvestmentBankMember_ifrs-fullBorrowingsByNameAxis_bntxThreePointFiveZeroPercentageSecuredBankLoanMember_20201221">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">bntx:ThreePointFiveZeroPercentageSecuredBankLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bntx:EuropeanInvestmentBankMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_deiLegalEntityAxis_bntxEuropeanInvestmentBankMember_ifrs-fullBorrowingsByNameAxis_bntxThreePointFiveZeroPercentageSecuredBankLoanMember_ifrs-fullTypesOfInterestRatesAxis_bntxCashInterestFixedRateMember_20201221">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">bntx:ThreePointFiveZeroPercentageSecuredBankLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">bntx:CashInterestFixedRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bntx:EuropeanInvestmentBankMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_deiLegalEntityAxis_bntxEuropeanInvestmentBankMember_ifrs-fullBorrowingsByNameAxis_bntxThreePointFiveZeroPercentageSecuredBankLoanMember_ifrs-fullTypesOfInterestRatesAxis_bntxDeferredInterestAtFixedRateMember_20201221">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">bntx:ThreePointFiveZeroPercentageSecuredBankLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">bntx:DeferredInterestAtFixedRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bntx:EuropeanInvestmentBankMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_deiLegalEntityAxis_bntxEuropeanInvestmentBankMember_ifrs-fullBorrowingsByNameAxis_bntxThreePointFiveZeroPercentageSecuredBankLoanMember_20201221_20201221">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">bntx:ThreePointFiveZeroPercentageSecuredBankLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bntx:EuropeanInvestmentBankMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-21</xbrli:startDate>
      <xbrli:endDate>2020-12-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfFinancialInstrumentsAxis_bntxJuneTwentyTwentyPrivatePlacementMember_ifrs-fullClassesOfLiabilitiesAxis_bntxConvertibleNoteMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">bntx:ConvertibleNoteMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:JuneTwentyTwentyPrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfFinancialInstrumentsAxis_bntxJuneTwentyTwentyPrivatePlacementMember_ifrs-fullClassesOfLiabilitiesAxis_bntxConvertibleNoteMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">bntx:ConvertibleNoteMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:JuneTwentyTwentyPrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfAssetsAxis_bntxUSDollarBankAccountsMember_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:USDollarBankAccountsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfAssetsAxis_bntxUSDollarBankAccountsMember_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:USDollarBankAccountsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfFinancialAssetsAxis_bntxOtherFinancialAssetsMember_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:OtherFinancialAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxFinancialLiabilityMember_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullGeographicalAreasAxis_countryUS_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_srtCurrencyAxis_currencyUSD_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullGeographicalAreasAxis_countryUS_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_srtCurrencyAxis_currencyUSD_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullGeographicalAreasAxis_countryUS_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_srtCurrencyAxis_currencyUSD_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullGeographicalAreasAxis_countryUS_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_srtCurrencyAxis_currencyUSD_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullHedgingInstrumentsAxis_bntxPositiveFivePercentageChangeInForeignExchangeRateMember_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">bntx:PositiveFivePercentageChangeInForeignExchangeRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullHedgingInstrumentsAxis_bntxNegativeFivePercentageChangeInForeignExchangeRateMember_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">bntx:NegativeFivePercentageChangeInForeignExchangeRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullHedgingInstrumentsAxis_bntxPositiveFivePercentageChangeInForeignExchangeRateMember_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">bntx:PositiveFivePercentageChangeInForeignExchangeRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullHedgingInstrumentsAxis_bntxNegativeFivePercentageChangeInForeignExchangeRateMember_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">bntx:NegativeFivePercentageChangeInForeignExchangeRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMaturityAxis_ifrs-fullNotLaterThanOneYearMember_ifrs-fullTypesOfRisksAxis_ifrs-fullLiquidityRiskMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMaturityAxis_ifrs-fullLaterThanTwoYearsAndNotLaterThanFiveYearsMember_ifrs-fullTypesOfRisksAxis_ifrs-fullLiquidityRiskMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMaturityAxis_ifrs-fullLaterThanFiveYearsMember_ifrs-fullTypesOfRisksAxis_ifrs-fullLiquidityRiskMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfRisksAxis_ifrs-fullLiquidityRiskMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxCurrentObligationsUnderLeaseContractsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:CurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxNoncurrentObligationsUnderLeaseContractsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:NoncurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxCurrentObligationsUnderLeaseContractsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:CurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxConvertibleNoteEmbeddedDerivativeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:ConvertibleNoteEmbeddedDerivativeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxNoncurrentObligationsUnderLeaseContractsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:NoncurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxCurrentObligationsUnderLeaseContractsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:CurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxNoncurrentObligationsUnderLeaseContractsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:NoncurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxConvertibleNoteEmbeddedDerivativeMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:ConvertibleNoteEmbeddedDerivativeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxCurrentObligationsUnderLeaseContractsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:CurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxNoncurrentObligationsUnderLeaseContractsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:NoncurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxCurrentObligationsUnderLeaseContractsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:CurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxNoncurrentObligationsUnderLeaseContractsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:NoncurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_srtCounterpartyNameAxis_bntxShanghaiFosunPharmaceuticalGroupCoLtdMember_20200316_20200316">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:ShanghaiFosunPharmaceuticalGroupCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-03-16</xbrli:startDate>
      <xbrli:endDate>2020-03-16</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_srtCounterpartyNameAxis_bntxShanghaiFosunPharmaceuticalGroupCoLtdMember_20200316">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:ShanghaiFosunPharmaceuticalGroupCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_srtCounterpartyNameAxis_bntxShanghaiFosunPharmaceuticalGroupCoLtdMember_20200423_20200423">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:ShanghaiFosunPharmaceuticalGroupCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-23</xbrli:startDate>
      <xbrli:endDate>2020-04-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_srtCounterpartyNameAxis_bntxShanghaiFosunPharmaceuticalGroupCoLtdMember_20200423_20200423">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:ShanghaiFosunPharmaceuticalGroupCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-23</xbrli:startDate>
      <xbrli:endDate>2020-04-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_srtCounterpartyNameAxis_bntxPfizerIncMember_20200317_20200317">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:PfizerIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-03-17</xbrli:startDate>
      <xbrli:endDate>2020-03-17</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_srtCounterpartyNameAxis_bntxPfizerIncMember_20200505">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:PfizerIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-05-05</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_srtCounterpartyNameAxis_bntxPfizerIncMember_20200505_20200505">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:PfizerIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-05-05</xbrli:startDate>
      <xbrli:endDate>2020-05-05</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_srtCounterpartyNameAxis_bntxPfizerIncMember_20200505_20200505">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:PfizerIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-05-05</xbrli:startDate>
      <xbrli:endDate>2020-05-05</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxNeonTherapeuticsIncMember_20200508">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">bntx:NeonTherapeuticsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-05-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxNeonTherapeuticsIncMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20200508_20200508">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">bntx:NeonTherapeuticsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-05-08</xbrli:startDate>
      <xbrli:endDate>2020-05-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxNeonTherapeuticsIncMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20200508_20200508">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">bntx:NeonTherapeuticsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-05-08</xbrli:startDate>
      <xbrli:endDate>2020-05-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxGlobalOfferingMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20200727_20200727">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">bntx:GlobalOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-27</xbrli:startDate>
      <xbrli:endDate>2020-07-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxGlobalOfferingMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20200827_20200827">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">bntx:GlobalOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-08-27</xbrli:startDate>
      <xbrli:endDate>2020-08-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxGlobalOfferingMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">bntx:GlobalOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxGlobalOfferingMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">bntx:GlobalOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxGlobalOfferingMember_20200727">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">bntx:GlobalOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxGlobalOfferingMember_20200827">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">bntx:GlobalOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxGlobalOfferingMember_20200727_20200727">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">bntx:GlobalOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-27</xbrli:startDate>
      <xbrli:endDate>2020-07-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxGlobalOfferingMember_20200827_20200827">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">bntx:GlobalOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-08-27</xbrli:startDate>
      <xbrli:endDate>2020-08-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxGlobalOfferingMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">bntx:GlobalOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxJune2020PrivatePlacementMember_20200629">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">bntx:June2020PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxJune2020PrivatePlacementMember_ifrs-fullClassesOfLiabilitiesAxis_bntxConvertibleNoteMember_20200908_20200908">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">bntx:June2020PrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">bntx:ConvertibleNoteMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-08</xbrli:startDate>
      <xbrli:endDate>2020-09-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxJune2020PrivatePlacementMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20200629_20200629">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">bntx:June2020PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-06-29</xbrli:startDate>
      <xbrli:endDate>2020-06-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxJune2020PrivatePlacementMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20200908_20200908">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">bntx:June2020PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-08</xbrli:startDate>
      <xbrli:endDate>2020-09-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxJune2020PrivatePlacementMember_20200908">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">bntx:June2020PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxAtMarketOfferingProgramMember_20201130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">bntx:AtMarketOfferingProgramMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxAtMarketOfferingProgramMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullTreasurySharesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">bntx:AtMarketOfferingProgramMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxAtMarketOfferingProgramMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">bntx:AtMarketOfferingProgramMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxAtMarketOfferingProgramMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">bntx:AtMarketOfferingProgramMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxAtMarketOfferingProgramMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">bntx:AtMarketOfferingProgramMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxAtMarketOfferingProgramMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullTreasurySharesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">bntx:AtMarketOfferingProgramMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_20190131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20190101_20190131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechCellAndGeneTherapiesGmbHMember_20190314_20190314">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">bntx:BioNTechCellAndGeneTherapiesGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-03-14</xbrli:startDate>
      <xbrli:endDate>2019-03-14</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechCellAndGeneTherapiesGmbHMember_20190314">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">bntx:BioNTechCellAndGeneTherapiesGmbHMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-14</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechCellAndGeneTherapiesGmbHMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20190314">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">bntx:BioNTechCellAndGeneTherapiesGmbHMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-14</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_bntxOrdinarySharesSeriesBMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">bntx:OrdinarySharesSeriesBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_bntxOrdinarySharesSeriesBMember_ifrs-fullGeographicalAreasAxis_countryHK_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">bntx:OrdinarySharesSeriesBMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:HK</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_bntxOrdinarySharesSeriesBMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">bntx:OrdinarySharesSeriesBMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullSignificantInvestmentsInAssociatesAxis_bntxBillAndMeLindaGatesFoundationMember_20190926">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">bntx:BillAndMeLindaGatesFoundationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-09-26</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_ifrs-fullSignificantInvestmentsInAssociatesAxis_bntxBillAndMeLindaGatesFoundationMember_20190926">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">bntx:BillAndMeLindaGatesFoundationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-09-26</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxInitialPublicOfferingMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20191010">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">bntx:InitialPublicOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-10-10</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxInitialPublicOfferingMember_20191010">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">bntx:InitialPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-10-10</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxInitialPublicOfferingMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20191106">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">bntx:InitialPublicOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-11-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxInitialPublicOfferingMember_20191106">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">bntx:InitialPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-11-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxInitialPublicOfferingMember_20191106_20191106">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">bntx:InitialPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-06</xbrli:startDate>
      <xbrli:endDate>2019-11-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxInitialPublicOfferingMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20191106">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CapitalRequirementsAxis">bntx:InitialPublicOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-11-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxTwoThousandTwentyRestrictedStockUnitPlanMember_20201201_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:TwoThousandTwentyRestrictedStockUnitPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeEquityPlanLongTermIncentiveProgramMember_20201201_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentiveProgramMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeEquityPlanLongTermIncentivePlusProgramMember_20201201_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentivePlusProgramMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeEquityPlanLongTermIncentiveProgramMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentiveProgramMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeEquityPlanLongTermIncentivePlusProgramMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentivePlusProgramMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeEquityPlanMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxNatureOfExpensesAxis_bntxCostOfSales1Member_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeEquityPlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:NatureOfExpensesAxis">bntx:CostOfSales1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxNatureOfExpensesAxis_bntxResearchAndDevelopmentExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeEquityPlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:NatureOfExpensesAxis">bntx:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxNatureOfExpensesAxis_bntxSalesAndMarketingExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeEquityPlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:NatureOfExpensesAxis">bntx:SalesAndMarketingExpensesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxNatureOfExpensesAxis_bntxGeneralAndAdministrativeExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeEquityPlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:NatureOfExpensesAxis">bntx:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtRangeAxis_ifrs-fullTopOfRangeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxNatureOfExpensesAxis_bntxResearchAndDevelopmentExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:NatureOfExpensesAxis">bntx:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxNatureOfExpensesAxis_bntxGeneralAndAdministrativeExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:NatureOfExpensesAxis">bntx:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxProfessorUgurSahinMDMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:ProfessorUgurSahinMDMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxSeanMarettMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:SeanMarettMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrSierkPoettingMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:DrSierkPoettingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrOzlemTureciMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:DrOzlemTureciMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxRyanRichardsonMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:RyanRichardsonMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200213">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-02-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateOneMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20211231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateTwoMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20221231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200213_20200213">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-02-13</xbrli:startDate>
      <xbrli:endDate>2020-02-13</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateOneMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20210101_20211231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateTwoMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20220101_20221231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-01-01</xbrli:startDate>
      <xbrli:endDate>2022-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxProfessorUgurSahinMDMember_20200213">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:ProfessorUgurSahinMDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-02-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxSeanMarettMember_20200213">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:SeanMarettMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-02-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrSierkPoettingMember_20200213">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:DrSierkPoettingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-02-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrOzlemTureciMDMember_20200213">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:DrOzlemTureciMDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-02-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxRyanRichardsonMember_20200213">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:RyanRichardsonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-02-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateOneMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxProfessorUgurSahinMDMember_20211231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:ProfessorUgurSahinMDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateOneMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxSeanMarettMember_20211231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:SeanMarettMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateOneMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrSierkPoettingMember_20211231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:DrSierkPoettingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateOneMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrOzlemTureciMDMember_20211231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:DrOzlemTureciMDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateOneMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxRyanRichardsonMember_20211231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:RyanRichardsonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateTwoMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxProfessorUgurSahinMDMember_20221231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:ProfessorUgurSahinMDMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateTwoMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxSeanMarettMember_20221231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:SeanMarettMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateTwoMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrSierkPoettingMember_20221231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:DrSierkPoettingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateTwoMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrOzlemTureciMDMember_20221231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:DrOzlemTureciMDMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateTwoMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxRyanRichardsonMember_20221231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:RyanRichardsonMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_ifrs-fullOrdinarySharesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_20190901_20190930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ChiefExecutiveOfficerGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-09-01</xbrli:startDate>
      <xbrli:endDate>2019-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_ifrs-fullOrdinarySharesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ChiefExecutiveOfficerGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_ifrs-fullOrdinarySharesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_srtRangeAxis_srtMaximumMember_20190901_20190930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ChiefExecutiveOfficerGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-09-01</xbrli:startDate>
      <xbrli:endDate>2019-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_20191010">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ChiefExecutiveOfficerGrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-10-10</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_20191010_20191010">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ChiefExecutiveOfficerGrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-10-10</xbrli:startDate>
      <xbrli:endDate>2019-10-10</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxNatureOfExpensesAxis_bntxResearchAndDevelopmentExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ChiefExecutiveOfficerGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="bntx:NatureOfExpensesAxis">bntx:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxNatureOfExpensesAxis_bntxResearchAndDevelopmentExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ChiefExecutiveOfficerGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="bntx:NatureOfExpensesAxis">bntx:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20181115_20181115">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-15</xbrli:startDate>
      <xbrli:endDate>2018-11-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190221_20190403">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-21</xbrli:startDate>
      <xbrli:endDate>2019-04-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190429_20190531">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-29</xbrli:startDate>
      <xbrli:endDate>2019-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20191201_20191201">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-12-01</xbrli:startDate>
      <xbrli:endDate>2019-12-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20181115">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-11-15</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190403">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190531">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20191201">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190222_20190403">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-22</xbrli:startDate>
      <xbrli:endDate>2019-04-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190430_20190531">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-30</xbrli:startDate>
      <xbrli:endDate>2019-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxProfessorUgurSahinMDMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:ProfessorUgurSahinMDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxSeanMarettMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:SeanMarettMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrSierkPoettingMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:DrSierkPoettingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrOzlemTureciMDMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:DrOzlemTureciMDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxRyanRichardsonMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:RyanRichardsonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxNatureOfExpensesAxis_bntxCostOfSales1Member_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:NatureOfExpensesAxis">bntx:CostOfSales1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxNatureOfExpensesAxis_bntxCostOfSales1Member_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:NatureOfExpensesAxis">bntx:CostOfSales1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxNatureOfExpensesAxis_bntxCostOfSales1Member_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:NatureOfExpensesAxis">bntx:CostOfSales1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxNatureOfExpensesAxis_bntxResearchAndDevelopmentExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:NatureOfExpensesAxis">bntx:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxNatureOfExpensesAxis_bntxResearchAndDevelopmentExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:NatureOfExpensesAxis">bntx:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxNatureOfExpensesAxis_bntxResearchAndDevelopmentExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:NatureOfExpensesAxis">bntx:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxNatureOfExpensesAxis_bntxSalesAndMarketingExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:NatureOfExpensesAxis">bntx:SalesAndMarketingExpensesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxNatureOfExpensesAxis_bntxSalesAndMarketingExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:NatureOfExpensesAxis">bntx:SalesAndMarketingExpensesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxNatureOfExpensesAxis_bntxSalesAndMarketingExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:NatureOfExpensesAxis">bntx:SalesAndMarketingExpensesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxNatureOfExpensesAxis_bntxGeneralAndAdministrativeExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:NatureOfExpensesAxis">bntx:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxNatureOfExpensesAxis_bntxGeneralAndAdministrativeExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:NatureOfExpensesAxis">bntx:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_bntxNatureOfExpensesAxis_bntxGeneralAndAdministrativeExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="bntx:NatureOfExpensesAxis">bntx:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfAssetsAxis_ifrs-fullBuildingsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfAssetsAxis_ifrs-fullBuildingsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfAssetsAxis_bntxEquipmentToolsAndInstallationsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfAssetsAxis_bntxEquipmentToolsAndInstallationsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfAssetsAxis_ifrs-fullVehiclesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfAssetsAxis_ifrs-fullVehiclesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfAssetsAxis_bntxProductionFacilitiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:ProductionFacilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfAssetsAxis_bntxAdvancePaymentsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMaturityAxis_ifrs-fullNotLaterThanOneYearMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullMaturityAxis_ifrs-fullLaterThanOneYearMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfAssetsAxis_ifrs-fullBuildingsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfAssetsAxis_ifrs-fullBuildingsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfAssetsAxis_ifrs-fullBuildingsMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfAssetsAxis_bntxEquipmentToolsAndInstallationsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfAssetsAxis_bntxEquipmentToolsAndInstallationsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfAssetsAxis_bntxEquipmentToolsAndInstallationsMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfAssetsAxis_ifrs-fullVehiclesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfAssetsAxis_ifrs-fullVehiclesMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfAssetsAxis_ifrs-fullVehiclesMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullClassesOfAssetsAxis_bntxProductionFacilitiesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:ProductionFacilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_srtRangeAxis_ifrs-fullTopOfRangeMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CharacteristicsOfDefinedBenefitPlansAxis">ifrs-full:FinalSalaryPensionDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CharacteristicsOfDefinedBenefitPlansAxis">ifrs-full:FinalSalaryPensionDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_srtRangeAxis_ifrs-fullTopOfRangeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CharacteristicsOfDefinedBenefitPlansAxis">ifrs-full:FinalSalaryPensionDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CharacteristicsOfDefinedBenefitPlansAxis">ifrs-full:FinalSalaryPensionDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_ifrs-fullDefinedBenefitPlansAxis_bntxBasePlanMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">bntx:BasePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CharacteristicsOfDefinedBenefitPlansAxis">ifrs-full:FinalSalaryPensionDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_ifrs-fullDefinedBenefitPlansAxis_bntxSupplementPlanMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">bntx:SupplementPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CharacteristicsOfDefinedBenefitPlansAxis">ifrs-full:FinalSalaryPensionDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullActuarialAssumptionsAxis_ifrs-fullActuarialAssumptionOfDiscountRatesMember_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CharacteristicsOfDefinedBenefitPlansAxis">ifrs-full:FinalSalaryPensionDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullActuarialAssumptionsAxis_ifrs-fullActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CharacteristicsOfDefinedBenefitPlansAxis">ifrs-full:FinalSalaryPensionDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_ifrs-fullFundingArrangementsOfDefinedBenefitPlansAxis_ifrs-fullWhollyOrPartlyFundedDefinedBenefitPlansMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:FundingArrangementsOfDefinedBenefitPlansAxis">ifrs-full:WhollyOrPartlyFundedDefinedBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CharacteristicsOfDefinedBenefitPlansAxis">ifrs-full:FinalSalaryPensionDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_ifrs-fullFundingArrangementsOfDefinedBenefitPlansAxis_ifrs-fullWhollyUnfundedDefinedBenefitPlansMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:FundingArrangementsOfDefinedBenefitPlansAxis">ifrs-full:WhollyUnfundedDefinedBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CharacteristicsOfDefinedBenefitPlansAxis">ifrs-full:FinalSalaryPensionDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_ifrs-fullMaturityAxis_ifrs-fullNotLaterThanOneYearMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CharacteristicsOfDefinedBenefitPlansAxis">ifrs-full:FinalSalaryPensionDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_ifrs-fullMaturityAxis_ifrs-fullLaterThanOneYearAndNotLaterThanFiveYearsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CharacteristicsOfDefinedBenefitPlansAxis">ifrs-full:FinalSalaryPensionDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_ifrs-fullMaturityAxis_ifrs-fullLaterThanFiveYearsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CharacteristicsOfDefinedBenefitPlansAxis">ifrs-full:FinalSalaryPensionDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_bntxCofounderAndChiefExecutiveOfficerMember_ifrs-fullClassesOfShareCapitalAxis_ifrs-fullOrdinarySharesMember_20190901_20190930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">bntx:CofounderAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-09-01</xbrli:startDate>
      <xbrli:endDate>2019-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullKeyManagementPersonnelOfEntityOrParentMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullKeyManagementPersonnelOfEntityOrParentMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullKeyManagementPersonnelOfEntityOrParentMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullKeyManagementPersonnelOfEntityOrParentMember_srtCounterpartyNameAxis_bntxConsultingServiceProviderMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:ConsultingServiceProviderMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullKeyManagementPersonnelOfEntityOrParentMember_srtCounterpartyNameAxis_bntxTRONMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:TRONMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullKeyManagementPersonnelOfEntityOrParentMember_srtCounterpartyNameAxis_bntxTRONMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:TRONMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullKeyManagementPersonnelOfEntityOrParentMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullKeyManagementPersonnelOfEntityOrParentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullOtherRelatedPartiesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullOtherRelatedPartiesMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullOtherRelatedPartiesMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullOtherRelatedPartiesMember_srtCounterpartyNameAxis_bntxATHOSKGMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:ATHOSKGMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullOtherRelatedPartiesMember_srtCounterpartyNameAxis_bntxATHOSKGMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:ATHOSKGMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullOtherRelatedPartiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullOtherRelatedPartiesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCounterpartiesAxis_bntxPfizerIncMember_ifrs-fullMajorCustomersAxis_bntxUnitedStatesGovernmentMember_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxSupplyOfCOVID19VaccineMember_20210212_20210212">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:SupplyOfCOVID19VaccineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">bntx:PfizerIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:UnitedStatesGovernmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-02-12</xbrli:startDate>
      <xbrli:endDate>2021-02-12</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCounterpartiesAxis_bntxPfizerIncMember_ifrs-fullMajorCustomersAxis_bntxEuropeanUnionMemberStatesMember_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxSupplyOfCOVID19VaccineMember_20210217_20210217">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:SupplyOfCOVID19VaccineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">bntx:PfizerIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:EuropeanUnionMemberStatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-02-17</xbrli:startDate>
      <xbrli:endDate>2021-02-17</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001776985_ifrs-fullCounterpartiesAxis_bntxPfizerIncMember_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxSupplyOfCOVID19VaccineMember_20210217_20210217">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:SupplyOfCOVID19VaccineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">bntx:PfizerIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-02-17</xbrli:startDate>
      <xbrli:endDate>2021-02-17</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <dei:DocumentType id="F_000000" contextRef="C_0001776985_20200101_20201231">20-F</dei:DocumentType>
  <dei:AmendmentFlag id="F_000001" contextRef="C_0001776985_20200101_20201231">false</dei:AmendmentFlag>
  <dei:DocumentPeriodEndDate id="F_000002" contextRef="C_0001776985_20200101_20201231">2020-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalYearFocus id="F_000003" contextRef="C_0001776985_20200101_20201231">2020</dei:DocumentFiscalYearFocus>
  <dei:CurrentFiscalYearEndDate id="F_000004" contextRef="C_0001776985_20200101_20201231">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus id="F_000005" contextRef="C_0001776985_20200101_20201231">FY</dei:DocumentFiscalPeriodFocus>
  <dei:EntityRegistrantName id="F_000006" contextRef="C_0001776985_20200101_20201231">BioNTech SE</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="F_000007" contextRef="C_0001776985_20200101_20201231">0001776985</dei:EntityCentralIndexKey>
  <dei:DocumentAnnualReport id="F_000008" contextRef="C_0001776985_20200101_20201231">true</dei:DocumentAnnualReport>
  <dei:DocumentTransitionReport id="F_000009" contextRef="C_0001776985_20200101_20201231">false</dei:DocumentTransitionReport>
  <dei:DocumentRegistrationStatement id="F_000010" contextRef="C_0001776985_20200101_20201231">false</dei:DocumentRegistrationStatement>
  <dei:DocumentShellCompanyReport id="F_000011" contextRef="C_0001776985_20200101_20201231">false</dei:DocumentShellCompanyReport>
  <dei:EntityCurrentReportingStatus id="F_000012" contextRef="C_0001776985_20200101_20201231">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityVoluntaryFilers id="F_000013" contextRef="C_0001776985_20200101_20201231">No</dei:EntityVoluntaryFilers>
  <dei:EntityInteractiveDataCurrent id="F_000014" contextRef="C_0001776985_20200101_20201231">Yes</dei:EntityInteractiveDataCurrent>
  <dei:IcfrAuditorAttestationFlag id="F_000015" contextRef="C_0001776985_20200101_20201231">true</dei:IcfrAuditorAttestationFlag>
  <dei:EntityFilerCategory id="F_000016" contextRef="C_0001776985_20200101_20201231">Large Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityWellKnownSeasonedIssuer id="F_000017" contextRef="C_0001776985_20200101_20201231">Yes</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityCommonStockSharesOutstanding id="F_000018" contextRef="C_0001776985_20210330" decimals="-3" unitRef="U_xbrlishares">241521065000</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityShellCompany id="F_000019" contextRef="C_0001776985_20200101_20201231">false</dei:EntityShellCompany>
  <dei:EntityEmergingGrowthCompany id="F_000020" contextRef="C_0001776985_20200101_20201231">false</dei:EntityEmergingGrowthCompany>
  <dei:TradingSymbol id="F_000021" contextRef="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_bntxAmericanDepositarySharesEachRepresentingOneOrdinaryShareMember_20200101_20201231">BNTX</dei:TradingSymbol>
  <dei:Security12bTitle id="F_000022" contextRef="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_bntxAmericanDepositarySharesEachRepresentingOneOrdinaryShareMember_20200101_20201231">American Depositary Shares, each Representing one ordinary share</dei:Security12bTitle>
  <dei:SecurityExchangeName id="F_000023" contextRef="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_bntxAmericanDepositarySharesEachRepresentingOneOrdinaryShareMember_20200101_20201231">NASDAQ</dei:SecurityExchangeName>
  <dei:Security12bTitle id="F_000024" contextRef="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_bntxOrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareOfOneMember_20200101_20201231">Ordinary shares, no par value, with a notional amount attributable to each ordinary share of &#8364;1*</dei:Security12bTitle>
  <dei:NoTradingSymbolFlag id="F_000025" contextRef="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_bntxOrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareOfOneMember_20200101_20201231">true</dei:NoTradingSymbolFlag>
  <dei:SecurityExchangeName id="F_000026" contextRef="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_bntxOrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareOfOneMember_20200101_20201231">NASDAQ</dei:SecurityExchangeName>
  <dei:EntityIncorporationStateCountryCode id="F_000027" contextRef="C_0001776985_20200101_20201231">2M</dei:EntityIncorporationStateCountryCode>
  <dei:EntityFileNumber id="F_000028" contextRef="C_0001776985_20200101_20201231">001-39081</dei:EntityFileNumber>
  <dei:EntityAddressAddressLine1 id="F_000029" contextRef="C_0001776985_20200101_20201231">An der Goldgrube 12</dei:EntityAddressAddressLine1>
  <dei:EntityAddressCityOrTown id="F_000030" contextRef="C_0001776985_20200101_20201231">Mainz</dei:EntityAddressCityOrTown>
  <dei:EntityAddressCountry id="F_000031" contextRef="C_0001776985_20200101_20201231">DE</dei:EntityAddressCountry>
  <dei:EntityAddressPostalZipCode id="F_000032" contextRef="C_0001776985_20200101_20201231">D-55131</dei:EntityAddressPostalZipCode>
  <dei:ContactPersonnelName id="F_000033" contextRef="C_0001776985_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember_20200101_20201231">Prof. Ugur Sahin, M.D.</dei:ContactPersonnelName>
  <dei:CityAreaCode id="F_000034" contextRef="C_0001776985_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember_20200101_20201231">+49</dei:CityAreaCode>
  <dei:LocalPhoneNumber id="F_000035" contextRef="C_0001776985_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember_20200101_20201231">6131-9084-0</dei:LocalPhoneNumber>
  <dei:ContactPersonnelEmailAddress id="F_000036" contextRef="C_0001776985_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember_20200101_20201231">info@biontech.de</dei:ContactPersonnelEmailAddress>
  <dei:EntityAddressAddressLine1 id="F_000037" contextRef="C_0001776985_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember_20200101_20201231">An der Goldgrube 12</dei:EntityAddressAddressLine1>
  <dei:EntityAddressPostalZipCode id="F_000038" contextRef="C_0001776985_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember_20200101_20201231">D-55131</dei:EntityAddressPostalZipCode>
  <dei:EntityAddressCityOrTown id="F_000039" contextRef="C_0001776985_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember_20200101_20201231">Mainz</dei:EntityAddressCityOrTown>
  <dei:EntityAddressCountry id="F_000040" contextRef="C_0001776985_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember_20200101_20201231">DE</dei:EntityAddressCountry>
  <dei:DocumentAccountingStandard id="F_000041" contextRef="C_0001776985_20200101_20201231">International Financial Reporting Standards</dei:DocumentAccountingStandard>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_000042" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">163490000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_000043" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">89434000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:PropertyPlantAndEquipment id="F_000044" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">226968000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_000045" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">93044000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:RightofuseAssets id="F_000046" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">98988000</ifrs-full:RightofuseAssets>
  <ifrs-full:RightofuseAssets id="F_000047" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">55018000</ifrs-full:RightofuseAssets>
  <ifrs-full:OtherNoncurrentAssets id="F_000048" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">1045000</ifrs-full:OtherNoncurrentAssets>
  <ifrs-full:DeferredTaxAssets id="F_000049" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">161233000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:NoncurrentAssets id="F_000050" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">651724000</ifrs-full:NoncurrentAssets>
  <ifrs-full:NoncurrentAssets id="F_000051" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">237496000</ifrs-full:NoncurrentAssets>
  <ifrs-full:Inventories id="F_000052" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">64120000</ifrs-full:Inventories>
  <ifrs-full:Inventories id="F_000053" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">11722000</ifrs-full:Inventories>
  <ifrs-full:CurrentTradeReceivables id="F_000054" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">165468000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables id="F_000055" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">11913000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:OtherCurrentFinancialAssets id="F_000056" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">137234000</ifrs-full:OtherCurrentFinancialAssets>
  <ifrs-full:OtherCurrentFinancialAssets id="F_000057" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">1680000</ifrs-full:OtherCurrentFinancialAssets>
  <ifrs-full:OtherCurrentAssets id="F_000058" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">60966000</ifrs-full:OtherCurrentAssets>
  <ifrs-full:OtherCurrentAssets id="F_000059" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">9069000</ifrs-full:OtherCurrentAssets>
  <ifrs-full:CurrentTaxAssetsCurrent id="F_000060" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">898000</ifrs-full:CurrentTaxAssetsCurrent>
  <ifrs-full:CurrentTaxAssetsCurrent id="F_000061" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">756000</ifrs-full:CurrentTaxAssetsCurrent>
  <bntx:DeferredExpenseCurrent id="F_000062" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">28001000</bntx:DeferredExpenseCurrent>
  <bntx:DeferredExpenseCurrent id="F_000063" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">5862000</bntx:DeferredExpenseCurrent>
  <ifrs-full:CashAndCashEquivalents id="F_000064" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">1210209000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents id="F_000065" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">519149000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CurrentAssets id="F_000066" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">1666896000</ifrs-full:CurrentAssets>
  <ifrs-full:CurrentAssets id="F_000067" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">560151000</ifrs-full:CurrentAssets>
  <ifrs-full:Assets id="F_000068" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">2318620000</ifrs-full:Assets>
  <ifrs-full:Assets id="F_000069" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">797647000</ifrs-full:Assets>
  <ifrs-full:IssuedCapital id="F_000070" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">246310000</ifrs-full:IssuedCapital>
  <ifrs-full:IssuedCapital id="F_000071" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">232304000</ifrs-full:IssuedCapital>
  <ifrs-full:CapitalReserve id="F_000072" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">1514451000</ifrs-full:CapitalReserve>
  <ifrs-full:CapitalReserve id="F_000073" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">686714000</ifrs-full:CapitalReserve>
  <ifrs-full:TreasuryShares id="F_000074" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">4789000</ifrs-full:TreasuryShares>
  <ifrs-full:TreasuryShares id="F_000075" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">5525000</ifrs-full:TreasuryShares>
  <ifrs-full:AccumulatedOtherComprehensiveIncome id="F_000076" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">-409629000</ifrs-full:AccumulatedOtherComprehensiveIncome>
  <ifrs-full:AccumulatedOtherComprehensiveIncome id="F_000077" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">-424827000</ifrs-full:AccumulatedOtherComprehensiveIncome>
  <ifrs-full:OtherReserves id="F_000078" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">25503000</ifrs-full:OtherReserves>
  <ifrs-full:OtherReserves id="F_000079" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">4826000</ifrs-full:OtherReserves>
  <ifrs-full:Equity id="F_000080" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">1371846000</ifrs-full:Equity>
  <ifrs-full:Equity id="F_000081" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">493492000</ifrs-full:Equity>
  <ifrs-full:LongtermBorrowings id="F_000082" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">231047000</ifrs-full:LongtermBorrowings>
  <ifrs-full:LongtermBorrowings id="F_000083" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">68904000</ifrs-full:LongtermBorrowings>
  <ifrs-full:OtherNoncurrentFinancialLiabilities id="F_000084" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">31476000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <ifrs-full:NoncurrentProvisions id="F_000085" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">5498000</ifrs-full:NoncurrentProvisions>
  <ifrs-full:NoncurrentContractLiabilities id="F_000086" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">71892000</ifrs-full:NoncurrentContractLiabilities>
  <ifrs-full:NoncurrentContractLiabilities id="F_000087" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">97109000</ifrs-full:NoncurrentContractLiabilities>
  <ifrs-full:OtherNoncurrentLiabilities id="F_000088" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">566000</ifrs-full:OtherNoncurrentLiabilities>
  <ifrs-full:DeferredTaxLiabilities id="F_000089" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">281000</ifrs-full:DeferredTaxLiabilities>
  <ifrs-full:NoncurrentLiabilities id="F_000090" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">340760000</ifrs-full:NoncurrentLiabilities>
  <ifrs-full:NoncurrentLiabilities id="F_000091" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">166013000</ifrs-full:NoncurrentLiabilities>
  <ifrs-full:ShorttermBorrowings id="F_000092" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">9142000</ifrs-full:ShorttermBorrowings>
  <ifrs-full:ShorttermBorrowings id="F_000093" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">5307000</ifrs-full:ShorttermBorrowings>
  <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers id="F_000094" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">102288000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
  <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers id="F_000095" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">20498000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
  <ifrs-full:OtherCurrentFinancialLiabilities id="F_000096" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">74075000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities id="F_000097" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">10352000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:CurrentGovernmentGrants id="F_000098" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">91951000</ifrs-full:CurrentGovernmentGrants>
  <ifrs-full:CurrentTaxLiabilitiesCurrent id="F_000099" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">11000</ifrs-full:CurrentTaxLiabilitiesCurrent>
  <ifrs-full:CurrentTaxLiabilitiesCurrent id="F_000100" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">150000</ifrs-full:CurrentTaxLiabilitiesCurrent>
  <ifrs-full:OtherShorttermProvisions id="F_000101" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">903000</ifrs-full:OtherShorttermProvisions>
  <ifrs-full:OtherShorttermProvisions id="F_000102" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">762000</ifrs-full:OtherShorttermProvisions>
  <ifrs-full:CurrentContractLiabilities id="F_000103" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">299583000</ifrs-full:CurrentContractLiabilities>
  <ifrs-full:CurrentContractLiabilities id="F_000104" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">93583000</ifrs-full:CurrentContractLiabilities>
  <ifrs-full:OtherCurrentLiabilities id="F_000105" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">28061000</ifrs-full:OtherCurrentLiabilities>
  <ifrs-full:OtherCurrentLiabilities id="F_000106" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">7490000</ifrs-full:OtherCurrentLiabilities>
  <ifrs-full:CurrentLiabilities id="F_000107" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">606014000</ifrs-full:CurrentLiabilities>
  <ifrs-full:CurrentLiabilities id="F_000108" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">138142000</ifrs-full:CurrentLiabilities>
  <ifrs-full:Liabilities id="F_000109" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">946774000</ifrs-full:Liabilities>
  <ifrs-full:Liabilities id="F_000110" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">304155000</ifrs-full:Liabilities>
  <ifrs-full:EquityAndLiabilities id="F_000111" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">2318620000</ifrs-full:EquityAndLiabilities>
  <ifrs-full:EquityAndLiabilities id="F_000112" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">797647000</ifrs-full:EquityAndLiabilities>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000113" contextRef="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">178849000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000114" contextRef="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">84428000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000115" contextRef="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">101837000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000116" contextRef="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">303476000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000117" contextRef="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">24161000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000118" contextRef="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">25738000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000119" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">482325000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000120" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">108589000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000121" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">127575000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:CostOfSales id="F_000122" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">59333000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales id="F_000123" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">17361000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales id="F_000124" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">13690000</ifrs-full:CostOfSales>
  <ifrs-full:ResearchAndDevelopmentExpense id="F_000125" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">645029000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense id="F_000126" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">226466000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense id="F_000127" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">143040000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:SalesAndMarketingExpense id="F_000128" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">14512000</ifrs-full:SalesAndMarketingExpense>
  <ifrs-full:SalesAndMarketingExpense id="F_000129" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">2718000</ifrs-full:SalesAndMarketingExpense>
  <ifrs-full:SalesAndMarketingExpense id="F_000130" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">3041000</ifrs-full:SalesAndMarketingExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000131" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">94049000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000132" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">45547000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000133" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">26334000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:MiscellaneousOtherOperatingExpense id="F_000134" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">2358000</ifrs-full:MiscellaneousOtherOperatingExpense>
  <ifrs-full:MiscellaneousOtherOperatingExpense id="F_000135" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">739000</ifrs-full:MiscellaneousOtherOperatingExpense>
  <ifrs-full:MiscellaneousOtherOperatingExpense id="F_000136" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">720000</ifrs-full:MiscellaneousOtherOperatingExpense>
  <ifrs-full:MiscellaneousOtherOperatingIncome id="F_000137" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">250539000</ifrs-full:MiscellaneousOtherOperatingIncome>
  <ifrs-full:MiscellaneousOtherOperatingIncome id="F_000138" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">2724000</ifrs-full:MiscellaneousOtherOperatingIncome>
  <ifrs-full:MiscellaneousOtherOperatingIncome id="F_000139" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">5396000</ifrs-full:MiscellaneousOtherOperatingIncome>
  <ifrs-full:ProfitLossFromOperatingActivities id="F_000140" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-82417000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities id="F_000141" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-181518000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities id="F_000142" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">-53854000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:FinanceIncome id="F_000143" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">1564000</ifrs-full:FinanceIncome>
  <ifrs-full:FinanceIncome id="F_000144" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">4122000</ifrs-full:FinanceIncome>
  <ifrs-full:FinanceIncome id="F_000145" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">8046000</ifrs-full:FinanceIncome>
  <ifrs-full:FinanceCosts id="F_000146" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">62946000</ifrs-full:FinanceCosts>
  <ifrs-full:FinanceCosts id="F_000147" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">326000</ifrs-full:FinanceCosts>
  <ifrs-full:FinanceCosts id="F_000148" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">48000</ifrs-full:FinanceCosts>
  <ifrs-full:InterestExpenseOnLeaseLiabilities id="F_000149" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">2003000</ifrs-full:InterestExpenseOnLeaseLiabilities>
  <ifrs-full:InterestExpenseOnLeaseLiabilities id="F_000150" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">1718000</ifrs-full:InterestExpenseOnLeaseLiabilities>
  <ifrs-full:InterestExpenseOnLeaseLiabilities id="F_000151" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">1721000</ifrs-full:InterestExpenseOnLeaseLiabilities>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod id="F_000152" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">-84000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ProfitLossBeforeTax id="F_000153" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-145802000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossBeforeTax id="F_000154" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-179440000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossBeforeTax id="F_000155" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">-47662000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:IncomeTaxExpenseContinuingOperations id="F_000156" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-161000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:IncomeTaxExpenseContinuingOperations id="F_000157" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-268000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:IncomeTaxExpenseContinuingOperations id="F_000158" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">600000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:ProfitLoss id="F_000159" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">15198000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss id="F_000160" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-179172000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss id="F_000161" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">-48262000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLossAttributableToOwnersOfParent id="F_000162" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">15198000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
  <ifrs-full:ProfitLossAttributableToOwnersOfParent id="F_000163" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-179056000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
  <ifrs-full:ProfitLossAttributableToOwnersOfParent id="F_000164" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">-48019000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
  <ifrs-full:ProfitLossAttributableToNoncontrollingInterests id="F_000165" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-116000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
  <ifrs-full:ProfitLossAttributableToNoncontrollingInterests id="F_000166" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">-243000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
  <ifrs-full:BasicAndDilutedEarningsLossPerShare id="F_000167" contextRef="C_0001776985_20200101_20201231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">0.06</ifrs-full:BasicAndDilutedEarningsLossPerShare>
  <ifrs-full:BasicAndDilutedEarningsLossPerShare id="F_000168" contextRef="C_0001776985_20190101_20191231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">-0.85</ifrs-full:BasicAndDilutedEarningsLossPerShare>
  <ifrs-full:BasicAndDilutedEarningsLossPerShare id="F_000169" contextRef="C_0001776985_20180101_20181231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">-0.25</ifrs-full:BasicAndDilutedEarningsLossPerShare>
  <bntx:StockSplitConversionRatio id="F_000170" contextRef="C_0001776985_20190918_20190918" decimals="5" unitRef="U_xbrlipure">0.05556</bntx:StockSplitConversionRatio>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation id="F_000171" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-11096000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation id="F_000172" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">77000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation id="F_000173" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">10000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax id="F_000174" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-11096000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax id="F_000175" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">77000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax id="F_000176" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">10000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans id="F_000177" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-273000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax id="F_000178" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-273000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:OtherComprehensiveIncome id="F_000179" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-11369000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome id="F_000180" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">77000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome id="F_000181" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">10000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome id="F_000182" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">3829000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome id="F_000183" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-179095000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome id="F_000184" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">-48252000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent id="F_000185" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">3829000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent id="F_000186" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-178979000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent id="F_000187" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">-48009000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests id="F_000188" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-116000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
  <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests id="F_000189" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">-243000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
  <ifrs-full:Equity id="F_000190" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20171231" decimals="-3" unitRef="U_iso4217EUR">166764000</ifrs-full:Equity>
  <ifrs-full:Equity id="F_000191" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20171231" decimals="-3" unitRef="U_iso4217EUR">8922000</ifrs-full:Equity>
  <ifrs-full:Equity id="F_000192" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullAccumulatedOtherComprehensiveIncomeMember_20171231" decimals="-3" unitRef="U_iso4217EUR">-197753000</ifrs-full:Equity>
  <ifrs-full:Equity id="F_000193" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullOtherReservesMember_20171231" decimals="-3" unitRef="U_iso4217EUR">-27206000</ifrs-full:Equity>
  <ifrs-full:Equity id="F_000194" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_bntxForeignCurrencyTranslationReserveMember_20171231" decimals="-3" unitRef="U_iso4217EUR">-23000</ifrs-full:Equity>
  <ifrs-full:Equity id="F_000195" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20171231" decimals="-3" unitRef="U_iso4217EUR">-49296000</ifrs-full:Equity>
  <ifrs-full:Equity id="F_000196" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullNoncontrollingInterestsMember_20171231" decimals="-3" unitRef="U_iso4217EUR">1090000</ifrs-full:Equity>
  <ifrs-full:Equity id="F_000197" contextRef="C_0001776985_20171231" decimals="-3" unitRef="U_iso4217EUR">-48206000</ifrs-full:Equity>
  <ifrs-full:ProfitLoss id="F_000198" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullAccumulatedOtherComprehensiveIncomeMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">-48019000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss id="F_000199" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">-48019000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss id="F_000200" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullNoncontrollingInterestsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">-243000</ifrs-full:ProfitLoss>
  <ifrs-full:OtherComprehensiveIncome id="F_000201" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_bntxForeignCurrencyTranslationReserveMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">10000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome id="F_000202" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">10000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome id="F_000203" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullAccumulatedOtherComprehensiveIncomeMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">-48019000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome id="F_000204" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_bntxForeignCurrencyTranslationReserveMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">10000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome id="F_000205" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">-48009000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome id="F_000206" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullNoncontrollingInterestsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">-243000</ifrs-full:ComprehensiveIncome>
  <bntx:IssuanceOfShareCapital id="F_000207" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">25949000</bntx:IssuanceOfShareCapital>
  <bntx:IssuanceOfShareCapital id="F_000208" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">329867000</bntx:IssuanceOfShareCapital>
  <bntx:IssuanceOfShareCapital id="F_000209" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">355816000</bntx:IssuanceOfShareCapital>
  <bntx:IssuanceOfShareCapital id="F_000210" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">355816000</bntx:IssuanceOfShareCapital>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions id="F_000211" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullOtherReservesMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">7641000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions id="F_000212" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">7641000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions id="F_000213" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">7641000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <bntx:IncreaseDecreaseThroughSettlementOfSharebasedPaymentPlan id="F_000214" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">583000</bntx:IncreaseDecreaseThroughSettlementOfSharebasedPaymentPlan>
  <bntx:IncreaseDecreaseThroughSettlementOfSharebasedPaymentPlan id="F_000215" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">5326000</bntx:IncreaseDecreaseThroughSettlementOfSharebasedPaymentPlan>
  <bntx:IncreaseDecreaseThroughSettlementOfSharebasedPaymentPlan id="F_000216" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullOtherReservesMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">-5909000</bntx:IncreaseDecreaseThroughSettlementOfSharebasedPaymentPlan>
  <ifrs-full:Equity id="F_000217" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20181231" decimals="-3" unitRef="U_iso4217EUR">193296000</ifrs-full:Equity>
  <ifrs-full:Equity id="F_000218" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20181231" decimals="-3" unitRef="U_iso4217EUR">344115000</ifrs-full:Equity>
  <ifrs-full:Equity id="F_000219" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullAccumulatedOtherComprehensiveIncomeMember_20181231" decimals="-3" unitRef="U_iso4217EUR">-245771000</ifrs-full:Equity>
  <ifrs-full:Equity id="F_000220" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullOtherReservesMember_20181231" decimals="-3" unitRef="U_iso4217EUR">-25474000</ifrs-full:Equity>
  <ifrs-full:Equity id="F_000221" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_bntxForeignCurrencyTranslationReserveMember_20181231" decimals="-3" unitRef="U_iso4217EUR">-13000</ifrs-full:Equity>
  <ifrs-full:Equity id="F_000222" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20181231" decimals="-3" unitRef="U_iso4217EUR">266153000</ifrs-full:Equity>
  <ifrs-full:Equity id="F_000223" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullNoncontrollingInterestsMember_20181231" decimals="-3" unitRef="U_iso4217EUR">847000</ifrs-full:Equity>
  <ifrs-full:Equity id="F_000224" contextRef="C_0001776985_20181231" decimals="-3" unitRef="U_iso4217EUR">267000000</ifrs-full:Equity>
  <ifrs-full:ProfitLoss id="F_000225" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-179056000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss id="F_000226" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-179056000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss id="F_000227" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullNoncontrollingInterestsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-116000</ifrs-full:ProfitLoss>
  <ifrs-full:OtherComprehensiveIncome id="F_000228" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_bntxForeignCurrencyTranslationReserveMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">77000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome id="F_000229" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">77000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome id="F_000230" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-179056000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome id="F_000231" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_bntxForeignCurrencyTranslationReserveMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">77000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome id="F_000232" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-178979000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome id="F_000233" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullNoncontrollingInterestsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-116000</ifrs-full:ComprehensiveIncome>
  <bntx:IssuanceOfShareCapital id="F_000234" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">8126000</bntx:IssuanceOfShareCapital>
  <bntx:IssuanceOfShareCapital id="F_000235" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">41748000</bntx:IssuanceOfShareCapital>
  <bntx:IssuanceOfShareCapital id="F_000236" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">49874000</bntx:IssuanceOfShareCapital>
  <bntx:IssuanceOfShareCapital id="F_000237" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">49874000</bntx:IssuanceOfShareCapital>
  <bntx:IssuanceOfShareCapital id="F_000238" contextRef="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_bntxCapitalIncreaseSeriesBMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">17990000</bntx:IssuanceOfShareCapital>
  <bntx:IssuanceOfShareCapital id="F_000239" contextRef="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_bntxCapitalIncreaseSeriesBMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">186390000</bntx:IssuanceOfShareCapital>
  <bntx:IssuanceOfShareCapital id="F_000240" contextRef="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_bntxCapitalIncreaseSeriesBMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullTreasurySharesMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-5525000</bntx:IssuanceOfShareCapital>
  <bntx:IssuanceOfShareCapital id="F_000241" contextRef="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_bntxCapitalIncreaseSeriesBMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">198855000</bntx:IssuanceOfShareCapital>
  <bntx:IssuanceOfShareCapital id="F_000242" contextRef="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_bntxCapitalIncreaseSeriesBMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">198855000</bntx:IssuanceOfShareCapital>
  <bntx:IncreaseDecreaseThroughInitialPublicOffering id="F_000243" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">10517000</bntx:IncreaseDecreaseThroughInitialPublicOffering>
  <bntx:IncreaseDecreaseThroughInitialPublicOffering id="F_000244" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">132743000</bntx:IncreaseDecreaseThroughInitialPublicOffering>
  <bntx:IncreaseDecreaseThroughInitialPublicOffering id="F_000245" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">143260000</bntx:IncreaseDecreaseThroughInitialPublicOffering>
  <bntx:IncreaseDecreaseThroughInitialPublicOffering id="F_000246" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">143260000</bntx:IncreaseDecreaseThroughInitialPublicOffering>
  <bntx:IncreaseDecreaseThroughAcquisitionOfNoncontrollingInterests id="F_000247" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">2375000</bntx:IncreaseDecreaseThroughAcquisitionOfNoncontrollingInterests>
  <bntx:IncreaseDecreaseThroughAcquisitionOfNoncontrollingInterests id="F_000248" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-1644000</bntx:IncreaseDecreaseThroughAcquisitionOfNoncontrollingInterests>
  <bntx:IncreaseDecreaseThroughAcquisitionOfNoncontrollingInterests id="F_000249" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">731000</bntx:IncreaseDecreaseThroughAcquisitionOfNoncontrollingInterests>
  <bntx:IncreaseDecreaseThroughAcquisitionOfNoncontrollingInterests id="F_000250" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullNoncontrollingInterestsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-731000</bntx:IncreaseDecreaseThroughAcquisitionOfNoncontrollingInterests>
  <ifrs-full:ShareIssueRelatedCost id="F_000251" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">16638000</ifrs-full:ShareIssueRelatedCost>
  <ifrs-full:ShareIssueRelatedCost id="F_000252" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">16638000</ifrs-full:ShareIssueRelatedCost>
  <ifrs-full:ShareIssueRelatedCost id="F_000253" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">16638000</ifrs-full:ShareIssueRelatedCost>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions id="F_000254" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullOtherReservesMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">30236000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions id="F_000255" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">30236000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions id="F_000256" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">30236000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:Equity id="F_000257" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20191231" decimals="-3" unitRef="U_iso4217EUR">232304000</ifrs-full:Equity>
  <ifrs-full:Equity id="F_000258" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20191231" decimals="-3" unitRef="U_iso4217EUR">686714000</ifrs-full:Equity>
  <ifrs-full:Equity id="F_000259" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullTreasurySharesMember_20191231" decimals="-3" unitRef="U_iso4217EUR">-5525000</ifrs-full:Equity>
  <ifrs-full:Equity id="F_000260" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullAccumulatedOtherComprehensiveIncomeMember_20191231" decimals="-3" unitRef="U_iso4217EUR">-424827000</ifrs-full:Equity>
  <ifrs-full:Equity id="F_000261" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullOtherReservesMember_20191231" decimals="-3" unitRef="U_iso4217EUR">4762000</ifrs-full:Equity>
  <ifrs-full:Equity id="F_000262" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_bntxForeignCurrencyTranslationReserveMember_20191231" decimals="-3" unitRef="U_iso4217EUR">64000</ifrs-full:Equity>
  <ifrs-full:Equity id="F_000263" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20191231" decimals="-3" unitRef="U_iso4217EUR">493492000</ifrs-full:Equity>
  <ifrs-full:ProfitLoss id="F_000264" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">15198000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss id="F_000265" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">15198000</ifrs-full:ProfitLoss>
  <ifrs-full:OtherComprehensiveIncome id="F_000266" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullOtherReservesMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-273000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome id="F_000267" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_bntxForeignCurrencyTranslationReserveMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-11096000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome id="F_000268" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-11369000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome id="F_000269" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">15198000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome id="F_000270" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullOtherReservesMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-273000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome id="F_000271" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_bntxForeignCurrencyTranslationReserveMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-11096000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome id="F_000272" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">3829000</ifrs-full:ComprehensiveIncome>
  <bntx:IssuanceOfShareCapital id="F_000273" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">14006000</bntx:IssuanceOfShareCapital>
  <bntx:IssuanceOfShareCapital id="F_000274" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">860960000</bntx:IssuanceOfShareCapital>
  <bntx:IssuanceOfShareCapital id="F_000275" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullTreasurySharesMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">736000</bntx:IssuanceOfShareCapital>
  <bntx:IssuanceOfShareCapital id="F_000276" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">875702000</bntx:IssuanceOfShareCapital>
  <bntx:IssuanceOfShareCapital id="F_000277" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">875702000</bntx:IssuanceOfShareCapital>
  <ifrs-full:ShareIssueRelatedCost id="F_000278" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">33223000</ifrs-full:ShareIssueRelatedCost>
  <ifrs-full:ShareIssueRelatedCost id="F_000279" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">33223000</ifrs-full:ShareIssueRelatedCost>
  <ifrs-full:ShareIssueRelatedCost id="F_000280" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">33223000</ifrs-full:ShareIssueRelatedCost>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions id="F_000281" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullOtherReservesMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">32046000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions id="F_000282" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">32046000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions id="F_000283" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">32046000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:Equity id="F_000284" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20201231" decimals="-3" unitRef="U_iso4217EUR">246310000</ifrs-full:Equity>
  <ifrs-full:Equity id="F_000285" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20201231" decimals="-3" unitRef="U_iso4217EUR">1514451000</ifrs-full:Equity>
  <ifrs-full:Equity id="F_000286" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullTreasurySharesMember_20201231" decimals="-3" unitRef="U_iso4217EUR">-4789000</ifrs-full:Equity>
  <ifrs-full:Equity id="F_000287" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullAccumulatedOtherComprehensiveIncomeMember_20201231" decimals="-3" unitRef="U_iso4217EUR">-409629000</ifrs-full:Equity>
  <ifrs-full:Equity id="F_000288" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullOtherReservesMember_20201231" decimals="-3" unitRef="U_iso4217EUR">36535000</ifrs-full:Equity>
  <ifrs-full:Equity id="F_000289" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_bntxForeignCurrencyTranslationReserveMember_20201231" decimals="-3" unitRef="U_iso4217EUR">-11032000</ifrs-full:Equity>
  <ifrs-full:Equity id="F_000290" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullEquityAttributableToOwnersOfParentMember_20201231" decimals="-3" unitRef="U_iso4217EUR">1371846000</ifrs-full:Equity>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense id="F_000291" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">38744000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense id="F_000292" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">33896000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense id="F_000293" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">21984000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
  <ifrs-full:AdjustmentsForSharebasedPayments id="F_000294" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">32142000</ifrs-full:AdjustmentsForSharebasedPayments>
  <ifrs-full:AdjustmentsForSharebasedPayments id="F_000295" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">30236000</ifrs-full:AdjustmentsForSharebasedPayments>
  <ifrs-full:AdjustmentsForSharebasedPayments id="F_000296" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">7641000</ifrs-full:AdjustmentsForSharebasedPayments>
  <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains id="F_000297" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">41275000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
  <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains id="F_000298" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">70000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
  <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains id="F_000299" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">459000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
  <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment id="F_000300" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-595000</ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment>
  <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment id="F_000301" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-542000</ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment>
  <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment id="F_000302" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">14000</ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment>
  <ifrs-full:AdjustmentsForFinanceIncome id="F_000303" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">1564000</ifrs-full:AdjustmentsForFinanceIncome>
  <ifrs-full:AdjustmentsForFinanceIncome id="F_000304" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">1782000</ifrs-full:AdjustmentsForFinanceIncome>
  <ifrs-full:AdjustmentsForFinanceIncome id="F_000305" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">1996000</ifrs-full:AdjustmentsForFinanceIncome>
  <bntx:AdjustmentsForInterestOnLeaseLiability id="F_000306" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">2003000</bntx:AdjustmentsForInterestOnLeaseLiability>
  <bntx:AdjustmentsForInterestOnLeaseLiability id="F_000307" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">1717000</bntx:AdjustmentsForInterestOnLeaseLiability>
  <bntx:AdjustmentsForInterestOnLeaseLiability id="F_000308" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">1721000</bntx:AdjustmentsForInterestOnLeaseLiability>
  <ifrs-full:AdjustmentsForFinanceCosts id="F_000309" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">20336000</ifrs-full:AdjustmentsForFinanceCosts>
  <ifrs-full:AdjustmentsForFinanceCosts id="F_000310" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">326000</ifrs-full:AdjustmentsForFinanceCosts>
  <ifrs-full:AdjustmentsForFinanceCosts id="F_000311" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">48000</ifrs-full:AdjustmentsForFinanceCosts>
  <bntx:AdjustmentsForMovementsInGovernmentGrants id="F_000312" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">91951000</bntx:AdjustmentsForMovementsInGovernmentGrants>
  <ifrs-full:OtherAdjustmentsForNoncashItems id="F_000313" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">1749000</ifrs-full:OtherAdjustmentsForNoncashItems>
  <bntx:AdjustmentsForIncreaseDecreaseInTradeAccountReceivableAndContractAssets id="F_000314" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-247886000</bntx:AdjustmentsForIncreaseDecreaseInTradeAccountReceivableAndContractAssets>
  <bntx:AdjustmentsForIncreaseDecreaseInTradeAccountReceivableAndContractAssets id="F_000315" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">2939000</bntx:AdjustmentsForIncreaseDecreaseInTradeAccountReceivableAndContractAssets>
  <bntx:AdjustmentsForIncreaseDecreaseInTradeAccountReceivableAndContractAssets id="F_000316" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">-18732000</bntx:AdjustmentsForIncreaseDecreaseInTradeAccountReceivableAndContractAssets>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories id="F_000317" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-49794000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories id="F_000318" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-5798000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories id="F_000319" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">-1253000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
  <bntx:AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions id="F_000320" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">204583000</bntx:AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions>
  <bntx:AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions id="F_000321" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-80577000</bntx:AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions>
  <bntx:AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions id="F_000322" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">-21080000</bntx:AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions>
  <ifrs-full:InterestReceivedClassifiedAsOperatingActivities id="F_000323" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">1444000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
  <ifrs-full:InterestReceivedClassifiedAsOperatingActivities id="F_000324" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">1256000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
  <ifrs-full:InterestReceivedClassifiedAsOperatingActivities id="F_000325" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">1996000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
  <ifrs-full:InterestPaidClassifiedAsOperatingActivities id="F_000326" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">3628000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
  <ifrs-full:InterestPaidClassifiedAsOperatingActivities id="F_000327" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">2044000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
  <ifrs-full:InterestPaidClassifiedAsOperatingActivities id="F_000328" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">1769000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities id="F_000329" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-378000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities id="F_000330" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-122000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities id="F_000331" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">304000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <ifrs-full:CashFlowsFromUsedInOperatingActivities id="F_000332" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-13474000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <ifrs-full:CashFlowsFromUsedInOperatingActivities id="F_000333" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-198537000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <ifrs-full:CashFlowsFromUsedInOperatingActivities id="F_000334" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">-58877000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities id="F_000335" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">66033000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities id="F_000336" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">38592000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities id="F_000337" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">29901000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities id="F_000338" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">1241000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities id="F_000339" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">21000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities id="F_000340" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">705000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <bntx:PurchaseOfIntangibleAssetsAndRightOfUseAssets id="F_000341" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">19413000</bntx:PurchaseOfIntangibleAssetsAndRightOfUseAssets>
  <bntx:PurchaseOfIntangibleAssetsAndRightOfUseAssets id="F_000342" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">32488000</bntx:PurchaseOfIntangibleAssetsAndRightOfUseAssets>
  <bntx:PurchaseOfIntangibleAssetsAndRightOfUseAssets id="F_000343" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">37256000</bntx:PurchaseOfIntangibleAssetsAndRightOfUseAssets>
  <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities id="F_000344" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">60643000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
  <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities id="F_000345" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">6056000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
  <ifrs-full:CashFlowsFromUsedInInvestingActivities id="F_000346" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-144848000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <ifrs-full:CashFlowsFromUsedInInvestingActivities id="F_000347" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-77115000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <ifrs-full:CashFlowsFromUsedInInvestingActivities id="F_000348" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">-66452000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <ifrs-full:ProceedsFromIssuingShares id="F_000349" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">753007000</ifrs-full:ProceedsFromIssuingShares>
  <ifrs-full:ProceedsFromIssuingShares id="F_000350" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">375351000</ifrs-full:ProceedsFromIssuingShares>
  <ifrs-full:ProceedsFromIssuingShares id="F_000351" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">361725000</ifrs-full:ProceedsFromIssuingShares>
  <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities id="F_000352" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">156027000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
  <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities id="F_000353" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">11000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
  <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities id="F_000354" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">5600000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
  <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities id="F_000355" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">1566000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
  <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities id="F_000356" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">12743000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
  <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities id="F_000357" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">3061000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
  <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities id="F_000358" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">2148000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
  <ifrs-full:CashFlowsFromUsedInFinancingActivities id="F_000359" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">894725000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <ifrs-full:CashFlowsFromUsedInFinancingActivities id="F_000360" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">383290000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <ifrs-full:CashFlowsFromUsedInFinancingActivities id="F_000361" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">365177000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges id="F_000362" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">736403000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges id="F_000363" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">107638000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges id="F_000364" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">239848000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents id="F_000365" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-45343000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents id="F_000366" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">16000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents id="F_000367" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">-459000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents id="F_000368" contextRef="C_0001776985_20181231" decimals="-3" unitRef="U_iso4217EUR">411495000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents id="F_000369" contextRef="C_0001776985_20171231" decimals="-3" unitRef="U_iso4217EUR">172106000</ifrs-full:CashAndCashEquivalents>
  <bntx:DisclosureOfCorporateInformationExplanatory id="F_000370" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="color:#000000;"&gt;Corporate Information&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech SE is a limited company incorporated and domiciled in Germany. American Depositary Shares (ADS) representing BioNTech SE&amp;#8217;s ordinary shares have been publicly traded on Nasdaq Global Select Market since October 10, 2019. The registered office is located in Mainz, Germany (An der Goldgrube 12, 55131 Mainz). The accompanying International Financial Reporting Standards (IFRS) consolidated financial statements present the financial position and the results of operation of BioNTech SE and its subsidiaries, hereinafter also referred to as &amp;#8220;BioNTech&amp;#8221; or the &amp;#8220;Group&amp;#8221;.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December&amp;#160;31, 2020 the following changes to the Group structure occurred:&lt;/p&gt;
&lt;p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;On February 16, 2020, BioNTech Protein Therapeutics GmbH was renamed to BioNTech Delivery Technologies GmbH and the company&amp;#8217;s registered office was changed from Mainz to Halle. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;On May 6, 2020, BioNTech SE acquired Neon Therapeutics, Inc., Cambridge, Massachusetts, United States (formerly Nasdaq: NTGN), or Neon. Under the merger agreement by and among BioNTech, Neon and BioNTech&amp;#8217;s wholly-owned subsidiary, Endor Lights, Inc., New York, United States, Endor Lights, Inc. merged with and into Neon. The new subsidiary operates under the name BioNTech US Inc., is held indirectly via BioNTech USA Holding, LLC. as a wholly-owned subsidiary and serves as BioNTech&amp;#8217;s headquarters in the United States.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;On July 17, 2020, BioNTech IVAC GmbH was renamed to BioNTech Manufacturing GmbH and on August 7, 2020, BioNTech Small Molecules GmbH was renamed to BioNTech Europe GmbH. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;On September 17, 2020, the liquidation process for BioNTech Austria Beteiligungen GmbH was initiated by a resolution of the shareholders. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="color:#000000;"&gt;On October 15, 2020, BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. was founded and is a wholly-owned subsidiary of BioNTech SE. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Three new real estate entities have been founded in Germany: BioNTech Real Estate An der Goldgrube GmbH &amp;amp; Co. KG, BioNTech Real Estate Adam-Opel-Stra&amp;#223;e GmbH &amp;amp; Co. KG and BioNTech Real Estate Haus Vier GmbH &amp;amp; Co. KG, all Holzkirchen. All are partnerships wholly-owned by its limited partner BioNTech Real Estate Holding GmbH, a wholly-owned subsidiary of BioNTech SE. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;On October 31, 2020, BioNTech SE acquired Novartis Manufacturing GmbH, Marburg, Germany. The new production site operates under the name BioNTech Manufacturing Marburg GmbH, a wholly-owned subsidiary of BioNTech SE.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="color:#000000;"&gt;On November 11, 2020, BioNTech UK Limited was founded and is a wholly-owned subsidiary of BioNTech SE.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="color:#000000;"&gt;On December 15, 2020, reBOOST Management GmbH was renamed to reSano GmbH.&lt;/font&gt; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All entities listed above are included in the Group&amp;#8217;s consolidated financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Information on the Group&amp;#8217;s structure is provided in Note 4. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements of the Group for the year ended December&amp;#160;31, 2020 were authorized for issue in accordance with a resolution of the Supervisory Board on March 30, 2021.&lt;/p&gt;</bntx:DisclosureOfCorporateInformationExplanatory>
  <ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory id="F_000371" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="color:#000000;"&gt;Significant Accounting Policies&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.1&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Basis of Preparation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;General&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements have been prepared on a going concern basis in accordance with the IFRS as issued by the International Accounting Standards Board (IASB). &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech prepares and publishes its consolidated financial statements in Euros and rounds numbers to thousands or millions of Euros, respectively. Accordingly, numerical figures shown as totals in some tables may not be exact arithmetic aggregations of the figures that preceded them and figures presented in the explanatory notes may not add up to the rounded arithmetic aggregations. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Segment Information&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Historically &lt;font style="color:#000000;"&gt;BioNTech &lt;/font&gt;reported four segments: Clinical, Technology Platform, Manufacturing and Product Sales &amp;amp; External Services. In the course of the year ended December&amp;#160;31, 2020, &lt;font style="color:#000000;"&gt;BioNTech &lt;/font&gt;leveraged the breadth of its immunotherapy technologies and used its expertise to mobilize these rapidly to address the COVID-19 pandemic. In December 2020, BioNTech&amp;#8217;s COVID-19 vaccine was authorized or approved for emergency or temporary use or granted conditional marketing authorization in over 65 countries worldwide. Beginning in the fourth quarter, given the financial and operational significance of the activities to develop and then market, produce and transport the COVID-19 vaccine, BioNTech&amp;#8217;s Management Board, as the chief operating decision maker (CODM), reviewed financial information presented on a consolidated basis. Decisions with respect to business operations and resource allocations are made by the CODM based on BioNTech as a whole. Accordingly, BioNTech operates and makes decisions as a single operating segment, which is also its reporting segment. &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Basis of Consolidation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements comprise the financial statements of BioNTech SE and its controlled investees (subsidiaries). &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group controls an investee if, and only if, the Group has&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.14%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;power over the investee (&lt;/font&gt;&lt;font style="font-style:italic;font-family:Times New Roman;"&gt;i.e.&lt;/font&gt;&lt;font style="font-family:Times New Roman;"&gt;, existing rights that give it the current ability to direct the relevant activities of the investee); &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;exposure, or rights, to variable returns from its involvement with the investee; and &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;the ability to use its power over the investee to affect its returns. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Generally, there is a presumption that a majority of voting rights results in control. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group re-assesses whether it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The profit / (loss) and each component of other comprehensive income / (loss) for the period are attributed to the equity holders of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. When necessary, adjustments are made to the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;financial statements of subsidiaries to bring their accounting policies in line with the Group&amp;#8217;s accounting policies. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated on consolidation.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If the Group loses control over a subsidiary, it derecognizes the related assets (including goodwill), liabilities, non-controlling interests and other components of equity, while any resultant gain or loss is recognized in the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;statements of operations. Any investment retained is recognized at fair value.&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Summary of Significant Accounting Policies&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.1&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Business combinations and Goodwill&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Business combinations are accounted for using the acquisition method. The cost of an acquisition is measured as the aggregate of the consideration transferred, which is measured at acquisition date fair value, and the amount of any non-controlling interests in the acquiree.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill is initially measured at cost as the excess of the aggregate of the consideration transferred and the amount recognized for non-controlling interests and any previous interest held over the net identifiable assets acquired and liabilities assumed.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;After initial recognition, goodwill is tested at least annually or when there is an indication for impairment. See Note&amp;#160;2.3.13. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Group&amp;#8217;s cash-generating units that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those units. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Where goodwill has been allocated to a cash-generating unit (CGU) and part of the operation within that unit is disposed of, the goodwill associated with the disposed operation is included in the carrying amount of the operation when determining the gain or loss on disposal. Goodwill disposed in these circumstances is measured based on the relative values of the disposed operation and the portion of the cash-generating unit retained.&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Current versus Non-Current Classifications&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group presents assets and liabilities in the consolidated statements of financial position based on current or non-current classification. An asset is current when it is either: (i)&amp;#160;expected to be realized within 12&amp;#160;months after the reporting period or (ii)&amp;#160;cash or cash equivalents, unless it is restricted from being exchanged or used to settle a liability for at least 12&amp;#160;months after the reporting period. All other assets are classified as non-current. A liability is current when it is due to be settled within 12&amp;#160;months after the reporting period. The Group classifies all other liabilities as non-current. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets and liabilities are classified as non-current assets and liabilities, respectively.&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.3&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Fair Value Measurement&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value is a market-based measurement. For some assets and liabilities, observable market transactions or market information is available. For other assets and liabilities, observable market transactions or market information might not be available. When a price for an identical asset or liability is not observable, another valuation technique is used. To increase consistency and comparability in fair value measurements, there are three levels of the fair value hierarchy:&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.14%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;Level 1 contains the use of quoted prices in active markets for identical assets or liabilities.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.14%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.14%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;Level&amp;#160;3 inputs are unobservable. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Within this hierarchy, estimated values are made by management based on reasonable assumptions, including other fair value methods.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For assets and liabilities that are recognized in the financial statements at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the fair value hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the purpose of fair value disclosures, the Group has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy, as explained above.&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.93%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.62%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.4&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Revenue from Contracts with Customers&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech generates revenues from collaboration and license agreements under which BioNTech grants licenses to use, research, develop, manufacture and commercialize product candidates and products. BioNTech determined that those collaboration and license agreements qualify as contracts with its customers. If the grant of a license is bundled together with the rendering of services, it is assessed whether these agreements are comprised of more than one performance obligation. A performance obligation is only accounted for as the grant of a license if the grant of a license is the sole or the predominant promise of the performance obligation. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If the consideration in an agreement includes a variable amount, BioNTech estimates the amount of consideration to which BioNTech will be entitled in exchange for transferring the goods to the customer. At contract inception, the variable consideration is estimated based on the most likely amount of consideration expected from the transaction and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with respect the variable consideration is subsequently resolved. The estimated revenue is updated at each reporting date to reflect the current facts and circumstances.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If a contract with a customer contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative-stand-alone selling prices.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For each separate performance obligation, it is evaluated whether control is transferred either at a point in time or over time. For performance obligations that are satisfied over time, revenue is recognized based on a measure of progress, which depicts the performance in transferring control to the customer. Under the terms of its licensing arrangements, BioNTech provides the licensee with a research and development license, which represents a right to access BioNTech&amp;#8217;s intellectual property as it exists throughout the license period (as BioNTech&amp;#8217;s intellectual property is still subject to further research). Therefore, the promise to grant a license is accounted for as a performance obligation satisfied over time, as the licensee simultaneously receives and consumes the benefits of BioNTech&amp;#8217;s performance.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Earnings based on the collaboration partners&amp;#8217; gross profit, which is shared under the respective collaboration agreements are recognized based on the sales-based or usage-based royalty &lt;font style="color:#000000;"&gt;exemption; &lt;/font&gt;&lt;font style="font-style:italic;color:#000000;"&gt;i.e. &lt;/font&gt;when, or as, the underlying sales occur, which is when the performance obligation has been satisfied. As described further in Note 3, BioNTech uses certain information from its collaboration partners, some of which is based on preliminary data shared between the partners and might vary once final data is available. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue arrangements that involve two or more partners who contribute to the provision of a specific good or service to a customer are assessed in terms of principal-agent considerations in order to determine the appropriate treatment for the transactions between BioNTech and the collaborator and the transactions between BioNTech and other third parties. The classification of transactions under such arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which BioNTech is considered the principal, which includes being in control of the good or service before such good or service is transferred to the customer, are accounted for as gross revenue. Any consideration related to activities in which BioNTech is considered the agent, are accounted for as net revenue.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue from the sale of pharmaceutical and medical products (&lt;font style="font-style:italic;"&gt;e.g&lt;/font&gt;. COVID-19 vaccine sales and other sales of peptides and retroviral vectors for clinical supply) is recognized when BioNTech transfers control of the product to the customer. Control of the product normally transfers when the customer gains physical possession and BioNTech has not retained any significant risks of ownership or future obligations with respect to the product. A receivable is recognized, as the consideration is unconditional and only the passage of time is required before payment is due. The transaction price is quoted in the relevant price lists in force at the date of customer placing the respective order for such products. Payments from customers are due within 20 days (Europe) or 30 days (non-Europe) after invoice.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract Balances&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract Assets&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A contract asset is the right to consideration in exchange for goods or services transferred to the customer. If BioNTech performs by transferring goods or services to a customer before the customer pays consideration or before payment is due, a contract asset is recognized for the earned consideration that is conditional.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trade Receivables&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A receivable represents BioNTech&amp;#8217;s right to an amount of consideration that is unconditional (&lt;font style="font-style:italic;"&gt;i.e&lt;/font&gt;., only the passage of time is required before payment of the consideration is due).&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract Liabilities&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A contract liability is the obligation to transfer goods or services to a customer for which BioNTech has received consideration (or an amount of consideration is due) from the customer. If a customer pays consideration before BioNTech transfers goods or services to the customer, a contract liability is recognized when the payment is made or when the payment is due (whichever is earlier). Contract liabilities are recognized as revenue when BioNTech performs under the contract.&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.5&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Government Grants&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government grants are recognized where there is reasonable assurance that the grant will be received and all attached conditions will be complied with. When the grant relates to an expense item, it is recognized as other income on a systematic basis over the periods that the related costs, for which the grant is intended to compensate, are expensed. When the grant relates to an asset, it is recognized as deferred income within the consolidated statements of financial position. Other income is subsequently recognized in profit or loss over the useful live of the underlying asset subject to funding. &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.6&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Taxes&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current Income Tax&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the reporting date in the countries where the Group operates and generates taxable income. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition, current income taxes presented for the period include adjustments for uncertain tax payments or tax refunds for periods not yet finally assessed, excluding interest expenses and penalties on the underpayment of taxes. Due to the increasing complexity of tax laws and the corresponding uncertainty regarding the legal interpretation by the fiscal authorities, tax calculations are generally subject to an elevated amount of uncertainty. In the event that amounts included in the tax return are considered unlikely to be accepted by the tax authorities (uncertain tax positions), a provision for income taxes is recognized. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Tax&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities are recognized for all taxable temporary differences, except: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;when the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; or &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;in respect of taxable temporary differences associated with investments in subsidiaries, associates and interests in joint arrangements, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets are recognized for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, the carry forward of unused tax credits and unused tax losses can be utilized, except:&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;when the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; or&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;in respect of deductible temporary differences associated with investments in subsidiaries, associates and interests in joint arrangements, deferred tax assets are recognized only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year in which the asset is realized, or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognition of Taxes&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current and deferred tax items are recognized similar to the underlying transaction either in profit or loss, other comprehensive income or directly in equity.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group offsets current tax assets and current tax liabilities if, and only if, it has a legally enforceable right to set off the recognized amounts and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously. Deferred tax assets and deferred tax liabilities are only offset when the Group has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same taxation authority on either (i) the same taxable entity or (ii) different taxable entities, which intend either to settle current tax liabilities and assets on a net basis, or to realize the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales Tax&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expenses and assets are recognized net of sales tax, except when the sales tax incurred on a purchase of assets or services is not recoverable from the taxation authority.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The net amount of sales tax recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the &lt;font style="color:#000000;"&gt;consolidated&lt;/font&gt; statements of financial position.&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.7&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Foreign Currencies&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group&amp;#8217;s consolidated financial statements are presented in Euros, which is also BioNTech SE&amp;#8217;s functional currency. For each entity, the Group determines the functional currency, and items included in the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;financial statements of such entity are measured using that functional currency. The Group uses the direct method of consolidation and on disposal of a foreign operation, the gain or loss that is reclassified to the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;statements of operations reflects the amount that arises from using this method.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Transactions and Balances&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Transactions in foreign currencies are initially recorded by the Group&amp;#8217;s entities at their respective functional currency spot rates at the date the transaction first qualifies for recognition.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In determining the spot exchange rate to use on initial recognition of the related asset, expense or income (or part of it) on the derecognition of a non-monetary asset or non-monetary liability relating to advance consideration, the date of the transaction is the date on which the Group initially recognizes the non-monetary asset or non-monetary liability arising from the advance consideration. If there are multiple payments or receipts in advance, the Group determines the transaction date for each payment or receipt of advance consideration.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign Currency Translation&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On consolidation, the assets and liabilities of foreign operations are translated into Euros at the rate of exchange prevailing at the reporting date and their &lt;font style="color:#000000;"&gt;consolidated&lt;/font&gt; statements of operations are translated at exchange rates prevailing at the dates of the transactions.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The exchange differences arising on translation for consolidation are recognized in other comprehensive income. On disposal of a foreign operation, the component of other comprehensive income relating to that particular foreign operation is reclassified to profit or loss.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Any goodwill arising on the acquisition of a foreign operation and any fair value adjustments to the carrying amounts of assets and liabilities arising upon the acquisition are treated as assets and liabilities of the foreign operation and translated at the spot rate of exchange at the reporting date.&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.8&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Property, Plant and Equipment&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress is stated at cost, net of accumulated impairment losses, if any. Property, plant and equipment are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Such cost includes the cost of replacing part of the property, plant and equipment if the recognition criteria are met. All other repair and maintenance costs are expensed as incurred.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, plant and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Useful life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Years)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Buildings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7-33&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equipment, tools and installations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3-15&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;An item of property, plant and equipment initially recognized is derecognized upon disposal (&lt;font style="font-style:italic;"&gt;i.e&lt;/font&gt;., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;statements of operations when the asset is derecognized.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year-end and adjusted prospectively, if appropriate.&lt;/p&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.9&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Leases&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the inception of a contract, the Group assesses whether the contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, the Group assesses whether: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;the contract involves the use of an identified asset&amp;#8212;this may be specified explicitly or implicitly and should be physically distinct or represent substantially all of the capacity of a physically distinct asset. If the supplier has a substantive substitution right, then the asset is not identified; &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;the Group has the right to obtain substantially all of the economic benefits from use of the asset throughout the period of use; and&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;the Group has the right to direct the use of the asset. The Group has this right when it has the decision-making rights that are most relevant to changing how and for what purpose the asset is used. In rare cases where the decision about how and for what purpose the asset is used is predetermined, the Group has the right to direct the use of the asset if either:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:9.08%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;the Group has the right to operate the asset; or&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:9.08%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;the Group designed the asset in a way that predetermines how and for what purpose it will be used. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At inception or on reassessment of a contract that contains a lease component, the Group allocates the consideration in the contract to each lease component on the basis of their relative stand-alone prices. However, for the leases of land and buildings in which it is a lessee, the Group has elected not to separate non-lease components, and instead accounts for the lease and non-lease components as a single lease component.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group recognizes a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of the costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received by the Group.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset and the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of property and equipment. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the incremental borrowing interest rate implicit in the lease or, if that rate cannot be readily determined, the Group&amp;#8217;s incremental borrowing rate. Generally, the Group uses its incremental borrowing rate as the discount rate.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease payments included in the measurement of the lease liability comprise the following: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;fixed payments, including in-substance fixed payments;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;variable lease payments that depend on an index or a rate, initially measured using the index or rate as of the commencement date; &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;amounts expected to be payable under a residual value guarantee; and&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;the exercise price under a purchase option that the Group is reasonably certain to exercise, lease payments in an optional renewal period if the Group is reasonably certain to exercise an extension option, and penalties for early termination of a lease unless the Group is reasonably certain not to terminate early.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The lease liability is subsequently measured at amortized cost using the effective interest method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the Group&amp;#8217;s estimate of the amount expected to be payable under a residual value guarantee, or if the Group changes its assessment of whether it will exercise a purchase, extension or termination option. When the lease liability is remeasured, a corresponding adjustment is made to the carrying amount of the right-of-use asset or is recorded in the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;statements of operations if the carrying amount of the right-of-use asset has been reduced to zero.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group presents right-of-use assets separately and lease liabilities in &amp;#8216;financial liabilities&amp;#8217; in the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;statements of financial position.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets or shorter lease term, as follows:&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Useful life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Years)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Buildings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2-25&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equipment, tools and installations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2-5&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Production facilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2-3&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Automobiles&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3-4&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-Term Leases and Leases of Low-Value Assets&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group has elected not to recognize right-of-use assets and lease liabilities for short-term leases of machinery that have a lease term of 12 months or less or leases of low-value assets. The Group recognizes the lease payments associated with these leases as an expense in the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;statements of operations on a straight-line basis over the lease term.&lt;/p&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.10&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Intangible Assets&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The useful lives of intangible assets are assessed as either finite or indefinite. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets with finite lives are amortized generally on a straight-line basis over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are at least reviewed at the end of each reporting period. The amortization expense on intangible assets with finite lives is recognized in the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;statements of operations in the expense category that is consistent with the function of the intangible assets.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the useful lives applied to the Group&amp;#8217;s intangible assets is as follows:&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Useful life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Years)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intellectual property rights&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10-20&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Licenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3-20&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3-8&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets with indefinite useful lives are not amortized, but are tested for impairment at least annually, or when there is an indication for impairment, either individually or at the level of a cash-generating unit (see Note 2.3.13 for further details). The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group has classified advanced payments on intangible assets as intangible assets, which are not yet ready for use. Advanced payments on intangible assets are tested for impairment on an annual basis.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;An intangible asset is derecognized upon disposal (&lt;font style="font-style:italic;"&gt;i.e&lt;/font&gt;., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising upon derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;statements of operations.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Costs&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research costs are expensed as incurred. Development expenditures on an individual project are recognized as an intangible asset if, and only if, all of the following six criteria can be demonstrated by the Group:&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;the technical feasibility of completing the intangible asset so that the asset will be available for use or sale;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;its intention to complete the project;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;the ability and intention to use or sell the asset;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;how the asset will generate future economic benefits;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;the availability of resources to complete the asset; and&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;the ability to reliably measure the expenditure during development.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due to the inherent risk of failure in pharmaceutical development and the uncertainty of approval, management has determined that these criteria are not met in the biotech sector until regulatory approval has been obtained. The related expenditure is reflected in the consolidated statements of operations in the period in which the expenditure is incurred. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Following initial recognition of the development expenditure as an asset, the asset is carried at cost less any accumulated amortization and accumulated impairment losses. Amortization of the asset begins when development is complete and the asset is available for use. It is amortized over the period of expected future benefit. Amortization is recorded in cost of sales. During the period of development, the asset is tested for impairment annually.&lt;/p&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.11&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Financial Instruments &amp;#8211; Initial Recognition and Subsequent Measurement&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;i) Financial Assets&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Initial recognition and Measurement&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets are initially measured at fair value. The Group&amp;#8217;s financial assets mainly include trade receivables as well as other receivables that reflect BioNTech&amp;#8217;s entitlement to cash. With respect to trade receivable, the Group has applied the practical expedient which means that they are measured at the transaction price determined under IFRS 15. Refer to the accounting policies in Note 2.3.4. Other financial assets are measured at amortized costs since they are held by the Group to collect contractual cash flows, which are solely payments of principal and interest. Gains and losses are recognized in profit or loss when the financial asset is derecognized, modified or impaired. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derecognition&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e., removed from the Group&amp;#8217;s consolidated statements of financial position) when the rights to receive cash flows from the asset have expired or have been transferred in terms of fulfilling the derecognition criteria. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impairment of Financial Assets&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;An allowance for expected credit losses (ECLs) is considered for all debt instruments of the Group. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all of the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For trade receivables and contract assets, the Group applies a simplified approach in calculating ECLs. Therefore, the Group does not track changes in credit risk, but instead recognizes a loss allowance based on lifetime ECLs at each reporting date. The Group has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment. In this analysis BioNTech also considered that governments and health ministries which are BioNTech&amp;#8217;s customers established in connection with progressing the commercial activities of the Group with respect to BioNTech&amp;#8217;s COVID-19 vaccine. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;ii) Financial Liabilities&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Initial Recognition and Measurement&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings or as payables.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group&amp;#8217;s financial liabilities include trade payables and other financial liabilities.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Subsequent Measurement&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The measurement of financial liabilities depends on their classification, as described below.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Financial Liabilities at Fair Value through Profit or Loss&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial liabilities at fair value through profit of the Group include the embedded derivative, which was bifurcated from the convertible note, as host contract, and is recognized as a separate financial instrument until it is extinguished upon conversion. Financial liabilities at fair value further include contingent considerations resulting from the Group&amp;#8217;s business combinations. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains or losses arising from fair value measurement adjustments of the embedded derivative and the contingent consideration are recognized in profit and loss within the consolidated statements of operations.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Loans, Borrowings, Trade Payables and Other Financial Liabilities&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;After initial recognition, interest-bearing loans and borrowings, trade payables and other financial liabilities are subsequently measured at amortized cost using the EIR method. Gains and losses are recognized in the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;statements of operations when the liabilities are derecognized as well as through the EIR amortization process.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortization is included as finance costs in the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;statements of operations.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;This category generally applies to interest-bearing loans and borrowings.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derecognition&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;statements of operations.&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.12&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Inventories&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories are valued at the lower of cost and net realizable value.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs incurred in bringing each product to its present location and condition are accounted for as follows:&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;raw materials and supplies: purchase cost on a first-in/first-out basis; or&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;unfinished goods and finished goods: cost of direct materials and labor, including both internal manufacturing and third-party contract manufacturing organizations, or CMOs, and a proportion of manufacturing overheads based on the normal operating capacity, but excluding borrowing costs.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.13&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Impairment of Non-Financial Assets&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group assesses, at each reporting date, whether there is an indication that an asset may be impaired. Goodwill is tested for impairment annually as of October 1. Impairment is determined for goodwill by assessing the recoverable amount of each cash generating unit (or group of CGUs) to which the goodwill relates. If any indication exists, or when annual impairment testing is performed, the Group estimates the asset&amp;#8217;s or CGU&amp;#8217;s recoverable amount. The recoverable amount is the higher of an asset&amp;#8217;s or CGU&amp;#8217;s fair value less costs of disposal and its value in use. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. When the carrying amount of an asset or cash generating unit exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used. These calculations are corroborated by valuation multiples, quoted share prices for publicly traded companies or other available fair value indicators.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group bases its impairment calculation on detailed budgets and forecast calculations, which are prepared separately for each of the Group&amp;#8217;s cash generating units to which the individual assets are allocated. These budgets and forecast calculations generally cover a period of five years. A long-term growth rate is calculated and applied to project future cash flows after the fifth year.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impairment losses of continuing operations are recognized in the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;statements of operations in expense categories consistent with the function of the impaired asset.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For assets excluding goodwill, an assessment is made at each reporting date to determine whether there is an indication that previously recognized impairment losses no longer exist or have decreased. If such indication exists, the Group estimates the asset&amp;#8217;s or cash generating unit&amp;#8217;s recoverable amount. A previously recognized impairment loss is reversed only if there has been a change in the assumptions used to determine the asset&amp;#8217;s recoverable amount since the last impairment loss was recognized. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognized for the asset in prior years. Such reversal is recognized in the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;statements of operations unless the asset is carried at a revalued amount, in which case, the reversal is treated as a revaluation increase.&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.14&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents comprise cash in banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.15&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Pension&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The liability in respect of defined benefit pension plans is the defined benefit obligation calculated annually by independent actuaries using the projected unit credit method. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions of the respective employees, while the net interest on the net defined benefit liability or asset is recognized in finance expenses or finance income.&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;16&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Provisions&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Group expects some or all of a provision to be reimbursed, for example, under an insurance contract, the reimbursement is recognized as a separate asset, but only when the reimbursement is virtually certain. The expense relating to a provision is presented in the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;statements of operations net of any reimbursement.&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.1&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Share-Based Payments&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employees (and others providing similar services) receive remuneration in the form of share-based payments, which are settled in equity instruments (equity-settled transactions).&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The cost of equity-settled transactions is determined by the fair value at the date when the grant is made using an appropriate valuation model, further details of which are given in Note 17. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;These costs are recognized in cost of sales, research and development expenses, sales and marketing expenses or general and administrative expenses, together with a corresponding increase in equity (other reserves), over the period in which the service is provided (the vesting period). The cumulative expense recognized for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Group&amp;#8217;s best estimate of the number of equity instruments that will ultimately vest.&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.4&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Standards applied for the First Time&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2020 several new and amended standards and interpretations became effective but did not have an impact on the consolidated financial statements of the Group. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Standards/Interpretations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Date of application&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amendments to IFRS 3 Business Combinations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amendments to IFRS 9, IAS 39 and IFRS 7 Interest Rate Benchmark Reform&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amendments to IAS 1 and IAS 8 Definition of Material&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amendments to References to the Conceptual Framework in IFRS Standards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amendment to IFRS 16 Leases COVID-19-Related Rent Concessions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.5&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Standard issued but not yet effective&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The new and amended standards and interpretations that are issued, but not yet effective, up to the date of issuance of the Group&amp;#8217;s financial statements and that might have an impact on the Group&amp;#8217;s financial statements are disclosed below. The Group has not early adopted any standards and intends to adopt these new and amended standards and interpretations, if applicable, when they become effective. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Standards/Interpretations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Date of application&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amendments to IFRS 4 Insurance Contracts &amp;#8211; deferral of IFRS 9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2021&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 Interest Rate Benchmark Reform &amp;#8211; Phase 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2021&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amendments to IFRS 3 Business Combinations: Reference to the Conceptual Framework&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2022&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amendments to IAS 16 Property, Plant and Equipment: Proceeds before Intended Use&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2022&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amendments to IAS 37 Provisions, Contingent Liabilities and Contingent Assets - Onerous Contracts &amp;#8211; Cost of Fulfilling a Contract Amendments to IAS 37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2022&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Annual Improvements to IFRS Standards 2018-2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2022&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amendments to IAS 1 Presentation of Financial Statements: Classification of Liabilities as Current or Non-current - Deferral of Effective Date&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2023&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;IFRS 17 Insurance Contracts (issued on 18 May 2017); including Amendments to IFRS 17&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2023&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group does not expect a significant impact of the application of any of these amendments. &lt;/p&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
  <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory id="F_000372" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="color:#000000;"&gt;Significant Accounting Judgments, Estimates and Assumptions&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of the Group&amp;#8217;s consolidated financial statements requires management to make &lt;font style="color:#000000;"&gt;judgments&lt;/font&gt;, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, the accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Judgments&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the process of applying the Group&amp;#8217;s accounting policies, management has made the following judgments, which have the most significant effect on the amounts recognized in the consolidated financial statements:&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue from Contracts with Customers&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech applied the following &lt;font style="color:#000000;"&gt;judgments &lt;/font&gt;that significantly affect the determination of the amount and timing of revenue from contracts with customers:&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;Identification and Determination of Performance Obligations&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech generates revenues from collaboration and license agreements, which c&lt;font style="color:#000000;"&gt;ontain multiple elements, including licenses to use, research, develop, manufacture and commercialize candidates and products, research and development services as well as obligations to develop and manufacture preclinical and clinical material and products. &lt;/font&gt;BioNTech determined that those collaboration and license agreements qualify as contracts with its customers. &lt;font style="color:#000000;"&gt;At inception of each agreement, BioNTech applies judgment when determining which promises represent distinct performance obligations. &lt;/font&gt;If promises are not distinct, they are combined until the bundle of promised goods and services is distinct. For some agreements, this results in BioNTech accounting for goods and services promised in a collaboration and license agreement as a single performance obligation with a single measure of progress. For these combined performance obligations, BioNTech assesses which of these promises is the predominant promise to determine the nature of the performance obligation. &lt;font style="color:#000000;"&gt;When licenses are granted, BioNTech determined that the grant of the license is the predominant promise within the combined performance obligations. &lt;/font&gt;It is assessed that BioNTech grants their customers a right to access or a right to use BioNTech&amp;#8217;s intellectual property due to the collaboration and license agreements. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;Measurement of the Transaction Price&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech&amp;#8217;s collaboration and license agreements often include variable considerations, which are contingent on the occurrence or non-occurrence of a future event &lt;font style="font-style:italic;"&gt;(i.e.&lt;/font&gt;, reaching a certain milestone). When determining deferred revenues of a collaboration and license agreement, BioNTech is required to estimate the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to the customer. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As there are usually only two possible outcomes (&lt;font style="font-style:italic;"&gt;i.e.,&lt;/font&gt; milestone is reached or not), BioNTech has assessed that the method of the most likely amount is the best method to predict the amount of consideration to which BioNTech will be entitled. At contract inception, the most likely amount for milestone payments is estimated to be zero. BioNTech has assessed that the likelihood of achieving the respective milestone decreases depending on how far the expected date of achieving the milestone lies in the future. At each reporting date, BioNTech uses judgment to determine when to include variable consideration in the transaction price such that it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with respect to the variable consideration is subsequently resolved. BioNTech has concluded that future milestone payments are fully constrained at the end of the current fiscal year.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future milestone payments would become unconstrained at the satisfaction of the milestone event, specifically a development event, a regulatory approval or achievement of a sales milestone.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;Allocation of the Transaction Price to Performance Obligations and Revenue Recognition as Performance Obligations are satisfied&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech allocates the transaction price to performance obligations based on their relative standalone selling prices, which are generally based on best estimates and interpretations of &lt;font style="color:#000000;"&gt;facts and circumstances of each contractual agreement and may &lt;/font&gt;require significant judgment to determine appropriate allocation. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upfront payments and reimbursement for expenses are initially deferred on BioNTech&amp;#8217;s &lt;font style="color:#000000;"&gt;consolidated&lt;/font&gt; statements of financial position. BioNTech assessed that no significant financing component exists within its collaboration agreements since the overall business purpose of advanced payments is to support the payment structure other than to provide a significant benefit of financing. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For performance obligations in which the costs vary based on progress, an input-based measure considering cost incurred depicts most reliably the progress of the related research activities. In other cases, revenue recognition on a straight-line basis may most reliably depict BioNTech&amp;#8217;s performance toward complete satisfaction. In case the contractual activities progress, the achievement of development milestones will be used to measure the progress toward complete satisfaction. &lt;font style="color:#000000;"&gt;BioNTech evaluates the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net loss in the period of adjustment.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon successfully commercializing a pharmaceutical product, the collaboration and license agreements also provide for additional profit-sharing or tiered royalties earned when customers recognize net sales of licensed products as well as sales milestone payments. Revenue is recognized based on the sales-based or usage-based royalty exemption when, or as, the underlying sales occur, which is when the performance obligation has been satisfied. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;Principal-Agent Considerations&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Collaboration agreements that involve two or more partners who contribute to the provision of a specific good or service to a customer are assessed in terms of principal-agent considerations. Under BioNTech&amp;#8217;s current collaboration agreements, the allocation of marketing and distribution rights defines territories in which the collaboration partner act as a principal respectively. BioNTech recognizes revenue net based on the collaboration partners&amp;#8217; gross profit in territories where the partner is responsible for supply and on a gross basis when directly supplying customers in its territories when control has been transferred. Amounts paid to collaboration partners for their share of BioNTech&amp;#8217;s profits where BioNTech is the principal in the transaction are recorded as cost of sales. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Pfizer Agreement Characteristics&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;With respect to the collaboration with Pfizer, commercial revenue is recognized based on the collaboration partners&amp;#8217; gross profit from COVID-19 vaccine sales, which is shared under the respective collaboration agreement. In determining commercial revenue pursuant to this collaboration agreement, BioNTech is reliant on the collaboration partner for detail regarding its gross profit for the period at hand. BioNTech has been informed by its collaboration partner that certain of the information it intends to provide BioNTech with regard to the gross profit will be, by necessity, preliminary and subject to change. This is mainly due to the fact that the partner&amp;#8217;s financial reporting cycle differs from BioNTech&amp;#8217;s. Pfizer&amp;#8217;s subsidiaries outside the United States have a fiscal year-end of November 30; that is, the details on sales in these territories are required in advance of closing the respective reporting periods. As a result, BioNTech&amp;#8217;s determination of its share of such gross profit for purposes of recognizing revenues will be subject to risks that amounts reported might vary from actual amounts reported once the collaboration partner&amp;#8217;s final financial results are available. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the period covered in these consolidated financial statements, Pfizer has calculated gross profit for COVID-19 vaccine sales in the U.S. territory as well as shared preliminary gross profit for COVID-19 vaccine sales in territories outside the United States, both of which will be reconciled and finalized. The respective gross profit shares are calculated based on sales and include consideration of transfer prices. The latter includes manufacturing and shipping costs which represent standard prices and include mark-ups on manufacturing costs as specified by the terms of the agreement. Manufacturing and shipping cost variances were considered as far as those have been identified. Nevertheless, those input parameters maybe adjusted once actual costs are determined. The sales for the U.S. territory, as reported by Pfizer, as well as sales preliminary reported for territories outside the United States have been used to estimate license obligations in terms of royalties and sales milestones. Sales milestones and royalties are recognized as they are earned by the partners. Sales milestones are shared equally, while royalty payments are shared on the basis of revenue in the territories for which the partners are responsible. The estimated royalty fees applied to net sales reflect the license obligations to the extent currently identified from third party contractual arrangements. Changes in estimates are accounted for prospectively, when determined. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;These estimated figures are likely to change prospectively in future periods as BioNTech receives final data from Pfizer. Those changes in BioNTech&amp;#8217;s share of the collaboration partner&amp;#8217;s gross profit will be recognized prospectively as changes to BioNTech&amp;#8217;s commercial revenues. To the extent that Pfizer does not provide such preliminary information in the future, BioNTech&amp;#8217;s provisional sales figures for territories outside of the United States will be subject to a greater level of estimation and judgment. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:1.09%;width:99.88%;"&gt;
&lt;tr&gt;
&lt;td style="width:35.4%;"&gt;&lt;/td&gt;
&lt;td style="width:14.27%;"&gt;&lt;/td&gt;
&lt;td style="width:14.27%;"&gt;&lt;/td&gt;
&lt;td style="width:21.19%;"&gt;&lt;/td&gt;
&lt;td style="width:14.75%;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="4" valign="bottom" bgcolor="#FFFFFF"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-bottom:solid 1pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-bottom:solid 1pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;German territory&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-bottom:solid 1pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. territory&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-bottom:solid 1pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Territories outside the U.S.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-bottom:solid 1pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" style=" border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style=" border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Direct product sales to BioNTech customers&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364; 20,553&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style=" border-right:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364; 20,553&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style=" border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share of collaboration partner&apos;s gross profit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364; 46,997&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style=" border-right:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364; 141,480&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364; 188,477&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Input parameters used within gross profit share calculation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-right:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:10pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Sales&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;reported&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-right:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;preliminary&lt;br /&gt;reported&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Transfer price (manufacturing, shipping costs and respective variances)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;standard&lt;br /&gt;prices&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;standard&lt;br /&gt;prices&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;License payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;identified&lt;br /&gt;royalty rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;identified&lt;br /&gt;royalty rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pfizer&amp;#8217;s determination of manufacturing and shipping costs also affects the transfer prices that have been charged to COVID-19 vaccine supplies that it manufactures and supplies to BioNTech and may be subject to adjustment whenever manufacturing and shipping cost variances are identified. &lt;font style="color:#000000;"&gt;Likewise, &lt;/font&gt;BioNTech&amp;#8217;s &lt;font style="color:#000000;"&gt;own cost of sales and the respective gross profit share owed to &lt;/font&gt;BioNTech&amp;#8217;s &lt;font style="color:#000000;"&gt;partner may be adjusted prospectively&lt;/font&gt;, when changes are determined&lt;font style="color:#000000;"&gt;. &lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the carrying amounts of the revenue recognition-related contract balances, see Note 6.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses consist of costs incurred in performing research and development activities, including personnel-related expenses, contract services and costs for purchased materials, laboratory supplies and non-capital equipment used in the research and development process. Research and development expenses include BioNTech&amp;#8217;s share of expenses under the terms of collaboration agreements and 100% of the expenses for wholly-owned product candidates. Research and development expenses shared under collaboration agreements, which are initially incurred by the collaboration partners and subsequently charged to BioNTech, are recorded as purchased services classified within research and development. Cost reimbursements from partners for research and development expenses initially incurred by BioNTech and due to BioNTech under the agreements, are recorded as a reduction to purchased services classified within research and development expenses. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech has entered into agreements under which third parties grant licenses to BioNTech. Consideration paid under those agreements include upfront payments, development milestone payments and development expense reimbursements as well as sales-based milestone and royalty payments. Milestone payments are recorded when the specific milestone has been achieved. If those licenses grant access to technologies, both parties jointly perform research or development activities and both are exposed to significant risks and rewards of the activities. Costs incurred with the agreements are not treated differently from costs related to own product candidates. If the agreements grant BioNTech rights to use certain patents and technologies, that meet the definition of an identifiable assets, they are treated as acquired intangible assets. This assessment is made based on the facts and circumstances of each contractual agreement. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The value of goods and services received from contract research organizations, or CROs, and contract manufacturing organizations, or CMOs, in the reporting period are estimated based on the level of services performed and progress made in the respective period. Amounts are recorded as accrued expenses if BioNTech has not received an invoice from the service provider. Advance payments for goods or services that will be used or rendered for future research and development activities are recognized as other current assets or other current financial assets respectively. The amounts are currently expensed as the related goods are delivered or the services performed. Management&amp;#8217;s estimates are based on the best information available at the time. However, additional information may become available in the future and management may adjust the estimate in such future periods. In this event, BioNTech may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. BioNTech considers resulting increases or decreases in cost as changes in estimates and reflects such changes in research and development expenses in the period identified.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research costs are expensed as incurred. Development expenditures on an individual project are recognized as an intangible asset if, and only if, all of the six criteria can be demonstrated by the Group as shown under Note&amp;#160;2.3.10 above. Due to the inherent risk of failure in pharmaceutical development and the uncertainty of approval, management has determined that these criteria are not met in the biotech sector until regulatory approval has been obtained. The related expenditure is reflected in the consolidated statements of operations in the period in which the expenditure is incurred.&lt;font style="color:#000000;"&gt; Sales-based milestone or royalty payments incurred under license agreements relating to self-developed intangibles after the approval date of the respective pharmaceutical product are considered as contingent considerations. These contingent considerations are recognized as expenses as incurred. &lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to initial regulatory approval, costs relating to production of products are expensed as research and development expenses in the period incurred. If pre-launch products are sold, the respective product gross margin may be higher compared to the expected recurring margin as the underlying costs will not be included in cost of sales.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimates and Assumptions&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are described below. The Group based its assumptions and estimates on parameters available when the consolidated financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Group. Such changes are reflected in the assumptions when they occur.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Business Combinations&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The allocation of the purchase price for business acquisitions to the identifiable assets acquired and liabilities assumed based on their respective fair values, requires use of accounting estimates and judgment. Acquired intangible assets are valued using valuation models such as the Multi Period Excess Earnings Method under which fair values are derived from future net cash flows, which are discounted to the acquisition date using an appropriate discount factor. BioNTech has estimated fair values of assets acquired, liabilities assumed and contingent considerations based on reasonable assumptions. BioNTech continues to collect information and reevaluate these provisional estimates and assumptions in accordance with IFRS 3. Any adjustments to these provisional estimates and assumptions is recorded against goodwill provided they arise within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statements of operations.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For further disclosures relating to business combinations, see Note 5.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Impairment of Non-Financial Assets&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impairment exists when the carrying value of an asset or cash generating unit exceeds its recoverable amount, which is the higher of its fair value less costs of disposal and its value in use. The fair value less costs of disposal calculation is based on DCF model less incremental costs of disposing of the asset. The value in use calculation is based on a DCF model as well. The cash flows are derived from the budget for the next five years and do not include restructuring activities that the Group is not yet committed to or significant future investments that will enhance the performance of the assets of the CGU being tested. The recoverable amount is sensitive to the discount rate used for the DCF model as well as the expected future cash-inflows and the growth rate used for extrapolation purposes. These estimates are most relevant to goodwill and other intangibles with indefinite useful lives recognized by the Group. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The key assumptions used to determine the recoverable amount for the different CGUs, including a sensitivity analysis, are disclosed and further explained in Note&amp;#160;11.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Share-Based Payments&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Determining the fair value of share-based payment transactions requires the most appropriate valuation for the specific program, which depends on the underlying terms and conditions.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group has used valuation models like a binomial or Monte-Carlo simulation model for the measurement of the cash- and equity-settled transactions&amp;#8217; fair value at the grant date considering certain assumption relating to, &lt;font style="font-style:italic;"&gt;e.g.&lt;/font&gt;, the volatility of stock price, the determination of an appropriate risk-free interest rate, expected dividends and the probability of reaching a minimum hurdle to exercise the relevant options. For awards which were granted prior to the initial public offering, at a time where no quoted market prices existed, the valuation model assumptions included the option&amp;#8217;s underlying share price. For awards which were granted post the initial public offering, the grant date&amp;#8217;s share prices on the Nasdaq Global Select Market were included in the valuation. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For further disclosures relating to share-based payments, see Note 17.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Embedded Derivatives&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Defining the fair value of the embedded derivative which was bifurcated from the convertible note, as host contract, requires significant judgment. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group has used the Cox-Rubinstein binomial tree model when determining the fair value of the conversion right. The primary inputs used in the model include stock price volatility, credit spreads, risk-free interest rate and foreign exchange forward rates. Stock price volatility is based on implied volatility for BioNTech, credit risk is model implied and adjusted for movement in credit spreads for B-rated corporates at each valuation date, the risk-free interest rate is based on currency specific time congruent IBOR and swap rates whereas the foreign exchange forward rates are based on observable market data. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For further disclosures relating to financial instruments, see Note 12.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets are measured at the amount equal to the lease liability, adjusted by the amount of any prepaid or accrued lease payments relating to that lease.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant accounting judgments are required for the determination of the appropriate incremental borrowing rate, which is to be used in the calculation of the asset and liability that are recognized in the financial statements regarding the lease contracts.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the carrying amounts of right-of-use assets and the related lease liability, see Note 19.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Taxes&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group is subject to income taxes in more than one tax jurisdictions. Due to the increasing complexity of tax laws and the corresponding uncertainty regarding the legal interpretation by the fiscal authorities, tax calculations are generally subject to an elevated amount of uncertainty. To the extent necessary, possible tax risks are taken into account in form of provisions. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group does not recognize or impairs deferred tax assets when it is unlikely that a corresponding amount of future taxable profit will be available against which the deductible temporary differences, tax loss carry forwards and tax credits can be utilized. Significant management &lt;font style="color:#000000;"&gt;judgment &lt;/font&gt;is required when determining whether sufficient future taxable profit will be available against which the deductible temporary differences, tax loss carry forwards and tax credits can be utilized. This includes management&amp;#8217;s assessment on the character and amounts of taxable future profits, the periods in which those profits are expected to occur, and the availability of tax planning opportunities. As a matter of policy, convincing evidence supporting the recognition of deferred tax assets is required if an entity has suffered a loss in either the current or the preceding periods.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, based on BioNTech&amp;#8217;s &lt;font style="color:#000000;"&gt;product-based business plan, including commercial supply commitments agreed with various governments and health ministries under which BioNTech either directly supplies the COVID-19 vaccine or, if they relate to territories which have been allocated to Pfizer, BioNTech will receive the profit share to which its eligible, it is now considered highly probable that taxable profits for the German tax group will be available &lt;/font&gt;against which the tax losses can be utilized. On this basis, BioNTech has determined that a deferred tax asset with respect to the German tax group&amp;#8217;s tax losses carried forward can be recognized. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On the other hand, management has determined that deferred tax assets on tax losses carried forward that relate to subsidiaries which have a loss making history cannot be recognized. This includes the assessment that those subsidiaries neither have any taxable temporary difference nor any tax planning opportunities available that could support the recognition of deferred tax assets. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For further disclosures relating to deferred taxes, see Note 8.&lt;/p&gt;</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
  <ifrs-full:DisclosureOfCompositionOfGroupExplanatory id="F_000373" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="color:#000000;"&gt;Group Information&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Information about Subsidiaries&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements of the Group include the following subsidiaries: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.98%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;% equity interest&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Name&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Country of incorporation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Registered office&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech RNA Pharmaceuticals GmbH&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Mainz&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Delivery Technologies GmbH&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Halle&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Diagnostics GmbH&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Mainz&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Europe GmbH&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(previously BioNTech Small Molecules GmbH)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Mainz&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Manufacturing GmbH&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(previously BioNTech IVAC GmbH)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Mainz&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Manufacturing Marburg GmbH&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marburg&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;n/a&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Austria Beteiligungen GmbH&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Austria&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vienna&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Innovative Manufacturing Services GmbH&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Idar-Oberstein&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;reSano GmbH (previously reBOOST Management GmbH)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Mainz&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;JPT Peptide Technologies GmbH&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Berlin&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;JPT Peptide Technologies Inc.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cambridge (previously Acton)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech USA Holding, LLC&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cambridge (previously New York)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Research and Development, Inc.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cambridge (previously New York)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech US Inc.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cambridge&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;n/a&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Pharmaceuticals Asia Pacific Pte. Ltd&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Singapore&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Singapore&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;n/a&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech UK Limited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United Kingdom&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reading&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;n/a&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Cell &amp;amp; Gene Therapies GmbH&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Mainz&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Real Estate Holding GmbH&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holzkirchen&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Real Estate Verwaltungs GmbH&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holzkirchen&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Real Estate GmbH &amp;amp; Co. KG&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holzkirchen&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Real Estate An der Goldgrube GmbH &amp;amp; Co. KG&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holzkirchen&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;n/a&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Real Estate Haus Vier GmbH &amp;amp; Co. KG&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holzkirchen&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;n/a&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Real Estate Adam Opel Stra&amp;#223;e GmbH &amp;amp; Co. KG&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holzkirchen&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;n/a&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December&amp;#160;31, 2020, two entities were acquired: Neon Therapeutics, Inc. (subsequently renamed BioNTech US Inc.) and Novartis Manufacturing GmbH (subsequently renamed BioNTech Manufacturing Marburg GmbH). Additionally, BioNTech UK Limited., BioNTech Pharmaceuticals Asia Pacific Pte. Ltd, BioNTech Real Estate Haus Vier GmbH &amp;amp; Co. KG, BioNTech Real Estate An der Goldgrube GmbH &amp;amp; Co. KG and BioNTech Real Estate Adam Opel Stra&amp;#223;e GmbH &amp;amp; Co. KG were established.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During&lt;font style="color:#000000;"&gt; the year ended December&amp;#160;31, 2019, two entities were founded in the United States: BioNTech USA Holding, LLC, a wholly-owned subsidiary of BioNTech SE, and BioNTech Research and Development, Inc. a wholly-owned subsidiary of BioNTech USA Holding, LLC. Additionally, reSano GmbH (previously reBOOST Management GmbH), was acquired through a share purchase which represents a related party transaction. &lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Parent Company&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ATHOS KG, Holzkirchen, Germany is the sole shareholder of AT Impf GmbH, Munich, Germany and beneficial owner of the following percentage of ordinary shares in BioNTech at the dates as indicated. ATHOS KG via AT Impf GmbH has de facto control over BioNTech based on its substantial shareholding, which enabled it to exercise the majority of voting rights to pass resolutions at BioNTech&amp;#8217;s Annual General Meeting, or AGM. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.16%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ownership of ordinary shares in BioNTech (in %)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Name&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Country of incorporation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Registered office&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;AT Impf GmbH&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Munich&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C5E0B3" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47.37%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50.33%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Entity with significant Influence over the Group&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Medine GmbH, Mainz owned the following percentage of ordinary shares in BioNTech at the following dates as indicated: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.16%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ownership of ordinary shares in BioNTech (in %)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Name&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Country of incorporation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Registered office&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Medine GmbH&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Mainz&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C5E0B3" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.25%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18.38%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCompositionOfGroupExplanatory>
  <ifrs-full:DisclosureOfBusinessCombinationsExplanatory id="F_000374" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="color:#000000;"&gt;Business Combinations&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lipocalyx GmbH&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, BioNTech Delivery Technologies GmbH (previously BioNTech Protein Therapeutics GmbH), or BioNTech Delivery Technologies, a wholly-owned subsidiary of BioNTech&amp;#160;SE, entered into an agreement to acquire all assets, employees and proprietary know-how of Lipocalyx GmbH, or Lipocalyx, and its related parties in exchange for a total cash consideration at an amount of &amp;#8364;6.5&amp;#160;million and additional contingent consideration estimated at the closing date of January 6, 2020 in an amount of &amp;#8364;0.6&amp;#160;million. The employees of Lipocalyx were transferred automatically to BioNTech Delivery Technologies with effect as of the closing date. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="color:#000000;"&gt; Group acquired the assets of Lipocalyx and its related parties to combine the acquired technologies and the related know-how with already existing product candidates of the Group to improve their functionality and performance. &lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The final fair values of the identifiable net assets of Lipocalyx as at the date of acquisition were:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;recognized on&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;acquisition&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lipocalyx GmbH&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;896&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,978&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, plant and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;139&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total identifiable net assets at fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;7,088&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consideration&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;6,516&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;572&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total consideration&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;7,088&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated statements of operations include the result of Lipocalyx since the acquisition date. From the date of acquisition through December&amp;#160;31, 2020, Lipocalyx contributed &amp;#8364;1.7&amp;#160;million as operating loss to the respective result of the Group. From the date of acquisition through December 31, 2020, Lipocalyx generated &amp;#8364;0.2&amp;#160;million of revenues. Given the timing of closing, the contribution to operating loss and revenues, if the transaction had occurred at the beginning of the reporting period, would not differ materially. Goodwill recognized is primarily attributed to the expected synergies and other benefits from combining the assets and activities of Lipocalyx with those of the Group. The goodwill resulting from the Lipocalyx acquisition during the year ended December 31, 2020 was allocated to the CGU Immunotherapies. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Transaction costs of &amp;#8364;17&amp;#160;thousand relating to the acquisition have been expensed and are included in the general and administrative expenses in the consolidated statements of operations and are included in cash flows used in operating activities in the consolidated statements of cash flows.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The purchase &lt;font style="color:#000000;"&gt;agreement&lt;/font&gt; with Lipocalyx includes the following contingent cash considerations to the previous owners: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.09%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.04%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1.0&amp;#160;million upon successful completion of a Phase 1 clinical trial designed to show and establish a sufficient safety margin justifying further development of the first pharmaceutical product relating to acquired technologies formulated in a manner covered by a valid granted claim in a major country of a patent within the assigned IP rights; and&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.09%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.04%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1.0&amp;#160;million upon successful completion of the first Phase 2 clinical trial of the first pharmaceutical product relating to acquired technologies formulated in a manner covered by a valid granted claim in a major country of a patent within the assigned IP rights. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the &lt;font style="color:#000000;"&gt;acquisition&lt;/font&gt; date, the fair value of the contingent consideration was &amp;#8364;0.6&amp;#160;million. The contingent consideration is presented in &amp;#8216;non-current financial liabilities&amp;#8217; in the consolidated statements of financial position (see Note 12). &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech US Inc. (previously Neon Therapeutics, Inc., or Neon)&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On May 6, 2020, BioNTech acquired Neon, a biotechnology company developing novel neoantigen-based T-cell therapies, to leverage Neon&amp;#8217;s expertise in the development of neoantigen therapies, with both vaccine and T cell capabilities. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Based on the acquisition date share price, the aggregate value of the merger consideration was &amp;#8364;89.9&amp;#160;million ($97.1&amp;#160;million) financed by &lt;font style="color:#000000;"&gt;issuing&lt;/font&gt; 1,935,488 American Depositary Shares representing BioNTech&amp;#8217;s ordinary shares as a stock transaction and including a de minimis cash consideration which was paid to settle Neon&amp;#8217;s outstanding stock options. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair values and values in accordance with IFRS 3 of the identifiable net assets of BioNTech US Inc. as at the date of acquisition &lt;font style="color:#000000;"&gt;were&lt;/font&gt; as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;recognized on&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;acquisition&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech US Inc.&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;29,867&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, plant and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,617&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,896&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other assets non-current and current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,704&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,749&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;52,833&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trade payables&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,723&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other liabilities non-current and current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,793&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;19,516&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total identifiable net assets at fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;33,317&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill from the acquisition&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,573&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consideration transferred&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;89,890&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consideration&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares issued, at fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89,548&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;342&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total consideration&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;89,890&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The intangible assets comprise two neoantigen targeted therapies, BNT221 (NEO-PTC-01) and BNT222 (NEO-STC-01), which were identified and recorded as in-process R&amp;amp;D. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities relating to temporary differences of the assets acquired in the business combination were recognized at an amount of &amp;#8364;&amp;#160;8.0&amp;#160;million. To the extent of those deferred tax liabilities assumed, deferred tax assets relating to temporary differences and tax loss carryforwards which existed as of the acquisition date were recognized. Since the conditions to offset were fulfilled, the deferred tax assets and liabilities were offset. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated statements of operations include the results of BioNTech US since the acquisition date. From the date of acquisition through December 31, 2020, BioNTech US contributed &amp;#8364;28.5&amp;#160;million operating loss to respective result of the Group. If the transaction had occurred at the beginning of the reporting period, &amp;#8364;59.8&amp;#160;million would have contributed to the operating loss. This amount includes expenses resulting from the merger and should not necessarily be &lt;font style="color:#000000;"&gt;considered&lt;/font&gt; representative of the future consolidated results of operations or financial condition on a consolidated basis. From the date of acquisition, BioNTech US did not generate any revenue and no revenue would have been generated if the transaction had occurred at the beginning of the reporting period. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill recognized is primarily attributable to the expected synergies and other benefits from combining two organizations with a common culture of pioneering translational science and a shared vision for the future of cancer immunotherapy as described above. The goodwill resulting from the BioNTech US acquisition during the year ended December 31, 2020 was allocated to the CGU Immunotherapies. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Transaction costs of &amp;#8364;1.1&amp;#160;million relating to the acquisition have been expensed and are included in the general and administrative expenses in the consolidated statements of operations. In the consolidated statements of cash flows they are included in cash flows used in operating activities. The attributable costs of the issuance of the shares of &amp;#8364;1.3&amp;#160;million were recorded in &lt;font style="color:#000000;"&gt;equity&lt;/font&gt; as a deduction from the capital reserve and are included in cash flows from financing activities in the consolidated statements of cash flows. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Manufacturing Marburg GmbH (previously Novartis Manufacturing GmbH)&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 31, 2020, BioNTech acquired Novartis Manufacturing GmbH, a manufacturing facility in Marburg. Through the acquisition, BioNTech plans to produce its COVID-19 vaccine for global supply.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair values and values in accordance with IFRS 3 of the identifiable net assets of BioNTech Manufacturing Marburg GmbH, or BioNTech Marburg, as at the date of acquisition &lt;font style="color:#000000;"&gt;were&lt;/font&gt; as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;recognized on&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;acquisition&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Manufacturing Marburg GmbH&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, plant and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79,828&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,514&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,466&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other assets non-current and current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,343&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,319&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;131,470&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provisions non-current and current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,127&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trade payables&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,105&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other liabilities non-current and current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,383&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;46,615&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total identifiable net assets at fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;84,855&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Bargain purchase&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,002)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consideration transferred&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;77,853&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consideration&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77,853&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total consideration&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;77,853&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated statements of operations include the results of BioNTech Marburg since the acquisition date. From the date of acquisition, the transition into a GMP certified manufacturing facility for BioNTech&amp;#8217;s COVID-19 vaccine was initiated rapidly. During this time, no revenues have been recognized and set-up, retooling and prepping expenses led to a &amp;#8364;6.7&amp;#160;million operating loss, which contributed to the respective result of the Group. Projecting the revenue and result of the joint company as if the acquisition had occurred at the beginning of the reporting period is impracticable, since BioNTech intends to use the facility for manufacturing its COVID-19 vaccine&lt;font style="color:#000000;"&gt;. Information about revenues and net income generated by BioNTech Marburg before the acquisition were&lt;/font&gt; &lt;font style="color:#000000;"&gt;considered&lt;/font&gt; &lt;font style="color:#000000;"&gt;not to be useful as they are not &lt;/font&gt;representative of the future consolidated results of operations or financial condition on a consolidated basis. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The contracting parties shared the understanding that the manufacturing facility is well-equipped to make an important contribution in BioNTech&amp;#8217;s effort to develop and manufacture a COVID-19 vaccine. The possibility of acquiring a GMP certified manufacturing facility with well-established biotechnology drug substance and drug product manufacturing equipment as well as an experienced team was a very good opportunity for BioNTech to accelerate its efforts to scale-up the commercial manufacturing capacity for its COVID-19 vaccine production. The fact that the offer to sell and the need to acquire the facility overlapped at a convenient time, the underlying opportunities ultimately resulted in a bargain purchase of &amp;#8364;7.0&amp;#160;million which was recognized in other operating income. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Transaction costs of &amp;#8364;1.4&amp;#160;million relating to the acquisition have been expensed and are included in the general and administrative expenses in the consolidated statements of operations and are included in cash flows used in operating activities in the consolidated statements of cash flows.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reconciliation of Goodwill&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amount of goodwill equals the acquisition costs adjusted by currency translation adjustments. The reconciliation of this carrying amount at the beginning and end of the reporting period is presented below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,978&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquisition of subsidiaries and businesses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,469&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,750)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;53,697&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="line-height:5pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</ifrs-full:DisclosureOfBusinessCombinationsExplanatory>
  <ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory id="F_000375" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="margin-top:7pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:7pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="color:#000000;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.1&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Disaggregated revenue information&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Set out below is the disaggregation of the Group&amp;#8217;s revenues from contracts with customers:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research &amp;amp; development revenues from collaborations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;178,849&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;84,428&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;101,837&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Pfizer Inc.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;121,597&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;14,348&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;7,173&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Genentech Inc.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;49,195&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;64,026&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;49,536&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Shanghai Fosun Pharmaceutical (Group) Co., Ltd&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;5,074&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;2,983&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;6,054&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;45,128&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;303,476&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,161&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,738&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;COVID-19 vaccine revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;270,490&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Sales to collaboration partner*&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;61,460&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Direct product sales to BioNTech customers&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;20,553&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Share of collaboration partner&apos;s gross profit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;188,477&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other sales&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,986&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,161&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,738&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;482,325&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;108,589&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;127,575&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*Represents sales to collaboration partner of products manufactured by BioNTech. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December&amp;#160;31, 2020, revenues from contracts with customers mainly increased since revenues were recognized for the first time under two new collaboration agreements, which BioNTech entered into during the year ended December&amp;#160;31, 2020 in order to develop a COVID-19 vaccine, and ultimately led to the recognition of COVID-19 vaccine commercial revenues. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December&amp;#160;31, 2020, revenues&lt;font style="color:#000000;"&gt; recognized from two customers, Pfizer (&amp;#8364;371.5&amp;#160;million) and Genentech (&amp;#8364;49.2&amp;#160;million), &lt;/font&gt;each account for more than 10% of total revenues. During the year ended December 31, 2019 revenues recognized from one customer, &lt;font style="color:#000000;"&gt;Genentech (&amp;#8364;64.0&amp;#160;million), accounted for more than 10% of total revenues. D&lt;/font&gt;uring the year ended December 31, 2018&lt;font style="color:#000000;"&gt; &lt;/font&gt;revenues recognized from two customers, &lt;font style="color:#000000;"&gt;Genentech (&amp;#8364;49.5&amp;#160;million) and Sanofi (&amp;#8364;41.7&amp;#160;million), accounted for more than 10% of total revenue. The geographic region which recognized revenues was mainly Germany (also the Country of BioNTech&amp;#8217;s domicile) and is based upon the location will bills customers. &lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research &amp;amp; Development Revenues from Collaborations&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of its BNT162 vaccine program against COVID-19, BioNTech collaborates with Pfizer and Fosun Pharma. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue from Pfizer was mainly derived from the collaboration and license agreement to develop a COVID-19 vaccine and, in addition, includes an amount of &amp;#8364;3.5&amp;#160;million revenue derived from the existing Influenza collaboration. During the year ended December&amp;#160;31, 2020, a non-refundable upfront cash payment of &amp;#8364;66.3&amp;#160;million was received. A regulatory milestone payment of &amp;#8364;51.8&amp;#160;million became due, but has not yet been received. Both were fully recognized as revenue during the year ended December&amp;#160;31, 2020. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fosun Pharma is the collaboration partner with whom BioNTech works together on the development of a COVID-19 vaccine in China. Through the collaboration agreement BioNTech is conducting clinical trials in China, using BioNTech&amp;#8217;s proprietary mRNA technology and leveraging Fosun Pharma&amp;#8217;s extensive clinical development, regulatory, and commercial capabilities in the country. Fosun Pharma has paid a non-refundable upfront cash payment of &amp;#8364;0.9 million and development milestones of &amp;#8364;4.2&amp;#160;million that were recognized as revenue during year ended December&amp;#160;31, 2020. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other collaboration programs have been progressed during the year ended December&amp;#160;31, 2020 and revenues of &amp;#8364;52.1&lt;font style="color:#000000;"&gt;&amp;#160;&lt;/font&gt;million have been derived from deferred upfront payments measured based on the costs incurred under the respective research programs. For certain collaboration programs, the commencement of trials has been delayed, partially due to slowed patient enrollment or other delays as a result of the COVID-19 pandemic. Accordingly, during the year ended December&amp;#160;31, 2020, revenues from collaboration programs with Genentech and from the Influenza collaboration with Pfizer have generally decreased compared to the prior year periods. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The revenues recorded during the year ended December&amp;#160;31, 2019 mainly included revenues resulting from collaboration and license agreements processed in the research and development phase. The amounts were mainly derived from deferred upfront fees received under the Genentech, Pfizer (Influenza) and Sanofi collaboration. The amounts were recognized as revenue as BioNTech performed under the agreement and measured based on the costs incurred under the respective research programs. Compared to the revenues recognized from collaboration and license agreements during the year ended December 31, 2018, revenues decreased since the revenue recognized in the year ended December&amp;#160;31, 2018 included an amount of &amp;#8364;33.2&amp;#160;million collaboration revenue from the Sanofi collaboration for a reimbursement of 50% of CellScript sublicense costs pursuant to a separate sub-sublicense agreement dated December 22, 2018. This transaction only occurred in the year ended December&amp;#160;31, 2018. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial Revenues&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech&amp;#8217;s COVID-19 vaccine has evolved from the BNT162 program and has been authorized or approved for emergency or temporary use or has been granted conditional marketing authorization in over 65 countries worldwide, which resulted in recognition of revenues from the sale of pharmaceutical products for the first time. BioNTech is the marketing authorization holder in the European Union, and holder of emergency use authorizations or equivalent in the United States, United Kingdom, Canada and other countries in advance of a planned application for full marketing authorizations in these countries. BioNTech has marketing and distribution rights in Germany and Turkey. Pfizer has marketing and distribution rights worldwide with the exception of China, Germany, and Turkey. Fosun Pharma has marketing and distribution rights in China. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The COVID-19 vaccine manufacturing process leverages Pfizer&amp;#8217;s and BioNTech&amp;#8217;s manufacturing facilities, consequently responsibilities are shared between BioNTech and Pfizer. Whenever responsibilities in the manufacturing and supply process of the COVID-19 vaccine shift and the COVID-19 vaccine is transferred, it is sold from one partner to the other. During &lt;font style="color:#000000;"&gt;the year ended December&amp;#160;31, 2020, BioNTech has recognized &amp;#8364;61.5&amp;#160;million of revenues from selling &lt;/font&gt;d&lt;font style="Background-color:#FFFFFF;"&gt;rug product batches manufactured by BioNTech to Pfizer&amp;#8217;s manufacturing site for fill and finish&lt;/font&gt;&lt;font style="color:#000000;"&gt;.&lt;/font&gt; &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon receiving a conditional marketing authorization, emergency or temporary use authorization, BioNTech and Pfizer started selling the product. The allocation of marketing and distribution rights defines territories in which the collaboration partners act as a principal respectively. For supplying BioNTech&amp;#8217;s territory, Germany, BioNTech acquired COVID-19 vaccine from Pfizer and recognized &amp;#8364;20.6&amp;#160;million of revenues from direct COVID-19 vaccine sales during the year ended December&amp;#160;31, 2020. The share of gross profit that Pfizer as collaboration partner has earned based on these sales is recognized as cost of sales. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Based on Pfizer&amp;#8217;s COVID-19 vaccine sales in the collaboration partner&amp;#8217;s territory, BioNTech is eligible to receive a share of the respective gross profit which represents a net figure and is recognized as collaboration revenue during the commercial phase. During the year ended December&amp;#160;31, 2020, a gross profit share of &amp;#8364;188.5&amp;#160;million has been recognized. In order to determine our share of collaboration partner&amp;#8217;s gross profits, BioNTech used certain information from the collaboration partner, including revenue from the sale of products, some of which is based on preliminary data shared between the partners and might vary once final data is available. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December&amp;#160;31, 2020, &amp;#8364;33.0&amp;#160;million of revenues compared to &amp;#8364;24.2&amp;#160;million of revenues during the year ended December&amp;#160;31, 2019, and &amp;#8364;25.7&amp;#160;million during the year ended December 31, 2018 were recognized from other sales transactions based on sales of diagnostic products, peptides, retroviral vectors for clinical supply, and development and manufacturing services that were sold to third-party customers. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The revenues from contracts with customers disclosed above were recognized as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Timing of revenue recognition&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Goods and services transferred at a point in time&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;108,840&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;16,955&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;22,828&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Goods and services transferred over time&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;373,485&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,634&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104,747&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;482,325&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;108,589&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;127,575&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December&amp;#160;31, 2019, BioNTech recognized revenue of &amp;#8364;1.1&amp;#160;million under a bill-and-hold transaction for which the customer already had obtained control. The bill-and-hold arrangement is substantive since the request to retain the product in BioNTech&amp;#8217;s facilities until January 2020 was initiated by the customer. &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Contract Balances&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trade receivables&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;165,468&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;11,913&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;371,475&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;190,692&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trade receivables are non-interest bearing and are generally settled within 20 to 30 days.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract assets are recognized for revenue earned from sales and services based on individual customer contracts of BioNTech Innovative Manufacturing Services GmbH. However, the customers&amp;#8217; advance payments exceeded BioNTech&amp;#8217;s transferred goods and services for which a conditional right to consideration exists. Therefore, only contract liabilities net of contract assets are presented as of December&amp;#160;31, 2020 and December&amp;#160;31, 2019, respectively. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract liabilities mainly include upfront fees received from BioNTech&amp;#8217;s major collaboration and license agreements as well as advance payments received for future COVID-19 vaccine sales and other sales. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The contract liabilities from collaboration and commercial supply agreements as &lt;font style="color:#000000;"&gt;o&lt;/font&gt;f December&amp;#160;31, 2020 comprise &amp;#8364;131.8&amp;#160;million remaining upfront fees from collaboration agreements, &lt;font style="color:#000000;"&gt;&amp;#8364;235.8&lt;/font&gt;&amp;#160;million of advance payments for future COVID-19 vaccine sales, which had been received during the year ended December&amp;#160;31, 2020 or for which an unconditional right of consideration exists as well as &amp;#8364;3.9&amp;#160;million advance payments received on other sales (as of December&amp;#160;31, 2019: &amp;#8364;187.6&amp;#160;million of remaining upfront fees from collaborations as well as &amp;#8364;3.1&amp;#160;million advance payments received on other sales). &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December&amp;#160;31, 2020, the increase from payments received exceeded revenues recognized from contract liabilities recorded at the beginning of the year (during the year ended December&amp;#160;31, 2019: decrease in contract liabilities since recognizing revenues from amounts which had been included in contract liabilities at the beginning of the year exceeded advance payments on other sales received). &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Set out below is the amount of revenue recognized &lt;font style="color:#000000;"&gt;for the periods &lt;/font&gt;indicated:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts included in contract liabilities at the beginning of the year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;58,895&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;84,112&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;59,583&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.3&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Performance Obligations&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The contract liabilities allocated to the remaining performance obligations from collaboration or commercial supply agreements (unsatisfied or partially unsatisfied) as at year-end are as follows: &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Within one year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;299,583&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;93,583&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;More than one year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71,892&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;97,109&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;371,475&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;190,692&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory>
  <bntx:DisclosureOfIncomeAndExpensesExplanatory id="F_000376" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="color:#000000;"&gt;Income and Expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.1&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Costs of Sales&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.93%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of sales related to COVID-19 vaccine revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;35,616&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost related to other sales&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,717&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,361&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,690&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;59,333&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;17,361&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;13,690&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December&amp;#160;31, 2020, cost of sales mainly increased compared to the year ended December&amp;#160;31, 2019 since costs were &lt;font style="color:#000000;"&gt;recognized&lt;/font&gt; for the first time with respect to BioNTech&amp;#8217;s COVID-19 vaccine sales and included Pfizer&amp;#8217;s share of gross profits earned by BioNTech in transactions, where BioNTech is the principal. Costs of sales do not include costs relating to production of pre-launch products since those are expensed as research and development expenses in the period incurred. &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Research and Development Expenses&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchased services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;359,880&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;65,552&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;42,079&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Wages, benefits and social security expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;126,298&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;83,213&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,668&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory supplies&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;107,792&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,218&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,921&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,192&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,533&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,312&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;IT costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,118&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,572&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease and lease related cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,725&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,527&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,404&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Transport costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,135&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,081&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;668&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,889&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,542&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,416&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;645,029&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;226,466&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;143,040&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December&amp;#160;31, 2020, r&lt;font style="color:#000000;"&gt;esearch and development expenses increased compared to the year ended December&amp;#160;31, 2019 due to an increase in research and development expenses from BioNTech&amp;#8217;s BNT162 program. Research and development expenses include BioNTech&amp;#8217;s share of expenses under the terms of the Pfizer collaboration agreement. Development costs, which are shared, are divided equally between BioNTech and Pfizer. The amount of shared development expenses, which were initially incurred by Pfizer and subsequently charged to BioNTech, were recorded as purchased services classified within research and development and the reimbursement from Pfizer for research and development expenses initially incurred by BioNTech were recorded as a reduction to research and development expenses. The increase was further driven by an increase in expenses for purchased laboratory supplies as well as an increase in headcount leading to higher wages, benefits and social security expenses. In addition, from May 6, 2020, the date of acquisition, the new U.S.-based subsidiary, BioNTech US Inc., contributed &amp;#8364;21.0&amp;#160;million to the research and development expenses of the Group&lt;/font&gt;. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December&amp;#160;31, 2019, research and development costs increased compared to the year ended December&amp;#160;31, 2018 based on an increase in wages, benefits and social security expenses due to an increase in headcount and the full-year reflection of the Employee Stock Ownership Plan (&amp;#8220;ESOP&amp;#8221;) expenses during the year ended December&amp;#160;31, 2019 as well as higher development expenses spent on purchased services and laboratory supplies. &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.3&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Sales and Marketing Expenses&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchased services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;10,929&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;247&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;794&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Wages, benefits and social security expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,636&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,938&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,728&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,947&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;533&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;519&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;14,512&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,718&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;3,041&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December&amp;#160;31, 2020, sales and marketing expenses increased compared to the year ended December&amp;#160;31, 2019 due to an increase in purchased service, which we incurred in connection with progressing the commercial activities of the Group with respect to BioNTech&amp;#8217;s COVID-19 vaccine. &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.4&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;General and Administrative Expenses&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Wages, benefits and social security expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;33,007&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;19,122&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;8,582&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchased services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,419&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,177&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;IT and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,404&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,573&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,774&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,104&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,855&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,284&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Insurance premiums&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,840&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,061&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;145&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Job advertisement expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,897&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;548&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;861&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease and lease related cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,390&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,715&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,012&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,033&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;232&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory supplies&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,191&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;785&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;456&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract staffing&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,108&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;686&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;781&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,053&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,551&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,236&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;94,049&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;45,547&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;26,334&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December&amp;#160;31, 2020, general and administrative &lt;font style="color:#000000;"&gt;expenses increased compared to the year ended December&amp;#160;31, 2019 due to higher expenses for purchased management consulting and legal services, an increase in headcount leading to higher wages, benefits and social security expenses and higher insurance premiums. In addition, from May 6, 2020, the date of acquisition, the new U.S.-based subsidiary, BioNTech US Inc., contributed &amp;#8364;7.4&amp;#160;million to the general and administrative expenses of the Group, respectively&lt;/font&gt;. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December&amp;#160;31, 2019, &lt;font style="color:#000000;"&gt;general and administrative &lt;/font&gt;expenses increased compared to the year ended December&amp;#160;31, 2018 based on an increase in headcount and the full-year reflection of the ESOP program expenses during the year ended December&amp;#160;31, 2019 as well as a charge of &amp;#8364;2.6 million in connection with certain withholding tax payments for intellectual property licenses related to prior years that was recorded during the year ended December&amp;#160;31, 2019 but not during the year ended December&amp;#160;31, 2018. &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.5&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Other Operating Income&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government grants&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;239,017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,547&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;4,228&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Bargain purchase&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,002&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,520&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,177&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,118&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;250,539&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,724&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;5,396&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December&amp;#160;31, 2020, the other income increased compared to the year ended December&amp;#160;31, 2019. The increase mainly results from government grants for which BioNTech became eligible as part of an initiative by the German Federal Ministry of Education (&lt;font style="font-style:italic;"&gt;Bundesministerium f&amp;#252;r Bildung und Forschung&lt;/font&gt;, or the BMBF) to support its COVID-19 vaccine program, BNT162. The BMBF funding was granted to accelerate BioNTech&amp;#8217;s vaccine development, and to upscale its manufacturing capabilities in Germany. The funding will also compensate further costs that incur since the COVID-19 vaccine continues to be tested in clinical trials, for example to test it against new variants or to approve it for additional groups (pregnant women, individuals less 16 years), and because study participants will continue to be followed for two years to continue evaluating safety and efficacy. The proportion of the grant that related to expenses incurred by BioNTech is recognized as other operating income with an amount of &amp;#8364;238.9 million; the proportion which was received and will compensate BioNTech for future expenses, has been deferred and is presented as government grant in the consolidated statements of financial position with an amount of &amp;#8364;88.0 million. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table illustrates the changes regarding the government grants:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Received during the year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;330,968&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,547&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,228&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Released to the consolidated statements of operations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(239,017)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,547)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,228)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;91,951&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,951&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total non-current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.6&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Finance Income&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.78%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,564&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,781&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,996&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign exchange gains, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,341&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,050&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,564&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;4,122&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;8,046&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December&amp;#160;31, 2019, finance income included &amp;#8364;2.3&amp;#160;million foreign exchange gains. Foreign exchange differences on a cumulative basis, are either shown as finance income or expenses.&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.7&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Finance Expense&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.78%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization of financial instruments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;3,048&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;326&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;48&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value adjustments of financial instruments measured at fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,289&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign exchange loss, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,609&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;62,946&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;326&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;48&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December&amp;#160;31, 2020, finance expenses included &amp;#8364;42.6&amp;#160;million foreign exchange losses as well as &amp;#8364;17.3&amp;#160;million in expenses arising from fair value measurement adjustments of the derivative embedded within the convertible note. The increase in foreign exchange losses is mainly due to higher &lt;font style="color:#000000;"&gt;balances in&lt;/font&gt; U.S. dollar bank accounts&lt;font style="color:#000000;"&gt; and the weakening of the U.S. dollar when compared to the Euro&lt;/font&gt;. &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Employee Benefits Expense&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Wages and salaries&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;160,655&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;98,568&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;54,149&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Social security costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,988&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,394&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,231&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pension costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;761&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;517&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;324&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;179,404&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;111,479&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;62,704&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The item wages and salaries includes, among other things, expenses for share-based payments.&lt;/p&gt;</bntx:DisclosureOfIncomeAndExpensesExplanatory>
  <ifrs-full:DisclosureOfIncomeTaxExplanatory id="F_000377" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="color:#000000;"&gt;Income Tax&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax for the years ended December&amp;#160;31, 2020, December&amp;#160;31, 2019 and December&amp;#160;31, 2018 comprised current income taxes, other taxes and deferred taxes. BioNTech SE is subject to corporate taxes, the solidarity surcharge and trade taxes. The Company&amp;#8217;s corporate tax rate in the reporting year remained unchanged (15.0%) as did the solidarity surcharge (5.5%) whereas the average trade tax rate (15.0%) changed. BioNTech USA Holding, LLC is subject to Federal Corporate Income Tax (21.0%) as well as State Income Tax in various state jurisdictions (average rate of 8.1%). &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table illustrates the current and deferred taxes for the periods indicated: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C5E0B3" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;17&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(296)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;600&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C5E0B3" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(161,034)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(161,000)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(268)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;600&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table reconciles the expected income taxes to the actual current income taxes and deferred taxes as presented in the table above. The combined income tax rate of 30.79% in the year ended December&amp;#160;31, 2020 (during the years ended December 31, 2019 and 2018: 30.78% and 30.99%, respectively) was applied to loss before taxes to calculate the expected income taxes. This rate consists of above outlined tax rates of BioNTech SE applicable to the Group. The slight decrease of the tax rate results from the Lipocalyx GmbH business combination. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss before tax&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(145,802)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(179,440)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(47,662)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected tax benefit (based on BioNTech`s statutory tax rate of 30.79%, 2019: 30.78%, 2018: 30.99%)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,891&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,240&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,776&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Effects&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government grants exempted from taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-deductible expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(770)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(58)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Add-back for trade tax purposes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(595)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(110)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(96)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-tax effective bargain purchase&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,156&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-recognition of tax effect on share-based payment expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,806)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,308)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax-effective equity transaction costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,229&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,121&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Utilization of tax losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,165&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-recognition of deferred taxes on tax losses and temporary differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12,961)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(51,197)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,634)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognition of deferred taxes on tax losses not recognized in prior periods&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,231&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognition of deferred taxes on temporary differences not recognized in prior periods&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,241&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;192&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effect from lower foreign income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,304)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(102)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustment prior year tax&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(326)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;316&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,059&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other effects&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(59)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;126&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,821)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;161,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;268&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(600)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Taxes&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred taxes for the periods indicated relate to the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognized in P&amp;amp;L*&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognized in OCI&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquisition of subsidiaries and businesses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(655)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(2,370)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;8,637&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;5,612&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;596&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;329&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;971&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;512&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,091)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,593)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,543&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(174)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,369&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest-bearing loans and borrowings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,741)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;195&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,546)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net employee defined benefit liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;169&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(63)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;698&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;804&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provisions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;187&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;886&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;419&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,492&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other (incl. deferred expenses)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,087&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,336&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;202&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,625&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax loss carryforward / tax credit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;109,764&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,660&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,280&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;175,704&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Tax Assets Net (before valuation)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;136,034&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;40,721&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(63)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;34,746&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;211,438&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation Adjustment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(136,034)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;120,313&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(34,765)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(50,486)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Tax Assets Net (after valuation)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;161,034&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(63)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(19)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;160,952&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*Includes all changes in deferred taxes related to U.S. tax group other than those acquired in business combination&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognized in P&amp;amp;L&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognized in OCI&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquisition of subsidiaries and businesses &lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(90)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(565)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(655)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;596&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;596&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;306&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;206&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;512&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,441&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,898)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;23,543&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provisions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;134&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;187&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other (incl. deferred expenses)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;161&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,926&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,087&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax loss carryforward / tax credit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,848&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,916&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;109,764&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Tax Assets Net (before valuation)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;84,799&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;51,235&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;136,034&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation Adjustment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(84,799)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(51,235)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(136,034)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Tax Assets Net (after valuation)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated tax losses of the German tax group, German &lt;font style="color:#000000;"&gt;entities&lt;/font&gt; &lt;font style="color:#000000;"&gt;not within the tax group &lt;/font&gt;and U.S. tax group for the periods indicated amount to the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate Tax&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;596,359&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;356,044&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;179,264&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trade Tax&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;513,561&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;352,341&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;176,425&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal Tax Credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;756&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State Tax Credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accumulated tax losses related to the German tax group include &amp;#8364;457.9 million of corporate income tax losses and &amp;#8364;450.9&amp;#160;million of trade tax losses. &lt;font style="color:#000000;"&gt;Under German law, tax losses do not expire. &lt;/font&gt;Deferred tax assets on tax losses had not been capitalized in previous years, as there was not sufficient probability in terms of IAS 12 that there would have been future taxable profits available against which the unused tax losses could have been utilized. &lt;font style="color:#000000;"&gt;Following the authorization and approval of the COVID-19 vaccine for emergency or temporary use or having been granted conditional marketing authorization in over 65 countries worldwide, BioNTech re-evaluated previously unrecognized tax losses. Based on BioNTech&amp;#8217;s product-based business plan, including commercial supply commitments agreed with various governments and health ministries under which BioNTech either directly supplies the COVID-19 vaccine or, if they relate to territories which have been allocated to Pfizer, BioNTech will receive the profit share to which it is eligible, it is now considered highly probable that taxable profits for the German tax group will be available against which the tax losses can be utilized. On this basis, BioNTech recognized deferred tax assets and liabilities with a net amount of &amp;#8364;161.0&amp;#160;million for the losses and temporary differences determined for the German tax group as of December&amp;#160;31, 2020. &lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accumulated tax losses related to German entities not within the tax group include &amp;#8364;1.7 million of corporate income tax losses and &amp;#8364;1.8&amp;#160;million of trade tax losses. With respect to those tax losses, no deferred tax assets have been capitalized, as there is not sufficient probability in terms of IAS 12 that there will be future taxable profits available against which the unused tax losses can be utilized.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accumulated tax losses related to U.S. tax group include &amp;#8364;136.8&amp;#160;million of corporate income tax losses and &amp;#8364;60.9&amp;#160;million of trade tax losses. The tax losses related to the U.S. tax group include &amp;#8364;20.9&amp;#160;million of federal losses that are expected to expire in 2033 and &amp;#8364;115.9&amp;#160;million of federal losses which have no expiration date and can be carried forward indefinitely. In addition, the U.S. tax group has state tax losses of &amp;#8364;60.9&amp;#160;million, which may be available to offset future taxable profit and that expire at various dates beginning in 2033. BioNTech&amp;#8217;s forecast for the U.S. tax group does not provide sufficient probability for the use of existing tax loss carryforwards in the near future. Therefore, the requirements set out by IAS 12 are not fulfilled for the U.S. tax group. As of December&amp;#160;31, 2020, deferred tax assets are only recognized up to the amount of deferred tax liabilities. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition to accumulated tax losses, BioNTech had accumulated federal tax credits of &amp;#8364;0.8&amp;#160;million and state tax credits of &amp;#8364;0.3&amp;#160;million in the United States as of December 31, 2020. The tax credits in the United States will expire at various dates beginning in 2035 if they are not used.&lt;/p&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
  <ifrs-full:DisclosureOfEarningsPerShareExplanatory id="F_000378" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="color:#000000;"&gt;Earnings per Share&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic earnings per share (EPS) is calculated by &lt;font style="color:#000000;"&gt;dividing&lt;/font&gt; the profit / (loss) for the year attributable to ordinary equity holders of the parent by the weighted average number of ordinary shares outstanding during the year.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Diluted EPS is calculated by dividing the profit / (loss) attributable to ordinary equity holders of the parent by the weighted average number of ordinary shares outstanding during the year plus the weighted average number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 18, 2019, BioNTech effected a 1:18 share split by issuing 206,595,492 shares by way of a capital increase from its own funds; thus, no outside proceeds were received. This capital increase came into effect upon registration with the commercial register (&lt;font style="font-style:italic;"&gt;Handelsregister&lt;/font&gt;). The accompanying financial statements and notes to the financial statements including the EPS information below give retroactive effect to the share split for all periods presented.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table reflects the income and share data used in the basic and diluted EPS calculations:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gain (loss) attributable to ordinary equity holders of the parent for basic earnings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;15,198&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(179,056)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(48,019)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of ordinary shares for basic EPS&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;235,442&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;211,499&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;190,710&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effects of dilution from share options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C5E0B3" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,085&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of ordinary shares adjusted for the effect of dilution&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;248,527&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;211,499&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;190,710&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Earnings per share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;in EUR&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted, profit / (loss) for the period attributable to ordinary equity holders of the parent*&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;0.06&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(0.85)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(0.25)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;* Numbers of shares for calculating the earnings per share for the years ended December 31, 2019 and December 31, 2018 have been adjusted to reflect capital increase due to 1:18 share split, which occurred on September 18, 2019.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There have been no other transactions involving ordinary shares or potential ordinary shares between the reporting date and the date of authorization of these financial statements. Share options were not included in the calculation of diluted EPS for periods in which they were antidilutive; i.e. for the periods in which a loss was incurred. &lt;/p&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
  <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory id="F_000379" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="color:#000000;"&gt;Property, Plant and Equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Land and buildings&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equipment, tools and installations&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress and advance payments&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquisition and production costs&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;22,147&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;73,613&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;7,091&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;102,853&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,269&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,700&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,623&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,592&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(105)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(115)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassifications&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(53)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquisition of subsidiaries and businesses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;999&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;999&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;29,469&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;83,206&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;29,652&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;142,329&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;29,469&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;83,206&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;29,652&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;142,329&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,927&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,093&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,033&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,892)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(958)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,891)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassifications&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,561&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,832&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,391)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(52)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(638)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(690)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquisition of subsidiaries and businesses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,400&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,817&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,302&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,519&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;61,264&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;142,418&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;81,618&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;285,300&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Land and buildings&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equipment, tools and installations&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress and advance payments&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cumulative depreciation and impairment charges&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;6,472&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;30,180&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;36,652&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,854&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,861&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,715&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(79)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(79)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassifications&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;8,326&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;40,959&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;49,285&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;8,326&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;40,959&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;49,285&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,074&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,753&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,827&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,683)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,724)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassifications&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(53)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(56)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;10,356&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;47,976&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;58,332&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Land and buildings&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equipment, tools and installations&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress and advance payments&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Carrying amount&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;15,675&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;43,433&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;7,091&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;66,200&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;21,143&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;42,247&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;29,652&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;93,044&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;50,908&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;94,442&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;81,618&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;226,968&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
  <ifrs-full:DisclosureOfIntangibleAssetsExplanatory id="F_000380" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;11&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="color:#000000;"&gt;Intangible Assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concessions, licenses, in-process R&amp;amp;D and similar rights&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Advance payments&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquisition costs&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;534&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;101,853&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,497&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;103,883&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,744&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,529&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,273&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(133)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(477)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(610)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassifications&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;146&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(146)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquisition of subsidiaries and businesses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,444&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,726&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,170&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,978&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;116,313&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,403&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;121,693&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,978&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;116,313&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,403&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;121,693&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,187&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,426&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,613&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,435)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(643)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,078)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassifications&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;233&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(233)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,750)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,897)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,647)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquisition of subsidiaries and businesses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,469&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,845&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;93,314&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;53,697&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;147,246&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;5,953&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;206,895&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concessions, licenses, in-process R&amp;amp;D and similar rights&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Advance payments&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cumulative depreciation and impairment charges&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;15,842&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;15,842&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,502&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,502&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(81)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(81)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassifications&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;32,260&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;32,260&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;32,260&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;32,260&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,627&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,627&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,410)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,410)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassifications&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(72)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(72)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;43,405&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;43,405&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concessions, licenses, in-process R&amp;amp;D and similar rights&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Advance payments&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Carrying amount&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;534&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;86,011&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,497&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;88,042&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,978&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;84,053&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,403&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;89,434&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;53,697&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;103,841&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;5,953&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;163,490&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill and intangible assets with indefinite useful lives&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For impairment testing, goodwill acquired through business combinations has been allocated to the cash-generating units (CGU) as shown in the following table: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.72%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;CGU Immunotherapies&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.72%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;External Product Sales of JPT&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.12%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;53,163&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,444&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;534&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;534&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;53,697&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,978&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group performs its annual goodwill impairment test for the respective year as of October 1. As a result of the change to one reportable segment (Note 2.1), BioNTech evaluated the implications on its determination of CGUs for allocation of goodwill. As a result, two CGUs were identified: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;The Immunotheraopies CGU focuses on the development of therapies to address a range of rare and infectious diseases and includes BioNTech&amp;#8217;s broad pipeline includes mRNA-based immune activators, antigen-targeting T-cells and antibodies, and defined immunomodulators of various immune cell mechanisms. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;The External Products Sales of JPT Peptide Technologies GmbH CGU includes the distribution of innovative peptide-based products to external customers.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;CGU Immunotherapies&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The recoverable amount of the CGU Immunotherapies has been determined based on a value in use calculation using cash flow projections from financial budgets approved by the Management Board covering a fifteen-year period. The projected cash flows have been updated to reflect the near-term effect from&lt;font style="color:#000000;"&gt; BioNTech&amp;#8217;s COVID-19 vaccine. &lt;/font&gt;The discount rate applied to cash flow projections is 8.9% and cash flows beyond the forecast period are extrapolated using a 1.0% growth rate that is the same as the long-term average growth rate for the biotech industry. It was concluded that the fair value less costs of disposal did not exceed the value in use. As a result of the analysis, management did not identify an impairment for this CGU.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;CGU External Product Sales of JPT Peptide Technologies GmbH&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The recoverable amount of the CGU External Product Sales of JPT Peptide Technologies GmbH has been determined based on a value in use calculation using cash flow projections from financial budgets approved by senior management covering a ten-year period. The discount rate applied to cash flow projections is 7.9% and cash flows beyond the forecast period are extrapolated using a 1.0% growth rate which is in line with industry standard. It was concluded that the fair value less costs of disposal did not exceed the value in use. As a result of the analysis, management did not identify an impairment for this CGU.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Key assumptions used in value in use calculations and sensitivity to changes in assumptions&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The calculation of value in use for both CGUs, Immunotherapies and External Product Sales of JPT Peptide Technologies GmbH, is most sensitive to the following assumptions:&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.14%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;Discount rates&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.14%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;Growth rates used to extrapolate cash flows beyond the forecast period&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Discount rates &amp;#8722; Discount rates represent the current market assessment of the risks specific to the CGU, taking into consideration the time value of money and individual risks of the underlying assets that have not been incorporated in the cash flow estimates. The discount rate calculation is based on the specific circumstances of the Group and the respective CGU. It is derived from its weighted average cost of capital (WACC). The WACC takes into account both debt and equity. The cost of equity is derived from the expected return on investment by the Group&amp;#8217;s investors. The cost of debt is based on the interest-bearing borrowings the Group is obliged to service. CGU-specific risk is incorporated by applying individual beta factors. The beta factors are evaluated annually based on publicly available market data. Adjustments to the discount rate are made to factor in the specific amount and timing of the future tax flows in order to reflect a pre-tax discount rate.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;An increase in the discount rate to 9.4% (i.e., +1.5%point) in the CGU External Product Sales of JPT Peptide Technologies GmbH would result in a goodwill impairment as of October 1, 2020. With respect to the CGU Immunotherapies, no reasonable rise in the discount rate would result in an impairment.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Growth rate estimates &amp;#8722; Rates are based on published industry research. Management recognizes that the speed of technological change and the possibility of new entrants (further market approvals) can have a significant impact on growth rate assumptions. The effect of new entrants is not expected to have an adverse impact on the forecasts, but could yield a reasonably possible alternative to the estimated long-term growth rate of 1.0%.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;With respect to both CGUs, no reasonable reduction in the growth rate estimate would result in an impairment. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In general, BioNTech concluded that no reasonable possible change of key assumptions on which the calculation of the recoverable amount is based would cause the carrying amount of the CGU to exceed its recoverable amount.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible Assets not yet Available for Use&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets not yet available for use did not exist in the years ended December&amp;#160;31, 2020 and December&amp;#160;31, 2019.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-Current assets by Region&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020 and December&amp;#160;31, 2019, non-current assets comprised &amp;#8364;89.2&amp;#160;million respectively &amp;#8364;3.8&amp;#160;million intangible assets, property, plant and equipment, right-of-use assets and other assets of our subsidiaries incorporated in the United States respectively. The remaining non-current assets relate to subsidiaries incorporated in Germany.&amp;nbsp;&amp;nbsp;&lt;/p&gt;</ifrs-full:DisclosureOfIntangibleAssetsExplanatory>
  <ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory id="F_000381" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;12&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="color:#000000;"&gt;Financial Assets and Financial Liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.1&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Capital Risk Management&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech&amp;#8217;s capital management objectives are designed primarily to finance the Group&amp;#8217;s growth strategy.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group&amp;#8217;s controlling committee reviews the total amount of cash of the Group on a weekly basis. As part of this review, the committee considers the total cash and cash equivalents, the cash outflow, currency translation differences and refinancing activities. The Group monitors cash using a burn rate. The cash burn rate is defined as the average monthly net cash flow from operating and investing activities during a financial year.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents at banks and on hand&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,210,209&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;519,149&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,210,209&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;519,149&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In meeting its financing objectives, the Group negotiates and enters into research cooperation agreements. In general, the aim is to maximize the financial resources available for further research and development projects.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech is not subject to externally imposed capital requirements. BioNTech&amp;#8217;s capital management objectives were achieved in the reporting year.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;No changes were made in the objectives, policies or processes for managing cash during the years ended December&amp;#160;31, 2020 and December&amp;#160;31, 2019. &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Categories of Financial Instruments&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets at amortized cost&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Set out below, is an overview of financial assets, other than cash and cash equivalents, held by the Group as of the dates indicated: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td colspan="4" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets at amortized cost&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trade receivables&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;165,468&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;11,913&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;137,234&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,680&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;302,702&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;13,593&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;302,702&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,593&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total non-current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, other financial assets mainly include advance-payments received by BioNTech&amp;#8217;s collaboration partner on future deliveries and payable to BioNTech. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial liabilities: Financial liabilities at amortized cost (including Interest-bearing loans and borrowings and other financial liabilities)&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Set out below, is an overview of financial liabilities, other financial liabilities and trade payables held by the Group as of the dates indicated: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td colspan="4" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest-bearing loans and borrowings&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturity&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;84,158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;57,611&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible note - host contract&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;08/28/2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;87,457&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.50% &amp;#8364; 50,000,000 secured bank loan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12/21/2026&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,176&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.15% &amp;#8364; 10,000,000 secured bank loan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12/30/2027&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,032&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,000&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.08% &amp;#8364; 9,450,000 secured bank loan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;09/30/2028&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,877&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,600&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.90% &amp;#8364; 3,528,892.48 secured bank loan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;05/30/2039&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,489&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;240,189&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;74,211&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,142&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,307&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total non-current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;231,047&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68,904&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td colspan="4" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other financial liabilities&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivatives not designated as hedging instrument&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible note - embedded derivative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;30,903&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial liabilities at fair value through profit or loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;572&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial liabilities at fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;31,475&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other financial liabilities at amortized cost, other than interest-bearing loans and borrowings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trade payables&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,288&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,498&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other financial liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74,076&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,352&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total other financial liabilities at amortized cost, other than interest-bearing loans and borrowings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;176,364&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;30,850&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total other financial liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;207,839&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;30,850&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;176,363&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,850&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total non-current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,476&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td colspan="4" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial liabilities&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest-bearing loans and borrowings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;240,189&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;74,211&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other financial liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;207,839&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;30,850&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;448,028&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;105,061&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;185,505&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,157&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total non-current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;262,523&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68,904&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest-Bearing Loans and Borrowings&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;2.15% and 2.08% Secured Bank Loan&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech maintains two secured loans with Deutsche Bank AG, or Deutsche Bank, to finance the buildouts of the JPT Peptide Technologies GmbH facility and BioNTech Innovative Manufacturing Services GmbH facility. The &amp;#8364;10.0&amp;#160;million secured credit facility, entered into with Deutsche Bank by the subsidiary BioNTech Innovative Manufacturing Services GmbH, bears interest at a rate of 2.15% and matures on December 30, 2027. The loan is repayable in equal quarterly installments of &amp;#8364;0.3&amp;#160;million commencing on June 30, 2020. As of December 31, 2020, the full amount under this facility is drawn down and the first three scheduled repayments have occurred. The &amp;#8364;9.45&amp;#160;million secured credit facility, entered into with Deutsche Bank by the subsidiary JPT Peptide Technologies GmbH, bears interest at a rate of 2.08% and matures on September 30, 2028. The loan is repayable by quarterly installments of &amp;#8364;0.3&amp;#160;million commencing on September 30, 2020. As of December 31, 2020, the full amount under this facility is drawn down and the first two scheduled repayments have occurred. Each of these facilities is secured by liens over property. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;EIB Manufacturing Financing &amp;#8211; 3.50% Secured Bank Loan&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2020, BioNTech entered into an agreement with the EIB for a &amp;#8364;100.0&amp;#160;million credit facility to partially support the development of BNT162 and fund expansion of the manufacturing capacity to provide worldwide supply of BNT162 in response to the COVID-19 pandemic. The credit consists of (i) a term loan in the amount of &amp;#8364;50 million that may be drawn in a single tranche upon the achievement of certain milestone events (Credit A), and (ii) a term loan in the amount of &amp;#8364;50.0&amp;#160;million that may be drawn in a single tranche (Credit B). Credit B may only be drawn down after Credit A has been drawn down and upon the achievement of certain milestone events. The financing arrangement is to be secured by way of liens over certain of our property. On December 21, 2020, &amp;#8364;50.0&amp;#160;million from Credit A was drawn down. Interest is payable on the outstanding balance of Credit A at the cash interest fixed rate of 1% per annum quarterly in arrears, plus deferred interest at fixed rate of 2.5% per annum. The nominal amount must be repaid on December 21, 2026. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;June 2020 Private Placement &amp;#8211; Convertible Note&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A fund associated with Temasek Capital Management Pte. Ltd., or Temasek, and another accredited investor, contributed a private investment which closed as of August 28, 2020 following the satisfaction of customary closing conditions. The private placement includes an investment in ordinary shares (see Note 16) and a &amp;#8364;100.0&amp;#160;million investment in a 4-year mandatory convertible note with a coupon of 4.5% per annum and a conversion premium of 20% above its reference price. As of closing, the convertible note has been classified as a financial liability according to IAS 32 because the conversion features of the note lead to a conversion into a variable number of shares and is measured at amortized costs since the fair value option was not applied. On initial recognition, the financial liability was measured at the present value of the contractually determined future cash flows discounted at the effective interest rate of 9.0%. The financial liability is subsequently measured at amortized cost by using the effective interest rate method until extinguished upon conversion. The conversion features provided for in the contract were identified as a combined embedded derivative since they share the same risk exposure and are interdependent. The embedded derivative was bifurcated from the convertible note, as host contract, and is recognized as a separate financial instrument. Based on the classification as derivative, the instrument is measured at fair value through profit and loss until it is extinguished upon conversion. The fair value of the embedded derivative is determined by modeling the stock price movement using the Cox-Rubinstein binomial tree model to derive the value of the conversion right. The primary inputs used in the model include stock price volatility, credit spreads, risk-free interest rate and foreign exchange forward rates. Stock price volatility is based on implied volatility for BioNTech, credit risk is model implied and adjusted for movement in credit spreads for B-rated corporates at each valuation date, the risk-free interest rate is based on currency specific time congruent IBOR and swap rates whereas the foreign exchange forward rates are based on observable market data.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other Financial Liabilities at Amortized Cost&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other financial liabilities at amortized cost mainly include provision for outstanding services and obligations derived from license agreements as well as CRO and CMO contracts. &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.3&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Fair Values&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair values of cash and cash equivalents, trade receivables, trade payables and other current financial assets and liabilities approximate their carrying amounts as of December&amp;#160;31, 2020, largely due to the short-term maturities of these instruments.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The liabilities measured at amortized cost include four fixed-interest rate loans as well as a recently issued convertible note. As of December&amp;#160;31, 2020, the carrying value approximates their fair values as there have been no significant changes in relevant interest rates since the inception of the respective loans and note. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair values of financial instruments measured at fair value are reassessed on a quarterly basis. The valuation technique used for measuring the fair value of the embedded derivative is based on significant observable inputs (Level 2).&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December&amp;#160;31, 2020, the fair value adjustment derived from remeasuring the embedded derivative was recognized as finance expenses in profit or loss and amounted to &amp;#8364;17.3&amp;#160;million. The initial fair value of the contingent consideration determined at acquisition remains valid since no changes of the underlying performance criteria have occurred.&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.4&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Financial Instruments Risk Management Objectives and Policies&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group&amp;#8217;s financial liabilities comprise of bank loans, lease liabilities, trade and other payables as well as the recently issued convertible note. The main purpose of these financial liabilities is to enable the Group&amp;#8217;s operations. The Group&amp;#8217;s principal financial assets include mainly cash and trade receivables that derive directly from its operations.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group is exposed to market risk, credit risk and liquidity risk. The Group&amp;#8217;s Management Board oversees the management of these risks. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The controlling committee provides assurance to the Group&amp;#8217;s Management Board that the Group&amp;#8217;s financial risk activities are governed by appropriate policies and procedures and that financial risks are identified, measured and managed in accordance with the Group&amp;#8217;s policies and risk objectives. The Management Board reviews and agrees policies for managing each of these risks, which are summarized below.&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.5&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Market Risk&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate due to changes in market prices. Market risk comprises of three types of risk: interest risk, foreign currency risk and other price risk. Financial instruments affected by market risk include cash and cash equivalents. Interest risk as well as other price risk are not considered as risks for the Group.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The sensitivity analysis in the following sections relate to the position as of December&amp;#160;31, 2020 and December&amp;#160;31, 2019.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There were no material changes in the Group&amp;#8217;s market risk exposures or changes in the way risk was managed and valued during the periods.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign Currency Risk&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The Group&amp;#8217;s exposure to the risk of changes in foreign currency rates relates primarily to the Group&amp;#8217;s operating activities (when revenue or expense is denominated in a foreign currency).&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In order to reduce exchange rate risk, BioNTech makes every effort to generate expenses and income in the same functional currency. The Group does not hedge exchange rate risks.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amount of the monetary assets (the Group&amp;#8217;s cash and cash equivalents) of BioNTech denominated in foreign currencies at the dates indicated are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.82%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.82%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. dollar Bank accounts&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;673,545&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;213,913&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other financial assets in U.S. dollar&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,573&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.82%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial liabilities in U.S. dollar&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,821&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;686,297&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;213,913&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables demonstrate the sensitivity to a reasonably possible change in U.S. dollar exchange rates, with all other variables held constant. The impact on the Group&amp;#8217;s profit before tax is due to changes in the fair value of monetary assets. The Group&amp;#8217;s exposure to foreign currency changes for all other currencies is not material.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;1 &amp;#8364; =&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.08%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Closing rate&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.08%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average rate&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Country&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. dollar&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.2271&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.1234&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.1422&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.1195&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in U.S. dollar rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effect on loss before tax&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effect on pre-tax equity&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;+5 %&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(32,491)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(32,681)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-5%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;35,911&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;36,121&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-right:solid 1pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-left:solid 1pt #70AD47; border-right:solid 1pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;+5 %&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-left:solid 1pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-right:solid 1pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(10,186)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-left:solid 1pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(10,186)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-5%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;11,259&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;11,259&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.6&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Credit Risk Management&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Credit risk is the risk that a counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The Group is exposed to credit risk from its operating activities, including deposits with banks and financial institutions, foreign exchange transactions and trade accounts receivable.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trade Receivables and Contract Assets&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group&amp;#8217;s exposure to credit risk of trade receivables and contract assets is primarily on transactions with corporate customers in the biopharma/biotech industry that operate in Germany or in the United States as well as &lt;font style="color:#231F20;"&gt;governments&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/font&gt;which are BioNTech&amp;#8217;s customers established in connection with progressing the commercial activities of the Group with respect to BioNTech&amp;#8217;s COVID-19 vaccine. An analysis of the aging of receivables and the creditworthiness of customers is used to evaluate this risk at each reporting date. The Group follows risk control procedures to assess the credit quality of the customers taking into account their financial position, past experience and other factors. The compliance with credit limits by corporate customers is regularly monitored by BioNTech.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, the outstanding trade receivables were mainly due from BioNTech&amp;#8217;s collaboration partner Pfizer as well as the German government. To a smaller extent, BioNTech&amp;#8217;s other customers are medical universities, other public institutions and peers in the biopharma industry, which all have a very high credit rating. Due to this customer portfolio, the credit risk on trade receivables and contract assets is very low. BioNTech has not incurred bad debt expense and does not expect that this will change with respect to the trade receivables recognized as of December 31, 2020. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Generally, trade receivables are written off if past due for more than one year and are not subject to enforcement activity. The maximum exposure to credit risk at the reporting date is the carrying value of each class of financial assets disclosed in Note 12.2. The expected credit risk on trade accounts receivables and other financial assets was estimated to be not material as of December 31, 2020 as well as December 31, 2019. The Group does not hold collateral as security. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Credit risk from balances with banks and financial institutions is managed by the Group&amp;#8217;s controlling department in accordance with the Group&amp;#8217;s policy. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Credit risk stemming from cash and cash equivalents is very low due to its demand feature and the high credit rating of the respective banks.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group&amp;#8217;s maximum exposure to credit risk for the components of the consolidated statements of financial position as of December&amp;#160;31, 2020 and December&amp;#160;31, 2019 are the carrying amounts as illustrated in Note 12.1.&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;12&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.7&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Liquidity Risk&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Generally, BioNTech has relied on the financing from shareholders and collaborators in order to ensure sufficient liquidity. Lack of external financial support could pose a risk of going concern. The liquidity management of BioNTech ensures the availability of cash and cash equivalents for operational activities and further investments through appropriate budget planning. In addition, a sufficient level of cash and cash equivalents, which is managed centrally, is always maintained to finance the operational activities.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group monitors liquidity risks using a liquidity planning tool.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ultimately, the responsibility for liquidity risk management lies with the Management Board, which has established an appropriate approach to managing short-, medium- and long-term financing and liquidity requirements. BioNTech manages liquidity risks by holding appropriate reserves, as well as by monitoring forecasted and actual cash flows and reconciling the maturity profiles of financial assets and liabilities.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk Concentration&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concentrations arise when a number of counterparties are engaged in similar business activities, or activities in the same geographical region, or have economic features that would cause their ability to meet contractual obligations to be affected similarly by changes in economic, political or other conditions. Concentrations indicate the relative sensitivity of the Group&amp;#8217;s performance to developments affecting a particular industry.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In order to avoid concentrations of risk, the Group&amp;#8217;s policies and procedures include specific guidelines to focus on the maintenance of an effective diversification in the sources of funding and distribution of cash deposits. Identified concentrations of credit risks are controlled and managed accordingly.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The maturity profile of the Group&amp;#8217;s financial liabilities based on contractual undiscounted payments is summarized as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="4" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.36%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less than 1 year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1 to 5 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;More than 5 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest bearing loans and borrowings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;3,173&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;12,643&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;66,730&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;82,546&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trade and other payables&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,288&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;102,288&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,525&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,283&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71,780&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;107,588&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;572&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;572&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other financial liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74,076&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;74,076&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;188,062&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;39,926&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;139,082&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;367,070&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The mandatory convertible note, which was issued during the year ended December&amp;#160;31, 2020 and which is expected to be settled in equity is excluded from the table above. &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.8&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Changes in Liabilities arising from Financing Activities&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash flows&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquisition of subsidiaries and businesses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;New leases and disposals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassification&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current obligations under lease contracts&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;3,485&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(12,743)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,719&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;8,684&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;3,982&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;6,127&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-current obligations under lease contracts&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,126&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,331&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,444)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,982)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;78,031&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest-bearing loans and borrowings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,600&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;140,847&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,416)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;156,031&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible note - embedded derivative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,614&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,289&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,903&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;74,211&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;141,718&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;35,050&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;4,240&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;15,873&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;271,092&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash flows&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquisition of subsidiaries and businesses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;New leases and disposals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassification&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current obligations under lease contracts&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,134&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(3,061)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,484&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,928&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;3,485&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-current obligations under lease contracts&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,618&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,436&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,928)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,126&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest-bearing loans and borrowings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,600&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,600&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;56,352&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;7,939&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;9,920&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;74,211&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory>
  <ifrs-full:DisclosureOfInventoriesExplanatory id="F_000382" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;13&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="color:#000000;"&gt;Inventories&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Raw materials and supplies&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;44,283&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;8,201&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unfinished goods&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,380&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,888&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;457&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;633&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;64,120&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;11,722&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech has not pledged any inventories as securities for liabilities.&lt;/p&gt;</ifrs-full:DisclosureOfInventoriesExplanatory>
  <ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory id="F_000383" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;14&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="color:#000000;"&gt;Other Assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepayments on inventories&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,845&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;351&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepayments related to CRO and CMO contracts&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,140&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales tax receivable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,155&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,536&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepayments related to service contracts&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,825&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,046&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,182&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;62,011&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;9,069&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60,966&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,069&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total non-current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,045&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory>
  <bntx:DisclosureOfDeferredExpensesExplanatory id="F_000384" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;15&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="color:#000000;"&gt;Deferred Expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred expenses from insurance contracts&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;13,845&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,758&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred expenses from CRO and CMO contracts&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,725&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,431&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,104&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;28,001&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;5,862&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,001&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,862&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total non-current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</bntx:DisclosureOfDeferredExpensesExplanatory>
  <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory id="F_000385" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;16&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="color:#000000;"&gt;Issued Capital and Reserves&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 18, 2019, BioNTech effected a 1:18 share split by issuing 206,595,492 shares by way of a capital increase from its own funds; thus, no outside proceeds were received. This capital increase came into effect upon registration with the commercial register (&lt;font style="font-style:italic;"&gt;Handelsregister&lt;/font&gt;). The accompanying consolidated financial statements and notes to the consolidated financial statements give retroactive effect to the share split for all periods presented. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capital transactions during the year ended December&amp;#160;31, 2020&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December&amp;#160;31, 2020, the issued share capital of BioNTech increased by &amp;#8364;14.0&amp;#160;million. Each share has a nominal value of &amp;#8364;1.00. As a result of the financing transactions, treasury shares decreased by &amp;#8364;0.7&amp;#160;million and capital reserve increased by &amp;#8364;861.0&amp;#160;million. Costs of &amp;#8364;33.2&amp;#160;million related to these equity transactions were recorded in equity as deduction from the capital reserve. The financing transactions that occurred during year ended December&amp;#160;31, 2020 were as follows: &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Shanghai Fosun Pharmaceuticals (Group) Co., Ltd&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of the BNT162 program, BioNTech entered a strategic alliance with Fosun Pharma to develop COVID-19 vaccine candidates in China. Fosun Pharma agreed to make an equity investment of &amp;#8364;45.6&amp;#160;million ($50.0&amp;#160;million) for 1,580,777 ordinary shares in BioNTech via Fosun Industrial Co., Limited, Hong Kong. The increase in share capital with a nominal amount of &amp;#8364;1.6&amp;#160;million was subject to execution of share subscription documentation and approval from regulatory authorities in China and became effective with the registration with the commercial register (&lt;font style="font-style:italic;"&gt;Handelsregister&lt;/font&gt;) on April 23, 2020. As a result of the transaction the capital reserve increased by &amp;#8364;44.0&amp;#160;million.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Pfizer Inc., New York, New York, United States&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of the collaboration between BioNTech and Pfizer, for the co-development of BNT162, Pfizer agreed to make an equity investment of &amp;#8364;103.9&amp;#160;million ($113.0&amp;#160;million). The issuance of 2,377,446&amp;#160;ordinary shares with the nominal amount of &amp;#8364;&amp;#160;2.4&amp;#160;million was registered with the commercial register (&lt;font style="font-style:italic;"&gt;Handelsregister&lt;/font&gt;) on May 5, 2020. As a result of the transaction the capital reserve increased by &amp;#8364;101.5&amp;#160;million. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Neon Therapeutics, Inc., Cambridge, Massachusetts, United States&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech acquired Neon by issuing 1,935,488 ADS representing BioNTech&amp;#8217;s ordinary shares with the nominal amount of &amp;#8364;&amp;#160;1.9&amp;#160;million to former stockholders of Neon in the Merger. The capital increase was registered with the commercial register (&lt;font style="font-style:italic;"&gt;Handelsregister&lt;/font&gt;) on May 8, 2020. As a result of the transaction the capital reserve increased by &amp;#8364;87.6&amp;#160;million. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Global Offering&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July 27, 2020 BioNTech increased its share capital by &amp;#8364;5.5&amp;#160;million ($6.4&amp;#160;million) in conjunction with the underwritten offering of 5,500,000 ADS each representing one of BioNTech&amp;#8217;s ordinary shares at a public offering price of $93.00 per ADS (&amp;#8220;Underwritten Offering&amp;#8221;). On August 27, 2020, following the Underwritten Offering, BioNTech increased its share capital by additional &amp;#8364;16&amp;#160;thousand ($19&amp;#160;thousand) in conjunction with the rights offering of 16,124 ADS each representing one of BioNTech&amp;#8217;s ordinary shares at a public offering price of $93.00 per ADS (&amp;#8220;Rights Offering&amp;#8221;). The Underwritten Offering and the Rights Offering are part of a single, global offering which BioNTech refers to as the Global Offering. The gross proceeds of the Global Offering were &amp;#8364;436.3&amp;#160;million ($513.0&amp;#160;million) including &amp;#8364;5.5&amp;#160;million increase in share capital and &amp;#8364;430.8&amp;#160;million increase in capital reserve. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;June 2020 Private Placement &amp;#8211; Equity Investment&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A fund associated with Temasek Capital Management Pte. Ltd., or Temasek, and another accredited investor, contributed a private investment. The private placement includes an investment in a 4-year mandatory convertible note (see Note 12) and an investment of &amp;#8364;123.9&amp;#160;million in ordinary shares. The issuance of 2,595,996&amp;#160;ordinary shares with the nominal amount of &amp;#8364;&amp;#160;2.6&amp;#160;million was registered with the commercial register (&lt;font style="font-style:italic;"&gt;Handelsregister&lt;/font&gt;) on September 8, 2020. As result of the transaction the capital reserve increased by &amp;#8364;121.3&amp;#160;million.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;At-The-Market Offering Program&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2020, &lt;font style="color:#000000;"&gt;BioNTech &lt;/font&gt;entered into a sales agreement (&amp;#8220;Sales Agreement&amp;#8221;) with Jefferies LLC and SVB Leerink LLC, as sales agents, to establish an at-the-market offering program, pursuant to which BioNTech may sell, from time to time, ADS representing ordinary shares for aggregate gross proceeds of up to $500.0&amp;#160;million. During the year ended December&amp;#160;31, 2020, BioNTech sold 735,490 ADSs, each representing one of its ordinary shares that had previously been held in treasury, under the Sales Agreement for aggregate gross proceeds of &amp;#8364;76.5&amp;#160;million ($92.9&amp;#160;million). Re-issuing 735,490 ordinary shares was registered as decrease of &amp;#8364;0.7&amp;#160;million in treasury shares. As a result of the transaction the capital reserve increased by &amp;#8364;75.8&amp;#160;million. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capital transactions during the year ended December&amp;#160;31, 2019&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December&amp;#160;31, 2019, the issued share capital of BioNTech increased by &amp;#8364;39.0&amp;#160;million. Each share has a nominal value of &amp;#8364;1.00. As a result of the financing transactions the capital reserve increased by &amp;#8364;359.2&amp;#160;million. Costs of &amp;#8364;16.6&amp;#160;million related to these equity transactions were recorded in equity as deduction from the capital reserve. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2019, BioNTech issued 5,088,204 shares and increased its share capital by &amp;#8364;5.1&amp;#160;million. The cash investment of &amp;#8364;80.0&amp;#160;million was received in 2018. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March 14, 2019, BioNTech acquired the remaining 5.5% of non-controlling interests in BioNTech Cell &amp;amp; Gene Therapies GmbH previously held by Eli Lilly Nederland B.V. in exchange for issuing 2,374,794 new ordinary shares with an imputed nominal value of &amp;#8364;1.00 each. This acquisition was recognized within equity and resulted in the derecognition of the non-controlling interest of &amp;#8364;0.7&amp;#160;million as well as an increase in share capital of &amp;#8364;2.4&amp;#160;million. The net effect of the transaction of &amp;#8364;1.6&amp;#160;million was recognized as a decrease in capital reserve. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Of the share capital issued in 2019, &amp;#8364;12.5&amp;#160;million related to a new financing round (referred to as the Series B round). As part of the Series B round, 12,465,288 ordinary shares (excluding 5,524,506 ordinary shares which were issued to a Hong Kong-based investor and subsequently transferred to BioNTech for no consideration; these shares are held as treasury shares) were issued to certain new and existing shareholders. As a result of the Series B round, the capital reserve increased by &amp;#8364;186.1&amp;#160;million.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August 30, 2019, BioNTech entered into agreements with the Bill &amp;amp; Melinda Gates Foundation under which BioNTech is required to perform certain research and development activities. The issuance of 3,038,674 ordinary shares with the nominal amount of &amp;#8364;3.0&amp;#160;million was registered with the commercial register (&lt;font style="font-style:italic;"&gt;Handelsregister&lt;/font&gt;) on September 26, 2019. As result of the transaction the capital reserve increased by &amp;#8364;46.8&amp;#160;million. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 10, 2019, BioNTech increased its share capital by &amp;#8364;10.0&amp;#160;million in conjunction with the Initial Public Offering. American Depositary Shares which represent ordinary shares were offered on the Nasdaq Global Select Market at a price of $15.00. On November 6, 2019, BioNTech increased its share capital by &amp;#8364;0.5&amp;#160;million upon the execution of the underwriter&amp;#180;s option. American Depositary Shares which represent ordinary shares were issued at a price of $15.00 (under both issuances). The gross proceeds were &amp;#8364;143.3&amp;#160;million ($157.8&amp;#160;million) including &amp;#8364;10.5&amp;#160;million increase in share capital and &amp;#8364;132.7&amp;#160;million increase in capital reserve. &lt;/p&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
  <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory id="F_000386" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="color:#000000;"&gt;Share-Based Payments&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December&amp;#160;31, 2020, December&amp;#160;31, 2019 and December&amp;#160;31, 2018, the Group had the following share-based arrangements. &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.1&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;BioNTech Employee Equity Plan (LTI and LTI-plus Program) (Equity-Settled)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2020, BioNTech adopted the BioNTech Employee 2020 Equity Plan and the BioNTech 2020 Restricted Stock Unit Plan for North America Employees. Under the plans Restricted Cash Units, or RSUs, will be offered to employees based in Europe and the United States respectively. The plan to which employees based in Europe will be eligible, was communicated in December 2020. Since those employees obtained a valid expectation of the award as of the announcement date and started rendering services as of such date, BioNTech concluded that the service commencement date for the BioNTech Employee 2020 Equity Plan was December 17, 2020. This is the date as of which BioNTech started to recognize the expenses related to the services received. Since the BioNTech 2020 Restricted Stock Unit Plan for North America Employees had not been communicated in detail to employees based in the United States during the year ended December 31, 2020, no expenses have been recognized in the Consolidated Statements of Operations for the year ended December 31, 2020. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;BioNTech Employee 2020 Equity Plan for employees based in Europe&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Description of Share-Based Payments&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The BioNTech Employee 2020 Equity Plan share-based payment transaction for employees based in Europe includes two programs, LTI and LTI-plus. The LTI program will be offered to all employees. The LTI-plus program intends to compensate employees who did not participate in the ESOP. Under both programs, RSUs will be offered to employees based in Europe. Both programs are classified as equity-settled because BioNTech has the ability to determine the method of settlement. The LTI will vest annually in equal installments after four years commencing on December 15, 2020. The LTI-plus will vest annually in equal installments after two years commencing on December 15, 2020. Moreover, the LTI-plus contains a non-vesting condition concerning 50% of the granted RSUs. These units will be awarded to the participant after the FDA fully approves BNT162b2. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Measurement of Fair Values&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech estimates the grant date fair value of the awards for services received in advance of grant date based upon the share-price at the reporting date. The estimate is revised at subsequent reporting periods until the date of grant has been established (refer to Note 22). An estimate for the number of equity instruments for which service conditions are expected to be satisfied is calculated considering a retention assumption and will be revised in case material differences arise. Ultimately, a true-up to the number satisfied until Settlement Date will be recorded. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reconciliation of Outstanding Share-Options&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted Stock Units (expected to be allocated)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share price (in &amp;#8364;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected to be allocated under LTI Program&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;252,766&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66.43&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected to be allocated under LTI-plus Program&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;396,938&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66.43&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;649,704&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;66.43&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expense recognized in the Consolidated Statements of Operations&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of sales&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;179&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;681&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales and marketing expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;147&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,015&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Management Board Grant (Cash-Settled)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since the beginning of 2020, the first year following the completion of BioNTech&amp;#8217;s initial public offering (&amp;#8220;IPO&amp;#8221;), the current service agreements with BioNTech&amp;#8217;s Management Board have provided for a short-term incentive compensation of up to a maximum of fifty percent of the annual base salary for the years 2020, 2021 and 2022. The amount of such short-term incentive compensation will depend on the achievement of certain company goals in the particular fiscal year, which goals will be set uniformly for all members of the Management Board. Fifty percent of the incentive compensation will be paid promptly upon achievement of the applicable company goals (first installment), with the remaining amount payable one year later, subject to adjustment relative to the performance of the price of the American Depositary Shares representing BioNTech&amp;#8217;s ordinary shares during that year (second installment).&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For each of the three yearly awards, the second installment of the short-term incentive compensation that is dependent on the price of the American Depositary Shares representing BioNTech&amp;#8217;s ordinary shares, represents a cash-settled share-based payment arrangement. The fair values of the liabilities are recognized over the award&amp;#8217;s vesting period beginning as of the service commencement date (January 1, 2020) until each separate determination date and are remeasured until settlement date. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December&amp;#160;31, 2020, the Group recognized share-based payment expenses of &amp;#8364;0.3&amp;#160;million as research and development expenses and of &amp;#8364;0.4&amp;#160;million as general and administrative expenses in the consolidated statements of operations and &amp;#8364;0.7&amp;#160;million of other financial liabilities in the statements of financial position as of December 31, 2020.&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.3&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Management Board Grant (Equity-Settled)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Description of Share-Based Payments&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From the beginning of 2020, the first year following the completion of BioNTech&amp;#8217;s IPO, until the end of the term of the Management Board member&amp;#8217;s employment agreement, the service agreements with BioNTech&amp;#8217;s Management Board provide for a long-term incentive compensation in terms of a yearly grant of options to purchase BioNTech shares. The right to receive options in 2020, 2021 and 2022 represents an equity-settled share-based payment arrangement. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The options allocated each year will be subject to the terms, conditions, definitions and provisions of the ESOP and the applicable option agreement thereunder. The number of options to be allocated each year to Prof. Ugur Sahin, Sean Marett, Dr. Sierk Poetting, Dr. &amp;#214;zlem T&amp;#252;reci and Ryan Richardson is to be calculated based on a value of &amp;#8364;750,000, &amp;#8364;300,000, &amp;#8364;300,000, &amp;#8364;300,000 and &amp;#8364;260,000, respectively, in each case divided by the amount by which a certain target share price exceeds the exercise price. The value used to calculate the number of options for Ryan Richardson increases to &amp;#8364;280,000 for the year 2022.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The allocation of the number of issued options in 2020 occurred as of February 13, 2020 (allocation date). As of December 31, 2020, the assessment about options expected to be granted in 2021 and 2022 was based on estimated allocation dates in the middle of the years 2021 and 2022, respectively. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The share options allocated and expected to be allocated to BioNTech&amp;#8217;s Management Board as of the dates indicated are presented in the tables below. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share options (expected to be allocated)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average exercise price (&amp;#8364;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted as of allocation date February 13, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;248,096&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28.32&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected to be allocated as of estimated allocation date 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;101,422&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.26*&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected to be allocated as of estimated allocation date 2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,463&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.27*&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;451,981&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;45.89&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*Valuation parameter derived from the Monte-Carlo simulation model&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the awards with estimated allocation dates the numbers of options expected to be allocated have been derived from the Monte-Carlo simulation model. Those will be adjusted until the actual allocation has occurred and the number of options granted has ultimately been determined. The options will vest annually in equal installments over four years commencing on the first anniversary of the allocation date and will be exercisable four years after the allocation date.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The options will be subject to the terms, conditions, definitions and provisions of the ESOP and the applicable option agreement thereunder. The vested options can only be exercised if and to the extent that each of the following performance criteria has been achieved: (i) at the time of exercise, the current price is equal to or greater than the threshold amount (that is, the exercise price, provided that such amount increases by seven percentage points on each anniversary of the allocation date); (ii) at the time of exercise, the current price is at least equal to the target price (that is, (a) for the twelve-month period starting on the fourth anniversary of the allocation date, $8.5 billion divided by the total number of the ordinary shares outstanding immediately following the initial public offering (other than ordinary shares owned by BioNTech), and (b) for each twelve-month period starting on the fifth or subsequent anniversary of the allocation date, 107% of the target share price applicable for the prior twelve-month period); and (iii) the closing price for the fifth trading day prior to the start of the relevant exercise window is higher than the exercise price by at least the same percentage by which the Nasdaq Biotechnology Index or a comparable successor index as of such time is higher than such index was as of the last trading day before the allocation date. The options expire ten years after the allocation date. If they have not been exercised by that date, they will lapse without compensation.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Measurement of Fair Values&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A Monte-Carlo simulation model has been used to measure the fair values at the (estimated) allocation dates of the Management Board Grant. This model incorporates the impact of the performance criteria regarding share price and index development described above. The parameters used for measuring the fair values as of the respective (estimated) allocation dates were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Allocation date February 13, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated allocation date&amp;nbsp;&amp;nbsp;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated allocation date 2022&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average fair value*&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;10.83&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;26.85&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;26.61&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average share price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;28.20&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364; 66.43*&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364; 66.43*&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;28.32&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364; 67.26*&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364; 67.27*&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility (%)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36.6%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41.0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40.7%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life (years)*&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.75&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.01&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.05&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate (%)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.61 %&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.88%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.88%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*Valuation parameter derived from the Monte-Carlo simulation model&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The exercise of the option rights in accordance with the terms of the ESOP gives the Management Board members the right to obtain shares against payment of the exercise price. The per share exercise price of the options is the Euro equivalent of the arithmetic mean of the closing prices of the ten last trading days prior to the allocation date. For the award allocated as of February 13, 2020, the exercise price has been determined to be $30.78 (&amp;#8364;28.32). For the awards with estimated allocation dates &lt;font style="color:#231F20;"&gt;the exercise prices &lt;/font&gt;of &lt;font style="color:#231F20;"&gt;options &lt;/font&gt;expected to be allocated have been derived from the Monte-Carlo simulation model.&lt;font style="color:#231F20;"&gt; Those will be adjusted until the actual allocation has occurred and the exercise price has ultimately been determined.&lt;/font&gt; Expected volatility was based on an evaluation of the historical volatilities of comparable companies over the historical period commensurate with the expected option term. The expected term was based on general optionholder behavior for employee options. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reconciliation of Outstanding Share-Options&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The share options allocated and expected to be allocated under the Management Board Grant were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Allocation date February 13, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share options&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average exercise price (&amp;#8364;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prof. Ugur Sahin, M.D.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;97,420&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28.32&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sean Marett&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,968&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28.32&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dr. Sierk Poetting&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,968&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28.32&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dr. &amp;#214;zlem T&amp;#252;reci, M.D.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,968&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28.32&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ryan Richardson&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,772&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28.32&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated allocation date 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share options&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;outstanding (expected to be allocated)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average exercise price (&amp;#8364;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prof. Ugur Sahin, M.D.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,826&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.26*&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sean Marett&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,930&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.26*&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dr. Sierk Poetting&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,930&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.26*&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dr. &amp;#214;zlem T&amp;#252;reci, M.D.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,930&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.26*&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ryan Richardson&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,806&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.26*&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*Valuation parameter derived from the Monte-Carlo simulation model&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated allocation date 2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share options&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;outstanding (expected to be allocated)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average exercise price (&amp;#8364;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prof. Ugur Sahin, M.D.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,817&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.27*&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sean Marett&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,927&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.27*&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dr. Sierk Poetting&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,927&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.27*&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dr. &amp;#214;zlem T&amp;#252;reci, M.D.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,927&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.27*&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ryan Richardson&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,865&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.27*&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*Valuation parameter derived from the Monte-Carlo simulation model&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020, the share options allocated and expected to be allocated had a remaining weighted-average expected life of 4.63 years.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expense recognized in the Consolidated Statements of Operations&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The expenses recognized for employee services received during the periods indicated are shown in the following table: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,514&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,246&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,760&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Chief Executive Officer Grant (Equity-Settled)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Description of Share-Based Payments&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2019, BioNTech granted Prof. Ugur Sahin, M.D. an option to purchase 4,374,963 ordinary shares, subject to Prof. Sahin&amp;#8217;s continuous employment with BioNTech. The options&amp;#8217; exercise price per share is the Euro translation of the public offering price from BioNTech&amp;#8217;s initial public offering, &amp;#8364;13.60 ($15.00). The option vests annually in equal installments after four years commencing on the first anniversary of the initial public offering and will be exercisable four years after the initial public offering. The option is subject to the terms, conditions, definitions and provisions of the ESOP and the applicable option agreement thereunder. The vested option rights can only be exercised if and to the extent that each of the following performance criteria has been achieved: (i) at the time of exercise, the current price is equal to or greater than the threshold amount (that is, the exercise price, provided that such amount increases by seven percentage points on each anniversary of the allocation date); (ii) at the time of exercise, the current price is at least equal to the Target Price (that is, (a) for the twelve-month period starting on the fourth anniversary of the allocation date, $8.5 billion divided by the total number of the shares outstanding immediately following the initial public offering (other than shares owned by BioNTech), and (b) for each twelve-month period starting on the fifth or subsequent anniversary of the allocation date, 107% of the target share price applicable for the prior twelve-month period); and (iii) the closing price for the fifth trading day prior to the start of the relevant exercise window is higher than the exercise price by at least the same percentage by which the Nasdaq Biotechnology Index or a comparable successor index as of such time is higher than such index was as of the last trading day before the allocation date. The option rights can be exercised up to ten years after the allocation date. If they have not been exercised by that date, they will lapse without compensation.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Measurement of Fair Values&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A Monte-Carlo simulation model has been used to measure the fair value at grant date of the Chief Executive Officer Grant. This model incorporates the impact of the performance criteria regarding share price and index development described above in the calculation of the award&amp;#8217;s fair value at grant date. The inputs used in the measurement of the fair value at grant date of the Chief Executive Officer Grant were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant date October 10, 2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;5.63&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average share price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;13.60&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;13.60&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility (%)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41.4%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.37&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate (%)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.52 %&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility was based on an evaluation of the historical volatilities of comparable companies over the historical period commensurate with the expected term. The expected term was based on general optionholder behavior for employee options.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reconciliation of Outstanding Share-Options&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December&amp;#160;31, 2020, no further options were granted or forfeited. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020, the share options outstanding had a remaining weighted-average expected life of 4.12 years.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expense recognized in the Statement of Operations&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December&amp;#160;31, 2020, the Group has recognized &amp;#8364;11.3&amp;#160;million of share-based payment expenses as research and development expenses in the consolidated statements of operations (during the year ended December&amp;#160;31, 2019: &amp;#8364;3.2 million).&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Employee Stock Ownership Plan (Equity-Settled)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Description of Share-Based Payments&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On November 15, 2018, the Group established a share option program that grants selected employees options to receive shares in the Company. The program is designed as an ESOP. The Group has offered the participants a certain number of rights (Option Rights) by explicit acceptance of the participants. The exercise of the Option Rights in accordance with the terms of the ESOP, gives the participants the right to obtain shares against payment of the exercise price. The Option Rights vest over four years and can only be exercised if the company has executed a public offering in the United States (IPO) and when the Threshold Amount is met. Threshold Amount means the exercise price provided that such price increases by eight percentage points on the first and then each subsequent anniversary of the Allocation Date (September 26, 2018). The Option Rights can be exercised at the latest eight years after the Allocation Date. If they have not been exercised by that date, they will be forfeited without compensation.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Measurement of Fair Values&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of the ESOP has been measured using a binomial model. Service conditions attached to the arrangement were not taken into account in measuring the fair value.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The share options can only be exercised by the grantee if the price of the share is equal or greater to the Threshold Amount as defined in the arrangement. Moreover, the option rights can only be exercised if the IPO has occurred. Both conditions have been incorporated into the fair value at grant date.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The inputs used in the measurement of the fair values at grant date of the ESOP was as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant date&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;15 November 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant dates&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;between&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;February 21 -&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;April 3, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant dates&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;between&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;April 29 -&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;May 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant date December 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;7.41&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;6.93&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;7.04&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;9.49&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average share price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;14.40&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;15.72&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;16.03&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;19.84&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;10.14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;15.03&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;15.39&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;15.82&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility (%)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46.0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46.0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46.0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46.0%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.84&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.50&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate (%)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.05%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.05%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.05%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.05%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility has been based on an evaluation of the historical and the implied volatilities of comparable companies over the historical period commensurate with the expected term. The expected term has been based on general option holder behavior for employee options.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reconciliation of Outstanding Share-Options&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Set out below is an overview of changes to share options outstanding and number of ordinary shares underlying these options that occurred during the periods indicated: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share options&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of ordinary shares underlying options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average exercise price (&amp;#8364;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;658,109&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,845,962&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.14&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,511&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;261,198&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.17&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17,237)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(310,266)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.85&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;655,383&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,796,894&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.23&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;655,383&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,796,894&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.23&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,491)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(170,838)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.81&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;645,892&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,626,056&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.23&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020, the share options outstanding had a remaining weighted-average expected life of 3.73 years.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The share options outstanding as of December 31, 2020 issued to the Management Board Grant were as follows:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share options&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of ordinary shares underlying options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average exercise price (&amp;#8364;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prof. Ugur Sahin, M.D.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;101,686&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,830,348&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.14&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sean Marett&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,895&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;610,110&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.14&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dr. Sierk Poetting&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,895&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;610,110&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.14&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dr. &amp;#214;zlem T&amp;#252;reci, M.D.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;108,463*&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,952,334&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.14&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ryan Richardson**&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,306***&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;149,508&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.14&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Options fully vested on March 16, 2019, however these options will not become exercisable until September&amp;#160;16,&amp;#160;2022.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;**&amp;#160;&amp;#160;&amp;#160;Ryan Richardson was appointed to the Management Board as Chief Strategy Officer (CSO) and Managing Director on January 12, 2020. The share options granted on November 15, 2018 under the Employee&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Stock Ownership Plan were granted before his appointment to the Management Board. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;***&amp;#160;Options fully vested on October 10, 2019, however these options will not become exercisable until September&amp;#160;16,&amp;#160;2022.&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The expenses recognized for employee services received during the periods indicated are shown in the following table:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of sales&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;869&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;896&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;114&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,120&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,786&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales and marketing expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;111&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;108&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,975&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,008&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;728&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;17,075&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;27,028&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;7,641&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
  <ifrs-full:DisclosureOfOtherLiabilitiesExplanatory id="F_000387" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;18&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="color:#000000;"&gt;Other Liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities to employees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;24,248&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;6,710&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,379&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;780&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;28,627&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;7,490&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,061&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,490&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total non-current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;566&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOtherLiabilitiesExplanatory>
  <ifrs-full:DisclosureOfLeasesExplanatory id="F_000388" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;19&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="color:#000000;"&gt;Leases&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.1&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Amounts Recognized in the Consolidated Statements of Financial Position&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-Use Assets&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following amounts are presented as right-of-use assets within the consolidated statements of financial position as of the dates indicated: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Buildings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;80,875&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;54,956&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equipment, tools and installations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Automobiles&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;108&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Production facilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,202&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Advance payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;98,988&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;55,018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions to the right-of-use assets during the year ended December&amp;#160;31, 2020 were &amp;#8364;22.1 million (during the year ended December&amp;#160;31, 2019: &amp;#8364;10.0&amp;#160;million) including advanced payments of &amp;#8364;10.8 million related to embedded leases under contract manufacturing agreements that not yet commenced. Since the advanced lease payments have already been settled, the amounts are not included in the lease liability presented below.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease Liability&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following amounts are included in interest-bearing loans and borrowings as of the dates indicated: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;6,127&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;3,485&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78,031&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,126&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;84,158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;57,611&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group has various lease contracts that have not yet commenced as of December&amp;#160;31, 2020. The future lease payments for these non-cancellable lease contracts are &amp;#8364;2.8&amp;#160;million for the year 2021 and &amp;#8364;10.2&amp;#160;million for the years 2022 and beyond.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Several lease contracts include extension and termination options. These options are negoiated by management to provide flexibility in managing the leased-asset portfolio and align with the Group&amp;#8217;s business needs. Management exercises significant judgement in determining whether these extension and termination options are reasonably certain to be exercised.&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;19&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Amounts Recognized in the Consolidated Statements of Operations&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation Charge of Right-of-Use Assets&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Buildings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;4,628&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;4,614&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,751&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equipment, tools and installations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Automobiles&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Production facilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,613&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total depreciation charge&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;6,290&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;4,679&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,846&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,003&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,718&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,721&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expense related to short-term leases&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(included in other expenses)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;875&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;442&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;431&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expense relating to leases of low-value assets that are not short-term leases (included in other expenses)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;300&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total amounts recognized in profit or loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;9,468&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;6,929&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;5,088&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;19&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.3&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Amounts recognized in the Consolidated Statements of Cash Flows&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December&amp;#160;31, 2020, the total cash outflow for leases amounted to &amp;#8364;14.7 million (during the year ended December&amp;#160;31, 2019: &amp;#8364;4.8 million; during the year ended December&amp;#160;31, 2018: &amp;#8364;2.3&amp;#160;million).&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.3&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Extension Options&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group has several lease contracts that include extension options. These options are negotiated by management to provide flexibility in managing the leased-asset portfolio and align with the Group&amp;#8217;s business needs. Management exercises judgement in determining whether these extension options are reasonably certain to be exercised. The undiscounted potential future lease payments, which relate to periods after the exercise date of renewal options and are not included in lease liabilities, amount to up to &amp;#8364;38.3 million until 2049.&lt;/p&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
  <ifrs-full:DisclosureOfEmployeeBenefitsExplanatory id="F_000389" contextRef="C_0001776985_20200101_20201231">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;20&lt;font style="margin-left:14pt;"&gt;&lt;/font&gt;Pensions&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2020, BioNTech adopted a defined benefit pension plan through the acquisition of BioNTech Manufacturing Marburg GmbH in Germany. The defined benefit pension plan is a final salary plan for German employees, which requires contributions to be made to a separately administered fund.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The pension plan is governed by the employment laws of Germany and consists of a funded base plan and a non-funded supplement plan. The base plan through &lt;font style="font-style:italic;"&gt;Pensionskasse&lt;/font&gt; &lt;font style="font-style:italic;"&gt;Hoechst&lt;/font&gt; is a multi-employer plan. &lt;font style="font-style:italic;"&gt;Pensionskasse&lt;/font&gt; &lt;font style="font-style:italic;"&gt;Hoechst&lt;/font&gt; is a legally independent insurance company that is subject to the Insurance Supervision Act (&lt;font style="font-style:italic;"&gt;BaFin&lt;/font&gt;). Plan participants may elect to contribute a percentage of their income (between 1.5% and 2.5% of salary components up to the social security contribution ceiling). A &amp;#8364;1.00 employee contribution results in an annual pension entitlement of &amp;#8364;0.42. The aforementioned contributions include contributions to the &lt;font style="font-style:italic;"&gt;Pensionskasse H&amp;#246;chst&lt;/font&gt; in the amount of &amp;#8364;34&amp;#160;thousand. Contributions in the amount of &amp;#8364;0.2&amp;#160;million are expected for the following financial year. Since the obligation of the sponsoring company is not limited to the payment of the contributions for the financial year, this is a multi-employer defined benefit plan, which is generally to be accounted for proportionally as such. However, pension fund benefits are financed in accordance with the financing methodology of the pension fund (&lt;font style="font-style:italic;"&gt;Bedarfdeckungsverfahren&lt;/font&gt;). Consequently, the actuarial valuation is performed to determine the present valuate of future contributions based upon the present value of future benefit obligation less plan assets for all employers and the level of the pension fund portfolio, not at the level of an individual insurer&amp;#8217;s risk. The calculation of the contribution rates is based on the future coverage of the total obligation, so that all sponsoring companies pay the same contribution rates. Accordingly, the portion of the base plan financed through &lt;font style="font-style:italic;"&gt;Pensionskasse&lt;/font&gt; &lt;font style="font-style:italic;"&gt;Hoechst&lt;/font&gt; is not accounted for as a defined benefit plan, but as a defined contribution plan. There are no minimum funding requirements. It is not possible to withdraw the funds from the multi-employer plan or to transfer them to another pension fund. It is not possible to withdraw from the pension fund. Upon expiry of the plan, any underfunding is to be made up by the employer and therefore recognized as liability in the consolidated statement of financial positions; any remaining surplus would be used for charitable purposes. Both plans have been closed so that no further employees can obtain entitlements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since the German Company Pension Act (&lt;font style="font-style:italic;"&gt;Betriebsrentengesetz&lt;/font&gt;) applies to the pension obligation, the pensions are subject to adjustments at least every three years by the increase in the consumer price index or by the net wage development of comparable groups of employees. Therefore, the pension obligation is subject to inflation risk. In addition, there is longevity risk as the pensions are paid for life. Part of the obligations is also based on the level of salaries, so that the obligations will also increase if salaries develop more strongly than expected. Plan assets benefits from pension funds are offset. In this case, there is a risk that the external pension provider will not be able to provide the benefits to the extent expected and that the payments to be made directly by the employer will therefore increase.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the defined benefit obligation recognized in non-current provisions:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Base plan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,140&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplement plan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,125&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;4,265&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the components of net benefit expense recognized in the statement of profit or loss for both plans: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Service cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;24&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net interest expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;30&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The current service cost is included in the personnel expenses of the various functions of the respective employees, while the net interest is recognized in finance expenses or finance income.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the components of remeasurements recognized in other comprehensive income for both plans:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Actuarial changes arising from changes in financial assumptions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;227&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Experience adjustments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;210&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Set out below is an overview of changes to the defined benefit obligation during the period indicated for both plans:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Defined benefit obligations&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquisition of subsidiaries and businesses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,029)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Service cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(24)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net interest expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Benefits paid&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Actuarial changes arising from changes in financial assumptions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(227)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Experience adjustments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(4,265)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The principal assumptions used in determining the defined benefit obligation for the Group&amp;#8217;s plans are shown below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.34%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.36%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.34%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Discount rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.80%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price inflation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.36%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.00%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rate of salary increase&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.36%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.50%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pension increases for in-payment benefits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.36%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.75%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sensitivity analysis&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The main actuarial assumptions that are used to calculate the provisions for post-employment benefits are the discount rate and the trend for future increases in post-employment benefit payments. A reasonably possible increase, or respective decrease, in the significant actuarial assumptions would have impacted the present value of the post-employment benefit obligations as of December&amp;#160;31, 2020 as shown below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td colspan="3" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quantitative sensitivity analysis&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Discount rate increase 0.25%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(282)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Discount rate decrease 0.25%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;309&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pension increases for in payment benefits 0.25%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;475&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pension decreases for in payment benefits 0.25%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(447)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Duration&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The average duration of the German obligations are 35.92 years for the base plan and 19.77 years for the supplement plan.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected benefit payments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following are the expected payments or contributions to the plans in future years:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td colspan="3" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected payments or contributions in future years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less than 1 year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;29&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1 to 5 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;317&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;More than 5 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;340&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;686&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEmployeeBenefitsExplanatory>
  <ifrs-full:DisclosureOfRelatedPartyExplanatory id="F_000390" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/font&gt;&lt;font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="color:#000000;"&gt;Related Party Disclosures&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.1&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Parent and Ultimate Controlling Party&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ATHOS KG, Holzkirchen, Germany is the sole shareholder of AT Impf GmbH, Munich, Germany and beneficial owner of ordinary shares in BioNTech. ATHOS KG via AT Impf GmbH has de facto control over BioNTech based on its substantial shareholding, which enabled it to exercise the majority of voting rights to pass resolutions at BioNTech&amp;#8217;s Annual General Meeting, or AGM.&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Transactions with Key Management Personnel&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Key Management Personnel Compensation&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Key management personnel at BioNTech has been defined as the members of the Management Board and of the Supervisory Board. Key management personnel compensation is comprised of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compensation of key management personnel of the Group&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term employee benefits incurred&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,627&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,847&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,161&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term employee benefits accrued*&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;740&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share-based payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,700**&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,151&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,163&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total compensation paid to key management personnel&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;24,067&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;19,998&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;7,324&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:2pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:2.86%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"&gt;Includes the fair value of the second installment of the short-term incentive compensation, which has been classified as cash-settled share-based payment arrangement was determined pursuant to the regulations of IFRS 2 &amp;#8220;Share-based Payments&amp;#8221;. This table shows the pro-rata share of personnel expenses for the respective financial year that are recognized over the award&amp;#8217;s vesting period beginning as of the service commencement date (January 1, 2020) until each separate determination date and are remeasured until settlement date.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:2.86%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;**&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"&gt;Includes expenses from a bonus arrangement agreed with Ryan Richardson in advance of his appointment to the Management Board. During the year ended December 31, 2020, the arrangement was modified from an all-equity share-based payment arrangement into a partly cash and partly equity settled share-based payment arrangement including 4,534 ordinary shares which have not yet been issued. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2019, BioNTech agreed to grant Prof. Ugur Sahin, M.D., BioNTech&amp;#8217;s co-founder and Chief Executive Officer, an option to purchase 4,374,963 ordinary shares (see Note 17). &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Management Board members participate in the Group&amp;#8217;s ESOP program (see Note 17). &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Key Management Personnel Transactions&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A number of key management personnel, or their related parties, hold positions in other companies that result in them having control or significant influence over these companies. A number of these companies have entered into transactions with the Group during the year.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group purchases various goods and services from&lt;font style="color:#231F20;"&gt; Translationale Onkologie an der Universit&amp;#228;tsmedizin der Johannes Gutenberg-Universit&amp;#228;t Mainz gemeinn&amp;#252;tzige GmbH, or TRON, an&lt;/font&gt; institute which was co-founded by &lt;font style="color:#231F20;"&gt;Prof.&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;Ugur Sahin, M.D., the co-founder and Chief&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;Executive&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;Officer of BioNTech. Prof.&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;Ugur Sahin, M.D. served&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;as Managing&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;Director&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.1pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;at&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;TRON&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:-0.05pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;until&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.05pt;"&gt; September 10, &lt;/font&gt;&lt;font style="color:#231F20;"&gt;2019 and currently&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.1pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;serves&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;as scientific advisor at TRON and as a Professor&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.1pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;of Medicine&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.1pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;at&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;the&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;University&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.1pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;of Mainz. Additionally,&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.1pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;Prof.&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;Christoph&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;Huber, M.D., a member&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.1pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;of our Supervisory&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;Board, served&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;on TRON&amp;#8217;s&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:-0.05pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;supervisory&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.1pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;board&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;until&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;his&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;resignation&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.1pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;in April&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;2019. Prof.&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;Ugur Sahin, M.D., our co-founder and Chief&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;Executive&lt;/font&gt;&lt;font style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/font&gt;&lt;font style="color:#231F20;"&gt;Officer, owns a significant amount of shares in TRON. &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate value of transactions related to key management personnel were as follows for the periods indicated:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consulting services / patent assignment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;25&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;56&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;25&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchases of various goods and services from TRON&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,105&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,968&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,160&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;10,130&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;10,024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;11,185&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The outstanding balances of transactions related to key management personnel were as follows as at the periods indicated:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consulting service provider&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;TRON&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,229&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,843&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,236&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,843&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.3&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Other Related Party Transactions&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The total amount of transactions with ATHOS KG or entities controlled by it was as follows for the periods indicated:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchases of various goods and services from entities controlled by ATHOS KG&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,296&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,071&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,431&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchases of property and other assets from entities controlled by ATHOS KG&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,349&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,748&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;4,645&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,071&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;7,179&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The outstanding balances of transactions with ATHOS KG or entities controlled by them were as follows as at the periods indicated:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ATHOS KG&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;51&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;51&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;None of the balances are secured and no bad debt expense has been recognized in respect of amounts owed by related parties. &lt;/p&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
  <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory id="F_000391" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/font&gt;&lt;font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="color:#000000;"&gt;Events After the Reporting Period&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On February 12, 2021, BioNTech and Pfizer announced that the U.S. government has exercised its option to purchase an additional 100 million doses of the Pfizer-BioNTech COVID-19 vaccine. This brings the total number of doses to be supplied by the companies to the U.S. government to 300 million.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On February 17, 2021, BioNTech and Pfizer announced an agreement with the European Commission (EC) to supply an additional 200 million doses of COVID-19 vaccine to the 27 European Union member states. The EC has the option to request supply of an additional 100 million doses.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2021, RSUs under the BioNTech Employee 2020 Equity Plan were offered to employees based in Europe which determined the grant date fair value. Given that the share price had increased since the plan was established, a significant true-up in fair value occurred. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2021, RSUs under the BioNTech 2020 Restricted Stock Unit Plan for North America Employees were offered to employees based in the United States. As from this date, BioNTech started recognizing expenses for this plan in the Consolidated Statements of Operations. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 12, 2021, BioNTech &lt;font style="color:#000000;"&gt;Turkey T&amp;#305;bbi &amp;#220;r&amp;#252;nler Ve Klinik Ara&amp;#351;tirma Ticaret Anonim &amp;#350;irketi&lt;/font&gt;, translates as BioNTech Turkey Pharmaceutical Products and Clinical Trials Trading JSC, Istanbul, Turkey, was founded and is a wholly-owned subsidiary of BioNTech SE. &lt;/p&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
  <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory id="F_000392" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.1&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Basis of Preparation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;General&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements have been prepared on a going concern basis in accordance with the IFRS as issued by the International Accounting Standards Board (IASB). &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech prepares and publishes its consolidated financial statements in Euros and rounds numbers to thousands or millions of Euros, respectively. Accordingly, numerical figures shown as totals in some tables may not be exact arithmetic aggregations of the figures that preceded them and figures presented in the explanatory notes may not add up to the rounded arithmetic aggregations. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Segment Information&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Historically &lt;font style="color:#000000;"&gt;BioNTech &lt;/font&gt;reported four segments: Clinical, Technology Platform, Manufacturing and Product Sales &amp;amp; External Services. In the course of the year ended December&amp;#160;31, 2020, &lt;font style="color:#000000;"&gt;BioNTech &lt;/font&gt;leveraged the breadth of its immunotherapy technologies and used its expertise to mobilize these rapidly to address the COVID-19 pandemic. In December 2020, BioNTech&amp;#8217;s COVID-19 vaccine was authorized or approved for emergency or temporary use or granted conditional marketing authorization in over 65 countries worldwide. Beginning in the fourth quarter, given the financial and operational significance of the activities to develop and then market, produce and transport the COVID-19 vaccine, BioNTech&amp;#8217;s Management Board, as the chief operating decision maker (CODM), reviewed financial information presented on a consolidated basis. Decisions with respect to business operations and resource allocations are made by the CODM based on BioNTech as a whole. Accordingly, BioNTech operates and makes decisions as a single operating segment, which is also its reporting segment. &lt;/p&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
  <ifrs-full:DisclosureOfBasisOfConsolidationExplanatory id="F_000393" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Basis of Consolidation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements comprise the financial statements of BioNTech SE and its controlled investees (subsidiaries). &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group controls an investee if, and only if, the Group has&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.14%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;power over the investee (&lt;/font&gt;&lt;font style="font-style:italic;font-family:Times New Roman;"&gt;i.e.&lt;/font&gt;&lt;font style="font-family:Times New Roman;"&gt;, existing rights that give it the current ability to direct the relevant activities of the investee); &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;exposure, or rights, to variable returns from its involvement with the investee; and &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;the ability to use its power over the investee to affect its returns. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Generally, there is a presumption that a majority of voting rights results in control. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group re-assesses whether it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The profit / (loss) and each component of other comprehensive income / (loss) for the period are attributed to the equity holders of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. When necessary, adjustments are made to the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;financial statements of subsidiaries to bring their accounting policies in line with the Group&amp;#8217;s accounting policies. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated on consolidation.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If the Group loses control over a subsidiary, it derecognizes the related assets (including goodwill), liabilities, non-controlling interests and other components of equity, while any resultant gain or loss is recognized in the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;statements of operations. Any investment retained is recognized at fair value.&lt;/p&gt;</ifrs-full:DisclosureOfBasisOfConsolidationExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory id="F_000394" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.1&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Business combinations and Goodwill&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Business combinations are accounted for using the acquisition method. The cost of an acquisition is measured as the aggregate of the consideration transferred, which is measured at acquisition date fair value, and the amount of any non-controlling interests in the acquiree.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill is initially measured at cost as the excess of the aggregate of the consideration transferred and the amount recognized for non-controlling interests and any previous interest held over the net identifiable assets acquired and liabilities assumed.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;After initial recognition, goodwill is tested at least annually or when there is an indication for impairment. See Note&amp;#160;2.3.13. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Group&amp;#8217;s cash-generating units that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those units. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Where goodwill has been allocated to a cash-generating unit (CGU) and part of the operation within that unit is disposed of, the goodwill associated with the disposed operation is included in the carrying amount of the operation when determining the gain or loss on disposal. Goodwill disposed in these circumstances is measured based on the relative values of the disposed operation and the portion of the cash-generating unit retained.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory>
  <bntx:DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatory id="F_000395" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Current versus Non-Current Classifications&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group presents assets and liabilities in the consolidated statements of financial position based on current or non-current classification. An asset is current when it is either: (i)&amp;#160;expected to be realized within 12&amp;#160;months after the reporting period or (ii)&amp;#160;cash or cash equivalents, unless it is restricted from being exchanged or used to settle a liability for at least 12&amp;#160;months after the reporting period. All other assets are classified as non-current. A liability is current when it is due to be settled within 12&amp;#160;months after the reporting period. The Group classifies all other liabilities as non-current. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets and liabilities are classified as non-current assets and liabilities, respectively.&lt;/p&gt;</bntx:DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory id="F_000396" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.3&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Fair Value Measurement&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value is a market-based measurement. For some assets and liabilities, observable market transactions or market information is available. For other assets and liabilities, observable market transactions or market information might not be available. When a price for an identical asset or liability is not observable, another valuation technique is used. To increase consistency and comparability in fair value measurements, there are three levels of the fair value hierarchy:&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.14%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;Level 1 contains the use of quoted prices in active markets for identical assets or liabilities.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.14%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.14%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;Level&amp;#160;3 inputs are unobservable. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Within this hierarchy, estimated values are made by management based on reasonable assumptions, including other fair value methods.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For assets and liabilities that are recognized in the financial statements at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the fair value hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the purpose of fair value disclosures, the Group has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy, as explained above.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory>
  <bntx:DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory id="F_000397" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.93%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.62%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.4&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Revenue from Contracts with Customers&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech generates revenues from collaboration and license agreements under which BioNTech grants licenses to use, research, develop, manufacture and commercialize product candidates and products. BioNTech determined that those collaboration and license agreements qualify as contracts with its customers. If the grant of a license is bundled together with the rendering of services, it is assessed whether these agreements are comprised of more than one performance obligation. A performance obligation is only accounted for as the grant of a license if the grant of a license is the sole or the predominant promise of the performance obligation. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If the consideration in an agreement includes a variable amount, BioNTech estimates the amount of consideration to which BioNTech will be entitled in exchange for transferring the goods to the customer. At contract inception, the variable consideration is estimated based on the most likely amount of consideration expected from the transaction and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with respect the variable consideration is subsequently resolved. The estimated revenue is updated at each reporting date to reflect the current facts and circumstances.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If a contract with a customer contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative-stand-alone selling prices.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For each separate performance obligation, it is evaluated whether control is transferred either at a point in time or over time. For performance obligations that are satisfied over time, revenue is recognized based on a measure of progress, which depicts the performance in transferring control to the customer. Under the terms of its licensing arrangements, BioNTech provides the licensee with a research and development license, which represents a right to access BioNTech&amp;#8217;s intellectual property as it exists throughout the license period (as BioNTech&amp;#8217;s intellectual property is still subject to further research). Therefore, the promise to grant a license is accounted for as a performance obligation satisfied over time, as the licensee simultaneously receives and consumes the benefits of BioNTech&amp;#8217;s performance.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Earnings based on the collaboration partners&amp;#8217; gross profit, which is shared under the respective collaboration agreements are recognized based on the sales-based or usage-based royalty &lt;font style="color:#000000;"&gt;exemption; &lt;/font&gt;&lt;font style="font-style:italic;color:#000000;"&gt;i.e. &lt;/font&gt;when, or as, the underlying sales occur, which is when the performance obligation has been satisfied. As described further in Note 3, BioNTech uses certain information from its collaboration partners, some of which is based on preliminary data shared between the partners and might vary once final data is available. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue arrangements that involve two or more partners who contribute to the provision of a specific good or service to a customer are assessed in terms of principal-agent considerations in order to determine the appropriate treatment for the transactions between BioNTech and the collaborator and the transactions between BioNTech and other third parties. The classification of transactions under such arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which BioNTech is considered the principal, which includes being in control of the good or service before such good or service is transferred to the customer, are accounted for as gross revenue. Any consideration related to activities in which BioNTech is considered the agent, are accounted for as net revenue.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue from the sale of pharmaceutical and medical products (&lt;font style="font-style:italic;"&gt;e.g&lt;/font&gt;. COVID-19 vaccine sales and other sales of peptides and retroviral vectors for clinical supply) is recognized when BioNTech transfers control of the product to the customer. Control of the product normally transfers when the customer gains physical possession and BioNTech has not retained any significant risks of ownership or future obligations with respect to the product. A receivable is recognized, as the consideration is unconditional and only the passage of time is required before payment is due. The transaction price is quoted in the relevant price lists in force at the date of customer placing the respective order for such products. Payments from customers are due within 20 days (Europe) or 30 days (non-Europe) after invoice.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract Balances&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract Assets&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A contract asset is the right to consideration in exchange for goods or services transferred to the customer. If BioNTech performs by transferring goods or services to a customer before the customer pays consideration or before payment is due, a contract asset is recognized for the earned consideration that is conditional.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trade Receivables&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A receivable represents BioNTech&amp;#8217;s right to an amount of consideration that is unconditional (&lt;font style="font-style:italic;"&gt;i.e&lt;/font&gt;., only the passage of time is required before payment of the consideration is due).&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract Liabilities&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A contract liability is the obligation to transfer goods or services to a customer for which BioNTech has received consideration (or an amount of consideration is due) from the customer. If a customer pays consideration before BioNTech transfers goods or services to the customer, a contract liability is recognized when the payment is made or when the payment is due (whichever is earlier). Contract liabilities are recognized as revenue when BioNTech performs under the contract.&lt;/p&gt;</bntx:DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants id="F_000398" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.5&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Government Grants&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government grants are recognized where there is reasonable assurance that the grant will be received and all attached conditions will be complied with. When the grant relates to an expense item, it is recognized as other income on a systematic basis over the periods that the related costs, for which the grant is intended to compensate, are expensed. When the grant relates to an asset, it is recognized as deferred income within the consolidated statements of financial position. Other income is subsequently recognized in profit or loss over the useful live of the underlying asset subject to funding. &lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants>
  <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory id="F_000399" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.6&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Taxes&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current Income Tax&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the reporting date in the countries where the Group operates and generates taxable income. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition, current income taxes presented for the period include adjustments for uncertain tax payments or tax refunds for periods not yet finally assessed, excluding interest expenses and penalties on the underpayment of taxes. Due to the increasing complexity of tax laws and the corresponding uncertainty regarding the legal interpretation by the fiscal authorities, tax calculations are generally subject to an elevated amount of uncertainty. In the event that amounts included in the tax return are considered unlikely to be accepted by the tax authorities (uncertain tax positions), a provision for income taxes is recognized. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Tax&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities are recognized for all taxable temporary differences, except: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;when the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; or &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;in respect of taxable temporary differences associated with investments in subsidiaries, associates and interests in joint arrangements, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets are recognized for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, the carry forward of unused tax credits and unused tax losses can be utilized, except:&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;when the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; or&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;in respect of deductible temporary differences associated with investments in subsidiaries, associates and interests in joint arrangements, deferred tax assets are recognized only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year in which the asset is realized, or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognition of Taxes&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current and deferred tax items are recognized similar to the underlying transaction either in profit or loss, other comprehensive income or directly in equity.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group offsets current tax assets and current tax liabilities if, and only if, it has a legally enforceable right to set off the recognized amounts and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously. Deferred tax assets and deferred tax liabilities are only offset when the Group has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same taxation authority on either (i) the same taxable entity or (ii) different taxable entities, which intend either to settle current tax liabilities and assets on a net basis, or to realize the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales Tax&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expenses and assets are recognized net of sales tax, except when the sales tax incurred on a purchase of assets or services is not recoverable from the taxation authority.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The net amount of sales tax recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the &lt;font style="color:#000000;"&gt;consolidated&lt;/font&gt; statements of financial position.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory id="F_000400" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.7&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Foreign Currencies&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group&amp;#8217;s consolidated financial statements are presented in Euros, which is also BioNTech SE&amp;#8217;s functional currency. For each entity, the Group determines the functional currency, and items included in the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;financial statements of such entity are measured using that functional currency. The Group uses the direct method of consolidation and on disposal of a foreign operation, the gain or loss that is reclassified to the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;statements of operations reflects the amount that arises from using this method.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Transactions and Balances&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Transactions in foreign currencies are initially recorded by the Group&amp;#8217;s entities at their respective functional currency spot rates at the date the transaction first qualifies for recognition.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In determining the spot exchange rate to use on initial recognition of the related asset, expense or income (or part of it) on the derecognition of a non-monetary asset or non-monetary liability relating to advance consideration, the date of the transaction is the date on which the Group initially recognizes the non-monetary asset or non-monetary liability arising from the advance consideration. If there are multiple payments or receipts in advance, the Group determines the transaction date for each payment or receipt of advance consideration.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign Currency Translation&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On consolidation, the assets and liabilities of foreign operations are translated into Euros at the rate of exchange prevailing at the reporting date and their &lt;font style="color:#000000;"&gt;consolidated&lt;/font&gt; statements of operations are translated at exchange rates prevailing at the dates of the transactions.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The exchange differences arising on translation for consolidation are recognized in other comprehensive income. On disposal of a foreign operation, the component of other comprehensive income relating to that particular foreign operation is reclassified to profit or loss.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Any goodwill arising on the acquisition of a foreign operation and any fair value adjustments to the carrying amounts of assets and liabilities arising upon the acquisition are treated as assets and liabilities of the foreign operation and translated at the spot rate of exchange at the reporting date.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory id="F_000401" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.8&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Property, Plant and Equipment&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress is stated at cost, net of accumulated impairment losses, if any. Property, plant and equipment are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Such cost includes the cost of replacing part of the property, plant and equipment if the recognition criteria are met. All other repair and maintenance costs are expensed as incurred.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, plant and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Useful life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Years)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Buildings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7-33&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equipment, tools and installations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3-15&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;An item of property, plant and equipment initially recognized is derecognized upon disposal (&lt;font style="font-style:italic;"&gt;i.e&lt;/font&gt;., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;statements of operations when the asset is derecognized.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year-end and adjusted prospectively, if appropriate.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory id="F_000402" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.9&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Leases&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the inception of a contract, the Group assesses whether the contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, the Group assesses whether: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;the contract involves the use of an identified asset&amp;#8212;this may be specified explicitly or implicitly and should be physically distinct or represent substantially all of the capacity of a physically distinct asset. If the supplier has a substantive substitution right, then the asset is not identified; &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;the Group has the right to obtain substantially all of the economic benefits from use of the asset throughout the period of use; and&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;the Group has the right to direct the use of the asset. The Group has this right when it has the decision-making rights that are most relevant to changing how and for what purpose the asset is used. In rare cases where the decision about how and for what purpose the asset is used is predetermined, the Group has the right to direct the use of the asset if either:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:9.08%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;the Group has the right to operate the asset; or&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:9.08%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;the Group designed the asset in a way that predetermines how and for what purpose it will be used. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At inception or on reassessment of a contract that contains a lease component, the Group allocates the consideration in the contract to each lease component on the basis of their relative stand-alone prices. However, for the leases of land and buildings in which it is a lessee, the Group has elected not to separate non-lease components, and instead accounts for the lease and non-lease components as a single lease component.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group recognizes a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of the costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received by the Group.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset and the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of property and equipment. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the incremental borrowing interest rate implicit in the lease or, if that rate cannot be readily determined, the Group&amp;#8217;s incremental borrowing rate. Generally, the Group uses its incremental borrowing rate as the discount rate.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease payments included in the measurement of the lease liability comprise the following: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;fixed payments, including in-substance fixed payments;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;variable lease payments that depend on an index or a rate, initially measured using the index or rate as of the commencement date; &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;amounts expected to be payable under a residual value guarantee; and&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;the exercise price under a purchase option that the Group is reasonably certain to exercise, lease payments in an optional renewal period if the Group is reasonably certain to exercise an extension option, and penalties for early termination of a lease unless the Group is reasonably certain not to terminate early.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The lease liability is subsequently measured at amortized cost using the effective interest method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the Group&amp;#8217;s estimate of the amount expected to be payable under a residual value guarantee, or if the Group changes its assessment of whether it will exercise a purchase, extension or termination option. When the lease liability is remeasured, a corresponding adjustment is made to the carrying amount of the right-of-use asset or is recorded in the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;statements of operations if the carrying amount of the right-of-use asset has been reduced to zero.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group presents right-of-use assets separately and lease liabilities in &amp;#8216;financial liabilities&amp;#8217; in the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;statements of financial position.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets or shorter lease term, as follows:&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Useful life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Years)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Buildings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2-25&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equipment, tools and installations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2-5&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Production facilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2-3&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Automobiles&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3-4&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-Term Leases and Leases of Low-Value Assets&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group has elected not to recognize right-of-use assets and lease liabilities for short-term leases of machinery that have a lease term of 12 months or less or leases of low-value assets. The Group recognizes the lease payments associated with these leases as an expense in the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;statements of operations on a straight-line basis over the lease term.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory id="F_000403" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.10&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Intangible Assets&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The useful lives of intangible assets are assessed as either finite or indefinite. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets with finite lives are amortized generally on a straight-line basis over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are at least reviewed at the end of each reporting period. The amortization expense on intangible assets with finite lives is recognized in the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;statements of operations in the expense category that is consistent with the function of the intangible assets.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the useful lives applied to the Group&amp;#8217;s intangible assets is as follows:&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Useful life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Years)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intellectual property rights&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10-20&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Licenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3-20&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3-8&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets with indefinite useful lives are not amortized, but are tested for impairment at least annually, or when there is an indication for impairment, either individually or at the level of a cash-generating unit (see Note 2.3.13 for further details). The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group has classified advanced payments on intangible assets as intangible assets, which are not yet ready for use. Advanced payments on intangible assets are tested for impairment on an annual basis.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;An intangible asset is derecognized upon disposal (&lt;font style="font-style:italic;"&gt;i.e&lt;/font&gt;., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising upon derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;statements of operations.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Costs&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research costs are expensed as incurred. Development expenditures on an individual project are recognized as an intangible asset if, and only if, all of the following six criteria can be demonstrated by the Group:&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;the technical feasibility of completing the intangible asset so that the asset will be available for use or sale;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;its intention to complete the project;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;the ability and intention to use or sell the asset;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;how the asset will generate future economic benefits;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;the availability of resources to complete the asset; and&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;the ability to reliably measure the expenditure during development.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due to the inherent risk of failure in pharmaceutical development and the uncertainty of approval, management has determined that these criteria are not met in the biotech sector until regulatory approval has been obtained. The related expenditure is reflected in the consolidated statements of operations in the period in which the expenditure is incurred. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Following initial recognition of the development expenditure as an asset, the asset is carried at cost less any accumulated amortization and accumulated impairment losses. Amortization of the asset begins when development is complete and the asset is available for use. It is amortized over the period of expected future benefit. Amortization is recorded in cost of sales. During the period of development, the asset is tested for impairment annually.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory id="F_000404" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.11&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Financial Instruments &amp;#8211; Initial Recognition and Subsequent Measurement&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;i) Financial Assets&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Initial recognition and Measurement&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets are initially measured at fair value. The Group&amp;#8217;s financial assets mainly include trade receivables as well as other receivables that reflect BioNTech&amp;#8217;s entitlement to cash. With respect to trade receivable, the Group has applied the practical expedient which means that they are measured at the transaction price determined under IFRS 15. Refer to the accounting policies in Note 2.3.4. Other financial assets are measured at amortized costs since they are held by the Group to collect contractual cash flows, which are solely payments of principal and interest. Gains and losses are recognized in profit or loss when the financial asset is derecognized, modified or impaired. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derecognition&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e., removed from the Group&amp;#8217;s consolidated statements of financial position) when the rights to receive cash flows from the asset have expired or have been transferred in terms of fulfilling the derecognition criteria. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impairment of Financial Assets&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;An allowance for expected credit losses (ECLs) is considered for all debt instruments of the Group. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all of the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For trade receivables and contract assets, the Group applies a simplified approach in calculating ECLs. Therefore, the Group does not track changes in credit risk, but instead recognizes a loss allowance based on lifetime ECLs at each reporting date. The Group has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment. In this analysis BioNTech also considered that governments and health ministries which are BioNTech&amp;#8217;s customers established in connection with progressing the commercial activities of the Group with respect to BioNTech&amp;#8217;s COVID-19 vaccine. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;ii) Financial Liabilities&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Initial Recognition and Measurement&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings or as payables.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group&amp;#8217;s financial liabilities include trade payables and other financial liabilities.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Subsequent Measurement&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The measurement of financial liabilities depends on their classification, as described below.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Financial Liabilities at Fair Value through Profit or Loss&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial liabilities at fair value through profit of the Group include the embedded derivative, which was bifurcated from the convertible note, as host contract, and is recognized as a separate financial instrument until it is extinguished upon conversion. Financial liabilities at fair value further include contingent considerations resulting from the Group&amp;#8217;s business combinations. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains or losses arising from fair value measurement adjustments of the embedded derivative and the contingent consideration are recognized in profit and loss within the consolidated statements of operations.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Loans, Borrowings, Trade Payables and Other Financial Liabilities&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;After initial recognition, interest-bearing loans and borrowings, trade payables and other financial liabilities are subsequently measured at amortized cost using the EIR method. Gains and losses are recognized in the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;statements of operations when the liabilities are derecognized as well as through the EIR amortization process.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortization is included as finance costs in the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;statements of operations.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;This category generally applies to interest-bearing loans and borrowings.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derecognition&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;statements of operations.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories id="F_000405" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.12&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Inventories&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories are valued at the lower of cost and net realizable value.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs incurred in bringing each product to its present location and condition are accounted for as follows:&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;raw materials and supplies: purchase cost on a first-in/first-out basis; or&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.05%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.03%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;"&gt;unfinished goods and finished goods: cost of direct materials and labor, including both internal manufacturing and third-party contract manufacturing organizations, or CMOs, and a proportion of manufacturing overheads based on the normal operating capacity, but excluding borrowing costs.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories>
  <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory id="F_000406" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.13&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Impairment of Non-Financial Assets&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group assesses, at each reporting date, whether there is an indication that an asset may be impaired. Goodwill is tested for impairment annually as of October 1. Impairment is determined for goodwill by assessing the recoverable amount of each cash generating unit (or group of CGUs) to which the goodwill relates. If any indication exists, or when annual impairment testing is performed, the Group estimates the asset&amp;#8217;s or CGU&amp;#8217;s recoverable amount. The recoverable amount is the higher of an asset&amp;#8217;s or CGU&amp;#8217;s fair value less costs of disposal and its value in use. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. When the carrying amount of an asset or cash generating unit exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used. These calculations are corroborated by valuation multiples, quoted share prices for publicly traded companies or other available fair value indicators.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group bases its impairment calculation on detailed budgets and forecast calculations, which are prepared separately for each of the Group&amp;#8217;s cash generating units to which the individual assets are allocated. These budgets and forecast calculations generally cover a period of five years. A long-term growth rate is calculated and applied to project future cash flows after the fifth year.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impairment losses of continuing operations are recognized in the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;statements of operations in expense categories consistent with the function of the impaired asset.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For assets excluding goodwill, an assessment is made at each reporting date to determine whether there is an indication that previously recognized impairment losses no longer exist or have decreased. If such indication exists, the Group estimates the asset&amp;#8217;s or cash generating unit&amp;#8217;s recoverable amount. A previously recognized impairment loss is reversed only if there has been a change in the assumptions used to determine the asset&amp;#8217;s recoverable amount since the last impairment loss was recognized. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognized for the asset in prior years. Such reversal is recognized in the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;statements of operations unless the asset is carried at a revalued amount, in which case, the reversal is treated as a revaluation increase.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents id="F_000407" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.14&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents comprise cash in banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents>
  <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory id="F_000408" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.15&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Pension&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The liability in respect of defined benefit pension plans is the defined benefit obligation calculated annually by independent actuaries using the projected unit credit method. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions of the respective employees, while the net interest on the net defined benefit liability or asset is recognized in finance expenses or finance income.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory id="F_000409" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;16&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Provisions&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Group expects some or all of a provision to be reimbursed, for example, under an insurance contract, the reimbursement is recognized as a separate asset, but only when the reimbursement is virtually certain. The expense relating to a provision is presented in the &lt;font style="color:#000000;"&gt;consolidated &lt;/font&gt;statements of operations net of any reimbursement.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory id="F_000410" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.59%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3.1&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Share-Based Payments&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employees (and others providing similar services) receive remuneration in the form of share-based payments, which are settled in equity instruments (equity-settled transactions).&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The cost of equity-settled transactions is determined by the fair value at the date when the grant is made using an appropriate valuation model, further details of which are given in Note 17. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;These costs are recognized in cost of sales, research and development expenses, sales and marketing expenses or general and administrative expenses, together with a corresponding increase in equity (other reserves), over the period in which the service is provided (the vesting period). The cumulative expense recognized for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Group&amp;#8217;s best estimate of the number of equity instruments that will ultimately vest.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
  <bntx:DescriptionOfAccountingPolicyForInitialApplicationOfStandardsExplanatory id="F_000411" contextRef="C_0001776985_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.4&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Standards applied for the First Time&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2020 several new and amended standards and interpretations became effective but did not have an impact on the consolidated financial statements of the Group. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Standards/Interpretations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Date of application&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amendments to IFRS 3 Business Combinations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amendments to IFRS 9, IAS 39 and IFRS 7 Interest Rate Benchmark Reform&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amendments to IAS 1 and IAS 8 Definition of Material&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amendments to References to the Conceptual Framework in IFRS Standards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amendment to IFRS 16 Leases COVID-19-Related Rent Concessions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</bntx:DescriptionOfAccountingPolicyForInitialApplicationOfStandardsExplanatory>
  <bntx:DescriptionOfAccountingPolicyForStandardIssuedButNotYetEffectiveExplanatory id="F_000412" contextRef="C_0001776985_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.91%;white-space:nowrap"&gt;
&lt;p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.5&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Standard issued but not yet effective&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The new and amended standards and interpretations that are issued, but not yet effective, up to the date of issuance of the Group&amp;#8217;s financial statements and that might have an impact on the Group&amp;#8217;s financial statements are disclosed below. The Group has not early adopted any standards and intends to adopt these new and amended standards and interpretations, if applicable, when they become effective. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Standards/Interpretations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Date of application&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amendments to IFRS 4 Insurance Contracts &amp;#8211; deferral of IFRS 9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2021&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 Interest Rate Benchmark Reform &amp;#8211; Phase 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2021&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amendments to IFRS 3 Business Combinations: Reference to the Conceptual Framework&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2022&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amendments to IAS 16 Property, Plant and Equipment: Proceeds before Intended Use&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2022&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amendments to IAS 37 Provisions, Contingent Liabilities and Contingent Assets - Onerous Contracts &amp;#8211; Cost of Fulfilling a Contract Amendments to IAS 37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2022&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Annual Improvements to IFRS Standards 2018-2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2022&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amendments to IAS 1 Presentation of Financial Statements: Classification of Liabilities as Current or Non-current - Deferral of Effective Date&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2023&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;IFRS 17 Insurance Contracts (issued on 18 May 2017); including Amendments to IFRS 17&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2023&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Group does not expect a significant impact of the application of any of these amendments. &lt;/p&gt;</bntx:DescriptionOfAccountingPolicyForStandardIssuedButNotYetEffectiveExplanatory>
  <bntx:DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatory id="F_000413" contextRef="C_0001776985_20200101_20201231">
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, plant and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Useful life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Years)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Buildings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7-33&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equipment, tools and installations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3-15&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatory>
  <bntx:DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatory id="F_000414" contextRef="C_0001776985_20200101_20201231">
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets or shorter lease term, as follows:&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Useful life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Years)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Buildings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2-25&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equipment, tools and installations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2-5&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Production facilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2-3&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Automobiles&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3-4&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatory>
  <bntx:DisclosureOfIntangibleAssetsUsefulLifeExplanatory id="F_000415" contextRef="C_0001776985_20200101_20201231">
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the useful lives applied to the Group&amp;#8217;s intangible assets is as follows:&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Useful life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Years)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intellectual property rights&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10-20&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Licenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3-20&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3-8&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfIntangibleAssetsUsefulLifeExplanatory>
  <bntx:DisclosureOfDetailedInformationAboutProvisionalSalesFiguresForTerritoriesExplanatory id="F_000416" contextRef="C_0001776985_20200101_20201231">
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;These estimated figures are likely to change prospectively in future periods as BioNTech receives final data from Pfizer. Those changes in BioNTech&amp;#8217;s share of the collaboration partner&amp;#8217;s gross profit will be recognized prospectively as changes to BioNTech&amp;#8217;s commercial revenues. To the extent that Pfizer does not provide such preliminary information in the future, BioNTech&amp;#8217;s provisional sales figures for territories outside of the United States will be subject to a greater level of estimation and judgment. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:1.09%;width:99.88%;"&gt;
&lt;tr&gt;
&lt;td style="width:35.4%;"&gt;&lt;/td&gt;
&lt;td style="width:14.27%;"&gt;&lt;/td&gt;
&lt;td style="width:14.27%;"&gt;&lt;/td&gt;
&lt;td style="width:21.19%;"&gt;&lt;/td&gt;
&lt;td style="width:14.75%;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="4" valign="bottom" bgcolor="#FFFFFF"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-bottom:solid 1pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-bottom:solid 1pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;German territory&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-bottom:solid 1pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. territory&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-bottom:solid 1pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Territories outside the U.S.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-bottom:solid 1pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" style=" border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style=" border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Direct product sales to BioNTech customers&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364; 20,553&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style=" border-right:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364; 20,553&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style=" border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share of collaboration partner&apos;s gross profit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364; 46,997&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style=" border-right:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364; 141,480&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364; 188,477&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Input parameters used within gross profit share calculation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-right:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:10pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Sales&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;reported&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-right:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;preliminary&lt;br /&gt;reported&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Transfer price (manufacturing, shipping costs and respective variances)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;standard&lt;br /&gt;prices&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;standard&lt;br /&gt;prices&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;License payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;identified&lt;br /&gt;royalty rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;identified&lt;br /&gt;royalty rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfDetailedInformationAboutProvisionalSalesFiguresForTerritoriesExplanatory>
  <ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory id="F_000417" contextRef="C_0001776985_20200101_20201231">
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements of the Group include the following subsidiaries: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.98%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;% equity interest&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Name&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Country of incorporation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Registered office&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech RNA Pharmaceuticals GmbH&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Mainz&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Delivery Technologies GmbH&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Halle&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Diagnostics GmbH&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Mainz&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Europe GmbH&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(previously BioNTech Small Molecules GmbH)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Mainz&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Manufacturing GmbH&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(previously BioNTech IVAC GmbH)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Mainz&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Manufacturing Marburg GmbH&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marburg&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;n/a&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Austria Beteiligungen GmbH&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Austria&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vienna&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Innovative Manufacturing Services GmbH&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Idar-Oberstein&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;reSano GmbH (previously reBOOST Management GmbH)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Mainz&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;JPT Peptide Technologies GmbH&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Berlin&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;JPT Peptide Technologies Inc.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cambridge (previously Acton)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech USA Holding, LLC&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cambridge (previously New York)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Research and Development, Inc.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cambridge (previously New York)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech US Inc.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cambridge&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;n/a&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Pharmaceuticals Asia Pacific Pte. Ltd&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Singapore&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Singapore&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;n/a&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech UK Limited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United Kingdom&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reading&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;n/a&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Cell &amp;amp; Gene Therapies GmbH&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Mainz&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Real Estate Holding GmbH&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holzkirchen&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Real Estate Verwaltungs GmbH&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holzkirchen&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Real Estate GmbH &amp;amp; Co. KG&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holzkirchen&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Real Estate An der Goldgrube GmbH &amp;amp; Co. KG&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holzkirchen&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;n/a&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Real Estate Haus Vier GmbH &amp;amp; Co. KG&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holzkirchen&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;n/a&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Real Estate Adam Opel Stra&amp;#223;e GmbH &amp;amp; Co. KG&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holzkirchen&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;n/a&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory>
  <bntx:DisclosureOfSignificantInvestmentsByParentCompanyExplanatory id="F_000418" contextRef="C_0001776985_20200101_20201231">
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ATHOS KG, Holzkirchen, Germany is the sole shareholder of AT Impf GmbH, Munich, Germany and beneficial owner of the following percentage of ordinary shares in BioNTech at the dates as indicated. ATHOS KG via AT Impf GmbH has de facto control over BioNTech based on its substantial shareholding, which enabled it to exercise the majority of voting rights to pass resolutions at BioNTech&amp;#8217;s Annual General Meeting, or AGM. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.16%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ownership of ordinary shares in BioNTech (in %)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Name&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Country of incorporation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Registered office&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;AT Impf GmbH&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Munich&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C5E0B3" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47.37%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50.33%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfSignificantInvestmentsByParentCompanyExplanatory>
  <bntx:DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatory id="F_000419" contextRef="C_0001776985_20200101_20201231">
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Medine GmbH, Mainz owned the following percentage of ordinary shares in BioNTech at the following dates as indicated: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.16%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ownership of ordinary shares in BioNTech (in %)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Name&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Country of incorporation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Registered office&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Medine GmbH&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Germany&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Mainz&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C5E0B3" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.25%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18.38%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</bntx:DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatory>
  <ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory id="F_000420" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxLipocalyxGmbHMember_20200101_20201231">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The final fair values of the identifiable net assets of Lipocalyx as at the date of acquisition were:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;recognized on&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;acquisition&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lipocalyx GmbH&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;896&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,978&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, plant and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;139&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total identifiable net assets at fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;7,088&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consideration&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;6,516&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;572&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total consideration&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;7,088&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory>
  <ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory id="F_000421" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200101_20201231">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair values and values in accordance with IFRS 3 of the identifiable net assets of BioNTech US Inc. as at the date of acquisition &lt;font style="color:#000000;"&gt;were&lt;/font&gt; as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;recognized on&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;acquisition&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech US Inc.&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;29,867&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, plant and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,617&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,896&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other assets non-current and current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,704&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,749&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;52,833&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trade payables&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,723&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other liabilities non-current and current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,793&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;19,516&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total identifiable net assets at fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;33,317&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill from the acquisition&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,573&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consideration transferred&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;89,890&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consideration&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares issued, at fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89,548&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;342&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total consideration&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;89,890&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory>
  <ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory id="F_000422" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechManufacturingMarburgGmbHMember_20200101_20201231">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair values and values in accordance with IFRS 3 of the identifiable net assets of BioNTech Manufacturing Marburg GmbH, or BioNTech Marburg, as at the date of acquisition &lt;font style="color:#000000;"&gt;were&lt;/font&gt; as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;recognized on&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;acquisition&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioNTech Manufacturing Marburg GmbH&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, plant and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79,828&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,514&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,466&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other assets non-current and current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,343&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,319&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;131,470&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provisions non-current and current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,127&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trade payables&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,105&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other liabilities non-current and current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,383&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;46,615&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total identifiable net assets at fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;84,855&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Bargain purchase&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,002)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consideration transferred&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;77,853&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consideration&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77,853&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total consideration&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;77,853&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory>
  <ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory id="F_000423" contextRef="C_0001776985_20200101_20201231">The reconciliation of this carrying amount at the beginning and end of the reporting period is presented below:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,978&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquisition of subsidiaries and businesses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,469&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,750)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;53,697&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="line-height:5pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&amp;nbsp;&lt;/p&gt;</ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory>
  <ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory id="F_000424" contextRef="C_0001776985_20200101_20201231">
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Set out below is the disaggregation of the Group&amp;#8217;s revenues from contracts with customers:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research &amp;amp; development revenues from collaborations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;178,849&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;84,428&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;101,837&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Pfizer Inc.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;121,597&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;14,348&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;7,173&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Genentech Inc.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;49,195&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;64,026&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;49,536&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Shanghai Fosun Pharmaceutical (Group) Co., Ltd&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;5,074&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;2,983&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;6,054&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;45,128&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;303,476&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,161&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,738&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;COVID-19 vaccine revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;270,490&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Sales to collaboration partner*&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;61,460&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Direct product sales to BioNTech customers&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;20,553&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Share of collaboration partner&apos;s gross profit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;188,477&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other sales&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,986&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,161&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,738&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;482,325&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;108,589&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;127,575&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*Represents sales to collaboration partner of products manufactured by BioNTech. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The revenues from contracts with customers disclosed above were recognized as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Timing of revenue recognition&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Goods and services transferred at a point in time&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;108,840&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;16,955&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;22,828&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Goods and services transferred over time&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;373,485&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,634&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104,747&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;482,325&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;108,589&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;127,575&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory>
  <bntx:DisclosureOfContractBalancesFromContractsWithCustomersExplanatory id="F_000425" contextRef="C_0001776985_20200101_20201231">
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trade receivables&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;165,468&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;11,913&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;371,475&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;190,692&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</bntx:DisclosureOfContractBalancesFromContractsWithCustomersExplanatory>
  <bntx:DisclosureOfRecognitionOfRevenueExplanatory id="F_000426" contextRef="C_0001776985_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Set out below is the amount of revenue recognized &lt;font style="color:#000000;"&gt;for the periods &lt;/font&gt;indicated:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts included in contract liabilities at the beginning of the year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;58,895&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;84,112&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;59,583&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</bntx:DisclosureOfRecognitionOfRevenueExplanatory>
  <ifrs-full:DisclosureOfPerformanceObligationsExplanatory id="F_000427" contextRef="C_0001776985_20200101_20201231">
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The contract liabilities allocated to the remaining performance obligations from collaboration or commercial supply agreements (unsatisfied or partially unsatisfied) as at year-end are as follows: &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Within one year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;299,583&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;93,583&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;More than one year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71,892&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;97,109&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;371,475&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;190,692&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;</ifrs-full:DisclosureOfPerformanceObligationsExplanatory>
  <ifrs-full:DisclosureOfCostOfSalesExplanatory id="F_000428" contextRef="C_0001776985_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.93%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of sales related to COVID-19 vaccine revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;35,616&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost related to other sales&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,717&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,361&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,690&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;59,333&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;17,361&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;13,690&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</ifrs-full:DisclosureOfCostOfSalesExplanatory>
  <ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory id="F_000429" contextRef="C_0001776985_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchased services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;359,880&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;65,552&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;42,079&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Wages, benefits and social security expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;126,298&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;83,213&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,668&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory supplies&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;107,792&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,218&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,921&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,192&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,533&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,312&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;IT costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,118&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,572&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease and lease related cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,725&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,527&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,404&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Transport costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,135&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,081&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;668&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,889&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,542&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,416&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;645,029&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;226,466&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;143,040&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory>
  <bntx:DisclosureOfSalesAndMarketingExpensesExplanatory id="F_000430" contextRef="C_0001776985_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchased services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;10,929&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;247&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;794&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Wages, benefits and social security expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,636&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,938&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,728&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,947&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;533&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;519&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;14,512&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,718&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;3,041&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</bntx:DisclosureOfSalesAndMarketingExpensesExplanatory>
  <ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory id="F_000431" contextRef="C_0001776985_20200101_20201231">
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Wages, benefits and social security expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;33,007&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;19,122&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;8,582&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchased services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,419&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,177&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;IT and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,404&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,573&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,774&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,104&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,855&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,284&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Insurance premiums&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,840&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,061&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;145&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Job advertisement expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,897&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;548&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;861&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease and lease related cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,390&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,715&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,012&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,033&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;232&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory supplies&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,191&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;785&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;456&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract staffing&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,108&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;686&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;781&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,053&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,551&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,236&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;94,049&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;45,547&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;26,334&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory>
  <ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory id="F_000432" contextRef="C_0001776985_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government grants&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;239,017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,547&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;4,228&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Bargain purchase&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,002&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,520&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,177&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,118&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;250,539&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,724&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;5,396&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory>
  <bntx:DisclosureOfChangesRegardingGovernmentGrantsExplanatory id="F_000433" contextRef="C_0001776985_20200101_20201231">
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Received during the year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;330,968&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,547&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,228&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Released to the consolidated statements of operations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(239,017)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,547)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,228)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;91,951&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,951&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total non-current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</bntx:DisclosureOfChangesRegardingGovernmentGrantsExplanatory>
  <ifrs-full:DisclosureOfFinanceIncomeExplanatory id="F_000434" contextRef="C_0001776985_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.78%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,564&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,781&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,996&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign exchange gains, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,341&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,050&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,564&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;4,122&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;8,046&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</ifrs-full:DisclosureOfFinanceIncomeExplanatory>
  <ifrs-full:DisclosureOfFinanceCostExplanatory id="F_000435" contextRef="C_0001776985_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.78%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization of financial instruments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;3,048&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;326&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;48&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value adjustments of financial instruments measured at fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,289&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign exchange loss, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,609&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;62,946&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;326&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;48&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</ifrs-full:DisclosureOfFinanceCostExplanatory>
  <bntx:DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatory id="F_000436" contextRef="C_0001776985_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Wages and salaries&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;160,655&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;98,568&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;54,149&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Social security costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,988&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,394&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,231&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pension costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;761&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;517&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;324&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;179,404&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;111,479&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;62,704&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</bntx:DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatory>
  <bntx:DisclosureOfCurrentAndDeferredTaxExpenseExplanatory id="F_000437" contextRef="C_0001776985_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table illustrates the current and deferred taxes for the periods indicated: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C5E0B3" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;17&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(296)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;600&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C5E0B3" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(161,034)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(161,000)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(268)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;600&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfCurrentAndDeferredTaxExpenseExplanatory>
  <bntx:DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatory id="F_000438" contextRef="C_0001776985_20200101_20201231">
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table reconciles the expected income taxes to the actual current income taxes and deferred taxes as presented in the table above. The combined income tax rate of 30.79% in the year ended December&amp;#160;31, 2020 (during the years ended December 31, 2019 and 2018: 30.78% and 30.99%, respectively) was applied to loss before taxes to calculate the expected income taxes. This rate consists of above outlined tax rates of BioNTech SE applicable to the Group. The slight decrease of the tax rate results from the Lipocalyx GmbH business combination. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss before tax&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(145,802)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(179,440)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(47,662)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected tax benefit (based on BioNTech`s statutory tax rate of 30.79%, 2019: 30.78%, 2018: 30.99%)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,891&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,240&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,776&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Effects&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government grants exempted from taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-deductible expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(770)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(58)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Add-back for trade tax purposes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(595)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(110)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(96)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-tax effective bargain purchase&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,156&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-recognition of tax effect on share-based payment expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,806)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,308)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax-effective equity transaction costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,229&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,121&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Utilization of tax losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,165&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-recognition of deferred taxes on tax losses and temporary differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12,961)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(51,197)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,634)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognition of deferred taxes on tax losses not recognized in prior periods&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,231&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognition of deferred taxes on temporary differences not recognized in prior periods&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,241&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;192&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effect from lower foreign income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,304)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(102)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustment prior year tax&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(326)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;316&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,059&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other effects&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(59)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;126&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,821)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;161,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;268&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(600)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</bntx:DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatory>
  <ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory id="F_000439" contextRef="C_0001776985_20200101_20201231">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred taxes for the periods indicated relate to the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognized in P&amp;amp;L*&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognized in OCI&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquisition of subsidiaries and businesses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(655)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(2,370)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;8,637&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;5,612&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;596&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;329&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;971&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;512&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,091)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,593)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,543&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(174)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,369&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest-bearing loans and borrowings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,741)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;195&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,546)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net employee defined benefit liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;169&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(63)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;698&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;804&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provisions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;187&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;886&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;419&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,492&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other (incl. deferred expenses)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,087&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,336&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;202&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,625&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax loss carryforward / tax credit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;109,764&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,660&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,280&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;175,704&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Tax Assets Net (before valuation)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;136,034&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;40,721&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(63)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;34,746&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;211,438&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation Adjustment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(136,034)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;120,313&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(34,765)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(50,486)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Tax Assets Net (after valuation)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;161,034&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(63)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(19)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;160,952&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*Includes all changes in deferred taxes related to U.S. tax group other than those acquired in business combination&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognized in P&amp;amp;L&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognized in OCI&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquisition of subsidiaries and businesses &lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(90)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(565)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(655)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;596&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;596&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;306&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;206&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;512&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,441&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,898)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;23,543&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provisions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;134&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;187&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other (incl. deferred expenses)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;161&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,926&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,087&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax loss carryforward / tax credit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,848&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,916&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;109,764&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Tax Assets Net (before valuation)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;84,799&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;51,235&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;136,034&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation Adjustment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(84,799)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(51,235)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(136,034)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Tax Assets Net (after valuation)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory>
  <bntx:DisclosureOfAccumulatedTaxLossesExplanatory id="F_000440" contextRef="C_0001776985_20200101_20201231">
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated tax losses of the German tax group, German &lt;font style="color:#000000;"&gt;entities&lt;/font&gt; &lt;font style="color:#000000;"&gt;not within the tax group &lt;/font&gt;and U.S. tax group for the periods indicated amount to the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate Tax&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;596,359&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;356,044&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;179,264&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trade Tax&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;513,561&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;352,341&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;176,425&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal Tax Credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;756&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State Tax Credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfAccumulatedTaxLossesExplanatory>
  <ifrs-full:EarningsPerShareExplanatory id="F_000441" contextRef="C_0001776985_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table reflects the income and share data used in the basic and diluted EPS calculations:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gain (loss) attributable to ordinary equity holders of the parent for basic earnings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;15,198&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(179,056)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(48,019)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of ordinary shares for basic EPS&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;235,442&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;211,499&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;190,710&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effects of dilution from share options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C5E0B3" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,085&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of ordinary shares adjusted for the effect of dilution&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;248,527&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;211,499&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;190,710&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Earnings per share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;in EUR&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted, profit / (loss) for the period attributable to ordinary equity holders of the parent*&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;0.06&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(0.85)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(0.25)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;"&gt;&amp;nbsp;&lt;/p&gt;</ifrs-full:EarningsPerShareExplanatory>
  <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory id="F_000442" contextRef="C_0001776985_20200101_20201231">
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Land and buildings&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equipment, tools and installations&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress and advance payments&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquisition and production costs&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;22,147&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;73,613&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;7,091&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;102,853&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,269&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,700&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,623&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,592&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(105)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(115)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassifications&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(53)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquisition of subsidiaries and businesses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;999&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;999&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;29,469&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;83,206&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;29,652&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;142,329&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;29,469&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;83,206&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;29,652&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;142,329&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,927&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,093&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,033&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,892)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(958)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,891)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassifications&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,561&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,832&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,391)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(52)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(638)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(690)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquisition of subsidiaries and businesses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,400&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,817&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,302&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,519&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;61,264&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;142,418&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;81,618&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;285,300&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Land and buildings&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equipment, tools and installations&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress and advance payments&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cumulative depreciation and impairment charges&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;6,472&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;30,180&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;36,652&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,854&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,861&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,715&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(79)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(79)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassifications&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;8,326&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;40,959&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;49,285&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;8,326&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;40,959&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;49,285&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,074&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,753&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,827&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,683)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,724)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassifications&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(53)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(56)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;10,356&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;47,976&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;58,332&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Land and buildings&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equipment, tools and installations&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress and advance payments&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Carrying amount&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;15,675&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;43,433&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;7,091&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;66,200&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;21,143&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;42,247&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;29,652&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;93,044&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;50,908&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;94,442&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;81,618&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;226,968&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
  <ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory id="F_000443" contextRef="C_0001776985_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concessions, licenses, in-process R&amp;amp;D and similar rights&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Advance payments&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquisition costs&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;534&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;101,853&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,497&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;103,883&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,744&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,529&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,273&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(133)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(477)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(610)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassifications&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;146&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(146)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquisition of subsidiaries and businesses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,444&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,726&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,170&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,978&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;116,313&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,403&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;121,693&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,978&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;116,313&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,403&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;121,693&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,187&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,426&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,613&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,435)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(643)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,078)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassifications&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;233&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(233)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,750)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,897)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,647)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquisition of subsidiaries and businesses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,469&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,845&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;93,314&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;53,697&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;147,246&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;5,953&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;206,895&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concessions, licenses, in-process R&amp;amp;D and similar rights&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Advance payments&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cumulative depreciation and impairment charges&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;15,842&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;15,842&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,502&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,502&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(81)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(81)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassifications&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;32,260&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;32,260&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;32,260&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;32,260&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,627&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,627&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Disposals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,410)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,410)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassifications&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(72)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(72)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;43,405&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;43,405&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concessions, licenses, in-process R&amp;amp;D and similar rights&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Advance payments&lt;/p&gt;&lt;/td&gt;
&lt;td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Carrying amount&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;534&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;86,011&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,497&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;88,042&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,978&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;84,053&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,403&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;89,434&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;53,697&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;103,841&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;5,953&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;163,490&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory>
  <bntx:DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatory id="F_000444" contextRef="C_0001776985_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.72%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;CGU Immunotherapies&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.72%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;External Product Sales of JPT&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.12%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;53,163&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,444&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;534&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;534&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;53,697&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,978&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</bntx:DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatory>
  <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory id="F_000445" contextRef="C_0001776985_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents at banks and on hand&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,210,209&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;519,149&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,210,209&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;519,149&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
  <ifrs-full:DisclosureOfFinancialAssetsExplanatory id="F_000446" contextRef="C_0001776985_20200101_20201231">
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td colspan="4" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets at amortized cost&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trade receivables&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;165,468&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;11,913&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;137,234&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,680&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;302,702&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;13,593&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;302,702&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,593&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total non-current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</ifrs-full:DisclosureOfFinancialAssetsExplanatory>
  <ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory id="F_000447" contextRef="C_0001776985_20200101_20201231">
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td colspan="4" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest-bearing loans and borrowings&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturity&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;84,158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;57,611&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible note - host contract&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;08/28/2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;87,457&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.50% &amp;#8364; 50,000,000 secured bank loan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12/21/2026&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,176&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.15% &amp;#8364; 10,000,000 secured bank loan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12/30/2027&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,032&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,000&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.08% &amp;#8364; 9,450,000 secured bank loan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;09/30/2028&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,877&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,600&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.90% &amp;#8364; 3,528,892.48 secured bank loan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;05/30/2039&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,489&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;240,189&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;74,211&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,142&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,307&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total non-current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;231,047&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68,904&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td colspan="4" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other financial liabilities&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivatives not designated as hedging instrument&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible note - embedded derivative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;30,903&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial liabilities at fair value through profit or loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;572&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial liabilities at fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;31,475&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.6%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other financial liabilities at amortized cost, other than interest-bearing loans and borrowings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trade payables&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,288&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,498&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other financial liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74,076&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,352&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total other financial liabilities at amortized cost, other than interest-bearing loans and borrowings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;176,364&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;30,850&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total other financial liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;207,839&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;30,850&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;176,363&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,850&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total non-current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,476&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td colspan="4" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial liabilities&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest-bearing loans and borrowings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;240,189&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;74,211&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other financial liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;207,839&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;30,850&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;448,028&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;105,061&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;185,505&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,157&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total non-current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;262,523&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68,904&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The maturity profile of the Group&amp;#8217;s financial liabilities based on contractual undiscounted payments is summarized as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="4" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.36%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less than 1 year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1 to 5 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;More than 5 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest bearing loans and borrowings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;3,173&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;12,643&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;66,730&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;82,546&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trade and other payables&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,288&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;102,288&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,525&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,283&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71,780&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;107,588&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;572&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;572&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other financial liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74,076&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;74,076&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;188,062&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;39,926&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;139,082&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;367,070&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory>
  <bntx:DisclosureOfForeignCurrencyRiskExplanatory id="F_000448" contextRef="C_0001776985_20200101_20201231">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amount of the monetary assets (the Group&amp;#8217;s cash and cash equivalents) of BioNTech denominated in foreign currencies at the dates indicated are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.82%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.82%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. dollar Bank accounts&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;673,545&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;213,913&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other financial assets in U.S. dollar&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,573&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.82%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial liabilities in U.S. dollar&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,821&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;686,297&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;213,913&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</bntx:DisclosureOfForeignCurrencyRiskExplanatory>
  <ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory id="F_000449" contextRef="C_0001776985_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;1 &amp;#8364; =&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.08%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Closing rate&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.08%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average rate&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Country&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. dollar&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.2271&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.1234&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.1422&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.1195&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in U.S. dollar rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effect on loss before tax&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effect on pre-tax equity&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;+5 %&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(32,491)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(32,681)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-5%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;35,911&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;36,121&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-right:solid 1pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-left:solid 1pt #70AD47; border-right:solid 1pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;+5 %&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-left:solid 1pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-right:solid 1pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(10,186)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-left:solid 1pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(10,186)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-5%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;11,259&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;11,259&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory>
  <ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory id="F_000450" contextRef="C_0001776985_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash flows&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquisition of subsidiaries and businesses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;New leases and disposals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassification&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current obligations under lease contracts&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;3,485&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(12,743)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,719&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;8,684&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;3,982&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;6,127&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-current obligations under lease contracts&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,126&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,331&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,444)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,982)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;78,031&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest-bearing loans and borrowings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,600&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;140,847&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,416)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;156,031&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible note - embedded derivative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,614&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,289&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,903&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;74,211&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;141,718&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;35,050&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;4,240&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;15,873&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;271,092&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash flows&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquisition of subsidiaries and businesses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;New leases and disposals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassification&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current obligations under lease contracts&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,134&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(3,061)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,484&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,928&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;3,485&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-current obligations under lease contracts&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,618&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,436&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,928)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,126&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest-bearing loans and borrowings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,600&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,600&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;56,352&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;7,939&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;9,920&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;74,211&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory>
  <bntx:DisclosureOfClassesOfInventoriesExplanatory id="F_000451" contextRef="C_0001776985_20200101_20201231">
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Raw materials and supplies&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;44,283&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;8,201&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unfinished goods&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,380&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,888&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;457&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;633&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;64,120&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;11,722&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</bntx:DisclosureOfClassesOfInventoriesExplanatory>
  <bntx:DisclosureOfDetailedInformationAboutOtherAssetsExplanatory id="F_000452" contextRef="C_0001776985_20200101_20201231">
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepayments on inventories&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,845&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;351&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepayments related to CRO and CMO contracts&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,140&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales tax receivable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,155&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,536&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepayments related to service contracts&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,825&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,046&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,182&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;62,011&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;9,069&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60,966&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,069&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total non-current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,045&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</bntx:DisclosureOfDetailedInformationAboutOtherAssetsExplanatory>
  <ifrs-full:DisclosureOfExpensesExplanatory id="F_000453" contextRef="C_0001776985_20200101_20201231">
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred expenses from insurance contracts&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;13,845&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,758&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred expenses from CRO and CMO contracts&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,725&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,431&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,104&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;28,001&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;5,862&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,001&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,862&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total non-current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</ifrs-full:DisclosureOfExpensesExplanatory>
  <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory id="F_000454" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeEquityPlanMember_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reconciliation of Outstanding Share-Options&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted Stock Units (expected to be allocated)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share price (in &amp;#8364;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected to be allocated under LTI Program&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;252,766&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66.43&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected to be allocated under LTI-plus Program&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;396,938&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66.43&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;649,704&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;66.43&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory>
  <ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss id="F_000455" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeEquityPlanMember_20200101_20201231">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expense recognized in the Consolidated Statements of Operations&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of sales&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;179&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;681&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales and marketing expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;147&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,015&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss>
  <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory id="F_000456" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200101_20201231">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The share options allocated and expected to be allocated to BioNTech&amp;#8217;s Management Board as of the dates indicated are presented in the tables below. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share options (expected to be allocated)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average exercise price (&amp;#8364;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted as of allocation date February 13, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;248,096&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28.32&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected to be allocated as of estimated allocation date 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;101,422&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.26*&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected to be allocated as of estimated allocation date 2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,463&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.27*&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;451,981&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;45.89&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*Valuation parameter derived from the Monte-Carlo simulation model&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The share options allocated and expected to be allocated under the Management Board Grant were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Allocation date February 13, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share options&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average exercise price (&amp;#8364;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prof. Ugur Sahin, M.D.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;97,420&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28.32&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sean Marett&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,968&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28.32&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dr. Sierk Poetting&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,968&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28.32&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dr. &amp;#214;zlem T&amp;#252;reci, M.D.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,968&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28.32&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ryan Richardson&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,772&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28.32&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated allocation date 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share options&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;outstanding (expected to be allocated)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average exercise price (&amp;#8364;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prof. Ugur Sahin, M.D.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,826&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.26*&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sean Marett&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,930&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.26*&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dr. Sierk Poetting&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,930&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.26*&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dr. &amp;#214;zlem T&amp;#252;reci, M.D.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,930&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.26*&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ryan Richardson&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,806&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.26*&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*Valuation parameter derived from the Monte-Carlo simulation model&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated allocation date 2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share options&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;outstanding (expected to be allocated)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average exercise price (&amp;#8364;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prof. Ugur Sahin, M.D.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,817&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.27*&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sean Marett&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,927&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.27*&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dr. Sierk Poetting&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,927&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.27*&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dr. &amp;#214;zlem T&amp;#252;reci, M.D.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,927&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.27*&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ryan Richardson&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,865&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.27*&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*Valuation parameter derived from the Monte-Carlo simulation model&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The share options outstanding as of December 31, 2020 issued to the Management Board Grant were as follows:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share options&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of ordinary shares underlying options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average exercise price (&amp;#8364;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prof. Ugur Sahin, M.D.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;101,686&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,830,348&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.14&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sean Marett&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,895&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;610,110&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.14&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dr. Sierk Poetting&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,895&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;610,110&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.14&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dr. &amp;#214;zlem T&amp;#252;reci, M.D.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;108,463*&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,952,334&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.14&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ryan Richardson**&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,306***&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;149,508&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.14&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Options fully vested on March 16, 2019, however these options will not become exercisable until September&amp;#160;16,&amp;#160;2022.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;**&amp;#160;&amp;#160;&amp;#160;Ryan Richardson was appointed to the Management Board as Chief Strategy Officer (CSO) and Managing Director on January 12, 2020. The share options granted on November 15, 2018 under the Employee&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Stock Ownership Plan were granted before his appointment to the Management Board. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;***&amp;#160;Options fully vested on October 10, 2019, however these options will not become exercisable until September&amp;#160;16,&amp;#160;2022.&lt;/p&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
  <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory id="F_000457" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200101_20201231">The parameters used for measuring the fair values as of the respective (estimated) allocation dates were as follows:
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Allocation date February 13, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated allocation date&amp;nbsp;&amp;nbsp;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated allocation date 2022&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average fair value*&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;10.83&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;26.85&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;26.61&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average share price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;28.20&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364; 66.43*&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364; 66.43*&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;28.32&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364; 67.26*&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364; 67.27*&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility (%)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36.6%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41.0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40.7%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life (years)*&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.75&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.01&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.05&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate (%)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.61 %&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.88%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.88%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*Valuation parameter derived from the Monte-Carlo simulation model&lt;/p&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
  <ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss id="F_000458" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200101_20201231">
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The expenses recognized for employee services received during the periods indicated are shown in the following table: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,514&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,246&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,760&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss>
  <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory id="F_000459" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_20200101_20201231">The inputs used in the measurement of the fair value at grant date of the Chief Executive Officer Grant were as follows:
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant date October 10, 2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;5.63&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average share price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;13.60&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;13.60&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility (%)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41.4%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.37&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate (%)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.52 %&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
  <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory id="F_000460" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20200101_20201231">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The inputs used in the measurement of the fair values at grant date of the ESOP was as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant date&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;15 November 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant dates&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;between&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;February 21 -&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;April 3, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant dates&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;between&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;April 29 -&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;May 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant date December 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;7.41&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;6.93&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;7.04&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;9.49&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average share price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;14.40&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;15.72&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;16.03&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;19.84&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;10.14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;15.03&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;15.39&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;15.82&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility (%)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46.0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46.0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46.0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46.0%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.84&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.50&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate (%)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.05%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.05%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.05%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.05%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
  <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory id="F_000461" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20200101_20201231">Set out below is an overview of changes to share options outstanding and number of ordinary shares underlying these options that occurred during the periods indicated:
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share options&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of ordinary shares underlying options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average exercise price (&amp;#8364;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;658,109&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,845,962&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.14&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,511&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;261,198&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.17&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17,237)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(310,266)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.85&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;655,383&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,796,894&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.23&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;655,383&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,796,894&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.23&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,491)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(170,838)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.81&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;645,892&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,626,056&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.23&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
  <ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss id="F_000462" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20200101_20201231">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The expenses recognized for employee services received during the periods indicated are shown in the following table:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of sales&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;869&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;896&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;114&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,120&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,786&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales and marketing expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;111&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;108&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,975&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,008&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;728&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;17,075&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;27,028&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;7,641&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss>
  <bntx:DisclosureOfDetailedInformationAboutOtherLiabilitiesExplanatory id="F_000463" contextRef="C_0001776985_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities to employees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;24,248&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;6,710&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,379&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;780&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;28,627&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;7,490&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,061&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,490&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total non-current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;566&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</bntx:DisclosureOfDetailedInformationAboutOtherLiabilitiesExplanatory>
  <ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory id="F_000464" contextRef="C_0001776985_20200101_20201231">
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following amounts are presented as right-of-use assets within the consolidated statements of financial position as of the dates indicated: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Buildings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;80,875&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;54,956&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equipment, tools and installations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Automobiles&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;108&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Production facilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,202&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Advance payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;98,988&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;55,018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory>
  <bntx:DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatory id="F_000465" contextRef="C_0001776985_20200101_20201231">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following amounts are included in interest-bearing loans and borrowings as of the dates indicated: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;6,127&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;3,485&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78,031&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,126&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;84,158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;57,611&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatory>
  <bntx:DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInstatementOfOperationsExplanatory id="F_000466" contextRef="C_0001776985_20200101_20201231">
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation Charge of Right-of-Use Assets&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Buildings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;4,628&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;4,614&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,751&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equipment, tools and installations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Automobiles&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Production facilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,613&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total depreciation charge&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;6,290&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;4,679&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,846&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,003&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,718&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,721&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expense related to short-term leases&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(included in other expenses)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;875&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;442&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;431&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expense relating to leases of low-value assets that are not short-term leases (included in other expenses)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;300&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total amounts recognized in profit or loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;9,468&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;6,929&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;5,088&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInstatementOfOperationsExplanatory>
  <ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory id="F_000467" contextRef="C_0001776985_20200101_20201231">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the defined benefit obligation recognized in non-current provisions:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Base plan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,140&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplement plan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,125&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;4,265&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory>
  <bntx:DisclosureOfDetailedInformationAboutNetBenefitExpenseRecognizedInStatementOfProfitOrLossExplanatory id="F_000468" contextRef="C_0001776985_20200101_20201231">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the components of net benefit expense recognized in the statement of profit or loss for both plans: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Service cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;24&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net interest expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;30&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfDetailedInformationAboutNetBenefitExpenseRecognizedInStatementOfProfitOrLossExplanatory>
  <bntx:DisclosureOfDetailedInformationAboutRemeasurementsRecognizedInOtherComprehensiveIncomeExplanatory id="F_000469" contextRef="C_0001776985_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the components of remeasurements recognized in other comprehensive income for both plans:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Actuarial changes arising from changes in financial assumptions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;227&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Experience adjustments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;210&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfDetailedInformationAboutRemeasurementsRecognizedInOtherComprehensiveIncomeExplanatory>
  <ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory id="F_000470" contextRef="C_0001776985_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Set out below is an overview of changes to the defined benefit obligation during the period indicated for both plans:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Defined benefit obligations&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquisition of subsidiaries and businesses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,029)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Service cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(24)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net interest expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Benefits paid&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Actuarial changes arising from changes in financial assumptions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(227)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Experience adjustments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(4,265)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory>
  <ifrs-full:DisclosureOfAnalysisOfPresentValueOfDefinedBenefitObligationThatDistinguishesNatureCharacteristicsAndRisksExplanatory id="F_000471" contextRef="C_0001776985_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The principal assumptions used in determining the defined benefit obligation for the Group&amp;#8217;s plans are shown below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.34%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.36%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.34%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Discount rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.80%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price inflation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.36%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.00%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rate of salary increase&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.36%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.50%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pension increases for in-payment benefits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.36%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.75%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfAnalysisOfPresentValueOfDefinedBenefitObligationThatDistinguishesNatureCharacteristicsAndRisksExplanatory>
  <ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory id="F_000472" contextRef="C_0001776985_20200101_20201231">
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The main actuarial assumptions that are used to calculate the provisions for post-employment benefits are the discount rate and the trend for future increases in post-employment benefit payments. A reasonably possible increase, or respective decrease, in the significant actuarial assumptions would have impacted the present value of the post-employment benefit obligations as of December&amp;#160;31, 2020 as shown below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td colspan="3" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quantitative sensitivity analysis&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Discount rate increase 0.25%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;(282)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Discount rate decrease 0.25%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;309&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pension increases for in payment benefits 0.25%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;475&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pension decreases for in payment benefits 0.25%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(447)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory>
  <bntx:DisclosureOfDetailedInformationAboutExpectedPaymentsOrContributionsToDefinedBenefitPlanExplanatory id="F_000473" contextRef="C_0001776985_20200101_20201231">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following are the expected payments or contributions to the plans in future years:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td colspan="3" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected payments or contributions in future years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less than 1 year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;29&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1 to 5 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;317&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;More than 5 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;340&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;686&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfDetailedInformationAboutExpectedPaymentsOrContributionsToDefinedBenefitPlanExplanatory>
  <ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory id="F_000474" contextRef="C_0001776985_20200101_20201231">Key management personnel compensation is comprised of the following:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compensation of key management personnel of the Group&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term employee benefits incurred&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,627&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,847&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,161&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term employee benefits accrued*&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;740&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share-based payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,700**&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,151&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,163&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total compensation paid to key management personnel&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;24,067&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;19,998&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;7,324&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:2pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:2.86%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"&gt;Includes the fair value of the second installment of the short-term incentive compensation, which has been classified as cash-settled share-based payment arrangement was determined pursuant to the regulations of IFRS 2 &amp;#8220;Share-based Payments&amp;#8221;. This table shows the pro-rata share of personnel expenses for the respective financial year that are recognized over the award&amp;#8217;s vesting period beginning as of the service commencement date (January 1, 2020) until each separate determination date and are remeasured until settlement date.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:2.86%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;**&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"&gt;Includes expenses from a bonus arrangement agreed with Ryan Richardson in advance of his appointment to the Management Board. During the year ended December 31, 2020, the arrangement was modified from an all-equity share-based payment arrangement into a partly cash and partly equity settled share-based payment arrangement including 4,534 ordinary shares which have not yet been issued. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate value of transactions related to key management personnel were as follows for the periods indicated:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consulting services / patent assignment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;25&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;56&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;25&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchases of various goods and services from TRON&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,105&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,968&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,160&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;10,130&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;10,024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;11,185&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The outstanding balances of transactions related to key management personnel were as follows as at the periods indicated:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt; (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consulting service provider&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;TRON&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,229&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,843&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,236&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;1,843&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory>
  <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory id="F_000475" contextRef="C_0001776985_20200101_20201231">
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The total amount of transactions with ATHOS KG or entities controlled by it was as follows for the periods indicated:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchases of various goods and services from entities controlled by ATHOS KG&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,296&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,071&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,431&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchases of property and other assets from entities controlled by ATHOS KG&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,349&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,748&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;4,645&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;2,071&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;7,179&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The outstanding balances of transactions with ATHOS KG or entities controlled by them were as follows as at the periods indicated:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ATHOS KG&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;51&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8364;51&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
  <bntx:NumberOfNewRealEstateEntitiesFounded id="F_000476" contextRef="C_0001776985_ifrs-fullGeographicalAreasAxis_countryDE_20200101_20201231" decimals="INF" unitRef="U_bntxEntity">3</bntx:NumberOfNewRealEstateEntitiesFounded>
  <bntx:NumberOfOperationSegments id="F_000477" contextRef="C_0001776985_20200101_20200930" decimals="INF" unitRef="U_bntxOperationSegment">4</bntx:NumberOfOperationSegments>
  <bntx:NumberOfOperationSegments id="F_000478" contextRef="C_0001776985_20201201_20201231" decimals="INF" unitRef="U_bntxOperationSegment">1</bntx:NumberOfOperationSegments>
  <bntx:NumberOfReportingSegments id="F_000479" contextRef="C_0001776985_20201201_20201231" decimals="INF" unitRef="U_bntxReportingSegment">1</bntx:NumberOfReportingSegments>
  <bntx:MinimumNumberOfCountriesInWhichCOVID19VaccineAuthorizedOrApprovedForEmergencyOrTemporaryUseOrGrantedConditionalMarketingAuthorization id="F_000480" contextRef="C_0001776985_20201201_20201231" decimals="INF" unitRef="U_bntxCountry">65</bntx:MinimumNumberOfCountriesInWhichCOVID19VaccineAuthorizedOrApprovedForEmergencyOrTemporaryUseOrGrantedConditionalMarketingAuthorization>
  <ifrs-full:DescriptionOfSignificantPaymentTermsInContractsWithCustomers id="F_000481" contextRef="C_0001776985_20200101_20201231">Payments from customers are due within 20 days (Europe) or 30 days (non-Europe) after invoice.</ifrs-full:DescriptionOfSignificantPaymentTermsInContractsWithCustomers>
  <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment id="F_000482" contextRef="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullBuildingsMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20200101_20201231">P7Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
  <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment id="F_000483" contextRef="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullBuildingsMember_srtRangeAxis_ifrs-fullTopOfRangeMember_20200101_20201231">P33Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
  <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment id="F_000484" contextRef="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20200101_20201231">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
  <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment id="F_000485" contextRef="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_srtRangeAxis_ifrs-fullTopOfRangeMember_20200101_20201231">P15Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
  <bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets id="F_000486" contextRef="C_0001776985_ifrs-fullClassesOfAssetsAxis_ifrs-fullBuildingsMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20200101_20201231">P2Y</bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets>
  <bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets id="F_000487" contextRef="C_0001776985_ifrs-fullClassesOfAssetsAxis_ifrs-fullBuildingsMember_srtRangeAxis_ifrs-fullTopOfRangeMember_20200101_20201231">P25Y</bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets>
  <bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets id="F_000488" contextRef="C_0001776985_ifrs-fullClassesOfAssetsAxis_bntxEquipmentToolsAndInstallationsMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20200101_20201231">P2Y</bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets>
  <bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets id="F_000489" contextRef="C_0001776985_ifrs-fullClassesOfAssetsAxis_bntxEquipmentToolsAndInstallationsMember_srtRangeAxis_ifrs-fullTopOfRangeMember_20200101_20201231">P5Y</bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets>
  <bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets id="F_000490" contextRef="C_0001776985_ifrs-fullClassesOfAssetsAxis_bntxProductionFacilitiesMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20200101_20201231">P2Y</bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets>
  <bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets id="F_000491" contextRef="C_0001776985_ifrs-fullClassesOfAssetsAxis_bntxProductionFacilitiesMember_srtRangeAxis_ifrs-fullTopOfRangeMember_20200101_20201231">P3Y</bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets>
  <bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets id="F_000492" contextRef="C_0001776985_ifrs-fullClassesOfAssetsAxis_ifrs-fullVehiclesMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20200101_20201231">P3Y</bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets>
  <bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets id="F_000493" contextRef="C_0001776985_ifrs-fullClassesOfAssetsAxis_ifrs-fullVehiclesMember_srtRangeAxis_ifrs-fullTopOfRangeMember_20200101_20201231">P4Y</bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets>
  <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill id="F_000494" contextRef="C_0001776985_ifrs-fullClassesOfIntangibleAssetsOtherThanGoodwillAxis_bntxIntellectualPropertyRightsMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20200101_20201231">P10Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill id="F_000495" contextRef="C_0001776985_ifrs-fullClassesOfIntangibleAssetsOtherThanGoodwillAxis_bntxIntellectualPropertyRightsMember_srtRangeAxis_ifrs-fullTopOfRangeMember_20200101_20201231">P20Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill id="F_000496" contextRef="C_0001776985_ifrs-fullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrs-fullLicencesMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20200101_20201231">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill id="F_000497" contextRef="C_0001776985_ifrs-fullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrs-fullLicencesMember_srtRangeAxis_ifrs-fullTopOfRangeMember_20200101_20201231">P20Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill id="F_000498" contextRef="C_0001776985_ifrs-fullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrs-fullComputerSoftwareMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20200101_20201231">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill id="F_000499" contextRef="C_0001776985_ifrs-fullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrs-fullComputerSoftwareMember_srtRangeAxis_ifrs-fullTopOfRangeMember_20200101_20201231">P8Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
  <bntx:EstimatedMilestonePaymentToBeReceivedAtContractInception id="F_000500" contextRef="C_0001776985_20201231" decimals="INF" unitRef="U_iso4217EUR">0</bntx:EstimatedMilestonePaymentToBeReceivedAtContractInception>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000501" contextRef="C_0001776985_ifrs-fullGeographicalAreasAxis_countryDE_ifrs-fullSalesChannelsAxis_ifrs-fullGoodsSoldDirectlyToConsumersMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">20553000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000502" contextRef="C_0001776985_ifrs-fullSalesChannelsAxis_ifrs-fullGoodsSoldDirectlyToConsumersMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">20553000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000503" contextRef="C_0001776985_ifrs-fullGeographicalAreasAxis_countryUS_ifrs-fullProductsAndServicesAxis_bntxCollaborationAgreementMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">46997000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000504" contextRef="C_0001776985_ifrs-fullGeographicalAreasAxis_bntxOutsideUSMember_ifrs-fullProductsAndServicesAxis_bntxCollaborationAgreementMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">141480000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000505" contextRef="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxCollaborationAgreementMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">188477000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary id="F_000506" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRNAPharmaceuticalsGmbHMember_20200101_20201231">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary id="F_000507" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechDeliveryTechnologiesGmbHMember_20200101_20201231">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary id="F_000508" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechDiagnosticsGmbHMember_20200101_20201231">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary id="F_000509" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechEuropeGmbHMember_20200101_20201231">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary id="F_000510" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechManufacturingGmbHMember_20200101_20201231">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary id="F_000511" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechManufacturingMarburgGmbHMember_20200101_20201231">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary id="F_000512" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechAustriaBeteiligungenGmbHMember_20200101_20201231">Austria</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary id="F_000513" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechInnovativeManufacturingServicesGmbHMember_20200101_20201231">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary id="F_000514" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxReSanoGmbHMember_20200101_20201231">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary id="F_000515" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxJPTPeptideTechnologiesGmbHMember_20200101_20201231">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary id="F_000516" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxJPTPeptideTechnologiesIncMember_20200101_20201231">United States</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary id="F_000517" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechUSAHoldingLLCMember_20200101_20201231">United States</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary id="F_000518" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechResearchAndDevelopmentIncMember_20200101_20201231">United States</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary id="F_000519" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechUSIncMember_20200101_20201231">United States</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary id="F_000520" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechPharmaceuticalsAsiaPacificPteLtdMember_20200101_20201231">Singapore</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary id="F_000521" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechUKLimitedMember_20200101_20201231">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary id="F_000522" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechCellAndGeneTherapiesGmbHMember_20200101_20201231">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary id="F_000523" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateHoldingGmbHMember_20200101_20201231">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary id="F_000524" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateVerwaltungsGmbHMember_20200101_20201231">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary id="F_000525" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateGmbHAndCoKGMember_20200101_20201231">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary id="F_000526" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateDerGoldgrubeGmbHCoKGMember_20200101_20201231">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary id="F_000527" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateHausVierGmbHCoKGMember_20200101_20201231">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary id="F_000528" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateAdamOpelStraeGmbHCoKGMember_20200101_20201231">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary id="F_000529" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRNAPharmaceuticalsGmbHMember_20200101_20201231">Mainz</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary id="F_000530" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechDeliveryTechnologiesGmbHMember_20200101_20201231">Halle</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary id="F_000531" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechDiagnosticsGmbHMember_20200101_20201231">Mainz</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary id="F_000532" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechEuropeGmbHMember_20200101_20201231">Mainz</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary id="F_000533" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechManufacturingGmbHMember_20200101_20201231">Mainz</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary id="F_000534" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechManufacturingMarburgGmbHMember_20200101_20201231">Marburg</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary id="F_000535" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechAustriaBeteiligungenGmbHMember_20200101_20201231">Vienna</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary id="F_000536" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechInnovativeManufacturingServicesGmbHMember_20200101_20201231">Idar-Oberstein</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary id="F_000537" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxReSanoGmbHMember_20200101_20201231">Mainz</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary id="F_000538" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxJPTPeptideTechnologiesGmbHMember_20200101_20201231">Berlin</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary id="F_000539" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxJPTPeptideTechnologiesIncMember_20200101_20201231">Cambridge (previously Acton)</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary id="F_000540" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechUSAHoldingLLCMember_20200101_20201231">Cambridge (previously New York)</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary id="F_000541" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechResearchAndDevelopmentIncMember_20200101_20201231">Cambridge (previously New York)</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary id="F_000542" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechUSIncMember_20200101_20201231">Cambridge</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary id="F_000543" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechPharmaceuticalsAsiaPacificPteLtdMember_20200101_20201231">Singapore</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary id="F_000544" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechUKLimitedMember_20200101_20201231">Reading</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary id="F_000545" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechCellAndGeneTherapiesGmbHMember_20200101_20201231">Mainz</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary id="F_000546" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateHoldingGmbHMember_20200101_20201231">Holzkirchen</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary id="F_000547" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateVerwaltungsGmbHMember_20200101_20201231">Holzkirchen</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary id="F_000548" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateGmbHAndCoKGMember_20200101_20201231">Holzkirchen</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary id="F_000549" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateDerGoldgrubeGmbHCoKGMember_20200101_20201231">Holzkirchen</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary id="F_000550" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateHausVierGmbHCoKGMember_20200101_20201231">Holzkirchen</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary id="F_000551" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateAdamOpelStraeGmbHCoKGMember_20200101_20201231">Holzkirchen</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000552" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRNAPharmaceuticalsGmbHMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000553" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechDeliveryTechnologiesGmbHMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000554" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechDiagnosticsGmbHMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000555" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechEuropeGmbHMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000556" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechManufacturingGmbHMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000557" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechManufacturingMarburgGmbHMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000558" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechAustriaBeteiligungenGmbHMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000559" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechInnovativeManufacturingServicesGmbHMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000560" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxReSanoGmbHMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000561" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxJPTPeptideTechnologiesGmbHMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000562" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxJPTPeptideTechnologiesIncMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000563" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechUSAHoldingLLCMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000564" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechResearchAndDevelopmentIncMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000565" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechUSIncMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000566" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechPharmaceuticalsAsiaPacificPteLtdMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000567" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechUKLimitedMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000568" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechCellAndGeneTherapiesGmbHMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000569" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateHoldingGmbHMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000570" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateVerwaltungsGmbHMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000571" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateGmbHAndCoKGMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000572" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateDerGoldgrubeGmbHCoKGMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000573" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateHausVierGmbHCoKGMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000574" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateAdamOpelStraeGmbHCoKGMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000575" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRNAPharmaceuticalsGmbHMember_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000576" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechDeliveryTechnologiesGmbHMember_20190101_20191231" decimals="2" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000577" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechDiagnosticsGmbHMember_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000578" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechEuropeGmbHMember_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000579" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechManufacturingGmbHMember_20190101_20191231" decimals="2" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000580" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechAustriaBeteiligungenGmbHMember_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000581" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechInnovativeManufacturingServicesGmbHMember_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000582" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxReSanoGmbHMember_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000583" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxJPTPeptideTechnologiesGmbHMember_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000584" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxJPTPeptideTechnologiesIncMember_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000585" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechUSAHoldingLLCMember_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000586" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechResearchAndDevelopmentIncMember_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000587" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechCellAndGeneTherapiesGmbHMember_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000588" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateHoldingGmbHMember_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000589" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateVerwaltungsGmbHMember_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000590" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechRealEstateGmbHAndCoKGMember_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <bntx:NumberOfEntitiesAcquiredDuringPeriod id="F_000591" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxNeonTherapeuticsIncAndNovartisManufacturingGmbHMember_20200101_20201231" decimals="INF" unitRef="U_bntxEntity">2</bntx:NumberOfEntitiesAcquiredDuringPeriod>
  <bntx:NumberOfNewEntities id="F_000592" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_bntxReSanoGmbHMember_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechUSAHoldingLLCAndBioNTechResearchAndDevelopmentIncMember_20190101_20191231" decimals="INF" unitRef="U_bntxEntity">3</bntx:NumberOfNewEntities>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary id="F_000593" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_bntxATImpfGmbHMember_srtOwnershipAxis_bntxBioNTechMember_20200101_20201231">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary id="F_000594" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_bntxATImpfGmbHMember_srtOwnershipAxis_bntxBioNTechMember_20200101_20201231">Munich</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000595" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_bntxATImpfGmbHMember_srtOwnershipAxis_bntxBioNTechMember_20200101_20201231" decimals="4" unitRef="U_xbrlipure">0.4737</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000596" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_bntxATImpfGmbHMember_srtOwnershipAxis_bntxBioNTechMember_20190101_20191231" decimals="4" unitRef="U_xbrlipure">0.5033</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary id="F_000597" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_bntxMedineGmbHMember_srtOwnershipAxis_bntxBioNTechMember_20200101_20201231">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary id="F_000598" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_bntxMedineGmbHMember_srtOwnershipAxis_bntxBioNTechMember_20200101_20201231">Mainz</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000599" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_bntxMedineGmbHMember_srtOwnershipAxis_bntxBioNTechMember_20200101_20201231" decimals="4" unitRef="U_xbrlipure">0.1725</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary id="F_000600" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_bntxMedineGmbHMember_srtOwnershipAxis_bntxBioNTechMember_20190101_20191231" decimals="4" unitRef="U_xbrlipure">0.1838</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:NameOfAcquiree id="F_000601" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxLipocalyxGmbHMember_20200106_20200106">Lipocalyx GmbH</ifrs-full:NameOfAcquiree>
  <ifrs-full:CashTransferred id="F_000602" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxLipocalyxGmbHMember_20200106" decimals="-5" unitRef="U_iso4217EUR">6500000</ifrs-full:CashTransferred>
  <ifrs-full:DateOfAcquisition2013 id="F_000603" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxLipocalyxGmbHMember_20200106_20200106">2020-01-06</ifrs-full:DateOfAcquisition2013>
  <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate id="F_000604" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxLipocalyxGmbHMember_20200106" decimals="-5" unitRef="U_iso4217EUR">600000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
  <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate id="F_000605" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxLipocalyxGmbHMember_20191231" decimals="-3" unitRef="U_iso4217EUR">896000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
  <ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate id="F_000606" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxLipocalyxGmbHMember_20191231" decimals="-3" unitRef="U_iso4217EUR">5978000</ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate>
  <ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate id="F_000607" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxLipocalyxGmbHMember_20191231" decimals="-3" unitRef="U_iso4217EUR">75000</ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate>
  <ifrs-full:InventoryRecognisedAsOfAcquisitionDate id="F_000608" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxLipocalyxGmbHMember_20191231" decimals="-3" unitRef="U_iso4217EUR">139000</ifrs-full:InventoryRecognisedAsOfAcquisitionDate>
  <bntx:IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill id="F_000609" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxLipocalyxGmbHMember_20191231" decimals="-3" unitRef="U_iso4217EUR">7088000</bntx:IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill>
  <ifrs-full:CashTransferred id="F_000610" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxLipocalyxGmbHMember_20191231" decimals="-3" unitRef="U_iso4217EUR">6516000</ifrs-full:CashTransferred>
  <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate id="F_000611" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxLipocalyxGmbHMember_20191231" decimals="-3" unitRef="U_iso4217EUR">572000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
  <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred id="F_000612" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxLipocalyxGmbHMember_20191231" decimals="-3" unitRef="U_iso4217EUR">7088000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
  <ifrs-full:ProfitLossFromOperatingActivities id="F_000613" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxLipocalyxGmbHMember_20200106_20200106" decimals="-5" unitRef="U_iso4217EUR">-1700000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000614" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxLipocalyxGmbHMember_20200106_20200106" decimals="-5" unitRef="U_iso4217EUR">200000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination id="F_000615" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxLipocalyxGmbHMember_20200106_20200106" decimals="-3" unitRef="U_iso4217EUR">17000</ifrs-full:AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination>
  <bntx:BusinessCombinationContingentCashConsideration id="F_000616" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxLipocalyxGmbHMember_ifrs-fullItemsOfContingentLiabilitiesAxis_bntxPhaseOneClinicalTrialMember_20191231" decimals="-5" unitRef="U_iso4217EUR">1000000</bntx:BusinessCombinationContingentCashConsideration>
  <bntx:BusinessCombinationContingentCashConsideration id="F_000617" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxLipocalyxGmbHMember_ifrs-fullItemsOfContingentLiabilitiesAxis_bntxPhaseTwoClinicalTrialMember_20191231" decimals="-5" unitRef="U_iso4217EUR">1000000</bntx:BusinessCombinationContingentCashConsideration>
  <bntx:ConsiderationTransferred id="F_000618" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200506" decimals="-5" unitRef="U_iso4217EUR">89900000</bntx:ConsiderationTransferred>
  <bntx:ConsiderationTransferred id="F_000619" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200506" decimals="-5" unitRef="U_iso4217USD">97100000</bntx:ConsiderationTransferred>
  <bntx:AmericanDepositaryShares id="F_000620" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200506" decimals="-6" unitRef="U_xbrlishares">1935488000000</bntx:AmericanDepositaryShares>
  <ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate id="F_000621" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200506" decimals="-3" unitRef="U_iso4217EUR">29867000</ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate>
  <ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate id="F_000622" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200506" decimals="-3" unitRef="U_iso4217EUR">5617000</ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate>
  <bntx:RightOfUseAssetsRecognisedAsOfAcquisitionDate id="F_000623" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200506" decimals="-3" unitRef="U_iso4217EUR">6896000</bntx:RightOfUseAssetsRecognisedAsOfAcquisitionDate>
  <bntx:OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate id="F_000624" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200506" decimals="-3" unitRef="U_iso4217EUR">2704000</bntx:OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate>
  <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate id="F_000625" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200506" decimals="-3" unitRef="U_iso4217EUR">7749000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
  <bntx:AssetsRecognizedAsOfAcquisitionDate id="F_000626" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200506" decimals="-3" unitRef="U_iso4217EUR">52833000</bntx:AssetsRecognizedAsOfAcquisitionDate>
  <bntx:TradePayablesRecognisedAsOfAcquisitionDate id="F_000627" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200506" decimals="-3" unitRef="U_iso4217EUR">1723000</bntx:TradePayablesRecognisedAsOfAcquisitionDate>
  <bntx:OtherLiabilitiesNonCurrentAndCurrentRecognisedAsOfAcquisitionDate id="F_000628" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200506" decimals="-3" unitRef="U_iso4217EUR">17793000</bntx:OtherLiabilitiesNonCurrentAndCurrentRecognisedAsOfAcquisitionDate>
  <bntx:LiabilitiesRecognizedAsOfAcquisitionDate id="F_000629" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200506" decimals="-3" unitRef="U_iso4217EUR">19516000</bntx:LiabilitiesRecognizedAsOfAcquisitionDate>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed id="F_000630" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200506" decimals="-3" unitRef="U_iso4217EUR">33317000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate id="F_000631" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200506" decimals="-3" unitRef="U_iso4217EUR">56573000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
  <bntx:IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill id="F_000632" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200506" decimals="-3" unitRef="U_iso4217EUR">89890000</bntx:IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill>
  <bntx:SharesIssuedAtFairValue id="F_000633" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200506" decimals="-3" unitRef="U_iso4217EUR">89548000</bntx:SharesIssuedAtFairValue>
  <ifrs-full:CashTransferred id="F_000634" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200506" decimals="-3" unitRef="U_iso4217EUR">342000</ifrs-full:CashTransferred>
  <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred id="F_000635" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200506" decimals="-3" unitRef="U_iso4217EUR">89890000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
  <bntx:IntangibleAssetsNumberOfNeoantigenTargetedTherapiesUnderDevelopment id="F_000636" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_ifrs-fullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrs-fullIntangibleAssetsUnderDevelopmentMember_20200506_20200506" decimals="INF" unitRef="U_bntxNeoantigenTargetedTherapy">2</bntx:IntangibleAssetsNumberOfNeoantigenTargetedTherapiesUnderDevelopment>
  <ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate id="F_000637" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200506" decimals="-5" unitRef="U_iso4217EUR">8000000</ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:ProfitLossFromOperatingActivities id="F_000638" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">-28500000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities id="F_000639" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200101_20200101" decimals="-5" unitRef="U_iso4217EUR">-59800000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000640" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200101_20201231" decimals="INF" unitRef="U_iso4217EUR">0</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination id="F_000641" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200506_20200506" decimals="-5" unitRef="U_iso4217EUR">1100000</ifrs-full:AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination>
  <ifrs-full:IssuedCapital id="F_000642" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechUSIncMember_20200506" decimals="-5" unitRef="U_iso4217EUR">1300000</ifrs-full:IssuedCapital>
  <ifrs-full:NameOfAcquiree id="F_000643" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechManufacturingMarburgGmbHMember_20201031_20201031">Novartis Manufacturing GmbH</ifrs-full:NameOfAcquiree>
  <ifrs-full:DateOfAcquisition2013 id="F_000644" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechManufacturingMarburgGmbHMember_20201031_20201031">2020-10-31</ifrs-full:DateOfAcquisition2013>
  <ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate id="F_000645" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechManufacturingMarburgGmbHMember_20201031" decimals="-3" unitRef="U_iso4217EUR">79828000</ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate>
  <bntx:RightOfUseAssetsRecognisedAsOfAcquisitionDate id="F_000646" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechManufacturingMarburgGmbHMember_20201031" decimals="-3" unitRef="U_iso4217EUR">28514000</bntx:RightOfUseAssetsRecognisedAsOfAcquisitionDate>
  <ifrs-full:InventoryRecognisedAsOfAcquisitionDate id="F_000647" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechManufacturingMarburgGmbHMember_20201031" decimals="-3" unitRef="U_iso4217EUR">2466000</ifrs-full:InventoryRecognisedAsOfAcquisitionDate>
  <bntx:OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate id="F_000648" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechManufacturingMarburgGmbHMember_20201031" decimals="-3" unitRef="U_iso4217EUR">4343000</bntx:OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate>
  <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate id="F_000649" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechManufacturingMarburgGmbHMember_20201031" decimals="-3" unitRef="U_iso4217EUR">16319000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
  <bntx:AssetsRecognizedAsOfAcquisitionDate id="F_000650" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechManufacturingMarburgGmbHMember_20201031" decimals="-3" unitRef="U_iso4217EUR">131470000</bntx:AssetsRecognizedAsOfAcquisitionDate>
  <bntx:ProvisionsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate id="F_000651" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechManufacturingMarburgGmbHMember_20201031" decimals="-3" unitRef="U_iso4217EUR">5127000</bntx:ProvisionsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate>
  <bntx:TradePayablesRecognisedAsOfAcquisitionDate id="F_000652" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechManufacturingMarburgGmbHMember_20201031" decimals="-3" unitRef="U_iso4217EUR">8105000</bntx:TradePayablesRecognisedAsOfAcquisitionDate>
  <bntx:OtherLiabilitiesNonCurrentAndCurrentRecognisedAsOfAcquisitionDate id="F_000653" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechManufacturingMarburgGmbHMember_20201031" decimals="-3" unitRef="U_iso4217EUR">33383000</bntx:OtherLiabilitiesNonCurrentAndCurrentRecognisedAsOfAcquisitionDate>
  <bntx:LiabilitiesRecognizedAsOfAcquisitionDate id="F_000654" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechManufacturingMarburgGmbHMember_20201031" decimals="-3" unitRef="U_iso4217EUR">46615000</bntx:LiabilitiesRecognizedAsOfAcquisitionDate>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed id="F_000655" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechManufacturingMarburgGmbHMember_20201031" decimals="-3" unitRef="U_iso4217EUR">84855000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <bntx:BargainPurchaseGainOnAcquisition id="F_000656" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechManufacturingMarburgGmbHMember_20201031" decimals="-3" unitRef="U_iso4217EUR">7002000</bntx:BargainPurchaseGainOnAcquisition>
  <bntx:IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwillNetOfBargainPurchase id="F_000657" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechManufacturingMarburgGmbHMember_20201031" decimals="-3" unitRef="U_iso4217EUR">77853000</bntx:IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwillNetOfBargainPurchase>
  <ifrs-full:CashTransferred id="F_000658" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechManufacturingMarburgGmbHMember_20201031" decimals="-3" unitRef="U_iso4217EUR">77853000</ifrs-full:CashTransferred>
  <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred id="F_000659" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechManufacturingMarburgGmbHMember_20201031" decimals="-3" unitRef="U_iso4217EUR">77853000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000660" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechManufacturingMarburgGmbHMember_20200101_20201231" decimals="INF" unitRef="U_iso4217EUR">0</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:ProfitLossFromOperatingActivities id="F_000661" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechManufacturingMarburgGmbHMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">-6700000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination id="F_000662" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechManufacturingMarburgGmbHMember_20201031_20201031" decimals="-5" unitRef="U_iso4217EUR">1400000</ifrs-full:AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination>
  <ifrs-full:Goodwill id="F_000663" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">2978000</ifrs-full:Goodwill>
  <ifrs-full:AdditionalRecognitionGoodwill id="F_000664" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">57469000</ifrs-full:AdditionalRecognitionGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesGoodwill id="F_000665" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-6750000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesGoodwill>
  <ifrs-full:Goodwill id="F_000666" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">53697000</ifrs-full:Goodwill>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000667" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxPfizerIncMember_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">121597000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000668" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxPfizerIncMember_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">14348000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000669" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxPfizerIncMember_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">7173000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000670" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxGenentechIncMember_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">49195000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000671" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxGenentechIncMember_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">64026000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000672" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxGenentechIncMember_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">49536000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000673" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxShanghaiFosunPharmaceuticalGroupCoLtdMember_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">5074000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000674" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxOtherMember_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">2983000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000675" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxOtherMember_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">6054000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000676" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxOtherMember_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">45128000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000677" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxCOVID19VaccineRevenuesMember_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">270490000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000678" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxSalesToCollaborationPartnerMember_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">61460000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000679" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxDirectProductSalesToBioNTechCustomersMember_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">20553000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000680" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxShareOfCollaborationPartnersGrossProfitMember_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">188477000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000681" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxOtherSalesMember_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">32986000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000682" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxOtherSalesMember_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">24161000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000683" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxOtherSalesMember_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">25738000</ifrs-full:RevenueFromContractsWithCustomers>
  <bntx:NumberOfCustomers id="F_000684" contextRef="C_0001776985_20200101_20201231" decimals="INF" unitRef="U_bntxCustomer">2</bntx:NumberOfCustomers>
  <bntx:NumberOfCustomers id="F_000685" contextRef="C_0001776985_20190101_20191231" decimals="INF" unitRef="U_bntxCustomer">1</bntx:NumberOfCustomers>
  <bntx:NumberOfCustomers id="F_000686" contextRef="C_0001776985_20180101_20181231" decimals="INF" unitRef="U_bntxCustomer">2</bntx:NumberOfCustomers>
  <ifrs-full:PercentageOfEntitysRevenue id="F_000687" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxPfizerIncMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.10</ifrs-full:PercentageOfEntitysRevenue>
  <ifrs-full:PercentageOfEntitysRevenue id="F_000688" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxGenentechIncMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.10</ifrs-full:PercentageOfEntitysRevenue>
  <ifrs-full:PercentageOfEntitysRevenue id="F_000689" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxSanofiSAMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20180101_20181231" decimals="2" unitRef="U_xbrlipure">0.10</ifrs-full:PercentageOfEntitysRevenue>
  <ifrs-full:PercentageOfEntitysRevenue id="F_000690" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxGenentechIncMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.10</ifrs-full:PercentageOfEntitysRevenue>
  <ifrs-full:PercentageOfEntitysRevenue id="F_000691" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxGenentechIncMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20180101_20181231" decimals="2" unitRef="U_xbrlipure">0.10</ifrs-full:PercentageOfEntitysRevenue>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000692" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxPfizerIncMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">371500000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000693" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxGenentechIncMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">49200000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000694" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxSanofiSAMember_20180101_20181231" decimals="-5" unitRef="U_iso4217EUR">41700000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000695" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxGenentechIncMember_20190101_20191231" decimals="-5" unitRef="U_iso4217EUR">64000000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000696" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxGenentechIncMember_20180101_20181231" decimals="-5" unitRef="U_iso4217EUR">49500000</ifrs-full:RevenueFromContractsWithCustomers>
  <bntx:RevenueFromCollaboration id="F_000697" contextRef="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">3500000</bntx:RevenueFromCollaboration>
  <bntx:NonRefundableUpfrontCashPayment id="F_000698" contextRef="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">66300000</bntx:NonRefundableUpfrontCashPayment>
  <bntx:MilestonePaymentRecognizedAsRevenue id="F_000699" contextRef="C_0001776985_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">51800000</bntx:MilestonePaymentRecognizedAsRevenue>
  <bntx:NonRefundableUpfrontCashPayment id="F_000700" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxFosunPharmaMember_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">900000</bntx:NonRefundableUpfrontCashPayment>
  <bntx:MilestonePaymentRecognizedAsRevenue id="F_000701" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxFosunPharmaMember_ifrs-fullProductsAndServicesAxis_bntxResearchAndDevelopmentMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">4200000</bntx:MilestonePaymentRecognizedAsRevenue>
  <bntx:RevenuesDerivedFromDeferredUpfrontPayments id="F_000702" contextRef="C_0001776985_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">52100000</bntx:RevenuesDerivedFromDeferredUpfrontPayments>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000703" contextRef="C_0001776985_ifrs-fullIntangibleAssetsWithIndefiniteUsefulLifeAxis_bntxCellscriptSublicenseMember_ifrs-fullMajorCustomersAxis_bntxSanofiSAMember_20180101_20181231" decimals="-5" unitRef="U_iso4217EUR">33200000</ifrs-full:RevenueFromContractsWithCustomers>
  <bntx:PercentageOfReimbursementOfSublicenseCosts id="F_000704" contextRef="C_0001776985_ifrs-fullIntangibleAssetsWithIndefiniteUsefulLifeAxis_bntxCellscriptSublicenseMember_ifrs-fullMajorCustomersAxis_bntxSanofiSAMember_20180101_20181231" decimals="2" unitRef="U_xbrlipure">0.50</bntx:PercentageOfReimbursementOfSublicenseCosts>
  <bntx:SublicenseAgreementDate id="F_000705" contextRef="C_0001776985_ifrs-fullIntangibleAssetsWithIndefiniteUsefulLifeAxis_bntxCellscriptSublicenseMember_ifrs-fullMajorCustomersAxis_bntxSanofiSAMember_20180101_20181231">2018-12-22</bntx:SublicenseAgreementDate>
  <bntx:ConditionalMarketingAuthorizationCountries id="F_000706" contextRef="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20201231" decimals="INF" unitRef="U_bntxCountry">65</bntx:ConditionalMarketingAuthorizationCountries>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000707" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxRevenuesFromSellingDrugProductBatchesToPfizersManufacturingSiteMember_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">61500000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000708" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxBioNTechMember_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_srtStatementGeographicalAxis_countryDE_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">20600000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000709" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxRevenueFromShareOfCollaborationPartnersGrossProfitMember_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">188500000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000710" contextRef="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxOtherSalesTransactionsMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">33000000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000711" contextRef="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxOtherSalesTransactionsMember_20190101_20191231" decimals="-5" unitRef="U_iso4217EUR">24200000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000712" contextRef="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxOtherSalesTransactionsMember_20180101_20181231" decimals="-5" unitRef="U_iso4217EUR">25700000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000713" contextRef="C_0001776985_ifrs-fullPerformanceObligationsAxis_ifrs-fullPerformanceObligationsSatisfiedAtPointInTimeMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">108840000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000714" contextRef="C_0001776985_ifrs-fullPerformanceObligationsAxis_ifrs-fullPerformanceObligationsSatisfiedAtPointInTimeMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">16955000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000715" contextRef="C_0001776985_ifrs-fullPerformanceObligationsAxis_ifrs-fullPerformanceObligationsSatisfiedAtPointInTimeMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">22828000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000716" contextRef="C_0001776985_ifrs-fullPerformanceObligationsAxis_ifrs-fullPerformanceObligationsSatisfiedOverTimeMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">373485000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000717" contextRef="C_0001776985_ifrs-fullPerformanceObligationsAxis_ifrs-fullPerformanceObligationsSatisfiedOverTimeMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">91634000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000718" contextRef="C_0001776985_ifrs-fullPerformanceObligationsAxis_ifrs-fullPerformanceObligationsSatisfiedOverTimeMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">104747000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers id="F_000719" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxBioNTechMember_ifrs-fullProductsAndServicesAxis_bntxBillAndHoldTransactionMember_20190101_20191231" decimals="-5" unitRef="U_iso4217EUR">1100000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:ContractLiabilities id="F_000720" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">371475000</ifrs-full:ContractLiabilities>
  <ifrs-full:ContractLiabilities id="F_000721" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">190692000</ifrs-full:ContractLiabilities>
  <bntx:TradeReceivableMaturityPeriod id="F_000722" contextRef="C_0001776985_srtRangeAxis_ifrs-fullBottomOfRangeMember_20200101_20201231">P20D</bntx:TradeReceivableMaturityPeriod>
  <bntx:TradeReceivableMaturityPeriod id="F_000723" contextRef="C_0001776985_srtRangeAxis_ifrs-fullTopOfRangeMember_20200101_20201231">P30D</bntx:TradeReceivableMaturityPeriod>
  <bntx:RemainingUpfrontFeesContractLiabilities id="F_000724" contextRef="C_0001776985_20201231" decimals="-5" unitRef="U_iso4217EUR">131800000</bntx:RemainingUpfrontFeesContractLiabilities>
  <bntx:RemainingUpfrontFeesContractLiabilities id="F_000725" contextRef="C_0001776985_20191231" decimals="-5" unitRef="U_iso4217EUR">187600000</bntx:RemainingUpfrontFeesContractLiabilities>
  <bntx:AdvancePaymentReceivedForFutureCOVID19VaccineSale id="F_000726" contextRef="C_0001776985_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">235800000</bntx:AdvancePaymentReceivedForFutureCOVID19VaccineSale>
  <ifrs-full:CurrentAdvances id="F_000727" contextRef="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxOtherSalesTransactionsMember_20201231" decimals="-5" unitRef="U_iso4217EUR">3900000</ifrs-full:CurrentAdvances>
  <ifrs-full:CurrentAdvances id="F_000728" contextRef="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxOtherSalesTransactionsMember_20191231" decimals="-5" unitRef="U_iso4217EUR">3100000</ifrs-full:CurrentAdvances>
  <bntx:DeferredRevenueRecognizedIncludedContractLiabilities id="F_000729" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">58895000</bntx:DeferredRevenueRecognizedIncludedContractLiabilities>
  <bntx:DeferredRevenueRecognizedIncludedContractLiabilities id="F_000730" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">84112000</bntx:DeferredRevenueRecognizedIncludedContractLiabilities>
  <bntx:DeferredRevenueRecognizedIncludedContractLiabilities id="F_000731" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">59583000</bntx:DeferredRevenueRecognizedIncludedContractLiabilities>
  <ifrs-full:ContractLiabilities id="F_000732" contextRef="C_0001776985_ifrs-fullMaturityAxis_ifrs-fullNotLaterThanOneYearMember_ifrs-fullPerformanceObligationsAxis_bntxUnsatisfiedOrPartiallyUnsatisfiedMember_20201231" decimals="-3" unitRef="U_iso4217EUR">299583000</ifrs-full:ContractLiabilities>
  <ifrs-full:ContractLiabilities id="F_000733" contextRef="C_0001776985_ifrs-fullMaturityAxis_ifrs-fullNotLaterThanOneYearMember_ifrs-fullPerformanceObligationsAxis_bntxUnsatisfiedOrPartiallyUnsatisfiedMember_20191231" decimals="-3" unitRef="U_iso4217EUR">93583000</ifrs-full:ContractLiabilities>
  <ifrs-full:ContractLiabilities id="F_000734" contextRef="C_0001776985_ifrs-fullMaturityAxis_ifrs-fullLaterThanOneYearMember_ifrs-fullPerformanceObligationsAxis_bntxUnsatisfiedOrPartiallyUnsatisfiedMember_20201231" decimals="-3" unitRef="U_iso4217EUR">71892000</ifrs-full:ContractLiabilities>
  <ifrs-full:ContractLiabilities id="F_000735" contextRef="C_0001776985_ifrs-fullMaturityAxis_ifrs-fullLaterThanOneYearMember_ifrs-fullPerformanceObligationsAxis_bntxUnsatisfiedOrPartiallyUnsatisfiedMember_20191231" decimals="-3" unitRef="U_iso4217EUR">97109000</ifrs-full:ContractLiabilities>
  <ifrs-full:ContractLiabilities id="F_000736" contextRef="C_0001776985_ifrs-fullPerformanceObligationsAxis_bntxUnsatisfiedOrPartiallyUnsatisfiedMember_20201231" decimals="-3" unitRef="U_iso4217EUR">371475000</ifrs-full:ContractLiabilities>
  <ifrs-full:ContractLiabilities id="F_000737" contextRef="C_0001776985_ifrs-fullPerformanceObligationsAxis_bntxUnsatisfiedOrPartiallyUnsatisfiedMember_20191231" decimals="-3" unitRef="U_iso4217EUR">190692000</ifrs-full:ContractLiabilities>
  <ifrs-full:CostOfSales id="F_000738" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxCOVID19VaccineRevenuesMember_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">35616000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales id="F_000739" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxOtherSalesMember_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">23717000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales id="F_000740" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxOtherSalesMember_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">17361000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales id="F_000741" contextRef="C_0001776985_ifrs-fullMajorCustomersAxis_bntxOtherSalesMember_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">13690000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales id="F_000742" contextRef="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">59333000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales id="F_000743" contextRef="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">17361000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales id="F_000744" contextRef="C_0001776985_ifrs-fullProductsAndServicesAxis_bntxCommercialMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">13690000</ifrs-full:CostOfSales>
  <ifrs-full:ResearchAndDevelopmentExpense id="F_000745" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxPurchasedServicesMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">359880000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense id="F_000746" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxPurchasedServicesMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">65552000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense id="F_000747" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxPurchasedServicesMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">42079000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense id="F_000748" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxWagesBenefitsAndSocialSecurityExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">126298000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense id="F_000749" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxWagesBenefitsAndSocialSecurityExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">83213000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense id="F_000750" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxWagesBenefitsAndSocialSecurityExpenseMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">45668000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense id="F_000751" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxLaboratorySuppliesMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">107792000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense id="F_000752" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxLaboratorySuppliesMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">37218000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense id="F_000753" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxLaboratorySuppliesMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">22921000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense id="F_000754" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAndAmortisationMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">30192000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense id="F_000755" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAndAmortisationMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">27533000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense id="F_000756" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAndAmortisationMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">18312000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense id="F_000757" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxITCostsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">5118000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense id="F_000758" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxITCostsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">3800000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense id="F_000759" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxITCostsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">1572000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense id="F_000760" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxLeaseAndLeaseRelatedCostMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">3725000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense id="F_000761" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxLeaseAndLeaseRelatedCostMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">2527000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense id="F_000762" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxLeaseAndLeaseRelatedCostMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">2404000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense id="F_000763" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxTransportCostsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">2135000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense id="F_000764" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxTransportCostsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">1081000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense id="F_000765" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxTransportCostsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">668000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense id="F_000766" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxOtherIncomeExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">9889000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense id="F_000767" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxOtherIncomeExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">5542000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense id="F_000768" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxOtherIncomeExpenseMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">9416000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense id="F_000769" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechUSIncMember_20200506_20200506" decimals="-5" unitRef="U_iso4217EUR">21000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:SalesAndMarketingExpense id="F_000770" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxPurchasedServicesMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">10929000</ifrs-full:SalesAndMarketingExpense>
  <ifrs-full:SalesAndMarketingExpense id="F_000771" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxPurchasedServicesMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">247000</ifrs-full:SalesAndMarketingExpense>
  <ifrs-full:SalesAndMarketingExpense id="F_000772" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxPurchasedServicesMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">794000</ifrs-full:SalesAndMarketingExpense>
  <ifrs-full:SalesAndMarketingExpense id="F_000773" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxWagesBenefitsAndSocialSecurityExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">1636000</ifrs-full:SalesAndMarketingExpense>
  <ifrs-full:SalesAndMarketingExpense id="F_000774" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxWagesBenefitsAndSocialSecurityExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">1938000</ifrs-full:SalesAndMarketingExpense>
  <ifrs-full:SalesAndMarketingExpense id="F_000775" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxWagesBenefitsAndSocialSecurityExpenseMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">1728000</ifrs-full:SalesAndMarketingExpense>
  <ifrs-full:SalesAndMarketingExpense id="F_000776" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxOtherIncomeExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">1947000</ifrs-full:SalesAndMarketingExpense>
  <ifrs-full:SalesAndMarketingExpense id="F_000777" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxOtherIncomeExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">533000</ifrs-full:SalesAndMarketingExpense>
  <ifrs-full:SalesAndMarketingExpense id="F_000778" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxOtherIncomeExpenseMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">519000</ifrs-full:SalesAndMarketingExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000779" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxWagesBenefitsAndSocialSecurityExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">33007000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000780" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxWagesBenefitsAndSocialSecurityExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">19122000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000781" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxWagesBenefitsAndSocialSecurityExpenseMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">8582000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000782" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxPurchasedServicesMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">26022000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000783" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxPurchasedServicesMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">6419000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000784" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxPurchasedServicesMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">5177000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000785" contextRef="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullOfficeEquipmentMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">7404000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000786" contextRef="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullOfficeEquipmentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">4573000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000787" contextRef="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullOfficeEquipmentMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">3774000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000788" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAndAmortisationMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">5104000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000789" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAndAmortisationMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">4855000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000790" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAndAmortisationMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">2284000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000791" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxInsurancePremiumsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">4840000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000792" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxInsurancePremiumsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">1061000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000793" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxInsurancePremiumsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">145000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000794" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxJobAdvertisementExpensesMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">2897000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000795" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxJobAdvertisementExpensesMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">548000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000796" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxJobAdvertisementExpensesMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">861000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000797" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxLeaseAndLeaseRelatedCostMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">2390000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000798" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxLeaseAndLeaseRelatedCostMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">1715000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000799" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxLeaseAndLeaseRelatedCostMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">1012000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000800" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxResearchServicesMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">2033000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000801" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxResearchServicesMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">232000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000802" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxResearchServicesMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">26000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000803" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxLaboratorySuppliesMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">1191000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000804" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxLaboratorySuppliesMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">785000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000805" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxLaboratorySuppliesMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">456000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000806" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxContractStaffingMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">1108000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000807" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxContractStaffingMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">686000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000808" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxContractStaffingMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">781000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000809" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxOtherIncomeExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">8053000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000810" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxOtherIncomeExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">5551000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000811" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxOtherIncomeExpenseMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">3236000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense id="F_000812" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechUSIncMember_20200506_20200506" decimals="-5" unitRef="U_iso4217EUR">7400000</ifrs-full:GeneralAndAdministrativeExpense>
  <bntx:ChargeInConnectionWithCertainWithholdingTaxPaymentsForIntellectualPropertyLicenses id="F_000813" contextRef="C_0001776985_bntxNatureOfExpensesAxis_bntxGeneralAndAdministrativeExpensesMember_20190101_20191231" decimals="-5" unitRef="U_iso4217EUR">2600000</bntx:ChargeInConnectionWithCertainWithholdingTaxPaymentsForIntellectualPropertyLicenses>
  <ifrs-full:MiscellaneousOtherOperatingIncome id="F_000814" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxGovernmentGrantsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">239017000</ifrs-full:MiscellaneousOtherOperatingIncome>
  <ifrs-full:MiscellaneousOtherOperatingIncome id="F_000815" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxGovernmentGrantsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">1547000</ifrs-full:MiscellaneousOtherOperatingIncome>
  <ifrs-full:MiscellaneousOtherOperatingIncome id="F_000816" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxGovernmentGrantsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">4228000</ifrs-full:MiscellaneousOtherOperatingIncome>
  <ifrs-full:MiscellaneousOtherOperatingIncome id="F_000817" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxBargainPurchaseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">7002000</ifrs-full:MiscellaneousOtherOperatingIncome>
  <ifrs-full:MiscellaneousOtherOperatingIncome id="F_000818" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxBargainPurchaseMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">50000</ifrs-full:MiscellaneousOtherOperatingIncome>
  <ifrs-full:MiscellaneousOtherOperatingIncome id="F_000819" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxOtherIncomeExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">4520000</ifrs-full:MiscellaneousOtherOperatingIncome>
  <ifrs-full:MiscellaneousOtherOperatingIncome id="F_000820" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxOtherIncomeExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">1177000</ifrs-full:MiscellaneousOtherOperatingIncome>
  <ifrs-full:MiscellaneousOtherOperatingIncome id="F_000821" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxOtherIncomeExpenseMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">1118000</ifrs-full:MiscellaneousOtherOperatingIncome>
  <ifrs-full:MiscellaneousOtherOperatingIncome id="F_000822" contextRef="C_0001776985_bntxIncomeAndExpensesByNatureAxis_bntxGovernmentGrantsMember_srtStatementGeographicalAxis_countryDE_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">238900000</ifrs-full:MiscellaneousOtherOperatingIncome>
  <ifrs-full:CurrentGovernmentGrants id="F_000823" contextRef="C_0001776985_srtStatementGeographicalAxis_countryDE_20201231" decimals="-5" unitRef="U_iso4217EUR">88000000</ifrs-full:CurrentGovernmentGrants>
  <bntx:GovernmentGrantsReceived id="F_000824" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">330968000</bntx:GovernmentGrantsReceived>
  <bntx:GovernmentGrantsReceived id="F_000825" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">1547000</bntx:GovernmentGrantsReceived>
  <bntx:GovernmentGrantsReceived id="F_000826" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">4228000</bntx:GovernmentGrantsReceived>
  <ifrs-full:RevenueFromGovernmentGrants id="F_000827" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">239017000</ifrs-full:RevenueFromGovernmentGrants>
  <ifrs-full:RevenueFromGovernmentGrants id="F_000828" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">1547000</ifrs-full:RevenueFromGovernmentGrants>
  <ifrs-full:RevenueFromGovernmentGrants id="F_000829" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">4228000</ifrs-full:RevenueFromGovernmentGrants>
  <ifrs-full:GovernmentGrants id="F_000830" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">91951000</ifrs-full:GovernmentGrants>
  <ifrs-full:RevenueFromInterest id="F_000831" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">1564000</ifrs-full:RevenueFromInterest>
  <ifrs-full:RevenueFromInterest id="F_000832" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">1781000</ifrs-full:RevenueFromInterest>
  <ifrs-full:RevenueFromInterest id="F_000833" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">1996000</ifrs-full:RevenueFromInterest>
  <ifrs-full:NetForeignExchangeGain id="F_000834" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">2341000</ifrs-full:NetForeignExchangeGain>
  <ifrs-full:NetForeignExchangeGain id="F_000835" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">6050000</ifrs-full:NetForeignExchangeGain>
  <bntx:AmortizationOfFinancialInstruments id="F_000836" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">3048000</bntx:AmortizationOfFinancialInstruments>
  <bntx:AmortizationOfFinancialInstruments id="F_000837" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">326000</bntx:AmortizationOfFinancialInstruments>
  <bntx:AmortizationOfFinancialInstruments id="F_000838" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">48000</bntx:AmortizationOfFinancialInstruments>
  <bntx:FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue id="F_000839" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">17289000</bntx:FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue>
  <ifrs-full:NetForeignExchangeLoss id="F_000840" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">42609000</ifrs-full:NetForeignExchangeLoss>
  <ifrs-full:WagesAndSalaries id="F_000841" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">160655000</ifrs-full:WagesAndSalaries>
  <ifrs-full:WagesAndSalaries id="F_000842" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">98568000</ifrs-full:WagesAndSalaries>
  <ifrs-full:WagesAndSalaries id="F_000843" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">54149000</ifrs-full:WagesAndSalaries>
  <ifrs-full:SocialSecurityContributions id="F_000844" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">17988000</ifrs-full:SocialSecurityContributions>
  <ifrs-full:SocialSecurityContributions id="F_000845" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">12394000</ifrs-full:SocialSecurityContributions>
  <ifrs-full:SocialSecurityContributions id="F_000846" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">8231000</ifrs-full:SocialSecurityContributions>
  <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans id="F_000847" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">761000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
  <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans id="F_000848" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">517000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
  <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans id="F_000849" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">324000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
  <ifrs-full:EmployeeBenefitsExpense id="F_000850" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">179404000</ifrs-full:EmployeeBenefitsExpense>
  <ifrs-full:EmployeeBenefitsExpense id="F_000851" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">111479000</ifrs-full:EmployeeBenefitsExpense>
  <ifrs-full:EmployeeBenefitsExpense id="F_000852" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">62704000</ifrs-full:EmployeeBenefitsExpense>
  <bntx:CorporateIncomeTaxRate id="F_000853" contextRef="C_0001776985_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.150</bntx:CorporateIncomeTaxRate>
  <bntx:SolidaritySurchargeRate id="F_000854" contextRef="C_0001776985_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.055</bntx:SolidaritySurchargeRate>
  <bntx:ChangeInAverageTradeTaxRate id="F_000855" contextRef="C_0001776985_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.150</bntx:ChangeInAverageTradeTaxRate>
  <ifrs-full:ApplicableTaxRate id="F_000856" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechUSAHoldingLLCMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.210</ifrs-full:ApplicableTaxRate>
  <ifrs-full:AverageEffectiveTaxRate id="F_000857" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechUSAHoldingLLCMember_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.081</ifrs-full:AverageEffectiveTaxRate>
  <ifrs-full:CurrentTaxExpenseIncome id="F_000858" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">17000</ifrs-full:CurrentTaxExpenseIncome>
  <ifrs-full:CurrentTaxExpenseIncome id="F_000859" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-296000</ifrs-full:CurrentTaxExpenseIncome>
  <ifrs-full:CurrentTaxExpenseIncome id="F_000860" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">600000</ifrs-full:CurrentTaxExpenseIncome>
  <ifrs-full:DeferredTaxExpenseIncome id="F_000861" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-161034000</ifrs-full:DeferredTaxExpenseIncome>
  <bntx:OtherComponentsOfTaxExpenseIncome id="F_000862" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">17000</bntx:OtherComponentsOfTaxExpenseIncome>
  <bntx:OtherComponentsOfTaxExpenseIncome id="F_000863" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">28000</bntx:OtherComponentsOfTaxExpenseIncome>
  <ifrs-full:ApplicableTaxRate id="F_000864" contextRef="C_0001776985_20200101_20201231" decimals="4" unitRef="U_xbrlipure">0.3079</ifrs-full:ApplicableTaxRate>
  <ifrs-full:ApplicableTaxRate id="F_000865" contextRef="C_0001776985_20190101_20191231" decimals="4" unitRef="U_xbrlipure">0.3078</ifrs-full:ApplicableTaxRate>
  <ifrs-full:ApplicableTaxRate id="F_000866" contextRef="C_0001776985_20180101_20181231" decimals="4" unitRef="U_xbrlipure">0.3099</ifrs-full:ApplicableTaxRate>
  <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate id="F_000867" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-44891000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
  <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate id="F_000868" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-55240000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
  <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate id="F_000869" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">-14776000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
  <bntx:GovernmentGrantsExemptedFromTaxes id="F_000870" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">14000</bntx:GovernmentGrantsExemptedFromTaxes>
  <bntx:GovernmentGrantsExemptedFromTaxes id="F_000871" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">48000</bntx:GovernmentGrantsExemptedFromTaxes>
  <bntx:GovernmentGrantsExemptedFromTaxes id="F_000872" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">28000</bntx:GovernmentGrantsExemptedFromTaxes>
  <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss id="F_000873" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">770000</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
  <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss id="F_000874" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">58000</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
  <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss id="F_000875" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">18000</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
  <bntx:AddBackForTradeTaxPurposes id="F_000876" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">595000</bntx:AddBackForTradeTaxPurposes>
  <bntx:AddBackForTradeTaxPurposes id="F_000877" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">110000</bntx:AddBackForTradeTaxPurposes>
  <bntx:AddBackForTradeTaxPurposes id="F_000878" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">96000</bntx:AddBackForTradeTaxPurposes>
  <bntx:NonTaxEffectiveBargainPurchase id="F_000879" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">2156000</bntx:NonTaxEffectiveBargainPurchase>
  <bntx:NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses id="F_000880" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">9806000</bntx:NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses>
  <bntx:NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses id="F_000881" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">9308000</bntx:NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses>
  <bntx:TaxEffectiveEquityTransactionCosts id="F_000882" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-10229000</bntx:TaxEffectiveEquityTransactionCosts>
  <bntx:TaxEffectiveEquityTransactionCosts id="F_000883" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-5121000</bntx:TaxEffectiveEquityTransactionCosts>
  <ifrs-full:TaxEffectOfTaxLosses id="F_000884" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">-1165000</ifrs-full:TaxEffectOfTaxLosses>
  <bntx:TaxEffectOfNonrecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences id="F_000885" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">12961000</bntx:TaxEffectOfNonrecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences>
  <bntx:TaxEffectOfNonrecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences id="F_000886" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">51197000</bntx:TaxEffectOfNonrecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences>
  <bntx:TaxEffectOfNonrecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences id="F_000887" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">13634000</bntx:TaxEffectOfNonrecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences>
  <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense id="F_000888" contextRef="C_0001776985_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-fullUnusedTaxLossesMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">102231000</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense>
  <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense id="F_000889" contextRef="C_0001776985_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-fullTemporaryDifferenceMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">26241000</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense>
  <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense id="F_000890" contextRef="C_0001776985_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-fullTemporaryDifferenceMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">192000</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense>
  <ifrs-full:TaxEffectOfForeignTaxRates id="F_000891" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">1304000</ifrs-full:TaxEffectOfForeignTaxRates>
  <ifrs-full:TaxEffectOfForeignTaxRates id="F_000892" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">102000</ifrs-full:TaxEffectOfForeignTaxRates>
  <ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod id="F_000893" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">326000</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
  <ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod id="F_000894" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-316000</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
  <bntx:TaxEffectOfTaxCredit id="F_000895" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">1059000</bntx:TaxEffectOfTaxCredit>
  <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome id="F_000896" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">59000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
  <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome id="F_000897" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-126000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
  <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome id="F_000898" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">2821000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000899" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxFixedAssetsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">-655000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000900" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxInventoryMember_20191231" decimals="-3" unitRef="U_iso4217EUR">596000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000901" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxLeasesMember_20191231" decimals="-3" unitRef="U_iso4217EUR">512000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000902" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxContractLiabilitiesMember_20191231" decimals="-3" unitRef="U_iso4217EUR">23543000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000903" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxProvisionsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">187000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000904" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxOtherDeferredTaxesMember_20191231" decimals="-3" unitRef="U_iso4217EUR">2087000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000905" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-fullUnusedTaxCreditsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">109764000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000906" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20191231" decimals="-3" unitRef="U_iso4217EUR">136034000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000907" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bntxValuationAdjustmentMember_20191231" decimals="-3" unitRef="U_iso4217EUR">-136034000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss id="F_000908" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxFixedAssetsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-2370000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss id="F_000909" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxInventoryMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">46000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss id="F_000910" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxLeasesMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-5091000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss id="F_000911" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxContractLiabilitiesMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-174000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss id="F_000912" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxInterestBearingLoansAndBorrowingsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-2741000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss id="F_000913" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-fullNetDefinedBenefitLiabilityAssetMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">169000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss id="F_000914" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxProvisionsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">886000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss id="F_000915" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxOtherDeferredTaxesMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">8336000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss id="F_000916" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-fullUnusedTaxCreditsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">41660000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss id="F_000917" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">40721000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss id="F_000918" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bntxValuationAdjustmentMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">120313000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss id="F_000919" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">161034000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome id="F_000920" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-fullNetDefinedBenefitLiabilityAssetMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-63000</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
  <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome id="F_000921" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-63000</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
  <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome id="F_000922" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-63000</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset id="F_000923" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxFixedAssetsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">8637000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset id="F_000924" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxInventoryMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">329000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset id="F_000925" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxLeasesMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-14000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset id="F_000926" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxInterestBearingLoansAndBorrowingsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">195000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset id="F_000927" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-fullNetDefinedBenefitLiabilityAssetMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">698000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset id="F_000928" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxProvisionsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">419000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset id="F_000929" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxOtherDeferredTaxesMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">202000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset id="F_000930" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-fullUnusedTaxCreditsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">24280000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset id="F_000931" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">34746000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset id="F_000932" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bntxValuationAdjustmentMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-34765000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset id="F_000933" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-19000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000934" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxFixedAssetsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">5612000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000935" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxInventoryMember_20201231" decimals="-3" unitRef="U_iso4217EUR">971000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000936" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxLeasesMember_20201231" decimals="-3" unitRef="U_iso4217EUR">-4593000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000937" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxContractLiabilitiesMember_20201231" decimals="-3" unitRef="U_iso4217EUR">23369000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000938" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxInterestBearingLoansAndBorrowingsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">-2546000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000939" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-fullNetDefinedBenefitLiabilityAssetMember_20201231" decimals="-3" unitRef="U_iso4217EUR">804000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000940" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxProvisionsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">1492000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000941" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxOtherDeferredTaxesMember_20201231" decimals="-3" unitRef="U_iso4217EUR">10625000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000942" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-fullUnusedTaxCreditsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">175704000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000943" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20201231" decimals="-3" unitRef="U_iso4217EUR">211438000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000944" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bntxValuationAdjustmentMember_20201231" decimals="-3" unitRef="U_iso4217EUR">-50486000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000945" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">160952000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000946" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxFixedAssetsMember_20181231" decimals="-3" unitRef="U_iso4217EUR">-90000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000947" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxLeasesMember_20181231" decimals="-3" unitRef="U_iso4217EUR">306000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000948" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxContractLiabilitiesMember_20181231" decimals="-3" unitRef="U_iso4217EUR">28441000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000949" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxProvisionsMember_20181231" decimals="-3" unitRef="U_iso4217EUR">134000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000950" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxOtherDeferredTaxesMember_20181231" decimals="-3" unitRef="U_iso4217EUR">161000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000951" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-fullUnusedTaxCreditsMember_20181231" decimals="-3" unitRef="U_iso4217EUR">55848000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000952" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20181231" decimals="-3" unitRef="U_iso4217EUR">84799000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000953" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bntxValuationAdjustmentMember_20181231" decimals="-3" unitRef="U_iso4217EUR">-84799000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss id="F_000954" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxFixedAssetsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-565000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss id="F_000955" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxInventoryMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">596000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss id="F_000956" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxLeasesMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">206000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss id="F_000957" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxContractLiabilitiesMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-4898000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss id="F_000958" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxProvisionsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">53000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss id="F_000959" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxOtherDeferredTaxesMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">1926000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss id="F_000960" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-fullUnusedTaxCreditsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">53916000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss id="F_000961" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">51235000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss id="F_000962" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bntxValuationAdjustmentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-51235000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <bntx:AccumulatedTaxLossesInCorporateTax id="F_000963" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">596359000</bntx:AccumulatedTaxLossesInCorporateTax>
  <bntx:AccumulatedTaxLossesInCorporateTax id="F_000964" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">356044000</bntx:AccumulatedTaxLossesInCorporateTax>
  <bntx:AccumulatedTaxLossesInCorporateTax id="F_000965" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">179264000</bntx:AccumulatedTaxLossesInCorporateTax>
  <bntx:AccumulatedTaxLossesInTradeTax id="F_000966" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">513561000</bntx:AccumulatedTaxLossesInTradeTax>
  <bntx:AccumulatedTaxLossesInTradeTax id="F_000967" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">352341000</bntx:AccumulatedTaxLossesInTradeTax>
  <bntx:AccumulatedTaxLossesInTradeTax id="F_000968" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">176425000</bntx:AccumulatedTaxLossesInTradeTax>
  <bntx:AccumulatedTaxLossesInFederalTaxCredits id="F_000969" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">756000</bntx:AccumulatedTaxLossesInFederalTaxCredits>
  <bntx:AccumulatedTaxLossesInStateTaxCredits id="F_000970" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">250000</bntx:AccumulatedTaxLossesInStateTaxCredits>
  <bntx:AccumulatedTaxLossesInCorporateTax id="F_000971" contextRef="C_0001776985_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxGermanTaxGroupMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">457900000</bntx:AccumulatedTaxLossesInCorporateTax>
  <bntx:AccumulatedTaxLossesInTradeTax id="F_000972" contextRef="C_0001776985_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxGermanTaxGroupMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">450900000</bntx:AccumulatedTaxLossesInTradeTax>
  <bntx:DeferredTaxAssetsForUnusedTaxLossesRecognized id="F_000973" contextRef="C_0001776985_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxGermanTaxGroupMember_20201231" decimals="INF" unitRef="U_iso4217EUR">0</bntx:DeferredTaxAssetsForUnusedTaxLossesRecognized>
  <ifrs-full:DeferredTaxLiabilityAsset id="F_000974" contextRef="C_0001776985_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxGermanTaxGroupMember_20201231" decimals="-5" unitRef="U_iso4217EUR">161000000</ifrs-full:DeferredTaxLiabilityAsset>
  <bntx:AccumulatedTaxLossesInCorporateTax id="F_000975" contextRef="C_0001776985_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxGermanEntitiesNotWithinTaxGroupMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">1700000</bntx:AccumulatedTaxLossesInCorporateTax>
  <bntx:AccumulatedTaxLossesInTradeTax id="F_000976" contextRef="C_0001776985_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxGermanEntitiesNotWithinTaxGroupMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">1800000</bntx:AccumulatedTaxLossesInTradeTax>
  <bntx:DeferredTaxAssetsForUnusedTaxLossesRecognized id="F_000977" contextRef="C_0001776985_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxGermanEntitiesNotWithinTaxGroupMember_20201231" decimals="INF" unitRef="U_iso4217EUR">0</bntx:DeferredTaxAssetsForUnusedTaxLossesRecognized>
  <bntx:AccumulatedTaxLossesInCorporateTax id="F_000978" contextRef="C_0001776985_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxUnitedStatesTaxGroupMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">136800000</bntx:AccumulatedTaxLossesInCorporateTax>
  <bntx:AccumulatedTaxLossesInTradeTax id="F_000979" contextRef="C_0001776985_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxUnitedStatesTaxGroupMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">60900000</bntx:AccumulatedTaxLossesInTradeTax>
  <bntx:FederalDeferredTaxAssetsOperatingLossCarryforwardsExpectedToExpire id="F_000980" contextRef="C_0001776985_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxUnitedStatesTaxGroupMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">20900000</bntx:FederalDeferredTaxAssetsOperatingLossCarryforwardsExpectedToExpire>
  <bntx:FederalTaxLossesExpirationYear id="F_000981" contextRef="C_0001776985_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxUnitedStatesTaxGroupMember_20200101_20201231">2033</bntx:FederalTaxLossesExpirationYear>
  <bntx:FederalDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration id="F_000982" contextRef="C_0001776985_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxUnitedStatesTaxGroupMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">115900000</bntx:FederalDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
  <bntx:StateDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration id="F_000983" contextRef="C_0001776985_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxUnitedStatesTaxGroupMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">60900000</bntx:StateDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
  <bntx:StateTaxLossesExpirationYear id="F_000984" contextRef="C_0001776985_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_bntxUnitedStatesTaxGroupMember_20200101_20201231">2033</bntx:StateTaxLossesExpirationYear>
  <bntx:SharesIssuedDuringPeriodStockSplit id="F_000985" contextRef="C_0001776985_20190918_20190918" decimals="INF" unitRef="U_xbrlishares">206595492</bntx:SharesIssuedDuringPeriodStockSplit>
  <ifrs-full:WeightedAverageShares id="F_000986" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_xbrlishares">235442000</ifrs-full:WeightedAverageShares>
  <ifrs-full:WeightedAverageShares id="F_000987" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_xbrlishares">211499000</ifrs-full:WeightedAverageShares>
  <ifrs-full:WeightedAverageShares id="F_000988" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_xbrlishares">190710000</ifrs-full:WeightedAverageShares>
  <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares id="F_000989" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_xbrlishares">13085000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
  <ifrs-full:AdjustedWeightedAverageShares id="F_000990" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_xbrlishares">248527000</ifrs-full:AdjustedWeightedAverageShares>
  <ifrs-full:AdjustedWeightedAverageShares id="F_000991" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_xbrlishares">211499000</ifrs-full:AdjustedWeightedAverageShares>
  <ifrs-full:AdjustedWeightedAverageShares id="F_000992" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_xbrlishares">190710000</ifrs-full:AdjustedWeightedAverageShares>
  <ifrs-full:PropertyPlantAndEquipment id="F_000993" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20181231" decimals="-3" unitRef="U_iso4217EUR">22147000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_000994" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20181231" decimals="-3" unitRef="U_iso4217EUR">73613000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_000995" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxConstructionInProgressAndAdvancePaymentsMember_20181231" decimals="-3" unitRef="U_iso4217EUR">7091000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_000996" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20181231" decimals="-3" unitRef="U_iso4217EUR">102853000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment id="F_000997" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">7269000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment id="F_000998" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">8700000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment id="F_000999" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxConstructionInProgressAndAdvancePaymentsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">22623000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment id="F_001000" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">38592000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="F_001001" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">105000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="F_001002" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxConstructionInProgressAndAdvancePaymentsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">10000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="F_001003" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">115000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <bntx:ReclassificationsPropertyPlantAndEquipment id="F_001004" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">53000</bntx:ReclassificationsPropertyPlantAndEquipment>
  <bntx:ReclassificationsPropertyPlantAndEquipment id="F_001005" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxConstructionInProgressAndAdvancePaymentsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-53000</bntx:ReclassificationsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment id="F_001006" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-1000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment id="F_001007" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxConstructionInProgressAndAdvancePaymentsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">1000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment id="F_001008" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">999000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment id="F_001009" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">999000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_001010" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">29469000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_001011" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">83206000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_001012" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxConstructionInProgressAndAdvancePaymentsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">29652000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_001013" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20191231" decimals="-3" unitRef="U_iso4217EUR">142329000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment id="F_001014" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">14927000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment id="F_001015" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">10093000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment id="F_001016" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxConstructionInProgressAndAdvancePaymentsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">41013000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment id="F_001017" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">66033000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="F_001018" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">41000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="F_001019" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">6892000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="F_001020" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxConstructionInProgressAndAdvancePaymentsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">958000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="F_001021" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">7891000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <bntx:ReclassificationsPropertyPlantAndEquipment id="F_001022" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">8561000</bntx:ReclassificationsPropertyPlantAndEquipment>
  <bntx:ReclassificationsPropertyPlantAndEquipment id="F_001023" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">1832000</bntx:ReclassificationsPropertyPlantAndEquipment>
  <bntx:ReclassificationsPropertyPlantAndEquipment id="F_001024" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxConstructionInProgressAndAdvancePaymentsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-10391000</bntx:ReclassificationsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment id="F_001025" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-52000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment id="F_001026" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-638000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment id="F_001027" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-690000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment id="F_001028" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">8400000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment id="F_001029" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">54817000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment id="F_001030" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxConstructionInProgressAndAdvancePaymentsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">22302000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment id="F_001031" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">85519000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_001032" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">61264000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_001033" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">142418000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_001034" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxConstructionInProgressAndAdvancePaymentsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">81618000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_001035" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20201231" decimals="-3" unitRef="U_iso4217EUR">285300000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_001036" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20181231" decimals="-3" unitRef="U_iso4217EUR">-6472000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_001037" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20181231" decimals="-3" unitRef="U_iso4217EUR">-30180000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_001038" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_20181231" decimals="-3" unitRef="U_iso4217EUR">-36652000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment id="F_001039" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">1854000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment id="F_001040" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">10861000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment id="F_001041" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">12715000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="F_001042" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-79000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="F_001043" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-79000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment id="F_001044" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-3000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment id="F_001045" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-3000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_001046" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">-8326000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_001047" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">-40959000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_001048" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_20191231" decimals="-3" unitRef="U_iso4217EUR">-49285000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment id="F_001049" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">2074000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment id="F_001050" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">13753000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment id="F_001051" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">15827000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="F_001052" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-41000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="F_001053" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-6683000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="F_001054" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-6724000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment id="F_001055" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-3000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment id="F_001056" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-53000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment id="F_001057" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-56000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_001058" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">-10356000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_001059" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">-47976000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_001060" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_20201231" decimals="-3" unitRef="U_iso4217EUR">-58332000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_001061" contextRef="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20181231" decimals="-3" unitRef="U_iso4217EUR">15675000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_001062" contextRef="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20181231" decimals="-3" unitRef="U_iso4217EUR">43433000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_001063" contextRef="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxConstructionInProgressAndAdvancePaymentsMember_20181231" decimals="-3" unitRef="U_iso4217EUR">7091000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_001064" contextRef="C_0001776985_20181231" decimals="-3" unitRef="U_iso4217EUR">66200000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_001065" contextRef="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">21143000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_001066" contextRef="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">42247000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_001067" contextRef="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxConstructionInProgressAndAdvancePaymentsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">29652000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_001068" contextRef="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_ifrs-fullLandAndBuildingsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">50908000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_001069" contextRef="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxEquipmentToolsAndInstallationsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">94442000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment id="F_001070" contextRef="C_0001776985_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_bntxConstructionInProgressAndAdvancePaymentsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">81618000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_001071" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-fullGoodwillMember_20181231" decimals="-3" unitRef="U_iso4217EUR">534000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_001072" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20181231" decimals="-3" unitRef="U_iso4217EUR">101853000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_001073" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxAdvancePaymentsMember_20181231" decimals="-3" unitRef="U_iso4217EUR">1497000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_001074" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20181231" decimals="-3" unitRef="U_iso4217EUR">103883000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill id="F_001075" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">11744000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill id="F_001076" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxAdvancePaymentsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">1529000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill id="F_001077" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">13273000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill id="F_001078" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">133000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill id="F_001079" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxAdvancePaymentsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">477000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill id="F_001080" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">610000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsOtherThanGoodwill id="F_001081" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">146000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsOtherThanGoodwill id="F_001082" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxAdvancePaymentsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-146000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill id="F_001083" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-23000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill id="F_001084" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-23000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill id="F_001085" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-fullGoodwillMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">2444000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill id="F_001086" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">2726000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill id="F_001087" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">5170000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_001088" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-fullGoodwillMember_20191231" decimals="-3" unitRef="U_iso4217EUR">2978000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_001089" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">116313000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_001090" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxAdvancePaymentsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">2403000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_001091" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20191231" decimals="-3" unitRef="U_iso4217EUR">121693000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill id="F_001092" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">4187000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill id="F_001093" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxAdvancePaymentsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">4426000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill id="F_001094" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">8613000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill id="F_001095" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">5435000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill id="F_001096" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxAdvancePaymentsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">643000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill id="F_001097" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">6078000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsOtherThanGoodwill id="F_001098" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">233000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsOtherThanGoodwill id="F_001099" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxAdvancePaymentsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-233000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill id="F_001100" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-fullGoodwillMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-6750000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill id="F_001101" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-3897000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill id="F_001102" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-10647000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill id="F_001103" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-fullGoodwillMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">57469000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill id="F_001104" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">35845000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill id="F_001105" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">93314000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_001106" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-fullGoodwillMember_20201231" decimals="-3" unitRef="U_iso4217EUR">53697000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_001107" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">147246000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_001108" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxAdvancePaymentsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">5953000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_001109" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullGrossCarryingAmountMember_20201231" decimals="-3" unitRef="U_iso4217EUR">206895000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_001110" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20181231" decimals="-3" unitRef="U_iso4217EUR">-15842000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_001111" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_20181231" decimals="-3" unitRef="U_iso4217EUR">-15842000</ifrs-full:IntangibleAssetsAndGoodwill>
  <bntx:AccumulatedDepreciationAmortisationAndImpairment id="F_001112" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">16502000</bntx:AccumulatedDepreciationAmortisationAndImpairment>
  <bntx:AccumulatedDepreciationAmortisationAndImpairment id="F_001113" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_20191231" decimals="-3" unitRef="U_iso4217EUR">16502000</bntx:AccumulatedDepreciationAmortisationAndImpairment>
  <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill id="F_001114" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-81000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill id="F_001115" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-81000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill id="F_001116" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-3000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill id="F_001117" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-3000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_001118" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">-32260000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_001119" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_20191231" decimals="-3" unitRef="U_iso4217EUR">-32260000</ifrs-full:IntangibleAssetsAndGoodwill>
  <bntx:AccumulatedDepreciationAmortisationAndImpairment id="F_001120" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">16627000</bntx:AccumulatedDepreciationAmortisationAndImpairment>
  <bntx:AccumulatedDepreciationAmortisationAndImpairment id="F_001121" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_20201231" decimals="-3" unitRef="U_iso4217EUR">16627000</bntx:AccumulatedDepreciationAmortisationAndImpairment>
  <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill id="F_001122" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-5410000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill id="F_001123" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-5410000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill id="F_001124" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-72000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill id="F_001125" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-72000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_001126" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">-43405000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_001127" contextRef="C_0001776985_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-fullAccumulatedDepreciationAmortisationAndImpairmentMember_20201231" decimals="-3" unitRef="U_iso4217EUR">-43405000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_001128" contextRef="C_0001776985_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-fullGoodwillMember_20181231" decimals="-3" unitRef="U_iso4217EUR">534000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_001129" contextRef="C_0001776985_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20181231" decimals="-3" unitRef="U_iso4217EUR">86011000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_001130" contextRef="C_0001776985_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxAdvancePaymentsMember_20181231" decimals="-3" unitRef="U_iso4217EUR">1497000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_001131" contextRef="C_0001776985_20181231" decimals="-3" unitRef="U_iso4217EUR">88042000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_001132" contextRef="C_0001776985_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-fullGoodwillMember_20191231" decimals="-3" unitRef="U_iso4217EUR">2978000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_001133" contextRef="C_0001776985_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">84053000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_001134" contextRef="C_0001776985_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxAdvancePaymentsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">2403000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_001135" contextRef="C_0001776985_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_ifrs-fullGoodwillMember_20201231" decimals="-3" unitRef="U_iso4217EUR">53697000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_001136" contextRef="C_0001776985_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">103841000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill id="F_001137" contextRef="C_0001776985_ifrs-fullClassesOfIntangibleAssetsAndGoodwillAxis_bntxAdvancePaymentsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">5953000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:Goodwill id="F_001138" contextRef="C_0001776985_ifrs-fullConsolidatedStructuredEntitiesAxis_bntxCGUImmunotherapiesMember_20201231" decimals="-3" unitRef="U_iso4217EUR">53163000</ifrs-full:Goodwill>
  <ifrs-full:Goodwill id="F_001139" contextRef="C_0001776985_ifrs-fullConsolidatedStructuredEntitiesAxis_bntxCGUImmunotherapiesMember_20191231" decimals="-3" unitRef="U_iso4217EUR">2444000</ifrs-full:Goodwill>
  <ifrs-full:Goodwill id="F_001140" contextRef="C_0001776985_ifrs-fullConsolidatedStructuredEntitiesAxis_bntxExternalProductSalesOfJPTMember_20201231" decimals="-3" unitRef="U_iso4217EUR">534000</ifrs-full:Goodwill>
  <ifrs-full:Goodwill id="F_001141" contextRef="C_0001776985_ifrs-fullConsolidatedStructuredEntitiesAxis_bntxExternalProductSalesOfJPTMember_20191231" decimals="-3" unitRef="U_iso4217EUR">534000</ifrs-full:Goodwill>
  <ifrs-full:ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows id="F_001142" contextRef="C_0001776985_ifrs-fullConsolidatedStructuredEntitiesAxis_bntxCGUImmunotherapiesMember_20200101_20201231">fifteen-year</ifrs-full:ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows>
  <ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections id="F_001143" contextRef="C_0001776985_ifrs-fullConsolidatedStructuredEntitiesAxis_bntxCGUImmunotherapiesMember_20201231" decimals="3" unitRef="U_xbrlipure">0.089</ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections>
  <ifrs-full:DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse id="F_001144" contextRef="C_0001776985_ifrs-fullConsolidatedStructuredEntitiesAxis_bntxCGUImmunotherapiesMember_20201231" decimals="3" unitRef="U_xbrlipure">0.010</ifrs-full:DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse>
  <ifrs-full:ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows id="F_001145" contextRef="C_0001776985_ifrs-fullConsolidatedStructuredEntitiesAxis_bntxExternalProductSalesOfJPTMember_20200101_20201231">ten-year</ifrs-full:ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows>
  <ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections id="F_001146" contextRef="C_0001776985_ifrs-fullConsolidatedStructuredEntitiesAxis_bntxExternalProductSalesOfJPTMember_20201231" decimals="INF" unitRef="U_xbrlipure">0.079</ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections>
  <ifrs-full:DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse id="F_001147" contextRef="C_0001776985_ifrs-fullConsolidatedStructuredEntitiesAxis_bntxExternalProductSalesOfJPTMember_20201231" decimals="INF" unitRef="U_xbrlipure">0.010</ifrs-full:DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse>
  <bntx:IncreaseInGrowthRateCashFlowProjections id="F_001148" contextRef="C_0001776985_ifrs-fullConsolidatedStructuredEntitiesAxis_bntxExternalProductSalesOfJPTMember_20201231" decimals="3" unitRef="U_xbrlipure">0.094</bntx:IncreaseInGrowthRateCashFlowProjections>
  <ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections id="F_001149" contextRef="C_0001776985_20201231" decimals="3" unitRef="U_xbrlipure">0.010</ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections>
  <ifrs-full:NoncurrentAssets id="F_001150" contextRef="C_0001776985_ifrs-fullGeographicalAreasAxis_countryUS_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_ifrs-fullSubsidiariesMember_20201231" decimals="-5" unitRef="U_iso4217EUR">89200000</ifrs-full:NoncurrentAssets>
  <ifrs-full:NoncurrentAssets id="F_001151" contextRef="C_0001776985_ifrs-fullGeographicalAreasAxis_countryUS_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_ifrs-fullSubsidiariesMember_20191231" decimals="-5" unitRef="U_iso4217EUR">3800000</ifrs-full:NoncurrentAssets>
  <ifrs-full:FinancialAssetsAtAmortisedCost id="F_001152" contextRef="C_0001776985_ifrs-fullClassesOfFinancialAssetsAxis_ifrs-fullTradeReceivablesMember_20201231" decimals="-3" unitRef="U_iso4217EUR">165468000</ifrs-full:FinancialAssetsAtAmortisedCost>
  <ifrs-full:FinancialAssetsAtAmortisedCost id="F_001153" contextRef="C_0001776985_ifrs-fullClassesOfFinancialAssetsAxis_ifrs-fullTradeReceivablesMember_20191231" decimals="-3" unitRef="U_iso4217EUR">11913000</ifrs-full:FinancialAssetsAtAmortisedCost>
  <ifrs-full:FinancialAssetsAtAmortisedCost id="F_001154" contextRef="C_0001776985_ifrs-fullClassesOfFinancialAssetsAxis_bntxOtherFinancialAssetsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">137234000</ifrs-full:FinancialAssetsAtAmortisedCost>
  <ifrs-full:FinancialAssetsAtAmortisedCost id="F_001155" contextRef="C_0001776985_ifrs-fullClassesOfFinancialAssetsAxis_bntxOtherFinancialAssetsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">1680000</ifrs-full:FinancialAssetsAtAmortisedCost>
  <ifrs-full:FinancialAssetsAtAmortisedCost id="F_001156" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">302702000</ifrs-full:FinancialAssetsAtAmortisedCost>
  <ifrs-full:FinancialAssetsAtAmortisedCost id="F_001157" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">13593000</ifrs-full:FinancialAssetsAtAmortisedCost>
  <ifrs-full:CurrentFinancialAssetsAtAmortisedCost id="F_001158" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">302702000</ifrs-full:CurrentFinancialAssetsAtAmortisedCost>
  <ifrs-full:CurrentFinancialAssetsAtAmortisedCost id="F_001159" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">13593000</ifrs-full:CurrentFinancialAssetsAtAmortisedCost>
  <ifrs-full:FinancialLiabilitiesAtAmortisedCost id="F_001160" contextRef="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_ifrs-fullLeaseLiabilitiesMember_20201231" decimals="-3" unitRef="U_iso4217EUR">84158000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
  <ifrs-full:FinancialLiabilitiesAtAmortisedCost id="F_001161" contextRef="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_ifrs-fullLeaseLiabilitiesMember_20191231" decimals="-3" unitRef="U_iso4217EUR">57611000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
  <ifrs-full:FinancialLiabilitiesAtAmortisedCost id="F_001162" contextRef="C_0001776985_ifrs-fullBorrowingsByNameAxis_bntxConvertibleNoteHostContractMember_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">87457000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
  <ifrs-full:FinancialLiabilitiesAtAmortisedCost id="F_001163" contextRef="C_0001776985_ifrs-fullBorrowingsByNameAxis_bntxThreePointFiveZeroPercentageSecuredBankLoanMember_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">47176000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
  <ifrs-full:FinancialLiabilitiesAtAmortisedCost id="F_001164" contextRef="C_0001776985_ifrs-fullBorrowingsByNameAxis_bntxTwoPointOneFivePercentageSecuredBankLoanMember_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">9032000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
  <ifrs-full:FinancialLiabilitiesAtAmortisedCost id="F_001165" contextRef="C_0001776985_ifrs-fullBorrowingsByNameAxis_bntxTwoPointOneFivePercentageSecuredBankLoanMember_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">9000000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
  <ifrs-full:FinancialLiabilitiesAtAmortisedCost id="F_001166" contextRef="C_0001776985_ifrs-fullBorrowingsByNameAxis_bntxTwoPointZeroEightPercentageSecuredBankLoanMember_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">8877000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
  <ifrs-full:FinancialLiabilitiesAtAmortisedCost id="F_001167" contextRef="C_0001776985_ifrs-fullBorrowingsByNameAxis_bntxTwoPointZeroEightPercentageSecuredBankLoanMember_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">7600000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
  <ifrs-full:FinancialLiabilitiesAtAmortisedCost id="F_001168" contextRef="C_0001776985_ifrs-fullBorrowingsByNameAxis_bntxOnePointNineZeroPercentageSecuredBankLoanMember_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">3489000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
  <ifrs-full:FinancialLiabilitiesAtAmortisedCost id="F_001169" contextRef="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">240189000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
  <ifrs-full:FinancialLiabilitiesAtAmortisedCost id="F_001170" contextRef="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">74211000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
  <ifrs-full:CurrentFinancialLiabilitiesAtAmortisedCost id="F_001171" contextRef="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">9142000</ifrs-full:CurrentFinancialLiabilitiesAtAmortisedCost>
  <ifrs-full:CurrentFinancialLiabilitiesAtAmortisedCost id="F_001172" contextRef="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">5307000</ifrs-full:CurrentFinancialLiabilitiesAtAmortisedCost>
  <ifrs-full:NoncurrentFinancialLiabilitiesAtAmortisedCost id="F_001173" contextRef="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">231047000</ifrs-full:NoncurrentFinancialLiabilitiesAtAmortisedCost>
  <ifrs-full:NoncurrentFinancialLiabilitiesAtAmortisedCost id="F_001174" contextRef="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">68904000</ifrs-full:NoncurrentFinancialLiabilitiesAtAmortisedCost>
  <bntx:FinancialLiabilitiesMaturityDate id="F_001175" contextRef="C_0001776985_ifrs-fullBorrowingsByNameAxis_bntxConvertibleNoteHostContractMember_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20200101_20201231">2024-08-28</bntx:FinancialLiabilitiesMaturityDate>
  <bntx:FinancialLiabilitiesMaturityDate id="F_001176" contextRef="C_0001776985_ifrs-fullBorrowingsByNameAxis_bntxThreePointFiveZeroPercentageSecuredBankLoanMember_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20200101_20201231">2026-12-21</bntx:FinancialLiabilitiesMaturityDate>
  <ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities id="F_001177" contextRef="C_0001776985_ifrs-fullBorrowingsByNameAxis_bntxThreePointFiveZeroPercentageSecuredBankLoanMember_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20201231" decimals="0" unitRef="U_iso4217EUR">50000000</ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities>
  <bntx:FinancialLiabilitiesMaturityDate id="F_001178" contextRef="C_0001776985_ifrs-fullBorrowingsByNameAxis_bntxTwoPointOneFivePercentageSecuredBankLoanMember_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20200101_20201231">2027-12-30</bntx:FinancialLiabilitiesMaturityDate>
  <ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities id="F_001179" contextRef="C_0001776985_ifrs-fullBorrowingsByNameAxis_bntxTwoPointOneFivePercentageSecuredBankLoanMember_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20201231" decimals="0" unitRef="U_iso4217EUR">10000000</ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities>
  <bntx:FinancialLiabilitiesMaturityDate id="F_001180" contextRef="C_0001776985_ifrs-fullBorrowingsByNameAxis_bntxTwoPointZeroEightPercentageSecuredBankLoanMember_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20200101_20201231">2028-09-30</bntx:FinancialLiabilitiesMaturityDate>
  <ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities id="F_001181" contextRef="C_0001776985_ifrs-fullBorrowingsByNameAxis_bntxTwoPointZeroEightPercentageSecuredBankLoanMember_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20201231" decimals="0" unitRef="U_iso4217EUR">9450000</ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities>
  <bntx:FinancialLiabilitiesMaturityDate id="F_001182" contextRef="C_0001776985_ifrs-fullBorrowingsByNameAxis_bntxOnePointNineZeroPercentageSecuredBankLoanMember_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20200101_20201231">2039-05-30</bntx:FinancialLiabilitiesMaturityDate>
  <ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities id="F_001183" contextRef="C_0001776985_ifrs-fullBorrowingsByNameAxis_bntxOnePointNineZeroPercentageSecuredBankLoanMember_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20201231" decimals="2" unitRef="U_iso4217EUR">3528892.48</ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities>
  <bntx:DerivativeFinancialLiabilitiesNotDesignatedAsHedgingInstrumentsAtFairValue id="F_001184" contextRef="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxOtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember_ifrs-fullClassesOfLiabilitiesAxis_bntxConvertibleNoteEmbeddedDerivativeMember_20201231" decimals="-3" unitRef="U_iso4217EUR">30903000</bntx:DerivativeFinancialLiabilitiesNotDesignatedAsHedgingInstrumentsAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss id="F_001185" contextRef="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxOtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember_ifrs-fullClassesOfLiabilitiesAxis_ifrs-fullContingentConsiderationMember_20201231" decimals="-3" unitRef="U_iso4217EUR">572000</ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss>
  <ifrs-full:FinancialLiabilitiesAtFairValue id="F_001186" contextRef="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxOtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">31475000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtAmortisedCost id="F_001187" contextRef="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxOtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxTradePayablesMember_20201231" decimals="-3" unitRef="U_iso4217EUR">102288000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
  <ifrs-full:FinancialLiabilitiesAtAmortisedCost id="F_001188" contextRef="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxOtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxTradePayablesMember_20191231" decimals="-3" unitRef="U_iso4217EUR">20498000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
  <ifrs-full:FinancialLiabilitiesAtAmortisedCost id="F_001189" contextRef="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxOtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxOtherFinancialLiabilitiesMember_20201231" decimals="-3" unitRef="U_iso4217EUR">74076000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
  <ifrs-full:FinancialLiabilitiesAtAmortisedCost id="F_001190" contextRef="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxOtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxOtherFinancialLiabilitiesMember_20191231" decimals="-3" unitRef="U_iso4217EUR">10352000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
  <ifrs-full:FinancialLiabilitiesAtAmortisedCost id="F_001191" contextRef="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxOtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">176364000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
  <ifrs-full:FinancialLiabilitiesAtAmortisedCost id="F_001192" contextRef="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxOtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">30850000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
  <ifrs-full:FinancialLiabilities id="F_001193" contextRef="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxOtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">207839000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities id="F_001194" contextRef="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxOtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">30850000</ifrs-full:FinancialLiabilities>
  <ifrs-full:CurrentFinancialLiabilities id="F_001195" contextRef="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxOtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">176363000</ifrs-full:CurrentFinancialLiabilities>
  <ifrs-full:CurrentFinancialLiabilities id="F_001196" contextRef="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxOtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">30850000</ifrs-full:CurrentFinancialLiabilities>
  <ifrs-full:NoncurrentFinancialLiabilities id="F_001197" contextRef="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxOtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">31476000</ifrs-full:NoncurrentFinancialLiabilities>
  <ifrs-full:FinancialLiabilities id="F_001198" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">448028000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities id="F_001199" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">105061000</ifrs-full:FinancialLiabilities>
  <ifrs-full:CurrentFinancialLiabilities id="F_001200" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">185505000</ifrs-full:CurrentFinancialLiabilities>
  <ifrs-full:CurrentFinancialLiabilities id="F_001201" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">36157000</ifrs-full:CurrentFinancialLiabilities>
  <ifrs-full:NoncurrentFinancialLiabilities id="F_001202" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">262523000</ifrs-full:NoncurrentFinancialLiabilities>
  <ifrs-full:NoncurrentFinancialLiabilities id="F_001203" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">68904000</ifrs-full:NoncurrentFinancialLiabilities>
  <bntx:NumberOfSecuredBankLoanMaintained id="F_001204" contextRef="C_0001776985_deiLegalEntityAxis_bntxDeutscheBankAGMember_20200101_20201231" decimals="INF" unitRef="U_bntxLoan">2</bntx:NumberOfSecuredBankLoanMaintained>
  <ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities id="F_001205" contextRef="C_0001776985_deiLegalEntityAxis_bntxDeutscheBankAGMember_ifrs-fullBorrowingsByNameAxis_bntxTwoPointOneFivePercentageSecuredLoanMember_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechInnovativeManufacturingServicesGmbHMember_20201231" decimals="-5" unitRef="U_iso4217EUR">10000000</ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities>
  <ifrs-full:BorrowingsInterestRate id="F_001206" contextRef="C_0001776985_deiLegalEntityAxis_bntxDeutscheBankAGMember_ifrs-fullBorrowingsByNameAxis_bntxTwoPointOneFivePercentageSecuredLoanMember_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechInnovativeManufacturingServicesGmbHMember_20201231" decimals="4" unitRef="U_xbrlipure">0.0215</ifrs-full:BorrowingsInterestRate>
  <bntx:FinancialLiabilitiesMaturityDate id="F_001207" contextRef="C_0001776985_deiLegalEntityAxis_bntxDeutscheBankAGMember_ifrs-fullBorrowingsByNameAxis_bntxTwoPointOneFivePercentageSecuredLoanMember_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechInnovativeManufacturingServicesGmbHMember_20200101_20201231">2027-12-30</bntx:FinancialLiabilitiesMaturityDate>
  <bntx:LoanRepayableQuarterlyInstallment id="F_001208" contextRef="C_0001776985_deiLegalEntityAxis_bntxDeutscheBankAGMember_ifrs-fullBorrowingsByNameAxis_bntxTwoPointOneFivePercentageSecuredLoanMember_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechInnovativeManufacturingServicesGmbHMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">300000</bntx:LoanRepayableQuarterlyInstallment>
  <bntx:LoanRepayableQuarterlyInstallmentCommencementDate id="F_001209" contextRef="C_0001776985_deiLegalEntityAxis_bntxDeutscheBankAGMember_ifrs-fullBorrowingsByNameAxis_bntxTwoPointOneFivePercentageSecuredLoanMember_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxBioNTechInnovativeManufacturingServicesGmbHMember_20200101_20201231">2020-06-30</bntx:LoanRepayableQuarterlyInstallmentCommencementDate>
  <ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities id="F_001210" contextRef="C_0001776985_deiLegalEntityAxis_bntxDeutscheBankAGMember_ifrs-fullBorrowingsByNameAxis_bntxTwoPointZeroEightPercentageBankLoanMember_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxJPTPeptideTechnologiesGmbHMember_20201231" decimals="-4" unitRef="U_iso4217EUR">9450000</ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities>
  <ifrs-full:BorrowingsInterestRate id="F_001211" contextRef="C_0001776985_deiLegalEntityAxis_bntxDeutscheBankAGMember_ifrs-fullBorrowingsByNameAxis_bntxTwoPointZeroEightPercentageBankLoanMember_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxJPTPeptideTechnologiesGmbHMember_20201231" decimals="4" unitRef="U_xbrlipure">0.0208</ifrs-full:BorrowingsInterestRate>
  <bntx:FinancialLiabilitiesMaturityDate id="F_001212" contextRef="C_0001776985_deiLegalEntityAxis_bntxDeutscheBankAGMember_ifrs-fullBorrowingsByNameAxis_bntxTwoPointZeroEightPercentageBankLoanMember_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxJPTPeptideTechnologiesGmbHMember_20200101_20201231">2028-09-30</bntx:FinancialLiabilitiesMaturityDate>
  <bntx:LoanRepayableQuarterlyInstallment id="F_001213" contextRef="C_0001776985_deiLegalEntityAxis_bntxDeutscheBankAGMember_ifrs-fullBorrowingsByNameAxis_bntxTwoPointZeroEightPercentageBankLoanMember_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxJPTPeptideTechnologiesGmbHMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">300000</bntx:LoanRepayableQuarterlyInstallment>
  <bntx:LoanRepayableQuarterlyInstallmentCommencementDate id="F_001214" contextRef="C_0001776985_deiLegalEntityAxis_bntxDeutscheBankAGMember_ifrs-fullBorrowingsByNameAxis_bntxTwoPointZeroEightPercentageBankLoanMember_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_bntxJPTPeptideTechnologiesGmbHMember_20200101_20201231">2020-09-30</bntx:LoanRepayableQuarterlyInstallmentCommencementDate>
  <ifrs-full:NotionalAmount id="F_001215" contextRef="C_0001776985_deiLegalEntityAxis_bntxEuropeanInvestmentBankMember_ifrs-fullBorrowingsByNameAxis_bntxThreePointFiveZeroPercentageSecuredBankLoanMember_20200630" decimals="INF" unitRef="U_iso4217EUR">100000000</ifrs-full:NotionalAmount>
  <bntx:TermLoanCreditA id="F_001216" contextRef="C_0001776985_deiLegalEntityAxis_bntxEuropeanInvestmentBankMember_ifrs-fullBorrowingsByNameAxis_bntxThreePointFiveZeroPercentageSecuredBankLoanMember_20200630" decimals="-6" unitRef="U_iso4217EUR">50000000</bntx:TermLoanCreditA>
  <bntx:TermLoanCreditB id="F_001217" contextRef="C_0001776985_deiLegalEntityAxis_bntxEuropeanInvestmentBankMember_ifrs-fullBorrowingsByNameAxis_bntxThreePointFiveZeroPercentageSecuredBankLoanMember_20200630" decimals="-5" unitRef="U_iso4217EUR">50000000</bntx:TermLoanCreditB>
  <bntx:TermLoanCreditA id="F_001218" contextRef="C_0001776985_deiLegalEntityAxis_bntxEuropeanInvestmentBankMember_ifrs-fullBorrowingsByNameAxis_bntxThreePointFiveZeroPercentageSecuredBankLoanMember_20201221" decimals="-5" unitRef="U_iso4217EUR">50000000</bntx:TermLoanCreditA>
  <ifrs-full:BorrowingsInterestRate id="F_001219" contextRef="C_0001776985_deiLegalEntityAxis_bntxEuropeanInvestmentBankMember_ifrs-fullBorrowingsByNameAxis_bntxThreePointFiveZeroPercentageSecuredBankLoanMember_ifrs-fullTypesOfInterestRatesAxis_bntxCashInterestFixedRateMember_20201221" decimals="INF" unitRef="U_xbrlipure">0.01</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:BorrowingsInterestRate id="F_001220" contextRef="C_0001776985_deiLegalEntityAxis_bntxEuropeanInvestmentBankMember_ifrs-fullBorrowingsByNameAxis_bntxThreePointFiveZeroPercentageSecuredBankLoanMember_ifrs-fullTypesOfInterestRatesAxis_bntxDeferredInterestAtFixedRateMember_20201221" decimals="INF" unitRef="U_xbrlipure">0.025</ifrs-full:BorrowingsInterestRate>
  <bntx:FinancialLiabilitiesMaturityDate id="F_001221" contextRef="C_0001776985_deiLegalEntityAxis_bntxEuropeanInvestmentBankMember_ifrs-fullBorrowingsByNameAxis_bntxThreePointFiveZeroPercentageSecuredBankLoanMember_20201221_20201221">2026-12-21</bntx:FinancialLiabilitiesMaturityDate>
  <ifrs-full:InvestmentAccountedForUsingEquityMethod id="F_001222" contextRef="C_0001776985_ifrs-fullClassesOfFinancialInstrumentsAxis_bntxJuneTwentyTwentyPrivatePlacementMember_ifrs-fullClassesOfLiabilitiesAxis_bntxConvertibleNoteMember_20201231" decimals="-5" unitRef="U_iso4217EUR">100000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
  <bntx:FinancialLiabilityMaturityTerm id="F_001223" contextRef="C_0001776985_ifrs-fullClassesOfFinancialInstrumentsAxis_bntxJuneTwentyTwentyPrivatePlacementMember_ifrs-fullClassesOfLiabilitiesAxis_bntxConvertibleNoteMember_20200101_20201231">P4Y</bntx:FinancialLiabilityMaturityTerm>
  <bntx:FinancialLiabilitiesCouponRatePerAnnum id="F_001224" contextRef="C_0001776985_ifrs-fullClassesOfFinancialInstrumentsAxis_bntxJuneTwentyTwentyPrivatePlacementMember_ifrs-fullClassesOfLiabilitiesAxis_bntxConvertibleNoteMember_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.045</bntx:FinancialLiabilitiesCouponRatePerAnnum>
  <bntx:FinancialLiabilitiesConversionPremiumPercentageAboveReferencePrice id="F_001225" contextRef="C_0001776985_ifrs-fullClassesOfFinancialInstrumentsAxis_bntxJuneTwentyTwentyPrivatePlacementMember_ifrs-fullClassesOfLiabilitiesAxis_bntxConvertibleNoteMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.20</bntx:FinancialLiabilitiesConversionPremiumPercentageAboveReferencePrice>
  <bntx:EffectiveInterestRateOfFinancialLiabilities id="F_001226" contextRef="C_0001776985_ifrs-fullClassesOfFinancialInstrumentsAxis_bntxJuneTwentyTwentyPrivatePlacementMember_ifrs-fullClassesOfLiabilitiesAxis_bntxConvertibleNoteMember_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.090</bntx:EffectiveInterestRateOfFinancialLiabilities>
  <ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities id="F_001227" contextRef="C_0001776985_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">17300000</ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities>
  <bntx:CashAndCashEquivalent id="F_001228" contextRef="C_0001776985_ifrs-fullClassesOfAssetsAxis_bntxUSDollarBankAccountsMember_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_20201231" decimals="-3" unitRef="U_iso4217EUR">673545000</bntx:CashAndCashEquivalent>
  <bntx:CashAndCashEquivalent id="F_001229" contextRef="C_0001776985_ifrs-fullClassesOfAssetsAxis_bntxUSDollarBankAccountsMember_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_20191231" decimals="-3" unitRef="U_iso4217EUR">213913000</bntx:CashAndCashEquivalent>
  <bntx:CashAndCashEquivalent id="F_001230" contextRef="C_0001776985_ifrs-fullClassesOfFinancialAssetsAxis_bntxOtherFinancialAssetsMember_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_20201231" decimals="-3" unitRef="U_iso4217EUR">85573000</bntx:CashAndCashEquivalent>
  <bntx:CashAndCashEquivalent id="F_001231" contextRef="C_0001776985_ifrs-fullClassesOfFinancialLiabilitiesAxis_bntxFinancialLiabilityMember_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_20201231" decimals="-3" unitRef="U_iso4217EUR">72821000</bntx:CashAndCashEquivalent>
  <bntx:CashAndCashEquivalent id="F_001232" contextRef="C_0001776985_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_20201231" decimals="-3" unitRef="U_iso4217EUR">686297000</bntx:CashAndCashEquivalent>
  <bntx:CashAndCashEquivalent id="F_001233" contextRef="C_0001776985_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_20191231" decimals="-3" unitRef="U_iso4217EUR">213913000</bntx:CashAndCashEquivalent>
  <ifrs-full:ClosingForeignExchangeRate id="F_001234" contextRef="C_0001776985_ifrs-fullGeographicalAreasAxis_countryUS_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_srtCurrencyAxis_currencyUSD_20201231" decimals="4" unitRef="U_xbrlipure">1.2271</ifrs-full:ClosingForeignExchangeRate>
  <ifrs-full:ClosingForeignExchangeRate id="F_001235" contextRef="C_0001776985_ifrs-fullGeographicalAreasAxis_countryUS_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_srtCurrencyAxis_currencyUSD_20191231" decimals="4" unitRef="U_xbrlipure">1.1234</ifrs-full:ClosingForeignExchangeRate>
  <ifrs-full:AverageForeignExchangeRate id="F_001236" contextRef="C_0001776985_ifrs-fullGeographicalAreasAxis_countryUS_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_srtCurrencyAxis_currencyUSD_20200101_20201231" decimals="4" unitRef="U_xbrlipure">1.1422</ifrs-full:AverageForeignExchangeRate>
  <ifrs-full:AverageForeignExchangeRate id="F_001237" contextRef="C_0001776985_ifrs-fullGeographicalAreasAxis_countryUS_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_srtCurrencyAxis_currencyUSD_20190101_20191231" decimals="4" unitRef="U_xbrlipure">1.1195</ifrs-full:AverageForeignExchangeRate>
  <bntx:ForeignCurrencyChangesEffectOnLossBeforeTax id="F_001238" contextRef="C_0001776985_ifrs-fullHedgingInstrumentsAxis_bntxPositiveFivePercentageChangeInForeignExchangeRateMember_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-32491000</bntx:ForeignCurrencyChangesEffectOnLossBeforeTax>
  <bntx:ForeignCurrencyChangesEffectOnLossBeforeTax id="F_001239" contextRef="C_0001776985_ifrs-fullHedgingInstrumentsAxis_bntxNegativeFivePercentageChangeInForeignExchangeRateMember_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">35911000</bntx:ForeignCurrencyChangesEffectOnLossBeforeTax>
  <bntx:ForeignCurrencyChangesEffectOnLossBeforeTax id="F_001240" contextRef="C_0001776985_ifrs-fullHedgingInstrumentsAxis_bntxPositiveFivePercentageChangeInForeignExchangeRateMember_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-10186000</bntx:ForeignCurrencyChangesEffectOnLossBeforeTax>
  <bntx:ForeignCurrencyChangesEffectOnLossBeforeTax id="F_001241" contextRef="C_0001776985_ifrs-fullHedgingInstrumentsAxis_bntxNegativeFivePercentageChangeInForeignExchangeRateMember_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">11259000</bntx:ForeignCurrencyChangesEffectOnLossBeforeTax>
  <bntx:ForeignCurrencyChangesEffectOnPretaxEquity id="F_001242" contextRef="C_0001776985_ifrs-fullHedgingInstrumentsAxis_bntxPositiveFivePercentageChangeInForeignExchangeRateMember_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-32681000</bntx:ForeignCurrencyChangesEffectOnPretaxEquity>
  <bntx:ForeignCurrencyChangesEffectOnPretaxEquity id="F_001243" contextRef="C_0001776985_ifrs-fullHedgingInstrumentsAxis_bntxNegativeFivePercentageChangeInForeignExchangeRateMember_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">36121000</bntx:ForeignCurrencyChangesEffectOnPretaxEquity>
  <bntx:ForeignCurrencyChangesEffectOnPretaxEquity id="F_001244" contextRef="C_0001776985_ifrs-fullHedgingInstrumentsAxis_bntxPositiveFivePercentageChangeInForeignExchangeRateMember_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-10186000</bntx:ForeignCurrencyChangesEffectOnPretaxEquity>
  <bntx:ForeignCurrencyChangesEffectOnPretaxEquity id="F_001245" contextRef="C_0001776985_ifrs-fullHedgingInstrumentsAxis_bntxNegativeFivePercentageChangeInForeignExchangeRateMember_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">11259000</bntx:ForeignCurrencyChangesEffectOnPretaxEquity>
  <bntx:InterestBearingLoansAndBorrowings id="F_001246" contextRef="C_0001776985_ifrs-fullMaturityAxis_ifrs-fullNotLaterThanOneYearMember_ifrs-fullTypesOfRisksAxis_ifrs-fullLiquidityRiskMember_20201231" decimals="-3" unitRef="U_iso4217EUR">3173000</bntx:InterestBearingLoansAndBorrowings>
  <bntx:InterestBearingLoansAndBorrowings id="F_001247" contextRef="C_0001776985_ifrs-fullMaturityAxis_ifrs-fullLaterThanTwoYearsAndNotLaterThanFiveYearsMember_ifrs-fullTypesOfRisksAxis_ifrs-fullLiquidityRiskMember_20201231" decimals="-3" unitRef="U_iso4217EUR">12643000</bntx:InterestBearingLoansAndBorrowings>
  <bntx:InterestBearingLoansAndBorrowings id="F_001248" contextRef="C_0001776985_ifrs-fullMaturityAxis_ifrs-fullLaterThanFiveYearsMember_ifrs-fullTypesOfRisksAxis_ifrs-fullLiquidityRiskMember_20201231" decimals="-3" unitRef="U_iso4217EUR">66730000</bntx:InterestBearingLoansAndBorrowings>
  <bntx:InterestBearingLoansAndBorrowings id="F_001249" contextRef="C_0001776985_ifrs-fullTypesOfRisksAxis_ifrs-fullLiquidityRiskMember_20201231" decimals="-3" unitRef="U_iso4217EUR">82546000</bntx:InterestBearingLoansAndBorrowings>
  <ifrs-full:TradeAndOtherPayables id="F_001250" contextRef="C_0001776985_ifrs-fullMaturityAxis_ifrs-fullNotLaterThanOneYearMember_ifrs-fullTypesOfRisksAxis_ifrs-fullLiquidityRiskMember_20201231" decimals="-3" unitRef="U_iso4217EUR">102288000</ifrs-full:TradeAndOtherPayables>
  <ifrs-full:TradeAndOtherPayables id="F_001251" contextRef="C_0001776985_ifrs-fullTypesOfRisksAxis_ifrs-fullLiquidityRiskMember_20201231" decimals="-3" unitRef="U_iso4217EUR">102288000</ifrs-full:TradeAndOtherPayables>
  <ifrs-full:LeaseLiabilities id="F_001252" contextRef="C_0001776985_ifrs-fullMaturityAxis_ifrs-fullNotLaterThanOneYearMember_ifrs-fullTypesOfRisksAxis_ifrs-fullLiquidityRiskMember_20201231" decimals="-3" unitRef="U_iso4217EUR">8525000</ifrs-full:LeaseLiabilities>
  <ifrs-full:LeaseLiabilities id="F_001253" contextRef="C_0001776985_ifrs-fullMaturityAxis_ifrs-fullLaterThanTwoYearsAndNotLaterThanFiveYearsMember_ifrs-fullTypesOfRisksAxis_ifrs-fullLiquidityRiskMember_20201231" decimals="-3" unitRef="U_iso4217EUR">27283000</ifrs-full:LeaseLiabilities>
  <ifrs-full:LeaseLiabilities id="F_001254" contextRef="C_0001776985_ifrs-fullMaturityAxis_ifrs-fullLaterThanFiveYearsMember_ifrs-fullTypesOfRisksAxis_ifrs-fullLiquidityRiskMember_20201231" decimals="-3" unitRef="U_iso4217EUR">71780000</ifrs-full:LeaseLiabilities>
  <ifrs-full:LeaseLiabilities id="F_001255" contextRef="C_0001776985_ifrs-fullTypesOfRisksAxis_ifrs-fullLiquidityRiskMember_20201231" decimals="-3" unitRef="U_iso4217EUR">107588000</ifrs-full:LeaseLiabilities>
  <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination id="F_001256" contextRef="C_0001776985_ifrs-fullMaturityAxis_ifrs-fullLaterThanFiveYearsMember_ifrs-fullTypesOfRisksAxis_ifrs-fullLiquidityRiskMember_20201231" decimals="-3" unitRef="U_iso4217EUR">572000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
  <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination id="F_001257" contextRef="C_0001776985_ifrs-fullTypesOfRisksAxis_ifrs-fullLiquidityRiskMember_20201231" decimals="-3" unitRef="U_iso4217EUR">572000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
  <ifrs-full:OtherFinancialLiabilities id="F_001258" contextRef="C_0001776985_ifrs-fullMaturityAxis_ifrs-fullNotLaterThanOneYearMember_ifrs-fullTypesOfRisksAxis_ifrs-fullLiquidityRiskMember_20201231" decimals="-3" unitRef="U_iso4217EUR">74076000</ifrs-full:OtherFinancialLiabilities>
  <ifrs-full:OtherFinancialLiabilities id="F_001259" contextRef="C_0001776985_ifrs-fullTypesOfRisksAxis_ifrs-fullLiquidityRiskMember_20201231" decimals="-3" unitRef="U_iso4217EUR">74076000</ifrs-full:OtherFinancialLiabilities>
  <ifrs-full:FinancialLiabilities id="F_001260" contextRef="C_0001776985_ifrs-fullMaturityAxis_ifrs-fullNotLaterThanOneYearMember_ifrs-fullTypesOfRisksAxis_ifrs-fullLiquidityRiskMember_20201231" decimals="-3" unitRef="U_iso4217EUR">188062000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities id="F_001261" contextRef="C_0001776985_ifrs-fullMaturityAxis_ifrs-fullLaterThanTwoYearsAndNotLaterThanFiveYearsMember_ifrs-fullTypesOfRisksAxis_ifrs-fullLiquidityRiskMember_20201231" decimals="-3" unitRef="U_iso4217EUR">39926000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities id="F_001262" contextRef="C_0001776985_ifrs-fullMaturityAxis_ifrs-fullLaterThanFiveYearsMember_ifrs-fullTypesOfRisksAxis_ifrs-fullLiquidityRiskMember_20201231" decimals="-3" unitRef="U_iso4217EUR">139082000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities id="F_001263" contextRef="C_0001776985_ifrs-fullTypesOfRisksAxis_ifrs-fullLiquidityRiskMember_20201231" decimals="-3" unitRef="U_iso4217EUR">367070000</ifrs-full:FinancialLiabilities>
  <ifrs-full:LiabilitiesArisingFromFinancingActivities id="F_001264" contextRef="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxCurrentObligationsUnderLeaseContractsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">3485000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
  <ifrs-full:LiabilitiesArisingFromFinancingActivities id="F_001265" contextRef="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxNoncurrentObligationsUnderLeaseContractsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">54126000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
  <ifrs-full:LiabilitiesArisingFromFinancingActivities id="F_001266" contextRef="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">16600000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
  <ifrs-full:LiabilitiesArisingFromFinancingActivities id="F_001267" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">74211000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities id="F_001268" contextRef="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxCurrentObligationsUnderLeaseContractsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-12743000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities id="F_001269" contextRef="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">140847000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities id="F_001270" contextRef="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxConvertibleNoteEmbeddedDerivativeMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">13614000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities id="F_001271" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">141718000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities id="F_001272" contextRef="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxCurrentObligationsUnderLeaseContractsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">2719000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities id="F_001273" contextRef="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxNoncurrentObligationsUnderLeaseContractsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">32331000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities id="F_001274" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">35050000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities id="F_001275" contextRef="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxCurrentObligationsUnderLeaseContractsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">8684000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities id="F_001276" contextRef="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxNoncurrentObligationsUnderLeaseContractsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-4444000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities id="F_001277" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">4240000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
  <bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities id="F_001278" contextRef="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxCurrentObligationsUnderLeaseContractsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">3982000</bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities>
  <bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities id="F_001279" contextRef="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxNoncurrentObligationsUnderLeaseContractsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-3982000</bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities id="F_001280" contextRef="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-1416000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities id="F_001281" contextRef="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxConvertibleNoteEmbeddedDerivativeMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">17289000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities id="F_001282" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">15873000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:LiabilitiesArisingFromFinancingActivities id="F_001283" contextRef="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxCurrentObligationsUnderLeaseContractsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">6127000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
  <ifrs-full:LiabilitiesArisingFromFinancingActivities id="F_001284" contextRef="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxNoncurrentObligationsUnderLeaseContractsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">78031000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
  <ifrs-full:LiabilitiesArisingFromFinancingActivities id="F_001285" contextRef="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">156031000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
  <ifrs-full:LiabilitiesArisingFromFinancingActivities id="F_001286" contextRef="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxConvertibleNoteEmbeddedDerivativeMember_20201231" decimals="-3" unitRef="U_iso4217EUR">30903000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
  <ifrs-full:LiabilitiesArisingFromFinancingActivities id="F_001287" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">271092000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
  <ifrs-full:LiabilitiesArisingFromFinancingActivities id="F_001288" contextRef="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxCurrentObligationsUnderLeaseContractsMember_20181231" decimals="-3" unitRef="U_iso4217EUR">2134000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
  <ifrs-full:LiabilitiesArisingFromFinancingActivities id="F_001289" contextRef="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxNoncurrentObligationsUnderLeaseContractsMember_20181231" decimals="-3" unitRef="U_iso4217EUR">48618000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
  <ifrs-full:LiabilitiesArisingFromFinancingActivities id="F_001290" contextRef="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20181231" decimals="-3" unitRef="U_iso4217EUR">5600000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
  <ifrs-full:LiabilitiesArisingFromFinancingActivities id="F_001291" contextRef="C_0001776985_20181231" decimals="-3" unitRef="U_iso4217EUR">56352000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities id="F_001292" contextRef="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxCurrentObligationsUnderLeaseContractsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-3061000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities id="F_001293" contextRef="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxInterestBearingLoansAndBorrowingsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">11000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities id="F_001294" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">7939000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities id="F_001295" contextRef="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxCurrentObligationsUnderLeaseContractsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">1484000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities id="F_001296" contextRef="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxNoncurrentObligationsUnderLeaseContractsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">8436000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities id="F_001297" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">9920000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
  <bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities id="F_001298" contextRef="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxCurrentObligationsUnderLeaseContractsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">2928000</bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities>
  <bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities id="F_001299" contextRef="C_0001776985_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_bntxNoncurrentObligationsUnderLeaseContractsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">-2928000</bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies id="F_001300" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">44283000</ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies>
  <ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies id="F_001301" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">8201000</ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies>
  <ifrs-full:WorkInProgress id="F_001302" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">19380000</ifrs-full:WorkInProgress>
  <ifrs-full:WorkInProgress id="F_001303" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">2888000</ifrs-full:WorkInProgress>
  <ifrs-full:FinishedGoods id="F_001304" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">457000</ifrs-full:FinishedGoods>
  <ifrs-full:FinishedGoods id="F_001305" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">633000</ifrs-full:FinishedGoods>
  <ifrs-full:CurrentPrepaidExpenses id="F_001306" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">29845000</ifrs-full:CurrentPrepaidExpenses>
  <ifrs-full:CurrentPrepaidExpenses id="F_001307" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">351000</ifrs-full:CurrentPrepaidExpenses>
  <ifrs-full:CurrentAdvancesToSuppliers id="F_001308" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">14140000</ifrs-full:CurrentAdvancesToSuppliers>
  <ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax id="F_001309" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">4155000</ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax>
  <ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax id="F_001310" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">7536000</ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax>
  <bntx:CurrentPrepaymentsRelatedToServiceContracts id="F_001311" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">3825000</bntx:CurrentPrepaymentsRelatedToServiceContracts>
  <bntx:OtherCurrentAssetsOther id="F_001312" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">10046000</bntx:OtherCurrentAssetsOther>
  <bntx:OtherCurrentAssetsOther id="F_001313" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">1182000</bntx:OtherCurrentAssetsOther>
  <ifrs-full:OtherAssets id="F_001314" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">62011000</ifrs-full:OtherAssets>
  <ifrs-full:OtherAssets id="F_001315" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">9069000</ifrs-full:OtherAssets>
  <bntx:DeferredExpensesFromInsuranceContracts id="F_001316" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">13845000</bntx:DeferredExpensesFromInsuranceContracts>
  <bntx:DeferredExpensesFromInsuranceContracts id="F_001317" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">1758000</bntx:DeferredExpensesFromInsuranceContracts>
  <bntx:DeferredExpensesFromContractManufacturingAndContractResearchOrganizations id="F_001318" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">5725000</bntx:DeferredExpensesFromContractManufacturingAndContractResearchOrganizations>
  <bntx:OtherDeferredExpenses id="F_001319" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">8431000</bntx:OtherDeferredExpenses>
  <bntx:OtherDeferredExpenses id="F_001320" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">4104000</bntx:OtherDeferredExpenses>
  <bntx:DeferredExpense id="F_001321" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">28001000</bntx:DeferredExpense>
  <bntx:DeferredExpense id="F_001322" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">5862000</bntx:DeferredExpense>
  <bntx:DeferredExpenseNonCurrent id="F_001323" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">0</bntx:DeferredExpenseNonCurrent>
  <bntx:DeferredExpenseNonCurrent id="F_001324" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">0</bntx:DeferredExpenseNonCurrent>
  <ifrs-full:IssueOfEquity id="F_001325" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">14000000</ifrs-full:IssueOfEquity>
  <ifrs-full:ParValuePerShare id="F_001326" contextRef="C_0001776985_20201231" decimals="INF" unitRef="U_iso4217EUR_xbrlishares">1.00</ifrs-full:ParValuePerShare>
  <ifrs-full:IssueOfEquity id="F_001327" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullTreasurySharesMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">700000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity id="F_001328" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">861000000</ifrs-full:IssueOfEquity>
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares id="F_001329" contextRef="C_0001776985_srtCounterpartyNameAxis_bntxShanghaiFosunPharmaceuticalGroupCoLtdMember_20200316_20200316" decimals="-5" unitRef="U_iso4217EUR">45600000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares id="F_001330" contextRef="C_0001776985_srtCounterpartyNameAxis_bntxShanghaiFosunPharmaceuticalGroupCoLtdMember_20200316_20200316" decimals="-5" unitRef="U_iso4217USD">50000000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <bntx:NumberOfOrdinarySharesIssuable id="F_001331" contextRef="C_0001776985_srtCounterpartyNameAxis_bntxShanghaiFosunPharmaceuticalGroupCoLtdMember_20200316" decimals="INF" unitRef="U_xbrlishares">1580777</bntx:NumberOfOrdinarySharesIssuable>
  <ifrs-full:IssueOfEquity id="F_001332" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_srtCounterpartyNameAxis_bntxShanghaiFosunPharmaceuticalGroupCoLtdMember_20200423_20200423" decimals="-5" unitRef="U_iso4217EUR">1600000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity id="F_001333" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_srtCounterpartyNameAxis_bntxShanghaiFosunPharmaceuticalGroupCoLtdMember_20200423_20200423" decimals="-5" unitRef="U_iso4217EUR">44000000</ifrs-full:IssueOfEquity>
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares id="F_001334" contextRef="C_0001776985_srtCounterpartyNameAxis_bntxPfizerIncMember_20200317_20200317" decimals="-5" unitRef="U_iso4217EUR">103900000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares id="F_001335" contextRef="C_0001776985_srtCounterpartyNameAxis_bntxPfizerIncMember_20200317_20200317" decimals="-5" unitRef="U_iso4217USD">113000000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <ifrs-full:NumberOfSharesIssued id="F_001336" contextRef="C_0001776985_srtCounterpartyNameAxis_bntxPfizerIncMember_20200505" decimals="INF" unitRef="U_xbrlishares">2377446</ifrs-full:NumberOfSharesIssued>
  <ifrs-full:IssueOfEquity id="F_001337" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_srtCounterpartyNameAxis_bntxPfizerIncMember_20200505_20200505" decimals="-5" unitRef="U_iso4217EUR">2400000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity id="F_001338" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_srtCounterpartyNameAxis_bntxPfizerIncMember_20200505_20200505" decimals="-5" unitRef="U_iso4217EUR">101500000</ifrs-full:IssueOfEquity>
  <ifrs-full:NumberOfSharesIssued id="F_001339" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxNeonTherapeuticsIncMember_20200508" decimals="INF" unitRef="U_xbrlishares">1935488</ifrs-full:NumberOfSharesIssued>
  <ifrs-full:IssueOfEquity id="F_001340" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxNeonTherapeuticsIncMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20200508_20200508" decimals="-5" unitRef="U_iso4217EUR">1900000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity id="F_001341" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxNeonTherapeuticsIncMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20200508_20200508" decimals="-5" unitRef="U_iso4217EUR">87600000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity id="F_001342" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxGlobalOfferingMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20200727_20200727" decimals="-5" unitRef="U_iso4217EUR">5500000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity id="F_001343" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxGlobalOfferingMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20200727_20200727" decimals="-5" unitRef="U_iso4217USD">6400000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity id="F_001344" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxGlobalOfferingMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20200827_20200827" decimals="-3" unitRef="U_iso4217EUR">16000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity id="F_001345" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxGlobalOfferingMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20200827_20200827" decimals="-3" unitRef="U_iso4217USD">19000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity id="F_001346" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxGlobalOfferingMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">5500000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity id="F_001347" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxGlobalOfferingMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">430800000</ifrs-full:IssueOfEquity>
  <ifrs-full:NumberOfSharesIssued id="F_001348" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxGlobalOfferingMember_20200727" decimals="INF" unitRef="U_xbrlishares">5500000</ifrs-full:NumberOfSharesIssued>
  <ifrs-full:NumberOfSharesIssued id="F_001349" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxGlobalOfferingMember_20200827" decimals="INF" unitRef="U_xbrlishares">16124</ifrs-full:NumberOfSharesIssued>
  <bntx:PercentageOfAmericanDepositorySharesToOrdinaryShares id="F_001350" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxGlobalOfferingMember_20200727_20200727" decimals="0" unitRef="U_xbrlipure">1</bntx:PercentageOfAmericanDepositorySharesToOrdinaryShares>
  <bntx:PercentageOfAmericanDepositorySharesToOrdinaryShares id="F_001351" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxGlobalOfferingMember_20200827_20200827" decimals="0" unitRef="U_xbrlipure">1</bntx:PercentageOfAmericanDepositorySharesToOrdinaryShares>
  <bntx:SharesIssuedPricePerShare1 id="F_001352" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxGlobalOfferingMember_20200727" decimals="INF" unitRef="U_iso4217USD_xbrlishares">93.00</bntx:SharesIssuedPricePerShare1>
  <bntx:SharesIssuedPricePerShare1 id="F_001353" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxGlobalOfferingMember_20200827" decimals="INF" unitRef="U_iso4217USD_xbrlishares">93.00</bntx:SharesIssuedPricePerShare1>
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares id="F_001354" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxGlobalOfferingMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">436300000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares id="F_001355" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxGlobalOfferingMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">513000000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <bntx:EquityIssuable id="F_001356" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxJune2020PrivatePlacementMember_20200629" decimals="-5" unitRef="U_iso4217EUR">123900000</bntx:EquityIssuable>
  <bntx:FinancialLiabilityMaturityTerm id="F_001357" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxJune2020PrivatePlacementMember_ifrs-fullClassesOfLiabilitiesAxis_bntxConvertibleNoteMember_20200908_20200908">P4Y</bntx:FinancialLiabilityMaturityTerm>
  <ifrs-full:IssueOfEquity id="F_001358" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxJune2020PrivatePlacementMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20200629_20200629" decimals="-5" unitRef="U_iso4217EUR">2600000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity id="F_001359" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxJune2020PrivatePlacementMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20200908_20200908" decimals="-5" unitRef="U_iso4217EUR">121300000</ifrs-full:IssueOfEquity>
  <ifrs-full:NumberOfSharesIssued id="F_001360" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxJune2020PrivatePlacementMember_20200908" decimals="INF" unitRef="U_xbrlishares">2595996</ifrs-full:NumberOfSharesIssued>
  <bntx:MaximumProceedsReceivableFromIssuanceOfOrdinaryShares id="F_001361" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxAtMarketOfferingProgramMember_20201130" decimals="INF" unitRef="U_iso4217USD">500000000</bntx:MaximumProceedsReceivableFromIssuanceOfOrdinaryShares>
  <ifrs-full:IssueOfEquity id="F_001362" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxAtMarketOfferingProgramMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullTreasurySharesMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">700000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity id="F_001363" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxAtMarketOfferingProgramMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">75800000</ifrs-full:IssueOfEquity>
  <ifrs-full:NumberOfSharesIssued id="F_001364" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxAtMarketOfferingProgramMember_20201231" decimals="INF" unitRef="U_xbrlishares">735490</ifrs-full:NumberOfSharesIssued>
  <bntx:PercentageOfAmericanDepositorySharesToOrdinaryShares id="F_001365" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxAtMarketOfferingProgramMember_20200101_20201231" decimals="0" unitRef="U_xbrlipure">1</bntx:PercentageOfAmericanDepositorySharesToOrdinaryShares>
  <ifrs-full:NumberOfSharesIssued id="F_001366" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxAtMarketOfferingProgramMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullTreasurySharesMember_20201231" decimals="INF" unitRef="U_xbrlishares">-735490</ifrs-full:NumberOfSharesIssued>
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares id="F_001367" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxAtMarketOfferingProgramMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">76500000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares id="F_001368" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxAtMarketOfferingProgramMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">92900000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <ifrs-full:IssueOfEquity id="F_001369" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20190101_20191231" decimals="-5" unitRef="U_iso4217EUR">39000000</ifrs-full:IssueOfEquity>
  <ifrs-full:ParValuePerShare id="F_001370" contextRef="C_0001776985_20191231" decimals="INF" unitRef="U_iso4217EUR_xbrlishares">1.00</ifrs-full:ParValuePerShare>
  <ifrs-full:IssueOfEquity id="F_001371" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20190101_20191231" decimals="-5" unitRef="U_iso4217EUR">359200000</ifrs-full:IssueOfEquity>
  <ifrs-full:NumberOfSharesIssued id="F_001372" contextRef="C_0001776985_20190131" decimals="INF" unitRef="U_xbrlishares">5088204</ifrs-full:NumberOfSharesIssued>
  <ifrs-full:IssueOfEquity id="F_001373" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20190101_20190131" decimals="-5" unitRef="U_iso4217EUR">5100000</ifrs-full:IssueOfEquity>
  <bntx:CashInvestment id="F_001374" contextRef="C_0001776985_20181231" decimals="-5" unitRef="U_iso4217EUR">80000000</bntx:CashInvestment>
  <bntx:RemainingNoncontrollingInterestsAcquiredPercentage id="F_001375" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechCellAndGeneTherapiesGmbHMember_20190314_20190314" decimals="3" unitRef="U_xbrlipure">0.055</bntx:RemainingNoncontrollingInterestsAcquiredPercentage>
  <ifrs-full:NumberOfSharesIssued id="F_001376" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechCellAndGeneTherapiesGmbHMember_20190314" decimals="INF" unitRef="U_xbrlishares">2374794</ifrs-full:NumberOfSharesIssued>
  <ifrs-full:ParValuePerShare id="F_001377" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechCellAndGeneTherapiesGmbHMember_20190314" decimals="INF" unitRef="U_iso4217EUR_xbrlishares">1.00</ifrs-full:ParValuePerShare>
  <bntx:DerecognitionOfNonControllingInterest id="F_001378" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechCellAndGeneTherapiesGmbHMember_20190314_20190314" decimals="-5" unitRef="U_iso4217EUR">700000</bntx:DerecognitionOfNonControllingInterest>
  <ifrs-full:IssuedCapital id="F_001379" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechCellAndGeneTherapiesGmbHMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20190314" decimals="-5" unitRef="U_iso4217EUR">2400000</ifrs-full:IssuedCapital>
  <bntx:DecreaseInCapitalReserve id="F_001380" contextRef="C_0001776985_ifrs-fullBusinessCombinationsAxis_bntxBioNTechCellAndGeneTherapiesGmbHMember_20190314_20190314" decimals="-5" unitRef="U_iso4217EUR">1600000</bntx:DecreaseInCapitalReserve>
  <ifrs-full:NumberOfSharesIssuedAndFullyPaid id="F_001381" contextRef="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_bntxOrdinarySharesSeriesBMember_20191231" decimals="INF" unitRef="U_xbrlishares">12465288</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
  <ifrs-full:NumberOfSharesIssuedButNotFullyPaid id="F_001382" contextRef="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_bntxOrdinarySharesSeriesBMember_ifrs-fullGeographicalAreasAxis_countryHK_20191231" decimals="INF" unitRef="U_xbrlishares">5524506</ifrs-full:NumberOfSharesIssuedButNotFullyPaid>
  <ifrs-full:IssuedCapital id="F_001383" contextRef="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_bntxOrdinarySharesSeriesBMember_20191231" decimals="-5" unitRef="U_iso4217EUR">12500000</ifrs-full:IssuedCapital>
  <ifrs-full:IssuedCapital id="F_001384" contextRef="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_bntxOrdinarySharesSeriesBMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20191231" decimals="-5" unitRef="U_iso4217EUR">186100000</ifrs-full:IssuedCapital>
  <ifrs-full:NumberOfSharesIssuedAndFullyPaid id="F_001385" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInAssociatesAxis_bntxBillAndMeLindaGatesFoundationMember_20190926" decimals="INF" unitRef="U_xbrlishares">3038674</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
  <ifrs-full:IssuedCapital id="F_001386" contextRef="C_0001776985_ifrs-fullSignificantInvestmentsInAssociatesAxis_bntxBillAndMeLindaGatesFoundationMember_20190926" decimals="-5" unitRef="U_iso4217EUR">3000000</ifrs-full:IssuedCapital>
  <ifrs-full:IssuedCapital id="F_001387" contextRef="C_0001776985_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_ifrs-fullSignificantInvestmentsInAssociatesAxis_bntxBillAndMeLindaGatesFoundationMember_20190926" decimals="-5" unitRef="U_iso4217EUR">46800000</ifrs-full:IssuedCapital>
  <ifrs-full:IssuedCapital id="F_001388" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxInitialPublicOfferingMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20191010" decimals="-5" unitRef="U_iso4217EUR">10000000</ifrs-full:IssuedCapital>
  <bntx:SharesIssuedPricePerShare1 id="F_001389" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxInitialPublicOfferingMember_20191010" decimals="2" unitRef="U_iso4217USD_xbrlishares">15.00</bntx:SharesIssuedPricePerShare1>
  <ifrs-full:IssuedCapital id="F_001390" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxInitialPublicOfferingMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullIssuedCapitalMember_20191106" decimals="-5" unitRef="U_iso4217EUR">500000</ifrs-full:IssuedCapital>
  <bntx:SharesIssuedPricePerShare1 id="F_001391" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxInitialPublicOfferingMember_20191106" decimals="2" unitRef="U_iso4217USD_xbrlishares">15.00</bntx:SharesIssuedPricePerShare1>
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares id="F_001392" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxInitialPublicOfferingMember_20191106_20191106" decimals="-5" unitRef="U_iso4217EUR">143300000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares id="F_001393" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxInitialPublicOfferingMember_20191106_20191106" decimals="-5" unitRef="U_iso4217USD">157800000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <ifrs-full:ChangesInEquity id="F_001394" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxInitialPublicOfferingMember_20191106_20191106" decimals="-5" unitRef="U_iso4217EUR">10500000</ifrs-full:ChangesInEquity>
  <ifrs-full:IssuedCapital id="F_001395" contextRef="C_0001776985_ifrs-fullCapitalRequirementsAxis_bntxInitialPublicOfferingMember_ifrs-fullComponentsOfEquityAxis_ifrs-fullCapitalReserveMember_20191106" decimals="-5" unitRef="U_iso4217EUR">132700000</ifrs-full:IssuedCapital>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="F_001396" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxTwoThousandTwentyRestrictedStockUnitPlanMember_20201201_20201231" decimals="INF" unitRef="U_iso4217EUR">0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement id="F_001397" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeEquityPlanMember_20200101_20201231">The BioNTech Employee 2020 Equity Plan share-based payment transaction for employees based in Europe includes two programs, LTI and LTI-plus. The LTI program will be offered to all employees. The LTI-plus program intends to compensate employees who did not participate in the ESOP. Under both programs, RSUs will be offered to employees based in Europe. Both programs are classified as equity-settled because BioNTech has the ability to determine the method of settlement. The LTI will vest annually in equal installments after four years commencing on December 15, 2020. The LTI-plus will vest annually in equal installments after two years commencing on December 15, 2020. Moreover, the LTI-plus contains a non-vesting condition concerning 50% of the granted RSUs. These units will be awarded to the participant after the FDA fully approves BNT162b2.</ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement>
  <bntx:OptionVestingPeriod id="F_001398" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeEquityPlanLongTermIncentiveProgramMember_20201201_20201231">P4Y</bntx:OptionVestingPeriod>
  <bntx:OptionVestingPeriod id="F_001399" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeEquityPlanLongTermIncentivePlusProgramMember_20201201_20201231">P2Y</bntx:OptionVestingPeriod>
  <bntx:PercentageOfOtherEquityInstrumentNonVestingRate id="F_001400" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeEquityPlanLongTermIncentivePlusProgramMember_20201201_20201231" decimals="2" unitRef="U_xbrlipure">0.50</bntx:PercentageOfOtherEquityInstrumentNonVestingRate>
  <bntx:NumberOfInstrumentsOtherEquityInstrumentsExpectedToBeAllocated id="F_001401" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeEquityPlanLongTermIncentiveProgramMember_20200101_20201231" decimals="0" unitRef="U_xbrlishares">252766</bntx:NumberOfInstrumentsOtherEquityInstrumentsExpectedToBeAllocated>
  <bntx:NumberOfInstrumentsOtherEquityInstrumentsExpectedToBeAllocated id="F_001402" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeEquityPlanLongTermIncentivePlusProgramMember_20200101_20201231" decimals="0" unitRef="U_xbrlishares">396938</bntx:NumberOfInstrumentsOtherEquityInstrumentsExpectedToBeAllocated>
  <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement id="F_001403" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeEquityPlanMember_20201231" decimals="0" unitRef="U_xbrlishares">649704</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
  <bntx:WeightedAverageExercisePriceOfOtherEquityInstrumentsExpectedToBeAllocatedInSharebasedPaymentArrangement id="F_001404" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeEquityPlanLongTermIncentiveProgramMember_20200101_20201231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">66.43</bntx:WeightedAverageExercisePriceOfOtherEquityInstrumentsExpectedToBeAllocatedInSharebasedPaymentArrangement>
  <bntx:WeightedAverageExercisePriceOfOtherEquityInstrumentsExpectedToBeAllocatedInSharebasedPaymentArrangement id="F_001405" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeEquityPlanLongTermIncentivePlusProgramMember_20200101_20201231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">66.43</bntx:WeightedAverageExercisePriceOfOtherEquityInstrumentsExpectedToBeAllocatedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019 id="F_001406" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeEquityPlanMember_20201231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">66.43</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="F_001407" contextRef="C_0001776985_bntxNatureOfExpensesAxis_bntxCostOfSales1Member_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeEquityPlanMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">179000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="F_001408" contextRef="C_0001776985_bntxNatureOfExpensesAxis_bntxResearchAndDevelopmentExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeEquityPlanMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">681000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="F_001409" contextRef="C_0001776985_bntxNatureOfExpensesAxis_bntxSalesAndMarketingExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeEquityPlanMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">8000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="F_001410" contextRef="C_0001776985_bntxNatureOfExpensesAxis_bntxGeneralAndAdministrativeExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeEquityPlanMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">147000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="F_001411" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeEquityPlanMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">1015000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <bntx:PercentageOfAmericanDepositorySharesToOrdinaryShares id="F_001412" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtRangeAxis_ifrs-fullTopOfRangeMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.50</bntx:PercentageOfAmericanDepositorySharesToOrdinaryShares>
  <bntx:CashSettledExpenseFromSharebasedPaymentTransactionsWithEmployees id="F_001413" contextRef="C_0001776985_bntxNatureOfExpensesAxis_bntxResearchAndDevelopmentExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">300000</bntx:CashSettledExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <bntx:CashSettledExpenseFromSharebasedPaymentTransactionsWithEmployees id="F_001414" contextRef="C_0001776985_bntxNatureOfExpensesAxis_bntxGeneralAndAdministrativeExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">400000</bntx:CashSettledExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:OtherFinancialLiabilities id="F_001415" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20201231" decimals="-5" unitRef="U_iso4217EUR">700000</ifrs-full:OtherFinancialLiabilities>
  <ifrs-full:ExpectedDividendShareOptionsGranted id="F_001416" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxProfessorUgurSahinMDMember_20200101_20201231" decimals="0" unitRef="U_iso4217EUR">750000</ifrs-full:ExpectedDividendShareOptionsGranted>
  <ifrs-full:ExpectedDividendShareOptionsGranted id="F_001417" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxSeanMarettMember_20200101_20201231" decimals="0" unitRef="U_iso4217EUR">300000</ifrs-full:ExpectedDividendShareOptionsGranted>
  <ifrs-full:ExpectedDividendShareOptionsGranted id="F_001418" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrSierkPoettingMember_20200101_20201231" decimals="0" unitRef="U_iso4217EUR">300000</ifrs-full:ExpectedDividendShareOptionsGranted>
  <ifrs-full:ExpectedDividendShareOptionsGranted id="F_001419" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrOzlemTureciMember_20200101_20201231" decimals="0" unitRef="U_iso4217EUR">300000</ifrs-full:ExpectedDividendShareOptionsGranted>
  <ifrs-full:ExpectedDividendShareOptionsGranted id="F_001420" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxRyanRichardsonMember_20200101_20201231" decimals="0" unitRef="U_iso4217EUR">260000</ifrs-full:ExpectedDividendShareOptionsGranted>
  <bntx:IncreaseDecreaseInShareBasedPaymentValue id="F_001421" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxRyanRichardsonMember_20200101_20201231" decimals="0" unitRef="U_iso4217EUR">280000</bntx:IncreaseDecreaseInShareBasedPaymentValue>
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement id="F_001422" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200101_20201231" decimals="0" unitRef="U_xbrlishares">248096</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <bntx:NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne id="F_001423" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200101_20201231" decimals="0" unitRef="U_xbrlishares">101422</bntx:NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne>
  <bntx:NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo id="F_001424" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200101_20201231" decimals="0" unitRef="U_xbrlishares">102463</bntx:NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo>
  <ifrs-full:NumberOfOutstandingShareOptions id="F_001425" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20201231" decimals="0" unitRef="U_xbrlishares">451981</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019 id="F_001426" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200101_20201231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">28.32</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
  <bntx:WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne id="F_001427" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200101_20201231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">67.26</bntx:WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne>
  <bntx:WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo id="F_001428" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200101_20201231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">67.27</bntx:WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 id="F_001429" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20201231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">45.89</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <bntx:PercentageOfIncreaseInExercisePrice id="F_001430" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.07</bntx:PercentageOfIncreaseInExercisePrice>
  <bntx:ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering id="F_001431" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200101_20201231" decimals="-8" unitRef="U_iso4217USD">8500000000</bntx:ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering>
  <bntx:PercentageOfTargetSharePriceApplicableForPriorTwelveMonth id="F_001432" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">1.07</bntx:PercentageOfTargetSharePriceApplicableForPriorTwelveMonth>
  <bntx:OptionExpirationPeriod id="F_001433" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200101_20201231">P10Y</bntx:OptionExpirationPeriod>
  <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted id="F_001434" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200213" decimals="2" unitRef="U_iso4217EUR">10.83</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
  <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted id="F_001435" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateOneMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20211231" decimals="2" unitRef="U_iso4217EUR">26.85</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
  <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted id="F_001436" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateTwoMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20221231" decimals="2" unitRef="U_iso4217EUR">26.61</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
  <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019 id="F_001437" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200213_20200213" decimals="2" unitRef="U_iso4217EUR_xbrlishares">28.20</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
  <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019 id="F_001438" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateOneMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20210101_20211231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">66.43</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
  <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019 id="F_001439" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateTwoMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20220101_20221231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">66.43</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
  <ifrs-full:ExercisePriceShareOptionsGranted2019 id="F_001440" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200213_20200213" decimals="2" unitRef="U_iso4217EUR_xbrlishares">28.32</ifrs-full:ExercisePriceShareOptionsGranted2019>
  <ifrs-full:ExercisePriceShareOptionsGranted2019 id="F_001441" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateOneMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20210101_20211231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">67.26</ifrs-full:ExercisePriceShareOptionsGranted2019>
  <ifrs-full:ExercisePriceShareOptionsGranted2019 id="F_001442" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateTwoMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20220101_20221231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">67.27</ifrs-full:ExercisePriceShareOptionsGranted2019>
  <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted id="F_001443" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200213_20200213" decimals="3" unitRef="U_xbrlipure">0.366</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
  <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted id="F_001444" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateOneMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20210101_20211231" decimals="3" unitRef="U_xbrlipure">0.410</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
  <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted id="F_001445" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateTwoMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20220101_20221231" decimals="3" unitRef="U_xbrlipure">0.407</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
  <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted id="F_001446" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200213_20200213" decimals="2" unitRef="U_utrY">4.75</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
  <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted id="F_001447" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateOneMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20210101_20211231" decimals="2" unitRef="U_utrY">5.01</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
  <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted id="F_001448" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateTwoMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20220101_20221231" decimals="2" unitRef="U_utrY">6.05</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted id="F_001449" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200213_20200213" decimals="4" unitRef="U_xbrlipure">0.0161</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted id="F_001450" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateOneMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20210101_20211231" decimals="4" unitRef="U_xbrlipure">0.0088</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted id="F_001451" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateTwoMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20220101_20221231" decimals="4" unitRef="U_xbrlipure">0.0088</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <ifrs-full:ExercisePriceShareOptionsGranted2019 id="F_001452" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200213_20200213" decimals="2" unitRef="U_iso4217USD_xbrlishares">30.78</ifrs-full:ExercisePriceShareOptionsGranted2019>
  <ifrs-full:NumberOfOutstandingShareOptions id="F_001453" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxProfessorUgurSahinMDMember_20200213" decimals="0" unitRef="U_xbrlishares">97420</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions id="F_001454" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxSeanMarettMember_20200213" decimals="0" unitRef="U_xbrlishares">38968</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions id="F_001455" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrSierkPoettingMember_20200213" decimals="0" unitRef="U_xbrlishares">38968</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions id="F_001456" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrOzlemTureciMDMember_20200213" decimals="0" unitRef="U_xbrlishares">38968</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions id="F_001457" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxRyanRichardsonMember_20200213" decimals="0" unitRef="U_xbrlishares">33772</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 id="F_001458" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxProfessorUgurSahinMDMember_20200213" decimals="2" unitRef="U_iso4217EUR_xbrlishares">28.32</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 id="F_001459" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxSeanMarettMember_20200213" decimals="2" unitRef="U_iso4217EUR_xbrlishares">28.32</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 id="F_001460" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrSierkPoettingMember_20200213" decimals="2" unitRef="U_iso4217EUR_xbrlishares">28.32</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 id="F_001461" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrOzlemTureciMDMember_20200213" decimals="2" unitRef="U_iso4217EUR_xbrlishares">28.32</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 id="F_001462" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxRyanRichardsonMember_20200213" decimals="2" unitRef="U_iso4217EUR_xbrlishares">28.32</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfOutstandingShareOptions id="F_001463" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateOneMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxProfessorUgurSahinMDMember_20211231" decimals="0" unitRef="U_xbrlishares">39826</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions id="F_001464" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateOneMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxSeanMarettMember_20211231" decimals="0" unitRef="U_xbrlishares">15930</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions id="F_001465" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateOneMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrSierkPoettingMember_20211231" decimals="0" unitRef="U_xbrlishares">15930</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions id="F_001466" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateOneMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrOzlemTureciMDMember_20211231" decimals="0" unitRef="U_xbrlishares">15930</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions id="F_001467" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateOneMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxRyanRichardsonMember_20211231" decimals="0" unitRef="U_xbrlishares">13806</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 id="F_001468" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateOneMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxProfessorUgurSahinMDMember_20211231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">67.26</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 id="F_001469" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateOneMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxSeanMarettMember_20211231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">67.26</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 id="F_001470" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateOneMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrSierkPoettingMember_20211231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">67.26</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 id="F_001471" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateOneMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrOzlemTureciMDMember_20211231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">67.26</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 id="F_001472" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateOneMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxRyanRichardsonMember_20211231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">67.26</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfOutstandingShareOptions id="F_001473" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateTwoMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxProfessorUgurSahinMDMember_20221231" decimals="0" unitRef="U_xbrlishares">39817</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions id="F_001474" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateTwoMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxSeanMarettMember_20221231" decimals="0" unitRef="U_xbrlishares">15927</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions id="F_001475" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateTwoMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrSierkPoettingMember_20221231" decimals="0" unitRef="U_xbrlishares">15927</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions id="F_001476" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateTwoMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrOzlemTureciMDMember_20221231" decimals="0" unitRef="U_xbrlishares">15927</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions id="F_001477" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateTwoMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxRyanRichardsonMember_20221231" decimals="0" unitRef="U_xbrlishares">14865</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 id="F_001478" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateTwoMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxProfessorUgurSahinMDMember_20221231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">67.27</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 id="F_001479" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateTwoMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxSeanMarettMember_20221231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">67.27</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 id="F_001480" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateTwoMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrSierkPoettingMember_20221231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">67.27</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 id="F_001481" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateTwoMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrOzlemTureciMDMember_20221231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">67.27</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 id="F_001482" contextRef="C_0001776985_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxEstimatedAllocationDateTwoMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxRyanRichardsonMember_20221231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">67.27</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <bntx:WeightedAverageRemainingContractualLifeOfShareOptionsAllocatedAndExpectedToBeAllocated id="F_001483" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200101_20201231">P4Y7M17D</bntx:WeightedAverageRemainingContractualLifeOfShareOptionsAllocatedAndExpectedToBeAllocated>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="F_001484" contextRef="C_0001776985_bntxNatureOfExpensesAxis_bntxResearchAndDevelopmentExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">1514000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="F_001485" contextRef="C_0001776985_bntxNatureOfExpensesAxis_bntxGeneralAndAdministrativeExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">1246000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="F_001486" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">2760000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement id="F_001487" contextRef="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_ifrs-fullOrdinarySharesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_20190901_20190930" decimals="INF" unitRef="U_xbrlishares">4374963</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
  <bntx:ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare id="F_001488" contextRef="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_ifrs-fullOrdinarySharesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_20190901_20190930" decimals="2" unitRef="U_iso4217EUR_xbrlishares">13.60</bntx:ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare>
  <bntx:ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare id="F_001489" contextRef="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_ifrs-fullOrdinarySharesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_20190901_20190930" decimals="2" unitRef="U_iso4217USD_xbrlishares">15.00</bntx:ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare>
  <ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement id="F_001490" contextRef="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_ifrs-fullOrdinarySharesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_20200101_20201231">The option vests annually in equal installments after four years commencing on the first anniversary of the initial public offering and will be exercisable four years after the initial public offering. The option is subject to the terms, conditions, definitions and provisions of the ESOP and the applicable option agreement thereunder.</ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement>
  <bntx:OptionVestingPeriod id="F_001491" contextRef="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_ifrs-fullOrdinarySharesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_20190901_20190930">P4Y</bntx:OptionVestingPeriod>
  <bntx:PercentageOfIncreaseInExercisePrice id="F_001492" contextRef="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_ifrs-fullOrdinarySharesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_20190901_20190930" decimals="2" unitRef="U_xbrlipure">0.07</bntx:PercentageOfIncreaseInExercisePrice>
  <bntx:ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering id="F_001493" contextRef="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_ifrs-fullOrdinarySharesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_20190901_20190930" decimals="-8" unitRef="U_iso4217USD">8500000000</bntx:ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering>
  <bntx:PercentageOfTargetSharePriceApplicableForPriorTwelveMonth id="F_001494" contextRef="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_ifrs-fullOrdinarySharesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_20190901_20190930" decimals="2" unitRef="U_xbrlipure">1.07</bntx:PercentageOfTargetSharePriceApplicableForPriorTwelveMonth>
  <bntx:OptionExercisablePeriod id="F_001495" contextRef="C_0001776985_ifrs-fullClassesOfShareCapitalAxis_ifrs-fullOrdinarySharesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_srtRangeAxis_srtMaximumMember_20190901_20190930">P10Y</bntx:OptionExercisablePeriod>
  <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted id="F_001496" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_20191010" decimals="2" unitRef="U_iso4217EUR">5.63</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
  <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019 id="F_001497" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_20191010_20191010" decimals="2" unitRef="U_iso4217EUR_xbrlishares">13.60</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
  <ifrs-full:ExercisePriceShareOptionsGranted2019 id="F_001498" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_20191010_20191010" decimals="2" unitRef="U_iso4217EUR_xbrlishares">13.60</ifrs-full:ExercisePriceShareOptionsGranted2019>
  <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted id="F_001499" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_20191010_20191010" decimals="3" unitRef="U_xbrlipure">0.414</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
  <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted id="F_001500" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_20191010_20191010" decimals="2" unitRef="U_utrY">5.37</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted id="F_001501" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_20191010_20191010" decimals="4" unitRef="U_xbrlipure">0.0152</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement id="F_001502" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">0</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement id="F_001503" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">0</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 id="F_001504" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_20200101_20201231">P4Y1M13D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="F_001505" contextRef="C_0001776985_bntxNatureOfExpensesAxis_bntxResearchAndDevelopmentExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">11300000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="F_001506" contextRef="C_0001776985_bntxNatureOfExpensesAxis_bntxResearchAndDevelopmentExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxChiefExecutiveOfficerGrantMember_20190101_20191231" decimals="-5" unitRef="U_iso4217EUR">3200000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement id="F_001507" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20200101_20201231">The Option Rights vest over four years and can only be exercised if the company has executed a public offering in the United States (IPO) and when the Threshold Amount is met. Threshold Amount means the exercise price provided that such price increases by eight percentage points on the first and then each subsequent anniversary of the Allocation Date (September 26, 2018). The Option Rights can be exercised at the latest eight years after the Allocation Date. If they have not been exercised by that date, they will be forfeited without compensation.</ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement>
  <bntx:OptionVestingPeriod id="F_001508" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20181115_20181115">P4Y</bntx:OptionVestingPeriod>
  <bntx:PercentageOfIncreaseInExercisePrice id="F_001509" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20181115_20181115" decimals="2" unitRef="U_xbrlipure">0.08</bntx:PercentageOfIncreaseInExercisePrice>
  <bntx:PercentageOfIncreaseInExercisePrice id="F_001510" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190221_20190403" decimals="2" unitRef="U_xbrlipure">0.08</bntx:PercentageOfIncreaseInExercisePrice>
  <bntx:PercentageOfIncreaseInExercisePrice id="F_001511" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190429_20190531" decimals="2" unitRef="U_xbrlipure">0.08</bntx:PercentageOfIncreaseInExercisePrice>
  <bntx:PercentageOfIncreaseInExercisePrice id="F_001512" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20191201_20191201" decimals="2" unitRef="U_xbrlipure">0.08</bntx:PercentageOfIncreaseInExercisePrice>
  <bntx:OptionExercisablePeriod id="F_001513" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20181115_20181115">P8Y</bntx:OptionExercisablePeriod>
  <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted id="F_001514" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20181115" decimals="2" unitRef="U_iso4217EUR">7.41</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
  <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted id="F_001515" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190403" decimals="2" unitRef="U_iso4217EUR">6.93</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
  <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted id="F_001516" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190531" decimals="2" unitRef="U_iso4217EUR">7.04</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
  <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted id="F_001517" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20191201" decimals="2" unitRef="U_iso4217EUR">9.49</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
  <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019 id="F_001518" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20181115_20181115" decimals="2" unitRef="U_iso4217EUR_xbrlishares">14.40</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
  <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019 id="F_001519" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190222_20190403" decimals="2" unitRef="U_iso4217EUR_xbrlishares">15.72</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
  <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019 id="F_001520" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190430_20190531" decimals="2" unitRef="U_iso4217EUR_xbrlishares">16.03</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
  <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019 id="F_001521" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20191201_20191201" decimals="2" unitRef="U_iso4217EUR_xbrlishares">19.84</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
  <ifrs-full:ExercisePriceShareOptionsGranted2019 id="F_001522" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20181115_20181115" decimals="2" unitRef="U_iso4217EUR_xbrlishares">10.14</ifrs-full:ExercisePriceShareOptionsGranted2019>
  <ifrs-full:ExercisePriceShareOptionsGranted2019 id="F_001523" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190222_20190403" decimals="2" unitRef="U_iso4217EUR_xbrlishares">15.03</ifrs-full:ExercisePriceShareOptionsGranted2019>
  <ifrs-full:ExercisePriceShareOptionsGranted2019 id="F_001524" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190430_20190531" decimals="2" unitRef="U_iso4217EUR_xbrlishares">15.39</ifrs-full:ExercisePriceShareOptionsGranted2019>
  <ifrs-full:ExercisePriceShareOptionsGranted2019 id="F_001525" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20191201_20191201" decimals="2" unitRef="U_iso4217EUR_xbrlishares">15.82</ifrs-full:ExercisePriceShareOptionsGranted2019>
  <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted id="F_001526" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20181115_20181115" decimals="3" unitRef="U_xbrlipure">0.460</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
  <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted id="F_001527" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190222_20190403" decimals="3" unitRef="U_xbrlipure">0.460</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
  <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted id="F_001528" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190430_20190531" decimals="3" unitRef="U_xbrlipure">0.460</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
  <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted id="F_001529" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20191201_20191201" decimals="3" unitRef="U_xbrlipure">0.460</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
  <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted id="F_001530" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20181115_20181115" decimals="2" unitRef="U_utrY">5.84</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
  <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted id="F_001531" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190222_20190403" decimals="2" unitRef="U_utrY">6.00</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
  <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted id="F_001532" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190430_20190531" decimals="2" unitRef="U_utrY">6.00</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
  <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted id="F_001533" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20191201_20191201" decimals="2" unitRef="U_utrY">5.50</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted id="F_001534" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20181115_20181115" decimals="4" unitRef="U_xbrlipure">0.0005</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted id="F_001535" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190222_20190403" decimals="4" unitRef="U_xbrlipure">0.0005</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted id="F_001536" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190430_20190531" decimals="4" unitRef="U_xbrlipure">0.0005</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted id="F_001537" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20191201_20191201" decimals="4" unitRef="U_xbrlipure">0.0005</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <ifrs-full:NumberOfOutstandingShareOptions id="F_001538" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20181231" decimals="0" unitRef="U_xbrlishares">658109</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement id="F_001539" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">14511</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement id="F_001540" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">17237</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfOutstandingShareOptions id="F_001541" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20191231" decimals="0" unitRef="U_xbrlishares">655383</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement id="F_001542" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20200101_20201231" decimals="0" unitRef="U_xbrlishares">9491</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfOutstandingShareOptions id="F_001543" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20201231" decimals="0" unitRef="U_xbrlishares">645892</ifrs-full:NumberOfOutstandingShareOptions>
  <bntx:NumberOfOrdinarySharesUnderlyingOptionsOutstanding id="F_001544" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20181231" decimals="0" unitRef="U_xbrlishares">11845962</bntx:NumberOfOrdinarySharesUnderlyingOptionsOutstanding>
  <bntx:NumberOfOrdinarySharesUnderlyingOptionsGrantedInSharebasedPaymentArrangement id="F_001545" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">261198</bntx:NumberOfOrdinarySharesUnderlyingOptionsGrantedInSharebasedPaymentArrangement>
  <bntx:NumberOfOrdinarySharesUnderlyingOptionsForfeitedInSharebasedPaymentArrangement id="F_001546" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">310266</bntx:NumberOfOrdinarySharesUnderlyingOptionsForfeitedInSharebasedPaymentArrangement>
  <bntx:NumberOfOrdinarySharesUnderlyingOptionsOutstanding id="F_001547" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20191231" decimals="0" unitRef="U_xbrlishares">11796894</bntx:NumberOfOrdinarySharesUnderlyingOptionsOutstanding>
  <bntx:NumberOfOrdinarySharesUnderlyingOptionsForfeitedInSharebasedPaymentArrangement id="F_001548" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20200101_20201231" decimals="0" unitRef="U_xbrlishares">170838</bntx:NumberOfOrdinarySharesUnderlyingOptionsForfeitedInSharebasedPaymentArrangement>
  <bntx:NumberOfOrdinarySharesUnderlyingOptionsOutstanding id="F_001549" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20201231" decimals="0" unitRef="U_xbrlishares">11626056</bntx:NumberOfOrdinarySharesUnderlyingOptionsOutstanding>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 id="F_001550" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20181231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">10.14</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019 id="F_001551" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190101_20191231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">15.17</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019 id="F_001552" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190101_20191231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">10.85</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 id="F_001553" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20191231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">10.23</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019 id="F_001554" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20200101_20201231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">10.81</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 id="F_001555" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20201231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">10.23</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 id="F_001556" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20200101_20201231">P3Y8M23D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
  <ifrs-full:NumberOfOutstandingShareOptions id="F_001557" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxProfessorUgurSahinMDMember_20201231" decimals="0" unitRef="U_xbrlishares">101686</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions id="F_001558" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxSeanMarettMember_20201231" decimals="0" unitRef="U_xbrlishares">33895</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions id="F_001559" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrSierkPoettingMember_20201231" decimals="0" unitRef="U_xbrlishares">33895</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions id="F_001560" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrOzlemTureciMDMember_20201231" decimals="0" unitRef="U_xbrlishares">108463</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions id="F_001561" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxRyanRichardsonMember_20201231" decimals="0" unitRef="U_xbrlishares">8306</ifrs-full:NumberOfOutstandingShareOptions>
  <bntx:NumberOfOrdinarySharesUnderlyingOptionsOutstanding id="F_001562" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxProfessorUgurSahinMDMember_20201231" decimals="0" unitRef="U_xbrlishares">1830348</bntx:NumberOfOrdinarySharesUnderlyingOptionsOutstanding>
  <bntx:NumberOfOrdinarySharesUnderlyingOptionsOutstanding id="F_001563" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxSeanMarettMember_20201231" decimals="0" unitRef="U_xbrlishares">610110</bntx:NumberOfOrdinarySharesUnderlyingOptionsOutstanding>
  <bntx:NumberOfOrdinarySharesUnderlyingOptionsOutstanding id="F_001564" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrSierkPoettingMember_20201231" decimals="0" unitRef="U_xbrlishares">610110</bntx:NumberOfOrdinarySharesUnderlyingOptionsOutstanding>
  <bntx:NumberOfOrdinarySharesUnderlyingOptionsOutstanding id="F_001565" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrOzlemTureciMDMember_20201231" decimals="0" unitRef="U_xbrlishares">1952334</bntx:NumberOfOrdinarySharesUnderlyingOptionsOutstanding>
  <bntx:NumberOfOrdinarySharesUnderlyingOptionsOutstanding id="F_001566" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxRyanRichardsonMember_20201231" decimals="0" unitRef="U_xbrlishares">149508</bntx:NumberOfOrdinarySharesUnderlyingOptionsOutstanding>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 id="F_001567" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxProfessorUgurSahinMDMember_20201231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">10.14</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 id="F_001568" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxSeanMarettMember_20201231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">10.14</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 id="F_001569" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrSierkPoettingMember_20201231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">10.14</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 id="F_001570" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxDrOzlemTureciMDMember_20201231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">10.14</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 id="F_001571" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxManagementBoardGrantMember_srtTitleOfIndividualAxis_bntxRyanRichardsonMember_20201231" decimals="2" unitRef="U_iso4217EUR_xbrlishares">10.14</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="F_001572" contextRef="C_0001776985_bntxNatureOfExpensesAxis_bntxCostOfSales1Member_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">869000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="F_001573" contextRef="C_0001776985_bntxNatureOfExpensesAxis_bntxCostOfSales1Member_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">896000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="F_001574" contextRef="C_0001776985_bntxNatureOfExpensesAxis_bntxCostOfSales1Member_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">114000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="F_001575" contextRef="C_0001776985_bntxNatureOfExpensesAxis_bntxResearchAndDevelopmentExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">11120000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="F_001576" contextRef="C_0001776985_bntxNatureOfExpensesAxis_bntxResearchAndDevelopmentExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">20016000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="F_001577" contextRef="C_0001776985_bntxNatureOfExpensesAxis_bntxResearchAndDevelopmentExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">6786000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="F_001578" contextRef="C_0001776985_bntxNatureOfExpensesAxis_bntxSalesAndMarketingExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">111000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="F_001579" contextRef="C_0001776985_bntxNatureOfExpensesAxis_bntxSalesAndMarketingExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">108000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="F_001580" contextRef="C_0001776985_bntxNatureOfExpensesAxis_bntxSalesAndMarketingExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">13000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="F_001581" contextRef="C_0001776985_bntxNatureOfExpensesAxis_bntxGeneralAndAdministrativeExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">4975000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="F_001582" contextRef="C_0001776985_bntxNatureOfExpensesAxis_bntxGeneralAndAdministrativeExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">6008000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="F_001583" contextRef="C_0001776985_bntxNatureOfExpensesAxis_bntxGeneralAndAdministrativeExpensesMember_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">728000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="F_001584" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">17075000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="F_001585" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">27028000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="F_001586" contextRef="C_0001776985_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_bntxEmployeeStockOwnershipPlanMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">7641000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <bntx:CurrentLiabilitiesForEmployeesBenefits id="F_001587" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">24248000</bntx:CurrentLiabilitiesForEmployeesBenefits>
  <bntx:CurrentLiabilitiesForEmployeesBenefits id="F_001588" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">6710000</bntx:CurrentLiabilitiesForEmployeesBenefits>
  <bntx:OtherLiabilitiesOther id="F_001589" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">4379000</bntx:OtherLiabilitiesOther>
  <bntx:OtherLiabilitiesOther id="F_001590" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">780000</bntx:OtherLiabilitiesOther>
  <ifrs-full:OtherLiabilities id="F_001591" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">28627000</ifrs-full:OtherLiabilities>
  <ifrs-full:OtherLiabilities id="F_001592" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">7490000</ifrs-full:OtherLiabilities>
  <ifrs-full:RightofuseAssets id="F_001593" contextRef="C_0001776985_ifrs-fullClassesOfAssetsAxis_ifrs-fullBuildingsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">80875000</ifrs-full:RightofuseAssets>
  <ifrs-full:RightofuseAssets id="F_001594" contextRef="C_0001776985_ifrs-fullClassesOfAssetsAxis_ifrs-fullBuildingsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">54956000</ifrs-full:RightofuseAssets>
  <ifrs-full:RightofuseAssets id="F_001595" contextRef="C_0001776985_ifrs-fullClassesOfAssetsAxis_bntxEquipmentToolsAndInstallationsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">3000</ifrs-full:RightofuseAssets>
  <ifrs-full:RightofuseAssets id="F_001596" contextRef="C_0001776985_ifrs-fullClassesOfAssetsAxis_bntxEquipmentToolsAndInstallationsMember_20191231" decimals="-3" unitRef="U_iso4217EUR">7000</ifrs-full:RightofuseAssets>
  <ifrs-full:RightofuseAssets id="F_001597" contextRef="C_0001776985_ifrs-fullClassesOfAssetsAxis_ifrs-fullVehiclesMember_20201231" decimals="-3" unitRef="U_iso4217EUR">108000</ifrs-full:RightofuseAssets>
  <ifrs-full:RightofuseAssets id="F_001598" contextRef="C_0001776985_ifrs-fullClassesOfAssetsAxis_ifrs-fullVehiclesMember_20191231" decimals="-3" unitRef="U_iso4217EUR">55000</ifrs-full:RightofuseAssets>
  <ifrs-full:RightofuseAssets id="F_001599" contextRef="C_0001776985_ifrs-fullClassesOfAssetsAxis_bntxProductionFacilitiesMember_20201231" decimals="-3" unitRef="U_iso4217EUR">7202000</ifrs-full:RightofuseAssets>
  <ifrs-full:RightofuseAssets id="F_001600" contextRef="C_0001776985_ifrs-fullClassesOfAssetsAxis_bntxAdvancePaymentsMember_20201231" decimals="-3" unitRef="U_iso4217EUR">10800000</ifrs-full:RightofuseAssets>
  <ifrs-full:AdditionsToRightofuseAssets id="F_001601" contextRef="C_0001776985_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">22100000</ifrs-full:AdditionsToRightofuseAssets>
  <ifrs-full:AdditionsToRightofuseAssets id="F_001602" contextRef="C_0001776985_20190101_20191231" decimals="-5" unitRef="U_iso4217EUR">10000000</ifrs-full:AdditionsToRightofuseAssets>
  <bntx:AdvancePaymentsRelatedToEmbeddedLeases id="F_001603" contextRef="C_0001776985_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">10800000</bntx:AdvancePaymentsRelatedToEmbeddedLeases>
  <ifrs-full:CurrentLeaseLiabilities id="F_001604" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">6127000</ifrs-full:CurrentLeaseLiabilities>
  <ifrs-full:CurrentLeaseLiabilities id="F_001605" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">3485000</ifrs-full:CurrentLeaseLiabilities>
  <ifrs-full:NoncurrentLeaseLiabilities id="F_001606" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">78031000</ifrs-full:NoncurrentLeaseLiabilities>
  <ifrs-full:NoncurrentLeaseLiabilities id="F_001607" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">54126000</ifrs-full:NoncurrentLeaseLiabilities>
  <ifrs-full:LeaseLiabilities id="F_001608" contextRef="C_0001776985_20201231" decimals="-3" unitRef="U_iso4217EUR">84158000</ifrs-full:LeaseLiabilities>
  <ifrs-full:LeaseLiabilities id="F_001609" contextRef="C_0001776985_20191231" decimals="-3" unitRef="U_iso4217EUR">57611000</ifrs-full:LeaseLiabilities>
  <ifrs-full:GrossLeaseLiabilities id="F_001610" contextRef="C_0001776985_ifrs-fullMaturityAxis_ifrs-fullNotLaterThanOneYearMember_20201231" decimals="-5" unitRef="U_iso4217EUR">2800000</ifrs-full:GrossLeaseLiabilities>
  <ifrs-full:GrossLeaseLiabilities id="F_001611" contextRef="C_0001776985_ifrs-fullMaturityAxis_ifrs-fullLaterThanOneYearMember_20201231" decimals="-5" unitRef="U_iso4217EUR">10200000</ifrs-full:GrossLeaseLiabilities>
  <ifrs-full:DepreciationRightofuseAssets id="F_001612" contextRef="C_0001776985_ifrs-fullClassesOfAssetsAxis_ifrs-fullBuildingsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">4628000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets id="F_001613" contextRef="C_0001776985_ifrs-fullClassesOfAssetsAxis_ifrs-fullBuildingsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">4614000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets id="F_001614" contextRef="C_0001776985_ifrs-fullClassesOfAssetsAxis_ifrs-fullBuildingsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">2751000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets id="F_001615" contextRef="C_0001776985_ifrs-fullClassesOfAssetsAxis_bntxEquipmentToolsAndInstallationsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">4000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets id="F_001616" contextRef="C_0001776985_ifrs-fullClassesOfAssetsAxis_bntxEquipmentToolsAndInstallationsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">25000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets id="F_001617" contextRef="C_0001776985_ifrs-fullClassesOfAssetsAxis_bntxEquipmentToolsAndInstallationsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">60000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets id="F_001618" contextRef="C_0001776985_ifrs-fullClassesOfAssetsAxis_ifrs-fullVehiclesMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">45000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets id="F_001619" contextRef="C_0001776985_ifrs-fullClassesOfAssetsAxis_ifrs-fullVehiclesMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">40000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets id="F_001620" contextRef="C_0001776985_ifrs-fullClassesOfAssetsAxis_ifrs-fullVehiclesMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">35000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets id="F_001621" contextRef="C_0001776985_ifrs-fullClassesOfAssetsAxis_bntxProductionFacilitiesMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">1613000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets id="F_001622" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">6290000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets id="F_001623" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">4679000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets id="F_001624" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">2846000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed id="F_001625" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">875000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
  <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed id="F_001626" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">442000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
  <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed id="F_001627" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">431000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
  <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed id="F_001628" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">300000</ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed>
  <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed id="F_001629" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">90000</ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed>
  <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed id="F_001630" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">90000</ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed>
  <bntx:LeaseExpensesRecognizedInProfitOrLoss id="F_001631" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">9468000</bntx:LeaseExpensesRecognizedInProfitOrLoss>
  <bntx:LeaseExpensesRecognizedInProfitOrLoss id="F_001632" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">6929000</bntx:LeaseExpensesRecognizedInProfitOrLoss>
  <bntx:LeaseExpensesRecognizedInProfitOrLoss id="F_001633" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">5088000</bntx:LeaseExpensesRecognizedInProfitOrLoss>
  <ifrs-full:CashOutflowForLeases id="F_001634" contextRef="C_0001776985_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">14700000</ifrs-full:CashOutflowForLeases>
  <ifrs-full:CashOutflowForLeases id="F_001635" contextRef="C_0001776985_20190101_20191231" decimals="-5" unitRef="U_iso4217EUR">4800000</ifrs-full:CashOutflowForLeases>
  <ifrs-full:CashOutflowForLeases id="F_001636" contextRef="C_0001776985_20180101_20181231" decimals="-5" unitRef="U_iso4217EUR">2300000</ifrs-full:CashOutflowForLeases>
  <bntx:UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities id="F_001637" contextRef="C_0001776985_srtRangeAxis_ifrs-fullTopOfRangeMember_20201231" decimals="-5" unitRef="U_iso4217EUR">38300000</bntx:UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities>
  <ifrs-full:ExplanationOfWhetherParticipantsContributeToRetirementBenefitPlan id="F_001638" contextRef="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20200101_20201231">Plan participants may elect to contribute a percentage of their income (between 1.5% and 2.5% of salary components up to the social security contribution ceiling). A &#8364;1.00 employee contribution results in an annual pension entitlement of &#8364;0.42.</ifrs-full:ExplanationOfWhetherParticipantsContributeToRetirementBenefitPlan>
  <bntx:PercentageOfDefinedContributionPlanOfSalary id="F_001639" contextRef="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_srtRangeAxis_ifrs-fullBottomOfRangeMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.015</bntx:PercentageOfDefinedContributionPlanOfSalary>
  <bntx:PercentageOfDefinedContributionPlanOfSalary id="F_001640" contextRef="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_srtRangeAxis_ifrs-fullTopOfRangeMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.025</bntx:PercentageOfDefinedContributionPlanOfSalary>
  <bntx:AnnualPensionEntitlementOfEmployeeContribution id="F_001641" contextRef="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20200101_20201231" decimals="INF" unitRef="U_iso4217EUR">0.42</bntx:AnnualPensionEntitlementOfEmployeeContribution>
  <bntx:MaximumPensionFundContributions id="F_001642" contextRef="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20201231" decimals="INF" unitRef="U_iso4217EUR">34000</bntx:MaximumPensionFundContributions>
  <bntx:PensionFundContributionsExpectedForFollowingFinancialYear id="F_001643" contextRef="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20201231" decimals="-5" unitRef="U_iso4217EUR">200000</bntx:PensionFundContributionsExpectedForFollowingFinancialYear>
  <ifrs-full:NoncurrentProvisionsForEmployeeBenefits id="F_001644" contextRef="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_ifrs-fullDefinedBenefitPlansAxis_bntxBasePlanMember_20201231" decimals="-3" unitRef="U_iso4217EUR">2140000</ifrs-full:NoncurrentProvisionsForEmployeeBenefits>
  <ifrs-full:NoncurrentProvisionsForEmployeeBenefits id="F_001645" contextRef="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_ifrs-fullDefinedBenefitPlansAxis_bntxSupplementPlanMember_20201231" decimals="-3" unitRef="U_iso4217EUR">2125000</ifrs-full:NoncurrentProvisionsForEmployeeBenefits>
  <ifrs-full:NoncurrentProvisionsForEmployeeBenefits id="F_001646" contextRef="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20201231" decimals="-3" unitRef="U_iso4217EUR">4265000</ifrs-full:NoncurrentProvisionsForEmployeeBenefits>
  <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset id="F_001647" contextRef="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">24000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
  <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset id="F_001648" contextRef="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">6000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
  <ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAsset id="F_001649" contextRef="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">30000</ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAsset>
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset id="F_001650" contextRef="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">227000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
  <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset id="F_001651" contextRef="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">-17000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
  <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset id="F_001652" contextRef="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">210000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset id="F_001653" contextRef="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">4029000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset>
  <ifrs-full:BenefitsPaidOrPayable id="F_001654" contextRef="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">4000</ifrs-full:BenefitsPaidOrPayable>
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans id="F_001655" contextRef="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20201231" decimals="-3" unitRef="U_iso4217EUR">4265000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <ifrs-full:ActuarialAssumptionOfDiscountRates id="F_001656" contextRef="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20201231" decimals="4" unitRef="U_xbrlipure">0.0080</ifrs-full:ActuarialAssumptionOfDiscountRates>
  <ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation id="F_001657" contextRef="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20201231" decimals="4" unitRef="U_xbrlipure">0.0200</ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation>
  <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases id="F_001658" contextRef="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20201231" decimals="4" unitRef="U_xbrlipure">0.0250</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
  <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases id="F_001659" contextRef="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20201231" decimals="4" unitRef="U_xbrlipure">0.0175</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption id="F_001660" contextRef="C_0001776985_ifrs-fullActuarialAssumptionsAxis_ifrs-fullActuarialAssumptionOfDiscountRatesMember_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20201231" decimals="-3" unitRef="U_iso4217EUR">-282000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption id="F_001661" contextRef="C_0001776985_ifrs-fullActuarialAssumptionsAxis_ifrs-fullActuarialAssumptionOfDiscountRatesMember_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20201231" decimals="-3" unitRef="U_iso4217EUR">309000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption id="F_001662" contextRef="C_0001776985_ifrs-fullActuarialAssumptionsAxis_ifrs-fullActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20201231" decimals="-3" unitRef="U_iso4217EUR">475000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption id="F_001663" contextRef="C_0001776985_ifrs-fullActuarialAssumptionsAxis_ifrs-fullActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20201231" decimals="-3" unitRef="U_iso4217EUR">-447000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
  <ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption id="F_001664" contextRef="C_0001776985_ifrs-fullActuarialAssumptionsAxis_ifrs-fullActuarialAssumptionOfDiscountRatesMember_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20201231" decimals="4" unitRef="U_xbrlipure">0.0025</ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption>
  <ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption id="F_001665" contextRef="C_0001776985_ifrs-fullActuarialAssumptionsAxis_ifrs-fullActuarialAssumptionOfDiscountRatesMember_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20201231" decimals="4" unitRef="U_xbrlipure">0.0025</ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption>
  <ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption id="F_001666" contextRef="C_0001776985_ifrs-fullActuarialAssumptionsAxis_ifrs-fullActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20201231" decimals="4" unitRef="U_xbrlipure">0.0025</ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption>
  <ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption id="F_001667" contextRef="C_0001776985_ifrs-fullActuarialAssumptionsAxis_ifrs-fullActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20201231" decimals="4" unitRef="U_xbrlipure">0.0025</ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption>
  <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019 id="F_001668" contextRef="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_ifrs-fullFundingArrangementsOfDefinedBenefitPlansAxis_ifrs-fullWhollyOrPartlyFundedDefinedBenefitPlansMember_20200101_20201231">P35Y11M1D</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
  <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019 id="F_001669" contextRef="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_ifrs-fullFundingArrangementsOfDefinedBenefitPlansAxis_ifrs-fullWhollyUnfundedDefinedBenefitPlansMember_20200101_20201231">P19Y9M7D</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
  <ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan id="F_001670" contextRef="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_ifrs-fullMaturityAxis_ifrs-fullNotLaterThanOneYearMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">29000</ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan>
  <ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan id="F_001671" contextRef="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_ifrs-fullMaturityAxis_ifrs-fullLaterThanOneYearAndNotLaterThanFiveYearsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">317000</ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan>
  <ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan id="F_001672" contextRef="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_ifrs-fullMaturityAxis_ifrs-fullLaterThanFiveYearsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">340000</ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan>
  <ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan id="F_001673" contextRef="C_0001776985_ifrs-fullCharacteristicsOfDefinedBenefitPlansAxis_ifrs-fullFinalSalaryPensionDefinedBenefitPlansMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">686000</ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits id="F_001674" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">2627000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits id="F_001675" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">1847000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits id="F_001676" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">1161000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <bntx:KeyManagementPersonnelCompensationShortTermEmployeeBenefitsAccrued id="F_001677" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">740000</bntx:KeyManagementPersonnelCompensationShortTermEmployeeBenefitsAccrued>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment id="F_001678" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">20700000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment id="F_001679" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">18151000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment id="F_001680" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">6163000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensation id="F_001681" contextRef="C_0001776985_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">24067000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensation id="F_001682" contextRef="C_0001776985_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">19998000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensation id="F_001683" contextRef="C_0001776985_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">7324000</ifrs-full:KeyManagementPersonnelCompensation>
  <bntx:KeyManagementPersonnelCompensationShareBasedPaymentOrdinaryShares id="F_001684" contextRef="C_0001776985_20200101_20201231" decimals="0" unitRef="U_xbrlishares">4534</bntx:KeyManagementPersonnelCompensationShareBasedPaymentOrdinaryShares>
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement id="F_001685" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_bntxCofounderAndChiefExecutiveOfficerMember_ifrs-fullClassesOfShareCapitalAxis_ifrs-fullOrdinarySharesMember_20190901_20190930" decimals="0" unitRef="U_xbrlishares">4374963</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <bntx:ConsultingServicesAndPatentAssignment id="F_001686" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullKeyManagementPersonnelOfEntityOrParentMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">25000</bntx:ConsultingServicesAndPatentAssignment>
  <bntx:ConsultingServicesAndPatentAssignment id="F_001687" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullKeyManagementPersonnelOfEntityOrParentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">56000</bntx:ConsultingServicesAndPatentAssignment>
  <bntx:ConsultingServicesAndPatentAssignment id="F_001688" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullKeyManagementPersonnelOfEntityOrParentMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">25000</bntx:ConsultingServicesAndPatentAssignment>
  <bntx:PurchasesOfGoodsAndServiceRelatedPartyTransactions id="F_001689" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullKeyManagementPersonnelOfEntityOrParentMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">10105000</bntx:PurchasesOfGoodsAndServiceRelatedPartyTransactions>
  <bntx:PurchasesOfGoodsAndServiceRelatedPartyTransactions id="F_001690" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullKeyManagementPersonnelOfEntityOrParentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">9968000</bntx:PurchasesOfGoodsAndServiceRelatedPartyTransactions>
  <bntx:PurchasesOfGoodsAndServiceRelatedPartyTransactions id="F_001691" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullKeyManagementPersonnelOfEntityOrParentMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">11160000</bntx:PurchasesOfGoodsAndServiceRelatedPartyTransactions>
  <bntx:GoodsAndServicesFromRelatedPartyTransactions id="F_001692" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullKeyManagementPersonnelOfEntityOrParentMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">10130000</bntx:GoodsAndServicesFromRelatedPartyTransactions>
  <bntx:GoodsAndServicesFromRelatedPartyTransactions id="F_001693" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullKeyManagementPersonnelOfEntityOrParentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">10024000</bntx:GoodsAndServicesFromRelatedPartyTransactions>
  <bntx:GoodsAndServicesFromRelatedPartyTransactions id="F_001694" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullKeyManagementPersonnelOfEntityOrParentMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">11185000</bntx:GoodsAndServicesFromRelatedPartyTransactions>
  <ifrs-full:AmountsPayableRelatedPartyTransactions id="F_001695" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullKeyManagementPersonnelOfEntityOrParentMember_srtCounterpartyNameAxis_bntxConsultingServiceProviderMember_20201231" decimals="-3" unitRef="U_iso4217EUR">7000</ifrs-full:AmountsPayableRelatedPartyTransactions>
  <ifrs-full:AmountsPayableRelatedPartyTransactions id="F_001696" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullKeyManagementPersonnelOfEntityOrParentMember_srtCounterpartyNameAxis_bntxTRONMember_20201231" decimals="-3" unitRef="U_iso4217EUR">1229000</ifrs-full:AmountsPayableRelatedPartyTransactions>
  <ifrs-full:AmountsPayableRelatedPartyTransactions id="F_001697" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullKeyManagementPersonnelOfEntityOrParentMember_srtCounterpartyNameAxis_bntxTRONMember_20191231" decimals="-3" unitRef="U_iso4217EUR">1843000</ifrs-full:AmountsPayableRelatedPartyTransactions>
  <ifrs-full:AmountsPayableRelatedPartyTransactions id="F_001698" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullKeyManagementPersonnelOfEntityOrParentMember_20201231" decimals="-3" unitRef="U_iso4217EUR">1236000</ifrs-full:AmountsPayableRelatedPartyTransactions>
  <ifrs-full:AmountsPayableRelatedPartyTransactions id="F_001699" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullKeyManagementPersonnelOfEntityOrParentMember_20191231" decimals="-3" unitRef="U_iso4217EUR">1843000</ifrs-full:AmountsPayableRelatedPartyTransactions>
  <bntx:PurchasesOfGoodsAndServiceRelatedPartyTransactions id="F_001700" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullOtherRelatedPartiesMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">2296000</bntx:PurchasesOfGoodsAndServiceRelatedPartyTransactions>
  <bntx:PurchasesOfGoodsAndServiceRelatedPartyTransactions id="F_001701" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullOtherRelatedPartiesMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">2071000</bntx:PurchasesOfGoodsAndServiceRelatedPartyTransactions>
  <bntx:PurchasesOfGoodsAndServiceRelatedPartyTransactions id="F_001702" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullOtherRelatedPartiesMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">2431000</bntx:PurchasesOfGoodsAndServiceRelatedPartyTransactions>
  <ifrs-full:PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions id="F_001703" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullOtherRelatedPartiesMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">2349000</ifrs-full:PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions>
  <ifrs-full:PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions id="F_001704" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullOtherRelatedPartiesMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">4748000</ifrs-full:PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions>
  <bntx:PurchasesFromRelatedPartyTransactions id="F_001705" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullOtherRelatedPartiesMember_20200101_20201231" decimals="-3" unitRef="U_iso4217EUR">4645000</bntx:PurchasesFromRelatedPartyTransactions>
  <bntx:PurchasesFromRelatedPartyTransactions id="F_001706" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullOtherRelatedPartiesMember_20190101_20191231" decimals="-3" unitRef="U_iso4217EUR">2071000</bntx:PurchasesFromRelatedPartyTransactions>
  <bntx:PurchasesFromRelatedPartyTransactions id="F_001707" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullOtherRelatedPartiesMember_20180101_20181231" decimals="-3" unitRef="U_iso4217EUR">7179000</bntx:PurchasesFromRelatedPartyTransactions>
  <ifrs-full:AmountsPayableRelatedPartyTransactions id="F_001708" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullOtherRelatedPartiesMember_srtCounterpartyNameAxis_bntxATHOSKGMember_20201231" decimals="-3" unitRef="U_iso4217EUR">500000</ifrs-full:AmountsPayableRelatedPartyTransactions>
  <ifrs-full:AmountsPayableRelatedPartyTransactions id="F_001709" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullOtherRelatedPartiesMember_srtCounterpartyNameAxis_bntxATHOSKGMember_20191231" decimals="-3" unitRef="U_iso4217EUR">51000</ifrs-full:AmountsPayableRelatedPartyTransactions>
  <ifrs-full:AmountsPayableRelatedPartyTransactions id="F_001710" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullOtherRelatedPartiesMember_20201231" decimals="-3" unitRef="U_iso4217EUR">500000</ifrs-full:AmountsPayableRelatedPartyTransactions>
  <ifrs-full:AmountsPayableRelatedPartyTransactions id="F_001711" contextRef="C_0001776985_ifrs-fullCategoriesOfRelatedPartiesAxis_ifrs-fullOtherRelatedPartiesMember_20191231" decimals="-3" unitRef="U_iso4217EUR">51000</ifrs-full:AmountsPayableRelatedPartyTransactions>
  <ifrs-full:ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction id="F_001712" contextRef="C_0001776985_20201231" decimals="INF" unitRef="U_iso4217EUR">0</ifrs-full:ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction>
  <ifrs-full:ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction id="F_001713" contextRef="C_0001776985_20200101_20201231" decimals="INF" unitRef="U_iso4217EUR">0</ifrs-full:ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction>
  <bntx:NumberOfAdditionalDosesToBeSupplied id="F_001714" contextRef="C_0001776985_ifrs-fullCounterpartiesAxis_bntxPfizerIncMember_ifrs-fullMajorCustomersAxis_bntxUnitedStatesGovernmentMember_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxSupplyOfCOVID19VaccineMember_20210212_20210212" decimals="INF" unitRef="U_bntxDose">100000000</bntx:NumberOfAdditionalDosesToBeSupplied>
  <bntx:AggregateNumberOfDosesToBeSupplied id="F_001715" contextRef="C_0001776985_ifrs-fullCounterpartiesAxis_bntxPfizerIncMember_ifrs-fullMajorCustomersAxis_bntxUnitedStatesGovernmentMember_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxSupplyOfCOVID19VaccineMember_20210212_20210212" decimals="INF" unitRef="U_bntxDose">300000000</bntx:AggregateNumberOfDosesToBeSupplied>
  <bntx:NumberOfAdditionalDosesToBeSupplied id="F_001716" contextRef="C_0001776985_ifrs-fullCounterpartiesAxis_bntxPfizerIncMember_ifrs-fullMajorCustomersAxis_bntxEuropeanUnionMemberStatesMember_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxSupplyOfCOVID19VaccineMember_20210217_20210217" decimals="INF" unitRef="U_bntxDose">200000000</bntx:NumberOfAdditionalDosesToBeSupplied>
  <bntx:NumberOfEuropeanUnionMemberStates id="F_001717" contextRef="C_0001776985_ifrs-fullCounterpartiesAxis_bntxPfizerIncMember_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxSupplyOfCOVID19VaccineMember_20210217_20210217" decimals="INF" unitRef="U_bntxState">27</bntx:NumberOfEuropeanUnionMemberStates>
  <bntx:OptionToRequestSupplyOfNumberOfAdditionalDoses id="F_001718" contextRef="C_0001776985_ifrs-fullCounterpartiesAxis_bntxPfizerIncMember_ifrs-fullMajorCustomersAxis_bntxEuropeanUnionMemberStatesMember_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis_bntxSupplyOfCOVID19VaccineMember_20210217_20210217" decimals="INF" unitRef="U_bntxDose">100000000</bntx:OptionToRequestSupplyOfNumberOfAdditionalDoses>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="#F_000143" xlink:label="F_000143_lbl" />
    <link:footnote xlink:type="resource" xlink:label="FNT_000000" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Foreign exchange differences on a cumulative basis are shown either as finance income or expenses and might switch between those two positions during the year-to-date reporting periods.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000143_lbl" xlink:to="FNT_000000" />
    <link:loc xlink:type="locator" xlink:href="#F_000144" xlink:label="F_000144_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000144_lbl" xlink:to="FNT_000000" />
    <link:loc xlink:type="locator" xlink:href="#F_000145" xlink:label="F_000145_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000145_lbl" xlink:to="FNT_000000" />
    <link:loc xlink:type="locator" xlink:href="#F_000146" xlink:label="F_000146_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000146_lbl" xlink:to="FNT_000000" />
    <link:loc xlink:type="locator" xlink:href="#F_000147" xlink:label="F_000147_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000147_lbl" xlink:to="FNT_000000" />
    <link:loc xlink:type="locator" xlink:href="#F_000148" xlink:label="F_000148_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000148_lbl" xlink:to="FNT_000000" />
    <link:loc xlink:type="locator" xlink:href="#F_000167" xlink:label="F_000167_lbl" />
    <link:footnote xlink:type="resource" xlink:label="FNT_000001" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Numbers of shares for calculating the earnings per share for the years ended December 31, 2019 and December 31, 2018 have been adjusted to reflect capital increase due to 1:18 share split, which occurred on September 18, 2019.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000167_lbl" xlink:to="FNT_000001" />
    <link:loc xlink:type="locator" xlink:href="#F_000168" xlink:label="F_000168_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000168_lbl" xlink:to="FNT_000001" />
    <link:loc xlink:type="locator" xlink:href="#F_000169" xlink:label="F_000169_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000169_lbl" xlink:to="FNT_000001" />
    <link:loc xlink:type="locator" xlink:href="#F_000678" xlink:label="F_000678_lbl" />
    <link:footnote xlink:type="resource" xlink:label="FNT_000002" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Represents sales to collaboration partner of products manufactured by BioNTech.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000678_lbl" xlink:to="FNT_000002" />
    <link:loc xlink:type="locator" xlink:href="#F_000908" xlink:label="F_000908_lbl" />
    <link:footnote xlink:type="resource" xlink:label="FNT_000003" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Includes all changes in deferred taxes related to U.S. tax group other than those acquired in business combination</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000908_lbl" xlink:to="FNT_000003" />
    <link:loc xlink:type="locator" xlink:href="#F_000909" xlink:label="F_000909_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000909_lbl" xlink:to="FNT_000003" />
    <link:loc xlink:type="locator" xlink:href="#F_000910" xlink:label="F_000910_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000910_lbl" xlink:to="FNT_000003" />
    <link:loc xlink:type="locator" xlink:href="#F_000911" xlink:label="F_000911_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000911_lbl" xlink:to="FNT_000003" />
    <link:loc xlink:type="locator" xlink:href="#F_000912" xlink:label="F_000912_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000912_lbl" xlink:to="FNT_000003" />
    <link:loc xlink:type="locator" xlink:href="#F_000913" xlink:label="F_000913_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000913_lbl" xlink:to="FNT_000003" />
    <link:loc xlink:type="locator" xlink:href="#F_000914" xlink:label="F_000914_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000914_lbl" xlink:to="FNT_000003" />
    <link:loc xlink:type="locator" xlink:href="#F_000915" xlink:label="F_000915_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000915_lbl" xlink:to="FNT_000003" />
    <link:loc xlink:type="locator" xlink:href="#F_000916" xlink:label="F_000916_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000916_lbl" xlink:to="FNT_000003" />
    <link:loc xlink:type="locator" xlink:href="#F_000917" xlink:label="F_000917_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000917_lbl" xlink:to="FNT_000003" />
    <link:loc xlink:type="locator" xlink:href="#F_000918" xlink:label="F_000918_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000918_lbl" xlink:to="FNT_000003" />
    <link:loc xlink:type="locator" xlink:href="#F_000919" xlink:label="F_000919_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000919_lbl" xlink:to="FNT_000003" />
  </link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>45
<FILENAME>bntx-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-30T14:14:26.4316036+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : a6c3372c9f8947078f9b74c1e02df132 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:bntx="http://www.biontech.de/20201231" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biontech.de/20201231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd" namespace="http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.biontech.de/20201231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bntx-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bntx-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bntx-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bntx-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DocumentDocumentAndEntityInformationDetails" id="Role_DocumentDocumentAndEntityInformationDetails">
        <link:definition>100000 - Document - Document and Entity Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" id="Role_StatementConsolidatedStatementsOfFinancialPosition">
        <link:definition>100010 - Statement - Consolidated Statements of Financial Position</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" id="Role_StatementConsolidatedStatementsOfOperations">
        <link:definition>100020 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations2" id="Role_StatementConsolidatedStatementsOfOperations2">
        <link:definition>100030 - Statement - Consolidated Statements of Operations2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsParenthetical" id="Role_StatementConsolidatedStatementsOfOperationsParenthetical">
        <link:definition>100040 - Statement - Consolidated Statements of Operations (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" id="Role_StatementConsolidatedStatementsOfComprehensiveIncomeLoss">
        <link:definition>100050 - Statement - Consolidated Statements of Comprehensive Income / (Loss)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss2" id="Role_StatementConsolidatedStatementsOfComprehensiveIncomeLoss2">
        <link:definition>100060 - Statement - Consolidated Statements of Comprehensive Income / (Loss)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" id="Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>100070 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" id="Role_StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical">
        <link:definition>100080 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100090 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureCorporateInformation" id="Role_DisclosureCorporateInformation">
        <link:definition>100100 - Disclosure - Corporate information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPolicies" id="Role_DisclosureSignificantAccountingPolicies">
        <link:definition>100110 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptions" id="Role_DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptions">
        <link:definition>100120 - Disclosure - Significant Accounting Judgments, Estimates and Assumptions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformation" id="Role_DisclosureGroupInformation">
        <link:definition>100130 - Disclosure - Group information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinations" id="Role_DisclosureBusinessCombinations">
        <link:definition>100140 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomers" id="Role_DisclosureRevenueFromContractsWithCustomers">
        <link:definition>100150 - Disclosure - Revenue from Contracts with Customers</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpenses" id="Role_DisclosureIncomeAndExpenses">
        <link:definition>100160 - Disclosure - Income and Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTax" id="Role_DisclosureIncomeTax">
        <link:definition>100170 - Disclosure - Income Tax</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureEarningsPerShare" id="Role_DisclosureEarningsPerShare">
        <link:definition>100180 - Disclosure - Earnings per share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipment" id="Role_DisclosurePropertyPlantAndEquipment">
        <link:definition>100190 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIntangibleAssets" id="Role_DisclosureIntangibleAssets">
        <link:definition>100200 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilities" id="Role_DisclosureFinancialAssetsAndFinancialLiabilities">
        <link:definition>100210 - Disclosure - Financial Assets and Financial Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureInventories" id="Role_DisclosureInventories">
        <link:definition>100220 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherAssets" id="Role_DisclosureOtherAssets">
        <link:definition>100230 - Disclosure - Other Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureDeferredExpenses" id="Role_DisclosureDeferredExpenses">
        <link:definition>100240 - Disclosure - Deferred Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIssuedCapitalAndReserves" id="Role_DisclosureIssuedCapitalAndReserves">
        <link:definition>100250 - Disclosure - Issued Capital and Reserves</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPayments" id="Role_DisclosureShareBasedPayments">
        <link:definition>100260 - Disclosure - Share-based payments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherLiabilities" id="Role_DisclosureOtherLiabilities">
        <link:definition>100270 - Disclosure - Other Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100280 - Disclosure - Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensions" id="Role_DisclosurePensions">
        <link:definition>100290 - Disclosure - Pensions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosures" id="Role_DisclosureRelatedPartyDisclosures">
        <link:definition>100300 - Disclosure - Related Party Disclosures</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureEventsAfterReportingPeriod" id="Role_DisclosureEventsAfterReportingPeriod">
        <link:definition>100310 - Disclosure - Events After the Reporting Period</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" id="Role_DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>100320 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables" id="Role_DisclosureSignificantAccountingPoliciesTables">
        <link:definition>100330 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptionsTables" id="Role_DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptionsTables">
        <link:definition>100340 - Disclosure - Significant Accounting Judgments, Estimates and Assumptions (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformationTables" id="Role_DisclosureGroupInformationTables">
        <link:definition>100350 - Disclosure - Group Information (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinationsTables" id="Role_DisclosureBusinessCombinationsTables">
        <link:definition>100360 - Disclosure - Business Combinations (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersTables" id="Role_DisclosureRevenueFromContractsWithCustomersTables">
        <link:definition>100370 - Disclosure - Revenue from Contracts with Customers (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesTables" id="Role_DisclosureIncomeAndExpensesTables">
        <link:definition>100380 - Disclosure -  Income and Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxTables" id="Role_DisclosureIncomeTaxTables">
        <link:definition>100390 - Disclosure - Income Tax (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureEarningsPerShareTables" id="Role_DisclosureEarningsPerShareTables">
        <link:definition>100400 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipmentTables" id="Role_DisclosurePropertyPlantAndEquipmentTables">
        <link:definition>100410 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIntangibleAssetsTables" id="Role_DisclosureIntangibleAssetsTables">
        <link:definition>100420 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesTables" id="Role_DisclosureFinancialAssetsAndFinancialLiabilitiesTables">
        <link:definition>100430 - Disclosure - Financial Assets and Financial Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureInventoriesTables" id="Role_DisclosureInventoriesTables">
        <link:definition>100440 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherAssetsTables" id="Role_DisclosureOtherAssetsTables">
        <link:definition>100450 - Disclosure - Other Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureDeferredExpensesTables" id="Role_DisclosureDeferredExpensesTables">
        <link:definition>100460 - Disclosure - Deferred Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsTables" id="Role_DisclosureShareBasedPaymentsTables">
        <link:definition>100470 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherLiabilitiesTables" id="Role_DisclosureOtherLiabilitiesTables">
        <link:definition>100480 - Disclosure - Other Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100490 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsTables" id="Role_DisclosurePensionsTables">
        <link:definition>100500 - Disclosure - Pensions (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresTables" id="Role_DisclosureRelatedPartyDisclosuresTables">
        <link:definition>100510 - Disclosure - Related Party Disclosures (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureCorporateInformationAdditionalInformationDetails" id="Role_DisclosureCorporateInformationAdditionalInformationDetails">
        <link:definition>100520 - Disclosure - Corporate Information - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100530 - Disclosure - Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesUsefulLivesAppliedToGroupSPropertyPlantAndEquipmentDetails" id="Role_DisclosureSignificantAccountingPoliciesUsefulLivesAppliedToGroupSPropertyPlantAndEquipmentDetails">
        <link:definition>100540 - Disclosure - Significant Accounting Policies - Useful Lives Applied to the Group&apos;s Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesUsefulLivesAppliedToGroupSRightOfUseAssetsDetails" id="Role_DisclosureSignificantAccountingPoliciesUsefulLivesAppliedToGroupSRightOfUseAssetsDetails">
        <link:definition>100550 - Disclosure - Significant Accounting Policies - Useful Lives Applied to the Group&apos;s Right-of-use Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesUsefulLivesAppliedToGroupSIntangibleAssetsDetails" id="Role_DisclosureSignificantAccountingPoliciesUsefulLivesAppliedToGroupSIntangibleAssetsDetails">
        <link:definition>100560 - Disclosure - Significant Accounting Policies - Useful Lives Applied to the Group&apos;s Intangible Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptionsAdditionalInformationDetails" id="Role_DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptionsAdditionalInformationDetails">
        <link:definition>100570 - Disclosure - Significant Accounting Judgments, Estimates and Assumptions - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptionsScheduleOfProvisionalSalesFiguresForTerritoriesDetails" id="Role_DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptionsScheduleOfProvisionalSalesFiguresForTerritoriesDetails">
        <link:definition>100580 - Disclosure - Significant Accounting Judgments, Estimates and Assumptions - Schedule of Provisional Sales Figures for Territories (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformationSummaryOfInformationAboutSubsidiariesDetails" id="Role_DisclosureGroupInformationSummaryOfInformationAboutSubsidiariesDetails">
        <link:definition>100590 - Disclosure - Group Information - Summary of Information about Subsidiaries (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformationAdditionalInformationDetails" id="Role_DisclosureGroupInformationAdditionalInformationDetails">
        <link:definition>100600 - Disclosure - Group Information - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformationSummaryOfInformationAboutParentCompanyDetails" id="Role_DisclosureGroupInformationSummaryOfInformationAboutParentCompanyDetails">
        <link:definition>100610 - Disclosure - Group Information - Summary of Information about Parent Company (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformationSummaryOfInformationAboutEntityWithSignificantInfluenceOverGroupDetails" id="Role_DisclosureGroupInformationSummaryOfInformationAboutEntityWithSignificantInfluenceOverGroupDetails">
        <link:definition>100620 - Disclosure - Group Information - Summary of Information about Entity with Significant Influence Over Group (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails" id="Role_DisclosureBusinessCombinationsAdditionalInformationDetails">
        <link:definition>100630 - Disclosure - Business Combinations - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfFairValuesOfIdentifiableNetAssetsDetails" id="Role_DisclosureBusinessCombinationsSummaryOfFairValuesOfIdentifiableNetAssetsDetails">
        <link:definition>100640 - Disclosure - Business Combinations - Summary of Fair Values of Identifiable Net Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfReconciliationOfGoodwillDetails" id="Role_DisclosureBusinessCombinationsSummaryOfReconciliationOfGoodwillDetails">
        <link:definition>100650 - Disclosure - Business Combinations - Summary of Reconciliation of Goodwill (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesFromContractsWithCustomersDetails" id="Role_DisclosureRevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesFromContractsWithCustomersDetails">
        <link:definition>100660 - Disclosure - Revenue from Contracts with Customers - Summary of Disaggregation of Revenues from Contracts with Customers (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails" id="Role_DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails">
        <link:definition>100670 - Disclosure - Revenue from Contracts with Customers - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfContractBalancesDetails" id="Role_DisclosureRevenueFromContractsWithCustomersSummaryOfContractBalancesDetails">
        <link:definition>100680 - Disclosure - Revenue from Contracts with Customers - Summary of Contract Balances (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfRevenueRecognizedDetails" id="Role_DisclosureRevenueFromContractsWithCustomersSummaryOfRevenueRecognizedDetails">
        <link:definition>100690 - Disclosure - Revenue from Contracts with Customers - Summary of Revenue Recognized (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfContractLiabilitiesAllocatedToRemainingPerformanceObligationsUnsatisfiedOrPartiallyUnsatisfiedDetails" id="Role_DisclosureRevenueFromContractsWithCustomersSummaryOfContractLiabilitiesAllocatedToRemainingPerformanceObligationsUnsatisfiedOrPartiallyUnsatisfiedDetails">
        <link:definition>100700 - Disclosure - Revenue from Contracts with Customers - Summary of Contract Liabilities Allocated to Remaining Performance Obligations (Unsatisfied or Partially Unsatisfied) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesCostOfSalesDetails" id="Role_DisclosureIncomeAndExpensesCostOfSalesDetails">
        <link:definition>100710 - Disclosure - Income and Expenses - Cost of Sales (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesResearchAndDevelopmentExpensesDetails" id="Role_DisclosureIncomeAndExpensesResearchAndDevelopmentExpensesDetails">
        <link:definition>100720 - Disclosure - Income and Expenses - Research and Development Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesAdditionalInformationDetails" id="Role_DisclosureIncomeAndExpensesAdditionalInformationDetails">
        <link:definition>100730 - Disclosure - Income and Expenses - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesSalesAndMarketingExpensesDetails" id="Role_DisclosureIncomeAndExpensesSalesAndMarketingExpensesDetails">
        <link:definition>100740 - Disclosure - Income and Expenses - Sales and Marketing Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesGeneralAndAdministrativeExpensesDetails" id="Role_DisclosureIncomeAndExpensesGeneralAndAdministrativeExpensesDetails">
        <link:definition>100750 - Disclosure - Income and Expenses - General and Administrative Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesOtherOperatingIncomeDetails" id="Role_DisclosureIncomeAndExpensesOtherOperatingIncomeDetails">
        <link:definition>100760 - Disclosure - Income and Expenses - Other Operating Income (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesChangesRegardingGovernmentGrantsDetails" id="Role_DisclosureIncomeAndExpensesChangesRegardingGovernmentGrantsDetails">
        <link:definition>100770 - Disclosure - Income and Expenses - Changes Regarding Government Grants (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesFinanceIncomeDetails" id="Role_DisclosureIncomeAndExpensesFinanceIncomeDetails">
        <link:definition>100780 - Disclosure - Income and Expenses - Finance Income (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesFinanceExpenseDetails" id="Role_DisclosureIncomeAndExpensesFinanceExpenseDetails">
        <link:definition>100790 - Disclosure - Income and Expenses - Finance Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesEmployeeBenefitsExpenseDetails" id="Role_DisclosureIncomeAndExpensesEmployeeBenefitsExpenseDetails">
        <link:definition>100800 - Disclosure - Income and Expenses - Employee Benefits Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" id="Role_DisclosureIncomeTaxAdditionalInformationDetails">
        <link:definition>100810 - Disclosure - Income Tax - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxSummaryOfCurrentAndDeferredTaxExpenseDetails" id="Role_DisclosureIncomeTaxSummaryOfCurrentAndDeferredTaxExpenseDetails">
        <link:definition>100820 - Disclosure - Income Tax - Summary of Current and Deferred Tax Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitDetails" id="Role_DisclosureIncomeTaxSummaryOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitDetails">
        <link:definition>100830 - Disclosure - Income Tax - Summary of Reconciliation of Expected Income Tax Benefit to Actual Income Tax Benefit (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitParentheticalDetails" id="Role_DisclosureIncomeTaxSummaryOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitParentheticalDetails">
        <link:definition>100840 - Disclosure - Income Tax - Summary of Reconciliation of Expected Income Tax Benefit to Actual Income Tax Benefit (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxSummaryOfDeferredTaxesDetails" id="Role_DisclosureIncomeTaxSummaryOfDeferredTaxesDetails">
        <link:definition>100850 - Disclosure - Income Tax - Summary of Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxSummaryOfAccumulatedTaxLossesDetails" id="Role_DisclosureIncomeTaxSummaryOfAccumulatedTaxLossesDetails">
        <link:definition>100860 - Disclosure - Income Tax - Summary of Accumulated Tax Losses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureEarningsPerShareAdditionalInformationDetails" id="Role_DisclosureEarningsPerShareAdditionalInformationDetails">
        <link:definition>100870 - Disclosure - Earnings Per Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureEarningsPerShareSummaryOfIncomeAndShareDataUsedInBasicAndDilutedEPSCalculationsDetails" id="Role_DisclosureEarningsPerShareSummaryOfIncomeAndShareDataUsedInBasicAndDilutedEPSCalculationsDetails">
        <link:definition>100880 - Disclosure - Earnings Per Share - Summary of Income and Share Data Used in the Basic and Diluted EPS Calculations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureEarningsPerShareSummaryOfIncomeAndShareDataUsedInBasicAndDilutedEPSCalculationsParentheticalDetails" id="Role_DisclosureEarningsPerShareSummaryOfIncomeAndShareDataUsedInBasicAndDilutedEPSCalculationsParentheticalDetails">
        <link:definition>100890 - Disclosure - Earnings Per Share - Summary of Income and Share Data Used in the Basic and Diluted EPS Calculations (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" id="Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails">
        <link:definition>100900 - Disclosure - Property Plant and Equipment - Summary of Property Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfDetailedInformationAboutIntangibleAssetsDetails" id="Role_DisclosureIntangibleAssetsSummaryOfDetailedInformationAboutIntangibleAssetsDetails">
        <link:definition>100910 - Disclosure - Intangible Assets - Summary of Detailed Information About Intangible Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfGoodwillRecognizedDetails" id="Role_DisclosureIntangibleAssetsSummaryOfGoodwillRecognizedDetails">
        <link:definition>100920 - Disclosure - Intangible Assets - Summary of Goodwill Recognized (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" id="Role_DisclosureIntangibleAssetsAdditionalInformationDetails">
        <link:definition>100930 - Disclosure - Intangible Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfCashAndCashEquivalentsDetails" id="Role_DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfCashAndCashEquivalentsDetails">
        <link:definition>100940 - Disclosure - Financial Assets and Financial Liabilities - Summary of Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialAssetsAtAmortizedCostDetails" id="Role_DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialAssetsAtAmortizedCostDetails">
        <link:definition>100950 - Disclosure - Financial Assets and Financial Liabilities - Summary of Financial Assets at Amortized Cost (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialLiabilitiesDetails" id="Role_DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialLiabilitiesDetails">
        <link:definition>100960 - Disclosure - Financial Assets and Financial Liabilities - Summary of Financial Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialLiabilitiesDetails2" id="Role_DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialLiabilitiesDetails2">
        <link:definition>100970 - Disclosure - Financial Assets and Financial Liabilities - Summary of Financial Liabilities (Details)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialLiabilitiesParentheticalDetails" id="Role_DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialLiabilitiesParentheticalDetails">
        <link:definition>100980 - Disclosure - Financial Assets and Financial Liabilities - Summary of Financial Liabilities (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesAdditionalInformationDetails" id="Role_DisclosureFinancialAssetsAndFinancialLiabilitiesAdditionalInformationDetails">
        <link:definition>100990 - Disclosure - Financial Assets and Financial Liabilities - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfCarryingAmountOfMonetaryAssetsDetails" id="Role_DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfCarryingAmountOfMonetaryAssetsDetails">
        <link:definition>101000 - Disclosure - Financial Assets and Financial Liabilities - Summary of Carrying Amount of Monetary Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfEffectOfChangesInForeignExchangeRatesDetails" id="Role_DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfEffectOfChangesInForeignExchangeRatesDetails">
        <link:definition>101010 - Disclosure - Financial Assets and Financial Liabilities - Summary of Effect of Changes in Foreign Exchange Rates (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" id="Role_DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails">
        <link:definition>101020 - Disclosure - Financial Assets and Financial Liabilities - Summary of Maturity Profile of Financial Liabilities Based on Contractual Undiscounted Payments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails" id="Role_DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails">
        <link:definition>101030 - Disclosure - Financial Assets and Financial Liabilities - Summary of Changes in Liabilities Arising From Financing Activities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureInventoriesSummaryOfInventoriesDetails" id="Role_DisclosureInventoriesSummaryOfInventoriesDetails">
        <link:definition>101040 - Disclosure - Inventories - Summary of Inventories (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherAssetsDetails" id="Role_DisclosureOtherAssetsSummaryOfOtherAssetsDetails">
        <link:definition>101050 - Disclosure - Other Assets - Summary of Other Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherAssetsDetails2" id="Role_DisclosureOtherAssetsSummaryOfOtherAssetsDetails2">
        <link:definition>101060 - Disclosure - Other Assets - Summary of Other Assets (Details)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureDeferredExpensesSummaryOfDeferredExpensesDetails" id="Role_DisclosureDeferredExpensesSummaryOfDeferredExpensesDetails">
        <link:definition>101070 - Disclosure - Deferred Expenses - Summary of Deferred Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureDeferredExpensesSummaryOfDeferredExpensesDetails2" id="Role_DisclosureDeferredExpensesSummaryOfDeferredExpensesDetails2">
        <link:definition>101080 - Disclosure - Deferred Expenses - Summary of Deferred Expenses (Details)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIssuedCapitalAndReservesAdditionalInformationDetails" id="Role_DisclosureIssuedCapitalAndReservesAdditionalInformationDetails">
        <link:definition>101090 - Disclosure - Issued Capital and Reserves - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsAdditionalInformationDetails" id="Role_DisclosureShareBasedPaymentsAdditionalInformationDetails">
        <link:definition>101100 - Disclosure - Share-Based Payments - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfNumberAndSharePriceOfRestrictedStockUnitsDetails" id="Role_DisclosureShareBasedPaymentsScheduleOfNumberAndSharePriceOfRestrictedStockUnitsDetails">
        <link:definition>101110 - Disclosure - Share-Based Payments - Schedule of Number and Share Price of Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfExpenseRecognizedForEmployeeServicesReceivedDetails" id="Role_DisclosureShareBasedPaymentsScheduleOfExpenseRecognizedForEmployeeServicesReceivedDetails">
        <link:definition>101120 - Disclosure - Share-Based Payments - Schedule of Expense Recognized for Employee Services Received (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfNumberAndWeightedAverageExercisePriceOfShareOptionsDetails" id="Role_DisclosureShareBasedPaymentsScheduleOfNumberAndWeightedAverageExercisePriceOfShareOptionsDetails">
        <link:definition>101130 - Disclosure - Share-Based Payments - Schedule of Number and Weighted-Average Exercise Price of Share Options (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsSummaryOfInputsUsedInMeasurementOfFairValueAtGrantDateDetails" id="Role_DisclosureShareBasedPaymentsSummaryOfInputsUsedInMeasurementOfFairValueAtGrantDateDetails">
        <link:definition>101140 - Disclosure - Share-Based Payments - Summary of Inputs Used in Measurement of Fair Value at Grant Date (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfNumberAndWeightedAverageExercisePriceOfShareOptionsAllocatedAndExpectedToBeAllocatedDetails" id="Role_DisclosureShareBasedPaymentsScheduleOfNumberAndWeightedAverageExercisePriceOfShareOptionsAllocatedAndExpectedToBeAllocatedDetails">
        <link:definition>101150 - Disclosure - Share-Based Payments - Schedule of Number and Weighted-Average Exercise Price of Share Options Allocated and Expected to be Allocated (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfNumberOfShareOptionsOutstandingDetails" id="Role_DisclosureShareBasedPaymentsScheduleOfNumberOfShareOptionsOutstandingDetails">
        <link:definition>101160 - Disclosure - Share-Based Payments - Schedule of Number of Share Options Outstanding (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherLiabilitiesSummaryOfOtherLiabilitiesDetails" id="Role_DisclosureOtherLiabilitiesSummaryOfOtherLiabilitiesDetails">
        <link:definition>101170 - Disclosure - Other Liabilities - Summary of Other Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherLiabilitiesSummaryOfOtherLiabilitiesDetails2" id="Role_DisclosureOtherLiabilitiesSummaryOfOtherLiabilitiesDetails2">
        <link:definition>101180 - Disclosure - Other Liabilities - Summary of Other Liabilities (Details)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesSummaryOfRightOfUseAssetsWithinConsolidatedStatementsOfFinancialPositionDetails" id="Role_DisclosureLeasesSummaryOfRightOfUseAssetsWithinConsolidatedStatementsOfFinancialPositionDetails">
        <link:definition>101190 - Disclosure - Leases - Summary of Right-of-Use Assets within Consolidated Statements of Financial Position (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="Role_DisclosureLeasesAdditionalInformationDetails">
        <link:definition>101200 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilityIncludedInInterestBearingLoansAndBorrowingsDetails" id="Role_DisclosureLeasesSummaryOfLeaseLiabilityIncludedInInterestBearingLoansAndBorrowingsDetails">
        <link:definition>101210 - Disclosure - Leases - Summary of Lease Liability Included in Interest-Bearing Loans and Borrowings (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesSummaryOfAmountsRecognizedInConsolidatedStatementOfOperationsDetails" id="Role_DisclosureLeasesSummaryOfAmountsRecognizedInConsolidatedStatementOfOperationsDetails">
        <link:definition>101220 - Disclosure - Leases - Summary of Amounts Recognized in Consolidated Statement of Operations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsAdditionalInformationDetails" id="Role_DisclosurePensionsAdditionalInformationDetails">
        <link:definition>101230 - Disclosure - Pensions - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsSummaryOfDefinedBenefitObligationRecognizedInNonCurrentProvisionsDetails" id="Role_DisclosurePensionsSummaryOfDefinedBenefitObligationRecognizedInNonCurrentProvisionsDetails">
        <link:definition>101240 - Disclosure - Pensions - Summary of Defined Benefit Obligation Recognized in Non-current Provisions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsSummaryOfComponentsOfNetBenefitExpenseRecognizedInStatementOfProfitOrLossDetails" id="Role_DisclosurePensionsSummaryOfComponentsOfNetBenefitExpenseRecognizedInStatementOfProfitOrLossDetails">
        <link:definition>101250 - Disclosure - Pensions - Summary of Components of Net Benefit Expense Recognized in Statement of Profit or Loss (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsSummaryOfComponentsOfRemeasurementsRecognizedInOtherComprehensiveIncomeDetails" id="Role_DisclosurePensionsSummaryOfComponentsOfRemeasurementsRecognizedInOtherComprehensiveIncomeDetails">
        <link:definition>101260 - Disclosure - Pensions - Summary of Components of Remeasurements Recognized in Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfChangesToDefinedBenefitObligationDetails" id="Role_DisclosurePensionsScheduleOfChangesToDefinedBenefitObligationDetails">
        <link:definition>101270 - Disclosure - Pensions - Schedule of Changes to Defined Benefit Obligation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfPrincipalAssumptionsUsedInDeterminingDefinedBenefitObligationsDetails" id="Role_DisclosurePensionsScheduleOfPrincipalAssumptionsUsedInDeterminingDefinedBenefitObligationsDetails">
        <link:definition>101280 - Disclosure - Pensions - Schedule of Principal Assumptions used in Determining Defined Benefit Obligations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfQuantitativeSensitivityAnalysisDetails" id="Role_DisclosurePensionsScheduleOfQuantitativeSensitivityAnalysisDetails">
        <link:definition>101290 - Disclosure - Pensions - Schedule of Quantitative Sensitivity Analysis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfQuantitativeSensitivityAnalysisParentheticalDetails" id="Role_DisclosurePensionsScheduleOfQuantitativeSensitivityAnalysisParentheticalDetails">
        <link:definition>101300 - Disclosure - Pensions - Schedule of Quantitative Sensitivity Analysis (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfExpectedPaymentsOrContributionsToPlansInFutureYearsDetails" id="Role_DisclosurePensionsScheduleOfExpectedPaymentsOrContributionsToPlansInFutureYearsDetails">
        <link:definition>101310 - Disclosure - Pensions - Schedule of Expected Payments or Contributions to Plans in Future Years (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfCompensationOfKeyManagementPersonnelDetails" id="Role_DisclosureRelatedPartyDisclosuresSummaryOfCompensationOfKeyManagementPersonnelDetails">
        <link:definition>101320 - Disclosure - Related Party Disclosures - Summary of Compensation of Key Management Personnel (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfCompensationOfKeyManagementPersonnelParentheticalDetails" id="Role_DisclosureRelatedPartyDisclosuresSummaryOfCompensationOfKeyManagementPersonnelParentheticalDetails">
        <link:definition>101330 - Disclosure - Related Party Disclosures - Summary of Compensation of Key Management Personnel (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresAdditionalInformationDetails" id="Role_DisclosureRelatedPartyDisclosuresAdditionalInformationDetails">
        <link:definition>101340 - Disclosure - Related Party Disclosures - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfAggregateValueOfTransactionsRelatedToKeyManagementPersonnelDetails" id="Role_DisclosureRelatedPartyDisclosuresSummaryOfAggregateValueOfTransactionsRelatedToKeyManagementPersonnelDetails">
        <link:definition>101350 - Disclosure - Related Party Disclosures - Summary of Aggregate Value of Transactions Related to Key Management Personnel (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfOutstandingBalancesOfTransactionsRelatedToKeyManagementPersonnelDetails" id="Role_DisclosureRelatedPartyDisclosuresSummaryOfOutstandingBalancesOfTransactionsRelatedToKeyManagementPersonnelDetails">
        <link:definition>101360 - Disclosure - Related Party Disclosures - Summary of Outstanding Balances of Transactions Related to Key Management Personnel (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfTransactionsBetweenRelatedPartiesAmountDetails" id="Role_DisclosureRelatedPartyDisclosuresSummaryOfTransactionsBetweenRelatedPartiesAmountDetails">
        <link:definition>101370 - Disclosure - Related Party Disclosures - Summary of Transactions Between Related Parties Amount (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfTransactionsBetweenRelatedPartiesOutstandingBalancesDetails" id="Role_DisclosureRelatedPartyDisclosuresSummaryOfTransactionsBetweenRelatedPartiesOutstandingBalancesDetails">
        <link:definition>101380 - Disclosure - Related Party Disclosures - Summary of Transactions Between Related Parties Outstanding Balances (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureEventsAfterReportingPeriodAdditionalInformationDetails" id="Role_DisclosureEventsAfterReportingPeriodAdditionalInformationDetails">
        <link:definition>101390 - Disclosure - Events After the Reporting Period - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate" name="RightOfUseAssetsRecognisedAsOfAcquisitionDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" name="OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_ProvisionsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" name="ProvisionsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_TradePayablesRecognisedAsOfAcquisitionDate" name="TradePayablesRecognisedAsOfAcquisitionDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_OtherLiabilitiesNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" name="OtherLiabilitiesNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_AssetsRecognizedAsOfAcquisitionDate" name="AssetsRecognizedAsOfAcquisitionDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_LiabilitiesRecognizedAsOfAcquisitionDate" name="LiabilitiesRecognizedAsOfAcquisitionDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_SharesIssuedAtFairValue" name="SharesIssuedAtFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_BargainPurchaseGainOnAcquisition" name="BargainPurchaseGainOnAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_OtherComponentsOfTaxExpenseIncome" name="OtherComponentsOfTaxExpenseIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_GovernmentGrantsExemptedFromTaxes" name="GovernmentGrantsExemptedFromTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_AddBackForTradeTaxPurposes" name="AddBackForTradeTaxPurposes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_NonTaxEffectiveBargainPurchase" name="NonTaxEffectiveBargainPurchase" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses" name="NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_TaxEffectiveEquityTransactionCosts" name="TaxEffectiveEquityTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_TaxEffectOfNonrecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences" name="TaxEffectOfNonrecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_TaxEffectOfTaxCredit" name="TaxEffectOfTaxCredit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_InterestBearingLoansAndBorrowings" name="InterestBearingLoansAndBorrowings" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_CurrentPrepaymentsRelatedToServiceContracts" name="CurrentPrepaymentsRelatedToServiceContracts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_OtherCurrentAssetsOther" name="OtherCurrentAssetsOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_DeferredExpensesFromInsuranceContracts" name="DeferredExpensesFromInsuranceContracts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_DeferredExpensesFromContractManufacturingAndContractResearchOrganizations" name="DeferredExpensesFromContractManufacturingAndContractResearchOrganizations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_OtherDeferredExpenses" name="OtherDeferredExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_DeferredExpenseCurrent" name="DeferredExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_DeferredExpenseNonCurrent" name="DeferredExpenseNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_CurrentLiabilitiesForEmployeesBenefits" name="CurrentLiabilitiesForEmployeesBenefits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_OtherLiabilitiesOther" name="OtherLiabilitiesOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember" name="AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareOfOneMember" name="OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareOfOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_IncomeStatementLineItems" name="IncomeStatementLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_IncomeStatementTable" name="IncomeStatementTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_ResearchAndDevelopmentMember" name="ResearchAndDevelopmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_CommercialMember" name="CommercialMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_StockSplitConversionRatio" name="StockSplitConversionRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_IssuanceOfShareCapital" name="IssuanceOfShareCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_IncreaseDecreaseThroughSettlementOfSharebasedPaymentPlan" name="IncreaseDecreaseThroughSettlementOfSharebasedPaymentPlan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_IncreaseDecreaseThroughInitialPublicOffering" name="IncreaseDecreaseThroughInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_IncreaseDecreaseThroughAcquisitionOfNoncontrollingInterests" name="IncreaseDecreaseThroughAcquisitionOfNoncontrollingInterests" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_ForeignCurrencyTranslationReserveMember" name="ForeignCurrencyTranslationReserveMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_CapitalIncreaseSeriesBMember" name="CapitalIncreaseSeriesBMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_AdjustmentsForInterestOnLeaseLiability" name="AdjustmentsForInterestOnLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_AdjustmentsForMovementsInGovernmentGrants" name="AdjustmentsForMovementsInGovernmentGrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_AdjustmentsForIncreaseDecreaseInTradeAccountReceivableAndContractAssets" name="AdjustmentsForIncreaseDecreaseInTradeAccountReceivableAndContractAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions" name="AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssets" name="PurchaseOfIntangibleAssetsAndRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_WorkingCapitalAdjustmentsAbstract" name="WorkingCapitalAdjustmentsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_DisclosureOfCorporateInformationExplanatory" name="DisclosureOfCorporateInformationExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DisclosureOfCorporateInformationExplanatoryAbstract" name="DisclosureOfCorporateInformationExplanatoryAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" name="DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_DisclosureOfAccountingJudgementsAndEstimatesAbstract" name="DisclosureOfAccountingJudgementsAndEstimatesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_DisclosureOfRevenueFromContractsWithCustomersAbstract" name="DisclosureOfRevenueFromContractsWithCustomersAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_DisclosureOfIncomeAndExpensesExplanatory" name="DisclosureOfIncomeAndExpensesExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DisclosureOfDeferredExpensesExplanatory" name="DisclosureOfDeferredExpensesExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DisclosureOfDeferredExpensesAbstract" name="DisclosureOfDeferredExpensesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_DisclosureOfEventsAfterReportingPeriodAbstract" name="DisclosureOfEventsAfterReportingPeriodAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatory" name="DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory" name="DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DescriptionOfAccountingPolicyForInitialApplicationOfStandardsExplanatory" name="DescriptionOfAccountingPolicyForInitialApplicationOfStandardsExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DescriptionOfAccountingPolicyForStandardIssuedButNotYetEffectiveExplanatory" name="DescriptionOfAccountingPolicyForStandardIssuedButNotYetEffectiveExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatory" name="DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatory" name="DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DisclosureOfIntangibleAssetsUsefulLifeExplanatory" name="DisclosureOfIntangibleAssetsUsefulLifeExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DisclosureOfDetailedInformationAboutProvisionalSalesFiguresForTerritoriesExplanatory" name="DisclosureOfDetailedInformationAboutProvisionalSalesFiguresForTerritoriesExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatory" name="DisclosureOfSignificantInvestmentsByParentCompanyExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatory" name="DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_LipocalyxGmbHMember" name="LipocalyxGmbHMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_BioNTechUSIncMember" name="BioNTechUSIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_BioNTechManufacturingMarburgGmbHMember" name="BioNTechManufacturingMarburgGmbHMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatory" name="DisclosureOfContractBalancesFromContractsWithCustomersExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DisclosureOfRecognitionOfRevenueExplanatory" name="DisclosureOfRecognitionOfRevenueExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DisclosureOfSalesAndMarketingExpensesExplanatory" name="DisclosureOfSalesAndMarketingExpensesExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DisclosureOfChangesRegardingGovernmentGrantsExplanatory" name="DisclosureOfChangesRegardingGovernmentGrantsExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatory" name="DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatory" name="DisclosureOfCurrentAndDeferredTaxExpenseExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatory" name="DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DisclosureOfAccumulatedTaxLossesExplanatory" name="DisclosureOfAccumulatedTaxLossesExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatory" name="DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DisclosureOfForeignCurrencyRiskExplanatory" name="DisclosureOfForeignCurrencyRiskExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DisclosureOfClassesOfInventoriesExplanatory" name="DisclosureOfClassesOfInventoriesExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatory" name="DisclosureOfDetailedInformationAboutOtherAssetsExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_EmployeeEquityPlanMember" name="EmployeeEquityPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_ManagementBoardGrantMember" name="ManagementBoardGrantMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_ChiefExecutiveOfficerGrantMember" name="ChiefExecutiveOfficerGrantMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_EmployeeStockOwnershipPlanMember" name="EmployeeStockOwnershipPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_DisclosureOfDetailedInformationAboutOtherLiabilitiesExplanatory" name="DisclosureOfDetailedInformationAboutOtherLiabilitiesExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatory" name="DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInstatementOfOperationsExplanatory" name="DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInstatementOfOperationsExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DisclosureOfDetailedInformationAboutNetBenefitExpenseRecognizedInStatementOfProfitOrLossExplanatory" name="DisclosureOfDetailedInformationAboutNetBenefitExpenseRecognizedInStatementOfProfitOrLossExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DisclosureOfDetailedInformationAboutRemeasurementsRecognizedInOtherComprehensiveIncomeExplanatory" name="DisclosureOfDetailedInformationAboutRemeasurementsRecognizedInOtherComprehensiveIncomeExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DisclosureOfDetailedInformationAboutExpectedPaymentsOrContributionsToDefinedBenefitPlanExplanatory" name="DisclosureOfDetailedInformationAboutExpectedPaymentsOrContributionsToDefinedBenefitPlanExplanatory" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_NumberOfNewRealEstateEntitiesFounded" name="NumberOfNewRealEstateEntitiesFounded" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DisclosureOfCorporateInformationLineItems" name="DisclosureOfCorporateInformationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_DisclosureOfCorporateInformationTable" name="DisclosureOfCorporateInformationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_NumberOfOperationSegments" name="NumberOfOperationSegments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_NumberOfReportingSegments" name="NumberOfReportingSegments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_MinimumNumberOfCountriesInWhichCOVID19VaccineAuthorizedOrApprovedForEmergencyOrTemporaryUseOrGrantedConditionalMarketingAuthorization" name="MinimumNumberOfCountriesInWhichCOVID19VaccineAuthorizedOrApprovedForEmergencyOrTemporaryUseOrGrantedConditionalMarketingAuthorization" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_EquipmentToolsAndInstallationsMember" name="EquipmentToolsAndInstallationsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" name="UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_ProductionFacilitiesMember" name="ProductionFacilitiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_IntellectualPropertyRightsMember" name="IntellectualPropertyRightsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception" name="EstimatedMilestonePaymentToBeReceivedAtContractInception" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsAbstract" name="SignificantAccountingJudgmentsEstimatesAndAssumptionsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsLineItems" name="SignificantAccountingJudgmentsEstimatesAndAssumptionsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsTable" name="SignificantAccountingJudgmentsEstimatesAndAssumptionsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_OutsideUSMember" name="OutsideUSMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_CollaborationAgreementMember" name="CollaborationAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_BioNTechRNAPharmaceuticalsGmbHMember" name="BioNTechRNAPharmaceuticalsGmbHMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_BioNTechDeliveryTechnologiesGmbHMember" name="BioNTechDeliveryTechnologiesGmbHMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_BioNTechDiagnosticsGmbHMember" name="BioNTechDiagnosticsGmbHMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_BioNTechEuropeGmbHMember" name="BioNTechEuropeGmbHMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_BioNTechManufacturingGmbHMember" name="BioNTechManufacturingGmbHMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_BioNTechAustriaBeteiligungenGmbHMember" name="BioNTechAustriaBeteiligungenGmbHMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_BioNTechInnovativeManufacturingServicesGmbHMember" name="BioNTechInnovativeManufacturingServicesGmbHMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_ReSanoGmbHMember" name="ReSanoGmbHMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_JPTPeptideTechnologiesGmbHMember" name="JPTPeptideTechnologiesGmbHMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_JPTPeptideTechnologiesIncMember" name="JPTPeptideTechnologiesIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_BioNTechUSAHoldingLLCMember" name="BioNTechUSAHoldingLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_BioNTechResearchAndDevelopmentIncMember" name="BioNTechResearchAndDevelopmentIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_BioNTechCellAndGeneTherapiesGmbHMember" name="BioNTechCellAndGeneTherapiesGmbHMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_BioNTechPharmaceuticalsAsiaPacificPteLtdMember" name="BioNTechPharmaceuticalsAsiaPacificPteLtdMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_BioNTechRealEstateVerwaltungsGmbHMember" name="BioNTechRealEstateVerwaltungsGmbHMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_BioNTechUKLimitedMember" name="BioNTechUKLimitedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_BioNTechRealEstateGmbHAndCoKGMember" name="BioNTechRealEstateGmbHAndCoKGMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_BioNTechRealEstateHoldingGmbHMember" name="BioNTechRealEstateHoldingGmbHMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_BioNTechRealEstateDerGoldgrubeGmbHCoKGMember" name="BioNTechRealEstateDerGoldgrubeGmbHCoKGMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_BioNTechRealEstateHausVierGmbHCoKGMember" name="BioNTechRealEstateHausVierGmbHCoKGMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_BioNTechRealEstateAdamOpelStraeGmbHCoKGMember" name="BioNTechRealEstateAdamOpelStraeGmbHCoKGMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_NumberOfEntitiesAcquiredDuringPeriod" name="NumberOfEntitiesAcquiredDuringPeriod" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_NumberOfNewEntities" name="NumberOfNewEntities" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_NeonTherapeuticsIncAndNovartisManufacturingGmbHMember" name="NeonTherapeuticsIncAndNovartisManufacturingGmbHMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_BioNTechUSAHoldingLLCAndBioNTechResearchAndDevelopmentIncMember" name="BioNTechUSAHoldingLLCAndBioNTechResearchAndDevelopmentIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_BioNTechMember" name="BioNTechMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_ATImpfGmbHMember" name="ATImpfGmbHMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_MedineGmbHMember" name="MedineGmbHMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_PhaseOneClinicalTrialMember" name="PhaseOneClinicalTrialMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_PhaseTwoClinicalTrialMember" name="PhaseTwoClinicalTrialMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill" name="IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwillNetOfBargainPurchase" name="IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwillNetOfBargainPurchase" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_BusinessCombinationContingentCashConsideration" name="BusinessCombinationContingentCashConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_ConsiderationTransferred" name="ConsiderationTransferred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_AmericanDepositaryShares" name="AmericanDepositaryShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="bntx_IntangibleAssetsNumberOfNeoantigenTargetedTherapiesUnderDevelopment" name="IntangibleAssetsNumberOfNeoantigenTargetedTherapiesUnderDevelopment" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_PfizerIncMember" name="PfizerIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_GenentechIncMember" name="GenentechIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_ShanghaiFosunPharmaceuticalGroupCoLtdMember" name="ShanghaiFosunPharmaceuticalGroupCoLtdMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_OtherMember" name="OtherMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_COVID19VaccineRevenuesMember" name="COVID19VaccineRevenuesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_SalesToCollaborationPartnerMember" name="SalesToCollaborationPartnerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_DirectProductSalesToBioNTechCustomersMember" name="DirectProductSalesToBioNTechCustomersMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_ShareOfCollaborationPartnersGrossProfitMember" name="ShareOfCollaborationPartnersGrossProfitMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_OtherSalesMember" name="OtherSalesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_NumberOfCustomers" name="NumberOfCustomers" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_SanofiSAMember" name="SanofiSAMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_FosunPharmaMember" name="FosunPharmaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_CellscriptSublicenseMember" name="CellscriptSublicenseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_RevenuesFromSellingDrugProductBatchesToPfizersManufacturingSiteMember" name="RevenuesFromSellingDrugProductBatchesToPfizersManufacturingSiteMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_RevenueFromShareOfCollaborationPartnersGrossProfitMember" name="RevenueFromShareOfCollaborationPartnersGrossProfitMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_OtherSalesTransactionsMember" name="OtherSalesTransactionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_BillAndHoldTransactionMember" name="BillAndHoldTransactionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_NonRefundableUpfrontCashPayment" name="NonRefundableUpfrontCashPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_RevenueFromCollaboration" name="RevenueFromCollaboration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_MilestonePaymentRecognizedAsRevenue" name="MilestonePaymentRecognizedAsRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_RevenuesDerivedFromDeferredUpfrontPayments" name="RevenuesDerivedFromDeferredUpfrontPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_PercentageOfReimbursementOfSublicenseCosts" name="PercentageOfReimbursementOfSublicenseCosts" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_SublicenseAgreementDate" name="SublicenseAgreementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_ConditionalMarketingAuthorizationCountries" name="ConditionalMarketingAuthorizationCountries" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="bntx_TradeReceivableMaturityPeriod" name="TradeReceivableMaturityPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_RemainingUpfrontFeesContractLiabilities" name="RemainingUpfrontFeesContractLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale" name="AdvancePaymentReceivedForFutureCOVID19VaccineSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_DeferredRevenueRecognizedIncludedContractLiabilities" name="DeferredRevenueRecognizedIncludedContractLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_UnsatisfiedOrPartiallyUnsatisfiedMember" name="UnsatisfiedOrPartiallyUnsatisfiedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_DisclosureOfIncomeAndExpensesLineItems" name="DisclosureOfIncomeAndExpensesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_DisclosureOfIncomeAndExpensesTable" name="DisclosureOfIncomeAndExpensesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_IncomeAndExpensesByNatureAxis" name="IncomeAndExpensesByNatureAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_IncomeAndExpensesByNatureMember" name="IncomeAndExpensesByNatureMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_WagesBenefitsAndSocialSecurityExpenseMember" name="WagesBenefitsAndSocialSecurityExpenseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_LaboratorySuppliesMember" name="LaboratorySuppliesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_PurchasedServicesMember" name="PurchasedServicesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_LeaseAndLeaseRelatedCostMember" name="LeaseAndLeaseRelatedCostMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_OtherIncomeExpenseMember" name="OtherIncomeExpenseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_ITCostsMember" name="ITCostsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_TransportCostsMember" name="TransportCostsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_NatureOfExpensesAxis" name="NatureOfExpensesAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_NatureOfExpensesMember" name="NatureOfExpensesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_GeneralAndAdministrativeExpensesMember" name="GeneralAndAdministrativeExpensesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_GovernmentGrantsMember" name="GovernmentGrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_InsurancePremiumsMember" name="InsurancePremiumsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_ResearchServicesMember" name="ResearchServicesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_JobAdvertisementExpensesMember" name="JobAdvertisementExpensesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_ContractStaffingMember" name="ContractStaffingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_ChargeInConnectionWithCertainWithholdingTaxPaymentsForIntellectualPropertyLicenses" name="ChargeInConnectionWithCertainWithholdingTaxPaymentsForIntellectualPropertyLicenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_BargainPurchaseMember" name="BargainPurchaseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_GovernmentGrantsReceived" name="GovernmentGrantsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_GovernmentGrantsAbstract" name="GovernmentGrantsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_AmortizationOfFinancialInstruments" name="AmortizationOfFinancialInstruments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" name="FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_CorporateIncomeTaxRate" name="CorporateIncomeTaxRate" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_SolidaritySurchargeRate" name="SolidaritySurchargeRate" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_ChangeInAverageTradeTaxRate" name="ChangeInAverageTradeTaxRate" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_GermanTaxGroupMember" name="GermanTaxGroupMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_GermanEntitiesNotWithinTaxGroupMember" name="GermanEntitiesNotWithinTaxGroupMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_UnitedStatesTaxGroupMember" name="UnitedStatesTaxGroupMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" name="DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeTable" name="DisclosureOfMajorComponentsOfTaxExpenseIncomeTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" name="DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_ValuationAdjustmentMember" name="ValuationAdjustmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_FixedAssetsMember" name="FixedAssetsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_InventoryMember" name="InventoryMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_LeasesMember" name="LeasesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_ContractLiabilitiesMember" name="ContractLiabilitiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_InterestBearingLoansAndBorrowingsMember" name="InterestBearingLoansAndBorrowingsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_ProvisionsMember" name="ProvisionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_OtherDeferredTaxesMember" name="OtherDeferredTaxesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_AccumulatedTaxLossesInCorporateTax" name="AccumulatedTaxLossesInCorporateTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_AccumulatedTaxLossesInTradeTax" name="AccumulatedTaxLossesInTradeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_AccumulatedTaxLossesInFederalTaxCredits" name="AccumulatedTaxLossesInFederalTaxCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_AccumulatedTaxLossesInStateTaxCredits" name="AccumulatedTaxLossesInStateTaxCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_DeferredTaxAssetsForUnusedTaxLossesRecognized" name="DeferredTaxAssetsForUnusedTaxLossesRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsExpectedToExpire" name="FederalDeferredTaxAssetsOperatingLossCarryforwardsExpectedToExpire" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_FederalTaxLossesExpirationYear" name="FederalTaxLossesExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" name="FederalDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_StateDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" name="StateDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_StateTaxLossesExpirationYear" name="StateTaxLossesExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_SharesIssuedDuringPeriodStockSplit" name="SharesIssuedDuringPeriodStockSplit" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_ReclassificationsPropertyPlantAndEquipment" name="ReclassificationsPropertyPlantAndEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_ConstructionInProgressAndAdvancePaymentsMember" name="ConstructionInProgressAndAdvancePaymentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_AccumulatedDepreciationAmortisationAndImpairment" name="AccumulatedDepreciationAmortisationAndImpairment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember" name="ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_AdvancePaymentsMember" name="AdvancePaymentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_CGUImmunotherapiesMember" name="CGUImmunotherapiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_ExternalProductSalesOfJPTMember" name="ExternalProductSalesOfJPTMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_IncreaseInGrowthRateCashFlowProjections" name="IncreaseInGrowthRateCashFlowProjections" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="bntx_OtherFinancialAssetsMember" name="OtherFinancialAssetsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_DerivativeFinancialLiabilitiesNotDesignatedAsHedgingInstrumentsAtFairValue" name="DerivativeFinancialLiabilitiesNotDesignatedAsHedgingInstrumentsAtFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_TwoPointOneFivePercentageSecuredBankLoanMember" name="TwoPointOneFivePercentageSecuredBankLoanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_TwoPointZeroEightPercentageSecuredBankLoanMember" name="TwoPointZeroEightPercentageSecuredBankLoanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_ConvertibleNoteHostContractMember" name="ConvertibleNoteHostContractMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember" name="ThreePointFiveZeroPercentageSecuredBankLoanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_OnePointNineZeroPercentageSecuredBankLoanMember" name="OnePointNineZeroPercentageSecuredBankLoanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember" name="OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_ConvertibleNoteEmbeddedDerivativeMember" name="ConvertibleNoteEmbeddedDerivativeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_TradePayablesMember" name="TradePayablesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_OtherFinancialLiabilitiesMember" name="OtherFinancialLiabilitiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_FinancialLiabilitiesMaturityDate" name="FinancialLiabilitiesMaturityDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_NumberOfSecuredBankLoanMaintained" name="NumberOfSecuredBankLoanMaintained" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_LoanRepayableQuarterlyInstallment" name="LoanRepayableQuarterlyInstallment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_LoanRepayableQuarterlyInstallmentCommencementDate" name="LoanRepayableQuarterlyInstallmentCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_TwoPointOneFivePercentageSecuredLoanMember" name="TwoPointOneFivePercentageSecuredLoanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_TwoPointZeroEightPercentageBankLoanMember" name="TwoPointZeroEightPercentageBankLoanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_DeutscheBankAGMember" name="DeutscheBankAGMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_CashInterestFixedRateMember" name="CashInterestFixedRateMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_DeferredInterestAtFixedRateMember" name="DeferredInterestAtFixedRateMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_EuropeanInvestmentBankMember" name="EuropeanInvestmentBankMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_JuneTwentyTwentyPrivatePlacementMember" name="JuneTwentyTwentyPrivatePlacementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_ConvertibleNoteMember" name="ConvertibleNoteMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_TermLoanCreditA" name="TermLoanCreditA" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_TermLoanCreditB" name="TermLoanCreditB" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_FinancialLiabilityMaturityTerm" name="FinancialLiabilityMaturityTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_FinancialLiabilitiesCouponRatePerAnnum" name="FinancialLiabilitiesCouponRatePerAnnum" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_FinancialLiabilitiesConversionPremiumPercentageAboveReferencePrice" name="FinancialLiabilitiesConversionPremiumPercentageAboveReferencePrice" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_EffectiveInterestRateOfFinancialLiabilities" name="EffectiveInterestRateOfFinancialLiabilities" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_CashAndCashEquivalent" name="CashAndCashEquivalent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_DisclosureOfCashAndCashEquivalentsLineItems" name="DisclosureOfCashAndCashEquivalentsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_DisclosureOfCashAndCashEquivalentsTable" name="DisclosureOfCashAndCashEquivalentsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_USDollarBankAccountsMember" name="USDollarBankAccountsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_FinancialLiabilityMember" name="FinancialLiabilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesAbstract" name="DisclosureOfEffectOfChangesInForeignExchangeRatesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems" name="DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable" name="DisclosureOfEffectOfChangesInForeignExchangeRatesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_PositiveFivePercentageChangeInForeignExchangeRateMember" name="PositiveFivePercentageChangeInForeignExchangeRateMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_NegativeFivePercentageChangeInForeignExchangeRateMember" name="NegativeFivePercentageChangeInForeignExchangeRateMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_ForeignCurrencyChangesEffectOnLossBeforeTax" name="ForeignCurrencyChangesEffectOnLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_ForeignCurrencyChangesEffectOnPretaxEquity" name="ForeignCurrencyChangesEffectOnPretaxEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities" name="IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_CurrentObligationsUnderLeaseContractsMember" name="CurrentObligationsUnderLeaseContractsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_NoncurrentObligationsUnderLeaseContractsMember" name="NoncurrentObligationsUnderLeaseContractsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_DeferredExpense" name="DeferredExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_NeonTherapeuticsIncMember" name="NeonTherapeuticsIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_GlobalOfferingMember" name="GlobalOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_June2020PrivatePlacementMember" name="June2020PrivatePlacementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_AtMarketOfferingProgramMember" name="AtMarketOfferingProgramMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_OrdinarySharesSeriesBMember" name="OrdinarySharesSeriesBMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_BillAndMeLindaGatesFoundationMember" name="BillAndMeLindaGatesFoundationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_InitialPublicOfferingMember" name="InitialPublicOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_NumberOfOrdinarySharesIssuable" name="NumberOfOrdinarySharesIssuable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares" name="PercentageOfAmericanDepositorySharesToOrdinaryShares" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_SharesIssuedPricePerShare1" name="SharesIssuedPricePerShare1" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="bntx_EquityIssuable" name="EquityIssuable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_MaximumProceedsReceivableFromIssuanceOfOrdinaryShares" name="MaximumProceedsReceivableFromIssuanceOfOrdinaryShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_CashInvestment" name="CashInvestment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_RemainingNoncontrollingInterestsAcquiredPercentage" name="RemainingNoncontrollingInterestsAcquiredPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DerecognitionOfNonControllingInterest" name="DerecognitionOfNonControllingInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_DecreaseInCapitalReserve" name="DecreaseInCapitalReserve" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_OptionVestingPeriod" name="OptionVestingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_PercentageOfOtherEquityInstrumentNonVestingRate" name="PercentageOfOtherEquityInstrumentNonVestingRate" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_TwoThousandTwentyRestrictedStockUnitPlanMember" name="TwoThousandTwentyRestrictedStockUnitPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_EmployeeEquityPlanLongTermIncentiveProgramMember" name="EmployeeEquityPlanLongTermIncentiveProgramMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember" name="EmployeeEquityPlanLongTermIncentivePlusProgramMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_ResearchAndDevelopmentExpensesMember" name="ResearchAndDevelopmentExpensesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_ProfessorUgurSahinMDMember" name="ProfessorUgurSahinMDMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_SeanMarettMember" name="SeanMarettMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_DrSierkPoettingMember" name="DrSierkPoettingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_DrOzlemTureciMember" name="DrOzlemTureciMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_RyanRichardsonMember" name="RyanRichardsonMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_NumberOfInstrumentsOtherEquityInstrumentsExpectedToBeAllocated" name="NumberOfInstrumentsOtherEquityInstrumentsExpectedToBeAllocated" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpectedToBeAllocatedInSharebasedPaymentArrangement" name="WeightedAverageExercisePriceOfOtherEquityInstrumentsExpectedToBeAllocatedInSharebasedPaymentArrangement" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_CostOfSales1Member" name="CostOfSales1Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_SalesAndMarketingExpensesMember" name="SalesAndMarketingExpensesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_CashSettledExpenseFromSharebasedPaymentTransactionsWithEmployees" name="CashSettledExpenseFromSharebasedPaymentTransactionsWithEmployees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_IncreaseDecreaseInShareBasedPaymentValue" name="IncreaseDecreaseInShareBasedPaymentValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne" name="NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo" name="NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne" name="WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo" name="WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_PercentageOfIncreaseInExercisePrice" name="PercentageOfIncreaseInExercisePrice" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering" name="ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth" name="PercentageOfTargetSharePriceApplicableForPriorTwelveMonth" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_OptionExpirationPeriod" name="OptionExpirationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_EstimatedAllocationDateOneMember" name="EstimatedAllocationDateOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_EstimatedAllocationDateTwoMember" name="EstimatedAllocationDateTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_DrOzlemTureciMDMember" name="DrOzlemTureciMDMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_WeightedAverageRemainingContractualLifeOfShareOptionsAllocatedAndExpectedToBeAllocated" name="WeightedAverageRemainingContractualLifeOfShareOptionsAllocatedAndExpectedToBeAllocated" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_OptionExercisablePeriod" name="OptionExercisablePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare" name="ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_NumberOfOrdinarySharesUnderlyingOptionsGrantedInSharebasedPaymentArrangement" name="NumberOfOrdinarySharesUnderlyingOptionsGrantedInSharebasedPaymentArrangement" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInSharebasedPaymentArrangement" name="NumberOfOrdinarySharesUnderlyingOptionsForfeitedInSharebasedPaymentArrangement" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding" name="NumberOfOrdinarySharesUnderlyingOptionsOutstanding" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="bntx_AdvancePaymentsRelatedToEmbeddedLeases" name="AdvancePaymentsRelatedToEmbeddedLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_LeaseExpensesRecognizedInProfitOrLoss" name="LeaseExpensesRecognizedInProfitOrLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities" name="UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_PercentageOfDefinedContributionPlanOfSalary" name="PercentageOfDefinedContributionPlanOfSalary" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_MaximumPensionFundContributions" name="MaximumPensionFundContributions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_PensionFundContributionsExpectedForFollowingFinancialYear" name="PensionFundContributionsExpectedForFollowingFinancialYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bntx_AnnualPensionEntitlementOfEmployeeContribution" name="AnnualPensionEntitlementOfEmployeeContribution" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_BasePlanMember" name="BasePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_SupplementPlanMember" name="SupplementPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsAccrued" name="KeyManagementPersonnelCompensationShortTermEmployeeBenefitsAccrued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_KeyManagementPersonnelCompensationShareBasedPaymentOrdinaryShares" name="KeyManagementPersonnelCompensationShareBasedPaymentOrdinaryShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_CofounderAndChiefExecutiveOfficerMember" name="CofounderAndChiefExecutiveOfficerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_ConsultingServicesAndPatentAssignment" name="ConsultingServicesAndPatentAssignment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" name="PurchasesOfGoodsAndServiceRelatedPartyTransactions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_GoodsAndServicesFromRelatedPartyTransactions" name="GoodsAndServicesFromRelatedPartyTransactions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_ConsultingServiceProviderMember" name="ConsultingServiceProviderMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_TRONMember" name="TRONMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_PurchasesFromRelatedPartyTransactions" name="PurchasesFromRelatedPartyTransactions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bntx_ATHOSKGMember" name="ATHOSKGMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_NumberOfAdditionalDosesToBeSupplied" name="NumberOfAdditionalDosesToBeSupplied" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_AggregateNumberOfDosesToBeSupplied" name="AggregateNumberOfDosesToBeSupplied" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_NumberOfEuropeanUnionMemberStates" name="NumberOfEuropeanUnionMemberStates" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_OptionToRequestSupplyOfNumberOfAdditionalDoses" name="OptionToRequestSupplyOfNumberOfAdditionalDoses" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bntx_DisclosureOfEventsAfterReportingPeriodLineItems" name="DisclosureOfEventsAfterReportingPeriodLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_DisclosureOfEventsAfterReportingPeriodTable" name="DisclosureOfEventsAfterReportingPeriodTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_SupplyOfCOVID19VaccineMember" name="SupplyOfCOVID19VaccineMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_UnitedStatesGovernmentMember" name="UnitedStatesGovernmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bntx_EuropeanUnionMemberStatesMember" name="EuropeanUnionMemberStatesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>46
<FILENAME>bntx-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-30T14:14:26.4316036+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : a6c3372c9f8947078f9b74c1e02df132 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="bntx-20201231.xsd#TemplateLink" roleURI="http://www.biontech.de/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" xlink:href="bntx-20201231.xsd#Role_StatementConsolidatedStatementsOfFinancialPosition" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxAssets" xlink:type="locator" xlink:label="ifrs-full_DeferredTaxAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherNoncurrentAssets" xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RightofuseAssets" xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredExpenseCurrent" xlink:type="locator" xlink:label="bntx_DeferredExpenseCurrent" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:type="locator" xlink:label="ifrs-full_CurrentTaxAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentAssets" xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTradeReceivables" xlink:type="locator" xlink:label="ifrs-full_CurrentTradeReceivables" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Inventories" xlink:type="locator" xlink:label="ifrs-full_Inventories" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssets" xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssets" xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets" xlink:type="locator" xlink:label="ifrs-full_Assets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReserves" xlink:type="locator" xlink:label="ifrs-full_OtherReserves" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:type="locator" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TreasuryShares" xlink:type="locator" xlink:label="ifrs-full_TreasuryShares" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CapitalReserve" xlink:type="locator" xlink:label="ifrs-full_CapitalReserve" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital" xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxLiabilities" xlink:type="locator" xlink:label="ifrs-full_DeferredTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:type="locator" xlink:label="ifrs-full_NoncurrentContractLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentProvisions" xlink:type="locator" xlink:label="ifrs-full_NoncurrentProvisions" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LongtermBorrowings" xlink:type="locator" xlink:label="ifrs-full_LongtermBorrowings" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentLiabilities" xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentContractLiabilities" xlink:type="locator" xlink:label="ifrs-full_CurrentContractLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherShorttermProvisions" xlink:type="locator" xlink:label="ifrs-full_OtherShorttermProvisions" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:type="locator" xlink:label="ifrs-full_CurrentTaxLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentGovernmentGrants" xlink:type="locator" xlink:label="ifrs-full_CurrentGovernmentGrants" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShorttermBorrowings" xlink:type="locator" xlink:label="ifrs-full_ShorttermBorrowings" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilities" xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilities" xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities" xlink:type="locator" xlink:label="ifrs-full_Liabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:type="locator" xlink:label="ifrs-full_Equity" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilities" xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Equity" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Liabilities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_NoncurrentLiabilities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_CurrentLiabilities" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_ShorttermBorrowings" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_OtherCurrentFinancialLiabilities" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentGovernmentGrants" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentTaxLiabilitiesCurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_OtherShorttermProvisions" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentContractLiabilities" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_LongtermBorrowings" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_OtherNoncurrentFinancialLiabilities" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentProvisions" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentContractLiabilities" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_OtherNoncurrentLiabilities" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_DeferredTaxLiabilities" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_IssuedCapital" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_CapitalReserve" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_TreasuryShares" order="10210.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncome" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_OtherReserves" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_NoncurrentAssets" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_CurrentAssets" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_Inventories" order="10260.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentTradeReceivables" order="10270.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_OtherCurrentFinancialAssets" order="10280.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets" order="10290.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentTaxAssetsCurrent" order="10300.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="bntx_DeferredExpenseCurrent" order="10310.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CashAndCashEquivalents" order="10320.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" order="10330.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="10340.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_RightofuseAssets" order="10350.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_OtherNoncurrentAssets" order="10360.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_DeferredTaxAssets" order="10370.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="bntx-20201231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:type="locator" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MiscellaneousOtherOperatingExpense" xlink:type="locator" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SalesAndMarketingExpense" xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CostOfSales" xlink:type="locator" xlink:label="ifrs-full_CostOfSales" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:type="locator" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceCosts" xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncome" xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLossBeforeTax" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_FinanceIncome" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_FinanceCosts" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_CostOfSales" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_SalesAndMarketingExpense" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="10120.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_MiscellaneousOtherOperatingExpense" order="10130.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome" order="10140.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations2" xlink:href="bntx-20201231.xsd#Role_StatementConsolidatedStatementsOfOperations2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations2">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="bntx-20201231.xsd#Role_StatementConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncome" xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncome" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ProfitLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss2" xlink:href="bntx-20201231.xsd#Role_StatementConsolidatedStatementsOfComprehensiveIncomeLoss2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss2">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="bntx-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="locator" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:type="locator" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions" xlink:type="locator" xlink:label="bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AdjustmentsForIncreaseDecreaseInTradeAccountReceivableAndContractAssets" xlink:type="locator" xlink:label="bntx_AdjustmentsForIncreaseDecreaseInTradeAccountReceivableAndContractAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherAdjustmentsForNoncashItems" xlink:type="locator" xlink:label="ifrs-full_OtherAdjustmentsForNoncashItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AdjustmentsForMovementsInGovernmentGrants" xlink:type="locator" xlink:label="bntx_AdjustmentsForMovementsInGovernmentGrants" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForFinanceCosts" xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceCosts" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AdjustmentsForInterestOnLeaseLiability" xlink:type="locator" xlink:label="bntx_AdjustmentsForInterestOnLeaseLiability" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForFinanceIncome" xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncome" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="locator" xlink:label="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssets" xlink:type="locator" xlink:label="bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator" xlink:label="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssets" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_ProfitLossBeforeTax" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" order="10160.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForFinanceIncome" order="10170.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="bntx_AdjustmentsForInterestOnLeaseLiability" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForFinanceCosts" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="bntx_AdjustmentsForMovementsInGovernmentGrants" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" order="10210.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_OtherAdjustmentsForNoncashItems" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="bntx_AdjustmentsForIncreaseDecreaseInTradeAccountReceivableAndContractAssets" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" order="10260.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities" order="10270.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" order="10280.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfFairValuesOfIdentifiableNetAssetsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureBusinessCombinationsSummaryOfFairValuesOfIdentifiableNetAssetsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfFairValuesOfIdentifiableNetAssetsDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherLiabilitiesNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="bntx_OtherLiabilitiesNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TradePayablesRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="bntx_TradePayablesRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ProvisionsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="bntx_ProvisionsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LiabilitiesRecognizedAsOfAcquisitionDate" xlink:type="locator" xlink:label="bntx_LiabilitiesRecognizedAsOfAcquisitionDate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AssetsRecognizedAsOfAcquisitionDate" xlink:type="locator" xlink:label="bntx_AssetsRecognizedAsOfAcquisitionDate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_InventoryRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill" xlink:type="locator" xlink:label="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BargainPurchaseGainOnAcquisition" xlink:type="locator" xlink:label="bntx_BargainPurchaseGainOnAcquisition" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="locator" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwillNetOfBargainPurchase" xlink:type="locator" xlink:label="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwillNetOfBargainPurchase" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashTransferred" xlink:type="locator" xlink:label="ifrs-full_CashTransferred" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SharesIssuedAtFairValue" xlink:type="locator" xlink:label="bntx_SharesIssuedAtFairValue" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="locator" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:to="bntx_SharesIssuedAtFairValue" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:to="ifrs-full_CashTransferred" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:to="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwillNetOfBargainPurchase" xlink:to="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwillNetOfBargainPurchase" xlink:to="bntx_BargainPurchaseGainOnAcquisition" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill" xlink:to="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill" xlink:to="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill" xlink:to="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill" xlink:to="ifrs-full_InventoryRecognisedAsOfAcquisitionDate" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill" xlink:to="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:to="bntx_AssetsRecognizedAsOfAcquisitionDate" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:to="bntx_LiabilitiesRecognizedAsOfAcquisitionDate" order="10120.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_LiabilitiesRecognizedAsOfAcquisitionDate" xlink:to="bntx_ProvisionsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_LiabilitiesRecognizedAsOfAcquisitionDate" xlink:to="bntx_TradePayablesRecognisedAsOfAcquisitionDate" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_LiabilitiesRecognizedAsOfAcquisitionDate" xlink:to="bntx_OtherLiabilitiesNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_AssetsRecognizedAsOfAcquisitionDate" xlink:to="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_AssetsRecognizedAsOfAcquisitionDate" xlink:to="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_AssetsRecognizedAsOfAcquisitionDate" xlink:to="bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_AssetsRecognizedAsOfAcquisitionDate" xlink:to="ifrs-full_InventoryRecognisedAsOfAcquisitionDate" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_AssetsRecognizedAsOfAcquisitionDate" xlink:to="bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_AssetsRecognizedAsOfAcquisitionDate" xlink:to="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" order="10210.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesFinanceIncomeDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeAndExpensesFinanceIncomeDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesFinanceIncomeDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetForeignExchangeGain" xlink:type="locator" xlink:label="ifrs-full_NetForeignExchangeGain" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromInterest" xlink:type="locator" xlink:label="ifrs-full_RevenueFromInterest" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncome" xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_RevenueFromInterest" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_NetForeignExchangeGain" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesFinanceExpenseDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeAndExpensesFinanceExpenseDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesFinanceExpenseDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetForeignExchangeLoss" xlink:type="locator" xlink:label="ifrs-full_NetForeignExchangeLoss" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" xlink:type="locator" xlink:label="bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AmortizationOfFinancialInstruments" xlink:type="locator" xlink:label="bntx_AmortizationOfFinancialInstruments" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceCosts" xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts" xlink:to="bntx_AmortizationOfFinancialInstruments" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts" xlink:to="bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_NetForeignExchangeLoss" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesEmployeeBenefitsExpenseDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeAndExpensesEmployeeBenefitsExpenseDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesEmployeeBenefitsExpenseDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:type="locator" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SocialSecurityContributions" xlink:type="locator" xlink:label="ifrs-full_SocialSecurityContributions" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WagesAndSalaries" xlink:type="locator" xlink:label="ifrs-full_WagesAndSalaries" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_WagesAndSalaries" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_SocialSecurityContributions" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxSummaryOfCurrentAndDeferredTaxExpenseDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeTaxSummaryOfCurrentAndDeferredTaxExpenseDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxSummaryOfCurrentAndDeferredTaxExpenseDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherComponentsOfTaxExpenseIncome" xlink:type="locator" xlink:label="bntx_OtherComponentsOfTaxExpenseIncome" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:type="locator" xlink:label="ifrs-full_DeferredTaxExpenseIncome" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:type="locator" xlink:label="ifrs-full_CurrentTaxExpenseIncome" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_CurrentTaxExpenseIncome" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_DeferredTaxExpenseIncome" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="bntx_OtherComponentsOfTaxExpenseIncome" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeTaxSummaryOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="locator" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TaxEffectOfTaxCredit" xlink:type="locator" xlink:label="bntx_TaxEffectOfTaxCredit" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfForeignTaxRates" xlink:type="locator" xlink:label="ifrs-full_TaxEffectOfForeignTaxRates" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:type="locator" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TaxEffectOfNonrecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences" xlink:type="locator" xlink:label="bntx_TaxEffectOfNonrecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfTaxLosses" xlink:type="locator" xlink:label="ifrs-full_TaxEffectOfTaxLosses" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TaxEffectiveEquityTransactionCosts" xlink:type="locator" xlink:label="bntx_TaxEffectiveEquityTransactionCosts" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses" xlink:type="locator" xlink:label="bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NonTaxEffectiveBargainPurchase" xlink:type="locator" xlink:label="bntx_NonTaxEffectiveBargainPurchase" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AddBackForTradeTaxPurposes" xlink:type="locator" xlink:label="bntx_AddBackForTradeTaxPurposes" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:type="locator" xlink:label="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GovernmentGrantsExemptedFromTaxes" xlink:type="locator" xlink:label="bntx_GovernmentGrantsExemptedFromTaxes" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:type="locator" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="bntx_GovernmentGrantsExemptedFromTaxes" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="bntx_AddBackForTradeTaxPurposes" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="bntx_NonTaxEffectiveBargainPurchase" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="bntx_TaxEffectiveEquityTransactionCosts" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_TaxEffectOfTaxLosses" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="bntx_TaxEffectOfNonrecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_TaxEffectOfForeignTaxRates" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="bntx_TaxEffectOfTaxCredit" order="10140.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" order="10150.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureEarningsPerShareSummaryOfIncomeAndShareDataUsedInBasicAndDilutedEPSCalculationsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureEarningsPerShareSummaryOfIncomeAndShareDataUsedInBasicAndDilutedEPSCalculationsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureEarningsPerShareSummaryOfIncomeAndShareDataUsedInBasicAndDilutedEPSCalculationsDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:type="locator" xlink:label="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageShares" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:type="locator" xlink:label="ifrs-full_AdjustedWeightedAverageShares" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialAssetsAtAmortizedCostDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialAssetsAtAmortizedCostDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialAssetsAtAmortizedCostDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentFinancialAssetsAtAmortisedCost" xlink:type="locator" xlink:label="ifrs-full_NoncurrentFinancialAssetsAtAmortisedCost" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentFinancialAssetsAtAmortisedCost" xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialAssetsAtAmortisedCost" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsAtAmortisedCost" xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_CurrentFinancialAssetsAtAmortisedCost" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_NoncurrentFinancialAssetsAtAmortisedCost" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialLiabilitiesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentFinancialLiabilitiesAtAmortisedCost" xlink:type="locator" xlink:label="ifrs-full_NoncurrentFinancialLiabilitiesAtAmortisedCost" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentFinancialLiabilitiesAtAmortisedCost" xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialLiabilitiesAtAmortisedCost" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DerivativeFinancialLiabilitiesNotDesignatedAsHedgingInstrumentsAtFairValue" xlink:type="locator" xlink:label="bntx_DerivativeFinancialLiabilitiesNotDesignatedAsHedgingInstrumentsAtFairValue" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilities" xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValue" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCost" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilitiesAtFairValue" xlink:to="bntx_DerivativeFinancialLiabilitiesNotDesignatedAsHedgingInstrumentsAtFairValue" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilitiesAtFairValue" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:to="ifrs-full_CurrentFinancialLiabilitiesAtAmortisedCost" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:to="ifrs-full_NoncurrentFinancialLiabilitiesAtAmortisedCost" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialLiabilitiesDetails2" xlink:href="bntx-20201231.xsd#Role_DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialLiabilitiesDetails2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialLiabilitiesDetails2">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentFinancialLiabilities" xlink:type="locator" xlink:label="ifrs-full_NoncurrentFinancialLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentFinancialLiabilities" xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilities" xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_CurrentFinancialLiabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_NoncurrentFinancialLiabilities" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherFinancialLiabilities" xlink:type="locator" xlink:label="ifrs-full_OtherFinancialLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:type="locator" xlink:label="ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseLiabilities" xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherPayables" xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayables" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_InterestBearingLoansAndBorrowings" xlink:type="locator" xlink:label="bntx_InterestBearingLoansAndBorrowings" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilities" xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="bntx_InterestBearingLoansAndBorrowings" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_TradeAndOtherPayables" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_LeaseLiabilities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_OtherFinancialLiabilities" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureInventoriesSummaryOfInventoriesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureInventoriesSummaryOfInventoriesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureInventoriesSummaryOfInventoriesDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinishedGoods" xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WorkInProgress" xlink:type="locator" xlink:label="ifrs-full_WorkInProgress" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" xlink:type="locator" xlink:label="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Inventories" xlink:type="locator" xlink:label="ifrs-full_Inventories" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_WorkInProgress" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_FinishedGoods" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherAssetsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureOtherAssetsSummaryOfOtherAssetsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherAssetsDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherCurrentAssetsOther" xlink:type="locator" xlink:label="bntx_OtherCurrentAssetsOther" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CurrentPrepaymentsRelatedToServiceContracts" xlink:type="locator" xlink:label="bntx_CurrentPrepaymentsRelatedToServiceContracts" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:type="locator" xlink:label="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAdvancesToSuppliers" xlink:type="locator" xlink:label="ifrs-full_CurrentAdvancesToSuppliers" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherAssets" xlink:type="locator" xlink:label="ifrs-full_OtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherAssets" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherAssets" xlink:to="ifrs-full_CurrentAdvancesToSuppliers" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherAssets" xlink:to="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherAssets" xlink:to="bntx_CurrentPrepaymentsRelatedToServiceContracts" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherAssets" xlink:to="bntx_OtherCurrentAssetsOther" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherAssetsDetails2" xlink:href="bntx-20201231.xsd#Role_DisclosureOtherAssetsSummaryOfOtherAssetsDetails2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherAssetsDetails2">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherNoncurrentAssets" xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentAssets" xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherAssets" xlink:type="locator" xlink:label="ifrs-full_OtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherAssets" xlink:to="ifrs-full_OtherCurrentAssets" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherAssets" xlink:to="ifrs-full_OtherNoncurrentAssets" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureDeferredExpensesSummaryOfDeferredExpensesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureDeferredExpensesSummaryOfDeferredExpensesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureDeferredExpensesSummaryOfDeferredExpensesDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherDeferredExpenses" xlink:type="locator" xlink:label="bntx_OtherDeferredExpenses" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredExpensesFromContractManufacturingAndContractResearchOrganizations" xlink:type="locator" xlink:label="bntx_DeferredExpensesFromContractManufacturingAndContractResearchOrganizations" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredExpensesFromInsuranceContracts" xlink:type="locator" xlink:label="bntx_DeferredExpensesFromInsuranceContracts" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredExpense" xlink:type="locator" xlink:label="bntx_DeferredExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_DeferredExpense" xlink:to="bntx_DeferredExpensesFromInsuranceContracts" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_DeferredExpense" xlink:to="bntx_DeferredExpensesFromContractManufacturingAndContractResearchOrganizations" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_DeferredExpense" xlink:to="bntx_OtherDeferredExpenses" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureDeferredExpensesSummaryOfDeferredExpensesDetails2" xlink:href="bntx-20201231.xsd#Role_DisclosureDeferredExpensesSummaryOfDeferredExpensesDetails2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureDeferredExpensesSummaryOfDeferredExpensesDetails2">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredExpenseNonCurrent" xlink:type="locator" xlink:label="bntx_DeferredExpenseNonCurrent" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredExpenseCurrent" xlink:type="locator" xlink:label="bntx_DeferredExpenseCurrent" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredExpense" xlink:type="locator" xlink:label="bntx_DeferredExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_DeferredExpense" xlink:to="bntx_DeferredExpenseCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_DeferredExpense" xlink:to="bntx_DeferredExpenseNonCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherLiabilitiesSummaryOfOtherLiabilitiesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureOtherLiabilitiesSummaryOfOtherLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherLiabilitiesSummaryOfOtherLiabilitiesDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherLiabilitiesOther" xlink:type="locator" xlink:label="bntx_OtherLiabilitiesOther" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CurrentLiabilitiesForEmployeesBenefits" xlink:type="locator" xlink:label="bntx_CurrentLiabilitiesForEmployeesBenefits" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherLiabilities" xlink:type="locator" xlink:label="ifrs-full_OtherLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherLiabilities" xlink:to="bntx_CurrentLiabilitiesForEmployeesBenefits" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherLiabilities" xlink:to="bntx_OtherLiabilitiesOther" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherLiabilitiesSummaryOfOtherLiabilitiesDetails2" xlink:href="bntx-20201231.xsd#Role_DisclosureOtherLiabilitiesSummaryOfOtherLiabilitiesDetails2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherLiabilitiesSummaryOfOtherLiabilitiesDetails2">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentLiabilities" xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherLiabilities" xlink:type="locator" xlink:label="ifrs-full_OtherLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherLiabilities" xlink:to="ifrs-full_OtherNoncurrentLiabilities" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilityIncludedInInterestBearingLoansAndBorrowingsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureLeasesSummaryOfLeaseLiabilityIncludedInInterestBearingLoansAndBorrowingsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilityIncludedInInterestBearingLoansAndBorrowingsDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseLiabilities" xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesSummaryOfAmountsRecognizedInConsolidatedStatementOfOperationsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureLeasesSummaryOfAmountsRecognizedInConsolidatedStatementOfOperationsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesSummaryOfAmountsRecognizedInConsolidatedStatementOfOperationsDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:type="locator" xlink:label="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:type="locator" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:type="locator" xlink:label="ifrs-full_DepreciationRightofuseAssets" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LeaseExpensesRecognizedInProfitOrLoss" xlink:type="locator" xlink:label="bntx_LeaseExpensesRecognizedInProfitOrLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_LeaseExpensesRecognizedInProfitOrLoss" xlink:to="ifrs-full_DepreciationRightofuseAssets" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_LeaseExpensesRecognizedInProfitOrLoss" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_LeaseExpensesRecognizedInProfitOrLoss" xlink:to="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_LeaseExpensesRecognizedInProfitOrLoss" xlink:to="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsSummaryOfComponentsOfNetBenefitExpenseRecognizedInStatementOfProfitOrLossDetails" xlink:href="bntx-20201231.xsd#Role_DisclosurePensionsSummaryOfComponentsOfNetBenefitExpenseRecognizedInStatementOfProfitOrLossDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsSummaryOfComponentsOfNetBenefitExpenseRecognizedInStatementOfProfitOrLossDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsSummaryOfComponentsOfRemeasurementsRecognizedInOtherComprehensiveIncomeDetails" xlink:href="bntx-20201231.xsd#Role_DisclosurePensionsSummaryOfComponentsOfRemeasurementsRecognizedInOtherComprehensiveIncomeDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsSummaryOfComponentsOfRemeasurementsRecognizedInOtherComprehensiveIncomeDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfCompensationOfKeyManagementPersonnelDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureRelatedPartyDisclosuresSummaryOfCompensationOfKeyManagementPersonnelDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfCompensationOfKeyManagementPersonnelDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsAccrued" xlink:type="locator" xlink:label="bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsAccrued" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsAccrued" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfAggregateValueOfTransactionsRelatedToKeyManagementPersonnelDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureRelatedPartyDisclosuresSummaryOfAggregateValueOfTransactionsRelatedToKeyManagementPersonnelDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfAggregateValueOfTransactionsRelatedToKeyManagementPersonnelDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" xlink:type="locator" xlink:label="bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConsultingServicesAndPatentAssignment" xlink:type="locator" xlink:label="bntx_ConsultingServicesAndPatentAssignment" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GoodsAndServicesFromRelatedPartyTransactions" xlink:type="locator" xlink:label="bntx_GoodsAndServicesFromRelatedPartyTransactions" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_GoodsAndServicesFromRelatedPartyTransactions" xlink:to="bntx_ConsultingServicesAndPatentAssignment" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_GoodsAndServicesFromRelatedPartyTransactions" xlink:to="bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfTransactionsBetweenRelatedPartiesAmountDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureRelatedPartyDisclosuresSummaryOfTransactionsBetweenRelatedPartiesAmountDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfTransactionsBetweenRelatedPartiesAmountDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions" xlink:type="locator" xlink:label="ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" xlink:type="locator" xlink:label="bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PurchasesFromRelatedPartyTransactions" xlink:type="locator" xlink:label="bntx_PurchasesFromRelatedPartyTransactions" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_PurchasesFromRelatedPartyTransactions" xlink:to="bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="bntx_PurchasesFromRelatedPartyTransactions" xlink:to="ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>47
<FILENAME>bntx-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-30T14:14:26.4316036+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : a6c3372c9f8947078f9b74c1e02df132 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="bntx-20201231.xsd#TemplateLink" roleURI="http://www.biontech.de/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DocumentDocumentAndEntityInformationDetails" xlink:href="bntx-20201231.xsd#Role_DocumentDocumentAndEntityInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DocumentDocumentAndEntityInformationDetails">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelEmailAddress" xlink:type="locator" xlink:label="dei_ContactPersonnelEmailAddress" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelName" xlink:type="locator" xlink:label="dei_ContactPersonnelName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:type="locator" xlink:label="dei_NoTradingSymbolFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_BusinessContactMember" xlink:type="locator" xlink:label="dei_BusinessContactMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AddressTypeDomain" xlink:type="locator" xlink:label="dei_AddressTypeDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AddressTypeDomain" xlink:type="locator" xlink:label="dei_AddressTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesAddressTypeAxis" xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareOfOneMember" xlink:type="locator" xlink:label="bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareOfOneMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember" xlink:type="locator" xlink:label="bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:type="locator" xlink:label="dei_DocumentInformationTable" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentInformationTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentInformationLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember_2" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareOfOneMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_2" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_NoTradingSymbolFlag" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelEmailAddress" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="11270.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="bntx-20201231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:type="locator" xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareAbstract" xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToAbstract" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceCosts" xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncome" xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:type="locator" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MiscellaneousOtherOperatingExpense" xlink:type="locator" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SalesAndMarketingExpense" xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CostOfSales" xlink:type="locator" xlink:label="ifrs-full_CostOfSales" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:type="locator" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueAbstract" xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CommercialMember" xlink:type="locator" xlink:label="bntx_CommercialMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ResearchAndDevelopmentMember" xlink:type="locator" xlink:label="bntx_ResearchAndDevelopmentMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:type="locator" xlink:label="ifrs-full_ProductsAndServicesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:type="locator" xlink:label="ifrs-full_ProductsAndServicesMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:type="locator" xlink:label="ifrs-full_ProductsAndServicesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeStatementLineItems" xlink:type="locator" xlink:label="bntx_IncomeStatementLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeStatementTable" xlink:type="locator" xlink:label="bntx_IncomeStatementTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAbstract" xlink:type="locator" xlink:label="ifrs-full_ProfitLossAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_ProfitLossAbstract" xlink:to="bntx_IncomeStatementTable" order="10150.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProfitLossAbstract" xlink:to="bntx_IncomeStatementLineItems" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_IncomeStatementTable" xlink:to="ifrs-full_ProductsAndServicesAxis" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember_2" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="bntx_ResearchAndDevelopmentMember" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="bntx_CommercialMember" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_RevenueAbstract" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_CostOfSales" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_SalesAndMarketingExpense" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_MiscellaneousOtherOperatingExpense" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_FinanceIncome" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_FinanceCosts" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_ProfitLossBeforeTax" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_ProfitLoss" order="11370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_ProfitLossAttributableToAbstract" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_EarningsPerShareAbstract" order="11730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_BasicAndDilutedEarningsLossPerShare" order="11850.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="bntx-20201231.xsd#Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncreaseDecreaseThroughSettlementOfSharebasedPaymentPlan" xlink:type="locator" xlink:label="bntx_IncreaseDecreaseThroughSettlementOfSharebasedPaymentPlan" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost" xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncreaseDecreaseThroughAcquisitionOfNoncontrollingInterests" xlink:type="locator" xlink:label="bntx_IncreaseDecreaseThroughAcquisitionOfNoncontrollingInterests" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncreaseDecreaseThroughInitialPublicOffering" xlink:type="locator" xlink:label="bntx_IncreaseDecreaseThroughInitialPublicOffering" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IssuanceOfShareCapital" xlink:type="locator" xlink:label="bntx_IssuanceOfShareCapital" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncome" xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncome" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:type="locator" xlink:label="ifrs-full_Equity" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CapitalIncreaseSeriesBMember" xlink:type="locator" xlink:label="bntx_CapitalIncreaseSeriesBMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterestsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ForeignCurrencyTranslationReserveMember" xlink:type="locator" xlink:label="bntx_ForeignCurrencyTranslationReserveMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReservesMember" xlink:type="locator" xlink:label="ifrs-full_OtherReservesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TreasurySharesMember" xlink:type="locator" xlink:label="ifrs-full_TreasurySharesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CapitalReserveMember" xlink:type="locator" xlink:label="ifrs-full_CapitalReserveMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:type="locator" xlink:label="ifrs-full_EquityMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:type="locator" xlink:label="ifrs-full_EquityMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember_2" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_CapitalReserveMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_TreasurySharesMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncomeMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_OtherReservesMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="bntx_ForeignCurrencyTranslationReserveMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_EquityAttributableToOwnersOfParentMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_NoncontrollingInterestsMember" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="bntx_CapitalIncreaseSeriesBMember" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_OtherComprehensiveIncome" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ComprehensiveIncome" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="bntx_IssuanceOfShareCapital" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="bntx_IncreaseDecreaseThroughInitialPublicOffering" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="bntx_IncreaseDecreaseThroughAcquisitionOfNoncontrollingInterests" order="11890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" order="12110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" order="12330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="bntx_IncreaseDecreaseThroughSettlementOfSharebasedPaymentPlan" order="12550.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinationsTables" xlink:href="bntx-20201231.xsd#Role_DisclosureBusinessCombinationsTables" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinationsTables">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechManufacturingMarburgGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechManufacturingMarburgGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechUSIncMember" xlink:type="locator" xlink:label="bntx_BioNTechUSIncMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LipocalyxGmbHMember" xlink:type="locator" xlink:label="bntx_LipocalyxGmbHMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BusinessCombinationsAxis" xlink:type="locator" xlink:label="ifrs-full_BusinessCombinationsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_BusinessCombinationsAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_2" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="bntx_LipocalyxGmbHMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="bntx_BioNTechUSIncMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="bntx_BioNTechManufacturingMarburgGmbHMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" order="10430.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsTables" xlink:href="bntx-20201231.xsd#Role_DisclosureShareBasedPaymentsTables" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsTables">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss" xlink:type="locator" xlink:label="ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeStockOwnershipPlanMember" xlink:type="locator" xlink:label="bntx_EmployeeStockOwnershipPlanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ChiefExecutiveOfficerGrantMember" xlink:type="locator" xlink:label="bntx_ChiefExecutiveOfficerGrantMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ManagementBoardGrantMember" xlink:type="locator" xlink:label="bntx_ManagementBoardGrantMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeEquityPlanMember" xlink:type="locator" xlink:label="bntx_EmployeeEquityPlanMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_2" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_EmployeeEquityPlanMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_ManagementBoardGrantMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_ChiefExecutiveOfficerGrantMember" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_EmployeeStockOwnershipPlanMember" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" order="11150.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureCorporateInformationAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureCorporateInformationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureCorporateInformationAdditionalInformationDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfNewRealEstateEntitiesFounded" xlink:type="locator" xlink:label="bntx_NumberOfNewRealEstateEntitiesFounded" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_DE" xlink:type="locator" xlink:label="country_DE" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfCorporateInformationLineItems" xlink:type="locator" xlink:label="bntx_DisclosureOfCorporateInformationLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfCorporateInformationTable" xlink:type="locator" xlink:label="bntx_DisclosureOfCorporateInformationTable" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfCorporateInformationExplanatoryAbstract" xlink:type="locator" xlink:label="bntx_DisclosureOfCorporateInformationExplanatoryAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bntx_DisclosureOfCorporateInformationExplanatoryAbstract" xlink:to="bntx_DisclosureOfCorporateInformationTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfCorporateInformationExplanatoryAbstract" xlink:to="bntx_DisclosureOfCorporateInformationLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_DisclosureOfCorporateInformationTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember_2" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_DE" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfCorporateInformationLineItems" xlink:to="bntx_NumberOfNewRealEstateEntitiesFounded" order="10130.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesUsefulLivesAppliedToGroupSPropertyPlantAndEquipmentDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureSignificantAccountingPoliciesUsefulLivesAppliedToGroupSPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesUsefulLivesAppliedToGroupSPropertyPlantAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:type="locator" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EquipmentToolsAndInstallationsMember" xlink:type="locator" xlink:label="bntx_EquipmentToolsAndInstallationsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BuildingsMember" xlink:type="locator" xlink:label="ifrs-full_BuildingsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_2" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_BuildingsMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="bntx_EquipmentToolsAndInstallationsMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="ifrs-full_BottomOfRangeMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="ifrs-full_TopOfRangeMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" order="10230.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesUsefulLivesAppliedToGroupSRightOfUseAssetsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureSignificantAccountingPoliciesUsefulLivesAppliedToGroupSRightOfUseAssetsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesUsefulLivesAppliedToGroupSRightOfUseAssetsDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" xlink:type="locator" xlink:label="bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_VehiclesMember" xlink:type="locator" xlink:label="ifrs-full_VehiclesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ProductionFacilitiesMember" xlink:type="locator" xlink:label="bntx_ProductionFacilitiesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EquipmentToolsAndInstallationsMember" xlink:type="locator" xlink:label="bntx_EquipmentToolsAndInstallationsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BuildingsMember" xlink:type="locator" xlink:label="ifrs-full_BuildingsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="srt_RangeAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="ifrs-full_BottomOfRangeMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="ifrs-full_TopOfRangeMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember_2" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_BuildingsMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="bntx_EquipmentToolsAndInstallationsMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="bntx_ProductionFacilitiesMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_VehiclesMember" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" order="10270.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesUsefulLivesAppliedToGroupSIntangibleAssetsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureSignificantAccountingPoliciesUsefulLivesAppliedToGroupSIntangibleAssetsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesUsefulLivesAppliedToGroupSIntangibleAssetsDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:type="locator" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComputerSoftwareMember" xlink:type="locator" xlink:label="ifrs-full_ComputerSoftwareMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LicencesMember" xlink:type="locator" xlink:label="ifrs-full_LicencesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IntellectualPropertyRightsMember" xlink:type="locator" xlink:label="bntx_IntellectualPropertyRightsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="srt_RangeAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="ifrs-full_BottomOfRangeMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="ifrs-full_TopOfRangeMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_2" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="bntx_IntellectualPropertyRightsMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="ifrs-full_LicencesMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="ifrs-full_ComputerSoftwareMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" order="10250.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptionsScheduleOfProvisionalSalesFiguresForTerritoriesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptionsScheduleOfProvisionalSalesFiguresForTerritoriesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptionsScheduleOfProvisionalSalesFiguresForTerritoriesDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:type="locator" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CollaborationAgreementMember" xlink:type="locator" xlink:label="bntx_CollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:type="locator" xlink:label="ifrs-full_ProductsAndServicesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:type="locator" xlink:label="ifrs-full_ProductsAndServicesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GoodsSoldDirectlyToConsumersMember" xlink:type="locator" xlink:label="ifrs-full_GoodsSoldDirectlyToConsumersMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SalesChannelsMember" xlink:type="locator" xlink:label="ifrs-full_SalesChannelsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SalesChannelsMember" xlink:type="locator" xlink:label="ifrs-full_SalesChannelsMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SalesChannelsAxis" xlink:type="locator" xlink:label="ifrs-full_SalesChannelsAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OutsideUSMember" xlink:type="locator" xlink:label="bntx_OutsideUSMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_DE" xlink:type="locator" xlink:label="country_DE" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsLineItems" xlink:type="locator" xlink:label="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsTable" xlink:type="locator" xlink:label="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsTable" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsAbstract" xlink:type="locator" xlink:label="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsAbstract" xlink:to="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsAbstract" xlink:to="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_DE" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_US" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="bntx_OutsideUSMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsTable" xlink:to="ifrs-full_SalesChannelsAxis" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SalesChannelsAxis" xlink:to="ifrs-full_SalesChannelsMember_2" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SalesChannelsAxis" xlink:to="ifrs-full_SalesChannelsMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SalesChannelsMember" xlink:to="ifrs-full_GoodsSoldDirectlyToConsumersMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsTable" xlink:to="ifrs-full_ProductsAndServicesAxis" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="bntx_CollaborationAgreementMember" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" order="10290.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformationSummaryOfInformationAboutSubsidiariesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureGroupInformationSummaryOfInformationAboutSubsidiariesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformationSummaryOfInformationAboutSubsidiariesDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" xlink:type="locator" xlink:label="ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:type="locator" xlink:label="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechRealEstateAdamOpelStraeGmbHCoKGMember" xlink:type="locator" xlink:label="bntx_BioNTechRealEstateAdamOpelStraeGmbHCoKGMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechRealEstateHausVierGmbHCoKGMember" xlink:type="locator" xlink:label="bntx_BioNTechRealEstateHausVierGmbHCoKGMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechRealEstateDerGoldgrubeGmbHCoKGMember" xlink:type="locator" xlink:label="bntx_BioNTechRealEstateDerGoldgrubeGmbHCoKGMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechRealEstateHoldingGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechRealEstateHoldingGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechRealEstateGmbHAndCoKGMember" xlink:type="locator" xlink:label="bntx_BioNTechRealEstateGmbHAndCoKGMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechUKLimitedMember" xlink:type="locator" xlink:label="bntx_BioNTechUKLimitedMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechRealEstateVerwaltungsGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechRealEstateVerwaltungsGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechPharmaceuticalsAsiaPacificPteLtdMember" xlink:type="locator" xlink:label="bntx_BioNTechPharmaceuticalsAsiaPacificPteLtdMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechUSIncMember" xlink:type="locator" xlink:label="bntx_BioNTechUSIncMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechCellAndGeneTherapiesGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechCellAndGeneTherapiesGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechResearchAndDevelopmentIncMember" xlink:type="locator" xlink:label="bntx_BioNTechResearchAndDevelopmentIncMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechUSAHoldingLLCMember" xlink:type="locator" xlink:label="bntx_BioNTechUSAHoldingLLCMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_JPTPeptideTechnologiesIncMember" xlink:type="locator" xlink:label="bntx_JPTPeptideTechnologiesIncMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_JPTPeptideTechnologiesGmbHMember" xlink:type="locator" xlink:label="bntx_JPTPeptideTechnologiesGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ReSanoGmbHMember" xlink:type="locator" xlink:label="bntx_ReSanoGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechInnovativeManufacturingServicesGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechInnovativeManufacturingServicesGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechAustriaBeteiligungenGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechAustriaBeteiligungenGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechManufacturingMarburgGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechManufacturingMarburgGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechManufacturingGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechManufacturingGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechEuropeGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechEuropeGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechDiagnosticsGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechDiagnosticsGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechDeliveryTechnologiesGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechDeliveryTechnologiesGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechRNAPharmaceuticalsGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechRNAPharmaceuticalsGmbHMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember_2" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechRNAPharmaceuticalsGmbHMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechDeliveryTechnologiesGmbHMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechDiagnosticsGmbHMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechEuropeGmbHMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechManufacturingGmbHMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechManufacturingMarburgGmbHMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechAustriaBeteiligungenGmbHMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechInnovativeManufacturingServicesGmbHMember" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_ReSanoGmbHMember" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_JPTPeptideTechnologiesGmbHMember" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_JPTPeptideTechnologiesIncMember" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechUSAHoldingLLCMember" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechResearchAndDevelopmentIncMember" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechCellAndGeneTherapiesGmbHMember" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechUSIncMember" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechPharmaceuticalsAsiaPacificPteLtdMember" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechRealEstateVerwaltungsGmbHMember" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechUKLimitedMember" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechRealEstateGmbHAndCoKGMember" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechRealEstateHoldingGmbHMember" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechRealEstateDerGoldgrubeGmbHCoKGMember" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechRealEstateHausVierGmbHCoKGMember" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechRealEstateAdamOpelStraeGmbHCoKGMember" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="11570.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformationAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureGroupInformationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformationAdditionalInformationDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfNewEntities" xlink:type="locator" xlink:label="bntx_NumberOfNewEntities" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfEntitiesAcquiredDuringPeriod" xlink:type="locator" xlink:label="bntx_NumberOfEntitiesAcquiredDuringPeriod" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ReSanoGmbHMember" xlink:type="locator" xlink:label="bntx_ReSanoGmbHMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechUSAHoldingLLCAndBioNTechResearchAndDevelopmentIncMember" xlink:type="locator" xlink:label="bntx_BioNTechUSAHoldingLLCAndBioNTechResearchAndDevelopmentIncMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NeonTherapeuticsIncAndNovartisManufacturingGmbHMember" xlink:type="locator" xlink:label="bntx_NeonTherapeuticsIncAndNovartisManufacturingGmbHMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_NeonTherapeuticsIncAndNovartisManufacturingGmbHMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechUSAHoldingLLCAndBioNTechResearchAndDevelopmentIncMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_2" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="bntx_ReSanoGmbHMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="bntx_NumberOfEntitiesAcquiredDuringPeriod" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="bntx_NumberOfNewEntities" order="10250.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformationSummaryOfInformationAboutParentCompanyDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureGroupInformationSummaryOfInformationAboutParentCompanyDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformationSummaryOfInformationAboutParentCompanyDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" xlink:type="locator" xlink:label="ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:type="locator" xlink:label="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ATImpfGmbHMember" xlink:type="locator" xlink:label="bntx_ATImpfGmbHMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechMember" xlink:type="locator" xlink:label="bntx_BioNTechMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:type="locator" xlink:label="srt_OwnershipAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="srt_OwnershipAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_2" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="bntx_BioNTechMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="bntx_ATImpfGmbHMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="10310.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformationSummaryOfInformationAboutEntityWithSignificantInfluenceOverGroupDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureGroupInformationSummaryOfInformationAboutEntityWithSignificantInfluenceOverGroupDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformationSummaryOfInformationAboutEntityWithSignificantInfluenceOverGroupDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" xlink:type="locator" xlink:label="ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:type="locator" xlink:label="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_MedineGmbHMember" xlink:type="locator" xlink:label="bntx_MedineGmbHMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechMember" xlink:type="locator" xlink:label="bntx_BioNTechMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:type="locator" xlink:label="srt_OwnershipAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="srt_OwnershipAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="bntx_BioNTechMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="bntx_MedineGmbHMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="10310.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureBusinessCombinationsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BargainPurchaseGainOnAcquisition" xlink:type="locator" xlink:label="bntx_BargainPurchaseGainOnAcquisition" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital" xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IntangibleAssetsNumberOfNeoantigenTargetedTherapiesUnderDevelopment" xlink:type="locator" xlink:label="bntx_IntangibleAssetsNumberOfNeoantigenTargetedTherapiesUnderDevelopment" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AmericanDepositaryShares" xlink:type="locator" xlink:label="bntx_AmericanDepositaryShares" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConsiderationTransferred" xlink:type="locator" xlink:label="bntx_ConsiderationTransferred" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BusinessCombinationContingentCashConsideration" xlink:type="locator" xlink:label="bntx_BusinessCombinationContingentCashConsideration" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:type="locator" xlink:label="ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:type="locator" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DateOfAcquisition2013" xlink:type="locator" xlink:label="ifrs-full_DateOfAcquisition2013" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashTransferred" xlink:type="locator" xlink:label="ifrs-full_CashTransferred" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NameOfAcquiree" xlink:type="locator" xlink:label="ifrs-full_NameOfAcquiree" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechManufacturingMarburgGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechManufacturingMarburgGmbHMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsUnderDevelopmentMember" xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsUnderDevelopmentMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechUSIncMember" xlink:type="locator" xlink:label="bntx_BioNTechUSIncMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PhaseTwoClinicalTrialMember" xlink:type="locator" xlink:label="bntx_PhaseTwoClinicalTrialMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PhaseOneClinicalTrialMember" xlink:type="locator" xlink:label="bntx_PhaseOneClinicalTrialMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ItemsOfContingentLiabilitiesMember" xlink:type="locator" xlink:label="ifrs-full_ItemsOfContingentLiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ItemsOfContingentLiabilitiesMember" xlink:type="locator" xlink:label="ifrs-full_ItemsOfContingentLiabilitiesMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ItemsOfContingentLiabilitiesAxis" xlink:type="locator" xlink:label="ifrs-full_ItemsOfContingentLiabilitiesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LipocalyxGmbHMember" xlink:type="locator" xlink:label="bntx_LipocalyxGmbHMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BusinessCombinationsAxis" xlink:type="locator" xlink:label="ifrs-full_BusinessCombinationsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_BusinessCombinationsAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="bntx_LipocalyxGmbHMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_ItemsOfContingentLiabilitiesAxis" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ItemsOfContingentLiabilitiesAxis" xlink:to="ifrs-full_ItemsOfContingentLiabilitiesMember_2" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ItemsOfContingentLiabilitiesAxis" xlink:to="ifrs-full_ItemsOfContingentLiabilitiesMember" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ItemsOfContingentLiabilitiesMember" xlink:to="bntx_PhaseOneClinicalTrialMember" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ItemsOfContingentLiabilitiesMember" xlink:to="bntx_PhaseTwoClinicalTrialMember" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="bntx_BioNTechUSIncMember" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="ifrs-full_IntangibleAssetsUnderDevelopmentMember" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="bntx_BioNTechManufacturingMarburgGmbHMember" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_NameOfAcquiree" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_CashTransferred" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DateOfAcquisition2013" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="bntx_BusinessCombinationContingentCashConsideration" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="bntx_ConsiderationTransferred" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="bntx_AmericanDepositaryShares" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="bntx_IntangibleAssetsNumberOfNeoantigenTargetedTherapiesUnderDevelopment" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_IssuedCapital" order="11810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="bntx_BargainPurchaseGainOnAcquisition" order="12030.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfFairValuesOfIdentifiableNetAssetsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureBusinessCombinationsSummaryOfFairValuesOfIdentifiableNetAssetsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfFairValuesOfIdentifiableNetAssetsDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="locator" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashTransferred" xlink:type="locator" xlink:label="ifrs-full_CashTransferred" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SharesIssuedAtFairValue" xlink:type="locator" xlink:label="bntx_SharesIssuedAtFairValue" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" xlink:type="locator" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwillNetOfBargainPurchase" xlink:type="locator" xlink:label="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwillNetOfBargainPurchase" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BargainPurchaseGainOnAcquisition" xlink:type="locator" xlink:label="bntx_BargainPurchaseGainOnAcquisition" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill" xlink:type="locator" xlink:label="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="locator" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LiabilitiesRecognizedAsOfAcquisitionDate" xlink:type="locator" xlink:label="bntx_LiabilitiesRecognizedAsOfAcquisitionDate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherLiabilitiesNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="bntx_OtherLiabilitiesNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TradePayablesRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="bntx_TradePayablesRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ProvisionsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="bntx_ProvisionsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_LiabilitiesAbstract" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AssetsRecognizedAsOfAcquisitionDate" xlink:type="locator" xlink:label="bntx_AssetsRecognizedAsOfAcquisitionDate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_InventoryRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:type="locator" xlink:label="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechManufacturingMarburgGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechManufacturingMarburgGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechUSIncMember" xlink:type="locator" xlink:label="bntx_BioNTechUSIncMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LipocalyxGmbHMember" xlink:type="locator" xlink:label="bntx_LipocalyxGmbHMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BusinessCombinationsAxis" xlink:type="locator" xlink:label="ifrs-full_BusinessCombinationsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable" order="10220.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsLineItems" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_BusinessCombinationsAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="bntx_LipocalyxGmbHMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="bntx_BioNTechUSIncMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="bntx_BioNTechManufacturingMarburgGmbHMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="ifrs-full_InventoryRecognisedAsOfAcquisitionDate" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="bntx_AssetsRecognizedAsOfAcquisitionDate" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="ifrs-full_LiabilitiesAbstract" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="bntx_ProvisionsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="bntx_TradePayablesRecognisedAsOfAcquisitionDate" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="bntx_OtherLiabilitiesNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="bntx_LiabilitiesRecognizedAsOfAcquisitionDate" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="bntx_BargainPurchaseGainOnAcquisition" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwillNetOfBargainPurchase" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" xlink:to="bntx_SharesIssuedAtFairValue" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" xlink:to="ifrs-full_CashTransferred" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" xlink:to="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" xlink:to="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" order="11080.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesFromContractsWithCustomersDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureRevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesFromContractsWithCustomersDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesFromContractsWithCustomersDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:type="locator" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsSatisfiedOverTimeMember" xlink:type="locator" xlink:label="ifrs-full_PerformanceObligationsSatisfiedOverTimeMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember" xlink:type="locator" xlink:label="ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsMember" xlink:type="locator" xlink:label="ifrs-full_PerformanceObligationsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsMember" xlink:type="locator" xlink:label="ifrs-full_PerformanceObligationsMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsAxis" xlink:type="locator" xlink:label="ifrs-full_PerformanceObligationsAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CommercialMember" xlink:type="locator" xlink:label="bntx_CommercialMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ResearchAndDevelopmentMember" xlink:type="locator" xlink:label="bntx_ResearchAndDevelopmentMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:type="locator" xlink:label="ifrs-full_ProductsAndServicesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:type="locator" xlink:label="ifrs-full_ProductsAndServicesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherSalesMember" xlink:type="locator" xlink:label="bntx_OtherSalesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ShareOfCollaborationPartnersGrossProfitMember" xlink:type="locator" xlink:label="bntx_ShareOfCollaborationPartnersGrossProfitMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DirectProductSalesToBioNTechCustomersMember" xlink:type="locator" xlink:label="bntx_DirectProductSalesToBioNTechCustomersMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SalesToCollaborationPartnerMember" xlink:type="locator" xlink:label="bntx_SalesToCollaborationPartnerMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_COVID19VaccineRevenuesMember" xlink:type="locator" xlink:label="bntx_COVID19VaccineRevenuesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherMember" xlink:type="locator" xlink:label="bntx_OtherMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ShanghaiFosunPharmaceuticalGroupCoLtdMember" xlink:type="locator" xlink:label="bntx_ShanghaiFosunPharmaceuticalGroupCoLtdMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GenentechIncMember" xlink:type="locator" xlink:label="bntx_GenentechIncMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PfizerIncMember" xlink:type="locator" xlink:label="bntx_PfizerIncMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorCustomersMember" xlink:type="locator" xlink:label="ifrs-full_MajorCustomersMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorCustomersMember" xlink:type="locator" xlink:label="ifrs-full_MajorCustomersMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorCustomersAxis" xlink:type="locator" xlink:label="ifrs-full_MajorCustomersAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_MajorCustomersAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember_2" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_PfizerIncMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_GenentechIncMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_ShanghaiFosunPharmaceuticalGroupCoLtdMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_OtherMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_COVID19VaccineRevenuesMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_SalesToCollaborationPartnerMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_DirectProductSalesToBioNTechCustomersMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_ShareOfCollaborationPartnersGrossProfitMember" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_OtherSalesMember" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_ProductsAndServicesAxis" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="bntx_ResearchAndDevelopmentMember" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="bntx_CommercialMember" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_PerformanceObligationsAxis" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_PerformanceObligationsAxis" xlink:to="ifrs-full_PerformanceObligationsMember_2" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_PerformanceObligationsAxis" xlink:to="ifrs-full_PerformanceObligationsMember" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PerformanceObligationsMember" xlink:to="ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PerformanceObligationsMember" xlink:to="ifrs-full_PerformanceObligationsSatisfiedOverTimeMember" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" order="10630.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAdvances" xlink:type="locator" xlink:label="ifrs-full_CurrentAdvances" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale" xlink:type="locator" xlink:label="bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RemainingUpfrontFeesContractLiabilities" xlink:type="locator" xlink:label="bntx_RemainingUpfrontFeesContractLiabilities" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TradeReceivableMaturityPeriod" xlink:type="locator" xlink:label="bntx_TradeReceivableMaturityPeriod" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConditionalMarketingAuthorizationCountries" xlink:type="locator" xlink:label="bntx_ConditionalMarketingAuthorizationCountries" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SublicenseAgreementDate" xlink:type="locator" xlink:label="bntx_SublicenseAgreementDate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PercentageOfReimbursementOfSublicenseCosts" xlink:type="locator" xlink:label="bntx_PercentageOfReimbursementOfSublicenseCosts" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RevenuesDerivedFromDeferredUpfrontPayments" xlink:type="locator" xlink:label="bntx_RevenuesDerivedFromDeferredUpfrontPayments" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_MilestonePaymentRecognizedAsRevenue" xlink:type="locator" xlink:label="bntx_MilestonePaymentRecognizedAsRevenue" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NonRefundableUpfrontCashPayment" xlink:type="locator" xlink:label="bntx_NonRefundableUpfrontCashPayment" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RevenueFromCollaboration" xlink:type="locator" xlink:label="bntx_RevenueFromCollaboration" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:type="locator" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:type="locator" xlink:label="ifrs-full_PercentageOfEntitysRevenue" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfCustomers" xlink:type="locator" xlink:label="bntx_NumberOfCustomers" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BillAndHoldTransactionMember" xlink:type="locator" xlink:label="bntx_BillAndHoldTransactionMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherSalesTransactionsMember" xlink:type="locator" xlink:label="bntx_OtherSalesTransactionsMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RevenueFromShareOfCollaborationPartnersGrossProfitMember" xlink:type="locator" xlink:label="bntx_RevenueFromShareOfCollaborationPartnersGrossProfitMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_DE" xlink:type="locator" xlink:label="country_DE" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechMember" xlink:type="locator" xlink:label="bntx_BioNTechMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RevenuesFromSellingDrugProductBatchesToPfizersManufacturingSiteMember" xlink:type="locator" xlink:label="bntx_RevenuesFromSellingDrugProductBatchesToPfizersManufacturingSiteMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CommercialMember" xlink:type="locator" xlink:label="bntx_CommercialMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CellscriptSublicenseMember" xlink:type="locator" xlink:label="bntx_CellscriptSublicenseMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember" xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember" xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis" xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FosunPharmaMember" xlink:type="locator" xlink:label="bntx_FosunPharmaMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ResearchAndDevelopmentMember" xlink:type="locator" xlink:label="bntx_ResearchAndDevelopmentMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:type="locator" xlink:label="ifrs-full_ProductsAndServicesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:type="locator" xlink:label="ifrs-full_ProductsAndServicesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SanofiSAMember" xlink:type="locator" xlink:label="bntx_SanofiSAMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GenentechIncMember" xlink:type="locator" xlink:label="bntx_GenentechIncMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PfizerIncMember" xlink:type="locator" xlink:label="bntx_PfizerIncMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorCustomersMember" xlink:type="locator" xlink:label="ifrs-full_MajorCustomersMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorCustomersAxis" xlink:type="locator" xlink:label="ifrs-full_MajorCustomersAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_MajorCustomersAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_PfizerIncMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_GenentechIncMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_SanofiSAMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="srt_RangeAxis" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="ifrs-full_BottomOfRangeMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="ifrs-full_TopOfRangeMember" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_ProductsAndServicesAxis" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="bntx_ResearchAndDevelopmentMember" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_FosunPharmaMember" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis" xlink:to="ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember_2" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis" xlink:to="ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember" xlink:to="bntx_CellscriptSublicenseMember" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="bntx_CommercialMember" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_RevenuesFromSellingDrugProductBatchesToPfizersManufacturingSiteMember" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_BioNTechMember" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="srt_StatementGeographicalAxis" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_DE" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_RevenueFromShareOfCollaborationPartnersGrossProfitMember" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="bntx_OtherSalesTransactionsMember" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="bntx_BillAndHoldTransactionMember" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="bntx_NumberOfCustomers" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_PercentageOfEntitysRevenue" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" order="11970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="bntx_RevenueFromCollaboration" order="12370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="bntx_NonRefundableUpfrontCashPayment" order="12390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="bntx_MilestonePaymentRecognizedAsRevenue" order="12450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="bntx_RevenuesDerivedFromDeferredUpfrontPayments" order="12590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="bntx_PercentageOfReimbursementOfSublicenseCosts" order="12670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="bntx_SublicenseAgreementDate" order="12690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="bntx_ConditionalMarketingAuthorizationCountries" order="12750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="bntx_TradeReceivableMaturityPeriod" order="13150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="bntx_RemainingUpfrontFeesContractLiabilities" order="13230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale" order="13270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_CurrentAdvances" order="13310.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfContractLiabilitiesAllocatedToRemainingPerformanceObligationsUnsatisfiedOrPartiallyUnsatisfiedDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureRevenueFromContractsWithCustomersSummaryOfContractLiabilitiesAllocatedToRemainingPerformanceObligationsUnsatisfiedOrPartiallyUnsatisfiedDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfContractLiabilitiesAllocatedToRemainingPerformanceObligationsUnsatisfiedOrPartiallyUnsatisfiedDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContractLiabilities" xlink:type="locator" xlink:label="ifrs-full_ContractLiabilities" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_UnsatisfiedOrPartiallyUnsatisfiedMember" xlink:type="locator" xlink:label="bntx_UnsatisfiedOrPartiallyUnsatisfiedMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsMember" xlink:type="locator" xlink:label="ifrs-full_PerformanceObligationsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsAxis" xlink:type="locator" xlink:label="ifrs-full_PerformanceObligationsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanOneYearMember" xlink:type="locator" xlink:label="ifrs-full_LaterThanOneYearMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:type="locator" xlink:label="ifrs-full_NotLaterThanOneYearMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:type="locator" xlink:label="ifrs-full_AggregatedTimeBandsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:type="locator" xlink:label="ifrs-full_AggregatedTimeBandsMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:type="locator" xlink:label="ifrs-full_MaturityAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPerformanceObligationsLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPerformanceObligationsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPerformanceObligationsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPerformanceObligationsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPerformanceObligationsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsAbstract" xlink:to="ifrs-full_DisclosureOfPerformanceObligationsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsAbstract" xlink:to="ifrs-full_DisclosureOfPerformanceObligationsLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsTable" xlink:to="ifrs-full_MaturityAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember_2" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_NotLaterThanOneYearMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanOneYearMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsTable" xlink:to="ifrs-full_PerformanceObligationsAxis" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_PerformanceObligationsAxis" xlink:to="ifrs-full_PerformanceObligationsMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PerformanceObligationsMember" xlink:to="bntx_UnsatisfiedOrPartiallyUnsatisfiedMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="ifrs-full_ContractLiabilities" order="10250.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesCostOfSalesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeAndExpensesCostOfSalesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesCostOfSalesDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CostOfSales" xlink:type="locator" xlink:label="ifrs-full_CostOfSales" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherSalesMember" xlink:type="locator" xlink:label="bntx_OtherSalesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_COVID19VaccineRevenuesMember" xlink:type="locator" xlink:label="bntx_COVID19VaccineRevenuesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorCustomersMember" xlink:type="locator" xlink:label="ifrs-full_MajorCustomersMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorCustomersAxis" xlink:type="locator" xlink:label="ifrs-full_MajorCustomersAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CommercialMember" xlink:type="locator" xlink:label="bntx_CommercialMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:type="locator" xlink:label="ifrs-full_ProductsAndServicesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:type="locator" xlink:label="ifrs-full_ProductsAndServicesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:type="locator" xlink:label="bntx_DisclosureOfIncomeAndExpensesLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIncomeAndExpensesTable" xlink:type="locator" xlink:label="bntx_DisclosureOfIncomeAndExpensesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="locator" xlink:label="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_DisclosureOfIncomeAndExpensesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_DisclosureOfIncomeAndExpensesLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_DisclosureOfIncomeAndExpensesTable" xlink:to="ifrs-full_ProductsAndServicesAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="bntx_CommercialMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_DisclosureOfIncomeAndExpensesTable" xlink:to="ifrs-full_MajorCustomersAxis" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_COVID19VaccineRevenuesMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_OtherSalesMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:to="ifrs-full_CostOfSales" order="10250.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesResearchAndDevelopmentExpensesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeAndExpensesResearchAndDevelopmentExpensesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesResearchAndDevelopmentExpensesDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:type="locator" xlink:label="ifrs-full_AccumulatedDepreciationAndAmortisationMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:type="locator" xlink:label="ifrs-full_CarryingAmountMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:type="locator" xlink:label="ifrs-full_CarryingAmountMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TransportCostsMember" xlink:type="locator" xlink:label="bntx_TransportCostsMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ITCostsMember" xlink:type="locator" xlink:label="bntx_ITCostsMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherIncomeExpenseMember" xlink:type="locator" xlink:label="bntx_OtherIncomeExpenseMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LeaseAndLeaseRelatedCostMember" xlink:type="locator" xlink:label="bntx_LeaseAndLeaseRelatedCostMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PurchasedServicesMember" xlink:type="locator" xlink:label="bntx_PurchasedServicesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LaboratorySuppliesMember" xlink:type="locator" xlink:label="bntx_LaboratorySuppliesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_WagesBenefitsAndSocialSecurityExpenseMember" xlink:type="locator" xlink:label="bntx_WagesBenefitsAndSocialSecurityExpenseMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeAndExpensesByNatureMember" xlink:type="locator" xlink:label="bntx_IncomeAndExpensesByNatureMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeAndExpensesByNatureMember" xlink:type="locator" xlink:label="bntx_IncomeAndExpensesByNatureMember_2" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeAndExpensesByNatureAxis" xlink:type="locator" xlink:label="bntx_IncomeAndExpensesByNatureAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:type="locator" xlink:label="bntx_DisclosureOfIncomeAndExpensesLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIncomeAndExpensesTable" xlink:type="locator" xlink:label="bntx_DisclosureOfIncomeAndExpensesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="locator" xlink:label="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_DisclosureOfIncomeAndExpensesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_DisclosureOfIncomeAndExpensesLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_DisclosureOfIncomeAndExpensesTable" xlink:to="bntx_IncomeAndExpensesByNatureAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="bntx_IncomeAndExpensesByNatureAxis" xlink:to="bntx_IncomeAndExpensesByNatureMember_2" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="bntx_IncomeAndExpensesByNatureAxis" xlink:to="bntx_IncomeAndExpensesByNatureMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_WagesBenefitsAndSocialSecurityExpenseMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_LaboratorySuppliesMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_PurchasedServicesMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_LeaseAndLeaseRelatedCostMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_OtherIncomeExpenseMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_ITCostsMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_TransportCostsMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_DisclosureOfIncomeAndExpensesTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember_2" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_AccumulatedDepreciationAndAmortisationMember" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="10310.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeAndExpensesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesAdditionalInformationDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" xlink:type="locator" xlink:label="bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetForeignExchangeLoss" xlink:type="locator" xlink:label="ifrs-full_NetForeignExchangeLoss" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetForeignExchangeGain" xlink:type="locator" xlink:label="ifrs-full_NetForeignExchangeGain" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentGovernmentGrants" xlink:type="locator" xlink:label="ifrs-full_CurrentGovernmentGrants" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:type="locator" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ChargeInConnectionWithCertainWithholdingTaxPaymentsForIntellectualPropertyLicenses" xlink:type="locator" xlink:label="bntx_ChargeInConnectionWithCertainWithholdingTaxPaymentsForIntellectualPropertyLicenses" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_DE" xlink:type="locator" xlink:label="country_DE" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GovernmentGrantsMember" xlink:type="locator" xlink:label="bntx_GovernmentGrantsMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeAndExpensesByNatureMember" xlink:type="locator" xlink:label="bntx_IncomeAndExpensesByNatureMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeAndExpensesByNatureAxis" xlink:type="locator" xlink:label="bntx_IncomeAndExpensesByNatureAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="bntx_GeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NatureOfExpensesMember" xlink:type="locator" xlink:label="bntx_NatureOfExpensesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NatureOfExpensesMember" xlink:type="locator" xlink:label="bntx_NatureOfExpensesMember_2" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NatureOfExpensesAxis" xlink:type="locator" xlink:label="bntx_NatureOfExpensesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechUSIncMember" xlink:type="locator" xlink:label="bntx_BioNTechUSIncMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:type="locator" xlink:label="bntx_DisclosureOfIncomeAndExpensesLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIncomeAndExpensesTable" xlink:type="locator" xlink:label="bntx_DisclosureOfIncomeAndExpensesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="locator" xlink:label="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_DisclosureOfIncomeAndExpensesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_DisclosureOfIncomeAndExpensesLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_DisclosureOfIncomeAndExpensesTable" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechUSIncMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_DisclosureOfIncomeAndExpensesTable" xlink:to="bntx_NatureOfExpensesAxis" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="bntx_NatureOfExpensesAxis" xlink:to="bntx_NatureOfExpensesMember_2" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="bntx_NatureOfExpensesAxis" xlink:to="bntx_NatureOfExpensesMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_NatureOfExpensesMember" xlink:to="bntx_GeneralAndAdministrativeExpensesMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_DisclosureOfIncomeAndExpensesTable" xlink:to="bntx_IncomeAndExpensesByNatureAxis" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="bntx_IncomeAndExpensesByNatureAxis" xlink:to="bntx_IncomeAndExpensesByNatureMember" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_GovernmentGrantsMember" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_DisclosureOfIncomeAndExpensesTable" xlink:to="srt_StatementGeographicalAxis" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_DE" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:to="bntx_ChargeInConnectionWithCertainWithholdingTaxPaymentsForIntellectualPropertyLicenses" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:to="ifrs-full_CurrentGovernmentGrants" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:to="ifrs-full_NetForeignExchangeGain" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:to="ifrs-full_NetForeignExchangeLoss" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:to="bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" order="10730.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesSalesAndMarketingExpensesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeAndExpensesSalesAndMarketingExpensesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesSalesAndMarketingExpensesDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SalesAndMarketingExpense" xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherIncomeExpenseMember" xlink:type="locator" xlink:label="bntx_OtherIncomeExpenseMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PurchasedServicesMember" xlink:type="locator" xlink:label="bntx_PurchasedServicesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_WagesBenefitsAndSocialSecurityExpenseMember" xlink:type="locator" xlink:label="bntx_WagesBenefitsAndSocialSecurityExpenseMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeAndExpensesByNatureMember" xlink:type="locator" xlink:label="bntx_IncomeAndExpensesByNatureMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeAndExpensesByNatureAxis" xlink:type="locator" xlink:label="bntx_IncomeAndExpensesByNatureAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:type="locator" xlink:label="bntx_DisclosureOfIncomeAndExpensesLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIncomeAndExpensesTable" xlink:type="locator" xlink:label="bntx_DisclosureOfIncomeAndExpensesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="locator" xlink:label="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_DisclosureOfIncomeAndExpensesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_DisclosureOfIncomeAndExpensesLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_DisclosureOfIncomeAndExpensesTable" xlink:to="bntx_IncomeAndExpensesByNatureAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="bntx_IncomeAndExpensesByNatureAxis" xlink:to="bntx_IncomeAndExpensesByNatureMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_WagesBenefitsAndSocialSecurityExpenseMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_PurchasedServicesMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_OtherIncomeExpenseMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:to="ifrs-full_SalesAndMarketingExpense" order="10170.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesGeneralAndAdministrativeExpensesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeAndExpensesGeneralAndAdministrativeExpensesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesGeneralAndAdministrativeExpensesDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ContractStaffingMember" xlink:type="locator" xlink:label="bntx_ContractStaffingMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_JobAdvertisementExpensesMember" xlink:type="locator" xlink:label="bntx_JobAdvertisementExpensesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LaboratorySuppliesMember" xlink:type="locator" xlink:label="bntx_LaboratorySuppliesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ResearchServicesMember" xlink:type="locator" xlink:label="bntx_ResearchServicesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_InsurancePremiumsMember" xlink:type="locator" xlink:label="bntx_InsurancePremiumsMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherIncomeExpenseMember" xlink:type="locator" xlink:label="bntx_OtherIncomeExpenseMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LeaseAndLeaseRelatedCostMember" xlink:type="locator" xlink:label="bntx_LeaseAndLeaseRelatedCostMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PurchasedServicesMember" xlink:type="locator" xlink:label="bntx_PurchasedServicesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_WagesBenefitsAndSocialSecurityExpenseMember" xlink:type="locator" xlink:label="bntx_WagesBenefitsAndSocialSecurityExpenseMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeAndExpensesByNatureMember" xlink:type="locator" xlink:label="bntx_IncomeAndExpensesByNatureMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeAndExpensesByNatureAxis" xlink:type="locator" xlink:label="bntx_IncomeAndExpensesByNatureAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OfficeEquipmentMember" xlink:type="locator" xlink:label="ifrs-full_OfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:type="locator" xlink:label="ifrs-full_AccumulatedDepreciationAndAmortisationMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:type="locator" xlink:label="ifrs-full_CarryingAmountMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:type="locator" xlink:label="bntx_DisclosureOfIncomeAndExpensesLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIncomeAndExpensesTable" xlink:type="locator" xlink:label="bntx_DisclosureOfIncomeAndExpensesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="locator" xlink:label="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_DisclosureOfIncomeAndExpensesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_DisclosureOfIncomeAndExpensesLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_DisclosureOfIncomeAndExpensesTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_AccumulatedDepreciationAndAmortisationMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_DisclosureOfIncomeAndExpensesTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OfficeEquipmentMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_DisclosureOfIncomeAndExpensesTable" xlink:to="bntx_IncomeAndExpensesByNatureAxis" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="bntx_IncomeAndExpensesByNatureAxis" xlink:to="bntx_IncomeAndExpensesByNatureMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_WagesBenefitsAndSocialSecurityExpenseMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_PurchasedServicesMember" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_LeaseAndLeaseRelatedCostMember" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_OtherIncomeExpenseMember" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_InsurancePremiumsMember" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_ResearchServicesMember" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_LaboratorySuppliesMember" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_JobAdvertisementExpensesMember" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_ContractStaffingMember" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="10410.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesOtherOperatingIncomeDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeAndExpensesOtherOperatingIncomeDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesOtherOperatingIncomeDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:type="locator" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherIncomeExpenseMember" xlink:type="locator" xlink:label="bntx_OtherIncomeExpenseMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BargainPurchaseMember" xlink:type="locator" xlink:label="bntx_BargainPurchaseMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GovernmentGrantsMember" xlink:type="locator" xlink:label="bntx_GovernmentGrantsMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeAndExpensesByNatureMember" xlink:type="locator" xlink:label="bntx_IncomeAndExpensesByNatureMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeAndExpensesByNatureAxis" xlink:type="locator" xlink:label="bntx_IncomeAndExpensesByNatureAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:type="locator" xlink:label="bntx_DisclosureOfIncomeAndExpensesLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIncomeAndExpensesTable" xlink:type="locator" xlink:label="bntx_DisclosureOfIncomeAndExpensesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="locator" xlink:label="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_DisclosureOfIncomeAndExpensesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_DisclosureOfIncomeAndExpensesLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_DisclosureOfIncomeAndExpensesTable" xlink:to="bntx_IncomeAndExpensesByNatureAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="bntx_IncomeAndExpensesByNatureAxis" xlink:to="bntx_IncomeAndExpensesByNatureMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_GovernmentGrantsMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_BargainPurchaseMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_OtherIncomeExpenseMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome" order="10170.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeTaxAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AccumulatedTaxLossesInStateTaxCredits" xlink:type="locator" xlink:label="bntx_AccumulatedTaxLossesInStateTaxCredits" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AccumulatedTaxLossesInFederalTaxCredits" xlink:type="locator" xlink:label="bntx_AccumulatedTaxLossesInFederalTaxCredits" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_StateTaxLossesExpirationYear" xlink:type="locator" xlink:label="bntx_StateTaxLossesExpirationYear" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_StateDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="locator" xlink:label="bntx_StateDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="locator" xlink:label="bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FederalTaxLossesExpirationYear" xlink:type="locator" xlink:label="bntx_FederalTaxLossesExpirationYear" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsExpectedToExpire" xlink:type="locator" xlink:label="bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsExpectedToExpire" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_DeferredTaxLiabilityAsset" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredTaxAssetsForUnusedTaxLossesRecognized" xlink:type="locator" xlink:label="bntx_DeferredTaxAssetsForUnusedTaxLossesRecognized" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AccumulatedTaxLossesInTradeTax" xlink:type="locator" xlink:label="bntx_AccumulatedTaxLossesInTradeTax" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AccumulatedTaxLossesInCorporateTax" xlink:type="locator" xlink:label="bntx_AccumulatedTaxLossesInCorporateTax" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AverageEffectiveTaxRate" xlink:type="locator" xlink:label="ifrs-full_AverageEffectiveTaxRate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ApplicableTaxRate" xlink:type="locator" xlink:label="ifrs-full_ApplicableTaxRate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ChangeInAverageTradeTaxRate" xlink:type="locator" xlink:label="bntx_ChangeInAverageTradeTaxRate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SolidaritySurchargeRate" xlink:type="locator" xlink:label="bntx_SolidaritySurchargeRate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CorporateIncomeTaxRate" xlink:type="locator" xlink:label="bntx_CorporateIncomeTaxRate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_UnitedStatesTaxGroupMember" xlink:type="locator" xlink:label="bntx_UnitedStatesTaxGroupMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GermanEntitiesNotWithinTaxGroupMember" xlink:type="locator" xlink:label="bntx_GermanEntitiesNotWithinTaxGroupMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GermanTaxGroupMember" xlink:type="locator" xlink:label="bntx_GermanTaxGroupMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:type="locator" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:type="locator" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:type="locator" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechUSAHoldingLLCMember" xlink:type="locator" xlink:label="bntx_BioNTechUSAHoldingLLCMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechUSAHoldingLLCMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="bntx_GermanTaxGroupMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="bntx_GermanEntitiesNotWithinTaxGroupMember" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="bntx_UnitedStatesTaxGroupMember" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="bntx_CorporateIncomeTaxRate" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="bntx_SolidaritySurchargeRate" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="bntx_ChangeInAverageTradeTaxRate" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_ApplicableTaxRate" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_AverageEffectiveTaxRate" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="bntx_AccumulatedTaxLossesInCorporateTax" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="bntx_AccumulatedTaxLossesInTradeTax" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="bntx_DeferredTaxAssetsForUnusedTaxLossesRecognized" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_DeferredTaxLiabilityAsset" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsExpectedToExpire" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="bntx_FederalTaxLossesExpirationYear" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="bntx_StateDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="bntx_StateTaxLossesExpirationYear" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="bntx_AccumulatedTaxLossesInFederalTaxCredits" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="bntx_AccumulatedTaxLossesInStateTaxCredits" order="11090.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeTaxSummaryOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="locator" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TaxEffectOfTaxCredit" xlink:type="locator" xlink:label="bntx_TaxEffectOfTaxCredit" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfForeignTaxRates" xlink:type="locator" xlink:label="ifrs-full_TaxEffectOfForeignTaxRates" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:type="locator" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TaxEffectOfNonrecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences" xlink:type="locator" xlink:label="bntx_TaxEffectOfNonrecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfTaxLosses" xlink:type="locator" xlink:label="ifrs-full_TaxEffectOfTaxLosses" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TaxEffectiveEquityTransactionCosts" xlink:type="locator" xlink:label="bntx_TaxEffectiveEquityTransactionCosts" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses" xlink:type="locator" xlink:label="bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NonTaxEffectiveBargainPurchase" xlink:type="locator" xlink:label="bntx_NonTaxEffectiveBargainPurchase" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AddBackForTradeTaxPurposes" xlink:type="locator" xlink:label="bntx_AddBackForTradeTaxPurposes" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:type="locator" xlink:label="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GovernmentGrantsExemptedFromTaxes" xlink:type="locator" xlink:label="bntx_GovernmentGrantsExemptedFromTaxes" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:type="locator" xlink:label="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:type="locator" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceMember" xlink:type="locator" xlink:label="ifrs-full_TemporaryDifferenceMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxLossesMember" xlink:type="locator" xlink:label="ifrs-full_UnusedTaxLossesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:type="locator" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:type="locator" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:type="locator" xlink:label="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeTable" xlink:type="locator" xlink:label="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeTable" order="10160.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeTable" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="ifrs-full_UnusedTaxLossesMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="ifrs-full_TemporaryDifferenceMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="ifrs-full_ProfitLossBeforeTax" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="bntx_GovernmentGrantsExemptedFromTaxes" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="bntx_AddBackForTradeTaxPurposes" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="bntx_NonTaxEffectiveBargainPurchase" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="bntx_TaxEffectiveEquityTransactionCosts" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="ifrs-full_TaxEffectOfTaxLosses" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="bntx_TaxEffectOfNonrecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="ifrs-full_TaxEffectOfForeignTaxRates" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="bntx_TaxEffectOfTaxCredit" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="11460.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxSummaryOfDeferredTaxesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeTaxSummaryOfDeferredTaxesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxSummaryOfDeferredTaxesDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" xlink:type="locator" xlink:label="bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="locator" xlink:label="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_DeferredTaxLiabilityAsset" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxCreditsMember" xlink:type="locator" xlink:label="ifrs-full_UnusedTaxCreditsMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherDeferredTaxesMember" xlink:type="locator" xlink:label="bntx_OtherDeferredTaxesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:type="locator" xlink:label="ifrs-full_NetDefinedBenefitLiabilityAssetMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ProvisionsMember" xlink:type="locator" xlink:label="bntx_ProvisionsMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_InterestBearingLoansAndBorrowingsMember" xlink:type="locator" xlink:label="bntx_InterestBearingLoansAndBorrowingsMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ContractLiabilitiesMember" xlink:type="locator" xlink:label="bntx_ContractLiabilitiesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LeasesMember" xlink:type="locator" xlink:label="bntx_LeasesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_InventoryMember" xlink:type="locator" xlink:label="bntx_InventoryMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FixedAssetsMember" xlink:type="locator" xlink:label="bntx_FixedAssetsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:type="locator" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:type="locator" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ValuationAdjustmentMember" xlink:type="locator" xlink:label="bntx_ValuationAdjustmentMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GrossCarryingAmountMember" xlink:type="locator" xlink:label="ifrs-full_GrossCarryingAmountMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:type="locator" xlink:label="ifrs-full_CarryingAmountMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_NetDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_NetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="bntx_ValuationAdjustmentMember" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="bntx_FixedAssetsMember" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="bntx_InventoryMember" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="bntx_LeasesMember" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="bntx_ContractLiabilitiesMember" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="bntx_InterestBearingLoansAndBorrowingsMember" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="bntx_ProvisionsMember" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="ifrs-full_NetDefinedBenefitLiabilityAssetMember" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="bntx_OtherDeferredTaxesMember" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="ifrs-full_UnusedTaxCreditsMember" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_DeferredTaxLiabilityAsset" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" order="11790.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" xlink:href="bntx-20201231.xsd#Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ReclassificationsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="bntx_ReclassificationsPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GrossCarryingAmountMember" xlink:type="locator" xlink:label="ifrs-full_GrossCarryingAmountMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:type="locator" xlink:label="ifrs-full_CarryingAmountMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConstructionInProgressAndAdvancePaymentsMember" xlink:type="locator" xlink:label="bntx_ConstructionInProgressAndAdvancePaymentsMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EquipmentToolsAndInstallationsMember" xlink:type="locator" xlink:label="bntx_EquipmentToolsAndInstallationsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LandAndBuildingsMember" xlink:type="locator" xlink:label="ifrs-full_LandAndBuildingsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_LandAndBuildingsMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="bntx_EquipmentToolsAndInstallationsMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="bntx_ConstructionInProgressAndAdvancePaymentsMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="bntx_ReclassificationsPropertyPlantAndEquipment" order="11390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" order="11590.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfDetailedInformationAboutIntangibleAssetsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIntangibleAssetsSummaryOfDetailedInformationAboutIntangibleAssetsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfDetailedInformationAboutIntangibleAssetsDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="locator" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsOtherThanGoodwill" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsOtherThanGoodwill" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:type="locator" xlink:label="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AccumulatedDepreciationAmortisationAndImpairment" xlink:type="locator" xlink:label="bntx_AccumulatedDepreciationAmortisationAndImpairment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GrossCarryingAmountMember" xlink:type="locator" xlink:label="ifrs-full_GrossCarryingAmountMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:type="locator" xlink:label="ifrs-full_CarryingAmountMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AdvancePaymentsMember" xlink:type="locator" xlink:label="bntx_AdvancePaymentsMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember" xlink:type="locator" xlink:label="bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GoodwillMember" xlink:type="locator" xlink:label="ifrs-full_GoodwillMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillMember_2" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="ifrs-full_GoodwillMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="bntx_AdvancePaymentsMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="bntx_AccumulatedDepreciationAmortisationAndImpairment" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsOtherThanGoodwill" order="11390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" order="11590.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfGoodwillRecognizedDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIntangibleAssetsSummaryOfGoodwillRecognizedDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfGoodwillRecognizedDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Goodwill" xlink:type="locator" xlink:label="ifrs-full_Goodwill" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ExternalProductSalesOfJPTMember" xlink:type="locator" xlink:label="bntx_ExternalProductSalesOfJPTMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CGUImmunotherapiesMember" xlink:type="locator" xlink:label="bntx_CGUImmunotherapiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ConsolidatedStructuredEntitiesAxis" xlink:type="locator" xlink:label="ifrs-full_ConsolidatedStructuredEntitiesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_ConsolidatedStructuredEntitiesAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ConsolidatedStructuredEntitiesAxis" xlink:to="ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_2" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ConsolidatedStructuredEntitiesAxis" xlink:to="ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:to="bntx_CGUImmunotherapiesMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:to="bntx_ExternalProductSalesOfJPTMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_Goodwill" order="10190.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssets" xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncreaseInGrowthRateCashFlowProjections" xlink:type="locator" xlink:label="bntx_IncreaseInGrowthRateCashFlowProjections" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows" xlink:type="locator" xlink:label="ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SubsidiariesMember" xlink:type="locator" xlink:label="ifrs-full_SubsidiariesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ExternalProductSalesOfJPTMember" xlink:type="locator" xlink:label="bntx_ExternalProductSalesOfJPTMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CGUImmunotherapiesMember" xlink:type="locator" xlink:label="bntx_CGUImmunotherapiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ConsolidatedStructuredEntitiesAxis" xlink:type="locator" xlink:label="ifrs-full_ConsolidatedStructuredEntitiesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_ConsolidatedStructuredEntitiesAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ConsolidatedStructuredEntitiesAxis" xlink:to="ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:to="bntx_CGUImmunotherapiesMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:to="bntx_ExternalProductSalesOfJPTMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="ifrs-full_SubsidiariesMember" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_US" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="bntx_IncreaseInGrowthRateCashFlowProjections" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_NoncurrentAssets" order="10730.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialAssetsAtAmortizedCostDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialAssetsAtAmortizedCostDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialAssetsAtAmortizedCostDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentFinancialAssetsAtAmortisedCost" xlink:type="locator" xlink:label="ifrs-full_NoncurrentFinancialAssetsAtAmortisedCost" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentFinancialAssetsAtAmortisedCost" xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialAssetsAtAmortisedCost" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsAtAmortisedCost" xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherFinancialAssetsMember" xlink:type="locator" xlink:label="bntx_OtherFinancialAssetsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeReceivablesMember" xlink:type="locator" xlink:label="ifrs-full_TradeReceivablesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsMember" xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsMember" xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsLineItems" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialAssetsTable" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsMember_2" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="ifrs-full_TradeReceivablesMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="bntx_OtherFinancialAssetsMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_CurrentFinancialAssetsAtAmortisedCost" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_NoncurrentFinancialAssetsAtAmortisedCost" order="10330.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialLiabilitiesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialLiabilitiesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentFinancialLiabilities" xlink:type="locator" xlink:label="ifrs-full_NoncurrentFinancialLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentFinancialLiabilities" xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilities" xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DerivativeFinancialLiabilitiesNotDesignatedAsHedgingInstrumentsAtFairValue" xlink:type="locator" xlink:label="bntx_DerivativeFinancialLiabilitiesNotDesignatedAsHedgingInstrumentsAtFairValue" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentFinancialLiabilitiesAtAmortisedCost" xlink:type="locator" xlink:label="ifrs-full_NoncurrentFinancialLiabilitiesAtAmortisedCost" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentFinancialLiabilitiesAtAmortisedCost" xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialLiabilitiesAtAmortisedCost" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherFinancialLiabilitiesMember" xlink:type="locator" xlink:label="bntx_OtherFinancialLiabilitiesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TradePayablesMember" xlink:type="locator" xlink:label="bntx_TradePayablesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContingentConsiderationMember" xlink:type="locator" xlink:label="ifrs-full_ContingentConsiderationMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConvertibleNoteEmbeddedDerivativeMember" xlink:type="locator" xlink:label="bntx_ConvertibleNoteEmbeddedDerivativeMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesMember" xlink:type="locator" xlink:label="ifrs-full_LiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesMember" xlink:type="locator" xlink:label="ifrs-full_LiabilitiesMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember" xlink:type="locator" xlink:label="bntx_OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:type="locator" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:type="locator" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:type="locator" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OnePointNineZeroPercentageSecuredBankLoanMember" xlink:type="locator" xlink:label="bntx_OnePointNineZeroPercentageSecuredBankLoanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember" xlink:type="locator" xlink:label="bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConvertibleNoteHostContractMember" xlink:type="locator" xlink:label="bntx_ConvertibleNoteHostContractMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TwoPointZeroEightPercentageSecuredBankLoanMember" xlink:type="locator" xlink:label="bntx_TwoPointZeroEightPercentageSecuredBankLoanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TwoPointOneFivePercentageSecuredBankLoanMember" xlink:type="locator" xlink:label="bntx_TwoPointOneFivePercentageSecuredBankLoanMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsByNameMember" xlink:type="locator" xlink:label="ifrs-full_BorrowingsByNameMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsByNameMember" xlink:type="locator" xlink:label="ifrs-full_BorrowingsByNameMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsByNameAxis" xlink:type="locator" xlink:label="ifrs-full_BorrowingsByNameAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_InterestBearingLoansAndBorrowingsMember" xlink:type="locator" xlink:label="bntx_InterestBearingLoansAndBorrowingsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesTable" order="10070.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember_2" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="bntx_InterestBearingLoansAndBorrowingsMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:to="ifrs-full_BorrowingsByNameAxis" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember_2" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="bntx_TwoPointOneFivePercentageSecuredBankLoanMember" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="bntx_TwoPointZeroEightPercentageSecuredBankLoanMember" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="bntx_ConvertibleNoteHostContractMember" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="bntx_OnePointNineZeroPercentageSecuredBankLoanMember" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_2" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:to="ifrs-full_LeaseLiabilitiesMember" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="bntx_OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_LiabilitiesMember_2" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_LiabilitiesMember" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesMember" xlink:to="bntx_ConvertibleNoteEmbeddedDerivativeMember" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesMember" xlink:to="ifrs-full_ContingentConsiderationMember" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:to="bntx_TradePayablesMember" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:to="bntx_OtherFinancialLiabilitiesMember" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCost" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_CurrentFinancialLiabilitiesAtAmortisedCost" order="11450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_NoncurrentFinancialLiabilitiesAtAmortisedCost" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="bntx_DerivativeFinancialLiabilitiesNotDesignatedAsHedgingInstrumentsAtFairValue" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" order="11650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValue" order="11690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_FinancialLiabilities" order="11850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_CurrentFinancialLiabilities" order="11930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_NoncurrentFinancialLiabilities" order="11970.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialLiabilitiesParentheticalDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialLiabilitiesParentheticalDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialLiabilitiesParentheticalDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FinancialLiabilitiesMaturityDate" xlink:type="locator" xlink:label="bntx_FinancialLiabilitiesMaturityDate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OnePointNineZeroPercentageSecuredBankLoanMember" xlink:type="locator" xlink:label="bntx_OnePointNineZeroPercentageSecuredBankLoanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TwoPointZeroEightPercentageSecuredBankLoanMember" xlink:type="locator" xlink:label="bntx_TwoPointZeroEightPercentageSecuredBankLoanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TwoPointOneFivePercentageSecuredBankLoanMember" xlink:type="locator" xlink:label="bntx_TwoPointOneFivePercentageSecuredBankLoanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember" xlink:type="locator" xlink:label="bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConvertibleNoteHostContractMember" xlink:type="locator" xlink:label="bntx_ConvertibleNoteHostContractMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsByNameMember" xlink:type="locator" xlink:label="ifrs-full_BorrowingsByNameMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsByNameAxis" xlink:type="locator" xlink:label="ifrs-full_BorrowingsByNameAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_InterestBearingLoansAndBorrowingsMember" xlink:type="locator" xlink:label="bntx_InterestBearingLoansAndBorrowingsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="bntx_InterestBearingLoansAndBorrowingsMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:to="ifrs-full_BorrowingsByNameAxis" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="bntx_ConvertibleNoteHostContractMember" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="bntx_TwoPointOneFivePercentageSecuredBankLoanMember" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="bntx_TwoPointZeroEightPercentageSecuredBankLoanMember" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="bntx_OnePointNineZeroPercentageSecuredBankLoanMember" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="bntx_FinancialLiabilitiesMaturityDate" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" order="10550.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureFinancialAssetsAndFinancialLiabilitiesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EffectiveInterestRateOfFinancialLiabilities" xlink:type="locator" xlink:label="bntx_EffectiveInterestRateOfFinancialLiabilities" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FinancialLiabilitiesConversionPremiumPercentageAboveReferencePrice" xlink:type="locator" xlink:label="bntx_FinancialLiabilitiesConversionPremiumPercentageAboveReferencePrice" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FinancialLiabilitiesCouponRatePerAnnum" xlink:type="locator" xlink:label="bntx_FinancialLiabilitiesCouponRatePerAnnum" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FinancialLiabilityMaturityTerm" xlink:type="locator" xlink:label="bntx_FinancialLiabilityMaturityTerm" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:type="locator" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TermLoanCreditB" xlink:type="locator" xlink:label="bntx_TermLoanCreditB" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TermLoanCreditA" xlink:type="locator" xlink:label="bntx_TermLoanCreditA" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotionalAmount" xlink:type="locator" xlink:label="ifrs-full_NotionalAmount" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LoanRepayableQuarterlyInstallmentCommencementDate" xlink:type="locator" xlink:label="bntx_LoanRepayableQuarterlyInstallmentCommencementDate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LoanRepayableQuarterlyInstallment" xlink:type="locator" xlink:label="bntx_LoanRepayableQuarterlyInstallment" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FinancialLiabilitiesMaturityDate" xlink:type="locator" xlink:label="bntx_FinancialLiabilitiesMaturityDate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsInterestRate" xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfSecuredBankLoanMaintained" xlink:type="locator" xlink:label="bntx_NumberOfSecuredBankLoanMaintained" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConvertibleNoteMember" xlink:type="locator" xlink:label="bntx_ConvertibleNoteMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesMember" xlink:type="locator" xlink:label="ifrs-full_LiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_JuneTwentyTwentyPrivatePlacementMember" xlink:type="locator" xlink:label="bntx_JuneTwentyTwentyPrivatePlacementMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EuropeanInvestmentBankMember" xlink:type="locator" xlink:label="bntx_EuropeanInvestmentBankMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredInterestAtFixedRateMember" xlink:type="locator" xlink:label="bntx_DeferredInterestAtFixedRateMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CashInterestFixedRateMember" xlink:type="locator" xlink:label="bntx_CashInterestFixedRateMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestRateTypesMember" xlink:type="locator" xlink:label="ifrs-full_InterestRateTypesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestRateTypesMember" xlink:type="locator" xlink:label="ifrs-full_InterestRateTypesMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:type="locator" xlink:label="ifrs-full_TypesOfInterestRatesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember" xlink:type="locator" xlink:label="bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_JPTPeptideTechnologiesGmbHMember" xlink:type="locator" xlink:label="bntx_JPTPeptideTechnologiesGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechInnovativeManufacturingServicesGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechInnovativeManufacturingServicesGmbHMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeutscheBankAGMember" xlink:type="locator" xlink:label="bntx_DeutscheBankAGMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain_2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TwoPointZeroEightPercentageBankLoanMember" xlink:type="locator" xlink:label="bntx_TwoPointZeroEightPercentageBankLoanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TwoPointOneFivePercentageSecuredLoanMember" xlink:type="locator" xlink:label="bntx_TwoPointOneFivePercentageSecuredLoanMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsByNameMember" xlink:type="locator" xlink:label="ifrs-full_BorrowingsByNameMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsByNameAxis" xlink:type="locator" xlink:label="ifrs-full_BorrowingsByNameAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesTable" xlink:to="ifrs-full_BorrowingsByNameAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="bntx_TwoPointOneFivePercentageSecuredLoanMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="bntx_TwoPointZeroEightPercentageBankLoanMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesTable" xlink:to="dei_LegalEntityAxis" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bntx_DeutscheBankAGMember" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesTable" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechInnovativeManufacturingServicesGmbHMember" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_JPTPeptideTechnologiesGmbHMember" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesTable" xlink:to="ifrs-full_TypesOfInterestRatesAxis" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_InterestRateTypesMember_2" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_InterestRateTypesMember" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_InterestRateTypesMember" xlink:to="bntx_CashInterestFixedRateMember" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_InterestRateTypesMember" xlink:to="bntx_DeferredInterestAtFixedRateMember" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bntx_EuropeanInvestmentBankMember" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_2" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="bntx_JuneTwentyTwentyPrivatePlacementMember" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesTable" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis" order="11370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_LiabilitiesMember" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesMember" xlink:to="bntx_ConvertibleNoteMember" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="bntx_NumberOfSecuredBankLoanMaintained" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" order="11570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="bntx_FinancialLiabilitiesMaturityDate" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="bntx_LoanRepayableQuarterlyInstallment" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="bntx_LoanRepayableQuarterlyInstallmentCommencementDate" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="ifrs-full_NotionalAmount" order="11790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="bntx_TermLoanCreditA" order="11830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="bntx_TermLoanCreditB" order="11870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod" order="12110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="bntx_FinancialLiabilityMaturityTerm" order="12130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="bntx_FinancialLiabilitiesCouponRatePerAnnum" order="12150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="bntx_FinancialLiabilitiesConversionPremiumPercentageAboveReferencePrice" order="12170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="bntx_EffectiveInterestRateOfFinancialLiabilities" order="12190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" order="12250.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfCarryingAmountOfMonetaryAssetsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfCarryingAmountOfMonetaryAssetsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfCarryingAmountOfMonetaryAssetsDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CashAndCashEquivalent" xlink:type="locator" xlink:label="bntx_CashAndCashEquivalent" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FinancialLiabilityMember" xlink:type="locator" xlink:label="bntx_FinancialLiabilityMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherFinancialAssetsMember" xlink:type="locator" xlink:label="bntx_OtherFinancialAssetsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsMember" xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_USDollarBankAccountsMember" xlink:type="locator" xlink:label="bntx_USDollarBankAccountsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrencyRiskMember" xlink:type="locator" xlink:label="ifrs-full_CurrencyRiskMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfCashAndCashEquivalentsLineItems" xlink:type="locator" xlink:label="bntx_DisclosureOfCashAndCashEquivalentsLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfCashAndCashEquivalentsTable" xlink:type="locator" xlink:label="bntx_DisclosureOfCashAndCashEquivalentsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalentsAbstract" xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="bntx_DisclosureOfCashAndCashEquivalentsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="bntx_DisclosureOfCashAndCashEquivalentsLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_DisclosureOfCashAndCashEquivalentsTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember_2" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_CurrencyRiskMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_DisclosureOfCashAndCashEquivalentsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="bntx_USDollarBankAccountsMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_DisclosureOfCashAndCashEquivalentsTable" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsMember" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="bntx_OtherFinancialAssetsMember" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_DisclosureOfCashAndCashEquivalentsTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="bntx_FinancialLiabilityMember" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfCashAndCashEquivalentsLineItems" xlink:to="bntx_CashAndCashEquivalent" order="10370.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfEffectOfChangesInForeignExchangeRatesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfEffectOfChangesInForeignExchangeRatesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfEffectOfChangesInForeignExchangeRatesDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ForeignCurrencyChangesEffectOnPretaxEquity" xlink:type="locator" xlink:label="bntx_ForeignCurrencyChangesEffectOnPretaxEquity" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ForeignCurrencyChangesEffectOnLossBeforeTax" xlink:type="locator" xlink:label="bntx_ForeignCurrencyChangesEffectOnLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AverageForeignExchangeRate" xlink:type="locator" xlink:label="ifrs-full_AverageForeignExchangeRate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:type="locator" xlink:label="ifrs-full_ClosingForeignExchangeRate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NegativeFivePercentageChangeInForeignExchangeRateMember" xlink:type="locator" xlink:label="bntx_NegativeFivePercentageChangeInForeignExchangeRateMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PositiveFivePercentageChangeInForeignExchangeRateMember" xlink:type="locator" xlink:label="bntx_PositiveFivePercentageChangeInForeignExchangeRateMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_HedgingInstrumentsMember" xlink:type="locator" xlink:label="ifrs-full_HedgingInstrumentsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_HedgingInstrumentsMember" xlink:type="locator" xlink:label="ifrs-full_HedgingInstrumentsMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:type="locator" xlink:label="ifrs-full_HedgingInstrumentsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrencyRiskMember" xlink:type="locator" xlink:label="ifrs-full_CurrencyRiskMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_USD" xlink:type="locator" xlink:label="currency_USD" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:type="locator" xlink:label="currency_AllCurrenciesDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:type="locator" xlink:label="srt_CurrencyAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems" xlink:type="locator" xlink:label="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable" xlink:type="locator" xlink:label="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesAbstract" xlink:type="locator" xlink:label="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesAbstract" xlink:to="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesAbstract" xlink:to="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_US" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable" xlink:to="srt_CurrencyAxis" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain_2" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_CurrencyRiskMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable" xlink:to="ifrs-full_HedgingInstrumentsAxis" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_HedgingInstrumentsAxis" xlink:to="ifrs-full_HedgingInstrumentsMember_2" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_HedgingInstrumentsAxis" xlink:to="ifrs-full_HedgingInstrumentsMember" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_HedgingInstrumentsMember" xlink:to="bntx_PositiveFivePercentageChangeInForeignExchangeRateMember" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_HedgingInstrumentsMember" xlink:to="bntx_NegativeFivePercentageChangeInForeignExchangeRateMember" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems" xlink:to="ifrs-full_ClosingForeignExchangeRate" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems" xlink:to="ifrs-full_AverageForeignExchangeRate" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems" xlink:to="bntx_ForeignCurrencyChangesEffectOnLossBeforeTax" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems" xlink:to="bntx_ForeignCurrencyChangesEffectOnPretaxEquity" order="10850.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilities" xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherFinancialLiabilities" xlink:type="locator" xlink:label="ifrs-full_OtherFinancialLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:type="locator" xlink:label="ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseLiabilities" xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherPayables" xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayables" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_InterestBearingLoansAndBorrowings" xlink:type="locator" xlink:label="bntx_InterestBearingLoansAndBorrowings" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiquidityRiskMember" xlink:type="locator" xlink:label="ifrs-full_LiquidityRiskMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:type="locator" xlink:label="ifrs-full_LaterThanFiveYearsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xlink:type="locator" xlink:label="ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:type="locator" xlink:label="ifrs-full_NotLaterThanOneYearMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:type="locator" xlink:label="ifrs-full_AggregatedTimeBandsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:type="locator" xlink:label="ifrs-full_MaturityAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesTable" order="10060.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:to="ifrs-full_MaturityAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_NotLaterThanOneYearMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanFiveYearsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_LiquidityRiskMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="bntx_InterestBearingLoansAndBorrowings" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_TradeAndOtherPayables" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_LeaseLiabilities" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_OtherFinancialLiabilities" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_FinancialLiabilities" order="10780.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities" xlink:type="locator" xlink:label="bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConvertibleNoteEmbeddedDerivativeMember" xlink:type="locator" xlink:label="bntx_ConvertibleNoteEmbeddedDerivativeMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_InterestBearingLoansAndBorrowingsMember" xlink:type="locator" xlink:label="bntx_InterestBearingLoansAndBorrowingsMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NoncurrentObligationsUnderLeaseContractsMember" xlink:type="locator" xlink:label="bntx_NoncurrentObligationsUnderLeaseContractsMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CurrentObligationsUnderLeaseContractsMember" xlink:type="locator" xlink:label="bntx_CurrentObligationsUnderLeaseContractsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:type="locator" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:type="locator" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:to="bntx_CurrentObligationsUnderLeaseContractsMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:to="bntx_NoncurrentObligationsUnderLeaseContractsMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:to="bntx_InterestBearingLoansAndBorrowingsMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:to="bntx_ConvertibleNoteEmbeddedDerivativeMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivities" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" order="10990.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIssuedCapitalAndReservesAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIssuedCapitalAndReservesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIssuedCapitalAndReservesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ChangesInEquity" xlink:type="locator" xlink:label="ifrs-full_ChangesInEquity" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssuedButNotFullyPaid" xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedButNotFullyPaid" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DecreaseInCapitalReserve" xlink:type="locator" xlink:label="bntx_DecreaseInCapitalReserve" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital" xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DerecognitionOfNonControllingInterest" xlink:type="locator" xlink:label="bntx_DerecognitionOfNonControllingInterest" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RemainingNoncontrollingInterestsAcquiredPercentage" xlink:type="locator" xlink:label="bntx_RemainingNoncontrollingInterestsAcquiredPercentage" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CashInvestment" xlink:type="locator" xlink:label="bntx_CashInvestment" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_MaximumProceedsReceivableFromIssuanceOfOrdinaryShares" xlink:type="locator" xlink:label="bntx_MaximumProceedsReceivableFromIssuanceOfOrdinaryShares" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FinancialLiabilityMaturityTerm" xlink:type="locator" xlink:label="bntx_FinancialLiabilityMaturityTerm" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EquityIssuable" xlink:type="locator" xlink:label="bntx_EquityIssuable" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SharesIssuedPricePerShare1" xlink:type="locator" xlink:label="bntx_SharesIssuedPricePerShare1" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares" xlink:type="locator" xlink:label="bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssued" xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfOrdinarySharesIssuable" xlink:type="locator" xlink:label="bntx_NumberOfOrdinarySharesIssuable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost" xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ParValuePerShare" xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssueOfEquity" xlink:type="locator" xlink:label="ifrs-full_IssueOfEquity" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SharesIssuedDuringPeriodStockSplit" xlink:type="locator" xlink:label="bntx_SharesIssuedDuringPeriodStockSplit" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_StockSplitConversionRatio" xlink:type="locator" xlink:label="bntx_StockSplitConversionRatio" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_InitialPublicOfferingMember" xlink:type="locator" xlink:label="bntx_InitialPublicOfferingMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BillAndMeLindaGatesFoundationMember" xlink:type="locator" xlink:label="bntx_BillAndMeLindaGatesFoundationMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForAssociatesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForAssociatesMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:type="locator" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_HK" xlink:type="locator" xlink:label="country_HK" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OrdinarySharesSeriesBMember" xlink:type="locator" xlink:label="bntx_OrdinarySharesSeriesBMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechCellAndGeneTherapiesGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechCellAndGeneTherapiesGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AtMarketOfferingProgramMember" xlink:type="locator" xlink:label="bntx_AtMarketOfferingProgramMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConvertibleNoteMember" xlink:type="locator" xlink:label="bntx_ConvertibleNoteMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesMember" xlink:type="locator" xlink:label="ifrs-full_LiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_June2020PrivatePlacementMember" xlink:type="locator" xlink:label="bntx_June2020PrivatePlacementMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GlobalOfferingMember" xlink:type="locator" xlink:label="bntx_GlobalOfferingMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CapitalRequirementsMember" xlink:type="locator" xlink:label="ifrs-full_CapitalRequirementsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CapitalRequirementsMember" xlink:type="locator" xlink:label="ifrs-full_CapitalRequirementsMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CapitalRequirementsAxis" xlink:type="locator" xlink:label="ifrs-full_CapitalRequirementsAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NeonTherapeuticsIncMember" xlink:type="locator" xlink:label="bntx_NeonTherapeuticsIncMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BusinessCombinationsAxis" xlink:type="locator" xlink:label="ifrs-full_BusinessCombinationsAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PfizerIncMember" xlink:type="locator" xlink:label="bntx_PfizerIncMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ShanghaiFosunPharmaceuticalGroupCoLtdMember" xlink:type="locator" xlink:label="bntx_ShanghaiFosunPharmaceuticalGroupCoLtdMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CapitalReserveMember" xlink:type="locator" xlink:label="ifrs-full_CapitalReserveMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TreasurySharesMember" xlink:type="locator" xlink:label="ifrs-full_TreasurySharesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:type="locator" xlink:label="ifrs-full_EquityMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_TreasurySharesMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_CapitalReserveMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="srt_CounterpartyNameAxis" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bntx_ShanghaiFosunPharmaceuticalGroupCoLtdMember" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bntx_PfizerIncMember" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_BusinessCombinationsAxis" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="bntx_NeonTherapeuticsIncMember" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_CapitalRequirementsAxis" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CapitalRequirementsAxis" xlink:to="ifrs-full_CapitalRequirementsMember_2" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CapitalRequirementsAxis" xlink:to="ifrs-full_CapitalRequirementsMember" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CapitalRequirementsMember" xlink:to="bntx_GlobalOfferingMember" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CapitalRequirementsMember" xlink:to="bntx_June2020PrivatePlacementMember" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_LiabilitiesMember" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesMember" xlink:to="bntx_ConvertibleNoteMember" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CapitalRequirementsMember" xlink:to="bntx_AtMarketOfferingProgramMember" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="bntx_BioNTechCellAndGeneTherapiesGmbHMember" order="11600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="11770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="11800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="bntx_OrdinarySharesSeriesBMember" order="11820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="11830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" order="11860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_HK" order="11880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis" order="12010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_EntitysTotalForAssociatesMember_2" order="12020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_EntitysTotalForAssociatesMember" order="12040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForAssociatesMember" xlink:to="bntx_BillAndMeLindaGatesFoundationMember" order="12060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CapitalRequirementsMember" xlink:to="bntx_InitialPublicOfferingMember" order="12160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="bntx_StockSplitConversionRatio" order="12410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="bntx_SharesIssuedDuringPeriodStockSplit" order="12430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_IssueOfEquity" order="12490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ParValuePerShare" order="12510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" order="12550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares" order="12630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="bntx_NumberOfOrdinarySharesIssuable" order="12670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="12890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares" order="13570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="bntx_SharesIssuedPricePerShare1" order="13690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="bntx_EquityIssuable" order="13970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="bntx_FinancialLiabilityMaturityTerm" order="14010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="bntx_MaximumProceedsReceivableFromIssuanceOfOrdinaryShares" order="14210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="bntx_CashInvestment" order="14870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="bntx_RemainingNoncontrollingInterestsAcquiredPercentage" order="14950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="bntx_DerecognitionOfNonControllingInterest" order="15010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_IssuedCapital" order="15030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="bntx_DecreaseInCapitalReserve" order="15050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid" order="15110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedButNotFullyPaid" order="15130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ChangesInEquity" order="15690.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureShareBasedPaymentsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OptionExercisablePeriod" xlink:type="locator" xlink:label="bntx_OptionExercisablePeriod" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare" xlink:type="locator" xlink:label="bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:type="locator" xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_WeightedAverageRemainingContractualLifeOfShareOptionsAllocatedAndExpectedToBeAllocated" xlink:type="locator" xlink:label="bntx_WeightedAverageRemainingContractualLifeOfShareOptionsAllocatedAndExpectedToBeAllocated" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OptionExpirationPeriod" xlink:type="locator" xlink:label="bntx_OptionExpirationPeriod" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth" xlink:type="locator" xlink:label="bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering" xlink:type="locator" xlink:label="bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PercentageOfIncreaseInExercisePrice" xlink:type="locator" xlink:label="bntx_PercentageOfIncreaseInExercisePrice" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncreaseDecreaseInShareBasedPaymentValue" xlink:type="locator" xlink:label="bntx_IncreaseDecreaseInShareBasedPaymentValue" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpectedDividendShareOptionsGranted" xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendShareOptionsGranted" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherFinancialLiabilities" xlink:type="locator" xlink:label="ifrs-full_OtherFinancialLiabilities" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CashSettledExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator" xlink:label="bntx_CashSettledExpenseFromSharebasedPaymentTransactionsWithEmployees" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares" xlink:type="locator" xlink:label="bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PercentageOfOtherEquityInstrumentNonVestingRate" xlink:type="locator" xlink:label="bntx_PercentageOfOtherEquityInstrumentNonVestingRate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OptionVestingPeriod" xlink:type="locator" xlink:label="bntx_OptionVestingPeriod" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeStockOwnershipPlanMember" xlink:type="locator" xlink:label="bntx_EmployeeStockOwnershipPlanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ChiefExecutiveOfficerGrantMember" xlink:type="locator" xlink:label="bntx_ChiefExecutiveOfficerGrantMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OrdinarySharesMember" xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RyanRichardsonMember" xlink:type="locator" xlink:label="bntx_RyanRichardsonMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DrOzlemTureciMember" xlink:type="locator" xlink:label="bntx_DrOzlemTureciMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DrSierkPoettingMember" xlink:type="locator" xlink:label="bntx_DrSierkPoettingMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SeanMarettMember" xlink:type="locator" xlink:label="bntx_SeanMarettMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ProfessorUgurSahinMDMember" xlink:type="locator" xlink:label="bntx_ProfessorUgurSahinMDMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="bntx_GeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ResearchAndDevelopmentExpensesMember" xlink:type="locator" xlink:label="bntx_ResearchAndDevelopmentExpensesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NatureOfExpensesMember" xlink:type="locator" xlink:label="bntx_NatureOfExpensesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NatureOfExpensesAxis" xlink:type="locator" xlink:label="bntx_NatureOfExpensesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ManagementBoardGrantMember" xlink:type="locator" xlink:label="bntx_ManagementBoardGrantMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember" xlink:type="locator" xlink:label="bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeEquityPlanLongTermIncentiveProgramMember" xlink:type="locator" xlink:label="bntx_EmployeeEquityPlanLongTermIncentiveProgramMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeEquityPlanMember" xlink:type="locator" xlink:label="bntx_EmployeeEquityPlanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TwoThousandTwentyRestrictedStockUnitPlanMember" xlink:type="locator" xlink:label="bntx_TwoThousandTwentyRestrictedStockUnitPlanMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_TwoThousandTwentyRestrictedStockUnitPlanMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_EmployeeEquityPlanMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_EmployeeEquityPlanLongTermIncentiveProgramMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_ManagementBoardGrantMember" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="srt_RangeAxis" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="ifrs-full_TopOfRangeMember" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="ifrs-full_BottomOfRangeMember" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="bntx_NatureOfExpensesAxis" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="bntx_NatureOfExpensesAxis" xlink:to="bntx_NatureOfExpensesMember" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_NatureOfExpensesMember" xlink:to="bntx_ResearchAndDevelopmentExpensesMember" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_NatureOfExpensesMember" xlink:to="bntx_GeneralAndAdministrativeExpensesMember" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="srt_TitleOfIndividualAxis" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_ProfessorUgurSahinMDMember" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_SeanMarettMember" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_DrSierkPoettingMember" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_DrOzlemTureciMember" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_RyanRichardsonMember" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_OrdinarySharesMember" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_ChiefExecutiveOfficerGrantMember" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_EmployeeStockOwnershipPlanMember" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_OptionVestingPeriod" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_PercentageOfOtherEquityInstrumentNonVestingRate" order="11570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_CashSettledExpenseFromSharebasedPaymentTransactionsWithEmployees" order="11690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_OtherFinancialLiabilities" order="11730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpectedDividendShareOptionsGranted" order="11790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_IncreaseDecreaseInShareBasedPaymentValue" order="11890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_PercentageOfIncreaseInExercisePrice" order="12030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering" order="12050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth" order="12070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_OptionExpirationPeriod" order="12090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="12150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_WeightedAverageRemainingContractualLifeOfShareOptionsAllocatedAndExpectedToBeAllocated" order="12230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" order="12290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare" order="12330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_OptionExercisablePeriod" order="12570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="12650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" order="12690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" order="12730.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfNumberAndSharePriceOfRestrictedStockUnitsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureShareBasedPaymentsScheduleOfNumberAndSharePriceOfRestrictedStockUnitsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfNumberAndSharePriceOfRestrictedStockUnitsDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpectedToBeAllocatedInSharebasedPaymentArrangement" xlink:type="locator" xlink:label="bntx_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpectedToBeAllocatedInSharebasedPaymentArrangement" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfInstrumentsOtherEquityInstrumentsExpectedToBeAllocated" xlink:type="locator" xlink:label="bntx_NumberOfInstrumentsOtherEquityInstrumentsExpectedToBeAllocated" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember" xlink:type="locator" xlink:label="bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeEquityPlanLongTermIncentiveProgramMember" xlink:type="locator" xlink:label="bntx_EmployeeEquityPlanLongTermIncentiveProgramMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeEquityPlanMember" xlink:type="locator" xlink:label="bntx_EmployeeEquityPlanMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_EmployeeEquityPlanMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_EmployeeEquityPlanLongTermIncentiveProgramMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_NumberOfInstrumentsOtherEquityInstrumentsExpectedToBeAllocated" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpectedToBeAllocatedInSharebasedPaymentArrangement" order="10450.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfExpenseRecognizedForEmployeeServicesReceivedDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureShareBasedPaymentsScheduleOfExpenseRecognizedForEmployeeServicesReceivedDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfExpenseRecognizedForEmployeeServicesReceivedDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeStockOwnershipPlanMember" xlink:type="locator" xlink:label="bntx_EmployeeStockOwnershipPlanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ManagementBoardGrantMember" xlink:type="locator" xlink:label="bntx_ManagementBoardGrantMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeEquityPlanMember" xlink:type="locator" xlink:label="bntx_EmployeeEquityPlanMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="bntx_GeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SalesAndMarketingExpensesMember" xlink:type="locator" xlink:label="bntx_SalesAndMarketingExpensesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ResearchAndDevelopmentExpensesMember" xlink:type="locator" xlink:label="bntx_ResearchAndDevelopmentExpensesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CostOfSales1Member" xlink:type="locator" xlink:label="bntx_CostOfSales1Member" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NatureOfExpensesMember" xlink:type="locator" xlink:label="bntx_NatureOfExpensesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NatureOfExpensesAxis" xlink:type="locator" xlink:label="bntx_NatureOfExpensesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="bntx_NatureOfExpensesAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="bntx_NatureOfExpensesAxis" xlink:to="bntx_NatureOfExpensesMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_NatureOfExpensesMember" xlink:to="bntx_CostOfSales1Member" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_NatureOfExpensesMember" xlink:to="bntx_ResearchAndDevelopmentExpensesMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_NatureOfExpensesMember" xlink:to="bntx_SalesAndMarketingExpensesMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_NatureOfExpensesMember" xlink:to="bntx_GeneralAndAdministrativeExpensesMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_EmployeeEquityPlanMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_ManagementBoardGrantMember" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_EmployeeStockOwnershipPlanMember" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" order="10650.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfNumberAndWeightedAverageExercisePriceOfShareOptionsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureShareBasedPaymentsScheduleOfNumberAndWeightedAverageExercisePriceOfShareOptionsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfNumberAndWeightedAverageExercisePriceOfShareOptionsDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="locator" xlink:label="bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInSharebasedPaymentArrangement" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsGrantedInSharebasedPaymentArrangement" xlink:type="locator" xlink:label="bntx_NumberOfOrdinarySharesUnderlyingOptionsGrantedInSharebasedPaymentArrangement" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding" xlink:type="locator" xlink:label="bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo" xlink:type="locator" xlink:label="bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne" xlink:type="locator" xlink:label="bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo" xlink:type="locator" xlink:label="bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne" xlink:type="locator" xlink:label="bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeStockOwnershipPlanMember" xlink:type="locator" xlink:label="bntx_EmployeeStockOwnershipPlanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ManagementBoardGrantMember" xlink:type="locator" xlink:label="bntx_ManagementBoardGrantMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_ManagementBoardGrantMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_EmployeeStockOwnershipPlanMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding" order="11650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_NumberOfOrdinarySharesUnderlyingOptionsGrantedInSharebasedPaymentArrangement" order="11730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInSharebasedPaymentArrangement" order="11810.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsSummaryOfInputsUsedInMeasurementOfFairValueAtGrantDateDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureShareBasedPaymentsSummaryOfInputsUsedInMeasurementOfFairValueAtGrantDateDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsSummaryOfInputsUsedInMeasurementOfFairValueAtGrantDateDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeStockOwnershipPlanMember" xlink:type="locator" xlink:label="bntx_EmployeeStockOwnershipPlanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ChiefExecutiveOfficerGrantMember" xlink:type="locator" xlink:label="bntx_ChiefExecutiveOfficerGrantMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EstimatedAllocationDateTwoMember" xlink:type="locator" xlink:label="bntx_EstimatedAllocationDateTwoMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EstimatedAllocationDateOneMember" xlink:type="locator" xlink:label="bntx_EstimatedAllocationDateOneMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ManagementBoardGrantMember" xlink:type="locator" xlink:label="bntx_ManagementBoardGrantMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_ManagementBoardGrantMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember_2" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="bntx_EstimatedAllocationDateOneMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="bntx_EstimatedAllocationDateTwoMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_ChiefExecutiveOfficerGrantMember" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_EmployeeStockOwnershipPlanMember" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="10730.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfNumberAndWeightedAverageExercisePriceOfShareOptionsAllocatedAndExpectedToBeAllocatedDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureShareBasedPaymentsScheduleOfNumberAndWeightedAverageExercisePriceOfShareOptionsAllocatedAndExpectedToBeAllocatedDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfNumberAndWeightedAverageExercisePriceOfShareOptionsAllocatedAndExpectedToBeAllocatedDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EstimatedAllocationDateTwoMember" xlink:type="locator" xlink:label="bntx_EstimatedAllocationDateTwoMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EstimatedAllocationDateOneMember" xlink:type="locator" xlink:label="bntx_EstimatedAllocationDateOneMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ManagementBoardGrantMember" xlink:type="locator" xlink:label="bntx_ManagementBoardGrantMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RyanRichardsonMember" xlink:type="locator" xlink:label="bntx_RyanRichardsonMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DrOzlemTureciMDMember" xlink:type="locator" xlink:label="bntx_DrOzlemTureciMDMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DrSierkPoettingMember" xlink:type="locator" xlink:label="bntx_DrSierkPoettingMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SeanMarettMember" xlink:type="locator" xlink:label="bntx_SeanMarettMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ProfessorUgurSahinMDMember" xlink:type="locator" xlink:label="bntx_ProfessorUgurSahinMDMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="srt_TitleOfIndividualAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_ProfessorUgurSahinMDMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_SeanMarettMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_DrSierkPoettingMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_DrOzlemTureciMDMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_RyanRichardsonMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_ManagementBoardGrantMember" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="bntx_EstimatedAllocationDateOneMember" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="bntx_EstimatedAllocationDateTwoMember" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" order="10970.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfNumberOfShareOptionsOutstandingDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureShareBasedPaymentsScheduleOfNumberOfShareOptionsOutstandingDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfNumberOfShareOptionsOutstandingDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding" xlink:type="locator" xlink:label="bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ManagementBoardGrantMember" xlink:type="locator" xlink:label="bntx_ManagementBoardGrantMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RyanRichardsonMember" xlink:type="locator" xlink:label="bntx_RyanRichardsonMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DrOzlemTureciMDMember" xlink:type="locator" xlink:label="bntx_DrOzlemTureciMDMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DrSierkPoettingMember" xlink:type="locator" xlink:label="bntx_DrSierkPoettingMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SeanMarettMember" xlink:type="locator" xlink:label="bntx_SeanMarettMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ProfessorUgurSahinMDMember" xlink:type="locator" xlink:label="bntx_ProfessorUgurSahinMDMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="srt_TitleOfIndividualAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_ProfessorUgurSahinMDMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_SeanMarettMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_DrSierkPoettingMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_DrOzlemTureciMDMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_RyanRichardsonMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_ManagementBoardGrantMember" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" order="10590.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesSummaryOfRightOfUseAssetsWithinConsolidatedStatementsOfFinancialPositionDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureLeasesSummaryOfRightOfUseAssetsWithinConsolidatedStatementsOfFinancialPositionDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesSummaryOfRightOfUseAssetsWithinConsolidatedStatementsOfFinancialPositionDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RightofuseAssets" xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AdvancePaymentsMember" xlink:type="locator" xlink:label="bntx_AdvancePaymentsMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ProductionFacilitiesMember" xlink:type="locator" xlink:label="bntx_ProductionFacilitiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_VehiclesMember" xlink:type="locator" xlink:label="ifrs-full_VehiclesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EquipmentToolsAndInstallationsMember" xlink:type="locator" xlink:label="bntx_EquipmentToolsAndInstallationsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BuildingsMember" xlink:type="locator" xlink:label="ifrs-full_BuildingsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_BuildingsMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="bntx_EquipmentToolsAndInstallationsMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_VehiclesMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="bntx_ProductionFacilitiesMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="bntx_AdvancePaymentsMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_RightofuseAssets" order="10210.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities" xlink:type="locator" xlink:label="bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashOutflowForLeases" xlink:type="locator" xlink:label="ifrs-full_CashOutflowForLeases" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GrossLeaseLiabilities" xlink:type="locator" xlink:label="ifrs-full_GrossLeaseLiabilities" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AdvancePaymentsRelatedToEmbeddedLeases" xlink:type="locator" xlink:label="bntx_AdvancePaymentsRelatedToEmbeddedLeases" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:type="locator" xlink:label="ifrs-full_AdditionsToRightofuseAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanOneYearMember" xlink:type="locator" xlink:label="ifrs-full_LaterThanOneYearMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:type="locator" xlink:label="ifrs-full_NotLaterThanOneYearMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:type="locator" xlink:label="ifrs-full_AggregatedTimeBandsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:type="locator" xlink:label="ifrs-full_MaturityAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="ifrs-full_MaturityAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_NotLaterThanOneYearMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanOneYearMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="srt_RangeAxis" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="ifrs-full_TopOfRangeMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="ifrs-full_BottomOfRangeMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_AdditionsToRightofuseAssets" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="bntx_AdvancePaymentsRelatedToEmbeddedLeases" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_GrossLeaseLiabilities" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_CashOutflowForLeases" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities" order="10570.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesSummaryOfAmountsRecognizedInConsolidatedStatementOfOperationsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureLeasesSummaryOfAmountsRecognizedInConsolidatedStatementOfOperationsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesSummaryOfAmountsRecognizedInConsolidatedStatementOfOperationsDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LeaseExpensesRecognizedInProfitOrLoss" xlink:type="locator" xlink:label="bntx_LeaseExpensesRecognizedInProfitOrLoss" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:type="locator" xlink:label="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:type="locator" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:type="locator" xlink:label="ifrs-full_DepreciationRightofuseAssets" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ProductionFacilitiesMember" xlink:type="locator" xlink:label="bntx_ProductionFacilitiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_VehiclesMember" xlink:type="locator" xlink:label="ifrs-full_VehiclesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EquipmentToolsAndInstallationsMember" xlink:type="locator" xlink:label="bntx_EquipmentToolsAndInstallationsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BuildingsMember" xlink:type="locator" xlink:label="ifrs-full_BuildingsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_BuildingsMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="bntx_EquipmentToolsAndInstallationsMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_VehiclesMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="bntx_ProductionFacilitiesMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_DepreciationRightofuseAssets" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="bntx_LeaseExpensesRecognizedInProfitOrLoss" order="10710.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosurePensionsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PensionFundContributionsExpectedForFollowingFinancialYear" xlink:type="locator" xlink:label="bntx_PensionFundContributionsExpectedForFollowingFinancialYear" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_MaximumPensionFundContributions" xlink:type="locator" xlink:label="bntx_MaximumPensionFundContributions" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AnnualPensionEntitlementOfEmployeeContribution" xlink:type="locator" xlink:label="bntx_AnnualPensionEntitlementOfEmployeeContribution" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PercentageOfDefinedContributionPlanOfSalary" xlink:type="locator" xlink:label="bntx_PercentageOfDefinedContributionPlanOfSalary" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExplanationOfWhetherParticipantsContributeToRetirementBenefitPlan" xlink:type="locator" xlink:label="ifrs-full_ExplanationOfWhetherParticipantsContributeToRetirementBenefitPlan" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WhollyUnfundedDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_WhollyUnfundedDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis" xlink:type="locator" xlink:label="ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember_2" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:to="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="srt_RangeAxis" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="ifrs-full_BottomOfRangeMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="ifrs-full_TopOfRangeMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis" xlink:to="ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember_2" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis" xlink:to="ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember" xlink:to="ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember" xlink:to="ifrs-full_WhollyUnfundedDefinedBenefitPlansMember" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_ExplanationOfWhetherParticipantsContributeToRetirementBenefitPlan" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="bntx_PercentageOfDefinedContributionPlanOfSalary" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="bntx_AnnualPensionEntitlementOfEmployeeContribution" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="bntx_MaximumPensionFundContributions" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="bntx_PensionFundContributionsExpectedForFollowingFinancialYear" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019" order="10750.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsSummaryOfDefinedBenefitObligationRecognizedInNonCurrentProvisionsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosurePensionsSummaryOfDefinedBenefitObligationRecognizedInNonCurrentProvisionsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsSummaryOfDefinedBenefitObligationRecognizedInNonCurrentProvisionsDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:type="locator" xlink:label="ifrs-full_NoncurrentProvisionsForEmployeeBenefits" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SupplementPlanMember" xlink:type="locator" xlink:label="bntx_SupplementPlanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BasePlanMember" xlink:type="locator" xlink:label="bntx_BasePlanMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_DefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_DefinedBenefitPlansMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:type="locator" xlink:label="ifrs-full_DefinedBenefitPlansAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="ifrs-full_DefinedBenefitPlansAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_DefinedBenefitPlansAxis" xlink:to="ifrs-full_DefinedBenefitPlansMember_2" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_DefinedBenefitPlansAxis" xlink:to="ifrs-full_DefinedBenefitPlansMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefinedBenefitPlansMember" xlink:to="bntx_BasePlanMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefinedBenefitPlansMember" xlink:to="bntx_SupplementPlanMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:to="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_NoncurrentProvisionsForEmployeeBenefits" order="10210.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsSummaryOfComponentsOfNetBenefitExpenseRecognizedInStatementOfProfitOrLossDetails" xlink:href="bntx-20201231.xsd#Role_DisclosurePensionsSummaryOfComponentsOfNetBenefitExpenseRecognizedInStatementOfProfitOrLossDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsSummaryOfComponentsOfNetBenefitExpenseRecognizedInStatementOfProfitOrLossDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:to="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" order="10190.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsSummaryOfComponentsOfRemeasurementsRecognizedInOtherComprehensiveIncomeDetails" xlink:href="bntx-20201231.xsd#Role_DisclosurePensionsSummaryOfComponentsOfRemeasurementsRecognizedInOtherComprehensiveIncomeDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsSummaryOfComponentsOfRemeasurementsRecognizedInOtherComprehensiveIncomeDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:to="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" order="10190.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfChangesToDefinedBenefitObligationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosurePensionsScheduleOfChangesToDefinedBenefitObligationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfChangesToDefinedBenefitObligationDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BenefitsPaidOrPayable" xlink:type="locator" xlink:label="ifrs-full_BenefitsPaidOrPayable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:type="locator" xlink:label="ifrs-full_LiabilityAssetOfDefinedBenefitPlans" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:to="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_LiabilityAssetOfDefinedBenefitPlans" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_BenefitsPaidOrPayable" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" order="10370.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfPrincipalAssumptionsUsedInDeterminingDefinedBenefitObligationsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosurePensionsScheduleOfPrincipalAssumptionsUsedInDeterminingDefinedBenefitObligationsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfPrincipalAssumptionsUsedInDeterminingDefinedBenefitObligationsDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionOfDiscountRates" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:to="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_ActuarialAssumptionOfDiscountRates" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" order="10190.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfQuantitativeSensitivityAnalysisDetails" xlink:href="bntx-20201231.xsd#Role_DisclosurePensionsScheduleOfQuantitativeSensitivityAnalysisDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfQuantitativeSensitivityAnalysisDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionOfDiscountRatesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionsMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionsAxis" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="ifrs-full_ActuarialAssumptionsAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ActuarialAssumptionsAxis" xlink:to="ifrs-full_ActuarialAssumptionsMember_2" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ActuarialAssumptionsAxis" xlink:to="ifrs-full_ActuarialAssumptionsMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ActuarialAssumptionsMember" xlink:to="ifrs-full_ActuarialAssumptionOfDiscountRatesMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ActuarialAssumptionsMember" xlink:to="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:to="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" order="10270.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfQuantitativeSensitivityAnalysisParentheticalDetails" xlink:href="bntx-20201231.xsd#Role_DisclosurePensionsScheduleOfQuantitativeSensitivityAnalysisParentheticalDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfQuantitativeSensitivityAnalysisParentheticalDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="locator" xlink:label="ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="locator" xlink:label="ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionOfDiscountRatesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionsAxis" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="ifrs-full_ActuarialAssumptionsAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ActuarialAssumptionsAxis" xlink:to="ifrs-full_ActuarialAssumptionsMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ActuarialAssumptionsMember" xlink:to="ifrs-full_ActuarialAssumptionOfDiscountRatesMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ActuarialAssumptionsMember" xlink:to="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:to="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" order="10270.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfExpectedPaymentsOrContributionsToPlansInFutureYearsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosurePensionsScheduleOfExpectedPaymentsOrContributionsToPlansInFutureYearsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfExpectedPaymentsOrContributionsToPlansInFutureYearsDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan" xlink:type="locator" xlink:label="ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:type="locator" xlink:label="ifrs-full_LaterThanFiveYearsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="locator" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:type="locator" xlink:label="ifrs-full_NotLaterThanOneYearMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:type="locator" xlink:label="ifrs-full_AggregatedTimeBandsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:type="locator" xlink:label="ifrs-full_MaturityAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="ifrs-full_MaturityAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_NotLaterThanOneYearMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanFiveYearsMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:to="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan" order="10230.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureRelatedPartyDisclosuresAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction" xlink:type="locator" xlink:label="ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction" xlink:type="locator" xlink:label="ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OrdinarySharesMember" xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CofounderAndChiefExecutiveOfficerMember" xlink:type="locator" xlink:label="bntx_CofounderAndChiefExecutiveOfficerMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="bntx_CofounderAndChiefExecutiveOfficerMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_OrdinarySharesMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction" order="10270.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfAggregateValueOfTransactionsRelatedToKeyManagementPersonnelDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureRelatedPartyDisclosuresSummaryOfAggregateValueOfTransactionsRelatedToKeyManagementPersonnelDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfAggregateValueOfTransactionsRelatedToKeyManagementPersonnelDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GoodsAndServicesFromRelatedPartyTransactions" xlink:type="locator" xlink:label="bntx_GoodsAndServicesFromRelatedPartyTransactions" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" xlink:type="locator" xlink:label="bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConsultingServicesAndPatentAssignment" xlink:type="locator" xlink:label="bntx_ConsultingServicesAndPatentAssignment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="bntx_ConsultingServicesAndPatentAssignment" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="bntx_GoodsAndServicesFromRelatedPartyTransactions" order="10310.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfOutstandingBalancesOfTransactionsRelatedToKeyManagementPersonnelDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureRelatedPartyDisclosuresSummaryOfOutstandingBalancesOfTransactionsRelatedToKeyManagementPersonnelDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfOutstandingBalancesOfTransactionsRelatedToKeyManagementPersonnelDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:type="locator" xlink:label="ifrs-full_AmountsPayableRelatedPartyTransactions" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TRONMember" xlink:type="locator" xlink:label="bntx_TRONMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConsultingServiceProviderMember" xlink:type="locator" xlink:label="bntx_ConsultingServiceProviderMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="srt_CounterpartyNameAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bntx_ConsultingServiceProviderMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bntx_TRONMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_AmountsPayableRelatedPartyTransactions" order="10250.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfTransactionsBetweenRelatedPartiesAmountDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureRelatedPartyDisclosuresSummaryOfTransactionsBetweenRelatedPartiesAmountDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfTransactionsBetweenRelatedPartiesAmountDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PurchasesFromRelatedPartyTransactions" xlink:type="locator" xlink:label="bntx_PurchasesFromRelatedPartyTransactions" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions" xlink:type="locator" xlink:label="ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" xlink:type="locator" xlink:label="bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherRelatedPartiesMember" xlink:type="locator" xlink:label="ifrs-full_OtherRelatedPartiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_OtherRelatedPartiesMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="bntx_PurchasesFromRelatedPartyTransactions" order="10310.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfTransactionsBetweenRelatedPartiesOutstandingBalancesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureRelatedPartyDisclosuresSummaryOfTransactionsBetweenRelatedPartiesOutstandingBalancesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfTransactionsBetweenRelatedPartiesOutstandingBalancesDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:type="locator" xlink:label="ifrs-full_AmountsPayableRelatedPartyTransactions" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ATHOSKGMember" xlink:type="locator" xlink:label="bntx_ATHOSKGMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherRelatedPartiesMember" xlink:type="locator" xlink:label="ifrs-full_OtherRelatedPartiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_OtherRelatedPartiesMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="srt_CounterpartyNameAxis" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bntx_ATHOSKGMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_AmountsPayableRelatedPartyTransactions" order="10210.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureEventsAfterReportingPeriodAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureEventsAfterReportingPeriodAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureEventsAfterReportingPeriodAdditionalInformationDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OptionToRequestSupplyOfNumberOfAdditionalDoses" xlink:type="locator" xlink:label="bntx_OptionToRequestSupplyOfNumberOfAdditionalDoses" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfEuropeanUnionMemberStates" xlink:type="locator" xlink:label="bntx_NumberOfEuropeanUnionMemberStates" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AggregateNumberOfDosesToBeSupplied" xlink:type="locator" xlink:label="bntx_AggregateNumberOfDosesToBeSupplied" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfAdditionalDosesToBeSupplied" xlink:type="locator" xlink:label="bntx_NumberOfAdditionalDosesToBeSupplied" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EuropeanUnionMemberStatesMember" xlink:type="locator" xlink:label="bntx_EuropeanUnionMemberStatesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_UnitedStatesGovernmentMember" xlink:type="locator" xlink:label="bntx_UnitedStatesGovernmentMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorCustomersMember" xlink:type="locator" xlink:label="ifrs-full_MajorCustomersMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorCustomersAxis" xlink:type="locator" xlink:label="ifrs-full_MajorCustomersAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PfizerIncMember" xlink:type="locator" xlink:label="bntx_PfizerIncMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesMember" xlink:type="locator" xlink:label="ifrs-full_CounterpartiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesMember" xlink:type="locator" xlink:label="ifrs-full_CounterpartiesMember_2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesAxis" xlink:type="locator" xlink:label="ifrs-full_CounterpartiesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SupplyOfCOVID19VaccineMember" xlink:type="locator" xlink:label="bntx_SupplyOfCOVID19VaccineMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfEventsAfterReportingPeriodLineItems" xlink:type="locator" xlink:label="bntx_DisclosureOfEventsAfterReportingPeriodLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfEventsAfterReportingPeriodTable" xlink:type="locator" xlink:label="bntx_DisclosureOfEventsAfterReportingPeriodTable" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfEventsAfterReportingPeriodAbstract" xlink:type="locator" xlink:label="bntx_DisclosureOfEventsAfterReportingPeriodAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bntx_DisclosureOfEventsAfterReportingPeriodAbstract" xlink:to="bntx_DisclosureOfEventsAfterReportingPeriodTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfEventsAfterReportingPeriodAbstract" xlink:to="bntx_DisclosureOfEventsAfterReportingPeriodLineItems" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_DisclosureOfEventsAfterReportingPeriodTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="bntx_SupplyOfCOVID19VaccineMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_DisclosureOfEventsAfterReportingPeriodTable" xlink:to="ifrs-full_CounterpartiesAxis" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember_2" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="bntx_PfizerIncMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bntx_DisclosureOfEventsAfterReportingPeriodTable" xlink:to="ifrs-full_MajorCustomersAxis" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_UnitedStatesGovernmentMember" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_EuropeanUnionMemberStatesMember" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfEventsAfterReportingPeriodLineItems" xlink:to="bntx_NumberOfAdditionalDosesToBeSupplied" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfEventsAfterReportingPeriodLineItems" xlink:to="bntx_AggregateNumberOfDosesToBeSupplied" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfEventsAfterReportingPeriodLineItems" xlink:to="bntx_NumberOfEuropeanUnionMemberStates" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bntx_DisclosureOfEventsAfterReportingPeriodLineItems" xlink:to="bntx_OptionToRequestSupplyOfNumberOfAdditionalDoses" order="10470.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>48
<FILENAME>bntx-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-30T14:14:26.4326032+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : a6c3372c9f8947078f9b74c1e02df132 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/deprecatedDateLabel" xlink:href="http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd#deprecatedDateLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate" />
    <link:label xml:lang="en-US" xlink:label="bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Right-of-use assets recognised as of acquisition date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate" xlink:to="bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" />
    <link:label xml:lang="en-US" xlink:label="bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other assets non-current and current recognised as of acquisition date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" xlink:to="bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ProvisionsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="bntx_ProvisionsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" />
    <link:label xml:lang="en-US" xlink:label="bntx_ProvisionsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Provisions non-current and current recognised as of acquisition date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ProvisionsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" xlink:to="bntx_ProvisionsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TradePayablesRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="bntx_TradePayablesRecognisedAsOfAcquisitionDate" />
    <link:label xml:lang="en-US" xlink:label="bntx_TradePayablesRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Trade payables recognised as of acquisition date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_TradePayablesRecognisedAsOfAcquisitionDate" xlink:to="bntx_TradePayablesRecognisedAsOfAcquisitionDate_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherLiabilitiesNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="bntx_OtherLiabilitiesNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" />
    <link:label xml:lang="en-US" xlink:label="bntx_OtherLiabilitiesNonCurrentAndCurrentRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other liabilities non-current and current recognised as of acquisition date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_OtherLiabilitiesNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" xlink:to="bntx_OtherLiabilitiesNonCurrentAndCurrentRecognisedAsOfAcquisitionDate_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AssetsRecognizedAsOfAcquisitionDate" xlink:type="locator" xlink:label="bntx_AssetsRecognizedAsOfAcquisitionDate" />
    <link:label xml:lang="en-US" xlink:label="bntx_AssetsRecognizedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Assets recognized as of acquisition date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_AssetsRecognizedAsOfAcquisitionDate" xlink:to="bntx_AssetsRecognizedAsOfAcquisitionDate_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LiabilitiesRecognizedAsOfAcquisitionDate" xlink:type="locator" xlink:label="bntx_LiabilitiesRecognizedAsOfAcquisitionDate" />
    <link:label xml:lang="en-US" xlink:label="bntx_LiabilitiesRecognizedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Liabilities recognized as of acquisition date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_LiabilitiesRecognizedAsOfAcquisitionDate" xlink:to="bntx_LiabilitiesRecognizedAsOfAcquisitionDate_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SharesIssuedAtFairValue" xlink:type="locator" xlink:label="bntx_SharesIssuedAtFairValue" />
    <link:label xml:lang="en-US" xlink:label="bntx_SharesIssuedAtFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued, at fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_SharesIssuedAtFairValue" xlink:to="bntx_SharesIssuedAtFairValue_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BargainPurchaseGainOnAcquisition" xlink:type="locator" xlink:label="bntx_BargainPurchaseGainOnAcquisition" />
    <link:label xml:lang="en-US" xlink:label="bntx_BargainPurchaseGainOnAcquisition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Bargain purchase gain on acquisition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_BargainPurchaseGainOnAcquisition" xlink:to="bntx_BargainPurchaseGainOnAcquisition_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherComponentsOfTaxExpenseIncome" xlink:type="locator" xlink:label="bntx_OtherComponentsOfTaxExpenseIncome" />
    <link:label xml:lang="en-US" xlink:label="bntx_OtherComponentsOfTaxExpenseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other components of tax expense (income).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_OtherComponentsOfTaxExpenseIncome" xlink:to="bntx_OtherComponentsOfTaxExpenseIncome_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GovernmentGrantsExemptedFromTaxes" xlink:type="locator" xlink:label="bntx_GovernmentGrantsExemptedFromTaxes" />
    <link:label xml:lang="en-US" xlink:label="bntx_GovernmentGrantsExemptedFromTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Government grants exempted from taxes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_GovernmentGrantsExemptedFromTaxes" xlink:to="bntx_GovernmentGrantsExemptedFromTaxes_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AddBackForTradeTaxPurposes" xlink:type="locator" xlink:label="bntx_AddBackForTradeTaxPurposes" />
    <link:label xml:lang="en-US" xlink:label="bntx_AddBackForTradeTaxPurposes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Add back for trade tax purposes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_AddBackForTradeTaxPurposes" xlink:to="bntx_AddBackForTradeTaxPurposes_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NonTaxEffectiveBargainPurchase" xlink:type="locator" xlink:label="bntx_NonTaxEffectiveBargainPurchase" />
    <link:label xml:lang="en-US" xlink:label="bntx_NonTaxEffectiveBargainPurchase_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-tax effective bargain purchase.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_NonTaxEffectiveBargainPurchase" xlink:to="bntx_NonTaxEffectiveBargainPurchase_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses" xlink:type="locator" xlink:label="bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses" />
    <link:label xml:lang="en-US" xlink:label="bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non recognition of tax effect on share based payment expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses" xlink:to="bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TaxEffectiveEquityTransactionCosts" xlink:type="locator" xlink:label="bntx_TaxEffectiveEquityTransactionCosts" />
    <link:label xml:lang="en-US" xlink:label="bntx_TaxEffectiveEquityTransactionCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax effective equity transaction costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_TaxEffectiveEquityTransactionCosts" xlink:to="bntx_TaxEffectiveEquityTransactionCosts_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TaxEffectOfNonrecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences" xlink:type="locator" xlink:label="bntx_TaxEffectOfNonrecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences" />
    <link:label xml:lang="en-US" xlink:label="bntx_TaxEffectOfNonrecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax effect of nonrecognition of deferred taxes on tax losses and temporary differences.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_TaxEffectOfNonrecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences" xlink:to="bntx_TaxEffectOfNonrecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TaxEffectOfTaxCredit" xlink:type="locator" xlink:label="bntx_TaxEffectOfTaxCredit" />
    <link:label xml:lang="en-US" xlink:label="bntx_TaxEffectOfTaxCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax effect of tax credit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_TaxEffectOfTaxCredit" xlink:to="bntx_TaxEffectOfTaxCredit_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_InterestBearingLoansAndBorrowings" xlink:type="locator" xlink:label="bntx_InterestBearingLoansAndBorrowings" />
    <link:label xml:lang="en-US" xlink:label="bntx_InterestBearingLoansAndBorrowings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest bearing loans and borrowings.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_InterestBearingLoansAndBorrowings" xlink:to="bntx_InterestBearingLoansAndBorrowings_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CurrentPrepaymentsRelatedToServiceContracts" xlink:type="locator" xlink:label="bntx_CurrentPrepaymentsRelatedToServiceContracts" />
    <link:label xml:lang="en-US" xlink:label="bntx_CurrentPrepaymentsRelatedToServiceContracts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Current prepayments related to service contracts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_CurrentPrepaymentsRelatedToServiceContracts" xlink:to="bntx_CurrentPrepaymentsRelatedToServiceContracts_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherCurrentAssetsOther" xlink:type="locator" xlink:label="bntx_OtherCurrentAssetsOther" />
    <link:label xml:lang="en-US" xlink:label="bntx_OtherCurrentAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other current assets other.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_OtherCurrentAssetsOther" xlink:to="bntx_OtherCurrentAssetsOther_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredExpensesFromInsuranceContracts" xlink:type="locator" xlink:label="bntx_DeferredExpensesFromInsuranceContracts" />
    <link:label xml:lang="en-US" xlink:label="bntx_DeferredExpensesFromInsuranceContracts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred expenses from insurance contracts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DeferredExpensesFromInsuranceContracts" xlink:to="bntx_DeferredExpensesFromInsuranceContracts_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredExpensesFromContractManufacturingAndContractResearchOrganizations" xlink:type="locator" xlink:label="bntx_DeferredExpensesFromContractManufacturingAndContractResearchOrganizations" />
    <link:label xml:lang="en-US" xlink:label="bntx_DeferredExpensesFromContractManufacturingAndContractResearchOrganizations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred expenses from contract manufacturing and contract research organizations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DeferredExpensesFromContractManufacturingAndContractResearchOrganizations" xlink:to="bntx_DeferredExpensesFromContractManufacturingAndContractResearchOrganizations_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherDeferredExpenses" xlink:type="locator" xlink:label="bntx_OtherDeferredExpenses" />
    <link:label xml:lang="en-US" xlink:label="bntx_OtherDeferredExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other deferred expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_OtherDeferredExpenses" xlink:to="bntx_OtherDeferredExpenses_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredExpenseCurrent" xlink:type="locator" xlink:label="bntx_DeferredExpenseCurrent" />
    <link:label xml:lang="en-US" xlink:label="bntx_DeferredExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred expense current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DeferredExpenseCurrent" xlink:to="bntx_DeferredExpenseCurrent_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredExpenseNonCurrent" xlink:type="locator" xlink:label="bntx_DeferredExpenseNonCurrent" />
    <link:label xml:lang="en-US" xlink:label="bntx_DeferredExpenseNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred expense, non-current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DeferredExpenseNonCurrent" xlink:to="bntx_DeferredExpenseNonCurrent_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CurrentLiabilitiesForEmployeesBenefits" xlink:type="locator" xlink:label="bntx_CurrentLiabilitiesForEmployeesBenefits" />
    <link:label xml:lang="en-US" xlink:label="bntx_CurrentLiabilitiesForEmployeesBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Current liabilities for employees benefits.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_CurrentLiabilitiesForEmployeesBenefits" xlink:to="bntx_CurrentLiabilitiesForEmployeesBenefits_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherLiabilitiesOther" xlink:type="locator" xlink:label="bntx_OtherLiabilitiesOther" />
    <link:label xml:lang="en-US" xlink:label="bntx_OtherLiabilitiesOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other liabilities other.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_OtherLiabilitiesOther" xlink:to="bntx_OtherLiabilitiesOther_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:type="locator" xlink:label="dei_DocumentInformationTable" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Information [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classes of share capital [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Classes Of Share Capital [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ClassesOfShareCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share capital [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_ClassesOfShareCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ClassesOfShareCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Classes Of Share Capital [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember" xlink:type="locator" xlink:label="bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">American Depositary Shares, each Representing one ordinary share.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember" xlink:to="bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">American Depositary Shares, each Representing one ordinary share</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">American Depositary Shares Each Representing One Ordinary Share [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareOfOneMember" xlink:type="locator" xlink:label="bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareOfOneMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareOfOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Ordinary shares, no par value, with national amount attributable to each ordinary share of &#8364;1.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareOfOneMember" xlink:to="bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareOfOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareOfOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares, no par value, with national amount attributable to each ordinary share of ?1</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareOfOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ordinary Shares No Par Value With National Amount Attributable To Each Ordinary Share Of One [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesAddressTypeAxis" xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Addresses, Address Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Addresses Address Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AddressTypeDomain" xlink:type="locator" xlink:label="dei_AddressTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="dei_AddressTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Address Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AddressTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Address Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_BusinessContactMember" xlink:type="locator" xlink:label="dei_BusinessContactMember" />
    <link:label xml:lang="en-US" xlink:label="dei_BusinessContactMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Contact</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_BusinessContactMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Contact [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Information [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentRegistrationStatement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Registration Statement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentRegistrationStatement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Registration Statement</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentShellCompanyReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Shell Company Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentShellCompanyReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Shell Company Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:type="locator" xlink:label="dei_NoTradingSymbolFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">No Trading Symbol Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelName" xlink:type="locator" xlink:label="dei_ContactPersonnelName" />
    <link:label xml:lang="en-US" xlink:label="dei_ContactPersonnelName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contact Personnel Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_ContactPersonnelName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contact Personnel Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Country</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelEmailAddress" xlink:type="locator" xlink:label="dei_ContactPersonnelEmailAddress" />
    <link:label xml:lang="en-US" xlink:label="dei_ContactPersonnelEmailAddress_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contact Personnel Email Address</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelEmailAddress" xlink:to="dei_ContactPersonnelEmailAddress_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_ContactPersonnelEmailAddress_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contact Personnel Email Address</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAccountingStandard_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Accounting Standard</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAccountingStandard_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Accounting Standard</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncurrent Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsAndGoodwill" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets And Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RightofuseAssets" xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_RightofuseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_RightofuseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Rightofuse Assets</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherNoncurrentAssets" xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentAssets" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherNoncurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentAssets" xlink:to="ifrs-full_OtherNoncurrentAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherNoncurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Assets</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxAssets" xlink:type="locator" xlink:label="ifrs-full_DeferredTaxAssets" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DeferredTaxAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxAssets" xlink:to="ifrs-full_DeferredTaxAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DeferredTaxAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssets" xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NoncurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NoncurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncurrent Assets</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Inventories" xlink:type="locator" xlink:label="ifrs-full_Inventories" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_Inventories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_Inventories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventories</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTradeReceivables" xlink:type="locator" xlink:label="ifrs-full_CurrentTradeReceivables" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentTradeReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTradeReceivables" xlink:to="ifrs-full_CurrentTradeReceivables_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentTradeReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Trade Receivables</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialAssets" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherCurrentFinancialAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other financial assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialAssets" xlink:to="ifrs-full_OtherCurrentFinancialAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherCurrentFinancialAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Financial Assets</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentAssets" xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherCurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherCurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Assets</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:type="locator" xlink:label="ifrs-full_CurrentTaxAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentTaxAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxAssetsCurrent" xlink:to="ifrs-full_CurrentTaxAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentTaxAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Tax Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DeferredExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DeferredExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Expense Current</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssets" xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Assets</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets" xlink:type="locator" xlink:label="ifrs-full_Assets" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity and liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity And Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAbstract" xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital" xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IssuedCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IssuedCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issued Capital</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CapitalReserve" xlink:type="locator" xlink:label="ifrs-full_CapitalReserve" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CapitalReserve_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital reserve</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalReserve" xlink:to="ifrs-full_CapitalReserve_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CapitalReserve_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Reserve</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TreasuryShares" xlink:type="locator" xlink:label="ifrs-full_TreasuryShares" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TreasuryShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Treasury shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TreasuryShares" xlink:to="ifrs-full_TreasuryShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TreasuryShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Shares</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:type="locator" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReserves" xlink:type="locator" xlink:label="ifrs-full_OtherReserves" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other reserves</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReserves" xlink:to="ifrs-full_OtherReserves_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Reserves</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:type="locator" xlink:label="ifrs-full_Equity" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_Equity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_Equity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncurrent Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LongtermBorrowings" xlink:type="locator" xlink:label="ifrs-full_LongtermBorrowings" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LongtermBorrowings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest-bearing loans and borrowings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LongtermBorrowings" xlink:to="ifrs-full_LongtermBorrowings_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LongtermBorrowings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Borrowings</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialLiabilities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherNoncurrentFinancialLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other financial liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:to="ifrs-full_OtherNoncurrentFinancialLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherNoncurrentFinancialLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Financial Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentProvisions" xlink:type="locator" xlink:label="ifrs-full_NoncurrentProvisions" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NoncurrentProvisions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provisions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentProvisions" xlink:to="ifrs-full_NoncurrentProvisions_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NoncurrentProvisions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncurrent Provisions</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:type="locator" xlink:label="ifrs-full_NoncurrentContractLiabilities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NoncurrentContractLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentContractLiabilities" xlink:to="ifrs-full_NoncurrentContractLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NoncurrentContractLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncurrent Contract Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentLiabilities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherNoncurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentLiabilities" xlink:to="ifrs-full_OtherNoncurrentLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherNoncurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxLiabilities" xlink:type="locator" xlink:label="ifrs-full_DeferredTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DeferredTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxLiabilities" xlink:to="ifrs-full_DeferredTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DeferredTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilities" xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncurrent Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShorttermBorrowings" xlink:type="locator" xlink:label="ifrs-full_ShorttermBorrowings" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ShorttermBorrowings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest-bearing loans and borrowings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermBorrowings" xlink:to="ifrs-full_ShorttermBorrowings_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ShorttermBorrowings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shortterm Borrowings</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade payables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trade And Other Current Payables To Trade Suppliers</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other financial liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_OtherCurrentFinancialLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Financial Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentGovernmentGrants" xlink:type="locator" xlink:label="ifrs-full_CurrentGovernmentGrants" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentGovernmentGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentGovernmentGrants" xlink:to="ifrs-full_CurrentGovernmentGrants_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentGovernmentGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Government Grants</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:type="locator" xlink:label="ifrs-full_CurrentTaxLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentTaxLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax provisions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:to="ifrs-full_CurrentTaxLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentTaxLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Tax Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherShorttermProvisions" xlink:type="locator" xlink:label="ifrs-full_OtherShorttermProvisions" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherShorttermProvisions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other provisions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherShorttermProvisions" xlink:to="ifrs-full_OtherShorttermProvisions_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherShorttermProvisions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Shortterm Provisions</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentContractLiabilities" xlink:type="locator" xlink:label="ifrs-full_CurrentContractLiabilities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentContractLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentContractLiabilities" xlink:to="ifrs-full_CurrentContractLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentContractLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Contract Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentLiabilities" xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilities" xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities" xlink:type="locator" xlink:label="ifrs-full_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilities" xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total equity and liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity And Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAbstract" xlink:type="locator" xlink:label="ifrs-full_ProfitLossAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProfitLossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAbstract" xlink:to="ifrs-full_ProfitLossAbstract_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeStatementLineItems" xlink:type="locator" xlink:label="bntx_IncomeStatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="bntx_IncomeStatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income statement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_IncomeStatementLineItems" xlink:to="bntx_IncomeStatementLineItems_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeStatementTable" xlink:type="locator" xlink:label="bntx_IncomeStatementTable" />
    <link:label xml:lang="en-US" xlink:label="bntx_IncomeStatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income statement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_IncomeStatementTable" xlink:to="bntx_IncomeStatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_IncomeStatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_IncomeStatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:type="locator" xlink:label="ifrs-full_ProductsAndServicesAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProductsAndServicesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Products and services [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProductsAndServicesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:type="locator" xlink:label="ifrs-full_ProductsAndServicesMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProductsAndServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Products and services [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="ifrs-full_ProductsAndServicesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProductsAndServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ResearchAndDevelopmentMember" xlink:type="locator" xlink:label="bntx_ResearchAndDevelopmentMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_ResearchAndDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ResearchAndDevelopmentMember" xlink:to="bntx_ResearchAndDevelopmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ResearchAndDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research &amp; Development</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ResearchAndDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CommercialMember" xlink:type="locator" xlink:label="bntx_CommercialMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_CommercialMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_CommercialMember" xlink:to="bntx_CommercialMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_CommercialMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_CommercialMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_IncomeStatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_IncomeStatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueAbstract" xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_RevenueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_RevenueAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_RevenueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:type="locator" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromContractsWithCustomers" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contracts With Customers</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CostOfSales" xlink:type="locator" xlink:label="ifrs-full_CostOfSales" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CostOfSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cost of sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CostOfSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Sales</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SalesAndMarketingExpense" xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Sales and marketing expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales And Marketing Expense</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">General and administrative expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MiscellaneousOtherOperatingExpense" xlink:type="locator" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MiscellaneousOtherOperatingExpense" xlink:to="ifrs-full_MiscellaneousOtherOperatingExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Miscellaneous Other Operating Expense</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:type="locator" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other operating income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MiscellaneousOtherOperatingIncome" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Miscellaneous Other Operating Income</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss From Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncome" xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FinanceIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FinanceIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Income</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceCosts" xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FinanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Finance expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FinanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Costs</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expenses related to lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense On Lease Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share of loss of equity method investees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Profit / (Loss) for the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProfitLossAttributableToAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Attributable to:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProfitLossAttributableToAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss Attributable To [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity holders of the parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss Attributable To Owners Of Parent</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-controlling interests</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss Attributable To Noncontrolling Interests</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareAbstract" xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:type="locator" xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and diluted, profit / (loss) for the period attributable to ordinary equity holders of the parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:to="ifrs-full_BasicAndDilutedEarningsLossPerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basic And Diluted Earnings Loss Per Share</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_StockSplitConversionRatio" xlink:type="locator" xlink:label="bntx_StockSplitConversionRatio" />
    <link:label xml:lang="en-US" xlink:label="bntx_StockSplitConversionRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock split conversion ratio.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_StockSplitConversionRatio" xlink:to="bntx_StockSplitConversionRatio_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_StockSplitConversionRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock split ratio</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_StockSplitConversionRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Split Conversion Ratio</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Comprehensive Income [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Profit / (Loss) for the period</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income / (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="locator" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income / (loss) that may be reclassified to profit or loss in subsequent periods, net of tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net Of Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange differences on translation of foreign operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Net Of Tax Exchange Differences On Translation</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net other comprehensive income / (loss) that may be reclassified to profit or loss in subsequent periods</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="locator" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss that will not be reclassified to profit or loss in subsequent periods, net of tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net Of Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remeasurement loss on defined benefit plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Net Of Tax Gains Losses On Remeasurements Of Defined Benefit Plans</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net other comprehensive loss that will not be reclassified to profit or loss in subsequent periods</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncome" xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncome" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other comprehensive income / (loss) for the period, net of tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive income / (loss) for the period, net of tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Attributable to:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Attributable To [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity holders of the parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Attributable To Owners Of Parent</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-controlling interests</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Attributable To Noncontrolling Interests</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IssuanceOfShareCapital" xlink:type="locator" xlink:label="bntx_IssuanceOfShareCapital" />
    <link:label xml:lang="en-US" xlink:label="bntx_IssuanceOfShareCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of share capital.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_IssuanceOfShareCapital" xlink:to="bntx_IssuanceOfShareCapital_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncreaseDecreaseThroughSettlementOfSharebasedPaymentPlan" xlink:type="locator" xlink:label="bntx_IncreaseDecreaseThroughSettlementOfSharebasedPaymentPlan" />
    <link:label xml:lang="en-US" xlink:label="bntx_IncreaseDecreaseThroughSettlementOfSharebasedPaymentPlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) through settlement of sharebased payment plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_IncreaseDecreaseThroughSettlementOfSharebasedPaymentPlan" xlink:to="bntx_IncreaseDecreaseThroughSettlementOfSharebasedPaymentPlan_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncreaseDecreaseThroughInitialPublicOffering" xlink:type="locator" xlink:label="bntx_IncreaseDecreaseThroughInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="bntx_IncreaseDecreaseThroughInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease through initial public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_IncreaseDecreaseThroughInitialPublicOffering" xlink:to="bntx_IncreaseDecreaseThroughInitialPublicOffering_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncreaseDecreaseThroughAcquisitionOfNoncontrollingInterests" xlink:type="locator" xlink:label="bntx_IncreaseDecreaseThroughAcquisitionOfNoncontrollingInterests" />
    <link:label xml:lang="en-US" xlink:label="bntx_IncreaseDecreaseThroughAcquisitionOfNoncontrollingInterests_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease through acquisition of noncontrolling interests.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_IncreaseDecreaseThroughAcquisitionOfNoncontrollingInterests" xlink:to="bntx_IncreaseDecreaseThroughAcquisitionOfNoncontrollingInterests_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Changes In Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement Of Changes In Equity [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Changes In Equity [Table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of equity [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Equity [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:type="locator" xlink:label="ifrs-full_EquityMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EquityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_EquityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EquityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issued Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CapitalReserveMember" xlink:type="locator" xlink:label="ifrs-full_CapitalReserveMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CapitalReserveMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital Reserve</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalReserveMember" xlink:to="ifrs-full_CapitalReserveMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CapitalReserveMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Reserve [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TreasurySharesMember" xlink:type="locator" xlink:label="ifrs-full_TreasurySharesMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TreasurySharesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TreasurySharesMember" xlink:to="ifrs-full_TreasurySharesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TreasurySharesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReservesMember" xlink:type="locator" xlink:label="ifrs-full_OtherReservesMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherReservesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Reserves</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReservesMember" xlink:to="ifrs-full_OtherReservesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherReservesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Reserves [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ForeignCurrencyTranslationReserveMember" xlink:type="locator" xlink:label="bntx_ForeignCurrencyTranslationReserveMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_ForeignCurrencyTranslationReserveMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Foreign currency translation reserve.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ForeignCurrencyTranslationReserveMember" xlink:to="bntx_ForeignCurrencyTranslationReserveMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ForeignCurrencyTranslationReserveMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Translation Reserve</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ForeignCurrencyTranslationReserveMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Translation Reserve [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:to="ifrs-full_EquityAttributableToOwnersOfParentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Attributable To Owners Of Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterestsMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NoncontrollingInterestsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-controlling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterestsMember" xlink:to="ifrs-full_NoncontrollingInterestsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NoncontrollingInterestsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interests [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CapitalIncreaseSeriesBMember" xlink:type="locator" xlink:label="bntx_CapitalIncreaseSeriesBMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_CapitalIncreaseSeriesBMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Capital increase series B.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_CapitalIncreaseSeriesBMember" xlink:to="bntx_CapitalIncreaseSeriesBMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_CapitalIncreaseSeriesBMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_CapitalIncreaseSeriesBMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Increase Series B [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement Of Changes In Equity [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Changes In Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_Equity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Profit / (Loss) for the period</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other comprehensive income / (loss)</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_IssuanceOfShareCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of share capital</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_IssuanceOfShareCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Share Capital</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_IncreaseDecreaseThroughInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital increase initial public offering (referred to as IPO)</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_IncreaseDecreaseThroughInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease Through Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_IncreaseDecreaseThroughAcquisitionOfNoncontrollingInterests_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition of non-controlling interest</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_IncreaseDecreaseThroughAcquisitionOfNoncontrollingInterests_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease Through Acquisition Of Noncontrolling Interests</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost" xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Transaction costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Issue Related Cost</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease Through Sharebased Payment Transactions</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_IncreaseDecreaseThroughSettlementOfSharebasedPaymentPlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement of share-based payment plan</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_IncreaseDecreaseThroughSettlementOfSharebasedPaymentPlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease Through Settlement Of Sharebased Payment Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_Equity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AdjustmentsForInterestOnLeaseLiability" xlink:type="locator" xlink:label="bntx_AdjustmentsForInterestOnLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="bntx_AdjustmentsForInterestOnLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments for interest on lease liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_AdjustmentsForInterestOnLeaseLiability" xlink:to="bntx_AdjustmentsForInterestOnLeaseLiability_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AdjustmentsForMovementsInGovernmentGrants" xlink:type="locator" xlink:label="bntx_AdjustmentsForMovementsInGovernmentGrants" />
    <link:label xml:lang="en-US" xlink:label="bntx_AdjustmentsForMovementsInGovernmentGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments for movements in government grants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_AdjustmentsForMovementsInGovernmentGrants" xlink:to="bntx_AdjustmentsForMovementsInGovernmentGrants_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AdjustmentsForIncreaseDecreaseInTradeAccountReceivableAndContractAssets" xlink:type="locator" xlink:label="bntx_AdjustmentsForIncreaseDecreaseInTradeAccountReceivableAndContractAssets" />
    <link:label xml:lang="en-US" xlink:label="bntx_AdjustmentsForIncreaseDecreaseInTradeAccountReceivableAndContractAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments for increase decrease in trade account receivable and contract assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_AdjustmentsForIncreaseDecreaseInTradeAccountReceivableAndContractAssets" xlink:to="bntx_AdjustmentsForIncreaseDecreaseInTradeAccountReceivableAndContractAssets_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions" xlink:type="locator" xlink:label="bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions" />
    <link:label xml:lang="en-US" xlink:label="bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments for increase (decrease) in trade payables, other liabilities, contract liabilities and provisions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions" xlink:to="bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssets" xlink:type="locator" xlink:label="bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssets" />
    <link:label xml:lang="en-US" xlink:label="bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase of intangible assets and right of use assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssets" xlink:to="bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssets_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_WorkingCapitalAdjustmentsAbstract" xlink:type="locator" xlink:label="bntx_WorkingCapitalAdjustmentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="bntx_WorkingCapitalAdjustmentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Working capital adjustments abstract.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_WorkingCapitalAdjustmentsAbstract" xlink:to="bntx_WorkingCapitalAdjustmentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flows From Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss before tax</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile loss before tax to net cash flows:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For Reconcile Profit Loss [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization of property, plant, equipment and intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For Depreciation And Amortisation Expense</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For Sharebased Payments</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net foreign exchange differences</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For Unrealised Foreign Exchange Losses Gains</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">(Gain) / Loss on disposal of property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For Gain Loss On Disposals Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForFinanceIncome" xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncome" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AdjustmentsForFinanceIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Finance income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceIncome" xlink:to="ifrs-full_AdjustmentsForFinanceIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AdjustmentsForFinanceIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For Finance Income</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AdjustmentsForInterestOnLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest on lease liability</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AdjustmentsForInterestOnLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For Interest On Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForFinanceCosts" xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceCosts" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AdjustmentsForFinanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceCosts" xlink:to="ifrs-full_AdjustmentsForFinanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AdjustmentsForFinanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For Finance Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AdjustmentsForMovementsInGovernmentGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Movements in government grants</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AdjustmentsForMovementsInGovernmentGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For Movements In Government Grants</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Share of loss of an associate and a joint venture</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherAdjustmentsForNoncashItems" xlink:type="locator" xlink:label="ifrs-full_OtherAdjustmentsForNoncashItems" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherAdjustmentsForNoncashItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-cash income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAdjustmentsForNoncashItems" xlink:to="ifrs-full_OtherAdjustmentsForNoncashItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherAdjustmentsForNoncashItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Adjustments For Noncash Items</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_WorkingCapitalAdjustmentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Working capital adjustments:</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_WorkingCapitalAdjustmentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Working Capital Adjustments [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AdjustmentsForIncreaseDecreaseInTradeAccountReceivableAndContractAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease / (Increase) in trade receivable and contract assets</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AdjustmentsForIncreaseDecreaseInTradeAccountReceivableAndContractAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For Increase Decrease In Trade Account Receivable And Contract Assets</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease / (Increase) in inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For Decrease Increase In Inventories</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Decrease) / Increase in trade payables, other liabilities, contract liabilities and provisions</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For Increase Decrease In Trade Payables Other Liabilities Contract Liabilities And Provisions</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:type="locator" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Received Classified As Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid Classified As Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="locator" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax received (paid), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid Refund Classified As Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash flows used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flows From Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flows From Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Of Property Plant And Equipment Classified As Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator" xlink:label="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of intangibles assets and right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Of Intangible Assets And Right Of Use Assets</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="locator" xlink:label="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisition of subsidiaries and businesses, net of cash acquired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:to="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash flows used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flows From Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flows From Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of share capital, net of costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuing Shares</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from loans and borrowings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Borrowings Classified As Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayment of loans and borrowings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Borrowings Classified As Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments related to lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Lease Liabilities Classified As Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash flows from financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flows From Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="locator" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in cash and cash equivalents resulting from exchange rate differences</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effect Of Exchange Rate Changes On Cash And Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at January 1</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at December 31</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfCorporateInformationExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfCorporateInformationExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfCorporateInformationExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of corporate information explanatory.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfCorporateInformationExplanatory" xlink:to="bntx_DisclosureOfCorporateInformationExplanatory_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfCorporateInformationExplanatoryAbstract" xlink:type="locator" xlink:label="bntx_DisclosureOfCorporateInformationExplanatoryAbstract" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfCorporateInformationExplanatoryAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of corporate information explanatory.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfCorporateInformationExplanatoryAbstract" xlink:to="bntx_DisclosureOfCorporateInformationExplanatoryAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfCorporateInformationExplanatoryAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Corporate Information Explanatory [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfCorporateInformationExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate information</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfCorporateInformationExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Corporate Information Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:type="locator" xlink:label="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of summary of significant accounting policies abstract.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Summary Of Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Summary Of Significant Accounting Policies Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfAccountingJudgementsAndEstimatesAbstract" xlink:type="locator" xlink:label="bntx_DisclosureOfAccountingJudgementsAndEstimatesAbstract" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfAccountingJudgementsAndEstimatesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting judgements and estimates.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfAccountingJudgementsAndEstimatesAbstract" xlink:to="bntx_DisclosureOfAccountingJudgementsAndEstimatesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfAccountingJudgementsAndEstimatesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Accounting Judgements And Estimates [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Judgments, Estimates and Assumptions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Accounting Judgements And Estimates Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Significant Investments In Subsidiaries [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfCompositionOfGroupExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCompositionOfGroupExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfCompositionOfGroupExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Group information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCompositionOfGroupExplanatory" xlink:to="ifrs-full_DisclosureOfCompositionOfGroupExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfCompositionOfGroupExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Composition Of Group Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Business Combinations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combinations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Business Combinations Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfRevenueFromContractsWithCustomersAbstract" xlink:type="locator" xlink:label="bntx_DisclosureOfRevenueFromContractsWithCustomersAbstract" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfRevenueFromContractsWithCustomersAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of revenue from contracts with customers.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfRevenueFromContractsWithCustomersAbstract" xlink:to="bntx_DisclosureOfRevenueFromContractsWithCustomersAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfRevenueFromContractsWithCustomersAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Revenue From Contracts With Customers [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue from Contracts with Customers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:to="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Revenue From Contracts With Customers Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIncomeAndExpensesExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfIncomeAndExpensesExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfIncomeAndExpensesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The detailed information about income and expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfIncomeAndExpensesExplanatory" xlink:to="bntx_DisclosureOfIncomeAndExpensesExplanatory_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="locator" xlink:label="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AnalysisOfIncomeAndExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Analysis Of Income And Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="ifrs-full_AnalysisOfIncomeAndExpenseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfIncomeAndExpensesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income and Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfIncomeAndExpensesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Income And Expenses Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Major Components Of Tax Expense Income [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Income Tax Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Earnings Per Share Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Property Plant And Equipment Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Intangible Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Intangible Assets Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Financial Instruments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Assets and Financial Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Offsetting Of Financial Assets And Financial Liabilities Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfInventoriesAbstract" xlink:type="locator" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ClassesOfInventoriesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Classes Of Inventories [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_ClassesOfInventoriesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInventoriesExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Inventories Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MiscellaneousCurrentAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_MiscellaneousCurrentAssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_MiscellaneousCurrentAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Miscellaneous Current Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MiscellaneousCurrentAssetsAbstract" xlink:to="ifrs-full_MiscellaneousCurrentAssetsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Other Current Assets Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfDeferredExpensesExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfDeferredExpensesExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDeferredExpensesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of deferred expenses explanatory.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfDeferredExpensesExplanatory" xlink:to="bntx_DisclosureOfDeferredExpensesExplanatory_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfDeferredExpensesAbstract" xlink:type="locator" xlink:label="bntx_DisclosureOfDeferredExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDeferredExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of deferred expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfDeferredExpensesAbstract" xlink:to="bntx_DisclosureOfDeferredExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDeferredExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Deferred Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDeferredExpensesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDeferredExpensesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Deferred Expenses Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Classes Of Share Capital [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issued Capital and Reserves</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Share Capital Reserves And Other Equity Interest Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Sharebased Payment Arrangements Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MiscellaneousCurrentLiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_MiscellaneousCurrentLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_MiscellaneousCurrentLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Miscellaneous Current Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MiscellaneousCurrentLiabilitiesAbstract" xlink:to="ifrs-full_MiscellaneousCurrentLiabilitiesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Other Liabilities Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Presentation Of Leases For Lessee [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Leases Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Information About Defined Benefit Plans [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pensions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Employee Benefits Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Transactions Between Related Parties [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Disclosures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Related Party Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfEventsAfterReportingPeriodAbstract" xlink:type="locator" xlink:label="bntx_DisclosureOfEventsAfterReportingPeriodAbstract" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfEventsAfterReportingPeriodAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of events after reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfEventsAfterReportingPeriodAbstract" xlink:to="bntx_DisclosureOfEventsAfterReportingPeriodAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfEventsAfterReportingPeriodAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Events After Reporting Period [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Events After the Reporting Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Events After Reporting Period Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Preparation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Basis Of Preparation Of Financial Statements Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Basis Of Consolidation Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business combinations and Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Accounting Policy For Business Combinations And Goodwill Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatory" xlink:type="locator" xlink:label="bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of accounting policy for assets and liabilities explanatory.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatory" xlink:to="bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current versus Non-Current Classifications</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Accounting Policy For Assets And Liabilities Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Accounting Policy For Fair Value Measurement Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory" xlink:type="locator" xlink:label="bntx_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of accounting policy for revenue from contracts with customers explanatory.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory" xlink:to="bntx_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue from Contracts with Customers</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Accounting Policy For Revenue From Contracts With Customers Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government Grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Accounting Policy For Government Grants</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Accounting Policy For Income Tax Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Accounting Policy For Foreign Currency Translation Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Accounting Policy For Property Plant And Equipment Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Accounting Policy For Leases Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Accounting Policy For Intangible Assets And Goodwill Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments &#8211; Initial Recognition and Subsequent Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Accounting Policy For Financial Instruments Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Accounting Policy For Measuring Inventories</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Non-Financial Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Accounting Policy For Impairment Of Nonfinancial Assets Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:to="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Accounting Policy To Determine Components Of Cash And Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pension</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Accounting Policy For Employee Benefits Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provisions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Accounting Policy For Provisions Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Accounting Policy For Sharebased Payment Transactions Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DescriptionOfAccountingPolicyForInitialApplicationOfStandardsExplanatory" xlink:type="locator" xlink:label="bntx_DescriptionOfAccountingPolicyForInitialApplicationOfStandardsExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DescriptionOfAccountingPolicyForInitialApplicationOfStandardsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of accounting policy for initial application of standards explanatory.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DescriptionOfAccountingPolicyForInitialApplicationOfStandardsExplanatory" xlink:to="bntx_DescriptionOfAccountingPolicyForInitialApplicationOfStandardsExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DescriptionOfAccountingPolicyForInitialApplicationOfStandardsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Standards Applied for the First Time</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DescriptionOfAccountingPolicyForInitialApplicationOfStandardsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Accounting Policy For Initial Application Of Standards Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DescriptionOfAccountingPolicyForStandardIssuedButNotYetEffectiveExplanatory" xlink:type="locator" xlink:label="bntx_DescriptionOfAccountingPolicyForStandardIssuedButNotYetEffectiveExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DescriptionOfAccountingPolicyForStandardIssuedButNotYetEffectiveExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of accounting policy for standard issued but not yet effective explanatory.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DescriptionOfAccountingPolicyForStandardIssuedButNotYetEffectiveExplanatory" xlink:to="bntx_DescriptionOfAccountingPolicyForStandardIssuedButNotYetEffectiveExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DescriptionOfAccountingPolicyForStandardIssuedButNotYetEffectiveExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Standard Issued but not yet Effective</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DescriptionOfAccountingPolicyForStandardIssuedButNotYetEffectiveExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Accounting Policy For Standard Issued But Not Yet Effective Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of property plant and equipment estimated useful lives explanatory.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatory" xlink:to="bntx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Useful Lives Applied to the Group&apos;s Property, Plant and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Property Plant And Equipment Estimated Useful Lives Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of right of use assets estimated useful lives explanatory.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatory" xlink:to="bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Useful Lives Applied to the Group&apos;s Right-of-use Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Right Of Use Assets Estimated Useful Lives Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIntangibleAssetsUsefulLifeExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfIntangibleAssetsUsefulLifeExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfIntangibleAssetsUsefulLifeExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of intangible assets useful life explanatory.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfIntangibleAssetsUsefulLifeExplanatory" xlink:to="bntx_DisclosureOfIntangibleAssetsUsefulLifeExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfIntangibleAssetsUsefulLifeExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Useful Lives Applied to the Group&apos;s Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfIntangibleAssetsUsefulLifeExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Intangible Assets Useful Life Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfDetailedInformationAboutProvisionalSalesFiguresForTerritoriesExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfDetailedInformationAboutProvisionalSalesFiguresForTerritoriesExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDetailedInformationAboutProvisionalSalesFiguresForTerritoriesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of detailed information about provisional sales figures for territories.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfDetailedInformationAboutProvisionalSalesFiguresForTerritoriesExplanatory" xlink:to="bntx_DisclosureOfDetailedInformationAboutProvisionalSalesFiguresForTerritoriesExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDetailedInformationAboutProvisionalSalesFiguresForTerritoriesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Provisional Sales Figures for Territories</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDetailedInformationAboutProvisionalSalesFiguresForTerritoriesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Detailed Information About Provisional Sales Figures For Territories Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Information about Subsidiaries</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Significant Investments In Subsidiaries Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of significant investments by parent company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatory" xlink:to="bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Information about Parent Company</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Significant Investments By Parent Company Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of entity with significant influence over the group.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatory" xlink:to="bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Information about Entity with Significant Influence Over Group</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Entity With Significant Influence Over Group Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Business Combinations [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Business Combinations [Table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BusinessCombinationsAxis" xlink:type="locator" xlink:label="ifrs-full_BusinessCombinationsAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_BusinessCombinationsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business combinations [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_BusinessCombinationsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_BusinessCombinationsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity&apos;s total for business combinations [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entitys Total For Business Combinations [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LipocalyxGmbHMember" xlink:type="locator" xlink:label="bntx_LipocalyxGmbHMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_LipocalyxGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lipocalyx GmbH.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_LipocalyxGmbHMember" xlink:to="bntx_LipocalyxGmbHMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_LipocalyxGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lipocalyx GmbH</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_LipocalyxGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lipocalyx Gmb H [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechUSIncMember" xlink:type="locator" xlink:label="bntx_BioNTechUSIncMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechUSIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">BioNTech US Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_BioNTechUSIncMember" xlink:to="bntx_BioNTechUSIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechUSIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BioNTech US Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechUSIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bio N Tech U S Inc [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechManufacturingMarburgGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechManufacturingMarburgGmbHMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechManufacturingMarburgGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">BioNTech Manufacturing Marburg GmbH.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_BioNTechManufacturingMarburgGmbHMember" xlink:to="bntx_BioNTechManufacturingMarburgGmbHMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechManufacturingMarburgGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BioNTech Manufacturing Marburg GmbH</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechManufacturingMarburgGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bio N Tech Manufacturing Marburg Gmb H [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Business Combinations [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Business Combinations [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Values of Identifiable Net Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Detailed Information About Business Combinations Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reconciliation of Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" xlink:to="ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Reconciliation Of Changes In Goodwill Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Disaggregation of Revenues from Contracts with Customers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Disaggregation Of Revenue From Contracts With Customers Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of contract balances from contracts with customers explanatory.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatory" xlink:to="bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Contract Balances</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Contract Balances From Contracts With Customers Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfRecognitionOfRevenueExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfRecognitionOfRevenueExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfRecognitionOfRevenueExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue recognized in the reporting period, which has been included in contract liabilities at the beginning of the year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfRecognitionOfRevenueExplanatory" xlink:to="bntx_DisclosureOfRecognitionOfRevenueExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfRecognitionOfRevenueExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Revenue Recognized</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfRecognitionOfRevenueExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Recognition Of Revenue Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPerformanceObligationsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPerformanceObligationsExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfPerformanceObligationsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Contract Liabilities Allocated to Remaining Performance Obligations (Unsatisfied or Partially Unsatisfied)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsExplanatory" xlink:to="ifrs-full_DisclosureOfPerformanceObligationsExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfPerformanceObligationsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Performance Obligations Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfCostOfSalesExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCostOfSalesExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfCostOfSalesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of Sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCostOfSalesExplanatory" xlink:to="ifrs-full_DisclosureOfCostOfSalesExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfCostOfSalesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Cost Of Sales Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Research And Development Expense Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfSalesAndMarketingExpensesExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfSalesAndMarketingExpensesExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfSalesAndMarketingExpensesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of sales and marketing expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfSalesAndMarketingExpensesExplanatory" xlink:to="bntx_DisclosureOfSalesAndMarketingExpensesExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfSalesAndMarketingExpensesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales and Marketing Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfSalesAndMarketingExpensesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Sales And Marketing Expenses Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of General And Administrative Expense Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Operating Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Other Operating Income Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfChangesRegardingGovernmentGrantsExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfChangesRegardingGovernmentGrantsExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfChangesRegardingGovernmentGrantsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of changes regarding government grants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfChangesRegardingGovernmentGrantsExplanatory" xlink:to="bntx_DisclosureOfChangesRegardingGovernmentGrantsExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfChangesRegardingGovernmentGrantsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes Regarding Government Grants</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfChangesRegardingGovernmentGrantsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Changes Regarding Government Grants Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinanceIncomeExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceIncomeExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Finance Income Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceCostExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfFinanceCostExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceCostExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfFinanceCostExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Finance Cost Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of detailed information about employee benefits expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatory" xlink:to="bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefits Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Detailed Information About Employee Benefits Expense Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of current and deferred tax expense explanatory.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatory" xlink:to="bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Current and Deferred Tax Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Current And Deferred Tax Expense Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of reconciliation of expected income tax benefit to actual income tax benefit explanatory.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatory" xlink:to="bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reconciliation of Expected Income Tax Benefit to Actual Income Tax Benefit</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Reconciliation Of Expected Income Tax Benefit To Actual Income Tax Benefit Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Deferred Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfAccumulatedTaxLossesExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfAccumulatedTaxLossesExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfAccumulatedTaxLossesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accumulated tax losses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfAccumulatedTaxLossesExplanatory" xlink:to="bntx_DisclosureOfAccumulatedTaxLossesExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfAccumulatedTaxLossesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accumulated Tax Losses</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfAccumulatedTaxLossesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Accumulated Tax Losses Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Income and Share Data Used in the Basic and Diluted EPS Calculations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareExplanatory" xlink:to="ifrs-full_EarningsPerShareExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property Plant and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Detailed Information About Property Plant And Equipment Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Detailed Information About Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Detailed Information About Intangible Assets Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of goodwill acquired in respective business combinations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatory" xlink:to="bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Goodwill Recognized</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Goodwill Acquired In Respective Business Combinations Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Cash And Cash Equivalents Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Assets at Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Financial Assets Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Liabilities at Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Financial Liabilities Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfForeignCurrencyRiskExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfForeignCurrencyRiskExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfForeignCurrencyRiskExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of foreign currency risk.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfForeignCurrencyRiskExplanatory" xlink:to="bntx_DisclosureOfForeignCurrencyRiskExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfForeignCurrencyRiskExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Carrying Amount of Monetary Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfForeignCurrencyRiskExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Foreign Currency Risk Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Effect of Changes in Foreign Exchange Rates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:to="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Effect Of Changes In Foreign Exchange Rates Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in Liabilities Arising From Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfClassesOfInventoriesExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfClassesOfInventoriesExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfClassesOfInventoriesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of classes of inventories.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfClassesOfInventoriesExplanatory" xlink:to="bntx_DisclosureOfClassesOfInventoriesExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfClassesOfInventoriesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Inventories</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfClassesOfInventoriesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Classes Of Inventories Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of detailed information about other assets explanatory.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatory" xlink:to="bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Detailed Information About Other Assets Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfExpensesExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfExpensesExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfExpensesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Deferred Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfExpensesExplanatory" xlink:to="ifrs-full_DisclosureOfExpensesExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfExpensesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Expenses Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Types of share-based payment arrangements [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Types Of Sharebased Payment Arrangements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment arrangements [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Payment Arrangements [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeEquityPlanMember" xlink:type="locator" xlink:label="bntx_EmployeeEquityPlanMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_EmployeeEquityPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee equity plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_EmployeeEquityPlanMember" xlink:to="bntx_EmployeeEquityPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_EmployeeEquityPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Equity Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_EmployeeEquityPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Equity Plan [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ManagementBoardGrantMember" xlink:type="locator" xlink:label="bntx_ManagementBoardGrantMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_ManagementBoardGrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Management board grant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ManagementBoardGrantMember" xlink:to="bntx_ManagementBoardGrantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ManagementBoardGrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Management Board Grant</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ManagementBoardGrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Management Board Grant [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ChiefExecutiveOfficerGrantMember" xlink:type="locator" xlink:label="bntx_ChiefExecutiveOfficerGrantMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_ChiefExecutiveOfficerGrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Chief executive officer grant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ChiefExecutiveOfficerGrantMember" xlink:to="bntx_ChiefExecutiveOfficerGrantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ChiefExecutiveOfficerGrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Chief Executive Officer Grant</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ChiefExecutiveOfficerGrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Chief Executive Officer Grant [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeStockOwnershipPlanMember" xlink:type="locator" xlink:label="bntx_EmployeeStockOwnershipPlanMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_EmployeeStockOwnershipPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock ownership plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_EmployeeStockOwnershipPlanMember" xlink:to="bntx_EmployeeStockOwnershipPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_EmployeeStockOwnershipPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Ownership Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_EmployeeStockOwnershipPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Ownership Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Number and Share Price of Restricted Stock Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss" xlink:type="locator" xlink:label="ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Expense Recognized for Employee Services Received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss" xlink:to="ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Explanation Of Effect Of Sharebased Payments On Profit Or Loss</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Number and Weighted-Average Exercise Price of Share Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Number And Weighted Average Exercise Prices Of Share Options Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Inputs Used in Measurement of Fair Value at Grant Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Indirect Measurement Of Fair Value Of Goods Or Services Received Share Options Granted During Period Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfDetailedInformationAboutOtherLiabilitiesExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfDetailedInformationAboutOtherLiabilitiesExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDetailedInformationAboutOtherLiabilitiesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of Detailed Information About Other Liabilities Explanatory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfDetailedInformationAboutOtherLiabilitiesExplanatory" xlink:to="bntx_DisclosureOfDetailedInformationAboutOtherLiabilitiesExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDetailedInformationAboutOtherLiabilitiesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Other Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDetailedInformationAboutOtherLiabilitiesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Detailed Information About Other Liabilities Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Right-of-Use Assets within Consolidated Statements of Financial Position</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Quantitative Information About Rightofuse Assets Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of detailed information about lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatory" xlink:to="bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Lease Liability Included in Interest-Bearing Loans and Borrowings</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Detailed Information About Lease Liabilities Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInstatementOfOperationsExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInstatementOfOperationsExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInstatementOfOperationsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of detailed information about lease expense recognized instatement of operations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInstatementOfOperationsExplanatory" xlink:to="bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInstatementOfOperationsExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInstatementOfOperationsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Amounts Recognized in Consolidated Statement of Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInstatementOfOperationsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Detailed Information About Lease Expense Recognized Instatement Of Operations Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Defined Benefit Obligation Recognized in Non-current Provisions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Defined Benefit Plans Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfDetailedInformationAboutNetBenefitExpenseRecognizedInStatementOfProfitOrLossExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfDetailedInformationAboutNetBenefitExpenseRecognizedInStatementOfProfitOrLossExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDetailedInformationAboutNetBenefitExpenseRecognizedInStatementOfProfitOrLossExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of detailed information about net benefit expense recognized in statement of profit or loss.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfDetailedInformationAboutNetBenefitExpenseRecognizedInStatementOfProfitOrLossExplanatory" xlink:to="bntx_DisclosureOfDetailedInformationAboutNetBenefitExpenseRecognizedInStatementOfProfitOrLossExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDetailedInformationAboutNetBenefitExpenseRecognizedInStatementOfProfitOrLossExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Components of Net Benefit Expense Recognized in Statement of Profit or Loss</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDetailedInformationAboutNetBenefitExpenseRecognizedInStatementOfProfitOrLossExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Detailed Information About Net Benefit Expense Recognized In Statement Of Profit Or Loss Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfDetailedInformationAboutRemeasurementsRecognizedInOtherComprehensiveIncomeExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfDetailedInformationAboutRemeasurementsRecognizedInOtherComprehensiveIncomeExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDetailedInformationAboutRemeasurementsRecognizedInOtherComprehensiveIncomeExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of detailed information about remeasurements recognized in other comprehensive income.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfDetailedInformationAboutRemeasurementsRecognizedInOtherComprehensiveIncomeExplanatory" xlink:to="bntx_DisclosureOfDetailedInformationAboutRemeasurementsRecognizedInOtherComprehensiveIncomeExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDetailedInformationAboutRemeasurementsRecognizedInOtherComprehensiveIncomeExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Components of Remeasurements Recognized in Other Comprehensive Income</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDetailedInformationAboutRemeasurementsRecognizedInOtherComprehensiveIncomeExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Detailed Information About Remeasurements Recognized In Other Comprehensive Income Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Changes to Defined Benefit Obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:to="ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Net Defined Benefit Liability Asset Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfAnalysisOfPresentValueOfDefinedBenefitObligationThatDistinguishesNatureCharacteristicsAndRisksExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAnalysisOfPresentValueOfDefinedBenefitObligationThatDistinguishesNatureCharacteristicsAndRisksExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfAnalysisOfPresentValueOfDefinedBenefitObligationThatDistinguishesNatureCharacteristicsAndRisksExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Principal Assumptions used in Determining Defined Benefit Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAnalysisOfPresentValueOfDefinedBenefitObligationThatDistinguishesNatureCharacteristicsAndRisksExplanatory" xlink:to="ifrs-full_DisclosureOfAnalysisOfPresentValueOfDefinedBenefitObligationThatDistinguishesNatureCharacteristicsAndRisksExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfAnalysisOfPresentValueOfDefinedBenefitObligationThatDistinguishesNatureCharacteristicsAndRisksExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Analysis Of Present Value Of Defined Benefit Obligation That Distinguishes Nature Characteristics And Risks Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Quantitative Sensitivity Analysis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Sensitivity Analysis For Actuarial Assumptions Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfDetailedInformationAboutExpectedPaymentsOrContributionsToDefinedBenefitPlanExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfDetailedInformationAboutExpectedPaymentsOrContributionsToDefinedBenefitPlanExplanatory" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDetailedInformationAboutExpectedPaymentsOrContributionsToDefinedBenefitPlanExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of detailed information about expected payments or contributions to defined benefit plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfDetailedInformationAboutExpectedPaymentsOrContributionsToDefinedBenefitPlanExplanatory" xlink:to="bntx_DisclosureOfDetailedInformationAboutExpectedPaymentsOrContributionsToDefinedBenefitPlanExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDetailedInformationAboutExpectedPaymentsOrContributionsToDefinedBenefitPlanExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Expected Payments or Contributions to Plans in Future Years</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfDetailedInformationAboutExpectedPaymentsOrContributionsToDefinedBenefitPlanExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Detailed Information About Expected Payments Or Contributions To Defined Benefit Plan Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Compensation of Key Management Personnel</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Information About Key Management Personnel Explanatory</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Transactions Between Other Related Parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Transactions Between Related Parties Explanatory</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfNewRealEstateEntitiesFounded" xlink:type="locator" xlink:label="bntx_NumberOfNewRealEstateEntitiesFounded" />
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfNewRealEstateEntitiesFounded_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of new real estate entities founded.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_NumberOfNewRealEstateEntitiesFounded" xlink:to="bntx_NumberOfNewRealEstateEntitiesFounded_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfCorporateInformationLineItems" xlink:type="locator" xlink:label="bntx_DisclosureOfCorporateInformationLineItems" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfCorporateInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of corporate information.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfCorporateInformationLineItems" xlink:to="bntx_DisclosureOfCorporateInformationLineItems_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfCorporateInformationTable" xlink:type="locator" xlink:label="bntx_DisclosureOfCorporateInformationTable" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfCorporateInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of corporate information.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfCorporateInformationTable" xlink:to="bntx_DisclosureOfCorporateInformationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfCorporateInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Corporate Information [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfCorporateInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Corporate Information [Table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_GeographicalAreasAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical areas [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_GeographicalAreasAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Geographical Areas [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_GeographicalAreasMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical areas [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="ifrs-full_GeographicalAreasMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_GeographicalAreasMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Geographical Areas [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_DE" xlink:type="locator" xlink:label="country_DE" />
    <link:label xml:lang="en-US" xlink:label="country_DE_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Germany</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_DE" xlink:to="country_DE_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_DE_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">GERMANY</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfCorporateInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Corporate Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfCorporateInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Corporate Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfNewRealEstateEntitiesFounded_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of new real estate entities founded</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfNewRealEstateEntitiesFounded_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of New Real Estate Entities Founded</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfOperationSegments" xlink:type="locator" xlink:label="bntx_NumberOfOperationSegments" />
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfOperationSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of operation segments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_NumberOfOperationSegments" xlink:to="bntx_NumberOfOperationSegments_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfReportingSegments" xlink:type="locator" xlink:label="bntx_NumberOfReportingSegments" />
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfReportingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of reporting segments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_NumberOfReportingSegments" xlink:to="bntx_NumberOfReportingSegments_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_MinimumNumberOfCountriesInWhichCOVID19VaccineAuthorizedOrApprovedForEmergencyOrTemporaryUseOrGrantedConditionalMarketingAuthorization" xlink:type="locator" xlink:label="bntx_MinimumNumberOfCountriesInWhichCOVID19VaccineAuthorizedOrApprovedForEmergencyOrTemporaryUseOrGrantedConditionalMarketingAuthorization" />
    <link:label xml:lang="en-US" xlink:label="bntx_MinimumNumberOfCountriesInWhichCOVID19VaccineAuthorizedOrApprovedForEmergencyOrTemporaryUseOrGrantedConditionalMarketingAuthorization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum number of countries in which COVID-19 vaccine authorized or approved for emergency or temporary use or granted conditional marketing authorization.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_MinimumNumberOfCountriesInWhichCOVID19VaccineAuthorizedOrApprovedForEmergencyOrTemporaryUseOrGrantedConditionalMarketingAuthorization" xlink:to="bntx_MinimumNumberOfCountriesInWhichCOVID19VaccineAuthorizedOrApprovedForEmergencyOrTemporaryUseOrGrantedConditionalMarketingAuthorization_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfOperationSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operation segments</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfOperationSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operation Segments</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfReportingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reporting segment</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfReportingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Reporting Segments</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_MinimumNumberOfCountriesInWhichCOVID19VaccineAuthorizedOrApprovedForEmergencyOrTemporaryUseOrGrantedConditionalMarketingAuthorization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum number of countries in which COVID-19 vaccine was authorized or approved for emergency or temporary use or granted conditional marketing authorization</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_MinimumNumberOfCountriesInWhichCOVID19VaccineAuthorizedOrApprovedForEmergencyOrTemporaryUseOrGrantedConditionalMarketingAuthorization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Number Of Countries In Which C O V I D19 Vaccine Authorized Or Approved For Emergency Or Temporary Use Or Granted Conditional Marketing Authorization</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment terms in contracts with customers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers" xlink:to="ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Significant Payment Terms In Contracts With Customers</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classes of property, plant and equipment [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Classes Of Property Plant And Equipment [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BuildingsMember" xlink:type="locator" xlink:label="ifrs-full_BuildingsMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_BuildingsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Buildings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BuildingsMember" xlink:to="ifrs-full_BuildingsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_BuildingsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Buildings [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EquipmentToolsAndInstallationsMember" xlink:type="locator" xlink:label="bntx_EquipmentToolsAndInstallationsMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_EquipmentToolsAndInstallationsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equipment, tools and installations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_EquipmentToolsAndInstallationsMember" xlink:to="bntx_EquipmentToolsAndInstallationsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_EquipmentToolsAndInstallationsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment, Tools and Installations</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_EquipmentToolsAndInstallationsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equipment Tools And Installations [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bottom Of Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TopOfRangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TopOfRangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Top Of Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:type="locator" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, Useful life (Years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Useful Life Measured As Period Of Time Property Plant And Equipment</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" xlink:type="locator" xlink:label="bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" />
    <link:label xml:lang="en-US" xlink:label="bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Useful life measured as period of time right-of-use-assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" xlink:to="bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Quantitative Information About Leases For Lessee [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Quantitative Information About Rightofuse Assets [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Quantitative Information About Rightofuse Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ClassesOfAssetsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classes of assets [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ClassesOfAssetsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Classes Of Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ClassesOfAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_ClassesOfAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ClassesOfAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Classes Of Assets [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ProductionFacilitiesMember" xlink:type="locator" xlink:label="bntx_ProductionFacilitiesMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_ProductionFacilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Production facilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ProductionFacilitiesMember" xlink:to="bntx_ProductionFacilitiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ProductionFacilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Production Facilities</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ProductionFacilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Production Facilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_VehiclesMember" xlink:type="locator" xlink:label="ifrs-full_VehiclesMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_VehiclesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Automobiles</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_VehiclesMember" xlink:to="ifrs-full_VehiclesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_VehiclesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vehicles [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets, Useful life (Years)</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Useful Life Measured As Period Of Time Right Of Use Assets</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Intangible Assets [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classes of intangible assets other than goodwill [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Classes Of Intangible Assets Other Than Goodwill [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets other than goodwill [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Other Than Goodwill [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IntellectualPropertyRightsMember" xlink:type="locator" xlink:label="bntx_IntellectualPropertyRightsMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_IntellectualPropertyRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Intellectual property rights.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_IntellectualPropertyRightsMember" xlink:to="bntx_IntellectualPropertyRightsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_IntellectualPropertyRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intellectual Property Rights</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_IntellectualPropertyRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intellectual Property Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LicencesMember" xlink:type="locator" xlink:label="ifrs-full_LicencesMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LicencesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LicencesMember" xlink:to="ifrs-full_LicencesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LicencesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Licences [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComputerSoftwareMember" xlink:type="locator" xlink:label="ifrs-full_ComputerSoftwareMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ComputerSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComputerSoftwareMember" xlink:to="ifrs-full_ComputerSoftwareMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ComputerSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Software [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Intangible Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:type="locator" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, Useful life (Years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Useful Life Measured As Period Of Time Intangible Assets Other Than Goodwill</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception" xlink:type="locator" xlink:label="bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception" />
    <link:label xml:lang="en-US" xlink:label="bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated milestone payment to be received at contract inception.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception" xlink:to="bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsAbstract" xlink:type="locator" xlink:label="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting judgments, estimates and assumptions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsAbstract" xlink:to="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Judgments Estimates And Assumptions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated milestone payment to be received</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Milestone Payment To Be Received At Contract Inception</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsLineItems" xlink:type="locator" xlink:label="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting judgments estimates and assumptions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsLineItems" xlink:to="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsLineItems_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsTable" xlink:type="locator" xlink:label="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsTable" />
    <link:label xml:lang="en-US" xlink:label="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting judgments estimates and assumptions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsTable" xlink:to="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Judgments Estimates And Assumptions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Judgments Estimates And Assumptions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="country_DE_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">German Territory</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:label xml:lang="en-US" xlink:label="country_US_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Territory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_US_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OutsideUSMember" xlink:type="locator" xlink:label="bntx_OutsideUSMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_OutsideUSMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Outside US.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_OutsideUSMember" xlink:to="bntx_OutsideUSMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_OutsideUSMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Territories Outside the U.S.</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OutsideUSMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Outside U S [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SalesChannelsAxis" xlink:type="locator" xlink:label="ifrs-full_SalesChannelsAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_SalesChannelsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales channels [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesChannelsAxis" xlink:to="ifrs-full_SalesChannelsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_SalesChannelsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Channels [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SalesChannelsMember" xlink:type="locator" xlink:label="ifrs-full_SalesChannelsMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_SalesChannelsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales channels [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesChannelsMember" xlink:to="ifrs-full_SalesChannelsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_SalesChannelsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Channels [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GoodsSoldDirectlyToConsumersMember" xlink:type="locator" xlink:label="ifrs-full_GoodsSoldDirectlyToConsumersMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_GoodsSoldDirectlyToConsumersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct Product Sales to BioNTech Customers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GoodsSoldDirectlyToConsumersMember" xlink:to="ifrs-full_GoodsSoldDirectlyToConsumersMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_GoodsSoldDirectlyToConsumersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goods Sold Directly To Consumers [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CollaborationAgreementMember" xlink:type="locator" xlink:label="bntx_CollaborationAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_CollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_CollaborationAgreementMember" xlink:to="bntx_CollaborationAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_CollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share of Collaboration Partner&apos;s Gross Profit</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_CollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Judgments Estimates And Assumptions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Judgments Estimates And Assumptions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel">Revenue from contracts with customers</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Significant Investments In Subsidiaries [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Significant Investments In Subsidiaries [Table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiaries [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Investments In Subsidiaries [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity&apos;s total for subsidiaries [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entitys Total For Subsidiaries [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechRNAPharmaceuticalsGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechRNAPharmaceuticalsGmbHMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechRNAPharmaceuticalsGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">BioNTech RNA Pharmaceuticals GmbH.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_BioNTechRNAPharmaceuticalsGmbHMember" xlink:to="bntx_BioNTechRNAPharmaceuticalsGmbHMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechRNAPharmaceuticalsGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BioNTech RNA Pharmaceuticals GmbH</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechRNAPharmaceuticalsGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bio N Tech R N A Pharmaceuticals Gmb H [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechDeliveryTechnologiesGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechDeliveryTechnologiesGmbHMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechDeliveryTechnologiesGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">BioNTech Delivery Technologies GmbH.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_BioNTechDeliveryTechnologiesGmbHMember" xlink:to="bntx_BioNTechDeliveryTechnologiesGmbHMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechDeliveryTechnologiesGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BioNTech Delivery Technologies GmbH</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechDeliveryTechnologiesGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bio N Tech Delivery Technologies Gmb H [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechDiagnosticsGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechDiagnosticsGmbHMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechDiagnosticsGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">BioNTech Diagnostics GmbH.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_BioNTechDiagnosticsGmbHMember" xlink:to="bntx_BioNTechDiagnosticsGmbHMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechDiagnosticsGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BioNTech Diagnostics GmbH</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechDiagnosticsGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bio N Tech Diagnostics Gmb H [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechEuropeGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechEuropeGmbHMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechEuropeGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">BioNTech Europe GmbH.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_BioNTechEuropeGmbHMember" xlink:to="bntx_BioNTechEuropeGmbHMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechEuropeGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BioNTech Europe GmbH (previously BioNTech Small Molecules GmbH)</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechEuropeGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bio N Tech Europe Gmb H [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechManufacturingGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechManufacturingGmbHMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechManufacturingGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">BioNTech Manufacturing GmbH.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_BioNTechManufacturingGmbHMember" xlink:to="bntx_BioNTechManufacturingGmbHMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechManufacturingGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BioNTech Manufacturing GmbH (previously BioNTech IVAC GmbH)</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechManufacturingGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bio N Tech Manufacturing Gmb H [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechAustriaBeteiligungenGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechAustriaBeteiligungenGmbHMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechAustriaBeteiligungenGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">BioNTech Austria Beteiligungen GmbH.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_BioNTechAustriaBeteiligungenGmbHMember" xlink:to="bntx_BioNTechAustriaBeteiligungenGmbHMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechAustriaBeteiligungenGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BioNTech Austria Beteiligungen GmbH</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechAustriaBeteiligungenGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bio N Tech Austria Beteiligungen Gmb H [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechInnovativeManufacturingServicesGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechInnovativeManufacturingServicesGmbHMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechInnovativeManufacturingServicesGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">BioNTech Innovative Manufacturing Services GmbH</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_BioNTechInnovativeManufacturingServicesGmbHMember" xlink:to="bntx_BioNTechInnovativeManufacturingServicesGmbHMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechInnovativeManufacturingServicesGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BioNTech Innovative Manufacturing Services GmbH</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechInnovativeManufacturingServicesGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bio N Tech Innovative Manufacturing Services Gmb H [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ReSanoGmbHMember" xlink:type="locator" xlink:label="bntx_ReSanoGmbHMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_ReSanoGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">ReSano GmbH.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ReSanoGmbHMember" xlink:to="bntx_ReSanoGmbHMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ReSanoGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ReSano GmbH (previously reBOOST Management GmbH)</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ReSanoGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Re Sano Gmb H [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_JPTPeptideTechnologiesGmbHMember" xlink:type="locator" xlink:label="bntx_JPTPeptideTechnologiesGmbHMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_JPTPeptideTechnologiesGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">JPT Peptide Technologies GmbH</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_JPTPeptideTechnologiesGmbHMember" xlink:to="bntx_JPTPeptideTechnologiesGmbHMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_JPTPeptideTechnologiesGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">JPT Peptide Technologies GmbH</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_JPTPeptideTechnologiesGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">J P T Peptide Technologies Gmb H [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_JPTPeptideTechnologiesIncMember" xlink:type="locator" xlink:label="bntx_JPTPeptideTechnologiesIncMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_JPTPeptideTechnologiesIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">JPT Peptide Technologies Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_JPTPeptideTechnologiesIncMember" xlink:to="bntx_JPTPeptideTechnologiesIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_JPTPeptideTechnologiesIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">JPT Peptide Technologies Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_JPTPeptideTechnologiesIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">J P T Peptide Technologies Inc [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechUSAHoldingLLCMember" xlink:type="locator" xlink:label="bntx_BioNTechUSAHoldingLLCMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechUSAHoldingLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">BioNTech USA Holding LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_BioNTechUSAHoldingLLCMember" xlink:to="bntx_BioNTechUSAHoldingLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechUSAHoldingLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BioNTech USA Holding LLC</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechUSAHoldingLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bio N Tech U S A Holding L L C [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechResearchAndDevelopmentIncMember" xlink:type="locator" xlink:label="bntx_BioNTechResearchAndDevelopmentIncMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechResearchAndDevelopmentIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">BioNTech Research and Development Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_BioNTechResearchAndDevelopmentIncMember" xlink:to="bntx_BioNTechResearchAndDevelopmentIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechResearchAndDevelopmentIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BioNTech Research and Development Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechResearchAndDevelopmentIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bio N Tech Research And Development Inc [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechCellAndGeneTherapiesGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechCellAndGeneTherapiesGmbHMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechCellAndGeneTherapiesGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">BioNTech Cell &amp; Gene Therapies GmbH.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_BioNTechCellAndGeneTherapiesGmbHMember" xlink:to="bntx_BioNTechCellAndGeneTherapiesGmbHMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechCellAndGeneTherapiesGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BioNTech Cell &amp; Gene Therapies GmbH</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechCellAndGeneTherapiesGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bio N Tech Cell And Gene Therapies Gmb H [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechPharmaceuticalsAsiaPacificPteLtdMember" xlink:type="locator" xlink:label="bntx_BioNTechPharmaceuticalsAsiaPacificPteLtdMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechPharmaceuticalsAsiaPacificPteLtdMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">BioNTech Pharmaceuticals Asia Pacific Pte. Ltd.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_BioNTechPharmaceuticalsAsiaPacificPteLtdMember" xlink:to="bntx_BioNTechPharmaceuticalsAsiaPacificPteLtdMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechPharmaceuticalsAsiaPacificPteLtdMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BioNTech Pharmaceuticals Asia Pacific Pte. Ltd</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechPharmaceuticalsAsiaPacificPteLtdMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bio N Tech Pharmaceuticals Asia Pacific Pte Ltd [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechRealEstateVerwaltungsGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechRealEstateVerwaltungsGmbHMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechRealEstateVerwaltungsGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">BioNTech Real Estate Verwaltungs GmbH.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_BioNTechRealEstateVerwaltungsGmbHMember" xlink:to="bntx_BioNTechRealEstateVerwaltungsGmbHMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechRealEstateVerwaltungsGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BioNTech Real Estate Verwaltungs GmbH</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechRealEstateVerwaltungsGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bio N Tech Real Estate Verwaltungs Gmb H [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechUKLimitedMember" xlink:type="locator" xlink:label="bntx_BioNTechUKLimitedMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechUKLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">BioNTech UK Limited.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_BioNTechUKLimitedMember" xlink:to="bntx_BioNTechUKLimitedMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechUKLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BioNTech UK Limited</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechUKLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bio N Tech U K Limited [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechRealEstateGmbHAndCoKGMember" xlink:type="locator" xlink:label="bntx_BioNTechRealEstateGmbHAndCoKGMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechRealEstateGmbHAndCoKGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">BioNTech Real Estate GmbH &amp; Co. KG.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_BioNTechRealEstateGmbHAndCoKGMember" xlink:to="bntx_BioNTechRealEstateGmbHAndCoKGMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechRealEstateGmbHAndCoKGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BioNTech Real Estate GmbH &amp; Co. KG</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechRealEstateGmbHAndCoKGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bio N Tech Real Estate Gmb H And Co K G [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechRealEstateHoldingGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechRealEstateHoldingGmbHMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechRealEstateHoldingGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">BioNTech Real Estate Holding GmbH.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_BioNTechRealEstateHoldingGmbHMember" xlink:to="bntx_BioNTechRealEstateHoldingGmbHMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechRealEstateHoldingGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BioNTech Real Estate Holding GmbH</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechRealEstateHoldingGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bio N Tech Real Estate Holding Gmb H [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechRealEstateDerGoldgrubeGmbHCoKGMember" xlink:type="locator" xlink:label="bntx_BioNTechRealEstateDerGoldgrubeGmbHCoKGMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechRealEstateDerGoldgrubeGmbHCoKGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">BioNTech Real Estate an der Goldgrube GmbH &amp; Co. KG.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_BioNTechRealEstateDerGoldgrubeGmbHCoKGMember" xlink:to="bntx_BioNTechRealEstateDerGoldgrubeGmbHCoKGMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechRealEstateDerGoldgrubeGmbHCoKGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BioNTech Real Estate An der Goldgrube GmbH &amp; Co. KG</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechRealEstateDerGoldgrubeGmbHCoKGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bio N Tech Real Estate Der Goldgrube Gmb H Co K G [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechRealEstateHausVierGmbHCoKGMember" xlink:type="locator" xlink:label="bntx_BioNTechRealEstateHausVierGmbHCoKGMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechRealEstateHausVierGmbHCoKGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">BioNTech Real Estate Haus Vier GmbH &amp; Co. KG.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_BioNTechRealEstateHausVierGmbHCoKGMember" xlink:to="bntx_BioNTechRealEstateHausVierGmbHCoKGMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechRealEstateHausVierGmbHCoKGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BioNTech Real Estate Haus Vier GmbH &amp; Co. KG</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechRealEstateHausVierGmbHCoKGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bio N Tech Real Estate Haus Vier Gmb H Co K G [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechRealEstateAdamOpelStraeGmbHCoKGMember" xlink:type="locator" xlink:label="bntx_BioNTechRealEstateAdamOpelStraeGmbHCoKGMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechRealEstateAdamOpelStraeGmbHCoKGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">BioNTech Real Estate Adam Opel Stra&#223;e GmbH &amp; Co. KG.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_BioNTechRealEstateAdamOpelStraeGmbHCoKGMember" xlink:to="bntx_BioNTechRealEstateAdamOpelStraeGmbHCoKGMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechRealEstateAdamOpelStraeGmbHCoKGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BioNTech Real Estate Adam Opel Stra&#223;e GmbH &amp; Co. KG</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechRealEstateAdamOpelStraeGmbHCoKGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bio N Tech Real Estate Adam Opel Strae Gmb H Co K G [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Significant Investments In Subsidiaries [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Significant Investments In Subsidiaries [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:type="locator" xlink:label="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Country of incorporation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:to="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Country Of Incorporation Or Residence Of Subsidiary</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" xlink:type="locator" xlink:label="ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registered office</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" xlink:to="ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Principal Place Of Business Of Subsidiary</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">% equity interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proportion Of Ownership Interest In Subsidiary</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfEntitiesAcquiredDuringPeriod" xlink:type="locator" xlink:label="bntx_NumberOfEntitiesAcquiredDuringPeriod" />
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfEntitiesAcquiredDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of entities acquired during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_NumberOfEntitiesAcquiredDuringPeriod" xlink:to="bntx_NumberOfEntitiesAcquiredDuringPeriod_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfNewEntities" xlink:type="locator" xlink:label="bntx_NumberOfNewEntities" />
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfNewEntities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of new entities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_NumberOfNewEntities" xlink:to="bntx_NumberOfNewEntities_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NeonTherapeuticsIncAndNovartisManufacturingGmbHMember" xlink:type="locator" xlink:label="bntx_NeonTherapeuticsIncAndNovartisManufacturingGmbHMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_NeonTherapeuticsIncAndNovartisManufacturingGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Neon Therapeutics Inc and Novartis Manufacturing GmbH.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_NeonTherapeuticsIncAndNovartisManufacturingGmbHMember" xlink:to="bntx_NeonTherapeuticsIncAndNovartisManufacturingGmbHMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_NeonTherapeuticsIncAndNovartisManufacturingGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Neon Therapeutics Inc. (subsequently renamed BioNTech US Inc.) and Novartis Manufacturing GmbH (subsequently renamed BioNTech Manufacturing Marburg GmbH)</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NeonTherapeuticsIncAndNovartisManufacturingGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Neon Therapeutics Inc And Novartis Manufacturing Gmb H [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechUSAHoldingLLCAndBioNTechResearchAndDevelopmentIncMember" xlink:type="locator" xlink:label="bntx_BioNTechUSAHoldingLLCAndBioNTechResearchAndDevelopmentIncMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechUSAHoldingLLCAndBioNTechResearchAndDevelopmentIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">BioNTech USA Holding, LLC and BioNTech Research &amp; Development, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_BioNTechUSAHoldingLLCAndBioNTechResearchAndDevelopmentIncMember" xlink:to="bntx_BioNTechUSAHoldingLLCAndBioNTechResearchAndDevelopmentIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechUSAHoldingLLCAndBioNTechResearchAndDevelopmentIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BioNTech USA Holding, LLC and BioNTech Research &amp; Development, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechUSAHoldingLLCAndBioNTechResearchAndDevelopmentIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bio N Tech U S A Holding L L C And Bio N Tech Research And Development Inc [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Categories of related parties [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Categories Of Related Parties [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity&apos;s total for related parties [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entitys Total For Related Parties [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfEntitiesAcquiredDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of entities acquired during the period</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfEntitiesAcquiredDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Entities Acquired During Period</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfNewEntities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of entities</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfNewEntities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of New Entities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:type="locator" xlink:label="srt_OwnershipAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_OwnershipAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_OwnershipAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_OwnershipDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_OwnershipDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Domain]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechMember" xlink:type="locator" xlink:label="bntx_BioNTechMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">BioNTech.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_BioNTechMember" xlink:to="bntx_BioNTechMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BioNTech</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BioNTechMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bio N Tech [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ATImpfGmbHMember" xlink:type="locator" xlink:label="bntx_ATImpfGmbHMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_ATImpfGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">AT Impf GmbH, parent company of BioNTech.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ATImpfGmbHMember" xlink:to="bntx_ATImpfGmbHMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ATImpfGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AT Impf GmbH</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ATImpfGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A T Impf Gmb H [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Ownership of ordinary shares in BioNTech</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_MedineGmbHMember" xlink:type="locator" xlink:label="bntx_MedineGmbHMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_MedineGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Medine GmbH.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_MedineGmbHMember" xlink:to="bntx_MedineGmbHMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_MedineGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Medine GmbH</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_MedineGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Medine Gmb H [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ItemsOfContingentLiabilitiesAxis" xlink:type="locator" xlink:label="ifrs-full_ItemsOfContingentLiabilitiesAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ItemsOfContingentLiabilitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Items of contingent liabilities [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ItemsOfContingentLiabilitiesAxis" xlink:to="ifrs-full_ItemsOfContingentLiabilitiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ItemsOfContingentLiabilitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Items Of Contingent Liabilities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ItemsOfContingentLiabilitiesMember" xlink:type="locator" xlink:label="ifrs-full_ItemsOfContingentLiabilitiesMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ItemsOfContingentLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Items of contingent liabilities [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ItemsOfContingentLiabilitiesMember" xlink:to="ifrs-full_ItemsOfContingentLiabilitiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ItemsOfContingentLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Items Of Contingent Liabilities [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PhaseOneClinicalTrialMember" xlink:type="locator" xlink:label="bntx_PhaseOneClinicalTrialMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_PhaseOneClinicalTrialMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Phase 1 clinical trial.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_PhaseOneClinicalTrialMember" xlink:to="bntx_PhaseOneClinicalTrialMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_PhaseOneClinicalTrialMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Phase 1 Clinical Trial</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_PhaseOneClinicalTrialMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Phase One Clinical Trial [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PhaseTwoClinicalTrialMember" xlink:type="locator" xlink:label="bntx_PhaseTwoClinicalTrialMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_PhaseTwoClinicalTrialMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Phase 2 clinical trial.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_PhaseTwoClinicalTrialMember" xlink:to="bntx_PhaseTwoClinicalTrialMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_PhaseTwoClinicalTrialMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Phase 2 Clinical Trial</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_PhaseTwoClinicalTrialMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Phase Two Clinical Trial [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsUnderDevelopmentMember" xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsUnderDevelopmentMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IntangibleAssetsUnderDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-process R&amp;D</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsUnderDevelopmentMember" xlink:to="ifrs-full_IntangibleAssetsUnderDevelopmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IntangibleAssetsUnderDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Under Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NameOfAcquiree" xlink:type="locator" xlink:label="ifrs-full_NameOfAcquiree" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NameOfAcquiree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Name of acquiree</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NameOfAcquiree" xlink:to="ifrs-full_NameOfAcquiree_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NameOfAcquiree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Name Of Acquiree</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashTransferred" xlink:type="locator" xlink:label="ifrs-full_CashTransferred" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CashTransferred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashTransferred" xlink:to="ifrs-full_CashTransferred_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CashTransferred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Transferred</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DateOfAcquisition2013" xlink:type="locator" xlink:label="ifrs-full_DateOfAcquisition2013" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DateOfAcquisition2013_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Date of acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DateOfAcquisition2013" xlink:to="ifrs-full_DateOfAcquisition2013_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DateOfAcquisition2013_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Date Of Acquisition2013</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Estimated contingent consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Recognised As Of Acquisition Date</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill" xlink:type="locator" xlink:label="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill" />
    <link:label xml:lang="en-US" xlink:label="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Identifiable assets acquired (liabilities assumed) and goodwill.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill" xlink:to="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwillNetOfBargainPurchase" xlink:type="locator" xlink:label="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwillNetOfBargainPurchase" />
    <link:label xml:lang="en-US" xlink:label="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwillNetOfBargainPurchase_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Identifiable assets acquired (liabilities assumed) and goodwill net of bargain purchase.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwillNetOfBargainPurchase" xlink:to="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwillNetOfBargainPurchase_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:type="locator" xlink:label="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amounts Recognised As Of Acquisition Date For Each Major Class Of Assets Acquired And Liabilities Assumed [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill Recognised As Of Acquisition Date</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Identifiable Intangible Assets Recognised As Of Acquisition Date</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Recognised As Of Acquisition Date</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Assets Recognised As Of Acquisition Date</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_InventoryRecognisedAsOfAcquisitionDate" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_InventoryRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_InventoryRecognisedAsOfAcquisitionDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_InventoryRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Recognised As Of Acquisition Date</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets non-current and current</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Non Current And Current Recognised As Of Acquisition Date</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Recognised As Of Acquisition Date</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AssetsRecognizedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AssetsRecognizedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Recognized As Of Acquisition Date</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_LiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_LiabilitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ProvisionsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provisions non-current and current</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ProvisionsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Provisions Non Current And Current Recognised As Of Acquisition Date</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_TradePayablesRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade payables</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_TradePayablesRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trade Payables Recognised As Of Acquisition Date</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OtherLiabilitiesNonCurrentAndCurrentRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities non-current and current</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OtherLiabilitiesNonCurrentAndCurrentRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Non Current And Current Recognised As Of Acquisition Date</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_LiabilitiesRecognizedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_LiabilitiesRecognizedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Recognized As Of Acquisition Date</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="locator" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total identifiable net assets at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:to="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Identifiable Assets Acquired Liabilities Assumed</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Consideration transferred</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Identifiable Assets Acquired Liabilities Assumed And Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BargainPurchaseGainOnAcquisition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Bargain purchase</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BargainPurchaseGainOnAcquisition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bargain Purchase Gain On Acquisition</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwillNetOfBargainPurchase_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Consideration transferred</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwillNetOfBargainPurchase_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Identifiable Assets Acquired Liabilities Assumed And Goodwill Net Of Bargain Purchase</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" xlink:type="locator" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" xlink:to="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Acquisitiondate Fair Value Of Total Consideration Transferred [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_SharesIssuedAtFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued, at fair value</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_SharesIssuedAtFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued At Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CashTransferred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration liability</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="locator" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:to="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Acquisitiondate Fair Value Of Total Consideration Transferred</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:type="locator" xlink:label="ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:to="ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Acquisitionrelated Costs Recognised As Expense For Transaction Recognised Separately From Acquisition Of Assets And Assumption Of Liabilities In Business Combination</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BusinessCombinationContingentCashConsideration" xlink:type="locator" xlink:label="bntx_BusinessCombinationContingentCashConsideration" />
    <link:label xml:lang="en-US" xlink:label="bntx_BusinessCombinationContingentCashConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination maximum potential contingent cash consideration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_BusinessCombinationContingentCashConsideration" xlink:to="bntx_BusinessCombinationContingentCashConsideration_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_BusinessCombinationContingentCashConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent cash consideration</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BusinessCombinationContingentCashConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Cash Consideration</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConsiderationTransferred" xlink:type="locator" xlink:label="bntx_ConsiderationTransferred" />
    <link:label xml:lang="en-US" xlink:label="bntx_ConsiderationTransferred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Consideration transferred.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ConsiderationTransferred" xlink:to="bntx_ConsiderationTransferred_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AmericanDepositaryShares" xlink:type="locator" xlink:label="bntx_AmericanDepositaryShares" />
    <link:label xml:lang="en-US" xlink:label="bntx_AmericanDepositaryShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">American depositary shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_AmericanDepositaryShares" xlink:to="bntx_AmericanDepositaryShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ConsiderationTransferred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate value of merger consideration</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ConsiderationTransferred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consideration Transferred</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AmericanDepositaryShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">American depositary shares</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AmericanDepositaryShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">American Depositary Shares</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IntangibleAssetsNumberOfNeoantigenTargetedTherapiesUnderDevelopment" xlink:type="locator" xlink:label="bntx_IntangibleAssetsNumberOfNeoantigenTargetedTherapiesUnderDevelopment" />
    <link:label xml:lang="en-US" xlink:label="bntx_IntangibleAssetsNumberOfNeoantigenTargetedTherapiesUnderDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Intangible assets, number of neoantigen targeted therapies under development.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_IntangibleAssetsNumberOfNeoantigenTargetedTherapiesUnderDevelopment" xlink:to="bntx_IntangibleAssetsNumberOfNeoantigenTargetedTherapiesUnderDevelopment_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_IntangibleAssetsNumberOfNeoantigenTargetedTherapiesUnderDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, number of neoantigen targeted therapies under development</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_IntangibleAssetsNumberOfNeoantigenTargetedTherapiesUnderDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Number Of Neoantigen Targeted Therapies Under Development</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Recognised As Of Acquisition Date</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BargainPurchaseGainOnAcquisition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bargain purchase</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Goodwill" xlink:type="locator" xlink:label="ifrs-full_Goodwill" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_Goodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">As of January 1, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Goodwill" xlink:to="ifrs-full_Goodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_Goodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionalRecognitionGoodwill" xlink:type="locator" xlink:label="ifrs-full_AdditionalRecognitionGoodwill" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AdditionalRecognitionGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition of subsidiaries and businesses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionalRecognitionGoodwill" xlink:to="ifrs-full_AdditionalRecognitionGoodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AdditionalRecognitionGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Recognition Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currency differences</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease Through Net Exchange Differences Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_Goodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">As of December 31, 2020</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorCustomersAxis" xlink:type="locator" xlink:label="ifrs-full_MajorCustomersAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_MajorCustomersAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Major customers [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_MajorCustomersAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Major Customers [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorCustomersMember" xlink:type="locator" xlink:label="ifrs-full_MajorCustomersMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_MajorCustomersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customers [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="ifrs-full_MajorCustomersMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_MajorCustomersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Major Customers [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PfizerIncMember" xlink:type="locator" xlink:label="bntx_PfizerIncMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_PfizerIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Pfizer Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_PfizerIncMember" xlink:to="bntx_PfizerIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_PfizerIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pfizer Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_PfizerIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pfizer Inc [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GenentechIncMember" xlink:type="locator" xlink:label="bntx_GenentechIncMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_GenentechIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Genentech Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_GenentechIncMember" xlink:to="bntx_GenentechIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_GenentechIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Genentech Inc</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_GenentechIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Genentech Inc [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ShanghaiFosunPharmaceuticalGroupCoLtdMember" xlink:type="locator" xlink:label="bntx_ShanghaiFosunPharmaceuticalGroupCoLtdMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_ShanghaiFosunPharmaceuticalGroupCoLtdMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Shanghai Fosun Pharmaceutical (Group) Co., Ltd.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ShanghaiFosunPharmaceuticalGroupCoLtdMember" xlink:to="bntx_ShanghaiFosunPharmaceuticalGroupCoLtdMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ShanghaiFosunPharmaceuticalGroupCoLtdMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shanghai Fosun Pharmaceutical (Group) Co., Ltd</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ShanghaiFosunPharmaceuticalGroupCoLtdMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shanghai Fosun Pharmaceutical Group Co Ltd [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherMember" xlink:type="locator" xlink:label="bntx_OtherMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_OtherMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_OtherMember" xlink:to="bntx_OtherMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_OtherMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OtherMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_COVID19VaccineRevenuesMember" xlink:type="locator" xlink:label="bntx_COVID19VaccineRevenuesMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_COVID19VaccineRevenuesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">COVID-19 vaccine revenues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_COVID19VaccineRevenuesMember" xlink:to="bntx_COVID19VaccineRevenuesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_COVID19VaccineRevenuesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COVID-19 Vaccine Revenues</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_COVID19VaccineRevenuesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">C O V I D19 Vaccine Revenues [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SalesToCollaborationPartnerMember" xlink:type="locator" xlink:label="bntx_SalesToCollaborationPartnerMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_SalesToCollaborationPartnerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales to collaboration partner.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_SalesToCollaborationPartnerMember" xlink:to="bntx_SalesToCollaborationPartnerMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_SalesToCollaborationPartnerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales To Collaboration Partner</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_SalesToCollaborationPartnerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales To Collaboration Partner [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DirectProductSalesToBioNTechCustomersMember" xlink:type="locator" xlink:label="bntx_DirectProductSalesToBioNTechCustomersMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_DirectProductSalesToBioNTechCustomersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Direct product sales to BioNTech customers.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DirectProductSalesToBioNTechCustomersMember" xlink:to="bntx_DirectProductSalesToBioNTechCustomersMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DirectProductSalesToBioNTechCustomersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct Product Sales to BioNTech Customers</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DirectProductSalesToBioNTechCustomersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Direct Product Sales To Bio N Tech Customers [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ShareOfCollaborationPartnersGrossProfitMember" xlink:type="locator" xlink:label="bntx_ShareOfCollaborationPartnersGrossProfitMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_ShareOfCollaborationPartnersGrossProfitMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share of collaboration partners gross profit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ShareOfCollaborationPartnersGrossProfitMember" xlink:to="bntx_ShareOfCollaborationPartnersGrossProfitMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ShareOfCollaborationPartnersGrossProfitMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Of Collaboration Partners Gross Profit</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ShareOfCollaborationPartnersGrossProfitMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Of Collaboration Partners Gross Profit [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherSalesMember" xlink:type="locator" xlink:label="bntx_OtherSalesMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_OtherSalesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other sales.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_OtherSalesMember" xlink:to="bntx_OtherSalesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_OtherSalesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Sales</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OtherSalesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsAxis" xlink:type="locator" xlink:label="ifrs-full_PerformanceObligationsAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PerformanceObligationsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance obligations [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PerformanceObligationsAxis" xlink:to="ifrs-full_PerformanceObligationsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PerformanceObligationsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Performance Obligations [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsMember" xlink:type="locator" xlink:label="ifrs-full_PerformanceObligationsMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PerformanceObligationsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance obligations [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PerformanceObligationsMember" xlink:to="ifrs-full_PerformanceObligationsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PerformanceObligationsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Performance Obligations [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember" xlink:type="locator" xlink:label="ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goods and Services Transferred at a Point in Time</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember" xlink:to="ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Performance Obligations Satisfied At Point In Time [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsSatisfiedOverTimeMember" xlink:type="locator" xlink:label="ifrs-full_PerformanceObligationsSatisfiedOverTimeMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PerformanceObligationsSatisfiedOverTimeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goods and Services Transferred Over Time</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PerformanceObligationsSatisfiedOverTimeMember" xlink:to="ifrs-full_PerformanceObligationsSatisfiedOverTimeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PerformanceObligationsSatisfiedOverTimeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Performance Obligations Satisfied Over Time [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel">Revenues from contracts with customers</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfCustomers" xlink:type="locator" xlink:label="bntx_NumberOfCustomers" />
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfCustomers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of customers.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_NumberOfCustomers" xlink:to="bntx_NumberOfCustomers_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SanofiSAMember" xlink:type="locator" xlink:label="bntx_SanofiSAMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_SanofiSAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sanofi S.A.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_SanofiSAMember" xlink:to="bntx_SanofiSAMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_SanofiSAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sanofi S.A.</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_SanofiSAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sanofi S A [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FosunPharmaMember" xlink:type="locator" xlink:label="bntx_FosunPharmaMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_FosunPharmaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fosun Pharma.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_FosunPharmaMember" xlink:to="bntx_FosunPharmaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_FosunPharmaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fosun Pharma</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_FosunPharmaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fosun Pharma [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis" xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets with indefinite useful life [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis" xlink:to="ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets With Indefinite Useful Life [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember" xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets with indefinite useful life [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember" xlink:to="ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets With Indefinite Useful Life [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CellscriptSublicenseMember" xlink:type="locator" xlink:label="bntx_CellscriptSublicenseMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_CellscriptSublicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cellscript sublicense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_CellscriptSublicenseMember" xlink:to="bntx_CellscriptSublicenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_CellscriptSublicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cellscript Sublicense</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_CellscriptSublicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cellscript Sublicense [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RevenuesFromSellingDrugProductBatchesToPfizersManufacturingSiteMember" xlink:type="locator" xlink:label="bntx_RevenuesFromSellingDrugProductBatchesToPfizersManufacturingSiteMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_RevenuesFromSellingDrugProductBatchesToPfizersManufacturingSiteMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenues from selling drug product batches to Pfizers manufacturing site.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_RevenuesFromSellingDrugProductBatchesToPfizersManufacturingSiteMember" xlink:to="bntx_RevenuesFromSellingDrugProductBatchesToPfizersManufacturingSiteMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_RevenuesFromSellingDrugProductBatchesToPfizersManufacturingSiteMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues from Selling Drug Product Batches to Pfizer&apos;s Manufacturing Site</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_RevenuesFromSellingDrugProductBatchesToPfizersManufacturingSiteMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues From Selling Drug Product Batches To Pfizers Manufacturing Site [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RevenueFromShareOfCollaborationPartnersGrossProfitMember" xlink:type="locator" xlink:label="bntx_RevenueFromShareOfCollaborationPartnersGrossProfitMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_RevenueFromShareOfCollaborationPartnersGrossProfitMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue from share of collaboration partner&apos;s gross profit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_RevenueFromShareOfCollaborationPartnersGrossProfitMember" xlink:to="bntx_RevenueFromShareOfCollaborationPartnersGrossProfitMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_RevenueFromShareOfCollaborationPartnersGrossProfitMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue from Share of Collaboration Partner&apos;s Gross Profit</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_RevenueFromShareOfCollaborationPartnersGrossProfitMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Share Of Collaboration Partners Gross Profit [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherSalesTransactionsMember" xlink:type="locator" xlink:label="bntx_OtherSalesTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_OtherSalesTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other sales transactions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_OtherSalesTransactionsMember" xlink:to="bntx_OtherSalesTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_OtherSalesTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Sales Transactions</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OtherSalesTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Sales Transactions [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BillAndHoldTransactionMember" xlink:type="locator" xlink:label="bntx_BillAndHoldTransactionMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_BillAndHoldTransactionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Bill-and-hold Transaction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_BillAndHoldTransactionMember" xlink:to="bntx_BillAndHoldTransactionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_BillAndHoldTransactionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bill and Hold Transaction</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BillAndHoldTransactionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bill And Hold Transaction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfCustomers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of customers</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfCustomers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Customers</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:type="locator" xlink:label="ifrs-full_PercentageOfEntitysRevenue" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PercentageOfEntitysRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PercentageOfEntitysRevenue" xlink:to="ifrs-full_PercentageOfEntitysRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PercentageOfEntitysRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Entitys Revenue</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NonRefundableUpfrontCashPayment" xlink:type="locator" xlink:label="bntx_NonRefundableUpfrontCashPayment" />
    <link:label xml:lang="en-US" xlink:label="bntx_NonRefundableUpfrontCashPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non refundable upfront cash payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_NonRefundableUpfrontCashPayment" xlink:to="bntx_NonRefundableUpfrontCashPayment_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RevenueFromCollaboration" xlink:type="locator" xlink:label="bntx_RevenueFromCollaboration" />
    <link:label xml:lang="en-US" xlink:label="bntx_RevenueFromCollaboration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue from collaboration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_RevenueFromCollaboration" xlink:to="bntx_RevenueFromCollaboration_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_RevenueFromCollaboration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue from collaboration</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_RevenueFromCollaboration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Collaboration</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NonRefundableUpfrontCashPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non refundable upfront cash payment</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NonRefundableUpfrontCashPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Upfront Cash Payment</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_MilestonePaymentRecognizedAsRevenue" xlink:type="locator" xlink:label="bntx_MilestonePaymentRecognizedAsRevenue" />
    <link:label xml:lang="en-US" xlink:label="bntx_MilestonePaymentRecognizedAsRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment recognized as revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_MilestonePaymentRecognizedAsRevenue" xlink:to="bntx_MilestonePaymentRecognizedAsRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_MilestonePaymentRecognizedAsRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment recognized as revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_MilestonePaymentRecognizedAsRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Recognized As Revenue</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RevenuesDerivedFromDeferredUpfrontPayments" xlink:type="locator" xlink:label="bntx_RevenuesDerivedFromDeferredUpfrontPayments" />
    <link:label xml:lang="en-US" xlink:label="bntx_RevenuesDerivedFromDeferredUpfrontPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenues derived from deferred upfront payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_RevenuesDerivedFromDeferredUpfrontPayments" xlink:to="bntx_RevenuesDerivedFromDeferredUpfrontPayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_RevenuesDerivedFromDeferredUpfrontPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues derived from deferred upfront payments</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_RevenuesDerivedFromDeferredUpfrontPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues Derived From Deferred Upfront Payments</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PercentageOfReimbursementOfSublicenseCosts" xlink:type="locator" xlink:label="bntx_PercentageOfReimbursementOfSublicenseCosts" />
    <link:label xml:lang="en-US" xlink:label="bntx_PercentageOfReimbursementOfSublicenseCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of reimbursement of sublicense costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_PercentageOfReimbursementOfSublicenseCosts" xlink:to="bntx_PercentageOfReimbursementOfSublicenseCosts_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SublicenseAgreementDate" xlink:type="locator" xlink:label="bntx_SublicenseAgreementDate" />
    <link:label xml:lang="en-US" xlink:label="bntx_SublicenseAgreementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublicense agreement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_SublicenseAgreementDate" xlink:to="bntx_SublicenseAgreementDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_PercentageOfReimbursementOfSublicenseCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of reimbursement of sublicense costs</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_PercentageOfReimbursementOfSublicenseCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Reimbursement Of Sublicense Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_SublicenseAgreementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublicense agreement date</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_SublicenseAgreementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sublicense Agreement Date</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConditionalMarketingAuthorizationCountries" xlink:type="locator" xlink:label="bntx_ConditionalMarketingAuthorizationCountries" />
    <link:label xml:lang="en-US" xlink:label="bntx_ConditionalMarketingAuthorizationCountries_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Conditional marketing authorization countries.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ConditionalMarketingAuthorizationCountries" xlink:to="bntx_ConditionalMarketingAuthorizationCountries_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ConditionalMarketingAuthorizationCountries_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conditional marketing authorization countries</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ConditionalMarketingAuthorizationCountries_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conditional Marketing Authorization Countries</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContractLiabilities" xlink:type="locator" xlink:label="ifrs-full_ContractLiabilities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ContractLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContractLiabilities" xlink:to="ifrs-full_ContractLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ContractLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract Liabilities</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TradeReceivableMaturityPeriod" xlink:type="locator" xlink:label="bntx_TradeReceivableMaturityPeriod" />
    <link:label xml:lang="en-US" xlink:label="bntx_TradeReceivableMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Trade receivable maturity period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_TradeReceivableMaturityPeriod" xlink:to="bntx_TradeReceivableMaturityPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_TradeReceivableMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade receivable maturity period</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_TradeReceivableMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trade Receivable Maturity Period</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RemainingUpfrontFeesContractLiabilities" xlink:type="locator" xlink:label="bntx_RemainingUpfrontFeesContractLiabilities" />
    <link:label xml:lang="en-US" xlink:label="bntx_RemainingUpfrontFeesContractLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining upfront fees contract liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_RemainingUpfrontFeesContractLiabilities" xlink:to="bntx_RemainingUpfrontFeesContractLiabilities_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale" xlink:type="locator" xlink:label="bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale" />
    <link:label xml:lang="en-US" xlink:label="bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Advance payment received for future COVID 19 vaccine sale.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale" xlink:to="bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_RemainingUpfrontFeesContractLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining upfront fees contract liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_RemainingUpfrontFeesContractLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Upfront Fees Contract Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advance payment received for future COVID 19 vaccine sale</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Advance Payment Received For Future C O V I D19 Vaccine Sale</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAdvances" xlink:type="locator" xlink:label="ifrs-full_CurrentAdvances" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentAdvances_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advance payments received on other sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAdvances" xlink:to="ifrs-full_CurrentAdvances_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentAdvances_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Advances</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredRevenueRecognizedIncludedContractLiabilities" xlink:type="locator" xlink:label="bntx_DeferredRevenueRecognizedIncludedContractLiabilities" />
    <link:label xml:lang="en-US" xlink:label="bntx_DeferredRevenueRecognizedIncludedContractLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue recognized included in contract liabilities at the beginning of the year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DeferredRevenueRecognizedIncludedContractLiabilities" xlink:to="bntx_DeferredRevenueRecognizedIncludedContractLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DeferredRevenueRecognizedIncludedContractLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amounts included in contract liabilities at the beginning of the year</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DeferredRevenueRecognizedIncludedContractLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Recognized Included Contract Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPerformanceObligationsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPerformanceObligationsAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfPerformanceObligationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Performance Obligations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsAbstract" xlink:to="ifrs-full_DisclosureOfPerformanceObligationsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPerformanceObligationsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPerformanceObligationsTable" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfPerformanceObligationsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Performance Obligations [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsTable" xlink:to="ifrs-full_DisclosureOfPerformanceObligationsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfPerformanceObligationsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Performance Obligations [Table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:type="locator" xlink:label="ifrs-full_MaturityAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_MaturityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_MaturityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maturity [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:type="locator" xlink:label="ifrs-full_AggregatedTimeBandsMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AggregatedTimeBandsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregated time bands [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_AggregatedTimeBandsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AggregatedTimeBandsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Aggregated Time Bands [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:type="locator" xlink:label="ifrs-full_NotLaterThanOneYearMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Within One Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotLaterThanOneYearMember" xlink:to="ifrs-full_NotLaterThanOneYearMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Not Later Than One Year [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanOneYearMember" xlink:type="locator" xlink:label="ifrs-full_LaterThanOneYearMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LaterThanOneYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">More Than One Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearMember" xlink:to="ifrs-full_LaterThanOneYearMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LaterThanOneYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Later Than One Year [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_UnsatisfiedOrPartiallyUnsatisfiedMember" xlink:type="locator" xlink:label="bntx_UnsatisfiedOrPartiallyUnsatisfiedMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_UnsatisfiedOrPartiallyUnsatisfiedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unsatisfied or partially unsatisfied.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_UnsatisfiedOrPartiallyUnsatisfiedMember" xlink:to="bntx_UnsatisfiedOrPartiallyUnsatisfiedMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_UnsatisfiedOrPartiallyUnsatisfiedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unsatisfied Or Partially Unsatisfied</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_UnsatisfiedOrPartiallyUnsatisfiedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unsatisfied Or Partially Unsatisfied [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPerformanceObligationsLineItems" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfPerformanceObligationsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Performance Obligations [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="ifrs-full_DisclosureOfPerformanceObligationsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfPerformanceObligationsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Performance Obligations [Line Items]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:type="locator" xlink:label="bntx_DisclosureOfIncomeAndExpensesLineItems" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfIncomeAndExpensesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Line items representing income and expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:to="bntx_DisclosureOfIncomeAndExpensesLineItems_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIncomeAndExpensesTable" xlink:type="locator" xlink:label="bntx_DisclosureOfIncomeAndExpensesTable" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfIncomeAndExpensesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of Income and expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfIncomeAndExpensesTable" xlink:to="bntx_DisclosureOfIncomeAndExpensesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfIncomeAndExpensesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Income And Expenses [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfIncomeAndExpensesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Income And Expenses [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfIncomeAndExpensesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Income And Expenses [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfIncomeAndExpensesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Income And Expenses [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CostOfSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Costs of sales</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeAndExpensesByNatureAxis" xlink:type="locator" xlink:label="bntx_IncomeAndExpensesByNatureAxis" />
    <link:label xml:lang="en-US" xlink:label="bntx_IncomeAndExpensesByNatureAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Axis representing income and expenses by nature.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_IncomeAndExpensesByNatureAxis" xlink:to="bntx_IncomeAndExpensesByNatureAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_IncomeAndExpensesByNatureAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income And Expenses By Nature</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_IncomeAndExpensesByNatureAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income And Expenses By Nature [Axis]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeAndExpensesByNatureMember" xlink:type="locator" xlink:label="bntx_IncomeAndExpensesByNatureMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_IncomeAndExpensesByNatureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income and expense by nature.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_IncomeAndExpensesByNatureMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_IncomeAndExpensesByNatureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income And Expenses By Nature Member</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_IncomeAndExpensesByNatureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income And Expenses By Nature [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_WagesBenefitsAndSocialSecurityExpenseMember" xlink:type="locator" xlink:label="bntx_WagesBenefitsAndSocialSecurityExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_WagesBenefitsAndSocialSecurityExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Wages, benefits and social security expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_WagesBenefitsAndSocialSecurityExpenseMember" xlink:to="bntx_WagesBenefitsAndSocialSecurityExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_WagesBenefitsAndSocialSecurityExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Wages, Benefits and Social Security Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_WagesBenefitsAndSocialSecurityExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Wages Benefits And Social Security Expense [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LaboratorySuppliesMember" xlink:type="locator" xlink:label="bntx_LaboratorySuppliesMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_LaboratorySuppliesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory supplies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_LaboratorySuppliesMember" xlink:to="bntx_LaboratorySuppliesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_LaboratorySuppliesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Supplies</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_LaboratorySuppliesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Supplies [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PurchasedServicesMember" xlink:type="locator" xlink:label="bntx_PurchasedServicesMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_PurchasedServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchased Services.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_PurchasedServicesMember" xlink:to="bntx_PurchasedServicesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_PurchasedServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchased Services</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_PurchasedServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchased Services [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LeaseAndLeaseRelatedCostMember" xlink:type="locator" xlink:label="bntx_LeaseAndLeaseRelatedCostMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_LeaseAndLeaseRelatedCostMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease and lease related cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_LeaseAndLeaseRelatedCostMember" xlink:to="bntx_LeaseAndLeaseRelatedCostMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_LeaseAndLeaseRelatedCostMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease and Lease Related Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_LeaseAndLeaseRelatedCostMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease And Lease Related Cost [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherIncomeExpenseMember" xlink:type="locator" xlink:label="bntx_OtherIncomeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_OtherIncomeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other income expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_OtherIncomeExpenseMember" xlink:to="bntx_OtherIncomeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_OtherIncomeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OtherIncomeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Income Expense [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ITCostsMember" xlink:type="locator" xlink:label="bntx_ITCostsMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_ITCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">IT costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ITCostsMember" xlink:to="bntx_ITCostsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ITCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IT Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ITCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I T Costs [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TransportCostsMember" xlink:type="locator" xlink:label="bntx_TransportCostsMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_TransportCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Transport costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_TransportCostsMember" xlink:to="bntx_TransportCostsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_TransportCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transport Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_TransportCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transport Costs [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:type="locator" xlink:label="ifrs-full_CarryingAmountMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CarryingAmountMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying amount [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_CarryingAmountMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CarryingAmountMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Carrying Amount [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:type="locator" xlink:label="ifrs-full_AccumulatedDepreciationAndAmortisationMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AccumulatedDepreciationAndAmortisationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:to="ifrs-full_AccumulatedDepreciationAndAmortisationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AccumulatedDepreciationAndAmortisationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation And Amortisation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NatureOfExpensesAxis" xlink:type="locator" xlink:label="bntx_NatureOfExpensesAxis" />
    <link:label xml:lang="en-US" xlink:label="bntx_NatureOfExpensesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Nature of expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_NatureOfExpensesAxis" xlink:to="bntx_NatureOfExpensesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_NatureOfExpensesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature Of Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NatureOfExpensesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Expenses [Axis]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NatureOfExpensesMember" xlink:type="locator" xlink:label="bntx_NatureOfExpensesMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_NatureOfExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Nature of expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_NatureOfExpensesMember" xlink:to="bntx_NatureOfExpensesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_NatureOfExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature Of Expenses Member</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NatureOfExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Expenses [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="bntx_GeneralAndAdministrativeExpensesMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_GeneralAndAdministrativeExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">General and administrative expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_GeneralAndAdministrativeExpensesMember" xlink:to="bntx_GeneralAndAdministrativeExpensesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_GeneralAndAdministrativeExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General And Administrative Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_GeneralAndAdministrativeExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GovernmentGrantsMember" xlink:type="locator" xlink:label="bntx_GovernmentGrantsMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_GovernmentGrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Government grant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_GovernmentGrantsMember" xlink:to="bntx_GovernmentGrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_GovernmentGrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant by Bundesministerium fuer Bildung und Forschung (BMBF)</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_GovernmentGrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Government Grants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales and marketing expenses</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OfficeEquipmentMember" xlink:type="locator" xlink:label="ifrs-full_OfficeEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IT and Office Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OfficeEquipmentMember" xlink:to="ifrs-full_OfficeEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Equipment [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_InsurancePremiumsMember" xlink:type="locator" xlink:label="bntx_InsurancePremiumsMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_InsurancePremiumsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Insurance premiums.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_InsurancePremiumsMember" xlink:to="bntx_InsurancePremiumsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_InsurancePremiumsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance Premiums</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_InsurancePremiumsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Insurance Premiums [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ResearchServicesMember" xlink:type="locator" xlink:label="bntx_ResearchServicesMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_ResearchServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research services.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ResearchServicesMember" xlink:to="bntx_ResearchServicesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ResearchServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Services</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ResearchServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Services [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_JobAdvertisementExpensesMember" xlink:type="locator" xlink:label="bntx_JobAdvertisementExpensesMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_JobAdvertisementExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Job advertisement expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_JobAdvertisementExpensesMember" xlink:to="bntx_JobAdvertisementExpensesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_JobAdvertisementExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Job Advertisement Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_JobAdvertisementExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Job Advertisement Expenses [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ContractStaffingMember" xlink:type="locator" xlink:label="bntx_ContractStaffingMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_ContractStaffingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract staffing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ContractStaffingMember" xlink:to="bntx_ContractStaffingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ContractStaffingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Staffing</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ContractStaffingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract Staffing [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expenses</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ChargeInConnectionWithCertainWithholdingTaxPaymentsForIntellectualPropertyLicenses" xlink:type="locator" xlink:label="bntx_ChargeInConnectionWithCertainWithholdingTaxPaymentsForIntellectualPropertyLicenses" />
    <link:label xml:lang="en-US" xlink:label="bntx_ChargeInConnectionWithCertainWithholdingTaxPaymentsForIntellectualPropertyLicenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Charge in connection with certain withholding tax payments for intellectual property licenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ChargeInConnectionWithCertainWithholdingTaxPaymentsForIntellectualPropertyLicenses" xlink:to="bntx_ChargeInConnectionWithCertainWithholdingTaxPaymentsForIntellectualPropertyLicenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ChargeInConnectionWithCertainWithholdingTaxPaymentsForIntellectualPropertyLicenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Charge in connection with certain withholding tax payments for intellectual property licenses</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ChargeInConnectionWithCertainWithholdingTaxPaymentsForIntellectualPropertyLicenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Charge In Connection With Certain Withholding Tax Payments For Intellectual Property Licenses</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_GovernmentGrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Government Grants</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BargainPurchaseMember" xlink:type="locator" xlink:label="bntx_BargainPurchaseMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_BargainPurchaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Bargain purchase.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_BargainPurchaseMember" xlink:to="bntx_BargainPurchaseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_BargainPurchaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bargain Purchase</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BargainPurchaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bargain Purchase [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentGovernmentGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Government grant</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GovernmentGrantsReceived" xlink:type="locator" xlink:label="bntx_GovernmentGrantsReceived" />
    <link:label xml:lang="en-US" xlink:label="bntx_GovernmentGrantsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Government grants received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_GovernmentGrantsReceived" xlink:to="bntx_GovernmentGrantsReceived_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GovernmentGrantsAbstract" xlink:type="locator" xlink:label="bntx_GovernmentGrantsAbstract" />
    <link:label xml:lang="en-US" xlink:label="bntx_GovernmentGrantsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Government grants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_GovernmentGrantsAbstract" xlink:to="bntx_GovernmentGrantsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_GovernmentGrantsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government Grants [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_GovernmentGrantsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Government Grants [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GovernmentGrants" xlink:type="locator" xlink:label="ifrs-full_GovernmentGrants" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_GovernmentGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">As of January 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GovernmentGrants" xlink:to="ifrs-full_GovernmentGrants_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_GovernmentGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Government Grants</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_GovernmentGrantsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Received during the year</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_GovernmentGrantsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Government Grants Received</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:type="locator" xlink:label="ifrs-full_RevenueFromGovernmentGrants" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_RevenueFromGovernmentGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Released to the consolidated statements of operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromGovernmentGrants" xlink:to="ifrs-full_RevenueFromGovernmentGrants_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_RevenueFromGovernmentGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Government Grants</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_GovernmentGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">As of December 31</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentGovernmentGrants" xlink:type="locator" xlink:label="ifrs-full_NoncurrentGovernmentGrants" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NoncurrentGovernmentGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total non-current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentGovernmentGrants" xlink:to="ifrs-full_NoncurrentGovernmentGrants_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NoncurrentGovernmentGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncurrent Government Grants</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromInterest" xlink:type="locator" xlink:label="ifrs-full_RevenueFromInterest" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_RevenueFromInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromInterest" xlink:to="ifrs-full_RevenueFromInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_RevenueFromInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Interest</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetForeignExchangeGain" xlink:type="locator" xlink:label="ifrs-full_NetForeignExchangeGain" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NetForeignExchangeGain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign exchange gains, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetForeignExchangeGain" xlink:to="ifrs-full_NetForeignExchangeGain_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NetForeignExchangeGain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Foreign Exchange Gain</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FinanceIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NetForeignExchangeGain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Foreign exchange gains</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AmortizationOfFinancialInstruments" xlink:type="locator" xlink:label="bntx_AmortizationOfFinancialInstruments" />
    <link:label xml:lang="en-US" xlink:label="bntx_AmortizationOfFinancialInstruments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of financial instruments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_AmortizationOfFinancialInstruments" xlink:to="bntx_AmortizationOfFinancialInstruments_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" xlink:type="locator" xlink:label="bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" />
    <link:label xml:lang="en-US" xlink:label="bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value adjustments of financial instruments measured at fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" xlink:to="bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_AmortizationOfFinancialInstruments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of financial instruments</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AmortizationOfFinancialInstruments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value adjustments of financial instruments measured at fair value</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustments Of Financial Instruments Measured At Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetForeignExchangeLoss" xlink:type="locator" xlink:label="ifrs-full_NetForeignExchangeLoss" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NetForeignExchangeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign exchange loss, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetForeignExchangeLoss" xlink:to="ifrs-full_NetForeignExchangeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NetForeignExchangeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Foreign Exchange Loss</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FinanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NetForeignExchangeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Foreign exchange losses</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expenses arising from fair value measurement adjustments of derivative embedded within convertible note</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WagesAndSalaries" xlink:type="locator" xlink:label="ifrs-full_WagesAndSalaries" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WagesAndSalaries_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Wages and salaries</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WagesAndSalaries" xlink:to="ifrs-full_WagesAndSalaries_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WagesAndSalaries_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Wages And Salaries</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SocialSecurityContributions" xlink:type="locator" xlink:label="ifrs-full_SocialSecurityContributions" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_SocialSecurityContributions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Social security costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SocialSecurityContributions" xlink:to="ifrs-full_SocialSecurityContributions_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_SocialSecurityContributions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Social Security Contributions</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:type="locator" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pension costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:to="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Postemployment Benefit Expense Defined Benefit Plans</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Benefits Expense</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CorporateIncomeTaxRate" xlink:type="locator" xlink:label="bntx_CorporateIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="bntx_CorporateIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Corporate income tax rate during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_CorporateIncomeTaxRate" xlink:to="bntx_CorporateIncomeTaxRate_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SolidaritySurchargeRate" xlink:type="locator" xlink:label="bntx_SolidaritySurchargeRate" />
    <link:label xml:lang="en-US" xlink:label="bntx_SolidaritySurchargeRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Solidarity surcharge rate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_SolidaritySurchargeRate" xlink:to="bntx_SolidaritySurchargeRate_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ChangeInAverageTradeTaxRate" xlink:type="locator" xlink:label="bntx_ChangeInAverageTradeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="bntx_ChangeInAverageTradeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in average trade tax rate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ChangeInAverageTradeTaxRate" xlink:to="bntx_ChangeInAverageTradeTaxRate_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:type="locator" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Difference Unused Tax Losses And Unused Tax Credits [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:type="locator" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary difference, unused tax losses and unused tax credits [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Difference Unused Tax Losses And Unused Tax Credits [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GermanTaxGroupMember" xlink:type="locator" xlink:label="bntx_GermanTaxGroupMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_GermanTaxGroupMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">German Tax Group.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_GermanTaxGroupMember" xlink:to="bntx_GermanTaxGroupMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_GermanTaxGroupMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">German Tax Group</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_GermanTaxGroupMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">German Tax Group [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GermanEntitiesNotWithinTaxGroupMember" xlink:type="locator" xlink:label="bntx_GermanEntitiesNotWithinTaxGroupMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_GermanEntitiesNotWithinTaxGroupMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">German entities not within tax group.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_GermanEntitiesNotWithinTaxGroupMember" xlink:to="bntx_GermanEntitiesNotWithinTaxGroupMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_GermanEntitiesNotWithinTaxGroupMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">German Entities Not Within Tax Group</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_GermanEntitiesNotWithinTaxGroupMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">German Entities Not Within Tax Group [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_UnitedStatesTaxGroupMember" xlink:type="locator" xlink:label="bntx_UnitedStatesTaxGroupMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_UnitedStatesTaxGroupMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">U.S. tax group.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_UnitedStatesTaxGroupMember" xlink:to="bntx_UnitedStatesTaxGroupMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_UnitedStatesTaxGroupMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Tax Group</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_UnitedStatesTaxGroupMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">United States Tax Group [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_CorporateIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate income tax rate</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_CorporateIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Income Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_SolidaritySurchargeRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Solidarity surcharge rate</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_SolidaritySurchargeRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Solidarity Surcharge Rate</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ChangeInAverageTradeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in average trade tax rate</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ChangeInAverageTradeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Average Trade Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ApplicableTaxRate" xlink:type="locator" xlink:label="ifrs-full_ApplicableTaxRate" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ApplicableTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statutory tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ApplicableTaxRate" xlink:to="ifrs-full_ApplicableTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ApplicableTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Applicable Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AverageEffectiveTaxRate" xlink:type="locator" xlink:label="ifrs-full_AverageEffectiveTaxRate" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AverageEffectiveTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income tax with average rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AverageEffectiveTaxRate" xlink:to="ifrs-full_AverageEffectiveTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AverageEffectiveTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Average Effective Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:type="locator" xlink:label="ifrs-full_CurrentTaxExpenseIncome" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentTaxExpenseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxExpenseIncome" xlink:to="ifrs-full_CurrentTaxExpenseIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentTaxExpenseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Tax Expense Income</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:type="locator" xlink:label="ifrs-full_DeferredTaxExpenseIncome" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DeferredTaxExpenseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxExpenseIncome" xlink:to="ifrs-full_DeferredTaxExpenseIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DeferredTaxExpenseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Expense Income</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OtherComponentsOfTaxExpenseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other taxes</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OtherComponentsOfTaxExpenseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Components Of Tax Expense Income</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income taxes</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:type="locator" xlink:label="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of major components of tax expense income.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeTable" xlink:type="locator" xlink:label="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeTable" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of major components of tax expense income table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeTable" xlink:to="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Major Components Of Tax Expense Income [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Major Components Of Tax Expense Income [Table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxLossesMember" xlink:type="locator" xlink:label="ifrs-full_UnusedTaxLossesMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_UnusedTaxLossesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnusedTaxLossesMember" xlink:to="ifrs-full_UnusedTaxLossesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_UnusedTaxLossesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unused Tax Losses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceMember" xlink:type="locator" xlink:label="ifrs-full_TemporaryDifferenceMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TemporaryDifferenceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Differences</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TemporaryDifferenceMember" xlink:to="ifrs-full_TemporaryDifferenceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TemporaryDifferenceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Difference [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Major Components Of Tax Expense Income [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Major Components Of Tax Expense Income [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:type="locator" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Expected tax benefit (based on BioNTech`s statutory tax rate of 30.79%, 2019: 30.78%, 2018: 30.99%)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:to="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Expense Income At Applicable Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:type="locator" xlink:label="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effects</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation Of Accounting Profit Multiplied By Applicable Tax Rates [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_GovernmentGrantsExemptedFromTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government grants exempted from taxes</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_GovernmentGrantsExemptedFromTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Government Grants Exempted From Taxes</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:type="locator" xlink:label="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Non-deductible expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:to="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Effect Of Expense Not Deductible In Determining Taxable Profit Tax Loss</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AddBackForTradeTaxPurposes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Add-back for trade tax purposes</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AddBackForTradeTaxPurposes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Add Back For Trade Tax Purposes</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NonTaxEffectiveBargainPurchase_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-tax effective bargain purchase</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NonTaxEffectiveBargainPurchase_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Tax Effective Bargain Purchase</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Non-recognition of tax effect on share-based payment expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Recognition Of Tax Effect On Share Based Payment Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_TaxEffectiveEquityTransactionCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax-effective equity transaction costs</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_TaxEffectiveEquityTransactionCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Effective Equity Transaction Costs</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfTaxLosses" xlink:type="locator" xlink:label="ifrs-full_TaxEffectOfTaxLosses" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TaxEffectOfTaxLosses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Utilization of tax losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxEffectOfTaxLosses" xlink:to="ifrs-full_TaxEffectOfTaxLosses_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TaxEffectOfTaxLosses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Effect Of Tax Losses</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_TaxEffectOfNonrecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Non-recognition of deferred taxes on tax losses and temporary differences</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_TaxEffectOfNonrecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Effect Of Nonrecognition Of Deferred Taxes On Tax Losses And Temporary Differences</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:type="locator" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognition of deferred taxes not recognized in prior periods</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:to="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Benefit Arising From Previously Unrecognised Tax Loss Tax Credit Or Temporary Difference Of Prior Period Used To Reduce Deferred Tax Expense</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfForeignTaxRates" xlink:type="locator" xlink:label="ifrs-full_TaxEffectOfForeignTaxRates" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TaxEffectOfForeignTaxRates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Effect from lower foreign income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxEffectOfForeignTaxRates" xlink:to="ifrs-full_TaxEffectOfForeignTaxRates_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TaxEffectOfForeignTaxRates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Effect Of Foreign Tax Rates</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Adjustment prior year tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:to="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For Current Tax Of Prior Period</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_TaxEffectOfTaxCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_TaxEffectOfTaxCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Effect Of Tax Credit</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="locator" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other effects</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:to="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Tax Effects For Reconciliation Between Accounting Profit And Tax Expense Income</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Income taxes</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" xlink:type="locator" xlink:label="bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" />
    <link:label xml:lang="en-US" xlink:label="bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax expense income recognised in other comprehensive income.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" xlink:to="bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_NetDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NetDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Deferred Tax Assets And Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_NetDeferredTaxAssetsAndLiabilitiesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GrossCarryingAmountMember" xlink:type="locator" xlink:label="ifrs-full_GrossCarryingAmountMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_GrossCarryingAmountMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Carrying Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossCarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_GrossCarryingAmountMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gross Carrying Amount [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ValuationAdjustmentMember" xlink:type="locator" xlink:label="bntx_ValuationAdjustmentMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_ValuationAdjustmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Valuation adjustment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ValuationAdjustmentMember" xlink:to="bntx_ValuationAdjustmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ValuationAdjustmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Adjustment</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ValuationAdjustmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Adjustment [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FixedAssetsMember" xlink:type="locator" xlink:label="bntx_FixedAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_FixedAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fixed assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_FixedAssetsMember" xlink:to="bntx_FixedAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_FixedAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed assets</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_FixedAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fixed Assets [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_InventoryMember" xlink:type="locator" xlink:label="bntx_InventoryMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_InventoryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Inventory.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_InventoryMember" xlink:to="bntx_InventoryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_InventoryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_InventoryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LeasesMember" xlink:type="locator" xlink:label="bntx_LeasesMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_LeasesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_LeasesMember" xlink:to="bntx_LeasesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_LeasesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_LeasesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ContractLiabilitiesMember" xlink:type="locator" xlink:label="bntx_ContractLiabilitiesMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_ContractLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ContractLiabilitiesMember" xlink:to="bntx_ContractLiabilitiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ContractLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ContractLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract Liabilities [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_InterestBearingLoansAndBorrowingsMember" xlink:type="locator" xlink:label="bntx_InterestBearingLoansAndBorrowingsMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_InterestBearingLoansAndBorrowingsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest bearing loans and borrowings.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_InterestBearingLoansAndBorrowingsMember" xlink:to="bntx_InterestBearingLoansAndBorrowingsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_InterestBearingLoansAndBorrowingsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest-bearing loans and borrowings</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_InterestBearingLoansAndBorrowingsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Bearing Loans And Borrowings [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ProvisionsMember" xlink:type="locator" xlink:label="bntx_ProvisionsMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_ProvisionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Provisions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ProvisionsMember" xlink:to="bntx_ProvisionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ProvisionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provisions</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ProvisionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Provisions [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:type="locator" xlink:label="ifrs-full_NetDefinedBenefitLiabilityAssetMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NetDefinedBenefitLiabilityAssetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net employee defined benefit liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:to="ifrs-full_NetDefinedBenefitLiabilityAssetMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NetDefinedBenefitLiabilityAssetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Defined Benefit Liability Asset [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherDeferredTaxesMember" xlink:type="locator" xlink:label="bntx_OtherDeferredTaxesMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_OtherDeferredTaxesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other deferred taxes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_OtherDeferredTaxesMember" xlink:to="bntx_OtherDeferredTaxesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_OtherDeferredTaxesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other (incl. deferred expenses)</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OtherDeferredTaxesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Deferred Taxes [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxCreditsMember" xlink:type="locator" xlink:label="ifrs-full_UnusedTaxCreditsMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_UnusedTaxCreditsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Loss Carryforward / Tax Credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnusedTaxCreditsMember" xlink:to="ifrs-full_UnusedTaxCreditsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_UnusedTaxCreditsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unused Tax Credits [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_DeferredTaxLiabilityAsset" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DeferredTaxLiabilityAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Deferred tax assets net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxLiabilityAsset" xlink:to="ifrs-full_DeferredTaxLiabilityAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DeferredTaxLiabilityAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liability Asset</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="locator" xlink:label="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognized in P&amp;L</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:to="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Expense Income Recognised In Profit Or Loss</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognized in OCI</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Expense Income Recognised In Other Comprehensive Income</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition of subsidiaries and businesses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:to="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease Through Business Combinations Deferred Tax Liability Asset</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DeferredTaxLiabilityAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Deferred tax assets net</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AccumulatedTaxLossesInCorporateTax" xlink:type="locator" xlink:label="bntx_AccumulatedTaxLossesInCorporateTax" />
    <link:label xml:lang="en-US" xlink:label="bntx_AccumulatedTaxLossesInCorporateTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accumulated tax losses in corporate tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_AccumulatedTaxLossesInCorporateTax" xlink:to="bntx_AccumulatedTaxLossesInCorporateTax_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AccumulatedTaxLossesInTradeTax" xlink:type="locator" xlink:label="bntx_AccumulatedTaxLossesInTradeTax" />
    <link:label xml:lang="en-US" xlink:label="bntx_AccumulatedTaxLossesInTradeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accumulated tax losses in trade tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_AccumulatedTaxLossesInTradeTax" xlink:to="bntx_AccumulatedTaxLossesInTradeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_AccumulatedTaxLossesInCorporateTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AccumulatedTaxLossesInCorporateTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Tax Losses In Corporate Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AccumulatedTaxLossesInTradeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AccumulatedTaxLossesInTradeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Tax Losses In Trade Tax</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AccumulatedTaxLossesInFederalTaxCredits" xlink:type="locator" xlink:label="bntx_AccumulatedTaxLossesInFederalTaxCredits" />
    <link:label xml:lang="en-US" xlink:label="bntx_AccumulatedTaxLossesInFederalTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accumulated tax losses in federal tax credits.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_AccumulatedTaxLossesInFederalTaxCredits" xlink:to="bntx_AccumulatedTaxLossesInFederalTaxCredits_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AccumulatedTaxLossesInStateTaxCredits" xlink:type="locator" xlink:label="bntx_AccumulatedTaxLossesInStateTaxCredits" />
    <link:label xml:lang="en-US" xlink:label="bntx_AccumulatedTaxLossesInStateTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accumulated tax losses in state tax credits.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_AccumulatedTaxLossesInStateTaxCredits" xlink:to="bntx_AccumulatedTaxLossesInStateTaxCredits_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_AccumulatedTaxLossesInFederalTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal Tax Credits</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AccumulatedTaxLossesInFederalTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Tax Losses In Federal Tax Credits</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AccumulatedTaxLossesInStateTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State Tax Credits</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AccumulatedTaxLossesInStateTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Tax Losses In State Tax Credits</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredTaxAssetsForUnusedTaxLossesRecognized" xlink:type="locator" xlink:label="bntx_DeferredTaxAssetsForUnusedTaxLossesRecognized" />
    <link:label xml:lang="en-US" xlink:label="bntx_DeferredTaxAssetsForUnusedTaxLossesRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets for unused tax losses recognized.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DeferredTaxAssetsForUnusedTaxLossesRecognized" xlink:to="bntx_DeferredTaxAssetsForUnusedTaxLossesRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_AccumulatedTaxLossesInCorporateTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Corporate income tax losses</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AccumulatedTaxLossesInTradeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Trade tax losses</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DeferredTaxAssetsForUnusedTaxLossesRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets for unused tax losses recognized</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DeferredTaxAssetsForUnusedTaxLossesRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets For Unused Tax Losses Recognized</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DeferredTaxLiabilityAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred tax assets and liabilities, net recognized</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsExpectedToExpire" xlink:type="locator" xlink:label="bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsExpectedToExpire" />
    <link:label xml:lang="en-US" xlink:label="bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsExpectedToExpire_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal deferred tax assets operating loss carryforwards expected to expire.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsExpectedToExpire" xlink:to="bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsExpectedToExpire_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FederalTaxLossesExpirationYear" xlink:type="locator" xlink:label="bntx_FederalTaxLossesExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="bntx_FederalTaxLossesExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal tax losses expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_FederalTaxLossesExpirationYear" xlink:to="bntx_FederalTaxLossesExpirationYear_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="locator" xlink:label="bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
    <link:label xml:lang="en-US" xlink:label="bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal deferred tax assets operating loss carryforwards not subject to expiration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_StateDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="locator" xlink:label="bntx_StateDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
    <link:label xml:lang="en-US" xlink:label="bntx_StateDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">State deferred tax assets operating loss carryforwards subject to expiration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_StateDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="bntx_StateDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_StateTaxLossesExpirationYear" xlink:type="locator" xlink:label="bntx_StateTaxLossesExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="bntx_StateTaxLossesExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">State tax losses expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_StateTaxLossesExpirationYear" xlink:to="bntx_StateTaxLossesExpirationYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsExpectedToExpire_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal tax losses subject to expiration</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsExpectedToExpire_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Federal Deferred Tax Assets Operating Loss Carryforwards Expected To Expire</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_FederalTaxLossesExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal tax losses expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_FederalTaxLossesExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Federal Tax Losses Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal tax losses not subject to expiration</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Federal Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_StateDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State tax losses subject to expiration</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_StateDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_StateTaxLossesExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State tax losses expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_StateTaxLossesExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State Tax Losses Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AccumulatedTaxLossesInFederalTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated federal tax credits</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AccumulatedTaxLossesInStateTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated state tax credits</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SharesIssuedDuringPeriodStockSplit" xlink:type="locator" xlink:label="bntx_SharesIssuedDuringPeriodStockSplit" />
    <link:label xml:lang="en-US" xlink:label="bntx_SharesIssuedDuringPeriodStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued during period stock split.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_SharesIssuedDuringPeriodStockSplit" xlink:to="bntx_SharesIssuedDuringPeriodStockSplit_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_SharesIssuedDuringPeriodStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued during period stock split</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_SharesIssuedDuringPeriodStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued During Period Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gain (loss) attributable to ordinary equity holders of the parent for basic earnings</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageShares" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WeightedAverageShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number of ordinary shares for basic EPS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WeightedAverageShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Shares</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:type="locator" xlink:label="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effects of dilution from share options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:to="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dilutive Effect Of Share Options On Number Of Ordinary Shares</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:type="locator" xlink:label="ifrs-full_AdjustedWeightedAverageShares" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted average number of ordinary shares adjusted for the effect of dilution</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjusted Weighted Average Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Basic and diluted, profit / (loss) for the period attributable to ordinary equity holders of the parent</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ReclassificationsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="bntx_ReclassificationsPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="bntx_ReclassificationsPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassifications property plant and equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ReclassificationsPropertyPlantAndEquipment" xlink:to="bntx_ReclassificationsPropertyPlantAndEquipment_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LandAndBuildingsMember" xlink:type="locator" xlink:label="ifrs-full_LandAndBuildingsMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LandAndBuildingsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Land and Buildings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LandAndBuildingsMember" xlink:to="ifrs-full_LandAndBuildingsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LandAndBuildingsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Land And Buildings [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConstructionInProgressAndAdvancePaymentsMember" xlink:type="locator" xlink:label="bntx_ConstructionInProgressAndAdvancePaymentsMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_ConstructionInProgressAndAdvancePaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Construction in progress and advance payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ConstructionInProgressAndAdvancePaymentsMember" xlink:to="bntx_ConstructionInProgressAndAdvancePaymentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ConstructionInProgressAndAdvancePaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress and Advance Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ConstructionInProgressAndAdvancePaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress And Advance Payments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative Depreciation and Impairment Charges</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Amortisation And Impairment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property plant and equipment, Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additions Other Than Through Business Combinations Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Disposals</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposals Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ReclassificationsPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassifications</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ReclassificationsPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reclassifications Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currency differences</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease Through Net Exchange Differences Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition of subsidiaries and businesses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Acquisitions Through Business Combinations Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property plant and equipment, Ending balance</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AccumulatedDepreciationAmortisationAndImpairment" xlink:type="locator" xlink:label="bntx_AccumulatedDepreciationAmortisationAndImpairment" />
    <link:label xml:lang="en-US" xlink:label="bntx_AccumulatedDepreciationAmortisationAndImpairment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accumulated depreciation amortisation and impairment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_AccumulatedDepreciationAmortisationAndImpairment" xlink:to="bntx_AccumulatedDepreciationAmortisationAndImpairment_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classes of intangible assets and goodwill [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Classes Of Intangible Assets And Goodwill [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets and goodwill [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets And Goodwill [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GoodwillMember" xlink:type="locator" xlink:label="ifrs-full_GoodwillMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_GoodwillMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GoodwillMember" xlink:to="ifrs-full_GoodwillMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_GoodwillMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember" xlink:type="locator" xlink:label="bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Concessions licenses in-process research and development and similar rights.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember" xlink:to="bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concessions, Licenses, in-process R&amp;D and Similar Rights</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concessions Licenses In Process Research And Development And Similar Rights [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AdvancePaymentsMember" xlink:type="locator" xlink:label="bntx_AdvancePaymentsMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_AdvancePaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Advance payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_AdvancePaymentsMember" xlink:to="bntx_AdvancePaymentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_AdvancePaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advance Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AdvancePaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Advance Payments [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AccumulatedDepreciationAmortisationAndImpairment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AccumulatedDepreciationAmortisationAndImpairment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Amortisation And Impairment</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additions Other Than Through Business Combinations Intangible Assets Other Than Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:type="locator" xlink:label="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Disposals</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposals Intangible Assets Other Than Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsOtherThanGoodwill" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsOtherThanGoodwill" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsOtherThanGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassifications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsOtherThanGoodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsOtherThanGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease Through Transfers And Other Changes Intangible Assets Other Than Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currency differences</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease Through Net Exchange Differences Intangible Assets And Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="locator" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition of subsidiaries and businesses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Acquisitions Through Business Combinations Intangible Assets Other Than Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ConsolidatedStructuredEntitiesAxis" xlink:type="locator" xlink:label="ifrs-full_ConsolidatedStructuredEntitiesAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ConsolidatedStructuredEntitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated structured entities [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ConsolidatedStructuredEntitiesAxis" xlink:to="ifrs-full_ConsolidatedStructuredEntitiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ConsolidatedStructuredEntitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Structured Entities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity&apos;s total for consolidated structured entities [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:to="ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entitys Total For Consolidated Structured Entities [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CGUImmunotherapiesMember" xlink:type="locator" xlink:label="bntx_CGUImmunotherapiesMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_CGUImmunotherapiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">CGU Immunotherapies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_CGUImmunotherapiesMember" xlink:to="bntx_CGUImmunotherapiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_CGUImmunotherapiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CGU Immunotherapies</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_CGUImmunotherapiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">C G U Immunotherapies [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ExternalProductSalesOfJPTMember" xlink:type="locator" xlink:label="bntx_ExternalProductSalesOfJPTMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_ExternalProductSalesOfJPTMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">External product sales of JPT.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ExternalProductSalesOfJPTMember" xlink:to="bntx_ExternalProductSalesOfJPTMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ExternalProductSalesOfJPTMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">External Product Sales of JPT</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ExternalProductSalesOfJPTMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">External Product Sales Of J P T [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_Goodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SubsidiariesMember" xlink:type="locator" xlink:label="ifrs-full_SubsidiariesMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_SubsidiariesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiaries</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SubsidiariesMember" xlink:to="ifrs-full_SubsidiariesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_SubsidiariesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiaries [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="country_US_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">United States</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows" xlink:type="locator" xlink:label="ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recoverable amount period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows" xlink:to="ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Explanation Of Period Over Which Management Has Projected Cash Flows</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount rate cash flow projection</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:to="ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Discount Rates Applied To Cash Flow Projections</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Growth rate extrapolated</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse" xlink:to="ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Discount Rates Used In Current Estimate Of Value In Use</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncreaseInGrowthRateCashFlowProjections" xlink:type="locator" xlink:label="bntx_IncreaseInGrowthRateCashFlowProjections" />
    <link:label xml:lang="en-US" xlink:label="bntx_IncreaseInGrowthRateCashFlowProjections_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in growth rate cash flow projections.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_IncreaseInGrowthRateCashFlowProjections" xlink:to="bntx_IncreaseInGrowthRateCashFlowProjections_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_IncreaseInGrowthRateCashFlowProjections_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in discount rate</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_IncreaseInGrowthRateCashFlowProjections_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Growth Rate Cash Flow Projections</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Growth rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:to="ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Growth Rate Used To Extrapolate Cash Flow Projections</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NoncurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current assets</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalentsAbstract" xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="ifrs-full_CashAndCashEquivalentsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Financial Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsTable" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfFinancialAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Financial Assets [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsTable" xlink:to="ifrs-full_DisclosureOfFinancialAssetsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfFinancialAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Financial Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classes of financial assets [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Classes Of Financial Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsMember" xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FinancialAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets, class [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="ifrs-full_FinancialAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FinancialAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeReceivablesMember" xlink:type="locator" xlink:label="ifrs-full_TradeReceivablesMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TradeReceivablesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade Receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeReceivablesMember" xlink:to="ifrs-full_TradeReceivablesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TradeReceivablesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trade Receivables [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherFinancialAssetsMember" xlink:type="locator" xlink:label="bntx_OtherFinancialAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_OtherFinancialAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other financial assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_OtherFinancialAssetsMember" xlink:to="bntx_OtherFinancialAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_OtherFinancialAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Financial Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OtherFinancialAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Financial Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Financial Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialAssetsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Financial Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsAtAmortisedCost" xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Financial assets at amortized cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Assets At Amortised Cost</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentFinancialAssetsAtAmortisedCost" xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialAssetsAtAmortisedCost" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentFinancialAssetsAtAmortisedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentFinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_CurrentFinancialAssetsAtAmortisedCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentFinancialAssetsAtAmortisedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Financial Assets At Amortised Cost</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentFinancialAssetsAtAmortisedCost" xlink:type="locator" xlink:label="ifrs-full_NoncurrentFinancialAssetsAtAmortisedCost" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NoncurrentFinancialAssetsAtAmortisedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total non-current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentFinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_NoncurrentFinancialAssetsAtAmortisedCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NoncurrentFinancialAssetsAtAmortisedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncurrent Financial Assets At Amortised Cost</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DerivativeFinancialLiabilitiesNotDesignatedAsHedgingInstrumentsAtFairValue" xlink:type="locator" xlink:label="bntx_DerivativeFinancialLiabilitiesNotDesignatedAsHedgingInstrumentsAtFairValue" />
    <link:label xml:lang="en-US" xlink:label="bntx_DerivativeFinancialLiabilitiesNotDesignatedAsHedgingInstrumentsAtFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Derivative, financial liabilities not designated as hedging instruments, at fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DerivativeFinancialLiabilitiesNotDesignatedAsHedgingInstrumentsAtFairValue" xlink:to="bntx_DerivativeFinancialLiabilitiesNotDesignatedAsHedgingInstrumentsAtFairValue_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Financial Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesTable" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Financial Liabilities [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Financial Liabilities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classes of financial liabilities [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Classes Of Financial Liabilities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FinancialLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities, class [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="ifrs-full_FinancialLiabilitiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FinancialLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsByNameAxis" xlink:type="locator" xlink:label="ifrs-full_BorrowingsByNameAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_BorrowingsByNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings by name [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_BorrowingsByNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings By Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsByNameMember" xlink:type="locator" xlink:label="ifrs-full_BorrowingsByNameMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_BorrowingsByNameMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings by name [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="ifrs-full_BorrowingsByNameMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_BorrowingsByNameMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings By Name [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TwoPointOneFivePercentageSecuredBankLoanMember" xlink:type="locator" xlink:label="bntx_TwoPointOneFivePercentageSecuredBankLoanMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_TwoPointOneFivePercentageSecuredBankLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two point one five percentage secured bank loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_TwoPointOneFivePercentageSecuredBankLoanMember" xlink:to="bntx_TwoPointOneFivePercentageSecuredBankLoanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_TwoPointOneFivePercentageSecuredBankLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2.15% Secured Bank Loan</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_TwoPointOneFivePercentageSecuredBankLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Point One Five Percentage Secured Bank Loan [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TwoPointZeroEightPercentageSecuredBankLoanMember" xlink:type="locator" xlink:label="bntx_TwoPointZeroEightPercentageSecuredBankLoanMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_TwoPointZeroEightPercentageSecuredBankLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two point zero eight percentage secured bank loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_TwoPointZeroEightPercentageSecuredBankLoanMember" xlink:to="bntx_TwoPointZeroEightPercentageSecuredBankLoanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_TwoPointZeroEightPercentageSecuredBankLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2.08% Secured Bank Loan</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_TwoPointZeroEightPercentageSecuredBankLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Point Zero Eight Percentage Secured Bank Loan [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConvertibleNoteHostContractMember" xlink:type="locator" xlink:label="bntx_ConvertibleNoteHostContractMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_ConvertibleNoteHostContractMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible note - host contract.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ConvertibleNoteHostContractMember" xlink:to="bntx_ConvertibleNoteHostContractMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ConvertibleNoteHostContractMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Note - Host Contract</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ConvertibleNoteHostContractMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Note Host Contract [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember" xlink:type="locator" xlink:label="bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Three point five zero percentage secured bank loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember" xlink:to="bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">3.50% Secured Bank Loan</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Three Point Five Zero Percentage Secured Bank Loan [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OnePointNineZeroPercentageSecuredBankLoanMember" xlink:type="locator" xlink:label="bntx_OnePointNineZeroPercentageSecuredBankLoanMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_OnePointNineZeroPercentageSecuredBankLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">One point nine zero percentage secured bank loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_OnePointNineZeroPercentageSecuredBankLoanMember" xlink:to="bntx_OnePointNineZeroPercentageSecuredBankLoanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_OnePointNineZeroPercentageSecuredBankLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">1.90% Secured Bank loan</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OnePointNineZeroPercentageSecuredBankLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">One Point Nine Zero Percentage Secured Bank Loan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:type="locator" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities arising from financing activities [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Arising From Financing Activities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:type="locator" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities arising from financing activities [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Arising From Financing Activities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilitiesMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LeaseLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilitiesMember" xlink:to="ifrs-full_LeaseLiabilitiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LeaseLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Liabilities [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember" xlink:type="locator" xlink:label="bntx_OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other financial liabilities, other than interest-bearing loans and borrowings.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember" xlink:to="bntx_OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Financial Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Financial Liabilities Other Than Interest Bearing Loans And Borrowings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classes of liabilities [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Classes Of Liabilities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesMember" xlink:type="locator" xlink:label="ifrs-full_LiabilitiesMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesMember" xlink:to="ifrs-full_LiabilitiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConvertibleNoteEmbeddedDerivativeMember" xlink:type="locator" xlink:label="bntx_ConvertibleNoteEmbeddedDerivativeMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_ConvertibleNoteEmbeddedDerivativeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible note - embedded derivative.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ConvertibleNoteEmbeddedDerivativeMember" xlink:to="bntx_ConvertibleNoteEmbeddedDerivativeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ConvertibleNoteEmbeddedDerivativeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Note - Embedded Derivative</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ConvertibleNoteEmbeddedDerivativeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Note Embedded Derivative [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContingentConsiderationMember" xlink:type="locator" xlink:label="ifrs-full_ContingentConsiderationMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ContingentConsiderationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContingentConsiderationMember" xlink:to="ifrs-full_ContingentConsiderationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ContingentConsiderationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TradePayablesMember" xlink:type="locator" xlink:label="bntx_TradePayablesMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_TradePayablesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Trade payables.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_TradePayablesMember" xlink:to="bntx_TradePayablesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_TradePayablesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade Payables</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_TradePayablesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trade Payables [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherFinancialLiabilitiesMember" xlink:type="locator" xlink:label="bntx_OtherFinancialLiabilitiesMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_OtherFinancialLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other financial liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_OtherFinancialLiabilitiesMember" xlink:to="bntx_OtherFinancialLiabilitiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_OtherFinancialLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Financial Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OtherFinancialLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Financial Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Financial Liabilities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Financial Liabilities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Financial liabilities at amortized cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liabilities At Amortised Cost</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentFinancialLiabilitiesAtAmortisedCost" xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialLiabilitiesAtAmortisedCost" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentFinancialLiabilitiesAtAmortisedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentFinancialLiabilitiesAtAmortisedCost" xlink:to="ifrs-full_CurrentFinancialLiabilitiesAtAmortisedCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentFinancialLiabilitiesAtAmortisedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Financial Liabilities At Amortised Cost</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentFinancialLiabilitiesAtAmortisedCost" xlink:type="locator" xlink:label="ifrs-full_NoncurrentFinancialLiabilitiesAtAmortisedCost" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NoncurrentFinancialLiabilitiesAtAmortisedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total non-current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentFinancialLiabilitiesAtAmortisedCost" xlink:to="ifrs-full_NoncurrentFinancialLiabilitiesAtAmortisedCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NoncurrentFinancialLiabilitiesAtAmortisedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncurrent Financial Liabilities At Amortised Cost</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FinancialLiabilitiesMaturityDate" xlink:type="locator" xlink:label="bntx_FinancialLiabilitiesMaturityDate" />
    <link:label xml:lang="en-US" xlink:label="bntx_FinancialLiabilitiesMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial liabilities maturity date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_FinancialLiabilitiesMaturityDate" xlink:to="bntx_FinancialLiabilitiesMaturityDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_FinancialLiabilitiesMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_FinancialLiabilitiesMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liabilities Maturity Date</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Secured bank loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" xlink:to="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Assets Pledged As Collateral For Liabilities Or Contingent Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DerivativeFinancialLiabilitiesNotDesignatedAsHedgingInstrumentsAtFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivatives not designated as hedging instrument</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DerivativeFinancialLiabilitiesNotDesignatedAsHedgingInstrumentsAtFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Financial Liabilities Not Designated As Hedging Instruments At Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities at fair value through profit or loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liabilities At Fair Value Through Profit Or Loss</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total financial liabilities at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtFairValue" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liabilities At Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilities" xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FinancialLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Financial liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FinancialLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentFinancialLiabilities" xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialLiabilities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentFinancialLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentFinancialLiabilities" xlink:to="ifrs-full_CurrentFinancialLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentFinancialLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Financial Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentFinancialLiabilities" xlink:type="locator" xlink:label="ifrs-full_NoncurrentFinancialLiabilities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NoncurrentFinancialLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total non-current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentFinancialLiabilities" xlink:to="ifrs-full_NoncurrentFinancialLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NoncurrentFinancialLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncurrent Financial Liabilities</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfSecuredBankLoanMaintained" xlink:type="locator" xlink:label="bntx_NumberOfSecuredBankLoanMaintained" />
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfSecuredBankLoanMaintained_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of secured bank loan maintained.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_NumberOfSecuredBankLoanMaintained" xlink:to="bntx_NumberOfSecuredBankLoanMaintained_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LoanRepayableQuarterlyInstallment" xlink:type="locator" xlink:label="bntx_LoanRepayableQuarterlyInstallment" />
    <link:label xml:lang="en-US" xlink:label="bntx_LoanRepayableQuarterlyInstallment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan repayable quarterly installment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_LoanRepayableQuarterlyInstallment" xlink:to="bntx_LoanRepayableQuarterlyInstallment_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LoanRepayableQuarterlyInstallmentCommencementDate" xlink:type="locator" xlink:label="bntx_LoanRepayableQuarterlyInstallmentCommencementDate" />
    <link:label xml:lang="en-US" xlink:label="bntx_LoanRepayableQuarterlyInstallmentCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan repayable quarterly installment commencement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_LoanRepayableQuarterlyInstallmentCommencementDate" xlink:to="bntx_LoanRepayableQuarterlyInstallmentCommencementDate_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Redesignated Financial Assets And Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesTable" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Redesignated Financial Assets And Liabilities [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesTable" xlink:to="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Redesignated Financial Assets And Liabilities [Table]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TwoPointOneFivePercentageSecuredLoanMember" xlink:type="locator" xlink:label="bntx_TwoPointOneFivePercentageSecuredLoanMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_TwoPointOneFivePercentageSecuredLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2.15% secured loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_TwoPointOneFivePercentageSecuredLoanMember" xlink:to="bntx_TwoPointOneFivePercentageSecuredLoanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_TwoPointOneFivePercentageSecuredLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2.15% Secured Loan</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_TwoPointOneFivePercentageSecuredLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Point One Five Percentage Secured Loan [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TwoPointZeroEightPercentageBankLoanMember" xlink:type="locator" xlink:label="bntx_TwoPointZeroEightPercentageBankLoanMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_TwoPointZeroEightPercentageBankLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2.08% bank loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_TwoPointZeroEightPercentageBankLoanMember" xlink:to="bntx_TwoPointZeroEightPercentageBankLoanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_TwoPointZeroEightPercentageBankLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2.08% Bank Loan</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_TwoPointZeroEightPercentageBankLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Point Zero Eight Percentage Bank Loan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeutscheBankAGMember" xlink:type="locator" xlink:label="bntx_DeutscheBankAGMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_DeutscheBankAGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deutsche Bank AG.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DeutscheBankAGMember" xlink:to="bntx_DeutscheBankAGMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DeutscheBankAGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deutsche Bank AG</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DeutscheBankAGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deutsche Bank A G [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:type="locator" xlink:label="ifrs-full_TypesOfInterestRatesAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TypesOfInterestRatesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Types of interest rates [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_TypesOfInterestRatesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TypesOfInterestRatesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Types Of Interest Rates [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestRateTypesMember" xlink:type="locator" xlink:label="ifrs-full_InterestRateTypesMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_InterestRateTypesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate types [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestRateTypesMember" xlink:to="ifrs-full_InterestRateTypesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_InterestRateTypesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Rate Types [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CashInterestFixedRateMember" xlink:type="locator" xlink:label="bntx_CashInterestFixedRateMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_CashInterestFixedRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash interest fixed rate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_CashInterestFixedRateMember" xlink:to="bntx_CashInterestFixedRateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_CashInterestFixedRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Interest Fixed Rate</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_CashInterestFixedRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Interest Fixed Rate [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredInterestAtFixedRateMember" xlink:type="locator" xlink:label="bntx_DeferredInterestAtFixedRateMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_DeferredInterestAtFixedRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred interest at fixed rate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DeferredInterestAtFixedRateMember" xlink:to="bntx_DeferredInterestAtFixedRateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DeferredInterestAtFixedRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Interest at Fixed Rate</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DeferredInterestAtFixedRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Interest At Fixed Rate [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EuropeanInvestmentBankMember" xlink:type="locator" xlink:label="bntx_EuropeanInvestmentBankMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_EuropeanInvestmentBankMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">European Investment Bank.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_EuropeanInvestmentBankMember" xlink:to="bntx_EuropeanInvestmentBankMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_EuropeanInvestmentBankMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">EIB Manufacturing Financing</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_EuropeanInvestmentBankMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">European Investment Bank [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classes of financial instruments [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Classes Of Financial Instruments [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial instruments, class [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Classes Of Financial Instruments [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_JuneTwentyTwentyPrivatePlacementMember" xlink:type="locator" xlink:label="bntx_JuneTwentyTwentyPrivatePlacementMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_JuneTwentyTwentyPrivatePlacementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">June twenty twenty private placement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_JuneTwentyTwentyPrivatePlacementMember" xlink:to="bntx_JuneTwentyTwentyPrivatePlacementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_JuneTwentyTwentyPrivatePlacementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">June 2020 Private Placement</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_JuneTwentyTwentyPrivatePlacementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">June Twenty Twenty Private Placement [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConvertibleNoteMember" xlink:type="locator" xlink:label="bntx_ConvertibleNoteMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_ConvertibleNoteMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible note.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ConvertibleNoteMember" xlink:to="bntx_ConvertibleNoteMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ConvertibleNoteMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Note</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ConvertibleNoteMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Note [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Redesignated Financial Assets And Liabilities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Redesignated Financial Assets And Liabilities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfSecuredBankLoanMaintained_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of secured bank loan</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfSecuredBankLoanMaintained_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Secured Bank Loan Maintained</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsInterestRate" xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_BorrowingsInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_BorrowingsInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_LoanRepayableQuarterlyInstallment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan repayable quarterly Installment</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_LoanRepayableQuarterlyInstallment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loan Repayable Quarterly Installment</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_LoanRepayableQuarterlyInstallmentCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan repayable quarterly installment commencing date</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_LoanRepayableQuarterlyInstallmentCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loan Repayable Quarterly Installment Commencement Date</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TermLoanCreditA" xlink:type="locator" xlink:label="bntx_TermLoanCreditA" />
    <link:label xml:lang="en-US" xlink:label="bntx_TermLoanCreditA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Term Loan (Credit A).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_TermLoanCreditA" xlink:to="bntx_TermLoanCreditA_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TermLoanCreditB" xlink:type="locator" xlink:label="bntx_TermLoanCreditB" />
    <link:label xml:lang="en-US" xlink:label="bntx_TermLoanCreditB_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Term Loan (Credit B).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_TermLoanCreditB" xlink:to="bntx_TermLoanCreditB_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotionalAmount" xlink:type="locator" xlink:label="ifrs-full_NotionalAmount" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NotionalAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notional amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotionalAmount" xlink:to="ifrs-full_NotionalAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NotionalAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Notional Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_TermLoanCreditA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan (Credit A)</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_TermLoanCreditA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan Credit A</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_TermLoanCreditB_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan (Credit B)</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_TermLoanCreditB_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan Credit B</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FinancialLiabilityMaturityTerm" xlink:type="locator" xlink:label="bntx_FinancialLiabilityMaturityTerm" />
    <link:label xml:lang="en-US" xlink:label="bntx_FinancialLiabilityMaturityTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial liability, maturity term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_FinancialLiabilityMaturityTerm" xlink:to="bntx_FinancialLiabilityMaturityTerm_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FinancialLiabilitiesCouponRatePerAnnum" xlink:type="locator" xlink:label="bntx_FinancialLiabilitiesCouponRatePerAnnum" />
    <link:label xml:lang="en-US" xlink:label="bntx_FinancialLiabilitiesCouponRatePerAnnum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial liabilities coupon rate per annum.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_FinancialLiabilitiesCouponRatePerAnnum" xlink:to="bntx_FinancialLiabilitiesCouponRatePerAnnum_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FinancialLiabilitiesConversionPremiumPercentageAboveReferencePrice" xlink:type="locator" xlink:label="bntx_FinancialLiabilitiesConversionPremiumPercentageAboveReferencePrice" />
    <link:label xml:lang="en-US" xlink:label="bntx_FinancialLiabilitiesConversionPremiumPercentageAboveReferencePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial liabilities conversion premium percentage above reference price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_FinancialLiabilitiesConversionPremiumPercentageAboveReferencePrice" xlink:to="bntx_FinancialLiabilitiesConversionPremiumPercentageAboveReferencePrice_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EffectiveInterestRateOfFinancialLiabilities" xlink:type="locator" xlink:label="bntx_EffectiveInterestRateOfFinancialLiabilities" />
    <link:label xml:lang="en-US" xlink:label="bntx_EffectiveInterestRateOfFinancialLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective interest rate of financial liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_EffectiveInterestRateOfFinancialLiabilities" xlink:to="bntx_EffectiveInterestRateOfFinancialLiabilities_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:type="locator" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment in convertible note</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Accounted For Using Equity Method</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_FinancialLiabilityMaturityTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity period</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_FinancialLiabilityMaturityTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liability Maturity Term</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_FinancialLiabilitiesCouponRatePerAnnum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible note coupon rate</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_FinancialLiabilitiesCouponRatePerAnnum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liabilities Coupon Rate Per Annum</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_FinancialLiabilitiesConversionPremiumPercentageAboveReferencePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion premium of convertible note</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_FinancialLiabilitiesConversionPremiumPercentageAboveReferencePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liabilities Conversion Premium Percentage Above Reference Price</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_EffectiveInterestRateOfFinancialLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective interest rate</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_EffectiveInterestRateOfFinancialLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Interest Rate Of Financial Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value adjustment derived from remeasuring embedded derivative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" xlink:to="ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease Through Changes In Fair Values Liabilities Arising From Financing Activities</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CashAndCashEquivalent" xlink:type="locator" xlink:label="bntx_CashAndCashEquivalent" />
    <link:label xml:lang="en-US" xlink:label="bntx_CashAndCashEquivalent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of cash on hand and demand deposits denominated in foreign currencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_CashAndCashEquivalent" xlink:to="bntx_CashAndCashEquivalent_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfCashAndCashEquivalentsLineItems" xlink:type="locator" xlink:label="bntx_DisclosureOfCashAndCashEquivalentsLineItems" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfCashAndCashEquivalentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of cash and cash equivalents.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfCashAndCashEquivalentsLineItems" xlink:to="bntx_DisclosureOfCashAndCashEquivalentsLineItems_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfCashAndCashEquivalentsTable" xlink:type="locator" xlink:label="bntx_DisclosureOfCashAndCashEquivalentsTable" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfCashAndCashEquivalentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of cash and cash equivalents.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfCashAndCashEquivalentsTable" xlink:to="bntx_DisclosureOfCashAndCashEquivalentsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfCashAndCashEquivalentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Cash And Cash Equivalents [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfCashAndCashEquivalentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Cash And Cash Equivalents [Table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TypesOfRisksAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Types of risks [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TypesOfRisksAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Types Of Risks [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TypesOfRisksMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risks [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_TypesOfRisksMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TypesOfRisksMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Types Of Risks [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrencyRiskMember" xlink:type="locator" xlink:label="ifrs-full_CurrencyRiskMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrencyRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currency Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrencyRiskMember" xlink:to="ifrs-full_CurrencyRiskMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrencyRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Currency Risk [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_USDollarBankAccountsMember" xlink:type="locator" xlink:label="bntx_USDollarBankAccountsMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_USDollarBankAccountsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">US dollar bank accounts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_USDollarBankAccountsMember" xlink:to="bntx_USDollarBankAccountsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_USDollarBankAccountsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US Dollar Bank Accounts</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_USDollarBankAccountsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Dollar Bank Accounts [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OtherFinancialAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other Financial Assets in U.S. Dollar</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FinancialLiabilityMember" xlink:type="locator" xlink:label="bntx_FinancialLiabilityMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_FinancialLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_FinancialLiabilityMember" xlink:to="bntx_FinancialLiabilityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_FinancialLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Liabilities in U.S. Dollar</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_FinancialLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liability [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfCashAndCashEquivalentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Cash And Cash Equivalents [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfCashAndCashEquivalentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Cash And Cash Equivalents [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_CashAndCashEquivalent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_CashAndCashEquivalent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalent</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesAbstract" xlink:type="locator" xlink:label="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesAbstract" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of effect of changes in foreign exchange rates.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesAbstract" xlink:to="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Effect Of Changes In Foreign Exchange Rates [Abstract]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems" xlink:type="locator" xlink:label="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of effect of changes in foreign exchange rates.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems" xlink:to="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable" xlink:type="locator" xlink:label="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of effect of changes in foreign exchange rates table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable" xlink:to="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Effect Of Changes In Foreign Exchange Rates [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Effect Of Changes In Foreign Exchange Rates [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:type="locator" xlink:label="srt_CurrencyAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CurrencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CurrencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Currency [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" />
    <link:label xml:lang="en-US" xlink:label="currency_AllCurrenciesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">All Currencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="currency_AllCurrenciesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">All Currencies [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_USD" xlink:type="locator" xlink:label="currency_USD" />
    <link:label xml:lang="en-US" xlink:label="currency_USD_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">USD</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_USD" xlink:to="currency_USD_lbl" />
    <link:label xml:lang="en-US" xlink:label="currency_USD_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S D</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:type="locator" xlink:label="ifrs-full_HedgingInstrumentsAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_HedgingInstrumentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hedging instruments [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_HedgingInstrumentsAxis" xlink:to="ifrs-full_HedgingInstrumentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_HedgingInstrumentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Hedging Instruments [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_HedgingInstrumentsMember" xlink:type="locator" xlink:label="ifrs-full_HedgingInstrumentsMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_HedgingInstrumentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hedging instruments [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_HedgingInstrumentsMember" xlink:to="ifrs-full_HedgingInstrumentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_HedgingInstrumentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Hedging Instruments [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PositiveFivePercentageChangeInForeignExchangeRateMember" xlink:type="locator" xlink:label="bntx_PositiveFivePercentageChangeInForeignExchangeRateMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_PositiveFivePercentageChangeInForeignExchangeRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Positive five percentage change in foreign exchange rate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_PositiveFivePercentageChangeInForeignExchangeRateMember" xlink:to="bntx_PositiveFivePercentageChangeInForeignExchangeRateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_PositiveFivePercentageChangeInForeignExchangeRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">+5 %</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_PositiveFivePercentageChangeInForeignExchangeRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Positive Five Percentage Change In Foreign Exchange Rate [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NegativeFivePercentageChangeInForeignExchangeRateMember" xlink:type="locator" xlink:label="bntx_NegativeFivePercentageChangeInForeignExchangeRateMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_NegativeFivePercentageChangeInForeignExchangeRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Negative five percentage change in foreign exchange rate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_NegativeFivePercentageChangeInForeignExchangeRateMember" xlink:to="bntx_NegativeFivePercentageChangeInForeignExchangeRateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_NegativeFivePercentageChangeInForeignExchangeRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">-5%</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NegativeFivePercentageChangeInForeignExchangeRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Negative Five Percentage Change In Foreign Exchange Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:type="locator" xlink:label="ifrs-full_ClosingForeignExchangeRate" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ClosingForeignExchangeRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Closing rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClosingForeignExchangeRate" xlink:to="ifrs-full_ClosingForeignExchangeRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ClosingForeignExchangeRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Closing Foreign Exchange Rate</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AverageForeignExchangeRate" xlink:type="locator" xlink:label="ifrs-full_AverageForeignExchangeRate" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AverageForeignExchangeRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Average rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AverageForeignExchangeRate" xlink:to="ifrs-full_AverageForeignExchangeRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AverageForeignExchangeRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Average Foreign Exchange Rate</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ForeignCurrencyChangesEffectOnLossBeforeTax" xlink:type="locator" xlink:label="bntx_ForeignCurrencyChangesEffectOnLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="bntx_ForeignCurrencyChangesEffectOnLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Foreign currency changes effect on loss before tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ForeignCurrencyChangesEffectOnLossBeforeTax" xlink:to="bntx_ForeignCurrencyChangesEffectOnLossBeforeTax_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ForeignCurrencyChangesEffectOnPretaxEquity" xlink:type="locator" xlink:label="bntx_ForeignCurrencyChangesEffectOnPretaxEquity" />
    <link:label xml:lang="en-US" xlink:label="bntx_ForeignCurrencyChangesEffectOnPretaxEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Foreign currency changes effect on pretax equity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ForeignCurrencyChangesEffectOnPretaxEquity" xlink:to="bntx_ForeignCurrencyChangesEffectOnPretaxEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ForeignCurrencyChangesEffectOnLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect on loss before tax</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ForeignCurrencyChangesEffectOnLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Changes Effect On Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ForeignCurrencyChangesEffectOnPretaxEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect on pre-tax equity</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ForeignCurrencyChangesEffectOnPretaxEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Changes Effect On Pretax Equity</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xlink:type="locator" xlink:label="ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">1 to 5 Years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xlink:to="ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Later Than Two Years And Not Later Than Five Years [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:type="locator" xlink:label="ifrs-full_LaterThanFiveYearsMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LaterThanFiveYearsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">More than 5 years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanFiveYearsMember" xlink:to="ifrs-full_LaterThanFiveYearsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LaterThanFiveYearsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Later Than Five Years [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiquidityRiskMember" xlink:type="locator" xlink:label="ifrs-full_LiquidityRiskMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LiquidityRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiquidityRiskMember" xlink:to="ifrs-full_LiquidityRiskMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LiquidityRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity Risk [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_InterestBearingLoansAndBorrowings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Interest bearing loans and borrowings</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_InterestBearingLoansAndBorrowings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Bearing Loans And Borrowings</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherPayables" xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayables" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TradeAndOtherPayables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade and other payables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayables" xlink:to="ifrs-full_TradeAndOtherPayables_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TradeAndOtherPayables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trade And Other Payables</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseLiabilities" xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:type="locator" xlink:label="ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:to="ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Liabilities Recognised In Business Combination</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherFinancialLiabilities" xlink:type="locator" xlink:label="ifrs-full_OtherFinancialLiabilities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherFinancialLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other financial liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinancialLiabilities" xlink:to="ifrs-full_OtherFinancialLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherFinancialLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Financial Liabilities</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities" xlink:type="locator" xlink:label="bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) through reclassification liabilities arising from financing activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities" xlink:to="bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Table]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CurrentObligationsUnderLeaseContractsMember" xlink:type="locator" xlink:label="bntx_CurrentObligationsUnderLeaseContractsMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_CurrentObligationsUnderLeaseContractsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Current obligations under lease contracts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_CurrentObligationsUnderLeaseContractsMember" xlink:to="bntx_CurrentObligationsUnderLeaseContractsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_CurrentObligationsUnderLeaseContractsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Obligations under Lease Contracts</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_CurrentObligationsUnderLeaseContractsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Obligations Under Lease Contracts [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NoncurrentObligationsUnderLeaseContractsMember" xlink:type="locator" xlink:label="bntx_NoncurrentObligationsUnderLeaseContractsMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_NoncurrentObligationsUnderLeaseContractsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncurrent obligations under lease contracts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_NoncurrentObligationsUnderLeaseContractsMember" xlink:to="bntx_NoncurrentObligationsUnderLeaseContractsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_NoncurrentObligationsUnderLeaseContractsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current Obligations under Lease Contracts</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NoncurrentObligationsUnderLeaseContractsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncurrent Obligations Under Lease Contracts [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_InterestBearingLoansAndBorrowingsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Interest-bearing Loans and Borrowings</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Arising From Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:to="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition of subsidiaries and businesses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:to="ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease Through Obtaining Or Losing Control Of Subsidiaries Or Other Businesses Liabilities Arising From Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New leases and disposals</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:to="ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Through New Leases Liabilities Arising From Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease Through Reclassification Liabilities Arising From Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xlink:to="ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease Through Other Changes Liabilities Arising From Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" xlink:type="locator" xlink:label="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Raw materials and supplies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" xlink:to="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Raw Materials And Current Production Supplies</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WorkInProgress" xlink:type="locator" xlink:label="ifrs-full_WorkInProgress" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WorkInProgress_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unfinished goods</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WorkInProgress" xlink:to="ifrs-full_WorkInProgress_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WorkInProgress_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Work In Progress</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinishedGoods" xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FinishedGoods_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finished goods</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinishedGoods" xlink:to="ifrs-full_FinishedGoods_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FinishedGoods_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finished Goods</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_Inventories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherReceivablesAbstract" xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trade And Other Receivables [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_TradeAndOtherReceivablesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayments on inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Prepaid Expenses</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAdvancesToSuppliers" xlink:type="locator" xlink:label="ifrs-full_CurrentAdvancesToSuppliers" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentAdvancesToSuppliers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayments related to CRO and CMO contracts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAdvancesToSuppliers" xlink:to="ifrs-full_CurrentAdvancesToSuppliers_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentAdvancesToSuppliers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Advances To Suppliers</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:type="locator" xlink:label="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales tax receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:to="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Receivables From Taxes Other Than Income Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_CurrentPrepaymentsRelatedToServiceContracts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayments related to service contracts</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_CurrentPrepaymentsRelatedToServiceContracts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Prepayments Related To Service Contracts</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OtherCurrentAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OtherCurrentAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Assets Other</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherAssets" xlink:type="locator" xlink:label="ifrs-full_OtherAssets" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAssets" xlink:to="ifrs-full_OtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherCurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total current</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherNoncurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total non-current</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredExpense" xlink:type="locator" xlink:label="bntx_DeferredExpense" />
    <link:label xml:lang="en-US" xlink:label="bntx_DeferredExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DeferredExpense" xlink:to="bntx_DeferredExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DeferredExpensesFromInsuranceContracts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred expenses from insurance contracts</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DeferredExpensesFromInsuranceContracts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Expenses From Insurance Contracts</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DeferredExpensesFromContractManufacturingAndContractResearchOrganizations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred expenses from CRO and CMO contracts</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DeferredExpensesFromContractManufacturingAndContractResearchOrganizations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Expenses From Contract Manufacturing And Contract Research Organizations</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OtherDeferredExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OtherDeferredExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Deferred Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DeferredExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DeferredExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DeferredExpenseNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total non-current</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DeferredExpenseNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Expense Non Current</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Classes Of Share Capital [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Classes Of Share Capital [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ShanghaiFosunPharmaceuticalGroupCoLtdMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shanghai Fosun Pharmaceuticals (Group) Co., Ltd</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NeonTherapeuticsIncMember" xlink:type="locator" xlink:label="bntx_NeonTherapeuticsIncMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_NeonTherapeuticsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Neon Therapeutics Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_NeonTherapeuticsIncMember" xlink:to="bntx_NeonTherapeuticsIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_NeonTherapeuticsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Neon Therapeutics, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NeonTherapeuticsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Neon Therapeutics Inc [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CapitalRequirementsAxis" xlink:type="locator" xlink:label="ifrs-full_CapitalRequirementsAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CapitalRequirementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital requirements [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalRequirementsAxis" xlink:to="ifrs-full_CapitalRequirementsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CapitalRequirementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Requirements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CapitalRequirementsMember" xlink:type="locator" xlink:label="ifrs-full_CapitalRequirementsMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CapitalRequirementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital requirements [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalRequirementsMember" xlink:to="ifrs-full_CapitalRequirementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CapitalRequirementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Requirements [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GlobalOfferingMember" xlink:type="locator" xlink:label="bntx_GlobalOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_GlobalOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Global offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_GlobalOfferingMember" xlink:to="bntx_GlobalOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_GlobalOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Global Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_GlobalOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Global Offering [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_June2020PrivatePlacementMember" xlink:type="locator" xlink:label="bntx_June2020PrivatePlacementMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_June2020PrivatePlacementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">June 2020 private placement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_June2020PrivatePlacementMember" xlink:to="bntx_June2020PrivatePlacementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_June2020PrivatePlacementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">June 2020 Private Placement</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_June2020PrivatePlacementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">June2020 Private Placement [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AtMarketOfferingProgramMember" xlink:type="locator" xlink:label="bntx_AtMarketOfferingProgramMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_AtMarketOfferingProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-market offering program.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_AtMarketOfferingProgramMember" xlink:to="bntx_AtMarketOfferingProgramMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_AtMarketOfferingProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-The-Market Offering Program</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AtMarketOfferingProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">At Market Offering Program [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OrdinarySharesSeriesBMember" xlink:type="locator" xlink:label="bntx_OrdinarySharesSeriesBMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_OrdinarySharesSeriesBMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Ordinary shares series B.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_OrdinarySharesSeriesBMember" xlink:to="bntx_OrdinarySharesSeriesBMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_OrdinarySharesSeriesBMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary Shares Series B</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OrdinarySharesSeriesBMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ordinary Shares Series B [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_HK" xlink:type="locator" xlink:label="country_HK" />
    <link:label xml:lang="en-US" xlink:label="country_HK_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">HONG KONG</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_HK" xlink:to="country_HK_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_HK_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">HONG KONG</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:type="locator" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Associates [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Investments In Associates [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForAssociatesMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EntitysTotalForAssociatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity&apos;s total for associates [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForAssociatesMember" xlink:to="ifrs-full_EntitysTotalForAssociatesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EntitysTotalForAssociatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entitys Total For Associates [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BillAndMeLindaGatesFoundationMember" xlink:type="locator" xlink:label="bntx_BillAndMeLindaGatesFoundationMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_BillAndMeLindaGatesFoundationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Bill &amp; Me linda Gates Foundation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_BillAndMeLindaGatesFoundationMember" xlink:to="bntx_BillAndMeLindaGatesFoundationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_BillAndMeLindaGatesFoundationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bill &amp; Melinda Gates Foundation</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BillAndMeLindaGatesFoundationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bill And Me Linda Gates Foundation [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_InitialPublicOfferingMember" xlink:type="locator" xlink:label="bntx_InitialPublicOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_InitialPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_InitialPublicOfferingMember" xlink:to="bntx_InitialPublicOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_InitialPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering (IPO)</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_InitialPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offering [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Classes Of Share Capital [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Classes Of Share Capital [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssueOfEquity" xlink:type="locator" xlink:label="ifrs-full_IssueOfEquity" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IssueOfEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of share capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfEquity" xlink:to="ifrs-full_IssueOfEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IssueOfEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issue Of Equity</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ParValuePerShare" xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ParValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nominal value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ParValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Par Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity transaction costs</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfOrdinarySharesIssuable" xlink:type="locator" xlink:label="bntx_NumberOfOrdinarySharesIssuable" />
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfOrdinarySharesIssuable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of ordinary shares issuable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_NumberOfOrdinarySharesIssuable" xlink:to="bntx_NumberOfOrdinarySharesIssuable_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate proceeds from issuance of ordinary share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issue Of Ordinary Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfOrdinarySharesIssuable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of ordinary shares issuable</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfOrdinarySharesIssuable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Ordinary Shares Issuable</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssued" xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Shares Issued</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares" xlink:type="locator" xlink:label="bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares" />
    <link:label xml:lang="en-US" xlink:label="bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of American depository shares to ordinary shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares" xlink:to="bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SharesIssuedPricePerShare1" xlink:type="locator" xlink:label="bntx_SharesIssuedPricePerShare1" />
    <link:label xml:lang="en-US" xlink:label="bntx_SharesIssuedPricePerShare1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued price per share 1.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_SharesIssuedPricePerShare1" xlink:to="bntx_SharesIssuedPricePerShare1_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of ADS to ordinary shares</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of American Depository Shares To Ordinary Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_SharesIssuedPricePerShare1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares issued price per share</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_SharesIssuedPricePerShare1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share1</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EquityIssuable" xlink:type="locator" xlink:label="bntx_EquityIssuable" />
    <link:label xml:lang="en-US" xlink:label="bntx_EquityIssuable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity issuable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_EquityIssuable" xlink:to="bntx_EquityIssuable_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_EquityIssuable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity issuable</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_EquityIssuable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Issuable</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_MaximumProceedsReceivableFromIssuanceOfOrdinaryShares" xlink:type="locator" xlink:label="bntx_MaximumProceedsReceivableFromIssuanceOfOrdinaryShares" />
    <link:label xml:lang="en-US" xlink:label="bntx_MaximumProceedsReceivableFromIssuanceOfOrdinaryShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum proceeds receivable from issuance of ordinary shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_MaximumProceedsReceivableFromIssuanceOfOrdinaryShares" xlink:to="bntx_MaximumProceedsReceivableFromIssuanceOfOrdinaryShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_MaximumProceedsReceivableFromIssuanceOfOrdinaryShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum gross proceeds receivable from issuance of ordinary shares</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_MaximumProceedsReceivableFromIssuanceOfOrdinaryShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Proceeds Receivable From Issuance Of Ordinary Shares</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CashInvestment" xlink:type="locator" xlink:label="bntx_CashInvestment" />
    <link:label xml:lang="en-US" xlink:label="bntx_CashInvestment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash investment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_CashInvestment" xlink:to="bntx_CashInvestment_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_CashInvestment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash investment</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_CashInvestment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Investment</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RemainingNoncontrollingInterestsAcquiredPercentage" xlink:type="locator" xlink:label="bntx_RemainingNoncontrollingInterestsAcquiredPercentage" />
    <link:label xml:lang="en-US" xlink:label="bntx_RemainingNoncontrollingInterestsAcquiredPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquisition of non-controlling interest.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_RemainingNoncontrollingInterestsAcquiredPercentage" xlink:to="bntx_RemainingNoncontrollingInterestsAcquiredPercentage_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DerecognitionOfNonControllingInterest" xlink:type="locator" xlink:label="bntx_DerecognitionOfNonControllingInterest" />
    <link:label xml:lang="en-US" xlink:label="bntx_DerecognitionOfNonControllingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Derecognition of non controlling interest.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DerecognitionOfNonControllingInterest" xlink:to="bntx_DerecognitionOfNonControllingInterest_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DecreaseInCapitalReserve" xlink:type="locator" xlink:label="bntx_DecreaseInCapitalReserve" />
    <link:label xml:lang="en-US" xlink:label="bntx_DecreaseInCapitalReserve_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Decrease in capital reserve.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DecreaseInCapitalReserve" xlink:to="bntx_DecreaseInCapitalReserve_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_RemainingNoncontrollingInterestsAcquiredPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining non-controlling interests acquired</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_RemainingNoncontrollingInterestsAcquiredPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Noncontrolling Interests Acquired Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DerecognitionOfNonControllingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derecognition of non-controlling interest</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DerecognitionOfNonControllingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derecognition Of Non Controlling Interest</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DecreaseInCapitalReserve_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease in capital reserve</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DecreaseInCapitalReserve_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Decrease In Capital Reserve</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Shares Issued And Fully Paid</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssuedButNotFullyPaid" xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedButNotFullyPaid" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NumberOfSharesIssuedButNotFullyPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares issued but not fully paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedButNotFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedButNotFullyPaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NumberOfSharesIssuedButNotFullyPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Shares Issued But Not Fully Paid</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ChangesInEquity" xlink:type="locator" xlink:label="ifrs-full_ChangesInEquity" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ChangesInEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in share capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ChangesInEquity" xlink:to="ifrs-full_ChangesInEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ChangesInEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Changes In Equity</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OptionVestingPeriod" xlink:type="locator" xlink:label="bntx_OptionVestingPeriod" />
    <link:label xml:lang="en-US" xlink:label="bntx_OptionVestingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Option vesting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_OptionVestingPeriod" xlink:to="bntx_OptionVestingPeriod_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PercentageOfOtherEquityInstrumentNonVestingRate" xlink:type="locator" xlink:label="bntx_PercentageOfOtherEquityInstrumentNonVestingRate" />
    <link:label xml:lang="en-US" xlink:label="bntx_PercentageOfOtherEquityInstrumentNonVestingRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of other equity instrument non vesting rate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_PercentageOfOtherEquityInstrumentNonVestingRate" xlink:to="bntx_PercentageOfOtherEquityInstrumentNonVestingRate_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TwoThousandTwentyRestrictedStockUnitPlanMember" xlink:type="locator" xlink:label="bntx_TwoThousandTwentyRestrictedStockUnitPlanMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_TwoThousandTwentyRestrictedStockUnitPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty restricted stock unit plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_TwoThousandTwentyRestrictedStockUnitPlanMember" xlink:to="bntx_TwoThousandTwentyRestrictedStockUnitPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_TwoThousandTwentyRestrictedStockUnitPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Restricted Stock Unit Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_TwoThousandTwentyRestrictedStockUnitPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Restricted Stock Unit Plan [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeEquityPlanLongTermIncentiveProgramMember" xlink:type="locator" xlink:label="bntx_EmployeeEquityPlanLongTermIncentiveProgramMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_EmployeeEquityPlanLongTermIncentiveProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee equity plan long term incentive program.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_EmployeeEquityPlanLongTermIncentiveProgramMember" xlink:to="bntx_EmployeeEquityPlanLongTermIncentiveProgramMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_EmployeeEquityPlanLongTermIncentiveProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LTI Program</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_EmployeeEquityPlanLongTermIncentiveProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Equity Plan Long Term Incentive Program [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember" xlink:type="locator" xlink:label="bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee equity plan long term incentive-plus program.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember" xlink:to="bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LTI-plus Program</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Equity Plan Long Term Incentive Plus Program [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ResearchAndDevelopmentExpensesMember" xlink:type="locator" xlink:label="bntx_ResearchAndDevelopmentExpensesMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_ResearchAndDevelopmentExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ResearchAndDevelopmentExpensesMember" xlink:to="bntx_ResearchAndDevelopmentExpensesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ResearchAndDevelopmentExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ResearchAndDevelopmentExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ProfessorUgurSahinMDMember" xlink:type="locator" xlink:label="bntx_ProfessorUgurSahinMDMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_ProfessorUgurSahinMDMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prof. Ugur Sahin, M.D.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ProfessorUgurSahinMDMember" xlink:to="bntx_ProfessorUgurSahinMDMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ProfessorUgurSahinMDMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prof. Ugur Sahin, M.D.</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ProfessorUgurSahinMDMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Professor Ugur Sahin M D [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SeanMarettMember" xlink:type="locator" xlink:label="bntx_SeanMarettMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_SeanMarettMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sean Marett.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_SeanMarettMember" xlink:to="bntx_SeanMarettMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_SeanMarettMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sean Marett</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_SeanMarettMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sean Marett [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DrSierkPoettingMember" xlink:type="locator" xlink:label="bntx_DrSierkPoettingMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_DrSierkPoettingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Dr. Sierk Poetting.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DrSierkPoettingMember" xlink:to="bntx_DrSierkPoettingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DrSierkPoettingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dr. Sierk Poetting</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DrSierkPoettingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dr Sierk Poetting [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DrOzlemTureciMember" xlink:type="locator" xlink:label="bntx_DrOzlemTureciMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_DrOzlemTureciMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Dr. Ozlem Tureci.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DrOzlemTureciMember" xlink:to="bntx_DrOzlemTureciMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DrOzlemTureciMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dr. Ozlem Tureci</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DrOzlemTureciMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dr Ozlem Tureci [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RyanRichardsonMember" xlink:type="locator" xlink:label="bntx_RyanRichardsonMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_RyanRichardsonMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Ryan Richardson.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_RyanRichardsonMember" xlink:to="bntx_RyanRichardsonMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_RyanRichardsonMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ryan Richardson</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_RyanRichardsonMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ryan Richardson [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OrdinarySharesMember" xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ordinary Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based payment expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Expense From Sharebased Payment Transactions With Employees</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option rights vesting term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:to="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Vesting Requirements For Sharebased Payment Arrangement</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OptionVestingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option rights vesting period</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OptionVestingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Option Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_PercentageOfOtherEquityInstrumentNonVestingRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of non-vesting rate</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_PercentageOfOtherEquityInstrumentNonVestingRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Other Equity Instrument Non Vesting Rate</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfInstrumentsOtherEquityInstrumentsExpectedToBeAllocated" xlink:type="locator" xlink:label="bntx_NumberOfInstrumentsOtherEquityInstrumentsExpectedToBeAllocated" />
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfInstrumentsOtherEquityInstrumentsExpectedToBeAllocated_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of instruments other equity instruments expected to be allocated.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_NumberOfInstrumentsOtherEquityInstrumentsExpectedToBeAllocated" xlink:to="bntx_NumberOfInstrumentsOtherEquityInstrumentsExpectedToBeAllocated_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Restricted Stock Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Other Equity Instruments Outstanding In Sharebased Payment Arrangement</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfInstrumentsOtherEquityInstrumentsExpectedToBeAllocated_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected to be allocated, Restricted Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfInstrumentsOtherEquityInstrumentsExpectedToBeAllocated_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Instruments Other Equity Instruments Expected To Be Allocated</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Restricted Stock Units</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpectedToBeAllocatedInSharebasedPaymentArrangement" xlink:type="locator" xlink:label="bntx_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpectedToBeAllocatedInSharebasedPaymentArrangement" />
    <link:label xml:lang="en-US" xlink:label="bntx_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpectedToBeAllocatedInSharebasedPaymentArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average exercise price of other equity instruments expected to be allocated in share based payment arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpectedToBeAllocatedInSharebasedPaymentArrangement" xlink:to="bntx_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpectedToBeAllocatedInSharebasedPaymentArrangement_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Share price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Exercise Price Of Other Equity Instruments Outstanding In Sharebased Payment Arrangement2019</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpectedToBeAllocatedInSharebasedPaymentArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected to be allocated, Share price</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpectedToBeAllocatedInSharebasedPaymentArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Exercise Price Of Other Equity Instruments Expected To Be Allocated In Sharebased Payment Arrangement</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Share price</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Expense From Sharebased Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CostOfSales1Member" xlink:type="locator" xlink:label="bntx_CostOfSales1Member" />
    <link:label xml:lang="en-US" xlink:label="bntx_CostOfSales1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of sales1.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_CostOfSales1Member" xlink:to="bntx_CostOfSales1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_CostOfSales1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of Sales</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_CostOfSales1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Sales1 [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SalesAndMarketingExpensesMember" xlink:type="locator" xlink:label="bntx_SalesAndMarketingExpensesMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_SalesAndMarketingExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales and marketing expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_SalesAndMarketingExpensesMember" xlink:to="bntx_SalesAndMarketingExpensesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_SalesAndMarketingExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales and Marketing Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_SalesAndMarketingExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales And Marketing Expenses [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expense recognized for employee services received</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CashSettledExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator" xlink:label="bntx_CashSettledExpenseFromSharebasedPaymentTransactionsWithEmployees" />
    <link:label xml:lang="en-US" xlink:label="bntx_CashSettledExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash settled expense from share based payment transactions with employees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_CashSettledExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="bntx_CashSettledExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_CashSettledExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based payment expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_CashSettledExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Settled Expense From Sharebased Payment Transactions With Employees</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncreaseDecreaseInShareBasedPaymentValue" xlink:type="locator" xlink:label="bntx_IncreaseDecreaseInShareBasedPaymentValue" />
    <link:label xml:lang="en-US" xlink:label="bntx_IncreaseDecreaseInShareBasedPaymentValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in share based payment value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_IncreaseDecreaseInShareBasedPaymentValue" xlink:to="bntx_IncreaseDecreaseInShareBasedPaymentValue_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpectedDividendShareOptionsGranted" xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendShareOptionsGranted" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ExpectedDividendShareOptionsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant of options, base value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendShareOptionsGranted_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ExpectedDividendShareOptionsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Expected Dividend Share Options Granted</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_IncreaseDecreaseInShareBasedPaymentValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (decrease) in grant of options, base value, for the year 2022</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_IncreaseDecreaseInShareBasedPaymentValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Share Based Payment Value</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne" xlink:type="locator" xlink:label="bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne" />
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of share options expected to be allocated in share based payment arrangement year one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne" xlink:to="bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo" xlink:type="locator" xlink:label="bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo" />
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of share options expected to be allocated in share based payment arrangement year two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo" xlink:to="bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Share options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Outstanding Share Options</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted, share options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Share Options Granted In Sharebased Payment Arrangement</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected to be allocated as of estimated allocation date 2021, share options</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Share Options Expected To Be Allocated In Share Based Payment Arrangement Year One</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected to be allocated as of estimated allocation date 2022, share options</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Share Options Expected To Be Allocated In Share Based Payment Arrangement Year Two</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited, share options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Share Options Forfeited In Sharebased Payment Arrangement</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Share options</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne" xlink:type="locator" xlink:label="bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne" />
    <link:label xml:lang="en-US" xlink:label="bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average exercise price of share options expected to be allocated in share based payment arrangement year one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne" xlink:to="bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo" xlink:type="locator" xlink:label="bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo" />
    <link:label xml:lang="en-US" xlink:label="bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average exercise price of share options expected to be allocated in share based payment arrangement year two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo" xlink:to="bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Weighted-average exercise price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Exercise Price Of Share Options Outstanding In Sharebased Payment Arrangement2019</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, Weighted-average exercise price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Exercise Price Of Share Options Granted In Sharebased Payment Arrangement2019</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected to be allocated as of estimated allocation date 2021, Weighted-average exercise price</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Exercise Price Of Share Options Expected To Be Allocated In Share Based Payment Arrangement Year One</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected to be allocated as of estimated allocation date 2022, Weighted-average exercise price</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Exercise Price Of Share Options Expected To Be Allocated In Share Based Payment Arrangement Year Two</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited, Weighted-average exercise price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Exercise Price Of Share Options Forfeited In Sharebased Payment Arrangement2019</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Weighted-average exercise price</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PercentageOfIncreaseInExercisePrice" xlink:type="locator" xlink:label="bntx_PercentageOfIncreaseInExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="bntx_PercentageOfIncreaseInExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Input parameter for performance criterion 1 - Threshold Amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_PercentageOfIncreaseInExercisePrice" xlink:to="bntx_PercentageOfIncreaseInExercisePrice_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering" xlink:type="locator" xlink:label="bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Input parameter capitalization for performance criterion 2 - Target Price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering" xlink:to="bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth" xlink:type="locator" xlink:label="bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth" />
    <link:label xml:lang="en-US" xlink:label="bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Input parameter increase factor for performance criterion 2 - Target Price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth" xlink:to="bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OptionExpirationPeriod" xlink:type="locator" xlink:label="bntx_OptionExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="bntx_OptionExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Option expiration period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_OptionExpirationPeriod" xlink:to="bntx_OptionExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_PercentageOfIncreaseInExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of exercise price increase</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_PercentageOfIncreaseInExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Increase In Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Threshold amount of dividend by number of shares outstanding immediately following initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Threshold Amount Of Dividend By Number Of Shares Outstanding Immediately Following Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of target share price applicable for prior twelve month period</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Target Share Price Applicable For Prior Twelve Month</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OptionExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option rights expiration period</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OptionExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Option Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-adjusting events after reporting period [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonadjusting Events After Reporting Period [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NonadjustingEventsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-adjusting events after reporting period [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="ifrs-full_NonadjustingEventsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NonadjustingEventsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonadjusting Events [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EstimatedAllocationDateOneMember" xlink:type="locator" xlink:label="bntx_EstimatedAllocationDateOneMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_EstimatedAllocationDateOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated allocation date one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_EstimatedAllocationDateOneMember" xlink:to="bntx_EstimatedAllocationDateOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_EstimatedAllocationDateOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Allocation Date 2021</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_EstimatedAllocationDateOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Allocation Date One [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EstimatedAllocationDateTwoMember" xlink:type="locator" xlink:label="bntx_EstimatedAllocationDateTwoMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_EstimatedAllocationDateTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated allocation date two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_EstimatedAllocationDateTwoMember" xlink:to="bntx_EstimatedAllocationDateTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_EstimatedAllocationDateTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Allocation Date 2022</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_EstimatedAllocationDateTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Allocation Date Two [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Fair Value At Measurement Date Share Options Granted</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average share price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Share Price Share Options Granted2019</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Share Options Granted2019</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility (%)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Expected Volatility Share Options Granted</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life (years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Option Life Share Options Granted</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate (%)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Risk Free Interest Rate Share Options Granted</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DrOzlemTureciMDMember" xlink:type="locator" xlink:label="bntx_DrOzlemTureciMDMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_DrOzlemTureciMDMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Dr. Ozlem Tureci, M.D.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DrOzlemTureciMDMember" xlink:to="bntx_DrOzlemTureciMDMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DrOzlemTureciMDMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dr. Ozlem Tureci, M.D.</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DrOzlemTureciMDMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dr Ozlem Tureci M D [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share options outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average exercise price</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_WeightedAverageRemainingContractualLifeOfShareOptionsAllocatedAndExpectedToBeAllocated" xlink:type="locator" xlink:label="bntx_WeightedAverageRemainingContractualLifeOfShareOptionsAllocatedAndExpectedToBeAllocated" />
    <link:label xml:lang="en-US" xlink:label="bntx_WeightedAverageRemainingContractualLifeOfShareOptionsAllocatedAndExpectedToBeAllocated_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average remaining contractual life of share options allocated and expected to be allocated.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_WeightedAverageRemainingContractualLifeOfShareOptionsAllocatedAndExpectedToBeAllocated" xlink:to="bntx_WeightedAverageRemainingContractualLifeOfShareOptionsAllocatedAndExpectedToBeAllocated_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_WeightedAverageRemainingContractualLifeOfShareOptionsAllocatedAndExpectedToBeAllocated_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options allocated and expected to be allocated, weighted-average expected life</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_WeightedAverageRemainingContractualLifeOfShareOptionsAllocatedAndExpectedToBeAllocated_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Remaining Contractual Life Of Share Options Allocated And Expected To Be Allocated</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OptionExercisablePeriod" xlink:type="locator" xlink:label="bntx_OptionExercisablePeriod" />
    <link:label xml:lang="en-US" xlink:label="bntx_OptionExercisablePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The option rights can be exercised at the latest eight years after the allocation date. If they have not been exercised by that date, they will forfeit without compensation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_OptionExercisablePeriod" xlink:to="bntx_OptionExercisablePeriod_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare" xlink:type="locator" xlink:label="bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise price currency translation of public offering price per share.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare" xlink:to="bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:type="locator" xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to purchase ordinary shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Instruments Granted In Sharebased Payment Arrangement</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price in translation for IPO</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Currency Translation Of Public Offering Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OptionExercisablePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option rights exercisable period</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OptionExercisablePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Option Exercisable Period</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, share options</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited, share options</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, weighted-average expected life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Remaining Contractual Life Of Outstanding Share Options2019</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsGrantedInSharebasedPaymentArrangement" xlink:type="locator" xlink:label="bntx_NumberOfOrdinarySharesUnderlyingOptionsGrantedInSharebasedPaymentArrangement" />
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfOrdinarySharesUnderlyingOptionsGrantedInSharebasedPaymentArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of ordinary shares underlying options granted in sharebased payment arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_NumberOfOrdinarySharesUnderlyingOptionsGrantedInSharebasedPaymentArrangement" xlink:to="bntx_NumberOfOrdinarySharesUnderlyingOptionsGrantedInSharebasedPaymentArrangement_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="locator" xlink:label="bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInSharebasedPaymentArrangement" />
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInSharebasedPaymentArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of ordinary shares underlying options forfeited in sharebased payment arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInSharebasedPaymentArrangement_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding" xlink:type="locator" xlink:label="bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding" />
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of ordinary shares underlying options outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding" xlink:to="bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Number of Ordinary Shares underlying options</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Ordinary Shares Underlying Options Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfOrdinarySharesUnderlyingOptionsGrantedInSharebasedPaymentArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted, Shares underlying options</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfOrdinarySharesUnderlyingOptionsGrantedInSharebasedPaymentArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Ordinary Shares Underlying Options Granted In Sharebased Payment Arrangement</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInSharebasedPaymentArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited, Shares underlying options</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInSharebasedPaymentArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Ordinary Shares Underlying Options Forfeited In Sharebased Payment Arrangement</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Number of Ordinary Shares underlying options</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of ordinary shares underlying options</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_CurrentLiabilitiesForEmployeesBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities to employees</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_CurrentLiabilitiesForEmployeesBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Liabilities For Employees Benefits</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OtherLiabilitiesOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OtherLiabilitiesOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Other</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherLiabilities" xlink:type="locator" xlink:label="ifrs-full_OtherLiabilities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherLiabilities" xlink:to="ifrs-full_OtherLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Quantitative Information About Rightofuse Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AdvancePaymentsRelatedToEmbeddedLeases" xlink:type="locator" xlink:label="bntx_AdvancePaymentsRelatedToEmbeddedLeases" />
    <link:label xml:lang="en-US" xlink:label="bntx_AdvancePaymentsRelatedToEmbeddedLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Advance payments related to embedded leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_AdvancePaymentsRelatedToEmbeddedLeases" xlink:to="bntx_AdvancePaymentsRelatedToEmbeddedLeases_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:type="locator" xlink:label="ifrs-full_AdditionsToRightofuseAssets" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AdditionsToRightofuseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions to right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsToRightofuseAssets" xlink:to="ifrs-full_AdditionsToRightofuseAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AdditionsToRightofuseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additions To Rightofuse Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AdvancePaymentsRelatedToEmbeddedLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advance payments related to embedded leases</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AdvancePaymentsRelatedToEmbeddedLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Advance Payments Related To Embedded Leases</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseLiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LeaseLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LeaseLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Lease Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncurrent Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GrossLeaseLiabilities" xlink:type="locator" xlink:label="ifrs-full_GrossLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_GrossLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future lease payments for non-cancellable lease contracts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossLeaseLiabilities" xlink:to="ifrs-full_GrossLeaseLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_GrossLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gross Lease Liabilities</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LeaseExpensesRecognizedInProfitOrLoss" xlink:type="locator" xlink:label="bntx_LeaseExpensesRecognizedInProfitOrLoss" />
    <link:label xml:lang="en-US" xlink:label="bntx_LeaseExpensesRecognizedInProfitOrLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expenses recognized in profit or loss.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_LeaseExpensesRecognizedInProfitOrLoss" xlink:to="bntx_LeaseExpensesRecognizedInProfitOrLoss_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:type="locator" xlink:label="ifrs-full_DepreciationRightofuseAssets" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DepreciationRightofuseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation charge</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationRightofuseAssets" xlink:to="ifrs-full_DepreciationRightofuseAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DepreciationRightofuseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Rightofuse Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest on lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:type="locator" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expense related to short-term leases (included in other expenses)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:to="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Expense Relating To Shortterm Leases For Which Recognition Exemption Has Been Used</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:type="locator" xlink:label="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expense relating to leases of low-value assets that are not short-term leases (included in other expenses)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:to="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Expense Relating To Leases Of Lowvalue Assets For Which Recognition Exemption Has Been Used</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_LeaseExpensesRecognizedInProfitOrLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total amounts recognized in profit or loss</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_LeaseExpensesRecognizedInProfitOrLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expenses Recognized In Profit Or Loss</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashOutflowForLeases" xlink:type="locator" xlink:label="ifrs-full_CashOutflowForLeases" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CashOutflowForLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cash outflow for leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOutflowForLeases" xlink:to="ifrs-full_CashOutflowForLeases_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CashOutflowForLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Outflow For Leases</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities" xlink:type="locator" xlink:label="bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Undiscounted future lease payments related to renewal options not included in lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities" xlink:to="bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Undiscounted potential future lease payments related to renewal options not included in lease liabilities until 2049</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Undiscounted Future Lease Payments Related To Renewal Options Not Included In Lease Liabilities</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PercentageOfDefinedContributionPlanOfSalary" xlink:type="locator" xlink:label="bntx_PercentageOfDefinedContributionPlanOfSalary" />
    <link:label xml:lang="en-US" xlink:label="bntx_PercentageOfDefinedContributionPlanOfSalary_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of defined contribution plan of salary.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_PercentageOfDefinedContributionPlanOfSalary" xlink:to="bntx_PercentageOfDefinedContributionPlanOfSalary_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_MaximumPensionFundContributions" xlink:type="locator" xlink:label="bntx_MaximumPensionFundContributions" />
    <link:label xml:lang="en-US" xlink:label="bntx_MaximumPensionFundContributions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum pension fund contributions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_MaximumPensionFundContributions" xlink:to="bntx_MaximumPensionFundContributions_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PensionFundContributionsExpectedForFollowingFinancialYear" xlink:type="locator" xlink:label="bntx_PensionFundContributionsExpectedForFollowingFinancialYear" />
    <link:label xml:lang="en-US" xlink:label="bntx_PensionFundContributionsExpectedForFollowingFinancialYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">pension fund contributions expected for the following financial year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_PensionFundContributionsExpectedForFollowingFinancialYear" xlink:to="bntx_PensionFundContributionsExpectedForFollowingFinancialYear_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AnnualPensionEntitlementOfEmployeeContribution" xlink:type="locator" xlink:label="bntx_AnnualPensionEntitlementOfEmployeeContribution" />
    <link:label xml:lang="en-US" xlink:label="bntx_AnnualPensionEntitlementOfEmployeeContribution_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual pension entitlement of employee contribution.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_AnnualPensionEntitlementOfEmployeeContribution" xlink:to="bntx_AnnualPensionEntitlementOfEmployeeContribution_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansTable" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Defined Benefit Plans [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Defined Benefit Plans [Table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Characteristics of defined benefit plans [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Characteristics Of Defined Benefit Plans [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Characteristics of defined benefit plans [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Characteristics Of Defined Benefit Plans [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Final Salary Defined Benefit Pension Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" xlink:to="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Final Salary Pension Defined Benefit Plans [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis" xlink:type="locator" xlink:label="ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funding arrangements of defined benefit plans [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis" xlink:to="ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Funding Arrangements Of Defined Benefit Plans [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funding arrangements of defined benefit plans [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember" xlink:to="ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Funding Arrangements Of Defined Benefit Plans [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funded Base Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember" xlink:to="ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Wholly Or Partly Funded Defined Benefit Plans [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WhollyUnfundedDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_WhollyUnfundedDefinedBenefitPlansMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WhollyUnfundedDefinedBenefitPlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-funded Supplement Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WhollyUnfundedDefinedBenefitPlansMember" xlink:to="ifrs-full_WhollyUnfundedDefinedBenefitPlansMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WhollyUnfundedDefinedBenefitPlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Wholly Unfunded Defined Benefit Plans [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Defined Benefit Plans [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Defined Benefit Plans [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExplanationOfWhetherParticipantsContributeToRetirementBenefitPlan" xlink:type="locator" xlink:label="ifrs-full_ExplanationOfWhetherParticipantsContributeToRetirementBenefitPlan" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ExplanationOfWhetherParticipantsContributeToRetirementBenefitPlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of participants contribute to retirement benefit plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExplanationOfWhetherParticipantsContributeToRetirementBenefitPlan" xlink:to="ifrs-full_ExplanationOfWhetherParticipantsContributeToRetirementBenefitPlan_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ExplanationOfWhetherParticipantsContributeToRetirementBenefitPlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Explanation Of Whether Participants Contribute To Retirement Benefit Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_PercentageOfDefinedContributionPlanOfSalary_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of defined contribution plan of salary</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_PercentageOfDefinedContributionPlanOfSalary_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Defined Contribution Plan Of Salary</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AnnualPensionEntitlementOfEmployeeContribution_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual pension entitlement of employee contribution for one Euro</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AnnualPensionEntitlementOfEmployeeContribution_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual Pension Entitlement Of Employee Contribution</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_MaximumPensionFundContributions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum pension fund contributions</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_MaximumPensionFundContributions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Pension Fund Contributions</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_PensionFundContributionsExpectedForFollowingFinancialYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pension fund contributions expected for the following financial year</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_PensionFundContributionsExpectedForFollowingFinancialYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pension Fund Contributions Expected For Following Financial Year</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:type="locator" xlink:label="ifrs-full_DefinedBenefitPlansAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DefinedBenefitPlansAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined benefit plans [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DefinedBenefitPlansAxis" xlink:to="ifrs-full_DefinedBenefitPlansAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DefinedBenefitPlansAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plans [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_DefinedBenefitPlansMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DefinedBenefitPlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined benefit plans [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DefinedBenefitPlansMember" xlink:to="ifrs-full_DefinedBenefitPlansMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DefinedBenefitPlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plans [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BasePlanMember" xlink:type="locator" xlink:label="bntx_BasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_BasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Base plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_BasePlanMember" xlink:to="bntx_BasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_BasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Base Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_BasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Base Plan [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SupplementPlanMember" xlink:type="locator" xlink:label="bntx_SupplementPlanMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_SupplementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Supplement plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_SupplementPlanMember" xlink:to="bntx_SupplementPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_SupplementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplement Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_SupplementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplement Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:type="locator" xlink:label="ifrs-full_NoncurrentProvisionsForEmployeeBenefits" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NoncurrentProvisionsForEmployeeBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined benefit obligation recognized in non-current provisions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:to="ifrs-full_NoncurrentProvisionsForEmployeeBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NoncurrentProvisionsForEmployeeBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncurrent Provisions For Employee Benefits</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Service cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Service Cost Net Defined Benefit Liability Asset</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense Income Net Defined Benefit Liability Asset</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Net Defined Benefit Liability Asset</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Actuarial changes arising from changes in financial assumptions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Actuarial Gains Losses Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Experience adjustments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Actuarial Gains Losses Arising From Experience Adjustments Net Defined Benefit Liability Asset</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Remeasurement Of Net Defined Benefit Liability Asset</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:type="locator" xlink:label="ifrs-full_LiabilityAssetOfDefinedBenefitPlans" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel">As of January 1, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:to="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liability Asset Of Defined Benefit Plans</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisition of subsidiaries and businesses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease Through Business Combinations And Disposals Net Defined Benefit Liability Asset</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Service cost</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net interest expense</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BenefitsPaidOrPayable" xlink:type="locator" xlink:label="ifrs-full_BenefitsPaidOrPayable" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_BenefitsPaidOrPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Benefits paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BenefitsPaidOrPayable" xlink:to="ifrs-full_BenefitsPaidOrPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_BenefitsPaidOrPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Benefits Paid Or Payable</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Actuarial changes arising from changes in financial assumptions</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Experience adjustments</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel">As of December 31, 2020</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionOfDiscountRates" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ActuarialAssumptionOfDiscountRates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:to="ifrs-full_ActuarialAssumptionOfDiscountRates_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ActuarialAssumptionOfDiscountRates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Actuarial Assumption Of Discount Rates</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price inflation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation" xlink:to="ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Actuarial Assumption Of Expected Rates Of Inflation</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rate of salary increase</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:to="ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Actuarial Assumption Of Expected Rates Of Salary Increases</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pension increases for in-payment benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:to="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Actuarial Assumption Of Expected Rates Of Pension Increases</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Sensitivity Analysis For Actuarial Assumptions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Sensitivity Analysis For Actuarial Assumptions [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Sensitivity Analysis For Actuarial Assumptions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionsAxis" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionsAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ActuarialAssumptionsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Actuarial assumptions [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ActuarialAssumptionsAxis" xlink:to="ifrs-full_ActuarialAssumptionsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ActuarialAssumptionsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Actuarial Assumptions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionsMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ActuarialAssumptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Actuarial assumptions [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ActuarialAssumptionsMember" xlink:to="ifrs-full_ActuarialAssumptionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ActuarialAssumptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Actuarial Assumptions [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionOfDiscountRatesMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ActuarialAssumptionOfDiscountRatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:to="ifrs-full_ActuarialAssumptionOfDiscountRatesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ActuarialAssumptionOfDiscountRatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Actuarial Assumption Of Discount Rates [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pension Increases (Decreases)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:to="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Actuarial Assumption Of Expected Rates Of Pension Increases [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined benefit obligation due to reasonably possible increase in actuarial assumption</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:to="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Defined Benefit Obligation Due To Reasonably Possible Increase In Actuarial Assumption</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined benefit obligation due to reasonably possible decrease in actuarial assumption</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:to="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Defined Benefit Obligation Due To Reasonably Possible Decrease In Actuarial Assumption</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Sensitivity Analysis For Actuarial Assumptions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Sensitivity Analysis For Actuarial Assumptions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="locator" xlink:label="ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of reasonably possible increase in actuarial assumption</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:to="ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Reasonably Possible Increase In Actuarial Assumption</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="locator" xlink:label="ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of reasonably possible decrease in actuarial assumption</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:to="ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Reasonably Possible Decrease In Actuarial Assumption</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average duration of defined benefit obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:to="ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Duration Of Defined Benefit Obligation2019</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="locator" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">1 to 5 Years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Later Than One Year And Not Later Than Five Years [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan" xlink:type="locator" xlink:label="ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected payments or contributions in future years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan" xlink:to="ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Estimate Of Contributions Expected To Be Paid To Plan</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsAccrued" xlink:type="locator" xlink:label="bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsAccrued" />
    <link:label xml:lang="en-US" xlink:label="bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Key management personnel compensation, short term employee benefits accrued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsAccrued" xlink:to="bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsAccrued_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term employee benefits incurred</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Key Management Personnel Compensation Shortterm Employee Benefits</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term employee benefits accrued*</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Key Management Personnel Compensation Short Term Employee Benefits Accrued</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Key Management Personnel Compensation Sharebased Payment</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensation" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_KeyManagementPersonnelCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total compensation paid to key management personnel</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_KeyManagementPersonnelCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Key Management Personnel Compensation</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_KeyManagementPersonnelCompensationShareBasedPaymentOrdinaryShares" xlink:type="locator" xlink:label="bntx_KeyManagementPersonnelCompensationShareBasedPaymentOrdinaryShares" />
    <link:label xml:lang="en-US" xlink:label="bntx_KeyManagementPersonnelCompensationShareBasedPaymentOrdinaryShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Key management personnel compensation share based payment ordinary shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_KeyManagementPersonnelCompensationShareBasedPaymentOrdinaryShares" xlink:to="bntx_KeyManagementPersonnelCompensationShareBasedPaymentOrdinaryShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_KeyManagementPersonnelCompensationShareBasedPaymentOrdinaryShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment, ordinary shares</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_KeyManagementPersonnelCompensationShareBasedPaymentOrdinaryShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Key Management Personnel Compensation Share Based Payment Ordinary Shares</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Transactions Between Related Parties [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Transactions Between Related Parties [Table]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CofounderAndChiefExecutiveOfficerMember" xlink:type="locator" xlink:label="bntx_CofounderAndChiefExecutiveOfficerMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_CofounderAndChiefExecutiveOfficerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cofounder and chief executive officer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_CofounderAndChiefExecutiveOfficerMember" xlink:to="bntx_CofounderAndChiefExecutiveOfficerMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_CofounderAndChiefExecutiveOfficerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Co-founder and Chief Executive Officer</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_CofounderAndChiefExecutiveOfficerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cofounder And Chief Executive Officer [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Transactions Between Related Parties [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Transactions Between Related Parties [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Granted shares</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConsultingServicesAndPatentAssignment" xlink:type="locator" xlink:label="bntx_ConsultingServicesAndPatentAssignment" />
    <link:label xml:lang="en-US" xlink:label="bntx_ConsultingServicesAndPatentAssignment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Consulting services and patent assignment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ConsultingServicesAndPatentAssignment" xlink:to="bntx_ConsultingServicesAndPatentAssignment_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" xlink:type="locator" xlink:label="bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" />
    <link:label xml:lang="en-US" xlink:label="bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchases of goods and service related party transactions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" xlink:to="bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GoodsAndServicesFromRelatedPartyTransactions" xlink:type="locator" xlink:label="bntx_GoodsAndServicesFromRelatedPartyTransactions" />
    <link:label xml:lang="en-US" xlink:label="bntx_GoodsAndServicesFromRelatedPartyTransactions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Goods and services from related party transactions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_GoodsAndServicesFromRelatedPartyTransactions" xlink:to="bntx_GoodsAndServicesFromRelatedPartyTransactions_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Key Management Personnel of Entity or Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Key Management Personnel Of Entity Or Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ConsultingServicesAndPatentAssignment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting services / patent assignment</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ConsultingServicesAndPatentAssignment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consulting Services And Patent Assignment</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of various goods and services from TRON</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchases Of Goods And Service Related Party Transactions</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_GoodsAndServicesFromRelatedPartyTransactions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_GoodsAndServicesFromRelatedPartyTransactions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goods And Services From Related Party Transactions</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConsultingServiceProviderMember" xlink:type="locator" xlink:label="bntx_ConsultingServiceProviderMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_ConsultingServiceProviderMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Consulting service provider.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ConsultingServiceProviderMember" xlink:to="bntx_ConsultingServiceProviderMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ConsultingServiceProviderMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting Service Provider</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ConsultingServiceProviderMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consulting Service Provider [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TRONMember" xlink:type="locator" xlink:label="bntx_TRONMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_TRONMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">TRON.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_TRONMember" xlink:to="bntx_TRONMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_TRONMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">TRON</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_TRONMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">T R O N [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:type="locator" xlink:label="ifrs-full_AmountsPayableRelatedPartyTransactions" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AmountsPayableRelatedPartyTransactions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding balances</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:to="ifrs-full_AmountsPayableRelatedPartyTransactions_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_AmountsPayableRelatedPartyTransactions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amounts Payable Related Party Transactions</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PurchasesFromRelatedPartyTransactions" xlink:type="locator" xlink:label="bntx_PurchasesFromRelatedPartyTransactions" />
    <link:label xml:lang="en-US" xlink:label="bntx_PurchasesFromRelatedPartyTransactions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchases from related party transactions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_PurchasesFromRelatedPartyTransactions" xlink:to="bntx_PurchasesFromRelatedPartyTransactions_lbl" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherRelatedPartiesMember" xlink:type="locator" xlink:label="ifrs-full_OtherRelatedPartiesMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherRelatedPartiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Related Parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherRelatedPartiesMember" xlink:to="ifrs-full_OtherRelatedPartiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_OtherRelatedPartiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Related Parties [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Purchases of various goods and services from entities controlled by ATHOS KG</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions" xlink:type="locator" xlink:label="ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and other assets from entities controlled by ATHOS KG</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions" xlink:to="ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchases Of Property And Other Assets Related Party Transactions</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_PurchasesFromRelatedPartyTransactions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_PurchasesFromRelatedPartyTransactions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchases From Related Party Transactions</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ATHOSKGMember" xlink:type="locator" xlink:label="bntx_ATHOSKGMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_ATHOSKGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">ATHOSKG.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_ATHOSKGMember" xlink:to="bntx_ATHOSKGMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_ATHOSKGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATHOS KG</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_ATHOSKGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A T H O S K G [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction" xlink:type="locator" xlink:label="ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding balances of related party transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction" xlink:to="ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Provisions For Doubtful Debts Related To Outstanding Balances Of Related Party Transaction</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction" xlink:type="locator" xlink:label="ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bad debt expense has been recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction" xlink:to="ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Expense Recognised During Period For Bad And Doubtful Debts For Related Party Transaction</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfAdditionalDosesToBeSupplied" xlink:type="locator" xlink:label="bntx_NumberOfAdditionalDosesToBeSupplied" />
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfAdditionalDosesToBeSupplied_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of additional doses to be supplied.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_NumberOfAdditionalDosesToBeSupplied" xlink:to="bntx_NumberOfAdditionalDosesToBeSupplied_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AggregateNumberOfDosesToBeSupplied" xlink:type="locator" xlink:label="bntx_AggregateNumberOfDosesToBeSupplied" />
    <link:label xml:lang="en-US" xlink:label="bntx_AggregateNumberOfDosesToBeSupplied_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate number of doses to be supplied.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_AggregateNumberOfDosesToBeSupplied" xlink:to="bntx_AggregateNumberOfDosesToBeSupplied_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfEuropeanUnionMemberStates" xlink:type="locator" xlink:label="bntx_NumberOfEuropeanUnionMemberStates" />
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfEuropeanUnionMemberStates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of European Union member states.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_NumberOfEuropeanUnionMemberStates" xlink:to="bntx_NumberOfEuropeanUnionMemberStates_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OptionToRequestSupplyOfNumberOfAdditionalDoses" xlink:type="locator" xlink:label="bntx_OptionToRequestSupplyOfNumberOfAdditionalDoses" />
    <link:label xml:lang="en-US" xlink:label="bntx_OptionToRequestSupplyOfNumberOfAdditionalDoses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Option to request supply of number of additional doses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_OptionToRequestSupplyOfNumberOfAdditionalDoses" xlink:to="bntx_OptionToRequestSupplyOfNumberOfAdditionalDoses_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfEventsAfterReportingPeriodLineItems" xlink:type="locator" xlink:label="bntx_DisclosureOfEventsAfterReportingPeriodLineItems" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfEventsAfterReportingPeriodLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of events after reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfEventsAfterReportingPeriodLineItems" xlink:to="bntx_DisclosureOfEventsAfterReportingPeriodLineItems_lbl" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfEventsAfterReportingPeriodTable" xlink:type="locator" xlink:label="bntx_DisclosureOfEventsAfterReportingPeriodTable" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfEventsAfterReportingPeriodTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of events after reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_DisclosureOfEventsAfterReportingPeriodTable" xlink:to="bntx_DisclosureOfEventsAfterReportingPeriodTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfEventsAfterReportingPeriodTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Events After Reporting Period [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfEventsAfterReportingPeriodTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Events After Reporting Period [Table]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SupplyOfCOVID19VaccineMember" xlink:type="locator" xlink:label="bntx_SupplyOfCOVID19VaccineMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_SupplyOfCOVID19VaccineMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Supply of COVID-19 vaccine.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_SupplyOfCOVID19VaccineMember" xlink:to="bntx_SupplyOfCOVID19VaccineMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_SupplyOfCOVID19VaccineMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supply Of COVID-19 Vaccine</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_SupplyOfCOVID19VaccineMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supply Of C O V I D19 Vaccine [Member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesAxis" xlink:type="locator" xlink:label="ifrs-full_CounterpartiesAxis" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CounterpartiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparties [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CounterpartiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparties [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesMember" xlink:type="locator" xlink:label="ifrs-full_CounterpartiesMember" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CounterpartiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparties [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="ifrs-full_CounterpartiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ifrs-full_CounterpartiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparties [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_UnitedStatesGovernmentMember" xlink:type="locator" xlink:label="bntx_UnitedStatesGovernmentMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_UnitedStatesGovernmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">United States government.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_UnitedStatesGovernmentMember" xlink:to="bntx_UnitedStatesGovernmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_UnitedStatesGovernmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_UnitedStatesGovernmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">United States Government [Member]</link:label>
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EuropeanUnionMemberStatesMember" xlink:type="locator" xlink:label="bntx_EuropeanUnionMemberStatesMember" />
    <link:label xml:lang="en-US" xlink:label="bntx_EuropeanUnionMemberStatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">European Union member states.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bntx_EuropeanUnionMemberStatesMember" xlink:to="bntx_EuropeanUnionMemberStatesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bntx_EuropeanUnionMemberStatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">European Union Member States</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_EuropeanUnionMemberStatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">European Union Member States [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfEventsAfterReportingPeriodLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Events After Reporting Period [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_DisclosureOfEventsAfterReportingPeriodLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Events After Reporting Period [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfAdditionalDosesToBeSupplied_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional doses of COVID-19 vaccine to be supplied</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfAdditionalDosesToBeSupplied_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Additional Doses To Be Supplied</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AggregateNumberOfDosesToBeSupplied_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total number of doses of COVID-19 vaccine to be supplied</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_AggregateNumberOfDosesToBeSupplied_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Number Of Doses To Be Supplied</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfEuropeanUnionMemberStates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of European Union member states.</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_NumberOfEuropeanUnionMemberStates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of European Union Member States</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OptionToRequestSupplyOfNumberOfAdditionalDoses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to request supply of number of additional doses of COVID-19 vaccine</link:label>
    <link:label xml:lang="en-US" xlink:label="bntx_OptionToRequestSupplyOfNumberOfAdditionalDoses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Option To Request Supply Of Number Of Additional Doses</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>49
<FILENAME>bntx-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-30T14:14:26.4336031+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : a6c3372c9f8947078f9b74c1e02df132 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biontech.de/20201231/role/TemplateLink" xlink:href="bntx-20201231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DocumentDocumentAndEntityInformationDetails" xlink:href="bntx-20201231.xsd#Role_DocumentDocumentAndEntityInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DocumentDocumentAndEntityInformationDetails">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown_li0l2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelEmailAddress" xlink:type="locator" xlink:label="dei_ContactPersonnelEmailAddress" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelName" xlink:type="locator" xlink:label="dei_ContactPersonnelName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:type="locator" xlink:label="dei_NoTradingSymbolFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_BusinessContactMember" xlink:type="locator" xlink:label="dei_BusinessContactMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AddressTypeDomain" xlink:type="locator" xlink:label="dei_AddressTypeDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesAddressTypeAxis" xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareOfOneMember" xlink:type="locator" xlink:label="bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareOfOneMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember" xlink:type="locator" xlink:label="bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:type="locator" xlink:label="dei_DocumentInformationTable" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentInformationTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareOfOneMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentInformationLineItems" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_NoTradingSymbolFlag" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelEmailAddress" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown_li0l2" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" xlink:href="bntx-20201231.xsd#Role_StatementConsolidatedStatementsOfFinancialPosition" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilities" xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities" xlink:type="locator" xlink:label="ifrs-full_Liabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilities" xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentLiabilities" xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentContractLiabilities" xlink:type="locator" xlink:label="ifrs-full_CurrentContractLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherShorttermProvisions" xlink:type="locator" xlink:label="ifrs-full_OtherShorttermProvisions" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:type="locator" xlink:label="ifrs-full_CurrentTaxLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentGovernmentGrants" xlink:type="locator" xlink:label="ifrs-full_CurrentGovernmentGrants" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShorttermBorrowings" xlink:type="locator" xlink:label="ifrs-full_ShorttermBorrowings" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilities" xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxLiabilities" xlink:type="locator" xlink:label="ifrs-full_DeferredTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:type="locator" xlink:label="ifrs-full_NoncurrentContractLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentProvisions" xlink:type="locator" xlink:label="ifrs-full_NoncurrentProvisions" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LongtermBorrowings" xlink:type="locator" xlink:label="ifrs-full_LongtermBorrowings" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:type="locator" xlink:label="ifrs-full_Equity" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReserves" xlink:type="locator" xlink:label="ifrs-full_OtherReserves" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:type="locator" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TreasuryShares" xlink:type="locator" xlink:label="ifrs-full_TreasuryShares" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CapitalReserve" xlink:type="locator" xlink:label="ifrs-full_CapitalReserve" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital" xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAbstract" xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets" xlink:type="locator" xlink:label="ifrs-full_Assets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssets" xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredExpenseCurrent" xlink:type="locator" xlink:label="bntx_DeferredExpenseCurrent" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:type="locator" xlink:label="ifrs-full_CurrentTaxAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentAssets" xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTradeReceivables" xlink:type="locator" xlink:label="ifrs-full_CurrentTradeReceivables" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Inventories" xlink:type="locator" xlink:label="ifrs-full_Inventories" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssets" xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxAssets" xlink:type="locator" xlink:label="ifrs-full_DeferredTaxAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherNoncurrentAssets" xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RightofuseAssets" xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_AssetsAbstract" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_RightofuseAssets" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_OtherNoncurrentAssets" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_DeferredTaxAssets" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_Inventories" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentTradeReceivables" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentFinancialAssets" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentAssets" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentTaxAssetsCurrent" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="bntx_DeferredExpenseCurrent" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssets" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_Assets" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAbstract" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_IssuedCapital" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_CapitalReserve" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_TreasuryShares" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncome" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_OtherReserves" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_Equity" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_LongtermBorrowings" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherNoncurrentFinancialLiabilities" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentProvisions" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentContractLiabilities" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherNoncurrentLiabilities" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_DeferredTaxLiabilities" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilities" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" order="11980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_ShorttermBorrowings" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="12100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentFinancialLiabilities" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentGovernmentGrants" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentTaxLiabilitiesCurrent" order="12220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherShorttermProvisions" order="12260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentContractLiabilities" order="12300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentLiabilities" order="12340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilities" order="12380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_Liabilities" order="12420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilities" order="12460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="bntx-20201231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:type="locator" xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareAbstract" xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToAbstract" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceCosts" xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncome" xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:type="locator" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MiscellaneousOtherOperatingExpense" xlink:type="locator" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SalesAndMarketingExpense" xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CostOfSales" xlink:type="locator" xlink:label="ifrs-full_CostOfSales" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:type="locator" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueAbstract" xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeStatementLineItems" xlink:type="locator" xlink:label="bntx_IncomeStatementLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CommercialMember" xlink:type="locator" xlink:label="bntx_CommercialMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ResearchAndDevelopmentMember" xlink:type="locator" xlink:label="bntx_ResearchAndDevelopmentMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:type="locator" xlink:label="ifrs-full_ProductsAndServicesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:type="locator" xlink:label="ifrs-full_ProductsAndServicesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeStatementTable" xlink:type="locator" xlink:label="bntx_IncomeStatementTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAbstract" xlink:type="locator" xlink:label="ifrs-full_ProfitLossAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossAbstract" xlink:to="bntx_IncomeStatementTable" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeStatementTable" xlink:to="ifrs-full_ProductsAndServicesAxis" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="bntx_ResearchAndDevelopmentMember" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="bntx_CommercialMember" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossAbstract" xlink:to="bntx_IncomeStatementLineItems" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_RevenueAbstract" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_CostOfSales" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_SalesAndMarketingExpense" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_MiscellaneousOtherOperatingExpense" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_FinanceIncome" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_FinanceCosts" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_ProfitLossBeforeTax" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_ProfitLoss" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_ProfitLossAttributableToAbstract" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLoss" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_EarningsPerShareAbstract" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeStatementLineItems" xlink:to="ifrs-full_BasicAndDilutedEarningsLossPerShare" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsParenthetical" xlink:href="bntx-20201231.xsd#Role_StatementConsolidatedStatementsOfOperationsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsParenthetical">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_StockSplitConversionRatio" xlink:type="locator" xlink:label="bntx_StockSplitConversionRatio" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAbstract" xlink:type="locator" xlink:label="ifrs-full_ProfitLossAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossAbstract" xlink:to="bntx_StockSplitConversionRatio" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="bntx-20201231.xsd#Role_StatementConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToAbstract" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncome" xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncome" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="locator" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="locator" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ProfitLoss" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="ifrs-full_OtherComprehensiveIncome" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="ifrs-full_ComprehensiveIncome" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToAbstract" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:to="ifrs-full_ComprehensiveIncome" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="bntx-20201231.xsd#Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:type="locator" xlink:label="ifrs-full_Equity_li0l2" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncreaseDecreaseThroughSettlementOfSharebasedPaymentPlan" xlink:type="locator" xlink:label="bntx_IncreaseDecreaseThroughSettlementOfSharebasedPaymentPlan" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost" xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncreaseDecreaseThroughAcquisitionOfNoncontrollingInterests" xlink:type="locator" xlink:label="bntx_IncreaseDecreaseThroughAcquisitionOfNoncontrollingInterests" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncreaseDecreaseThroughInitialPublicOffering" xlink:type="locator" xlink:label="bntx_IncreaseDecreaseThroughInitialPublicOffering" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IssuanceOfShareCapital" xlink:type="locator" xlink:label="bntx_IssuanceOfShareCapital" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncome" xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncome" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:type="locator" xlink:label="ifrs-full_Equity" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CapitalIncreaseSeriesBMember" xlink:type="locator" xlink:label="bntx_CapitalIncreaseSeriesBMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterestsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ForeignCurrencyTranslationReserveMember" xlink:type="locator" xlink:label="bntx_ForeignCurrencyTranslationReserveMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReservesMember" xlink:type="locator" xlink:label="ifrs-full_OtherReservesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TreasurySharesMember" xlink:type="locator" xlink:label="ifrs-full_TreasurySharesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CapitalReserveMember" xlink:type="locator" xlink:label="ifrs-full_CapitalReserveMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:type="locator" xlink:label="ifrs-full_EquityMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_CapitalReserveMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_TreasurySharesMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncomeMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_OtherReservesMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember" xlink:to="bntx_ForeignCurrencyTranslationReserveMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_EquityAttributableToOwnersOfParentMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_NoncontrollingInterestsMember" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="bntx_CapitalIncreaseSeriesBMember" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_OtherComprehensiveIncome" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ComprehensiveIncome" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="bntx_IssuanceOfShareCapital" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="bntx_IncreaseDecreaseThroughInitialPublicOffering" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="bntx_IncreaseDecreaseThroughAcquisitionOfNoncontrollingInterests" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" order="12100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" order="12320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="bntx_IncreaseDecreaseThroughSettlementOfSharebasedPaymentPlan" order="12540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity_li0l2" order="12760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:href="bntx-20201231.xsd#Role_StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_StockSplitConversionRatio" xlink:type="locator" xlink:label="bntx_StockSplitConversionRatio" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="bntx_StockSplitConversionRatio" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="bntx-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents_li0l2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="locator" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="locator" xlink:label="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssets" xlink:type="locator" xlink:label="bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator" xlink:label="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="locator" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:type="locator" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions" xlink:type="locator" xlink:label="bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AdjustmentsForIncreaseDecreaseInTradeAccountReceivableAndContractAssets" xlink:type="locator" xlink:label="bntx_AdjustmentsForIncreaseDecreaseInTradeAccountReceivableAndContractAssets" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_WorkingCapitalAdjustmentsAbstract" xlink:type="locator" xlink:label="bntx_WorkingCapitalAdjustmentsAbstract" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherAdjustmentsForNoncashItems" xlink:type="locator" xlink:label="ifrs-full_OtherAdjustmentsForNoncashItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AdjustmentsForMovementsInGovernmentGrants" xlink:type="locator" xlink:label="bntx_AdjustmentsForMovementsInGovernmentGrants" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForFinanceCosts" xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceCosts" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AdjustmentsForInterestOnLeaseLiability" xlink:type="locator" xlink:label="bntx_AdjustmentsForInterestOnLeaseLiability" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForFinanceIncome" xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncome" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_ProfitLoss" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForFinanceIncome" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="bntx_AdjustmentsForInterestOnLeaseLiability" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForFinanceCosts" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="bntx_AdjustmentsForMovementsInGovernmentGrants" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_OtherAdjustmentsForNoncashItems" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="bntx_WorkingCapitalAdjustmentsAbstract" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_WorkingCapitalAdjustmentsAbstract" xlink:to="bntx_AdjustmentsForIncreaseDecreaseInTradeAccountReceivableAndContractAssets" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_WorkingCapitalAdjustmentsAbstract" xlink:to="bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="12030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="12090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssets" order="12150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" order="12210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" order="12330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="12450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" order="12510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" order="12570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="12630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="12690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" order="12750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" order="12810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="12870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_li0l2" order="12930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureCorporateInformation" xlink:href="bntx-20201231.xsd#Role_DisclosureCorporateInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureCorporateInformation">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfCorporateInformationExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfCorporateInformationExplanatory" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfCorporateInformationExplanatoryAbstract" xlink:type="locator" xlink:label="bntx_DisclosureOfCorporateInformationExplanatoryAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfCorporateInformationExplanatoryAbstract" xlink:to="bntx_DisclosureOfCorporateInformationExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPolicies" xlink:href="bntx-20201231.xsd#Role_DisclosureSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:type="locator" xlink:label="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptions" xlink:href="bntx-20201231.xsd#Role_DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptions" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptions">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfAccountingJudgementsAndEstimatesAbstract" xlink:type="locator" xlink:label="bntx_DisclosureOfAccountingJudgementsAndEstimatesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfAccountingJudgementsAndEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformation" xlink:href="bntx-20201231.xsd#Role_DisclosureGroupInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformation">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfCompositionOfGroupExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCompositionOfGroupExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="ifrs-full_DisclosureOfCompositionOfGroupExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinations" xlink:href="bntx-20201231.xsd#Role_DisclosureBusinessCombinations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinations">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomers" xlink:href="bntx-20201231.xsd#Role_DisclosureRevenueFromContractsWithCustomers" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomers">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfRevenueFromContractsWithCustomersAbstract" xlink:type="locator" xlink:label="bntx_DisclosureOfRevenueFromContractsWithCustomersAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfRevenueFromContractsWithCustomersAbstract" xlink:to="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpenses" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeAndExpenses" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpenses">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIncomeAndExpensesExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfIncomeAndExpensesExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="locator" xlink:label="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_DisclosureOfIncomeAndExpensesExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTax" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeTax" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTax">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureEarningsPerShare" xlink:href="bntx-20201231.xsd#Role_DisclosureEarningsPerShare" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureEarningsPerShare">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareAbstract" xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipment" xlink:href="bntx-20201231.xsd#Role_DisclosurePropertyPlantAndEquipment" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipment">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIntangibleAssets" xlink:href="bntx-20201231.xsd#Role_DisclosureIntangibleAssets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIntangibleAssets">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilities" xlink:href="bntx-20201231.xsd#Role_DisclosureFinancialAssetsAndFinancialLiabilities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilities">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureInventories" xlink:href="bntx-20201231.xsd#Role_DisclosureInventories" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureInventories">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInventoriesExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfInventoriesAbstract" xlink:type="locator" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherAssets" xlink:href="bntx-20201231.xsd#Role_DisclosureOtherAssets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherAssets">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MiscellaneousCurrentAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_MiscellaneousCurrentAssetsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MiscellaneousCurrentAssetsAbstract" xlink:to="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureDeferredExpenses" xlink:href="bntx-20201231.xsd#Role_DisclosureDeferredExpenses" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureDeferredExpenses">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfDeferredExpensesExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfDeferredExpensesExplanatory" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfDeferredExpensesAbstract" xlink:type="locator" xlink:label="bntx_DisclosureOfDeferredExpensesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfDeferredExpensesAbstract" xlink:to="bntx_DisclosureOfDeferredExpensesExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIssuedCapitalAndReserves" xlink:href="bntx-20201231.xsd#Role_DisclosureIssuedCapitalAndReserves" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIssuedCapitalAndReserves">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPayments" xlink:href="bntx-20201231.xsd#Role_DisclosureShareBasedPayments" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPayments">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherLiabilities" xlink:href="bntx-20201231.xsd#Role_DisclosureOtherLiabilities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherLiabilities">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MiscellaneousCurrentLiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_MiscellaneousCurrentLiabilitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MiscellaneousCurrentLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureLeases" xlink:href="bntx-20201231.xsd#Role_DisclosureLeases" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureLeases">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensions" xlink:href="bntx-20201231.xsd#Role_DisclosurePensions" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensions">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosures" xlink:href="bntx-20201231.xsd#Role_DisclosureRelatedPartyDisclosures" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosures">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureEventsAfterReportingPeriod" xlink:href="bntx-20201231.xsd#Role_DisclosureEventsAfterReportingPeriod" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureEventsAfterReportingPeriod">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfEventsAfterReportingPeriodAbstract" xlink:type="locator" xlink:label="bntx_DisclosureOfEventsAfterReportingPeriodAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:href="bntx-20201231.xsd#Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DescriptionOfAccountingPolicyForStandardIssuedButNotYetEffectiveExplanatory" xlink:type="locator" xlink:label="bntx_DescriptionOfAccountingPolicyForStandardIssuedButNotYetEffectiveExplanatory" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DescriptionOfAccountingPolicyForInitialApplicationOfStandardsExplanatory" xlink:type="locator" xlink:label="bntx_DescriptionOfAccountingPolicyForInitialApplicationOfStandardsExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory" xlink:type="locator" xlink:label="bntx_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatory" xlink:type="locator" xlink:label="bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:type="locator" xlink:label="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatory" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="bntx_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="bntx_DescriptionOfAccountingPolicyForInitialApplicationOfStandardsExplanatory" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="bntx_DescriptionOfAccountingPolicyForStandardIssuedButNotYetEffectiveExplanatory" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables" xlink:href="bntx-20201231.xsd#Role_DisclosureSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIntangibleAssetsUsefulLifeExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfIntangibleAssetsUsefulLifeExplanatory" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatory" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatory" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:type="locator" xlink:label="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="bntx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatory" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="bntx_DisclosureOfIntangibleAssetsUsefulLifeExplanatory" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptionsTables" xlink:href="bntx-20201231.xsd#Role_DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptionsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptionsTables">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfDetailedInformationAboutProvisionalSalesFiguresForTerritoriesExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfDetailedInformationAboutProvisionalSalesFiguresForTerritoriesExplanatory" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfAccountingJudgementsAndEstimatesAbstract" xlink:type="locator" xlink:label="bntx_DisclosureOfAccountingJudgementsAndEstimatesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfAccountingJudgementsAndEstimatesAbstract" xlink:to="bntx_DisclosureOfDetailedInformationAboutProvisionalSalesFiguresForTerritoriesExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformationTables" xlink:href="bntx-20201231.xsd#Role_DisclosureGroupInformationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformationTables">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatory" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatory" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatory" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinationsTables" xlink:href="bntx-20201231.xsd#Role_DisclosureBusinessCombinationsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinationsTables">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechManufacturingMarburgGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechManufacturingMarburgGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechUSIncMember" xlink:type="locator" xlink:label="bntx_BioNTechUSIncMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LipocalyxGmbHMember" xlink:type="locator" xlink:label="bntx_LipocalyxGmbHMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BusinessCombinationsAxis" xlink:type="locator" xlink:label="ifrs-full_BusinessCombinationsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_BusinessCombinationsAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="bntx_LipocalyxGmbHMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="bntx_BioNTechUSIncMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="bntx_BioNTechManufacturingMarburgGmbHMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsLineItems" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersTables" xlink:href="bntx-20201231.xsd#Role_DisclosureRevenueFromContractsWithCustomersTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersTables">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPerformanceObligationsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPerformanceObligationsExplanatory" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfRecognitionOfRevenueExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfRecognitionOfRevenueExplanatory" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfRevenueFromContractsWithCustomersAbstract" xlink:type="locator" xlink:label="bntx_DisclosureOfRevenueFromContractsWithCustomersAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfRevenueFromContractsWithCustomersAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfRevenueFromContractsWithCustomersAbstract" xlink:to="bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatory" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfRevenueFromContractsWithCustomersAbstract" xlink:to="bntx_DisclosureOfRecognitionOfRevenueExplanatory" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfRevenueFromContractsWithCustomersAbstract" xlink:to="ifrs-full_DisclosureOfPerformanceObligationsExplanatory" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesTables" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeAndExpensesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesTables">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceCostExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinanceIncomeExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExplanatory" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfChangesRegardingGovernmentGrantsExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfChangesRegardingGovernmentGrantsExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfSalesAndMarketingExpensesExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfSalesAndMarketingExpensesExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfCostOfSalesExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCostOfSalesExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="locator" xlink:label="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="ifrs-full_DisclosureOfCostOfSalesExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_DisclosureOfSalesAndMarketingExpensesExplanatory" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_DisclosureOfChangesRegardingGovernmentGrantsExplanatory" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExplanatory" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="ifrs-full_DisclosureOfFinanceCostExplanatory" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatory" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxTables" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeTaxTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxTables">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfAccumulatedTaxLossesExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfAccumulatedTaxLossesExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatory" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatory" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="bntx_DisclosureOfAccumulatedTaxLossesExplanatory" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureEarningsPerShareTables" xlink:href="bntx-20201231.xsd#Role_DisclosureEarningsPerShareTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureEarningsPerShareTables">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareAbstract" xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipmentTables" xlink:href="bntx-20201231.xsd#Role_DisclosurePropertyPlantAndEquipmentTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipmentTables">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIntangibleAssetsTables" xlink:href="bntx-20201231.xsd#Role_DisclosureIntangibleAssetsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIntangibleAssetsTables">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatory" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesTables" xlink:href="bntx-20201231.xsd#Role_DisclosureFinancialAssetsAndFinancialLiabilitiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesTables">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfForeignCurrencyRiskExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfForeignCurrencyRiskExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsExplanatory" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="bntx_DisclosureOfForeignCurrencyRiskExplanatory" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureInventoriesTables" xlink:href="bntx-20201231.xsd#Role_DisclosureInventoriesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureInventoriesTables">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfClassesOfInventoriesExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfClassesOfInventoriesExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfInventoriesAbstract" xlink:type="locator" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="bntx_DisclosureOfClassesOfInventoriesExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherAssetsTables" xlink:href="bntx-20201231.xsd#Role_DisclosureOtherAssetsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherAssetsTables">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MiscellaneousCurrentAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_MiscellaneousCurrentAssetsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MiscellaneousCurrentAssetsAbstract" xlink:to="bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureDeferredExpensesTables" xlink:href="bntx-20201231.xsd#Role_DisclosureDeferredExpensesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureDeferredExpensesTables">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfExpensesExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfExpensesExplanatory" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfDeferredExpensesAbstract" xlink:type="locator" xlink:label="bntx_DisclosureOfDeferredExpensesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfDeferredExpensesAbstract" xlink:to="ifrs-full_DisclosureOfExpensesExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsTables" xlink:href="bntx-20201231.xsd#Role_DisclosureShareBasedPaymentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsTables">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss" xlink:type="locator" xlink:label="ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeStockOwnershipPlanMember" xlink:type="locator" xlink:label="bntx_EmployeeStockOwnershipPlanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ChiefExecutiveOfficerGrantMember" xlink:type="locator" xlink:label="bntx_ChiefExecutiveOfficerGrantMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ManagementBoardGrantMember" xlink:type="locator" xlink:label="bntx_ManagementBoardGrantMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeEquityPlanMember" xlink:type="locator" xlink:label="bntx_EmployeeEquityPlanMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_EmployeeEquityPlanMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_ManagementBoardGrantMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_ChiefExecutiveOfficerGrantMember" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_EmployeeStockOwnershipPlanMember" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherLiabilitiesTables" xlink:href="bntx-20201231.xsd#Role_DisclosureOtherLiabilitiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherLiabilitiesTables">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfDetailedInformationAboutOtherLiabilitiesExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfDetailedInformationAboutOtherLiabilitiesExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MiscellaneousCurrentLiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_MiscellaneousCurrentLiabilitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MiscellaneousCurrentLiabilitiesAbstract" xlink:to="bntx_DisclosureOfDetailedInformationAboutOtherLiabilitiesExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesTables" xlink:href="bntx-20201231.xsd#Role_DisclosureLeasesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesTables">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInstatementOfOperationsExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInstatementOfOperationsExplanatory" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatory" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInstatementOfOperationsExplanatory" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsTables" xlink:href="bntx-20201231.xsd#Role_DisclosurePensionsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsTables">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfDetailedInformationAboutExpectedPaymentsOrContributionsToDefinedBenefitPlanExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfDetailedInformationAboutExpectedPaymentsOrContributionsToDefinedBenefitPlanExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfAnalysisOfPresentValueOfDefinedBenefitObligationThatDistinguishesNatureCharacteristicsAndRisksExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAnalysisOfPresentValueOfDefinedBenefitObligationThatDistinguishesNatureCharacteristicsAndRisksExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfDetailedInformationAboutRemeasurementsRecognizedInOtherComprehensiveIncomeExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfDetailedInformationAboutRemeasurementsRecognizedInOtherComprehensiveIncomeExplanatory" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfDetailedInformationAboutNetBenefitExpenseRecognizedInStatementOfProfitOrLossExplanatory" xlink:type="locator" xlink:label="bntx_DisclosureOfDetailedInformationAboutNetBenefitExpenseRecognizedInStatementOfProfitOrLossExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="bntx_DisclosureOfDetailedInformationAboutNetBenefitExpenseRecognizedInStatementOfProfitOrLossExplanatory" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="bntx_DisclosureOfDetailedInformationAboutRemeasurementsRecognizedInOtherComprehensiveIncomeExplanatory" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfAnalysisOfPresentValueOfDefinedBenefitObligationThatDistinguishesNatureCharacteristicsAndRisksExplanatory" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="bntx_DisclosureOfDetailedInformationAboutExpectedPaymentsOrContributionsToDefinedBenefitPlanExplanatory" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresTables" xlink:href="bntx-20201231.xsd#Role_DisclosureRelatedPartyDisclosuresTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresTables">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureCorporateInformationAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureCorporateInformationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureCorporateInformationAdditionalInformationDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfNewRealEstateEntitiesFounded" xlink:type="locator" xlink:label="bntx_NumberOfNewRealEstateEntitiesFounded" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfCorporateInformationLineItems" xlink:type="locator" xlink:label="bntx_DisclosureOfCorporateInformationLineItems" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_DE" xlink:type="locator" xlink:label="country_DE" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfCorporateInformationTable" xlink:type="locator" xlink:label="bntx_DisclosureOfCorporateInformationTable" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfCorporateInformationExplanatoryAbstract" xlink:type="locator" xlink:label="bntx_DisclosureOfCorporateInformationExplanatoryAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfCorporateInformationExplanatoryAbstract" xlink:to="bntx_DisclosureOfCorporateInformationTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfCorporateInformationTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_DE" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfCorporateInformationExplanatoryAbstract" xlink:to="bntx_DisclosureOfCorporateInformationLineItems" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfCorporateInformationLineItems" xlink:to="bntx_NumberOfNewRealEstateEntitiesFounded" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_MinimumNumberOfCountriesInWhichCOVID19VaccineAuthorizedOrApprovedForEmergencyOrTemporaryUseOrGrantedConditionalMarketingAuthorization" xlink:type="locator" xlink:label="bntx_MinimumNumberOfCountriesInWhichCOVID19VaccineAuthorizedOrApprovedForEmergencyOrTemporaryUseOrGrantedConditionalMarketingAuthorization" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfReportingSegments" xlink:type="locator" xlink:label="bntx_NumberOfReportingSegments" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfOperationSegments" xlink:type="locator" xlink:label="bntx_NumberOfOperationSegments" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:type="locator" xlink:label="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="bntx_NumberOfOperationSegments" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="bntx_NumberOfReportingSegments" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="bntx_MinimumNumberOfCountriesInWhichCOVID19VaccineAuthorizedOrApprovedForEmergencyOrTemporaryUseOrGrantedConditionalMarketingAuthorization" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesUsefulLivesAppliedToGroupSPropertyPlantAndEquipmentDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureSignificantAccountingPoliciesUsefulLivesAppliedToGroupSPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesUsefulLivesAppliedToGroupSPropertyPlantAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:type="locator" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EquipmentToolsAndInstallationsMember" xlink:type="locator" xlink:label="bntx_EquipmentToolsAndInstallationsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BuildingsMember" xlink:type="locator" xlink:label="ifrs-full_BuildingsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_BuildingsMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="bntx_EquipmentToolsAndInstallationsMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="ifrs-full_BottomOfRangeMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="ifrs-full_TopOfRangeMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesUsefulLivesAppliedToGroupSRightOfUseAssetsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureSignificantAccountingPoliciesUsefulLivesAppliedToGroupSRightOfUseAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesUsefulLivesAppliedToGroupSRightOfUseAssetsDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" xlink:type="locator" xlink:label="bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_VehiclesMember" xlink:type="locator" xlink:label="ifrs-full_VehiclesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ProductionFacilitiesMember" xlink:type="locator" xlink:label="bntx_ProductionFacilitiesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EquipmentToolsAndInstallationsMember" xlink:type="locator" xlink:label="bntx_EquipmentToolsAndInstallationsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BuildingsMember" xlink:type="locator" xlink:label="ifrs-full_BuildingsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="ifrs-full_BottomOfRangeMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="ifrs-full_TopOfRangeMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_BuildingsMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="bntx_EquipmentToolsAndInstallationsMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="bntx_ProductionFacilitiesMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_VehiclesMember" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesUsefulLivesAppliedToGroupSIntangibleAssetsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureSignificantAccountingPoliciesUsefulLivesAppliedToGroupSIntangibleAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesUsefulLivesAppliedToGroupSIntangibleAssetsDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:type="locator" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComputerSoftwareMember" xlink:type="locator" xlink:label="ifrs-full_ComputerSoftwareMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LicencesMember" xlink:type="locator" xlink:label="ifrs-full_LicencesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IntellectualPropertyRightsMember" xlink:type="locator" xlink:label="bntx_IntellectualPropertyRightsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="ifrs-full_BottomOfRangeMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="ifrs-full_TopOfRangeMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="bntx_IntellectualPropertyRightsMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="ifrs-full_LicencesMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="ifrs-full_ComputerSoftwareMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptionsAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptionsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptionsAdditionalInformationDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception" xlink:type="locator" xlink:label="bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsAbstract" xlink:type="locator" xlink:label="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsAbstract" xlink:to="bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptionsScheduleOfProvisionalSalesFiguresForTerritoriesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptionsScheduleOfProvisionalSalesFiguresForTerritoriesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptionsScheduleOfProvisionalSalesFiguresForTerritoriesDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:type="locator" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsLineItems" xlink:type="locator" xlink:label="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CollaborationAgreementMember" xlink:type="locator" xlink:label="bntx_CollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:type="locator" xlink:label="ifrs-full_ProductsAndServicesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:type="locator" xlink:label="ifrs-full_ProductsAndServicesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GoodsSoldDirectlyToConsumersMember" xlink:type="locator" xlink:label="ifrs-full_GoodsSoldDirectlyToConsumersMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SalesChannelsMember" xlink:type="locator" xlink:label="ifrs-full_SalesChannelsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SalesChannelsAxis" xlink:type="locator" xlink:label="ifrs-full_SalesChannelsAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OutsideUSMember" xlink:type="locator" xlink:label="bntx_OutsideUSMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_DE" xlink:type="locator" xlink:label="country_DE" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsTable" xlink:type="locator" xlink:label="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsTable" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsAbstract" xlink:type="locator" xlink:label="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsAbstract" xlink:to="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_DE" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_US" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="bntx_OutsideUSMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsTable" xlink:to="ifrs-full_SalesChannelsAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SalesChannelsAxis" xlink:to="ifrs-full_SalesChannelsMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SalesChannelsMember" xlink:to="ifrs-full_GoodsSoldDirectlyToConsumersMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsTable" xlink:to="ifrs-full_ProductsAndServicesAxis" order="10040.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="bntx_CollaborationAgreementMember" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsAbstract" xlink:to="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsLineItems" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformationSummaryOfInformationAboutSubsidiariesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureGroupInformationSummaryOfInformationAboutSubsidiariesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformationSummaryOfInformationAboutSubsidiariesDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" xlink:type="locator" xlink:label="ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:type="locator" xlink:label="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechRealEstateAdamOpelStraeGmbHCoKGMember" xlink:type="locator" xlink:label="bntx_BioNTechRealEstateAdamOpelStraeGmbHCoKGMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechRealEstateHausVierGmbHCoKGMember" xlink:type="locator" xlink:label="bntx_BioNTechRealEstateHausVierGmbHCoKGMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechRealEstateDerGoldgrubeGmbHCoKGMember" xlink:type="locator" xlink:label="bntx_BioNTechRealEstateDerGoldgrubeGmbHCoKGMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechRealEstateHoldingGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechRealEstateHoldingGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechRealEstateGmbHAndCoKGMember" xlink:type="locator" xlink:label="bntx_BioNTechRealEstateGmbHAndCoKGMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechUKLimitedMember" xlink:type="locator" xlink:label="bntx_BioNTechUKLimitedMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechRealEstateVerwaltungsGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechRealEstateVerwaltungsGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechPharmaceuticalsAsiaPacificPteLtdMember" xlink:type="locator" xlink:label="bntx_BioNTechPharmaceuticalsAsiaPacificPteLtdMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechUSIncMember" xlink:type="locator" xlink:label="bntx_BioNTechUSIncMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechCellAndGeneTherapiesGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechCellAndGeneTherapiesGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechResearchAndDevelopmentIncMember" xlink:type="locator" xlink:label="bntx_BioNTechResearchAndDevelopmentIncMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechUSAHoldingLLCMember" xlink:type="locator" xlink:label="bntx_BioNTechUSAHoldingLLCMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_JPTPeptideTechnologiesIncMember" xlink:type="locator" xlink:label="bntx_JPTPeptideTechnologiesIncMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_JPTPeptideTechnologiesGmbHMember" xlink:type="locator" xlink:label="bntx_JPTPeptideTechnologiesGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ReSanoGmbHMember" xlink:type="locator" xlink:label="bntx_ReSanoGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechInnovativeManufacturingServicesGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechInnovativeManufacturingServicesGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechAustriaBeteiligungenGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechAustriaBeteiligungenGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechManufacturingMarburgGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechManufacturingMarburgGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechManufacturingGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechManufacturingGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechEuropeGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechEuropeGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechDiagnosticsGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechDiagnosticsGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechDeliveryTechnologiesGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechDeliveryTechnologiesGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechRNAPharmaceuticalsGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechRNAPharmaceuticalsGmbHMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechRNAPharmaceuticalsGmbHMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechDeliveryTechnologiesGmbHMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechDiagnosticsGmbHMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechEuropeGmbHMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechManufacturingGmbHMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechManufacturingMarburgGmbHMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechAustriaBeteiligungenGmbHMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechInnovativeManufacturingServicesGmbHMember" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_ReSanoGmbHMember" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_JPTPeptideTechnologiesGmbHMember" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_JPTPeptideTechnologiesIncMember" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechUSAHoldingLLCMember" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechResearchAndDevelopmentIncMember" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechCellAndGeneTherapiesGmbHMember" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechUSIncMember" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechPharmaceuticalsAsiaPacificPteLtdMember" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechRealEstateVerwaltungsGmbHMember" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechUKLimitedMember" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechRealEstateGmbHAndCoKGMember" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechRealEstateHoldingGmbHMember" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechRealEstateDerGoldgrubeGmbHCoKGMember" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechRealEstateHausVierGmbHCoKGMember" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechRealEstateAdamOpelStraeGmbHCoKGMember" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformationAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureGroupInformationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformationAdditionalInformationDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfNewEntities" xlink:type="locator" xlink:label="bntx_NumberOfNewEntities" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfEntitiesAcquiredDuringPeriod" xlink:type="locator" xlink:label="bntx_NumberOfEntitiesAcquiredDuringPeriod" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ReSanoGmbHMember" xlink:type="locator" xlink:label="bntx_ReSanoGmbHMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechUSAHoldingLLCAndBioNTechResearchAndDevelopmentIncMember" xlink:type="locator" xlink:label="bntx_BioNTechUSAHoldingLLCAndBioNTechResearchAndDevelopmentIncMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NeonTherapeuticsIncAndNovartisManufacturingGmbHMember" xlink:type="locator" xlink:label="bntx_NeonTherapeuticsIncAndNovartisManufacturingGmbHMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_NeonTherapeuticsIncAndNovartisManufacturingGmbHMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechUSAHoldingLLCAndBioNTechResearchAndDevelopmentIncMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="bntx_ReSanoGmbHMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="bntx_NumberOfEntitiesAcquiredDuringPeriod" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="bntx_NumberOfNewEntities" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformationSummaryOfInformationAboutParentCompanyDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureGroupInformationSummaryOfInformationAboutParentCompanyDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformationSummaryOfInformationAboutParentCompanyDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" xlink:type="locator" xlink:label="ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:type="locator" xlink:label="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ATImpfGmbHMember" xlink:type="locator" xlink:label="bntx_ATImpfGmbHMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechMember" xlink:type="locator" xlink:label="bntx_BioNTechMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:type="locator" xlink:label="srt_OwnershipAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="srt_OwnershipAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="bntx_BioNTechMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="bntx_ATImpfGmbHMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformationSummaryOfInformationAboutEntityWithSignificantInfluenceOverGroupDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureGroupInformationSummaryOfInformationAboutEntityWithSignificantInfluenceOverGroupDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformationSummaryOfInformationAboutEntityWithSignificantInfluenceOverGroupDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" xlink:type="locator" xlink:label="ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:type="locator" xlink:label="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_MedineGmbHMember" xlink:type="locator" xlink:label="bntx_MedineGmbHMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechMember" xlink:type="locator" xlink:label="bntx_BioNTechMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:type="locator" xlink:label="srt_OwnershipAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="srt_OwnershipAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="bntx_BioNTechMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="bntx_MedineGmbHMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureBusinessCombinationsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BargainPurchaseGainOnAcquisition" xlink:type="locator" xlink:label="bntx_BargainPurchaseGainOnAcquisition" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital" xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IntangibleAssetsNumberOfNeoantigenTargetedTherapiesUnderDevelopment" xlink:type="locator" xlink:label="bntx_IntangibleAssetsNumberOfNeoantigenTargetedTherapiesUnderDevelopment" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AmericanDepositaryShares" xlink:type="locator" xlink:label="bntx_AmericanDepositaryShares" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConsiderationTransferred" xlink:type="locator" xlink:label="bntx_ConsiderationTransferred" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BusinessCombinationContingentCashConsideration" xlink:type="locator" xlink:label="bntx_BusinessCombinationContingentCashConsideration" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:type="locator" xlink:label="ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:type="locator" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DateOfAcquisition2013" xlink:type="locator" xlink:label="ifrs-full_DateOfAcquisition2013" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashTransferred" xlink:type="locator" xlink:label="ifrs-full_CashTransferred" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NameOfAcquiree" xlink:type="locator" xlink:label="ifrs-full_NameOfAcquiree" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechManufacturingMarburgGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechManufacturingMarburgGmbHMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsUnderDevelopmentMember" xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsUnderDevelopmentMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechUSIncMember" xlink:type="locator" xlink:label="bntx_BioNTechUSIncMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PhaseTwoClinicalTrialMember" xlink:type="locator" xlink:label="bntx_PhaseTwoClinicalTrialMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PhaseOneClinicalTrialMember" xlink:type="locator" xlink:label="bntx_PhaseOneClinicalTrialMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ItemsOfContingentLiabilitiesMember" xlink:type="locator" xlink:label="ifrs-full_ItemsOfContingentLiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ItemsOfContingentLiabilitiesAxis" xlink:type="locator" xlink:label="ifrs-full_ItemsOfContingentLiabilitiesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LipocalyxGmbHMember" xlink:type="locator" xlink:label="bntx_LipocalyxGmbHMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BusinessCombinationsAxis" xlink:type="locator" xlink:label="ifrs-full_BusinessCombinationsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_BusinessCombinationsAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="bntx_LipocalyxGmbHMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_ItemsOfContingentLiabilitiesAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ItemsOfContingentLiabilitiesAxis" xlink:to="ifrs-full_ItemsOfContingentLiabilitiesMember" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ItemsOfContingentLiabilitiesMember" xlink:to="bntx_PhaseOneClinicalTrialMember" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ItemsOfContingentLiabilitiesMember" xlink:to="bntx_PhaseTwoClinicalTrialMember" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="bntx_BioNTechUSIncMember" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" order="10040.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="ifrs-full_IntangibleAssetsUnderDevelopmentMember" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="bntx_BioNTechManufacturingMarburgGmbHMember" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsLineItems" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_NameOfAcquiree" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_CashTransferred" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DateOfAcquisition2013" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="bntx_BusinessCombinationContingentCashConsideration" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="bntx_ConsiderationTransferred" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="bntx_AmericanDepositaryShares" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="bntx_IntangibleAssetsNumberOfNeoantigenTargetedTherapiesUnderDevelopment" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_IssuedCapital" order="11800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="bntx_BargainPurchaseGainOnAcquisition" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfFairValuesOfIdentifiableNetAssetsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureBusinessCombinationsSummaryOfFairValuesOfIdentifiableNetAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfFairValuesOfIdentifiableNetAssetsDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="locator" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashTransferred" xlink:type="locator" xlink:label="ifrs-full_CashTransferred" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SharesIssuedAtFairValue" xlink:type="locator" xlink:label="bntx_SharesIssuedAtFairValue" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" xlink:type="locator" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwillNetOfBargainPurchase" xlink:type="locator" xlink:label="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwillNetOfBargainPurchase" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BargainPurchaseGainOnAcquisition" xlink:type="locator" xlink:label="bntx_BargainPurchaseGainOnAcquisition" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill" xlink:type="locator" xlink:label="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="locator" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LiabilitiesRecognizedAsOfAcquisitionDate" xlink:type="locator" xlink:label="bntx_LiabilitiesRecognizedAsOfAcquisitionDate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherLiabilitiesNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="bntx_OtherLiabilitiesNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TradePayablesRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="bntx_TradePayablesRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ProvisionsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="bntx_ProvisionsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_LiabilitiesAbstract" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AssetsRecognizedAsOfAcquisitionDate" xlink:type="locator" xlink:label="bntx_AssetsRecognizedAsOfAcquisitionDate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_InventoryRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:type="locator" xlink:label="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:type="locator" xlink:label="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechManufacturingMarburgGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechManufacturingMarburgGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechUSIncMember" xlink:type="locator" xlink:label="bntx_BioNTechUSIncMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LipocalyxGmbHMember" xlink:type="locator" xlink:label="bntx_LipocalyxGmbHMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BusinessCombinationsAxis" xlink:type="locator" xlink:label="ifrs-full_BusinessCombinationsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_BusinessCombinationsAxis" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="bntx_LipocalyxGmbHMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="bntx_BioNTechUSIncMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="bntx_BioNTechManufacturingMarburgGmbHMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsLineItems" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="ifrs-full_InventoryRecognisedAsOfAcquisitionDate" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="bntx_AssetsRecognizedAsOfAcquisitionDate" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="ifrs-full_LiabilitiesAbstract" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="bntx_ProvisionsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="bntx_TradePayablesRecognisedAsOfAcquisitionDate" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="bntx_OtherLiabilitiesNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="bntx_LiabilitiesRecognizedAsOfAcquisitionDate" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="bntx_BargainPurchaseGainOnAcquisition" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwillNetOfBargainPurchase" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" xlink:to="bntx_SharesIssuedAtFairValue" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" xlink:to="ifrs-full_CashTransferred" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" xlink:to="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" xlink:to="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfReconciliationOfGoodwillDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureBusinessCombinationsSummaryOfReconciliationOfGoodwillDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfReconciliationOfGoodwillDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Goodwill" xlink:type="locator" xlink:label="ifrs-full_Goodwill_li0l2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionalRecognitionGoodwill" xlink:type="locator" xlink:label="ifrs-full_AdditionalRecognitionGoodwill" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Goodwill" xlink:type="locator" xlink:label="ifrs-full_Goodwill" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:to="ifrs-full_Goodwill" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:to="ifrs-full_AdditionalRecognitionGoodwill" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:to="ifrs-full_Goodwill_li0l2" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesFromContractsWithCustomersDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureRevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesFromContractsWithCustomersDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesFromContractsWithCustomersDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:type="locator" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsSatisfiedOverTimeMember" xlink:type="locator" xlink:label="ifrs-full_PerformanceObligationsSatisfiedOverTimeMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember" xlink:type="locator" xlink:label="ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsMember" xlink:type="locator" xlink:label="ifrs-full_PerformanceObligationsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsAxis" xlink:type="locator" xlink:label="ifrs-full_PerformanceObligationsAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CommercialMember" xlink:type="locator" xlink:label="bntx_CommercialMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ResearchAndDevelopmentMember" xlink:type="locator" xlink:label="bntx_ResearchAndDevelopmentMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:type="locator" xlink:label="ifrs-full_ProductsAndServicesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:type="locator" xlink:label="ifrs-full_ProductsAndServicesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherSalesMember" xlink:type="locator" xlink:label="bntx_OtherSalesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ShareOfCollaborationPartnersGrossProfitMember" xlink:type="locator" xlink:label="bntx_ShareOfCollaborationPartnersGrossProfitMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DirectProductSalesToBioNTechCustomersMember" xlink:type="locator" xlink:label="bntx_DirectProductSalesToBioNTechCustomersMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SalesToCollaborationPartnerMember" xlink:type="locator" xlink:label="bntx_SalesToCollaborationPartnerMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_COVID19VaccineRevenuesMember" xlink:type="locator" xlink:label="bntx_COVID19VaccineRevenuesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherMember" xlink:type="locator" xlink:label="bntx_OtherMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ShanghaiFosunPharmaceuticalGroupCoLtdMember" xlink:type="locator" xlink:label="bntx_ShanghaiFosunPharmaceuticalGroupCoLtdMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GenentechIncMember" xlink:type="locator" xlink:label="bntx_GenentechIncMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PfizerIncMember" xlink:type="locator" xlink:label="bntx_PfizerIncMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorCustomersMember" xlink:type="locator" xlink:label="ifrs-full_MajorCustomersMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorCustomersAxis" xlink:type="locator" xlink:label="ifrs-full_MajorCustomersAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_MajorCustomersAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_PfizerIncMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_GenentechIncMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_ShanghaiFosunPharmaceuticalGroupCoLtdMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_OtherMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_COVID19VaccineRevenuesMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_SalesToCollaborationPartnerMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_DirectProductSalesToBioNTechCustomersMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_ShareOfCollaborationPartnersGrossProfitMember" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_OtherSalesMember" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_ProductsAndServicesAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="bntx_ResearchAndDevelopmentMember" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="bntx_CommercialMember" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_PerformanceObligationsAxis" order="10040.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PerformanceObligationsAxis" xlink:to="ifrs-full_PerformanceObligationsMember" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PerformanceObligationsMember" xlink:to="ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PerformanceObligationsMember" xlink:to="ifrs-full_PerformanceObligationsSatisfiedOverTimeMember" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAdvances" xlink:type="locator" xlink:label="ifrs-full_CurrentAdvances" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale" xlink:type="locator" xlink:label="bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RemainingUpfrontFeesContractLiabilities" xlink:type="locator" xlink:label="bntx_RemainingUpfrontFeesContractLiabilities" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TradeReceivableMaturityPeriod" xlink:type="locator" xlink:label="bntx_TradeReceivableMaturityPeriod" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConditionalMarketingAuthorizationCountries" xlink:type="locator" xlink:label="bntx_ConditionalMarketingAuthorizationCountries" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SublicenseAgreementDate" xlink:type="locator" xlink:label="bntx_SublicenseAgreementDate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PercentageOfReimbursementOfSublicenseCosts" xlink:type="locator" xlink:label="bntx_PercentageOfReimbursementOfSublicenseCosts" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RevenuesDerivedFromDeferredUpfrontPayments" xlink:type="locator" xlink:label="bntx_RevenuesDerivedFromDeferredUpfrontPayments" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_MilestonePaymentRecognizedAsRevenue" xlink:type="locator" xlink:label="bntx_MilestonePaymentRecognizedAsRevenue" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NonRefundableUpfrontCashPayment" xlink:type="locator" xlink:label="bntx_NonRefundableUpfrontCashPayment" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RevenueFromCollaboration" xlink:type="locator" xlink:label="bntx_RevenueFromCollaboration" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:type="locator" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:type="locator" xlink:label="ifrs-full_PercentageOfEntitysRevenue" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfCustomers" xlink:type="locator" xlink:label="bntx_NumberOfCustomers" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BillAndHoldTransactionMember" xlink:type="locator" xlink:label="bntx_BillAndHoldTransactionMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherSalesTransactionsMember" xlink:type="locator" xlink:label="bntx_OtherSalesTransactionsMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RevenueFromShareOfCollaborationPartnersGrossProfitMember" xlink:type="locator" xlink:label="bntx_RevenueFromShareOfCollaborationPartnersGrossProfitMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_DE" xlink:type="locator" xlink:label="country_DE" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechMember" xlink:type="locator" xlink:label="bntx_BioNTechMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RevenuesFromSellingDrugProductBatchesToPfizersManufacturingSiteMember" xlink:type="locator" xlink:label="bntx_RevenuesFromSellingDrugProductBatchesToPfizersManufacturingSiteMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CommercialMember" xlink:type="locator" xlink:label="bntx_CommercialMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CellscriptSublicenseMember" xlink:type="locator" xlink:label="bntx_CellscriptSublicenseMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember" xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis" xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FosunPharmaMember" xlink:type="locator" xlink:label="bntx_FosunPharmaMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ResearchAndDevelopmentMember" xlink:type="locator" xlink:label="bntx_ResearchAndDevelopmentMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:type="locator" xlink:label="ifrs-full_ProductsAndServicesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:type="locator" xlink:label="ifrs-full_ProductsAndServicesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SanofiSAMember" xlink:type="locator" xlink:label="bntx_SanofiSAMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GenentechIncMember" xlink:type="locator" xlink:label="bntx_GenentechIncMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PfizerIncMember" xlink:type="locator" xlink:label="bntx_PfizerIncMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorCustomersMember" xlink:type="locator" xlink:label="ifrs-full_MajorCustomersMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorCustomersAxis" xlink:type="locator" xlink:label="ifrs-full_MajorCustomersAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_MajorCustomersAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_PfizerIncMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_GenentechIncMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_SanofiSAMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="srt_RangeAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="ifrs-full_BottomOfRangeMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="ifrs-full_TopOfRangeMember" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_ProductsAndServicesAxis" order="10040.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="bntx_ResearchAndDevelopmentMember" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_FosunPharmaMember" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis" order="10040.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis" xlink:to="ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember" xlink:to="bntx_CellscriptSublicenseMember" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="bntx_CommercialMember" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_RevenuesFromSellingDrugProductBatchesToPfizersManufacturingSiteMember" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_BioNTechMember" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="srt_StatementGeographicalAxis" order="10040.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_DE" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_RevenueFromShareOfCollaborationPartnersGrossProfitMember" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="bntx_OtherSalesTransactionsMember" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="bntx_BillAndHoldTransactionMember" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="bntx_NumberOfCustomers" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_PercentageOfEntitysRevenue" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="bntx_RevenueFromCollaboration" order="12360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="bntx_NonRefundableUpfrontCashPayment" order="12380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="bntx_MilestonePaymentRecognizedAsRevenue" order="12440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="bntx_RevenuesDerivedFromDeferredUpfrontPayments" order="12580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="bntx_PercentageOfReimbursementOfSublicenseCosts" order="12660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="bntx_SublicenseAgreementDate" order="12680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="bntx_ConditionalMarketingAuthorizationCountries" order="12740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="bntx_TradeReceivableMaturityPeriod" order="13140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="bntx_RemainingUpfrontFeesContractLiabilities" order="13220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale" order="13260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_CurrentAdvances" order="13300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfContractBalancesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureRevenueFromContractsWithCustomersSummaryOfContractBalancesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfContractBalancesDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContractLiabilities" xlink:type="locator" xlink:label="ifrs-full_ContractLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTradeReceivables" xlink:type="locator" xlink:label="ifrs-full_CurrentTradeReceivables" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="ifrs-full_CurrentTradeReceivables" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="ifrs-full_ContractLiabilities" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfRevenueRecognizedDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureRevenueFromContractsWithCustomersSummaryOfRevenueRecognizedDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfRevenueRecognizedDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredRevenueRecognizedIncludedContractLiabilities" xlink:type="locator" xlink:label="bntx_DeferredRevenueRecognizedIncludedContractLiabilities" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfRevenueFromContractsWithCustomersAbstract" xlink:type="locator" xlink:label="bntx_DisclosureOfRevenueFromContractsWithCustomersAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfRevenueFromContractsWithCustomersAbstract" xlink:to="bntx_DeferredRevenueRecognizedIncludedContractLiabilities" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfContractLiabilitiesAllocatedToRemainingPerformanceObligationsUnsatisfiedOrPartiallyUnsatisfiedDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureRevenueFromContractsWithCustomersSummaryOfContractLiabilitiesAllocatedToRemainingPerformanceObligationsUnsatisfiedOrPartiallyUnsatisfiedDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfContractLiabilitiesAllocatedToRemainingPerformanceObligationsUnsatisfiedOrPartiallyUnsatisfiedDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContractLiabilities" xlink:type="locator" xlink:label="ifrs-full_ContractLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPerformanceObligationsLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_UnsatisfiedOrPartiallyUnsatisfiedMember" xlink:type="locator" xlink:label="bntx_UnsatisfiedOrPartiallyUnsatisfiedMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsMember" xlink:type="locator" xlink:label="ifrs-full_PerformanceObligationsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsAxis" xlink:type="locator" xlink:label="ifrs-full_PerformanceObligationsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanOneYearMember" xlink:type="locator" xlink:label="ifrs-full_LaterThanOneYearMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:type="locator" xlink:label="ifrs-full_NotLaterThanOneYearMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:type="locator" xlink:label="ifrs-full_AggregatedTimeBandsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:type="locator" xlink:label="ifrs-full_MaturityAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPerformanceObligationsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPerformanceObligationsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPerformanceObligationsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPerformanceObligationsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsAbstract" xlink:to="ifrs-full_DisclosureOfPerformanceObligationsTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsTable" xlink:to="ifrs-full_MaturityAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_NotLaterThanOneYearMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanOneYearMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsTable" xlink:to="ifrs-full_PerformanceObligationsAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PerformanceObligationsAxis" xlink:to="ifrs-full_PerformanceObligationsMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PerformanceObligationsMember" xlink:to="bntx_UnsatisfiedOrPartiallyUnsatisfiedMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsAbstract" xlink:to="ifrs-full_DisclosureOfPerformanceObligationsLineItems" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="ifrs-full_ContractLiabilities" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesCostOfSalesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeAndExpensesCostOfSalesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesCostOfSalesDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CostOfSales" xlink:type="locator" xlink:label="ifrs-full_CostOfSales" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:type="locator" xlink:label="bntx_DisclosureOfIncomeAndExpensesLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherSalesMember" xlink:type="locator" xlink:label="bntx_OtherSalesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_COVID19VaccineRevenuesMember" xlink:type="locator" xlink:label="bntx_COVID19VaccineRevenuesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorCustomersMember" xlink:type="locator" xlink:label="ifrs-full_MajorCustomersMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorCustomersAxis" xlink:type="locator" xlink:label="ifrs-full_MajorCustomersAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CommercialMember" xlink:type="locator" xlink:label="bntx_CommercialMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:type="locator" xlink:label="ifrs-full_ProductsAndServicesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:type="locator" xlink:label="ifrs-full_ProductsAndServicesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIncomeAndExpensesTable" xlink:type="locator" xlink:label="bntx_DisclosureOfIncomeAndExpensesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="locator" xlink:label="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_DisclosureOfIncomeAndExpensesTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfIncomeAndExpensesTable" xlink:to="ifrs-full_ProductsAndServicesAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="bntx_CommercialMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfIncomeAndExpensesTable" xlink:to="ifrs-full_MajorCustomersAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_COVID19VaccineRevenuesMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_OtherSalesMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_DisclosureOfIncomeAndExpensesLineItems" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:to="ifrs-full_CostOfSales" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesResearchAndDevelopmentExpensesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeAndExpensesResearchAndDevelopmentExpensesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesResearchAndDevelopmentExpensesDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:type="locator" xlink:label="bntx_DisclosureOfIncomeAndExpensesLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:type="locator" xlink:label="ifrs-full_AccumulatedDepreciationAndAmortisationMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:type="locator" xlink:label="ifrs-full_CarryingAmountMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TransportCostsMember" xlink:type="locator" xlink:label="bntx_TransportCostsMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ITCostsMember" xlink:type="locator" xlink:label="bntx_ITCostsMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherIncomeExpenseMember" xlink:type="locator" xlink:label="bntx_OtherIncomeExpenseMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LeaseAndLeaseRelatedCostMember" xlink:type="locator" xlink:label="bntx_LeaseAndLeaseRelatedCostMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PurchasedServicesMember" xlink:type="locator" xlink:label="bntx_PurchasedServicesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LaboratorySuppliesMember" xlink:type="locator" xlink:label="bntx_LaboratorySuppliesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_WagesBenefitsAndSocialSecurityExpenseMember" xlink:type="locator" xlink:label="bntx_WagesBenefitsAndSocialSecurityExpenseMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeAndExpensesByNatureMember" xlink:type="locator" xlink:label="bntx_IncomeAndExpensesByNatureMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeAndExpensesByNatureAxis" xlink:type="locator" xlink:label="bntx_IncomeAndExpensesByNatureAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIncomeAndExpensesTable" xlink:type="locator" xlink:label="bntx_DisclosureOfIncomeAndExpensesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="locator" xlink:label="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_DisclosureOfIncomeAndExpensesTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfIncomeAndExpensesTable" xlink:to="bntx_IncomeAndExpensesByNatureAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeAndExpensesByNatureAxis" xlink:to="bntx_IncomeAndExpensesByNatureMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_WagesBenefitsAndSocialSecurityExpenseMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_LaboratorySuppliesMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_PurchasedServicesMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_LeaseAndLeaseRelatedCostMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_OtherIncomeExpenseMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_ITCostsMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_TransportCostsMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfIncomeAndExpensesTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_AccumulatedDepreciationAndAmortisationMember" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_DisclosureOfIncomeAndExpensesLineItems" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeAndExpensesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesAdditionalInformationDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" xlink:type="locator" xlink:label="bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetForeignExchangeLoss" xlink:type="locator" xlink:label="ifrs-full_NetForeignExchangeLoss" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetForeignExchangeGain" xlink:type="locator" xlink:label="ifrs-full_NetForeignExchangeGain" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentGovernmentGrants" xlink:type="locator" xlink:label="ifrs-full_CurrentGovernmentGrants" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:type="locator" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ChargeInConnectionWithCertainWithholdingTaxPaymentsForIntellectualPropertyLicenses" xlink:type="locator" xlink:label="bntx_ChargeInConnectionWithCertainWithholdingTaxPaymentsForIntellectualPropertyLicenses" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:type="locator" xlink:label="bntx_DisclosureOfIncomeAndExpensesLineItems" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_DE" xlink:type="locator" xlink:label="country_DE" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GovernmentGrantsMember" xlink:type="locator" xlink:label="bntx_GovernmentGrantsMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeAndExpensesByNatureMember" xlink:type="locator" xlink:label="bntx_IncomeAndExpensesByNatureMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeAndExpensesByNatureAxis" xlink:type="locator" xlink:label="bntx_IncomeAndExpensesByNatureAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="bntx_GeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NatureOfExpensesMember" xlink:type="locator" xlink:label="bntx_NatureOfExpensesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NatureOfExpensesAxis" xlink:type="locator" xlink:label="bntx_NatureOfExpensesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechUSIncMember" xlink:type="locator" xlink:label="bntx_BioNTechUSIncMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIncomeAndExpensesTable" xlink:type="locator" xlink:label="bntx_DisclosureOfIncomeAndExpensesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="locator" xlink:label="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_DisclosureOfIncomeAndExpensesTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfIncomeAndExpensesTable" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechUSIncMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfIncomeAndExpensesTable" xlink:to="bntx_NatureOfExpensesAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_NatureOfExpensesAxis" xlink:to="bntx_NatureOfExpensesMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_NatureOfExpensesMember" xlink:to="bntx_GeneralAndAdministrativeExpensesMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfIncomeAndExpensesTable" xlink:to="bntx_IncomeAndExpensesByNatureAxis" order="10040.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeAndExpensesByNatureAxis" xlink:to="bntx_IncomeAndExpensesByNatureMember" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_GovernmentGrantsMember" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfIncomeAndExpensesTable" xlink:to="srt_StatementGeographicalAxis" order="10040.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_DE" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_DisclosureOfIncomeAndExpensesLineItems" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:to="bntx_ChargeInConnectionWithCertainWithholdingTaxPaymentsForIntellectualPropertyLicenses" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:to="ifrs-full_CurrentGovernmentGrants" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:to="ifrs-full_NetForeignExchangeGain" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:to="ifrs-full_NetForeignExchangeLoss" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:to="bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesSalesAndMarketingExpensesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeAndExpensesSalesAndMarketingExpensesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesSalesAndMarketingExpensesDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SalesAndMarketingExpense" xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:type="locator" xlink:label="bntx_DisclosureOfIncomeAndExpensesLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherIncomeExpenseMember" xlink:type="locator" xlink:label="bntx_OtherIncomeExpenseMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PurchasedServicesMember" xlink:type="locator" xlink:label="bntx_PurchasedServicesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_WagesBenefitsAndSocialSecurityExpenseMember" xlink:type="locator" xlink:label="bntx_WagesBenefitsAndSocialSecurityExpenseMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeAndExpensesByNatureMember" xlink:type="locator" xlink:label="bntx_IncomeAndExpensesByNatureMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeAndExpensesByNatureAxis" xlink:type="locator" xlink:label="bntx_IncomeAndExpensesByNatureAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIncomeAndExpensesTable" xlink:type="locator" xlink:label="bntx_DisclosureOfIncomeAndExpensesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="locator" xlink:label="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_DisclosureOfIncomeAndExpensesTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfIncomeAndExpensesTable" xlink:to="bntx_IncomeAndExpensesByNatureAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeAndExpensesByNatureAxis" xlink:to="bntx_IncomeAndExpensesByNatureMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_WagesBenefitsAndSocialSecurityExpenseMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_PurchasedServicesMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_OtherIncomeExpenseMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_DisclosureOfIncomeAndExpensesLineItems" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:to="ifrs-full_SalesAndMarketingExpense" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesGeneralAndAdministrativeExpensesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeAndExpensesGeneralAndAdministrativeExpensesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesGeneralAndAdministrativeExpensesDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:type="locator" xlink:label="bntx_DisclosureOfIncomeAndExpensesLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ContractStaffingMember" xlink:type="locator" xlink:label="bntx_ContractStaffingMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_JobAdvertisementExpensesMember" xlink:type="locator" xlink:label="bntx_JobAdvertisementExpensesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LaboratorySuppliesMember" xlink:type="locator" xlink:label="bntx_LaboratorySuppliesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ResearchServicesMember" xlink:type="locator" xlink:label="bntx_ResearchServicesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_InsurancePremiumsMember" xlink:type="locator" xlink:label="bntx_InsurancePremiumsMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherIncomeExpenseMember" xlink:type="locator" xlink:label="bntx_OtherIncomeExpenseMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LeaseAndLeaseRelatedCostMember" xlink:type="locator" xlink:label="bntx_LeaseAndLeaseRelatedCostMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PurchasedServicesMember" xlink:type="locator" xlink:label="bntx_PurchasedServicesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_WagesBenefitsAndSocialSecurityExpenseMember" xlink:type="locator" xlink:label="bntx_WagesBenefitsAndSocialSecurityExpenseMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeAndExpensesByNatureMember" xlink:type="locator" xlink:label="bntx_IncomeAndExpensesByNatureMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeAndExpensesByNatureAxis" xlink:type="locator" xlink:label="bntx_IncomeAndExpensesByNatureAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OfficeEquipmentMember" xlink:type="locator" xlink:label="ifrs-full_OfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:type="locator" xlink:label="ifrs-full_AccumulatedDepreciationAndAmortisationMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:type="locator" xlink:label="ifrs-full_CarryingAmountMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIncomeAndExpensesTable" xlink:type="locator" xlink:label="bntx_DisclosureOfIncomeAndExpensesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="locator" xlink:label="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_DisclosureOfIncomeAndExpensesTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfIncomeAndExpensesTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_AccumulatedDepreciationAndAmortisationMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfIncomeAndExpensesTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OfficeEquipmentMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfIncomeAndExpensesTable" xlink:to="bntx_IncomeAndExpensesByNatureAxis" order="10040.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeAndExpensesByNatureAxis" xlink:to="bntx_IncomeAndExpensesByNatureMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_WagesBenefitsAndSocialSecurityExpenseMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_PurchasedServicesMember" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_LeaseAndLeaseRelatedCostMember" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_OtherIncomeExpenseMember" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_InsurancePremiumsMember" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_ResearchServicesMember" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_LaboratorySuppliesMember" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_JobAdvertisementExpensesMember" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_ContractStaffingMember" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_DisclosureOfIncomeAndExpensesLineItems" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesOtherOperatingIncomeDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeAndExpensesOtherOperatingIncomeDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesOtherOperatingIncomeDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:type="locator" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:type="locator" xlink:label="bntx_DisclosureOfIncomeAndExpensesLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherIncomeExpenseMember" xlink:type="locator" xlink:label="bntx_OtherIncomeExpenseMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BargainPurchaseMember" xlink:type="locator" xlink:label="bntx_BargainPurchaseMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GovernmentGrantsMember" xlink:type="locator" xlink:label="bntx_GovernmentGrantsMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeAndExpensesByNatureMember" xlink:type="locator" xlink:label="bntx_IncomeAndExpensesByNatureMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncomeAndExpensesByNatureAxis" xlink:type="locator" xlink:label="bntx_IncomeAndExpensesByNatureAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfIncomeAndExpensesTable" xlink:type="locator" xlink:label="bntx_DisclosureOfIncomeAndExpensesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="locator" xlink:label="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_DisclosureOfIncomeAndExpensesTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfIncomeAndExpensesTable" xlink:to="bntx_IncomeAndExpensesByNatureAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeAndExpensesByNatureAxis" xlink:to="bntx_IncomeAndExpensesByNatureMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_GovernmentGrantsMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_BargainPurchaseMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_IncomeAndExpensesByNatureMember" xlink:to="bntx_OtherIncomeExpenseMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_DisclosureOfIncomeAndExpensesLineItems" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesChangesRegardingGovernmentGrantsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeAndExpensesChangesRegardingGovernmentGrantsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesChangesRegardingGovernmentGrantsDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentGovernmentGrants" xlink:type="locator" xlink:label="ifrs-full_NoncurrentGovernmentGrants" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentGovernmentGrants" xlink:type="locator" xlink:label="ifrs-full_CurrentGovernmentGrants" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GovernmentGrants" xlink:type="locator" xlink:label="ifrs-full_GovernmentGrants_li0l2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:type="locator" xlink:label="ifrs-full_RevenueFromGovernmentGrants" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GovernmentGrantsReceived" xlink:type="locator" xlink:label="bntx_GovernmentGrantsReceived" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GovernmentGrants" xlink:type="locator" xlink:label="ifrs-full_GovernmentGrants" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GovernmentGrantsAbstract" xlink:type="locator" xlink:label="bntx_GovernmentGrantsAbstract" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="locator" xlink:label="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_GovernmentGrantsAbstract" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_GovernmentGrantsAbstract" xlink:to="ifrs-full_GovernmentGrants" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_GovernmentGrantsAbstract" xlink:to="bntx_GovernmentGrantsReceived" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_GovernmentGrantsAbstract" xlink:to="ifrs-full_RevenueFromGovernmentGrants" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_GovernmentGrantsAbstract" xlink:to="ifrs-full_GovernmentGrants_li0l2" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_GovernmentGrantsAbstract" xlink:to="ifrs-full_CurrentGovernmentGrants" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_GovernmentGrantsAbstract" xlink:to="ifrs-full_NoncurrentGovernmentGrants" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesFinanceIncomeDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeAndExpensesFinanceIncomeDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesFinanceIncomeDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncome" xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetForeignExchangeGain" xlink:type="locator" xlink:label="ifrs-full_NetForeignExchangeGain" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromInterest" xlink:type="locator" xlink:label="ifrs-full_RevenueFromInterest" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="locator" xlink:label="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="ifrs-full_RevenueFromInterest" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="ifrs-full_NetForeignExchangeGain" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="ifrs-full_FinanceIncome" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesFinanceExpenseDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeAndExpensesFinanceExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesFinanceExpenseDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceCosts" xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetForeignExchangeLoss" xlink:type="locator" xlink:label="ifrs-full_NetForeignExchangeLoss" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" xlink:type="locator" xlink:label="bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AmortizationOfFinancialInstruments" xlink:type="locator" xlink:label="bntx_AmortizationOfFinancialInstruments" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="locator" xlink:label="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_AmortizationOfFinancialInstruments" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="ifrs-full_NetForeignExchangeLoss" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="ifrs-full_FinanceCosts" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesEmployeeBenefitsExpenseDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeAndExpensesEmployeeBenefitsExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesEmployeeBenefitsExpenseDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:type="locator" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SocialSecurityContributions" xlink:type="locator" xlink:label="ifrs-full_SocialSecurityContributions" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WagesAndSalaries" xlink:type="locator" xlink:label="ifrs-full_WagesAndSalaries" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="locator" xlink:label="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="ifrs-full_WagesAndSalaries" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="ifrs-full_SocialSecurityContributions" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="ifrs-full_EmployeeBenefitsExpense" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeTaxAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AccumulatedTaxLossesInStateTaxCredits" xlink:type="locator" xlink:label="bntx_AccumulatedTaxLossesInStateTaxCredits" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AccumulatedTaxLossesInFederalTaxCredits" xlink:type="locator" xlink:label="bntx_AccumulatedTaxLossesInFederalTaxCredits" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_StateTaxLossesExpirationYear" xlink:type="locator" xlink:label="bntx_StateTaxLossesExpirationYear" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_StateDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="locator" xlink:label="bntx_StateDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="locator" xlink:label="bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FederalTaxLossesExpirationYear" xlink:type="locator" xlink:label="bntx_FederalTaxLossesExpirationYear" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsExpectedToExpire" xlink:type="locator" xlink:label="bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsExpectedToExpire" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_DeferredTaxLiabilityAsset" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredTaxAssetsForUnusedTaxLossesRecognized" xlink:type="locator" xlink:label="bntx_DeferredTaxAssetsForUnusedTaxLossesRecognized" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AccumulatedTaxLossesInTradeTax" xlink:type="locator" xlink:label="bntx_AccumulatedTaxLossesInTradeTax" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AccumulatedTaxLossesInCorporateTax" xlink:type="locator" xlink:label="bntx_AccumulatedTaxLossesInCorporateTax" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AverageEffectiveTaxRate" xlink:type="locator" xlink:label="ifrs-full_AverageEffectiveTaxRate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ApplicableTaxRate" xlink:type="locator" xlink:label="ifrs-full_ApplicableTaxRate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ChangeInAverageTradeTaxRate" xlink:type="locator" xlink:label="bntx_ChangeInAverageTradeTaxRate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SolidaritySurchargeRate" xlink:type="locator" xlink:label="bntx_SolidaritySurchargeRate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CorporateIncomeTaxRate" xlink:type="locator" xlink:label="bntx_CorporateIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_UnitedStatesTaxGroupMember" xlink:type="locator" xlink:label="bntx_UnitedStatesTaxGroupMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GermanEntitiesNotWithinTaxGroupMember" xlink:type="locator" xlink:label="bntx_GermanEntitiesNotWithinTaxGroupMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GermanTaxGroupMember" xlink:type="locator" xlink:label="bntx_GermanTaxGroupMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:type="locator" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:type="locator" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechUSAHoldingLLCMember" xlink:type="locator" xlink:label="bntx_BioNTechUSAHoldingLLCMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechUSAHoldingLLCMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="bntx_GermanTaxGroupMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="bntx_GermanEntitiesNotWithinTaxGroupMember" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="bntx_UnitedStatesTaxGroupMember" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="bntx_CorporateIncomeTaxRate" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="bntx_SolidaritySurchargeRate" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="bntx_ChangeInAverageTradeTaxRate" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_ApplicableTaxRate" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_AverageEffectiveTaxRate" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="bntx_AccumulatedTaxLossesInCorporateTax" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="bntx_AccumulatedTaxLossesInTradeTax" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="bntx_DeferredTaxAssetsForUnusedTaxLossesRecognized" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_DeferredTaxLiabilityAsset" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsExpectedToExpire" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="bntx_FederalTaxLossesExpirationYear" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="bntx_StateDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="bntx_StateTaxLossesExpirationYear" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="bntx_AccumulatedTaxLossesInFederalTaxCredits" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="bntx_AccumulatedTaxLossesInStateTaxCredits" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxSummaryOfCurrentAndDeferredTaxExpenseDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeTaxSummaryOfCurrentAndDeferredTaxExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxSummaryOfCurrentAndDeferredTaxExpenseDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherComponentsOfTaxExpenseIncome" xlink:type="locator" xlink:label="bntx_OtherComponentsOfTaxExpenseIncome" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:type="locator" xlink:label="ifrs-full_DeferredTaxExpenseIncome" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:type="locator" xlink:label="ifrs-full_CurrentTaxExpenseIncome" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_CurrentTaxExpenseIncome" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DeferredTaxExpenseIncome" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="bntx_OtherComponentsOfTaxExpenseIncome" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeTaxSummaryOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="locator" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TaxEffectOfTaxCredit" xlink:type="locator" xlink:label="bntx_TaxEffectOfTaxCredit" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfForeignTaxRates" xlink:type="locator" xlink:label="ifrs-full_TaxEffectOfForeignTaxRates" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:type="locator" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TaxEffectOfNonrecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences" xlink:type="locator" xlink:label="bntx_TaxEffectOfNonrecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfTaxLosses" xlink:type="locator" xlink:label="ifrs-full_TaxEffectOfTaxLosses" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TaxEffectiveEquityTransactionCosts" xlink:type="locator" xlink:label="bntx_TaxEffectiveEquityTransactionCosts" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses" xlink:type="locator" xlink:label="bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NonTaxEffectiveBargainPurchase" xlink:type="locator" xlink:label="bntx_NonTaxEffectiveBargainPurchase" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AddBackForTradeTaxPurposes" xlink:type="locator" xlink:label="bntx_AddBackForTradeTaxPurposes" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:type="locator" xlink:label="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GovernmentGrantsExemptedFromTaxes" xlink:type="locator" xlink:label="bntx_GovernmentGrantsExemptedFromTaxes" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:type="locator" xlink:label="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:type="locator" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:type="locator" xlink:label="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceMember" xlink:type="locator" xlink:label="ifrs-full_TemporaryDifferenceMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxLossesMember" xlink:type="locator" xlink:label="ifrs-full_UnusedTaxLossesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:type="locator" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:type="locator" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeTable" xlink:type="locator" xlink:label="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeTable" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeTable" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="ifrs-full_UnusedTaxLossesMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="ifrs-full_TemporaryDifferenceMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="ifrs-full_ProfitLossBeforeTax" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="bntx_GovernmentGrantsExemptedFromTaxes" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="bntx_AddBackForTradeTaxPurposes" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="bntx_NonTaxEffectiveBargainPurchase" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="bntx_TaxEffectiveEquityTransactionCosts" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="ifrs-full_TaxEffectOfTaxLosses" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="bntx_TaxEffectOfNonrecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="ifrs-full_TaxEffectOfForeignTaxRates" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="bntx_TaxEffectOfTaxCredit" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitParentheticalDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeTaxSummaryOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitParentheticalDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitParentheticalDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ApplicableTaxRate" xlink:type="locator" xlink:label="ifrs-full_ApplicableTaxRate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_ApplicableTaxRate" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxSummaryOfDeferredTaxesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeTaxSummaryOfDeferredTaxesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxSummaryOfDeferredTaxesDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_DeferredTaxLiabilityAsset_li0l2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" xlink:type="locator" xlink:label="bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="locator" xlink:label="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_DeferredTaxLiabilityAsset" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxCreditsMember" xlink:type="locator" xlink:label="ifrs-full_UnusedTaxCreditsMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherDeferredTaxesMember" xlink:type="locator" xlink:label="bntx_OtherDeferredTaxesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:type="locator" xlink:label="ifrs-full_NetDefinedBenefitLiabilityAssetMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ProvisionsMember" xlink:type="locator" xlink:label="bntx_ProvisionsMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_InterestBearingLoansAndBorrowingsMember" xlink:type="locator" xlink:label="bntx_InterestBearingLoansAndBorrowingsMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ContractLiabilitiesMember" xlink:type="locator" xlink:label="bntx_ContractLiabilitiesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LeasesMember" xlink:type="locator" xlink:label="bntx_LeasesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_InventoryMember" xlink:type="locator" xlink:label="bntx_InventoryMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FixedAssetsMember" xlink:type="locator" xlink:label="bntx_FixedAssetsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:type="locator" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:type="locator" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ValuationAdjustmentMember" xlink:type="locator" xlink:label="bntx_ValuationAdjustmentMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GrossCarryingAmountMember" xlink:type="locator" xlink:label="ifrs-full_GrossCarryingAmountMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:type="locator" xlink:label="ifrs-full_CarryingAmountMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_NetDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="bntx_ValuationAdjustmentMember" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="bntx_FixedAssetsMember" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="bntx_InventoryMember" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="bntx_LeasesMember" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="bntx_ContractLiabilitiesMember" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="bntx_InterestBearingLoansAndBorrowingsMember" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="bntx_ProvisionsMember" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="ifrs-full_NetDefinedBenefitLiabilityAssetMember" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="bntx_OtherDeferredTaxesMember" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="ifrs-full_UnusedTaxCreditsMember" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_DeferredTaxLiabilityAsset" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_DeferredTaxLiabilityAsset_li0l2" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxSummaryOfAccumulatedTaxLossesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIncomeTaxSummaryOfAccumulatedTaxLossesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxSummaryOfAccumulatedTaxLossesDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AccumulatedTaxLossesInStateTaxCredits" xlink:type="locator" xlink:label="bntx_AccumulatedTaxLossesInStateTaxCredits" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AccumulatedTaxLossesInFederalTaxCredits" xlink:type="locator" xlink:label="bntx_AccumulatedTaxLossesInFederalTaxCredits" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AccumulatedTaxLossesInTradeTax" xlink:type="locator" xlink:label="bntx_AccumulatedTaxLossesInTradeTax" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AccumulatedTaxLossesInCorporateTax" xlink:type="locator" xlink:label="bntx_AccumulatedTaxLossesInCorporateTax" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:to="bntx_AccumulatedTaxLossesInCorporateTax" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:to="bntx_AccumulatedTaxLossesInTradeTax" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:to="bntx_AccumulatedTaxLossesInFederalTaxCredits" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:to="bntx_AccumulatedTaxLossesInStateTaxCredits" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureEarningsPerShareAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureEarningsPerShareAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureEarningsPerShareAdditionalInformationDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_StockSplitConversionRatio" xlink:type="locator" xlink:label="bntx_StockSplitConversionRatio" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SharesIssuedDuringPeriodStockSplit" xlink:type="locator" xlink:label="bntx_SharesIssuedDuringPeriodStockSplit" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareAbstract" xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="bntx_SharesIssuedDuringPeriodStockSplit" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="bntx_StockSplitConversionRatio" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureEarningsPerShareSummaryOfIncomeAndShareDataUsedInBasicAndDilutedEPSCalculationsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureEarningsPerShareSummaryOfIncomeAndShareDataUsedInBasicAndDilutedEPSCalculationsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureEarningsPerShareSummaryOfIncomeAndShareDataUsedInBasicAndDilutedEPSCalculationsDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:type="locator" xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:type="locator" xlink:label="ifrs-full_AdjustedWeightedAverageShares" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:type="locator" xlink:label="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageShares" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareAbstract" xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_WeightedAverageShares" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_AdjustedWeightedAverageShares" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_BasicAndDilutedEarningsLossPerShare" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureEarningsPerShareSummaryOfIncomeAndShareDataUsedInBasicAndDilutedEPSCalculationsParentheticalDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureEarningsPerShareSummaryOfIncomeAndShareDataUsedInBasicAndDilutedEPSCalculationsParentheticalDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureEarningsPerShareSummaryOfIncomeAndShareDataUsedInBasicAndDilutedEPSCalculationsParentheticalDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_StockSplitConversionRatio" xlink:type="locator" xlink:label="bntx_StockSplitConversionRatio" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareAbstract" xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="bntx_StockSplitConversionRatio" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" xlink:href="bntx-20201231.xsd#Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment_li0l2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ReclassificationsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="bntx_ReclassificationsPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GrossCarryingAmountMember" xlink:type="locator" xlink:label="ifrs-full_GrossCarryingAmountMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:type="locator" xlink:label="ifrs-full_CarryingAmountMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConstructionInProgressAndAdvancePaymentsMember" xlink:type="locator" xlink:label="bntx_ConstructionInProgressAndAdvancePaymentsMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EquipmentToolsAndInstallationsMember" xlink:type="locator" xlink:label="bntx_EquipmentToolsAndInstallationsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LandAndBuildingsMember" xlink:type="locator" xlink:label="ifrs-full_LandAndBuildingsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_LandAndBuildingsMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="bntx_EquipmentToolsAndInstallationsMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="bntx_ConstructionInProgressAndAdvancePaymentsMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="bntx_ReclassificationsPropertyPlantAndEquipment" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_PropertyPlantAndEquipment_li0l2" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfDetailedInformationAboutIntangibleAssetsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIntangibleAssetsSummaryOfDetailedInformationAboutIntangibleAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfDetailedInformationAboutIntangibleAssetsDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_li0l2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="locator" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsOtherThanGoodwill" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsOtherThanGoodwill" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:type="locator" xlink:label="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AccumulatedDepreciationAmortisationAndImpairment" xlink:type="locator" xlink:label="bntx_AccumulatedDepreciationAmortisationAndImpairment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GrossCarryingAmountMember" xlink:type="locator" xlink:label="ifrs-full_GrossCarryingAmountMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:type="locator" xlink:label="ifrs-full_CarryingAmountMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AdvancePaymentsMember" xlink:type="locator" xlink:label="bntx_AdvancePaymentsMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember" xlink:type="locator" xlink:label="bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GoodwillMember" xlink:type="locator" xlink:label="ifrs-full_GoodwillMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="ifrs-full_GoodwillMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="bntx_AdvancePaymentsMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="bntx_AccumulatedDepreciationAmortisationAndImpairment" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsOtherThanGoodwill" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill_li0l2" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfGoodwillRecognizedDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIntangibleAssetsSummaryOfGoodwillRecognizedDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfGoodwillRecognizedDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Goodwill" xlink:type="locator" xlink:label="ifrs-full_Goodwill" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ExternalProductSalesOfJPTMember" xlink:type="locator" xlink:label="bntx_ExternalProductSalesOfJPTMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CGUImmunotherapiesMember" xlink:type="locator" xlink:label="bntx_CGUImmunotherapiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ConsolidatedStructuredEntitiesAxis" xlink:type="locator" xlink:label="ifrs-full_ConsolidatedStructuredEntitiesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_ConsolidatedStructuredEntitiesAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ConsolidatedStructuredEntitiesAxis" xlink:to="ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:to="bntx_CGUImmunotherapiesMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:to="bntx_ExternalProductSalesOfJPTMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_Goodwill" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssets" xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncreaseInGrowthRateCashFlowProjections" xlink:type="locator" xlink:label="bntx_IncreaseInGrowthRateCashFlowProjections" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows" xlink:type="locator" xlink:label="ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SubsidiariesMember" xlink:type="locator" xlink:label="ifrs-full_SubsidiariesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ExternalProductSalesOfJPTMember" xlink:type="locator" xlink:label="bntx_ExternalProductSalesOfJPTMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CGUImmunotherapiesMember" xlink:type="locator" xlink:label="bntx_CGUImmunotherapiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ConsolidatedStructuredEntitiesAxis" xlink:type="locator" xlink:label="ifrs-full_ConsolidatedStructuredEntitiesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_ConsolidatedStructuredEntitiesAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ConsolidatedStructuredEntitiesAxis" xlink:to="ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:to="bntx_CGUImmunotherapiesMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:to="bntx_ExternalProductSalesOfJPTMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="ifrs-full_SubsidiariesMember" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="10040.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_US" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="bntx_IncreaseInGrowthRateCashFlowProjections" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_NoncurrentAssets" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfCashAndCashEquivalentsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfCashAndCashEquivalentsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfCashAndCashEquivalentsDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents_li0l2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalentsAbstract" xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_li0l2" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialAssetsAtAmortizedCostDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialAssetsAtAmortizedCostDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialAssetsAtAmortizedCostDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentFinancialAssetsAtAmortisedCost" xlink:type="locator" xlink:label="ifrs-full_NoncurrentFinancialAssetsAtAmortisedCost" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentFinancialAssetsAtAmortisedCost" xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialAssetsAtAmortisedCost" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsAtAmortisedCost" xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherFinancialAssetsMember" xlink:type="locator" xlink:label="bntx_OtherFinancialAssetsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeReceivablesMember" xlink:type="locator" xlink:label="ifrs-full_TradeReceivablesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsMember" xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsTable" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="ifrs-full_TradeReceivablesMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="bntx_OtherFinancialAssetsMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsLineItems" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_CurrentFinancialAssetsAtAmortisedCost" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_NoncurrentFinancialAssetsAtAmortisedCost" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialLiabilitiesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentFinancialLiabilities" xlink:type="locator" xlink:label="ifrs-full_NoncurrentFinancialLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentFinancialLiabilities" xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilities" xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DerivativeFinancialLiabilitiesNotDesignatedAsHedgingInstrumentsAtFairValue" xlink:type="locator" xlink:label="bntx_DerivativeFinancialLiabilitiesNotDesignatedAsHedgingInstrumentsAtFairValue" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentFinancialLiabilitiesAtAmortisedCost" xlink:type="locator" xlink:label="ifrs-full_NoncurrentFinancialLiabilitiesAtAmortisedCost" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentFinancialLiabilitiesAtAmortisedCost" xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialLiabilitiesAtAmortisedCost" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherFinancialLiabilitiesMember" xlink:type="locator" xlink:label="bntx_OtherFinancialLiabilitiesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TradePayablesMember" xlink:type="locator" xlink:label="bntx_TradePayablesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContingentConsiderationMember" xlink:type="locator" xlink:label="ifrs-full_ContingentConsiderationMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConvertibleNoteEmbeddedDerivativeMember" xlink:type="locator" xlink:label="bntx_ConvertibleNoteEmbeddedDerivativeMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesMember" xlink:type="locator" xlink:label="ifrs-full_LiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember" xlink:type="locator" xlink:label="bntx_OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:type="locator" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:type="locator" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OnePointNineZeroPercentageSecuredBankLoanMember" xlink:type="locator" xlink:label="bntx_OnePointNineZeroPercentageSecuredBankLoanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember" xlink:type="locator" xlink:label="bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConvertibleNoteHostContractMember" xlink:type="locator" xlink:label="bntx_ConvertibleNoteHostContractMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TwoPointZeroEightPercentageSecuredBankLoanMember" xlink:type="locator" xlink:label="bntx_TwoPointZeroEightPercentageSecuredBankLoanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TwoPointOneFivePercentageSecuredBankLoanMember" xlink:type="locator" xlink:label="bntx_TwoPointOneFivePercentageSecuredBankLoanMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsByNameMember" xlink:type="locator" xlink:label="ifrs-full_BorrowingsByNameMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsByNameAxis" xlink:type="locator" xlink:label="ifrs-full_BorrowingsByNameAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_InterestBearingLoansAndBorrowingsMember" xlink:type="locator" xlink:label="bntx_InterestBearingLoansAndBorrowingsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesTable" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="bntx_InterestBearingLoansAndBorrowingsMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:to="ifrs-full_BorrowingsByNameAxis" order="10100.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="bntx_TwoPointOneFivePercentageSecuredBankLoanMember" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="bntx_TwoPointZeroEightPercentageSecuredBankLoanMember" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="bntx_ConvertibleNoteHostContractMember" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="bntx_OnePointNineZeroPercentageSecuredBankLoanMember" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" order="10100.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:to="ifrs-full_LeaseLiabilitiesMember" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="bntx_OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis" order="10100.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_LiabilitiesMember" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesMember" xlink:to="bntx_ConvertibleNoteEmbeddedDerivativeMember" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesMember" xlink:to="ifrs-full_ContingentConsiderationMember" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:to="bntx_TradePayablesMember" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:to="bntx_OtherFinancialLiabilitiesMember" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCost" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_CurrentFinancialLiabilitiesAtAmortisedCost" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_NoncurrentFinancialLiabilitiesAtAmortisedCost" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="bntx_DerivativeFinancialLiabilitiesNotDesignatedAsHedgingInstrumentsAtFairValue" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValue" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_FinancialLiabilities" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_CurrentFinancialLiabilities" order="11920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_NoncurrentFinancialLiabilities" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialLiabilitiesParentheticalDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialLiabilitiesParentheticalDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialLiabilitiesParentheticalDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FinancialLiabilitiesMaturityDate" xlink:type="locator" xlink:label="bntx_FinancialLiabilitiesMaturityDate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OnePointNineZeroPercentageSecuredBankLoanMember" xlink:type="locator" xlink:label="bntx_OnePointNineZeroPercentageSecuredBankLoanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TwoPointZeroEightPercentageSecuredBankLoanMember" xlink:type="locator" xlink:label="bntx_TwoPointZeroEightPercentageSecuredBankLoanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TwoPointOneFivePercentageSecuredBankLoanMember" xlink:type="locator" xlink:label="bntx_TwoPointOneFivePercentageSecuredBankLoanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember" xlink:type="locator" xlink:label="bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConvertibleNoteHostContractMember" xlink:type="locator" xlink:label="bntx_ConvertibleNoteHostContractMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsByNameMember" xlink:type="locator" xlink:label="ifrs-full_BorrowingsByNameMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsByNameAxis" xlink:type="locator" xlink:label="ifrs-full_BorrowingsByNameAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_InterestBearingLoansAndBorrowingsMember" xlink:type="locator" xlink:label="bntx_InterestBearingLoansAndBorrowingsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="bntx_InterestBearingLoansAndBorrowingsMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:to="ifrs-full_BorrowingsByNameAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="bntx_ConvertibleNoteHostContractMember" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="bntx_TwoPointOneFivePercentageSecuredBankLoanMember" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="bntx_TwoPointZeroEightPercentageSecuredBankLoanMember" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="bntx_OnePointNineZeroPercentageSecuredBankLoanMember" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="bntx_FinancialLiabilitiesMaturityDate" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureFinancialAssetsAndFinancialLiabilitiesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EffectiveInterestRateOfFinancialLiabilities" xlink:type="locator" xlink:label="bntx_EffectiveInterestRateOfFinancialLiabilities" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FinancialLiabilitiesConversionPremiumPercentageAboveReferencePrice" xlink:type="locator" xlink:label="bntx_FinancialLiabilitiesConversionPremiumPercentageAboveReferencePrice" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FinancialLiabilitiesCouponRatePerAnnum" xlink:type="locator" xlink:label="bntx_FinancialLiabilitiesCouponRatePerAnnum" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FinancialLiabilityMaturityTerm" xlink:type="locator" xlink:label="bntx_FinancialLiabilityMaturityTerm" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:type="locator" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TermLoanCreditB" xlink:type="locator" xlink:label="bntx_TermLoanCreditB" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TermLoanCreditA" xlink:type="locator" xlink:label="bntx_TermLoanCreditA" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotionalAmount" xlink:type="locator" xlink:label="ifrs-full_NotionalAmount" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LoanRepayableQuarterlyInstallmentCommencementDate" xlink:type="locator" xlink:label="bntx_LoanRepayableQuarterlyInstallmentCommencementDate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LoanRepayableQuarterlyInstallment" xlink:type="locator" xlink:label="bntx_LoanRepayableQuarterlyInstallment" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FinancialLiabilitiesMaturityDate" xlink:type="locator" xlink:label="bntx_FinancialLiabilitiesMaturityDate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsInterestRate" xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfSecuredBankLoanMaintained" xlink:type="locator" xlink:label="bntx_NumberOfSecuredBankLoanMaintained" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConvertibleNoteMember" xlink:type="locator" xlink:label="bntx_ConvertibleNoteMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesMember" xlink:type="locator" xlink:label="ifrs-full_LiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_JuneTwentyTwentyPrivatePlacementMember" xlink:type="locator" xlink:label="bntx_JuneTwentyTwentyPrivatePlacementMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EuropeanInvestmentBankMember" xlink:type="locator" xlink:label="bntx_EuropeanInvestmentBankMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredInterestAtFixedRateMember" xlink:type="locator" xlink:label="bntx_DeferredInterestAtFixedRateMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CashInterestFixedRateMember" xlink:type="locator" xlink:label="bntx_CashInterestFixedRateMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestRateTypesMember" xlink:type="locator" xlink:label="ifrs-full_InterestRateTypesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:type="locator" xlink:label="ifrs-full_TypesOfInterestRatesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember" xlink:type="locator" xlink:label="bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_JPTPeptideTechnologiesGmbHMember" xlink:type="locator" xlink:label="bntx_JPTPeptideTechnologiesGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechInnovativeManufacturingServicesGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechInnovativeManufacturingServicesGmbHMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeutscheBankAGMember" xlink:type="locator" xlink:label="bntx_DeutscheBankAGMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TwoPointZeroEightPercentageBankLoanMember" xlink:type="locator" xlink:label="bntx_TwoPointZeroEightPercentageBankLoanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TwoPointOneFivePercentageSecuredLoanMember" xlink:type="locator" xlink:label="bntx_TwoPointOneFivePercentageSecuredLoanMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsByNameMember" xlink:type="locator" xlink:label="ifrs-full_BorrowingsByNameMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsByNameAxis" xlink:type="locator" xlink:label="ifrs-full_BorrowingsByNameAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesTable" xlink:to="ifrs-full_BorrowingsByNameAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="bntx_TwoPointOneFivePercentageSecuredLoanMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="bntx_TwoPointZeroEightPercentageBankLoanMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesTable" xlink:to="dei_LegalEntityAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="bntx_DeutscheBankAGMember" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesTable" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" order="10040.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_BioNTechInnovativeManufacturingServicesGmbHMember" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="bntx_JPTPeptideTechnologiesGmbHMember" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesTable" xlink:to="ifrs-full_TypesOfInterestRatesAxis" order="10040.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_InterestRateTypesMember" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InterestRateTypesMember" xlink:to="bntx_CashInterestFixedRateMember" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InterestRateTypesMember" xlink:to="bntx_DeferredInterestAtFixedRateMember" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="bntx_EuropeanInvestmentBankMember" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="10040.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="bntx_JuneTwentyTwentyPrivatePlacementMember" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesTable" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis" order="10040.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_LiabilitiesMember" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesMember" xlink:to="bntx_ConvertibleNoteMember" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="bntx_NumberOfSecuredBankLoanMaintained" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="bntx_FinancialLiabilitiesMaturityDate" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="bntx_LoanRepayableQuarterlyInstallment" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="bntx_LoanRepayableQuarterlyInstallmentCommencementDate" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="ifrs-full_NotionalAmount" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="bntx_TermLoanCreditA" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="bntx_TermLoanCreditB" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod" order="12100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="bntx_FinancialLiabilityMaturityTerm" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="bntx_FinancialLiabilitiesCouponRatePerAnnum" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="bntx_FinancialLiabilitiesConversionPremiumPercentageAboveReferencePrice" order="12160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="bntx_EffectiveInterestRateOfFinancialLiabilities" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities" order="12240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfCarryingAmountOfMonetaryAssetsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfCarryingAmountOfMonetaryAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfCarryingAmountOfMonetaryAssetsDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CashAndCashEquivalent" xlink:type="locator" xlink:label="bntx_CashAndCashEquivalent" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfCashAndCashEquivalentsLineItems" xlink:type="locator" xlink:label="bntx_DisclosureOfCashAndCashEquivalentsLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FinancialLiabilityMember" xlink:type="locator" xlink:label="bntx_FinancialLiabilityMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherFinancialAssetsMember" xlink:type="locator" xlink:label="bntx_OtherFinancialAssetsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsMember" xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_USDollarBankAccountsMember" xlink:type="locator" xlink:label="bntx_USDollarBankAccountsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrencyRiskMember" xlink:type="locator" xlink:label="ifrs-full_CurrencyRiskMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfCashAndCashEquivalentsTable" xlink:type="locator" xlink:label="bntx_DisclosureOfCashAndCashEquivalentsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalentsAbstract" xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="bntx_DisclosureOfCashAndCashEquivalentsTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfCashAndCashEquivalentsTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_CurrencyRiskMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfCashAndCashEquivalentsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="bntx_USDollarBankAccountsMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfCashAndCashEquivalentsTable" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis" order="10040.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsMember" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="bntx_OtherFinancialAssetsMember" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfCashAndCashEquivalentsTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" order="10040.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="bntx_FinancialLiabilityMember" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="bntx_DisclosureOfCashAndCashEquivalentsLineItems" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfCashAndCashEquivalentsLineItems" xlink:to="bntx_CashAndCashEquivalent" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfEffectOfChangesInForeignExchangeRatesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfEffectOfChangesInForeignExchangeRatesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfEffectOfChangesInForeignExchangeRatesDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ForeignCurrencyChangesEffectOnPretaxEquity" xlink:type="locator" xlink:label="bntx_ForeignCurrencyChangesEffectOnPretaxEquity" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ForeignCurrencyChangesEffectOnLossBeforeTax" xlink:type="locator" xlink:label="bntx_ForeignCurrencyChangesEffectOnLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AverageForeignExchangeRate" xlink:type="locator" xlink:label="ifrs-full_AverageForeignExchangeRate" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:type="locator" xlink:label="ifrs-full_ClosingForeignExchangeRate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems" xlink:type="locator" xlink:label="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NegativeFivePercentageChangeInForeignExchangeRateMember" xlink:type="locator" xlink:label="bntx_NegativeFivePercentageChangeInForeignExchangeRateMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PositiveFivePercentageChangeInForeignExchangeRateMember" xlink:type="locator" xlink:label="bntx_PositiveFivePercentageChangeInForeignExchangeRateMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_HedgingInstrumentsMember" xlink:type="locator" xlink:label="ifrs-full_HedgingInstrumentsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:type="locator" xlink:label="ifrs-full_HedgingInstrumentsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrencyRiskMember" xlink:type="locator" xlink:label="ifrs-full_CurrencyRiskMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_USD" xlink:type="locator" xlink:label="currency_USD" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:type="locator" xlink:label="srt_CurrencyAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable" xlink:type="locator" xlink:label="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesAbstract" xlink:type="locator" xlink:label="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesAbstract" xlink:to="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_US" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable" xlink:to="srt_CurrencyAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="10040.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_CurrencyRiskMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable" xlink:to="ifrs-full_HedgingInstrumentsAxis" order="10040.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_HedgingInstrumentsAxis" xlink:to="ifrs-full_HedgingInstrumentsMember" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_HedgingInstrumentsMember" xlink:to="bntx_PositiveFivePercentageChangeInForeignExchangeRateMember" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_HedgingInstrumentsMember" xlink:to="bntx_NegativeFivePercentageChangeInForeignExchangeRateMember" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesAbstract" xlink:to="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems" xlink:to="ifrs-full_ClosingForeignExchangeRate" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems" xlink:to="ifrs-full_AverageForeignExchangeRate" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems" xlink:to="bntx_ForeignCurrencyChangesEffectOnLossBeforeTax" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems" xlink:to="bntx_ForeignCurrencyChangesEffectOnPretaxEquity" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilities" xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherFinancialLiabilities" xlink:type="locator" xlink:label="ifrs-full_OtherFinancialLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:type="locator" xlink:label="ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseLiabilities" xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherPayables" xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayables" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_InterestBearingLoansAndBorrowings" xlink:type="locator" xlink:label="bntx_InterestBearingLoansAndBorrowings" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiquidityRiskMember" xlink:type="locator" xlink:label="ifrs-full_LiquidityRiskMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:type="locator" xlink:label="ifrs-full_LaterThanFiveYearsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xlink:type="locator" xlink:label="ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:type="locator" xlink:label="ifrs-full_NotLaterThanOneYearMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:type="locator" xlink:label="ifrs-full_AggregatedTimeBandsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:type="locator" xlink:label="ifrs-full_MaturityAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesTable" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:to="ifrs-full_MaturityAxis" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_NotLaterThanOneYearMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanFiveYearsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="10090.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_LiquidityRiskMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="bntx_InterestBearingLoansAndBorrowings" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_TradeAndOtherPayables" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_LeaseLiabilities" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_OtherFinancialLiabilities" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_FinancialLiabilities" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities_li0l2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities" xlink:type="locator" xlink:label="bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:type="locator" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConvertibleNoteEmbeddedDerivativeMember" xlink:type="locator" xlink:label="bntx_ConvertibleNoteEmbeddedDerivativeMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_InterestBearingLoansAndBorrowingsMember" xlink:type="locator" xlink:label="bntx_InterestBearingLoansAndBorrowingsMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NoncurrentObligationsUnderLeaseContractsMember" xlink:type="locator" xlink:label="bntx_NoncurrentObligationsUnderLeaseContractsMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CurrentObligationsUnderLeaseContractsMember" xlink:type="locator" xlink:label="bntx_CurrentObligationsUnderLeaseContractsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:type="locator" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:type="locator" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:to="bntx_CurrentObligationsUnderLeaseContractsMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:to="bntx_NoncurrentObligationsUnderLeaseContractsMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:to="bntx_InterestBearingLoansAndBorrowingsMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:to="bntx_ConvertibleNoteEmbeddedDerivativeMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivities" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivities_li0l2" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureInventoriesSummaryOfInventoriesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureInventoriesSummaryOfInventoriesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureInventoriesSummaryOfInventoriesDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Inventories" xlink:type="locator" xlink:label="ifrs-full_Inventories" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinishedGoods" xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WorkInProgress" xlink:type="locator" xlink:label="ifrs-full_WorkInProgress" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" xlink:type="locator" xlink:label="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfInventoriesAbstract" xlink:type="locator" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_WorkInProgress" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_FinishedGoods" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_Inventories" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherAssetsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureOtherAssetsSummaryOfOtherAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherAssetsDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherNoncurrentAssets" xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentAssets" xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherAssets" xlink:type="locator" xlink:label="ifrs-full_OtherAssets" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherCurrentAssetsOther" xlink:type="locator" xlink:label="bntx_OtherCurrentAssetsOther" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CurrentPrepaymentsRelatedToServiceContracts" xlink:type="locator" xlink:label="bntx_CurrentPrepaymentsRelatedToServiceContracts" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:type="locator" xlink:label="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAdvancesToSuppliers" xlink:type="locator" xlink:label="ifrs-full_CurrentAdvancesToSuppliers" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherReceivablesAbstract" xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_CurrentAdvancesToSuppliers" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="bntx_CurrentPrepaymentsRelatedToServiceContracts" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="bntx_OtherCurrentAssetsOther" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_OtherAssets" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_OtherCurrentAssets" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_OtherNoncurrentAssets" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureDeferredExpensesSummaryOfDeferredExpensesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureDeferredExpensesSummaryOfDeferredExpensesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureDeferredExpensesSummaryOfDeferredExpensesDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredExpenseNonCurrent" xlink:type="locator" xlink:label="bntx_DeferredExpenseNonCurrent" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredExpenseCurrent" xlink:type="locator" xlink:label="bntx_DeferredExpenseCurrent" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredExpense" xlink:type="locator" xlink:label="bntx_DeferredExpense" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherDeferredExpenses" xlink:type="locator" xlink:label="bntx_OtherDeferredExpenses" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredExpensesFromContractManufacturingAndContractResearchOrganizations" xlink:type="locator" xlink:label="bntx_DeferredExpensesFromContractManufacturingAndContractResearchOrganizations" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DeferredExpensesFromInsuranceContracts" xlink:type="locator" xlink:label="bntx_DeferredExpensesFromInsuranceContracts" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfDeferredExpensesAbstract" xlink:type="locator" xlink:label="bntx_DisclosureOfDeferredExpensesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfDeferredExpensesAbstract" xlink:to="bntx_DeferredExpensesFromInsuranceContracts" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfDeferredExpensesAbstract" xlink:to="bntx_DeferredExpensesFromContractManufacturingAndContractResearchOrganizations" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfDeferredExpensesAbstract" xlink:to="bntx_OtherDeferredExpenses" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfDeferredExpensesAbstract" xlink:to="bntx_DeferredExpense" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfDeferredExpensesAbstract" xlink:to="bntx_DeferredExpenseCurrent" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfDeferredExpensesAbstract" xlink:to="bntx_DeferredExpenseNonCurrent" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureIssuedCapitalAndReservesAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureIssuedCapitalAndReservesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureIssuedCapitalAndReservesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ChangesInEquity" xlink:type="locator" xlink:label="ifrs-full_ChangesInEquity" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssuedButNotFullyPaid" xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedButNotFullyPaid" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DecreaseInCapitalReserve" xlink:type="locator" xlink:label="bntx_DecreaseInCapitalReserve" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital" xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DerecognitionOfNonControllingInterest" xlink:type="locator" xlink:label="bntx_DerecognitionOfNonControllingInterest" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RemainingNoncontrollingInterestsAcquiredPercentage" xlink:type="locator" xlink:label="bntx_RemainingNoncontrollingInterestsAcquiredPercentage" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CashInvestment" xlink:type="locator" xlink:label="bntx_CashInvestment" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_MaximumProceedsReceivableFromIssuanceOfOrdinaryShares" xlink:type="locator" xlink:label="bntx_MaximumProceedsReceivableFromIssuanceOfOrdinaryShares" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_FinancialLiabilityMaturityTerm" xlink:type="locator" xlink:label="bntx_FinancialLiabilityMaturityTerm" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EquityIssuable" xlink:type="locator" xlink:label="bntx_EquityIssuable" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SharesIssuedPricePerShare1" xlink:type="locator" xlink:label="bntx_SharesIssuedPricePerShare1" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares" xlink:type="locator" xlink:label="bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssued" xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfOrdinarySharesIssuable" xlink:type="locator" xlink:label="bntx_NumberOfOrdinarySharesIssuable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost" xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ParValuePerShare" xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssueOfEquity" xlink:type="locator" xlink:label="ifrs-full_IssueOfEquity" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SharesIssuedDuringPeriodStockSplit" xlink:type="locator" xlink:label="bntx_SharesIssuedDuringPeriodStockSplit" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_StockSplitConversionRatio" xlink:type="locator" xlink:label="bntx_StockSplitConversionRatio" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_InitialPublicOfferingMember" xlink:type="locator" xlink:label="bntx_InitialPublicOfferingMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BillAndMeLindaGatesFoundationMember" xlink:type="locator" xlink:label="bntx_BillAndMeLindaGatesFoundationMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForAssociatesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:type="locator" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_HK" xlink:type="locator" xlink:label="country_HK" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OrdinarySharesSeriesBMember" xlink:type="locator" xlink:label="bntx_OrdinarySharesSeriesBMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BioNTechCellAndGeneTherapiesGmbHMember" xlink:type="locator" xlink:label="bntx_BioNTechCellAndGeneTherapiesGmbHMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AtMarketOfferingProgramMember" xlink:type="locator" xlink:label="bntx_AtMarketOfferingProgramMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConvertibleNoteMember" xlink:type="locator" xlink:label="bntx_ConvertibleNoteMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesMember" xlink:type="locator" xlink:label="ifrs-full_LiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_June2020PrivatePlacementMember" xlink:type="locator" xlink:label="bntx_June2020PrivatePlacementMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GlobalOfferingMember" xlink:type="locator" xlink:label="bntx_GlobalOfferingMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CapitalRequirementsMember" xlink:type="locator" xlink:label="ifrs-full_CapitalRequirementsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CapitalRequirementsAxis" xlink:type="locator" xlink:label="ifrs-full_CapitalRequirementsAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NeonTherapeuticsIncMember" xlink:type="locator" xlink:label="bntx_NeonTherapeuticsIncMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BusinessCombinationsAxis" xlink:type="locator" xlink:label="ifrs-full_BusinessCombinationsAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PfizerIncMember" xlink:type="locator" xlink:label="bntx_PfizerIncMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ShanghaiFosunPharmaceuticalGroupCoLtdMember" xlink:type="locator" xlink:label="bntx_ShanghaiFosunPharmaceuticalGroupCoLtdMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CapitalReserveMember" xlink:type="locator" xlink:label="ifrs-full_CapitalReserveMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TreasurySharesMember" xlink:type="locator" xlink:label="ifrs-full_TreasurySharesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:type="locator" xlink:label="ifrs-full_EquityMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_TreasurySharesMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_CapitalReserveMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="srt_CounterpartyNameAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bntx_ShanghaiFosunPharmaceuticalGroupCoLtdMember" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bntx_PfizerIncMember" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_BusinessCombinationsAxis" order="10040.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="bntx_NeonTherapeuticsIncMember" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_CapitalRequirementsAxis" order="10040.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CapitalRequirementsAxis" xlink:to="ifrs-full_CapitalRequirementsMember" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CapitalRequirementsMember" xlink:to="bntx_GlobalOfferingMember" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CapitalRequirementsMember" xlink:to="bntx_June2020PrivatePlacementMember" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis" order="10040.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_LiabilitiesMember" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesMember" xlink:to="bntx_ConvertibleNoteMember" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CapitalRequirementsMember" xlink:to="bntx_AtMarketOfferingProgramMember" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="bntx_BioNTechCellAndGeneTherapiesGmbHMember" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="10040.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="bntx_OrdinarySharesSeriesBMember" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="10040.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_HK" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis" order="10040.14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_EntitysTotalForAssociatesMember" order="12030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForAssociatesMember" xlink:to="bntx_BillAndMeLindaGatesFoundationMember" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CapitalRequirementsMember" xlink:to="bntx_InitialPublicOfferingMember" order="12150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" order="12390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="bntx_StockSplitConversionRatio" order="12400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="bntx_SharesIssuedDuringPeriodStockSplit" order="12420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_IssueOfEquity" order="12480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ParValuePerShare" order="12500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" order="12540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares" order="12620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="bntx_NumberOfOrdinarySharesIssuable" order="12660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="12880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares" order="13560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="bntx_SharesIssuedPricePerShare1" order="13680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="bntx_EquityIssuable" order="13960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="bntx_FinancialLiabilityMaturityTerm" order="14000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="bntx_MaximumProceedsReceivableFromIssuanceOfOrdinaryShares" order="14200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="bntx_CashInvestment" order="14860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="bntx_RemainingNoncontrollingInterestsAcquiredPercentage" order="14940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="bntx_DerecognitionOfNonControllingInterest" order="15000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_IssuedCapital" order="15020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="bntx_DecreaseInCapitalReserve" order="15040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid" order="15100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedButNotFullyPaid" order="15120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ChangesInEquity" order="15680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureShareBasedPaymentsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OptionExercisablePeriod" xlink:type="locator" xlink:label="bntx_OptionExercisablePeriod" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare" xlink:type="locator" xlink:label="bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:type="locator" xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_WeightedAverageRemainingContractualLifeOfShareOptionsAllocatedAndExpectedToBeAllocated" xlink:type="locator" xlink:label="bntx_WeightedAverageRemainingContractualLifeOfShareOptionsAllocatedAndExpectedToBeAllocated" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OptionExpirationPeriod" xlink:type="locator" xlink:label="bntx_OptionExpirationPeriod" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth" xlink:type="locator" xlink:label="bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering" xlink:type="locator" xlink:label="bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PercentageOfIncreaseInExercisePrice" xlink:type="locator" xlink:label="bntx_PercentageOfIncreaseInExercisePrice" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_IncreaseDecreaseInShareBasedPaymentValue" xlink:type="locator" xlink:label="bntx_IncreaseDecreaseInShareBasedPaymentValue" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpectedDividendShareOptionsGranted" xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendShareOptionsGranted" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherFinancialLiabilities" xlink:type="locator" xlink:label="ifrs-full_OtherFinancialLiabilities" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CashSettledExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator" xlink:label="bntx_CashSettledExpenseFromSharebasedPaymentTransactionsWithEmployees" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares" xlink:type="locator" xlink:label="bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PercentageOfOtherEquityInstrumentNonVestingRate" xlink:type="locator" xlink:label="bntx_PercentageOfOtherEquityInstrumentNonVestingRate" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OptionVestingPeriod" xlink:type="locator" xlink:label="bntx_OptionVestingPeriod" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeStockOwnershipPlanMember" xlink:type="locator" xlink:label="bntx_EmployeeStockOwnershipPlanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ChiefExecutiveOfficerGrantMember" xlink:type="locator" xlink:label="bntx_ChiefExecutiveOfficerGrantMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OrdinarySharesMember" xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RyanRichardsonMember" xlink:type="locator" xlink:label="bntx_RyanRichardsonMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DrOzlemTureciMember" xlink:type="locator" xlink:label="bntx_DrOzlemTureciMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DrSierkPoettingMember" xlink:type="locator" xlink:label="bntx_DrSierkPoettingMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SeanMarettMember" xlink:type="locator" xlink:label="bntx_SeanMarettMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ProfessorUgurSahinMDMember" xlink:type="locator" xlink:label="bntx_ProfessorUgurSahinMDMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="bntx_GeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ResearchAndDevelopmentExpensesMember" xlink:type="locator" xlink:label="bntx_ResearchAndDevelopmentExpensesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NatureOfExpensesMember" xlink:type="locator" xlink:label="bntx_NatureOfExpensesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NatureOfExpensesAxis" xlink:type="locator" xlink:label="bntx_NatureOfExpensesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ManagementBoardGrantMember" xlink:type="locator" xlink:label="bntx_ManagementBoardGrantMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember" xlink:type="locator" xlink:label="bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeEquityPlanLongTermIncentiveProgramMember" xlink:type="locator" xlink:label="bntx_EmployeeEquityPlanLongTermIncentiveProgramMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeEquityPlanMember" xlink:type="locator" xlink:label="bntx_EmployeeEquityPlanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TwoThousandTwentyRestrictedStockUnitPlanMember" xlink:type="locator" xlink:label="bntx_TwoThousandTwentyRestrictedStockUnitPlanMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_TwoThousandTwentyRestrictedStockUnitPlanMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_EmployeeEquityPlanMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_EmployeeEquityPlanLongTermIncentiveProgramMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_ManagementBoardGrantMember" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="srt_RangeAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="ifrs-full_TopOfRangeMember" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="ifrs-full_BottomOfRangeMember" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="bntx_NatureOfExpensesAxis" order="10040.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_NatureOfExpensesAxis" xlink:to="bntx_NatureOfExpensesMember" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_NatureOfExpensesMember" xlink:to="bntx_ResearchAndDevelopmentExpensesMember" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_NatureOfExpensesMember" xlink:to="bntx_GeneralAndAdministrativeExpensesMember" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="srt_TitleOfIndividualAxis" order="10040.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_ProfessorUgurSahinMDMember" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_SeanMarettMember" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_DrSierkPoettingMember" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_DrOzlemTureciMember" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_RyanRichardsonMember" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="10040.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_OrdinarySharesMember" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_ChiefExecutiveOfficerGrantMember" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_EmployeeStockOwnershipPlanMember" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_OptionVestingPeriod" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_PercentageOfOtherEquityInstrumentNonVestingRate" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_CashSettledExpenseFromSharebasedPaymentTransactionsWithEmployees" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_OtherFinancialLiabilities" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpectedDividendShareOptionsGranted" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_IncreaseDecreaseInShareBasedPaymentValue" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_PercentageOfIncreaseInExercisePrice" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering" order="12040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_OptionExpirationPeriod" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_WeightedAverageRemainingContractualLifeOfShareOptionsAllocatedAndExpectedToBeAllocated" order="12220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" order="12280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare" order="12320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_OptionExercisablePeriod" order="12560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="12640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" order="12680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" order="12720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfNumberAndSharePriceOfRestrictedStockUnitsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureShareBasedPaymentsScheduleOfNumberAndSharePriceOfRestrictedStockUnitsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfNumberAndSharePriceOfRestrictedStockUnitsDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_li0l2" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpectedToBeAllocatedInSharebasedPaymentArrangement" xlink:type="locator" xlink:label="bntx_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpectedToBeAllocatedInSharebasedPaymentArrangement" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_li0l2" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfInstrumentsOtherEquityInstrumentsExpectedToBeAllocated" xlink:type="locator" xlink:label="bntx_NumberOfInstrumentsOtherEquityInstrumentsExpectedToBeAllocated" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember" xlink:type="locator" xlink:label="bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeEquityPlanLongTermIncentiveProgramMember" xlink:type="locator" xlink:label="bntx_EmployeeEquityPlanLongTermIncentiveProgramMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeEquityPlanMember" xlink:type="locator" xlink:label="bntx_EmployeeEquityPlanMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_EmployeeEquityPlanMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_EmployeeEquityPlanLongTermIncentiveProgramMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_NumberOfInstrumentsOtherEquityInstrumentsExpectedToBeAllocated" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_li0l2" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpectedToBeAllocatedInSharebasedPaymentArrangement" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_li0l2" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfExpenseRecognizedForEmployeeServicesReceivedDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureShareBasedPaymentsScheduleOfExpenseRecognizedForEmployeeServicesReceivedDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfExpenseRecognizedForEmployeeServicesReceivedDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeStockOwnershipPlanMember" xlink:type="locator" xlink:label="bntx_EmployeeStockOwnershipPlanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ManagementBoardGrantMember" xlink:type="locator" xlink:label="bntx_ManagementBoardGrantMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeEquityPlanMember" xlink:type="locator" xlink:label="bntx_EmployeeEquityPlanMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="bntx_GeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SalesAndMarketingExpensesMember" xlink:type="locator" xlink:label="bntx_SalesAndMarketingExpensesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ResearchAndDevelopmentExpensesMember" xlink:type="locator" xlink:label="bntx_ResearchAndDevelopmentExpensesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CostOfSales1Member" xlink:type="locator" xlink:label="bntx_CostOfSales1Member" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NatureOfExpensesMember" xlink:type="locator" xlink:label="bntx_NatureOfExpensesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NatureOfExpensesAxis" xlink:type="locator" xlink:label="bntx_NatureOfExpensesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="bntx_NatureOfExpensesAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_NatureOfExpensesAxis" xlink:to="bntx_NatureOfExpensesMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_NatureOfExpensesMember" xlink:to="bntx_CostOfSales1Member" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_NatureOfExpensesMember" xlink:to="bntx_ResearchAndDevelopmentExpensesMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_NatureOfExpensesMember" xlink:to="bntx_SalesAndMarketingExpensesMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_NatureOfExpensesMember" xlink:to="bntx_GeneralAndAdministrativeExpensesMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_EmployeeEquityPlanMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_ManagementBoardGrantMember" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_EmployeeStockOwnershipPlanMember" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfNumberAndWeightedAverageExercisePriceOfShareOptionsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureShareBasedPaymentsScheduleOfNumberAndWeightedAverageExercisePriceOfShareOptionsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfNumberAndWeightedAverageExercisePriceOfShareOptionsDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding" xlink:type="locator" xlink:label="bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding_li0l2" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="locator" xlink:label="bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInSharebasedPaymentArrangement" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsGrantedInSharebasedPaymentArrangement" xlink:type="locator" xlink:label="bntx_NumberOfOrdinarySharesUnderlyingOptionsGrantedInSharebasedPaymentArrangement" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding" xlink:type="locator" xlink:label="bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_li0l2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo" xlink:type="locator" xlink:label="bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne" xlink:type="locator" xlink:label="bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_li0l2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo" xlink:type="locator" xlink:label="bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne" xlink:type="locator" xlink:label="bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeStockOwnershipPlanMember" xlink:type="locator" xlink:label="bntx_EmployeeStockOwnershipPlanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ManagementBoardGrantMember" xlink:type="locator" xlink:label="bntx_ManagementBoardGrantMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_ManagementBoardGrantMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_EmployeeStockOwnershipPlanMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_li0l2" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_li0l2" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_NumberOfOrdinarySharesUnderlyingOptionsGrantedInSharebasedPaymentArrangement" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInSharebasedPaymentArrangement" order="11800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding_li0l2" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsSummaryOfInputsUsedInMeasurementOfFairValueAtGrantDateDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureShareBasedPaymentsSummaryOfInputsUsedInMeasurementOfFairValueAtGrantDateDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsSummaryOfInputsUsedInMeasurementOfFairValueAtGrantDateDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EmployeeStockOwnershipPlanMember" xlink:type="locator" xlink:label="bntx_EmployeeStockOwnershipPlanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ChiefExecutiveOfficerGrantMember" xlink:type="locator" xlink:label="bntx_ChiefExecutiveOfficerGrantMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EstimatedAllocationDateTwoMember" xlink:type="locator" xlink:label="bntx_EstimatedAllocationDateTwoMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EstimatedAllocationDateOneMember" xlink:type="locator" xlink:label="bntx_EstimatedAllocationDateOneMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ManagementBoardGrantMember" xlink:type="locator" xlink:label="bntx_ManagementBoardGrantMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_ManagementBoardGrantMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="bntx_EstimatedAllocationDateOneMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="bntx_EstimatedAllocationDateTwoMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_ChiefExecutiveOfficerGrantMember" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_EmployeeStockOwnershipPlanMember" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfNumberAndWeightedAverageExercisePriceOfShareOptionsAllocatedAndExpectedToBeAllocatedDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureShareBasedPaymentsScheduleOfNumberAndWeightedAverageExercisePriceOfShareOptionsAllocatedAndExpectedToBeAllocatedDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfNumberAndWeightedAverageExercisePriceOfShareOptionsAllocatedAndExpectedToBeAllocatedDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EstimatedAllocationDateTwoMember" xlink:type="locator" xlink:label="bntx_EstimatedAllocationDateTwoMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EstimatedAllocationDateOneMember" xlink:type="locator" xlink:label="bntx_EstimatedAllocationDateOneMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ManagementBoardGrantMember" xlink:type="locator" xlink:label="bntx_ManagementBoardGrantMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RyanRichardsonMember" xlink:type="locator" xlink:label="bntx_RyanRichardsonMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DrOzlemTureciMDMember" xlink:type="locator" xlink:label="bntx_DrOzlemTureciMDMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DrSierkPoettingMember" xlink:type="locator" xlink:label="bntx_DrSierkPoettingMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SeanMarettMember" xlink:type="locator" xlink:label="bntx_SeanMarettMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ProfessorUgurSahinMDMember" xlink:type="locator" xlink:label="bntx_ProfessorUgurSahinMDMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="srt_TitleOfIndividualAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_ProfessorUgurSahinMDMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_SeanMarettMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_DrSierkPoettingMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_DrOzlemTureciMDMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_RyanRichardsonMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_ManagementBoardGrantMember" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="10040.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="bntx_EstimatedAllocationDateOneMember" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="bntx_EstimatedAllocationDateTwoMember" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfNumberOfShareOptionsOutstandingDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureShareBasedPaymentsScheduleOfNumberOfShareOptionsOutstandingDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfNumberOfShareOptionsOutstandingDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding" xlink:type="locator" xlink:label="bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ManagementBoardGrantMember" xlink:type="locator" xlink:label="bntx_ManagementBoardGrantMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_RyanRichardsonMember" xlink:type="locator" xlink:label="bntx_RyanRichardsonMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DrOzlemTureciMDMember" xlink:type="locator" xlink:label="bntx_DrOzlemTureciMDMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DrSierkPoettingMember" xlink:type="locator" xlink:label="bntx_DrSierkPoettingMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SeanMarettMember" xlink:type="locator" xlink:label="bntx_SeanMarettMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ProfessorUgurSahinMDMember" xlink:type="locator" xlink:label="bntx_ProfessorUgurSahinMDMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="srt_TitleOfIndividualAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_ProfessorUgurSahinMDMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_SeanMarettMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_DrSierkPoettingMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_DrOzlemTureciMDMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bntx_RyanRichardsonMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="bntx_ManagementBoardGrantMember" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherLiabilitiesSummaryOfOtherLiabilitiesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureOtherLiabilitiesSummaryOfOtherLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherLiabilitiesSummaryOfOtherLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentLiabilities" xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherLiabilities" xlink:type="locator" xlink:label="ifrs-full_OtherLiabilities" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OtherLiabilitiesOther" xlink:type="locator" xlink:label="bntx_OtherLiabilitiesOther" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CurrentLiabilitiesForEmployeesBenefits" xlink:type="locator" xlink:label="bntx_CurrentLiabilitiesForEmployeesBenefits" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MiscellaneousCurrentLiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_MiscellaneousCurrentLiabilitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MiscellaneousCurrentLiabilitiesAbstract" xlink:to="bntx_CurrentLiabilitiesForEmployeesBenefits" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MiscellaneousCurrentLiabilitiesAbstract" xlink:to="bntx_OtherLiabilitiesOther" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MiscellaneousCurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherLiabilities" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MiscellaneousCurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentLiabilities" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MiscellaneousCurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherNoncurrentLiabilities" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesSummaryOfRightOfUseAssetsWithinConsolidatedStatementsOfFinancialPositionDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureLeasesSummaryOfRightOfUseAssetsWithinConsolidatedStatementsOfFinancialPositionDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesSummaryOfRightOfUseAssetsWithinConsolidatedStatementsOfFinancialPositionDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RightofuseAssets" xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AdvancePaymentsMember" xlink:type="locator" xlink:label="bntx_AdvancePaymentsMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ProductionFacilitiesMember" xlink:type="locator" xlink:label="bntx_ProductionFacilitiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_VehiclesMember" xlink:type="locator" xlink:label="ifrs-full_VehiclesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EquipmentToolsAndInstallationsMember" xlink:type="locator" xlink:label="bntx_EquipmentToolsAndInstallationsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BuildingsMember" xlink:type="locator" xlink:label="ifrs-full_BuildingsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_BuildingsMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="bntx_EquipmentToolsAndInstallationsMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_VehiclesMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="bntx_ProductionFacilitiesMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="bntx_AdvancePaymentsMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_RightofuseAssets" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities" xlink:type="locator" xlink:label="bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashOutflowForLeases" xlink:type="locator" xlink:label="ifrs-full_CashOutflowForLeases" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GrossLeaseLiabilities" xlink:type="locator" xlink:label="ifrs-full_GrossLeaseLiabilities" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AdvancePaymentsRelatedToEmbeddedLeases" xlink:type="locator" xlink:label="bntx_AdvancePaymentsRelatedToEmbeddedLeases" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:type="locator" xlink:label="ifrs-full_AdditionsToRightofuseAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanOneYearMember" xlink:type="locator" xlink:label="ifrs-full_LaterThanOneYearMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:type="locator" xlink:label="ifrs-full_NotLaterThanOneYearMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:type="locator" xlink:label="ifrs-full_AggregatedTimeBandsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:type="locator" xlink:label="ifrs-full_MaturityAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="ifrs-full_MaturityAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_NotLaterThanOneYearMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanOneYearMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="srt_RangeAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="ifrs-full_TopOfRangeMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="ifrs-full_BottomOfRangeMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_AdditionsToRightofuseAssets" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="bntx_AdvancePaymentsRelatedToEmbeddedLeases" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_GrossLeaseLiabilities" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_CashOutflowForLeases" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilityIncludedInInterestBearingLoansAndBorrowingsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureLeasesSummaryOfLeaseLiabilityIncludedInInterestBearingLoansAndBorrowingsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilityIncludedInInterestBearingLoansAndBorrowingsDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseLiabilities" xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseLiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilitiesAbstract" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilitiesAbstract" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilities" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesSummaryOfAmountsRecognizedInConsolidatedStatementOfOperationsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureLeasesSummaryOfAmountsRecognizedInConsolidatedStatementOfOperationsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesSummaryOfAmountsRecognizedInConsolidatedStatementOfOperationsDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_LeaseExpensesRecognizedInProfitOrLoss" xlink:type="locator" xlink:label="bntx_LeaseExpensesRecognizedInProfitOrLoss" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:type="locator" xlink:label="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:type="locator" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:type="locator" xlink:label="ifrs-full_DepreciationRightofuseAssets" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ProductionFacilitiesMember" xlink:type="locator" xlink:label="bntx_ProductionFacilitiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_VehiclesMember" xlink:type="locator" xlink:label="ifrs-full_VehiclesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EquipmentToolsAndInstallationsMember" xlink:type="locator" xlink:label="bntx_EquipmentToolsAndInstallationsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BuildingsMember" xlink:type="locator" xlink:label="ifrs-full_BuildingsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_BuildingsMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="bntx_EquipmentToolsAndInstallationsMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_VehiclesMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="bntx_ProductionFacilitiesMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_DepreciationRightofuseAssets" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="bntx_LeaseExpensesRecognizedInProfitOrLoss" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosurePensionsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:type="locator" xlink:label="ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PensionFundContributionsExpectedForFollowingFinancialYear" xlink:type="locator" xlink:label="bntx_PensionFundContributionsExpectedForFollowingFinancialYear" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_MaximumPensionFundContributions" xlink:type="locator" xlink:label="bntx_MaximumPensionFundContributions" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AnnualPensionEntitlementOfEmployeeContribution" xlink:type="locator" xlink:label="bntx_AnnualPensionEntitlementOfEmployeeContribution" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PercentageOfDefinedContributionPlanOfSalary" xlink:type="locator" xlink:label="bntx_PercentageOfDefinedContributionPlanOfSalary" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExplanationOfWhetherParticipantsContributeToRetirementBenefitPlan" xlink:type="locator" xlink:label="ifrs-full_ExplanationOfWhetherParticipantsContributeToRetirementBenefitPlan" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WhollyUnfundedDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_WhollyUnfundedDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis" xlink:type="locator" xlink:label="ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:to="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="srt_RangeAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="ifrs-full_BottomOfRangeMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="ifrs-full_TopOfRangeMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis" order="10040.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis" xlink:to="ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember" xlink:to="ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember" xlink:to="ifrs-full_WhollyUnfundedDefinedBenefitPlansMember" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_ExplanationOfWhetherParticipantsContributeToRetirementBenefitPlan" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="bntx_PercentageOfDefinedContributionPlanOfSalary" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="bntx_AnnualPensionEntitlementOfEmployeeContribution" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="bntx_MaximumPensionFundContributions" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="bntx_PensionFundContributionsExpectedForFollowingFinancialYear" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsSummaryOfDefinedBenefitObligationRecognizedInNonCurrentProvisionsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosurePensionsSummaryOfDefinedBenefitObligationRecognizedInNonCurrentProvisionsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsSummaryOfDefinedBenefitObligationRecognizedInNonCurrentProvisionsDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:type="locator" xlink:label="ifrs-full_NoncurrentProvisionsForEmployeeBenefits" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SupplementPlanMember" xlink:type="locator" xlink:label="bntx_SupplementPlanMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_BasePlanMember" xlink:type="locator" xlink:label="bntx_BasePlanMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_DefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:type="locator" xlink:label="ifrs-full_DefinedBenefitPlansAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="ifrs-full_DefinedBenefitPlansAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DefinedBenefitPlansAxis" xlink:to="ifrs-full_DefinedBenefitPlansMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DefinedBenefitPlansMember" xlink:to="bntx_BasePlanMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DefinedBenefitPlansMember" xlink:to="bntx_SupplementPlanMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:to="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_NoncurrentProvisionsForEmployeeBenefits" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsSummaryOfComponentsOfNetBenefitExpenseRecognizedInStatementOfProfitOrLossDetails" xlink:href="bntx-20201231.xsd#Role_DisclosurePensionsSummaryOfComponentsOfNetBenefitExpenseRecognizedInStatementOfProfitOrLossDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsSummaryOfComponentsOfNetBenefitExpenseRecognizedInStatementOfProfitOrLossDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:to="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsSummaryOfComponentsOfRemeasurementsRecognizedInOtherComprehensiveIncomeDetails" xlink:href="bntx-20201231.xsd#Role_DisclosurePensionsSummaryOfComponentsOfRemeasurementsRecognizedInOtherComprehensiveIncomeDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsSummaryOfComponentsOfRemeasurementsRecognizedInOtherComprehensiveIncomeDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:to="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfChangesToDefinedBenefitObligationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosurePensionsScheduleOfChangesToDefinedBenefitObligationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfChangesToDefinedBenefitObligationDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:type="locator" xlink:label="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_li0l2" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BenefitsPaidOrPayable" xlink:type="locator" xlink:label="ifrs-full_BenefitsPaidOrPayable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:type="locator" xlink:label="ifrs-full_LiabilityAssetOfDefinedBenefitPlans" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:to="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_LiabilityAssetOfDefinedBenefitPlans" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_BenefitsPaidOrPayable" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_li0l2" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfPrincipalAssumptionsUsedInDeterminingDefinedBenefitObligationsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosurePensionsScheduleOfPrincipalAssumptionsUsedInDeterminingDefinedBenefitObligationsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfPrincipalAssumptionsUsedInDeterminingDefinedBenefitObligationsDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionOfDiscountRates" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:to="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_ActuarialAssumptionOfDiscountRates" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfQuantitativeSensitivityAnalysisDetails" xlink:href="bntx-20201231.xsd#Role_DisclosurePensionsScheduleOfQuantitativeSensitivityAnalysisDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfQuantitativeSensitivityAnalysisDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionOfDiscountRatesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionsAxis" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="ifrs-full_ActuarialAssumptionsAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ActuarialAssumptionsAxis" xlink:to="ifrs-full_ActuarialAssumptionsMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ActuarialAssumptionsMember" xlink:to="ifrs-full_ActuarialAssumptionOfDiscountRatesMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ActuarialAssumptionsMember" xlink:to="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:to="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfQuantitativeSensitivityAnalysisParentheticalDetails" xlink:href="bntx-20201231.xsd#Role_DisclosurePensionsScheduleOfQuantitativeSensitivityAnalysisParentheticalDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfQuantitativeSensitivityAnalysisParentheticalDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="locator" xlink:label="ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="locator" xlink:label="ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionOfDiscountRatesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionsAxis" xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionsAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="ifrs-full_ActuarialAssumptionsAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ActuarialAssumptionsAxis" xlink:to="ifrs-full_ActuarialAssumptionsMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ActuarialAssumptionsMember" xlink:to="ifrs-full_ActuarialAssumptionOfDiscountRatesMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ActuarialAssumptionsMember" xlink:to="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:to="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfExpectedPaymentsOrContributionsToPlansInFutureYearsDetails" xlink:href="bntx-20201231.xsd#Role_DisclosurePensionsScheduleOfExpectedPaymentsOrContributionsToPlansInFutureYearsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfExpectedPaymentsOrContributionsToPlansInFutureYearsDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan" xlink:type="locator" xlink:label="ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:type="locator" xlink:label="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:type="locator" xlink:label="ifrs-full_LaterThanFiveYearsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="locator" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:type="locator" xlink:label="ifrs-full_NotLaterThanOneYearMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:type="locator" xlink:label="ifrs-full_AggregatedTimeBandsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:type="locator" xlink:label="ifrs-full_MaturityAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="ifrs-full_MaturityAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_NotLaterThanOneYearMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanFiveYearsMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:to="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CharacteristicsOfDefinedBenefitPlansMember" xlink:to="ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfCompensationOfKeyManagementPersonnelDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureRelatedPartyDisclosuresSummaryOfCompensationOfKeyManagementPersonnelDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfCompensationOfKeyManagementPersonnelDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensation" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsAccrued" xlink:type="locator" xlink:label="bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsAccrued" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsAccrued" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensation" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfCompensationOfKeyManagementPersonnelParentheticalDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureRelatedPartyDisclosuresSummaryOfCompensationOfKeyManagementPersonnelParentheticalDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfCompensationOfKeyManagementPersonnelParentheticalDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_KeyManagementPersonnelCompensationShareBasedPaymentOrdinaryShares" xlink:type="locator" xlink:label="bntx_KeyManagementPersonnelCompensationShareBasedPaymentOrdinaryShares" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="bntx_KeyManagementPersonnelCompensationShareBasedPaymentOrdinaryShares" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureRelatedPartyDisclosuresAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction" xlink:type="locator" xlink:label="ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction" xlink:type="locator" xlink:label="ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OrdinarySharesMember" xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_CofounderAndChiefExecutiveOfficerMember" xlink:type="locator" xlink:label="bntx_CofounderAndChiefExecutiveOfficerMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="bntx_CofounderAndChiefExecutiveOfficerMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_OrdinarySharesMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfAggregateValueOfTransactionsRelatedToKeyManagementPersonnelDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureRelatedPartyDisclosuresSummaryOfAggregateValueOfTransactionsRelatedToKeyManagementPersonnelDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfAggregateValueOfTransactionsRelatedToKeyManagementPersonnelDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_GoodsAndServicesFromRelatedPartyTransactions" xlink:type="locator" xlink:label="bntx_GoodsAndServicesFromRelatedPartyTransactions" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" xlink:type="locator" xlink:label="bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConsultingServicesAndPatentAssignment" xlink:type="locator" xlink:label="bntx_ConsultingServicesAndPatentAssignment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="bntx_ConsultingServicesAndPatentAssignment" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="bntx_GoodsAndServicesFromRelatedPartyTransactions" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfOutstandingBalancesOfTransactionsRelatedToKeyManagementPersonnelDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureRelatedPartyDisclosuresSummaryOfOutstandingBalancesOfTransactionsRelatedToKeyManagementPersonnelDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfOutstandingBalancesOfTransactionsRelatedToKeyManagementPersonnelDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:type="locator" xlink:label="ifrs-full_AmountsPayableRelatedPartyTransactions" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_TRONMember" xlink:type="locator" xlink:label="bntx_TRONMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ConsultingServiceProviderMember" xlink:type="locator" xlink:label="bntx_ConsultingServiceProviderMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bntx_ConsultingServiceProviderMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bntx_TRONMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_AmountsPayableRelatedPartyTransactions" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfTransactionsBetweenRelatedPartiesAmountDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureRelatedPartyDisclosuresSummaryOfTransactionsBetweenRelatedPartiesAmountDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfTransactionsBetweenRelatedPartiesAmountDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PurchasesFromRelatedPartyTransactions" xlink:type="locator" xlink:label="bntx_PurchasesFromRelatedPartyTransactions" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions" xlink:type="locator" xlink:label="ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" xlink:type="locator" xlink:label="bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherRelatedPartiesMember" xlink:type="locator" xlink:label="ifrs-full_OtherRelatedPartiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_OtherRelatedPartiesMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="bntx_PurchasesFromRelatedPartyTransactions" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfTransactionsBetweenRelatedPartiesOutstandingBalancesDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureRelatedPartyDisclosuresSummaryOfTransactionsBetweenRelatedPartiesOutstandingBalancesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfTransactionsBetweenRelatedPartiesOutstandingBalancesDetails">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:type="locator" xlink:label="ifrs-full_AmountsPayableRelatedPartyTransactions" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_ATHOSKGMember" xlink:type="locator" xlink:label="bntx_ATHOSKGMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherRelatedPartiesMember" xlink:type="locator" xlink:label="ifrs-full_OtherRelatedPartiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_OtherRelatedPartiesMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="srt_CounterpartyNameAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bntx_ATHOSKGMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_AmountsPayableRelatedPartyTransactions" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/20201231/taxonomy/role/DisclosureEventsAfterReportingPeriodAdditionalInformationDetails" xlink:href="bntx-20201231.xsd#Role_DisclosureEventsAfterReportingPeriodAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biontech.de/20201231/taxonomy/role/DisclosureEventsAfterReportingPeriodAdditionalInformationDetails">
    <link:loc xlink:href="bntx-20201231.xsd#bntx_OptionToRequestSupplyOfNumberOfAdditionalDoses" xlink:type="locator" xlink:label="bntx_OptionToRequestSupplyOfNumberOfAdditionalDoses" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfEuropeanUnionMemberStates" xlink:type="locator" xlink:label="bntx_NumberOfEuropeanUnionMemberStates" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_AggregateNumberOfDosesToBeSupplied" xlink:type="locator" xlink:label="bntx_AggregateNumberOfDosesToBeSupplied" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_NumberOfAdditionalDosesToBeSupplied" xlink:type="locator" xlink:label="bntx_NumberOfAdditionalDosesToBeSupplied" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfEventsAfterReportingPeriodLineItems" xlink:type="locator" xlink:label="bntx_DisclosureOfEventsAfterReportingPeriodLineItems" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_EuropeanUnionMemberStatesMember" xlink:type="locator" xlink:label="bntx_EuropeanUnionMemberStatesMember" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_UnitedStatesGovernmentMember" xlink:type="locator" xlink:label="bntx_UnitedStatesGovernmentMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorCustomersMember" xlink:type="locator" xlink:label="ifrs-full_MajorCustomersMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorCustomersAxis" xlink:type="locator" xlink:label="ifrs-full_MajorCustomersAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_PfizerIncMember" xlink:type="locator" xlink:label="bntx_PfizerIncMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesMember" xlink:type="locator" xlink:label="ifrs-full_CounterpartiesMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesAxis" xlink:type="locator" xlink:label="ifrs-full_CounterpartiesAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_SupplyOfCOVID19VaccineMember" xlink:type="locator" xlink:label="bntx_SupplyOfCOVID19VaccineMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsMember" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfEventsAfterReportingPeriodTable" xlink:type="locator" xlink:label="bntx_DisclosureOfEventsAfterReportingPeriodTable" />
    <link:loc xlink:href="bntx-20201231.xsd#bntx_DisclosureOfEventsAfterReportingPeriodAbstract" xlink:type="locator" xlink:label="bntx_DisclosureOfEventsAfterReportingPeriodAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfEventsAfterReportingPeriodAbstract" xlink:to="bntx_DisclosureOfEventsAfterReportingPeriodTable" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfEventsAfterReportingPeriodTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="bntx_SupplyOfCOVID19VaccineMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfEventsAfterReportingPeriodTable" xlink:to="ifrs-full_CounterpartiesAxis" order="10040.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="bntx_PfizerIncMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfEventsAfterReportingPeriodTable" xlink:to="ifrs-full_MajorCustomersAxis" order="10040.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_UnitedStatesGovernmentMember" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="bntx_EuropeanUnionMemberStatesMember" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfEventsAfterReportingPeriodAbstract" xlink:to="bntx_DisclosureOfEventsAfterReportingPeriodLineItems" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfEventsAfterReportingPeriodLineItems" xlink:to="bntx_NumberOfAdditionalDosesToBeSupplied" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfEventsAfterReportingPeriodLineItems" xlink:to="bntx_AggregateNumberOfDosesToBeSupplied" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfEventsAfterReportingPeriodLineItems" xlink:to="bntx_NumberOfEuropeanUnionMemberStates" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bntx_DisclosureOfEventsAfterReportingPeriodLineItems" xlink:to="bntx_OptionToRequestSupplyOfNumberOfAdditionalDoses" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891298008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BioNTech SE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001776985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,521,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">2M<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">An der Goldgrube 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Mainz<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">D-55131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Mainz<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Prof. Ugur Sahin, M.D.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">An der Goldgrube 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Mainz<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">D-55131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">6131-9084-0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelEmailAddress', window );">Contact Personnel Email Address</a></td>
<td class="text">info@biontech.de<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Mainz<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember', window );">American Depositary Shares, each Representing one ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BNTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each Representing one ordinary share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareOfOneMember', window );">Ordinary shares, no par value, with national amount attributable to each ordinary share of ?1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, no par value, with a notional amount attributable to each ordinary share of &#8364;1*<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_NoTradingSymbolFlag', window );">No Trading Symbol Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelEmailAddress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Email address of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelEmailAddress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number Section<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_NoTradingSymbolFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a security having no trading symbol.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_NoTradingSymbolFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareOfOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareOfOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891718632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Financial Position - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets</a></td>
<td class="nump">&#8364; 163,490<span></span>
</td>
<td class="nump">&#8364; 89,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">226,968<span></span>
</td>
<td class="nump">93,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">98,988<span></span>
</td>
<td class="nump">55,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">1,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">161,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">651,724<span></span>
</td>
<td class="nump">237,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">64,120<span></span>
</td>
<td class="nump">11,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">165,468<span></span>
</td>
<td class="nump">11,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Other financial assets</a></td>
<td class="nump">137,234<span></span>
</td>
<td class="nump">1,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other assets</a></td>
<td class="nump">60,966<span></span>
</td>
<td class="nump">9,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTaxAssetsCurrent', window );">Income tax assets</a></td>
<td class="nump">898<span></span>
</td>
<td class="nump">756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DeferredExpenseCurrent', window );">Deferred expenses</a></td>
<td class="nump">28,001<span></span>
</td>
<td class="nump">5,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">1,210,209<span></span>
</td>
<td class="nump">519,149<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">1,666,896<span></span>
</td>
<td class="nump">560,151<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">2,318,620<span></span>
</td>
<td class="nump">797,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">246,310<span></span>
</td>
<td class="nump">232,304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CapitalReserve', window );">Capital reserve</a></td>
<td class="nump">1,514,451<span></span>
</td>
<td class="nump">686,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Treasury shares</a></td>
<td class="num">(4,789)<span></span>
</td>
<td class="num">(5,525)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AccumulatedOtherComprehensiveIncome', window );">Accumulated losses</a></td>
<td class="num">(409,629)<span></span>
</td>
<td class="num">(424,827)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Other reserves</a></td>
<td class="nump">25,503<span></span>
</td>
<td class="nump">4,826<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">1,371,846<span></span>
</td>
<td class="nump">493,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Interest-bearing loans and borrowings</a></td>
<td class="nump">231,047<span></span>
</td>
<td class="nump">68,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialLiabilities', window );">Other financial liabilities</a></td>
<td class="nump">31,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Provisions</a></td>
<td class="nump">5,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">71,892<span></span>
</td>
<td class="nump">97,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">340,760<span></span>
</td>
<td class="nump">166,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermBorrowings', window );">Interest-bearing loans and borrowings</a></td>
<td class="nump">9,142<span></span>
</td>
<td class="nump">5,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">102,288<span></span>
</td>
<td class="nump">20,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Other financial liabilities</a></td>
<td class="nump">74,075<span></span>
</td>
<td class="nump">10,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentGovernmentGrants', window );">Government grants</a></td>
<td class="nump">91,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilitiesCurrent', window );">Tax provisions</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherShorttermProvisions', window );">Other provisions</a></td>
<td class="nump">903<span></span>
</td>
<td class="nump">762<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">299,583<span></span>
</td>
<td class="nump">93,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">28,061<span></span>
</td>
<td class="nump">7,490<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">606,014<span></span>
</td>
<td class="nump">138,142<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">946,774<span></span>
</td>
<td class="nump">304,155<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total equity and liabilities</a></td>
<td class="nump">&#8364; 2,318,620<span></span>
</td>
<td class="nump">&#8364; 797,647<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DeferredExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred expense current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DeferredExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccumulatedOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccumulatedOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the capital reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current government grants recognised in the statement of financial position as deferred income. [Refer: Government [member]; Deferred income; Government grants]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax assets. [Refer: Current tax assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax liabilities. [Refer: Current tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 56<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 56<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph m<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph m<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherShorttermProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions other than provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherShorttermProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 70<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An entity&#8217;s own equity instruments, held by the entity or other members of the consolidated group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2020-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891797848">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenues</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 482,325<span></span>
</td>
<td class="nump">&#8364; 108,589<span></span>
</td>
<td class="nump">&#8364; 127,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(59,333)<span></span>
</td>
<td class="num">(17,361)<span></span>
</td>
<td class="num">(13,690)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(645,029)<span></span>
</td>
<td class="num">(226,466)<span></span>
</td>
<td class="num">(143,040)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14,512)<span></span>
</td>
<td class="num">(2,718)<span></span>
</td>
<td class="num">(3,041)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(94,049)<span></span>
</td>
<td class="num">(45,547)<span></span>
</td>
<td class="num">(26,334)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,358)<span></span>
</td>
<td class="num">(739)<span></span>
</td>
<td class="num">(720)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">250,539<span></span>
</td>
<td class="nump">2,724<span></span>
</td>
<td class="nump">5,396<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(82,417)<span></span>
</td>
<td class="num">(181,518)<span></span>
</td>
<td class="num">(53,854)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,564<span></span>
</td>
<td class="nump">4,122<span></span>
</td>
<td class="nump">8,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(62,946)<span></span>
</td>
<td class="num">(326)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expenses related to lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,003)<span></span>
</td>
<td class="num">(1,718)<span></span>
</td>
<td class="num">(1,721)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of loss of equity method investees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(145,802)<span></span>
</td>
<td class="num">(179,440)<span></span>
</td>
<td class="num">(47,662)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">161,000<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="num">(600)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit / (Loss) for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,198<span></span>
</td>
<td class="num">(179,172)<span></span>
</td>
<td class="num">(48,262)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToAbstract', window );"><strong>Attributable to:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Equity holders of the parent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,198<span></span>
</td>
<td class="num">(179,056)<span></span>
</td>
<td class="num">(48,019)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(116)<span></span>
</td>
<td class="num">(243)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit / (Loss) for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 15,198<span></span>
</td>
<td class="num">&#8364; (179,172)<span></span>
</td>
<td class="num">&#8364; (48,262)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicAndDilutedEarningsLossPerShare', window );">Basic and diluted, profit / (loss) for the period attributable to ordinary equity holders of the parent</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">&#8364; 0.06<span></span>
</td>
<td class="num">&#8364; (0.85)<span></span>
</td>
<td class="num">&#8364; (0.25)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=bntx_ResearchAndDevelopmentMember', window );">Research &amp; Development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenues</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 178,849<span></span>
</td>
<td class="nump">&#8364; 84,428<span></span>
</td>
<td class="nump">&#8364; 101,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=bntx_CommercialMember', window );">Commercial</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenues</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">303,476<span></span>
</td>
<td class="nump">24,161<span></span>
</td>
<td class="nump">25,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (59,333)<span></span>
</td>
<td class="num">&#8364; (17,361)<span></span>
</td>
<td class="num">&#8364; (13,690)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Foreign exchange differences on a cumulative basis are shown either as finance income or expenses and might switch between those two positions during the year-to-date reporting periods.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Numbers of shares for calculating the earnings per share for the years ended December 31, 2019 and December 31, 2018 have been adjusted to reflect capital increase due to 1:18 share split, which occurred on September 18, 2019.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicAndDilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of earnings per share when the basic and diluted measurements are equal. [Refer: Basic earnings (loss) per share; Diluted earnings (loss) per share]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicAndDilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs relating to expenses directly or indirectly attributed to the goods or services sold, which may include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, unallocated production overheads and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2020-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2020-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2020-01-01<br> -Paragraph IE33<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39M<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39M_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=bntx_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=bntx_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=bntx_CommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=bntx_CommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891936024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Operations (Parenthetical)<br></strong></div></th>
<th class="th"><div>Sep. 18, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAbstract', window );"><strong>Profit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_StockSplitConversionRatio', window );">Stock split ratio</a></td>
<td class="nump">0.05556<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_StockSplitConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock split conversion ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_StockSplitConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891735816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income / (Loss) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Statement Of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit / (Loss) for the period</a></td>
<td class="nump">&#8364; 15,198<span></span>
</td>
<td class="num">&#8364; (179,172)<span></span>
</td>
<td class="num">&#8364; (48,262)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Other comprehensive income / (loss) that may be reclassified to profit or loss in subsequent periods, net of tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange differences on translation of foreign operations</a></td>
<td class="num">(11,096)<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Net other comprehensive income / (loss) that may be reclassified to profit or loss in subsequent periods</a></td>
<td class="num">(11,096)<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Other comprehensive loss that will not be reclassified to profit or loss in subsequent periods, net of tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Remeasurement loss on defined benefit plans</a></td>
<td class="num">(273)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax', window );">Net other comprehensive loss that will not be reclassified to profit or loss in subsequent periods</a></td>
<td class="num">(273)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income / (loss) for the period, net of tax</a></td>
<td class="num">(11,369)<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income / (loss) for the period, net of tax</a></td>
<td class="nump">3,829<span></span>
</td>
<td class="num">(179,095)<span></span>
</td>
<td class="num">(48,252)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract', window );"><strong>Attributable to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent', window );">Equity holders of the parent</a></td>
<td class="nump">3,829<span></span>
</td>
<td class="num">(178,979)<span></span>
</td>
<td class="num">(48,009)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(116)<span></span>
</td>
<td class="num">(243)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income / (loss) for the period, net of tax</a></td>
<td class="nump">&#8364; 3,829<span></span>
</td>
<td class="num">&#8364; (179,095)<span></span>
</td>
<td class="num">&#8364; (48,252)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81B_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81B_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 82A<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 82A<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567887866408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series B</div></th>
<th class="th"><div>Share Capital</div></th>
<th class="th">
<div>Share Capital </div>
<div>Series B</div>
</th>
<th class="th"><div>Capital Reserve</div></th>
<th class="th">
<div>Capital Reserve </div>
<div>Series B</div>
</th>
<th class="th"><div>Treasury Shares</div></th>
<th class="th">
<div>Treasury Shares </div>
<div>Series B</div>
</th>
<th class="th"><div>Accumulated Losses</div></th>
<th class="th"><div>Other Reserves</div></th>
<th class="th"><div>Foreign Currency Translation Reserve</div></th>
<th class="th"><div>Total</div></th>
<th class="th">
<div>Total </div>
<div>Series B</div>
</th>
<th class="th"><div>Non-controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="num">&#8364; (48,206)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 166,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (197,753)<span></span>
</td>
<td class="num">&#8364; (27,206)<span></span>
</td>
<td class="num">&#8364; (23)<span></span>
</td>
<td class="num">&#8364; (49,296)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit / (Loss) for the period</a></td>
<td class="num">(48,262)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48,019)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48,019)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(243)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income / (loss)</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income / (loss) for the period, net of tax</a></td>
<td class="num">(48,252)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48,019)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="num">(48,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(243)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IssuanceOfShareCapital', window );">Issuance of share capital</a></td>
<td class="nump">355,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share based payments</a></td>
<td class="nump">7,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncreaseDecreaseThroughSettlementOfSharebasedPaymentPlan', window );">Settlement of share-based payment plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,909)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Dec. 31, 2018</a></td>
<td class="nump">267,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(245,771)<span></span>
</td>
<td class="num">(25,474)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="nump">266,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit / (Loss) for the period</a></td>
<td class="num">(179,172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(179,056)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(179,056)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(116)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income / (loss)</a></td>
<td class="nump">77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income / (loss) for the period, net of tax</a></td>
<td class="num">(179,095)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(179,056)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="num">(178,979)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(116)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IssuanceOfShareCapital', window );">Issuance of share capital</a></td>
<td class="nump">49,874<span></span>
</td>
<td class="nump">&#8364; 198,855<span></span>
</td>
<td class="nump">8,126<span></span>
</td>
<td class="nump">&#8364; 17,990<span></span>
</td>
<td class="nump">41,748<span></span>
</td>
<td class="nump">&#8364; 186,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (5,525)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,874<span></span>
</td>
<td class="nump">&#8364; 198,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncreaseDecreaseThroughInitialPublicOffering', window );">Capital increase initial public offering (referred to as IPO)</a></td>
<td class="nump">143,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncreaseDecreaseThroughAcquisitionOfNoncontrollingInterests', window );">Acquisition of non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,644)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (731)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Transaction costs</a></td>
<td class="num">(16,638)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,638)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,638)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share based payments</a></td>
<td class="nump">30,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">493,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">686,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (5,525)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(424,827)<span></span>
</td>
<td class="nump">4,762<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">493,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit / (Loss) for the period</a></td>
<td class="nump">15,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income / (loss)</a></td>
<td class="num">(11,369)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(273)<span></span>
</td>
<td class="num">(11,096)<span></span>
</td>
<td class="num">(11,369)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income / (loss) for the period, net of tax</a></td>
<td class="nump">3,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,198<span></span>
</td>
<td class="num">(273)<span></span>
</td>
<td class="num">(11,096)<span></span>
</td>
<td class="nump">3,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IssuanceOfShareCapital', window );">Issuance of share capital</a></td>
<td class="nump">875,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">860,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">875,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Transaction costs</a></td>
<td class="num">(33,223)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,223)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,223)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share based payments</a></td>
<td class="nump">32,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">&#8364; 1,371,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 246,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,514,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (4,789)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (409,629)<span></span>
</td>
<td class="nump">&#8364; 36,535<span></span>
</td>
<td class="num">&#8364; (11,032)<span></span>
</td>
<td class="nump">&#8364; 1,371,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncreaseDecreaseThroughAcquisitionOfNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease through acquisition of noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncreaseDecreaseThroughAcquisitionOfNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncreaseDecreaseThroughInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease through initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncreaseDecreaseThroughInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncreaseDecreaseThroughSettlementOfSharebasedPaymentPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through settlement of sharebased payment plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncreaseDecreaseThroughSettlementOfSharebasedPaymentPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IssuanceOfShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of share capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IssuanceOfShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567974870712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)<br></strong></div></th>
<th class="th"><div>Sep. 18, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement Of Changes In Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_StockSplitConversionRatio', window );">Stock split ratio</a></td>
<td class="nump">0.05556<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_StockSplitConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock split conversion ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_StockSplitConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891876008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit / (Loss) for the period</a></td>
<td class="nump">&#8364; 15,198<span></span>
</td>
<td class="num">&#8364; (179,172)<span></span>
</td>
<td class="num">&#8364; (48,262)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income taxes</a></td>
<td class="num">(161,000)<span></span>
</td>
<td class="num">(268)<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before tax</a></td>
<td class="num">(145,802)<span></span>
</td>
<td class="num">(179,440)<span></span>
</td>
<td class="num">(47,662)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments to reconcile loss before tax to net cash flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation and amortization of property, plant, equipment and intangible assets</a></td>
<td class="nump">38,744<span></span>
</td>
<td class="nump">33,896<span></span>
</td>
<td class="nump">21,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based payment expense</a></td>
<td class="nump">32,142<span></span>
</td>
<td class="nump">30,236<span></span>
</td>
<td class="nump">7,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Net foreign exchange differences</a></td>
<td class="nump">41,275<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment', window );">(Gain) / Loss on disposal of property, plant and equipment</a></td>
<td class="nump">595<span></span>
</td>
<td class="nump">542<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncome', window );">Finance income</a></td>
<td class="num">(1,564)<span></span>
</td>
<td class="num">(1,782)<span></span>
</td>
<td class="num">(1,996)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AdjustmentsForInterestOnLeaseLiability', window );">Interest on lease liability</a></td>
<td class="nump">2,003<span></span>
</td>
<td class="nump">1,717<span></span>
</td>
<td class="nump">1,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceCosts', window );">Finance expense</a></td>
<td class="nump">20,336<span></span>
</td>
<td class="nump">326<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AdjustmentsForMovementsInGovernmentGrants', window );">Movements in government grants</a></td>
<td class="nump">91,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of loss of an associate and a joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherAdjustmentsForNoncashItems', window );">Other non-cash income</a></td>
<td class="nump">1,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_WorkingCapitalAdjustmentsAbstract', window );"><strong>Working capital adjustments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AdjustmentsForIncreaseDecreaseInTradeAccountReceivableAndContractAssets', window );">Decrease / (Increase) in trade receivable and contract assets</a></td>
<td class="num">(247,886)<span></span>
</td>
<td class="nump">2,939<span></span>
</td>
<td class="num">(18,732)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">Decrease / (Increase) in inventories</a></td>
<td class="num">(49,794)<span></span>
</td>
<td class="num">(5,798)<span></span>
</td>
<td class="num">(1,253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions', window );">(Decrease) / Increase in trade payables, other liabilities, contract liabilities and provisions</a></td>
<td class="nump">204,583<span></span>
</td>
<td class="num">(80,577)<span></span>
</td>
<td class="num">(21,080)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities', window );">Interest received</a></td>
<td class="nump">1,444<span></span>
</td>
<td class="nump">1,256<span></span>
</td>
<td class="nump">1,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Interest paid</a></td>
<td class="num">(3,628)<span></span>
</td>
<td class="num">(2,044)<span></span>
</td>
<td class="num">(1,769)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Income tax received (paid), net</a></td>
<td class="nump">378<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="num">(304)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash flows used in operating activities</a></td>
<td class="num">(13,474)<span></span>
</td>
<td class="num">(198,537)<span></span>
</td>
<td class="num">(58,877)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Purchase of property, plant and equipment</a></td>
<td class="num">(66,033)<span></span>
</td>
<td class="num">(38,592)<span></span>
</td>
<td class="num">(29,901)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Proceeds from sale of property, plant and equipment</a></td>
<td class="nump">1,241<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssets', window );">Purchase of intangibles assets and right-of-use assets</a></td>
<td class="num">(19,413)<span></span>
</td>
<td class="num">(32,488)<span></span>
</td>
<td class="num">(37,256)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Acquisition of subsidiaries and businesses, net of cash acquired</a></td>
<td class="num">(60,643)<span></span>
</td>
<td class="num">(6,056)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash flows used in investing activities</a></td>
<td class="num">(144,848)<span></span>
</td>
<td class="num">(77,115)<span></span>
</td>
<td class="num">(66,452)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issuance of share capital, net of costs</a></td>
<td class="nump">753,007<span></span>
</td>
<td class="nump">375,351<span></span>
</td>
<td class="nump">361,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from loans and borrowings</a></td>
<td class="nump">156,027<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayment of loans and borrowings</a></td>
<td class="num">(1,566)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payments related to lease liabilities</a></td>
<td class="num">(12,743)<span></span>
</td>
<td class="num">(3,061)<span></span>
</td>
<td class="num">(2,148)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash flows from financing activities</a></td>
<td class="nump">894,725<span></span>
</td>
<td class="nump">383,290<span></span>
</td>
<td class="nump">365,177<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">736,403<span></span>
</td>
<td class="nump">107,638<span></span>
</td>
<td class="nump">239,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Change in cash and cash equivalents resulting from exchange rate differences</a></td>
<td class="num">(45,343)<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="num">(459)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at January 1</a></td>
<td class="nump">519,149<span></span>
</td>
<td class="nump">411,495<span></span>
</td>
<td class="nump">172,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at December 31</a></td>
<td class="nump">&#8364; 1,210,209<span></span>
</td>
<td class="nump">&#8364; 519,149<span></span>
</td>
<td class="nump">&#8364; 411,495<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AdjustmentsForIncreaseDecreaseInTradeAccountReceivableAndContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase decrease in trade account receivable and contract assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AdjustmentsForIncreaseDecreaseInTradeAccountReceivableAndContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade payables, other liabilities, contract liabilities and provisions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AdjustmentsForInterestOnLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for interest on lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AdjustmentsForInterestOnLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AdjustmentsForMovementsInGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for movements in government grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AdjustmentsForMovementsInGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of intangible assets and right of use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_WorkingCapitalAdjustmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working capital adjustments abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_WorkingCapitalAdjustmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for gain (loss) on disposals of property, plant and equipment to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Property, plant and equipment; Disposals, property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 39<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_39&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2020-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 14<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAdjustmentsForNoncashItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAdjustmentsForNoncashItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2020-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39M<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39M_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140568065123672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Corporate information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfCorporateInformationExplanatoryAbstract', window );"><strong>Disclosure Of Corporate Information Explanatory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfCorporateInformationExplanatory', window );">Corporate information</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Corporate Information</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech SE is a limited company incorporated and domiciled in Germany. American Depositary Shares (ADS) representing BioNTech SE&#8217;s ordinary shares have been publicly traded on Nasdaq Global Select Market since October 10, 2019. The registered office is located in Mainz, Germany (An der Goldgrube 12, 55131 Mainz). The accompanying International Financial Reporting Standards (IFRS) consolidated financial statements present the financial position and the results of operation of BioNTech SE and its subsidiaries, hereinafter also referred to as &#8220;BioNTech&#8221; or the &#8220;Group&#8221;.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020 the following changes to the Group structure occurred:</p>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">On February 16, 2020, BioNTech Protein Therapeutics GmbH was renamed to BioNTech Delivery Technologies GmbH and the company&#8217;s registered office was changed from Mainz to Halle. </p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">On May 6, 2020, BioNTech SE acquired Neon Therapeutics, Inc., Cambridge, Massachusetts, United States (formerly Nasdaq: NTGN), or Neon. Under the merger agreement by and among BioNTech, Neon and BioNTech&#8217;s wholly-owned subsidiary, Endor Lights, Inc., New York, United States, Endor Lights, Inc. merged with and into Neon. The new subsidiary operates under the name BioNTech US Inc., is held indirectly via BioNTech USA Holding, LLC. as a wholly-owned subsidiary and serves as BioNTech&#8217;s headquarters in the United States.</p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">On July 17, 2020, BioNTech IVAC GmbH was renamed to BioNTech Manufacturing GmbH and on August 7, 2020, BioNTech Small Molecules GmbH was renamed to BioNTech Europe GmbH. </p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">On September 17, 2020, the liquidation process for BioNTech Austria Beteiligungen GmbH was initiated by a resolution of the shareholders. </p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">On October 15, 2020, BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. was founded and is a wholly-owned subsidiary of BioNTech SE. </font></p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Three new real estate entities have been founded in Germany: BioNTech Real Estate An der Goldgrube GmbH &amp; Co. KG, BioNTech Real Estate Adam-Opel-Stra&#223;e GmbH &amp; Co. KG and BioNTech Real Estate Haus Vier GmbH &amp; Co. KG, all Holzkirchen. All are partnerships wholly-owned by its limited partner BioNTech Real Estate Holding GmbH, a wholly-owned subsidiary of BioNTech SE. </p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;text-indent:-3.03%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">On October 31, 2020, BioNTech SE acquired Novartis Manufacturing GmbH, Marburg, Germany. The new production site operates under the name BioNTech Manufacturing Marburg GmbH, a wholly-owned subsidiary of BioNTech SE.</p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">On November 11, 2020, BioNTech UK Limited was founded and is a wholly-owned subsidiary of BioNTech SE.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">On December 15, 2020, reBOOST Management GmbH was renamed to reSano GmbH.</font> </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All entities listed above are included in the Group&#8217;s consolidated financial statements.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information on the Group&#8217;s structure is provided in Note 4. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements of the Group for the year ended December&#160;31, 2020 were authorized for issue in accordance with a resolution of the Supervisory Board on March 30, 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfCorporateInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of corporate information explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfCorporateInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfCorporateInformationExplanatoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of corporate information explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfCorporateInformationExplanatoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567974870840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Disclosure Of Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">Significant Accounting Policies</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Significant Accounting Policies</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.1</font></p></td>
<td valign="top">
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Basis of Preparation</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">General</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements have been prepared on a going concern basis in accordance with the IFRS as issued by the International Accounting Standards Board (IASB). </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech prepares and publishes its consolidated financial statements in Euros and rounds numbers to thousands or millions of Euros, respectively. Accordingly, numerical figures shown as totals in some tables may not be exact arithmetic aggregations of the figures that preceded them and figures presented in the explanatory notes may not add up to the rounded arithmetic aggregations. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Segment Information</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Historically <font style="color:#000000;">BioNTech </font>reported four segments: Clinical, Technology Platform, Manufacturing and Product Sales &amp; External Services. In the course of the year ended December&#160;31, 2020, <font style="color:#000000;">BioNTech </font>leveraged the breadth of its immunotherapy technologies and used its expertise to mobilize these rapidly to address the COVID-19 pandemic. In December 2020, BioNTech&#8217;s COVID-19 vaccine was authorized or approved for emergency or temporary use or granted conditional marketing authorization in over 65 countries worldwide. Beginning in the fourth quarter, given the financial and operational significance of the activities to develop and then market, produce and transport the COVID-19 vaccine, BioNTech&#8217;s Management Board, as the chief operating decision maker (CODM), reviewed financial information presented on a consolidated basis. Decisions with respect to business operations and resource allocations are made by the CODM based on BioNTech as a whole. Accordingly, BioNTech operates and makes decisions as a single operating segment, which is also its reporting segment. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.2</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Basis of Consolidation</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements comprise the financial statements of BioNTech SE and its controlled investees (subsidiaries). </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group controls an investee if, and only if, the Group has</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.14%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">power over the investee (</font><font style="font-style:italic;font-family:Times New Roman;">i.e.</font><font style="font-family:Times New Roman;">, existing rights that give it the current ability to direct the relevant activities of the investee); </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">exposure, or rights, to variable returns from its involvement with the investee; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the ability to use its power over the investee to affect its returns. </font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally, there is a presumption that a majority of voting rights results in control. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group re-assesses whether it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The profit / (loss) and each component of other comprehensive income / (loss) for the period are attributed to the equity holders of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. When necessary, adjustments are made to the <font style="color:#000000;">consolidated </font>financial statements of subsidiaries to bring their accounting policies in line with the Group&#8217;s accounting policies. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated on consolidation.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Group loses control over a subsidiary, it derecognizes the related assets (including goodwill), liabilities, non-controlling interests and other components of equity, while any resultant gain or loss is recognized in the <font style="color:#000000;">consolidated </font>statements of operations. Any investment retained is recognized at fair value.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Summary of Significant Accounting Policies</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Business combinations and Goodwill</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Business combinations are accounted for using the acquisition method. The cost of an acquisition is measured as the aggregate of the consideration transferred, which is measured at acquisition date fair value, and the amount of any non-controlling interests in the acquiree.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill is initially measured at cost as the excess of the aggregate of the consideration transferred and the amount recognized for non-controlling interests and any previous interest held over the net identifiable assets acquired and liabilities assumed.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After initial recognition, goodwill is tested at least annually or when there is an indication for impairment. See Note&#160;2.3.13. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Group&#8217;s cash-generating units that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those units. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Where goodwill has been allocated to a cash-generating unit (CGU) and part of the operation within that unit is disposed of, the goodwill associated with the disposed operation is included in the carrying amount of the operation when determining the gain or loss on disposal. Goodwill disposed in these circumstances is measured based on the relative values of the disposed operation and the portion of the cash-generating unit retained.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Current versus Non-Current Classifications</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group presents assets and liabilities in the consolidated statements of financial position based on current or non-current classification. An asset is current when it is either: (i)&#160;expected to be realized within 12&#160;months after the reporting period or (ii)&#160;cash or cash equivalents, unless it is restricted from being exchanged or used to settle a liability for at least 12&#160;months after the reporting period. All other assets are classified as non-current. A liability is current when it is due to be settled within 12&#160;months after the reporting period. The Group classifies all other liabilities as non-current. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets and liabilities are classified as non-current assets and liabilities, respectively.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Fair Value Measurement</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is a market-based measurement. For some assets and liabilities, observable market transactions or market information is available. For other assets and liabilities, observable market transactions or market information might not be available. When a price for an identical asset or liability is not observable, another valuation technique is used. To increase consistency and comparability in fair value measurements, there are three levels of the fair value hierarchy:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.14%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Level 1 contains the use of quoted prices in active markets for identical assets or liabilities.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.14%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.14%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Level&#160;3 inputs are unobservable. </font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within this hierarchy, estimated values are made by management based on reasonable assumptions, including other fair value methods.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For assets and liabilities that are recognized in the financial statements at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the fair value hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the purpose of fair value disclosures, the Group has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy, as explained above.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.93%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.4</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Revenue from Contracts with Customers</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech generates revenues from collaboration and license agreements under which BioNTech grants licenses to use, research, develop, manufacture and commercialize product candidates and products. BioNTech determined that those collaboration and license agreements qualify as contracts with its customers. If the grant of a license is bundled together with the rendering of services, it is assessed whether these agreements are comprised of more than one performance obligation. A performance obligation is only accounted for as the grant of a license if the grant of a license is the sole or the predominant promise of the performance obligation. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the consideration in an agreement includes a variable amount, BioNTech estimates the amount of consideration to which BioNTech will be entitled in exchange for transferring the goods to the customer. At contract inception, the variable consideration is estimated based on the most likely amount of consideration expected from the transaction and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with respect the variable consideration is subsequently resolved. The estimated revenue is updated at each reporting date to reflect the current facts and circumstances.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a contract with a customer contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative-stand-alone selling prices.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each separate performance obligation, it is evaluated whether control is transferred either at a point in time or over time. For performance obligations that are satisfied over time, revenue is recognized based on a measure of progress, which depicts the performance in transferring control to the customer. Under the terms of its licensing arrangements, BioNTech provides the licensee with a research and development license, which represents a right to access BioNTech&#8217;s intellectual property as it exists throughout the license period (as BioNTech&#8217;s intellectual property is still subject to further research). Therefore, the promise to grant a license is accounted for as a performance obligation satisfied over time, as the licensee simultaneously receives and consumes the benefits of BioNTech&#8217;s performance.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Earnings based on the collaboration partners&#8217; gross profit, which is shared under the respective collaboration agreements are recognized based on the sales-based or usage-based royalty <font style="color:#000000;">exemption; </font><font style="font-style:italic;color:#000000;">i.e. </font>when, or as, the underlying sales occur, which is when the performance obligation has been satisfied. As described further in Note 3, BioNTech uses certain information from its collaboration partners, some of which is based on preliminary data shared between the partners and might vary once final data is available. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue arrangements that involve two or more partners who contribute to the provision of a specific good or service to a customer are assessed in terms of principal-agent considerations in order to determine the appropriate treatment for the transactions between BioNTech and the collaborator and the transactions between BioNTech and other third parties. The classification of transactions under such arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which BioNTech is considered the principal, which includes being in control of the good or service before such good or service is transferred to the customer, are accounted for as gross revenue. Any consideration related to activities in which BioNTech is considered the agent, are accounted for as net revenue.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue from the sale of pharmaceutical and medical products (<font style="font-style:italic;">e.g</font>. COVID-19 vaccine sales and other sales of peptides and retroviral vectors for clinical supply) is recognized when BioNTech transfers control of the product to the customer. Control of the product normally transfers when the customer gains physical possession and BioNTech has not retained any significant risks of ownership or future obligations with respect to the product. A receivable is recognized, as the consideration is unconditional and only the passage of time is required before payment is due. The transaction price is quoted in the relevant price lists in force at the date of customer placing the respective order for such products. Payments from customers are due within 20 days (Europe) or 30 days (non-Europe) after invoice.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contract Balances</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contract Assets</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A contract asset is the right to consideration in exchange for goods or services transferred to the customer. If BioNTech performs by transferring goods or services to a customer before the customer pays consideration or before payment is due, a contract asset is recognized for the earned consideration that is conditional.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Trade Receivables</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A receivable represents BioNTech&#8217;s right to an amount of consideration that is unconditional (<font style="font-style:italic;">i.e</font>., only the passage of time is required before payment of the consideration is due).</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contract Liabilities</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A contract liability is the obligation to transfer goods or services to a customer for which BioNTech has received consideration (or an amount of consideration is due) from the customer. If a customer pays consideration before BioNTech transfers goods or services to the customer, a contract liability is recognized when the payment is made or when the payment is due (whichever is earlier). Contract liabilities are recognized as revenue when BioNTech performs under the contract.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.5</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Government Grants</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government grants are recognized where there is reasonable assurance that the grant will be received and all attached conditions will be complied with. When the grant relates to an expense item, it is recognized as other income on a systematic basis over the periods that the related costs, for which the grant is intended to compensate, are expensed. When the grant relates to an asset, it is recognized as deferred income within the consolidated statements of financial position. Other income is subsequently recognized in profit or loss over the useful live of the underlying asset subject to funding. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.6</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Taxes</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Current Income Tax</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the reporting date in the countries where the Group operates and generates taxable income. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, current income taxes presented for the period include adjustments for uncertain tax payments or tax refunds for periods not yet finally assessed, excluding interest expenses and penalties on the underpayment of taxes. Due to the increasing complexity of tax laws and the corresponding uncertainty regarding the legal interpretation by the fiscal authorities, tax calculations are generally subject to an elevated amount of uncertainty. In the event that amounts included in the tax return are considered unlikely to be accepted by the tax authorities (uncertain tax positions), a provision for income taxes is recognized. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred Tax</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities are recognized for all taxable temporary differences, except: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">when the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">in respect of taxable temporary differences associated with investments in subsidiaries, associates and interests in joint arrangements, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future. </font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets are recognized for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, the carry forward of unused tax credits and unused tax losses can be utilized, except:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">when the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">in respect of deductible temporary differences associated with investments in subsidiaries, associates and interests in joint arrangements, deferred tax assets are recognized only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized. </font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year in which the asset is realized, or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recognition of Taxes</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current and deferred tax items are recognized similar to the underlying transaction either in profit or loss, other comprehensive income or directly in equity.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group offsets current tax assets and current tax liabilities if, and only if, it has a legally enforceable right to set off the recognized amounts and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously. Deferred tax assets and deferred tax liabilities are only offset when the Group has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same taxation authority on either (i) the same taxable entity or (ii) different taxable entities, which intend either to settle current tax liabilities and assets on a net basis, or to realize the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sales Tax</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expenses and assets are recognized net of sales tax, except when the sales tax incurred on a purchase of assets or services is not recoverable from the taxation authority.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The net amount of sales tax recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the <font style="color:#000000;">consolidated</font> statements of financial position.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.7</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Foreign Currencies</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group&#8217;s consolidated financial statements are presented in Euros, which is also BioNTech SE&#8217;s functional currency. For each entity, the Group determines the functional currency, and items included in the <font style="color:#000000;">consolidated </font>financial statements of such entity are measured using that functional currency. The Group uses the direct method of consolidation and on disposal of a foreign operation, the gain or loss that is reclassified to the <font style="color:#000000;">consolidated </font>statements of operations reflects the amount that arises from using this method.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Transactions and Balances</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transactions in foreign currencies are initially recorded by the Group&#8217;s entities at their respective functional currency spot rates at the date the transaction first qualifies for recognition.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In determining the spot exchange rate to use on initial recognition of the related asset, expense or income (or part of it) on the derecognition of a non-monetary asset or non-monetary liability relating to advance consideration, the date of the transaction is the date on which the Group initially recognizes the non-monetary asset or non-monetary liability arising from the advance consideration. If there are multiple payments or receipts in advance, the Group determines the transaction date for each payment or receipt of advance consideration.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Foreign Currency Translation</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On consolidation, the assets and liabilities of foreign operations are translated into Euros at the rate of exchange prevailing at the reporting date and their <font style="color:#000000;">consolidated</font> statements of operations are translated at exchange rates prevailing at the dates of the transactions.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The exchange differences arising on translation for consolidation are recognized in other comprehensive income. On disposal of a foreign operation, the component of other comprehensive income relating to that particular foreign operation is reclassified to profit or loss.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any goodwill arising on the acquisition of a foreign operation and any fair value adjustments to the carrying amounts of assets and liabilities arising upon the acquisition are treated as assets and liabilities of the foreign operation and translated at the spot rate of exchange at the reporting date.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.8</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Property, Plant and Equipment</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress is stated at cost, net of accumulated impairment losses, if any. Property, plant and equipment are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Such cost includes the cost of replacing part of the property, plant and equipment if the recognition criteria are met. All other repair and maintenance costs are expensed as incurred.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Useful life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7-33</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equipment, tools and installations</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-15</p></td>
</tr>
</table>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An item of property, plant and equipment initially recognized is derecognized upon disposal (<font style="font-style:italic;">i.e</font>., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the <font style="color:#000000;">consolidated </font>statements of operations when the asset is derecognized.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year-end and adjusted prospectively, if appropriate.</p></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.9</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Leases</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of a contract, the Group assesses whether the contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, the Group assesses whether: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the contract involves the use of an identified asset&#8212;this may be specified explicitly or implicitly and should be physically distinct or represent substantially all of the capacity of a physically distinct asset. If the supplier has a substantive substitution right, then the asset is not identified; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the Group has the right to obtain substantially all of the economic benefits from use of the asset throughout the period of use; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the Group has the right to direct the use of the asset. The Group has this right when it has the decision-making rights that are most relevant to changing how and for what purpose the asset is used. In rare cases where the decision about how and for what purpose the asset is used is predetermined, the Group has the right to direct the use of the asset if either:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the Group has the right to operate the asset; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the Group designed the asset in a way that predetermines how and for what purpose it will be used. </font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At inception or on reassessment of a contract that contains a lease component, the Group allocates the consideration in the contract to each lease component on the basis of their relative stand-alone prices. However, for the leases of land and buildings in which it is a lessee, the Group has elected not to separate non-lease components, and instead accounts for the lease and non-lease components as a single lease component.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group recognizes a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of the costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received by the Group.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset and the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of property and equipment. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the incremental borrowing interest rate implicit in the lease or, if that rate cannot be readily determined, the Group&#8217;s incremental borrowing rate. Generally, the Group uses its incremental borrowing rate as the discount rate.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease payments included in the measurement of the lease liability comprise the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">fixed payments, including in-substance fixed payments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">variable lease payments that depend on an index or a rate, initially measured using the index or rate as of the commencement date; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">amounts expected to be payable under a residual value guarantee; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the exercise price under a purchase option that the Group is reasonably certain to exercise, lease payments in an optional renewal period if the Group is reasonably certain to exercise an extension option, and penalties for early termination of a lease unless the Group is reasonably certain not to terminate early.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The lease liability is subsequently measured at amortized cost using the effective interest method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the Group&#8217;s estimate of the amount expected to be payable under a residual value guarantee, or if the Group changes its assessment of whether it will exercise a purchase, extension or termination option. When the lease liability is remeasured, a corresponding adjustment is made to the carrying amount of the right-of-use asset or is recorded in the <font style="color:#000000;">consolidated </font>statements of operations if the carrying amount of the right-of-use asset has been reduced to zero.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group presents right-of-use assets separately and lease liabilities in &#8216;financial liabilities&#8217; in the <font style="color:#000000;">consolidated </font>statements of financial position.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets or shorter lease term, as follows:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Useful life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2-25</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equipment, tools and installations</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2-5</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Production facilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2-3</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Automobiles</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-4</p></td>
</tr>
</table>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Short-Term Leases and Leases of Low-Value Assets</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group has elected not to recognize right-of-use assets and lease liabilities for short-term leases of machinery that have a lease term of 12 months or less or leases of low-value assets. The Group recognizes the lease payments associated with these leases as an expense in the <font style="color:#000000;">consolidated </font>statements of operations on a straight-line basis over the lease term.</p></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.10</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Intangible Assets</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The useful lives of intangible assets are assessed as either finite or indefinite. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets with finite lives are amortized generally on a straight-line basis over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are at least reviewed at the end of each reporting period. The amortization expense on intangible assets with finite lives is recognized in the <font style="color:#000000;">consolidated </font>statements of operations in the expense category that is consistent with the function of the intangible assets.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the useful lives applied to the Group&#8217;s intangible assets is as follows:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Useful life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intellectual property rights</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-20</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Licenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-20</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-8</p></td>
</tr>
</table>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets with indefinite useful lives are not amortized, but are tested for impairment at least annually, or when there is an indication for impairment, either individually or at the level of a cash-generating unit (see Note 2.3.13 for further details). The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group has classified advanced payments on intangible assets as intangible assets, which are not yet ready for use. Advanced payments on intangible assets are tested for impairment on an annual basis.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An intangible asset is derecognized upon disposal (<font style="font-style:italic;">i.e</font>., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising upon derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the <font style="color:#000000;">consolidated </font>statements of operations.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Costs</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research costs are expensed as incurred. Development expenditures on an individual project are recognized as an intangible asset if, and only if, all of the following six criteria can be demonstrated by the Group:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the technical feasibility of completing the intangible asset so that the asset will be available for use or sale;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">its intention to complete the project;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the ability and intention to use or sell the asset;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">how the asset will generate future economic benefits;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the availability of resources to complete the asset; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the ability to reliably measure the expenditure during development.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to the inherent risk of failure in pharmaceutical development and the uncertainty of approval, management has determined that these criteria are not met in the biotech sector until regulatory approval has been obtained. The related expenditure is reflected in the consolidated statements of operations in the period in which the expenditure is incurred. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following initial recognition of the development expenditure as an asset, the asset is carried at cost less any accumulated amortization and accumulated impairment losses. Amortization of the asset begins when development is complete and the asset is available for use. It is amortized over the period of expected future benefit. Amortization is recorded in cost of sales. During the period of development, the asset is tested for impairment annually.</p></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.11</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Financial Instruments &#8211; Initial Recognition and Subsequent Measurement</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">i) Financial Assets</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Initial recognition and Measurement</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets are initially measured at fair value. The Group&#8217;s financial assets mainly include trade receivables as well as other receivables that reflect BioNTech&#8217;s entitlement to cash. With respect to trade receivable, the Group has applied the practical expedient which means that they are measured at the transaction price determined under IFRS 15. Refer to the accounting policies in Note 2.3.4. Other financial assets are measured at amortized costs since they are held by the Group to collect contractual cash flows, which are solely payments of principal and interest. Gains and losses are recognized in profit or loss when the financial asset is derecognized, modified or impaired. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Derecognition</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e., removed from the Group&#8217;s consolidated statements of financial position) when the rights to receive cash flows from the asset have expired or have been transferred in terms of fulfilling the derecognition criteria. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Impairment of Financial Assets</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An allowance for expected credit losses (ECLs) is considered for all debt instruments of the Group. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all of the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For trade receivables and contract assets, the Group applies a simplified approach in calculating ECLs. Therefore, the Group does not track changes in credit risk, but instead recognizes a loss allowance based on lifetime ECLs at each reporting date. The Group has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment. In this analysis BioNTech also considered that governments and health ministries which are BioNTech&#8217;s customers established in connection with progressing the commercial activities of the Group with respect to BioNTech&#8217;s COVID-19 vaccine. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ii) Financial Liabilities</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Initial Recognition and Measurement</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings or as payables.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group&#8217;s financial liabilities include trade payables and other financial liabilities.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Subsequent Measurement</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The measurement of financial liabilities depends on their classification, as described below.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Financial Liabilities at Fair Value through Profit or Loss</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial liabilities at fair value through profit of the Group include the embedded derivative, which was bifurcated from the convertible note, as host contract, and is recognized as a separate financial instrument until it is extinguished upon conversion. Financial liabilities at fair value further include contingent considerations resulting from the Group&#8217;s business combinations. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gains or losses arising from fair value measurement adjustments of the embedded derivative and the contingent consideration are recognized in profit and loss within the consolidated statements of operations.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Loans, Borrowings, Trade Payables and Other Financial Liabilities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After initial recognition, interest-bearing loans and borrowings, trade payables and other financial liabilities are subsequently measured at amortized cost using the EIR method. Gains and losses are recognized in the <font style="color:#000000;">consolidated </font>statements of operations when the liabilities are derecognized as well as through the EIR amortization process.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortization is included as finance costs in the <font style="color:#000000;">consolidated </font>statements of operations.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This category generally applies to interest-bearing loans and borrowings.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Derecognition</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the <font style="color:#000000;">consolidated </font>statements of operations.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.12</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Inventories</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories are valued at the lower of cost and net realizable value.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs incurred in bringing each product to its present location and condition are accounted for as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">raw materials and supplies: purchase cost on a first-in/first-out basis; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">unfinished goods and finished goods: cost of direct materials and labor, including both internal manufacturing and third-party contract manufacturing organizations, or CMOs, and a proportion of manufacturing overheads based on the normal operating capacity, but excluding borrowing costs.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.13</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Impairment of Non-Financial Assets</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group assesses, at each reporting date, whether there is an indication that an asset may be impaired. Goodwill is tested for impairment annually as of October 1. Impairment is determined for goodwill by assessing the recoverable amount of each cash generating unit (or group of CGUs) to which the goodwill relates. If any indication exists, or when annual impairment testing is performed, the Group estimates the asset&#8217;s or CGU&#8217;s recoverable amount. The recoverable amount is the higher of an asset&#8217;s or CGU&#8217;s fair value less costs of disposal and its value in use. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. When the carrying amount of an asset or cash generating unit exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used. These calculations are corroborated by valuation multiples, quoted share prices for publicly traded companies or other available fair value indicators.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group bases its impairment calculation on detailed budgets and forecast calculations, which are prepared separately for each of the Group&#8217;s cash generating units to which the individual assets are allocated. These budgets and forecast calculations generally cover a period of five years. A long-term growth rate is calculated and applied to project future cash flows after the fifth year.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment losses of continuing operations are recognized in the <font style="color:#000000;">consolidated </font>statements of operations in expense categories consistent with the function of the impaired asset.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For assets excluding goodwill, an assessment is made at each reporting date to determine whether there is an indication that previously recognized impairment losses no longer exist or have decreased. If such indication exists, the Group estimates the asset&#8217;s or cash generating unit&#8217;s recoverable amount. A previously recognized impairment loss is reversed only if there has been a change in the assumptions used to determine the asset&#8217;s recoverable amount since the last impairment loss was recognized. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognized for the asset in prior years. Such reversal is recognized in the <font style="color:#000000;">consolidated </font>statements of operations unless the asset is carried at a revalued amount, in which case, the reversal is treated as a revaluation increase.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.14</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Cash and Cash Equivalents</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents comprise cash in banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.15</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Pension</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The liability in respect of defined benefit pension plans is the defined benefit obligation calculated annually by independent actuaries using the projected unit credit method. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions of the respective employees, while the net interest on the net defined benefit liability or asset is recognized in finance expenses or finance income.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Provisions</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Group expects some or all of a provision to be reimbursed, for example, under an insurance contract, the reimbursement is recognized as a separate asset, but only when the reimbursement is virtually certain. The expense relating to a provision is presented in the <font style="color:#000000;">consolidated </font>statements of operations net of any reimbursement.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Share-Based Payments</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employees (and others providing similar services) receive remuneration in the form of share-based payments, which are settled in equity instruments (equity-settled transactions).</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cost of equity-settled transactions is determined by the fair value at the date when the grant is made using an appropriate valuation model, further details of which are given in Note 17. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These costs are recognized in cost of sales, research and development expenses, sales and marketing expenses or general and administrative expenses, together with a corresponding increase in equity (other reserves), over the period in which the service is provided (the vesting period). The cumulative expense recognized for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Group&#8217;s best estimate of the number of equity instruments that will ultimately vest.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.4</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Standards applied for the First Time</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020 several new and amended standards and interpretations became effective but did not have an impact on the consolidated financial statements of the Group. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Standards/Interpretations</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Date of application</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to IFRS 3 Business Combinations</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to IFRS 9, IAS 39 and IFRS 7 Interest Rate Benchmark Reform</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to IAS 1 and IAS 8 Definition of Material</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to References to the Conceptual Framework in IFRS Standards</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment to IFRS 16 Leases COVID-19-Related Rent Concessions</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 1, 2020</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.5</font></p></td>
<td valign="top">
<p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Standard issued but not yet effective</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The new and amended standards and interpretations that are issued, but not yet effective, up to the date of issuance of the Group&#8217;s financial statements and that might have an impact on the Group&#8217;s financial statements are disclosed below. The Group has not early adopted any standards and intends to adopt these new and amended standards and interpretations, if applicable, when they become effective. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Standards/Interpretations</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Date of application</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to IFRS 4 Insurance Contracts &#8211; deferral of IFRS 9</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2021</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 Interest Rate Benchmark Reform &#8211; Phase 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2021</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to IFRS 3 Business Combinations: Reference to the Conceptual Framework</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2022</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to IAS 16 Property, Plant and Equipment: Proceeds before Intended Use</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2022</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to IAS 37 Provisions, Contingent Liabilities and Contingent Assets - Onerous Contracts &#8211; Cost of Fulfilling a Contract Amendments to IAS 37</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2022</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual Improvements to IFRS Standards 2018-2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2022</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to IAS 1 Presentation of Financial Statements: Classification of Liabilities as Current or Non-current - Deferral of Effective Date</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2023</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IFRS 17 Insurance Contracts (issued on 18 May 2017); including Amendments to IFRS 17</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2023</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group does not expect a significant impact of the application of any of these amendments. </p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of summary of significant accounting policies abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting policies applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567911729320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Judgments, Estimates and Assumptions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfAccountingJudgementsAndEstimatesAbstract', window );"><strong>Disclosure Of Accounting Judgements And Estimates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">Significant Accounting Judgments, Estimates and Assumptions</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Significant Accounting Judgments, Estimates and Assumptions</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Group&#8217;s consolidated financial statements requires management to make <font style="color:#000000;">judgments</font>, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, the accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Judgments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the process of applying the Group&#8217;s accounting policies, management has made the following judgments, which have the most significant effect on the amounts recognized in the consolidated financial statements:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue from Contracts with Customers</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech applied the following <font style="color:#000000;">judgments </font>that significantly affect the determination of the amount and timing of revenue from contracts with customers:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Identification and Determination of Performance Obligations</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech generates revenues from collaboration and license agreements, which c<font style="color:#000000;">ontain multiple elements, including licenses to use, research, develop, manufacture and commercialize candidates and products, research and development services as well as obligations to develop and manufacture preclinical and clinical material and products. </font>BioNTech determined that those collaboration and license agreements qualify as contracts with its customers. <font style="color:#000000;">At inception of each agreement, BioNTech applies judgment when determining which promises represent distinct performance obligations. </font>If promises are not distinct, they are combined until the bundle of promised goods and services is distinct. For some agreements, this results in BioNTech accounting for goods and services promised in a collaboration and license agreement as a single performance obligation with a single measure of progress. For these combined performance obligations, BioNTech assesses which of these promises is the predominant promise to determine the nature of the performance obligation. <font style="color:#000000;">When licenses are granted, BioNTech determined that the grant of the license is the predominant promise within the combined performance obligations. </font>It is assessed that BioNTech grants their customers a right to access or a right to use BioNTech&#8217;s intellectual property due to the collaboration and license agreements. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Measurement of the Transaction Price</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech&#8217;s collaboration and license agreements often include variable considerations, which are contingent on the occurrence or non-occurrence of a future event <font style="font-style:italic;">(i.e.</font>, reaching a certain milestone). When determining deferred revenues of a collaboration and license agreement, BioNTech is required to estimate the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to the customer. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As there are usually only two possible outcomes (<font style="font-style:italic;">i.e.,</font> milestone is reached or not), BioNTech has assessed that the method of the most likely amount is the best method to predict the amount of consideration to which BioNTech will be entitled. At contract inception, the most likely amount for milestone payments is estimated to be zero. BioNTech has assessed that the likelihood of achieving the respective milestone decreases depending on how far the expected date of achieving the milestone lies in the future. At each reporting date, BioNTech uses judgment to determine when to include variable consideration in the transaction price such that it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with respect to the variable consideration is subsequently resolved. BioNTech has concluded that future milestone payments are fully constrained at the end of the current fiscal year.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future milestone payments would become unconstrained at the satisfaction of the milestone event, specifically a development event, a regulatory approval or achievement of a sales milestone.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Allocation of the Transaction Price to Performance Obligations and Revenue Recognition as Performance Obligations are satisfied</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech allocates the transaction price to performance obligations based on their relative standalone selling prices, which are generally based on best estimates and interpretations of <font style="color:#000000;">facts and circumstances of each contractual agreement and may </font>require significant judgment to determine appropriate allocation. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront payments and reimbursement for expenses are initially deferred on BioNTech&#8217;s <font style="color:#000000;">consolidated</font> statements of financial position. BioNTech assessed that no significant financing component exists within its collaboration agreements since the overall business purpose of advanced payments is to support the payment structure other than to provide a significant benefit of financing. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For performance obligations in which the costs vary based on progress, an input-based measure considering cost incurred depicts most reliably the progress of the related research activities. In other cases, revenue recognition on a straight-line basis may most reliably depict BioNTech&#8217;s performance toward complete satisfaction. In case the contractual activities progress, the achievement of development milestones will be used to measure the progress toward complete satisfaction. <font style="color:#000000;">BioNTech evaluates the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net loss in the period of adjustment.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon successfully commercializing a pharmaceutical product, the collaboration and license agreements also provide for additional profit-sharing or tiered royalties earned when customers recognize net sales of licensed products as well as sales milestone payments. Revenue is recognized based on the sales-based or usage-based royalty exemption when, or as, the underlying sales occur, which is when the performance obligation has been satisfied. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Principal-Agent Considerations</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration agreements that involve two or more partners who contribute to the provision of a specific good or service to a customer are assessed in terms of principal-agent considerations. Under BioNTech&#8217;s current collaboration agreements, the allocation of marketing and distribution rights defines territories in which the collaboration partner act as a principal respectively. BioNTech recognizes revenue net based on the collaboration partners&#8217; gross profit in territories where the partner is responsible for supply and on a gross basis when directly supplying customers in its territories when control has been transferred. Amounts paid to collaboration partners for their share of BioNTech&#8217;s profits where BioNTech is the principal in the transaction are recorded as cost of sales. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Pfizer Agreement Characteristics</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to the collaboration with Pfizer, commercial revenue is recognized based on the collaboration partners&#8217; gross profit from COVID-19 vaccine sales, which is shared under the respective collaboration agreement. In determining commercial revenue pursuant to this collaboration agreement, BioNTech is reliant on the collaboration partner for detail regarding its gross profit for the period at hand. BioNTech has been informed by its collaboration partner that certain of the information it intends to provide BioNTech with regard to the gross profit will be, by necessity, preliminary and subject to change. This is mainly due to the fact that the partner&#8217;s financial reporting cycle differs from BioNTech&#8217;s. Pfizer&#8217;s subsidiaries outside the United States have a fiscal year-end of November 30; that is, the details on sales in these territories are required in advance of closing the respective reporting periods. As a result, BioNTech&#8217;s determination of its share of such gross profit for purposes of recognizing revenues will be subject to risks that amounts reported might vary from actual amounts reported once the collaboration partner&#8217;s final financial results are available. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the period covered in these consolidated financial statements, Pfizer has calculated gross profit for COVID-19 vaccine sales in the U.S. territory as well as shared preliminary gross profit for COVID-19 vaccine sales in territories outside the United States, both of which will be reconciled and finalized. The respective gross profit shares are calculated based on sales and include consideration of transfer prices. The latter includes manufacturing and shipping costs which represent standard prices and include mark-ups on manufacturing costs as specified by the terms of the agreement. Manufacturing and shipping cost variances were considered as far as those have been identified. Nevertheless, those input parameters maybe adjusted once actual costs are determined. The sales for the U.S. territory, as reported by Pfizer, as well as sales preliminary reported for territories outside the United States have been used to estimate license obligations in terms of royalties and sales milestones. Sales milestones and royalties are recognized as they are earned by the partners. Sales milestones are shared equally, while royalty payments are shared on the basis of revenue in the territories for which the partners are responsible. The estimated royalty fees applied to net sales reflect the license obligations to the extent currently identified from third party contractual arrangements. Changes in estimates are accounted for prospectively, when determined. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These estimated figures are likely to change prospectively in future periods as BioNTech receives final data from Pfizer. Those changes in BioNTech&#8217;s share of the collaboration partner&#8217;s gross profit will be recognized prospectively as changes to BioNTech&#8217;s commercial revenues. To the extent that Pfizer does not provide such preliminary information in the future, BioNTech&#8217;s provisional sales figures for territories outside of the United States will be subject to a greater level of estimation and judgment. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:1.09%;width:99.88%;">
<tr>
<td style="width:35.4%;"></td>
<td style="width:14.27%;"></td>
<td style="width:14.27%;"></td>
<td style="width:21.19%;"></td>
<td style="width:14.75%;"></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="bottom" bgcolor="#FFFFFF">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style=" border-bottom:solid 1pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-bottom:solid 1pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">German territory</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-bottom:solid 1pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">U.S. territory</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-bottom:solid 1pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Territories outside the U.S.</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-bottom:solid 1pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style=" border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#C6E0B4" style=" border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct product sales to BioNTech customers</p></td>
<td valign="middle" bgcolor="#C6E0B4" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 20,553</p></td>
<td valign="middle" bgcolor="#C6E0B4" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style=" border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 20,553</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#C6E0B4" style=" border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share of collaboration partner's gross profit</p></td>
<td valign="middle" bgcolor="#C6E0B4" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 46,997</p></td>
<td valign="middle" bgcolor="#C6E0B4" style=" border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 141,480</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 188,477</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Input parameters used within gross profit share calculation</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:10pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Sales</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">reported</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">preliminary<br />reported</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Transfer price (manufacturing, shipping costs and respective variances)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">standard<br />prices</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">standard<br />prices</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">License payments</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">identified<br />royalty rate</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">identified<br />royalty rate</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer&#8217;s determination of manufacturing and shipping costs also affects the transfer prices that have been charged to COVID-19 vaccine supplies that it manufactures and supplies to BioNTech and may be subject to adjustment whenever manufacturing and shipping cost variances are identified. <font style="color:#000000;">Likewise, </font>BioNTech&#8217;s <font style="color:#000000;">own cost of sales and the respective gross profit share owed to </font>BioNTech&#8217;s <font style="color:#000000;">partner may be adjusted prospectively</font>, when changes are determined<font style="color:#000000;">. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the carrying amounts of the revenue recognition-related contract balances, see Note 6.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist of costs incurred in performing research and development activities, including personnel-related expenses, contract services and costs for purchased materials, laboratory supplies and non-capital equipment used in the research and development process. Research and development expenses include BioNTech&#8217;s share of expenses under the terms of collaboration agreements and 100% of the expenses for wholly-owned product candidates. Research and development expenses shared under collaboration agreements, which are initially incurred by the collaboration partners and subsequently charged to BioNTech, are recorded as purchased services classified within research and development. Cost reimbursements from partners for research and development expenses initially incurred by BioNTech and due to BioNTech under the agreements, are recorded as a reduction to purchased services classified within research and development expenses. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech has entered into agreements under which third parties grant licenses to BioNTech. Consideration paid under those agreements include upfront payments, development milestone payments and development expense reimbursements as well as sales-based milestone and royalty payments. Milestone payments are recorded when the specific milestone has been achieved. If those licenses grant access to technologies, both parties jointly perform research or development activities and both are exposed to significant risks and rewards of the activities. Costs incurred with the agreements are not treated differently from costs related to own product candidates. If the agreements grant BioNTech rights to use certain patents and technologies, that meet the definition of an identifiable assets, they are treated as acquired intangible assets. This assessment is made based on the facts and circumstances of each contractual agreement. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The value of goods and services received from contract research organizations, or CROs, and contract manufacturing organizations, or CMOs, in the reporting period are estimated based on the level of services performed and progress made in the respective period. Amounts are recorded as accrued expenses if BioNTech has not received an invoice from the service provider. Advance payments for goods or services that will be used or rendered for future research and development activities are recognized as other current assets or other current financial assets respectively. The amounts are currently expensed as the related goods are delivered or the services performed. Management&#8217;s estimates are based on the best information available at the time. However, additional information may become available in the future and management may adjust the estimate in such future periods. In this event, BioNTech may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. BioNTech considers resulting increases or decreases in cost as changes in estimates and reflects such changes in research and development expenses in the period identified.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research costs are expensed as incurred. Development expenditures on an individual project are recognized as an intangible asset if, and only if, all of the six criteria can be demonstrated by the Group as shown under Note&#160;2.3.10 above. Due to the inherent risk of failure in pharmaceutical development and the uncertainty of approval, management has determined that these criteria are not met in the biotech sector until regulatory approval has been obtained. The related expenditure is reflected in the consolidated statements of operations in the period in which the expenditure is incurred.<font style="color:#000000;"> Sales-based milestone or royalty payments incurred under license agreements relating to self-developed intangibles after the approval date of the respective pharmaceutical product are considered as contingent considerations. These contingent considerations are recognized as expenses as incurred. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to initial regulatory approval, costs relating to production of products are expensed as research and development expenses in the period incurred. If pre-launch products are sold, the respective product gross margin may be higher compared to the expected recurring margin as the underlying costs will not be included in cost of sales.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimates and Assumptions</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are described below. The Group based its assumptions and estimates on parameters available when the consolidated financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Group. Such changes are reflected in the assumptions when they occur.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Business Combinations</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The allocation of the purchase price for business acquisitions to the identifiable assets acquired and liabilities assumed based on their respective fair values, requires use of accounting estimates and judgment. Acquired intangible assets are valued using valuation models such as the Multi Period Excess Earnings Method under which fair values are derived from future net cash flows, which are discounted to the acquisition date using an appropriate discount factor. BioNTech has estimated fair values of assets acquired, liabilities assumed and contingent considerations based on reasonable assumptions. BioNTech continues to collect information and reevaluate these provisional estimates and assumptions in accordance with IFRS 3. Any adjustments to these provisional estimates and assumptions is recorded against goodwill provided they arise within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statements of operations.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For further disclosures relating to business combinations, see Note 5.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Impairment of Non-Financial Assets</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment exists when the carrying value of an asset or cash generating unit exceeds its recoverable amount, which is the higher of its fair value less costs of disposal and its value in use. The fair value less costs of disposal calculation is based on DCF model less incremental costs of disposing of the asset. The value in use calculation is based on a DCF model as well. The cash flows are derived from the budget for the next five years and do not include restructuring activities that the Group is not yet committed to or significant future investments that will enhance the performance of the assets of the CGU being tested. The recoverable amount is sensitive to the discount rate used for the DCF model as well as the expected future cash-inflows and the growth rate used for extrapolation purposes. These estimates are most relevant to goodwill and other intangibles with indefinite useful lives recognized by the Group. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The key assumptions used to determine the recoverable amount for the different CGUs, including a sensitivity analysis, are disclosed and further explained in Note&#160;11.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Share-Based Payments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Determining the fair value of share-based payment transactions requires the most appropriate valuation for the specific program, which depends on the underlying terms and conditions.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group has used valuation models like a binomial or Monte-Carlo simulation model for the measurement of the cash- and equity-settled transactions&#8217; fair value at the grant date considering certain assumption relating to, <font style="font-style:italic;">e.g.</font>, the volatility of stock price, the determination of an appropriate risk-free interest rate, expected dividends and the probability of reaching a minimum hurdle to exercise the relevant options. For awards which were granted prior to the initial public offering, at a time where no quoted market prices existed, the valuation model assumptions included the option&#8217;s underlying share price. For awards which were granted post the initial public offering, the grant date&#8217;s share prices on the Nasdaq Global Select Market were included in the valuation. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For further disclosures relating to share-based payments, see Note 17.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Embedded Derivatives</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Defining the fair value of the embedded derivative which was bifurcated from the convertible note, as host contract, requires significant judgment. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group has used the Cox-Rubinstein binomial tree model when determining the fair value of the conversion right. The primary inputs used in the model include stock price volatility, credit spreads, risk-free interest rate and foreign exchange forward rates. Stock price volatility is based on implied volatility for BioNTech, credit risk is model implied and adjusted for movement in credit spreads for B-rated corporates at each valuation date, the risk-free interest rate is based on currency specific time congruent IBOR and swap rates whereas the foreign exchange forward rates are based on observable market data. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For further disclosures relating to financial instruments, see Note 12.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Leases</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets are measured at the amount equal to the lease liability, adjusted by the amount of any prepaid or accrued lease payments relating to that lease.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant accounting judgments are required for the determination of the appropriate incremental borrowing rate, which is to be used in the calculation of the asset and liability that are recognized in the financial statements regarding the lease contracts.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the carrying amounts of right-of-use assets and the related lease liability, see Note 19.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Taxes</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group is subject to income taxes in more than one tax jurisdictions. Due to the increasing complexity of tax laws and the corresponding uncertainty regarding the legal interpretation by the fiscal authorities, tax calculations are generally subject to an elevated amount of uncertainty. To the extent necessary, possible tax risks are taken into account in form of provisions. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group does not recognize or impairs deferred tax assets when it is unlikely that a corresponding amount of future taxable profit will be available against which the deductible temporary differences, tax loss carry forwards and tax credits can be utilized. Significant management <font style="color:#000000;">judgment </font>is required when determining whether sufficient future taxable profit will be available against which the deductible temporary differences, tax loss carry forwards and tax credits can be utilized. This includes management&#8217;s assessment on the character and amounts of taxable future profits, the periods in which those profits are expected to occur, and the availability of tax planning opportunities. As a matter of policy, convincing evidence supporting the recognition of deferred tax assets is required if an entity has suffered a loss in either the current or the preceding periods.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, based on BioNTech&#8217;s <font style="color:#000000;">product-based business plan, including commercial supply commitments agreed with various governments and health ministries under which BioNTech either directly supplies the COVID-19 vaccine or, if they relate to territories which have been allocated to Pfizer, BioNTech will receive the profit share to which its eligible, it is now considered highly probable that taxable profits for the German tax group will be available </font>against which the tax losses can be utilized. On this basis, BioNTech has determined that a deferred tax asset with respect to the German tax group&#8217;s tax losses carried forward can be recognized. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the other hand, management has determined that deferred tax assets on tax losses carried forward that relate to subsidiaries which have a loss making history cannot be recognized. This includes the assessment that those subsidiaries neither have any taxable temporary difference nor any tax planning opportunities available that could support the recognition of deferred tax assets. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For further disclosures relating to deferred taxes, see Note 8.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfAccountingJudgementsAndEstimatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting judgements and estimates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfAccountingJudgementsAndEstimatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567919291112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Group information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCompositionOfGroupExplanatory', window );">Group information</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Group Information</font></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Information about Subsidiaries</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements of the Group include the following subsidiaries: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">% equity interest</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Country of incorporation</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registered office</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech RNA Pharmaceuticals GmbH</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mainz</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Delivery Technologies GmbH</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Halle</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Diagnostics GmbH</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mainz</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Europe GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(previously BioNTech Small Molecules GmbH)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mainz</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Manufacturing GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(previously BioNTech IVAC GmbH)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mainz</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Manufacturing Marburg GmbH</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marburg</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n/a</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Austria Beteiligungen GmbH</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Austria</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vienna</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Innovative Manufacturing Services GmbH</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Idar-Oberstein</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reSano GmbH (previously reBOOST Management GmbH)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mainz</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JPT Peptide Technologies GmbH</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Berlin</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JPT Peptide Technologies Inc.</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cambridge (previously Acton)</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech USA Holding, LLC</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cambridge (previously New York)</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Research and Development, Inc.</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cambridge (previously New York)</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech US Inc.</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cambridge</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n/a</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Pharmaceuticals Asia Pacific Pte. Ltd</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Singapore</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Singapore</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n/a</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech UK Limited</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Kingdom</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reading</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n/a</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Cell &amp; Gene Therapies GmbH</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mainz</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Real Estate Holding GmbH</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holzkirchen</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Real Estate Verwaltungs GmbH</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holzkirchen</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Real Estate GmbH &amp; Co. KG</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holzkirchen</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Real Estate An der Goldgrube GmbH &amp; Co. KG</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holzkirchen</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n/a</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Real Estate Haus Vier GmbH &amp; Co. KG</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holzkirchen</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n/a</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Real Estate Adam Opel Stra&#223;e GmbH &amp; Co. KG</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holzkirchen</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n/a</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, two entities were acquired: Neon Therapeutics, Inc. (subsequently renamed BioNTech US Inc.) and Novartis Manufacturing GmbH (subsequently renamed BioNTech Manufacturing Marburg GmbH). Additionally, BioNTech UK Limited., BioNTech Pharmaceuticals Asia Pacific Pte. Ltd, BioNTech Real Estate Haus Vier GmbH &amp; Co. KG, BioNTech Real Estate An der Goldgrube GmbH &amp; Co. KG and BioNTech Real Estate Adam Opel Stra&#223;e GmbH &amp; Co. KG were established.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During<font style="color:#000000;"> the year ended December&#160;31, 2019, two entities were founded in the United States: BioNTech USA Holding, LLC, a wholly-owned subsidiary of BioNTech SE, and BioNTech Research and Development, Inc. a wholly-owned subsidiary of BioNTech USA Holding, LLC. Additionally, reSano GmbH (previously reBOOST Management GmbH), was acquired through a share purchase which represents a related party transaction. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Parent Company</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATHOS KG, Holzkirchen, Germany is the sole shareholder of AT Impf GmbH, Munich, Germany and beneficial owner of the following percentage of ordinary shares in BioNTech at the dates as indicated. ATHOS KG via AT Impf GmbH has de facto control over BioNTech based on its substantial shareholding, which enabled it to exercise the majority of voting rights to pass resolutions at BioNTech&#8217;s Annual General Meeting, or AGM. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ownership of ordinary shares in BioNTech (in %)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Country of incorporation</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registered office</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AT Impf GmbH</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Munich</p></td>
<td valign="top" bgcolor="#C5E0B3" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47.37%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50.33%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Entity with significant Influence over the Group</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medine GmbH, Mainz owned the following percentage of ordinary shares in BioNTech at the following dates as indicated: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ownership of ordinary shares in BioNTech (in %)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Country of incorporation</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registered office</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medine GmbH</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mainz</p></td>
<td valign="top" bgcolor="#C5E0B3" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.25%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.38%</p></td>
</tr>
</table>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCompositionOfGroupExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the composition of the group (the parent and all its subsidiaries). [Refer: Subsidiaries [member]; Parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCompositionOfGroupExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567915897592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsAbstract', window );"><strong>Disclosure Of Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsExplanatory', window );">Business Combinations</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5</font></p></td>
<td valign="top">
<p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Business Combinations</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Lipocalyx GmbH</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, BioNTech Delivery Technologies GmbH (previously BioNTech Protein Therapeutics GmbH), or BioNTech Delivery Technologies, a wholly-owned subsidiary of BioNTech&#160;SE, entered into an agreement to acquire all assets, employees and proprietary know-how of Lipocalyx GmbH, or Lipocalyx, and its related parties in exchange for a total cash consideration at an amount of &#8364;6.5&#160;million and additional contingent consideration estimated at the closing date of January 6, 2020 in an amount of &#8364;0.6&#160;million. The employees of Lipocalyx were transferred automatically to BioNTech Delivery Technologies with effect as of the closing date. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="color:#000000;"> Group acquired the assets of Lipocalyx and its related parties to combine the acquired technologies and the related know-how with already existing product candidates of the Group to improve their functionality and performance. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The final fair values of the identifiable net assets of Lipocalyx as at the date of acquisition were:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">recognized on</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">acquisition</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lipocalyx GmbH</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;896</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other intangible assets</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,978</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total identifiable net assets at fair value</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7,088</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;6,516</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration liability</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">572</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total consideration</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7,088</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated statements of operations include the result of Lipocalyx since the acquisition date. From the date of acquisition through December&#160;31, 2020, Lipocalyx contributed &#8364;1.7&#160;million as operating loss to the respective result of the Group. From the date of acquisition through December 31, 2020, Lipocalyx generated &#8364;0.2&#160;million of revenues. Given the timing of closing, the contribution to operating loss and revenues, if the transaction had occurred at the beginning of the reporting period, would not differ materially. Goodwill recognized is primarily attributed to the expected synergies and other benefits from combining the assets and activities of Lipocalyx with those of the Group. The goodwill resulting from the Lipocalyx acquisition during the year ended December 31, 2020 was allocated to the CGU Immunotherapies. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transaction costs of &#8364;17&#160;thousand relating to the acquisition have been expensed and are included in the general and administrative expenses in the consolidated statements of operations and are included in cash flows used in operating activities in the consolidated statements of cash flows.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The purchase <font style="color:#000000;">agreement</font> with Lipocalyx includes the following contingent cash considerations to the previous owners: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.09%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.04%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1.0&#160;million upon successful completion of a Phase 1 clinical trial designed to show and establish a sufficient safety margin justifying further development of the first pharmaceutical product relating to acquired technologies formulated in a manner covered by a valid granted claim in a major country of a patent within the assigned IP rights; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.09%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.04%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1.0&#160;million upon successful completion of the first Phase 2 clinical trial of the first pharmaceutical product relating to acquired technologies formulated in a manner covered by a valid granted claim in a major country of a patent within the assigned IP rights. </p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the <font style="color:#000000;">acquisition</font> date, the fair value of the contingent consideration was &#8364;0.6&#160;million. The contingent consideration is presented in &#8216;non-current financial liabilities&#8217; in the consolidated statements of financial position (see Note 12). </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">BioNTech US Inc. (previously Neon Therapeutics, Inc., or Neon)</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 6, 2020, BioNTech acquired Neon, a biotechnology company developing novel neoantigen-based T-cell therapies, to leverage Neon&#8217;s expertise in the development of neoantigen therapies, with both vaccine and T cell capabilities. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the acquisition date share price, the aggregate value of the merger consideration was &#8364;89.9&#160;million ($97.1&#160;million) financed by <font style="color:#000000;">issuing</font> 1,935,488 American Depositary Shares representing BioNTech&#8217;s ordinary shares as a stock transaction and including a de minimis cash consideration which was paid to settle Neon&#8217;s outstanding stock options. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair values and values in accordance with IFRS 3 of the identifiable net assets of BioNTech US Inc. as at the date of acquisition <font style="color:#000000;">were</font> as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">recognized on</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">acquisition</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech US Inc.</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;29,867</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,617</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,896</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets non-current and current</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,704</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,749</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;52,833</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade payables</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,723</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities non-current and current</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,793</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;19,516</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total identifiable net assets at fair value</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;33,317</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill from the acquisition</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,573</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consideration transferred</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;89,890</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issued, at fair value</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,548</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">342</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total consideration</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;89,890</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The intangible assets comprise two neoantigen targeted therapies, BNT221 (NEO-PTC-01) and BNT222 (NEO-STC-01), which were identified and recorded as in-process R&amp;D. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities relating to temporary differences of the assets acquired in the business combination were recognized at an amount of &#8364;&#160;8.0&#160;million. To the extent of those deferred tax liabilities assumed, deferred tax assets relating to temporary differences and tax loss carryforwards which existed as of the acquisition date were recognized. Since the conditions to offset were fulfilled, the deferred tax assets and liabilities were offset. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated statements of operations include the results of BioNTech US since the acquisition date. From the date of acquisition through December 31, 2020, BioNTech US contributed &#8364;28.5&#160;million operating loss to respective result of the Group. If the transaction had occurred at the beginning of the reporting period, &#8364;59.8&#160;million would have contributed to the operating loss. This amount includes expenses resulting from the merger and should not necessarily be <font style="color:#000000;">considered</font> representative of the future consolidated results of operations or financial condition on a consolidated basis. From the date of acquisition, BioNTech US did not generate any revenue and no revenue would have been generated if the transaction had occurred at the beginning of the reporting period. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill recognized is primarily attributable to the expected synergies and other benefits from combining two organizations with a common culture of pioneering translational science and a shared vision for the future of cancer immunotherapy as described above. The goodwill resulting from the BioNTech US acquisition during the year ended December 31, 2020 was allocated to the CGU Immunotherapies. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transaction costs of &#8364;1.1&#160;million relating to the acquisition have been expensed and are included in the general and administrative expenses in the consolidated statements of operations. In the consolidated statements of cash flows they are included in cash flows used in operating activities. The attributable costs of the issuance of the shares of &#8364;1.3&#160;million were recorded in <font style="color:#000000;">equity</font> as a deduction from the capital reserve and are included in cash flows from financing activities in the consolidated statements of cash flows. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Manufacturing Marburg GmbH (previously Novartis Manufacturing GmbH)</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 31, 2020, BioNTech acquired Novartis Manufacturing GmbH, a manufacturing facility in Marburg. Through the acquisition, BioNTech plans to produce its COVID-19 vaccine for global supply.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair values and values in accordance with IFRS 3 of the identifiable net assets of BioNTech Manufacturing Marburg GmbH, or BioNTech Marburg, as at the date of acquisition <font style="color:#000000;">were</font> as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">recognized on</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">acquisition</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Manufacturing Marburg GmbH</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,828</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,514</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,466</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets non-current and current</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,343</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,319</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;131,470</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions non-current and current</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,127</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade payables</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,105</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities non-current and current</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,383</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;46,615</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total identifiable net assets at fair value</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;84,855</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bargain purchase</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,002)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consideration transferred</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;77,853</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,853</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total consideration</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;77,853</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated statements of operations include the results of BioNTech Marburg since the acquisition date. From the date of acquisition, the transition into a GMP certified manufacturing facility for BioNTech&#8217;s COVID-19 vaccine was initiated rapidly. During this time, no revenues have been recognized and set-up, retooling and prepping expenses led to a &#8364;6.7&#160;million operating loss, which contributed to the respective result of the Group. Projecting the revenue and result of the joint company as if the acquisition had occurred at the beginning of the reporting period is impracticable, since BioNTech intends to use the facility for manufacturing its COVID-19 vaccine<font style="color:#000000;">. Information about revenues and net income generated by BioNTech Marburg before the acquisition were</font> <font style="color:#000000;">considered</font> <font style="color:#000000;">not to be useful as they are not </font>representative of the future consolidated results of operations or financial condition on a consolidated basis. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The contracting parties shared the understanding that the manufacturing facility is well-equipped to make an important contribution in BioNTech&#8217;s effort to develop and manufacture a COVID-19 vaccine. The possibility of acquiring a GMP certified manufacturing facility with well-established biotechnology drug substance and drug product manufacturing equipment as well as an experienced team was a very good opportunity for BioNTech to accelerate its efforts to scale-up the commercial manufacturing capacity for its COVID-19 vaccine production. The fact that the offer to sell and the need to acquire the facility overlapped at a convenient time, the underlying opportunities ultimately resulted in a bargain purchase of &#8364;7.0&#160;million which was recognized in other operating income. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transaction costs of &#8364;1.4&#160;million relating to the acquisition have been expensed and are included in the general and administrative expenses in the consolidated statements of operations and are included in cash flows used in operating activities in the consolidated statements of cash flows.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reconciliation of Goodwill</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amount of goodwill equals the acquisition costs adjusted by currency translation adjustments. The reconciliation of this carrying amount at the beginning and end of the reporting period is presented below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,978</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,469</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency differences</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,750)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;53,697</p></td>
</tr>
</table>
<p style="line-height:5pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Section Disclosures<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IFRS03_g59-63_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567911720280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from Contracts with Customers<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Disclosure Of Revenue From Contracts With Customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory', window );">Revenue from Contracts with Customers</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:7pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6</font></p></td>
<td valign="top">
<p style="margin-top:7pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Revenue from Contracts with Customers</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.1</font></p></td>
<td valign="top">
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disaggregated revenue information</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Set out below is the disaggregation of the Group&#8217;s revenues from contracts with customers:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research &amp; development revenues from collaborations</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;178,849</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;84,428</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;101,837</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Pfizer Inc.</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">121,597</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">14,348</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">7,173</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Genentech Inc.</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">49,195</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">64,026</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">49,536</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Shanghai Fosun Pharmaceutical (Group) Co., Ltd</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">5,074</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2,983</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">6,054</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">45,128</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commercial revenues</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">303,476</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">24,161</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">25,738</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 vaccine revenues</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">270,490</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Sales to collaboration partner*</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">61,460</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Direct product sales to BioNTech customers</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">20,553</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Share of collaboration partner's gross profit</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">188,477</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other sales</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,986</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,161</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,738</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;482,325</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;108,589</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;127,575</p></td>
</tr>
</table>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Represents sales to collaboration partner of products manufactured by BioNTech. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, revenues from contracts with customers mainly increased since revenues were recognized for the first time under two new collaboration agreements, which BioNTech entered into during the year ended December&#160;31, 2020 in order to develop a COVID-19 vaccine, and ultimately led to the recognition of COVID-19 vaccine commercial revenues. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, revenues<font style="color:#000000;"> recognized from two customers, Pfizer (&#8364;371.5&#160;million) and Genentech (&#8364;49.2&#160;million), </font>each account for more than 10% of total revenues. During the year ended December 31, 2019 revenues recognized from one customer, <font style="color:#000000;">Genentech (&#8364;64.0&#160;million), accounted for more than 10% of total revenues. D</font>uring the year ended December 31, 2018<font style="color:#000000;"> </font>revenues recognized from two customers, <font style="color:#000000;">Genentech (&#8364;49.5&#160;million) and Sanofi (&#8364;41.7&#160;million), accounted for more than 10% of total revenue. The geographic region which recognized revenues was mainly Germany (also the Country of BioNTech&#8217;s domicile) and is based upon the location will bills customers. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research &amp; Development Revenues from Collaborations</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of its BNT162 vaccine program against COVID-19, BioNTech collaborates with Pfizer and Fosun Pharma. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue from Pfizer was mainly derived from the collaboration and license agreement to develop a COVID-19 vaccine and, in addition, includes an amount of &#8364;3.5&#160;million revenue derived from the existing Influenza collaboration. During the year ended December&#160;31, 2020, a non-refundable upfront cash payment of &#8364;66.3&#160;million was received. A regulatory milestone payment of &#8364;51.8&#160;million became due, but has not yet been received. Both were fully recognized as revenue during the year ended December&#160;31, 2020. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fosun Pharma is the collaboration partner with whom BioNTech works together on the development of a COVID-19 vaccine in China. Through the collaboration agreement BioNTech is conducting clinical trials in China, using BioNTech&#8217;s proprietary mRNA technology and leveraging Fosun Pharma&#8217;s extensive clinical development, regulatory, and commercial capabilities in the country. Fosun Pharma has paid a non-refundable upfront cash payment of &#8364;0.9 million and development milestones of &#8364;4.2&#160;million that were recognized as revenue during year ended December&#160;31, 2020. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other collaboration programs have been progressed during the year ended December&#160;31, 2020 and revenues of &#8364;52.1<font style="color:#000000;">&#160;</font>million have been derived from deferred upfront payments measured based on the costs incurred under the respective research programs. For certain collaboration programs, the commencement of trials has been delayed, partially due to slowed patient enrollment or other delays as a result of the COVID-19 pandemic. Accordingly, during the year ended December&#160;31, 2020, revenues from collaboration programs with Genentech and from the Influenza collaboration with Pfizer have generally decreased compared to the prior year periods. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenues recorded during the year ended December&#160;31, 2019 mainly included revenues resulting from collaboration and license agreements processed in the research and development phase. The amounts were mainly derived from deferred upfront fees received under the Genentech, Pfizer (Influenza) and Sanofi collaboration. The amounts were recognized as revenue as BioNTech performed under the agreement and measured based on the costs incurred under the respective research programs. Compared to the revenues recognized from collaboration and license agreements during the year ended December 31, 2018, revenues decreased since the revenue recognized in the year ended December&#160;31, 2018 included an amount of &#8364;33.2&#160;million collaboration revenue from the Sanofi collaboration for a reimbursement of 50% of CellScript sublicense costs pursuant to a separate sub-sublicense agreement dated December 22, 2018. This transaction only occurred in the year ended December&#160;31, 2018. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commercial Revenues</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech&#8217;s COVID-19 vaccine has evolved from the BNT162 program and has been authorized or approved for emergency or temporary use or has been granted conditional marketing authorization in over 65 countries worldwide, which resulted in recognition of revenues from the sale of pharmaceutical products for the first time. BioNTech is the marketing authorization holder in the European Union, and holder of emergency use authorizations or equivalent in the United States, United Kingdom, Canada and other countries in advance of a planned application for full marketing authorizations in these countries. BioNTech has marketing and distribution rights in Germany and Turkey. Pfizer has marketing and distribution rights worldwide with the exception of China, Germany, and Turkey. Fosun Pharma has marketing and distribution rights in China. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 vaccine manufacturing process leverages Pfizer&#8217;s and BioNTech&#8217;s manufacturing facilities, consequently responsibilities are shared between BioNTech and Pfizer. Whenever responsibilities in the manufacturing and supply process of the COVID-19 vaccine shift and the COVID-19 vaccine is transferred, it is sold from one partner to the other. During <font style="color:#000000;">the year ended December&#160;31, 2020, BioNTech has recognized &#8364;61.5&#160;million of revenues from selling </font>d<font style="Background-color:#FFFFFF;">rug product batches manufactured by BioNTech to Pfizer&#8217;s manufacturing site for fill and finish</font><font style="color:#000000;">.</font> </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon receiving a conditional marketing authorization, emergency or temporary use authorization, BioNTech and Pfizer started selling the product. The allocation of marketing and distribution rights defines territories in which the collaboration partners act as a principal respectively. For supplying BioNTech&#8217;s territory, Germany, BioNTech acquired COVID-19 vaccine from Pfizer and recognized &#8364;20.6&#160;million of revenues from direct COVID-19 vaccine sales during the year ended December&#160;31, 2020. The share of gross profit that Pfizer as collaboration partner has earned based on these sales is recognized as cost of sales. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on Pfizer&#8217;s COVID-19 vaccine sales in the collaboration partner&#8217;s territory, BioNTech is eligible to receive a share of the respective gross profit which represents a net figure and is recognized as collaboration revenue during the commercial phase. During the year ended December&#160;31, 2020, a gross profit share of &#8364;188.5&#160;million has been recognized. In order to determine our share of collaboration partner&#8217;s gross profits, BioNTech used certain information from the collaboration partner, including revenue from the sale of products, some of which is based on preliminary data shared between the partners and might vary once final data is available. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, &#8364;33.0&#160;million of revenues compared to &#8364;24.2&#160;million of revenues during the year ended December&#160;31, 2019, and &#8364;25.7&#160;million during the year ended December 31, 2018 were recognized from other sales transactions based on sales of diagnostic products, peptides, retroviral vectors for clinical supply, and development and manufacturing services that were sold to third-party customers. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenues from contracts with customers disclosed above were recognized as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Timing of revenue recognition</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Goods and services transferred at a point in time</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;108,840</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;16,955</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;22,828</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Goods and services transferred over time</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">373,485</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,634</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,747</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;482,325</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;108,589</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;127,575</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2019, BioNTech recognized revenue of &#8364;1.1&#160;million under a bill-and-hold transaction for which the customer already had obtained control. The bill-and-hold arrangement is substantive since the request to retain the product in BioNTech&#8217;s facilities until January 2020 was initiated by the customer. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.2</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Contract Balances</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade receivables</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;165,468</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;11,913</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">371,475</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">190,692</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade receivables are non-interest bearing and are generally settled within 20 to 30 days.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract assets are recognized for revenue earned from sales and services based on individual customer contracts of BioNTech Innovative Manufacturing Services GmbH. However, the customers&#8217; advance payments exceeded BioNTech&#8217;s transferred goods and services for which a conditional right to consideration exists. Therefore, only contract liabilities net of contract assets are presented as of December&#160;31, 2020 and December&#160;31, 2019, respectively. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities mainly include upfront fees received from BioNTech&#8217;s major collaboration and license agreements as well as advance payments received for future COVID-19 vaccine sales and other sales. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The contract liabilities from collaboration and commercial supply agreements as <font style="color:#000000;">o</font>f December&#160;31, 2020 comprise &#8364;131.8&#160;million remaining upfront fees from collaboration agreements, <font style="color:#000000;">&#8364;235.8</font>&#160;million of advance payments for future COVID-19 vaccine sales, which had been received during the year ended December&#160;31, 2020 or for which an unconditional right of consideration exists as well as &#8364;3.9&#160;million advance payments received on other sales (as of December&#160;31, 2019: &#8364;187.6&#160;million of remaining upfront fees from collaborations as well as &#8364;3.1&#160;million advance payments received on other sales). </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, the increase from payments received exceeded revenues recognized from contract liabilities recorded at the beginning of the year (during the year ended December&#160;31, 2019: decrease in contract liabilities since recognizing revenues from amounts which had been included in contract liabilities at the beginning of the year exceeded advance payments on other sales received). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Set out below is the amount of revenue recognized <font style="color:#000000;">for the periods </font>indicated:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts included in contract liabilities at the beginning of the year</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;58,895</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;84,112</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;59,583</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.3</font></p></td>
<td valign="top">
<p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Performance Obligations</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The contract liabilities allocated to the remaining performance obligations from collaboration or commercial supply agreements (unsatisfied or partially unsatisfied) as at year-end are as follows: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within one year</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;299,583</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;93,583</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">More than one year</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,892</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,109</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;371,475</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;190,692</p></td>
</tr>
</table>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfRevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfRevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue from contracts with customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Section Presentation<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g105-109_TI<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g110-129_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567913468776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income and Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis Of Income And Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesExplanatory', window );">Income and Expenses</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</font></p></td>
<td valign="top">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Income and Expenses</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.1</font></p></td>
<td valign="top">
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Costs of Sales</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.93%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of sales related to COVID-19 vaccine revenues</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;35,616</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost related to other sales</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,717</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,361</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,690</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;59,333</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;17,361</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;13,690</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, cost of sales mainly increased compared to the year ended December&#160;31, 2019 since costs were <font style="color:#000000;">recognized</font> for the first time with respect to BioNTech&#8217;s COVID-19 vaccine sales and included Pfizer&#8217;s share of gross profits earned by BioNTech in transactions, where BioNTech is the principal. Costs of sales do not include costs relating to production of pre-launch products since those are expensed as research and development expenses in the period incurred. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.2</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Research and Development Expenses</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchased services</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;359,880</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;65,552</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;42,079</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wages, benefits and social security expense</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,298</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,213</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,668</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory supplies</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,792</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,218</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,921</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,192</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,533</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,312</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IT costs</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,118</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,800</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,572</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease and lease related cost</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,725</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,527</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,404</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transport costs</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,135</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,081</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">668</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,889</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,542</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,416</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;645,029</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;226,466</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;143,040</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, r<font style="color:#000000;">esearch and development expenses increased compared to the year ended December&#160;31, 2019 due to an increase in research and development expenses from BioNTech&#8217;s BNT162 program. Research and development expenses include BioNTech&#8217;s share of expenses under the terms of the Pfizer collaboration agreement. Development costs, which are shared, are divided equally between BioNTech and Pfizer. The amount of shared development expenses, which were initially incurred by Pfizer and subsequently charged to BioNTech, were recorded as purchased services classified within research and development and the reimbursement from Pfizer for research and development expenses initially incurred by BioNTech were recorded as a reduction to research and development expenses. The increase was further driven by an increase in expenses for purchased laboratory supplies as well as an increase in headcount leading to higher wages, benefits and social security expenses. In addition, from May 6, 2020, the date of acquisition, the new U.S.-based subsidiary, BioNTech US Inc., contributed &#8364;21.0&#160;million to the research and development expenses of the Group</font>. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2019, research and development costs increased compared to the year ended December&#160;31, 2018 based on an increase in wages, benefits and social security expenses due to an increase in headcount and the full-year reflection of the Employee Stock Ownership Plan (&#8220;ESOP&#8221;) expenses during the year ended December&#160;31, 2019 as well as higher development expenses spent on purchased services and laboratory supplies. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.3</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Sales and Marketing Expenses</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchased services</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;10,929</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;247</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;794</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wages, benefits and social security expense</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,636</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,938</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,728</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,947</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">533</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">519</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;14,512</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,718</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;3,041</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, sales and marketing expenses increased compared to the year ended December&#160;31, 2019 due to an increase in purchased service, which we incurred in connection with progressing the commercial activities of the Group with respect to BioNTech&#8217;s COVID-19 vaccine. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.4</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">General and Administrative Expenses</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wages, benefits and social security expense</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;33,007</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;19,122</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;8,582</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchased services</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,022</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,419</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,177</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IT and office equipment</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,404</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,573</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,774</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,104</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,855</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,284</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance premiums</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,840</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,061</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Job advertisement expenses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,897</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">548</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">861</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease and lease related cost</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,390</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,715</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,012</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research services</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,033</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory supplies</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,191</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">785</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">456</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract staffing</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,108</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">686</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">781</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,053</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,551</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,236</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;94,049</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;45,547</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;26,334</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, general and administrative <font style="color:#000000;">expenses increased compared to the year ended December&#160;31, 2019 due to higher expenses for purchased management consulting and legal services, an increase in headcount leading to higher wages, benefits and social security expenses and higher insurance premiums. In addition, from May 6, 2020, the date of acquisition, the new U.S.-based subsidiary, BioNTech US Inc., contributed &#8364;7.4&#160;million to the general and administrative expenses of the Group, respectively</font>. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2019, <font style="color:#000000;">general and administrative </font>expenses increased compared to the year ended December&#160;31, 2018 based on an increase in headcount and the full-year reflection of the ESOP program expenses during the year ended December&#160;31, 2019 as well as a charge of &#8364;2.6 million in connection with certain withholding tax payments for intellectual property licenses related to prior years that was recorded during the year ended December&#160;31, 2019 but not during the year ended December&#160;31, 2018. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.5</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Other Operating Income</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government grants</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;239,017</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,547</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;4,228</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bargain purchase</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,002</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,520</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,177</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,118</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;250,539</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,724</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;5,396</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, the other income increased compared to the year ended December&#160;31, 2019. The increase mainly results from government grants for which BioNTech became eligible as part of an initiative by the German Federal Ministry of Education (<font style="font-style:italic;">Bundesministerium f&#252;r Bildung und Forschung</font>, or the BMBF) to support its COVID-19 vaccine program, BNT162. The BMBF funding was granted to accelerate BioNTech&#8217;s vaccine development, and to upscale its manufacturing capabilities in Germany. The funding will also compensate further costs that incur since the COVID-19 vaccine continues to be tested in clinical trials, for example to test it against new variants or to approve it for additional groups (pregnant women, individuals less 16 years), and because study participants will continue to be followed for two years to continue evaluating safety and efficacy. The proportion of the grant that related to expenses incurred by BioNTech is recognized as other operating income with an amount of &#8364;238.9 million; the proportion which was received and will compensate BioNTech for future expenses, has been deferred and is presented as government grant in the consolidated statements of financial position with an amount of &#8364;88.0 million. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table illustrates the changes regarding the government grants:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Received during the year</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">330,968</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,547</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,228</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Released to the consolidated statements of operations</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(239,017)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,547)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,228)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;91,951</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,951</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
</table>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.6</font></p></td>
<td valign="top">
<p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Finance Income</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,564</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,781</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,996</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange gains, net</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,341</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,050</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,564</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;4,122</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;8,046</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2019, finance income included &#8364;2.3&#160;million foreign exchange gains. Foreign exchange differences on a cumulative basis, are either shown as finance income or expenses.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.7</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Finance Expense</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of financial instruments</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;3,048</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;326</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;48</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value adjustments of financial instruments measured at fair value</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,289</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange loss, net</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,609</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;62,946</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;326</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;48</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, finance expenses included &#8364;42.6&#160;million foreign exchange losses as well as &#8364;17.3&#160;million in expenses arising from fair value measurement adjustments of the derivative embedded within the convertible note. The increase in foreign exchange losses is mainly due to higher <font style="color:#000000;">balances in</font> U.S. dollar bank accounts<font style="color:#000000;"> and the weakening of the U.S. dollar when compared to the Euro</font>. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Employee Benefits Expense</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wages and salaries</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;160,655</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;98,568</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;54,149</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Social security costs</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,988</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,394</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,231</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pension costs</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">761</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">517</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">324</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;179,404</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;111,479</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;62,704</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The item wages and salaries includes, among other things, expenses for share-based payments.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfIncomeAndExpensesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The detailed information about income and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfIncomeAndExpensesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567910803560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Major Components Of Tax Expense Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income Tax</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Income Tax</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax for the years ended December&#160;31, 2020, December&#160;31, 2019 and December&#160;31, 2018 comprised current income taxes, other taxes and deferred taxes. BioNTech SE is subject to corporate taxes, the solidarity surcharge and trade taxes. The Company&#8217;s corporate tax rate in the reporting year remained unchanged (15.0%) as did the solidarity surcharge (5.5%) whereas the average trade tax rate (15.0%) changed. BioNTech USA Holding, LLC is subject to Federal Corporate Income Tax (21.0%) as well as State Income Tax in various state jurisdictions (average rate of 8.1%). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table illustrates the current and deferred taxes for the periods indicated: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current income taxes</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C5E0B3" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;17</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(296)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;600</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred taxes</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C5E0B3" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(161,034)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other taxes</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Income taxes</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(161,000)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(268)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;600</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table reconciles the expected income taxes to the actual current income taxes and deferred taxes as presented in the table above. The combined income tax rate of 30.79% in the year ended December&#160;31, 2020 (during the years ended December 31, 2019 and 2018: 30.78% and 30.99%, respectively) was applied to loss before taxes to calculate the expected income taxes. This rate consists of above outlined tax rates of BioNTech SE applicable to the Group. The slight decrease of the tax rate results from the Lipocalyx GmbH business combination. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before tax</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(145,802)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(179,440)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(47,662)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected tax benefit (based on BioNTech`s statutory tax rate of 30.79%, 2019: 30.78%, 2018: 30.99%)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,891</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,240</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,776</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Effects</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government grants exempted from taxes</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible expenses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(770)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Add-back for trade tax purposes</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(595)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(110)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-tax effective bargain purchase</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,156</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-recognition of tax effect on share-based payment expenses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,806)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,308)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax-effective equity transaction costs</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,229</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,121</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utilization of tax losses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,165</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-recognition of deferred taxes on tax losses and temporary differences</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,961)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,197)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,634)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition of deferred taxes on tax losses not recognized in prior periods</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,231</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition of deferred taxes on temporary differences not recognized in prior periods</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,241</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effect from lower foreign income tax rate</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,304)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(102)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustment prior year tax</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(326)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">316</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credit</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,059</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other effects</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,821)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Income taxes</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;161,000</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;268</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(600)</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred taxes for the periods indicated relate to the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">January 1,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recognized in P&amp;L*</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recognized in OCI</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(655)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(2,370)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;8,637</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;5,612</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">596</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">329</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">971</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leases</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">512</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,091)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,593)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,543</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(174)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,369</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest-bearing loans and borrowings</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,741)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">195</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,546)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net employee defined benefit liabilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">169</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(63)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">698</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">804</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">187</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">886</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">419</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,492</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other (incl. deferred expenses)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,087</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,336</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,625</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax loss carryforward / tax credit</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,764</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,660</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,280</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">175,704</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred Tax Assets Net (before valuation)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;136,034</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;40,721</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(63)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;34,746</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;211,438</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation Adjustment</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(136,034)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">120,313</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(34,765)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(50,486)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred Tax Assets Net (after valuation)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;161,034</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(63)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(19)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;160,952</p></td>
</tr>
</table>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Includes all changes in deferred taxes related to U.S. tax group other than those acquired in business combination</p></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">January 1,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recognized in P&amp;L</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recognized in OCI</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses </p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(90)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(565)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(655)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">596</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;596</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leases</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">306</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;512</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,441</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,898)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;23,543</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;187</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other (incl. deferred expenses)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,926</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,087</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax loss carryforward / tax credit</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,848</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,916</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;109,764</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred Tax Assets Net (before valuation)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;84,799</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;51,235</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;136,034</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation Adjustment</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(84,799)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(51,235)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(136,034)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred Tax Assets Net (after valuation)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated tax losses of the German tax group, German <font style="color:#000000;">entities</font> <font style="color:#000000;">not within the tax group </font>and U.S. tax group for the periods indicated amount to the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate Tax</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;596,359</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;356,044</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;179,264</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade Tax</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,561</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">352,341</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176,425</p></td>
</tr>
</table>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal Tax Credits</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;756</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State Tax Credits</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
</table></div></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accumulated tax losses related to the German tax group include &#8364;457.9 million of corporate income tax losses and &#8364;450.9&#160;million of trade tax losses. <font style="color:#000000;">Under German law, tax losses do not expire. </font>Deferred tax assets on tax losses had not been capitalized in previous years, as there was not sufficient probability in terms of IAS 12 that there would have been future taxable profits available against which the unused tax losses could have been utilized. <font style="color:#000000;">Following the authorization and approval of the COVID-19 vaccine for emergency or temporary use or having been granted conditional marketing authorization in over 65 countries worldwide, BioNTech re-evaluated previously unrecognized tax losses. Based on BioNTech&#8217;s product-based business plan, including commercial supply commitments agreed with various governments and health ministries under which BioNTech either directly supplies the COVID-19 vaccine or, if they relate to territories which have been allocated to Pfizer, BioNTech will receive the profit share to which it is eligible, it is now considered highly probable that taxable profits for the German tax group will be available against which the tax losses can be utilized. On this basis, BioNTech recognized deferred tax assets and liabilities with a net amount of &#8364;161.0&#160;million for the losses and temporary differences determined for the German tax group as of December&#160;31, 2020. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accumulated tax losses related to German entities not within the tax group include &#8364;1.7 million of corporate income tax losses and &#8364;1.8&#160;million of trade tax losses. With respect to those tax losses, no deferred tax assets have been capitalized, as there is not sufficient probability in terms of IAS 12 that there will be future taxable profits available against which the unused tax losses can be utilized.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accumulated tax losses related to U.S. tax group include &#8364;136.8&#160;million of corporate income tax losses and &#8364;60.9&#160;million of trade tax losses. The tax losses related to the U.S. tax group include &#8364;20.9&#160;million of federal losses that are expected to expire in 2033 and &#8364;115.9&#160;million of federal losses which have no expiration date and can be carried forward indefinitely. In addition, the U.S. tax group has state tax losses of &#8364;60.9&#160;million, which may be available to offset future taxable profit and that expire at various dates beginning in 2033. BioNTech&#8217;s forecast for the U.S. tax group does not provide sufficient probability for the use of existing tax loss carryforwards in the near future. Therefore, the requirements set out by IAS 12 are not fulfilled for the U.S. tax group. As of December&#160;31, 2020, deferred tax assets are only recognized up to the amount of deferred tax liabilities. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to accumulated tax losses, BioNTech had accumulated federal tax credits of &#8364;0.8&#160;million and state tax credits of &#8364;0.3&#160;million in the United States as of December 31, 2020. The tax credits in the United States will expire at various dates beginning in 2035 if they are not used.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567911806152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">Earnings per share</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Earnings per Share</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic earnings per share (EPS) is calculated by <font style="color:#000000;">dividing</font> the profit / (loss) for the year attributable to ordinary equity holders of the parent by the weighted average number of ordinary shares outstanding during the year.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted EPS is calculated by dividing the profit / (loss) attributable to ordinary equity holders of the parent by the weighted average number of ordinary shares outstanding during the year plus the weighted average number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 18, 2019, BioNTech effected a 1:18 share split by issuing 206,595,492 shares by way of a capital increase from its own funds; thus, no outside proceeds were received. This capital increase came into effect upon registration with the commercial register (<font style="font-style:italic;">Handelsregister</font>). The accompanying financial statements and notes to the financial statements including the EPS information below give retroactive effect to the share split for all periods presented.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table reflects the income and share data used in the basic and diluted EPS calculations:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Gain (loss) attributable to ordinary equity holders of the parent for basic earnings</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15,198</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(179,056)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(48,019)</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of ordinary shares for basic EPS</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">235,442</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">211,499</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">190,710</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effects of dilution from share options</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C5E0B3" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,085</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of ordinary shares adjusted for the effect of dilution</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">248,527</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">211,499</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">190,710</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Earnings per share</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">in EUR</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted, profit / (loss) for the period attributable to ordinary equity holders of the parent*</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;0.06</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(0.85)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(0.25)</p></td>
</tr>
</table>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* Numbers of shares for calculating the earnings per share for the years ended December 31, 2019 and December 31, 2018 have been adjusted to reflect capital increase due to 1:18 share split, which occurred on September 18, 2019.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no other transactions involving ordinary shares or potential ordinary shares between the reporting date and the date of authorization of these financial statements. Share options were not included in the calculation of diluted EPS for periods in which they were antidilutive; i.e. for the periods in which a loss was incurred. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567911803128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure Of Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property, Plant and Equipment</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Property, Plant and Equipment</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Land and buildings</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Equipment, tools and installations</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress and advance payments</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Acquisition and production costs</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;22,147</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;73,613</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7,091</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;102,853</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,269</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,700</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,623</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,592</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disposals</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(105)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(115)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency differences</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">999</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">999</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;29,469</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;83,206</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;29,652</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;142,329</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;29,469</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;83,206</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;29,652</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;142,329</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,927</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,093</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,013</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,033</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disposals</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,892)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(958)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,891)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,561</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,832</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,391)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency differences</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(638)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(690)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,400</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,817</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,302</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,519</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;61,264</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;142,418</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;81,618</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;285,300</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Land and buildings</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Equipment, tools and installations</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress and advance payments</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cumulative depreciation and impairment charges</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;6,472</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;30,180</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;36,652</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,854</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,861</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,715</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disposals</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(79)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(79)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency differences</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;8,326</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;40,959</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;49,285</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;8,326</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;40,959</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;49,285</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,074</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,753</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,827</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disposals</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,683)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,724)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency differences</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;10,356</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;47,976</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;58,332</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Land and buildings</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Equipment, tools and installations</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress and advance payments</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Carrying amount</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15,675</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;43,433</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7,091</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;66,200</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;21,143</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;42,247</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;29,652</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;93,044</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;50,908</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;94,442</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;81,618</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;226,968</p></td>
</tr>
</table></div></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891091896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract', window );"><strong>Disclosure Of Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory', window );">Intangible Assets</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Intangible Assets</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concessions, licenses, in-process R&amp;D and similar rights</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Advance payments</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Acquisition costs</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;534</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;101,853</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,497</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;103,883</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,744</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,529</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,273</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disposals</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(133)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(477)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(610)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(146)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency differences</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,444</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,726</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,170</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,978</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;116,313</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,403</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;121,693</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,978</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;116,313</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,403</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;121,693</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,187</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,426</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,613</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disposals</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,435)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(643)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,078)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">233</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(233)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency differences</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,750)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,897)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,647)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,469</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,845</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,314</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;53,697</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;147,246</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;5,953</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;206,895</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concessions, licenses, in-process R&amp;D and similar rights</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Advance payments</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cumulative depreciation and impairment charges</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15,842</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15,842</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,502</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,502</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disposals</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency differences</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;32,260</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;32,260</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;32,260</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;32,260</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,627</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,627</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disposals</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,410)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,410)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency differences</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(72)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(72)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;43,405</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;43,405</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concessions, licenses, in-process R&amp;D and similar rights</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Advance payments</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Carrying amount</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;534</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;86,011</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,497</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;88,042</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,978</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;84,053</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,403</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;89,434</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;53,697</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;103,841</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;5,953</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;163,490</p></td>
</tr>
</table></div></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Goodwill and intangible assets with indefinite useful lives</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For impairment testing, goodwill acquired through business combinations has been allocated to the cash-generating units (CGU) as shown in the following table: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CGU Immunotherapies</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">External Product Sales of JPT</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;53,163</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,444</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;534</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;534</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;53,697</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,978</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group performs its annual goodwill impairment test for the respective year as of October 1. As a result of the change to one reportable segment (Note 2.1), BioNTech evaluated the implications on its determination of CGUs for allocation of goodwill. As a result, two CGUs were identified: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">The Immunotheraopies CGU focuses on the development of therapies to address a range of rare and infectious diseases and includes BioNTech&#8217;s broad pipeline includes mRNA-based immune activators, antigen-targeting T-cells and antibodies, and defined immunomodulators of various immune cell mechanisms. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">The External Products Sales of JPT Peptide Technologies GmbH CGU includes the distribution of innovative peptide-based products to external customers.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">CGU Immunotherapies</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The recoverable amount of the CGU Immunotherapies has been determined based on a value in use calculation using cash flow projections from financial budgets approved by the Management Board covering a fifteen-year period. The projected cash flows have been updated to reflect the near-term effect from<font style="color:#000000;"> BioNTech&#8217;s COVID-19 vaccine. </font>The discount rate applied to cash flow projections is 8.9% and cash flows beyond the forecast period are extrapolated using a 1.0% growth rate that is the same as the long-term average growth rate for the biotech industry. It was concluded that the fair value less costs of disposal did not exceed the value in use. As a result of the analysis, management did not identify an impairment for this CGU.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">CGU External Product Sales of JPT Peptide Technologies GmbH</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The recoverable amount of the CGU External Product Sales of JPT Peptide Technologies GmbH has been determined based on a value in use calculation using cash flow projections from financial budgets approved by senior management covering a ten-year period. The discount rate applied to cash flow projections is 7.9% and cash flows beyond the forecast period are extrapolated using a 1.0% growth rate which is in line with industry standard. It was concluded that the fair value less costs of disposal did not exceed the value in use. As a result of the analysis, management did not identify an impairment for this CGU.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Key assumptions used in value in use calculations and sensitivity to changes in assumptions</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The calculation of value in use for both CGUs, Immunotherapies and External Product Sales of JPT Peptide Technologies GmbH, is most sensitive to the following assumptions:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.14%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Discount rates</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.14%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Growth rates used to extrapolate cash flows beyond the forecast period</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rates &#8722; Discount rates represent the current market assessment of the risks specific to the CGU, taking into consideration the time value of money and individual risks of the underlying assets that have not been incorporated in the cash flow estimates. The discount rate calculation is based on the specific circumstances of the Group and the respective CGU. It is derived from its weighted average cost of capital (WACC). The WACC takes into account both debt and equity. The cost of equity is derived from the expected return on investment by the Group&#8217;s investors. The cost of debt is based on the interest-bearing borrowings the Group is obliged to service. CGU-specific risk is incorporated by applying individual beta factors. The beta factors are evaluated annually based on publicly available market data. Adjustments to the discount rate are made to factor in the specific amount and timing of the future tax flows in order to reflect a pre-tax discount rate.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An increase in the discount rate to 9.4% (i.e., +1.5%point) in the CGU External Product Sales of JPT Peptide Technologies GmbH would result in a goodwill impairment as of October 1, 2020. With respect to the CGU Immunotherapies, no reasonable rise in the discount rate would result in an impairment.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Growth rate estimates &#8722; Rates are based on published industry research. Management recognizes that the speed of technological change and the possibility of new entrants (further market approvals) can have a significant impact on growth rate assumptions. The effect of new entrants is not expected to have an adverse impact on the forecasts, but could yield a reasonably possible alternative to the estimated long-term growth rate of 1.0%.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to both CGUs, no reasonable reduction in the growth rate estimate would result in an impairment. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In general, BioNTech concluded that no reasonable possible change of key assumptions on which the calculation of the recoverable amount is based would cause the carrying amount of the CGU to exceed its recoverable amount.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intangible Assets not yet Available for Use</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets not yet available for use did not exist in the years ended December&#160;31, 2020 and December&#160;31, 2019.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Non-Current assets by Region</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and December&#160;31, 2019, non-current assets comprised &#8364;89.2&#160;million respectively &#8364;3.8&#160;million intangible assets, property, plant and equipment, right-of-use assets and other assets of our subsidiaries incorporated in the United States respectively. The remaining non-current assets relate to subsidiaries incorporated in Germany.&nbsp;&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS38_g118-128_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567944700776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Financial Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure Of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory', window );">Financial Assets and Financial Liabilities</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Financial Assets and Financial Liabilities</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.1</font></p></td>
<td valign="top">
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Capital Risk Management</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech&#8217;s capital management objectives are designed primarily to finance the Group&#8217;s growth strategy.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group&#8217;s controlling committee reviews the total amount of cash of the Group on a weekly basis. As part of this review, the committee considers the total cash and cash equivalents, the cash outflow, currency translation differences and refinancing activities. The Group monitors cash using a burn rate. The cash burn rate is defined as the average monthly net cash flow from operating and investing activities during a financial year.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at banks and on hand</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,210,209</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;519,149</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,210,209</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;519,149</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In meeting its financing objectives, the Group negotiates and enters into research cooperation agreements. In general, the aim is to maximize the financial resources available for further research and development projects.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech is not subject to externally imposed capital requirements. BioNTech&#8217;s capital management objectives were achieved in the reporting year.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No changes were made in the objectives, policies or processes for managing cash during the years ended December&#160;31, 2020 and December&#160;31, 2019. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.2</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Categories of Financial Instruments</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial assets at amortized cost</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Set out below, is an overview of financial assets, other than cash and cash equivalents, held by the Group as of the dates indicated: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="4" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial assets at amortized cost</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade receivables</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;165,468</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;11,913</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other financial assets</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137,234</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,680</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;302,702</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;13,593</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">302,702</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,593</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, other financial assets mainly include advance-payments received by BioNTech&#8217;s collaboration partner on future deliveries and payable to BioNTech. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial liabilities: Financial liabilities at amortized cost (including Interest-bearing loans and borrowings and other financial liabilities)</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Set out below, is an overview of financial liabilities, other financial liabilities and trade payables held by the Group as of the dates indicated: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="4" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Interest-bearing loans and borrowings</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Maturity</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;84,158</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;57,611</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible note - host contract</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">08/28/2024</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,457</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.50% &#8364; 50,000,000 secured bank loan</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/21/2026</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,176</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.15% &#8364; 10,000,000 secured bank loan</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/30/2027</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,032</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,000</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.08% &#8364; 9,450,000 secured bank loan</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/30/2028</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,877</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,600</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.90% &#8364; 3,528,892.48 secured bank loan</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">05/30/2039</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,489</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;240,189</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;74,211</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,142</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,307</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">231,047</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,904</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="4" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other financial liabilities</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Derivatives not designated as hedging instrument</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible note - embedded derivative</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;30,903</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial liabilities at fair value through profit or loss</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">572</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total financial liabilities at fair value</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;31,475</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other financial liabilities at amortized cost, other than interest-bearing loans and borrowings</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade payables</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,288</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,498</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other financial liabilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,076</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,352</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total other financial liabilities at amortized cost, other than interest-bearing loans and borrowings</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;176,364</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;30,850</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total other financial liabilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;207,839</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;30,850</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176,363</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,850</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,476</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="4" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total financial liabilities</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest-bearing loans and borrowings</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;240,189</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;74,211</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other financial liabilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;207,839</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;30,850</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;448,028</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;105,061</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">185,505</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,157</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262,523</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,904</p></td>
</tr>
</table></div></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Interest-Bearing Loans and Borrowings</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2.15% and 2.08% Secured Bank Loan</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech maintains two secured loans with Deutsche Bank AG, or Deutsche Bank, to finance the buildouts of the JPT Peptide Technologies GmbH facility and BioNTech Innovative Manufacturing Services GmbH facility. The &#8364;10.0&#160;million secured credit facility, entered into with Deutsche Bank by the subsidiary BioNTech Innovative Manufacturing Services GmbH, bears interest at a rate of 2.15% and matures on December 30, 2027. The loan is repayable in equal quarterly installments of &#8364;0.3&#160;million commencing on June 30, 2020. As of December 31, 2020, the full amount under this facility is drawn down and the first three scheduled repayments have occurred. The &#8364;9.45&#160;million secured credit facility, entered into with Deutsche Bank by the subsidiary JPT Peptide Technologies GmbH, bears interest at a rate of 2.08% and matures on September 30, 2028. The loan is repayable by quarterly installments of &#8364;0.3&#160;million commencing on September 30, 2020. As of December 31, 2020, the full amount under this facility is drawn down and the first two scheduled repayments have occurred. Each of these facilities is secured by liens over property. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">EIB Manufacturing Financing &#8211; 3.50% Secured Bank Loan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2020, BioNTech entered into an agreement with the EIB for a &#8364;100.0&#160;million credit facility to partially support the development of BNT162 and fund expansion of the manufacturing capacity to provide worldwide supply of BNT162 in response to the COVID-19 pandemic. The credit consists of (i) a term loan in the amount of &#8364;50 million that may be drawn in a single tranche upon the achievement of certain milestone events (Credit A), and (ii) a term loan in the amount of &#8364;50.0&#160;million that may be drawn in a single tranche (Credit B). Credit B may only be drawn down after Credit A has been drawn down and upon the achievement of certain milestone events. The financing arrangement is to be secured by way of liens over certain of our property. On December 21, 2020, &#8364;50.0&#160;million from Credit A was drawn down. Interest is payable on the outstanding balance of Credit A at the cash interest fixed rate of 1% per annum quarterly in arrears, plus deferred interest at fixed rate of 2.5% per annum. The nominal amount must be repaid on December 21, 2026. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">June 2020 Private Placement &#8211; Convertible Note</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A fund associated with Temasek Capital Management Pte. Ltd., or Temasek, and another accredited investor, contributed a private investment which closed as of August 28, 2020 following the satisfaction of customary closing conditions. The private placement includes an investment in ordinary shares (see Note 16) and a &#8364;100.0&#160;million investment in a 4-year mandatory convertible note with a coupon of 4.5% per annum and a conversion premium of 20% above its reference price. As of closing, the convertible note has been classified as a financial liability according to IAS 32 because the conversion features of the note lead to a conversion into a variable number of shares and is measured at amortized costs since the fair value option was not applied. On initial recognition, the financial liability was measured at the present value of the contractually determined future cash flows discounted at the effective interest rate of 9.0%. The financial liability is subsequently measured at amortized cost by using the effective interest rate method until extinguished upon conversion. The conversion features provided for in the contract were identified as a combined embedded derivative since they share the same risk exposure and are interdependent. The embedded derivative was bifurcated from the convertible note, as host contract, and is recognized as a separate financial instrument. Based on the classification as derivative, the instrument is measured at fair value through profit and loss until it is extinguished upon conversion. The fair value of the embedded derivative is determined by modeling the stock price movement using the Cox-Rubinstein binomial tree model to derive the value of the conversion right. The primary inputs used in the model include stock price volatility, credit spreads, risk-free interest rate and foreign exchange forward rates. Stock price volatility is based on implied volatility for BioNTech, credit risk is model implied and adjusted for movement in credit spreads for B-rated corporates at each valuation date, the risk-free interest rate is based on currency specific time congruent IBOR and swap rates whereas the foreign exchange forward rates are based on observable market data.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other Financial Liabilities at Amortized Cost</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other financial liabilities at amortized cost mainly include provision for outstanding services and obligations derived from license agreements as well as CRO and CMO contracts. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.3</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fair Values</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair values of cash and cash equivalents, trade receivables, trade payables and other current financial assets and liabilities approximate their carrying amounts as of December&#160;31, 2020, largely due to the short-term maturities of these instruments.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The liabilities measured at amortized cost include four fixed-interest rate loans as well as a recently issued convertible note. As of December&#160;31, 2020, the carrying value approximates their fair values as there have been no significant changes in relevant interest rates since the inception of the respective loans and note. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair values of financial instruments measured at fair value are reassessed on a quarterly basis. The valuation technique used for measuring the fair value of the embedded derivative is based on significant observable inputs (Level 2).</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, the fair value adjustment derived from remeasuring the embedded derivative was recognized as finance expenses in profit or loss and amounted to &#8364;17.3&#160;million. The initial fair value of the contingent consideration determined at acquisition remains valid since no changes of the underlying performance criteria have occurred.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.4</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Instruments Risk Management Objectives and Policies</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group&#8217;s financial liabilities comprise of bank loans, lease liabilities, trade and other payables as well as the recently issued convertible note. The main purpose of these financial liabilities is to enable the Group&#8217;s operations. The Group&#8217;s principal financial assets include mainly cash and trade receivables that derive directly from its operations.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group is exposed to market risk, credit risk and liquidity risk. The Group&#8217;s Management Board oversees the management of these risks. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The controlling committee provides assurance to the Group&#8217;s Management Board that the Group&#8217;s financial risk activities are governed by appropriate policies and procedures and that financial risks are identified, measured and managed in accordance with the Group&#8217;s policies and risk objectives. The Management Board reviews and agrees policies for managing each of these risks, which are summarized below.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.5</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Market Risk</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate due to changes in market prices. Market risk comprises of three types of risk: interest risk, foreign currency risk and other price risk. Financial instruments affected by market risk include cash and cash equivalents. Interest risk as well as other price risk are not considered as risks for the Group.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The sensitivity analysis in the following sections relate to the position as of December&#160;31, 2020 and December&#160;31, 2019.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no material changes in the Group&#8217;s market risk exposures or changes in the way risk was managed and valued during the periods.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Foreign Currency Risk</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The Group&#8217;s exposure to the risk of changes in foreign currency rates relates primarily to the Group&#8217;s operating activities (when revenue or expense is denominated in a foreign currency).</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to reduce exchange rate risk, BioNTech makes every effort to generate expenses and income in the same functional currency. The Group does not hedge exchange rate risks.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amount of the monetary assets (the Group&#8217;s cash and cash equivalents) of BioNTech denominated in foreign currencies at the dates indicated are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.82%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.82%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. dollar Bank accounts</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;673,545</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;213,913</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other financial assets in U.S. dollar</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,573</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.82%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial liabilities in U.S. dollar</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,821</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;686,297</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;213,913</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables demonstrate the sensitivity to a reasonably possible change in U.S. dollar exchange rates, with all other variables held constant. The impact on the Group&#8217;s profit before tax is due to changes in the fair value of monetary assets. The Group&#8217;s exposure to foreign currency changes for all other currencies is not material.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">1 &#8364; =</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Closing rate</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average rate</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Currency</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Country</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. dollar</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2271</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1234</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1422</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1195</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change in U.S. dollar rate</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Effect on loss before tax</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Effect on pre-tax equity</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+5 %</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(32,491)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(32,681)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-5%</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;35,911</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;36,121</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-right:solid 1pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-left:solid 1pt #70AD47; border-right:solid 1pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+5 %</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-left:solid 1pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-right:solid 1pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(10,186)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-left:solid 1pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(10,186)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-5%</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;11,259</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;11,259</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.6</font></p></td>
<td valign="top">
<p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Credit Risk Management</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Credit risk is the risk that a counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The Group is exposed to credit risk from its operating activities, including deposits with banks and financial institutions, foreign exchange transactions and trade accounts receivable.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Trade Receivables and Contract Assets</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group&#8217;s exposure to credit risk of trade receivables and contract assets is primarily on transactions with corporate customers in the biopharma/biotech industry that operate in Germany or in the United States as well as <font style="color:#231F20;">governments</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font>which are BioNTech&#8217;s customers established in connection with progressing the commercial activities of the Group with respect to BioNTech&#8217;s COVID-19 vaccine. An analysis of the aging of receivables and the creditworthiness of customers is used to evaluate this risk at each reporting date. The Group follows risk control procedures to assess the credit quality of the customers taking into account their financial position, past experience and other factors. The compliance with credit limits by corporate customers is regularly monitored by BioNTech.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the outstanding trade receivables were mainly due from BioNTech&#8217;s collaboration partner Pfizer as well as the German government. To a smaller extent, BioNTech&#8217;s other customers are medical universities, other public institutions and peers in the biopharma industry, which all have a very high credit rating. Due to this customer portfolio, the credit risk on trade receivables and contract assets is very low. BioNTech has not incurred bad debt expense and does not expect that this will change with respect to the trade receivables recognized as of December 31, 2020. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally, trade receivables are written off if past due for more than one year and are not subject to enforcement activity. The maximum exposure to credit risk at the reporting date is the carrying value of each class of financial assets disclosed in Note 12.2. The expected credit risk on trade accounts receivables and other financial assets was estimated to be not material as of December 31, 2020 as well as December 31, 2019. The Group does not hold collateral as security. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Credit risk from balances with banks and financial institutions is managed by the Group&#8217;s controlling department in accordance with the Group&#8217;s policy. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Credit risk stemming from cash and cash equivalents is very low due to its demand feature and the high credit rating of the respective banks.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group&#8217;s maximum exposure to credit risk for the components of the consolidated statements of financial position as of December&#160;31, 2020 and December&#160;31, 2019 are the carrying amounts as illustrated in Note 12.1.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.7</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Liquidity Risk</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally, BioNTech has relied on the financing from shareholders and collaborators in order to ensure sufficient liquidity. Lack of external financial support could pose a risk of going concern. The liquidity management of BioNTech ensures the availability of cash and cash equivalents for operational activities and further investments through appropriate budget planning. In addition, a sufficient level of cash and cash equivalents, which is managed centrally, is always maintained to finance the operational activities.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group monitors liquidity risks using a liquidity planning tool.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ultimately, the responsibility for liquidity risk management lies with the Management Board, which has established an appropriate approach to managing short-, medium- and long-term financing and liquidity requirements. BioNTech manages liquidity risks by holding appropriate reserves, as well as by monitoring forecasted and actual cash flows and reconciling the maturity profiles of financial assets and liabilities.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risk Concentration</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentrations arise when a number of counterparties are engaged in similar business activities, or activities in the same geographical region, or have economic features that would cause their ability to meet contractual obligations to be affected similarly by changes in economic, political or other conditions. Concentrations indicate the relative sensitivity of the Group&#8217;s performance to developments affecting a particular industry.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to avoid concentrations of risk, the Group&#8217;s policies and procedures include specific guidelines to focus on the maintenance of an effective diversification in the sources of funding and distribution of cash deposits. Identified concentrations of credit risks are controlled and managed accordingly.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturity profile of the Group&#8217;s financial liabilities based on contractual undiscounted payments is summarized as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2020</p></td>
<td colspan="4" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Less than 1 year</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1 to 5 years</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">More than 5 years</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest bearing loans and borrowings</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;3,173</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;12,643</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;66,730</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;82,546</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade and other payables</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,288</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;102,288</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,525</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,283</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,780</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;107,588</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">572</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;572</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other financial liabilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,076</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;74,076</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;188,062</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;39,926</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;139,082</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;367,070</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The mandatory convertible note, which was issued during the year ended December&#160;31, 2020 and which is expected to be settled in equity is excluded from the table above. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.8</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Changes in Liabilities arising from Financing Activities</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">January 1,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">New leases and disposals</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reclassification</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current obligations under lease contracts</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;3,485</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(12,743)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,719</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;8,684</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;3,982</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;6,127</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current obligations under lease contracts</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,126</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,331</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,444)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,982)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">78,031</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest-bearing loans and borrowings</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,600</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140,847</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,416)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">156,031</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible note - embedded derivative</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,614</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,289</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">30,903</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;74,211</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;141,718</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;35,050</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;4,240</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15,873</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;271,092</p></td>
</tr>
</table>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">January 1,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">New leases and disposals</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reclassification</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current obligations under lease contracts</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,134</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(3,061)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,484</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,928</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;3,485</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current obligations under lease contracts</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,618</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,436</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,928)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">54,126</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest-bearing loans and borrowings</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,600</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,000</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16,600</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;56,352</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7,939</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;9,920</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;74,211</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the offsetting of financial assets and financial liabilities. [Refer: Financial assets; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Section Offsetting financial assets and financial liabilities<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g13A-13F_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891948248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Classes Of Inventories [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInventoriesExplanatory', window );">Inventories</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">13</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Inventories</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials and supplies</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;44,283</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;8,201</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unfinished goods</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,380</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,888</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">457</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">633</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;64,120</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;11,722</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech has not pledged any inventories as securities for liabilities.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS02_g36-39_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567974765432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MiscellaneousCurrentAssetsAbstract', window );"><strong>Miscellaneous Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory', window );">Other Assets</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">14</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Other Assets</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepayments on inventories</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,845</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">351</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepayments related to CRO and CMO contracts</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,140</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales tax receivable</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,155</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,536</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepayments related to service contracts</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,825</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,046</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,182</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;62,011</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;9,069</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,966</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,069</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,045</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
</table>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other current assets. [Refer: Other current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567919538936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfDeferredExpensesAbstract', window );"><strong>Disclosure Of Deferred Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfDeferredExpensesExplanatory', window );">Deferred Expenses</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Deferred Expenses</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred expenses from insurance contracts</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;13,845</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,758</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred expenses from CRO and CMO contracts</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,725</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,431</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,104</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;28,001</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;5,862</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,001</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,862</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
</table>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfDeferredExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of deferred expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfDeferredExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfDeferredExpensesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of deferred expenses explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfDeferredExpensesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567913496808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Issued Capital and Reserves<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Disclosure Of Classes Of Share Capital [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Issued Capital and Reserves</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16</font></p></td>
<td valign="top">
<p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Issued Capital and Reserves</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 18, 2019, BioNTech effected a 1:18 share split by issuing 206,595,492 shares by way of a capital increase from its own funds; thus, no outside proceeds were received. This capital increase came into effect upon registration with the commercial register (<font style="font-style:italic;">Handelsregister</font>). The accompanying consolidated financial statements and notes to the consolidated financial statements give retroactive effect to the share split for all periods presented. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Capital transactions during the year ended December&#160;31, 2020</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, the issued share capital of BioNTech increased by &#8364;14.0&#160;million. Each share has a nominal value of &#8364;1.00. As a result of the financing transactions, treasury shares decreased by &#8364;0.7&#160;million and capital reserve increased by &#8364;861.0&#160;million. Costs of &#8364;33.2&#160;million related to these equity transactions were recorded in equity as deduction from the capital reserve. The financing transactions that occurred during year ended December&#160;31, 2020 were as follows: </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Shanghai Fosun Pharmaceuticals (Group) Co., Ltd</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the BNT162 program, BioNTech entered a strategic alliance with Fosun Pharma to develop COVID-19 vaccine candidates in China. Fosun Pharma agreed to make an equity investment of &#8364;45.6&#160;million ($50.0&#160;million) for 1,580,777 ordinary shares in BioNTech via Fosun Industrial Co., Limited, Hong Kong. The increase in share capital with a nominal amount of &#8364;1.6&#160;million was subject to execution of share subscription documentation and approval from regulatory authorities in China and became effective with the registration with the commercial register (<font style="font-style:italic;">Handelsregister</font>) on April 23, 2020. As a result of the transaction the capital reserve increased by &#8364;44.0&#160;million.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Pfizer Inc., New York, New York, United States</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the collaboration between BioNTech and Pfizer, for the co-development of BNT162, Pfizer agreed to make an equity investment of &#8364;103.9&#160;million ($113.0&#160;million). The issuance of 2,377,446&#160;ordinary shares with the nominal amount of &#8364;&#160;2.4&#160;million was registered with the commercial register (<font style="font-style:italic;">Handelsregister</font>) on May 5, 2020. As a result of the transaction the capital reserve increased by &#8364;101.5&#160;million. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Neon Therapeutics, Inc., Cambridge, Massachusetts, United States</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech acquired Neon by issuing 1,935,488 ADS representing BioNTech&#8217;s ordinary shares with the nominal amount of &#8364;&#160;1.9&#160;million to former stockholders of Neon in the Merger. The capital increase was registered with the commercial register (<font style="font-style:italic;">Handelsregister</font>) on May 8, 2020. As a result of the transaction the capital reserve increased by &#8364;87.6&#160;million. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Global Offering</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 27, 2020 BioNTech increased its share capital by &#8364;5.5&#160;million ($6.4&#160;million) in conjunction with the underwritten offering of 5,500,000 ADS each representing one of BioNTech&#8217;s ordinary shares at a public offering price of $93.00 per ADS (&#8220;Underwritten Offering&#8221;). On August 27, 2020, following the Underwritten Offering, BioNTech increased its share capital by additional &#8364;16&#160;thousand ($19&#160;thousand) in conjunction with the rights offering of 16,124 ADS each representing one of BioNTech&#8217;s ordinary shares at a public offering price of $93.00 per ADS (&#8220;Rights Offering&#8221;). The Underwritten Offering and the Rights Offering are part of a single, global offering which BioNTech refers to as the Global Offering. The gross proceeds of the Global Offering were &#8364;436.3&#160;million ($513.0&#160;million) including &#8364;5.5&#160;million increase in share capital and &#8364;430.8&#160;million increase in capital reserve. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">June 2020 Private Placement &#8211; Equity Investment</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A fund associated with Temasek Capital Management Pte. Ltd., or Temasek, and another accredited investor, contributed a private investment. The private placement includes an investment in a 4-year mandatory convertible note (see Note 12) and an investment of &#8364;123.9&#160;million in ordinary shares. The issuance of 2,595,996&#160;ordinary shares with the nominal amount of &#8364;&#160;2.6&#160;million was registered with the commercial register (<font style="font-style:italic;">Handelsregister</font>) on September 8, 2020. As result of the transaction the capital reserve increased by &#8364;121.3&#160;million.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">At-The-Market Offering Program</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, <font style="color:#000000;">BioNTech </font>entered into a sales agreement (&#8220;Sales Agreement&#8221;) with Jefferies LLC and SVB Leerink LLC, as sales agents, to establish an at-the-market offering program, pursuant to which BioNTech may sell, from time to time, ADS representing ordinary shares for aggregate gross proceeds of up to $500.0&#160;million. During the year ended December&#160;31, 2020, BioNTech sold 735,490 ADSs, each representing one of its ordinary shares that had previously been held in treasury, under the Sales Agreement for aggregate gross proceeds of &#8364;76.5&#160;million ($92.9&#160;million). Re-issuing 735,490 ordinary shares was registered as decrease of &#8364;0.7&#160;million in treasury shares. As a result of the transaction the capital reserve increased by &#8364;75.8&#160;million. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Capital transactions during the year ended December&#160;31, 2019</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2019, the issued share capital of BioNTech increased by &#8364;39.0&#160;million. Each share has a nominal value of &#8364;1.00. As a result of the financing transactions the capital reserve increased by &#8364;359.2&#160;million. Costs of &#8364;16.6&#160;million related to these equity transactions were recorded in equity as deduction from the capital reserve. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2019, BioNTech issued 5,088,204 shares and increased its share capital by &#8364;5.1&#160;million. The cash investment of &#8364;80.0&#160;million was received in 2018. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 14, 2019, BioNTech acquired the remaining 5.5% of non-controlling interests in BioNTech Cell &amp; Gene Therapies GmbH previously held by Eli Lilly Nederland B.V. in exchange for issuing 2,374,794 new ordinary shares with an imputed nominal value of &#8364;1.00 each. This acquisition was recognized within equity and resulted in the derecognition of the non-controlling interest of &#8364;0.7&#160;million as well as an increase in share capital of &#8364;2.4&#160;million. The net effect of the transaction of &#8364;1.6&#160;million was recognized as a decrease in capital reserve. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the share capital issued in 2019, &#8364;12.5&#160;million related to a new financing round (referred to as the Series B round). As part of the Series B round, 12,465,288 ordinary shares (excluding 5,524,506 ordinary shares which were issued to a Hong Kong-based investor and subsequently transferred to BioNTech for no consideration; these shares are held as treasury shares) were issued to certain new and existing shareholders. As a result of the Series B round, the capital reserve increased by &#8364;186.1&#160;million.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 30, 2019, BioNTech entered into agreements with the Bill &amp; Melinda Gates Foundation under which BioNTech is required to perform certain research and development activities. The issuance of 3,038,674 ordinary shares with the nominal amount of &#8364;3.0&#160;million was registered with the commercial register (<font style="font-style:italic;">Handelsregister</font>) on September 26, 2019. As result of the transaction the capital reserve increased by &#8364;46.8&#160;million. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 10, 2019, BioNTech increased its share capital by &#8364;10.0&#160;million in conjunction with the Initial Public Offering. American Depositary Shares which represent ordinary shares were offered on the Nasdaq Global Select Market at a price of $15.00. On November 6, 2019, BioNTech increased its share capital by &#8364;0.5&#160;million upon the execution of the underwriter&#180;s option. American Depositary Shares which represent ordinary shares were issued at a price of $15.00 (under both issuances). The gross proceeds were &#8364;143.3&#160;million ($157.8&#160;million) including &#8364;10.5&#160;million increase in share capital and &#8364;132.7&#160;million increase in capital reserve. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567919034536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share-based payments</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">17</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Share-Based Payments</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2020, December&#160;31, 2019 and December&#160;31, 2018, the Group had the following share-based arrangements. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">17.1</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">BioNTech Employee Equity Plan (LTI and LTI-plus Program) (Equity-Settled)</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, BioNTech adopted the BioNTech Employee 2020 Equity Plan and the BioNTech 2020 Restricted Stock Unit Plan for North America Employees. Under the plans Restricted Cash Units, or RSUs, will be offered to employees based in Europe and the United States respectively. The plan to which employees based in Europe will be eligible, was communicated in December 2020. Since those employees obtained a valid expectation of the award as of the announcement date and started rendering services as of such date, BioNTech concluded that the service commencement date for the BioNTech Employee 2020 Equity Plan was December 17, 2020. This is the date as of which BioNTech started to recognize the expenses related to the services received. Since the BioNTech 2020 Restricted Stock Unit Plan for North America Employees had not been communicated in detail to employees based in the United States during the year ended December 31, 2020, no expenses have been recognized in the Consolidated Statements of Operations for the year ended December 31, 2020. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">BioNTech Employee 2020 Equity Plan for employees based in Europe</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Description of Share-Based Payments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The BioNTech Employee 2020 Equity Plan share-based payment transaction for employees based in Europe includes two programs, LTI and LTI-plus. The LTI program will be offered to all employees. The LTI-plus program intends to compensate employees who did not participate in the ESOP. Under both programs, RSUs will be offered to employees based in Europe. Both programs are classified as equity-settled because BioNTech has the ability to determine the method of settlement. The LTI will vest annually in equal installments after four years commencing on December 15, 2020. The LTI-plus will vest annually in equal installments after two years commencing on December 15, 2020. Moreover, the LTI-plus contains a non-vesting condition concerning 50% of the granted RSUs. These units will be awarded to the participant after the FDA fully approves BNT162b2. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Measurement of Fair Values</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech estimates the grant date fair value of the awards for services received in advance of grant date based upon the share-price at the reporting date. The estimate is revised at subsequent reporting periods until the date of grant has been established (refer to Note 22). An estimate for the number of equity instruments for which service conditions are expected to be satisfied is calculated considering a retention assumption and will be revised in case material differences arise. Ultimately, a true-up to the number satisfied until Settlement Date will be recorded. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reconciliation of Outstanding Share-Options</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Restricted Stock Units (expected to be allocated)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share price (in &#8364;)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected to be allocated under LTI Program</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">252,766</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66.43</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected to be allocated under LTI-plus Program</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">396,938</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66.43</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">649,704</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">66.43</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Expense recognized in the Consolidated Statements of Operations</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of sales</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;179</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">681</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,015</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">17.</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Management Board Grant (Cash-Settled)</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the beginning of 2020, the first year following the completion of BioNTech&#8217;s initial public offering (&#8220;IPO&#8221;), the current service agreements with BioNTech&#8217;s Management Board have provided for a short-term incentive compensation of up to a maximum of fifty percent of the annual base salary for the years 2020, 2021 and 2022. The amount of such short-term incentive compensation will depend on the achievement of certain company goals in the particular fiscal year, which goals will be set uniformly for all members of the Management Board. Fifty percent of the incentive compensation will be paid promptly upon achievement of the applicable company goals (first installment), with the remaining amount payable one year later, subject to adjustment relative to the performance of the price of the American Depositary Shares representing BioNTech&#8217;s ordinary shares during that year (second installment).</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each of the three yearly awards, the second installment of the short-term incentive compensation that is dependent on the price of the American Depositary Shares representing BioNTech&#8217;s ordinary shares, represents a cash-settled share-based payment arrangement. The fair values of the liabilities are recognized over the award&#8217;s vesting period beginning as of the service commencement date (January 1, 2020) until each separate determination date and are remeasured until settlement date. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, the Group recognized share-based payment expenses of &#8364;0.3&#160;million as research and development expenses and of &#8364;0.4&#160;million as general and administrative expenses in the consolidated statements of operations and &#8364;0.7&#160;million of other financial liabilities in the statements of financial position as of December 31, 2020.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">17.3</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Management Board Grant (Equity-Settled)</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Description of Share-Based Payments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From the beginning of 2020, the first year following the completion of BioNTech&#8217;s IPO, until the end of the term of the Management Board member&#8217;s employment agreement, the service agreements with BioNTech&#8217;s Management Board provide for a long-term incentive compensation in terms of a yearly grant of options to purchase BioNTech shares. The right to receive options in 2020, 2021 and 2022 represents an equity-settled share-based payment arrangement. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The options allocated each year will be subject to the terms, conditions, definitions and provisions of the ESOP and the applicable option agreement thereunder. The number of options to be allocated each year to Prof. Ugur Sahin, Sean Marett, Dr. Sierk Poetting, Dr. &#214;zlem T&#252;reci and Ryan Richardson is to be calculated based on a value of &#8364;750,000, &#8364;300,000, &#8364;300,000, &#8364;300,000 and &#8364;260,000, respectively, in each case divided by the amount by which a certain target share price exceeds the exercise price. The value used to calculate the number of options for Ryan Richardson increases to &#8364;280,000 for the year 2022.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The allocation of the number of issued options in 2020 occurred as of February 13, 2020 (allocation date). As of December 31, 2020, the assessment about options expected to be granted in 2021 and 2022 was based on estimated allocation dates in the middle of the years 2021 and 2022, respectively. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The share options allocated and expected to be allocated to BioNTech&#8217;s Management Board as of the dates indicated are presented in the tables below. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share options (expected to be allocated)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average exercise price (&#8364;)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted as of allocation date February 13, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">248,096</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.32</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected to be allocated as of estimated allocation date 2021</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,422</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.26*</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected to be allocated as of estimated allocation date 2022</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,463</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.27*</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">451,981</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">45.89</p></td>
</tr>
</table>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Valuation parameter derived from the Monte-Carlo simulation model</p></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the awards with estimated allocation dates the numbers of options expected to be allocated have been derived from the Monte-Carlo simulation model. Those will be adjusted until the actual allocation has occurred and the number of options granted has ultimately been determined. The options will vest annually in equal installments over four years commencing on the first anniversary of the allocation date and will be exercisable four years after the allocation date.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The options will be subject to the terms, conditions, definitions and provisions of the ESOP and the applicable option agreement thereunder. The vested options can only be exercised if and to the extent that each of the following performance criteria has been achieved: (i) at the time of exercise, the current price is equal to or greater than the threshold amount (that is, the exercise price, provided that such amount increases by seven percentage points on each anniversary of the allocation date); (ii) at the time of exercise, the current price is at least equal to the target price (that is, (a) for the twelve-month period starting on the fourth anniversary of the allocation date, $8.5 billion divided by the total number of the ordinary shares outstanding immediately following the initial public offering (other than ordinary shares owned by BioNTech), and (b) for each twelve-month period starting on the fifth or subsequent anniversary of the allocation date, 107% of the target share price applicable for the prior twelve-month period); and (iii) the closing price for the fifth trading day prior to the start of the relevant exercise window is higher than the exercise price by at least the same percentage by which the Nasdaq Biotechnology Index or a comparable successor index as of such time is higher than such index was as of the last trading day before the allocation date. The options expire ten years after the allocation date. If they have not been exercised by that date, they will lapse without compensation.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Measurement of Fair Values</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Monte-Carlo simulation model has been used to measure the fair values at the (estimated) allocation dates of the Management Board Grant. This model incorporates the impact of the performance criteria regarding share price and index development described above. The parameters used for measuring the fair values as of the respective (estimated) allocation dates were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Allocation date February 13, 2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated allocation date&nbsp;&nbsp;2021</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated allocation date 2022</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average fair value*</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;10.83</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;26.85</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;26.61</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average share price</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;28.20</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 66.43*</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 66.43*</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;28.32</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 67.26*</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 67.27*</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility (%)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36.6%</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.0%</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40.7%</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (years)*</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.75</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.01</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.05</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate (%)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.61 %</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.88%</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.88%</p></td>
</tr>
</table>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Valuation parameter derived from the Monte-Carlo simulation model</p></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The exercise of the option rights in accordance with the terms of the ESOP gives the Management Board members the right to obtain shares against payment of the exercise price. The per share exercise price of the options is the Euro equivalent of the arithmetic mean of the closing prices of the ten last trading days prior to the allocation date. For the award allocated as of February 13, 2020, the exercise price has been determined to be $30.78 (&#8364;28.32). For the awards with estimated allocation dates <font style="color:#231F20;">the exercise prices </font>of <font style="color:#231F20;">options </font>expected to be allocated have been derived from the Monte-Carlo simulation model.<font style="color:#231F20;"> Those will be adjusted until the actual allocation has occurred and the exercise price has ultimately been determined.</font> Expected volatility was based on an evaluation of the historical volatilities of comparable companies over the historical period commensurate with the expected option term. The expected term was based on general optionholder behavior for employee options. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reconciliation of Outstanding Share-Options</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The share options allocated and expected to be allocated under the Management Board Grant were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Allocation date February 13, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share options</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">outstanding</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average exercise price (&#8364;)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prof. Ugur Sahin, M.D.</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,420</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.32</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sean Marett</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,968</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.32</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Sierk Poetting</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,968</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.32</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. &#214;zlem T&#252;reci, M.D.</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,968</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.32</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ryan Richardson</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,772</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.32</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated allocation date 2021</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share options</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">outstanding (expected to be allocated)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average exercise price (&#8364;)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prof. Ugur Sahin, M.D.</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,826</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.26*</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sean Marett</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,930</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.26*</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Sierk Poetting</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,930</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.26*</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. &#214;zlem T&#252;reci, M.D.</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,930</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.26*</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ryan Richardson</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,806</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.26*</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Valuation parameter derived from the Monte-Carlo simulation model</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated allocation date 2022</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share options</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">outstanding (expected to be allocated)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average exercise price (&#8364;)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prof. Ugur Sahin, M.D.</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,817</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.27*</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sean Marett</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,927</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.27*</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Sierk Poetting</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,927</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.27*</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. &#214;zlem T&#252;reci, M.D.</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,927</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.27*</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ryan Richardson</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,865</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.27*</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Valuation parameter derived from the Monte-Carlo simulation model</p></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the share options allocated and expected to be allocated had a remaining weighted-average expected life of 4.63 years.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Expense recognized in the Consolidated Statements of Operations</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The expenses recognized for employee services received during the periods indicated are shown in the following table: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,514</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,246</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,760</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">17</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4</font></p></td>
<td valign="top">
<p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Chief Executive Officer Grant (Equity-Settled)</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Description of Share-Based Payments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2019, BioNTech granted Prof. Ugur Sahin, M.D. an option to purchase 4,374,963 ordinary shares, subject to Prof. Sahin&#8217;s continuous employment with BioNTech. The options&#8217; exercise price per share is the Euro translation of the public offering price from BioNTech&#8217;s initial public offering, &#8364;13.60 ($15.00). The option vests annually in equal installments after four years commencing on the first anniversary of the initial public offering and will be exercisable four years after the initial public offering. The option is subject to the terms, conditions, definitions and provisions of the ESOP and the applicable option agreement thereunder. The vested option rights can only be exercised if and to the extent that each of the following performance criteria has been achieved: (i) at the time of exercise, the current price is equal to or greater than the threshold amount (that is, the exercise price, provided that such amount increases by seven percentage points on each anniversary of the allocation date); (ii) at the time of exercise, the current price is at least equal to the Target Price (that is, (a) for the twelve-month period starting on the fourth anniversary of the allocation date, $8.5 billion divided by the total number of the shares outstanding immediately following the initial public offering (other than shares owned by BioNTech), and (b) for each twelve-month period starting on the fifth or subsequent anniversary of the allocation date, 107% of the target share price applicable for the prior twelve-month period); and (iii) the closing price for the fifth trading day prior to the start of the relevant exercise window is higher than the exercise price by at least the same percentage by which the Nasdaq Biotechnology Index or a comparable successor index as of such time is higher than such index was as of the last trading day before the allocation date. The option rights can be exercised up to ten years after the allocation date. If they have not been exercised by that date, they will lapse without compensation.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Measurement of Fair Values</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Monte-Carlo simulation model has been used to measure the fair value at grant date of the Chief Executive Officer Grant. This model incorporates the impact of the performance criteria regarding share price and index development described above in the calculation of the award&#8217;s fair value at grant date. The inputs used in the measurement of the fair value at grant date of the Chief Executive Officer Grant were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant date October 10, 2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average fair value</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;5.63</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average share price</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;13.60</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;13.60</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility (%)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.4%</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (years)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.37</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate (%)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.52 %</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility was based on an evaluation of the historical volatilities of comparable companies over the historical period commensurate with the expected term. The expected term was based on general optionholder behavior for employee options.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reconciliation of Outstanding Share-Options</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, no further options were granted or forfeited. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the share options outstanding had a remaining weighted-average expected life of 4.12 years.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Expense recognized in the Statement of Operations</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, the Group has recognized &#8364;11.3&#160;million of share-based payment expenses as research and development expenses in the consolidated statements of operations (during the year ended December&#160;31, 2019: &#8364;3.2 million).</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Employee Stock Ownership Plan (Equity-Settled)</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Description of Share-Based Payments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 15, 2018, the Group established a share option program that grants selected employees options to receive shares in the Company. The program is designed as an ESOP. The Group has offered the participants a certain number of rights (Option Rights) by explicit acceptance of the participants. The exercise of the Option Rights in accordance with the terms of the ESOP, gives the participants the right to obtain shares against payment of the exercise price. The Option Rights vest over four years and can only be exercised if the company has executed a public offering in the United States (IPO) and when the Threshold Amount is met. Threshold Amount means the exercise price provided that such price increases by eight percentage points on the first and then each subsequent anniversary of the Allocation Date (September 26, 2018). The Option Rights can be exercised at the latest eight years after the Allocation Date. If they have not been exercised by that date, they will be forfeited without compensation.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Measurement of Fair Values</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the ESOP has been measured using a binomial model. Service conditions attached to the arrangement were not taken into account in measuring the fair value.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The share options can only be exercised by the grantee if the price of the share is equal or greater to the Threshold Amount as defined in the arrangement. Moreover, the option rights can only be exercised if the IPO has occurred. Both conditions have been incorporated into the fair value at grant date.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The inputs used in the measurement of the fair values at grant date of the ESOP was as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant date</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15 November 2018</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant dates</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">between</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">February 21 -</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">April 3, 2019</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant dates</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">between</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">April 29 -</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">May 31, 2019</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant date December 1, 2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average fair value</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7.41</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;6.93</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7.04</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;9.49</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average share price</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;14.40</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15.72</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;16.03</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;19.84</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;10.14</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15.03</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15.39</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15.82</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility (%)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46.0%</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46.0%</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46.0%</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46.0%</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (years)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.84</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.00</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.00</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.50</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate (%)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.05%</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.05%</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.05%</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.05%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility has been based on an evaluation of the historical and the implied volatilities of comparable companies over the historical period commensurate with the expected term. The expected term has been based on general option holder behavior for employee options.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reconciliation of Outstanding Share-Options</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Set out below is an overview of changes to share options outstanding and number of ordinary shares underlying these options that occurred during the periods indicated: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share options</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">outstanding</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number of ordinary shares underlying options</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average exercise price (&#8364;)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">658,109</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,845,962</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,511</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">261,198</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.17</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,237)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(310,266)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.85</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">655,383</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11,796,894</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.23</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">655,383</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,796,894</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.23</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,491)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(170,838)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.81</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">645,892</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11,626,056</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.23</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the share options outstanding had a remaining weighted-average expected life of 3.73 years.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The share options outstanding as of December 31, 2020 issued to the Management Board Grant were as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share options</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">outstanding</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number of ordinary shares underlying options</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average exercise price (&#8364;)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prof. Ugur Sahin, M.D.</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,686</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,830,348</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sean Marett</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,895</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">610,110</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Sierk Poetting</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,895</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">610,110</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. &#214;zlem T&#252;reci, M.D.</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108,463*</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,952,334</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ryan Richardson**</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,306***</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149,508</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
</tr>
</table>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*&#160;&#160;&#160;&#160;&#160;Options fully vested on March 16, 2019, however these options will not become exercisable until September&#160;16,&#160;2022.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**&#160;&#160;&#160;Ryan Richardson was appointed to the Management Board as Chief Strategy Officer (CSO) and Managing Director on January 12, 2020. The share options granted on November 15, 2018 under the Employee<font style="letter-spacing:0.05pt;"> </font>Stock Ownership Plan were granted before his appointment to the Management Board. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***&#160;Options fully vested on October 10, 2019, however these options will not become exercisable until September&#160;16,&#160;2022.</p></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The expenses recognized for employee services received during the periods indicated are shown in the following table:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of sales</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;869</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;896</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;114</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,120</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,016</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,786</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,975</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,008</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">728</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;17,075</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;27,028</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7,641</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 44<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567888518920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MiscellaneousCurrentLiabilitiesAbstract', window );"><strong>Miscellaneous Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory', window );">Other Liabilities</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">18</font></p></td>
<td valign="top">
<p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Other Liabilities</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities to employees</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;24,248</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;6,710</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,379</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">780</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;28,627</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7,490</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,061</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,490</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">566</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other liabilities. [Refer: Other liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567961853816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation Of Leases For Lessee [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">Leases</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">19</font></p></td>
<td valign="top">
<p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Leases</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.1</font></p></td>
<td valign="top">
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Amounts Recognized in the Consolidated Statements of Financial Position</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Right-of-Use Assets</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following amounts are presented as right-of-use assets within the consolidated statements of financial position as of the dates indicated: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;80,875</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;54,956</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equipment, tools and installations</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Automobiles</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Production facilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,202</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Advance payments</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,800</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;98,988</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;55,018</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions to the right-of-use assets during the year ended December&#160;31, 2020 were &#8364;22.1 million (during the year ended December&#160;31, 2019: &#8364;10.0&#160;million) including advanced payments of &#8364;10.8 million related to embedded leases under contract manufacturing agreements that not yet commenced. Since the advanced lease payments have already been settled, the amounts are not included in the lease liability presented below.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Lease Liability</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following amounts are included in interest-bearing loans and borrowings as of the dates indicated: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;6,127</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;3,485</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,031</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,126</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;84,158</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;57,611</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group has various lease contracts that have not yet commenced as of December&#160;31, 2020. The future lease payments for these non-cancellable lease contracts are &#8364;2.8&#160;million for the year 2021 and &#8364;10.2&#160;million for the years 2022 and beyond.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Several lease contracts include extension and termination options. These options are negoiated by management to provide flexibility in managing the leased-asset portfolio and align with the Group&#8217;s business needs. Management exercises significant judgement in determining whether these extension and termination options are reasonably certain to be exercised.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">19</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.2</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Amounts Recognized in the Consolidated Statements of Operations</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Depreciation Charge of Right-of-Use Assets</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;4,628</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;4,614</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,751</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equipment, tools and installations</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Automobiles</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Production facilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,613</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total depreciation charge</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;6,290</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;4,679</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,846</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on lease liabilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,003</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,718</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,721</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expense related to short-term leases</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(included in other expenses)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">875</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">442</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">431</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expense relating to leases of low-value assets that are not short-term leases (included in other expenses)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total amounts recognized in profit or loss</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;9,468</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;6,929</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;5,088</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">19</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.3</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Amounts recognized in the Consolidated Statements of Cash Flows</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, the total cash outflow for leases amounted to &#8364;14.7 million (during the year ended December&#160;31, 2019: &#8364;4.8 million; during the year ended December&#160;31, 2018: &#8364;2.3&#160;million).</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">19.3</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Extension Options</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group has several lease contracts that include extension options. These options are negotiated by management to provide flexibility in managing the leased-asset portfolio and align with the Group&#8217;s business needs. Management exercises judgement in determining whether these extension options are reasonably certain to be exercised. The undiscounted potential future lease payments, which relate to periods after the exercise date of renewal options and are not included in lease liabilities, amount to up to &#8364;38.3 million until 2049.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Section Presentation<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567934931880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract', window );"><strong>Disclosure Of Information About Defined Benefit Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory', window );">Pensions</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">20<font style="margin-left:14pt;"></font>Pensions</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, BioNTech adopted a defined benefit pension plan through the acquisition of BioNTech Manufacturing Marburg GmbH in Germany. The defined benefit pension plan is a final salary plan for German employees, which requires contributions to be made to a separately administered fund.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The pension plan is governed by the employment laws of Germany and consists of a funded base plan and a non-funded supplement plan. The base plan through <font style="font-style:italic;">Pensionskasse</font> <font style="font-style:italic;">Hoechst</font> is a multi-employer plan. <font style="font-style:italic;">Pensionskasse</font> <font style="font-style:italic;">Hoechst</font> is a legally independent insurance company that is subject to the Insurance Supervision Act (<font style="font-style:italic;">BaFin</font>). Plan participants may elect to contribute a percentage of their income (between 1.5% and 2.5% of salary components up to the social security contribution ceiling). A &#8364;1.00 employee contribution results in an annual pension entitlement of &#8364;0.42. The aforementioned contributions include contributions to the <font style="font-style:italic;">Pensionskasse H&#246;chst</font> in the amount of &#8364;34&#160;thousand. Contributions in the amount of &#8364;0.2&#160;million are expected for the following financial year. Since the obligation of the sponsoring company is not limited to the payment of the contributions for the financial year, this is a multi-employer defined benefit plan, which is generally to be accounted for proportionally as such. However, pension fund benefits are financed in accordance with the financing methodology of the pension fund (<font style="font-style:italic;">Bedarfdeckungsverfahren</font>). Consequently, the actuarial valuation is performed to determine the present valuate of future contributions based upon the present value of future benefit obligation less plan assets for all employers and the level of the pension fund portfolio, not at the level of an individual insurer&#8217;s risk. The calculation of the contribution rates is based on the future coverage of the total obligation, so that all sponsoring companies pay the same contribution rates. Accordingly, the portion of the base plan financed through <font style="font-style:italic;">Pensionskasse</font> <font style="font-style:italic;">Hoechst</font> is not accounted for as a defined benefit plan, but as a defined contribution plan. There are no minimum funding requirements. It is not possible to withdraw the funds from the multi-employer plan or to transfer them to another pension fund. It is not possible to withdraw from the pension fund. Upon expiry of the plan, any underfunding is to be made up by the employer and therefore recognized as liability in the consolidated statement of financial positions; any remaining surplus would be used for charitable purposes. Both plans have been closed so that no further employees can obtain entitlements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the German Company Pension Act (<font style="font-style:italic;">Betriebsrentengesetz</font>) applies to the pension obligation, the pensions are subject to adjustments at least every three years by the increase in the consumer price index or by the net wage development of comparable groups of employees. Therefore, the pension obligation is subject to inflation risk. In addition, there is longevity risk as the pensions are paid for life. Part of the obligations is also based on the level of salaries, so that the obligations will also increase if salaries develop more strongly than expected. Plan assets benefits from pension funds are offset. In this case, there is a risk that the external pension provider will not be able to provide the benefits to the extent expected and that the payments to be made directly by the employer will therefore increase.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the defined benefit obligation recognized in non-current provisions:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Base plan</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,140</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplement plan</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,125</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;4,265</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the components of net benefit expense recognized in the statement of profit or loss for both plans: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Service cost</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;24</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net interest expense</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;30</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current service cost is included in the personnel expenses of the various functions of the respective employees, while the net interest is recognized in finance expenses or finance income.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the components of remeasurements recognized in other comprehensive income for both plans:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Actuarial changes arising from changes in financial assumptions</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;227</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Experience adjustments</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;210</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Set out below is an overview of changes to the defined benefit obligation during the period indicated for both plans:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Defined benefit obligations</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,029)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Service cost</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net interest expense</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Benefits paid</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Actuarial changes arising from changes in financial assumptions</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(227)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Experience adjustments</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(4,265)</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The principal assumptions used in determining the defined benefit obligation for the Group&#8217;s plans are shown below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.34%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.36%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.34%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.80%</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Price inflation</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.00%</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rate of salary increase</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.50%</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pension increases for in-payment benefits</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.75%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sensitivity analysis</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The main actuarial assumptions that are used to calculate the provisions for post-employment benefits are the discount rate and the trend for future increases in post-employment benefit payments. A reasonably possible increase, or respective decrease, in the significant actuarial assumptions would have impacted the present value of the post-employment benefit obligations as of December&#160;31, 2020 as shown below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="3" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Quantitative sensitivity analysis</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate increase 0.25%</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(282)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate decrease 0.25%</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">309</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pension increases for in payment benefits 0.25%</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">475</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pension decreases for in payment benefits 0.25%</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(447)</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Duration</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The average duration of the German obligations are 35.92 years for the base plan and 19.77 years for the supplement plan.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Expected benefit payments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following are the expected payments or contributions to the plans in future years:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="3" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Expected payments or contributions in future years</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less than 1 year</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;29</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 to 5 years</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">317</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">More than 5 years</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">340</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;686</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for employee benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Section Scope<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS19_g2-7_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567962863912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Disclosure Of Transactions Between Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related Party Disclosures</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font></p></td>
<td valign="top">
<p style="margin-top:2pt;text-align:justify;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Related Party Disclosures</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.1</font></p></td>
<td valign="top">
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Parent and Ultimate Controlling Party</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATHOS KG, Holzkirchen, Germany is the sole shareholder of AT Impf GmbH, Munich, Germany and beneficial owner of ordinary shares in BioNTech. ATHOS KG via AT Impf GmbH has de facto control over BioNTech based on its substantial shareholding, which enabled it to exercise the majority of voting rights to pass resolutions at BioNTech&#8217;s Annual General Meeting, or AGM.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.2</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Transactions with Key Management Personnel</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Key Management Personnel Compensation</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Key management personnel at BioNTech has been defined as the members of the Management Board and of the Supervisory Board. Key management personnel compensation is comprised of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation of key management personnel of the Group</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term employee benefits incurred</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,627</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,847</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,161</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term employee benefits accrued*</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">740</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based payments</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,700**</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,151</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,163</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total compensation paid to key management personnel</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;24,067</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;19,998</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7,324</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:2pt;">&nbsp;</p></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Includes the fair value of the second installment of the short-term incentive compensation, which has been classified as cash-settled share-based payment arrangement was determined pursuant to the regulations of IFRS 2 &#8220;Share-based Payments&#8221;. This table shows the pro-rata share of personnel expenses for the respective financial year that are recognized over the award&#8217;s vesting period beginning as of the service commencement date (January 1, 2020) until each separate determination date and are remeasured until settlement date.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Includes expenses from a bonus arrangement agreed with Ryan Richardson in advance of his appointment to the Management Board. During the year ended December 31, 2020, the arrangement was modified from an all-equity share-based payment arrangement into a partly cash and partly equity settled share-based payment arrangement including 4,534 ordinary shares which have not yet been issued. </p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2019, BioNTech agreed to grant Prof. Ugur Sahin, M.D., BioNTech&#8217;s co-founder and Chief Executive Officer, an option to purchase 4,374,963 ordinary shares (see Note 17). </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management Board members participate in the Group&#8217;s ESOP program (see Note 17). </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Key Management Personnel Transactions</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A number of key management personnel, or their related parties, hold positions in other companies that result in them having control or significant influence over these companies. A number of these companies have entered into transactions with the Group during the year.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group purchases various goods and services from<font style="color:#231F20;"> Translationale Onkologie an der Universit&#228;tsmedizin der Johannes Gutenberg-Universit&#228;t Mainz gemeinn&#252;tzige GmbH, or TRON, an</font> institute which was co-founded by <font style="color:#231F20;">Prof.</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Ugur Sahin, M.D., the co-founder and Chief</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Executive</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Officer of BioNTech. Prof.</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Ugur Sahin, M.D. served</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">as Managing</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Director</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">at</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">TRON</font><font style="color:#231F20;letter-spacing:-0.05pt;"> </font><font style="color:#231F20;">until</font><font style="color:#231F20;letter-spacing:0.05pt;"> September 10, </font><font style="color:#231F20;">2019 and currently</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">serves</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">as scientific advisor at TRON and as a Professor</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">of Medicine</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">at</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">the</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">University</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">of Mainz. Additionally,</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">Prof.</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Christoph</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Huber, M.D., a member</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">of our Supervisory</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Board, served</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">on TRON&#8217;s</font><font style="color:#231F20;letter-spacing:-0.05pt;"> </font><font style="color:#231F20;">supervisory</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">board</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">until</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">his</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">resignation</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">in April</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">2019. Prof.</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Ugur Sahin, M.D., our co-founder and Chief</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Executive</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">Officer, owns a significant amount of shares in TRON. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate value of transactions related to key management personnel were as follows for the periods indicated:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consulting services / patent assignment</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;25</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;56</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;25</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of various goods and services from TRON</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,105</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,968</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,160</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;10,130</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;10,024</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;11,185</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The outstanding balances of transactions related to key management personnel were as follows as at the periods indicated:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consulting service provider</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TRON</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,229</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,843</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,236</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,843</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.3</font></p></td>
<td valign="top">
<p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Other Related Party Transactions</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total amount of transactions with ATHOS KG or entities controlled by it was as follows for the periods indicated:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of various goods and services from entities controlled by ATHOS KG</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,296</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,071</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,431</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and other assets from entities controlled by ATHOS KG</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,349</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,748</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;4,645</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,071</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7,179</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The outstanding balances of transactions with ATHOS KG or entities controlled by them were as follows as at the periods indicated:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATHOS KG</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;500</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;51</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;500</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;51</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None of the balances are secured and no bad debt expense has been recognized in respect of amounts owed by related parties. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Section Disclosures<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567934962872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events After the Reporting Period<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfEventsAfterReportingPeriodAbstract', window );"><strong>Disclosure Of Events After Reporting Period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Events After the Reporting Period</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="color:#000000;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Events After the Reporting Period</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 12, 2021, BioNTech and Pfizer announced that the U.S. government has exercised its option to purchase an additional 100 million doses of the Pfizer-BioNTech COVID-19 vaccine. This brings the total number of doses to be supplied by the companies to the U.S. government to 300 million.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 17, 2021, BioNTech and Pfizer announced an agreement with the European Commission (EC) to supply an additional 200 million doses of COVID-19 vaccine to the 27 European Union member states. The EC has the option to request supply of an additional 100 million doses.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021, RSUs under the BioNTech Employee 2020 Equity Plan were offered to employees based in Europe which determined the grant date fair value. Given that the share price had increased since the plan was established, a significant true-up in fair value occurred. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021, RSUs under the BioNTech 2020 Restricted Stock Unit Plan for North America Employees were offered to employees based in the United States. As from this date, BioNTech started recognizing expenses for this plan in the Consolidated Statements of Operations. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 12, 2021, BioNTech <font style="color:#000000;">Turkey T&#305;bbi &#220;r&#252;nler Ve Klinik Ara&#351;tirma Ticaret Anonim &#350;irketi</font>, translates as BioNTech Turkey Pharmaceutical Products and Clinical Trials Trading JSC, Istanbul, Turkey, was founded and is a wholly-owned subsidiary of BioNTech SE. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of events after reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891352840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Disclosure Of Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of Preparation</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.1</font></p></td>
<td valign="top">
<p style="margin-top:6pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Basis of Preparation</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">General</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements have been prepared on a going concern basis in accordance with the IFRS as issued by the International Accounting Standards Board (IASB). </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech prepares and publishes its consolidated financial statements in Euros and rounds numbers to thousands or millions of Euros, respectively. Accordingly, numerical figures shown as totals in some tables may not be exact arithmetic aggregations of the figures that preceded them and figures presented in the explanatory notes may not add up to the rounded arithmetic aggregations. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Segment Information</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Historically <font style="color:#000000;">BioNTech </font>reported four segments: Clinical, Technology Platform, Manufacturing and Product Sales &amp; External Services. In the course of the year ended December&#160;31, 2020, <font style="color:#000000;">BioNTech </font>leveraged the breadth of its immunotherapy technologies and used its expertise to mobilize these rapidly to address the COVID-19 pandemic. In December 2020, BioNTech&#8217;s COVID-19 vaccine was authorized or approved for emergency or temporary use or granted conditional marketing authorization in over 65 countries worldwide. Beginning in the fourth quarter, given the financial and operational significance of the activities to develop and then market, produce and transport the COVID-19 vaccine, BioNTech&#8217;s Management Board, as the chief operating decision maker (CODM), reviewed financial information presented on a consolidated basis. Decisions with respect to business operations and resource allocations are made by the CODM based on BioNTech as a whole. Accordingly, BioNTech operates and makes decisions as a single operating segment, which is also its reporting segment. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory', window );">Basis of Consolidation</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.2</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Basis of Consolidation</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements comprise the financial statements of BioNTech SE and its controlled investees (subsidiaries). </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group controls an investee if, and only if, the Group has</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.14%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">power over the investee (</font><font style="font-style:italic;font-family:Times New Roman;">i.e.</font><font style="font-family:Times New Roman;">, existing rights that give it the current ability to direct the relevant activities of the investee); </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">exposure, or rights, to variable returns from its involvement with the investee; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the ability to use its power over the investee to affect its returns. </font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally, there is a presumption that a majority of voting rights results in control. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group re-assesses whether it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The profit / (loss) and each component of other comprehensive income / (loss) for the period are attributed to the equity holders of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. When necessary, adjustments are made to the <font style="color:#000000;">consolidated </font>financial statements of subsidiaries to bring their accounting policies in line with the Group&#8217;s accounting policies. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated on consolidation.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Group loses control over a subsidiary, it derecognizes the related assets (including goodwill), liabilities, non-controlling interests and other components of equity, while any resultant gain or loss is recognized in the <font style="color:#000000;">consolidated </font>statements of operations. Any investment retained is recognized at fair value.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory', window );">Business combinations and Goodwill</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Business combinations and Goodwill</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Business combinations are accounted for using the acquisition method. The cost of an acquisition is measured as the aggregate of the consideration transferred, which is measured at acquisition date fair value, and the amount of any non-controlling interests in the acquiree.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill is initially measured at cost as the excess of the aggregate of the consideration transferred and the amount recognized for non-controlling interests and any previous interest held over the net identifiable assets acquired and liabilities assumed.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After initial recognition, goodwill is tested at least annually or when there is an indication for impairment. See Note&#160;2.3.13. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Group&#8217;s cash-generating units that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those units. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Where goodwill has been allocated to a cash-generating unit (CGU) and part of the operation within that unit is disposed of, the goodwill associated with the disposed operation is included in the carrying amount of the operation when determining the gain or loss on disposal. Goodwill disposed in these circumstances is measured based on the relative values of the disposed operation and the portion of the cash-generating unit retained.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatory', window );">Current versus Non-Current Classifications</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Current versus Non-Current Classifications</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group presents assets and liabilities in the consolidated statements of financial position based on current or non-current classification. An asset is current when it is either: (i)&#160;expected to be realized within 12&#160;months after the reporting period or (ii)&#160;cash or cash equivalents, unless it is restricted from being exchanged or used to settle a liability for at least 12&#160;months after the reporting period. All other assets are classified as non-current. A liability is current when it is due to be settled within 12&#160;months after the reporting period. The Group classifies all other liabilities as non-current. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets and liabilities are classified as non-current assets and liabilities, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory', window );">Fair Value Measurement</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Fair Value Measurement</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is a market-based measurement. For some assets and liabilities, observable market transactions or market information is available. For other assets and liabilities, observable market transactions or market information might not be available. When a price for an identical asset or liability is not observable, another valuation technique is used. To increase consistency and comparability in fair value measurements, there are three levels of the fair value hierarchy:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.14%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Level 1 contains the use of quoted prices in active markets for identical assets or liabilities.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.14%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.14%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Level&#160;3 inputs are unobservable. </font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within this hierarchy, estimated values are made by management based on reasonable assumptions, including other fair value methods.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For assets and liabilities that are recognized in the financial statements at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the fair value hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the purpose of fair value disclosures, the Group has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy, as explained above.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory', window );">Revenue from Contracts with Customers</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.93%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.4</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Revenue from Contracts with Customers</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech generates revenues from collaboration and license agreements under which BioNTech grants licenses to use, research, develop, manufacture and commercialize product candidates and products. BioNTech determined that those collaboration and license agreements qualify as contracts with its customers. If the grant of a license is bundled together with the rendering of services, it is assessed whether these agreements are comprised of more than one performance obligation. A performance obligation is only accounted for as the grant of a license if the grant of a license is the sole or the predominant promise of the performance obligation. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the consideration in an agreement includes a variable amount, BioNTech estimates the amount of consideration to which BioNTech will be entitled in exchange for transferring the goods to the customer. At contract inception, the variable consideration is estimated based on the most likely amount of consideration expected from the transaction and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with respect the variable consideration is subsequently resolved. The estimated revenue is updated at each reporting date to reflect the current facts and circumstances.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a contract with a customer contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative-stand-alone selling prices.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each separate performance obligation, it is evaluated whether control is transferred either at a point in time or over time. For performance obligations that are satisfied over time, revenue is recognized based on a measure of progress, which depicts the performance in transferring control to the customer. Under the terms of its licensing arrangements, BioNTech provides the licensee with a research and development license, which represents a right to access BioNTech&#8217;s intellectual property as it exists throughout the license period (as BioNTech&#8217;s intellectual property is still subject to further research). Therefore, the promise to grant a license is accounted for as a performance obligation satisfied over time, as the licensee simultaneously receives and consumes the benefits of BioNTech&#8217;s performance.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Earnings based on the collaboration partners&#8217; gross profit, which is shared under the respective collaboration agreements are recognized based on the sales-based or usage-based royalty <font style="color:#000000;">exemption; </font><font style="font-style:italic;color:#000000;">i.e. </font>when, or as, the underlying sales occur, which is when the performance obligation has been satisfied. As described further in Note 3, BioNTech uses certain information from its collaboration partners, some of which is based on preliminary data shared between the partners and might vary once final data is available. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue arrangements that involve two or more partners who contribute to the provision of a specific good or service to a customer are assessed in terms of principal-agent considerations in order to determine the appropriate treatment for the transactions between BioNTech and the collaborator and the transactions between BioNTech and other third parties. The classification of transactions under such arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which BioNTech is considered the principal, which includes being in control of the good or service before such good or service is transferred to the customer, are accounted for as gross revenue. Any consideration related to activities in which BioNTech is considered the agent, are accounted for as net revenue.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue from the sale of pharmaceutical and medical products (<font style="font-style:italic;">e.g</font>. COVID-19 vaccine sales and other sales of peptides and retroviral vectors for clinical supply) is recognized when BioNTech transfers control of the product to the customer. Control of the product normally transfers when the customer gains physical possession and BioNTech has not retained any significant risks of ownership or future obligations with respect to the product. A receivable is recognized, as the consideration is unconditional and only the passage of time is required before payment is due. The transaction price is quoted in the relevant price lists in force at the date of customer placing the respective order for such products. Payments from customers are due within 20 days (Europe) or 30 days (non-Europe) after invoice.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contract Balances</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contract Assets</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A contract asset is the right to consideration in exchange for goods or services transferred to the customer. If BioNTech performs by transferring goods or services to a customer before the customer pays consideration or before payment is due, a contract asset is recognized for the earned consideration that is conditional.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Trade Receivables</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A receivable represents BioNTech&#8217;s right to an amount of consideration that is unconditional (<font style="font-style:italic;">i.e</font>., only the passage of time is required before payment of the consideration is due).</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contract Liabilities</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A contract liability is the obligation to transfer goods or services to a customer for which BioNTech has received consideration (or an amount of consideration is due) from the customer. If a customer pays consideration before BioNTech transfers goods or services to the customer, a contract liability is recognized when the payment is made or when the payment is due (whichever is earlier). Contract liabilities are recognized as revenue when BioNTech performs under the contract.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants', window );">Government Grants</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.5</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Government Grants</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government grants are recognized where there is reasonable assurance that the grant will be received and all attached conditions will be complied with. When the grant relates to an expense item, it is recognized as other income on a systematic basis over the periods that the related costs, for which the grant is intended to compensate, are expensed. When the grant relates to an asset, it is recognized as deferred income within the consolidated statements of financial position. Other income is subsequently recognized in profit or loss over the useful live of the underlying asset subject to funding. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Taxes</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.6</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Taxes</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Current Income Tax</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the reporting date in the countries where the Group operates and generates taxable income. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, current income taxes presented for the period include adjustments for uncertain tax payments or tax refunds for periods not yet finally assessed, excluding interest expenses and penalties on the underpayment of taxes. Due to the increasing complexity of tax laws and the corresponding uncertainty regarding the legal interpretation by the fiscal authorities, tax calculations are generally subject to an elevated amount of uncertainty. In the event that amounts included in the tax return are considered unlikely to be accepted by the tax authorities (uncertain tax positions), a provision for income taxes is recognized. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred Tax</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities are recognized for all taxable temporary differences, except: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">when the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">in respect of taxable temporary differences associated with investments in subsidiaries, associates and interests in joint arrangements, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future. </font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets are recognized for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, the carry forward of unused tax credits and unused tax losses can be utilized, except:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">when the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">in respect of deductible temporary differences associated with investments in subsidiaries, associates and interests in joint arrangements, deferred tax assets are recognized only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized. </font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year in which the asset is realized, or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recognition of Taxes</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current and deferred tax items are recognized similar to the underlying transaction either in profit or loss, other comprehensive income or directly in equity.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group offsets current tax assets and current tax liabilities if, and only if, it has a legally enforceable right to set off the recognized amounts and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously. Deferred tax assets and deferred tax liabilities are only offset when the Group has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same taxation authority on either (i) the same taxable entity or (ii) different taxable entities, which intend either to settle current tax liabilities and assets on a net basis, or to realize the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sales Tax</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expenses and assets are recognized net of sales tax, except when the sales tax incurred on a purchase of assets or services is not recoverable from the taxation authority.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The net amount of sales tax recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the <font style="color:#000000;">consolidated</font> statements of financial position.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign Currencies</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.7</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Foreign Currencies</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group&#8217;s consolidated financial statements are presented in Euros, which is also BioNTech SE&#8217;s functional currency. For each entity, the Group determines the functional currency, and items included in the <font style="color:#000000;">consolidated </font>financial statements of such entity are measured using that functional currency. The Group uses the direct method of consolidation and on disposal of a foreign operation, the gain or loss that is reclassified to the <font style="color:#000000;">consolidated </font>statements of operations reflects the amount that arises from using this method.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Transactions and Balances</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transactions in foreign currencies are initially recorded by the Group&#8217;s entities at their respective functional currency spot rates at the date the transaction first qualifies for recognition.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In determining the spot exchange rate to use on initial recognition of the related asset, expense or income (or part of it) on the derecognition of a non-monetary asset or non-monetary liability relating to advance consideration, the date of the transaction is the date on which the Group initially recognizes the non-monetary asset or non-monetary liability arising from the advance consideration. If there are multiple payments or receipts in advance, the Group determines the transaction date for each payment or receipt of advance consideration.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Foreign Currency Translation</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On consolidation, the assets and liabilities of foreign operations are translated into Euros at the rate of exchange prevailing at the reporting date and their <font style="color:#000000;">consolidated</font> statements of operations are translated at exchange rates prevailing at the dates of the transactions.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The exchange differences arising on translation for consolidation are recognized in other comprehensive income. On disposal of a foreign operation, the component of other comprehensive income relating to that particular foreign operation is reclassified to profit or loss.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any goodwill arising on the acquisition of a foreign operation and any fair value adjustments to the carrying amounts of assets and liabilities arising upon the acquisition are treated as assets and liabilities of the foreign operation and translated at the spot rate of exchange at the reporting date.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property, Plant and Equipment</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.8</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Property, Plant and Equipment</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress is stated at cost, net of accumulated impairment losses, if any. Property, plant and equipment are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Such cost includes the cost of replacing part of the property, plant and equipment if the recognition criteria are met. All other repair and maintenance costs are expensed as incurred.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Useful life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7-33</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equipment, tools and installations</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-15</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An item of property, plant and equipment initially recognized is derecognized upon disposal (<font style="font-style:italic;">i.e</font>., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the <font style="color:#000000;">consolidated </font>statements of operations when the asset is derecognized.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year-end and adjusted prospectively, if appropriate.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.9</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Leases</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of a contract, the Group assesses whether the contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, the Group assesses whether: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the contract involves the use of an identified asset&#8212;this may be specified explicitly or implicitly and should be physically distinct or represent substantially all of the capacity of a physically distinct asset. If the supplier has a substantive substitution right, then the asset is not identified; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the Group has the right to obtain substantially all of the economic benefits from use of the asset throughout the period of use; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the Group has the right to direct the use of the asset. The Group has this right when it has the decision-making rights that are most relevant to changing how and for what purpose the asset is used. In rare cases where the decision about how and for what purpose the asset is used is predetermined, the Group has the right to direct the use of the asset if either:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the Group has the right to operate the asset; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the Group designed the asset in a way that predetermines how and for what purpose it will be used. </font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At inception or on reassessment of a contract that contains a lease component, the Group allocates the consideration in the contract to each lease component on the basis of their relative stand-alone prices. However, for the leases of land and buildings in which it is a lessee, the Group has elected not to separate non-lease components, and instead accounts for the lease and non-lease components as a single lease component.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group recognizes a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of the costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received by the Group.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset and the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of property and equipment. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the incremental borrowing interest rate implicit in the lease or, if that rate cannot be readily determined, the Group&#8217;s incremental borrowing rate. Generally, the Group uses its incremental borrowing rate as the discount rate.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease payments included in the measurement of the lease liability comprise the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">fixed payments, including in-substance fixed payments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">variable lease payments that depend on an index or a rate, initially measured using the index or rate as of the commencement date; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">amounts expected to be payable under a residual value guarantee; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the exercise price under a purchase option that the Group is reasonably certain to exercise, lease payments in an optional renewal period if the Group is reasonably certain to exercise an extension option, and penalties for early termination of a lease unless the Group is reasonably certain not to terminate early.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The lease liability is subsequently measured at amortized cost using the effective interest method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the Group&#8217;s estimate of the amount expected to be payable under a residual value guarantee, or if the Group changes its assessment of whether it will exercise a purchase, extension or termination option. When the lease liability is remeasured, a corresponding adjustment is made to the carrying amount of the right-of-use asset or is recorded in the <font style="color:#000000;">consolidated </font>statements of operations if the carrying amount of the right-of-use asset has been reduced to zero.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group presents right-of-use assets separately and lease liabilities in &#8216;financial liabilities&#8217; in the <font style="color:#000000;">consolidated </font>statements of financial position.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets or shorter lease term, as follows:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Useful life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2-25</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equipment, tools and installations</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2-5</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Production facilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2-3</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Automobiles</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-4</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Short-Term Leases and Leases of Low-Value Assets</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group has elected not to recognize right-of-use assets and lease liabilities for short-term leases of machinery that have a lease term of 12 months or less or leases of low-value assets. The Group recognizes the lease payments associated with these leases as an expense in the <font style="color:#000000;">consolidated </font>statements of operations on a straight-line basis over the lease term.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory', window );">Intangible Assets</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.10</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Intangible Assets</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The useful lives of intangible assets are assessed as either finite or indefinite. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets with finite lives are amortized generally on a straight-line basis over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are at least reviewed at the end of each reporting period. The amortization expense on intangible assets with finite lives is recognized in the <font style="color:#000000;">consolidated </font>statements of operations in the expense category that is consistent with the function of the intangible assets.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the useful lives applied to the Group&#8217;s intangible assets is as follows:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Useful life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intellectual property rights</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-20</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Licenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-20</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-8</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets with indefinite useful lives are not amortized, but are tested for impairment at least annually, or when there is an indication for impairment, either individually or at the level of a cash-generating unit (see Note 2.3.13 for further details). The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group has classified advanced payments on intangible assets as intangible assets, which are not yet ready for use. Advanced payments on intangible assets are tested for impairment on an annual basis.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An intangible asset is derecognized upon disposal (<font style="font-style:italic;">i.e</font>., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising upon derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the <font style="color:#000000;">consolidated </font>statements of operations.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Costs</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research costs are expensed as incurred. Development expenditures on an individual project are recognized as an intangible asset if, and only if, all of the following six criteria can be demonstrated by the Group:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the technical feasibility of completing the intangible asset so that the asset will be available for use or sale;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">its intention to complete the project;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the ability and intention to use or sell the asset;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">how the asset will generate future economic benefits;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the availability of resources to complete the asset; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the ability to reliably measure the expenditure during development.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to the inherent risk of failure in pharmaceutical development and the uncertainty of approval, management has determined that these criteria are not met in the biotech sector until regulatory approval has been obtained. The related expenditure is reflected in the consolidated statements of operations in the period in which the expenditure is incurred. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following initial recognition of the development expenditure as an asset, the asset is carried at cost less any accumulated amortization and accumulated impairment losses. Amortization of the asset begins when development is complete and the asset is available for use. It is amortized over the period of expected future benefit. Amortization is recorded in cost of sales. During the period of development, the asset is tested for impairment annually.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory', window );">Financial Instruments &#8211; Initial Recognition and Subsequent Measurement</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.11</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Financial Instruments &#8211; Initial Recognition and Subsequent Measurement</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">i) Financial Assets</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Initial recognition and Measurement</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets are initially measured at fair value. The Group&#8217;s financial assets mainly include trade receivables as well as other receivables that reflect BioNTech&#8217;s entitlement to cash. With respect to trade receivable, the Group has applied the practical expedient which means that they are measured at the transaction price determined under IFRS 15. Refer to the accounting policies in Note 2.3.4. Other financial assets are measured at amortized costs since they are held by the Group to collect contractual cash flows, which are solely payments of principal and interest. Gains and losses are recognized in profit or loss when the financial asset is derecognized, modified or impaired. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Derecognition</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e., removed from the Group&#8217;s consolidated statements of financial position) when the rights to receive cash flows from the asset have expired or have been transferred in terms of fulfilling the derecognition criteria. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Impairment of Financial Assets</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An allowance for expected credit losses (ECLs) is considered for all debt instruments of the Group. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all of the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For trade receivables and contract assets, the Group applies a simplified approach in calculating ECLs. Therefore, the Group does not track changes in credit risk, but instead recognizes a loss allowance based on lifetime ECLs at each reporting date. The Group has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment. In this analysis BioNTech also considered that governments and health ministries which are BioNTech&#8217;s customers established in connection with progressing the commercial activities of the Group with respect to BioNTech&#8217;s COVID-19 vaccine. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ii) Financial Liabilities</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Initial Recognition and Measurement</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings or as payables.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group&#8217;s financial liabilities include trade payables and other financial liabilities.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Subsequent Measurement</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The measurement of financial liabilities depends on their classification, as described below.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Financial Liabilities at Fair Value through Profit or Loss</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial liabilities at fair value through profit of the Group include the embedded derivative, which was bifurcated from the convertible note, as host contract, and is recognized as a separate financial instrument until it is extinguished upon conversion. Financial liabilities at fair value further include contingent considerations resulting from the Group&#8217;s business combinations. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gains or losses arising from fair value measurement adjustments of the embedded derivative and the contingent consideration are recognized in profit and loss within the consolidated statements of operations.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Loans, Borrowings, Trade Payables and Other Financial Liabilities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After initial recognition, interest-bearing loans and borrowings, trade payables and other financial liabilities are subsequently measured at amortized cost using the EIR method. Gains and losses are recognized in the <font style="color:#000000;">consolidated </font>statements of operations when the liabilities are derecognized as well as through the EIR amortization process.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortization is included as finance costs in the <font style="color:#000000;">consolidated </font>statements of operations.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This category generally applies to interest-bearing loans and borrowings.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Derecognition</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the <font style="color:#000000;">consolidated </font>statements of operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories', window );">Inventories</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.12</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Inventories</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories are valued at the lower of cost and net realizable value.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs incurred in bringing each product to its present location and condition are accounted for as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">raw materials and supplies: purchase cost on a first-in/first-out basis; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">unfinished goods and finished goods: cost of direct materials and labor, including both internal manufacturing and third-party contract manufacturing organizations, or CMOs, and a proportion of manufacturing overheads based on the normal operating capacity, but excluding borrowing costs.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory', window );">Impairment of Non-Financial Assets</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.13</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Impairment of Non-Financial Assets</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group assesses, at each reporting date, whether there is an indication that an asset may be impaired. Goodwill is tested for impairment annually as of October 1. Impairment is determined for goodwill by assessing the recoverable amount of each cash generating unit (or group of CGUs) to which the goodwill relates. If any indication exists, or when annual impairment testing is performed, the Group estimates the asset&#8217;s or CGU&#8217;s recoverable amount. The recoverable amount is the higher of an asset&#8217;s or CGU&#8217;s fair value less costs of disposal and its value in use. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. When the carrying amount of an asset or cash generating unit exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used. These calculations are corroborated by valuation multiples, quoted share prices for publicly traded companies or other available fair value indicators.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group bases its impairment calculation on detailed budgets and forecast calculations, which are prepared separately for each of the Group&#8217;s cash generating units to which the individual assets are allocated. These budgets and forecast calculations generally cover a period of five years. A long-term growth rate is calculated and applied to project future cash flows after the fifth year.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment losses of continuing operations are recognized in the <font style="color:#000000;">consolidated </font>statements of operations in expense categories consistent with the function of the impaired asset.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For assets excluding goodwill, an assessment is made at each reporting date to determine whether there is an indication that previously recognized impairment losses no longer exist or have decreased. If such indication exists, the Group estimates the asset&#8217;s or cash generating unit&#8217;s recoverable amount. A previously recognized impairment loss is reversed only if there has been a change in the assumptions used to determine the asset&#8217;s recoverable amount since the last impairment loss was recognized. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognized for the asset in prior years. Such reversal is recognized in the <font style="color:#000000;">consolidated </font>statements of operations unless the asset is carried at a revalued amount, in which case, the reversal is treated as a revaluation increase.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.14</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Cash and Cash Equivalents</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents comprise cash in banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory', window );">Pension</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.15</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Pension</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The liability in respect of defined benefit pension plans is the defined benefit obligation calculated annually by independent actuaries using the projected unit credit method. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions of the respective employees, while the net interest on the net defined benefit liability or asset is recognized in finance expenses or finance income.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory', window );">Provisions</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Provisions</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Group expects some or all of a provision to be reimbursed, for example, under an insurance contract, the reimbursement is recognized as a separate asset, but only when the reimbursement is virtually certain. The expense relating to a provision is presented in the <font style="color:#000000;">consolidated </font>statements of operations net of any reimbursement.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share-Based Payments</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.59%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3.1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Share-Based Payments</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employees (and others providing similar services) receive remuneration in the form of share-based payments, which are settled in equity instruments (equity-settled transactions).</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cost of equity-settled transactions is determined by the fair value at the date when the grant is made using an appropriate valuation model, further details of which are given in Note 17. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These costs are recognized in cost of sales, research and development expenses, sales and marketing expenses or general and administrative expenses, together with a corresponding increase in equity (other reserves), over the period in which the service is provided (the vesting period). The cumulative expense recognized for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Group&#8217;s best estimate of the number of equity instruments that will ultimately vest.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DescriptionOfAccountingPolicyForInitialApplicationOfStandardsExplanatory', window );">Standards Applied for the First Time</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.4</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Standards applied for the First Time</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020 several new and amended standards and interpretations became effective but did not have an impact on the consolidated financial statements of the Group. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Standards/Interpretations</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Date of application</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to IFRS 3 Business Combinations</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to IFRS 9, IAS 39 and IFRS 7 Interest Rate Benchmark Reform</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to IAS 1 and IAS 8 Definition of Material</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to References to the Conceptual Framework in IFRS Standards</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment to IFRS 16 Leases COVID-19-Related Rent Concessions</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 1, 2020</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DescriptionOfAccountingPolicyForStandardIssuedButNotYetEffectiveExplanatory', window );">Standard Issued but not yet Effective</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.91%;white-space:nowrap">
<p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.5</font></p></td>
<td valign="top">
<p style="margin-top:2pt;text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Standard issued but not yet effective</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The new and amended standards and interpretations that are issued, but not yet effective, up to the date of issuance of the Group&#8217;s financial statements and that might have an impact on the Group&#8217;s financial statements are disclosed below. The Group has not early adopted any standards and intends to adopt these new and amended standards and interpretations, if applicable, when they become effective. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Standards/Interpretations</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Date of application</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to IFRS 4 Insurance Contracts &#8211; deferral of IFRS 9</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2021</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 Interest Rate Benchmark Reform &#8211; Phase 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2021</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to IFRS 3 Business Combinations: Reference to the Conceptual Framework</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2022</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to IAS 16 Property, Plant and Equipment: Proceeds before Intended Use</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2022</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to IAS 37 Provisions, Contingent Liabilities and Contingent Assets - Onerous Contracts &#8211; Cost of Fulfilling a Contract Amendments to IAS 37</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2022</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual Improvements to IFRS Standards 2018-2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2022</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments to IAS 1 Presentation of Financial Statements: Classification of Liabilities as Current or Non-current - Deferral of Effective Date</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2023</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IFRS 17 Insurance Contracts (issued on 18 May 2017); including Amendments to IFRS 17</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%; border-right:solid 0.75pt #92D050;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-left:solid 0.75pt #92D050;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2023</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Group does not expect a significant impact of the application of any of these amendments. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for assets and liabilities explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DescriptionOfAccountingPolicyForInitialApplicationOfStandardsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for initial application of standards explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DescriptionOfAccountingPolicyForInitialApplicationOfStandardsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for revenue from contracts with customers explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DescriptionOfAccountingPolicyForStandardIssuedButNotYetEffectiveExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for standard issued but not yet effective explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DescriptionOfAccountingPolicyForStandardIssuedButNotYetEffectiveExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of summary of significant accounting policies abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for business combinations and goodwill. [Refer: Business combinations [member]; Goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for fair value measurement. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2020-01-01<br> -Paragraph 39<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for the impairment of non-financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 36<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_36_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 46<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_46&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for consolidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfConsolidationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567945291000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Disclosure Of Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatory', window );">Useful Lives Applied to the Group's Property, Plant and Equipment</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Useful life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7-33</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equipment, tools and installations</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-15</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatory', window );">Useful Lives Applied to the Group's Right-of-use Assets</a></td>
<td class="text">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets or shorter lease term, as follows:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Useful life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2-25</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equipment, tools and installations</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2-5</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Production facilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2-3</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Automobiles</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-4</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIntangibleAssetsUsefulLifeExplanatory', window );">Useful Lives Applied to the Group's Intangible Assets</a></td>
<td class="text">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the useful lives applied to the Group&#8217;s intangible assets is as follows:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Useful life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intellectual property rights</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-20</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Licenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-20</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-8</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfIntangibleAssetsUsefulLifeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of intangible assets useful life explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfIntangibleAssetsUsefulLifeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of property plant and equipment estimated useful lives explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLivesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of right of use assets estimated useful lives explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of summary of significant accounting policies abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567892379320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Judgments, Estimates and Assumptions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfAccountingJudgementsAndEstimatesAbstract', window );"><strong>Disclosure Of Accounting Judgements And Estimates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfDetailedInformationAboutProvisionalSalesFiguresForTerritoriesExplanatory', window );">Schedule of Provisional Sales Figures for Territories</a></td>
<td class="text">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These estimated figures are likely to change prospectively in future periods as BioNTech receives final data from Pfizer. Those changes in BioNTech&#8217;s share of the collaboration partner&#8217;s gross profit will be recognized prospectively as changes to BioNTech&#8217;s commercial revenues. To the extent that Pfizer does not provide such preliminary information in the future, BioNTech&#8217;s provisional sales figures for territories outside of the United States will be subject to a greater level of estimation and judgment. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:1.09%;width:99.88%;">
<tr>
<td style="width:35.4%;"></td>
<td style="width:14.27%;"></td>
<td style="width:14.27%;"></td>
<td style="width:21.19%;"></td>
<td style="width:14.75%;"></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="bottom" bgcolor="#FFFFFF">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style=" border-bottom:solid 1pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-bottom:solid 1pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">German territory</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-bottom:solid 1pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">U.S. territory</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-bottom:solid 1pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Territories outside the U.S.</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-bottom:solid 1pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style=" border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#C6E0B4" style=" border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct product sales to BioNTech customers</p></td>
<td valign="middle" bgcolor="#C6E0B4" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 20,553</p></td>
<td valign="middle" bgcolor="#C6E0B4" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style=" border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 20,553</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#C6E0B4" style=" border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share of collaboration partner's gross profit</p></td>
<td valign="middle" bgcolor="#C6E0B4" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 46,997</p></td>
<td valign="middle" bgcolor="#C6E0B4" style=" border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 141,480</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 188,477</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Input parameters used within gross profit share calculation</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:10pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Sales</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">reported</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">preliminary<br />reported</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Transfer price (manufacturing, shipping costs and respective variances)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">standard<br />prices</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">standard<br />prices</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">License payments</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">identified<br />royalty rate</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">identified<br />royalty rate</p></td>
<td valign="middle" bgcolor="#FFFFFF" style=" border-left:solid 0.75pt #70AD47;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfAccountingJudgementsAndEstimatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting judgements and estimates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfAccountingJudgementsAndEstimatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfDetailedInformationAboutProvisionalSalesFiguresForTerritoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about provisional sales figures for territories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfDetailedInformationAboutProvisionalSalesFiguresForTerritoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567890921816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Group Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory', window );">Summary of Information about Subsidiaries</a></td>
<td class="text">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements of the Group include the following subsidiaries: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">% equity interest</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Country of incorporation</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registered office</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech RNA Pharmaceuticals GmbH</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mainz</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Delivery Technologies GmbH</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Halle</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Diagnostics GmbH</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mainz</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Europe GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(previously BioNTech Small Molecules GmbH)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mainz</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Manufacturing GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(previously BioNTech IVAC GmbH)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mainz</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Manufacturing Marburg GmbH</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marburg</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n/a</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Austria Beteiligungen GmbH</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Austria</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vienna</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Innovative Manufacturing Services GmbH</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Idar-Oberstein</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reSano GmbH (previously reBOOST Management GmbH)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mainz</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JPT Peptide Technologies GmbH</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Berlin</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JPT Peptide Technologies Inc.</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cambridge (previously Acton)</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech USA Holding, LLC</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cambridge (previously New York)</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Research and Development, Inc.</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cambridge (previously New York)</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech US Inc.</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cambridge</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n/a</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Pharmaceuticals Asia Pacific Pte. Ltd</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Singapore</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Singapore</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n/a</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech UK Limited</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Kingdom</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reading</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n/a</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Cell &amp; Gene Therapies GmbH</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mainz</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Real Estate Holding GmbH</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holzkirchen</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Real Estate Verwaltungs GmbH</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holzkirchen</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Real Estate GmbH &amp; Co. KG</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holzkirchen</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Real Estate An der Goldgrube GmbH &amp; Co. KG</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holzkirchen</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n/a</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Real Estate Haus Vier GmbH &amp; Co. KG</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holzkirchen</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n/a</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Real Estate Adam Opel Stra&#223;e GmbH &amp; Co. KG</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holzkirchen</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n/a</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatory', window );">Summary of Information about Parent Company</a></td>
<td class="text">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATHOS KG, Holzkirchen, Germany is the sole shareholder of AT Impf GmbH, Munich, Germany and beneficial owner of the following percentage of ordinary shares in BioNTech at the dates as indicated. ATHOS KG via AT Impf GmbH has de facto control over BioNTech based on its substantial shareholding, which enabled it to exercise the majority of voting rights to pass resolutions at BioNTech&#8217;s Annual General Meeting, or AGM. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ownership of ordinary shares in BioNTech (in %)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Country of incorporation</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registered office</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AT Impf GmbH</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Munich</p></td>
<td valign="top" bgcolor="#C5E0B3" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47.37%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50.33%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatory', window );">Summary of Information about Entity with Significant Influence Over Group</a></td>
<td class="text">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medine GmbH, Mainz owned the following percentage of ordinary shares in BioNTech at the following dates as indicated: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ownership of ordinary shares in BioNTech (in %)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Country of incorporation</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registered office</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medine GmbH</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mainz</p></td>
<td valign="top" bgcolor="#C5E0B3" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.25%</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.38%</p></td>
</tr>
</table>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of entity with significant influence over the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of significant investments by parent company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of subsidiaries. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B4<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B4_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567888364728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure Of Business Combinations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory', window );">Summary of Reconciliation of Goodwill</a></td>
<td class="text">The reconciliation of this carrying amount at the beginning and end of the reporting period is presented below:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,978</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,469</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency differences</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,750)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;53,697</p></td>
</tr>
</table></div>
<p style="line-height:5pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=bntx_LipocalyxGmbHMember', window );">Lipocalyx GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure Of Business Combinations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory', window );">Summary of Fair Values of Identifiable Net Assets</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The final fair values of the identifiable net assets of Lipocalyx as at the date of acquisition were:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">recognized on</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">acquisition</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lipocalyx GmbH</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;896</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other intangible assets</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,978</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total identifiable net assets at fair value</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7,088</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;6,516</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration liability</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">572</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total consideration</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7,088</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=bntx_BioNTechUSIncMember', window );">BioNTech US Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure Of Business Combinations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory', window );">Summary of Fair Values of Identifiable Net Assets</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair values and values in accordance with IFRS 3 of the identifiable net assets of BioNTech US Inc. as at the date of acquisition <font style="color:#000000;">were</font> as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">recognized on</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">acquisition</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech US Inc.</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;29,867</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,617</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,896</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets non-current and current</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,704</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,749</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;52,833</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade payables</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,723</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities non-current and current</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,793</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;19,516</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total identifiable net assets at fair value</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;33,317</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill from the acquisition</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,573</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consideration transferred</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;89,890</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issued, at fair value</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,548</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">342</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total consideration</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.44%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;89,890</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=bntx_BioNTechManufacturingMarburgGmbHMember', window );">BioNTech Manufacturing Marburg GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure Of Business Combinations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory', window );">Summary of Fair Values of Identifiable Net Assets</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair values and values in accordance with IFRS 3 of the identifiable net assets of BioNTech Manufacturing Marburg GmbH, or BioNTech Marburg, as at the date of acquisition <font style="color:#000000;">were</font> as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">recognized on</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">acquisition</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Manufacturing Marburg GmbH</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,828</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,514</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,466</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets non-current and current</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,343</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,319</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;131,470</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions non-current and current</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,127</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade payables</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,105</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities non-current and current</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,383</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;46,615</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total identifiable net assets at fair value</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;84,855</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bargain purchase</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,002)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consideration transferred</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;77,853</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,853</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.7%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total consideration</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;77,853</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about business combinations. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Section Disclosures application of paragraphs 59 and 61<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;doctype=Appendix&amp;subtype=B&amp;dita_xref=IFRS03_gB64-B67_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the reconciliation of changes in goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=bntx_LipocalyxGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=bntx_LipocalyxGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=bntx_BioNTechUSIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=bntx_BioNTechUSIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=bntx_BioNTechManufacturingMarburgGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=bntx_BioNTechManufacturingMarburgGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567892355176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from Contracts with Customers (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Disclosure Of Revenue From Contracts With Customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory', window );">Summary of Disaggregation of Revenues from Contracts with Customers</a></td>
<td class="text">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Set out below is the disaggregation of the Group&#8217;s revenues from contracts with customers:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research &amp; development revenues from collaborations</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;178,849</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;84,428</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;101,837</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Pfizer Inc.</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">121,597</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">14,348</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">7,173</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Genentech Inc.</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">49,195</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">64,026</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">49,536</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Shanghai Fosun Pharmaceutical (Group) Co., Ltd</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">5,074</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2,983</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">6,054</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">45,128</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commercial revenues</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">303,476</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">24,161</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">25,738</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 vaccine revenues</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">270,490</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Sales to collaboration partner*</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">61,460</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Direct product sales to BioNTech customers</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">20,553</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Share of collaboration partner's gross profit</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">188,477</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other sales</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,986</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,161</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,738</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;482,325</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;108,589</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;127,575</p></td>
</tr>
</table>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Represents sales to collaboration partner of products manufactured by BioNTech. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenues from contracts with customers disclosed above were recognized as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Timing of revenue recognition</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Goods and services transferred at a point in time</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;108,840</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;16,955</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;22,828</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Goods and services transferred over time</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">373,485</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,634</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,747</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;482,325</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;108,589</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;127,575</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatory', window );">Summary of Contract Balances</a></td>
<td class="text">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade receivables</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;165,468</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;11,913</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">371,475</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">190,692</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfRecognitionOfRevenueExplanatory', window );">Summary of Revenue Recognized</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Set out below is the amount of revenue recognized <font style="color:#000000;">for the periods </font>indicated:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts included in contract liabilities at the beginning of the year</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;58,895</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;84,112</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;59,583</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPerformanceObligationsExplanatory', window );">Summary of Contract Liabilities Allocated to Remaining Performance Obligations (Unsatisfied or Partially Unsatisfied)</a></td>
<td class="text">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The contract liabilities allocated to the remaining performance obligations from collaboration or commercial supply agreements (unsatisfied or partially unsatisfied) as at year-end are as follows: </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within one year</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;299,583</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;93,583</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">More than one year</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,892</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,109</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;371,475</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;190,692</p></td>
</tr>
</table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of contract balances from contracts with customers explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfRecognitionOfRevenueExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognized in the reporting period, which has been included in contract liabilities at the beginning of the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfRecognitionOfRevenueExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfRevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfRevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPerformanceObligationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of performance obligations in contracts with customers. [Refer: Performance obligations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 119<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_119&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPerformanceObligationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891644072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income and Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis Of Income And Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCostOfSalesExplanatory', window );">Cost of Sales</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.93%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of sales related to COVID-19 vaccine revenues</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;35,616</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost related to other sales</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,717</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,361</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,690</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;59,333</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;17,361</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;13,690</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory', window );">Research and Development Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchased services</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;359,880</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;65,552</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;42,079</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wages, benefits and social security expense</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,298</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,213</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,668</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory supplies</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,792</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,218</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,921</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,192</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,533</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,312</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IT costs</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,118</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,800</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,572</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease and lease related cost</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,725</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,527</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,404</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transport costs</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,135</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,081</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">668</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,889</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,542</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,416</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;645,029</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;226,466</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;143,040</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfSalesAndMarketingExpensesExplanatory', window );">Sales and Marketing Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchased services</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;10,929</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;247</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;794</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wages, benefits and social security expense</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,636</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,938</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,728</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,947</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">533</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">519</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;14,512</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,718</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;3,041</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory', window );">General and Administrative Expenses</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wages, benefits and social security expense</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;33,007</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;19,122</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;8,582</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchased services</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,022</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,419</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,177</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IT and office equipment</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,404</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,573</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,774</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,104</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,855</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,284</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance premiums</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,840</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,061</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Job advertisement expenses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,897</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">548</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">861</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease and lease related cost</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,390</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,715</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,012</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research services</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,033</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory supplies</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,191</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">785</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">456</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract staffing</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,108</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">686</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">781</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,053</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,551</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,236</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;94,049</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;45,547</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;26,334</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory', window );">Other Operating Income</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government grants</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;239,017</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,547</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;4,228</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bargain purchase</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,002</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,520</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,177</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,118</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;250,539</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,724</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;5,396</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfChangesRegardingGovernmentGrantsExplanatory', window );">Changes Regarding Government Grants</a></td>
<td class="text">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Received during the year</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">330,968</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,547</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,228</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Released to the consolidated statements of operations</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(239,017)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,547)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,228)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;91,951</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,951</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExplanatory', window );">Finance Income</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,564</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,781</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,996</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange gains, net</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,341</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,050</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,564</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;4,122</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;8,046</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceCostExplanatory', window );">Finance Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of financial instruments</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;3,048</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;326</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;48</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value adjustments of financial instruments measured at fair value</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,289</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange loss, net</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,609</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;62,946</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;326</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;48</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatory', window );">Employee Benefits Expense</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wages and salaries</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;160,655</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;98,568</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;54,149</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Social security costs</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,988</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,394</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,231</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pension costs</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">761</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">517</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">324</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;179,404</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;111,479</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;62,704</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfChangesRegardingGovernmentGrantsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of changes regarding government grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfChangesRegardingGovernmentGrantsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about employee benefits expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfSalesAndMarketingExpensesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of sales and marketing expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfSalesAndMarketingExpensesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCostOfSalesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the cost of sales. [Refer: Cost of sales]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCostOfSalesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceCostExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance cost. [Refer: Finance costs]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceCostExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income. [Refer: Finance income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of general and administrative expenses. [Refer: Administrative expenses]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891837624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Major Components Of Tax Expense Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatory', window );">Summary of Current and Deferred Tax Expense</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table illustrates the current and deferred taxes for the periods indicated: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current income taxes</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C5E0B3" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;17</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(296)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;600</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred taxes</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C5E0B3" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(161,034)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other taxes</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Income taxes</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(161,000)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(268)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;600</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatory', window );">Summary of Reconciliation of Expected Income Tax Benefit to Actual Income Tax Benefit</a></td>
<td class="text">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table reconciles the expected income taxes to the actual current income taxes and deferred taxes as presented in the table above. The combined income tax rate of 30.79% in the year ended December&#160;31, 2020 (during the years ended December 31, 2019 and 2018: 30.78% and 30.99%, respectively) was applied to loss before taxes to calculate the expected income taxes. This rate consists of above outlined tax rates of BioNTech SE applicable to the Group. The slight decrease of the tax rate results from the Lipocalyx GmbH business combination. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before tax</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(145,802)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(179,440)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(47,662)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected tax benefit (based on BioNTech`s statutory tax rate of 30.79%, 2019: 30.78%, 2018: 30.99%)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,891</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,240</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,776</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Effects</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government grants exempted from taxes</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible expenses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(770)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Add-back for trade tax purposes</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(595)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(110)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-tax effective bargain purchase</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,156</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-recognition of tax effect on share-based payment expenses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,806)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,308)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax-effective equity transaction costs</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,229</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,121</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utilization of tax losses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,165</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-recognition of deferred taxes on tax losses and temporary differences</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,961)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,197)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,634)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition of deferred taxes on tax losses not recognized in prior periods</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,231</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition of deferred taxes on temporary differences not recognized in prior periods</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,241</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effect from lower foreign income tax rate</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,304)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(102)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustment prior year tax</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(326)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">316</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credit</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,059</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other effects</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,821)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Income taxes</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;161,000</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;268</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(600)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory', window );">Summary of Deferred Taxes</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred taxes for the periods indicated relate to the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">January 1,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recognized in P&amp;L*</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recognized in OCI</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses</p></td>
<td valign="top" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(655)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(2,370)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;8,637</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;5,612</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">596</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">329</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">971</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leases</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">512</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,091)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,593)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,543</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(174)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,369</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest-bearing loans and borrowings</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,741)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">195</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,546)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net employee defined benefit liabilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">169</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(63)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">698</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">804</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">187</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">886</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">419</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,492</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other (incl. deferred expenses)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,087</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,336</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,625</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax loss carryforward / tax credit</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,764</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,660</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,280</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">175,704</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred Tax Assets Net (before valuation)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;136,034</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;40,721</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(63)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;34,746</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;211,438</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation Adjustment</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(136,034)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">120,313</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(34,765)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(50,486)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred Tax Assets Net (after valuation)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;161,034</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(63)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(19)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;160,952</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Includes all changes in deferred taxes related to U.S. tax group other than those acquired in business combination</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">January 1,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recognized in P&amp;L</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recognized in OCI</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses </p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(90)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(565)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(655)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">596</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;596</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leases</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">306</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;512</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,441</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,898)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;23,543</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;187</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other (incl. deferred expenses)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,926</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,087</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax loss carryforward / tax credit</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,848</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,916</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;109,764</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred Tax Assets Net (before valuation)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;84,799</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;51,235</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;136,034</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation Adjustment</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(84,799)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(51,235)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(136,034)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred Tax Assets Net (after valuation)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfAccumulatedTaxLossesExplanatory', window );">Summary of Accumulated Tax Losses</a></td>
<td class="text">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated tax losses of the German tax group, German <font style="color:#000000;">entities</font> <font style="color:#000000;">not within the tax group </font>and U.S. tax group for the periods indicated amount to the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate Tax</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;596,359</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;356,044</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;179,264</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade Tax</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,561</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">352,341</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176,425</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal Tax Credits</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;756</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State Tax Credits</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.74%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfAccumulatedTaxLossesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accumulated tax losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfAccumulatedTaxLossesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of current and deferred tax expense explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reconciliation of expected income tax benefit to actual income tax benefit explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_g&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567919689128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Summary of Income and Share Data Used in the Basic and Diluted EPS Calculations</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table reflects the income and share data used in the basic and diluted EPS calculations:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Gain (loss) attributable to ordinary equity holders of the parent for basic earnings</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15,198</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(179,056)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(48,019)</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of ordinary shares for basic EPS</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">235,442</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">211,499</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">190,710</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effects of dilution from share options</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C5E0B3" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,085</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of ordinary shares adjusted for the effect of dilution</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">248,527</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">211,499</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">190,710</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Earnings per share</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">in EUR</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted, profit / (loss) for the period attributable to ordinary equity holders of the parent*</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;0.06</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(0.85)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(0.25)</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567919684008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure Of Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Summary of Property Plant and Equipment</a></td>
<td class="text">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Land and buildings</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Equipment, tools and installations</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress and advance payments</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Acquisition and production costs</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;22,147</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;73,613</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7,091</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;102,853</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,269</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,700</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,623</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,592</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disposals</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(105)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(115)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency differences</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">999</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">999</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;29,469</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;83,206</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;29,652</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;142,329</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;29,469</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;83,206</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;29,652</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;142,329</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,927</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,093</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,013</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,033</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disposals</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,892)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(958)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,891)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,561</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,832</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,391)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency differences</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(638)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(690)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,400</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,817</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,302</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,519</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;61,264</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;142,418</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;81,618</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;285,300</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Land and buildings</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Equipment, tools and installations</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress and advance payments</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cumulative depreciation and impairment charges</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;6,472</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;30,180</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;36,652</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,854</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,861</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,715</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disposals</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(79)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(79)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency differences</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;8,326</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;40,959</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;49,285</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;8,326</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;40,959</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;49,285</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,074</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,753</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,827</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disposals</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,683)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,724)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency differences</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;10,356</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;47,976</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;58,332</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Land and buildings</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Equipment, tools and installations</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress and advance payments</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Carrying amount</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15,675</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;43,433</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7,091</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;66,200</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;21,143</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;42,247</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;29,652</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;93,044</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;50,908</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;94,442</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;81,618</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;226,968</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 73<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891510696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract', window );"><strong>Disclosure Of Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory', window );">Summary of Detailed Information About Intangible Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concessions, licenses, in-process R&amp;D and similar rights</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Advance payments</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Acquisition costs</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;534</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;101,853</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,497</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;103,883</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,744</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,529</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,273</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disposals</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(133)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(477)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(610)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(146)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency differences</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,444</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,726</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,170</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,978</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;116,313</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,403</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;121,693</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,978</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;116,313</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,403</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;121,693</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,187</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,426</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,613</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disposals</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,435)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(643)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,078)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">233</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(233)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency differences</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,750)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,897)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,647)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,469</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,845</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,314</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;53,697</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;147,246</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;5,953</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;206,895</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concessions, licenses, in-process R&amp;D and similar rights</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Advance payments</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cumulative depreciation and impairment charges</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15,842</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15,842</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,502</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,502</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disposals</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency differences</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;32,260</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;32,260</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;32,260</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;32,260</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,627</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,627</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disposals</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,410)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,410)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency differences</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(72)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(72)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;43,405</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;43,405</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concessions, licenses, in-process R&amp;D and similar rights</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Advance payments</p></td>
<td rowspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Carrying amount</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;534</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;86,011</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,497</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;88,042</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,978</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;84,053</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,403</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;89,434</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;53,697</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;103,841</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;5,953</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;163,490</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatory', window );">Summary of Goodwill Recognized</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CGU Immunotherapies</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">External Product Sales of JPT</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;53,163</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,444</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;534</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;534</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;53,697</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,978</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of goodwill acquired in respective business combinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Paragraph 118<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567888324344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Financial Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure Of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory', window );">Summary of Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at banks and on hand</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,210,209</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;519,149</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,210,209</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;519,149</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory', window );">Summary of Financial Assets at Amortized Cost</a></td>
<td class="text">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="4" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial assets at amortized cost</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade receivables</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;165,468</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;11,913</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other financial assets</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137,234</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,680</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;302,702</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;13,593</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">302,702</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,593</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory', window );">Summary of Financial Liabilities at Amortized Cost</a></td>
<td class="text">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="4" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Interest-bearing loans and borrowings</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Maturity</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;84,158</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;57,611</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible note - host contract</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">08/28/2024</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,457</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.50% &#8364; 50,000,000 secured bank loan</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/21/2026</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,176</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.15% &#8364; 10,000,000 secured bank loan</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/30/2027</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,032</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,000</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.08% &#8364; 9,450,000 secured bank loan</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/30/2028</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,877</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,600</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.90% &#8364; 3,528,892.48 secured bank loan</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">05/30/2039</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,489</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;240,189</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;74,211</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,142</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,307</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">231,047</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,904</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="4" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other financial liabilities</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Derivatives not designated as hedging instrument</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible note - embedded derivative</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;30,903</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial liabilities at fair value through profit or loss</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">572</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total financial liabilities at fair value</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;31,475</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.6%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other financial liabilities at amortized cost, other than interest-bearing loans and borrowings</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade payables</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,288</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,498</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other financial liabilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,076</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,352</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.6%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total other financial liabilities at amortized cost, other than interest-bearing loans and borrowings</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;176,364</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;30,850</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total other financial liabilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;207,839</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;30,850</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176,363</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,850</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.12%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,476</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="4" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total financial liabilities</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest-bearing loans and borrowings</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;240,189</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;74,211</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other financial liabilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;207,839</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;30,850</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;448,028</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;105,061</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">185,505</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,157</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262,523</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,904</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturity profile of the Group&#8217;s financial liabilities based on contractual undiscounted payments is summarized as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2020</p></td>
<td colspan="4" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Less than 1 year</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1 to 5 years</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">More than 5 years</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest bearing loans and borrowings</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;3,173</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;12,643</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;66,730</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;82,546</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade and other payables</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,288</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;102,288</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,525</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,283</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,780</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;107,588</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">572</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;572</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other financial liabilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,076</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;74,076</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.96%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;188,062</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;39,926</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;139,082</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;367,070</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfForeignCurrencyRiskExplanatory', window );">Summary of Carrying Amount of Monetary Assets</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amount of the monetary assets (the Group&#8217;s cash and cash equivalents) of BioNTech denominated in foreign currencies at the dates indicated are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.82%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.82%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. dollar Bank accounts</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;673,545</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;213,913</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other financial assets in U.S. dollar</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,573</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.82%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial liabilities in U.S. dollar</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,821</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;686,297</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;213,913</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory', window );">Summary of Effect of Changes in Foreign Exchange Rates</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">1 &#8364; =</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Closing rate</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average rate</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Currency</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Country</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. dollar</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.16%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2271</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1234</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1422</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1195</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change in U.S. dollar rate</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Effect on loss before tax</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Effect on pre-tax equity</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+5 %</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(32,491)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(32,681)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-5%</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;35,911</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;36,121</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-right:solid 1pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-left:solid 1pt #70AD47; border-right:solid 1pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+5 %</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-left:solid 1pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-right:solid 1pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(10,186)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-left:solid 1pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(10,186)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-5%</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;11,259</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;11,259</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory', window );">Summary of Changes in Liabilities Arising From Financing Activities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">January 1,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">New leases and disposals</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reclassification</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current obligations under lease contracts</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;3,485</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(12,743)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,719</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;8,684</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;3,982</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;6,127</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current obligations under lease contracts</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,126</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,331</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,444)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,982)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">78,031</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest-bearing loans and borrowings</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,600</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140,847</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,416)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">156,031</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible note - embedded derivative</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,614</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,289</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">30,903</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;74,211</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;141,718</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;35,050</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;4,240</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15,873</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;271,092</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">January 1,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">New leases and disposals</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reclassification</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current obligations under lease contracts</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,134</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(3,061)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,484</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,928</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;3,485</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current obligations under lease contracts</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,618</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,436</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,928)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">54,126</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest-bearing loans and borrowings</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,600</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,000</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16,600</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.34%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;56,352</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7,939</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;9,920</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;74,211</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfForeignCurrencyRiskExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of foreign currency risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfForeignCurrencyRiskExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the effect of changes in foreign exchange rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS21_g51-57_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 44D<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_44D&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567911959016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Classes Of Inventories [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfClassesOfInventoriesExplanatory', window );">Summary of Inventories</a></td>
<td class="text">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials and supplies</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;44,283</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;8,201</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unfinished goods</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,380</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,888</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">457</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">633</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;64,120</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;11,722</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfClassesOfInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of classes of inventories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfClassesOfInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567911978520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MiscellaneousCurrentAssetsAbstract', window );"><strong>Miscellaneous Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatory', window );">Summary of Other Assets</a></td>
<td class="text">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepayments on inventories</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,845</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">351</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepayments related to CRO and CMO contracts</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,140</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales tax receivable</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,155</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,536</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepayments related to service contracts</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,825</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,046</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,182</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;62,011</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;9,069</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,966</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,069</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.76%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,045</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
</table>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about other assets explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567911990920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfDeferredExpensesAbstract', window );"><strong>Disclosure Of Deferred Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfExpensesExplanatory', window );">Summary of Deferred Expenses</a></td>
<td class="text">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred expenses from insurance contracts</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;13,845</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,758</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred expenses from CRO and CMO contracts</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,725</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,431</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,104</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;28,001</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;5,862</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,001</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,862</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfDeferredExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of deferred expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfDeferredExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfExpensesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfExpensesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891651208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanMember', window );">Employee Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">Schedule of Number and Share Price of Restricted Stock Units</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reconciliation of Outstanding Share-Options</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Restricted Stock Units (expected to be allocated)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share price (in &#8364;)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected to be allocated under LTI Program</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">252,766</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66.43</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected to be allocated under LTI-plus Program</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">396,938</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66.43</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">649,704</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">66.43</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss', window );">Schedule of Expense Recognized for Employee Services Received</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Expense recognized in the Consolidated Statements of Operations</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of sales</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;179</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">681</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,015</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember', window );">Management Board Grant</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss', window );">Schedule of Expense Recognized for Employee Services Received</a></td>
<td class="text">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The expenses recognized for employee services received during the periods indicated are shown in the following table: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,514</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,246</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,760</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Schedule of Number and Weighted-Average Exercise Price of Share Options</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The share options allocated and expected to be allocated to BioNTech&#8217;s Management Board as of the dates indicated are presented in the tables below. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share options (expected to be allocated)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average exercise price (&#8364;)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted as of allocation date February 13, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">248,096</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.32</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected to be allocated as of estimated allocation date 2021</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,422</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.26*</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected to be allocated as of estimated allocation date 2022</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,463</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.27*</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">451,981</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">45.89</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Valuation parameter derived from the Monte-Carlo simulation model</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The share options allocated and expected to be allocated under the Management Board Grant were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Allocation date February 13, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share options</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">outstanding</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average exercise price (&#8364;)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prof. Ugur Sahin, M.D.</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,420</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.32</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sean Marett</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,968</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.32</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Sierk Poetting</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,968</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.32</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. &#214;zlem T&#252;reci, M.D.</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,968</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.32</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ryan Richardson</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,772</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.32</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated allocation date 2021</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share options</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">outstanding (expected to be allocated)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average exercise price (&#8364;)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prof. Ugur Sahin, M.D.</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,826</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.26*</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sean Marett</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,930</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.26*</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Sierk Poetting</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,930</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.26*</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. &#214;zlem T&#252;reci, M.D.</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,930</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.26*</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ryan Richardson</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,806</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.26*</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Valuation parameter derived from the Monte-Carlo simulation model</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated allocation date 2022</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share options</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">outstanding (expected to be allocated)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average exercise price (&#8364;)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prof. Ugur Sahin, M.D.</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,817</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.27*</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sean Marett</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,927</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.27*</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Sierk Poetting</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,927</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.27*</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. &#214;zlem T&#252;reci, M.D.</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,927</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.27*</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.56%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ryan Richardson</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,865</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.27*</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Valuation parameter derived from the Monte-Carlo simulation model</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The share options outstanding as of December 31, 2020 issued to the Management Board Grant were as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share options</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">outstanding</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number of ordinary shares underlying options</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average exercise price (&#8364;)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prof. Ugur Sahin, M.D.</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,686</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,830,348</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sean Marett</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,895</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">610,110</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Sierk Poetting</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,895</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">610,110</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. &#214;zlem T&#252;reci, M.D.</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108,463*</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,952,334</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.18%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ryan Richardson**</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,306***</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149,508</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*&#160;&#160;&#160;&#160;&#160;Options fully vested on March 16, 2019, however these options will not become exercisable until September&#160;16,&#160;2022.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**&#160;&#160;&#160;Ryan Richardson was appointed to the Management Board as Chief Strategy Officer (CSO) and Managing Director on January 12, 2020. The share options granted on November 15, 2018 under the Employee<font style="letter-spacing:0.05pt;"> </font>Stock Ownership Plan were granted before his appointment to the Management Board. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***&#160;Options fully vested on October 10, 2019, however these options will not become exercisable until September&#160;16,&#160;2022.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Summary of Inputs Used in Measurement of Fair Value at Grant Date</a></td>
<td class="text">The parameters used for measuring the fair values as of the respective (estimated) allocation dates were as follows:
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Allocation date February 13, 2020</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated allocation date&nbsp;&nbsp;2021</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated allocation date 2022</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average fair value*</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;10.83</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;26.85</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;26.61</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average share price</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;28.20</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 66.43*</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 66.43*</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;28.32</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 67.26*</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364; 67.27*</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility (%)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36.6%</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.0%</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40.7%</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (years)*</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.75</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.01</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.05</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate (%)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.61 %</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.88%</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.88%</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Valuation parameter derived from the Monte-Carlo simulation model</p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember', window );">Chief Executive Officer Grant</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Summary of Inputs Used in Measurement of Fair Value at Grant Date</a></td>
<td class="text">The inputs used in the measurement of the fair value at grant date of the Chief Executive Officer Grant were as follows:
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant date October 10, 2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average fair value</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;5.63</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average share price</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;13.60</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;13.60</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility (%)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.4%</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (years)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.37</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate (%)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.52 %</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember', window );">Employee Stock Ownership Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss', window );">Schedule of Expense Recognized for Employee Services Received</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The expenses recognized for employee services received during the periods indicated are shown in the following table:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of sales</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;869</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;896</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;114</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,120</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,016</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,786</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,975</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,008</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">728</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;17,075</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;27,028</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7,641</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Schedule of Number and Weighted-Average Exercise Price of Share Options</a></td>
<td class="text">Set out below is an overview of changes to share options outstanding and number of ordinary shares underlying these options that occurred during the periods indicated:
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share options</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">outstanding</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number of ordinary shares underlying options</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average exercise price (&#8364;)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">658,109</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,845,962</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,511</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">261,198</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.17</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,237)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(310,266)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.85</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">655,383</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11,796,894</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.23</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">655,383</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,796,894</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.23</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,491)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(170,838)</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.81</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">645,892</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11,626,056</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.23</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Summary of Inputs Used in Measurement of Fair Value at Grant Date</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The inputs used in the measurement of the fair values at grant date of the ESOP was as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant date</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15 November 2018</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant dates</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">between</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">February 21 -</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">April 3, 2019</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant dates</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">between</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">April 29 -</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">May 31, 2019</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant date December 1, 2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average fair value</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7.41</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;6.93</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7.04</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;9.49</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average share price</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;14.40</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15.72</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;16.03</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;19.84</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;10.14</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15.03</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15.39</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;15.82</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility (%)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46.0%</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46.0%</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46.0%</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46.0%</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (years)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.84</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.00</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.00</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.50</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate (%)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.05%</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.05%</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.05%</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.05%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The explanation that enables users of financial statements to understand the effect of share-based payment transactions on the entity's profit (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 50<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_50&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567911978520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MiscellaneousCurrentLiabilitiesAbstract', window );"><strong>Miscellaneous Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfDetailedInformationAboutOtherLiabilitiesExplanatory', window );">Summary of Other Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities to employees</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;24,248</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;6,710</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,379</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">780</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;28,627</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7,490</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,061</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,490</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">566</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfDetailedInformationAboutOtherLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Detailed Information About Other Liabilities Explanatory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfDetailedInformationAboutOtherLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567919420360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation Of Leases For Lessee [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory', window );">Summary of Right-of-Use Assets within Consolidated Statements of Financial Position</a></td>
<td class="text">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following amounts are presented as right-of-use assets within the consolidated statements of financial position as of the dates indicated: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;80,875</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;54,956</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equipment, tools and installations</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Automobiles</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Production facilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,202</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Advance payments</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,800</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;98,988</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;55,018</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatory', window );">Summary of Lease Liability Included in Interest-Bearing Loans and Borrowings</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following amounts are included in interest-bearing loans and borrowings as of the dates indicated: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;6,127</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;3,485</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,031</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,126</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;84,158</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;57,611</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInstatementOfOperationsExplanatory', window );">Summary of Amounts Recognized in Consolidated Statement of Operations</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Depreciation Charge of Right-of-Use Assets</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;4,628</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;4,614</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,751</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equipment, tools and installations</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Automobiles</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Production facilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,613</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total depreciation charge</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;6,290</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;4,679</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,846</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on lease liabilities</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,003</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,718</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,721</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expense related to short-term leases</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(included in other expenses)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">875</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">442</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">431</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expense relating to leases of low-value assets that are not short-term leases (included in other expenses)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total amounts recognized in profit or loss</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;9,468</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;6,929</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;5,088</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInstatementOfOperationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about lease expense recognized instatement of operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInstatementOfOperationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567888324632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract', window );"><strong>Disclosure Of Information About Defined Benefit Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory', window );">Summary of Defined Benefit Obligation Recognized in Non-current Provisions</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the defined benefit obligation recognized in non-current provisions:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Base plan</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,140</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplement plan</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,125</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;4,265</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfDetailedInformationAboutNetBenefitExpenseRecognizedInStatementOfProfitOrLossExplanatory', window );">Summary of Components of Net Benefit Expense Recognized in Statement of Profit or Loss</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the components of net benefit expense recognized in the statement of profit or loss for both plans: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Service cost</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;24</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net interest expense</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;30</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfDetailedInformationAboutRemeasurementsRecognizedInOtherComprehensiveIncomeExplanatory', window );">Summary of Components of Remeasurements Recognized in Other Comprehensive Income</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the components of remeasurements recognized in other comprehensive income for both plans:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Actuarial changes arising from changes in financial assumptions</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;227</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Experience adjustments</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;210</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory', window );">Schedule of Changes to Defined Benefit Obligation</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Set out below is an overview of changes to the defined benefit obligation during the period indicated for both plans:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Defined benefit obligations</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of subsidiaries and businesses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,029)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Service cost</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net interest expense</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Benefits paid</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Actuarial changes arising from changes in financial assumptions</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(227)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Experience adjustments</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(4,265)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfPresentValueOfDefinedBenefitObligationThatDistinguishesNatureCharacteristicsAndRisksExplanatory', window );">Schedule of Principal Assumptions used in Determining Defined Benefit Obligations</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The principal assumptions used in determining the defined benefit obligation for the Group&#8217;s plans are shown below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.34%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.36%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.34%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.36%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.80%</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Price inflation</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.00%</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rate of salary increase</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.50%</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pension increases for in-payment benefits</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.36%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.75%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory', window );">Schedule of Quantitative Sensitivity Analysis</a></td>
<td class="text">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The main actuarial assumptions that are used to calculate the provisions for post-employment benefits are the discount rate and the trend for future increases in post-employment benefit payments. A reasonably possible increase, or respective decrease, in the significant actuarial assumptions would have impacted the present value of the post-employment benefit obligations as of December&#160;31, 2020 as shown below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="3" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Quantitative sensitivity analysis</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate increase 0.25%</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;(282)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate decrease 0.25%</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">309</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pension increases for in payment benefits 0.25%</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">475</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pension decreases for in payment benefits 0.25%</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(447)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfDetailedInformationAboutExpectedPaymentsOrContributionsToDefinedBenefitPlanExplanatory', window );">Schedule of Expected Payments or Contributions to Plans in Future Years</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following are the expected payments or contributions to the plans in future years:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="3" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Expected payments or contributions in future years</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less than 1 year</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;29</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 to 5 years</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">317</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">More than 5 years</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">340</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.36%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8364;686</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfDetailedInformationAboutExpectedPaymentsOrContributionsToDefinedBenefitPlanExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about expected payments or contributions to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfDetailedInformationAboutExpectedPaymentsOrContributionsToDefinedBenefitPlanExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfDetailedInformationAboutNetBenefitExpenseRecognizedInStatementOfProfitOrLossExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about net benefit expense recognized in statement of profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfDetailedInformationAboutNetBenefitExpenseRecognizedInStatementOfProfitOrLossExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfDetailedInformationAboutRemeasurementsRecognizedInOtherComprehensiveIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about remeasurements recognized in other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfDetailedInformationAboutRemeasurementsRecognizedInOtherComprehensiveIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAnalysisOfPresentValueOfDefinedBenefitObligationThatDistinguishesNatureCharacteristicsAndRisksExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of an analysis of the present value of a defined benefit obligation that distinguishes the nature, characteristics and risks of the obligation. Such a disclosure could distinguish: (a) between amounts owing to active members, deferred members, and pensioners; (b) between vested benefits and accrued but not vested benefits; and (c) between conditional benefits, amounts attributable to future salary increases and other benefits. [Refer: Defined benefit obligation, at present value]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 137<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_137&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAnalysisOfPresentValueOfDefinedBenefitObligationThatDistinguishesNatureCharacteristicsAndRisksExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of defined benefit plans. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 138<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_138&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 140<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_140_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a sensitivity analysis for significant actuarial assumptions used to determine the present value of a defined benefit obligation. [Refer: Actuarial assumptions [member]; Defined benefit obligation, at present value]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 145<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_145&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567914614248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Disclosure Of Transactions Between Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory', window );">Summary of Compensation of Key Management Personnel</a></td>
<td class="text">Key management personnel compensation is comprised of the following:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation of key management personnel of the Group</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term employee benefits incurred</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,627</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,847</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,161</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term employee benefits accrued*</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">740</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based payments</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,700**</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,151</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,163</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total compensation paid to key management personnel</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;24,067</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;19,998</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7,324</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-size:2pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Includes the fair value of the second installment of the short-term incentive compensation, which has been classified as cash-settled share-based payment arrangement was determined pursuant to the regulations of IFRS 2 &#8220;Share-based Payments&#8221;. This table shows the pro-rata share of personnel expenses for the respective financial year that are recognized over the award&#8217;s vesting period beginning as of the service commencement date (January 1, 2020) until each separate determination date and are remeasured until settlement date.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Includes expenses from a bonus arrangement agreed with Ryan Richardson in advance of his appointment to the Management Board. During the year ended December 31, 2020, the arrangement was modified from an all-equity share-based payment arrangement into a partly cash and partly equity settled share-based payment arrangement including 4,534 ordinary shares which have not yet been issued. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate value of transactions related to key management personnel were as follows for the periods indicated:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consulting services / patent assignment</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;25</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;56</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;25</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of various goods and services from TRON</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,105</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,968</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,160</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;10,130</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;10,024</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;11,185</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The outstanding balances of transactions related to key management personnel were as follows as at the periods indicated:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consulting service provider</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TRON</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,229</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,843</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,236</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;1,843</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">Summary of Transactions Between Other Related Parties</a></td>
<td class="text">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.93%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total amount of transactions with ATHOS KG or entities controlled by it was as follows for the periods indicated:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of various goods and services from entities controlled by ATHOS KG</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,296</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,071</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,431</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and other assets from entities controlled by ATHOS KG</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,349</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,748</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.92%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;4,645</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;2,071</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;7,179</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The outstanding balances of transactions with ATHOS KG or entities controlled by them were as follows as at the periods indicated:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATHOS KG</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;500</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8364;51</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#C6E0B4" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47; border-right:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;500</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.68%; border-top:solid 0.75pt #70AD47; border-bottom:solid 0.75pt #70AD47; border-left:solid 0.75pt #70AD47;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8364;51</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567914609688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Corporate Information - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>Entity</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfCorporateInformationLineItems', window );"><strong>Disclosure Of Corporate Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NumberOfNewRealEstateEntitiesFounded', window );">Number of new real estate entities founded</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfCorporateInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of corporate information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfCorporateInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfNewRealEstateEntitiesFounded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new real estate entities founded.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfNewRealEstateEntitiesFounded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891768488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>OperationSegment </div>
<div>ReportingSegment </div>
<div>Country</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>OperationSegment</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Disclosure Of Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NumberOfOperationSegments', window );">Number of operation segments | OperationSegment</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NumberOfReportingSegments', window );">Number of reporting segment | ReportingSegment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_MinimumNumberOfCountriesInWhichCOVID19VaccineAuthorizedOrApprovedForEmergencyOrTemporaryUseOrGrantedConditionalMarketingAuthorization', window );">Minimum number of countries in which COVID-19 vaccine was authorized or approved for emergency or temporary use or granted conditional marketing authorization | Country</a></td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers', window );">Payment terms in contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Payments from customers are due within 20 days (Europe) or 30 days (non-Europe) after invoice.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of summary of significant accounting policies abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_MinimumNumberOfCountriesInWhichCOVID19VaccineAuthorizedOrApprovedForEmergencyOrTemporaryUseOrGrantedConditionalMarketingAuthorization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum number of countries in which COVID-19 vaccine authorized or approved for emergency or temporary use or granted conditional marketing authorization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_MinimumNumberOfCountriesInWhichCOVID19VaccineAuthorizedOrApprovedForEmergencyOrTemporaryUseOrGrantedConditionalMarketingAuthorization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfOperationSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operation segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfOperationSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfReportingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfReportingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the significant payment terms in contracts with customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 119<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_119_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567887837336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Useful Lives Applied to the Group's Property, Plant and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember', window );">Buildings | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure Of Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Property, plant and equipment, Useful life (Years)</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember', window );">Buildings | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure Of Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Property, plant and equipment, Useful life (Years)</a></td>
<td class="text">33 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_EquipmentToolsAndInstallationsMember', window );">Equipment, Tools and Installations | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure Of Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Property, plant and equipment, Useful life (Years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_EquipmentToolsAndInstallationsMember', window );">Equipment, Tools and Installations | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure Of Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Property, plant and equipment, Useful life (Years)</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 73<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_73_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_EquipmentToolsAndInstallationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_EquipmentToolsAndInstallationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891667192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Useful Lives Applied to the Group's Right-of-use Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Minimum | Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets', window );">Right-of-use assets, Useful life (Years)</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Minimum | Equipment, Tools and Installations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets', window );">Right-of-use assets, Useful life (Years)</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Minimum | Production Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets', window );">Right-of-use assets, Useful life (Years)</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Minimum | Automobiles</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets', window );">Right-of-use assets, Useful life (Years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=ifrs-full_TopOfRangeMember', window );">Maximum | Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets', window );">Right-of-use assets, Useful life (Years)</a></td>
<td class="text">25 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=ifrs-full_TopOfRangeMember', window );">Maximum | Equipment, Tools and Installations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets', window );">Right-of-use assets, Useful life (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=ifrs-full_TopOfRangeMember', window );">Maximum | Production Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets', window );">Right-of-use assets, Useful life (Years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=ifrs-full_TopOfRangeMember', window );">Maximum | Automobiles</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets', window );">Right-of-use assets, Useful life (Years)</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life measured as period of time right-of-use-assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=bntx_EquipmentToolsAndInstallationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=bntx_EquipmentToolsAndInstallationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=bntx_ProductionFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=bntx_ProductionFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567888344680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Useful Lives Applied to the Group's Intangible Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Minimum | Intellectual Property Rights</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Intangible assets, Useful life (Years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Minimum | Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Intangible assets, Useful life (Years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Minimum | Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Intangible assets, Useful life (Years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=ifrs-full_TopOfRangeMember', window );">Maximum | Intellectual Property Rights</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Intangible assets, Useful life (Years)</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=ifrs-full_TopOfRangeMember', window );">Maximum | Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Intangible assets, Useful life (Years)</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=ifrs-full_TopOfRangeMember', window );">Maximum | Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Intangible assets, Useful life (Years)</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Paragraph 118<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_118_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=bntx_IntellectualPropertyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=bntx_IntellectualPropertyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567912010504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Judgments, Estimates and Assumptions - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsAbstract', window );"><strong>Significant Accounting Judgments Estimates And Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception', window );">Estimated milestone payment to be received</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated milestone payment to be received at contract inception.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant accounting judgments, estimates and assumptions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567892042168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Judgments, Estimates and Assumptions - Schedule of Provisional Sales Figures for Territories (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsLineItems', window );"><strong>Significant Accounting Judgments Estimates And Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from contracts with customers</a></td>
<td class="nump">&#8364; 482,325<span></span>
</td>
<td class="nump">&#8364; 108,589<span></span>
</td>
<td class="nump">&#8364; 127,575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=bntx_CollaborationAgreementMember', window );">Share of Collaboration Partner's Gross Profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsLineItems', window );"><strong>Significant Accounting Judgments Estimates And Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from contracts with customers</a></td>
<td class="nump">188,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SalesChannelsAxis=ifrs-full_GoodsSoldDirectlyToConsumersMember', window );">Direct Product Sales to BioNTech Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsLineItems', window );"><strong>Significant Accounting Judgments Estimates And Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from contracts with customers</a></td>
<td class="nump">20,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_DE', window );">German Territory | Direct Product Sales to BioNTech Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsLineItems', window );"><strong>Significant Accounting Judgments Estimates And Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from contracts with customers</a></td>
<td class="nump">20,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">U.S. Territory | Share of Collaboration Partner's Gross Profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsLineItems', window );"><strong>Significant Accounting Judgments Estimates And Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from contracts with customers</a></td>
<td class="nump">46,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=bntx_OutsideUSMember', window );">Territories Outside the U.S. | Share of Collaboration Partner's Gross Profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsLineItems', window );"><strong>Significant Accounting Judgments Estimates And Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from contracts with customers</a></td>
<td class="nump">&#8364; 141,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant accounting judgments estimates and assumptions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_SignificantAccountingJudgmentsEstimatesAndAssumptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=bntx_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=bntx_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesChannelsAxis=ifrs-full_GoodsSoldDirectlyToConsumersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesChannelsAxis=ifrs-full_GoodsSoldDirectlyToConsumersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=bntx_OutsideUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=bntx_OutsideUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567886248536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Group Information - Summary of Information about Subsidiaries (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRNAPharmaceuticalsGmbHMember', window );">BioNTech RNA Pharmaceuticals GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Registered office</a></td>
<td class="text">Mainz<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechDeliveryTechnologiesGmbHMember', window );">BioNTech Delivery Technologies GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Registered office</a></td>
<td class="text">Halle<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechDiagnosticsGmbHMember', window );">BioNTech Diagnostics GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Registered office</a></td>
<td class="text">Mainz<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechEuropeGmbHMember', window );">BioNTech Europe GmbH (previously BioNTech Small Molecules GmbH)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Registered office</a></td>
<td class="text">Mainz<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechManufacturingGmbHMember', window );">BioNTech Manufacturing GmbH (previously BioNTech IVAC GmbH)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Registered office</a></td>
<td class="text">Mainz<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechManufacturingMarburgGmbHMember', window );">BioNTech Manufacturing Marburg GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Registered office</a></td>
<td class="text">Marburg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechAustriaBeteiligungenGmbHMember', window );">BioNTech Austria Beteiligungen GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Austria<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Registered office</a></td>
<td class="text">Vienna<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechInnovativeManufacturingServicesGmbHMember', window );">BioNTech Innovative Manufacturing Services GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Registered office</a></td>
<td class="text">Idar-Oberstein<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_ReSanoGmbHMember', window );">ReSano GmbH (previously reBOOST Management GmbH)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Registered office</a></td>
<td class="text">Mainz<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_JPTPeptideTechnologiesGmbHMember', window );">JPT Peptide Technologies GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Registered office</a></td>
<td class="text">Berlin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_JPTPeptideTechnologiesIncMember', window );">JPT Peptide Technologies Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Registered office</a></td>
<td class="text">Cambridge (previously Acton)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechUSAHoldingLLCMember', window );">BioNTech USA Holding LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Registered office</a></td>
<td class="text">Cambridge (previously New York)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechResearchAndDevelopmentIncMember', window );">BioNTech Research and Development Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Registered office</a></td>
<td class="text">Cambridge (previously New York)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechCellAndGeneTherapiesGmbHMember', window );">BioNTech Cell &amp; Gene Therapies GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Registered office</a></td>
<td class="text">Mainz<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechUSIncMember', window );">BioNTech US Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Registered office</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechPharmaceuticalsAsiaPacificPteLtdMember', window );">BioNTech Pharmaceuticals Asia Pacific Pte. Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Singapore<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Registered office</a></td>
<td class="text">Singapore<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRealEstateVerwaltungsGmbHMember', window );">BioNTech Real Estate Verwaltungs GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Registered office</a></td>
<td class="text">Holzkirchen<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechUKLimitedMember', window );">BioNTech UK Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">United Kingdom<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Registered office</a></td>
<td class="text">Reading<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRealEstateGmbHAndCoKGMember', window );">BioNTech Real Estate GmbH &amp; Co. KG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Registered office</a></td>
<td class="text">Holzkirchen<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRealEstateHoldingGmbHMember', window );">BioNTech Real Estate Holding GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Registered office</a></td>
<td class="text">Holzkirchen<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRealEstateDerGoldgrubeGmbHCoKGMember', window );">BioNTech Real Estate An der Goldgrube GmbH &amp; Co. KG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Registered office</a></td>
<td class="text">Holzkirchen<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRealEstateHausVierGmbHCoKGMember', window );">BioNTech Real Estate Haus Vier GmbH &amp; Co. KG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Registered office</a></td>
<td class="text">Holzkirchen<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRealEstateAdamOpelStraeGmbHCoKGMember', window );">BioNTech Real Estate Adam Opel Stra&#223;e GmbH &amp; Co. KG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Registered office</a></td>
<td class="text">Holzkirchen<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The country in which a subsidiary of the entity is incorporated. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 12<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_12_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 19B<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_19B_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The principal place of business of a subsidiary. [Refer: Principal place of business; Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 12<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_12_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 19B<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_19B_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRNAPharmaceuticalsGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRNAPharmaceuticalsGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechDeliveryTechnologiesGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechDeliveryTechnologiesGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechDiagnosticsGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechDiagnosticsGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechEuropeGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechEuropeGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechManufacturingGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechManufacturingGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechManufacturingMarburgGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechManufacturingMarburgGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechAustriaBeteiligungenGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechAustriaBeteiligungenGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechInnovativeManufacturingServicesGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechInnovativeManufacturingServicesGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_ReSanoGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_ReSanoGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_JPTPeptideTechnologiesGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_JPTPeptideTechnologiesGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_JPTPeptideTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_JPTPeptideTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechUSAHoldingLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechUSAHoldingLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechResearchAndDevelopmentIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechResearchAndDevelopmentIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechCellAndGeneTherapiesGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechCellAndGeneTherapiesGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechUSIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechUSIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechPharmaceuticalsAsiaPacificPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechPharmaceuticalsAsiaPacificPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRealEstateVerwaltungsGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRealEstateVerwaltungsGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechUKLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechUKLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRealEstateGmbHAndCoKGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRealEstateGmbHAndCoKGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRealEstateHoldingGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRealEstateHoldingGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRealEstateDerGoldgrubeGmbHCoKGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRealEstateDerGoldgrubeGmbHCoKGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRealEstateHausVierGmbHCoKGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRealEstateHausVierGmbHCoKGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRealEstateAdamOpelStraeGmbHCoKGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRealEstateAdamOpelStraeGmbHCoKGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567888290840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Group Information - Additional Information (Details) - Entity<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_NeonTherapeuticsIncAndNovartisManufacturingGmbHMember', window );">Neon Therapeutics Inc. (subsequently renamed BioNTech US Inc.) and Novartis Manufacturing GmbH (subsequently renamed BioNTech Manufacturing Marburg GmbH)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NumberOfEntitiesAcquiredDuringPeriod', window );">Number of entities acquired during the period</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechUSAHoldingLLCAndBioNTechResearchAndDevelopmentIncMember', window );">BioNTech USA Holding, LLC and BioNTech Research &amp; Development, Inc. | ReSano GmbH (previously reBOOST Management GmbH)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NumberOfNewEntities', window );">Number of entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfEntitiesAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of entities acquired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfEntitiesAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfNewEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfNewEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_NeonTherapeuticsIncAndNovartisManufacturingGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_NeonTherapeuticsIncAndNovartisManufacturingGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechUSAHoldingLLCAndBioNTechResearchAndDevelopmentIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechUSAHoldingLLCAndBioNTechResearchAndDevelopmentIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=bntx_ReSanoGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=bntx_ReSanoGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140568065123640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Group Information - Summary of Information about Parent Company (Details) - BioNTech - AT Impf GmbH<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Registered office</a></td>
<td class="text">Munich<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership of ordinary shares in BioNTech</a></td>
<td class="nump">47.37%<span></span>
</td>
<td class="nump">50.33%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The country in which a subsidiary of the entity is incorporated. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 12<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_12_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 19B<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_19B_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The principal place of business of a subsidiary. [Refer: Principal place of business; Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 12<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_12_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 19B<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_19B_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bntx_BioNTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bntx_BioNTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=bntx_ATImpfGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=bntx_ATImpfGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891627144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Group Information - Summary of Information about Entity with Significant Influence Over Group (Details) - BioNTech - Medine GmbH<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure Of Significant Investments In Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Registered office</a></td>
<td class="text">Mainz<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership of ordinary shares in BioNTech</a></td>
<td class="nump">17.25%<span></span>
</td>
<td class="nump">18.38%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The country in which a subsidiary of the entity is incorporated. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 12<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_12_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 19B<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_19B_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The principal place of business of a subsidiary. [Refer: Principal place of business; Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 12<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_12_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 19B<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_19B_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bntx_BioNTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bntx_BioNTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=bntx_MedineGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=bntx_MedineGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567886596808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Additional Information (Details)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>May 06, 2020 </div>
<div>EUR (&#8364;) </div>
<div>NeoantigenTargetedTherapy </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 06, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 01, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>May 06, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure Of Business Combinations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (82,417,000)<span></span>
</td>
<td class="num">&#8364; (181,518,000)<span></span>
</td>
<td class="num">&#8364; (53,854,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">482,325,000<span></span>
</td>
<td class="nump">108,589,000<span></span>
</td>
<td class="nump">&#8364; 127,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">246,310,000<span></span>
</td>
<td class="nump">232,304,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=bntx_LipocalyxGmbHMember', window );">Lipocalyx GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure Of Business Combinations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NameOfAcquiree', window );">Name of acquiree</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Lipocalyx GmbH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,516,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfAcquisition2013', window );">Date of acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  06,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate', window );">Estimated contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">572,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=bntx_LipocalyxGmbHMember', window );">Lipocalyx GmbH | Phase 1 Clinical Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure Of Business Combinations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_BusinessCombinationContingentCashConsideration', window );">Contingent cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=bntx_LipocalyxGmbHMember', window );">Lipocalyx GmbH | Phase 2 Clinical Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure Of Business Combinations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_BusinessCombinationContingentCashConsideration', window );">Contingent cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=bntx_BioNTechUSIncMember', window );">BioNTech US Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure Of Business Combinations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 342,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (59,800,000)<span></span>
</td>
<td class="num">(28,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_ConsiderationTransferred', window );">Aggregate value of merger consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 89,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AmericanDepositaryShares', window );">American depositary shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,935,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,935,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate', window );">Deferred tax liabilities recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=bntx_BioNTechUSIncMember', window );">BioNTech US Inc. | In-process R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure Of Business Combinations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IntangibleAssetsNumberOfNeoantigenTargetedTherapiesUnderDevelopment', window );">Intangible assets, number of neoantigen targeted therapies under development | NeoantigenTargetedTherapy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=bntx_BioNTechManufacturingMarburgGmbHMember', window );">BioNTech Manufacturing Marburg GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure Of Business Combinations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NameOfAcquiree', window );">Name of acquiree</a></td>
<td class="text">Novartis Manufacturing GmbH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash consideration</a></td>
<td class="nump">&#8364; 77,853,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateOfAcquisition2013', window );">Date of acquisition</a></td>
<td class="text">Oct. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination', window );">Transaction costs</a></td>
<td class="nump">&#8364; 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_BargainPurchaseGainOnAcquisition', window );">Bargain purchase</a></td>
<td class="nump">&#8364; 7,002,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AmericanDepositaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>American depositary shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AmericanDepositaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_BargainPurchaseGainOnAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bargain purchase gain on acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_BargainPurchaseGainOnAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_BusinessCombinationContingentCashConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination maximum potential contingent cash consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_BusinessCombinationContingentCashConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration transferred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IntangibleAssetsNumberOfNeoantigenTargetedTherapiesUnderDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets, number of neoantigen targeted therapies under development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IntangibleAssetsNumberOfNeoantigenTargetedTherapiesUnderDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of acquisition-related costs recognised as an expense for transactions that are recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B64<br> -Subparagraph m<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B64_m&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B64_f_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount, at acquisition date, of contingent consideration arrangements recognised as consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B64<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B64_g_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DateOfAcquisition2013">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The date on which the acquirer obtains control of the acquiree in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B64<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B64_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DateOfAcquisition2013</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for deferred tax liabilities assumed in a business combination. [Refer: Deferred tax liabilities; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NameOfAcquiree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The name of the business or businesses that the acquirer obtains control of in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B64<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B64_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NameOfAcquiree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2020-01-01<br> -Paragraph IE33<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=bntx_LipocalyxGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=bntx_LipocalyxGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ItemsOfContingentLiabilitiesAxis=bntx_PhaseOneClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ItemsOfContingentLiabilitiesAxis=bntx_PhaseOneClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ItemsOfContingentLiabilitiesAxis=bntx_PhaseTwoClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ItemsOfContingentLiabilitiesAxis=bntx_PhaseTwoClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=bntx_BioNTechUSIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=bntx_BioNTechUSIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_IntangibleAssetsUnderDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_IntangibleAssetsUnderDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=bntx_BioNTechManufacturingMarburgGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=bntx_BioNTechManufacturingMarburgGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567886282504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combinations - Summary of Fair Values of Identifiable Net Assets (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>May 06, 2020</div></th>
<th class="th"><div>Jan. 06, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=bntx_LipocalyxGmbHMember', window );">Lipocalyx GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InventoryRecognisedAsOfAcquisitionDate', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract', window );"><strong>Consideration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6,500<span></span>
</td>
<td class="nump">6,516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 600<span></span>
</td>
<td class="nump">572<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 7,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=bntx_BioNTechUSIncMember', window );">BioNTech US Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 56,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate', window );">Other assets non-current and current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AssetsRecognizedAsOfAcquisitionDate', window );">Total Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_TradePayablesRecognisedAsOfAcquisitionDate', window );">Trade payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_OtherLiabilitiesNonCurrentAndCurrentRecognisedAsOfAcquisitionDate', window );">Other liabilities non-current and current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_LiabilitiesRecognizedAsOfAcquisitionDate', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Total identifiable net assets at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract', window );"><strong>Consideration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_SharesIssuedAtFairValue', window );">Shares issued, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 89,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=bntx_BioNTechManufacturingMarburgGmbHMember', window );">BioNTech Manufacturing Marburg GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate', window );">Property, plant and equipment</a></td>
<td class="nump">&#8364; 79,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate', window );">Right-of-use assets</a></td>
<td class="nump">28,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InventoryRecognisedAsOfAcquisitionDate', window );">Inventories</a></td>
<td class="nump">2,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate', window );">Other assets non-current and current</a></td>
<td class="nump">4,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate', window );">Cash and cash equivalents</a></td>
<td class="nump">16,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AssetsRecognizedAsOfAcquisitionDate', window );">Total Assets</a></td>
<td class="nump">131,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_ProvisionsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate', window );">Provisions non-current and current</a></td>
<td class="nump">5,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_TradePayablesRecognisedAsOfAcquisitionDate', window );">Trade payables</a></td>
<td class="nump">8,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_OtherLiabilitiesNonCurrentAndCurrentRecognisedAsOfAcquisitionDate', window );">Other liabilities non-current and current</a></td>
<td class="nump">33,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_LiabilitiesRecognizedAsOfAcquisitionDate', window );">Total liabilities</a></td>
<td class="nump">46,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Total identifiable net assets at fair value</a></td>
<td class="nump">84,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_BargainPurchaseGainOnAcquisition', window );">Bargain purchase</a></td>
<td class="num">(7,002)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwillNetOfBargainPurchase', window );">Consideration transferred</a></td>
<td class="nump">77,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract', window );"><strong>Consideration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash paid</a></td>
<td class="nump">77,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Total consideration</a></td>
<td class="nump">&#8364; 77,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AssetsRecognizedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets recognized as of acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AssetsRecognizedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_BargainPurchaseGainOnAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bargain purchase gain on acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_BargainPurchaseGainOnAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identifiable assets acquired (liabilities assumed) and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwillNetOfBargainPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identifiable assets acquired (liabilities assumed) and goodwill net of bargain purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IdentifiableAssetsAcquiredLiabilitiesAssumedAndGoodwillNetOfBargainPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_LiabilitiesRecognizedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liabilities recognized as of acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_LiabilitiesRecognizedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other assets non-current and current recognised as of acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_OtherLiabilitiesNonCurrentAndCurrentRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other liabilities non-current and current recognised as of acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_OtherLiabilitiesNonCurrentAndCurrentRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ProvisionsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provisions non-current and current recognised as of acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ProvisionsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-of-use assets recognised as of acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_SharesIssuedAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued, at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_SharesIssuedAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_TradePayablesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trade payables recognised as of acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_TradePayablesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B64_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B64_f_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount, at acquisition date, of contingent consideration arrangements recognised as consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B64<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B64_g_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the business combination's acquisition date for goodwill. [Refer: Goodwill; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B64<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B64&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph IE72<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GoodwillRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph IE72<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph IE72<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InventoryRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for inventory acquired in a business combination. [Refer: Inventories; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph IE72<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InventoryRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for plant, property and equipment acquired in a business combination. [Refer: Property, plant and equipment; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph IE72<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=bntx_LipocalyxGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=bntx_LipocalyxGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=bntx_BioNTechUSIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=bntx_BioNTechUSIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=bntx_BioNTechManufacturingMarburgGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=bntx_BioNTechManufacturingMarburgGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567911746920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Summary of Reconciliation of Goodwill (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsAbstract', window );"><strong>Disclosure Of Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">As of January 1, 2020</a></td>
<td class="nump">&#8364; 2,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="nump">57,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill', window );">Currency differences</a></td>
<td class="num">(6,750)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">As of December 31, 2020</a></td>
<td class="nump">&#8364; 53,697<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalRecognitionGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additional goodwill recognised, except goodwill included in a disposal group that, on acquisition, meets the criteria to be classified as held for sale in accordance with IFRS 5. [Refer: Goodwill; Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B67_d_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalRecognitionGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2020-01-01<br> -Paragraph 134<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2020-01-01<br> -Paragraph 135<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B67_d_vi&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567888039176">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Revenue from Contracts with Customers - Summary of Disaggregation of Revenues from Contracts with Customers (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 482,325<span></span>
</td>
<td class="nump">&#8364; 108,589<span></span>
</td>
<td class="nump">&#8364; 127,575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PerformanceObligationsAxis=ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember', window );">Goods and Services Transferred at a Point in Time</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">108,840<span></span>
</td>
<td class="nump">16,955<span></span>
</td>
<td class="nump">22,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PerformanceObligationsAxis=ifrs-full_PerformanceObligationsSatisfiedOverTimeMember', window );">Goods and Services Transferred Over Time</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">373,485<span></span>
</td>
<td class="nump">91,634<span></span>
</td>
<td class="nump">104,747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=bntx_ResearchAndDevelopmentMember', window );">Research &amp; Development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">178,849<span></span>
</td>
<td class="nump">84,428<span></span>
</td>
<td class="nump">101,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=bntx_CommercialMember', window );">Commercial</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">303,476<span></span>
</td>
<td class="nump">24,161<span></span>
</td>
<td class="nump">25,738<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_PfizerIncMember', window );">Pfizer Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">371,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_PfizerIncMember', window );">Pfizer Inc. | Research &amp; Development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">121,597<span></span>
</td>
<td class="nump">14,348<span></span>
</td>
<td class="nump">7,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_GenentechIncMember', window );">Genentech Inc</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49,200<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
<td class="nump">49,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_GenentechIncMember', window );">Genentech Inc | Research &amp; Development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49,195<span></span>
</td>
<td class="nump">64,026<span></span>
</td>
<td class="nump">49,536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_ShanghaiFosunPharmaceuticalGroupCoLtdMember', window );">Shanghai Fosun Pharmaceutical (Group) Co., Ltd | Research &amp; Development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_OtherMember', window );">Other | Research &amp; Development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,983<span></span>
</td>
<td class="nump">6,054<span></span>
</td>
<td class="nump">45,128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_COVID19VaccineRevenuesMember', window );">COVID-19 Vaccine Revenues | Commercial</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">270,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_SalesToCollaborationPartnerMember', window );">Sales To Collaboration Partner | Commercial</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">61,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_DirectProductSalesToBioNTechCustomersMember', window );">Direct Product Sales to BioNTech Customers | Commercial</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_ShareOfCollaborationPartnersGrossProfitMember', window );">Share Of Collaboration Partners Gross Profit | Commercial</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">188,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_OtherSalesMember', window );">Other Sales | Commercial</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 32,986<span></span>
</td>
<td class="nump">&#8364; 24,161<span></span>
</td>
<td class="nump">&#8364; 25,738<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents sales to collaboration partner of products manufactured by BioNTech.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PerformanceObligationsAxis=ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PerformanceObligationsAxis=ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PerformanceObligationsAxis=ifrs-full_PerformanceObligationsSatisfiedOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PerformanceObligationsAxis=ifrs-full_PerformanceObligationsSatisfiedOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=bntx_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=bntx_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=bntx_CommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=bntx_CommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_PfizerIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_PfizerIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_GenentechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_GenentechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_ShanghaiFosunPharmaceuticalGroupCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_ShanghaiFosunPharmaceuticalGroupCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_COVID19VaccineRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_COVID19VaccineRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_SalesToCollaborationPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_SalesToCollaborationPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_DirectProductSalesToBioNTechCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_DirectProductSalesToBioNTechCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_ShareOfCollaborationPartnersGrossProfitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_ShareOfCollaborationPartnersGrossProfitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_OtherSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_OtherSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567886903272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from Contracts with Customers - Additional Information (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;) </div>
<div>Country </div>
<div>Customer</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;) </div>
<div>Customer</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;) </div>
<div>Customer</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NumberOfCustomers', window );">Number of customers | Customer</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="nump">&#8364; 482,325<span></span>
</td>
<td class="nump">&#8364; 108,589<span></span>
</td>
<td class="nump">&#8364; 127,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_MilestonePaymentRecognizedAsRevenue', window );">Milestone payment recognized as revenue</a></td>
<td class="nump">51,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_RevenuesDerivedFromDeferredUpfrontPayments', window );">Revenues derived from deferred upfront payments</a></td>
<td class="nump">52,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_RemainingUpfrontFeesContractLiabilities', window );">Remaining upfront fees contract liabilities</a></td>
<td class="nump">131,800<span></span>
</td>
<td class="nump">187,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale', window );">Advance payment received for future COVID 19 vaccine sale</a></td>
<td class="nump">235,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=bntx_ResearchAndDevelopmentMember', window );">Research &amp; Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="nump">178,849<span></span>
</td>
<td class="nump">84,428<span></span>
</td>
<td class="nump">101,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_RevenueFromCollaboration', window );">Revenue from collaboration</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NonRefundableUpfrontCashPayment', window );">Non refundable upfront cash payment</a></td>
<td class="nump">66,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=bntx_CommercialMember', window );">Commercial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="nump">&#8364; 303,476<span></span>
</td>
<td class="nump">24,161<span></span>
</td>
<td class="nump">25,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_ConditionalMarketingAuthorizationCountries', window );">Conditional marketing authorization countries | Country</a></td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=bntx_OtherSalesTransactionsMember', window );">Other Sales Transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="nump">&#8364; 33,000<span></span>
</td>
<td class="nump">24,200<span></span>
</td>
<td class="nump">25,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAdvances', window );">Advance payments received on other sales</a></td>
<td class="nump">&#8364; 3,900<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_TradeReceivableMaturityPeriod', window );">Trade receivable maturity period</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=ifrs-full_TopOfRangeMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_TradeReceivableMaturityPeriod', window );">Trade receivable maturity period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_PfizerIncMember', window );">Pfizer Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="nump">&#8364; 371,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_PfizerIncMember', window );">Pfizer Inc. | Research &amp; Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="nump">&#8364; 121,597<span></span>
</td>
<td class="nump">14,348<span></span>
</td>
<td class="nump">7,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_PfizerIncMember', window );">Pfizer Inc. | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of revenue</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_GenentechIncMember', window );">Genentech Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="nump">&#8364; 49,200<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
<td class="nump">49,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_GenentechIncMember', window );">Genentech Inc | Research &amp; Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="nump">&#8364; 49,195<span></span>
</td>
<td class="nump">&#8364; 64,026<span></span>
</td>
<td class="nump">&#8364; 49,536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_GenentechIncMember', window );">Genentech Inc | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of revenue</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_SanofiSAMember', window );">Sanofi S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 41,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_SanofiSAMember', window );">Sanofi S.A. | Cellscript Sublicense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 33,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_PercentageOfReimbursementOfSublicenseCosts', window );">Percentage of reimbursement of sublicense costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_SublicenseAgreementDate', window );">Sublicense agreement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 22,  2018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_SanofiSAMember', window );">Sanofi S.A. | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_FosunPharmaMember', window );">Fosun Pharma | Research &amp; Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NonRefundableUpfrontCashPayment', window );">Non refundable upfront cash payment</a></td>
<td class="nump">&#8364; 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_MilestonePaymentRecognizedAsRevenue', window );">Milestone payment recognized as revenue</a></td>
<td class="nump">4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_RevenuesFromSellingDrugProductBatchesToPfizersManufacturingSiteMember', window );">Revenues from Selling Drug Product Batches to Pfizer's Manufacturing Site | Commercial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="nump">61,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_BioNTechMember', window );">BioNTech | Commercial | Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="nump">20,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_BioNTechMember', window );">BioNTech | Bill and Hold Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_RevenueFromShareOfCollaborationPartnersGrossProfitMember', window );">Revenue from Share of Collaboration Partner's Gross Profit | Commercial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues from contracts with customers</a></td>
<td class="nump">&#8364; 188,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advance payment received for future COVID 19 vaccine sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ConditionalMarketingAuthorizationCountries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conditional marketing authorization countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ConditionalMarketingAuthorizationCountries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_MilestonePaymentRecognizedAsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_MilestonePaymentRecognizedAsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NonRefundableUpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non refundable upfront cash payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NonRefundableUpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PercentageOfReimbursementOfSublicenseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of reimbursement of sublicense costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PercentageOfReimbursementOfSublicenseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_RemainingUpfrontFeesContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining upfront fees contract liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_RemainingUpfrontFeesContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_RevenueFromCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_RevenueFromCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_RevenuesDerivedFromDeferredUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues derived from deferred upfront payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_RevenuesDerivedFromDeferredUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_SublicenseAgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sublicense agreement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_SublicenseAgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_TradeReceivableMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trade receivable maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_TradeReceivableMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current payments received for goods or services to be provided in the future. [Refer: Advances received]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfEntitysRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of the entity's revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfEntitysRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=bntx_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=bntx_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=bntx_CommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=bntx_CommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=bntx_OtherSalesTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=bntx_OtherSalesTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_PfizerIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_PfizerIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_GenentechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_GenentechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_SanofiSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_SanofiSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis=bntx_CellscriptSublicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis=bntx_CellscriptSublicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_FosunPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_FosunPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_RevenuesFromSellingDrugProductBatchesToPfizersManufacturingSiteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_RevenuesFromSellingDrugProductBatchesToPfizersManufacturingSiteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_BioNTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_BioNTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=bntx_BillAndHoldTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=bntx_BillAndHoldTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_RevenueFromShareOfCollaborationPartnersGrossProfitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_RevenueFromShareOfCollaborationPartnersGrossProfitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567963587640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue from Contracts with Customers - Summary of Contract Balances (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">&#8364; 165,468<span></span>
</td>
<td class="nump">&#8364; 11,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">&#8364; 371,475<span></span>
</td>
<td class="nump">&#8364; 190,692<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891571720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from Contracts with Customers - Summary of Revenue Recognized (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Disclosure Of Revenue From Contracts With Customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DeferredRevenueRecognizedIncludedContractLiabilities', window );">Amounts included in contract liabilities at the beginning of the year</a></td>
<td class="nump">&#8364; 58,895<span></span>
</td>
<td class="nump">&#8364; 84,112<span></span>
</td>
<td class="nump">&#8364; 59,583<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DeferredRevenueRecognizedIncludedContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognized included in contract liabilities at the beginning of the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DeferredRevenueRecognizedIncludedContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfRevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfRevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567888025128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue from Contracts with Customers - Summary of Contract Liabilities Allocated to Remaining Performance Obligations (Unsatisfied or Partially Unsatisfied) (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPerformanceObligationsLineItems', window );"><strong>Disclosure Of Performance Obligations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">&#8364; 371,475<span></span>
</td>
<td class="nump">&#8364; 190,692<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PerformanceObligationsAxis=bntx_UnsatisfiedOrPartiallyUnsatisfiedMember', window );">Unsatisfied Or Partially Unsatisfied</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPerformanceObligationsLineItems', window );"><strong>Disclosure Of Performance Obligations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">371,475<span></span>
</td>
<td class="nump">190,692<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Within One Year | Unsatisfied Or Partially Unsatisfied</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPerformanceObligationsLineItems', window );"><strong>Disclosure Of Performance Obligations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">299,583<span></span>
</td>
<td class="nump">93,583<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember', window );">More Than One Year | Unsatisfied Or Partially Unsatisfied</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPerformanceObligationsLineItems', window );"><strong>Disclosure Of Performance Obligations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">&#8364; 71,892<span></span>
</td>
<td class="nump">&#8364; 97,109<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPerformanceObligationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPerformanceObligationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PerformanceObligationsAxis=bntx_UnsatisfiedOrPartiallyUnsatisfiedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PerformanceObligationsAxis=bntx_UnsatisfiedOrPartiallyUnsatisfiedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891778552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income and Expenses - Cost of Sales (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Costs of sales</a></td>
<td class="nump">&#8364; 59,333<span></span>
</td>
<td class="nump">&#8364; 17,361<span></span>
</td>
<td class="nump">&#8364; 13,690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=bntx_CommercialMember', window );">Commercial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Costs of sales</a></td>
<td class="nump">59,333<span></span>
</td>
<td class="nump">17,361<span></span>
</td>
<td class="nump">13,690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=bntx_CommercialMember', window );">Commercial | COVID-19 Vaccine Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Costs of sales</a></td>
<td class="nump">35,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=bntx_CommercialMember', window );">Commercial | Other Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Costs of sales</a></td>
<td class="nump">&#8364; 23,717<span></span>
</td>
<td class="nump">&#8364; 17,361<span></span>
</td>
<td class="nump">&#8364; 13,690<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfIncomeAndExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items representing income and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfIncomeAndExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs relating to expenses directly or indirectly attributed to the goods or services sold, which may include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, unallocated production overheads and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=bntx_CommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=bntx_CommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_COVID19VaccineRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_COVID19VaccineRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_OtherSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_OtherSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567886548280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income and Expenses - Research and Development Expenses (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">&#8364; 645,029<span></span>
</td>
<td class="nump">&#8364; 226,466<span></span>
</td>
<td class="nump">&#8364; 143,040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Depreciation and Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">30,192<span></span>
</td>
<td class="nump">27,533<span></span>
</td>
<td class="nump">18,312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_WagesBenefitsAndSocialSecurityExpenseMember', window );">Wages, Benefits and Social Security Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">126,298<span></span>
</td>
<td class="nump">83,213<span></span>
</td>
<td class="nump">45,668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_LaboratorySuppliesMember', window );">Laboratory Supplies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">107,792<span></span>
</td>
<td class="nump">37,218<span></span>
</td>
<td class="nump">22,921<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_PurchasedServicesMember', window );">Purchased Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">359,880<span></span>
</td>
<td class="nump">65,552<span></span>
</td>
<td class="nump">42,079<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_LeaseAndLeaseRelatedCostMember', window );">Lease and Lease Related Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">3,725<span></span>
</td>
<td class="nump">2,527<span></span>
</td>
<td class="nump">2,404<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_OtherIncomeExpenseMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">9,889<span></span>
</td>
<td class="nump">5,542<span></span>
</td>
<td class="nump">9,416<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_ITCostsMember', window );">IT Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">5,118<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="nump">1,572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_TransportCostsMember', window );">Transport Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">&#8364; 2,135<span></span>
</td>
<td class="nump">&#8364; 1,081<span></span>
</td>
<td class="nump">&#8364; 668<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfIncomeAndExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items representing income and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfIncomeAndExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_WagesBenefitsAndSocialSecurityExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_WagesBenefitsAndSocialSecurityExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_LaboratorySuppliesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_LaboratorySuppliesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_PurchasedServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_PurchasedServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_LeaseAndLeaseRelatedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_LeaseAndLeaseRelatedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_OtherIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_OtherIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_ITCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_ITCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_TransportCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_TransportCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567886217928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income and Expenses - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 06, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 645,029<span></span>
</td>
<td class="nump">&#8364; 226,466<span></span>
</td>
<td class="nump">&#8364; 143,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,049<span></span>
</td>
<td class="nump">45,547<span></span>
</td>
<td class="nump">26,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,539<span></span>
</td>
<td class="nump">2,724<span></span>
</td>
<td class="nump">5,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentGovernmentGrants', window );">Government grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeGain', window );">Foreign exchange gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,341<span></span>
</td>
<td class="nump">6,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeLoss', window );">Foreign exchange losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue', window );">Expenses arising from fair value measurement adjustments of derivative embedded within convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentGovernmentGrants', window );">Government grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_GovernmentGrantsMember', window );">Grant by Bundesministerium fuer Bildung und Forschung (BMBF)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239,017<span></span>
</td>
<td class="nump">1,547<span></span>
</td>
<td class="nump">&#8364; 4,228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_GovernmentGrantsMember', window );">Grant by Bundesministerium fuer Bildung und Forschung (BMBF) | Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 238,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NatureOfExpensesAxis=bntx_GeneralAndAdministrativeExpensesMember', window );">General And Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_ChargeInConnectionWithCertainWithholdingTaxPaymentsForIntellectualPropertyLicenses', window );">Charge in connection with certain withholding tax payments for intellectual property licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechUSIncMember', window );">BioNTech US Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">&#8364; 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">&#8364; 7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ChargeInConnectionWithCertainWithholdingTaxPaymentsForIntellectualPropertyLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charge in connection with certain withholding tax payments for intellectual property licenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ChargeInConnectionWithCertainWithholdingTaxPaymentsForIntellectualPropertyLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfIncomeAndExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items representing income and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfIncomeAndExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value adjustments of financial instruments measured at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current government grants recognised in the statement of financial position as deferred income. [Refer: Government [member]; Deferred income; Government grants]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net gain arising from foreign exchange differences. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2020-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net loss arising from foreign exchange differences. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2020-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_GovernmentGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_GovernmentGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NatureOfExpensesAxis=bntx_GeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NatureOfExpensesAxis=bntx_GeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechUSIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechUSIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567886201496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income and Expenses - Sales and Marketing Expenses (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">&#8364; 14,512<span></span>
</td>
<td class="nump">&#8364; 2,718<span></span>
</td>
<td class="nump">&#8364; 3,041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_WagesBenefitsAndSocialSecurityExpenseMember', window );">Wages, Benefits and Social Security Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">1,636<span></span>
</td>
<td class="nump">1,938<span></span>
</td>
<td class="nump">1,728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_PurchasedServicesMember', window );">Purchased Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">10,929<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="nump">794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_OtherIncomeExpenseMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">&#8364; 1,947<span></span>
</td>
<td class="nump">&#8364; 533<span></span>
</td>
<td class="nump">&#8364; 519<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfIncomeAndExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items representing income and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfIncomeAndExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_WagesBenefitsAndSocialSecurityExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_WagesBenefitsAndSocialSecurityExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_PurchasedServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_PurchasedServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_OtherIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_OtherIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891926360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income and Expenses - General and Administrative Expenses (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">&#8364; 94,049<span></span>
</td>
<td class="nump">&#8364; 45,547<span></span>
</td>
<td class="nump">&#8364; 26,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_WagesBenefitsAndSocialSecurityExpenseMember', window );">Wages, Benefits and Social Security Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">33,007<span></span>
</td>
<td class="nump">19,122<span></span>
</td>
<td class="nump">8,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_PurchasedServicesMember', window );">Purchased Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">26,022<span></span>
</td>
<td class="nump">6,419<span></span>
</td>
<td class="nump">5,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_LeaseAndLeaseRelatedCostMember', window );">Lease and Lease Related Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">2,390<span></span>
</td>
<td class="nump">1,715<span></span>
</td>
<td class="nump">1,012<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_OtherIncomeExpenseMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">8,053<span></span>
</td>
<td class="nump">5,551<span></span>
</td>
<td class="nump">3,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_InsurancePremiumsMember', window );">Insurance Premiums</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">4,840<span></span>
</td>
<td class="nump">1,061<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_ResearchServicesMember', window );">Research Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">2,033<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_LaboratorySuppliesMember', window );">Laboratory Supplies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">1,191<span></span>
</td>
<td class="nump">785<span></span>
</td>
<td class="nump">456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_JobAdvertisementExpensesMember', window );">Job Advertisement Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">2,897<span></span>
</td>
<td class="nump">548<span></span>
</td>
<td class="nump">861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_ContractStaffingMember', window );">Contract Staffing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">1,108<span></span>
</td>
<td class="nump">686<span></span>
</td>
<td class="nump">781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">IT and Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">7,404<span></span>
</td>
<td class="nump">4,573<span></span>
</td>
<td class="nump">3,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Depreciation and Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">&#8364; 5,104<span></span>
</td>
<td class="nump">&#8364; 4,855<span></span>
</td>
<td class="nump">&#8364; 2,284<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfIncomeAndExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items representing income and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfIncomeAndExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_WagesBenefitsAndSocialSecurityExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_WagesBenefitsAndSocialSecurityExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_PurchasedServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_PurchasedServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_LeaseAndLeaseRelatedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_LeaseAndLeaseRelatedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_OtherIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_OtherIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_InsurancePremiumsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_InsurancePremiumsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_ResearchServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_ResearchServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_LaboratorySuppliesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_LaboratorySuppliesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_JobAdvertisementExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_JobAdvertisementExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_ContractStaffingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_ContractStaffingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891781624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income and Expenses - Other Operating Income (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">&#8364; 250,539<span></span>
</td>
<td class="nump">&#8364; 2,724<span></span>
</td>
<td class="nump">&#8364; 5,396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_GovernmentGrantsMember', window );">Government Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">239,017<span></span>
</td>
<td class="nump">1,547<span></span>
</td>
<td class="nump">4,228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_BargainPurchaseMember', window );">Bargain Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">7,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_OtherIncomeExpenseMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">&#8364; 4,520<span></span>
</td>
<td class="nump">&#8364; 1,177<span></span>
</td>
<td class="nump">&#8364; 1,118<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfIncomeAndExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items representing income and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfIncomeAndExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_GovernmentGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_GovernmentGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_BargainPurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_BargainPurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_OtherIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_OtherIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567888454968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income and Expenses - Changes Regarding Government Grants (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_GovernmentGrantsAbstract', window );"><strong>Government Grants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_GovernmentGrantsReceived', window );">Received during the year</a></td>
<td class="nump">&#8364; 330,968<span></span>
</td>
<td class="nump">&#8364; 1,547<span></span>
</td>
<td class="nump">&#8364; 4,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Released to the consolidated statements of operations</a></td>
<td class="num">(239,017)<span></span>
</td>
<td class="num">&#8364; (1,547)<span></span>
</td>
<td class="num">&#8364; (4,228)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GovernmentGrants', window );">As of December 31</a></td>
<td class="nump">91,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentGovernmentGrants', window );">Government grants</a></td>
<td class="nump">&#8364; 91,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_GovernmentGrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Government grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_GovernmentGrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_GovernmentGrantsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Government grants received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_GovernmentGrantsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current government grants recognised in the statement of financial position as deferred income. [Refer: Government [member]; Deferred income; Government grants]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assistance by government in the form of transfers of resources to an entity in return for past or future compliance with certain conditions relating to the operating activities of the entity, recognised as deferred income. They exclude those forms of government assistance that cannot reasonably have a value placed upon them and transactions with government that cannot be distinguished from the normal trading transactions of the entity. [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income recognised in relation to government grants. [Refer: Government grants]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2020-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891739944">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Income and Expenses - Finance Income (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis Of Income And Expense [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromInterest', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 1,564<span></span>
</td>
<td class="nump">&#8364; 1,781<span></span>
</td>
<td class="nump">&#8364; 1,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeGain', window );">Foreign exchange gains, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,341<span></span>
</td>
<td class="nump">6,050<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 1,564<span></span>
</td>
<td class="nump">&#8364; 4,122<span></span>
</td>
<td class="nump">&#8364; 8,046<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Foreign exchange differences on a cumulative basis are shown either as finance income or expenses and might switch between those two positions during the year-to-date reporting periods.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net gain arising from foreign exchange differences. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2020-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567919089192">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Income and Expenses - Finance Expense (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis Of Income And Expense [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AmortizationOfFinancialInstruments', window );">Amortization of financial instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 3,048<span></span>
</td>
<td class="nump">&#8364; 326<span></span>
</td>
<td class="nump">&#8364; 48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue', window );">Fair value adjustments of financial instruments measured at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeLoss', window );">Foreign exchange loss, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 62,946<span></span>
</td>
<td class="nump">&#8364; 326<span></span>
</td>
<td class="nump">&#8364; 48<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Foreign exchange differences on a cumulative basis are shown either as finance income or expenses and might switch between those two positions during the year-to-date reporting periods.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AmortizationOfFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AmortizationOfFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value adjustments of financial instruments measured at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net loss arising from foreign exchange differences. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2020-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567888524072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income and Expenses - Employee Benefits Expense (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis Of Income And Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Wages and salaries</a></td>
<td class="nump">&#8364; 160,655<span></span>
</td>
<td class="nump">&#8364; 98,568<span></span>
</td>
<td class="nump">&#8364; 54,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SocialSecurityContributions', window );">Social security costs</a></td>
<td class="nump">17,988<span></span>
</td>
<td class="nump">12,394<span></span>
</td>
<td class="nump">8,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans', window );">Pension costs</a></td>
<td class="nump">761<span></span>
</td>
<td class="nump">517<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Total</a></td>
<td class="nump">&#8364; 179,404<span></span>
</td>
<td class="nump">&#8364; 111,479<span></span>
</td>
<td class="nump">&#8364; 62,704<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 104<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of post-employment benefit expense relating to defined benefit plans. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 5<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_5&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SocialSecurityContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents social security contributions. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 9<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SocialSecurityContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WagesAndSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 9<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WagesAndSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567887909112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Additional Information (Details) - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_CorporateIncomeTaxRate', window );">Corporate income tax rate</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_SolidaritySurchargeRate', window );">Solidarity surcharge rate</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_ChangeInAverageTradeTaxRate', window );">Change in average trade tax rate</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">30.79%<span></span>
</td>
<td class="nump">30.78%<span></span>
</td>
<td class="nump">30.99%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AccumulatedTaxLossesInCorporateTax', window );">Corporate income tax losses</a></td>
<td class="nump">&#8364; 596,359,000<span></span>
</td>
<td class="nump">&#8364; 356,044,000<span></span>
</td>
<td class="nump">&#8364; 179,264,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AccumulatedTaxLossesInTradeTax', window );">Trade tax losses</a></td>
<td class="nump">513,561,000<span></span>
</td>
<td class="nump">&#8364; 352,341,000<span></span>
</td>
<td class="nump">&#8364; 176,425,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax assets and liabilities, net recognized</a></td>
<td class="nump">160,952,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AccumulatedTaxLossesInFederalTaxCredits', window );">Accumulated federal tax credits</a></td>
<td class="nump">756,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AccumulatedTaxLossesInStateTaxCredits', window );">Accumulated state tax credits</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_GermanTaxGroupMember', window );">German Tax Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AccumulatedTaxLossesInCorporateTax', window );">Corporate income tax losses</a></td>
<td class="nump">457,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AccumulatedTaxLossesInTradeTax', window );">Trade tax losses</a></td>
<td class="nump">450,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DeferredTaxAssetsForUnusedTaxLossesRecognized', window );">Deferred tax assets for unused tax losses recognized</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax assets and liabilities, net recognized</a></td>
<td class="nump">161,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_GermanEntitiesNotWithinTaxGroupMember', window );">German Entities Not Within Tax Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AccumulatedTaxLossesInCorporateTax', window );">Corporate income tax losses</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AccumulatedTaxLossesInTradeTax', window );">Trade tax losses</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DeferredTaxAssetsForUnusedTaxLossesRecognized', window );">Deferred tax assets for unused tax losses recognized</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_UnitedStatesTaxGroupMember', window );">U.S. Tax Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AccumulatedTaxLossesInCorporateTax', window );">Corporate income tax losses</a></td>
<td class="nump">136,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AccumulatedTaxLossesInTradeTax', window );">Trade tax losses</a></td>
<td class="nump">60,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsExpectedToExpire', window );">Federal tax losses subject to expiration</a></td>
<td class="nump">&#8364; 20,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_FederalTaxLossesExpirationYear', window );">Federal tax losses expiration year</a></td>
<td class="text">2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Federal tax losses not subject to expiration</a></td>
<td class="nump">&#8364; 115,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_StateDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">State tax losses subject to expiration</a></td>
<td class="nump">&#8364; 60,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_StateTaxLossesExpirationYear', window );">State tax losses expiration year</a></td>
<td class="text">2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechUSAHoldingLLCMember', window );">BioNTech USA Holding LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AverageEffectiveTaxRate', window );">State income tax with average rate</a></td>
<td class="nump">8.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AccumulatedTaxLossesInCorporateTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated tax losses in corporate tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AccumulatedTaxLossesInCorporateTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AccumulatedTaxLossesInFederalTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated tax losses in federal tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AccumulatedTaxLossesInFederalTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AccumulatedTaxLossesInStateTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated tax losses in state tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AccumulatedTaxLossesInStateTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AccumulatedTaxLossesInTradeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated tax losses in trade tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AccumulatedTaxLossesInTradeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ChangeInAverageTradeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in average trade tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ChangeInAverageTradeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_CorporateIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Corporate income tax rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_CorporateIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DeferredTaxAssetsForUnusedTaxLossesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets for unused tax losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DeferredTaxAssetsForUnusedTaxLossesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsExpectedToExpire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal deferred tax assets operating loss carryforwards expected to expire.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsExpectedToExpire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal deferred tax assets operating loss carryforwards not subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_FederalDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_FederalTaxLossesExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal tax losses expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_FederalTaxLossesExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_SolidaritySurchargeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Solidarity surcharge rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_SolidaritySurchargeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_StateDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State deferred tax assets operating loss carryforwards subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_StateDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_StateTaxLossesExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State tax losses expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_StateTaxLossesExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_GermanTaxGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_GermanTaxGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_GermanEntitiesNotWithinTaxGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_GermanEntitiesNotWithinTaxGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_UnitedStatesTaxGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_UnitedStatesTaxGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechUSAHoldingLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechUSAHoldingLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567888464632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Summary of Current and Deferred Tax Expense (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Major Components Of Tax Expense Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current income taxes</a></td>
<td class="nump">&#8364; 17<span></span>
</td>
<td class="num">&#8364; (296)<span></span>
</td>
<td class="nump">&#8364; 600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">Deferred taxes</a></td>
<td class="num">(161,034)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_OtherComponentsOfTaxExpenseIncome', window );">Other taxes</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income taxes</a></td>
<td class="num">&#8364; (161,000)<span></span>
</td>
<td class="num">&#8364; (268)<span></span>
</td>
<td class="nump">&#8364; 600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_OtherComponentsOfTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other components of tax expense (income).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_OtherComponentsOfTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 80<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2020-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567887498536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Summary of Reconciliation of Expected Income Tax Benefit to Actual Income Tax Benefit (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems', window );"><strong>Disclosure Of Major Components Of Tax Expense Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before tax</a></td>
<td class="num">&#8364; (145,802)<span></span>
</td>
<td class="num">&#8364; (179,440)<span></span>
</td>
<td class="num">&#8364; (47,662)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate', window );">Expected tax benefit (based on BioNTech`s statutory tax rate of 30.79%, 2019: 30.78%, 2018: 30.99%)</a></td>
<td class="nump">44,891<span></span>
</td>
<td class="nump">55,240<span></span>
</td>
<td class="nump">14,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract', window );"><strong>Effects</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_GovernmentGrantsExemptedFromTaxes', window );">Government grants exempted from taxes</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss', window );">Non-deductible expenses</a></td>
<td class="num">(770)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AddBackForTradeTaxPurposes', window );">Add-back for trade tax purposes</a></td>
<td class="num">(595)<span></span>
</td>
<td class="num">(110)<span></span>
</td>
<td class="num">(96)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NonTaxEffectiveBargainPurchase', window );">Non-tax effective bargain purchase</a></td>
<td class="nump">2,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses', window );">Non-recognition of tax effect on share-based payment expenses</a></td>
<td class="num">(9,806)<span></span>
</td>
<td class="num">(9,308)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_TaxEffectiveEquityTransactionCosts', window );">Tax-effective equity transaction costs</a></td>
<td class="nump">10,229<span></span>
</td>
<td class="nump">5,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxEffectOfTaxLosses', window );">Utilization of tax losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_TaxEffectOfNonrecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences', window );">Non-recognition of deferred taxes on tax losses and temporary differences</a></td>
<td class="num">(12,961)<span></span>
</td>
<td class="num">(51,197)<span></span>
</td>
<td class="num">(13,634)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxEffectOfForeignTaxRates', window );">Effect from lower foreign income tax rate</a></td>
<td class="num">(1,304)<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod', window );">Adjustment prior year tax</a></td>
<td class="num">(326)<span></span>
</td>
<td class="nump">316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_TaxEffectOfTaxCredit', window );">Tax credit</a></td>
<td class="nump">1,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome', window );">Other effects</a></td>
<td class="num">(59)<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="num">(2,821)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income taxes</a></td>
<td class="nump">161,000<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="num">&#8364; (600)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember', window );">Tax Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract', window );"><strong>Effects</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense', window );">Recognition of deferred taxes not recognized in prior periods</a></td>
<td class="nump">102,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_TemporaryDifferenceMember', window );">Temporary Differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract', window );"><strong>Effects</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense', window );">Recognition of deferred taxes not recognized in prior periods</a></td>
<td class="nump">&#8364; 26,241<span></span>
</td>
<td class="nump">&#8364; 192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AddBackForTradeTaxPurposes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Add back for trade tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AddBackForTradeTaxPurposes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of major components of tax expense income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfMajorComponentsOfTaxExpenseIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_GovernmentGrantsExemptedFromTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Government grants exempted from taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_GovernmentGrantsExemptedFromTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non recognition of tax effect on share based payment expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NonTaxEffectiveBargainPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-tax effective bargain purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NonTaxEffectiveBargainPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_TaxEffectOfNonrecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax effect of nonrecognition of deferred taxes on tax losses and temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_TaxEffectOfNonrecognitionOfDeferredTaxesOnTaxLossesAndTemporaryDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_TaxEffectOfTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax effect of tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_TaxEffectOfTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_TaxEffectiveEquityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax effective equity transaction costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_TaxEffectiveEquityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments of tax expense (income) recognised in the period for current tax of prior periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 80<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_80_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2020-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2020-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of benefit arising from a previously unrecognised tax loss, tax credit or temporary difference of a prior period that is used to reduce deferred tax expense. [Refer: Deferred tax expense (income); Temporary differences [member]; Unused tax losses [member]; Unused tax credits [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 80<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_80_f&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfForeignTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfForeignTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfTaxLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfTaxLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxExpenseIncomeAtApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_TemporaryDifferenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_TemporaryDifferenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567892322760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Summary of Reconciliation of Expected Income Tax Benefit to Actual Income Tax Benefit (Parenthetical) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Major Components Of Tax Expense Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">30.79%<span></span>
</td>
<td class="nump">30.78%<span></span>
</td>
<td class="nump">30.99%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567887274312">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Summary of Deferred Taxes (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 161,034<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome', window );">Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(63)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(19)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax assets net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">160,952<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross Carrying Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax assets net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">136,034<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 84,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,721<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">51,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome', window );">Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(63)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34,746<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax assets net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">211,438<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">136,034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross Carrying Amount | Fixed assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax assets net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(655)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,370)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(565)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,637<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax assets net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,612<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(655)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross Carrying Amount | Inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax assets net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">596<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">46<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">329<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax assets net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">971<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross Carrying Amount | Leases</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax assets net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">512<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,091)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax assets net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,593)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross Carrying Amount | Contract liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax assets net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23,543<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">28,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(174)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(4,898)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax assets net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23,369<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">23,543<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross Carrying Amount | Interest-bearing loans and borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(2,741)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">195<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax assets net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,546)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross Carrying Amount | Provisions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax assets net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">187<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">886<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">419<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax assets net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,492<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross Carrying Amount | Net employee defined benefit liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">169<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome', window );">Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(63)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">698<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax assets net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">804<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross Carrying Amount | Other (incl. deferred expenses)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax assets net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,087<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,336<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">202<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax assets net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,625<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,087<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross Carrying Amount | Tax Loss Carryforward / Tax Credit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax assets net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">109,764<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">55,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">41,660<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">53,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,280<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax assets net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">175,704<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">109,764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=bntx_ValuationAdjustmentMember', window );">Valuation Adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax assets net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(136,034)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(84,799)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">120,313<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(51,235)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(34,765)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax assets net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (50,486)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">&#8364; (136,034)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes all changes in deferred taxes related to U.S. tax group other than those acquired in business combination</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax expense income recognised in other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense or income relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss. [Refer: Deferred tax assets; Deferred tax expense (income); Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in deferred tax liability (asset) resulting from business combinations. [Refer: Deferred tax liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_FixedAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_FixedAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_InventoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_InventoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_LeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_LeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_ContractLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_ContractLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_InterestBearingLoansAndBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_InterestBearingLoansAndBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_ProvisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_ProvisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_NetDefinedBenefitLiabilityAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_NetDefinedBenefitLiabilityAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_OtherDeferredTaxesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_OtherDeferredTaxesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=bntx_ValuationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=bntx_ValuationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567892411864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Summary of Accumulated Tax Losses (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract', window );"><strong>Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AccumulatedTaxLossesInCorporateTax', window );">Corporate Tax</a></td>
<td class="nump">&#8364; 596,359<span></span>
</td>
<td class="nump">&#8364; 356,044<span></span>
</td>
<td class="nump">&#8364; 179,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AccumulatedTaxLossesInTradeTax', window );">Trade Tax</a></td>
<td class="nump">513,561<span></span>
</td>
<td class="nump">&#8364; 352,341<span></span>
</td>
<td class="nump">&#8364; 176,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AccumulatedTaxLossesInFederalTaxCredits', window );">Federal Tax Credits</a></td>
<td class="nump">756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AccumulatedTaxLossesInStateTaxCredits', window );">State Tax Credits</a></td>
<td class="nump">&#8364; 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AccumulatedTaxLossesInCorporateTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated tax losses in corporate tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AccumulatedTaxLossesInCorporateTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AccumulatedTaxLossesInFederalTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated tax losses in federal tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AccumulatedTaxLossesInFederalTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AccumulatedTaxLossesInStateTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated tax losses in state tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AccumulatedTaxLossesInStateTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AccumulatedTaxLossesInTradeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated tax losses in trade tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AccumulatedTaxLossesInTradeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567912032456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Earnings Per Share - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 18, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_SharesIssuedDuringPeriodStockSplit', window );">Shares issued during period stock split</a></td>
<td class="nump">206,595,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_StockSplitConversionRatio', window );">Stock split ratio</a></td>
<td class="nump">0.05556<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_SharesIssuedDuringPeriodStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued during period stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_SharesIssuedDuringPeriodStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_StockSplitConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock split conversion ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_StockSplitConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567945902504">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Summary of Income and Share Data Used in the Basic and Diluted EPS Calculations (Details) - EUR (&#8364;)<br> &#8364; / shares in Units, &#8364; in Thousands, shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Gain (loss) attributable to ordinary equity holders of the parent for basic earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 15,198<span></span>
</td>
<td class="num">&#8364; (179,056)<span></span>
</td>
<td class="num">&#8364; (48,019)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of ordinary shares for basic EPS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">235,442<span></span>
</td>
<td class="nump">211,499<span></span>
</td>
<td class="nump">190,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares', window );">Effects of dilution from share options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of ordinary shares adjusted for the effect of dilution</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">248,527<span></span>
</td>
<td class="nump">211,499<span></span>
</td>
<td class="nump">190,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicAndDilutedEarningsLossPerShare', window );">Basic and diluted, profit / (loss) for the period attributable to ordinary equity holders of the parent</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 0.06<span></span>
</td>
<td class="num">&#8364; (0.85)<span></span>
</td>
<td class="num">&#8364; (0.25)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Numbers of shares for calculating the earnings per share for the years ended December 31, 2019 and December 31, 2018 have been adjusted to reflect capital increase due to 1:18 share split, which occurred on September 18, 2019.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicAndDilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of earnings per share when the basic and diluted measurements are equal. [Refer: Basic earnings (loss) per share; Diluted earnings (loss) per share]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicAndDilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of dilutive potential ordinary shares that relate to the assumed exercise of the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567963532392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Earnings Per Share - Summary of Income and Share Data Used in the Basic and Diluted EPS Calculations (Parenthetical) (Details)<br></strong></div></th>
<th class="th"><div>Sep. 18, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_StockSplitConversionRatio', window );">Stock split ratio</a></td>
<td class="nump">0.05556<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_StockSplitConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock split conversion ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_StockSplitConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567887366184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property Plant and Equipment - Summary of Property Plant and Equipment (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure Of Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property plant and equipment, Beginning balance</a></td>
<td class="nump">&#8364; 93,044<span></span>
</td>
<td class="nump">&#8364; 66,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property plant and equipment, Ending balance</a></td>
<td class="nump">226,968<span></span>
</td>
<td class="nump">93,044<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure Of Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property plant and equipment, Beginning balance</a></td>
<td class="nump">142,329<span></span>
</td>
<td class="nump">102,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">66,033<span></span>
</td>
<td class="nump">38,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(7,891)<span></span>
</td>
<td class="num">(115)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency differences</a></td>
<td class="num">(690)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="nump">85,519<span></span>
</td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property plant and equipment, Ending balance</a></td>
<td class="nump">285,300<span></span>
</td>
<td class="nump">142,329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Cumulative Depreciation and Impairment Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure Of Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property plant and equipment, Beginning balance</a></td>
<td class="num">(49,285)<span></span>
</td>
<td class="num">(36,652)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">15,827<span></span>
</td>
<td class="nump">12,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">6,724<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency differences</a></td>
<td class="num">(56)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property plant and equipment, Ending balance</a></td>
<td class="num">(58,332)<span></span>
</td>
<td class="num">(49,285)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandAndBuildingsMember', window );">Land and Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure Of Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property plant and equipment, Beginning balance</a></td>
<td class="nump">21,143<span></span>
</td>
<td class="nump">15,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property plant and equipment, Ending balance</a></td>
<td class="nump">50,908<span></span>
</td>
<td class="nump">21,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandAndBuildingsMember', window );">Land and Buildings | Gross Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure Of Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property plant and equipment, Beginning balance</a></td>
<td class="nump">29,469<span></span>
</td>
<td class="nump">22,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">14,927<span></span>
</td>
<td class="nump">7,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_ReclassificationsPropertyPlantAndEquipment', window );">Reclassifications</a></td>
<td class="nump">8,561<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency differences</a></td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="nump">8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property plant and equipment, Ending balance</a></td>
<td class="nump">61,264<span></span>
</td>
<td class="nump">29,469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandAndBuildingsMember', window );">Land and Buildings | Cumulative Depreciation and Impairment Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure Of Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property plant and equipment, Beginning balance</a></td>
<td class="num">(8,326)<span></span>
</td>
<td class="num">(6,472)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">2,074<span></span>
</td>
<td class="nump">1,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency differences</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property plant and equipment, Ending balance</a></td>
<td class="num">(10,356)<span></span>
</td>
<td class="num">(8,326)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_EquipmentToolsAndInstallationsMember', window );">Equipment, Tools and Installations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure Of Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property plant and equipment, Beginning balance</a></td>
<td class="nump">42,247<span></span>
</td>
<td class="nump">43,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property plant and equipment, Ending balance</a></td>
<td class="nump">94,442<span></span>
</td>
<td class="nump">42,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_EquipmentToolsAndInstallationsMember', window );">Equipment, Tools and Installations | Gross Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure Of Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property plant and equipment, Beginning balance</a></td>
<td class="nump">83,206<span></span>
</td>
<td class="nump">73,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">10,093<span></span>
</td>
<td class="nump">8,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(6,892)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_ReclassificationsPropertyPlantAndEquipment', window );">Reclassifications</a></td>
<td class="nump">1,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency differences</a></td>
<td class="num">(638)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="nump">54,817<span></span>
</td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property plant and equipment, Ending balance</a></td>
<td class="nump">142,418<span></span>
</td>
<td class="nump">83,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_EquipmentToolsAndInstallationsMember', window );">Equipment, Tools and Installations | Cumulative Depreciation and Impairment Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure Of Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property plant and equipment, Beginning balance</a></td>
<td class="num">(40,959)<span></span>
</td>
<td class="num">(30,180)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">13,753<span></span>
</td>
<td class="nump">10,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">6,683<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency differences</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property plant and equipment, Ending balance</a></td>
<td class="num">(47,976)<span></span>
</td>
<td class="num">(40,959)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_ConstructionInProgressAndAdvancePaymentsMember', window );">Construction in Progress and Advance Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure Of Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property plant and equipment, Beginning balance</a></td>
<td class="nump">29,652<span></span>
</td>
<td class="nump">7,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property plant and equipment, Ending balance</a></td>
<td class="nump">81,618<span></span>
</td>
<td class="nump">29,652<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_ConstructionInProgressAndAdvancePaymentsMember', window );">Construction in Progress and Advance Payments | Gross Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure Of Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property plant and equipment, Beginning balance</a></td>
<td class="nump">29,652<span></span>
</td>
<td class="nump">7,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">41,013<span></span>
</td>
<td class="nump">22,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(958)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_ReclassificationsPropertyPlantAndEquipment', window );">Reclassifications</a></td>
<td class="num">(10,391)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="nump">22,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property plant and equipment, Ending balance</a></td>
<td class="nump">&#8364; 81,618<span></span>
</td>
<td class="nump">&#8364; 29,652<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ReclassificationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassifications property plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ReclassificationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in property, plant and equipment resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_73_e_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_73_e_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_73_e_viii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandAndBuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandAndBuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_EquipmentToolsAndInstallationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_EquipmentToolsAndInstallationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_ConstructionInProgressAndAdvancePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_ConstructionInProgressAndAdvancePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567887010088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Summary of Detailed Information About Intangible Assets (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning Balance</a></td>
<td class="nump">&#8364; 89,434<span></span>
</td>
<td class="nump">&#8364; 88,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending Balance</a></td>
<td class="nump">163,490<span></span>
</td>
<td class="nump">89,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning Balance</a></td>
<td class="nump">121,693<span></span>
</td>
<td class="nump">103,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">8,613<span></span>
</td>
<td class="nump">13,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposals</a></td>
<td class="num">(6,078)<span></span>
</td>
<td class="num">(610)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency differences</a></td>
<td class="num">(10,647)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="nump">93,314<span></span>
</td>
<td class="nump">5,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending Balance</a></td>
<td class="nump">206,895<span></span>
</td>
<td class="nump">121,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Cumulative Depreciation and Impairment Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning Balance</a></td>
<td class="num">(32,260)<span></span>
</td>
<td class="num">(15,842)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AccumulatedDepreciationAmortisationAndImpairment', window );">Amortization</a></td>
<td class="nump">16,627<span></span>
</td>
<td class="nump">16,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposals</a></td>
<td class="nump">5,410<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency differences</a></td>
<td class="num">(72)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending Balance</a></td>
<td class="num">(43,405)<span></span>
</td>
<td class="num">(32,260)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning Balance</a></td>
<td class="nump">2,978<span></span>
</td>
<td class="nump">534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending Balance</a></td>
<td class="nump">53,697<span></span>
</td>
<td class="nump">2,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember', window );">Goodwill | Gross Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning Balance</a></td>
<td class="nump">2,978<span></span>
</td>
<td class="nump">534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency differences</a></td>
<td class="num">(6,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="nump">57,469<span></span>
</td>
<td class="nump">2,444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending Balance</a></td>
<td class="nump">53,697<span></span>
</td>
<td class="nump">2,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember', window );">Concessions, Licenses, in-process R&amp;D and Similar Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning Balance</a></td>
<td class="nump">84,053<span></span>
</td>
<td class="nump">86,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending Balance</a></td>
<td class="nump">103,841<span></span>
</td>
<td class="nump">84,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember', window );">Concessions, Licenses, in-process R&amp;D and Similar Rights | Gross Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning Balance</a></td>
<td class="nump">116,313<span></span>
</td>
<td class="nump">101,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">4,187<span></span>
</td>
<td class="nump">11,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposals</a></td>
<td class="num">(5,435)<span></span>
</td>
<td class="num">(133)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsOtherThanGoodwill', window );">Reclassifications</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency differences</a></td>
<td class="num">(3,897)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="nump">35,845<span></span>
</td>
<td class="nump">2,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending Balance</a></td>
<td class="nump">147,246<span></span>
</td>
<td class="nump">116,313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember', window );">Concessions, Licenses, in-process R&amp;D and Similar Rights | Cumulative Depreciation and Impairment Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning Balance</a></td>
<td class="num">(32,260)<span></span>
</td>
<td class="num">(15,842)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AccumulatedDepreciationAmortisationAndImpairment', window );">Amortization</a></td>
<td class="nump">16,627<span></span>
</td>
<td class="nump">16,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposals</a></td>
<td class="nump">5,410<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency differences</a></td>
<td class="num">(72)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending Balance</a></td>
<td class="num">(43,405)<span></span>
</td>
<td class="num">(32,260)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=bntx_AdvancePaymentsMember', window );">Advance Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning Balance</a></td>
<td class="nump">2,403<span></span>
</td>
<td class="nump">1,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending Balance</a></td>
<td class="nump">5,953<span></span>
</td>
<td class="nump">2,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=bntx_AdvancePaymentsMember', window );">Advance Payments | Gross Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning Balance</a></td>
<td class="nump">2,403<span></span>
</td>
<td class="nump">1,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">4,426<span></span>
</td>
<td class="nump">1,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposals</a></td>
<td class="num">(643)<span></span>
</td>
<td class="num">(477)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsOtherThanGoodwill', window );">Reclassifications</a></td>
<td class="num">(233)<span></span>
</td>
<td class="num">(146)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending Balance</a></td>
<td class="nump">&#8364; 5,953<span></span>
</td>
<td class="nump">&#8364; 2,403<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AccumulatedDepreciationAmortisationAndImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated depreciation amortisation and impairment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AccumulatedDepreciationAmortisationAndImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in intangible assets other than goodwill resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_118_e_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets and goodwill resulting from the net exchange differences arising when the financial statements are translated from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_118_e_vii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets other than goodwill resulting from transfers and changes that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=bntx_AdvancePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=bntx_AdvancePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567888415272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Summary of Goodwill Recognized (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">&#8364; 53,697<span></span>
</td>
<td class="nump">&#8364; 2,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ConsolidatedStructuredEntitiesAxis=bntx_CGUImmunotherapiesMember', window );">CGU Immunotherapies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">53,163<span></span>
</td>
<td class="nump">2,444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ConsolidatedStructuredEntitiesAxis=bntx_ExternalProductSalesOfJPTMember', window );">External Product Sales of JPT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">&#8364; 534<span></span>
</td>
<td class="nump">&#8364; 534<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2020-01-01<br> -Paragraph 134<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2020-01-01<br> -Paragraph 135<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ConsolidatedStructuredEntitiesAxis=bntx_CGUImmunotherapiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ConsolidatedStructuredEntitiesAxis=bntx_CGUImmunotherapiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ConsolidatedStructuredEntitiesAxis=bntx_ExternalProductSalesOfJPTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ConsolidatedStructuredEntitiesAxis=bntx_ExternalProductSalesOfJPTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567887499496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections', window );">Growth rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">&#8364; 651,724<span></span>
</td>
<td class="nump">&#8364; 237,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">&#8364; 89,200<span></span>
</td>
<td class="nump">&#8364; 3,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ConsolidatedStructuredEntitiesAxis=bntx_CGUImmunotherapiesMember', window );">CGU Immunotherapies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows', window );">Recoverable amount period</a></td>
<td class="text">fifteen-year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections', window );">Discount rate cash flow projection</a></td>
<td class="nump">8.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse', window );">Growth rate extrapolated</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ConsolidatedStructuredEntitiesAxis=bntx_ExternalProductSalesOfJPTMember', window );">External Product Sales of JPT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows', window );">Recoverable amount period</a></td>
<td class="text">ten-year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections', window );">Discount rate cash flow projection</a></td>
<td class="nump">7.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse', window );">Growth rate extrapolated</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncreaseInGrowthRateCashFlowProjections', window );">Increase in discount rate</a></td>
<td class="nump">9.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncreaseInGrowthRateCashFlowProjections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in growth rate cash flow projections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncreaseInGrowthRateCashFlowProjections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The discount rate applied to cash flow projections for a cash-generating unit (group of units). [Refer: Cash-generating units [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2020-01-01<br> -Paragraph 134<br> -Subparagraph d<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_134_d_v&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2020-01-01<br> -Paragraph 134<br> -Subparagraph e<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_134_e_v&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The discount rate used in the current estimate of the present value of the future cash flows expected to be derived from an asset or cash-generating unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2020-01-01<br> -Paragraph 130<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_130_g&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The growth rate used to extrapolate cash flow projections beyond the period covered by the most recent budgets/forecasts for a cash-generating unit (group of units). [Refer: Cash-generating units [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2020-01-01<br> -Paragraph 134<br> -Subparagraph d<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_134_d_iv&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2020-01-01<br> -Paragraph 134<br> -Subparagraph e<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_134_e_iv&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The explanation of the period over which management has projected cash flows based on financial budgets/forecasts approved by management including, when a period greater than five years is used for a cash-generating unit (group of units), an explanation of why that longer period is justified. [Refer: Cash-generating units [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2020-01-01<br> -Paragraph 134<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_134_d_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2020-01-01<br> -Paragraph 134<br> -Subparagraph e<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_134_e_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ConsolidatedStructuredEntitiesAxis=bntx_CGUImmunotherapiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ConsolidatedStructuredEntitiesAxis=bntx_CGUImmunotherapiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ConsolidatedStructuredEntitiesAxis=bntx_ExternalProductSalesOfJPTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ConsolidatedStructuredEntitiesAxis=bntx_ExternalProductSalesOfJPTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891360648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Assets and Financial Liabilities - Summary of Cash and Cash Equivalents (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash And Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">&#8364; 1,210,209<span></span>
</td>
<td class="nump">&#8364; 519,149<span></span>
</td>
<td class="nump">&#8364; 411,495<span></span>
</td>
<td class="nump">&#8364; 172,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Total</a></td>
<td class="nump">&#8364; 1,210,209<span></span>
</td>
<td class="nump">&#8364; 519,149<span></span>
</td>
<td class="nump">&#8364; 411,495<span></span>
</td>
<td class="nump">&#8364; 172,106<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891855736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Assets and Financial Liabilities - Summary of Financial Assets at Amortized Cost (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure Of Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtAmortisedCost', window );">Financial assets at amortized cost</a></td>
<td class="nump">&#8364; 302,702<span></span>
</td>
<td class="nump">&#8364; 13,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssetsAtAmortisedCost', window );">Total current</a></td>
<td class="nump">302,702<span></span>
</td>
<td class="nump">13,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember', window );">Trade Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure Of Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtAmortisedCost', window );">Financial assets at amortized cost</a></td>
<td class="nump">165,468<span></span>
</td>
<td class="nump">11,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=bntx_OtherFinancialAssetsMember', window );">Other Financial Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure Of Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtAmortisedCost', window );">Financial assets at amortized cost</a></td>
<td class="nump">&#8364; 137,234<span></span>
</td>
<td class="nump">&#8364; 1,680<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialAssetsAtAmortisedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets measured at amortised cost. [Refer: Financial assets at amortised cost]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 8<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_8_f&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialAssetsAtAmortisedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtAmortisedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets at amortised cost. The amortised cost is the amount at which financial assets are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, and adjusted for any impairment. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 8<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_8_f&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtAmortisedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=bntx_OtherFinancialAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=bntx_OtherFinancialAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567887457160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Assets and Financial Liabilities - Summary of Financial Liabilities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">&#8364; 448,028<span></span>
</td>
<td class="nump">&#8364; 105,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Total current</a></td>
<td class="nump">185,505<span></span>
</td>
<td class="nump">36,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Total non-current</a></td>
<td class="nump">262,523<span></span>
</td>
<td class="nump">68,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_InterestBearingLoansAndBorrowingsMember', window );">Interest-bearing loans and borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtAmortisedCost', window );">Financial liabilities at amortized cost</a></td>
<td class="nump">240,189<span></span>
</td>
<td class="nump">74,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilitiesAtAmortisedCost', window );">Total current</a></td>
<td class="nump">9,142<span></span>
</td>
<td class="nump">5,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilitiesAtAmortisedCost', window );">Total non-current</a></td>
<td class="nump">231,047<span></span>
</td>
<td class="nump">68,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_InterestBearingLoansAndBorrowingsMember', window );">Interest-bearing loans and borrowings | Lease Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtAmortisedCost', window );">Financial liabilities at amortized cost</a></td>
<td class="nump">84,158<span></span>
</td>
<td class="nump">57,611<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_InterestBearingLoansAndBorrowingsMember', window );">Interest-bearing loans and borrowings | 2.15% Secured Bank Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtAmortisedCost', window );">Financial liabilities at amortized cost</a></td>
<td class="nump">9,032<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_InterestBearingLoansAndBorrowingsMember', window );">Interest-bearing loans and borrowings | 2.08% Secured Bank Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtAmortisedCost', window );">Financial liabilities at amortized cost</a></td>
<td class="nump">8,877<span></span>
</td>
<td class="nump">7,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_InterestBearingLoansAndBorrowingsMember', window );">Interest-bearing loans and borrowings | Convertible Note - Host Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtAmortisedCost', window );">Financial liabilities at amortized cost</a></td>
<td class="nump">87,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_InterestBearingLoansAndBorrowingsMember', window );">Interest-bearing loans and borrowings | 3.50% Secured Bank Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtAmortisedCost', window );">Financial liabilities at amortized cost</a></td>
<td class="nump">47,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_InterestBearingLoansAndBorrowingsMember', window );">Interest-bearing loans and borrowings | 1.90% Secured Bank loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtAmortisedCost', window );">Financial liabilities at amortized cost</a></td>
<td class="nump">3,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember', window );">Other Financial Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtAmortisedCost', window );">Financial liabilities at amortized cost</a></td>
<td class="nump">176,364<span></span>
</td>
<td class="nump">30,850<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Total financial liabilities at fair value</a></td>
<td class="nump">31,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">207,839<span></span>
</td>
<td class="nump">30,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Total current</a></td>
<td class="nump">176,363<span></span>
</td>
<td class="nump">30,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Total non-current</a></td>
<td class="nump">31,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember', window );">Other Financial Liabilities | Convertible Note - Embedded Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DerivativeFinancialLiabilitiesNotDesignatedAsHedgingInstrumentsAtFairValue', window );">Derivatives not designated as hedging instrument</a></td>
<td class="nump">30,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember', window );">Other Financial Liabilities | Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss', window );">Financial liabilities at fair value through profit or loss</a></td>
<td class="nump">572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember', window );">Other Financial Liabilities | Trade Payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtAmortisedCost', window );">Financial liabilities at amortized cost</a></td>
<td class="nump">102,288<span></span>
</td>
<td class="nump">20,498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember', window );">Other Financial Liabilities | Other Financial Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtAmortisedCost', window );">Financial liabilities at amortized cost</a></td>
<td class="nump">&#8364; 74,076<span></span>
</td>
<td class="nump">&#8364; 10,352<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DerivativeFinancialLiabilitiesNotDesignatedAsHedgingInstrumentsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative, financial liabilities not designated as hedging instruments, at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DerivativeFinancialLiabilitiesNotDesignatedAsHedgingInstrumentsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialLiabilitiesAtAmortisedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities measured at amortised cost. [Refer: Financial liabilities at amortised cost]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 8<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_8_g&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2021-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 8<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_8_f&amp;doctype=Standard&amp;book=b<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialLiabilitiesAtAmortisedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtAmortisedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities at amortised cost. The amortised cost is the amount at which financial liabilities are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 8<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_8_g&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2021-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 8<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_8_f&amp;doctype=Standard&amp;book=b<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtAmortisedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities that meet either of the following conditions: (a) they meet the definition of held for trading; or (b) upon initial recognition they are designated by the entity as at fair value through profit or loss. An entity may use this designation only when permitted by paragraph 4.3.5 of IFRS 9 (embedded derivatives) or when doing so results in more relevant information, because either: (a) it eliminates or significantly reduces a measurement or recognition inconsistency (sometimes referred to as &#8216;an accounting mismatch&#8217;) that would otherwise arise from measuring assets or liabilities or recognising the gains and losses on them on different bases; or (b) a group of financial liabilities or financial assets and financial liabilities is managed and its performance is evaluated on a fair value basis, in accordance with a documented risk management or investment strategy, and information about the group is provided internally on that basis to the entity&#8217;s key management personnel (as defined in IAS 24). [Refer: At fair value [member]; Key management personnel of entity or parent [member]; Derivatives [member]; Financial assets; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 8<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_8_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialLiabilitiesAtAmortisedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial liabilities measured at amortised cost. [Refer: Financial liabilities at amortised cost]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 8<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_8_g&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2021-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 8<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_8_f&amp;doctype=Standard&amp;book=b<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialLiabilitiesAtAmortisedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_InterestBearingLoansAndBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_InterestBearingLoansAndBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=bntx_TwoPointOneFivePercentageSecuredBankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=bntx_TwoPointOneFivePercentageSecuredBankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=bntx_TwoPointZeroEightPercentageSecuredBankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=bntx_TwoPointZeroEightPercentageSecuredBankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=bntx_ConvertibleNoteHostContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=bntx_ConvertibleNoteHostContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=bntx_OnePointNineZeroPercentageSecuredBankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=bntx_OnePointNineZeroPercentageSecuredBankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_OtherFinancialLiabilitiesOtherThanInterestBearingLoansAndBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=bntx_ConvertibleNoteEmbeddedDerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=bntx_ConvertibleNoteEmbeddedDerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=bntx_TradePayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=bntx_TradePayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=bntx_OtherFinancialLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=bntx_OtherFinancialLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567886877544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Financial Liabilities - Summary of Financial Liabilities (Parenthetical) (Details) - Interest-bearing loans and borrowings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_InterestBearingLoansAndBorrowingsMember', window );">Convertible Note - Host Contract</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_FinancialLiabilitiesMaturityDate', window );">Maturity Date</a></td>
<td class="text">Aug. 28,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_InterestBearingLoansAndBorrowingsMember', window );">3.50% Secured Bank Loan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_FinancialLiabilitiesMaturityDate', window );">Maturity Date</a></td>
<td class="text">Dec. 21,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities', window );">Secured bank loan</a></td>
<td class="nump">&#8364; 50,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_InterestBearingLoansAndBorrowingsMember', window );">2.15% Secured Bank Loan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_FinancialLiabilitiesMaturityDate', window );">Maturity Date</a></td>
<td class="text">Dec. 30,  2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities', window );">Secured bank loan</a></td>
<td class="nump">&#8364; 10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_InterestBearingLoansAndBorrowingsMember', window );">2.08% Secured Bank Loan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_FinancialLiabilitiesMaturityDate', window );">Maturity Date</a></td>
<td class="text">Sep. 30,  2028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities', window );">Secured bank loan</a></td>
<td class="nump">&#8364; 9,450,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_InterestBearingLoansAndBorrowingsMember', window );">1.90% Secured Bank loan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_FinancialLiabilitiesMaturityDate', window );">Maturity Date</a></td>
<td class="text">May 30,  2039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities', window );">Secured bank loan</a></td>
<td class="nump">&#8364; 3,528,892.48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_FinancialLiabilitiesMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial liabilities maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_FinancialLiabilitiesMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets that the entity has pledged as collateral for liabilities or contingent liabilities, including amounts that have been reclassified in accordance with paragraph 3.2.23(a) of IFRS 9. [Refer: Contingent liabilities [member]; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 14<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_14_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_InterestBearingLoansAndBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_InterestBearingLoansAndBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=bntx_ConvertibleNoteHostContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=bntx_ConvertibleNoteHostContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=bntx_TwoPointOneFivePercentageSecuredBankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=bntx_TwoPointOneFivePercentageSecuredBankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=bntx_TwoPointZeroEightPercentageSecuredBankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=bntx_TwoPointZeroEightPercentageSecuredBankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=bntx_OnePointNineZeroPercentageSecuredBankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=bntx_OnePointNineZeroPercentageSecuredBankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567887023336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Financial Liabilities - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 21, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;) </div>
<div>Loan</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Redesignated Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities', window );">Fair value adjustment derived from remeasuring embedded derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 17,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=bntx_JuneTwentyTwentyPrivatePlacementMember', window );">June 2020 Private Placement | Convertible Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Redesignated Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investment in convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_FinancialLiabilityMaturityTerm', window );">Maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_FinancialLiabilitiesCouponRatePerAnnum', window );">Convertible note coupon rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_FinancialLiabilitiesConversionPremiumPercentageAboveReferencePrice', window );">Conversion premium of convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_EffectiveInterestRateOfFinancialLiabilities', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bntx_DeutscheBankAGMember', window );">Deutsche Bank AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Redesignated Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NumberOfSecuredBankLoanMaintained', window );">Number of secured bank loan | Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=bntx_TwoPointOneFivePercentageSecuredLoanMember', window );">2.15% Secured Loan | Deutsche Bank AG | BioNTech Innovative Manufacturing Services GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Redesignated Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities', window );">Secured bank loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_FinancialLiabilitiesMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 30,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_LoanRepayableQuarterlyInstallment', window );">Loan repayable quarterly Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_LoanRepayableQuarterlyInstallmentCommencementDate', window );">Loan repayable quarterly installment commencing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=bntx_TwoPointZeroEightPercentageBankLoanMember', window );">2.08% Bank Loan | Deutsche Bank AG | JPT Peptide Technologies GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Redesignated Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities', window );">Secured bank loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 9,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.08%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_FinancialLiabilitiesMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 30,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_LoanRepayableQuarterlyInstallment', window );">Loan repayable quarterly Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_LoanRepayableQuarterlyInstallmentCommencementDate', window );">Loan repayable quarterly installment commencing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember', window );">3.50% Secured Bank Loan | EIB Manufacturing Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Redesignated Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_FinancialLiabilitiesMaturityDate', window );">Maturity Date</a></td>
<td class="text">Dec. 21,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_TermLoanCreditA', window );">Term loan (Credit A)</a></td>
<td class="nump">&#8364; 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_TermLoanCreditB', window );">Term loan (Credit B)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 50,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember', window );">3.50% Secured Bank Loan | EIB Manufacturing Financing | Cash Interest Fixed Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Redesignated Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember', window );">3.50% Secured Bank Loan | EIB Manufacturing Financing | Deferred Interest at Fixed Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Redesignated Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_EffectiveInterestRateOfFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate of financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_EffectiveInterestRateOfFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_FinancialLiabilitiesConversionPremiumPercentageAboveReferencePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial liabilities conversion premium percentage above reference price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_FinancialLiabilitiesConversionPremiumPercentageAboveReferencePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_FinancialLiabilitiesCouponRatePerAnnum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial liabilities coupon rate per annum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_FinancialLiabilitiesCouponRatePerAnnum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_FinancialLiabilitiesMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial liabilities maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_FinancialLiabilitiesMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_FinancialLiabilityMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial liability, maturity term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_FinancialLiabilityMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_LoanRepayableQuarterlyInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan repayable quarterly installment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_LoanRepayableQuarterlyInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_LoanRepayableQuarterlyInstallmentCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan repayable quarterly installment commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_LoanRepayableQuarterlyInstallmentCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfSecuredBankLoanMaintained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of secured bank loan maintained.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfSecuredBankLoanMaintained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_TermLoanCreditA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan (Credit A).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_TermLoanCreditA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_TermLoanCreditB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan (Credit B).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_TermLoanCreditB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets that the entity has pledged as collateral for liabilities or contingent liabilities, including amounts that have been reclassified in accordance with paragraph 3.2.23(a) of IFRS 9. [Refer: Contingent liabilities [member]; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 14<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_14_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from changes in fair values. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 44B<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_44B_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=bntx_JuneTwentyTwentyPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=bntx_JuneTwentyTwentyPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=bntx_ConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=bntx_ConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bntx_DeutscheBankAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bntx_DeutscheBankAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=bntx_TwoPointOneFivePercentageSecuredLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=bntx_TwoPointOneFivePercentageSecuredLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechInnovativeManufacturingServicesGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechInnovativeManufacturingServicesGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=bntx_TwoPointZeroEightPercentageBankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=bntx_TwoPointZeroEightPercentageBankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_JPTPeptideTechnologiesGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_JPTPeptideTechnologiesGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=bntx_ThreePointFiveZeroPercentageSecuredBankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bntx_EuropeanInvestmentBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bntx_EuropeanInvestmentBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=bntx_CashInterestFixedRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=bntx_CashInterestFixedRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=bntx_DeferredInterestAtFixedRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=bntx_DeferredInterestAtFixedRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567886539688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Assets and Financial Liabilities - Summary of Carrying Amount of Monetary Assets (Details) - Currency Risk - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfCashAndCashEquivalentsLineItems', window );"><strong>Disclosure Of Cash And Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_CashAndCashEquivalent', window );">Total</a></td>
<td class="nump">&#8364; 686,297<span></span>
</td>
<td class="nump">&#8364; 213,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Financial Liabilities in U.S. Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfCashAndCashEquivalentsLineItems', window );"><strong>Disclosure Of Cash And Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_CashAndCashEquivalent', window );">Total</a></td>
<td class="nump">72,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Other Financial Assets in U.S. Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfCashAndCashEquivalentsLineItems', window );"><strong>Disclosure Of Cash And Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_CashAndCashEquivalent', window );">Total</a></td>
<td class="nump">85,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">US Dollar Bank Accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfCashAndCashEquivalentsLineItems', window );"><strong>Disclosure Of Cash And Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_CashAndCashEquivalent', window );">Total</a></td>
<td class="nump">&#8364; 673,545<span></span>
</td>
<td class="nump">&#8364; 213,913<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_CashAndCashEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits denominated in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_CashAndCashEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfCashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfCashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_FinancialLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_FinancialLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=bntx_OtherFinancialAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=bntx_OtherFinancialAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=bntx_USDollarBankAccountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=bntx_USDollarBankAccountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567886915576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Financial Liabilities - Summary of Effect of Changes in Foreign Exchange Rates (Details) - Currency Risk<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">+5 %</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems', window );"><strong>Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_ForeignCurrencyChangesEffectOnLossBeforeTax', window );">Effect on loss before tax</a></td>
<td class="num">&#8364; (32,491)<span></span>
</td>
<td class="num">&#8364; (10,186)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_ForeignCurrencyChangesEffectOnPretaxEquity', window );">Effect on pre-tax equity</a></td>
<td class="num">(32,681)<span></span>
</td>
<td class="num">(10,186)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">-5%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems', window );"><strong>Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_ForeignCurrencyChangesEffectOnLossBeforeTax', window );">Effect on loss before tax</a></td>
<td class="nump">35,911<span></span>
</td>
<td class="nump">11,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_ForeignCurrencyChangesEffectOnPretaxEquity', window );">Effect on pre-tax equity</a></td>
<td class="nump">&#8364; 36,121<span></span>
</td>
<td class="nump">&#8364; 11,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems', window );"><strong>Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Closing rate</a></td>
<td class="nump">1.2271<span></span>
</td>
<td class="nump">1.1234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average rate</a></td>
<td class="nump">1.1422<span></span>
</td>
<td class="nump">1.1195<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of effect of changes in foreign exchange rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ForeignCurrencyChangesEffectOnLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign currency changes effect on loss before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ForeignCurrencyChangesEffectOnLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ForeignCurrencyChangesEffectOnPretaxEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign currency changes effect on pretax equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ForeignCurrencyChangesEffectOnPretaxEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClosingForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClosingForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=bntx_PositiveFivePercentageChangeInForeignExchangeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=bntx_PositiveFivePercentageChangeInForeignExchangeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=bntx_NegativeFivePercentageChangeInForeignExchangeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=bntx_NegativeFivePercentageChangeInForeignExchangeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567887601608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Assets and Financial Liabilities - Summary of Maturity Profile of Financial Liabilities Based on Contractual Undiscounted Payments (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">&#8364; 84,158<span></span>
</td>
<td class="nump">&#8364; 57,611<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">448,028<span></span>
</td>
<td class="nump">&#8364; 105,061<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember', window );">Liquidity Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_InterestBearingLoansAndBorrowings', window );">Interest bearing loans and borrowings</a></td>
<td class="nump">82,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade and other payables</a></td>
<td class="nump">102,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">107,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Contingent consideration</a></td>
<td class="nump">572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherFinancialLiabilities', window );">Other financial liabilities</a></td>
<td class="nump">74,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">367,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Within One Year | Liquidity Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_InterestBearingLoansAndBorrowings', window );">Interest bearing loans and borrowings</a></td>
<td class="nump">3,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade and other payables</a></td>
<td class="nump">102,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">8,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherFinancialLiabilities', window );">Other financial liabilities</a></td>
<td class="nump">74,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">188,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember', window );">1 to 5 Years | Liquidity Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_InterestBearingLoansAndBorrowings', window );">Interest bearing loans and borrowings</a></td>
<td class="nump">12,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">27,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">39,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">More than 5 years | Liquidity Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_InterestBearingLoansAndBorrowings', window );">Interest bearing loans and borrowings</a></td>
<td class="nump">66,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">71,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Contingent consideration</a></td>
<td class="nump">572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">&#8364; 139,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_InterestBearingLoansAndBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest bearing loans and borrowings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_InterestBearingLoansAndBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2020-01-01<br> -Paragraph B67<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B67_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph m<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of trade payables and other payables. [Refer: Trade payables; Other payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567886154280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Financial Liabilities - Summary of Changes in Liabilities Arising From Financing Activities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning balance</a></td>
<td class="nump">&#8364; 74,211<span></span>
</td>
<td class="nump">&#8364; 56,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flows</a></td>
<td class="nump">141,718<span></span>
</td>
<td class="nump">7,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="nump">35,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">New leases and disposals</a></td>
<td class="nump">4,240<span></span>
</td>
<td class="nump">9,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Other</a></td>
<td class="nump">15,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="nump">271,092<span></span>
</td>
<td class="nump">74,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=bntx_CurrentObligationsUnderLeaseContractsMember', window );">Current Obligations under Lease Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning balance</a></td>
<td class="nump">3,485<span></span>
</td>
<td class="nump">2,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flows</a></td>
<td class="num">(12,743)<span></span>
</td>
<td class="num">(3,061)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="nump">2,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">New leases and disposals</a></td>
<td class="nump">8,684<span></span>
</td>
<td class="nump">1,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities', window );">Reclassification</a></td>
<td class="nump">3,982<span></span>
</td>
<td class="nump">2,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="nump">6,127<span></span>
</td>
<td class="nump">3,485<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=bntx_NoncurrentObligationsUnderLeaseContractsMember', window );">Non-current Obligations under Lease Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning balance</a></td>
<td class="nump">54,126<span></span>
</td>
<td class="nump">48,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="nump">32,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">New leases and disposals</a></td>
<td class="num">(4,444)<span></span>
</td>
<td class="nump">8,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities', window );">Reclassification</a></td>
<td class="num">(3,982)<span></span>
</td>
<td class="num">(2,928)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="nump">78,031<span></span>
</td>
<td class="nump">54,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=bntx_InterestBearingLoansAndBorrowingsMember', window );">Interest-bearing Loans and Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning balance</a></td>
<td class="nump">16,600<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flows</a></td>
<td class="nump">140,847<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Other</a></td>
<td class="num">(1,416)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="nump">156,031<span></span>
</td>
<td class="nump">&#8364; 16,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=bntx_ConvertibleNoteEmbeddedDerivativeMember', window );">Convertible Note - Embedded Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flows</a></td>
<td class="nump">13,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Other</a></td>
<td class="nump">17,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="nump">&#8364; 30,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through reclassification liabilities arising from financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 44B<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_44B_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from obtaining or losing control of subsidiaries or other businesses. [Refer: Liabilities arising from financing activities; Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 44B<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_44B_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 44B<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_44B_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 44B<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_44B&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 44D<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_44D&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=bntx_CurrentObligationsUnderLeaseContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=bntx_CurrentObligationsUnderLeaseContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=bntx_NoncurrentObligationsUnderLeaseContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=bntx_NoncurrentObligationsUnderLeaseContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=bntx_InterestBearingLoansAndBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=bntx_InterestBearingLoansAndBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=bntx_ConvertibleNoteEmbeddedDerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=bntx_ConvertibleNoteEmbeddedDerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891137384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Summary of Inventories (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Classes Of Inventories [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies', window );">Raw materials and supplies</a></td>
<td class="nump">&#8364; 44,283<span></span>
</td>
<td class="nump">&#8364; 8,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WorkInProgress', window );">Unfinished goods</a></td>
<td class="nump">19,380<span></span>
</td>
<td class="nump">2,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinishedGoods', window );">Finished goods</a></td>
<td class="nump">457<span></span>
</td>
<td class="nump">633<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Total</a></td>
<td class="nump">&#8364; 64,120<span></span>
</td>
<td class="nump">&#8364; 11,722<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of current raw materials and current production supplies. [Refer: Current production supplies; Current raw materials]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 37<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 37<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WorkInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of assets currently in production, which require further processes to be converted into finished goods or services. [Refer: Current finished goods; Inventories]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 37<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WorkInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567888493688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Assets - Summary of Other Assets (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Trade And Other Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepayments on inventories</a></td>
<td class="nump">&#8364; 29,845<span></span>
</td>
<td class="nump">&#8364; 351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAdvancesToSuppliers', window );">Prepayments related to CRO and CMO contracts</a></td>
<td class="nump">14,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax', window );">Sales tax receivable</a></td>
<td class="nump">4,155<span></span>
</td>
<td class="nump">7,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_CurrentPrepaymentsRelatedToServiceContracts', window );">Prepayments related to service contracts</a></td>
<td class="nump">3,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_OtherCurrentAssetsOther', window );">Other</a></td>
<td class="nump">10,046<span></span>
</td>
<td class="nump">1,182<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Total</a></td>
<td class="nump">62,011<span></span>
</td>
<td class="nump">9,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Total current</a></td>
<td class="nump">60,966<span></span>
</td>
<td class="nump">&#8364; 9,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Total non-current</a></td>
<td class="nump">&#8364; 1,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_CurrentPrepaymentsRelatedToServiceContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current prepayments related to service contracts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_CurrentPrepaymentsRelatedToServiceContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_OtherCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other current assets other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_OtherCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAdvancesToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current advances made to suppliers before goods or services are received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAdvancesToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current receivables from taxes other than income tax. [Refer: Receivables from taxes other than income tax]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567888016152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Deferred Expenses - Summary of Deferred Expenses (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfDeferredExpensesAbstract', window );"><strong>Disclosure Of Deferred Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DeferredExpensesFromInsuranceContracts', window );">Deferred expenses from insurance contracts</a></td>
<td class="nump">&#8364; 13,845<span></span>
</td>
<td class="nump">&#8364; 1,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DeferredExpensesFromContractManufacturingAndContractResearchOrganizations', window );">Deferred expenses from CRO and CMO contracts</a></td>
<td class="nump">5,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_OtherDeferredExpenses', window );">Other</a></td>
<td class="nump">8,431<span></span>
</td>
<td class="nump">4,104<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DeferredExpense', window );">Total</a></td>
<td class="nump">28,001<span></span>
</td>
<td class="nump">5,862<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DeferredExpenseCurrent', window );">Deferred expenses</a></td>
<td class="nump">28,001<span></span>
</td>
<td class="nump">5,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DeferredExpenseNonCurrent', window );">Total non-current</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DeferredExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DeferredExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DeferredExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred expense current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DeferredExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DeferredExpenseNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred expense, non-current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DeferredExpenseNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DeferredExpensesFromContractManufacturingAndContractResearchOrganizations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred expenses from contract manufacturing and contract research organizations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DeferredExpensesFromContractManufacturingAndContractResearchOrganizations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DeferredExpensesFromInsuranceContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred expenses from insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DeferredExpensesFromInsuranceContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfDeferredExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of deferred expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfDeferredExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_OtherDeferredExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other deferred expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_OtherDeferredExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567872811656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Issued Capital and Reserves - Additional Information (Details)<br> &#8364; / shares in Units, $ / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 08, 2020 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 27, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Aug. 27, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 27, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jul. 27, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 29, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>May 08, 2020 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 05, 2020 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 23, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 17, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 17, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 16, 2020 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 16, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 06, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Nov. 06, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 18, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 14, 2019 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 06, 2019 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 10, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 10, 2019 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 26, 2019 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_StockSplitConversionRatio', window );">Stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.05556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_SharesIssuedDuringPeriodStockSplit', window );">Shares issued during period stock split | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,595,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Nominal value | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Equity transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 33,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,088,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_CashInvestment', window );">Cash investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 80,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">246,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=bntx_BillAndMeLindaGatesFoundationMember', window );">Bill &amp; Melinda Gates Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Ordinary shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,038,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=bntx_OrdinarySharesSeriesBMember', window );">Ordinary Shares Series B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Ordinary shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,465,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=bntx_OrdinarySharesSeriesBMember', window );">Ordinary Shares Series B | HONG KONG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedButNotFullyPaid', window );">Ordinary shares issued but not fully paid | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,524,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CapitalRequirementsAxis=bntx_GlobalOfferingMember', window );">Global Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Aggregate proceeds from issuance of ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">436,300<span></span>
</td>
<td class="nump">$ 513,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares', window );">Percentage of ADS to ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_SharesIssuedPricePerShare1', window );">Ordinary shares issued price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CapitalRequirementsAxis=bntx_June2020PrivatePlacementMember', window );">June 2020 Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued | shares</a></td>
<td class="nump">2,595,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_EquityIssuable', window );">Equity issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 123,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CapitalRequirementsAxis=bntx_June2020PrivatePlacementMember', window );">June 2020 Private Placement | Convertible Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_FinancialLiabilityMaturityTerm', window );">Maturity period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CapitalRequirementsAxis=bntx_AtMarketOfferingProgramMember', window );">At-The-Market Offering Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Aggregate proceeds from issuance of ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 76,500<span></span>
</td>
<td class="nump">$ 92,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">735,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares', window );">Percentage of ADS to ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_MaximumProceedsReceivableFromIssuanceOfOrdinaryShares', window );">Maximum gross proceeds receivable from issuance of ordinary shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CapitalRequirementsAxis=bntx_InitialPublicOfferingMember', window );">Initial Public Offering (IPO)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Aggregate proceeds from issuance of ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 143,300<span></span>
</td>
<td class="nump">$ 157,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_SharesIssuedPricePerShare1', window );">Ordinary shares issued price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInEquity', window );">Increase in share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=bntx_NeonTherapeuticsIncMember', window );">Neon Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,935,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=bntx_BioNTechCellAndGeneTherapiesGmbHMember', window );">BioNTech Cell &amp; Gene Therapies GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Nominal value | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,374,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_RemainingNoncontrollingInterestsAcquiredPercentage', window );">Remaining non-controlling interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DerecognitionOfNonControllingInterest', window );">Derecognition of non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DecreaseInCapitalReserve', window );">Decrease in capital reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bntx_ShanghaiFosunPharmaceuticalGroupCoLtdMember', window );">Shanghai Fosun Pharmaceuticals (Group) Co., Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Aggregate proceeds from issuance of ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 45,600<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NumberOfOrdinarySharesIssuable', window );">Number of ordinary shares issuable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,580,777<span></span>
</td>
<td class="nump">1,580,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bntx_PfizerIncMember', window );">Pfizer Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Aggregate proceeds from issuance of ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 103,900<span></span>
</td>
<td class="nump">$ 113,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,377,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,100<span></span>
</td>
<td class="nump">&#8364; 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital | Global Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16<span></span>
</td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="nump">&#8364; 5,500<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital | June 2020 Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital | Initial Public Offering (IPO)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital | Neon Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital | BioNTech Cell &amp; Gene Therapies GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital | Shanghai Fosun Pharmaceuticals (Group) Co., Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital | Pfizer Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_TreasurySharesMember', window );">Treasury Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_TreasurySharesMember', window );">Treasury Shares | At-The-Market Offering Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(735,490)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_CapitalReserveMember', window );">Capital Reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 861,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Equity transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_CapitalReserveMember', window );">Capital Reserve | Bill &amp; Melinda Gates Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 46,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_CapitalReserveMember', window );">Capital Reserve | Ordinary Shares Series B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 186,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_CapitalReserveMember', window );">Capital Reserve | Global Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_CapitalReserveMember', window );">Capital Reserve | June 2020 Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital</a></td>
<td class="nump">&#8364; 121,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_CapitalReserveMember', window );">Capital Reserve | At-The-Market Offering Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 75,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_CapitalReserveMember', window );">Capital Reserve | Initial Public Offering (IPO)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 132,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_CapitalReserveMember', window );">Capital Reserve | Neon Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 87,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_CapitalReserveMember', window );">Capital Reserve | Shanghai Fosun Pharmaceuticals (Group) Co., Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_CapitalReserveMember', window );">Capital Reserve | Pfizer Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 101,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_CashInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_CashInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DecreaseInCapitalReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in capital reserve.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DecreaseInCapitalReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DerecognitionOfNonControllingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derecognition of non controlling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DerecognitionOfNonControllingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_EquityIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity issuable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_EquityIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_FinancialLiabilityMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial liability, maturity term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_FinancialLiabilityMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_MaximumProceedsReceivableFromIssuanceOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum proceeds receivable from issuance of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_MaximumProceedsReceivableFromIssuanceOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfOrdinarySharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of ordinary shares issuable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfOrdinarySharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of American depository shares to ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_RemainingNoncontrollingInterestsAcquiredPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition of non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_RemainingNoncontrollingInterestsAcquiredPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_SharesIssuedDuringPeriodStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued during period stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_SharesIssuedDuringPeriodStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_SharesIssuedPricePerShare1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued price per share 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_SharesIssuedPricePerShare1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_StockSplitConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock split conversion ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_StockSplitConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has been received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAndFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedButNotFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has not been received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedButNotFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=bntx_BillAndMeLindaGatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=bntx_BillAndMeLindaGatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=bntx_OrdinarySharesSeriesBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=bntx_OrdinarySharesSeriesBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_HK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_HK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalRequirementsAxis=bntx_GlobalOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalRequirementsAxis=bntx_GlobalOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalRequirementsAxis=bntx_June2020PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalRequirementsAxis=bntx_June2020PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=bntx_ConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=bntx_ConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalRequirementsAxis=bntx_AtMarketOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalRequirementsAxis=bntx_AtMarketOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalRequirementsAxis=bntx_InitialPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalRequirementsAxis=bntx_InitialPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=bntx_NeonTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=bntx_NeonTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=bntx_BioNTechCellAndGeneTherapiesGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=bntx_BioNTechCellAndGeneTherapiesGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bntx_ShanghaiFosunPharmaceuticalGroupCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bntx_ShanghaiFosunPharmaceuticalGroupCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bntx_PfizerIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bntx_PfizerIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_TreasurySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_TreasurySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_CapitalReserveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_CapitalReserveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567880679112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Additional Information (Details)<br> &#8364; / shares in Units, $ / shares in Units, $ in Billions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 13, 2020 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Feb. 13, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 01, 2019 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Oct. 10, 2019 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Nov. 15, 2018 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th">
<div>May 31, 2019 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Apr. 03, 2019 </div>
<div>&#8364; / shares</div>
</th>
<th class="th"><div>Apr. 03, 2019</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_TwoThousandTwentyRestrictedStockUnitPlanMember', window );">2020 Restricted Stock Unit Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payment expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanMember', window );">Employee Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payment expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,015,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement', window );">Option rights vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The BioNTech Employee 2020 Equity Plan share-based payment transaction for employees based in Europe includes two programs, LTI and LTI-plus. The LTI program will be offered to all employees. The LTI-plus program intends to compensate employees who did not participate in the ESOP. Under both programs, RSUs will be offered to employees based in Europe. Both programs are classified as equity-settled because BioNTech has the ability to determine the method of settlement. The LTI will vest annually in equal installments after four years commencing on December 15, 2020. The LTI-plus will vest annually in equal installments after two years commencing on December 15, 2020. Moreover, the LTI-plus contains a non-vesting condition concerning 50% of the granted RSUs. These units will be awarded to the participant after the FDA fully approves BNT162b2.<span></span>
</td>
<td class="text">The BioNTech Employee 2020 Equity Plan share-based payment transaction for employees based in Europe includes two programs, LTI and LTI-plus. The LTI program will be offered to all employees. The LTI-plus program intends to compensate employees who did not participate in the ESOP. Under both programs, RSUs will be offered to employees based in Europe. Both programs are classified as equity-settled because BioNTech has the ability to determine the method of settlement. The LTI will vest annually in equal installments after four years commencing on December 15, 2020. The LTI-plus will vest annually in equal installments after two years commencing on December 15, 2020. Moreover, the LTI-plus contains a non-vesting condition concerning 50% of the granted RSUs. These units will be awarded to the participant after the FDA fully approves BNT162b2.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanMember', window );">Employee Equity Plan | Research and Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payment expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 681,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanMember', window );">Employee Equity Plan | General And Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payment expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentiveProgramMember', window );">LTI Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_OptionVestingPeriod', window );">Option rights vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember', window );">LTI-plus Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_OptionVestingPeriod', window );">Option rights vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_PercentageOfOtherEquityInstrumentNonVestingRate', window );">Percentage of non-vesting rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember', window );">Management Board Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payment expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherFinancialLiabilities', window );">Other financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_PercentageOfIncreaseInExercisePrice', window );">Percentage of exercise price increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering', window );">Threshold amount of dividend by number of shares outstanding immediately following initial public offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth', window );">Percentage of target share price applicable for prior twelve month period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107.00%<span></span>
</td>
<td class="nump">107.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_OptionExpirationPeriod', window );">Option rights expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price | (per share)</a></td>
<td class="nump">&#8364; 28.32<span></span>
</td>
<td class="nump">$ 30.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_WeightedAverageRemainingContractualLifeOfShareOptionsAllocatedAndExpectedToBeAllocated', window );">Options allocated and expected to be allocated, weighted-average expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 7 months 17 days<span></span>
</td>
<td class="text">4 years 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted, share options | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248,096<span></span>
</td>
<td class="nump">248,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember', window );">Management Board Grant | Prof. Ugur Sahin, M.D.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendShareOptionsGranted', window );">Grant of options, base value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember', window );">Management Board Grant | Sean Marett</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendShareOptionsGranted', window );">Grant of options, base value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember', window );">Management Board Grant | Dr. Sierk Poetting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendShareOptionsGranted', window );">Grant of options, base value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember', window );">Management Board Grant | Dr. Ozlem Tureci</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendShareOptionsGranted', window );">Grant of options, base value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember', window );">Management Board Grant | Ryan Richardson</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendShareOptionsGranted', window );">Grant of options, base value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_IncreaseDecreaseInShareBasedPaymentValue', window );">Increase (decrease) in grant of options, base value, for the year 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember', window );">Management Board Grant | Research and Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payment expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,514,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_CashSettledExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payment expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember', window );">Management Board Grant | General And Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payment expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,246,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_CashSettledExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payment expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember', window );">Management Board Grant | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares', window );">Percentage of ADS to ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember', window );">Chief Executive Officer Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted, share options | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited, share options | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Options outstanding, weighted-average expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 1 month 13 days<span></span>
</td>
<td class="text">4 years 1 month 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember', window );">Chief Executive Officer Grant | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement', window );">Option rights vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The option vests annually in equal installments after four years commencing on the first anniversary of the initial public offering and will be exercisable four years after the initial public offering. The option is subject to the terms, conditions, definitions and provisions of the ESOP and the applicable option agreement thereunder.<span></span>
</td>
<td class="text">The option vests annually in equal installments after four years commencing on the first anniversary of the initial public offering and will be exercisable four years after the initial public offering. The option is subject to the terms, conditions, definitions and provisions of the ESOP and the applicable option agreement thereunder.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_OptionVestingPeriod', window );">Option rights vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_PercentageOfIncreaseInExercisePrice', window );">Percentage of exercise price increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering', window );">Threshold amount of dividend by number of shares outstanding immediately following initial public offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth', window );">Percentage of target share price applicable for prior twelve month period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Option to purchase ordinary shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,374,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare', window );">Exercise price in translation for IPO | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.60<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember', window );">Chief Executive Officer Grant | Research and Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payment expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember', window );">Chief Executive Officer Grant | Maximum | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_OptionExercisablePeriod', window );">Option rights exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember', window );">Employee Stock Ownership Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payment expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 17,075,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 27,028,000<span></span>
</td>
<td class="nump">&#8364; 7,641,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement', window );">Option rights vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Option Rights vest over four years and can only be exercised if the company has executed a public offering in the United States (IPO) and when the Threshold Amount is met. Threshold Amount means the exercise price provided that such price increases by eight percentage points on the first and then each subsequent anniversary of the Allocation Date (September 26, 2018). The Option Rights can be exercised at the latest eight years after the Allocation Date. If they have not been exercised by that date, they will be forfeited without compensation.<span></span>
</td>
<td class="text">The Option Rights vest over four years and can only be exercised if the company has executed a public offering in the United States (IPO) and when the Threshold Amount is met. Threshold Amount means the exercise price provided that such price increases by eight percentage points on the first and then each subsequent anniversary of the Allocation Date (September 26, 2018). The Option Rights can be exercised at the latest eight years after the Allocation Date. If they have not been exercised by that date, they will be forfeited without compensation.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_OptionVestingPeriod', window );">Option rights vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_PercentageOfIncreaseInExercisePrice', window );">Percentage of exercise price increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.39<span></span>
</td>
<td class="nump">&#8364; 15.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_OptionExercisablePeriod', window );">Option rights exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted, share options | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited, share options | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,491<span></span>
</td>
<td class="nump">9,491<span></span>
</td>
<td class="nump">17,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Options outstanding, weighted-average expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 8 months 23 days<span></span>
</td>
<td class="text">3 years 8 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember', window );">Employee Stock Ownership Plan | Research and Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payment expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 20,016,000<span></span>
</td>
<td class="nump">6,786,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember', window );">Employee Stock Ownership Plan | General And Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payment expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,975,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6,008,000<span></span>
</td>
<td class="nump">&#8364; 728,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_CashSettledExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash settled expense from share based payment transactions with employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_CashSettledExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price currency translation of public offering price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncreaseDecreaseInShareBasedPaymentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in share based payment value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncreaseDecreaseInShareBasedPaymentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_OptionExercisablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The option rights can be exercised at the latest eight years after the allocation date. If they have not been exercised by that date, they will forfeit without compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_OptionExercisablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_OptionExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_OptionExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_OptionVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option vesting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_OptionVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of American depository shares to ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PercentageOfIncreaseInExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Input parameter for performance criterion 1 - Threshold Amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PercentageOfIncreaseInExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PercentageOfOtherEquityInstrumentNonVestingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of other equity instrument non vesting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PercentageOfOtherEquityInstrumentNonVestingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Input parameter increase factor for performance criterion 2 - Target Price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Input parameter capitalization for performance criterion 2 - Target Price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_WeightedAverageRemainingContractualLifeOfShareOptionsAllocatedAndExpectedToBeAllocated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual life of share options allocated and expected to be allocated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_WeightedAverageRemainingContractualLifeOfShareOptionsAllocatedAndExpectedToBeAllocated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the vesting requirements for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of instruments granted in share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph IG23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_IG23&amp;doctype=Implementation%20Guidance<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph m<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_TwoThousandTwentyRestrictedStockUnitPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_TwoThousandTwentyRestrictedStockUnitPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NatureOfExpensesAxis=bntx_ResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NatureOfExpensesAxis=bntx_ResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NatureOfExpensesAxis=bntx_GeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NatureOfExpensesAxis=bntx_GeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentiveProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentiveProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bntx_ProfessorUgurSahinMDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bntx_ProfessorUgurSahinMDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bntx_SeanMarettMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bntx_SeanMarettMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bntx_DrSierkPoettingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bntx_DrSierkPoettingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bntx_DrOzlemTureciMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bntx_DrOzlemTureciMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bntx_RyanRichardsonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bntx_RyanRichardsonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567892123720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Schedule of Number and Share Price of Restricted Stock Units (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanMember', window );">Employee Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Ending Balance, Restricted Stock Units | shares</a></td>
<td class="nump">649,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Ending Balance, Share price | &#8364; / shares</a></td>
<td class="nump">&#8364; 66.43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentiveProgramMember', window );">LTI Program</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NumberOfInstrumentsOtherEquityInstrumentsExpectedToBeAllocated', window );">Expected to be allocated, Restricted Stock Units | shares</a></td>
<td class="nump">252,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpectedToBeAllocatedInSharebasedPaymentArrangement', window );">Expected to be allocated, Share price | &#8364; / shares</a></td>
<td class="nump">&#8364; 66.43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember', window );">LTI-plus Program</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NumberOfInstrumentsOtherEquityInstrumentsExpectedToBeAllocated', window );">Expected to be allocated, Restricted Stock Units | shares</a></td>
<td class="nump">396,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpectedToBeAllocatedInSharebasedPaymentArrangement', window );">Expected to be allocated, Share price | &#8364; / shares</a></td>
<td class="nump">&#8364; 66.43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfInstrumentsOtherEquityInstrumentsExpectedToBeAllocated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of instruments other equity instruments expected to be allocated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfInstrumentsOtherEquityInstrumentsExpectedToBeAllocated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpectedToBeAllocatedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of other equity instruments expected to be allocated in share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpectedToBeAllocatedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentiveProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentiveProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567886952664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Schedule of Expense Recognized for Employee Services Received (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanMember', window );">Employee Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expense recognized for employee services received</a></td>
<td class="nump">&#8364; 1,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember', window );">Management Board Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expense recognized for employee services received</a></td>
<td class="nump">2,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember', window );">Employee Stock Ownership Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expense recognized for employee services received</a></td>
<td class="nump">17,075<span></span>
</td>
<td class="nump">&#8364; 27,028<span></span>
</td>
<td class="nump">&#8364; 7,641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NatureOfExpensesAxis=bntx_CostOfSales1Member', window );">Cost of Sales | Employee Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expense recognized for employee services received</a></td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NatureOfExpensesAxis=bntx_CostOfSales1Member', window );">Cost of Sales | Employee Stock Ownership Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expense recognized for employee services received</a></td>
<td class="nump">869<span></span>
</td>
<td class="nump">896<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NatureOfExpensesAxis=bntx_ResearchAndDevelopmentExpensesMember', window );">Research and Development Expenses | Employee Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expense recognized for employee services received</a></td>
<td class="nump">681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NatureOfExpensesAxis=bntx_ResearchAndDevelopmentExpensesMember', window );">Research and Development Expenses | Management Board Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expense recognized for employee services received</a></td>
<td class="nump">1,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NatureOfExpensesAxis=bntx_ResearchAndDevelopmentExpensesMember', window );">Research and Development Expenses | Employee Stock Ownership Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expense recognized for employee services received</a></td>
<td class="nump">11,120<span></span>
</td>
<td class="nump">20,016<span></span>
</td>
<td class="nump">6,786<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NatureOfExpensesAxis=bntx_SalesAndMarketingExpensesMember', window );">Sales and Marketing Expenses | Employee Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expense recognized for employee services received</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NatureOfExpensesAxis=bntx_SalesAndMarketingExpensesMember', window );">Sales and Marketing Expenses | Employee Stock Ownership Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expense recognized for employee services received</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NatureOfExpensesAxis=bntx_GeneralAndAdministrativeExpensesMember', window );">General And Administrative Expenses | Employee Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expense recognized for employee services received</a></td>
<td class="nump">147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NatureOfExpensesAxis=bntx_GeneralAndAdministrativeExpensesMember', window );">General And Administrative Expenses | Management Board Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expense recognized for employee services received</a></td>
<td class="nump">1,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NatureOfExpensesAxis=bntx_GeneralAndAdministrativeExpensesMember', window );">General And Administrative Expenses | Employee Stock Ownership Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expense recognized for employee services received</a></td>
<td class="nump">&#8364; 4,975<span></span>
</td>
<td class="nump">&#8364; 6,008<span></span>
</td>
<td class="nump">&#8364; 728<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NatureOfExpensesAxis=bntx_CostOfSales1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NatureOfExpensesAxis=bntx_CostOfSales1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NatureOfExpensesAxis=bntx_ResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NatureOfExpensesAxis=bntx_ResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NatureOfExpensesAxis=bntx_SalesAndMarketingExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NatureOfExpensesAxis=bntx_SalesAndMarketingExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NatureOfExpensesAxis=bntx_GeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NatureOfExpensesAxis=bntx_GeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567887521752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Schedule of Number and Weighted-Average Exercise Price of Share Options (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember', window );">Management Board Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted, share options</a></td>
<td class="nump">248,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne', window );">Expected to be allocated as of estimated allocation date 2021, share options</a></td>
<td class="nump">101,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo', window );">Expected to be allocated as of estimated allocation date 2022, share options</a></td>
<td class="nump">102,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Ending Balance, Share options</a></td>
<td class="nump">451,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Granted, Weighted-average exercise price | &#8364; / shares</a></td>
<td class="nump">&#8364; 28.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne', window );">Expected to be allocated as of estimated allocation date 2021, Weighted-average exercise price | &#8364; / shares</a></td>
<td class="nump">67.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo', window );">Expected to be allocated as of estimated allocation date 2022, Weighted-average exercise price | &#8364; / shares</a></td>
<td class="nump">67.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Ending Balance, Weighted-average exercise price | &#8364; / shares</a></td>
<td class="nump">&#8364; 45.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember', window );">Employee Stock Ownership Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Beginning Balance, Share options</a></td>
<td class="nump">655,383<span></span>
</td>
<td class="nump">658,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted, share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited, share options</a></td>
<td class="num">(9,491)<span></span>
</td>
<td class="num">(17,237)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Ending Balance, Share options</a></td>
<td class="nump">645,892<span></span>
</td>
<td class="nump">655,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Beginning Balance, Weighted-average exercise price | &#8364; / shares</a></td>
<td class="nump">&#8364; 10.23<span></span>
</td>
<td class="nump">&#8364; 10.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Granted, Weighted-average exercise price | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">Forfeited, Weighted-average exercise price | &#8364; / shares</a></td>
<td class="nump">10.81<span></span>
</td>
<td class="nump">10.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Ending Balance, Weighted-average exercise price | &#8364; / shares</a></td>
<td class="nump">&#8364; 10.23<span></span>
</td>
<td class="nump">&#8364; 10.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding', window );">Beginning Balance, Number of Ordinary Shares underlying options</a></td>
<td class="nump">11,796,894<span></span>
</td>
<td class="nump">11,845,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NumberOfOrdinarySharesUnderlyingOptionsGrantedInSharebasedPaymentArrangement', window );">Granted, Shares underlying options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited, Shares underlying options</a></td>
<td class="num">(170,838)<span></span>
</td>
<td class="num">(310,266)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding', window );">Ending Balance, Number of Ordinary Shares underlying options</a></td>
<td class="nump">11,626,056<span></span>
</td>
<td class="nump">11,796,894<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of ordinary shares underlying options forfeited in sharebased payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfOrdinarySharesUnderlyingOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of ordinary shares underlying options granted in sharebased payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfOrdinarySharesUnderlyingOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of ordinary shares underlying options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options expected to be allocated in share based payment arrangement year one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options expected to be allocated in share based payment arrangement year two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of share options expected to be allocated in share based payment arrangement year one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of share options expected to be allocated in share based payment arrangement year two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_WeightedAverageExercisePriceOfShareOptionsExpectedToBeAllocatedInShareBasedPaymentArrangementYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567886383496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Summary of Inputs Used in Measurement of Fair Value at Grant Date (Details)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 13, 2020 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Feb. 13, 2020 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 01, 2019 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Oct. 10, 2019 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Nov. 15, 2018 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Apr. 03, 2019 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember', window );">Management Board Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value | &#8364;</a></td>
<td class="nump">&#8364; 10.83<span></span>
</td>
<td class="nump">&#8364; 10.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Weighted average share price</a></td>
<td class="nump">&#8364; 28.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price | (per share)</a></td>
<td class="nump">&#8364; 28.32<span></span>
</td>
<td class="nump">&#8364; 30.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="nump">36.60%<span></span>
</td>
<td class="nump">36.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (years) | yr</a></td>
<td class="nump">4.75<span></span>
</td>
<td class="nump">4.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="nump">1.61%<span></span>
</td>
<td class="nump">1.61%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember', window );">Management Board Grant | Estimated Allocation Date 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 26.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Weighted average share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 66.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 67.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.88%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember', window );">Management Board Grant | Estimated Allocation Date 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 26.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Weighted average share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 66.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 67.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.88%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember', window );">Chief Executive Officer Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Weighted average share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.52%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember', window );">Employee Stock Ownership Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 9.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 7.41<span></span>
</td>
<td class="nump">&#8364; 7.04<span></span>
</td>
<td class="nump">&#8364; 6.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Weighted average share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 19.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.40<span></span>
</td>
<td class="nump">&#8364; 16.03<span></span>
</td>
<td class="nump">&#8364; 15.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10.14<span></span>
</td>
<td class="nump">&#8364; 15.39<span></span>
</td>
<td class="nump">&#8364; 15.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.84<span></span>
</td>
<td class="nump">6.00<span></span>
</td>
<td class="nump">6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.05%<span></span>
</td>
<td class="nump">0.05%<span></span>
</td>
<td class="nump">0.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=bntx_EstimatedAllocationDateOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=bntx_EstimatedAllocationDateOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=bntx_EstimatedAllocationDateTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=bntx_EstimatedAllocationDateTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567886666408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-Based Payments - Schedule of Number and Weighted-Average Exercise Price of Share Options Allocated and Expected to be Allocated (Details) - Management Board Grant<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Feb. 13, 2020 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">451,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted-average exercise price | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 45.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bntx_ProfessorUgurSahinMDMember', window );">Prof. Ugur Sahin, M.D.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,686<span></span>
</td>
<td class="nump">97,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted-average exercise price | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10.14<span></span>
</td>
<td class="nump">&#8364; 28.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bntx_ProfessorUgurSahinMDMember', window );">Prof. Ugur Sahin, M.D. | Estimated Allocation Date 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted-average exercise price | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 67.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bntx_ProfessorUgurSahinMDMember', window );">Prof. Ugur Sahin, M.D. | Estimated Allocation Date 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options outstanding | shares</a></td>
<td class="nump">39,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted-average exercise price | &#8364; / shares</a></td>
<td class="nump">&#8364; 67.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bntx_SeanMarettMember', window );">Sean Marett</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,895<span></span>
</td>
<td class="nump">38,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted-average exercise price | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10.14<span></span>
</td>
<td class="nump">&#8364; 28.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bntx_SeanMarettMember', window );">Sean Marett | Estimated Allocation Date 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted-average exercise price | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 67.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bntx_SeanMarettMember', window );">Sean Marett | Estimated Allocation Date 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options outstanding | shares</a></td>
<td class="nump">15,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted-average exercise price | &#8364; / shares</a></td>
<td class="nump">&#8364; 67.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bntx_DrSierkPoettingMember', window );">Dr. Sierk Poetting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,895<span></span>
</td>
<td class="nump">38,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted-average exercise price | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10.14<span></span>
</td>
<td class="nump">&#8364; 28.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bntx_DrSierkPoettingMember', window );">Dr. Sierk Poetting | Estimated Allocation Date 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted-average exercise price | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 67.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bntx_DrSierkPoettingMember', window );">Dr. Sierk Poetting | Estimated Allocation Date 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options outstanding | shares</a></td>
<td class="nump">15,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted-average exercise price | &#8364; / shares</a></td>
<td class="nump">&#8364; 67.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bntx_DrOzlemTureciMDMember', window );">Dr. Ozlem Tureci, M.D.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,463<span></span>
</td>
<td class="nump">38,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted-average exercise price | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10.14<span></span>
</td>
<td class="nump">&#8364; 28.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bntx_DrOzlemTureciMDMember', window );">Dr. Ozlem Tureci, M.D. | Estimated Allocation Date 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted-average exercise price | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 67.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bntx_DrOzlemTureciMDMember', window );">Dr. Ozlem Tureci, M.D. | Estimated Allocation Date 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options outstanding | shares</a></td>
<td class="nump">15,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted-average exercise price | &#8364; / shares</a></td>
<td class="nump">&#8364; 67.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bntx_RyanRichardsonMember', window );">Ryan Richardson</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,306<span></span>
</td>
<td class="nump">33,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted-average exercise price | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10.14<span></span>
</td>
<td class="nump">&#8364; 28.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bntx_RyanRichardsonMember', window );">Ryan Richardson | Estimated Allocation Date 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted-average exercise price | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 67.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bntx_RyanRichardsonMember', window );">Ryan Richardson | Estimated Allocation Date 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options outstanding | shares</a></td>
<td class="nump">14,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted-average exercise price | &#8364; / shares</a></td>
<td class="nump">&#8364; 67.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bntx_ProfessorUgurSahinMDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bntx_ProfessorUgurSahinMDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=bntx_EstimatedAllocationDateOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=bntx_EstimatedAllocationDateOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=bntx_EstimatedAllocationDateTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=bntx_EstimatedAllocationDateTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bntx_SeanMarettMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bntx_SeanMarettMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bntx_DrSierkPoettingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bntx_DrSierkPoettingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bntx_DrOzlemTureciMDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bntx_DrOzlemTureciMDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bntx_RyanRichardsonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bntx_RyanRichardsonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567880655224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-Based Payments - Schedule of Number of Share Options Outstanding (Details) - Management Board Grant<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Feb. 13, 2020 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options outstanding</a></td>
<td class="nump">451,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted-average exercise price | &#8364; / shares</a></td>
<td class="nump">&#8364; 45.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bntx_ProfessorUgurSahinMDMember', window );">Prof. Ugur Sahin, M.D.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options outstanding</a></td>
<td class="nump">101,686<span></span>
</td>
<td class="nump">97,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding', window );">Number of ordinary shares underlying options</a></td>
<td class="nump">1,830,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted-average exercise price | &#8364; / shares</a></td>
<td class="nump">&#8364; 10.14<span></span>
</td>
<td class="nump">&#8364; 28.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bntx_SeanMarettMember', window );">Sean Marett</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options outstanding</a></td>
<td class="nump">33,895<span></span>
</td>
<td class="nump">38,968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding', window );">Number of ordinary shares underlying options</a></td>
<td class="nump">610,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted-average exercise price | &#8364; / shares</a></td>
<td class="nump">&#8364; 10.14<span></span>
</td>
<td class="nump">&#8364; 28.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bntx_DrSierkPoettingMember', window );">Dr. Sierk Poetting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options outstanding</a></td>
<td class="nump">33,895<span></span>
</td>
<td class="nump">38,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding', window );">Number of ordinary shares underlying options</a></td>
<td class="nump">610,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted-average exercise price | &#8364; / shares</a></td>
<td class="nump">&#8364; 10.14<span></span>
</td>
<td class="nump">&#8364; 28.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bntx_DrOzlemTureciMDMember', window );">Dr. Ozlem Tureci, M.D.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options outstanding</a></td>
<td class="nump">108,463<span></span>
</td>
<td class="nump">38,968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding', window );">Number of ordinary shares underlying options</a></td>
<td class="nump">1,952,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted-average exercise price | &#8364; / shares</a></td>
<td class="nump">&#8364; 10.14<span></span>
</td>
<td class="nump">&#8364; 28.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bntx_RyanRichardsonMember', window );">Ryan Richardson</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options outstanding</a></td>
<td class="nump">8,306<span></span>
</td>
<td class="nump">33,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding', window );">Number of ordinary shares underlying options</a></td>
<td class="nump">149,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted-average exercise price | &#8364; / shares</a></td>
<td class="nump">&#8364; 10.14<span></span>
</td>
<td class="nump">&#8364; 28.32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of ordinary shares underlying options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bntx_ProfessorUgurSahinMDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bntx_ProfessorUgurSahinMDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bntx_SeanMarettMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bntx_SeanMarettMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bntx_DrSierkPoettingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bntx_DrSierkPoettingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bntx_DrOzlemTureciMDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bntx_DrOzlemTureciMDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bntx_RyanRichardsonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bntx_RyanRichardsonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567888338440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Liabilities - Summary of Other Liabilities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MiscellaneousCurrentLiabilitiesAbstract', window );"><strong>Miscellaneous Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_CurrentLiabilitiesForEmployeesBenefits', window );">Liabilities to employees</a></td>
<td class="nump">&#8364; 24,248<span></span>
</td>
<td class="nump">&#8364; 6,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_OtherLiabilitiesOther', window );">Other</a></td>
<td class="nump">4,379<span></span>
</td>
<td class="nump">780<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherLiabilities', window );">Total</a></td>
<td class="nump">28,627<span></span>
</td>
<td class="nump">7,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">28,061<span></span>
</td>
<td class="nump">&#8364; 7,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">&#8364; 566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_CurrentLiabilitiesForEmployeesBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current liabilities for employees benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_CurrentLiabilitiesForEmployeesBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_OtherLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other liabilities other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_OtherLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567886151176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Right-of-Use Assets within Consolidated Statements of Financial Position (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">&#8364; 98,988<span></span>
</td>
<td class="nump">&#8364; 55,018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">80,875<span></span>
</td>
<td class="nump">54,956<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=bntx_EquipmentToolsAndInstallationsMember', window );">Equipment, Tools and Installations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember', window );">Automobiles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">&#8364; 55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=bntx_ProductionFacilitiesMember', window );">Production Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">7,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=bntx_AdvancePaymentsMember', window );">Advance Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">&#8364; 10,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=bntx_EquipmentToolsAndInstallationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=bntx_EquipmentToolsAndInstallationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=bntx_ProductionFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=bntx_ProductionFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=bntx_AdvancePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=bntx_AdvancePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567886153048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="nump">&#8364; 22.1<span></span>
</td>
<td class="nump">&#8364; 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AdvancePaymentsRelatedToEmbeddedLeases', window );">Advance payments related to embedded leases</a></td>
<td class="nump">10.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Total cash outflow for leases</a></td>
<td class="nump">14.7<span></span>
</td>
<td class="nump">&#8364; 4.8<span></span>
</td>
<td class="nump">&#8364; 2.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=ifrs-full_TopOfRangeMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities', window );">Undiscounted potential future lease payments related to renewal options not included in lease liabilities until 2049</a></td>
<td class="nump">38.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Within One Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Future lease payments for non-cancellable lease contracts</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember', window );">More Than One Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Future lease payments for non-cancellable lease contracts</a></td>
<td class="nump">&#8364; 10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AdvancePaymentsRelatedToEmbeddedLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advance payments related to embedded leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AdvancePaymentsRelatedToEmbeddedLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Undiscounted future lease payments related to renewal options not included in lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 58<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_58&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph B11D<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B11D_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567919654520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Lease Liability Included in Interest-Bearing Loans and Borrowings (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilitiesAbstract', window );"><strong>Lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Current</a></td>
<td class="nump">&#8364; 6,127<span></span>
</td>
<td class="nump">&#8364; 3,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Non-current</a></td>
<td class="nump">78,031<span></span>
</td>
<td class="nump">54,126<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Total</a></td>
<td class="nump">&#8364; 84,158<span></span>
</td>
<td class="nump">&#8364; 57,611<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567886596136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Amounts Recognized in Consolidated Statement of Operations (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge</a></td>
<td class="nump">&#8364; 6,290<span></span>
</td>
<td class="nump">&#8364; 4,679<span></span>
</td>
<td class="nump">&#8364; 2,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest on lease liabilities</a></td>
<td class="nump">2,003<span></span>
</td>
<td class="nump">1,718<span></span>
</td>
<td class="nump">1,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed', window );">Expense related to short-term leases (included in other expenses)</a></td>
<td class="nump">875<span></span>
</td>
<td class="nump">442<span></span>
</td>
<td class="nump">431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed', window );">Expense relating to leases of low-value assets that are not short-term leases (included in other expenses)</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_LeaseExpensesRecognizedInProfitOrLoss', window );">Total amounts recognized in profit or loss</a></td>
<td class="nump">9,468<span></span>
</td>
<td class="nump">6,929<span></span>
</td>
<td class="nump">5,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge</a></td>
<td class="nump">4,628<span></span>
</td>
<td class="nump">4,614<span></span>
</td>
<td class="nump">2,751<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=bntx_EquipmentToolsAndInstallationsMember', window );">Equipment, Tools and Installations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember', window );">Automobiles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">&#8364; 40<span></span>
</td>
<td class="nump">&#8364; 35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=bntx_ProductionFacilitiesMember', window );">Production Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge</a></td>
<td class="nump">&#8364; 1,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_LeaseExpensesRecognizedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease expenses recognized in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_LeaseExpensesRecognizedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the expense relating to leases of low-value assets accounted for applying paragraph 6 of IFRS 16. This expense shall not include the expense relating to short-term leases of low-value assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=bntx_EquipmentToolsAndInstallationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=bntx_EquipmentToolsAndInstallationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=bntx_ProductionFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=bntx_ProductionFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567887519096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions - Additional Information (Details) - Final Salary Defined Benefit Pension Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure Of Defined Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExplanationOfWhetherParticipantsContributeToRetirementBenefitPlan', window );">Description of participants contribute to retirement benefit plan</a></td>
<td class="text">Plan participants may elect to contribute a percentage of their income (between 1.5% and 2.5% of salary components up to the social security contribution ceiling). A &#8364;1.00 employee contribution results in an annual pension entitlement of &#8364;0.42.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AnnualPensionEntitlementOfEmployeeContribution', window );">Annual pension entitlement of employee contribution for one Euro</a></td>
<td class="nump">&#8364; 0.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_MaximumPensionFundContributions', window );">Maximum pension fund contributions</a></td>
<td class="nump">34,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_PensionFundContributionsExpectedForFollowingFinancialYear', window );">Pension fund contributions expected for the following financial year</a></td>
<td class="nump">&#8364; 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember', window );">Funded Base Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure Of Defined Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019', window );">Weighted average duration of defined benefit obligation</a></td>
<td class="text">35 years 11 months 1 day<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember', window );">Non-funded Supplement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure Of Defined Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019', window );">Weighted average duration of defined benefit obligation</a></td>
<td class="text">19 years 9 months 7 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure Of Defined Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_PercentageOfDefinedContributionPlanOfSalary', window );">Percentage of defined contribution plan of salary</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure Of Defined Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_PercentageOfDefinedContributionPlanOfSalary', window );">Percentage of defined contribution plan of salary</a></td>
<td class="nump">2.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AnnualPensionEntitlementOfEmployeeContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual pension entitlement of employee contribution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AnnualPensionEntitlementOfEmployeeContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_MaximumPensionFundContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum pension fund contributions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_MaximumPensionFundContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PensionFundContributionsExpectedForFollowingFinancialYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>pension fund contributions expected for the following financial year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PensionFundContributionsExpectedForFollowingFinancialYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PercentageOfDefinedContributionPlanOfSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of defined contribution plan of salary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PercentageOfDefinedContributionPlanOfSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfWhetherParticipantsContributeToRetirementBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The explanation of whether participants contribute to retirement benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2020-01-01<br> -Paragraph 36<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_36_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfWhetherParticipantsContributeToRetirementBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average duration of a defined benefit obligation. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 147<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_147_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis=ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis=ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis=ifrs-full_WhollyUnfundedDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis=ifrs-full_WhollyUnfundedDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891882680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pensions - Summary of Defined Benefit Obligation Recognized in Non-current Provisions (Details) - Final Salary Defined Benefit Pension Plan<br> &#8364; in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure Of Defined Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisionsForEmployeeBenefits', window );">Defined benefit obligation recognized in non-current provisions</a></td>
<td class="nump">&#8364; 4,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=bntx_BasePlanMember', window );">Base Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure Of Defined Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisionsForEmployeeBenefits', window );">Defined benefit obligation recognized in non-current provisions</a></td>
<td class="nump">2,140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=bntx_SupplementPlanMember', window );">Supplement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure Of Defined Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisionsForEmployeeBenefits', window );">Defined benefit obligation recognized in non-current provisions</a></td>
<td class="nump">&#8364; 2,125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisionsForEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisionsForEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=bntx_BasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=bntx_BasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=bntx_SupplementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=bntx_SupplementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567914546776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions - Summary of Components of Net Benefit Expense Recognized in Statement of Profit or Loss (Details) - Final Salary Defined Benefit Pension Plan<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure Of Defined Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Service cost</a></td>
<td class="nump">&#8364; 24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Net interest expense</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset', window );">Total</a></td>
<td class="nump">&#8364; 30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from the passage of time. [Refer: Interest expense; Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567945325496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions - Summary of Components of Remeasurements Recognized in Other Comprehensive Income (Details) - Final Salary Defined Benefit Pension Plan<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure Of Defined Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset', window );">Actuarial changes arising from changes in financial assumptions</a></td>
<td class="nump">&#8364; 227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset', window );">Experience adjustments</a></td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Total</a></td>
<td class="nump">&#8364; 210<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141_c_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments that result in remeasurements of the net defined benefit liability (asset). Experience adjustments deal with the effects of differences between the previous actuarial assumptions and what has actually occurred. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567942931848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions - Schedule of Changes to Defined Benefit Obligation (Details) - Final Salary Defined Benefit Pension Plan<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure Of Defined Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="num">&#8364; (4,029)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Service cost</a></td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Net interest expense</a></td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BenefitsPaidOrPayable', window );">Benefits paid</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset', window );">Actuarial changes arising from changes in financial assumptions</a></td>
<td class="num">(227)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset', window );">Experience adjustments</a></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">As of December 31, 2020</a></td>
<td class="num">&#8364; (4,265)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141_c_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments that result in remeasurements of the net defined benefit liability (asset). Experience adjustments deal with the effects of differences between the previous actuarial assumptions and what has actually occurred. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BenefitsPaidOrPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of benefits paid or payable for retirement benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2020-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35_b_v&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BenefitsPaidOrPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from business combinations and disposals. [Refer: Business combinations [member]; Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141_h&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from the passage of time. [Refer: Interest expense; Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 140<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_140_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilityAssetOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567919643032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pensions - Schedule of Principal Assumptions used in Determining Defined Benefit Obligations (Details) - Final Salary Defined Benefit Pension Plan<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure Of Defined Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfDiscountRates', window );">Discount rate</a></td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation', window );">Price inflation</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases', window );">Rate of salary increase</a></td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases', window );">Pension increases for in-payment benefits</a></td>
<td class="nump">1.75%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfDiscountRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 144<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfDiscountRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected rate of inflation that is used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 144<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected rate of increases in pension that is used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 144<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected rate of salary increases used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 144<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891452008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pensions - Schedule of Quantitative Sensitivity Analysis (Details) - Final Salary Defined Benefit Pension Plan<br> &#8364; in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember', window );">Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure Of Defined Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Defined benefit obligation due to reasonably possible increase in actuarial assumption</a></td>
<td class="num">&#8364; (282)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption', window );">Defined benefit obligation due to reasonably possible decrease in actuarial assumption</a></td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember', window );">Pension Increases (Decreases)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure Of Defined Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Defined benefit obligation due to reasonably possible increase in actuarial assumption</a></td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption', window );">Defined benefit obligation due to reasonably possible decrease in actuarial assumption</a></td>
<td class="num">&#8364; (447)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in a defined benefit obligation that would have been caused by a decrease in a significant actuarial assumption that was reasonably possible at the end of the reporting period. [Refer: Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 145<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_145_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in a defined benefit obligation that would have been caused by an increase in a significant actuarial assumption that was reasonably possible at the end of the reporting period. [Refer: Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 145<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_145_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>R125.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567887830584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pensions - Schedule of Quantitative Sensitivity Analysis (Parenthetical) (Details) - Final Salary Defined Benefit Pension Plan<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember', window );">Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure Of Sensitivity Analysis For Actuarial Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption', window );">Percentage of reasonably possible increase in actuarial assumption</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption', window );">Percentage of reasonably possible decrease in actuarial assumption</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember', window );">Pension Increases (Decreases)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure Of Sensitivity Analysis For Actuarial Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption', window );">Percentage of reasonably possible increase in actuarial assumption</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption', window );">Percentage of reasonably possible decrease in actuarial assumption</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reasonably possible percentage of the decrease in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 145<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_145_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reasonably possible percentage of the increase in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 145<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_145_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>175
<FILENAME>R126.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567888365288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions - Schedule of Expected Payments or Contributions to Plans in Future Years (Details) - Final Salary Defined Benefit Pension Plan<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure Of Defined Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan', window );">Expected payments or contributions in future years</a></td>
<td class="nump">&#8364; 686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Within One Year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure Of Defined Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan', window );">Expected payments or contributions in future years</a></td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember', window );">1 to 5 Years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure Of Defined Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan', window );">Expected payments or contributions in future years</a></td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">More than 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure Of Defined Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan', window );">Expected payments or contributions in future years</a></td>
<td class="nump">&#8364; 340<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimate of the expected contributions to be made to a defined benefit plan for the next annual reporting period. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 147<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_147_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 148<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_148_d_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=ifrs-full_FinalSalaryPensionDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>176
<FILENAME>R127.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567934926360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Disclosures - Summary of Compensation of Key Management Personnel (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Disclosure Of Transactions Between Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short-term employee benefits incurred</a></td>
<td class="nump">&#8364; 2,627<span></span>
</td>
<td class="nump">&#8364; 1,847<span></span>
</td>
<td class="nump">&#8364; 1,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsAccrued', window );">Short-term employee benefits accrued*</a></td>
<td class="nump">740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based payments</a></td>
<td class="nump">20,700<span></span>
</td>
<td class="nump">18,151<span></span>
</td>
<td class="nump">6,163<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total compensation paid to key management personnel</a></td>
<td class="nump">&#8364; 24,067<span></span>
</td>
<td class="nump">&#8364; 19,998<span></span>
</td>
<td class="nump">&#8364; 7,324<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Key management personnel compensation, short term employee benefits accrued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>R128.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567963318408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Disclosures - Summary of Compensation of Key Management Personnel (Parenthetical) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Disclosure Of Transactions Between Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_KeyManagementPersonnelCompensationShareBasedPaymentOrdinaryShares', window );">Share-based payment, ordinary shares</a></td>
<td class="nump">4,534<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_KeyManagementPersonnelCompensationShareBasedPaymentOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Key management personnel compensation share based payment ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_KeyManagementPersonnelCompensationShareBasedPaymentOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>R129.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891449784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Disclosures - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure Of Transactions Between Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction', window );">Outstanding balances of related party transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction', window );">Bad debt expense has been recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=bntx_CofounderAndChiefExecutiveOfficerMember', window );">Co-founder and Chief Executive Officer | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure Of Transactions Between Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted shares | shares</a></td>
<td class="nump">4,374,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised during the period in respect of bad or doubtful debts due from related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of provisions for doubtful debts related to the amount of outstanding balances in related party transactions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=bntx_CofounderAndChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=bntx_CofounderAndChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>179
<FILENAME>R130.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891098248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Disclosures - Summary of Aggregate Value of Transactions Related to Key Management Personnel (Details) - Key Management Personnel of Entity or Parent - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure Of Transactions Between Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_ConsultingServicesAndPatentAssignment', window );">Consulting services / patent assignment</a></td>
<td class="nump">&#8364; 25<span></span>
</td>
<td class="nump">&#8364; 56<span></span>
</td>
<td class="nump">&#8364; 25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions', window );">Purchases of various goods and services from TRON</a></td>
<td class="nump">10,105<span></span>
</td>
<td class="nump">9,968<span></span>
</td>
<td class="nump">11,160<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_GoodsAndServicesFromRelatedPartyTransactions', window );">Total</a></td>
<td class="nump">&#8364; 10,130<span></span>
</td>
<td class="nump">&#8364; 10,024<span></span>
</td>
<td class="nump">&#8364; 11,185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ConsultingServicesAndPatentAssignment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consulting services and patent assignment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ConsultingServicesAndPatentAssignment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_GoodsAndServicesFromRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goods and services from related party transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_GoodsAndServicesFromRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases of goods and service related party transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>180
<FILENAME>R131.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891663896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Disclosures - Summary of Outstanding Balances of Transactions Related to Key Management Personnel (Details) - Key Management Personnel of Entity or Parent - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure Of Transactions Between Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Outstanding balances</a></td>
<td class="nump">&#8364; 1,236<span></span>
</td>
<td class="nump">&#8364; 1,843<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bntx_ConsultingServiceProviderMember', window );">Consulting Service Provider</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure Of Transactions Between Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Outstanding balances</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bntx_TRONMember', window );">TRON</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure Of Transactions Between Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Outstanding balances</a></td>
<td class="nump">&#8364; 1,229<span></span>
</td>
<td class="nump">&#8364; 1,843<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsPayableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts payable resulting from related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsPayableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bntx_ConsultingServiceProviderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bntx_ConsultingServiceProviderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bntx_TRONMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bntx_TRONMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>181
<FILENAME>R132.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567886532024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Disclosures - Summary of Transactions Between Related Parties Amount (Details) - Other Related Parties - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure Of Transactions Between Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions', window );">Purchases of various goods and services from entities controlled by ATHOS KG</a></td>
<td class="nump">&#8364; 2,296<span></span>
</td>
<td class="nump">&#8364; 2,071<span></span>
</td>
<td class="nump">&#8364; 2,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions', window );">Purchases of property and other assets from entities controlled by ATHOS KG</a></td>
<td class="nump">2,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,748<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_PurchasesFromRelatedPartyTransactions', window );">Total</a></td>
<td class="nump">&#8364; 4,645<span></span>
</td>
<td class="nump">&#8364; 2,071<span></span>
</td>
<td class="nump">&#8364; 7,179<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PurchasesFromRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases from related party transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PurchasesFromRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases of goods and service related party transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property and other assets purchased by the entity in related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 21<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_21_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>182
<FILENAME>R133.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567887025368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Disclosures - Summary of Transactions Between Related Parties Outstanding Balances (Details) - Other Related Parties - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure Of Transactions Between Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Outstanding balances</a></td>
<td class="nump">&#8364; 500<span></span>
</td>
<td class="nump">&#8364; 51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember', window );">ATHOS KG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure Of Transactions Between Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Outstanding balances</a></td>
<td class="nump">&#8364; 500<span></span>
</td>
<td class="nump">&#8364; 51<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsPayableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts payable resulting from related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsPayableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bntx_ATHOSKGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bntx_ATHOSKGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>183
<FILENAME>R134.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140567891969288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Events After the Reporting Period - Additional Information (Details) - Supply Of COVID-19 Vaccine - Pfizer Inc.<br></strong></div></th>
<th class="th">
<div>Feb. 17, 2021 </div>
<div>Dose </div>
<div>State</div>
</th>
<th class="th">
<div>Feb. 12, 2021 </div>
<div>Dose</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure Of Events After Reporting Period [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NumberOfEuropeanUnionMemberStates', window );">Number of European Union member states. | State</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=bntx_SupplyOfCOVID19VaccineMember', window );">U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure Of Events After Reporting Period [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NumberOfAdditionalDosesToBeSupplied', window );">Number of additional doses of COVID-19 vaccine to be supplied</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_AggregateNumberOfDosesToBeSupplied', window );">Total number of doses of COVID-19 vaccine to be supplied</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=bntx_SupplyOfCOVID19VaccineMember', window );">European Union Member States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_DisclosureOfEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure Of Events After Reporting Period [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_NumberOfAdditionalDosesToBeSupplied', window );">Number of additional doses of COVID-19 vaccine to be supplied</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntx_OptionToRequestSupplyOfNumberOfAdditionalDoses', window );">Option to request supply of number of additional doses of COVID-19 vaccine</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AggregateNumberOfDosesToBeSupplied">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of doses to be supplied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AggregateNumberOfDosesToBeSupplied</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of events after reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfAdditionalDosesToBeSupplied">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional doses to be supplied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfAdditionalDosesToBeSupplied</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfEuropeanUnionMemberStates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of European Union member states.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfEuropeanUnionMemberStates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_OptionToRequestSupplyOfNumberOfAdditionalDoses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option to request supply of number of additional doses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_OptionToRequestSupplyOfNumberOfAdditionalDoses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=bntx_SupplyOfCOVID19VaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=bntx_SupplyOfCOVID19VaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=bntx_PfizerIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=bntx_PfizerIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_UnitedStatesGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_UnitedStatesGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_EuropeanUnionMemberStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_EuropeanUnionMemberStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>184
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MB"M<S$8MUT#<[4GQY>S2QBXEK$-UNM,;KFCU9M#NXFQNO5TF4&F1"<\7M'C
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M6]0_+J@/)%_H]_,S+B7/]=>$42ACU07P_VO.Y?) ==#^Q./@/U!+ P04
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M AW?>Z>SH<^FX?C[#^\?V\'#8!YX+9:R_*=8Z^WU+)M%:['AAU)_D4^_BWY
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M,&$Q2I!'J0D0Z)(($5#HXCV"%;5 :1NF><IHZE%H(@,*AX8/L-CZ)91"FI"
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M_])?(X"IJ5NYPSB4@<-@\UY8F\U!!U.[$+8+Q@@E9BI7-^)NQ. 1-7&,,^[
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M7WUL+Y1<UU]PWTNEY*I^N13Q0A050'_^(*7:753?F>]_>W/^#U!+ P04
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M*"D>!GB2<)]3B*(YS7U*&(I-!==8#]!X07#8F4B&&"R<L^!^\-\B,,[\#(&
M1#'!851_&I?_+_IQJ%RA)GV +VW39;V'%H('3P^AB)>T3*=6<]1Q&A?R+O>Z
M".[T#CZKQDF)=J(D>TDB?VC0&?(($]RWV'HO:*C-4YI 1V&F>71FOT*5UY)&
M-[-.<R.!F"-^)J;RW2C-M(A6!K]#!^BJV66U4Q:R7#56"C'IIZ/JT;CL00'>
M=A$)M2W4@]WUI7,(VU8KZ4H1J1ZK3MMA&Z N@?M+&Q%Z&JK9C(F\* +'#X&L
MY*7O^8@Y6N1\HN)BHSRRN#Q.$E>-<S+=!IW#T$V%NC83)=2*'CT,E^9^![#
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MK0/ _]=:V\,7]X#C&R\W_P=02P,$%     @ "(I^4N#J7NNT!@  :Q   !@
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M48[7W39JY4E0 :XQ.36,D>R^T70/S @+O!^Q,G5.9D-3\+39@>*F\":("H2
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M@)]"=-R7 'TWY]>C(FL2%E3-H&"(86CV8E:)!E3*AU&X8A0R:,?D2CX,)E%
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M/8IOKNR-&C*+QR_5AD#2!,(&V1&"QCLK=_#K/DP$D6]RYM;#35C[;Z3GZ+9
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M61F$RM%1)>NN=_M53#19?+#.E&H@LN;#,<#3)5812LA-$_%LIH9T"A7,6$:
M>>E(MPD>SQ8LU2>2A-LC1)RKEDQS0^'^D^<@T3%_@$I3/W*&F-3]PG3B9?%7
MBXJINVL#QU)W%;.SBJ$AN,U0 PG>1>5.%%5S^I<$8&:Q-QC39A+[YNRM>,#O
M&(2/Y>="_R10/9#>LJ4=)F0PR6:N$6 -7Z!?6/JH0& +L7N'?H<U?-&*PLV[
M& O$W^KR/L2L)%XMV:-I8TZ[M$'C''CA34F@H.@ _&(%$>76X@>1M+)80;S1
M >U>#K2+7I)BNX-+L*7(*IX&69#Q!R*OP=I9J0%93Y";5>&.2N+$4,J*RJB@
M2(,IA!*15B0;"6%N0Z7*&W:_B7\P.',$2D BQ#(3-<"QWE33'+$61CA$ K"
MI=H&Q8FZ5$(BQ>$9+HL?AN@72 Z-G6R0'.")<EEFO,!D=5,Q1TLTF<6(L!*(
MRJ4E;KZEJ!0 >,"4/ZN*HV13 IE)B796M!'\<4TQ*RW*VFHEJ>4'E%A8,4MT
M$/69@80ND.R%.ZJ@(:JB!Z=5%XQ]+%R54&ZT#(=&XGO,#^C/'_I4X$Y,E@Y0
MG(]N6 1&>+JB/*BZ793QLY24B:K+XL\IW<6$(+77&ND):658X)-KI@<)HVA=
M"TYV/R27C(4O>&#@A'-XD5[=9I@W^![=(56/!BQRY\+\>#9E-^/;F9P[RJDL
M >^#AE\J4VZ7C #.V!$)@T,,;EYW+"J_@14<V<WJW.GA;\O3"2(A8-^-*VV8
M[9*L-QDLSEB%>7$S*B@X85&0+P%Z6>7,[(&(KX'$4F8Y&C?5W#Y'K.0/F@YB
M)IZ4L"$^8FV2F( SR7?4Z#;.J?8M=1',EY@!.E>*%PXD;L8.^$JJP]&+\IH^
M41>+PYZD(!N6@H2:7&>^A!\B.GP3:9H%TS(N)V587 X>>T1LG\ J/<Q$DM5*
M_I."I7GX,-X+G%L21TP=$HI73,Q"MBX;ML]B_P*W- @_F(#_\AHQ>,];1L6'
M=GAPCM/Y P8/%HI>YLD3.!$\57^"0GNM4\-W[K%]AR0O*W<4X+"1-T6;YB.\
M3E(Z#\.C=>2?^RB^9_&3DXQ:OK$*!?QZ#/7WQMK\?4\X.9U>[M![J@1[+$LS
M2W*& .5@^QA@'\O^_W]8_J';^_=R_?3&)H1+F=O'4N]I[GZ0L]6\_E(6."F5
ME' ?7RLW=B:2^3];)XQ6QU$/=02_/!DD?:S#8+]8.$C,ZRPX((6#*Q-MC=N>
M6[?C*4.1NAS_;XX%)IC,-2]3PD6,DB]D,TDP/D;:<0DSV8DYW<CMYS<O1(-9
MR?LE\3)RZRZS<A/@KH]DCJHKR3DO:ZX!X4P(/H "K,M.SV"\6"M:1!),/.+5
MJ9ZCUM2;>>V*L>6?[69#F%?_;$2H]L]9$?&XZ4^07;+'0J0 W+9F7HO!0!*@
M&U7T*;0@%J1*$'3B5/#%$EP*F& @66K"VHZSVEQ%D^@>%Y%7<I+/DV3+S#EK
M)RJGTH$9:>,NLB\X_Q=B6[W&698Y!3%'=MC],-X2^'T^^6"AW,^$(HY%HCDL
MT\Z>Q$-1)<DQEEZK'.SS!TA):/8#;W9ZL:=.K<6<C[O[L'3YN%Q^_2MB!Y0M
M(@IBY$&@M64B2I^D/1=0W6:UW:,PD-9H8[-I$AT?,(U)+MV/-O PKQ4;(AU.
M?>+F:A4E*HP?X65S"23A#?RO]:[D(J54'!N#R6*M"%RL&V.IS80J6'8@,"EH
MD#8>+[+BB->1!6^[6E@T:^0 +M(6DLYD'M)"LRT,%-;[0VJ#2.TW#W9/(Z*S
M?G!I8X_YZ[(.K6V?CFMOAF8M60LFXO715)\P@RP4KY(Y,GU])7X,:HE):XL]
M2?;+1YMAQ05B6BS[Q%/@Q %AZWXJU5+'&MY@5R7AD"-365H4O.]L*G_F.$4X
M(&FQ><@V 9<CC2J"-KX#\XJ+%''YC3"**-9+'*#A>FKBG3>B*M=029[<X,(Q
M:<NZ-!;* S!C.:ZF!1=LFK^TS<5>H>.+BS9;-.MLMG\7AP%P2R#Y$". CV-P
M4V@GPC/!JNEW9Q?&)MXIFC=N>Z*39@MJOSJE1&<=(9N+D%2!9CY24.Z<N)69
MV/=/-8(:^VE39W=CT1<]K.RO28-;WZZL[BC-DV715HG$IEZ59@KY8VLP,W?F
M3&"Z?K\(1O0G$<34.#@'J):$2K\$:B9_J%T6TB;I=V!72A8Y(4SL0;F]5>50
M#%G')0GU\V#])(3X5@GQHQ AKOO7QLB=B.ZE4O)-I&I3=#&B:[ )6ITU(OPE
MEQ?)$EM6P1&C2.-LOL*$)#.A:)DE\V_EAK2UMDX=IMGI9IH8EBWM2T2.M@TR
M:4].+W&11XX+R ,9.,V$"E4&]!0F2TL /+5<P4NYF\#%'JG#TB!AEW>WS@,?
MHU&F>M^F9S0G/8X*GP@E"PC#808(IA,G8N8$C:E?/P5V*NVC9'^$8">#XMNS
MMU1</*RU2D2++KDJ4!='0;Y2$ZU<2]$PTDQJ0>;@U@IKS0&-E\6O4E^X*G#R
M#/LMZ)]Q=21E#QY>O\(2#(R_Q!MZW.8?!AI<$4S5.=-F$,,+8%I3I,ET\QY.
M0NPSMXX 6H-Q!V9U*<JPMXV0.)_(<\493DH#UT#$43 F=!/X^M6@1:?-'!CK
M5239I<8N58*#MW6!PZ#&2?54.6V2QWG["H6T@* P!A"^.SMY26=_TU4VH/+^
MRY5=>'KV9O UIN_"V1\N7KPX^U$?QO$R/%4%)0E<;2V)HK,7%U=?8\,L&@]2
MUWL*S5,M57'UG/F=6"I*(ZZHF0A'(&-?824=]XNM<J1P]16U>['?8_#^() L
M.<')O#=!G&1\8\CJPC52@T%"Q%''2^K_9%(U.3#BQS^>W?2::>7. Y966D!B
M]>-DMDUO*DT*\2*UDGU%GCLX29>VR&CI(:7U^"#\<.>.TPHSKK/>Q4[&V+\I
M;;%H2E#>(#8R;S@F/*Y'&VGICZT<+QZN_%V .86_[[+Y1J8'A,IGPP,KDPMQ
M_9*:%G&R%CK%7#:+=?6?,8OJM2ER'W\C=W[7#C5V\Q6'W3%((K>B65%K,6K$
M>TO!2$[UUS&)M"X/(,XX%U_.KD- QD:=,&!>%]#*,1T3Y.2??3]PM22BEY#6
M)!&B'G5"P<L,=2E:E-T0CS!:/@-P-_HXZU3#32;FD+J/)$*9U[TGPH(GIW.J
M%H Q@[7&&]CH(;_GM=Q/^]-UN0HN&'/:%_ORTWBR%ZD$5#=Q<!=2*5(\/KEK
M[WE>&Y4YH?$C;8\9EKEY&1R;CJH.=+23%*OH[MA,",AX_)*<9G"I'GG<4OE8
M5*&<D%$'CZ( KJM)[V=9'&OYZP"/M!'JOOOR6.C<.^,=+![<Y#H8DS>]%:R=
M-@FC'-"B%R-G:*O8"J2B,9JWF2R11A^U,D:EMYE T5:@T7)SK:D4?Y#N+-L0
MI(U ?VKO,0&TBN5%M=/RAKH4]7.K^CJ%_J1KL<")$<Z-+Y_&IV) KI60KO08
MH3\X@CFLHKIW9:4)O)"#0X_,O<QM(6@BUVZ,C7R.6_16I7/FHMU<("VF@+C>
MCO%3>P,"=:3"S=,M<USCHU)FOMC)\48:,]-6SI"%(_*)+!-XU S@.0='>2 Z
MQ%2K6O:F_%F<J1QPM$>&0 OHOL*@;%G&T"C??S0)T^BEP,X,:(8]2*6:[Z=S
M^_;.C=,S,19 P6@,ZYQX!-6*MY$')C/I@%L1M9F#(R.2QC'%R#8F=^J&LFK*
M:+EE8:3<3I8J(3MW*$=KS*]Q#7#42=RR+K(OVL(:)IJGQ=&+?%R45N/VQK&1
M/EV//073.!(;A/8J*4C(2L-\:A2SUNJH4G$!<A_R4K(.T^A\)XM^UBHW<,F0
MD^HV' .09F<L, 4C9,PIBRS(/AJ;0C)-P2X;62GJ7Q1A5(\J+\]P$PX6D%Z.
M1#Q4YX@/ 7?=MEW7WF=EE"0.U8I3^<XPM-V*C>=2'EN7C<P]P0':GNAU1NV:
M%KVYK3L26?G$3)&. XHA'N"Y]*:VT^E99;E?<JR-P_%VFL."3,OGLI)/"7LF
M6V#C/Z/?(SO8R1N^N1!#$">_9(\E8S)V#\_=+[ ],5DC@]3<9TI1T=E6<P1D
MKU>>5N1$V3@BCP2*1GM&>2]-_7"I?SER.8OM4&(!^MS\5/<9)R0$T>5Q@93+
M,B-030C7] (<(Z^A12'+K<:XXB9\7HV"W8V[QTIUR09NOF1Q[@+H93Y[*YWQ
M>2TQ1V4[K' A*C=#3ADR&53UT+9B?>@B+)F7!4:F$;*IB'L,>OU+&@MLGH$J
MD#@>*7RM@QO?27%)7&<TN,\,^)3DZ@CI68S</FY)50AU,[_P5#*,-?E\0?YC
M*9(<_^SZ=9ZM[W6BA;*^&9Y+]G2BATBO*TL877[W!_;I8U/&S/4E7'.OCRT>
M3T'8V-(S'XL]H9;;3BNHNZ6$8[(W8]/7G#Y6<UB<]_PLTDI(5_;-RQ0/,I]K
M*_$<"/_VV!_EQ7? $#@"+9HE>43P_?30#\0!KR^NOWY,'/#ZXFN,-U82;-Z4
M:\$)?/+B[&;HVWT+:'(8,?RJ^(!P7GP$^%A1\8J_1 ?GE_;^XN]$T](1F7OM
M(R\F^A#S1M;L36X46Q>()>-;[<%]@QOHQ!NENK'2(!2?26/J,#]!PU [ZYX!
M]))C(! 6_)T9XV9F=&2(CI_,!M9.K84R@JOG9^_ 3&BV?FX"JJ5PF^-=2)F*
M:Y2/N_7+RY\:1RH^K\W F*0ZI09B!@53>6)PS,&UFH.A8YGADT>7O!*;6!"E
M\<BL Q]]S'7SVZ?*OU@!MD'H);F,4ZCQ-S39QZ_3;<O#$L+NG-%OJ0OF86$A
MP,:0&W&VUN80?/D\6M* 3MZ>&U\;[93QL348RFOIB)<,P3HF/(W^39^IXR:S
M <>+RPP.P8IUT7CHN RQM*%ZXYTM3"*; !CS_U,(YJ[EP;G5Q8U^(\[$N:1K
M/7!/IFBYL7\P!H!]P"B_)X0S*[W?S4X"X?CEV=7SB^OG9[_(Y"^0QO#;AW;3
MWP-2X;=OEX@ST>_H0.**15I=@0"0CCX7/4=#;9/IR:LO&Y^\2L6DE;\C^X=#
M[S$H)-/:EH;]AGSZ,K?^R$B4"B?3UOK%$;FE9#! Z"924-K32=#9F N;O!F_
MC2%#3[/<I,IN.""M\I3$=QO$J:3<H]EH68"_VB&MB4VB_%-LC>;IFS$MQ6)B
M' "W@TZYJ*(R=1QS/%'.T*G&SI08CM3+4%9'F:2.F:E'KKY(-^P,,J+U+#<S
M8N.+TXGO[9"?'\R0G[<43HL?/YS=3:_2$Y7OZ?M:HALKY(JW0IUUTZ[S.3DX
M*5<V>97HEQ?!?TXI:ZGEK]R>QXN9ID6Z^CRBSS-5Z7MML %4+'<:$(!]H'UR
MK4>0A3;I!I79X_8#(0"R3LO:>-T<UL"*=QE[(+LY3=<CBE[.?B])++765W4#
M5]<F 1'?W4E)O(%1.W_5R9LDJ$8[\WDB9G"H&7A'S+T9X)+[./&5*IU#0S2Y
MLJRU$L$4U4 C-\R\J5&C[HYKE7%^I8S2K <JA!Q/(;$CJU0%VW[=5M+4=SCF
MQ8Q9'8W>U$O&8+NMBD!6W[L8);OU+9(27,.ZIWYG'&<G7:7XU42Z51K.SFE#
M-1RT,L_B@H3L1NS]A]OU3;&6/#PNC1XCVUL6/FEU*L]5\WPN[&M2T6F(^+_#
M+KVQSV>)._LM,Q98'Q*I1H-,89QPK(9*DA$ZFN_ =4@ZX)#92+AG!-W(/5='
M@DJOD;3CV,:TL(%[A,P%JT(4,)=:7%V=W9B2#4]E4(J#DN<&F3S@EC,5,O&L
M-&]*A&%#(P*E:8!34M,  !DA\M4M9D<J*>"R(5[@LO!/BY_BZ^+AOIMSOV"G
M/YM([4\Y7./R9QL:2VZ6T?BI]GN\$%8Q49<-CR[H:7:.K6 'XKYW].4&L00J
M?<@1<1G1.)FF(U,[^:LL6C+*> ZT[4\?[SA.7$:[F70#EHJB?$/RJSS[,,C<
M@ &=4@@/CGQ<;4^;#',TDHXC:_1]=E=?8W_4QL76)MO"J-\A"-0<3<FO=#+(
M!+MC,/*X)79W\,P7@9B^U<2J:U8R9-)G4\3HFP(VZ!I8 PS'O>+HT&AGF2%M
M69_C9?$S9[\Q0L+=J].JT=$$D]BP,>:1D=D%ZJ2MV*Z,C,I&DB7PF\DRYYAD
MB4,$9#P!S4^06KX9[NS,AUMI#(M]:>/+>,H%$AX\-$[8F..>X[2]E>1+34;Q
M1%/&0]-BGB:,:0%)JSE1<W^FXIK.1&$GH&Z*JK2=:5^TH[QL93YX!AO/HT19
M2<W5,H),-P;U9BJ%;O@+4^XY=8/R3 4\=STKG9S_^/871J49EY&:R&][(P%C
MG%)2O_@J$5HV*,]T-=NQ#O/D3@.>%KZ,,HT1DQE)L8PJOCU*O/ 9[<UDJ4-D
MV(:-E\]^G^G;%NX49[/,)1RZ6(F0<)A X*\4$G$[1P<Z5XY&'/;T?9[\;4?Z
M)0YR(:[9E9+6,LE1A&*+[Z0O,<MG#\I,]JF<-X,*HW.74,5BF$L[,$?*CB.B
MIJ0FN32_!>@0+WHR6E2J@%K'=6:XT:>4GFCT6&C;<B1!"U"R2A&218E2(R6A
M;TPUB$QDLQVX8Q<X33*ILCDM<-4=.%7:%1_W0,?%]L$DQJ";!DN/FAVRS+E,
M$KBHVY:*R7!V<=N%-'TS-OS?TM]CJ8&Z):ZY\UW;Q)0_%:Z!P5X?,?:7IEMB
MMU<VVQ#-FSB1C!?>N;(&9L%>FJ!#DE1Y3+1W'*^>X8FG/S;R7<S$>UI<KA(H
M#8J?^59+QOYX2,UD\[=__?N['RZN_@B6S'H-"AI,I\QVLO/UU(!Z_R@#:OD+
M7VB^P6S0N0PS5I\TE)FPMM0P3CJ=Z[8491LS^-)Y&9L#N<9\89.Q:E:S+]^=
M)C3$[Y/BTI'9G?GKKGC?6)X?^ZWU.QVY^=&83&2QG+8I\XR9M2AC$V2:PCK[
M&M;X:\XWN\"/T]J%^7VY@D#'7V%[33;:=<43X0(HQEN,C>"WF5\N$!;@E[[(
MY^_9[?X:;_<7Y/P%RCI)&%E^7O&$3+\'F"IJD.A +O>DD)A%[]%S]INAX\GC
MIN:I 1[GP1CX#<!TOAWZ6:FZG$R_\52\,M4 SOI+=B:]^XPR=& )0&$UWC9P
MQN81&- P:U1\% 2=FQO,7QN9]:+EY#:790IJT0K/F3X=6F7IZTQ,)Y#6ADVO
MP(P_FP=ZV7A6 _N1,P=3$.,2B*O$VOTWD6]7,MCT5\M*['?,D^^)[S946^7B
MUI7D@\\)BM47\J[.#OO"DHT?W[V/-1J/<$NF:9=\X3S#CLX45W%3SYYX<A0)
MB'53Z$8 0?AA3P%;V\Z%]<>.V[BEQ%+M+([7LJEENXW@-"PC\5CE*!9BN\49
MA5JZ.5^[0&>A[_0YFD2@FF(ZGNVA>SSE>V7U&IE+%+T7,Z(VS3[-WP-,[LI.
MOH-NC<>J96X >S)!OQ2L2=^7O0 #]W#QS6GTQ)C&>TSS$!3MN.G C') .S=.
MCXF.DMW==KZZT4+JOZYDX+=I:J%)ZU6:$T[3K&.[W]3]&GL+TZ\8FK86N_MQ
M*:7QD+Q^.V,:13]N77PP4<F!LNNS=PV.2&P[95V2CS%:4O/W?F^8JZC:FW,[
M-1 T:AN),;W-"Y1AOUND1/IJPI*_9H&^* BIM8_#,[F 6'DLSK"=G\,M6=!7
MS_K7KY[Y /]9P_^!NN&_H))<_T/9EZ]?@=&Y=6^!] )/ ?W^R=43\U>,4WW_
MY.;JNYOK)\_@S?3XZU>'<NO^#!2,TJ=V&WCU^>4?OG["GKO^TK<'7!(XJP?#
MF'X$@QHN'!^ SS<MZ%_Y!3>X;[M/!-[K_P502P,$%     @ "(I^4G>AM%4P
M&@  /5   !D   !X;"]W;W)K<VAE971S+W-H965T,3$N>&ULO5Q;CQM'=GZ?
M7]%0D,0+D)R+9$OVR@)&(]FKP+($25XC"/)0["Z2936[>JNZ9X;Y]3FWNC6;
MTC@+Y&'7(J>[ZM2Y?N=2?'YGW6>_TWJH[O=MYW]\M!N&_H?S<U_O]%[YE>UU
M!W_96+=7 WQTVW/?.ZT:>FG?GE]=7'QWOE>F>_3B.7WWWKUX;L>A-9U^[RH_
M[O?*'5[JUM[]^.CR4?CB@]GN!OSB_,7S7FWU1SW\UK]W\.D\KM*8O>Z\L5WE
M].;'1]>7/[Q\@L_3 W\W^LYG_Z[P)&MK/^.'-\V/CRZ0(-WJ>L 5%/SG5M_H
MML6%@(Q_R)J/XI;X8O[OL/I/='8XRUIY?6/;WTTS['Y\].Q1U>B-&MOA@[W[
MFY;S?(OKU;;U]/_5'3_['>Q8CWZP>WD9/N]-Q_]5]\*'[(5G%R=>N)(7KHAN
MWHBH?*4&]>*YLW>5PZ=A-?P''97>!N),AT+Y.#CXJX'WAA<?S;8S&U.K;JBN
MZ]J.W6"Z;?4?8[,%U@]^4;WV@X'3:U^IKJFN/8BO1X;ZY^<#$(#+G->RV4O>
M[.K$9I=7U5O;#3M?O>X:W90+G /ED?RK0/[+JR^N^$K7J^KQY:*ZNKBZ^,)Z
MCR,['M-ZCT^M9WS=6C\Z7;W;3!FBB2/5-; A,>6_KM=^<*!<__V%[9_$[9_0
M]D_^?Z3QY<T>G_T3VU6?=KH"-] KI\B\[*8:X*N?G1W[?_N79U>73__JJQJ>
MM*UI8(6FVIA.=;51;>4'^(*9Z?0_1N-@_;WJ%'.X&BQ\^JRK/P(=B:+J34?;
M],[6VGO<5?5]>T"RC[=7Z4P]D%$;#4?*-MHIW+?1].K&MN"A\-D_TOGO=J;>
MP7.W_,S>^J'R&=?T9@/NI;),E=KC=GBHVL(S_P.'-OR7KS+BA^J#OM7="'0X
MNZ]NP$Q0J3RX@V%7W9 CT,Y7+XW]]9,&FO#8!A8[07KUIH'_$)GL_4!\K_2@
M'?B0*+#WVI%;[VI0]W5KMHIE&S?9ZDX[$K]CZCR3!UZG56OKTMK 7?#4P(*M
MT[I@7@W<&2 Z5'MPE*9O=04N69XP7=V.#1(N[WL4_NCU C;T6KEZMP ?>PNQ
MHR?)C1M@"EHG[EG;/? $&0FLKD >#3&8=14TI!EKW"2L1%_+8B1^K]TM; O/
M YLA+N!_;<8&($4>IU?S[4'S:[ GX&[+I(0/:"S.R+>!AE5U/>!9=1\XKQ72
M$WBUF(K51T$"$W4'9+#DD%/,55AZ;SP)IL<#PI.- 6/M0!O[3*S9>5;5[[A6
MY+2"<VP=:+%N,@+"5J1::B#]HJ>"A0=)&R^6J!N+2@5/"%&DLU'Q]VM:["11
M;[5"?TN'E2T^P7Y><=A^[V"_2%[F6;ZN@;#<  =F)=/5K0+!K%LV1M-H?C?J
M*;(#_H+>@DAA^FU=C\YIHMI5G>V6^3?@?:K-2!J!]C%4WYB5!FD3:U!+X7^C
M'U7;'F!!^+_ASH(K\MX@'8"1@#T@B6\J?&U1_<1+[4VKP=X[8*XZ\$GN[-@V
MU5KC\]78X0G /Q!C148>3N,WPC3A8UJ(J%M4OM<U^00D2!7&($\H4*CMV*K!
MN@,JH[.WH,QP=%!8 \\$,2G8L$6W';: 4X,3JHM@<"Q',*E33@=E&'S@!W:@
M+%M_^A47SHV>,-D0$Z)908>,B#X0<4(;"> U(GOC@!? "4"-Z*B[1K7(2D"4
M+4447*O0'O:6R-JXS!J84^DBB!HP. =6,\B6P*L->7KR(\;5XQYW0[\4'$4M
MT6!$OQ+46WS2H?JM!Y^,UA>4!?_@M-FO1^?Y43AKI>_[9/<&F4ND H+5H,Y$
M[8R596$+4/!)OH&U,Q_8YCU0 >:6,0(4"0CWP"^%%MF/PY+_MF?SCT:)K,4%
MT&Q'(JS1O4'^4/ %B: 1'P(*H$6#OI&X=)-Y?,3\<%(-?@:0@T6KA$#A-84%
MUC67Z1JJ6T66!5A^B8 )3V \\;G<GZDZ9EG.H<'>*4=Q"L+>4-HH$82D!'R0
M)!R)SKA&\*(TP=QZHQDB8(!(MD:_@R[<1@87#/LR9=&2-!C_&"TIK 1[QX5(
M/R$&6<<P"P1H&]1 ".Z;JM.(TD 10.S-'P!BCM;)N,5J&R1X)!QP,-T!DD<4
M*ZTERN[X*=>PHBG(FO:CF"UX@7JW''N68K!5=J:*H5L$-KA]!UDPP'\?8)L<
M!_U=W'(%!@?[ "%XMLV(1I0C$62#JOJ=@F/5>AP(%@@26(BP'Q"[5.LMOG8+
M1D'VJYJ&^,"K;<RP]+ '[@9_!&U!4W'VH%K2'-!_# Z$'NJ('B,PI9.R!X?#
MR?8)L.2(:.+GHYM916]M"L2;NU!^62P=R!P]0&_YR+0>P"]ISBF(V 7%&E'X
M$;)$Q^!>:,78&\0(V]+Q1% S?HD _EK#,S%*K# 0 ?CN5;N\ID!_4Z !^%@(
M)PF$T)#I;FV+R0#$<2!T;Q$+*C=TR-V[G65#-NMQH# C-G=KO$1%%4-PM;66
M>"(H%!]7452DULJ#H_*21  H\VQY@7Q%Y)=@!I03>3;CR0FS#%/=R] Z>9@B
MA.^5^ZS)K DY [RDDU$Y!AVDQ^!AT.< =<X 9$#-FX2"?#OA%'HXU"R5#H,N
MN]=4H6D/F0.*>A4S$-+<0L=F]_!R<L"N:,]L,<+(2.H=@302DE!&JNQ[Y"DB
M-+0[/V*"22P@]\(+<EA@< [Y:SVT!WF2 EBT.-C1#'ZZ:\=Z8MNDH013.!2#
MIY-$LE>&?/C\$8D\!BKH"LBA'L<C.GDX:V1L1.]! .+Q<K14N%;E.2S#'F2+
M8$@;D(NKKB,@N0$BX%7PF0!X:E_]CJFK"#980WD22FYYG47F1*.LO^!9_H34
M.:-^]_<WKY:7WP,NJ6L,['2*S)<0"QOV.8(F@DJ>LAJ*X7EN-G.$'D#8J#IA
M@#G*7&9R0#HUP(R4A<R;$8H?=E<&=]M"/$<24-;EZ5E)8FC&LD?79#865=!T
MZ$.1T0=:9GY7\H.U=I33"_#B-_DY,C/(NQI*H$,$B[O=L5(@N4$G"G(%OBR0
M"(8/9@#XT"-',,UT;(I^7/\A:E7#>;:0?WQ"[A)6,YAJ-6-TP0AL4C8K!XD6
MDLHQ"<?4AQK,OS& $9S4/*:6%0P@K@,D@2<VBHP<<CMTR[3A;P!@@*L?!T)2
M5$R"M-%X! 8'"-1+W1'&^-4"N%L#BQ]?_%7"C?AEEK)'=>! R-:*X#%S+&RO
M5$^CF*&:6R5I*A8U0XTLT^LI</.4NV(.Z,<V4\EXQF9:0D(]B<Z'P-F1\H$%
M0,K+2"-8,VX9D5= K)E,P85\EI";BFI(*V8,&'LXO2#!!-@\?<X2!#]E/87X
MVT()\.S,374+;,>:P8JRG\R,:I"5B_4]_X *WR(X3+0W$'T],M0]XM>\IPH.
M^K?5QU64^J$ :NS <DOY,VMGBG12><$J(8="00J2%LFA6.&\K2;HSRQ%E[VB
M,G&F< 5!1# S.N-']/),&J?,7,$IL [Y'@F:DHSS=K#,@*&<7_)9W2Y &;\S
M?1\232]G284T3O9=(ZL6)" F@H2"3+%<F-=".3#"8S]*,35@-X)8*7B\_3)A
M7+"B0L"=SC)D#L8;A3@9E@338I_"/ES*OLC[7\' '.S92@:)3U+JC3:@]FC*
ME-F" #F]"48C%B4G<CHK"C*+630ALI0JN4"RHA$""T)\/\HI<DV-+]"B#]'%
M[- AU0V%EIA/34H441 I3R*NEQD.J-''R3><FZ:7G,YQ"8E!'^AKR;M$\@&6
MS*V(M2NV6'#96(HA+ )1)R1&J9Z3'A4\P.B3_*D I2YH6F0<,C(!\8@9F?8(
M<5F>@7$I*]MHI#'T&&R6+SJ]:<E+[^;Y+#%7WP^4;W#> ?$X:2:[;0!#:&)
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M9^_DETJ(.SNZ>O^5'MJ<(=@N*I]F]3,<$2C,TFN)C<55MXR/BI5WKSZC9NQ
MG-B) :64KD-RZ.&Z7KBD$V*!#)Q(BHS31<5>G2@![P:A,?!MSIZ \2X\1&I+
M0-'VV&/ $@G5E"(;^5XC_30 :A8\$[.X;9JPF6'=PY!%_F(QI/IL-??#8>?9
M3[J!>6WIA^NPF@).B'_=+7Y;A=_&N^:?A$N/\P_KO:6N$*1(>@.O7JR>?ON(
MXU[X,-B>?B!N;8?![NF?8)*@K/@ _'UC@4[Y@!O$7PQ\\;]02P,$%     @
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M&S9@O6^,GP[" ;.WKY._ %!+ P04    "  (BGY27F"'H(P-  " *@  &0
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M:/]%YA4I./'906(>XMWK3FK>77)<RU0[%EG#X )QG[M46;*]K%!V( M^1@S
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M<_@4RMTQ(IPCQ:A-Z$0L$%NT+,ZD7M6+/QM:"PCD4:5$LRA).,J4X!#DE3?
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M5QMMGOS[$09FCH&986#V_];\HV0IB)_I@L?BQ06B5 MU)RY>+H*S3@L6HRB
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M#MKRWW6;6@[P-N>[@UG[_N@ +Z!= =HMN\55QHM=87;G$H$_%NVK99^\5.M
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MG.P 2HN60WP=-U# &7 [_HG8$:E.1&_"UB\&$03+4]6TX3FGT%U-M4UMT-X
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M"BL Z]P"X4HOL/26P7*Q\ !M6"":K!P,0 UCN+N*)\ER;(T9KS%=>=,@6:X
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M<F^CCIA(W\)#@HT\9R3T6R3@V3_ U6G=LE26Y0 37O:Z)LD&JWVH:FZ/-K[
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MEF'9;-TUX_MKN@S+I;%.S4B-U2"^9\L+%IKG+7!@UR$V?48O0;5U777EAFA
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MVT6GJV 5S[NS^:L@7'8WYPM8(-3B=&X0V7@OS!MT_SM[V@P%4=?Z?)O%F',
M39.S!>:Z&S]#^NN,7%+]EF>9=4=QJ<M]9/!Z UZ@1#;4ZX[6W%K[_4TB^VM:
MMEA4-;?OK$_S;IUY"9Q&-F>MC$$RG@1V_$T\\."!,I8"K$*:*^^#Z$]Y,NM'
M*O-W>A+KM#;' PUV.JQ3A&0YZVJ+<;!(IK;6"-\B6U%<!O-E=R8V6"WC3K:P
M=KGP?NL.9CX!@%D"+Z&$3N-@.HV\RR1(DN3*NZ2UK^#& H03;CSMR&HTYY/K
M21@LDP4)_K5W&05)-+_RHMF<EGKBR>UK_.F)>93H52)4V)6G#W+W%$@?B34:
MDX!.1TNGP!O.K(;#DTGH6(E9L.Q,4 S6(%S%C\@<,.(QF3._L//_+7.X[[?*
M7!Q$TZ0KC^.YWRN',""12??H*EYV]UA:OTW.$A#<B WT,DBF<^^2%L4=M0@^
M3<!F+%\1_<+"M1$-EKJ>3("LX9%U(R'!:KKJ,$ +&P[,,DB0/_839#?.K[\5
MHM[1;]PI#E#YA^#L5?LS>K?\ZW'=X_P;?&_3>H>#6KG8PJOA9#&[X/EG\Z6I
M#O1;<NNJ::J"/NX%^+P:'X#[VPK417_!#>R/"_[X+U!+ P04    "  (BGY2
M,VVCP7H"  !/!0  &0   'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6R=5$MO
MVS ,OOM7"!XP;( 1/YNZ71*@:3>LAVY%']MAV$&QZ5BH+'F27+?_?I3L>.FP
MYK"++3Z^CZ1$<M%+]:!K $.>&B[TTJ^-:4_#4!<U-%3/9 L"+954#34HJFVH
M6P6T=*"&ATD4S<.&,N&O%DYWK58+V1G.!%PKHKNFH>IY#5SV2S_V=XH;MJV-
M582K14NW< OFOKU6*(432\D:$)I)01142_\L/EUGUM\Y?&/0Z[TSL95LI'RP
MPF6Y]".;$' HC&6@^'N$<^#<$F$:OT9.?PII@?OG'?LG5SO6LJ$:SB7_SDI3
M+_W<)R54M./F1O:?8:SGR/(5DFOW)?W@FV8^*3IM9#.",8.&B>%/G\9[V /D
MT2N 9 0D+N\AD,OR@AJZ6BC9$V6]D<T>7*D.C<DQ81_EUBBT,L29U:5X!&&D
M8J 7H4%"JPZ+$;P>P,DKX#@A5U*86I./HH3R)4&(F4SI)+MTULE!Q@LH9B2-
M Y)$272 +YW*2QU?^@K?.:=:@R9?*[)7*?EQMM%&84?\/! CFV)D+D;V?U=X
M&!RGWA[>>\<$,;7L-!6E?N_A=4"S 35=R=^:^,2[H3TVA '%*-<$<3A@;<LM
MV]LW>3K//F19D.3I3LH#A'GWHF*"8=^49"MEJ;WX)$CSR$N"/,^]3R]MV=&Q
M-T]3[TX:RG<\\RR(,:%1BN/@.$G(FLDO=U#4I*::"&E(RZ'<(A$5SX3MO0":
M-12=8L9*N%P(9W3#N)-G_WJ5<*_)&U!;-\J:%+(39NCW23MMB[-A2/ZX#ZOF
MBJHM$YIPJ! :S8Z/?**&\1T$(ULW,AMI< #=L<:-!\HZH+V2TNP$&V#:H:O?
M4$L#!!0    (  B*?E*XSVD^J@(  + %   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;)U42X_:,!"^^U=8J52U4G;SSL(6D("V:@]HT6X?AZH'DPS$
MVL1.;0.[_[YC!U*V*AQZ(9[']\U\-C.CO52/N@(P]*FIA1Y[E3'M;1#HHH*&
MZ6O9@L#(6JJ&&335)M"M E8Z4%,'<1CF0<.X\"8CYUNJR4AN3<T%+!75VZ9A
MZGD&M=R/O<@[.N[YIC+6$4Q&+=O  YBO[5*A%?0L)6] :"X%5; >>]/H=I;:
M?)?PC<->GYRI5;*2\M$:G\NQ%]J&H(;"6 :&GQW,H:XM$;;QZ\#I]24M\/1\
M9/_HM*.6%=,PE_5W7IIJ[ T\6L*:;6MS+_>?X* GLWR%K+7[I?LN-PT]6FRU
MD<T!C!TT7'1?]G2XAQ/ X!P@/@!BUW=7R'7YGADV&2FYI\IF(YL].*D.C<UQ
M81_EP2B,<L29R9VI0-&IUF#T*##(:/U!<4#/.G1\!AW%="&%J33]($HH7Q($
MV$K?3WSL9Q9?9'P/Q35-(I_&81Q>X$MZ?8GC2\[P+;@N\,F9 +G5=+Y5"H0Y
MZ*4_IBMM%/XQ?EZHE/:54E<I_<^;O(BVLW>K6U; V,/ATJ!VX$VBE)RRDC=<
M4%.A$"9*_9;@74&SPO#QOO[V1$.R5-"R9YPBE(M#P,4.CU)QT"0>^H,T(TD6
MO<A24#,#)362SN_O*):B\\4=+?"=[55I$J5^E(;DBCRP&C0U[ DQ!? =6]5
M,)AEY,;/DOP<K57'"SBA3/Q!G"&C4TNBT _3G$1^-(C)%VE835Z_&B1Y^BZ/
M_3"*CM;0#_-AEX"CXEZ6Y*$_S'-R&A)27!W#$3)C(?JO]PY.IJ@!M7&[0F.7
M6V&Z@>J]_3J:=E/X)[W;90NF-EQH6L,:H>'U3>91U>V'SC"R=3.YD@8GW!TK
M7*F@; +&UU*:HV$+]$MZ\AM02P,$%     @ "(I^4OVY(H1\ @  B@4  !D
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MKLIB4?)5EW54NS/P&%4FDB[[E->L*?XM;9X4ZTHHSG8'Q,:-47' 1E-J\57
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MJ =-2@1 W&)-2VP A3<<1]XU=J,F*UY^$V1?ML'8^RARX"JC!CP!UY]B2H>
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M:O?EWE L3(I:VC)-*3)QRRG9UHH/TDZ*.U2N)<1XUW2V8CS(U*H?T84@YIJ
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MRD= -DOCQ2 M9LEI[V!>L.NU9SS"-/*F)B'%T6 ^25/OB/RK]<'D:=>@=FZ
M-2ED*[![Y:-VW!'GW6C\<N\6S#55.R8TX; UT/!X8492=4/;"2@;-R@;B6;L
MW+4R>PZ4=3#VK90X"#; N#GSGU!+ P04    "  (BGY2FIWQ%XD&  "*$0
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MTM.E+QG-OO\BD>P:[ZNGW6/"]&C7M>/^$F(: &+UIN\G']O^<7L(J0=ZLF7
M86/^1B/6_]=._.SN^\QN:Z.*BQI764N(M8 J;>[P]XYE'Y9Y5K;E;6/$<!W(
M8;'0#D^OWMYL#(=QZ6 ;:.S!F=C<<RD[:#I^2U1C!XG?D35.=Y0!?LTK,"J9
MC^Y[E1OOO1^O&/JA^15 $>NP>U7N=_L?&L[<^_7NN/N5X@/:*3HV@!80#48S
MO-=+]^;O%EJL[=OV0FAT</NUQ.V427, SPN!\+8+8Z#_^>7T7U!+ P04
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MT$QKRTHNDV#RW>$Y0&#Z^R(SFC<L[_:J)E('OO/TZWD$-\>RW-Z 5;;.ST2
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M8D@ WU.M7?M"&W0_F)S_ U!+ P04    "  (BGY26%3\514)  !(%P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6RU6&MOVS@6_>Y?07B 05LH?LB.
MG30/((].VAFD"9)T%XO%?J EVN)6(C4D%3?]]7,N*<F/U)GL8@8!',LD+^\]
M//?<2QTOM?EJ,R$<^U;DRIYT,^?*]_V^33)1<-O3I5 8F6M3<(='L^C;T@B>
M^D5%WH\'@TF_X%)U3X_];[?F]%A7+I=*W!IFJZ+@YNE<Y'IYTAUVFQ_NY")S
M]$/_]+CD"W$OW)?RUN"IWUI)92&4E5HQ(^8GW;/A^_,QS?<3_B'%TJY]9Q3)
M3.NO]/ I/>D.R"&1B\21!8Y_C^)"Y#D9@AN_US:[[9:T</U[8_T7'SMBF7$K
M+G3^3YFZ[*1[T&6IF/,J=W=Z^5'4\>R3O43GUG^R99@[B;LLJ:S31;T8'A12
MA?_\6XW#VH*#P8X%<;T@]GZ'C;R7E]SQTV.CE\S0;%BC+SY4OQK.246'<N\,
M1B76N=,[D7,G4G;+C7MBE](FN;:5$?:X[V">)O63VM1Y,!7O,#6,V;56+K/L
M@TI%NFF@#[]:Y^+&N?/X18N7(NFQT3!B\2 >O&!OU 8[\O9&N^RUX;&;.7LP
M7%GNR6'9N7!+(11;QT,*R_Y]-K/.8-9_7MA_W.X_]ON/_PJP7S1%N?K>ECP1
M)UTDHQ7F471/8S;L[-RC@U'6&W8P()1C7*7L2^XDB"W8!<[-Z!R;+.J%9P\?
M;^[9;U<1^ZCS[U^E@1JHB%T)9()Z8M(REPEF=8Z/#!8SG:?",#W'2O:I*.?L
MJIA]C-AUI622K1;2MC.AQ%PFDN=,+U58I4TJ%50A6+-,*G8N]><'D62]UAGV
M*/F&?99QBQQD<QR09DF(@NE'V&Q6^YQ-&01 .@OMP7%RY6COUF]$';%E!C^9
M4'R68[IT# ;%-V$2:86/M>#_U48"&GC[J!U!92CE+<TLN;70*.!1!3YQUWKP
M\T\'\7!Z9-F94A7VO4+X!O^OD;-^:VW8V=5U+QQ0W-G@Y5*ZC/TFGM@U5Q#)
M@H[N5ABKE1+Y[H$+74"V+??*1[.*U:RRG;7FI$=R1AD 20/74L;#$1>BF&$!
M14V/:[N=:VY2?Z#UV'T%TX_2:ARC'^SMWCI9=Q!LHF<C_4D%8W/042^!S_O.
M1C 8_KK+:+WTRNBJ[/Q+<+@M2(H8A,2'06+2>0-NN4Q7%J[;MQW2%GP,#^GC
MH'.?:>/V'.C*1%'F^DF(FK".6)E4QHBT@S,=3<9'<32)I\W#,#H8KST,)\.7
MC?$D,95(WW6FXT%G#W_W1,B]P->2/U%PR-I!-!T,WKWK# ^BX?ZP,X'A4>=!
M.[X%8LEE2E3<A4[K\S@:3%9^'D:'AP?-TS0:Q>/.N\XGE>15*@(#YEP:]LCS
M2C0 6X%40Y(HY%*>^VV:D57 P H#*+D;;C:)UM(MR9$Z<BX#XQ)NLSTKG*,D
MM,_Q8-P@.^K0EC[Y:3-/V+(RMD)N$PCDBQ&+*N<AC>#>IU_N[EG,*!OCP=$Z
MUK<UUGYH>-1C#QGI&RD!!;0,,)1&[QF4V. 665P13WRC ($7NJ1Z;UL*WW P
M9!-77NR>P$B,<HJ"IB1ZH>1WHCP)%BWC2V1-JQ>/PGJ9P3Y2DVPNI%+T [>K
MDT#")1YBA) $7%*2]#>_<J@-,K$NGV]9A=. JQSH6U%R0[,:^ *%_$)*Z.!?
M(3A5CK1>&8ZEW:'7>;=&E!4"1A>,LYE6E=TX+;XP K:\H-T]<91:\ #A6A(
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MP%<1&V^ _5QKMWGQ ;;?6>-_ 5!+ P04    "  (BGY2,FH#QFLQ  !2KP
M&0   'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6S=?5MO&T>6\+M^1<,++"2
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M" V3;#F"T;"(!>L9*08C^@#.E&6]RD4TD,2Q[!^5CO.7;V#$O-V>WI+20#I
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MB1LPR8KI BNKAK#P)%,EZC=(UZYLT.2QBB4VAL8FPUY_-.T<H[K?L^QG3B]
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MW;2A3Z]O@+&D[WTNAYI;KKHKFKKR.164&0B&2'E GV;H@XM%AU$75%1O?'M
M'GCK\A*(!4NZ6FT:IL)C(+W]10P1G+A/;.58C!+M:3V!<J!PI<3(1<D,_;1I
MTV#RZ]_^=O/CZ?FWH,FL5B"@076*="?;B7-*VQQ7H*9OSZ)^'Z/.]+P=T?JD
MKM&XZR5)=%#Y7]:Y"%N?(B&5R+Y8ELL*)B9)1;.J??'LU+'$7QW(N3FC,_/-
MACROK\CP_0?TFF N!C8J$VDL\SIE')*T&J4O"@[]FD=?.YNP$6C:)#ED?%Y.
MT=!V<%CE%36!7G![QA8$XQ)]/F!#W9]-(!; U]QLIJ?[WI_N+TCY$Y@UBQA1
M H3""8E^!VM:4TU, WRY(X'$)'J/'H%BTS=\1X%)*JN QKE1#%YZ3_O;HOT8
MTO=)]4M;5.8AR7+47K*W5[@OR$-[Y@#D+N1I6XY$/0("ZC[V@H^<NV,=QODF
MXJ@D,D:WL>A9JQJMT)PI%Z-1IFYD,@5IFGPW/ +/DZ<6/:T\JX+]R :@P3ES
M!LB58W'$6T^W"VF!_-Z2$ML=X^@[<XVMZBJG2Y>3;V&,42R^DG:UE]Y7YL2\
MN_G@DV >898,PTGQP'$* QI3G"9/I:-BR9$GP">FH1D!"%'T.W)$VZI"3/!V
MW-9 <EA5SV(_-*M:ML ,=L,\$K>5)SX>VSV!0:BYL>/)(;07NI;L8 *<JHII
MN\*'SG'.]HH28B*3R%LOIIEUZ)(<OP>0W.:-7.BYPFV5TD>#+9E6[S6L^$(,
MHLOQ-7#9'I^<>D^,:KS#\!6MHDZK.DQK$]1S?3<E;RC9V6T!MDL&4OMU(5<#
MF*HANI-A'6X4H+[WONIT:'ZEUL+PEK1AA;N[3W-5C854Z$6\X=**M(+VX0#L
MG <P7+1[/G\;[DV%#4?K9JK]QL-WZ9Y?')E!Z""(17N'#=ZZU[ IU#(OY=[]
MV$^&U!-Q<UW'2>BPY242 UTUF_.=,'2K&1),Y_O9<I*XDKGO:3U^:8 /,&O(
MHLGOT4Y VUKRCJ2\J7T=\BG9CTL-&[!CQ6E1/>4_L'2&(G11,4I?8822A"SW
M62?^$WWUVON&)0$_7@/=GF%37I=UQRU]&D2_</D;(0RA8 '&"3(PXQJ-'ZN;
MV[P2)L94=?WK;U*$05:3N>,Y>1-4!# YULF]+17>ZU*JL*.K%[F0C,V^T/$W
M)!2+[OG7D>/7-@TA%2VZ@DD)H,9NO9AS  ?;L'*LBH14"80!F"6;\)Y6B$?3
M\%-@"<'+.#!@UR[_[+P-/^MH#S?KGL]?B1N[;;![2.JZ&:6^V4%GW.>7YGYK
MK55<3)C3"QN^GTR+\2T9!ZDP_C[R!V,6DB[]&YC.2YCN//)FQ;>UZ(49'&?5
M3M*J:]C.1R%_D_9&KIA!*@2.IH[%ZY]_QR9[M8F3^9FD,SS?K4!E,AX*? 54
MR.&0 +W9)FZ>5!1_[5%<'9?<L^<K/U$;1G+\^?=PU<5@@QHY'&Q<Z 9OIF,N
MJR<U-;91HDO6OX5,?.X -R-JE3 KCI)-SY^<6YP#('%"D[K->.0]2#Y"34=7
M5,;%ASR\1(V$0AML$OJ2 JQ;X3[OG;G664_:M* PZ<,C6;^VU^@H\F#G+[?F
MW.;A_M,(:'#=*(6HW7;?%%V'D<KZOE(9-G;.-Y7!=GL$BX1S22C2.!^IX"<X
M/MDG531)X0OK[,CSW2GV$8M*.Z)84.A4*%=?AT0A;VF1M\Y7U&!K'*,5T1VS
MJ8],RXGCSD0/HN6"_)QA+=$=4)1.([W%@X$@"4:L $;/2^)(*$->>!^Q7'X5
M;MT&5=&5YL9MS@](^[YCXGE-EUZQUFO>ES8_P#SD=FJZO4SOJ*8&^CUHYZOR
MP*::W-Q=2:<[P>\0MS87JS-_JILHWXG;BE/>2>!.9L$HP3D!#)?:KV\UCQF]
MO"M,6;.[LZ&I/?;*2/)K?<<AZP\)[L<1DFIC[ILR"\D)U8L<%>(/+M385D15
M4>> #2K9V.T!?7097N?%F=G +.[1B9ES1IFQ.4DQ"EF,FLLT0G5DH'-,;0-C
MX2R1:!,CF#012H8CK2KNCO2 KF]N[0Z*E8JMA3(QR>$K0D7HQ,6=HZE[D[(?
M>S$5_AI O\S!!H'2$+ 8*$=AZ>->:\<7U*^)'HD81P3KHP7E&$K-2LZKQ^U
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M1-$/7;W'(3%%I*MW]"<F:[@&'X#?-S58&O(!)T"BH^7]\#]02P,$%     @
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M<Y7UD6R9\:%8#W_UI=%Z&V:;FUYF!LMVYH<%HZKP&7,#7<@(SIKD2$@QR-2
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M7-M'ES\JUX^VV*J@5^:NAPF907X)MBA&:%C<%*>GTWMVH[A>SLB+2SJVQ(%
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M1:$M@1_?6J.C'E,K;H\[Z]<F> AFCB6YXL4?-%/+\U$R0AG)<5VH6[YZ2]J
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M+%)\CX\,J7DOU;-N  QY;;G0"[\QIKL(0UTVT%)](CL0>%-+U5*#IEJ'NE-
M*P=J>9A$T2QL*1-^,7>^.U7,Y<9P)N!.$;UI6ZK^+('+?N''_M9QS]:-L8ZP
MF'=T#0]@GKH[A58XL52L!:&9%$1!O? OXXME9N-=P'<&O=XY$UO)2LIG:]Q4
M"S^R@H!#:2P#Q<\+7 'GE@AE_!XY_2FE!>Z>M^Q?7.U8RXIJN)+\!ZM,L_!S
MGU10TPTW][+_"F,]IY:OE%R[7](/L6GFDW*CC6Q',"IHF1B^]'7LPPX@C_8
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M;YVU @  M 4  !D   !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL?51+;]I
M$+[[5ZQ<J4HD)WX[D (2D%;M 06%M#U4/2SV@%>Q=]W=!9)_W]DU=DD5<K'G
M^<UK9T8'(9]4":#)<UUQ-79+K9M;WU=Y"355UZ(!CIJ-D#75R,JMKQH)M+!.
M=>5'09#Y-67<G8RL;"DG(['3%>.PE$3MZIK*EQE4XC!V0[<3/+!MJ8W GXP:
MNH45Z._-4B+G]R@%JX$K)CB1L!F[T_!VEAA[:_"#P4&=T,14LA;BR3#?BK$;
MF(2@@EP;!(J_/<RAJ@P0IO'GB.GV(8WC*=VA?[&U8RUKJF NJI^LT.78';BD
M@ W=5?I!'+["L9[4X.6B4O9+#JUM$K@DWRDMZJ,S9E SWO[I\[$/)PZ#<P[1
MT2&R>;>!;)9W5-/)2(H#D<8:T0QA2[7>F!SC9B@K+5'+T$]/[G4)DDR5 JW(
MQ2-=5Z N1[Y&:&/@YT>860L3G8$)([(07)>*?.8%%*\!?,RI3RSJ$IM%[R+>
M07Y-XM C41 %[^#%?:&QQ8O/X"V8RG'VE(/8*3+?20E<=X7_FJZ5EOA"?K\3
M*>DC)392<B;2JGW?1&S(:7??:NJ[0&8?;U5#<QB[N' *Y![<R07C1)=8 ^6%
MNG2P35"O,4C7JO\EX=!92FCH"VX25HJ+P/@>22$9*"<:>H,D=>(T?&4EH:(:
M"J(%F3_<$PQ%YHM[DN.(39>4$R9>F 3.E;.B^&"(IL_HDP/;FP?DH#)-G1LO
MC;-SL*8:EL,)9.P-HA01;<^<,/"")'-"+QQ$SJ/0M'(^?AC$6?(IB[P@##MN
MZ 79L#7 =;%#=;+ &V:9<ZKB@E]UZA"1,1!Y:]3^R2;5(+?V7BC,<L=UNU2]
MM#])TW83_YFW]VQ!Y99Q12K8H&MP?9.Z1+8WHF6T:.Q>KH7&+;=DB6<5I#%
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M0[VSB]@FLA_\7M"BZ89M(S2.;G<M<5>"- YH+X30HV 23-LW_0U02P,$%
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M#UVU0U3Y4T/Y8F1NK_=P[C RLX\)HS%3: #?UU*:Z@4GJ'_PN?H74$L#!!0
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M9X8/;M"T ==G2MGU@ RT3_C+OP!02P,$%     @ "(I^4A+ 3>PH @  U 0
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M:/+I.F"FLVN7H&Z\178:R7 ^W-,+!^,*:+_4&D^)<]WPGY&] E!+ P04
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M8'[<DOG5M$'R \U7OY)+9BSW:<D47;48R\=P"8@[O 0D< E(W%T"$"E\+)\
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MS.O%I;GG9JK:P'P_EU(_KU0-;-_#<OH/4$L#!!0    (  B*?E+G6HQE"P,
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MF.-_!93=@.NIE&8_L!_H_E3SOU!+ P04    "  (BGY24(6:A; "  #1!@
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M$2P7A!H@?U\P)IX?U"N7^D7DR7]02P,$%     @ "(I^4B =113V!0  SQL
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M4-":ZZ7<?H(VG\CB99*C^R7;UC?P2%:CEE4;;!143#1?^MS682\@'!P("-N
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MP@L4+=#&XD6WU G0V&XV0+LQDEX>BCXP,FT+E40O22?MHA^_U"6B+5.*D<*
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MK],V;.*Z+Q<0LI61%:X6<[HHXC9<3?6!W>5GS%/M0A33I"M@ANZAVR,<346
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MPOW?D%5_ Y2YVNPMV$+#IL^=S=@->JXWM#?UFK^.\OJZ/O6@Z>L@WPG<*NA
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M!C.!9)'G1/R=0,;7(\=W-@MW=)$JL^".ATNR@'M0#\N9T#.W9DEH#DQ2SI"
M^<@Y]\^F?F  UN([A;5LC)&1\LCY;S.Y3D:.9R*"#&)E*(C^K. "LLPPZ3C^
M5*1.[=, F^,-^V<K7HMY)!(N>/:#)BH=.0,')3 G1:;N^/H+5((BPQ?S3-I?
MM*YL/0?%A50\K\ Z@IRR\DN>JD0T '[O  !7 +P+" \ @@H0O!005H#09J:4
M8O,P)8J,AX*OD3#6FLT,;#(M6LNGS-3]7@F]2S5.C:]9S'- A"7H\DD?)@D2
M?42W*@6!;I<@B*)L@2JKHRDH0C-YK$TN'^[0T?MW@Z 7?CI&U0!1AKZEO)":
M3PY=I0,T;MRX"F92!H,/!.-C=,.92B6Z9 DDSPE<K:R6AS?R)KB3<0KQ"0K\
M#PA[V&L)Z.+%</^T!3Y].7S0H2:HBQ58ON 0'Y5QQF4A -W.-T4Y;Y;NYU<-
M0=<*<OFKPV%8.PRMP_" P_(<\/H<4.NRK; E3\_RF+MF-<:1%P4Z::MFNEO,
M^CA\;C3=-])$O=KHF9*H5A)U*KGB*Q!,7U@*70G"E.S(3J_F[+U-.?JUP_XK
ME:/DB9IY#DX]O[]3CGTS/PIWC*;[1B'&@_9R#&HE@TXE$R(6^E%"LT+$J;ZV
M.Y)S6E.>ODTU?&][=WJO5(^*J)G$ON?AG4RW6$5>>Z+]Q@7O_S_(+KEXRX3?
M*,/;"\\/7BO#P=ZM$4;8VSGP+5:^W]\]\:U6_NZ1=QNO;@YB8;L7B6)>,%6^
M4/5JW2&=V[Y@9WUB.B?[FF]IRK;K1O]-*),H@[FF]$[Z^FB(LI,I)XHO[=O^
MR)7N%.PPU=T?"&.@]^><J\W$.*C[R?$_4$L#!!0    (  B*?E+<7>!5VP(
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M5+9=9,446R;39];#,/1Z,:I<[Z?WT,SO1-VW1M-#HR@(7IG>:.DT6CK_T5(
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M?<C;9J'O;1 &H.>7G*M]QQ1H_@F,_@-02P,$%     @ "(I^4M2..U,Y!0
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MJ>X'(EN@OU]SKIX?L@VJ?Q_,_P=02P,$%     @ "(I^4JH*K8>\ @  K0<
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M@.7?*RRA*)20M/&[U32ZD(K87^_4O^C<92XKS&%)B^]Y(K*Y,3-0 BFN"_%
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M% UD+'9:ZG->W!@-@9G<A?$#)@BQ@5E)@XJW4--6,G+Z&8+](6<.>!B_Z(P
MTMT4Z9YQ6]]T:Y%;*MBTZC0E?38%,I9+]?N.8Q8Z02?\5C'7&4@63%H\9!0/
M<,JT#2S[NDO5LTZ;0M)JXHNY[/:+VG'2+V2'D*CK>%_,QP0/^-V2)79'_?ZD
M8.CY1@_W ,C3'N-5;>O(51SX SZT9(G'V=*2"S#*,B$JWF%2YT/K&8*Y"0%3
MEUSHZ2U)(>R"%?% 7GB6@B-1T"43FYR/<33OE*;5GANXWD 46J;%+U!ME?JF
MZ</G"1.Z\\ <7\"\:&:4/:]:4?99#KQRNH1@%7,&9@3<DB$.7NB5GV%T-R5:
MBA3ZY3.C8FCPJ6T=^>"27IWVI5P\U'5:KL7C9*LGOQC2*E56SRR4ZOC1P$M;
M/L3CA/A1;6$SF6UBJ-]KH[A>_?>%<#=J*YLE$@YVB98+\3@97C49.%!D?<+"
M 7:<+I=;Y$C0)?-:Z&B4#0Y,'7_CM/1'QNE/[_T[2VL[-M<2&,$_. &2ECS(
M.'G<C#:_@BM4M\=O<%/SM2FRDL&?_0N2V#G%'4@$TM(%&:>+NZ;MKH;:[K'E
ME@2(]Z/Q;%LI&6^E_W\\_5Y*DH!X70ZQB.&HVUUG!Z<7.1,;<PHD83[8%:KZ
M9F_N-B=-9^9\I7/_')^LJO.BUDQU?/4>YKJTD"AC:S )'UW@EZA.A*J%XJ4Y
M([GG2O'<7&X9C+A""\#S->=JO] O:,[EEO\!4$L#!!0    (  B*?E(!%^J;
M:P(  "\&   9    >&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;(U5VV[;, S]
M%<' @!;8:L=.N[1( N3287TH%C2[/ Q[4&PZUBJ+GD0OV=]/DATO"Y*T+[9$
MZ1SRD"8]W*!^-@4 L6TIE1D%!5%U%X8F+:#DY@HK4/8D1UURLEN]#DVE@6<>
M5,HPCJ*;L.1"!>.AMRWT>(@U2:%@H9FIRY+K/U.0N!D%O6!G>!+K@IPA' \K
MOH8ET)=JH>TN[%@R48(R A73D(^"2>]NWG?W_86O C9F;\V<DA7BL]L\9*,@
M<@&!A)0< [>OWS #*1V1#>-7RQET+AUP?[UC_^"U6RTK;F"&\IO(J!@%@X!E
MD/-:TA-N/D*KY]KQI2B-?[)->S<*6%H;PK(%VPA*H9HWW[9YV /T;DX XA80
M'P+Z)P!)"TA>"^BW )_JL)'B\S#GQ,=#C1NFW6W+YA8^F1YMY0OERKXD;4^%
MQ='X0:58 OO,M^P=6S:U9YBS)TA1I4(*[LMC+??;RM8*,K8'F8*"7! C9).4
M:BZ/'5XLN 9%!9!(N;QD%W,@+J2Y'(9D%;@XPK2-=MI$&Y^(MA>S1[14AMVK
M#++_"4(KO=,?[_1/X[.,<TBO6-)[R^(HCHX$-'LUO'=[!#Y_/7QP1DW253/Q
M?,D)OD?^$S6;85FALBDW[%/N2^%JIPSLJO-]LC*D;<O]...SW_GL>Y_]$SZ7
MQ*DFM)\-64^:$QRKZWF.)+IZ?_OF6/I?Q@V.X>8OXFX/_37BP[U6*D&O_4@R
M+,5:4?-5==9NZDU\LQ_8IW8:-L/K'TTS2A^Y7@MEF(3<4EH%UP'3S7AJ-H25
M;]@5DFU_ORSL1 ?M+MCS')%V&^>@^T>,_P)02P,$%     @ "(I^4F<)Q.,;
M"   W3   !D   !X;"]W;W)K<VAE971S+W-H965T.#0N>&ULS5M;;^.V$OXK
MA L4NT 3BU=):1(@L=-S FS/!GOI>2CZH-BTK5-)="4ZR1;]\8>ZQ)0EDHZS
M"N"7C2QQAL/AS/>1'.[YH\C_+%:<2_"4)EEQ,5I)N3X;CXO9BJ=1<2K6/%-?
M%B)/(ZE^YLMQL<YY-*^$TF2,/(^-TRC.1I?GU;N[_/)<;&029_PN!\4F3:/\
MVS5/Q./%"(Z>7WR*ERM9OAA?GJ^C)?_,Y=?U7:Y^C;=:YG'*LR(6&<CYXF)T
M!<]N?%(*5"U^B_ECT7H&Y5#NA?BS_'$[OQAYI44\X3-9JHC4GP<^X4E2:E)V
M_-4H'6W[+ 7;S\_:?ZD&KP9S'Q5\(I+_QG.YNA@%(S#GBVB3R$_B\=^\&1 M
M]<U$4E3_@L>FK3<"LTTA1=H(*PO2.*O_1D^-(UXB@!H!U!& S"* &P'<%< 6
M =((D*X L0C01J :^K@>>^6X:22CR_-</(*\;*VTE0^5]RMIY:\X*P/EL\S5
MUUC)R<O;;"92#KY$3^ $?*ZC!8@%F/(%SW,^+[_P KR;<AG%2?%>M;KY^@F\
M^_&' #/R\WO0/( X U]68E-$V;PX'TME6MG!>-:8,:G-0!8S( *_BDRN"G"3
MS?E\5\%8C6D[,/0\L ER:ISRV2G \"> /.09#+IYL3@,'>;@K9]QI0_;],7%
M+!'%)N?@XP)\X>E:Y*6KI_%".9IG,PZ^9INB=CCX((I">?TJF[??3M1\Q+(
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MD+-IMBB:&_'X"UM-B.K^)J*0[;_@<64;#<!D(1M1KAHK!26OEG^S[RM';#2
ML:<!6C5 _0;$TP"O&N!VHDME[;0NLR8[.ZG%(ZBUM>I-7[2^:5NKV?!*+^-M
M4ZM?N6K7G%U535;=\[N"@7,I62/!$;A=+BD04W#)FHP7+ =7U7++:->?WZG]
M .R6KY?6\HWJX\.7&_#ZU4\ICLG[-V!U 7@%?IN)A<RJ7)X,&Z5?JQA.5EHO
MEEJ11RM$X+.HFID$'ZJ<Y=T.AFKBZ]FCY]E?H&"/EVQR##!\"U"$(H>@\=;-
MX2@@!Z\7 [?]85]_7$X*(1<U [].'0[^\Y-J *X:5LJ_ L.1]7"D'8YXAKM@
M][RJ>'4/+K(BJR;,M23++N*V"\V$A[-T1# Y&3YL^LEAE48$K:TZ^NA:'PWJ
M4ZO\@KAE>[HQ+(PQ&44]=;99=PX==?%:71Q4][$64H)Q5M=/6N5Y*195$UB5
M9-UO<HA-D*Z'2W??!*GM9P3C$>[YV6$6X33%;D>/U@I'087G><XU=YS$&-E+
M&\.^+ML(8I1X9,'(H#,*"E,K-1<R*]PHBZQ!C^(H27O2G&8P\DC;H#H,2ALO
MZII5DR>0\^F4Z4OF5@GMX6$4DZ0OTV&'? Y$1B4*K^SDVX++=G%UL)&+.\ES
MGM6<2:!"!+A;2-5";7NW=F1I&F$,^VARF%&8^#QL4 WQCG!:=; Y,(KB=$3[
M FV[WNGJ2C1XAV&^CQ?EHLATFJ3BN$KR)GP9O[5KK\IYQFN5CS5@/,OJ^[Z+
MNT,:8D-Z"'A! V$8IO!6^%KUT=F]&*&X'R=<=I"FOC@&#=)A$M[HI:@;_G?K
M?J? Q!'(8F2=0I<9C7SR3 B X1@0!IE-=4J@Y3K;*H4>70;\,$S^K2EF _XH
M07V%#B//$4,F!*!P"'B9 L@!>)5[1'T*N.RZ>[0KT80"% X%'X7('WE1A-)E
M0VR$#G&^D<$L"F-VJ_.-'*0=6:'6845]22 RD$5AR&ZQ XACW'C4/]P.L\XD
MNOH,D5$XB7Y>?O /^*\9*S(41O%!MH4!*@H#=;MM8>/2M2UL*_^V,$A%8:1N
MBRYD<_,H3JCOU!MTHA>2YIU2*V2SDB8D'O5=9YLA0CR^PP:J>%>H8AN6KB/E
M,/,?*6R(BE](KH5>35W(DF_!)SYAE7+C6\"KHWDM]"_@YE56SM]?MIZ^Y24O
MLAJT%;)0EH4-A?%!*(PWZA)[H#"V^9JJ.-=_&7.9Q1'T) O8@!CO"F)L$U:_
MGQ+85VC;=2?256A0C,,HWF7?_ "^L<$W/@B^L<$WW@.^L2/;A3&VWNY==A%,
MO>ME&([## \6'K -;@)3BT".D@A,O(@T>,=AO <S=NS(="G!_8S390:QQVO$
MT)N$Z7W#)D6F=OF43S*O]XB#S+B_L XC2&*//D-OLI_2"'&4/'!JQ1B7F:\R
M0@SAR?]9&2%VR0.KU]C^!G"8H03Y'&R"!=FU,D(<%0^2H(VU70ETV'4)T)6X
M4?A^H3*R&XGW5E@A)G:0@Q16B(D)9 ^%%;)E8<5E%RBL$!-(R&Z%%;)=8<5I
MYBVL$!-!R Z%%;)58<5AY2NL$!,^R'X**V2;PHK+R'-"J8DB=-=W +IE8<5E
M%RBL4!-(:#B0G.</6ANXSI[T<0^=<VK 3P^2VE-#:[J'U)XZ"BPDZL=KAQ4D
M&P&SJ]# FNZ:V%-'A65DO7@XK#J3Z,K;^$_*<%;?WP8_D*E30V5ZD$R=&L#2
M/63JU%%H<6P/!V3]V\,PENZ0I5-'EDY0/\]P6$&*1AYEAK)TAR2=.J@9$\MG
M#BN2>'P6&[K&>\C18P<X[23=9>7-TF,#US@,UY</_:J#.'SH'5:.0S_<^("F
M9"IIT]\523#1YW;Y-<GZZ?K;I?/VBYW>\POX;KS\ LETL_P@ZK/*!7DE0<&F
MJLOH.%$>JY??&"UO&C%O/].Y$TTCRO9RQK*<U=I _3X5HGF^T0.LO_0Z^Q=0
M2P,$%     @ "(I^4FPVBMZ* @  4 <  !D   !X;"]W;W)K<VAE971S+W-H
M965T.3$N>&ULO571;ILP%/T5BTE3*VV% "&A(TAMVK69-BU*VNUAVH,#EV#5
MV,PVI=O7SP:"TC:)JC[T!7SM>\X]]QCLJ.;B3N8 "CT4E,F)E2M5GMJV3'(H
ML#SA)3"]DG%18*5#L;9E*0"G#:B@MNLX@5U@PJPX:N;F(HYXI2AA,!=(5D6!
MQ=]SH+R>6 -K,[$@ZUR9"3N.2KR&):C;<BYT9/<L*2F 2<(9$I!-K+/!Z30T
M^4W"#P*UW!HCT\F*\SL3S-*)Y1A!0"%1A@'KUSU,@5)#I&7\Z3BMOJ0!;H\W
M[)^;WG4O*RQARNE/DJI\8HTME$*&*ZH6O+Z&KI^AX4LXE<T3U5VN8Z&DDHH7
M'5@K* AKW_BA\V$+,/#W -P.X+X4X'4 KVFT5=:T=8$5CB/!:R1,MF8S@\:;
M!JV[(<SLXE()O4HT3L4SIC!;DQ4%="8E*(D^HF6[HXAGZ(KSM":4H@4D?,W(
M/TC1T04H3*@\UJF7MPMT]/[=V O\3\>H&R#"T$W.*XE9*B-;:9FFF)UTDLY;
M2>X>21>0G"!O\ &YCNOL@$]?#!^$C^&V-J=WR.T=<AL^;Q\?D0GELA* OF?H
MN5^_OFH FBDHY.\#Y;R^G->4\_>4VSB^R[<6&31(\WO>QT,O"$>1?;]MS_,L
M-QR-^Z1'JOQ>E7]0U?3J%LV*HF)<Y2!P24 >Z'78LP[?PMJ@+Q>\VMH6.7QD
M[2#PGEC[/,OU?7^WM:->U>B@JLL'!8)ABN:"IU6BT!)3D.;G^S*_.=#UN.<?
MOX7)85\N?+7)X8[OUW]B\>&<5I*]==Z9N^8;%FO")**0:91S,M([)-KSNPT4
M+YLC<,65/E";8:ZO/! F0:]GG*M-8$[5_A*-_P-02P,$%     @ "(I^4KO%
MM^^0 P  YPP  !D   !X;"]W;W)K<VAE971S+W-H965T.3(N>&ULO5=M;]LV
M$/XK!P\;6F"Q1,FOG6T@<=+.0[L9<;-]&/:!EDX65XGT2"I.@?[XD90C.8W-
MI,"6+S9)W3WWW.GTZ#39"?E)Y8@:[LJ"JVDGUWK[)@A4DF-)55=LD9LKF9 E
MU68K-X':2J2I<RJ+( K#05!2QCNSB3M;RME$5+I@')<25%665'Z^P$+LIAW2
MN3^X9IM<VX-@-MG2#:Y0WVR7TNR"!B5E)7+%! >)V;1S3M[,R=@Z.(O?&>[4
MP1IL*FLA/MG-(IUV0LL("TRTA:#F[Q;G6!06R?#X9P_::6):Q\/U/?I;E[Q)
M9DT5SD7Q!TMU/NV,.I!B1JM"7XO=S[A/J&_Q$E$H]PN[VG9HC)-*:5'NG0V#
MDO'ZG][M"W'@0 8G'**]0_2U0^^$0[QWB%VB-3.7UB75=#:18@?26ALTNW"U
M<=XF&\;M;5QI::XRXZ=G"ZXIW[!U@7"N%&H%9W">ILS6F!:PX'6GV(J_ND1-
M6:%>&Y.KFVMX]<-WHWC0^^DU[!? .'S,1:4H3]4DT(:>#1(D>RH7-97H!!42
MP0?!=:[@BJ>8/@0(3%Y-<M%]<A>1%_$2DR[$Y$>(PB@\0FC^;'<R]M")FUK'
M#B\^A<=44@A5283?,GA<^3_?&P=8:"S57YYPO29<SX7KG0CWSMCK'"35>.QF
M^)U)-PR_]Y#H-R3Z7IQ?!3]+*BF1:Z NS6-<:HR!P[#"<SL;],DPZDV"V\/;
M]=@LBH>]\: Q>T!QT% <>"FNJK5B*:.2H8(O<,.9QA16VM1->2HP;."'+W'7
M1TVXT7]0\-&C2H[&1OF_JO=CJWAT8/2 W[CA-_;RF[^[@4595ESH'"7=,F^1
M2=CJ6/@2928'PDF\B5QC(FY-!C8&+45EZKU%R41Z5/G\6!G+-"(_^XQ4^LA%
M+;G("VBKX2C9IQ\2JG+(S!L;ME+\7;] C[+T@XZZ8Z\FD%8(2?Q<:0*\TZ8-
M1&'6QTOGAWI*J$@KE\0O>5=W&J5]Z2VE2*M$PXH61A%$!K\L/_HBM%I(^B_2
MHZVR$;^T?5N/^K'T,_JSU40R_#_ZTP\Z?*H_6PTE?A']IO[T0SW9GZUP$K]R
M+GAB!G6%=LQ*#^MWE)4?:]SM'6<5'(R2)<J-F[ 5N&#U5-F<-E/\N9M=@]:\
M_@3X0.6&<04%9L8U[ [-PR'KJ;K>:+%U@^E::#/FNF5NOD106@-S/1-"WV]L
M@.;;9O8O4$L#!!0    (  B*?E(RLQTJ;0(  -(&   9    >&PO=V]R:W-H
M965T<R]S:&5E=#DS+GAM;(U5[V_:,!#]5ZQ,FEII:WX";0>1*%!MTB8A:+</
MTSZ8<!"KCDUM ]U_O[.3IC!"E2_D;+_W[IXO7/I[J9YT#F#(2\&%'GBY,9M;
MW]=9#@755W(# D]64A74X%*M?;U10)>.5' _"H*N7U FO+3O]J8J[<NMX4S
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M(8#M%-? >R^)VP[K$->SXGK=X@3. 4TA [+",PJRXXABRQF_PP/1M]GZ;_!
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M*B/^Y0E82-VK2-Q5A$(43UJ*=,TBBM' ?)[4:4\.F\^33JL31'$KM:Y10.#
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M-(5WRAB;F\VIN-0BX8H5I^2>8:$.T/1H@*8.T/21@'9\ V:MY':U!ALEE\(
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M<<#>GTD[0E6+(D']9V;T"U!+ P04    "  (BGY2S5[A.W %  !1&0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Y-RYX;6S%F5UOVS84AJ^[7T%XZ- !G2U1
MMF-WCH'83MH4268DZ78Q[(*6CFVNDNA25-( _?$[E!11B24JZP8X%[$EZQR^
M/!\/:7IR+^3G9 N@R-<HC)/CSE:IW;M>+_&W$+&D*W80XR=K(2.F\%)N>LE.
M @LRHRCL4<<9]B+&X\YTDMU;RNE$I"KD,2PE2=(H8O)A!J&X/^ZXG<<;UWRS
M5?I&;SK9L0W<@/JT6TJ\ZI5> AY!G' 1$PGKX\Z)^V[AC;5!]L3O'.Z3RGNB
MI[(2XK.^. ^..XY6!"'X2KM@^'('<PA#[0EU?"F<=LHQM6'U_:/WLVSR.)D5
M2V NPC]XH+;'G5&'!+!F::BNQ?T'*"8TT/Y\$2;9?W)?/.MTB)\F2D2%,2J(
M>)R_LJ]%("H&U&TPH(4!?6XP:##P"@/OI2/T"X-^%IE\*ED<%DRQZ42*>R+U
MT^A-O\F"F5GC]'FL\WZC)'[*T4Y-SWC,8I^SD)PD":B$L#@@YN8%9RL><L4A
M(;^0DR#@.EOXP7F<UYS.W9L%*,;#Y.=)3Z$D[;CG%\//\N%IP_ +\+N$NF\)
M=:AS^NF:O/GIQY$W[/]:YVO^ E]>G:\+P>(:?PN[OX]IC/Z<5FT]#'D9=UK&
MG6;.O2:Q//%#D:02R&]K<@T!)'P3,P75Z!<I.<&45!/QYP4Z(^<*HN0OBQ2O
ME.)E4OI-)<"X)'<L3(&PX&\L.6QKA;TCL2$#LI8BP@:/@*%8'F\(1"L( OPD
M>X+IMJW+53[F,!M3P^=NZAYYCOZ;].YJU/9+M7VK6LP*9!DARVQX(,N0^9!I
M_D;F(KX#J?@J!'(E%%C",R@''!PZ4\-2RM Z]W.<7)$>'A._,M=X;ZYY%H;[
M67"*O_HT')52CJQ2+IG"<E /9(=5((*ZL>T.^N0!F$PL41F54D963_-G<<#
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M1-G;+;  I'X /U\+H1XO]"%Y^2O*]!]02P,$%     @ "(I^4E?S'/C7 @
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M+Z$ SB%'5\_JQ1 @T FZ:W<4L0(-EX\N0>**B&,5>/6P0$<?/\1^%'PY1MT
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MP3<^GUO@88!N.I] BX((Z=K:V&_Y'CX3>K[F)DYH_$23X[RWY0O]. (2#3!
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MI6KRE24*#C0N.V6I16S;MS*:Y(/)N'PWYY,QV\@TR6'.D=AD&>4O4TC9]FJ
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MF9^H5L50G:THVQLI1+E;Y &CW'"=1F';ZGO%5OL'J_T*JRNQRQ+#M8D#POW
MYSMP]J[0I5D(NY9KORLJ)<WS,CWQ#CWQZO4D\!>B=.XH8<E[,?8[5M29O1;$
M1Z/I6/U>;LBKHC)&!P>C Z/1!S]Y^;!@E(JM *<"2QRPM-H7#[M9#%HN+!SU
MQFF9OD!;[WWL%D 4XSY.N"_VWN*&7 9!/"/I5C[=UDA2F]H^VG?!-\-,J"L$
M-)>(MM2<*MT,!US+*YEN4%<6B'\F$J=*[MB'ZUH.MO4/+/&D*PLTEY8L(@M=
MG)8'MV\AMX8+72N@N5C4I]^T0LF!EFW$&-3% U95CP8@FRJQ#*-Z5NG0Z+H
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M >+S11SSUQ/YE>[A?R,N_@=02P,$%     @ "(I^4@CI%Y,(!@  .2D  !H
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M"T4XG7!V#W@>+:OE!\7J%]ERO:(T!\J-X/)J)//$]&83<GKFRZ5>@7GX54)
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M#F#==CMDC!J\$U2T#4_@NP-8-]XMQ0TJ*H=/4'E[^)@4#2JVAOVQYU"Q-.S
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M;"]W;W)K<VAE971S+W-H965T,3$T+GAM;,U7WV_:,!#^5ZQ,FC:I;>) (&R
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M",VD( KRF;<(WZS"4ZO@)+XPV.G.,[&AK*7\80^7V<P++"+@D!IK@N+?'5P
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MI$M2=O+W75**X,0'\B+M+G>&LR.1V5:J)UT!&/)<<Z$G7F7,^M+W=5%!3?5
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M\,LO.MRY)NT?YPN1*VKD,<A-6G1Y97HEFUN\F6A1N9MS*;2YA]VP,#\^D#;
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ME:6%X8\%;6C4+H"^9TK9C>$(NIT_^0-02P,$%     @ "(I^4@.[Z9L4 P
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MW2"[:=KWC^O-%/P@[$YR*U!8,#2YFK+OMADLS<:9?6CF6^-X-(1ER<,8K;_
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M971S+W-H965T,3(T+GAM;,U5WV_30 S^5ZP@H4UB2YK^'FVE=6-B$HC2,GA
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MVV:I:19V+#FO4!JN)&A<3X.K^.,B=?$^X#O'G3D8@W/RH-0/-[G)IT'D!*'
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MU6JAFQ*:.;V.71N)7H>O%*,9C@3(59H2\3I QC==I^YL%\9TD2BSX/8Z2[+
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M(*J\A<N.D;F[R);2X+7HFFM\N8"R$]">2FD>.O9NK-]"H[]02P,$%     @
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    (  B*?E(J&?W_<P@  /!7   /
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MJG<'Z-U5[P[0NZO>':!W5[T[0.^N>G> WEWU[@"]N[O9&Z!W5[T[0.^A>@^
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M]$^6HN[F)U!+ 0(4 Q0    (  B*?E('04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ "(I^4F?AK]WO
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ "(I^4IE<G",0!@  G"<  !,              ( !S0$  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  (BGY2XB%AL/\&  #N(0
M&               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ "(I^4K>:!J=S!@  91T  !@              ("!0P\  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (  B*?E*%U$CY* <
M %D<   8              " @>P5  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    "  (BGY2 =KAP>,!  #' P  &               @(%*
M'0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ "(I^4K<>
M*M8P!   6 \  !@              ("!8Q\  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    (  B*?E)D3W@B-P<  (<C   8
M  " @<DC  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  (
MBGY2UY(7[?8!  #O P  &               @($V*P  >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ "(I^4N%BZL)P"   _2(  !@
M         ("!8BT  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   (  B*?E+@ZE[KM 8  &L0   8              " @0@V  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  (BGY2]"P[GO8F  "<A0
M&0              @('R/   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    (  B*?E)WH;15,!H  #U0   9              " @1]D  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ "(I^4K)%J!F1
M!@  !Q,  !D              ("!AGX  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    "  (BGY27F"'H(P-  " *@  &0
M@(%.A0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (  B*
M?E+;FP7-=0X  " L   9              " @1&3  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ "(I^4N21\A29"@  LAX  !D
M         ("!O:$  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    "  (BGY29BX[K5\,  "+(0  &0              @(&-K   >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (  B*?E(@%A-_"04   X,
M   9              " @2.Y  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ "(I^4K1UD>>#!   .0P  !D              ("!8[X
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  (BGY2A!ZI
MZ;D+  !%(   &0              @($=PP  >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    (  B*?E*\Q4K)2QH  &A0   9
M  " @0W/  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
M"(I^4C-MH\%Z @  3P4  !D              ("!C^D  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    "  (BGY2N,]I/JH"  "P!0  &0
M            @(% [   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    (  B*?E+]N2*$? (  (H%   9              " @2'O  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ "(I^4B%G>:XW"@
M]QT  !D              ("!U/$  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    "  (BGY22>,,5[D6  "R50  &0              @(%"
M_   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (  B*?E*-
M\Y=*9@(  $4%   9              " @3(3 0!X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ "(I^4IJ=\1>)!@  BA$  !D
M     ("!SQ4! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  B*?E(O4@A*50,  *8(   9              "
M@=UB 0!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ "(I^
M4C>VM8$C!   N@@  !D              ("!:68! 'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    "  (BGY2 RUKBL\%  ")$   &0
M        @('#:@$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   (  B*?E).[OY=@ 4  !P2   9              " @<EP 0!X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ "(I^4@#9CH:?!0  =0X
M !D              ("!@'8! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    "  (BGY2/<KYA_4&   %%   &0              @(%6? $
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (  B*?E(6SJ9/
MA @  $D6   9              " @8*# 0!X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ "(I^4A=L0K!3 P  50<  !D
M ("!/8P! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  (
MBGY2@/[&5'X$   5#   &0              @(''CP$ >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (  B*?E)9U#U]J00  &,-   9
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M970T-2YX;6Q02P$"% ,4    "  (BGY2C\];% \*   U)0  &0
M    @(%KJ@$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M  B*?E*43A43= (  $0%   9              " @;&T 0!X;"]W;W)K<VAE
M971S+W-H965T-#<N>&UL4$L! A0#%     @ "(I^4A#9T<YX!   ( L  !D
M             ("!7+<! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"
M% ,4    "  (BGY2)MI@>A(&  #\$0  &0              @($+O $ >&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (  B*?E(2'"FE"@8
M ,X/   9              " @53" 0!X;"]W;W)K<VAE971S+W-H965T-3 N
M>&UL4$L! A0#%     @ "(I^4A+ 3>PH @  U 0  !D              ("!
ME<@! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    "  (BGY2
MJN8QWDL#  #\"   &0              @('TR@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4R+GAM;%!+ 0(4 Q0    (  B*?E)/QT/^RP(  / )   9
M      " @7;. 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%
M  @ "(I^4K-5N@%G P  91   !D              ("!>-$! 'AL+W=O<FMS
M:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    "  (BGY2_GN=J/D"  !5#
M&0              @($6U0$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+
M 0(4 Q0    (  B*?E+0 .BU%P(  #\$   9              " @4;8 0!X
M;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ "(I^4G'B+ONC
M P  2PX  !D              ("!E-H! 'AL+W=O<FMS:&5E=',O<VAE970U
M-RYX;6Q02P$"% ,4    "  (BGY2FS]V!UT(  "310  &0
M@(%NW@$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    (  B*
M?E+G6HQE"P,  +L'   9              " @0+G 0!X;"]W;W)K<VAE971S
M+W-H965T-3DN>&UL4$L! A0#%     @ "(I^4O3"]!:I @  M08  !D
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M=#8T+GAM;%!+ 0(4 Q0    (  B*?E(G]+D'(08  !TB   9
M  " @7/_ 0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @
M"(I^4LQ1P8<$"   JRT  !D              ("!RP4" 'AL+W=O<FMS:&5E
M=',O<VAE970V-BYX;6Q02P$"% ,4    "  (BGY2*DY;)U\"  ![!0  &0
M            @($&#@( >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4
M Q0    (  B*?E)2;J:ME@(  #$&   9              " @9P0 @!X;"]W
M;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ "(I^4B*+@-_Q @
MPPD  !D              ("!:1," 'AL+W=O<FMS:&5E=',O<VAE970V.2YX
M;6Q02P$"% ,4    "  (BGY22.&"X_P"   V"@  &0              @(&1
M%@( >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    (  B*?E)D
MLJ'E3 0  !D3   9              " @<09 @!X;"]W;W)K<VAE971S+W-H
M965T-S$N>&UL4$L! A0#%     @ "(I^4L_2(:VI!   Q1$  !D
M     ("!1QX" 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  B*?E(Y-/J82 ,  /D(   9              "
M@?DQ @!X;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ "(I^
M4@;A]3M[ P  E0D  !D              ("!>#4" 'AL+W=O<FMS:&5E=',O
M<VAE970W."YX;6Q02P$"% ,4    "  (BGY2C;X[J>$"   5"   &0
M        @($J.0( >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0
M   (  B*?E+4CCM3.04  $H8   9              " @4(\ @!X;"]W;W)K
M<VAE971S+W-H965T.# N>&UL4$L! A0#%     @ "(I^4JH*K8>\ @  K0<
M !D              ("!LD$" 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q0
M2P$"% ,4    "  (BGY2'"P5%WH%  "C$P  &0              @(&E1 (
M>&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    (  B*?E(!%^J;
M:P(  "\&   9              " @59* @!X;"]W;W)K<VAE971S+W-H965T
M.#,N>&UL4$L! A0#%     @ "(I^4F<)Q.,;"   W3   !D
M ("!^$P" 'AL+W=O<FMS:&5E=',O<VAE970X-"YX;6Q02P$"% ,4    "  (
MBGY2O*GM:=("  "P!P  &0              @(%*50( >&PO=V]R:W-H965T
M<R]S:&5E=#@U+GAM;%!+ 0(4 Q0    (  B*?E+104^I# (  &@$   9
M          " @5-8 @!X;"]W;W)K<VAE971S+W-H965T.#8N>&UL4$L! A0#
M%     @ "(I^4IB62ADJ!   & P  !D              ("!EEH" 'AL+W=O
M<FMS:&5E=',O<VAE970X-RYX;6Q02P$"% ,4    "  (BGY2'VW0<PL"   7
M!   &0              @('W7@( >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM
M;%!+ 0(4 Q0    (  B*?E*]GQ'TC0<  !TO   9              " @3EA
M @!X;"]W;W)K<VAE971S+W-H965T.#DN>&UL4$L! A0#%     @ "(I^4IM4
MMUC1!@  ]24  !D              ("!_6@" 'AL+W=O<FMS:&5E=',O<VAE
M970Y,"YX;6Q02P$"% ,4    "  (BGY2;#:*WHH"  !0!P  &0
M    @($%< ( >&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+ 0(4 Q0    (
M  B*?E*[Q;?OD ,  .<,   9              " @<9R @!X;"]W;W)K<VAE
M971S+W-H965T.3(N>&UL4$L! A0#%     @ "(I^4C*S'2IM @  T@8  !D
M             ("!C78" 'AL+W=O<FMS:&5E=',O<VAE970Y,RYX;6Q02P$"
M% ,4    "  (BGY29#WLY:P"  !D"   &0              @($Q>0( >&PO
M=V]R:W-H965T<R]S:&5E=#DT+GAM;%!+ 0(4 Q0    (  B*?E*@<16B;@4
M /4<   9              " @11\ @!X;"]W;W)K<VAE971S+W-H965T.34N
M>&UL4$L! A0#%     @ "(I^4@<KE\YK P  V P  !D              ("!
MN8$" 'AL+W=O<FMS:&5E=',O<VAE970Y-BYX;6Q02P$"% ,4    "  (BGY2
MS5[A.W %  !1&0  &0              @(%;A0( >&PO=V]R:W-H965T<R]S
M:&5E=#DW+GAM;%!+ 0(4 Q0    (  B*?E)7\QSXUP(  -P(   9
M      " @0*+ @!X;"]W;W)K<VAE971S+W-H965T.3@N>&UL4$L! A0#%
M  @ "(I^4E\>E3]8 P  [0H  !D              ("!$(X" 'AL+W=O<FMS
M:&5E=',O<VAE970Y.2YX;6Q02P$"% ,4    "  (BGY2V#;S&3T$  !$$@
M&@              @(&?D0( >&PO=V]R:W-H965T<R]S:&5E=#$P,"YX;6Q0
M2P$"% ,4    "  (BGY2..\K.$8%  !8%P  &@              @($4E@(
M>&PO=V]R:W-H965T<R]S:&5E=#$P,2YX;6Q02P$"% ,4    "  (BGY2W1F,
M@7("  !7!@  &@              @(&2FP( >&PO=V]R:W-H965T<R]S:&5E
M=#$P,BYX;6Q02P$"% ,4    "  (BGY2]LX^(.8"  "6"   &@
M    @($\G@( >&PO=V]R:W-H965T<R]S:&5E=#$P,RYX;6Q02P$"% ,4
M"  (BGY2<]GW<9H"  "A!P  &@              @(%:H0( >&PO=V]R:W-H
M965T<R]S:&5E=#$P-"YX;6Q02P$"% ,4    "  (BGY2OOIS#IT,  #!4
M&@              @($LI ( >&PO=V]R:W-H965T<R]S:&5E=#$P-2YX;6Q0
M2P$"% ,4    "  (BGY2Y9^WK]<-  "J4P  &@              @($!L0(
M>&PO=V]R:W-H965T<R]S:&5E=#$P-BYX;6Q02P$"% ,4    "  (BGY200&J
M81T#  !;"@  &@              @($0OP( >&PO=V]R:W-H965T<R]S:&5E
M=#$P-RYX;6Q02P$"% ,4    "  (BGY2PD VC. $  "F&P  &@
M    @(%EP@( >&PO=V]R:W-H965T<R]S:&5E=#$P."YX;6Q02P$"% ,4
M"  (BGY2J4:BG<D$  ",%   &@              @(%]QP( >&PO=V]R:W-H
M965T<R]S:&5E=#$P.2YX;6Q02P$"% ,4    "  (BGY2I#Y2'2L&   G(0
M&@              @(%^S ( >&PO=V]R:W-H965T<R]S:&5E=#$Q,"YX;6Q0
M2P$"% ,4    "  (BGY2".D7DP@&   Y*0  &@              @('AT@(
M>&PO=V]R:W-H965T<R]S:&5E=#$Q,2YX;6Q02P$"% ,4    "  (BGY254B<
M&2T$   Z%   &@              @($AV0( >&PO=V]R:W-H965T<R]S:&5E
M=#$Q,BYX;6Q02P$"% ,4    "  (BGY2CG7V3WP"  #<!@  &@
M    @(&&W0( >&PO=V]R:W-H965T<R]S:&5E=#$Q,RYX;6Q02P$"% ,4
M"  (BGY2$LK_>D,#   _#   &@              @($ZX ( >&PO=V]R:W-H
M965T<R]S:&5E=#$Q-"YX;6Q02P$"% ,4    "  (BGY2K66P2:$#  #W"P
M&@              @(&UXP( >&PO=V]R:W-H965T<R]S:&5E=#$Q-2YX;6Q0
M2P$"% ,4    "  (BGY2X%?6)%L"  #'!0  &@              @(&.YP(
M>&PO=V]R:W-H965T<R]S:&5E=#$Q-BYX;6Q02P$"% ,4    "  (BGY22()O
MMU($   Q$   &@              @($AZ@( >&PO=V]R:W-H965T<R]S:&5E
M=#$Q-RYX;6Q02P$"% ,4    "  (BGY2O67/<@P$  "_#0  &@
M    @(&K[@( >&PO=V]R:W-H965T<R]S:&5E=#$Q."YX;6Q02P$"% ,4
M"  (BGY2GZVCHH0"  !6!P  &@              @('O\@( >&PO=V]R:W-H
M965T<R]S:&5E=#$Q.2YX;6Q02P$"% ,4    "  (BGY2(2(T!(X"  #,!0
M&@              @(&K]0( >&PO=V]R:W-H965T<R]S:&5E=#$R,"YX;6Q0
M2P$"% ,4    "  (BGY2M(I?SZP"  #_!0  &@              @(%Q^ (
M>&PO=V]R:W-H965T<R]S:&5E=#$R,2YX;6Q02P$"% ,4    "  (BGY2 [OI
MFQ0#  #J!P  &@              @(%5^P( >&PO=V]R:W-H965T<R]S:&5E
M=#$R,BYX;6Q02P$"% ,4    "  (BGY27 .FAV0"   &!@  &@
M    @(&A_@( >&PO=V]R:W-H965T<R]S:&5E=#$R,RYX;6Q02P$"% ,4
M"  (BGY2@6JV!*P"  #9!P  &@              @($] 0, >&PO=V]R:W-H
M965T<R]S:&5E=#$R-"YX;6Q02P$"% ,4    "  (BGY2#6OW+XH"  #S!P
M&@              @($A! , >&PO=V]R:W-H965T<R]S:&5E=#$R-2YX;6Q0
M2P$"% ,4    "  (BGY2%NI)0-X"   C"0  &@              @('C!@,
M>&PO=V]R:W-H965T<R]S:&5E=#$R-BYX;6Q02P$"% ,4    "  (BGY2PK.+
M0A@#  !2"   &@              @('Y"0, >&PO=V]R:W-H965T<R]S:&5E
M=#$R-RYX;6Q02P$"% ,4    "  (BGY2OU0@/DD"  #%!   &@
M    @(%)#0, >&PO=V]R:W-H965T<R]S:&5E=#$R."YX;6Q02P$"% ,4
M"  (BGY2]5/%$-P"  !I!P  &@              @('*#P, >&PO=V]R:W-H
M965T<R]S:&5E=#$R.2YX;6Q02P$"% ,4    "  (BGY2/!HIWPT#  #^!P
M&@              @('>$@, >&PO=V]R:W-H965T<R]S:&5E=#$S,"YX;6Q0
M2P$"% ,4    "  (BGY2V*1J+JX"  #@!P  &@              @($C%@,
M>&PO=V]R:W-H965T<R]S:&5E=#$S,2YX;6Q02P$"% ,4    "  (BGY26-"M
MQNX"  #J!P  &@              @($)&0, >&PO=V]R:W-H965T<R]S:&5E
M=#$S,BYX;6Q02P$"% ,4    "  (BGY2>.MMO%H"  !?!@  &@
M    @($O' , >&PO=V]R:W-H965T<R]S:&5E=#$S,RYX;6Q02P$"% ,4
M"  (BGY2U.JY .<"   7"0  &@              @('!'@, >&PO=V]R:W-H
M965T<R]S:&5E=#$S-"YX;6Q02P$"% ,4    "  (BGY2R(*=3FH#  #8%@
M#0              @ '@(0, >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    (  B*
M?E*7BKL<P    !,"   +              "  74E P!?<F5L<R\N<F5L<U!+
M 0(4 Q0    (  B*?E(J&?W_<P@  /!7   /              "  5XF P!X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  (BGY2JPE\+*(#  "13@  &@
M            @ '^+@, >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    "  (BGY20 MY7\4"   72P  $P              @ '8,@, 6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     C@". #PG  #.-0,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>185
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>186
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>187
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>648</ContextCount>
  <ElementCount>595</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>214</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>16</UnitCount>
  <MyReports>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DocumentDocumentAndEntityInformationDetails</Role>
      <ShortName>Document and Entity Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition</Role>
      <ShortName>Consolidated Statements of Financial Position</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Operations (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>Consolidated Statements of Operations (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Comprehensive Income / (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Income / (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100080 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100090 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Corporate information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureCorporateInformation</Role>
      <ShortName>Corporate information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Significant Accounting Judgments, Estimates and Assumptions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptions</Role>
      <ShortName>Significant Accounting Judgments, Estimates and Assumptions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Group information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformation</Role>
      <ShortName>Group information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Business Combinations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinations</Role>
      <ShortName>Business Combinations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Revenue from Contracts with Customers</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomers</Role>
      <ShortName>Revenue from Contracts with Customers</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Income and Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpenses</Role>
      <ShortName>Income and Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Income Tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTax</Role>
      <ShortName>Income Tax</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Earnings per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureEarningsPerShare</Role>
      <ShortName>Earnings per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureIntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Financial Assets and Financial Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilities</Role>
      <ShortName>Financial Assets and Financial Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureInventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Other Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherAssets</Role>
      <ShortName>Other Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Deferred Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureDeferredExpenses</Role>
      <ShortName>Deferred Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Issued Capital and Reserves</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureIssuedCapitalAndReserves</Role>
      <ShortName>Issued Capital and Reserves</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Share-based payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPayments</Role>
      <ShortName>Share-based payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Other Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherLiabilities</Role>
      <ShortName>Other Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Pensions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosurePensions</Role>
      <ShortName>Pensions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Related Party Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosures</Role>
      <ShortName>Related Party Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Events After the Reporting Period</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureEventsAfterReportingPeriod</Role>
      <ShortName>Events After the Reporting Period</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Significant Accounting Judgments, Estimates and Assumptions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptionsTables</Role>
      <ShortName>Significant Accounting Judgments, Estimates and Assumptions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptions</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Group Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformationTables</Role>
      <ShortName>Group Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Business Combinations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinationsTables</Role>
      <ShortName>Business Combinations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinations</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Revenue from Contracts with Customers (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersTables</Role>
      <ShortName>Revenue from Contracts with Customers (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomers</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100380 - Disclosure -  Income and Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesTables</Role>
      <ShortName>Income and Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpenses</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Income Tax (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxTables</Role>
      <ShortName>Income Tax (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTax</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureEarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipment</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureIntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/20201231/taxonomy/role/DisclosureIntangibleAssets</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Financial Assets and Financial Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesTables</Role>
      <ShortName>Financial Assets and Financial Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilities</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureInventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/20201231/taxonomy/role/DisclosureInventories</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Other Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherAssetsTables</Role>
      <ShortName>Other Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherAssets</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Deferred Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureDeferredExpensesTables</Role>
      <ShortName>Deferred Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/20201231/taxonomy/role/DisclosureDeferredExpenses</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Other Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherLiabilitiesTables</Role>
      <ShortName>Other Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherLiabilities</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/20201231/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Pensions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsTables</Role>
      <ShortName>Pensions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/20201231/taxonomy/role/DisclosurePensions</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Related Party Disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresTables</Role>
      <ShortName>Related Party Disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosures</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Corporate Information - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureCorporateInformationAdditionalInformationDetails</Role>
      <ShortName>Corporate Information - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Significant Accounting Policies - Useful Lives Applied to the Group's Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesUsefulLivesAppliedToGroupSPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Significant Accounting Policies - Useful Lives Applied to the Group's Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Significant Accounting Policies - Useful Lives Applied to the Group's Right-of-use Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesUsefulLivesAppliedToGroupSRightOfUseAssetsDetails</Role>
      <ShortName>Significant Accounting Policies - Useful Lives Applied to the Group's Right-of-use Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Significant Accounting Policies - Useful Lives Applied to the Group's Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesUsefulLivesAppliedToGroupSIntangibleAssetsDetails</Role>
      <ShortName>Significant Accounting Policies - Useful Lives Applied to the Group's Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Significant Accounting Judgments, Estimates and Assumptions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptionsAdditionalInformationDetails</Role>
      <ShortName>Significant Accounting Judgments, Estimates and Assumptions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Significant Accounting Judgments, Estimates and Assumptions - Schedule of Provisional Sales Figures for Territories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptionsScheduleOfProvisionalSalesFiguresForTerritoriesDetails</Role>
      <ShortName>Significant Accounting Judgments, Estimates and Assumptions - Schedule of Provisional Sales Figures for Territories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Group Information - Summary of Information about Subsidiaries (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformationSummaryOfInformationAboutSubsidiariesDetails</Role>
      <ShortName>Group Information - Summary of Information about Subsidiaries (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Group Information - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformationAdditionalInformationDetails</Role>
      <ShortName>Group Information - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Group Information - Summary of Information about Parent Company (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformationSummaryOfInformationAboutParentCompanyDetails</Role>
      <ShortName>Group Information - Summary of Information about Parent Company (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Group Information - Summary of Information about Entity with Significant Influence Over Group (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureGroupInformationSummaryOfInformationAboutEntityWithSignificantInfluenceOverGroupDetails</Role>
      <ShortName>Group Information - Summary of Information about Entity with Significant Influence Over Group (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Business Combinations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails</Role>
      <ShortName>Business Combinations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Business Combinations - Summary of Fair Values of Identifiable Net Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfFairValuesOfIdentifiableNetAssetsDetails</Role>
      <ShortName>Business Combinations - Summary of Fair Values of Identifiable Net Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Business Combinations - Summary of Reconciliation of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfReconciliationOfGoodwillDetails</Role>
      <ShortName>Business Combinations - Summary of Reconciliation of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Revenue from Contracts with Customers - Summary of Disaggregation of Revenues from Contracts with Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesFromContractsWithCustomersDetails</Role>
      <ShortName>Revenue from Contracts with Customers - Summary of Disaggregation of Revenues from Contracts with Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Revenue from Contracts with Customers - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails</Role>
      <ShortName>Revenue from Contracts with Customers - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Revenue from Contracts with Customers - Summary of Contract Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfContractBalancesDetails</Role>
      <ShortName>Revenue from Contracts with Customers - Summary of Contract Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Revenue from Contracts with Customers - Summary of Revenue Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfRevenueRecognizedDetails</Role>
      <ShortName>Revenue from Contracts with Customers - Summary of Revenue Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Revenue from Contracts with Customers - Summary of Contract Liabilities Allocated to Remaining Performance Obligations (Unsatisfied or Partially Unsatisfied) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfContractLiabilitiesAllocatedToRemainingPerformanceObligationsUnsatisfiedOrPartiallyUnsatisfiedDetails</Role>
      <ShortName>Revenue from Contracts with Customers - Summary of Contract Liabilities Allocated to Remaining Performance Obligations (Unsatisfied or Partially Unsatisfied) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Income and Expenses - Cost of Sales (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesCostOfSalesDetails</Role>
      <ShortName>Income and Expenses - Cost of Sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>100720 - Disclosure - Income and Expenses - Research and Development Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesResearchAndDevelopmentExpensesDetails</Role>
      <ShortName>Income and Expenses - Research and Development Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>100730 - Disclosure - Income and Expenses - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesAdditionalInformationDetails</Role>
      <ShortName>Income and Expenses - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>100740 - Disclosure - Income and Expenses - Sales and Marketing Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesSalesAndMarketingExpensesDetails</Role>
      <ShortName>Income and Expenses - Sales and Marketing Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>100750 - Disclosure - Income and Expenses - General and Administrative Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesGeneralAndAdministrativeExpensesDetails</Role>
      <ShortName>Income and Expenses - General and Administrative Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>100760 - Disclosure - Income and Expenses - Other Operating Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesOtherOperatingIncomeDetails</Role>
      <ShortName>Income and Expenses - Other Operating Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>100770 - Disclosure - Income and Expenses - Changes Regarding Government Grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesChangesRegardingGovernmentGrantsDetails</Role>
      <ShortName>Income and Expenses - Changes Regarding Government Grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>100780 - Disclosure - Income and Expenses - Finance Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesFinanceIncomeDetails</Role>
      <ShortName>Income and Expenses - Finance Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>100790 - Disclosure - Income and Expenses - Finance Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesFinanceExpenseDetails</Role>
      <ShortName>Income and Expenses - Finance Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>100800 - Disclosure - Income and Expenses - Employee Benefits Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeAndExpensesEmployeeBenefitsExpenseDetails</Role>
      <ShortName>Income and Expenses - Employee Benefits Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>100810 - Disclosure - Income Tax - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails</Role>
      <ShortName>Income Tax - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>100820 - Disclosure - Income Tax - Summary of Current and Deferred Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxSummaryOfCurrentAndDeferredTaxExpenseDetails</Role>
      <ShortName>Income Tax - Summary of Current and Deferred Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>100830 - Disclosure - Income Tax - Summary of Reconciliation of Expected Income Tax Benefit to Actual Income Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitDetails</Role>
      <ShortName>Income Tax - Summary of Reconciliation of Expected Income Tax Benefit to Actual Income Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>100840 - Disclosure - Income Tax - Summary of Reconciliation of Expected Income Tax Benefit to Actual Income Tax Benefit (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitParentheticalDetails</Role>
      <ShortName>Income Tax - Summary of Reconciliation of Expected Income Tax Benefit to Actual Income Tax Benefit (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>100850 - Disclosure - Income Tax - Summary of Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxSummaryOfDeferredTaxesDetails</Role>
      <ShortName>Income Tax - Summary of Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>100860 - Disclosure - Income Tax - Summary of Accumulated Tax Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureIncomeTaxSummaryOfAccumulatedTaxLossesDetails</Role>
      <ShortName>Income Tax - Summary of Accumulated Tax Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>100870 - Disclosure - Earnings Per Share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureEarningsPerShareAdditionalInformationDetails</Role>
      <ShortName>Earnings Per Share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>100880 - Disclosure - Earnings Per Share - Summary of Income and Share Data Used in the Basic and Diluted EPS Calculations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureEarningsPerShareSummaryOfIncomeAndShareDataUsedInBasicAndDilutedEPSCalculationsDetails</Role>
      <ShortName>Earnings Per Share - Summary of Income and Share Data Used in the Basic and Diluted EPS Calculations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>100890 - Disclosure - Earnings Per Share - Summary of Income and Share Data Used in the Basic and Diluted EPS Calculations (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureEarningsPerShareSummaryOfIncomeAndShareDataUsedInBasicAndDilutedEPSCalculationsParentheticalDetails</Role>
      <ShortName>Earnings Per Share - Summary of Income and Share Data Used in the Basic and Diluted EPS Calculations (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>100900 - Disclosure - Property Plant and Equipment - Summary of Property Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property Plant and Equipment - Summary of Property Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>100910 - Disclosure - Intangible Assets - Summary of Detailed Information About Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfDetailedInformationAboutIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets - Summary of Detailed Information About Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>100920 - Disclosure - Intangible Assets - Summary of Goodwill Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfGoodwillRecognizedDetails</Role>
      <ShortName>Intangible Assets - Summary of Goodwill Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>100930 - Disclosure - Intangible Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Intangible Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>100940 - Disclosure - Financial Assets and Financial Liabilities - Summary of Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfCashAndCashEquivalentsDetails</Role>
      <ShortName>Financial Assets and Financial Liabilities - Summary of Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>100950 - Disclosure - Financial Assets and Financial Liabilities - Summary of Financial Assets at Amortized Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialAssetsAtAmortizedCostDetails</Role>
      <ShortName>Financial Assets and Financial Liabilities - Summary of Financial Assets at Amortized Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>100960 - Disclosure - Financial Assets and Financial Liabilities - Summary of Financial Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialLiabilitiesDetails</Role>
      <ShortName>Financial Assets and Financial Liabilities - Summary of Financial Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>100980 - Disclosure - Financial Assets and Financial Liabilities - Summary of Financial Liabilities (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfFinancialLiabilitiesParentheticalDetails</Role>
      <ShortName>Financial Assets and Financial Liabilities - Summary of Financial Liabilities (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>100990 - Disclosure - Financial Assets and Financial Liabilities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesAdditionalInformationDetails</Role>
      <ShortName>Financial Assets and Financial Liabilities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>101000 - Disclosure - Financial Assets and Financial Liabilities - Summary of Carrying Amount of Monetary Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfCarryingAmountOfMonetaryAssetsDetails</Role>
      <ShortName>Financial Assets and Financial Liabilities - Summary of Carrying Amount of Monetary Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>101010 - Disclosure - Financial Assets and Financial Liabilities - Summary of Effect of Changes in Foreign Exchange Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfEffectOfChangesInForeignExchangeRatesDetails</Role>
      <ShortName>Financial Assets and Financial Liabilities - Summary of Effect of Changes in Foreign Exchange Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>101020 - Disclosure - Financial Assets and Financial Liabilities - Summary of Maturity Profile of Financial Liabilities Based on Contractual Undiscounted Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails</Role>
      <ShortName>Financial Assets and Financial Liabilities - Summary of Maturity Profile of Financial Liabilities Based on Contractual Undiscounted Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>101030 - Disclosure - Financial Assets and Financial Liabilities - Summary of Changes in Liabilities Arising From Financing Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureFinancialAssetsAndFinancialLiabilitiesSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails</Role>
      <ShortName>Financial Assets and Financial Liabilities - Summary of Changes in Liabilities Arising From Financing Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>101040 - Disclosure - Inventories - Summary of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureInventoriesSummaryOfInventoriesDetails</Role>
      <ShortName>Inventories - Summary of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>101050 - Disclosure - Other Assets - Summary of Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherAssetsDetails</Role>
      <ShortName>Other Assets - Summary of Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>101070 - Disclosure - Deferred Expenses - Summary of Deferred Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureDeferredExpensesSummaryOfDeferredExpensesDetails</Role>
      <ShortName>Deferred Expenses - Summary of Deferred Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>101090 - Disclosure - Issued Capital and Reserves - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureIssuedCapitalAndReservesAdditionalInformationDetails</Role>
      <ShortName>Issued Capital and Reserves - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>101100 - Disclosure - Share-Based Payments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsAdditionalInformationDetails</Role>
      <ShortName>Share-Based Payments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>101110 - Disclosure - Share-Based Payments - Schedule of Number and Share Price of Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfNumberAndSharePriceOfRestrictedStockUnitsDetails</Role>
      <ShortName>Share-Based Payments - Schedule of Number and Share Price of Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>101120 - Disclosure - Share-Based Payments - Schedule of Expense Recognized for Employee Services Received (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfExpenseRecognizedForEmployeeServicesReceivedDetails</Role>
      <ShortName>Share-Based Payments - Schedule of Expense Recognized for Employee Services Received (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>101130 - Disclosure - Share-Based Payments - Schedule of Number and Weighted-Average Exercise Price of Share Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfNumberAndWeightedAverageExercisePriceOfShareOptionsDetails</Role>
      <ShortName>Share-Based Payments - Schedule of Number and Weighted-Average Exercise Price of Share Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>101140 - Disclosure - Share-Based Payments - Summary of Inputs Used in Measurement of Fair Value at Grant Date (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsSummaryOfInputsUsedInMeasurementOfFairValueAtGrantDateDetails</Role>
      <ShortName>Share-Based Payments - Summary of Inputs Used in Measurement of Fair Value at Grant Date (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>101150 - Disclosure - Share-Based Payments - Schedule of Number and Weighted-Average Exercise Price of Share Options Allocated and Expected to be Allocated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfNumberAndWeightedAverageExercisePriceOfShareOptionsAllocatedAndExpectedToBeAllocatedDetails</Role>
      <ShortName>Share-Based Payments - Schedule of Number and Weighted-Average Exercise Price of Share Options Allocated and Expected to be Allocated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>101160 - Disclosure - Share-Based Payments - Schedule of Number of Share Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfNumberOfShareOptionsOutstandingDetails</Role>
      <ShortName>Share-Based Payments - Schedule of Number of Share Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>101170 - Disclosure - Other Liabilities - Summary of Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureOtherLiabilitiesSummaryOfOtherLiabilitiesDetails</Role>
      <ShortName>Other Liabilities - Summary of Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>101190 - Disclosure - Leases - Summary of Right-of-Use Assets within Consolidated Statements of Financial Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesSummaryOfRightOfUseAssetsWithinConsolidatedStatementsOfFinancialPositionDetails</Role>
      <ShortName>Leases - Summary of Right-of-Use Assets within Consolidated Statements of Financial Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>101200 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>115</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>101210 - Disclosure - Leases - Summary of Lease Liability Included in Interest-Bearing Loans and Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilityIncludedInInterestBearingLoansAndBorrowingsDetails</Role>
      <ShortName>Leases - Summary of Lease Liability Included in Interest-Bearing Loans and Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>101220 - Disclosure - Leases - Summary of Amounts Recognized in Consolidated Statement of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureLeasesSummaryOfAmountsRecognizedInConsolidatedStatementOfOperationsDetails</Role>
      <ShortName>Leases - Summary of Amounts Recognized in Consolidated Statement of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>117</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>101230 - Disclosure - Pensions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsAdditionalInformationDetails</Role>
      <ShortName>Pensions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>118</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>101240 - Disclosure - Pensions - Summary of Defined Benefit Obligation Recognized in Non-current Provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsSummaryOfDefinedBenefitObligationRecognizedInNonCurrentProvisionsDetails</Role>
      <ShortName>Pensions - Summary of Defined Benefit Obligation Recognized in Non-current Provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>119</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>101250 - Disclosure - Pensions - Summary of Components of Net Benefit Expense Recognized in Statement of Profit or Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsSummaryOfComponentsOfNetBenefitExpenseRecognizedInStatementOfProfitOrLossDetails</Role>
      <ShortName>Pensions - Summary of Components of Net Benefit Expense Recognized in Statement of Profit or Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>120</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>101260 - Disclosure - Pensions - Summary of Components of Remeasurements Recognized in Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsSummaryOfComponentsOfRemeasurementsRecognizedInOtherComprehensiveIncomeDetails</Role>
      <ShortName>Pensions - Summary of Components of Remeasurements Recognized in Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>121</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>101270 - Disclosure - Pensions - Schedule of Changes to Defined Benefit Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfChangesToDefinedBenefitObligationDetails</Role>
      <ShortName>Pensions - Schedule of Changes to Defined Benefit Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>122</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>101280 - Disclosure - Pensions - Schedule of Principal Assumptions used in Determining Defined Benefit Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfPrincipalAssumptionsUsedInDeterminingDefinedBenefitObligationsDetails</Role>
      <ShortName>Pensions - Schedule of Principal Assumptions used in Determining Defined Benefit Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>123</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>101290 - Disclosure - Pensions - Schedule of Quantitative Sensitivity Analysis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfQuantitativeSensitivityAnalysisDetails</Role>
      <ShortName>Pensions - Schedule of Quantitative Sensitivity Analysis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>124</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R125.htm</HtmlFileName>
      <LongName>101300 - Disclosure - Pensions - Schedule of Quantitative Sensitivity Analysis (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfQuantitativeSensitivityAnalysisParentheticalDetails</Role>
      <ShortName>Pensions - Schedule of Quantitative Sensitivity Analysis (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>125</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R126.htm</HtmlFileName>
      <LongName>101310 - Disclosure - Pensions - Schedule of Expected Payments or Contributions to Plans in Future Years (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosurePensionsScheduleOfExpectedPaymentsOrContributionsToPlansInFutureYearsDetails</Role>
      <ShortName>Pensions - Schedule of Expected Payments or Contributions to Plans in Future Years (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>126</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R127.htm</HtmlFileName>
      <LongName>101320 - Disclosure - Related Party Disclosures - Summary of Compensation of Key Management Personnel (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfCompensationOfKeyManagementPersonnelDetails</Role>
      <ShortName>Related Party Disclosures - Summary of Compensation of Key Management Personnel (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>127</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R128.htm</HtmlFileName>
      <LongName>101330 - Disclosure - Related Party Disclosures - Summary of Compensation of Key Management Personnel (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfCompensationOfKeyManagementPersonnelParentheticalDetails</Role>
      <ShortName>Related Party Disclosures - Summary of Compensation of Key Management Personnel (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>128</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R129.htm</HtmlFileName>
      <LongName>101340 - Disclosure - Related Party Disclosures - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresAdditionalInformationDetails</Role>
      <ShortName>Related Party Disclosures - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>129</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R130.htm</HtmlFileName>
      <LongName>101350 - Disclosure - Related Party Disclosures - Summary of Aggregate Value of Transactions Related to Key Management Personnel (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfAggregateValueOfTransactionsRelatedToKeyManagementPersonnelDetails</Role>
      <ShortName>Related Party Disclosures - Summary of Aggregate Value of Transactions Related to Key Management Personnel (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>130</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R131.htm</HtmlFileName>
      <LongName>101360 - Disclosure - Related Party Disclosures - Summary of Outstanding Balances of Transactions Related to Key Management Personnel (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfOutstandingBalancesOfTransactionsRelatedToKeyManagementPersonnelDetails</Role>
      <ShortName>Related Party Disclosures - Summary of Outstanding Balances of Transactions Related to Key Management Personnel (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>131</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R132.htm</HtmlFileName>
      <LongName>101370 - Disclosure - Related Party Disclosures - Summary of Transactions Between Related Parties Amount (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfTransactionsBetweenRelatedPartiesAmountDetails</Role>
      <ShortName>Related Party Disclosures - Summary of Transactions Between Related Parties Amount (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>132</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R133.htm</HtmlFileName>
      <LongName>101380 - Disclosure - Related Party Disclosures - Summary of Transactions Between Related Parties Outstanding Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureRelatedPartyDisclosuresSummaryOfTransactionsBetweenRelatedPartiesOutstandingBalancesDetails</Role>
      <ShortName>Related Party Disclosures - Summary of Transactions Between Related Parties Outstanding Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>133</Position>
    </Report>
    <Report instance="bntx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R134.htm</HtmlFileName>
      <LongName>101390 - Disclosure - Events After the Reporting Period - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/20201231/taxonomy/role/DisclosureEventsAfterReportingPeriodAdditionalInformationDetails</Role>
      <ShortName>Events After the Reporting Period - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>134</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>bntx-20201231.xml</File>
    <File>bntx-20201231.xsd</File>
    <File>bntx-20201231_cal.xml</File>
    <File>bntx-20201231_def.xml</File>
    <File>bntx-20201231_lab.xml</File>
    <File>bntx-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>189
<FILENAME>0001564590-21-016723-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-016723-xbrl.zip
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M;UF7N@JKKS4W(:$ _Y5-F-CK"R\A:%+K"2Q,Y"K#LHS5PYS_U#UKFX]IP51
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M)F J?*'J-7OTP@#V/LR?L,;^4A^!B5F9D IC/VS6Y *]5'PH/^=VX;X8[=F
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M^\*FY0:]/; 1U=B6A$V[#6&+8--J(_49(Q,NX/\^8>X+ $-[9[6R&2'-6.7
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M@%("VU0-*(&=IX108KHEM802SB(4($H9:;_G)4I/F\/VB^R 2":5$$J![(A
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M*O9T1;;934'=K__A*PQWZ#[6'ZC*)L];?CRS=V+S*H#1EB^_TL;N@C1C](W
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M\%,*2YN%!7:)403EC)?JBNC$M"B"=8^4F;UD)A];I>@(+CKE8/\%Z<CY[LI
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MHU3\86C,ZB*Z^40TYJ0&7U]0!WXU@F^//#?ZVGNP]$B!S91,.2&7UN#;"^K
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MXU@[BG*DY@P5[>S151\VBD2,]AA@':7L#%,7LW-QQEA'O3O$^^)MI&L>XNX
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M#H>UKK'&ZAXRVV+O[8P6\D''SCF*)8HW,AMB[V^BBG31OC@['Y4=127>6VJ
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MI/RY8/?KZK$KY9_X_W+HJXB039H6LAN;GST,S-E@1 =8!PBS%0QONN?PASG
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MD@<2489F>^DG> %/ZS&'GVDG4ZIOJ;ZE^A9 14KUW2IH[ZZ 81K>KWPXC6=
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M:BI;<^"3P15FD@+'9'GJ#<##N.FV$#@:+)ARUB/=]?CF5:^+'A@$?RVG^"!
MVY[QC(TJFS+-6'O-@727WB.W+ 4[/X"\ (;#W'9YEL+:0("<F_4C;B$ DTN"
M_69_;'S0']<$EJS0GXPA/UP_W'SY$4S0&\'O(?M& L'+K?KGWDG((G+GY 0
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MW*Y0^?F#?IA.Q]:  %.9@\+]!2_>X+67C 0>X'=[A=6>SOKEW()@K3/?WFS
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M=U(PQ#8NCH$6 ZJ=DGYH;M08)3DK:E4*LM"4VB+K^:U)4L3(DN,>52$,L&.
M[]N+$4BR-M%=P/F;R/B8GEQ>P;.2O4/8AZ,4:YSS>L_SRAMJ;*"QQ4N\^@=J
M9&4NW=]"DNH@Q+1A]K@&TR0:#F/QPAM<TU[]\D)NEGZ+7,<>&GFT2>H77XAS
M]GNGQ\8OO^%.VK]Z4VTWK^OX[*?7\NL5+<A_\OA&[[].]R_>'IV^;E!]=U)0
M_J@7:Y&4?C&G"!^&[?Z T[)4BJYD'_ ^/"OQ#OJK$4]=0P6VSTG?AY'S"?H$
M5[?/-W 6UR4GO7E5:AK6%8NNNR5PE\[O[TI-C<0*89)MW(&7_RN"+'^UF+G_
M8BJ=-NH?W/4=%4YORBC&#6JN^&J9JEE()Z=G.J=G[J3EYI5,FXA[NG=XV&$)
M^_P6?IN(IR-6OE>D::P:Z?(BB.58^BY(7V?H;Y4 [H:AWR;Z'N[UCU>3P574
MN0-!J8?&P;L1E;Q(J)0/(XEWA('GRZ>&!,0LC)\I.:MS]@\ 9J\7RV+D=!I1
MBG^ *#.YFGKZ2@-$)ZGJB87U8&%HZ U$(FCZ@]7;2J5;^-LRE^WUO-Z>1SEO
ML]K=R'O/%;=5K=LOC5!NH,KO]2@V$\P"(_UZ>V"_0R&&!KB0G0VW7O+*:LA[
MC"Z$A94RNF53SU@Q:;S#M2^9R*-A"92C>H;<MV/QE/&@W@/9<6V$^^\\75P8
M<Q.)6V,V2M4G@O-O]D0B<6>IC@*N@T>JXG/J#!\M@.&92_%M87E"RY.\SUB+
MX H/UBD\.'^LPH.6,^!]J@Q^%8B[Y,H)5C&C"MF/@$,/=%D<V2A!6)AUW7("
M%JE9/0157>C)*2'X,UHY/DUF 2J ;7+W12I5KR^$?]R(&5LD>IB+-)QX4)&<
MNP!&(&XE%SJRVJ>QY&J\"%HB.-05AX^H0CA5W6D4O7]+Y>?ICPL>93'+]L_!
M2[5^_*4;ZNJ&NFX?5R^A5>-05UO.)S=I?".KLQ8+/MU\>O":>YN#&<UE JN?
MKP*G%MSH"(?#87O61/]$$Z7&:1D/\8;I>)9+4%%P/PM04[)?2/;;5R,N&6PW
MUL@C88 "DM%P@\;GT$)5PQ,\"#%&0?+S6#%C=";_.RI*TH^D 4BNUWQ-G/93
M;<-K!T?E5(-3#4XU=(JK[Z,:JF&,EH',X<[%\GD^UBGG80@[1EF,X?G7H!#8
M4:GL^A*E%6@+)V>=G'5RULG9+G'U(\I9.2_),,>U[#3G*_%]V!I*-U*J1,X0
MY@D(891'.#D@^(Z)'+K*').!?1B9B,4-I@ P_H&Q%+QRG-Z2S3ZB=!;VIC)
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M)YV<[!Y7WZ=*0OP068BQ1DIJ:]DX+;-P3"%GSM:3A6K F.64N4\3$& SG8K
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MD@!U\M&6CP\2CQLX>SLC'C]GZ5#"68^"4,5IG41L.]V<1.PT^0[VNH8_M_'
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MVE3T:S>/U)71]#EZB(74O3.68,M5>HN=LA2<T:&A$/@G4G$K[^6[RU_Y=-"
M960>.:,ZQF#LH#!L[5S%M>AD]#R\E53!(,AY@/Z2+LEFA>0-2XH"H]+,AK18
M/=U9.Q'D$53]8\;=NE>"]1]_HWG0?.S,)'TL56K",=T?( G,2%T*1Q2X TP%
M6#QW=BOUYV$-"5M)U1Y62Z!2$V44-1UK#*MQZP?B#^-<<];<L,=L)DF"B&2,
MW\\;31_&YELAKO$>:5V8VT@28$=;E]_#]C68H,G08!O94%[Q!UN'.8Z4!U,C
MELWJR \X/AU#H;+G%V4I<C>1':S6-+,LS6$*#R$$)GC1=SE,@*P\24O,<_#(
M!CP](AB:X$>!;$36QU,?'QQ"4,!6RI-5U,>Z#S4G&H!0.48<HGR,GX)FV$V4
MT[CYH,BB'WI\NGX'5M*/H[P CD?3V) &Q-Y9A"<75.\0F4;* OC?;9 -]^(T
M_8[K& 68+@&#%(X#;&*HF!/E!?Y>1;-UQ95(;J(L32ACYEVA0*! 01#/<):_
M<@=@2_+4E$,</< X=R)!HN#!8Q'$("' $(>OR)"<E4W;Z%B$\"'I1&3V7E'@
M.TD$6_@D=&#SKN'$YTJ3AND$;F,K F4"PV>9,I#O,_R3Q@5<?OKGU=N]_CDX
M7&$(_L-NZN+(BE'\6@&2[7"@HAYWW+E A8E+1_ U>H@(#8QH!+X)\H;H(#W
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MPF(E>'/+DV]BOC9AV7+E@!SV!4I@AH!)53/Y![!HN$WOKG%5-+M@Y'T*BW0
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M'IV/L^>))2UL-_KMW89B?3AL!8C-\D\?(,DLZJ-SAAN24M^ :E"CKG,YD9X
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MQ7^@-0OTPS*L+AS83C09MXG:I_[ID1N5N=.Q7YXYT!UC>4LG#6R,_D9,ZOC
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M.W"&6ZG2VT3G-[#:($J\:9F%XR!O+="*B^P]@,@O3_W]_8,E,QXZ<)*=]?[
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M$Q@_$:>PU&\91ZMX/,R[T!/E!"GT!,ZLHNT!GPM8U5'#P4_(&T"D@08D0?0
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M6U,,E[*K*@PC?+F?>7F*[S'\)6X#GH7PZ.*'LM)[.HD2H?)UBSRRRL?$W3!
MT&JX&KOLBWL11#/,!UY>E*@>+,J+8SNR&*!>*\M>P]"J(T)B4"5L*4:_IK$O
MJ:,#?2*8-(ZM<M>:=F1LU24DYS+!59^K^N%]13^LA&=>(=ZJ"=4 KF0[.UM
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M9*-$^I+'<XN]E=$O7X4W8;]]@5=X+0N[G\9RE&%T8F66]EN=Y=B"" :8+;/
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M#$G"923!T=QUZD1RT&R0.Y;K&DK'ZK\POX76HM= Z4*D[61<(5O$I4SB4K1
M'NBY8-FVSCD2"=OCL;TU'M<&@M;=8236F;Y0SH6%:Y&VTT[_,SN=L#2.^]3E
MV$8G(>A873JV:S#^CN7T3;$:&7%RIQFXM3V\HYP+^N=<.%7N#,JY8!Y9HT#Z
MJP90=VVKVS;%)8=DY:JR8O7=';'V39*4)HM!UVH/]TS0=<XPL6>F7Z"4"X]3
M+N"E49KG$, XP.<F3VBQKY/E0]B4RS"88_1^%F!@-*8AN'OL=J;BI1\FTILL
MLPN,A,>A-0+0D1CFQQ,&C4E5M@(,RI:IS /61_,\38" 40C9C\)7D>U_SV/:
MYWC]!S_SN(K>OD'X<?168E-7G.3SH]H,>IGD<?$BEMF4C?.>NEWW=0R-#/P,
MAAFN8C]&<>)-LB*+/CX/'V QZ!$VZ^W?W_[X'0X@U@N*H/V8U>'=IW]\?'_K
M#$%S>IX,11G3;K&WOWQU>FX^AG@K&\,[$%$,"5>#E<,!]XD  SC%8L2*N>HZ
M_=?)XL&^N!=!-,.QMO(0^XAEL\3C,*+8$ABR;,R]-!<;C\_X2 8PM"KDOQC3
M>=Z<14LDALX'2:3D0X0)-F*<Q4J&L#AU$<0.(I#%+)&8E )'8JW3F#9"AAF\
M"AHU@HM$@KW#>/L 1A[:R%(0\2"QE'R(;]#!0"7FP"NA^8SC>3I\Q&P5Q71(
MU,## ,U@3.^QD^KF,A$&/!,C=F<)NYG%XBZ$.]@#2'UHP7M!44D_@Q>R0"0)
M<WIY3/YW^<BA0&8@T4F:^7,EB]*3,_5*-21E=XK>C*,@B!Z@/_CZ]"$JX_NC
MY84"%LXLC\%-^%BD<_4>,1Y#W[UBU#%Q (A-)0F"DH)\B"LY!*J9&K(8)RW,
MB\5DDGD^@;L0=(^/4RF?\=$B!KB8^RJ[ <PB/E4Y&1XE16@/6L,R+<)KU99*
MZ_+I6V0N$# Q?=6;8F@6@K)H$@[+. /!6V;\L-@$;A\)$8+<CH7J!3X#6@]@
M)4()/\Z#1_J#J9 A)5!JV59CDJ3PGSP; W1C+ %JE49E%N5Y3G;W=3!HV657
MSYY@1*<%1,UT);IY4@M4O3 ,F<H/@E,5QWG"PSN5PN*.QWZYWJQI]5?;ANV:
M:S_%CR]-:=UMP;(4/W[VP7=;=B.<W@R+'W=;G1[%CU/\N%EG(KDBI_AQ[)P9
M\>.Y^M?_<$,34(T[WB"+]*GUL];QX^U6C\!O:OQXVS 7%*U@-<[_9)5K-3AX
M_(TRK/V-AQF/YTS;PCRK3.N:H>.]UJ"K/:K&,:U:Q SKHY+U#9I9Y5@$>U-@
MI[#PDT.J,[-JQ"K[N3PB?92C7==9N$JBB",9QI%,6 MU KC=MJUA;\?6]-IK
MX@H5(G0/#7O1.1-.FP+#MT0B&IC:YG('<T8LG)]%D'N6%@ZE.QRV"M<TN$#7
MF:K5$9X1\!O'F^IRD*.3$-P4*0FU/9JOZ6&>5C*@*)C&$F#8B9Y6V"JBM@-;
M$Y@:A94_>?!7\9?3=1X?>/1W>@I7[S,#X^@<Q1%?,X!TZ%C#KK:ZXM#C11(5
M.H*D /.F'E*2^U>>7(BI6-,PU77JDO-7PQF="4NP3A)0+Y)&Z#>1@EV=7AD"
MJ0D$J]GIM'..!1?=&L6SS#"DZ02T<<2K+N8/G81 X]673D2;BSV=A9Z;?"WS
M)>Z;7NK2J9/4IVKJ)/A<9D-"+"K9C0[-J73*)$HP"(L'%@E=U! \3&0J;K$5
M".1#S&?;N6.9^7'#X+_EWN^8/2[T;PLIRZ??!E36+*R7/',)-N0XO%);<C];
M_%VWEK5Z:TU[4O^B?%U%<([KYZ$S_T>5)$^PCRH9X,81J:BN5<VUIB&>G>U-
M-:ZW2RM10K='>V>GM3EY%>5S.S]/.M_0Z\1H#$OGUFOU-X<4UCR9&:5S,SF=
MF](EE,U->9,:D<UM;\ HF9L9QL[>P?9L$PQ>^FAGK9.Y$?@-3N;6:?5-*RFH
M%;+&A>BNK-T-]N?[B'L 55=CN_5' [SV@XL*.)O(L\B?ZQP2D$=?.%:WIV\5
M-Y*#R\E!?Z"O?^<J^R)/OZ-!'NY;JT]3(M9LO[\?HQB>%S+Q+2^UQ%2=,XN%
M0EL/0/U-8#H!;!PUJXL51"<AT-?GB[ _-_:NU>Z80L.,,(+I!&[/LKL[S-L&
MT"_*?[(#7A65H>W</1F,USVKU )IXV@:I:VXCHS4T,9&DG)&2>E8CNMJ*RD'
M6N&,X(=:BL' LCM[VNFVQ8CH$A"R9TWT?4NB7Y? OU^MRI [4BXRWN4 .CW[
M==NQ&'HS6$5]>5$<GN)_@@SOJ8#MMMK+.XO2\FR\T=+78FL60%^.QR(6\(Z$
MP7V<>=DT"W@J[P4;\40F%N.Q8$)"HV.63*('N"AYW*X(^O)M)L)$)*UU/_JZ
M1?0<$8F!,NIL%M(U#7))G1'H$SBC<4C/>M..#.FYA.1<-J;G0S[M-XY)9:U9
M76JV:WD*ZJ&@GJOOKBFHAX)ZMFCM.H:T4% /!?74(@"$@GKJAZEQIG*R;YY:
M.U-03Z/!IZ">VB)+03V&[NS>3*,XE?]5A?2P:$MN#I8\8#),TCA3Y?:TG;84
MZE-;]D4A'N?S_F];=D??VL4D!Q>3 W?'V;)6C(P"?8[U(S&3F=5_0?Z1RQC'
M.1.,^WB$N"ALO)&"L:G@218+G_&4C1?W:CM]J\R,B)=)Q(O6T\, =OJ6.]#7
MLD'@UC,":Y4?$?W9#S2-*0\%-BM:]-BM,8@2BFNN#[[&T:&Z' 3I) 0=U^K9
MIE F$H#FTBHC#@(- =8 ZD5!S3N@I:#FIB!M'$>C4-5KQBCV7&NX*TA1*S9'
MHG)-4:G1@:,1U%!+(=CW2)("FK4-:';M94!S&2Z\,:2YX[9Z>\0THY$/GL 3
M]B"" /];39K1WQ07+</EFZ%#";9^'$?3RN%H>6:*!ZB/#UFQHS!%Y7T>((V]
M]+'M#S*=J. #P;PHO!=Q*C&X,(Q2T6)?)RI..H;'XH>M_9 )FW(9!G/F0RO2
MB$T *A$SE!J$H!2<U=FH<!CQ@*L0;ADJ@</+\7OV6^M+B_D8DABS$0]_9]SS
MHJQPSGOBH8R'ONK2@^"_BQ"'JAB"ZE,?)B*$3D]G'(^9H=5XP8<LCE8:TF*/
M0HLH+)S"PO<+"V^M")).31NLM:SQ8>$?IK,@F@O!WHI0C"5H30H0/X5BND(\
M;-=N=2A"_$J#[[3:EW=G>P-#%=#PP_#W6\,KN!-J-OZZQ.7;+=>EN'R*RS_^
MB*ANJZ<Q*H16T*8./ZV@5S[KZK3<@5D>O/JL.UIG''#5S")@CXPYU]>!;%]@
MFXB:<?%H.?VCO$S8.5/R,K6/!JSF^S#],RKV5W0GH6<T6;V&,TW-5*[^,_81
MW2',"?-G.T,U$% 3V&^#$V7]D]^AIU'HLX0'<('0."M6^SC$SL*>=,)0?[VZ
MRGX)/)/)+V6N.F/]\IYM];I=7:?Q(WI$DG ^21@.K&Y/WV1V)Q.$9J/<[5A.
M9X?!7V?R7']N_"52Z<H2X66Q3.?,BQ*=D\9N=B<@ G5U:+:Z&A VNI%;8BP'
M9XD;#DRA*03N@>"Z5GNH;UUGS=P1=$)N8+EMQTQ:2?GBL'._BC#!<%#]*:=.
M1]HZ(6@*+27\:D)=ZY+A0R<AZ/=VK*):T1]"__3H=YU^(]!O(+1M=\>^Q@1Z
M3#G]=J"K>4Z_??P8=*)E^@!K&JDF>.O-N2GMWG5DI,R@-;0ZMBD&2I*5J\J*
MXUB=OBFQ=92F\6R"T'.M_BZ=0:D:K[0E4UD(4S%E#VLNR64.QL1B?!IAFK\4
M\PYB2L,[^&Z1,!%>PY()C\7MB"?"9S,^5YD16\LQ_//WHS#]]NJ]3+P@PBR*
MG\8?0R^:BC>A7V0"2^"_ 0]Y&L7SO_SI?QC[LQS'R>TX"X(-]WWEWRK7,^G_
M\.+'?X-XM_O]%YAK$0?ALQC_\.(=?NOT^[WAH/MO#."V'=M1'QRW[;SX2X.R
M#E9D<TN*N V:0I-4@_JT[)S9_4Z#T'&=.UA5[D1(79)/509S]>DQJRP"JVO
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M$#H=3NP#Q=/G$_EH7('F7OGT(1]XF<(P>">%]< 3)AG")BW*$A[ZR7ZGR%=
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M?V0RD2I<RHN273/6!+2?M->1GYI9(13=0XRQ9)(_]IBO?6PUMTLS=I*!<\F
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M3O]UPD9QQ'TVDS,12%#WBXNGGW]Y<SN"A\ #L-'P#EQ'>!K%B07/3>6= *
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M(E)TT&,CH5ST)))(AA&@Z &(HC)^-#Q6$=V4PGJ[R_UO@@'9U<0<1;X!E1]
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M;9Y-#OH=RS75%9BR;1J3;?,@Q7]]E:T3Q/5;V$U8M'62@*'E= PY+J94FX<
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M_R$%AO8"L,"0HJZGN*)UKB!')TY &4< 37^&=BQ^<>\ETBP#E7-3^PX$VJ3
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M<9QY/KQ@X45+! TH![)#:*;/5$1>1.]-,_A"#OQ!0HWB#"?BQ6IY#]UR"Y"
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M_R7K 2."U!8IB4GJC1;ZN;1\BP0 *@O#CF&8=DPI,&D^7Y1=/@I^+@!")Q?
M[;A@ZEL2"!+@$;D)"5P#0C^4&PJ7#CP:5LZO92YU97.K94D0WI12E[U%6*S>
M*Y/_=LL#TYC_"T>9"FJH=-$^Y1E0241G4-)T^D0(V"D-CFJR>O2)[LX^JT5,
M\O0PI H\^92N\+A1R7/T?^^V^H-S-H _KSRO(Y$]T<:S]'H?],SK]6XN0I^^
MU_NPU1TUK]?[ECKZ,:KX(>54$]VBE,4UHP+\D)BB5_6A\:91RL61 5DA*BOG
M"DR^2FK+'HSK.:1E74F??R#:F>L1BIJ1K4ZV.JMN(P:C6;U]J#1NZF"TLU'
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MSQ\%X28(?,UH1%KJ'6<X.##LL4IRT>* =2NM!#X79Z:(A<H9Z+$GKX]YU I
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MHO])T>^ZSJC7=\8#?9O9/!H%7")Z]Q?Q:VMS-5_S4FMT'IAA1%D;R20;R>K
M(X5DS^F[^C:ZMLC]$>1V!J[CCO4=,W<H=B\0=6Z_Y0X--%[L[%K<W/LXF7)A
MC(ECCSR;9@8UY:Q')R*X<H=.ISL\M2+#DD #2*#KMIW.8&!IX')IP&VW1GV#
M+;,'@XAG2E#3XCQ7'O:5\_I^<$"C;L=]6MIY^B#?."OO41!N@OS7AT8&_;[3
M'>G;-=82R)D)Q'6=X7C@C,;Z]C5Y5AJY/ )HMSI[Y(.Y]F'SPSPUJ5Z=4UN=
MZ&;[V?A=HRP[$Y2R3A30,+O-HO_2K;*S6UQ:H==PF\N>EMK3TN;@TSAKJRE1
M$)V(X&KL],:N/2B[8 IPAVUGU!U=!@U<((+Q)'1/ZJCV5I<]"3WV)+0QT3 M
M;3A]D&^<!6</NI[_)+37=T;CQI3.60)Y@I/006?@M/L#2R.720"'1^56G3RU
MZ%]'GVK;B3:AD^>Z:2<[E+B#]LO"QG.HR^#N?H8S+V >2_C<$Q'^?;_=!*4Z
M;0G>U6T-NXR&+CU+S\RS0?;K7KAY]28U$VF:8V/2F.#^T8L AG/8$GL=>TG
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MM]UJKRY1SWS!1.2'>4#5CC(Z$)3A 2Q+7'_ J%Q+PD.J;J0!2!,>X$)":B#
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M,2V )"(-7* KB4@5+CON\&7*)GDJ(IZFL 8>P.(^KM[.O_/$%YBGF,)#Q%0
M:67L/WF@?H=E!%SN$%=R/^,X]$R1XH-PH(TGL/(X EI=,I\GF8=).#$03?GN
M+=)IX*"DFAS?'\B?/&?")&X+?]5AZD_-.#-=EM;J;"WMQ(%$ST$ZIVWT6!OA
MI(E$GQ8@BW?WF:R80X=:0XV81/26+Q+N"RENW\Q@J1RA]?" (IL=6SHT_79K
MW'FJKC^&GQ,\0S5E?_2DL-?'J7L8#[ ^8#M 1/>G$B<2 ,^*D]ZPU:M'2D4)
M2>9OEN_]+_)HJ(#H@"2[)D*@/L_0B+,')<9MD0-NSHP:!RG\]3]$T 2I!APC
M]%NC!I[ZZR.?M<[PM\@_9PI\@Y!_B9@]L)V!KN;6!1<W&#!UK&^GCC75QK+E
M#4^7^=YS!AU]\S L'3PC';B]YM/!92.YXPS[!R;;Z&:$-5\MFSQ^KF^G%QAJ
M6UF5>1R"3=&1%J]'AB?T';U[*&(O$&N#/9%B:\V<$S-&S!:T9HLU6RY#4/;,
M5V\6L;6(->6LU-HM%:QU36LV<O;,(YVP9]AH2>T3D'3"K7&64%-R4'0B M<9
MN%UM&=KB_ZGQOV?N5H-P;Q%KFMEEF\WLP2TUFV%!M5K,IVHQ;9GYN)PE+4TW
M?=!OG.%F&]"<L_'(P.F,30F=6$HY)Z7TG,'0E)QTVZGHR<B@XXQZ/]2K\ Q5
MKOJ;CSHY!T=:$&? YR-:C!:=&J#S$86WQ:?%I\6GQ:?>^#0ZR-9\%'Y00U)9
M'&T,RS7F@-.6_EU6D,R$L(9V%%!XM.VV*:><E@Z>C@Y<9[BO-+\I='#Q2.[8
MTC]-\?3N^X)'*380#JDO:!:S=!8G\ 2>S*4EMMG<LJF@N%*MIZEA:DPMF+F$
MCBD]OJR!:9*!:>V&XQ \&MI*@F9BMM?K&(_92T3;OOEX.IMU-FJZ9?H)'($1
M*X,/FYR'\3W<%N:<T3@,-76%AFS$V;:-R,RWGK3,<M.)8(RSL)J2G*03$73;
MIN2N6>P_/O:-25PT(MO,%,R:8,MI>$2N3S*A+%#PU&B@9&TTT"*)IR)C<0(F
M7]J4HU8M;3E]Z,$X2\[FH9\S 7GL] :-.::SE/*$E#)PQAU;L7#Q9-!WVJ,#
M6^[O&29H1Y06I&!'E!H[HK2[M30[HK36#WE@1.D;+YVQ]V%\_V@C2FL 6H';
MP\-)@>V[YYZB_39/A!I>37/&:;K>GO'G#EV:D3OH(T3C/)L"4&GLN(KD2S=1
MYH)4TWAZK2$KII1?!4>]V!W_4GU4KS4JGO22'?FDT2_KD]>[6R/47]A1UU:/
MG*A'K+C>%M?OR@GTGQ:/.B.Z"0+X*XBM7P&G"S;S4I;R.YZ :)45##[<E7A^
M<7:J#D@9+^$92WBV&#P%KE=_RD-6?AMG@O3@9,E@+]XMZ4(4RHLDOA/PH&G(
MOPNJD5BB J6+"E%**PBNZ>R6+>(DFX)>C:FQ/T$<)%4VHRMI]4JD=MSARY1-
M\E1$/$UA$3R U7U<O9U_YXDO4$O\)P_4=_#J@.-1L(CP[?<S3J>_&>UI:[.T
MNP16%T= (4L0L4GFH?J/V827SP\()@Q81:2^4D>+&!X%, G9-,_R1.V1+;PE
M&0D.O%GX,Y7)2'#BB8@#>.,TD^LI'\_0PD"K(N$1OX<GEHM#^*@S[NJ!]E9)
MBJ/4)+X'D+^N*KNC5K=4E7"1"$%S]<85O?27_Q'3)+V>YF'XRUO88ABGL*-/
MT]](!;_[O@@!YEF<+/_WO_^+L;_47_QNO@CC)>>O81-3D55O8R+XZT_O_PT>
M8'<T_HDH$3#QA4__^M,;_-8=#@?C4?_?:!.TW;9+']Q.U_WI?X_AT1W2:LU)
M/>\(=SG0L:I@JBZUVRN$W)K8_RQ)=F?B:Q,$UX=(&82O1?S[5PZ,XP7 !4#N
M'K#S% 0 2!Y)6&RA6!C)"_@(!,:ME!V>_T<N4D$=CX";RD>!Q,BG(/FD:??1
M2R9Y<LM^G4_^ALST*\@*+UI*%M_[+@$<R>!WX-#4"SV@:_H:C57Y$,85#U38
M'Y:4 #!)^HI)+AE;BI>Y%Y!D\$!2+[P$A !(("] R95B_5D HB4*-NW'QV,&
M'1"/0-\$\FT,>BN2NH;D)$&5I'OHW9/_I9!&$A) FP+ Z'N/0(:WDC#&!Y(0
MA7=&U^JG-%\L0JDL\ *)^-7U!475FH)RIVHZ\$]5[OR&RFV-;P]]PM]B(-(T
M6[^7:&V>AYFX5D25J-5JL*Z0WWIAB&H^X M.Q(0#>G) NH^&QGR!N)%F!I@A
M^>0_W"?=A-C\4%YXDX-.O!.$^U=PP=6!"WOMO1?1VK)>M-AGQ!UP429\ :\'
M<IA[2\9#]>:2_T!,H"K&@>Y@1B#-P*)$@OHUGG-V->'9/><1<UO]GXEV.O@!
M+E,LC[L#DL872$V+>TIC'RV!E/L@8[+E&K>#30%:.KJ%-;Y:\V!;[78I,-;O
M ($!F$]1.A$!1SD\O. 2M#HR1;^PK,H3VZU>1U*S!ZQ'5\ -/-@0/H7EMR62
M<">G4!?[FUQ$IS=X64,Q,IBB#)3U%7=[*W^Y&&'>PKC+VG)WW]]N=;8<;K*8
M,-G/1_6!PAEO!X,SC.]1_J, CPA=Z."WV(U 6L1KX@D(4Z]0'X37!8: 2&T4
M5 T$C>98*.9"127P0F7V%?>M@[9<P]J;,?@!#ZMC]"TM!+1=:!24C_!U0@PH
M]8CG%T8IO@GL<;2PX<UT"?H!N3]KL;_%]^@/."4AH3@L7B$-8;E :6/B0Y.
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MJ+!2VLB'=]"1@0]4$&ZVA#EN9HQW0?C])DN+)-K5^Z[,P :.:9.P::]X:9=
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M]]_W>\U A6&Z.T+X,K@MDOIB+/B(??C!PX(4YI?1"-19UD-&2J>DE! &L<B
MQR4'RAZ<'/;.C@]FJ+LC.6>_I:"_!B=O7&(^/W'6#HPU V9EP*[PX(A03%&-
M4P^N ?%Q*?#AZLM7-&B >)/7W#;#TVV#4W.QZ1[W_MV 4SMG24''>0'T$P&&
M MN \9]IN&[B*2Y[#"%-V325P@X^3^'*C"S](!'D.(!Y"X>QB'/-?A.4MRB2
M+89JQB3L(FB,,""9/0(7@_25-H,E+V_89^Z::U\J24XH" BLBIHDGT$9M">
M154=5T=$W2P!<6U?VTA.<";@PA1LB9LTC23)7NT[*%NC;@GJ4-+^P>#CO@9P
M5R=%>5<!6.A?DN]PT8U EX&A0/\] 1&> 8,H>;._?_HVEQ,>B?\(=<'?TG$
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M#GQXX/E-"!\?,/&!ETQ:/SN!7CE 4#F>70@1K-T%6\Y1QF1N1G9*10?+2@+
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M1$-4$5-@8$K*)EB?H&IMAB+%5!V3/,PQJY;D A&7;K#N!X%(S*/*X:BJ5LD
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MC0,1P&NPS7Z'??;%X-_.DLM=1NFZJ+8$*;"5QJYXS.-JQ;^*3A-NDI7 V(J
M6\E&"$OI=HN!@XWXSF53V C?$Q8TQ17I2@G8>O"&/E&[$<UZ(.^MWM2 88DL
M!<?)=@V93LH965]KE^JQ21JI)CCK$*WHIK]"^\WK2*_W;G/5)LNI\QFNV$DS
M9$ULO*43'*JS'0!W9DK%SQH-F?/E#;$_^N0"WBF8/5O4.0;L#9L#[USMV-L1
M?=[O 3]/TEO3&]<,^KH@+%4^<)HJ</(WY2%0P&5ZF@K'-MCR2);/4^]%,U%
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M$=G:WSB]0\4_4EX/:M!$C56(P>% N:PJI[?3]K_03I7JJ$6]/T2EB)8!E:N
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MY]D#9]X>Z*:<]?9 =^R!&6N@+8L;''M#925#Q8I3;ZN46U3N2CT7:/%$G*E
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M2\#M*_@Z9I_3F(=%K*,PR_5^>T/*&U*;2@-O2&VC4O:&5/=HY@VIM1M2GUV
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M^</!27__R*>.MY+TIZ@-5TT=+YMG?>U$X0,I[=5ST2JIW=R2_I[G@8AY!#?
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MWCYXQ>;ZV3 6TP'@'"2-46#NM<D'7N?M@0Y_PS2F3P.CKD_M0X6,=70'4K,
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M,2(QVNM+81&)T1-;P0T?2R=!(C$+P*'-^J5Q'=7-G57C.<#N._@M?2!AB8X
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MD(-U)XT )6+#3D%ZG^7J^U(F?T1UD(]=A'%:<)9*L,E(\%U@D !&1\UT\8)
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M*GN";2I[NBY>O4!NV_I0N<@C!6..Q-Z:SB)WO_2X^'O3NT!J @1;T+WL#52
ME/4=1$?F-;>*NF2E&144YM$=*LT2'';;>"/#?VK;-/I9+[YRJ@QS52::*[M+
M0 $&ZN1:YN&%? (HD#["N4TBSY':;G/&#-4Z$53W4%5%"SE8I!H> =J!AY".
M]-O<Q-$P<@IG0T,NF"3P>RTII)VO.?@#V?D#1!9=I? CB@TPT Z)MV'(."5
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M=RX@=P6U4-Z;%'@\L,!VRJ!1"%HR=D)U)ULWX($)UB5) R[TV[@TX&*8N--
M"RACZ#:=9_'D.CU8EMU,KGC](I[DQ?/)+$E>OHV+*,F*62[/)E]DE*51G,1U
M6<'9Y%,<GJN_RE@6)WE<*,E[GV=7[^,T3*N9%B=1&5_7K[[[,4W"-"RS_.:G
MO_Z%L=?G:?GCP5>?5MUJ9'$V^9A>JSO)\H>?8O'XS='[WQ2LMB..ZAH&==M?
MY.3-T6GUK/ \-_"=WTS#5'\8HGX@3$L<_41C.!Z9 /6&->/(^K=.95AZI_H;
M)GX<W(D&"57X<V.%/W(U3.6!8Y$7VR?="\&05J"R@&#UV2[%GV1[@+*-KA_:
M(]HUX'YH7\+O["I45#H.DR:3NIA-ITD,N&7L _I%#="TXE[4 FU_75YLFYM^
MURFOAV8A\!N" $79Y\H>XS3'^NOC7]-)G,;%I1RSBRP;([&Q9$(QF5"RD!NF
M; ;<\K$<SLGJ+1X\N>^W-&R!;.JHGK>ZN?<(C2%(?S\D4-$93%W\_9"$P'8\
ML-L9H;L;$K2NU>)#P&!SJ;ZE!5W@]2T;N7Y!FFHX4*,SU%3?TF<NG5NU3\)R
M3J:<RKW)@1#<,UOJG/::4VF/ K&KM,I-TQY7)$N^E648)W+\,:T6LD[&/#G/
M9F4]#NY$?6&Y*G?2I-S);6G=FI7J^F?94>ZDCJBBHVC$P"B_C'(GB562;&N=
M.^D.(5GC<RZGX<V5NK:"92F+[P\%8+41I6V@94X86!$D@,V ^W;+["M0O(#
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M8!:^!/#KYA/XV0G80#2)-PTLT0-I!TMLA\0):I\5+\/W /XN?601^G[XGGX
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M&?#B9YSC,RDR8,//+F?.N<@ &\<[6T>S,\*[,18_NYPZCR.#,'41Y2;)^DB
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MEXDS*)O4[/QVKRG7^398=8MA633.^JM>]%.X.KYBG7K%#^#5]0(O>-G$I+\
M$!^1BV.5@S3[3#_,*Q&NIMGZCU484OG3MM5L_9?S-W0&[%,=($T6A-&7->08
M.+SF@;R>/"7'KLHSQ5UT\X EU LL:9E-&[3L/0><:)R9/AH;H D)3$LZO[!T
M"LH:9Z"/>OLTE)5/LTK*4GYO<U2;\VZ??+L)9OYZCCJ/8'<7>_89<V?2<::Y
M)G(L2VR/0NP4)U9+UC%451.&PB,G/Y,I:D[-?+]$=@I)[1>RV4K;@_'PL+T-
MDV]NDLU+N0O '\ MWPVK-_(1@3_@GMW:\A$*_WJN[W_D?HM34KBKL#L86S3U
MR*8Q]0\5G7.H\T"*L$JP"BDQ)0KZM.26.3%,A'6%O<)$)TVVJI3:33>&J6E$
MBJ-<\'$JR48K]<-B.B<U_TB,JB>0K9:GM$F"5J#;W;IIJ<7KC3F*"<%H$A7J
M^7ZG!G=",81&#0#9("4Q[VRJ4$\5[VS2 R#$#5_&**INE?H;T /0./'9FD2;
M4UTO6T:T]) E,.414+),HX#R5EV2N^D'FJ<09Y0A J#K!?<=&N23?3;^]'&+
M3+1]/=ZV6_2.^,:'R]1QRI%V##W,Q.-,K:;$,_;H,4VS:&[PH1UG=#6FG:W9
MCJ;817.:#^TX,XR,]G^Z+_"W(  ++]OX(=KCCV"6.B^;CS5NQ6EITW(VG <@
M.%.,!R", 3%=4\O=7#C@@9WCPP4/QNY4EM6)?&!']Y#A\2VK>PRCC\?U:N5[
MC8\)5;'MDF?&AWJ<E=:8>K:MH-N:V@WK<29=<^(9JX2F6KEA# _BB>R_*S>*
M/E#)_"LJ<+Z<S=:OZ[0?^S5819">-%(!_X@F9&8_!_.;UY7K1:_9**"T KCP
MEH/P5]T[@WG^M4WM+BB!W>PGHD"@<*@R-C>".ZB;,XLH;B@>JFS>D*.KW<AJ
M<S/YYBF].M74/U<[TO?-;>,BP8PG7'FL.1^"F]N^)8+99-JT.Q%I[/0=PA,=
M#7> #Z3_?=@/'VE<W*J52UMY(-"".7L, <;3PM3*E9D\$&C!I#V* )MM9RCE
MZET>"#2W:],BG!4\T]K0[]"S[4;V<29M([H9X[2*TXDICYV!TXQN)CGOR'/'
M3LXA(SM-M&2/M1/7FCI.)V$^[$2>QK2SB;MI&MT<\LW-.!SM3"(_-4I)8SZT
M$R66'[V7P%MX,Q==77H#<9*VW;@)'M?/L3?W7'3=O70)X<=CH8N9J5B['TB+
M:;/*2W8<TH0/?')W5[\, 7;(33]I'569:L5M7T<)"\7-;;JV<SE:Z99-F_0V
MM^#:SM_8TZ+EUB:]S>VU3G(V5FDX3IL@-#?>NLC3J--2B^HV06ANR761G%'M
MTDW6-D$0T*Y3IUP5GHC67"FTVR;! IIPILIZA*/^F)&+;F5>SE^]P(L3U 7E
M#530W74RFC%8I:>]"0_GB.*)9,<$.U9$),6O:D7WAA\FS2V^+LX!QW2Z@X2G
M4<@8U[*4#D6BN9'8>D&745*9_,AO;AZV[1.8:FEH$#_RR?+*OAM#RN\6]U&X
M E'R<>^[:6;S\[_77NIV'^8S[Q8+B,/NCPVW@UT.;_/#@RPCW!(>;-O#,$O3
M?_GA073/I#4\F/:+;I<F@?+#@^@VBG 5 ZSY\PXW'E$ 4CA@&7>P4^IKQ0U8
MLB$MX@'+V@NK,XG%CGLA+(((XG64=H6(P*NW?FUJ.!KEKG+\R&]N-]>3SYH7
M+5U?X4=^<[,90SY;],SH3JDTMYK_'CY?SM\ VOD@E[AI[#LYT\Z,9^S4EY90
M8 RR&<4X*C\0FD=5CX/ %D7H4!LT#[1RJ@_3]-(5.'XH-(^^<JH14[/Y7]V@
MT#P6RZE.#'ZDJ["2@YU 0X;"-L'?5E1-*64>^%'?W#:LI9XQL:YWQ_KFEF$]
M\6QN03&_S(]VKE=_&'.,4% ZH[^Y8=CZO2^[U/R7'_G-+<+6;WX99G?2W]P6
MW/:)>4S<Q<(+7AK+OM*5)>Q@A[4TI)XQD>)TQ_KFME\]\6RE5:4B:7[$-S?Y
M6J\L@;JH,W,'.YRDMZIALS/^8X>2]%1VHFNEJCI^]!/UY.FM>MC.IN)20X'6
M\9>KI1N]@)L :J< I-UCTV[E($I<+_UQ&?ISJ*V>W)_;.81?0LC)!/@^?'[M
M^MNDV+=L)EJ<!^Z8N9A)R=UB*S<'LW,Q!#2>9W/0CKE]#(JR]MV+9_!A-P#A
M.D[WPAU\WD7%4=FFR(/6W,;\&KZ!*$@G;D50'!N[ECH$N1AV/$I2(PR:&YJU
M&#"&6,Q2)2-?!)K;FO4(,/;B*56O\D6@N;WY">YKN(6W%2Q-"S44I1ADX M
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M-5 "=F.';PV%W;RB[)J1-GJ3CN>##?;HAETJP)*!(?V6B/")VI]#9I0:Z\C
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MA\S2XZ"H#@7DYW/D>ROXUE]^4RX49WH0RV8BDARJ'S&8WP17ZRB"L'^.$[C
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M, K&)VZ&+:/0-_,M1(E+5$F\C21>5\21>"+O0@*HR<5=%4W<'2)'1H*@197
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M2F#M#-I-J(/)"$0KM!Z5?DGATO_1#^,,N?- =@:)1EI!FFPA#- \R"[CHXH
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M%"C9)GF +X5("U?\3%GCA,3@4#XI26&#96TW7#QIB\[-*ME#F <;Y5!:*=]
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M- KMJZ$>?X)_P.M_>XMS4?R,_OOW_P!02P,$%     @ "(I^4KCB2W[R,P
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M]XXSO]<''5S5[2<!FB[8O.<11]P8,Y<MUJ_P$M;N5X3.$:58;-X-#L>>]9N
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M8U*\?2-+GM)M=R*F!QL36MI<,%9 2W:N>#SN,C H>NRN=6!@ D*5OUL'PK@
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M>U+.*GVVP%XDP0U3SC1<]^=U""U5]C?T:*#.+ ZA7<JN&:G+HO+[ZE[P$-I
M)!N 9-W9:GWR0)+\GA4WF+D!BJ[P$C)AP.$>-M?#3,&:Z<%>>!]"2RJK_.N0
M?0["U76V%5D(X02<&VX-+=:=QR&TS"7D0-["O*:@WR)(X"#']!%1+IFA;?IP
ML;5U;O"&>&ZP??ZT?OBEN+U7^<K&7;TS3&[GR%M]F;'5?5&'RE<VZU (-?_L
MTH>$+G73M*6V4=.BBU8L-61>HFY+FMT9V?I5%GUURLFT=)EFFB.9BAR"WGQ
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M]!6A5PDS(2HZ[F!ZF&UW="]H31_=8I=/#C3I&*3FH?*"Q$=^ U#ZE;6F==K
MY@N;2L<X6F!((P*K(>P&P59Y6IR&MR:W<4;>>-5G8ZJE)NK"IJ =Q\H;1:]-
MLE1'V4/!ESLFK@E]MKV%,0M-GG%F2@-1/P5]O(;D=6+\>P4%R^E##&0V?I!_
ML&EP)*]28++/B,?ZDQGR^)PCU:2H9Z<B-NI\(]:\A&YG"=P,6?;EU[^W41L9
M^./+@ZBE'?:ZUS;JPO.NPHVP\.\]XC<2P$JL9!\#E8V:<9=@EF-3_ZCJW]NH
MS?6<KX]+_5_QH8UR<[\E9,6K$+_ZG8U:B%%%7&7";]%6QMGJ=U8/KV612Z<*
M:M[::!@(!Z(N.,DG_IHM;Z%D>F-NA69MJ:W4M'1754FSFK<V:G(=LJDW7WU3
MM,;)6LL)5_/:1EWD>9+JF4#=6QLU^94\3'P&(K:DY6^JOR 3E8V:27_%+'87
M"[@5LI22JOJME9JL(!;U&F*O0\3W OE%CLP<3#KXN1)GGN;NL]Q;X%>RZTD6
M;X3#.G?S[H&S-2ZA-F'QQ9#^TC9L]4L;$5(>!Z1GLVZ<R-\?DK7*6I232=:_
MM]!O-5E#SFBQF3)=7.&0-0.&6_$8BZ2PH]B&\I#,>.5B^KL;)&CB_S-)[].N
MUBO+[QMG9;)@KMV8'%)[*0GATQL3[Y5MR+JW-FZHD@#[+OBN9KQ/94./JDGM
M:PM5$5?*7H<3UN.X2\1W$LN&:2*Q4*5/B*[=D$G(*RVOH*K>63D2<DGEZ?];
M$L,L!C>J922V4<\O(>/O\PM\HFKEFBALU$C=GOGL_I/P6W-(*#KV_-I=T<TU
M[F!U*6WAS*"3*K4[7&U+6KWCI=^Z+&1/=Z>CIAN6RAO;_7B\WD2AJ5U@%B.2
M*6>SG^+'WT!@X[=_A9\A1A!.8I9B]O47-LHO+ZS=EGU:I<<VRLXW=\H;<X5G
M-DI=$8U2[>"I(+!1'_"I4!3%9\B%/OB&N"%L^9X12LD3>U!Q@T8K<AMUO:/D
M$4=Z-+_^W$;I^5BA#"J5!]0JW]NH3=6-]. /3!>5[%GFAFA!:<VRNE448:5"
M<IW6K'9.]2=0^0I!GHN /3GG/*)FW2O(_P2-P!=*;9M (SZH!E Z)S&UNB+T
M2YA$BHIY^&?%-+I-H8$;9)BH\!2YFBKIC80PCD;1N4OI=D'HDTO]2-XY.B?L
M%Z:Y^W$ 3M9@IHW/-OOFA:FY#KRZO[,92*E5:JE4C9?PZ/574MT->4O@V.T_
MF3%34Q8.?0W'[Y#@,1-9<5OKW-" @[ ZN+8S?%C--!9^5B*+U'44)<6<LK.8
M>%]GFP#G-\"UH"SXJ';-1378.1PO<*.(WT<&["*Y$P[W3L<0G"POYLS#0MJ7
M."0 0Z8TQHR'#UR'3*DE,Q"_A:UPVD9?GW<J9?GBZ0)M*/*P\+GQ#=M(_ []
MZ_7&Q51%0O=RKS:=Z@4'CUD2\PL)15 (MR\\K,[#"Z'M>(T#EU9=%CH</RLA
MU/2-'-"G</[IR_5ZG80DEOGR2E:L?6^C-I?/,:(ACV[*\D9-%[_>S8M*&<EL
MU.TZ9&M$%W9!6*5/\0HVI"$)PU5 GI@B_Q1Q8.IYHG;D0VYI#[/<XYZX+"2D
M:GNAB<)&V_&D CQV.1-:\6^SE<0%BO RA(%E$OV"_"5LY^6A,!5Q-$-RM&60
M:N,#F3^1.X+#>!HRQ1]1GJJ 'Z]"_ID;?@6O>NGH0L=2-F)(ZO!_$267,#YV
MU+U].1NU9[,)'L?,BC-PHU](E%VXK4T[3(0VZC=?482XG0"@8*NVYNU>T$;]
MV9?)E;C%81?M.Q>S4O?":*9TX_S%?.6&'7<9!V1H8WN5/O%+)JGOPY),#HF-
M/4(]N8VZ\@TKMI" \OIY//V5C3K4PK$E:FW6K5+>-"&-FG7(3*?.PNQ(/R1S
MGI:[4M;N<,X$:;=2-1"JVEF3+!6$O$<;\0G]5^)2UBD&6Y@FNT&@.GY:$!Z2
MY\^HSCE9LW\\+7=6CX+VP=JT&.B^?+!]@M&P!.B\9CB$"=4%2N+(6W%9)Z4+
M ZO?V:@%>&OD/(W'4X(+IS2U:2*Q42>Y02B%GM1IUH+01OTN$]@;@OGU(Q+A
MNX"SDO>QD<9&K7Y-0C1_8H^VXO_O^,P9W06NZ.E+AXY;4MNH:6FMT+B0L%F/
M.:)KZ*5%H-,DZ]?+CP_*]5<0_JQ:I[/#TDE;%FSEH@#4JET\E*@*<RQK,EY6
M+7G.6?4DA%Z<S2@F\,4T+9"JJ(?<KMBKHM!7P.YGFA<CGT%-'L@CNH?Q#?&T
M&=AK7"5VY61A UTN%K#=!*=SQ&@.)E5._5:DM>Q4Q$*5868&=\>S?R \Y-$-
ME.5DS4M;.JXV&4N5$VN5VD2-)_V,10J10_8=[ZN6O_9,7R-Y#U5?[B#?E]D%
MI,"G?+7D>9 \NN2U:Z*P<694,9:63J[5O;=1&Q5EHLMD:.,'V"'@GU"$E^'E
ML\>?0 ^JY=[8@8'EWV@K;1I[J:X<_@P-4MN'=2EM=9=V!Q>F\K@)U9,GLSY4
M:%4Z[-:WN(W=QRU:NCNT1>_B-K9%*NYY0F$VO4UQGL(^A CN,[1@-,H9LTY%
M#FF#H%DQM@Z)W6>8R<3;=DU1+'%(+2'#Z"Z0^'>^8B(M5^68</46<HHCUN/!
M!3+I7")<3F I4UC?#,_7FE9M=8LWQTD\?0CP4@35\VN:^?EU&:Y3CD3M4L3&
M#N:6A%YWM;N6LE%SZ<Q/\WB4??S9XP-: -\B$HHKQOF=SY%V\W4#@8TF^A00
MIOZ4]==4R[E9_<Y&+6#KX?3=Z3OS!D43E8V:36)QGY.T C]XXZY+YPZ:B6S4
M:TI]-IC1K3A.-D-P-=59*2ZHB<1&G=)[(#]#OBK?_00+HRL"MR<"Z\HK(YM)
M;=3Q.L1PK\X=OTRMNMMH)+%1)QG&5 0<''%4%\4FJL+B=]=#C\,<J,C79M/%
M9,W8>VYX@3:PDB52@3DI*I2M=WN5M= CKQY8Y5LE3#/^[*3J2&N9HJ 0?_CJ
M5A7+J3(\RT]MF5.UNK+4?<;K9,T/"2(_RJ_X@T4/5XFQ*G]Y4O&>A6UIGS8G
M-'FTCPP:*<8 Y4\/2*'LDD-8Y,!"AO![P>667S3Q&)@9;O(^2"K=IZ2%?=(%
MDY;G7@%>T\4MW,^I*:,<^6I#;(T?H-7%A_*0XKF[P;$;P,%@^JBL$.O>'Y*6
MTPVP_IU9)\N2D,UMJU[9&<ZA3@1XJ'XZTF2'"F\S1=1TRIV+6?B9SI_(?$62
MR U]$=+&8!BS"0+/TTN\KY"R%Y)!:$&TG4K9."6^7&\"LD5(& VDO2'A$J*.
MKD.P#3C^JU:BW<L=JO9!$O5N ;VLC:U0G:RA^L*9=K0V:LD,L4!11.B794)G
M[@J'GR^T-)>U%#9J-$-P!(>BN.3^TI_;*/T%G6%$O]X1)J?F6JAY::<>TW^S
M9_,$TL64M:AX9:,.]ULWO,=PM8,?E3U8U>]LU$(Z;I0T")43$B7EWQF:! 'Q
M((M"V?W3ETMA<L?LOG:#UY_@_('@D _RTSLO+I_9S M'(J*T9MI6K=]UR-?5
M#W"?:IK^9D(I[ 6K2]87JVY0K\U0D:$DBJ<+GG/FI'R^0']CXX?$)02O-=]L
M8/UO]5S 2&:C;N!-F;%1)<BV)<%]I*%L#G>ANB*%#EP^(F=[^0UM._,YI!5N
M.9HA_2[/%$T+V6O:T[]>*[0Z&0U2BS5\8P=U5MU!0<['::CM+ S%U<JA9D E
MV0)[#TW'N5K9=,W#YK!8?)FZ;!R?]ZZY MN7J<O&5E;=@GFJND(#5'D0:TEM
M]!JN*(K@(M;)&DY%3!<7^!'[*/3/MH7N*IHF,>RQP(6MU^LU\C&S;;"](LS,
M3]RU7[&/GCD9]UO)(4U"5)S,X1;"F&O. 3+9;)A>?#>04/:$L"\#!8_H,PGC
M5170.C*P$'ZBX\AS3E=M/.AO[=Q[N&2UKGDN0]'U,8Z0782-(26GJY'.QC5'
MC=2L[VZEG4)GHW9%+]=%DPO,:G=J::S.=J!E!&X"1\86I6$[&ZHA37B36VE?
MW.W\GF7OPX=PX%+=.6FO[=2F,!61)R#XRCYPQ5Y]<5@MQ!9E'_=N3&R<XU5'
MRO'8]6#+5$A1S"_];NLZ'):GE<N\EBJR><@"X:$;KC770VXZ92[<L7D*)8=M
M@F&" DNIY^^1N *+R*R7XH;(+&"\)?4A+0.XS-+5G%]MQ>\>6.!X2N%<GFR
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M)J4.=#P&#)!,S:..GU<$" *FMQTZP)AGS&8%*4F0?U*J?U?<^[CV>)SE(:-
M1)U@WM(V6>B#K[05?+8J-O 51+KJK&$S2MG4,R_J5"UG.)@$K4C2;B4%,U#U
M,-I,J6_%6Y7KT/:JX_X#1#+J,]JAFD)015[Z<K<6LKYAE^UB!:K^6,-R)6_#
M)K&)=%_LHBGX.G2M6\@5YO(B,P\S1I/I+%UDCIG^^4 (?=")P$O$\),GECE5
M3<KC+1&>$D\LF:)_H&"*R;148 =2 LMDD_WJ?Q-NDH.CW>C0[A?*[M!ZYL=5
M8:-:W;,O'BU0$J9=V/Y)HVIFTRWH;L?/0FJ(KIM==_R,I(ZI;%QAJTU#AV[<
M," CS:5"Y_.2+BZXSZRMN,]6W8=]67*?]7/-;7*1W<M5M;%E])\^MEW/LK%K
MWHQ_W38#]S<Z_,V+97E!Z>>%J%K9RHR',9$E"#U9P>0["7B+XLA>G@JQFZ#R
M]OAUT#!N01@V2]!TU\@-9*P9T?QB^,UK -,CB4F$"8JB$9T_<L[%*-.TKJ 6
M;,GC&O'Q".[@S;>MI7:+!$(^0>606UYAJ0>FA@0H>+Z\%^8">8P/AFOJ$:$^
M+BAC]%D<D56.B2M0^M-EV[VSHMHW;\9GJYD]>Q@%K<:_J0KW,(I9LV@!6;P]
M#%XVY-RT+61ZGT*SO%"T[/"6/H,6J-0AVH<E@2+']BPRCF8H^$IIH&^*RZ]:
M2S*A[/<KPE=04VY8=;-+UMZU'*B[\Y[YBA Q/NFCXHY9SIZL"D+)?2(*RP"#
M=^K$[94?RF>%'L*5%_N@ZJN05$7MU/O$<:^P52#K,]%Q+[ 5[YKR="C3HW0C
M=F[/2I_!S+H>T3Z8=46.X7=89!=D2&KR$^4 0.W[H,!$KI30(@LUWJ%0',IX
MH/>(/6$?+2.3ZB$*+9JVC3+R$7Z2B].\<%F:%#_S2)Y7#S/)BJ0M2V 8/(E;
M B/>.:D]8C /I)*.96QR".) IX!K.PU;F$KZ!Q!V7[[8!_M9A:3*@=H0O>-^
MDBKNRJGDN,^DBEU5:SH>3:L1A[[]=#QLUB2'6D_'H3"9FB.I>_!,DZH['K6U
M V.2E>*<"=C,;I*PZBZ,.L(9]0C+VW!]JL2^[VY/S<QQZ%C7LBKCTE7-5=SZ
M%[  "I1\'Q2_-N_@H,HZ0;V0RN;;P#3)53+"B5VZ:]\\DDS$(2]Q.D!$A+//
M[U"$^)2:C=G4(_@/]5+\IELTAOB*\*X7:QC]Z)$J.1.\0IFRJ5<;<5!-(3II
M6< 2 ,X*)U?>2D*J47P.[5?H6A?=E1:8OHNFMV7UI:93N1^7N:]0[5JF8$++
M=V3'*"]OQ>+D0GLS%J8\:AU:N4@34)6]L/Y%AZU? /D^J$]MWL$KEQ(MP&;P
MYMM=MH)+U+Y0]IEW 'U%*,IN-]#>!6XE9S6FU"V5I7>GU&LQ4<U.<5)K:\BA
M9M[LL=X&;3% Z+NHN?NR[=!-'=70Z<,&1#=@543^-!N[49<*7;''QD)MACED
M-F1:4J$/5[*47J^('R:!R-!IS62#K0:VU'H?3(YI:-8+IW3+!&ZB8_E08#=@
MM43V,V/;CDJNQ51U8JPIT]))@Z2&OFF&N6N0AG-1^&*9+?J'4)DC2B(:XD"<
M@+N/^;_B2!QWY?.KS8S8(@,-]] ,=4%E29]EX51YY%'<CDU32-RDTN<G4?HP
M/1[RA;)?9]B?E>X"3F\@Y[_\PXLN$"+B3C$];6BZ;5LV80/'_8RR6-PXG@+:
MC?"@C=K+4$Q]LPS(F'0SK0KD;"&]1 N&_/2*QSNA_>F$&P7( ;MF2J XM!33
M<F>RK+ETBZ3K4+.\UZ2'F:KW@).N4%>1*,P\=\]T=)"+,0WM9/*%<>EU= XZ
M9V[LSDF_Y<"%:YC[E2,Z7U B4E/&DQL49QM'N80*L98\S+*$82[[MMGH@P._
M-8S]<*K2#"Z.XY*C("C(X.21,CF'.OE9BBU8#D+EB5Q1;%08 /+VW&V?"0UZ
MB=*?5\3PL- FWX?@#UPJ5;$QG7'@I*MH7' P;>)0P*W1P-QQ ^*)I[*TT\*Z
MI+M__%&&9H+"4R::+5CRSDSTWH[#$5K2U4-1F5@4,OKJ81()MP)%0X8C[@>+
M@_5BLC",B(_2VY,E+*/:?"L,6+MSO1G,:.:1*8JN2+G>=)*N('8JU6Z,V)*N
MP"*@C,G*-)/>LSG1P5OI@['L+".ZLV'DN%NR4TG#U*!#SDM6"./68_%K\>FJ
MD>5F4_(PGOPO>OWF$6\J)7Z+6$0)02',8]E"RWUP4TS"LJ3OJYDJ,WX_\QAZ
M%!<M9/<IZ*EZ4 .@K0^5EBB+'Q";+P]M+\]L#WV?)6I;=L::LF7A%7F/*W@W
MW_.U#?57.J:%T ]+JX&;&NMDQ[T3/9D94QQ.[K[M9J1M&!*'DK';G(GA=,K0
ME#\BKS =3QZ8QW'+6LA%B;-=.FWF&'+!ES. %N+4W";,GZ4[I;(>\I $65BZ
MS'"9&64G!D(:EAO)7TU"L>V;T1=-W?(69+4B/"6J7J4.-1"G:W*0=2\ZRUF/
MJ.4M?I $J%[7.&GVNTL',M_V*+I0!G:!XF>$2.D5<8VR/&Z['5L%:]P%NZ2)
MS-*RJC3V;QE=( YF>;U5>O"GBY8UT@S(7NR#=<X;,F+L%*E9UN-ZF,TH<-=L
MG;:,C$S#[1F\[ OQCU@C_NW_ 5!+ P04    "  (BGY2$SG[18YU  #UFPD
M%0   &)N='@M,C R,#$R,S%?9&5F+GAM;.V];9/;.+(F^OU&W/_@V^?+;MQU
MVV6WN]L39W9#]>:NF7*I3I7<O;-?.E@D)+&;(C0@67;UKU^ E A*X@N0! 6
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MV_J$E?*^$Y;W/]_LB4M?_*>ZCG1E])Y^J 1'84#_&I0_3*;SZ1H5WI]81SH
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MYI @IJ\=1Q@%;&XZ:-_L/ZQQ(&J]<85(U4GL%*34.MYJV[NXD<<>4T [:)J
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MKPX:ZN:V^MOB*I][R5.N\H2D!3,H2A/VMWUNQ.8CM3#806 PGCOG5W7QW$P
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M;6WE6P@OJ)VD2O.B";-%H#JN)B+&2"4?1VT@H4NBQ^PI"8/0(\"H>-WSAJ0
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M4FO2V(CJ[+TYWN)Q1FB=63'25GJ$UJ&8-CA(B@ $6YT(U!_Q&3"Z3\_CZF>
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M;$1#CZ;F(]9Q3'O%E,BY+!.>PY]3\NN[X(4I6,R5Z@'(C+BYJ6DS\V6 91&
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M-U%.D)LD9)5I'013& &E)XPTM.7"&.K#WJ;V(%-P8Q(UQ4FLXHU\(0"@:71
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M;U>Q!0^CI\8\A:8@>UHD:_8'.USP',14+MV57P\-*X?HI.FAK$<9\.,N(?N
M:U9@XM,P0$15:5#!B"4<V!$7_N%*!8?3U+TMZMT."ZV^=GE@[O H)*N.\U1_
M*2JXY-3$K%W8LU]#AF7 0Y;KRF0]V"H8&V7S0?Y"IX?;*%A%<91'V' #<IB2
MC?Z'*'NX3\RY\<PEKOE!L7<EO(B>]F!C$S=@88F,Q K6GJ50AHW[N'08SRX"
MS"54G,"UV7LT=%"&S1^WI*N4?40S ,WM^.97K;:,95(>W@9A+Q'2U2HG#\6X
MNS5/1M0"3,OEUCRGC"[&-#QAB89+<H\SG#XK]37K_ZY=%4"FY:,4P^FCM&
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MYU"/.6W_QNGV$,BORDB[SOS8J7]N<(M97X*9SOR5!$@2 4DR.&VR.WD<;B3
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MVS-]U$D6]>/;]0]OX;TIX-Z4>OW) 5:OR&PZ@VPM5S/D2B^;=UH3L*F6/YV
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MEYO_8C'C5%=T6=L1^=R,D![]7,H/82>AC.8.E]6*)&UL2XF%^^!3LH42?O3
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MQ0-MP^8S/W8N_<S ?Y8_G3I4\&KR>FH7T3((:QDLUW<GZ?4TT#/VH12"VRT
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M(>XXB,\09DM^.=2!7=[+\;=]4BTBS9NXR&AZ5R5%I:QJ)9I*_"W)]TGQBGZ
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MJZKYCK'!>7)QM$4OKE',E%-'+YP\2EJ9!@T6/2NY4%*A;?-="'8<QFYH.*2
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M!ZA&.#-2G&"YR"0VU%Q;<'$@!Q#8N(GI'FI=/>'BG#[O:"Y+V<0W*<'2Q)X
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MP0:"]PUKGH[K!9:6=2_35>SO79$$)KJL:H4<RINN\A=F<+1XM?2EH^\Y8GQ
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M#"\G7!2^:+3[EQ-Z*!!K";;=T*2Q#0]6*OG,K$ N6V2J8WBK9AS>*Q:JU!^
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M</SP7L4-]M$_KO%C0C[D55:]FA:9[?V:O4'UD(E1SYXQ0)+#:?U[3-ET1!N
M%$N.=>I2_M7:1B6K"\KO,$P-M/L=-R7J-,*;)A2C[-4N'=( %$T278GH%TG:
M>Q%U@?=5N7D2$\#JH^5ZJ?_+CC-M'[$HJZ":D9QY5A\A+(-&8:"3&@*G\N[3
MBZZ^0SRMB"4WZ149?814,NJ>C:Y<;^LR_[=)Y5(N?YB*SR'6$-4(R3"<$[_Y
MKYN%H((S U8O?Q(K:JX]N+@0'9+UMNU <2LA@5(P7Q^^$-:E].\@$1]\!HB&
M=YLKW5M0)1"#5DI_"B9JK#FPD) #-#@3)/TG6)']I'RJZ5]FWW#*>=@6UA^C
MX5J*?9AFG +ZC%\[26PY1V'\$)9])AA14[U!Q:-3;9R#T5B]8"=L/T !_-C#
M(.,C".:W%WB+BP*G-8^5L_<:4'+>.$Q0CK1QDUQ;;TZ@.;0Y>-1.E;"!ZF[W
M%$I7&DHA/7VF,9&AX:RBN/V'?4%WF#>6>V%,N-7SO:>EQX\3<;2A,:)1_+QF
MB%J.8B,.P<&-8*+&F@,+2>?<]NH,?4KR_3;9\$)%O+-QW=38WYOC#Z4^.!VP
M*DA'.TU;NR;51J\(XMX2<9A<D"9\0^2C-DELG[!G6ET26,<_YGCV]TT<5^P"
ML"-=V#H5O?5R,F".B$;UXM0IRH1@-"1C30F7?<[W#FVX+.#.DVPP-??#8.VD
MYL+/V!<#K6C_ML_Q_5=&\E7^_T84GL(W))$O."S7MJ;D')=49N2CK'<Y:U0)
MKO4?.\D=[6KV$-:^EH!2!\TN #P]# KDN.4CQ1$U+/U7QG,.BFCCD=SJ/XX&
M%JL+K%_/U[ =7F?LYPK!L<>1&.C3&KXKZUP]6(-W6YVCMRJ@7:K32Y5K_T96
M+KQF?Y%S/5?+*\NG.=>P6V%YV)'_"Z[K.$VS3F4S9$YS 50<1/>5D<H@BQD/
MZ0R%85@_HVE3YEN6 .:%,UH4]&N6/Y9Z[H1=O!^BX>.3_33#8,0FZ0?:GUT#
M)<Q.P$)-5045 N4F+8MN_IF_N\]4B:;SBF.H#(C&=3$#(]J8&G;H?TXTICAE
M7(S ZZGAPF_3TGFL-,[ +<!%N@1VS4Z&GH#BXIES/F>S8E:MC \/CK[G^CJP
M2R=.SWK&0T[VWTDV:/4'"(<&0[JG8[IQJB[5I73FB/)9()3/9D+Y#"#*9Q,H
MGYVVBLQGRI7)]EC/=&]6PV[XNWZU)W5:$38WBC[OG+N'5 :T5_UT2C705$T.
MM+PRT/+)9HO.FQ@>1$AWJ@ J-M$D%F&O%CBTO('"];B:SX*K.9#80VH^"]Y#
M\K7N8L=Y&4_14V1"=27LD)VI>^3KN[9Y)#.?9PC3N2%L@ZTC>_3HM*3KJ\E\
M3O<[FO,M^PTN5GF^]S"C 7(!FUP>DY^Q*>E&,)=ON':X0 GG#]*^QG$=:U$Z
MI." ]L:OV$JFYIL"/V?[Y[8HR>J!ON!;GOG-MZLW1;8Q.L8,QBJHG=JPGM6&
M:\'03DK&3;FN"I-PV5!1"\<38C8@[LH#6M*X]=O#YN09'[9;O.'M /6#62T9
MS;+S@CU-UQ1X<QYQ'BG4_+L/T+N9R9J]0[!=%ZRIJ[Y/=0C0IO>O-AN^<</I
M)2V^E%G^^.%?>[Z$P=43->J9X$#4[\6Q$9,8C\*;%Q%9K@)SFZ$$Y7C!%ECJ
MK-O%@$B.\&N8BL:_@BV2?)%D'*%C>H3-E6Z=37MTMCS(EC( A<QQ/YC7MMT[
MYQ:G@7VLS<E05AT/$_JF9%FC&L2*+U,E4_G6D[%%@F^L\<V_5#]&M+,B9ZL9
MN^E@26.?P+U1AI)(+UHI9$*-4$A(%> QY-R+VLXSS_X5[0)'10X'U*VSTGGY
M JOUW56^*7!2X@LL_U0=EL^?F(9Q>94W#69+O85#D?%Y_I*MEYJ'N2L^<(=^
M>5$$\%M/!1<HPG.XMB%ZDOYSK]9B*5NOO+"5&%_((A9#F/CR^33/Y$Y3]AOQ
M+Q)NHG 6V?$,D,Z"ZYLTMF:A+^5"M8!-"W8E(HMT6E?HLMLP6LJ)N*#M"W[4
MBAJBXM0J3_D??,O!_ %;=)(;^+9'5:,C:G$R-YZPNH<7JR5>'HBM&1@<*>+_
MI?A9_K&C95:5["]LDLAD&C;;;&]I@;/'7#7&W0 Y*!I'DD[KV.DH4L^=[Z5M
M]XC$GJ9KD1US'G'J(K6)_K4%<I,3?\&M$! ,RP5BZJKF2$9HW';*CEXTXPO8
M(^@M&]Y16RA[]2X!PN$'9:*R'7\()/ZB<3?K^@5NI"3P(.<N\'R;E;^Z%W;6
MOAV@<'!#+6(AYX+S %; 9Q"*OKK-!TJ"IW:B:YR_"90:AU)[1Q^T2ZF=ON^'
M B'6VW0% ;"*.2-(#!I^J'HXL;0^8/QPGM6?RRW@*Q?,J=)4S_>]"A,=T8MP
MY:!X"#2@6/\($-1$01"53GKT':R2RY>["TI(4HA^'/("VB* 3Y)P7%8/DXRR
M&?IRAU+!3[XT3Q1'")L? WRHH=* 8J''% :$9*:ZMRAV_KN7V(-0/OH%]0_
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M*-USD[SR]T^V=4C[27B5!NPC&:$B*6<C#(V*RD4[Q0E*%!L'AQIJ#"@01,>
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M."ZE38?\;/$^^89+,4_R<M97^88^FS9\<B8=XKC%B%5X7[Q+^#J)][DH&@F
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M*T,]E]W3\(OPV-[7FX1>COD@_#&1S@I/\D&"47M>]X/ODD,>H5D?;1U^S3$
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M/UU8KCO'2+A>.PV2C'/#Q-A]CS@O))B]0Y^^OX"PKC1 AQJJ#"@2G<(=#C!
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M>3*?9;Z,$<50+[.'.$3(G^D\P59\D6*,!&?TB^ -\I'U)+B##ZG'5;P,($E
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M-0>UQV<-];H8 +M^6C.%[Y\3%W37[(.K"C_;5E0PIAKQ<K'A<J*;8LX?"0'
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MO6.\FE.=>_5,$ W3+6:42?Q5('T@V:,\I.Z65,S;=C^\O**2$<HRT1;Y@39
M!LI?#,JDR2FI86N9BD.-YCRRY@O @U7SKSM<O&0;?$[+ZC.NNBOONGS3JZAV
M:N?+#N0#M$LS9Q=A?I&\T88QA^*L[B#W=;FSU>X" 56N7'?&JS'E_!$3X"AC
MH9%!5@0&X-<'?2JN\@U]QD%=VXV#CS&X<(R0,XAYO4#5DD/5$8?BZ%ZHTS"Z
M7B;"RN.;7BMU 7 IPF*<?E/PBHL76/YYE0?V>&OR?L9@R6[V/HES.[<KNC2
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M:I<Z3:/'#J0P[/M7<,RSG*;7&-_6*\KIYE8CX("/6:C9DNCJ<RQV$ZM.0(+
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M/S$)?!QL!H. YF=@]7IH>!^W$@9=::T;1;)(FC ]@_7TVSNUB5;4;Z!DU_P
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MTY-!7YP^VI.@]$U9_F2MS-[+5+OJ9ES0.GZ+,)5ON3Z94*I?8I*M)&LM-9&
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M$1*G%@9G.IAG:"/3:1N9?V01FGZGPN.U^/^3/%$134*ON)@E-X\H.>-K4![
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ME9_I3I[3GS5WE'2Y#E+EA@9@+J5P66894LRQD1WGI+!1S\8!#&592 T<K-H
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M?RL# &)N='@M,C R,#$R,S$N>'-D4$L! A0#%     @ "(I^4DKE\3 <&P
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I='@M,C R,#$R,S%?<')E+GAM;%!+!08     !@ & (H!   @@ 4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
